#0
0	Here	O	['N']	[0]
1	we	O	['N']	[1]
2	present	O	['N']	[2]
3	the	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	generalized	B	['N']	[7]
8	lichen	I	['N']	[8]
9	nitidus	I-Adverse_Effect	['N']	[9]
10	with	O	['N']	[10]
11	involvement	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	palms	O	['N']	[14]
15	in	O	['N']	[15]
16	a	O	['N']	[16]
17	patient	O	['N']	[17]
18	with	O	['N']	[18]
19	hepatitis	O	['N']	[19]
20	C	O	['N']	[20]
21	after	O	['N']	[21]
22	systemic	O	['N']	[22]
23	treatment	O	['N']	[23]
24	with	O	['N']	[24]
25	interferon	O	['N']	[25]
26	alpha	O	['N']	[26]
27	and	O	['N']	[27]
28	ribavirin	B-Drug	['Causes']	[9]
29	.	O	['N']	[29]
#1
0	Mitomycin	B	['N']	[0]
1	-	I	['N']	[1]
2	C	I-Drug	['Causes']	[6]
3	induced	O	['N']	[3]
4	hemolytic	B	['N']	[4]
5	uremic	I	['N']	[5]
6	syndrome	I-Adverse_Effect	['N']	[6]
7	:	O	['N']	[7]
8	a	O	['N']	[8]
9	case	O	['N']	[9]
10	report	O	['N']	[10]
11	.	O	['N']	[11]
#2
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	present	O	['N']	[2]
3	an	O	['N']	[3]
4	elderly	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	mixed	O	['N']	[7]
8	dementia	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	TD	O	['N']	[11]
12	at	O	['N']	[12]
13	multiple	O	['N']	[13]
14	sites	O	['N']	[14]
15	,	O	['N']	[15]
16	(	O	['N']	[16]
17	including	O	['N']	[17]
18	respiratory	O	['N']	[18]
19	dyskinesia	O	['N']	[19]
20	[	O	['N']	[20]
21	RD	O	['N']	[21]
22	]	O	['N']	[22]
23	,	O	['N']	[23]
24	limb	B	['N']	[24]
25	dyskinesia	I-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	orofacial	O	['N']	[28]
29	dyskinesia	O	['N']	[29]
30	)	O	['N']	[30]
31	following	O	['N']	[31]
32	abrupt	O	['N']	[32]
33	withdrawal	O	['N']	[33]
34	of	O	['N']	[34]
35	risperidone	B-Drug	['Causes']	[25]
36	therapy	O	['N']	[36]
37	.	O	['N']	[37]
#3
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	2	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	severe	O	['N']	[5]
6	erosive	O	['N']	[6]
7	rheumatoid	O	['N']	[7]
8	arthritis	O	['N']	[8]
9	and	O	['N']	[9]
10	rheumatoid	O	['N']	[10]
11	vasculitis	O	['N']	[11]
12	,	O	['N']	[12]
13	respectively	O	['N']	[13]
14	,	O	['N']	[14]
15	in	O	['N']	[15]
16	whom	O	['N']	[16]
17	infliximab	B-Drug	['Causes']	[23]
18	therapy	O	['N']	[18]
19	was	O	['N']	[19]
20	associated	O	['N']	[20]
21	with	O	['N']	[21]
22	peripheral	B	['N']	[22]
23	neuropathy	I-Adverse_Effect	['N']	[23]
24	due	O	['N']	[24]
25	to	O	['N']	[25]
26	necrotizing	O	['N']	[26]
27	vasculitis	O	['N']	[27]
28	in	O	['N']	[28]
29	one	O	['N']	[29]
30	patient	O	['N']	[30]
31	and	O	['N']	[31]
32	to	O	['N']	[32]
33	progression	O	['N']	[33]
34	of	O	['N']	[34]
35	preexisting	O	['N']	[35]
36	mononeuritis	O	['N']	[36]
37	multiplex	O	['N']	[37]
38	in	O	['N']	[38]
39	the	O	['N']	[39]
40	other	O	['N']	[40]
41	.	O	['N']	[41]
#4
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	adults	O	['N']	[3]
4	who	O	['N']	[4]
5	received	O	['N']	[5]
6	gabapentin	O	['N']	[6]
7	(	O	['N']	[7]
8	GBP	B-Drug	['Causes']	[15]
9	)	O	['N']	[9]
10	and	O	['N']	[10]
11	subsequently	O	['N']	[11]
12	developed	O	['N']	[12]
13	behavioural	B	['N']	[13]
14	side	I	['N']	[14]
15	effects	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#5
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	recurrent	O	['N']	[5]
6	torsades	B	['N']	[6]
7	de	I	['N']	[7]
8	pointes	I-Adverse_Effect	['N']	[8]
9	following	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	pentavalent	O	['N']	[12]
13	antimonial	O	['N']	[13]
14	drugs	O	['N']	[14]
15	and	O	['N']	[15]
16	amiodarone	B-Drug	['Causes']	[8]
17	.	O	['N']	[17]
#6
0	On	O	['N']	[0]
1	the	O	['N']	[1]
2	3rd	O	['N']	[2]
3	day	O	['N']	[3]
4	,	O	['N']	[4]
5	an	O	['N']	[5]
6	inferior	O	['N']	[6]
7	vena	O	['N']	[7]
8	cava	O	['N']	[8]
9	(	O	['N']	[9]
10	IVC	O	['N']	[10]
11	)	O	['N']	[11]
12	filter	O	['N']	[12]
13	was	O	['N']	[13]
14	placed	O	['N']	[14]
15	with	O	['N']	[15]
16	a	O	['N']	[16]
17	heparin	B-Drug	['Causes']	[24]
18	flush	O	['N']	[18]
19	,	O	['N']	[19]
20	after	O	['N']	[20]
21	which	O	['N']	[21]
22	massive	O	['N']	[22]
23	IVC	B	['N']	[23]
24	thrombosis	I-Adverse_Effect	['N']	[24]
25	developed	O	['N']	[25]
26	.	O	['N']	[26]
#7
0	We	O	['N']	[0]
1	discuss	O	['N']	[1]
2	our	O	['N']	[2]
3	observations	O	['N']	[3]
4	in	O	['N']	[4]
5	the	O	['N']	[5]
6	cases	O	['N']	[6]
7	of	O	['N']	[7]
8	two	O	['N']	[8]
9	patients	O	['N']	[9]
10	with	O	['N']	[10]
11	acyclovir	B-Drug	['Causes']	[12]
12	neurotoxicity	B-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	review	O	['N']	[14]
15	the	O	['N']	[15]
16	findings	O	['N']	[16]
17	of	O	['N']	[17]
18	all	O	['N']	[18]
19	previous	O	['N']	[19]
20	reports	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	English	O	['N']	[23]
24	language	O	['N']	[24]
25	literature	O	['N']	[25]
26	.	O	['N']	[26]
#8
0	Lamotrigine	B	['N']	[0]
1	toxicity	I-Adverse_Effect	['N']	[1]
2	secondary	O	['N']	[2]
3	to	O	['N']	[3]
4	sertraline	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#9
0	Autopsy	O	['N']	[0]
1	evidence	O	['N']	[1]
2	of	O	['N']	[2]
3	herpesvirus	B	['N']	[3]
4	infection	I-Adverse_Effect	['N']	[4]
5	was	O	['N']	[5]
6	found	O	['N']	[6]
7	in	O	['N']	[7]
8	visceral	O	['N']	[8]
9	organs	O	['N']	[9]
10	of	O	['N']	[10]
11	four	O	['N']	[11]
12	leukemic	O	['N']	[12]
13	patients	O	['N']	[13]
14	who	O	['N']	[14]
15	had	O	['N']	[15]
16	received	O	['N']	[16]
17	large	O	['N']	[17]
18	doses	O	['N']	[18]
19	of	O	['N']	[19]
20	cytarabine	B-Drug	['Causes']	[4]
21	(	O	['N']	[21]
22	cytosine	O	['N']	[22]
23	arabinoside	O	['N']	[23]
24	;	O	['N']	[24]
25	Ara	O	['N']	[25]
26	-	O	['N']	[26]
27	C	O	['N']	[27]
28	)	O	['N']	[28]
29	shortly	O	['N']	[29]
30	before	O	['N']	[30]
31	their	O	['N']	[31]
32	death	O	['N']	[32]
33	.	O	['N']	[33]
#10
0	Myocardial	O	['N']	[0]
1	ischemia	O	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	high	B	['N']	[4]
5	-	I	['N']	[5]
6	dose	I-Dose	['N']	[6]
7	carmustine	B-Drug	['Dosage']	[6]
8	infusion	O	['N']	[8]
9	.	O	['N']	[9]
#11
0	Intravenous	O	['N']	[0]
1	haloperidol	B-Drug	['Causes']	[10]
2	is	O	['N']	[2]
3	generally	O	['N']	[3]
4	well	O	['N']	[4]
5	tolerated	O	['N']	[5]
6	,	O	['N']	[6]
7	but	O	['N']	[7]
8	multiform	B	['N']	[8]
9	ventricular	I	['N']	[9]
10	tachycardia	I-Adverse_Effect	['N']	[10]
11	has	O	['N']	[11]
12	been	O	['N']	[12]
13	reported	O	['N']	[13]
14	.	O	['N']	[14]
#12
0	Oxygen	B-Drug	['Causes']	[7]
1	potentiation	O	['N']	[1]
2	of	O	['N']	[2]
3	bleomycin	O	['N']	[3]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	pulmonary	B	['N']	[6]
7	toxicity	I-Adverse_Effect	['N']	[7]
8	is	O	['N']	[8]
9	discussed	O	['N']	[9]
10	.	O	['N']	[10]
#13
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	severe	B	['N']	[5]
6	AVP	I-Adverse_Effect	['N']	[6]
7	three	O	['N']	[7]
8	weeks	O	['N']	[8]
9	following	O	['N']	[9]
10	the	O	['N']	[10]
11	administration	O	['N']	[11]
12	of	O	['N']	[12]
13	infliximab	B-Drug	['Causes']	[6]
14	for	O	['N']	[14]
15	the	O	['N']	[15]
16	treatment	O	['N']	[16]
17	of	O	['N']	[17]
18	Crohn	O	['N']	[18]
19	's	O	['N']	[19]
20	disease	O	['N']	[20]
21	(	O	['N']	[21]
22	CD	O	['N']	[22]
23	)	O	['N']	[23]
24	.	O	['N']	[24]
#14
0	Vancomycin	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	vasculitis	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#15
0	Gigantomastia	B-Adverse_Effect	['N']	[0]
1	induced	O	['N']	[1]
2	by	O	['N']	[2]
3	bucillamine	B-Drug	['Causes']	[0]
4	.	O	['N']	[4]
#16
0	Possible	O	['N']	[0]
1	mechanisms	O	['N']	[1]
2	by	O	['N']	[2]
3	which	O	['N']	[3]
4	clonidine	B-Drug	['Causes']	[14]
5	decreases	O	['N']	[5]
6	spasticity	O	['N']	[6]
7	are	O	['N']	[7]
8	described	O	['N']	[8]
9	,	O	['N']	[9]
10	probable	O	['N']	[10]
11	mechanisms	O	['N']	[11]
12	of	O	['N']	[12]
13	induced	O	['N']	[13]
14	bradycardia	B-Adverse_Effect	['N']	[14]
15	are	O	['N']	[15]
16	reviewed	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	specific	O	['N']	[19]
20	treatment	O	['N']	[20]
21	recommendations	O	['N']	[21]
22	for	O	['N']	[22]
23	the	O	['N']	[23]
24	use	O	['N']	[24]
25	of	O	['N']	[25]
26	clonidine	O	['N']	[26]
27	in	O	['N']	[27]
28	spinal	O	['N']	[28]
29	cord	O	['N']	[29]
30	injured	O	['N']	[30]
31	patients	O	['N']	[31]
32	are	O	['N']	[32]
33	presented	O	['N']	[33]
34	.	O	['N']	[34]
#17
0	CASE	O	['N']	[0]
1	REPORT	O	['N']	[1]
2	:	O	['N']	[2]
3	We	O	['N']	[3]
4	report	O	['N']	[4]
5	the	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	a	O	['N']	[8]
9	58	O	['N']	[9]
10	year	O	['N']	[10]
11	old	O	['N']	[11]
12	patient	O	['N']	[12]
13	who	O	['N']	[13]
14	,	O	['N']	[14]
15	after	O	['N']	[15]
16	2	O	['N']	[16]
17	days	O	['N']	[17]
18	of	O	['N']	[18]
19	treatment	O	['N']	[19]
20	with	O	['N']	[20]
21	roxithromycin	B-Drug	['Causes']	[27]
22	and	O	['N']	[22]
23	betamethasone	O	['N']	[23]
24	,	O	['N']	[24]
25	manifested	O	['N']	[25]
26	acute	B	['N']	[26]
27	pancreatitis	I-Adverse_Effect	['N']	[27]
28	.	O	['N']	[28]
#18
0	Central	B	['N']	[0]
1	nervous	I	['N']	[1]
2	system	I	['N']	[2]
3	toxicity	I-Adverse_Effect	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	meperidine	B-Drug	['Causes']	[3]
7	use	O	['N']	[7]
8	in	O	['N']	[8]
9	hepatic	O	['N']	[9]
10	disease	O	['N']	[10]
11	.	O	['N']	[11]
#19
0	Transient	B	['N']	[0]
1	left	I	['N']	[1]
2	homonymous	I	['N']	[2]
3	hemianopsia	I-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	encephalopathy	O	['N']	[5]
6	following	O	['N']	[6]
7	treatment	O	['N']	[7]
8	of	O	['N']	[8]
9	testicular	O	['N']	[9]
10	carcinoma	O	['N']	[10]
11	with	O	['N']	[11]
12	cisplatinum	O	['N']	[12]
13	,	O	['N']	[13]
14	vinblastine	B-Drug	['Causes']	[3]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	bleomycin	O	['N']	[17]
18	.	O	['N']	[18]
#20
0	Photo	B	['N']	[0]
1	-	I	['N']	[1]
2	onycholysis	I-Adverse_Effect	['N']	[2]
3	caused	O	['N']	[3]
4	by	O	['N']	[4]
5	olanzapine	B-Drug	['Causes']	[2]
6	and	O	['N']	[6]
7	aripiprazole	O	['N']	[7]
8	.	O	['N']	[8]
#21
0	Common	O	['N']	[0]
1	adverse	O	['N']	[1]
2	events	O	['N']	[2]
3	(	O	['N']	[3]
4	frequency	O	['N']	[4]
5	10	O	['N']	[5]
6	%	O	['N']	[6]
7	)	O	['N']	[7]
8	of	O	['N']	[8]
9	lacosamide	B-Drug	['Causes']	[33]
10	doses	O	['N']	[10]
11	up	O	['N']	[11]
12	to	O	['N']	[12]
13	600	O	['N']	[13]
14	mg	O	['N']	[14]
15	/	O	['N']	[15]
16	day	O	['N']	[16]
17	include	O	['N']	[17]
18	nonspecific	O	['N']	[18]
19	central	O	['N']	[19]
20	nervous	O	['N']	[20]
21	system	O	['N']	[21]
22	effects	O	['N']	[22]
23	(	O	['N']	[23]
24	e.g.	O	['N']	[24]
25	,	O	['N']	[25]
26	dizziness	O	['N']	[26]
27	,	O	['N']	[27]
28	ataxia	O	['N']	[28]
29	,	O	['N']	[29]
30	diplopia	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	somnolence	B-Adverse_Effect	['N']	[33]
34	)	O	['N']	[34]
35	.	O	['N']	[35]
#22
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	there	O	['N']	[2]
3	remain	O	['N']	[3]
4	questions	O	['N']	[4]
5	concerning	O	['N']	[5]
6	whether	O	['N']	[6]
7	these	O	['N']	[7]
8	drugs	O	['N']	[8]
9	,	O	['N']	[9]
10	especially	O	['N']	[10]
11	methimazole	O	['N']	[11]
12	(	O	['N']	[12]
13	MMI	B-Drug	['Causes']	[24]
14	)	O	['N']	[14]
15	,	O	['N']	[15]
16	may	O	['N']	[16]
17	be	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	aplasia	O	['N']	[20]
21	cutis	O	['N']	[21]
22	congenita	O	['N']	[22]
23	(	O	['N']	[23]
24	ACC	B-Adverse_Effect	['N']	[24]
25	)	O	['N']	[25]
26	and	O	['N']	[26]
27	how	O	['N']	[27]
28	best	O	['N']	[28]
29	to	O	['N']	[29]
30	avoid	O	['N']	[30]
31	impairment	O	['N']	[31]
32	of	O	['N']	[32]
33	fetal	O	['N']	[33]
34	thyroid	O	['N']	[34]
35	function	O	['N']	[35]
36	during	O	['N']	[36]
37	their	O	['N']	[37]
38	use	O	['N']	[38]
39	.	O	['N']	[39]
#23
0	A	O	['N']	[0]
1	57-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	developed	O	['N']	[5]
6	chronic	B	['N']	[6]
7	,	I	['N']	[7]
8	watery	I	['N']	[8]
9	diarrhea	I-Adverse_Effect	['N']	[9]
10	four	O	['N']	[10]
11	weeks	O	['N']	[11]
12	after	O	['N']	[12]
13	Helicobacter	O	['N']	[13]
14	pylori	O	['N']	[14]
15	eradication	O	['N']	[15]
16	therapy	O	['N']	[16]
17	including	O	['N']	[17]
18	lansoprazole	B-Drug	['Causes']	[9]
19	followed	O	['N']	[19]
20	by	O	['N']	[20]
21	lansoprazole	O	['N']	[21]
22	monotherapy	O	['N']	[22]
23	for	O	['N']	[23]
24	gastroesophageal	O	['N']	[24]
25	reflux	O	['N']	[25]
26	disease	O	['N']	[26]
27	.	O	['N']	[27]
#24
0	Such	O	['N']	[0]
1	a	O	['N']	[1]
2	case	O	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	hypothyroidism	B-Adverse_Effect	['N']	[5]
6	complicating	O	['N']	[6]
7	long	O	['N']	[7]
8	-	O	['N']	[8]
9	term	O	['N']	[9]
10	therapy	O	['N']	[10]
11	with	O	['N']	[11]
12	amiodarone	B-Drug	['Causes']	[5]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	45	O	['N']	[15]
16	year	O	['N']	[16]
17	old	O	['N']	[17]
18	woman	O	['N']	[18]
19	with	O	['N']	[19]
20	pre	O	['N']	[20]
21	-	O	['N']	[21]
22	excitation	O	['N']	[22]
23	is	O	['N']	[23]
24	presented	O	['N']	[24]
25	.	O	['N']	[25]
#25
0	Multiple	B	['N']	[0]
1	seizures	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	bupropion	B-Drug	['Causes']	[1]
4	overdose	O	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	small	O	['N']	[7]
8	child	O	['N']	[8]
9	.	O	['N']	[9]
#26
0	A	O	['N']	[0]
1	drug	O	['N']	[1]
2	addict	O	['N']	[2]
3	with	O	['N']	[3]
4	staphylococcal	O	['N']	[4]
5	endocarditis	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	methicillin	B-Drug	['Causes']	[13]
9	,	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	massive	B	['N']	[12]
13	proteinuria	I-Adverse_Effect	['N']	[13]
14	and	O	['N']	[14]
15	acute	O	['N']	[15]
16	nephritic	O	['N']	[16]
17	syndrome	O	['N']	[17]
18	is	O	['N']	[18]
19	described	O	['N']	[19]
20	.	O	['N']	[20]
#27
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	phenytoin	B-Drug	['Causes']	[18]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	hepatitis	O	['N']	[6]
7	with	O	['N']	[7]
8	mononucleosis	O	['N']	[8]
9	is	O	['N']	[9]
10	reported	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	syndromes	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	phenytoin	O	['N']	[16]
17	hypersensitivity	B	['N']	[17]
18	reactions	I-Adverse_Effect	['N']	[18]
19	are	O	['N']	[19]
20	discussed	O	['N']	[20]
21	.	O	['N']	[21]
#28
0	Probable	O	['N']	[0]
1	propafenone	B-Drug	['Causes']	[6]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	transient	B	['N']	[4]
5	global	I	['N']	[5]
6	amnesia	I-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#29
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	combined	O	['N']	[6]
7	lithium	B-Drug	['Causes']	[18]
8	and	O	['N']	[8]
9	haloperidol	O	['N']	[9]
10	toxicity	O	['N']	[10]
11	characterized	O	['N']	[11]
12	by	O	['N']	[12]
13	hyperpyrexia	O	['N']	[13]
14	,	O	['N']	[14]
15	severe	O	['N']	[15]
16	rigidity	O	['N']	[16]
17	,	O	['N']	[17]
18	mutism	B-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	development	O	['N']	[21]
22	of	O	['N']	[22]
23	irreversible	O	['N']	[23]
24	tardive	O	['N']	[24]
25	dyskinesia	O	['N']	[25]
26	.	O	['N']	[26]
#30
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	there	O	['N']	[2]
3	are	O	['N']	[3]
4	few	O	['N']	[4]
5	reports	O	['N']	[5]
6	in	O	['N']	[6]
7	the	O	['N']	[7]
8	literature	O	['N']	[8]
9	of	O	['N']	[9]
10	ampicillin	B-Drug	['Causes']	[17]
11	as	O	['N']	[11]
12	a	O	['N']	[12]
13	cause	O	['N']	[13]
14	of	O	['N']	[14]
15	acute	B	['N']	[15]
16	interstitial	I	['N']	[16]
17	nephritis	I-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#31
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	14-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	female	O	['N']	[9]
10	with	O	['N']	[10]
11	acute	O	['N']	[11]
12	promyelocytic	O	['N']	[12]
13	leukemia	O	['N']	[13]
14	who	O	['N']	[14]
15	developed	O	['N']	[15]
16	symptomatic	B	['N']	[16]
17	cardiomyopathy	I-Adverse_Effect	['N']	[17]
18	only	O	['N']	[18]
19	4	O	['N']	[19]
20	months	O	['N']	[20]
21	into	O	['N']	[21]
22	treatment	O	['N']	[22]
23	with	O	['N']	[23]
24	a	O	['N']	[24]
25	combination	O	['N']	[25]
26	of	O	['N']	[26]
27	daunomycin	O	['N']	[27]
28	and	O	['N']	[28]
29	all	O	['N']	[29]
30	-	O	['N']	[30]
31	trans	O	['N']	[31]
32	retinoic	O	['N']	[32]
33	acid	O	['N']	[33]
34	(	O	['N']	[34]
35	ATRA	B-Drug	['Causes']	[17]
36	)	O	['N']	[36]
37	.	O	['N']	[37]
#32
0	A	O	['N']	[0]
1	67-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	developed	O	['N']	[5]
6	diarrhea	B-Adverse_Effect	['N']	[6]
7	shortly	O	['N']	[7]
8	after	O	['N']	[8]
9	a	O	['N']	[9]
10	10-day	O	['N']	[10]
11	course	O	['N']	[11]
12	of	O	['N']	[12]
13	oral	O	['N']	[13]
14	ampicillin	B-Drug	['Causes']	[6]
15	.	O	['N']	[15]
#33
0	Sunburn	O	['N']	[0]
1	may	O	['N']	[1]
2	sometimes	O	['N']	[2]
3	be	O	['N']	[3]
4	a	O	['N']	[4]
5	major	O	['N']	[5]
6	injury	O	['N']	[6]
7	in	O	['N']	[7]
8	psoralen	B-Drug	['Causes']	[24]
9	users	O	['N']	[9]
10	because	O	['N']	[10]
11	high	O	['N']	[11]
12	doses	O	['N']	[12]
13	or	O	['N']	[13]
14	inappropriate	O	['N']	[14]
15	use	O	['N']	[15]
16	of	O	['N']	[16]
17	the	O	['N']	[17]
18	drug	O	['N']	[18]
19	may	O	['N']	[19]
20	render	O	['N']	[20]
21	the	O	['N']	[21]
22	skin	B	['N']	[22]
23	extremely	I	['N']	[23]
24	sensitive	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#34
0	Anterior	B	['N']	[0]
1	lumbosacral	I	['N']	[1]
2	radiculopathy	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	intrathecal	O	['N']	[4]
5	methotrexate	B-Drug	['Causes']	[2]
6	treatment	O	['N']	[6]
7	.	O	['N']	[7]
#35
0	Can	O	['N']	[0]
1	roxithromycin	O	['N']	[1]
2	and	O	['N']	[2]
3	betamethasone	B-Drug	['Causes']	[6]
4	induce	O	['N']	[4]
5	acute	B	['N']	[5]
6	pancreatitis	I-Adverse_Effect	['N']	[6]
7	?	O	['N']	[7]
8	A	O	['N']	[8]
9	case	O	['N']	[9]
10	report	O	['N']	[10]
11	.	O	['N']	[11]
#36
0	Exacerbations	B	['N']	[0]
1	of	I	['N']	[1]
2	the	I	['N']	[2]
3	heart	I	['N']	[3]
4	failure	I-Adverse_Effect	['N']	[4]
5	were	O	['N']	[5]
6	temporally	O	['N']	[6]
7	related	O	['N']	[7]
8	to	O	['N']	[8]
9	the	O	['N']	[9]
10	administration	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	antitumor	O	['N']	[13]
14	antibiotics	O	['N']	[14]
15	actinomycin	O	['N']	[15]
16	-	O	['N']	[16]
17	D	O	['N']	[17]
18	(	O	['N']	[18]
19	NSC-3053	O	['N']	[19]
20	)	O	['N']	[20]
21	and	O	['N']	[21]
22	mithramycin	O	['N']	[22]
23	(	O	['N']	[23]
24	NSC-24559	B-Drug	['Causes']	[4]
25	)	O	['N']	[25]
26	.	O	['N']	[26]
#37
0	Two	O	['N']	[0]
1	of	O	['N']	[1]
2	the	O	['N']	[2]
3	five	O	['N']	[3]
4	patients	O	['N']	[4]
5	who	O	['N']	[5]
6	worsened	B	['N']	[6]
7	motorically	I-Adverse_Effect	['N']	[7]
8	also	O	['N']	[8]
9	developed	O	['N']	[9]
10	encephalopathy	O	['N']	[10]
11	during	O	['N']	[11]
12	risperidone	B-Drug	['Causes']	[7]
13	treatment	O	['N']	[13]
14	;	O	['N']	[14]
15	the	O	['N']	[15]
16	encephalopathy	O	['N']	[16]
17	resolved	O	['N']	[17]
18	when	O	['N']	[18]
19	the	O	['N']	[19]
20	patients	O	['N']	[20]
21	were	O	['N']	[21]
22	switched	O	['N']	[22]
23	to	O	['N']	[23]
24	clozapine	O	['N']	[24]
25	treatment	O	['N']	[25]
26	.	O	['N']	[26]
#38
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	EO	B-Drug	['Causes']	[7]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	noncardiogenic	B	['N']	[5]
6	pulmonary	I	['N']	[6]
7	edema	I-Adverse_Effect	['N']	[7]
8	has	O	['N']	[8]
9	not	O	['N']	[9]
10	been	O	['N']	[10]
11	reported	O	['N']	[11]
12	in	O	['N']	[12]
13	human	O	['N']	[13]
14	.	O	['N']	[14]
#39
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	anaphylaxis	B-Adverse_Effect	['N']	[5]
6	under	O	['N']	[6]
7	anaesthesia	O	['N']	[7]
8	where	O	['N']	[8]
9	return	O	['N']	[9]
10	of	O	['N']	[10]
11	spontaneous	O	['N']	[11]
12	circulation	O	['N']	[12]
13	was	O	['N']	[13]
14	refractory	O	['N']	[14]
15	to	O	['N']	[15]
16	epinephrine	O	['N']	[16]
17	,	O	['N']	[17]
18	but	O	['N']	[18]
19	occurred	O	['N']	[19]
20	following	O	['N']	[20]
21	the	O	['N']	[21]
22	administration	O	['N']	[22]
23	of	O	['N']	[23]
24	the	O	['N']	[24]
25	alpha	O	['N']	[25]
26	-	O	['N']	[26]
27	agonist	O	['N']	[27]
28	metaraminol	B-Drug	['Causes']	[5]
29	.	O	['N']	[29]
#40
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	After	O	['N']	[2]
3	4-	O	['N']	[3]
4	to	O	['N']	[4]
5	14-month	O	['N']	[5]
6	period	O	['N']	[6]
7	of	O	['N']	[7]
8	therapy	O	['N']	[8]
9	with	O	['N']	[9]
10	the	O	['N']	[10]
11	combination	O	['N']	[11]
12	of	O	['N']	[12]
13	indapamide	B-Drug	['Causes']	[58]
14	(	O	['N']	[14]
15	2.5	O	['N']	[15]
16	mg	O	['N']	[16]
17	/	O	['N']	[17]
18	day	O	['N']	[18]
19	)	O	['N']	[19]
20	and	O	['N']	[20]
21	fosinopril	O	['N']	[21]
22	(	O	['N']	[22]
23	10	O	['N']	[23]
24	mg	O	['N']	[24]
25	/	O	['N']	[25]
26	day	O	['N']	[26]
27	)	O	['N']	[27]
28	in	O	['N']	[28]
29	three	O	['N']	[29]
30	patients	O	['N']	[30]
31	and	O	['N']	[31]
32	6-month	O	['N']	[32]
33	period	O	['N']	[33]
34	of	O	['N']	[34]
35	monotherapy	O	['N']	[35]
36	with	O	['N']	[36]
37	indapamide	O	['N']	[37]
38	(	O	['N']	[38]
39	2.5	O	['N']	[39]
40	mg	O	['N']	[40]
41	/	O	['N']	[41]
42	day	O	['N']	[42]
43	)	O	['N']	[43]
44	in	O	['N']	[44]
45	one	O	['N']	[45]
46	patient	O	['N']	[46]
47	,	O	['N']	[47]
48	glucose	O	['N']	[48]
49	levels	O	['N']	[49]
50	of	O	['N']	[50]
51	all	O	['N']	[51]
52	patients	O	['N']	[52]
53	increased	O	['N']	[53]
54	and	O	['N']	[54]
55	achieve	O	['N']	[55]
56	criteria	O	['N']	[56]
57	of	O	['N']	[57]
58	diabetes	B-Adverse_Effect	['N']	[58]
59	diagnoses	O	['N']	[59]
60	.	O	['N']	[60]
#41
0	In	O	['N']	[0]
1	the	O	['N']	[1]
2	following	O	['N']	[2]
3	case	O	['N']	[3]
4	report	O	['N']	[4]
5	,	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	developed	O	['N']	[8]
9	acute	O	['N']	[9]
10	interstitial	O	['N']	[10]
11	nephritis	O	['N']	[11]
12	with	O	['N']	[12]
13	renal	O	['N']	[13]
14	failure	O	['N']	[14]
15	and	O	['N']	[15]
16	exfoliative	B	['N']	[16]
17	dermatitis	I-Adverse_Effect	['N']	[17]
18	following	O	['N']	[18]
19	ampicillin	B-Drug	['Causes']	[17]
20	therapy	O	['N']	[20]
21	.	O	['N']	[21]
#42
0	A	O	['N']	[0]
1	study	O	['N']	[1]
2	following	O	['N']	[2]
3	large	O	['N']	[3]
4	patient	O	['N']	[4]
5	groups	O	['N']	[5]
6	on	O	['N']	[6]
7	theophylline	B-Drug	['Causes']	[20]
8	and	O	['N']	[8]
9	a	O	['N']	[9]
10	combination	O	['N']	[10]
11	of	O	['N']	[11]
12	theophylline	O	['N']	[12]
13	and	O	['N']	[13]
14	steroids	O	['N']	[14]
15	might	O	['N']	[15]
16	clarify	O	['N']	[16]
17	the	O	['N']	[17]
18	risk	O	['N']	[18]
19	of	O	['N']	[19]
20	ulcer	B-Adverse_Effect	['N']	[20]
21	formation	O	['N']	[21]
22	in	O	['N']	[22]
23	patients	O	['N']	[23]
24	being	O	['N']	[24]
25	treated	O	['N']	[25]
26	with	O	['N']	[26]
27	these	O	['N']	[27]
28	medications	O	['N']	[28]
29	for	O	['N']	[29]
30	asthma	O	['N']	[30]
31	.	O	['N']	[31]
#43
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	13	O	['N']	[3]
4	year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	male	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	life	O	['N']	[10]
11	-	O	['N']	[11]
12	threatening	O	['N']	[12]
13	anaphylaxis	B-Adverse_Effect	['N']	[13]
14	early	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	course	O	['N']	[17]
18	of	O	['N']	[18]
19	Increlex	B-Drug	['Causes']	[13]
20	therapy	O	['N']	[20]
21	.	O	['N']	[21]
#44
0	This	O	['N']	[0]
1	review	O	['N']	[1]
2	presents	O	['N']	[2]
3	the	O	['N']	[3]
4	first	O	['N']	[4]
5	case	O	['N']	[5]
6	series	O	['N']	[6]
7	of	O	['N']	[7]
8	DIC	O	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	acute	B	['N']	[11]
12	hemoglobinemia	I-Adverse_Effect	['N']	[12]
13	or	O	['N']	[13]
14	hemoglobinuria	O	['N']	[14]
15	following	O	['N']	[15]
16	anti	B	['N']	[16]
17	-	I	['N']	[17]
18	D	I	['N']	[18]
19	IGIV	I-Drug	['Causes']	[12]
20	administration	O	['N']	[20]
21	for	O	['N']	[21]
22	ITP	O	['N']	[22]
23	.	O	['N']	[23]
#45
0	Mean	O	['N']	[0]
1	time	O	['N']	[1]
2	between	O	['N']	[2]
3	initiation	O	['N']	[3]
4	of	O	['N']	[4]
5	gemcitabine	B-Drug	['Causes']	[10]
6	therapy	O	['N']	[6]
7	and	O	['N']	[7]
8	onset	O	['N']	[8]
9	of	O	['N']	[9]
10	HUS	B-Adverse_Effect	['N']	[10]
11	was	O	['N']	[11]
12	7.4	O	['N']	[12]
13	+	O	['N']	[13]
14	/-	O	['N']	[14]
15	3.5	O	['N']	[15]
16	months	O	['N']	[16]
17	,	O	['N']	[17]
18	or	O	['N']	[18]
19	21.9	O	['N']	[19]
20	+	O	['N']	[20]
21	/-	O	['N']	[21]
22	10.9	O	['N']	[22]
23	doses	O	['N']	[23]
24	of	O	['N']	[24]
25	gemcitabine	O	['N']	[25]
26	.	O	['N']	[26]
#46
0	Cyclosporin	B-Drug	['Causes']	[4]
1	side	O	['N']	[1]
2	effects	O	['N']	[2]
3	included	O	['N']	[3]
4	hirsutism	B-Adverse_Effect	['N']	[4]
5	,	O	['N']	[5]
6	hypertension	O	['N']	[6]
7	,	O	['N']	[7]
8	increased	O	['N']	[8]
9	blood	O	['N']	[9]
10	levels	O	['N']	[10]
11	of	O	['N']	[11]
12	urea	O	['N']	[12]
13	and	O	['N']	[13]
14	creatinine	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	abnormalities	O	['N']	[17]
18	in	O	['N']	[18]
19	liver	O	['N']	[19]
20	function	O	['N']	[20]
21	tests	O	['N']	[21]
22	.	O	['N']	[22]
#47
0	The	O	['N']	[0]
1	diagnosis	O	['N']	[1]
2	of	O	['N']	[2]
3	hypothermia	B-Adverse_Effect	['N']	[3]
4	was	O	['N']	[4]
5	delayed	O	['N']	[5]
6	until	O	['N']	[6]
7	it	O	['N']	[7]
8	was	O	['N']	[8]
9	apparent	O	['N']	[9]
10	for	O	['N']	[10]
11	several	O	['N']	[11]
12	days	O	['N']	[12]
13	but	O	['N']	[13]
14	resolved	O	['N']	[14]
15	with	O	['N']	[15]
16	the	O	['N']	[16]
17	discontinuation	O	['N']	[17]
18	of	O	['N']	[18]
19	risperidone	B-Drug	['Causes']	[3]
20	and	O	['N']	[20]
21	continuation	O	['N']	[21]
22	of	O	['N']	[22]
23	clozapine	O	['N']	[23]
24	.	O	['N']	[24]
#48
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	is	O	['N']	[3]
4	the	O	['N']	[4]
5	first	O	['N']	[5]
6	report	O	['N']	[6]
7	of	O	['N']	[7]
8	a	O	['N']	[8]
9	possible	O	['N']	[9]
10	interaction	O	['N']	[10]
11	between	O	['N']	[11]
12	propafenone	B-Drug	['Causes']	[24]
13	and	O	['N']	[13]
14	citalopram	O	['N']	[14]
15	,	O	['N']	[15]
16	which	O	['N']	[16]
17	caused	O	['N']	[17]
18	propafenone	O	['N']	[18]
19	adverse	O	['N']	[19]
20	effects	O	['N']	[20]
21	(	O	['N']	[21]
22	eg	O	['N']	[22]
23	,	O	['N']	[23]
24	dizziness	B-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	falls	O	['N']	[26]
27	)	O	['N']	[27]
28	and	O	['N']	[28]
29	mimicked	O	['N']	[29]
30	coronary	O	['N']	[30]
31	artery	O	['N']	[31]
32	disease	O	['N']	[32]
33	.	O	['N']	[33]
#49
0	Generalized	B	['N']	[0]
1	pustular	I	['N']	[1]
2	psoriasis	I-Adverse_Effect	['N']	[2]
3	precipitated	O	['N']	[3]
4	by	O	['N']	[4]
5	trazodone	B-Drug	['Causes']	[2]
6	in	O	['N']	[6]
7	the	O	['N']	[7]
8	treatment	O	['N']	[8]
9	of	O	['N']	[9]
10	depression	O	['N']	[10]
11	.	O	['N']	[11]
#50
0	According	O	['N']	[0]
1	to	O	['N']	[1]
2	the	O	['N']	[2]
3	Naranjo	O	['N']	[3]
4	probability	O	['N']	[4]
5	scale	O	['N']	[5]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	papular	B	['N']	[8]
9	eruption	I-Adverse_Effect	['N']	[9]
10	was	O	['N']	[10]
11	probably	O	['N']	[11]
12	caused	O	['N']	[12]
13	by	O	['N']	[13]
14	methotrexate	B-Drug	['Causes']	[9]
15	.	O	['N']	[15]
#51
0	Reversible	O	['N']	[0]
1	valproic	B	['N']	[1]
2	acid	I-Drug	['Causes']	[5]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	dementia	B-Adverse_Effect	['N']	[5]
6	:	O	['N']	[6]
7	a	O	['N']	[7]
8	case	O	['N']	[8]
9	report	O	['N']	[9]
10	.	O	['N']	[10]
#52
0	Carboplatin	B-Drug	['Dosage']	[6]
1	hypersensitivity	O	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	low	B	['N']	[4]
5	-	I	['N']	[5]
6	dose	I-Dose	['N']	[6]
7	paclitaxel	O	['N']	[7]
8	/	O	['N']	[8]
9	carboplatin	O	['N']	[9]
10	in	O	['N']	[10]
11	multiple	O	['N']	[11]
12	platinum	O	['N']	[12]
13	-	O	['N']	[13]
14	treated	O	['N']	[14]
15	patients	O	['N']	[15]
16	with	O	['N']	[16]
17	recurrent	O	['N']	[17]
18	ovarian	O	['N']	[18]
19	cancer	O	['N']	[19]
20	.	O	['N']	[20]
#53
0	Apparent	O	['N']	[0]
1	cyclophosphamide	B-Drug	['Causes']	[5]
2	(	O	['N']	[2]
3	cytoxan	O	['N']	[3]
4	)	O	['N']	[4]
5	embryopathy	B-Adverse_Effect	['N']	[5]
6	:	O	['N']	[6]
7	a	O	['N']	[7]
8	distinct	O	['N']	[8]
9	phenotype	O	['N']	[9]
10	?	O	['N']	[10]
#54
0	Bilateral	O	['N']	[0]
1	acoustic	O	['N']	[1]
2	(	O	['N']	[2]
3	VIII	O	['N']	[3]
4	)	O	['N']	[4]
5	nerve	O	['N']	[5]
6	palsy	O	['N']	[6]
7	in	O	['N']	[7]
8	this	O	['N']	[8]
9	patient	O	['N']	[9]
10	was	O	['N']	[10]
11	most	O	['N']	[11]
12	likely	O	['N']	[12]
13	a	O	['N']	[13]
14	manifestation	O	['N']	[14]
15	of	O	['N']	[15]
16	vincristine	B-Drug	['Causes']	[17]
17	neurotoxicity	B-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#55
0	A	O	['N']	[0]
1	7-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	girl	O	['N']	[4]
5	developed	O	['N']	[5]
6	diabetes	B	['N']	[6]
7	mellitus	I-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	exocrine	O	['N']	[9]
10	pancreatic	O	['N']	[10]
11	insufficiency	O	['N']	[11]
12	after	O	['N']	[12]
13	3.5	O	['N']	[13]
14	years	O	['N']	[14]
15	of	O	['N']	[15]
16	almost	O	['N']	[16]
17	continuous	O	['N']	[17]
18	treatment	O	['N']	[18]
19	with	O	['N']	[19]
20	azathioprine	O	['N']	[20]
21	and/or	O	['N']	[21]
22	prednisone	B-Drug	['Causes']	[7]
23	for	O	['N']	[23]
24	idiopathic	O	['N']	[24]
25	auto	O	['N']	[25]
26	-	O	['N']	[26]
27	immune	O	['N']	[27]
28	haemolytic	O	['N']	[28]
29	anaemia	O	['N']	[29]
30	.	O	['N']	[30]
#56
0	After	O	['N']	[0]
1	discontinuation	O	['N']	[1]
2	of	O	['N']	[2]
3	danazol	B-Drug	['Causes']	[5]
4	the	O	['N']	[4]
5	diabetes	B-Adverse_Effect	['N']	[5]
6	completely	O	['N']	[6]
7	resolved	O	['N']	[7]
8	.	O	['N']	[8]
#57
0	Cardiac	O	['N']	[0]
1	glycosides	O	['N']	[1]
2	are	O	['N']	[2]
3	thought	O	['N']	[3]
4	to	O	['N']	[4]
5	prevent	O	['N']	[5]
6	doxorubicin	B-Drug	['Causes']	[7]
7	cardiomyopathy	B-Adverse_Effect	['N']	[7]
8	by	O	['N']	[8]
9	competitively	O	['N']	[9]
10	inhibiting	O	['N']	[10]
11	doxorubicin	O	['N']	[11]
12	at	O	['N']	[12]
13	its	O	['N']	[13]
14	receptor	O	['N']	[14]
15	sites	O	['N']	[15]
16	,	O	['N']	[16]
17	but	O	['N']	[17]
18	ouabain	O	['N']	[18]
19	has	O	['N']	[19]
20	a	O	['N']	[20]
21	much	O	['N']	[21]
22	shorter	O	['N']	[22]
23	half	O	['N']	[23]
24	life	O	['N']	[24]
25	than	O	['N']	[25]
26	doxorubicin	O	['N']	[26]
27	and	O	['N']	[27]
28	its	O	['N']	[28]
29	metabolites	O	['N']	[29]
30	and	O	['N']	[30]
31	so	O	['N']	[31]
32	is	O	['N']	[32]
33	less	O	['N']	[33]
34	effective	O	['N']	[34]
35	than	O	['N']	[35]
36	digoxin	O	['N']	[36]
37	.	O	['N']	[37]
#58
0	This	O	['N']	[0]
1	latest	O	['N']	[1]
2	(	O	['N']	[2]
3	third	O	['N']	[3]
4	)	O	['N']	[4]
5	report	O	['N']	[5]
6	suggests	O	['N']	[6]
7	that	O	['N']	[7]
8	the	O	['N']	[8]
9	safety	O	['N']	[9]
10	profile	O	['N']	[10]
11	should	O	['N']	[11]
12	be	O	['N']	[12]
13	reexamined	O	['N']	[13]
14	and	O	['N']	[14]
15	at	O	['N']	[15]
16	least	O	['N']	[16]
17	raises	O	['N']	[17]
18	the	O	['N']	[18]
19	question	O	['N']	[19]
20	of	O	['N']	[20]
21	potential	O	['N']	[21]
22	renal	B	['N']	[22]
23	toxicity	I-Adverse_Effect	['N']	[23]
24	of	O	['N']	[24]
25	interferons	B-Drug	['Causes']	[23]
26	in	O	['N']	[26]
27	MS	O	['N']	[27]
28	.	O	['N']	[28]
#59
0	Severe	B	['N']	[0]
1	hepatotoxicity	I-Adverse_Effect	['N']	[1]
2	related	O	['N']	[2]
3	to	O	['N']	[3]
4	benzarone	B-Drug	['Causes']	[1]
5	:	O	['N']	[5]
6	a	O	['N']	[6]
7	report	O	['N']	[7]
8	of	O	['N']	[8]
9	three	O	['N']	[9]
10	cases	O	['N']	[10]
11	with	O	['N']	[11]
12	two	O	['N']	[12]
13	fatalities	O	['N']	[13]
14	.	O	['N']	[14]
#60
0	Concomitant	O	['N']	[0]
1	administration	O	['N']	[1]
2	of	O	['N']	[2]
3	lithium	O	['N']	[3]
4	with	O	['N']	[4]
5	olanzapine	B-Drug	['Causes']	[12]
6	may	O	['N']	[6]
7	place	O	['N']	[7]
8	patients	O	['N']	[8]
9	at	O	['N']	[9]
10	risk	O	['N']	[10]
11	for	O	['N']	[11]
12	NMS	B-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#61
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	concluded	O	['N']	[2]
3	that	O	['N']	[3]
4	simultaneous	O	['N']	[4]
5	administration	O	['N']	[5]
6	of	O	['N']	[6]
7	ciprofloxacin	O	['N']	[7]
8	and	O	['N']	[8]
9	tazobactam	O	['N']	[9]
10	/	O	['N']	[10]
11	piperacillin	B-Drug	['Causes']	[15]
12	may	O	['N']	[12]
13	cause	O	['N']	[13]
14	marked	O	['N']	[14]
15	thrombocytosis	B-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#62
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	experienced	O	['N']	[2]
3	hallucinations	O	['N']	[3]
4	,	O	['N']	[4]
5	agitation	O	['N']	[5]
6	,	O	['N']	[6]
7	vomiting	O	['N']	[7]
8	,	O	['N']	[8]
9	tachycardia	O	['N']	[9]
10	and	O	['N']	[10]
11	seizures	B-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	ingestion	O	['N']	[13]
14	of	O	['N']	[14]
15	1050	O	['N']	[15]
16	(	O	['N']	[16]
17	48	O	['N']	[17]
18	mg	O	['N']	[18]
19	/	O	['N']	[19]
20	kg	O	['N']	[20]
21	)	O	['N']	[21]
22	of	O	['N']	[22]
23	extended	O	['N']	[23]
24	-	O	['N']	[24]
25	release	O	['N']	[25]
26	bupropion	B-Drug	['Causes']	[11]
27	.	O	['N']	[27]
#63
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	four	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	encephalopathy	O	['N']	[5]
6	coincident	O	['N']	[6]
7	with	O	['N']	[7]
8	elevated	O	['N']	[8]
9	aluminum	-	['N']	[9]
10	levels	O	['N']	[10]
11	as	O	['N']	[11]
12	well	O	['N']	[12]
13	as	O	['N']	[13]
14	one	O	['N']	[14]
15	patient	O	['N']	[15]
16	who	O	['N']	[16]
17	developed	O	['N']	[17]
18	seizures	B-Adverse_Effect	['N']	[18]
19	while	O	['N']	[19]
20	receiving	O	['N']	[20]
21	continuous	O	['N']	[21]
22	bladder	O	['N']	[22]
23	irrigations	O	['N']	[23]
24	with	O	['N']	[24]
25	alum	O	['N']	[25]
26	.	O	['N']	[26]
#64
0	He	O	['N']	[0]
1	had	O	['N']	[1]
2	been	O	['N']	[2]
3	taking	O	['N']	[3]
4	trimethoprim	O	['N']	[4]
5	-	O	['N']	[5]
6	sulfamethoxazole	B-Drug	['Causes']	[22]
7	for	O	['N']	[7]
8	approximately	O	['N']	[8]
9	eight	O	['N']	[9]
10	days	O	['N']	[10]
11	when	O	['N']	[11]
12	he	O	['N']	[12]
13	revisited	O	['N']	[13]
14	his	O	['N']	[14]
15	family	O	['N']	[15]
16	physician	O	['N']	[16]
17	,	O	['N']	[17]
18	complaining	O	['N']	[18]
19	of	O	['N']	[19]
20	headaches	O	['N']	[20]
21	,	O	['N']	[21]
22	dizziness	B-Adverse_Effect	['N']	[22]
23	,	O	['N']	[23]
24	difficulty	O	['N']	[24]
25	with	O	['N']	[25]
26	speech	O	['N']	[26]
27	,	O	['N']	[27]
28	weakness	O	['N']	[28]
29	,	O	['N']	[29]
30	and	O	['N']	[30]
31	itching	O	['N']	[31]
32	on	O	['N']	[32]
33	the	O	['N']	[33]
34	trunk	O	['N']	[34]
35	of	O	['N']	[35]
36	his	O	['N']	[36]
37	body	O	['N']	[37]
38	and	O	['N']	[38]
39	legs	O	['N']	[39]
40	,	O	['N']	[40]
41	where	O	['N']	[41]
42	a	O	['N']	[42]
43	maculopapular	O	['N']	[43]
44	rash	O	['N']	[44]
45	was	O	['N']	[45]
46	noted	O	['N']	[46]
47	.	O	['N']	[47]
#65
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	showed	O	['N']	[2]
3	sequential	O	['N']	[3]
4	manifestation	O	['N']	[4]
5	from	O	['N']	[5]
6	transient	O	['N']	[6]
7	thyrotoxicosis	O	['N']	[7]
8	to	O	['N']	[8]
9	the	O	['N']	[9]
10	appearance	O	['N']	[10]
11	of	O	['N']	[11]
12	TSH	O	['N']	[12]
13	-	O	['N']	[13]
14	receptor	O	['N']	[14]
15	autoantibodies	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	then	O	['N']	[18]
19	the	O	['N']	[19]
20	occurrence	O	['N']	[20]
21	of	O	['N']	[21]
22	Graves	B	['N']	[22]
23	'	I	['N']	[23]
24	hyperthyroidism	I-Adverse_Effect	['N']	[24]
25	during	O	['N']	[25]
26	IFN	B-Drug	['Causes']	[24]
27	therapy	O	['N']	[27]
28	.	O	['N']	[28]
#66
0	Intravenous	O	['N']	[0]
1	verapamil	B-Drug	['Causes']	[18]
2	therapy	O	['N']	[2]
3	in	O	['N']	[3]
4	babies	O	['N']	[4]
5	may	O	['N']	[5]
6	cause	O	['N']	[6]
7	apnea	O	['N']	[7]
8	,	O	['N']	[8]
9	hypotension	O	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	bradycardia	O	['N']	[12]
13	;	O	['N']	[13]
14	continued	O	['N']	[14]
15	episodes	O	['N']	[15]
16	of	O	['N']	[16]
17	atrial	B	['N']	[17]
18	flutter	I-Adverse_Effect	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	child	O	['N']	[21]
22	may	O	['N']	[22]
23	cause	O	['N']	[23]
24	sudden	O	['N']	[24]
25	death	O	['N']	[25]
26	;	O	['N']	[26]
27	quinidine	O	['N']	[27]
28	may	O	['N']	[28]
29	be	O	['N']	[29]
30	related	O	['N']	[30]
31	to	O	['N']	[31]
32	the	O	['N']	[32]
33	death	O	['N']	[33]
34	;	O	['N']	[34]
35	children	O	['N']	[35]
36	with	O	['N']	[36]
37	"	O	['N']	[37]
38	familial	O	['N']	[38]
39	seizure	O	['N']	[39]
40	disorders	O	['N']	[40]
41	"	O	['N']	[41]
42	may	O	['N']	[42]
43	in	O	['N']	[43]
44	fact	O	['N']	[44]
45	have	O	['N']	[45]
46	the	O	['N']	[46]
47	long	O	['N']	[47]
48	QT	O	['N']	[48]
49	interval	O	['N']	[49]
50	syndrome	O	['N']	[50]
51	.	O	['N']	[51]
#67
0	Hyperkalaemia	B-Adverse_Effect	['N']	[0]
1	with	O	['N']	[1]
2	renal	O	['N']	[2]
3	tubular	O	['N']	[3]
4	dysfunction	O	['N']	[4]
5	by	O	['N']	[5]
6	sulfamethoxazole	B	['N']	[6]
7	-	I	['N']	[7]
8	trimethoprim	I-Drug	['Causes']	[0]
9	for	O	['N']	[9]
10	Pneumocystis	O	['N']	[10]
11	carinii	O	['N']	[11]
12	pneumonia	O	['N']	[12]
13	in	O	['N']	[13]
14	patients	O	['N']	[14]
15	with	O	['N']	[15]
16	lymphoid	O	['N']	[16]
17	malignancy	O	['N']	[17]
18	.	O	['N']	[18]
#68
0	Angioimmunoblastic	B	['N']	[0]
1	lymphadenopathy	I	['N']	[1]
2	with	I	['N']	[2]
3	dysproteinemia	I-Adverse_Effect	['N']	[3]
4	following	O	['N']	[4]
5	doxycycline	B-Drug	['Causes']	[3]
6	administration	O	['N']	[6]
7	.	O	['N']	[7]
#69
0	Based	O	['N']	[0]
1	on	O	['N']	[1]
2	the	O	['N']	[2]
3	clinical	O	['N']	[3]
4	status	O	['N']	[4]
5	of	O	['N']	[5]
6	the	O	['N']	[6]
7	patient	O	['N']	[7]
8	,	O	['N']	[8]
9	it	O	['N']	[9]
10	was	O	['N']	[10]
11	suspected	O	['N']	[11]
12	that	O	['N']	[12]
13	several	O	['N']	[13]
14	conditions	O	['N']	[14]
15	contributed	O	['N']	[15]
16	to	O	['N']	[16]
17	the	O	['N']	[17]
18	abnormal	B	['N']	[18]
19	hypersensitivity	I-Adverse_Effect	['N']	[19]
20	to	O	['N']	[20]
21	warfarin	B-Drug	['Causes']	[19]
22	.	O	['N']	[22]
#70
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	17-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	male	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	chest	O	['N']	[12]
13	pain	O	['N']	[13]
14	,	O	['N']	[14]
15	elevated	O	['N']	[15]
16	cardiac	O	['N']	[16]
17	biomarkers	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	acute	B	['N']	[20]
21	left	I	['N']	[21]
22	ventricular	I	['N']	[22]
23	dysfunction	I-Adverse_Effect	['N']	[23]
24	following	O	['N']	[24]
25	a	O	['N']	[25]
26	single	O	['N']	[26]
27	dose	O	['N']	[27]
28	of	O	['N']	[28]
29	methylphenidate	B-Drug	['Causes']	[23]
30	.	O	['N']	[30]
#71
0	We	O	['N']	[0]
1	discuss	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	severe	O	['N']	[6]
7	renal	O	['N']	[7]
8	tubular	O	['N']	[8]
9	dysfunction	O	['N']	[9]
10	secondary	O	['N']	[10]
11	to	O	['N']	[11]
12	short	O	['N']	[12]
13	-	O	['N']	[13]
14	term	O	['N']	[14]
15	therapy	O	['N']	[15]
16	with	O	['N']	[16]
17	Amikacin	B-Drug	['Causes']	[26]
18	,	O	['N']	[18]
19	resulting	O	['N']	[19]
20	in	O	['N']	[20]
21	refractory	O	['N']	[21]
22	hypokalemia	O	['N']	[22]
23	,	O	['N']	[23]
24	hypocalcemia	O	['N']	[24]
25	,	O	['N']	[25]
26	hypomagnesemia	B-Adverse_Effect	['N']	[26]
27	,	O	['N']	[27]
28	metabolic	O	['N']	[28]
29	alkalosis	O	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	polyuria	O	['N']	[32]
33	.	O	['N']	[33]
#72
0	Interferon	O	['N']	[0]
1	-	O	['N']	[1]
2	alpha	O	['N']	[2]
3	(	O	['N']	[3]
4	IFN	B	['N']	[4]
5	-	I	['N']	[5]
6	alpha	I-Drug	['Causes']	[15]
7	)	O	['N']	[7]
8	may	O	['N']	[8]
9	precipitate	O	['N']	[9]
10	or	O	['N']	[10]
11	exacerbate	O	['N']	[11]
12	the	O	['N']	[12]
13	occurrence	O	['N']	[13]
14	of	O	['N']	[14]
15	MPGN	B-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#73
0	Detection	O	['N']	[0]
1	of	O	['N']	[1]
2	activated	O	['N']	[2]
3	eosinophils	O	['N']	[3]
4	in	O	['N']	[4]
5	nasal	O	['N']	[5]
6	polyps	O	['N']	[6]
7	of	O	['N']	[7]
8	an	O	['N']	[8]
9	aspirin	B-Drug	['Causes']	[12]
10	-	O	['N']	[10]
11	induced	O	['N']	[11]
12	asthma	B-Adverse_Effect	['N']	[12]
13	patient	O	['N']	[13]
14	.	O	['N']	[14]
#74
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	assess	O	['N']	[3]
4	the	O	['N']	[4]
5	nature	O	['N']	[5]
6	,	O	['N']	[6]
7	incidence	O	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	risk	O	['N']	[10]
11	factors	O	['N']	[11]
12	of	O	['N']	[12]
13	retinopathy	B-Adverse_Effect	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	pegylated	B	['N']	[16]
17	interferon	I-Drug	['Causes']	[13]
18	and	O	['N']	[18]
19	ribavirin	O	['N']	[19]
20	combination	O	['N']	[20]
21	therapy	O	['N']	[21]
22	in	O	['N']	[22]
23	chronic	O	['N']	[23]
24	hepatitis	O	['N']	[24]
25	C	O	['N']	[25]
26	patients	O	['N']	[26]
27	.	O	['N']	[27]
#75
0	Reye	B	['N']	[0]
1	syndrome	I-Adverse_Effect	['N']	[1]
2	(	O	['N']	[2]
3	RS	O	['N']	[3]
4	)	O	['N']	[4]
5	is	O	['N']	[5]
6	believed	O	['N']	[6]
7	to	O	['N']	[7]
8	occur	O	['N']	[8]
9	infrequently	O	['N']	[9]
10	among	O	['N']	[10]
11	children	O	['N']	[11]
12	receiving	O	['N']	[12]
13	long	O	['N']	[13]
14	-	O	['N']	[14]
15	term	O	['N']	[15]
16	aspirin	B-Drug	['Causes']	[1]
17	therapy	O	['N']	[17]
18	.	O	['N']	[18]
#76
0	Ticlopidine	B-Drug	['Causes']	[22]
1	is	O	['N']	[1]
2	an	O	['N']	[2]
3	oral	O	['N']	[3]
4	antiplatelet	O	['N']	[4]
5	agent	O	['N']	[5]
6	frequently	O	['N']	[6]
7	utilized	O	['N']	[7]
8	in	O	['N']	[8]
9	the	O	['N']	[9]
10	treatment	O	['N']	[10]
11	of	O	['N']	[11]
12	cerebrovascular	O	['N']	[12]
13	disease	O	['N']	[13]
14	and	O	['N']	[14]
15	is	O	['N']	[15]
16	rarely	O	['N']	[16]
17	associated	O	['N']	[17]
18	with	O	['N']	[18]
19	severe	B	['N']	[19]
20	bone	I	['N']	[20]
21	marrow	I	['N']	[21]
22	suppression	I-Adverse_Effect	['N']	[22]
23	,	O	['N']	[23]
24	typically	O	['N']	[24]
25	aplastic	O	['N']	[25]
26	anemia	O	['N']	[26]
27	.	O	['N']	[27]
#77
0	Thirty	O	['N']	[0]
1	-	O	['N']	[1]
2	six	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	AL	O	['N']	[5]
6	received	O	['N']	[6]
7	,	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	three	O	['N']	[10]
11	-	O	['N']	[11]
12	month	O	['N']	[12]
13	period	O	['N']	[13]
14	,	O	['N']	[14]
15	51	O	['N']	[15]
16	cycles	O	['N']	[16]
17	of	O	['N']	[17]
18	combined	O	['N']	[18]
19	chemotherapy	O	['N']	[19]
20	which	O	['N']	[20]
21	included	O	['N']	[21]
22	,	O	['N']	[22]
23	in	O	['N']	[23]
24	all	O	['N']	[24]
25	of	O	['N']	[25]
26	them	O	['N']	[26]
27	,	O	['N']	[27]
28	cytosine	B	['N']	[28]
29	arabinoside	I-Drug	['Causes']	[55]
30	(	O	['N']	[30]
31	ARA	O	['N']	[31]
32	-	O	['N']	[32]
33	C	O	['N']	[33]
34	)	O	['N']	[34]
35	;	O	['N']	[35]
36	among	O	['N']	[36]
37	them	O	['N']	[37]
38	,	O	['N']	[38]
39	along	O	['N']	[39]
40	with	O	['N']	[40]
41	myelosuppression	O	['N']	[41]
42	,	O	['N']	[42]
43	five	O	['N']	[43]
44	experienced	O	['N']	[44]
45	fever	O	['N']	[45]
46	,	O	['N']	[46]
47	infectious	O	['N']	[47]
48	complications	O	['N']	[48]
49	,	O	['N']	[49]
50	gastrointestinal	O	['N']	[50]
51	tract	O	['N']	[51]
52	symptoms	O	['N']	[52]
53	and	O	['N']	[53]
54	severe	B	['N']	[54]
55	myalgias	I-Adverse_Effect	['N']	[55]
56	.	O	['N']	[56]
#78
0	Isoniazid	B-Drug	['Causes']	[4]
1	causing	O	['N']	[1]
2	breast	B	['N']	[2]
3	tissue	I	['N']	[3]
4	enlargement	I-Adverse_Effect	['N']	[4]
5	has	O	['N']	[5]
6	been	O	['N']	[6]
7	very	O	['N']	[7]
8	rarely	O	['N']	[8]
9	reported	O	['N']	[9]
10	.	O	['N']	[10]
#79
0	Severe	B	['N']	[0]
1	loss	I	['N']	[1]
2	of	I	['N']	[2]
3	vision	I-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	removal	O	['N']	[5]
6	of	O	['N']	[6]
7	cataract	O	['N']	[7]
8	caused	O	['N']	[8]
9	by	O	['N']	[9]
10	intravitreal	O	['N']	[10]
11	triamcinolone	B-Drug	['Causes']	[3]
12	in	O	['N']	[12]
13	combination	O	['N']	[13]
14	with	O	['N']	[14]
15	photodynamic	O	['N']	[15]
16	therapy	O	['N']	[16]
17	for	O	['N']	[17]
18	exudative	O	['N']	[18]
19	age	O	['N']	[19]
20	-	O	['N']	[20]
21	related	O	['N']	[21]
22	macular	O	['N']	[22]
23	degeneration	O	['N']	[23]
24	.	O	['N']	[24]
#80
0	Sagittal	B	['N']	[0]
1	sinus	I	['N']	[1]
2	thrombosis	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	transient	O	['N']	[5]
6	free	O	['N']	[6]
7	protein	O	['N']	[7]
8	S	O	['N']	[8]
9	deficiency	O	['N']	[9]
10	after	O	['N']	[10]
11	L	B	['N']	[11]
12	-	I	['N']	[12]
13	asparaginase	I-Drug	['Causes']	[2]
14	treatment	O	['N']	[14]
15	:	O	['N']	[15]
16	case	O	['N']	[16]
17	report	O	['N']	[17]
18	and	O	['N']	[18]
19	review	O	['N']	[19]
20	of	O	['N']	[20]
21	the	O	['N']	[21]
22	literature	O	['N']	[22]
23	.	O	['N']	[23]
#81
0	Patients	O	['N']	[0]
1	receiving	O	['N']	[1]
2	amifostine	B-Drug	['Causes']	[20]
3	who	O	['N']	[3]
4	develop	O	['N']	[4]
5	only	O	['N']	[5]
6	fever	O	['N']	[6]
7	should	O	['N']	[7]
8	be	O	['N']	[8]
9	evaluated	O	['N']	[9]
10	for	O	['N']	[10]
11	an	O	['N']	[11]
12	adverse	O	['N']	[12]
13	drug	O	['N']	[13]
14	reaction	O	['N']	[14]
15	,	O	['N']	[15]
16	as	O	['N']	[16]
17	well	O	['N']	[17]
18	as	O	['N']	[18]
19	for	O	['N']	[19]
20	sepsis	B-Adverse_Effect	['N']	[20]
21	and	O	['N']	[21]
22	fevers	O	['N']	[22]
23	of	O	['N']	[23]
24	neutropenia	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	it	O	['N']	[27]
28	may	O	['N']	[28]
29	be	O	['N']	[29]
30	necessary	O	['N']	[30]
31	to	O	['N']	[31]
32	discontinue	O	['N']	[32]
33	the	O	['N']	[33]
34	drug	O	['N']	[34]
35	.	O	['N']	[35]
#82
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	the	O	['N']	[4]
5	clinical	O	['N']	[5]
6	and	O	['N']	[6]
7	electrophysiological	O	['N']	[7]
8	findings	O	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	young	O	['N']	[11]
12	boy	O	['N']	[12]
13	with	O	['N']	[13]
14	decreased	O	['N']	[14]
15	vision	O	['N']	[15]
16	possibly	O	['N']	[16]
17	due	O	['N']	[17]
18	to	O	['N']	[18]
19	retinal	B	['N']	[19]
20	damage	I-Adverse_Effect	['N']	[20]
21	by	O	['N']	[21]
22	rifabutin	B-Drug	['Causes']	[20]
23	.	O	['N']	[23]
#83
0	Metoclopramide	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	parkinsonism	B-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	not	O	['N']	[5]
6	rare	O	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	appropriate	O	['N']	[9]
10	dose	O	['N']	[10]
11	reduction	O	['N']	[11]
12	in	O	['N']	[12]
13	patients	O	['N']	[13]
14	with	O	['N']	[14]
15	renal	O	['N']	[15]
16	failure	O	['N']	[16]
17	will	O	['N']	[17]
18	help	O	['N']	[18]
19	reduce	O	['N']	[19]
20	the	O	['N']	[20]
21	incidence	O	['N']	[21]
22	of	O	['N']	[22]
23	this	O	['N']	[23]
24	morbidity	O	['N']	[24]
25	.	O	['N']	[25]
#84
0	Chronic	O	['N']	[0]
1	myelogenous	O	['N']	[1]
2	leukemia	O	['N']	[2]
3	(	O	['N']	[3]
4	CML	O	['N']	[4]
5	)	O	['N']	[5]
6	,	O	['N']	[6]
7	hepatitis	O	['N']	[7]
8	C	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	interferon	B	['N']	[11]
12	alpha	I-Drug	['Causes']	[22]
13	(	O	['N']	[13]
14	IFNalpha	O	['N']	[14]
15	)	O	['N']	[15]
16	have	O	['N']	[16]
17	all	O	['N']	[17]
18	been	O	['N']	[18]
19	associated	O	['N']	[19]
20	with	O	['N']	[20]
21	renal	B	['N']	[21]
22	dysfunction	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#85
0	Anaphylactic	B	['N']	[0]
1	reaction	I-Adverse_Effect	['N']	[1]
2	to	O	['N']	[2]
3	oral	O	['N']	[3]
4	prednisone	B-Drug	['Causes']	[1]
5	:	O	['N']	[5]
6	a	O	['N']	[6]
7	case	O	['N']	[7]
8	report	O	['N']	[8]
9	and	O	['N']	[9]
10	review	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	literature	O	['N']	[13]
14	.	O	['N']	[14]
#86
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	ST	O	['N']	[5]
6	elevation	O	['N']	[6]
7	in	O	['N']	[7]
8	right	O	['N']	[8]
9	precordial	O	['N']	[9]
10	leads	O	['N']	[10]
11	compatible	O	['N']	[11]
12	with	O	['N']	[12]
13	type	B	['N']	[13]
14	1	I	['N']	[14]
15	Brugada	I	['N']	[15]
16	syndrome	I-Adverse_Effect	['N']	[16]
17	following	O	['N']	[17]
18	administration	O	['N']	[18]
19	of	O	['N']	[19]
20	propafenone	B-Drug	['Causes']	[16]
21	in	O	['N']	[21]
22	a	O	['N']	[22]
23	patient	O	['N']	[23]
24	with	O	['N']	[24]
25	Wolff	O	['N']	[25]
26	-	O	['N']	[26]
27	Parkinson	O	['N']	[27]
28	-	O	['N']	[28]
29	White	O	['N']	[29]
30	syndrome	O	['N']	[30]
31	who	O	['N']	[31]
32	was	O	['N']	[32]
33	receiving	O	['N']	[33]
34	lithium	O	['N']	[34]
35	at	O	['N']	[35]
36	concentrations	O	['N']	[36]
37	within	O	['N']	[37]
38	therapeutic	O	['N']	[38]
39	levels	O	['N']	[39]
40	.	O	['N']	[40]
#87
0	Nephropathy	B-Adverse_Effect	['N']	[0]
1	caused	O	['N']	[1]
2	by	O	['N']	[2]
3	methicillin	B-Drug	['Causes']	[0]
4	therapy	O	['N']	[4]
5	for	O	['N']	[5]
6	staphylococcal	O	['N']	[6]
7	septicemia	O	['N']	[7]
8	.	O	['N']	[8]
#88
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	priapism	B-Adverse_Effect	['N']	[9]
10	after	O	['N']	[10]
11	oral	O	['N']	[11]
12	intake	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	phenothiazine	O	['N']	[15]
16	prothipendylhydrochloride	B-Drug	['Causes']	[9]
17	.	O	['N']	[17]
#89
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	had	O	['N']	[2]
3	radiation	O	['N']	[3]
4	fibrosis	O	['N']	[4]
5	,	O	['N']	[5]
6	so	O	['N']	[6]
7	we	O	['N']	[7]
8	suggest	O	['N']	[8]
9	that	O	['N']	[9]
10	radiation	O	['N']	[10]
11	fibrosis	O	['N']	[11]
12	may	O	['N']	[12]
13	be	O	['N']	[13]
14	another	O	['N']	[14]
15	contributor	O	['N']	[15]
16	of	O	['N']	[16]
17	the	O	['N']	[17]
18	occurrence	O	['N']	[18]
19	of	O	['N']	[19]
20	ILD	B-Adverse_Effect	['N']	[20]
21	in	O	['N']	[21]
22	patients	O	['N']	[22]
23	taking	O	['N']	[23]
24	erlotinib	B-Drug	['Causes']	[20]
25	.	O	['N']	[25]
#90
0	Presently	O	['N']	[0]
1	,	O	['N']	[1]
2	treatment	O	['N']	[2]
3	of	O	['N']	[3]
4	acute	O	['N']	[4]
5	ibuprofen	B-Drug	['Causes']	[6]
6	intoxication	I-Adverse_Effect	['N']	[6]
7	with	O	['N']	[7]
8	complications	O	['N']	[8]
9	requires	O	['N']	[9]
10	supportive	O	['N']	[10]
11	therapy	O	['N']	[11]
12	until	O	['N']	[12]
13	the	O	['N']	[13]
14	symptoms	O	['N']	[14]
15	resolve	O	['N']	[15]
16	over	O	['N']	[16]
17	24	O	['N']	[17]
18	to	O	['N']	[18]
19	48	O	['N']	[19]
20	hours	O	['N']	[20]
21	.	O	['N']	[21]
#91
0	Rhabdomyolysis	B-Adverse_Effect	['N']	[0]
1	has	O	['N']	[1]
2	been	O	['N']	[2]
3	recognized	O	['N']	[3]
4	as	O	['N']	[4]
5	a	O	['N']	[5]
6	complication	O	['N']	[6]
7	of	O	['N']	[7]
8	tocolytic	O	['N']	[8]
9	therapy	O	['N']	[9]
10	with	O	['N']	[10]
11	ritodrine	B	['N']	[11]
12	hydrochloride	I-Drug	['Causes']	[0]
13	.	O	['N']	[13]
#92
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	previously	O	['N']	[6]
7	healthy	O	['N']	[7]
8	,	O	['N']	[8]
9	postmenopausal	O	['N']	[9]
10	woman	O	['N']	[10]
11	who	O	['N']	[11]
12	developed	O	['N']	[12]
13	anticonvulsant	B	['N']	[13]
14	hypersensitivity	I	['N']	[14]
15	syndrome	I-Adverse_Effect	['N']	[15]
16	while	O	['N']	[16]
17	taking	O	['N']	[17]
18	Bellamine	B	['N']	[18]
19	S	I-Drug	['Causes']	[15]
20	(	O	['N']	[20]
21	belladonna	O	['N']	[21]
22	alkaloids	O	['N']	[22]
23	;	O	['N']	[23]
24	ergotamine	O	['N']	[24]
25	;	O	['N']	[25]
26	phenobarbital	O	['N']	[26]
27	)	O	['N']	[27]
28	for	O	['N']	[28]
29	hot	O	['N']	[29]
30	flashes	O	['N']	[30]
31	.	O	['N']	[31]
#93
0	The	O	['N']	[0]
1	harlequin	B	['N']	[1]
2	color	I	['N']	[2]
3	change	I-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	association	O	['N']	[5]
6	with	O	['N']	[6]
7	prostaglandin	B	['N']	[7]
8	E1	I-Drug	['Causes']	[3]
9	.	O	['N']	[9]
#94
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	Stevens	B	['N']	[5]
6	-	I	['N']	[6]
7	Johnson	I	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	/	O	['N']	[9]
10	toxic	O	['N']	[10]
11	epidermal	O	['N']	[11]
12	necrolysis	O	['N']	[12]
13	(	O	['N']	[13]
14	SJS	O	['N']	[14]
15	/	O	['N']	[15]
16	TEN	O	['N']	[16]
17	)	O	['N']	[17]
18	secondary	O	['N']	[18]
19	to	O	['N']	[19]
20	trimethoprim	O	['N']	[20]
21	-	O	['N']	[21]
22	sulfamethoxazole	O	['N']	[22]
23	(	O	['N']	[23]
24	TMP	B	['N']	[24]
25	-	I	['N']	[25]
26	Sx	I-Drug	['Causes']	[8]
27	)	O	['N']	[27]
28	therapy	O	['N']	[28]
29	for	O	['N']	[29]
30	presumed	O	['N']	[30]
31	community	O	['N']	[31]
32	-	O	['N']	[32]
33	associated	O	['N']	[33]
34	methicillin	O	['N']	[34]
35	-	O	['N']	[35]
36	resistant	O	['N']	[36]
37	Staphylococcus	O	['N']	[37]
38	aureus	O	['N']	[38]
39	(	O	['N']	[39]
40	CA	O	['N']	[40]
41	-	O	['N']	[41]
42	MRSA	O	['N']	[42]
43	)	O	['N']	[43]
44	infection	O	['N']	[44]
45	.	O	['N']	[45]
#95
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	several	O	['N']	[2]
3	case	O	['N']	[3]
4	reports	O	['N']	[4]
5	have	O	['N']	[5]
6	suggested	O	['N']	[6]
7	that	O	['N']	[7]
8	clozapine	B-Drug	['Causes']	[12]
9	could	O	['N']	[9]
10	also	O	['N']	[10]
11	cause	O	['N']	[11]
12	TD	B-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#96
0	All	O	['N']	[0]
1	patients	O	['N']	[1]
2	had	O	['N']	[2]
3	taken	O	['N']	[3]
4	phenytoin	B-Drug	['Causes']	[28]
5	for	O	['N']	[5]
6	variable	O	['N']	[6]
7	time	O	['N']	[7]
8	periods	O	['N']	[8]
9	(	O	['N']	[9]
10	range	O	['N']	[10]
11	16	O	['N']	[11]
12	-	O	['N']	[12]
13	80	O	['N']	[13]
14	days	O	['N']	[14]
15	;	O	['N']	[15]
16	mean	O	['N']	[16]
17	:	O	['N']	[17]
18	40	O	['N']	[18]
19	)	O	['N']	[19]
20	and	O	['N']	[20]
21	were	O	['N']	[21]
22	on	O	['N']	[22]
23	the	O	['N']	[23]
24	medication	O	['N']	[24]
25	when	O	['N']	[25]
26	the	O	['N']	[26]
27	skin	B	['N']	[27]
28	lesions	I-Adverse_Effect	['N']	[28]
29	first	O	['N']	[29]
30	appeared	O	['N']	[30]
31	.	O	['N']	[31]
#97
0	Pathogenesis	O	['N']	[0]
1	of	O	['N']	[1]
2	methotrexate	B-Drug	['Causes']	[6]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	papular	B	['N']	[5]
6	eruption	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	psoriasis	O	['N']	[8]
9	may	O	['N']	[9]
10	involve	O	['N']	[10]
11	immune	O	['N']	[11]
12	mechanisms	O	['N']	[12]
13	other	O	['N']	[13]
14	than	O	['N']	[14]
15	those	O	['N']	[15]
16	of	O	['N']	[16]
17	methotrexate	O	['N']	[17]
18	-	O	['N']	[18]
19	induced	O	['N']	[19]
20	cutaneous	O	['N']	[20]
21	vasculitis	O	['N']	[21]
22	in	O	['N']	[22]
23	collagen	O	['N']	[23]
24	vascular	O	['N']	[24]
25	disease	O	['N']	[25]
26	.	O	['N']	[26]
#98
0	Reduction	O	['N']	[0]
1	of	O	['N']	[1]
2	methylprednisolone	B-Drug	['Causes']	[13]
3	dosage	O	['N']	[3]
4	rather	O	['N']	[4]
5	than	O	['N']	[5]
6	insulin	O	['N']	[6]
7	therapy	O	['N']	[7]
8	resulted	O	['N']	[8]
9	in	O	['N']	[9]
10	better	O	['N']	[10]
11	control	O	['N']	[11]
12	of	O	['N']	[12]
13	glycemia	B-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#99
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	patient	O	['N']	[3]
4	developed	O	['N']	[4]
5	a	O	['N']	[5]
6	bilaterally	B	['N']	[6]
7	symmetric	I	['N']	[7]
8	bull's	I	['N']	[8]
9	-	I	['N']	[9]
10	eye	I	['N']	[10]
11	maculopathy	I-Adverse_Effect	['N']	[11]
12	45	O	['N']	[12]
13	years	O	['N']	[13]
14	after	O	['N']	[14]
15	taking	O	['N']	[15]
16	quinacrine	B-Drug	['Causes']	[11]
17	for	O	['N']	[17]
18	18	O	['N']	[18]
19	months	O	['N']	[19]
20	as	O	['N']	[20]
21	prophylaxis	O	['N']	[21]
22	against	O	['N']	[22]
23	malaria	O	['N']	[23]
24	.	O	['N']	[24]
#100
0	The	O	['N']	[0]
1	more	O	['N']	[1]
2	common	O	['N']	[2]
3	grade	O	['N']	[3]
4	3	O	['N']	[4]
5	or	O	['N']	[5]
6	4	O	['N']	[6]
7	adverse	O	['N']	[7]
8	effects	O	['N']	[8]
9	of	O	['N']	[9]
10	sunitinib	B-Drug	['Causes']	[12]
11	include	O	['N']	[11]
12	hypertension	B-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	fatigue	O	['N']	[14]
15	,	O	['N']	[15]
16	hand	O	['N']	[16]
17	-	O	['N']	[17]
18	foot	O	['N']	[18]
19	syndrome	O	['N']	[19]
20	,	O	['N']	[20]
21	elevated	O	['N']	[21]
22	lipase	O	['N']	[22]
23	and	O	['N']	[23]
24	lymphopenia	O	['N']	[24]
25	.	O	['N']	[25]
#101
0	The	O	['N']	[0]
1	literature	O	['N']	[1]
2	search	O	['N']	[2]
3	revealed	O	['N']	[3]
4	22	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	hypersensitivity	B	['N']	[7]
8	reaction	I-Adverse_Effect	['N']	[8]
9	to	O	['N']	[9]
10	cyclosporine	B-Drug	['Causes']	[8]
11	.	O	['N']	[11]
#102
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	Stevens	O	['N']	[5]
6	-	O	['N']	[6]
7	Johnson	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	/	O	['N']	[9]
10	toxic	B	['N']	[10]
11	epidermal	I	['N']	[11]
12	necrolysis	I-Adverse_Effect	['N']	[12]
13	(	O	['N']	[13]
14	SJS	O	['N']	[14]
15	/	O	['N']	[15]
16	TEN	O	['N']	[16]
17	)	O	['N']	[17]
18	secondary	O	['N']	[18]
19	to	O	['N']	[19]
20	trimethoprim	B	['N']	[20]
21	-	I	['N']	[21]
22	sulfamethoxazole	I-Drug	['Causes']	[12]
23	(	O	['N']	[23]
24	TMP	O	['N']	[24]
25	-	O	['N']	[25]
26	Sx	O	['N']	[26]
27	)	O	['N']	[27]
28	therapy	O	['N']	[28]
29	for	O	['N']	[29]
30	presumed	O	['N']	[30]
31	community	O	['N']	[31]
32	-	O	['N']	[32]
33	associated	O	['N']	[33]
34	methicillin	O	['N']	[34]
35	-	O	['N']	[35]
36	resistant	O	['N']	[36]
37	Staphylococcus	O	['N']	[37]
38	aureus	O	['N']	[38]
39	(	O	['N']	[39]
40	CA	O	['N']	[40]
41	-	O	['N']	[41]
42	MRSA	O	['N']	[42]
43	)	O	['N']	[43]
44	infection	O	['N']	[44]
45	.	O	['N']	[45]
#103
0	After	O	['N']	[0]
1	5-ASA	B-Drug	['Causes']	[6]
2	was	O	['N']	[2]
3	discontinued	O	['N']	[3]
4	,	O	['N']	[4]
5	the	O	['N']	[5]
6	polyneuropathy	B-Adverse_Effect	['N']	[6]
7	symptoms	O	['N']	[7]
8	recovered	O	['N']	[8]
9	gradually	O	['N']	[9]
10	.	O	['N']	[10]
#104
0	Although	O	['N']	[0]
1	no	O	['N']	[1]
2	coagulation	O	['N']	[2]
3	study	O	['N']	[3]
4	was	O	['N']	[4]
5	done	O	['N']	[5]
6	and	O	['N']	[6]
7	the	O	['N']	[7]
8	Meckel	O	['N']	[8]
9	's	O	['N']	[9]
10	diverticulum	O	['N']	[10]
11	is	O	['N']	[11]
12	normally	O	['N']	[12]
13	associated	O	['N']	[13]
14	with	O	['N']	[14]
15	bleeding	O	['N']	[15]
16	,	O	['N']	[16]
17	the	O	['N']	[17]
18	particular	O	['N']	[18]
19	intensity	O	['N']	[19]
20	of	O	['N']	[20]
21	the	O	['N']	[21]
22	following	O	['N']	[22]
23	hemorrhage	B-Adverse_Effect	['N']	[23]
24	may	O	['N']	[24]
25	have	O	['N']	[25]
26	been	O	['N']	[26]
27	favored	O	['N']	[27]
28	by	O	['N']	[28]
29	metformin	B-Drug	['Causes']	[23]
30	.	O	['N']	[30]
#105
0	A	O	['N']	[0]
1	high	O	['N']	[1]
2	dose	O	['N']	[2]
3	of	O	['N']	[3]
4	cotrimoxazole	B-Drug	['Causes']	[23]
5	induced	O	['N']	[5]
6	hyperkalaemia	O	['N']	[6]
7	with	O	['N']	[7]
8	the	O	['N']	[8]
9	elevation	O	['N']	[9]
10	of	O	['N']	[10]
11	serum	O	['N']	[11]
12	creatinine	O	['N']	[12]
13	and	O	['N']	[13]
14	blood	O	['N']	[14]
15	urea	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	increased	B	['N']	[18]
19	urinary	I	['N']	[19]
20	N	I	['N']	[20]
21	-	I	['N']	[21]
22	acetyl	I	['N']	[22]
23	glucosaminase	I-Adverse_Effect	['N']	[23]
24	after	O	['N']	[24]
25	several	O	['N']	[25]
26	days	O	['N']	[26]
27	of	O	['N']	[27]
28	the	O	['N']	[28]
29	drug	O	['N']	[29]
30	administration	O	['N']	[30]
31	in	O	['N']	[31]
32	these	O	['N']	[32]
33	patients	O	['N']	[33]
34	;	O	['N']	[34]
35	one	O	['N']	[35]
36	patient	O	['N']	[36]
37	became	O	['N']	[37]
38	unconscious	O	['N']	[38]
39	.	O	['N']	[39]
#106
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	suffering	O	['N']	[2]
3	from	O	['N']	[3]
4	heparin	B-Drug	['Causes']	[13]
5	-	O	['N']	[5]
6	associated	O	['N']	[6]
7	thrombocytopenia	O	['N']	[7]
8	(	O	['N']	[8]
9	HAT	O	['N']	[9]
10	)	O	['N']	[10]
11	,	O	['N']	[11]
12	recurrent	B	['N']	[12]
13	arteriothromboses	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	acute	O	['N']	[16]
17	renal	O	['N']	[17]
18	failure	O	['N']	[18]
19	after	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	standard	O	['N']	[22]
23	heparin	O	['N']	[23]
24	is	O	['N']	[24]
25	described	O	['N']	[25]
26	.	O	['N']	[26]
#107
0	Severe	O	['N']	[0]
1	dapsone	B-Drug	['Causes']	[3]
2	hypersensitivity	B	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#108
0	Surprisingly	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	found	O	['N']	[3]
4	that	O	['N']	[4]
5	three	O	['N']	[5]
6	patients	O	['N']	[6]
7	appeared	O	['N']	[7]
8	to	O	['N']	[8]
9	develop	O	['N']	[9]
10	tardive	B	['N']	[10]
11	OGC	I-Adverse_Effect	['N']	[11]
12	while	O	['N']	[12]
13	taking	O	['N']	[13]
14	clozapine	B-Drug	['Causes']	[11]
15	.	O	['N']	[15]
#109
0	Flurbiprofen	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	acute	B	['N']	[3]
4	tubulointerstitial	I	['N']	[4]
5	nephritis	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#110
0	Massive	O	['N']	[0]
1	CBZ	B-Drug	['Causes']	[24]
2	OD	O	['N']	[2]
3	may	O	['N']	[3]
4	produce	O	['N']	[4]
5	a	O	['N']	[5]
6	reversible	O	['N']	[6]
7	encephalopathy	O	['N']	[7]
8	that	O	['N']	[8]
9	includes	O	['N']	[9]
10	cortical	O	['N']	[10]
11	hyperexcitability	O	['N']	[11]
12	,	O	['N']	[12]
13	a	O	['N']	[13]
14	profound	O	['N']	[14]
15	burst	O	['N']	[15]
16	-	O	['N']	[16]
17	suppression	O	['N']	[17]
18	EEG	O	['N']	[18]
19	pattern	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	cranial	B	['N']	[22]
23	nerve	I	['N']	[23]
24	areflexia	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#111
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	two	O	['N']	[2]
3	patients	O	['N']	[3]
4	in	O	['N']	[4]
5	whom	O	['N']	[5]
6	painful	B	['N']	[6]
7	erosions	I	['N']	[7]
8	of	I	['N']	[8]
9	their	I	['N']	[9]
10	psoriasis	I-Adverse_Effect	['N']	[10]
11	developed	O	['N']	[11]
12	as	O	['N']	[12]
13	the	O	['N']	[13]
14	presenting	O	['N']	[14]
15	sign	O	['N']	[15]
16	of	O	['N']	[16]
17	methotrexate	B-Drug	['Causes']	[10]
18	toxicity	O	['N']	[18]
19	and	O	['N']	[19]
20	review	O	['N']	[20]
21	the	O	['N']	[21]
22	literature	O	['N']	[22]
23	,	O	['N']	[23]
24	emphasizing	O	['N']	[24]
25	the	O	['N']	[25]
26	risk	O	['N']	[26]
27	factors	O	['N']	[27]
28	associated	O	['N']	[28]
29	with	O	['N']	[29]
30	this	O	['N']	[30]
31	manifestation	O	['N']	[31]
32	.	O	['N']	[32]
#112
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Clinicians	O	['N']	[2]
3	should	O	['N']	[3]
4	be	O	['N']	[4]
5	aware	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	risk	O	['N']	[8]
9	of	O	['N']	[9]
10	serotonin	O	['N']	[10]
11	syndrome	O	['N']	[11]
12	with	O	['N']	[12]
13	serious	O	['N']	[13]
14	extrapyramidal	O	['N']	[14]
15	reactions	O	['N']	[15]
16	in	O	['N']	[16]
17	patients	O	['N']	[17]
18	receiving	O	['N']	[18]
19	sertraline	O	['N']	[19]
20	or	O	['N']	[20]
21	venlafaxine	O	['N']	[21]
22	when	O	['N']	[22]
23	metoclopramide	B-Drug	['Dosage']	[31]
24	is	O	['N']	[24]
25	coadministered	O	['N']	[25]
26	even	O	['N']	[26]
27	in	O	['N']	[27]
28	a	O	['N']	[28]
29	single	O	['N']	[29]
30	,	O	['N']	[30]
31	conventional	B-Dose	['N']	[31]
32	dose	O	['N']	[32]
33	.	O	['N']	[33]
#113
0	Acute	B	['N']	[0]
1	non	I	['N']	[1]
2	-	I	['N']	[2]
3	lymphocytic	I	['N']	[3]
4	leukemia	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	patients	O	['N']	[6]
7	with	O	['N']	[7]
8	ovarian	O	['N']	[8]
9	carcinoma	O	['N']	[9]
10	following	O	['N']	[10]
11	long	O	['N']	[11]
12	-	O	['N']	[12]
13	term	O	['N']	[13]
14	treatment	O	['N']	[14]
15	with	O	['N']	[15]
16	Treosulfan	O	['N']	[16]
17	(=	O	['N']	[17]
18	dihydroxybusulfan	B-Drug	['Causes']	[4]
19	)	O	['N']	[19]
20	.	O	['N']	[20]
#114
0	On	O	['N']	[0]
1	day	O	['N']	[1]
2	7	O	['N']	[2]
3	of	O	['N']	[3]
4	linezolid	B-Drug	['Causes']	[26]
5	treatment	O	['N']	[5]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	patient	O	['N']	[8]
9	developed	O	['N']	[9]
10	severe	O	['N']	[10]
11	pruritus	O	['N']	[11]
12	,	O	['N']	[12]
13	macular	O	['N']	[13]
14	rash	O	['N']	[14]
15	,	O	['N']	[15]
16	facial	O	['N']	[16]
17	edema	O	['N']	[17]
18	,	O	['N']	[18]
19	eosinophilia	O	['N']	[19]
20	,	O	['N']	[20]
21	marked	B	['N']	[21]
22	increase	I	['N']	[22]
23	in	I	['N']	[23]
24	serum	I	['N']	[24]
25	creatinine	I	['N']	[25]
26	level	I-Adverse_Effect	['N']	[26]
27	,	O	['N']	[27]
28	and	O	['N']	[28]
29	mild	O	['N']	[29]
30	hepatitis	O	['N']	[30]
31	.	O	['N']	[31]
#115
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	ibuprofen	B-Drug	['Causes']	[8]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	meningitis	B-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	an	O	['N']	[10]
11	otherwise	O	['N']	[11]
12	healthy	O	['N']	[12]
13	individual	O	['N']	[13]
14	.	O	['N']	[14]
#116
0	Despite	O	['N']	[0]
1	a	O	['N']	[1]
2	postulated	O	['N']	[2]
3	dopaminergic	O	['N']	[3]
4	mechanism	O	['N']	[4]
5	,	O	['N']	[5]
6	there	O	['N']	[6]
7	seems	O	['N']	[7]
8	to	O	['N']	[8]
9	have	O	['N']	[9]
10	been	O	['N']	[10]
11	only	O	['N']	[11]
12	one	O	['N']	[12]
13	previous	O	['N']	[13]
14	report	O	['N']	[14]
15	of	O	['N']	[15]
16	amantadine	B-Drug	['Causes']	[19]
17	's	O	['N']	[17]
18	precipitating	B	['N']	[18]
19	psychosis	I-Adverse_Effect	['N']	[19]
20	in	O	['N']	[20]
21	a	O	['N']	[21]
22	schizophrenic	O	['N']	[22]
23	patient	O	['N']	[23]
24	.	O	['N']	[24]
#117
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	that	O	['N']	[4]
5	illustrate	O	['N']	[5]
6	the	O	['N']	[6]
7	use	O	['N']	[7]
8	of	O	['N']	[8]
9	lithium	B-Drug	['Causes']	[23]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	treatment	O	['N']	[12]
13	of	O	['N']	[13]
14	veterans	O	['N']	[14]
15	with	O	['N']	[15]
16	PTSD	O	['N']	[16]
17	who	O	['N']	[17]
18	complained	O	['N']	[18]
19	of	O	['N']	[19]
20	serious	O	['N']	[20]
21	problems	O	['N']	[21]
22	with	O	['N']	[22]
23	irritability	B-Adverse_Effect	['N']	[23]
24	or	O	['N']	[24]
25	angry	O	['N']	[25]
26	outbursts	O	['N']	[26]
27	.	O	['N']	[27]
#118
0	Detection	O	['N']	[0]
1	of	O	['N']	[1]
2	antineutrophil	O	['N']	[2]
3	cytoplasmic	O	['N']	[3]
4	antibody	O	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	L	B	['N']	[9]
10	-	I	['N']	[10]
11	tryptophan	I-Drug	['Causes']	[16]
12	induced	O	['N']	[12]
13	eosinophilia	B	['N']	[13]
14	-	I	['N']	[14]
15	myalgia	I	['N']	[15]
16	syndrome	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#119
0	The	O	['N']	[0]
1	typical	O	['N']	[1]
2	fluoxetine	B-Drug	['Causes']	[22]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	symptoms	O	['N']	[5]
6	of	O	['N']	[6]
7	restlessness	O	['N']	[7]
8	,	O	['N']	[8]
9	constant	O	['N']	[9]
10	pacing	O	['N']	[10]
11	,	O	['N']	[11]
12	purposeless	O	['N']	[12]
13	movements	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	feet	O	['N']	[16]
17	and	O	['N']	[17]
18	legs	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	marked	B	['N']	[21]
22	anxiety	I-Adverse_Effect	['N']	[22]
23	were	O	['N']	[23]
24	indistinguishable	O	['N']	[24]
25	from	O	['N']	[25]
26	those	O	['N']	[26]
27	of	O	['N']	[27]
28	neuroleptic	O	['N']	[28]
29	-	O	['N']	[29]
30	induced	O	['N']	[30]
31	akathisia	O	['N']	[31]
32	.	O	['N']	[32]
#120
0	Common	O	['N']	[0]
1	adverse	O	['N']	[1]
2	events	O	['N']	[2]
3	(	O	['N']	[3]
4	frequency	O	['N']	[4]
5	10	O	['N']	[5]
6	%	O	['N']	[6]
7	)	O	['N']	[7]
8	of	O	['N']	[8]
9	lacosamide	B-Drug	['Causes']	[30]
10	doses	O	['N']	[10]
11	up	O	['N']	[11]
12	to	O	['N']	[12]
13	600	O	['N']	[13]
14	mg	O	['N']	[14]
15	/	O	['N']	[15]
16	day	O	['N']	[16]
17	include	O	['N']	[17]
18	nonspecific	O	['N']	[18]
19	central	O	['N']	[19]
20	nervous	O	['N']	[20]
21	system	O	['N']	[21]
22	effects	O	['N']	[22]
23	(	O	['N']	[23]
24	e.g.	O	['N']	[24]
25	,	O	['N']	[25]
26	dizziness	O	['N']	[26]
27	,	O	['N']	[27]
28	ataxia	O	['N']	[28]
29	,	O	['N']	[29]
30	diplopia	B-Adverse_Effect	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	somnolence	O	['N']	[33]
34	)	O	['N']	[34]
35	.	O	['N']	[35]
#121
0	Leflunomide	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	infections	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	rheumatoid	O	['N']	[5]
6	arthritis	O	['N']	[6]
7	.	O	['N']	[7]
#122
0	Alternating	O	['N']	[0]
1	sinus	O	['N']	[1]
2	rhythm	O	['N']	[2]
3	and	O	['N']	[3]
4	intermittent	B	['N']	[4]
5	sinoatrial	I	['N']	[5]
6	(	I	['N']	[6]
7	S	I	['N']	[7]
8	-	I	['N']	[8]
9	A	I	['N']	[9]
10	)	I	['N']	[10]
11	block	I-Adverse_Effect	['N']	[11]
12	was	O	['N']	[12]
13	observed	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	57-year	O	['N']	[16]
17	-	O	['N']	[17]
18	old	O	['N']	[18]
19	woman	O	['N']	[19]
20	,	O	['N']	[20]
21	under	O	['N']	[21]
22	treatment	O	['N']	[22]
23	for	O	['N']	[23]
24	angina	O	['N']	[24]
25	with	O	['N']	[25]
26	80	O	['N']	[26]
27	mg	O	['N']	[27]
28	propranolol	B-Drug	['Causes']	[11]
29	daily	O	['N']	[29]
30	.	O	['N']	[30]
#123
0	A	O	['N']	[0]
1	58-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	rheumatoid	O	['N']	[6]
7	arthritis	O	['N']	[7]
8	developed	O	['N']	[8]
9	lichen	B	['N']	[9]
10	planus	I-Adverse_Effect	['N']	[10]
11	during	O	['N']	[11]
12	treatment	O	['N']	[12]
13	with	O	['N']	[13]
14	gold	B-Drug	['Causes']	[10]
15	.	O	['N']	[15]
#124
0	Subsequent	O	['N']	[0]
1	in	O	['N']	[1]
2	vivo	O	['N']	[2]
3	/	O	['N']	[3]
4	vitro	O	['N']	[4]
5	studies	O	['N']	[5]
6	clearly	O	['N']	[6]
7	demonstrated	O	['N']	[7]
8	that	O	['N']	[8]
9	the	O	['N']	[9]
10	neurological	B	['N']	[10]
11	effects	I-Adverse_Effect	['N']	[11]
12	were	O	['N']	[12]
13	due	O	['N']	[13]
14	to	O	['N']	[14]
15	a	O	['N']	[15]
16	synergistic	O	['N']	[16]
17	action	O	['N']	[17]
18	of	O	['N']	[18]
19	desferrioxamine	O	['N']	[19]
20	and	O	['N']	[20]
21	prochlorperazine	B-Drug	['Causes']	[11]
22	,	O	['N']	[22]
23	probably	O	['N']	[23]
24	resulting	O	['N']	[24]
25	in	O	['N']	[25]
26	exceptional	O	['N']	[26]
27	fluxes	O	['N']	[27]
28	of	O	['N']	[28]
29	intra	O	['N']	[29]
30	/	O	['N']	[30]
31	extra	O	['N']	[31]
32	cellular	O	['N']	[32]
33	iron	O	['N']	[33]
34	/	O	['N']	[34]
35	copper	O	['N']	[35]
36	disturbing	O	['N']	[36]
37	noradrenergic	O	['N']	[37]
38	and	O	['N']	[38]
39	serotonergic	O	['N']	[39]
40	systems	O	['N']	[40]
41	.	O	['N']	[41]
#125
0	Due	O	['N']	[0]
1	to	O	['N']	[1]
2	discomfort	O	['N']	[2]
3	,	O	['N']	[3]
4	diplopia	B-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	lagophthalmos	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	haematoma	O	['N']	[9]
10	necessitated	O	['N']	[10]
11	suspension	O	['N']	[11]
12	of	O	['N']	[12]
13	warfarin	B-Drug	['Causes']	[4]
14	therapy	O	['N']	[14]
15	and	O	['N']	[15]
16	a	O	['N']	[16]
17	surgical	O	['N']	[17]
18	evacuation	O	['N']	[18]
19	.	O	['N']	[19]
#126
0	PET	O	['N']	[0]
1	scintigraphy	O	['N']	[1]
2	of	O	['N']	[2]
3	etoposide	B-Drug	['Causes']	[7]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	pulmonary	B	['N']	[6]
7	toxicity	I-Adverse_Effect	['N']	[7]
8	.	O	['N']	[8]
#127
0	We	O	['N']	[0]
1	hypothesize	O	['N']	[1]
2	that	O	['N']	[2]
3	caffeine	B-Drug	['Causes']	[17]
4	toxicity	O	['N']	[4]
5	injured	O	['N']	[5]
6	the	O	['N']	[6]
7	muscle	O	['N']	[7]
8	cells	O	['N']	[8]
9	,	O	['N']	[9]
10	which	O	['N']	[10]
11	were	O	['N']	[11]
12	fragile	O	['N']	[12]
13	due	O	['N']	[13]
14	to	O	['N']	[14]
15	the	O	['N']	[15]
16	potassium	B	['N']	[16]
17	depletion	I-Adverse_Effect	['N']	[17]
18	induced	O	['N']	[18]
19	by	O	['N']	[19]
20	the	O	['N']	[20]
21	coexisting	O	['N']	[21]
22	hyponatremia	O	['N']	[22]
23	,	O	['N']	[23]
24	to	O	['N']	[24]
25	result	O	['N']	[25]
26	in	O	['N']	[26]
27	unusually	O	['N']	[27]
28	severe	O	['N']	[28]
29	rhabdomyolysis	O	['N']	[29]
30	.	O	['N']	[30]
#128
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	10-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	boy	O	['N']	[6]
7	with	O	['N']	[7]
8	ulcerative	O	['N']	[8]
9	colitis	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	acute	B	['N']	[12]
13	pancreatitis	I-Adverse_Effect	['N']	[13]
14	while	O	['N']	[14]
15	on	O	['N']	[15]
16	long	O	['N']	[16]
17	-	O	['N']	[17]
18	term	O	['N']	[18]
19	treatment	O	['N']	[19]
20	with	O	['N']	[20]
21	5-aminosalicylic	B	['N']	[21]
22	acid	I-Drug	['Causes']	[13]
23	.	O	['N']	[23]
#129
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	a	O	['N']	[3]
4	13-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	female	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	right	O	['N']	[10]
11	frontal	O	['N']	[11]
12	high	O	['N']	[12]
13	-	O	['N']	[13]
14	grade	O	['N']	[14]
15	glioma	O	['N']	[15]
16	and	O	['N']	[16]
17	complex	O	['N']	[17]
18	partial	O	['N']	[18]
19	seizures	O	['N']	[19]
20	who	O	['N']	[20]
21	developed	O	['N']	[21]
22	localized	B	['N']	[22]
23	purpura	I-Adverse_Effect	['N']	[23]
24	after	O	['N']	[24]
25	23	O	['N']	[25]
26	months	O	['N']	[26]
27	of	O	['N']	[27]
28	lamotrigine	B-Drug	['Causes']	[23]
29	monotherapy	O	['N']	[29]
30	.	O	['N']	[30]
#130
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	the	O	['N']	[3]
4	Rett	O	['N']	[4]
5	syndrome	O	['N']	[5]
6	with	O	['N']	[6]
7	acute	B	['N']	[7]
8	encephalopathy	I-Adverse_Effect	['N']	[8]
9	induced	O	['N']	[9]
10	during	O	['N']	[10]
11	calcium	B	['N']	[11]
12	hopantenate	I-Drug	['Causes']	[8]
13	treatment	O	['N']	[13]
14	.	O	['N']	[14]
#131
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	receiving	O	['N']	[4]
5	chronic	O	['N']	[5]
6	lithium	B-Drug	['Causes']	[13]
7	therapy	O	['N']	[7]
8	who	O	['N']	[8]
9	presented	O	['N']	[9]
10	with	O	['N']	[10]
11	a	O	['N']	[11]
12	transient	O	['N']	[12]
13	CDI	B-Adverse_Effect	['N']	[13]
14	occurring	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	setting	O	['N']	[17]
18	of	O	['N']	[18]
19	underlying	O	['N']	[19]
20	chronic	O	['N']	[20]
21	NDI	O	['N']	[21]
22	.	O	['N']	[22]
#132
0	Carboplatin	B-Drug	['Causes']	[5]
1	hypersensitivity	O	['N']	[1]
2	presenting	O	['N']	[2]
3	as	O	['N']	[3]
4	coronary	B	['N']	[4]
5	vasospasm	I-Adverse_Effect	['N']	[5]
6	-	O	['N']	[6]
7	a	O	['N']	[7]
8	case	O	['N']	[8]
9	report	O	['N']	[9]
10	.	O	['N']	[10]
#133
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	fulminant	O	['N']	[6]
7	adult	B	['N']	[7]
8	respiratory	I	['N']	[8]
9	distress	I	['N']	[9]
10	syndrome	I-Adverse_Effect	['N']	[10]
11	(	O	['N']	[11]
12	ARDS	O	['N']	[12]
13	)	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	pegylated	O	['N']	[16]
17	interferon	O	['N']	[17]
18	alpha-2a	O	['N']	[18]
19	(	O	['N']	[19]
20	pegIFNalpha-2a	B-Drug	['Causes']	[10]
21	)	O	['N']	[21]
22	and	O	['N']	[22]
23	ribavirin	O	['N']	[23]
24	use	O	['N']	[24]
25	for	O	['N']	[25]
26	hepatitis	O	['N']	[26]
27	C	O	['N']	[27]
28	,	O	['N']	[28]
29	complicated	O	['N']	[29]
30	by	O	['N']	[30]
31	subsequent	O	['N']	[31]
32	and	O	['N']	[32]
33	ultimately	O	['N']	[33]
34	fatal	O	['N']	[34]
35	sepsis	O	['N']	[35]
36	and	O	['N']	[36]
37	multiorgan	O	['N']	[37]
38	failure	O	['N']	[38]
39	.	O	['N']	[39]
#134
0	The	O	['N']	[0]
1	first	O	['N']	[1]
2	patient	O	['N']	[2]
3	developed	O	['N']	[3]
4	mild	B	['N']	[4]
5	nitritoid	I	['N']	[5]
6	symptoms	I-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	pain	O	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	band	O	['N']	[11]
12	-	O	['N']	[12]
13	like	O	['N']	[13]
14	distribution	O	['N']	[14]
15	,	O	['N']	[15]
16	corresponding	O	['N']	[16]
17	to	O	['N']	[17]
18	T10-T12	O	['N']	[18]
19	dermatomes	O	['N']	[19]
20	,	O	['N']	[20]
21	shortly	O	['N']	[21]
22	after	O	['N']	[22]
23	gold	B	['N']	[23]
24	sodium	I	['N']	[24]
25	thiomalate	I-Drug	['Causes']	[6]
26	(	O	['N']	[26]
27	GSTM	O	['N']	[27]
28	)	O	['N']	[28]
29	injection	O	['N']	[29]
30	.	O	['N']	[30]
#135
0	Hypoglycemia	O	['N']	[0]
1	can	O	['N']	[1]
2	be	O	['N']	[2]
3	a	O	['N']	[3]
4	serious	O	['N']	[4]
5	side	O	['N']	[5]
6	effect	O	['N']	[6]
7	of	O	['N']	[7]
8	etanercept	O	['N']	[8]
9	in	O	['N']	[9]
10	patients	O	['N']	[10]
11	already	O	['N']	[11]
12	on	O	['N']	[12]
13	antidiabetic	O	['N']	[13]
14	medications	O	['N']	[14]
15	known	O	['N']	[15]
16	to	O	['N']	[16]
17	cause	O	['N']	[17]
18	hypoglycemia	B-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	such	O	['N']	[20]
21	as	O	['N']	[21]
22	sulfonylureas	O	['N']	[22]
23	,	O	['N']	[23]
24	meglitinides	B-Drug	['Causes']	[18]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	insulin	O	['N']	[27]
28	.	O	['N']	[28]
#136
0	The	O	['N']	[0]
1	HIV	O	['N']	[1]
2	protease	O	['N']	[2]
3	inhibitor	O	['N']	[3]
4	indinavir	B-Drug	['Causes']	[10]
5	may	O	['N']	[5]
6	cause	O	['N']	[6]
7	nephrolithiasis	O	['N']	[7]
8	and	O	['N']	[8]
9	interstitial	B	['N']	[9]
10	nephritis	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#137
0	Acute	B	['N']	[0]
1	non	I	['N']	[1]
2	-	I	['N']	[2]
3	lymphocytic	I	['N']	[3]
4	leukemia	I-Adverse_Effect	['N']	[4]
5	occurred	O	['N']	[5]
6	in	O	['N']	[6]
7	eight	O	['N']	[7]
8	women	O	['N']	[8]
9	following	O	['N']	[9]
10	long	O	['N']	[10]
11	-	O	['N']	[11]
12	term	O	['N']	[12]
13	treatment	O	['N']	[13]
14	with	O	['N']	[14]
15	Treosulfan	O	['N']	[15]
16	(=	O	['N']	[16]
17	dihydroxybusulfan	B-Drug	['Causes']	[4]
18	)	O	['N']	[18]
19	for	O	['N']	[19]
20	ovarian	O	['N']	[20]
21	carcinoma	O	['N']	[21]
22	.	O	['N']	[22]
#138
0	These	O	['N']	[0]
1	are	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	reported	O	['N']	[4]
5	patients	O	['N']	[5]
6	to	O	['N']	[6]
7	show	O	['N']	[7]
8	mfERG	B	['N']	[8]
9	abnormalities	I-Adverse_Effect	['N']	[9]
10	that	O	['N']	[10]
11	correspond	O	['N']	[11]
12	to	O	['N']	[12]
13	bitemporal	O	['N']	[13]
14	visual	O	['N']	[14]
15	field	O	['N']	[15]
16	defects	O	['N']	[16]
17	and	O	['N']	[17]
18	add	O	['N']	[18]
19	to	O	['N']	[19]
20	the	O	['N']	[20]
21	growing	O	['N']	[21]
22	evidence	O	['N']	[22]
23	that	O	['N']	[23]
24	ethambutol	B-Drug	['Causes']	[9]
25	damages	O	['N']	[25]
26	the	O	['N']	[26]
27	retina	O	['N']	[27]
28	.	O	['N']	[28]
#139
0	The	O	['N']	[0]
1	knowledge	O	['N']	[1]
2	concerning	O	['N']	[2]
3	VGB	B-Drug	['Causes']	[7]
4	-	O	['N']	[4]
5	associated	O	['N']	[5]
6	visual	B	['N']	[6]
7	dysfunction	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	pediatric	O	['N']	[9]
10	patients	O	['N']	[10]
11	,	O	['N']	[11]
12	particularly	O	['N']	[12]
13	in	O	['N']	[13]
14	those	O	['N']	[14]
15	who	O	['N']	[15]
16	have	O	['N']	[16]
17	been	O	['N']	[17]
18	exposed	O	['N']	[18]
19	to	O	['N']	[19]
20	VGB	O	['N']	[20]
21	in	O	['N']	[21]
22	utero	O	['N']	[22]
23	is	O	['N']	[23]
24	limited	O	['N']	[24]
25	.	O	['N']	[25]
#140
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	one	O	['N']	[2]
3	patient	O	['N']	[3]
4	exhibited	O	['N']	[4]
5	severe	O	['N']	[5]
6	hypersensitivity	O	['N']	[6]
7	reactions	O	['N']	[7]
8	including	O	['N']	[8]
9	cardiac	O	['N']	[9]
10	arrest	O	['N']	[10]
11	and	O	['N']	[11]
12	apnea	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	another	O	['N']	[15]
16	four	O	['N']	[16]
17	patients	O	['N']	[17]
18	developed	O	['N']	[18]
19	eruptions	O	['N']	[19]
20	,	O	['N']	[20]
21	hypotension	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	tachycardia	B-Adverse_Effect	['N']	[24]
25	soon	O	['N']	[25]
26	after	O	['N']	[26]
27	administration	O	['N']	[27]
28	of	O	['N']	[28]
29	CBDCA	B-Drug	['Causes']	[24]
30	.	O	['N']	[30]
#141
0	Allergic	B	['N']	[0]
1	contact	I	['N']	[1]
2	dermatitis	I-Adverse_Effect	['N']	[2]
3	to	O	['N']	[3]
4	compound	O	['N']	[4]
5	tincture	O	['N']	[5]
6	of	O	['N']	[6]
7	benzoin	B-Drug	['Causes']	[2]
8	.	O	['N']	[8]
#142
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	bilateral	B	['N']	[4]
5	optic	I	['N']	[5]
6	neuritis	I-Adverse_Effect	['N']	[6]
7	that	O	['N']	[7]
8	occurred	O	['N']	[8]
9	as	O	['N']	[9]
10	an	O	['N']	[10]
11	adverse	O	['N']	[11]
12	effect	O	['N']	[12]
13	of	O	['N']	[13]
14	recombinant	O	['N']	[14]
15	and	O	['N']	[15]
16	natural	O	['N']	[16]
17	interferon	B	['N']	[17]
18	alpha	I-Drug	['Causes']	[6]
19	administration	O	['N']	[19]
20	.	O	['N']	[20]
#143
0	A	O	['N']	[0]
1	58-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	rheumatoid	O	['N']	[6]
7	arthritis	O	['N']	[7]
8	(	O	['N']	[8]
9	RA	O	['N']	[9]
10	)	O	['N']	[10]
11	developed	O	['N']	[11]
12	fever	O	['N']	[12]
13	,	O	['N']	[13]
14	skin	O	['N']	[14]
15	eruptions	O	['N']	[15]
16	,	O	['N']	[16]
17	leukocytopenia	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	thrombocytopenia	B-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	3	O	['N']	[22]
23	weeks	O	['N']	[23]
24	after	O	['N']	[24]
25	treatment	O	['N']	[25]
26	with	O	['N']	[26]
27	sulfasalazine	B-Drug	['Causes']	[20]
28	.	O	['N']	[28]
#144
0	A	O	['N']	[0]
1	40-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	relapsing	O	['N']	[6]
7	-	O	['N']	[7]
8	remitting	O	['N']	[8]
9	multiple	O	['N']	[9]
10	sclerosis	O	['N']	[10]
11	(	O	['N']	[11]
12	MS	O	['N']	[12]
13	)	O	['N']	[13]
14	developed	O	['N']	[14]
15	primary	B	['N']	[15]
16	central	I	['N']	[16]
17	nervous	I	['N']	[17]
18	system	I	['N']	[18]
19	lymphoma	I-Adverse_Effect	['N']	[19]
20	(	O	['N']	[20]
21	PCNSL	O	['N']	[21]
22	)	O	['N']	[22]
23	after	O	['N']	[23]
24	having	O	['N']	[24]
25	received	O	['N']	[25]
26	21	O	['N']	[26]
27	doses	O	['N']	[27]
28	of	O	['N']	[28]
29	natalizumab	B-Drug	['Causes']	[19]
30	monotherapy	O	['N']	[30]
31	.	O	['N']	[31]
#145
0	This	O	['N']	[0]
1	increase	O	['N']	[1]
2	when	O	['N']	[2]
3	clozapine	B-Drug	['Causes']	[21]
4	was	O	['N']	[4]
5	switched	O	['N']	[5]
6	to	O	['N']	[6]
7	risperidone	O	['N']	[7]
8	and	O	['N']	[8]
9	vice	O	['N']	[9]
10	versa	O	['N']	[10]
11	is	O	['N']	[11]
12	consistent	O	['N']	[12]
13	with	O	['N']	[13]
14	our	O	['N']	[14]
15	previous	O	['N']	[15]
16	report	O	['N']	[16]
17	of	O	['N']	[17]
18	elevated	B	['N']	[18]
19	serum	I	['N']	[19]
20	triglyceride	I	['N']	[20]
21	levels	I-Adverse_Effect	['N']	[21]
22	in	O	['N']	[22]
23	clozapine	O	['N']	[23]
24	-	O	['N']	[24]
25	treated	O	['N']	[25]
26	patients	O	['N']	[26]
27	.	O	['N']	[27]
#146
0	After	O	['N']	[0]
1	discontinuing	O	['N']	[1]
2	captopril	B-Drug	['Causes']	[18]
3	and	O	['N']	[3]
4	starting	O	['N']	[4]
5	systemic	O	['N']	[5]
6	steroids	O	['N']	[6]
7	,	O	['N']	[7]
8	her	O	['N']	[8]
9	symptomatology	O	['N']	[9]
10	rapidly	O	['N']	[10]
11	improved	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	her	O	['N']	[14]
15	eosinophilia	O	['N']	[15]
16	and	O	['N']	[16]
17	radiographic	B	['N']	[17]
18	abnormalities	I-Adverse_Effect	['N']	[18]
19	both	O	['N']	[19]
20	resolved	O	['N']	[20]
21	.	O	['N']	[21]
#147
0	PATIENT	O	['N']	[0]
1	AND	O	['N']	[1]
2	METHOD	O	['N']	[2]
3	:	O	['N']	[3]
4	A	O	['N']	[4]
5	34-year	O	['N']	[5]
6	-	O	['N']	[6]
7	old	O	['N']	[7]
8	woman	O	['N']	[8]
9	with	O	['N']	[9]
10	chronic	O	['N']	[10]
11	hepatitis	O	['N']	[11]
12	C	O	['N']	[12]
13	,	O	['N']	[13]
14	genotype	O	['N']	[14]
15	3	O	['N']	[15]
16	,	O	['N']	[16]
17	receiving	O	['N']	[17]
18	pegylated	B	['N']	[18]
19	interferon	I	['N']	[19]
20	alpha-2a	I-Drug	['Causes']	[29]
21	and	O	['N']	[21]
22	ribavirin	O	['N']	[22]
23	for	O	['N']	[23]
24	6	O	['N']	[24]
25	months	O	['N']	[25]
26	,	O	['N']	[26]
27	developed	O	['N']	[27]
28	progressive	B	['N']	[28]
29	malaise	I-Adverse_Effect	['N']	[29]
30	and	O	['N']	[30]
31	anemia	O	['N']	[31]
32	6	O	['N']	[32]
33	months	O	['N']	[33]
34	after	O	['N']	[34]
35	the	O	['N']	[35]
36	end	O	['N']	[36]
37	of	O	['N']	[37]
38	treatment	O	['N']	[38]
39	.	O	['N']	[39]
#148
0	The	O	['N']	[0]
1	purpose	O	['N']	[1]
2	of	O	['N']	[2]
3	this	O	['N']	[3]
4	study	O	['N']	[4]
5	was	O	['N']	[5]
6	to	O	['N']	[6]
7	examine	O	['N']	[7]
8	the	O	['N']	[8]
9	incidence	O	['N']	[9]
10	and	O	['N']	[10]
11	cause	O	['N']	[11]
12	of	O	['N']	[12]
13	Clostridium	B	['N']	[13]
14	difficile	I	['N']	[14]
15	colitis	I-Adverse_Effect	['N']	[15]
16	occurring	O	['N']	[16]
17	after	O	['N']	[17]
18	cisplatin	B-Drug	['Causes']	[15]
19	-	O	['N']	[19]
20	based	O	['N']	[20]
21	combination	O	['N']	[21]
22	chemotherapy	O	['N']	[22]
23	in	O	['N']	[23]
24	ovarian	O	['N']	[24]
25	cancer	O	['N']	[25]
26	patients	O	['N']	[26]
27	.	O	['N']	[27]
#149
0	DATA	O	['N']	[0]
1	SYNTHESIS	O	['N']	[1]
2	:	O	['N']	[2]
3	Genetic	O	['N']	[3]
4	deficiencies	O	['N']	[4]
5	in	O	['N']	[5]
6	DPD	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	rate	O	['N']	[9]
10	-	O	['N']	[10]
11	limiting	O	['N']	[11]
12	enzyme	O	['N']	[12]
13	responsible	O	['N']	[13]
14	for	O	['N']	[14]
15	5-FU	B-Drug	['Causes']	[44]
16	catabolism	O	['N']	[16]
17	,	O	['N']	[17]
18	may	O	['N']	[18]
19	occur	O	['N']	[19]
20	in	O	['N']	[20]
21	3	O	['N']	[21]
22	%	O	['N']	[22]
23	or	O	['N']	[23]
24	more	O	['N']	[24]
25	of	O	['N']	[25]
26	patients	O	['N']	[26]
27	with	O	['N']	[27]
28	cancer	O	['N']	[28]
29	putting	O	['N']	[29]
30	them	O	['N']	[30]
31	at	O	['N']	[31]
32	increased	O	['N']	[32]
33	risk	O	['N']	[33]
34	for	O	['N']	[34]
35	unusually	O	['N']	[35]
36	severe	O	['N']	[36]
37	adverse	O	['N']	[37]
38	reactions	O	['N']	[38]
39	(	O	['N']	[39]
40	e.g.	O	['N']	[40]
41	,	O	['N']	[41]
42	diarrhea	O	['N']	[42]
43	,	O	['N']	[43]
44	stomatitis	B-Adverse_Effect	['N']	[44]
45	,	O	['N']	[45]
46	mucositis	O	['N']	[46]
47	,	O	['N']	[47]
48	myelosuppression	O	['N']	[48]
49	,	O	['N']	[49]
50	neurotoxicity	O	['N']	[50]
51	)	O	['N']	[51]
52	to	O	['N']	[52]
53	standard	O	['N']	[53]
54	doses	O	['N']	[54]
55	of	O	['N']	[55]
56	5-FU	O	['N']	[56]
57	.	O	['N']	[57]
#150
0	Transient	B	['N']	[0]
1	hemiparesis	I-Adverse_Effect	['N']	[1]
2	caused	O	['N']	[2]
3	by	O	['N']	[3]
4	phenytoin	B-Drug	['Causes']	[1]
5	toxicity	O	['N']	[5]
6	.	O	['N']	[6]
#151
0	We	O	['N']	[0]
1	recommend	O	['N']	[1]
2	that	O	['N']	[2]
3	clinicians	O	['N']	[3]
4	monitor	O	['N']	[4]
5	patients	O	['N']	[5]
6	for	O	['N']	[6]
7	signs	O	['N']	[7]
8	and	O	['N']	[8]
9	symptoms	O	['N']	[9]
10	of	O	['N']	[10]
11	pancreatitis	B-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	including	O	['N']	[13]
14	abdominal	O	['N']	[14]
15	pain	O	['N']	[15]
16	,	O	['N']	[16]
17	during	O	['N']	[17]
18	treatment	O	['N']	[18]
19	with	O	['N']	[19]
20	tigecycline	B-Drug	['Causes']	[11]
21	.	O	['N']	[21]
#152
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	in	O	['N']	[4]
5	whom	O	['N']	[5]
6	noncardiogenic	B	['N']	[6]
7	pulmonary	I	['N']	[7]
8	edema	I-Adverse_Effect	['N']	[8]
9	developed	O	['N']	[9]
10	during	O	['N']	[10]
11	intrabiliary	O	['N']	[11]
12	infusion	O	['N']	[12]
13	of	O	['N']	[13]
14	monooctanoin	B-Drug	['Causes']	[8]
15	.	O	['N']	[15]
#153
0	Three	O	['N']	[0]
1	years	O	['N']	[1]
2	later	O	['N']	[2]
3	,	O	['N']	[3]
4	treatment	O	['N']	[4]
5	with	O	['N']	[5]
6	ampicillin	B-Drug	['Causes']	[17]
7	caused	O	['N']	[7]
8	another	O	['N']	[8]
9	episode	O	['N']	[9]
10	of	O	['N']	[10]
11	cholestatic	O	['N']	[11]
12	hepatitis	O	['N']	[12]
13	with	O	['N']	[13]
14	cholestasis	O	['N']	[14]
15	and	O	['N']	[15]
16	duct	B	['N']	[16]
17	paucity	I-Adverse_Effect	['N']	[17]
18	on	O	['N']	[18]
19	rebiopsy	O	['N']	[19]
20	.	O	['N']	[20]
#154
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	we	O	['N']	[4]
5	describe	O	['N']	[5]
6	the	O	['N']	[6]
7	first	O	['N']	[7]
8	reported	O	['N']	[8]
9	case	O	['N']	[9]
10	of	O	['N']	[10]
11	isolated	B	['N']	[11]
12	paresthesia	I-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	peripheral	O	['N']	[14]
15	neuropathy	O	['N']	[15]
16	,	O	['N']	[16]
17	without	O	['N']	[17]
18	systemic	O	['N']	[18]
19	involvement	O	['N']	[19]
20	,	O	['N']	[20]
21	secondary	O	['N']	[21]
22	to	O	['N']	[22]
23	sulindac	B-Drug	['Causes']	[12]
24	administration	O	['N']	[24]
25	.	O	['N']	[25]
#155
0	The	O	['N']	[0]
1	possibility	O	['N']	[1]
2	of	O	['N']	[2]
3	severe	O	['N']	[3]
4	rhabdomyolysis	B-Adverse_Effect	['N']	[4]
5	should	O	['N']	[5]
6	be	O	['N']	[6]
7	considered	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	with	O	['N']	[11]
12	water	O	['N']	[12]
13	intoxication	O	['N']	[13]
14	due	O	['N']	[14]
15	to	O	['N']	[15]
16	massive	O	['N']	[16]
17	ingestion	O	['N']	[17]
18	of	O	['N']	[18]
19	caffeine	B-Drug	['Causes']	[4]
20	-	O	['N']	[20]
21	containing	O	['N']	[21]
22	beverages	O	['N']	[22]
23	.	O	['N']	[23]
#156
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	4-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	girl	O	['N']	[6]
7	who	O	['N']	[7]
8	presented	O	['N']	[8]
9	with	O	['N']	[9]
10	acute	B	['N']	[10]
11	bilateral	I	['N']	[11]
12	blindness	I-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	a	O	['N']	[14]
15	focal	O	['N']	[15]
16	seizure	O	['N']	[16]
17	and	O	['N']	[17]
18	hypertension	O	['N']	[18]
19	10	O	['N']	[19]
20	days	O	['N']	[20]
21	after	O	['N']	[21]
22	commencing	O	['N']	[22]
23	oxybutynin	B-Drug	['Causes']	[12]
24	to	O	['N']	[24]
25	treat	O	['N']	[25]
26	enuresis	O	['N']	[26]
27	.	O	['N']	[27]
#157
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	investigate	O	['N']	[3]
4	the	O	['N']	[4]
5	mechanisms	O	['N']	[5]
6	involved	O	['N']	[6]
7	in	O	['N']	[7]
8	hypersensitivity	B	['N']	[8]
9	reactions	I-Adverse_Effect	['N']	[9]
10	to	O	['N']	[10]
11	cyclosporine	B-Drug	['Causes']	[9]
12	and	O	['N']	[12]
13	determine	O	['N']	[13]
14	the	O	['N']	[14]
15	feasibility	O	['N']	[15]
16	of	O	['N']	[16]
17	future	O	['N']	[17]
18	cyclosporine	O	['N']	[18]
19	use	O	['N']	[19]
20	.	O	['N']	[20]
#158
0	Clinicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	cognizant	O	['N']	[3]
4	of	O	['N']	[4]
5	this	O	['N']	[5]
6	possibility	O	['N']	[6]
7	and	O	['N']	[7]
8	consider	O	['N']	[8]
9	a	O	['N']	[9]
10	diagnosis	O	['N']	[10]
11	of	O	['N']	[11]
12	HDAs	O	['N']	[12]
13	in	O	['N']	[13]
14	patients	O	['N']	[14]
15	with	O	['N']	[15]
16	ongoing	O	['N']	[16]
17	thrombosis	B-Adverse_Effect	['N']	[17]
18	who	O	['N']	[18]
19	are	O	['N']	[19]
20	receiving	O	['N']	[20]
21	heparin	B-Drug	['Causes']	[17]
22	therapy	O	['N']	[22]
23	.	O	['N']	[23]
#159
0	An	O	['N']	[0]
1	infertile	O	['N']	[1]
2	patient	O	['N']	[2]
3	with	O	['N']	[3]
4	amenorrhea	O	['N']	[4]
5	-	O	['N']	[5]
6	galactorrhea	O	['N']	[6]
7	syndrome	O	['N']	[7]
8	lost	B	['N']	[8]
9	vision	I-Adverse_Effect	['N']	[9]
10	during	O	['N']	[10]
11	a	O	['N']	[11]
12	pregnancy	O	['N']	[12]
13	occurring	O	['N']	[13]
14	after	O	['N']	[14]
15	Bromocryptine	B-Drug	['Causes']	[9]
16	treatment	O	['N']	[16]
17	.	O	['N']	[17]
#160
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	case	O	['N']	[3]
4	is	O	['N']	[4]
5	presented	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	45-year	O	['N']	[8]
9	-	O	['N']	[9]
10	old	O	['N']	[10]
11	woman	O	['N']	[11]
12	on	O	['N']	[12]
13	prolonged	O	['N']	[13]
14	gemcitabine	B-Drug	['Causes']	[21]
15	treatment	O	['N']	[15]
16	for	O	['N']	[16]
17	ovarian	O	['N']	[17]
18	cancer	O	['N']	[18]
19	who	O	['N']	[19]
20	developed	O	['N']	[20]
21	HUS	B-Adverse_Effect	['N']	[21]
22	and	O	['N']	[22]
23	recovered	O	['N']	[23]
24	after	O	['N']	[24]
25	drug	O	['N']	[25]
26	discontinuation	O	['N']	[26]
27	.	O	['N']	[27]
#161
0	A	O	['N']	[0]
1	mentally	O	['N']	[1]
2	retarded	O	['N']	[2]
3	23-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	with	O	['N']	[7]
8	myoclonic	O	['N']	[8]
9	astatic	O	['N']	[9]
10	epilepsy	O	['N']	[10]
11	developed	O	['N']	[11]
12	an	O	['N']	[12]
13	abnormal	B	['N']	[13]
14	posture	I	['N']	[14]
15	of	I	['N']	[15]
16	extreme	I	['N']	[16]
17	forward	I	['N']	[17]
18	flexion	I-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	called	O	['N']	[20]
21	camptocormia	O	['N']	[21]
22	,	O	['N']	[22]
23	during	O	['N']	[23]
24	valproate	B-Drug	['Causes']	[18]
25	monotherapy	O	['N']	[25]
26	.	O	['N']	[26]
#162
0	Localized	O	['N']	[0]
1	panniculitis	O	['N']	[1]
2	and	O	['N']	[2]
3	subsequent	O	['N']	[3]
4	lipoatrophy	B-Adverse_Effect	['N']	[4]
5	with	O	['N']	[5]
6	subcutaneous	O	['N']	[6]
7	glatiramer	O	['N']	[7]
8	acetate	O	['N']	[8]
9	(	O	['N']	[9]
10	Copaxone	B-Drug	['Causes']	[4]
11	)	O	['N']	[11]
12	injection	O	['N']	[12]
13	for	O	['N']	[13]
14	the	O	['N']	[14]
15	treatment	O	['N']	[15]
16	of	O	['N']	[16]
17	multiple	O	['N']	[17]
18	sclerosis	O	['N']	[18]
19	.	O	['N']	[19]
#163
0	Hyperammonemia	O	['N']	[0]
1	has	O	['N']	[1]
2	been	O	['N']	[2]
3	described	O	['N']	[3]
4	as	O	['N']	[4]
5	a	O	['N']	[5]
6	complication	O	['N']	[6]
7	of	O	['N']	[7]
8	valproic	B	['N']	[8]
9	acid	I-Drug	['Causes']	[20]
10	therapy	O	['N']	[10]
11	but	O	['N']	[11]
12	may	O	['N']	[12]
13	often	O	['N']	[13]
14	be	O	['N']	[14]
15	overlooked	O	['N']	[15]
16	as	O	['N']	[16]
17	a	O	['N']	[17]
18	cause	O	['N']	[18]
19	of	O	['N']	[19]
20	lethargy	B-Adverse_Effect	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	postictal	O	['N']	[23]
24	patient	O	['N']	[24]
25	who	O	['N']	[25]
26	presents	O	['N']	[26]
27	to	O	['N']	[27]
28	the	O	['N']	[28]
29	emergency	O	['N']	[29]
30	department	O	['N']	[30]
31	.	O	['N']	[31]
#164
0	Rifampin	B-Drug	['Causes']	[19]
1	(	O	['N']	[1]
2	RFP	O	['N']	[2]
3	)	O	['N']	[3]
4	increases	O	['N']	[4]
5	hepatic	O	['N']	[5]
6	microsomal	O	['N']	[6]
7	enzyme	O	['N']	[7]
8	activity	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	there	O	['N']	[11]
12	are	O	['N']	[12]
13	case	O	['N']	[13]
14	reports	O	['N']	[14]
15	of	O	['N']	[15]
16	RFP	O	['N']	[16]
17	-	O	['N']	[17]
18	induced	O	['N']	[18]
19	hypothyroidism	B-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	all	O	['N']	[21]
22	associated	O	['N']	[22]
23	with	O	['N']	[23]
24	Hashimoto	O	['N']	[24]
25	's	O	['N']	[25]
26	thyroiditis	O	['N']	[26]
27	.	O	['N']	[27]
#165
0	Acute	B	['N']	[0]
1	myocardial	I	['N']	[1]
2	infarction	I-Adverse_Effect	['N']	[2]
3	due	O	['N']	[3]
4	to	O	['N']	[4]
5	coronary	O	['N']	[5]
6	spasm	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	L	B	['N']	[9]
10	-	I	['N']	[10]
11	thyroxine	I-Drug	['Causes']	[2]
12	therapy	O	['N']	[12]
13	.	O	['N']	[13]
#166
0	After	O	['N']	[0]
1	3-	O	['N']	[1]
2	to	O	['N']	[2]
3	13-month	O	['N']	[3]
4	period	O	['N']	[4]
5	of	O	['N']	[5]
6	therapy	O	['N']	[6]
7	without	O	['N']	[7]
8	indapamide	B-Drug	['Causes']	[17]
9	,	O	['N']	[9]
10	glucose	O	['N']	[10]
11	levels	O	['N']	[11]
12	of	O	['N']	[12]
13	all	O	['N']	[13]
14	patients	O	['N']	[14]
15	decreased	O	['N']	[15]
16	and	O	['N']	[16]
17	diabetes	B-Adverse_Effect	['N']	[17]
18	disappeared	O	['N']	[18]
19	.	O	['N']	[19]
#167
0	Dapsone	B-Drug	['Causes']	[1]
1	syndrome	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	cutaneous	O	['N']	[3]
4	lupus	O	['N']	[4]
5	erythematosus	O	['N']	[5]
6	.	O	['N']	[6]
#168
0	A	O	['N']	[0]
1	possible	O	['N']	[1]
2	case	O	['N']	[2]
3	of	O	['N']	[3]
4	carbamazepine	B-Drug	['Causes']	[6]
5	induced	O	['N']	[5]
6	pancreatitis	B-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#169
0	In	O	['N']	[0]
1	all	O	['N']	[1]
2	cases	O	['N']	[2]
3	,	O	['N']	[3]
4	drugs	O	['N']	[4]
5	in	O	['N']	[5]
6	addition	O	['N']	[6]
7	to	O	['N']	[7]
8	quetiapine	B-Drug	['Causes']	[24]
9	were	O	['N']	[9]
10	detected	O	['N']	[10]
11	,	O	['N']	[11]
12	but	O	['N']	[12]
13	in	O	['N']	[13]
14	cases	O	['N']	[14]
15	#	O	['N']	[15]
16	1	O	['N']	[16]
17	and	O	['N']	[17]
18	#	O	['N']	[18]
19	2	O	['N']	[19]
20	,	O	['N']	[20]
21	the	O	['N']	[21]
22	cause	O	['N']	[22]
23	of	O	['N']	[23]
24	death	B-Adverse_Effect	['N']	[24]
25	was	O	['N']	[25]
26	considered	O	['N']	[26]
27	to	O	['N']	[27]
28	be	O	['N']	[28]
29	a	O	['N']	[29]
30	quetiapine	O	['N']	[30]
31	overdose	O	['N']	[31]
32	and	O	['N']	[32]
33	the	O	['N']	[33]
34	other	O	['N']	[34]
35	drugs	O	['N']	[35]
36	were	O	['N']	[36]
37	not	O	['N']	[37]
38	considered	O	['N']	[38]
39	to	O	['N']	[39]
40	be	O	['N']	[40]
41	contributory	O	['N']	[41]
42	.	O	['N']	[42]
#170
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	long	O	['N']	[5]
6	lasting	O	['N']	[6]
7	respiratory	B	['N']	[7]
8	depression	I-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	intravenous	O	['N']	[10]
11	administration	O	['N']	[11]
12	of	O	['N']	[12]
13	morphine	B-Drug	['Causes']	[8]
14	to	O	['N']	[14]
15	a	O	['N']	[15]
16	7	O	['N']	[16]
17	year	O	['N']	[17]
18	old	O	['N']	[18]
19	girl	O	['N']	[19]
20	with	O	['N']	[20]
21	haemolytic	O	['N']	[21]
22	uraemic	O	['N']	[22]
23	syndrome	O	['N']	[23]
24	.	O	['N']	[24]
#171
0	Minor	B	['N']	[0]
1	electrocardiographical	I	['N']	[1]
2	changes	I-Adverse_Effect	['N']	[2]
3	were	O	['N']	[3]
4	noted	O	['N']	[4]
5	in	O	['N']	[5]
6	five	O	['N']	[6]
7	out	O	['N']	[7]
8	of	O	['N']	[8]
9	six	O	['N']	[9]
10	patients	O	['N']	[10]
11	who	O	['N']	[11]
12	were	O	['N']	[12]
13	not	O	['N']	[13]
14	receiving	O	['N']	[14]
15	a	O	['N']	[15]
16	cardiac	O	['N']	[16]
17	glycoside	O	['N']	[17]
18	and	O	['N']	[18]
19	four	O	['N']	[19]
20	out	O	['N']	[20]
21	of	O	['N']	[21]
22	six	O	['N']	[22]
23	who	O	['N']	[23]
24	were	O	['N']	[24]
25	receiving	O	['N']	[25]
26	ouabain	B-Drug	['Causes']	[2]
27	,	O	['N']	[27]
28	and	O	['N']	[28]
29	none	O	['N']	[29]
30	of	O	['N']	[30]
31	the	O	['N']	[31]
32	16	O	['N']	[32]
33	who	O	['N']	[33]
34	were	O	['N']	[34]
35	receiving	O	['N']	[35]
36	digoxin	O	['N']	[36]
37	.	O	['N']	[37]
#172
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	chronic	O	['N']	[3]
4	myeloid	O	['N']	[4]
5	leukaemia	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	busulphan	B-Drug	['Causes']	[29]
9	for	O	['N']	[9]
10	4	O	['N']	[10]
11	-	O	['N']	[11]
12	5	O	['N']	[12]
13	years	O	['N']	[13]
14	,	O	['N']	[14]
15	developed	O	['N']	[15]
16	signs	O	['N']	[16]
17	of	O	['N']	[17]
18	busulphan	O	['N']	[18]
19	toxicity	O	['N']	[19]
20	and	O	['N']	[20]
21	portal	O	['N']	[21]
22	hypertension	O	['N']	[22]
23	with	O	['N']	[23]
24	ascites	O	['N']	[24]
25	,	O	['N']	[25]
26	oesophageal	O	['N']	[26]
27	varices	O	['N']	[27]
28	and	O	['N']	[28]
29	jaundice	B-Adverse_Effect	['N']	[29]
30	.	O	['N']	[30]
#173
0	A	O	['N']	[0]
1	36-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	being	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	cisplatinum	B-Drug	['Causes']	[24]
9	,	O	['N']	[9]
10	vinblastine	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	bleomycin	O	['N']	[13]
14	for	O	['N']	[14]
15	testicular	O	['N']	[15]
16	carcinoma	O	['N']	[16]
17	developed	O	['N']	[17]
18	a	O	['N']	[18]
19	dense	O	['N']	[19]
20	left	O	['N']	[20]
21	homonymous	O	['N']	[21]
22	hemianopsia	O	['N']	[22]
23	,	O	['N']	[23]
24	encephalopathy	B-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	a	O	['N']	[27]
28	partial	O	['N']	[28]
29	nondominant	O	['N']	[29]
30	parietal	O	['N']	[30]
31	lobe	O	['N']	[31]
32	syndrome	O	['N']	[32]
33	.	O	['N']	[33]
#174
0	Mitomycin	B	['N']	[0]
1	-	I	['N']	[1]
2	C	I-Drug	['Causes']	[26]
3	is	O	['N']	[3]
4	used	O	['N']	[4]
5	widely	O	['N']	[5]
6	in	O	['N']	[6]
7	the	O	['N']	[7]
8	treatment	O	['N']	[8]
9	of	O	['N']	[9]
10	malignancies	O	['N']	[10]
11	and	O	['N']	[11]
12	is	O	['N']	[12]
13	associated	O	['N']	[13]
14	with	O	['N']	[14]
15	serious	O	['N']	[15]
16	dose	O	['N']	[16]
17	related	O	['N']	[17]
18	adverse	O	['N']	[18]
19	effects	O	['N']	[19]
20	including	O	['N']	[20]
21	the	O	['N']	[21]
22	occurrence	O	['N']	[22]
23	of	O	['N']	[23]
24	hemolytic	B	['N']	[24]
25	uremic	I	['N']	[25]
26	syndrome	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#175
0	Rapamycin	O	['N']	[0]
1	/	O	['N']	[1]
2	sirolimus	B-Drug	['Causes']	[27]
3	(	O	['N']	[3]
4	SR	O	['N']	[4]
5	)	O	['N']	[5]
6	,	O	['N']	[6]
7	trade	O	['N']	[7]
8	named	O	['N']	[8]
9	Rapammune	O	['N']	[9]
10	(	O	['N']	[10]
11	Wyeth	O	['N']	[11]
12	-	O	['N']	[12]
13	Ayerst	O	['N']	[13]
14	,	O	['N']	[14]
15	Sydney	O	['N']	[15]
16	,	O	['N']	[16]
17	Australia	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	is	O	['N']	[20]
21	a	O	['N']	[21]
22	potent	O	['N']	[22]
23	immunosuppressive	O	['N']	[23]
24	drug	O	['N']	[24]
25	associated	O	['N']	[25]
26	with	O	['N']	[26]
27	myelosuppression	B-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	hypertension	O	['N']	[29]
30	,	O	['N']	[30]
31	hyperlipidemia	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	infection	O	['N']	[34]
35	.	O	['N']	[35]
#176
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	longitudinal	O	['N']	[2]
3	diffusion	O	['N']	[3]
4	-	O	['N']	[4]
5	weighted	O	['N']	[5]
6	MRI	O	['N']	[6]
7	findings	O	['N']	[7]
8	of	O	['N']	[8]
9	sub	B	['N']	[9]
10	-	I	['N']	[10]
11	acute	I	['N']	[11]
12	leukoencephalopathy	I-Adverse_Effect	['N']	[12]
13	following	O	['N']	[13]
14	methotrexate	B-Drug	['Causes']	[12]
15	therapy	O	['N']	[15]
16	in	O	['N']	[16]
17	a	O	['N']	[17]
18	24-year	O	['N']	[18]
19	-	O	['N']	[19]
20	old	O	['N']	[20]
21	man	O	['N']	[21]
22	diagnosed	O	['N']	[22]
23	with	O	['N']	[23]
24	pre	O	['N']	[24]
25	-	O	['N']	[25]
26	B	O	['N']	[26]
27	-	O	['N']	[27]
28	cell	O	['N']	[28]
29	acute	O	['N']	[29]
30	lymphoblastic	O	['N']	[30]
31	leukemia	O	['N']	[31]
32	(	O	['N']	[32]
33	ALL	O	['N']	[33]
34	)	O	['N']	[34]
35	,	O	['N']	[35]
36	presenting	O	['N']	[36]
37	with	O	['N']	[37]
38	right	O	['N']	[38]
39	-	O	['N']	[39]
40	sided	O	['N']	[40]
41	paralysis	O	['N']	[41]
42	and	O	['N']	[42]
43	aphasia	O	['N']	[43]
44	after	O	['N']	[44]
45	second	O	['N']	[45]
46	consolidation	O	['N']	[46]
47	with	O	['N']	[47]
48	intrathecal	O	['N']	[48]
49	triple	O	['N']	[49]
50	-	O	['N']	[50]
51	drug	O	['N']	[51]
52	therapy	O	['N']	[52]
53	given	O	['N']	[53]
54	intrathecally	O	['N']	[54]
55	.	O	['N']	[55]
#177
0	The	O	['N']	[0]
1	use	O	['N']	[1]
2	of	O	['N']	[2]
3	pamidronate	O	['N']	[3]
4	for	O	['N']	[4]
5	hypercalcemia	O	['N']	[5]
6	secondary	O	['N']	[6]
7	to	O	['N']	[7]
8	acute	O	['N']	[8]
9	vitamin	B	['N']	[9]
10	D	I-Drug	['Causes']	[11]
11	intoxication	I-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#178
0	Two	O	['N']	[0]
1	children	O	['N']	[1]
2	,	O	['N']	[2]
3	1	O	['N']	[3]
4	with	O	['N']	[4]
5	idiopathic	O	['N']	[5]
6	nephrotic	O	['N']	[6]
7	syndrome	O	['N']	[7]
8	and	O	['N']	[8]
9	1	O	['N']	[9]
10	with	O	['N']	[10]
11	endo	O	['N']	[11]
12	-	O	['N']	[12]
13	extracapillary	O	['N']	[13]
14	glomerulonephritis	O	['N']	[14]
15	,	O	['N']	[15]
16	presented	O	['N']	[16]
17	an	O	['N']	[17]
18	episode	O	['N']	[18]
19	of	O	['N']	[19]
20	seizures	B-Adverse_Effect	['N']	[20]
21	and	O	['N']	[21]
22	transient	O	['N']	[22]
23	blindness	O	['N']	[23]
24	at	O	['N']	[24]
25	different	O	['N']	[25]
26	times	O	['N']	[26]
27	after	O	['N']	[27]
28	i.v	O	['N']	[28]
29	.	O	['N']	[29]
30	pulse	O	['N']	[30]
31	methylprednisolone	B-Drug	['Causes']	[20]
32	(	O	['N']	[32]
33	IVPMP	O	['N']	[33]
34	)	O	['N']	[34]
35	treatment	O	['N']	[35]
36	.	O	['N']	[36]
#179
0	Pulmonary	B	['N']	[0]
1	fibrosis	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	nabumetone	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#180
0	Several	O	['N']	[0]
1	possible	O	['N']	[1]
2	explanations	O	['N']	[2]
3	of	O	['N']	[3]
4	the	O	['N']	[4]
5	mechanism	O	['N']	[5]
6	of	O	['N']	[6]
7	renal	B	['N']	[7]
8	failure	I-Adverse_Effect	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	use	O	['N']	[12]
13	of	O	['N']	[13]
14	dextran-40	B-Drug	['Causes']	[8]
15	are	O	['N']	[15]
16	discussed	O	['N']	[16]
17	.	O	['N']	[17]
#181
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Clinicians	O	['N']	[2]
3	should	O	['N']	[3]
4	be	O	['N']	[4]
5	aware	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	possible	O	['N']	[8]
9	association	O	['N']	[9]
10	of	O	['N']	[10]
11	thrombocytopenia	B-Adverse_Effect	['N']	[11]
12	with	O	['N']	[12]
13	lansoprazole	B-Drug	['Causes']	[11]
14	and	O	['N']	[14]
15	discontinue	O	['N']	[15]
16	the	O	['N']	[16]
17	drug	O	['N']	[17]
18	if	O	['N']	[18]
19	thrombocytopenia	O	['N']	[19]
20	becomes	O	['N']	[20]
21	apparent	O	['N']	[21]
22	.	O	['N']	[22]
#182
0	We	O	['N']	[0]
1	conclude	O	['N']	[1]
2	peripheral	B	['N']	[2]
3	neuropathy	I-Adverse_Effect	['N']	[3]
4	with	O	['N']	[4]
5	5-FU	B-Drug	['Causes']	[3]
6	is	O	['N']	[6]
7	rare	O	['N']	[7]
8	.	O	['N']	[8]
#183
0	The	O	['N']	[0]
1	potential	O	['N']	[1]
2	development	O	['N']	[2]
3	of	O	['N']	[3]
4	SJS	B-Adverse_Effect	['N']	[4]
5	/	O	['N']	[5]
6	TEN	O	['N']	[6]
7	,	O	['N']	[7]
8	a	O	['N']	[8]
9	severe	O	['N']	[9]
10	life	O	['N']	[10]
11	-	O	['N']	[11]
12	threatening	O	['N']	[12]
13	illness	O	['N']	[13]
14	,	O	['N']	[14]
15	emphasizes	O	['N']	[15]
16	the	O	['N']	[16]
17	need	O	['N']	[17]
18	for	O	['N']	[18]
19	judicious	O	['N']	[19]
20	use	O	['N']	[20]
21	of	O	['N']	[21]
22	TMP	B	['N']	[22]
23	-	I	['N']	[23]
24	Sx	I-Drug	['Causes']	[4]
25	and	O	['N']	[25]
26	close	O	['N']	[26]
27	monitoring	O	['N']	[27]
28	and	O	['N']	[28]
29	follow	O	['N']	[29]
30	-	O	['N']	[30]
31	up	O	['N']	[31]
32	for	O	['N']	[32]
33	patients	O	['N']	[33]
34	who	O	['N']	[34]
35	were	O	['N']	[35]
36	given	O	['N']	[36]
37	TMP	O	['N']	[37]
38	-	O	['N']	[38]
39	Sx	O	['N']	[39]
40	for	O	['N']	[40]
41	SSTIs	O	['N']	[41]
42	.	O	['N']	[42]
#184
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	4	O	['N']	[2]
3	patients	O	['N']	[3]
4	,	O	['N']	[4]
5	2	O	['N']	[5]
6	on	O	['N']	[6]
7	methylphenidate	O	['N']	[7]
8	and	O	['N']	[8]
9	2	O	['N']	[9]
10	on	O	['N']	[10]
11	dextroamphetamine	B-Drug	['Causes']	[19]
12	who	O	['N']	[12]
13	presented	O	['N']	[13]
14	with	O	['N']	[14]
15	acral	O	['N']	[15]
16	cyanosis	O	['N']	[16]
17	,	O	['N']	[17]
18	livedo	B	['N']	[18]
19	reticularis	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	or	O	['N']	[21]
22	Raynaud	O	['N']	[22]
23	phenomenon	O	['N']	[23]
24	.	O	['N']	[24]
#185
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	3	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	severe	B	['N']	[5]
6	hepatocellular	I	['N']	[6]
7	damage	I-Adverse_Effect	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	CPA	B-Drug	['Causes']	[7]
11	therapy	O	['N']	[11]
12	,	O	['N']	[12]
13	2	O	['N']	[13]
14	with	O	['N']	[14]
15	fatal	O	['N']	[15]
16	fulminant	O	['N']	[16]
17	hepatitis	O	['N']	[17]
18	.	O	['N']	[18]
#186
0	Currently	O	['N']	[0]
1	the	O	['N']	[1]
2	use	O	['N']	[2]
3	of	O	['N']	[3]
4	zidovudine	B-Drug	['Causes']	[18]
5	is	O	['N']	[5]
6	one	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	few	O	['N']	[9]
10	specific	O	['N']	[10]
11	measures	O	['N']	[11]
12	available	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	as	O	['N']	[15]
16	a	O	['N']	[16]
17	potentially	O	['N']	[17]
18	teratogenic	B-Adverse_Effect	['N']	[18]
19	and	O	['N']	[19]
20	fetotoxic	O	['N']	[20]
21	agent	O	['N']	[21]
22	,	O	['N']	[22]
23	any	O	['N']	[23]
24	decision	O	['N']	[24]
25	for	O	['N']	[25]
26	its	O	['N']	[26]
27	use	O	['N']	[27]
28	requires	O	['N']	[28]
29	evaluation	O	['N']	[29]
30	of	O	['N']	[30]
31	the	O	['N']	[31]
32	potential	O	['N']	[32]
33	for	O	['N']	[33]
34	fetal	O	['N']	[34]
35	damage	O	['N']	[35]
36	.	O	['N']	[36]
#187
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Itraconazole	B-Drug	['Causes']	[20]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	liver	O	['N']	[5]
6	injury	O	['N']	[6]
7	presents	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	cholestatic	O	['N']	[10]
11	pattern	O	['N']	[11]
12	of	O	['N']	[12]
13	injury	O	['N']	[13]
14	with	O	['N']	[14]
15	damage	B	['N']	[15]
16	to	I	['N']	[16]
17	the	I	['N']	[17]
18	interlobular	I	['N']	[18]
19	bile	I	['N']	[19]
20	ducts	I-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	possibly	O	['N']	[22]
23	leading	O	['N']	[23]
24	to	O	['N']	[24]
25	ductopenia	O	['N']	[25]
26	.	O	['N']	[26]
#188
0	After	O	['N']	[0]
1	administration	O	['N']	[1]
2	of	O	['N']	[2]
3	Oxybutynin	O	['N']	[3]
4	concomitantly	O	['N']	[4]
5	with	O	['N']	[5]
6	an	O	['N']	[6]
7	increase	O	['N']	[7]
8	in	O	['N']	[8]
9	the	O	['N']	[9]
10	dose	O	['N']	[10]
11	of	O	['N']	[11]
12	Dantrolene	O	['N']	[12]
13	,	O	['N']	[13]
14	she	O	['N']	[14]
15	presented	O	['N']	[15]
16	the	O	['N']	[16]
17	clinical	O	['N']	[17]
18	symptoms	O	['N']	[18]
19	and	O	['N']	[19]
20	laboratory	O	['N']	[20]
21	finding	O	['N']	[21]
22	of	O	['N']	[22]
23	Carbamazepine	B-Drug	['Causes']	[24]
24	intoxication	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#189
0	On	O	['N']	[0]
1	day	O	['N']	[1]
2	7	O	['N']	[2]
3	of	O	['N']	[3]
4	linezolid	B-Drug	['Causes']	[19]
5	treatment	O	['N']	[5]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	patient	O	['N']	[8]
9	developed	O	['N']	[9]
10	severe	O	['N']	[10]
11	pruritus	O	['N']	[11]
12	,	O	['N']	[12]
13	macular	O	['N']	[13]
14	rash	O	['N']	[14]
15	,	O	['N']	[15]
16	facial	O	['N']	[16]
17	edema	O	['N']	[17]
18	,	O	['N']	[18]
19	eosinophilia	B-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	marked	O	['N']	[21]
22	increase	O	['N']	[22]
23	in	O	['N']	[23]
24	serum	O	['N']	[24]
25	creatinine	O	['N']	[25]
26	level	O	['N']	[26]
27	,	O	['N']	[27]
28	and	O	['N']	[28]
29	mild	O	['N']	[29]
30	hepatitis	O	['N']	[30]
31	.	O	['N']	[31]
#190
0	A	O	['N']	[0]
1	5-month	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	infant	O	['N']	[4]
5	became	O	['N']	[5]
6	lethargic	O	['N']	[6]
7	and	O	['N']	[7]
8	poorly	O	['N']	[8]
9	responsive	O	['N']	[9]
10	after	O	['N']	[10]
11	receiving	O	['N']	[11]
12	1	B	['N']	[12]
13	drop	I-Dose	['N']	[13]
14	of	O	['N']	[14]
15	brimonidine	B-Drug	['Dosage']	[13]
16	in	O	['N']	[16]
17	each	O	['N']	[17]
18	eye	O	['N']	[18]
19	.	O	['N']	[19]
#191
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	heatstroke	B-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	reported	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	32-year	O	['N']	[8]
9	-	O	['N']	[9]
10	old	O	['N']	[10]
11	man	O	['N']	[11]
12	diagnosed	O	['N']	[12]
13	with	O	['N']	[13]
14	schizophrenia	O	['N']	[14]
15	and	O	['N']	[15]
16	on	O	['N']	[16]
17	clozapine	B-Drug	['Causes']	[3]
18	monotherapy	O	['N']	[18]
19	.	O	['N']	[19]
#192
0	Amiodarone	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	thyrotoxicosis	B-Adverse_Effect	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	thyrotropin	O	['N']	[6]
7	receptor	O	['N']	[7]
8	antibody	O	['N']	[8]
9	.	O	['N']	[9]
#193
0	These	O	['N']	[0]
1	two	O	['N']	[1]
2	cases	O	['N']	[2]
3	highlight	O	['N']	[3]
4	the	O	['N']	[4]
5	importance	O	['N']	[5]
6	of	O	['N']	[6]
7	considering	O	['N']	[7]
8	lopinavir	B-Drug	['Causes']	[12]
9	/	O	['N']	[9]
10	ritonavir	O	['N']	[10]
11	induced	O	['N']	[11]
12	arrhythmias	B-Adverse_Effect	['N']	[12]
13	when	O	['N']	[13]
14	dealing	O	['N']	[14]
15	with	O	['N']	[15]
16	HIV	O	['N']	[16]
17	-	O	['N']	[17]
18	positive	O	['N']	[18]
19	individuals	O	['N']	[19]
20	.	O	['N']	[20]
#194
0	Sweet	B	['N']	[0]
1	's	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	is	O	['N']	[3]
4	an	O	['N']	[4]
5	acute	O	['N']	[5]
6	febrile	O	['N']	[6]
7	neutrophilic	O	['N']	[7]
8	dermatosis	O	['N']	[8]
9	that	O	['N']	[9]
10	is	O	['N']	[10]
11	a	O	['N']	[11]
12	known	O	['N']	[12]
13	complication	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	administration	O	['N']	[16]
17	of	O	['N']	[17]
18	filgrastim	B-Drug	['Causes']	[2]
19	,	O	['N']	[19]
20	a	O	['N']	[20]
21	drug	O	['N']	[21]
22	that	O	['N']	[22]
23	causes	O	['N']	[23]
24	increased	O	['N']	[24]
25	neutrophil	O	['N']	[25]
26	proliferation	O	['N']	[26]
27	and	O	['N']	[27]
28	differentiation	O	['N']	[28]
29	.	O	['N']	[29]
#195
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	advanced	O	['N']	[5]
6	ovarian	O	['N']	[6]
7	carcinoma	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	difficulty	O	['N']	[10]
11	walking	O	['N']	[11]
12	because	O	['N']	[12]
13	of	O	['N']	[13]
14	marked	O	['N']	[14]
15	pain	O	['N']	[15]
16	in	O	['N']	[16]
17	the	O	['N']	[17]
18	lower	O	['N']	[18]
19	extremities	O	['N']	[19]
20	and	O	['N']	[20]
21	loss	B	['N']	[21]
22	of	I	['N']	[22]
23	proprioception	I-Adverse_Effect	['N']	[23]
24	25	O	['N']	[24]
25	days	O	['N']	[25]
26	after	O	['N']	[26]
27	treatment	O	['N']	[27]
28	with	O	['N']	[28]
29	weekly	O	['N']	[29]
30	taxol	B-Drug	['Causes']	[23]
31	(	O	['N']	[31]
32	80	O	['N']	[32]
33	mg	O	['N']	[33]
34	/	O	['N']	[34]
35	m(2)x3	O	['N']	[35]
36	)	O	['N']	[36]
37	.	O	['N']	[37]
#196
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	case	O	['N']	[3]
4	suggests	O	['N']	[4]
5	that	O	['N']	[5]
6	losartan	B-Drug	['Causes']	[12]
7	can	O	['N']	[7]
8	induce	O	['N']	[8]
9	late	O	['N']	[9]
10	-	O	['N']	[10]
11	onset	O	['N']	[11]
12	angioedema	B-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	patients	O	['N']	[14]
15	with	O	['N']	[15]
16	normal	O	['N']	[16]
17	renal	O	['N']	[17]
18	function	O	['N']	[18]
19	and	O	['N']	[19]
20	that	O	['N']	[20]
21	the	O	['N']	[21]
22	reaction	O	['N']	[22]
23	can	O	['N']	[23]
24	recur	O	['N']	[24]
25	after	O	['N']	[25]
26	initial	O	['N']	[26]
27	resolution	O	['N']	[27]
28	of	O	['N']	[28]
29	the	O	['N']	[29]
30	symptoms	O	['N']	[30]
31	.	O	['N']	[31]
#197
0	To	O	['N']	[0]
1	the	O	['N']	[1]
2	best	O	['N']	[2]
3	of	O	['N']	[3]
4	the	O	['N']	[4]
5	authors	O	['N']	[5]
6	'	O	['N']	[6]
7	knowledge	O	['N']	[7]
8	,	O	['N']	[8]
9	this	O	['N']	[9]
10	is	O	['N']	[10]
11	the	O	['N']	[11]
12	first	O	['N']	[12]
13	reported	O	['N']	[13]
14	case	O	['N']	[14]
15	of	O	['N']	[15]
16	Propecia	B-Drug	['Causes']	[19]
17	-	O	['N']	[17]
18	associated	O	['N']	[18]
19	cataract	B-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#198
0	An	O	['N']	[0]
1	adult	O	['N']	[1]
2	male	O	['N']	[2]
3	presented	O	['N']	[3]
4	with	O	['N']	[4]
5	central	B	['N']	[5]
6	blindness	I-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	ingesting	O	['N']	[8]
9	methanol	B-Drug	['Causes']	[6]
10	.	O	['N']	[10]
#199
0	In	O	['N']	[0]
1	deciding	O	['N']	[1]
2	if	O	['N']	[2]
3	tamoxifen	B-Drug	['Causes']	[24]
4	therapy	O	['N']	[4]
5	is	O	['N']	[5]
6	warranted	O	['N']	[6]
7	,	O	['N']	[7]
8	all	O	['N']	[8]
9	potentially	O	['N']	[9]
10	life	O	['N']	[10]
11	-	O	['N']	[11]
12	threatening	O	['N']	[12]
13	adverse	O	['N']	[13]
14	events	O	['N']	[14]
15	associated	O	['N']	[15]
16	with	O	['N']	[16]
17	tamoxifen	O	['N']	[17]
18	should	O	['N']	[18]
19	be	O	['N']	[19]
20	considered	O	['N']	[20]
21	,	O	['N']	[21]
22	including	O	['N']	[22]
23	endometrial	B	['N']	[23]
24	adenocarcinoma	I-Adverse_Effect	['N']	[24]
25	or	O	['N']	[25]
26	uterine	O	['N']	[26]
27	sarcoma	O	['N']	[27]
28	.	O	['N']	[28]
#200
0	We	O	['N']	[0]
1	believe	O	['N']	[1]
2	that	O	['N']	[2]
3	mucositis	O	['N']	[3]
4	was	O	['N']	[4]
5	a	O	['N']	[5]
6	contributing	O	['N']	[6]
7	factor	O	['N']	[7]
8	to	O	['N']	[8]
9	this	O	['N']	[9]
10	case	O	['N']	[10]
11	of	O	['N']	[11]
12	fatal	B	['N']	[12]
13	hyperkalemia	I-Adverse_Effect	['N']	[13]
14	after	O	['N']	[14]
15	administration	O	['N']	[15]
16	of	O	['N']	[16]
17	succinylcholine	B-Drug	['Causes']	[13]
18	,	O	['N']	[18]
19	with	O	['N']	[19]
20	a	O	['N']	[20]
21	mechanism	O	['N']	[21]
22	similar	O	['N']	[22]
23	to	O	['N']	[23]
24	that	O	['N']	[24]
25	reported	O	['N']	[25]
26	with	O	['N']	[26]
27	thermal	O	['N']	[27]
28	injury	O	['N']	[28]
29	.	O	['N']	[29]
#201
0	Carbamazepine	B-Drug	['Causes']	[1]
1	toxicity	I-Adverse_Effect	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	clarithromycin	O	['N']	[4]
5	coadministration	O	['N']	[5]
6	in	O	['N']	[6]
7	psychiatric	O	['N']	[7]
8	patients	O	['N']	[8]
9	.	O	['N']	[9]
#202
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	polymorphic	B	['N']	[6]
7	ventricular	I	['N']	[7]
8	tachycardia	I-Adverse_Effect	['N']	[8]
9	with	O	['N']	[9]
10	normal	O	['N']	[10]
11	QT	O	['N']	[11]
12	interval	O	['N']	[12]
13	associated	O	['N']	[13]
14	with	O	['N']	[14]
15	the	O	['N']	[15]
16	oral	O	['N']	[16]
17	use	O	['N']	[17]
18	of	O	['N']	[18]
19	levofloxacin	B-Drug	['Causes']	[8]
20	in	O	['N']	[20]
21	the	O	['N']	[21]
22	absence	O	['N']	[22]
23	of	O	['N']	[23]
24	other	O	['N']	[24]
25	etiologies	O	['N']	[25]
26	known	O	['N']	[26]
27	to	O	['N']	[27]
28	cause	O	['N']	[28]
29	these	O	['N']	[29]
30	arrhythmias	O	['N']	[30]
31	.	O	['N']	[31]
#203
0	CASE	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	woman	O	['N']	[8]
9	with	O	['N']	[9]
10	severe	O	['N']	[10]
11	human	B	['N']	[11]
12	insulin	I-Drug	['Causes']	[15]
13	-	O	['N']	[13]
14	induced	O	['N']	[14]
15	lipoatrophy	B-Adverse_Effect	['N']	[15]
16	who	O	['N']	[16]
17	has	O	['N']	[17]
18	been	O	['N']	[18]
19	treated	O	['N']	[19]
20	exclusively	O	['N']	[20]
21	with	O	['N']	[21]
22	recombinant	O	['N']	[22]
23	DNA	O	['N']	[23]
24	human	O	['N']	[24]
25	insulin	O	['N']	[25]
26	since	O	['N']	[26]
27	the	O	['N']	[27]
28	onset	O	['N']	[28]
29	of	O	['N']	[29]
30	IDDM	O	['N']	[30]
31	.	O	['N']	[31]
#204
0	The	O	['N']	[0]
1	first	O	['N']	[1]
2	patient	O	['N']	[2]
3	is	O	['N']	[3]
4	undergoing	O	['N']	[4]
5	hemodialysis	O	['N']	[5]
6	and	O	['N']	[6]
7	,	O	['N']	[7]
8	though	O	['N']	[8]
9	responding	O	['N']	[9]
10	to	O	['N']	[10]
11	sunitinib	B-Drug	['Causes']	[18]
12	,	O	['N']	[12]
13	is	O	['N']	[13]
14	having	O	['N']	[14]
15	significant	O	['N']	[15]
16	fatigue	O	['N']	[16]
17	and	O	['N']	[17]
18	hypertension	B-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#205
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	also	O	['N']	[2]
3	determined	O	['N']	[3]
4	that	O	['N']	[4]
5	their	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	myositis	O	['N']	[8]
9	developing	O	['N']	[9]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	rectus	O	['N']	[12]
13	abdominus	O	['N']	[13]
14	muscle	O	['N']	[14]
15	of	O	['N']	[15]
16	a	O	['N']	[16]
17	patient	O	['N']	[17]
18	with	O	['N']	[18]
19	pancreatic	O	['N']	[19]
20	adenocarcinoma	O	['N']	[20]
21	was	O	['N']	[21]
22	the	O	['N']	[22]
23	manifestation	O	['N']	[23]
24	of	O	['N']	[24]
25	radiation	B	['N']	[25]
26	recall	I-Adverse_Effect	['N']	[26]
27	,	O	['N']	[27]
28	thereby	O	['N']	[28]
29	bringing	O	['N']	[29]
30	the	O	['N']	[30]
31	number	O	['N']	[31]
32	of	O	['N']	[32]
33	patients	O	['N']	[33]
34	who	O	['N']	[34]
35	developed	O	['N']	[35]
36	radiation	O	['N']	[36]
37	recall	O	['N']	[37]
38	to	O	['N']	[38]
39	gemcitabine	B-Drug	['Causes']	[26]
40	and	O	['N']	[40]
41	were	O	['N']	[41]
42	discussed	O	['N']	[42]
43	in	O	['N']	[43]
44	the	O	['N']	[44]
45	current	O	['N']	[45]
46	study	O	['N']	[46]
47	to	O	['N']	[47]
48	13	O	['N']	[48]
49	.	O	['N']	[49]
#206
0	Lichenoid	B	['N']	[0]
1	drug	I	['N']	[1]
2	eruption	I-Adverse_Effect	['N']	[2]
3	to	O	['N']	[3]
4	salsalate	B-Drug	['Causes']	[2]
5	.	O	['N']	[5]
#207
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Clinicians	O	['N']	[2]
3	should	O	['N']	[3]
4	be	O	['N']	[4]
5	aware	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	risk	O	['N']	[8]
9	of	O	['N']	[9]
10	serotonin	B	['N']	[10]
11	syndrome	I-Adverse_Effect	['N']	[11]
12	with	O	['N']	[12]
13	serious	O	['N']	[13]
14	extrapyramidal	O	['N']	[14]
15	reactions	O	['N']	[15]
16	in	O	['N']	[16]
17	patients	O	['N']	[17]
18	receiving	O	['N']	[18]
19	sertraline	O	['N']	[19]
20	or	O	['N']	[20]
21	venlafaxine	B-Drug	['Causes']	[11]
22	when	O	['N']	[22]
23	metoclopramide	O	['N']	[23]
24	is	O	['N']	[24]
25	coadministered	O	['N']	[25]
26	even	O	['N']	[26]
27	in	O	['N']	[27]
28	a	O	['N']	[28]
29	single	O	['N']	[29]
30	,	O	['N']	[30]
31	conventional	O	['N']	[31]
32	dose	O	['N']	[32]
33	.	O	['N']	[33]
#208
0	She	O	['N']	[0]
1	developed	O	['N']	[1]
2	a	O	['N']	[2]
3	generalized	B	['N']	[3]
4	rash	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	itching	O	['N']	[6]
7	,	O	['N']	[7]
8	sore	O	['N']	[8]
9	throat	O	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	dizziness	O	['N']	[12]
13	approximately	O	['N']	[13]
14	4	O	['N']	[14]
15	hours	O	['N']	[15]
16	after	O	['N']	[16]
17	the	O	['N']	[17]
18	first	O	['N']	[18]
19	dose	O	['N']	[19]
20	of	O	['N']	[20]
21	capecitabine	B-Drug	['Causes']	[4]
22	.	O	['N']	[22]
#209
0	Pseudomembranous	B	['N']	[0]
1	colitis	I-Adverse_Effect	['N']	[1]
2	readily	O	['N']	[2]
3	occurs	O	['N']	[3]
4	in	O	['N']	[4]
5	at	O	['N']	[5]
6	least	O	['N']	[6]
7	certain	O	['N']	[7]
8	population	O	['N']	[8]
9	groups	O	['N']	[9]
10	receiving	O	['N']	[10]
11	trimethoprim	O	['N']	[11]
12	-	O	['N']	[12]
13	sulfamethoxazole	B-Drug	['Causes']	[1]
14	.	O	['N']	[14]
#210
0	The	O	['N']	[0]
1	development	O	['N']	[1]
2	of	O	['N']	[2]
3	cutaneous	O	['N']	[3]
4	ecchymosis	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	a	O	['N']	[7]
8	sudden	O	['N']	[8]
9	fall	O	['N']	[9]
10	in	O	['N']	[10]
11	hemoglobin	O	['N']	[11]
12	after	O	['N']	[12]
13	the	O	['N']	[13]
14	administration	O	['N']	[14]
15	of	O	['N']	[15]
16	alteplase	B-Drug	['Causes']	[25]
17	should	O	['N']	[17]
18	strongly	O	['N']	[18]
19	suggest	O	['N']	[19]
20	the	O	['N']	[20]
21	possibility	O	['N']	[21]
22	of	O	['N']	[22]
23	diffuse	B	['N']	[23]
24	subfascial	I	['N']	[24]
25	hematoma	I-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#211
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	that	O	['N']	[4]
5	developed	O	['N']	[5]
6	acute	O	['N']	[6]
7	myeloid	O	['N']	[7]
8	leukaemia	O	['N']	[8]
9	(	O	['N']	[9]
10	AML	B-Adverse_Effect	['N']	[10]
11	)	O	['N']	[11]
12	during	O	['N']	[12]
13	tamoxifen	B-Drug	['Causes']	[10]
14	therapy	O	['N']	[14]
15	for	O	['N']	[15]
16	breast	O	['N']	[16]
17	cancer	O	['N']	[17]
18	.	O	['N']	[18]
#212
0	An	O	['N']	[0]
1	infant	O	['N']	[1]
2	girl	O	['N']	[2]
3	with	O	['N']	[3]
4	choanal	O	['N']	[4]
5	atresia	O	['N']	[5]
6	,	O	['N']	[6]
7	athelia	B-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	minor	O	['N']	[9]
10	anomalies	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	mild	O	['N']	[13]
14	to	O	['N']	[14]
15	moderate	O	['N']	[15]
16	mental	O	['N']	[16]
17	retardation	O	['N']	[17]
18	was	O	['N']	[18]
19	born	O	['N']	[19]
20	to	O	['N']	[20]
21	a	O	['N']	[21]
22	woman	O	['N']	[22]
23	treated	O	['N']	[23]
24	for	O	['N']	[24]
25	hyperthyroidism	O	['N']	[25]
26	throughout	O	['N']	[26]
27	pregnancy	O	['N']	[27]
28	with	O	['N']	[28]
29	methimazole	O	['N']	[29]
30	and	O	['N']	[30]
31	propranolol	B-Drug	['Causes']	[7]
32	.	O	['N']	[32]
#213
0	Ibopamine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	reversible	O	['N']	[3]
4	leukopenia	B-Adverse_Effect	['N']	[4]
5	during	O	['N']	[5]
6	treatment	O	['N']	[6]
7	for	O	['N']	[7]
8	congestive	O	['N']	[8]
9	heart	O	['N']	[9]
10	failure	O	['N']	[10]
11	.	O	['N']	[11]
#214
0	The	O	['N']	[0]
1	uncomplicated	O	['N']	[1]
2	long	O	['N']	[2]
3	-	O	['N']	[3]
4	term	O	['N']	[4]
5	use	O	['N']	[5]
6	of	O	['N']	[6]
7	adequately	O	['N']	[7]
8	-	O	['N']	[8]
9	dosed	O	['N']	[9]
10	AZA	B-Drug	['Causes']	[29]
11	and	O	['N']	[11]
12	stable	O	['N']	[12]
13	non	O	['N']	[13]
14	-	O	['N']	[14]
15	toxic	O	['N']	[15]
16	metabolite	O	['N']	[16]
17	levels	O	['N']	[17]
18	could	O	['N']	[18]
19	not	O	['N']	[19]
20	acknowledge	O	['N']	[20]
21	TPMT	O	['N']	[21]
22	deficiency	O	['N']	[22]
23	as	O	['N']	[23]
24	a	O	['N']	[24]
25	primary	O	['N']	[25]
26	cause	O	['N']	[26]
27	of	O	['N']	[27]
28	the	O	['N']	[28]
29	leukopenia	B-Adverse_Effect	['N']	[29]
30	.	O	['N']	[30]
#215
0	A	O	['N']	[0]
1	40-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	advanced	O	['N']	[6]
7	HIV	O	['N']	[7]
8	infection	O	['N']	[8]
9	and	O	['N']	[9]
10	Mycobacterium	O	['N']	[10]
11	avium	O	['N']	[11]
12	complex	O	['N']	[12]
13	infection	O	['N']	[13]
14	experienced	O	['N']	[14]
15	rapid	B	['N']	[15]
16	cognitive	I	['N']	[16]
17	decline	I-Adverse_Effect	['N']	[17]
18	after	O	['N']	[18]
19	commencement	O	['N']	[19]
20	of	O	['N']	[20]
21	ethambutol	B-Drug	['Causes']	[17]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	symptoms	O	['N']	[24]
25	fully	O	['N']	[25]
26	resolved	O	['N']	[26]
27	with	O	['N']	[27]
28	cessation	O	['N']	[28]
29	.	O	['N']	[29]
#216
0	A	O	['N']	[0]
1	child	O	['N']	[1]
2	in	O	['N']	[2]
3	whom	O	['N']	[3]
4	a	O	['N']	[4]
5	phenobarbital	B-Drug	['Causes']	[28]
6	hypersensitivity	O	['N']	[6]
7	drug	O	['N']	[7]
8	reaction	O	['N']	[8]
9	developed	O	['N']	[9]
10	which	O	['N']	[10]
11	consisted	O	['N']	[11]
12	of	O	['N']	[12]
13	fever	O	['N']	[13]
14	,	O	['N']	[14]
15	a	O	['N']	[15]
16	pruritic	O	['N']	[16]
17	desquamating	O	['N']	[17]
18	erythrodermic	O	['N']	[18]
19	rash	O	['N']	[19]
20	,	O	['N']	[20]
21	alopecia	O	['N']	[21]
22	,	O	['N']	[22]
23	icterus	O	['N']	[23]
24	,	O	['N']	[24]
25	protein	B	['N']	[25]
26	-	I	['N']	[26]
27	losing	I	['N']	[27]
28	enteropathy	I-Adverse_Effect	['N']	[28]
29	,	O	['N']	[29]
30	myositis	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	nephritis	O	['N']	[33]
34	,	O	['N']	[34]
35	is	O	['N']	[35]
36	described	O	['N']	[36]
37	.	O	['N']	[37]
#217
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	the	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	young	O	['N']	[8]
9	woman	O	['N']	[9]
10	with	O	['N']	[10]
11	Graves	O	['N']	[11]
12	'	O	['N']	[12]
13	disease	O	['N']	[13]
14	in	O	['N']	[14]
15	whom	O	['N']	[15]
16	ototoxicity	O	['N']	[16]
17	developed	O	['N']	[17]
18	because	O	['N']	[18]
19	of	O	['N']	[19]
20	propylthiouracil	O	['N']	[20]
21	(	O	['N']	[21]
22	PTU)-induced	-	['N']	[22]
23	antineutrophil	B	['N']	[23]
24	cytoplasmic	I	['N']	[24]
25	antibody	I	['N']	[25]
26	(	I	['N']	[26]
27	ANCA)-associated	I	['N']	[27]
28	vasculitis	I-Adverse_Effect	['N']	[28]
29	.	O	['N']	[29]
#218
0	Thus	O	['N']	[0]
1	,	O	['N']	[1]
2	tacrolimus	B-Drug	['Causes']	[5]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	HUS	B-Adverse_Effect	['N']	[5]
6	is	O	['N']	[6]
7	a	O	['N']	[7]
8	rare	O	['N']	[8]
9	cause	O	['N']	[9]
10	of	O	['N']	[10]
11	ARF	O	['N']	[11]
12	in	O	['N']	[12]
13	nephrotic	O	['N']	[13]
14	syndrome	O	['N']	[14]
15	.	O	['N']	[15]
#219
0	Lithium	B-Drug	['Causes']	[9]
1	treatment	O	['N']	[1]
2	was	O	['N']	[2]
3	terminated	O	['N']	[3]
4	in	O	['N']	[4]
5	1975	O	['N']	[5]
6	because	O	['N']	[6]
7	of	O	['N']	[7]
8	lithium	B	['N']	[8]
9	intoxication	I-Adverse_Effect	['N']	[9]
10	with	O	['N']	[10]
11	a	O	['N']	[11]
12	diabetes	O	['N']	[12]
13	insipidus	O	['N']	[13]
14	-	O	['N']	[14]
15	like	O	['N']	[15]
16	syndrome	O	['N']	[16]
17	.	O	['N']	[17]
#220
0	Studies	O	['N']	[0]
1	performed	O	['N']	[1]
2	10	O	['N']	[2]
3	years	O	['N']	[3]
4	ago	O	['N']	[4]
5	on	O	['N']	[5]
6	25	O	['N']	[6]
7	patients	O	['N']	[7]
8	with	O	['N']	[8]
9	MTX	B-Drug	['Causes']	[13]
10	-	O	['N']	[10]
11	induced	O	['N']	[11]
12	liver	O	['N']	[12]
13	cirrhosis	B-Adverse_Effect	['N']	[13]
14	indicated	O	['N']	[14]
15	that	O	['N']	[15]
16	this	O	['N']	[16]
17	type	O	['N']	[17]
18	of	O	['N']	[18]
19	cirrhosis	O	['N']	[19]
20	was	O	['N']	[20]
21	not	O	['N']	[21]
22	of	O	['N']	[22]
23	an	O	['N']	[23]
24	aggressive	O	['N']	[24]
25	nature	O	['N']	[25]
26	.	O	['N']	[26]
#221
0	Visual	B	['N']	[0]
1	loss	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	a	O	['N']	[3]
4	single	O	['N']	[4]
5	small	O	['N']	[5]
6	dose	O	['N']	[6]
7	of	O	['N']	[7]
8	vincristine	B-Drug	['Causes']	[1]
9	has	O	['N']	[9]
10	never	O	['N']	[10]
11	been	O	['N']	[11]
12	reported	O	['N']	[12]
13	.	O	['N']	[13]
#222
0	Asthma	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	urticaria	O	['N']	[2]
3	during	O	['N']	[3]
4	disodium	B	['N']	[4]
5	cromoglycate	I-Drug	['Causes']	[0]
6	treatment	O	['N']	[6]
7	.	O	['N']	[7]
#223
0	On	O	['N']	[0]
1	the	O	['N']	[1]
2	other	O	['N']	[2]
3	hand	O	['N']	[3]
4	,	O	['N']	[4]
5	MTX	B-Drug	['Causes']	[8]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	pneumonitis	B-Adverse_Effect	['N']	[8]
9	seems	O	['N']	[9]
10	to	O	['N']	[10]
11	be	O	['N']	[11]
12	very	O	['N']	[12]
13	rare	O	['N']	[13]
14	in	O	['N']	[14]
15	psoriatic	O	['N']	[15]
16	arthritis	O	['N']	[16]
17	(	O	['N']	[17]
18	PsA	O	['N']	[18]
19	)	O	['N']	[19]
20	.	O	['N']	[20]
#224
0	Our	O	['N']	[0]
1	report	O	['N']	[1]
2	suggested	O	['N']	[2]
3	that	O	['N']	[3]
4	CBDCA	B-Drug	['Dosage']	[50]
5	hypersensitivity	O	['N']	[5]
6	was	O	['N']	[6]
7	correlated	O	['N']	[7]
8	with	O	['N']	[8]
9	the	O	['N']	[9]
10	total	O	['N']	[10]
11	dose	O	['N']	[11]
12	of	O	['N']	[12]
13	previously	O	['N']	[13]
14	administered	O	['N']	[14]
15	platinum	O	['N']	[15]
16	agents	O	['N']	[16]
17	and	O	['N']	[17]
18	that	O	['N']	[18]
19	CBDCA	O	['N']	[19]
20	should	O	['N']	[20]
21	be	O	['N']	[21]
22	excluded	O	['N']	[22]
23	in	O	['N']	[23]
24	patients	O	['N']	[24]
25	who	O	['N']	[25]
26	have	O	['N']	[26]
27	received	O	['N']	[27]
28	multiple	O	['N']	[28]
29	platinum	O	['N']	[29]
30	-	O	['N']	[30]
31	based	O	['N']	[31]
32	chemotherapy	O	['N']	[32]
33	,	O	['N']	[33]
34	even	O	['N']	[34]
35	in	O	['N']	[35]
36	platinum	O	['N']	[36]
37	-	O	['N']	[37]
38	sensitive	O	['N']	[38]
39	cases	O	['N']	[39]
40	,	O	['N']	[40]
41	because	O	['N']	[41]
42	CBDCA	O	['N']	[42]
43	hypersensitivity	O	['N']	[43]
44	can	O	['N']	[44]
45	occur	O	['N']	[45]
46	even	O	['N']	[46]
47	with	O	['N']	[47]
48	low	B	['N']	[48]
49	-	I	['N']	[49]
50	dose	I-Dose	['N']	[50]
51	CBDCA	O	['N']	[51]
52	administration	O	['N']	[52]
53	.	O	['N']	[53]
#225
0	Psoriasis	B-Adverse_Effect	['N']	[0]
1	triggered	O	['N']	[1]
2	by	O	['N']	[2]
3	toll	O	['N']	[3]
4	-	O	['N']	[4]
5	like	O	['N']	[5]
6	receptor	O	['N']	[6]
7	7	O	['N']	[7]
8	agonist	O	['N']	[8]
9	imiquimod	B-Drug	['Causes']	[0]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	presence	O	['N']	[12]
13	of	O	['N']	[13]
14	dermal	O	['N']	[14]
15	plasmacytoid	O	['N']	[15]
16	dendritic	O	['N']	[16]
17	cell	O	['N']	[17]
18	precursors	O	['N']	[18]
19	.	O	['N']	[19]
#226
0	Severe	B	['N']	[0]
1	hepatitis	I-Adverse_Effect	['N']	[1]
2	caused	O	['N']	[2]
3	by	O	['N']	[3]
4	cyproterone	B	['N']	[4]
5	acetate	I-Drug	['Causes']	[1]
6	.	O	['N']	[6]
#227
0	Delusional	B	['N']	[0]
1	parasitosis	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	phenelzine	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#228
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Phenolphthalein	B-Drug	['Causes']	[24]
3	is	O	['N']	[3]
4	the	O	['N']	[4]
5	active	O	['N']	[5]
6	ingredient	O	['N']	[6]
7	in	O	['N']	[7]
8	several	O	['N']	[8]
9	over	O	['N']	[9]
10	-	O	['N']	[10]
11	the	O	['N']	[11]
12	-	O	['N']	[12]
13	counter	O	['N']	[13]
14	laxative	O	['N']	[14]
15	preparations	O	['N']	[15]
16	and	O	['N']	[16]
17	has	O	['N']	[17]
18	only	O	['N']	[18]
19	rarely	O	['N']	[19]
20	been	O	['N']	[20]
21	reported	O	['N']	[21]
22	to	O	['N']	[22]
23	cause	O	['N']	[23]
24	TEN	B-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#229
0	Magnesium	B-Drug	['Causes']	[7]
1	tocolysis	O	['N']	[1]
2	as	O	['N']	[2]
3	the	O	['N']	[3]
4	cause	O	['N']	[4]
5	of	O	['N']	[5]
6	urinary	B	['N']	[6]
7	calculus	I-Adverse_Effect	['N']	[7]
8	during	O	['N']	[8]
9	pregnancy	O	['N']	[9]
10	.	O	['N']	[10]
#230
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	torsade	O	['N']	[5]
6	de	O	['N']	[6]
7	pointes	O	['N']	[7]
8	following	O	['N']	[8]
9	a	O	['N']	[9]
10	single	O	['N']	[10]
11	oral	O	['N']	[11]
12	dose	O	['N']	[12]
13	of	O	['N']	[13]
14	amiodarone	B-Drug	['Dosage']	[17]
15	(	O	['N']	[15]
16	1400	B	['N']	[16]
17	mg	I-Dose	['N']	[17]
18	or	O	['N']	[18]
19	30	O	['N']	[19]
20	mg	O	['N']	[20]
21	kg-1	O	['N']	[21]
22	)	O	['N']	[22]
23	administered	O	['N']	[23]
24	after	O	['N']	[24]
25	short	O	['N']	[25]
26	intravenous	O	['N']	[26]
27	loading	O	['N']	[27]
28	for	O	['N']	[28]
29	prevention	O	['N']	[29]
30	of	O	['N']	[30]
31	paroxysmal	O	['N']	[31]
32	atrial	O	['N']	[32]
33	flutter	O	['N']	[33]
34	.	O	['N']	[34]
#231
0	Multiple	O	['N']	[0]
1	complications	O	['N']	[1]
2	of	O	['N']	[2]
3	propylthiouracil	B-Drug	['Causes']	[16]
4	treatment	O	['N']	[4]
5	:	O	['N']	[5]
6	granulocytopenia	O	['N']	[6]
7	,	O	['N']	[7]
8	eosinophilia	O	['N']	[8]
9	,	O	['N']	[9]
10	skin	O	['N']	[10]
11	reaction	O	['N']	[11]
12	and	O	['N']	[12]
13	hepatitis	O	['N']	[13]
14	with	O	['N']	[14]
15	lymphocyte	B	['N']	[15]
16	sensitization	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#232
0	Postoperative	O	['N']	[0]
1	hypocalcemic	B	['N']	[1]
2	tetany	I-Adverse_Effect	['N']	[2]
3	caused	O	['N']	[3]
4	by	O	['N']	[4]
5	fleet	O	['N']	[5]
6	phospho	O	['N']	[6]
7	-	O	['N']	[7]
8	soda	O	['N']	[8]
9	preparation	O	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	patient	O	['N']	[12]
13	taking	O	['N']	[13]
14	alendronate	B	['N']	[14]
15	sodium	I-Drug	['Causes']	[2]
16	:	O	['N']	[16]
17	report	O	['N']	[17]
18	of	O	['N']	[18]
19	a	O	['N']	[19]
20	case	O	['N']	[20]
21	.	O	['N']	[21]
#233
0	The	O	['N']	[0]
1	cause	O	['N']	[1]
2	is	O	['N']	[2]
3	presumed	O	['N']	[3]
4	to	O	['N']	[4]
5	be	O	['N']	[5]
6	secondary	O	['N']	[6]
7	to	O	['N']	[7]
8	hypercoagulability	O	['N']	[8]
9	due	O	['N']	[9]
10	to	O	['N']	[10]
11	asparaginase	B-Drug	['Causes']	[16]
12	-	O	['N']	[12]
13	induced	O	['N']	[13]
14	antithrombin	B	['N']	[14]
15	III	I	['N']	[15]
16	deficiency	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#234
0	Unique	O	['N']	[0]
1	behavioral	B	['N']	[1]
2	change	I-Adverse_Effect	['N']	[2]
3	with	O	['N']	[3]
4	cinepazide	B-Drug	['Causes']	[2]
5	in	O	['N']	[5]
6	parkinsonism	O	['N']	[6]
7	.	O	['N']	[7]
#235
0	Acute	B	['N']	[0]
1	myopathy	I-Adverse_Effect	['N']	[1]
2	with	O	['N']	[2]
3	selective	O	['N']	[3]
4	degeneration	O	['N']	[4]
5	of	O	['N']	[5]
6	myosin	O	['N']	[6]
7	filaments	O	['N']	[7]
8	following	O	['N']	[8]
9	status	O	['N']	[9]
10	asthmaticus	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	methylprednisolone	B-Drug	['Causes']	[1]
14	and	O	['N']	[14]
15	vecuronium	O	['N']	[15]
16	.	O	['N']	[16]
#236
0	The	O	['N']	[0]
1	third	O	['N']	[1]
2	patient	O	['N']	[2]
3	had	O	['N']	[3]
4	been	O	['N']	[4]
5	suffering	O	['N']	[5]
6	from	O	['N']	[6]
7	serious	O	['N']	[7]
8	akathisia	B-Adverse_Effect	['N']	[8]
9	while	O	['N']	[9]
10	on	O	['N']	[10]
11	risperidone	B-Drug	['Causes']	[8]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	was	O	['N']	[14]
15	cured	O	['N']	[15]
16	after	O	['N']	[16]
17	switching	O	['N']	[17]
18	to	O	['N']	[18]
19	olanzapine	O	['N']	[19]
20	,	O	['N']	[20]
21	but	O	['N']	[21]
22	thereafter	O	['N']	[22]
23	the	O	['N']	[23]
24	patient	O	['N']	[24]
25	suffered	O	['N']	[25]
26	from	O	['N']	[26]
27	RLS	O	['N']	[27]
28	at	O	['N']	[28]
29	nighttime	O	['N']	[29]
30	.	O	['N']	[30]
#237
0	Diphenylhydantoin	B-Drug	['Causes']	[14]
1	apparently	O	['N']	[1]
2	adversely	O	['N']	[2]
3	affected	O	['N']	[3]
4	both	O	['N']	[4]
5	the	O	['N']	[5]
6	clinical	O	['N']	[6]
7	and	O	['N']	[7]
8	biochemical	O	['N']	[8]
9	parameters	O	['N']	[9]
10	of	O	['N']	[10]
11	the	O	['N']	[11]
12	acute	B	['N']	[12]
13	intermittent	I	['N']	[13]
14	porphyria	I-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#238
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	additional	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	isotretinoin	B-Drug	['Causes']	[24]
7	teratogenicity	O	['N']	[7]
8	in	O	['N']	[8]
9	which	O	['N']	[9]
10	the	O	['N']	[10]
11	patient	O	['N']	[11]
12	had	O	['N']	[12]
13	agenesis	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	cerebellar	O	['N']	[16]
17	vermis	O	['N']	[17]
18	,	O	['N']	[18]
19	multiple	O	['N']	[19]
20	leptomeningeal	O	['N']	[20]
21	neuroglial	O	['N']	[21]
22	heterotopias	O	['N']	[22]
23	,	O	['N']	[23]
24	hydrocephalus	B-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	abnormalities	O	['N']	[27]
28	of	O	['N']	[28]
29	the	O	['N']	[29]
30	corticospinal	O	['N']	[30]
31	tracts	O	['N']	[31]
32	.	O	['N']	[32]
#239
0	Neurophysiological	O	['N']	[0]
1	mechanisms	O	['N']	[1]
2	which	O	['N']	[2]
3	aid	O	['N']	[3]
4	in	O	['N']	[4]
5	elucidating	O	['N']	[5]
6	the	O	['N']	[6]
7	role	O	['N']	[7]
8	of	O	['N']	[8]
9	disulfiram	B-Drug	['Causes']	[14]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	etiology	O	['N']	[12]
13	of	O	['N']	[13]
14	catatonia	B-Adverse_Effect	['N']	[14]
15	are	O	['N']	[15]
16	discussed	O	['N']	[16]
17	.	O	['N']	[17]
#240
0	Anaphylactoid	B	['N']	[0]
1	reaction	I-Adverse_Effect	['N']	[1]
2	to	O	['N']	[2]
3	50	O	['N']	[3]
4	%	O	['N']	[4]
5	solution	O	['N']	[5]
6	of	O	['N']	[6]
7	dextrose	B-Drug	['Causes']	[1]
8	.	O	['N']	[8]
#241
0	In	O	['N']	[0]
1	addition	O	['N']	[1]
2	to	O	['N']	[2]
3	the	O	['N']	[3]
4	recognized	O	['N']	[4]
5	arrhythmic	O	['N']	[5]
6	complications	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	authors	O	['N']	[9]
10	emphasize	O	['N']	[10]
11	myocardial	O	['N']	[11]
12	necrosis	O	['N']	[12]
13	as	O	['N']	[13]
14	a	O	['N']	[14]
15	possible	O	['N']	[15]
16	further	O	['N']	[16]
17	manifestation	O	['N']	[17]
18	of	O	['N']	[18]
19	amsacrine	B-Drug	['Causes']	[22]
20	-	O	['N']	[20]
21	related	O	['N']	[21]
22	cardiotoxicity	B-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#242
0	Visual	B	['N']	[0]
1	hallucinations	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	zonisamide	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#243
0	Quetiapine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	myoclonus	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#244
0	ARDS	B-Adverse_Effect	['N']	[0]
1	has	O	['N']	[1]
2	been	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	the	O	['N']	[5]
6	administration	O	['N']	[6]
7	of	O	['N']	[7]
8	other	O	['N']	[8]
9	monoclonal	O	['N']	[9]
10	antibodies	O	['N']	[10]
11	,	O	['N']	[11]
12	such	O	['N']	[12]
13	as	O	['N']	[13]
14	infliximab	B-Drug	['Causes']	[0]
15	,	O	['N']	[15]
16	gemtuzumab	O	['N']	[16]
17	ozogamicin	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	OKT3	O	['N']	[20]
21	and	O	['N']	[21]
22	is	O	['N']	[22]
23	believed	O	['N']	[23]
24	to	O	['N']	[24]
25	be	O	['N']	[25]
26	directly	O	['N']	[26]
27	mediated	O	['N']	[27]
28	by	O	['N']	[28]
29	release	O	['N']	[29]
30	of	O	['N']	[30]
31	proinflammatory	O	['N']	[31]
32	cytokines	O	['N']	[32]
33	.	O	['N']	[33]
#245
0	A	O	['N']	[0]
1	small	O	['N']	[1]
2	initial	O	['N']	[2]
3	dose	O	['N']	[3]
4	of	O	['N']	[4]
5	prazosin	B-Drug	['Causes']	[31]
6	ranging	O	['N']	[6]
7	from	O	['N']	[7]
8	0.5	O	['N']	[8]
9	to	O	['N']	[9]
10	1	O	['N']	[10]
11	mg	O	['N']	[11]
12	has	O	['N']	[12]
13	been	O	['N']	[13]
14	recommended	O	['N']	[14]
15	to	O	['N']	[15]
16	avoid	O	['N']	[16]
17	the	O	['N']	[17]
18	first	O	['N']	[18]
19	-	O	['N']	[19]
20	dose	O	['N']	[20]
21	phenomenon	O	['N']	[21]
22	characterized	O	['N']	[22]
23	by	O	['N']	[23]
24	a	O	['N']	[24]
25	sudden	O	['N']	[25]
26	and	O	['N']	[26]
27	severe	B	['N']	[27]
28	drop	I	['N']	[28]
29	in	I	['N']	[29]
30	blood	I	['N']	[30]
31	pressure	I-Adverse_Effect	['N']	[31]
32	after	O	['N']	[32]
33	the	O	['N']	[33]
34	administration	O	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	first	O	['N']	[37]
38	dose	O	['N']	[38]
39	of	O	['N']	[39]
40	prazosin	O	['N']	[40]
41	.	O	['N']	[41]
#246
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	this	O	['N']	[4]
5	is	O	['N']	[5]
6	the	O	['N']	[6]
7	first	O	['N']	[7]
8	case	O	['N']	[8]
9	of	O	['N']	[9]
10	griseofulvin	B-Drug	['Causes']	[13]
11	-	O	['N']	[11]
12	exacerbated	O	['N']	[12]
13	lupus	B-Adverse_Effect	['N']	[13]
14	in	O	['N']	[14]
15	which	O	['N']	[15]
16	nephrotic	O	['N']	[16]
17	syndrome	O	['N']	[17]
18	has	O	['N']	[18]
19	been	O	['N']	[19]
20	observed	O	['N']	[20]
21	.	O	['N']	[21]
#247
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Both	O	['N']	[2]
3	cases	O	['N']	[3]
4	presented	O	['N']	[4]
5	here	O	['N']	[5]
6	describe	O	['N']	[6]
7	corneal	B	['N']	[7]
8	ulcers	I-Adverse_Effect	['N']	[8]
9	that	O	['N']	[9]
10	persisted	O	['N']	[10]
11	and	O	['N']	[11]
12	showed	O	['N']	[12]
13	signs	O	['N']	[13]
14	of	O	['N']	[14]
15	worsening	O	['N']	[15]
16	during	O	['N']	[16]
17	weeks	O	['N']	[17]
18	of	O	['N']	[18]
19	frequent	O	['N']	[19]
20	topical	O	['N']	[20]
21	dosing	O	['N']	[21]
22	with	O	['N']	[22]
23	moxifloxacin	B-Drug	['Causes']	[8]
24	.	O	['N']	[24]
#248
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	five	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	restless	O	['N']	[5]
6	legs	O	['N']	[6]
7	syndrome	O	['N']	[7]
8	(	O	['N']	[8]
9	RLS	O	['N']	[9]
10	)	O	['N']	[10]
11	and	O	['N']	[11]
12	periodic	B	['N']	[12]
13	limb	I	['N']	[13]
14	movements	I	['N']	[14]
15	during	I	['N']	[15]
16	sleep	I-Adverse_Effect	['N']	[16]
17	(	O	['N']	[17]
18	PLMS	O	['N']	[18]
19	)	O	['N']	[19]
20	that	O	['N']	[20]
21	were	O	['N']	[21]
22	probably	O	['N']	[22]
23	associated	O	['N']	[23]
24	with	O	['N']	[24]
25	olanzapine	B-Drug	['Causes']	[16]
26	.	O	['N']	[26]
#249
0	An	O	['N']	[0]
1	episode	O	['N']	[1]
2	of	O	['N']	[2]
3	subacute	O	['N']	[3]
4	encephalopathy	B-Adverse_Effect	['N']	[4]
5	after	O	['N']	[5]
6	the	O	['N']	[6]
7	infusion	O	['N']	[7]
8	of	O	['N']	[8]
9	a	O	['N']	[9]
10	moderate	O	['N']	[10]
11	dose	O	['N']	[11]
12	of	O	['N']	[12]
13	methotrexate	B-Drug	['Causes']	[4]
14	(	O	['N']	[14]
15	1500	O	['N']	[15]
16	mg	O	['N']	[16]
17	/	O	['N']	[17]
18	m2	O	['N']	[18]
19	)	O	['N']	[19]
20	(	O	['N']	[20]
21	MTX	O	['N']	[21]
22	)	O	['N']	[22]
23	is	O	['N']	[23]
24	reported	O	['N']	[24]
25	in	O	['N']	[25]
26	a	O	['N']	[26]
27	young	O	['N']	[27]
28	adult	O	['N']	[28]
29	with	O	['N']	[29]
30	metastastic	O	['N']	[30]
31	gastric	O	['N']	[31]
32	cancer	O	['N']	[32]
33	.	O	['N']	[33]
#250
0	Interstitial	B	['N']	[0]
1	granulomatous	I	['N']	[1]
2	dermatitis	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	darifenacin	B-Drug	['Causes']	[2]
6	.	O	['N']	[6]
#251
0	Transtentorial	O	['N']	[0]
1	herniation	O	['N']	[1]
2	caused	O	['N']	[2]
3	by	O	['N']	[3]
4	an	O	['N']	[4]
5	intracranial	B	['N']	[5]
6	mass	I	['N']	[6]
7	lesion	I-Adverse_Effect	['N']	[7]
8	following	O	['N']	[8]
9	high	O	['N']	[9]
10	-	O	['N']	[10]
11	dose	O	['N']	[11]
12	methotrexate	B-Drug	['Causes']	[7]
13	.	O	['N']	[13]
#252
0	Although	O	['N']	[0]
1	combinations	O	['N']	[1]
2	of	O	['N']	[2]
3	belladonna	O	['N']	[3]
4	,	O	['N']	[4]
5	ergotamine	O	['N']	[5]
6	,	O	['N']	[6]
7	and	O	['N']	[7]
8	phenobarbital	B-Drug	['Causes']	[35]
9	have	O	['N']	[9]
10	been	O	['N']	[10]
11	used	O	['N']	[11]
12	for	O	['N']	[12]
13	medical	O	['N']	[13]
14	treatment	O	['N']	[14]
15	of	O	['N']	[15]
16	menopausal	O	['N']	[16]
17	symptoms	O	['N']	[17]
18	since	O	['N']	[18]
19	the	O	['N']	[19]
20	1960s	O	['N']	[20]
21	,	O	['N']	[21]
22	this	O	['N']	[22]
23	is	O	['N']	[23]
24	the	O	['N']	[24]
25	first	O	['N']	[25]
26	known	O	['N']	[26]
27	case	O	['N']	[27]
28	report	O	['N']	[28]
29	of	O	['N']	[29]
30	its	O	['N']	[30]
31	association	O	['N']	[31]
32	with	O	['N']	[32]
33	anticonvulsant	B	['N']	[33]
34	hypersensitivity	I	['N']	[34]
35	syndrome	I-Adverse_Effect	['N']	[35]
36	.	O	['N']	[36]
#253
0	Levofloxacin	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	toxic	B	['N']	[3]
4	epidermal	I	['N']	[4]
5	necrolysis	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	an	O	['N']	[7]
8	elderly	O	['N']	[8]
9	patient	O	['N']	[9]
10	.	O	['N']	[10]
#254
0	Additive	B	['N']	[0]
1	pulmonary	I	['N']	[1]
2	toxicity	I-Adverse_Effect	['N']	[2]
3	with	O	['N']	[3]
4	melphalan	B-Drug	['Causes']	[2]
5	and	O	['N']	[5]
6	busulfan	O	['N']	[6]
7	therapy	O	['N']	[7]
8	.	O	['N']	[8]
#255
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	is	O	['N']	[2]
3	reported	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	40	O	['N']	[6]
7	year	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	intraventricular	O	['N']	[12]
13	IL-2	B-Drug	['Causes']	[21]
14	for	O	['N']	[14]
15	leptomeningeal	O	['N']	[15]
16	disease	O	['N']	[16]
17	who	O	['N']	[17]
18	developed	O	['N']	[18]
19	progressive	O	['N']	[19]
20	cognitive	B	['N']	[20]
21	dysfunction	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#256
0	Although	O	['N']	[0]
1	this	O	['N']	[1]
2	combination	O	['N']	[2]
3	agent	O	['N']	[3]
4	has	O	['N']	[4]
5	been	O	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	a	O	['N']	[8]
9	hypersensitivity	O	['N']	[9]
10	syndrome	O	['N']	[10]
11	involving	O	['N']	[11]
12	cutaneous	O	['N']	[12]
13	skin	O	['N']	[13]
14	eruptions	O	['N']	[14]
15	,	O	['N']	[15]
16	pediatric	O	['N']	[16]
17	cases	O	['N']	[17]
18	of	O	['N']	[18]
19	TMP	B	['N']	[19]
20	-	I	['N']	[20]
21	SMX	I-Drug	['Causes']	[24]
22	-	O	['N']	[22]
23	induced	O	['N']	[23]
24	hepatotoxicity	B-Adverse_Effect	['N']	[24]
25	are	O	['N']	[25]
26	rare	O	['N']	[26]
27	.	O	['N']	[27]
#257
0	A	O	['N']	[0]
1	new	O	['N']	[1]
2	case	O	['N']	[2]
3	of	O	['N']	[3]
4	Creutzfeldt	B	['N']	[4]
5	-	I	['N']	[5]
6	Jakob	I	['N']	[6]
7	disease	I-Adverse_Effect	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	human	B	['N']	[10]
11	growth	I	['N']	[11]
12	hormone	I-Drug	['Causes']	[7]
13	therapy	O	['N']	[13]
14	in	O	['N']	[14]
15	New	O	['N']	[15]
16	Zealand	O	['N']	[16]
17	.	O	['N']	[17]
#258
0	Erythema	B	['N']	[0]
1	multiforme	I	['N']	[1]
2	bullosum	I-Adverse_Effect	['N']	[2]
3	due	O	['N']	[3]
4	to	O	['N']	[4]
5	rifampicin	B-Drug	['Causes']	[2]
6	.	O	['N']	[6]
#259
0	DATA	O	['N']	[0]
1	SYNTHESIS	O	['N']	[1]
2	:	O	['N']	[2]
3	Genetic	O	['N']	[3]
4	deficiencies	O	['N']	[4]
5	in	O	['N']	[5]
6	DPD	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	rate	O	['N']	[9]
10	-	O	['N']	[10]
11	limiting	O	['N']	[11]
12	enzyme	O	['N']	[12]
13	responsible	O	['N']	[13]
14	for	O	['N']	[14]
15	5-FU	B-Drug	['Causes']	[42]
16	catabolism	O	['N']	[16]
17	,	O	['N']	[17]
18	may	O	['N']	[18]
19	occur	O	['N']	[19]
20	in	O	['N']	[20]
21	3	O	['N']	[21]
22	%	O	['N']	[22]
23	or	O	['N']	[23]
24	more	O	['N']	[24]
25	of	O	['N']	[25]
26	patients	O	['N']	[26]
27	with	O	['N']	[27]
28	cancer	O	['N']	[28]
29	putting	O	['N']	[29]
30	them	O	['N']	[30]
31	at	O	['N']	[31]
32	increased	O	['N']	[32]
33	risk	O	['N']	[33]
34	for	O	['N']	[34]
35	unusually	O	['N']	[35]
36	severe	O	['N']	[36]
37	adverse	O	['N']	[37]
38	reactions	O	['N']	[38]
39	(	O	['N']	[39]
40	e.g.	O	['N']	[40]
41	,	O	['N']	[41]
42	diarrhea	B-Adverse_Effect	['N']	[42]
43	,	O	['N']	[43]
44	stomatitis	O	['N']	[44]
45	,	O	['N']	[45]
46	mucositis	O	['N']	[46]
47	,	O	['N']	[47]
48	myelosuppression	O	['N']	[48]
49	,	O	['N']	[49]
50	neurotoxicity	O	['N']	[50]
51	)	O	['N']	[51]
52	to	O	['N']	[52]
53	standard	O	['N']	[53]
54	doses	O	['N']	[54]
55	of	O	['N']	[55]
56	5-FU	O	['N']	[56]
57	.	O	['N']	[57]
#260
0	From	O	['N']	[0]
1	1996	O	['N']	[1]
2	to	O	['N']	[2]
3	2002	O	['N']	[3]
4	several	O	['N']	[4]
5	medications	O	['N']	[5]
6	were	O	['N']	[6]
7	changed	O	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	their	O	['N']	[10]
11	adverse	O	['N']	[11]
12	effects	O	['N']	[12]
13	:	O	['N']	[13]
14	indinavir	B-Drug	['Causes']	[17]
15	(	O	['N']	[15]
16	renal	B	['N']	[16]
17	colic	I-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	fever	O	['N']	[19]
20	)	O	['N']	[20]
21	,	O	['N']	[21]
22	nelfinavir	O	['N']	[22]
23	(	O	['N']	[23]
24	cutaneous	O	['N']	[24]
25	rash	O	['N']	[25]
26	)	O	['N']	[26]
27	,	O	['N']	[27]
28	and	O	['N']	[28]
29	efavirenz	O	['N']	[29]
30	(	O	['N']	[30]
31	nausea	O	['N']	[31]
32	and	O	['N']	[32]
33	temporary	O	['N']	[33]
34	memory	O	['N']	[34]
35	loss	O	['N']	[35]
36	)	O	['N']	[36]
37	.	O	['N']	[37]
#261
0	We	O	['N']	[0]
1	observed	O	['N']	[1]
2	ventricular	O	['N']	[2]
3	fibrillation	O	['N']	[3]
4	in	O	['N']	[4]
5	2	O	['N']	[5]
6	patients	O	['N']	[6]
7	who	O	['N']	[7]
8	presented	O	['N']	[8]
9	to	O	['N']	[9]
10	the	O	['N']	[10]
11	emergency	O	['N']	[11]
12	department	O	['N']	[12]
13	with	O	['N']	[13]
14	pre	O	['N']	[14]
15	-	O	['N']	[15]
16	excited	O	['N']	[16]
17	atrial	O	['N']	[17]
18	fibrillation	O	['N']	[18]
19	and	O	['N']	[19]
20	were	O	['N']	[20]
21	given	O	['N']	[21]
22	12	B	['N']	[22]
23	mg	I-Dose	['N']	[23]
24	of	O	['N']	[24]
25	adenosine	B-Drug	['Dosage']	[23]
26	.	O	['N']	[26]
#262
0	Acute	B	['N']	[0]
1	vision	I	['N']	[1]
2	loss	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	intravitreal	O	['N']	[4]
5	injection	O	['N']	[5]
6	of	O	['N']	[6]
7	bevacizumab	B-Drug	['Causes']	[2]
8	(	O	['N']	[8]
9	avastin	O	['N']	[9]
10	)	O	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	ocular	O	['N']	[13]
14	ischemic	O	['N']	[14]
15	syndrome	O	['N']	[15]
16	.	O	['N']	[16]
#263
0	Lithium	O	['N']	[0]
1	treatment	O	['N']	[1]
2	was	O	['N']	[2]
3	terminated	O	['N']	[3]
4	in	O	['N']	[4]
5	1975	O	['N']	[5]
6	because	O	['N']	[6]
7	of	O	['N']	[7]
8	lithium	B-Drug	['Causes']	[16]
9	intoxication	O	['N']	[9]
10	with	O	['N']	[10]
11	a	O	['N']	[11]
12	diabetes	B	['N']	[12]
13	insipidus	I	['N']	[13]
14	-	I	['N']	[14]
15	like	I	['N']	[15]
16	syndrome	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#264
0	Sirolimus	B	['N']	[0]
1	-	I	['N']	[1]
2	eluting	I	['N']	[2]
3	stent	I	['N']	[3]
4	thrombosis	I-Adverse_Effect	['N']	[4]
5	several	O	['N']	[5]
6	years	O	['N']	[6]
7	after	O	['N']	[7]
8	clopidogrel	B-Drug	['Causes']	[4]
9	discontinuation	O	['N']	[9]
10	.	O	['N']	[10]
#265
0	Embolia	B	['N']	[0]
1	cutis	I	['N']	[1]
2	medicamentosa	I-Adverse_Effect	['N']	[2]
3	following	O	['N']	[3]
4	subcutaneous	O	['N']	[4]
5	injection	O	['N']	[5]
6	of	O	['N']	[6]
7	glatiramer	B	['N']	[7]
8	acetate	I-Drug	['Causes']	[2]
9	.	O	['N']	[9]
#266
0	A	O	['N']	[0]
1	young	O	['N']	[1]
2	diamond	O	['N']	[2]
3	dealer	O	['N']	[3]
4	developed	O	['N']	[4]
5	visual	O	['N']	[5]
6	impairment	O	['N']	[6]
7	attributed	O	['N']	[7]
8	to	O	['N']	[8]
9	bilateral	B	['N']	[9]
10	posterior	I	['N']	[10]
11	subcapsular	I	['N']	[11]
12	cataracts	I-Adverse_Effect	['N']	[12]
13	following	O	['N']	[13]
14	only	O	['N']	[14]
15	four	O	['N']	[15]
16	courses	O	['N']	[16]
17	of	O	['N']	[17]
18	intermittent	O	['N']	[18]
19	Decadron	B-Drug	['Causes']	[12]
20	used	O	['N']	[20]
21	as	O	['N']	[21]
22	part	O	['N']	[22]
23	of	O	['N']	[23]
24	a	O	['N']	[24]
25	five	O	['N']	[25]
26	-	O	['N']	[26]
27	drug	O	['N']	[27]
28	antiemetic	O	['N']	[28]
29	regimen	O	['N']	[29]
30	for	O	['N']	[30]
31	cisplatin	O	['N']	[31]
32	-	O	['N']	[32]
33	associated	O	['N']	[33]
34	nausea	O	['N']	[34]
35	.	O	['N']	[35]
#267
0	Potential	O	['N']	[0]
1	causes	O	['N']	[1]
2	of	O	['N']	[2]
3	methamphetamine	O	['N']	[3]
4	-	O	['N']	[4]
5	related	O	['N']	[5]
6	keratitis	B-Adverse_Effect	['N']	[6]
7	can	O	['N']	[7]
8	be	O	['N']	[8]
9	divided	O	['N']	[9]
10	into	O	['N']	[10]
11	four	O	['N']	[11]
12	categories	O	['N']	[12]
13	resulting	O	['N']	[13]
14	from	O	['N']	[14]
15	(	O	['N']	[15]
16	a	O	['N']	[16]
17	)	O	['N']	[17]
18	direct	O	['N']	[18]
19	pharmacologic	O	['N']	[19]
20	and	O	['N']	[20]
21	physical	O	['N']	[21]
22	effects	O	['N']	[22]
23	of	O	['N']	[23]
24	methamphetamine	O	['N']	[24]
25	;	O	['N']	[25]
26	(	O	['N']	[26]
27	b	O	['N']	[27]
28	)	O	['N']	[28]
29	the	O	['N']	[29]
30	toxic	O	['N']	[30]
31	effects	O	['N']	[31]
32	of	O	['N']	[32]
33	diluting	O	['N']	[33]
34	or	O	['N']	[34]
35	"	O	['N']	[35]
36	cutting	O	['N']	[36]
37	"	O	['N']	[37]
38	agents	O	['N']	[38]
39	such	O	['N']	[39]
40	as	O	['N']	[40]
41	lidocaine	B-Drug	['Causes']	[6]
42	and	O	['N']	[42]
43	quinine	O	['N']	[43]
44	;	O	['N']	[44]
45	(	O	['N']	[45]
46	c	O	['N']	[46]
47	)	O	['N']	[47]
48	effects	O	['N']	[48]
49	related	O	['N']	[49]
50	to	O	['N']	[50]
51	the	O	['N']	[51]
52	route	O	['N']	[52]
53	of	O	['N']	[53]
54	drug	O	['N']	[54]
55	administration	O	['N']	[55]
56	(	O	['N']	[56]
57	intravenous	O	['N']	[57]
58	,	O	['N']	[58]
59	inhalation	O	['N']	[59]
60	,	O	['N']	[60]
61	smoking	O	['N']	[61]
62	)	O	['N']	[62]
63	;	O	['N']	[63]
64	and	O	['N']	[64]
65	(	O	['N']	[65]
66	d	O	['N']	[66]
67	)	O	['N']	[67]
68	manufacture	O	['N']	[68]
69	-	O	['N']	[69]
70	related	O	['N']	[70]
71	effects	O	['N']	[71]
72	of	O	['N']	[72]
73	exposure	O	['N']	[73]
74	to	O	['N']	[74]
75	unintentional	O	['N']	[75]
76	caustic	O	['N']	[76]
77	contaminants	O	['N']	[77]
78	in	O	['N']	[78]
79	the	O	['N']	[79]
80	final	O	['N']	[80]
81	product	O	['N']	[81]
82	.	O	['N']	[82]
#268
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Squamous	B	['N']	[2]
3	metaplasia	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	these	O	['N']	[5]
6	cases	O	['N']	[6]
7	appears	O	['N']	[7]
8	to	O	['N']	[8]
9	be	O	['N']	[9]
10	a	O	['N']	[10]
11	consequence	O	['N']	[11]
12	of	O	['N']	[12]
13	progestin	B-Drug	['Causes']	[3]
14	therapy	O	['N']	[14]
15	.	O	['N']	[15]
#269
0	Potential	O	['N']	[0]
1	causes	O	['N']	[1]
2	of	O	['N']	[2]
3	methamphetamine	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	related	O	['N']	[5]
6	keratitis	B-Adverse_Effect	['N']	[6]
7	can	O	['N']	[7]
8	be	O	['N']	[8]
9	divided	O	['N']	[9]
10	into	O	['N']	[10]
11	four	O	['N']	[11]
12	categories	O	['N']	[12]
13	resulting	O	['N']	[13]
14	from	O	['N']	[14]
15	(	O	['N']	[15]
16	a	O	['N']	[16]
17	)	O	['N']	[17]
18	direct	O	['N']	[18]
19	pharmacologic	O	['N']	[19]
20	and	O	['N']	[20]
21	physical	O	['N']	[21]
22	effects	O	['N']	[22]
23	of	O	['N']	[23]
24	methamphetamine	O	['N']	[24]
25	;	O	['N']	[25]
26	(	O	['N']	[26]
27	b	O	['N']	[27]
28	)	O	['N']	[28]
29	the	O	['N']	[29]
30	toxic	O	['N']	[30]
31	effects	O	['N']	[31]
32	of	O	['N']	[32]
33	diluting	O	['N']	[33]
34	or	O	['N']	[34]
35	"	O	['N']	[35]
36	cutting	O	['N']	[36]
37	"	O	['N']	[37]
38	agents	O	['N']	[38]
39	such	O	['N']	[39]
40	as	O	['N']	[40]
41	lidocaine	O	['N']	[41]
42	and	O	['N']	[42]
43	quinine	O	['N']	[43]
44	;	O	['N']	[44]
45	(	O	['N']	[45]
46	c	O	['N']	[46]
47	)	O	['N']	[47]
48	effects	O	['N']	[48]
49	related	O	['N']	[49]
50	to	O	['N']	[50]
51	the	O	['N']	[51]
52	route	O	['N']	[52]
53	of	O	['N']	[53]
54	drug	O	['N']	[54]
55	administration	O	['N']	[55]
56	(	O	['N']	[56]
57	intravenous	O	['N']	[57]
58	,	O	['N']	[58]
59	inhalation	O	['N']	[59]
60	,	O	['N']	[60]
61	smoking	O	['N']	[61]
62	)	O	['N']	[62]
63	;	O	['N']	[63]
64	and	O	['N']	[64]
65	(	O	['N']	[65]
66	d	O	['N']	[66]
67	)	O	['N']	[67]
68	manufacture	O	['N']	[68]
69	-	O	['N']	[69]
70	related	O	['N']	[70]
71	effects	O	['N']	[71]
72	of	O	['N']	[72]
73	exposure	O	['N']	[73]
74	to	O	['N']	[74]
75	unintentional	O	['N']	[75]
76	caustic	O	['N']	[76]
77	contaminants	O	['N']	[77]
78	in	O	['N']	[78]
79	the	O	['N']	[79]
80	final	O	['N']	[80]
81	product	O	['N']	[81]
82	.	O	['N']	[82]
#270
0	Agranulocytosis	B-Adverse_Effect	['N']	[0]
1	induced	O	['N']	[1]
2	by	O	['N']	[2]
3	vancomycin	B-Drug	['Causes']	[0]
4	in	O	['N']	[4]
5	an	O	['N']	[5]
6	ESRD	O	['N']	[6]
7	patient	O	['N']	[7]
8	on	O	['N']	[8]
9	CAPD	O	['N']	[9]
10	.	O	['N']	[10]
#271
0	Isonicotinic	B	['N']	[0]
1	acid	I	['N']	[1]
2	hydrazide	I-Drug	['Causes']	[5]
3	induced	O	['N']	[3]
4	anagen	B	['N']	[4]
5	effluvium	I-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	associated	O	['N']	[7]
8	lichenoid	O	['N']	[8]
9	eruption	O	['N']	[9]
10	.	O	['N']	[10]
#272
0	The	O	['N']	[0]
1	vomiting	B-Adverse_Effect	['N']	[1]
2	occurred	O	['N']	[2]
3	on	O	['N']	[3]
4	switching	O	['N']	[4]
5	to	O	['N']	[5]
6	different	O	['N']	[6]
7	pancreatic	O	['N']	[7]
8	enzymes	O	['N']	[8]
9	preparations	O	['N']	[9]
10	,	O	['N']	[10]
11	ie	O	['N']	[11]
12	,	O	['N']	[12]
13	Creon	O	['N']	[13]
14	10	O	['N']	[14]
15	,	O	['N']	[15]
16	Viokase	B-Drug	['Causes']	[1]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	Pancrease	O	['N']	[19]
20	MT	O	['N']	[20]
21	16	O	['N']	[21]
22	.	O	['N']	[22]
#273
0	Discontinuation	O	['N']	[0]
1	of	O	['N']	[1]
2	simvastatin	B-Drug	['Causes']	[9]
3	and	O	['N']	[3]
4	cyclosporine	O	['N']	[4]
5	resulted	O	['N']	[5]
6	in	O	['N']	[6]
7	resolution	O	['N']	[7]
8	of	O	['N']	[8]
9	rhabdomyolysis	B-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	normalization	O	['N']	[11]
12	of	O	['N']	[12]
13	renal	O	['N']	[13]
14	function	O	['N']	[14]
15	.	O	['N']	[15]
#274
0	The	O	['N']	[0]
1	wide	O	['N']	[1]
2	use	O	['N']	[2]
3	of	O	['N']	[3]
4	phenytoin	B-Drug	['Causes']	[29]
5	during	O	['N']	[5]
6	the	O	['N']	[6]
7	recent	O	['N']	[7]
8	tuberculosis	O	['N']	[8]
9	epidemic	O	['N']	[9]
10	makes	O	['N']	[10]
11	it	O	['N']	[11]
12	imperative	O	['N']	[12]
13	to	O	['N']	[13]
14	suspect	O	['N']	[14]
15	this	O	['N']	[15]
16	drug	O	['N']	[16]
17	interaction	O	['N']	[17]
18	in	O	['N']	[18]
19	patients	O	['N']	[19]
20	exhibiting	O	['N']	[20]
21	clinical	O	['N']	[21]
22	features	O	['N']	[22]
23	that	O	['N']	[23]
24	might	O	['N']	[24]
25	be	O	['N']	[25]
26	related	O	['N']	[26]
27	to	O	['N']	[27]
28	phenytoin	B	['N']	[28]
29	toxicity	I-Adverse_Effect	['N']	[29]
30	.	O	['N']	[30]
#275
0	While	O	['N']	[0]
1	most	O	['N']	[1]
2	physicians	O	['N']	[2]
3	are	O	['N']	[3]
4	aware	O	['N']	[4]
5	of	O	['N']	[5]
6	heparin	B-Drug	['Causes']	[12]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	thrombocytopenia	O	['N']	[9]
10	and	O	['N']	[10]
11	skin	B	['N']	[11]
12	necrosis	I-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	the	O	['N']	[14]
15	association	O	['N']	[15]
16	of	O	['N']	[16]
17	heparin	O	['N']	[17]
18	and	O	['N']	[18]
19	hyperkalemia	O	['N']	[19]
20	is	O	['N']	[20]
21	less	O	['N']	[21]
22	well	O	['N']	[22]
23	recognized	O	['N']	[23]
24	.	O	['N']	[24]
#276
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	was	O	['N']	[2]
3	given	O	['N']	[3]
4	methimazole	B-Drug	['Causes']	[14]
5	instead	O	['N']	[5]
6	of	O	['N']	[6]
7	propylthiouracil	O	['N']	[7]
8	but	O	['N']	[8]
9	,	O	['N']	[9]
10	10	O	['N']	[10]
11	weeks	O	['N']	[11]
12	later	O	['N']	[12]
13	,	O	['N']	[13]
14	agranulocytosis	B-Adverse_Effect	['N']	[14]
15	again	O	['N']	[15]
16	occurred	O	['N']	[16]
17	.	O	['N']	[17]
#277
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	angiographically	O	['N']	[7]
8	documented	O	['N']	[8]
9	cystoid	B	['N']	[9]
10	macula	I	['N']	[10]
11	edema	I-Adverse_Effect	['N']	[11]
12	occurring	O	['N']	[12]
13	after	O	['N']	[13]
14	switching	O	['N']	[14]
15	a	O	['N']	[15]
16	pseudophakic	O	['N']	[16]
17	patient	O	['N']	[17]
18	from	O	['N']	[18]
19	latanoprost	O	['N']	[19]
20	to	O	['N']	[20]
21	bimatoprost	B-Drug	['Causes']	[11]
22	.	O	['N']	[22]
#278
0	Thrombocytosis	B-Adverse_Effect	['N']	[0]
1	under	O	['N']	[1]
2	ciprofloxacin	O	['N']	[2]
3	and	O	['N']	[3]
4	tazobactam	B-Drug	['Causes']	[0]
5	/	O	['N']	[5]
6	piperacillin	O	['N']	[6]
7	.	O	['N']	[7]
#279
0	Myoclonus	O	['N']	[0]
1	and	O	['N']	[1]
2	seizures	B-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	parkinsonism	O	['N']	[7]
8	:	O	['N']	[8]
9	induction	O	['N']	[9]
10	by	O	['N']	[10]
11	levodopa	B-Drug	['Causes']	[2]
12	and	O	['N']	[12]
13	its	O	['N']	[13]
14	confirmation	O	['N']	[14]
15	on	O	['N']	[15]
16	SEPs	O	['N']	[16]
17	.	O	['N']	[17]
#280
0	Angioedema	B-Adverse_Effect	['N']	[0]
1	,	O	['N']	[1]
2	a	O	['N']	[2]
3	rare	O	['N']	[3]
4	side	O	['N']	[4]
5	effect	O	['N']	[5]
6	of	O	['N']	[6]
7	carbamazepine	B-Drug	['Causes']	[0]
8	,	O	['N']	[8]
9	involves	O	['N']	[9]
10	vascular	O	['N']	[10]
11	leakage	O	['N']	[11]
12	in	O	['N']	[12]
13	dermis	O	['N']	[13]
14	and	O	['N']	[14]
15	subcutis	O	['N']	[15]
16	mediated	O	['N']	[16]
17	by	O	['N']	[17]
18	immunoglobulin	O	['N']	[18]
19	E	O	['N']	[19]
20	and/or	O	['N']	[20]
21	bradykinins	O	['N']	[21]
22	.	O	['N']	[22]
#281
0	Acute	O	['N']	[0]
1	renal	O	['N']	[1]
2	failure	O	['N']	[2]
3	with	O	['N']	[3]
4	severe	B	['N']	[4]
5	tubulointerstitial	I	['N']	[5]
6	changes	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	minimal	O	['N']	[11]
12	change	O	['N']	[12]
13	nephrotic	O	['N']	[13]
14	syndrome	O	['N']	[14]
15	treated	O	['N']	[15]
16	with	O	['N']	[16]
17	enalapril	B-Drug	['Causes']	[6]
18	.	O	['N']	[18]
#282
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	is	O	['N']	[2]
3	described	O	['N']	[3]
4	with	O	['N']	[4]
5	the	O	['N']	[5]
6	characteristic	O	['N']	[6]
7	features	O	['N']	[7]
8	of	O	['N']	[8]
9	phenytoin	B-Drug	['Causes']	[29]
10	hypersensitivity	O	['N']	[10]
11	syndrome	O	['N']	[11]
12	(	O	['N']	[12]
13	PHS	O	['N']	[13]
14	)	O	['N']	[14]
15	including	O	['N']	[15]
16	fever	O	['N']	[16]
17	,	O	['N']	[17]
18	erythroderma	O	['N']	[18]
19	,	O	['N']	[19]
20	tibial	O	['N']	[20]
21	and	O	['N']	[21]
22	facial	O	['N']	[22]
23	oedema	O	['N']	[23]
24	,	O	['N']	[24]
25	pinhead	B	['N']	[25]
26	-	I	['N']	[26]
27	sized	I	['N']	[27]
28	facial	I	['N']	[28]
29	pustules	I-Adverse_Effect	['N']	[29]
30	and	O	['N']	[30]
31	abnormal	O	['N']	[31]
32	liver	O	['N']	[32]
33	function	O	['N']	[33]
34	tests	O	['N']	[34]
35	.	O	['N']	[35]
#283
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Under	O	['N']	[2]
3	certain	O	['N']	[3]
4	circumstances	O	['N']	[4]
5	topical	O	['N']	[5]
6	brimonidine	B-Drug	['Causes']	[11]
7	can	O	['N']	[7]
8	cause	O	['N']	[8]
9	paradoxical	B	['N']	[9]
10	raised	I	['N']	[10]
11	IOP	I-Adverse_Effect	['N']	[11]
12	necessitating	O	['N']	[12]
13	vigilance	O	['N']	[13]
14	in	O	['N']	[14]
15	follow	O	['N']	[15]
16	-	O	['N']	[16]
17	up	O	['N']	[17]
18	of	O	['N']	[18]
19	patients	O	['N']	[19]
20	on	O	['N']	[20]
21	topical	O	['N']	[21]
22	brimonidine	O	['N']	[22]
23	.	O	['N']	[23]
#284
0	Chlorambucil	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	chromosome	B	['N']	[3]
4	damage	I-Adverse_Effect	['N']	[4]
5	to	O	['N']	[5]
6	human	O	['N']	[6]
7	lymphocytes	O	['N']	[7]
8	is	O	['N']	[8]
9	dose	O	['N']	[9]
10	-	O	['N']	[10]
11	dependent	O	['N']	[11]
12	and	O	['N']	[12]
13	cumulative	O	['N']	[13]
14	.	O	['N']	[14]
#285
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	histories	O	['N']	[4]
5	of	O	['N']	[5]
6	identical	O	['N']	[6]
7	twin	O	['N']	[7]
8	brothers	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	concordant	O	['N']	[11]
12	acute	O	['N']	[12]
13	lymphoblastic	O	['N']	[13]
14	leukemia	O	['N']	[14]
15	at	O	['N']	[15]
16	the	O	['N']	[16]
17	age	O	['N']	[17]
18	of	O	['N']	[18]
19	4	O	['N']	[19]
20	years	O	['N']	[20]
21	and	O	['N']	[21]
22	who	O	['N']	[22]
23	later	O	['N']	[23]
24	developed	O	['N']	[24]
25	leukoencephalopathy	B-Adverse_Effect	['N']	[25]
26	and	O	['N']	[26]
27	hydrocephalus	O	['N']	[27]
28	related	O	['N']	[28]
29	to	O	['N']	[29]
30	central	O	['N']	[30]
31	nervous	O	['N']	[31]
32	system	O	['N']	[32]
33	prophylaxis	O	['N']	[33]
34	by	O	['N']	[34]
35	,	O	['N']	[35]
36	in	O	['N']	[36]
37	the	O	['N']	[37]
38	first	O	['N']	[38]
39	case	O	['N']	[39]
40	intrathecally	O	['N']	[40]
41	administered	O	['N']	[41]
42	methotrexate	B-Drug	['Causes']	[25]
43	and	O	['N']	[43]
44	,	O	['N']	[44]
45	in	O	['N']	[45]
46	the	O	['N']	[46]
47	second	O	['N']	[47]
48	by	O	['N']	[48]
49	intrathecally	O	['N']	[49]
50	administered	O	['N']	[50]
51	methotrexate	O	['N']	[51]
52	and	O	['N']	[52]
53	cranial	O	['N']	[53]
54	irradiation	O	['N']	[54]
55	.	O	['N']	[55]
#286
0	Thus	O	['N']	[0]
1	cabergoline	B-Drug	['Causes']	[6]
2	may	O	['N']	[2]
3	cause	O	['N']	[3]
4	similar	O	['N']	[4]
5	pleuropulmonary	B	['N']	[5]
6	abnormalities	I-Adverse_Effect	['N']	[6]
7	to	O	['N']	[7]
8	bromocriptine	O	['N']	[8]
9	.	O	['N']	[9]
#287
0	Interferon	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	psychosis	B-Adverse_Effect	['N']	[3]
4	as	O	['N']	[4]
5	a	O	['N']	[5]
6	"	O	['N']	[6]
7	psychiatric	O	['N']	[7]
8	contraindication	O	['N']	[8]
9	"	O	['N']	[9]
10	to	O	['N']	[10]
11	hepatitis	O	['N']	[11]
12	C	O	['N']	[12]
13	treatment	O	['N']	[13]
14	:	O	['N']	[14]
15	a	O	['N']	[15]
16	review	O	['N']	[16]
17	and	O	['N']	[17]
18	case	O	['N']	[18]
19	-	O	['N']	[19]
20	based	O	['N']	[20]
21	discussion	O	['N']	[21]
22	.	O	['N']	[22]
#288
0	Myoglobinuria	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	acute	O	['N']	[2]
3	renal	O	['N']	[3]
4	failure	O	['N']	[4]
5	were	O	['N']	[5]
6	observed	O	['N']	[6]
7	in	O	['N']	[7]
8	two	O	['N']	[8]
9	patients	O	['N']	[9]
10	with	O	['N']	[10]
11	vasopressin	B-Drug	['Causes']	[0]
12	-	O	['N']	[12]
13	treated	O	['N']	[13]
14	gastrointestinal	O	['N']	[14]
15	hemorrhage	O	['N']	[15]
16	.	O	['N']	[16]
#289
0	Serious	O	['N']	[0]
1	phenytoin	B-Drug	['Causes']	[13]
2	hypersensitivity	O	['N']	[2]
3	reactions	O	['N']	[3]
4	may	O	['N']	[4]
5	appear	O	['N']	[5]
6	as	O	['N']	[6]
7	dermatologic	B	['N']	[7]
8	,	I	['N']	[8]
9	lymphoid	I	['N']	[9]
10	,	I	['N']	[10]
11	or	I	['N']	[11]
12	hepatic	I	['N']	[12]
13	syndromes	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#290
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	acute	O	['N']	[6]
7	pancreatitis	B-Adverse_Effect	['N']	[7]
8	(	O	['N']	[8]
9	AP	O	['N']	[9]
10	)	O	['N']	[10]
11	occurring	O	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	patient	O	['N']	[14]
15	under	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	carbamazepine	B-Drug	['Causes']	[7]
19	(	O	['N']	[19]
20	CBZ	O	['N']	[20]
21	)	O	['N']	[21]
22	for	O	['N']	[22]
23	post	O	['N']	[23]
24	-	O	['N']	[24]
25	traumatic	O	['N']	[25]
26	petit	O	['N']	[26]
27	mal	O	['N']	[27]
28	epilepsy	O	['N']	[28]
29	,	O	['N']	[29]
30	and	O	['N']	[30]
31	review	O	['N']	[31]
32	the	O	['N']	[32]
33	current	O	['N']	[33]
34	literature	O	['N']	[34]
35	of	O	['N']	[35]
36	drug	O	['N']	[36]
37	-	O	['N']	[37]
38	induced	O	['N']	[38]
39	AP	O	['N']	[39]
40	.	O	['N']	[40]
#291
0	Atrioventricular	B	['N']	[0]
1	block	I-Adverse_Effect	['N']	[1]
2	complicating	O	['N']	[2]
3	amiodarone	B-Drug	['Causes']	[1]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	hypothyroidism	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	pre	O	['N']	[11]
12	-	O	['N']	[12]
13	excitation	O	['N']	[13]
14	and	O	['N']	[14]
15	rate	O	['N']	[15]
16	-	O	['N']	[16]
17	dependent	O	['N']	[17]
18	bilateral	O	['N']	[18]
19	bundle	O	['N']	[19]
20	branch	O	['N']	[20]
21	block	O	['N']	[21]
22	.	O	['N']	[22]
#292
0	Pheripheral	B	['N']	[0]
1	edema	I-Adverse_Effect	['N']	[1]
2	was	O	['N']	[2]
3	observed	O	['N']	[3]
4	in	O	['N']	[4]
5	five	O	['N']	[5]
6	female	O	['N']	[6]
7	patients	O	['N']	[7]
8	after	O	['N']	[8]
9	taking	O	['N']	[9]
10	proton	O	['N']	[10]
11	pump	O	['N']	[11]
12	inhibitors	O	['N']	[12]
13	omeprazole	O	['N']	[13]
14	,	O	['N']	[14]
15	lansoprazole	O	['N']	[15]
16	,	O	['N']	[16]
17	or	O	['N']	[17]
18	pantoprazole	B-Drug	['Causes']	[1]
19	for	O	['N']	[19]
20	7	O	['N']	[20]
21	-	O	['N']	[21]
22	15	O	['N']	[22]
23	days	O	['N']	[23]
24	for	O	['N']	[24]
25	peptic	O	['N']	[25]
26	acid	O	['N']	[26]
27	diseases	O	['N']	[27]
28	in	O	['N']	[28]
29	recommended	O	['N']	[29]
30	standard	O	['N']	[30]
31	doses	O	['N']	[31]
32	.	O	['N']	[32]
#293
0	Choanal	O	['N']	[0]
1	atresia	O	['N']	[1]
2	and	O	['N']	[2]
3	athelia	B-Adverse_Effect	['N']	[3]
4	:	O	['N']	[4]
5	methimazole	B-Drug	['Causes']	[3]
6	teratogenicity	O	['N']	[6]
7	or	O	['N']	[7]
8	a	O	['N']	[8]
9	new	O	['N']	[9]
10	syndrome	O	['N']	[10]
11	?	O	['N']	[11]
#294
0	Interferon	B-Drug	['Causes']	[23]
1	-	O	['N']	[1]
2	based	O	['N']	[2]
3	treatments	O	['N']	[3]
4	have	O	['N']	[4]
5	the	O	['N']	[5]
6	potential	O	['N']	[6]
7	to	O	['N']	[7]
8	decrease	O	['N']	[8]
9	the	O	['N']	[9]
10	burden	O	['N']	[10]
11	of	O	['N']	[11]
12	disease	O	['N']	[12]
13	,	O	['N']	[13]
14	but	O	['N']	[14]
15	are	O	['N']	[15]
16	complicated	O	['N']	[16]
17	by	O	['N']	[17]
18	side	O	['N']	[18]
19	effects	O	['N']	[19]
20	,	O	['N']	[20]
21	including	O	['N']	[21]
22	neuropsychiatric	B	['N']	[22]
23	symptoms	I-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#295
0	Possible	O	['N']	[0]
1	pathophysiological	O	['N']	[1]
2	mechanisms	O	['N']	[2]
3	which	O	['N']	[3]
4	may	O	['N']	[4]
5	have	O	['N']	[5]
6	been	O	['N']	[6]
7	operative	O	['N']	[7]
8	in	O	['N']	[8]
9	this	O	['N']	[9]
10	case	O	['N']	[10]
11	include	O	['N']	[11]
12	:	O	['N']	[12]
13	a	O	['N']	[13]
14	direct	O	['N']	[14]
15	central	O	['N']	[15]
16	nervous	O	['N']	[16]
17	system	O	['N']	[17]
18	(	O	['N']	[18]
19	CNS	O	['N']	[19]
20	)	O	['N']	[20]
21	toxic	O	['N']	[21]
22	effect	O	['N']	[22]
23	of	O	['N']	[23]
24	valproic	B	['N']	[24]
25	acid	I-Drug	['Causes']	[48]
26	;	O	['N']	[26]
27	a	O	['N']	[27]
28	paradoxical	O	['N']	[28]
29	epileptogenic	O	['N']	[29]
30	effect	O	['N']	[30]
31	secondary	O	['N']	[31]
32	to	O	['N']	[32]
33	the	O	['N']	[33]
34	drug	O	['N']	[34]
35	;	O	['N']	[35]
36	and	O	['N']	[36]
37	an	O	['N']	[37]
38	indirect	O	['N']	[38]
39	CNS	O	['N']	[39]
40	toxic	O	['N']	[40]
41	effect	O	['N']	[41]
42	mediated	O	['N']	[42]
43	through	O	['N']	[43]
44	valproic	O	['N']	[44]
45	acid	O	['N']	[45]
46	-	O	['N']	[46]
47	induced	O	['N']	[47]
48	hyperammonemia	B-Adverse_Effect	['N']	[48]
49	.	O	['N']	[49]
#296
0	Hypokalemia	B-Adverse_Effect	['N']	[0]
1	after	O	['N']	[1]
2	normal	O	['N']	[2]
3	doses	O	['N']	[3]
4	of	O	['N']	[4]
5	neubulized	O	['N']	[5]
6	albuterol	B-Drug	['Causes']	[0]
7	(	O	['N']	[7]
8	salbutamol	O	['N']	[8]
9	)	O	['N']	[9]
10	.	O	['N']	[10]
#297
0	A	O	['N']	[0]
1	73-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	presented	O	['N']	[5]
6	with	O	['N']	[6]
7	fever	O	['N']	[7]
8	and	O	['N']	[8]
9	cough	B-Adverse_Effect	['N']	[9]
10	2	O	['N']	[10]
11	weeks	O	['N']	[11]
12	after	O	['N']	[12]
13	completing	O	['N']	[13]
14	the	O	['N']	[14]
15	third	O	['N']	[15]
16	cycle	O	['N']	[16]
17	of	O	['N']	[17]
18	fludarabine	B-Drug	['Causes']	[9]
19	for	O	['N']	[19]
20	chronic	O	['N']	[20]
21	lymphocytic	O	['N']	[21]
22	leukemia	O	['N']	[22]
23	(	O	['N']	[23]
24	CLL	O	['N']	[24]
25	)	O	['N']	[25]
26	.	O	['N']	[26]
#298
0	To	O	['N']	[0]
1	the	O	['N']	[1]
2	best	O	['N']	[2]
3	of	O	['N']	[3]
4	our	O	['N']	[4]
5	knowledge	O	['N']	[5]
6	only	O	['N']	[6]
7	two	O	['N']	[7]
8	previous	O	['N']	[8]
9	cases	O	['N']	[9]
10	of	O	['N']	[10]
11	AML	B-Adverse_Effect	['N']	[11]
12	have	O	['N']	[12]
13	been	O	['N']	[13]
14	linked	O	['N']	[14]
15	to	O	['N']	[15]
16	treatment	O	['N']	[16]
17	of	O	['N']	[17]
18	HCL	O	['N']	[18]
19	with	O	['N']	[19]
20	purine	O	['N']	[20]
21	analogs	O	['N']	[21]
22	,	O	['N']	[22]
23	both	O	['N']	[23]
24	with	O	['N']	[24]
25	2-chlorodeoxyadenosine	B-Drug	['Causes']	[11]
26	.	O	['N']	[26]
#299
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	skin	O	['N']	[23]
24	eruptions	O	['N']	[24]
25	,	O	['N']	[25]
26	cervical	O	['N']	[26]
27	lymphadenopathy	O	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	O	['N']	[31]
32	lymphocytosis	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	O	['N']	[40]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	O	['N']	[42]
43	(	O	['N']	[43]
44	SMX	B-Drug	['Causes']	[21]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#300
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	who	O	['N']	[2]
3	received	O	['N']	[3]
4	clindamycin	B-Drug	['Causes']	[18]
5	had	O	['N']	[5]
6	liver	O	['N']	[6]
7	biopsy	O	['N']	[7]
8	findings	O	['N']	[8]
9	of	O	['N']	[9]
10	marked	O	['N']	[10]
11	cholestasis	O	['N']	[11]
12	,	O	['N']	[12]
13	portal	O	['N']	[13]
14	inflammation	O	['N']	[14]
15	,	O	['N']	[15]
16	bile	B	['N']	[16]
17	duct	I	['N']	[17]
18	injury	I-Adverse_Effect	['N']	[18]
19	and	O	['N']	[19]
20	bile	O	['N']	[20]
21	duct	O	['N']	[21]
22	paucity	O	['N']	[22]
23	(	O	['N']	[23]
24	ductopenia	O	['N']	[24]
25	)	O	['N']	[25]
26	.	O	['N']	[26]
#301
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	severe	B	['N']	[3]
4	acute	I	['N']	[4]
5	hepatitis	I-Adverse_Effect	['N']	[5]
6	caused	O	['N']	[6]
7	by	O	['N']	[7]
8	cyproterone	B	['N']	[8]
9	acetate	I-Drug	['Causes']	[5]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	71	O	['N']	[12]
13	year	O	['N']	[13]
14	old	O	['N']	[14]
15	man	O	['N']	[15]
16	with	O	['N']	[16]
17	prostatic	O	['N']	[17]
18	carcinoma	O	['N']	[18]
19	is	O	['N']	[19]
20	reported	O	['N']	[20]
21	with	O	['N']	[21]
22	a	O	['N']	[22]
23	review	O	['N']	[23]
24	of	O	['N']	[24]
25	the	O	['N']	[25]
26	literature	O	['N']	[26]
27	on	O	['N']	[27]
28	hepatic	O	['N']	[28]
29	reactions	O	['N']	[29]
30	to	O	['N']	[30]
31	this	O	['N']	[31]
32	drug	O	['N']	[32]
33	.	O	['N']	[33]
#302
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	acute	O	['N']	[5]
6	epinephrine	B-Drug	['Causes']	[26]
7	toxicity	O	['N']	[7]
8	resulting	O	['N']	[8]
9	in	O	['N']	[9]
10	acute	O	['N']	[10]
11	myocardial	O	['N']	[11]
12	ischemia	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	young	O	['N']	[15]
16	boy	O	['N']	[16]
17	with	O	['N']	[17]
18	combined	O	['N']	[18]
19	variable	O	['N']	[19]
20	immunodeficiency	O	['N']	[20]
21	syndrome	O	['N']	[21]
22	who	O	['N']	[22]
23	developed	O	['N']	[23]
24	severe	B	['N']	[24]
25	allergic	I	['N']	[25]
26	reaction	I-Adverse_Effect	['N']	[26]
27	to	O	['N']	[27]
28	intravenous	O	['N']	[28]
29	immunoglobulin	O	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	was	O	['N']	[32]
33	subsequently	O	['N']	[33]
34	given	O	['N']	[34]
35	epinephrine	O	['N']	[35]
36	by	O	['N']	[36]
37	mistake	O	['N']	[37]
38	intravenously	O	['N']	[38]
39	rather	O	['N']	[39]
40	than	O	['N']	[40]
41	subcutaneously	O	['N']	[41]
42	.	O	['N']	[42]
#303
0	Gliclazide	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	acute	B	['N']	[3]
4	hepatitis	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#304
0	Ocular	B	['N']	[0]
1	hypertension	I-Adverse_Effect	['N']	[1]
2	occurred	O	['N']	[2]
3	1	O	['N']	[3]
4	month	O	['N']	[4]
5	after	O	['N']	[5]
6	the	O	['N']	[6]
7	second	O	['N']	[7]
8	ranibizumab	B-Drug	['Causes']	[1]
9	injection	O	['N']	[9]
10	in	O	['N']	[10]
11	patients	O	['N']	[11]
12	1	O	['N']	[12]
13	and	O	['N']	[13]
14	3	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	1	O	['N']	[17]
18	month	O	['N']	[18]
19	after	O	['N']	[19]
20	the	O	['N']	[20]
21	first	O	['N']	[21]
22	ranibizumab	O	['N']	[22]
23	in	O	['N']	[23]
24	patient	O	['N']	[24]
25	2	O	['N']	[25]
26	.	O	['N']	[26]
#305
0	Multifocal	O	['N']	[0]
1	electroretinographic	O	['N']	[1]
2	abnormalities	O	['N']	[2]
3	in	O	['N']	[3]
4	ethambutol	B-Drug	['Causes']	[8]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	visual	B	['N']	[7]
8	loss	I-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#306
0	During	O	['N']	[0]
1	intravenous	O	['N']	[1]
2	treatment	O	['N']	[2]
3	with	O	['N']	[3]
4	terlipressin	B-Drug	['Causes']	[33]
5	for	O	['N']	[5]
6	recurrent	O	['N']	[6]
7	gastrointestinal	O	['N']	[7]
8	(	O	['N']	[8]
9	GI	O	['N']	[9]
10	)	O	['N']	[10]
11	bleeding	O	['N']	[11]
12	,	O	['N']	[12]
13	a	O	['N']	[13]
14	50-year	O	['N']	[14]
15	-	O	['N']	[15]
16	old	O	['N']	[16]
17	male	O	['N']	[17]
18	with	O	['N']	[18]
19	no	O	['N']	[19]
20	history	O	['N']	[20]
21	of	O	['N']	[21]
22	heart	O	['N']	[22]
23	disease	O	['N']	[23]
24	developed	O	['N']	[24]
25	a	O	['N']	[25]
26	newly	O	['N']	[26]
27	prolonged	O	['N']	[27]
28	QT	O	['N']	[28]
29	interval	O	['N']	[29]
30	and	O	['N']	[30]
31	torsade	B	['N']	[31]
32	de	I	['N']	[32]
33	pointes	I-Adverse_Effect	['N']	[33]
34	.	O	['N']	[34]
#307
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	a	O	['N']	[2]
3	large	O	['N']	[3]
4	case	O	['N']	[4]
5	-	O	['N']	[5]
6	control	O	['N']	[6]
7	study	O	['N']	[7]
8	included	O	['N']	[8]
9	three	O	['N']	[9]
10	cases	O	['N']	[10]
11	of	O	['N']	[11]
12	either	O	['N']	[12]
13	Stevens	O	['N']	[13]
14	-	O	['N']	[14]
15	Johnson	O	['N']	[15]
16	syndrome	O	['N']	[16]
17	or	O	['N']	[17]
18	toxic	B	['N']	[18]
19	epidermal	I	['N']	[19]
20	necrolysis	I-Adverse_Effect	['N']	[20]
21	associated	O	['N']	[21]
22	with	O	['N']	[22]
23	ofloxacin	B-Drug	['Causes']	[20]
24	use	O	['N']	[24]
25	,	O	['N']	[25]
26	but	O	['N']	[26]
27	no	O	['N']	[27]
28	details	O	['N']	[28]
29	of	O	['N']	[29]
30	the	O	['N']	[30]
31	cases	O	['N']	[31]
32	were	O	['N']	[32]
33	given	O	['N']	[33]
34	.	O	['N']	[34]
#308
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	rhabdomyolysis	B-Adverse_Effect	['N']	[6]
7	related	O	['N']	[7]
8	to	O	['N']	[8]
9	the	O	['N']	[9]
10	administration	O	['N']	[10]
11	of	O	['N']	[11]
12	clarithromycin	B-Drug	['Causes']	[6]
13	without	O	['N']	[13]
14	concurrent	O	['N']	[14]
15	use	O	['N']	[15]
16	of	O	['N']	[16]
17	other	O	['N']	[17]
18	medications	O	['N']	[18]
19	.	O	['N']	[19]
#309
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Zidovudine	B-Drug	['Causes']	[9]
3	is	O	['N']	[3]
4	well	O	['N']	[4]
5	a	O	['N']	[5]
6	known	O	['N']	[6]
7	cause	O	['N']	[7]
8	of	O	['N']	[8]
9	anaemia	B-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	thus	O	['N']	[11]
12	should	O	['N']	[12]
13	be	O	['N']	[13]
14	used	O	['N']	[14]
15	with	O	['N']	[15]
16	caution	O	['N']	[16]
17	in	O	['N']	[17]
18	the	O	['N']	[18]
19	initiation	O	['N']	[19]
20	of	O	['N']	[20]
21	antiretroviral	O	['N']	[21]
22	therapy	O	['N']	[22]
23	.	O	['N']	[23]
#310
0	PATIENTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Two	O	['N']	[2]
3	patients	O	['N']	[3]
4	,	O	['N']	[4]
5	ages	O	['N']	[5]
6	40	O	['N']	[6]
7	and	O	['N']	[7]
8	51	O	['N']	[8]
9	years	O	['N']	[9]
10	,	O	['N']	[10]
11	undergoing	O	['N']	[11]
12	treatment	O	['N']	[12]
13	with	O	['N']	[13]
14	interferon	B	['N']	[14]
15	alfa	I-Drug	['Causes']	[25]
16	for	O	['N']	[16]
17	malignant	O	['N']	[17]
18	neoplasms	O	['N']	[18]
19	experienced	O	['N']	[19]
20	sudden	B	['N']	[20]
21	bilateral	I	['N']	[21]
22	,	I	['N']	[22]
23	sequential	I	['N']	[23]
24	visual	I	['N']	[24]
25	loss	I-Adverse_Effect	['N']	[25]
26	with	O	['N']	[26]
27	disc	O	['N']	[27]
28	-	O	['N']	[28]
29	related	O	['N']	[29]
30	field	O	['N']	[30]
31	defects	O	['N']	[31]
32	and	O	['N']	[32]
33	segmental	O	['N']	[33]
34	optic	O	['N']	[34]
35	disc	O	['N']	[35]
36	edema	O	['N']	[36]
37	.	O	['N']	[37]
#311
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	55-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	became	O	['N']	[7]
8	stuporous	O	['N']	[8]
9	after	O	['N']	[9]
10	overdose	B-Dose	['N']	[10]
11	with	O	['N']	[11]
12	lamotrigine	O	['N']	[12]
13	(	O	['N']	[13]
14	LTG	O	['N']	[14]
15	)	O	['N']	[15]
16	and	O	['N']	[16]
17	valproic	B	['N']	[17]
18	acid	I-Drug	['Dosage']	[10]
19	(	O	['N']	[19]
20	VPA	O	['N']	[20]
21	)	O	['N']	[21]
22	tablets	O	['N']	[22]
23	.	O	['N']	[23]
#312
0	Hepatocellular	B	['N']	[0]
1	damage	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	therapeutic	O	['N']	[3]
4	intravenous	O	['N']	[4]
5	iron	B	['N']	[5]
6	sucrose	I-Drug	['Causes']	[1]
7	infusion	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	child	O	['N']	[10]
11	.	O	['N']	[11]
#313
0	CASES	O	['N']	[0]
1	:	O	['N']	[1]
2	Two	O	['N']	[2]
3	postmenopausal	O	['N']	[3]
4	women	O	['N']	[4]
5	treated	O	['N']	[5]
6	with	O	['N']	[6]
7	tamoxifen	B-Drug	['Causes']	[19]
8	and	O	['N']	[8]
9	progestational	O	['N']	[9]
10	agents	O	['N']	[10]
11	for	O	['N']	[11]
12	breast	O	['N']	[12]
13	carcinoma	O	['N']	[13]
14	developed	O	['N']	[14]
15	uterine	O	['N']	[15]
16	enlargement	O	['N']	[16]
17	and	O	['N']	[17]
18	intermittent	B	['N']	[18]
19	spotting	I-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#314
0	Dipyrone	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	granulocytopenia	B-Adverse_Effect	['N']	[3]
4	:	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	for	O	['N']	[7]
8	awareness	O	['N']	[8]
9	.	O	['N']	[9]
#315
0	Clinicians	O	['N']	[0]
1	who	O	['N']	[1]
2	manage	O	['N']	[2]
3	cachectic	O	['N']	[3]
4	patients	O	['N']	[4]
5	,	O	['N']	[5]
6	particularly	O	['N']	[6]
7	those	O	['N']	[7]
8	with	O	['N']	[8]
9	protracted	O	['N']	[9]
10	diarrhoea	O	['N']	[10]
11	and/or	O	['N']	[11]
12	receiving	O	['N']	[12]
13	anti	O	['N']	[13]
14	-	O	['N']	[14]
15	malarial	O	['N']	[15]
16	drugs	O	['N']	[16]
17	including	O	['N']	[17]
18	mefloquine	B-Drug	['Causes']	[28]
19	,	O	['N']	[19]
20	should	O	['N']	[20]
21	be	O	['N']	[21]
22	aware	O	['N']	[22]
23	of	O	['N']	[23]
24	the	O	['N']	[24]
25	risk	O	['N']	[25]
26	of	O	['N']	[26]
27	severe	B	['N']	[27]
28	hypoglycaemia	I-Adverse_Effect	['N']	[28]
29	.	O	['N']	[29]
#316
0	Transient	B	['N']	[0]
1	anuria	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	administration	O	['N']	[3]
4	of	O	['N']	[4]
5	angiotensin	O	['N']	[5]
6	I	O	['N']	[6]
7	-	O	['N']	[7]
8	converting	O	['N']	[8]
9	enzyme	O	['N']	[9]
10	inhibitor	O	['N']	[10]
11	(	O	['N']	[11]
12	SQ	B	['N']	[12]
13	14225	I-Drug	['Causes']	[1]
14	)	O	['N']	[14]
15	in	O	['N']	[15]
16	a	O	['N']	[16]
17	patient	O	['N']	[17]
18	with	O	['N']	[18]
19	renal	O	['N']	[19]
20	artery	O	['N']	[20]
21	stenosis	O	['N']	[21]
22	of	O	['N']	[22]
23	the	O	['N']	[23]
24	solitary	O	['N']	[24]
25	kidney	O	['N']	[25]
26	successfully	O	['N']	[26]
27	treated	O	['N']	[27]
28	with	O	['N']	[28]
29	renal	O	['N']	[29]
30	autotransplantation	O	['N']	[30]
31	.	O	['N']	[31]
#317
0	Three	O	['N']	[0]
1	of	O	['N']	[1]
2	these	O	['N']	[2]
3	patients	O	['N']	[3]
4	had	O	['N']	[4]
5	convulsions	O	['N']	[5]
6	attributed	O	['N']	[6]
7	to	O	['N']	[7]
8	imipenem	O	['N']	[8]
9	/	O	['N']	[9]
10	cilastatin	B-Drug	['Causes']	[18]
11	;	O	['N']	[11]
12	3.6	O	['N']	[12]
13	%	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	patients	O	['N']	[16]
17	had	O	['N']	[17]
18	seizure	B-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	or	O	['N']	[20]
21	2	O	['N']	[21]
22	%	O	['N']	[22]
23	of	O	['N']	[23]
24	imipenem	O	['N']	[24]
25	/	O	['N']	[25]
26	cilastatin	O	['N']	[26]
27	administrations	O	['N']	[27]
28	was	O	['N']	[28]
29	followed	O	['N']	[29]
30	by	O	['N']	[30]
31	a	O	['N']	[31]
32	seizure	O	['N']	[32]
33	attack	O	['N']	[33]
34	.	O	['N']	[34]
#318
0	She	O	['N']	[0]
1	received	O	['N']	[1]
2	an	O	['N']	[2]
3	accidental	O	['N']	[3]
4	450-mg	O	['N']	[4]
5	bolus	O	['N']	[5]
6	injection	O	['N']	[6]
7	of	O	['N']	[7]
8	morphine	B-Drug	['Causes']	[12]
9	intrathecally	O	['N']	[9]
10	and	O	['N']	[10]
11	developed	O	['N']	[11]
12	hypertension	B-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	status	O	['N']	[14]
15	epilepticus	O	['N']	[15]
16	,	O	['N']	[16]
17	intracerebral	O	['N']	[17]
18	hemorrhage	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	respiratory	O	['N']	[21]
22	failure	O	['N']	[22]
23	.	O	['N']	[23]
#319
0	Cis	O	['N']	[0]
1	-	O	['N']	[1]
2	retinoic	O	['N']	[2]
3	acid	O	['N']	[3]
4	(	O	['N']	[4]
5	RA	B-Drug	['Causes']	[14]
6	)	O	['N']	[6]
7	may	O	['N']	[7]
8	further	O	['N']	[8]
9	increase	O	['N']	[9]
10	the	O	['N']	[10]
11	risk	O	['N']	[11]
12	of	O	['N']	[12]
13	developing	O	['N']	[13]
14	BMTN	B-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#320
0	A	O	['N']	[0]
1	16-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	developed	O	['N']	[5]
6	fever	O	['N']	[6]
7	,	O	['N']	[7]
8	generalized	O	['N']	[8]
9	rigidity	O	['N']	[9]
10	,	O	['N']	[10]
11	leukocytosis	B-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	increased	O	['N']	[14]
15	serum	O	['N']	[15]
16	transaminase	O	['N']	[16]
17	and	O	['N']	[17]
18	creatine	O	['N']	[18]
19	kinase	O	['N']	[19]
20	levels	O	['N']	[20]
21	while	O	['N']	[21]
22	receiving	O	['N']	[22]
23	treatment	O	['N']	[23]
24	with	O	['N']	[24]
25	olanzapine	B-Drug	['Causes']	[11]
26	and	O	['N']	[26]
27	lithium	O	['N']	[27]
28	.	O	['N']	[28]
#321
0	Gentamicin	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	acute	B	['N']	[3]
4	renal	I	['N']	[4]
5	failure	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#322
0	Massive	O	['N']	[0]
1	CBZ	B-Drug	['Causes']	[7]
2	OD	O	['N']	[2]
3	may	O	['N']	[3]
4	produce	O	['N']	[4]
5	a	O	['N']	[5]
6	reversible	B	['N']	[6]
7	encephalopathy	I-Adverse_Effect	['N']	[7]
8	that	O	['N']	[8]
9	includes	O	['N']	[9]
10	cortical	O	['N']	[10]
11	hyperexcitability	O	['N']	[11]
12	,	O	['N']	[12]
13	a	O	['N']	[13]
14	profound	O	['N']	[14]
15	burst	O	['N']	[15]
16	-	O	['N']	[16]
17	suppression	O	['N']	[17]
18	EEG	O	['N']	[18]
19	pattern	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	cranial	O	['N']	[22]
23	nerve	O	['N']	[23]
24	areflexia	O	['N']	[24]
25	.	O	['N']	[25]
#323
0	Severe	B	['N']	[0]
1	neurotoxicity	I-Adverse_Effect	['N']	[1]
2	with	O	['N']	[2]
3	methyl	B	['N']	[3]
4	G	I	['N']	[4]
5	:	I	['N']	[5]
6	CALGB	I-Drug	['Causes']	[1]
7	experience	O	['N']	[7]
8	.	O	['N']	[8]
#324
0	Since	O	['N']	[0]
1	early	O	['N']	[1]
2	symptoms	O	['N']	[2]
3	of	O	['N']	[3]
4	the	O	['N']	[4]
5	toxic	O	['N']	[5]
6	effects	O	['N']	[6]
7	of	O	['N']	[7]
8	theophylline	B-Drug	['Causes']	[13]
9	can	O	['N']	[9]
10	mimic	O	['N']	[10]
11	peptic	B	['N']	[11]
12	ulcer	I	['N']	[12]
13	disease	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	cimetidine	O	['N']	[15]
16	might	O	['N']	[16]
17	be	O	['N']	[17]
18	prescribed	O	['N']	[18]
19	for	O	['N']	[19]
20	the	O	['N']	[20]
21	gastrointestinal	O	['N']	[21]
22	symptoms	O	['N']	[22]
23	with	O	['N']	[23]
24	subsequent	O	['N']	[24]
25	worsening	O	['N']	[25]
26	of	O	['N']	[26]
27	theophylline	O	['N']	[27]
28	poisoning	O	['N']	[28]
29	.	O	['N']	[29]
#325
0	Since	O	['N']	[0]
1	the	O	['N']	[1]
2	thrombocyte	B	['N']	[2]
3	count	I	['N']	[3]
4	started	I	['N']	[4]
5	to	I	['N']	[5]
6	increase	I-Adverse_Effect	['N']	[6]
7	immediately	O	['N']	[7]
8	after	O	['N']	[8]
9	initiation	O	['N']	[9]
10	and	O	['N']	[10]
11	dropped	O	['N']	[11]
12	immediately	O	['N']	[12]
13	after	O	['N']	[13]
14	discontinuation	O	['N']	[14]
15	of	O	['N']	[15]
16	ciprofloxacin	B-Drug	['Causes']	[6]
17	and	O	['N']	[17]
18	tazobactam	O	['N']	[18]
19	/	O	['N']	[19]
20	piperacillin	O	['N']	[20]
21	and	O	['N']	[21]
22	all	O	['N']	[22]
23	other	O	['N']	[23]
24	drugs	O	['N']	[24]
25	were	O	['N']	[25]
26	discontinued	O	['N']	[26]
27	already	O	['N']	[27]
28	before	O	['N']	[28]
29	or	O	['N']	[29]
30	were	O	['N']	[30]
31	started	O	['N']	[31]
32	after	O	['N']	[32]
33	the	O	['N']	[33]
34	nadir	O	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	thrombocyte	O	['N']	[37]
38	count	O	['N']	[38]
39	,	O	['N']	[39]
40	these	O	['N']	[40]
41	two	O	['N']	[41]
42	antibiotics	O	['N']	[42]
43	were	O	['N']	[43]
44	regarded	O	['N']	[44]
45	causative	O	['N']	[45]
46	.	O	['N']	[46]
#326
0	Four	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	oesophageal	B	['N']	[3]
4	damage	I-Adverse_Effect	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	ingestion	O	['N']	[7]
8	of	O	['N']	[8]
9	the	O	['N']	[9]
10	urinary	O	['N']	[10]
11	anti	O	['N']	[11]
12	-	O	['N']	[12]
13	spasmodic	O	['N']	[13]
14	agent	O	['N']	[14]
15	emepronium	B	['N']	[15]
16	bromide	I-Drug	['Causes']	[4]
17	are	O	['N']	[17]
18	described	O	['N']	[18]
19	.	O	['N']	[19]
#327
0	FINDINGS	O	['N']	[0]
1	:	O	['N']	[1]
2	Six	O	['N']	[2]
3	children	O	['N']	[3]
4	with	O	['N']	[4]
5	growth	B	['N']	[5]
6	retardation	I-Adverse_Effect	['N']	[6]
7	noted	O	['N']	[7]
8	after	O	['N']	[8]
9	treatment	O	['N']	[9]
10	with	O	['N']	[10]
11	high	O	['N']	[11]
12	-	O	['N']	[12]
13	dose	O	['N']	[13]
14	fluticasone	B	['N']	[14]
15	propionate	I-Drug	['Causes']	[6]
16	were	O	['N']	[16]
17	found	O	['N']	[17]
18	to	O	['N']	[18]
19	have	O	['N']	[19]
20	adrenal	O	['N']	[20]
21	suppression	O	['N']	[21]
22	.	O	['N']	[22]
#328
0	Recently	O	['N']	[0]
1	,	O	['N']	[1]
2	some	O	['N']	[2]
3	studies	O	['N']	[3]
4	have	O	['N']	[4]
5	also	O	['N']	[5]
6	reported	O	['N']	[6]
7	association	O	['N']	[7]
8	between	O	['N']	[8]
9	patients	O	['N']	[9]
10	with	O	['N']	[10]
11	juvenile	O	['N']	[11]
12	rheumatoid	O	['N']	[12]
13	arthritis	O	['N']	[13]
14	(	O	['N']	[14]
15	JRA	O	['N']	[15]
16	)	O	['N']	[16]
17	treated	O	['N']	[17]
18	with	O	['N']	[18]
19	Methotrexate	B-Drug	['Causes']	[25]
20	(	O	['N']	[20]
21	MTX	O	['N']	[21]
22	)	O	['N']	[22]
23	and	O	['N']	[23]
24	malignant	B	['N']	[24]
25	lymphoma	I-Adverse_Effect	['N']	[25]
26	developing	O	['N']	[26]
27	.	O	['N']	[27]
#329
0	Although	O	['N']	[0]
1	major	O	['N']	[1]
2	hazards	O	['N']	[2]
3	of	O	['N']	[3]
4	treatment	O	['N']	[4]
5	of	O	['N']	[5]
6	hypophosphatemic	O	['N']	[6]
7	osteomalacia	O	['N']	[7]
8	with	O	['N']	[8]
9	phosphate	O	['N']	[9]
10	and	O	['N']	[10]
11	calcitriol	B-Drug	['Causes']	[21]
12	are	O	['N']	[12]
13	secondary	O	['N']	[13]
14	hyperparathyroidism	O	['N']	[14]
15	and	O	['N']	[15]
16	vitamin	O	['N']	[16]
17	D	O	['N']	[17]
18	intoxication	O	['N']	[18]
19	,	O	['N']	[19]
20	potassium	B	['N']	[20]
21	loss	I-Adverse_Effect	['N']	[21]
22	also	O	['N']	[22]
23	should	O	['N']	[23]
24	be	O	['N']	[24]
25	kept	O	['N']	[25]
26	in	O	['N']	[26]
27	mind	O	['N']	[27]
28	.	O	['N']	[28]
#330
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Similar	O	['N']	[2]
3	to	O	['N']	[3]
4	previous	O	['N']	[4]
5	findings	O	['N']	[5]
6	of	O	['N']	[6]
7	drug	O	['N']	[7]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	vortex	B	['N']	[10]
11	keratopathy	I-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	atovaquone	B-Drug	['Causes']	[11]
14	vortex	O	['N']	[14]
15	keratopathy	O	['N']	[15]
16	is	O	['N']	[16]
17	presumably	O	['N']	[17]
18	caused	O	['N']	[18]
19	by	O	['N']	[19]
20	its	O	['N']	[20]
21	lipophilic	O	['N']	[21]
22	properties	O	['N']	[22]
23	.	O	['N']	[23]
#331
0	This	O	['N']	[0]
1	article	O	['N']	[1]
2	describes	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	suspected	O	['N']	[6]
7	ciprofloxacin	B-Drug	['Causes']	[11]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	interstitial	B	['N']	[10]
11	nephritis	I-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#332
0	Myoclonus	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	continuous	O	['N']	[3]
4	dobutamine	B-Drug	['Causes']	[0]
5	infusion	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	end	O	['N']	[10]
11	-	O	['N']	[11]
12	stage	O	['N']	[12]
13	renal	O	['N']	[13]
14	disease	O	['N']	[14]
15	.	O	['N']	[15]
#333
0	Several	O	['N']	[0]
1	case	O	['N']	[1]
2	reports	O	['N']	[2]
3	of	O	['N']	[3]
4	aplastic	B	['N']	[4]
5	anemia	I-Adverse_Effect	['N']	[5]
6	with	O	['N']	[6]
7	use	O	['N']	[7]
8	of	O	['N']	[8]
9	acetazolamide	O	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	two	O	['N']	[12]
13	cases	O	['N']	[13]
14	with	O	['N']	[14]
15	use	O	['N']	[15]
16	of	O	['N']	[16]
17	methazolamide	B-Drug	['Causes']	[5]
18	,	O	['N']	[18]
19	have	O	['N']	[19]
20	appeared	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	literature	O	['N']	[23]
24	.	O	['N']	[24]
#334
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	51-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	man	O	['N']	[9]
10	in	O	['N']	[10]
11	whom	O	['N']	[11]
12	IFN	B	['N']	[12]
13	-	I	['N']	[13]
14	alpha	I-Drug	['Causes']	[23]
15	treatment	O	['N']	[15]
16	was	O	['N']	[16]
17	followed	O	['N']	[17]
18	by	O	['N']	[18]
19	recurrence	O	['N']	[19]
20	of	O	['N']	[20]
21	Graves	B	['N']	[21]
22	'	I	['N']	[22]
23	disease	I-Adverse_Effect	['N']	[23]
24	10	O	['N']	[24]
25	years	O	['N']	[25]
26	after	O	['N']	[26]
27	thyroidectomy	O	['N']	[27]
28	was	O	['N']	[28]
29	performed	O	['N']	[29]
30	and	O	['N']	[30]
31	the	O	['N']	[31]
32	patient	O	['N']	[32]
33	was	O	['N']	[33]
34	declared	O	['N']	[34]
35	cured	O	['N']	[35]
36	.	O	['N']	[36]
#335
0	Visceral	O	['N']	[0]
1	leishmaniasis	O	['N']	[1]
2	and	O	['N']	[2]
3	macrophagic	B	['N']	[3]
4	activation	I	['N']	[4]
5	syndrome	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	rheumatoid	O	['N']	[10]
11	arthritis	O	['N']	[11]
12	under	O	['N']	[12]
13	treatment	O	['N']	[13]
14	with	O	['N']	[14]
15	adalimumab	B-Drug	['Causes']	[5]
16	.	O	['N']	[16]
#336
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	this	O	['N']	[3]
4	is	O	['N']	[4]
5	the	O	['N']	[5]
6	first	O	['N']	[6]
7	report	O	['N']	[7]
8	of	O	['N']	[8]
9	pancytopenia	O	['N']	[9]
10	due	O	['N']	[10]
11	to	O	['N']	[11]
12	MMI	B-Drug	['Causes']	[23]
13	,	O	['N']	[13]
14	where	O	['N']	[14]
15	the	O	['N']	[15]
16	usual	O	['N']	[16]
17	hypoplasia	O	['N']	[17]
18	found	O	['N']	[18]
19	is	O	['N']	[19]
20	replaced	O	['N']	[20]
21	by	O	['N']	[21]
22	massive	B	['N']	[22]
23	plasmocytosis	I-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#337
0	Concurrent	O	['N']	[0]
1	acute	O	['N']	[1]
2	megaloblastic	O	['N']	[2]
3	anaemia	O	['N']	[3]
4	and	O	['N']	[4]
5	pneumonitis	O	['N']	[5]
6	:	O	['N']	[6]
7	a	O	['N']	[7]
8	severe	O	['N']	[8]
9	side	O	['N']	[9]
10	-	O	['N']	[10]
11	effect	O	['N']	[11]
12	of	O	['N']	[12]
13	low	B	['N']	[13]
14	-	I	['N']	[14]
15	dose	I-Dose	['N']	[15]
16	methotrexate	B-Drug	['Dosage']	[15]
17	therapy	O	['N']	[17]
18	during	O	['N']	[18]
19	rheumatoid	O	['N']	[19]
20	arthritis	O	['N']	[20]
21	.	O	['N']	[21]
#338
0	FK506	B-Drug	['Causes']	[35]
1	,	O	['N']	[1]
2	which	O	['N']	[2]
3	began	O	['N']	[3]
4	to	O	['N']	[4]
5	be	O	['N']	[5]
6	administered	O	['N']	[6]
7	12	O	['N']	[7]
8	days	O	['N']	[8]
9	earlier	O	['N']	[9]
10	,	O	['N']	[10]
11	rose	O	['N']	[11]
12	to	O	['N']	[12]
13	a	O	['N']	[13]
14	level	O	['N']	[14]
15	of	O	['N']	[15]
16	44	O	['N']	[16]
17	ng	O	['N']	[17]
18	/	O	['N']	[18]
19	mL	O	['N']	[19]
20	(	O	['N']	[20]
21	normal	O	['N']	[21]
22	range	O	['N']	[22]
23	,	O	['N']	[23]
24	10	O	['N']	[24]
25	-	O	['N']	[25]
26	20	O	['N']	[26]
27	ng	O	['N']	[27]
28	/	O	['N']	[28]
29	mL	O	['N']	[29]
30	)	O	['N']	[30]
31	1	O	['N']	[31]
32	day	O	['N']	[32]
33	before	O	['N']	[33]
34	neurologic	B	['N']	[34]
35	abnormalities	I-Adverse_Effect	['N']	[35]
36	began	O	['N']	[36]
37	.	O	['N']	[37]
#339
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	adult	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	acute	O	['N']	[9]
10	lymphoblastic	O	['N']	[10]
11	leukemia	O	['N']	[11]
12	who	O	['N']	[12]
13	presented	O	['N']	[13]
14	with	O	['N']	[14]
15	repeated	O	['N']	[15]
16	transient	B	['N']	[16]
17	ischemic	I	['N']	[17]
18	attacks	I-Adverse_Effect	['N']	[18]
19	followed	O	['N']	[19]
20	by	O	['N']	[20]
21	a	O	['N']	[21]
22	seizure	O	['N']	[22]
23	during	O	['N']	[23]
24	consolidation	O	['N']	[24]
25	treatment	O	['N']	[25]
26	with	O	['N']	[26]
27	L	B	['N']	[27]
28	-	I	['N']	[28]
29	asparaginase	I-Drug	['Causes']	[18]
30	.	O	['N']	[30]
#340
0	Hepatotoxicity	B-Adverse_Effect	['N']	[0]
1	of	O	['N']	[1]
2	hycanthone	B-Drug	['Causes']	[0]
3	in	O	['N']	[3]
4	patients	O	['N']	[4]
5	with	O	['N']	[5]
6	metastatic	O	['N']	[6]
7	breast	O	['N']	[7]
8	cancer	O	['N']	[8]
9	.	O	['N']	[9]
#341
0	The	O	['N']	[0]
1	clinical	O	['N']	[1]
2	course	O	['N']	[2]
3	suggests	O	['N']	[3]
4	that	O	['N']	[4]
5	the	O	['N']	[5]
6	interstitial	B	['N']	[6]
7	pneumonitis	I-Adverse_Effect	['N']	[7]
8	was	O	['N']	[8]
9	induced	O	['N']	[9]
10	by	O	['N']	[10]
11	hydroxyurea	B-Drug	['Causes']	[7]
12	.	O	['N']	[12]
#342
0	After	O	['N']	[0]
1	gastric	B	['N']	[1]
2	-	I	['N']	[2]
3	outlet	I	['N']	[3]
4	obstruction	I-Adverse_Effect	['N']	[4]
5	was	O	['N']	[5]
6	recognized	O	['N']	[6]
7	in	O	['N']	[7]
8	several	O	['N']	[8]
9	infants	O	['N']	[9]
10	who	O	['N']	[10]
11	received	O	['N']	[11]
12	prostaglandin	B	['N']	[12]
13	E1	I-Drug	['Causes']	[4]
14	,	O	['N']	[14]
15	we	O	['N']	[15]
16	studied	O	['N']	[16]
17	the	O	['N']	[17]
18	association	O	['N']	[18]
19	between	O	['N']	[19]
20	the	O	['N']	[20]
21	drug	O	['N']	[21]
22	and	O	['N']	[22]
23	this	O	['N']	[23]
24	complication	O	['N']	[24]
25	.	O	['N']	[25]
#343
0	Zolpidem	O	['N']	[0]
1	(	O	['N']	[1]
2	Ambien	B-Drug	['Causes']	[17]
3	)	O	['N']	[3]
4	,	O	['N']	[4]
5	a	O	['N']	[5]
6	relatively	O	['N']	[6]
7	new	O	['N']	[7]
8	nonbenzodiazepine	O	['N']	[8]
9	sedative	O	['N']	[9]
10	-	O	['N']	[10]
11	hypnotic	O	['N']	[11]
12	,	O	['N']	[12]
13	was	O	['N']	[13]
14	involved	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	death	B-Adverse_Effect	['N']	[17]
18	of	O	['N']	[18]
19	a	O	['N']	[19]
20	39-year	O	['N']	[20]
21	-	O	['N']	[21]
22	old	O	['N']	[22]
23	obese	O	['N']	[23]
24	male	O	['N']	[24]
25	who	O	['N']	[25]
26	was	O	['N']	[26]
27	being	O	['N']	[27]
28	treated	O	['N']	[28]
29	for	O	['N']	[29]
30	depression	O	['N']	[30]
31	and	O	['N']	[31]
32	insomnia	O	['N']	[32]
33	.	O	['N']	[33]
#344
0	Acute	O	['N']	[0]
1	INH	B-Drug	['Causes']	[2]
2	neurotoxicity	B-Adverse_Effect	['N']	[2]
3	was	O	['N']	[3]
4	not	O	['N']	[4]
5	suspected	O	['N']	[5]
6	on	O	['N']	[6]
7	the	O	['N']	[7]
8	first	O	['N']	[8]
9	admission	O	['N']	[9]
10	;	O	['N']	[10]
11	however	O	['N']	[11]
12	,	O	['N']	[12]
13	when	O	['N']	[13]
14	readmitted	O	['N']	[14]
15	4	O	['N']	[15]
16	weeks	O	['N']	[16]
17	later	O	['N']	[17]
18	with	O	['N']	[18]
19	another	O	['N']	[19]
20	seizure	O	['N']	[20]
21	,	O	['N']	[21]
22	the	O	['N']	[22]
23	diagnosis	O	['N']	[23]
24	of	O	['N']	[24]
25	acute	O	['N']	[25]
26	INH	O	['N']	[26]
27	neurotoxicity	O	['N']	[27]
28	was	O	['N']	[28]
29	made	O	['N']	[29]
30	.	O	['N']	[30]
#345
0	Oxygen	O	['N']	[0]
1	potentiation	O	['N']	[1]
2	of	O	['N']	[2]
3	bleomycin	B-Drug	['Causes']	[7]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	pulmonary	B	['N']	[6]
7	toxicity	I-Adverse_Effect	['N']	[7]
8	is	O	['N']	[8]
9	discussed	O	['N']	[9]
10	.	O	['N']	[10]
#346
0	ADH	B	['N']	[0]
1	hypersecretion	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	relation	O	['N']	[3]
4	to	O	['N']	[4]
5	plasma	O	['N']	[5]
6	osmolality	O	['N']	[6]
7	was	O	['N']	[7]
8	reversed	O	['N']	[8]
9	by	O	['N']	[9]
10	mizoribin	B-Drug	['Causes']	[1]
11	withdrawal	O	['N']	[11]
12	,	O	['N']	[12]
13	suggesting	O	['N']	[13]
14	that	O	['N']	[14]
15	bredinin	O	['N']	[15]
16	might	O	['N']	[16]
17	adversely	O	['N']	[17]
18	induce	O	['N']	[18]
19	SIADH	O	['N']	[19]
20	.	O	['N']	[20]
#347
0	Toxic	B	['N']	[0]
1	hepatitis	I-Adverse_Effect	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	combination	O	['N']	[4]
5	therapy	O	['N']	[5]
6	with	O	['N']	[6]
7	methotrexate	O	['N']	[7]
8	and	O	['N']	[8]
9	etretinate	B-Drug	['Causes']	[1]
10	in	O	['N']	[10]
11	psoriasis	O	['N']	[11]
12	.	O	['N']	[12]
#348
0	Reports	O	['N']	[0]
1	of	O	['N']	[1]
2	colonic	B	['N']	[2]
3	perforation	I-Adverse_Effect	['N']	[3]
4	as	O	['N']	[4]
5	a	O	['N']	[5]
6	result	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	administration	O	['N']	[9]
10	of	O	['N']	[10]
11	calcium	O	['N']	[11]
12	polystyrene	O	['N']	[12]
13	sulfonate	O	['N']	[13]
14	and	O	['N']	[14]
15	sorbitol	B-Drug	['Causes']	[3]
16	are	O	['N']	[16]
17	rare	O	['N']	[17]
18	.	O	['N']	[18]
#349
0	A	O	['N']	[0]
1	74-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	hypercholestrerolaemic	O	['N']	[4]
5	woman	O	['N']	[5]
6	taking	O	['N']	[6]
7	cerivastatin	B-Drug	['Causes']	[21]
8	(	O	['N']	[8]
9	0.15	O	['N']	[9]
10	mg	O	['N']	[10]
11	/	O	['N']	[11]
12	day	O	['N']	[12]
13	)	O	['N']	[13]
14	for	O	['N']	[14]
15	22	O	['N']	[15]
16	days	O	['N']	[16]
17	complained	O	['N']	[17]
18	of	O	['N']	[18]
19	general	O	['N']	[19]
20	muscle	B	['N']	[20]
21	weakness	I-Adverse_Effect	['N']	[21]
22	and	O	['N']	[22]
23	muscle	O	['N']	[23]
24	pain	O	['N']	[24]
25	.	O	['N']	[25]
#350
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	had	O	['N']	[2]
3	severe	B	['N']	[3]
4	temporary	I	['N']	[4]
5	weakness	I-Adverse_Effect	['N']	[5]
6	after	O	['N']	[6]
7	an	O	['N']	[7]
8	ampicillin	B	['N']	[8]
9	sodium	I-Drug	['Causes']	[5]
10	challenge	O	['N']	[10]
11	.	O	['N']	[11]
#351
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	5	O	['N']	[2]
3	patients	O	['N']	[3]
4	(	O	['N']	[4]
5	3	O	['N']	[5]
6	patients	O	['N']	[6]
7	with	O	['N']	[7]
8	chronic	O	['N']	[8]
9	hepatitis	O	['N']	[9]
10	C	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	pegylated	B	['N']	[13]
14	interferon	I	['N']	[14]
15	alfa-2b	I-Drug	['Causes']	[33]
16	in	O	['N']	[16]
17	association	O	['N']	[17]
18	with	O	['N']	[18]
19	oral	O	['N']	[19]
20	ribavirin	O	['N']	[20]
21	and	O	['N']	[21]
22	two	O	['N']	[22]
23	patients	O	['N']	[23]
24	with	O	['N']	[24]
25	chronic	O	['N']	[25]
26	myelocytic	O	['N']	[26]
27	leukemia	O	['N']	[27]
28	)	O	['N']	[28]
29	who	O	['N']	[29]
30	developed	O	['N']	[30]
31	local	B	['N']	[31]
32	cutaneous	I	['N']	[32]
33	reactions	I-Adverse_Effect	['N']	[33]
34	at	O	['N']	[34]
35	sites	O	['N']	[35]
36	of	O	['N']	[36]
37	injection	O	['N']	[37]
38	after	O	['N']	[38]
39	the	O	['N']	[39]
40	administration	O	['N']	[40]
41	of	O	['N']	[41]
42	weekly	O	['N']	[42]
43	subcutaneous	O	['N']	[43]
44	injections	O	['N']	[44]
45	of	O	['N']	[45]
46	pegylated	O	['N']	[46]
47	interferon	O	['N']	[47]
48	alfa-2b	O	['N']	[48]
49	at	O	['N']	[49]
50	different	O	['N']	[50]
51	doses	O	['N']	[51]
52	.	O	['N']	[52]
#352
0	A	O	['N']	[0]
1	toxic	B	['N']	[1]
2	encephalopathy	I-Adverse_Effect	['N']	[2]
3	characterized	O	['N']	[3]
4	by	O	['N']	[4]
5	depressed	O	['N']	[5]
6	level	O	['N']	[6]
7	of	O	['N']	[7]
8	consciousness	O	['N']	[8]
9	,	O	['N']	[9]
10	marked	O	['N']	[10]
11	irritability	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	ataxia	O	['N']	[14]
15	developed	O	['N']	[15]
16	in	O	['N']	[16]
17	seven	O	['N']	[17]
18	children	O	['N']	[18]
19	,	O	['N']	[19]
20	5	O	['N']	[20]
21	years	O	['N']	[21]
22	of	O	['N']	[22]
23	age	O	['N']	[23]
24	and	O	['N']	[24]
25	younger	O	['N']	[25]
26	,	O	['N']	[26]
27	following	O	['N']	[27]
28	administration	O	['N']	[28]
29	of	O	['N']	[29]
30	an	O	['N']	[30]
31	antiemetic	O	['N']	[31]
32	combination	O	['N']	[32]
33	of	O	['N']	[33]
34	pentobarbital	O	['N']	[34]
35	and	O	['N']	[35]
36	pyrilamine	B	['N']	[36]
37	maleate	I-Drug	['Causes']	[2]
38	.	O	['N']	[38]
#353
0	Acute	O	['N']	[0]
1	INH	B-Drug	['Causes']	[2]
2	neurotoxicity	B-Adverse_Effect	['N']	[2]
3	was	O	['N']	[3]
4	not	O	['N']	[4]
5	suspected	O	['N']	[5]
6	on	O	['N']	[6]
7	the	O	['N']	[7]
8	first	O	['N']	[8]
9	admission	O	['N']	[9]
10	;	O	['N']	[10]
11	however	O	['N']	[11]
12	,	O	['N']	[12]
13	when	O	['N']	[13]
14	readmitted	O	['N']	[14]
15	4	O	['N']	[15]
16	weeks	O	['N']	[16]
17	later	O	['N']	[17]
18	with	O	['N']	[18]
19	another	O	['N']	[19]
20	seizure	O	['N']	[20]
21	,	O	['N']	[21]
22	the	O	['N']	[22]
23	diagnosis	O	['N']	[23]
24	of	O	['N']	[24]
25	acute	O	['N']	[25]
26	INH	O	['N']	[26]
27	neurotoxicity	O	['N']	[27]
28	was	O	['N']	[28]
29	made	O	['N']	[29]
30	.	O	['N']	[30]
#354
0	The	O	['N']	[0]
1	medical	O	['N']	[1]
2	examiner	O	['N']	[2]
3	's	O	['N']	[3]
4	report	O	['N']	[4]
5	indicated	O	['N']	[5]
6	death	B-Adverse_Effect	['N']	[6]
7	caused	O	['N']	[7]
8	by	O	['N']	[8]
9	fluoxetine	B-Drug	['Causes']	[6]
10	toxicity	O	['N']	[10]
11	.	O	['N']	[11]
#355
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	experienced	O	['N']	[2]
3	muscle	O	['N']	[3]
4	twitches	O	['N']	[4]
5	,	O	['N']	[5]
6	tremulousness	O	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	anxiety	B-Adverse_Effect	['N']	[9]
10	on	O	['N']	[10]
11	day	O	['N']	[11]
12	17	O	['N']	[12]
13	of	O	['N']	[13]
14	foscarnet	B-Drug	['Causes']	[9]
15	therapy	O	['N']	[15]
16	.	O	['N']	[16]
#356
0	Syndrome	O	['N']	[0]
1	of	O	['N']	[1]
2	inappropriate	O	['N']	[2]
3	secretion	O	['N']	[3]
4	of	O	['N']	[4]
5	ADH	O	['N']	[5]
6	(	O	['N']	[6]
7	SIADH	B-Adverse_Effect	['N']	[7]
8	)	O	['N']	[8]
9	following	O	['N']	[9]
10	cisplatin	B-Drug	['Causes']	[7]
11	administration	O	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	pulmonary	O	['N']	[14]
15	adenocarcinoma	O	['N']	[15]
16	patient	O	['N']	[16]
17	with	O	['N']	[17]
18	a	O	['N']	[18]
19	malignant	O	['N']	[19]
20	pleural	O	['N']	[20]
21	effusion	O	['N']	[21]
22	.	O	['N']	[22]
#357
0	An	O	['N']	[0]
1	association	O	['N']	[1]
2	of	O	['N']	[2]
3	granulocytopenia	B-Adverse_Effect	['N']	[3]
4	,	O	['N']	[4]
5	eosinophilia	O	['N']	[5]
6	,	O	['N']	[6]
7	skin	O	['N']	[7]
8	reaction	O	['N']	[8]
9	and	O	['N']	[9]
10	hepatitis	O	['N']	[10]
11	during	O	['N']	[11]
12	propylthiouracil	O	['N']	[12]
13	(	O	['N']	[13]
14	PTU	B-Drug	['Causes']	[3]
15	)	O	['N']	[15]
16	therapy	O	['N']	[16]
17	for	O	['N']	[17]
18	thyrotoxicosis	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	47	O	['N']	[21]
22	year	O	['N']	[22]
23	old	O	['N']	[23]
24	black	O	['N']	[24]
25	female	O	['N']	[25]
26	is	O	['N']	[26]
27	reported	O	['N']	[27]
28	.	O	['N']	[28]
#358
0	Temporary	B	['N']	[0]
1	neurologic	I	['N']	[1]
2	abnormalities	I-Adverse_Effect	['N']	[2]
3	were	O	['N']	[3]
4	observed	O	['N']	[4]
5	in	O	['N']	[5]
6	one	O	['N']	[6]
7	out	O	['N']	[7]
8	of	O	['N']	[8]
9	23	O	['N']	[9]
10	patients	O	['N']	[10]
11	undergoing	O	['N']	[11]
12	chemotherapy	O	['N']	[12]
13	with	O	['N']	[13]
14	high	O	['N']	[14]
15	-	O	['N']	[15]
16	dose	O	['N']	[16]
17	methotrexate	B-Drug	['Causes']	[2]
18	(	O	['N']	[18]
19	HD	O	['N']	[19]
20	-	O	['N']	[20]
21	MTX	O	['N']	[21]
22	)	O	['N']	[22]
23	for	O	['N']	[23]
24	osteogenic	O	['N']	[24]
25	sarcoma	O	['N']	[25]
26	.	O	['N']	[26]
#359
0	He	O	['N']	[0]
1	had	O	['N']	[1]
2	an	O	['N']	[2]
3	immediate	O	['N']	[3]
4	hypersensitivity	O	['N']	[4]
5	reaction	O	['N']	[5]
6	during	O	['N']	[6]
7	the	O	['N']	[7]
8	initiation	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	MTX	B-Drug	['Causes']	[20]
12	infusion	O	['N']	[12]
13	with	O	['N']	[13]
14	diffuse	O	['N']	[14]
15	urticaria	O	['N']	[15]
16	,	O	['N']	[16]
17	facial	O	['N']	[17]
18	swelling	O	['N']	[18]
19	,	O	['N']	[19]
20	cough	B-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	chest	O	['N']	[23]
24	tightness	O	['N']	[24]
25	.	O	['N']	[25]
#360
0	Thus	O	['N']	[0]
1	cabergoline	O	['N']	[1]
2	may	O	['N']	[2]
3	cause	O	['N']	[3]
4	similar	O	['N']	[4]
5	pleuropulmonary	B	['N']	[5]
6	abnormalities	I-Adverse_Effect	['N']	[6]
7	to	O	['N']	[7]
8	bromocriptine	B-Drug	['Causes']	[6]
9	.	O	['N']	[9]
#361
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	presents	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	colon	B	['N']	[6]
7	perforation	I-Adverse_Effect	['N']	[7]
8	which	O	['N']	[8]
9	occurred	O	['N']	[9]
10	4	O	['N']	[10]
11	months	O	['N']	[11]
12	after	O	['N']	[12]
13	treatment	O	['N']	[13]
14	with	O	['N']	[14]
15	intraperitoneal	O	['N']	[15]
16	chromic	B	['N']	[16]
17	phosphate	I-Drug	['Causes']	[7]
18	for	O	['N']	[18]
19	stage	O	['N']	[19]
20	IB	O	['N']	[20]
21	ovarian	O	['N']	[21]
22	papillary	O	['N']	[22]
23	serous	O	['N']	[23]
24	cystadenocarcinoma	O	['N']	[24]
25	.	O	['N']	[25]
#362
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	While	O	['N']	[2]
3	thrombosis	B-Adverse_Effect	['N']	[3]
4	has	O	['N']	[4]
5	been	O	['N']	[5]
6	reported	O	['N']	[6]
7	with	O	['N']	[7]
8	GnRH	B	['N']	[8]
9	-	I	['N']	[9]
10	a	I-Drug	['Causes']	[3]
11	therapy	O	['N']	[11]
12	in	O	['N']	[12]
13	men	O	['N']	[13]
14	with	O	['N']	[14]
15	prostate	O	['N']	[15]
16	cancer	O	['N']	[16]
17	,	O	['N']	[17]
18	its	O	['N']	[18]
19	association	O	['N']	[19]
20	with	O	['N']	[20]
21	treatment	O	['N']	[21]
22	in	O	['N']	[22]
23	this	O	['N']	[23]
24	benign	O	['N']	[24]
25	case	O	['N']	[25]
26	may	O	['N']	[26]
27	have	O	['N']	[27]
28	been	O	['N']	[28]
29	a	O	['N']	[29]
30	consequence	O	['N']	[30]
31	of	O	['N']	[31]
32	the	O	['N']	[32]
33	massive	O	['N']	[33]
34	tumor	O	['N']	[34]
35	size	O	['N']	[35]
36	.	O	['N']	[36]
#363
0	The	O	['N']	[0]
1	mechanism	O	['N']	[1]
2	by	O	['N']	[2]
3	which	O	['N']	[3]
4	sunitinib	B-Drug	['Causes']	[6]
5	induces	O	['N']	[5]
6	gynaecomastia	B-Adverse_Effect	['N']	[6]
7	is	O	['N']	[7]
8	thought	O	['N']	[8]
9	to	O	['N']	[9]
10	be	O	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	an	O	['N']	[13]
14	unknown	O	['N']	[14]
15	direct	O	['N']	[15]
16	action	O	['N']	[16]
17	on	O	['N']	[17]
18	breast	O	['N']	[18]
19	hormonal	O	['N']	[19]
20	receptors	O	['N']	[20]
21	.	O	['N']	[21]
#364
0	Acute	B	['N']	[0]
1	kidney	I	['N']	[1]
2	injury	I-Adverse_Effect	['N']	[2]
3	caused	O	['N']	[3]
4	by	O	['N']	[4]
5	zonisamide	B-Drug	['Causes']	[2]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	hypersensitivity	O	['N']	[8]
9	syndrome	O	['N']	[9]
10	.	O	['N']	[10]
#365
0	The	O	['N']	[0]
1	risk	O	['N']	[1]
2	of	O	['N']	[2]
3	cardiac	B	['N']	[3]
4	decompensation	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	infants	O	['N']	[6]
7	with	O	['N']	[7]
8	supraventricular	O	['N']	[8]
9	tachycardia	O	['N']	[9]
10	and	O	['N']	[10]
11	congestive	O	['N']	[11]
12	cardiac	O	['N']	[12]
13	failure	O	['N']	[13]
14	should	O	['N']	[14]
15	be	O	['N']	[15]
16	kept	O	['N']	[16]
17	in	O	['N']	[17]
18	mind	O	['N']	[18]
19	prior	O	['N']	[19]
20	to	O	['N']	[20]
21	administration	O	['N']	[21]
22	of	O	['N']	[22]
23	verapamil	B-Drug	['Causes']	[4]
24	.	O	['N']	[24]
#366
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	presentation	O	['N']	[2]
3	is	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	had	O	['N']	[8]
9	the	O	['N']	[9]
10	clinical	O	['N']	[10]
11	appearance	O	['N']	[11]
12	of	O	['N']	[12]
13	epiglottitis	B-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	but	O	['N']	[15]
16	actually	O	['N']	[16]
17	had	O	['N']	[17]
18	an	O	['N']	[18]
19	oro	O	['N']	[19]
20	-	O	['N']	[20]
21	pharyngeal	O	['N']	[21]
22	dystonic	O	['N']	[22]
23	reaction	O	['N']	[23]
24	to	O	['N']	[24]
25	prochlorperazine	B-Drug	['Causes']	[13]
26	.	O	['N']	[26]
#367
0	Squamous	B	['N']	[0]
1	-	I	['N']	[1]
2	cell	I	['N']	[2]
3	carcinoma	I-Adverse_Effect	['N']	[3]
4	arising	O	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	basal	O	['N']	[7]
8	-	O	['N']	[8]
9	cell	O	['N']	[9]
10	epithelioma	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	5-fluorouracil	B-Drug	['Causes']	[3]
14	.	O	['N']	[14]
#368
0	Papilloedema	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	hepatic	O	['N']	[2]
3	dysfunction	O	['N']	[3]
4	apparently	O	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	perhexiline	B	['N']	[7]
8	maleate	I-Drug	['Causes']	[0]
9	(	O	['N']	[9]
10	Pexid	O	['N']	[10]
11	)	O	['N']	[11]
12	.	O	['N']	[12]
#369
0	Niacin	B-Drug	['Causes']	[1]
1	maculopathy	B-Adverse_Effect	['N']	[1]
2	.	O	['N']	[2]
#370
0	This	O	['N']	[0]
1	eruption	B-Adverse_Effect	['N']	[1]
2	appears	O	['N']	[2]
3	to	O	['N']	[3]
4	be	O	['N']	[4]
5	a	O	['N']	[5]
6	distinct	O	['N']	[6]
7	cutaneous	O	['N']	[7]
8	toxicity	O	['N']	[8]
9	of	O	['N']	[9]
10	PLD	B-Drug	['Causes']	[1]
11	.	O	['N']	[11]
#371
0	A	O	['N']	[0]
1	32-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	a	O	['N']	[6]
7	family	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	type	O	['N']	[10]
11	2	O	['N']	[11]
12	diabetes	O	['N']	[12]
13	mellitus	O	['N']	[13]
14	presented	O	['N']	[14]
15	with	O	['N']	[15]
16	circulatory	B	['N']	[16]
17	collapse	I-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	deep	O	['N']	[19]
20	coma	O	['N']	[20]
21	after	O	['N']	[21]
22	9	O	['N']	[22]
23	days	O	['N']	[23]
24	of	O	['N']	[24]
25	treatment	O	['N']	[25]
26	with	O	['N']	[26]
27	perospirone	B	['N']	[27]
28	hydrochloride	I-Drug	['Causes']	[17]
29	,	O	['N']	[29]
30	a	O	['N']	[30]
31	recently	O	['N']	[31]
32	developed	O	['N']	[32]
33	atypical	O	['N']	[33]
34	antipsychotic	O	['N']	[34]
35	agent	O	['N']	[35]
36	available	O	['N']	[36]
37	only	O	['N']	[37]
38	in	O	['N']	[38]
39	Japan	O	['N']	[39]
40	.	O	['N']	[40]
#372
0	We	O	['N']	[0]
1	attribute	O	['N']	[1]
2	the	O	['N']	[2]
3	clinical	O	['N']	[3]
4	and	O	['N']	[4]
5	radiographic	O	['N']	[5]
6	findings	O	['N']	[6]
7	to	O	['N']	[7]
8	cytotoxic	B	['N']	[8]
9	edema	I-Adverse_Effect	['N']	[9]
10	secondary	O	['N']	[10]
11	to	O	['N']	[11]
12	intrathecal	O	['N']	[12]
13	methotrexate	B-Drug	['Causes']	[9]
14	.	O	['N']	[14]
#373
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	combined	O	['N']	[6]
7	lithium	O	['N']	[7]
8	and	O	['N']	[8]
9	haloperidol	B-Drug	['Causes']	[16]
10	toxicity	O	['N']	[10]
11	characterized	O	['N']	[11]
12	by	O	['N']	[12]
13	hyperpyrexia	O	['N']	[13]
14	,	O	['N']	[14]
15	severe	B	['N']	[15]
16	rigidity	I-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	mutism	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	development	O	['N']	[21]
22	of	O	['N']	[22]
23	irreversible	O	['N']	[23]
24	tardive	O	['N']	[24]
25	dyskinesia	O	['N']	[25]
26	.	O	['N']	[26]
#374
0	Allergic	O	['N']	[0]
1	and	O	['N']	[1]
2	irritant	B	['N']	[2]
3	contact	I	['N']	[3]
4	dermatitis	I-Adverse_Effect	['N']	[4]
5	to	O	['N']	[5]
6	calcipotriol	B-Drug	['Causes']	[4]
7	.	O	['N']	[7]
#375
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	an	O	['N']	[6]
7	acute	O	['N']	[7]
8	flare	O	['N']	[8]
9	of	O	['N']	[9]
10	eosinophilic	B	['N']	[10]
11	cystitis	I-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	51-year	O	['N']	[14]
15	-	O	['N']	[15]
16	old	O	['N']	[16]
17	woman	O	['N']	[17]
18	after	O	['N']	[18]
19	bladder	O	['N']	[19]
20	instillation	O	['N']	[20]
21	with	O	['N']	[21]
22	dimethyl	B	['N']	[22]
23	sulfoxide	I-Drug	['Causes']	[11]
24	(	O	['N']	[24]
25	DMSO	O	['N']	[25]
26	)	O	['N']	[26]
27	for	O	['N']	[27]
28	presumed	O	['N']	[28]
29	interstitial	O	['N']	[29]
30	cystitis	O	['N']	[30]
31	.	O	['N']	[31]
#376
0	Complications	O	['N']	[0]
1	of	O	['N']	[1]
2	chemotherapy	O	['N']	[2]
3	for	O	['N']	[3]
4	a	O	['N']	[4]
5	synovial	O	['N']	[5]
6	sarcoma	O	['N']	[6]
7	in	O	['N']	[7]
8	an	O	['N']	[8]
9	eight	O	['N']	[9]
10	-	O	['N']	[10]
11	year	O	['N']	[11]
12	old	O	['N']	[12]
13	boy	O	['N']	[13]
14	included	O	['N']	[14]
15	cisplatinum	O	['N']	[15]
16	nephrotoxicity	O	['N']	[16]
17	and	O	['N']	[17]
18	adriamycin	B-Drug	['Causes']	[19]
19	cardiotoxicity	B-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#377
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	given	O	['N']	[2]
3	the	O	['N']	[3]
4	clinically	O	['N']	[4]
5	significant	O	['N']	[5]
6	result	O	['N']	[6]
7	to	O	['N']	[7]
8	the	O	['N']	[8]
9	interaction	O	['N']	[9]
10	between	O	['N']	[10]
11	tolazoline	B-Drug	['Causes']	[26]
12	and	O	['N']	[12]
13	cimetidine	O	['N']	[13]
14	we	O	['N']	[14]
15	report	O	['N']	[15]
16	,	O	['N']	[16]
17	the	O	['N']	[17]
18	use	O	['N']	[18]
19	of	O	['N']	[19]
20	cimetidine	O	['N']	[20]
21	in	O	['N']	[21]
22	tolazoline	O	['N']	[22]
23	induced	O	['N']	[23]
24	upper	B	['N']	[24]
25	gastrointestinal	I	['N']	[25]
26	hemorrhage	I-Adverse_Effect	['N']	[26]
27	should	O	['N']	[27]
28	deserve	O	['N']	[28]
29	more	O	['N']	[29]
30	attention	O	['N']	[30]
31	.	O	['N']	[31]
#378
0	He	O	['N']	[0]
1	had	O	['N']	[1]
2	been	O	['N']	[2]
3	taking	O	['N']	[3]
4	trimethoprim	B-Drug	['Causes']	[44]
5	-	O	['N']	[5]
6	sulfamethoxazole	O	['N']	[6]
7	for	O	['N']	[7]
8	approximately	O	['N']	[8]
9	eight	O	['N']	[9]
10	days	O	['N']	[10]
11	when	O	['N']	[11]
12	he	O	['N']	[12]
13	revisited	O	['N']	[13]
14	his	O	['N']	[14]
15	family	O	['N']	[15]
16	physician	O	['N']	[16]
17	,	O	['N']	[17]
18	complaining	O	['N']	[18]
19	of	O	['N']	[19]
20	headaches	O	['N']	[20]
21	,	O	['N']	[21]
22	dizziness	O	['N']	[22]
23	,	O	['N']	[23]
24	difficulty	O	['N']	[24]
25	with	O	['N']	[25]
26	speech	O	['N']	[26]
27	,	O	['N']	[27]
28	weakness	O	['N']	[28]
29	,	O	['N']	[29]
30	and	O	['N']	[30]
31	itching	O	['N']	[31]
32	on	O	['N']	[32]
33	the	O	['N']	[33]
34	trunk	O	['N']	[34]
35	of	O	['N']	[35]
36	his	O	['N']	[36]
37	body	O	['N']	[37]
38	and	O	['N']	[38]
39	legs	O	['N']	[39]
40	,	O	['N']	[40]
41	where	O	['N']	[41]
42	a	O	['N']	[42]
43	maculopapular	B	['N']	[43]
44	rash	I-Adverse_Effect	['N']	[44]
45	was	O	['N']	[45]
46	noted	O	['N']	[46]
47	.	O	['N']	[47]
#379
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	HIV	O	['N']	[3]
4	-	O	['N']	[4]
5	infected	O	['N']	[5]
6	woman	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	mild	O	['N']	[9]
10	leukopenia	O	['N']	[10]
11	as	O	['N']	[11]
12	the	O	['N']	[12]
13	first	O	['N']	[13]
14	sign	O	['N']	[14]
15	of	O	['N']	[15]
16	a	O	['N']	[16]
17	nevirapine	B-Drug	['Causes']	[30]
18	-	O	['N']	[18]
19	related	O	['N']	[19]
20	adverse	O	['N']	[20]
21	event	O	['N']	[21]
22	,	O	['N']	[22]
23	which	O	['N']	[23]
24	was	O	['N']	[24]
25	followed	O	['N']	[25]
26	by	O	['N']	[26]
27	skin	B	['N']	[27]
28	and	I	['N']	[28]
29	hepatic	I	['N']	[29]
30	toxicity	I-Adverse_Effect	['N']	[30]
31	associated	O	['N']	[31]
32	with	O	['N']	[32]
33	a	O	['N']	[33]
34	more	O	['N']	[34]
35	severe	O	['N']	[35]
36	leukopenia	O	['N']	[36]
37	.	O	['N']	[37]
#380
0	New	O	['N']	[0]
1	onset	O	['N']	[1]
2	of	O	['N']	[2]
3	CD	B-Adverse_Effect	['N']	[3]
4	may	O	['N']	[4]
5	be	O	['N']	[5]
6	considered	O	['N']	[6]
7	as	O	['N']	[7]
8	an	O	['N']	[8]
9	immune	O	['N']	[9]
10	-	O	['N']	[10]
11	mediated	O	['N']	[11]
12	injury	O	['N']	[12]
13	induced	O	['N']	[13]
14	by	O	['N']	[14]
15	etanercept	B-Drug	['Causes']	[3]
16	.	O	['N']	[16]
#381
0	Nonoliguric	B	['N']	[0]
1	acute	I	['N']	[1]
2	renal	I	['N']	[2]
3	failure	I-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	captopril	B-Drug	['Causes']	[3]
6	therapy	O	['N']	[6]
7	.	O	['N']	[7]
#382
0	A	O	['N']	[0]
1	young	O	['N']	[1]
2	woman	O	['N']	[2]
3	with	O	['N']	[3]
4	epilepsy	O	['N']	[4]
5	had	O	['N']	[5]
6	tonic	B	['N']	[6]
7	-	I	['N']	[7]
8	clonic	I	['N']	[8]
9	seizures	I-Adverse_Effect	['N']	[9]
10	during	O	['N']	[10]
11	antineoplastic	O	['N']	[11]
12	therapy	O	['N']	[12]
13	with	O	['N']	[13]
14	adriamycin	O	['N']	[14]
15	and	O	['N']	[15]
16	cisplatin	B-Drug	['Causes']	[9]
17	.	O	['N']	[17]
#383
0	Inadvertent	O	['N']	[0]
1	and	O	['N']	[1]
2	accidental	O	['N']	[2]
3	epinephrine	B-Drug	['Causes']	[10]
4	overdose	O	['N']	[4]
5	might	O	['N']	[5]
6	result	O	['N']	[6]
7	in	O	['N']	[7]
8	potentially	O	['N']	[8]
9	lethal	B	['N']	[9]
10	complications	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#384
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	placed	O	['N']	[2]
3	on	O	['N']	[3]
4	adjuvant	O	['N']	[4]
5	Adriamycin	O	['N']	[5]
6	(	O	['N']	[6]
7	doxorubicin	B-Drug	['Causes']	[18]
8	)	O	['N']	[8]
9	chemotherapy	O	['N']	[9]
10	,	O	['N']	[10]
11	but	O	['N']	[11]
12	6	O	['N']	[12]
13	months	O	['N']	[13]
14	later	O	['N']	[14]
15	died	O	['N']	[15]
16	of	O	['N']	[16]
17	Adriamycin	B	['N']	[17]
18	toxicity	I-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#385
0	In	O	['N']	[0]
1	addition	O	['N']	[1]
2	to	O	['N']	[2]
3	its	O	['N']	[3]
4	known	O	['N']	[4]
5	effect	O	['N']	[5]
6	on	O	['N']	[6]
7	gallbladder	O	['N']	[7]
8	stasis	O	['N']	[8]
9	,	O	['N']	[9]
10	octreotide	B-Drug	['Causes']	[23]
11	alters	O	['N']	[11]
12	bile	O	['N']	[12]
13	acid	O	['N']	[13]
14	composition	O	['N']	[14]
15	and	O	['N']	[15]
16	may	O	['N']	[16]
17	thus	O	['N']	[17]
18	hasten	O	['N']	[18]
19	intrahepatic	O	['N']	[19]
20	sludge	O	['N']	[20]
21	and	O	['N']	[21]
22	stone	B	['N']	[22]
23	formation	I-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#386
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	we	O	['N']	[3]
4	described	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	juvenile	O	['N']	[8]
9	idiopathic	O	['N']	[9]
10	arthritis	O	['N']	[10]
11	patient	O	['N']	[11]
12	who	O	['N']	[12]
13	developed	O	['N']	[13]
14	thymic	O	['N']	[14]
15	enlargement	O	['N']	[15]
16	(	O	['N']	[16]
17	true	O	['N']	[17]
18	thymic	O	['N']	[18]
19	hyperplasia	O	['N']	[19]
20	)	O	['N']	[20]
21	,	O	['N']	[21]
22	mediastinal	B	['N']	[22]
23	lymphadenopathy	I-Adverse_Effect	['N']	[23]
24	and	O	['N']	[24]
25	pleurisy	O	['N']	[25]
26	associated	O	['N']	[26]
27	with	O	['N']	[27]
28	systemic	O	['N']	[28]
29	symptoms	O	['N']	[29]
30	under	O	['N']	[30]
31	Etanercept	B-Drug	['Causes']	[23]
32	treatment	O	['N']	[32]
33	.	O	['N']	[33]
#387
0	After	O	['N']	[0]
1	extensive	O	['N']	[1]
2	neurological	O	['N']	[2]
3	'	O	['N']	[3]
4	work	O	['N']	[4]
5	up	O	['N']	[5]
6	'	O	['N']	[6]
7	,	O	['N']	[7]
8	we	O	['N']	[8]
9	realized	O	['N']	[9]
10	that	O	['N']	[10]
11	the	O	['N']	[11]
12	anisocoria	B-Adverse_Effect	['N']	[12]
13	was	O	['N']	[13]
14	related	O	['N']	[14]
15	to	O	['N']	[15]
16	the	O	['N']	[16]
17	transdermal	O	['N']	[17]
18	scopolamine	B-Drug	['Causes']	[12]
19	patch	O	['N']	[19]
20	that	O	['N']	[20]
21	we	O	['N']	[21]
22	had	O	['N']	[22]
23	prescribed	O	['N']	[23]
24	for	O	['N']	[24]
25	weaning	O	['N']	[25]
26	off	O	['N']	[26]
27	the	O	['N']	[27]
28	opioid	O	['N']	[28]
29	.	O	['N']	[29]
#388
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	tempting	O	['N']	[2]
3	to	O	['N']	[3]
4	speculate	O	['N']	[4]
5	that	O	['N']	[5]
6	interferon	B	['N']	[6]
7	alpha	I-Drug	['Causes']	[16]
8	may	O	['N']	[8]
9	be	O	['N']	[9]
10	involved	O	['N']	[10]
11	in	O	['N']	[11]
12	the	O	['N']	[12]
13	pathogenesis	O	['N']	[13]
14	of	O	['N']	[14]
15	lichen	B	['N']	[15]
16	nitidus	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#389
0	Propranolol	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hypertension	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	treatment	O	['N']	[5]
6	of	O	['N']	[6]
7	cocaine	O	['N']	[7]
8	intoxication	O	['N']	[8]
9	.	O	['N']	[9]
#390
0	Case	O	['N']	[0]
1	studies	O	['N']	[1]
2	in	O	['N']	[2]
3	heparin	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	thrombocytopenia	B-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#391
0	Successful	O	['N']	[0]
1	desensitization	O	['N']	[1]
2	to	O	['N']	[2]
3	high	B-Dose	['N']	[3]
4	-	O	['N']	[4]
5	dose	O	['N']	[5]
6	methotrexate	B-Drug	['Dosage']	[3]
7	after	O	['N']	[7]
8	systemic	O	['N']	[8]
9	anaphylaxis	O	['N']	[9]
10	.	O	['N']	[10]
#392
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	investigate	O	['N']	[3]
4	the	O	['N']	[4]
5	mechanisms	O	['N']	[5]
6	involved	O	['N']	[6]
7	in	O	['N']	[7]
8	hypersensitivity	B	['N']	[8]
9	reactions	I-Adverse_Effect	['N']	[9]
10	to	O	['N']	[10]
11	cyclosporine	B-Drug	['Causes']	[9]
12	and	O	['N']	[12]
13	determine	O	['N']	[13]
14	the	O	['N']	[14]
15	feasibility	O	['N']	[15]
16	of	O	['N']	[16]
17	future	O	['N']	[17]
18	cyclosporine	O	['N']	[18]
19	use	O	['N']	[19]
20	.	O	['N']	[20]
#393
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	is	O	['N']	[2]
3	reported	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	elderly	O	['N']	[6]
7	woman	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	febrile	B	['N']	[10]
11	agranulocytosis	I-Adverse_Effect	['N']	[11]
12	several	O	['N']	[12]
13	weeks	O	['N']	[13]
14	after	O	['N']	[14]
15	commencing	O	['N']	[15]
16	ticlopidine	B-Drug	['Causes']	[11]
17	but	O	['N']	[17]
18	who	O	['N']	[18]
19	had	O	['N']	[19]
20	a	O	['N']	[20]
21	favorable	O	['N']	[21]
22	outcome	O	['N']	[22]
23	after	O	['N']	[23]
24	cessation	O	['N']	[24]
25	of	O	['N']	[25]
26	that	O	['N']	[26]
27	drug	O	['N']	[27]
28	and	O	['N']	[28]
29	treatment	O	['N']	[29]
30	with	O	['N']	[30]
31	filgastrim	O	['N']	[31]
32	.	O	['N']	[32]
#394
0	Statin	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	myasthenia	B	['N']	[3]
4	gravis	I-Adverse_Effect	['N']	[4]
5	:	O	['N']	[5]
6	report	O	['N']	[6]
7	of	O	['N']	[7]
8	4	O	['N']	[8]
9	cases	O	['N']	[9]
10	and	O	['N']	[10]
11	review	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	literature	O	['N']	[14]
15	.	O	['N']	[15]
#395
0	A	O	['N']	[0]
1	21-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	Tourette	O	['N']	[6]
7	's	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	,	O	['N']	[9]
10	pedophilia	O	['N']	[10]
11	,	O	['N']	[11]
12	Asperger	O	['N']	[12]
13	's	O	['N']	[13]
14	syndrome	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	multiple	O	['N']	[17]
18	sclerosis	O	['N']	[18]
19	experienced	O	['N']	[19]
20	seizures	B-Adverse_Effect	['N']	[20]
21	after	O	['N']	[21]
22	receiving	O	['N']	[22]
23	therapy	O	['N']	[23]
24	with	O	['N']	[24]
25	interferon	B	['N']	[25]
26	beta-1a	I-Drug	['Causes']	[20]
27	.	O	['N']	[27]
#396
0	Moreover	O	['N']	[0]
1	,	O	['N']	[1]
2	these	O	['N']	[2]
3	findings	O	['N']	[3]
4	suggest	O	['N']	[4]
5	that	O	['N']	[5]
6	the	O	['N']	[6]
7	incidence	O	['N']	[7]
8	of	O	['N']	[8]
9	BOOP	B-Adverse_Effect	['N']	[9]
10	following	O	['N']	[10]
11	rituximab	B-Drug	['Causes']	[9]
12	therapy	O	['N']	[12]
13	may	O	['N']	[13]
14	be	O	['N']	[14]
15	higher	O	['N']	[15]
16	than	O	['N']	[16]
17	has	O	['N']	[17]
18	been	O	['N']	[18]
19	previously	O	['N']	[19]
20	appreciated	O	['N']	[20]
21	.	O	['N']	[21]
#397
0	Severe	B	['N']	[0]
1	acidosis	I-Adverse_Effect	['N']	[1]
2	from	O	['N']	[2]
3	acetazolamide	B-Drug	['Causes']	[1]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	diabetic	O	['N']	[6]
7	patient	O	['N']	[7]
8	.	O	['N']	[8]
#398
0	Our	O	['N']	[0]
1	patient	O	['N']	[1]
2	had	O	['N']	[2]
3	headache	O	['N']	[3]
4	,	O	['N']	[4]
5	mild	B	['N']	[5]
6	fever	I-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	nausea	O	['N']	[8]
9	,	O	['N']	[9]
10	vomiting	O	['N']	[10]
11	,	O	['N']	[11]
12	rash	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	eosinophilia	O	['N']	[15]
16	after	O	['N']	[16]
17	3	O	['N']	[17]
18	weeks	O	['N']	[18]
19	of	O	['N']	[19]
20	disulfiram	B-Drug	['Causes']	[6]
21	therapy	O	['N']	[21]
22	.	O	['N']	[22]
#399
0	Cutaneous	O	['N']	[0]
1	rashes	O	['N']	[1]
2	and	O	['N']	[2]
3	eruptions	B-Adverse_Effect	['N']	[3]
4	can	O	['N']	[4]
5	be	O	['N']	[5]
6	caused	O	['N']	[6]
7	by	O	['N']	[7]
8	many	O	['N']	[8]
9	medications	O	['N']	[9]
10	,	O	['N']	[10]
11	including	O	['N']	[11]
12	carbamazepine	B-Drug	['Causes']	[3]
13	.	O	['N']	[13]
#400
0	Visual	O	['N']	[0]
1	system	O	['N']	[1]
2	side	O	['N']	[2]
3	effects	O	['N']	[3]
4	caused	O	['N']	[4]
5	by	O	['N']	[5]
6	parasympathetic	B	['N']	[6]
7	dysfunction	I-Adverse_Effect	['N']	[7]
8	after	O	['N']	[8]
9	botulinum	B	['N']	[9]
10	toxin	I	['N']	[10]
11	type	I	['N']	[11]
12	B	I-Drug	['Causes']	[7]
13	injections	O	['N']	[13]
14	.	O	['N']	[14]
#401
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	continued	O	['N']	[2]
3	to	O	['N']	[3]
4	have	O	['N']	[4]
5	fever	B-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	autonomic	O	['N']	[7]
8	instability	O	['N']	[8]
9	without	O	['N']	[9]
10	evidence	O	['N']	[10]
11	of	O	['N']	[11]
12	infection	O	['N']	[12]
13	which	O	['N']	[13]
14	entirely	O	['N']	[14]
15	resolved	O	['N']	[15]
16	within	O	['N']	[16]
17	24	O	['N']	[17]
18	hours	O	['N']	[18]
19	of	O	['N']	[19]
20	reinstitution	O	['N']	[20]
21	of	O	['N']	[21]
22	full	O	['N']	[22]
23	preadmission	O	['N']	[23]
24	dosing	O	['N']	[24]
25	of	O	['N']	[25]
26	oral	O	['N']	[26]
27	baclofen	B-Drug	['Causes']	[5]
28	.	O	['N']	[28]
#402
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	in	O	['N']	[4]
5	whom	O	['N']	[5]
6	the	O	['N']	[6]
7	anti	O	['N']	[7]
8	-	O	['N']	[8]
9	depressant	O	['N']	[9]
10	trazodone	O	['N']	[10]
11	hydrochloride	O	['N']	[11]
12	(	O	['N']	[12]
13	Molipaxin	B-Drug	['Causes']	[27]
14	,	O	['N']	[14]
15	Roussel	O	['N']	[15]
16	)	O	['N']	[16]
17	,	O	['N']	[17]
18	a	O	['N']	[18]
19	serotonin	O	['N']	[19]
20	antagonist	O	['N']	[20]
21	,	O	['N']	[21]
22	provoked	O	['N']	[22]
23	generalized	O	['N']	[23]
24	pustular	O	['N']	[24]
25	psoriasis	O	['N']	[25]
26	(	O	['N']	[26]
27	GPP	B-Adverse_Effect	['N']	[27]
28	)	O	['N']	[28]
29	.	O	['N']	[29]
#403
0	Sustained	B	['N']	[0]
1	monomorphic	I	['N']	[1]
2	ventricular	I	['N']	[2]
3	tachycardia	I-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	adenosine	B-Drug	['Causes']	[3]
6	infusion	O	['N']	[6]
7	.	O	['N']	[7]
#404
0	Delayed	O	['N']	[0]
1	bowel	B	['N']	[1]
2	injury	I-Adverse_Effect	['N']	[2]
3	is	O	['N']	[3]
4	an	O	['N']	[4]
5	infrequently	O	['N']	[5]
6	observed	O	['N']	[6]
7	complication	O	['N']	[7]
8	of	O	['N']	[8]
9	chromic	B	['N']	[9]
10	phosphate	I-Drug	['Causes']	[2]
11	administration	O	['N']	[11]
12	.	O	['N']	[12]
#405
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	our	O	['N']	[3]
4	knowledge	O	['N']	[4]
5	this	O	['N']	[5]
6	is	O	['N']	[6]
7	the	O	['N']	[7]
8	first	O	['N']	[8]
9	reported	O	['N']	[9]
10	case	O	['N']	[10]
11	of	O	['N']	[11]
12	tuberculous	B	['N']	[12]
13	uveitis	I-Adverse_Effect	['N']	[13]
14	following	O	['N']	[14]
15	treatment	O	['N']	[15]
16	with	O	['N']	[16]
17	etanercept	B-Drug	['Causes']	[13]
18	.	O	['N']	[18]
#406
0	Clinicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	signs	O	['N']	[6]
7	and	O	['N']	[7]
8	symptoms	O	['N']	[8]
9	of	O	['N']	[9]
10	neurotoxicity	B-Adverse_Effect	['N']	[10]
11	during	O	['N']	[11]
12	treatment	O	['N']	[12]
13	,	O	['N']	[13]
14	as	O	['N']	[14]
15	well	O	['N']	[15]
16	as	O	['N']	[16]
17	predisposing	O	['N']	[17]
18	factors	O	['N']	[18]
19	that	O	['N']	[19]
20	put	O	['N']	[20]
21	patients	O	['N']	[21]
22	receiving	O	['N']	[22]
23	methotrexate	B-Drug	['Causes']	[10]
24	at	O	['N']	[24]
25	risk	O	['N']	[25]
26	for	O	['N']	[26]
27	neurotoxic	O	['N']	[27]
28	effects	O	['N']	[28]
29	.	O	['N']	[29]
#407
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	chronic	O	['N']	[5]
6	renal	O	['N']	[6]
7	failure	O	['N']	[7]
8	and	O	['N']	[8]
9	ischemic	O	['N']	[9]
10	heart	O	['N']	[10]
11	disease	O	['N']	[11]
12	who	O	['N']	[12]
13	developed	O	['N']	[13]
14	clinically	O	['N']	[14]
15	significant	O	['N']	[15]
16	methemoglobinemia	B-Adverse_Effect	['N']	[16]
17	after	O	['N']	[17]
18	an	O	['N']	[18]
19	axillary	O	['N']	[19]
20	block	O	['N']	[20]
21	with	O	['N']	[21]
22	bupivacaine	O	['N']	[22]
23	and	O	['N']	[23]
24	additional	O	['N']	[24]
25	injection	O	['N']	[25]
26	of	O	['N']	[26]
27	lidocaine	B-Drug	['Causes']	[16]
28	in	O	['N']	[28]
29	the	O	['N']	[29]
30	operative	O	['N']	[30]
31	field	O	['N']	[31]
32	.	O	['N']	[32]
#408
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	in	O	['N']	[4]
5	which	O	['N']	[5]
6	both	O	['N']	[6]
7	patients	O	['N']	[7]
8	suffered	O	['N']	[8]
9	with	O	['N']	[9]
10	CLS	B-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	which	O	['N']	[12]
13	we	O	['N']	[13]
14	believe	O	['N']	[14]
15	was	O	['N']	[15]
16	caused	O	['N']	[16]
17	following	O	['N']	[17]
18	administration	O	['N']	[18]
19	of	O	['N']	[19]
20	granulocyte	B	['N']	[20]
21	colony	I	['N']	[21]
22	-	I	['N']	[22]
23	stimulating	I	['N']	[23]
24	factor	I-Drug	['Causes']	[10]
25	,	O	['N']	[25]
26	to	O	['N']	[26]
27	our	O	['N']	[27]
28	knowledge	O	['N']	[28]
29	not	O	['N']	[29]
30	described	O	['N']	[30]
31	in	O	['N']	[31]
32	the	O	['N']	[32]
33	intensive	O	['N']	[33]
34	care	O	['N']	[34]
35	patient	O	['N']	[35]
36	previously	O	['N']	[36]
37	.	O	['N']	[37]
#409
0	An	O	['N']	[0]
1	11-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	who	O	['N']	[5]
6	was	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	relatively	O	['N']	[10]
11	high	O	['N']	[11]
12	dose	O	['N']	[12]
13	of	O	['N']	[13]
14	methotrimeprazine	B	['N']	[14]
15	meleate	I-Drug	['Causes']	[36]
16	(	O	['N']	[16]
17	Levemepromazine	O	['N']	[17]
18	)	O	['N']	[18]
19	a	O	['N']	[19]
20	phenothiazine	O	['N']	[20]
21	antipsychotic	O	['N']	[21]
22	drug	O	['N']	[22]
23	,	O	['N']	[23]
24	was	O	['N']	[24]
25	admitted	O	['N']	[25]
26	to	O	['N']	[26]
27	the	O	['N']	[27]
28	pediatric	O	['N']	[28]
29	intensive	O	['N']	[29]
30	care	O	['N']	[30]
31	unit	O	['N']	[31]
32	suffering	O	['N']	[32]
33	from	O	['N']	[33]
34	respiratory	B	['N']	[34]
35	distress	I	['N']	[35]
36	syndrome	I-Adverse_Effect	['N']	[36]
37	.	O	['N']	[37]
#410
0	Eosinophilia	B-Adverse_Effect	['N']	[0]
1	caused	O	['N']	[1]
2	by	O	['N']	[2]
3	clozapine	B-Drug	['Causes']	[0]
4	was	O	['N']	[4]
5	observed	O	['N']	[5]
6	in	O	['N']	[6]
7	challenge	O	['N']	[7]
8	,	O	['N']	[8]
9	preceded	O	['N']	[9]
10	by	O	['N']	[10]
11	a	O	['N']	[11]
12	faster	O	['N']	[12]
13	neutrophil	O	['N']	[13]
14	production	O	['N']	[14]
15	and	O	['N']	[15]
16	consecutive	O	['N']	[16]
17	decrease	O	['N']	[17]
18	(	O	['N']	[18]
19	z	O	['N']	[19]
20	=	O	['N']	[20]
21	2.27	O	['N']	[21]
22	,	O	['N']	[22]
23	p	O	['N']	[23]
24	=	O	['N']	[24]
25	0.01	O	['N']	[25]
26	)	O	['N']	[26]
27	.	O	['N']	[27]
#411
0	This	O	['N']	[0]
1	therapy	O	['N']	[1]
2	was	O	['N']	[2]
3	also	O	['N']	[3]
4	complicated	O	['N']	[4]
5	by	O	['N']	[5]
6	Warfarin	B-Drug	['Causes']	[10]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	skin	B	['N']	[9]
10	necrosis	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#412
0	Transtentorial	B	['N']	[0]
1	herniation	I-Adverse_Effect	['N']	[1]
2	caused	O	['N']	[2]
3	by	O	['N']	[3]
4	an	O	['N']	[4]
5	intracranial	O	['N']	[5]
6	mass	O	['N']	[6]
7	lesion	O	['N']	[7]
8	following	O	['N']	[8]
9	high	O	['N']	[9]
10	-	O	['N']	[10]
11	dose	O	['N']	[11]
12	methotrexate	B-Drug	['Causes']	[1]
13	.	O	['N']	[13]
#413
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	demonstrates	O	['N']	[2]
3	the	O	['N']	[3]
4	association	O	['N']	[4]
5	of	O	['N']	[5]
6	selective	O	['N']	[6]
7	IgA	B	['N']	[7]
8	deficiency	I-Adverse_Effect	['N']	[8]
9	with	O	['N']	[9]
10	remission	O	['N']	[10]
11	in	O	['N']	[11]
12	rheumatoid	O	['N']	[12]
13	arthritis	O	['N']	[13]
14	induced	O	['N']	[14]
15	by	O	['N']	[15]
16	fenclofenac	O	['N']	[16]
17	as	O	['N']	[17]
18	well	O	['N']	[18]
19	as	O	['N']	[19]
20	aurothiomalate	O	['N']	[20]
21	and	O	['N']	[21]
22	sulphasalazine	B-Drug	['Causes']	[8]
23	.	O	['N']	[23]
#414
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	PSVT	O	['N']	[5]
6	that	O	['N']	[6]
7	changed	O	['N']	[7]
8	to	O	['N']	[8]
9	non	B	['N']	[9]
10	-	I	['N']	[10]
11	sustained	I	['N']	[11]
12	polymorphic	I	['N']	[12]
13	ventricular	I	['N']	[13]
14	tachycardia	I-Adverse_Effect	['N']	[14]
15	after	O	['N']	[15]
16	administration	O	['N']	[16]
17	of	O	['N']	[17]
18	verapamil	B-Drug	['Causes']	[14]
19	.	O	['N']	[19]
#415
0	Toxic	B	['N']	[0]
1	epidermal	I	['N']	[1]
2	necrolysis	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	interleukin-2	B-Drug	['Causes']	[2]
6	.	O	['N']	[6]
#416
0	The	O	['N']	[0]
1	pulmonary	B	['N']	[1]
2	toxicity	I-Adverse_Effect	['N']	[2]
3	is	O	['N']	[3]
4	probably	O	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	piritrexim	B-Drug	['Causes']	[2]
8	.	O	['N']	[8]
#417
0	Ptosis	B-Adverse_Effect	['N']	[0]
1	occurring	O	['N']	[1]
2	24	O	['N']	[2]
3	h	O	['N']	[3]
4	after	O	['N']	[4]
5	chloroquine	B-Drug	['Causes']	[0]
6	therapy	O	['N']	[6]
7	,	O	['N']	[7]
8	with	O	['N']	[8]
9	full	O	['N']	[9]
10	recovery	O	['N']	[10]
11	48	O	['N']	[11]
12	h	O	['N']	[12]
13	after	O	['N']	[13]
14	cessation	O	['N']	[14]
15	of	O	['N']	[15]
16	chloroquine	O	['N']	[16]
17	,	O	['N']	[17]
18	has	O	['N']	[18]
19	not	O	['N']	[19]
20	been	O	['N']	[20]
21	described	O	['N']	[21]
22	previously	O	['N']	[22]
23	.	O	['N']	[23]
#418
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	O	['N']	[19]
20	developed	O	['N']	[20]
21	confusion	O	['N']	[21]
22	,	O	['N']	[22]
23	agitation	O	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	O	['N']	[25]
26	,	O	['N']	[26]
27	tremors	O	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	O	['N']	[29]
30	jerks	O	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	B	['N']	[32]
33	gait	I-Adverse_Effect	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	B-Drug	['Causes']	[33]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#419
0	The	O	['N']	[0]
1	renal	O	['N']	[1]
2	biopsy	O	['N']	[2]
3	showed	O	['N']	[3]
4	focal	B	['N']	[4]
5	segmental	I	['N']	[5]
6	glomerulosclerosis	I-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	which	O	['N']	[8]
9	has	O	['N']	[9]
10	only	O	['N']	[10]
11	been	O	['N']	[11]
12	previously	O	['N']	[12]
13	reported	O	['N']	[13]
14	in	O	['N']	[14]
15	two	O	['N']	[15]
16	cases	O	['N']	[16]
17	of	O	['N']	[17]
18	CML	O	['N']	[18]
19	treated	O	['N']	[19]
20	with	O	['N']	[20]
21	IFNalpha	B-Drug	['Causes']	[6]
22	.	O	['N']	[22]
#420
0	After	O	['N']	[0]
1	a	O	['N']	[1]
2	second	O	['N']	[2]
3	dose	O	['N']	[3]
4	of	O	['N']	[4]
5	metoclopramide	B-Drug	['Causes']	[14]
6	,	O	['N']	[6]
7	these	O	['N']	[7]
8	symptoms	O	['N']	[8]
9	recurred	O	['N']	[9]
10	and	O	['N']	[10]
11	were	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	confusion	B-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	agitation	O	['N']	[16]
17	,	O	['N']	[17]
18	fever	O	['N']	[18]
19	,	O	['N']	[19]
20	diaphoresis	O	['N']	[20]
21	,	O	['N']	[21]
22	tachypnea	O	['N']	[22]
23	,	O	['N']	[23]
24	tachycardia	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	hypertension	O	['N']	[27]
28	.	O	['N']	[28]
#421
0	Our	O	['N']	[0]
1	patient	O	['N']	[1]
2	had	O	['N']	[2]
3	headache	O	['N']	[3]
4	,	O	['N']	[4]
5	mild	O	['N']	[5]
6	fever	O	['N']	[6]
7	,	O	['N']	[7]
8	nausea	O	['N']	[8]
9	,	O	['N']	[9]
10	vomiting	O	['N']	[10]
11	,	O	['N']	[11]
12	rash	B-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	eosinophilia	O	['N']	[15]
16	after	O	['N']	[16]
17	3	O	['N']	[17]
18	weeks	O	['N']	[18]
19	of	O	['N']	[19]
20	disulfiram	B-Drug	['Causes']	[12]
21	therapy	O	['N']	[21]
22	.	O	['N']	[22]
#422
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	additional	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	isotretinoin	B-Drug	['Causes']	[22]
7	teratogenicity	O	['N']	[7]
8	in	O	['N']	[8]
9	which	O	['N']	[9]
10	the	O	['N']	[10]
11	patient	O	['N']	[11]
12	had	O	['N']	[12]
13	agenesis	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	cerebellar	O	['N']	[16]
17	vermis	O	['N']	[17]
18	,	O	['N']	[18]
19	multiple	B	['N']	[19]
20	leptomeningeal	I	['N']	[20]
21	neuroglial	I	['N']	[21]
22	heterotopias	I-Adverse_Effect	['N']	[22]
23	,	O	['N']	[23]
24	hydrocephalus	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	abnormalities	O	['N']	[27]
28	of	O	['N']	[28]
29	the	O	['N']	[29]
30	corticospinal	O	['N']	[30]
31	tracts	O	['N']	[31]
32	.	O	['N']	[32]
#423
0	Similar	O	['N']	[0]
1	to	O	['N']	[1]
2	reports	O	['N']	[2]
3	in	O	['N']	[3]
4	patients	O	['N']	[4]
5	receiving	O	['N']	[5]
6	gefitinib	O	['N']	[6]
7	,	O	['N']	[7]
8	those	O	['N']	[8]
9	with	O	['N']	[9]
10	pathologic	O	['N']	[10]
11	findings	O	['N']	[11]
12	of	O	['N']	[12]
13	UIP	O	['N']	[13]
14	on	O	['N']	[14]
15	resected	O	['N']	[15]
16	lung	O	['N']	[16]
17	specimens	O	['N']	[17]
18	or	O	['N']	[18]
19	known	O	['N']	[19]
20	pulmonary	B	['N']	[20]
21	fibrosis	I-Adverse_Effect	['N']	[21]
22	may	O	['N']	[22]
23	be	O	['N']	[23]
24	at	O	['N']	[24]
25	particular	O	['N']	[25]
26	risk	O	['N']	[26]
27	for	O	['N']	[27]
28	erlotinib	B-Drug	['Causes']	[21]
29	pulmonary	O	['N']	[29]
30	toxicity	O	['N']	[30]
31	.	O	['N']	[31]
#424
0	At	O	['N']	[0]
1	the	O	['N']	[1]
2	end	O	['N']	[2]
3	of	O	['N']	[3]
4	his	O	['N']	[4]
5	fifth	O	['N']	[5]
6	cycle	O	['N']	[6]
7	of	O	['N']	[7]
8	sunitinib	B-Drug	['Causes']	[24]
9	therapy	O	['N']	[9]
10	,	O	['N']	[10]
11	the	O	['N']	[11]
12	patient	O	['N']	[12]
13	complained	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	development	O	['N']	[16]
17	of	O	['N']	[17]
18	abnormally	O	['N']	[18]
19	large	O	['N']	[19]
20	mammary	O	['N']	[20]
21	glands	O	['N']	[21]
22	associated	O	['N']	[22]
23	with	O	['N']	[23]
24	pain	B-Adverse_Effect	['N']	[24]
25	and	O	['N']	[25]
26	peri	O	['N']	[26]
27	-	O	['N']	[27]
28	areolar	O	['N']	[28]
29	erythema	O	['N']	[29]
30	.	O	['N']	[30]
#425
0	The	O	['N']	[0]
1	chemotherapeutics	O	['N']	[1]
2	,	O	['N']	[2]
3	including	O	['N']	[3]
4	vincristine	B-Drug	['Causes']	[27]
5	,	O	['N']	[5]
6	actinomycin	O	['N']	[6]
7	D	O	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	epirubicin	O	['N']	[10]
11	in	O	['N']	[11]
12	case	O	['N']	[12]
13	1	O	['N']	[13]
14	and	O	['N']	[14]
15	vincristine	O	['N']	[15]
16	and	O	['N']	[16]
17	actinomycin	O	['N']	[17]
18	D	O	['N']	[18]
19	in	O	['N']	[19]
20	case	O	['N']	[20]
21	2	O	['N']	[21]
22	,	O	['N']	[22]
23	were	O	['N']	[23]
24	given	O	['N']	[24]
25	before	O	['N']	[25]
26	the	O	['N']	[26]
27	hepatotoxicity	B-Adverse_Effect	['N']	[27]
28	developed	O	['N']	[28]
29	.	O	['N']	[29]
#426
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	had	O	['N']	[2]
3	a	O	['N']	[3]
4	lower	O	['N']	[4]
5	average	O	['N']	[5]
6	heart	O	['N']	[6]
7	rate	O	['N']	[7]
8	and	O	['N']	[8]
9	two	O	['N']	[9]
10	patients	O	['N']	[10]
11	had	O	['N']	[11]
12	lower	B	['N']	[12]
13	average	I	['N']	[13]
14	mean	I	['N']	[14]
15	blood	I	['N']	[15]
16	pressure	I-Adverse_Effect	['N']	[16]
17	values	O	['N']	[17]
18	during	O	['N']	[18]
19	propranolol	B-Drug	['Causes']	[16]
20	treatment	O	['N']	[20]
21	,	O	['N']	[21]
22	none	O	['N']	[22]
23	of	O	['N']	[23]
24	which	O	['N']	[24]
25	was	O	['N']	[25]
26	clinically	O	['N']	[26]
27	significant	O	['N']	[27]
28	.	O	['N']	[28]
#427
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	polyserositis	B-Adverse_Effect	['N']	[9]
10	(	O	['N']	[10]
11	pericardial	O	['N']	[11]
12	effusion	O	['N']	[12]
13	,	O	['N']	[13]
14	pleural	O	['N']	[14]
15	effusion	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	pericarditis	O	['N']	[18]
19	)	O	['N']	[19]
20	after	O	['N']	[20]
21	being	O	['N']	[21]
22	started	O	['N']	[22]
23	on	O	['N']	[23]
24	clozapine	B-Drug	['Causes']	[9]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	whose	O	['N']	[27]
28	symptoms	O	['N']	[28]
29	remitted	O	['N']	[29]
30	upon	O	['N']	[30]
31	discontinuation	O	['N']	[31]
32	of	O	['N']	[32]
33	clozapine	O	['N']	[33]
34	.	O	['N']	[34]
#428
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	the	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	young	O	['N']	[8]
9	woman	O	['N']	[9]
10	with	O	['N']	[10]
11	Graves	O	['N']	[11]
12	'	O	['N']	[12]
13	disease	O	['N']	[13]
14	in	O	['N']	[14]
15	whom	O	['N']	[15]
16	ototoxicity	B-Adverse_Effect	['N']	[16]
17	developed	O	['N']	[17]
18	because	O	['N']	[18]
19	of	O	['N']	[19]
20	propylthiouracil	O	['N']	[20]
21	(	O	['N']	[21]
22	PTU)-induced	-	['N']	[22]
23	antineutrophil	O	['N']	[23]
24	cytoplasmic	O	['N']	[24]
25	antibody	O	['N']	[25]
26	(	O	['N']	[26]
27	ANCA)-associated	O	['N']	[27]
28	vasculitis	O	['N']	[28]
29	.	O	['N']	[29]
#429
0	A	O	['N']	[0]
1	7-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	with	O	['N']	[4]
5	congenital	O	['N']	[5]
6	toxoplasmosis	O	['N']	[6]
7	who	O	['N']	[7]
8	took	O	['N']	[8]
9	pyrimethamine	B-Drug	['Causes']	[22]
10	and	O	['N']	[10]
11	sulfadiazine	O	['N']	[11]
12	for	O	['N']	[12]
13	reactivated	O	['N']	[13]
14	chorioretinitis	O	['N']	[14]
15	developed	O	['N']	[15]
16	fever	O	['N']	[16]
17	,	O	['N']	[17]
18	severe	O	['N']	[18]
19	cutaneous	O	['N']	[19]
20	involvement	O	['N']	[20]
21	,	O	['N']	[21]
22	swelling	B-Adverse_Effect	['N']	[22]
23	,	O	['N']	[23]
24	abdominal	O	['N']	[24]
25	pain	O	['N']	[25]
26	and	O	['N']	[26]
27	transaminitis	O	['N']	[27]
28	,	O	['N']	[28]
29	persisting	O	['N']	[29]
30	weeks	O	['N']	[30]
31	after	O	['N']	[31]
32	withholding	O	['N']	[32]
33	medicines	O	['N']	[33]
34	.	O	['N']	[34]
#430
0	Cardiac	B	['N']	[0]
1	toxicity	I-Adverse_Effect	['N']	[1]
2	related	O	['N']	[2]
3	to	O	['N']	[3]
4	BCNU	B-Drug	['Causes']	[1]
5	has	O	['N']	[5]
6	not	O	['N']	[6]
7	been	O	['N']	[7]
8	described	O	['N']	[8]
9	well	O	['N']	[9]
10	.	O	['N']	[10]
#431
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	1	O	['N']	[2]
3	,	O	['N']	[3]
4	a	O	['N']	[4]
5	total	O	['N']	[5]
6	daily	O	['N']	[6]
7	dose	O	['N']	[7]
8	of	O	['N']	[8]
9	25	B	['N']	[9]
10	mg	I-Dose	['N']	[10]
11	sertraline	O	['N']	[11]
12	,	O	['N']	[12]
13	with	O	['N']	[13]
14	nondetectable	O	['N']	[14]
15	sertraline	O	['N']	[15]
16	and	O	['N']	[16]
17	desmethylsertraline	O	['N']	[17]
18	blood	O	['N']	[18]
19	levels	O	['N']	[19]
20	,	O	['N']	[20]
21	resulted	O	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	doubling	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	lamotrigine	B-Drug	['Dosage']	[10]
28	blood	O	['N']	[28]
29	level	O	['N']	[29]
30	with	O	['N']	[30]
31	symptoms	O	['N']	[31]
32	of	O	['N']	[32]
33	toxicity	O	['N']	[33]
34	.	O	['N']	[34]
#432
0	During	O	['N']	[0]
1	her	O	['N']	[1]
2	third	O	['N']	[2]
3	cycle	O	['N']	[3]
4	,	O	['N']	[4]
5	she	O	['N']	[5]
6	again	O	['N']	[6]
7	received	O	['N']	[7]
8	cisplatin	B-Drug	['Causes']	[24]
9	100	O	['N']	[9]
10	mg	O	['N']	[10]
11	/	O	['N']	[11]
12	m2	O	['N']	[12]
13	over	O	['N']	[13]
14	30	O	['N']	[14]
15	minutes	O	['N']	[15]
16	and	O	['N']	[16]
17	developed	O	['N']	[17]
18	palmar	O	['N']	[18]
19	pruritus	O	['N']	[19]
20	,	O	['N']	[20]
21	urticaria	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	edema	B-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#433
0	Allopurinol	B-Drug	['Causes']	[1]
1	hypersensitivity	B-Adverse_Effect	['N']	[1]
2	.	O	['N']	[2]
#434
0	The	O	['N']	[0]
1	induction	O	['N']	[1]
2	of	O	['N']	[2]
3	hypoglycaemia	B-Adverse_Effect	['N']	[3]
4	with	O	['N']	[4]
5	PAS	B-Drug	['Causes']	[3]
6	in	O	['N']	[6]
7	this	O	['N']	[7]
8	patient	O	['N']	[8]
9	suggests	O	['N']	[9]
10	a	O	['N']	[10]
11	potential	O	['N']	[11]
12	role	O	['N']	[12]
13	for	O	['N']	[13]
14	PAS	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	treatment	O	['N']	[17]
18	of	O	['N']	[18]
19	diabetes	O	['N']	[19]
20	mellitus	O	['N']	[20]
21	.	O	['N']	[21]
#435
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	monocular	O	['N']	[3]
4	open	O	['N']	[4]
5	-	O	['N']	[5]
6	angle	O	['N']	[6]
7	glaucoma	O	['N']	[7]
8	had	O	['N']	[8]
9	trichiasis	B-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	a	O	['N']	[11]
12	condition	O	['N']	[12]
13	associated	O	['N']	[13]
14	with	O	['N']	[14]
15	the	O	['N']	[15]
16	use	O	['N']	[16]
17	of	O	['N']	[17]
18	a	O	['N']	[18]
19	prostaglandin	B-Drug	['Causes']	[9]
20	analog	O	['N']	[20]
21	.	O	['N']	[21]
#436
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	required	O	['N']	[2]
3	nursing	O	['N']	[3]
4	home	O	['N']	[4]
5	placement	O	['N']	[5]
6	and	O	['N']	[6]
7	a	O	['N']	[7]
8	feeding	B	['N']	[8]
9	gastrostomy	I-Adverse_Effect	['N']	[9]
10	as	O	['N']	[10]
11	a	O	['N']	[11]
12	result	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	worsening	O	['N']	[15]
16	parkinsonism	O	['N']	[16]
17	during	O	['N']	[17]
18	risperidone	B-Drug	['Causes']	[9]
19	treatment	O	['N']	[19]
20	,	O	['N']	[20]
21	but	O	['N']	[21]
22	was	O	['N']	[22]
23	able	O	['N']	[23]
24	to	O	['N']	[24]
25	return	O	['N']	[25]
26	home	O	['N']	[26]
27	and	O	['N']	[27]
28	have	O	['N']	[28]
29	the	O	['N']	[29]
30	gastrostomy	O	['N']	[30]
31	removed	O	['N']	[31]
32	after	O	['N']	[32]
33	switching	O	['N']	[33]
34	from	O	['N']	[34]
35	risperidone	O	['N']	[35]
36	to	O	['N']	[36]
37	clozapine	O	['N']	[37]
38	.	O	['N']	[38]
#437
0	Rituximab	B	['N']	[0]
1	-	I	['N']	[1]
2	CHOP	I-Drug	['Causes']	[5]
3	induced	O	['N']	[3]
4	interstitial	B	['N']	[4]
5	pneumonitis	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	patients	O	['N']	[7]
8	with	O	['N']	[8]
9	disseminated	O	['N']	[9]
10	extranodal	O	['N']	[10]
11	marginal	O	['N']	[11]
12	zone	O	['N']	[12]
13	B	O	['N']	[13]
14	cell	O	['N']	[14]
15	lymphoma	O	['N']	[15]
16	.	O	['N']	[16]
#438
0	Heparin	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	thrombocytopenia	O	['N']	[3]
4	and	O	['N']	[4]
5	thrombosis	B-Adverse_Effect	['N']	[5]
6	is	O	['N']	[6]
7	a	O	['N']	[7]
8	severe	O	['N']	[8]
9	complication	O	['N']	[9]
10	of	O	['N']	[10]
11	systemic	O	['N']	[11]
12	heparin	O	['N']	[12]
13	therapy	O	['N']	[13]
14	.	O	['N']	[14]
#439
0	Scleritis	B-Adverse_Effect	['N']	[0]
1	complicating	O	['N']	[1]
2	zoledronic	B	['N']	[2]
3	acid	I-Drug	['Causes']	[0]
4	infusion	O	['N']	[4]
5	.	O	['N']	[5]
#440
0	Can	O	['N']	[0]
1	roxithromycin	B-Drug	['Causes']	[6]
2	and	O	['N']	[2]
3	betamethasone	O	['N']	[3]
4	induce	O	['N']	[4]
5	acute	B	['N']	[5]
6	pancreatitis	I-Adverse_Effect	['N']	[6]
7	?	O	['N']	[7]
8	A	O	['N']	[8]
9	case	O	['N']	[9]
10	report	O	['N']	[10]
11	.	O	['N']	[11]
#441
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	chronic	O	['N']	[6]
7	schizophrenia	O	['N']	[7]
8	who	O	['N']	[8]
9	experienced	O	['N']	[9]
10	delirium	O	['N']	[10]
11	,	O	['N']	[11]
12	grand	B	['N']	[12]
13	mal	I	['N']	[13]
14	seizure	I-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	photosensitivity	O	['N']	[17]
18	after	O	['N']	[18]
19	the	O	['N']	[19]
20	addition	O	['N']	[20]
21	of	O	['N']	[21]
22	propranolol	B-Drug	['Causes']	[14]
23	to	O	['N']	[23]
24	her	O	['N']	[24]
25	neuroleptic	O	['N']	[25]
26	regimen	O	['N']	[26]
27	.	O	['N']	[27]
#442
0	A	O	['N']	[0]
1	48-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	who	O	['N']	[5]
6	was	O	['N']	[6]
7	treated	O	['N']	[7]
8	for	O	['N']	[8]
9	thyrotoxicosis	O	['N']	[9]
10	with	O	['N']	[10]
11	methimazole	B-Drug	['Causes']	[13]
12	developed	O	['N']	[12]
13	agranulocytosis	B-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#443
0	Itch	O	['N']	[0]
1	and	O	['N']	[1]
2	skin	B	['N']	[2]
3	rash	I-Adverse_Effect	['N']	[3]
4	from	O	['N']	[4]
5	chocolate	O	['N']	[5]
6	during	O	['N']	[6]
7	fluoxetine	B-Drug	['Causes']	[3]
8	and	O	['N']	[8]
9	sertraline	O	['N']	[9]
10	treatment	O	['N']	[10]
11	:	O	['N']	[11]
12	case	O	['N']	[12]
13	report	O	['N']	[13]
14	.	O	['N']	[14]
#444
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	patient	O	['N']	[3]
4	required	O	['N']	[4]
5	insulin	B-Drug	['Causes']	[9]
6	desensitization	O	['N']	[6]
7	for	O	['N']	[7]
8	severe	B	['N']	[8]
9	urticaria	I-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	angioedema	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	occasional	O	['N']	[14]
15	wheezing	O	['N']	[15]
16	resulting	O	['N']	[16]
17	from	O	['N']	[17]
18	her	O	['N']	[18]
19	insulin	O	['N']	[19]
20	dose	O	['N']	[20]
21	.	O	['N']	[21]
#445
0	Prenatal	O	['N']	[0]
1	cytomegalovirus	O	['N']	[1]
2	(	O	['N']	[2]
3	CMV	O	['N']	[3]
4	)	O	['N']	[4]
5	infection	O	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	severe	O	['N']	[8]
9	brain	B	['N']	[9]
10	damage	I-Adverse_Effect	['N']	[10]
11	was	O	['N']	[11]
12	detected	O	['N']	[12]
13	in	O	['N']	[13]
14	an	O	['N']	[14]
15	infant	O	['N']	[15]
16	whose	O	['N']	[16]
17	mother	O	['N']	[17]
18	had	O	['N']	[18]
19	been	O	['N']	[19]
20	treated	O	['N']	[20]
21	with	O	['N']	[21]
22	prednisolone	O	['N']	[22]
23	and	O	['N']	[23]
24	azathioprine	B-Drug	['Causes']	[10]
25	for	O	['N']	[25]
26	systemic	O	['N']	[26]
27	lupus	O	['N']	[27]
28	erythematosus	O	['N']	[28]
29	(	O	['N']	[29]
30	SLE	O	['N']	[30]
31	)	O	['N']	[31]
32	.	O	['N']	[32]
#446
0	Bisphosphonate	B-Drug	['Causes']	[7]
1	-	O	['N']	[1]
2	related	O	['N']	[2]
3	osteonecrosis	B	['N']	[3]
4	of	I	['N']	[4]
5	the	I	['N']	[5]
6	skull	I	['N']	[6]
7	base	I-Adverse_Effect	['N']	[7]
8	.	O	['N']	[8]
#447
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	what	O	['N']	[4]
5	is	O	['N']	[5]
6	believed	O	['N']	[6]
7	,	O	['N']	[7]
8	as	O	['N']	[8]
9	of	O	['N']	[9]
10	November	O	['N']	[10]
11	4	O	['N']	[11]
12	,	O	['N']	[12]
13	2003	O	['N']	[13]
14	,	O	['N']	[14]
15	to	O	['N']	[15]
16	be	O	['N']	[16]
17	the	O	['N']	[17]
18	first	O	['N']	[18]
19	case	O	['N']	[19]
20	published	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	literature	O	['N']	[23]
24	of	O	['N']	[24]
25	acute	B	['N']	[25]
26	interstitial	I	['N']	[26]
27	nephritis	I-Adverse_Effect	['N']	[27]
28	(	O	['N']	[28]
29	AIN	O	['N']	[29]
30	)	O	['N']	[30]
31	due	O	['N']	[31]
32	to	O	['N']	[32]
33	pantoprazole	B-Drug	['Causes']	[27]
34	.	O	['N']	[34]
#448
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	two	O	['N']	[5]
6	patients	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	acute	O	['N']	[9]
10	hepatitis	B-Adverse_Effect	['N']	[10]
11	after	O	['N']	[11]
12	taking	O	['N']	[12]
13	riluzole	B-Drug	['Causes']	[10]
14	at	O	['N']	[14]
15	the	O	['N']	[15]
16	recommended	O	['N']	[16]
17	dose	O	['N']	[17]
18	(	O	['N']	[18]
19	100	O	['N']	[19]
20	mg	O	['N']	[20]
21	daily	O	['N']	[21]
22	)	O	['N']	[22]
23	for	O	['N']	[23]
24	7	O	['N']	[24]
25	and	O	['N']	[25]
26	4	O	['N']	[26]
27	weeks	O	['N']	[27]
28	,	O	['N']	[28]
29	respectively	O	['N']	[29]
30	.	O	['N']	[30]
#449
0	Portal	B	['N']	[0]
1	vein	I	['N']	[1]
2	thrombosis	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	severe	O	['N']	[7]
8	haemophilia	O	['N']	[8]
9	A	O	['N']	[9]
10	and	O	['N']	[10]
11	F	O	['N']	[11]
12	V	O	['N']	[12]
13	G1691A	O	['N']	[13]
14	mutation	O	['N']	[14]
15	during	O	['N']	[15]
16	continuous	O	['N']	[16]
17	infusion	O	['N']	[17]
18	of	O	['N']	[18]
19	F	B	['N']	[19]
20	VIII	I-Drug	['Causes']	[2]
21	after	O	['N']	[21]
22	intramural	O	['N']	[22]
23	jejunal	O	['N']	[23]
24	bleeding	O	['N']	[24]
25	--	O	['N']	[25]
26	successful	O	['N']	[26]
27	thrombolysis	O	['N']	[27]
28	under	O	['N']	[28]
29	heparin	O	['N']	[29]
30	therapy	O	['N']	[30]
31	.	O	['N']	[31]
#450
0	After	O	['N']	[0]
1	a	O	['N']	[1]
2	second	O	['N']	[2]
3	dose	O	['N']	[3]
4	of	O	['N']	[4]
5	metoclopramide	B-Drug	['Causes']	[16]
6	,	O	['N']	[6]
7	these	O	['N']	[7]
8	symptoms	O	['N']	[8]
9	recurred	O	['N']	[9]
10	and	O	['N']	[10]
11	were	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	confusion	O	['N']	[14]
15	,	O	['N']	[15]
16	agitation	B-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	fever	O	['N']	[18]
19	,	O	['N']	[19]
20	diaphoresis	O	['N']	[20]
21	,	O	['N']	[21]
22	tachypnea	O	['N']	[22]
23	,	O	['N']	[23]
24	tachycardia	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	hypertension	O	['N']	[27]
28	.	O	['N']	[28]
#451
0	Administration	O	['N']	[0]
1	of	O	['N']	[1]
2	intravenous	O	['N']	[2]
3	nitroglycerin	B-Drug	['Causes']	[36]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	idiopathic	O	['N']	[8]
9	pulmonary	O	['N']	[9]
10	hypertension	O	['N']	[10]
11	resulted	O	['N']	[11]
12	in	O	['N']	[12]
13	an	O	['N']	[13]
14	increase	O	['N']	[14]
15	in	O	['N']	[15]
16	pulmonary	O	['N']	[16]
17	artery	O	['N']	[17]
18	pressure	O	['N']	[18]
19	associated	O	['N']	[19]
20	with	O	['N']	[20]
21	a	O	['N']	[21]
22	decrease	O	['N']	[22]
23	in	O	['N']	[23]
24	blood	O	['N']	[24]
25	flow	O	['N']	[25]
26	that	O	['N']	[26]
27	is	O	['N']	[27]
28	best	O	['N']	[28]
29	explained	O	['N']	[29]
30	by	O	['N']	[30]
31	an	O	['N']	[31]
32	increase	B	['N']	[32]
33	in	I	['N']	[33]
34	pulmonary	I	['N']	[34]
35	vascular	I	['N']	[35]
36	resistance	I-Adverse_Effect	['N']	[36]
37	.	O	['N']	[37]
#452
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	repeated	O	['N']	[2]
3	intracameral	O	['N']	[3]
4	tPA	B-Drug	['Causes']	[13]
5	injections	O	['N']	[5]
6	may	O	['N']	[6]
7	cause	O	['N']	[7]
8	unwanted	O	['N']	[8]
9	complications	O	['N']	[9]
10	such	O	['N']	[10]
11	as	O	['N']	[11]
12	vitreous	B	['N']	[12]
13	hemorrhage	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#453
0	We	O	['N']	[0]
1	stress	O	['N']	[1]
2	the	O	['N']	[2]
3	potential	O	['N']	[3]
4	of	O	['N']	[4]
5	benzarone	B-Drug	['Causes']	[16]
6	to	O	['N']	[6]
7	cause	O	['N']	[7]
8	hepatotoxicity	O	['N']	[8]
9	,	O	['N']	[9]
10	which	O	['N']	[10]
11	usually	O	['N']	[11]
12	resembles	O	['N']	[12]
13	severe	B	['N']	[13]
14	chronic	I	['N']	[14]
15	active	I	['N']	[15]
16	hepatitis	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#454
0	Physicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	potentially	O	['N']	[6]
7	lethal	B-Adverse_Effect	['N']	[7]
8	side	O	['N']	[8]
9	effects	O	['N']	[9]
10	of	O	['N']	[10]
11	dapsone	B-Drug	['Causes']	[7]
12	.	O	['N']	[12]
#455
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	skin	O	['N']	[23]
24	eruptions	O	['N']	[24]
25	,	O	['N']	[25]
26	cervical	O	['N']	[26]
27	lymphadenopathy	O	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	B	['N']	[31]
32	lymphocytosis	I-Adverse_Effect	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	O	['N']	[40]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	-	['N']	[42]
43	(	O	['N']	[43]
44	SMX	O	['N']	[44]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#456
0	Herein	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	describe	O	['N']	[3]
4	2	O	['N']	[4]
5	patients	O	['N']	[5]
6	who	O	['N']	[6]
7	developed	O	['N']	[7]
8	unusual	O	['N']	[8]
9	CD8	B	['N']	[9]
10	+	I	['N']	[10]
11	cutaneous	I	['N']	[11]
12	lymphoproliferative	I	['N']	[12]
13	disorders	I-Adverse_Effect	['N']	[13]
14	after	O	['N']	[14]
15	treatment	O	['N']	[15]
16	with	O	['N']	[16]
17	efalizumab	O	['N']	[17]
18	and	O	['N']	[18]
19	infliximab	B-Drug	['Causes']	[13]
20	.	O	['N']	[20]
#457
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	20-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	who	O	['N']	[10]
11	ingested	O	['N']	[11]
12	900	B	['N']	[12]
13	mg	I-Dose	['N']	[13]
14	of	O	['N']	[14]
15	glyburide	B-Drug	['Dosage']	[13]
16	causing	O	['N']	[16]
17	refractory	O	['N']	[17]
18	hypoglycemia	O	['N']	[18]
19	resistant	O	['N']	[19]
20	to	O	['N']	[20]
21	treatment	O	['N']	[21]
22	with	O	['N']	[22]
23	intravenous	O	['N']	[23]
24	dextrose	O	['N']	[24]
25	,	O	['N']	[25]
26	glucagon	O	['N']	[26]
27	,	O	['N']	[27]
28	and	O	['N']	[28]
29	diazoxide	O	['N']	[29]
30	.	O	['N']	[30]
#458
0	Metabolic	B	['N']	[0]
1	acidosis	I-Adverse_Effect	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	cetrimide	O	['N']	[4]
5	-	O	['N']	[5]
6	chlorhexidine	B-Drug	['Causes']	[1]
7	solution	O	['N']	[7]
8	in	O	['N']	[8]
9	hydatid	O	['N']	[9]
10	cyst	O	['N']	[10]
11	surgery	O	['N']	[11]
12	.	O	['N']	[12]
#459
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	phenolphthalein	B-Drug	['Causes']	[12]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	toxic	B	['N']	[10]
11	epidermal	I	['N']	[11]
12	necrolysis	I-Adverse_Effect	['N']	[12]
13	(	O	['N']	[13]
14	TEN	O	['N']	[14]
15	)	O	['N']	[15]
16	in	O	['N']	[16]
17	a	O	['N']	[17]
18	patient	O	['N']	[18]
19	maintained	O	['N']	[19]
20	on	O	['N']	[20]
21	several	O	['N']	[21]
22	other	O	['N']	[22]
23	medications	O	['N']	[23]
24	more	O	['N']	[24]
25	commonly	O	['N']	[25]
26	known	O	['N']	[26]
27	to	O	['N']	[27]
28	be	O	['N']	[28]
29	associated	O	['N']	[29]
30	with	O	['N']	[30]
31	TEN	O	['N']	[31]
32	.	O	['N']	[32]
#460
0	Lupus	B	['N']	[0]
1	-	I	['N']	[1]
2	like	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	caused	O	['N']	[4]
5	by	O	['N']	[5]
6	5-aminosalicylic	B	['N']	[6]
7	acid	I-Drug	['Causes']	[3]
8	in	O	['N']	[8]
9	patients	O	['N']	[9]
10	with	O	['N']	[10]
11	inflammatory	O	['N']	[11]
12	bowel	O	['N']	[12]
13	disease	O	['N']	[13]
14	.	O	['N']	[14]
#461
0	Visceral	B	['N']	[0]
1	herpesvirus	I	['N']	[1]
2	infections	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	leukemic	O	['N']	[4]
5	patients	O	['N']	[5]
6	receiving	O	['N']	[6]
7	cytarabine	B-Drug	['Causes']	[2]
8	.	O	['N']	[8]
#462
0	In	O	['N']	[0]
1	four	O	['N']	[1]
2	patients	O	['N']	[2]
3	,	O	['N']	[3]
4	thrombosis	B-Adverse_Effect	['N']	[4]
5	occurred	O	['N']	[5]
6	2	O	['N']	[6]
7	-	O	['N']	[7]
8	45	O	['N']	[8]
9	days	O	['N']	[9]
10	after	O	['N']	[10]
11	severe	O	['N']	[11]
12	hepatic	O	['N']	[12]
13	veno	O	['N']	[13]
14	-	O	['N']	[14]
15	occlusive	O	['N']	[15]
16	disease	O	['N']	[16]
17	(	O	['N']	[17]
18	HVOD	O	['N']	[18]
19	)	O	['N']	[19]
20	secondary	O	['N']	[20]
21	to	O	['N']	[21]
22	intensive	O	['N']	[22]
23	chemotherapy	O	['N']	[23]
24	containing	O	['N']	[24]
25	busulfan	B-Drug	['Causes']	[4]
26	.	O	['N']	[26]
#463
0	Prior	O	['N']	[0]
1	neurologic	O	['N']	[1]
2	illness	O	['N']	[2]
3	and	O	['N']	[3]
4	the	O	['N']	[4]
5	syndrome	O	['N']	[5]
6	of	O	['N']	[6]
7	irreversible	O	['N']	[7]
8	lithium	B-Drug	['Causes']	[11]
9	-	O	['N']	[9]
10	effectuated	O	['N']	[10]
11	neurotoxicity	B-Adverse_Effect	['N']	[11]
12	(	O	['N']	[12]
13	SILENT	O	['N']	[13]
14	)	O	['N']	[14]
15	.	O	['N']	[15]
#464
0	Prolonged	O	['N']	[0]
1	severe	O	['N']	[1]
2	5-fluorouracil	B-Drug	['Causes']	[5]
3	-	O	['N']	[3]
4	associated	O	['N']	[4]
5	neurotoxicity	B-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	dihydropyrimidine	O	['N']	[10]
11	dehydrogenase	O	['N']	[11]
12	deficiency	O	['N']	[12]
13	.	O	['N']	[13]
#465
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	treated	O	['N']	[2]
3	with	O	['N']	[3]
4	Pancrease	B	['N']	[4]
5	MT	I	['N']	[5]
6	16	I-Drug	['Causes']	[11]
7	,	O	['N']	[7]
8	but	O	['N']	[8]
9	had	O	['N']	[9]
10	consistent	O	['N']	[10]
11	vomiting	B-Adverse_Effect	['N']	[11]
12	1	O	['N']	[12]
13	to	O	['N']	[13]
14	2	O	['N']	[14]
15	hours	O	['N']	[15]
16	after	O	['N']	[16]
17	administration	O	['N']	[17]
18	of	O	['N']	[18]
19	enzymes	O	['N']	[19]
20	.	O	['N']	[20]
#466
0	Four	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	the	O	['N']	[3]
4	initial	O	['N']	[4]
5	injection	O	['N']	[5]
6	of	O	['N']	[6]
7	3.6	O	['N']	[7]
8	mg	O	['N']	[8]
9	of	O	['N']	[9]
10	goserelin	B	['N']	[10]
11	acetate	I-Drug	['Causes']	[29]
12	,	O	['N']	[12]
13	severe	O	['N']	[13]
14	dyspnea	O	['N']	[14]
15	developed	O	['N']	[15]
16	due	O	['N']	[16]
17	to	O	['N']	[17]
18	worsening	O	['N']	[18]
19	pleuritis	O	['N']	[19]
20	carcinomatosa	O	['N']	[20]
21	,	O	['N']	[21]
22	which	O	['N']	[22]
23	was	O	['N']	[23]
24	considered	O	['N']	[24]
25	as	O	['N']	[25]
26	a	O	['N']	[26]
27	flare	B	['N']	[27]
28	-	I	['N']	[28]
29	up	I-Adverse_Effect	['N']	[29]
30	.	O	['N']	[30]
#467
0	Following	O	['N']	[0]
1	discontinuation	O	['N']	[1]
2	of	O	['N']	[2]
3	clozapine	B-Drug	['Causes']	[14]
4	,	O	['N']	[4]
5	she	O	['N']	[5]
6	was	O	['N']	[6]
7	rechallenged	O	['N']	[7]
8	and	O	['N']	[8]
9	again	O	['N']	[9]
10	was	O	['N']	[10]
11	observed	O	['N']	[11]
12	to	O	['N']	[12]
13	have	O	['N']	[13]
14	seizures	B-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#468
0	Retinal	O	['N']	[0]
1	abnormalities	O	['N']	[1]
2	,	O	['N']	[2]
3	including	O	['N']	[3]
4	retinal	O	['N']	[4]
5	hemorrhage	O	['N']	[5]
6	and	O	['N']	[6]
7	"	B	['N']	[7]
8	cotton	I	['N']	[8]
9	-	I	['N']	[9]
10	wool	I	['N']	[10]
11	"	I	['N']	[11]
12	spots	I-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	often	O	['N']	[14]
15	occur	O	['N']	[15]
16	within	O	['N']	[16]
17	the	O	['N']	[17]
18	first	O	['N']	[18]
19	8	O	['N']	[19]
20	weeks	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	course	O	['N']	[23]
24	of	O	['N']	[24]
25	interferon	B-Drug	['Causes']	[12]
26	therapy	O	['N']	[26]
27	in	O	['N']	[27]
28	patients	O	['N']	[28]
29	with	O	['N']	[29]
30	chronic	O	['N']	[30]
31	hepatitis	O	['N']	[31]
32	C.	O	['N']	[32]
#469
0	Allergic	B	['N']	[0]
1	contact	I	['N']	[1]
2	dermatitis	I-Adverse_Effect	['N']	[2]
3	from	O	['N']	[3]
4	4-chloro-7-nitrobenzofurazan	B-Drug	['Causes']	[2]
5	.	O	['N']	[5]
#470
0	Acyclovir	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	neurotoxicity	B-Adverse_Effect	['N']	[3]
4	:	O	['N']	[4]
5	concentration	O	['N']	[5]
6	-	O	['N']	[6]
7	side	O	['N']	[7]
8	effect	O	['N']	[8]
9	relationship	O	['N']	[9]
10	in	O	['N']	[10]
11	acyclovir	O	['N']	[11]
12	overdose	O	['N']	[12]
13	.	O	['N']	[13]
#471
0	Methotrexate	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	liver	B	['N']	[3]
4	cirrhosis	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#472
0	Comeoscleral	B	['N']	[0]
1	perforation	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	pterygium	O	['N']	[3]
4	excision	O	['N']	[4]
5	and	O	['N']	[5]
6	intraoperative	O	['N']	[6]
7	mitomycin	-	['N']	[7]
8	C.	-	['N']	[8]
#473
0	Phenytoin	B-Drug	['Causes']	[9]
1	toxicity	O	['N']	[1]
2	:	O	['N']	[2]
3	an	O	['N']	[3]
4	easily	O	['N']	[4]
5	missed	O	['N']	[5]
6	cause	O	['N']	[6]
7	of	O	['N']	[7]
8	cerebellar	B	['N']	[8]
9	syndrome	I-Adverse_Effect	['N']	[9]
10	.	O	['N']	[10]
#474
0	Caution	O	['N']	[0]
1	in	O	['N']	[1]
2	longterm	O	['N']	[2]
3	usage	O	['N']	[3]
4	and	O	['N']	[4]
5	early	O	['N']	[5]
6	recognition	O	['N']	[6]
7	of	O	['N']	[7]
8	pentazocine	B-Drug	['Causes']	[28]
9	toxicity	O	['N']	[9]
10	as	O	['N']	[10]
11	a	O	['N']	[11]
12	neuromuscular	O	['N']	[12]
13	complication	O	['N']	[13]
14	are	O	['N']	[14]
15	important	O	['N']	[15]
16	in	O	['N']	[16]
17	order	O	['N']	[17]
18	to	O	['N']	[18]
19	prevent	O	['N']	[19]
20	irreversible	O	['N']	[20]
21	drug	O	['N']	[21]
22	-	O	['N']	[22]
23	induced	O	['N']	[23]
24	fibrous	O	['N']	[24]
25	myopathy	O	['N']	[25]
26	and	O	['N']	[26]
27	localized	O	['N']	[27]
28	neuropathy	B-Adverse_Effect	['N']	[28]
29	.	O	['N']	[29]
#475
0	Ovarian	B	['N']	[0]
1	endometrioid	I	['N']	[1]
2	adenocarcinoma	I-Adverse_Effect	['N']	[2]
3	arising	O	['N']	[3]
4	from	O	['N']	[4]
5	an	O	['N']	[5]
6	endometriotic	O	['N']	[6]
7	cyst	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	postmenopausal	O	['N']	[10]
11	woman	O	['N']	[11]
12	under	O	['N']	[12]
13	tamoxifen	B-Drug	['Causes']	[2]
14	therapy	O	['N']	[14]
15	for	O	['N']	[15]
16	breast	O	['N']	[16]
17	cancer	O	['N']	[17]
18	:	O	['N']	[18]
19	a	O	['N']	[19]
20	case	O	['N']	[20]
21	report	O	['N']	[21]
22	.	O	['N']	[22]
#476
0	Pulmonary	B	['N']	[0]
1	edema	I-Adverse_Effect	['N']	[1]
2	occurred	O	['N']	[2]
3	24	O	['N']	[3]
4	hours	O	['N']	[4]
5	after	O	['N']	[5]
6	intravenous	O	['N']	[6]
7	ritodrine	O	['N']	[7]
8	therapy	O	['N']	[8]
9	and	O	['N']	[9]
10	10	O	['N']	[10]
11	hours	O	['N']	[11]
12	after	O	['N']	[12]
13	subcutaneous	O	['N']	[13]
14	terbutaline	B-Drug	['Causes']	[1]
15	therapy	O	['N']	[15]
16	.	O	['N']	[16]
#477
0	The	O	['N']	[0]
1	most	O	['N']	[1]
2	likely	O	['N']	[2]
3	cause	O	['N']	[3]
4	of	O	['N']	[4]
5	liver	O	['N']	[5]
6	failure	O	['N']	[6]
7	in	O	['N']	[7]
8	this	O	['N']	[8]
9	patient	O	['N']	[9]
10	was	O	['N']	[10]
11	,	O	['N']	[11]
12	therefore	O	['N']	[12]
13	,	O	['N']	[13]
14	clarithromycin	B-Drug	['Causes']	[28]
15	,	O	['N']	[15]
16	which	O	['N']	[16]
17	undergoes	O	['N']	[17]
18	hepatic	O	['N']	[18]
19	metabolism	O	['N']	[19]
20	and	O	['N']	[20]
21	has	O	['N']	[21]
22	been	O	['N']	[22]
23	reported	O	['N']	[23]
24	to	O	['N']	[24]
25	cause	O	['N']	[25]
26	fulminant	B	['N']	[26]
27	hepatic	I	['N']	[27]
28	failure	I-Adverse_Effect	['N']	[28]
29	.	O	['N']	[29]
#478
0	Ticlopidine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	marrow	B	['N']	[3]
4	aplasia	I-Adverse_Effect	['N']	[4]
5	treated	O	['N']	[5]
6	with	O	['N']	[6]
7	cyclosporine	O	['N']	[7]
8	.	O	['N']	[8]
#479
0	Hepatotoxicity	B-Adverse_Effect	['N']	[0]
1	of	O	['N']	[1]
2	paracetamol	B-Drug	['Causes']	[0]
3	enhanced	O	['N']	[3]
4	by	O	['N']	[4]
5	ingestion	O	['N']	[5]
6	of	O	['N']	[6]
7	alcohol	O	['N']	[7]
8	:	O	['N']	[8]
9	report	O	['N']	[9]
10	of	O	['N']	[10]
11	two	O	['N']	[11]
12	cases	O	['N']	[12]
13	.	O	['N']	[13]
#480
0	Slow	O	['N']	[0]
1	acetylators	O	['N']	[1]
2	,	O	['N']	[2]
3	who	O	['N']	[3]
4	comprise	O	['N']	[4]
5	roughly	O	['N']	[5]
6	50	O	['N']	[6]
7	%	O	['N']	[7]
8	of	O	['N']	[8]
9	the	O	['N']	[9]
10	South	O	['N']	[10]
11	African	O	['N']	[11]
12	population	O	['N']	[12]
13	,	O	['N']	[13]
14	are	O	['N']	[14]
15	likely	O	['N']	[15]
16	to	O	['N']	[16]
17	develop	O	['N']	[17]
18	clinical	O	['N']	[18]
19	and	O	['N']	[19]
20	biochemical	O	['N']	[20]
21	features	O	['N']	[21]
22	of	O	['N']	[22]
23	phenytoin	B-Drug	['Causes']	[24]
24	toxicity	I-Adverse_Effect	['N']	[24]
25	when	O	['N']	[25]
26	this	O	['N']	[26]
27	drug	O	['N']	[27]
28	is	O	['N']	[28]
29	given	O	['N']	[29]
30	together	O	['N']	[30]
31	with	O	['N']	[31]
32	antituberculosis	O	['N']	[32]
33	therapy	O	['N']	[33]
34	.	O	['N']	[34]
#481
0	After	O	['N']	[0]
1	cessation	O	['N']	[1]
2	of	O	['N']	[2]
3	amantadine	B-Drug	['Causes']	[6]
4	,	O	['N']	[4]
5	the	O	['N']	[5]
6	edema	B-Adverse_Effect	['N']	[6]
7	resolved	O	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	the	O	['N']	[10]
11	endothelial	O	['N']	[11]
12	cell	O	['N']	[12]
13	densities	O	['N']	[13]
14	were	O	['N']	[14]
15	<	O	['N']	[15]
16	or=600/mm	O	['N']	[16]
17	.	O	['N']	[17]
#482
0	Therefore	O	['N']	[0]
1	,	O	['N']	[1]
2	although	O	['N']	[2]
3	garenoxacin	B-Drug	['Causes']	[30]
4	reportedly	O	['N']	[4]
5	causes	O	['N']	[5]
6	fewer	O	['N']	[6]
7	adverse	O	['N']	[7]
8	reactions	O	['N']	[8]
9	for	O	['N']	[9]
10	cardiac	O	['N']	[10]
11	rhythms	O	['N']	[11]
12	than	O	['N']	[12]
13	third	O	['N']	[13]
14	-	O	['N']	[14]
15	generation	O	['N']	[15]
16	quinolone	O	['N']	[16]
17	antibiotics	O	['N']	[17]
18	,	O	['N']	[18]
19	one	O	['N']	[19]
20	must	O	['N']	[20]
21	be	O	['N']	[21]
22	cautious	O	['N']	[22]
23	of	O	['N']	[23]
24	the	O	['N']	[24]
25	interference	O	['N']	[25]
26	of	O	['N']	[26]
27	other	O	['N']	[27]
28	drugs	O	['N']	[28]
29	during	O	['N']	[29]
30	hypokalemia	B-Adverse_Effect	['N']	[30]
31	in	O	['N']	[31]
32	order	O	['N']	[32]
33	to	O	['N']	[33]
34	prevent	O	['N']	[34]
35	TdP.	O	['N']	[35]
#483
0	High	B-Dose	['N']	[0]
1	-	O	['N']	[1]
2	dose	O	['N']	[2]
3	phosphate	B-Drug	['Dosage']	[0]
4	treatment	O	['N']	[4]
5	leads	O	['N']	[5]
6	to	O	['N']	[6]
7	hypokalemia	O	['N']	[7]
8	in	O	['N']	[8]
9	hypophosphatemic	O	['N']	[9]
10	osteomalacia	O	['N']	[10]
11	.	O	['N']	[11]
#484
0	The	O	['N']	[0]
1	increasing	O	['N']	[1]
2	prevalence	O	['N']	[2]
3	of	O	['N']	[3]
4	methamphetamine	B-Drug	['Causes']	[12]
5	abuse	O	['N']	[5]
6	and	O	['N']	[6]
7	the	O	['N']	[7]
8	severity	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	associated	O	['N']	[11]
12	ulcers	B-Adverse_Effect	['N']	[12]
13	should	O	['N']	[13]
14	alert	O	['N']	[14]
15	ophthalmologists	O	['N']	[15]
16	to	O	['N']	[16]
17	the	O	['N']	[17]
18	problem	O	['N']	[18]
19	of	O	['N']	[19]
20	methamphetamine	O	['N']	[20]
21	-	O	['N']	[21]
22	related	O	['N']	[22]
23	keratitis	O	['N']	[23]
24	.	O	['N']	[24]
#485
0	Hepatotoxic	B	['N']	[0]
1	effects	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	a	O	['N']	[3]
4	child	O	['N']	[4]
5	receiving	O	['N']	[5]
6	valproate	O	['N']	[6]
7	and	O	['N']	[7]
8	carnitine	B-Drug	['Causes']	[1]
9	.	O	['N']	[9]
#486
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Methotrexate	B-Drug	['Causes']	[9]
3	(	O	['N']	[3]
4	MTX	O	['N']	[4]
5	)	O	['N']	[5]
6	may	O	['N']	[6]
7	induce	O	['N']	[7]
8	liver	B	['N']	[8]
9	damage	I-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	which	O	['N']	[11]
12	in	O	['N']	[12]
13	some	O	['N']	[13]
14	psoriatics	O	['N']	[14]
15	will	O	['N']	[15]
16	lead	O	['N']	[16]
17	to	O	['N']	[17]
18	fibrosis	O	['N']	[18]
19	or	O	['N']	[19]
20	cirrhosis	O	['N']	[20]
21	.	O	['N']	[21]
#487
0	Retinoic	B	['N']	[0]
1	acid	I-Drug	['Causes']	[10]
2	may	O	['N']	[2]
3	increase	O	['N']	[3]
4	the	O	['N']	[4]
5	risk	O	['N']	[5]
6	of	O	['N']	[6]
7	bone	B	['N']	[7]
8	marrow	I	['N']	[8]
9	transplant	I	['N']	[9]
10	nephropathy	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#488
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	acute	B	['N']	[6]
7	kidney	I	['N']	[7]
8	injury	I-Adverse_Effect	['N']	[8]
9	due	O	['N']	[9]
10	to	O	['N']	[10]
11	zonisamide	B-Drug	['Causes']	[8]
12	-	O	['N']	[12]
13	induced	O	['N']	[13]
14	DRESS	O	['N']	[14]
15	/	O	['N']	[15]
16	DIHS	O	['N']	[16]
17	.	O	['N']	[17]
#489
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	cerebrospinal	O	['N']	[5]
6	fluid	O	['N']	[6]
7	eosinophilia	O	['N']	[7]
8	(	O	['N']	[8]
9	CSFE	B-Adverse_Effect	['N']	[9]
10	)	O	['N']	[10]
11	secondary	O	['N']	[11]
12	to	O	['N']	[12]
13	the	O	['N']	[13]
14	intraventricular	O	['N']	[14]
15	administration	O	['N']	[15]
16	of	O	['N']	[16]
17	vancomycin	B-Drug	['Causes']	[9]
18	.	O	['N']	[18]
#490
0	A	O	['N']	[0]
1	healthy	O	['N']	[1]
2	,	O	['N']	[2]
3	30-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	,	O	['N']	[7]
8	exposed	O	['N']	[8]
9	to	O	['N']	[9]
10	sulindac	B-Drug	['Causes']	[22]
11	on	O	['N']	[11]
12	two	O	['N']	[12]
13	separate	O	['N']	[13]
14	occasions	O	['N']	[14]
15	,	O	['N']	[15]
16	had	O	['N']	[16]
17	an	O	['N']	[17]
18	incapacitating	O	['N']	[18]
19	isolated	B	['N']	[19]
20	idential	I	['N']	[20]
21	sensory	I	['N']	[21]
22	neuropathy	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#491
0	A	O	['N']	[0]
1	36-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	being	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	cisplatinum	O	['N']	[8]
9	,	O	['N']	[9]
10	vinblastine	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	bleomycin	B-Drug	['Causes']	[24]
14	for	O	['N']	[14]
15	testicular	O	['N']	[15]
16	carcinoma	O	['N']	[16]
17	developed	O	['N']	[17]
18	a	O	['N']	[18]
19	dense	O	['N']	[19]
20	left	O	['N']	[20]
21	homonymous	O	['N']	[21]
22	hemianopsia	O	['N']	[22]
23	,	O	['N']	[23]
24	encephalopathy	B-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	a	O	['N']	[27]
28	partial	O	['N']	[28]
29	nondominant	O	['N']	[29]
30	parietal	O	['N']	[30]
31	lobe	O	['N']	[31]
32	syndrome	O	['N']	[32]
33	.	O	['N']	[33]
#492
0	Rifampin	O	['N']	[0]
1	(	O	['N']	[1]
2	RFP	B-Drug	['Causes']	[26]
3	)	O	['N']	[3]
4	increases	O	['N']	[4]
5	hepatic	O	['N']	[5]
6	microsomal	O	['N']	[6]
7	enzyme	O	['N']	[7]
8	activity	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	there	O	['N']	[11]
12	are	O	['N']	[12]
13	case	O	['N']	[13]
14	reports	O	['N']	[14]
15	of	O	['N']	[15]
16	RFP	O	['N']	[16]
17	-	O	['N']	[17]
18	induced	O	['N']	[18]
19	hypothyroidism	O	['N']	[19]
20	,	O	['N']	[20]
21	all	O	['N']	[21]
22	associated	O	['N']	[22]
23	with	O	['N']	[23]
24	Hashimoto	B	['N']	[24]
25	's	I	['N']	[25]
26	thyroiditis	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#493
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	7	O	['N']	[3]
4	patients	O	['N']	[4]
5	(	O	['N']	[5]
6	2	O	['N']	[6]
7	women	O	['N']	[7]
8	,	O	['N']	[8]
9	5	O	['N']	[9]
10	men	O	['N']	[10]
11	)	O	['N']	[11]
12	with	O	['N']	[12]
13	chronic	O	['N']	[13]
14	renal	O	['N']	[14]
15	failure	O	['N']	[15]
16	,	O	['N']	[16]
17	who	O	['N']	[17]
18	developed	O	['N']	[18]
19	under	O	['N']	[19]
20	a	O	['N']	[20]
21	high	B	['N']	[21]
22	dosage	I-Dose	['N']	[22]
23	of	O	['N']	[23]
24	the	O	['N']	[24]
25	new	O	['N']	[25]
26	diuretic	O	['N']	[26]
27	muzolimine	B-Drug	['Dosage']	[22]
28	(	O	['N']	[28]
29	range	O	['N']	[29]
30	240	O	['N']	[30]
31	to	O	['N']	[31]
32	1440	O	['N']	[32]
33	mg	O	['N']	[33]
34	per	O	['N']	[34]
35	day	O	['N']	[35]
36	)	O	['N']	[36]
37	fatal	O	['N']	[37]
38	neuromyeloencephalopathy	O	['N']	[38]
39	.	O	['N']	[39]
#494
0	We	O	['N']	[0]
1	consider	O	['N']	[1]
2	asterixis	O	['N']	[2]
3	to	O	['N']	[3]
4	be	O	['N']	[4]
5	an	O	['N']	[5]
6	easily	O	['N']	[6]
7	overlooked	O	['N']	[7]
8	sign	O	['N']	[8]
9	of	O	['N']	[9]
10	neurotoxicity	O	['N']	[10]
11	,	O	['N']	[11]
12	which	O	['N']	[12]
13	may	O	['N']	[13]
14	occur	O	['N']	[14]
15	even	O	['N']	[15]
16	at	O	['N']	[16]
17	low	B	['N']	[17]
18	or	I	['N']	[18]
19	moderate	I	['N']	[19]
20	dosage	I-Dose	['N']	[20]
21	levels	O	['N']	[21]
22	,	O	['N']	[22]
23	if	O	['N']	[23]
24	certain	O	['N']	[24]
25	drugs	O	['N']	[25]
26	as	O	['N']	[26]
27	lithium	O	['N']	[27]
28	or	O	['N']	[28]
29	clozapine	B-Drug	['Dosage']	[20]
30	are	O	['N']	[30]
31	used	O	['N']	[31]
32	in	O	['N']	[32]
33	combination	O	['N']	[33]
34	with	O	['N']	[34]
35	CBZ	O	['N']	[35]
36	.	O	['N']	[36]
#495
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	clinical	O	['N']	[3]
4	course	O	['N']	[4]
5	of	O	['N']	[5]
6	2	O	['N']	[6]
7	patients	O	['N']	[7]
8	with	O	['N']	[8]
9	Crohn	O	['N']	[9]
10	's	O	['N']	[10]
11	disease	O	['N']	[11]
12	(	O	['N']	[12]
13	CD	O	['N']	[13]
14	)	O	['N']	[14]
15	in	O	['N']	[15]
16	whom	O	['N']	[16]
17	lymphoma	B-Adverse_Effect	['N']	[17]
18	was	O	['N']	[18]
19	diagnosed	O	['N']	[19]
20	after	O	['N']	[20]
21	treatment	O	['N']	[21]
22	with	O	['N']	[22]
23	infliximab	B-Drug	['Causes']	[17]
24	.	O	['N']	[24]
#496
0	Risperidone	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	psychosis	B-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	depression	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	child	O	['N']	[8]
9	with	O	['N']	[9]
10	a	O	['N']	[10]
11	mitochondrial	O	['N']	[11]
12	disorder	O	['N']	[12]
13	.	O	['N']	[13]
#497
0	A	O	['N']	[0]
1	7-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	developed	O	['N']	[5]
6	a	O	['N']	[6]
7	severe	B	['N']	[7]
8	unilateral	I	['N']	[8]
9	grand	I	['N']	[9]
10	mal	I	['N']	[10]
11	seizure	I-Adverse_Effect	['N']	[11]
12	at	O	['N']	[12]
13	the	O	['N']	[13]
14	age	O	['N']	[14]
15	of	O	['N']	[15]
16	5	O	['N']	[16]
17	years	O	['N']	[17]
18	(	O	['N']	[18]
19	phenobarbitone	B-Drug	['Causes']	[11]
20	therapy	O	['N']	[20]
21	)	O	['N']	[21]
22	;	O	['N']	[22]
23	1.5	O	['N']	[23]
24	years	O	['N']	[24]
25	later	O	['N']	[25]
26	valproate	O	['N']	[26]
27	(	O	['N']	[27]
28	2-propylpentanoic	O	['N']	[28]
29	acid	O	['N']	[29]
30	,	O	['N']	[30]
31	VPA	O	['N']	[31]
32	)	O	['N']	[32]
33	was	O	['N']	[33]
34	added	O	['N']	[34]
35	to	O	['N']	[35]
36	the	O	['N']	[36]
37	therapy	O	['N']	[37]
38	.	O	['N']	[38]
#498
0	DIAGNOSIS	O	['N']	[0]
1	:	O	['N']	[1]
2	Severe	O	['N']	[2]
3	temozolomide	B-Drug	['Causes']	[37]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	immunosuppression	O	['N']	[6]
7	,	O	['N']	[7]
8	exacerbated	O	['N']	[8]
9	by	O	['N']	[9]
10	corticosteroids	O	['N']	[10]
11	,	O	['N']	[11]
12	with	O	['N']	[12]
13	profound	O	['N']	[13]
14	T	O	['N']	[14]
15	-	O	['N']	[15]
16	cell	O	['N']	[16]
17	lymphocytopenia	O	['N']	[17]
18	and	O	['N']	[18]
19	simultaneous	O	['N']	[19]
20	opportunistic	O	['N']	[20]
21	infections	O	['N']	[21]
22	with	O	['N']	[22]
23	Pneumocystis	O	['N']	[23]
24	jiroveci	O	['N']	[24]
25	pneumonia	O	['N']	[25]
26	,	O	['N']	[26]
27	brain	O	['N']	[27]
28	abscess	O	['N']	[28]
29	with	O	['N']	[29]
30	Listeria	O	['N']	[30]
31	monocytogenes	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	cutaneous	B	['N']	[34]
35	Kaposi	I	['N']	[35]
36	's	I	['N']	[36]
37	sarcoma	I-Adverse_Effect	['N']	[37]
38	.	O	['N']	[38]
#499
0	Hepatotoxicity	O	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	choline	O	['N']	[3]
4	magnesium	O	['N']	[4]
5	trisalicylate	-	['N']	[5]
6	:	O	['N']	[6]
7	case	O	['N']	[7]
8	report	O	['N']	[8]
9	and	O	['N']	[9]
10	review	O	['N']	[10]
11	of	O	['N']	[11]
12	salicylate	O	['N']	[12]
13	-	O	['N']	[13]
14	induced	O	['N']	[14]
15	hepatotoxicity	B-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#500
0	An	O	['N']	[0]
1	83-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	receiving	O	['N']	[5]
6	glipizide	O	['N']	[6]
7	10	B	['N']	[7]
8	mg	I-Dose	['N']	[8]
9	bid	O	['N']	[9]
10	developed	O	['N']	[10]
11	symptomatic	O	['N']	[11]
12	hypoglycemia	O	['N']	[12]
13	within	O	['N']	[13]
14	three	O	['N']	[14]
15	days	O	['N']	[15]
16	of	O	['N']	[16]
17	adding	O	['N']	[17]
18	trimethoprim	O	['N']	[18]
19	/	O	['N']	[19]
20	sulfamethoxazole	O	['N']	[20]
21	(	O	['N']	[21]
22	TMP	B-Drug	['Dosage']	[8]
23	/	O	['N']	[23]
24	SMX	O	['N']	[24]
25	)	O	['N']	[25]
26	to	O	['N']	[26]
27	his	O	['N']	[27]
28	regimen	O	['N']	[28]
29	.	O	['N']	[29]
#501
0	Mannitol	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	ARF	B-Adverse_Effect	['N']	[3]
4	responds	O	['N']	[4]
5	promptly	O	['N']	[5]
6	to	O	['N']	[6]
7	hemodialysis	O	['N']	[7]
8	with	O	['N']	[8]
9	rapid	O	['N']	[9]
10	resolution	O	['N']	[10]
11	of	O	['N']	[11]
12	anuria	O	['N']	[12]
13	and	O	['N']	[13]
14	recovery	O	['N']	[14]
15	of	O	['N']	[15]
16	renal	O	['N']	[16]
17	failure	O	['N']	[17]
18	.	O	['N']	[18]
#502
0	A	O	['N']	[0]
1	50-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	diabetic	O	['N']	[4]
5	and	O	['N']	[5]
6	hypertensive	O	['N']	[6]
7	male	O	['N']	[7]
8	patient	O	['N']	[8]
9	is	O	['N']	[9]
10	reported	O	['N']	[10]
11	who	O	['N']	[11]
12	had	O	['N']	[12]
13	ticlopidine	B-Drug	['Causes']	[17]
14	-	O	['N']	[14]
15	induced	O	['N']	[15]
16	marrow	B	['N']	[16]
17	aplasia	I-Adverse_Effect	['N']	[17]
18	partially	O	['N']	[18]
19	responsive	O	['N']	[19]
20	to	O	['N']	[20]
21	colony	O	['N']	[21]
22	-	O	['N']	[22]
23	stimulating	O	['N']	[23]
24	factors	O	['N']	[24]
25	and	O	['N']	[25]
26	corticosteroids	O	['N']	[26]
27	,	O	['N']	[27]
28	but	O	['N']	[28]
29	experienced	O	['N']	[29]
30	complete	O	['N']	[30]
31	recovery	O	['N']	[31]
32	with	O	['N']	[32]
33	cyclosporine	O	['N']	[33]
34	.	O	['N']	[34]
#503
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	the	O	['N']	[4]
5	clinical	O	['N']	[5]
6	course	O	['N']	[6]
7	of	O	['N']	[7]
8	a	O	['N']	[8]
9	woman	O	['N']	[9]
10	with	O	['N']	[10]
11	cryptococcal	O	['N']	[11]
12	meningitis	O	['N']	[12]
13	and	O	['N']	[13]
14	no	O	['N']	[14]
15	previous	O	['N']	[15]
16	cardiac	O	['N']	[16]
17	disease	O	['N']	[17]
18	who	O	['N']	[18]
19	developed	O	['N']	[19]
20	a	O	['N']	[20]
21	fatal	B	['N']	[21]
22	cardiac	I	['N']	[22]
23	arrhythmia	I-Adverse_Effect	['N']	[23]
24	after	O	['N']	[24]
25	an	O	['N']	[25]
26	acute	O	['N']	[26]
27	overdose	O	['N']	[27]
28	of	O	['N']	[28]
29	amphotericin	B	['N']	[29]
30	B	I-Drug	['Causes']	[23]
31	and	O	['N']	[31]
32	to	O	['N']	[32]
33	review	O	['N']	[33]
34	its	O	['N']	[34]
35	toxicity	O	['N']	[35]
36	.	O	['N']	[36]
#504
0	The	O	['N']	[0]
1	known	O	['N']	[1]
2	side	O	['N']	[2]
3	effects	O	['N']	[3]
4	of	O	['N']	[4]
5	sibutramine	B-Drug	['Causes']	[9]
6	,	O	['N']	[6]
7	ie	O	['N']	[7]
8	,	O	['N']	[8]
9	hypertension	B-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	tachycardia	O	['N']	[11]
12	,	O	['N']	[12]
13	depend	O	['N']	[13]
14	on	O	['N']	[14]
15	its	O	['N']	[15]
16	adrenergic	O	['N']	[16]
17	and	O	['N']	[17]
18	serotoninergic	O	['N']	[18]
19	effects	O	['N']	[19]
20	.	O	['N']	[20]
#505
0	After	O	['N']	[0]
1	treatment	O	['N']	[1]
2	with	O	['N']	[2]
3	cimetidine	B-Drug	['Causes']	[16]
4	,	O	['N']	[4]
5	there	O	['N']	[5]
6	was	O	['N']	[6]
7	a	O	['N']	[7]
8	rapid	O	['N']	[8]
9	deterioration	O	['N']	[9]
10	with	O	['N']	[10]
11	decreased	B	['N']	[11]
12	oxygen	I	['N']	[12]
13	saturation	I	['N']	[13]
14	and	I	['N']	[14]
15	arterial	I	['N']	[15]
16	PO2	I-Adverse_Effect	['N']	[16]
17	values	O	['N']	[17]
18	.	O	['N']	[18]
#506
0	The	O	['N']	[0]
1	fetal	O	['N']	[1]
2	valproate	B-Drug	['Causes']	[12]
3	syndrome	O	['N']	[3]
4	(	O	['N']	[4]
5	FVS	O	['N']	[5]
6	)	O	['N']	[6]
7	is	O	['N']	[7]
8	characterized	O	['N']	[8]
9	by	O	['N']	[9]
10	distinctive	B	['N']	[10]
11	facial	I	['N']	[11]
12	appearance	I-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	major	O	['N']	[14]
15	and	O	['N']	[15]
16	minor	O	['N']	[16]
17	malformations	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	developmental	O	['N']	[20]
21	delay	O	['N']	[21]
22	.	O	['N']	[22]
#507
0	We	O	['N']	[0]
1	conclude	O	['N']	[1]
2	that	O	['N']	[2]
3	the	O	['N']	[3]
4	presence	O	['N']	[4]
5	of	O	['N']	[5]
6	this	O	['N']	[6]
7	metabolic	O	['N']	[7]
8	defect	O	['N']	[8]
9	combined	O	['N']	[9]
10	with	O	['N']	[10]
11	topical	O	['N']	[11]
12	5-FU	B-Drug	['Causes']	[31]
13	(	O	['N']	[13]
14	a	O	['N']	[14]
15	drug	O	['N']	[15]
16	demonstrating	O	['N']	[16]
17	a	O	['N']	[17]
18	narrow	O	['N']	[18]
19	therapeutic	O	['N']	[19]
20	index	O	['N']	[20]
21	)	O	['N']	[21]
22	results	O	['N']	[22]
23	in	O	['N']	[23]
24	the	O	['N']	[24]
25	unusual	O	['N']	[25]
26	presentation	O	['N']	[26]
27	of	O	['N']	[27]
28	life	B	['N']	[28]
29	-	I	['N']	[29]
30	threatening	I	['N']	[30]
31	toxicity	I-Adverse_Effect	['N']	[31]
32	after	O	['N']	[32]
33	treatment	O	['N']	[33]
34	with	O	['N']	[34]
35	a	O	['N']	[35]
36	topical	O	['N']	[36]
37	drug	O	['N']	[37]
38	.	O	['N']	[38]
#508
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	here	O	['N']	[2]
3	a	O	['N']	[3]
4	26-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	female	O	['N']	[7]
8	with	O	['N']	[8]
9	diffuse	O	['N']	[9]
10	large	O	['N']	[10]
11	B	O	['N']	[11]
12	-	O	['N']	[12]
13	cell	O	['N']	[13]
14	lymphoma	O	['N']	[14]
15	who	O	['N']	[15]
16	died	O	['N']	[16]
17	of	O	['N']	[17]
18	severe	O	['N']	[18]
19	pulmonary	O	['N']	[19]
20	fibrosis	O	['N']	[20]
21	81	O	['N']	[21]
22	days	O	['N']	[22]
23	after	O	['N']	[23]
24	the	O	['N']	[24]
25	administration	O	['N']	[25]
26	of	O	['N']	[26]
27	high	B	['N']	[27]
28	-	I	['N']	[28]
29	dose	I-Dose	['N']	[29]
30	BCNU	B-Drug	['Dosage']	[29]
31	(	O	['N']	[31]
32	600	O	['N']	[32]
33	mg	O	['N']	[33]
34	/	O	['N']	[34]
35	m2	O	['N']	[35]
36	)	O	['N']	[36]
37	.	O	['N']	[37]
#509
0	Papilloedema	O	['N']	[0]
1	and	O	['N']	[1]
2	hepatic	B	['N']	[2]
3	dysfunction	I-Adverse_Effect	['N']	[3]
4	apparently	O	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	perhexiline	B	['N']	[7]
8	maleate	I-Drug	['Causes']	[3]
9	(	O	['N']	[9]
10	Pexid	O	['N']	[10]
11	)	O	['N']	[11]
12	.	O	['N']	[12]
#510
0	During	O	['N']	[0]
1	dose	O	['N']	[1]
2	-	O	['N']	[2]
3	finding	O	['N']	[3]
4	studies	O	['N']	[4]
5	for	O	['N']	[5]
6	intravenous	O	['N']	[6]
7	proton	O	['N']	[7]
8	pump	O	['N']	[8]
9	inhibitors	O	['N']	[9]
10	omeprazole	B-Drug	['Causes']	[31]
11	and	O	['N']	[11]
12	pantoprazole	O	['N']	[12]
13	,	O	['N']	[13]
14	three	O	['N']	[14]
15	of	O	['N']	[15]
16	six	O	['N']	[16]
17	young	O	['N']	[17]
18	female	O	['N']	[18]
19	volunteers	O	['N']	[19]
20	receiving	O	['N']	[20]
21	omeprazole	O	['N']	[21]
22	and	O	['N']	[22]
23	two	O	['N']	[23]
24	young	O	['N']	[24]
25	female	O	['N']	[25]
26	volunteers	O	['N']	[26]
27	receiving	O	['N']	[27]
28	pantoprazole	O	['N']	[28]
29	developed	O	['N']	[29]
30	peripheral	B	['N']	[30]
31	edema	I-Adverse_Effect	['N']	[31]
32	within	O	['N']	[32]
33	8	O	['N']	[33]
34	hr	O	['N']	[34]
35	when	O	['N']	[35]
36	high	O	['N']	[36]
37	doses	O	['N']	[37]
38	of	O	['N']	[38]
39	the	O	['N']	[39]
40	proton	O	['N']	[40]
41	pump	O	['N']	[41]
42	inhibitors	O	['N']	[42]
43	were	O	['N']	[43]
44	applied	O	['N']	[44]
45	by	O	['N']	[45]
46	continuous	O	['N']	[46]
47	infusion	O	['N']	[47]
48	together	O	['N']	[48]
49	with	O	['N']	[49]
50	large	O	['N']	[50]
51	volumes	O	['N']	[51]
52	of	O	['N']	[52]
53	fluid	O	['N']	[53]
54	.	O	['N']	[54]
#511
0	After	O	['N']	[0]
1	intravitreal	O	['N']	[1]
2	injection	O	['N']	[2]
3	of	O	['N']	[3]
4	triamcinolone	B	['N']	[4]
5	acetonide	I-Drug	['Causes']	[7]
6	,	O	['N']	[6]
7	cataract	B-Adverse_Effect	['N']	[7]
8	may	O	['N']	[8]
9	rapidly	O	['N']	[9]
10	develop	O	['N']	[10]
11	in	O	['N']	[11]
12	eyes	O	['N']	[12]
13	that	O	['N']	[13]
14	have	O	['N']	[14]
15	been	O	['N']	[15]
16	intensively	O	['N']	[16]
17	treated	O	['N']	[17]
18	,	O	['N']	[18]
19	topically	O	['N']	[19]
20	and	O	['N']	[20]
21	systemically	O	['N']	[21]
22	,	O	['N']	[22]
23	by	O	['N']	[23]
24	corticosteroids	O	['N']	[24]
25	for	O	['N']	[25]
26	several	O	['N']	[26]
27	years	O	['N']	[27]
28	.	O	['N']	[28]
#512
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	nitrofurantoin	B-Drug	['Causes']	[32]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	pulmonary	O	['N']	[8]
9	toxicity	O	['N']	[9]
10	in	O	['N']	[10]
11	which	O	['N']	[11]
12	the	O	['N']	[12]
13	initial	O	['N']	[13]
14	HRCT	O	['N']	[14]
15	showed	O	['N']	[15]
16	a	O	['N']	[16]
17	widespread	O	['N']	[17]
18	reticular	O	['N']	[18]
19	pattern	O	['N']	[19]
20	and	O	['N']	[20]
21	associated	O	['N']	[21]
22	distortion	O	['N']	[22]
23	of	O	['N']	[23]
24	the	O	['N']	[24]
25	lung	O	['N']	[25]
26	parenchyma	O	['N']	[26]
27	,	O	['N']	[27]
28	thought	O	['N']	[28]
29	to	O	['N']	[29]
30	represent	O	['N']	[30]
31	established	O	['N']	[31]
32	fibrosis	B-Adverse_Effect	['N']	[32]
33	.	O	['N']	[33]
#513
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	findings	O	['N']	[2]
3	from	O	['N']	[3]
4	three	O	['N']	[4]
5	patients	O	['N']	[5]
6	who	O	['N']	[6]
7	experienced	O	['N']	[7]
8	a	O	['N']	[8]
9	psoriasiform	B	['N']	[9]
10	eruption	I-Adverse_Effect	['N']	[10]
11	apparently	O	['N']	[11]
12	due	O	['N']	[12]
13	to	O	['N']	[13]
14	the	O	['N']	[14]
15	antiepileptic	O	['N']	[15]
16	agents	O	['N']	[16]
17	sodium	B	['N']	[17]
18	valproate	I-Drug	['Causes']	[10]
19	and	O	['N']	[19]
20	carbamazepine	O	['N']	[20]
21	.	O	['N']	[21]
#514
0	Goiter	O	['N']	[0]
1	and	O	['N']	[1]
2	hypothyroidism	B-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	re	O	['N']	[4]
5	-	O	['N']	[5]
6	treatment	O	['N']	[6]
7	with	O	['N']	[7]
8	amiodarone	B-Drug	['Causes']	[2]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	patient	O	['N']	[11]
12	who	O	['N']	[12]
13	previously	O	['N']	[13]
14	experienced	O	['N']	[14]
15	amiodarone	O	['N']	[15]
16	-	O	['N']	[16]
17	induced	O	['N']	[17]
18	thyrotoxicosis	O	['N']	[18]
19	.	O	['N']	[19]
#515
0	Extrapyramidal	B	['N']	[0]
1	side	I	['N']	[1]
2	effects	I-Adverse_Effect	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	some	O	['N']	[5]
6	selective	O	['N']	[6]
7	serotonin	O	['N']	[7]
8	reuptake	O	['N']	[8]
9	inhibitors	O	['N']	[9]
10	(	O	['N']	[10]
11	SSRIs	O	['N']	[11]
12	)	O	['N']	[12]
13	,	O	['N']	[13]
14	i.e.	O	['N']	[14]
15	fluoxetine	B-Drug	['Causes']	[2]
16	and	O	['N']	[16]
17	sertraline	O	['N']	[17]
18	,	O	['N']	[18]
19	have	O	['N']	[19]
20	been	O	['N']	[20]
21	previously	O	['N']	[21]
22	reported	O	['N']	[22]
23	in	O	['N']	[23]
24	patients	O	['N']	[24]
25	with	O	['N']	[25]
26	depression	O	['N']	[26]
27	and	O	['N']	[27]
28	obsessive	O	['N']	[28]
29	-	O	['N']	[29]
30	compulsive	O	['N']	[30]
31	disorder	O	['N']	[31]
32	(	O	['N']	[32]
33	OCD	O	['N']	[33]
34	)	O	['N']	[34]
35	.	O	['N']	[35]
#516
0	Controversy	O	['N']	[0]
1	concerning	O	['N']	[1]
2	the	O	['N']	[2]
3	nephrotoxicity	O	['N']	[3]
4	of	O	['N']	[4]
5	lithium	B-Drug	['Causes']	[16]
6	is	O	['N']	[6]
7	discussed	O	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	recommendations	O	['N']	[10]
11	for	O	['N']	[11]
12	the	O	['N']	[12]
13	evaluation	O	['N']	[13]
14	of	O	['N']	[14]
15	renal	B	['N']	[15]
16	failure	I-Adverse_Effect	['N']	[16]
17	during	O	['N']	[17]
18	lithium	O	['N']	[18]
19	therapy	O	['N']	[19]
20	are	O	['N']	[20]
21	provided	O	['N']	[21]
22	.	O	['N']	[22]
#517
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	these	O	['N']	[4]
5	cases	O	['N']	[5]
6	are	O	['N']	[6]
7	the	O	['N']	[7]
8	first	O	['N']	[8]
9	published	O	['N']	[9]
10	reports	O	['N']	[10]
11	of	O	['N']	[11]
12	lovastatin	O	['N']	[12]
13	-	O	['N']	[13]
14	induced	O	['N']	[14]
15	rhabdomyolysis	B-Adverse_Effect	['N']	[15]
16	associated	O	['N']	[16]
17	with	O	['N']	[17]
18	azithromycin	O	['N']	[18]
19	and	O	['N']	[19]
20	clarithromycin	B-Drug	['Causes']	[15]
21	.	O	['N']	[21]
#518
0	After	O	['N']	[0]
1	seven	O	['N']	[1]
2	months	O	['N']	[2]
3	'	O	['N']	[3]
4	continuous	O	['N']	[4]
5	treatment	O	['N']	[5]
6	for	O	['N']	[6]
7	suspected	O	['N']	[7]
8	tuberculosis	O	['N']	[8]
9	with	O	['N']	[9]
10	rifampicin	O	['N']	[10]
11	and	O	['N']	[11]
12	ethambutol	B-Drug	['Causes']	[33]
13	a	O	['N']	[13]
14	nine	O	['N']	[14]
15	-	O	['N']	[15]
16	year	O	['N']	[16]
17	-	O	['N']	[17]
18	old	O	['N']	[18]
19	boy	O	['N']	[19]
20	developed	O	['N']	[20]
21	polyarthritis	O	['N']	[21]
22	,	O	['N']	[22]
23	rash	O	['N']	[23]
24	and	O	['N']	[24]
25	hepatitis	O	['N']	[25]
26	in	O	['N']	[26]
27	association	O	['N']	[27]
28	with	O	['N']	[28]
29	anti	B	['N']	[29]
30	-	I	['N']	[30]
31	native	I	['N']	[31]
32	DNA	I	['N']	[32]
33	antibodies	I-Adverse_Effect	['N']	[33]
34	and	O	['N']	[34]
35	positive	O	['N']	[35]
36	antinuclear	O	['N']	[36]
37	factor	O	['N']	[37]
38	.	O	['N']	[38]
#519
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	fatal	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	subacute	O	['N']	[6]
7	methanol	B-Drug	['Causes']	[24]
8	toxicity	O	['N']	[8]
9	with	O	['N']	[9]
10	associated	O	['N']	[10]
11	diffuse	O	['N']	[11]
12	brain	O	['N']	[12]
13	involvement	O	['N']	[13]
14	,	O	['N']	[14]
15	including	O	['N']	[15]
16	bilateral	O	['N']	[16]
17	putaminal	O	['N']	[17]
18	necrosis	O	['N']	[18]
19	and	O	['N']	[19]
20	cerebral	O	['N']	[20]
21	edema	O	['N']	[21]
22	with	O	['N']	[22]
23	ventricular	B	['N']	[23]
24	compression	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#520
0	While	O	['N']	[0]
1	the	O	['N']	[1]
2	mechanism	O	['N']	[2]
3	of	O	['N']	[3]
4	dextran	B-Drug	['Causes']	[8]
5	-	O	['N']	[5]
6	associated	O	['N']	[6]
7	renal	B	['N']	[7]
8	failure	I-Adverse_Effect	['N']	[8]
9	remains	O	['N']	[9]
10	unsolved	O	['N']	[10]
11	,	O	['N']	[11]
12	plasma	O	['N']	[12]
13	exchange	O	['N']	[13]
14	seems	O	['N']	[14]
15	to	O	['N']	[15]
16	be	O	['N']	[16]
17	effective	O	['N']	[17]
18	therapy	O	['N']	[18]
19	.	O	['N']	[19]
#521
0	Deposits	B	['N']	[0]
1	of	I	['N']	[1]
2	plasma	I	['N']	[2]
3	proteins	I	['N']	[3]
4	in	I	['N']	[4]
5	the	I	['N']	[5]
6	skin	I-Adverse_Effect	['N']	[6]
7	during	O	['N']	[7]
8	treatment	O	['N']	[8]
9	with	O	['N']	[9]
10	carbamazepine	B-Drug	['Causes']	[6]
11	and	O	['N']	[11]
12	diphenylhydantoin	O	['N']	[12]
13	.	O	['N']	[13]
#522
0	The	O	['N']	[0]
1	electrocardiogram	O	['N']	[1]
2	(	O	['N']	[2]
3	ECG	O	['N']	[3]
4	)	O	['N']	[4]
5	,	O	['N']	[5]
6	which	O	['N']	[6]
7	was	O	['N']	[7]
8	read	O	['N']	[8]
9	as	O	['N']	[9]
10	normal	O	['N']	[10]
11	prior	O	['N']	[11]
12	to	O	['N']	[12]
13	ritodrine	B-Drug	['Causes']	[24]
14	infusion	O	['N']	[14]
15	,	O	['N']	[15]
16	demonstrated	O	['N']	[16]
17	a	O	['N']	[17]
18	type	B	['N']	[18]
19	I	I	['N']	[19]
20	second	I	['N']	[20]
21	-	I	['N']	[21]
22	degree	I	['N']	[22]
23	AV	I	['N']	[23]
24	block	I-Adverse_Effect	['N']	[24]
25	which	O	['N']	[25]
26	disappeared	O	['N']	[26]
27	upon	O	['N']	[27]
28	discontinuation	O	['N']	[28]
29	of	O	['N']	[29]
30	ritodrine	O	['N']	[30]
31	therapy	O	['N']	[31]
32	.	O	['N']	[32]
#523
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	is	O	['N']	[2]
3	presented	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	experienced	O	['N']	[8]
9	benzodiazepine	B	['N']	[9]
10	withdrawal	I	['N']	[10]
11	symptoms	I-Adverse_Effect	['N']	[11]
12	on	O	['N']	[12]
13	discontinuation	O	['N']	[13]
14	of	O	['N']	[14]
15	nefazodone	B-Drug	['Causes']	[11]
16	,	O	['N']	[16]
17	an	O	['N']	[17]
18	antidepressant	O	['N']	[18]
19	that	O	['N']	[19]
20	inhibits	O	['N']	[20]
21	the	O	['N']	[21]
22	cytochrome	O	['N']	[22]
23	P450	O	['N']	[23]
24	3A4	O	['N']	[24]
25	isoenzyme	O	['N']	[25]
26	.	O	['N']	[26]
#524
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	pediatric	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	leukemia	O	['N']	[6]
7	and	O	['N']	[7]
8	a	O	['N']	[8]
9	severe	O	['N']	[9]
10	,	O	['N']	[10]
11	L	B	['N']	[11]
12	-	I	['N']	[12]
13	asparaginase	I-Drug	['Causes']	[17]
14	-	O	['N']	[14]
15	induced	O	['N']	[15]
16	necrotizing	B	['N']	[16]
17	pancreatitis	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	treated	O	['N']	[19]
20	successfully	O	['N']	[20]
21	with	O	['N']	[21]
22	percutaneous	O	['N']	[22]
23	drainage	O	['N']	[23]
24	used	O	['N']	[24]
25	to	O	['N']	[25]
26	flush	O	['N']	[26]
27	the	O	['N']	[27]
28	infected	O	['N']	[28]
29	necrotic	O	['N']	[29]
30	parts	O	['N']	[30]
31	.	O	['N']	[31]
#525
0	Carbamyl	O	['N']	[0]
1	phosphate	O	['N']	[1]
2	synthetase-1	O	['N']	[2]
3	deficiency	O	['N']	[3]
4	discovered	O	['N']	[4]
5	after	O	['N']	[5]
6	valproic	B	['N']	[6]
7	acid	I-Drug	['Causes']	[10]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	coma	B-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#526
0	Although	O	['N']	[0]
1	they	O	['N']	[1]
2	had	O	['N']	[2]
3	complex	O	['N']	[3]
4	medical	O	['N']	[4]
5	problems	O	['N']	[5]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	high	O	['N']	[8]
9	serum	O	['N']	[9]
10	concentrations	O	['N']	[10]
11	of	O	['N']	[11]
12	ampicillin	B-Drug	['Causes']	[17]
13	at	O	['N']	[13]
14	the	O	['N']	[14]
15	time	O	['N']	[15]
16	of	O	['N']	[16]
17	seizures	B-Adverse_Effect	['N']	[17]
18	without	O	['N']	[18]
19	their	O	['N']	[19]
20	recurrence	O	['N']	[20]
21	after	O	['N']	[21]
22	discontinuing	O	['N']	[22]
23	the	O	['N']	[23]
24	antibiotic	O	['N']	[24]
25	suggest	O	['N']	[25]
26	that	O	['N']	[26]
27	the	O	['N']	[27]
28	seizures	O	['N']	[28]
29	were	O	['N']	[29]
30	related	O	['N']	[30]
31	to	O	['N']	[31]
32	the	O	['N']	[32]
33	ampicillin	O	['N']	[33]
34	therapy	O	['N']	[34]
35	.	O	['N']	[35]
#527
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	43-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	sore	O	['N']	[9]
10	throat	O	['N']	[10]
11	,	O	['N']	[11]
12	swelling	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	lips	O	['N']	[15]
16	and	O	['N']	[16]
17	oral	O	['N']	[17]
18	cavity	O	['N']	[18]
19	and	O	['N']	[19]
20	dysphagia	B-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	2	O	['N']	[22]
23	weeks	O	['N']	[23]
24	after	O	['N']	[24]
25	the	O	['N']	[25]
26	use	O	['N']	[26]
27	of	O	['N']	[27]
28	budesonide	O	['N']	[28]
29	spray	O	['N']	[29]
30	(	O	['N']	[30]
31	Budefat	B-Drug	['Causes']	[20]
32	)	O	['N']	[32]
33	for	O	['N']	[33]
34	treatment	O	['N']	[34]
35	of	O	['N']	[35]
36	bronchial	O	['N']	[36]
37	asthma	O	['N']	[37]
38	.	O	['N']	[38]
#528
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	we	O	['N']	[3]
4	present	O	['N']	[4]
5	four	O	['N']	[5]
6	patients	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	combination	O	['N']	[10]
11	of	O	['N']	[11]
12	different	O	['N']	[12]
13	psychotropic	O	['N']	[13]
14	drugs	O	['N']	[14]
15	,	O	['N']	[15]
16	in	O	['N']	[16]
17	whom	O	['N']	[17]
18	asterixis	B-Adverse_Effect	['N']	[18]
19	was	O	['N']	[19]
20	triggered	O	['N']	[20]
21	either	O	['N']	[21]
22	by	O	['N']	[22]
23	adding	O	['N']	[23]
24	carbamazepine	O	['N']	[24]
25	(	O	['N']	[25]
26	CBZ	B-Drug	['Causes']	[18]
27	)	O	['N']	[27]
28	to	O	['N']	[28]
29	a	O	['N']	[29]
30	treatment	O	['N']	[30]
31	regimen	O	['N']	[31]
32	,	O	['N']	[32]
33	or	O	['N']	[33]
34	by	O	['N']	[34]
35	increasing	O	['N']	[35]
36	its	O	['N']	[36]
37	dosage	O	['N']	[37]
38	.	O	['N']	[38]
#529
0	Rapid	O	['N']	[0]
1	resolution	O	['N']	[1]
2	of	O	['N']	[2]
3	topiramate	O	['N']	[3]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	angle	B	['N']	[6]
7	-	I	['N']	[7]
8	closure	I	['N']	[8]
9	glaucoma	I-Adverse_Effect	['N']	[9]
10	with	O	['N']	[10]
11	methylprednisolone	O	['N']	[11]
12	and	O	['N']	[12]
13	mannitol	B-Drug	['Causes']	[9]
14	.	O	['N']	[14]
#530
0	Our	O	['N']	[0]
1	cases	O	['N']	[1]
2	constitute	O	['N']	[2]
3	the	O	['N']	[3]
4	most	O	['N']	[4]
5	severe	O	['N']	[5]
6	cases	O	['N']	[6]
7	of	O	['N']	[7]
8	benzarone	B-Drug	['Causes']	[22]
9	hepatotoxicity	O	['N']	[9]
10	reported	O	['N']	[10]
11	so	O	['N']	[11]
12	far	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	comprise	O	['N']	[15]
16	the	O	['N']	[16]
17	first	O	['N']	[17]
18	cases	O	['N']	[18]
19	of	O	['N']	[19]
20	(	B	['N']	[20]
21	sub)fulminant	I	['N']	[21]
22	hepatitis	I-Adverse_Effect	['N']	[22]
23	and	O	['N']	[23]
24	cirrhosis	O	['N']	[24]
25	related	O	['N']	[25]
26	to	O	['N']	[26]
27	benzarone	O	['N']	[27]
28	.	O	['N']	[28]
#531
0	In	O	['N']	[0]
1	a	O	['N']	[1]
2	patient	O	['N']	[2]
3	suffering	O	['N']	[3]
4	from	O	['N']	[4]
5	rheumatoid	O	['N']	[5]
6	arthritis	O	['N']	[6]
7	,	O	['N']	[7]
8	we	O	['N']	[8]
9	report	O	['N']	[9]
10	the	O	['N']	[10]
11	first	O	['N']	[11]
12	simultaneous	O	['N']	[12]
13	occurrence	O	['N']	[13]
14	of	O	['N']	[14]
15	two	O	['N']	[15]
16	side	O	['N']	[16]
17	effects	O	['N']	[17]
18	of	O	['N']	[18]
19	low	O	['N']	[19]
20	-	O	['N']	[20]
21	dose	O	['N']	[21]
22	methotrexate	B-Drug	['Causes']	[30]
23	:	O	['N']	[23]
24	an	O	['N']	[24]
25	acute	O	['N']	[25]
26	megaloblastic	O	['N']	[26]
27	anaemia	O	['N']	[27]
28	and	O	['N']	[28]
29	a	O	['N']	[29]
30	pneumonitis	B-Adverse_Effect	['N']	[30]
31	.	O	['N']	[31]
#532
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Amphotericin	B	['N']	[2]
3	B	I	['N']	[3]
4	deoxycholate	I-Drug	['Causes']	[12]
5	has	O	['N']	[5]
6	been	O	['N']	[6]
7	reported	O	['N']	[7]
8	to	O	['N']	[8]
9	produce	O	['N']	[9]
10	significant	O	['N']	[10]
11	cardiac	B	['N']	[11]
12	toxicity	I-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	with	O	['N']	[14]
15	ventricular	O	['N']	[15]
16	arrhythmias	O	['N']	[16]
17	and	O	['N']	[17]
18	bradycardia	O	['N']	[18]
19	reported	O	['N']	[19]
20	in	O	['N']	[20]
21	overdoses	O	['N']	[21]
22	in	O	['N']	[22]
23	children	O	['N']	[23]
24	and	O	['N']	[24]
25	in	O	['N']	[25]
26	adults	O	['N']	[26]
27	with	O	['N']	[27]
28	preexisting	O	['N']	[28]
29	cardiac	O	['N']	[29]
30	disease	O	['N']	[30]
31	,	O	['N']	[31]
32	even	O	['N']	[32]
33	when	O	['N']	[33]
34	administered	O	['N']	[34]
35	in	O	['N']	[35]
36	conventional	O	['N']	[36]
37	dosages	O	['N']	[37]
38	and	O	['N']	[38]
39	infusion	O	['N']	[39]
40	rates	O	['N']	[40]
41	.	O	['N']	[41]
#533
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	40-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	fulminant	O	['N']	[12]
13	hepatic	O	['N']	[13]
14	failure	O	['N']	[14]
15	and	O	['N']	[15]
16	aplastic	B	['N']	[16]
17	anaemia	I-Adverse_Effect	['N']	[17]
18	following	O	['N']	[18]
19	a	O	['N']	[19]
20	course	O	['N']	[20]
21	of	O	['N']	[21]
22	oral	O	['N']	[22]
23	flucloxacillin	B-Drug	['Causes']	[17]
24	.	O	['N']	[24]
#534
0	Asterixis	B-Adverse_Effect	['N']	[0]
1	induced	O	['N']	[1]
2	by	O	['N']	[2]
3	carbamazepine	B-Drug	['Causes']	[0]
4	therapy	O	['N']	[4]
5	.	O	['N']	[5]
#535
0	On	O	['N']	[0]
1	day	O	['N']	[1]
2	7	O	['N']	[2]
3	of	O	['N']	[3]
4	linezolid	B-Drug	['Causes']	[17]
5	treatment	O	['N']	[5]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	patient	O	['N']	[8]
9	developed	O	['N']	[9]
10	severe	O	['N']	[10]
11	pruritus	O	['N']	[11]
12	,	O	['N']	[12]
13	macular	O	['N']	[13]
14	rash	O	['N']	[14]
15	,	O	['N']	[15]
16	facial	B	['N']	[16]
17	edema	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	eosinophilia	O	['N']	[19]
20	,	O	['N']	[20]
21	marked	O	['N']	[21]
22	increase	O	['N']	[22]
23	in	O	['N']	[23]
24	serum	O	['N']	[24]
25	creatinine	O	['N']	[25]
26	level	O	['N']	[26]
27	,	O	['N']	[27]
28	and	O	['N']	[28]
29	mild	O	['N']	[29]
30	hepatitis	O	['N']	[30]
31	.	O	['N']	[31]
#536
0	Carboplatin	O	['N']	[0]
1	hypersensitivity	B-Adverse_Effect	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	low	O	['N']	[4]
5	-	O	['N']	[5]
6	dose	O	['N']	[6]
7	paclitaxel	O	['N']	[7]
8	/	O	['N']	[8]
9	carboplatin	B-Drug	['Causes']	[1]
10	in	O	['N']	[10]
11	multiple	O	['N']	[11]
12	platinum	O	['N']	[12]
13	-	O	['N']	[13]
14	treated	O	['N']	[14]
15	patients	O	['N']	[15]
16	with	O	['N']	[16]
17	recurrent	O	['N']	[17]
18	ovarian	O	['N']	[18]
19	cancer	O	['N']	[19]
20	.	O	['N']	[20]
#537
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	two	O	['N']	[2]
3	dark	O	['N']	[3]
4	-	O	['N']	[4]
5	skinned	O	['N']	[5]
6	patients	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	hyperpigmented	B	['N']	[9]
10	skin	I-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	tongue	O	['N']	[12]
13	lesions	O	['N']	[13]
14	during	O	['N']	[14]
15	combination	O	['N']	[15]
16	therapy	O	['N']	[16]
17	with	O	['N']	[17]
18	IFN	B-Drug	['Causes']	[10]
19	and	O	['N']	[19]
20	ribavirin	O	['N']	[20]
21	.	O	['N']	[21]
#538
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	seropositive	O	['N']	[3]
4	rheumatoid	O	['N']	[4]
5	arthritis	O	['N']	[5]
6	developed	O	['N']	[6]
7	ascites	B-Adverse_Effect	['N']	[7]
8	while	O	['N']	[8]
9	taking	O	['N']	[9]
10	weekly	O	['N']	[10]
11	doses	O	['N']	[11]
12	of	O	['N']	[12]
13	methotrexate	B-Drug	['Causes']	[7]
14	(	O	['N']	[14]
15	MTX	O	['N']	[15]
16	)	O	['N']	[16]
17	.	O	['N']	[17]
#539
0	Two	O	['N']	[0]
1	65-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	white	O	['N']	[4]
5	men	O	['N']	[5]
6	with	O	['N']	[6]
7	coronary	O	['N']	[7]
8	heart	O	['N']	[8]
9	disease	O	['N']	[9]
10	,	O	['N']	[10]
11	given	O	['N']	[11]
12	niacin	B-Drug	['Causes']	[25]
13	therapy	O	['N']	[13]
14	for	O	['N']	[14]
15	dyslipidemia	O	['N']	[15]
16	for	O	['N']	[16]
17	5	O	['N']	[17]
18	months	O	['N']	[18]
19	,	O	['N']	[19]
20	developed	O	['N']	[20]
21	intense	B	['N']	[21]
22	dental	I	['N']	[22]
23	and	I	['N']	[23]
24	gingival	I	['N']	[24]
25	pain	I-Adverse_Effect	['N']	[25]
26	that	O	['N']	[26]
27	was	O	['N']	[27]
28	associated	O	['N']	[28]
29	with	O	['N']	[29]
30	increases	O	['N']	[30]
31	in	O	['N']	[31]
32	dose	O	['N']	[32]
33	and	O	['N']	[33]
34	that	O	['N']	[34]
35	was	O	['N']	[35]
36	relieved	O	['N']	[36]
37	with	O	['N']	[37]
38	discontinuance	O	['N']	[38]
39	of	O	['N']	[39]
40	niacin	O	['N']	[40]
41	treatment	O	['N']	[41]
42	.	O	['N']	[42]
#540
0	Splenic	B	['N']	[0]
1	hemorrhage	I-Adverse_Effect	['N']	[1]
2	:	O	['N']	[2]
3	a	O	['N']	[3]
4	complication	O	['N']	[4]
5	of	O	['N']	[5]
6	tissue	B	['N']	[6]
7	plasminogen	I	['N']	[7]
8	activator	I-Drug	['Causes']	[1]
9	treatment	O	['N']	[9]
10	.	O	['N']	[10]
#541
0	A	O	['N']	[0]
1	MEDLINE	O	['N']	[1]
2	search	O	['N']	[2]
3	identified	O	['N']	[3]
4	all	O	['N']	[4]
5	the	O	['N']	[5]
6	reported	O	['N']	[6]
7	cases	O	['N']	[7]
8	of	O	['N']	[8]
9	hypersensitivity	B	['N']	[9]
10	reactions	I-Adverse_Effect	['N']	[10]
11	to	O	['N']	[11]
12	cyclosporine	B-Drug	['Causes']	[10]
13	.	O	['N']	[13]
#542
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	fulminant	O	['N']	[6]
7	adult	B	['N']	[7]
8	respiratory	I	['N']	[8]
9	distress	I	['N']	[9]
10	syndrome	I-Adverse_Effect	['N']	[10]
11	(	O	['N']	[11]
12	ARDS	O	['N']	[12]
13	)	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	pegylated	B	['N']	[16]
17	interferon	I	['N']	[17]
18	alpha-2a	I-Drug	['Causes']	[10]
19	(	O	['N']	[19]
20	pegIFNalpha-2a	O	['N']	[20]
21	)	O	['N']	[21]
22	and	O	['N']	[22]
23	ribavirin	O	['N']	[23]
24	use	O	['N']	[24]
25	for	O	['N']	[25]
26	hepatitis	O	['N']	[26]
27	C	O	['N']	[27]
28	,	O	['N']	[28]
29	complicated	O	['N']	[29]
30	by	O	['N']	[30]
31	subsequent	O	['N']	[31]
32	and	O	['N']	[32]
33	ultimately	O	['N']	[33]
34	fatal	O	['N']	[34]
35	sepsis	O	['N']	[35]
36	and	O	['N']	[36]
37	multiorgan	O	['N']	[37]
38	failure	O	['N']	[38]
39	.	O	['N']	[39]
#543
0	The	O	['N']	[0]
1	temporal	O	['N']	[1]
2	sequence	O	['N']	[2]
3	of	O	['N']	[3]
4	the	O	['N']	[4]
5	respiratory	B	['N']	[5]
6	insufficiency	I-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	the	O	['N']	[8]
9	histopathology	O	['N']	[9]
10	,	O	['N']	[10]
11	when	O	['N']	[11]
12	compared	O	['N']	[12]
13	to	O	['N']	[13]
14	the	O	['N']	[14]
15	previous	O	['N']	[15]
16	examples	O	['N']	[16]
17	in	O	['N']	[17]
18	the	O	['N']	[18]
19	literature	O	['N']	[19]
20	,	O	['N']	[20]
21	suggest	O	['N']	[21]
22	that	O	['N']	[22]
23	cyclophosphamide	B-Drug	['Causes']	[6]
24	was	O	['N']	[24]
25	aetiologically	O	['N']	[25]
26	responsible	O	['N']	[26]
27	for	O	['N']	[27]
28	the	O	['N']	[28]
29	lung	O	['N']	[29]
30	disease	O	['N']	[30]
31	.	O	['N']	[31]
#544
0	Quinine	B-Drug	['Causes']	[12]
1	and	O	['N']	[1]
2	its	O	['N']	[2]
3	isomer	O	['N']	[3]
4	quinidine	O	['N']	[4]
5	are	O	['N']	[5]
6	well	O	['N']	[6]
7	-	O	['N']	[7]
8	known	O	['N']	[8]
9	causes	O	['N']	[9]
10	of	O	['N']	[10]
11	iatrogenic	B	['N']	[11]
12	hypoglycaemia	I-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	due	O	['N']	[14]
15	to	O	['N']	[15]
16	excessive	O	['N']	[16]
17	insulin	O	['N']	[17]
18	secretion	O	['N']	[18]
19	.	O	['N']	[19]
#545
0	Tardive	B	['N']	[0]
1	oculogyric	I	['N']	[1]
2	crisis	I-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	treatment	O	['N']	[4]
5	with	O	['N']	[5]
6	clozapine	B-Drug	['Causes']	[2]
7	:	O	['N']	[7]
8	report	O	['N']	[8]
9	of	O	['N']	[9]
10	three	O	['N']	[10]
11	cases	O	['N']	[11]
12	.	O	['N']	[12]
#546
0	A	O	['N']	[0]
1	33-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	male	O	['N']	[4]
5	presented	O	['N']	[5]
6	with	O	['N']	[6]
7	brown	B	['N']	[7]
8	discolouration	I	['N']	[8]
9	of	I	['N']	[9]
10	the	I	['N']	[10]
11	fingernails	I-Adverse_Effect	['N']	[11]
12	following	O	['N']	[12]
13	the	O	['N']	[13]
14	application	O	['N']	[14]
15	of	O	['N']	[15]
16	4	B	['N']	[16]
17	%	I	['N']	[17]
18	hydroquinone	I	['N']	[18]
19	in	I	['N']	[19]
20	sorbolene	I	['N']	[20]
21	cream	I-Drug	['Causes']	[11]
22	and	O	['N']	[22]
23	0.1	O	['N']	[23]
24	%	O	['N']	[24]
25	tretinoin	O	['N']	[25]
26	cream	O	['N']	[26]
27	to	O	['N']	[27]
28	the	O	['N']	[28]
29	face	O	['N']	[29]
30	intermittently	O	['N']	[30]
31	for	O	['N']	[31]
32	9	O	['N']	[32]
33	months	O	['N']	[33]
34	.	O	['N']	[34]
#547
0	In	O	['N']	[0]
1	summary	O	['N']	[1]
2	,	O	['N']	[2]
3	we	O	['N']	[3]
4	report	O	['N']	[4]
5	herein	O	['N']	[5]
6	the	O	['N']	[6]
7	first	O	['N']	[7]
8	case	O	['N']	[8]
9	of	O	['N']	[9]
10	SIADH	B-Adverse_Effect	['N']	[10]
11	believed	O	['N']	[11]
12	to	O	['N']	[12]
13	be	O	['N']	[13]
14	an	O	['N']	[14]
15	adverse	O	['N']	[15]
16	effect	O	['N']	[16]
17	of	O	['N']	[17]
18	mizoribin	B-Drug	['Causes']	[10]
19	,	O	['N']	[19]
20	which	O	['N']	[20]
21	may	O	['N']	[21]
22	therefore	O	['N']	[22]
23	needed	O	['N']	[23]
24	to	O	['N']	[24]
25	be	O	['N']	[25]
26	added	O	['N']	[26]
27	to	O	['N']	[27]
28	the	O	['N']	[28]
29	list	O	['N']	[29]
30	of	O	['N']	[30]
31	drugs	O	['N']	[31]
32	which	O	['N']	[32]
33	can	O	['N']	[33]
34	induce	O	['N']	[34]
35	SIADH	O	['N']	[35]
36	.	O	['N']	[36]
#548
0	Cholesterol	O	['N']	[0]
1	crystal	O	['N']	[1]
2	embolization	O	['N']	[2]
3	-	O	['N']	[3]
4	associated	O	['N']	[4]
5	renal	B	['N']	[5]
6	failure	I-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	therapy	O	['N']	[8]
9	with	O	['N']	[9]
10	recombinant	O	['N']	[10]
11	tissue	B	['N']	[11]
12	-	I	['N']	[12]
13	type	I	['N']	[13]
14	plasminogen	I	['N']	[14]
15	activator	I-Drug	['Causes']	[6]
16	.	O	['N']	[16]
#549
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	idiopathic	O	['N']	[5]
6	RLS	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	augmentation	B-Adverse_Effect	['N']	[9]
10	after	O	['N']	[10]
11	8	O	['N']	[11]
12	months	O	['N']	[12]
13	of	O	['N']	[13]
14	levodopa	B-Drug	['Causes']	[9]
15	treatment	O	['N']	[15]
16	.	O	['N']	[16]
#550
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	44-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	with	O	['N']	[7]
8	t	O	['N']	[8]
9	-	O	['N']	[9]
10	MDS	O	['N']	[10]
11	(	O	['N']	[11]
12	refractory	B	['N']	[12]
13	anemia	I	['N']	[13]
14	with	I	['N']	[14]
15	excess	I	['N']	[15]
16	blasts	I-Adverse_Effect	['N']	[16]
17	)	O	['N']	[17]
18	following	O	['N']	[18]
19	treatment	O	['N']	[19]
20	of	O	['N']	[20]
21	recurrent	O	['N']	[21]
22	anaplastic	O	['N']	[22]
23	astrocytoma	O	['N']	[23]
24	with	O	['N']	[24]
25	temozolomide	O	['N']	[25]
26	(	O	['N']	[26]
27	TMZ	B-Drug	['Causes']	[16]
28	)	O	['N']	[28]
29	.	O	['N']	[29]
#551
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	ovarian	O	['N']	[3]
4	cancer	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	received	O	['N']	[7]
8	multiple	O	['N']	[8]
9	courses	O	['N']	[9]
10	of	O	['N']	[10]
11	cisplatin	B-Drug	['Causes']	[31]
12	without	O	['N']	[12]
13	complications	O	['N']	[13]
14	experienced	O	['N']	[14]
15	hypersensitivity	O	['N']	[15]
16	reactions	O	['N']	[16]
17	to	O	['N']	[17]
18	cisplatin	O	['N']	[18]
19	:	O	['N']	[19]
20	one	O	['N']	[20]
21	,	O	['N']	[21]
22	involving	O	['N']	[22]
23	intrahepatic	O	['N']	[23]
24	artery	O	['N']	[24]
25	infusion	O	['N']	[25]
26	,	O	['N']	[26]
27	manifested	O	['N']	[27]
28	general	O	['N']	[28]
29	erythema	O	['N']	[29]
30	,	O	['N']	[30]
31	dyspnea	B-Adverse_Effect	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	hypotension	O	['N']	[34]
35	;	O	['N']	[35]
36	the	O	['N']	[36]
37	other	O	['N']	[37]
38	,	O	['N']	[38]
39	involving	O	['N']	[39]
40	intravenous	O	['N']	[40]
41	infusion	O	['N']	[41]
42	,	O	['N']	[42]
43	manifested	O	['N']	[43]
44	abdominal	O	['N']	[44]
45	pain	O	['N']	[45]
46	,	O	['N']	[46]
47	general	O	['N']	[47]
48	erythema	O	['N']	[48]
49	,	O	['N']	[49]
50	and	O	['N']	[50]
51	fever	O	['N']	[51]
52	.	O	['N']	[52]
#552
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	had	O	['N']	[2]
3	recurrence	O	['N']	[3]
4	of	O	['N']	[4]
5	urticaria	O	['N']	[5]
6	and	O	['N']	[6]
7	angioedema	B-Adverse_Effect	['N']	[7]
8	a	O	['N']	[8]
9	year	O	['N']	[9]
10	and	O	['N']	[10]
11	a	O	['N']	[11]
12	half	O	['N']	[12]
13	later	O	['N']	[13]
14	,	O	['N']	[14]
15	at	O	['N']	[15]
16	which	O	['N']	[16]
17	point	O	['N']	[17]
18	the	O	['N']	[18]
19	NPH	O	['N']	[19]
20	was	O	['N']	[20]
21	stopped	O	['N']	[21]
22	and	O	['N']	[22]
23	she	O	['N']	[23]
24	was	O	['N']	[24]
25	desensitized	O	['N']	[25]
26	to	O	['N']	[26]
27	regular	O	['N']	[27]
28	insulin	B-Drug	['Causes']	[7]
29	.	O	['N']	[29]
#553
0	A	O	['N']	[0]
1	search	O	['N']	[1]
2	of	O	['N']	[2]
3	the	O	['N']	[3]
4	United	O	['N']	[4]
5	States	O	['N']	[5]
6	Food	O	['N']	[6]
7	and	O	['N']	[7]
8	Drug	O	['N']	[8]
9	Administration	O	['N']	[9]
10	's	O	['N']	[10]
11	Adverse	O	['N']	[11]
12	Event	O	['N']	[12]
13	Reporting	O	['N']	[13]
14	System	O	['N']	[14]
15	identified	O	['N']	[15]
16	nine	O	['N']	[16]
17	cases	O	['N']	[17]
18	of	O	['N']	[18]
19	oxcarbazepine	B-Drug	['Causes']	[22]
20	-	O	['N']	[20]
21	associated	O	['N']	[21]
22	angioedema	B-Adverse_Effect	['N']	[22]
23	in	O	['N']	[23]
24	pediatric	O	['N']	[24]
25	patients	O	['N']	[25]
26	aged	O	['N']	[26]
27	16	O	['N']	[27]
28	years	O	['N']	[28]
29	and	O	['N']	[29]
30	younger	O	['N']	[30]
31	.	O	['N']	[31]
#554
0	An	O	['N']	[0]
1	amiodarone	B-Drug	['Causes']	[3]
2	optic	B	['N']	[2]
3	neuropathy	I-Adverse_Effect	['N']	[3]
4	has	O	['N']	[4]
5	been	O	['N']	[5]
6	described	O	['N']	[6]
7	.	O	['N']	[7]
#555
0	Methimazole	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	cholestatic	B	['N']	[3]
4	liver	I	['N']	[4]
5	injury	I-Adverse_Effect	['N']	[5]
6	:	O	['N']	[6]
7	case	O	['N']	[7]
8	report	O	['N']	[8]
9	and	O	['N']	[9]
10	brief	O	['N']	[10]
11	literature	O	['N']	[11]
12	review	O	['N']	[12]
13	.	O	['N']	[13]
#556
0	We	O	['N']	[0]
1	have	O	['N']	[1]
2	recently	O	['N']	[2]
3	encountered	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	acquired	O	['N']	[7]
8	haemophilia	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	a	O	['N']	[11]
12	thrombotic	B	['N']	[12]
13	left	I	['N']	[13]
14	middle	I	['N']	[14]
15	cerebral	I	['N']	[15]
16	artery	I	['N']	[16]
17	distribution	I	['N']	[17]
18	stroke	I-Adverse_Effect	['N']	[18]
19	while	O	['N']	[19]
20	being	O	['N']	[20]
21	treated	O	['N']	[21]
22	with	O	['N']	[22]
23	pFVIII	B-Drug	['Causes']	[18]
24	.	O	['N']	[24]
#557
0	Colonic	B	['N']	[0]
1	necrosis	I-Adverse_Effect	['N']	[1]
2	is	O	['N']	[2]
3	known	O	['N']	[3]
4	as	O	['N']	[4]
5	a	O	['N']	[5]
6	rare	O	['N']	[6]
7	complication	O	['N']	[7]
8	following	O	['N']	[8]
9	the	O	['N']	[9]
10	administration	O	['N']	[10]
11	of	O	['N']	[11]
12	Kayexalate	B-Drug	['Causes']	[1]
13	(	O	['N']	[13]
14	sodium	O	['N']	[14]
15	polystryrene	O	['N']	[15]
16	sulfonate	O	['N']	[16]
17	)	O	['N']	[17]
18	in	O	['N']	[18]
19	sorbitol	O	['N']	[19]
20	.	O	['N']	[20]
#558
0	In	O	['N']	[0]
1	a	O	['N']	[1]
2	patient	O	['N']	[2]
3	with	O	['N']	[3]
4	severe	O	['N']	[4]
5	renovascular	O	['N']	[5]
6	hypertension	O	['N']	[6]
7	,	O	['N']	[7]
8	nonoliguric	B	['N']	[8]
9	acute	I	['N']	[9]
10	renal	I	['N']	[10]
11	failure	I-Adverse_Effect	['N']	[11]
12	developed	O	['N']	[12]
13	after	O	['N']	[13]
14	she	O	['N']	[14]
15	received	O	['N']	[15]
16	captopril	B-Drug	['Causes']	[11]
17	treatment	O	['N']	[17]
18	.	O	['N']	[18]
#559
0	The	O	['N']	[0]
1	most	O	['N']	[1]
2	common	O	['N']	[2]
3	side	O	['N']	[3]
4	effects	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	amifostine	B-Drug	['Causes']	[9]
8	are	O	['N']	[8]
9	nausea	B-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	vomiting	O	['N']	[11]
12	,	O	['N']	[12]
13	hypotension	O	['N']	[13]
14	,	O	['N']	[14]
15	hypocalcemia	O	['N']	[15]
16	and	O	['N']	[16]
17	allergic	O	['N']	[17]
18	reactions	O	['N']	[18]
19	.	O	['N']	[19]
#560
0	Nitrofurantoin	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	pulmonary	B	['N']	[3]
4	toxicity	I-Adverse_Effect	['N']	[4]
5	during	O	['N']	[5]
6	pregnancy	O	['N']	[6]
7	:	O	['N']	[7]
8	a	O	['N']	[8]
9	report	O	['N']	[9]
10	of	O	['N']	[10]
11	a	O	['N']	[11]
12	case	O	['N']	[12]
13	and	O	['N']	[13]
14	review	O	['N']	[14]
15	of	O	['N']	[15]
16	the	O	['N']	[16]
17	literature	O	['N']	[17]
18	.	O	['N']	[18]
#561
0	Special	O	['N']	[0]
1	care	O	['N']	[1]
2	should	O	['N']	[2]
3	be	O	['N']	[3]
4	taken	O	['N']	[4]
5	when	O	['N']	[5]
6	pulmonary	B	['N']	[6]
7	symptoms	I-Adverse_Effect	['N']	[7]
8	appear	O	['N']	[8]
9	in	O	['N']	[9]
10	association	O	['N']	[10]
11	with	O	['N']	[11]
12	ticlopidine	B-Drug	['Causes']	[7]
13	treatment	O	['N']	[13]
14	.	O	['N']	[14]
#562
0	A	O	['N']	[0]
1	15-kg	B	['N']	[1]
2	weight	I	['N']	[2]
3	gain	I-Adverse_Effect	['N']	[3]
4	developed	O	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	during	O	['N']	[8]
9	the	O	['N']	[9]
10	third	O	['N']	[10]
11	week	O	['N']	[11]
12	of	O	['N']	[12]
13	ibuprofen	B-Drug	['Causes']	[3]
14	therapy	O	['N']	[14]
15	.	O	['N']	[15]
#563
0	Case	O	['N']	[0]
1	study	O	['N']	[1]
2	:	O	['N']	[2]
3	adverse	B	['N']	[3]
4	response	I-Adverse_Effect	['N']	[4]
5	to	O	['N']	[5]
6	clonidine	B-Drug	['Causes']	[4]
7	.	O	['N']	[7]
#564
0	Toxicity	B-Adverse_Effect	['N']	[0]
1	related	O	['N']	[1]
2	to	O	['N']	[2]
3	chloroquine	B-Drug	['Causes']	[0]
4	treatment	O	['N']	[4]
5	of	O	['N']	[5]
6	resistant	O	['N']	[6]
7	vivax	O	['N']	[7]
8	malaria	O	['N']	[8]
9	.	O	['N']	[9]
#565
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	case	O	['N']	[3]
4	describes	O	['N']	[4]
5	the	O	['N']	[5]
6	clinically	O	['N']	[6]
7	significant	O	['N']	[7]
8	increase	B	['N']	[8]
9	of	I	['N']	[9]
10	INR	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	an	O	['N']	[12]
13	elderly	O	['N']	[13]
14	patient	O	['N']	[14]
15	after	O	['N']	[15]
16	adding	O	['N']	[16]
17	a	O	['N']	[17]
18	chemotherapy	O	['N']	[18]
19	regimen	O	['N']	[19]
20	of	O	['N']	[20]
21	levamisole	O	['N']	[21]
22	and	O	['N']	[22]
23	5-FU	O	['N']	[23]
24	to	O	['N']	[24]
25	a	O	['N']	[25]
26	previous	O	['N']	[26]
27	regimen	O	['N']	[27]
28	of	O	['N']	[28]
29	warfarin	B-Drug	['Causes']	[10]
30	alone	O	['N']	[30]
31	.	O	['N']	[31]
#566
0	Syncope	B-Adverse_Effect	['N']	[0]
1	induced	O	['N']	[1]
2	by	O	['N']	[2]
3	propranolol	B-Drug	['Causes']	[0]
4	in	O	['N']	[4]
5	hypertrophic	O	['N']	[5]
6	cardiomyopathy	O	['N']	[6]
7	.	O	['N']	[7]
#567
0	These	O	['N']	[0]
1	findings	O	['N']	[1]
2	suggest	O	['N']	[2]
3	that	O	['N']	[3]
4	bicytopenia	B-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	this	O	['N']	[6]
7	patient	O	['N']	[7]
8	was	O	['N']	[8]
9	caused	O	['N']	[9]
10	by	O	['N']	[10]
11	D	B	['N']	[11]
12	-	I	['N']	[12]
13	Pen	I-Drug	['Causes']	[4]
14	and	O	['N']	[14]
15	may	O	['N']	[15]
16	be	O	['N']	[16]
17	due	O	['N']	[17]
18	to	O	['N']	[18]
19	different	O	['N']	[19]
20	sensitivities	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	hematopoietic	O	['N']	[23]
24	lineage	O	['N']	[24]
25	.	O	['N']	[25]
#568
0	OBSERVATIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	observed	O	['N']	[3]
4	aggravation	B	['N']	[4]
5	and	I	['N']	[5]
6	spreading	I	['N']	[6]
7	of	I	['N']	[7]
8	a	I	['N']	[8]
9	psoriatic	I	['N']	[9]
10	plaque	I-Adverse_Effect	['N']	[10]
11	when	O	['N']	[11]
12	treated	O	['N']	[12]
13	topically	O	['N']	[13]
14	with	O	['N']	[14]
15	the	O	['N']	[15]
16	toll	O	['N']	[16]
17	-	O	['N']	[17]
18	like	O	['N']	[18]
19	receptor	O	['N']	[19]
20	(	O	['N']	[20]
21	TLR	O	['N']	[21]
22	)	O	['N']	[22]
23	7	O	['N']	[23]
24	agonist	O	['N']	[24]
25	imiquimod	B-Drug	['Causes']	[10]
26	.	O	['N']	[26]
#569
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	presented	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	pulmonary	B	['N']	[6]
7	hypertension	I-Adverse_Effect	['N']	[7]
8	during	O	['N']	[8]
9	lithium	B-Drug	['Causes']	[7]
10	therapy	O	['N']	[10]
11	,	O	['N']	[11]
12	while	O	['N']	[12]
13	she	O	['N']	[13]
14	has	O	['N']	[14]
15	been	O	['N']	[15]
16	on	O	['N']	[16]
17	lithium	O	['N']	[17]
18	for	O	['N']	[18]
19	6	O	['N']	[19]
20	years	O	['N']	[20]
21	.	O	['N']	[21]
#570
0	MTX	B-Drug	['Causes']	[8]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hepatic	O	['N']	[3]
4	injury	O	['N']	[4]
5	and	O	['N']	[5]
6	liver	B	['N']	[6]
7	enzyme	I	['N']	[7]
8	elevations	I-Adverse_Effect	['N']	[8]
9	have	O	['N']	[9]
10	been	O	['N']	[10]
11	demonstrated	O	['N']	[11]
12	after	O	['N']	[12]
13	treatment	O	['N']	[13]
14	of	O	['N']	[14]
15	leukemia	O	['N']	[15]
16	,	O	['N']	[16]
17	gestational	O	['N']	[17]
18	disease	O	['N']	[18]
19	and	O	['N']	[19]
20	during	O	['N']	[20]
21	treatment	O	['N']	[21]
22	of	O	['N']	[22]
23	psoriasis	O	['N']	[23]
24	and	O	['N']	[24]
25	rheumatoid	O	['N']	[25]
26	arthritis	O	['N']	[26]
27	.	O	['N']	[27]
#571
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	45-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	psoriasis	O	['N']	[6]
7	patient	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	eruptive	B	['N']	[10]
11	mollusca	I	['N']	[11]
12	contagiosa	I-Adverse_Effect	['N']	[12]
13	during	O	['N']	[13]
14	an	O	['N']	[14]
15	antipsoriatic	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	efalizumab	B-Drug	['Causes']	[12]
19	.	O	['N']	[19]
#572
0	Poorly	O	['N']	[0]
1	controlled	O	['N']	[1]
2	hypertension	O	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	painter	O	['N']	[5]
6	with	O	['N']	[6]
7	chronic	O	['N']	[7]
8	lead	B-Drug	['Causes']	[9]
9	toxicity	I-Adverse_Effect	['N']	[9]
10	.	O	['N']	[10]
#573
0	Ulcer	B	['N']	[0]
1	became	I	['N']	[1]
2	worse	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	tobramycin	B-Drug	['Causes']	[2]
5	and	O	['N']	[5]
6	gentamycin	O	['N']	[6]
7	treatment	O	['N']	[7]
8	for	O	['N']	[8]
9	2	O	['N']	[9]
10	days	O	['N']	[10]
11	.	O	['N']	[11]
#574
0	The	O	['N']	[0]
1	first	O	['N']	[1]
2	known	O	['N']	[2]
3	report	O	['N']	[3]
4	of	O	['N']	[4]
5	quetiapine	B-Drug	['Causes']	[7]
6	exacerbating	B	['N']	[6]
7	OCS	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	43-year	O	['N']	[10]
11	-	O	['N']	[11]
12	old	O	['N']	[12]
13	man	O	['N']	[13]
14	with	O	['N']	[14]
15	obsessive	O	['N']	[15]
16	-	O	['N']	[16]
17	compulsive	O	['N']	[17]
18	disorder	O	['N']	[18]
19	(	O	['N']	[19]
20	OCD	O	['N']	[20]
21	)	O	['N']	[21]
22	,	O	['N']	[22]
23	trichotillomania	O	['N']	[23]
24	,	O	['N']	[24]
25	delusional	O	['N']	[25]
26	disorder	O	['N']	[26]
27	and	O	['N']	[27]
28	bipolar	O	['N']	[28]
29	II	O	['N']	[29]
30	disorder	O	['N']	[30]
31	is	O	['N']	[31]
32	presented	O	['N']	[32]
33	.	O	['N']	[33]
#575
0	Fulminant	O	['N']	[0]
1	metoclopramide	B-Drug	['Causes']	[5]
2	induced	O	['N']	[2]
3	neuroleptic	B	['N']	[3]
4	malignant	I	['N']	[4]
5	syndrome	I-Adverse_Effect	['N']	[5]
6	rapidly	O	['N']	[6]
7	responsive	O	['N']	[7]
8	to	O	['N']	[8]
9	intravenous	O	['N']	[9]
10	dantrolene	O	['N']	[10]
11	.	O	['N']	[11]
#576
0	We	O	['N']	[0]
1	propose	O	['N']	[1]
2	a	O	['N']	[2]
3	mechanism	O	['N']	[3]
4	of	O	['N']	[4]
5	vancomycin	B-Drug	['Causes']	[22]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	mast	O	['N']	[8]
9	cell	O	['N']	[9]
10	degranulation	O	['N']	[10]
11	and	O	['N']	[11]
12	subsequent	O	['N']	[12]
13	release	O	['N']	[13]
14	of	O	['N']	[14]
15	eosinophil	O	['N']	[15]
16	chemotactic	O	['N']	[16]
17	factor	O	['N']	[17]
18	as	O	['N']	[18]
19	a	O	['N']	[19]
20	cause	O	['N']	[20]
21	of	O	['N']	[21]
22	CSFE	B-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#577
0	An	O	['N']	[0]
1	association	O	['N']	[1]
2	of	O	['N']	[2]
3	granulocytopenia	B-Adverse_Effect	['N']	[3]
4	,	O	['N']	[4]
5	eosinophilia	O	['N']	[5]
6	,	O	['N']	[6]
7	skin	O	['N']	[7]
8	reaction	O	['N']	[8]
9	and	O	['N']	[9]
10	hepatitis	O	['N']	[10]
11	during	O	['N']	[11]
12	propylthiouracil	B-Drug	['Causes']	[3]
13	(	O	['N']	[13]
14	PTU	O	['N']	[14]
15	)	O	['N']	[15]
16	therapy	O	['N']	[16]
17	for	O	['N']	[17]
18	thyrotoxicosis	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	47	O	['N']	[21]
22	year	O	['N']	[22]
23	old	O	['N']	[23]
24	black	O	['N']	[24]
25	female	O	['N']	[25]
26	is	O	['N']	[26]
27	reported	O	['N']	[27]
28	.	O	['N']	[28]
#578
0	Pulmonary	O	['N']	[0]
1	hemorrhage	O	['N']	[1]
2	as	O	['N']	[2]
3	a	O	['N']	[3]
4	clinical	O	['N']	[4]
5	manifestation	O	['N']	[5]
6	of	O	['N']	[6]
7	hemolytic	B	['N']	[7]
8	-	I	['N']	[8]
9	uremic	I	['N']	[9]
10	syndrome	I-Adverse_Effect	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	mitomycin	B	['N']	[13]
14	C	I-Drug	['Causes']	[10]
15	therapy	O	['N']	[15]
16	.	O	['N']	[16]
#579
0	These	O	['N']	[0]
1	data	O	['N']	[1]
2	indicated	O	['N']	[2]
3	that	O	['N']	[3]
4	infliximab	B-Drug	['Causes']	[12]
5	possibly	O	['N']	[5]
6	triggered	O	['N']	[6]
7	production	B	['N']	[7]
8	of	I	['N']	[8]
9	granulocyte	I	['N']	[9]
10	and	I	['N']	[10]
11	neutrophil	I	['N']	[11]
12	autoantibodies	I-Adverse_Effect	['N']	[12]
13	with	O	['N']	[13]
14	resultant	O	['N']	[14]
15	autoimmune	O	['N']	[15]
16	agranulocytosis	O	['N']	[16]
17	.	O	['N']	[17]
#580
0	Based	O	['N']	[0]
1	upon	O	['N']	[1]
2	the	O	['N']	[2]
3	observed	O	['N']	[3]
4	fall	O	['N']	[4]
5	of	O	['N']	[5]
6	the	O	['N']	[6]
7	filtration	O	['N']	[7]
8	fraction	O	['N']	[8]
9	,	O	['N']	[9]
10	the	O	['N']	[10]
11	rise	O	['N']	[11]
12	in	O	['N']	[12]
13	the	O	['N']	[13]
14	relative	O	['N']	[14]
15	clearance	O	['N']	[15]
16	of	O	['N']	[16]
17	99Tc	O	['N']	[17]
18	-	O	['N']	[18]
19	dimercaptosuccinic	O	['N']	[19]
20	acid	O	['N']	[20]
21	and	O	['N']	[21]
22	the	O	['N']	[22]
23	increase	O	['N']	[23]
24	in	O	['N']	[24]
25	proteinuria	O	['N']	[25]
26	,	O	['N']	[26]
27	we	O	['N']	[27]
28	suggest	O	['N']	[28]
29	that	O	['N']	[29]
30	in	O	['N']	[30]
31	this	O	['N']	[31]
32	case	O	['N']	[32]
33	the	O	['N']	[33]
34	tubules	O	['N']	[34]
35	and/or	O	['N']	[35]
36	interstitium	O	['N']	[36]
37	are	O	['N']	[37]
38	the	O	['N']	[38]
39	main	O	['N']	[39]
40	targets	O	['N']	[40]
41	for	O	['N']	[41]
42	cyclosporine	B	['N']	[42]
43	A	I-Drug	['Causes']	[44]
44	nephrotoxicity	B-Adverse_Effect	['N']	[44]
45	.	O	['N']	[45]
#581
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	present	O	['N']	[3]
4	a	O	['N']	[4]
5	single	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	zuclopenthixol	B-Drug	['Causes']	[11]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	priapism	B-Adverse_Effect	['N']	[11]
12	and	O	['N']	[12]
13	a	O	['N']	[13]
14	literature	O	['N']	[14]
15	review	O	['N']	[15]
16	.	O	['N']	[16]
#582
0	The	O	['N']	[0]
1	ototoxicity	B-Adverse_Effect	['N']	[1]
2	of	O	['N']	[2]
3	quinine	B-Drug	['Causes']	[1]
4	can	O	['N']	[4]
5	accurately	O	['N']	[5]
6	be	O	['N']	[6]
7	studied	O	['N']	[7]
8	with	O	['N']	[8]
9	ultrahigh	O	['N']	[9]
10	frequency	O	['N']	[10]
11	audiometry	O	['N']	[11]
12	(	O	['N']	[12]
13	up	O	['N']	[13]
14	to	O	['N']	[14]
15	20	O	['N']	[15]
16	kHz	O	['N']	[16]
17	)	O	['N']	[17]
18	.	O	['N']	[18]
#583
0	He	O	['N']	[0]
1	had	O	['N']	[1]
2	been	O	['N']	[2]
3	taking	O	['N']	[3]
4	trimethoprim	B-Drug	['Causes']	[22]
5	-	O	['N']	[5]
6	sulfamethoxazole	O	['N']	[6]
7	for	O	['N']	[7]
8	approximately	O	['N']	[8]
9	eight	O	['N']	[9]
10	days	O	['N']	[10]
11	when	O	['N']	[11]
12	he	O	['N']	[12]
13	revisited	O	['N']	[13]
14	his	O	['N']	[14]
15	family	O	['N']	[15]
16	physician	O	['N']	[16]
17	,	O	['N']	[17]
18	complaining	O	['N']	[18]
19	of	O	['N']	[19]
20	headaches	O	['N']	[20]
21	,	O	['N']	[21]
22	dizziness	B-Adverse_Effect	['N']	[22]
23	,	O	['N']	[23]
24	difficulty	O	['N']	[24]
25	with	O	['N']	[25]
26	speech	O	['N']	[26]
27	,	O	['N']	[27]
28	weakness	O	['N']	[28]
29	,	O	['N']	[29]
30	and	O	['N']	[30]
31	itching	O	['N']	[31]
32	on	O	['N']	[32]
33	the	O	['N']	[33]
34	trunk	O	['N']	[34]
35	of	O	['N']	[35]
36	his	O	['N']	[36]
37	body	O	['N']	[37]
38	and	O	['N']	[38]
39	legs	O	['N']	[39]
40	,	O	['N']	[40]
41	where	O	['N']	[41]
42	a	O	['N']	[42]
43	maculopapular	O	['N']	[43]
44	rash	O	['N']	[44]
45	was	O	['N']	[45]
46	noted	O	['N']	[46]
47	.	O	['N']	[47]
#584
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	who	O	['N']	[2]
3	had	O	['N']	[3]
4	been	O	['N']	[4]
5	treated	O	['N']	[5]
6	with	O	['N']	[6]
7	large	O	['N']	[7]
8	doses	O	['N']	[8]
9	of	O	['N']	[9]
10	thyroid	B	['N']	[10]
11	hormone	I-Drug	['Causes']	[19]
12	for	O	['N']	[12]
13	several	O	['N']	[13]
14	years	O	['N']	[14]
15	developed	O	['N']	[15]
16	features	O	['N']	[16]
17	of	O	['N']	[17]
18	secondary	O	['N']	[18]
19	hypothyroidism	B-Adverse_Effect	['N']	[19]
20	after	O	['N']	[20]
21	thyroid	O	['N']	[21]
22	hormone	O	['N']	[22]
23	withdrawal	O	['N']	[23]
24	.	O	['N']	[24]
#585
0	Unaccountable	O	['N']	[0]
1	severe	O	['N']	[1]
2	hypercalcemia	B-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	treated	O	['N']	[6]
7	for	O	['N']	[7]
8	hypoparathyroidism	O	['N']	[8]
9	with	O	['N']	[9]
10	dihydrotachysterol	B-Drug	['Causes']	[2]
11	.	O	['N']	[11]
#586
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	propranolol	B-Drug	['Causes']	[8]
4	overdose	O	['N']	[4]
5	complicated	O	['N']	[5]
6	by	O	['N']	[6]
7	esophageal	B	['N']	[7]
8	spasm	I-Adverse_Effect	['N']	[8]
9	preventing	O	['N']	[9]
10	extrication	O	['N']	[10]
11	of	O	['N']	[11]
12	an	O	['N']	[12]
13	orogastric	O	['N']	[13]
14	lavage	O	['N']	[14]
15	tube	O	['N']	[15]
16	and	O	['N']	[16]
17	relieved	O	['N']	[17]
18	by	O	['N']	[18]
19	intravenous	O	['N']	[19]
20	glucagon	O	['N']	[20]
21	is	O	['N']	[21]
22	presented	O	['N']	[22]
23	.	O	['N']	[23]
#587
0	Painful	B-Adverse_Effect	['N']	[0]
1	neutrophilic	O	['N']	[1]
2	skin	O	['N']	[2]
3	lesions	O	['N']	[3]
4	were	O	['N']	[4]
5	observed	O	['N']	[5]
6	in	O	['N']	[6]
7	two	O	['N']	[7]
8	children	O	['N']	[8]
9	receiving	O	['N']	[9]
10	granulocyte	O	['N']	[10]
11	colony	O	['N']	[11]
12	-	O	['N']	[12]
13	stimulating	O	['N']	[13]
14	factor	O	['N']	[14]
15	(	O	['N']	[15]
16	G	B	['N']	[16]
17	-	I	['N']	[17]
18	CSF	I-Drug	['Causes']	[0]
19	)	O	['N']	[19]
20	for	O	['N']	[20]
21	treatment	O	['N']	[21]
22	of	O	['N']	[22]
23	idiopathic	O	['N']	[23]
24	neutropenia	O	['N']	[24]
25	.	O	['N']	[25]
#588
0	Renal	B	['N']	[0]
1	failure	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	high	O	['N']	[3]
4	-	O	['N']	[4]
5	dose	O	['N']	[5]
6	methotrexate	B-Drug	['Causes']	[1]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	child	O	['N']	[9]
10	homozygous	O	['N']	[10]
11	for	O	['N']	[11]
12	MTHFR	O	['N']	[12]
13	C677	O	['N']	[13]
14	T	O	['N']	[14]
15	polymorphism	O	['N']	[15]
16	.	O	['N']	[16]
#589
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	acute	B	['N']	[3]
4	cardiomyopathy	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	pericarditis	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	methylphenidate	B-Drug	['Causes']	[4]
10	.	O	['N']	[10]
#590
0	Acute	B	['N']	[0]
1	lung	I	['N']	[1]
2	injury	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	5-fluorouracil	B-Drug	['Causes']	[2]
6	and	O	['N']	[6]
7	oxaliplatinum	O	['N']	[7]
8	combined	O	['N']	[8]
9	chemotherapy	O	['N']	[9]
10	.	O	['N']	[10]
#591
0	A	O	['N']	[0]
1	53-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	developed	O	['N']	[5]
6	NMS	B-Adverse_Effect	['N']	[6]
7	without	O	['N']	[7]
8	rigidity	O	['N']	[8]
9	while	O	['N']	[9]
10	taking	O	['N']	[10]
11	olanzapine	B-Drug	['Causes']	[6]
12	.	O	['N']	[12]
#592
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	polyserositis	O	['N']	[9]
10	(	O	['N']	[10]
11	pericardial	O	['N']	[11]
12	effusion	O	['N']	[12]
13	,	O	['N']	[13]
14	pleural	O	['N']	[14]
15	effusion	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	pericarditis	B-Adverse_Effect	['N']	[18]
19	)	O	['N']	[19]
20	after	O	['N']	[20]
21	being	O	['N']	[21]
22	started	O	['N']	[22]
23	on	O	['N']	[23]
24	clozapine	B-Drug	['Causes']	[18]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	whose	O	['N']	[27]
28	symptoms	O	['N']	[28]
29	remitted	O	['N']	[29]
30	upon	O	['N']	[30]
31	discontinuation	O	['N']	[31]
32	of	O	['N']	[32]
33	clozapine	O	['N']	[33]
34	.	O	['N']	[34]
#593
0	Pathogenesis	O	['N']	[0]
1	of	O	['N']	[1]
2	methotrexate	B-Drug	['Causes']	[21]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	papular	O	['N']	[5]
6	eruption	O	['N']	[6]
7	in	O	['N']	[7]
8	psoriasis	O	['N']	[8]
9	may	O	['N']	[9]
10	involve	O	['N']	[10]
11	immune	O	['N']	[11]
12	mechanisms	O	['N']	[12]
13	other	O	['N']	[13]
14	than	O	['N']	[14]
15	those	O	['N']	[15]
16	of	O	['N']	[16]
17	methotrexate	O	['N']	[17]
18	-	O	['N']	[18]
19	induced	O	['N']	[19]
20	cutaneous	B	['N']	[20]
21	vasculitis	I-Adverse_Effect	['N']	[21]
22	in	O	['N']	[22]
23	collagen	O	['N']	[23]
24	vascular	O	['N']	[24]
25	disease	O	['N']	[25]
26	.	O	['N']	[26]
#594
0	Fulminant	B	['N']	[0]
1	hepatic	I	['N']	[1]
2	failure	I-Adverse_Effect	['N']	[2]
3	developed	O	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	24-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	black	O	['N']	[9]
10	woman	O	['N']	[10]
11	who	O	['N']	[11]
12	had	O	['N']	[12]
13	been	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	propylthiouracil	O	['N']	[16]
17	and	O	['N']	[17]
18	propranolol	B-Drug	['Causes']	[2]
19	for	O	['N']	[19]
20	hyperthyroidism	O	['N']	[20]
21	.	O	['N']	[21]
#595
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	case	O	['N']	[3]
4	describes	O	['N']	[4]
5	the	O	['N']	[5]
6	clinically	O	['N']	[6]
7	significant	O	['N']	[7]
8	increase	B	['N']	[8]
9	of	I	['N']	[9]
10	INR	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	an	O	['N']	[12]
13	elderly	O	['N']	[13]
14	patient	O	['N']	[14]
15	after	O	['N']	[15]
16	adding	O	['N']	[16]
17	a	O	['N']	[17]
18	chemotherapy	O	['N']	[18]
19	regimen	O	['N']	[19]
20	of	O	['N']	[20]
21	levamisole	O	['N']	[21]
22	and	O	['N']	[22]
23	5-FU	B-Drug	['Causes']	[10]
24	to	O	['N']	[24]
25	a	O	['N']	[25]
26	previous	O	['N']	[26]
27	regimen	O	['N']	[27]
28	of	O	['N']	[28]
29	warfarin	O	['N']	[29]
30	alone	O	['N']	[30]
31	.	O	['N']	[31]
#596
0	Fludarabine	B-Drug	['Causes']	[14]
1	induced	O	['N']	[1]
2	lung	O	['N']	[2]
3	toxicity	O	['N']	[3]
4	must	O	['N']	[4]
5	be	O	['N']	[5]
6	considered	O	['N']	[6]
7	in	O	['N']	[7]
8	all	O	['N']	[8]
9	patients	O	['N']	[9]
10	who	O	['N']	[10]
11	develop	O	['N']	[11]
12	unexplained	O	['N']	[12]
13	lung	B	['N']	[13]
14	disease	I-Adverse_Effect	['N']	[14]
15	while	O	['N']	[15]
16	receiving	O	['N']	[16]
17	fludarabine	O	['N']	[17]
18	.	O	['N']	[18]
#597
0	Recent	O	['N']	[0]
1	studies	O	['N']	[1]
2	have	O	['N']	[2]
3	shown	O	['N']	[3]
4	that	O	['N']	[4]
5	under	O	['N']	[5]
6	experimental	O	['N']	[6]
7	conditions	O	['N']	[7]
8	ferrous	B	['N']	[8]
9	sulfate	I-Drug	['Causes']	[19]
10	may	O	['N']	[10]
11	reduce	B	['N']	[11]
12	the	I	['N']	[12]
13	gastrointestinal	I	['N']	[13]
14	absorption	I	['N']	[14]
15	of	I	['N']	[15]
16	orally	I	['N']	[16]
17	administered	I	['N']	[17]
18	levothyroxine	I	['N']	[18]
19	sodium	I-Adverse_Effect	['N']	[19]
20	in	O	['N']	[20]
21	patients	O	['N']	[21]
22	with	O	['N']	[22]
23	primary	O	['N']	[23]
24	hypothyroidism	O	['N']	[24]
25	.	O	['N']	[25]
#598
0	Protease	O	['N']	[0]
1	inhibitors	O	['N']	[1]
2	(	O	['N']	[2]
3	ritonavir	B-Drug	['Causes']	[17]
4	and	O	['N']	[4]
5	saquinavir	O	['N']	[5]
6	)	O	['N']	[6]
7	were	O	['N']	[7]
8	added	O	['N']	[8]
9	to	O	['N']	[9]
10	the	O	['N']	[10]
11	treatment	O	['N']	[11]
12	and	O	['N']	[12]
13	the	O	['N']	[13]
14	patient	O	['N']	[14]
15	developed	O	['N']	[15]
16	progressive	B	['N']	[16]
17	ataxia	I-Adverse_Effect	['N']	[17]
18	related	O	['N']	[18]
19	to	O	['N']	[19]
20	carbamazepine	O	['N']	[20]
21	toxicity	O	['N']	[21]
22	.	O	['N']	[22]
#599
0	While	O	['N']	[0]
1	for	O	['N']	[1]
2	ribavirin	O	['N']	[2]
3	antidepressant	O	['N']	[3]
4	effects	O	['N']	[4]
5	are	O	['N']	[5]
6	not	O	['N']	[6]
7	known	O	['N']	[7]
8	,	O	['N']	[8]
9	we	O	['N']	[9]
10	suppose	O	['N']	[10]
11	that	O	['N']	[11]
12	antidepressants	O	['N']	[12]
13	may	O	['N']	[13]
14	prevent	O	['N']	[14]
15	changes	B	['N']	[15]
16	in	I	['N']	[16]
17	serotonergic	I	['N']	[17]
18	or	I	['N']	[18]
19	noradrenergic	I	['N']	[19]
20	neurotransmission	I-Adverse_Effect	['N']	[20]
21	caused	O	['N']	[21]
22	by	O	['N']	[22]
23	IFN	B	['N']	[23]
24	-	I	['N']	[24]
25	alpha	I-Drug	['Causes']	[20]
26	.	O	['N']	[26]
#600
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	development	O	['N']	[3]
4	of	O	['N']	[4]
5	ischemic	B	['N']	[5]
6	colitis	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	woman	O	['N']	[9]
10	who	O	['N']	[10]
11	was	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	tegaserod	B-Drug	['Causes']	[6]
15	and	O	['N']	[15]
16	review	O	['N']	[16]
17	the	O	['N']	[17]
18	relationship	O	['N']	[18]
19	among	O	['N']	[19]
20	ischemic	O	['N']	[20]
21	colitis	O	['N']	[21]
22	,	O	['N']	[22]
23	tegaserod	O	['N']	[23]
24	use	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	irritable	O	['N']	[27]
28	bowel	O	['N']	[28]
29	syndrome	O	['N']	[29]
30	.	O	['N']	[30]
#601
0	Approximately	O	['N']	[0]
1	15	O	['N']	[1]
2	min	O	['N']	[2]
3	after	O	['N']	[3]
4	the	O	['N']	[4]
5	first	O	['N']	[5]
6	administration	O	['N']	[6]
7	of	O	['N']	[7]
8	nebulised	O	['N']	[8]
9	morphine	B-Drug	['Causes']	[14]
10	the	O	['N']	[10]
11	patient	O	['N']	[11]
12	became	O	['N']	[12]
13	markedly	O	['N']	[13]
14	bradypneic	B-Adverse_Effect	['N']	[14]
15	(	O	['N']	[15]
16	respiratory	O	['N']	[16]
17	rate	O	['N']	[17]
18	:	O	['N']	[18]
19	4	O	['N']	[19]
20	-	O	['N']	[20]
21	5	O	['N']	[21]
22	bpm	O	['N']	[22]
23	)	O	['N']	[23]
24	,	O	['N']	[24]
25	hypotensive	O	['N']	[25]
26	(	O	['N']	[26]
27	BP	O	['N']	[27]
28	70/40	O	['N']	[28]
29	mmHg	O	['N']	[29]
30	)	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	responded	O	['N']	[33]
34	only	O	['N']	[34]
35	partially	O	['N']	[35]
36	to	O	['N']	[36]
37	command	O	['N']	[37]
38	.	O	['N']	[38]
#602
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	history	O	['N']	[2]
3	confirms	O	['N']	[3]
4	that	O	['N']	[4]
5	gold	B-Drug	['Causes']	[23]
6	treatment	O	['N']	[6]
7	,	O	['N']	[7]
8	even	O	['N']	[8]
9	in	O	['N']	[9]
10	the	O	['N']	[10]
11	same	O	['N']	[11]
12	patient	O	['N']	[12]
13	,	O	['N']	[13]
14	can	O	['N']	[14]
15	give	O	['N']	[15]
16	rise	O	['N']	[16]
17	to	O	['N']	[17]
18	a	O	['N']	[18]
19	wide	O	['N']	[19]
20	range	O	['N']	[20]
21	of	O	['N']	[21]
22	skin	B	['N']	[22]
23	disturbances	I-Adverse_Effect	['N']	[23]
24	,	O	['N']	[24]
25	which	O	['N']	[25]
26	in	O	['N']	[26]
27	many	O	['N']	[27]
28	cases	O	['N']	[28]
29	do	O	['N']	[29]
30	not	O	['N']	[30]
31	break	O	['N']	[31]
32	out	O	['N']	[32]
33	until	O	['N']	[33]
34	long	O	['N']	[34]
35	after	O	['N']	[35]
36	the	O	['N']	[36]
37	drug	O	['N']	[37]
38	has	O	['N']	[38]
39	been	O	['N']	[39]
40	withdrawn	O	['N']	[40]
41	.	O	['N']	[41]
#603
0	The	O	['N']	[0]
1	rash	B-Adverse_Effect	['N']	[1]
2	seen	O	['N']	[2]
3	in	O	['N']	[3]
4	this	O	['N']	[4]
5	patient	O	['N']	[5]
6	,	O	['N']	[6]
7	who	O	['N']	[7]
8	was	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	cephalexin	O	['N']	[11]
12	,	O	['N']	[12]
13	may	O	['N']	[13]
14	be	O	['N']	[14]
15	similar	O	['N']	[15]
16	to	O	['N']	[16]
17	the	O	['N']	[17]
18	rash	O	['N']	[18]
19	seen	O	['N']	[19]
20	with	O	['N']	[20]
21	ampicillin	B-Drug	['Causes']	[1]
22	treatment	O	['N']	[22]
23	of	O	['N']	[23]
24	patients	O	['N']	[24]
25	with	O	['N']	[25]
26	infectious	O	['N']	[26]
27	mononucleosis	O	['N']	[27]
28	.	O	['N']	[28]
#604
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	fatal	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	toxic	B	['N']	[8]
9	epidermal	I	['N']	[9]
10	necrolysis	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	man	O	['N']	[13]
14	who	O	['N']	[14]
15	was	O	['N']	[15]
16	treated	O	['N']	[16]
17	with	O	['N']	[17]
18	oral	O	['N']	[18]
19	ofloxacin	B-Drug	['Causes']	[10]
20	for	O	['N']	[20]
21	epididymitis	O	['N']	[21]
22	.	O	['N']	[22]
#605
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	was	O	['N']	[2]
3	enrolled	O	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	weight	O	['N']	[6]
7	-	O	['N']	[7]
8	loss	O	['N']	[8]
9	clinic	O	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	his	O	['N']	[12]
13	diabetes	O	['N']	[13]
14	medications	O	['N']	[14]
15	were	O	['N']	[15]
16	adjusted	O	['N']	[16]
17	.	O	['N']	[17]
18	Subsequently	O	['N']	[18]
19	,	O	['N']	[19]
20	olanzapine	B-Drug	['Causes']	[26]
21	was	O	['N']	[21]
22	discontinued	O	['N']	[22]
23	because	O	['N']	[23]
24	of	O	['N']	[24]
25	weight	B	['N']	[25]
26	gain	I-Adverse_Effect	['N']	[26]
27	and	O	['N']	[27]
28	uncontrolled	O	['N']	[28]
29	diabetes	O	['N']	[29]
30	.	O	['N']	[30]
#606
0	Lithium	B-Drug	['Causes']	[12]
1	is	O	['N']	[1]
2	known	O	['N']	[2]
3	to	O	['N']	[3]
4	cause	O	['N']	[4]
5	acute	O	['N']	[5]
6	renal	O	['N']	[6]
7	failure	O	['N']	[7]
8	and	O	['N']	[8]
9	tubulo	B	['N']	[9]
10	-	I	['N']	[10]
11	interstitial	I	['N']	[11]
12	disease	I-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	but	O	['N']	[14]
15	the	O	['N']	[15]
16	recently	O	['N']	[16]
17	described	O	['N']	[17]
18	association	O	['N']	[18]
19	with	O	['N']	[19]
20	proteinuria	O	['N']	[20]
21	or	O	['N']	[21]
22	nephrotic	O	['N']	[22]
23	syndrome	O	['N']	[23]
24	is	O	['N']	[24]
25	little	O	['N']	[25]
26	recognized	O	['N']	[26]
27	.	O	['N']	[27]
#607
0	Acute	O	['N']	[0]
1	vision	O	['N']	[1]
2	loss	O	['N']	[2]
3	after	O	['N']	[3]
4	intravitreal	O	['N']	[4]
5	injection	O	['N']	[5]
6	of	O	['N']	[6]
7	bevacizumab	B-Drug	['Causes']	[15]
8	(	O	['N']	[8]
9	avastin	O	['N']	[9]
10	)	O	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	ocular	B	['N']	[13]
14	ischemic	I	['N']	[14]
15	syndrome	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#608
0	We	O	['N']	[0]
1	discuss	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	severe	O	['N']	[6]
7	renal	O	['N']	[7]
8	tubular	O	['N']	[8]
9	dysfunction	O	['N']	[9]
10	secondary	O	['N']	[10]
11	to	O	['N']	[11]
12	short	O	['N']	[12]
13	-	O	['N']	[13]
14	term	O	['N']	[14]
15	therapy	O	['N']	[15]
16	with	O	['N']	[16]
17	Amikacin	B-Drug	['Causes']	[22]
18	,	O	['N']	[18]
19	resulting	O	['N']	[19]
20	in	O	['N']	[20]
21	refractory	B	['N']	[21]
22	hypokalemia	I-Adverse_Effect	['N']	[22]
23	,	O	['N']	[23]
24	hypocalcemia	O	['N']	[24]
25	,	O	['N']	[25]
26	hypomagnesemia	O	['N']	[26]
27	,	O	['N']	[27]
28	metabolic	O	['N']	[28]
29	alkalosis	O	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	polyuria	O	['N']	[32]
33	.	O	['N']	[33]
#609
0	A	O	['N']	[0]
1	36-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	being	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	cisplatinum	B-Drug	['Causes']	[32]
9	,	O	['N']	[9]
10	vinblastine	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	bleomycin	O	['N']	[13]
14	for	O	['N']	[14]
15	testicular	O	['N']	[15]
16	carcinoma	O	['N']	[16]
17	developed	O	['N']	[17]
18	a	O	['N']	[18]
19	dense	O	['N']	[19]
20	left	O	['N']	[20]
21	homonymous	O	['N']	[21]
22	hemianopsia	O	['N']	[22]
23	,	O	['N']	[23]
24	encephalopathy	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	a	O	['N']	[27]
28	partial	B	['N']	[28]
29	nondominant	I	['N']	[29]
30	parietal	I	['N']	[30]
31	lobe	I	['N']	[31]
32	syndrome	I-Adverse_Effect	['N']	[32]
33	.	O	['N']	[33]
#610
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	occurrence	O	['N']	[3]
4	of	O	['N']	[4]
5	myoclonus	B-Adverse_Effect	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	continuous	O	['N']	[8]
9	i.v	O	['N']	[9]
10	.	O	['N']	[10]
11	infusion	O	['N']	[11]
12	of	O	['N']	[12]
13	dobutamine	B-Drug	['Causes']	[5]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	patient	O	['N']	[16]
17	with	O	['N']	[17]
18	end	O	['N']	[18]
19	-	O	['N']	[19]
20	stage	O	['N']	[20]
21	renal	O	['N']	[21]
22	disease	O	['N']	[22]
23	(	O	['N']	[23]
24	ESRD	O	['N']	[24]
25	)	O	['N']	[25]
26	is	O	['N']	[26]
27	described	O	['N']	[27]
28	.	O	['N']	[28]
#611
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	new	O	['N']	[3]
4	quinolone	O	['N']	[4]
5	derivatives	O	['N']	[5]
6	(	O	['N']	[6]
7	levofloxacin	O	['N']	[7]
8	,	O	['N']	[8]
9	sparfloxacin	B-Drug	['Causes']	[43]
10	,	O	['N']	[10]
11	grepafloxacin	O	['N']	[11]
12	,	O	['N']	[12]
13	trovafloxacin	O	['N']	[13]
14	,	O	['N']	[14]
15	gatifloxacin	O	['N']	[15]
16	and	O	['N']	[16]
17	moxifloxacin	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	also	O	['N']	[20]
21	called	O	['N']	[21]
22	gyrase	O	['N']	[22]
23	inhibitors	O	['N']	[23]
24	,	O	['N']	[24]
25	are	O	['N']	[25]
26	known	O	['N']	[26]
27	for	O	['N']	[27]
28	their	O	['N']	[28]
29	potential	O	['N']	[29]
30	to	O	['N']	[30]
31	cause	O	['N']	[31]
32	central	O	['N']	[32]
33	nervous	O	['N']	[33]
34	system	O	['N']	[34]
35	-	O	['N']	[35]
36	related	O	['N']	[36]
37	adverse	O	['N']	[37]
38	effects	O	['N']	[38]
39	,	O	['N']	[39]
40	including	O	['N']	[40]
41	headache	O	['N']	[41]
42	,	O	['N']	[42]
43	dizziness	B-Adverse_Effect	['N']	[43]
44	and	O	['N']	[44]
45	insomnia	O	['N']	[45]
46	.	O	['N']	[46]
#612
0	The	O	['N']	[0]
1	relation	O	['N']	[1]
2	between	O	['N']	[2]
3	tacrolimus	B-Drug	['Causes']	[13]
4	treatment	O	['N']	[4]
5	and	O	['N']	[5]
6	staining	O	['N']	[6]
7	was	O	['N']	[7]
8	suggested	O	['N']	[8]
9	by	O	['N']	[9]
10	the	O	['N']	[10]
11	appearance	O	['N']	[11]
12	of	O	['N']	[12]
13	pigmentation	B-Adverse_Effect	['N']	[13]
14	during	O	['N']	[14]
15	topical	O	['N']	[15]
16	tacrolimus	O	['N']	[16]
17	treatment	O	['N']	[17]
18	and	O	['N']	[18]
19	its	O	['N']	[19]
20	clinical	O	['N']	[20]
21	disappearance	O	['N']	[21]
22	when	O	['N']	[22]
23	treatment	O	['N']	[23]
24	was	O	['N']	[24]
25	stopped	O	['N']	[25]
26	.	O	['N']	[26]
#613
0	A	O	['N']	[0]
1	16-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	developed	O	['N']	[5]
6	fever	O	['N']	[6]
7	,	O	['N']	[7]
8	generalized	B	['N']	[8]
9	rigidity	I-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	leukocytosis	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	increased	O	['N']	[14]
15	serum	O	['N']	[15]
16	transaminase	O	['N']	[16]
17	and	O	['N']	[17]
18	creatine	O	['N']	[18]
19	kinase	O	['N']	[19]
20	levels	O	['N']	[20]
21	while	O	['N']	[21]
22	receiving	O	['N']	[22]
23	treatment	O	['N']	[23]
24	with	O	['N']	[24]
25	olanzapine	O	['N']	[25]
26	and	O	['N']	[26]
27	lithium	B-Drug	['Causes']	[9]
28	.	O	['N']	[28]
#614
0	Cutaneous	B	['N']	[0]
1	vasculitis	I-Adverse_Effect	['N']	[1]
2	secondary	O	['N']	[2]
3	to	O	['N']	[3]
4	ramipril	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#615
0	Multiple	B	['N']	[0]
1	syncopal	I	['N']	[1]
2	episodes	I-Adverse_Effect	['N']	[2]
3	started	O	['N']	[3]
4	to	O	['N']	[4]
5	occur	O	['N']	[5]
6	during	O	['N']	[6]
7	thalidomide	B-Drug	['Causes']	[2]
8	treatment	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	a	O	['N']	[11]
12	Holter	O	['N']	[12]
13	electrocardiogram	O	['N']	[13]
14	showed	O	['N']	[14]
15	multiple	O	['N']	[15]
16	abnormalities	O	['N']	[16]
17	,	O	['N']	[17]
18	with	O	['N']	[18]
19	an	O	['N']	[19]
20	episode	O	['N']	[20]
21	of	O	['N']	[21]
22	sustained	O	['N']	[22]
23	ventricular	O	['N']	[23]
24	tachycardia	O	['N']	[24]
25	.	O	['N']	[25]
#616
0	After	O	['N']	[0]
1	abstinence	O	['N']	[1]
2	from	O	['N']	[2]
3	oolong	B	['N']	[3]
4	tea	I-Drug	['Causes']	[6]
5	his	O	['N']	[5]
6	delirium	B-Adverse_Effect	['N']	[6]
7	resolved	O	['N']	[7]
8	.	O	['N']	[8]
#617
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	fatal	B	['N']	[3]
4	case	I	['N']	[4]
5	of	I	['N']	[5]
6	acute	I	['N']	[6]
7	interstitial	I	['N']	[7]
8	pneumonitis	I-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	patient	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	carmustine	O	['N']	[14]
15	(	O	['N']	[15]
16	BCNU	B-Drug	['Causes']	[8]
17	)	O	['N']	[17]
18	for	O	['N']	[18]
19	a	O	['N']	[19]
20	brain	O	['N']	[20]
21	tumor	O	['N']	[21]
22	.	O	['N']	[22]
#618
0	Flaccid	B	['N']	[0]
1	quadriparesis	I-Adverse_Effect	['N']	[1]
2	was	O	['N']	[2]
3	noted	O	['N']	[3]
4	after	O	['N']	[4]
5	discontinuation	O	['N']	[5]
6	of	O	['N']	[6]
7	vecuronium	B-Drug	['Causes']	[1]
8	.	O	['N']	[8]
#619
0	A	O	['N']	[0]
1	7-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	with	O	['N']	[4]
5	congenital	O	['N']	[5]
6	toxoplasmosis	O	['N']	[6]
7	who	O	['N']	[7]
8	took	O	['N']	[8]
9	pyrimethamine	O	['N']	[9]
10	and	O	['N']	[10]
11	sulfadiazine	B-Drug	['Causes']	[27]
12	for	O	['N']	[12]
13	reactivated	O	['N']	[13]
14	chorioretinitis	O	['N']	[14]
15	developed	O	['N']	[15]
16	fever	O	['N']	[16]
17	,	O	['N']	[17]
18	severe	O	['N']	[18]
19	cutaneous	O	['N']	[19]
20	involvement	O	['N']	[20]
21	,	O	['N']	[21]
22	swelling	O	['N']	[22]
23	,	O	['N']	[23]
24	abdominal	O	['N']	[24]
25	pain	O	['N']	[25]
26	and	O	['N']	[26]
27	transaminitis	B-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	persisting	O	['N']	[29]
30	weeks	O	['N']	[30]
31	after	O	['N']	[31]
32	withholding	O	['N']	[32]
33	medicines	O	['N']	[33]
34	.	O	['N']	[34]
#620
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Anastrozole	B-Drug	['Causes']	[12]
3	may	O	['N']	[3]
4	be	O	['N']	[4]
5	the	O	['N']	[5]
6	causative	O	['N']	[6]
7	factor	O	['N']	[7]
8	in	O	['N']	[8]
9	patients	O	['N']	[9]
10	with	O	['N']	[10]
11	sclerosing	B	['N']	[11]
12	glomerulonephritis	I-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#621
0	In	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	swallowing	O	['N']	[3]
4	dysfunction	O	['N']	[4]
5	and	O	['N']	[5]
6	pneumonia	B-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	a	O	['N']	[8]
9	history	O	['N']	[9]
10	of	O	['N']	[10]
11	mineral	B	['N']	[11]
12	oil	I-Drug	['Causes']	[6]
13	use	O	['N']	[13]
14	should	O	['N']	[14]
15	be	O	['N']	[15]
16	obtained	O	['N']	[16]
17	and	O	['N']	[17]
18	a	O	['N']	[18]
19	diagnosis	O	['N']	[19]
20	of	O	['N']	[20]
21	ELP	O	['N']	[21]
22	should	O	['N']	[22]
23	be	O	['N']	[23]
24	considered	O	['N']	[24]
25	in	O	['N']	[25]
26	the	O	['N']	[26]
27	differential	O	['N']	[27]
28	diagnoses	O	['N']	[28]
29	if	O	['N']	[29]
30	mineral	O	['N']	[30]
31	oil	O	['N']	[31]
32	use	O	['N']	[32]
33	has	O	['N']	[33]
34	occurred	O	['N']	[34]
35	.	O	['N']	[35]
#622
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	angiographically	O	['N']	[7]
8	documented	O	['N']	[8]
9	cystoid	B	['N']	[9]
10	macula	I	['N']	[10]
11	edema	I-Adverse_Effect	['N']	[11]
12	occurring	O	['N']	[12]
13	after	O	['N']	[13]
14	switching	O	['N']	[14]
15	a	O	['N']	[15]
16	pseudophakic	O	['N']	[16]
17	patient	O	['N']	[17]
18	from	O	['N']	[18]
19	latanoprost	B-Drug	['Causes']	[11]
20	to	O	['N']	[20]
21	bimatoprost	O	['N']	[21]
22	.	O	['N']	[22]
#623
0	Intra	B	['N']	[0]
1	-	I	['N']	[1]
2	neural	I	['N']	[2]
3	ceroid	I	['N']	[3]
4	-	I	['N']	[4]
5	like	I	['N']	[5]
6	pigment	I-Adverse_Effect	['N']	[6]
7	following	O	['N']	[7]
8	the	O	['N']	[8]
9	treatment	O	['N']	[9]
10	of	O	['N']	[10]
11	lepromatous	O	['N']	[11]
12	leprosy	O	['N']	[12]
13	with	O	['N']	[13]
14	clofazimine	O	['N']	[14]
15	(	O	['N']	[15]
16	B663	O	['N']	[16]
17	;	O	['N']	[17]
18	Lamprene	B-Drug	['Causes']	[6]
19	)	O	['N']	[19]
20	.	O	['N']	[20]
#624
0	Bilateral	B	['N']	[0]
1	anterior	I	['N']	[1]
2	uveitis	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	clomiphene	B	['N']	[5]
6	citrate	I-Drug	['Causes']	[2]
7	.	O	['N']	[7]
#625
0	Hypo	B	['N']	[0]
1	-	I	['N']	[1]
2	oestrogenic	I	['N']	[2]
3	and	I	['N']	[3]
4	anabolic	I	['N']	[4]
5	/	I	['N']	[5]
6	androgenic	I	['N']	[6]
7	side	I	['N']	[7]
8	-	I	['N']	[8]
9	effects	I-Adverse_Effect	['N']	[9]
10	of	O	['N']	[10]
11	danazol	B-Drug	['Causes']	[9]
12	are	O	['N']	[12]
13	well	O	['N']	[13]
14	known	O	['N']	[14]
15	by	O	['N']	[15]
16	the	O	['N']	[16]
17	gynaecologist	O	['N']	[17]
18	and	O	['N']	[18]
19	some	O	['N']	[19]
20	of	O	['N']	[20]
21	them	O	['N']	[21]
22	are	O	['N']	[22]
23	present	O	['N']	[23]
24	in	O	['N']	[24]
25	>	O	['N']	[25]
26	50	O	['N']	[26]
27	%	O	['N']	[27]
28	of	O	['N']	[28]
29	patients	O	['N']	[29]
30	being	O	['N']	[30]
31	treated	O	['N']	[31]
32	for	O	['N']	[32]
33	endometriosis	O	['N']	[33]
34	.	O	['N']	[34]
#626
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	unintentional	O	['N']	[5]
6	overdose	O	['N']	[6]
7	of	O	['N']	[7]
8	oral	O	['N']	[8]
9	pilocarpine	B-Drug	['Causes']	[14]
10	tablets	O	['N']	[10]
11	that	O	['N']	[11]
12	resulted	O	['N']	[12]
13	in	O	['N']	[13]
14	bradycardia	B-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	mild	O	['N']	[16]
17	hypotension	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	muscarinic	O	['N']	[20]
21	symptoms	O	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	patient	O	['N']	[24]
25	with	O	['N']	[25]
26	Sjogren	O	['N']	[26]
27	's	O	['N']	[27]
28	syndrome	O	['N']	[28]
29	.	O	['N']	[29]
#627
0	Two	O	['N']	[0]
1	years	O	['N']	[1]
2	later	O	['N']	[2]
3	,	O	['N']	[3]
4	24	O	['N']	[4]
5	hours	O	['N']	[5]
6	following	O	['N']	[6]
7	an	O	['N']	[7]
8	increase	O	['N']	[8]
9	in	O	['N']	[9]
10	the	O	['N']	[10]
11	dose	O	['N']	[11]
12	of	O	['N']	[12]
13	disopyramide	B-Drug	['Dosage']	[20]
14	from	O	['N']	[14]
15	300	B	['N']	[15]
16	to	I	['N']	[16]
17	600	I	['N']	[17]
18	mg	I	['N']	[18]
19	/	I	['N']	[19]
20	day	I-Dose	['N']	[20]
21	,	O	['N']	[21]
22	AVT	O	['N']	[22]
23	with	O	['N']	[23]
24	syncope	O	['N']	[24]
25	occurred	O	['N']	[25]
26	;	O	['N']	[26]
27	isoproterenol	O	['N']	[27]
28	abolished	O	['N']	[28]
29	the	O	['N']	[29]
30	arrhythmia	O	['N']	[30]
31	instantly	O	['N']	[31]
32	.	O	['N']	[32]
#628
0	Aseptic	O	['N']	[0]
1	meningitis	O	['N']	[1]
2	,	O	['N']	[2]
3	hemolytic	O	['N']	[3]
4	anemia	O	['N']	[4]
5	,	O	['N']	[5]
6	hepatitis	O	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	orthostatic	B	['N']	[9]
10	hypotension	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	trimethoprim	O	['N']	[16]
17	-	O	['N']	[17]
18	sulfamethoxazole	B-Drug	['Causes']	[10]
19	.	O	['N']	[19]
#629
0	Gestational	B	['N']	[0]
1	diabetes	I-Adverse_Effect	['N']	[1]
2	was	O	['N']	[2]
3	no	O	['N']	[3]
4	less	O	['N']	[4]
5	severe	O	['N']	[5]
6	(	O	['N']	[6]
7	degree	O	['N']	[7]
8	of	O	['N']	[8]
9	hyperglycaemia	O	['N']	[9]
10	,	O	['N']	[10]
11	need	O	['N']	[11]
12	for	O	['N']	[12]
13	insulin	O	['N']	[13]
14	therapy	O	['N']	[14]
15	)	O	['N']	[15]
16	when	O	['N']	[16]
17	associated	O	['N']	[17]
18	with	O	['N']	[18]
19	norethisterone	B-Drug	['Causes']	[1]
20	.	O	['N']	[20]
#630
0	Case	O	['N']	[0]
1	3	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	29-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	female	O	['N']	[7]
8	alcoholic	O	['N']	[8]
9	complained	O	['N']	[9]
10	of	O	['N']	[10]
11	general	O	['N']	[11]
12	fatigue	B-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	a	O	['N']	[14]
15	slight	O	['N']	[15]
16	fever	O	['N']	[16]
17	after	O	['N']	[17]
18	1.5	O	['N']	[18]
19	years	O	['N']	[19]
20	of	O	['N']	[20]
21	abstinence	O	['N']	[21]
22	with	O	['N']	[22]
23	cyanamide	B-Drug	['Causes']	[12]
24	treatment	O	['N']	[24]
25	.	O	['N']	[25]
#631
0	One	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	tacrolimus	B-Drug	['Causes']	[7]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	hepatic	B	['N']	[6]
7	VOD	I-Adverse_Effect	['N']	[7]
8	developing	O	['N']	[8]
9	after	O	['N']	[9]
10	lung	O	['N']	[10]
11	transplantation	O	['N']	[11]
12	(	O	['N']	[12]
13	LT	O	['N']	[13]
14	)	O	['N']	[14]
15	has	O	['N']	[15]
16	been	O	['N']	[16]
17	recently	O	['N']	[17]
18	reported	O	['N']	[18]
19	.	O	['N']	[19]
#632
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	74-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	with	O	['N']	[7]
8	rheumatoid	O	['N']	[8]
9	arthritis	O	['N']	[9]
10	(	O	['N']	[10]
11	RA	O	['N']	[11]
12	)	O	['N']	[12]
13	who	O	['N']	[13]
14	developed	O	['N']	[14]
15	syndrome	B	['N']	[15]
16	of	I	['N']	[16]
17	inappropriate	I	['N']	[17]
18	secretion	I	['N']	[18]
19	of	I	['N']	[19]
20	antidiuretic	I	['N']	[20]
21	hormone	I-Adverse_Effect	['N']	[21]
22	(	O	['N']	[22]
23	SIADH	O	['N']	[23]
24	)	O	['N']	[24]
25	1.5	O	['N']	[25]
26	months	O	['N']	[26]
27	after	O	['N']	[27]
28	commencement	O	['N']	[28]
29	of	O	['N']	[29]
30	mizoribin	B-Drug	['Causes']	[21]
31	prescription	O	['N']	[31]
32	when	O	['N']	[32]
33	his	O	['N']	[33]
34	arthritis	O	['N']	[34]
35	was	O	['N']	[35]
36	improved	O	['N']	[36]
37	.	O	['N']	[37]
#633
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	fatal	O	['N']	[6]
7	cryptococcal	B	['N']	[7]
8	meningitis	I-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	child	O	['N']	[11]
12	with	O	['N']	[12]
13	systemic	O	['N']	[13]
14	lupus	O	['N']	[14]
15	erythematosus	O	['N']	[15]
16	being	O	['N']	[16]
17	treated	O	['N']	[17]
18	with	O	['N']	[18]
19	prednisolone	B-Drug	['Causes']	[8]
20	and	O	['N']	[20]
21	azathioprine	O	['N']	[21]
22	.	O	['N']	[22]
#634
0	With	O	['N']	[0]
1	the	O	['N']	[1]
2	use	O	['N']	[2]
3	of	O	['N']	[3]
4	optical	O	['N']	[4]
5	coherence	O	['N']	[5]
6	tomography	O	['N']	[6]
7	(	O	['N']	[7]
8	OCT	O	['N']	[8]
9	)	O	['N']	[9]
10	,	O	['N']	[10]
11	two	O	['N']	[11]
12	patients	O	['N']	[12]
13	with	O	['N']	[13]
14	IFN	B-Drug	['Causes']	[26]
15	-	O	['N']	[15]
16	associated	O	['N']	[16]
17	retinopathy	O	['N']	[17]
18	who	O	['N']	[18]
19	had	O	['N']	[19]
20	developed	O	['N']	[20]
21	macular	O	['N']	[21]
22	edema	O	['N']	[22]
23	and	O	['N']	[23]
24	reduced	B	['N']	[24]
25	visual	I	['N']	[25]
26	acuity	I-Adverse_Effect	['N']	[26]
27	during	O	['N']	[27]
28	the	O	['N']	[28]
29	clinical	O	['N']	[29]
30	course	O	['N']	[30]
31	of	O	['N']	[31]
32	IFN	O	['N']	[32]
33	therapy	O	['N']	[33]
34	were	O	['N']	[34]
35	observed	O	['N']	[35]
36	.	O	['N']	[36]
#635
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	,	O	['N']	[2]
3	in	O	['N']	[3]
4	whom	O	['N']	[4]
5	tumour	O	['N']	[5]
6	overkill	O	['N']	[6]
7	by	O	['N']	[7]
8	cytotoxic	O	['N']	[8]
9	treatment	O	['N']	[9]
10	,	O	['N']	[10]
11	including	O	['N']	[11]
12	high	O	['N']	[12]
13	dose	O	['N']	[13]
14	methotrexate	O	['N']	[14]
15	with	O	['N']	[15]
16	folinic	B	['N']	[16]
17	acid	I-Drug	['Causes']	[47]
18	rescue	O	['N']	[18]
19	,	O	['N']	[19]
20	resulted	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	'	O	['N']	[23]
24	phosphate	O	['N']	[24]
25	shower	O	['N']	[25]
26	syndrome	O	['N']	[26]
27	'	O	['N']	[27]
28	(	O	['N']	[28]
29	hyper	O	['N']	[29]
30	-	O	['N']	[30]
31	uricaemia	O	['N']	[31]
32	,	O	['N']	[32]
33	hyperkalaemia	O	['N']	[33]
34	and	O	['N']	[34]
35	hyperphosphataemia	O	['N']	[35]
36	with	O	['N']	[36]
37	hypocalcaemia	O	['N']	[37]
38	and	O	['N']	[38]
39	tetany	O	['N']	[39]
40	,	O	['N']	[40]
41	with	O	['N']	[41]
42	metabolic	O	['N']	[42]
43	acidosis	O	['N']	[43]
44	and	O	['N']	[44]
45	acute	B	['N']	[45]
46	renal	I	['N']	[46]
47	impairment	I-Adverse_Effect	['N']	[47]
48	)	O	['N']	[48]
49	are	O	['N']	[49]
50	described	O	['N']	[50]
51	.	O	['N']	[51]
#636
0	Acute	B	['N']	[0]
1	renal	I	['N']	[1]
2	failure	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	receiving	O	['N']	[6]
7	treatment	O	['N']	[7]
8	with	O	['N']	[8]
9	suramin	B-Drug	['Causes']	[2]
10	.	O	['N']	[10]
#637
0	This	O	['N']	[0]
1	review	O	['N']	[1]
2	presents	O	['N']	[2]
3	the	O	['N']	[3]
4	first	O	['N']	[4]
5	case	O	['N']	[5]
6	series	O	['N']	[6]
7	of	O	['N']	[7]
8	DIC	B-Adverse_Effect	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	acute	O	['N']	[11]
12	hemoglobinemia	O	['N']	[12]
13	or	O	['N']	[13]
14	hemoglobinuria	O	['N']	[14]
15	following	O	['N']	[15]
16	anti	B	['N']	[16]
17	-	I	['N']	[17]
18	D	I	['N']	[18]
19	IGIV	I-Drug	['Causes']	[8]
20	administration	O	['N']	[20]
21	for	O	['N']	[21]
22	ITP	O	['N']	[22]
23	.	O	['N']	[23]
#638
0	An	O	['N']	[0]
1	association	O	['N']	[1]
2	of	O	['N']	[2]
3	granulocytopenia	O	['N']	[3]
4	,	O	['N']	[4]
5	eosinophilia	O	['N']	[5]
6	,	O	['N']	[6]
7	skin	B	['N']	[7]
8	reaction	I-Adverse_Effect	['N']	[8]
9	and	O	['N']	[9]
10	hepatitis	O	['N']	[10]
11	during	O	['N']	[11]
12	propylthiouracil	B-Drug	['Causes']	[8]
13	(	O	['N']	[13]
14	PTU	O	['N']	[14]
15	)	O	['N']	[15]
16	therapy	O	['N']	[16]
17	for	O	['N']	[17]
18	thyrotoxicosis	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	47	O	['N']	[21]
22	year	O	['N']	[22]
23	old	O	['N']	[23]
24	black	O	['N']	[24]
25	female	O	['N']	[25]
26	is	O	['N']	[26]
27	reported	O	['N']	[27]
28	.	O	['N']	[28]
#639
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	this	O	['N']	[4]
5	is	O	['N']	[5]
6	the	O	['N']	[6]
7	first	O	['N']	[7]
8	report	O	['N']	[8]
9	of	O	['N']	[9]
10	an	O	['N']	[10]
11	angio	B	['N']	[11]
12	-	I	['N']	[12]
13	oedema	I-Adverse_Effect	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	VRC	B-Drug	['Causes']	[13]
17	.	O	['N']	[17]
#640
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Methotrexate	O	['N']	[2]
3	(	O	['N']	[3]
4	MTX	B-Drug	['Causes']	[18]
5	)	O	['N']	[5]
6	may	O	['N']	[6]
7	induce	O	['N']	[7]
8	liver	O	['N']	[8]
9	damage	O	['N']	[9]
10	,	O	['N']	[10]
11	which	O	['N']	[11]
12	in	O	['N']	[12]
13	some	O	['N']	[13]
14	psoriatics	O	['N']	[14]
15	will	O	['N']	[15]
16	lead	O	['N']	[16]
17	to	O	['N']	[17]
18	fibrosis	B-Adverse_Effect	['N']	[18]
19	or	O	['N']	[19]
20	cirrhosis	O	['N']	[20]
21	.	O	['N']	[21]
#641
0	A	O	['N']	[0]
1	58-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	developed	O	['N']	[5]
6	unilateral	B	['N']	[6]
7	acute	I	['N']	[7]
8	angle	I	['N']	[8]
9	-	I	['N']	[9]
10	closure	I	['N']	[10]
11	glaucoma	I-Adverse_Effect	['N']	[11]
12	four	O	['N']	[12]
13	days	O	['N']	[13]
14	after	O	['N']	[14]
15	the	O	['N']	[15]
16	application	O	['N']	[16]
17	of	O	['N']	[17]
18	a	O	['N']	[18]
19	patch	O	['N']	[19]
20	of	O	['N']	[20]
21	transdermal	O	['N']	[21]
22	scopolamine	B-Drug	['Causes']	[11]
23	delivery	O	['N']	[23]
24	system	O	['N']	[24]
25	(	O	['N']	[25]
26	TRANSDERM	O	['N']	[26]
27	-	O	['N']	[27]
28	V	O	['N']	[28]
29	)	O	['N']	[29]
30	.	O	['N']	[30]
#642
0	Successful	O	['N']	[0]
1	treatment	O	['N']	[1]
2	with	O	['N']	[2]
3	carbimazole	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	hyperthyroid	O	['N']	[6]
7	pregnancy	O	['N']	[7]
8	with	O	['N']	[8]
9	hepatic	B	['N']	[9]
10	impairment	I-Adverse_Effect	['N']	[10]
11	after	O	['N']	[11]
12	propylthiouracil	B-Drug	['Causes']	[10]
13	administration	O	['N']	[13]
14	:	O	['N']	[14]
15	a	O	['N']	[15]
16	case	O	['N']	[16]
17	report	O	['N']	[17]
18	.	O	['N']	[18]
#643
0	Reye	O	['N']	[0]
1	syndrome	O	['N']	[1]
2	(	O	['N']	[2]
3	RS	B-Adverse_Effect	['N']	[3]
4	)	O	['N']	[4]
5	is	O	['N']	[5]
6	believed	O	['N']	[6]
7	to	O	['N']	[7]
8	occur	O	['N']	[8]
9	infrequently	O	['N']	[9]
10	among	O	['N']	[10]
11	children	O	['N']	[11]
12	receiving	O	['N']	[12]
13	long	O	['N']	[13]
14	-	O	['N']	[14]
15	term	O	['N']	[15]
16	aspirin	B-Drug	['Causes']	[3]
17	therapy	O	['N']	[17]
18	.	O	['N']	[18]
#644
0	Since	O	['N']	[0]
1	this	O	['N']	[1]
2	amount	O	['N']	[2]
3	of	O	['N']	[3]
4	FAB	O	['N']	[4]
5	was	O	['N']	[5]
6	insufficient	O	['N']	[6]
7	to	O	['N']	[7]
8	bind	O	['N']	[8]
9	all	O	['N']	[9]
10	DGTX	B-Drug	['Causes']	[23]
11	present	O	['N']	[11]
12	in	O	['N']	[12]
13	the	O	['N']	[13]
14	serum	O	['N']	[14]
15	,	O	['N']	[15]
16	cardiac	O	['N']	[16]
17	DGTX	O	['N']	[17]
18	toxicity	O	['N']	[18]
19	(	O	['N']	[19]
20	total	B	['N']	[20]
21	AV	I	['N']	[21]
22	-	I	['N']	[22]
23	block	I-Adverse_Effect	['N']	[23]
24	)	O	['N']	[24]
25	persisted	O	['N']	[25]
26	.	O	['N']	[26]
#645
0	The	O	['N']	[0]
1	relationship	O	['N']	[1]
2	between	O	['N']	[2]
3	infliximab	B-Drug	['Causes']	[6]
4	treatment	O	['N']	[4]
5	and	O	['N']	[5]
6	lymphoma	B-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	Crohn	O	['N']	[8]
9	's	O	['N']	[9]
10	disease	O	['N']	[10]
11	.	O	['N']	[11]
#646
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	fatal	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	toxic	B	['N']	[6]
7	epidermal	I	['N']	[7]
8	necrolysis	I-Adverse_Effect	['N']	[8]
9	(	O	['N']	[9]
10	TEN	O	['N']	[10]
11	)	O	['N']	[11]
12	resulting	O	['N']	[12]
13	from	O	['N']	[13]
14	a	O	['N']	[14]
15	high	O	['N']	[15]
16	dose	O	['N']	[16]
17	of	O	['N']	[17]
18	cytosine	B	['N']	[18]
19	arabinoside	I-Drug	['Causes']	[8]
20	(	O	['N']	[20]
21	ARA	O	['N']	[21]
22	-	O	['N']	[22]
23	C	O	['N']	[23]
24	)	O	['N']	[24]
25	.	O	['N']	[25]
#647
0	During	O	['N']	[0]
1	the	O	['N']	[1]
2	first	O	['N']	[2]
3	days	O	['N']	[3]
4	of	O	['N']	[4]
5	arsenic	B	['N']	[5]
6	trioxide	I-Drug	['Causes']	[15]
7	treatment	O	['N']	[7]
8	a	O	['N']	[8]
9	rapid	O	['N']	[9]
10	decrease	B	['N']	[10]
11	in	I	['N']	[11]
12	the	I	['N']	[12]
13	D	I	['N']	[13]
14	-	I	['N']	[14]
15	dimers	I-Adverse_Effect	['N']	[15]
16	was	O	['N']	[16]
17	seen	O	['N']	[17]
18	(	O	['N']	[18]
19	normal	O	['N']	[19]
20	values	O	['N']	[20]
21	reached	O	['N']	[21]
22	until	O	['N']	[22]
23	day	O	['N']	[23]
24	7	O	['N']	[24]
25	)	O	['N']	[25]
26	,	O	['N']	[26]
27	together	O	['N']	[27]
28	with	O	['N']	[28]
29	a	O	['N']	[29]
30	slight	O	['N']	[30]
31	decrease	O	['N']	[31]
32	in	O	['N']	[32]
33	peripheral	O	['N']	[33]
34	blood	O	['N']	[34]
35	leukocytes	O	['N']	[35]
36	.	O	['N']	[36]
#648
0	Metronidazole	B-Drug	['Causes']	[1]
1	neuropathy	B-Adverse_Effect	['N']	[1]
2	.	O	['N']	[2]
#649
0	He	O	['N']	[0]
1	had	O	['N']	[1]
2	been	O	['N']	[2]
3	taking	O	['N']	[3]
4	trimethoprim	O	['N']	[4]
5	-	O	['N']	[5]
6	sulfamethoxazole	B-Drug	['Causes']	[44]
7	for	O	['N']	[7]
8	approximately	O	['N']	[8]
9	eight	O	['N']	[9]
10	days	O	['N']	[10]
11	when	O	['N']	[11]
12	he	O	['N']	[12]
13	revisited	O	['N']	[13]
14	his	O	['N']	[14]
15	family	O	['N']	[15]
16	physician	O	['N']	[16]
17	,	O	['N']	[17]
18	complaining	O	['N']	[18]
19	of	O	['N']	[19]
20	headaches	O	['N']	[20]
21	,	O	['N']	[21]
22	dizziness	O	['N']	[22]
23	,	O	['N']	[23]
24	difficulty	O	['N']	[24]
25	with	O	['N']	[25]
26	speech	O	['N']	[26]
27	,	O	['N']	[27]
28	weakness	O	['N']	[28]
29	,	O	['N']	[29]
30	and	O	['N']	[30]
31	itching	O	['N']	[31]
32	on	O	['N']	[32]
33	the	O	['N']	[33]
34	trunk	O	['N']	[34]
35	of	O	['N']	[35]
36	his	O	['N']	[36]
37	body	O	['N']	[37]
38	and	O	['N']	[38]
39	legs	O	['N']	[39]
40	,	O	['N']	[40]
41	where	O	['N']	[41]
42	a	O	['N']	[42]
43	maculopapular	B	['N']	[43]
44	rash	I-Adverse_Effect	['N']	[44]
45	was	O	['N']	[45]
46	noted	O	['N']	[46]
47	.	O	['N']	[47]
#650
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	skin	B	['N']	[23]
24	eruptions	I-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	cervical	O	['N']	[26]
27	lymphadenopathy	O	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	O	['N']	[31]
32	lymphocytosis	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	O	['N']	[40]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	O	['N']	[42]
43	(	O	['N']	[43]
44	SMX	B-Drug	['Causes']	[24]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#651
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	chronic	O	['N']	[6]
7	schizophrenia	O	['N']	[7]
8	who	O	['N']	[8]
9	experienced	O	['N']	[9]
10	delirium	B-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	grand	O	['N']	[12]
13	mal	O	['N']	[13]
14	seizure	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	photosensitivity	O	['N']	[17]
18	after	O	['N']	[18]
19	the	O	['N']	[19]
20	addition	O	['N']	[20]
21	of	O	['N']	[21]
22	propranolol	B-Drug	['Causes']	[10]
23	to	O	['N']	[23]
24	her	O	['N']	[24]
25	neuroleptic	O	['N']	[25]
26	regimen	O	['N']	[26]
27	.	O	['N']	[27]
#652
0	Thirty	O	['N']	[0]
1	-	O	['N']	[1]
2	six	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	AL	O	['N']	[5]
6	received	O	['N']	[6]
7	,	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	three	O	['N']	[10]
11	-	O	['N']	[11]
12	month	O	['N']	[12]
13	period	O	['N']	[13]
14	,	O	['N']	[14]
15	51	O	['N']	[15]
16	cycles	O	['N']	[16]
17	of	O	['N']	[17]
18	combined	O	['N']	[18]
19	chemotherapy	O	['N']	[19]
20	which	O	['N']	[20]
21	included	O	['N']	[21]
22	,	O	['N']	[22]
23	in	O	['N']	[23]
24	all	O	['N']	[24]
25	of	O	['N']	[25]
26	them	O	['N']	[26]
27	,	O	['N']	[27]
28	cytosine	B	['N']	[28]
29	arabinoside	I-Drug	['Causes']	[45]
30	(	O	['N']	[30]
31	ARA	O	['N']	[31]
32	-	O	['N']	[32]
33	C	O	['N']	[33]
34	)	O	['N']	[34]
35	;	O	['N']	[35]
36	among	O	['N']	[36]
37	them	O	['N']	[37]
38	,	O	['N']	[38]
39	along	O	['N']	[39]
40	with	O	['N']	[40]
41	myelosuppression	O	['N']	[41]
42	,	O	['N']	[42]
43	five	O	['N']	[43]
44	experienced	O	['N']	[44]
45	fever	B-Adverse_Effect	['N']	[45]
46	,	O	['N']	[46]
47	infectious	O	['N']	[47]
48	complications	O	['N']	[48]
49	,	O	['N']	[49]
50	gastrointestinal	O	['N']	[50]
51	tract	O	['N']	[51]
52	symptoms	O	['N']	[52]
53	and	O	['N']	[53]
54	severe	O	['N']	[54]
55	myalgias	O	['N']	[55]
56	.	O	['N']	[56]
#653
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	anhedonic	B	['N']	[5]
6	ejaculation	I-Adverse_Effect	['N']	[6]
7	(	O	['N']	[7]
8	ejaculation	O	['N']	[8]
9	without	O	['N']	[9]
10	orgasm	O	['N']	[10]
11	)	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	initiation	O	['N']	[14]
15	of	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	desipramine	B-Drug	['Causes']	[6]
19	.	O	['N']	[19]
#654
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	55-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	became	O	['N']	[7]
8	stuporous	B-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	overdose	O	['N']	[10]
11	with	O	['N']	[11]
12	lamotrigine	O	['N']	[12]
13	(	O	['N']	[13]
14	LTG	O	['N']	[14]
15	)	O	['N']	[15]
16	and	O	['N']	[16]
17	valproic	B	['N']	[17]
18	acid	I-Drug	['Causes']	[8]
19	(	O	['N']	[19]
20	VPA	O	['N']	[20]
21	)	O	['N']	[21]
22	tablets	O	['N']	[22]
23	.	O	['N']	[23]
#655
0	OBSERVATIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	48-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	presented	O	['N']	[7]
8	with	O	['N']	[8]
9	disfiguring	B	['N']	[9]
10	facial	I	['N']	[10]
11	edema	I-Adverse_Effect	['N']	[11]
12	10	O	['N']	[12]
13	weeks	O	['N']	[13]
14	after	O	['N']	[14]
15	she	O	['N']	[15]
16	began	O	['N']	[16]
17	antiviral	O	['N']	[17]
18	therapy	O	['N']	[18]
19	with	O	['N']	[19]
20	peginterferon	O	['N']	[20]
21	alfa-2a	O	['N']	[21]
22	and	O	['N']	[22]
23	ribavirin	B-Drug	['Causes']	[11]
24	for	O	['N']	[24]
25	chronic	O	['N']	[25]
26	hepatitis	O	['N']	[26]
27	C	O	['N']	[27]
28	infection	O	['N']	[28]
29	.	O	['N']	[29]
#656
0	Although	O	['N']	[0]
1	differential	O	['N']	[1]
2	diagnostic	O	['N']	[2]
3	alternatives	O	['N']	[3]
4	can	O	['N']	[4]
5	be	O	['N']	[5]
6	considered	O	['N']	[6]
7	in	O	['N']	[7]
8	all	O	['N']	[8]
9	described	O	['N']	[9]
10	cases	O	['N']	[10]
11	it	O	['N']	[11]
12	is	O	['N']	[12]
13	very	O	['N']	[13]
14	likely	O	['N']	[14]
15	that	O	['N']	[15]
16	vincristine	B-Drug	['Causes']	[21]
17	does	O	['N']	[17]
18	cause	O	['N']	[18]
19	severe	B	['N']	[19]
20	visual	I	['N']	[20]
21	loss	I-Adverse_Effect	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	small	O	['N']	[24]
25	number	O	['N']	[25]
26	of	O	['N']	[26]
27	patients	O	['N']	[27]
28	.	O	['N']	[28]
#657
0	Prior	O	['N']	[0]
1	reports	O	['N']	[1]
2	have	O	['N']	[2]
3	emphasized	O	['N']	[3]
4	the	O	['N']	[4]
5	tubular	B	['N']	[5]
6	and	I	['N']	[6]
7	interstitial	I	['N']	[7]
8	lesions	I-Adverse_Effect	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	intermittent	O	['N']	[11]
12	or	O	['N']	[12]
13	discontinuous	O	['N']	[13]
14	rifampin	B-Drug	['Causes']	[8]
15	therapy	O	['N']	[15]
16	for	O	['N']	[16]
17	tuberculosis	O	['N']	[17]
18	.	O	['N']	[18]
#658
0	Docetaxel	B-Drug	['Causes']	[7]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	Meibomian	B	['N']	[3]
4	duct	I	['N']	[4]
5	inflammation	I	['N']	[5]
6	and	I	['N']	[6]
7	blockage	I-Adverse_Effect	['N']	[7]
8	leading	O	['N']	[8]
9	to	O	['N']	[9]
10	chalazion	O	['N']	[10]
11	formation	O	['N']	[11]
12	.	O	['N']	[12]
#659
0	Neuroleptic	B	['N']	[0]
1	malignant	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	an	O	['N']	[4]
5	adolescent	O	['N']	[5]
6	receiving	O	['N']	[6]
7	olanzapine	O	['N']	[7]
8	-	O	['N']	[8]
9	lithium	B-Drug	['Causes']	[2]
10	combination	O	['N']	[10]
11	therapy	O	['N']	[11]
12	.	O	['N']	[12]
#660
0	Though	O	['N']	[0]
1	hypotension	O	['N']	[1]
2	,	O	['N']	[2]
3	dry	O	['N']	[3]
4	mouth	O	['N']	[4]
5	,	O	['N']	[5]
6	and	O	['N']	[6]
7	constipation	O	['N']	[7]
8	are	O	['N']	[8]
9	well	O	['N']	[9]
10	-	O	['N']	[10]
11	documented	O	['N']	[11]
12	possible	O	['N']	[12]
13	adverse	O	['N']	[13]
14	effects	O	['N']	[14]
15	,	O	['N']	[15]
16	the	O	['N']	[16]
17	possibility	O	['N']	[17]
18	of	O	['N']	[18]
19	clonidine	B-Drug	['Causes']	[22]
20	-	O	['N']	[20]
21	induced	O	['N']	[21]
22	bradycardia	B-Adverse_Effect	['N']	[22]
23	is	O	['N']	[23]
24	less	O	['N']	[24]
25	well	O	['N']	[25]
26	recognized	O	['N']	[26]
27	and	O	['N']	[27]
28	is	O	['N']	[28]
29	rare	O	['N']	[29]
30	.	O	['N']	[30]
#661
0	Visual	B	['N']	[0]
1	changes	I-Adverse_Effect	['N']	[1]
2	secondary	O	['N']	[2]
3	to	O	['N']	[3]
4	initiation	O	['N']	[4]
5	of	O	['N']	[5]
6	amiodarone	B-Drug	['Causes']	[1]
7	:	O	['N']	[7]
8	a	O	['N']	[8]
9	case	O	['N']	[9]
10	report	O	['N']	[10]
11	and	O	['N']	[11]
12	review	O	['N']	[12]
13	involving	O	['N']	[13]
14	ocular	O	['N']	[14]
15	management	O	['N']	[15]
16	in	O	['N']	[16]
17	cardiac	O	['N']	[17]
18	polypharmacy	O	['N']	[18]
19	.	O	['N']	[19]
#662
0	We	O	['N']	[0]
1	suspect	O	['N']	[1]
2	that	O	['N']	[2]
3	nefazodone	O	['N']	[3]
4	inhibits	B	['N']	[4]
5	metabolism	I	['N']	[5]
6	of	I	['N']	[6]
7	tacrolimus	B-Drug	['N']	[7]
8	.	O	['N']	[8]
#663
0	Given	O	['N']	[0]
1	that	O	['N']	[1]
2	discontinuation	O	['N']	[2]
3	of	O	['N']	[3]
4	nitrofurantoin	B-Drug	['Causes']	[34]
5	and	O	['N']	[5]
6	introduction	O	['N']	[6]
7	of	O	['N']	[7]
8	methylprednisolon	O	['N']	[8]
9	therapy	O	['N']	[9]
10	significantly	O	['N']	[10]
11	lowered	O	['N']	[11]
12	liver	O	['N']	[12]
13	enzyme	O	['N']	[13]
14	levels	O	['N']	[14]
15	,	O	['N']	[15]
16	restoring	O	['N']	[16]
17	most	O	['N']	[17]
18	of	O	['N']	[18]
19	them	O	['N']	[19]
20	to	O	['N']	[20]
21	normal	O	['N']	[21]
22	,	O	['N']	[22]
23	we	O	['N']	[23]
24	concluded	O	['N']	[24]
25	that	O	['N']	[25]
26	this	O	['N']	[26]
27	was	O	['N']	[27]
28	probably	O	['N']	[28]
29	the	O	['N']	[29]
30	case	O	['N']	[30]
31	of	O	['N']	[31]
32	toxic	B	['N']	[32]
33	liver	I	['N']	[33]
34	damage	I-Adverse_Effect	['N']	[34]
35	caused	O	['N']	[35]
36	by	O	['N']	[36]
37	nitrofurantoin	O	['N']	[37]
38	.	O	['N']	[38]
#664
0	Carboplatin	O	['N']	[0]
1	hypersensitivity	B-Adverse_Effect	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	low	O	['N']	[4]
5	-	O	['N']	[5]
6	dose	O	['N']	[6]
7	paclitaxel	B-Drug	['Causes']	[1]
8	/	O	['N']	[8]
9	carboplatin	O	['N']	[9]
10	in	O	['N']	[10]
11	multiple	O	['N']	[11]
12	platinum	O	['N']	[12]
13	-	O	['N']	[13]
14	treated	O	['N']	[14]
15	patients	O	['N']	[15]
16	with	O	['N']	[16]
17	recurrent	O	['N']	[17]
18	ovarian	O	['N']	[18]
19	cancer	O	['N']	[19]
20	.	O	['N']	[20]
#665
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	had	O	['N']	[2]
3	ampicillin	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	associated	O	['N']	[5]
6	seizures	B-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#666
0	L	O	['N']	[0]
1	-	O	['N']	[1]
2	Carnitine	O	['N']	[2]
3	supplementation	O	['N']	[3]
4	has	O	['N']	[4]
5	been	O	['N']	[5]
6	recommended	O	['N']	[6]
7	to	O	['N']	[7]
8	prevent	O	['N']	[8]
9	the	O	['N']	[9]
10	fatal	B	['N']	[10]
11	hepatotoxic	I	['N']	[11]
12	effects	I-Adverse_Effect	['N']	[12]
13	associated	O	['N']	[13]
14	with	O	['N']	[14]
15	valproic	B	['N']	[15]
16	acid	I-Drug	['Causes']	[12]
17	.	O	['N']	[17]
#667
0	In	O	['N']	[0]
1	some	O	['N']	[1]
2	cases	O	['N']	[2]
3	this	O	['N']	[3]
4	seems	O	['N']	[4]
5	to	O	['N']	[5]
6	happen	O	['N']	[6]
7	because	O	['N']	[7]
8	spironolactone	B-Drug	['Causes']	[10]
9	causes	O	['N']	[9]
10	diarrhoea	B-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#668
0	The	O	['N']	[0]
1	literature	O	['N']	[1]
2	on	O	['N']	[2]
3	thiabendazole	B-Drug	['Causes']	[12]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	cholestasis	O	['N']	[6]
7	and	O	['N']	[7]
8	its	O	['N']	[8]
9	association	O	['N']	[9]
10	with	O	['N']	[10]
11	sicca	B	['N']	[11]
12	complex	I-Adverse_Effect	['N']	[12]
13	is	O	['N']	[13]
14	reviewed	O	['N']	[14]
15	.	O	['N']	[15]
#669
0	Previous	O	['N']	[0]
1	studies	O	['N']	[1]
2	have	O	['N']	[2]
3	demonstrated	O	['N']	[3]
4	the	O	['N']	[4]
5	interaction	O	['N']	[5]
6	of	O	['N']	[6]
7	MTX	B-Drug	['Causes']	[36]
8	and	O	['N']	[8]
9	a	O	['N']	[9]
10	variety	O	['N']	[10]
11	of	O	['N']	[11]
12	non	O	['N']	[12]
13	-	O	['N']	[13]
14	steroidal	O	['N']	[14]
15	,	O	['N']	[15]
16	anti	O	['N']	[16]
17	-	O	['N']	[17]
18	inflammatory	O	['N']	[18]
19	drugs	O	['N']	[19]
20	(	O	['N']	[20]
21	NSAIDs	O	['N']	[21]
22	)	O	['N']	[22]
23	with	O	['N']	[23]
24	various	O	['N']	[24]
25	clinical	O	['N']	[25]
26	manifestations	O	['N']	[26]
27	including	O	['N']	[27]
28	acute	O	['N']	[28]
29	renal	O	['N']	[29]
30	failure	O	['N']	[30]
31	,	O	['N']	[31]
32	pancytopenia	O	['N']	[32]
33	,	O	['N']	[33]
34	vomiting	O	['N']	[34]
35	,	O	['N']	[35]
36	diarrhea	B-Adverse_Effect	['N']	[36]
37	,	O	['N']	[37]
38	elevated	O	['N']	[38]
39	liver	O	['N']	[39]
40	transaminases	O	['N']	[40]
41	,	O	['N']	[41]
42	jaundice	O	['N']	[42]
43	,	O	['N']	[43]
44	mucosal	O	['N']	[44]
45	ulcerations	O	['N']	[45]
46	,	O	['N']	[46]
47	and	O	['N']	[47]
48	pyrexia	O	['N']	[48]
49	.	O	['N']	[49]
#670
0	Patient	O	['N']	[0]
1	B	O	['N']	[1]
2	developed	O	['N']	[2]
3	perioral	B	['N']	[3]
4	and	I	['N']	[4]
5	upper	I	['N']	[5]
6	extremity	I	['N']	[6]
7	paresthesias	I-Adverse_Effect	['N']	[7]
8	during	O	['N']	[8]
9	the	O	['N']	[9]
10	fourth	O	['N']	[10]
11	cycle	O	['N']	[11]
12	of	O	['N']	[12]
13	CAP	B-Drug	['Causes']	[7]
14	alone	O	['N']	[14]
15	(	O	['N']	[15]
16	2500	O	['N']	[16]
17	mg	O	['N']	[17]
18	/	O	['N']	[18]
19	m2	O	['N']	[19]
20	)	O	['N']	[20]
21	.	O	['N']	[21]
#671
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	development	O	['N']	[3]
4	of	O	['N']	[4]
5	squamous	B	['N']	[5]
6	-	I	['N']	[6]
7	cell	I	['N']	[7]
8	carcinoma	I-Adverse_Effect	['N']	[8]
9	within	O	['N']	[9]
10	a	O	['N']	[10]
11	basal	O	['N']	[11]
12	-	O	['N']	[12]
13	cell	O	['N']	[13]
14	epithelioma	O	['N']	[14]
15	that	O	['N']	[15]
16	was	O	['N']	[16]
17	treated	O	['N']	[17]
18	with	O	['N']	[18]
19	intralesional	O	['N']	[19]
20	injections	O	['N']	[20]
21	of	O	['N']	[21]
22	5-FU	B-Drug	['Causes']	[8]
23	.	O	['N']	[23]
#672
0	Heat	B	['N']	[0]
1	stroke	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	schizophrenia	O	['N']	[3]
4	during	O	['N']	[4]
5	clozapine	B-Drug	['Causes']	[1]
6	treatment	O	['N']	[6]
7	:	O	['N']	[7]
8	rapid	O	['N']	[8]
9	recognition	O	['N']	[9]
10	and	O	['N']	[10]
11	management	O	['N']	[11]
12	.	O	['N']	[12]
#673
0	Fever	O	['N']	[0]
1	,	O	['N']	[1]
2	pulmonary	O	['N']	[2]
3	infiltrates	O	['N']	[3]
4	,	O	['N']	[4]
5	and	O	['N']	[5]
6	pleural	B	['N']	[6]
7	effusion	I-Adverse_Effect	['N']	[7]
8	following	O	['N']	[8]
9	acyclovir	B-Drug	['Causes']	[7]
10	therapy	O	['N']	[10]
11	for	O	['N']	[11]
12	herpes	O	['N']	[12]
13	zoster	O	['N']	[13]
14	ophthalmicus	O	['N']	[14]
15	.	O	['N']	[15]
#674
0	Rapamycin	O	['N']	[0]
1	/	O	['N']	[1]
2	sirolimus	O	['N']	[2]
3	(	O	['N']	[3]
4	SR	O	['N']	[4]
5	)	O	['N']	[5]
6	,	O	['N']	[6]
7	trade	O	['N']	[7]
8	named	O	['N']	[8]
9	Rapammune	B-Drug	['Causes']	[29]
10	(	O	['N']	[10]
11	Wyeth	O	['N']	[11]
12	-	O	['N']	[12]
13	Ayerst	O	['N']	[13]
14	,	O	['N']	[14]
15	Sydney	O	['N']	[15]
16	,	O	['N']	[16]
17	Australia	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	is	O	['N']	[20]
21	a	O	['N']	[21]
22	potent	O	['N']	[22]
23	immunosuppressive	O	['N']	[23]
24	drug	O	['N']	[24]
25	associated	O	['N']	[25]
26	with	O	['N']	[26]
27	myelosuppression	O	['N']	[27]
28	,	O	['N']	[28]
29	hypertension	B-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	hyperlipidemia	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	infection	O	['N']	[34]
35	.	O	['N']	[35]
#675
0	Rhabdomyolysis	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	the	O	['N']	[3]
4	use	O	['N']	[4]
5	of	O	['N']	[5]
6	intravenous	O	['N']	[6]
7	vasopressin	B-Drug	['Causes']	[0]
8	.	O	['N']	[8]
#676
0	After	O	['N']	[0]
1	excluding	O	['N']	[1]
2	other	O	['N']	[2]
3	causes	O	['N']	[3]
4	of	O	['N']	[4]
5	long	O	['N']	[5]
6	QT	O	['N']	[6]
7	syndrome	O	['N']	[7]
8	,	O	['N']	[8]
9	the	O	['N']	[9]
10	HCQ	B-Drug	['Causes']	[19]
11	was	O	['N']	[11]
12	suspected	O	['N']	[12]
13	as	O	['N']	[13]
14	the	O	['N']	[14]
15	cause	O	['N']	[15]
16	of	O	['N']	[16]
17	her	O	['N']	[17]
18	ventricular	B	['N']	[18]
19	tachycardia	I-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#677
0	Cerebrovascular	O	['N']	[0]
1	complications	O	['N']	[1]
2	of	O	['N']	[2]
3	L	B	['N']	[3]
4	-	I	['N']	[4]
5	asparaginase	I-Drug	['Causes']	[16]
6	therapy	O	['N']	[6]
7	in	O	['N']	[7]
8	children	O	['N']	[8]
9	with	O	['N']	[9]
10	leukemia	O	['N']	[10]
11	:	O	['N']	[11]
12	aphasia	O	['N']	[12]
13	and	O	['N']	[13]
14	other	O	['N']	[14]
15	neuropsychological	B	['N']	[15]
16	deficits	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#678
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	Stevens	O	['N']	[5]
6	-	O	['N']	[6]
7	Johnson	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	/	O	['N']	[9]
10	toxic	O	['N']	[10]
11	epidermal	O	['N']	[11]
12	necrolysis	O	['N']	[12]
13	(	O	['N']	[13]
14	SJS	O	['N']	[14]
15	/	O	['N']	[15]
16	TEN	B-Adverse_Effect	['N']	[16]
17	)	O	['N']	[17]
18	secondary	O	['N']	[18]
19	to	O	['N']	[19]
20	trimethoprim	B	['N']	[20]
21	-	I	['N']	[21]
22	sulfamethoxazole	I-Drug	['Causes']	[16]
23	(	O	['N']	[23]
24	TMP	O	['N']	[24]
25	-	O	['N']	[25]
26	Sx	O	['N']	[26]
27	)	O	['N']	[27]
28	therapy	O	['N']	[28]
29	for	O	['N']	[29]
30	presumed	O	['N']	[30]
31	community	O	['N']	[31]
32	-	O	['N']	[32]
33	associated	O	['N']	[33]
34	methicillin	O	['N']	[34]
35	-	O	['N']	[35]
36	resistant	O	['N']	[36]
37	Staphylococcus	O	['N']	[37]
38	aureus	O	['N']	[38]
39	(	O	['N']	[39]
40	CA	O	['N']	[40]
41	-	O	['N']	[41]
42	MRSA	O	['N']	[42]
43	)	O	['N']	[43]
44	infection	O	['N']	[44]
45	.	O	['N']	[45]
#679
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Our	O	['N']	[2]
3	patient	O	['N']	[3]
4	developed	O	['N']	[4]
5	Crohn	B	['N']	[5]
6	's	I	['N']	[6]
7	disease	I-Adverse_Effect	['N']	[7]
8	while	O	['N']	[8]
9	on	O	['N']	[9]
10	Copaxone	B-Drug	['Causes']	[7]
11	treatment	O	['N']	[11]
12	as	O	['N']	[12]
13	a	O	['N']	[13]
14	consequence	O	['N']	[14]
15	of	O	['N']	[15]
16	long	O	['N']	[16]
17	-	O	['N']	[17]
18	term	O	['N']	[18]
19	immunosuppression	O	['N']	[19]
20	.	O	['N']	[20]
#680
0	Sulfasalazine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hypersensitivity	B	['N']	[3]
4	syndrome	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	hemophagocytic	O	['N']	[6]
7	syndrome	O	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	reactivation	O	['N']	[10]
11	of	O	['N']	[11]
12	Epstein	O	['N']	[12]
13	-	O	['N']	[13]
14	Barr	O	['N']	[14]
15	virus	O	['N']	[15]
16	.	O	['N']	[16]
#681
0	The	O	['N']	[0]
1	development	O	['N']	[1]
2	of	O	['N']	[2]
3	an	O	['N']	[3]
4	IgG	B	['N']	[4]
5	lambda	I	['N']	[5]
6	-	I	['N']	[6]
7	type	I	['N']	[7]
8	monoclonal	I	['N']	[8]
9	gammopathy	I-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	subsequent	O	['N']	[11]
12	multiple	O	['N']	[12]
13	myeloma	O	['N']	[13]
14	in	O	['N']	[14]
15	an	O	['N']	[15]
16	epilepsy	O	['N']	[16]
17	patient	O	['N']	[17]
18	on	O	['N']	[18]
19	diphenylhydantoin	O	['N']	[19]
20	(	O	['N']	[20]
21	DILANTIN	B-Drug	['Causes']	[9]
22	)	O	['N']	[22]
23	therapy	O	['N']	[23]
24	for	O	['N']	[24]
25	20	O	['N']	[25]
26	years	O	['N']	[26]
27	is	O	['N']	[27]
28	reported	O	['N']	[28]
29	.	O	['N']	[29]
#682
0	The	O	['N']	[0]
1	second	O	['N']	[1]
2	patient	O	['N']	[2]
3	,	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	cholestasis	O	['N']	[6]
7	after	O	['N']	[7]
8	receiving	O	['N']	[8]
9	trimethoprim	B	['N']	[9]
10	-	I	['N']	[10]
11	sulfamethoxazole	I-Drug	['Causes']	[16]
12	,	O	['N']	[12]
13	had	O	['N']	[13]
14	marked	O	['N']	[14]
15	duct	B	['N']	[15]
16	paucity	I-Adverse_Effect	['N']	[16]
17	in	O	['N']	[17]
18	the	O	['N']	[18]
19	liver	O	['N']	[19]
20	biopsy	O	['N']	[20]
21	.	O	['N']	[21]
#683
0	Hyperammonemia	B-Adverse_Effect	['N']	[0]
1	secondary	O	['N']	[1]
2	to	O	['N']	[2]
3	valproic	B	['N']	[3]
4	acid	I-Drug	['Causes']	[0]
5	as	O	['N']	[5]
6	a	O	['N']	[6]
7	cause	O	['N']	[7]
8	of	O	['N']	[8]
9	lethargy	O	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	postictal	O	['N']	[12]
13	patient	O	['N']	[13]
14	.	O	['N']	[14]
#684
0	She	O	['N']	[0]
1	had	O	['N']	[1]
2	been	O	['N']	[2]
3	on	O	['N']	[3]
4	Copaxone	B-Drug	['Causes']	[18]
5	20	O	['N']	[5]
6	mg	O	['N']	[6]
7	/	O	['N']	[7]
8	day	O	['N']	[8]
9	treatment	O	['N']	[9]
10	for	O	['N']	[10]
11	2	O	['N']	[11]
12	years	O	['N']	[12]
13	when	O	['N']	[13]
14	she	O	['N']	[14]
15	first	O	['N']	[15]
16	exhibited	O	['N']	[16]
17	gastrointestinal	B	['N']	[17]
18	symptoms	I-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#685
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	this	O	['N']	[4]
5	recurrence	O	['N']	[5]
6	of	O	['N']	[6]
7	amiodarone	B-Drug	['Causes']	[9]
8	pulmonary	B	['N']	[8]
9	toxicity	I-Adverse_Effect	['N']	[9]
10	has	O	['N']	[10]
11	not	O	['N']	[11]
12	been	O	['N']	[12]
13	reported	O	['N']	[13]
14	previously	O	['N']	[14]
15	.	O	['N']	[15]
#686
0	After	O	['N']	[0]
1	rechallenge	O	['N']	[1]
2	with	O	['N']	[2]
3	monotherapy	O	['N']	[3]
4	pegvisomant	B-Drug	['Causes']	[48]
5	,	O	['N']	[5]
6	however	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	hepatic	O	['N']	[9]
10	enzyme	O	['N']	[10]
11	disturbances	O	['N']	[11]
12	reappeared	O	['N']	[12]
13	within	O	['N']	[13]
14	a	O	['N']	[14]
15	few	O	['N']	[15]
16	weeks	O	['N']	[16]
17	,	O	['N']	[17]
18	indicating	O	['N']	[18]
19	that	O	['N']	[19]
20	most	O	['N']	[20]
21	likely	O	['N']	[21]
22	pegvisomant	O	['N']	[22]
23	alone	O	['N']	[23]
24	and	O	['N']	[24]
25	not	O	['N']	[25]
26	the	O	['N']	[26]
27	long	O	['N']	[27]
28	-	O	['N']	[28]
29	acting	O	['N']	[29]
30	somatostatin	O	['N']	[30]
31	analog	O	['N']	[31]
32	or	O	['N']	[32]
33	the	O	['N']	[33]
34	combination	O	['N']	[34]
35	of	O	['N']	[35]
36	these	O	['N']	[36]
37	two	O	['N']	[37]
38	drugs	O	['N']	[38]
39	was	O	['N']	[39]
40	responsible	O	['N']	[40]
41	for	O	['N']	[41]
42	this	O	['N']	[42]
43	case	O	['N']	[43]
44	of	O	['N']	[44]
45	drug	O	['N']	[45]
46	-	O	['N']	[46]
47	induced	O	['N']	[47]
48	hepatitis	B-Adverse_Effect	['N']	[48]
49	.	O	['N']	[49]
#687
0	Biopsy	O	['N']	[0]
1	-	O	['N']	[1]
2	proven	O	['N']	[2]
3	acute	B	['N']	[3]
4	interstitial	I	['N']	[4]
5	nephritis	I-Adverse_Effect	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	the	O	['N']	[8]
9	tyrosine	O	['N']	[9]
10	kinase	O	['N']	[10]
11	inhibitor	O	['N']	[11]
12	sunitinib	B-Drug	['Causes']	[5]
13	:	O	['N']	[13]
14	a	O	['N']	[14]
15	class	O	['N']	[15]
16	effect	O	['N']	[16]
17	?	O	['N']	[17]
#688
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	transient	B	['N']	[4]
5	structured	I	['N']	[5]
6	visual	I	['N']	[6]
7	hallucinations	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	with	O	['N']	[11]
12	vascular	O	['N']	[12]
13	age	O	['N']	[13]
14	-	O	['N']	[14]
15	related	O	['N']	[15]
16	macular	O	['N']	[16]
17	degeneration	O	['N']	[17]
18	(	O	['N']	[18]
19	AMD	O	['N']	[19]
20	)	O	['N']	[20]
21	,	O	['N']	[21]
22	following	O	['N']	[22]
23	an	O	['N']	[23]
24	intravitreal	O	['N']	[24]
25	Avastin	B-Drug	['Causes']	[7]
26	-	O	['N']	[26]
27	injection	O	['N']	[27]
28	.	O	['N']	[28]
#689
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	37-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	African-	O	['N']	[6]
7	American	O	['N']	[7]
8	man	O	['N']	[8]
9	with	O	['N']	[9]
10	G6PD	O	['N']	[10]
11	deficiency	O	['N']	[11]
12	developed	O	['N']	[12]
13	hemolytic	O	['N']	[13]
14	anemia	O	['N']	[14]
15	,	O	['N']	[15]
16	hepatitis	O	['N']	[16]
17	,	O	['N']	[17]
18	orthostatic	O	['N']	[18]
19	hypotension	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	aseptic	B	['N']	[22]
23	meningitis	I-Adverse_Effect	['N']	[23]
24	simultaneously	O	['N']	[24]
25	after	O	['N']	[25]
26	using	O	['N']	[26]
27	trimethoprim	B-Drug	['Causes']	[23]
28	-	O	['N']	[28]
29	sulfamethoxazole	O	['N']	[29]
30	.	O	['N']	[30]
#690
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	ovarian	O	['N']	[3]
4	cancer	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	received	O	['N']	[7]
8	multiple	O	['N']	[8]
9	courses	O	['N']	[9]
10	of	O	['N']	[10]
11	cisplatin	B-Drug	['Causes']	[31]
12	without	O	['N']	[12]
13	complications	O	['N']	[13]
14	experienced	O	['N']	[14]
15	hypersensitivity	O	['N']	[15]
16	reactions	O	['N']	[16]
17	to	O	['N']	[17]
18	cisplatin	O	['N']	[18]
19	:	O	['N']	[19]
20	one	O	['N']	[20]
21	,	O	['N']	[21]
22	involving	O	['N']	[22]
23	intrahepatic	O	['N']	[23]
24	artery	O	['N']	[24]
25	infusion	O	['N']	[25]
26	,	O	['N']	[26]
27	manifested	O	['N']	[27]
28	general	O	['N']	[28]
29	erythema	O	['N']	[29]
30	,	O	['N']	[30]
31	dyspnea	B-Adverse_Effect	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	hypotension	O	['N']	[34]
35	;	O	['N']	[35]
36	the	O	['N']	[36]
37	other	O	['N']	[37]
38	,	O	['N']	[38]
39	involving	O	['N']	[39]
40	intravenous	O	['N']	[40]
41	infusion	O	['N']	[41]
42	,	O	['N']	[42]
43	manifested	O	['N']	[43]
44	abdominal	O	['N']	[44]
45	pain	O	['N']	[45]
46	,	O	['N']	[46]
47	general	O	['N']	[47]
48	erythema	O	['N']	[48]
49	,	O	['N']	[49]
50	and	O	['N']	[50]
51	fever	O	['N']	[51]
52	.	O	['N']	[52]
#691
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	two	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	delayed	B	['N']	[6]
7	elimination	I-Adverse_Effect	['N']	[7]
8	of	O	['N']	[8]
9	methotrexate	O	['N']	[9]
10	in	O	['N']	[10]
11	patients	O	['N']	[11]
12	receiving	O	['N']	[12]
13	ciprofloxacin	B-Drug	['Causes']	[7]
14	,	O	['N']	[14]
15	with	O	['N']	[15]
16	severe	O	['N']	[16]
17	toxicity	O	['N']	[17]
18	.	O	['N']	[18]
#692
0	Acute	O	['N']	[0]
1	dystonia	O	['N']	[1]
2	with	O	['N']	[2]
3	thalamic	B	['N']	[3]
4	and	I	['N']	[4]
5	brainstem	I	['N']	[5]
6	lesions	I-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	initial	O	['N']	[8]
9	penicillamine	B-Drug	['Causes']	[6]
10	treatment	O	['N']	[10]
11	in	O	['N']	[11]
12	Wilson	O	['N']	[12]
13	's	O	['N']	[13]
14	disease	O	['N']	[14]
15	.	O	['N']	[15]
#693
0	A	O	['N']	[0]
1	14-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	developed	O	['N']	[5]
6	systemic	B	['N']	[6]
7	lupus	I	['N']	[7]
8	erythematosus	I	['N']	[8]
9	(	I	['N']	[9]
10	SLE)-like	I	['N']	[10]
11	symptoms	I-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	rash	O	['N']	[13]
14	,	O	['N']	[14]
15	fever	O	['N']	[15]
16	,	O	['N']	[16]
17	leukopenia	O	['N']	[17]
18	and	O	['N']	[18]
19	positive	O	['N']	[19]
20	anti	O	['N']	[20]
21	-	O	['N']	[21]
22	nuclear	O	['N']	[22]
23	antibody	O	['N']	[23]
24	(	O	['N']	[24]
25	ANA	O	['N']	[25]
26	)	O	['N']	[26]
27	two	O	['N']	[27]
28	weeks	O	['N']	[28]
29	after	O	['N']	[29]
30	administration	O	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	O	['N']	[32]
33	(	O	['N']	[33]
34	CBZ	O	['N']	[34]
35	;	O	['N']	[35]
36	Tegretol	B-Drug	['Causes']	[11]
37	)	O	['N']	[37]
38	used	O	['N']	[38]
39	against	O	['N']	[39]
40	benign	O	['N']	[40]
41	Rolandic	O	['N']	[41]
42	epilepsy	O	['N']	[42]
43	.	O	['N']	[43]
#694
0	Diabetes	B	['N']	[0]
1	Mellitus	I-Adverse_Effect	['N']	[1]
2	was	O	['N']	[2]
3	observed	O	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	given	O	['N']	[7]
8	carbamazepine	B-Drug	['Causes']	[1]
9	.	O	['N']	[9]
#695
0	We	O	['N']	[0]
1	review	O	['N']	[1]
2	the	O	['N']	[2]
3	literature	O	['N']	[3]
4	on	O	['N']	[4]
5	previously	O	['N']	[5]
6	reported	O	['N']	[6]
7	cases	O	['N']	[7]
8	of	O	['N']	[8]
9	cutaneous	B	['N']	[9]
10	necrosis	I-Adverse_Effect	['N']	[10]
11	after	O	['N']	[11]
12	injection	O	['N']	[12]
13	of	O	['N']	[13]
14	standard	O	['N']	[14]
15	interferon	O	['N']	[15]
16	alfa	O	['N']	[16]
17	or	O	['N']	[17]
18	pegylated	B	['N']	[18]
19	interferon	I	['N']	[19]
20	alfa-2b	I-Drug	['Causes']	[10]
21	and	O	['N']	[21]
22	discuss	O	['N']	[22]
23	the	O	['N']	[23]
24	different	O	['N']	[24]
25	pathophysiologic	O	['N']	[25]
26	mechanisms	O	['N']	[26]
27	that	O	['N']	[27]
28	might	O	['N']	[28]
29	be	O	['N']	[29]
30	involved	O	['N']	[30]
31	.	O	['N']	[31]
#696
0	Baclofen	B-Drug	['Causes']	[7]
1	withdrawal	O	['N']	[1]
2	:	O	['N']	[2]
3	a	O	['N']	[3]
4	cause	O	['N']	[4]
5	of	O	['N']	[5]
6	prolonged	O	['N']	[6]
7	fever	B-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	the	O	['N']	[9]
10	intensive	O	['N']	[10]
11	care	O	['N']	[11]
12	unit	O	['N']	[12]
13	.	O	['N']	[13]
#697
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	an	O	['N']	[3]
4	individual	O	['N']	[4]
5	with	O	['N']	[5]
6	mental	O	['N']	[6]
7	retardation	O	['N']	[7]
8	who	O	['N']	[8]
9	experienced	O	['N']	[9]
10	behavioral	O	['N']	[10]
11	exacerbation	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	clonazepam	B-Drug	['Dosage']	[27]
15	prescribed	O	['N']	[15]
16	at	O	['N']	[16]
17	2	O	['N']	[17]
18	mg	O	['N']	[18]
19	/	O	['N']	[19]
20	day	O	['N']	[20]
21	(	O	['N']	[21]
22	0.02	B	['N']	[22]
23	mg	I	['N']	[23]
24	/	I	['N']	[24]
25	kg	I	['N']	[25]
26	/	I	['N']	[26]
27	day	I-Dose	['N']	[27]
28	)	O	['N']	[28]
29	to	O	['N']	[29]
30	treat	O	['N']	[30]
31	aggression	O	['N']	[31]
32	,	O	['N']	[32]
33	self	O	['N']	[33]
34	-	O	['N']	[34]
35	injurious	O	['N']	[35]
36	behavior	O	['N']	[36]
37	,	O	['N']	[37]
38	property	O	['N']	[38]
39	destruction	O	['N']	[39]
40	,	O	['N']	[40]
41	and	O	['N']	[41]
42	screaming	O	['N']	[42]
43	,	O	['N']	[43]
44	which	O	['N']	[44]
45	was	O	['N']	[45]
46	measured	O	['N']	[46]
47	with	O	['N']	[47]
48	a	O	['N']	[48]
49	15-minute	O	['N']	[49]
50	partial	O	['N']	[50]
51	interval	O	['N']	[51]
52	recording	O	['N']	[52]
53	measurement	O	['N']	[53]
54	method	O	['N']	[54]
55	.	O	['N']	[55]
#698
0	Are	O	['N']	[0]
1	nasal	O	['N']	[1]
2	decongestants	O	['N']	[2]
3	safer	O	['N']	[3]
4	than	O	['N']	[4]
5	rhinitis	O	['N']	[5]
6	?	O	['N']	[6]
7	A	O	['N']	[7]
8	case	O	['N']	[8]
9	of	O	['N']	[9]
10	oxymetazoline	B-Drug	['Causes']	[13]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	syncope	B-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#699
0	Dilated	B	['N']	[0]
1	cardiomyopathy	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	chronic	O	['N']	[4]
5	overuse	O	['N']	[5]
6	of	O	['N']	[6]
7	an	O	['N']	[7]
8	adrenaline	B-Drug	['Causes']	[1]
9	inhaler	O	['N']	[9]
10	.	O	['N']	[10]
#700
0	Fever	O	['N']	[0]
1	,	O	['N']	[1]
2	lymphadenopathy	B-Adverse_Effect	['N']	[2]
3	,	O	['N']	[3]
4	eosinophilia	O	['N']	[4]
5	,	O	['N']	[5]
6	lymphocytosis	O	['N']	[6]
7	,	O	['N']	[7]
8	hepatitis	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	dermatitis	O	['N']	[11]
12	:	O	['N']	[12]
13	a	O	['N']	[13]
14	severe	O	['N']	[14]
15	adverse	O	['N']	[15]
16	reaction	O	['N']	[16]
17	to	O	['N']	[17]
18	minocycline	B-Drug	['Causes']	[2]
19	.	O	['N']	[19]
#701
0	Noncardiogenic	B	['N']	[0]
1	pulmonary	I	['N']	[1]
2	edema	I-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	intrabiliary	O	['N']	[4]
5	infusion	O	['N']	[5]
6	of	O	['N']	[6]
7	mono	B	['N']	[7]
8	-	I	['N']	[8]
9	octanoin	I-Drug	['Causes']	[2]
10	.	O	['N']	[10]
#702
0	A	O	['N']	[0]
1	17-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	had	O	['N']	[7]
8	been	O	['N']	[8]
9	taking	O	['N']	[9]
10	oral	O	['N']	[10]
11	minocycline	B-Drug	['Causes']	[25]
12	(	O	['N']	[12]
13	50	O	['N']	[13]
14	mg	O	['N']	[14]
15	twice	O	['N']	[15]
16	daily	O	['N']	[16]
17	)	O	['N']	[17]
18	for	O	['N']	[18]
19	3	O	['N']	[19]
20	weeks	O	['N']	[20]
21	for	O	['N']	[21]
22	acne	O	['N']	[22]
23	developed	O	['N']	[23]
24	an	O	['N']	[24]
25	eruption	B-Adverse_Effect	['N']	[25]
26	that	O	['N']	[26]
27	progressed	O	['N']	[27]
28	to	O	['N']	[28]
29	an	O	['N']	[29]
30	exfoliative	O	['N']	[30]
31	dermatitis	O	['N']	[31]
32	.	O	['N']	[32]
#703
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	(	O	['N']	[2]
3	to	O	['N']	[3]
4	our	O	['N']	[4]
5	knowledge	O	['N']	[5]
6	,	O	['N']	[6]
7	for	O	['N']	[7]
8	the	O	['N']	[8]
9	first	O	['N']	[9]
10	time	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	child	O	['N']	[13]
14	)	O	['N']	[14]
15	the	O	['N']	[15]
16	emergence	O	['N']	[16]
17	of	O	['N']	[17]
18	psychosis	B-Adverse_Effect	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	12-year	O	['N']	[21]
22	old	O	['N']	[22]
23	white	O	['N']	[23]
24	girl	O	['N']	[24]
25	with	O	['N']	[25]
26	an	O	['N']	[26]
27	increased	O	['N']	[27]
28	efavirenz	B-Drug	['Causes']	[18]
29	concentration	O	['N']	[29]
30	and	O	['N']	[30]
31	heterozygous	O	['N']	[31]
32	gene	O	['N']	[32]
33	polymorphism	O	['N']	[33]
34	of	O	['N']	[34]
35	the	O	['N']	[35]
36	CYP2B6-G516T.	O	['N']	[36]
#704
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	,	O	['N']	[2]
3	in	O	['N']	[3]
4	whom	O	['N']	[4]
5	tumour	O	['N']	[5]
6	overkill	O	['N']	[6]
7	by	O	['N']	[7]
8	cytotoxic	O	['N']	[8]
9	treatment	O	['N']	[9]
10	,	O	['N']	[10]
11	including	O	['N']	[11]
12	high	O	['N']	[12]
13	dose	O	['N']	[13]
14	methotrexate	O	['N']	[14]
15	with	O	['N']	[15]
16	folinic	B	['N']	[16]
17	acid	I-Drug	['Causes']	[39]
18	rescue	O	['N']	[18]
19	,	O	['N']	[19]
20	resulted	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	'	O	['N']	[23]
24	phosphate	O	['N']	[24]
25	shower	O	['N']	[25]
26	syndrome	O	['N']	[26]
27	'	O	['N']	[27]
28	(	O	['N']	[28]
29	hyper	O	['N']	[29]
30	-	O	['N']	[30]
31	uricaemia	O	['N']	[31]
32	,	O	['N']	[32]
33	hyperkalaemia	O	['N']	[33]
34	and	O	['N']	[34]
35	hyperphosphataemia	O	['N']	[35]
36	with	O	['N']	[36]
37	hypocalcaemia	O	['N']	[37]
38	and	O	['N']	[38]
39	tetany	B-Adverse_Effect	['N']	[39]
40	,	O	['N']	[40]
41	with	O	['N']	[41]
42	metabolic	O	['N']	[42]
43	acidosis	O	['N']	[43]
44	and	O	['N']	[44]
45	acute	O	['N']	[45]
46	renal	O	['N']	[46]
47	impairment	O	['N']	[47]
48	)	O	['N']	[48]
49	are	O	['N']	[49]
50	described	O	['N']	[50]
51	.	O	['N']	[51]
#705
0	METHOD	O	['N']	[0]
1	:	O	['N']	[1]
2	Case	O	['N']	[2]
3	analysis	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	poly	O	['N']	[6]
7	-	O	['N']	[7]
8	drug	O	['N']	[8]
9	overdose	O	['N']	[9]
10	(	O	['N']	[10]
11	venlafaxine	O	['N']	[11]
12	,	O	['N']	[12]
13	topiramate	O	['N']	[13]
14	,	O	['N']	[14]
15	divalproex	O	['N']	[15]
16	sodium	O	['N']	[16]
17	,	O	['N']	[17]
18	risperidone	B-Drug	['Causes']	[26]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	carbamazepine	O	['N']	[21]
22	)	O	['N']	[22]
23	presenting	O	['N']	[23]
24	with	O	['N']	[24]
25	mixed	O	['N']	[25]
26	SS	B-Adverse_Effect	['N']	[26]
27	/	O	['N']	[27]
28	NMS	O	['N']	[28]
29	features	O	['N']	[29]
30	and	O	['N']	[30]
31	whose	O	['N']	[31]
32	clinical	O	['N']	[32]
33	management	O	['N']	[33]
34	suggests	O	['N']	[34]
35	a	O	['N']	[35]
36	practical	O	['N']	[36]
37	algorithm	O	['N']	[37]
38	for	O	['N']	[38]
39	treatment	O	['N']	[39]
40	of	O	['N']	[40]
41	undifferentiated	O	['N']	[41]
42	SS	O	['N']	[42]
43	/	O	['N']	[43]
44	NMS	O	['N']	[44]
45	in	O	['N']	[45]
46	critical	O	['N']	[46]
47	care	O	['N']	[47]
48	settings	O	['N']	[48]
49	.	O	['N']	[49]
#706
0	Renal	B	['N']	[0]
1	failure	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	the	O	['N']	[4]
5	use	O	['N']	[5]
6	of	O	['N']	[6]
7	dextran-40	B-Drug	['Causes']	[1]
8	.	O	['N']	[8]
#707
0	Therapy	O	['N']	[0]
1	with	O	['N']	[1]
2	IFN	B	['N']	[2]
3	-	I	['N']	[3]
4	alpha	I-Drug	['Causes']	[21]
5	may	O	['N']	[5]
6	be	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	number	O	['N']	[10]
11	of	O	['N']	[11]
12	neuropsychiatric	O	['N']	[12]
13	symptoms	O	['N']	[13]
14	,	O	['N']	[14]
15	such	O	['N']	[15]
16	as	O	['N']	[16]
17	Parkinsonism	O	['N']	[17]
18	,	O	['N']	[18]
19	akathisia	O	['N']	[19]
20	,	O	['N']	[20]
21	seizure	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	depressive	O	['N']	[24]
25	disorders	O	['N']	[25]
26	.	O	['N']	[26]
#708
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	's	O	['N']	[2]
3	clinical	O	['N']	[3]
4	presentation	O	['N']	[4]
5	,	O	['N']	[5]
6	histologic	O	['N']	[6]
7	features	O	['N']	[7]
8	on	O	['N']	[8]
9	liver	O	['N']	[9]
10	biopsy	O	['N']	[10]
11	and	O	['N']	[11]
12	favorable	O	['N']	[12]
13	course	O	['N']	[13]
14	after	O	['N']	[14]
15	stopping	O	['N']	[15]
16	the	O	['N']	[16]
17	drug	O	['N']	[17]
18	suggest	O	['N']	[18]
19	that	O	['N']	[19]
20	barbiturates	B-Drug	['Causes']	[34]
21	can	O	['N']	[21]
22	be	O	['N']	[22]
23	added	O	['N']	[23]
24	to	O	['N']	[24]
25	the	O	['N']	[25]
26	list	O	['N']	[26]
27	of	O	['N']	[27]
28	agents	O	['N']	[28]
29	which	O	['N']	[29]
30	can	O	['N']	[30]
31	cause	O	['N']	[31]
32	submassive	B	['N']	[32]
33	hepatic	I	['N']	[33]
34	necrosis	I-Adverse_Effect	['N']	[34]
35	.	O	['N']	[35]
#709
0	Telescoped	B	['N']	[0]
1	digits	I	['N']	[1]
2	of	I	['N']	[2]
3	the	I	['N']	[3]
4	hands	I	['N']	[4]
5	and	I	['N']	[5]
6	feet	I-Adverse_Effect	['N']	[6]
7	developed	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	69-year	O	['N']	[10]
11	-	O	['N']	[11]
12	old	O	['N']	[12]
13	male	O	['N']	[13]
14	with	O	['N']	[14]
15	severe	O	['N']	[15]
16	chronic	O	['N']	[16]
17	tophaceous	O	['N']	[17]
18	gout	O	['N']	[18]
19	during	O	['N']	[19]
20	allopurinol	B-Drug	['Causes']	[6]
21	treatment	O	['N']	[21]
22	.	O	['N']	[22]
#710
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	administration	O	['N']	[3]
4	of	O	['N']	[4]
5	tissue	B	['N']	[5]
6	plasminogen	I	['N']	[6]
7	activator	I-Drug	['Causes']	[15]
8	was	O	['N']	[8]
9	responsible	O	['N']	[9]
10	for	O	['N']	[10]
11	the	O	['N']	[11]
12	large	O	['N']	[12]
13	extent	O	['N']	[13]
14	of	O	['N']	[14]
15	hemorrhage	B-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	should	O	['N']	[17]
18	be	O	['N']	[18]
19	considered	O	['N']	[19]
20	in	O	['N']	[20]
21	the	O	['N']	[21]
22	differential	O	['N']	[22]
23	diagnosis	O	['N']	[23]
24	of	O	['N']	[24]
25	hemorrhagic	O	['N']	[25]
26	choroidal	O	['N']	[26]
27	detachment	O	['N']	[27]
28	.	O	['N']	[28]
#711
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	acute	B	['N']	[3]
4	respiratory	I	['N']	[4]
5	failure	I-Adverse_Effect	['N']	[5]
6	due	O	['N']	[6]
7	to	O	['N']	[7]
8	diaphragmatic	O	['N']	[8]
9	weakness	O	['N']	[9]
10	following	O	['N']	[10]
11	adalimumab	B-Drug	['Causes']	[5]
12	therapy	O	['N']	[12]
13	for	O	['N']	[13]
14	psoriasis	O	['N']	[14]
15	is	O	['N']	[15]
16	described	O	['N']	[16]
17	.	O	['N']	[17]
#712
0	The	O	['N']	[0]
1	potential	O	['N']	[1]
2	for	O	['N']	[2]
3	progressive	O	['N']	[3]
4	brain	O	['N']	[4]
5	injury	O	['N']	[5]
6	and	O	['N']	[6]
7	subsequent	O	['N']	[7]
8	disability	B-Adverse_Effect	['N']	[8]
9	related	O	['N']	[9]
10	to	O	['N']	[10]
11	intraventricular	O	['N']	[11]
12	IL-2	B-Drug	['Causes']	[8]
13	therapy	O	['N']	[13]
14	is	O	['N']	[14]
15	discussed	O	['N']	[15]
16	.	O	['N']	[16]
#713
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	3	O	['N']	[2]
3	elderly	O	['N']	[3]
4	patients	O	['N']	[4]
5	with	O	['N']	[5]
6	moderate	O	['N']	[6]
7	to	O	['N']	[7]
8	severe	O	['N']	[8]
9	ataxia	B-Adverse_Effect	['N']	[9]
10	that	O	['N']	[10]
11	occurred	O	['N']	[11]
12	while	O	['N']	[12]
13	they	O	['N']	[13]
14	were	O	['N']	[14]
15	taking	O	['N']	[15]
16	propafenone	B-Drug	['Causes']	[9]
17	.	O	['N']	[17]
#714
0	Discontinuation	O	['N']	[0]
1	of	O	['N']	[1]
2	the	O	['N']	[2]
3	itraconazole	B-Drug	['Causes']	[9]
4	caused	O	['N']	[4]
5	resolution	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	drug	B	['N']	[8]
9	eruption	I-Adverse_Effect	['N']	[9]
10	.	O	['N']	[10]
#715
0	Localized	O	['N']	[0]
1	dyskeratotic	O	['N']	[1]
2	plaque	O	['N']	[2]
3	with	O	['N']	[3]
4	milia	B-Adverse_Effect	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	sorafenib	B-Drug	['Causes']	[4]
8	.	O	['N']	[8]
#716
0	Cyclophosphamide	B-Drug	['Causes']	[7]
1	can	O	['N']	[1]
2	rarely	O	['N']	[2]
3	cause	O	['N']	[3]
4	interstitial	O	['N']	[4]
5	pneumonitis	O	['N']	[5]
6	and	O	['N']	[6]
7	fibrosis	B-Adverse_Effect	['N']	[7]
8	.	O	['N']	[8]
#717
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	generalized	O	['N']	[3]
4	MG	O	['N']	[4]
5	was	O	['N']	[5]
6	effectively	O	['N']	[6]
7	managed	O	['N']	[7]
8	with	O	['N']	[8]
9	MM	B-Drug	['Causes']	[13]
10	but	O	['N']	[10]
11	developed	O	['N']	[11]
12	CNS	B	['N']	[12]
13	lymphoma	I-Adverse_Effect	['N']	[13]
14	after	O	['N']	[14]
15	3	O	['N']	[15]
16	years	O	['N']	[16]
17	of	O	['N']	[17]
18	treatment	O	['N']	[18]
19	.	O	['N']	[19]
#718
0	Severe	B	['N']	[0]
1	acute	I	['N']	[1]
2	encephalopathy	I-Adverse_Effect	['N']	[2]
3	following	O	['N']	[3]
4	inadvertent	O	['N']	[4]
5	intrathecal	O	['N']	[5]
6	doxorubicin	B-Drug	['Causes']	[2]
7	administration	O	['N']	[7]
8	.	O	['N']	[8]
#719
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	presented	O	['N']	[2]
3	with	O	['N']	[3]
4	a	O	['N']	[4]
5	painful	B	['N']	[5]
6	,	I	['N']	[6]
7	oedematous	I	['N']	[7]
8	,	I	['N']	[8]
9	cyanosed	I	['N']	[9]
10	hand	I-Adverse_Effect	['N']	[10]
11	having	O	['N']	[11]
12	injected	O	['N']	[12]
13	a	O	['N']	[13]
14	solution	O	['N']	[14]
15	of	O	['N']	[15]
16	diamorphine	B-Drug	['Causes']	[10]
17	and	O	['N']	[17]
18	methylphenidate	O	['N']	[18]
19	into	O	['N']	[19]
20	his	O	['N']	[20]
21	radial	O	['N']	[21]
22	artery	O	['N']	[22]
23	.	O	['N']	[23]
#720
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	infectious	B	['N']	[5]
6	mononucleosis	I	['N']	[6]
7	-	I	['N']	[7]
8	like	I	['N']	[8]
9	syndrome	I-Adverse_Effect	['N']	[9]
10	induced	O	['N']	[10]
11	by	O	['N']	[11]
12	salazosulfapyridine	O	['N']	[12]
13	(	O	['N']	[13]
14	SASP	B-Drug	['Causes']	[9]
15	)	O	['N']	[15]
16	.	O	['N']	[16]
#721
0	Rifampin	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hypothyroidism	B-Adverse_Effect	['N']	[3]
4	without	O	['N']	[4]
5	underlying	O	['N']	[5]
6	thyroid	O	['N']	[6]
7	disease	O	['N']	[7]
8	.	O	['N']	[8]
#722
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	HLH	O	['N']	[3]
4	developed	O	['N']	[4]
5	etoposide	B-Drug	['Causes']	[11]
6	-	O	['N']	[6]
7	related	O	['N']	[7]
8	secondary	B	['N']	[8]
9	acute	I	['N']	[9]
10	myeloid	I	['N']	[10]
11	leukemia	I-Adverse_Effect	['N']	[11]
12	(	O	['N']	[12]
13	sAML	O	['N']	[13]
14	)	O	['N']	[14]
15	following	O	['N']	[15]
16	therapy	O	['N']	[16]
17	for	O	['N']	[17]
18	HLH	O	['N']	[18]
19	.	O	['N']	[19]
#723
0	Reversible	B	['N']	[0]
1	MR	I	['N']	[1]
2	imaging	I	['N']	[2]
3	and	I	['N']	[3]
4	MR	I	['N']	[4]
5	spectroscopy	I	['N']	[5]
6	abnormalities	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	association	O	['N']	[8]
9	with	O	['N']	[9]
10	metronidazole	B-Drug	['Causes']	[6]
11	therapy	O	['N']	[11]
12	.	O	['N']	[12]
#724
0	Spinal	B	['N']	[0]
1	cord	I	['N']	[1]
2	infarction	I-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	use	O	['N']	[4]
5	of	O	['N']	[5]
6	zolmitriptan	B-Drug	['Causes']	[2]
7	:	O	['N']	[7]
8	a	O	['N']	[8]
9	case	O	['N']	[9]
10	report	O	['N']	[10]
11	.	O	['N']	[11]
#725
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	fluoxetine	B-Drug	['Causes']	[10]
8	-	O	['N']	[8]
9	related	O	['N']	[9]
10	death	B-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	child	O	['N']	[13]
14	with	O	['N']	[14]
15	a	O	['N']	[15]
16	confirmed	O	['N']	[16]
17	genetic	O	['N']	[17]
18	polymorphism	O	['N']	[18]
19	of	O	['N']	[19]
20	the	O	['N']	[20]
21	CYP2D6	O	['N']	[21]
22	gene	O	['N']	[22]
23	that	O	['N']	[23]
24	results	O	['N']	[24]
25	in	O	['N']	[25]
26	impaired	O	['N']	[26]
27	drug	O	['N']	[27]
28	metabolism	O	['N']	[28]
29	.	O	['N']	[29]
#726
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	linezolid	B-Drug	['Causes']	[20]
4	-	O	['N']	[4]
5	associated	O	['N']	[5]
6	acute	O	['N']	[6]
7	interstitial	O	['N']	[7]
8	nephritis	O	['N']	[8]
9	within	O	['N']	[9]
10	the	O	['N']	[10]
11	context	O	['N']	[11]
12	of	O	['N']	[12]
13	a	O	['N']	[13]
14	drug	B	['N']	[14]
15	rash	I	['N']	[15]
16	with	I	['N']	[16]
17	eosinophilia	I	['N']	[17]
18	and	I	['N']	[18]
19	systemic	I	['N']	[19]
20	symptoms	I-Adverse_Effect	['N']	[20]
21	(	O	['N']	[21]
22	DRESS	O	['N']	[22]
23	)	O	['N']	[23]
24	syndrome	O	['N']	[24]
25	in	O	['N']	[25]
26	a	O	['N']	[26]
27	patient	O	['N']	[27]
28	treated	O	['N']	[28]
29	with	O	['N']	[29]
30	linezolid	O	['N']	[30]
31	raises	O	['N']	[31]
32	concerns	O	['N']	[32]
33	about	O	['N']	[33]
34	the	O	['N']	[34]
35	presumed	O	['N']	[35]
36	renal	O	['N']	[36]
37	safety	O	['N']	[37]
38	of	O	['N']	[38]
39	this	O	['N']	[39]
40	drug	O	['N']	[40]
41	.	O	['N']	[41]
#727
0	Used	O	['N']	[0]
1	injudiciously	O	['N']	[1]
2	,	O	['N']	[2]
3	naloxone	B-Drug	['Causes']	[13]
4	can	O	['N']	[4]
5	lead	O	['N']	[5]
6	to	O	['N']	[6]
7	withdrawal	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	,	O	['N']	[9]
10	return	O	['N']	[10]
11	of	O	['N']	[11]
12	severe	B	['N']	[12]
13	pain	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	other	O	['N']	[16]
17	adverse	O	['N']	[17]
18	effects	O	['N']	[18]
19	.	O	['N']	[19]
#728
0	A	O	['N']	[0]
1	7-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	girl	O	['N']	[4]
5	developed	O	['N']	[5]
6	diabetes	O	['N']	[6]
7	mellitus	O	['N']	[7]
8	and	O	['N']	[8]
9	exocrine	B	['N']	[9]
10	pancreatic	I	['N']	[10]
11	insufficiency	I-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	3.5	O	['N']	[13]
14	years	O	['N']	[14]
15	of	O	['N']	[15]
16	almost	O	['N']	[16]
17	continuous	O	['N']	[17]
18	treatment	O	['N']	[18]
19	with	O	['N']	[19]
20	azathioprine	O	['N']	[20]
21	and/or	O	['N']	[21]
22	prednisone	B-Drug	['Causes']	[11]
23	for	O	['N']	[23]
24	idiopathic	O	['N']	[24]
25	auto	O	['N']	[25]
26	-	O	['N']	[26]
27	immune	O	['N']	[27]
28	haemolytic	O	['N']	[28]
29	anaemia	O	['N']	[29]
30	.	O	['N']	[30]
#729
0	Piloerection	B-Adverse_Effect	['N']	[0]
1	induced	O	['N']	[1]
2	by	O	['N']	[2]
3	replacing	O	['N']	[3]
4	fluvoxamine	B-Drug	['Causes']	[0]
5	with	O	['N']	[5]
6	milnacipran	O	['N']	[6]
7	.	O	['N']	[7]
#730
0	One	O	['N']	[0]
1	week	O	['N']	[1]
2	after	O	['N']	[2]
3	the	O	['N']	[3]
4	initial	O	['N']	[4]
5	-	O	['N']	[5]
6	dose	O	['N']	[6]
7	of	O	['N']	[7]
8	adalimumab	B-Drug	['Dosage']	[11]
9	(	O	['N']	[9]
10	160	B	['N']	[10]
11	mg	I-Dose	['N']	[11]
12	)	O	['N']	[12]
13	,	O	['N']	[13]
14	which	O	['N']	[14]
15	was	O	['N']	[15]
16	initiated	O	['N']	[16]
17	due	O	['N']	[17]
18	to	O	['N']	[18]
19	an	O	['N']	[19]
20	acute	O	['N']	[20]
21	exacerbation	O	['N']	[21]
22	of	O	['N']	[22]
23	Crohn	O	['N']	[23]
24	's	O	['N']	[24]
25	disease	O	['N']	[25]
26	,	O	['N']	[26]
27	the	O	['N']	[27]
28	patient	O	['N']	[28]
29	developed	O	['N']	[29]
30	a	O	['N']	[30]
31	fulminant	O	['N']	[31]
32	cardiomyopathy	O	['N']	[32]
33	.	O	['N']	[33]
#731
0	Disulfiram	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	fulminant	B	['N']	[3]
4	hepatic	I	['N']	[4]
5	failure	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	an	O	['N']	[7]
8	active	O	['N']	[8]
9	duty	O	['N']	[9]
10	soldier	O	['N']	[10]
11	.	O	['N']	[11]
#732
0	Interstitial	B	['N']	[0]
1	pneumopathy	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	low	O	['N']	[3]
4	-	O	['N']	[4]
5	dosage	O	['N']	[5]
6	amiodarone	B-Drug	['Causes']	[1]
7	.	O	['N']	[7]
#733
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	4-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	girl	O	['N']	[6]
7	who	O	['N']	[7]
8	presented	O	['N']	[8]
9	with	O	['N']	[9]
10	acute	O	['N']	[10]
11	bilateral	O	['N']	[11]
12	blindness	O	['N']	[12]
13	,	O	['N']	[13]
14	a	O	['N']	[14]
15	focal	B	['N']	[15]
16	seizure	I-Adverse_Effect	['N']	[16]
17	and	O	['N']	[17]
18	hypertension	O	['N']	[18]
19	10	O	['N']	[19]
20	days	O	['N']	[20]
21	after	O	['N']	[21]
22	commencing	O	['N']	[22]
23	oxybutynin	B-Drug	['Causes']	[16]
24	to	O	['N']	[24]
25	treat	O	['N']	[25]
26	enuresis	O	['N']	[26]
27	.	O	['N']	[27]
#734
0	Thirty	O	['N']	[0]
1	-	O	['N']	[1]
2	six	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	AL	O	['N']	[5]
6	received	O	['N']	[6]
7	,	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	three	O	['N']	[10]
11	-	O	['N']	[11]
12	month	O	['N']	[12]
13	period	O	['N']	[13]
14	,	O	['N']	[14]
15	51	O	['N']	[15]
16	cycles	O	['N']	[16]
17	of	O	['N']	[17]
18	combined	O	['N']	[18]
19	chemotherapy	O	['N']	[19]
20	which	O	['N']	[20]
21	included	O	['N']	[21]
22	,	O	['N']	[22]
23	in	O	['N']	[23]
24	all	O	['N']	[24]
25	of	O	['N']	[25]
26	them	O	['N']	[26]
27	,	O	['N']	[27]
28	cytosine	O	['N']	[28]
29	arabinoside	O	['N']	[29]
30	(	O	['N']	[30]
31	ARA	B	['N']	[31]
32	-	I	['N']	[32]
33	C	I-Drug	['Causes']	[52]
34	)	O	['N']	[34]
35	;	O	['N']	[35]
36	among	O	['N']	[36]
37	them	O	['N']	[37]
38	,	O	['N']	[38]
39	along	O	['N']	[39]
40	with	O	['N']	[40]
41	myelosuppression	O	['N']	[41]
42	,	O	['N']	[42]
43	five	O	['N']	[43]
44	experienced	O	['N']	[44]
45	fever	O	['N']	[45]
46	,	O	['N']	[46]
47	infectious	O	['N']	[47]
48	complications	O	['N']	[48]
49	,	O	['N']	[49]
50	gastrointestinal	B	['N']	[50]
51	tract	I	['N']	[51]
52	symptoms	I-Adverse_Effect	['N']	[52]
53	and	O	['N']	[53]
54	severe	O	['N']	[54]
55	myalgias	O	['N']	[55]
56	.	O	['N']	[56]
#735
0	Fever	O	['N']	[0]
1	and	O	['N']	[1]
2	maculopapular	B	['N']	[2]
3	rashes	I-Adverse_Effect	['N']	[3]
4	appeared	O	['N']	[4]
5	at	O	['N']	[5]
6	10	O	['N']	[6]
7	days	O	['N']	[7]
8	after	O	['N']	[8]
9	phenytoin	B-Drug	['Causes']	[3]
10	initiation	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	then	O	['N']	[13]
14	the	O	['N']	[14]
15	drug	O	['N']	[15]
16	was	O	['N']	[16]
17	discontinued	O	['N']	[17]
18	.	O	['N']	[18]
#736
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	60-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	affected	O	['N']	[10]
11	by	O	['N']	[11]
12	squamous	O	['N']	[12]
13	lung	O	['N']	[13]
14	carcinoma	O	['N']	[14]
15	,	O	['N']	[15]
16	who	O	['N']	[16]
17	developed	O	['N']	[17]
18	paroxysmal	B	['N']	[18]
19	supraventricular	I	['N']	[19]
20	tachycardia	I-Adverse_Effect	['N']	[20]
21	during	O	['N']	[21]
22	cisplatin	B-Drug	['Causes']	[20]
23	and	O	['N']	[23]
24	etoposide	O	['N']	[24]
25	combination	O	['N']	[25]
26	chemotherapy	O	['N']	[26]
27	.	O	['N']	[27]
#737
0	Drug	B	['N']	[0]
1	rash	I	['N']	[1]
2	with	I	['N']	[2]
3	eosinophilia	I	['N']	[3]
4	and	I	['N']	[4]
5	systemic	I	['N']	[5]
6	symptoms	I-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	chlorambucil	B-Drug	['Causes']	[6]
9	treatment	O	['N']	[9]
10	in	O	['N']	[10]
11	chronic	O	['N']	[11]
12	lymphocytic	O	['N']	[12]
13	leukaemia	O	['N']	[13]
14	.	O	['N']	[14]
#738
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	disseminated	O	['N']	[5]
6	muscular	O	['N']	[6]
7	cysticercosis	O	['N']	[7]
8	followed	O	['N']	[8]
9	by	O	['N']	[9]
10	myositis	O	['N']	[10]
11	(	O	['N']	[11]
12	fever	O	['N']	[12]
13	,	O	['N']	[13]
14	diffuse	O	['N']	[14]
15	myalgia	O	['N']	[15]
16	,	O	['N']	[16]
17	weakness	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	lower	O	['N']	[20]
21	limbs	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	inflammatory	B	['N']	[24]
25	reaction	I	['N']	[25]
26	around	I	['N']	[26]
27	dying	I	['N']	[27]
28	cysticerci	I-Adverse_Effect	['N']	[28]
29	)	O	['N']	[29]
30	induced	O	['N']	[30]
31	by	O	['N']	[31]
32	praziquantel	B-Drug	['Causes']	[28]
33	therapy	O	['N']	[33]
34	,	O	['N']	[34]
35	an	O	['N']	[35]
36	event	O	['N']	[36]
37	not	O	['N']	[37]
38	described	O	['N']	[38]
39	previously	O	['N']	[39]
40	.	O	['N']	[40]
#739
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	the	O	['N']	[4]
5	syndrome	O	['N']	[5]
6	of	O	['N']	[6]
7	fever	O	['N']	[7]
8	,	O	['N']	[8]
9	pulmonary	O	['N']	[9]
10	infiltrates	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	pleural	B	['N']	[13]
14	effusion	I-Adverse_Effect	['N']	[14]
15	following	O	['N']	[15]
16	use	O	['N']	[16]
17	of	O	['N']	[17]
18	acyclovir	B-Drug	['Causes']	[14]
19	has	O	['N']	[19]
20	not	O	['N']	[20]
21	been	O	['N']	[21]
22	previously	O	['N']	[22]
23	reported	O	['N']	[23]
24	.	O	['N']	[24]
#740
0	Successful	O	['N']	[0]
1	treatment	O	['N']	[1]
2	of	O	['N']	[2]
3	visceral	O	['N']	[3]
4	leishmaniasis	O	['N']	[4]
5	with	O	['N']	[5]
6	allopurinol	O	['N']	[6]
7	plus	O	['N']	[7]
8	ketoconazole	O	['N']	[8]
9	in	O	['N']	[9]
10	an	O	['N']	[10]
11	infant	O	['N']	[11]
12	who	O	['N']	[12]
13	developed	O	['N']	[13]
14	pancreatitis	B-Adverse_Effect	['N']	[14]
15	caused	O	['N']	[15]
16	by	O	['N']	[16]
17	meglumine	B	['N']	[17]
18	antimoniate	I-Drug	['Causes']	[14]
19	.	O	['N']	[19]
#741
0	The	O	['N']	[0]
1	current	O	['N']	[1]
2	report	O	['N']	[2]
3	describes	O	['N']	[3]
4	a	O	['N']	[4]
5	man	O	['N']	[5]
6	who	O	['N']	[6]
7	was	O	['N']	[7]
8	prescribed	O	['N']	[8]
9	zonisamide	B-Drug	['Causes']	[26]
10	for	O	['N']	[10]
11	epilepsy	O	['N']	[11]
12	and	O	['N']	[12]
13	subsequently	O	['N']	[13]
14	developed	O	['N']	[14]
15	widespread	O	['N']	[15]
16	skin	O	['N']	[16]
17	rash	O	['N']	[17]
18	,	O	['N']	[18]
19	acute	O	['N']	[19]
20	kidney	O	['N']	[20]
21	injury	O	['N']	[21]
22	,	O	['N']	[22]
23	high	B	['N']	[23]
24	-	I	['N']	[24]
25	grade	I	['N']	[25]
26	fever	I-Adverse_Effect	['N']	[26]
27	,	O	['N']	[27]
28	eosinophilia	O	['N']	[28]
29	,	O	['N']	[29]
30	liver	O	['N']	[30]
31	dysfunction	O	['N']	[31]
32	,	O	['N']	[32]
33	lymphadenopathy	O	['N']	[33]
34	and	O	['N']	[34]
35	an	O	['N']	[35]
36	increase	O	['N']	[36]
37	in	O	['N']	[37]
38	antihuman	O	['N']	[38]
39	herpesvirus-6	O	['N']	[39]
40	immunoglobulin	O	['N']	[40]
41	G	O	['N']	[41]
42	titer	O	['N']	[42]
43	.	O	['N']	[43]
#742
0	Deposits	B	['N']	[0]
1	of	I	['N']	[1]
2	plasma	I	['N']	[2]
3	proteins	I	['N']	[3]
4	in	I	['N']	[4]
5	the	I	['N']	[5]
6	skin	I-Adverse_Effect	['N']	[6]
7	during	O	['N']	[7]
8	treatment	O	['N']	[8]
9	with	O	['N']	[9]
10	carbamazepine	O	['N']	[10]
11	and	O	['N']	[11]
12	diphenylhydantoin	B-Drug	['Causes']	[6]
13	.	O	['N']	[13]
#743
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	rheumatoid	O	['N']	[8]
9	arthritis	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	low	O	['N']	[12]
13	-	O	['N']	[13]
14	dose	O	['N']	[14]
15	methotrexate	B-Drug	['Causes']	[31]
16	(	O	['N']	[16]
17	15	O	['N']	[17]
18	mg	O	['N']	[18]
19	/	O	['N']	[19]
20	week	O	['N']	[20]
21	)	O	['N']	[21]
22	who	O	['N']	[22]
23	developed	O	['N']	[23]
24	infection	B	['N']	[24]
25	with	I	['N']	[25]
26	both	I	['N']	[26]
27	M.	I	['N']	[27]
28	tuberculosis	I	['N']	[28]
29	and	I	['N']	[29]
30	M.	I	['N']	[30]
31	chelonae	I-Adverse_Effect	['N']	[31]
32	after	O	['N']	[32]
33	the	O	['N']	[33]
34	revision	O	['N']	[34]
35	of	O	['N']	[35]
36	a	O	['N']	[36]
37	prosthetic	O	['N']	[37]
38	hip	O	['N']	[38]
39	.	O	['N']	[39]
#744
0	We	O	['N']	[0]
1	described	O	['N']	[1]
2	a	O	['N']	[2]
3	very	O	['N']	[3]
4	atypical	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	high	O	['N']	[8]
9	stage	O	['N']	[9]
10	,	O	['N']	[10]
11	high	O	['N']	[11]
12	grade	O	['N']	[12]
13	endometrial	B	['N']	[13]
14	cancer	I-Adverse_Effect	['N']	[14]
15	associated	O	['N']	[15]
16	with	O	['N']	[16]
17	tamoxifen	B-Drug	['Causes']	[14]
18	in	O	['N']	[18]
19	a	O	['N']	[19]
20	64-year	O	['N']	[20]
21	-	O	['N']	[21]
22	old	O	['N']	[22]
23	woman	O	['N']	[23]
24	with	O	['N']	[24]
25	a	O	['N']	[25]
26	past	O	['N']	[26]
27	history	O	['N']	[27]
28	of	O	['N']	[28]
29	breast	O	['N']	[29]
30	cancer	O	['N']	[30]
31	.	O	['N']	[31]
#745
0	To	O	['N']	[0]
1	date	O	['N']	[1]
2	,	O	['N']	[2]
3	eight	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	TEN	B-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	one	O	['N']	[8]
9	of	O	['N']	[9]
10	SJS	O	['N']	[10]
11	related	O	['N']	[11]
12	to	O	['N']	[12]
13	lamotrigine	B-Drug	['Causes']	[6]
14	administration	O	['N']	[14]
15	have	O	['N']	[15]
16	been	O	['N']	[16]
17	reported	O	['N']	[17]
18	in	O	['N']	[18]
19	the	O	['N']	[19]
20	literature	O	['N']	[20]
21	.	O	['N']	[21]
#746
0	Treatment	O	['N']	[0]
1	of	O	['N']	[1]
2	APL	O	['N']	[2]
3	in	O	['N']	[3]
4	pregnancy	O	['N']	[4]
5	is	O	['N']	[5]
6	controversial	O	['N']	[6]
7	as	O	['N']	[7]
8	the	O	['N']	[8]
9	use	O	['N']	[9]
10	of	O	['N']	[10]
11	ATRA	B-Drug	['Causes']	[19]
12	has	O	['N']	[12]
13	been	O	['N']	[13]
14	questioned	O	['N']	[14]
15	due	O	['N']	[15]
16	to	O	['N']	[16]
17	the	O	['N']	[17]
18	teratogenic	B	['N']	[18]
19	effect	I-Adverse_Effect	['N']	[19]
20	of	O	['N']	[20]
21	retinoids	O	['N']	[21]
22	.	O	['N']	[22]
#747
0	Life	O	['N']	[0]
1	-	O	['N']	[1]
2	threatening	O	['N']	[2]
3	anaphylactoid	B	['N']	[3]
4	reaction	I-Adverse_Effect	['N']	[4]
5	to	O	['N']	[5]
6	amifostine	B-Drug	['Causes']	[4]
7	used	O	['N']	[7]
8	with	O	['N']	[8]
9	concurrent	O	['N']	[9]
10	chemoradiotherapy	O	['N']	[10]
11	for	O	['N']	[11]
12	nasopharyngeal	O	['N']	[12]
13	cancer	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	patient	O	['N']	[16]
17	with	O	['N']	[17]
18	dermatomyositis	O	['N']	[18]
19	:	O	['N']	[19]
20	a	O	['N']	[20]
21	case	O	['N']	[21]
22	report	O	['N']	[22]
23	with	O	['N']	[23]
24	literature	O	['N']	[24]
25	review	O	['N']	[25]
26	.	O	['N']	[26]
#748
0	Ten	O	['N']	[0]
1	years	O	['N']	[1]
2	of	O	['N']	[2]
3	behavioral	O	['N']	[3]
4	data	O	['N']	[4]
5	are	O	['N']	[5]
6	presented	O	['N']	[6]
7	to	O	['N']	[7]
8	support	O	['N']	[8]
9	the	O	['N']	[9]
10	hypothesis	O	['N']	[10]
11	that	O	['N']	[11]
12	phenobarbital	B-Drug	['Causes']	[16]
13	was	O	['N']	[13]
14	exacerbating	O	['N']	[14]
15	maladaptive	B	['N']	[15]
16	behaviors	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#749
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	thrombocytopenia	B-Adverse_Effect	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	the	O	['N']	[10]
11	administration	O	['N']	[11]
12	of	O	['N']	[12]
13	lansoprazole	B-Drug	['Causes']	[7]
14	.	O	['N']	[14]
#750
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	pulmonary	O	['N']	[5]
6	adenocarcinoma	O	['N']	[6]
7	complicated	O	['N']	[7]
8	by	O	['N']	[8]
9	the	O	['N']	[9]
10	syndrome	O	['N']	[10]
11	of	O	['N']	[11]
12	inappropriate	O	['N']	[12]
13	secretion	O	['N']	[13]
14	of	O	['N']	[14]
15	antidiuretic	O	['N']	[15]
16	hormone	O	['N']	[16]
17	(	O	['N']	[17]
18	SIADH	B-Adverse_Effect	['N']	[18]
19	)	O	['N']	[19]
20	following	O	['N']	[20]
21	systemic	O	['N']	[21]
22	chemotherapy	O	['N']	[22]
23	with	O	['N']	[23]
24	cisplatin	O	['N']	[24]
25	(	O	['N']	[25]
26	CDDP	O	['N']	[26]
27	)	O	['N']	[27]
28	and	O	['N']	[28]
29	vindesine	O	['N']	[29]
30	(	O	['N']	[30]
31	VDS	B-Drug	['Causes']	[18]
32	)	O	['N']	[32]
33	.	O	['N']	[33]
#751
0	We	O	['N']	[0]
1	observed	O	['N']	[1]
2	3	O	['N']	[2]
3	diabetic	O	['N']	[3]
4	patients	O	['N']	[4]
5	with	O	['N']	[5]
6	intolerable	O	['N']	[6]
7	dizziness	O	['N']	[7]
8	followed	O	['N']	[8]
9	by	O	['N']	[9]
10	nausea	B-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	vomiting	O	['N']	[12]
13	immediately	O	['N']	[13]
14	after	O	['N']	[14]
15	an	O	['N']	[15]
16	initial	O	['N']	[16]
17	administration	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	alpha	O	['N']	[20]
21	-	O	['N']	[21]
22	glucosidase	O	['N']	[22]
23	inhibitor	O	['N']	[23]
24	,	O	['N']	[24]
25	voglibose	B-Drug	['Causes']	[10]
26	.	O	['N']	[26]
#752
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	the	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	two	O	['N']	[5]
6	female	O	['N']	[6]
7	patients	O	['N']	[7]
8	diagnosed	O	['N']	[8]
9	with	O	['N']	[9]
10	relapsing	O	['N']	[10]
11	-	O	['N']	[11]
12	remitting	O	['N']	[12]
13	multiple	O	['N']	[13]
14	sclerosis	O	['N']	[14]
15	(	O	['N']	[15]
16	RRMS	O	['N']	[16]
17	)	O	['N']	[17]
18	who	O	['N']	[18]
19	developed	O	['N']	[19]
20	inflammatory	B	['N']	[20]
21	musculoskeletal	I	['N']	[21]
22	manifestations	I-Adverse_Effect	['N']	[22]
23	,	O	['N']	[23]
24	following	O	['N']	[24]
25	IFN	B	['N']	[25]
26	-	I	['N']	[26]
27	beta	I-Drug	['Causes']	[22]
28	therapy	O	['N']	[28]
29	.	O	['N']	[29]
#753
0	Unintended	O	['N']	[0]
1	exposure	O	['N']	[1]
2	to	O	['N']	[2]
3	acyclovir	B-Drug	['Causes']	[19]
4	early	O	['N']	[4]
5	in	O	['N']	[5]
6	pregnancy	O	['N']	[6]
7	,	O	['N']	[7]
8	which	O	['N']	[8]
9	is	O	['N']	[9]
10	not	O	['N']	[10]
11	uncommon	O	['N']	[11]
12	,	O	['N']	[12]
13	may	O	['N']	[13]
14	cause	O	['N']	[14]
15	excessive	B	['N']	[15]
16	maternal	I	['N']	[16]
17	and	I	['N']	[17]
18	physician	I	['N']	[18]
19	anxiety	I-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#754
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	43-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	signs	O	['N']	[9]
10	and	O	['N']	[10]
11	symptoms	O	['N']	[11]
12	of	O	['N']	[12]
13	bilateral	B	['N']	[13]
14	optic	I	['N']	[14]
15	neuropathy	I-Adverse_Effect	['N']	[15]
16	during	O	['N']	[16]
17	treatment	O	['N']	[17]
18	with	O	['N']	[18]
19	ethambutol	B-Drug	['Causes']	[15]
20	.	O	['N']	[20]
#755
0	The	O	['N']	[0]
1	toxic	O	['N']	[1]
2	effects	O	['N']	[2]
3	of	O	['N']	[3]
4	methotrexate	B-Drug	['Causes']	[19]
5	included	O	['N']	[5]
6	elevated	O	['N']	[6]
7	liver	O	['N']	[7]
8	transaminases	O	['N']	[8]
9	(	O	['N']	[9]
10	3/4	O	['N']	[10]
11	)	O	['N']	[11]
12	,	O	['N']	[12]
13	nausea	O	['N']	[13]
14	(	O	['N']	[14]
15	2/4	O	['N']	[15]
16	)	O	['N']	[16]
17	,	O	['N']	[17]
18	abdominal	B	['N']	[18]
19	pain	I-Adverse_Effect	['N']	[19]
20	(	O	['N']	[20]
21	2/4	O	['N']	[21]
22	)	O	['N']	[22]
23	,	O	['N']	[23]
24	bone	O	['N']	[24]
25	pain	O	['N']	[25]
26	(	O	['N']	[26]
27	2/4	O	['N']	[27]
28	)	O	['N']	[28]
29	,	O	['N']	[29]
30	mild	O	['N']	[30]
31	neutropenia	O	['N']	[31]
32	(	O	['N']	[32]
33	1/4	O	['N']	[33]
34	)	O	['N']	[34]
35	,	O	['N']	[35]
36	and	O	['N']	[36]
37	mild	O	['N']	[37]
38	pruritus	O	['N']	[38]
39	(	O	['N']	[39]
40	1/4	O	['N']	[40]
41	)	O	['N']	[41]
42	.	O	['N']	[42]
#756
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	prolongation	O	['N']	[2]
3	of	O	['N']	[3]
4	5-FU	B-Drug	['Causes']	[12]
5	half	O	['N']	[5]
6	-	O	['N']	[6]
7	life	O	['N']	[7]
8	and	O	['N']	[8]
9	an	O	['N']	[9]
10	increase	B	['N']	[10]
11	in	I	['N']	[11]
12	INR	I-Adverse_Effect	['N']	[12]
13	have	O	['N']	[13]
14	been	O	['N']	[14]
15	reported	O	['N']	[15]
16	with	O	['N']	[16]
17	the	O	['N']	[17]
18	concurrent	O	['N']	[18]
19	use	O	['N']	[19]
20	of	O	['N']	[20]
21	5-FU	O	['N']	[21]
22	and	O	['N']	[22]
23	warfarin	O	['N']	[23]
24	.	O	['N']	[24]
#757
0	Interstitial	O	['N']	[0]
1	pneumopathy	O	['N']	[1]
2	and	O	['N']	[2]
3	low	B	['N']	[3]
4	-	I	['N']	[4]
5	dosage	I-Dose	['N']	[5]
6	amiodarone	B-Drug	['Dosage']	[5]
7	.	O	['N']	[7]
#758
0	A	O	['N']	[0]
1	44-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	is	O	['N']	[5]
6	described	O	['N']	[6]
7	in	O	['N']	[7]
8	whom	O	['N']	[8]
9	amiodarone	B-Drug	['Causes']	[25]
10	,	O	['N']	[10]
11	disopyramide	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	quinidine	O	['N']	[14]
15	,	O	['N']	[15]
16	administered	O	['N']	[16]
17	alone	O	['N']	[17]
18	separately	O	['N']	[18]
19	,	O	['N']	[19]
20	induced	O	['N']	[20]
21	atypical	O	['N']	[21]
22	ventricular	O	['N']	[22]
23	tachycardia	O	['N']	[23]
24	(	O	['N']	[24]
25	AVT	B-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	torsade	O	['N']	[27]
28	de	O	['N']	[28]
29	pointes	O	['N']	[29]
30	)	O	['N']	[30]
31	.	O	['N']	[31]
#759
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	14-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	female	O	['N']	[9]
10	with	O	['N']	[10]
11	acute	O	['N']	[11]
12	promyelocytic	O	['N']	[12]
13	leukemia	O	['N']	[13]
14	who	O	['N']	[14]
15	developed	O	['N']	[15]
16	symptomatic	B	['N']	[16]
17	cardiomyopathy	I-Adverse_Effect	['N']	[17]
18	only	O	['N']	[18]
19	4	O	['N']	[19]
20	months	O	['N']	[20]
21	into	O	['N']	[21]
22	treatment	O	['N']	[22]
23	with	O	['N']	[23]
24	a	O	['N']	[24]
25	combination	O	['N']	[25]
26	of	O	['N']	[26]
27	daunomycin	B-Drug	['Causes']	[17]
28	and	O	['N']	[28]
29	all	O	['N']	[29]
30	-	O	['N']	[30]
31	trans	O	['N']	[31]
32	retinoic	O	['N']	[32]
33	acid	O	['N']	[33]
34	(	O	['N']	[34]
35	ATRA	O	['N']	[35]
36	)	O	['N']	[36]
37	.	O	['N']	[37]
#760
0	Seizures	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	extrapyramidal	O	['N']	[2]
3	symptoms	O	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	Tourette	O	['N']	[8]
9	's	O	['N']	[9]
10	syndrome	O	['N']	[10]
11	,	O	['N']	[11]
12	Asperger	O	['N']	[12]
13	's	O	['N']	[13]
14	syndrome	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	multiple	O	['N']	[17]
18	sclerosis	O	['N']	[18]
19	treated	O	['N']	[19]
20	with	O	['N']	[20]
21	interferon	B	['N']	[21]
22	beta-1a	I-Drug	['Causes']	[0]
23	and	O	['N']	[23]
24	clomipramine	O	['N']	[24]
25	.	O	['N']	[25]
#761
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	here	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	cardiovascular	O	['N']	[6]
7	and	O	['N']	[7]
8	neurological	B	['N']	[8]
9	depression	I-Adverse_Effect	['N']	[9]
10	induced	O	['N']	[10]
11	by	O	['N']	[11]
12	oxymetalzoline	B-Drug	['Causes']	[9]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	toddler	O	['N']	[15]
16	.	O	['N']	[16]
#762
0	Administration	O	['N']	[0]
1	of	O	['N']	[1]
2	excessive	O	['N']	[2]
3	insulin	B-Drug	['Causes']	[5]
4	induced	O	['N']	[4]
5	hypoglycemia	B-Adverse_Effect	['N']	[5]
6	within	O	['N']	[6]
7	4	O	['N']	[7]
8	to	O	['N']	[8]
9	8	O	['N']	[9]
10	hours	O	['N']	[10]
11	,	O	['N']	[11]
12	followed	O	['N']	[12]
13	by	O	['N']	[13]
14	rebound	O	['N']	[14]
15	hyperglycemia	O	['N']	[15]
16	.	O	['N']	[16]
#763
0	We	O	['N']	[0]
1	reported	O	['N']	[1]
2	3	O	['N']	[2]
3	patients	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	acute	O	['N']	[6]
7	generalized	O	['N']	[7]
8	dystonia	O	['N']	[8]
9	and	O	['N']	[9]
10	akinetic	O	['N']	[10]
11	rigid	O	['N']	[11]
12	syndrome	O	['N']	[12]
13	following	O	['N']	[13]
14	an	O	['N']	[14]
15	initial	O	['N']	[15]
16	therapy	O	['N']	[16]
17	with	O	['N']	[17]
18	d	B	['N']	[18]
19	-	I	['N']	[19]
20	penicillamine	I-Drug	['Dosage']	[25]
21	125	B	['N']	[21]
22	-	I	['N']	[22]
23	500	I	['N']	[23]
24	mg	I	['N']	[24]
25	daily	I-Dose	['N']	[25]
26	.	O	['N']	[26]
#764
0	Intravenous	O	['N']	[0]
1	verapamil	B-Drug	['Causes']	[25]
2	therapy	O	['N']	[2]
3	in	O	['N']	[3]
4	babies	O	['N']	[4]
5	may	O	['N']	[5]
6	cause	O	['N']	[6]
7	apnea	O	['N']	[7]
8	,	O	['N']	[8]
9	hypotension	O	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	bradycardia	O	['N']	[12]
13	;	O	['N']	[13]
14	continued	O	['N']	[14]
15	episodes	O	['N']	[15]
16	of	O	['N']	[16]
17	atrial	O	['N']	[17]
18	flutter	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	child	O	['N']	[21]
22	may	O	['N']	[22]
23	cause	O	['N']	[23]
24	sudden	B	['N']	[24]
25	death	I-Adverse_Effect	['N']	[25]
26	;	O	['N']	[26]
27	quinidine	O	['N']	[27]
28	may	O	['N']	[28]
29	be	O	['N']	[29]
30	related	O	['N']	[30]
31	to	O	['N']	[31]
32	the	O	['N']	[32]
33	death	O	['N']	[33]
34	;	O	['N']	[34]
35	children	O	['N']	[35]
36	with	O	['N']	[36]
37	"	O	['N']	[37]
38	familial	O	['N']	[38]
39	seizure	O	['N']	[39]
40	disorders	O	['N']	[40]
41	"	O	['N']	[41]
42	may	O	['N']	[42]
43	in	O	['N']	[43]
44	fact	O	['N']	[44]
45	have	O	['N']	[45]
46	the	O	['N']	[46]
47	long	O	['N']	[47]
48	QT	O	['N']	[48]
49	interval	O	['N']	[49]
50	syndrome	O	['N']	[50]
51	.	O	['N']	[51]
#765
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	severe	O	['N']	[5]
6	hypotension	B-Adverse_Effect	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	intravenous	O	['N']	[9]
10	valproate	B-Drug	['Causes']	[6]
11	used	O	['N']	[11]
12	to	O	['N']	[12]
13	treat	O	['N']	[13]
14	status	O	['N']	[14]
15	epilepticus	O	['N']	[15]
16	in	O	['N']	[16]
17	an	O	['N']	[17]
18	11-year	O	['N']	[18]
19	-	O	['N']	[19]
20	old	O	['N']	[20]
21	girl	O	['N']	[21]
22	.	O	['N']	[22]
#766
0	Aliskiren	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	acute	B	['N']	[3]
4	renal	I	['N']	[4]
5	failure	I-Adverse_Effect	['N']	[5]
6	with	O	['N']	[6]
7	hyperkalemia	O	['N']	[7]
8	.	O	['N']	[8]
#767
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	thought	O	['N']	[2]
3	that	O	['N']	[3]
4	the	O	['N']	[4]
5	clinico	O	['N']	[5]
6	-	O	['N']	[6]
7	pathological	O	['N']	[7]
8	features	O	['N']	[8]
9	and	O	['N']	[9]
10	chronology	O	['N']	[10]
11	of	O	['N']	[11]
12	this	O	['N']	[12]
13	case	O	['N']	[13]
14	bore	O	['N']	[14]
15	the	O	['N']	[15]
16	hallmarks	O	['N']	[16]
17	of	O	['N']	[17]
18	the	O	['N']	[18]
19	so	O	['N']	[19]
20	-	O	['N']	[20]
21	called	O	['N']	[21]
22	"	O	['N']	[22]
23	3-week	O	['N']	[23]
24	sulphasalazine	B-Drug	['Causes']	[25]
25	syndrome	I-Adverse_Effect	['N']	[25]
26	"	O	['N']	[26]
27	,	O	['N']	[27]
28	a	O	['N']	[28]
29	rare	O	['N']	[29]
30	,	O	['N']	[30]
31	but	O	['N']	[31]
32	often	O	['N']	[32]
33	fatal	O	['N']	[33]
34	,	O	['N']	[34]
35	immunoallergic	O	['N']	[35]
36	reaction	O	['N']	[36]
37	to	O	['N']	[37]
38	sulphasalazine	O	['N']	[38]
39	.	O	['N']	[39]
#768
0	Three	O	['N']	[0]
1	of	O	['N']	[1]
2	50	O	['N']	[2]
3	patients	O	['N']	[3]
4	treated	O	['N']	[4]
5	with	O	['N']	[5]
6	isotretinoin	B-Drug	['Dosage']	[13]
7	(	O	['N']	[7]
8	1	B	['N']	[8]
9	mg	I	['N']	[9]
10	/	I	['N']	[10]
11	kg	I	['N']	[11]
12	/	I	['N']	[12]
13	day	I-Dose	['N']	[13]
14	)	O	['N']	[14]
15	for	O	['N']	[15]
16	cystic	O	['N']	[16]
17	acne	O	['N']	[17]
18	complained	O	['N']	[18]
19	of	O	['N']	[19]
20	poor	O	['N']	[20]
21	night	O	['N']	[21]
22	vision	O	['N']	[22]
23	and/or	O	['N']	[23]
24	excessive	O	['N']	[24]
25	glare	O	['N']	[25]
26	sensitivity	O	['N']	[26]
27	.	O	['N']	[27]
#769
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	marked	O	['N']	[2]
3	QT	O	['N']	[3]
4	prolongation	O	['N']	[4]
5	and	O	['N']	[5]
6	torsades	O	['N']	[6]
7	de	O	['N']	[7]
8	pointes	O	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	setting	O	['N']	[11]
12	of	O	['N']	[12]
13	flash	O	['N']	[13]
14	pulmonary	O	['N']	[14]
15	edema	O	['N']	[15]
16	resulting	O	['N']	[16]
17	from	O	['N']	[17]
18	acute	B	['N']	[18]
19	myocardial	I	['N']	[19]
20	ischemia	I-Adverse_Effect	['N']	[20]
21	in	O	['N']	[21]
22	a	O	['N']	[22]
23	patient	O	['N']	[23]
24	who	O	['N']	[24]
25	was	O	['N']	[25]
26	being	O	['N']	[26]
27	treated	O	['N']	[27]
28	with	O	['N']	[28]
29	dofetilide	B-Drug	['Causes']	[20]
30	for	O	['N']	[30]
31	atrial	O	['N']	[31]
32	fibrillation	O	['N']	[32]
33	.	O	['N']	[33]
#770
0	Hyperpigmentation	B-Adverse_Effect	['N']	[0]
1	during	O	['N']	[1]
2	interferon	B	['N']	[2]
3	-	I	['N']	[3]
4	alpha	I-Drug	['Causes']	[0]
5	therapy	O	['N']	[5]
6	for	O	['N']	[6]
7	chronic	O	['N']	[7]
8	hepatitis	O	['N']	[8]
9	C	O	['N']	[9]
10	virus	O	['N']	[10]
11	infection	O	['N']	[11]
12	.	O	['N']	[12]
#771
0	Risperidone	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	psychosis	O	['N']	[3]
4	and	O	['N']	[4]
5	depression	B-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	child	O	['N']	[8]
9	with	O	['N']	[9]
10	a	O	['N']	[10]
11	mitochondrial	O	['N']	[11]
12	disorder	O	['N']	[12]
13	.	O	['N']	[13]
#772
0	PURPOSE	O	['N']	[0]
1	/	O	['N']	[1]
2	OBJECTIVES	O	['N']	[2]
3	:	O	['N']	[3]
4	To	O	['N']	[4]
5	describe	O	['N']	[5]
6	the	O	['N']	[6]
7	pharmacogenetic	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	of	O	['N']	[9]
10	dihydropyrimidine	O	['N']	[10]
11	dehydrogenase	O	['N']	[11]
12	(	O	['N']	[12]
13	DPD	O	['N']	[13]
14	)	O	['N']	[14]
15	deficiency	O	['N']	[15]
16	,	O	['N']	[16]
17	which	O	['N']	[17]
18	predisposes	O	['N']	[18]
19	patients	O	['N']	[19]
20	with	O	['N']	[20]
21	cancer	O	['N']	[21]
22	to	O	['N']	[22]
23	potentially	O	['N']	[23]
24	lethal	B	['N']	[24]
25	adverse	I	['N']	[25]
26	reactions	I-Adverse_Effect	['N']	[26]
27	following	O	['N']	[27]
28	5-fluorouracil	B-Drug	['Causes']	[26]
29	(	O	['N']	[29]
30	5-FU)-based	O	['N']	[30]
31	chemotherapy	O	['N']	[31]
32	.	O	['N']	[32]
#773
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	amiodarone	B-Drug	['Causes']	[8]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	thyrotoxicosis	B-Adverse_Effect	['N']	[8]
9	of	O	['N']	[9]
10	protracted	O	['N']	[10]
11	duration	O	['N']	[11]
12	,	O	['N']	[12]
13	unresponsive	O	['N']	[13]
14	to	O	['N']	[14]
15	conventional	O	['N']	[15]
16	thionamide	O	['N']	[16]
17	therapy	O	['N']	[17]
18	,	O	['N']	[18]
19	with	O	['N']	[19]
20	therapy	O	['N']	[20]
21	limited	O	['N']	[21]
22	by	O	['N']	[22]
23	severe	O	['N']	[23]
24	adverse	O	['N']	[24]
25	drug	O	['N']	[25]
26	reactions	O	['N']	[26]
27	.	O	['N']	[27]
#774
0	She	O	['N']	[0]
1	died	O	['N']	[1]
2	within	O	['N']	[2]
3	six	O	['N']	[3]
4	weeks	O	['N']	[4]
5	of	O	['N']	[5]
6	developing	O	['N']	[6]
7	congestive	O	['N']	[7]
8	heart	O	['N']	[8]
9	failure	O	['N']	[9]
10	coupled	O	['N']	[10]
11	with	O	['N']	[11]
12	liver	B	['N']	[12]
13	failure	I-Adverse_Effect	['N']	[13]
14	due	O	['N']	[14]
15	to	O	['N']	[15]
16	haemosiderosis	O	['N']	[16]
17	despite	O	['N']	[17]
18	regular	O	['N']	[18]
19	use	O	['N']	[19]
20	of	O	['N']	[20]
21	desferrioxamine	B-Drug	['Causes']	[13]
22	.	O	['N']	[22]
#775
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	pericardial	B	['N']	[3]
4	hemorrhage	I-Adverse_Effect	['N']	[4]
5	,	O	['N']	[5]
6	which	O	['N']	[6]
7	is	O	['N']	[7]
8	related	O	['N']	[8]
9	to	O	['N']	[9]
10	the	O	['N']	[10]
11	use	O	['N']	[11]
12	of	O	['N']	[12]
13	low	O	['N']	[13]
14	-	O	['N']	[14]
15	dose	O	['N']	[15]
16	acetylsalicylic	B	['N']	[16]
17	acid	I-Drug	['Causes']	[4]
18	in	O	['N']	[18]
19	a	O	['N']	[19]
20	patient	O	['N']	[20]
21	with	O	['N']	[21]
22	essential	O	['N']	[22]
23	thrombocythemia	O	['N']	[23]
24	.	O	['N']	[24]
#776
0	Hepatotoxicity	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	use	O	['N']	[3]
4	of	O	['N']	[4]
5	D	B	['N']	[5]
6	-	I	['N']	[6]
7	penicillamine	I-Drug	['Causes']	[0]
8	in	O	['N']	[8]
9	rheumatoid	O	['N']	[9]
10	arthritis	O	['N']	[10]
11	.	O	['N']	[11]
#777
0	Triazolam	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	nocturnal	B	['N']	[3]
4	bingeing	I-Adverse_Effect	['N']	[4]
5	with	O	['N']	[5]
6	amnesia	O	['N']	[6]
7	.	O	['N']	[7]
#778
0	Fatal	B	['N']	[0]
1	eosinophilia	I	['N']	[1]
2	myalgia	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	marrow	O	['N']	[6]
7	transplant	O	['N']	[7]
8	patient	O	['N']	[8]
9	attributed	O	['N']	[9]
10	to	O	['N']	[10]
11	total	O	['N']	[11]
12	parenteral	O	['N']	[12]
13	nutrition	O	['N']	[13]
14	with	O	['N']	[14]
15	a	O	['N']	[15]
16	solution	O	['N']	[16]
17	containing	O	['N']	[17]
18	tryptophan	B-Drug	['Causes']	[3]
19	.	O	['N']	[19]
#779
0	Although	O	['N']	[0]
1	both	O	['N']	[1]
2	patients	O	['N']	[2]
3	recovered	O	['N']	[3]
4	from	O	['N']	[4]
5	the	O	['N']	[5]
6	colitis	B-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	the	O	['N']	[8]
9	administration	O	['N']	[9]
10	of	O	['N']	[10]
11	vancomycin	O	['N']	[11]
12	,	O	['N']	[12]
13	the	O	['N']	[13]
14	first	O	['N']	[14]
15	case	O	['N']	[15]
16	demonstrated	O	['N']	[16]
17	a	O	['N']	[17]
18	relapse	O	['N']	[18]
19	of	O	['N']	[19]
20	the	O	['N']	[20]
21	colitis	O	['N']	[21]
22	after	O	['N']	[22]
23	receiving	O	['N']	[23]
24	a	O	['N']	[24]
25	subsequent	O	['N']	[25]
26	course	O	['N']	[26]
27	of	O	['N']	[27]
28	the	O	['N']	[28]
29	same	O	['N']	[29]
30	chemotherapy	O	['N']	[30]
31	with	O	['N']	[31]
32	cisplatin	B-Drug	['Causes']	[6]
33	.	O	['N']	[33]
#780
0	We	O	['N']	[0]
1	consider	O	['N']	[1]
2	asterixis	B-Adverse_Effect	['N']	[2]
3	to	O	['N']	[3]
4	be	O	['N']	[4]
5	an	O	['N']	[5]
6	easily	O	['N']	[6]
7	overlooked	O	['N']	[7]
8	sign	O	['N']	[8]
9	of	O	['N']	[9]
10	neurotoxicity	O	['N']	[10]
11	,	O	['N']	[11]
12	which	O	['N']	[12]
13	may	O	['N']	[13]
14	occur	O	['N']	[14]
15	even	O	['N']	[15]
16	at	O	['N']	[16]
17	low	O	['N']	[17]
18	or	O	['N']	[18]
19	moderate	O	['N']	[19]
20	dosage	O	['N']	[20]
21	levels	O	['N']	[21]
22	,	O	['N']	[22]
23	if	O	['N']	[23]
24	certain	O	['N']	[24]
25	drugs	O	['N']	[25]
26	as	O	['N']	[26]
27	lithium	B-Drug	['Causes']	[2]
28	or	O	['N']	[28]
29	clozapine	O	['N']	[29]
30	are	O	['N']	[30]
31	used	O	['N']	[31]
32	in	O	['N']	[32]
33	combination	O	['N']	[33]
34	with	O	['N']	[34]
35	CBZ	O	['N']	[35]
36	.	O	['N']	[36]
#781
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	retrospective	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	the	O	['N']	[6]
7	first	O	['N']	[7]
8	case	O	['N']	[8]
9	of	O	['N']	[9]
10	gemcitabine	B-Drug	['Causes']	[13]
11	-	O	['N']	[11]
12	related	O	['N']	[12]
13	HUS	B-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	in	O	['N']	[15]
16	a	O	['N']	[16]
17	patient	O	['N']	[17]
18	with	O	['N']	[18]
19	metastatic	O	['N']	[19]
20	pancreatic	O	['N']	[20]
21	adenocarcinoma	O	['N']	[21]
22	,	O	['N']	[22]
23	treated	O	['N']	[23]
24	with	O	['N']	[24]
25	a	O	['N']	[25]
26	variety	O	['N']	[26]
27	of	O	['N']	[27]
28	standard	O	['N']	[28]
29	therapies	O	['N']	[29]
30	in	O	['N']	[30]
31	addition	O	['N']	[31]
32	to	O	['N']	[32]
33	rituximab	O	['N']	[33]
34	is	O	['N']	[34]
35	presented	O	['N']	[35]
36	.	O	['N']	[36]
#782
0	Three	O	['N']	[0]
1	years	O	['N']	[1]
2	later	O	['N']	[2]
3	,	O	['N']	[3]
4	treatment	O	['N']	[4]
5	with	O	['N']	[5]
6	ampicillin	B-Drug	['Causes']	[14]
7	caused	O	['N']	[7]
8	another	O	['N']	[8]
9	episode	O	['N']	[9]
10	of	O	['N']	[10]
11	cholestatic	O	['N']	[11]
12	hepatitis	O	['N']	[12]
13	with	O	['N']	[13]
14	cholestasis	B-Adverse_Effect	['N']	[14]
15	and	O	['N']	[15]
16	duct	O	['N']	[16]
17	paucity	O	['N']	[17]
18	on	O	['N']	[18]
19	rebiopsy	O	['N']	[19]
20	.	O	['N']	[20]
#783
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	re	O	['N']	[2]
3	-	O	['N']	[3]
4	initiation	O	['N']	[4]
5	of	O	['N']	[5]
6	sunitinib	B-Drug	['Causes']	[13]
7	treatment	O	['N']	[7]
8	was	O	['N']	[8]
9	followed	O	['N']	[9]
10	by	O	['N']	[10]
11	bilateral	B	['N']	[11]
12	breast	I	['N']	[12]
13	enlargement	I-Adverse_Effect	['N']	[13]
14	again	O	['N']	[14]
15	.	O	['N']	[15]
#784
0	As	O	['N']	[0]
1	far	O	['N']	[1]
2	as	O	['N']	[2]
3	we	O	['N']	[3]
4	know	O	['N']	[4]
5	,	O	['N']	[5]
6	this	O	['N']	[6]
7	is	O	['N']	[7]
8	the	O	['N']	[8]
9	first	O	['N']	[9]
10	case	O	['N']	[10]
11	report	O	['N']	[11]
12	of	O	['N']	[12]
13	acute	B	['N']	[13]
14	hemorrhagic	I	['N']	[14]
15	gastritis	I-Adverse_Effect	['N']	[15]
16	associated	O	['N']	[16]
17	with	O	['N']	[17]
18	AZ	B-Drug	['Causes']	[15]
19	intoxication	O	['N']	[19]
20	.	O	['N']	[20]
#785
0	Physicians	O	['N']	[0]
1	should	O	['N']	[1]
2	therefore	O	['N']	[2]
3	be	O	['N']	[3]
4	aware	O	['N']	[4]
5	of	O	['N']	[5]
6	its	O	['N']	[6]
7	occurrence	O	['N']	[7]
8	and	O	['N']	[8]
9	carefully	O	['N']	[9]
10	monitor	O	['N']	[10]
11	serum	O	['N']	[11]
12	levels	O	['N']	[12]
13	of	O	['N']	[13]
14	CPK	O	['N']	[14]
15	,	O	['N']	[15]
16	GOT	O	['N']	[16]
17	and	O	['N']	[17]
18	GPT	O	['N']	[18]
19	during	O	['N']	[19]
20	the	O	['N']	[20]
21	treatment	O	['N']	[21]
22	of	O	['N']	[22]
23	diabetes	O	['N']	[23]
24	insipidus	O	['N']	[24]
25	with	O	['N']	[25]
26	clofibrate	B-Drug	['Causes']	[45]
27	,	O	['N']	[27]
28	especially	O	['N']	[28]
29	in	O	['N']	[29]
30	patients	O	['N']	[30]
31	with	O	['N']	[31]
32	associated	O	['N']	[32]
33	hypothyroidism	O	['N']	[33]
34	,	O	['N']	[34]
35	latent	O	['N']	[35]
36	or	O	['N']	[36]
37	overt	O	['N']	[37]
38	,	O	['N']	[38]
39	which	O	['N']	[39]
40	possibly	O	['N']	[40]
41	favors	O	['N']	[41]
42	the	O	['N']	[42]
43	development	O	['N']	[43]
44	of	O	['N']	[44]
45	myopathy	B-Adverse_Effect	['N']	[45]
46	.	O	['N']	[46]
#786
0	The	O	['N']	[0]
1	evidence	O	['N']	[1]
2	of	O	['N']	[2]
3	high	O	['N']	[3]
4	plasmatic	O	['N']	[4]
5	levels	O	['N']	[5]
6	of	O	['N']	[6]
7	CBZ	B-Drug	['Causes']	[35]
8	and	O	['N']	[8]
9	the	O	['N']	[9]
10	absence	O	['N']	[10]
11	of	O	['N']	[11]
12	other	O	['N']	[12]
13	aetiologic	O	['N']	[13]
14	factors	O	['N']	[14]
15	lead	O	['N']	[15]
16	the	O	['N']	[16]
17	authors	O	['N']	[17]
18	to	O	['N']	[18]
19	conclude	O	['N']	[19]
20	that	O	['N']	[20]
21	the	O	['N']	[21]
22	overdose	O	['N']	[22]
23	of	O	['N']	[23]
24	CBZ	O	['N']	[24]
25	could	O	['N']	[25]
26	have	O	['N']	[26]
27	represented	O	['N']	[27]
28	the	O	['N']	[28]
29	precipitating	O	['N']	[29]
30	of	O	['N']	[30]
31	the	O	['N']	[31]
32	episode	O	['N']	[32]
33	of	O	['N']	[33]
34	acute	B	['N']	[34]
35	pancreatitis	I-Adverse_Effect	['N']	[35]
36	.	O	['N']	[36]
#787
0	Two	O	['N']	[0]
1	children	O	['N']	[1]
2	with	O	['N']	[2]
3	rheumatic	O	['N']	[3]
4	fever	O	['N']	[4]
5	developed	O	['N']	[5]
6	anicteric	B	['N']	[6]
7	hepatitis	I-Adverse_Effect	['N']	[7]
8	while	O	['N']	[8]
9	on	O	['N']	[9]
10	high	O	['N']	[10]
11	-	O	['N']	[11]
12	dose	O	['N']	[12]
13	aspirin	B-Drug	['Causes']	[7]
14	therapy	O	['N']	[14]
15	.	O	['N']	[15]
#788
0	We	O	['N']	[0]
1	suggest	O	['N']	[1]
2	that	O	['N']	[2]
3	nicotinic	B	['N']	[3]
4	acid	I-Drug	['Causes']	[11]
5	was	O	['N']	[5]
6	the	O	['N']	[6]
7	cause	O	['N']	[7]
8	of	O	['N']	[8]
9	his	O	['N']	[9]
10	liver	B	['N']	[10]
11	disease	I-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	that	O	['N']	[13]
14	this	O	['N']	[14]
15	case	O	['N']	[15]
16	is	O	['N']	[16]
17	of	O	['N']	[17]
18	particular	O	['N']	[18]
19	note	O	['N']	[19]
20	because	O	['N']	[20]
21	of	O	['N']	[21]
22	the	O	['N']	[22]
23	rather	O	['N']	[23]
24	short	O	['N']	[24]
25	period	O	['N']	[25]
26	of	O	['N']	[26]
27	therapy	O	['N']	[27]
28	before	O	['N']	[28]
29	the	O	['N']	[29]
30	onset	O	['N']	[30]
31	of	O	['N']	[31]
32	liver	O	['N']	[32]
33	injury	O	['N']	[33]
34	and	O	['N']	[34]
35	the	O	['N']	[35]
36	severity	O	['N']	[36]
37	of	O	['N']	[37]
38	the	O	['N']	[38]
39	hepatic	O	['N']	[39]
40	failure	O	['N']	[40]
41	,	O	['N']	[41]
42	and	O	['N']	[42]
43	that	O	['N']	[43]
44	the	O	['N']	[44]
45	probable	O	['N']	[45]
46	increased	O	['N']	[46]
47	use	O	['N']	[47]
48	of	O	['N']	[48]
49	nicotinic	O	['N']	[49]
50	acid	O	['N']	[50]
51	for	O	['N']	[51]
52	serum	O	['N']	[52]
53	cholesterol	O	['N']	[53]
54	control	O	['N']	[54]
55	makes	O	['N']	[55]
56	it	O	['N']	[56]
57	especially	O	['N']	[57]
58	important	O	['N']	[58]
59	for	O	['N']	[59]
60	physicians	O	['N']	[60]
61	and	O	['N']	[61]
62	their	O	['N']	[62]
63	patients	O	['N']	[63]
64	to	O	['N']	[64]
65	be	O	['N']	[65]
66	alert	O	['N']	[66]
67	to	O	['N']	[67]
68	the	O	['N']	[68]
69	signs	O	['N']	[69]
70	of	O	['N']	[70]
71	hepatotoxicity	O	['N']	[71]
72	.	O	['N']	[72]
#789
0	The	O	['N']	[0]
1	day	O	['N']	[1]
2	after	O	['N']	[2]
3	clozapine	O	['N']	[3]
4	was	O	['N']	[4]
5	stopped	O	['N']	[5]
6	,	O	['N']	[6]
7	while	O	['N']	[7]
8	he	O	['N']	[8]
9	was	O	['N']	[9]
10	still	O	['N']	[10]
11	receiving	O	['N']	[11]
12	clomipramine	B-Drug	['Causes']	[33]
13	150	O	['N']	[13]
14	mg	O	['N']	[14]
15	/	O	['N']	[15]
16	d	O	['N']	[16]
17	,	O	['N']	[17]
18	he	O	['N']	[18]
19	began	O	['N']	[19]
20	behaving	O	['N']	[20]
21	oddly	O	['N']	[21]
22	,	O	['N']	[22]
23	started	O	['N']	[23]
24	sweating	O	['N']	[24]
25	profusely	O	['N']	[25]
26	,	O	['N']	[26]
27	shivering	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	became	O	['N']	[30]
31	tremulous	O	['N']	[31]
32	,	O	['N']	[32]
33	agitated	B-Adverse_Effect	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	confused	O	['N']	[36]
37	.	O	['N']	[37]
#790
0	Gemcitabine	B-Drug	['Causes']	[6]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	pericardial	O	['N']	[3]
4	effusion	O	['N']	[4]
5	and	O	['N']	[5]
6	tamponade	B-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	unblocked	O	['N']	[8]
9	cardiac	O	['N']	[9]
10	irradiation	O	['N']	[10]
11	.	O	['N']	[11]
#791
0	A	O	['N']	[0]
1	possible	O	['N']	[1]
2	mechanism	O	['N']	[2]
3	for	O	['N']	[3]
4	focal	B	['N']	[4]
5	neurological	I	['N']	[5]
6	deficit	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	brain	O	['N']	[8]
9	-	O	['N']	[9]
10	damaged	O	['N']	[10]
11	patients	O	['N']	[11]
12	on	O	['N']	[12]
13	phenytoin	B-Drug	['Causes']	[6]
14	therapy	O	['N']	[14]
15	is	O	['N']	[15]
16	discussed	O	['N']	[16]
17	.	O	['N']	[17]
#792
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	five	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	restless	O	['N']	[5]
6	legs	O	['N']	[6]
7	syndrome	O	['N']	[7]
8	(	O	['N']	[8]
9	RLS	O	['N']	[9]
10	)	O	['N']	[10]
11	and	O	['N']	[11]
12	periodic	O	['N']	[12]
13	limb	O	['N']	[13]
14	movements	O	['N']	[14]
15	during	O	['N']	[15]
16	sleep	O	['N']	[16]
17	(	O	['N']	[17]
18	PLMS	B-Adverse_Effect	['N']	[18]
19	)	O	['N']	[19]
20	that	O	['N']	[20]
21	were	O	['N']	[21]
22	probably	O	['N']	[22]
23	associated	O	['N']	[23]
24	with	O	['N']	[24]
25	olanzapine	B-Drug	['Causes']	[18]
26	.	O	['N']	[26]
#793
0	Our	O	['N']	[0]
1	findings	O	['N']	[1]
2	suggest	O	['N']	[2]
3	that	O	['N']	[3]
4	hyperkalemia	B-Adverse_Effect	['N']	[4]
5	can	O	['N']	[5]
6	develop	O	['N']	[6]
7	with	O	['N']	[7]
8	the	O	['N']	[8]
9	use	O	['N']	[9]
10	of	O	['N']	[10]
11	low	O	['N']	[11]
12	-	O	['N']	[12]
13	dose	O	['N']	[13]
14	heparin	B-Drug	['Causes']	[4]
15	,	O	['N']	[15]
16	within	O	['N']	[16]
17	seven	O	['N']	[17]
18	days	O	['N']	[18]
19	of	O	['N']	[19]
20	initiating	O	['N']	[20]
21	heparin	O	['N']	[21]
22	therapy	O	['N']	[22]
23	,	O	['N']	[23]
24	and	O	['N']	[24]
25	that	O	['N']	[25]
26	patients	O	['N']	[26]
27	with	O	['N']	[27]
28	diabetes	O	['N']	[28]
29	mellitus	O	['N']	[29]
30	or	O	['N']	[30]
31	chronic	O	['N']	[31]
32	renal	O	['N']	[32]
33	insufficiency	O	['N']	[33]
34	are	O	['N']	[34]
35	especially	O	['N']	[35]
36	predisposed	O	['N']	[36]
37	to	O	['N']	[37]
38	this	O	['N']	[38]
39	complication	O	['N']	[39]
40	.	O	['N']	[40]
#794
0	Hypersensitivity	B-Adverse_Effect	['N']	[0]
1	to	O	['N']	[1]
2	carboplatin	B-Drug	['Causes']	[0]
3	has	O	['N']	[3]
4	been	O	['N']	[4]
5	reported	O	['N']	[5]
6	in	O	['N']	[6]
7	up	O	['N']	[7]
8	to	O	['N']	[8]
9	44	O	['N']	[9]
10	%	O	['N']	[10]
11	of	O	['N']	[11]
12	patients	O	['N']	[12]
13	receiving	O	['N']	[13]
14	this	O	['N']	[14]
15	antineoplastic	O	['N']	[15]
16	agent	O	['N']	[16]
17	,	O	['N']	[17]
18	usually	O	['N']	[18]
19	occurring	O	['N']	[19]
20	after	O	['N']	[20]
21	several	O	['N']	[21]
22	courses	O	['N']	[22]
23	of	O	['N']	[23]
24	treatment	O	['N']	[24]
25	.	O	['N']	[25]
#795
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	is	O	['N']	[2]
3	remarkable	O	['N']	[3]
4	since	O	['N']	[4]
5	1	O	['N']	[5]
6	)	O	['N']	[6]
7	ECM	O	['N']	[7]
8	developed	O	['N']	[8]
9	after	O	['N']	[9]
10	subcutaneous	O	['N']	[10]
11	and	O	['N']	[11]
12	not	O	['N']	[12]
13	after	O	['N']	[13]
14	intramuscular	O	['N']	[14]
15	injection	O	['N']	[15]
16	,	O	['N']	[16]
17	2	O	['N']	[17]
18	)	O	['N']	[18]
19	the	O	['N']	[19]
20	injection	O	['N']	[20]
21	was	O	['N']	[21]
22	given	O	['N']	[22]
23	by	O	['N']	[23]
24	the	O	['N']	[24]
25	patient	O	['N']	[25]
26	himself	O	['N']	[26]
27	,	O	['N']	[27]
28	and	O	['N']	[28]
29	3	O	['N']	[29]
30	)	O	['N']	[30]
31	glatiramer	B	['N']	[31]
32	acetate	I-Drug	['Causes']	[36]
33	can	O	['N']	[33]
34	induce	O	['N']	[34]
35	skin	B	['N']	[35]
36	necrosis	I-Adverse_Effect	['N']	[36]
37	as	O	['N']	[37]
38	a	O	['N']	[38]
39	side	O	['N']	[39]
40	effect	O	['N']	[40]
41	.	O	['N']	[41]
#796
0	The	O	['N']	[0]
1	course	O	['N']	[1]
2	of	O	['N']	[2]
3	delirium	B-Adverse_Effect	['N']	[3]
4	due	O	['N']	[4]
5	to	O	['N']	[5]
6	lithium	B-Drug	['Causes']	[3]
7	intoxication	O	['N']	[7]
8	.	O	['N']	[8]
#797
0	Monoclonal	O	['N']	[0]
1	gammopathy	O	['N']	[1]
2	and	O	['N']	[2]
3	subsequent	O	['N']	[3]
4	multiple	B	['N']	[4]
5	myeloma	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	on	O	['N']	[9]
10	chronic	O	['N']	[10]
11	diphenylhydantoin	B-Drug	['Causes']	[5]
12	therapy	O	['N']	[12]
13	.	O	['N']	[13]
#798
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	57-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	with	O	['N']	[7]
8	acral	O	['N']	[8]
9	erythrocyanosis	O	['N']	[9]
10	progressing	O	['N']	[10]
11	to	O	['N']	[11]
12	acute	B	['N']	[12]
13	digital	I	['N']	[13]
14	ischemia	I-Adverse_Effect	['N']	[14]
15	and	O	['N']	[15]
16	gangrene	O	['N']	[16]
17	that	O	['N']	[17]
18	developed	O	['N']	[18]
19	after	O	['N']	[19]
20	combined	O	['N']	[20]
21	chemotherapy	O	['N']	[21]
22	(	O	['N']	[22]
23	bleomycin	O	['N']	[23]
24	and	O	['N']	[24]
25	methotrexate	B-Drug	['Causes']	[14]
26	)	O	['N']	[26]
27	used	O	['N']	[27]
28	to	O	['N']	[28]
29	treat	O	['N']	[29]
30	a	O	['N']	[30]
31	metastatic	O	['N']	[31]
32	squamous	O	['N']	[32]
33	cell	O	['N']	[33]
34	carcinoma	O	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	hypopharynx	O	['N']	[37]
38	.	O	['N']	[38]
#799
0	A	O	['N']	[0]
1	fatal	B	['N']	[1]
2	case	I	['N']	[2]
3	of	I	['N']	[3]
4	pancytopenia	I-Adverse_Effect	['N']	[4]
5	due	O	['N']	[5]
6	to	O	['N']	[6]
7	levomepromazine	B-Drug	['Causes']	[4]
8	.	O	['N']	[8]
#800
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	papilloedema	B-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	hepatic	O	['N']	[5]
6	dysfunction	O	['N']	[6]
7	while	O	['N']	[7]
8	being	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	perhexiline	B	['N']	[11]
12	maleate	I-Drug	['Causes']	[3]
13	.	O	['N']	[13]
#801
0	Neonatal	O	['N']	[0]
1	mydriasis	B-Adverse_Effect	['N']	[1]
2	:	O	['N']	[2]
3	intravenous	O	['N']	[3]
4	lidocaine	B-Drug	['Causes']	[1]
5	adverse	O	['N']	[5]
6	reaction	O	['N']	[6]
7	.	O	['N']	[7]
#802
0	A	O	['N']	[0]
1	52-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	Black	O	['N']	[4]
5	woman	O	['N']	[5]
6	on	O	['N']	[6]
7	phenytoin	B-Drug	['Causes']	[16]
8	therapy	O	['N']	[8]
9	for	O	['N']	[9]
10	post	O	['N']	[10]
11	-	O	['N']	[11]
12	traumatic	O	['N']	[12]
13	epilepsy	O	['N']	[13]
14	developed	O	['N']	[14]
15	transient	B	['N']	[15]
16	hemiparesis	I-Adverse_Effect	['N']	[16]
17	contralateral	O	['N']	[17]
18	to	O	['N']	[18]
19	the	O	['N']	[19]
20	injury	O	['N']	[20]
21	.	O	['N']	[21]
#803
0	Corneal	B	['N']	[0]
1	endothelial	I	['N']	[1]
2	dysfunction	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	amantadine	B-Drug	['Causes']	[2]
6	toxicity	O	['N']	[6]
7	.	O	['N']	[7]
#804
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	occipital	O	['N']	[3]
4	infarcts	O	['N']	[4]
5	and	O	['N']	[5]
6	was	O	['N']	[6]
7	found	O	['N']	[7]
8	to	O	['N']	[8]
9	have	O	['N']	[9]
10	extremely	B	['N']	[10]
11	elevated	I	['N']	[11]
12	levels	I	['N']	[12]
13	of	I	['N']	[13]
14	PPA	B-Drug	['N']	[14]
15	in	O	['N']	[15]
16	his	O	['N']	[16]
17	blood	O	['N']	[17]
18	and	O	['N']	[18]
19	dialysis	O	['N']	[19]
20	fluid	O	['N']	[20]
21	.	O	['N']	[21]
#805
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	continuous	O	['N']	[3]
4	ambulatory	O	['N']	[4]
5	peritoneal	O	['N']	[5]
6	dialysis	O	['N']	[6]
7	(	O	['N']	[7]
8	CAPD	O	['N']	[8]
9	)	O	['N']	[9]
10	patient	O	['N']	[10]
11	that	O	['N']	[11]
12	developed	O	['N']	[12]
13	vancomycin	B-Drug	['Causes']	[16]
14	-	O	['N']	[14]
15	induced	O	['N']	[15]
16	agranulocytosis	B-Adverse_Effect	['N']	[16]
17	during	O	['N']	[17]
18	treatment	O	['N']	[18]
19	for	O	['N']	[19]
20	methicillin	O	['N']	[20]
21	-	O	['N']	[21]
22	resistant	O	['N']	[22]
23	Staphylococcus	O	['N']	[23]
24	aureus	O	['N']	[24]
25	(	O	['N']	[25]
26	MRSA)-associated	O	['N']	[26]
27	external	O	['N']	[27]
28	cuff	O	['N']	[28]
29	infection	O	['N']	[29]
30	and	O	['N']	[30]
31	pneumonia	O	['N']	[31]
32	.	O	['N']	[32]
#806
0	It	O	['N']	[0]
1	carries	O	['N']	[1]
2	a	O	['N']	[2]
3	well	O	['N']	[3]
4	-	O	['N']	[4]
5	known	O	['N']	[5]
6	risk	O	['N']	[6]
7	of	O	['N']	[7]
8	neutropenia	O	['N']	[8]
9	and	O	['N']	[9]
10	agranulocytosis	B-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	which	O	['N']	[12]
13	necessitates	O	['N']	[13]
14	the	O	['N']	[14]
15	immediate	O	['N']	[15]
16	discontinuation	O	['N']	[16]
17	of	O	['N']	[17]
18	clozapine	B-Drug	['Causes']	[10]
19	.	O	['N']	[19]
#807
0	Two	O	['N']	[0]
1	years	O	['N']	[1]
2	later	O	['N']	[2]
3	,	O	['N']	[3]
4	24	O	['N']	[4]
5	hours	O	['N']	[5]
6	following	O	['N']	[6]
7	an	O	['N']	[7]
8	increase	O	['N']	[8]
9	in	O	['N']	[9]
10	the	O	['N']	[10]
11	dose	O	['N']	[11]
12	of	O	['N']	[12]
13	disopyramide	B-Drug	['Causes']	[22]
14	from	O	['N']	[14]
15	300	O	['N']	[15]
16	to	O	['N']	[16]
17	600	O	['N']	[17]
18	mg	O	['N']	[18]
19	/	O	['N']	[19]
20	day	O	['N']	[20]
21	,	O	['N']	[21]
22	AVT	B-Adverse_Effect	['N']	[22]
23	with	O	['N']	[23]
24	syncope	O	['N']	[24]
25	occurred	O	['N']	[25]
26	;	O	['N']	[26]
27	isoproterenol	O	['N']	[27]
28	abolished	O	['N']	[28]
29	the	O	['N']	[29]
30	arrhythmia	O	['N']	[30]
31	instantly	O	['N']	[31]
32	.	O	['N']	[32]
#808
0	After	O	['N']	[0]
1	5	O	['N']	[1]
2	days	O	['N']	[2]
3	of	O	['N']	[3]
4	treatment	O	['N']	[4]
5	with	O	['N']	[5]
6	IL-2	B-Drug	['Causes']	[19]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	patient	O	['N']	[9]
10	developed	O	['N']	[10]
11	a	O	['N']	[11]
12	hemorrhagic	O	['N']	[12]
13	lesion	O	['N']	[13]
14	that	O	['N']	[14]
15	progressed	O	['N']	[15]
16	to	O	['N']	[16]
17	toxic	B	['N']	[17]
18	epidermal	I	['N']	[18]
19	necrolysis	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	as	O	['N']	[21]
22	well	O	['N']	[22]
23	as	O	['N']	[23]
24	grade	O	['N']	[24]
25	4	O	['N']	[25]
26	pancytopenia	O	['N']	[26]
27	.	O	['N']	[27]
#809
0	Coagulopathy	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	the	O	['N']	[3]
4	use	O	['N']	[4]
5	of	O	['N']	[5]
6	cephalosporin	B-Drug	['Causes']	[0]
7	or	O	['N']	[7]
8	moxalactam	O	['N']	[8]
9	antibiotics	O	['N']	[9]
10	in	O	['N']	[10]
11	acute	O	['N']	[11]
12	and	O	['N']	[12]
13	chronic	O	['N']	[13]
14	renal	O	['N']	[14]
15	failure	O	['N']	[15]
16	.	O	['N']	[16]
#810
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	an	O	['N']	[3]
4	unexpected	O	['N']	[4]
5	drug	O	['N']	[5]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	hepatitis	B-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	previously	O	['N']	[11]
12	healthy	O	['N']	[12]
13	young	O	['N']	[13]
14	woman	O	['N']	[14]
15	exposed	O	['N']	[15]
16	to	O	['N']	[16]
17	2	O	['N']	[17]
18	doses	O	['N']	[18]
19	of	O	['N']	[19]
20	amodiaquine	B-Drug	['Causes']	[8]
21	and	O	['N']	[21]
22	artesunate	O	['N']	[22]
23	.	O	['N']	[23]
#811
0	Gemcitabine	B-Drug	['Causes']	[6]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	rectus	B	['N']	[3]
4	abdominus	I	['N']	[4]
5	radiation	I	['N']	[5]
6	recall	I-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#812
0	Acceleration	B	['N']	[0]
1	of	I	['N']	[1]
2	ventricular	I	['N']	[2]
3	response	I-Adverse_Effect	['N']	[3]
4	to	O	['N']	[4]
5	atrial	O	['N']	[5]
6	flutter	O	['N']	[6]
7	after	O	['N']	[7]
8	intravenous	O	['N']	[8]
9	adenosine	B-Drug	['Causes']	[3]
10	.	O	['N']	[10]
#813
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	we	O	['N']	[4]
5	describe	O	['N']	[5]
6	the	O	['N']	[6]
7	first	O	['N']	[7]
8	reported	O	['N']	[8]
9	case	O	['N']	[9]
10	of	O	['N']	[10]
11	isolated	O	['N']	[11]
12	paresthesia	O	['N']	[12]
13	and	O	['N']	[13]
14	peripheral	B	['N']	[14]
15	neuropathy	I-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	without	O	['N']	[17]
18	systemic	O	['N']	[18]
19	involvement	O	['N']	[19]
20	,	O	['N']	[20]
21	secondary	O	['N']	[21]
22	to	O	['N']	[22]
23	sulindac	B-Drug	['Causes']	[15]
24	administration	O	['N']	[24]
25	.	O	['N']	[25]
#814
0	A	O	['N']	[0]
1	drug	O	['N']	[1]
2	addict	O	['N']	[2]
3	with	O	['N']	[3]
4	staphylococcal	O	['N']	[4]
5	endocarditis	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	methicillin	B-Drug	['Causes']	[17]
9	,	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	massive	O	['N']	[12]
13	proteinuria	O	['N']	[13]
14	and	O	['N']	[14]
15	acute	B	['N']	[15]
16	nephritic	I	['N']	[16]
17	syndrome	I-Adverse_Effect	['N']	[17]
18	is	O	['N']	[18]
19	described	O	['N']	[19]
20	.	O	['N']	[20]
#815
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	alcoholic	O	['N']	[3]
4	cerebellar	O	['N']	[4]
5	degeneration	O	['N']	[5]
6	had	O	['N']	[6]
7	periodic	B	['N']	[7]
8	alternating	I	['N']	[8]
9	nystagmus	I-Adverse_Effect	['N']	[9]
10	during	O	['N']	[10]
11	a	O	['N']	[11]
12	period	O	['N']	[12]
13	of	O	['N']	[13]
14	phenytoin	B-Drug	['Causes']	[9]
15	intoxication	O	['N']	[15]
16	.	O	['N']	[16]
#816
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Methotrexate	B-Drug	['Causes']	[18]
3	(	O	['N']	[3]
4	MTX	O	['N']	[4]
5	)	O	['N']	[5]
6	may	O	['N']	[6]
7	induce	O	['N']	[7]
8	liver	O	['N']	[8]
9	damage	O	['N']	[9]
10	,	O	['N']	[10]
11	which	O	['N']	[11]
12	in	O	['N']	[12]
13	some	O	['N']	[13]
14	psoriatics	O	['N']	[14]
15	will	O	['N']	[15]
16	lead	O	['N']	[16]
17	to	O	['N']	[17]
18	fibrosis	B-Adverse_Effect	['N']	[18]
19	or	O	['N']	[19]
20	cirrhosis	O	['N']	[20]
21	.	O	['N']	[21]
#817
0	Rifampin	B-Drug	['Causes']	[10]
1	can	O	['N']	[1]
2	be	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	severe	O	['N']	[5]
6	adverse	O	['N']	[6]
7	effects	O	['N']	[7]
8	such	O	['N']	[8]
9	as	O	['N']	[9]
10	hepatitis	B-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	acute	O	['N']	[12]
13	renal	O	['N']	[13]
14	failure	O	['N']	[14]
15	,	O	['N']	[15]
16	hemolytic	O	['N']	[16]
17	anemia	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	thrombocytopenia	O	['N']	[20]
21	.	O	['N']	[21]
#818
0	We	O	['N']	[0]
1	experienced	O	['N']	[1]
2	a	O	['N']	[2]
3	male	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	psoriasis	O	['N']	[6]
7	and	O	['N']	[7]
8	hypertension	O	['N']	[8]
9	whose	O	['N']	[9]
10	conditions	O	['N']	[10]
11	were	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	tacalcitol	O	['N']	[14]
15	ointment	O	['N']	[15]
16	and	O	['N']	[16]
17	thiazide	B-Drug	['Causes']	[25]
18	,	O	['N']	[18]
19	respectively	O	['N']	[19]
20	,	O	['N']	[20]
21	resulting	O	['N']	[21]
22	in	O	['N']	[22]
23	hypercalciuria	O	['N']	[23]
24	and	O	['N']	[24]
25	hypercalcemia	B-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#819
0	Acute	B	['N']	[0]
1	renal	I	['N']	[1]
2	failure	I-Adverse_Effect	['N']	[2]
3	is	O	['N']	[3]
4	a	O	['N']	[4]
5	rare	O	['N']	[5]
6	complication	O	['N']	[6]
7	following	O	['N']	[7]
8	the	O	['N']	[8]
9	administration	O	['N']	[9]
10	of	O	['N']	[10]
11	intravenous	O	['N']	[11]
12	immunoglobulin	B-Drug	['Causes']	[2]
13	(	O	['N']	[13]
14	IVIG	O	['N']	[14]
15	)	O	['N']	[15]
16	.	O	['N']	[16]
#820
0	Risperidone	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	tardive	B	['N']	[3]
4	dyskinesia	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#821
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	one	O	['N']	[2]
3	patient	O	['N']	[3]
4	exhibited	O	['N']	[4]
5	severe	B	['N']	[5]
6	hypersensitivity	I	['N']	[6]
7	reactions	I-Adverse_Effect	['N']	[7]
8	including	O	['N']	[8]
9	cardiac	O	['N']	[9]
10	arrest	O	['N']	[10]
11	and	O	['N']	[11]
12	apnea	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	another	O	['N']	[15]
16	four	O	['N']	[16]
17	patients	O	['N']	[17]
18	developed	O	['N']	[18]
19	eruptions	O	['N']	[19]
20	,	O	['N']	[20]
21	hypotension	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	tachycardia	O	['N']	[24]
25	soon	O	['N']	[25]
26	after	O	['N']	[26]
27	administration	O	['N']	[27]
28	of	O	['N']	[28]
29	CBDCA	B-Drug	['Causes']	[7]
30	.	O	['N']	[30]
#822
0	Symptomatic	B	['N']	[0]
1	hypoglycemia	I-Adverse_Effect	['N']	[1]
2	secondary	O	['N']	[2]
3	to	O	['N']	[3]
4	a	O	['N']	[4]
5	glipizide	O	['N']	[5]
6	-	O	['N']	[6]
7	trimethoprim	O	['N']	[7]
8	/	O	['N']	[8]
9	sulfamethoxazole	B-Drug	['Causes']	[1]
10	drug	O	['N']	[10]
11	interaction	O	['N']	[11]
12	.	O	['N']	[12]
#823
0	Severe	B	['N']	[0]
1	hyperkalemia	I-Adverse_Effect	['N']	[1]
2	occurred	O	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	radiation	O	['N']	[7]
8	pneumonitis	O	['N']	[8]
9	and	O	['N']	[9]
10	glaucoma	O	['N']	[10]
11	shortly	O	['N']	[11]
12	after	O	['N']	[12]
13	beginning	O	['N']	[13]
14	prednisone	B-Drug	['Causes']	[1]
15	therapy	O	['N']	[15]
16	.	O	['N']	[16]
#824
0	A	O	['N']	[0]
1	typical	O	['N']	[1]
2	case	O	['N']	[2]
3	of	O	['N']	[3]
4	dextran-40	B-Drug	['Causes']	[8]
5	associated	O	['N']	[5]
6	acute	B	['N']	[6]
7	renal	I	['N']	[7]
8	failure	I-Adverse_Effect	['N']	[8]
9	is	O	['N']	[9]
10	presented	O	['N']	[10]
11	.	O	['N']	[11]
#825
0	Iatrogenic	B	['N']	[0]
1	Cushing	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	epidural	O	['N']	[4]
5	triamcinolone	B-Drug	['Causes']	[2]
6	injections	O	['N']	[6]
7	in	O	['N']	[7]
8	an	O	['N']	[8]
9	HIV	O	['N']	[9]
10	type	O	['N']	[10]
11	1-infected	O	['N']	[11]
12	patient	O	['N']	[12]
13	receiving	O	['N']	[13]
14	therapy	O	['N']	[14]
15	with	O	['N']	[15]
16	ritonavir	O	['N']	[16]
17	-	O	['N']	[17]
18	lopinavir	O	['N']	[18]
19	.	O	['N']	[19]
#826
0	The	O	['N']	[0]
1	present	O	['N']	[1]
2	report	O	['N']	[2]
3	suggests	O	['N']	[3]
4	that	O	['N']	[4]
5	clarithromycin	O	['N']	[5]
6	coadministration	O	['N']	[6]
7	induces	O	['N']	[7]
8	increased	B	['N']	[8]
9	plasma	I	['N']	[9]
10	carbamazepine	B-Drug	['N']	[10]
11	concentrations	O	['N']	[11]
12	,	O	['N']	[12]
13	which	O	['N']	[13]
14	may	O	['N']	[14]
15	result	O	['N']	[15]
16	in	O	['N']	[16]
17	carbamazepine	O	['N']	[17]
18	toxicity	O	['N']	[18]
19	.	O	['N']	[19]
#827
0	He	O	['N']	[0]
1	had	O	['N']	[1]
2	an	O	['N']	[2]
3	immediate	O	['N']	[3]
4	hypersensitivity	O	['N']	[4]
5	reaction	O	['N']	[5]
6	during	O	['N']	[6]
7	the	O	['N']	[7]
8	initiation	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	MTX	B-Drug	['Causes']	[24]
12	infusion	O	['N']	[12]
13	with	O	['N']	[13]
14	diffuse	O	['N']	[14]
15	urticaria	O	['N']	[15]
16	,	O	['N']	[16]
17	facial	O	['N']	[17]
18	swelling	O	['N']	[18]
19	,	O	['N']	[19]
20	cough	O	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	chest	B	['N']	[23]
24	tightness	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#828
0	Our	O	['N']	[0]
1	findings	O	['N']	[1]
2	suggest	O	['N']	[2]
3	that	O	['N']	[3]
4	hyperkalemia	O	['N']	[4]
5	can	O	['N']	[5]
6	develop	O	['N']	[6]
7	with	O	['N']	[7]
8	the	O	['N']	[8]
9	use	O	['N']	[9]
10	of	O	['N']	[10]
11	low	B	['N']	[11]
12	-	I	['N']	[12]
13	dose	I-Dose	['N']	[13]
14	heparin	B-Drug	['Dosage']	[13]
15	,	O	['N']	[15]
16	within	O	['N']	[16]
17	seven	O	['N']	[17]
18	days	O	['N']	[18]
19	of	O	['N']	[19]
20	initiating	O	['N']	[20]
21	heparin	O	['N']	[21]
22	therapy	O	['N']	[22]
23	,	O	['N']	[23]
24	and	O	['N']	[24]
25	that	O	['N']	[25]
26	patients	O	['N']	[26]
27	with	O	['N']	[27]
28	diabetes	O	['N']	[28]
29	mellitus	O	['N']	[29]
30	or	O	['N']	[30]
31	chronic	O	['N']	[31]
32	renal	O	['N']	[32]
33	insufficiency	O	['N']	[33]
34	are	O	['N']	[34]
35	especially	O	['N']	[35]
36	predisposed	O	['N']	[36]
37	to	O	['N']	[37]
38	this	O	['N']	[38]
39	complication	O	['N']	[39]
40	.	O	['N']	[40]
#829
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	was	O	['N']	[2]
3	diagnosed	O	['N']	[3]
4	with	O	['N']	[4]
5	carbamazepine	B	['N']	[5]
6	toxicity	I-Adverse_Effect	['N']	[6]
7	related	O	['N']	[7]
8	to	O	['N']	[8]
9	the	O	['N']	[9]
10	introduction	O	['N']	[10]
11	of	O	['N']	[11]
12	ritonavir	B-Drug	['Causes']	[6]
13	.	O	['N']	[13]
#830
0	A	O	['N']	[0]
1	65-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	angina	O	['N']	[6]
7	pectoris	O	['N']	[7]
8	presented	O	['N']	[8]
9	with	O	['N']	[9]
10	syncope	B-Adverse_Effect	['N']	[10]
11	after	O	['N']	[11]
12	sublingual	O	['N']	[12]
13	ingestion	O	['N']	[13]
14	of	O	['N']	[14]
15	isosorbide	B	['N']	[15]
16	dinitrate	I-Drug	['Causes']	[10]
17	(	O	['N']	[17]
18	5	O	['N']	[18]
19	mg	O	['N']	[19]
20	)	O	['N']	[20]
21	.	O	['N']	[21]
#831
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	generalized	B	['N']	[5]
6	cutaneous	I	['N']	[6]
7	sclerosis	I-Adverse_Effect	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	muscle	O	['N']	[10]
11	and	O	['N']	[11]
12	oesophageal	O	['N']	[12]
13	involvement	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	patient	O	['N']	[16]
17	exposed	O	['N']	[17]
18	to	O	['N']	[18]
19	herbicides	O	['N']	[19]
20	containing	O	['N']	[20]
21	bromocil	B-Drug	['Causes']	[7]
22	,	O	['N']	[22]
23	diuron	O	['N']	[23]
24	and	O	['N']	[24]
25	aminotriazole	O	['N']	[25]
26	.	O	['N']	[26]
#832
0	Reinstitution	O	['N']	[0]
1	of	O	['N']	[1]
2	penicillamine	B-Drug	['Causes']	[19]
3	treatment	O	['N']	[3]
4	caused	O	['N']	[4]
5	a	O	['N']	[5]
6	recurrence	O	['N']	[6]
7	thus	O	['N']	[7]
8	proving	O	['N']	[8]
9	a	O	['N']	[9]
10	causal	O	['N']	[10]
11	relationship	O	['N']	[11]
12	between	O	['N']	[12]
13	penicillamine	O	['N']	[13]
14	and	O	['N']	[14]
15	the	O	['N']	[15]
16	described	O	['N']	[16]
17	nail	B	['N']	[17]
18	-	I	['N']	[18]
19	changes	I-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#833
0	The	O	['N']	[0]
1	pulmonary	O	['N']	[1]
2	toxicity	O	['N']	[2]
3	of	O	['N']	[3]
4	gold	B-Drug	['Causes']	[15]
5	salts	O	['N']	[5]
6	is	O	['N']	[6]
7	an	O	['N']	[7]
8	uncommon	O	['N']	[8]
9	cause	O	['N']	[9]
10	of	O	['N']	[10]
11	life	O	['N']	[11]
12	-	O	['N']	[12]
13	threatening	O	['N']	[13]
14	respiratory	B	['N']	[14]
15	failure	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#834
0	First	O	['N']	[0]
1	,	O	['N']	[1]
2	a	O	['N']	[2]
3	review	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	literature	O	['N']	[6]
7	produced	O	['N']	[7]
8	41	O	['N']	[8]
9	anecdotic	O	['N']	[9]
10	cases	O	['N']	[10]
11	of	O	['N']	[11]
12	neutropenia	B-Adverse_Effect	['N']	[12]
13	or	O	['N']	[13]
14	agranulocytosis	O	['N']	[14]
15	during	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	olanzapine	B-Drug	['Causes']	[12]
19	(	O	['N']	[19]
20	Zyprexa	O	['N']	[20]
21	)	O	['N']	[21]
22	reported	O	['N']	[22]
23	in	O	['N']	[23]
24	a	O	['N']	[24]
25	total	O	['N']	[25]
26	of	O	['N']	[26]
27	24	O	['N']	[27]
28	publications	O	['N']	[28]
29	.	O	['N']	[29]
#835
0	Gold	B-Drug	['Causes']	[1]
1	nephropathy	B-Adverse_Effect	['N']	[1]
2	:	O	['N']	[2]
3	tissue	O	['N']	[3]
4	analysis	O	['N']	[4]
5	by	O	['N']	[5]
6	X	O	['N']	[6]
7	-	O	['N']	[7]
8	ray	O	['N']	[8]
9	fluorescent	O	['N']	[9]
10	spectroscopy	O	['N']	[10]
11	.	O	['N']	[11]
#836
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Clinicians	O	['N']	[2]
3	should	O	['N']	[3]
4	be	O	['N']	[4]
5	aware	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	risk	O	['N']	[8]
9	of	O	['N']	[9]
10	serotonin	B	['N']	[10]
11	syndrome	I-Adverse_Effect	['N']	[11]
12	with	O	['N']	[12]
13	serious	O	['N']	[13]
14	extrapyramidal	O	['N']	[14]
15	reactions	O	['N']	[15]
16	in	O	['N']	[16]
17	patients	O	['N']	[17]
18	receiving	O	['N']	[18]
19	sertraline	O	['N']	[19]
20	or	O	['N']	[20]
21	venlafaxine	O	['N']	[21]
22	when	O	['N']	[22]
23	metoclopramide	B-Drug	['Causes']	[11]
24	is	O	['N']	[24]
25	coadministered	O	['N']	[25]
26	even	O	['N']	[26]
27	in	O	['N']	[27]
28	a	O	['N']	[28]
29	single	O	['N']	[29]
30	,	O	['N']	[30]
31	conventional	O	['N']	[31]
32	dose	O	['N']	[32]
33	.	O	['N']	[33]
#837
0	Motor	B	['N']	[0]
1	fluctuations	I-Adverse_Effect	['N']	[1]
2	appear	O	['N']	[2]
3	after	O	['N']	[3]
4	2	O	['N']	[4]
5	-	O	['N']	[5]
6	3	O	['N']	[6]
7	years	O	['N']	[7]
8	of	O	['N']	[8]
9	levodopa	B-Drug	['Causes']	[1]
10	treatment	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	affect	O	['N']	[13]
14	at	O	['N']	[14]
15	least	O	['N']	[15]
16	50	O	['N']	[16]
17	%	O	['N']	[17]
18	of	O	['N']	[18]
19	patients	O	['N']	[19]
20	after	O	['N']	[20]
21	five	O	['N']	[21]
22	years	O	['N']	[22]
23	.	O	['N']	[23]
#838
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	our	O	['N']	[4]
5	report	O	['N']	[5]
6	is	O	['N']	[6]
7	one	O	['N']	[7]
8	of	O	['N']	[8]
9	the	O	['N']	[9]
10	first	O	['N']	[10]
11	on	O	['N']	[11]
12	shock	O	['N']	[12]
13	and	O	['N']	[13]
14	angio	B	['N']	[14]
15	-	I	['N']	[15]
16	oedema	I-Adverse_Effect	['N']	[16]
17	from	O	['N']	[17]
18	irbesartan	B-Drug	['Causes']	[16]
19	.	O	['N']	[19]
#839
0	We	O	['N']	[0]
1	observed	O	['N']	[1]
2	3	O	['N']	[2]
3	diabetic	O	['N']	[3]
4	patients	O	['N']	[4]
5	with	O	['N']	[5]
6	intolerable	B	['N']	[6]
7	dizziness	I-Adverse_Effect	['N']	[7]
8	followed	O	['N']	[8]
9	by	O	['N']	[9]
10	nausea	O	['N']	[10]
11	and	O	['N']	[11]
12	vomiting	O	['N']	[12]
13	immediately	O	['N']	[13]
14	after	O	['N']	[14]
15	an	O	['N']	[15]
16	initial	O	['N']	[16]
17	administration	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	alpha	O	['N']	[20]
21	-	O	['N']	[21]
22	glucosidase	O	['N']	[22]
23	inhibitor	O	['N']	[23]
24	,	O	['N']	[24]
25	voglibose	B-Drug	['Causes']	[7]
26	.	O	['N']	[26]
#840
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	SD	O	['N']	[2]
3	-	O	['N']	[3]
4	OCT	O	['N']	[4]
5	and	O	['N']	[5]
6	AO	O	['N']	[6]
7	detected	O	['N']	[7]
8	abnormalities	O	['N']	[8]
9	that	O	['N']	[9]
10	correlate	O	['N']	[10]
11	topographically	O	['N']	[11]
12	with	O	['N']	[12]
13	visual	B	['N']	[13]
14	field	I	['N']	[14]
15	loss	I-Adverse_Effect	['N']	[15]
16	from	O	['N']	[16]
17	hydroxychloroquine	B-Drug	['Causes']	[15]
18	toxicity	O	['N']	[18]
19	as	O	['N']	[19]
20	demonstrated	O	['N']	[20]
21	by	O	['N']	[21]
22	HVF	O	['N']	[22]
23	10	O	['N']	[23]
24	-	O	['N']	[24]
25	2	O	['N']	[25]
26	and	O	['N']	[26]
27	may	O	['N']	[27]
28	be	O	['N']	[28]
29	useful	O	['N']	[29]
30	in	O	['N']	[30]
31	the	O	['N']	[31]
32	detection	O	['N']	[32]
33	of	O	['N']	[33]
34	subclinical	O	['N']	[34]
35	abnormalities	O	['N']	[35]
36	that	O	['N']	[36]
37	precede	O	['N']	[37]
38	symptoms	O	['N']	[38]
39	or	O	['N']	[39]
40	objective	O	['N']	[40]
41	visual	O	['N']	[41]
42	field	O	['N']	[42]
43	loss	O	['N']	[43]
44	.	O	['N']	[44]
#841
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	case	O	['N']	[2]
3	,	O	['N']	[3]
4	interferon	B	['N']	[4]
5	alpha	I-Drug	['Causes']	[9]
6	induced	O	['N']	[6]
7	polymyositis	O	['N']	[7]
8	and	O	['N']	[8]
9	cardiomyopathy	B-Adverse_Effect	['N']	[9]
10	is	O	['N']	[10]
11	diagnosed	O	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	33-yr	O	['N']	[14]
15	-	O	['N']	[15]
16	old	O	['N']	[16]
17	male	O	['N']	[17]
18	patient	O	['N']	[18]
19	with	O	['N']	[19]
20	history	O	['N']	[20]
21	of	O	['N']	[21]
22	chronic	O	['N']	[22]
23	hepatitis	O	['N']	[23]
24	B.	O	['N']	[24]
#842
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	17-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	male	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	chest	O	['N']	[12]
13	pain	O	['N']	[13]
14	,	O	['N']	[14]
15	elevated	B	['N']	[15]
16	cardiac	I	['N']	[16]
17	biomarkers	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	acute	O	['N']	[20]
21	left	O	['N']	[21]
22	ventricular	O	['N']	[22]
23	dysfunction	O	['N']	[23]
24	following	O	['N']	[24]
25	a	O	['N']	[25]
26	single	O	['N']	[26]
27	dose	O	['N']	[27]
28	of	O	['N']	[28]
29	methylphenidate	B-Drug	['Causes']	[17]
30	.	O	['N']	[30]
#843
0	A	O	['N']	[0]
1	66-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	mand	O	['N']	[4]
5	suffering	O	['N']	[5]
6	from	O	['N']	[6]
7	severe	O	['N']	[7]
8	coronary	O	['N']	[8]
9	heart	O	['N']	[9]
10	disease	O	['N']	[10]
11	took	O	['N']	[11]
12	digoxin	B-Drug	['Causes']	[24]
13	with	O	['N']	[13]
14	suicidal	O	['N']	[14]
15	intent	O	['N']	[15]
16	an	O	['N']	[16]
17	was	O	['N']	[17]
18	treated	O	['N']	[18]
19	for	O	['N']	[19]
20	the	O	['N']	[20]
21	ensuing	O	['N']	[21]
22	complete	B	['N']	[22]
23	atrioventricular	I	['N']	[23]
24	block	I-Adverse_Effect	['N']	[24]
25	with	O	['N']	[25]
26	digoxin	O	['N']	[26]
27	-	O	['N']	[27]
28	specific	O	['N']	[28]
29	antibody	O	['N']	[29]
30	fragments	O	['N']	[30]
31	.	O	['N']	[31]
#844
0	The	O	['N']	[0]
1	Center	O	['N']	[1]
2	for	O	['N']	[2]
3	Disease	O	['N']	[3]
4	Control	O	['N']	[4]
5	has	O	['N']	[5]
6	received	O	['N']	[6]
7	numerous	O	['N']	[7]
8	reports	O	['N']	[8]
9	of	O	['N']	[9]
10	an	O	['N']	[10]
11	eosinophilia	B	['N']	[11]
12	-	I	['N']	[12]
13	myalgia	I	['N']	[13]
14	syndrome	I-Adverse_Effect	['N']	[14]
15	related	O	['N']	[15]
16	to	O	['N']	[16]
17	products	O	['N']	[17]
18	containing	O	['N']	[18]
19	L	B	['N']	[19]
20	-	I	['N']	[20]
21	tryptophan	I-Drug	['Causes']	[14]
22	.	O	['N']	[22]
#845
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	receiving	O	['N']	[2]
3	phenytoin	O	['N']	[3]
4	sodium	O	['N']	[4]
5	300	O	['N']	[5]
6	mg	O	['N']	[6]
7	/	O	['N']	[7]
8	day	O	['N']	[8]
9	;	O	['N']	[9]
10	carbamazepine	B-Drug	['Dosage']	[12]
11	200	B	['N']	[11]
12	mg	I-Dose	['N']	[12]
13	four	O	['N']	[13]
14	times	O	['N']	[14]
15	daily	O	['N']	[15]
16	had	O	['N']	[16]
17	been	O	['N']	[17]
18	discontinued	O	['N']	[18]
19	four	O	['N']	[19]
20	days	O	['N']	[20]
21	before	O	['N']	[21]
22	admission	O	['N']	[22]
23	because	O	['N']	[23]
24	of	O	['N']	[24]
25	leukopenia	O	['N']	[25]
26	.	O	['N']	[26]
#846
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	4	O	['N']	[2]
3	patients	O	['N']	[3]
4	,	O	['N']	[4]
5	2	O	['N']	[5]
6	on	O	['N']	[6]
7	methylphenidate	O	['N']	[7]
8	and	O	['N']	[8]
9	2	O	['N']	[9]
10	on	O	['N']	[10]
11	dextroamphetamine	B-Drug	['Causes']	[16]
12	who	O	['N']	[12]
13	presented	O	['N']	[13]
14	with	O	['N']	[14]
15	acral	B	['N']	[15]
16	cyanosis	I-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	livedo	O	['N']	[18]
19	reticularis	O	['N']	[19]
20	,	O	['N']	[20]
21	or	O	['N']	[21]
22	Raynaud	O	['N']	[22]
23	phenomenon	O	['N']	[23]
24	.	O	['N']	[24]
#847
0	This	O	['N']	[0]
1	paper	O	['N']	[1]
2	reports	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	fatal	B	['N']	[6]
7	perhexiline	B	['N']	[7]
8	maleate	I-Drug	['Causes']	[10]
9	liver	I	['N']	[9]
10	injury	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#848
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	hemiparesis	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	the	O	['N']	[9]
10	syndrome	O	['N']	[10]
11	of	O	['N']	[11]
12	irreversible	O	['N']	[12]
13	lithium	B-Drug	['Causes']	[16]
14	-	O	['N']	[14]
15	effectuated	O	['N']	[15]
16	neurotoxicity	B-Adverse_Effect	['N']	[16]
17	(	O	['N']	[17]
18	SILENT	O	['N']	[18]
19	)	O	['N']	[19]
20	while	O	['N']	[20]
21	being	O	['N']	[21]
22	treated	O	['N']	[22]
23	with	O	['N']	[23]
24	lithium	O	['N']	[24]
25	for	O	['N']	[25]
26	a	O	['N']	[26]
27	manic	O	['N']	[27]
28	episode	O	['N']	[28]
29	.	O	['N']	[29]
#849
0	Depressive	B	['N']	[0]
1	symptoms	I-Adverse_Effect	['N']	[1]
2	disappeared	O	['N']	[2]
3	after	O	['N']	[3]
4	interferon	B-Drug	['Causes']	[1]
5	therapy	O	['N']	[5]
6	was	O	['N']	[6]
7	stopped	O	['N']	[7]
8	.	O	['N']	[8]
#850
0	Extensive	O	['N']	[0]
1	immunological	O	['N']	[1]
2	investigations	O	['N']	[2]
3	were	O	['N']	[3]
4	performed	O	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	definite	O	['N']	[9]
10	seronegative	O	['N']	[10]
11	rheumatoid	O	['N']	[11]
12	arthritis	O	['N']	[12]
13	who	O	['N']	[13]
14	developed	O	['N']	[14]
15	hypogammaglobulinemia	B-Adverse_Effect	['N']	[15]
16	in	O	['N']	[16]
17	the	O	['N']	[17]
18	course	O	['N']	[18]
19	of	O	['N']	[19]
20	gold	B-Drug	['Causes']	[15]
21	therapy	O	['N']	[21]
22	.	O	['N']	[22]
#851
0	Reversal	O	['N']	[0]
1	of	O	['N']	[1]
2	severe	O	['N']	[2]
3	methanol	B-Drug	['Causes']	[7]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	visual	B	['N']	[6]
7	impairment	I-Adverse_Effect	['N']	[7]
8	:	O	['N']	[8]
9	no	O	['N']	[9]
10	evidence	O	['N']	[10]
11	of	O	['N']	[11]
12	retinal	O	['N']	[12]
13	toxicity	O	['N']	[13]
14	due	O	['N']	[14]
15	to	O	['N']	[15]
16	fomepizole	O	['N']	[16]
17	.	O	['N']	[17]
#852
0	Graves	B	['N']	[0]
1	'	I	['N']	[1]
2	hyperthyroidism	I-Adverse_Effect	['N']	[2]
3	following	O	['N']	[3]
4	transient	O	['N']	[4]
5	thyrotoxicosis	O	['N']	[5]
6	during	O	['N']	[6]
7	interferon	B-Drug	['Causes']	[2]
8	therapy	O	['N']	[8]
9	for	O	['N']	[9]
10	chronic	O	['N']	[10]
11	hepatitis	O	['N']	[11]
12	type	O	['N']	[12]
13	C.	O	['N']	[13]
#853
0	Rifampin	B-Drug	['Causes']	[20]
1	can	O	['N']	[1]
2	be	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	severe	O	['N']	[5]
6	adverse	O	['N']	[6]
7	effects	O	['N']	[7]
8	such	O	['N']	[8]
9	as	O	['N']	[9]
10	hepatitis	O	['N']	[10]
11	,	O	['N']	[11]
12	acute	O	['N']	[12]
13	renal	O	['N']	[13]
14	failure	O	['N']	[14]
15	,	O	['N']	[15]
16	hemolytic	O	['N']	[16]
17	anemia	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	thrombocytopenia	B-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#854
0	His	O	['N']	[0]
1	symptoms	O	['N']	[1]
2	of	O	['N']	[2]
3	brain	O	['N']	[3]
4	stem	O	['N']	[4]
5	compression	O	['N']	[5]
6	were	O	['N']	[6]
7	alleviated	O	['N']	[7]
8	and	O	['N']	[8]
9	the	O	['N']	[9]
10	role	O	['N']	[10]
11	of	O	['N']	[11]
12	phenytoin	B-Drug	['Causes']	[19]
13	in	O	['N']	[13]
14	the	O	['N']	[14]
15	production	O	['N']	[15]
16	of	O	['N']	[16]
17	his	O	['N']	[17]
18	craniocervical	B	['N']	[18]
19	abnormality	I-Adverse_Effect	['N']	[19]
20	is	O	['N']	[20]
21	discussed	O	['N']	[21]
22	.	O	['N']	[22]
#855
0	Therefore	O	['N']	[0]
1	,	O	['N']	[1]
2	parenteral	O	['N']	[2]
3	amiodarone	B-Drug	['Causes']	[11]
4	was	O	['N']	[4]
5	implicated	O	['N']	[5]
6	as	O	['N']	[6]
7	the	O	['N']	[7]
8	cause	O	['N']	[8]
9	of	O	['N']	[9]
10	acute	B	['N']	[10]
11	hepatitis	I-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	this	O	['N']	[13]
14	patient	O	['N']	[14]
15	.	O	['N']	[15]
#856
0	A	O	['N']	[0]
1	35-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	presented	O	['N']	[5]
6	with	O	['N']	[6]
7	neurotoxicity	B-Adverse_Effect	['N']	[7]
8	correlated	O	['N']	[8]
9	to	O	['N']	[9]
10	an	O	['N']	[10]
11	i.v	O	['N']	[11]
12	.	O	['N']	[12]
13	regimen	O	['N']	[13]
14	of	O	['N']	[14]
15	5-fluorouracil	B-Drug	['Causes']	[7]
16	as	O	['N']	[16]
17	episodes	O	['N']	[17]
18	of	O	['N']	[18]
19	acute	O	['N']	[19]
20	confusional	O	['N']	[20]
21	state	O	['N']	[21]
22	and	O	['N']	[22]
23	abnormalities	O	['N']	[23]
24	of	O	['N']	[24]
25	symmetrically	O	['N']	[25]
26	restricted	O	['N']	[26]
27	diffusion	O	['N']	[27]
28	in	O	['N']	[28]
29	the	O	['N']	[29]
30	periventricular	O	['N']	[30]
31	white	O	['N']	[31]
32	matter	O	['N']	[32]
33	and	O	['N']	[33]
34	corpus	O	['N']	[34]
35	callosum	O	['N']	[35]
36	.	O	['N']	[36]
#857
0	Carbamazepine	B-Drug	['Causes']	[5]
1	induced	O	['N']	[1]
2	right	B	['N']	[2]
3	bundle	I	['N']	[3]
4	branch	I	['N']	[4]
5	block	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	Greenlandic	O	['N']	[8]
9	patient	O	['N']	[9]
10	.	O	['N']	[10]
#858
0	A	O	['N']	[0]
1	22-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	black	O	['N']	[4]
5	man	O	['N']	[5]
6	developed	O	['N']	[6]
7	fever	O	['N']	[7]
8	,	O	['N']	[8]
9	chills	O	['N']	[9]
10	,	O	['N']	[10]
11	fatigue	O	['N']	[11]
12	,	O	['N']	[12]
13	night	B	['N']	[13]
14	sweats	I-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	tender	O	['N']	[16]
17	lymphadenopathy	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	a	O	['N']	[20]
21	generalized	O	['N']	[21]
22	,	O	['N']	[22]
23	pruritic	O	['N']	[23]
24	,	O	['N']	[24]
25	macular	O	['N']	[25]
26	eruption	O	['N']	[26]
27	3	O	['N']	[27]
28	weeks	O	['N']	[28]
29	after	O	['N']	[29]
30	starting	O	['N']	[30]
31	minocycline	B-Drug	['Causes']	[14]
32	therapy	O	['N']	[32]
33	for	O	['N']	[33]
34	acne	O	['N']	[34]
35	.	O	['N']	[35]
#859
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	have	O	['N']	[3]
4	recently	O	['N']	[4]
5	had	O	['N']	[5]
6	four	O	['N']	[6]
7	cases	O	['N']	[7]
8	of	O	['N']	[8]
9	clofibrate	B-Drug	['Causes']	[12]
10	-	O	['N']	[10]
11	induced	O	['N']	[11]
12	myopathy	B-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	patients	O	['N']	[14]
15	with	O	['N']	[15]
16	diabetes	O	['N']	[16]
17	insipidus	O	['N']	[17]
18	due	O	['N']	[18]
19	to	O	['N']	[19]
20	hypothalamic	O	['N']	[20]
21	lesions	O	['N']	[21]
22	.	O	['N']	[22]
#860
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Clinicians	O	['N']	[2]
3	should	O	['N']	[3]
4	be	O	['N']	[4]
5	aware	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	risk	O	['N']	[8]
9	of	O	['N']	[9]
10	serotonin	O	['N']	[10]
11	syndrome	O	['N']	[11]
12	with	O	['N']	[12]
13	serious	O	['N']	[13]
14	extrapyramidal	B	['N']	[14]
15	reactions	I-Adverse_Effect	['N']	[15]
16	in	O	['N']	[16]
17	patients	O	['N']	[17]
18	receiving	O	['N']	[18]
19	sertraline	B-Drug	['Causes']	[15]
20	or	O	['N']	[20]
21	venlafaxine	O	['N']	[21]
22	when	O	['N']	[22]
23	metoclopramide	O	['N']	[23]
24	is	O	['N']	[24]
25	coadministered	O	['N']	[25]
26	even	O	['N']	[26]
27	in	O	['N']	[27]
28	a	O	['N']	[28]
29	single	O	['N']	[29]
30	,	O	['N']	[30]
31	conventional	O	['N']	[31]
32	dose	O	['N']	[32]
33	.	O	['N']	[33]
#861
0	We	O	['N']	[0]
1	postulate	O	['N']	[1]
2	that	O	['N']	[2]
3	the	O	['N']	[3]
4	bolus	O	['N']	[4]
5	of	O	['N']	[5]
6	sulprostone	B-Drug	['Causes']	[16]
7	resulted	O	['N']	[7]
8	in	O	['N']	[8]
9	possible	O	['N']	[9]
10	coronary	O	['N']	[10]
11	spasm	O	['N']	[11]
12	that	O	['N']	[12]
13	resulted	O	['N']	[13]
14	in	O	['N']	[14]
15	cardiac	B	['N']	[15]
16	arrest	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#862
0	None	O	['N']	[0]
1	of	O	['N']	[1]
2	them	O	['N']	[2]
3	had	O	['N']	[3]
4	a	O	['N']	[4]
5	history	O	['N']	[5]
6	of	O	['N']	[6]
7	cardiac	O	['N']	[7]
8	disease	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	with	O	['N']	[11]
12	the	O	['N']	[12]
13	possible	O	['N']	[13]
14	exception	O	['N']	[14]
15	of	O	['N']	[15]
16	one	O	['N']	[16]
17	case	O	['N']	[17]
18	of	O	['N']	[18]
19	cardiac	B	['N']	[19]
20	arrest	I-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	where	O	['N']	[22]
23	the	O	['N']	[23]
24	patient	O	['N']	[24]
25	received	O	['N']	[25]
26	doxorubicin	B-Drug	['Causes']	[20]
27	,	O	['N']	[27]
28	no	O	['N']	[28]
29	predisposing	O	['N']	[29]
30	factors	O	['N']	[30]
31	could	O	['N']	[31]
32	be	O	['N']	[32]
33	found	O	['N']	[33]
34	.	O	['N']	[34]
#863
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	Topiramate	B-Drug	['Causes']	[8]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	angle	B	['N']	[5]
6	-	I	['N']	[6]
7	closure	I	['N']	[7]
8	glaucoma	I-Adverse_Effect	['N']	[8]
9	(	O	['N']	[9]
10	TiACG	O	['N']	[10]
11	)	O	['N']	[11]
12	is	O	['N']	[12]
13	believed	O	['N']	[13]
14	to	O	['N']	[14]
15	be	O	['N']	[15]
16	related	O	['N']	[16]
17	to	O	['N']	[17]
18	its	O	['N']	[18]
19	sulfonamide	O	['N']	[19]
20	moiety	O	['N']	[20]
21	.	O	['N']	[21]
#864
0	Methemoglobinemia	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	dermal	O	['N']	[3]
4	application	O	['N']	[4]
5	of	O	['N']	[5]
6	benzocaine	B-Drug	['Causes']	[0]
7	cream	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	cat	O	['N']	[10]
11	.	O	['N']	[11]
#865
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Reproductive	O	['N']	[2]
3	endocrine	O	['N']	[3]
4	disorders	O	['N']	[4]
5	characterized	O	['N']	[5]
6	by	O	['N']	[6]
7	menstrual	B	['N']	[7]
8	disorders	I-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	polycystic	O	['N']	[10]
11	ovaries	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	hyperandrogenism	O	['N']	[14]
15	seem	O	['N']	[15]
16	to	O	['N']	[16]
17	be	O	['N']	[17]
18	common	O	['N']	[18]
19	among	O	['N']	[19]
20	women	O	['N']	[20]
21	treated	O	['N']	[21]
22	with	O	['N']	[22]
23	sodium	B	['N']	[23]
24	valproate	I-Drug	['Causes']	[8]
25	for	O	['N']	[25]
26	epilepsy	O	['N']	[26]
27	.	O	['N']	[27]
#866
0	Three	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	intravitreal	O	['N']	[3]
4	injection	O	['N']	[4]
5	of	O	['N']	[5]
6	bevacizumab	B-Drug	['Causes']	[11]
7	,	O	['N']	[7]
8	acute	B	['N']	[8]
9	ocular	I	['N']	[9]
10	ischemic	I	['N']	[10]
11	syndrome	I-Adverse_Effect	['N']	[11]
12	occurred	O	['N']	[12]
13	.	O	['N']	[13]
#867
0	Tiagabine	B-Drug	['Causes']	[8]
1	overdose	O	['N']	[1]
2	causes	O	['N']	[2]
3	an	O	['N']	[3]
4	unusual	B	['N']	[4]
5	array	I	['N']	[5]
6	of	I	['N']	[6]
7	neurological	I	['N']	[7]
8	symptoms	I-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	many	O	['N']	[10]
11	similar	O	['N']	[11]
12	to	O	['N']	[12]
13	reported	O	['N']	[13]
14	adverse	O	['N']	[14]
15	effects	O	['N']	[15]
16	during	O	['N']	[16]
17	therapeutic	O	['N']	[17]
18	use	O	['N']	[18]
19	.	O	['N']	[19]
#868
0	Paraplegia	B-Adverse_Effect	['N']	[0]
1	following	O	['N']	[1]
2	prophylactic	O	['N']	[2]
3	intrathecal	O	['N']	[3]
4	cytosine	B	['N']	[4]
5	arabinoside	I-Drug	['Causes']	[0]
6	(	O	['N']	[6]
7	Ara	O	['N']	[7]
8	-	O	['N']	[8]
9	C	O	['N']	[9]
10	)	O	['N']	[10]
11	is	O	['N']	[11]
12	described	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	patient	O	['N']	[15]
16	with	O	['N']	[16]
17	acute	O	['N']	[17]
18	myelogenous	O	['N']	[18]
19	leukemia	O	['N']	[19]
20	in	O	['N']	[20]
21	remission	O	['N']	[21]
22	who	O	['N']	[22]
23	received	O	['N']	[23]
24	doses	O	['N']	[24]
25	of	O	['N']	[25]
26	100	O	['N']	[26]
27	mg	O	['N']	[27]
28	/	O	['N']	[28]
29	m2/d	O	['N']	[29]
30	for	O	['N']	[30]
31	5	O	['N']	[31]
32	consecutive	O	['N']	[32]
33	days	O	['N']	[33]
34	.	O	['N']	[34]
#869
0	After	O	['N']	[0]
1	rechallenge	O	['N']	[1]
2	with	O	['N']	[2]
3	monotherapy	O	['N']	[3]
4	pegvisomant	B-Drug	['Causes']	[11]
5	,	O	['N']	[5]
6	however	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	hepatic	B	['N']	[9]
10	enzyme	I	['N']	[10]
11	disturbances	I-Adverse_Effect	['N']	[11]
12	reappeared	O	['N']	[12]
13	within	O	['N']	[13]
14	a	O	['N']	[14]
15	few	O	['N']	[15]
16	weeks	O	['N']	[16]
17	,	O	['N']	[17]
18	indicating	O	['N']	[18]
19	that	O	['N']	[19]
20	most	O	['N']	[20]
21	likely	O	['N']	[21]
22	pegvisomant	O	['N']	[22]
23	alone	O	['N']	[23]
24	and	O	['N']	[24]
25	not	O	['N']	[25]
26	the	O	['N']	[26]
27	long	O	['N']	[27]
28	-	O	['N']	[28]
29	acting	O	['N']	[29]
30	somatostatin	O	['N']	[30]
31	analog	O	['N']	[31]
32	or	O	['N']	[32]
33	the	O	['N']	[33]
34	combination	O	['N']	[34]
35	of	O	['N']	[35]
36	these	O	['N']	[36]
37	two	O	['N']	[37]
38	drugs	O	['N']	[38]
39	was	O	['N']	[39]
40	responsible	O	['N']	[40]
41	for	O	['N']	[41]
42	this	O	['N']	[42]
43	case	O	['N']	[43]
44	of	O	['N']	[44]
45	drug	O	['N']	[45]
46	-	O	['N']	[46]
47	induced	O	['N']	[47]
48	hepatitis	O	['N']	[48]
49	.	O	['N']	[49]
#870
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	37-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	African-	O	['N']	[6]
7	American	O	['N']	[7]
8	man	O	['N']	[8]
9	with	O	['N']	[9]
10	G6PD	O	['N']	[10]
11	deficiency	O	['N']	[11]
12	developed	O	['N']	[12]
13	hemolytic	O	['N']	[13]
14	anemia	O	['N']	[14]
15	,	O	['N']	[15]
16	hepatitis	O	['N']	[16]
17	,	O	['N']	[17]
18	orthostatic	O	['N']	[18]
19	hypotension	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	aseptic	B	['N']	[22]
23	meningitis	I-Adverse_Effect	['N']	[23]
24	simultaneously	O	['N']	[24]
25	after	O	['N']	[25]
26	using	O	['N']	[26]
27	trimethoprim	O	['N']	[27]
28	-	O	['N']	[28]
29	sulfamethoxazole	B-Drug	['Causes']	[23]
30	.	O	['N']	[30]
#871
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	baclofen	B-Drug	['Causes']	[7]
6	withdrawal	B	['N']	[6]
7	syndrome	I-Adverse_Effect	['N']	[7]
8	resulting	O	['N']	[8]
9	from	O	['N']	[9]
10	oral	O	['N']	[10]
11	baclofen	O	['N']	[11]
12	underdosing	O	['N']	[12]
13	.	O	['N']	[13]
#872
0	We	O	['N']	[0]
1	have	O	['N']	[1]
2	cared	O	['N']	[2]
3	for	O	['N']	[3]
4	three	O	['N']	[4]
5	children	O	['N']	[5]
6	in	O	['N']	[6]
7	whom	O	['N']	[7]
8	four	O	['N']	[8]
9	episodes	O	['N']	[9]
10	of	O	['N']	[10]
11	dystonia	O	['N']	[11]
12	proceeding	O	['N']	[12]
13	to	O	['N']	[13]
14	opisthotonus	B-Adverse_Effect	['N']	[14]
15	occurred	O	['N']	[15]
16	in	O	['N']	[16]
17	association	O	['N']	[17]
18	with	O	['N']	[18]
19	carbamazepine	B-Drug	['Causes']	[14]
20	use	O	['N']	[20]
21	.	O	['N']	[21]
#873
0	Graves	O	['N']	[0]
1	'	O	['N']	[1]
2	hyperthyroidism	O	['N']	[2]
3	following	O	['N']	[3]
4	transient	B	['N']	[4]
5	thyrotoxicosis	I-Adverse_Effect	['N']	[5]
6	during	O	['N']	[6]
7	interferon	B-Drug	['Causes']	[5]
8	therapy	O	['N']	[8]
9	for	O	['N']	[9]
10	chronic	O	['N']	[10]
11	hepatitis	O	['N']	[11]
12	type	O	['N']	[12]
13	C.	O	['N']	[13]
#874
0	After	O	['N']	[0]
1	three	O	['N']	[1]
2	weeks	O	['N']	[2]
3	of	O	['N']	[3]
4	carbamazepine	B-Drug	['Causes']	[19]
5	therapy	O	['N']	[5]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	patient	O	['N']	[8]
9	arrived	O	['N']	[9]
10	at	O	['N']	[10]
11	the	O	['N']	[11]
12	emergency	O	['N']	[12]
13	department	O	['N']	[13]
14	(	O	['N']	[14]
15	ED	O	['N']	[15]
16	)	O	['N']	[16]
17	with	O	['N']	[17]
18	severe	B	['N']	[18]
19	agitation	I-Adverse_Effect	['N']	[19]
20	and	O	['N']	[20]
21	aggressive	O	['N']	[21]
22	behavior	O	['N']	[22]
23	.	O	['N']	[23]
#875
0	A	O	['N']	[0]
1	lethal	B	['N']	[1]
2	complication	I-Adverse_Effect	['N']	[2]
3	of	O	['N']	[3]
4	peripheral	O	['N']	[4]
5	vein	O	['N']	[5]
6	vasopressin	B-Drug	['Causes']	[2]
7	infusion	O	['N']	[7]
8	.	O	['N']	[8]
#876
0	Reversible	B	['N']	[0]
1	leukopenia	I-Adverse_Effect	['N']	[1]
2	was	O	['N']	[2]
3	documented	O	['N']	[3]
4	in	O	['N']	[4]
5	an	O	['N']	[5]
6	81-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	adjunctive	O	['N']	[12]
13	ibopamine	B-Drug	['Causes']	[1]
14	100	O	['N']	[14]
15	mg	O	['N']	[15]
16	t.i.d	O	['N']	[16]
17	.	O	['N']	[17]
18	for	O	['N']	[18]
19	chronic	O	['N']	[19]
20	congestive	O	['N']	[20]
21	heart	O	['N']	[21]
22	failure	O	['N']	[22]
23	.	O	['N']	[23]
#877
0	Nine	O	['N']	[0]
1	delirious	B-Adverse_Effect	['N']	[1]
2	patients	O	['N']	[2]
3	suffering	O	['N']	[3]
4	from	O	['N']	[4]
5	lithium	B-Drug	['Causes']	[1]
6	intoxication	O	['N']	[6]
7	were	O	['N']	[7]
8	examined	O	['N']	[8]
9	with	O	['N']	[9]
10	the	O	['N']	[10]
11	Mini	O	['N']	[11]
12	-	O	['N']	[12]
13	Mental	O	['N']	[13]
14	State	O	['N']	[14]
15	Exam	O	['N']	[15]
16	(	O	['N']	[16]
17	MMS	O	['N']	[17]
18	)	O	['N']	[18]
19	to	O	['N']	[19]
20	describe	O	['N']	[20]
21	the	O	['N']	[21]
22	clinical	O	['N']	[22]
23	course	O	['N']	[23]
24	of	O	['N']	[24]
25	the	O	['N']	[25]
26	disorder	O	['N']	[26]
27	.	O	['N']	[27]
#878
0	Salicylate	B-Drug	['Causes']	[2]
1	hepato	B	['N']	[1]
2	toxicity	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	rheumatic	O	['N']	[4]
5	fever	O	['N']	[5]
6	.	O	['N']	[6]
#879
0	Introduction	O	['N']	[0]
1	of	O	['N']	[1]
2	etanercept	B-Drug	['Causes']	[14]
3	was	O	['N']	[3]
4	also	O	['N']	[4]
5	clinically	O	['N']	[5]
6	effective	O	['N']	[6]
7	but	O	['N']	[7]
8	followed	O	['N']	[8]
9	by	O	['N']	[9]
10	development	O	['N']	[10]
11	of	O	['N']	[11]
12	severe	B	['N']	[12]
13	heart	I	['N']	[13]
14	failure	I-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#880
0	Ceftriaxone	O	['N']	[0]
1	was	O	['N']	[1]
2	approved	O	['N']	[2]
3	in	O	['N']	[3]
4	1997	O	['N']	[4]
5	for	O	['N']	[5]
6	the	O	['N']	[6]
7	treatment	O	['N']	[7]
8	of	O	['N']	[8]
9	otitis	O	['N']	[9]
10	media	O	['N']	[10]
11	despite	O	['N']	[11]
12	previous	O	['N']	[12]
13	studies	O	['N']	[13]
14	that	O	['N']	[14]
15	documented	O	['N']	[15]
16	an	O	['N']	[16]
17	association	O	['N']	[17]
18	of	O	['N']	[18]
19	ceftriaxone	B-Drug	['Causes']	[25]
20	with	O	['N']	[20]
21	elevated	B	['N']	[21]
22	hepato	I	['N']	[22]
23	-	I	['N']	[23]
24	biliary	I	['N']	[24]
25	enzymes	I-Adverse_Effect	['N']	[25]
26	and	O	['N']	[26]
27	transient	O	['N']	[27]
28	biliary	O	['N']	[28]
29	stasis	O	['N']	[29]
30	.	O	['N']	[30]
#881
0	The	O	['N']	[0]
1	second	O	['N']	[1]
2	was	O	['N']	[2]
3	an	O	['N']	[3]
4	82-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	man	O	['N']	[7]
8	receiving	O	['N']	[8]
9	ticlopidine	B-Drug	['Causes']	[26]
10	for	O	['N']	[10]
11	2	O	['N']	[11]
12	years	O	['N']	[12]
13	when	O	['N']	[13]
14	,	O	['N']	[14]
15	during	O	['N']	[15]
16	a	O	['N']	[16]
17	febrile	O	['N']	[17]
18	episode	O	['N']	[18]
19	,	O	['N']	[19]
20	he	O	['N']	[20]
21	was	O	['N']	[21]
22	found	O	['N']	[22]
23	neutropenic	O	['N']	[23]
24	with	O	['N']	[24]
25	marrow	B	['N']	[25]
26	aplasia	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#882
0	Therefore	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	concluded	O	['N']	[3]
4	that	O	['N']	[4]
5	this	O	['N']	[5]
6	patient	O	['N']	[6]
7	's	O	['N']	[7]
8	pulmonary	B	['N']	[8]
9	disease	I-Adverse_Effect	['N']	[9]
10	was	O	['N']	[10]
11	caused	O	['N']	[11]
12	by	O	['N']	[12]
13	calcium	B	['N']	[13]
14	stearate	I-Drug	['Causes']	[9]
15	,	O	['N']	[15]
16	an	O	['N']	[16]
17	additive	O	['N']	[17]
18	for	O	['N']	[18]
19	an	O	['N']	[19]
20	antihistaminic	O	['N']	[20]
21	drug	O	['N']	[21]
22	.	O	['N']	[22]
#883
0	Baclofen	O	['N']	[0]
1	withdrawal	B	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	resulting	O	['N']	[3]
4	from	O	['N']	[4]
5	underdosing	O	['N']	[5]
6	of	O	['N']	[6]
7	oral	O	['N']	[7]
8	baclofen	B-Drug	['Causes']	[2]
9	should	O	['N']	[9]
10	be	O	['N']	[10]
11	considered	O	['N']	[11]
12	as	O	['N']	[12]
13	a	O	['N']	[13]
14	potential	O	['N']	[14]
15	source	O	['N']	[15]
16	of	O	['N']	[16]
17	prolonged	O	['N']	[17]
18	fever	O	['N']	[18]
19	in	O	['N']	[19]
20	the	O	['N']	[20]
21	intensive	O	['N']	[21]
22	care	O	['N']	[22]
23	unit	O	['N']	[23]
24	.	O	['N']	[24]
#884
0	Physicians	O	['N']	[0]
1	should	O	['N']	[1]
2	keep	O	['N']	[2]
3	in	O	['N']	[3]
4	mind	O	['N']	[4]
5	that	O	['N']	[5]
6	taxanes	O	['N']	[6]
7	such	O	['N']	[7]
8	as	O	['N']	[8]
9	paclitaxel	B-Drug	['Causes']	[15]
10	have	O	['N']	[10]
11	the	O	['N']	[11]
12	potential	O	['N']	[12]
13	to	O	['N']	[13]
14	cause	O	['N']	[14]
15	pneumonitis	B-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	lung	O	['N']	[17]
18	fibrosis	O	['N']	[18]
19	.	O	['N']	[19]
#885
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	was	O	['N']	[2]
3	an	O	['N']	[3]
4	80-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	woman	O	['N']	[7]
8	who	O	['N']	[8]
9	was	O	['N']	[9]
10	admitted	O	['N']	[10]
11	for	O	['N']	[11]
12	Staphylococcus	B	['N']	[12]
13	aureus	I	['N']	[13]
14	knee	I	['N']	[14]
15	arthritis	I-Adverse_Effect	['N']	[15]
16	after	O	['N']	[16]
17	several	O	['N']	[17]
18	intraarticular	O	['N']	[18]
19	injections	O	['N']	[19]
20	of	O	['N']	[20]
21	sodium	B	['N']	[21]
22	hyaluronate	I-Drug	['Causes']	[15]
23	and	O	['N']	[23]
24	corticosteroids	O	['N']	[24]
25	.	O	['N']	[25]
#886
0	Thalidomide	B-Drug	['Causes']	[1]
1	neuropathy	B-Adverse_Effect	['N']	[1]
2	is	O	['N']	[2]
3	often	O	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	proximal	O	['N']	[6]
7	weakness	O	['N']	[7]
8	and	O	['N']	[8]
9	may	O	['N']	[9]
10	progress	O	['N']	[10]
11	even	O	['N']	[11]
12	after	O	['N']	[12]
13	discontinuation	O	['N']	[13]
14	of	O	['N']	[14]
15	treatment	O	['N']	[15]
16	,	O	['N']	[16]
17	in	O	['N']	[17]
18	the	O	['N']	[18]
19	phenomenon	O	['N']	[19]
20	of	O	['N']	[20]
21	'	O	['N']	[21]
22	coasting	O	['N']	[22]
23	'	O	['N']	[23]
24	.	O	['N']	[24]
#887
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	the	O	['N']	[4]
5	occurrence	O	['N']	[5]
6	of	O	['N']	[6]
7	acute	B	['N']	[7]
8	cytolytic	I	['N']	[8]
9	hepatitis	I-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	patient	O	['N']	[12]
13	exposed	O	['N']	[13]
14	to	O	['N']	[14]
15	pulse	O	['N']	[15]
16	itraconazole	B-Drug	['Causes']	[9]
17	therapy	O	['N']	[17]
18	for	O	['N']	[18]
19	24	O	['N']	[19]
20	weeks	O	['N']	[20]
21	and	O	['N']	[21]
22	provide	O	['N']	[22]
23	a	O	['N']	[23]
24	concise	O	['N']	[24]
25	review	O	['N']	[25]
26	of	O	['N']	[26]
27	the	O	['N']	[27]
28	literature	O	['N']	[28]
29	on	O	['N']	[29]
30	cases	O	['N']	[30]
31	of	O	['N']	[31]
32	itraconazole	O	['N']	[32]
33	-	O	['N']	[33]
34	induced	O	['N']	[34]
35	hepatitis	O	['N']	[35]
36	.	O	['N']	[36]
#888
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	neuroleptic	B	['N']	[6]
7	malignant	I	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	that	O	['N']	[9]
10	occurred	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	on	O	['N']	[14]
15	amitriptyline	B-Drug	['Causes']	[8]
16	and	O	['N']	[16]
17	lithium	O	['N']	[17]
18	carbonate	O	['N']	[18]
19	.	O	['N']	[19]
#889
0	Two	O	['N']	[0]
1	of	O	['N']	[1]
2	these	O	['N']	[2]
3	patients	O	['N']	[3]
4	,	O	['N']	[4]
5	who	O	['N']	[5]
6	also	O	['N']	[6]
7	received	O	['N']	[7]
8	the	O	['N']	[8]
9	anti	O	['N']	[9]
10	-	O	['N']	[10]
11	emetic	O	['N']	[11]
12	prochlorperazine	B-Drug	['Causes']	[15]
13	,	O	['N']	[13]
14	lost	B	['N']	[14]
15	consciousness	I-Adverse_Effect	['N']	[15]
16	for	O	['N']	[16]
17	48	O	['N']	[17]
18	-	O	['N']	[18]
19	72	O	['N']	[19]
20	h	O	['N']	[20]
21	and	O	['N']	[21]
22	then	O	['N']	[22]
23	fully	O	['N']	[23]
24	recovered	O	['N']	[24]
25	.	O	['N']	[25]
#890
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	a	O	['N']	[5]
6	liver	B	['N']	[6]
7	abscess	I-Adverse_Effect	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	Entamoeba	O	['N']	[10]
11	histolytica	O	['N']	[11]
12	,	O	['N']	[12]
13	in	O	['N']	[13]
14	whom	O	['N']	[14]
15	metronidazole	B-Drug	['Causes']	[7]
16	therapy	O	['N']	[16]
17	(	O	['N']	[17]
18	total	O	['N']	[18]
19	dose	O	['N']	[19]
20	,	O	['N']	[20]
21	21	O	['N']	[21]
22	g	O	['N']	[22]
23	over	O	['N']	[23]
24	14	O	['N']	[24]
25	days	O	['N']	[25]
26	)	O	['N']	[26]
27	was	O	['N']	[27]
28	complicated	O	['N']	[28]
29	by	O	['N']	[29]
30	reversible	O	['N']	[30]
31	deafness	O	['N']	[31]
32	,	O	['N']	[32]
33	tinnitus	O	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	ataxia	O	['N']	[36]
37	and	O	['N']	[37]
38	who	O	['N']	[38]
39	relapsed	O	['N']	[39]
40	5	O	['N']	[40]
41	months	O	['N']	[41]
42	later	O	['N']	[42]
43	with	O	['N']	[43]
44	a	O	['N']	[44]
45	splenic	O	['N']	[45]
46	abscess	O	['N']	[46]
47	.	O	['N']	[47]
#891
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	the	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	young	O	['N']	[8]
9	woman	O	['N']	[9]
10	with	O	['N']	[10]
11	Graves	O	['N']	[11]
12	'	O	['N']	[12]
13	disease	O	['N']	[13]
14	in	O	['N']	[14]
15	whom	O	['N']	[15]
16	ototoxicity	B-Adverse_Effect	['N']	[16]
17	developed	O	['N']	[17]
18	because	O	['N']	[18]
19	of	O	['N']	[19]
20	propylthiouracil	B-Drug	['Causes']	[16]
21	(	O	['N']	[21]
22	PTU)-induced	O	['N']	[22]
23	antineutrophil	O	['N']	[23]
24	cytoplasmic	O	['N']	[24]
25	antibody	O	['N']	[25]
26	(	O	['N']	[26]
27	ANCA)-associated	O	['N']	[27]
28	vasculitis	O	['N']	[28]
29	.	O	['N']	[29]
#892
0	Insulin	B	['N']	[0]
1	-	I	['N']	[1]
2	dependent	I	['N']	[2]
3	diabetes	I	['N']	[3]
4	mellitus	I-Adverse_Effect	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	danazol	B-Drug	['Causes']	[4]
8	.	O	['N']	[8]
#893
0	Pulmonary	O	['N']	[0]
1	fibrosis	O	['N']	[1]
2	subsequent	O	['N']	[2]
3	to	O	['N']	[3]
4	high	B	['N']	[4]
5	doses	I-Dose	['N']	[5]
6	of	O	['N']	[6]
7	CCNU	B-Drug	['Dosage']	[5]
8	for	O	['N']	[8]
9	chronic	O	['N']	[9]
10	myeloid	O	['N']	[10]
11	leukemia	O	['N']	[11]
12	.	O	['N']	[12]
#894
0	Increased	B	['N']	[0]
1	lash	I	['N']	[1]
2	length	I-Adverse_Effect	['N']	[2]
3	,	O	['N']	[3]
4	thickness	O	['N']	[4]
5	,	O	['N']	[5]
6	and	O	['N']	[6]
7	pigmentation	O	['N']	[7]
8	are	O	['N']	[8]
9	well	O	['N']	[9]
10	-	O	['N']	[10]
11	documented	O	['N']	[11]
12	side	O	['N']	[12]
13	effects	O	['N']	[13]
14	of	O	['N']	[14]
15	prostaglandin	B-Drug	['Causes']	[2]
16	analog	O	['N']	[16]
17	glaucoma	O	['N']	[17]
18	drops	O	['N']	[18]
19	.	O	['N']	[19]
#895
0	We	O	['N']	[0]
1	conclude	O	['N']	[1]
2	that	O	['N']	[2]
3	while	O	['N']	[3]
4	thrombocytopenia	O	['N']	[4]
5	and	O	['N']	[5]
6	schistocytosis	O	['N']	[6]
7	can	O	['N']	[7]
8	be	O	['N']	[8]
9	seen	O	['N']	[9]
10	in	O	['N']	[10]
11	quinine	B-Drug	['Causes']	[16]
12	-	O	['N']	[12]
13	associated	O	['N']	[13]
14	TTP	B	['N']	[14]
15	/	I	['N']	[15]
16	HUS	I-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	the	O	['N']	[18]
19	pathophysiology	O	['N']	[19]
20	seems	O	['N']	[20]
21	to	O	['N']	[21]
22	be	O	['N']	[22]
23	distinct	O	['N']	[23]
24	from	O	['N']	[24]
25	that	O	['N']	[25]
26	seen	O	['N']	[26]
27	in	O	['N']	[27]
28	most	O	['N']	[28]
29	cases	O	['N']	[29]
30	of	O	['N']	[30]
31	idiopathic	O	['N']	[31]
32	TTP	O	['N']	[32]
33	(	O	['N']	[33]
34	i.e.	O	['N']	[34]
35	,	O	['N']	[35]
36	severely	O	['N']	[36]
37	decreased	O	['N']	[37]
38	ADAMTS13	O	['N']	[38]
39	with	O	['N']	[39]
40	an	O	['N']	[40]
41	inhibitor	O	['N']	[41]
42	)	O	['N']	[42]
43	.	O	['N']	[43]
#896
0	We	O	['N']	[0]
1	introduce	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	sixty	O	['N']	[6]
7	years	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	with	O	['N']	[10]
11	several	O	['N']	[11]
12	previous	O	['N']	[12]
13	episodes	O	['N']	[13]
14	of	O	['N']	[14]
15	rhinitis	B-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	conjunctivitis	O	['N']	[17]
18	and	O	['N']	[18]
19	perspiration	O	['N']	[19]
20	immediately	O	['N']	[20]
21	after	O	['N']	[21]
22	the	O	['N']	[22]
23	administration	O	['N']	[23]
24	of	O	['N']	[24]
25	salmon	O	['N']	[25]
26	calcitonin	O	['N']	[26]
27	with	O	['N']	[27]
28	nasal	O	['N']	[28]
29	spray	O	['N']	[29]
30	or	O	['N']	[30]
31	intramuscular	O	['N']	[31]
32	administration	O	['N']	[32]
33	(	O	['N']	[33]
34	Calsynar	B-Drug	['Causes']	[15]
35	)	O	['N']	[35]
36	.	O	['N']	[36]
#897
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Itraconazole	B-Drug	['Causes']	[13]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	liver	O	['N']	[5]
6	injury	O	['N']	[6]
7	presents	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	cholestatic	B	['N']	[10]
11	pattern	I	['N']	[11]
12	of	I	['N']	[12]
13	injury	I-Adverse_Effect	['N']	[13]
14	with	O	['N']	[14]
15	damage	O	['N']	[15]
16	to	O	['N']	[16]
17	the	O	['N']	[17]
18	interlobular	O	['N']	[18]
19	bile	O	['N']	[19]
20	ducts	O	['N']	[20]
21	,	O	['N']	[21]
22	possibly	O	['N']	[22]
23	leading	O	['N']	[23]
24	to	O	['N']	[24]
25	ductopenia	O	['N']	[25]
26	.	O	['N']	[26]
#898
0	High	O	['N']	[0]
1	-	O	['N']	[1]
2	dose	O	['N']	[2]
3	phosphate	B-Drug	['Causes']	[7]
4	treatment	O	['N']	[4]
5	leads	O	['N']	[5]
6	to	O	['N']	[6]
7	hypokalemia	B-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	hypophosphatemic	O	['N']	[9]
10	osteomalacia	O	['N']	[10]
11	.	O	['N']	[11]
#899
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	four	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	encephalopathy	B-Adverse_Effect	['N']	[5]
6	coincident	O	['N']	[6]
7	with	O	['N']	[7]
8	elevated	O	['N']	[8]
9	aluminum	-	['N']	[9]
10	levels	O	['N']	[10]
11	as	O	['N']	[11]
12	well	O	['N']	[12]
13	as	O	['N']	[13]
14	one	O	['N']	[14]
15	patient	O	['N']	[15]
16	who	O	['N']	[16]
17	developed	O	['N']	[17]
18	seizures	O	['N']	[18]
19	while	O	['N']	[19]
20	receiving	O	['N']	[20]
21	continuous	O	['N']	[21]
22	bladder	O	['N']	[22]
23	irrigations	O	['N']	[23]
24	with	O	['N']	[24]
25	alum	O	['N']	[25]
26	.	O	['N']	[26]
#900
0	An	O	['N']	[0]
1	11-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	who	O	['N']	[5]
6	was	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	relatively	O	['N']	[10]
11	high	B	['N']	[11]
12	dose	I-Dose	['N']	[12]
13	of	O	['N']	[13]
14	methotrimeprazine	B	['N']	[14]
15	meleate	I-Drug	['Dosage']	[12]
16	(	O	['N']	[16]
17	Levemepromazine	O	['N']	[17]
18	)	O	['N']	[18]
19	a	O	['N']	[19]
20	phenothiazine	O	['N']	[20]
21	antipsychotic	O	['N']	[21]
22	drug	O	['N']	[22]
23	,	O	['N']	[23]
24	was	O	['N']	[24]
25	admitted	O	['N']	[25]
26	to	O	['N']	[26]
27	the	O	['N']	[27]
28	pediatric	O	['N']	[28]
29	intensive	O	['N']	[29]
30	care	O	['N']	[30]
31	unit	O	['N']	[31]
32	suffering	O	['N']	[32]
33	from	O	['N']	[33]
34	respiratory	O	['N']	[34]
35	distress	O	['N']	[35]
36	syndrome	O	['N']	[36]
37	.	O	['N']	[37]
#901
0	Therapy	O	['N']	[0]
1	with	O	['N']	[1]
2	IFN	B	['N']	[2]
3	-	I	['N']	[3]
4	alpha	I-Drug	['Causes']	[19]
5	may	O	['N']	[5]
6	be	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	number	O	['N']	[10]
11	of	O	['N']	[11]
12	neuropsychiatric	O	['N']	[12]
13	symptoms	O	['N']	[13]
14	,	O	['N']	[14]
15	such	O	['N']	[15]
16	as	O	['N']	[16]
17	Parkinsonism	O	['N']	[17]
18	,	O	['N']	[18]
19	akathisia	B-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	seizure	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	depressive	O	['N']	[24]
25	disorders	O	['N']	[25]
26	.	O	['N']	[26]
#902
0	Physicians	O	['N']	[0]
1	using	O	['N']	[1]
2	this	O	['N']	[2]
3	"	O	['N']	[3]
4	new	O	['N']	[4]
5	"	O	['N']	[5]
6	drug	O	['N']	[6]
7	must	O	['N']	[7]
8	be	O	['N']	[8]
9	aware	O	['N']	[9]
10	of	O	['N']	[10]
11	the	O	['N']	[11]
12	potential	O	['N']	[12]
13	danger	O	['N']	[13]
14	of	O	['N']	[14]
15	sulfonamide	B-Drug	['Causes']	[22]
16	-	O	['N']	[16]
17	induced	O	['N']	[17]
18	injury	B	['N']	[18]
19	to	I	['N']	[19]
20	the	I	['N']	[20]
21	urinary	I	['N']	[21]
22	tract	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#903
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Interferon	O	['N']	[2]
3	(	O	['N']	[3]
4	IFN)-associated	-	['N']	[4]
5	retinopathy	O	['N']	[5]
6	is	O	['N']	[6]
7	typically	O	['N']	[7]
8	characterized	O	['N']	[8]
9	by	O	['N']	[9]
10	retinal	B	['N']	[10]
11	hemorrhages	I-Adverse_Effect	['N']	[11]
12	and	O	['N']	[12]
13	cotton	O	['N']	[13]
14	wool	O	['N']	[14]
15	spots	O	['N']	[15]
16	at	O	['N']	[16]
17	the	O	['N']	[17]
18	posterior	O	['N']	[18]
19	fundus	O	['N']	[19]
20	,	O	['N']	[20]
21	but	O	['N']	[21]
22	visual	O	['N']	[22]
23	function	O	['N']	[23]
24	is	O	['N']	[24]
25	usually	O	['N']	[25]
26	maintained	O	['N']	[26]
27	.	O	['N']	[27]
#904
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	reported	O	['N']	[2]
3	here	O	['N']	[3]
4	is	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	child	O	['N']	[7]
8	given	O	['N']	[8]
9	a	O	['N']	[9]
10	large	O	['N']	[10]
11	dose	O	['N']	[11]
12	of	O	['N']	[12]
13	intravenous	O	['N']	[13]
14	iron	B	['N']	[14]
15	sucrose	I-Drug	['Dosage']	[20]
16	(	O	['N']	[16]
17	16	B	['N']	[17]
18	mg	I	['N']	[18]
19	/	I	['N']	[19]
20	kg	I-Dose	['N']	[20]
21	)	O	['N']	[21]
22	over	O	['N']	[22]
23	3	O	['N']	[23]
24	hours	O	['N']	[24]
25	,	O	['N']	[25]
26	who	O	['N']	[26]
27	subsequently	O	['N']	[27]
28	developed	O	['N']	[28]
29	features	O	['N']	[29]
30	of	O	['N']	[30]
31	systemic	O	['N']	[31]
32	iron	O	['N']	[32]
33	toxicity	O	['N']	[33]
34	.	O	['N']	[34]
#905
0	The	O	['N']	[0]
1	administration	O	['N']	[1]
2	of	O	['N']	[2]
3	"	O	['N']	[3]
4	sweet	O	['N']	[4]
5	spirits	O	['N']	[5]
6	of	O	['N']	[6]
7	nitre	O	['N']	[7]
8	"	O	['N']	[8]
9	(	O	['N']	[9]
10	4	B	['N']	[10]
11	%	I	['N']	[11]
12	ethyl	I	['N']	[12]
13	nitrite	I	['N']	[13]
14	CH3CH2ONO	I	['N']	[14]
15	in	I	['N']	[15]
16	70	I	['N']	[16]
17	%	I	['N']	[17]
18	ethyl	I	['N']	[18]
19	alcohol	I-Drug	['Causes']	[51]
20	)	O	['N']	[20]
21	was	O	['N']	[21]
22	followed	O	['N']	[22]
23	by	O	['N']	[23]
24	acute	O	['N']	[24]
25	methemoglobinemia	O	['N']	[25]
26	and	O	['N']	[26]
27	severe	O	['N']	[27]
28	anoxic	O	['N']	[28]
29	metabolic	O	['N']	[29]
30	acidosis	O	['N']	[30]
31	in	O	['N']	[31]
32	infant	O	['N']	[32]
33	twins	O	['N']	[33]
34	,	O	['N']	[34]
35	Methylene	O	['N']	[35]
36	blue	O	['N']	[36]
37	administration	O	['N']	[37]
38	reversed	O	['N']	[38]
39	methemoglobinemia	O	['N']	[39]
40	in	O	['N']	[40]
41	both	O	['N']	[41]
42	,	O	['N']	[42]
43	but	O	['N']	[43]
44	one	O	['N']	[44]
45	twin	O	['N']	[45]
46	died	O	['N']	[46]
47	from	O	['N']	[47]
48	the	O	['N']	[48]
49	consequences	O	['N']	[49]
50	of	O	['N']	[50]
51	hypoxemia	B-Adverse_Effect	['N']	[51]
52	.	O	['N']	[52]
#906
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	fatal	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	toxic	B	['N']	[6]
7	epidermal	I	['N']	[7]
8	necrolysis	I-Adverse_Effect	['N']	[8]
9	(	O	['N']	[9]
10	TEN	O	['N']	[10]
11	)	O	['N']	[11]
12	resulting	O	['N']	[12]
13	from	O	['N']	[13]
14	a	O	['N']	[14]
15	high	O	['N']	[15]
16	dose	O	['N']	[16]
17	of	O	['N']	[17]
18	cytosine	O	['N']	[18]
19	arabinoside	O	['N']	[19]
20	(	O	['N']	[20]
21	ARA	B	['N']	[21]
22	-	I	['N']	[22]
23	C	I-Drug	['Causes']	[8]
24	)	O	['N']	[24]
25	.	O	['N']	[25]
#907
0	A	O	['N']	[0]
1	variety	O	['N']	[1]
2	of	O	['N']	[2]
3	movement	B	['N']	[3]
4	disorders	I-Adverse_Effect	['N']	[4]
5	are	O	['N']	[5]
6	known	O	['N']	[6]
7	to	O	['N']	[7]
8	occur	O	['N']	[8]
9	in	O	['N']	[9]
10	association	O	['N']	[10]
11	with	O	['N']	[11]
12	carbamazepine	O	['N']	[12]
13	(	O	['N']	[13]
14	CBZ	B-Drug	['Causes']	[4]
15	)	O	['N']	[15]
16	therapy	O	['N']	[16]
17	in	O	['N']	[17]
18	adults	O	['N']	[18]
19	and	O	['N']	[19]
20	children	O	['N']	[20]
21	,	O	['N']	[21]
22	but	O	['N']	[22]
23	development	O	['N']	[23]
24	of	O	['N']	[24]
25	tics	O	['N']	[25]
26	has	O	['N']	[26]
27	been	O	['N']	[27]
28	described	O	['N']	[28]
29	infrequently	O	['N']	[29]
30	and	O	['N']	[30]
31	only	O	['N']	[31]
32	in	O	['N']	[32]
33	patients	O	['N']	[33]
34	with	O	['N']	[34]
35	underlying	O	['N']	[35]
36	Tourette	O	['N']	[36]
37	's	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	or	O	['N']	[39]
40	other	O	['N']	[40]
41	movement	O	['N']	[41]
42	disorders	O	['N']	[42]
43	.	O	['N']	[43]
#908
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	report	O	['N']	[3]
4	two	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	pseudoporphyria	B-Adverse_Effect	['N']	[7]
8	caused	O	['N']	[8]
9	by	O	['N']	[9]
10	naproxen	B-Drug	['Causes']	[7]
11	and	O	['N']	[11]
12	oxaprozin	O	['N']	[12]
13	.	O	['N']	[13]
#909
0	A	O	['N']	[0]
1	44-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	is	O	['N']	[5]
6	described	O	['N']	[6]
7	in	O	['N']	[7]
8	whom	O	['N']	[8]
9	amiodarone	O	['N']	[9]
10	,	O	['N']	[10]
11	disopyramide	B-Drug	['Causes']	[23]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	quinidine	O	['N']	[14]
15	,	O	['N']	[15]
16	administered	O	['N']	[16]
17	alone	O	['N']	[17]
18	separately	O	['N']	[18]
19	,	O	['N']	[19]
20	induced	O	['N']	[20]
21	atypical	B	['N']	[21]
22	ventricular	I	['N']	[22]
23	tachycardia	I-Adverse_Effect	['N']	[23]
24	(	O	['N']	[24]
25	AVT	O	['N']	[25]
26	,	O	['N']	[26]
27	torsade	O	['N']	[27]
28	de	O	['N']	[28]
29	pointes	O	['N']	[29]
30	)	O	['N']	[30]
31	.	O	['N']	[31]
#910
0	Ticlopidine	B-Drug	['Causes']	[6]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	aplastic	O	['N']	[3]
4	anemia	O	['N']	[4]
5	(	O	['N']	[5]
6	TIAA	B-Adverse_Effect	['N']	[6]
7	)	O	['N']	[7]
8	is	O	['N']	[8]
9	considered	O	['N']	[9]
10	very	O	['N']	[10]
11	uncommon	O	['N']	[11]
12	.	O	['N']	[12]
#911
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	O	['N']	[19]
20	developed	O	['N']	[20]
21	confusion	O	['N']	[21]
22	,	O	['N']	[22]
23	agitation	O	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	B-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	tremors	O	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	O	['N']	[29]
30	jerks	O	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	O	['N']	[32]
33	gait	O	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	B-Drug	['Causes']	[25]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#912
0	Acute	O	['N']	[0]
1	aluminum	B	['N']	[1]
2	toxicity	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	continuous	O	['N']	[4]
5	intravesical	O	['N']	[5]
6	alum	O	['N']	[6]
7	irrigation	O	['N']	[7]
8	for	O	['N']	[8]
9	hemorrhagic	O	['N']	[9]
10	cystitis	O	['N']	[10]
11	.	O	['N']	[11]
#913
0	Rifampin	B-Drug	['Causes']	[26]
1	(	O	['N']	[1]
2	RFP	O	['N']	[2]
3	)	O	['N']	[3]
4	increases	O	['N']	[4]
5	hepatic	O	['N']	[5]
6	microsomal	O	['N']	[6]
7	enzyme	O	['N']	[7]
8	activity	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	there	O	['N']	[11]
12	are	O	['N']	[12]
13	case	O	['N']	[13]
14	reports	O	['N']	[14]
15	of	O	['N']	[15]
16	RFP	O	['N']	[16]
17	-	O	['N']	[17]
18	induced	O	['N']	[18]
19	hypothyroidism	O	['N']	[19]
20	,	O	['N']	[20]
21	all	O	['N']	[21]
22	associated	O	['N']	[22]
23	with	O	['N']	[23]
24	Hashimoto	B	['N']	[24]
25	's	I	['N']	[25]
26	thyroiditis	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#914
0	The	O	['N']	[0]
1	clinical	O	['N']	[1]
2	picture	O	['N']	[2]
3	was	O	['N']	[3]
4	identical	O	['N']	[4]
5	to	O	['N']	[5]
6	that	O	['N']	[6]
7	of	O	['N']	[7]
8	chloroquine	B-Drug	['Causes']	[11]
9	and	O	['N']	[9]
10	hydroxychloroquine	O	['N']	[10]
11	maculopathy	B-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#915
0	Bilateral	B	['N']	[0]
1	acoustic	I	['N']	[1]
2	(	I	['N']	[2]
3	VIII	I	['N']	[3]
4	)	I	['N']	[4]
5	nerve	I	['N']	[5]
6	palsy	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	this	O	['N']	[8]
9	patient	O	['N']	[9]
10	was	O	['N']	[10]
11	most	O	['N']	[11]
12	likely	O	['N']	[12]
13	a	O	['N']	[13]
14	manifestation	O	['N']	[14]
15	of	O	['N']	[15]
16	vincristine	B-Drug	['Causes']	[6]
17	neurotoxicity	O	['N']	[17]
18	.	O	['N']	[18]
#916
0	Barbiturate	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	submassive	B	['N']	[3]
4	hepatic	I	['N']	[4]
5	necrosis	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#917
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	case	O	['N']	[2]
3	senna	B-Drug	['Causes']	[22]
4	was	O	['N']	[4]
5	likely	O	['N']	[5]
6	the	O	['N']	[6]
7	cause	O	['N']	[7]
8	of	O	['N']	[8]
9	a	O	['N']	[9]
10	subacute	O	['N']	[10]
11	cholestatic	O	['N']	[11]
12	hepatitis	O	['N']	[12]
13	exemplifying	O	['N']	[13]
14	again	O	['N']	[14]
15	the	O	['N']	[15]
16	potential	O	['N']	[16]
17	role	O	['N']	[17]
18	of	O	['N']	[18]
19	herbal	O	['N']	[19]
20	related	O	['N']	[20]
21	liver	B	['N']	[21]
22	injury	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#918
0	In	O	['N']	[0]
1	addition	O	['N']	[1]
2	,	O	['N']	[2]
3	loading	O	['N']	[3]
4	with	O	['N']	[4]
5	one	O	['N']	[5]
6	low	O	['N']	[6]
7	oral	O	['N']	[7]
8	dose	O	['N']	[8]
9	of	O	['N']	[9]
10	serine	B-Drug	['Causes']	[13]
11	produced	O	['N']	[11]
12	psychotic	B	['N']	[12]
13	symptoms	I-Adverse_Effect	['N']	[13]
14	5	O	['N']	[14]
15	h	O	['N']	[15]
16	later	O	['N']	[16]
17	which	O	['N']	[17]
18	lasted	O	['N']	[18]
19	3	O	['N']	[19]
20	-	O	['N']	[20]
21	6	O	['N']	[21]
22	h.	O	['N']	[22]
#919
0	To	O	['N']	[0]
1	treat	O	['N']	[1]
2	hepatitis	O	['N']	[2]
3	B	O	['N']	[3]
4	,	O	['N']	[4]
5	interferon	B	['N']	[5]
6	alpha	I-Drug	['Causes']	[13]
7	was	O	['N']	[7]
8	administered	O	['N']	[8]
9	until	O	['N']	[9]
10	the	O	['N']	[10]
11	proximal	O	['N']	[11]
12	muscle	B	['N']	[12]
13	weakness	I-Adverse_Effect	['N']	[13]
14	developed	O	['N']	[14]
15	.	O	['N']	[15]
#920
0	Tumor	B	['N']	[0]
1	-	I	['N']	[1]
2	volume	I	['N']	[2]
3	increase	I-Adverse_Effect	['N']	[3]
4	at	O	['N']	[4]
5	beginning	O	['N']	[5]
6	of	O	['N']	[6]
7	primary	O	['N']	[7]
8	treatment	O	['N']	[8]
9	with	O	['N']	[9]
10	topical	O	['N']	[10]
11	interferon	B	['N']	[11]
12	alpha	I	['N']	[12]
13	2-beta	I-Drug	['Causes']	[3]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	case	O	['N']	[16]
17	of	O	['N']	[17]
18	conjunctiva	O	['N']	[18]
19	-	O	['N']	[19]
20	cornea	O	['N']	[20]
21	intraepithelial	O	['N']	[21]
22	neoplasia	O	['N']	[22]
23	.	O	['N']	[23]
#921
0	Anaphylaxis	B-Adverse_Effect	['N']	[0]
1	to	O	['N']	[1]
2	cisplatin	B-Drug	['Causes']	[0]
3	is	O	['N']	[3]
4	an	O	['N']	[4]
5	infrequent	O	['N']	[5]
6	life	O	['N']	[6]
7	-	O	['N']	[7]
8	threatening	O	['N']	[8]
9	complication	O	['N']	[9]
10	which	O	['N']	[10]
11	may	O	['N']	[11]
12	occur	O	['N']	[12]
13	even	O	['N']	[13]
14	in	O	['N']	[14]
15	patients	O	['N']	[15]
16	who	O	['N']	[16]
17	have	O	['N']	[17]
18	received	O	['N']	[18]
19	prior	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	cisplatin	O	['N']	[22]
23	.	O	['N']	[23]
#922
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Topiramate	B-Drug	['Causes']	[31]
3	may	O	['N']	[3]
4	be	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	ciliochoroidal	O	['N']	[7]
8	effusion	O	['N']	[8]
9	with	O	['N']	[9]
10	forward	O	['N']	[10]
11	displacement	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	lens	O	['N']	[14]
15	-	O	['N']	[15]
16	iris	O	['N']	[16]
17	diaphragm	O	['N']	[17]
18	and	O	['N']	[18]
19	anterior	O	['N']	[19]
20	chamber	O	['N']	[20]
21	shallowing	O	['N']	[21]
22	,	O	['N']	[22]
23	resulting	O	['N']	[23]
24	in	O	['N']	[24]
25	acute	O	['N']	[25]
26	myopia	O	['N']	[26]
27	and	O	['N']	[27]
28	angle	B	['N']	[28]
29	-	I	['N']	[29]
30	closure	I	['N']	[30]
31	glaucoma	I-Adverse_Effect	['N']	[31]
32	.	O	['N']	[32]
#923
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	are	O	['N']	[2]
3	described	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	sensory	O	['N']	[6]
7	neuropathy	O	['N']	[7]
8	after	O	['N']	[8]
9	the	O	['N']	[9]
10	ingestion	O	['N']	[10]
11	of	O	['N']	[11]
12	30.6	O	['N']	[12]
13	and	O	['N']	[13]
14	114	B	['N']	[14]
15	g	I-Dose	['N']	[15]
16	metronidazole	B-Drug	['Dosage']	[15]
17	respectively	O	['N']	[17]
18	.	O	['N']	[18]
#924
0	Early	O	['N']	[0]
1	recognition	O	['N']	[1]
2	of	O	['N']	[2]
3	hereditary	O	['N']	[3]
4	motor	O	['N']	[4]
5	and	O	['N']	[5]
6	sensory	O	['N']	[6]
7	neuropathy	O	['N']	[7]
8	type	O	['N']	[8]
9	1	O	['N']	[9]
10	can	O	['N']	[10]
11	avoid	O	['N']	[11]
12	life	B	['N']	[12]
13	-	I	['N']	[13]
14	threatening	I	['N']	[14]
15	vincristine	B-Drug	['Causes']	[16]
16	neurotoxicity	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#925
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	severe	O	['N']	[7]
8	corticosteroid	B-Drug	['Causes']	[11]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	glaucoma	B-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	intravitreal	O	['N']	[13]
14	injection	O	['N']	[14]
15	of	O	['N']	[15]
16	triamcinolone	O	['N']	[16]
17	acetate	O	['N']	[17]
18	in	O	['N']	[18]
19	a	O	['N']	[19]
20	34-year	O	['N']	[20]
21	-	O	['N']	[21]
22	old	O	['N']	[22]
23	man	O	['N']	[23]
24	without	O	['N']	[24]
25	a	O	['N']	[25]
26	history	O	['N']	[26]
27	of	O	['N']	[27]
28	glaucoma	O	['N']	[28]
29	.	O	['N']	[29]
#926
0	Ampicillin	B-Drug	['Causes']	[8]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	interstitial	O	['N']	[3]
4	nephritis	O	['N']	[4]
5	with	O	['N']	[5]
6	generalised	B	['N']	[6]
7	exfoliative	I	['N']	[7]
8	dermatitis	I-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#927
0	This	O	['N']	[0]
1	article	O	['N']	[1]
2	presents	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	an	O	['N']	[6]
7	atypical	B	['N']	[7]
8	localized	I	['N']	[8]
9	cutaneous	I	['N']	[9]
10	eruption	I-Adverse_Effect	['N']	[10]
11	with	O	['N']	[11]
12	an	O	['N']	[12]
13	unusual	O	['N']	[13]
14	course	O	['N']	[14]
15	and	O	['N']	[15]
16	protracted	O	['N']	[16]
17	resolution	O	['N']	[17]
18	time	O	['N']	[18]
19	associated	O	['N']	[19]
20	with	O	['N']	[20]
21	sorafenib	B-Drug	['Causes']	[10]
22	therapy	O	['N']	[22]
23	.	O	['N']	[23]
#928
0	Anaphylactoid	O	['N']	[0]
1	shock	O	['N']	[1]
2	,	O	['N']	[2]
3	disseminated	O	['N']	[3]
4	intravascular	O	['N']	[4]
5	coagulation	O	['N']	[5]
6	,	O	['N']	[6]
7	and	O	['N']	[7]
8	anuric	B	['N']	[8]
9	renal	I	['N']	[9]
10	failure	I-Adverse_Effect	['N']	[10]
11	requiring	O	['N']	[11]
12	dialysis	O	['N']	[12]
13	occurred	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	patient	O	['N']	[16]
17	receiving	O	['N']	[17]
18	zomepirac	B-Drug	['Causes']	[10]
19	sodium	O	['N']	[19]
20	for	O	['N']	[20]
21	toothache	O	['N']	[21]
22	.	O	['N']	[22]
#929
0	She	O	['N']	[0]
1	had	O	['N']	[1]
2	been	O	['N']	[2]
3	on	O	['N']	[3]
4	Copaxone	B-Drug	['Dosage']	[8]
5	20	B	['N']	[5]
6	mg	I	['N']	[6]
7	/	I	['N']	[7]
8	day	I-Dose	['N']	[8]
9	treatment	O	['N']	[9]
10	for	O	['N']	[10]
11	2	O	['N']	[11]
12	years	O	['N']	[12]
13	when	O	['N']	[13]
14	she	O	['N']	[14]
15	first	O	['N']	[15]
16	exhibited	O	['N']	[16]
17	gastrointestinal	O	['N']	[17]
18	symptoms	O	['N']	[18]
19	.	O	['N']	[19]
#930
0	Mental	B	['N']	[0]
1	nerve	I	['N']	[1]
2	neuropathy	I-Adverse_Effect	['N']	[2]
3	as	O	['N']	[3]
4	a	O	['N']	[4]
5	result	O	['N']	[5]
6	of	O	['N']	[6]
7	hepatitis	B	['N']	[7]
8	B	I	['N']	[8]
9	vaccination	I-Drug	['Causes']	[2]
10	.	O	['N']	[10]
#931
0	Two	O	['N']	[0]
1	other	O	['N']	[1]
2	patients	O	['N']	[2]
3	who	O	['N']	[3]
4	did	O	['N']	[4]
5	not	O	['N']	[5]
6	receive	O	['N']	[6]
7	prochlorperazine	O	['N']	[7]
8	,	O	['N']	[8]
9	developed	O	['N']	[9]
10	retinal	O	['N']	[10]
11	problems	O	['N']	[11]
12	which	O	['N']	[12]
13	later	O	['N']	[13]
14	improved	O	['N']	[14]
15	,	O	['N']	[15]
16	one	O	['N']	[16]
17	after	O	['N']	[17]
18	only	O	['N']	[18]
19	15	B	['N']	[19]
20	g	I-Dose	['N']	[20]
21	of	O	['N']	[21]
22	desferrioxamine	B-Drug	['Dosage']	[20]
23	.	O	['N']	[23]
#932
0	Magnesium	B-Drug	['Causes']	[1]
1	toxicosis	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	two	O	['N']	[3]
4	horses	O	['N']	[4]
5	.	O	['N']	[5]
#933
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	(	O	['N']	[5]
6	to	O	['N']	[6]
7	our	O	['N']	[7]
8	knowledge	O	['N']	[8]
9	)	O	['N']	[9]
10	of	O	['N']	[10]
11	a	O	['N']	[11]
12	potentially	O	['N']	[12]
13	serious	O	['N']	[13]
14	drug	B	['N']	[14]
15	-	I	['N']	[15]
16	drug	I	['N']	[16]
17	interaction	I-Adverse_Effect	['N']	[17]
18	between	O	['N']	[18]
19	zafirlukast	B-Drug	['Causes']	[17]
20	and	O	['N']	[20]
21	theophylline	O	['N']	[21]
22	.	O	['N']	[22]
#934
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	is	O	['N']	[2]
3	reported	O	['N']	[3]
4	in	O	['N']	[4]
5	which	O	['N']	[5]
6	severe	O	['N']	[6]
7	hypocalcemia	O	['N']	[7]
8	,	O	['N']	[8]
9	with	O	['N']	[9]
10	a	O	['N']	[10]
11	low	B	['N']	[11]
12	plasma	I	['N']	[12]
13	parathyroid	I	['N']	[13]
14	hormone	I-Adverse_Effect	['N']	[14]
15	(	O	['N']	[15]
16	PTH	O	['N']	[16]
17	)	O	['N']	[17]
18	concentration	O	['N']	[18]
19	,	O	['N']	[19]
20	resulted	O	['N']	[20]
21	from	O	['N']	[21]
22	the	O	['N']	[22]
23	therapeutic	O	['N']	[23]
24	use	O	['N']	[24]
25	of	O	['N']	[25]
26	magnesium	B	['N']	[26]
27	sulfate	I-Drug	['Causes']	[14]
28	for	O	['N']	[28]
29	toxemia	O	['N']	[29]
30	of	O	['N']	[30]
31	pregnancy	O	['N']	[31]
32	.	O	['N']	[32]
#935
0	Only	O	['N']	[0]
1	after	O	['N']	[1]
2	three	O	['N']	[2]
3	subsequent	O	['N']	[3]
4	episodes	O	['N']	[4]
5	of	O	['N']	[5]
6	severe	O	['N']	[6]
7	,	O	['N']	[7]
8	symptomatic	O	['N']	[8]
9	thrombocytopenia	B-Adverse_Effect	['N']	[9]
10	over	O	['N']	[10]
11	the	O	['N']	[11]
12	next	O	['N']	[12]
13	four	O	['N']	[13]
14	weeks	O	['N']	[14]
15	did	O	['N']	[15]
16	he	O	['N']	[16]
17	say	O	['N']	[17]
18	,	O	['N']	[18]
19	upon	O	['N']	[19]
20	repeat	O	['N']	[20]
21	questioning	O	['N']	[21]
22	,	O	['N']	[22]
23	that	O	['N']	[23]
24	he	O	['N']	[24]
25	had	O	['N']	[25]
26	continued	O	['N']	[26]
27	to	O	['N']	[27]
28	take	O	['N']	[28]
29	quinine	B-Drug	['Causes']	[9]
30	for	O	['N']	[30]
31	night	O	['N']	[31]
32	leg	O	['N']	[32]
33	cramps	O	['N']	[33]
34	.	O	['N']	[34]
#936
0	She	O	['N']	[0]
1	received	O	['N']	[1]
2	an	O	['N']	[2]
3	accidental	O	['N']	[3]
4	450-mg	O	['N']	[4]
5	bolus	O	['N']	[5]
6	injection	O	['N']	[6]
7	of	O	['N']	[7]
8	morphine	B-Drug	['Causes']	[15]
9	intrathecally	O	['N']	[9]
10	and	O	['N']	[10]
11	developed	O	['N']	[11]
12	hypertension	O	['N']	[12]
13	,	O	['N']	[13]
14	status	B	['N']	[14]
15	epilepticus	I-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	intracerebral	O	['N']	[17]
18	hemorrhage	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	respiratory	O	['N']	[21]
22	failure	O	['N']	[22]
23	.	O	['N']	[23]
#937
0	Common	O	['N']	[0]
1	adverse	O	['N']	[1]
2	events	O	['N']	[2]
3	(	O	['N']	[3]
4	frequency	O	['N']	[4]
5	10	O	['N']	[5]
6	%	O	['N']	[6]
7	)	O	['N']	[7]
8	of	O	['N']	[8]
9	lacosamide	B-Drug	['Causes']	[28]
10	doses	O	['N']	[10]
11	up	O	['N']	[11]
12	to	O	['N']	[12]
13	600	O	['N']	[13]
14	mg	O	['N']	[14]
15	/	O	['N']	[15]
16	day	O	['N']	[16]
17	include	O	['N']	[17]
18	nonspecific	O	['N']	[18]
19	central	O	['N']	[19]
20	nervous	O	['N']	[20]
21	system	O	['N']	[21]
22	effects	O	['N']	[22]
23	(	O	['N']	[23]
24	e.g.	O	['N']	[24]
25	,	O	['N']	[25]
26	dizziness	O	['N']	[26]
27	,	O	['N']	[27]
28	ataxia	B-Adverse_Effect	['N']	[28]
29	,	O	['N']	[29]
30	diplopia	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	somnolence	O	['N']	[33]
34	)	O	['N']	[34]
35	.	O	['N']	[35]
#938
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	and	O	['N']	[2]
3	other	O	['N']	[3]
4	published	O	['N']	[4]
5	evidence	O	['N']	[5]
6	should	O	['N']	[6]
7	alert	O	['N']	[7]
8	physicians	O	['N']	[8]
9	to	O	['N']	[9]
10	the	O	['N']	[10]
11	possibility	O	['N']	[11]
12	of	O	['N']	[12]
13	fatal	O	['N']	[13]
14	erlotinib	B-Drug	['Causes']	[17]
15	-	O	['N']	[15]
16	induced	O	['N']	[16]
17	ILD	B-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#939
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	penile	B	['N']	[5]
6	fibrosis	I-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	intracavernous	O	['N']	[8]
9	self	O	['N']	[9]
10	-	O	['N']	[10]
11	injection	O	['N']	[11]
12	of	O	['N']	[12]
13	a	O	['N']	[13]
14	combination	O	['N']	[14]
15	of	O	['N']	[15]
16	phentolamine	B-Drug	['Causes']	[6]
17	and	O	['N']	[17]
18	papaverine	O	['N']	[18]
19	.	O	['N']	[19]
#940
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	history	O	['N']	[2]
3	of	O	['N']	[3]
4	a	O	['N']	[4]
5	15-year	O	['N']	[5]
6	-	O	['N']	[6]
7	old	O	['N']	[7]
8	boy	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	incapacitating	O	['N']	[11]
12	tardive	B	['N']	[12]
13	dyskinesia	I-Adverse_Effect	['N']	[13]
14	that	O	['N']	[14]
15	resolved	O	['N']	[15]
16	during	O	['N']	[16]
17	treatment	O	['N']	[17]
18	with	O	['N']	[18]
19	deanol	B-Drug	['Causes']	[13]
20	is	O	['N']	[20]
21	presented	O	['N']	[21]
22	.	O	['N']	[22]
#941
0	Three	O	['N']	[0]
1	months	O	['N']	[1]
2	following	O	['N']	[2]
3	splenectomy	O	['N']	[3]
4	,	O	['N']	[4]
5	multiple	B	['N']	[5]
6	abscesses	I-Adverse_Effect	['N']	[6]
7	occurred	O	['N']	[7]
8	in	O	['N']	[8]
9	the	O	['N']	[9]
10	muscles	O	['N']	[10]
11	of	O	['N']	[11]
12	both	O	['N']	[12]
13	thighs	O	['N']	[13]
14	while	O	['N']	[14]
15	the	O	['N']	[15]
16	patient	O	['N']	[16]
17	was	O	['N']	[17]
18	receiving	O	['N']	[18]
19	the	O	['N']	[19]
20	third	O	['N']	[20]
21	course	O	['N']	[21]
22	of	O	['N']	[22]
23	the	O	['N']	[23]
24	CHOP	B-Drug	['Causes']	[6]
25	regimen	O	['N']	[25]
26	.	O	['N']	[26]
#942
0	Ziprasidone	B-Drug	['Causes']	[23]
1	is	O	['N']	[1]
2	an	O	['N']	[2]
3	atypical	O	['N']	[3]
4	antipsychotic	O	['N']	[4]
5	drug	O	['N']	[5]
6	that	O	['N']	[6]
7	is	O	['N']	[7]
8	believed	O	['N']	[8]
9	to	O	['N']	[9]
10	have	O	['N']	[10]
11	a	O	['N']	[11]
12	low	O	['N']	[12]
13	propensity	O	['N']	[13]
14	for	O	['N']	[14]
15	inducing	O	['N']	[15]
16	extrapyramidal	O	['N']	[16]
17	symptoms	O	['N']	[17]
18	,	O	['N']	[18]
19	including	O	['N']	[19]
20	tardive	O	['N']	[20]
21	dyskinesia	O	['N']	[21]
22	(	O	['N']	[22]
23	TD	B-Adverse_Effect	['N']	[23]
24	)	O	['N']	[24]
25	.	O	['N']	[25]
#943
0	We	O	['N']	[0]
1	stress	O	['N']	[1]
2	the	O	['N']	[2]
3	potential	O	['N']	[3]
4	of	O	['N']	[4]
5	benzarone	B-Drug	['Causes']	[8]
6	to	O	['N']	[6]
7	cause	O	['N']	[7]
8	hepatotoxicity	B-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	which	O	['N']	[10]
11	usually	O	['N']	[11]
12	resembles	O	['N']	[12]
13	severe	O	['N']	[13]
14	chronic	O	['N']	[14]
15	active	O	['N']	[15]
16	hepatitis	O	['N']	[16]
17	.	O	['N']	[17]
#944
0	Since	O	['N']	[0]
1	the	O	['N']	[1]
2	bronchospasm	B-Adverse_Effect	['N']	[2]
3	was	O	['N']	[3]
4	relieved	O	['N']	[4]
5	with	O	['N']	[5]
6	discontinuation	O	['N']	[6]
7	of	O	['N']	[7]
8	propranolol	B-Drug	['Causes']	[2]
9	and	O	['N']	[9]
10	supportive	O	['N']	[10]
11	bronchodilator	O	['N']	[11]
12	therapy	O	['N']	[12]
13	,	O	['N']	[13]
14	the	O	['N']	[14]
15	bronchospasm	O	['N']	[15]
16	was	O	['N']	[16]
17	believed	O	['N']	[17]
18	to	O	['N']	[18]
19	be	O	['N']	[19]
20	caused	O	['N']	[20]
21	by	O	['N']	[21]
22	propranolol	O	['N']	[22]
23	.	O	['N']	[23]
#945
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	3	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	severe	O	['N']	[5]
6	hepatocellular	O	['N']	[6]
7	damage	O	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	CPA	B-Drug	['Causes']	[17]
11	therapy	O	['N']	[11]
12	,	O	['N']	[12]
13	2	O	['N']	[13]
14	with	O	['N']	[14]
15	fatal	B	['N']	[15]
16	fulminant	I	['N']	[16]
17	hepatitis	I-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#946
0	Methanol	B-Drug	['Causes']	[1]
1	toxicity	I-Adverse_Effect	['N']	[1]
2	can	O	['N']	[2]
3	cause	O	['N']	[3]
4	severe	O	['N']	[4]
5	central	O	['N']	[5]
6	nervous	O	['N']	[6]
7	system	O	['N']	[7]
8	insult	O	['N']	[8]
9	in	O	['N']	[9]
10	which	O	['N']	[10]
11	a	O	['N']	[11]
12	characteristic	O	['N']	[12]
13	pattern	O	['N']	[13]
14	of	O	['N']	[14]
15	bilateral	O	['N']	[15]
16	putaminal	O	['N']	[16]
17	injury	O	['N']	[17]
18	is	O	['N']	[18]
19	noted	O	['N']	[19]
20	on	O	['N']	[20]
21	brain	O	['N']	[21]
22	imaging	O	['N']	[22]
23	studies	O	['N']	[23]
24	.	O	['N']	[24]
#947
0	According	O	['N']	[0]
1	to	O	['N']	[1]
2	the	O	['N']	[2]
3	Naranjo	O	['N']	[3]
4	adverse	O	['N']	[4]
5	drug	O	['N']	[5]
6	reaction	O	['N']	[6]
7	probability	O	['N']	[7]
8	scale	O	['N']	[8]
9	,	O	['N']	[9]
10	tigecycline	B-Drug	['Causes']	[18]
11	was	O	['N']	[11]
12	the	O	['N']	[12]
13	probable	O	['N']	[13]
14	cause	O	['N']	[14]
15	of	O	['N']	[15]
16	her	O	['N']	[16]
17	acute	B	['N']	[17]
18	pancreatitis	I-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#948
0	Flutamide	B-Drug	['Causes']	[2]
1	withdrawal	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	is	O	['N']	[3]
4	characterized	O	['N']	[4]
5	by	O	['N']	[5]
6	a	O	['N']	[6]
7	decrease	O	['N']	[7]
8	in	O	['N']	[8]
9	prostate	O	['N']	[9]
10	-	O	['N']	[10]
11	specific	O	['N']	[11]
12	antigen	O	['N']	[12]
13	(	O	['N']	[13]
14	PSA	O	['N']	[14]
15	)	O	['N']	[15]
16	after	O	['N']	[16]
17	flutamide	O	['N']	[17]
18	withdrawal	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	subset	O	['N']	[21]
22	of	O	['N']	[22]
23	patients	O	['N']	[23]
24	with	O	['N']	[24]
25	progressing	O	['N']	[25]
26	metastatic	O	['N']	[26]
27	carcinoma	O	['N']	[27]
28	of	O	['N']	[28]
29	the	O	['N']	[29]
30	prostate	O	['N']	[30]
31	.	O	['N']	[31]
#949
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	linezolid	B-Drug	['Causes']	[20]
4	-	O	['N']	[4]
5	associated	O	['N']	[5]
6	acute	O	['N']	[6]
7	interstitial	O	['N']	[7]
8	nephritis	O	['N']	[8]
9	within	O	['N']	[9]
10	the	O	['N']	[10]
11	context	O	['N']	[11]
12	of	O	['N']	[12]
13	a	O	['N']	[13]
14	drug	B	['N']	[14]
15	rash	I	['N']	[15]
16	with	I	['N']	[16]
17	eosinophilia	I	['N']	[17]
18	and	I	['N']	[18]
19	systemic	I	['N']	[19]
20	symptoms	I-Adverse_Effect	['N']	[20]
21	(	O	['N']	[21]
22	DRESS	O	['N']	[22]
23	)	O	['N']	[23]
24	syndrome	O	['N']	[24]
25	in	O	['N']	[25]
26	a	O	['N']	[26]
27	patient	O	['N']	[27]
28	treated	O	['N']	[28]
29	with	O	['N']	[29]
30	linezolid	O	['N']	[30]
31	raises	O	['N']	[31]
32	concerns	O	['N']	[32]
33	about	O	['N']	[33]
34	the	O	['N']	[34]
35	presumed	O	['N']	[35]
36	renal	O	['N']	[36]
37	safety	O	['N']	[37]
38	of	O	['N']	[38]
39	this	O	['N']	[39]
40	drug	O	['N']	[40]
41	.	O	['N']	[41]
#950
0	The	O	['N']	[0]
1	biochemistry	O	['N']	[1]
2	of	O	['N']	[2]
3	paracetamol	B-Drug	['Causes']	[4]
4	hepatotoxicity	B-Adverse_Effect	['N']	[4]
5	is	O	['N']	[5]
6	outlined	O	['N']	[6]
7	and	O	['N']	[7]
8	the	O	['N']	[8]
9	increased	O	['N']	[9]
10	susceptibility	O	['N']	[10]
11	of	O	['N']	[11]
12	alcoholic	O	['N']	[12]
13	patients	O	['N']	[13]
14	to	O	['N']	[14]
15	the	O	['N']	[15]
16	hepatotoxic	O	['N']	[16]
17	effects	O	['N']	[17]
18	of	O	['N']	[18]
19	paracetamol	O	['N']	[19]
20	is	O	['N']	[20]
21	remarked	O	['N']	[21]
22	upon	O	['N']	[22]
23	.	O	['N']	[23]
#951
0	Although	O	['N']	[0]
1	other	O	['N']	[1]
2	nitrites	O	['N']	[2]
3	induce	O	['N']	[3]
4	methemoglobinemia	B-Adverse_Effect	['N']	[4]
5	,	O	['N']	[5]
6	exposure	O	['N']	[6]
7	to	O	['N']	[7]
8	methyl	B	['N']	[8]
9	nitrite	I-Drug	['Causes']	[4]
10	during	O	['N']	[10]
11	phenylpropanolamine	O	['N']	[11]
12	production	O	['N']	[12]
13	appears	O	['N']	[13]
14	to	O	['N']	[14]
15	be	O	['N']	[15]
16	a	O	['N']	[16]
17	new	O	['N']	[17]
18	cause	O	['N']	[18]
19	of	O	['N']	[19]
20	occupational	O	['N']	[20]
21	methemoglobinemia	O	['N']	[21]
22	.	O	['N']	[22]
#952
0	Carbamazepine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	related	O	['N']	[2]
3	hyponatremia	B-Adverse_Effect	['N']	[3]
4	following	O	['N']	[4]
5	cardiopulmonary	O	['N']	[5]
6	bypass	O	['N']	[6]
7	.	O	['N']	[7]
#953
0	Stroke	O	['N']	[0]
1	-	O	['N']	[1]
2	like	O	['N']	[2]
3	syndrome	O	['N']	[3]
4	after	O	['N']	[4]
5	gold	B	['N']	[5]
6	sodium	I	['N']	[6]
7	thiomalate	I-Drug	['Causes']	[10]
8	induced	O	['N']	[8]
9	vasomotor	B	['N']	[9]
10	reaction	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#954
0	Hydroxyurea	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	acute	B	['N']	[3]
4	interstitial	I	['N']	[4]
5	pneumonitis	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	essential	O	['N']	[10]
11	thrombocythemia	O	['N']	[11]
12	.	O	['N']	[12]
#955
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	,	O	['N']	[2]
3	in	O	['N']	[3]
4	whom	O	['N']	[4]
5	tumour	O	['N']	[5]
6	overkill	O	['N']	[6]
7	by	O	['N']	[7]
8	cytotoxic	O	['N']	[8]
9	treatment	O	['N']	[9]
10	,	O	['N']	[10]
11	including	O	['N']	[11]
12	high	O	['N']	[12]
13	dose	O	['N']	[13]
14	methotrexate	B-Drug	['Causes']	[37]
15	with	O	['N']	[15]
16	folinic	O	['N']	[16]
17	acid	O	['N']	[17]
18	rescue	O	['N']	[18]
19	,	O	['N']	[19]
20	resulted	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	'	O	['N']	[23]
24	phosphate	O	['N']	[24]
25	shower	O	['N']	[25]
26	syndrome	O	['N']	[26]
27	'	O	['N']	[27]
28	(	O	['N']	[28]
29	hyper	O	['N']	[29]
30	-	O	['N']	[30]
31	uricaemia	O	['N']	[31]
32	,	O	['N']	[32]
33	hyperkalaemia	O	['N']	[33]
34	and	O	['N']	[34]
35	hyperphosphataemia	O	['N']	[35]
36	with	O	['N']	[36]
37	hypocalcaemia	B-Adverse_Effect	['N']	[37]
38	and	O	['N']	[38]
39	tetany	O	['N']	[39]
40	,	O	['N']	[40]
41	with	O	['N']	[41]
42	metabolic	O	['N']	[42]
43	acidosis	O	['N']	[43]
44	and	O	['N']	[44]
45	acute	O	['N']	[45]
46	renal	O	['N']	[46]
47	impairment	O	['N']	[47]
48	)	O	['N']	[48]
49	are	O	['N']	[49]
50	described	O	['N']	[50]
51	.	O	['N']	[51]
#956
0	Olanzapine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hyperglycaemic	B	['N']	[3]
4	coma	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	neuroleptic	O	['N']	[6]
7	malignant	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	:	O	['N']	[9]
10	case	O	['N']	[10]
11	report	O	['N']	[11]
12	and	O	['N']	[12]
13	review	O	['N']	[13]
14	of	O	['N']	[14]
15	literature	O	['N']	[15]
16	.	O	['N']	[16]
#957
0	Administration	O	['N']	[0]
1	of	O	['N']	[1]
2	steroid	O	['N']	[2]
3	and	O	['N']	[3]
4	decreasing	O	['N']	[4]
5	the	O	['N']	[5]
6	dose	O	['N']	[6]
7	of	O	['N']	[7]
8	PTU	B-Drug	['Causes']	[16]
9	produced	O	['N']	[9]
10	a	O	['N']	[10]
11	good	O	['N']	[11]
12	clinical	O	['N']	[12]
13	response	O	['N']	[13]
14	and	O	['N']	[14]
15	the	O	['N']	[15]
16	ANCA	B-Adverse_Effect	['N']	[16]
17	disappeared	O	['N']	[17]
18	.	O	['N']	[18]
#958
0	Methotrexate	O	['N']	[0]
1	(	O	['N']	[1]
2	MTX	B-Drug	['Causes']	[32]
3	)	O	['N']	[3]
4	is	O	['N']	[4]
5	a	O	['N']	[5]
6	commonly	O	['N']	[6]
7	used	O	['N']	[7]
8	second	O	['N']	[8]
9	line	O	['N']	[9]
10	agent	O	['N']	[10]
11	for	O	['N']	[11]
12	RA	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	there	O	['N']	[15]
16	have	O	['N']	[16]
17	been	O	['N']	[17]
18	several	O	['N']	[18]
19	recent	O	['N']	[19]
20	reports	O	['N']	[20]
21	of	O	['N']	[21]
22	Epstein	B	['N']	[22]
23	-	I	['N']	[23]
24	Barr	I	['N']	[24]
25	virus	I	['N']	[25]
26	(	I	['N']	[26]
27	EBV)-associated	I	['N']	[27]
28	polyclonal	I	['N']	[28]
29	B	I	['N']	[29]
30	cell	I	['N']	[30]
31	lymphoproliferative	I	['N']	[31]
32	disorder	I-Adverse_Effect	['N']	[32]
33	in	O	['N']	[33]
34	MTX	O	['N']	[34]
35	-	O	['N']	[35]
36	treated	O	['N']	[36]
37	RA	O	['N']	[37]
38	patients	O	['N']	[38]
39	.	O	['N']	[39]
#959
0	Polymyositis	B-Adverse_Effect	['N']	[0]
1	after	O	['N']	[1]
2	propylthiouracil	B-Drug	['Causes']	[0]
3	treatment	O	['N']	[3]
4	for	O	['N']	[4]
5	hyperthyroidism	O	['N']	[5]
6	.	O	['N']	[6]
#960
0	Though	O	['N']	[0]
1	hypotension	O	['N']	[1]
2	,	O	['N']	[2]
3	dry	B	['N']	[3]
4	mouth	I-Adverse_Effect	['N']	[4]
5	,	O	['N']	[5]
6	and	O	['N']	[6]
7	constipation	O	['N']	[7]
8	are	O	['N']	[8]
9	well	O	['N']	[9]
10	-	O	['N']	[10]
11	documented	O	['N']	[11]
12	possible	O	['N']	[12]
13	adverse	O	['N']	[13]
14	effects	O	['N']	[14]
15	,	O	['N']	[15]
16	the	O	['N']	[16]
17	possibility	O	['N']	[17]
18	of	O	['N']	[18]
19	clonidine	B-Drug	['Causes']	[4]
20	-	O	['N']	[20]
21	induced	O	['N']	[21]
22	bradycardia	O	['N']	[22]
23	is	O	['N']	[23]
24	less	O	['N']	[24]
25	well	O	['N']	[25]
26	recognized	O	['N']	[26]
27	and	O	['N']	[27]
28	is	O	['N']	[28]
29	rare	O	['N']	[29]
30	.	O	['N']	[30]
#961
0	INTERPRETATION	O	['N']	[0]
1	:	O	['N']	[1]
2	When	O	['N']	[2]
3	high	O	['N']	[3]
4	doses	O	['N']	[4]
5	of	O	['N']	[5]
6	fluticasone	B	['N']	[6]
7	propionate	I-Drug	['Causes']	[17]
8	are	O	['N']	[8]
9	used	O	['N']	[9]
10	,	O	['N']	[10]
11	growth	O	['N']	[11]
12	may	O	['N']	[12]
13	be	O	['N']	[13]
14	retarded	O	['N']	[14]
15	and	O	['N']	[15]
16	adrenal	B	['N']	[16]
17	suppression	I-Adverse_Effect	['N']	[17]
18	may	O	['N']	[18]
19	occur	O	['N']	[19]
20	.	O	['N']	[20]
#962
0	Physicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	risk	O	['N']	[6]
7	of	O	['N']	[7]
8	severe	O	['N']	[8]
9	AIHA	B-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	CLL	O	['N']	[11]
12	patients	O	['N']	[12]
13	with	O	['N']	[13]
14	a	O	['N']	[14]
15	history	O	['N']	[15]
16	of	O	['N']	[16]
17	AIHA	O	['N']	[17]
18	or	O	['N']	[18]
19	positivation	O	['N']	[19]
20	of	O	['N']	[20]
21	the	O	['N']	[21]
22	DAT	O	['N']	[22]
23	during	O	['N']	[23]
24	previous	O	['N']	[24]
25	fludarabine	B-Drug	['Causes']	[9]
26	administration	O	['N']	[26]
27	,	O	['N']	[27]
28	or	O	['N']	[28]
29	in	O	['N']	[29]
30	case	O	['N']	[30]
31	of	O	['N']	[31]
32	secondary	O	['N']	[32]
33	fixation	O	['N']	[33]
34	of	O	['N']	[34]
35	complement	O	['N']	[35]
36	to	O	['N']	[36]
37	the	O	['N']	[37]
38	red	O	['N']	[38]
39	cell	O	['N']	[39]
40	membrane	O	['N']	[40]
41	occurring	O	['N']	[41]
42	during	O	['N']	[42]
43	fludarabine	O	['N']	[43]
44	treatment	O	['N']	[44]
45	.	O	['N']	[45]
#963
0	Terbinafine	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	cholestatic	B	['N']	[3]
4	liver	I	['N']	[4]
5	disease	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#964
0	Hepatic	B	['N']	[0]
1	reactions	I-Adverse_Effect	['N']	[1]
2	to	O	['N']	[2]
3	cyclofenil	B-Drug	['Causes']	[1]
4	.	O	['N']	[4]
#965
0	A	O	['N']	[0]
1	variety	O	['N']	[1]
2	of	O	['N']	[2]
3	movement	O	['N']	[3]
4	disorders	O	['N']	[4]
5	are	O	['N']	[5]
6	known	O	['N']	[6]
7	to	O	['N']	[7]
8	occur	O	['N']	[8]
9	in	O	['N']	[9]
10	association	O	['N']	[10]
11	with	O	['N']	[11]
12	carbamazepine	O	['N']	[12]
13	(	O	['N']	[13]
14	CBZ	B-Drug	['Causes']	[25]
15	)	O	['N']	[15]
16	therapy	O	['N']	[16]
17	in	O	['N']	[17]
18	adults	O	['N']	[18]
19	and	O	['N']	[19]
20	children	O	['N']	[20]
21	,	O	['N']	[21]
22	but	O	['N']	[22]
23	development	O	['N']	[23]
24	of	O	['N']	[24]
25	tics	B-Adverse_Effect	['N']	[25]
26	has	O	['N']	[26]
27	been	O	['N']	[27]
28	described	O	['N']	[28]
29	infrequently	O	['N']	[29]
30	and	O	['N']	[30]
31	only	O	['N']	[31]
32	in	O	['N']	[32]
33	patients	O	['N']	[33]
34	with	O	['N']	[34]
35	underlying	O	['N']	[35]
36	Tourette	O	['N']	[36]
37	's	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	or	O	['N']	[39]
40	other	O	['N']	[40]
41	movement	O	['N']	[41]
42	disorders	O	['N']	[42]
43	.	O	['N']	[43]
#966
0	A	O	['N']	[0]
1	73	O	['N']	[1]
2	year	O	['N']	[2]
3	-	O	['N']	[3]
4	old	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	Wolff	O	['N']	[7]
8	-	O	['N']	[8]
9	Parkinson	O	['N']	[9]
10	-	O	['N']	[10]
11	White	O	['N']	[11]
12	syndrome	O	['N']	[12]
13	and	O	['N']	[13]
14	paroxysmic	O	['N']	[14]
15	supraventricular	O	['N']	[15]
16	tachycardia	O	['N']	[16]
17	developed	O	['N']	[17]
18	an	O	['N']	[18]
19	acute	B	['N']	[19]
20	reversible	I	['N']	[20]
21	encephalopathy	I-Adverse_Effect	['N']	[21]
22	within	O	['N']	[22]
23	15	O	['N']	[23]
24	days	O	['N']	[24]
25	of	O	['N']	[25]
26	initiation	O	['N']	[26]
27	of	O	['N']	[27]
28	flecainide	B-Drug	['Causes']	[21]
29	.	O	['N']	[29]
#967
0	Cimetidine	B-Drug	['Causes']	[9]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	rare	O	['N']	[3]
4	cause	O	['N']	[4]
5	of	O	['N']	[5]
6	drug	O	['N']	[6]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	fever	B-Adverse_Effect	['N']	[9]
10	.	O	['N']	[10]
#968
0	Our	O	['N']	[0]
1	series	O	['N']	[1]
2	of	O	['N']	[2]
3	3	O	['N']	[3]
4	patients	O	['N']	[4]
5	supports	O	['N']	[5]
6	a	O	['N']	[6]
7	causal	O	['N']	[7]
8	connection	O	['N']	[8]
9	between	O	['N']	[9]
10	bleomycin	B-Drug	['Causes']	[12]
11	and	O	['N']	[11]
12	scleroderma	B-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#969
0	Although	O	['N']	[0]
1	risk	O	['N']	[1]
2	factors	O	['N']	[2]
3	for	O	['N']	[3]
4	MTX	B-Drug	['Causes']	[8]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	pulmonary	B	['N']	[7]
8	toxicity	I-Adverse_Effect	['N']	[8]
9	are	O	['N']	[9]
10	poorly	O	['N']	[10]
11	understood	O	['N']	[11]
12	,	O	['N']	[12]
13	the	O	['N']	[13]
14	presence	O	['N']	[14]
15	in	O	['N']	[15]
16	3	O	['N']	[16]
17	out	O	['N']	[17]
18	of	O	['N']	[18]
19	5	O	['N']	[19]
20	of	O	['N']	[20]
21	our	O	['N']	[21]
22	patients	O	['N']	[22]
23	of	O	['N']	[23]
24	pre	O	['N']	[24]
25	-	O	['N']	[25]
26	existing	O	['N']	[26]
27	lung	O	['N']	[27]
28	disease	O	['N']	[28]
29	,	O	['N']	[29]
30	represented	O	['N']	[30]
31	by	O	['N']	[31]
32	diffuse	O	['N']	[32]
33	interstitial	O	['N']	[33]
34	changes	O	['N']	[34]
35	on	O	['N']	[35]
36	chest	O	['N']	[36]
37	X	O	['N']	[37]
38	-	O	['N']	[38]
39	ray	O	['N']	[39]
40	,	O	['N']	[40]
41	and	O	['N']	[41]
42	mild	O	['N']	[42]
43	bronchial	O	['N']	[43]
44	asthma	O	['N']	[44]
45	in	O	['N']	[45]
46	two	O	['N']	[46]
47	RA	O	['N']	[47]
48	patients	O	['N']	[48]
49	and	O	['N']	[49]
50	by	O	['N']	[50]
51	pulmonary	O	['N']	[51]
52	silicosis	O	['N']	[52]
53	in	O	['N']	[53]
54	the	O	['N']	[54]
55	patient	O	['N']	[55]
56	with	O	['N']	[56]
57	PsA	O	['N']	[57]
58	may	O	['N']	[58]
59	account	O	['N']	[59]
60	for	O	['N']	[60]
61	a	O	['N']	[61]
62	predisposition	O	['N']	[62]
63	to	O	['N']	[63]
64	the	O	['N']	[64]
65	development	O	['N']	[65]
66	of	O	['N']	[66]
67	MTX	O	['N']	[67]
68	pneumonitis	O	['N']	[68]
69	.	O	['N']	[69]
#970
0	Cyanamide	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	liver	B	['N']	[3]
4	dysfunction	I-Adverse_Effect	['N']	[4]
5	after	O	['N']	[5]
6	abstinence	O	['N']	[6]
7	in	O	['N']	[7]
8	alcoholics	O	['N']	[8]
9	:	O	['N']	[9]
10	a	O	['N']	[10]
11	long	O	['N']	[11]
12	-	O	['N']	[12]
13	term	O	['N']	[13]
14	follow	O	['N']	[14]
15	-	O	['N']	[15]
16	up	O	['N']	[16]
17	study	O	['N']	[17]
18	on	O	['N']	[18]
19	four	O	['N']	[19]
20	cases	O	['N']	[20]
21	.	O	['N']	[21]
#971
0	Ulcerative	B	['N']	[0]
1	proctitis	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	juvenile	O	['N']	[3]
4	systemic	O	['N']	[4]
5	lupus	O	['N']	[5]
6	erythematosus	O	['N']	[6]
7	after	O	['N']	[7]
8	ibuprofen	B-Drug	['Causes']	[1]
9	treatment	O	['N']	[9]
10	.	O	['N']	[10]
#972
0	During	O	['N']	[0]
1	her	O	['N']	[1]
2	third	O	['N']	[2]
3	cycle	O	['N']	[3]
4	,	O	['N']	[4]
5	she	O	['N']	[5]
6	again	O	['N']	[6]
7	received	O	['N']	[7]
8	cisplatin	B-Drug	['Causes']	[19]
9	100	O	['N']	[9]
10	mg	O	['N']	[10]
11	/	O	['N']	[11]
12	m2	O	['N']	[12]
13	over	O	['N']	[13]
14	30	O	['N']	[14]
15	minutes	O	['N']	[15]
16	and	O	['N']	[16]
17	developed	O	['N']	[17]
18	palmar	B	['N']	[18]
19	pruritus	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	urticaria	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	edema	O	['N']	[24]
25	.	O	['N']	[25]
#973
0	When	O	['N']	[0]
1	SASP	O	['N']	[1]
2	was	O	['N']	[2]
3	changed	O	['N']	[3]
4	to	O	['N']	[4]
5	5-aminosalicylic	O	['N']	[5]
6	acid	O	['N']	[6]
7	(	O	['N']	[7]
8	5-ASA	B-Drug	['Causes']	[35]
9	)	O	['N']	[9]
10	,	O	['N']	[10]
11	his	O	['N']	[11]
12	skin	O	['N']	[12]
13	eruptions	O	['N']	[13]
14	were	O	['N']	[14]
15	resolved	O	['N']	[15]
16	,	O	['N']	[16]
17	however	O	['N']	[17]
18	,	O	['N']	[18]
19	he	O	['N']	[19]
20	developed	O	['N']	[20]
21	weakness	O	['N']	[21]
22	and	O	['N']	[22]
23	atrophy	O	['N']	[23]
24	in	O	['N']	[24]
25	his	O	['N']	[25]
26	right	O	['N']	[26]
27	arm	O	['N']	[27]
28	as	O	['N']	[28]
29	well	O	['N']	[29]
30	as	O	['N']	[30]
31	progressive	O	['N']	[31]
32	worsening	B	['N']	[32]
33	of	I	['N']	[33]
34	the	I	['N']	[34]
35	dysesthesia	I-Adverse_Effect	['N']	[35]
36	in	O	['N']	[36]
37	his	O	['N']	[37]
38	legs	O	['N']	[38]
39	and	O	['N']	[39]
40	gait	O	['N']	[40]
41	disturbance	O	['N']	[41]
42	.	O	['N']	[42]
#974
0	Thus	O	['N']	[0]
1	any	O	['N']	[1]
2	case	O	['N']	[2]
3	of	O	['N']	[3]
4	severe	B	['N']	[4]
5	neutropenia	I-Adverse_Effect	['N']	[5]
6	occurring	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	receiving	O	['N']	[10]
11	olanzapine	B-Drug	['Causes']	[5]
12	is	O	['N']	[12]
13	alarming	O	['N']	[13]
14	to	O	['N']	[14]
15	clinicians	O	['N']	[15]
16	.	O	['N']	[16]
#975
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	of	O	['N']	[4]
5	organic	O	['N']	[5]
6	bipolar	O	['N']	[6]
7	affective	O	['N']	[7]
8	disorder	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	hiccups	B-Adverse_Effect	['N']	[11]
12	with	O	['N']	[12]
13	the	O	['N']	[13]
14	atypical	O	['N']	[14]
15	antipsychotic	O	['N']	[15]
16	aripiprazole	B-Drug	['Causes']	[11]
17	.	O	['N']	[17]
#976
0	Doxycycline	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hypoglycemia	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	nondiabetic	O	['N']	[6]
7	young	O	['N']	[7]
8	man	O	['N']	[8]
9	.	O	['N']	[9]
#977
0	Though	O	['N']	[0]
1	hypotension	O	['N']	[1]
2	,	O	['N']	[2]
3	dry	O	['N']	[3]
4	mouth	O	['N']	[4]
5	,	O	['N']	[5]
6	and	O	['N']	[6]
7	constipation	B-Adverse_Effect	['N']	[7]
8	are	O	['N']	[8]
9	well	O	['N']	[9]
10	-	O	['N']	[10]
11	documented	O	['N']	[11]
12	possible	O	['N']	[12]
13	adverse	O	['N']	[13]
14	effects	O	['N']	[14]
15	,	O	['N']	[15]
16	the	O	['N']	[16]
17	possibility	O	['N']	[17]
18	of	O	['N']	[18]
19	clonidine	B-Drug	['Causes']	[7]
20	-	O	['N']	[20]
21	induced	O	['N']	[21]
22	bradycardia	O	['N']	[22]
23	is	O	['N']	[23]
24	less	O	['N']	[24]
25	well	O	['N']	[25]
26	recognized	O	['N']	[26]
27	and	O	['N']	[27]
28	is	O	['N']	[28]
29	rare	O	['N']	[29]
30	.	O	['N']	[30]
#978
0	In	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	methotrexate	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	anaphylaxis	B-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	discontinuation	O	['N']	[8]
9	of	O	['N']	[9]
10	treatment	O	['N']	[10]
11	may	O	['N']	[11]
12	increase	O	['N']	[12]
13	the	O	['N']	[13]
14	risk	O	['N']	[14]
15	of	O	['N']	[15]
16	death	O	['N']	[16]
17	due	O	['N']	[17]
18	to	O	['N']	[18]
19	cancer	O	['N']	[19]
20	progression	O	['N']	[20]
21	.	O	['N']	[21]
#979
0	Neurologic	B	['N']	[0]
1	symptoms	I-Adverse_Effect	['N']	[1]
2	resolved	O	['N']	[2]
3	after	O	['N']	[3]
4	stopping	O	['N']	[4]
5	CAP	B-Drug	['Causes']	[1]
6	for	O	['N']	[6]
7	4	O	['N']	[7]
8	weeks	O	['N']	[8]
9	in	O	['N']	[9]
10	Patient	O	['N']	[10]
11	A	O	['N']	[11]
12	,	O	['N']	[12]
13	with	O	['N']	[13]
14	no	O	['N']	[14]
15	recurrence	O	['N']	[15]
16	after	O	['N']	[16]
17	reinitiating	O	['N']	[17]
18	CAP	O	['N']	[18]
19	alone	O	['N']	[19]
20	at	O	['N']	[20]
21	2000	O	['N']	[21]
22	mg	O	['N']	[22]
23	/	O	['N']	[23]
24	m2	O	['N']	[24]
25	.	O	['N']	[25]
#980
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	bilateral	B	['N']	[7]
8	anterior	I	['N']	[8]
9	uveitis	I-Adverse_Effect	['N']	[9]
10	associated	O	['N']	[10]
11	with	O	['N']	[11]
12	ovulation	O	['N']	[12]
13	induction	O	['N']	[13]
14	therapy	O	['N']	[14]
15	using	O	['N']	[15]
16	clomiphene	B	['N']	[16]
17	citrate	I-Drug	['Causes']	[9]
18	.	O	['N']	[18]
#981
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	suggests	O	['N']	[2]
3	that	O	['N']	[3]
4	acyclovir	O	['N']	[4]
5	when	O	['N']	[5]
6	given	O	['N']	[6]
7	intravenously	O	['N']	[7]
8	in	O	['N']	[8]
9	doses	O	['N']	[9]
10	of	O	['N']	[10]
11	10	O	['N']	[11]
12	mg	O	['N']	[12]
13	/	O	['N']	[13]
14	kg	O	['N']	[14]
15	may	O	['N']	[15]
16	result	O	['N']	[16]
17	in	O	['N']	[17]
18	increased	B	['N']	[18]
19	serum	I	['N']	[19]
20	lithium	B-Drug	['N']	[20]
21	concentrations	O	['N']	[21]
22	.	O	['N']	[22]
#982
0	Painful	O	['N']	[0]
1	erosion	O	['N']	[1]
2	of	O	['N']	[2]
3	psoriatic	O	['N']	[3]
4	plaques	O	['N']	[4]
5	is	O	['N']	[5]
6	a	O	['N']	[6]
7	less	O	['N']	[7]
8	common	O	['N']	[8]
9	sign	O	['N']	[9]
10	of	O	['N']	[10]
11	methotrexate	B-Drug	['Causes']	[12]
12	toxicity	I-Adverse_Effect	['N']	[12]
13	that	O	['N']	[13]
14	may	O	['N']	[14]
15	precede	O	['N']	[15]
16	evidence	O	['N']	[16]
17	of	O	['N']	[17]
18	bone	O	['N']	[18]
19	marrow	O	['N']	[19]
20	suppression	O	['N']	[20]
21	.	O	['N']	[21]
#983
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	pericardial	O	['N']	[3]
4	hemorrhage	O	['N']	[4]
5	,	O	['N']	[5]
6	which	O	['N']	[6]
7	is	O	['N']	[7]
8	related	O	['N']	[8]
9	to	O	['N']	[9]
10	the	O	['N']	[10]
11	use	O	['N']	[11]
12	of	O	['N']	[12]
13	low	B	['N']	[13]
14	-	I	['N']	[14]
15	dose	I-Dose	['N']	[15]
16	acetylsalicylic	B	['N']	[16]
17	acid	I-Drug	['Dosage']	[15]
18	in	O	['N']	[18]
19	a	O	['N']	[19]
20	patient	O	['N']	[20]
21	with	O	['N']	[21]
22	essential	O	['N']	[22]
23	thrombocythemia	O	['N']	[23]
24	.	O	['N']	[24]
#984
0	The	O	['N']	[0]
1	visual	B	['N']	[1]
2	loss	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	this	O	['N']	[4]
5	patient	O	['N']	[5]
6	seems	O	['N']	[6]
7	to	O	['N']	[7]
8	result	O	['N']	[8]
9	from	O	['N']	[9]
10	phenol	B-Drug	['Causes']	[2]
11	neurotoxicity	O	['N']	[11]
12	rather	O	['N']	[12]
13	than	O	['N']	[13]
14	mechanical	O	['N']	[14]
15	compression	O	['N']	[15]
16	of	O	['N']	[16]
17	the	O	['N']	[17]
18	intraorbital	O	['N']	[18]
19	optic	O	['N']	[19]
20	nerve	O	['N']	[20]
21	.	O	['N']	[21]
#985
0	The	O	['N']	[0]
1	interval	O	['N']	[1]
2	between	O	['N']	[2]
3	initiating	O	['N']	[3]
4	treatment	O	['N']	[4]
5	with	O	['N']	[5]
6	interferon	B	['N']	[6]
7	alfa	I-Drug	['Causes']	[14]
8	and	O	['N']	[8]
9	onset	O	['N']	[9]
10	of	O	['N']	[10]
11	anterior	B	['N']	[11]
12	ischemic	I	['N']	[12]
13	optic	I	['N']	[13]
14	neuropathy	I-Adverse_Effect	['N']	[14]
15	was	O	['N']	[15]
16	similar	O	['N']	[16]
17	to	O	['N']	[17]
18	that	O	['N']	[18]
19	of	O	['N']	[19]
20	interferon	O	['N']	[20]
21	-	O	['N']	[21]
22	associated	O	['N']	[22]
23	vascular	O	['N']	[23]
24	retinopathy	O	['N']	[24]
25	.	O	['N']	[25]
#986
0	Accordingly	O	['N']	[0]
1	,	O	['N']	[1]
2	camptocormia	B-Adverse_Effect	['N']	[2]
3	is	O	['N']	[3]
4	a	O	['N']	[4]
5	dose	O	['N']	[5]
6	-	O	['N']	[6]
7	dependent	O	['N']	[7]
8	side	O	['N']	[8]
9	effect	O	['N']	[9]
10	of	O	['N']	[10]
11	valproate	B-Drug	['Causes']	[2]
12	.	O	['N']	[12]
#987
0	However	O	['N']	[0]
1	here	O	['N']	[1]
2	we	O	['N']	[2]
3	reported	O	['N']	[3]
4	two	O	['N']	[4]
5	patients	O	['N']	[5]
6	,	O	['N']	[6]
7	presenting	O	['N']	[7]
8	with	O	['N']	[8]
9	PD	O	['N']	[9]
10	during	O	['N']	[10]
11	high	B-Dose	['N']	[11]
12	dose	O	['N']	[12]
13	colchicine	B-Drug	['Dosage']	[11]
14	treatment	O	['N']	[14]
15	for	O	['N']	[15]
16	familiar	O	['N']	[16]
17	mediterranean	O	['N']	[17]
18	fever	O	['N']	[18]
19	(	O	['N']	[19]
20	FMF	O	['N']	[20]
21	)	O	['N']	[21]
22	.	O	['N']	[22]
#988
0	Optic	B	['N']	[0]
1	neuropathy	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	penicillamine	B-Drug	['Causes']	[1]
5	therapy	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	rheumatoid	O	['N']	[10]
11	arthritis	O	['N']	[11]
12	.	O	['N']	[12]
#989
0	Neurotoxicity	B-Adverse_Effect	['N']	[0]
1	of	O	['N']	[1]
2	valacyclovir	B-Drug	['Causes']	[0]
3	in	O	['N']	[3]
4	peritoneal	O	['N']	[4]
5	dialysis	O	['N']	[5]
6	:	O	['N']	[6]
7	a	O	['N']	[7]
8	pharmacokinetic	O	['N']	[8]
9	study	O	['N']	[9]
10	.	O	['N']	[10]
#990
0	After	O	['N']	[0]
1	administration	O	['N']	[1]
2	of	O	['N']	[2]
3	Oxybutynin	B-Drug	['Causes']	[24]
4	concomitantly	O	['N']	[4]
5	with	O	['N']	[5]
6	an	O	['N']	[6]
7	increase	O	['N']	[7]
8	in	O	['N']	[8]
9	the	O	['N']	[9]
10	dose	O	['N']	[10]
11	of	O	['N']	[11]
12	Dantrolene	O	['N']	[12]
13	,	O	['N']	[13]
14	she	O	['N']	[14]
15	presented	O	['N']	[15]
16	the	O	['N']	[16]
17	clinical	O	['N']	[17]
18	symptoms	O	['N']	[18]
19	and	O	['N']	[19]
20	laboratory	O	['N']	[20]
21	finding	O	['N']	[21]
22	of	O	['N']	[22]
23	Carbamazepine	B	['N']	[23]
24	intoxication	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#991
0	Rapamycin	O	['N']	[0]
1	/	O	['N']	[1]
2	sirolimus	B-Drug	['Causes']	[30]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	pneumonitis	O	['N']	[5]
6	has	O	['N']	[6]
7	been	O	['N']	[7]
8	described	O	['N']	[8]
9	previously	O	['N']	[9]
10	in	O	['N']	[10]
11	renal	O	['N']	[11]
12	transplant	O	['N']	[12]
13	recipients	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	this	O	['N']	[16]
17	report	O	['N']	[17]
18	describes	O	['N']	[18]
19	a	O	['N']	[19]
20	stable	O	['N']	[20]
21	heart	O	['N']	[21]
22	-	O	['N']	[22]
23	lung	O	['N']	[23]
24	transplant	O	['N']	[24]
25	recipient	O	['N']	[25]
26	who	O	['N']	[26]
27	developed	O	['N']	[27]
28	a	O	['N']	[28]
29	pulmonary	B	['N']	[29]
30	infiltrate	I-Adverse_Effect	['N']	[30]
31	that	O	['N']	[31]
32	reversed	O	['N']	[32]
33	after	O	['N']	[33]
34	ceasing	O	['N']	[34]
35	SR	O	['N']	[35]
36	therapy	O	['N']	[36]
37	.	O	['N']	[37]
#992
0	Localized	B	['N']	[0]
1	dyskeratotic	I	['N']	[1]
2	plaque	I-Adverse_Effect	['N']	[2]
3	with	O	['N']	[3]
4	milia	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	sorafenib	B-Drug	['Causes']	[2]
8	.	O	['N']	[8]
#993
0	Behavioral	O	['N']	[0]
1	side	O	['N']	[1]
2	effects	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	clonazepam	B-Drug	['Causes']	[8]
6	may	O	['N']	[6]
7	include	O	['N']	[7]
8	agitation	B-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	aggression	O	['N']	[10]
11	,	O	['N']	[11]
12	hyperactivity	O	['N']	[12]
13	,	O	['N']	[13]
14	irritability	O	['N']	[14]
15	,	O	['N']	[15]
16	property	O	['N']	[16]
17	destruction	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	temper	O	['N']	[20]
21	tantrums	O	['N']	[21]
22	.	O	['N']	[22]
#994
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	biopsy	O	['N']	[5]
6	proven	O	['N']	[6]
7	myositis	B-Adverse_Effect	['N']	[7]
8	whose	O	['N']	[8]
9	symptoms	O	['N']	[9]
10	began	O	['N']	[10]
11	within	O	['N']	[11]
12	10	O	['N']	[12]
13	days	O	['N']	[13]
14	of	O	['N']	[14]
15	receiving	O	['N']	[15]
16	leuprolide	B	['N']	[16]
17	acetate	I-Drug	['Causes']	[7]
18	therapy	O	['N']	[18]
19	for	O	['N']	[19]
20	prostate	O	['N']	[20]
21	cancer	O	['N']	[21]
22	.	O	['N']	[22]
#995
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	TMP	B	['N']	[6]
7	-	I	['N']	[7]
8	SMX	I-Drug	['Causes']	[12]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	hypersensitivity	B	['N']	[11]
12	syndrome	I-Adverse_Effect	['N']	[12]
13	associated	O	['N']	[13]
14	with	O	['N']	[14]
15	the	O	['N']	[15]
16	reactivation	O	['N']	[16]
17	of	O	['N']	[17]
18	a	O	['N']	[18]
19	latent	O	['N']	[19]
20	viral	O	['N']	[20]
21	infection	O	['N']	[21]
22	.	O	['N']	[22]
#996
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	four	O	['N']	[2]
3	patients	O	['N']	[3]
4	,	O	['N']	[4]
5	three	O	['N']	[5]
6	of	O	['N']	[6]
7	whom	O	['N']	[7]
8	first	O	['N']	[8]
9	developed	O	['N']	[9]
10	psoriasis	B-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	one	O	['N']	[12]
13	who	O	['N']	[13]
14	had	O	['N']	[14]
15	an	O	['N']	[15]
16	aggravation	O	['N']	[16]
17	of	O	['N']	[17]
18	the	O	['N']	[18]
19	condition	O	['N']	[19]
20	during	O	['N']	[20]
21	treatment	O	['N']	[21]
22	with	O	['N']	[22]
23	interferon	B	['N']	[23]
24	-	I	['N']	[24]
25	alpha	I-Drug	['Causes']	[10]
26	.	O	['N']	[26]
#997
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Both	O	['N']	[2]
3	patients	O	['N']	[3]
4	experienced	O	['N']	[4]
5	a	O	['N']	[5]
6	previously	O	['N']	[6]
7	unreported	O	['N']	[7]
8	side	O	['N']	[8]
9	effect	O	['N']	[9]
10	--	O	['N']	[10]
11	falling	B	['N']	[11]
12	backward	I-Adverse_Effect	['N']	[12]
13	--	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	bupropion	B-Drug	['Causes']	[12]
17	use	O	['N']	[17]
18	.	O	['N']	[18]
#998
0	Bisphosphonate	B-Drug	['Causes']	[5]
1	induced	O	['N']	[1]
2	osteochemonecrosis	B	['N']	[2]
3	of	I	['N']	[3]
4	the	I	['N']	[4]
5	jaw	I-Adverse_Effect	['N']	[5]
6	mimicking	O	['N']	[6]
7	a	O	['N']	[7]
8	tumour	O	['N']	[8]
9	.	O	['N']	[9]
#999
0	A	O	['N']	[0]
1	child	O	['N']	[1]
2	in	O	['N']	[2]
3	whom	O	['N']	[3]
4	a	O	['N']	[4]
5	phenobarbital	B-Drug	['Causes']	[23]
6	hypersensitivity	O	['N']	[6]
7	drug	O	['N']	[7]
8	reaction	O	['N']	[8]
9	developed	O	['N']	[9]
10	which	O	['N']	[10]
11	consisted	O	['N']	[11]
12	of	O	['N']	[12]
13	fever	O	['N']	[13]
14	,	O	['N']	[14]
15	a	O	['N']	[15]
16	pruritic	O	['N']	[16]
17	desquamating	O	['N']	[17]
18	erythrodermic	O	['N']	[18]
19	rash	O	['N']	[19]
20	,	O	['N']	[20]
21	alopecia	O	['N']	[21]
22	,	O	['N']	[22]
23	icterus	B-Adverse_Effect	['N']	[23]
24	,	O	['N']	[24]
25	protein	O	['N']	[25]
26	-	O	['N']	[26]
27	losing	O	['N']	[27]
28	enteropathy	O	['N']	[28]
29	,	O	['N']	[29]
30	myositis	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	nephritis	O	['N']	[33]
34	,	O	['N']	[34]
35	is	O	['N']	[35]
36	described	O	['N']	[36]
37	.	O	['N']	[37]
#1000
0	All	B	['N']	[0]
1	-	I	['N']	[1]
2	trans	I	['N']	[2]
3	retinoic	I	['N']	[3]
4	acid	I-Drug	['Causes']	[10]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	focal	O	['N']	[7]
8	myositis	O	['N']	[8]
9	,	O	['N']	[9]
10	synovitis	B-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	mononeuritis	O	['N']	[13]
14	.	O	['N']	[14]
#1001
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	required	O	['N']	[2]
3	nursing	O	['N']	[3]
4	home	O	['N']	[4]
5	placement	O	['N']	[5]
6	and	O	['N']	[6]
7	a	O	['N']	[7]
8	feeding	O	['N']	[8]
9	gastrostomy	O	['N']	[9]
10	as	O	['N']	[10]
11	a	O	['N']	[11]
12	result	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	worsening	B	['N']	[15]
16	parkinsonism	I-Adverse_Effect	['N']	[16]
17	during	O	['N']	[17]
18	risperidone	B-Drug	['Causes']	[16]
19	treatment	O	['N']	[19]
20	,	O	['N']	[20]
21	but	O	['N']	[21]
22	was	O	['N']	[22]
23	able	O	['N']	[23]
24	to	O	['N']	[24]
25	return	O	['N']	[25]
26	home	O	['N']	[26]
27	and	O	['N']	[27]
28	have	O	['N']	[28]
29	the	O	['N']	[29]
30	gastrostomy	O	['N']	[30]
31	removed	O	['N']	[31]
32	after	O	['N']	[32]
33	switching	O	['N']	[33]
34	from	O	['N']	[34]
35	risperidone	O	['N']	[35]
36	to	O	['N']	[36]
37	clozapine	O	['N']	[37]
38	.	O	['N']	[38]
#1002
0	Children	O	['N']	[0]
1	with	O	['N']	[1]
2	acute	O	['N']	[2]
3	lymphoblastic	O	['N']	[3]
4	leukemia	O	['N']	[4]
5	(	O	['N']	[5]
6	ALL	O	['N']	[6]
7	)	O	['N']	[7]
8	,	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	L	B	['N']	[11]
12	-	I	['N']	[12]
13	asparaginase	I-Drug	['Causes']	[19]
14	are	O	['N']	[14]
15	at	O	['N']	[15]
16	risk	O	['N']	[16]
17	for	O	['N']	[17]
18	cerebral	B	['N']	[18]
19	thrombosis	I-Adverse_Effect	['N']	[19]
20	or	O	['N']	[20]
21	hemorrhage	O	['N']	[21]
22	because	O	['N']	[22]
23	of	O	['N']	[23]
24	coagulation	O	['N']	[24]
25	protein	O	['N']	[25]
26	deficiencies	O	['N']	[26]
27	.	O	['N']	[27]
#1003
0	An	O	['N']	[0]
1	association	O	['N']	[1]
2	of	O	['N']	[2]
3	granulocytopenia	O	['N']	[3]
4	,	O	['N']	[4]
5	eosinophilia	O	['N']	[5]
6	,	O	['N']	[6]
7	skin	B	['N']	[7]
8	reaction	I-Adverse_Effect	['N']	[8]
9	and	O	['N']	[9]
10	hepatitis	O	['N']	[10]
11	during	O	['N']	[11]
12	propylthiouracil	O	['N']	[12]
13	(	O	['N']	[13]
14	PTU	B-Drug	['Causes']	[8]
15	)	O	['N']	[15]
16	therapy	O	['N']	[16]
17	for	O	['N']	[17]
18	thyrotoxicosis	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	47	O	['N']	[21]
22	year	O	['N']	[22]
23	old	O	['N']	[23]
24	black	O	['N']	[24]
25	female	O	['N']	[25]
26	is	O	['N']	[26]
27	reported	O	['N']	[27]
28	.	O	['N']	[28]
#1004
0	We	O	['N']	[0]
1	consider	O	['N']	[1]
2	asterixis	B-Adverse_Effect	['N']	[2]
3	to	O	['N']	[3]
4	be	O	['N']	[4]
5	an	O	['N']	[5]
6	easily	O	['N']	[6]
7	overlooked	O	['N']	[7]
8	sign	O	['N']	[8]
9	of	O	['N']	[9]
10	neurotoxicity	O	['N']	[10]
11	,	O	['N']	[11]
12	which	O	['N']	[12]
13	may	O	['N']	[13]
14	occur	O	['N']	[14]
15	even	O	['N']	[15]
16	at	O	['N']	[16]
17	low	O	['N']	[17]
18	or	O	['N']	[18]
19	moderate	O	['N']	[19]
20	dosage	O	['N']	[20]
21	levels	O	['N']	[21]
22	,	O	['N']	[22]
23	if	O	['N']	[23]
24	certain	O	['N']	[24]
25	drugs	O	['N']	[25]
26	as	O	['N']	[26]
27	lithium	O	['N']	[27]
28	or	O	['N']	[28]
29	clozapine	B-Drug	['Causes']	[2]
30	are	O	['N']	[30]
31	used	O	['N']	[31]
32	in	O	['N']	[32]
33	combination	O	['N']	[33]
34	with	O	['N']	[34]
35	CBZ	O	['N']	[35]
36	.	O	['N']	[36]
#1005
0	Quetiapine	B-Drug	['Causes']	[5]
1	and	O	['N']	[1]
2	obsessive	B	['N']	[2]
3	-	I	['N']	[3]
4	compulsive	I	['N']	[4]
5	symptoms	I-Adverse_Effect	['N']	[5]
6	(	O	['N']	[6]
7	OCS	O	['N']	[7]
8	)	O	['N']	[8]
9	:	O	['N']	[9]
10	case	O	['N']	[10]
11	report	O	['N']	[11]
12	and	O	['N']	[12]
13	review	O	['N']	[13]
14	of	O	['N']	[14]
15	atypical	O	['N']	[15]
16	antipsychotic	O	['N']	[16]
17	-	O	['N']	[17]
18	induced	O	['N']	[18]
19	OCS	O	['N']	[19]
20	.	O	['N']	[20]
#1006
0	This	O	['N']	[0]
1	review	O	['N']	[1]
2	presents	O	['N']	[2]
3	the	O	['N']	[3]
4	first	O	['N']	[4]
5	case	O	['N']	[5]
6	series	O	['N']	[6]
7	of	O	['N']	[7]
8	DIC	O	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	acute	O	['N']	[11]
12	hemoglobinemia	O	['N']	[12]
13	or	O	['N']	[13]
14	hemoglobinuria	B-Adverse_Effect	['N']	[14]
15	following	O	['N']	[15]
16	anti	B	['N']	[16]
17	-	I	['N']	[17]
18	D	I	['N']	[18]
19	IGIV	I-Drug	['Causes']	[14]
20	administration	O	['N']	[20]
21	for	O	['N']	[21]
22	ITP	O	['N']	[22]
23	.	O	['N']	[23]
#1007
0	Clostridium	B	['N']	[0]
1	difficile	I	['N']	[1]
2	colitis	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	cisplatin	B-Drug	['Causes']	[2]
6	-	O	['N']	[6]
7	based	O	['N']	[7]
8	chemotherapy	O	['N']	[8]
9	in	O	['N']	[9]
10	ovarian	O	['N']	[10]
11	cancer	O	['N']	[11]
12	patients	O	['N']	[12]
13	.	O	['N']	[13]
#1008
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	acute	O	['N']	[5]
6	leukemia	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	Horner	B	['N']	[9]
10	's	I	['N']	[10]
11	syndrome	I-Adverse_Effect	['N']	[11]
12	and	O	['N']	[12]
13	a	O	['N']	[13]
14	severe	O	['N']	[14]
15	demyelinating	O	['N']	[15]
16	peripheral	O	['N']	[16]
17	neuropathy	O	['N']	[17]
18	leading	O	['N']	[18]
19	to	O	['N']	[19]
20	death	O	['N']	[20]
21	after	O	['N']	[21]
22	receiving	O	['N']	[22]
23	high	O	['N']	[23]
24	-	O	['N']	[24]
25	dose	O	['N']	[25]
26	cytosine	B	['N']	[26]
27	arabinoside	I-Drug	['Causes']	[11]
28	.	O	['N']	[28]
#1009
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	the	O	['N']	[4]
5	first	O	['N']	[5]
6	five	O	['N']	[6]
7	cases	O	['N']	[7]
8	of	O	['N']	[8]
9	amphotericin	B	['N']	[9]
10	B	I-Drug	['Dosage']	[11]
11	overdose	B-Dose	['N']	[11]
12	with	O	['N']	[12]
13	secondary	O	['N']	[13]
14	cardiac	O	['N']	[14]
15	complications	O	['N']	[15]
16	in	O	['N']	[16]
17	a	O	['N']	[17]
18	pediatric	O	['N']	[18]
19	population	O	['N']	[19]
20	.	O	['N']	[20]
#1010
0	Phenobarbital	B-Drug	['Causes']	[1]
1	hepatotoxicity	B-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	an	O	['N']	[3]
4	8-month	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	infant	O	['N']	[7]
8	.	O	['N']	[8]
#1011
0	A	O	['N']	[0]
1	68-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	advanced	O	['N']	[7]
8	ovarian	O	['N']	[8]
9	carcinoma	O	['N']	[9]
10	collapsed	B-Adverse_Effect	['N']	[10]
11	whilst	O	['N']	[11]
12	receiving	O	['N']	[12]
13	a	O	['N']	[13]
14	carboplatin	O	['N']	[14]
15	and	O	['N']	[15]
16	cyclophosphamide	B-Drug	['Causes']	[10]
17	infusion	O	['N']	[17]
18	.	O	['N']	[18]
#1012
0	Vitiligo	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	alpha	B	['N']	[3]
4	-	I	['N']	[4]
5	interferon	I-Drug	['Causes']	[0]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	chronic	O	['N']	[10]
11	active	O	['N']	[11]
12	hepatitis	O	['N']	[12]
13	C.	O	['N']	[13]
#1013
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	and	O	['N']	[2]
3	a	O	['N']	[3]
4	review	O	['N']	[4]
5	of	O	['N']	[5]
6	the	O	['N']	[6]
7	literature	O	['N']	[7]
8	show	O	['N']	[8]
9	the	O	['N']	[9]
10	severe	O	['N']	[10]
11	and	O	['N']	[11]
12	unpredictable	O	['N']	[12]
13	nature	O	['N']	[13]
14	of	O	['N']	[14]
15	ethambutol	B-Drug	['Causes']	[16]
16	toxicity	I-Adverse_Effect	['N']	[16]
17	and	O	['N']	[17]
18	its	O	['N']	[18]
19	potential	O	['N']	[19]
20	for	O	['N']	[20]
21	irreversible	O	['N']	[21]
22	vision	O	['N']	[22]
23	loss	O	['N']	[23]
24	despite	O	['N']	[24]
25	careful	O	['N']	[25]
26	ophthalmologic	O	['N']	[26]
27	monitoring	O	['N']	[27]
28	.	O	['N']	[28]
#1014
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	WES	B-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	an	O	['N']	[8]
9	infant	O	['N']	[9]
10	born	O	['N']	[10]
11	to	O	['N']	[11]
12	a	O	['N']	[12]
13	mother	O	['N']	[13]
14	taking	O	['N']	[14]
15	haloperidol	B-Drug	['Causes']	[6]
16	during	O	['N']	[16]
17	her	O	['N']	[17]
18	pregnancy	O	['N']	[18]
19	.	O	['N']	[19]
#1015
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	priapism	B-Adverse_Effect	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	trazodone	B-Drug	['Causes']	[3]
7	is	O	['N']	[7]
8	described	O	['N']	[8]
9	.	O	['N']	[9]
#1016
0	Reversible	O	['N']	[0]
1	cholestasis	O	['N']	[1]
2	with	O	['N']	[2]
3	bile	B	['N']	[3]
4	duct	I	['N']	[4]
5	injury	I-Adverse_Effect	['N']	[5]
6	following	O	['N']	[6]
7	azathioprine	B-Drug	['Causes']	[5]
8	therapy	O	['N']	[8]
9	.	O	['N']	[9]
#1017
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	onset	O	['N']	[4]
5	of	O	['N']	[5]
6	syndrome	O	['N']	[6]
7	of	O	['N']	[7]
8	inappropriate	O	['N']	[8]
9	antidiuretic	O	['N']	[9]
10	hormone	O	['N']	[10]
11	(	O	['N']	[11]
12	SIADH	B-Adverse_Effect	['N']	[12]
13	)	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	vinorelbine	B-Drug	['Causes']	[12]
17	therapy	O	['N']	[17]
18	for	O	['N']	[18]
19	advanced	O	['N']	[19]
20	breast	O	['N']	[20]
21	cancer	O	['N']	[21]
22	.	O	['N']	[22]
#1018
0	Sustained	B	['N']	[0]
1	ventricular	I	['N']	[1]
2	tachycardia	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	thalidomide	B-Drug	['Causes']	[2]
6	-	O	['N']	[6]
7	treated	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	primary	O	['N']	[10]
11	plasma	O	['N']	[11]
12	-	O	['N']	[12]
13	cell	O	['N']	[13]
14	leukemia	O	['N']	[14]
15	.	O	['N']	[15]
#1019
0	The	O	['N']	[0]
1	role	O	['N']	[1]
2	of	O	['N']	[2]
3	Adriamycin	B-Drug	['Causes']	[8]
4	in	O	['N']	[4]
5	the	O	['N']	[5]
6	production	O	['N']	[6]
7	of	O	['N']	[7]
8	cardiotoxicity	B-Adverse_Effect	['N']	[8]
9	is	O	['N']	[9]
10	reviewed	O	['N']	[10]
11	.	O	['N']	[11]
#1020
0	5-fluorouracil	B-Drug	['Causes']	[4]
1	(	O	['N']	[1]
2	5-FU)-associated	O	['N']	[2]
3	peripheral	B	['N']	[3]
4	neuropathy	I-Adverse_Effect	['N']	[4]
5	is	O	['N']	[5]
6	an	O	['N']	[6]
7	uncommon	O	['N']	[7]
8	event	O	['N']	[8]
9	.	O	['N']	[9]
#1021
0	Common	O	['N']	[0]
1	adverse	O	['N']	[1]
2	events	O	['N']	[2]
3	(	O	['N']	[3]
4	frequency	O	['N']	[4]
5	10	O	['N']	[5]
6	%	O	['N']	[6]
7	)	O	['N']	[7]
8	of	O	['N']	[8]
9	lacosamide	B-Drug	['Causes']	[26]
10	doses	O	['N']	[10]
11	up	O	['N']	[11]
12	to	O	['N']	[12]
13	600	O	['N']	[13]
14	mg	O	['N']	[14]
15	/	O	['N']	[15]
16	day	O	['N']	[16]
17	include	O	['N']	[17]
18	nonspecific	O	['N']	[18]
19	central	O	['N']	[19]
20	nervous	O	['N']	[20]
21	system	O	['N']	[21]
22	effects	O	['N']	[22]
23	(	O	['N']	[23]
24	e.g.	O	['N']	[24]
25	,	O	['N']	[25]
26	dizziness	B-Adverse_Effect	['N']	[26]
27	,	O	['N']	[27]
28	ataxia	O	['N']	[28]
29	,	O	['N']	[29]
30	diplopia	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	somnolence	O	['N']	[33]
34	)	O	['N']	[34]
35	.	O	['N']	[35]
#1022
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	torsade	O	['N']	[5]
6	de	O	['N']	[6]
7	pointes	O	['N']	[7]
8	following	O	['N']	[8]
9	a	O	['N']	[9]
10	single	O	['N']	[10]
11	oral	O	['N']	[11]
12	dose	O	['N']	[12]
13	of	O	['N']	[13]
14	amiodarone	B-Drug	['Dosage']	[21]
15	(	O	['N']	[15]
16	1400	O	['N']	[16]
17	mg	O	['N']	[17]
18	or	O	['N']	[18]
19	30	B	['N']	[19]
20	mg	I	['N']	[20]
21	kg-1	I-Dose	['N']	[21]
22	)	O	['N']	[22]
23	administered	O	['N']	[23]
24	after	O	['N']	[24]
25	short	O	['N']	[25]
26	intravenous	O	['N']	[26]
27	loading	O	['N']	[27]
28	for	O	['N']	[28]
29	prevention	O	['N']	[29]
30	of	O	['N']	[30]
31	paroxysmal	O	['N']	[31]
32	atrial	O	['N']	[32]
33	flutter	O	['N']	[33]
34	.	O	['N']	[34]
#1023
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Amantadine	B-Drug	['Causes']	[7]
3	can	O	['N']	[3]
4	cause	O	['N']	[4]
5	reversible	B	['N']	[5]
6	corneal	I	['N']	[6]
7	edema	I-Adverse_Effect	['N']	[7]
8	but	O	['N']	[8]
9	can	O	['N']	[9]
10	irreversibly	O	['N']	[10]
11	reduce	O	['N']	[11]
12	the	O	['N']	[12]
13	density	O	['N']	[13]
14	of	O	['N']	[14]
15	endothelial	O	['N']	[15]
16	cells	O	['N']	[16]
17	.	O	['N']	[17]
#1024
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	determine	O	['N']	[3]
4	the	O	['N']	[4]
5	cause	O	['N']	[5]
6	of	O	['N']	[6]
7	spontaneous	B	['N']	[7]
8	choroidal	I	['N']	[8]
9	hemorrhage	I-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	67-year	O	['N']	[12]
13	-	O	['N']	[13]
14	old	O	['N']	[14]
15	man	O	['N']	[15]
16	after	O	['N']	[16]
17	a	O	['N']	[17]
18	myocardial	O	['N']	[18]
19	infarction	O	['N']	[19]
20	and	O	['N']	[20]
21	administration	O	['N']	[21]
22	of	O	['N']	[22]
23	tissue	B	['N']	[23]
24	plasminogen	I	['N']	[24]
25	activator	I-Drug	['Causes']	[9]
26	.	O	['N']	[26]
#1025
0	The	O	['N']	[0]
1	most	O	['N']	[1]
2	common	O	['N']	[2]
3	side	O	['N']	[3]
4	effects	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	amifostine	B-Drug	['Causes']	[15]
8	are	O	['N']	[8]
9	nausea	O	['N']	[9]
10	,	O	['N']	[10]
11	vomiting	O	['N']	[11]
12	,	O	['N']	[12]
13	hypotension	O	['N']	[13]
14	,	O	['N']	[14]
15	hypocalcemia	B-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	allergic	O	['N']	[17]
18	reactions	O	['N']	[18]
19	.	O	['N']	[19]
#1026
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	In	O	['N']	[2]
3	a	O	['N']	[3]
4	22-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	Thai	O	['N']	[7]
8	woman	O	['N']	[8]
9	with	O	['N']	[9]
10	Graves	O	['N']	[10]
11	'	O	['N']	[11]
12	disease	O	['N']	[12]
13	,	O	['N']	[13]
14	tinnitus	O	['N']	[14]
15	,	O	['N']	[15]
16	hearing	O	['N']	[16]
17	impairment	O	['N']	[17]
18	in	O	['N']	[18]
19	the	O	['N']	[19]
20	left	O	['N']	[20]
21	ear	O	['N']	[21]
22	(	O	['N']	[22]
23	with	O	['N']	[23]
24	progression	O	['N']	[24]
25	to	O	['N']	[25]
26	the	O	['N']	[26]
27	right	O	['N']	[27]
28	ear	O	['N']	[28]
29	)	O	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	vertigo	B-Adverse_Effect	['N']	[32]
33	developed	O	['N']	[33]
34	after	O	['N']	[34]
35	3	O	['N']	[35]
36	years	O	['N']	[36]
37	of	O	['N']	[37]
38	therapy	O	['N']	[38]
39	with	O	['N']	[39]
40	PTU	B-Drug	['Causes']	[32]
41	.	O	['N']	[41]
#1027
0	Here	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	describe	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	Vogt	B	['N']	[7]
8	-	I	['N']	[8]
9	Koyanagi	I	['N']	[9]
10	-	I	['N']	[10]
11	Harada	I	['N']	[11]
12	disease	I-Adverse_Effect	['N']	[12]
13	occurring	O	['N']	[13]
14	4	O	['N']	[14]
15	months	O	['N']	[15]
16	after	O	['N']	[16]
17	the	O	['N']	[17]
18	start	O	['N']	[18]
19	of	O	['N']	[19]
20	interferon	B	['N']	[20]
21	alpha	I-Drug	['Causes']	[12]
22	treatment	O	['N']	[22]
23	,	O	['N']	[23]
24	probably	O	['N']	[24]
25	induced	O	['N']	[25]
26	by	O	['N']	[26]
27	the	O	['N']	[27]
28	immunomodulatory	O	['N']	[28]
29	effects	O	['N']	[29]
30	of	O	['N']	[30]
31	interferon	O	['N']	[31]
32	.	O	['N']	[32]
#1028
0	Ticlopidine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	aplastic	B	['N']	[3]
4	anemia	I-Adverse_Effect	['N']	[4]
5	:	O	['N']	[5]
6	two	O	['N']	[6]
7	new	O	['N']	[7]
8	case	O	['N']	[8]
9	reports	O	['N']	[9]
10	,	O	['N']	[10]
11	review	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	meta	O	['N']	[14]
15	-	O	['N']	[15]
16	analysis	O	['N']	[16]
17	of	O	['N']	[17]
18	55	O	['N']	[18]
19	additional	O	['N']	[19]
20	cases	O	['N']	[20]
21	.	O	['N']	[21]
#1029
0	Intravenous	O	['N']	[0]
1	cytarabine	B-Drug	['Causes']	[16]
2	and	O	['N']	[2]
3	methotrexate	O	['N']	[3]
4	appear	O	['N']	[4]
5	to	O	['N']	[5]
6	act	O	['N']	[6]
7	synergistically	O	['N']	[7]
8	to	O	['N']	[8]
9	enhance	O	['N']	[9]
10	the	O	['N']	[10]
11	potential	O	['N']	[11]
12	for	O	['N']	[12]
13	central	B	['N']	[13]
14	nervous	I	['N']	[14]
15	system	I	['N']	[15]
16	toxicity	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#1030
0	To	O	['N']	[0]
1	the	O	['N']	[1]
2	best	O	['N']	[2]
3	of	O	['N']	[3]
4	our	O	['N']	[4]
5	knowledge	O	['N']	[5]
6	,	O	['N']	[6]
7	corneoscleral	B	['N']	[7]
8	melting	I-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	the	O	['N']	[10]
11	first	O	['N']	[11]
12	postoperative	O	['N']	[12]
13	week	O	['N']	[13]
14	after	O	['N']	[14]
15	a	O	['N']	[15]
16	single	O	['N']	[16]
17	intraoperative	O	['N']	[17]
18	application	O	['N']	[18]
19	of	O	['N']	[19]
20	mitomycin	B	['N']	[20]
21	C	I-Drug	['Causes']	[8]
22	has	O	['N']	[22]
23	not	O	['N']	[23]
24	been	O	['N']	[24]
25	reported	O	['N']	[25]
26	.	O	['N']	[26]
#1031
0	A	O	['N']	[0]
1	high	O	['N']	[1]
2	dose	O	['N']	[2]
3	of	O	['N']	[3]
4	cotrimoxazole	B-Drug	['Causes']	[6]
5	induced	O	['N']	[5]
6	hyperkalaemia	B-Adverse_Effect	['N']	[6]
7	with	O	['N']	[7]
8	the	O	['N']	[8]
9	elevation	O	['N']	[9]
10	of	O	['N']	[10]
11	serum	O	['N']	[11]
12	creatinine	O	['N']	[12]
13	and	O	['N']	[13]
14	blood	O	['N']	[14]
15	urea	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	increased	O	['N']	[18]
19	urinary	O	['N']	[19]
20	N	O	['N']	[20]
21	-	O	['N']	[21]
22	acetyl	O	['N']	[22]
23	glucosaminase	O	['N']	[23]
24	after	O	['N']	[24]
25	several	O	['N']	[25]
26	days	O	['N']	[26]
27	of	O	['N']	[27]
28	the	O	['N']	[28]
29	drug	O	['N']	[29]
30	administration	O	['N']	[30]
31	in	O	['N']	[31]
32	these	O	['N']	[32]
33	patients	O	['N']	[33]
34	;	O	['N']	[34]
35	one	O	['N']	[35]
36	patient	O	['N']	[36]
37	became	O	['N']	[37]
38	unconscious	O	['N']	[38]
39	.	O	['N']	[39]
#1032
0	Three	O	['N']	[0]
1	years	O	['N']	[1]
2	later	O	['N']	[2]
3	,	O	['N']	[3]
4	treatment	O	['N']	[4]
5	with	O	['N']	[5]
6	ampicillin	B-Drug	['Causes']	[12]
7	caused	O	['N']	[7]
8	another	O	['N']	[8]
9	episode	O	['N']	[9]
10	of	O	['N']	[10]
11	cholestatic	B	['N']	[11]
12	hepatitis	I-Adverse_Effect	['N']	[12]
13	with	O	['N']	[13]
14	cholestasis	O	['N']	[14]
15	and	O	['N']	[15]
16	duct	O	['N']	[16]
17	paucity	O	['N']	[17]
18	on	O	['N']	[18]
19	rebiopsy	O	['N']	[19]
20	.	O	['N']	[20]
#1033
0	Exacerbation	O	['N']	[0]
1	of	O	['N']	[1]
2	5-FU	B-Drug	['Causes']	[4]
3	dermatologic	B	['N']	[3]
4	toxicities	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	patients	O	['N']	[6]
7	with	O	['N']	[7]
8	preexisting	O	['N']	[8]
9	conditions	O	['N']	[9]
10	suggests	O	['N']	[10]
11	the	O	['N']	[11]
12	importance	O	['N']	[12]
13	of	O	['N']	[13]
14	aggressive	O	['N']	[14]
15	ocular	O	['N']	[15]
16	prophylaxis	O	['N']	[16]
17	,	O	['N']	[17]
18	using	O	['N']	[18]
19	frequent	O	['N']	[19]
20	ocular	O	['N']	[20]
21	lubrication	O	['N']	[21]
22	and	O	['N']	[22]
23	topical	O	['N']	[23]
24	steroid	O	['N']	[24]
25	preparations	O	['N']	[25]
26	with	O	['N']	[26]
27	concurrent	O	['N']	[27]
28	medical	O	['N']	[28]
29	management	O	['N']	[29]
30	of	O	['N']	[30]
31	pre	O	['N']	[31]
32	-	O	['N']	[32]
33	existing	O	['N']	[33]
34	dermatologic	O	['N']	[34]
35	conditions	O	['N']	[35]
36	.	O	['N']	[36]
#1034
0	Aseptic	O	['N']	[0]
1	meningitis	O	['N']	[1]
2	,	O	['N']	[2]
3	hemolytic	O	['N']	[3]
4	anemia	O	['N']	[4]
5	,	O	['N']	[5]
6	hepatitis	B-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	orthostatic	O	['N']	[9]
10	hypotension	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	trimethoprim	B-Drug	['Causes']	[6]
17	-	O	['N']	[17]
18	sulfamethoxazole	O	['N']	[18]
19	.	O	['N']	[19]
#1035
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	suggest	O	['N']	[2]
3	that	O	['N']	[3]
4	risperidone	B-Drug	['Causes']	[7]
5	may	O	['N']	[5]
6	increase	B	['N']	[6]
7	affect	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	patients	O	['N']	[9]
10	with	O	['N']	[10]
11	schizophrenia	O	['N']	[11]
12	and	O	['N']	[12]
13	that	O	['N']	[13]
14	some	O	['N']	[14]
15	patients	O	['N']	[15]
16	,	O	['N']	[16]
17	especially	O	['N']	[17]
18	those	O	['N']	[18]
19	with	O	['N']	[19]
20	anxiety	O	['N']	[20]
21	,	O	['N']	[21]
22	may	O	['N']	[22]
23	have	O	['N']	[23]
24	difficulty	O	['N']	[24]
25	managing	O	['N']	[25]
26	the	O	['N']	[26]
27	increase	O	['N']	[27]
28	.	O	['N']	[28]
#1036
0	A	O	['N']	[0]
1	10-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	with	O	['N']	[5]
6	osteosarcoma	O	['N']	[6]
7	and	O	['N']	[7]
8	normal	O	['N']	[8]
9	renal	O	['N']	[9]
10	function	O	['N']	[10]
11	manifested	O	['N']	[11]
12	laboratory	O	['N']	[12]
13	evidence	O	['N']	[13]
14	of	O	['N']	[14]
15	impending	O	['N']	[15]
16	renal	O	['N']	[16]
17	toxicity	O	['N']	[17]
18	and	O	['N']	[18]
19	extreme	O	['N']	[19]
20	elevation	O	['N']	[20]
21	of	O	['N']	[21]
22	aspartate	O	['N']	[22]
23	aminotrasferase	O	['N']	[23]
24	and	O	['N']	[24]
25	alanine	O	['N']	[25]
26	aminotransferase	O	['N']	[26]
27	within	O	['N']	[27]
28	2	O	['N']	[28]
29	hours	O	['N']	[29]
30	after	O	['N']	[30]
31	the	O	['N']	[31]
32	completion	O	['N']	[32]
33	of	O	['N']	[33]
34	a	O	['N']	[34]
35	4-hour	O	['N']	[35]
36	infusion	O	['N']	[36]
37	of	O	['N']	[37]
38	high	B	['N']	[38]
39	-	I	['N']	[39]
40	dose	I-Dose	['N']	[40]
41	methotrexate	O	['N']	[41]
42	(	O	['N']	[42]
43	MTX	B-Drug	['Dosage']	[40]
44	)	O	['N']	[44]
45	(	O	['N']	[45]
46	12	O	['N']	[46]
47	g	O	['N']	[47]
48	/	O	['N']	[48]
49	m2	O	['N']	[49]
50	)	O	['N']	[50]
51	,	O	['N']	[51]
52	and	O	['N']	[52]
53	went	O	['N']	[53]
54	on	O	['N']	[54]
55	to	O	['N']	[55]
56	develop	O	['N']	[56]
57	acute	O	['N']	[57]
58	renal	O	['N']	[58]
59	failure	O	['N']	[59]
60	with	O	['N']	[60]
61	life	O	['N']	[61]
62	-	O	['N']	[62]
63	threatening	O	['N']	[63]
64	hyperkalemia	O	['N']	[64]
65	29	O	['N']	[65]
66	hours	O	['N']	[66]
67	later	O	['N']	[67]
68	.	O	['N']	[68]
#1037
0	Can	O	['N']	[0]
1	propofol	B-Drug	['Causes']	[3]
2	precipitate	O	['N']	[2]
3	pancreatitis	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	patients	O	['N']	[5]
6	with	O	['N']	[6]
7	Cushing	O	['N']	[7]
8	's	O	['N']	[8]
9	syndrome	O	['N']	[9]
10	?	O	['N']	[10]
#1038
0	A	O	['N']	[0]
1	mentally	O	['N']	[1]
2	retarded	O	['N']	[2]
3	23-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	with	O	['N']	[7]
8	myoclonic	O	['N']	[8]
9	astatic	O	['N']	[9]
10	epilepsy	O	['N']	[10]
11	developed	O	['N']	[11]
12	an	O	['N']	[12]
13	abnormal	O	['N']	[13]
14	posture	O	['N']	[14]
15	of	O	['N']	[15]
16	extreme	O	['N']	[16]
17	forward	O	['N']	[17]
18	flexion	O	['N']	[18]
19	,	O	['N']	[19]
20	called	O	['N']	[20]
21	camptocormia	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	during	O	['N']	[23]
24	valproate	B-Drug	['Causes']	[21]
25	monotherapy	O	['N']	[25]
26	.	O	['N']	[26]
#1039
0	Nifedipine	B-Drug	['Causes']	[14]
1	may	O	['N']	[1]
2	induce	O	['N']	[2]
3	,	O	['N']	[3]
4	or	O	['N']	[4]
5	aggravate	O	['N']	[5]
6	,	O	['N']	[6]
7	pre	O	['N']	[7]
8	-	O	['N']	[8]
9	existing	O	['N']	[9]
10	,	O	['N']	[10]
11	gastro	B	['N']	[11]
12	-	I	['N']	[12]
13	oesophageal	I	['N']	[13]
14	reflux	I-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#1040
0	Hypernatraemia	B-Adverse_Effect	['N']	[0]
1	induced	O	['N']	[1]
2	by	O	['N']	[2]
3	sodium	O	['N']	[3]
4	polystyrene	O	['N']	[4]
5	sulphonate	O	['N']	[5]
6	(	O	['N']	[6]
7	Kayexalate	B-Drug	['Causes']	[0]
8	)	O	['N']	[8]
9	in	O	['N']	[9]
10	two	O	['N']	[10]
11	extremely	O	['N']	[11]
12	low	O	['N']	[12]
13	birth	O	['N']	[13]
14	weight	O	['N']	[14]
15	newborns	O	['N']	[15]
16	.	O	['N']	[16]
#1041
0	Rapamycin	O	['N']	[0]
1	/	O	['N']	[1]
2	sirolimus	O	['N']	[2]
3	(	O	['N']	[3]
4	SR	B-Drug	['Causes']	[29]
5	)	O	['N']	[5]
6	,	O	['N']	[6]
7	trade	O	['N']	[7]
8	named	O	['N']	[8]
9	Rapammune	O	['N']	[9]
10	(	O	['N']	[10]
11	Wyeth	O	['N']	[11]
12	-	O	['N']	[12]
13	Ayerst	O	['N']	[13]
14	,	O	['N']	[14]
15	Sydney	O	['N']	[15]
16	,	O	['N']	[16]
17	Australia	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	is	O	['N']	[20]
21	a	O	['N']	[21]
22	potent	O	['N']	[22]
23	immunosuppressive	O	['N']	[23]
24	drug	O	['N']	[24]
25	associated	O	['N']	[25]
26	with	O	['N']	[26]
27	myelosuppression	O	['N']	[27]
28	,	O	['N']	[28]
29	hypertension	B-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	hyperlipidemia	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	infection	O	['N']	[34]
35	.	O	['N']	[35]
#1042
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	imminent	O	['N']	[3]
4	gangrene	B	['N']	[4]
5	of	I	['N']	[5]
6	the	I	['N']	[6]
7	extremities	I-Adverse_Effect	['N']	[7]
8	caused	O	['N']	[8]
9	by	O	['N']	[9]
10	ergot	B-Drug	['Causes']	[7]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	arteriospasm	O	['N']	[13]
14	underwent	O	['N']	[14]
15	mechanical	O	['N']	[15]
16	dilatation	O	['N']	[16]
17	of	O	['N']	[17]
18	the	O	['N']	[18]
19	arteries	O	['N']	[19]
20	when	O	['N']	[20]
21	conventional	O	['N']	[21]
22	measures	O	['N']	[22]
23	such	O	['N']	[23]
24	as	O	['N']	[24]
25	anticoagulation	O	['N']	[25]
26	,	O	['N']	[26]
27	vasodilation	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	sympathetic	O	['N']	[30]
31	blockade	O	['N']	[31]
32	produced	O	['N']	[32]
33	no	O	['N']	[33]
34	improvement	O	['N']	[34]
35	.	O	['N']	[35]
#1043
0	Rifampicin	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	renal	B	['N']	[3]
4	failure	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#1044
0	AIM	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	diabetic	O	['N']	[7]
8	rubeosis	O	['N']	[8]
9	who	O	['N']	[9]
10	suffered	O	['N']	[10]
11	from	O	['N']	[11]
12	acute	O	['N']	[12]
13	retinal	O	['N']	[13]
14	ischemic	O	['N']	[14]
15	change	O	['N']	[15]
16	and	O	['N']	[16]
17	stroke	B-Adverse_Effect	['N']	[17]
18	after	O	['N']	[18]
19	intravitreal	O	['N']	[19]
20	injection	O	['N']	[20]
21	of	O	['N']	[21]
22	bevacizumab	B-Drug	['Causes']	[17]
23	.	O	['N']	[23]
#1045
0	The	O	['N']	[0]
1	principle	O	['N']	[1]
2	treatment	O	['N']	[2]
3	for	O	['N']	[3]
4	DPD	O	['N']	[4]
5	-	O	['N']	[5]
6	deficient	O	['N']	[6]
7	patients	O	['N']	[7]
8	with	O	['N']	[8]
9	severe	O	['N']	[9]
10	acute	O	['N']	[10]
11	5-FU	B-Drug	['Causes']	[31]
12	reactions	O	['N']	[12]
13	is	O	['N']	[13]
14	supportive	O	['N']	[14]
15	care	O	['N']	[15]
16	;	O	['N']	[16]
17	however	O	['N']	[17]
18	,	O	['N']	[18]
19	the	O	['N']	[19]
20	administration	O	['N']	[20]
21	of	O	['N']	[21]
22	thymidine	O	['N']	[22]
23	potentially	O	['N']	[23]
24	may	O	['N']	[24]
25	reverse	O	['N']	[25]
26	severe	O	['N']	[26]
27	5-FU	O	['N']	[27]
28	-	O	['N']	[28]
29	induced	O	['N']	[29]
30	neurologic	B	['N']	[30]
31	symptoms	I-Adverse_Effect	['N']	[31]
32	such	O	['N']	[32]
33	as	O	['N']	[33]
34	encephalopathy	O	['N']	[34]
35	and	O	['N']	[35]
36	coma	O	['N']	[36]
37	.	O	['N']	[37]
#1046
0	Rapamycin	B-Drug	['Causes']	[5]
1	/	O	['N']	[1]
2	sirolimus	O	['N']	[2]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	pneumonitis	B-Adverse_Effect	['N']	[5]
6	has	O	['N']	[6]
7	been	O	['N']	[7]
8	described	O	['N']	[8]
9	previously	O	['N']	[9]
10	in	O	['N']	[10]
11	renal	O	['N']	[11]
12	transplant	O	['N']	[12]
13	recipients	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	this	O	['N']	[16]
17	report	O	['N']	[17]
18	describes	O	['N']	[18]
19	a	O	['N']	[19]
20	stable	O	['N']	[20]
21	heart	O	['N']	[21]
22	-	O	['N']	[22]
23	lung	O	['N']	[23]
24	transplant	O	['N']	[24]
25	recipient	O	['N']	[25]
26	who	O	['N']	[26]
27	developed	O	['N']	[27]
28	a	O	['N']	[28]
29	pulmonary	O	['N']	[29]
30	infiltrate	O	['N']	[30]
31	that	O	['N']	[31]
32	reversed	O	['N']	[32]
33	after	O	['N']	[33]
34	ceasing	O	['N']	[34]
35	SR	O	['N']	[35]
36	therapy	O	['N']	[36]
37	.	O	['N']	[37]
#1047
0	Despite	O	['N']	[0]
1	a	O	['N']	[1]
2	response	O	['N']	[2]
3	of	O	['N']	[3]
4	the	O	['N']	[4]
5	meningeal	O	['N']	[5]
6	tumor	O	['N']	[6]
7	the	O	['N']	[7]
8	patient	O	['N']	[8]
9	developed	O	['N']	[9]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	third	O	['N']	[12]
13	week	O	['N']	[13]
14	of	O	['N']	[14]
15	MTX	B-Drug	['Causes']	[36]
16	treatment	O	['N']	[16]
17	a	O	['N']	[17]
18	progressive	O	['N']	[18]
19	visual	O	['N']	[19]
20	loss	O	['N']	[20]
21	and	O	['N']	[21]
22	loss	O	['N']	[22]
23	of	O	['N']	[23]
24	consciousness	O	['N']	[24]
25	which	O	['N']	[25]
26	worsened	O	['N']	[26]
27	during	O	['N']	[27]
28	subsequent	O	['N']	[28]
29	Ara	O	['N']	[29]
30	-	O	['N']	[30]
31	C	O	['N']	[31]
32	treatment	O	['N']	[32]
33	and	O	['N']	[33]
34	led	O	['N']	[34]
35	to	O	['N']	[35]
36	death	B-Adverse_Effect	['N']	[36]
37	within	O	['N']	[37]
38	3	O	['N']	[38]
39	weeks	O	['N']	[39]
40	.	O	['N']	[40]
#1048
0	Attempts	O	['N']	[0]
1	were	O	['N']	[1]
2	made	O	['N']	[2]
3	to	O	['N']	[3]
4	stop	O	['N']	[4]
5	and	O	['N']	[5]
6	then	O	['N']	[6]
7	restart	O	['N']	[7]
8	the	O	['N']	[8]
9	theophylline	B-Drug	['Causes']	[31]
10	therapy	O	['N']	[10]
11	at	O	['N']	[11]
12	progressively	O	['N']	[12]
13	lower	O	['N']	[13]
14	doses	O	['N']	[14]
15	;	O	['N']	[15]
16	however	O	['N']	[16]
17	,	O	['N']	[17]
18	with	O	['N']	[18]
19	each	O	['N']	[19]
20	attempt	O	['N']	[20]
21	,	O	['N']	[21]
22	the	O	['N']	[22]
23	patient	O	['N']	[23]
24	's	O	['N']	[24]
25	reaction	B	['N']	[25]
26	to	I	['N']	[26]
27	the	I	['N']	[27]
28	drug	I	['N']	[28]
29	became	I	['N']	[29]
30	more	I	['N']	[30]
31	toxic	I-Adverse_Effect	['N']	[31]
32	,	O	['N']	[32]
33	with	O	['N']	[33]
34	serum	O	['N']	[34]
35	theophylline	O	['N']	[35]
36	levels	O	['N']	[36]
37	ranging	O	['N']	[37]
38	between	O	['N']	[38]
39	99.9	O	['N']	[39]
40	and	O	['N']	[40]
41	149.9	O	['N']	[41]
42	micromol	O	['N']	[42]
43	/	O	['N']	[43]
44	L	O	['N']	[44]
45	(	O	['N']	[45]
46	18	O	['N']	[46]
47	and	O	['N']	[47]
48	27	O	['N']	[48]
49	microg	O	['N']	[49]
50	/	O	['N']	[50]
51	mL	O	['N']	[51]
52	)	O	['N']	[52]
53	.	O	['N']	[53]
#1049
0	Hypersensitivity	O	['N']	[0]
1	to	O	['N']	[1]
2	aspirin	B-Drug	['Causes']	[12]
3	can	O	['N']	[3]
4	be	O	['N']	[4]
5	manifested	O	['N']	[5]
6	as	O	['N']	[6]
7	acute	O	['N']	[7]
8	asthma	O	['N']	[8]
9	,	O	['N']	[9]
10	urticaria	O	['N']	[10]
11	and/or	O	['N']	[11]
12	angioedema	B-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	or	O	['N']	[14]
15	a	O	['N']	[15]
16	systemic	O	['N']	[16]
17	anaphylactoid	O	['N']	[17]
18	reaction	O	['N']	[18]
19	.	O	['N']	[19]
#1050
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	child	O	['N']	[3]
4	with	O	['N']	[4]
5	yolk	O	['N']	[5]
6	sac	O	['N']	[6]
7	tumor	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	localized	B	['N']	[10]
11	pigmentation	I-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	the	O	['N']	[13]
14	first	O	['N']	[14]
15	course	O	['N']	[15]
16	of	O	['N']	[16]
17	chemotherapy	O	['N']	[17]
18	regimen	O	['N']	[18]
19	that	O	['N']	[19]
20	included	O	['N']	[20]
21	cisplatin	B-Drug	['Causes']	[11]
22	,	O	['N']	[22]
23	etoposide	O	['N']	[23]
24	and	O	['N']	[24]
25	bleomycin	O	['N']	[25]
26	.	O	['N']	[26]
#1051
0	The	O	['N']	[0]
1	ulcer	B-Adverse_Effect	['N']	[1]
2	did	O	['N']	[2]
3	not	O	['N']	[3]
4	respond	O	['N']	[4]
5	to	O	['N']	[5]
6	antibiotic	O	['N']	[6]
7	treatment	O	['N']	[7]
8	and	O	['N']	[8]
9	healed	O	['N']	[9]
10	shortly	O	['N']	[10]
11	after	O	['N']	[11]
12	withholding	O	['N']	[12]
13	ATRA	B-Drug	['Causes']	[1]
14	.	O	['N']	[14]
#1052
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	possible	O	['N']	[7]
8	foscarnet	B-Drug	['Causes']	[12]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	severe	B	['N']	[11]
12	hypomagnesemia	I-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	other	O	['N']	[14]
15	electrolyte	O	['N']	[15]
16	disorders	O	['N']	[16]
17	.	O	['N']	[17]
#1053
0	Hydroxyurea	B-Drug	['Causes']	[8]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	concomitant	O	['N']	[3]
4	occurrence	O	['N']	[4]
5	of	O	['N']	[5]
6	diffuse	B	['N']	[6]
7	longitudinal	I	['N']	[7]
8	melanonychia	I-Adverse_Effect	['N']	[8]
9	and	O	['N']	[9]
10	multiple	O	['N']	[10]
11	squamous	O	['N']	[11]
12	cell	O	['N']	[12]
13	carcinomas	O	['N']	[13]
14	in	O	['N']	[14]
15	an	O	['N']	[15]
16	elderly	O	['N']	[16]
17	subject	O	['N']	[17]
18	.	O	['N']	[18]
#1054
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	life	O	['N']	[3]
4	threatening	O	['N']	[4]
5	side	O	['N']	[5]
6	effect	O	['N']	[6]
7	of	O	['N']	[7]
8	acute	O	['N']	[8]
9	epoprostenol	B-Drug	['Causes']	[13]
10	infusion	O	['N']	[10]
11	(	O	['N']	[11]
12	pulmonary	B	['N']	[12]
13	edema	I-Adverse_Effect	['N']	[13]
14	)	O	['N']	[14]
15	in	O	['N']	[15]
16	a	O	['N']	[16]
17	patient	O	['N']	[17]
18	with	O	['N']	[18]
19	pulmonary	O	['N']	[19]
20	hypertension	O	['N']	[20]
21	associated	O	['N']	[21]
22	with	O	['N']	[22]
23	limited	O	['N']	[23]
24	scleroderma	O	['N']	[24]
25	and	O	['N']	[25]
26	discuss	O	['N']	[26]
27	its	O	['N']	[27]
28	management	O	['N']	[28]
29	and	O	['N']	[29]
30	potential	O	['N']	[30]
31	etiology	O	['N']	[31]
32	.	O	['N']	[32]
#1055
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	granulocytopenia	B-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	fever	O	['N']	[8]
9	after	O	['N']	[9]
10	taking	O	['N']	[10]
11	dipyrone	B-Drug	['Causes']	[6]
12	and	O	['N']	[12]
13	discuss	O	['N']	[13]
14	the	O	['N']	[14]
15	available	O	['N']	[15]
16	literature	O	['N']	[16]
17	.	O	['N']	[17]
#1056
0	Gastric	O	['N']	[0]
1	tumor	O	['N']	[1]
2	,	O	['N']	[2]
3	endometrial	B	['N']	[3]
4	carcinoma	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	cervical	O	['N']	[6]
7	adenocarcinoma	O	['N']	[7]
8	in	O	['N']	[8]
9	situ	O	['N']	[9]
10	were	O	['N']	[10]
11	detected	O	['N']	[11]
12	after	O	['N']	[12]
13	treatment	O	['N']	[13]
14	with	O	['N']	[14]
15	tamoxifen	B-Drug	['Causes']	[4]
16	for	O	['N']	[16]
17	breast	O	['N']	[17]
18	cancer	O	['N']	[18]
19	.	O	['N']	[19]
#1057
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	59-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	chronic	O	['N']	[8]
9	myeloid	O	['N']	[9]
10	leukemia	O	['N']	[10]
11	,	O	['N']	[11]
12	who	O	['N']	[12]
13	developed	O	['N']	[13]
14	severe	B	['N']	[14]
15	interstitial	I	['N']	[15]
16	lung	I	['N']	[16]
17	fibrosis	I-Adverse_Effect	['N']	[17]
18	after	O	['N']	[18]
19	short	O	['N']	[19]
20	term	O	['N']	[20]
21	and	O	['N']	[21]
22	sequential	O	['N']	[22]
23	treatment	O	['N']	[23]
24	with	O	['N']	[24]
25	melphalan	O	['N']	[25]
26	and	O	['N']	[26]
27	busulfan	B-Drug	['Causes']	[17]
28	.	O	['N']	[28]
#1058
0	Development	O	['N']	[0]
1	of	O	['N']	[1]
2	Crohn	B	['N']	[2]
3	's	I	['N']	[3]
4	disease	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	multiple	O	['N']	[9]
10	sclerosis	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	copaxone	B-Drug	['Causes']	[4]
14	.	O	['N']	[14]
#1059
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Amphotericin	B	['N']	[2]
3	B	I-Drug	['Dosage']	[4]
4	overdose	B-Dose	['N']	[4]
5	can	O	['N']	[5]
6	be	O	['N']	[6]
7	fatal	O	['N']	[7]
8	in	O	['N']	[8]
9	children	O	['N']	[9]
10	and	O	['N']	[10]
11	infants	O	['N']	[11]
12	.	O	['N']	[12]
#1060
0	The	O	['N']	[0]
1	day	O	['N']	[1]
2	after	O	['N']	[2]
3	clozapine	O	['N']	[3]
4	was	O	['N']	[4]
5	stopped	O	['N']	[5]
6	,	O	['N']	[6]
7	while	O	['N']	[7]
8	he	O	['N']	[8]
9	was	O	['N']	[9]
10	still	O	['N']	[10]
11	receiving	O	['N']	[11]
12	clomipramine	B-Drug	['Causes']	[25]
13	150	O	['N']	[13]
14	mg	O	['N']	[14]
15	/	O	['N']	[15]
16	d	O	['N']	[16]
17	,	O	['N']	[17]
18	he	O	['N']	[18]
19	began	O	['N']	[19]
20	behaving	O	['N']	[20]
21	oddly	O	['N']	[21]
22	,	O	['N']	[22]
23	started	O	['N']	[23]
24	sweating	B	['N']	[24]
25	profusely	I-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	shivering	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	became	O	['N']	[30]
31	tremulous	O	['N']	[31]
32	,	O	['N']	[32]
33	agitated	O	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	confused	O	['N']	[36]
37	.	O	['N']	[37]
#1061
0	Skin	O	['N']	[0]
1	manifestations	O	['N']	[1]
2	of	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	phenylbutazone	B-Drug	['Causes']	[13]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	serum	B	['N']	[9]
10	sickness	I	['N']	[10]
11	-	I	['N']	[11]
12	like	I	['N']	[12]
13	reactions	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#1062
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	estimated	O	['N']	[3]
4	number	O	['N']	[4]
5	of	O	['N']	[5]
6	Accutane	B-Drug	['Causes']	[29]
7	prescriptions	O	['N']	[7]
8	for	O	['N']	[8]
9	reproductive	O	['N']	[9]
10	-	O	['N']	[10]
11	aged	O	['N']	[11]
12	women	O	['N']	[12]
13	has	O	['N']	[13]
14	more	O	['N']	[14]
15	than	O	['N']	[15]
16	doubled	O	['N']	[16]
17	in	O	['N']	[17]
18	the	O	['N']	[18]
19	past	O	['N']	[19]
20	10	O	['N']	[20]
21	years	O	['N']	[21]
22	;	O	['N']	[22]
23	it	O	['N']	[23]
24	is	O	['N']	[24]
25	the	O	['N']	[25]
26	most	O	['N']	[26]
27	widely	O	['N']	[27]
28	used	O	['N']	[28]
29	teratogenic	B-Adverse_Effect	['N']	[29]
30	drug	O	['N']	[30]
31	in	O	['N']	[31]
32	the	O	['N']	[32]
33	United	O	['N']	[33]
34	States	O	['N']	[34]
35	,	O	['N']	[35]
36	with	O	['N']	[36]
37	approximately	O	['N']	[37]
38	2.5	O	['N']	[38]
39	per	O	['N']	[39]
40	1,000	O	['N']	[40]
41	reproductive	O	['N']	[41]
42	-	O	['N']	[42]
43	aged	O	['N']	[43]
44	women	O	['N']	[44]
45	exposed	O	['N']	[45]
46	to	O	['N']	[46]
47	Accutane	O	['N']	[47]
48	in	O	['N']	[48]
49	1999	O	['N']	[49]
50	.	O	['N']	[50]
#1063
0	This	O	['N']	[0]
1	paper	O	['N']	[1]
2	reports	O	['N']	[2]
3	on	O	['N']	[3]
4	a	O	['N']	[4]
5	6.9-year	O	['N']	[5]
6	-	O	['N']	[6]
7	old	O	['N']	[7]
8	autistic	O	['N']	[8]
9	male	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	repeated	O	['N']	[12]
13	episodes	O	['N']	[13]
14	of	O	['N']	[14]
15	acute	B	['N']	[15]
16	dystonic	I	['N']	[16]
17	reactions	I-Adverse_Effect	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	pimozide	O	['N']	[20]
21	administration	O	['N']	[21]
22	at	O	['N']	[22]
23	the	O	['N']	[23]
24	doses	O	['N']	[24]
25	of	O	['N']	[25]
26	0.096	O	['N']	[26]
27	mg	O	['N']	[27]
28	/	O	['N']	[28]
29	kg	O	['N']	[29]
30	/	O	['N']	[30]
31	day	O	['N']	[31]
32	and	O	['N']	[32]
33	0.032	O	['N']	[33]
34	mg	O	['N']	[34]
35	/	O	['N']	[35]
36	kg	O	['N']	[36]
37	/	O	['N']	[37]
38	day	O	['N']	[38]
39	and	O	['N']	[39]
40	32	O	['N']	[40]
41	hours	O	['N']	[41]
42	following	O	['N']	[42]
43	pimozide	O	['N']	[43]
44	withdrawal	O	['N']	[44]
45	,	O	['N']	[45]
46	as	O	['N']	[46]
47	well	O	['N']	[47]
48	as	O	['N']	[48]
49	during	O	['N']	[49]
50	subsequent	O	['N']	[50]
51	thioridazine	B-Drug	['Causes']	[17]
52	administration	O	['N']	[52]
53	.	O	['N']	[53]
#1064
0	After	O	['N']	[0]
1	five	O	['N']	[1]
2	and	O	['N']	[2]
3	six	O	['N']	[3]
4	weeks	O	['N']	[4]
5	of	O	['N']	[5]
6	continuous	O	['N']	[6]
7	oral	O	['N']	[7]
8	administration	O	['N']	[8]
9	of	O	['N']	[9]
10	methylprednisolone	B-Drug	['Causes']	[16]
11	,	O	['N']	[11]
12	the	O	['N']	[12]
13	boys	O	['N']	[13]
14	developed	O	['N']	[14]
15	steroid	B	['N']	[15]
16	diabetes	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#1065
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	ovarian	O	['N']	[3]
4	cancer	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	received	O	['N']	[7]
8	multiple	O	['N']	[8]
9	courses	O	['N']	[9]
10	of	O	['N']	[10]
11	cisplatin	B-Drug	['Causes']	[29]
12	without	O	['N']	[12]
13	complications	O	['N']	[13]
14	experienced	O	['N']	[14]
15	hypersensitivity	O	['N']	[15]
16	reactions	O	['N']	[16]
17	to	O	['N']	[17]
18	cisplatin	O	['N']	[18]
19	:	O	['N']	[19]
20	one	O	['N']	[20]
21	,	O	['N']	[21]
22	involving	O	['N']	[22]
23	intrahepatic	O	['N']	[23]
24	artery	O	['N']	[24]
25	infusion	O	['N']	[25]
26	,	O	['N']	[26]
27	manifested	O	['N']	[27]
28	general	B	['N']	[28]
29	erythema	I-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	dyspnea	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	hypotension	O	['N']	[34]
35	;	O	['N']	[35]
36	the	O	['N']	[36]
37	other	O	['N']	[37]
38	,	O	['N']	[38]
39	involving	O	['N']	[39]
40	intravenous	O	['N']	[40]
41	infusion	O	['N']	[41]
42	,	O	['N']	[42]
43	manifested	O	['N']	[43]
44	abdominal	O	['N']	[44]
45	pain	O	['N']	[45]
46	,	O	['N']	[46]
47	general	O	['N']	[47]
48	erythema	O	['N']	[48]
49	,	O	['N']	[49]
50	and	O	['N']	[50]
51	fever	O	['N']	[51]
52	.	O	['N']	[52]
#1066
0	Treatment	O	['N']	[0]
1	with	O	['N']	[1]
2	infliximab	B-Drug	['Causes']	[13]
3	is	O	['N']	[3]
4	known	O	['N']	[4]
5	to	O	['N']	[5]
6	produce	O	['N']	[6]
7	an	O	['N']	[7]
8	increase	O	['N']	[8]
9	of	O	['N']	[9]
10	autoantibodies	O	['N']	[10]
11	(	O	['N']	[11]
12	antinuclear	B	['N']	[12]
13	antibodies	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	anti	O	['N']	[15]
16	-	O	['N']	[16]
17	double	O	['N']	[17]
18	-	O	['N']	[18]
19	stranded	O	['N']	[19]
20	DNA	O	['N']	[20]
21	)	O	['N']	[21]
22	,	O	['N']	[22]
23	but	O	['N']	[23]
24	not	O	['N']	[24]
25	clinical	O	['N']	[25]
26	disease	O	['N']	[26]
27	.	O	['N']	[27]
#1067
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	we	O	['N']	[3]
4	described	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	juvenile	O	['N']	[8]
9	idiopathic	O	['N']	[9]
10	arthritis	O	['N']	[10]
11	patient	O	['N']	[11]
12	who	O	['N']	[12]
13	developed	O	['N']	[13]
14	thymic	O	['N']	[14]
15	enlargement	O	['N']	[15]
16	(	O	['N']	[16]
17	true	O	['N']	[17]
18	thymic	B	['N']	[18]
19	hyperplasia	I-Adverse_Effect	['N']	[19]
20	)	O	['N']	[20]
21	,	O	['N']	[21]
22	mediastinal	O	['N']	[22]
23	lymphadenopathy	O	['N']	[23]
24	and	O	['N']	[24]
25	pleurisy	O	['N']	[25]
26	associated	O	['N']	[26]
27	with	O	['N']	[27]
28	systemic	O	['N']	[28]
29	symptoms	O	['N']	[29]
30	under	O	['N']	[30]
31	Etanercept	B-Drug	['Causes']	[19]
32	treatment	O	['N']	[32]
33	.	O	['N']	[33]
#1068
0	Fortunately	O	['N']	[0]
1	,	O	['N']	[1]
2	a	O	['N']	[2]
3	hypersensitivity	B	['N']	[3]
4	reaction	I-Adverse_Effect	['N']	[4]
5	to	O	['N']	[5]
6	one	O	['N']	[6]
7	formulation	O	['N']	[7]
8	of	O	['N']	[8]
9	cyclosporine	B-Drug	['Causes']	[4]
10	does	O	['N']	[10]
11	not	O	['N']	[11]
12	preclude	O	['N']	[12]
13	use	O	['N']	[13]
14	of	O	['N']	[14]
15	a	O	['N']	[15]
16	different	O	['N']	[16]
17	formulation	O	['N']	[17]
18	.	O	['N']	[18]
#1069
0	Growth	O	['N']	[0]
1	and	O	['N']	[1]
2	adrenal	O	['N']	[2]
3	suppression	O	['N']	[3]
4	in	O	['N']	[4]
5	asthmatic	O	['N']	[5]
6	children	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	high	B-Dose	['N']	[9]
10	-	O	['N']	[10]
11	dose	O	['N']	[11]
12	fluticasone	B	['N']	[12]
13	propionate	I-Drug	['Dosage']	[9]
14	.	O	['N']	[14]
#1070
0	Fludarabine	O	['N']	[0]
1	induced	O	['N']	[1]
2	lung	O	['N']	[2]
3	toxicity	O	['N']	[3]
4	must	O	['N']	[4]
5	be	O	['N']	[5]
6	considered	O	['N']	[6]
7	in	O	['N']	[7]
8	all	O	['N']	[8]
9	patients	O	['N']	[9]
10	who	O	['N']	[10]
11	develop	O	['N']	[11]
12	unexplained	O	['N']	[12]
13	lung	B	['N']	[13]
14	disease	I-Adverse_Effect	['N']	[14]
15	while	O	['N']	[15]
16	receiving	O	['N']	[16]
17	fludarabine	B-Drug	['Causes']	[14]
18	.	O	['N']	[18]
#1071
0	After	O	['N']	[0]
1	therapy	O	['N']	[1]
2	for	O	['N']	[2]
3	diabetic	O	['N']	[3]
4	coma	O	['N']	[4]
5	with	O	['N']	[5]
6	insulin	B-Drug	['Causes']	[29]
7	(	O	['N']	[7]
8	containing	O	['N']	[8]
9	the	O	['N']	[9]
10	preservative	O	['N']	[10]
11	cresol	O	['N']	[11]
12	)	O	['N']	[12]
13	and	O	['N']	[13]
14	electrolyte	O	['N']	[14]
15	solutions	O	['N']	[15]
16	was	O	['N']	[16]
17	started	O	['N']	[17]
18	,	O	['N']	[18]
19	the	O	['N']	[19]
20	patient	O	['N']	[20]
21	complained	O	['N']	[21]
22	of	O	['N']	[22]
23	increasing	O	['N']	[23]
24	myalgia	O	['N']	[24]
25	,	O	['N']	[25]
26	developed	O	['N']	[26]
27	a	O	['N']	[27]
28	high	B	['N']	[28]
29	fever	I-Adverse_Effect	['N']	[29]
30	and	O	['N']	[30]
31	respiratory	O	['N']	[31]
32	and	O	['N']	[32]
33	metabolic	O	['N']	[33]
34	acidosis	O	['N']	[34]
35	and	O	['N']	[35]
36	lost	O	['N']	[36]
37	consciousness	O	['N']	[37]
38	.	O	['N']	[38]
#1072
0	The	O	['N']	[0]
1	mechanism	O	['N']	[1]
2	of	O	['N']	[2]
3	anaphylactoid	B	['N']	[3]
4	reaction	I-Adverse_Effect	['N']	[4]
5	to	O	['N']	[5]
6	zomepirac	B-Drug	['Causes']	[4]
7	in	O	['N']	[7]
8	this	O	['N']	[8]
9	case	O	['N']	[9]
10	,	O	['N']	[10]
11	therefore	O	['N']	[11]
12	,	O	['N']	[12]
13	remains	O	['N']	[13]
14	unclear	O	['N']	[14]
15	.	O	['N']	[15]
#1073
0	Thyroid	B	['N']	[0]
1	dysfunction	I-Adverse_Effect	['N']	[1]
2	has	O	['N']	[2]
3	been	O	['N']	[3]
4	reported	O	['N']	[4]
5	in	O	['N']	[5]
6	patients	O	['N']	[6]
7	with	O	['N']	[7]
8	malignant	O	['N']	[8]
9	disease	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	recombinant	B	['N']	[12]
13	alpha	I	['N']	[13]
14	interferon	I-Drug	['Causes']	[1]
15	.	O	['N']	[15]
#1074
0	We	O	['N']	[0]
1	believe	O	['N']	[1]
2	this	O	['N']	[2]
3	is	O	['N']	[3]
4	the	O	['N']	[4]
5	first	O	['N']	[5]
6	report	O	['N']	[6]
7	of	O	['N']	[7]
8	myocardial	O	['N']	[8]
9	infarction	O	['N']	[9]
10	due	O	['N']	[10]
11	to	O	['N']	[11]
12	coronary	B	['N']	[12]
13	spasm	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	demonstrated	O	['N']	[15]
16	by	O	['N']	[16]
17	angiography	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	L	B	['N']	[20]
21	-	I	['N']	[21]
22	thyroxine	I-Drug	['Causes']	[13]
23	therapy	O	['N']	[23]
24	.	O	['N']	[24]
#1075
0	Anaphylaxis	B-Adverse_Effect	['N']	[0]
1	to	O	['N']	[1]
2	cisplatin	B-Drug	['Causes']	[0]
3	following	O	['N']	[3]
4	nine	O	['N']	[4]
5	previous	O	['N']	[5]
6	uncomplicated	O	['N']	[6]
7	cycles	O	['N']	[7]
8	.	O	['N']	[8]
#1076
0	Tigecycline	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	acute	B	['N']	[3]
4	pancreatitis	I-Adverse_Effect	['N']	[4]
5	:	O	['N']	[5]
6	case	O	['N']	[6]
7	report	O	['N']	[7]
8	and	O	['N']	[8]
9	literature	O	['N']	[9]
10	review	O	['N']	[10]
11	.	O	['N']	[11]
#1077
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	Graves	B	['N']	[5]
6	'	I	['N']	[6]
7	hyperthyroidism	I-Adverse_Effect	['N']	[7]
8	induced	O	['N']	[8]
9	by	O	['N']	[9]
10	long	O	['N']	[10]
11	-	O	['N']	[11]
12	term	O	['N']	[12]
13	interferon	B-Drug	['Causes']	[7]
14	(	O	['N']	[14]
15	IFN	O	['N']	[15]
16	)	O	['N']	[16]
17	therapy	O	['N']	[17]
18	.	O	['N']	[18]
#1078
0	Recurrent	B	['N']	[0]
1	hyponatremia	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	citalopram	O	['N']	[4]
5	and	O	['N']	[5]
6	mirtazapine	B-Drug	['Causes']	[1]
7	.	O	['N']	[7]
#1079
0	A	O	['N']	[0]
1	57-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	presented	O	['N']	[5]
6	with	O	['N']	[6]
7	a	O	['N']	[7]
8	3-week	O	['N']	[8]
9	history	O	['N']	[9]
10	of	O	['N']	[10]
11	dysphagia	B	['N']	[11]
12	for	I	['N']	[12]
13	solids	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	6	O	['N']	[15]
16	months	O	['N']	[16]
17	after	O	['N']	[17]
18	starting	O	['N']	[18]
19	treatment	O	['N']	[19]
20	with	O	['N']	[20]
21	nifedipine	B-Drug	['Causes']	[13]
22	.	O	['N']	[22]
#1080
0	The	O	['N']	[0]
1	field	B	['N']	[1]
2	defects	I-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	some	O	['N']	[4]
5	electrophysiological	O	['N']	[5]
6	abnormalities	O	['N']	[6]
7	persist	O	['N']	[7]
8	when	O	['N']	[8]
9	vigabatrin	B-Drug	['Causes']	[2]
10	therapy	O	['N']	[10]
11	is	O	['N']	[11]
12	withdrawn	O	['N']	[12]
13	.	O	['N']	[13]
#1081
0	A	O	['N']	[0]
1	woman	O	['N']	[1]
2	developed	O	['N']	[2]
3	delusional	B	['N']	[3]
4	parasitosis	I-Adverse_Effect	['N']	[4]
5	when	O	['N']	[5]
6	taking	O	['N']	[6]
7	phenelzine	B-Drug	['Causes']	[4]
8	.	O	['N']	[8]
#1082
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	nodular	B	['N']	[7]
8	scleritis	I-Adverse_Effect	['N']	[8]
9	following	O	['N']	[9]
10	alendronate	B	['N']	[10]
11	sodium	I-Drug	['Causes']	[8]
12	.	O	['N']	[12]
#1083
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	is	O	['N']	[2]
3	presented	O	['N']	[3]
4	which	O	['N']	[4]
5	illustrates	O	['N']	[5]
6	a	O	['N']	[6]
7	probably	O	['N']	[7]
8	fatal	B	['N']	[8]
9	interaction	I-Adverse_Effect	['N']	[9]
10	between	O	['N']	[10]
11	minoxidil	B-Drug	['Causes']	[9]
12	and	O	['N']	[12]
13	a	O	['N']	[13]
14	coagulation	O	['N']	[14]
15	disorder	O	['N']	[15]
16	.	O	['N']	[16]
#1084
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	are	O	['N']	[2]
3	described	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	sensory	O	['N']	[6]
7	neuropathy	O	['N']	[7]
8	after	O	['N']	[8]
9	the	O	['N']	[9]
10	ingestion	O	['N']	[10]
11	of	O	['N']	[11]
12	30.6	B-Dose	['N']	[12]
13	and	O	['N']	[13]
14	114	O	['N']	[14]
15	g	O	['N']	[15]
16	metronidazole	B-Drug	['Dosage']	[12]
17	respectively	O	['N']	[17]
18	.	O	['N']	[18]
#1085
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	fatal	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	toxic	O	['N']	[6]
7	epidermal	O	['N']	[7]
8	necrolysis	O	['N']	[8]
9	(	O	['N']	[9]
10	TEN	B-Adverse_Effect	['N']	[10]
11	)	O	['N']	[11]
12	resulting	O	['N']	[12]
13	from	O	['N']	[13]
14	a	O	['N']	[14]
15	high	O	['N']	[15]
16	dose	O	['N']	[16]
17	of	O	['N']	[17]
18	cytosine	O	['N']	[18]
19	arabinoside	O	['N']	[19]
20	(	O	['N']	[20]
21	ARA	B	['N']	[21]
22	-	I	['N']	[22]
23	C	I-Drug	['Causes']	[10]
24	)	O	['N']	[24]
25	.	O	['N']	[25]
#1086
0	The	O	['N']	[0]
1	possibility	O	['N']	[1]
2	of	O	['N']	[2]
3	phenytoin	B-Drug	['Causes']	[20]
4	hypersensitivity	O	['N']	[4]
5	reactions	O	['N']	[5]
6	should	O	['N']	[6]
7	be	O	['N']	[7]
8	considered	O	['N']	[8]
9	when	O	['N']	[9]
10	patients	O	['N']	[10]
11	receiving	O	['N']	[11]
12	phenytoin	O	['N']	[12]
13	have	O	['N']	[13]
14	unusual	O	['N']	[14]
15	symptoms	O	['N']	[15]
16	,	O	['N']	[16]
17	particularly	O	['N']	[17]
18	fever	O	['N']	[18]
19	,	O	['N']	[19]
20	rash	B-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	lymphadenopathy	O	['N']	[23]
24	.	O	['N']	[24]
#1087
0	INTRODUCTION	O	['N']	[0]
1	:	O	['N']	[1]
2	In	O	['N']	[2]
3	resource	O	['N']	[3]
4	limited	O	['N']	[4]
5	settings	O	['N']	[5]
6	patients	O	['N']	[6]
7	on	O	['N']	[7]
8	antiretroviral	O	['N']	[8]
9	treatment	O	['N']	[9]
10	who	O	['N']	[10]
11	develop	O	['N']	[11]
12	stavudine	B-Drug	['Causes']	[14]
13	induced	O	['N']	[13]
14	hyperlactatemia	B-Adverse_Effect	['N']	[14]
15	are	O	['N']	[15]
16	often	O	['N']	[16]
17	switched	O	['N']	[17]
18	to	O	['N']	[18]
19	zidovudine	O	['N']	[19]
20	on	O	['N']	[20]
21	the	O	['N']	[21]
22	basis	O	['N']	[22]
23	of	O	['N']	[23]
24	published	O	['N']	[24]
25	studies	O	['N']	[25]
26	that	O	['N']	[26]
27	demonstrate	O	['N']	[27]
28	that	O	['N']	[28]
29	this	O	['N']	[29]
30	agent	O	['N']	[30]
31	can	O	['N']	[31]
32	be	O	['N']	[32]
33	a	O	['N']	[33]
34	safe	O	['N']	[34]
35	alternative	O	['N']	[35]
36	.	O	['N']	[36]
#1088
0	Primary	O	['N']	[0]
1	cutaneous	O	['N']	[1]
2	coccidioidomycosis	O	['N']	[2]
3	and	O	['N']	[3]
4	subsequent	O	['N']	[4]
5	drug	B	['N']	[5]
6	eruption	I-Adverse_Effect	['N']	[6]
7	to	O	['N']	[7]
8	itraconazole	B-Drug	['Causes']	[6]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	dog	O	['N']	[11]
12	.	O	['N']	[12]
#1089
0	Danazol	B-Drug	['Causes']	[2]
1	induced	O	['N']	[1]
2	thrombocytopenia	B-Adverse_Effect	['N']	[2]
3	.	O	['N']	[3]
#1090
0	Post	O	['N']	[0]
1	marketing	O	['N']	[1]
2	studies	O	['N']	[2]
3	of	O	['N']	[3]
4	Interferon	O	['N']	[4]
5	-	O	['N']	[5]
6	beta	O	['N']	[6]
7	(	O	['N']	[7]
8	IFN	B	['N']	[8]
9	beta	I-Drug	['Causes']	[24]
10	)	O	['N']	[10]
11	therapy	O	['N']	[11]
12	in	O	['N']	[12]
13	multiple	O	['N']	[13]
14	sclerosis	O	['N']	[14]
15	(	O	['N']	[15]
16	MS	O	['N']	[16]
17	)	O	['N']	[17]
18	have	O	['N']	[18]
19	demonstrated	O	['N']	[19]
20	surprisingly	O	['N']	[20]
21	high	O	['N']	[21]
22	rates	O	['N']	[22]
23	of	O	['N']	[23]
24	hepatotoxicity	B-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#1091
0	Akathisia	B-Adverse_Effect	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	relatively	O	['N']	[3]
4	rare	O	['N']	[4]
5	side	O	['N']	[5]
6	effect	O	['N']	[6]
7	with	O	['N']	[7]
8	the	O	['N']	[8]
9	newer	O	['N']	[9]
10	atypical	O	['N']	[10]
11	antipsychotic	O	['N']	[11]
12	agents	O	['N']	[12]
13	,	O	['N']	[13]
14	particularly	O	['N']	[14]
15	clozapine	B-Drug	['Causes']	[0]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	is	O	['N']	[18]
19	easily	O	['N']	[19]
20	misdiagnosed	O	['N']	[20]
21	in	O	['N']	[21]
22	children	O	['N']	[22]
23	.	O	['N']	[23]
#1092
0	Cerebrovascular	O	['N']	[0]
1	complications	O	['N']	[1]
2	of	O	['N']	[2]
3	L	B	['N']	[3]
4	-	I	['N']	[4]
5	asparaginase	I-Drug	['Causes']	[12]
6	therapy	O	['N']	[6]
7	in	O	['N']	[7]
8	children	O	['N']	[8]
9	with	O	['N']	[9]
10	leukemia	O	['N']	[10]
11	:	O	['N']	[11]
12	aphasia	B-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	other	O	['N']	[14]
15	neuropsychological	O	['N']	[15]
16	deficits	O	['N']	[16]
17	.	O	['N']	[17]
#1093
0	The	O	['N']	[0]
1	other	O	['N']	[1]
2	woman	O	['N']	[2]
3	had	O	['N']	[3]
4	rheumatoid	O	['N']	[4]
5	arthritis	O	['N']	[5]
6	and	O	['N']	[6]
7	developed	O	['N']	[7]
8	acute	B	['N']	[8]
9	tubular	I	['N']	[9]
10	necrosis	I-Adverse_Effect	['N']	[10]
11	after	O	['N']	[11]
12	treatment	O	['N']	[12]
13	with	O	['N']	[13]
14	gentamicin	O	['N']	[14]
15	and	O	['N']	[15]
16	cefoxitin	B-Drug	['Causes']	[10]
17	.	O	['N']	[17]
#1094
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	lung	O	['N']	[6]
7	cancer	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	bronquiloalveolar	O	['N']	[10]
11	carcinoma	O	['N']	[11]
12	(	O	['N']	[12]
13	BAC	O	['N']	[13]
14	)	O	['N']	[14]
15	presenting	O	['N']	[15]
16	with	O	['N']	[16]
17	BOOP	O	['N']	[17]
18	after	O	['N']	[18]
19	chemotherapy	O	['N']	[19]
20	with	O	['N']	[20]
21	docetaxel	B-Drug	['Causes']	[27]
22	and	O	['N']	[22]
23	gemcitabine	O	['N']	[23]
24	producing	O	['N']	[24]
25	severe	B	['N']	[25]
26	respiratory	I	['N']	[26]
27	insufficiency	I-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	simulating	O	['N']	[30]
31	a	O	['N']	[31]
32	progression	O	['N']	[32]
33	of	O	['N']	[33]
34	the	O	['N']	[34]
35	tumor	O	['N']	[35]
36	.	O	['N']	[36]
#1095
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Metoclopramide	B-Drug	['Causes']	[11]
3	may	O	['N']	[3]
4	cause	O	['N']	[4]
5	reversible	O	['N']	[5]
6	nonthrombocytopenic	B	['N']	[6]
7	vascular	I	['N']	[7]
8	-	I	['N']	[8]
9	type	I	['N']	[9]
10	palpable	I	['N']	[10]
11	purpura	I-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#1096
0	Since	O	['N']	[0]
1	elevated	O	['N']	[1]
2	cortisol	O	['N']	[2]
3	levels	O	['N']	[3]
4	in	O	['N']	[4]
5	Cushing	O	['N']	[5]
6	's	O	['N']	[6]
7	disease	O	['N']	[7]
8	poses	O	['N']	[8]
9	a	O	['N']	[9]
10	threat	O	['N']	[10]
11	for	O	['N']	[11]
12	pancreatitis	O	['N']	[12]
13	,	O	['N']	[13]
14	there	O	['N']	[14]
15	is	O	['N']	[15]
16	a	O	['N']	[16]
17	possibility	O	['N']	[17]
18	that	O	['N']	[18]
19	patients	O	['N']	[19]
20	with	O	['N']	[20]
21	Cushing	O	['N']	[21]
22	's	O	['N']	[22]
23	disease	O	['N']	[23]
24	might	O	['N']	[24]
25	be	O	['N']	[25]
26	more	O	['N']	[26]
27	prone	O	['N']	[27]
28	to	O	['N']	[28]
29	acute	B	['N']	[29]
30	pancreatitis	I-Adverse_Effect	['N']	[30]
31	following	O	['N']	[31]
32	propofol	B-Drug	['Causes']	[30]
33	administration	O	['N']	[33]
34	.	O	['N']	[34]
#1097
0	Recombinant	B	['N']	[0]
1	human	I	['N']	[1]
2	interferon	I	['N']	[2]
3	-	I	['N']	[3]
4	alpha	I-Drug	['Causes']	[30]
5	has	O	['N']	[5]
6	been	O	['N']	[6]
7	used	O	['N']	[7]
8	in	O	['N']	[8]
9	the	O	['N']	[9]
10	treatment	O	['N']	[10]
11	of	O	['N']	[11]
12	several	O	['N']	[12]
13	cancers	O	['N']	[13]
14	,	O	['N']	[14]
15	but	O	['N']	[15]
16	there	O	['N']	[16]
17	have	O	['N']	[17]
18	been	O	['N']	[18]
19	several	O	['N']	[19]
20	reports	O	['N']	[20]
21	that	O	['N']	[21]
22	it	O	['N']	[22]
23	may	O	['N']	[23]
24	exacerbate	B	['N']	[24]
25	psoriasis	I	['N']	[25]
26	or	I	['N']	[26]
27	trigger	I	['N']	[27]
28	off	I	['N']	[28]
29	its	I	['N']	[29]
30	onset	I-Adverse_Effect	['N']	[30]
31	.	O	['N']	[31]
#1098
0	Presented	O	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	story	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	woman	O	['N']	[7]
8	with	O	['N']	[8]
9	classical	O	['N']	[9]
10	rheumatoid	O	['N']	[10]
11	arthritis	O	['N']	[11]
12	,	O	['N']	[12]
13	who	O	['N']	[13]
14	during	O	['N']	[14]
15	introduction	O	['N']	[15]
16	of	O	['N']	[16]
17	sulphasalazine	O	['N']	[17]
18	(	O	['N']	[18]
19	SASP	B-Drug	['Causes']	[31]
20	)	O	['N']	[20]
21	therapy	O	['N']	[21]
22	developed	O	['N']	[22]
23	a	O	['N']	[23]
24	severe	O	['N']	[24]
25	and	O	['N']	[25]
26	lasting	O	['N']	[26]
27	psoriasis	B	['N']	[27]
28	-	I	['N']	[28]
29	like	I	['N']	[29]
30	skin	I	['N']	[30]
31	reaction	I-Adverse_Effect	['N']	[31]
32	.	O	['N']	[32]
#1099
0	Quinapril	B-Drug	['Causes']	[19]
1	is	O	['N']	[1]
2	an	O	['N']	[2]
3	angiotensin	O	['N']	[3]
4	-	O	['N']	[4]
5	converting	O	['N']	[5]
6	enzyme	O	['N']	[6]
7	inhibitor	O	['N']	[7]
8	(	O	['N']	[8]
9	ACE	O	['N']	[9]
10	-	O	['N']	[10]
11	inhibitor	O	['N']	[11]
12	)	O	['N']	[12]
13	and	O	['N']	[13]
14	overdose	O	['N']	[14]
15	can	O	['N']	[15]
16	lead	O	['N']	[16]
17	to	O	['N']	[17]
18	prolonged	B	['N']	[18]
19	hypotension	I-Adverse_Effect	['N']	[19]
20	and	O	['N']	[20]
21	,	O	['N']	[21]
22	less	O	['N']	[22]
23	frequently	O	['N']	[23]
24	,	O	['N']	[24]
25	transient	O	['N']	[25]
26	renal	O	['N']	[26]
27	impairment	O	['N']	[27]
28	.	O	['N']	[28]
#1100
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	,	O	['N']	[2]
3	in	O	['N']	[3]
4	whom	O	['N']	[4]
5	tumour	O	['N']	[5]
6	overkill	O	['N']	[6]
7	by	O	['N']	[7]
8	cytotoxic	O	['N']	[8]
9	treatment	O	['N']	[9]
10	,	O	['N']	[10]
11	including	O	['N']	[11]
12	high	O	['N']	[12]
13	dose	O	['N']	[13]
14	methotrexate	B-Drug	['Causes']	[43]
15	with	O	['N']	[15]
16	folinic	O	['N']	[16]
17	acid	O	['N']	[17]
18	rescue	O	['N']	[18]
19	,	O	['N']	[19]
20	resulted	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	'	O	['N']	[23]
24	phosphate	O	['N']	[24]
25	shower	O	['N']	[25]
26	syndrome	O	['N']	[26]
27	'	O	['N']	[27]
28	(	O	['N']	[28]
29	hyper	O	['N']	[29]
30	-	O	['N']	[30]
31	uricaemia	O	['N']	[31]
32	,	O	['N']	[32]
33	hyperkalaemia	O	['N']	[33]
34	and	O	['N']	[34]
35	hyperphosphataemia	O	['N']	[35]
36	with	O	['N']	[36]
37	hypocalcaemia	O	['N']	[37]
38	and	O	['N']	[38]
39	tetany	O	['N']	[39]
40	,	O	['N']	[40]
41	with	O	['N']	[41]
42	metabolic	B	['N']	[42]
43	acidosis	I-Adverse_Effect	['N']	[43]
44	and	O	['N']	[44]
45	acute	O	['N']	[45]
46	renal	O	['N']	[46]
47	impairment	O	['N']	[47]
48	)	O	['N']	[48]
49	are	O	['N']	[49]
50	described	O	['N']	[50]
51	.	O	['N']	[51]
#1101
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	describes	O	['N']	[2]
3	fulminant	B	['N']	[3]
4	hepatic	I	['N']	[4]
5	failure	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	taking	O	['N']	[9]
10	disulfiram	B-Drug	['Causes']	[5]
11	with	O	['N']	[11]
12	no	O	['N']	[12]
13	previous	O	['N']	[13]
14	liver	O	['N']	[14]
15	disease	O	['N']	[15]
16	and	O	['N']	[16]
17	report	O	['N']	[17]
18	of	O	['N']	[18]
19	being	O	['N']	[19]
20	compliant	O	['N']	[20]
21	with	O	['N']	[21]
22	alcohol	O	['N']	[22]
23	abstinence	O	['N']	[23]
24	.	O	['N']	[24]
#1102
0	Argatroban	O	['N']	[0]
1	for	O	['N']	[1]
2	heparin	B-Drug	['Causes']	[5]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	thrombocytopenia	B-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	hepato	O	['N']	[7]
8	-	O	['N']	[8]
9	renal	O	['N']	[9]
10	failure	O	['N']	[10]
11	and	O	['N']	[11]
12	CVVHD	O	['N']	[12]
13	.	O	['N']	[13]
#1103
0	Acute	B	['N']	[0]
1	pulmonary	I	['N']	[1]
2	reactions	I-Adverse_Effect	['N']	[2]
3	to	O	['N']	[3]
4	nitrofurantoin	B-Drug	['Causes']	[2]
5	are	O	['N']	[5]
6	an	O	['N']	[6]
7	uncommon	O	['N']	[7]
8	side	O	['N']	[8]
9	effect	O	['N']	[9]
10	of	O	['N']	[10]
11	therapy	O	['N']	[11]
12	and	O	['N']	[12]
13	can	O	['N']	[13]
14	cause	O	['N']	[14]
15	minor	O	['N']	[15]
16	or	O	['N']	[16]
17	life	O	['N']	[17]
18	-	O	['N']	[18]
19	threatening	O	['N']	[19]
20	pulmonary	O	['N']	[20]
21	dysfunction	O	['N']	[21]
22	.	O	['N']	[22]
#1104
0	A	O	['N']	[0]
1	child	O	['N']	[1]
2	in	O	['N']	[2]
3	whom	O	['N']	[3]
4	a	O	['N']	[4]
5	phenobarbital	B-Drug	['Causes']	[33]
6	hypersensitivity	O	['N']	[6]
7	drug	O	['N']	[7]
8	reaction	O	['N']	[8]
9	developed	O	['N']	[9]
10	which	O	['N']	[10]
11	consisted	O	['N']	[11]
12	of	O	['N']	[12]
13	fever	O	['N']	[13]
14	,	O	['N']	[14]
15	a	O	['N']	[15]
16	pruritic	O	['N']	[16]
17	desquamating	O	['N']	[17]
18	erythrodermic	O	['N']	[18]
19	rash	O	['N']	[19]
20	,	O	['N']	[20]
21	alopecia	O	['N']	[21]
22	,	O	['N']	[22]
23	icterus	O	['N']	[23]
24	,	O	['N']	[24]
25	protein	O	['N']	[25]
26	-	O	['N']	[26]
27	losing	O	['N']	[27]
28	enteropathy	O	['N']	[28]
29	,	O	['N']	[29]
30	myositis	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	nephritis	B-Adverse_Effect	['N']	[33]
34	,	O	['N']	[34]
35	is	O	['N']	[35]
36	described	O	['N']	[36]
37	.	O	['N']	[37]
#1105
0	Disseminated	B	['N']	[0]
1	intravascular	I	['N']	[1]
2	coagulation	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	acute	O	['N']	[5]
6	hemoglobinemia	O	['N']	[6]
7	or	O	['N']	[7]
8	hemoglobinuria	O	['N']	[8]
9	following	O	['N']	[9]
10	Rh(0)(D	B	['N']	[10]
11	)	I	['N']	[11]
12	immune	I	['N']	[12]
13	globulin	I-Drug	['Causes']	[2]
14	intravenous	O	['N']	[14]
15	administration	O	['N']	[15]
16	for	O	['N']	[16]
17	immune	O	['N']	[17]
18	thrombocytopenic	O	['N']	[18]
19	purpura	O	['N']	[19]
20	.	O	['N']	[20]
#1106
0	Normalization	O	['N']	[0]
1	of	O	['N']	[1]
2	generalized	O	['N']	[2]
3	retinal	O	['N']	[3]
4	function	O	['N']	[4]
5	and	O	['N']	[5]
6	progression	O	['N']	[6]
7	of	O	['N']	[7]
8	maculopathy	O	['N']	[8]
9	after	O	['N']	[9]
10	cessation	O	['N']	[10]
11	of	O	['N']	[11]
12	therapy	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	case	O	['N']	[15]
16	of	O	['N']	[16]
17	severe	O	['N']	[17]
18	hydroxychloroquine	B-Drug	['Causes']	[19]
19	retinopathy	B-Adverse_Effect	['N']	[19]
20	with	O	['N']	[20]
21	19	O	['N']	[21]
22	years	O	['N']	[22]
23	follow	O	['N']	[23]
24	-	O	['N']	[24]
25	up	O	['N']	[25]
26	.	O	['N']	[26]
#1107
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	nitrofurantoin	B-Drug	['Causes']	[26]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	pulmonary	O	['N']	[8]
9	toxicity	O	['N']	[9]
10	in	O	['N']	[10]
11	which	O	['N']	[11]
12	the	O	['N']	[12]
13	initial	O	['N']	[13]
14	HRCT	O	['N']	[14]
15	showed	O	['N']	[15]
16	a	O	['N']	[16]
17	widespread	O	['N']	[17]
18	reticular	O	['N']	[18]
19	pattern	O	['N']	[19]
20	and	O	['N']	[20]
21	associated	O	['N']	[21]
22	distortion	B	['N']	[22]
23	of	I	['N']	[23]
24	the	I	['N']	[24]
25	lung	I	['N']	[25]
26	parenchyma	I-Adverse_Effect	['N']	[26]
27	,	O	['N']	[27]
28	thought	O	['N']	[28]
29	to	O	['N']	[29]
30	represent	O	['N']	[30]
31	established	O	['N']	[31]
32	fibrosis	O	['N']	[32]
33	.	O	['N']	[33]
#1108
0	RTA	O	['N']	[0]
1	is	O	['N']	[1]
2	one	O	['N']	[2]
3	type	O	['N']	[3]
4	of	O	['N']	[4]
5	nephrotoxicity	B-Adverse_Effect	['N']	[5]
6	induced	O	['N']	[6]
7	by	O	['N']	[7]
8	FK506	B-Drug	['Causes']	[5]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	it	O	['N']	[11]
12	is	O	['N']	[12]
13	reversible	O	['N']	[13]
14	in	O	['N']	[14]
15	mild	O	['N']	[15]
16	cases	O	['N']	[16]
17	when	O	['N']	[17]
18	appropriately	O	['N']	[18]
19	treated	O	['N']	[19]
20	.	O	['N']	[20]
#1109
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	intoxication	B-Adverse_Effect	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	41-year	O	['N']	[8]
9	-	O	['N']	[9]
10	old	O	['N']	[10]
11	female	O	['N']	[11]
12	patient	O	['N']	[12]
13	suffering	O	['N']	[13]
14	from	O	['N']	[14]
15	major	O	['N']	[15]
16	depression	O	['N']	[16]
17	with	O	['N']	[17]
18	mirtazapine	B-Drug	['Causes']	[5]
19	complicated	O	['N']	[19]
20	by	O	['N']	[20]
21	severe	O	['N']	[21]
22	hypothermia	O	['N']	[22]
23	.	O	['N']	[23]
#1110
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Jet	O	['N']	[2]
3	-	O	['N']	[3]
4	injection	O	['N']	[4]
5	devices	O	['N']	[5]
6	might	O	['N']	[6]
7	constitute	O	['N']	[7]
8	a	O	['N']	[8]
9	helpful	O	['N']	[9]
10	method	O	['N']	[10]
11	to	O	['N']	[11]
12	treat	O	['N']	[12]
13	those	O	['N']	[13]
14	patients	O	['N']	[14]
15	affected	O	['N']	[15]
16	by	O	['N']	[16]
17	severe	O	['N']	[17]
18	human	B	['N']	[18]
19	insulin	I-Drug	['Causes']	[22]
20	-	O	['N']	[20]
21	induced	O	['N']	[21]
22	lipoatrophy	B-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#1111
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	a	O	['N']	[2]
3	recent	O	['N']	[3]
4	post	O	['N']	[4]
5	-	O	['N']	[5]
6	marketing	O	['N']	[6]
7	survey	O	['N']	[7]
8	in	O	['N']	[8]
9	Japan	O	['N']	[9]
10	revealed	O	['N']	[10]
11	that	O	['N']	[11]
12	interstitial	B	['N']	[12]
13	pneumonia	I-Adverse_Effect	['N']	[13]
14	occurred	O	['N']	[14]
15	in	O	['N']	[15]
16	4	O	['N']	[16]
17	among	O	['N']	[17]
18	approximately	O	['N']	[18]
19	2	O	['N']	[19]
20	000	O	['N']	[20]
21	Japanese	O	['N']	[21]
22	patients	O	['N']	[22]
23	treated	O	['N']	[23]
24	with	O	['N']	[24]
25	sorafenib	B-Drug	['Causes']	[13]
26	.	O	['N']	[26]
#1112
0	This	O	['N']	[0]
1	selective	O	['N']	[1]
2	closure	O	['N']	[2]
3	of	O	['N']	[3]
4	the	O	['N']	[4]
5	ductus	O	['N']	[5]
6	arteriosus	O	['N']	[6]
7	suggests	O	['N']	[7]
8	that	O	['N']	[8]
9	the	O	['N']	[9]
10	affected	O	['N']	[10]
11	twin	O	['N']	[11]
12	was	O	['N']	[12]
13	predisposed	O	['N']	[13]
14	to	O	['N']	[14]
15	hypoxia	O	['N']	[15]
16	and	O	['N']	[16]
17	thus	O	['N']	[17]
18	was	O	['N']	[18]
19	more	O	['N']	[19]
20	susceptible	O	['N']	[20]
21	to	O	['N']	[21]
22	ductal	B	['N']	[22]
23	closure	I-Adverse_Effect	['N']	[23]
24	in	O	['N']	[24]
25	response	O	['N']	[25]
26	to	O	['N']	[26]
27	indomethacin	B-Drug	['Causes']	[23]
28	exposure	O	['N']	[28]
29	.	O	['N']	[29]
#1113
0	There	O	['N']	[0]
1	have	O	['N']	[1]
2	been	O	['N']	[2]
3	several	O	['N']	[3]
4	reported	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	omeprazole	B-Drug	['Causes']	[10]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	AIN	B-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#1114
0	We	O	['N']	[0]
1	observed	O	['N']	[1]
2	5	O	['N']	[2]
3	reactions	O	['N']	[3]
4	in	O	['N']	[4]
5	3	O	['N']	[5]
6	patients	O	['N']	[6]
7	that	O	['N']	[7]
8	appear	O	['N']	[8]
9	to	O	['N']	[9]
10	be	O	['N']	[10]
11	related	O	['N']	[11]
12	to	O	['N']	[12]
13	a	O	['N']	[13]
14	high	O	['N']	[14]
15	dose	O	['N']	[15]
16	-	O	['N']	[16]
17	infusion	O	['N']	[17]
18	time	O	['N']	[18]
19	ratio	O	['N']	[19]
20	,	O	['N']	[20]
21	indicating	O	['N']	[21]
22	that	O	['N']	[22]
23	dose	O	['N']	[23]
24	and	O	['N']	[24]
25	rate	O	['N']	[25]
26	of	O	['N']	[26]
27	infusion	O	['N']	[27]
28	may	O	['N']	[28]
29	be	O	['N']	[29]
30	important	O	['N']	[30]
31	factors	O	['N']	[31]
32	in	O	['N']	[32]
33	precipitating	O	['N']	[33]
34	anaphylactoid	B	['N']	[34]
35	reactions	I-Adverse_Effect	['N']	[35]
36	with	O	['N']	[36]
37	cisplatin	B-Drug	['Causes']	[35]
38	.	O	['N']	[38]
#1115
0	Anterior	B	['N']	[0]
1	ischemic	I	['N']	[1]
2	optic	I	['N']	[2]
3	neuropathy	I-Adverse_Effect	['N']	[3]
4	secondary	O	['N']	[4]
5	to	O	['N']	[5]
6	interferon	B	['N']	[6]
7	alfa	I-Drug	['Causes']	[3]
8	.	O	['N']	[8]
#1116
0	Bleomycin	B-Drug	['Causes']	[2]
1	induced	O	['N']	[1]
2	hyperpigmentation	B-Adverse_Effect	['N']	[2]
3	with	O	['N']	[3]
4	yolk	O	['N']	[4]
5	sac	O	['N']	[5]
6	tumor	O	['N']	[6]
7	.	O	['N']	[7]
#1117
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	concluded	O	['N']	[2]
3	that	O	['N']	[3]
4	'	O	['N']	[4]
5	cerebral	B	['N']	[5]
6	atrophy	I-Adverse_Effect	['N']	[6]
7	'	O	['N']	[7]
8	on	O	['N']	[8]
9	CT	O	['N']	[9]
10	scans	O	['N']	[10]
11	may	O	['N']	[11]
12	represent	O	['N']	[12]
13	an	O	['N']	[13]
14	accumulative	O	['N']	[14]
15	effect	O	['N']	[15]
16	of	O	['N']	[16]
17	ACTH	B-Drug	['Causes']	[6]
18	and	O	['N']	[18]
19	that	O	['N']	[19]
20	ACTH	O	['N']	[20]
21	should	O	['N']	[21]
22	be	O	['N']	[22]
23	given	O	['N']	[23]
24	with	O	['N']	[24]
25	the	O	['N']	[25]
26	utmost	O	['N']	[26]
27	discretion	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	in	O	['N']	[30]
31	as	O	['N']	[31]
32	low	O	['N']	[32]
33	a	O	['N']	[33]
34	dose	O	['N']	[34]
35	as	O	['N']	[35]
36	possible	O	['N']	[36]
37	.	O	['N']	[37]
#1118
0	Cardiac	B	['N']	[0]
1	arrest	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	esmolol	B-Drug	['Causes']	[1]
4	administration	O	['N']	[4]
5	:	O	['N']	[5]
6	a	O	['N']	[6]
7	review	O	['N']	[7]
8	of	O	['N']	[8]
9	acute	O	['N']	[9]
10	beta	O	['N']	[10]
11	-	O	['N']	[11]
12	blocker	O	['N']	[12]
13	toxicity	O	['N']	[13]
14	.	O	['N']	[14]
#1119
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	NEH	B-Adverse_Effect	['N']	[6]
7	on	O	['N']	[7]
8	three	O	['N']	[8]
9	separate	O	['N']	[9]
10	occasions	O	['N']	[10]
11	provoked	O	['N']	[11]
12	by	O	['N']	[12]
13	two	O	['N']	[13]
14	different	O	['N']	[14]
15	chemotherapeutic	O	['N']	[15]
16	agents	O	['N']	[16]
17	--	O	['N']	[17]
18	cytarabine	O	['N']	[18]
19	and	O	['N']	[19]
20	mitoxantrone	B-Drug	['Causes']	[6]
21	.	O	['N']	[21]
#1120
0	Although	O	['N']	[0]
1	retinoic	B	['N']	[1]
2	acid	I-Drug	['Causes']	[18]
3	is	O	['N']	[3]
4	well	O	['N']	[4]
5	tolerated	O	['N']	[5]
6	by	O	['N']	[6]
7	the	O	['N']	[7]
8	majority	O	['N']	[8]
9	of	O	['N']	[9]
10	patients	O	['N']	[10]
11	with	O	['N']	[11]
12	this	O	['N']	[12]
13	disease	O	['N']	[13]
14	,	O	['N']	[14]
15	a	O	['N']	[15]
16	potentially	O	['N']	[16]
17	fatal	B	['N']	[17]
18	complication	I-Adverse_Effect	['N']	[18]
19	of	O	['N']	[19]
20	this	O	['N']	[20]
21	kind	O	['N']	[21]
22	of	O	['N']	[22]
23	treatment	O	['N']	[23]
24	has	O	['N']	[24]
25	been	O	['N']	[25]
26	reported	O	['N']	[26]
27	:	O	['N']	[27]
28	"	O	['N']	[28]
29	the	O	['N']	[29]
30	retinoic	O	['N']	[30]
31	acid	O	['N']	[31]
32	syndrome	O	['N']	[32]
33	"	O	['N']	[33]
34	.	O	['N']	[34]
#1121
0	Ibuprofen	B-Drug	['Causes']	[6]
1	rarely	O	['N']	[1]
2	causes	O	['N']	[2]
3	lower	O	['N']	[3]
4	gastrointestinal	B	['N']	[4]
5	adverse	I	['N']	[5]
6	reactions	I-Adverse_Effect	['N']	[6]
7	but	O	['N']	[7]
8	has	O	['N']	[8]
9	been	O	['N']	[9]
10	implicated	O	['N']	[10]
11	in	O	['N']	[11]
12	systemic	O	['N']	[12]
13	and	O	['N']	[13]
14	local	O	['N']	[14]
15	side	O	['N']	[15]
16	effects	O	['N']	[16]
17	in	O	['N']	[17]
18	patients	O	['N']	[18]
19	with	O	['N']	[19]
20	lupus	O	['N']	[20]
21	.	O	['N']	[21]
#1122
0	Atrial	O	['N']	[0]
1	fibrillation	O	['N']	[1]
2	was	O	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	diltiazem	O	['N']	[5]
6	in	O	['N']	[6]
7	two	O	['N']	[7]
8	patients	O	['N']	[8]
9	and	O	['N']	[9]
10	verapamil	B-Drug	['Causes']	[12]
11	induced	O	['N']	[11]
12	syncope	B-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	one	O	['N']	[14]
15	patient	O	['N']	[15]
16	.	O	['N']	[16]
#1123
0	Idiosyncratic	B	['N']	[0]
1	pulmonary	I	['N']	[1]
2	reactions	I-Adverse_Effect	['N']	[2]
3	to	O	['N']	[3]
4	nitrofurantoin	B-Drug	['Causes']	[2]
5	are	O	['N']	[5]
6	not	O	['N']	[6]
7	unusual	O	['N']	[7]
8	,	O	['N']	[8]
9	often	O	['N']	[9]
10	presenting	O	['N']	[10]
11	as	O	['N']	[11]
12	eosinophilic	O	['N']	[12]
13	pneumonia	O	['N']	[13]
14	.	O	['N']	[14]
#1124
0	Gangrene	B-Adverse_Effect	['N']	[0]
1	of	O	['N']	[1]
2	the	O	['N']	[2]
3	fingertips	O	['N']	[3]
4	after	O	['N']	[4]
5	bleomycin	B-Drug	['Causes']	[0]
6	and	O	['N']	[6]
7	methotrexate	O	['N']	[7]
8	.	O	['N']	[8]
#1125
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	acute	O	['N']	[5]
6	myeloblastic	O	['N']	[6]
7	leukemia	O	['N']	[7]
8	(	O	['N']	[8]
9	AML	O	['N']	[9]
10	)	O	['N']	[10]
11	who	O	['N']	[11]
12	developed	O	['N']	[12]
13	nephrotic	B	['N']	[13]
14	syndrome	I-Adverse_Effect	['N']	[14]
15	after	O	['N']	[15]
16	receiving	O	['N']	[16]
17	several	O	['N']	[17]
18	courses	O	['N']	[18]
19	of	O	['N']	[19]
20	chemotherapy	O	['N']	[20]
21	,	O	['N']	[21]
22	including	O	['N']	[22]
23	macrophage	B	['N']	[23]
24	-	I	['N']	[24]
25	colony	I	['N']	[25]
26	-	I	['N']	[26]
27	stimulating	I	['N']	[27]
28	factor	I-Drug	['Causes']	[14]
29	(	O	['N']	[29]
30	M	O	['N']	[30]
31	-	O	['N']	[31]
32	CSF	O	['N']	[32]
33	)	O	['N']	[33]
34	.	O	['N']	[34]
#1126
0	Acute	B	['N']	[0]
1	respiratory	I	['N']	[1]
2	distress	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	rituximab	B-Drug	['Causes']	[3]
6	infusion	O	['N']	[6]
7	.	O	['N']	[7]
#1127
0	With	O	['N']	[0]
1	the	O	['N']	[1]
2	use	O	['N']	[2]
3	of	O	['N']	[3]
4	optical	O	['N']	[4]
5	coherence	O	['N']	[5]
6	tomography	O	['N']	[6]
7	(	O	['N']	[7]
8	OCT	O	['N']	[8]
9	)	O	['N']	[9]
10	,	O	['N']	[10]
11	two	O	['N']	[11]
12	patients	O	['N']	[12]
13	with	O	['N']	[13]
14	IFN	B-Drug	['Causes']	[22]
15	-	O	['N']	[15]
16	associated	O	['N']	[16]
17	retinopathy	O	['N']	[17]
18	who	O	['N']	[18]
19	had	O	['N']	[19]
20	developed	O	['N']	[20]
21	macular	B	['N']	[21]
22	edema	I-Adverse_Effect	['N']	[22]
23	and	O	['N']	[23]
24	reduced	O	['N']	[24]
25	visual	O	['N']	[25]
26	acuity	O	['N']	[26]
27	during	O	['N']	[27]
28	the	O	['N']	[28]
29	clinical	O	['N']	[29]
30	course	O	['N']	[30]
31	of	O	['N']	[31]
32	IFN	O	['N']	[32]
33	therapy	O	['N']	[33]
34	were	O	['N']	[34]
35	observed	O	['N']	[35]
36	.	O	['N']	[36]
#1128
0	In	O	['N']	[0]
1	four	O	['N']	[1]
2	patients	O	['N']	[2]
3	,	O	['N']	[3]
4	spasm	B-Adverse_Effect	['N']	[4]
5	occurred	O	['N']	[5]
6	spontaneous	O	['N']	[6]
7	and	O	['N']	[7]
8	in	O	['N']	[8]
9	one	O	['N']	[9]
10	patient	O	['N']	[10]
11	after	O	['N']	[11]
12	0.05	O	['N']	[12]
13	mg	O	['N']	[13]
14	of	O	['N']	[14]
15	ergonovine	B-Drug	['Causes']	[4]
16	.	O	['N']	[16]
#1129
0	Here	O	['N']	[0]
1	we	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	Crohn	O	['N']	[6]
7	's	O	['N']	[7]
8	disease	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	a	O	['N']	[11]
12	severe	O	['N']	[12]
13	infliximab	B-Drug	['Causes']	[32]
14	infusion	O	['N']	[14]
15	reaction	O	['N']	[15]
16	(	O	['N']	[16]
17	IIR	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	complicated	O	['N']	[20]
21	1	O	['N']	[21]
22	day	O	['N']	[22]
23	later	O	['N']	[23]
24	by	O	['N']	[24]
25	severe	B	['N']	[25]
26	swelling	I	['N']	[26]
27	of	I	['N']	[27]
28	the	I	['N']	[28]
29	forearm	I	['N']	[29]
30	and	I	['N']	[30]
31	hand	I	['N']	[31]
32	ipsilateral	I-Adverse_Effect	['N']	[32]
33	to	O	['N']	[33]
34	the	O	['N']	[34]
35	site	O	['N']	[35]
36	of	O	['N']	[36]
37	infliximab	O	['N']	[37]
38	infusion	O	['N']	[38]
39	.	O	['N']	[39]
#1130
0	Renal	B	['N']	[0]
1	failure	I-Adverse_Effect	['N']	[1]
2	is	O	['N']	[2]
3	a	O	['N']	[3]
4	rare	O	['N']	[4]
5	complication	O	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	the	O	['N']	[8]
9	use	O	['N']	[9]
10	of	O	['N']	[10]
11	rifampicin	B-Drug	['Causes']	[1]
12	for	O	['N']	[12]
13	the	O	['N']	[13]
14	treatment	O	['N']	[14]
15	of	O	['N']	[15]
16	tuberculosis	O	['N']	[16]
17	,	O	['N']	[17]
18	usually	O	['N']	[18]
19	occurring	O	['N']	[19]
20	well	O	['N']	[20]
21	into	O	['N']	[21]
22	the	O	['N']	[22]
23	course	O	['N']	[23]
24	of	O	['N']	[24]
25	therapy	O	['N']	[25]
26	.	O	['N']	[26]
#1131
0	Type	B	['N']	[0]
1	1	I	['N']	[1]
2	diabetes	I	['N']	[2]
3	mellitus	I-Adverse_Effect	['N']	[3]
4	provoked	O	['N']	[4]
5	by	O	['N']	[5]
6	peginterferon	B	['N']	[6]
7	alpha-2b	I-Drug	['Causes']	[3]
8	plus	O	['N']	[8]
9	ribavirin	O	['N']	[9]
10	treatment	O	['N']	[10]
11	for	O	['N']	[11]
12	chronic	O	['N']	[12]
13	hepatitis	O	['N']	[13]
14	C.	O	['N']	[14]
#1132
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	fatal	O	['N']	[6]
7	cryptococcal	B	['N']	[7]
8	meningitis	I-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	child	O	['N']	[11]
12	with	O	['N']	[12]
13	systemic	O	['N']	[13]
14	lupus	O	['N']	[14]
15	erythematosus	O	['N']	[15]
16	being	O	['N']	[16]
17	treated	O	['N']	[17]
18	with	O	['N']	[18]
19	prednisolone	O	['N']	[19]
20	and	O	['N']	[20]
21	azathioprine	B-Drug	['Causes']	[8]
22	.	O	['N']	[22]
#1133
0	A	O	['N']	[0]
1	variety	O	['N']	[1]
2	of	O	['N']	[2]
3	movement	O	['N']	[3]
4	disorders	O	['N']	[4]
5	are	O	['N']	[5]
6	known	O	['N']	[6]
7	to	O	['N']	[7]
8	occur	O	['N']	[8]
9	in	O	['N']	[9]
10	association	O	['N']	[10]
11	with	O	['N']	[11]
12	carbamazepine	B-Drug	['Causes']	[25]
13	(	O	['N']	[13]
14	CBZ	O	['N']	[14]
15	)	O	['N']	[15]
16	therapy	O	['N']	[16]
17	in	O	['N']	[17]
18	adults	O	['N']	[18]
19	and	O	['N']	[19]
20	children	O	['N']	[20]
21	,	O	['N']	[21]
22	but	O	['N']	[22]
23	development	O	['N']	[23]
24	of	O	['N']	[24]
25	tics	B-Adverse_Effect	['N']	[25]
26	has	O	['N']	[26]
27	been	O	['N']	[27]
28	described	O	['N']	[28]
29	infrequently	O	['N']	[29]
30	and	O	['N']	[30]
31	only	O	['N']	[31]
32	in	O	['N']	[32]
33	patients	O	['N']	[33]
34	with	O	['N']	[34]
35	underlying	O	['N']	[35]
36	Tourette	O	['N']	[36]
37	's	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	or	O	['N']	[39]
40	other	O	['N']	[40]
41	movement	O	['N']	[41]
42	disorders	O	['N']	[42]
43	.	O	['N']	[43]
#1134
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	new	O	['N']	[3]
4	quinolone	O	['N']	[4]
5	derivatives	O	['N']	[5]
6	(	O	['N']	[6]
7	levofloxacin	O	['N']	[7]
8	,	O	['N']	[8]
9	sparfloxacin	O	['N']	[9]
10	,	O	['N']	[10]
11	grepafloxacin	B-Drug	['Causes']	[43]
12	,	O	['N']	[12]
13	trovafloxacin	O	['N']	[13]
14	,	O	['N']	[14]
15	gatifloxacin	O	['N']	[15]
16	and	O	['N']	[16]
17	moxifloxacin	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	also	O	['N']	[20]
21	called	O	['N']	[21]
22	gyrase	O	['N']	[22]
23	inhibitors	O	['N']	[23]
24	,	O	['N']	[24]
25	are	O	['N']	[25]
26	known	O	['N']	[26]
27	for	O	['N']	[27]
28	their	O	['N']	[28]
29	potential	O	['N']	[29]
30	to	O	['N']	[30]
31	cause	O	['N']	[31]
32	central	O	['N']	[32]
33	nervous	O	['N']	[33]
34	system	O	['N']	[34]
35	-	O	['N']	[35]
36	related	O	['N']	[36]
37	adverse	O	['N']	[37]
38	effects	O	['N']	[38]
39	,	O	['N']	[39]
40	including	O	['N']	[40]
41	headache	O	['N']	[41]
42	,	O	['N']	[42]
43	dizziness	B-Adverse_Effect	['N']	[43]
44	and	O	['N']	[44]
45	insomnia	O	['N']	[45]
46	.	O	['N']	[46]
#1135
0	In	O	['N']	[0]
1	the	O	['N']	[1]
2	following	O	['N']	[2]
3	case	O	['N']	[3]
4	report	O	['N']	[4]
5	,	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	developed	O	['N']	[8]
9	acute	B	['N']	[9]
10	interstitial	I	['N']	[10]
11	nephritis	I-Adverse_Effect	['N']	[11]
12	with	O	['N']	[12]
13	renal	O	['N']	[13]
14	failure	O	['N']	[14]
15	and	O	['N']	[15]
16	exfoliative	O	['N']	[16]
17	dermatitis	O	['N']	[17]
18	following	O	['N']	[18]
19	ampicillin	B-Drug	['Causes']	[11]
20	therapy	O	['N']	[20]
21	.	O	['N']	[21]
#1136
0	Fatal	B	['N']	[0]
1	venous	I	['N']	[1]
2	thrombembolism	I-Adverse_Effect	['N']	[2]
3	complicating	O	['N']	[3]
4	imatinib	B-Drug	['Causes']	[2]
5	therapy	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	metastatic	O	['N']	[10]
11	gastrointestinal	O	['N']	[11]
12	stromal	O	['N']	[12]
13	tumor	O	['N']	[13]
14	.	O	['N']	[14]
#1137
0	After	O	['N']	[0]
1	therapy	O	['N']	[1]
2	for	O	['N']	[2]
3	diabetic	O	['N']	[3]
4	coma	O	['N']	[4]
5	with	O	['N']	[5]
6	insulin	O	['N']	[6]
7	(	O	['N']	[7]
8	containing	O	['N']	[8]
9	the	O	['N']	[9]
10	preservative	O	['N']	[10]
11	cresol	B-Drug	['Causes']	[29]
12	)	O	['N']	[12]
13	and	O	['N']	[13]
14	electrolyte	O	['N']	[14]
15	solutions	O	['N']	[15]
16	was	O	['N']	[16]
17	started	O	['N']	[17]
18	,	O	['N']	[18]
19	the	O	['N']	[19]
20	patient	O	['N']	[20]
21	complained	O	['N']	[21]
22	of	O	['N']	[22]
23	increasing	O	['N']	[23]
24	myalgia	O	['N']	[24]
25	,	O	['N']	[25]
26	developed	O	['N']	[26]
27	a	O	['N']	[27]
28	high	B	['N']	[28]
29	fever	I-Adverse_Effect	['N']	[29]
30	and	O	['N']	[30]
31	respiratory	O	['N']	[31]
32	and	O	['N']	[32]
33	metabolic	O	['N']	[33]
34	acidosis	O	['N']	[34]
35	and	O	['N']	[35]
36	lost	O	['N']	[36]
37	consciousness	O	['N']	[37]
38	.	O	['N']	[38]
#1138
0	No	O	['N']	[0]
1	other	O	['N']	[1]
2	endogenous	O	['N']	[2]
3	or	O	['N']	[3]
4	exogenous	O	['N']	[4]
5	cause	O	['N']	[5]
6	for	O	['N']	[6]
7	the	O	['N']	[7]
8	gynecomastia	B-Adverse_Effect	['N']	[8]
9	could	O	['N']	[9]
10	be	O	['N']	[10]
11	found	O	['N']	[11]
12	except	O	['N']	[12]
13	for	O	['N']	[13]
14	the	O	['N']	[14]
15	theophylline	B-Drug	['Causes']	[8]
16	.	O	['N']	[16]
#1139
0	Although	O	['N']	[0]
1	combinations	O	['N']	[1]
2	of	O	['N']	[2]
3	belladonna	O	['N']	[3]
4	,	O	['N']	[4]
5	ergotamine	B-Drug	['Causes']	[35]
6	,	O	['N']	[6]
7	and	O	['N']	[7]
8	phenobarbital	O	['N']	[8]
9	have	O	['N']	[9]
10	been	O	['N']	[10]
11	used	O	['N']	[11]
12	for	O	['N']	[12]
13	medical	O	['N']	[13]
14	treatment	O	['N']	[14]
15	of	O	['N']	[15]
16	menopausal	O	['N']	[16]
17	symptoms	O	['N']	[17]
18	since	O	['N']	[18]
19	the	O	['N']	[19]
20	1960s	O	['N']	[20]
21	,	O	['N']	[21]
22	this	O	['N']	[22]
23	is	O	['N']	[23]
24	the	O	['N']	[24]
25	first	O	['N']	[25]
26	known	O	['N']	[26]
27	case	O	['N']	[27]
28	report	O	['N']	[28]
29	of	O	['N']	[29]
30	its	O	['N']	[30]
31	association	O	['N']	[31]
32	with	O	['N']	[32]
33	anticonvulsant	B	['N']	[33]
34	hypersensitivity	I	['N']	[34]
35	syndrome	I-Adverse_Effect	['N']	[35]
36	.	O	['N']	[36]
#1140
0	Fulminant	B	['N']	[0]
1	hepatic	I	['N']	[1]
2	failure	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	bicalutamide	B-Drug	['Causes']	[2]
6	.	O	['N']	[6]
#1141
0	Under	O	['N']	[0]
1	the	O	['N']	[1]
2	suspicion	O	['N']	[2]
3	of	O	['N']	[3]
4	amiodarone	B-Drug	['Causes']	[8]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	acute	B	['N']	[7]
8	pancreatitis	I-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	amiodarone	O	['N']	[10]
11	was	O	['N']	[11]
12	substituted	O	['N']	[12]
13	by	O	['N']	[13]
14	propafenone	O	['N']	[14]
15	.	O	['N']	[15]
#1142
0	First	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	ivermectin	B-Drug	['Causes']	[7]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	severe	B	['N']	[6]
7	hepatitis	I-Adverse_Effect	['N']	[7]
8	.	O	['N']	[8]
#1143
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	76-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	an	O	['N']	[9]
10	acute	O	['N']	[10]
11	blistering	O	['N']	[11]
12	eruption	O	['N']	[12]
13	following	O	['N']	[13]
14	high	B-Dose	['N']	[14]
15	-	O	['N']	[15]
16	dose	O	['N']	[16]
17	penicillin	B-Drug	['Dosage']	[14]
18	treatment	O	['N']	[18]
19	for	O	['N']	[19]
20	pneumococcal	O	['N']	[20]
21	septicaemia	O	['N']	[21]
22	.	O	['N']	[22]
#1144
0	Acute	B	['N']	[0]
1	hepatic	I	['N']	[1]
2	failure	I-Adverse_Effect	['N']	[2]
3	is	O	['N']	[3]
4	a	O	['N']	[4]
5	rare	O	['N']	[5]
6	and	O	['N']	[6]
7	potentially	O	['N']	[7]
8	lethal	O	['N']	[8]
9	complication	O	['N']	[9]
10	of	O	['N']	[10]
11	propylthiouracil	B-Drug	['Causes']	[2]
12	(	O	['N']	[12]
13	PTU	O	['N']	[13]
14	)	O	['N']	[14]
15	use	O	['N']	[15]
16	for	O	['N']	[16]
17	hyperthyroidism	O	['N']	[17]
18	.	O	['N']	[18]
#1145
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	case	O	['N']	[3]
4	describes	O	['N']	[4]
5	the	O	['N']	[5]
6	clinically	O	['N']	[6]
7	significant	O	['N']	[7]
8	increase	B	['N']	[8]
9	of	I	['N']	[9]
10	INR	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	an	O	['N']	[12]
13	elderly	O	['N']	[13]
14	patient	O	['N']	[14]
15	after	O	['N']	[15]
16	adding	O	['N']	[16]
17	a	O	['N']	[17]
18	chemotherapy	O	['N']	[18]
19	regimen	O	['N']	[19]
20	of	O	['N']	[20]
21	levamisole	B-Drug	['Causes']	[10]
22	and	O	['N']	[22]
23	5-FU	O	['N']	[23]
24	to	O	['N']	[24]
25	a	O	['N']	[25]
26	previous	O	['N']	[26]
27	regimen	O	['N']	[27]
28	of	O	['N']	[28]
29	warfarin	O	['N']	[29]
30	alone	O	['N']	[30]
31	.	O	['N']	[31]
#1146
0	Attempts	O	['N']	[0]
1	were	O	['N']	[1]
2	made	O	['N']	[2]
3	to	O	['N']	[3]
4	stop	O	['N']	[4]
5	and	O	['N']	[5]
6	then	O	['N']	[6]
7	restart	O	['N']	[7]
8	the	O	['N']	[8]
9	theophylline	B-Drug	['Causes']	[31]
10	therapy	O	['N']	[10]
11	at	O	['N']	[11]
12	progressively	O	['N']	[12]
13	lower	O	['N']	[13]
14	doses	O	['N']	[14]
15	;	O	['N']	[15]
16	however	O	['N']	[16]
17	,	O	['N']	[17]
18	with	O	['N']	[18]
19	each	O	['N']	[19]
20	attempt	O	['N']	[20]
21	,	O	['N']	[21]
22	the	O	['N']	[22]
23	patient	O	['N']	[23]
24	's	O	['N']	[24]
25	reaction	B	['N']	[25]
26	to	I	['N']	[26]
27	the	I	['N']	[27]
28	drug	I	['N']	[28]
29	became	I	['N']	[29]
30	more	I	['N']	[30]
31	toxic	I-Adverse_Effect	['N']	[31]
32	,	O	['N']	[32]
33	with	O	['N']	[33]
34	serum	O	['N']	[34]
35	theophylline	O	['N']	[35]
36	levels	O	['N']	[36]
37	ranging	O	['N']	[37]
38	between	O	['N']	[38]
39	99.9	O	['N']	[39]
40	and	O	['N']	[40]
41	149.9	O	['N']	[41]
42	micromol	O	['N']	[42]
43	/	O	['N']	[43]
44	L	O	['N']	[44]
45	(	O	['N']	[45]
46	18	O	['N']	[46]
47	and	O	['N']	[47]
48	27	O	['N']	[48]
49	microg	O	['N']	[49]
50	/	O	['N']	[50]
51	mL	O	['N']	[51]
52	)	O	['N']	[52]
53	.	O	['N']	[53]
#1147
0	Epsilon	B	['N']	[0]
1	-	I	['N']	[1]
2	aminocaproic	I	['N']	[2]
3	acid	I-Drug	['Causes']	[6]
4	and	O	['N']	[4]
5	renal	B	['N']	[5]
6	complications	I-Adverse_Effect	['N']	[6]
7	:	O	['N']	[7]
8	case	O	['N']	[8]
9	report	O	['N']	[9]
10	and	O	['N']	[10]
11	review	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	literature	O	['N']	[14]
15	.	O	['N']	[15]
#1148
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	here	O	['N']	[2]
3	two	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	dyserythropoietic	B	['N']	[6]
7	anaemia	I-Adverse_Effect	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	long	O	['N']	[10]
11	-	O	['N']	[11]
12	term	O	['N']	[12]
13	linezolid	B-Drug	['Causes']	[7]
14	use	O	['N']	[14]
15	that	O	['N']	[15]
16	share	O	['N']	[16]
17	striking	O	['N']	[17]
18	similarities	O	['N']	[18]
19	to	O	['N']	[19]
20	chloramphenicol	O	['N']	[20]
21	-	O	['N']	[21]
22	associated	O	['N']	[22]
23	myelotoxicity	O	['N']	[23]
24	.	O	['N']	[24]
#1149
0	Total	O	['N']	[0]
1	blindness	O	['N']	[1]
2	with	O	['N']	[2]
3	a	O	['N']	[3]
4	transient	O	['N']	[4]
5	tonic	O	['N']	[5]
6	pupillary	O	['N']	[6]
7	response	O	['N']	[7]
8	,	O	['N']	[8]
9	denervation	B	['N']	[9]
10	supersensitivity	I-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	abnormal	O	['N']	[13]
14	visual	O	['N']	[14]
15	-	O	['N']	[15]
16	evoked	O	['N']	[16]
17	potentials	O	['N']	[17]
18	developed	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	54-year	O	['N']	[21]
22	-	O	['N']	[22]
23	old	O	['N']	[23]
24	man	O	['N']	[24]
25	after	O	['N']	[25]
26	the	O	['N']	[26]
27	use	O	['N']	[27]
28	of	O	['N']	[28]
29	quinine	B	['N']	[29]
30	sulfate	I-Drug	['Causes']	[10]
31	for	O	['N']	[31]
32	leg	O	['N']	[32]
33	cramps	O	['N']	[33]
34	.	O	['N']	[34]
#1150
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	hemolytic	B	['N']	[5]
6	-	I	['N']	[6]
7	uremic	I	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	that	O	['N']	[9]
10	developed	O	['N']	[10]
11	during	O	['N']	[11]
12	the	O	['N']	[12]
13	4th	O	['N']	[13]
14	cycle	O	['N']	[14]
15	of	O	['N']	[15]
16	combination	O	['N']	[16]
17	chemotherapy	O	['N']	[17]
18	with	O	['N']	[18]
19	oxaliplatin	B-Drug	['Causes']	[8]
20	,	O	['N']	[20]
21	5-fluorouracil	O	['N']	[21]
22	and	O	['N']	[22]
23	leucovorin	O	['N']	[23]
24	.	O	['N']	[24]
#1151
0	Patients	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	informed	O	['N']	[3]
4	about	O	['N']	[4]
5	the	O	['N']	[5]
6	risk	O	['N']	[6]
7	of	O	['N']	[7]
8	osteonecrosis	B-Adverse_Effect	['N']	[8]
9	when	O	['N']	[9]
10	taking	O	['N']	[10]
11	dexamethasone	B-Drug	['Causes']	[8]
12	as	O	['N']	[12]
13	an	O	['N']	[13]
14	antiemetic	O	['N']	[14]
15	drug	O	['N']	[15]
16	.	O	['N']	[16]
#1152
0	On	O	['N']	[0]
1	day	O	['N']	[1]
2	7	O	['N']	[2]
3	of	O	['N']	[3]
4	linezolid	B-Drug	['Causes']	[30]
5	treatment	O	['N']	[5]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	patient	O	['N']	[8]
9	developed	O	['N']	[9]
10	severe	O	['N']	[10]
11	pruritus	O	['N']	[11]
12	,	O	['N']	[12]
13	macular	O	['N']	[13]
14	rash	O	['N']	[14]
15	,	O	['N']	[15]
16	facial	O	['N']	[16]
17	edema	O	['N']	[17]
18	,	O	['N']	[18]
19	eosinophilia	O	['N']	[19]
20	,	O	['N']	[20]
21	marked	O	['N']	[21]
22	increase	O	['N']	[22]
23	in	O	['N']	[23]
24	serum	O	['N']	[24]
25	creatinine	O	['N']	[25]
26	level	O	['N']	[26]
27	,	O	['N']	[27]
28	and	O	['N']	[28]
29	mild	B	['N']	[29]
30	hepatitis	I-Adverse_Effect	['N']	[30]
31	.	O	['N']	[31]
#1153
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	drug	O	['N']	[4]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	fever	B-Adverse_Effect	['N']	[7]
8	has	O	['N']	[8]
9	not	O	['N']	[9]
10	been	O	['N']	[10]
11	reported	O	['N']	[11]
12	with	O	['N']	[12]
13	the	O	['N']	[13]
14	use	O	['N']	[14]
15	of	O	['N']	[15]
16	diltiazem	B	['N']	[16]
17	hydrochloride	I-Drug	['Causes']	[7]
18	,	O	['N']	[18]
19	a	O	['N']	[19]
20	commonly	O	['N']	[20]
21	prescribed	O	['N']	[21]
22	calcium	O	['N']	[22]
23	channel	O	['N']	[23]
24	blocker	O	['N']	[24]
25	.	O	['N']	[25]
#1154
0	Cardiomyopathy	B-Adverse_Effect	['N']	[0]
1	after	O	['N']	[1]
2	widely	O	['N']	[2]
3	separated	O	['N']	[3]
4	courses	O	['N']	[4]
5	of	O	['N']	[5]
6	adriamycin	O	['N']	[6]
7	exacerbated	O	['N']	[7]
8	by	O	['N']	[8]
9	actinomycin	B	['N']	[9]
10	-	I	['N']	[10]
11	D	I-Drug	['Causes']	[0]
12	and	O	['N']	[12]
13	mithramycin	O	['N']	[13]
14	.	O	['N']	[14]
#1155
0	Phenytoin	O	['N']	[0]
1	was	O	['N']	[1]
2	discontinued	O	['N']	[2]
3	after	O	['N']	[3]
4	admission	O	['N']	[4]
5	;	O	['N']	[5]
6	however	O	['N']	[6]
7	,	O	['N']	[7]
8	phenytoin	B-Drug	['Causes']	[35]
9	1	O	['N']	[9]
10	g	O	['N']	[10]
11	i.v	O	['N']	[11]
12	.	O	['N']	[12]
13	was	O	['N']	[13]
14	given	O	['N']	[14]
15	for	O	['N']	[15]
16	a	O	['N']	[16]
17	tonic	O	['N']	[17]
18	-	O	['N']	[18]
19	clonic	O	['N']	[19]
20	seizure	O	['N']	[20]
21	two	O	['N']	[21]
22	days	O	['N']	[22]
23	after	O	['N']	[23]
24	admission	O	['N']	[24]
25	,	O	['N']	[25]
26	after	O	['N']	[26]
27	which	O	['N']	[27]
28	swelling	O	['N']	[28]
29	of	O	['N']	[29]
30	the	O	['N']	[30]
31	face	O	['N']	[31]
32	and	O	['N']	[32]
33	legs	O	['N']	[33]
34	and	O	['N']	[34]
35	pruritus	B-Adverse_Effect	['N']	[35]
36	developed	O	['N']	[36]
37	.	O	['N']	[37]
#1156
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	unusual	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	massive	O	['N']	[6]
7	fluoxetine	B-Drug	['Causes']	[14]
8	ingestion	O	['N']	[8]
9	resulting	O	['N']	[9]
10	in	O	['N']	[10]
11	neurological	B	['N']	[11]
12	and	I	['N']	[12]
13	cardiovascular	I	['N']	[13]
14	toxicity	I-Adverse_Effect	['N']	[14]
15	resulting	O	['N']	[15]
16	in	O	['N']	[16]
17	death	O	['N']	[17]
18	.	O	['N']	[18]
#1157
0	Pleuropulmonary	B	['N']	[0]
1	changes	I-Adverse_Effect	['N']	[1]
2	during	O	['N']	[2]
3	treatment	O	['N']	[3]
4	of	O	['N']	[4]
5	Parkinson	O	['N']	[5]
6	's	O	['N']	[6]
7	disease	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	long	O	['N']	[10]
11	-	O	['N']	[11]
12	acting	O	['N']	[12]
13	ergot	O	['N']	[13]
14	derivative	O	['N']	[14]
15	,	O	['N']	[15]
16	cabergoline	B-Drug	['Causes']	[1]
17	.	O	['N']	[17]
#1158
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	unintentional	O	['N']	[5]
6	overdose	B-Dose	['N']	[6]
7	of	O	['N']	[7]
8	oral	O	['N']	[8]
9	pilocarpine	B-Drug	['Dosage']	[6]
10	tablets	O	['N']	[10]
11	that	O	['N']	[11]
12	resulted	O	['N']	[12]
13	in	O	['N']	[13]
14	bradycardia	O	['N']	[14]
15	,	O	['N']	[15]
16	mild	O	['N']	[16]
17	hypotension	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	muscarinic	O	['N']	[20]
21	symptoms	O	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	patient	O	['N']	[24]
25	with	O	['N']	[25]
26	Sjogren	O	['N']	[26]
27	's	O	['N']	[27]
28	syndrome	O	['N']	[28]
29	.	O	['N']	[29]
#1159
0	Metipranolol	B-Drug	['Causes']	[4]
1	associated	O	['N']	[1]
2	granulomatous	B	['N']	[2]
3	anterior	I	['N']	[3]
4	uveitis	I-Adverse_Effect	['N']	[4]
5	:	O	['N']	[5]
6	not	O	['N']	[6]
7	so	O	['N']	[7]
8	uncommon	O	['N']	[8]
9	as	O	['N']	[9]
10	thought	O	['N']	[10]
11	.	O	['N']	[11]
#1160
0	Fatal	B	['N']	[0]
1	pulmonary	I	['N']	[1]
2	fibrosis	I-Adverse_Effect	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	paclitaxel	B-Drug	['Causes']	[2]
6	:	O	['N']	[6]
7	a	O	['N']	[7]
8	case	O	['N']	[8]
9	report	O	['N']	[9]
10	and	O	['N']	[10]
11	review	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	literature	O	['N']	[14]
15	.	O	['N']	[15]
#1161
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	recently	O	['N']	[3]
4	experienced	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	fatal	O	['N']	[8]
9	erlotinib	B-Drug	['Causes']	[12]
10	-	O	['N']	[10]
11	induced	O	['N']	[11]
12	ILD	B-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	diagnosed	O	['N']	[14]
15	based	O	['N']	[15]
16	on	O	['N']	[16]
17	clinical	O	['N']	[17]
18	and	O	['N']	[18]
19	radiologic	O	['N']	[19]
20	findings	O	['N']	[20]
21	,	O	['N']	[21]
22	which	O	['N']	[22]
23	occurred	O	['N']	[23]
24	in	O	['N']	[24]
25	a	O	['N']	[25]
26	patient	O	['N']	[26]
27	with	O	['N']	[27]
28	radiation	O	['N']	[28]
29	fibrosis	O	['N']	[29]
30	.	O	['N']	[30]
#1162
0	Despite	O	['N']	[0]
1	the	O	['N']	[1]
2	underlying	O	['N']	[2]
3	hepatitis	O	['N']	[3]
4	C	O	['N']	[4]
5	,	O	['N']	[5]
6	this	O	['N']	[6]
7	case	O	['N']	[7]
8	represents	O	['N']	[8]
9	renal	B	['N']	[9]
10	abnormalities	I-Adverse_Effect	['N']	[10]
11	consistent	O	['N']	[11]
12	with	O	['N']	[12]
13	IFNalpha	B-Drug	['Causes']	[10]
14	therapy	O	['N']	[14]
15	for	O	['N']	[15]
16	CML	O	['N']	[16]
17	.	O	['N']	[17]
#1163
0	Initial	O	['N']	[0]
1	treatment	O	['N']	[1]
2	with	O	['N']	[2]
3	heparin	B-Drug	['Causes']	[26]
4	was	O	['N']	[4]
5	substituted	O	['N']	[5]
6	with	O	['N']	[6]
7	thrombolysis	O	['N']	[7]
8	,	O	['N']	[8]
9	which	O	['N']	[9]
10	resulted	O	['N']	[10]
11	in	O	['N']	[11]
12	clinical	O	['N']	[12]
13	improvement	O	['N']	[13]
14	and	O	['N']	[14]
15	dissolution	O	['N']	[15]
16	of	O	['N']	[16]
17	right	O	['N']	[17]
18	heart	O	['N']	[18]
19	thrombus	O	['N']	[19]
20	but	O	['N']	[20]
21	was	O	['N']	[21]
22	followed	O	['N']	[22]
23	by	O	['N']	[23]
24	fatal	B	['N']	[24]
25	intracerebral	I	['N']	[25]
26	haemorrhage	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#1164
0	A	O	['N']	[0]
1	toxic	B	['N']	[1]
2	encephalopathy	I-Adverse_Effect	['N']	[2]
3	characterized	O	['N']	[3]
4	by	O	['N']	[4]
5	depressed	O	['N']	[5]
6	level	O	['N']	[6]
7	of	O	['N']	[7]
8	consciousness	O	['N']	[8]
9	,	O	['N']	[9]
10	marked	O	['N']	[10]
11	irritability	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	ataxia	O	['N']	[14]
15	developed	O	['N']	[15]
16	in	O	['N']	[16]
17	seven	O	['N']	[17]
18	children	O	['N']	[18]
19	,	O	['N']	[19]
20	5	O	['N']	[20]
21	years	O	['N']	[21]
22	of	O	['N']	[22]
23	age	O	['N']	[23]
24	and	O	['N']	[24]
25	younger	O	['N']	[25]
26	,	O	['N']	[26]
27	following	O	['N']	[27]
28	administration	O	['N']	[28]
29	of	O	['N']	[29]
30	an	O	['N']	[30]
31	antiemetic	O	['N']	[31]
32	combination	O	['N']	[32]
33	of	O	['N']	[33]
34	pentobarbital	B-Drug	['Causes']	[2]
35	and	O	['N']	[35]
36	pyrilamine	O	['N']	[36]
37	maleate	O	['N']	[37]
38	.	O	['N']	[38]
#1165
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	well	O	['N']	[2]
3	-	O	['N']	[3]
4	recognized	O	['N']	[4]
5	that	O	['N']	[5]
6	flucloxacillin	B-Drug	['Causes']	[13]
7	may	O	['N']	[7]
8	occasionally	O	['N']	[8]
9	result	O	['N']	[9]
10	in	O	['N']	[10]
11	fatal	B	['N']	[11]
12	hepatic	I	['N']	[12]
13	injury	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#1166
0	Lithium	B-Drug	['Causes']	[6]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	Creutzfeldt	B	['N']	[3]
4	-	I	['N']	[4]
5	Jakob	I	['N']	[5]
6	syndrome	I-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#1167
0	Sensory	O	['N']	[0]
1	neuropathy	O	['N']	[1]
2	revealing	O	['N']	[2]
3	necrotizing	B	['N']	[3]
4	vasculitis	I-Adverse_Effect	['N']	[4]
5	during	O	['N']	[5]
6	infliximab	B-Drug	['Causes']	[4]
7	therapy	O	['N']	[7]
8	for	O	['N']	[8]
9	rheumatoid	O	['N']	[9]
10	arthritis	O	['N']	[10]
11	.	O	['N']	[11]
#1168
0	Arterial	B	['N']	[0]
1	hypertension	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	topical	O	['N']	[4]
5	ocular	O	['N']	[5]
6	use	O	['N']	[6]
7	of	O	['N']	[7]
8	phenylephrine	B-Drug	['Causes']	[1]
9	in	O	['N']	[9]
10	dogs	O	['N']	[10]
11	.	O	['N']	[11]
#1169
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	61-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	woman	O	['N']	[7]
8	with	O	['N']	[8]
9	no	O	['N']	[9]
10	apparent	O	['N']	[10]
11	risk	O	['N']	[11]
12	factors	O	['N']	[12]
13	for	O	['N']	[13]
14	liver	O	['N']	[14]
15	injury	O	['N']	[15]
16	developed	O	['N']	[16]
17	acute	B	['N']	[17]
18	hepatitis	I-Adverse_Effect	['N']	[18]
19	one	O	['N']	[19]
20	week	O	['N']	[20]
21	after	O	['N']	[21]
22	the	O	['N']	[22]
23	final	O	['N']	[23]
24	dose	O	['N']	[24]
25	of	O	['N']	[25]
26	a	O	['N']	[26]
27	long	O	['N']	[27]
28	-	O	['N']	[28]
29	term	O	['N']	[29]
30	course	O	['N']	[30]
31	of	O	['N']	[31]
32	pulse	O	['N']	[32]
33	itraconazole	B-Drug	['Causes']	[18]
34	therapy	O	['N']	[34]
35	(	O	['N']	[35]
36	200	O	['N']	[36]
37	mg	O	['N']	[37]
38	orally	O	['N']	[38]
39	twice	O	['N']	[39]
40	daily	O	['N']	[40]
41	,	O	['N']	[41]
42	1	O	['N']	[42]
43	wk	O	['N']	[43]
44	on	O	['N']	[44]
45	,	O	['N']	[45]
46	3	O	['N']	[46]
47	wk	O	['N']	[47]
48	off	O	['N']	[48]
49	,	O	['N']	[49]
50	for	O	['N']	[50]
51	24	O	['N']	[51]
52	wk	O	['N']	[52]
53	)	O	['N']	[53]
54	for	O	['N']	[54]
55	onychomycosis	O	['N']	[55]
56	.	O	['N']	[56]
#1170
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	experienced	O	['N']	[2]
3	hallucinations	B-Adverse_Effect	['N']	[3]
4	,	O	['N']	[4]
5	agitation	O	['N']	[5]
6	,	O	['N']	[6]
7	vomiting	O	['N']	[7]
8	,	O	['N']	[8]
9	tachycardia	O	['N']	[9]
10	and	O	['N']	[10]
11	seizures	O	['N']	[11]
12	after	O	['N']	[12]
13	ingestion	O	['N']	[13]
14	of	O	['N']	[14]
15	1050	O	['N']	[15]
16	(	O	['N']	[16]
17	48	O	['N']	[17]
18	mg	O	['N']	[18]
19	/	O	['N']	[19]
20	kg	O	['N']	[20]
21	)	O	['N']	[21]
22	of	O	['N']	[22]
23	extended	O	['N']	[23]
24	-	O	['N']	[24]
25	release	O	['N']	[25]
26	bupropion	B-Drug	['Causes']	[3]
27	.	O	['N']	[27]
#1171
0	Destructive	O	['N']	[0]
1	thyrotoxicosis	O	['N']	[1]
2	appeared	O	['N']	[2]
3	4	O	['N']	[3]
4	-	O	['N']	[4]
5	6	O	['N']	[5]
6	months	O	['N']	[6]
7	after	O	['N']	[7]
8	starting	O	['N']	[8]
9	IFN	B	['N']	[9]
10	-	I	['N']	[10]
11	alpha	I-Drug	['Causes']	[17]
12	,	O	['N']	[12]
13	followed	O	['N']	[13]
14	by	O	['N']	[14]
15	Graves	B	['N']	[15]
16	'	I	['N']	[16]
17	hyperthyroidism	I-Adverse_Effect	['N']	[17]
18	within	O	['N']	[18]
19	8	O	['N']	[19]
20	to	O	['N']	[20]
21	11	O	['N']	[21]
22	months	O	['N']	[22]
23	.	O	['N']	[23]
#1172
0	A	O	['N']	[0]
1	previous	O	['N']	[1]
2	review	O	['N']	[2]
3	described	O	['N']	[3]
4	data	O	['N']	[4]
5	on	O	['N']	[5]
6	15	O	['N']	[6]
7	patients	O	['N']	[7]
8	who	O	['N']	[8]
9	experienced	O	['N']	[9]
10	acute	O	['N']	[10]
11	hemoglobinemia	O	['N']	[11]
12	or	O	['N']	[12]
13	hemoglobinuria	B-Adverse_Effect	['N']	[13]
14	following	O	['N']	[14]
15	anti	B	['N']	[15]
16	-	I	['N']	[16]
17	D	I	['N']	[17]
18	IGIV	I-Drug	['Causes']	[13]
19	administration	O	['N']	[19]
20	for	O	['N']	[20]
21	ITP	O	['N']	[21]
22	or	O	['N']	[22]
23	secondary	O	['N']	[23]
24	thrombocytopenia	O	['N']	[24]
25	.	O	['N']	[25]
#1173
0	A	O	['N']	[0]
1	macrophage	B	['N']	[1]
2	activation	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	,	O	['N']	[4]
5	possibly	O	['N']	[5]
6	related	O	['N']	[6]
7	to	O	['N']	[7]
8	methotrexate	B-Drug	['Causes']	[3]
9	toxicity	O	['N']	[9]
10	,	O	['N']	[10]
11	developed	O	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	boy	O	['N']	[14]
15	with	O	['N']	[15]
16	systemic	O	['N']	[16]
17	juvenile	O	['N']	[17]
18	rheumatoid	O	['N']	[18]
19	arthritis	O	['N']	[19]
20	.	O	['N']	[20]
#1174
0	Rapamycin	O	['N']	[0]
1	/	O	['N']	[1]
2	sirolimus	O	['N']	[2]
3	(	O	['N']	[3]
4	SR	O	['N']	[4]
5	)	O	['N']	[5]
6	,	O	['N']	[6]
7	trade	O	['N']	[7]
8	named	O	['N']	[8]
9	Rapammune	B-Drug	['Causes']	[31]
10	(	O	['N']	[10]
11	Wyeth	O	['N']	[11]
12	-	O	['N']	[12]
13	Ayerst	O	['N']	[13]
14	,	O	['N']	[14]
15	Sydney	O	['N']	[15]
16	,	O	['N']	[16]
17	Australia	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	is	O	['N']	[20]
21	a	O	['N']	[21]
22	potent	O	['N']	[22]
23	immunosuppressive	O	['N']	[23]
24	drug	O	['N']	[24]
25	associated	O	['N']	[25]
26	with	O	['N']	[26]
27	myelosuppression	O	['N']	[27]
28	,	O	['N']	[28]
29	hypertension	O	['N']	[29]
30	,	O	['N']	[30]
31	hyperlipidemia	B-Adverse_Effect	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	infection	O	['N']	[34]
35	.	O	['N']	[35]
#1175
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Tamoxifen	B-Drug	['Causes']	[8]
3	may	O	['N']	[3]
4	cause	O	['N']	[4]
5	malignant	B	['N']	[5]
6	transformation	I	['N']	[6]
7	of	I	['N']	[7]
8	endometriosis	I-Adverse_Effect	['N']	[8]
9	through	O	['N']	[9]
10	atypical	O	['N']	[10]
11	endometriosis	O	['N']	[11]
12	even	O	['N']	[12]
13	in	O	['N']	[13]
14	the	O	['N']	[14]
15	postmenopausal	O	['N']	[15]
16	state	O	['N']	[16]
17	.	O	['N']	[17]
#1176
0	Antibiotic	O	['N']	[0]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	colitis	B-Adverse_Effect	['N']	[3]
4	(	O	['N']	[4]
5	pseudomembranous	O	['N']	[5]
6	colitis	O	['N']	[6]
7	)	O	['N']	[7]
8	developed	O	['N']	[8]
9	in	O	['N']	[9]
10	four	O	['N']	[10]
11	patients	O	['N']	[11]
12	with	O	['N']	[12]
13	spinal	O	['N']	[13]
14	cord	O	['N']	[14]
15	injury	O	['N']	[15]
16	and	O	['N']	[16]
17	taking	O	['N']	[17]
18	oral	O	['N']	[18]
19	trimethoprim	B-Drug	['Causes']	[3]
20	-	O	['N']	[20]
21	sulfamethoxazole	O	['N']	[21]
22	.	O	['N']	[22]
#1177
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	in	O	['N']	[4]
5	which	O	['N']	[5]
6	hemorrhage	B-Adverse_Effect	['N']	[6]
7	occurred	O	['N']	[7]
8	in	O	['N']	[8]
9	an	O	['N']	[9]
10	asymptomatic	O	['N']	[10]
11	falx	O	['N']	[11]
12	meningioma	O	['N']	[12]
13	known	O	['N']	[13]
14	beforehand	O	['N']	[14]
15	,	O	['N']	[15]
16	after	O	['N']	[16]
17	the	O	['N']	[17]
18	internal	O	['N']	[18]
19	use	O	['N']	[19]
20	of	O	['N']	[20]
21	low	O	['N']	[21]
22	-	O	['N']	[22]
23	dose	O	['N']	[23]
24	aspirin	B-Drug	['Causes']	[6]
25	for	O	['N']	[25]
26	16	O	['N']	[26]
27	months	O	['N']	[27]
28	.	O	['N']	[28]
#1178
0	Penicillin	B-Drug	['Causes']	[6]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	Jarisch	B	['N']	[3]
4	-	I	['N']	[4]
5	Herxheimer	I	['N']	[5]
6	reaction	I-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#1179
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	four	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	interstitial	B	['N']	[7]
8	pneumonitis	I-Adverse_Effect	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	fludarabine	B-Drug	['Causes']	[8]
12	have	O	['N']	[12]
13	been	O	['N']	[13]
14	reported	O	['N']	[14]
15	in	O	['N']	[15]
16	medical	O	['N']	[16]
17	literature	O	['N']	[17]
18	.	O	['N']	[18]
#1180
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	girl	O	['N']	[3]
4	with	O	['N']	[4]
5	the	O	['N']	[5]
6	Rett	O	['N']	[6]
7	syndrome	O	['N']	[7]
8	who	O	['N']	[8]
9	had	O	['N']	[9]
10	acute	B	['N']	[10]
11	encephalopathy	I-Adverse_Effect	['N']	[11]
12	probably	O	['N']	[12]
13	induced	O	['N']	[13]
14	by	O	['N']	[14]
15	calcium	B	['N']	[15]
16	hopantenate	I-Drug	['Causes']	[11]
17	(	O	['N']	[17]
18	HOPA	O	['N']	[18]
19	)	O	['N']	[19]
20	.	O	['N']	[20]
#1181
0	In	O	['N']	[0]
1	rare	O	['N']	[1]
2	cases	O	['N']	[2]
3	mitomycin	B	['N']	[3]
4	C	I-Drug	['Causes']	[15]
5	(	O	['N']	[5]
6	MMC	O	['N']	[6]
7	)	O	['N']	[7]
8	may	O	['N']	[8]
9	induce	O	['N']	[9]
10	cancer	O	['N']	[10]
11	-	O	['N']	[11]
12	associated	O	['N']	[12]
13	hemolytic	B	['N']	[13]
14	uremic	I	['N']	[14]
15	syndrome	I-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	which	O	['N']	[17]
18	is	O	['N']	[18]
19	characterized	O	['N']	[19]
20	by	O	['N']	[20]
21	hemolytic	O	['N']	[21]
22	anemia	O	['N']	[22]
23	,	O	['N']	[23]
24	thrombocytopenia	O	['N']	[24]
25	and	O	['N']	[25]
26	progressive	O	['N']	[26]
27	renal	O	['N']	[27]
28	failure	O	['N']	[28]
29	.	O	['N']	[29]
#1182
0	Because	O	['N']	[0]
1	nephrotic	B	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	may	O	['N']	[3]
4	be	O	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	IFN	B-Drug	['Causes']	[2]
8	therapy	O	['N']	[8]
9	,	O	['N']	[9]
10	the	O	['N']	[10]
11	IFN	O	['N']	[11]
12	was	O	['N']	[12]
13	stopped	O	['N']	[13]
14	.	O	['N']	[14]
#1183
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	two	O	['N']	[3]
4	patients	O	['N']	[4]
5	who	O	['N']	[5]
6	developed	O	['N']	[6]
7	acute	B	['N']	[7]
8	myelocytic	I	['N']	[8]
9	leukemia	I-Adverse_Effect	['N']	[9]
10	only	O	['N']	[10]
11	after	O	['N']	[11]
12	exposure	O	['N']	[12]
13	to	O	['N']	[13]
14	cyclophosphamide	O	['N']	[14]
15	,	O	['N']	[15]
16	methotrexate	B-Drug	['Causes']	[9]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	5-fluorouracil	O	['N']	[19]
20	adjuvant	O	['N']	[20]
21	therapy	O	['N']	[21]
22	.	O	['N']	[22]
#1184
0	The	O	['N']	[0]
1	use	O	['N']	[1]
2	of	O	['N']	[2]
3	methotrexate	O	['N']	[3]
4	(	O	['N']	[4]
5	MTX	B-Drug	['Causes']	[37]
6	)	O	['N']	[6]
7	has	O	['N']	[7]
8	been	O	['N']	[8]
9	contraindicated	O	['N']	[9]
10	for	O	['N']	[10]
11	treatment	O	['N']	[11]
12	of	O	['N']	[12]
13	severe	O	['N']	[13]
14	psoriasis	O	['N']	[14]
15	in	O	['N']	[15]
16	HIV	O	['N']	[16]
17	infection	O	['N']	[17]
18	on	O	['N']	[18]
19	the	O	['N']	[19]
20	basis	O	['N']	[20]
21	of	O	['N']	[21]
22	six	O	['N']	[22]
23	previously	O	['N']	[23]
24	reported	O	['N']	[24]
25	cases	O	['N']	[25]
26	in	O	['N']	[26]
27	which	O	['N']	[27]
28	MTX	O	['N']	[28]
29	appeared	O	['N']	[29]
30	to	O	['N']	[30]
31	potentiate	O	['N']	[31]
32	opportunistic	O	['N']	[32]
33	infections	O	['N']	[33]
34	and	O	['N']	[34]
35	accelerate	B	['N']	[35]
36	HIV	I	['N']	[36]
37	disease	I-Adverse_Effect	['N']	[37]
38	.	O	['N']	[38]
#1185
0	A	O	['N']	[0]
1	girl	O	['N']	[1]
2	with	O	['N']	[2]
3	cystic	O	['N']	[3]
4	fibrosis	O	['N']	[4]
5	and	O	['N']	[5]
6	cyclic	O	['N']	[6]
7	neutropenia	O	['N']	[7]
8	developed	O	['N']	[8]
9	an	O	['N']	[9]
10	erythematous	B	['N']	[10]
11	papular	I	['N']	[11]
12	eruption	I-Adverse_Effect	['N']	[12]
13	without	O	['N']	[13]
14	fever	O	['N']	[14]
15	or	O	['N']	[15]
16	neutrophilia	O	['N']	[16]
17	7	O	['N']	[17]
18	months	O	['N']	[18]
19	after	O	['N']	[19]
20	commencing	O	['N']	[20]
21	therapy	O	['N']	[21]
22	with	O	['N']	[22]
23	G	B	['N']	[23]
24	-	I	['N']	[24]
25	CSF	I-Drug	['Causes']	[12]
26	.	O	['N']	[26]
#1186
0	Cutaneous	B	['N']	[0]
1	rashes	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	eruptions	O	['N']	[3]
4	can	O	['N']	[4]
5	be	O	['N']	[5]
6	caused	O	['N']	[6]
7	by	O	['N']	[7]
8	many	O	['N']	[8]
9	medications	O	['N']	[9]
10	,	O	['N']	[10]
11	including	O	['N']	[11]
12	carbamazepine	B-Drug	['Causes']	[1]
13	.	O	['N']	[13]
#1187
0	Visual	B	['N']	[0]
1	system	I	['N']	[1]
2	side	I	['N']	[2]
3	effects	I-Adverse_Effect	['N']	[3]
4	caused	O	['N']	[4]
5	by	O	['N']	[5]
6	parasympathetic	O	['N']	[6]
7	dysfunction	O	['N']	[7]
8	after	O	['N']	[8]
9	botulinum	B	['N']	[9]
10	toxin	I	['N']	[10]
11	type	I	['N']	[11]
12	B	I-Drug	['Causes']	[3]
13	injections	O	['N']	[13]
14	.	O	['N']	[14]
#1188
0	Amebic	B	['N']	[0]
1	abscess	I	['N']	[1]
2	of	I	['N']	[2]
3	the	I	['N']	[3]
4	spleen	I-Adverse_Effect	['N']	[4]
5	complicated	O	['N']	[5]
6	by	O	['N']	[6]
7	metronidazole	B-Drug	['Causes']	[4]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	neurotoxicity	O	['N']	[10]
11	:	O	['N']	[11]
12	case	O	['N']	[12]
13	report	O	['N']	[13]
14	.	O	['N']	[14]
#1189
0	Additive	B	['N']	[0]
1	pulmonary	I	['N']	[1]
2	toxicity	I-Adverse_Effect	['N']	[2]
3	with	O	['N']	[3]
4	melphalan	O	['N']	[4]
5	and	O	['N']	[5]
6	busulfan	B-Drug	['Causes']	[2]
7	therapy	O	['N']	[7]
8	.	O	['N']	[8]
#1190
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	article	O	['N']	[2]
3	,	O	['N']	[3]
4	we	O	['N']	[4]
5	describe	O	['N']	[5]
6	a	O	['N']	[6]
7	Japanese	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	severe	B	['N']	[10]
11	interstitial	I	['N']	[11]
12	pneumonia	I-Adverse_Effect	['N']	[12]
13	probably	O	['N']	[13]
14	caused	O	['N']	[14]
15	by	O	['N']	[15]
16	sorafenib	B-Drug	['Causes']	[12]
17	treatment	O	['N']	[17]
18	for	O	['N']	[18]
19	metastatic	O	['N']	[19]
20	renal	O	['N']	[20]
21	cell	O	['N']	[21]
22	carcinoma	O	['N']	[22]
23	.	O	['N']	[23]
#1191
0	Induction	O	['N']	[0]
1	of	O	['N']	[1]
2	rapid	B	['N']	[2]
3	mood	I	['N']	[3]
4	cycling	I-Adverse_Effect	['N']	[4]
5	during	O	['N']	[5]
6	L	B	['N']	[6]
7	-	I	['N']	[7]
8	dopa	I-Drug	['Causes']	[4]
9	treatment	O	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	bipolar	O	['N']	[12]
13	patient	O	['N']	[13]
14	.	O	['N']	[14]
#1192
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	new	O	['N']	[3]
4	quinolone	O	['N']	[4]
5	derivatives	O	['N']	[5]
6	(	O	['N']	[6]
7	levofloxacin	O	['N']	[7]
8	,	O	['N']	[8]
9	sparfloxacin	O	['N']	[9]
10	,	O	['N']	[10]
11	grepafloxacin	O	['N']	[11]
12	,	O	['N']	[12]
13	trovafloxacin	O	['N']	[13]
14	,	O	['N']	[14]
15	gatifloxacin	O	['N']	[15]
16	and	O	['N']	[16]
17	moxifloxacin	B-Drug	['Causes']	[45]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	also	O	['N']	[20]
21	called	O	['N']	[21]
22	gyrase	O	['N']	[22]
23	inhibitors	O	['N']	[23]
24	,	O	['N']	[24]
25	are	O	['N']	[25]
26	known	O	['N']	[26]
27	for	O	['N']	[27]
28	their	O	['N']	[28]
29	potential	O	['N']	[29]
30	to	O	['N']	[30]
31	cause	O	['N']	[31]
32	central	O	['N']	[32]
33	nervous	O	['N']	[33]
34	system	O	['N']	[34]
35	-	O	['N']	[35]
36	related	O	['N']	[36]
37	adverse	O	['N']	[37]
38	effects	O	['N']	[38]
39	,	O	['N']	[39]
40	including	O	['N']	[40]
41	headache	O	['N']	[41]
42	,	O	['N']	[42]
43	dizziness	O	['N']	[43]
44	and	O	['N']	[44]
45	insomnia	B-Adverse_Effect	['N']	[45]
46	.	O	['N']	[46]
#1193
0	Thrombocytosis	B-Adverse_Effect	['N']	[0]
1	under	O	['N']	[1]
2	ciprofloxacin	B-Drug	['Causes']	[0]
3	and	O	['N']	[3]
4	tazobactam	O	['N']	[4]
5	/	O	['N']	[5]
6	piperacillin	O	['N']	[6]
7	.	O	['N']	[7]
#1194
0	Ziprasidone	B-Drug	['Causes']	[21]
1	is	O	['N']	[1]
2	an	O	['N']	[2]
3	atypical	O	['N']	[3]
4	antipsychotic	O	['N']	[4]
5	drug	O	['N']	[5]
6	that	O	['N']	[6]
7	is	O	['N']	[7]
8	believed	O	['N']	[8]
9	to	O	['N']	[9]
10	have	O	['N']	[10]
11	a	O	['N']	[11]
12	low	O	['N']	[12]
13	propensity	O	['N']	[13]
14	for	O	['N']	[14]
15	inducing	O	['N']	[15]
16	extrapyramidal	O	['N']	[16]
17	symptoms	O	['N']	[17]
18	,	O	['N']	[18]
19	including	O	['N']	[19]
20	tardive	B	['N']	[20]
21	dyskinesia	I-Adverse_Effect	['N']	[21]
22	(	O	['N']	[22]
23	TD	O	['N']	[23]
24	)	O	['N']	[24]
25	.	O	['N']	[25]
#1195
0	The	O	['N']	[0]
1	association	O	['N']	[1]
2	between	O	['N']	[2]
3	heparin	B-Drug	['Causes']	[5]
4	and	O	['N']	[4]
5	priapism	B-Adverse_Effect	['N']	[5]
6	is	O	['N']	[6]
7	often	O	['N']	[7]
8	recognized	O	['N']	[8]
9	;	O	['N']	[9]
10	abnormal	O	['N']	[10]
11	platelet	O	['N']	[11]
12	aggregation	O	['N']	[12]
13	could	O	['N']	[13]
14	play	O	['N']	[14]
15	a	O	['N']	[15]
16	role	O	['N']	[16]
17	in	O	['N']	[17]
18	the	O	['N']	[18]
19	pathogenesis	O	['N']	[19]
20	of	O	['N']	[20]
21	this	O	['N']	[21]
22	side	O	['N']	[22]
23	effect	O	['N']	[23]
24	.	O	['N']	[24]
#1196
0	Recently	O	['N']	[0]
1	,	O	['N']	[1]
2	some	O	['N']	[2]
3	studies	O	['N']	[3]
4	have	O	['N']	[4]
5	also	O	['N']	[5]
6	reported	O	['N']	[6]
7	association	O	['N']	[7]
8	between	O	['N']	[8]
9	patients	O	['N']	[9]
10	with	O	['N']	[10]
11	juvenile	O	['N']	[11]
12	rheumatoid	O	['N']	[12]
13	arthritis	O	['N']	[13]
14	(	O	['N']	[14]
15	JRA	O	['N']	[15]
16	)	O	['N']	[16]
17	treated	O	['N']	[17]
18	with	O	['N']	[18]
19	Methotrexate	O	['N']	[19]
20	(	O	['N']	[20]
21	MTX	B-Drug	['Causes']	[25]
22	)	O	['N']	[22]
23	and	O	['N']	[23]
24	malignant	B	['N']	[24]
25	lymphoma	I-Adverse_Effect	['N']	[25]
26	developing	O	['N']	[26]
27	.	O	['N']	[27]
#1197
0	We	O	['N']	[0]
1	postulate	O	['N']	[1]
2	that	O	['N']	[2]
3	cyclosporin	O	['N']	[3]
4	,	O	['N']	[4]
5	possibly	O	['N']	[5]
6	together	O	['N']	[6]
7	with	O	['N']	[7]
8	ganciclovir	B-Drug	['Causes']	[21]
9	,	O	['N']	[9]
10	can	O	['N']	[10]
11	produce	O	['N']	[11]
12	transient	O	['N']	[12]
13	brain	O	['N']	[13]
14	stem	O	['N']	[14]
15	or	O	['N']	[15]
16	neuromuscular	O	['N']	[16]
17	dysfunction	O	['N']	[17]
18	with	O	['N']	[18]
19	eye	B	['N']	[19]
20	movement	I	['N']	[20]
21	abnormality	I-Adverse_Effect	['N']	[21]
22	in	O	['N']	[22]
23	occasional	O	['N']	[23]
24	patients	O	['N']	[24]
25	.	O	['N']	[25]
#1198
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	successful	O	['N']	[3]
4	treatment	O	['N']	[4]
5	of	O	['N']	[5]
6	heparin	B-Drug	['Causes']	[9]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	thrombocytopenia	B-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	subsequent	O	['N']	[11]
12	hemorrhagic	O	['N']	[12]
13	complications	O	['N']	[13]
14	postoperatively	O	['N']	[14]
15	in	O	['N']	[15]
16	a	O	['N']	[16]
17	2-year	O	['N']	[17]
18	-	O	['N']	[18]
19	old	O	['N']	[19]
20	child	O	['N']	[20]
21	with	O	['N']	[21]
22	Danaparoid	O	['N']	[22]
23	(	O	['N']	[23]
24	orgaran	O	['N']	[24]
25	)	O	['N']	[25]
26	.	O	['N']	[26]
#1199
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	These	O	['N']	[2]
3	results	O	['N']	[3]
4	suggest	O	['N']	[4]
5	that	O	['N']	[5]
6	clozapine	B-Drug	['Causes']	[9]
7	may	O	['N']	[7]
8	cause	O	['N']	[8]
9	TD	B-Adverse_Effect	['N']	[9]
10	;	O	['N']	[10]
11	however	O	['N']	[11]
12	,	O	['N']	[12]
13	the	O	['N']	[13]
14	prevalence	O	['N']	[14]
15	is	O	['N']	[15]
16	low	O	['N']	[16]
17	and	O	['N']	[17]
18	the	O	['N']	[18]
19	severity	O	['N']	[19]
20	is	O	['N']	[20]
21	relatively	O	['N']	[21]
22	mild	O	['N']	[22]
23	,	O	['N']	[23]
24	with	O	['N']	[24]
25	no	O	['N']	[25]
26	or	O	['N']	[26]
27	mild	O	['N']	[27]
28	self	O	['N']	[28]
29	-	O	['N']	[29]
30	reported	O	['N']	[30]
31	discomfort	O	['N']	[31]
32	.	O	['N']	[32]
#1200
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	interstitial	B	['N']	[5]
6	hypoxaemiant	I	['N']	[6]
7	pneumonitis	I-Adverse_Effect	['N']	[7]
8	probably	O	['N']	[8]
9	related	O	['N']	[9]
10	to	O	['N']	[10]
11	flecainide	B-Drug	['Causes']	[7]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	patient	O	['N']	[14]
15	with	O	['N']	[15]
16	the	O	['N']	[16]
17	LEOPARD	O	['N']	[17]
18	syndrome	O	['N']	[18]
19	,	O	['N']	[19]
20	a	O	['N']	[20]
21	rare	O	['N']	[21]
22	congenital	O	['N']	[22]
23	disorder	O	['N']	[23]
24	.	O	['N']	[24]
#1201
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Topiramate	B-Drug	['Causes']	[8]
3	may	O	['N']	[3]
4	be	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	ciliochoroidal	B	['N']	[7]
8	effusion	I-Adverse_Effect	['N']	[8]
9	with	O	['N']	[9]
10	forward	O	['N']	[10]
11	displacement	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	lens	O	['N']	[14]
15	-	O	['N']	[15]
16	iris	O	['N']	[16]
17	diaphragm	O	['N']	[17]
18	and	O	['N']	[18]
19	anterior	O	['N']	[19]
20	chamber	O	['N']	[20]
21	shallowing	O	['N']	[21]
22	,	O	['N']	[22]
23	resulting	O	['N']	[23]
24	in	O	['N']	[24]
25	acute	O	['N']	[25]
26	myopia	O	['N']	[26]
27	and	O	['N']	[27]
28	angle	O	['N']	[28]
29	-	O	['N']	[29]
30	closure	O	['N']	[30]
31	glaucoma	O	['N']	[31]
32	.	O	['N']	[32]
#1202
0	Sulindac	B-Drug	['Causes']	[17]
1	(	O	['N']	[1]
2	Clinoril	O	['N']	[2]
3	)	O	['N']	[3]
4	,	O	['N']	[4]
5	a	O	['N']	[5]
6	nonsteroidal	O	['N']	[6]
7	anti	O	['N']	[7]
8	-	O	['N']	[8]
9	inflammatory	O	['N']	[9]
10	agent	O	['N']	[10]
11	,	O	['N']	[11]
12	has	O	['N']	[12]
13	few	O	['N']	[13]
14	reported	O	['N']	[14]
15	neurologic	B	['N']	[15]
16	toxic	I	['N']	[16]
17	effects	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	all	O	['N']	[19]
20	of	O	['N']	[20]
21	which	O	['N']	[21]
22	have	O	['N']	[22]
23	been	O	['N']	[23]
24	associated	O	['N']	[24]
25	with	O	['N']	[25]
26	systemic	O	['N']	[26]
27	disease	O	['N']	[27]
28	.	O	['N']	[28]
#1203
0	Erosion	B	['N']	[0]
1	of	I	['N']	[1]
2	psoriatic	I	['N']	[2]
3	plaques	I-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	chronic	O	['N']	[5]
6	methotrexate	B-Drug	['Causes']	[3]
7	administration	O	['N']	[7]
8	.	O	['N']	[8]
#1204
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	cefazolin	B-Drug	['Causes']	[10]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	leukopenia	B-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	critically	O	['N']	[13]
14	ill	O	['N']	[14]
15	patient	O	['N']	[15]
16	who	O	['N']	[16]
17	developed	O	['N']	[17]
18	this	O	['N']	[18]
19	adverse	O	['N']	[19]
20	reaction	O	['N']	[20]
21	upon	O	['N']	[21]
22	rechallenge	O	['N']	[22]
23	with	O	['N']	[23]
24	cefoxitin	O	['N']	[24]
25	.	O	['N']	[25]
#1205
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	Five	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	contact	B	['N']	[5]
6	dermatitis	I-Adverse_Effect	['N']	[6]
7	due	O	['N']	[7]
8	to	O	['N']	[8]
9	budesonide	B-Drug	['Causes']	[6]
10	,	O	['N']	[10]
11	a	O	['N']	[11]
12	nonhalogenated	O	['N']	[12]
13	steroid	O	['N']	[13]
14	,	O	['N']	[14]
15	are	O	['N']	[15]
16	described	O	['N']	[16]
17	.	O	['N']	[17]
#1206
0	Fluoxetine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	related	O	['N']	[2]
3	death	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	child	O	['N']	[6]
7	with	O	['N']	[7]
8	cytochrome	O	['N']	[8]
9	P-450	O	['N']	[9]
10	2D6	O	['N']	[10]
11	genetic	O	['N']	[11]
12	deficiency	O	['N']	[12]
13	.	O	['N']	[13]
#1207
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	3	O	['N']	[2]
3	AS	O	['N']	[3]
4	patients	O	['N']	[4]
5	treated	O	['N']	[5]
6	with	O	['N']	[6]
7	etanercept	B-Drug	['Causes']	[16]
8	for	O	['N']	[8]
9	active	O	['N']	[9]
10	AS	O	['N']	[10]
11	who	O	['N']	[11]
12	developed	O	['N']	[12]
13	new	O	['N']	[13]
14	onset	O	['N']	[14]
15	of	O	['N']	[15]
16	CD	B-Adverse_Effect	['N']	[16]
17	while	O	['N']	[17]
18	AS	O	['N']	[18]
19	related	O	['N']	[19]
20	symptoms	O	['N']	[20]
21	responded	O	['N']	[21]
22	well	O	['N']	[22]
23	to	O	['N']	[23]
24	etanercept	O	['N']	[24]
25	.	O	['N']	[25]
#1208
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	doxycycline	B-Drug	['Causes']	[9]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	hypoglycemia	B-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	young	O	['N']	[12]
13	nondiabetic	O	['N']	[13]
14	man	O	['N']	[14]
15	.	O	['N']	[15]
#1209
0	Although	O	['N']	[0]
1	visual	B	['N']	[1]
2	hallucinations	I-Adverse_Effect	['N']	[2]
3	have	O	['N']	[3]
4	not	O	['N']	[4]
5	been	O	['N']	[5]
6	reported	O	['N']	[6]
7	as	O	['N']	[7]
8	an	O	['N']	[8]
9	adverse	O	['N']	[9]
10	effect	O	['N']	[10]
11	of	O	['N']	[11]
12	this	O	['N']	[12]
13	agent	O	['N']	[13]
14	,	O	['N']	[14]
15	we	O	['N']	[15]
16	describe	O	['N']	[16]
17	three	O	['N']	[17]
18	patients	O	['N']	[18]
19	who	O	['N']	[19]
20	experienced	O	['N']	[20]
21	complex	O	['N']	[21]
22	visual	O	['N']	[22]
23	hallucinations	O	['N']	[23]
24	and	O	['N']	[24]
25	altered	O	['N']	[25]
26	mental	O	['N']	[26]
27	status	O	['N']	[27]
28	after	O	['N']	[28]
29	zonisamide	B-Drug	['Causes']	[2]
30	treatment	O	['N']	[30]
31	was	O	['N']	[31]
32	begun	O	['N']	[32]
33	or	O	['N']	[33]
34	its	O	['N']	[34]
35	dosage	O	['N']	[35]
36	increased	O	['N']	[36]
37	.	O	['N']	[37]
#1210
0	Systemic	B	['N']	[0]
1	allergic	I	['N']	[1]
2	contact	I	['N']	[2]
3	dermatitis	I-Adverse_Effect	['N']	[3]
4	to	O	['N']	[4]
5	8-methoxypsoralen	O	['N']	[5]
6	(	O	['N']	[6]
7	8-MOP	B-Drug	['Causes']	[3]
8	)	O	['N']	[8]
9	.	O	['N']	[9]
#1211
0	Deepening	B	['N']	[0]
1	of	I	['N']	[1]
2	lid	I	['N']	[2]
3	sulcus	I-Adverse_Effect	['N']	[3]
4	from	O	['N']	[4]
5	topical	O	['N']	[5]
6	bimatoprost	B-Drug	['Causes']	[3]
7	therapy	O	['N']	[7]
8	.	O	['N']	[8]
#1212
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	side	O	['N']	[3]
4	effects	O	['N']	[4]
5	of	O	['N']	[5]
6	5-FU	B-Drug	['Causes']	[15]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	colon	O	['N']	[9]
10	cancer	O	['N']	[10]
11	patient	O	['N']	[11]
12	who	O	['N']	[12]
13	suffered	O	['N']	[13]
14	severe	B	['N']	[14]
15	mucositis	I-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	desquamating	O	['N']	[17]
18	dermatitis	O	['N']	[18]
19	,	O	['N']	[19]
20	prolonged	O	['N']	[20]
21	myelosuppression	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	neurologic	O	['N']	[24]
25	toxicity	O	['N']	[25]
26	that	O	['N']	[26]
27	required	O	['N']	[27]
28	admission	O	['N']	[28]
29	to	O	['N']	[29]
30	the	O	['N']	[30]
31	intensive	O	['N']	[31]
32	care	O	['N']	[32]
33	unit	O	['N']	[33]
34	.	O	['N']	[34]
#1213
0	Our	O	['N']	[0]
1	patient	O	['N']	[1]
2	had	O	['N']	[2]
3	headache	O	['N']	[3]
4	,	O	['N']	[4]
5	mild	O	['N']	[5]
6	fever	O	['N']	[6]
7	,	O	['N']	[7]
8	nausea	O	['N']	[8]
9	,	O	['N']	[9]
10	vomiting	O	['N']	[10]
11	,	O	['N']	[11]
12	rash	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	eosinophilia	B-Adverse_Effect	['N']	[15]
16	after	O	['N']	[16]
17	3	O	['N']	[17]
18	weeks	O	['N']	[18]
19	of	O	['N']	[19]
20	disulfiram	B-Drug	['Causes']	[15]
21	therapy	O	['N']	[21]
22	.	O	['N']	[22]
#1214
0	Here	O	['N']	[0]
1	we	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	Crohn	O	['N']	[6]
7	's	O	['N']	[7]
8	disease	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	a	O	['N']	[11]
12	severe	O	['N']	[12]
13	infliximab	B-Drug	['Causes']	[17]
14	infusion	O	['N']	[14]
15	reaction	O	['N']	[15]
16	(	O	['N']	[16]
17	IIR	B-Adverse_Effect	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	complicated	O	['N']	[20]
21	1	O	['N']	[21]
22	day	O	['N']	[22]
23	later	O	['N']	[23]
24	by	O	['N']	[24]
25	severe	O	['N']	[25]
26	swelling	O	['N']	[26]
27	of	O	['N']	[27]
28	the	O	['N']	[28]
29	forearm	O	['N']	[29]
30	and	O	['N']	[30]
31	hand	O	['N']	[31]
32	ipsilateral	O	['N']	[32]
33	to	O	['N']	[33]
34	the	O	['N']	[34]
35	site	O	['N']	[35]
36	of	O	['N']	[36]
37	infliximab	O	['N']	[37]
38	infusion	O	['N']	[38]
39	.	O	['N']	[39]
#1215
0	Administration	O	['N']	[0]
1	of	O	['N']	[1]
2	lamotrigine	O	['N']	[2]
3	,	O	['N']	[3]
4	especially	O	['N']	[4]
5	in	O	['N']	[5]
6	combination	O	['N']	[6]
7	with	O	['N']	[7]
8	valproic	B	['N']	[8]
9	acid	I-Drug	['Causes']	[17]
10	,	O	['N']	[10]
11	may	O	['N']	[11]
12	lead	O	['N']	[12]
13	to	O	['N']	[13]
14	the	O	['N']	[14]
15	development	O	['N']	[15]
16	of	O	['N']	[16]
17	TEN	B-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#1216
0	Hypertension	B-Adverse_Effect	['N']	[0]
1	develops	O	['N']	[1]
2	in	O	['N']	[2]
3	most	O	['N']	[3]
4	patients	O	['N']	[4]
5	after	O	['N']	[5]
6	transplantation	O	['N']	[6]
7	when	O	['N']	[7]
8	immunosuppression	O	['N']	[8]
9	is	O	['N']	[9]
10	based	O	['N']	[10]
11	on	O	['N']	[11]
12	cyclosporine	B-Drug	['Causes']	[0]
13	and	O	['N']	[13]
14	prednisone	O	['N']	[14]
15	.	O	['N']	[15]
#1217
0	After	O	['N']	[0]
1	seven	O	['N']	[1]
2	months	O	['N']	[2]
3	'	O	['N']	[3]
4	continuous	O	['N']	[4]
5	treatment	O	['N']	[5]
6	for	O	['N']	[6]
7	suspected	O	['N']	[7]
8	tuberculosis	O	['N']	[8]
9	with	O	['N']	[9]
10	rifampicin	O	['N']	[10]
11	and	O	['N']	[11]
12	ethambutol	B-Drug	['Causes']	[21]
13	a	O	['N']	[13]
14	nine	O	['N']	[14]
15	-	O	['N']	[15]
16	year	O	['N']	[16]
17	-	O	['N']	[17]
18	old	O	['N']	[18]
19	boy	O	['N']	[19]
20	developed	O	['N']	[20]
21	polyarthritis	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	rash	O	['N']	[23]
24	and	O	['N']	[24]
25	hepatitis	O	['N']	[25]
26	in	O	['N']	[26]
27	association	O	['N']	[27]
28	with	O	['N']	[28]
29	anti	O	['N']	[29]
30	-	O	['N']	[30]
31	native	O	['N']	[31]
32	DNA	O	['N']	[32]
33	antibodies	O	['N']	[33]
34	and	O	['N']	[34]
35	positive	O	['N']	[35]
36	antinuclear	O	['N']	[36]
37	factor	O	['N']	[37]
38	.	O	['N']	[38]
#1218
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	suggests	O	['N']	[2]
3	that	O	['N']	[3]
4	anemia	B-Adverse_Effect	['N']	[4]
5	can	O	['N']	[5]
6	occur	O	['N']	[6]
7	due	O	['N']	[7]
8	to	O	['N']	[8]
9	MMF	O	['N']	[9]
10	,	O	['N']	[10]
11	in	O	['N']	[11]
12	particular	O	['N']	[12]
13	when	O	['N']	[13]
14	it	O	['N']	[14]
15	is	O	['N']	[15]
16	given	O	['N']	[16]
17	with	O	['N']	[17]
18	prednisone	B-Drug	['Causes']	[4]
19	,	O	['N']	[19]
20	a	O	['N']	[20]
21	side	O	['N']	[21]
22	effect	O	['N']	[22]
23	well	O	['N']	[23]
24	documented	O	['N']	[24]
25	in	O	['N']	[25]
26	the	O	['N']	[26]
27	transplantation	O	['N']	[27]
28	literature	O	['N']	[28]
29	when	O	['N']	[29]
30	the	O	['N']	[30]
31	triple	O	['N']	[31]
32	combination	O	['N']	[32]
33	of	O	['N']	[33]
34	MMF	O	['N']	[34]
35	,	O	['N']	[35]
36	cyclosporine	O	['N']	[36]
37	and	O	['N']	[37]
38	prednisone	O	['N']	[38]
39	is	O	['N']	[39]
40	used	O	['N']	[40]
41	.	O	['N']	[41]
#1219
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Symptoms	O	['N']	[2]
3	and	O	['N']	[3]
4	pathologic	O	['N']	[4]
5	changes	O	['N']	[5]
6	of	O	['N']	[6]
7	colitis	B-Adverse_Effect	['N']	[7]
8	are	O	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	exposure	O	['N']	[11]
12	to	O	['N']	[12]
13	rofecoxib	B-Drug	['Causes']	[7]
14	.	O	['N']	[14]
#1220
0	Chlormadinone	B	['N']	[0]
1	acetate	I-Drug	['Causes']	[3]
2	withdrawal	B	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	under	O	['N']	[4]
5	combined	O	['N']	[5]
6	androgen	O	['N']	[6]
7	blockade	O	['N']	[7]
8	for	O	['N']	[8]
9	advanced	O	['N']	[9]
10	prostate	O	['N']	[10]
11	cancer	O	['N']	[11]
12	.	O	['N']	[12]
#1221
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	this	O	['N']	[3]
4	is	O	['N']	[4]
5	the	O	['N']	[5]
6	first	O	['N']	[6]
7	report	O	['N']	[7]
8	of	O	['N']	[8]
9	pancytopenia	B-Adverse_Effect	['N']	[9]
10	due	O	['N']	[10]
11	to	O	['N']	[11]
12	MMI	B-Drug	['Causes']	[9]
13	,	O	['N']	[13]
14	where	O	['N']	[14]
15	the	O	['N']	[15]
16	usual	O	['N']	[16]
17	hypoplasia	O	['N']	[17]
18	found	O	['N']	[18]
19	is	O	['N']	[19]
20	replaced	O	['N']	[20]
21	by	O	['N']	[21]
22	massive	O	['N']	[22]
23	plasmocytosis	O	['N']	[23]
24	.	O	['N']	[24]
#1222
0	Anterior	B	['N']	[0]
1	spinal	I	['N']	[1]
2	artery	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	--	O	['N']	[4]
5	a	O	['N']	[5]
6	complication	O	['N']	[6]
7	of	O	['N']	[7]
8	cervical	O	['N']	[8]
9	intrathecal	O	['N']	[9]
10	phenol	B-Drug	['Causes']	[3]
11	injection	O	['N']	[11]
12	.	O	['N']	[12]
#1223
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	combined	O	['N']	[6]
7	lithium	B-Drug	['Causes']	[13]
8	and	O	['N']	[8]
9	haloperidol	O	['N']	[9]
10	toxicity	O	['N']	[10]
11	characterized	O	['N']	[11]
12	by	O	['N']	[12]
13	hyperpyrexia	B-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	severe	O	['N']	[15]
16	rigidity	O	['N']	[16]
17	,	O	['N']	[17]
18	mutism	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	development	O	['N']	[21]
22	of	O	['N']	[22]
23	irreversible	O	['N']	[23]
24	tardive	O	['N']	[24]
25	dyskinesia	O	['N']	[25]
26	.	O	['N']	[26]
#1224
0	A	O	['N']	[0]
1	62-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	who	O	['N']	[5]
6	was	O	['N']	[6]
7	being	O	['N']	[7]
8	treated	O	['N']	[8]
9	for	O	['N']	[9]
10	squamous	O	['N']	[10]
11	cell	O	['N']	[11]
12	carcinoma	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	head	O	['N']	[15]
16	and	O	['N']	[16]
17	neck	O	['N']	[17]
18	developed	O	['N']	[18]
19	a	O	['N']	[19]
20	chemotherapy	O	['N']	[20]
21	-	O	['N']	[21]
22	related	O	['N']	[22]
23	hemolytic	B	['N']	[23]
24	-	I	['N']	[24]
25	uremic	I	['N']	[25]
26	syndrome	I-Adverse_Effect	['N']	[26]
27	during	O	['N']	[27]
28	the	O	['N']	[28]
29	second	O	['N']	[29]
30	cycle	O	['N']	[30]
31	of	O	['N']	[31]
32	neoadjuvant	O	['N']	[32]
33	chemotherapy	O	['N']	[33]
34	consisting	O	['N']	[34]
35	of	O	['N']	[35]
36	cisplatin	B-Drug	['Causes']	[26]
37	,	O	['N']	[37]
38	bleomycin	O	['N']	[38]
39	,	O	['N']	[39]
40	and	O	['N']	[40]
41	methotrexate	O	['N']	[41]
42	.	O	['N']	[42]
#1225
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Amphotericin	B	['N']	[2]
3	B	I-Drug	['Causes']	[7]
4	overdose	O	['N']	[4]
5	can	O	['N']	[5]
6	be	O	['N']	[6]
7	fatal	B-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	children	O	['N']	[9]
10	and	O	['N']	[10]
11	infants	O	['N']	[11]
12	.	O	['N']	[12]
#1226
0	Rebound	B	['N']	[0]
1	hyperglycemia	I-Adverse_Effect	['N']	[1]
2	was	O	['N']	[2]
3	observed	O	['N']	[3]
4	with	O	['N']	[4]
5	both	O	['N']	[5]
6	intermediate	O	['N']	[6]
7	(	O	['N']	[7]
8	neutral	O	['N']	[8]
9	protamine	O	['N']	[9]
10	hagedorn	O	['N']	[10]
11	)	O	['N']	[11]
12	and	O	['N']	[12]
13	long	O	['N']	[13]
14	-	O	['N']	[14]
15	acting	O	['N']	[15]
16	(	O	['N']	[16]
17	protamine	B	['N']	[17]
18	zinc	I	['N']	[18]
19	iletin	I-Drug	['Causes']	[1]
20	)	O	['N']	[20]
21	insulins	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	the	O	['N']	[24]
25	range	O	['N']	[25]
26	of	O	['N']	[26]
27	insulin	O	['N']	[27]
28	doses	O	['N']	[28]
29	at	O	['N']	[29]
30	which	O	['N']	[30]
31	the	O	['N']	[31]
32	disorder	O	['N']	[32]
33	developed	O	['N']	[33]
34	overlapped	O	['N']	[34]
35	previously	O	['N']	[35]
36	determined	O	['N']	[36]
37	therapeutic	O	['N']	[37]
38	doses	O	['N']	[38]
39	for	O	['N']	[39]
40	these	O	['N']	[40]
41	insulins	O	['N']	[41]
42	in	O	['N']	[42]
43	the	O	['N']	[43]
44	cat	O	['N']	[44]
45	.	O	['N']	[45]
#1227
0	IFNalpha	B-Drug	['Causes']	[7]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	recurrence	O	['N']	[3]
4	of	O	['N']	[4]
5	Graves	B	['N']	[5]
6	'	I	['N']	[6]
7	disease	I-Adverse_Effect	['N']	[7]
8	ten	O	['N']	[8]
9	years	O	['N']	[9]
10	after	O	['N']	[10]
11	thyroidectomy	O	['N']	[11]
12	in	O	['N']	[12]
13	chronic	O	['N']	[13]
14	viral	O	['N']	[14]
15	hepatitis	O	['N']	[15]
16	C.	O	['N']	[16]
#1228
0	Amiodarone	B-Drug	['Causes']	[4]
1	induced	O	['N']	[1]
2	torsades	B	['N']	[2]
3	de	I	['N']	[3]
4	pointe	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#1229
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	4	O	['N']	[2]
3	patients	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	symptoms	O	['N']	[6]
7	of	O	['N']	[7]
8	myasthenia	B	['N']	[8]
9	gravis	I-Adverse_Effect	['N']	[9]
10	within	O	['N']	[10]
11	2	O	['N']	[11]
12	weeks	O	['N']	[12]
13	of	O	['N']	[13]
14	starting	O	['N']	[14]
15	treatment	O	['N']	[15]
16	with	O	['N']	[16]
17	a	O	['N']	[17]
18	statin	B-Drug	['Causes']	[9]
19	drug	O	['N']	[19]
20	.	O	['N']	[20]
#1230
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	highlights	O	['N']	[2]
3	the	O	['N']	[3]
4	need	O	['N']	[4]
5	to	O	['N']	[5]
6	monitor	O	['N']	[6]
7	liver	O	['N']	[7]
8	enzymes	O	['N']	[8]
9	in	O	['N']	[9]
10	patients	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	6-TG	O	['N']	[13]
14	and	O	['N']	[14]
15	identifies	O	['N']	[15]
16	the	O	['N']	[16]
17	need	O	['N']	[17]
18	for	O	['N']	[18]
19	additional	O	['N']	[19]
20	research	O	['N']	[20]
21	focused	O	['N']	[21]
22	on	O	['N']	[22]
23	the	O	['N']	[23]
24	mechanism	O	['N']	[24]
25	of	O	['N']	[25]
26	thiopurine	B-Drug	['Causes']	[30]
27	-	O	['N']	[27]
28	induced	O	['N']	[28]
29	hepatic	B	['N']	[29]
30	injury	I-Adverse_Effect	['N']	[30]
31	.	O	['N']	[31]
#1231
0	Cyclosporin	B-Drug	['Causes']	[21]
1	side	O	['N']	[1]
2	effects	O	['N']	[2]
3	included	O	['N']	[3]
4	hirsutism	O	['N']	[4]
5	,	O	['N']	[5]
6	hypertension	O	['N']	[6]
7	,	O	['N']	[7]
8	increased	O	['N']	[8]
9	blood	O	['N']	[9]
10	levels	O	['N']	[10]
11	of	O	['N']	[11]
12	urea	O	['N']	[12]
13	and	O	['N']	[13]
14	creatinine	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	abnormalities	B	['N']	[17]
18	in	I	['N']	[18]
19	liver	I	['N']	[19]
20	function	I	['N']	[20]
21	tests	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#1232
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	experienced	O	['N']	[2]
3	muscle	B	['N']	[3]
4	twitches	I-Adverse_Effect	['N']	[4]
5	,	O	['N']	[5]
6	tremulousness	O	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	anxiety	O	['N']	[9]
10	on	O	['N']	[10]
11	day	O	['N']	[11]
12	17	O	['N']	[12]
13	of	O	['N']	[13]
14	foscarnet	B-Drug	['Causes']	[4]
15	therapy	O	['N']	[15]
16	.	O	['N']	[16]
#1233
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	severe	B	['N']	[5]
6	unilateral	I	['N']	[6]
7	posterior	I	['N']	[7]
8	scleritis	I-Adverse_Effect	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	zoledronic	B	['N']	[11]
12	acid	I-Drug	['Causes']	[8]
13	administration	O	['N']	[13]
14	that	O	['N']	[14]
15	was	O	['N']	[15]
16	recognized	O	['N']	[16]
17	and	O	['N']	[17]
18	treated	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	timely	O	['N']	[21]
22	manner	O	['N']	[22]
23	.	O	['N']	[23]
#1234
0	It	O	['N']	[0]
1	has	O	['N']	[1]
2	been	O	['N']	[2]
3	suggested	O	['N']	[3]
4	that	O	['N']	[4]
5	PPE	B-Adverse_Effect	['N']	[5]
6	caused	O	['N']	[6]
7	by	O	['N']	[7]
8	cytarabine	B-Drug	['Causes']	[5]
9	does	O	['N']	[9]
10	not	O	['N']	[10]
11	recur	O	['N']	[11]
12	with	O	['N']	[12]
13	subsequent	O	['N']	[13]
14	cytarabine	O	['N']	[14]
15	re	O	['N']	[15]
16	-	O	['N']	[16]
17	challenge	O	['N']	[17]
18	.	O	['N']	[18]
#1235
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	rare	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	PTU	B-Drug	['Causes']	[12]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	ANCA	B	['N']	[9]
10	-	I	['N']	[10]
11	associated	I	['N']	[11]
12	vasculitis	I-Adverse_Effect	['N']	[12]
13	manifested	O	['N']	[13]
14	with	O	['N']	[14]
15	ototoxicity	O	['N']	[15]
16	in	O	['N']	[16]
17	combination	O	['N']	[17]
18	with	O	['N']	[18]
19	systemic	O	['N']	[19]
20	involvement	O	['N']	[20]
21	.	O	['N']	[21]
#1236
0	The	O	['N']	[0]
1	latter	O	['N']	[1]
2	form	O	['N']	[2]
3	(	O	['N']	[3]
4	Macrodantin	B-Drug	['Causes']	[39]
5	)	O	['N']	[5]
6	is	O	['N']	[6]
7	reported	O	['N']	[7]
8	to	O	['N']	[8]
9	engender	O	['N']	[9]
10	less	O	['N']	[10]
11	gastrointestinal	O	['N']	[11]
12	intolerance	O	['N']	[12]
13	but	O	['N']	[13]
14	it	O	['N']	[14]
15	can	O	['N']	[15]
16	produce	O	['N']	[16]
17	the	O	['N']	[17]
18	same	O	['N']	[18]
19	adverse	O	['N']	[19]
20	effects	O	['N']	[20]
21	as	O	['N']	[21]
22	the	O	['N']	[22]
23	conventional	O	['N']	[23]
24	form	O	['N']	[24]
25	--	O	['N']	[25]
26	liver	O	['N']	[26]
27	damage	O	['N']	[27]
28	,	O	['N']	[28]
29	acute	O	['N']	[29]
30	and	O	['N']	[30]
31	chronic	O	['N']	[31]
32	pulmonary	O	['N']	[32]
33	reactions	O	['N']	[33]
34	,	O	['N']	[34]
35	peripheral	O	['N']	[35]
36	neuropathy	O	['N']	[36]
37	,	O	['N']	[37]
38	blood	B	['N']	[38]
39	dyscrasias	I-Adverse_Effect	['N']	[39]
40	and	O	['N']	[40]
41	allergic	O	['N']	[41]
42	reactions	O	['N']	[42]
43	--	O	['N']	[43]
44	and	O	['N']	[44]
45	does	O	['N']	[45]
46	so	O	['N']	[46]
47	just	O	['N']	[47]
48	as	O	['N']	[48]
49	rapidly	O	['N']	[49]
50	and	O	['N']	[50]
51	floridly	O	['N']	[51]
52	;	O	['N']	[52]
53	one	O	['N']	[53]
54	such	O	['N']	[54]
55	case	O	['N']	[55]
56	is	O	['N']	[56]
57	reported	O	['N']	[57]
58	here	O	['N']	[58]
59	.	O	['N']	[59]
#1237
0	Although	O	['N']	[0]
1	heparin	B-Drug	['Causes']	[11]
2	-	O	['N']	[2]
3	dependent	O	['N']	[3]
4	antibodies	O	['N']	[4]
5	(	O	['N']	[5]
6	HDAs	O	['N']	[6]
7	)	O	['N']	[7]
8	typically	O	['N']	[8]
9	manifest	O	['N']	[9]
10	with	O	['N']	[10]
11	thrombocytopenia	B-Adverse_Effect	['N']	[11]
12	as	O	['N']	[12]
13	in	O	['N']	[13]
14	heparin	O	['N']	[14]
15	-	O	['N']	[15]
16	induced	O	['N']	[16]
17	thrombocytopenia	O	['N']	[17]
18	(	O	['N']	[18]
19	HIT	O	['N']	[19]
20	)	O	['N']	[20]
21	,	O	['N']	[21]
22	they	O	['N']	[22]
23	may	O	['N']	[23]
24	also	O	['N']	[24]
25	manifest	O	['N']	[25]
26	with	O	['N']	[26]
27	preserved	O	['N']	[27]
28	platelet	O	['N']	[28]
29	counts	O	['N']	[29]
30	.	O	['N']	[30]
#1238
0	A	O	['N']	[0]
1	66-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	Japanese	O	['N']	[4]
5	woman	O	['N']	[5]
6	with	O	['N']	[6]
7	severe	O	['N']	[7]
8	scleroderma	O	['N']	[8]
9	developed	O	['N']	[9]
10	anemia	B-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	thrombocytopenia	O	['N']	[12]
13	due	O	['N']	[13]
14	to	O	['N']	[14]
15	D	B	['N']	[15]
16	-	I	['N']	[16]
17	penicillamine	I-Drug	['Causes']	[10]
18	(	O	['N']	[18]
19	D	O	['N']	[19]
20	-	O	['N']	[20]
21	Pen	O	['N']	[21]
22	)	O	['N']	[22]
23	treatment	O	['N']	[23]
24	,	O	['N']	[24]
25	although	O	['N']	[25]
26	the	O	['N']	[26]
27	leukopenia	O	['N']	[27]
28	was	O	['N']	[28]
29	not	O	['N']	[29]
30	markedly	O	['N']	[30]
31	severe	O	['N']	[31]
32	.	O	['N']	[32]
#1239
0	An	O	['N']	[0]
1	insulin	O	['N']	[1]
2	-	O	['N']	[2]
3	dependent	O	['N']	[3]
4	diabetic	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	nephropathy	O	['N']	[7]
8	developed	O	['N']	[8]
9	severe	B	['N']	[9]
10	acidosis	I-Adverse_Effect	['N']	[10]
11	after	O	['N']	[11]
12	treatment	O	['N']	[12]
13	with	O	['N']	[13]
14	acetazolamide	B-Drug	['Causes']	[10]
15	for	O	['N']	[15]
16	glaucoma	O	['N']	[16]
17	.	O	['N']	[17]
#1240
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	the	O	['N']	[2]
3	use	O	['N']	[3]
4	of	O	['N']	[4]
5	lithium	B-Drug	['Causes']	[32]
6	should	O	['N']	[6]
7	be	O	['N']	[7]
8	avoided	O	['N']	[8]
9	with	O	['N']	[9]
10	any	O	['N']	[10]
11	patient	O	['N']	[11]
12	who	O	['N']	[12]
13	is	O	['N']	[13]
14	purging	O	['N']	[14]
15	,	O	['N']	[15]
16	since	O	['N']	[16]
17	it	O	['N']	[17]
18	may	O	['N']	[18]
19	exacerbate	O	['N']	[19]
20	the	O	['N']	[20]
21	loss	O	['N']	[21]
22	of	O	['N']	[22]
23	intracellular	O	['N']	[23]
24	potassium	O	['N']	[24]
25	,	O	['N']	[25]
26	thereby	O	['N']	[26]
27	increasing	O	['N']	[27]
28	the	O	['N']	[28]
29	risk	O	['N']	[29]
30	of	O	['N']	[30]
31	cardiac	B	['N']	[31]
32	toxicity	I-Adverse_Effect	['N']	[32]
33	.	O	['N']	[33]
#1241
0	Cefuroxime	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	immune	B	['N']	[3]
4	hemolysis	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#1242
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	,	O	['N']	[3]
4	one	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	developed	O	['N']	[7]
8	gangrene	B-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	bleomycin	O	['N']	[10]
11	and	O	['N']	[11]
12	vincristine	O	['N']	[12]
13	/	O	['N']	[13]
14	vinblastine	B-Drug	['Causes']	[8]
15	chemotherapy	O	['N']	[15]
16	for	O	['N']	[16]
17	AIDS	O	['N']	[17]
18	-	O	['N']	[18]
19	related	O	['N']	[19]
20	Kaposi	O	['N']	[20]
21	's	O	['N']	[21]
22	sarcoma	O	['N']	[22]
23	and	O	['N']	[23]
24	another	O	['N']	[24]
25	HIV	O	['N']	[25]
26	-	O	['N']	[26]
27	infected	O	['N']	[27]
28	patient	O	['N']	[28]
29	who	O	['N']	[29]
30	exhibited	O	['N']	[30]
31	symptoms	O	['N']	[31]
32	of	O	['N']	[32]
33	severe	O	['N']	[33]
34	Raynaud	O	['N']	[34]
35	's	O	['N']	[35]
36	phenomenon	O	['N']	[36]
37	related	O	['N']	[37]
38	to	O	['N']	[38]
39	the	O	['N']	[39]
40	same	O	['N']	[40]
41	regimen	O	['N']	[41]
42	are	O	['N']	[42]
43	presented	O	['N']	[43]
44	.	O	['N']	[44]
#1243
0	We	O	['N']	[0]
1	assume	O	['N']	[1]
2	that	O	['N']	[2]
3	rIFN	B	['N']	[3]
4	-	I	['N']	[4]
5	gamma	I-Drug	['Causes']	[12]
6	induced	O	['N']	[6]
7	the	O	['N']	[7]
8	de	O	['N']	[8]
9	novo	O	['N']	[9]
10	development	O	['N']	[10]
11	of	O	['N']	[11]
12	SLE	B-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	our	O	['N']	[14]
15	patient	O	['N']	[15]
16	.	O	['N']	[16]
#1244
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	44-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	with	O	['N']	[7]
8	t	O	['N']	[8]
9	-	O	['N']	[9]
10	MDS	O	['N']	[10]
11	(	O	['N']	[11]
12	refractory	B	['N']	[12]
13	anemia	I	['N']	[13]
14	with	I	['N']	[14]
15	excess	I	['N']	[15]
16	blasts	I-Adverse_Effect	['N']	[16]
17	)	O	['N']	[17]
18	following	O	['N']	[18]
19	treatment	O	['N']	[19]
20	of	O	['N']	[20]
21	recurrent	O	['N']	[21]
22	anaplastic	O	['N']	[22]
23	astrocytoma	O	['N']	[23]
24	with	O	['N']	[24]
25	temozolomide	B-Drug	['Causes']	[16]
26	(	O	['N']	[26]
27	TMZ	O	['N']	[27]
28	)	O	['N']	[28]
29	.	O	['N']	[29]
#1245
0	Pheripheral	O	['N']	[0]
1	edema	O	['N']	[1]
2	was	O	['N']	[2]
3	observed	O	['N']	[3]
4	in	O	['N']	[4]
5	five	O	['N']	[5]
6	female	O	['N']	[6]
7	patients	O	['N']	[7]
8	after	O	['N']	[8]
9	taking	O	['N']	[9]
10	proton	O	['N']	[10]
11	pump	O	['N']	[11]
12	inhibitors	O	['N']	[12]
13	omeprazole	O	['N']	[13]
14	,	O	['N']	[14]
15	lansoprazole	B-Drug	['Dosage']	[30]
16	,	O	['N']	[16]
17	or	O	['N']	[17]
18	pantoprazole	O	['N']	[18]
19	for	O	['N']	[19]
20	7	O	['N']	[20]
21	-	O	['N']	[21]
22	15	O	['N']	[22]
23	days	O	['N']	[23]
24	for	O	['N']	[24]
25	peptic	O	['N']	[25]
26	acid	O	['N']	[26]
27	diseases	O	['N']	[27]
28	in	O	['N']	[28]
29	recommended	O	['N']	[29]
30	standard	B-Dose	['N']	[30]
31	doses	O	['N']	[31]
32	.	O	['N']	[32]
#1246
0	An	O	['N']	[0]
1	infant	O	['N']	[1]
2	girl	O	['N']	[2]
3	with	O	['N']	[3]
4	choanal	B	['N']	[4]
5	atresia	I-Adverse_Effect	['N']	[5]
6	,	O	['N']	[6]
7	athelia	O	['N']	[7]
8	,	O	['N']	[8]
9	minor	O	['N']	[9]
10	anomalies	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	mild	O	['N']	[13]
14	to	O	['N']	[14]
15	moderate	O	['N']	[15]
16	mental	O	['N']	[16]
17	retardation	O	['N']	[17]
18	was	O	['N']	[18]
19	born	O	['N']	[19]
20	to	O	['N']	[20]
21	a	O	['N']	[21]
22	woman	O	['N']	[22]
23	treated	O	['N']	[23]
24	for	O	['N']	[24]
25	hyperthyroidism	O	['N']	[25]
26	throughout	O	['N']	[26]
27	pregnancy	O	['N']	[27]
28	with	O	['N']	[28]
29	methimazole	O	['N']	[29]
30	and	O	['N']	[30]
31	propranolol	B-Drug	['Causes']	[5]
32	.	O	['N']	[32]
#1247
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	observation	O	['N']	[3]
4	that	O	['N']	[4]
5	neurotoxicity	B-Adverse_Effect	['N']	[5]
6	developed	O	['N']	[6]
7	with	O	['N']	[7]
8	a	O	['N']	[8]
9	delay	O	['N']	[9]
10	of	O	['N']	[10]
11	24	O	['N']	[11]
12	to	O	['N']	[12]
13	48	O	['N']	[13]
14	hours	O	['N']	[14]
15	after	O	['N']	[15]
16	acyclovir	B-Drug	['Causes']	[5]
17	peak	O	['N']	[17]
18	serum	O	['N']	[18]
19	concentrations	O	['N']	[19]
20	could	O	['N']	[20]
21	explain	O	['N']	[21]
22	the	O	['N']	[22]
23	wide	O	['N']	[23]
24	range	O	['N']	[24]
25	of	O	['N']	[25]
26	acyclovir	O	['N']	[26]
27	levels	O	['N']	[27]
28	reported	O	['N']	[28]
29	in	O	['N']	[29]
30	similar	O	['N']	[30]
31	cases	O	['N']	[31]
32	.	O	['N']	[32]
#1248
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	ethylenediamine	B-Drug	['Causes']	[10]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	delayed	B	['N']	[8]
9	hypersensitivity	I	['N']	[9]
10	reaction	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	46-year	O	['N']	[13]
14	-	O	['N']	[14]
15	old	O	['N']	[15]
16	woman	O	['N']	[16]
17	who	O	['N']	[17]
18	received	O	['N']	[18]
19	parenteral	O	['N']	[19]
20	aminophylline	O	['N']	[20]
21	for	O	['N']	[21]
22	an	O	['N']	[22]
23	acute	O	['N']	[23]
24	asthma	O	['N']	[24]
25	exacerbation	O	['N']	[25]
26	.	O	['N']	[26]
#1249
0	Minimal	B	['N']	[0]
1	change	I	['N']	[1]
2	nephrotic	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	developing	O	['N']	[4]
5	during	O	['N']	[5]
6	postoperative	O	['N']	[6]
7	interferon	B	['N']	[7]
8	-	I	['N']	[8]
9	beta	I-Drug	['Causes']	[3]
10	therapy	O	['N']	[10]
11	for	O	['N']	[11]
12	malignant	O	['N']	[12]
13	melanoma	O	['N']	[13]
14	.	O	['N']	[14]
#1250
0	Protease	O	['N']	[0]
1	inhibitor	O	['N']	[1]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	carbamazepine	B-Drug	['Causes']	[5]
5	toxicity	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#1251
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Optic	B	['N']	[2]
3	neuritis	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	combination	O	['N']	[5]
6	with	O	['N']	[6]
7	other	O	['N']	[7]
8	neurological	O	['N']	[8]
9	signs	O	['N']	[9]
10	,	O	['N']	[10]
11	simulating	O	['N']	[11]
12	multiple	O	['N']	[12]
13	sclerosis	O	['N']	[13]
14	,	O	['N']	[14]
15	should	O	['N']	[15]
16	be	O	['N']	[16]
17	included	O	['N']	[17]
18	in	O	['N']	[18]
19	the	O	['N']	[19]
20	list	O	['N']	[20]
21	of	O	['N']	[21]
22	adverse	O	['N']	[22]
23	effects	O	['N']	[23]
24	of	O	['N']	[24]
25	recombinant	O	['N']	[25]
26	and	O	['N']	[26]
27	natural	O	['N']	[27]
28	interferon	B	['N']	[28]
29	alpha	I-Drug	['Causes']	[3]
30	administration	O	['N']	[30]
31	.	O	['N']	[31]
#1252
0	Following	O	['N']	[0]
1	several	O	['N']	[1]
2	of	O	['N']	[2]
3	these	O	['N']	[3]
4	courses	O	['N']	[4]
5	of	O	['N']	[5]
6	therapy	O	['N']	[6]
7	,	O	['N']	[7]
8	respiratory	B	['N']	[8]
9	distress	I-Adverse_Effect	['N']	[9]
10	occurred	O	['N']	[10]
11	9	O	['N']	[11]
12	to	O	['N']	[12]
13	12	O	['N']	[13]
14	days	O	['N']	[14]
15	after	O	['N']	[15]
16	the	O	['N']	[16]
17	chlorambucil	B-Drug	['Causes']	[9]
18	was	O	['N']	[18]
19	given	O	['N']	[19]
20	.	O	['N']	[20]
#1253
0	Iatrogenic	O	['N']	[0]
1	hypercalcemia	B-Adverse_Effect	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	vitamin	O	['N']	[4]
5	D3	O	['N']	[5]
6	ointment	O	['N']	[6]
7	(	O	['N']	[7]
8	1,24(OH)2D3	B-Drug	['Causes']	[1]
9	)	O	['N']	[9]
10	combined	O	['N']	[10]
11	with	O	['N']	[11]
12	thiazide	O	['N']	[12]
13	diuretics	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	case	O	['N']	[16]
17	of	O	['N']	[17]
18	psoriasis	O	['N']	[18]
19	.	O	['N']	[19]
#1254
0	Two	O	['N']	[0]
1	children	O	['N']	[1]
2	,	O	['N']	[2]
3	1	O	['N']	[3]
4	with	O	['N']	[4]
5	idiopathic	O	['N']	[5]
6	nephrotic	O	['N']	[6]
7	syndrome	O	['N']	[7]
8	and	O	['N']	[8]
9	1	O	['N']	[9]
10	with	O	['N']	[10]
11	endo	O	['N']	[11]
12	-	O	['N']	[12]
13	extracapillary	O	['N']	[13]
14	glomerulonephritis	O	['N']	[14]
15	,	O	['N']	[15]
16	presented	O	['N']	[16]
17	an	O	['N']	[17]
18	episode	O	['N']	[18]
19	of	O	['N']	[19]
20	seizures	O	['N']	[20]
21	and	O	['N']	[21]
22	transient	B	['N']	[22]
23	blindness	I-Adverse_Effect	['N']	[23]
24	at	O	['N']	[24]
25	different	O	['N']	[25]
26	times	O	['N']	[26]
27	after	O	['N']	[27]
28	i.v	O	['N']	[28]
29	.	O	['N']	[29]
30	pulse	O	['N']	[30]
31	methylprednisolone	B-Drug	['Causes']	[23]
32	(	O	['N']	[32]
33	IVPMP	O	['N']	[33]
34	)	O	['N']	[34]
35	treatment	O	['N']	[35]
36	.	O	['N']	[36]
#1255
0	Although	O	['N']	[0]
1	other	O	['N']	[1]
2	nitrites	O	['N']	[2]
3	induce	O	['N']	[3]
4	methemoglobinemia	B-Adverse_Effect	['N']	[4]
5	,	O	['N']	[5]
6	exposure	O	['N']	[6]
7	to	O	['N']	[7]
8	methyl	B	['N']	[8]
9	nitrite	I-Drug	['Causes']	[4]
10	during	O	['N']	[10]
11	phenylpropanolamine	O	['N']	[11]
12	production	O	['N']	[12]
13	appears	O	['N']	[13]
14	to	O	['N']	[14]
15	be	O	['N']	[15]
16	a	O	['N']	[16]
17	new	O	['N']	[17]
18	cause	O	['N']	[18]
19	of	O	['N']	[19]
20	occupational	O	['N']	[20]
21	methemoglobinemia	O	['N']	[21]
22	.	O	['N']	[22]
#1256
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	fatal	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	toxic	O	['N']	[6]
7	epidermal	O	['N']	[7]
8	necrolysis	O	['N']	[8]
9	(	O	['N']	[9]
10	TEN	B-Adverse_Effect	['N']	[10]
11	)	O	['N']	[11]
12	resulting	O	['N']	[12]
13	from	O	['N']	[13]
14	a	O	['N']	[14]
15	high	O	['N']	[15]
16	dose	O	['N']	[16]
17	of	O	['N']	[17]
18	cytosine	B	['N']	[18]
19	arabinoside	I-Drug	['Causes']	[10]
20	(	O	['N']	[20]
21	ARA	O	['N']	[21]
22	-	O	['N']	[22]
23	C	O	['N']	[23]
24	)	O	['N']	[24]
25	.	O	['N']	[25]
#1257
0	Progressive	B	['N']	[0]
1	hypoxemia	I-Adverse_Effect	['N']	[1]
2	mandated	O	['N']	[2]
3	endotracheal	O	['N']	[3]
4	intubation	O	['N']	[4]
5	1	O	['N']	[5]
6	week	O	['N']	[6]
7	after	O	['N']	[7]
8	rituximab	B-Drug	['Causes']	[1]
9	administration	O	['N']	[9]
10	and	O	['N']	[10]
11	led	O	['N']	[11]
12	to	O	['N']	[12]
13	death	O	['N']	[13]
14	4	O	['N']	[14]
15	weeks	O	['N']	[15]
16	after	O	['N']	[16]
17	admission	O	['N']	[17]
18	.	O	['N']	[18]
#1258
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Atovaquone	B-Drug	['Causes']	[13]
3	should	O	['N']	[3]
4	be	O	['N']	[4]
5	added	O	['N']	[5]
6	to	O	['N']	[6]
7	the	O	['N']	[7]
8	list	O	['N']	[8]
9	of	O	['N']	[9]
10	agents	O	['N']	[10]
11	causing	O	['N']	[11]
12	vortex	B	['N']	[12]
13	keratopathy	I-Adverse_Effect	['N']	[13]
14	involving	O	['N']	[14]
15	the	O	['N']	[15]
16	corneal	O	['N']	[16]
17	epithelium	O	['N']	[17]
18	.	O	['N']	[18]
#1259
0	Ibuprofen	B-Drug	['Causes']	[7]
1	overdose	O	['N']	[1]
2	is	O	['N']	[2]
3	usually	O	['N']	[3]
4	characterized	O	['N']	[4]
5	by	O	['N']	[5]
6	GI	B	['N']	[6]
7	upset	I-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	dizziness	O	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	mild	O	['N']	[12]
13	sedation	O	['N']	[13]
14	.	O	['N']	[14]
#1260
0	Cholestatic	O	['N']	[0]
1	liver	O	['N']	[1]
2	disease	O	['N']	[2]
3	with	O	['N']	[3]
4	ductopenia	O	['N']	[4]
5	(	O	['N']	[5]
6	vanishing	B	['N']	[6]
7	bile	I	['N']	[7]
8	duct	I	['N']	[8]
9	syndrome	I-Adverse_Effect	['N']	[9]
10	)	O	['N']	[10]
11	after	O	['N']	[11]
12	administration	O	['N']	[12]
13	of	O	['N']	[13]
14	clindamycin	O	['N']	[14]
15	and	O	['N']	[15]
16	trimethoprim	B	['N']	[16]
17	-	I	['N']	[17]
18	sulfamethoxazole	I-Drug	['Causes']	[9]
19	.	O	['N']	[19]
#1261
0	This	O	['N']	[0]
1	entity	O	['N']	[1]
2	is	O	['N']	[2]
3	probably	O	['N']	[3]
4	related	O	['N']	[4]
5	to	O	['N']	[5]
6	a	O	['N']	[6]
7	combination	O	['N']	[7]
8	of	O	['N']	[8]
9	high	O	['N']	[9]
10	doses	O	['N']	[10]
11	of	O	['N']	[11]
12	corticosteroids	O	['N']	[12]
13	,	O	['N']	[13]
14	vecuronium	B-Drug	['Causes']	[22]
15	administration	O	['N']	[15]
16	and	O	['N']	[16]
17	metabolic	O	['N']	[17]
18	abnormalities	O	['N']	[18]
19	associated	O	['N']	[19]
20	with	O	['N']	[20]
21	respiratory	B	['N']	[21]
22	failure	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#1262
0	Pancytopenia	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	5-aminosalicylic	B	['N']	[3]
4	acid	I-Drug	['Causes']	[0]
5	use	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	Crohn	O	['N']	[10]
11	's	O	['N']	[11]
12	disease	O	['N']	[12]
13	.	O	['N']	[13]
#1263
0	Gold	B	['N']	[0]
1	nephropathy	I-Adverse_Effect	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	auranofin	B-Drug	['Causes']	[1]
5	obscured	O	['N']	[5]
6	by	O	['N']	[6]
7	tolmetin	O	['N']	[7]
8	pseudoproteinuria	O	['N']	[8]
9	.	O	['N']	[9]
#1264
0	Eleven	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	initiation	O	['N']	[3]
4	of	O	['N']	[4]
5	therapy	O	['N']	[5]
6	with	O	['N']	[6]
7	amiodarone	B-Drug	['Causes']	[12]
8	,	O	['N']	[8]
9	the	O	['N']	[9]
10	patient	O	['N']	[10]
11	experienced	O	['N']	[11]
12	syncope	B-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	was	O	['N']	[14]
15	noted	O	['N']	[15]
16	to	O	['N']	[16]
17	have	O	['N']	[17]
18	recurrent	O	['N']	[18]
19	episodes	O	['N']	[19]
20	of	O	['N']	[20]
21	polymorphous	O	['N']	[21]
22	ventricular	O	['N']	[22]
23	tachycardia	O	['N']	[23]
24	.	O	['N']	[24]
#1265
0	A	O	['N']	[0]
1	young	O	['N']	[1]
2	woman	O	['N']	[2]
3	developed	O	['N']	[3]
4	galactorrhea	B-Adverse_Effect	['N']	[4]
5	during	O	['N']	[5]
6	treatment	O	['N']	[6]
7	with	O	['N']	[7]
8	a	O	['N']	[8]
9	new	O	['N']	[9]
10	dibenzoxazepine	B-Drug	['Causes']	[4]
11	antidepressant	O	['N']	[11]
12	,	O	['N']	[12]
13	amoxapine	O	['N']	[13]
14	.	O	['N']	[14]
#1266
0	Gold	B-Drug	['Causes']	[1]
1	nephropathy	I-Adverse_Effect	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	auranofin	O	['N']	[4]
5	obscured	O	['N']	[5]
6	by	O	['N']	[6]
7	tolmetin	O	['N']	[7]
8	pseudoproteinuria	O	['N']	[8]
9	.	O	['N']	[9]
#1267
0	One	O	['N']	[0]
1	of	O	['N']	[1]
2	the	O	['N']	[2]
3	subjects	O	['N']	[3]
4	who	O	['N']	[4]
5	was	O	['N']	[5]
6	using	O	['N']	[6]
7	extemporaneous	O	['N']	[7]
8	topical	O	['N']	[8]
9	minoxidil	B-Drug	['Causes']	[11]
10	had	O	['N']	[10]
11	hypertension	B-Adverse_Effect	['N']	[11]
12	and	O	['N']	[12]
13	arteriosclerotic	O	['N']	[13]
14	disease	O	['N']	[14]
15	and	O	['N']	[15]
16	the	O	['N']	[16]
17	other	O	['N']	[17]
18	died	O	['N']	[18]
19	of	O	['N']	[19]
20	a	O	['N']	[20]
21	myocardial	O	['N']	[21]
22	infarction	O	['N']	[22]
23	.	O	['N']	[23]
#1268
0	Sulindac	O	['N']	[0]
1	(	O	['N']	[1]
2	Clinoril	B-Drug	['Causes']	[17]
3	)	O	['N']	[3]
4	,	O	['N']	[4]
5	a	O	['N']	[5]
6	nonsteroidal	O	['N']	[6]
7	anti	O	['N']	[7]
8	-	O	['N']	[8]
9	inflammatory	O	['N']	[9]
10	agent	O	['N']	[10]
11	,	O	['N']	[11]
12	has	O	['N']	[12]
13	few	O	['N']	[13]
14	reported	O	['N']	[14]
15	neurologic	B	['N']	[15]
16	toxic	I	['N']	[16]
17	effects	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	all	O	['N']	[19]
20	of	O	['N']	[20]
21	which	O	['N']	[21]
22	have	O	['N']	[22]
23	been	O	['N']	[23]
24	associated	O	['N']	[24]
25	with	O	['N']	[25]
26	systemic	O	['N']	[26]
27	disease	O	['N']	[27]
28	.	O	['N']	[28]
#1269
0	Transient	O	['N']	[0]
1	neurological	O	['N']	[1]
2	disturbances	O	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	the	O	['N']	[5]
6	chemotherapy	O	['N']	[6]
7	of	O	['N']	[7]
8	high	B	['N']	[8]
9	-	I	['N']	[9]
10	dose	I-Dose	['N']	[10]
11	methotrexate	B-Drug	['Dosage']	[10]
12	for	O	['N']	[12]
13	osteogenic	O	['N']	[13]
14	sarcoma	O	['N']	[14]
15	.	O	['N']	[15]
#1270
0	Pneumocystis	O	['N']	[0]
1	pneumonia	O	['N']	[1]
2	should	O	['N']	[2]
3	be	O	['N']	[3]
4	considered	O	['N']	[4]
5	in	O	['N']	[5]
6	asthmatic	O	['N']	[6]
7	patients	O	['N']	[7]
8	taking	O	['N']	[8]
9	methotrexate	B-Drug	['Causes']	[16]
10	who	O	['N']	[10]
11	present	O	['N']	[11]
12	with	O	['N']	[12]
13	fever	O	['N']	[13]
14	,	O	['N']	[14]
15	pulmonary	B	['N']	[15]
16	infiltrates	I-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	hypoxia	O	['N']	[19]
20	.	O	['N']	[20]
#1271
0	Transient	B	['N']	[0]
1	cardiac	I	['N']	[1]
2	arrhythmias	I-Adverse_Effect	['N']	[2]
3	related	O	['N']	[3]
4	to	O	['N']	[4]
5	lopinavir	O	['N']	[5]
6	/	O	['N']	[6]
7	ritonavir	B-Drug	['Causes']	[2]
8	in	O	['N']	[8]
9	two	O	['N']	[9]
10	patients	O	['N']	[10]
11	with	O	['N']	[11]
12	HIV	O	['N']	[12]
13	infection	O	['N']	[13]
14	.	O	['N']	[14]
#1272
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	illustrates	O	['N']	[2]
3	the	O	['N']	[3]
4	potential	O	['N']	[4]
5	decoupling	B	['N']	[5]
6	of	I	['N']	[6]
7	PSA	I	['N']	[7]
8	response	I-Adverse_Effect	['N']	[8]
9	from	O	['N']	[9]
10	disease	O	['N']	[10]
11	status	O	['N']	[11]
12	in	O	['N']	[12]
13	flutamide	B-Drug	['Causes']	[8]
14	withdrawal	O	['N']	[14]
15	.	O	['N']	[15]
#1273
0	A	O	['N']	[0]
1	79-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	ischemic	O	['N']	[6]
7	heart	O	['N']	[7]
8	disease	O	['N']	[8]
9	,	O	['N']	[9]
10	chronic	O	['N']	[10]
11	atrial	O	['N']	[11]
12	fibrillation	O	['N']	[12]
13	,	O	['N']	[13]
14	chronic	O	['N']	[14]
15	renal	O	['N']	[15]
16	failure	O	['N']	[16]
17	,	O	['N']	[17]
18	hypothyroidism	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	gout	O	['N']	[21]
22	arthritis	O	['N']	[22]
23	was	O	['N']	[23]
24	hospitalized	O	['N']	[24]
25	because	O	['N']	[25]
26	of	O	['N']	[26]
27	fatigue	O	['N']	[27]
28	,	O	['N']	[28]
29	myalgia	B-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	leg	O	['N']	[32]
33	weakness	O	['N']	[33]
34	,	O	['N']	[34]
35	shortly	O	['N']	[35]
36	after	O	['N']	[36]
37	starting	O	['N']	[37]
38	treatment	O	['N']	[38]
39	with	O	['N']	[39]
40	colchicine	B-Drug	['Causes']	[29]
41	.	O	['N']	[41]
#1274
0	We	O	['N']	[0]
1	recommend	O	['N']	[1]
2	that	O	['N']	[2]
3	clinicians	O	['N']	[3]
4	monitor	O	['N']	[4]
5	patients	O	['N']	[5]
6	for	O	['N']	[6]
7	signs	O	['N']	[7]
8	and	O	['N']	[8]
9	symptoms	O	['N']	[9]
10	of	O	['N']	[10]
11	pancreatitis	O	['N']	[11]
12	,	O	['N']	[12]
13	including	O	['N']	[13]
14	abdominal	B	['N']	[14]
15	pain	I-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	during	O	['N']	[17]
18	treatment	O	['N']	[18]
19	with	O	['N']	[19]
20	tigecycline	B-Drug	['Causes']	[15]
21	.	O	['N']	[21]
#1275
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	ovarian	O	['N']	[3]
4	cancer	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	received	O	['N']	[7]
8	multiple	O	['N']	[8]
9	courses	O	['N']	[9]
10	of	O	['N']	[10]
11	cisplatin	B-Drug	['Causes']	[29]
12	without	O	['N']	[12]
13	complications	O	['N']	[13]
14	experienced	O	['N']	[14]
15	hypersensitivity	O	['N']	[15]
16	reactions	O	['N']	[16]
17	to	O	['N']	[17]
18	cisplatin	O	['N']	[18]
19	:	O	['N']	[19]
20	one	O	['N']	[20]
21	,	O	['N']	[21]
22	involving	O	['N']	[22]
23	intrahepatic	O	['N']	[23]
24	artery	O	['N']	[24]
25	infusion	O	['N']	[25]
26	,	O	['N']	[26]
27	manifested	O	['N']	[27]
28	general	B	['N']	[28]
29	erythema	I-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	dyspnea	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	hypotension	O	['N']	[34]
35	;	O	['N']	[35]
36	the	O	['N']	[36]
37	other	O	['N']	[37]
38	,	O	['N']	[38]
39	involving	O	['N']	[39]
40	intravenous	O	['N']	[40]
41	infusion	O	['N']	[41]
42	,	O	['N']	[42]
43	manifested	O	['N']	[43]
44	abdominal	O	['N']	[44]
45	pain	O	['N']	[45]
46	,	O	['N']	[46]
47	general	O	['N']	[47]
48	erythema	O	['N']	[48]
49	,	O	['N']	[49]
50	and	O	['N']	[50]
51	fever	O	['N']	[51]
52	.	O	['N']	[52]
#1276
0	In	O	['N']	[0]
1	one	O	['N']	[1]
2	patient	O	['N']	[2]
3	the	O	['N']	[3]
4	vasculitis	O	['N']	[4]
5	resolved	O	['N']	[5]
6	after	O	['N']	[6]
7	termination	O	['N']	[7]
8	of	O	['N']	[8]
9	the	O	['N']	[9]
10	ciprofloxacin	B-Drug	['Causes']	[22]
11	therapy	O	['N']	[11]
12	;	O	['N']	[12]
13	in	O	['N']	[13]
14	the	O	['N']	[14]
15	other	O	['N']	[15]
16	patient	O	['N']	[16]
17	the	O	['N']	[17]
18	ciprofloxacin	O	['N']	[18]
19	-	O	['N']	[19]
20	induced	O	['N']	[20]
21	hemorrhagic	B	['N']	[21]
22	vasculitis	I-Adverse_Effect	['N']	[22]
23	was	O	['N']	[23]
24	superimposed	O	['N']	[24]
25	on	O	['N']	[25]
26	a	O	['N']	[26]
27	severe	O	['N']	[27]
28	forefoot	O	['N']	[28]
29	infection	O	['N']	[29]
30	,	O	['N']	[30]
31	leading	O	['N']	[31]
32	to	O	['N']	[32]
33	progressive	O	['N']	[33]
34	gangrene	O	['N']	[34]
35	and	O	['N']	[35]
36	a	O	['N']	[36]
37	below	O	['N']	[37]
38	-	O	['N']	[38]
39	knee	O	['N']	[39]
40	amputation	O	['N']	[40]
41	.	O	['N']	[41]
#1277
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	new	O	['N']	[3]
4	quinolone	O	['N']	[4]
5	derivatives	O	['N']	[5]
6	(	O	['N']	[6]
7	levofloxacin	O	['N']	[7]
8	,	O	['N']	[8]
9	sparfloxacin	O	['N']	[9]
10	,	O	['N']	[10]
11	grepafloxacin	B-Drug	['Causes']	[45]
12	,	O	['N']	[12]
13	trovafloxacin	O	['N']	[13]
14	,	O	['N']	[14]
15	gatifloxacin	O	['N']	[15]
16	and	O	['N']	[16]
17	moxifloxacin	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	also	O	['N']	[20]
21	called	O	['N']	[21]
22	gyrase	O	['N']	[22]
23	inhibitors	O	['N']	[23]
24	,	O	['N']	[24]
25	are	O	['N']	[25]
26	known	O	['N']	[26]
27	for	O	['N']	[27]
28	their	O	['N']	[28]
29	potential	O	['N']	[29]
30	to	O	['N']	[30]
31	cause	O	['N']	[31]
32	central	O	['N']	[32]
33	nervous	O	['N']	[33]
34	system	O	['N']	[34]
35	-	O	['N']	[35]
36	related	O	['N']	[36]
37	adverse	O	['N']	[37]
38	effects	O	['N']	[38]
39	,	O	['N']	[39]
40	including	O	['N']	[40]
41	headache	O	['N']	[41]
42	,	O	['N']	[42]
43	dizziness	O	['N']	[43]
44	and	O	['N']	[44]
45	insomnia	B-Adverse_Effect	['N']	[45]
46	.	O	['N']	[46]
#1278
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	polyserositis	O	['N']	[9]
10	(	O	['N']	[10]
11	pericardial	B	['N']	[11]
12	effusion	I-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	pleural	O	['N']	[14]
15	effusion	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	pericarditis	O	['N']	[18]
19	)	O	['N']	[19]
20	after	O	['N']	[20]
21	being	O	['N']	[21]
22	started	O	['N']	[22]
23	on	O	['N']	[23]
24	clozapine	B-Drug	['Causes']	[12]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	whose	O	['N']	[27]
28	symptoms	O	['N']	[28]
29	remitted	O	['N']	[29]
30	upon	O	['N']	[30]
31	discontinuation	O	['N']	[31]
32	of	O	['N']	[32]
33	clozapine	O	['N']	[33]
34	.	O	['N']	[34]
#1279
0	To	O	['N']	[0]
1	date	O	['N']	[1]
2	,	O	['N']	[2]
3	eight	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	TEN	O	['N']	[6]
7	and	O	['N']	[7]
8	one	O	['N']	[8]
9	of	O	['N']	[9]
10	SJS	B-Adverse_Effect	['N']	[10]
11	related	O	['N']	[11]
12	to	O	['N']	[12]
13	lamotrigine	B-Drug	['Causes']	[10]
14	administration	O	['N']	[14]
15	have	O	['N']	[15]
16	been	O	['N']	[16]
17	reported	O	['N']	[17]
18	in	O	['N']	[18]
19	the	O	['N']	[19]
20	literature	O	['N']	[20]
21	.	O	['N']	[21]
#1280
0	The	O	['N']	[0]
1	renal	O	['N']	[1]
2	insufficiency	O	['N']	[2]
3	of	O	['N']	[3]
4	three	O	['N']	[4]
5	patients	O	['N']	[5]
6	and	O	['N']	[6]
7	the	O	['N']	[7]
8	timing	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	seizures	B-Adverse_Effect	['N']	[11]
12	implicate	O	['N']	[12]
13	accumulation	O	['N']	[13]
14	of	O	['N']	[14]
15	ofloxacin	B-Drug	['Causes']	[11]
16	as	O	['N']	[16]
17	a	O	['N']	[17]
18	contributing	O	['N']	[18]
19	factor	O	['N']	[19]
20	.	O	['N']	[20]
#1281
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	illustrates	O	['N']	[2]
3	that	O	['N']	[3]
4	the	O	['N']	[4]
5	hemophagocytic	B	['N']	[5]
6	syndrome	I-Adverse_Effect	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	reactivation	O	['N']	[9]
10	of	O	['N']	[10]
11	EBV	O	['N']	[11]
12	can	O	['N']	[12]
13	occur	O	['N']	[13]
14	as	O	['N']	[14]
15	part	O	['N']	[15]
16	of	O	['N']	[16]
17	drug	O	['N']	[17]
18	hypersensitivity	O	['N']	[18]
19	reactions	O	['N']	[19]
20	in	O	['N']	[20]
21	RA	O	['N']	[21]
22	patients	O	['N']	[22]
23	taking	O	['N']	[23]
24	sulfasalazine	B-Drug	['Causes']	[6]
25	.	O	['N']	[25]
#1282
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	report	O	['N']	[3]
4	an	O	['N']	[4]
5	unusual	O	['N']	[5]
6	paradoxical	B	['N']	[6]
7	effect	I-Adverse_Effect	['N']	[7]
8	of	O	['N']	[8]
9	brimonidine	B-Drug	['Causes']	[7]
10	.	O	['N']	[10]
#1283
0	ARDS	B-Adverse_Effect	['N']	[0]
1	has	O	['N']	[1]
2	been	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	the	O	['N']	[5]
6	administration	O	['N']	[6]
7	of	O	['N']	[7]
8	other	O	['N']	[8]
9	monoclonal	O	['N']	[9]
10	antibodies	O	['N']	[10]
11	,	O	['N']	[11]
12	such	O	['N']	[12]
13	as	O	['N']	[13]
14	infliximab	O	['N']	[14]
15	,	O	['N']	[15]
16	gemtuzumab	O	['N']	[16]
17	ozogamicin	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	OKT3	B-Drug	['Causes']	[0]
21	and	O	['N']	[21]
22	is	O	['N']	[22]
23	believed	O	['N']	[23]
24	to	O	['N']	[24]
25	be	O	['N']	[25]
26	directly	O	['N']	[26]
27	mediated	O	['N']	[27]
28	by	O	['N']	[28]
29	release	O	['N']	[29]
30	of	O	['N']	[30]
31	proinflammatory	O	['N']	[31]
32	cytokines	O	['N']	[32]
33	.	O	['N']	[33]
#1284
0	Transient	O	['N']	[0]
1	left	O	['N']	[1]
2	homonymous	O	['N']	[2]
3	hemianopsia	O	['N']	[3]
4	and	O	['N']	[4]
5	encephalopathy	B-Adverse_Effect	['N']	[5]
6	following	O	['N']	[6]
7	treatment	O	['N']	[7]
8	of	O	['N']	[8]
9	testicular	O	['N']	[9]
10	carcinoma	O	['N']	[10]
11	with	O	['N']	[11]
12	cisplatinum	O	['N']	[12]
13	,	O	['N']	[13]
14	vinblastine	B-Drug	['Causes']	[5]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	bleomycin	O	['N']	[17]
18	.	O	['N']	[18]
#1285
0	Five	O	['N']	[0]
1	months	O	['N']	[1]
2	after	O	['N']	[2]
3	initiating	O	['N']	[3]
4	mirtazapine	B-Drug	['Causes']	[10]
5	therapy	O	['N']	[5]
6	,	O	['N']	[6]
7	she	O	['N']	[7]
8	developed	O	['N']	[8]
9	symptomatic	B	['N']	[9]
10	hyponatremia	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#1286
0	Primary	B	['N']	[0]
1	central	I	['N']	[1]
2	nervous	I	['N']	[2]
3	system	I	['N']	[3]
4	lymphoma	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	treated	O	['N']	[8]
9	with	O	['N']	[9]
10	natalizumab	B-Drug	['Causes']	[4]
11	.	O	['N']	[11]
#1287
0	Glomerulonephritis	B-Adverse_Effect	['N']	[0]
1	in	O	['N']	[1]
2	procainamide	B-Drug	['Causes']	[0]
3	induced	O	['N']	[3]
4	lupus	O	['N']	[4]
5	erythematosus	O	['N']	[5]
6	:	O	['N']	[6]
7	report	O	['N']	[7]
8	of	O	['N']	[8]
9	a	O	['N']	[9]
10	case	O	['N']	[10]
11	and	O	['N']	[11]
12	review	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	literature	O	['N']	[15]
16	.	O	['N']	[16]
#1288
0	Amikacin	B-Drug	['Causes']	[11]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	type	O	['N']	[3]
4	5	O	['N']	[4]
5	Bartter	O	['N']	[5]
6	-	O	['N']	[6]
7	like	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	with	O	['N']	[9]
10	severe	B	['N']	[10]
11	hypocalcemia	I-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#1289
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	expired	O	['N']	[2]
3	after	O	['N']	[3]
4	seven	O	['N']	[4]
5	cycles	O	['N']	[5]
6	of	O	['N']	[6]
7	treatment	O	['N']	[7]
8	had	O	['N']	[8]
9	been	O	['N']	[9]
10	completed	O	['N']	[10]
11	because	O	['N']	[11]
12	of	O	['N']	[12]
13	pulmonary	B	['N']	[13]
14	fibrosis	I-Adverse_Effect	['N']	[14]
15	and	O	['N']	[15]
16	the	O	['N']	[16]
17	drug	O	['N']	[17]
18	toxicity	O	['N']	[18]
19	of	O	['N']	[19]
20	bleomycin	B-Drug	['Causes']	[14]
21	.	O	['N']	[21]
#1290
0	Physicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	cognizant	O	['N']	[3]
4	of	O	['N']	[4]
5	this	O	['N']	[5]
6	potential	O	['N']	[6]
7	complication	O	['N']	[7]
8	in	O	['N']	[8]
9	patients	O	['N']	[9]
10	receiving	O	['N']	[10]
11	thalidomide	B-Drug	['Causes']	[20]
12	or	O	['N']	[12]
13	thalidomide	O	['N']	[13]
14	-	O	['N']	[14]
15	like	O	['N']	[15]
16	drugs	O	['N']	[16]
17	who	O	['N']	[17]
18	present	O	['N']	[18]
19	with	O	['N']	[19]
20	fever	B-Adverse_Effect	['N']	[20]
21	and	O	['N']	[21]
22	pulmonary	O	['N']	[22]
23	infiltrates	O	['N']	[23]
24	and	O	['N']	[24]
25	fail	O	['N']	[25]
26	to	O	['N']	[26]
27	improve	O	['N']	[27]
28	despite	O	['N']	[28]
29	treatment	O	['N']	[29]
30	with	O	['N']	[30]
31	broad	O	['N']	[31]
32	-	O	['N']	[32]
33	spectrum	O	['N']	[33]
34	antibiotics	O	['N']	[34]
35	.	O	['N']	[35]
#1291
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	53-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	-	O	['N']	[6]
7	man	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	rippling	O	['N']	[10]
11	muscle	O	['N']	[11]
12	disease	O	['N']	[12]
13	(	O	['N']	[13]
14	RMD	B-Adverse_Effect	['N']	[14]
15	)	O	['N']	[15]
16	2	O	['N']	[16]
17	months	O	['N']	[17]
18	after	O	['N']	[18]
19	starting	O	['N']	[19]
20	simvastatin	B-Drug	['Causes']	[14]
21	therapy	O	['N']	[21]
22	for	O	['N']	[22]
23	hypercholesterolemia	O	['N']	[23]
24	.	O	['N']	[24]
#1292
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	O	['N']	[19]
20	developed	O	['N']	[20]
21	confusion	O	['N']	[21]
22	,	O	['N']	[22]
23	agitation	O	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	O	['N']	[25]
26	,	O	['N']	[26]
27	tremors	O	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	B	['N']	[29]
30	jerks	I-Adverse_Effect	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	O	['N']	[32]
33	gait	O	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	B-Drug	['Causes']	[30]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#1293
0	Colitis	B-Adverse_Effect	['N']	[0]
1	as	O	['N']	[1]
2	a	O	['N']	[2]
3	manifestation	O	['N']	[3]
4	of	O	['N']	[4]
5	infliximab	B-Drug	['Causes']	[0]
6	-	O	['N']	[6]
7	associated	O	['N']	[7]
8	disseminated	O	['N']	[8]
9	cryptococcosis	O	['N']	[9]
10	.	O	['N']	[10]
#1294
0	CASE	O	['N']	[0]
1	PRESENTATION	O	['N']	[1]
2	:	O	['N']	[2]
3	Three	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	Leishmania	B	['N']	[6]
7	infantum	I	['N']	[7]
8	leishmaniasis	I-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	corticosteroid	O	['N']	[10]
11	(	O	['N']	[11]
12	CS)-treated	-	['N']	[12]
13	patients	O	['N']	[13]
14	are	O	['N']	[14]
15	reported	O	['N']	[15]
16	:	O	['N']	[16]
17	an	O	['N']	[17]
18	isolated	O	['N']	[18]
19	lingual	O	['N']	[19]
20	leishmaniasis	O	['N']	[20]
21	in	O	['N']	[21]
22	a	O	['N']	[22]
23	farmer	O	['N']	[23]
24	treated	O	['N']	[24]
25	with	O	['N']	[25]
26	CS	O	['N']	[26]
27	for	O	['N']	[27]
28	asthma	O	['N']	[28]
29	,	O	['N']	[29]
30	a	O	['N']	[30]
31	severe	O	['N']	[31]
32	visceral	O	['N']	[32]
33	leishmaniasis	O	['N']	[33]
34	associated	O	['N']	[34]
35	with	O	['N']	[35]
36	cutaneous	O	['N']	[36]
37	lesions	O	['N']	[37]
38	in	O	['N']	[38]
39	a	O	['N']	[39]
40	woman	O	['N']	[40]
41	with	O	['N']	[41]
42	myasthenia	O	['N']	[42]
43	gravis	O	['N']	[43]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	a	O	['N']	[46]
47	visceral	O	['N']	[47]
48	involvement	O	['N']	[48]
49	after	O	['N']	[49]
50	cutaneous	O	['N']	[50]
51	leishmaniasis	O	['N']	[51]
52	in	O	['N']	[52]
53	a	O	['N']	[53]
54	man	O	['N']	[54]
55	receiving	O	['N']	[55]
56	CS	O	['N']	[56]
57	.	O	['N']	[57]
#1295
0	PATIENT	O	['N']	[0]
1	AND	O	['N']	[1]
2	METHOD	O	['N']	[2]
3	:	O	['N']	[3]
4	A	O	['N']	[4]
5	34-year	O	['N']	[5]
6	-	O	['N']	[6]
7	old	O	['N']	[7]
8	woman	O	['N']	[8]
9	with	O	['N']	[9]
10	chronic	O	['N']	[10]
11	hepatitis	O	['N']	[11]
12	C	O	['N']	[12]
13	,	O	['N']	[13]
14	genotype	O	['N']	[14]
15	3	O	['N']	[15]
16	,	O	['N']	[16]
17	receiving	O	['N']	[17]
18	pegylated	O	['N']	[18]
19	interferon	O	['N']	[19]
20	alpha-2a	O	['N']	[20]
21	and	O	['N']	[21]
22	ribavirin	B-Drug	['Causes']	[31]
23	for	O	['N']	[23]
24	6	O	['N']	[24]
25	months	O	['N']	[25]
26	,	O	['N']	[26]
27	developed	O	['N']	[27]
28	progressive	O	['N']	[28]
29	malaise	O	['N']	[29]
30	and	O	['N']	[30]
31	anemia	B-Adverse_Effect	['N']	[31]
32	6	O	['N']	[32]
33	months	O	['N']	[33]
34	after	O	['N']	[34]
35	the	O	['N']	[35]
36	end	O	['N']	[36]
37	of	O	['N']	[37]
38	treatment	O	['N']	[38]
39	.	O	['N']	[39]
#1296
0	Chronic	O	['N']	[0]
1	hydroxychloroquine	B-Drug	['Causes']	[10]
2	use	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	QT	O	['N']	[5]
6	prolongation	O	['N']	[6]
7	and	O	['N']	[7]
8	refractory	B	['N']	[8]
9	ventricular	I	['N']	[9]
10	arrhythmia	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#1297
0	To	O	['N']	[0]
1	develop	O	['N']	[1]
2	information	O	['N']	[2]
3	on	O	['N']	[3]
4	the	O	['N']	[4]
5	relative	O	['N']	[5]
6	rarity	O	['N']	[6]
7	or	O	['N']	[7]
8	frequency	O	['N']	[8]
9	of	O	['N']	[9]
10	neurologic	B	['N']	[10]
11	worsening	I-Adverse_Effect	['N']	[11]
12	with	O	['N']	[12]
13	the	O	['N']	[13]
14	initiation	O	['N']	[14]
15	of	O	['N']	[15]
16	penicillamine	B-Drug	['Causes']	[11]
17	therapy	O	['N']	[17]
18	,	O	['N']	[18]
19	we	O	['N']	[19]
20	conducted	O	['N']	[20]
21	a	O	['N']	[21]
22	retrospective	O	['N']	[22]
23	survey	O	['N']	[23]
24	of	O	['N']	[24]
25	25	O	['N']	[25]
26	additional	O	['N']	[26]
27	patients	O	['N']	[27]
28	with	O	['N']	[28]
29	Wilson	O	['N']	[29]
30	's	O	['N']	[30]
31	disease	O	['N']	[31]
32	who	O	['N']	[32]
33	met	O	['N']	[33]
34	the	O	['N']	[34]
35	criteria	O	['N']	[35]
36	of	O	['N']	[36]
37	presenting	O	['N']	[37]
38	with	O	['N']	[38]
39	neurologic	O	['N']	[39]
40	disease	O	['N']	[40]
41	and	O	['N']	[41]
42	having	O	['N']	[42]
43	been	O	['N']	[43]
44	treated	O	['N']	[44]
45	with	O	['N']	[45]
46	penicillamine	O	['N']	[46]
47	.	O	['N']	[47]
#1298
0	Ten	O	['N']	[0]
1	to	O	['N']	[1]
2	15	O	['N']	[2]
3	%	O	['N']	[3]
4	of	O	['N']	[4]
5	patients	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	ifosfamide	B-Drug	['Causes']	[11]
9	develop	O	['N']	[9]
10	an	O	['N']	[10]
11	encephalopathy	B-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#1299
0	Clofazimine	B-Drug	['Causes']	[1]
1	enteropathy	B-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	a	O	['N']	[3]
4	pediatric	O	['N']	[4]
5	bone	O	['N']	[5]
6	marrow	O	['N']	[6]
7	transplant	O	['N']	[7]
8	recipient	O	['N']	[8]
9	.	O	['N']	[9]
#1300
0	Hypertension	B-Adverse_Effect	['N']	[0]
1	develops	O	['N']	[1]
2	in	O	['N']	[2]
3	most	O	['N']	[3]
4	patients	O	['N']	[4]
5	after	O	['N']	[5]
6	transplantation	O	['N']	[6]
7	when	O	['N']	[7]
8	immunosuppression	O	['N']	[8]
9	is	O	['N']	[9]
10	based	O	['N']	[10]
11	on	O	['N']	[11]
12	cyclosporine	O	['N']	[12]
13	and	O	['N']	[13]
14	prednisone	B-Drug	['Causes']	[0]
15	.	O	['N']	[15]
#1301
0	The	O	['N']	[0]
1	toxicity	B-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	plasma	O	['N']	[3]
4	concentrations	O	['N']	[4]
5	of	O	['N']	[5]
6	ifosfamide	O	['N']	[6]
7	,	O	['N']	[7]
8	chloroacetaldehyde	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	4-hydroxyifosfamide	B-Drug	['Causes']	[1]
12	were	O	['N']	[12]
13	then	O	['N']	[13]
14	determined	O	['N']	[14]
15	over	O	['N']	[15]
16	24	O	['N']	[16]
17	h	O	['N']	[17]
18	after	O	['N']	[18]
19	a	O	['N']	[19]
20	single	O	['N']	[20]
21	1.6	O	['N']	[21]
22	g	O	['N']	[22]
23	/	O	['N']	[23]
24	m2	O	['N']	[24]
25	dose	O	['N']	[25]
26	of	O	['N']	[26]
27	ifosfamide	O	['N']	[27]
28	.	O	['N']	[28]
#1302
0	A	O	['N']	[0]
1	5-month	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	infant	O	['N']	[4]
5	became	O	['N']	[5]
6	lethargic	O	['N']	[6]
7	and	O	['N']	[7]
8	poorly	B	['N']	[8]
9	responsive	I-Adverse_Effect	['N']	[9]
10	after	O	['N']	[10]
11	receiving	O	['N']	[11]
12	1	O	['N']	[12]
13	drop	O	['N']	[13]
14	of	O	['N']	[14]
15	brimonidine	B-Drug	['Causes']	[9]
16	in	O	['N']	[16]
17	each	O	['N']	[17]
18	eye	O	['N']	[18]
19	.	O	['N']	[19]
#1303
0	The	O	['N']	[0]
1	use	O	['N']	[1]
2	of	O	['N']	[2]
3	methotrexate	O	['N']	[3]
4	(	O	['N']	[4]
5	MTX	B-Drug	['Causes']	[37]
6	)	O	['N']	[6]
7	has	O	['N']	[7]
8	been	O	['N']	[8]
9	contraindicated	O	['N']	[9]
10	for	O	['N']	[10]
11	treatment	O	['N']	[11]
12	of	O	['N']	[12]
13	severe	O	['N']	[13]
14	psoriasis	O	['N']	[14]
15	in	O	['N']	[15]
16	HIV	O	['N']	[16]
17	infection	O	['N']	[17]
18	on	O	['N']	[18]
19	the	O	['N']	[19]
20	basis	O	['N']	[20]
21	of	O	['N']	[21]
22	six	O	['N']	[22]
23	previously	O	['N']	[23]
24	reported	O	['N']	[24]
25	cases	O	['N']	[25]
26	in	O	['N']	[26]
27	which	O	['N']	[27]
28	MTX	O	['N']	[28]
29	appeared	O	['N']	[29]
30	to	O	['N']	[30]
31	potentiate	O	['N']	[31]
32	opportunistic	O	['N']	[32]
33	infections	O	['N']	[33]
34	and	O	['N']	[34]
35	accelerate	B	['N']	[35]
36	HIV	I	['N']	[36]
37	disease	I-Adverse_Effect	['N']	[37]
38	.	O	['N']	[38]
#1304
0	Less	O	['N']	[0]
1	common	O	['N']	[1]
2	adverse	O	['N']	[2]
3	events	O	['N']	[3]
4	to	O	['N']	[4]
5	dapsone	B-Drug	['Causes']	[11]
6	include	O	['N']	[6]
7	the	O	['N']	[7]
8	idiosyncratic	O	['N']	[8]
9	reactions	O	['N']	[9]
10	of	O	['N']	[10]
11	leukopenia	B-Adverse_Effect	['N']	[11]
12	and	O	['N']	[12]
13	agranulocytosis	O	['N']	[13]
14	,	O	['N']	[14]
15	cutaneous	O	['N']	[15]
16	eruptions	O	['N']	[16]
17	,	O	['N']	[17]
18	peripheral	O	['N']	[18]
19	neuropathy	O	['N']	[19]
20	,	O	['N']	[20]
21	psychosis	O	['N']	[21]
22	,	O	['N']	[22]
23	toxic	O	['N']	[23]
24	hepatitis	O	['N']	[24]
25	,	O	['N']	[25]
26	cholestatic	O	['N']	[26]
27	jaundice	O	['N']	[27]
28	,	O	['N']	[28]
29	nephrotic	O	['N']	[29]
30	syndrome	O	['N']	[30]
31	,	O	['N']	[31]
32	renal	O	['N']	[32]
33	papillary	O	['N']	[33]
34	necrosis	O	['N']	[34]
35	,	O	['N']	[35]
36	severe	O	['N']	[36]
37	hypoalbuminemia	O	['N']	[37]
38	without	O	['N']	[38]
39	proteinuria	O	['N']	[39]
40	,	O	['N']	[40]
41	an	O	['N']	[41]
42	infectious	O	['N']	[42]
43	mononucleosis	O	['N']	[43]
44	-	O	['N']	[44]
45	like	O	['N']	[45]
46	syndrome	O	['N']	[46]
47	,	O	['N']	[47]
48	and	O	['N']	[48]
49	minor	O	['N']	[49]
50	neurological	O	['N']	[50]
51	and	O	['N']	[51]
52	gastrointestinal	O	['N']	[52]
53	complaints	O	['N']	[53]
54	.	O	['N']	[54]
#1305
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	acute	O	['N']	[6]
7	compromise	O	['N']	[7]
8	of	O	['N']	[8]
9	renal	O	['N']	[9]
10	function	O	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	hypotension	B-Adverse_Effect	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	7-year	O	['N']	[16]
17	-	O	['N']	[17]
18	old	O	['N']	[18]
19	boy	O	['N']	[19]
20	treated	O	['N']	[20]
21	with	O	['N']	[21]
22	the	O	['N']	[22]
23	ACE	O	['N']	[23]
24	inhibitor	O	['N']	[24]
25	lisinopril	B-Drug	['Causes']	[13]
26	and	O	['N']	[26]
27	the	O	['N']	[27]
28	ARB	O	['N']	[28]
29	losartan	O	['N']	[29]
30	.	O	['N']	[30]
#1306
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	our	O	['N']	[3]
4	knowledge	O	['N']	[4]
5	,	O	['N']	[5]
6	this	O	['N']	[6]
7	is	O	['N']	[7]
8	the	O	['N']	[8]
9	first	O	['N']	[9]
10	published	O	['N']	[10]
11	case	O	['N']	[11]
12	report	O	['N']	[12]
13	of	O	['N']	[13]
14	an	O	['N']	[14]
15	adolescent	O	['N']	[15]
16	girl	O	['N']	[16]
17	with	O	['N']	[17]
18	a	O	['N']	[18]
19	mitochondrial	O	['N']	[19]
20	disorder	O	['N']	[20]
21	and	O	['N']	[21]
22	depression	O	['N']	[22]
23	who	O	['N']	[23]
24	displayed	O	['N']	[24]
25	both	O	['N']	[25]
26	new	O	['N']	[26]
27	-	O	['N']	[27]
28	onset	O	['N']	[28]
29	psychotic	O	['N']	[29]
30	and	O	['N']	[30]
31	increased	B	['N']	[31]
32	mood	I	['N']	[32]
33	symptoms	I-Adverse_Effect	['N']	[33]
34	during	O	['N']	[34]
35	treatment	O	['N']	[35]
36	with	O	['N']	[36]
37	risperidone	B-Drug	['Causes']	[33]
38	.	O	['N']	[38]
#1307
0	Although	O	['N']	[0]
1	dyspnea	B-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	verapamil	B-Drug	['Causes']	[1]
5	administration	O	['N']	[5]
6	has	O	['N']	[6]
7	been	O	['N']	[7]
8	reported	O	['N']	[8]
9	,	O	['N']	[9]
10	this	O	['N']	[10]
11	is	O	['N']	[11]
12	the	O	['N']	[12]
13	first	O	['N']	[13]
14	report	O	['N']	[14]
15	of	O	['N']	[15]
16	an	O	['N']	[16]
17	elderly	O	['N']	[17]
18	asymptomatic	O	['N']	[18]
19	asthmatic	O	['N']	[19]
20	patient	O	['N']	[20]
21	with	O	['N']	[21]
22	hypertension	O	['N']	[22]
23	who	O	['N']	[23]
24	developed	O	['N']	[24]
25	an	O	['N']	[25]
26	acute	O	['N']	[26]
27	asthma	O	['N']	[27]
28	attack	O	['N']	[28]
29	following	O	['N']	[29]
30	sustained	O	['N']	[30]
31	-	O	['N']	[31]
32	release	O	['N']	[32]
33	verapamil	O	['N']	[33]
34	administration	O	['N']	[34]
35	.	O	['N']	[35]
#1308
0	A	O	['N']	[0]
1	dapsone	B-Drug	['Causes']	[11]
2	hypersensitivity	O	['N']	[2]
3	syndrome	O	['N']	[3]
4	,	O	['N']	[4]
5	consisting	O	['N']	[5]
6	of	O	['N']	[6]
7	fever	O	['N']	[7]
8	,	O	['N']	[8]
9	headache	O	['N']	[9]
10	,	O	['N']	[10]
11	nausea	B-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	vomiting	O	['N']	[13]
14	,	O	['N']	[14]
15	lymphadenopathy	O	['N']	[15]
16	,	O	['N']	[16]
17	hepatitis	O	['N']	[17]
18	,	O	['N']	[18]
19	hemolysis	O	['N']	[19]
20	,	O	['N']	[20]
21	leukopenia	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	mononucleosis	O	['N']	[24]
25	,	O	['N']	[25]
26	has	O	['N']	[26]
27	been	O	['N']	[27]
28	described	O	['N']	[28]
29	in	O	['N']	[29]
30	patients	O	['N']	[30]
31	treated	O	['N']	[31]
32	with	O	['N']	[32]
33	the	O	['N']	[33]
34	drug	O	['N']	[34]
35	for	O	['N']	[35]
36	leprosy	O	['N']	[36]
37	.	O	['N']	[37]
#1309
0	Thoracoscopic	O	['N']	[0]
1	biopsy	O	['N']	[1]
2	to	O	['N']	[2]
3	confirm	O	['N']	[3]
4	metastasis	O	['N']	[4]
5	revealed	O	['N']	[5]
6	instead	O	['N']	[6]
7	fibrotic	B	['N']	[7]
8	lesions	I-Adverse_Effect	['N']	[8]
9	apparently	O	['N']	[9]
10	attributable	O	['N']	[10]
11	to	O	['N']	[11]
12	bleomycin	O	['N']	[12]
13	or	O	['N']	[13]
14	cyclophosphamide	B-Drug	['Causes']	[8]
15	.	O	['N']	[15]
#1310
0	INTRODUCTION	O	['N']	[0]
1	:	O	['N']	[1]
2	Although	O	['N']	[2]
3	gefitinib	O	['N']	[3]
4	used	O	['N']	[4]
5	for	O	['N']	[5]
6	the	O	['N']	[6]
7	treatment	O	['N']	[7]
8	of	O	['N']	[8]
9	non	O	['N']	[9]
10	-	O	['N']	[10]
11	small	O	['N']	[11]
12	-	O	['N']	[12]
13	cell	O	['N']	[13]
14	lung	O	['N']	[14]
15	cancer	O	['N']	[15]
16	is	O	['N']	[16]
17	a	O	['N']	[17]
18	well	O	['N']	[18]
19	-	O	['N']	[19]
20	known	O	['N']	[20]
21	cause	O	['N']	[21]
22	of	O	['N']	[22]
23	interstitial	O	['N']	[23]
24	lung	O	['N']	[24]
25	disease	O	['N']	[25]
26	(	O	['N']	[26]
27	ILD	B-Adverse_Effect	['N']	[27]
28	)	O	['N']	[28]
29	,	O	['N']	[29]
30	few	O	['N']	[30]
31	case	O	['N']	[31]
32	reports	O	['N']	[32]
33	on	O	['N']	[33]
34	erlotinib	B-Drug	['Causes']	[27]
35	-	O	['N']	[35]
36	induced	O	['N']	[36]
37	ILD	O	['N']	[37]
38	have	O	['N']	[38]
39	been	O	['N']	[39]
40	issued	O	['N']	[40]
41	.	O	['N']	[41]
#1311
0	The	O	['N']	[0]
1	current	O	['N']	[1]
2	report	O	['N']	[2]
3	describes	O	['N']	[3]
4	a	O	['N']	[4]
5	man	O	['N']	[5]
6	who	O	['N']	[6]
7	was	O	['N']	[7]
8	prescribed	O	['N']	[8]
9	zonisamide	B-Drug	['Causes']	[33]
10	for	O	['N']	[10]
11	epilepsy	O	['N']	[11]
12	and	O	['N']	[12]
13	subsequently	O	['N']	[13]
14	developed	O	['N']	[14]
15	widespread	O	['N']	[15]
16	skin	O	['N']	[16]
17	rash	O	['N']	[17]
18	,	O	['N']	[18]
19	acute	O	['N']	[19]
20	kidney	O	['N']	[20]
21	injury	O	['N']	[21]
22	,	O	['N']	[22]
23	high	O	['N']	[23]
24	-	O	['N']	[24]
25	grade	O	['N']	[25]
26	fever	O	['N']	[26]
27	,	O	['N']	[27]
28	eosinophilia	O	['N']	[28]
29	,	O	['N']	[29]
30	liver	O	['N']	[30]
31	dysfunction	O	['N']	[31]
32	,	O	['N']	[32]
33	lymphadenopathy	B-Adverse_Effect	['N']	[33]
34	and	O	['N']	[34]
35	an	O	['N']	[35]
36	increase	O	['N']	[36]
37	in	O	['N']	[37]
38	antihuman	O	['N']	[38]
39	herpesvirus-6	O	['N']	[39]
40	immunoglobulin	O	['N']	[40]
41	G	O	['N']	[41]
42	titer	O	['N']	[42]
43	.	O	['N']	[43]
#1312
0	Central	B	['N']	[0]
1	nervous	I	['N']	[1]
2	system	I	['N']	[2]
3	manifestations	I-Adverse_Effect	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	ibuprofen	B-Drug	['Causes']	[3]
7	overdose	O	['N']	[7]
8	reversed	O	['N']	[8]
9	by	O	['N']	[9]
10	naloxone	O	['N']	[10]
11	.	O	['N']	[11]
#1313
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	who	O	['N']	[2]
3	were	O	['N']	[3]
4	receiving	O	['N']	[4]
5	Tolazoline	B-Drug	['Causes']	[14]
6	by	O	['N']	[6]
7	infusion	O	['N']	[7]
8	developed	O	['N']	[8]
9	duodenal	O	['N']	[9]
10	ulceration	O	['N']	[10]
11	and	O	['N']	[11]
12	subsequent	O	['N']	[12]
13	intestinal	B	['N']	[13]
14	perforation	I-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#1314
0	INTERPRETATION	O	['N']	[0]
1	:	O	['N']	[1]
2	When	O	['N']	[2]
3	high	B-Dose	['N']	[3]
4	doses	O	['N']	[4]
5	of	O	['N']	[5]
6	fluticasone	B	['N']	[6]
7	propionate	I-Drug	['Dosage']	[3]
8	are	O	['N']	[8]
9	used	O	['N']	[9]
10	,	O	['N']	[10]
11	growth	O	['N']	[11]
12	may	O	['N']	[12]
13	be	O	['N']	[13]
14	retarded	O	['N']	[14]
15	and	O	['N']	[15]
16	adrenal	O	['N']	[16]
17	suppression	O	['N']	[17]
18	may	O	['N']	[18]
19	occur	O	['N']	[19]
20	.	O	['N']	[20]
#1315
0	Treatment	O	['N']	[0]
1	with	O	['N']	[1]
2	infliximab	B-Drug	['Causes']	[10]
3	is	O	['N']	[3]
4	known	O	['N']	[4]
5	to	O	['N']	[5]
6	produce	O	['N']	[6]
7	an	O	['N']	[7]
8	increase	B	['N']	[8]
9	of	I	['N']	[9]
10	autoantibodies	I-Adverse_Effect	['N']	[10]
11	(	O	['N']	[11]
12	antinuclear	O	['N']	[12]
13	antibodies	O	['N']	[13]
14	,	O	['N']	[14]
15	anti	O	['N']	[15]
16	-	O	['N']	[16]
17	double	O	['N']	[17]
18	-	O	['N']	[18]
19	stranded	O	['N']	[19]
20	DNA	O	['N']	[20]
21	)	O	['N']	[21]
22	,	O	['N']	[22]
23	but	O	['N']	[23]
24	not	O	['N']	[24]
25	clinical	O	['N']	[25]
26	disease	O	['N']	[26]
27	.	O	['N']	[27]
#1316
0	He	O	['N']	[0]
1	developed	O	['N']	[1]
2	recurrent	O	['N']	[2]
3	skin	O	['N']	[3]
4	rash	O	['N']	[4]
5	,	O	['N']	[5]
6	fever	B-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	hypereosinophilia	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	acute	O	['N']	[11]
12	renal	O	['N']	[12]
13	failure	O	['N']	[13]
14	after	O	['N']	[14]
15	rechallenge	O	['N']	[15]
16	with	O	['N']	[16]
17	chlorambucil	B-Drug	['Causes']	[6]
18	.	O	['N']	[18]
#1317
0	A	O	['N']	[0]
1	dapsone	B-Drug	['Causes']	[3]
2	hypersensitivity	B	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	,	O	['N']	[4]
5	consisting	O	['N']	[5]
6	of	O	['N']	[6]
7	fever	O	['N']	[7]
8	,	O	['N']	[8]
9	headache	O	['N']	[9]
10	,	O	['N']	[10]
11	nausea	O	['N']	[11]
12	,	O	['N']	[12]
13	vomiting	O	['N']	[13]
14	,	O	['N']	[14]
15	lymphadenopathy	O	['N']	[15]
16	,	O	['N']	[16]
17	hepatitis	O	['N']	[17]
18	,	O	['N']	[18]
19	hemolysis	O	['N']	[19]
20	,	O	['N']	[20]
21	leukopenia	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	mononucleosis	O	['N']	[24]
25	,	O	['N']	[25]
26	has	O	['N']	[26]
27	been	O	['N']	[27]
28	described	O	['N']	[28]
29	in	O	['N']	[29]
30	patients	O	['N']	[30]
31	treated	O	['N']	[31]
32	with	O	['N']	[32]
33	the	O	['N']	[33]
34	drug	O	['N']	[34]
35	for	O	['N']	[35]
36	leprosy	O	['N']	[36]
37	.	O	['N']	[37]
#1318
0	Nitrendipine	B-Drug	['Causes']	[21]
1	is	O	['N']	[1]
2	an	O	['N']	[2]
3	experimental	O	['N']	[3]
4	calcium	O	['N']	[4]
5	channel	O	['N']	[5]
6	blocking	O	['N']	[6]
7	agent	O	['N']	[7]
8	that	O	['N']	[8]
9	also	O	['N']	[9]
10	appears	O	['N']	[10]
11	to	O	['N']	[11]
12	cause	O	['N']	[12]
13	the	O	['N']	[13]
14	side	O	['N']	[14]
15	effect	O	['N']	[15]
16	of	O	['N']	[16]
17	drug	O	['N']	[17]
18	-	O	['N']	[18]
19	induced	O	['N']	[19]
20	gingival	B	['N']	[20]
21	hyperplasia	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#1319
0	There	O	['N']	[0]
1	are	O	['N']	[1]
2	now	O	['N']	[2]
3	reports	O	['N']	[3]
4	of	O	['N']	[4]
5	liver	B	['N']	[5]
6	failure	I-Adverse_Effect	['N']	[6]
7	following	O	['N']	[7]
8	treatment	O	['N']	[8]
9	of	O	['N']	[9]
10	childhood	O	['N']	[10]
11	cancers	O	['N']	[11]
12	with	O	['N']	[12]
13	AMD	B-Drug	['Causes']	[6]
14	.	O	['N']	[14]
#1320
0	Although	O	['N']	[0]
1	gabapentin	B-Drug	['Causes']	[13]
2	withdrawal	O	['N']	[2]
3	has	O	['N']	[3]
4	been	O	['N']	[4]
5	previously	O	['N']	[5]
6	reported	O	['N']	[6]
7	and	O	['N']	[7]
8	usually	O	['N']	[8]
9	consists	O	['N']	[9]
10	of	O	['N']	[10]
11	anxiety	O	['N']	[11]
12	,	O	['N']	[12]
13	diaphoresis	B-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	palpitations	O	['N']	[16]
17	,	O	['N']	[17]
18	this	O	['N']	[18]
19	is	O	['N']	[19]
20	the	O	['N']	[20]
21	first	O	['N']	[21]
22	reported	O	['N']	[22]
23	patient	O	['N']	[23]
24	with	O	['N']	[24]
25	generalized	O	['N']	[25]
26	seizures	O	['N']	[26]
27	and	O	['N']	[27]
28	status	O	['N']	[28]
29	epilepticus	O	['N']	[29]
30	secondary	O	['N']	[30]
31	to	O	['N']	[31]
32	gabapentin	O	['N']	[32]
33	withdrawal	O	['N']	[33]
34	.	O	['N']	[34]
#1321
0	Clofazimine	B-Drug	['Causes']	[1]
1	enteropathy	B-Adverse_Effect	['N']	[1]
2	caused	O	['N']	[2]
3	by	O	['N']	[3]
4	crystal	O	['N']	[4]
5	deposition	O	['N']	[5]
6	can	O	['N']	[6]
7	be	O	['N']	[7]
8	life	O	['N']	[8]
9	-	O	['N']	[9]
10	threatening	O	['N']	[10]
11	.	O	['N']	[11]
#1322
0	Multiple	O	['N']	[0]
1	pulmonary	O	['N']	[1]
2	nodules	O	['N']	[2]
3	:	O	['N']	[3]
4	an	O	['N']	[4]
5	unusual	O	['N']	[5]
6	presentation	O	['N']	[6]
7	of	O	['N']	[7]
8	fludarabine	B-Drug	['Causes']	[10]
9	pulmonary	B	['N']	[9]
10	toxicity	I-Adverse_Effect	['N']	[10]
11	:	O	['N']	[11]
12	case	O	['N']	[12]
13	report	O	['N']	[13]
14	and	O	['N']	[14]
15	review	O	['N']	[15]
16	of	O	['N']	[16]
17	literature	O	['N']	[17]
18	.	O	['N']	[18]
#1323
0	Such	O	['N']	[0]
1	anagen	O	['N']	[1]
2	effluvium	O	['N']	[2]
3	with	O	['N']	[3]
4	lichenoid	B	['N']	[4]
5	eruption	I-Adverse_Effect	['N']	[5]
6	following	O	['N']	[6]
7	INH	B-Drug	['Causes']	[5]
8	therapy	O	['N']	[8]
9	has	O	['N']	[9]
10	not	O	['N']	[10]
11	been	O	['N']	[11]
12	observed	O	['N']	[12]
13	previously	O	['N']	[13]
14	.	O	['N']	[14]
#1324
0	Methotrexate	B-Drug	['Causes']	[1]
1	pneumonitis	B-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	nonsurgical	O	['N']	[3]
4	treatment	O	['N']	[4]
5	of	O	['N']	[5]
6	ectopic	O	['N']	[6]
7	pregnancy	O	['N']	[7]
8	.	O	['N']	[8]
#1325
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	young	O	['N']	[6]
7	woman	O	['N']	[7]
8	with	O	['N']	[8]
9	SLE	O	['N']	[9]
10	and	O	['N']	[10]
11	thrombocytopenia	O	['N']	[11]
12	,	O	['N']	[12]
13	who	O	['N']	[13]
14	developed	O	['N']	[14]
15	severe	O	['N']	[15]
16	perspiration	O	['N']	[16]
17	,	O	['N']	[17]
18	headache	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	seizure	B-Adverse_Effect	['N']	[21]
22	after	O	['N']	[22]
23	receiving	O	['N']	[23]
24	cyclosporine	B-Drug	['Causes']	[21]
25	.	O	['N']	[25]
#1326
0	Ampicillin	B-Drug	['Causes']	[7]
1	may	O	['N']	[1]
2	aggravate	O	['N']	[2]
3	clinical	O	['N']	[3]
4	and	O	['N']	[4]
5	experimental	O	['N']	[5]
6	myasthenia	B	['N']	[6]
7	gravis	I-Adverse_Effect	['N']	[7]
8	.	O	['N']	[8]
#1327
0	A	O	['N']	[0]
1	58-yr	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	male	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	essential	O	['N']	[7]
8	thrombocythaemia	O	['N']	[8]
9	(	O	['N']	[9]
10	ET	O	['N']	[10]
11	)	O	['N']	[11]
12	developed	O	['N']	[12]
13	chronic	B	['N']	[13]
14	myeloid	I	['N']	[14]
15	leukaemia	I-Adverse_Effect	['N']	[15]
16	(	O	['N']	[16]
17	CML	O	['N']	[17]
18	)	O	['N']	[18]
19	after	O	['N']	[19]
20	continuous	O	['N']	[20]
21	uneventful	O	['N']	[21]
22	treatment	O	['N']	[22]
23	with	O	['N']	[23]
24	hydroxyurea	B-Drug	['Causes']	[15]
25	for	O	['N']	[25]
26	18	O	['N']	[26]
27	yr	O	['N']	[27]
28	.	O	['N']	[28]
#1328
0	She	O	['N']	[0]
1	had	O	['N']	[1]
2	been	O	['N']	[2]
3	taking	O	['N']	[3]
4	nabumetone	B-Drug	['Causes']	[21]
5	for	O	['N']	[5]
6	6	O	['N']	[6]
7	months	O	['N']	[7]
8	,	O	['N']	[8]
9	but	O	['N']	[9]
10	had	O	['N']	[10]
11	discontinued	O	['N']	[11]
12	the	O	['N']	[12]
13	agent	O	['N']	[13]
14	2	O	['N']	[14]
15	weeks	O	['N']	[15]
16	before	O	['N']	[16]
17	admission	O	['N']	[17]
18	due	O	['N']	[18]
19	to	O	['N']	[19]
20	progressive	O	['N']	[20]
21	edema	B-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#1329
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	O	['N']	[19]
20	developed	O	['N']	[20]
21	confusion	O	['N']	[21]
22	,	O	['N']	[22]
23	agitation	O	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	O	['N']	[25]
26	,	O	['N']	[26]
27	tremors	O	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	O	['N']	[29]
30	jerks	O	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	O	['N']	[32]
33	gait	O	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	B	['N']	[37]
38	syndrome	I-Adverse_Effect	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	B-Drug	['Causes']	[38]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#1330
0	After	O	['N']	[0]
1	four	O	['N']	[1]
2	months	O	['N']	[2]
3	,	O	['N']	[3]
4	while	O	['N']	[4]
5	receiving	O	['N']	[5]
6	RH	B-Drug	['Causes']	[12]
7	,	O	['N']	[7]
8	he	O	['N']	[8]
9	developed	O	['N']	[9]
10	painful	O	['N']	[10]
11	bilateral	B	['N']	[11]
12	gynaecomastia	I-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#1331
0	INTRODUCTION	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	describe	O	['N']	[3]
4	the	O	['N']	[4]
5	neurointensive	O	['N']	[5]
6	care	O	['N']	[6]
7	(	O	['N']	[7]
8	NIC	O	['N']	[8]
9	)	O	['N']	[9]
10	management	O	['N']	[10]
11	of	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	severe	B	['N']	[15]
16	cerebral	I	['N']	[16]
17	swelling	I-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	raised	O	['N']	[19]
20	intracranial	O	['N']	[20]
21	pressure	O	['N']	[21]
22	(	O	['N']	[22]
23	ICP	O	['N']	[23]
24	)	O	['N']	[24]
25	after	O	['N']	[25]
26	severe	O	['N']	[26]
27	sodium	B	['N']	[27]
28	valproic	I	['N']	[28]
29	acid	I-Drug	['Causes']	[17]
30	(	O	['N']	[30]
31	VPA	O	['N']	[31]
32	)	O	['N']	[32]
33	intoxication	O	['N']	[33]
34	.	O	['N']	[34]
#1332
0	Hypokalemia	B-Adverse_Effect	['N']	[0]
1	after	O	['N']	[1]
2	normal	O	['N']	[2]
3	doses	O	['N']	[3]
4	of	O	['N']	[4]
5	neubulized	O	['N']	[5]
6	albuterol	O	['N']	[6]
7	(	O	['N']	[7]
8	salbutamol	B-Drug	['Causes']	[0]
9	)	O	['N']	[9]
10	.	O	['N']	[10]
#1333
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	propranolol	B-Drug	['Dosage']	[4]
4	overdose	B-Dose	['N']	[4]
5	complicated	O	['N']	[5]
6	by	O	['N']	[6]
7	esophageal	O	['N']	[7]
8	spasm	O	['N']	[8]
9	preventing	O	['N']	[9]
10	extrication	O	['N']	[10]
11	of	O	['N']	[11]
12	an	O	['N']	[12]
13	orogastric	O	['N']	[13]
14	lavage	O	['N']	[14]
15	tube	O	['N']	[15]
16	and	O	['N']	[16]
17	relieved	O	['N']	[17]
18	by	O	['N']	[18]
19	intravenous	O	['N']	[19]
20	glucagon	O	['N']	[20]
21	is	O	['N']	[21]
22	presented	O	['N']	[22]
23	.	O	['N']	[23]
#1334
0	Taxane	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	glaucoma	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#1335
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	46-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	African	O	['N']	[6]
7	-	O	['N']	[7]
8	American	O	['N']	[8]
9	man	O	['N']	[9]
10	with	O	['N']	[10]
11	AIDS	O	['N']	[11]
12	who	O	['N']	[12]
13	was	O	['N']	[13]
14	admitted	O	['N']	[14]
15	on	O	['N']	[15]
16	two	O	['N']	[16]
17	different	O	['N']	[17]
18	occasions	O	['N']	[18]
19	within	O	['N']	[19]
20	three	O	['N']	[20]
21	weeks	O	['N']	[21]
22	for	O	['N']	[22]
23	signs	O	['N']	[23]
24	and	O	['N']	[24]
25	symptoms	O	['N']	[25]
26	of	O	['N']	[26]
27	meningitis	B-Adverse_Effect	['N']	[27]
28	after	O	['N']	[28]
29	using	O	['N']	[29]
30	trimethoprim	O	['N']	[30]
31	/	O	['N']	[31]
32	sulfamethoxazole	O	['N']	[32]
33	(	O	['N']	[33]
34	TMP	O	['N']	[34]
35	/	O	['N']	[35]
36	SMX	B-Drug	['Causes']	[27]
37	)	O	['N']	[37]
38	.	O	['N']	[38]
#1336
0	Doxorubicin	B-Drug	['Causes']	[1]
1	cardiotoxicity	B-Adverse_Effect	['N']	[1]
2	:	O	['N']	[2]
3	possible	O	['N']	[3]
4	role	O	['N']	[4]
5	of	O	['N']	[5]
6	digoxin	O	['N']	[6]
7	in	O	['N']	[7]
8	its	O	['N']	[8]
9	prevention	O	['N']	[9]
10	.	O	['N']	[10]
#1337
0	A	O	['N']	[0]
1	34-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	lady	O	['N']	[4]
5	developed	O	['N']	[5]
6	a	O	['N']	[6]
7	constellation	O	['N']	[7]
8	of	O	['N']	[8]
9	dermatitis	O	['N']	[9]
10	,	O	['N']	[10]
11	fever	B-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	lymphadenopathy	O	['N']	[13]
14	and	O	['N']	[14]
15	hepatitis	O	['N']	[15]
16	,	O	['N']	[16]
17	beginning	O	['N']	[17]
18	on	O	['N']	[18]
19	the	O	['N']	[19]
20	17th	O	['N']	[20]
21	day	O	['N']	[21]
22	of	O	['N']	[22]
23	a	O	['N']	[23]
24	course	O	['N']	[24]
25	of	O	['N']	[25]
26	oral	O	['N']	[26]
27	sulphasalazine	B-Drug	['Causes']	[11]
28	for	O	['N']	[28]
29	sero	O	['N']	[29]
30	-	O	['N']	[30]
31	negative	O	['N']	[31]
32	rheumatoid	O	['N']	[32]
33	arthritis	O	['N']	[33]
34	.	O	['N']	[34]
#1338
0	Syndrome	B	['N']	[0]
1	of	I	['N']	[1]
2	inappropriate	I	['N']	[2]
3	antidiuretic	I	['N']	[3]
4	hormone	I-Adverse_Effect	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	vinorelbine	B-Drug	['Causes']	[4]
8	therapy	O	['N']	[8]
9	.	O	['N']	[9]
#1339
0	Type	O	['N']	[0]
1	I	O	['N']	[1]
2	second	O	['N']	[2]
3	-	O	['N']	[3]
4	degree	O	['N']	[4]
5	AV	O	['N']	[5]
6	block	O	['N']	[6]
7	(	O	['N']	[7]
8	Mobitz	B	['N']	[8]
9	type	I	['N']	[9]
10	I	I-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	Wenckebach	O	['N']	[12]
13	AV	O	['N']	[13]
14	block	O	['N']	[14]
15	)	O	['N']	[15]
16	during	O	['N']	[16]
17	ritodrine	B-Drug	['Causes']	[10]
18	therapy	O	['N']	[18]
19	for	O	['N']	[19]
20	preterm	O	['N']	[20]
21	labor	O	['N']	[21]
22	.	O	['N']	[22]
#1340
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	skin	B	['N']	[23]
24	eruptions	I-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	cervical	O	['N']	[26]
27	lymphadenopathy	O	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	O	['N']	[31]
32	lymphocytosis	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	O	['N']	[40]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	-	['N']	[42]
43	(	O	['N']	[43]
44	SMX	O	['N']	[44]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#1341
0	Codeine	B-Drug	['Causes']	[1]
1	intoxication	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	the	O	['N']	[3]
4	neonate	O	['N']	[4]
5	.	O	['N']	[5]
#1342
0	Clinical	O	['N']	[0]
1	and	O	['N']	[1]
2	morphological	O	['N']	[2]
3	features	O	['N']	[3]
4	of	O	['N']	[4]
5	gold	B-Drug	['Causes']	[6]
6	neuropathy	B-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#1343
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	five	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	carboplatin	B-Drug	['N']	[5]
6	(	O	['N']	[6]
7	CBDCA	O	['N']	[7]
8	)	O	['N']	[8]
9	hypersensitivity	O	['N']	[9]
10	after	O	['N']	[10]
11	weekly	O	['N']	[11]
12	low	O	['N']	[12]
13	-	O	['N']	[13]
14	dose	O	['N']	[14]
15	paclitaxel	O	['N']	[15]
16	(	O	['N']	[16]
17	60	-	['N']	[17]
18	mg	-	['N']	[18]
19	/	-	['N']	[19]
20	m2)/CBDCA	-	['N']	[20]
21	(	O	['N']	[21]
22	area	O	['N']	[22]
23	under	O	['N']	[23]
24	the	O	['N']	[24]
25	concentration	O	['N']	[25]
26	curve	O	['N']	[26]
27	=	O	['N']	[27]
28	2	O	['N']	[28]
29	)	O	['N']	[29]
30	therapy	O	['N']	[30]
31	in	O	['N']	[31]
32	patients	O	['N']	[32]
33	with	O	['N']	[33]
34	recurrent	O	['N']	[34]
35	ovarian	O	['N']	[35]
36	cancer	O	['N']	[36]
37	receiving	O	['N']	[37]
38	multiple	O	['N']	[38]
39	platinum	O	['N']	[39]
40	-	O	['N']	[40]
41	based	O	['N']	[41]
42	chemotherapy	O	['N']	[42]
43	.	O	['N']	[43]
#1344
0	Children	O	['N']	[0]
1	with	O	['N']	[1]
2	acute	O	['N']	[2]
3	lymphoblastic	O	['N']	[3]
4	leukemia	O	['N']	[4]
5	(	O	['N']	[5]
6	ALL	O	['N']	[6]
7	)	O	['N']	[7]
8	,	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	L	B	['N']	[11]
12	-	I	['N']	[12]
13	asparaginase	I-Drug	['Causes']	[26]
14	are	O	['N']	[14]
15	at	O	['N']	[15]
16	risk	O	['N']	[16]
17	for	O	['N']	[17]
18	cerebral	O	['N']	[18]
19	thrombosis	O	['N']	[19]
20	or	O	['N']	[20]
21	hemorrhage	O	['N']	[21]
22	because	O	['N']	[22]
23	of	O	['N']	[23]
24	coagulation	B	['N']	[24]
25	protein	I	['N']	[25]
26	deficiencies	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#1345
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	extrapyramidal	B	['N']	[3]
4	side	I	['N']	[4]
5	effects	I-Adverse_Effect	['N']	[5]
6	after	O	['N']	[6]
7	the	O	['N']	[7]
8	use	O	['N']	[8]
9	of	O	['N']	[9]
10	fluphenazine	B	['N']	[10]
11	decanoate	I-Drug	['Causes']	[5]
12	were	O	['N']	[12]
13	evaluated	O	['N']	[13]
14	by	O	['N']	[14]
15	means	O	['N']	[15]
16	of	O	['N']	[16]
17	IBZM	O	['N']	[17]
18	-	O	['N']	[18]
19	SPECT	O	['N']	[19]
20	.	O	['N']	[20]
#1346
0	FINDINGS	O	['N']	[0]
1	:	O	['N']	[1]
2	Six	O	['N']	[2]
3	children	O	['N']	[3]
4	with	O	['N']	[4]
5	growth	O	['N']	[5]
6	retardation	O	['N']	[6]
7	noted	O	['N']	[7]
8	after	O	['N']	[8]
9	treatment	O	['N']	[9]
10	with	O	['N']	[10]
11	high	B-Dose	['N']	[11]
12	-	O	['N']	[12]
13	dose	O	['N']	[13]
14	fluticasone	B	['N']	[14]
15	propionate	I-Drug	['Dosage']	[11]
16	were	O	['N']	[16]
17	found	O	['N']	[17]
18	to	O	['N']	[18]
19	have	O	['N']	[19]
20	adrenal	O	['N']	[20]
21	suppression	O	['N']	[21]
22	.	O	['N']	[22]
#1347
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	young	O	['N']	[3]
4	patients	O	['N']	[4]
5	with	O	['N']	[5]
6	cystic	O	['N']	[6]
7	fibrosis	O	['N']	[7]
8	who	O	['N']	[8]
9	presented	O	['N']	[9]
10	with	O	['N']	[10]
11	acute	B	['N']	[11]
12	renal	I	['N']	[12]
13	insufficiency	I-Adverse_Effect	['N']	[13]
14	after	O	['N']	[14]
15	2	O	['N']	[15]
16	-	O	['N']	[16]
17	3	O	['N']	[17]
18	weeks	O	['N']	[18]
19	of	O	['N']	[19]
20	oral	O	['N']	[20]
21	ciprofloxacin	B-Drug	['Causes']	[13]
22	therapy	O	['N']	[22]
23	.	O	['N']	[23]
#1348
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	pseudoephedrine	B-Drug	['Causes']	[9]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	intracerebral	B	['N']	[8]
9	hemorrhage	I-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	patient	O	['N']	[12]
13	with	O	['N']	[13]
14	an	O	['N']	[14]
15	underlying	O	['N']	[15]
16	vascular	O	['N']	[16]
17	malformation	O	['N']	[17]
18	.	O	['N']	[18]
#1349
0	Children	O	['N']	[0]
1	receiving	O	['N']	[1]
2	zonisamide	B-Drug	['Causes']	[13]
3	should	O	['N']	[3]
4	be	O	['N']	[4]
5	monitored	O	['N']	[5]
6	for	O	['N']	[6]
7	oligohidrosis	O	['N']	[7]
8	and	O	['N']	[8]
9	the	O	['N']	[9]
10	development	O	['N']	[10]
11	of	O	['N']	[11]
12	neurological	B	['N']	[12]
13	symptoms	I-Adverse_Effect	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	an	O	['N']	[16]
17	elevation	O	['N']	[17]
18	of	O	['N']	[18]
19	body	O	['N']	[19]
20	temperature	O	['N']	[20]
21	.	O	['N']	[21]
#1350
0	Patient	O	['N']	[0]
1	B	O	['N']	[1]
2	developed	O	['N']	[2]
3	perioral	O	['N']	[3]
4	and	O	['N']	[4]
5	upper	O	['N']	[5]
6	extremity	O	['N']	[6]
7	paresthesias	O	['N']	[7]
8	during	O	['N']	[8]
9	the	O	['N']	[9]
10	fourth	O	['N']	[10]
11	cycle	O	['N']	[11]
12	of	O	['N']	[12]
13	CAP	B-Drug	['Dosage']	[19]
14	alone	O	['N']	[14]
15	(	O	['N']	[15]
16	2500	B	['N']	[16]
17	mg	I	['N']	[17]
18	/	I	['N']	[18]
19	m2	I-Dose	['N']	[19]
20	)	O	['N']	[20]
21	.	O	['N']	[21]
#1351
0	Three	O	['N']	[0]
1	of	O	['N']	[1]
2	50	O	['N']	[2]
3	patients	O	['N']	[3]
4	treated	O	['N']	[4]
5	with	O	['N']	[5]
6	isotretinoin	B-Drug	['Causes']	[22]
7	(	O	['N']	[7]
8	1	O	['N']	[8]
9	mg	O	['N']	[9]
10	/	O	['N']	[10]
11	kg	O	['N']	[11]
12	/	O	['N']	[12]
13	day	O	['N']	[13]
14	)	O	['N']	[14]
15	for	O	['N']	[15]
16	cystic	O	['N']	[16]
17	acne	O	['N']	[17]
18	complained	O	['N']	[18]
19	of	O	['N']	[19]
20	poor	B	['N']	[20]
21	night	I	['N']	[21]
22	vision	I-Adverse_Effect	['N']	[22]
23	and/or	O	['N']	[23]
24	excessive	O	['N']	[24]
25	glare	O	['N']	[25]
26	sensitivity	O	['N']	[26]
27	.	O	['N']	[27]
#1352
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	girl	O	['N']	[3]
4	with	O	['N']	[4]
5	the	O	['N']	[5]
6	Rett	O	['N']	[6]
7	syndrome	O	['N']	[7]
8	who	O	['N']	[8]
9	had	O	['N']	[9]
10	acute	B	['N']	[10]
11	encephalopathy	I-Adverse_Effect	['N']	[11]
12	probably	O	['N']	[12]
13	induced	O	['N']	[13]
14	by	O	['N']	[14]
15	calcium	O	['N']	[15]
16	hopantenate	O	['N']	[16]
17	(	O	['N']	[17]
18	HOPA	B-Drug	['Causes']	[11]
19	)	O	['N']	[19]
20	.	O	['N']	[20]
#1353
0	Metamizole	B-Drug	['Causes']	[18]
1	,	O	['N']	[1]
2	a	O	['N']	[2]
3	nonsteroidal	O	['N']	[3]
4	antiinflammatory	O	['N']	[4]
5	agent	O	['N']	[5]
6	,	O	['N']	[6]
7	is	O	['N']	[7]
8	prohibited	O	['N']	[8]
9	in	O	['N']	[9]
10	the	O	['N']	[10]
11	United	O	['N']	[11]
12	States	O	['N']	[12]
13	because	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	risk	O	['N']	[16]
17	of	O	['N']	[17]
18	agranulocytosis	B-Adverse_Effect	['N']	[18]
19	but	O	['N']	[19]
20	is	O	['N']	[20]
21	widely	O	['N']	[21]
22	used	O	['N']	[22]
23	in	O	['N']	[23]
24	Mexico	O	['N']	[24]
25	and	O	['N']	[25]
26	other	O	['N']	[26]
27	countries	O	['N']	[27]
28	.	O	['N']	[28]
#1354
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	histories	O	['N']	[4]
5	of	O	['N']	[5]
6	identical	O	['N']	[6]
7	twin	O	['N']	[7]
8	brothers	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	concordant	O	['N']	[11]
12	acute	O	['N']	[12]
13	lymphoblastic	O	['N']	[13]
14	leukemia	O	['N']	[14]
15	at	O	['N']	[15]
16	the	O	['N']	[16]
17	age	O	['N']	[17]
18	of	O	['N']	[18]
19	4	O	['N']	[19]
20	years	O	['N']	[20]
21	and	O	['N']	[21]
22	who	O	['N']	[22]
23	later	O	['N']	[23]
24	developed	O	['N']	[24]
25	leukoencephalopathy	B-Adverse_Effect	['N']	[25]
26	and	O	['N']	[26]
27	hydrocephalus	O	['N']	[27]
28	related	O	['N']	[28]
29	to	O	['N']	[29]
30	central	O	['N']	[30]
31	nervous	O	['N']	[31]
32	system	O	['N']	[32]
33	prophylaxis	O	['N']	[33]
34	by	O	['N']	[34]
35	,	O	['N']	[35]
36	in	O	['N']	[36]
37	the	O	['N']	[37]
38	first	O	['N']	[38]
39	case	O	['N']	[39]
40	intrathecally	O	['N']	[40]
41	administered	O	['N']	[41]
42	methotrexate	B-Drug	['Causes']	[25]
43	and	O	['N']	[43]
44	,	O	['N']	[44]
45	in	O	['N']	[45]
46	the	O	['N']	[46]
47	second	O	['N']	[47]
48	by	O	['N']	[48]
49	intrathecally	O	['N']	[49]
50	administered	O	['N']	[50]
51	methotrexate	O	['N']	[51]
52	and	O	['N']	[52]
53	cranial	O	['N']	[53]
54	irradiation	O	['N']	[54]
55	.	O	['N']	[55]
#1355
0	Hair	B	['N']	[0]
1	loss	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	paroxetine	B-Drug	['Causes']	[1]
5	treatment	O	['N']	[5]
6	:	O	['N']	[6]
7	a	O	['N']	[7]
8	case	O	['N']	[8]
9	report	O	['N']	[9]
10	.	O	['N']	[10]
#1356
0	Colchicine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	rhabdomyolysis	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#1357
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	interstitial	B	['N']	[5]
6	pneumonitis	I-Adverse_Effect	['N']	[6]
7	induced	O	['N']	[7]
8	by	O	['N']	[8]
9	bicalutamide	B-Drug	['Causes']	[6]
10	and/or	O	['N']	[10]
11	leuprorelin	O	['N']	[11]
12	acetate	O	['N']	[12]
13	given	O	['N']	[13]
14	as	O	['N']	[14]
15	therapy	O	['N']	[15]
16	for	O	['N']	[16]
17	prostate	O	['N']	[17]
18	cancer	O	['N']	[18]
19	,	O	['N']	[19]
20	in	O	['N']	[20]
21	which	O	['N']	[21]
22	the	O	['N']	[22]
23	pneumonitis	O	['N']	[23]
24	was	O	['N']	[24]
25	successfully	O	['N']	[25]
26	managed	O	['N']	[26]
27	by	O	['N']	[27]
28	steroid	O	['N']	[28]
29	treatment	O	['N']	[29]
30	.	O	['N']	[30]
#1358
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	cough	B-Adverse_Effect	['N']	[5]
6	following	O	['N']	[6]
7	the	O	['N']	[7]
8	administration	O	['N']	[8]
9	of	O	['N']	[9]
10	quinapril	B-Drug	['Causes']	[5]
11	,	O	['N']	[11]
12	with	O	['N']	[12]
13	complete	O	['N']	[13]
14	resolution	O	['N']	[14]
15	after	O	['N']	[15]
16	changing	O	['N']	[16]
17	to	O	['N']	[17]
18	the	O	['N']	[18]
19	alternative	O	['N']	[19]
20	ACE	O	['N']	[20]
21	inhibitor	O	['N']	[21]
22	fosinopril	O	['N']	[22]
23	in	O	['N']	[23]
24	a	O	['N']	[24]
25	patient	O	['N']	[25]
26	with	O	['N']	[26]
27	essential	O	['N']	[27]
28	hypertension	O	['N']	[28]
29	.	O	['N']	[29]
#1359
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	report	O	['N']	[2]
3	describes	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	was	O	['N']	[7]
8	previously	O	['N']	[8]
9	prescribed	O	['N']	[9]
10	alendronate	O	['N']	[10]
11	(	O	['N']	[11]
12	Fosamax	O	['N']	[12]
13	)	O	['N']	[13]
14	and	O	['N']	[14]
15	presented	O	['N']	[15]
16	with	O	['N']	[16]
17	postoperative	O	['N']	[17]
18	hypophosphatemia	O	['N']	[18]
19	and	O	['N']	[19]
20	hypocalcemic	B	['N']	[20]
21	tetany	I-Adverse_Effect	['N']	[21]
22	after	O	['N']	[22]
23	bowel	O	['N']	[23]
24	preparation	O	['N']	[24]
25	with	O	['N']	[25]
26	Fleet	B	['N']	[26]
27	Phospho	I	['N']	[27]
28	-	I	['N']	[28]
29	Soda	I-Drug	['Causes']	[21]
30	.	O	['N']	[30]
#1360
0	Long	O	['N']	[0]
1	lasting	O	['N']	[1]
2	respiratory	B	['N']	[2]
3	depression	I-Adverse_Effect	['N']	[3]
4	induced	O	['N']	[4]
5	by	O	['N']	[5]
6	morphine-6-glucuronide	B-Drug	['Causes']	[3]
7	?	O	['N']	[7]
#1361
0	Scleromyxedema	B-Adverse_Effect	['N']	[0]
1	in	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	multiple	O	['N']	[5]
6	sclerosis	O	['N']	[6]
7	and	O	['N']	[7]
8	monoclonal	O	['N']	[8]
9	gammopathy	O	['N']	[9]
10	on	O	['N']	[10]
11	interferon	B	['N']	[11]
12	beta-1a	I-Drug	['Causes']	[0]
13	.	O	['N']	[13]
#1362
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	report	O	['N']	[2]
3	describes	O	['N']	[3]
4	an	O	['N']	[4]
5	adolescent	O	['N']	[5]
6	with	O	['N']	[6]
7	severe	B	['N']	[7]
8	lupus	I	['N']	[8]
9	erythematosus	I-Adverse_Effect	['N']	[9]
10	who	O	['N']	[10]
11	received	O	['N']	[11]
12	cyclophosphamide	O	['N']	[12]
13	(	O	['N']	[13]
14	CY	B-Drug	['Causes']	[9]
15	)	O	['N']	[15]
16	paired	O	['N']	[16]
17	with	O	['N']	[17]
18	taste	O	['N']	[18]
19	(	O	['N']	[19]
20	cod	O	['N']	[20]
21	liver	O	['N']	[21]
22	oil	O	['N']	[22]
23	)	O	['N']	[23]
24	and	O	['N']	[24]
25	smell	O	['N']	[25]
26	(	O	['N']	[26]
27	rose	O	['N']	[27]
28	perfume	O	['N']	[28]
29	)	O	['N']	[29]
30	as	O	['N']	[30]
31	conditioned	O	['N']	[31]
32	stimuli	O	['N']	[32]
33	.	O	['N']	[33]
#1363
0	We	O	['N']	[0]
1	cared	O	['N']	[1]
2	for	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	progressive	O	['N']	[6]
7	renal	O	['N']	[7]
8	impairment	O	['N']	[8]
9	who	O	['N']	[9]
10	presented	O	['N']	[10]
11	with	O	['N']	[11]
12	blurred	O	['N']	[12]
13	vision	O	['N']	[13]
14	,	O	['N']	[14]
15	QRS	O	['N']	[15]
16	broadening	O	['N']	[16]
17	and	O	['N']	[17]
18	cardiac	O	['N']	[18]
19	failure	O	['N']	[19]
20	due	O	['N']	[20]
21	to	O	['N']	[21]
22	chronic	O	['N']	[22]
23	cibenzoline	B-Drug	['Causes']	[24]
24	intoxication	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#1364
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	11-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	female	O	['N']	[9]
10	treated	O	['N']	[10]
11	for	O	['N']	[11]
12	mediastinal	O	['N']	[12]
13	T	O	['N']	[13]
14	-	O	['N']	[14]
15	cell	O	['N']	[15]
16	lymphoma	O	['N']	[16]
17	who	O	['N']	[17]
18	presented	O	['N']	[18]
19	renal	B	['N']	[19]
20	failure	I-Adverse_Effect	['N']	[20]
21	following	O	['N']	[21]
22	the	O	['N']	[22]
23	second	O	['N']	[23]
24	cycle	O	['N']	[24]
25	of	O	['N']	[25]
26	high	O	['N']	[26]
27	-	O	['N']	[27]
28	dose	O	['N']	[28]
29	methotrexate	B-Drug	['Causes']	[20]
30	(	O	['N']	[30]
31	HDMTX	O	['N']	[31]
32	)	O	['N']	[32]
33	.	O	['N']	[33]
#1365
0	Esophageal	B	['N']	[0]
1	candidiasis	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	omeprazole	B-Drug	['Causes']	[1]
4	therapy	O	['N']	[4]
5	:	O	['N']	[5]
6	a	O	['N']	[6]
7	report	O	['N']	[7]
8	of	O	['N']	[8]
9	two	O	['N']	[9]
10	cases	O	['N']	[10]
11	.	O	['N']	[11]
#1366
0	Didanosine	B-Drug	['Causes']	[7]
1	also	O	['N']	[1]
2	has	O	['N']	[2]
3	a	O	['N']	[3]
4	potential	O	['N']	[4]
5	for	O	['N']	[5]
6	inducing	O	['N']	[6]
7	seizures	B-Adverse_Effect	['N']	[7]
8	.	O	['N']	[8]
#1367
0	Pentazocine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	fibrous	B	['N']	[3]
4	myopathy	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	localized	O	['N']	[6]
7	neuropathy	O	['N']	[7]
8	.	O	['N']	[8]
#1368
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	AZA	B-Drug	['Causes']	[6]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	drug	B	['N']	[5]
6	eruption	I-Adverse_Effect	['N']	[6]
7	that	O	['N']	[7]
8	developed	O	['N']	[8]
9	in	O	['N']	[9]
10	two	O	['N']	[10]
11	cases	O	['N']	[11]
12	of	O	['N']	[12]
13	systemic	O	['N']	[13]
14	scleroderma	O	['N']	[14]
15	with	O	['N']	[15]
16	polymyositis	O	['N']	[16]
17	.	O	['N']	[17]
#1369
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	studied	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	vortex	B	['N']	[7]
8	keratopathy	I-Adverse_Effect	['N']	[8]
9	that	O	['N']	[9]
10	was	O	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	the	O	['N']	[13]
14	use	O	['N']	[14]
15	of	O	['N']	[15]
16	atovaquone	B-Drug	['Causes']	[8]
17	.	O	['N']	[17]
#1370
0	Flucytosine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	diarrhea	B-Adverse_Effect	['N']	[3]
4	has	O	['N']	[4]
5	been	O	['N']	[5]
6	previously	O	['N']	[6]
7	described	O	['N']	[7]
8	in	O	['N']	[8]
9	6%-10	O	['N']	[9]
10	%	O	['N']	[10]
11	of	O	['N']	[11]
12	patients	O	['N']	[12]
13	receiving	O	['N']	[13]
14	the	O	['N']	[14]
15	drug	O	['N']	[15]
16	.	O	['N']	[16]
#1371
0	A	O	['N']	[0]
1	36-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	being	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	cisplatinum	O	['N']	[8]
9	,	O	['N']	[9]
10	vinblastine	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	bleomycin	B-Drug	['Causes']	[22]
14	for	O	['N']	[14]
15	testicular	O	['N']	[15]
16	carcinoma	O	['N']	[16]
17	developed	O	['N']	[17]
18	a	O	['N']	[18]
19	dense	O	['N']	[19]
20	left	B	['N']	[20]
21	homonymous	I	['N']	[21]
22	hemianopsia	I-Adverse_Effect	['N']	[22]
23	,	O	['N']	[23]
24	encephalopathy	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	a	O	['N']	[27]
28	partial	O	['N']	[28]
29	nondominant	O	['N']	[29]
30	parietal	O	['N']	[30]
31	lobe	O	['N']	[31]
32	syndrome	O	['N']	[32]
33	.	O	['N']	[33]
#1372
0	In	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	swallowing	O	['N']	[3]
4	dysfunction	O	['N']	[4]
5	and	O	['N']	[5]
6	pneumonia	O	['N']	[6]
7	,	O	['N']	[7]
8	a	O	['N']	[8]
9	history	O	['N']	[9]
10	of	O	['N']	[10]
11	mineral	B	['N']	[11]
12	oil	I-Drug	['Causes']	[21]
13	use	O	['N']	[13]
14	should	O	['N']	[14]
15	be	O	['N']	[15]
16	obtained	O	['N']	[16]
17	and	O	['N']	[17]
18	a	O	['N']	[18]
19	diagnosis	O	['N']	[19]
20	of	O	['N']	[20]
21	ELP	B-Adverse_Effect	['N']	[21]
22	should	O	['N']	[22]
23	be	O	['N']	[23]
24	considered	O	['N']	[24]
25	in	O	['N']	[25]
26	the	O	['N']	[26]
27	differential	O	['N']	[27]
28	diagnoses	O	['N']	[28]
29	if	O	['N']	[29]
30	mineral	O	['N']	[30]
31	oil	O	['N']	[31]
32	use	O	['N']	[32]
33	has	O	['N']	[33]
34	occurred	O	['N']	[34]
35	.	O	['N']	[35]
#1373
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	an	O	['N']	[6]
7	acute	O	['N']	[7]
8	flare	O	['N']	[8]
9	of	O	['N']	[9]
10	eosinophilic	B	['N']	[10]
11	cystitis	I-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	51-year	O	['N']	[14]
15	-	O	['N']	[15]
16	old	O	['N']	[16]
17	woman	O	['N']	[17]
18	after	O	['N']	[18]
19	bladder	O	['N']	[19]
20	instillation	O	['N']	[20]
21	with	O	['N']	[21]
22	dimethyl	O	['N']	[22]
23	sulfoxide	O	['N']	[23]
24	(	O	['N']	[24]
25	DMSO	B-Drug	['Causes']	[11]
26	)	O	['N']	[26]
27	for	O	['N']	[27]
28	presumed	O	['N']	[28]
29	interstitial	O	['N']	[29]
30	cystitis	O	['N']	[30]
31	.	O	['N']	[31]
#1374
0	Less	O	['N']	[0]
1	common	O	['N']	[1]
2	adverse	O	['N']	[2]
3	events	O	['N']	[3]
4	to	O	['N']	[4]
5	dapsone	B-Drug	['Causes']	[13]
6	include	O	['N']	[6]
7	the	O	['N']	[7]
8	idiosyncratic	O	['N']	[8]
9	reactions	O	['N']	[9]
10	of	O	['N']	[10]
11	leukopenia	O	['N']	[11]
12	and	O	['N']	[12]
13	agranulocytosis	B-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	cutaneous	O	['N']	[15]
16	eruptions	O	['N']	[16]
17	,	O	['N']	[17]
18	peripheral	O	['N']	[18]
19	neuropathy	O	['N']	[19]
20	,	O	['N']	[20]
21	psychosis	O	['N']	[21]
22	,	O	['N']	[22]
23	toxic	O	['N']	[23]
24	hepatitis	O	['N']	[24]
25	,	O	['N']	[25]
26	cholestatic	O	['N']	[26]
27	jaundice	O	['N']	[27]
28	,	O	['N']	[28]
29	nephrotic	O	['N']	[29]
30	syndrome	O	['N']	[30]
31	,	O	['N']	[31]
32	renal	O	['N']	[32]
33	papillary	O	['N']	[33]
34	necrosis	O	['N']	[34]
35	,	O	['N']	[35]
36	severe	O	['N']	[36]
37	hypoalbuminemia	O	['N']	[37]
38	without	O	['N']	[38]
39	proteinuria	O	['N']	[39]
40	,	O	['N']	[40]
41	an	O	['N']	[41]
42	infectious	O	['N']	[42]
43	mononucleosis	O	['N']	[43]
44	-	O	['N']	[44]
45	like	O	['N']	[45]
46	syndrome	O	['N']	[46]
47	,	O	['N']	[47]
48	and	O	['N']	[48]
49	minor	O	['N']	[49]
50	neurological	O	['N']	[50]
51	and	O	['N']	[51]
52	gastrointestinal	O	['N']	[52]
53	complaints	O	['N']	[53]
54	.	O	['N']	[54]
#1375
0	To	O	['N']	[0]
1	the	O	['N']	[1]
2	best	O	['N']	[2]
3	of	O	['N']	[3]
4	our	O	['N']	[4]
5	knowledge	O	['N']	[5]
6	,	O	['N']	[6]
7	this	O	['N']	[7]
8	is	O	['N']	[8]
9	the	O	['N']	[9]
10	first	O	['N']	[10]
11	case	O	['N']	[11]
12	of	O	['N']	[12]
13	lithium	B-Drug	['Causes']	[18]
14	-	O	['N']	[14]
15	associated	O	['N']	[15]
16	CDI	O	['N']	[16]
17	and	O	['N']	[17]
18	NDI	B-Adverse_Effect	['N']	[18]
19	presenting	O	['N']	[19]
20	concurrently	O	['N']	[20]
21	.	O	['N']	[21]
#1376
0	Since	O	['N']	[0]
1	recent	O	['N']	[1]
2	studies	O	['N']	[2]
3	have	O	['N']	[3]
4	reported	O	['N']	[4]
5	no	O	['N']	[5]
6	negative	O	['N']	[6]
7	interactions	O	['N']	[7]
8	with	O	['N']	[8]
9	concurrent	O	['N']	[9]
10	use	O	['N']	[10]
11	,	O	['N']	[11]
12	we	O	['N']	[12]
13	here	O	['N']	[13]
14	report	O	['N']	[14]
15	three	O	['N']	[15]
16	cases	O	['N']	[16]
17	(	O	['N']	[17]
18	one	O	['N']	[18]
19	case	O	['N']	[19]
20	of	O	['N']	[20]
21	a	O	['N']	[21]
22	prolonged	B	['N']	[22]
23	seizure	I-Adverse_Effect	['N']	[23]
24	,	O	['N']	[24]
25	a	O	['N']	[25]
26	serotonin	O	['N']	[26]
27	syndrome	O	['N']	[27]
28	and	O	['N']	[28]
29	a	O	['N']	[29]
30	focal	O	['N']	[30]
31	seizure	O	['N']	[31]
32	)	O	['N']	[32]
33	of	O	['N']	[33]
34	severe	O	['N']	[34]
35	lithium	B-Drug	['Causes']	[23]
36	-	O	['N']	[36]
37	induced	O	['N']	[37]
38	side	O	['N']	[38]
39	effects	O	['N']	[39]
40	while	O	['N']	[40]
41	patients	O	['N']	[41]
42	underwent	O	['N']	[42]
43	ECT	O	['N']	[43]
44	without	O	['N']	[44]
45	complications	O	['N']	[45]
46	and	O	['N']	[46]
47	lithium	O	['N']	[47]
48	serum	O	['N']	[48]
49	levels	O	['N']	[49]
50	were	O	['N']	[50]
51	still	O	['N']	[51]
52	subtherapeutic	O	['N']	[52]
53	.	O	['N']	[53]
#1377
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	demonstrates	O	['N']	[2]
3	an	O	['N']	[3]
4	occupational	O	['N']	[4]
5	activity	O	['N']	[5]
6	(	O	['N']	[6]
7	construction	O	['N']	[7]
8	)	O	['N']	[8]
9	that	O	['N']	[9]
10	has	O	['N']	[10]
11	now	O	['N']	[11]
12	become	O	['N']	[12]
13	the	O	['N']	[13]
14	dominant	O	['N']	[14]
15	source	O	['N']	[15]
16	of	O	['N']	[16]
17	lead	B-Drug	['Causes']	[43]
18	exposure	O	['N']	[18]
19	for	O	['N']	[19]
20	U.S.	O	['N']	[20]
21	adults	O	['N']	[21]
22	,	O	['N']	[22]
23	the	O	['N']	[23]
24	importance	O	['N']	[24]
25	of	O	['N']	[25]
26	a	O	['N']	[26]
27	good	O	['N']	[27]
28	occupational	O	['N']	[28]
29	history	O	['N']	[29]
30	to	O	['N']	[30]
31	suspecting	O	['N']	[31]
32	and	O	['N']	[32]
33	making	O	['N']	[33]
34	a	O	['N']	[34]
35	diagnosis	O	['N']	[35]
36	,	O	['N']	[36]
37	the	O	['N']	[37]
38	possible	O	['N']	[38]
39	outcomes	O	['N']	[39]
40	of	O	['N']	[40]
41	chronic	O	['N']	[41]
42	lead	B	['N']	[42]
43	toxicity	I-Adverse_Effect	['N']	[43]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	the	O	['N']	[46]
47	importance	O	['N']	[47]
48	of	O	['N']	[48]
49	preventing	O	['N']	[49]
50	further	O	['N']	[50]
51	exposure	O	['N']	[51]
52	and	O	['N']	[52]
53	using	O	['N']	[53]
54	proper	O	['N']	[54]
55	methods	O	['N']	[55]
56	to	O	['N']	[56]
57	treat	O	['N']	[57]
58	acute	O	['N']	[58]
59	toxicity	O	['N']	[59]
60	.	O	['N']	[60]
#1378
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	two	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	delayed	B	['N']	[6]
7	elimination	I-Adverse_Effect	['N']	[7]
8	of	O	['N']	[8]
9	methotrexate	B-Drug	['Causes']	[7]
10	in	O	['N']	[10]
11	patients	O	['N']	[11]
12	receiving	O	['N']	[12]
13	ciprofloxacin	O	['N']	[13]
14	,	O	['N']	[14]
15	with	O	['N']	[15]
16	severe	O	['N']	[16]
17	toxicity	O	['N']	[17]
18	.	O	['N']	[18]
#1379
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	new	O	['N']	[3]
4	quinolone	O	['N']	[4]
5	derivatives	O	['N']	[5]
6	(	O	['N']	[6]
7	levofloxacin	B-Drug	['Causes']	[41]
8	,	O	['N']	[8]
9	sparfloxacin	O	['N']	[9]
10	,	O	['N']	[10]
11	grepafloxacin	O	['N']	[11]
12	,	O	['N']	[12]
13	trovafloxacin	O	['N']	[13]
14	,	O	['N']	[14]
15	gatifloxacin	O	['N']	[15]
16	and	O	['N']	[16]
17	moxifloxacin	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	also	O	['N']	[20]
21	called	O	['N']	[21]
22	gyrase	O	['N']	[22]
23	inhibitors	O	['N']	[23]
24	,	O	['N']	[24]
25	are	O	['N']	[25]
26	known	O	['N']	[26]
27	for	O	['N']	[27]
28	their	O	['N']	[28]
29	potential	O	['N']	[29]
30	to	O	['N']	[30]
31	cause	O	['N']	[31]
32	central	O	['N']	[32]
33	nervous	O	['N']	[33]
34	system	O	['N']	[34]
35	-	O	['N']	[35]
36	related	O	['N']	[36]
37	adverse	O	['N']	[37]
38	effects	O	['N']	[38]
39	,	O	['N']	[39]
40	including	O	['N']	[40]
41	headache	B-Adverse_Effect	['N']	[41]
42	,	O	['N']	[42]
43	dizziness	O	['N']	[43]
44	and	O	['N']	[44]
45	insomnia	O	['N']	[45]
46	.	O	['N']	[46]
#1380
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	,	O	['N']	[2]
3	in	O	['N']	[3]
4	whom	O	['N']	[4]
5	tumour	O	['N']	[5]
6	overkill	O	['N']	[6]
7	by	O	['N']	[7]
8	cytotoxic	O	['N']	[8]
9	treatment	O	['N']	[9]
10	,	O	['N']	[10]
11	including	O	['N']	[11]
12	high	O	['N']	[12]
13	dose	O	['N']	[13]
14	methotrexate	O	['N']	[14]
15	with	O	['N']	[15]
16	folinic	B	['N']	[16]
17	acid	I-Drug	['Causes']	[33]
18	rescue	O	['N']	[18]
19	,	O	['N']	[19]
20	resulted	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	'	O	['N']	[23]
24	phosphate	O	['N']	[24]
25	shower	O	['N']	[25]
26	syndrome	O	['N']	[26]
27	'	O	['N']	[27]
28	(	O	['N']	[28]
29	hyper	O	['N']	[29]
30	-	O	['N']	[30]
31	uricaemia	O	['N']	[31]
32	,	O	['N']	[32]
33	hyperkalaemia	B-Adverse_Effect	['N']	[33]
34	and	O	['N']	[34]
35	hyperphosphataemia	O	['N']	[35]
36	with	O	['N']	[36]
37	hypocalcaemia	O	['N']	[37]
38	and	O	['N']	[38]
39	tetany	O	['N']	[39]
40	,	O	['N']	[40]
41	with	O	['N']	[41]
42	metabolic	O	['N']	[42]
43	acidosis	O	['N']	[43]
44	and	O	['N']	[44]
45	acute	O	['N']	[45]
46	renal	O	['N']	[46]
47	impairment	O	['N']	[47]
48	)	O	['N']	[48]
49	are	O	['N']	[49]
50	described	O	['N']	[50]
51	.	O	['N']	[51]
#1381
0	Morphea	B-Adverse_Effect	['N']	[0]
1	after	O	['N']	[1]
2	bromocriptine	B-Drug	['Causes']	[0]
3	therapy	O	['N']	[3]
4	.	O	['N']	[4]
#1382
0	An	O	['N']	[0]
1	association	O	['N']	[1]
2	of	O	['N']	[2]
3	granulocytopenia	O	['N']	[3]
4	,	O	['N']	[4]
5	eosinophilia	O	['N']	[5]
6	,	O	['N']	[6]
7	skin	O	['N']	[7]
8	reaction	O	['N']	[8]
9	and	O	['N']	[9]
10	hepatitis	B-Adverse_Effect	['N']	[10]
11	during	O	['N']	[11]
12	propylthiouracil	B-Drug	['Causes']	[10]
13	(	O	['N']	[13]
14	PTU	O	['N']	[14]
15	)	O	['N']	[15]
16	therapy	O	['N']	[16]
17	for	O	['N']	[17]
18	thyrotoxicosis	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	47	O	['N']	[21]
22	year	O	['N']	[22]
23	old	O	['N']	[23]
24	black	O	['N']	[24]
25	female	O	['N']	[25]
26	is	O	['N']	[26]
27	reported	O	['N']	[27]
28	.	O	['N']	[28]
#1383
0	Second	O	['N']	[0]
1	cancers	O	['N']	[1]
2	including	O	['N']	[2]
3	various	O	['N']	[3]
4	types	O	['N']	[4]
5	of	O	['N']	[5]
6	hematological	B	['N']	[6]
7	malignancy	I-Adverse_Effect	['N']	[7]
8	have	O	['N']	[8]
9	been	O	['N']	[9]
10	reported	O	['N']	[10]
11	in	O	['N']	[11]
12	patients	O	['N']	[12]
13	with	O	['N']	[13]
14	hairy	O	['N']	[14]
15	cell	O	['N']	[15]
16	leukemia	O	['N']	[16]
17	treated	O	['N']	[17]
18	with	O	['N']	[18]
19	chemotherapy	O	['N']	[19]
20	or	O	['N']	[20]
21	interferon	B	['N']	[21]
22	alfa	I-Drug	['Causes']	[7]
23	.	O	['N']	[23]
#1384
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	3	O	['N']	[2]
3	children	O	['N']	[3]
4	with	O	['N']	[4]
5	epilepsy	O	['N']	[5]
6	who	O	['N']	[6]
7	developed	O	['N']	[7]
8	facial	B	['N']	[8]
9	motor	I	['N']	[9]
10	tics	I-Adverse_Effect	['N']	[10]
11	after	O	['N']	[11]
12	initiation	O	['N']	[12]
13	of	O	['N']	[13]
14	CBZ	B-Drug	['Causes']	[10]
15	for	O	['N']	[15]
16	complex	O	['N']	[16]
17	partial	O	['N']	[17]
18	seizures	O	['N']	[18]
19	.	O	['N']	[19]
#1385
0	Persistent	B	['N']	[0]
1	light	I	['N']	[1]
2	reactivity	I-Adverse_Effect	['N']	[2]
3	from	O	['N']	[3]
4	systemic	O	['N']	[4]
5	quinine	B-Drug	['Causes']	[2]
6	.	O	['N']	[6]
#1386
0	The	O	['N']	[0]
1	use	O	['N']	[1]
2	of	O	['N']	[2]
3	beclomethasone	B	['N']	[3]
4	diproprionate	I-Drug	['Causes']	[14]
5	inhaler	O	['N']	[5]
6	complicated	O	['N']	[6]
7	by	O	['N']	[7]
8	the	O	['N']	[8]
9	development	O	['N']	[9]
10	of	O	['N']	[10]
11	an	O	['N']	[11]
12	eosinophilic	B	['N']	[12]
13	pneumonia	I	['N']	[13]
14	reaction	I-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#1387
0	Hemorrhage	B-Adverse_Effect	['N']	[0]
1	from	O	['N']	[1]
2	a	O	['N']	[2]
3	falx	O	['N']	[3]
4	meningioma	O	['N']	[4]
5	after	O	['N']	[5]
6	internal	O	['N']	[6]
7	use	O	['N']	[7]
8	of	O	['N']	[8]
9	low	O	['N']	[9]
10	-	O	['N']	[10]
11	dose	O	['N']	[11]
12	aspirin	B-Drug	['Causes']	[0]
13	.	O	['N']	[13]
#1388
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	rare	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	recurrent	O	['N']	[6]
7	(	O	['N']	[7]
8	stuttering	O	['N']	[8]
9	)	O	['N']	[9]
10	priapism	B-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	protein	O	['N']	[15]
16	C	O	['N']	[16]
17	deficiency	O	['N']	[17]
18	while	O	['N']	[18]
19	maintained	O	['N']	[19]
20	on	O	['N']	[20]
21	Warfarin	B-Drug	['Causes']	[10]
22	therapy	O	['N']	[22]
23	.	O	['N']	[23]
#1389
0	Colonic	B	['N']	[0]
1	mucosal	I	['N']	[1]
2	necrosis	I-Adverse_Effect	['N']	[2]
3	following	O	['N']	[3]
4	administration	O	['N']	[4]
5	of	O	['N']	[5]
6	calcium	B	['N']	[6]
7	polystryrene	I	['N']	[7]
8	sulfonate	I-Drug	['Causes']	[2]
9	(	O	['N']	[9]
10	Kalimate	O	['N']	[10]
11	)	O	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	uremic	O	['N']	[14]
15	patient	O	['N']	[15]
16	.	O	['N']	[16]
#1390
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	one	O	['N']	[2]
3	patient	O	['N']	[3]
4	exhibited	O	['N']	[4]
5	severe	O	['N']	[5]
6	hypersensitivity	O	['N']	[6]
7	reactions	O	['N']	[7]
8	including	O	['N']	[8]
9	cardiac	O	['N']	[9]
10	arrest	O	['N']	[10]
11	and	O	['N']	[11]
12	apnea	B-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	another	O	['N']	[15]
16	four	O	['N']	[16]
17	patients	O	['N']	[17]
18	developed	O	['N']	[18]
19	eruptions	O	['N']	[19]
20	,	O	['N']	[20]
21	hypotension	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	tachycardia	O	['N']	[24]
25	soon	O	['N']	[25]
26	after	O	['N']	[26]
27	administration	O	['N']	[27]
28	of	O	['N']	[28]
29	CBDCA	B-Drug	['Causes']	[12]
30	.	O	['N']	[30]
#1391
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	teicoplanin	O	['N']	[4]
5	-	O	['N']	[5]
6	related	O	['N']	[6]
7	neutropenia	B-Adverse_Effect	['N']	[7]
8	that	O	['N']	[8]
9	developed	O	['N']	[9]
10	after	O	['N']	[10]
11	an	O	['N']	[11]
12	episode	O	['N']	[12]
13	of	O	['N']	[13]
14	neutropenia	O	['N']	[14]
15	induced	O	['N']	[15]
16	by	O	['N']	[16]
17	vancomycin	B-Drug	['Causes']	[7]
18	therapy	O	['N']	[18]
19	.	O	['N']	[19]
#1392
0	Acute	B	['N']	[0]
1	pancreatitis	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	a	O	['N']	[3]
4	child	O	['N']	[4]
5	with	O	['N']	[5]
6	idiopathic	O	['N']	[6]
7	ulcerative	O	['N']	[7]
8	colitis	O	['N']	[8]
9	on	O	['N']	[9]
10	long	O	['N']	[10]
11	-	O	['N']	[11]
12	term	O	['N']	[12]
13	5-aminosalicylic	B	['N']	[13]
14	acid	I-Drug	['Causes']	[1]
15	therapy	O	['N']	[15]
16	.	O	['N']	[16]
#1393
0	The	O	['N']	[0]
1	temporal	O	['N']	[1]
2	relationship	O	['N']	[2]
3	suggests	O	['N']	[3]
4	that	O	['N']	[4]
5	the	O	['N']	[5]
6	spinal	B	['N']	[6]
7	cord	I	['N']	[7]
8	infarction	I-Adverse_Effect	['N']	[8]
9	may	O	['N']	[9]
10	be	O	['N']	[10]
11	related	O	['N']	[11]
12	to	O	['N']	[12]
13	the	O	['N']	[13]
14	use	O	['N']	[14]
15	of	O	['N']	[15]
16	zolmitriptan	B-Drug	['Causes']	[8]
17	.	O	['N']	[17]
#1394
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Gemcitabine	B-Drug	['Causes']	[6]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	recall	B	['N']	[5]
6	pneumonitis	I-Adverse_Effect	['N']	[6]
7	is	O	['N']	[7]
8	a	O	['N']	[8]
9	rarely	O	['N']	[9]
10	reported	O	['N']	[10]
11	phenomenon	O	['N']	[11]
12	and	O	['N']	[12]
13	should	O	['N']	[13]
14	be	O	['N']	[14]
15	taken	O	['N']	[15]
16	into	O	['N']	[16]
17	account	O	['N']	[17]
18	even	O	['N']	[18]
19	after	O	['N']	[19]
20	extended	O	['N']	[20]
21	time	O	['N']	[21]
22	interval	O	['N']	[22]
23	to	O	['N']	[23]
24	the	O	['N']	[24]
25	previous	O	['N']	[25]
26	radiotherapy	O	['N']	[26]
27	.	O	['N']	[27]
#1395
0	The	O	['N']	[0]
1	introduction	O	['N']	[1]
2	of	O	['N']	[2]
3	para	O	['N']	[3]
4	-	O	['N']	[4]
5	aminosalicylic	O	['N']	[5]
6	acid	O	['N']	[6]
7	(	O	['N']	[7]
8	PAS	B-Drug	['Causes']	[13]
9	)	O	['N']	[9]
10	led	O	['N']	[10]
11	to	O	['N']	[11]
12	hypoglycaemic	B	['N']	[12]
13	coma	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#1396
0	Acute	B	['N']	[0]
1	erythroid	I	['N']	[1]
2	leukemia	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	cyclophosphamide	B-Drug	['Causes']	[2]
5	therapy	O	['N']	[5]
6	for	O	['N']	[6]
7	multiple	O	['N']	[7]
8	myeloma	O	['N']	[8]
9	:	O	['N']	[9]
10	report	O	['N']	[10]
11	of	O	['N']	[11]
12	two	O	['N']	[12]
13	cases	O	['N']	[13]
14	.	O	['N']	[14]
#1397
0	Protease	O	['N']	[0]
1	inhibitors	O	['N']	[1]
2	(	O	['N']	[2]
3	ritonavir	O	['N']	[3]
4	and	O	['N']	[4]
5	saquinavir	O	['N']	[5]
6	)	O	['N']	[6]
7	were	O	['N']	[7]
8	added	O	['N']	[8]
9	to	O	['N']	[9]
10	the	O	['N']	[10]
11	treatment	O	['N']	[11]
12	and	O	['N']	[12]
13	the	O	['N']	[13]
14	patient	O	['N']	[14]
15	developed	O	['N']	[15]
16	progressive	O	['N']	[16]
17	ataxia	O	['N']	[17]
18	related	O	['N']	[18]
19	to	O	['N']	[19]
20	carbamazepine	B-Drug	['Causes']	[21]
21	toxicity	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#1398
0	During	O	['N']	[0]
1	the	O	['N']	[1]
2	anti	O	['N']	[2]
3	-	O	['N']	[3]
4	tuberculous	O	['N']	[4]
5	therapy	O	['N']	[5]
6	,	O	['N']	[6]
7	visual	B	['N']	[7]
8	loss	I-Adverse_Effect	['N']	[8]
9	can	O	['N']	[9]
10	be	O	['N']	[10]
11	related	O	['N']	[11]
12	to	O	['N']	[12]
13	ethambutol	B-Drug	['Causes']	[8]
14	toxicity	O	['N']	[14]
15	or	O	['N']	[15]
16	the	O	['N']	[16]
17	tuberculosis	O	['N']	[17]
18	infection	O	['N']	[18]
19	itself	O	['N']	[19]
20	.	O	['N']	[20]
#1399
0	Our	O	['N']	[0]
1	review	O	['N']	[1]
2	of	O	['N']	[2]
3	194	O	['N']	[3]
4	RA	O	['N']	[4]
5	patients	O	['N']	[5]
6	and	O	['N']	[6]
7	38	O	['N']	[7]
8	PsA	O	['N']	[8]
9	patients	O	['N']	[9]
10	receiving	O	['N']	[10]
11	MTX	B-Drug	['Causes']	[25]
12	has	O	['N']	[12]
13	identified	O	['N']	[13]
14	four	O	['N']	[14]
15	RA	O	['N']	[15]
16	patients	O	['N']	[16]
17	and	O	['N']	[17]
18	one	O	['N']	[18]
19	PsA	O	['N']	[19]
20	patient	O	['N']	[20]
21	with	O	['N']	[21]
22	MTX	O	['N']	[22]
23	-	O	['N']	[23]
24	induced	O	['N']	[24]
25	pneumonitis	B-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	giving	O	['N']	[27]
28	a	O	['N']	[28]
29	prevalence	O	['N']	[29]
30	of	O	['N']	[30]
31	2.1	O	['N']	[31]
32	%	O	['N']	[32]
33	and	O	['N']	[33]
34	0.03	O	['N']	[34]
35	%	O	['N']	[35]
36	,	O	['N']	[36]
37	respectively	O	['N']	[37]
38	.	O	['N']	[38]
#1400
0	Our	O	['N']	[0]
1	report	O	['N']	[1]
2	suggested	O	['N']	[2]
3	that	O	['N']	[3]
4	CBDCA	B-Drug	['Dosage']	[50]
5	hypersensitivity	O	['N']	[5]
6	was	O	['N']	[6]
7	correlated	O	['N']	[7]
8	with	O	['N']	[8]
9	the	O	['N']	[9]
10	total	O	['N']	[10]
11	dose	O	['N']	[11]
12	of	O	['N']	[12]
13	previously	O	['N']	[13]
14	administered	O	['N']	[14]
15	platinum	O	['N']	[15]
16	agents	O	['N']	[16]
17	and	O	['N']	[17]
18	that	O	['N']	[18]
19	CBDCA	O	['N']	[19]
20	should	O	['N']	[20]
21	be	O	['N']	[21]
22	excluded	O	['N']	[22]
23	in	O	['N']	[23]
24	patients	O	['N']	[24]
25	who	O	['N']	[25]
26	have	O	['N']	[26]
27	received	O	['N']	[27]
28	multiple	O	['N']	[28]
29	platinum	O	['N']	[29]
30	-	O	['N']	[30]
31	based	O	['N']	[31]
32	chemotherapy	O	['N']	[32]
33	,	O	['N']	[33]
34	even	O	['N']	[34]
35	in	O	['N']	[35]
36	platinum	O	['N']	[36]
37	-	O	['N']	[37]
38	sensitive	O	['N']	[38]
39	cases	O	['N']	[39]
40	,	O	['N']	[40]
41	because	O	['N']	[41]
42	CBDCA	O	['N']	[42]
43	hypersensitivity	O	['N']	[43]
44	can	O	['N']	[44]
45	occur	O	['N']	[45]
46	even	O	['N']	[46]
47	with	O	['N']	[47]
48	low	B	['N']	[48]
49	-	I	['N']	[49]
50	dose	I-Dose	['N']	[50]
51	CBDCA	O	['N']	[51]
52	administration	O	['N']	[52]
53	.	O	['N']	[53]
#1401
0	A	O	['N']	[0]
1	second	O	['N']	[1]
2	episode	O	['N']	[2]
3	of	O	['N']	[3]
4	jaundice	B-Adverse_Effect	['N']	[4]
5	followed	O	['N']	[5]
6	the	O	['N']	[6]
7	intravaginal	O	['N']	[7]
8	administration	O	['N']	[8]
9	of	O	['N']	[9]
10	a	O	['N']	[10]
11	mixture	O	['N']	[11]
12	of	O	['N']	[12]
13	furazolidone	B-Drug	['Causes']	[4]
14	and	O	['N']	[14]
15	nifuroxime	O	['N']	[15]
16	.	O	['N']	[16]
#1402
0	The	O	['N']	[0]
1	reported	O	['N']	[1]
2	cases	O	['N']	[2]
3	of	O	['N']	[3]
4	in	O	['N']	[4]
5	utero	O	['N']	[5]
6	exposure	O	['N']	[6]
7	to	O	['N']	[7]
8	cyclosposphamide	B-Drug	['Causes']	[25]
9	shared	O	['N']	[9]
10	the	O	['N']	[10]
11	following	O	['N']	[11]
12	manifestations	O	['N']	[12]
13	with	O	['N']	[13]
14	our	O	['N']	[14]
15	patient	O	['N']	[15]
16	:	O	['N']	[16]
17	growth	O	['N']	[17]
18	deficiency	O	['N']	[18]
19	,	O	['N']	[19]
20	developmental	O	['N']	[20]
21	delay	O	['N']	[21]
22	,	O	['N']	[22]
23	craniosynostosis	O	['N']	[23]
24	,	O	['N']	[24]
25	blepharophimosis	B-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	flat	O	['N']	[27]
28	nasal	O	['N']	[28]
29	bridge	O	['N']	[29]
30	,	O	['N']	[30]
31	abnormal	O	['N']	[31]
32	ears	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	distal	O	['N']	[35]
36	limb	O	['N']	[36]
37	defects	O	['N']	[37]
38	including	O	['N']	[38]
39	hypoplastic	O	['N']	[39]
40	thumbs	O	['N']	[40]
41	and	O	['N']	[41]
42	oligodactyly	O	['N']	[42]
43	.	O	['N']	[43]
#1403
0	The	O	['N']	[0]
1	occurrence	O	['N']	[1]
2	of	O	['N']	[2]
3	a	O	['N']	[3]
4	myocardial	B	['N']	[4]
5	infarction	I-Adverse_Effect	['N']	[5]
6	is	O	['N']	[6]
7	reported	O	['N']	[7]
8	after	O	['N']	[8]
9	chemotherapy	O	['N']	[9]
10	containing	O	['N']	[10]
11	etoposide	B-Drug	['Causes']	[5]
12	,	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	man	O	['N']	[15]
16	with	O	['N']	[16]
17	no	O	['N']	[17]
18	risk	O	['N']	[18]
19	factors	O	['N']	[19]
20	for	O	['N']	[20]
21	coronary	O	['N']	[21]
22	heart	O	['N']	[22]
23	disease	O	['N']	[23]
24	.	O	['N']	[24]
#1404
0	Central	B	['N']	[0]
1	pontine	I	['N']	[1]
2	myelinolysis	I-Adverse_Effect	['N']	[2]
3	manifested	O	['N']	[3]
4	by	O	['N']	[4]
5	temporary	O	['N']	[5]
6	blindness	O	['N']	[6]
7	:	O	['N']	[7]
8	a	O	['N']	[8]
9	possible	O	['N']	[9]
10	complication	O	['N']	[10]
11	of	O	['N']	[11]
12	lithium	B-Drug	['Causes']	[2]
13	toxicity	O	['N']	[13]
14	.	O	['N']	[14]
#1405
0	Anaphylactoid	O	['N']	[0]
1	shock	O	['N']	[1]
2	,	O	['N']	[2]
3	disseminated	B	['N']	[3]
4	intravascular	I	['N']	[4]
5	coagulation	I-Adverse_Effect	['N']	[5]
6	,	O	['N']	[6]
7	and	O	['N']	[7]
8	anuric	O	['N']	[8]
9	renal	O	['N']	[9]
10	failure	O	['N']	[10]
11	requiring	O	['N']	[11]
12	dialysis	O	['N']	[12]
13	occurred	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	patient	O	['N']	[16]
17	receiving	O	['N']	[17]
18	zomepirac	B-Drug	['Causes']	[5]
19	sodium	O	['N']	[19]
20	for	O	['N']	[20]
21	toothache	O	['N']	[21]
22	.	O	['N']	[22]
#1406
0	Rebound	B	['N']	[0]
1	hyperglycemia	I-Adverse_Effect	['N']	[1]
2	was	O	['N']	[2]
3	observed	O	['N']	[3]
4	with	O	['N']	[4]
5	both	O	['N']	[5]
6	intermediate	O	['N']	[6]
7	(	O	['N']	[7]
8	neutral	O	['N']	[8]
9	protamine	B	['N']	[9]
10	hagedorn	I-Drug	['Causes']	[1]
11	)	O	['N']	[11]
12	and	O	['N']	[12]
13	long	O	['N']	[13]
14	-	O	['N']	[14]
15	acting	O	['N']	[15]
16	(	O	['N']	[16]
17	protamine	O	['N']	[17]
18	zinc	O	['N']	[18]
19	iletin	O	['N']	[19]
20	)	O	['N']	[20]
21	insulins	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	the	O	['N']	[24]
25	range	O	['N']	[25]
26	of	O	['N']	[26]
27	insulin	O	['N']	[27]
28	doses	O	['N']	[28]
29	at	O	['N']	[29]
30	which	O	['N']	[30]
31	the	O	['N']	[31]
32	disorder	O	['N']	[32]
33	developed	O	['N']	[33]
34	overlapped	O	['N']	[34]
35	previously	O	['N']	[35]
36	determined	O	['N']	[36]
37	therapeutic	O	['N']	[37]
38	doses	O	['N']	[38]
39	for	O	['N']	[39]
40	these	O	['N']	[40]
41	insulins	O	['N']	[41]
42	in	O	['N']	[42]
43	the	O	['N']	[43]
44	cat	O	['N']	[44]
45	.	O	['N']	[45]
#1407
0	Severe	B	['N']	[0]
1	rash	I-Adverse_Effect	['N']	[1]
2	,	O	['N']	[2]
3	including	O	['N']	[3]
4	the	O	['N']	[4]
5	Stevens	O	['N']	[5]
6	-	O	['N']	[6]
7	Johnson	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	(	O	['N']	[9]
10	SJS	O	['N']	[10]
11	)	O	['N']	[11]
12	,	O	['N']	[12]
13	is	O	['N']	[13]
14	the	O	['N']	[14]
15	major	O	['N']	[15]
16	toxicity	O	['N']	[16]
17	of	O	['N']	[17]
18	nevirapine	B-Drug	['Causes']	[1]
19	and	O	['N']	[19]
20	is	O	['N']	[20]
21	described	O	['N']	[21]
22	in	O	['N']	[22]
23	the	O	['N']	[23]
24	package	O	['N']	[24]
25	labeling	O	['N']	[25]
26	with	O	['N']	[26]
27	a	O	['N']	[27]
28	prominent	O	['N']	[28]
29	,	O	['N']	[29]
30	boxed	O	['N']	[30]
31	warning	O	['N']	[31]
32	.	O	['N']	[32]
#1408
0	After	O	['N']	[0]
1	the	O	['N']	[1]
2	chlorambucil	B-Drug	['Causes']	[18]
3	was	O	['N']	[3]
4	discontinued	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	wbc	O	['N']	[7]
8	count	O	['N']	[8]
9	began	O	['N']	[9]
10	to	O	['N']	[10]
11	slowly	O	['N']	[11]
12	rise	O	['N']	[12]
13	and	O	['N']	[13]
14	the	O	['N']	[14]
15	patient	O	['N']	[15]
16	developed	O	['N']	[16]
17	clinical	O	['N']	[17]
18	AML	B-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#1409
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	experienced	O	['N']	[2]
3	hallucinations	O	['N']	[3]
4	,	O	['N']	[4]
5	agitation	O	['N']	[5]
6	,	O	['N']	[6]
7	vomiting	B-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	tachycardia	O	['N']	[9]
10	and	O	['N']	[10]
11	seizures	O	['N']	[11]
12	after	O	['N']	[12]
13	ingestion	O	['N']	[13]
14	of	O	['N']	[14]
15	1050	O	['N']	[15]
16	(	O	['N']	[16]
17	48	O	['N']	[17]
18	mg	O	['N']	[18]
19	/	O	['N']	[19]
20	kg	O	['N']	[20]
21	)	O	['N']	[21]
22	of	O	['N']	[22]
23	extended	O	['N']	[23]
24	-	O	['N']	[24]
25	release	O	['N']	[25]
26	bupropion	B-Drug	['Causes']	[7]
27	.	O	['N']	[27]
#1410
0	Ifosfamide	B-Drug	['Causes']	[8]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	known	O	['N']	[3]
4	nephrotoxic	O	['N']	[4]
5	drug	O	['N']	[5]
6	with	O	['N']	[6]
7	demonstrated	O	['N']	[7]
8	tubulopathies	B-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#1411
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	optic	B	['N']	[3]
4	neuropathy	I-Adverse_Effect	['N']	[4]
5	while	O	['N']	[5]
6	being	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	isoniazid	B-Drug	['Causes']	[4]
10	and	O	['N']	[10]
11	ethambutol	O	['N']	[11]
12	.	O	['N']	[12]
#1412
0	Clofazimine	B-Drug	['Causes']	[3]
1	induced	O	['N']	[1]
2	nail	B	['N']	[2]
3	changes	I-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#1413
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	one	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	non	O	['N']	[5]
6	-	O	['N']	[6]
7	Hodgkin	O	['N']	[7]
8	lymphoma	O	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	patient	O	['N']	[11]
12	,	O	['N']	[12]
13	with	O	['N']	[13]
14	a	O	['N']	[14]
15	30-year	O	['N']	[15]
16	history	O	['N']	[16]
17	of	O	['N']	[17]
18	rheumatoid	O	['N']	[18]
19	arthritis	O	['N']	[19]
20	,	O	['N']	[20]
21	taking	O	['N']	[21]
22	low	B-Dose	['N']	[22]
23	dose	O	['N']	[23]
24	methotrexate	B-Drug	['Dosage']	[22]
25	weekly	O	['N']	[25]
26	over	O	['N']	[26]
27	a	O	['N']	[27]
28	10-month	O	['N']	[28]
29	period	O	['N']	[29]
30	.	O	['N']	[30]
#1414
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	37-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	African-	O	['N']	[6]
7	American	O	['N']	[7]
8	man	O	['N']	[8]
9	with	O	['N']	[9]
10	G6PD	O	['N']	[10]
11	deficiency	O	['N']	[11]
12	developed	O	['N']	[12]
13	hemolytic	B	['N']	[13]
14	anemia	I-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	hepatitis	O	['N']	[16]
17	,	O	['N']	[17]
18	orthostatic	O	['N']	[18]
19	hypotension	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	aseptic	O	['N']	[22]
23	meningitis	O	['N']	[23]
24	simultaneously	O	['N']	[24]
25	after	O	['N']	[25]
26	using	O	['N']	[26]
27	trimethoprim	B-Drug	['Causes']	[14]
28	-	O	['N']	[28]
29	sulfamethoxazole	O	['N']	[29]
30	.	O	['N']	[30]
#1415
0	Acute	B	['N']	[0]
1	coronary	I	['N']	[1]
2	syndromes	I-Adverse_Effect	['N']	[2]
3	can	O	['N']	[3]
4	be	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	the	O	['N']	[7]
8	infusion	O	['N']	[8]
9	of	O	['N']	[9]
10	rituximab	B-Drug	['Causes']	[2]
11	.	O	['N']	[11]
#1416
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	52-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	with	O	['N']	[7]
8	Parkinson	O	['N']	[8]
9	disease	O	['N']	[9]
10	who	O	['N']	[10]
11	had	O	['N']	[11]
12	taken	O	['N']	[12]
13	amantadine	B-Drug	['Causes']	[20]
14	for	O	['N']	[14]
15	6	O	['N']	[15]
16	years	O	['N']	[16]
17	had	O	['N']	[17]
18	bilateral	B	['N']	[18]
19	corneal	I	['N']	[19]
20	edema	I-Adverse_Effect	['N']	[20]
21	for	O	['N']	[21]
22	2	O	['N']	[22]
23	months	O	['N']	[23]
24	at	O	['N']	[24]
25	baseline	O	['N']	[25]
26	.	O	['N']	[26]
#1417
0	DESIGN	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	reviewed	O	['N']	[3]
4	the	O	['N']	[4]
5	medical	O	['N']	[5]
6	records	O	['N']	[6]
7	of	O	['N']	[7]
8	four	O	['N']	[8]
9	patients	O	['N']	[9]
10	,	O	['N']	[10]
11	who	O	['N']	[11]
12	were	O	['N']	[12]
13	seen	O	['N']	[13]
14	by	O	['N']	[14]
15	us	O	['N']	[15]
16	between	O	['N']	[16]
17	July	O	['N']	[17]
18	2000	O	['N']	[18]
19	and	O	['N']	[19]
20	February	O	['N']	[20]
21	2004	O	['N']	[21]
22	for	O	['N']	[22]
23	sudden	O	['N']	[23]
24	onset	O	['N']	[24]
25	of	O	['N']	[25]
26	a	O	['N']	[26]
27	central	B	['N']	[27]
28	neurological	I	['N']	[28]
29	syndrome	I-Adverse_Effect	['N']	[29]
30	within	O	['N']	[30]
31	days	O	['N']	[31]
32	of	O	['N']	[32]
33	intrathecal	O	['N']	[33]
34	MTX	B-Drug	['Causes']	[29]
35	.	O	['N']	[35]
#1418
0	These	O	['N']	[0]
1	cases	O	['N']	[1]
2	suggest	O	['N']	[2]
3	the	O	['N']	[3]
4	possibility	O	['N']	[4]
5	that	O	['N']	[5]
6	,	O	['N']	[6]
7	in	O	['N']	[7]
8	some	O	['N']	[8]
9	patients	O	['N']	[9]
10	,	O	['N']	[10]
11	leukopenia	O	['N']	[11]
12	or	O	['N']	[12]
13	agranulocytosis	B-Adverse_Effect	['N']	[13]
14	during	O	['N']	[14]
15	olanzapine	B-Drug	['Causes']	[13]
16	treatment	O	['N']	[16]
17	might	O	['N']	[17]
18	be	O	['N']	[18]
19	dose	O	['N']	[19]
20	-	O	['N']	[20]
21	related	O	['N']	[21]
22	.	O	['N']	[22]
#1419
0	Although	O	['N']	[0]
1	combinations	O	['N']	[1]
2	of	O	['N']	[2]
3	belladonna	B-Drug	['Causes']	[35]
4	,	O	['N']	[4]
5	ergotamine	O	['N']	[5]
6	,	O	['N']	[6]
7	and	O	['N']	[7]
8	phenobarbital	O	['N']	[8]
9	have	O	['N']	[9]
10	been	O	['N']	[10]
11	used	O	['N']	[11]
12	for	O	['N']	[12]
13	medical	O	['N']	[13]
14	treatment	O	['N']	[14]
15	of	O	['N']	[15]
16	menopausal	O	['N']	[16]
17	symptoms	O	['N']	[17]
18	since	O	['N']	[18]
19	the	O	['N']	[19]
20	1960s	O	['N']	[20]
21	,	O	['N']	[21]
22	this	O	['N']	[22]
23	is	O	['N']	[23]
24	the	O	['N']	[24]
25	first	O	['N']	[25]
26	known	O	['N']	[26]
27	case	O	['N']	[27]
28	report	O	['N']	[28]
29	of	O	['N']	[29]
30	its	O	['N']	[30]
31	association	O	['N']	[31]
32	with	O	['N']	[32]
33	anticonvulsant	B	['N']	[33]
34	hypersensitivity	I	['N']	[34]
35	syndrome	I-Adverse_Effect	['N']	[35]
36	.	O	['N']	[36]
#1420
0	Bone	B	['N']	[0]
1	marrow	I	['N']	[1]
2	aplasia	I-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	severe	O	['N']	[4]
5	skin	O	['N']	[5]
6	rash	O	['N']	[6]
7	after	O	['N']	[7]
8	a	O	['N']	[8]
9	single	O	['N']	[9]
10	low	O	['N']	[10]
11	dose	O	['N']	[11]
12	of	O	['N']	[12]
13	methotrexate	B-Drug	['Causes']	[2]
14	.	O	['N']	[14]
#1421
0	Metabolic	O	['N']	[0]
1	balance	O	['N']	[1]
2	studies	O	['N']	[2]
3	and	O	['N']	[3]
4	rechallenge	O	['N']	[4]
5	with	O	['N']	[5]
6	hydrochlorothiazide	B-Drug	['Causes']	[18]
7	were	O	['N']	[7]
8	undertaken	O	['N']	[8]
9	to	O	['N']	[9]
10	investigate	O	['N']	[10]
11	the	O	['N']	[11]
12	mechanism	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	thiazide	O	['N']	[15]
16	-	O	['N']	[16]
17	induced	O	['N']	[17]
18	hyponatremia	B-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#1422
0	Multiple	O	['N']	[0]
1	complications	O	['N']	[1]
2	of	O	['N']	[2]
3	propylthiouracil	B-Drug	['Causes']	[6]
4	treatment	O	['N']	[4]
5	:	O	['N']	[5]
6	granulocytopenia	B-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	eosinophilia	O	['N']	[8]
9	,	O	['N']	[9]
10	skin	O	['N']	[10]
11	reaction	O	['N']	[11]
12	and	O	['N']	[12]
13	hepatitis	O	['N']	[13]
14	with	O	['N']	[14]
15	lymphocyte	O	['N']	[15]
16	sensitization	O	['N']	[16]
17	.	O	['N']	[17]
#1423
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	chronic	O	['N']	[7]
8	,	O	['N']	[8]
9	nonproductive	O	['N']	[9]
10	cough	B-Adverse_Effect	['N']	[10]
11	secondary	O	['N']	[11]
12	to	O	['N']	[12]
13	the	O	['N']	[13]
14	angiotensin	O	['N']	[14]
15	-	O	['N']	[15]
16	converting	O	['N']	[16]
17	enzyme	O	['N']	[17]
18	(	O	['N']	[18]
19	ACE	O	['N']	[19]
20	)	O	['N']	[20]
21	inhibitor	O	['N']	[21]
22	quinapril	B-Drug	['Causes']	[10]
23	,	O	['N']	[23]
24	with	O	['N']	[24]
25	complete	O	['N']	[25]
26	resolution	O	['N']	[26]
27	after	O	['N']	[27]
28	switching	O	['N']	[28]
29	to	O	['N']	[29]
30	another	O	['N']	[30]
31	ACE	O	['N']	[31]
32	inhibitor	O	['N']	[32]
33	,	O	['N']	[33]
34	fosinopril	O	['N']	[34]
35	.	O	['N']	[35]
#1424
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	ciprofloxacin	B-Drug	['Causes']	[16]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	SJS	O	['N']	[11]
12	and	O	['N']	[12]
13	acute	O	['N']	[13]
14	onset	O	['N']	[14]
15	of	O	['N']	[15]
16	VBDS	B-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	reviewed	O	['N']	[19]
20	the	O	['N']	[20]
21	related	O	['N']	[21]
22	literature	O	['N']	[22]
23	.	O	['N']	[23]
#1425
0	New	O	['N']	[0]
1	onset	O	['N']	[1]
2	of	O	['N']	[2]
3	Crohn	B	['N']	[3]
4	's	I	['N']	[4]
5	disease	I-Adverse_Effect	['N']	[5]
6	during	O	['N']	[6]
7	treatment	O	['N']	[7]
8	of	O	['N']	[8]
9	active	O	['N']	[9]
10	ankylosing	O	['N']	[10]
11	spondylitis	O	['N']	[11]
12	with	O	['N']	[12]
13	etanercept	B-Drug	['Causes']	[5]
14	.	O	['N']	[14]
#1426
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	tuberculous	B	['N']	[6]
7	uveitis	I-Adverse_Effect	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	etanercept	B-Drug	['Causes']	[7]
11	.	O	['N']	[11]
#1427
0	Hepatobiliary	B	['N']	[0]
1	disorders	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	orally	O	['N']	[4]
5	administered	O	['N']	[5]
6	terbinafine	B-Drug	['Causes']	[1]
7	have	O	['N']	[7]
8	rarely	O	['N']	[8]
9	been	O	['N']	[9]
10	reported	O	['N']	[10]
11	.	O	['N']	[11]
#1428
0	Life	O	['N']	[0]
1	-	O	['N']	[1]
2	threatening	O	['N']	[2]
3	hyperkalemia	B-Adverse_Effect	['N']	[3]
4	induced	O	['N']	[4]
5	by	O	['N']	[5]
6	arginine	B-Drug	['Causes']	[3]
7	.	O	['N']	[7]
#1429
0	Early	O	['N']	[0]
1	-	O	['N']	[1]
2	onset	O	['N']	[2]
3	acute	B	['N']	[3]
4	transverse	I	['N']	[4]
5	myelitis	I-Adverse_Effect	['N']	[5]
6	following	O	['N']	[6]
7	hepatitis	B	['N']	[7]
8	B	I	['N']	[8]
9	vaccination	I-Drug	['Causes']	[5]
10	and	O	['N']	[10]
11	respiratory	O	['N']	[11]
12	infection	O	['N']	[12]
13	:	O	['N']	[13]
14	case	O	['N']	[14]
15	report	O	['N']	[15]
16	.	O	['N']	[16]
#1430
0	Neutropenia	B-Adverse_Effect	['N']	[0]
1	is	O	['N']	[1]
2	an	O	['N']	[2]
3	infrequent	O	['N']	[3]
4	complication	O	['N']	[4]
5	following	O	['N']	[5]
6	administration	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	angiotensin	O	['N']	[9]
10	-	O	['N']	[10]
11	converting	O	['N']	[11]
12	enzyme	O	['N']	[12]
13	(	O	['N']	[13]
14	ACE	O	['N']	[14]
15	)	O	['N']	[15]
16	inhibitor	O	['N']	[16]
17	,	O	['N']	[17]
18	captopril	B-Drug	['Causes']	[0]
19	.	O	['N']	[19]
#1431
0	The	O	['N']	[0]
1	visual	O	['N']	[1]
2	loss	O	['N']	[2]
3	in	O	['N']	[3]
4	this	O	['N']	[4]
5	patient	O	['N']	[5]
6	seems	O	['N']	[6]
7	to	O	['N']	[7]
8	result	O	['N']	[8]
9	from	O	['N']	[9]
10	phenol	B-Drug	['Causes']	[11]
11	neurotoxicity	B-Adverse_Effect	['N']	[11]
12	rather	O	['N']	[12]
13	than	O	['N']	[13]
14	mechanical	O	['N']	[14]
15	compression	O	['N']	[15]
16	of	O	['N']	[16]
17	the	O	['N']	[17]
18	intraorbital	O	['N']	[18]
19	optic	O	['N']	[19]
20	nerve	O	['N']	[20]
21	.	O	['N']	[21]
#1432
0	AIM	O	['N']	[0]
1	:	O	['N']	[1]
2	Report	O	['N']	[2]
3	of	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	woman	O	['N']	[8]
9	patient	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	celiac	B	['N']	[12]
13	disease	I-Adverse_Effect	['N']	[13]
14	after	O	['N']	[14]
15	pegylated	B	['N']	[15]
16	interferon	I	['N']	[16]
17	alpha-2a	I-Drug	['Causes']	[13]
18	and	O	['N']	[18]
19	ribavirin	O	['N']	[19]
20	use	O	['N']	[20]
21	for	O	['N']	[21]
22	chronic	O	['N']	[22]
23	hepatitis	O	['N']	[23]
24	C.	O	['N']	[24]
#1433
0	In	O	['N']	[0]
1	the	O	['N']	[1]
2	second	O	['N']	[2]
3	case	O	['N']	[3]
4	,	O	['N']	[4]
5	five	O	['N']	[5]
6	cardiac	B	['N']	[6]
7	arrests	I-Adverse_Effect	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	ventricular	O	['N']	[10]
11	tachycardia	O	['N']	[11]
12	and	O	['N']	[12]
13	fibrillation	O	['N']	[13]
14	occurred	O	['N']	[14]
15	during	O	['N']	[15]
16	several	O	['N']	[16]
17	hours	O	['N']	[17]
18	after	O	['N']	[18]
19	beginning	O	['N']	[19]
20	a	O	['N']	[20]
21	trial	O	['N']	[21]
22	of	O	['N']	[22]
23	bretylium	B-Drug	['Causes']	[7]
24	maintenance	O	['N']	[24]
25	therapy	O	['N']	[25]
26	for	O	['N']	[26]
27	complex	O	['N']	[27]
28	ventricular	O	['N']	[28]
29	ectopy	O	['N']	[29]
30	.	O	['N']	[30]
#1434
0	Possible	O	['N']	[0]
1	linkage	O	['N']	[1]
2	of	O	['N']	[2]
3	amprenavir	B-Drug	['Causes']	[6]
4	with	O	['N']	[4]
5	intracranial	B	['N']	[5]
6	bleeding	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	an	O	['N']	[8]
9	HIV	O	['N']	[9]
10	-	O	['N']	[10]
11	infected	O	['N']	[11]
12	hemophiliac	O	['N']	[12]
13	.	O	['N']	[13]
#1435
0	It	O	['N']	[0]
1	was	O	['N']	[1]
2	restarted	O	['N']	[2]
3	6	O	['N']	[3]
4	weeks	O	['N']	[4]
5	later	O	['N']	[5]
6	,	O	['N']	[6]
7	and	O	['N']	[7]
8	10	O	['N']	[8]
9	weeks	O	['N']	[9]
10	after	O	['N']	[10]
11	that	O	['N']	[11]
12	,	O	['N']	[12]
13	the	O	['N']	[13]
14	patient	O	['N']	[14]
15	presented	O	['N']	[15]
16	with	O	['N']	[16]
17	fulminant	B	['N']	[17]
18	hepatic	I	['N']	[18]
19	failure	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	which	O	['N']	[21]
22	resolved	O	['N']	[22]
23	rapidly	O	['N']	[23]
24	after	O	['N']	[24]
25	cessation	O	['N']	[25]
26	of	O	['N']	[26]
27	nicotinic	B	['N']	[27]
28	acid	I-Drug	['Causes']	[19]
29	therapy	O	['N']	[29]
30	.	O	['N']	[30]
#1436
0	Worsening	B	['N']	[0]
1	of	I	['N']	[1]
2	neurologic	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	patients	O	['N']	[5]
6	with	O	['N']	[6]
7	Wilson	O	['N']	[7]
8	's	O	['N']	[8]
9	disease	O	['N']	[9]
10	with	O	['N']	[10]
11	initial	O	['N']	[11]
12	penicillamine	B-Drug	['Causes']	[3]
13	therapy	O	['N']	[13]
14	.	O	['N']	[14]
#1437
0	A	O	['N']	[0]
1	64	O	['N']	[1]
2	year	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	recurrent	O	['N']	[6]
7	metastatic	O	['N']	[7]
8	squamous	O	['N']	[8]
9	cell	O	['N']	[9]
10	carcinoma	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	head	O	['N']	[13]
14	and	O	['N']	[14]
15	neck	O	['N']	[15]
16	developed	O	['N']	[16]
17	severe	B	['N']	[17]
18	skin	I	['N']	[18]
19	rash	I-Adverse_Effect	['N']	[19]
20	and	O	['N']	[20]
21	bone	O	['N']	[21]
22	marrow	O	['N']	[22]
23	aplasia	O	['N']	[23]
24	4	O	['N']	[24]
25	and	O	['N']	[25]
26	7	O	['N']	[26]
27	days	O	['N']	[27]
28	,	O	['N']	[28]
29	respectively	O	['N']	[29]
30	,	O	['N']	[30]
31	following	O	['N']	[31]
32	a	O	['N']	[32]
33	single	O	['N']	[33]
34	dose	O	['N']	[34]
35	of	O	['N']	[35]
36	40	O	['N']	[36]
37	mg	O	['N']	[37]
38	/	O	['N']	[38]
39	m2	O	['N']	[39]
40	methotrexate	O	['N']	[40]
41	(	O	['N']	[41]
42	MTX	B-Drug	['Causes']	[19]
43	)	O	['N']	[43]
44	.	O	['N']	[44]
#1438
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	the	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	young	O	['N']	[8]
9	woman	O	['N']	[9]
10	with	O	['N']	[10]
11	Graves	O	['N']	[11]
12	'	O	['N']	[12]
13	disease	O	['N']	[13]
14	in	O	['N']	[14]
15	whom	O	['N']	[15]
16	ototoxicity	O	['N']	[16]
17	developed	O	['N']	[17]
18	because	O	['N']	[18]
19	of	O	['N']	[19]
20	propylthiouracil	B-Drug	['Causes']	[28]
21	(	O	['N']	[21]
22	PTU)-induced	O	['N']	[22]
23	antineutrophil	B	['N']	[23]
24	cytoplasmic	I	['N']	[24]
25	antibody	I	['N']	[25]
26	(	I	['N']	[26]
27	ANCA)-associated	I	['N']	[27]
28	vasculitis	I-Adverse_Effect	['N']	[28]
29	.	O	['N']	[29]
#1439
0	Enalaprilat	B-Drug	['Causes']	[3]
1	induced	O	['N']	[1]
2	acute	B	['N']	[2]
3	parotitis	I-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#1440
0	Cryptococcus	B	['N']	[0]
1	neoformans	I	['N']	[1]
2	fatal	I	['N']	[2]
3	sepsis	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	chronic	O	['N']	[6]
7	lymphocytic	O	['N']	[7]
8	leukemia	O	['N']	[8]
9	patient	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	alemtuzumab	B-Drug	['Causes']	[3]
13	:	O	['N']	[13]
14	case	O	['N']	[14]
15	report	O	['N']	[15]
16	and	O	['N']	[16]
17	review	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	literature	O	['N']	[20]
21	.	O	['N']	[21]
#1441
0	Six	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	rheumatoid	O	['N']	[3]
4	arthritis	O	['N']	[4]
5	developed	O	['N']	[5]
6	a	O	['N']	[6]
7	syndrome	O	['N']	[7]
8	resembling	O	['N']	[8]
9	lupus	B	['N']	[9]
10	erythematosus	I-Adverse_Effect	['N']	[10]
11	while	O	['N']	[11]
12	being	O	['N']	[12]
13	treated	O	['N']	[13]
14	with	O	['N']	[14]
15	penicillamine	B-Drug	['Causes']	[10]
16	.	O	['N']	[16]
#1442
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	occurrence	O	['N']	[3]
4	of	O	['N']	[4]
5	renal	B	['N']	[5]
6	failure	I-Adverse_Effect	['N']	[6]
7	due	O	['N']	[7]
8	to	O	['N']	[8]
9	cholesterol	O	['N']	[9]
10	crystal	O	['N']	[10]
11	embolization	O	['N']	[11]
12	following	O	['N']	[12]
13	thrombolytic	O	['N']	[13]
14	therapy	O	['N']	[14]
15	with	O	['N']	[15]
16	intravenous	O	['N']	[16]
17	recombinant	O	['N']	[17]
18	tissue	O	['N']	[18]
19	-	O	['N']	[19]
20	type	O	['N']	[20]
21	plasminogen	O	['N']	[21]
22	activator	O	['N']	[22]
23	(	O	['N']	[23]
24	t	B	['N']	[24]
25	-	I	['N']	[25]
26	PA	I-Drug	['Causes']	[6]
27	)	O	['N']	[27]
28	.	O	['N']	[28]
#1443
0	Physicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	risk	O	['N']	[6]
7	of	O	['N']	[7]
8	severe	O	['N']	[8]
9	AIHA	O	['N']	[9]
10	in	O	['N']	[10]
11	CLL	O	['N']	[11]
12	patients	O	['N']	[12]
13	with	O	['N']	[13]
14	a	O	['N']	[14]
15	history	O	['N']	[15]
16	of	O	['N']	[16]
17	AIHA	O	['N']	[17]
18	or	O	['N']	[18]
19	positivation	B	['N']	[19]
20	of	I	['N']	[20]
21	the	I	['N']	[21]
22	DAT	I-Adverse_Effect	['N']	[22]
23	during	O	['N']	[23]
24	previous	O	['N']	[24]
25	fludarabine	B-Drug	['Causes']	[22]
26	administration	O	['N']	[26]
27	,	O	['N']	[27]
28	or	O	['N']	[28]
29	in	O	['N']	[29]
30	case	O	['N']	[30]
31	of	O	['N']	[31]
32	secondary	O	['N']	[32]
33	fixation	O	['N']	[33]
34	of	O	['N']	[34]
35	complement	O	['N']	[35]
36	to	O	['N']	[36]
37	the	O	['N']	[37]
38	red	O	['N']	[38]
39	cell	O	['N']	[39]
40	membrane	O	['N']	[40]
41	occurring	O	['N']	[41]
42	during	O	['N']	[42]
43	fludarabine	O	['N']	[43]
44	treatment	O	['N']	[44]
45	.	O	['N']	[45]
#1444
0	Though	O	['N']	[0]
1	proteinuria	O	['N']	[1]
2	and	O	['N']	[2]
3	nephrotic	B	['N']	[3]
4	syndrome	I-Adverse_Effect	['N']	[4]
5	is	O	['N']	[5]
6	a	O	['N']	[6]
7	rare	O	['N']	[7]
8	adverse	O	['N']	[8]
9	effect	O	['N']	[9]
10	of	O	['N']	[10]
11	IFN	B	['N']	[11]
12	-	I	['N']	[12]
13	beta-1b	I-Drug	['Causes']	[4]
14	therapy	O	['N']	[14]
15	,	O	['N']	[15]
16	physicians	O	['N']	[16]
17	treating	O	['N']	[17]
18	MS	O	['N']	[18]
19	patients	O	['N']	[19]
20	with	O	['N']	[20]
21	this	O	['N']	[21]
22	agent	O	['N']	[22]
23	should	O	['N']	[23]
24	pay	O	['N']	[24]
25	careful	O	['N']	[25]
26	attention	O	['N']	[26]
27	to	O	['N']	[27]
28	new	O	['N']	[28]
29	clinical	O	['N']	[29]
30	symptoms	O	['N']	[30]
31	and	O	['N']	[31]
32	laboratory	O	['N']	[32]
33	findings	O	['N']	[33]
34	.	O	['N']	[34]
#1445
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	Repeated	O	['N']	[2]
3	blood	O	['N']	[3]
4	samples	O	['N']	[4]
5	were	O	['N']	[5]
6	drawn	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	severe	O	['N']	[11]
12	acyclovir	B-Drug	['Dosage']	[13]
13	overdose	B-Dose	['N']	[13]
14	who	O	['N']	[14]
15	developed	O	['N']	[15]
16	coma	O	['N']	[16]
17	and	O	['N']	[17]
18	nonoliguric	O	['N']	[18]
19	renal	O	['N']	[19]
20	failure	O	['N']	[20]
21	.	O	['N']	[21]
#1446
0	Eleven	O	['N']	[0]
1	patients	O	['N']	[1]
2	developed	O	['N']	[2]
3	infection	O	['N']	[3]
4	requiring	O	['N']	[4]
5	hospitalization	O	['N']	[5]
6	while	O	['N']	[6]
7	taking	O	['N']	[7]
8	leflunomide	B-Drug	['Causes']	[19]
9	including	O	['N']	[9]
10	:	O	['N']	[10]
11	lower	O	['N']	[11]
12	respiratory	O	['N']	[12]
13	tract	O	['N']	[13]
14	infections	O	['N']	[14]
15	(	O	['N']	[15]
16	3	O	['N']	[16]
17	)	O	['N']	[17]
18	,	O	['N']	[18]
19	cellulitis	B-Adverse_Effect	['N']	[19]
20	(	O	['N']	[20]
21	2	O	['N']	[21]
22	)	O	['N']	[22]
23	,	O	['N']	[23]
24	disseminated	O	['N']	[24]
25	herpes	O	['N']	[25]
26	zoster	O	['N']	[26]
27	(	O	['N']	[27]
28	2	O	['N']	[28]
29	)	O	['N']	[29]
30	,	O	['N']	[30]
31	probable	O	['N']	[31]
32	TB	O	['N']	[32]
33	liver	O	['N']	[33]
34	(	O	['N']	[34]
35	1	O	['N']	[35]
36	)	O	['N']	[36]
37	,	O	['N']	[37]
38	abdominal	O	['N']	[38]
39	sepsis	O	['N']	[39]
40	(	O	['N']	[40]
41	1	O	['N']	[41]
42	)	O	['N']	[42]
43	,	O	['N']	[43]
44	mycotic	O	['N']	[44]
45	aneurysm	O	['N']	[45]
46	(	O	['N']	[46]
47	1	O	['N']	[47]
48	)	O	['N']	[48]
49	and	O	['N']	[49]
50	gastroenteritis	O	['N']	[50]
51	(	O	['N']	[51]
52	1	O	['N']	[52]
53	)	O	['N']	[53]
54	.	O	['N']	[54]
#1447
0	Acute	B	['N']	[0]
1	myelogenous	I	['N']	[1]
2	leukemia	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	patients	O	['N']	[4]
5	receiving	O	['N']	[5]
6	chlorambucil	B-Drug	['Causes']	[2]
7	as	O	['N']	[7]
8	long	O	['N']	[8]
9	-	O	['N']	[9]
10	term	O	['N']	[10]
11	adjuvant	O	['N']	[11]
12	chemotherapy	O	['N']	[12]
13	for	O	['N']	[13]
14	stage	O	['N']	[14]
15	II	O	['N']	[15]
16	breast	O	['N']	[16]
17	cancer	O	['N']	[17]
18	.	O	['N']	[18]
#1448
0	Dipyrone	O	['N']	[0]
1	,	O	['N']	[1]
2	also	O	['N']	[2]
3	known	O	['N']	[3]
4	as	O	['N']	[4]
5	metamizole	B-Drug	['Causes']	[29]
6	,	O	['N']	[6]
7	is	O	['N']	[7]
8	an	O	['N']	[8]
9	analgesic	O	['N']	[9]
10	and	O	['N']	[10]
11	antipyretic	O	['N']	[11]
12	drug	O	['N']	[12]
13	that	O	['N']	[13]
14	was	O	['N']	[14]
15	banned	O	['N']	[15]
16	by	O	['N']	[16]
17	the	O	['N']	[17]
18	United	O	['N']	[18]
19	States	O	['N']	[19]
20	Food	O	['N']	[20]
21	and	O	['N']	[21]
22	Drug	O	['N']	[22]
23	Administration	O	['N']	[23]
24	because	O	['N']	[24]
25	of	O	['N']	[25]
26	its	O	['N']	[26]
27	association	O	['N']	[27]
28	with	O	['N']	[28]
29	agranulocytosis	B-Adverse_Effect	['N']	[29]
30	.	O	['N']	[30]
#1449
0	We	O	['N']	[0]
1	now	O	['N']	[1]
2	report	O	['N']	[2]
3	the	O	['N']	[3]
4	first	O	['N']	[4]
5	known	O	['N']	[5]
6	cancer	O	['N']	[6]
7	patient	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	life	B	['N']	[10]
11	-	I	['N']	[11]
12	threatening	I	['N']	[12]
13	complications	I-Adverse_Effect	['N']	[13]
14	after	O	['N']	[14]
15	treatment	O	['N']	[15]
16	with	O	['N']	[16]
17	topical	O	['N']	[17]
18	5-FU	B-Drug	['Causes']	[13]
19	and	O	['N']	[19]
20	was	O	['N']	[20]
21	shown	O	['N']	[21]
22	subsequently	O	['N']	[22]
23	to	O	['N']	[23]
24	have	O	['N']	[24]
25	profound	O	['N']	[25]
26	DPD	O	['N']	[26]
27	deficiency	O	['N']	[27]
28	.	O	['N']	[28]
#1450
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	82-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	ventricular	B	['N']	[9]
10	tachycardia	I-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	Torsades	O	['N']	[12]
13	de	O	['N']	[13]
14	Pointes	O	['N']	[14]
15	(	O	['N']	[15]
16	TdP	O	['N']	[16]
17	)	O	['N']	[17]
18	after	O	['N']	[18]
19	oral	O	['N']	[19]
20	administration	O	['N']	[20]
21	of	O	['N']	[21]
22	garenoxacin	B-Drug	['Causes']	[10]
23	,	O	['N']	[23]
24	a	O	['N']	[24]
25	novel	O	['N']	[25]
26	quinolone	O	['N']	[26]
27	antibiotic	O	['N']	[27]
28	agent	O	['N']	[28]
29	that	O	['N']	[29]
30	differs	O	['N']	[30]
31	from	O	['N']	[31]
32	the	O	['N']	[32]
33	third	O	['N']	[33]
34	-	O	['N']	[34]
35	generation	O	['N']	[35]
36	quinolones	O	['N']	[36]
37	,	O	['N']	[37]
38	for	O	['N']	[38]
39	pneumonia	O	['N']	[39]
40	.	O	['N']	[40]
#1451
0	Cholestatic	O	['N']	[0]
1	liver	O	['N']	[1]
2	disease	O	['N']	[2]
3	with	O	['N']	[3]
4	ductopenia	O	['N']	[4]
5	(	O	['N']	[5]
6	vanishing	B	['N']	[6]
7	bile	I	['N']	[7]
8	duct	I	['N']	[8]
9	syndrome	I-Adverse_Effect	['N']	[9]
10	)	O	['N']	[10]
11	after	O	['N']	[11]
12	administration	O	['N']	[12]
13	of	O	['N']	[13]
14	clindamycin	B-Drug	['Causes']	[9]
15	and	O	['N']	[15]
16	trimethoprim	O	['N']	[16]
17	-	O	['N']	[17]
18	sulfamethoxazole	O	['N']	[18]
19	.	O	['N']	[19]
#1452
0	Inhaled	O	['N']	[0]
1	tobramycin	B-Drug	['Causes']	[10]
2	solution	O	['N']	[2]
3	-	O	['N']	[3]
4	associated	O	['N']	[4]
5	recurrent	O	['N']	[5]
6	eosinophilia	O	['N']	[6]
7	and	O	['N']	[7]
8	severe	B	['N']	[8]
9	persistent	I	['N']	[9]
10	bronchospasm	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	cystic	O	['N']	[15]
16	fibrosis	O	['N']	[16]
17	:	O	['N']	[17]
18	a	O	['N']	[18]
19	case	O	['N']	[19]
20	report	O	['N']	[20]
21	.	O	['N']	[21]
#1453
0	HUS	B-Adverse_Effect	['N']	[0]
1	has	O	['N']	[1]
2	been	O	['N']	[2]
3	reported	O	['N']	[3]
4	after	O	['N']	[4]
5	several	O	['N']	[5]
6	anticancer	O	['N']	[6]
7	chemotherapies	O	['N']	[7]
8	and	O	['N']	[8]
9	most	O	['N']	[9]
10	often	O	['N']	[10]
11	after	O	['N']	[11]
12	mitomycin	B	['N']	[12]
13	C	I-Drug	['Causes']	[0]
14	-	O	['N']	[14]
15	based	O	['N']	[15]
16	chemotherapy	O	['N']	[16]
17	regimens	O	['N']	[17]
18	.	O	['N']	[18]
#1454
0	Obsessive	B	['N']	[0]
1	-	I	['N']	[1]
2	compulsive	I	['N']	[2]
3	symptoms	I-Adverse_Effect	['N']	[3]
4	suddenly	O	['N']	[4]
5	emerged	O	['N']	[5]
6	10	O	['N']	[6]
7	days	O	['N']	[7]
8	after	O	['N']	[8]
9	starting	O	['N']	[9]
10	risperidone	B-Drug	['Causes']	[3]
11	and	O	['N']	[11]
12	resolved	O	['N']	[12]
13	within	O	['N']	[13]
14	3	O	['N']	[14]
15	days	O	['N']	[15]
16	of	O	['N']	[16]
17	discontinuation	O	['N']	[17]
18	.	O	['N']	[18]
#1455
0	Pseudoephedrine	B-Drug	['Causes']	[9]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hemorrhage	O	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	a	O	['N']	[6]
7	cerebral	B	['N']	[7]
8	vascular	I	['N']	[8]
9	malformation	I-Adverse_Effect	['N']	[9]
10	.	O	['N']	[10]
#1456
0	The	O	['N']	[0]
1	purpose	O	['N']	[1]
2	of	O	['N']	[2]
3	this	O	['N']	[3]
4	review	O	['N']	[4]
5	is	O	['N']	[5]
6	to	O	['N']	[6]
7	increase	O	['N']	[7]
8	awareness	O	['N']	[8]
9	among	O	['N']	[9]
10	physicians	O	['N']	[10]
11	and	O	['N']	[11]
12	other	O	['N']	[12]
13	health	O	['N']	[13]
14	care	O	['N']	[14]
15	professionals	O	['N']	[15]
16	that	O	['N']	[16]
17	DIC	B-Adverse_Effect	['N']	[17]
18	may	O	['N']	[18]
19	be	O	['N']	[19]
20	a	O	['N']	[20]
21	rare	O	['N']	[21]
22	but	O	['N']	[22]
23	potentially	O	['N']	[23]
24	severe	O	['N']	[24]
25	complication	O	['N']	[25]
26	of	O	['N']	[26]
27	anti	B	['N']	[27]
28	-	I	['N']	[28]
29	D	I	['N']	[29]
30	IGIV	I-Drug	['Causes']	[17]
31	treatment	O	['N']	[31]
32	.	O	['N']	[32]
#1457
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	diagnosed	O	['N']	[2]
3	with	O	['N']	[3]
4	Epstein	O	['N']	[4]
5	-	O	['N']	[5]
6	Barr	O	['N']	[6]
7	virus	O	['N']	[7]
8	-	O	['N']	[8]
9	associated	O	['N']	[9]
10	polymorphic	O	['N']	[10]
11	lymphoproliferative	O	['N']	[11]
12	disorder	O	['N']	[12]
13	(	O	['N']	[13]
14	LPD	O	['N']	[14]
15	)	O	['N']	[15]
16	due	O	['N']	[16]
17	to	O	['N']	[17]
18	immunodeficiency	B-Adverse_Effect	['N']	[18]
19	caused	O	['N']	[19]
20	by	O	['N']	[20]
21	MTX	B-Drug	['Causes']	[18]
22	administration	O	['N']	[22]
23	.	O	['N']	[23]
#1458
0	Central	O	['N']	[0]
1	nervous	O	['N']	[1]
2	system	O	['N']	[2]
3	manifestations	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	ibuprofen	B-Drug	['Dosage']	[7]
7	overdose	B-Dose	['N']	[7]
8	reversed	O	['N']	[8]
9	by	O	['N']	[9]
10	naloxone	O	['N']	[10]
11	.	O	['N']	[11]
#1459
0	Although	O	['N']	[0]
1	moderate	O	['N']	[1]
2	myelosuppression	O	['N']	[2]
3	is	O	['N']	[3]
4	not	O	['N']	[4]
5	uncommonly	O	['N']	[5]
6	seen	O	['N']	[6]
7	in	O	['N']	[7]
8	patients	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	lenalidomide	B-Drug	['Causes']	[14]
12	,	O	['N']	[12]
13	aplastic	B	['N']	[13]
14	anemia	I-Adverse_Effect	['N']	[14]
15	has	O	['N']	[15]
16	not	O	['N']	[16]
17	previously	O	['N']	[17]
18	been	O	['N']	[18]
19	reported	O	['N']	[19]
20	to	O	['N']	[20]
21	be	O	['N']	[21]
22	associated	O	['N']	[22]
23	with	O	['N']	[23]
24	this	O	['N']	[24]
25	agent	O	['N']	[25]
26	.	O	['N']	[26]
#1460
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	five	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	carboplatin	O	['N']	[5]
6	(	O	['N']	[6]
7	CBDCA	O	['N']	[7]
8	)	O	['N']	[8]
9	hypersensitivity	O	['N']	[9]
10	after	O	['N']	[10]
11	weekly	O	['N']	[11]
12	low	O	['N']	[12]
13	-	O	['N']	[13]
14	dose	O	['N']	[14]
15	paclitaxel	B-Drug	['N']	[15]
16	(	O	['N']	[16]
17	60	-	['N']	[17]
18	mg	-	['N']	[18]
19	/	-	['N']	[19]
20	m2)/CBDCA	-	['N']	[20]
21	(	O	['N']	[21]
22	area	O	['N']	[22]
23	under	O	['N']	[23]
24	the	O	['N']	[24]
25	concentration	O	['N']	[25]
26	curve	O	['N']	[26]
27	=	O	['N']	[27]
28	2	O	['N']	[28]
29	)	O	['N']	[29]
30	therapy	O	['N']	[30]
31	in	O	['N']	[31]
32	patients	O	['N']	[32]
33	with	O	['N']	[33]
34	recurrent	O	['N']	[34]
35	ovarian	O	['N']	[35]
36	cancer	O	['N']	[36]
37	receiving	O	['N']	[37]
38	multiple	O	['N']	[38]
39	platinum	O	['N']	[39]
40	-	O	['N']	[40]
41	based	O	['N']	[41]
42	chemotherapy	O	['N']	[42]
43	.	O	['N']	[43]
#1461
0	A	O	['N']	[0]
1	52	O	['N']	[1]
2	year	O	['N']	[2]
3	-	O	['N']	[3]
4	old	O	['N']	[4]
5	male	O	['N']	[5]
6	patient	O	['N']	[6]
7	diagnosed	O	['N']	[7]
8	of	O	['N']	[8]
9	ankylosing	O	['N']	[9]
10	spondylitis	O	['N']	[10]
11	presented	O	['N']	[11]
12	with	O	['N']	[12]
13	an	O	['N']	[13]
14	iron	B	['N']	[14]
15	deficiency	I	['N']	[15]
16	anemia	I-Adverse_Effect	['N']	[16]
17	after	O	['N']	[17]
18	a	O	['N']	[18]
19	ten	O	['N']	[19]
20	-	O	['N']	[20]
21	month	O	['N']	[21]
22	treatment	O	['N']	[22]
23	of	O	['N']	[23]
24	methotrexate	B-Drug	['Causes']	[16]
25	.	O	['N']	[25]
#1462
0	We	O	['N']	[0]
1	experienced	O	['N']	[1]
2	a	O	['N']	[2]
3	male	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	psoriasis	O	['N']	[6]
7	and	O	['N']	[7]
8	hypertension	O	['N']	[8]
9	whose	O	['N']	[9]
10	conditions	O	['N']	[10]
11	were	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	tacalcitol	B-Drug	['Causes']	[25]
15	ointment	O	['N']	[15]
16	and	O	['N']	[16]
17	thiazide	O	['N']	[17]
18	,	O	['N']	[18]
19	respectively	O	['N']	[19]
20	,	O	['N']	[20]
21	resulting	O	['N']	[21]
22	in	O	['N']	[22]
23	hypercalciuria	O	['N']	[23]
24	and	O	['N']	[24]
25	hypercalcemia	B-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#1463
0	Nephrogenic	O	['N']	[0]
1	diabetes	O	['N']	[1]
2	insipidus	O	['N']	[2]
3	(	O	['N']	[3]
4	NDI	B-Adverse_Effect	['N']	[4]
5	)	O	['N']	[5]
6	is	O	['N']	[6]
7	a	O	['N']	[7]
8	well	O	['N']	[8]
9	-	O	['N']	[9]
10	documented	O	['N']	[10]
11	complication	O	['N']	[11]
12	of	O	['N']	[12]
13	lithium	B-Drug	['Causes']	[4]
14	use	O	['N']	[14]
15	.	O	['N']	[15]
#1464
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	1	O	['N']	[2]
3	,	O	['N']	[3]
4	a	O	['N']	[4]
5	total	O	['N']	[5]
6	daily	O	['N']	[6]
7	dose	O	['N']	[7]
8	of	O	['N']	[8]
9	25	B	['N']	[9]
10	mg	I-Dose	['N']	[10]
11	sertraline	B-Drug	['Dosage']	[10]
12	,	O	['N']	[12]
13	with	O	['N']	[13]
14	nondetectable	O	['N']	[14]
15	sertraline	O	['N']	[15]
16	and	O	['N']	[16]
17	desmethylsertraline	O	['N']	[17]
18	blood	O	['N']	[18]
19	levels	O	['N']	[19]
20	,	O	['N']	[20]
21	resulted	O	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	doubling	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	lamotrigine	O	['N']	[27]
28	blood	O	['N']	[28]
29	level	O	['N']	[29]
30	with	O	['N']	[30]
31	symptoms	O	['N']	[31]
32	of	O	['N']	[32]
33	toxicity	O	['N']	[33]
34	.	O	['N']	[34]
#1465
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	46-yr	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	with	O	['N']	[7]
8	ovarian	O	['N']	[8]
9	carcinoma	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	porphyria	B	['N']	[12]
13	cutanea	I	['N']	[13]
14	tarda	I-Adverse_Effect	['N']	[14]
15	while	O	['N']	[15]
16	undergoing	O	['N']	[16]
17	treatment	O	['N']	[17]
18	with	O	['N']	[18]
19	cisplatin	O	['N']	[19]
20	and	O	['N']	[20]
21	cyclophosphamide	B-Drug	['Causes']	[14]
22	.	O	['N']	[22]
#1466
0	Myasthenia	B	['N']	[0]
1	gravis	I-Adverse_Effect	['N']	[1]
2	during	O	['N']	[2]
3	low	O	['N']	[3]
4	-	O	['N']	[4]
5	dose	O	['N']	[5]
6	IFN	B	['N']	[6]
7	-	I	['N']	[7]
8	alpha	I-Drug	['Causes']	[1]
9	therapy	O	['N']	[9]
10	for	O	['N']	[10]
11	chronic	O	['N']	[11]
12	hepatitis	O	['N']	[12]
13	C.	O	['N']	[13]
#1467
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	female	O	['N']	[6]
7	acromegalic	O	['N']	[7]
8	patient	O	['N']	[8]
9	in	O	['N']	[9]
10	whom	O	['N']	[10]
11	multiple	O	['N']	[11]
12	hepatic	B	['N']	[12]
13	adenomas	I-Adverse_Effect	['N']	[13]
14	appeared	O	['N']	[14]
15	soon	O	['N']	[15]
16	after	O	['N']	[16]
17	danazol	B-Drug	['Causes']	[13]
18	treatment	O	['N']	[18]
19	for	O	['N']	[19]
20	uterine	O	['N']	[20]
21	fibromatosis	O	['N']	[21]
22	.	O	['N']	[22]
#1468
0	We	O	['N']	[0]
1	thus	O	['N']	[1]
2	concluded	O	['N']	[2]
3	that	O	['N']	[3]
4	an	O	['N']	[4]
5	excessive	O	['N']	[5]
6	dose	O	['N']	[6]
7	of	O	['N']	[7]
8	AZ	B-Drug	['Causes']	[22]
9	had	O	['N']	[9]
10	probably	O	['N']	[10]
11	destroyed	O	['N']	[11]
12	the	O	['N']	[12]
13	gastric	O	['N']	[13]
14	mucosal	O	['N']	[14]
15	barrier	O	['N']	[15]
16	or	O	['N']	[16]
17	thrombocytopenia	B	['N']	[17]
18	due	I	['N']	[18]
19	to	I	['N']	[19]
20	bone	I	['N']	[20]
21	marrow	I	['N']	[21]
22	disorder	I-Adverse_Effect	['N']	[22]
23	and	O	['N']	[23]
24	thus	O	['N']	[24]
25	eventually	O	['N']	[25]
26	led	O	['N']	[26]
27	to	O	['N']	[27]
28	the	O	['N']	[28]
29	development	O	['N']	[29]
30	of	O	['N']	[30]
31	hemorrhagic	O	['N']	[31]
32	gastritis	O	['N']	[32]
33	.	O	['N']	[33]
#1469
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	In	O	['N']	[2]
3	a	O	['N']	[3]
4	22-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	Thai	O	['N']	[7]
8	woman	O	['N']	[8]
9	with	O	['N']	[9]
10	Graves	O	['N']	[10]
11	'	O	['N']	[11]
12	disease	O	['N']	[12]
13	,	O	['N']	[13]
14	tinnitus	B-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	hearing	O	['N']	[16]
17	impairment	O	['N']	[17]
18	in	O	['N']	[18]
19	the	O	['N']	[19]
20	left	O	['N']	[20]
21	ear	O	['N']	[21]
22	(	O	['N']	[22]
23	with	O	['N']	[23]
24	progression	O	['N']	[24]
25	to	O	['N']	[25]
26	the	O	['N']	[26]
27	right	O	['N']	[27]
28	ear	O	['N']	[28]
29	)	O	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	vertigo	O	['N']	[32]
33	developed	O	['N']	[33]
34	after	O	['N']	[34]
35	3	O	['N']	[35]
36	years	O	['N']	[36]
37	of	O	['N']	[37]
38	therapy	O	['N']	[38]
39	with	O	['N']	[39]
40	PTU	B-Drug	['Causes']	[14]
41	.	O	['N']	[41]
#1470
0	Paroxysmal	B	['N']	[0]
1	supraventricular	I	['N']	[1]
2	tachycardia	I-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	treatment	O	['N']	[4]
5	with	O	['N']	[5]
6	cisplatin	B-Drug	['Causes']	[2]
7	and	O	['N']	[7]
8	etoposide	O	['N']	[8]
9	combination	O	['N']	[9]
10	.	O	['N']	[10]
#1471
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	exfoliative	B	['N']	[5]
6	dermatitis	I-Adverse_Effect	['N']	[6]
7	clearly	O	['N']	[7]
8	linked	O	['N']	[8]
9	to	O	['N']	[9]
10	intravenous	O	['N']	[10]
11	and	O	['N']	[11]
12	intraperitoneal	O	['N']	[12]
13	administration	O	['N']	[13]
14	of	O	['N']	[14]
15	tobramycin	B-Drug	['Causes']	[6]
16	.	O	['N']	[16]
#1472
0	AIM	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	diabetic	O	['N']	[7]
8	rubeosis	O	['N']	[8]
9	who	O	['N']	[9]
10	suffered	O	['N']	[10]
11	from	O	['N']	[11]
12	acute	B	['N']	[12]
13	retinal	I	['N']	[13]
14	ischemic	I	['N']	[14]
15	change	I-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	stroke	O	['N']	[17]
18	after	O	['N']	[18]
19	intravitreal	O	['N']	[19]
20	injection	O	['N']	[20]
21	of	O	['N']	[21]
22	bevacizumab	B-Drug	['Causes']	[15]
23	.	O	['N']	[23]
#1473
0	Severe	B	['N']	[0]
1	cardiomyopathy	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	treatment	O	['N']	[3]
4	with	O	['N']	[4]
5	the	O	['N']	[5]
6	tumour	O	['N']	[6]
7	necrosis	O	['N']	[7]
8	factor	O	['N']	[8]
9	-	O	['N']	[9]
10	alpha	O	['N']	[10]
11	inhibitor	O	['N']	[11]
12	adalimumab	B-Drug	['Causes']	[1]
13	for	O	['N']	[13]
14	Crohn	O	['N']	[14]
15	's	O	['N']	[15]
16	disease	O	['N']	[16]
17	.	O	['N']	[17]
#1474
0	Eleven	O	['N']	[0]
1	patients	O	['N']	[1]
2	developed	O	['N']	[2]
3	infection	O	['N']	[3]
4	requiring	O	['N']	[4]
5	hospitalization	O	['N']	[5]
6	while	O	['N']	[6]
7	taking	O	['N']	[7]
8	leflunomide	B-Drug	['Causes']	[39]
9	including	O	['N']	[9]
10	:	O	['N']	[10]
11	lower	O	['N']	[11]
12	respiratory	O	['N']	[12]
13	tract	O	['N']	[13]
14	infections	O	['N']	[14]
15	(	O	['N']	[15]
16	3	O	['N']	[16]
17	)	O	['N']	[17]
18	,	O	['N']	[18]
19	cellulitis	O	['N']	[19]
20	(	O	['N']	[20]
21	2	O	['N']	[21]
22	)	O	['N']	[22]
23	,	O	['N']	[23]
24	disseminated	O	['N']	[24]
25	herpes	O	['N']	[25]
26	zoster	O	['N']	[26]
27	(	O	['N']	[27]
28	2	O	['N']	[28]
29	)	O	['N']	[29]
30	,	O	['N']	[30]
31	probable	O	['N']	[31]
32	TB	O	['N']	[32]
33	liver	O	['N']	[33]
34	(	O	['N']	[34]
35	1	O	['N']	[35]
36	)	O	['N']	[36]
37	,	O	['N']	[37]
38	abdominal	B	['N']	[38]
39	sepsis	I-Adverse_Effect	['N']	[39]
40	(	O	['N']	[40]
41	1	O	['N']	[41]
42	)	O	['N']	[42]
43	,	O	['N']	[43]
44	mycotic	O	['N']	[44]
45	aneurysm	O	['N']	[45]
46	(	O	['N']	[46]
47	1	O	['N']	[47]
48	)	O	['N']	[48]
49	and	O	['N']	[49]
50	gastroenteritis	O	['N']	[50]
51	(	O	['N']	[51]
52	1	O	['N']	[52]
53	)	O	['N']	[53]
54	.	O	['N']	[54]
#1475
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	this	O	['N']	[4]
5	is	O	['N']	[5]
6	the	O	['N']	[6]
7	first	O	['N']	[7]
8	case	O	['N']	[8]
9	reported	O	['N']	[9]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	English	O	['N']	[12]
13	literature	O	['N']	[13]
14	of	O	['N']	[14]
15	a	O	['N']	[15]
16	generalized	B	['N']	[16]
17	exanthem	I-Adverse_Effect	['N']	[17]
18	due	O	['N']	[18]
19	to	O	['N']	[19]
20	subcutaneous	O	['N']	[20]
21	injection	O	['N']	[21]
22	of	O	['N']	[22]
23	enoxaparin	B-Drug	['Causes']	[17]
24	.	O	['N']	[24]
#1476
0	The	O	['N']	[0]
1	reported	O	['N']	[1]
2	cases	O	['N']	[2]
3	of	O	['N']	[3]
4	in	O	['N']	[4]
5	utero	O	['N']	[5]
6	exposure	O	['N']	[6]
7	to	O	['N']	[7]
8	cyclosposphamide	B-Drug	['Causes']	[21]
9	shared	O	['N']	[9]
10	the	O	['N']	[10]
11	following	O	['N']	[11]
12	manifestations	O	['N']	[12]
13	with	O	['N']	[13]
14	our	O	['N']	[14]
15	patient	O	['N']	[15]
16	:	O	['N']	[16]
17	growth	O	['N']	[17]
18	deficiency	O	['N']	[18]
19	,	O	['N']	[19]
20	developmental	B	['N']	[20]
21	delay	I-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	craniosynostosis	O	['N']	[23]
24	,	O	['N']	[24]
25	blepharophimosis	O	['N']	[25]
26	,	O	['N']	[26]
27	flat	O	['N']	[27]
28	nasal	O	['N']	[28]
29	bridge	O	['N']	[29]
30	,	O	['N']	[30]
31	abnormal	O	['N']	[31]
32	ears	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	distal	O	['N']	[35]
36	limb	O	['N']	[36]
37	defects	O	['N']	[37]
38	including	O	['N']	[38]
39	hypoplastic	O	['N']	[39]
40	thumbs	O	['N']	[40]
41	and	O	['N']	[41]
42	oligodactyly	O	['N']	[42]
43	.	O	['N']	[43]
#1477
0	A	O	['N']	[0]
1	44-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	is	O	['N']	[5]
6	described	O	['N']	[6]
7	in	O	['N']	[7]
8	whom	O	['N']	[8]
9	amiodarone	O	['N']	[9]
10	,	O	['N']	[10]
11	disopyramide	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	quinidine	B-Drug	['Causes']	[29]
15	,	O	['N']	[15]
16	administered	O	['N']	[16]
17	alone	O	['N']	[17]
18	separately	O	['N']	[18]
19	,	O	['N']	[19]
20	induced	O	['N']	[20]
21	atypical	O	['N']	[21]
22	ventricular	O	['N']	[22]
23	tachycardia	O	['N']	[23]
24	(	O	['N']	[24]
25	AVT	O	['N']	[25]
26	,	O	['N']	[26]
27	torsade	B	['N']	[27]
28	de	I	['N']	[28]
29	pointes	I-Adverse_Effect	['N']	[29]
30	)	O	['N']	[30]
31	.	O	['N']	[31]
#1478
0	Colchicine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	myopathy	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	teenager	O	['N']	[6]
7	with	O	['N']	[7]
8	familial	O	['N']	[8]
9	Mediterranean	O	['N']	[9]
10	fever	O	['N']	[10]
11	.	O	['N']	[11]
#1479
0	Early	O	['N']	[0]
1	peritoneal	O	['N']	[1]
2	dialysis	O	['N']	[2]
3	has	O	['N']	[3]
4	not	O	['N']	[4]
5	previously	O	['N']	[5]
6	been	O	['N']	[6]
7	reported	O	['N']	[7]
8	for	O	['N']	[8]
9	lisinopril	B-Drug	['Causes']	[12]
10	induced	O	['N']	[10]
11	multiorgan	B	['N']	[11]
12	failure	I-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#1480
0	Because	O	['N']	[0]
1	nephrotic	B	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	may	O	['N']	[3]
4	be	O	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	IFN	B-Drug	['Causes']	[2]
8	therapy	O	['N']	[8]
9	,	O	['N']	[9]
10	the	O	['N']	[10]
11	IFN	O	['N']	[11]
12	was	O	['N']	[12]
13	stopped	O	['N']	[13]
14	.	O	['N']	[14]
#1481
0	There	O	['N']	[0]
1	are	O	['N']	[1]
2	no	O	['N']	[2]
3	previous	O	['N']	[3]
4	reports	O	['N']	[4]
5	in	O	['N']	[5]
6	the	O	['N']	[6]
7	literature	O	['N']	[7]
8	about	O	['N']	[8]
9	the	O	['N']	[9]
10	emergence	O	['N']	[10]
11	of	O	['N']	[11]
12	CML	B-Adverse_Effect	['N']	[12]
13	during	O	['N']	[13]
14	treatment	O	['N']	[14]
15	with	O	['N']	[15]
16	hydroxyurea	B-Drug	['Causes']	[12]
17	.	O	['N']	[17]
#1482
0	When	O	['N']	[0]
1	the	O	['N']	[1]
2	acute	O	['N']	[2]
3	manic	O	['N']	[3]
4	state	O	['N']	[4]
5	is	O	['N']	[5]
6	characterized	O	['N']	[6]
7	by	O	['N']	[7]
8	marked	O	['N']	[8]
9	psychotic	O	['N']	[9]
10	symptoms	O	['N']	[10]
11	and	O	['N']	[11]
12	intense	O	['N']	[12]
13	anxiety	O	['N']	[13]
14	,	O	['N']	[14]
15	it	O	['N']	[15]
16	may	O	['N']	[16]
17	be	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	increased	O	['N']	[20]
21	vulnerability	O	['N']	[21]
22	to	O	['N']	[22]
23	the	O	['N']	[23]
24	development	O	['N']	[24]
25	of	O	['N']	[25]
26	severe	O	['N']	[26]
27	lithium	B-Drug	['Causes']	[28]
28	neurotoxicity	B-Adverse_Effect	['N']	[28]
29	.	O	['N']	[29]
#1483
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	25-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	postpartum	O	['N']	[7]
8	white	O	['N']	[8]
9	woman	O	['N']	[9]
10	developed	O	['N']	[10]
11	multiple	O	['N']	[11]
12	watery	O	['N']	[12]
13	stools	O	['N']	[13]
14	and	O	['N']	[14]
15	abdominal	B	['N']	[15]
16	cramping	I-Adverse_Effect	['N']	[16]
17	on	O	['N']	[17]
18	day	O	['N']	[18]
19	6	O	['N']	[19]
20	of	O	['N']	[20]
21	therapy	O	['N']	[21]
22	with	O	['N']	[22]
23	clindamycin	B-Drug	['Causes']	[16]
24	vaginal	O	['N']	[24]
25	cream	O	['N']	[25]
26	for	O	['N']	[26]
27	bacterial	O	['N']	[27]
28	vaginosis	O	['N']	[28]
29	.	O	['N']	[29]
#1484
0	In	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	swallowing	O	['N']	[3]
4	dysfunction	O	['N']	[4]
5	and	O	['N']	[5]
6	pneumonia	B-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	a	O	['N']	[8]
9	history	O	['N']	[9]
10	of	O	['N']	[10]
11	mineral	B	['N']	[11]
12	oil	I-Drug	['Causes']	[6]
13	use	O	['N']	[13]
14	should	O	['N']	[14]
15	be	O	['N']	[15]
16	obtained	O	['N']	[16]
17	and	O	['N']	[17]
18	a	O	['N']	[18]
19	diagnosis	O	['N']	[19]
20	of	O	['N']	[20]
21	ELP	O	['N']	[21]
22	should	O	['N']	[22]
23	be	O	['N']	[23]
24	considered	O	['N']	[24]
25	in	O	['N']	[25]
26	the	O	['N']	[26]
27	differential	O	['N']	[27]
28	diagnoses	O	['N']	[28]
29	if	O	['N']	[29]
30	mineral	O	['N']	[30]
31	oil	O	['N']	[31]
32	use	O	['N']	[32]
33	has	O	['N']	[33]
34	occurred	O	['N']	[34]
35	.	O	['N']	[35]
#1485
0	OBJECTIVES	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	the	O	['N']	[4]
5	clinicopathologic	O	['N']	[5]
6	features	O	['N']	[6]
7	of	O	['N']	[7]
8	3	O	['N']	[8]
9	patients	O	['N']	[9]
10	with	O	['N']	[10]
11	CML	O	['N']	[11]
12	who	O	['N']	[12]
13	rapidly	O	['N']	[13]
14	progressed	O	['N']	[14]
15	from	O	['N']	[15]
16	chronic	O	['N']	[16]
17	phase	O	['N']	[17]
18	to	O	['N']	[18]
19	blast	B	['N']	[19]
20	crisis	I-Adverse_Effect	['N']	[20]
21	while	O	['N']	[21]
22	taking	O	['N']	[22]
23	imatinib	B-Drug	['Causes']	[20]
24	and	O	['N']	[24]
25	to	O	['N']	[25]
26	perform	O	['N']	[26]
27	a	O	['N']	[27]
28	review	O	['N']	[28]
29	of	O	['N']	[29]
30	the	O	['N']	[30]
31	literature	O	['N']	[31]
32	.	O	['N']	[32]
#1486
0	Neurotoxicity	B-Adverse_Effect	['N']	[0]
1	of	O	['N']	[1]
2	intrathecal	O	['N']	[2]
3	methotrexate	B-Drug	['Causes']	[0]
4	:	O	['N']	[4]
5	MR	O	['N']	[5]
6	imaging	O	['N']	[6]
7	findings	O	['N']	[7]
8	.	O	['N']	[8]
#1487
0	46-year	O	['N']	[0]
1	-	O	['N']	[1]
2	old	O	['N']	[2]
3	woman	O	['N']	[3]
4	developed	O	['N']	[4]
5	painful	B	['N']	[5]
6	ulcers	I-Adverse_Effect	['N']	[6]
7	over	O	['N']	[7]
8	her	O	['N']	[8]
9	lower	O	['N']	[9]
10	abdomen	O	['N']	[10]
11	in	O	['N']	[11]
12	the	O	['N']	[12]
13	form	O	['N']	[13]
14	of	O	['N']	[14]
15	reticulate	O	['N']	[15]
16	erythema	O	['N']	[16]
17	after	O	['N']	[17]
18	injecting	O	['N']	[18]
19	interferon	B	['N']	[19]
20	beta-1b	I-Drug	['Causes']	[6]
21	subcutaneously	O	['N']	[21]
22	for	O	['N']	[22]
23	multiple	O	['N']	[23]
24	sclerosis	O	['N']	[24]
25	.	O	['N']	[25]
#1488
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	had	O	['N']	[2]
3	MRI	O	['N']	[3]
4	T2	O	['N']	[4]
5	abnormalities	O	['N']	[5]
6	compatible	O	['N']	[6]
7	with	O	['N']	[7]
8	cyclosporin	B-Drug	['Causes']	[9]
9	neurotoxicity	B-Adverse_Effect	['N']	[9]
10	.	O	['N']	[10]
#1489
0	Easily	O	['N']	[0]
1	reversible	O	['N']	[1]
2	hypoxemia	O	['N']	[2]
3	and	O	['N']	[3]
4	hypotension	B-Adverse_Effect	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	nimodipine	B-Drug	['Causes']	[4]
8	.	O	['N']	[8]
#1490
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	became	O	['N']	[5]
6	hypothyroid	B-Adverse_Effect	['N']	[6]
7	while	O	['N']	[7]
8	taking	O	['N']	[8]
9	ferrous	B	['N']	[9]
10	sulfate	I-Drug	['Causes']	[6]
11	.	O	['N']	[11]
#1491
0	Calcification	O	['N']	[0]
1	and	O	['N']	[1]
2	ossification	B	['N']	[2]
3	of	I	['N']	[3]
4	the	I	['N']	[4]
5	spinal	I	['N']	[5]
6	arachnoid	I-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	intrathecal	O	['N']	[8]
9	administration	O	['N']	[9]
10	of	O	['N']	[10]
11	Depo	B	['N']	[11]
12	-	I	['N']	[12]
13	Medrol	I-Drug	['Causes']	[6]
14	.	O	['N']	[14]
#1492
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	intracranial	O	['N']	[3]
4	osteosarcoma	O	['N']	[4]
5	that	O	['N']	[5]
6	arose	O	['N']	[6]
7	16	O	['N']	[7]
8	years	O	['N']	[8]
9	after	O	['N']	[9]
10	radiation	O	['N']	[10]
11	therapy	O	['N']	[11]
12	for	O	['N']	[12]
13	hereditary	O	['N']	[13]
14	retinoblastoma	O	['N']	[14]
15	developed	O	['N']	[15]
16	fatal	B	['N']	[16]
17	cerebral	I	['N']	[17]
18	edema	I-Adverse_Effect	['N']	[18]
19	and	O	['N']	[19]
20	brainstem	O	['N']	[20]
21	herniation	O	['N']	[21]
22	after	O	['N']	[22]
23	she	O	['N']	[23]
24	received	O	['N']	[24]
25	a	O	['N']	[25]
26	single	O	['N']	[26]
27	dose	O	['N']	[27]
28	of	O	['N']	[28]
29	intravenous	O	['N']	[29]
30	methotrexate	B-Drug	['Causes']	[18]
31	.	O	['N']	[31]
#1493
0	The	O	['N']	[0]
1	administration	O	['N']	[1]
2	of	O	['N']	[2]
3	"	O	['N']	[3]
4	sweet	B	['N']	[4]
5	spirits	I	['N']	[5]
6	of	I	['N']	[6]
7	nitre	I-Drug	['Causes']	[30]
8	"	O	['N']	[8]
9	(	O	['N']	[9]
10	4	O	['N']	[10]
11	%	O	['N']	[11]
12	ethyl	O	['N']	[12]
13	nitrite	O	['N']	[13]
14	CH3CH2ONO	O	['N']	[14]
15	in	O	['N']	[15]
16	70	O	['N']	[16]
17	%	O	['N']	[17]
18	ethyl	O	['N']	[18]
19	alcohol	O	['N']	[19]
20	)	O	['N']	[20]
21	was	O	['N']	[21]
22	followed	O	['N']	[22]
23	by	O	['N']	[23]
24	acute	O	['N']	[24]
25	methemoglobinemia	O	['N']	[25]
26	and	O	['N']	[26]
27	severe	B	['N']	[27]
28	anoxic	I	['N']	[28]
29	metabolic	I	['N']	[29]
30	acidosis	I-Adverse_Effect	['N']	[30]
31	in	O	['N']	[31]
32	infant	O	['N']	[32]
33	twins	O	['N']	[33]
34	,	O	['N']	[34]
35	Methylene	O	['N']	[35]
36	blue	O	['N']	[36]
37	administration	O	['N']	[37]
38	reversed	O	['N']	[38]
39	methemoglobinemia	O	['N']	[39]
40	in	O	['N']	[40]
41	both	O	['N']	[41]
42	,	O	['N']	[42]
43	but	O	['N']	[43]
44	one	O	['N']	[44]
45	twin	O	['N']	[45]
46	died	O	['N']	[46]
47	from	O	['N']	[47]
48	the	O	['N']	[48]
49	consequences	O	['N']	[49]
50	of	O	['N']	[50]
51	hypoxemia	O	['N']	[51]
52	.	O	['N']	[52]
#1494
0	Keratitis	B-Adverse_Effect	['N']	[0]
1	in	O	['N']	[1]
2	methamphetamine	B-Drug	['Causes']	[0]
3	abusers	O	['N']	[3]
4	.	O	['N']	[4]
#1495
0	Fatal	B	['N']	[0]
1	hepatitis	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	long	O	['N']	[3]
4	-	O	['N']	[4]
5	term	O	['N']	[5]
6	pulse	O	['N']	[6]
7	itraconazole	B-Drug	['Causes']	[1]
8	treatment	O	['N']	[8]
9	for	O	['N']	[9]
10	onychomycosis	O	['N']	[10]
11	.	O	['N']	[11]
#1496
0	Dyspnea	B-Adverse_Effect	['N']	[0]
1	,	O	['N']	[1]
2	hypoxemia	O	['N']	[2]
3	,	O	['N']	[3]
4	and	O	['N']	[4]
5	pleuritic	O	['N']	[5]
6	chest	O	['N']	[6]
7	pain	O	['N']	[7]
8	occurred	O	['N']	[8]
9	within	O	['N']	[9]
10	24	O	['N']	[10]
11	hours	O	['N']	[11]
12	of	O	['N']	[12]
13	rituximab	B-Drug	['Causes']	[0]
14	administration	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	there	O	['N']	[17]
18	was	O	['N']	[18]
19	no	O	['N']	[19]
20	other	O	['N']	[20]
21	apparent	O	['N']	[21]
22	explanation	O	['N']	[22]
23	.	O	['N']	[23]
#1497
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	value	O	['N']	[3]
4	of	O	['N']	[4]
5	multihormonal	O	['N']	[5]
6	therapy	O	['N']	[6]
7	in	O	['N']	[7]
8	breast	O	['N']	[8]
9	carcinoma	O	['N']	[9]
10	is	O	['N']	[10]
11	not	O	['N']	[11]
12	established	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	the	O	['N']	[15]
16	addition	O	['N']	[16]
17	of	O	['N']	[17]
18	progestogens	O	['N']	[18]
19	to	O	['N']	[19]
20	tamoxifen	B-Drug	['Causes']	[27]
21	may	O	['N']	[21]
22	not	O	['N']	[22]
23	reduce	O	['N']	[23]
24	of	O	['N']	[24]
25	developing	O	['N']	[25]
26	endometrial	B	['N']	[26]
27	lesions	I-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	including	O	['N']	[29]
30	carcinoma	O	['N']	[30]
31	.	O	['N']	[31]
#1498
0	The	O	['N']	[0]
1	abnormal	B	['N']	[1]
2	rhythm	I-Adverse_Effect	['N']	[2]
3	disappeared	O	['N']	[3]
4	with	O	['N']	[4]
5	the	O	['N']	[5]
6	withdrawal	O	['N']	[6]
7	of	O	['N']	[7]
8	propranolol	B-Drug	['Causes']	[2]
9	and	O	['N']	[9]
10	when	O	['N']	[10]
11	the	O	['N']	[11]
12	drug	O	['N']	[12]
13	was	O	['N']	[13]
14	restarted	O	['N']	[14]
15	a	O	['N']	[15]
16	2/1	O	['N']	[16]
17	S	O	['N']	[17]
18	-	O	['N']	[18]
19	A	O	['N']	[19]
20	block	O	['N']	[20]
21	was	O	['N']	[21]
22	seen	O	['N']	[22]
23	.	O	['N']	[23]
#1499
0	Recombinant	O	['N']	[0]
1	VIIa	O	['N']	[1]
2	concentrate	O	['N']	[2]
3	in	O	['N']	[3]
4	the	O	['N']	[4]
5	management	O	['N']	[5]
6	of	O	['N']	[6]
7	bleeding	O	['N']	[7]
8	following	O	['N']	[8]
9	prothrombin	B	['N']	[9]
10	complex	I	['N']	[10]
11	concentrate	I-Drug	['Causes']	[15]
12	-	O	['N']	[12]
13	related	O	['N']	[13]
14	myocardial	B	['N']	[14]
15	infarction	I-Adverse_Effect	['N']	[15]
16	in	O	['N']	[16]
17	patients	O	['N']	[17]
18	with	O	['N']	[18]
19	haemophilia	O	['N']	[19]
20	and	O	['N']	[20]
21	inhibitors	O	['N']	[21]
22	.	O	['N']	[22]
#1500
0	Putaminal	O	['N']	[0]
1	infarct	O	['N']	[1]
2	in	O	['N']	[2]
3	methanol	B-Drug	['Causes']	[4]
4	intoxication	I-Adverse_Effect	['N']	[4]
5	:	O	['N']	[5]
6	case	O	['N']	[6]
7	report	O	['N']	[7]
8	and	O	['N']	[8]
9	role	O	['N']	[9]
10	of	O	['N']	[10]
11	brain	O	['N']	[11]
12	imaging	O	['N']	[12]
13	studies	O	['N']	[13]
14	.	O	['N']	[14]
#1501
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	two	O	['N']	[2]
3	women	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	HUS	O	['N']	[6]
7	after	O	['N']	[7]
8	MMC	B-Drug	['Causes']	[14]
9	therapy	O	['N']	[9]
10	and	O	['N']	[10]
11	presented	O	['N']	[11]
12	massive	B	['N']	[12]
13	pulmonary	I	['N']	[13]
14	bleeding	I-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#1502
0	Adriamycin	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	cardiomyopathy	B-Adverse_Effect	['N']	[3]
4	aggravated	O	['N']	[4]
5	by	O	['N']	[5]
6	cis	O	['N']	[6]
7	-	O	['N']	[7]
8	platinum	O	['N']	[8]
9	nephrotoxicity	O	['N']	[9]
10	requiring	O	['N']	[10]
11	dialysis	O	['N']	[11]
12	.	O	['N']	[12]
#1503
0	The	O	['N']	[0]
1	development	O	['N']	[1]
2	of	O	['N']	[2]
3	systemic	B	['N']	[3]
4	lupus	I	['N']	[4]
5	erythematosus	I-Adverse_Effect	['N']	[5]
6	(	O	['N']	[6]
7	SLE	O	['N']	[7]
8	)	O	['N']	[8]
9	after	O	['N']	[9]
10	38	O	['N']	[10]
11	months	O	['N']	[11]
12	of	O	['N']	[12]
13	therapy	O	['N']	[13]
14	with	O	['N']	[14]
15	recombinant	B	['N']	[15]
16	human	I	['N']	[16]
17	interferon	I	['N']	[17]
18	gamma	I-Drug	['Causes']	[5]
19	(	O	['N']	[19]
20	rIFN	O	['N']	[20]
21	-	O	['N']	[21]
22	gamma	O	['N']	[22]
23	)	O	['N']	[23]
24	was	O	['N']	[24]
25	observed	O	['N']	[25]
26	in	O	['N']	[26]
27	a	O	['N']	[27]
28	patient	O	['N']	[28]
29	with	O	['N']	[29]
30	rheumatoid	O	['N']	[30]
31	arthritis	O	['N']	[31]
32	.	O	['N']	[32]
#1504
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	unusually	O	['N']	[3]
4	short	O	['N']	[4]
5	lived	O	['N']	[5]
6	and	O	['N']	[6]
7	asymptomatic	O	['N']	[7]
8	episode	O	['N']	[8]
9	of	O	['N']	[9]
10	severe	O	['N']	[10]
11	cisplatin	B-Drug	['Causes']	[17]
12	-	O	['N']	[12]
13	induced	O	['N']	[13]
14	renal	B	['N']	[14]
15	tubular	I	['N']	[15]
16	salt	I	['N']	[16]
17	wasting	I-Adverse_Effect	['N']	[17]
18	in	O	['N']	[18]
19	a	O	['N']	[19]
20	fit	O	['N']	[20]
21	41-year	O	['N']	[21]
22	-	O	['N']	[22]
23	old	O	['N']	[23]
24	patient	O	['N']	[24]
25	with	O	['N']	[25]
26	malignant	O	['N']	[26]
27	teratoma	O	['N']	[27]
28	.	O	['N']	[28]
#1505
0	An	O	['N']	[0]
1	objective	O	['N']	[1]
2	causality	O	['N']	[2]
3	assessment	O	['N']	[3]
4	indicated	O	['N']	[4]
5	a	O	['N']	[5]
6	probable	O	['N']	[6]
7	relationship	O	['N']	[7]
8	between	O	['N']	[8]
9	clotting	B	['N']	[9]
10	abnormality	I-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	warfarin	B-Drug	['Causes']	[10]
13	administration	O	['N']	[13]
14	,	O	['N']	[14]
15	although	O	['N']	[15]
16	the	O	['N']	[16]
17	degree	O	['N']	[17]
18	of	O	['N']	[18]
19	elevation	O	['N']	[19]
20	of	O	['N']	[20]
21	the	O	['N']	[21]
22	INR	O	['N']	[22]
23	was	O	['N']	[23]
24	unusual	O	['N']	[24]
25	in	O	['N']	[25]
26	the	O	['N']	[26]
27	light	O	['N']	[27]
28	of	O	['N']	[28]
29	the	O	['N']	[29]
30	daily	O	['N']	[30]
31	warfarin	O	['N']	[31]
32	dose	O	['N']	[32]
33	and	O	['N']	[33]
34	duration	O	['N']	[34]
35	of	O	['N']	[35]
36	its	O	['N']	[36]
37	exposure	O	['N']	[37]
38	.	O	['N']	[38]
#1506
0	Generalized	B	['N']	[0]
1	lichen	I	['N']	[1]
2	nitidus	I-Adverse_Effect	['N']	[2]
3	with	O	['N']	[3]
4	involvement	O	['N']	[4]
5	of	O	['N']	[5]
6	the	O	['N']	[6]
7	palms	O	['N']	[7]
8	following	O	['N']	[8]
9	interferon	B	['N']	[9]
10	alpha	I-Drug	['Causes']	[2]
11	treatment	O	['N']	[11]
12	.	O	['N']	[12]
#1507
0	Acute	B	['N']	[0]
1	hepatic	I	['N']	[1]
2	failure	I-Adverse_Effect	['N']	[2]
3	is	O	['N']	[3]
4	a	O	['N']	[4]
5	rare	O	['N']	[5]
6	and	O	['N']	[6]
7	potentially	O	['N']	[7]
8	lethal	O	['N']	[8]
9	complication	O	['N']	[9]
10	of	O	['N']	[10]
11	propylthiouracil	O	['N']	[11]
12	(	O	['N']	[12]
13	PTU	B-Drug	['Causes']	[2]
14	)	O	['N']	[14]
15	use	O	['N']	[15]
16	for	O	['N']	[16]
17	hyperthyroidism	O	['N']	[17]
18	.	O	['N']	[18]
#1508
0	CASES	O	['N']	[0]
1	:	O	['N']	[1]
2	Two	O	['N']	[2]
3	postmenopausal	O	['N']	[3]
4	women	O	['N']	[4]
5	treated	O	['N']	[5]
6	with	O	['N']	[6]
7	tamoxifen	B-Drug	['Causes']	[16]
8	and	O	['N']	[8]
9	progestational	O	['N']	[9]
10	agents	O	['N']	[10]
11	for	O	['N']	[11]
12	breast	O	['N']	[12]
13	carcinoma	O	['N']	[13]
14	developed	O	['N']	[14]
15	uterine	B	['N']	[15]
16	enlargement	I-Adverse_Effect	['N']	[16]
17	and	O	['N']	[17]
18	intermittent	O	['N']	[18]
19	spotting	O	['N']	[19]
20	.	O	['N']	[20]
#1509
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	11-month	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	female	O	['N']	[9]
10	infant	O	['N']	[10]
11	with	O	['N']	[11]
12	a	O	['N']	[12]
13	depressed	B	['N']	[13]
14	level	I	['N']	[14]
15	of	I	['N']	[15]
16	consciousness	I-Adverse_Effect	['N']	[16]
17	after	O	['N']	[17]
18	ingestion	O	['N']	[18]
19	of	O	['N']	[19]
20	ibuprofen	B-Drug	['Causes']	[16]
21	whose	O	['N']	[21]
22	mental	O	['N']	[22]
23	status	O	['N']	[23]
24	markedly	O	['N']	[24]
25	improved	O	['N']	[25]
26	with	O	['N']	[26]
27	administration	O	['N']	[27]
28	of	O	['N']	[28]
29	naloxone	O	['N']	[29]
30	.	O	['N']	[30]
#1510
0	The	O	['N']	[0]
1	clinical	O	['N']	[1]
2	course	O	['N']	[2]
3	suggests	O	['N']	[3]
4	that	O	['N']	[4]
5	caffeine	B-Drug	['Causes']	[28]
6	,	O	['N']	[6]
7	which	O	['N']	[7]
8	is	O	['N']	[8]
9	present	O	['N']	[9]
10	in	O	['N']	[10]
11	oolong	O	['N']	[11]
12	tea	O	['N']	[12]
13	,	O	['N']	[13]
14	was	O	['N']	[14]
15	mainly	O	['N']	[15]
16	responsible	O	['N']	[16]
17	for	O	['N']	[17]
18	the	O	['N']	[18]
19	rhabdomyolysis	O	['N']	[19]
20	as	O	['N']	[20]
21	well	O	['N']	[21]
22	as	O	['N']	[22]
23	the	O	['N']	[23]
24	delirium	O	['N']	[24]
25	,	O	['N']	[25]
26	although	O	['N']	[26]
27	severe	O	['N']	[27]
28	hyponatremia	B-Adverse_Effect	['N']	[28]
29	has	O	['N']	[29]
30	been	O	['N']	[30]
31	reported	O	['N']	[31]
32	to	O	['N']	[32]
33	cause	O	['N']	[33]
34	rhabdomyolysis	O	['N']	[34]
35	on	O	['N']	[35]
36	rare	O	['N']	[36]
37	occasions	O	['N']	[37]
38	.	O	['N']	[38]
#1511
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	evaluate	O	['N']	[3]
4	the	O	['N']	[4]
5	efficacy	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	administration	O	['N']	[8]
9	of	O	['N']	[9]
10	insulin	O	['N']	[10]
11	by	O	['N']	[11]
12	a	O	['N']	[12]
13	jet	O	['N']	[13]
14	-	O	['N']	[14]
15	injector	O	['N']	[15]
16	device	O	['N']	[16]
17	in	O	['N']	[17]
18	stopping	O	['N']	[18]
19	and	O	['N']	[19]
20	reversing	O	['N']	[20]
21	severe	O	['N']	[21]
22	human	B	['N']	[22]
23	insulin	I-Drug	['Causes']	[26]
24	-	O	['N']	[24]
25	induced	O	['N']	[25]
26	lipoatrophy	B-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#1512
0	Fatal	B	['N']	[0]
1	interstitial	I	['N']	[1]
2	pneumonitis	I-Adverse_Effect	['N']	[2]
3	following	O	['N']	[3]
4	high	O	['N']	[4]
5	-	O	['N']	[5]
6	dose	O	['N']	[6]
7	intermittent	O	['N']	[7]
8	chlorambucil	B-Drug	['Causes']	[2]
9	therapy	O	['N']	[9]
10	for	O	['N']	[10]
11	chronic	O	['N']	[11]
12	lymphocyte	O	['N']	[12]
13	leukemia	O	['N']	[13]
14	.	O	['N']	[14]
#1513
0	When	O	['N']	[0]
1	thrombosis	B-Adverse_Effect	['N']	[1]
2	develops	O	['N']	[2]
3	during	O	['N']	[3]
4	heparin	B-Drug	['Causes']	[1]
5	treatment	O	['N']	[5]
6	,	O	['N']	[6]
7	it	O	['N']	[7]
8	is	O	['N']	[8]
9	important	O	['N']	[9]
10	to	O	['N']	[10]
11	suspect	O	['N']	[11]
12	HITTs	O	['N']	[12]
13	and	O	['N']	[13]
14	to	O	['N']	[14]
15	assay	O	['N']	[15]
16	for	O	['N']	[16]
17	the	O	['N']	[17]
18	associated	O	['N']	[18]
19	antibodies	O	['N']	[19]
20	,	O	['N']	[20]
21	regardless	O	['N']	[21]
22	of	O	['N']	[22]
23	the	O	['N']	[23]
24	actual	O	['N']	[24]
25	platelet	O	['N']	[25]
26	count	O	['N']	[26]
27	.	O	['N']	[27]
#1514
0	The	O	['N']	[0]
1	principle	O	['N']	[1]
2	treatment	O	['N']	[2]
3	for	O	['N']	[3]
4	DPD	O	['N']	[4]
5	-	O	['N']	[5]
6	deficient	O	['N']	[6]
7	patients	O	['N']	[7]
8	with	O	['N']	[8]
9	severe	O	['N']	[9]
10	acute	O	['N']	[10]
11	5-FU	B-Drug	['Causes']	[34]
12	reactions	O	['N']	[12]
13	is	O	['N']	[13]
14	supportive	O	['N']	[14]
15	care	O	['N']	[15]
16	;	O	['N']	[16]
17	however	O	['N']	[17]
18	,	O	['N']	[18]
19	the	O	['N']	[19]
20	administration	O	['N']	[20]
21	of	O	['N']	[21]
22	thymidine	O	['N']	[22]
23	potentially	O	['N']	[23]
24	may	O	['N']	[24]
25	reverse	O	['N']	[25]
26	severe	O	['N']	[26]
27	5-FU	O	['N']	[27]
28	-	O	['N']	[28]
29	induced	O	['N']	[29]
30	neurologic	O	['N']	[30]
31	symptoms	O	['N']	[31]
32	such	O	['N']	[32]
33	as	O	['N']	[33]
34	encephalopathy	B-Adverse_Effect	['N']	[34]
35	and	O	['N']	[35]
36	coma	O	['N']	[36]
37	.	O	['N']	[37]
#1515
0	Oxcarbazepine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	angioedema	B-Adverse_Effect	['N']	[3]
4	manifested	O	['N']	[4]
5	by	O	['N']	[5]
6	swelling	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	face	O	['N']	[9]
10	,	O	['N']	[10]
11	eyes	O	['N']	[11]
12	,	O	['N']	[12]
13	lips	O	['N']	[13]
14	,	O	['N']	[14]
15	or	O	['N']	[15]
16	tongue	O	['N']	[16]
17	or	O	['N']	[17]
18	difficulty	O	['N']	[18]
19	swallowing	O	['N']	[19]
20	or	O	['N']	[20]
21	breathing	O	['N']	[21]
22	(	O	['N']	[22]
23	or	O	['N']	[23]
24	both	O	['N']	[24]
25	)	O	['N']	[25]
26	is	O	['N']	[26]
27	a	O	['N']	[27]
28	rare	O	['N']	[28]
29	but	O	['N']	[29]
30	potentially	O	['N']	[30]
31	life	O	['N']	[31]
32	-	O	['N']	[32]
33	threatening	O	['N']	[33]
34	reaction	O	['N']	[34]
35	for	O	['N']	[35]
36	which	O	['N']	[36]
37	early	O	['N']	[37]
38	recognition	O	['N']	[38]
39	and	O	['N']	[39]
40	management	O	['N']	[40]
41	are	O	['N']	[41]
42	vital	O	['N']	[42]
43	.	O	['N']	[43]
#1516
0	When	O	['N']	[0]
1	measured	O	['N']	[1]
2	,	O	['N']	[2]
3	the	O	['N']	[3]
4	serum	B	['N']	[4]
5	lithium	B-Drug	['Causes']	[8]
6	level	I	['N']	[6]
7	had	I	['N']	[7]
8	increased	I-Adverse_Effect	['N']	[8]
9	4-fold	O	['N']	[9]
10	during	O	['N']	[10]
11	acyclovir	O	['N']	[11]
12	therapy	O	['N']	[12]
13	.	O	['N']	[13]
#1517
0	This	O	['N']	[0]
1	experience	O	['N']	[1]
2	supports	O	['N']	[2]
3	the	O	['N']	[3]
4	hypothesis	O	['N']	[4]
5	that	O	['N']	[5]
6	heparin	B-Drug	['Causes']	[17]
7	can	O	['N']	[7]
8	be	O	['N']	[8]
9	readministered	O	['N']	[9]
10	early	O	['N']	[10]
11	to	O	['N']	[11]
12	patients	O	['N']	[12]
13	with	O	['N']	[13]
14	heparin	O	['N']	[14]
15	-	O	['N']	[15]
16	associated	O	['N']	[16]
17	thrombocytopenia	B-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	thrombosis	O	['N']	[19]
20	,	O	['N']	[20]
21	provided	O	['N']	[21]
22	antiplatelet	O	['N']	[22]
23	therapy	O	['N']	[23]
24	is	O	['N']	[24]
25	given	O	['N']	[25]
26	.	O	['N']	[26]
#1518
0	OBJECTIVES	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	authors	O	['N']	[3]
4	described	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	Hashimoto	B	['N']	[8]
9	's	I	['N']	[9]
10	disease	I-Adverse_Effect	['N']	[10]
11	during	O	['N']	[11]
12	interferon	B	['N']	[12]
13	-	I	['N']	[13]
14	alpha	I-Drug	['Causes']	[10]
15	(	O	['N']	[15]
16	IFN	O	['N']	[16]
17	-	O	['N']	[17]
18	alpha	O	['N']	[18]
19	)	O	['N']	[19]
20	treatment	O	['N']	[20]
21	for	O	['N']	[21]
22	chronic	O	['N']	[22]
23	viral	O	['N']	[23]
24	C	O	['N']	[24]
25	hepatitis	O	['N']	[25]
26	in	O	['N']	[26]
27	a	O	['N']	[27]
28	patient	O	['N']	[28]
29	with	O	['N']	[29]
30	the	O	['N']	[30]
31	specific	O	['N']	[31]
32	genetic	O	['N']	[32]
33	susceptibility	O	['N']	[33]
34	associated	O	['N']	[34]
35	with	O	['N']	[35]
36	the	O	['N']	[36]
37	thyroid	O	['N']	[37]
38	disease	O	['N']	[38]
39	.	O	['N']	[39]
#1519
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	multiple	O	['N']	[8]
9	myeloma	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	acute	O	['N']	[12]
13	life	B	['N']	[13]
14	-	I	['N']	[14]
15	threatening	I	['N']	[15]
16	water	I	['N']	[16]
17	intoxication	I-Adverse_Effect	['N']	[17]
18	following	O	['N']	[18]
19	treatment	O	['N']	[19]
20	with	O	['N']	[20]
21	oral	O	['N']	[21]
22	indomethacin	O	['N']	[22]
23	and	O	['N']	[23]
24	low	O	['N']	[24]
25	dose	O	['N']	[25]
26	intravenous	O	['N']	[26]
27	cyclophosphamide	B-Drug	['Causes']	[17]
28	.	O	['N']	[28]
#1520
0	Less	O	['N']	[0]
1	common	O	['N']	[1]
2	adverse	O	['N']	[2]
3	events	O	['N']	[3]
4	to	O	['N']	[4]
5	dapsone	B-Drug	['Causes']	[19]
6	include	O	['N']	[6]
7	the	O	['N']	[7]
8	idiosyncratic	O	['N']	[8]
9	reactions	O	['N']	[9]
10	of	O	['N']	[10]
11	leukopenia	O	['N']	[11]
12	and	O	['N']	[12]
13	agranulocytosis	O	['N']	[13]
14	,	O	['N']	[14]
15	cutaneous	O	['N']	[15]
16	eruptions	O	['N']	[16]
17	,	O	['N']	[17]
18	peripheral	B	['N']	[18]
19	neuropathy	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	psychosis	O	['N']	[21]
22	,	O	['N']	[22]
23	toxic	O	['N']	[23]
24	hepatitis	O	['N']	[24]
25	,	O	['N']	[25]
26	cholestatic	O	['N']	[26]
27	jaundice	O	['N']	[27]
28	,	O	['N']	[28]
29	nephrotic	O	['N']	[29]
30	syndrome	O	['N']	[30]
31	,	O	['N']	[31]
32	renal	O	['N']	[32]
33	papillary	O	['N']	[33]
34	necrosis	O	['N']	[34]
35	,	O	['N']	[35]
36	severe	O	['N']	[36]
37	hypoalbuminemia	O	['N']	[37]
38	without	O	['N']	[38]
39	proteinuria	O	['N']	[39]
40	,	O	['N']	[40]
41	an	O	['N']	[41]
42	infectious	O	['N']	[42]
43	mononucleosis	O	['N']	[43]
44	-	O	['N']	[44]
45	like	O	['N']	[45]
46	syndrome	O	['N']	[46]
47	,	O	['N']	[47]
48	and	O	['N']	[48]
49	minor	O	['N']	[49]
50	neurological	O	['N']	[50]
51	and	O	['N']	[51]
52	gastrointestinal	O	['N']	[52]
53	complaints	O	['N']	[53]
54	.	O	['N']	[54]
#1521
0	Reversible	B	['N']	[0]
1	posterior	I	['N']	[1]
2	leukoencephalopathy	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	systemic	O	['N']	[5]
6	lupus	O	['N']	[6]
7	erythematosus	O	['N']	[7]
8	with	O	['N']	[8]
9	thrombocytopenia	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	cyclosporine	B-Drug	['Causes']	[3]
13	.	O	['N']	[13]
#1522
0	Linezolid	B-Drug	['Causes']	[15]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	acute	O	['N']	[3]
4	interstitial	O	['N']	[4]
5	nephritis	O	['N']	[5]
6	and	O	['N']	[6]
7	drug	O	['N']	[7]
8	rash	O	['N']	[8]
9	with	O	['N']	[9]
10	eosinophilia	O	['N']	[10]
11	and	O	['N']	[11]
12	systemic	O	['N']	[12]
13	symptoms	O	['N']	[13]
14	(	O	['N']	[14]
15	DRESS	B-Adverse_Effect	['N']	[15]
16	)	O	['N']	[16]
17	syndrome	O	['N']	[17]
18	.	O	['N']	[18]
#1523
0	Disseminated	B	['N']	[0]
1	salmonellosis	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	treated	O	['N']	[5]
6	with	O	['N']	[6]
7	temozolomide	B-Drug	['Causes']	[1]
8	.	O	['N']	[8]
#1524
0	After	O	['N']	[0]
1	administration	O	['N']	[1]
2	of	O	['N']	[2]
3	Oxybutynin	O	['N']	[3]
4	concomitantly	O	['N']	[4]
5	with	O	['N']	[5]
6	an	O	['N']	[6]
7	increase	O	['N']	[7]
8	in	O	['N']	[8]
9	the	O	['N']	[9]
10	dose	O	['N']	[10]
11	of	O	['N']	[11]
12	Dantrolene	B-Drug	['Causes']	[24]
13	,	O	['N']	[13]
14	she	O	['N']	[14]
15	presented	O	['N']	[15]
16	the	O	['N']	[16]
17	clinical	O	['N']	[17]
18	symptoms	O	['N']	[18]
19	and	O	['N']	[19]
20	laboratory	O	['N']	[20]
21	finding	O	['N']	[21]
22	of	O	['N']	[22]
23	Carbamazepine	B	['N']	[23]
24	intoxication	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#1525
0	The	O	['N']	[0]
1	main	O	['N']	[1]
2	side	O	['N']	[2]
3	-	O	['N']	[3]
4	effects	O	['N']	[4]
5	of	O	['N']	[5]
6	Lp	B	['N']	[6]
7	-	I	['N']	[7]
8	TAE	I-Drug	['Causes']	[16]
9	combined	O	['N']	[9]
10	with	O	['N']	[10]
11	HT	O	['N']	[11]
12	were	O	['N']	[12]
13	low	B	['N']	[13]
14	-	I	['N']	[14]
15	grade	I	['N']	[15]
16	fever	I-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	localized	O	['N']	[18]
19	pain	O	['N']	[19]
20	,	O	['N']	[20]
21	myelo	O	['N']	[21]
22	-	O	['N']	[22]
23	suppression	O	['N']	[23]
24	and	O	['N']	[24]
25	liver	O	['N']	[25]
26	dysfunction	O	['N']	[26]
27	,	O	['N']	[27]
28	but	O	['N']	[28]
29	these	O	['N']	[29]
30	were	O	['N']	[30]
31	transient	O	['N']	[31]
32	and	O	['N']	[32]
33	eventually	O	['N']	[33]
34	disappeared	O	['N']	[34]
35	.	O	['N']	[35]
#1526
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	subcutaneous	B	['N']	[5]
6	metastasis	I-Adverse_Effect	['N']	[6]
7	along	O	['N']	[7]
8	the	O	['N']	[8]
9	needle	O	['N']	[9]
10	track	O	['N']	[10]
11	after	O	['N']	[11]
12	percutaneous	O	['N']	[12]
13	ethanol	B-Drug	['Causes']	[6]
14	injection	O	['N']	[14]
15	(	O	['N']	[15]
16	PEI	O	['N']	[16]
17	)	O	['N']	[17]
18	for	O	['N']	[18]
19	treatment	O	['N']	[19]
20	of	O	['N']	[20]
21	hepatocellular	O	['N']	[21]
22	carcinoma	O	['N']	[22]
23	.	O	['N']	[23]
#1527
0	Pellagra	B	['N']	[0]
1	encephalopathy	I-Adverse_Effect	['N']	[1]
2	among	O	['N']	[2]
3	tuberculous	O	['N']	[3]
4	patients	O	['N']	[4]
5	:	O	['N']	[5]
6	its	O	['N']	[6]
7	relation	O	['N']	[7]
8	to	O	['N']	[8]
9	isoniazid	B-Drug	['Causes']	[1]
10	therapy	O	['N']	[10]
11	.	O	['N']	[11]
#1528
0	Agranulocytosis	B-Adverse_Effect	['N']	[0]
1	during	O	['N']	[1]
2	clozapine	B-Drug	['Causes']	[0]
3	therapy	O	['N']	[3]
4	.	O	['N']	[4]
#1529
0	Phenylpropanolamine	B-Drug	['Causes']	[17]
1	(	O	['N']	[1]
2	PPA	O	['N']	[2]
3	)	O	['N']	[3]
4	recently	O	['N']	[4]
5	has	O	['N']	[5]
6	been	O	['N']	[6]
7	publicly	O	['N']	[7]
8	implicated	O	['N']	[8]
9	as	O	['N']	[9]
10	a	O	['N']	[10]
11	cause	O	['N']	[11]
12	of	O	['N']	[12]
13	stroke	O	['N']	[13]
14	and	O	['N']	[14]
15	other	O	['N']	[15]
16	neurologic	B	['N']	[16]
17	events	I-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#1530
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	continued	O	['N']	[2]
3	low	O	['N']	[3]
4	-	O	['N']	[4]
5	dose	O	['N']	[5]
6	MTX	B-Drug	['Causes']	[26]
7	led	O	['N']	[7]
8	,	O	['N']	[8]
9	in	O	['N']	[9]
10	spite	O	['N']	[10]
11	of	O	['N']	[11]
12	normal	O	['N']	[12]
13	liver	O	['N']	[13]
14	tests	O	['N']	[14]
15	,	O	['N']	[15]
16	8	O	['N']	[16]
17	years	O	['N']	[17]
18	after	O	['N']	[18]
19	the	O	['N']	[19]
20	last	O	['N']	[20]
21	biopsy	O	['N']	[21]
22	to	O	['N']	[22]
23	liver	O	['N']	[23]
24	failure	O	['N']	[24]
25	and	O	['N']	[25]
26	death	B-Adverse_Effect	['N']	[26]
27	in	O	['N']	[27]
28	1	O	['N']	[28]
29	of	O	['N']	[29]
30	our	O	['N']	[30]
31	patients	O	['N']	[31]
32	.	O	['N']	[32]
#1531
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	three	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	severe	B	['N']	[5]
6	hepatotoxicity	I-Adverse_Effect	['N']	[6]
7	related	O	['N']	[7]
8	to	O	['N']	[8]
9	benzarone	B-Drug	['Causes']	[6]
10	,	O	['N']	[10]
11	a	O	['N']	[11]
12	benzofuran	O	['N']	[12]
13	derivative	O	['N']	[13]
14	.	O	['N']	[14]
#1532
0	Our	O	['N']	[0]
1	cases	O	['N']	[1]
2	constitute	O	['N']	[2]
3	the	O	['N']	[3]
4	most	O	['N']	[4]
5	severe	O	['N']	[5]
6	cases	O	['N']	[6]
7	of	O	['N']	[7]
8	benzarone	B-Drug	['Causes']	[9]
9	hepatotoxicity	B-Adverse_Effect	['N']	[9]
10	reported	O	['N']	[10]
11	so	O	['N']	[11]
12	far	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	comprise	O	['N']	[15]
16	the	O	['N']	[16]
17	first	O	['N']	[17]
18	cases	O	['N']	[18]
19	of	O	['N']	[19]
20	(	O	['N']	[20]
21	sub)fulminant	O	['N']	[21]
22	hepatitis	O	['N']	[22]
23	and	O	['N']	[23]
24	cirrhosis	O	['N']	[24]
25	related	O	['N']	[25]
26	to	O	['N']	[26]
27	benzarone	O	['N']	[27]
28	.	O	['N']	[28]
#1533
0	Skin	B	['N']	[0]
1	rash	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	splinter	O	['N']	[3]
4	hemorrhages	O	['N']	[4]
5	from	O	['N']	[5]
6	ganciclovir	B-Drug	['Causes']	[1]
7	.	O	['N']	[7]
#1534
0	Acute	B	['N']	[0]
1	dystonia	I-Adverse_Effect	['N']	[1]
2	with	O	['N']	[2]
3	thalamic	O	['N']	[3]
4	and	O	['N']	[4]
5	brainstem	O	['N']	[5]
6	lesions	O	['N']	[6]
7	after	O	['N']	[7]
8	initial	O	['N']	[8]
9	penicillamine	B-Drug	['Causes']	[1]
10	treatment	O	['N']	[10]
11	in	O	['N']	[11]
12	Wilson	O	['N']	[12]
13	's	O	['N']	[13]
14	disease	O	['N']	[14]
15	.	O	['N']	[15]
#1535
0	A	O	['N']	[0]
1	brief	O	['N']	[1]
2	review	O	['N']	[2]
3	of	O	['N']	[3]
4	reported	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	chloramphenicol	B-Drug	['Causes']	[8]
8	hypersensitivity	B-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	the	O	['N']	[10]
11	English	O	['N']	[11]
12	-	O	['N']	[12]
13	language	O	['N']	[13]
14	literature	O	['N']	[14]
15	,	O	['N']	[15]
16	as	O	['N']	[16]
17	well	O	['N']	[17]
18	as	O	['N']	[18]
19	possible	O	['N']	[19]
20	alternative	O	['N']	[20]
21	explanations	O	['N']	[21]
22	in	O	['N']	[22]
23	this	O	['N']	[23]
24	case	O	['N']	[24]
25	,	O	['N']	[25]
26	are	O	['N']	[26]
27	provided	O	['N']	[27]
28	.	O	['N']	[28]
#1536
0	In	O	['N']	[0]
1	both	O	['N']	[1]
2	cases	O	['N']	[2]
3	,	O	['N']	[3]
4	high	O	['N']	[4]
5	fever	O	['N']	[5]
6	,	O	['N']	[6]
7	skin	O	['N']	[7]
8	rash	O	['N']	[8]
9	,	O	['N']	[9]
10	liver	B	['N']	[10]
11	dysfunction	I-Adverse_Effect	['N']	[11]
12	and	O	['N']	[12]
13	atypical	O	['N']	[13]
14	lymphocytosis	O	['N']	[14]
15	developed	O	['N']	[15]
16	3	O	['N']	[16]
17	weeks	O	['N']	[17]
18	after	O	['N']	[18]
19	initiating	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	SASP	B-Drug	['Causes']	[11]
23	.	O	['N']	[23]
#1537
0	Dorzolamide	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	choroidal	B	['N']	[3]
4	detachment	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	surgically	O	['N']	[7]
8	untreated	O	['N']	[8]
9	eye	O	['N']	[9]
10	.	O	['N']	[10]
#1538
0	Fever	O	['N']	[0]
1	,	O	['N']	[1]
2	pulmonary	B	['N']	[2]
3	infiltrates	I-Adverse_Effect	['N']	[3]
4	,	O	['N']	[4]
5	and	O	['N']	[5]
6	pleural	O	['N']	[6]
7	effusion	O	['N']	[7]
8	following	O	['N']	[8]
9	acyclovir	B-Drug	['Causes']	[3]
10	therapy	O	['N']	[10]
11	for	O	['N']	[11]
12	herpes	O	['N']	[12]
13	zoster	O	['N']	[13]
14	ophthalmicus	O	['N']	[14]
15	.	O	['N']	[15]
#1539
0	We	O	['N']	[0]
1	experienced	O	['N']	[1]
2	2	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	mequitazine	B-Drug	['Causes']	[9]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	photosensitivity	B	['N']	[8]
9	reaction	I-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	patients	O	['N']	[11]
12	who	O	['N']	[12]
13	took	O	['N']	[13]
14	mequitazine	O	['N']	[14]
15	for	O	['N']	[15]
16	their	O	['N']	[16]
17	dermatologic	O	['N']	[17]
18	problems	O	['N']	[18]
19	.	O	['N']	[19]
#1540
0	Amphotericin	B	['N']	[0]
1	B	I-Drug	['Causes']	[26]
2	(	O	['N']	[2]
3	AmB	O	['N']	[3]
4	)	O	['N']	[4]
5	is	O	['N']	[5]
6	effective	O	['N']	[6]
7	,	O	['N']	[7]
8	but	O	['N']	[8]
9	its	O	['N']	[9]
10	use	O	['N']	[10]
11	is	O	['N']	[11]
12	limited	O	['N']	[12]
13	by	O	['N']	[13]
14	toxicity	O	['N']	[14]
15	:	O	['N']	[15]
16	renal	O	['N']	[16]
17	impairment	O	['N']	[17]
18	,	O	['N']	[18]
19	anaemia	O	['N']	[19]
20	,	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	malaise	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	hypokalaemia	B-Adverse_Effect	['N']	[26]
27	are	O	['N']	[27]
28	common	O	['N']	[28]
29	.	O	['N']	[29]
#1541
0	There	O	['N']	[0]
1	have	O	['N']	[1]
2	been	O	['N']	[2]
3	more	O	['N']	[3]
4	than	O	['N']	[4]
5	20	O	['N']	[5]
6	observations	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	appearance	O	['N']	[9]
10	or	O	['N']	[10]
11	aggravation	O	['N']	[11]
12	of	O	['N']	[12]
13	this	O	['N']	[13]
14	granulomatosis	B-Adverse_Effect	['N']	[14]
15	with	O	['N']	[15]
16	interferon	B	['N']	[16]
17	alfa	I-Drug	['Causes']	[14]
18	and	O	['N']	[18]
19	more	O	['N']	[19]
20	recently	O	['N']	[20]
21	with	O	['N']	[21]
22	the	O	['N']	[22]
23	combination	O	['N']	[23]
24	of	O	['N']	[24]
25	interferon	O	['N']	[25]
26	alfa	O	['N']	[26]
27	plus	O	['N']	[27]
28	ribavirin	O	['N']	[28]
29	.	O	['N']	[29]
#1542
0	Escape	O	['N']	[0]
1	atrial	O	['N']	[1]
2	complexes	O	['N']	[2]
3	,	O	['N']	[3]
4	which	O	['N']	[4]
5	occurred	O	['N']	[5]
6	following	O	['N']	[6]
7	junctional	O	['N']	[7]
8	premature	O	['N']	[8]
9	complexes	O	['N']	[9]
10	,	O	['N']	[10]
11	failed	O	['N']	[11]
12	to	O	['N']	[12]
13	initiate	O	['N']	[13]
14	tachycardia	B-Adverse_Effect	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	control	O	['N']	[17]
18	state	O	['N']	[18]
19	but	O	['N']	[19]
20	tachycardia	O	['N']	[20]
21	was	O	['N']	[21]
22	always	O	['N']	[22]
23	reinitiated	O	['N']	[23]
24	by	O	['N']	[24]
25	an	O	['N']	[25]
26	identical	O	['N']	[26]
27	escape	O	['N']	[27]
28	sequence	O	['N']	[28]
29	after	O	['N']	[29]
30	procainamide	B-Drug	['Causes']	[14]
31	.	O	['N']	[31]
#1543
0	Acetazolamide	B-Drug	['Causes']	[7]
1	may	O	['N']	[1]
2	have	O	['N']	[2]
3	accelerated	O	['N']	[3]
4	the	O	['N']	[4]
5	development	O	['N']	[5]
6	of	O	['N']	[6]
7	osteomalacia	B-Adverse_Effect	['N']	[7]
8	by	O	['N']	[8]
9	several	O	['N']	[9]
10	mechanisms	O	['N']	[10]
11	,	O	['N']	[11]
12	including	O	['N']	[12]
13	increased	O	['N']	[13]
14	renal	O	['N']	[14]
15	calcium	O	['N']	[15]
16	excretion	O	['N']	[16]
17	.	O	['N']	[17]
#1544
0	Sporadic	B	['N']	[0]
1	rippling	I	['N']	[1]
2	muscle	I	['N']	[2]
3	disease	I-Adverse_Effect	['N']	[3]
4	unmasked	O	['N']	[4]
5	by	O	['N']	[5]
6	simvastatin	B-Drug	['Causes']	[3]
7	.	O	['N']	[7]
#1545
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	noncardiogenic	B	['N']	[5]
6	pulmonary	I	['N']	[6]
7	edema	I-Adverse_Effect	['N']	[7]
8	developed	O	['N']	[8]
9	after	O	['N']	[9]
10	therapeutic	O	['N']	[10]
11	trial	O	['N']	[11]
12	of	O	['N']	[12]
13	EO	B-Drug	['Causes']	[7]
14	as	O	['N']	[14]
15	sclerosing	O	['N']	[15]
16	agent	O	['N']	[16]
17	for	O	['N']	[17]
18	esophageal	O	['N']	[18]
19	varix	O	['N']	[19]
20	.	O	['N']	[20]
#1546
0	We	O	['N']	[0]
1	wish	O	['N']	[1]
2	to	O	['N']	[2]
3	call	O	['N']	[3]
4	for	O	['N']	[4]
5	cautious	O	['N']	[5]
6	approach	O	['N']	[6]
7	at	O	['N']	[7]
8	time	O	['N']	[8]
9	of	O	['N']	[9]
10	cessation	O	['N']	[10]
11	of	O	['N']	[11]
12	prolonged	O	['N']	[12]
13	ACTH	B-Drug	['Causes']	[28]
14	therapy	O	['N']	[14]
15	because	O	['N']	[15]
16	of	O	['N']	[16]
17	possible	O	['N']	[17]
18	unexpected	O	['N']	[18]
19	and	O	['N']	[19]
20	only	O	['N']	[20]
21	partially	O	['N']	[21]
22	understood	O	['N']	[22]
23	hazardous	O	['N']	[23]
24	side	O	['N']	[24]
25	effects	O	['N']	[25]
26	such	O	['N']	[26]
27	as	O	['N']	[27]
28	hyperkalemia	B-Adverse_Effect	['N']	[28]
29	.	O	['N']	[29]
#1547
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	pulmonary	O	['N']	[8]
9	hypertension	O	['N']	[9]
10	and	O	['N']	[10]
11	undifferentiated	O	['N']	[11]
12	connective	O	['N']	[12]
13	tissue	O	['N']	[13]
14	disease	O	['N']	[14]
15	who	O	['N']	[15]
16	,	O	['N']	[16]
17	after	O	['N']	[17]
18	2	O	['N']	[18]
19	months	O	['N']	[19]
20	of	O	['N']	[20]
21	treatment	O	['N']	[21]
22	with	O	['N']	[22]
23	epoprostenol	B-Drug	['Causes']	[38]
24	,	O	['N']	[24]
25	presented	O	['N']	[25]
26	with	O	['N']	[26]
27	rapidly	O	['N']	[27]
28	progressive	O	['N']	[28]
29	erythema	O	['N']	[29]
30	,	O	['N']	[30]
31	scaling	O	['N']	[31]
32	,	O	['N']	[32]
33	nausea	O	['N']	[33]
34	and	O	['N']	[34]
35	vomiting	O	['N']	[35]
36	,	O	['N']	[36]
37	and	O	['N']	[37]
38	fever	B-Adverse_Effect	['N']	[38]
39	.	O	['N']	[39]
#1548
0	Sudden	O	['N']	[0]
1	cardiac	O	['N']	[1]
2	death	O	['N']	[2]
3	due	O	['N']	[3]
4	to	O	['N']	[4]
5	hypersensitivity	B	['N']	[5]
6	myocarditis	I-Adverse_Effect	['N']	[6]
7	during	O	['N']	[7]
8	clozapine	B-Drug	['Causes']	[6]
9	treatment	O	['N']	[9]
10	.	O	['N']	[10]
#1549
0	These	O	['N']	[0]
1	novel	O	['N']	[1]
2	findings	O	['N']	[2]
3	may	O	['N']	[3]
4	offer	O	['N']	[4]
5	specific	O	['N']	[5]
6	therapeutic	O	['N']	[6]
7	targets	O	['N']	[7]
8	in	O	['N']	[8]
9	the	O	['N']	[9]
10	treatment	O	['N']	[10]
11	of	O	['N']	[11]
12	BCNU	B-Drug	['Causes']	[16]
13	-	O	['N']	[13]
14	associated	O	['N']	[14]
15	pulmonary	B	['N']	[15]
16	fibrosis	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#1550
0	In	O	['N']	[0]
1	addition	O	['N']	[1]
2	,	O	['N']	[2]
3	an	O	['N']	[3]
4	immediate	O	['N']	[4]
5	erythematous	B	['N']	[5]
6	macule	I-Adverse_Effect	['N']	[6]
7	was	O	['N']	[7]
8	observed	O	['N']	[8]
9	on	O	['N']	[9]
10	the	O	['N']	[10]
11	photopatch	O	['N']	[11]
12	test	O	['N']	[12]
13	site	O	['N']	[13]
14	of	O	['N']	[14]
15	mequitazine	B-Drug	['Causes']	[6]
16	directly	O	['N']	[16]
17	after	O	['N']	[17]
18	UV	O	['N']	[18]
19	exposure	O	['N']	[19]
20	which	O	['N']	[20]
21	was	O	['N']	[21]
22	similar	O	['N']	[22]
23	to	O	['N']	[23]
24	the	O	['N']	[24]
25	immediate	O	['N']	[25]
26	erythema	O	['N']	[26]
27	noted	O	['N']	[27]
28	in	O	['N']	[28]
29	chlorpromazine	O	['N']	[29]
30	photoallergy	O	['N']	[30]
31	.	O	['N']	[31]
#1551
0	Alternating	O	['N']	[0]
1	sinus	O	['N']	[1]
2	rhythm	O	['N']	[2]
3	and	O	['N']	[3]
4	intermittent	O	['N']	[4]
5	sinoatrial	O	['N']	[5]
6	(	O	['N']	[6]
7	S	O	['N']	[7]
8	-	O	['N']	[8]
9	A	O	['N']	[9]
10	)	O	['N']	[10]
11	block	O	['N']	[11]
12	was	O	['N']	[12]
13	observed	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	57-year	O	['N']	[16]
17	-	O	['N']	[17]
18	old	O	['N']	[18]
19	woman	O	['N']	[19]
20	,	O	['N']	[20]
21	under	O	['N']	[21]
22	treatment	O	['N']	[22]
23	for	O	['N']	[23]
24	angina	O	['N']	[24]
25	with	O	['N']	[25]
26	80	B	['N']	[26]
27	mg	I-Dose	['N']	[27]
28	propranolol	B-Drug	['Dosage']	[27]
29	daily	O	['N']	[29]
30	.	O	['N']	[30]
#1552
0	The	O	['N']	[0]
1	international	O	['N']	[1]
2	literature	O	['N']	[2]
3	regarding	O	['N']	[3]
4	opportunistic	B	['N']	[4]
5	infections	I-Adverse_Effect	['N']	[5]
6	after	O	['N']	[6]
7	immunosuppressive	O	['N']	[7]
8	therapy	O	['N']	[8]
9	with	O	['N']	[9]
10	alemtuzumab	B-Drug	['Causes']	[5]
11	with	O	['N']	[11]
12	particular	O	['N']	[12]
13	attention	O	['N']	[13]
14	on	O	['N']	[14]
15	fungal	O	['N']	[15]
16	infections	O	['N']	[16]
17	has	O	['N']	[17]
18	also	O	['N']	[18]
19	been	O	['N']	[19]
20	reviewed	O	['N']	[20]
21	.	O	['N']	[21]
#1553
0	The	O	['N']	[0]
1	day	O	['N']	[1]
2	after	O	['N']	[2]
3	clozapine	O	['N']	[3]
4	was	O	['N']	[4]
5	stopped	O	['N']	[5]
6	,	O	['N']	[6]
7	while	O	['N']	[7]
8	he	O	['N']	[8]
9	was	O	['N']	[9]
10	still	O	['N']	[10]
11	receiving	O	['N']	[11]
12	clomipramine	B-Drug	['Dosage']	[16]
13	150	B	['N']	[13]
14	mg	I	['N']	[14]
15	/	I	['N']	[15]
16	d	I-Dose	['N']	[16]
17	,	O	['N']	[17]
18	he	O	['N']	[18]
19	began	O	['N']	[19]
20	behaving	O	['N']	[20]
21	oddly	O	['N']	[21]
22	,	O	['N']	[22]
23	started	O	['N']	[23]
24	sweating	O	['N']	[24]
25	profusely	O	['N']	[25]
26	,	O	['N']	[26]
27	shivering	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	became	O	['N']	[30]
31	tremulous	O	['N']	[31]
32	,	O	['N']	[32]
33	agitated	O	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	confused	O	['N']	[36]
37	.	O	['N']	[37]
#1554
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	adult	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	acute	O	['N']	[9]
10	lymphoblastic	O	['N']	[10]
11	leukemia	O	['N']	[11]
12	who	O	['N']	[12]
13	presented	O	['N']	[13]
14	with	O	['N']	[14]
15	repeated	O	['N']	[15]
16	transient	O	['N']	[16]
17	ischemic	O	['N']	[17]
18	attacks	O	['N']	[18]
19	followed	O	['N']	[19]
20	by	O	['N']	[20]
21	a	O	['N']	[21]
22	seizure	B-Adverse_Effect	['N']	[22]
23	during	O	['N']	[23]
24	consolidation	O	['N']	[24]
25	treatment	O	['N']	[25]
26	with	O	['N']	[26]
27	L	B	['N']	[27]
28	-	I	['N']	[28]
29	asparaginase	I-Drug	['Causes']	[22]
30	.	O	['N']	[30]
#1555
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	present	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	study	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	mentally	O	['N']	[8]
9	healthy	O	['N']	[9]
10	man	O	['N']	[10]
11	who	O	['N']	[11]
12	repeatedly	O	['N']	[12]
13	experienced	O	['N']	[13]
14	short	O	['N']	[14]
15	-	O	['N']	[15]
16	lived	O	['N']	[16]
17	,	O	['N']	[17]
18	obsessional	B	['N']	[18]
19	-	I	['N']	[19]
20	like	I	['N']	[20]
21	suicidal	I	['N']	[21]
22	ideas	I	['N']	[22]
23	and	I	['N']	[23]
24	images	I-Adverse_Effect	['N']	[24]
25	after	O	['N']	[25]
26	ingestion	O	['N']	[26]
27	of	O	['N']	[27]
28	the	O	['N']	[28]
29	anti	O	['N']	[29]
30	-	O	['N']	[30]
31	fungal	O	['N']	[31]
32	drug	O	['N']	[32]
33	ketoconazole	B-Drug	['Causes']	[24]
34	.	O	['N']	[34]
#1556
0	During	O	['N']	[0]
1	analysis	O	['N']	[1]
2	of	O	['N']	[2]
3	28	O	['N']	[3]
4	patients	O	['N']	[4]
5	receiving	O	['N']	[5]
6	CAP	B-Drug	['Causes']	[32]
7	with	O	['N']	[7]
8	concomitant	O	['N']	[8]
9	radiation	O	['N']	[9]
10	(	O	['N']	[10]
11	XRT	O	['N']	[11]
12	)	O	['N']	[12]
13	for	O	['N']	[13]
14	pancreatic	O	['N']	[14]
15	cancer	O	['N']	[15]
16	(	O	['N']	[16]
17	resected	O	['N']	[17]
18	or	O	['N']	[18]
19	locally	O	['N']	[19]
20	advanced	O	['N']	[20]
21	)	O	['N']	[21]
22	,	O	['N']	[22]
23	two	O	['N']	[23]
24	patients	O	['N']	[24]
25	developed	O	['N']	[25]
26	signs	O	['N']	[26]
27	and	O	['N']	[27]
28	symptoms	O	['N']	[28]
29	consistent	O	['N']	[29]
30	with	O	['N']	[30]
31	peripheral	B	['N']	[31]
32	neuropathy	I-Adverse_Effect	['N']	[32]
33	.	O	['N']	[33]
#1557
0	During	O	['N']	[0]
1	clarithromycin	O	['N']	[1]
2	coadministration	O	['N']	[2]
3	,	O	['N']	[3]
4	four	O	['N']	[4]
5	out	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	seven	O	['N']	[8]
9	patients	O	['N']	[9]
10	developed	O	['N']	[10]
11	moderate	O	['N']	[11]
12	-	O	['N']	[12]
13	to	O	['N']	[13]
14	-	O	['N']	[14]
15	severe	O	['N']	[15]
16	toxic	B	['N']	[16]
17	symptoms	I-Adverse_Effect	['N']	[17]
18	of	O	['N']	[18]
19	carbamazepine	B-Drug	['Causes']	[17]
20	,	O	['N']	[20]
21	such	O	['N']	[21]
22	as	O	['N']	[22]
23	drowsiness	O	['N']	[23]
24	,	O	['N']	[24]
25	dizziness	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	ataxia	O	['N']	[28]
29	,	O	['N']	[29]
30	which	O	['N']	[30]
31	resolved	O	['N']	[31]
32	within	O	['N']	[32]
33	5	O	['N']	[33]
34	days	O	['N']	[34]
35	after	O	['N']	[35]
36	clarithromycin	O	['N']	[36]
37	discontinuation	O	['N']	[37]
38	.	O	['N']	[38]
#1558
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	optic	B	['N']	[3]
4	neuropathy	I-Adverse_Effect	['N']	[4]
5	while	O	['N']	[5]
6	being	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	isoniazid	O	['N']	[9]
10	and	O	['N']	[10]
11	ethambutol	B-Drug	['Causes']	[4]
12	.	O	['N']	[12]
#1559
0	A	O	['N']	[0]
1	10-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	with	O	['N']	[5]
6	osteosarcoma	O	['N']	[6]
7	and	O	['N']	[7]
8	normal	O	['N']	[8]
9	renal	O	['N']	[9]
10	function	O	['N']	[10]
11	manifested	O	['N']	[11]
12	laboratory	O	['N']	[12]
13	evidence	O	['N']	[13]
14	of	O	['N']	[14]
15	impending	O	['N']	[15]
16	renal	O	['N']	[16]
17	toxicity	O	['N']	[17]
18	and	O	['N']	[18]
19	extreme	O	['N']	[19]
20	elevation	O	['N']	[20]
21	of	O	['N']	[21]
22	aspartate	O	['N']	[22]
23	aminotrasferase	O	['N']	[23]
24	and	O	['N']	[24]
25	alanine	O	['N']	[25]
26	aminotransferase	O	['N']	[26]
27	within	O	['N']	[27]
28	2	O	['N']	[28]
29	hours	O	['N']	[29]
30	after	O	['N']	[30]
31	the	O	['N']	[31]
32	completion	O	['N']	[32]
33	of	O	['N']	[33]
34	a	O	['N']	[34]
35	4-hour	O	['N']	[35]
36	infusion	O	['N']	[36]
37	of	O	['N']	[37]
38	high	O	['N']	[38]
39	-	O	['N']	[39]
40	dose	O	['N']	[40]
41	methotrexate	B-Drug	['Causes']	[59]
42	(	O	['N']	[42]
43	MTX	O	['N']	[43]
44	)	O	['N']	[44]
45	(	O	['N']	[45]
46	12	O	['N']	[46]
47	g	O	['N']	[47]
48	/	O	['N']	[48]
49	m2	O	['N']	[49]
50	)	O	['N']	[50]
51	,	O	['N']	[51]
52	and	O	['N']	[52]
53	went	O	['N']	[53]
54	on	O	['N']	[54]
55	to	O	['N']	[55]
56	develop	O	['N']	[56]
57	acute	B	['N']	[57]
58	renal	I	['N']	[58]
59	failure	I-Adverse_Effect	['N']	[59]
60	with	O	['N']	[60]
61	life	O	['N']	[61]
62	-	O	['N']	[62]
63	threatening	O	['N']	[63]
64	hyperkalemia	O	['N']	[64]
65	29	O	['N']	[65]
66	hours	O	['N']	[66]
67	later	O	['N']	[67]
68	.	O	['N']	[68]
#1560
0	CASE	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	present	O	['N']	[3]
4	an	O	['N']	[4]
5	11-year	O	['N']	[5]
6	old	O	['N']	[6]
7	male	O	['N']	[7]
8	with	O	['N']	[8]
9	Budd	O	['N']	[9]
10	-	O	['N']	[10]
11	Chiari	O	['N']	[11]
12	syndrome	O	['N']	[12]
13	who	O	['N']	[13]
14	experienced	O	['N']	[14]
15	profound	O	['N']	[15]
16	worsening	B	['N']	[16]
17	of	I	['N']	[17]
18	chronic	I	['N']	[18]
19	aphthous	I	['N']	[19]
20	ulcers	I-Adverse_Effect	['N']	[20]
21	after	O	['N']	[21]
22	immunosuppressive	O	['N']	[22]
23	therapy	O	['N']	[23]
24	was	O	['N']	[24]
25	changed	O	['N']	[25]
26	from	O	['N']	[26]
27	tacrolimus	O	['N']	[27]
28	to	O	['N']	[28]
29	sirolimus	B-Drug	['Causes']	[20]
30	.	O	['N']	[30]
#1561
0	Acute	B	['N']	[0]
1	pancreatitis	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	danazol	B-Drug	['Causes']	[1]
5	treatment	O	['N']	[5]
6	for	O	['N']	[6]
7	endometriosis	O	['N']	[7]
8	.	O	['N']	[8]
#1562
0	Horner	O	['N']	[0]
1	's	O	['N']	[1]
2	syndrome	O	['N']	[2]
3	and	O	['N']	[3]
4	demyelinating	B	['N']	[4]
5	peripheral	I	['N']	[5]
6	neuropathy	I-Adverse_Effect	['N']	[6]
7	caused	O	['N']	[7]
8	by	O	['N']	[8]
9	high	O	['N']	[9]
10	-	O	['N']	[10]
11	dose	O	['N']	[11]
12	cytosine	B	['N']	[12]
13	arabinoside	I-Drug	['Causes']	[6]
14	.	O	['N']	[14]
#1563
0	The	O	['N']	[0]
1	major	O	['N']	[1]
2	side	O	['N']	[2]
3	effect	O	['N']	[3]
4	of	O	['N']	[4]
5	infliximab	B-Drug	['Causes']	[7]
6	is	O	['N']	[6]
7	infection	B-Adverse_Effect	['N']	[7]
8	.	O	['N']	[8]
#1564
0	Red	B	['N']	[0]
1	blood	I	['N']	[1]
2	cell	I	['N']	[2]
3	anemia	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	pemphigus	O	['N']	[8]
9	vulgaris	O	['N']	[9]
10	induced	O	['N']	[10]
11	by	O	['N']	[11]
12	the	O	['N']	[12]
13	use	O	['N']	[13]
14	of	O	['N']	[14]
15	mycophenolate	B	['N']	[15]
16	mofetil	I-Drug	['Causes']	[3]
17	and	O	['N']	[17]
18	prednisone	O	['N']	[18]
19	.	O	['N']	[19]
#1565
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	1	O	['N']	[2]
3	,	O	['N']	[3]
4	a	O	['N']	[4]
5	total	O	['N']	[5]
6	daily	O	['N']	[6]
7	dose	O	['N']	[7]
8	of	O	['N']	[8]
9	25	O	['N']	[9]
10	mg	O	['N']	[10]
11	sertraline	O	['N']	[11]
12	,	O	['N']	[12]
13	with	O	['N']	[13]
14	nondetectable	O	['N']	[14]
15	sertraline	O	['N']	[15]
16	and	O	['N']	[16]
17	desmethylsertraline	O	['N']	[17]
18	blood	O	['N']	[18]
19	levels	O	['N']	[19]
20	,	O	['N']	[20]
21	resulted	O	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	doubling	B	['N']	[24]
25	of	I	['N']	[25]
26	the	I	['N']	[26]
27	lamotrigine	B-Drug	['Causes']	[29]
28	blood	I	['N']	[28]
29	level	I-Adverse_Effect	['N']	[29]
30	with	O	['N']	[30]
31	symptoms	O	['N']	[31]
32	of	O	['N']	[32]
33	toxicity	O	['N']	[33]
34	.	O	['N']	[34]
#1566
0	We	O	['N']	[0]
1	reviewed	O	['N']	[1]
2	the	O	['N']	[2]
3	literature	O	['N']	[3]
4	in	O	['N']	[4]
5	an	O	['N']	[5]
6	attempt	O	['N']	[6]
7	to	O	['N']	[7]
8	characterize	O	['N']	[8]
9	the	O	['N']	[9]
10	pattern	O	['N']	[10]
11	and	O	['N']	[11]
12	predictors	O	['N']	[12]
13	of	O	['N']	[13]
14	TMP	O	['N']	[14]
15	/	O	['N']	[15]
16	SMX	B-Drug	['Causes']	[20]
17	-	O	['N']	[17]
18	induced	O	['N']	[18]
19	aseptic	B	['N']	[19]
20	meningitis	I-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#1567
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	5-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	boy	O	['N']	[6]
7	with	O	['N']	[7]
8	CF	O	['N']	[8]
9	who	O	['N']	[9]
10	had	O	['N']	[10]
11	a	O	['N']	[11]
12	stricture	B	['N']	[12]
13	of	I	['N']	[13]
14	the	I	['N']	[14]
15	hepatic	I	['N']	[15]
16	flexure	I	['N']	[16]
17	region	I	['N']	[17]
18	with	I	['N']	[18]
19	associated	I	['N']	[19]
20	narrowing	I-Adverse_Effect	['N']	[20]
21	due	O	['N']	[21]
22	to	O	['N']	[22]
23	submucosal	O	['N']	[23]
24	fibrosis	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	transverse	O	['N']	[27]
28	colon	O	['N']	[28]
29	,	O	['N']	[29]
30	secondary	O	['N']	[30]
31	to	O	['N']	[31]
32	high	B	['N']	[32]
33	-	I	['N']	[33]
34	lipase	I	['N']	[34]
35	pancreatin	I-Drug	['Causes']	[20]
36	therapy	O	['N']	[36]
37	.	O	['N']	[37]
#1568
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	report	O	['N']	[3]
4	indicates	O	['N']	[4]
5	clindamycin	B-Drug	['Causes']	[40]
6	phosphate	O	['N']	[6]
7	vaginal	O	['N']	[7]
8	cream	O	['N']	[8]
9	as	O	['N']	[9]
10	the	O	['N']	[10]
11	most	O	['N']	[11]
12	probable	O	['N']	[12]
13	cause	O	['N']	[13]
14	of	O	['N']	[14]
15	CDIC	O	['N']	[15]
16	due	O	['N']	[16]
17	to	O	['N']	[17]
18	the	O	['N']	[18]
19	temporal	O	['N']	[19]
20	relationship	O	['N']	[20]
21	between	O	['N']	[21]
22	the	O	['N']	[22]
23	occurrence	O	['N']	[23]
24	of	O	['N']	[24]
25	diarrhea	O	['N']	[25]
26	and	O	['N']	[26]
27	clindamycin	O	['N']	[27]
28	administration	O	['N']	[28]
29	,	O	['N']	[29]
30	lack	O	['N']	[30]
31	of	O	['N']	[31]
32	concomitant	O	['N']	[32]
33	medications	O	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	documentation	O	['N']	[36]
37	of	O	['N']	[37]
38	C.	B	['N']	[38]
39	difficile	I	['N']	[39]
40	toxin	I-Adverse_Effect	['N']	[40]
41	.	O	['N']	[41]
#1569
0	Allergic	O	['N']	[0]
1	side	O	['N']	[1]
2	effects	O	['N']	[2]
3	of	O	['N']	[3]
4	AZA	B-Drug	['Causes']	[12]
5	are	O	['N']	[5]
6	rare	O	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	reported	O	['N']	[9]
10	allergic	B	['N']	[10]
11	skin	I	['N']	[11]
12	eruptions	I-Adverse_Effect	['N']	[12]
13	from	O	['N']	[13]
14	AZA	O	['N']	[14]
15	are	O	['N']	[15]
16	very	O	['N']	[16]
17	limited	O	['N']	[17]
18	in	O	['N']	[18]
19	Japan	O	['N']	[19]
20	.	O	['N']	[20]
#1570
0	I	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	35-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	with	O	['N']	[7]
8	occult	O	['N']	[8]
9	coronary	O	['N']	[9]
10	artery	O	['N']	[10]
11	disease	O	['N']	[11]
12	who	O	['N']	[12]
13	experienced	O	['N']	[13]
14	cardiac	B	['N']	[14]
15	arrest	I-Adverse_Effect	['N']	[15]
16	within	O	['N']	[16]
17	minutes	O	['N']	[17]
18	after	O	['N']	[18]
19	receiving	O	['N']	[19]
20	a	O	['N']	[20]
21	first	O	['N']	[21]
22	-	O	['N']	[22]
23	time	O	['N']	[23]
24	dose	O	['N']	[24]
25	of	O	['N']	[25]
26	subcutaneous	O	['N']	[26]
27	sumatriptan	B-Drug	['Causes']	[15]
28	for	O	['N']	[28]
29	migraine	O	['N']	[29]
30	.	O	['N']	[30]
#1571
0	Neutrophilic	B	['N']	[0]
1	dermatoses	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	two	O	['N']	[3]
4	children	O	['N']	[4]
5	with	O	['N']	[5]
6	idiopathic	O	['N']	[6]
7	neutropenia	O	['N']	[7]
8	:	O	['N']	[8]
9	association	O	['N']	[9]
10	with	O	['N']	[10]
11	granulocyte	O	['N']	[11]
12	colony	O	['N']	[12]
13	-	O	['N']	[13]
14	stimulating	O	['N']	[14]
15	factor	O	['N']	[15]
16	(	O	['N']	[16]
17	G	B	['N']	[17]
18	-	I	['N']	[18]
19	CSF	I-Drug	['Causes']	[1]
20	)	O	['N']	[20]
21	therapy	O	['N']	[21]
22	.	O	['N']	[22]
#1572
0	Rapid	O	['N']	[0]
1	identification	O	['N']	[1]
2	of	O	['N']	[2]
3	speech	B	['N']	[3]
4	loss	I-Adverse_Effect	['N']	[4]
5	linked	O	['N']	[5]
6	to	O	['N']	[6]
7	FK506	B-Drug	['Causes']	[4]
8	may	O	['N']	[8]
9	be	O	['N']	[9]
10	important	O	['N']	[10]
11	because	O	['N']	[11]
12	reduction	O	['N']	[12]
13	or	O	['N']	[13]
14	cessation	O	['N']	[14]
15	of	O	['N']	[15]
16	the	O	['N']	[16]
17	drug	O	['N']	[17]
18	may	O	['N']	[18]
19	be	O	['N']	[19]
20	associated	O	['N']	[20]
21	with	O	['N']	[21]
22	reverse	O	['N']	[22]
23	of	O	['N']	[23]
24	speech	O	['N']	[24]
25	loss	O	['N']	[25]
26	.	O	['N']	[26]
#1573
0	Mitomycin	B	['N']	[0]
1	C	I-Drug	['Causes']	[6]
2	-	O	['N']	[2]
3	related	O	['N']	[3]
4	hemolytic	B	['N']	[4]
5	uremic	I	['N']	[5]
6	syndrome	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	cancer	O	['N']	[8]
9	patients	O	['N']	[9]
10	.	O	['N']	[10]
#1574
0	The	O	['N']	[0]
1	observations	O	['N']	[1]
2	suggest	O	['N']	[2]
3	that	O	['N']	[3]
4	testicular	O	['N']	[4]
5	swelling	O	['N']	[5]
6	and	O	['N']	[6]
7	pain	B-Adverse_Effect	['N']	[7]
8	are	O	['N']	[8]
9	side	O	['N']	[9]
10	effects	O	['N']	[10]
11	of	O	['N']	[11]
12	desipramine	B-Drug	['Causes']	[7]
13	.	O	['N']	[13]
#1575
0	An	O	['N']	[0]
1	immediate	O	['N']	[1]
2	hemolytic	B	['N']	[2]
3	reaction	I-Adverse_Effect	['N']	[3]
4	induced	O	['N']	[4]
5	by	O	['N']	[5]
6	repeated	O	['N']	[6]
7	administration	O	['N']	[7]
8	of	O	['N']	[8]
9	oxaliplatin	B-Drug	['Causes']	[3]
10	.	O	['N']	[10]
#1576
0	A	O	['N']	[0]
1	42	O	['N']	[1]
2	year	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	,	O	['N']	[5]
6	treated	O	['N']	[6]
7	for	O	['N']	[7]
8	testicular	O	['N']	[8]
9	carcinoma	O	['N']	[9]
10	with	O	['N']	[10]
11	combination	O	['N']	[11]
12	chemotherapy	O	['N']	[12]
13	that	O	['N']	[13]
14	included	O	['N']	[14]
15	bleomycin	B-Drug	['Causes']	[21]
16	,	O	['N']	[16]
17	developed	O	['N']	[17]
18	life	O	['N']	[18]
19	threatening	O	['N']	[19]
20	interstitial	B	['N']	[20]
21	pneumonitis	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#1577
0	Severe	O	['N']	[0]
1	heparin	B-Drug	['Causes']	[3]
2	associated	O	['N']	[2]
3	thrombocytopenia	B-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	a	O	['N']	[5]
6	rare	O	['N']	[6]
7	complication	O	['N']	[7]
8	of	O	['N']	[8]
9	heparin	O	['N']	[9]
10	therapy	O	['N']	[10]
11	.	O	['N']	[11]
#1578
0	A	O	['N']	[0]
1	44-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	is	O	['N']	[5]
6	described	O	['N']	[6]
7	in	O	['N']	[7]
8	whom	O	['N']	[8]
9	amiodarone	O	['N']	[9]
10	,	O	['N']	[10]
11	disopyramide	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	quinidine	B-Drug	['Causes']	[23]
15	,	O	['N']	[15]
16	administered	O	['N']	[16]
17	alone	O	['N']	[17]
18	separately	O	['N']	[18]
19	,	O	['N']	[19]
20	induced	O	['N']	[20]
21	atypical	B	['N']	[21]
22	ventricular	I	['N']	[22]
23	tachycardia	I-Adverse_Effect	['N']	[23]
24	(	O	['N']	[24]
25	AVT	O	['N']	[25]
26	,	O	['N']	[26]
27	torsade	O	['N']	[27]
28	de	O	['N']	[28]
29	pointes	O	['N']	[29]
30	)	O	['N']	[30]
31	.	O	['N']	[31]
#1579
0	Warfarin	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	bleeding	B-Adverse_Effect	['N']	[3]
4	complication	O	['N']	[4]
5	saved	O	['N']	[5]
6	life	O	['N']	[6]
7	.	O	['N']	[7]
#1580
0	The	O	['N']	[0]
1	day	O	['N']	[1]
2	after	O	['N']	[2]
3	clozapine	B-Drug	['Dosage']	[16]
4	was	O	['N']	[4]
5	stopped	O	['N']	[5]
6	,	O	['N']	[6]
7	while	O	['N']	[7]
8	he	O	['N']	[8]
9	was	O	['N']	[9]
10	still	O	['N']	[10]
11	receiving	O	['N']	[11]
12	clomipramine	O	['N']	[12]
13	150	B	['N']	[13]
14	mg	I	['N']	[14]
15	/	I	['N']	[15]
16	d	I-Dose	['N']	[16]
17	,	O	['N']	[17]
18	he	O	['N']	[18]
19	began	O	['N']	[19]
20	behaving	O	['N']	[20]
21	oddly	O	['N']	[21]
22	,	O	['N']	[22]
23	started	O	['N']	[23]
24	sweating	O	['N']	[24]
25	profusely	O	['N']	[25]
26	,	O	['N']	[26]
27	shivering	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	became	O	['N']	[30]
31	tremulous	O	['N']	[31]
32	,	O	['N']	[32]
33	agitated	O	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	confused	O	['N']	[36]
37	.	O	['N']	[37]
#1581
0	Although	O	['N']	[0]
1	various	O	['N']	[1]
2	manifestations	O	['N']	[2]
3	of	O	['N']	[3]
4	pentamidine	B-Drug	['Causes']	[7]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	cardiotoxicity	B-Adverse_Effect	['N']	[7]
8	have	O	['N']	[8]
9	been	O	['N']	[9]
10	reported	O	['N']	[10]
11	,	O	['N']	[11]
12	to	O	['N']	[12]
13	our	O	['N']	[13]
14	knowledge	O	['N']	[14]
15	,	O	['N']	[15]
16	second	O	['N']	[16]
17	-	O	['N']	[17]
18	degree	O	['N']	[18]
19	heart	O	['N']	[19]
20	block	O	['N']	[20]
21	associated	O	['N']	[21]
22	with	O	['N']	[22]
23	this	O	['N']	[23]
24	agent	O	['N']	[24]
25	has	O	['N']	[25]
26	not	O	['N']	[26]
27	been	O	['N']	[27]
28	described	O	['N']	[28]
29	.	O	['N']	[29]
#1582
0	Intraventricular	O	['N']	[0]
1	nafcillin	B-Drug	['Causes']	[4]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	seizures	B-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	neonate	O	['N']	[7]
8	.	O	['N']	[8]
#1583
0	Therefore	O	['N']	[0]
1	,	O	['N']	[1]
2	amantadine	B-Drug	['Causes']	[8]
3	was	O	['N']	[3]
4	permanently	O	['N']	[4]
5	discontinued	O	['N']	[5]
6	and	O	['N']	[6]
7	the	O	['N']	[7]
8	cornea	B-Adverse_Effect	['N']	[8]
9	cleared	O	['N']	[9]
10	again	O	['N']	[10]
11	.	O	['N']	[11]
#1584
0	There	O	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	putative	O	['N']	[3]
4	role	O	['N']	[4]
5	of	O	['N']	[5]
6	liothyronine	B-Drug	['Causes']	[12]
7	administration	O	['N']	[7]
8	in	O	['N']	[8]
9	precipitating	O	['N']	[9]
10	or	O	['N']	[10]
11	activating	O	['N']	[11]
12	hyperthyroidism	B-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#1585
0	Within	O	['N']	[0]
1	24	O	['N']	[1]
2	hours	O	['N']	[2]
3	of	O	['N']	[3]
4	fluid	O	['N']	[4]
5	restriction	O	['N']	[5]
6	and	O	['N']	[6]
7	cessation	O	['N']	[7]
8	of	O	['N']	[8]
9	desmopressin	B-Drug	['Causes']	[14]
10	,	O	['N']	[10]
11	her	O	['N']	[11]
12	symptoms	O	['N']	[12]
13	and	O	['N']	[13]
14	hyponatremia	B-Adverse_Effect	['N']	[14]
15	resolved	O	['N']	[15]
16	.	O	['N']	[16]
#1586
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	report	O	['N']	[2]
3	is	O	['N']	[3]
4	presented	O	['N']	[4]
5	concerning	O	['N']	[5]
6	the	O	['N']	[6]
7	administration	O	['N']	[7]
8	of	O	['N']	[8]
9	ketanserin	O	['N']	[9]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	treatment	O	['N']	[12]
13	of	O	['N']	[13]
14	pulmonary	B	['N']	[14]
15	vasoconstriction	I-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	right	O	['N']	[17]
18	ventricular	O	['N']	[18]
19	failure	O	['N']	[19]
20	following	O	['N']	[20]
21	the	O	['N']	[21]
22	infusion	O	['N']	[22]
23	of	O	['N']	[23]
24	protamine	B-Drug	['Causes']	[15]
25	in	O	['N']	[25]
26	a	O	['N']	[26]
27	patient	O	['N']	[27]
28	undergoing	O	['N']	[28]
29	coronary	O	['N']	[29]
30	artery	O	['N']	[30]
31	bypass	O	['N']	[31]
32	surgery	O	['N']	[32]
33	and	O	['N']	[33]
34	mitral	O	['N']	[34]
35	valve	O	['N']	[35]
36	replacement	O	['N']	[36]
37	.	O	['N']	[37]
#1587
0	Oesophageal	B	['N']	[0]
1	ulceration	I-Adverse_Effect	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	emepronium	B	['N']	[4]
5	bromide	I-Drug	['Causes']	[1]
6	.	O	['N']	[6]
#1588
0	Five	O	['N']	[0]
1	and	O	['N']	[1]
2	one	O	['N']	[2]
3	-	O	['N']	[3]
4	half	O	['N']	[4]
5	years	O	['N']	[5]
6	after	O	['N']	[6]
7	the	O	['N']	[7]
8	diagnosis	O	['N']	[8]
9	of	O	['N']	[9]
10	myeloma	O	['N']	[10]
11	,	O	['N']	[11]
12	while	O	['N']	[12]
13	in	O	['N']	[13]
14	remission	O	['N']	[14]
15	on	O	['N']	[15]
16	cyclophosphamide	B-Drug	['Causes']	[33]
17	therapy	O	['N']	[17]
18	,	O	['N']	[18]
19	the	O	['N']	[19]
20	patient	O	['N']	[20]
21	experienced	O	['N']	[21]
22	severe	O	['N']	[22]
23	abdominal	O	['N']	[23]
24	right	O	['N']	[24]
25	lower	O	['N']	[25]
26	quadrant	O	['N']	[26]
27	pain	O	['N']	[27]
28	due	O	['N']	[28]
29	to	O	['N']	[29]
30	a	O	['N']	[30]
31	large	O	['N']	[31]
32	cecal	B	['N']	[32]
33	lymphoma	I-Adverse_Effect	['N']	[33]
34	.	O	['N']	[34]
#1589
0	The	O	['N']	[0]
1	9	O	['N']	[1]
2	other	O	['N']	[2]
3	reported	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	D	B	['N']	[6]
7	-	I	['N']	[7]
8	penicillamine	I-Drug	['Causes']	[12]
9	induced	O	['N']	[9]
10	rapidly	B	['N']	[10]
11	progressive	I	['N']	[11]
12	glomerulonephritis	I-Adverse_Effect	['N']	[12]
13	have	O	['N']	[13]
14	been	O	['N']	[14]
15	reviewed	O	['N']	[15]
16	.	O	['N']	[16]
#1590
0	Here	O	['N']	[0]
1	we	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	Crohn	O	['N']	[6]
7	's	O	['N']	[7]
8	disease	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	a	O	['N']	[11]
12	severe	B	['N']	[12]
13	infliximab	B-Drug	['Causes']	[15]
14	infusion	I	['N']	[14]
15	reaction	I-Adverse_Effect	['N']	[15]
16	(	O	['N']	[16]
17	IIR	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	complicated	O	['N']	[20]
21	1	O	['N']	[21]
22	day	O	['N']	[22]
23	later	O	['N']	[23]
24	by	O	['N']	[24]
25	severe	O	['N']	[25]
26	swelling	O	['N']	[26]
27	of	O	['N']	[27]
28	the	O	['N']	[28]
29	forearm	O	['N']	[29]
30	and	O	['N']	[30]
31	hand	O	['N']	[31]
32	ipsilateral	O	['N']	[32]
33	to	O	['N']	[33]
34	the	O	['N']	[34]
35	site	O	['N']	[35]
36	of	O	['N']	[36]
37	infliximab	O	['N']	[37]
38	infusion	O	['N']	[38]
39	.	O	['N']	[39]
#1591
0	Herein	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	present	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	severe	O	['N']	[7]
8	and	O	['N']	[8]
9	prolonged	B	['N']	[9]
10	hypoglycemia	I-Adverse_Effect	['N']	[10]
11	after	O	['N']	[11]
12	long	O	['N']	[12]
13	-	O	['N']	[13]
14	acting	O	['N']	[14]
15	octreotide	B-Drug	['Causes']	[10]
16	treatment	O	['N']	[16]
17	.	O	['N']	[17]
#1592
0	Vogt	B	['N']	[0]
1	-	I	['N']	[1]
2	Koyanagi	I	['N']	[2]
3	-	I	['N']	[3]
4	Harada	I	['N']	[4]
5	disease	I-Adverse_Effect	['N']	[5]
6	occurring	O	['N']	[6]
7	during	O	['N']	[7]
8	interferon	B	['N']	[8]
9	alpha	I-Drug	['Causes']	[5]
10	therapy	O	['N']	[10]
11	for	O	['N']	[11]
12	chronic	O	['N']	[12]
13	hepatitis	O	['N']	[13]
14	C.	O	['N']	[14]
#1593
0	In	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	cirrhosis	O	['N']	[3]
4	,	O	['N']	[4]
5	the	O	['N']	[5]
6	metabolism	O	['N']	[6]
7	of	O	['N']	[7]
8	meperidine	B-Drug	['Causes']	[18]
9	is	O	['N']	[9]
10	decreased	O	['N']	[10]
11	,	O	['N']	[11]
12	leading	O	['N']	[12]
13	to	O	['N']	[13]
14	accumulation	B	['N']	[14]
15	of	I	['N']	[15]
16	the	I	['N']	[16]
17	parent	I	['N']	[17]
18	drug	I-Adverse_Effect	['N']	[18]
19	and	O	['N']	[19]
20	possible	O	['N']	[20]
21	CNS	O	['N']	[21]
22	depressive	O	['N']	[22]
23	effects	O	['N']	[23]
24	similar	O	['N']	[24]
25	to	O	['N']	[25]
26	hepatic	O	['N']	[26]
27	encephalopathy	O	['N']	[27]
28	.	O	['N']	[28]
#1594
0	Sulfadiazine	B-Drug	['Causes']	[1]
1	crystalluria	B-Adverse_Effect	['N']	[1]
2	revisited	O	['N']	[2]
3	.	O	['N']	[3]
#1595
0	Atypical	O	['N']	[0]
1	ventricular	O	['N']	[1]
2	tachycardia	O	['N']	[2]
3	(	O	['N']	[3]
4	torsade	O	['N']	[4]
5	de	O	['N']	[5]
6	pointes	O	['N']	[6]
7	)	O	['N']	[7]
8	induced	O	['N']	[8]
9	by	O	['N']	[9]
10	amiodarone	O	['N']	[10]
11	:	O	['N']	[11]
12	arrhythmia	B-Adverse_Effect	['N']	[12]
13	previously	O	['N']	[13]
14	induced	O	['N']	[14]
15	by	O	['N']	[15]
16	quinidine	O	['N']	[16]
17	and	O	['N']	[17]
18	disopyramide	B-Drug	['Causes']	[12]
19	.	O	['N']	[19]
#1596
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	demonstrates	O	['N']	[2]
3	the	O	['N']	[3]
4	association	O	['N']	[4]
5	of	O	['N']	[5]
6	selective	O	['N']	[6]
7	IgA	B	['N']	[7]
8	deficiency	I-Adverse_Effect	['N']	[8]
9	with	O	['N']	[9]
10	remission	O	['N']	[10]
11	in	O	['N']	[11]
12	rheumatoid	O	['N']	[12]
13	arthritis	O	['N']	[13]
14	induced	O	['N']	[14]
15	by	O	['N']	[15]
16	fenclofenac	B-Drug	['Causes']	[8]
17	as	O	['N']	[17]
18	well	O	['N']	[18]
19	as	O	['N']	[19]
20	aurothiomalate	O	['N']	[20]
21	and	O	['N']	[21]
22	sulphasalazine	O	['N']	[22]
23	.	O	['N']	[23]
#1597
0	In	O	['N']	[0]
1	summary	O	['N']	[1]
2	,	O	['N']	[2]
3	we	O	['N']	[3]
4	report	O	['N']	[4]
5	herein	O	['N']	[5]
6	the	O	['N']	[6]
7	first	O	['N']	[7]
8	case	O	['N']	[8]
9	of	O	['N']	[9]
10	SIADH	B-Adverse_Effect	['N']	[10]
11	believed	O	['N']	[11]
12	to	O	['N']	[12]
13	be	O	['N']	[13]
14	an	O	['N']	[14]
15	adverse	O	['N']	[15]
16	effect	O	['N']	[16]
17	of	O	['N']	[17]
18	mizoribin	B-Drug	['Causes']	[10]
19	,	O	['N']	[19]
20	which	O	['N']	[20]
21	may	O	['N']	[21]
22	therefore	O	['N']	[22]
23	needed	O	['N']	[23]
24	to	O	['N']	[24]
25	be	O	['N']	[25]
26	added	O	['N']	[26]
27	to	O	['N']	[27]
28	the	O	['N']	[28]
29	list	O	['N']	[29]
30	of	O	['N']	[30]
31	drugs	O	['N']	[31]
32	which	O	['N']	[32]
33	can	O	['N']	[33]
34	induce	O	['N']	[34]
35	SIADH	O	['N']	[35]
36	.	O	['N']	[36]
#1598
0	The	O	['N']	[0]
1	latter	O	['N']	[1]
2	form	O	['N']	[2]
3	(	O	['N']	[3]
4	Macrodantin	B-Drug	['Causes']	[42]
5	)	O	['N']	[5]
6	is	O	['N']	[6]
7	reported	O	['N']	[7]
8	to	O	['N']	[8]
9	engender	O	['N']	[9]
10	less	O	['N']	[10]
11	gastrointestinal	O	['N']	[11]
12	intolerance	O	['N']	[12]
13	but	O	['N']	[13]
14	it	O	['N']	[14]
15	can	O	['N']	[15]
16	produce	O	['N']	[16]
17	the	O	['N']	[17]
18	same	O	['N']	[18]
19	adverse	O	['N']	[19]
20	effects	O	['N']	[20]
21	as	O	['N']	[21]
22	the	O	['N']	[22]
23	conventional	O	['N']	[23]
24	form	O	['N']	[24]
25	--	O	['N']	[25]
26	liver	O	['N']	[26]
27	damage	O	['N']	[27]
28	,	O	['N']	[28]
29	acute	O	['N']	[29]
30	and	O	['N']	[30]
31	chronic	O	['N']	[31]
32	pulmonary	O	['N']	[32]
33	reactions	O	['N']	[33]
34	,	O	['N']	[34]
35	peripheral	O	['N']	[35]
36	neuropathy	O	['N']	[36]
37	,	O	['N']	[37]
38	blood	O	['N']	[38]
39	dyscrasias	O	['N']	[39]
40	and	O	['N']	[40]
41	allergic	B	['N']	[41]
42	reactions	I-Adverse_Effect	['N']	[42]
43	--	O	['N']	[43]
44	and	O	['N']	[44]
45	does	O	['N']	[45]
46	so	O	['N']	[46]
47	just	O	['N']	[47]
48	as	O	['N']	[48]
49	rapidly	O	['N']	[49]
50	and	O	['N']	[50]
51	floridly	O	['N']	[51]
52	;	O	['N']	[52]
53	one	O	['N']	[53]
54	such	O	['N']	[54]
55	case	O	['N']	[55]
56	is	O	['N']	[56]
57	reported	O	['N']	[57]
58	here	O	['N']	[58]
59	.	O	['N']	[59]
#1599
0	The	O	['N']	[0]
1	third	O	['N']	[1]
2	patient	O	['N']	[2]
3	had	O	['N']	[3]
4	been	O	['N']	[4]
5	suffering	O	['N']	[5]
6	from	O	['N']	[6]
7	serious	O	['N']	[7]
8	akathisia	O	['N']	[8]
9	while	O	['N']	[9]
10	on	O	['N']	[10]
11	risperidone	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	was	O	['N']	[14]
15	cured	O	['N']	[15]
16	after	O	['N']	[16]
17	switching	O	['N']	[17]
18	to	O	['N']	[18]
19	olanzapine	B-Drug	['Causes']	[27]
20	,	O	['N']	[20]
21	but	O	['N']	[21]
22	thereafter	O	['N']	[22]
23	the	O	['N']	[23]
24	patient	O	['N']	[24]
25	suffered	O	['N']	[25]
26	from	O	['N']	[26]
27	RLS	B-Adverse_Effect	['N']	[27]
28	at	O	['N']	[28]
29	nighttime	O	['N']	[29]
30	.	O	['N']	[30]
#1600
0	Lithium	B-Drug	['Causes']	[23]
1	is	O	['N']	[1]
2	known	O	['N']	[2]
3	to	O	['N']	[3]
4	cause	O	['N']	[4]
5	acute	O	['N']	[5]
6	renal	O	['N']	[6]
7	failure	O	['N']	[7]
8	and	O	['N']	[8]
9	tubulo	O	['N']	[9]
10	-	O	['N']	[10]
11	interstitial	O	['N']	[11]
12	disease	O	['N']	[12]
13	,	O	['N']	[13]
14	but	O	['N']	[14]
15	the	O	['N']	[15]
16	recently	O	['N']	[16]
17	described	O	['N']	[17]
18	association	O	['N']	[18]
19	with	O	['N']	[19]
20	proteinuria	O	['N']	[20]
21	or	O	['N']	[21]
22	nephrotic	B	['N']	[22]
23	syndrome	I-Adverse_Effect	['N']	[23]
24	is	O	['N']	[24]
25	little	O	['N']	[25]
26	recognized	O	['N']	[26]
27	.	O	['N']	[27]
#1601
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	skin	O	['N']	[23]
24	eruptions	O	['N']	[24]
25	,	O	['N']	[25]
26	cervical	O	['N']	[26]
27	lymphadenopathy	O	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	B	['N']	[31]
32	lymphocytosis	I-Adverse_Effect	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	O	['N']	[40]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	-	['N']	[42]
43	(	O	['N']	[43]
44	SMX	O	['N']	[44]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#1602
0	It	O	['N']	[0]
1	was	O	['N']	[1]
2	hypothesized	O	['N']	[2]
3	that	O	['N']	[3]
4	valproic	O	['N']	[4]
5	acid	O	['N']	[5]
6	may	O	['N']	[6]
7	interfere	O	['N']	[7]
8	with	O	['N']	[8]
9	glucuronidation	O	['N']	[9]
10	of	O	['N']	[10]
11	lamotrigine	B-Drug	['Causes']	[18]
12	,	O	['N']	[12]
13	leading	O	['N']	[13]
14	to	O	['N']	[14]
15	increased	B	['N']	[15]
16	serum	I	['N']	[16]
17	lamotrigine	I	['N']	[17]
18	levels	I-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	or	O	['N']	[20]
21	perhaps	O	['N']	[21]
22	alter	O	['N']	[22]
23	the	O	['N']	[23]
24	drug	O	['N']	[24]
25	's	O	['N']	[25]
26	metabolism	O	['N']	[26]
27	,	O	['N']	[27]
28	resulting	O	['N']	[28]
29	in	O	['N']	[29]
30	accumulation	O	['N']	[30]
31	of	O	['N']	[31]
32	a	O	['N']	[32]
33	toxic	O	['N']	[33]
34	intermediate	O	['N']	[34]
35	metabolite	O	['N']	[35]
36	.	O	['N']	[36]
#1603
0	Hypoxia	O	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	predisposing	O	['N']	[3]
4	factor	O	['N']	[4]
5	for	O	['N']	[5]
6	premature	B	['N']	[6]
7	ductal	I	['N']	[7]
8	closure	I-Adverse_Effect	['N']	[8]
9	and	O	['N']	[9]
10	often	O	['N']	[10]
11	occurs	O	['N']	[11]
12	after	O	['N']	[12]
13	maternal	O	['N']	[13]
14	indomethacin	B-Drug	['Causes']	[8]
15	therapy	O	['N']	[15]
16	.	O	['N']	[16]
#1604
0	A	O	['N']	[0]
1	35-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	nephrotic	O	['N']	[4]
5	man	O	['N']	[5]
6	developed	O	['N']	[6]
7	acute	B	['N']	[7]
8	renal	I	['N']	[8]
9	failure	I-Adverse_Effect	['N']	[9]
10	with	O	['N']	[10]
11	serum	O	['N']	[11]
12	creatinine	O	['N']	[12]
13	to	O	['N']	[13]
14	1543	O	['N']	[14]
15	micromol	O	['N']	[15]
16	/	O	['N']	[16]
17	l	O	['N']	[17]
18	after	O	['N']	[18]
19	a	O	['N']	[19]
20	month	O	['N']	[20]
21	of	O	['N']	[21]
22	therapy	O	['N']	[22]
23	with	O	['N']	[23]
24	enalapril	B-Drug	['Causes']	[9]
25	.	O	['N']	[25]
#1605
0	In	O	['N']	[0]
1	the	O	['N']	[1]
2	second	O	['N']	[2]
3	case	O	['N']	[3]
4	,	O	['N']	[4]
5	five	O	['N']	[5]
6	cardiac	O	['N']	[6]
7	arrests	O	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	ventricular	O	['N']	[10]
11	tachycardia	O	['N']	[11]
12	and	O	['N']	[12]
13	fibrillation	B-Adverse_Effect	['N']	[13]
14	occurred	O	['N']	[14]
15	during	O	['N']	[15]
16	several	O	['N']	[16]
17	hours	O	['N']	[17]
18	after	O	['N']	[18]
19	beginning	O	['N']	[19]
20	a	O	['N']	[20]
21	trial	O	['N']	[21]
22	of	O	['N']	[22]
23	bretylium	B-Drug	['Causes']	[13]
24	maintenance	O	['N']	[24]
25	therapy	O	['N']	[25]
26	for	O	['N']	[26]
27	complex	O	['N']	[27]
28	ventricular	O	['N']	[28]
29	ectopy	O	['N']	[29]
30	.	O	['N']	[30]
#1606
0	The	O	['N']	[0]
1	fetal	O	['N']	[1]
2	valproate	B-Drug	['Causes']	[21]
3	syndrome	O	['N']	[3]
4	(	O	['N']	[4]
5	FVS	O	['N']	[5]
6	)	O	['N']	[6]
7	is	O	['N']	[7]
8	characterized	O	['N']	[8]
9	by	O	['N']	[9]
10	distinctive	O	['N']	[10]
11	facial	O	['N']	[11]
12	appearance	O	['N']	[12]
13	,	O	['N']	[13]
14	major	O	['N']	[14]
15	and	O	['N']	[15]
16	minor	O	['N']	[16]
17	malformations	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	developmental	B	['N']	[20]
21	delay	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#1607
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	observation	O	['N']	[3]
4	that	O	['N']	[4]
5	neurotoxicity	B-Adverse_Effect	['N']	[5]
6	developed	O	['N']	[6]
7	with	O	['N']	[7]
8	a	O	['N']	[8]
9	delay	O	['N']	[9]
10	of	O	['N']	[10]
11	24	O	['N']	[11]
12	to	O	['N']	[12]
13	48	O	['N']	[13]
14	hours	O	['N']	[14]
15	after	O	['N']	[15]
16	acyclovir	B-Drug	['Causes']	[5]
17	peak	O	['N']	[17]
18	serum	O	['N']	[18]
19	concentrations	O	['N']	[19]
20	could	O	['N']	[20]
21	explain	O	['N']	[21]
22	the	O	['N']	[22]
23	wide	O	['N']	[23]
24	range	O	['N']	[24]
25	of	O	['N']	[25]
26	acyclovir	O	['N']	[26]
27	levels	O	['N']	[27]
28	reported	O	['N']	[28]
29	in	O	['N']	[29]
30	similar	O	['N']	[30]
31	cases	O	['N']	[31]
32	.	O	['N']	[32]
#1608
0	Intravenous	O	['N']	[0]
1	verapamil	B-Drug	['Causes']	[7]
2	therapy	O	['N']	[2]
3	in	O	['N']	[3]
4	babies	O	['N']	[4]
5	may	O	['N']	[5]
6	cause	O	['N']	[6]
7	apnea	B-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	hypotension	O	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	bradycardia	O	['N']	[12]
13	;	O	['N']	[13]
14	continued	O	['N']	[14]
15	episodes	O	['N']	[15]
16	of	O	['N']	[16]
17	atrial	O	['N']	[17]
18	flutter	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	child	O	['N']	[21]
22	may	O	['N']	[22]
23	cause	O	['N']	[23]
24	sudden	O	['N']	[24]
25	death	O	['N']	[25]
26	;	O	['N']	[26]
27	quinidine	O	['N']	[27]
28	may	O	['N']	[28]
29	be	O	['N']	[29]
30	related	O	['N']	[30]
31	to	O	['N']	[31]
32	the	O	['N']	[32]
33	death	O	['N']	[33]
34	;	O	['N']	[34]
35	children	O	['N']	[35]
36	with	O	['N']	[36]
37	"	O	['N']	[37]
38	familial	O	['N']	[38]
39	seizure	O	['N']	[39]
40	disorders	O	['N']	[40]
41	"	O	['N']	[41]
42	may	O	['N']	[42]
43	in	O	['N']	[43]
44	fact	O	['N']	[44]
45	have	O	['N']	[45]
46	the	O	['N']	[46]
47	long	O	['N']	[47]
48	QT	O	['N']	[48]
49	interval	O	['N']	[49]
50	syndrome	O	['N']	[50]
51	.	O	['N']	[51]
#1609
0	Fatal	B	['N']	[0]
1	pulmonary	I	['N']	[1]
2	fibrosis	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	BCNU	B-Drug	['Causes']	[2]
6	:	O	['N']	[6]
7	the	O	['N']	[7]
8	relative	O	['N']	[8]
9	role	O	['N']	[9]
10	of	O	['N']	[10]
11	platelet	O	['N']	[11]
12	-	O	['N']	[12]
13	derived	O	['N']	[13]
14	growth	O	['N']	[14]
15	factor	O	['N']	[15]
16	-	O	['N']	[16]
17	B	O	['N']	[17]
18	,	O	['N']	[18]
19	insulin	O	['N']	[19]
20	-	O	['N']	[20]
21	like	O	['N']	[21]
22	growth	O	['N']	[22]
23	factor	O	['N']	[23]
24	I	O	['N']	[24]
25	,	O	['N']	[25]
26	transforming	O	['N']	[26]
27	growth	O	['N']	[27]
28	factor	O	['N']	[28]
29	-	O	['N']	[29]
30	beta1	O	['N']	[30]
31	and	O	['N']	[31]
32	cyclooxygenase-2	O	['N']	[32]
33	.	O	['N']	[33]
#1610
0	Severe	O	['N']	[0]
1	bleomycin	B-Drug	['Causes']	[3]
2	lung	B	['N']	[2]
3	toxicity	I-Adverse_Effect	['N']	[3]
4	:	O	['N']	[4]
5	reversal	O	['N']	[5]
6	with	O	['N']	[6]
7	high	O	['N']	[7]
8	dose	O	['N']	[8]
9	corticosteroids	O	['N']	[9]
10	.	O	['N']	[10]
#1611
0	We	O	['N']	[0]
1	observed	O	['N']	[1]
2	3	O	['N']	[2]
3	diabetic	O	['N']	[3]
4	patients	O	['N']	[4]
5	with	O	['N']	[5]
6	intolerable	O	['N']	[6]
7	dizziness	O	['N']	[7]
8	followed	O	['N']	[8]
9	by	O	['N']	[9]
10	nausea	O	['N']	[10]
11	and	O	['N']	[11]
12	vomiting	B-Adverse_Effect	['N']	[12]
13	immediately	O	['N']	[13]
14	after	O	['N']	[14]
15	an	O	['N']	[15]
16	initial	O	['N']	[16]
17	administration	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	alpha	O	['N']	[20]
21	-	O	['N']	[21]
22	glucosidase	O	['N']	[22]
23	inhibitor	O	['N']	[23]
24	,	O	['N']	[24]
25	voglibose	B-Drug	['Causes']	[12]
26	.	O	['N']	[26]
#1612
0	After	O	['N']	[0]
1	a	O	['N']	[1]
2	second	O	['N']	[2]
3	dose	O	['N']	[3]
4	of	O	['N']	[4]
5	metoclopramide	B-Drug	['Causes']	[20]
6	,	O	['N']	[6]
7	these	O	['N']	[7]
8	symptoms	O	['N']	[8]
9	recurred	O	['N']	[9]
10	and	O	['N']	[10]
11	were	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	confusion	O	['N']	[14]
15	,	O	['N']	[15]
16	agitation	O	['N']	[16]
17	,	O	['N']	[17]
18	fever	O	['N']	[18]
19	,	O	['N']	[19]
20	diaphoresis	B-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	tachypnea	O	['N']	[22]
23	,	O	['N']	[23]
24	tachycardia	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	hypertension	O	['N']	[27]
28	.	O	['N']	[28]
#1613
0	Pneumocystis	B	['N']	[0]
1	carinii	I	['N']	[1]
2	pneumonia	I-Adverse_Effect	['N']	[2]
3	as	O	['N']	[3]
4	a	O	['N']	[4]
5	complication	O	['N']	[5]
6	of	O	['N']	[6]
7	methotrexate	B-Drug	['Causes']	[2]
8	treatment	O	['N']	[8]
9	of	O	['N']	[9]
10	asthma	O	['N']	[10]
11	.	O	['N']	[11]
#1614
0	L	B	['N']	[0]
1	-	I	['N']	[1]
2	asparaginase	I-Drug	['Causes']	[12]
3	-	O	['N']	[3]
4	provoked	O	['N']	[4]
5	seizures	O	['N']	[5]
6	as	O	['N']	[6]
7	singular	O	['N']	[7]
8	expression	O	['N']	[8]
9	of	O	['N']	[9]
10	central	B	['N']	[10]
11	nervous	I	['N']	[11]
12	toxicity	I-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#1615
0	Ticlopidine	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	interstitial	B	['N']	[3]
4	pulmonary	I	['N']	[4]
5	disease	I-Adverse_Effect	['N']	[5]
6	:	O	['N']	[6]
7	a	O	['N']	[7]
8	case	O	['N']	[8]
9	report	O	['N']	[9]
10	.	O	['N']	[10]
#1616
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Extensive	O	['N']	[2]
3	squamous	B	['N']	[3]
4	metaplasia	I-Adverse_Effect	['N']	[4]
5	was	O	['N']	[5]
6	found	O	['N']	[6]
7	in	O	['N']	[7]
8	endometrial	O	['N']	[8]
9	glands	O	['N']	[9]
10	following	O	['N']	[10]
11	progestin	B-Drug	['Causes']	[4]
12	therapy	O	['N']	[12]
13	.	O	['N']	[13]
#1617
0	After	O	['N']	[0]
1	the	O	['N']	[1]
2	addition	O	['N']	[2]
3	of	O	['N']	[3]
4	citalopram	B-Drug	['Causes']	[18]
5	,	O	['N']	[5]
6	a	O	['N']	[6]
7	desmethylclomipramine	O	['N']	[7]
8	plasma	O	['N']	[8]
9	level	O	['N']	[9]
10	increase	O	['N']	[10]
11	and	O	['N']	[11]
12	an	O	['N']	[12]
13	8-hydroacy	B	['N']	[13]
14	-	I	['N']	[14]
15	desmethylclomipramine	I	['N']	[15]
16	plasma	I	['N']	[16]
17	level	I	['N']	[17]
18	decrease	I-Adverse_Effect	['N']	[18]
19	were	O	['N']	[19]
20	observed	O	['N']	[20]
21	.	O	['N']	[21]
#1618
0	Even	O	['N']	[0]
1	after	O	['N']	[1]
2	a	O	['N']	[2]
3	strict	O	['N']	[3]
4	warning	O	['N']	[4]
5	,	O	['N']	[5]
6	he	O	['N']	[6]
7	took	O	['N']	[7]
8	another	O	['N']	[8]
9	quinine	B-Drug	['Causes']	[21]
10	tablet	O	['N']	[10]
11	that	O	['N']	[11]
12	evening	O	['N']	[12]
13	,	O	['N']	[13]
14	which	O	['N']	[14]
15	triggered	O	['N']	[15]
16	his	O	['N']	[16]
17	fifth	O	['N']	[17]
18	episode	O	['N']	[18]
19	of	O	['N']	[19]
20	severe	O	['N']	[20]
21	thrombocytopenia	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	confirmed	O	['N']	[24]
25	the	O	['N']	[25]
26	etiology	O	['N']	[26]
27	of	O	['N']	[27]
28	quinine	O	['N']	[28]
29	-	O	['N']	[29]
30	induced	O	['N']	[30]
31	thrombocytopenia	O	['N']	[31]
32	.	O	['N']	[32]
#1619
0	In	O	['N']	[0]
1	addition	O	['N']	[1]
2	to	O	['N']	[2]
3	its	O	['N']	[3]
4	known	O	['N']	[4]
5	effect	O	['N']	[5]
6	on	O	['N']	[6]
7	gallbladder	O	['N']	[7]
8	stasis	O	['N']	[8]
9	,	O	['N']	[9]
10	octreotide	B-Drug	['Causes']	[14]
11	alters	B	['N']	[11]
12	bile	I	['N']	[12]
13	acid	I	['N']	[13]
14	composition	I-Adverse_Effect	['N']	[14]
15	and	O	['N']	[15]
16	may	O	['N']	[16]
17	thus	O	['N']	[17]
18	hasten	O	['N']	[18]
19	intrahepatic	O	['N']	[19]
20	sludge	O	['N']	[20]
21	and	O	['N']	[21]
22	stone	O	['N']	[22]
23	formation	O	['N']	[23]
24	.	O	['N']	[24]
#1620
0	Subacute	B	['N']	[0]
1	cholestatic	I	['N']	[1]
2	hepatitis	I-Adverse_Effect	['N']	[2]
3	likely	O	['N']	[3]
4	related	O	['N']	[4]
5	to	O	['N']	[5]
6	the	O	['N']	[6]
7	use	O	['N']	[7]
8	of	O	['N']	[8]
9	senna	B-Drug	['Causes']	[2]
10	for	O	['N']	[10]
11	chronic	O	['N']	[11]
12	constipation	O	['N']	[12]
13	.	O	['N']	[13]
#1621
0	These	O	['N']	[0]
1	observations	O	['N']	[1]
2	indicate	O	['N']	[2]
3	that	O	['N']	[3]
4	submassive	O	['N']	[4]
5	hepatic	O	['N']	[5]
6	necrosis	O	['N']	[6]
7	may	O	['N']	[7]
8	result	O	['N']	[8]
9	from	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	propylthiouracil	B-Drug	['Causes']	[28]
13	and	O	['N']	[13]
14	are	O	['N']	[14]
15	consistent	O	['N']	[15]
16	with	O	['N']	[16]
17	the	O	['N']	[17]
18	notion	O	['N']	[18]
19	that	O	['N']	[19]
20	sensitization	O	['N']	[20]
21	mechanisms	O	['N']	[21]
22	may	O	['N']	[22]
23	be	O	['N']	[23]
24	responsible	O	['N']	[24]
25	for	O	['N']	[25]
26	the	O	['N']	[26]
27	hepatic	B	['N']	[27]
28	injury	I-Adverse_Effect	['N']	[28]
29	induced	O	['N']	[29]
30	by	O	['N']	[30]
31	this	O	['N']	[31]
32	drug	O	['N']	[32]
33	.	O	['N']	[33]
#1622
0	Occurrence	O	['N']	[0]
1	of	O	['N']	[1]
2	withdrawal	O	['N']	[2]
3	dyskinesia	B-Adverse_Effect	['N']	[3]
4	indicates	O	['N']	[4]
5	that	O	['N']	[5]
6	the	O	['N']	[6]
7	neuroleptic	O	['N']	[7]
8	effects	O	['N']	[8]
9	of	O	['N']	[9]
10	amoxapine	B-Drug	['Causes']	[3]
11	may	O	['N']	[11]
12	be	O	['N']	[12]
13	clinically	O	['N']	[13]
14	significant	O	['N']	[14]
15	.	O	['N']	[15]
#1623
0	Gynecomastia	O	['N']	[0]
1	developed	O	['N']	[1]
2	in	O	['N']	[2]
3	two	O	['N']	[3]
4	epileptic	O	['N']	[4]
5	patients	O	['N']	[5]
6	some	O	['N']	[6]
7	months	O	['N']	[7]
8	after	O	['N']	[8]
9	the	O	['N']	[9]
10	addition	O	['N']	[10]
11	of	O	['N']	[11]
12	oral	O	['N']	[12]
13	fluoresone	O	['N']	[13]
14	750	B	['N']	[14]
15	mg	I-Dose	['N']	[15]
16	daily	O	['N']	[16]
17	to	O	['N']	[17]
18	the	O	['N']	[18]
19	phenobarbital	O	['N']	[19]
20	and	O	['N']	[20]
21	phenytoin	B-Drug	['Dosage']	[15]
22	already	O	['N']	[22]
23	being	O	['N']	[23]
24	administered	O	['N']	[24]
25	.	O	['N']	[25]
#1624
0	Since	O	['N']	[0]
1	its	O	['N']	[1]
2	FDA	O	['N']	[2]
3	approval	O	['N']	[3]
4	in	O	['N']	[4]
5	2002	O	['N']	[5]
6	,	O	['N']	[6]
7	there	O	['N']	[7]
8	are	O	['N']	[8]
9	no	O	['N']	[9]
10	known	O	['N']	[10]
11	citations	O	['N']	[11]
12	of	O	['N']	[12]
13	ezetimibe	B-Drug	['Causes']	[16]
14	-	O	['N']	[14]
15	induced	O	['N']	[15]
16	pancreatitis	B-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#1625
0	Vortex	B	['N']	[0]
1	keratopathy	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	atovaquone	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#1626
0	After	O	['N']	[0]
1	having	O	['N']	[1]
2	received	O	['N']	[2]
3	gemcitabine	B-Drug	['Causes']	[21]
4	on	O	['N']	[4]
5	day	O	['N']	[5]
6	1	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	second	O	['N']	[9]
10	course	O	['N']	[10]
11	,	O	['N']	[11]
12	the	O	['N']	[12]
13	patient	O	['N']	[13]
14	developed	O	['N']	[14]
15	dry	O	['N']	[15]
16	cough	O	['N']	[16]
17	,	O	['N']	[17]
18	subfebrile	O	['N']	[18]
19	temperatures	O	['N']	[19]
20	and	O	['N']	[20]
21	dyspnea	B-Adverse_Effect	['N']	[21]
22	within	O	['N']	[22]
23	48	O	['N']	[23]
24	h.	O	['N']	[24]
#1627
0	A	O	['N']	[0]
1	47	O	['N']	[1]
2	year	O	['N']	[2]
3	-	O	['N']	[3]
4	old	O	['N']	[4]
5	woman	O	['N']	[5]
6	who	O	['N']	[6]
7	had	O	['N']	[7]
8	a	O	['N']	[8]
9	4-year	O	['N']	[9]
10	history	O	['N']	[10]
11	of	O	['N']	[11]
12	intramuscular	O	['N']	[12]
13	pentazocine	B-Drug	['Causes']	[22]
14	injections	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	lower	O	['N']	[17]
18	extremities	O	['N']	[18]
19	,	O	['N']	[19]
20	developed	O	['N']	[20]
21	gradual	B	['N']	[21]
22	stiffness	I-Adverse_Effect	['N']	[22]
23	and	O	['N']	[23]
24	weakness	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	lower	O	['N']	[27]
28	extremities	O	['N']	[28]
29	.	O	['N']	[29]
#1628
0	We	O	['N']	[0]
1	concluded	O	['N']	[1]
2	that	O	['N']	[2]
3	the	O	['N']	[3]
4	colonic	O	['N']	[4]
5	ulcer	O	['N']	[5]
6	and	O	['N']	[6]
7	the	O	['N']	[7]
8	sigmoidovesical	B	['N']	[8]
9	fistula	I-Adverse_Effect	['N']	[9]
10	had	O	['N']	[10]
11	been	O	['N']	[11]
12	caused	O	['N']	[12]
13	by	O	['N']	[13]
14	the	O	['N']	[14]
15	administration	O	['N']	[15]
16	of	O	['N']	[16]
17	calcium	O	['N']	[17]
18	polystyrene	O	['N']	[18]
19	sulfonate	O	['N']	[19]
20	and	O	['N']	[20]
21	sorbitol	B-Drug	['Causes']	[9]
22	.	O	['N']	[22]
#1629
0	In	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	chronic	O	['N']	[3]
4	heart	O	['N']	[4]
5	failure	O	['N']	[5]
6	,	O	['N']	[6]
7	spironolactone	B-Drug	['Causes']	[21]
8	added	O	['N']	[8]
9	to	O	['N']	[9]
10	conventional	O	['N']	[10]
11	treatment	O	['N']	[11]
12	may	O	['N']	[12]
13	lead	O	['N']	[13]
14	to	O	['N']	[14]
15	serious	B	['N']	[15]
16	and	I	['N']	[16]
17	,	I	['N']	[17]
18	occasionally	I	['N']	[18]
19	,	I	['N']	[19]
20	fatal	I	['N']	[20]
21	hyperkalaemia	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#1630
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	pathogenesis	O	['N']	[3]
4	of	O	['N']	[4]
5	methotrexate	B-Drug	['Causes']	[9]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	papular	B	['N']	[8]
9	eruption	I-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	collagen	O	['N']	[11]
12	vascular	O	['N']	[12]
13	diseases	O	['N']	[13]
14	may	O	['N']	[14]
15	suggest	O	['N']	[15]
16	cutaneous	O	['N']	[16]
17	small	O	['N']	[17]
18	-	O	['N']	[18]
19	vessel	O	['N']	[19]
20	vasculitis	O	['N']	[20]
21	.	O	['N']	[21]
#1631
0	Muscle	O	['N']	[0]
1	biopsy	O	['N']	[1]
2	revealed	O	['N']	[2]
3	variation	O	['N']	[3]
4	in	O	['N']	[4]
5	muscle	O	['N']	[5]
6	fiber	O	['N']	[6]
7	size	O	['N']	[7]
8	and	O	['N']	[8]
9	few	O	['N']	[9]
10	vacuolated	O	['N']	[10]
11	fibers	O	['N']	[11]
12	which	O	['N']	[12]
13	were	O	['N']	[13]
14	features	O	['N']	[14]
15	of	O	['N']	[15]
16	colchicine	B-Drug	['Causes']	[19]
17	-	O	['N']	[17]
18	induced	O	['N']	[18]
19	myopathy	B-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#1632
0	The	O	['N']	[0]
1	renal	O	['N']	[1]
2	consequences	O	['N']	[2]
3	of	O	['N']	[3]
4	indinavir	B-Drug	['Causes']	[7]
5	-	O	['N']	[5]
6	associated	O	['N']	[6]
7	nephrotoxicity	B-Adverse_Effect	['N']	[7]
8	are	O	['N']	[8]
9	uncertain	O	['N']	[9]
10	.	O	['N']	[10]
#1633
0	To	O	['N']	[0]
1	date	O	['N']	[1]
2	,	O	['N']	[2]
3	only	O	['N']	[3]
4	three	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	seizures	B-Adverse_Effect	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	amphotericin	B	['N']	[10]
11	B	I-Drug	['Causes']	[7]
12	have	O	['N']	[12]
13	been	O	['N']	[13]
14	reported	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	literature	O	['N']	[17]
18	,	O	['N']	[18]
19	but	O	['N']	[19]
20	healthcare	O	['N']	[20]
21	providers	O	['N']	[21]
22	should	O	['N']	[22]
23	be	O	['N']	[23]
24	aware	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	potential	O	['N']	[27]
28	for	O	['N']	[28]
29	this	O	['N']	[29]
30	rare	O	['N']	[30]
31	adverse	O	['N']	[31]
32	effect	O	['N']	[32]
33	.	O	['N']	[33]
#1634
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	20-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	female	O	['N']	[9]
10	with	O	['N']	[10]
11	polyarteritis	O	['N']	[11]
12	nodosa	O	['N']	[12]
13	(	O	['N']	[13]
14	PAN	O	['N']	[14]
15	)	O	['N']	[15]
16	who	O	['N']	[16]
17	developed	O	['N']	[17]
18	bilateral	B	['N']	[18]
19	sensorineural	I	['N']	[19]
20	hearing	I	['N']	[20]
21	loss	I-Adverse_Effect	['N']	[21]
22	25	O	['N']	[22]
23	minutes	O	['N']	[23]
24	after	O	['N']	[24]
25	receiving	O	['N']	[25]
26	30	O	['N']	[26]
27	mg	O	['N']	[27]
28	of	O	['N']	[28]
29	intravenous	O	['N']	[29]
30	ketoralac	B-Drug	['Causes']	[21]
31	.	O	['N']	[31]
#1635
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	B-Drug	['Causes']	[25]
20	developed	O	['N']	[20]
21	confusion	O	['N']	[21]
22	,	O	['N']	[22]
23	agitation	O	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	B-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	tremors	O	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	O	['N']	[29]
30	jerks	O	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	O	['N']	[32]
33	gait	O	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	O	['N']	[43]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#1636
0	METHOD	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	describe	O	['N']	[3]
4	two	O	['N']	[4]
5	patients	O	['N']	[5]
6	who	O	['N']	[6]
7	presented	O	['N']	[7]
8	with	O	['N']	[8]
9	diabetic	B	['N']	[9]
10	ketoacidosis	I-Adverse_Effect	['N']	[10]
11	after	O	['N']	[11]
12	treatment	O	['N']	[12]
13	with	O	['N']	[13]
14	quetiapine	B-Drug	['Causes']	[10]
15	and	O	['N']	[15]
16	risperidone	O	['N']	[16]
17	,	O	['N']	[17]
18	respectively	O	['N']	[18]
19	.	O	['N']	[19]
#1637
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	All	O	['N']	[2]
3	doctors	O	['N']	[3]
4	need	O	['N']	[4]
5	to	O	['N']	[5]
6	be	O	['N']	[6]
7	aware	O	['N']	[7]
8	of	O	['N']	[8]
9	the	O	['N']	[9]
10	need	O	['N']	[10]
11	to	O	['N']	[11]
12	review	O	['N']	[12]
13	the	O	['N']	[13]
14	indications	O	['N']	[14]
15	for	O	['N']	[15]
16	gabapentin	B-Drug	['Causes']	[29]
17	use	O	['N']	[17]
18	during	O	['N']	[18]
19	periods	O	['N']	[19]
20	of	O	['N']	[20]
21	acute	O	['N']	[21]
22	illness	O	['N']	[22]
23	,	O	['N']	[23]
24	especially	O	['N']	[24]
25	with	O	['N']	[25]
26	regard	O	['N']	[26]
27	to	O	['N']	[27]
28	renal	B	['N']	[28]
29	impairment	I-Adverse_Effect	['N']	[29]
30	.	O	['N']	[30]
#1638
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	severe	O	['N']	[5]
6	respiratory	B	['N']	[6]
7	failure	I-Adverse_Effect	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	gold	B-Drug	['Causes']	[7]
11	salt	O	['N']	[11]
12	toxicity	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	patient	O	['N']	[15]
16	suffering	O	['N']	[16]
17	from	O	['N']	[17]
18	rheumatoid	O	['N']	[18]
19	arthritis	O	['N']	[19]
20	requiring	O	['N']	[20]
21	mechanical	O	['N']	[21]
22	ventilation	O	['N']	[22]
23	.	O	['N']	[23]
#1639
0	Prothipendylhydrochloride	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	priapism	B-Adverse_Effect	['N']	[3]
4	:	O	['N']	[4]
5	case	O	['N']	[5]
6	report	O	['N']	[6]
7	.	O	['N']	[7]
#1640
0	Generalised	B	['N']	[0]
1	cutaneous	I	['N']	[1]
2	rash	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	ganciclovir	B-Drug	['Causes']	[2]
6	therapy	O	['N']	[6]
7	has	O	['N']	[7]
8	rarely	O	['N']	[8]
9	been	O	['N']	[9]
10	reported	O	['N']	[10]
11	in	O	['N']	[11]
12	literature	O	['N']	[12]
13	.	O	['N']	[13]
#1641
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	acute	O	['N']	[5]
6	generalized	O	['N']	[6]
7	exanthematous	O	['N']	[7]
8	pustulosis	O	['N']	[8]
9	(	O	['N']	[9]
10	AGEP	B-Adverse_Effect	['N']	[10]
11	)	O	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	50-year	O	['N']	[14]
15	-	O	['N']	[15]
16	old	O	['N']	[16]
17	woman	O	['N']	[17]
18	that	O	['N']	[18]
19	was	O	['N']	[19]
20	attributed	O	['N']	[20]
21	to	O	['N']	[21]
22	the	O	['N']	[22]
23	ingestion	O	['N']	[23]
24	of	O	['N']	[24]
25	nimesulide	B-Drug	['Causes']	[10]
26	.	O	['N']	[26]
#1642
0	Diagnosis	O	['N']	[0]
1	:	O	['N']	[1]
2	practolol	B-Drug	['Causes']	[5]
3	induced	O	['N']	[3]
4	sclerosing	B	['N']	[4]
5	peritonitis	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#1643
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	ovarian	O	['N']	[3]
4	cancer	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	received	O	['N']	[7]
8	multiple	O	['N']	[8]
9	courses	O	['N']	[9]
10	of	O	['N']	[10]
11	cisplatin	B-Drug	['Causes']	[45]
12	without	O	['N']	[12]
13	complications	O	['N']	[13]
14	experienced	O	['N']	[14]
15	hypersensitivity	O	['N']	[15]
16	reactions	O	['N']	[16]
17	to	O	['N']	[17]
18	cisplatin	O	['N']	[18]
19	:	O	['N']	[19]
20	one	O	['N']	[20]
21	,	O	['N']	[21]
22	involving	O	['N']	[22]
23	intrahepatic	O	['N']	[23]
24	artery	O	['N']	[24]
25	infusion	O	['N']	[25]
26	,	O	['N']	[26]
27	manifested	O	['N']	[27]
28	general	O	['N']	[28]
29	erythema	O	['N']	[29]
30	,	O	['N']	[30]
31	dyspnea	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	hypotension	O	['N']	[34]
35	;	O	['N']	[35]
36	the	O	['N']	[36]
37	other	O	['N']	[37]
38	,	O	['N']	[38]
39	involving	O	['N']	[39]
40	intravenous	O	['N']	[40]
41	infusion	O	['N']	[41]
42	,	O	['N']	[42]
43	manifested	O	['N']	[43]
44	abdominal	B	['N']	[44]
45	pain	I-Adverse_Effect	['N']	[45]
46	,	O	['N']	[46]
47	general	O	['N']	[47]
48	erythema	O	['N']	[48]
49	,	O	['N']	[49]
50	and	O	['N']	[50]
51	fever	O	['N']	[51]
52	.	O	['N']	[52]
#1644
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	concluded	O	['N']	[2]
3	that	O	['N']	[3]
4	SIADH	B-Adverse_Effect	['N']	[4]
5	is	O	['N']	[5]
6	an	O	['N']	[6]
7	important	O	['N']	[7]
8	side	O	['N']	[8]
9	effect	O	['N']	[9]
10	of	O	['N']	[10]
11	lorcainide	B-Drug	['Causes']	[4]
12	therapy	O	['N']	[12]
13	.	O	['N']	[13]
#1645
0	While	O	['N']	[0]
1	both	O	['N']	[1]
2	amiodarone	B-Drug	['Causes']	[13]
3	and	O	['N']	[3]
4	digoxin	O	['N']	[4]
5	can	O	['N']	[5]
6	cause	O	['N']	[6]
7	permanent	O	['N']	[7]
8	visual	O	['N']	[8]
9	changes	O	['N']	[9]
10	,	O	['N']	[10]
11	the	O	['N']	[11]
12	ocular	B	['N']	[12]
13	effects	I-Adverse_Effect	['N']	[13]
14	are	O	['N']	[14]
15	often	O	['N']	[15]
16	reversible	O	['N']	[16]
17	.	O	['N']	[17]
#1646
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	severe	O	['N']	[5]
6	aplastic	O	['N']	[6]
7	anemia	O	['N']	[7]
8	(	O	['N']	[8]
9	AA	B-Adverse_Effect	['N']	[9]
10	)	O	['N']	[10]
11	that	O	['N']	[11]
12	was	O	['N']	[12]
13	probably	O	['N']	[13]
14	induced	O	['N']	[14]
15	by	O	['N']	[15]
16	lenalidomide	B-Drug	['Causes']	[9]
17	.	O	['N']	[17]
#1647
0	He	O	['N']	[0]
1	had	O	['N']	[1]
2	hypokalemia	B-Adverse_Effect	['N']	[2]
3	(	O	['N']	[3]
4	K	O	['N']	[4]
5	2.3	O	['N']	[5]
6	mmol	O	['N']	[6]
7	/	O	['N']	[7]
8	L	O	['N']	[8]
9	)	O	['N']	[9]
10	induced	O	['N']	[10]
11	by	O	['N']	[11]
12	licorice	B-Drug	['Causes']	[2]
13	and	O	['N']	[13]
14	also	O	['N']	[14]
15	had	O	['N']	[15]
16	received	O	['N']	[16]
17	disopyramide	O	['N']	[17]
18	for	O	['N']	[18]
19	arrhythmia	O	['N']	[19]
20	,	O	['N']	[20]
21	bicalutamide	O	['N']	[21]
22	for	O	['N']	[22]
23	prostate	O	['N']	[23]
24	cancer	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	silodosin	O	['N']	[27]
28	for	O	['N']	[28]
29	prostate	O	['N']	[29]
30	hypertrophy	O	['N']	[30]
31	.	O	['N']	[31]
#1648
0	2-CdA	B-Drug	['Causes']	[2]
1	induces	O	['N']	[1]
2	lymphocytopenia	B-Adverse_Effect	['N']	[2]
3	,	O	['N']	[3]
4	which	O	['N']	[4]
5	may	O	['N']	[5]
6	explain	O	['N']	[6]
7	the	O	['N']	[7]
8	improvement	O	['N']	[8]
9	in	O	['N']	[9]
10	this	O	['N']	[10]
11	patient	O	['N']	[11]
12	's	O	['N']	[12]
13	psoriasis	O	['N']	[13]
14	.	O	['N']	[14]
#1649
0	He	O	['N']	[0]
1	developed	O	['N']	[1]
2	fever	O	['N']	[2]
3	,	O	['N']	[3]
4	nausea	O	['N']	[4]
5	,	O	['N']	[5]
6	diarrhea	B-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	malaise	O	['N']	[9]
10	and	O	['N']	[10]
11	stopped	O	['N']	[11]
12	taking	O	['N']	[12]
13	on	O	['N']	[13]
14	the	O	['N']	[14]
15	third	O	['N']	[15]
16	day	O	['N']	[16]
17	after	O	['N']	[17]
18	commencing	O	['N']	[18]
19	Pentasa	B-Drug	['Causes']	[6]
20	.	O	['N']	[20]
#1650
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	EGE	B-Adverse_Effect	['N']	[5]
6	manifested	O	['N']	[6]
7	as	O	['N']	[7]
8	an	O	['N']	[8]
9	allergy	O	['N']	[9]
10	to	O	['N']	[10]
11	gemfibrozil	B-Drug	['Causes']	[5]
12	.	O	['N']	[12]
#1651
0	Amiodarone	B-Drug	['Causes']	[22]
1	is	O	['N']	[1]
2	well	O	['N']	[2]
3	recognized	O	['N']	[3]
4	as	O	['N']	[4]
5	an	O	['N']	[5]
6	anti	O	['N']	[6]
7	-	O	['N']	[7]
8	arrhythmic	O	['N']	[8]
9	drug	O	['N']	[9]
10	containing	O	['N']	[10]
11	a	O	['N']	[11]
12	high	O	['N']	[12]
13	dose	O	['N']	[13]
14	of	O	['N']	[14]
15	iodine	O	['N']	[15]
16	with	O	['N']	[16]
17	considerable	O	['N']	[17]
18	potential	O	['N']	[18]
19	to	O	['N']	[19]
20	cause	O	['N']	[20]
21	thyroid	B	['N']	[21]
22	dysfunction	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#1652
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	case	O	['N']	[3]
4	report	O	['N']	[4]
5	showed	O	['N']	[5]
6	that	O	['N']	[6]
7	the	O	['N']	[7]
8	clinical	O	['N']	[8]
9	appearance	O	['N']	[9]
10	of	O	['N']	[10]
11	Hashimoto	B	['N']	[11]
12	's	I	['N']	[12]
13	disease	I-Adverse_Effect	['N']	[13]
14	after	O	['N']	[14]
15	IFN	B	['N']	[15]
16	-	I	['N']	[16]
17	alpha	I-Drug	['Causes']	[13]
18	therapy	O	['N']	[18]
19	for	O	['N']	[19]
20	chronic	O	['N']	[20]
21	C	O	['N']	[21]
22	hepatitis	O	['N']	[22]
23	in	O	['N']	[23]
24	our	O	['N']	[24]
25	patient	O	['N']	[25]
26	was	O	['N']	[26]
27	associated	O	['N']	[27]
28	with	O	['N']	[28]
29	a	O	['N']	[29]
30	specific	O	['N']	[30]
31	genetic	O	['N']	[31]
32	predisposition	O	['N']	[32]
33	(	O	['N']	[33]
34	DR5	O	['N']	[34]
35	)	O	['N']	[35]
36	for	O	['N']	[36]
37	this	O	['N']	[37]
38	pathology	O	['N']	[38]
39	.	O	['N']	[39]
#1653
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	41	O	['N']	[3]
4	yr	O	['N']	[4]
5	old	O	['N']	[5]
6	leprosy	O	['N']	[6]
7	patient	O	['N']	[7]
8	treated	O	['N']	[8]
9	for	O	['N']	[9]
10	10	O	['N']	[10]
11	yrs	O	['N']	[11]
12	with	O	['N']	[12]
13	clofazimine	B-Drug	['Causes']	[20]
14	who	O	['N']	[14]
15	underwent	O	['N']	[15]
16	laparotomy	O	['N']	[16]
17	for	O	['N']	[17]
18	severe	O	['N']	[18]
19	abdominal	B	['N']	[19]
20	pain	I-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#1654
0	Physicians	O	['N']	[0]
1	who	O	['N']	[1]
2	use	O	['N']	[2]
3	sulfasalazine	B-Drug	['Causes']	[22]
4	to	O	['N']	[4]
5	treat	O	['N']	[5]
6	patients	O	['N']	[6]
7	with	O	['N']	[7]
8	inflammatory	O	['N']	[8]
9	bowel	O	['N']	[9]
10	disease	O	['N']	[10]
11	should	O	['N']	[11]
12	be	O	['N']	[12]
13	aware	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	signs	O	['N']	[16]
17	of	O	['N']	[17]
18	sulfasalazine	O	['N']	[18]
19	-	O	['N']	[19]
20	induced	O	['N']	[20]
21	lupus	B	['N']	[21]
22	syndrome	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#1655
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	cutaneous	B	['N']	[7]
8	KS	I	['N']	[8]
9	lesions	I-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	patient	O	['N']	[12]
13	affected	O	['N']	[13]
14	by	O	['N']	[14]
15	CML	O	['N']	[15]
16	treated	O	['N']	[16]
17	with	O	['N']	[17]
18	imatinib	B-Drug	['Causes']	[9]
19	.	O	['N']	[19]
#1656
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	possible	O	['N']	[7]
8	association	O	['N']	[8]
9	between	O	['N']	[9]
10	an	O	['N']	[10]
11	acute	B	['N']	[11]
12	cardiovascular	I	['N']	[12]
13	event	I-Adverse_Effect	['N']	[13]
14	and	O	['N']	[14]
15	venlafaxine	B-Drug	['Causes']	[13]
16	.	O	['N']	[16]
#1657
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	man	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	an	O	['N']	[9]
10	EGFR	O	['N']	[10]
11	-	O	['N']	[11]
12	inhibitor	O	['N']	[12]
13	(	O	['N']	[13]
14	erlotinib	B-Drug	['Causes']	[24]
15	)	O	['N']	[15]
16	for	O	['N']	[16]
17	a	O	['N']	[17]
18	cell	O	['N']	[18]
19	lung	O	['N']	[19]
20	cancer	O	['N']	[20]
21	who	O	['N']	[21]
22	developed	O	['N']	[22]
23	skin	B	['N']	[23]
24	manifestations	I-Adverse_Effect	['N']	[24]
25	localized	O	['N']	[25]
26	in	O	['N']	[26]
27	an	O	['N']	[27]
28	uncommon	O	['N']	[28]
29	area	O	['N']	[29]
30	and	O	['N']	[30]
31	with	O	['N']	[31]
32	an	O	['N']	[32]
33	atypical	O	['N']	[33]
34	evolution	O	['N']	[34]
35	.	O	['N']	[35]
#1658
0	Isoniazid	B-Drug	['Causes']	[6]
1	associated	O	['N']	[1]
2	,	O	['N']	[2]
3	painful	O	['N']	[3]
4	,	O	['N']	[4]
5	bilateral	B	['N']	[5]
6	gynaecomastia	I-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#1659
0	Severe	B	['N']	[0]
1	osteomalacia	I-Adverse_Effect	['N']	[1]
2	was	O	['N']	[2]
3	present	O	['N']	[3]
4	in	O	['N']	[4]
5	two	O	['N']	[5]
6	epileptic	O	['N']	[6]
7	patients	O	['N']	[7]
8	who	O	['N']	[8]
9	were	O	['N']	[9]
10	under	O	['N']	[10]
11	long	O	['N']	[11]
12	-	O	['N']	[12]
13	term	O	['N']	[13]
14	treatment	O	['N']	[14]
15	with	O	['N']	[15]
16	congeners	O	['N']	[16]
17	of	O	['N']	[17]
18	phenytoin	O	['N']	[18]
19	,	O	['N']	[19]
20	phenobarbital	B-Drug	['Causes']	[1]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	acetazolamide	O	['N']	[23]
24	.	O	['N']	[24]
#1660
0	Sixteen	O	['N']	[0]
1	hours	O	['N']	[1]
2	after	O	['N']	[2]
3	the	O	['N']	[3]
4	first	O	['N']	[4]
5	administration	O	['N']	[5]
6	of	O	['N']	[6]
7	IFN	B-Drug	['Causes']	[18]
8	,	O	['N']	[8]
9	IFN	O	['N']	[9]
10	was	O	['N']	[10]
11	suspended	O	['N']	[11]
12	by	O	['N']	[12]
13	the	O	['N']	[13]
14	symptoms	O	['N']	[14]
15	of	O	['N']	[15]
16	congestive	B	['N']	[16]
17	heart	I	['N']	[17]
18	failure	I-Adverse_Effect	['N']	[18]
19	(	O	['N']	[19]
20	CHF	O	['N']	[20]
21	)	O	['N']	[21]
22	.	O	['N']	[22]
#1661
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	the	O	['N']	[2]
3	occurrence	O	['N']	[3]
4	and	O	['N']	[4]
5	management	O	['N']	[5]
6	of	O	['N']	[6]
7	akathisia	B-Adverse_Effect	['N']	[7]
8	induced	O	['N']	[8]
9	by	O	['N']	[9]
10	fluvoxamine	B-Drug	['Causes']	[7]
11	have	O	['N']	[11]
12	not	O	['N']	[12]
13	been	O	['N']	[13]
14	described	O	['N']	[14]
15	.	O	['N']	[15]
#1662
0	Nephrotic	B	['N']	[0]
1	syndrome	I-Adverse_Effect	['N']	[1]
2	related	O	['N']	[2]
3	to	O	['N']	[3]
4	systemic	O	['N']	[4]
5	lupus	O	['N']	[5]
6	erythematosus	O	['N']	[6]
7	after	O	['N']	[7]
8	griseofulvin	B-Drug	['Causes']	[1]
9	therapy	O	['N']	[9]
10	.	O	['N']	[10]
#1663
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	ovarian	O	['N']	[3]
4	cancer	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	received	O	['N']	[7]
8	multiple	O	['N']	[8]
9	courses	O	['N']	[9]
10	of	O	['N']	[10]
11	cisplatin	B-Drug	['Causes']	[29]
12	without	O	['N']	[12]
13	complications	O	['N']	[13]
14	experienced	O	['N']	[14]
15	hypersensitivity	O	['N']	[15]
16	reactions	O	['N']	[16]
17	to	O	['N']	[17]
18	cisplatin	O	['N']	[18]
19	:	O	['N']	[19]
20	one	O	['N']	[20]
21	,	O	['N']	[21]
22	involving	O	['N']	[22]
23	intrahepatic	O	['N']	[23]
24	artery	O	['N']	[24]
25	infusion	O	['N']	[25]
26	,	O	['N']	[26]
27	manifested	O	['N']	[27]
28	general	B	['N']	[28]
29	erythema	I-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	dyspnea	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	hypotension	O	['N']	[34]
35	;	O	['N']	[35]
36	the	O	['N']	[36]
37	other	O	['N']	[37]
38	,	O	['N']	[38]
39	involving	O	['N']	[39]
40	intravenous	O	['N']	[40]
41	infusion	O	['N']	[41]
42	,	O	['N']	[42]
43	manifested	O	['N']	[43]
44	abdominal	O	['N']	[44]
45	pain	O	['N']	[45]
46	,	O	['N']	[46]
47	general	O	['N']	[47]
48	erythema	O	['N']	[48]
49	,	O	['N']	[49]
50	and	O	['N']	[50]
51	fever	O	['N']	[51]
52	.	O	['N']	[52]
#1664
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	hoped	O	['N']	[2]
3	that	O	['N']	[3]
4	this	O	['N']	[4]
5	case	O	['N']	[5]
6	report	O	['N']	[6]
7	creates	O	['N']	[7]
8	awareness	O	['N']	[8]
9	that	O	['N']	[9]
10	ofloxacin	B-Drug	['Causes']	[15]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	toxic	B	['N']	[13]
14	epidermal	I	['N']	[14]
15	necrolysis	I-Adverse_Effect	['N']	[15]
16	is	O	['N']	[16]
17	possible	O	['N']	[17]
18	.	O	['N']	[18]
#1665
0	Thirty	O	['N']	[0]
1	-	O	['N']	[1]
2	six	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	AL	O	['N']	[5]
6	received	O	['N']	[6]
7	,	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	three	O	['N']	[10]
11	-	O	['N']	[11]
12	month	O	['N']	[12]
13	period	O	['N']	[13]
14	,	O	['N']	[14]
15	51	O	['N']	[15]
16	cycles	O	['N']	[16]
17	of	O	['N']	[17]
18	combined	O	['N']	[18]
19	chemotherapy	O	['N']	[19]
20	which	O	['N']	[20]
21	included	O	['N']	[21]
22	,	O	['N']	[22]
23	in	O	['N']	[23]
24	all	O	['N']	[24]
25	of	O	['N']	[25]
26	them	O	['N']	[26]
27	,	O	['N']	[27]
28	cytosine	O	['N']	[28]
29	arabinoside	O	['N']	[29]
30	(	O	['N']	[30]
31	ARA	B	['N']	[31]
32	-	I	['N']	[32]
33	C	I-Drug	['Causes']	[55]
34	)	O	['N']	[34]
35	;	O	['N']	[35]
36	among	O	['N']	[36]
37	them	O	['N']	[37]
38	,	O	['N']	[38]
39	along	O	['N']	[39]
40	with	O	['N']	[40]
41	myelosuppression	O	['N']	[41]
42	,	O	['N']	[42]
43	five	O	['N']	[43]
44	experienced	O	['N']	[44]
45	fever	O	['N']	[45]
46	,	O	['N']	[46]
47	infectious	O	['N']	[47]
48	complications	O	['N']	[48]
49	,	O	['N']	[49]
50	gastrointestinal	O	['N']	[50]
51	tract	O	['N']	[51]
52	symptoms	O	['N']	[52]
53	and	O	['N']	[53]
54	severe	B	['N']	[54]
55	myalgias	I-Adverse_Effect	['N']	[55]
56	.	O	['N']	[56]
#1666
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	concerns	O	['N']	[2]
3	the	O	['N']	[3]
4	sudden	B	['N']	[4]
5	death	I-Adverse_Effect	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	29-year	O	['N']	[8]
9	-	O	['N']	[9]
10	old	O	['N']	[10]
11	male	O	['N']	[11]
12	during	O	['N']	[12]
13	clozapine	B-Drug	['Causes']	[5]
14	therapy	O	['N']	[14]
15	started	O	['N']	[15]
16	2	O	['N']	[16]
17	weeks	O	['N']	[17]
18	before	O	['N']	[18]
19	.	O	['N']	[19]
#1667
0	Cardiac	B	['N']	[0]
1	hypersensitivity	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	myopericarditis	O	['N']	[3]
4	have	O	['N']	[4]
5	been	O	['N']	[5]
6	reported	O	['N']	[6]
7	during	O	['N']	[7]
8	long	O	['N']	[8]
9	-	O	['N']	[9]
10	term	O	['N']	[10]
11	treatment	O	['N']	[11]
12	with	O	['N']	[12]
13	mesalazine	B-Drug	['Causes']	[1]
14	.	O	['N']	[14]
#1668
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Ovarian	B	['N']	[2]
3	cancer	I-Adverse_Effect	['N']	[3]
4	arising	O	['N']	[4]
5	from	O	['N']	[5]
6	an	O	['N']	[6]
7	endometriotic	O	['N']	[7]
8	cyst	O	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	postmenopausal	O	['N']	[11]
12	woman	O	['N']	[12]
13	under	O	['N']	[13]
14	tamoxifen	B-Drug	['Causes']	[3]
15	therapy	O	['N']	[15]
16	is	O	['N']	[16]
17	rare	O	['N']	[17]
18	.	O	['N']	[18]
#1669
0	After	O	['N']	[0]
1	taking	O	['N']	[1]
2	cholestyramine	B	['N']	[2]
3	II	I-Drug	['Causes']	[15]
4	sachets	O	['N']	[4]
5	twice	O	['N']	[5]
6	daily	O	['N']	[6]
7	for	O	['N']	[7]
8	two	O	['N']	[8]
9	months	O	['N']	[9]
10	she	O	['N']	[10]
11	presented	O	['N']	[11]
12	with	O	['N']	[12]
13	lethargy	O	['N']	[13]
14	,	O	['N']	[14]
15	confusion	B-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	drowsiness	O	['N']	[17]
18	.	O	['N']	[18]
#1670
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	rheumatoid	O	['N']	[8]
9	arthritis	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	low	B	['N']	[12]
13	-	I	['N']	[13]
14	dose	I-Dose	['N']	[14]
15	methotrexate	B-Drug	['Dosage']	[14]
16	(	O	['N']	[16]
17	15	O	['N']	[17]
18	mg	O	['N']	[18]
19	/	O	['N']	[19]
20	week	O	['N']	[20]
21	)	O	['N']	[21]
22	who	O	['N']	[22]
23	developed	O	['N']	[23]
24	infection	O	['N']	[24]
25	with	O	['N']	[25]
26	both	O	['N']	[26]
27	M.	O	['N']	[27]
28	tuberculosis	O	['N']	[28]
29	and	O	['N']	[29]
30	M.	O	['N']	[30]
31	chelonae	O	['N']	[31]
32	after	O	['N']	[32]
33	the	O	['N']	[33]
34	revision	O	['N']	[34]
35	of	O	['N']	[35]
36	a	O	['N']	[36]
37	prosthetic	O	['N']	[37]
38	hip	O	['N']	[38]
39	.	O	['N']	[39]
#1671
0	In	O	['N']	[0]
1	a	O	['N']	[1]
2	female	O	['N']	[2]
3	with	O	['N']	[3]
4	acute	O	['N']	[4]
5	lymphoblastic	O	['N']	[5]
6	leukemia	O	['N']	[6]
7	,	O	['N']	[7]
8	inadvertent	O	['N']	[8]
9	doxorubicin	B-Drug	['Causes']	[20]
10	administration	O	['N']	[10]
11	intrathecally	O	['N']	[11]
12	caused	O	['N']	[12]
13	severe	O	['N']	[13]
14	,	O	['N']	[14]
15	life	O	['N']	[15]
16	-	O	['N']	[16]
17	threatening	O	['N']	[17]
18	,	O	['N']	[18]
19	acute	B	['N']	[19]
20	encephalopathy	I-Adverse_Effect	['N']	[20]
21	with	O	['N']	[21]
22	high	O	['N']	[22]
23	-	O	['N']	[23]
24	pressure	O	['N']	[24]
25	hydrocephalus	O	['N']	[25]
26	.	O	['N']	[26]
#1672
0	Acute	O	['N']	[0]
1	myeloid	O	['N']	[1]
2	leukemia	O	['N']	[2]
3	and	O	['N']	[3]
4	lung	B	['N']	[4]
5	cancer	I-Adverse_Effect	['N']	[5]
6	occurring	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	chronic	O	['N']	[9]
10	lymphocytic	O	['N']	[10]
11	leukemia	O	['N']	[11]
12	patient	O	['N']	[12]
13	treated	O	['N']	[13]
14	with	O	['N']	[14]
15	fludarabine	B-Drug	['Causes']	[5]
16	and	O	['N']	[16]
17	autologous	O	['N']	[17]
18	peripheral	O	['N']	[18]
19	blood	O	['N']	[19]
20	stem	O	['N']	[20]
21	-	O	['N']	[21]
22	cell	O	['N']	[22]
23	transplantation	O	['N']	[23]
24	.	O	['N']	[24]
#1673
0	Suxamethonium	B-Drug	['Causes']	[1]
1	apnoea	B-Adverse_Effect	['N']	[1]
2	terminated	O	['N']	[2]
3	with	O	['N']	[3]
4	commercial	O	['N']	[4]
5	serumcholinesterase	O	['N']	[5]
6	.	O	['N']	[6]
#1674
0	Four	O	['N']	[0]
1	weeks	O	['N']	[1]
2	earlier	O	['N']	[2]
3	she	O	['N']	[3]
4	had	O	['N']	[4]
5	developed	O	['N']	[5]
6	hepatopathy	B-Adverse_Effect	['N']	[6]
7	during	O	['N']	[7]
8	a	O	['N']	[8]
9	regimen	O	['N']	[9]
10	of	O	['N']	[10]
11	carbamazepine	O	['N']	[11]
12	,	O	['N']	[12]
13	lynestrenol	O	['N']	[13]
14	and	O	['N']	[14]
15	sodium	B	['N']	[15]
16	valproate	I-Drug	['Causes']	[6]
17	.	O	['N']	[17]
#1675
0	Antithyroid	O	['N']	[0]
1	treatment	O	['N']	[1]
2	with	O	['N']	[2]
3	propylthiouracil	B-Drug	['Causes']	[11]
4	(	O	['N']	[4]
5	PTU	O	['N']	[5]
6	)	O	['N']	[6]
7	resulted	O	['N']	[7]
8	in	O	['N']	[8]
9	elevated	B	['N']	[9]
10	hepatic	I	['N']	[10]
11	enzymes	I-Adverse_Effect	['N']	[11]
12	and	O	['N']	[12]
13	after	O	['N']	[13]
14	the	O	['N']	[14]
15	12th	O	['N']	[15]
16	week	O	['N']	[16]
17	of	O	['N']	[17]
18	pregnancy	O	['N']	[18]
19	treatment	O	['N']	[19]
20	was	O	['N']	[20]
21	changed	O	['N']	[21]
22	to	O	['N']	[22]
23	carbimazole	O	['N']	[23]
24	(	O	['N']	[24]
25	CBZ	O	['N']	[25]
26	)	O	['N']	[26]
27	.	O	['N']	[27]
#1676
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	asymptomatic	O	['N']	[7]
8	bronchial	O	['N']	[8]
9	asthma	O	['N']	[9]
10	and	O	['N']	[10]
11	hypertension	O	['N']	[11]
12	who	O	['N']	[12]
13	developed	O	['N']	[13]
14	an	O	['N']	[14]
15	acute	B	['N']	[15]
16	asthma	I-Adverse_Effect	['N']	[16]
17	attack	O	['N']	[17]
18	after	O	['N']	[18]
19	receiving	O	['N']	[19]
20	sustained	O	['N']	[20]
21	-	O	['N']	[21]
22	release	O	['N']	[22]
23	verapamil	B-Drug	['Causes']	[16]
24	.	O	['N']	[24]
#1677
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	three	O	['N']	[3]
4	cases	O	['N']	[4]
5	wherein	O	['N']	[5]
6	treatment	O	['N']	[6]
7	of	O	['N']	[7]
8	dexmedetomidine	B-Drug	['Causes']	[11]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	bradycardia	B-Adverse_Effect	['N']	[11]
12	with	O	['N']	[12]
13	i.v	O	['N']	[13]
14	.	O	['N']	[14]
15	glycopyrrolate	O	['N']	[15]
16	(	O	['N']	[16]
17	5.0	O	['N']	[17]
18	microg	O	['N']	[18]
19	/	O	['N']	[19]
20	kg	O	['N']	[20]
21	)	O	['N']	[21]
22	not	O	['N']	[22]
23	only	O	['N']	[23]
24	resulting	O	['N']	[24]
25	in	O	['N']	[25]
26	resolution	O	['N']	[26]
27	of	O	['N']	[27]
28	bradycardia	O	['N']	[28]
29	but	O	['N']	[29]
30	also	O	['N']	[30]
31	resulting	O	['N']	[31]
32	in	O	['N']	[32]
33	an	O	['N']	[33]
34	exaggerated	O	['N']	[34]
35	increase	O	['N']	[35]
36	of	O	['N']	[36]
37	arterial	O	['N']	[37]
38	blood	O	['N']	[38]
39	pressure	O	['N']	[39]
40	.	O	['N']	[40]
#1678
0	Flare	O	['N']	[0]
1	of	O	['N']	[1]
2	Kaposi	O	['N']	[2]
3	's	O	['N']	[3]
4	sarcoma	O	['N']	[4]
5	(	O	['N']	[5]
6	KS	B-Adverse_Effect	['N']	[6]
7	)	O	['N']	[7]
8	is	O	['N']	[8]
9	well	O	['N']	[9]
10	described	O	['N']	[10]
11	in	O	['N']	[11]
12	immunosuppressed	O	['N']	[12]
13	patients	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	corticosteroids	O	['N']	[16]
17	and	O	['N']	[17]
18	rituximab	B-Drug	['Causes']	[6]
19	,	O	['N']	[19]
20	but	O	['N']	[20]
21	has	O	['N']	[21]
22	not	O	['N']	[22]
23	yet	O	['N']	[23]
24	been	O	['N']	[24]
25	reported	O	['N']	[25]
26	during	O	['N']	[26]
27	treatment	O	['N']	[27]
28	with	O	['N']	[28]
29	imatinib	O	['N']	[29]
30	.	O	['N']	[30]
#1679
0	Nineteen	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	unusual	O	['N']	[3]
4	enhanced	O	['N']	[4]
5	vincristine	O	['N']	[5]
6	neurotoxicity	B-Adverse_Effect	['N']	[6]
7	related	O	['N']	[7]
8	to	O	['N']	[8]
9	itraconazole	B-Drug	['Causes']	[6]
10	have	O	['N']	[10]
11	been	O	['N']	[11]
12	reported	O	['N']	[12]
13	in	O	['N']	[13]
14	children	O	['N']	[14]
15	.	O	['N']	[15]
#1680
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	46-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	African	O	['N']	[6]
7	-	O	['N']	[7]
8	American	O	['N']	[8]
9	man	O	['N']	[9]
10	with	O	['N']	[10]
11	AIDS	O	['N']	[11]
12	who	O	['N']	[12]
13	was	O	['N']	[13]
14	admitted	O	['N']	[14]
15	on	O	['N']	[15]
16	two	O	['N']	[16]
17	different	O	['N']	[17]
18	occasions	O	['N']	[18]
19	within	O	['N']	[19]
20	three	O	['N']	[20]
21	weeks	O	['N']	[21]
22	for	O	['N']	[22]
23	signs	O	['N']	[23]
24	and	O	['N']	[24]
25	symptoms	O	['N']	[25]
26	of	O	['N']	[26]
27	meningitis	B-Adverse_Effect	['N']	[27]
28	after	O	['N']	[28]
29	using	O	['N']	[29]
30	trimethoprim	O	['N']	[30]
31	/	O	['N']	[31]
32	sulfamethoxazole	B-Drug	['Causes']	[27]
33	(	O	['N']	[33]
34	TMP	O	['N']	[34]
35	/	O	['N']	[35]
36	SMX	O	['N']	[36]
37	)	O	['N']	[37]
38	.	O	['N']	[38]
#1681
0	A	O	['N']	[0]
1	58-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	rheumatoid	O	['N']	[6]
7	arthritis	O	['N']	[7]
8	(	O	['N']	[8]
9	RA	O	['N']	[9]
10	)	O	['N']	[10]
11	developed	O	['N']	[11]
12	fever	O	['N']	[12]
13	,	O	['N']	[13]
14	skin	B	['N']	[14]
15	eruptions	I-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	leukocytopenia	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	thrombocytopenia	O	['N']	[20]
21	,	O	['N']	[21]
22	3	O	['N']	[22]
23	weeks	O	['N']	[23]
24	after	O	['N']	[24]
25	treatment	O	['N']	[25]
26	with	O	['N']	[26]
27	sulfasalazine	B-Drug	['Causes']	[15]
28	.	O	['N']	[28]
#1682
0	A	O	['N']	[0]
1	43-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	white	O	['N']	[4]
5	man	O	['N']	[5]
6	developed	O	['N']	[6]
7	a	O	['N']	[7]
8	shallow	O	['N']	[8]
9	erosion	B	['N']	[9]
10	of	I	['N']	[10]
11	a	I	['N']	[11]
12	psoriatic	I	['N']	[12]
13	plaque	I-Adverse_Effect	['N']	[13]
14	after	O	['N']	[14]
15	chronic	O	['N']	[15]
16	administration	O	['N']	[16]
17	of	O	['N']	[17]
18	methotrexate	B-Drug	['Causes']	[13]
19	.	O	['N']	[19]
#1683
0	All	B	['N']	[0]
1	-	I	['N']	[1]
2	trans	I	['N']	[2]
3	retinoic	I	['N']	[3]
4	acid	I-Drug	['Causes']	[8]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	focal	B	['N']	[7]
8	myositis	I-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	synovitis	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	mononeuritis	O	['N']	[13]
14	.	O	['N']	[14]
#1684
0	Accelerated	B	['N']	[0]
1	nodulosis	I-Adverse_Effect	['N']	[1]
2	during	O	['N']	[2]
3	methotrexate	B-Drug	['Causes']	[1]
4	therapy	O	['N']	[4]
5	for	O	['N']	[5]
6	juvenile	O	['N']	[6]
7	rheumatoid	O	['N']	[7]
8	arthritis	O	['N']	[8]
9	.	O	['N']	[9]
#1685
0	Atypical	O	['N']	[0]
1	endometriosis	O	['N']	[1]
2	may	O	['N']	[2]
3	act	O	['N']	[3]
4	as	O	['N']	[4]
5	a	O	['N']	[5]
6	precancerous	O	['N']	[6]
7	lesion	O	['N']	[7]
8	in	O	['N']	[8]
9	the	O	['N']	[9]
10	process	O	['N']	[10]
11	of	O	['N']	[11]
12	tamoxifen	B-Drug	['Causes']	[18]
13	-	O	['N']	[13]
14	induced	O	['N']	[14]
15	malignant	B	['N']	[15]
16	transformation	I	['N']	[16]
17	of	I	['N']	[17]
18	endometriosis	I-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#1686
0	The	O	['N']	[0]
1	dermatology	O	['N']	[1]
2	literature	O	['N']	[2]
3	heretofore	O	['N']	[3]
4	has	O	['N']	[4]
5	not	O	['N']	[5]
6	noted	O	['N']	[6]
7	that	O	['N']	[7]
8	anemia	B-Adverse_Effect	['N']	[8]
9	is	O	['N']	[9]
10	a	O	['N']	[10]
11	side	O	['N']	[11]
12	effect	O	['N']	[12]
13	of	O	['N']	[13]
14	patients	O	['N']	[14]
15	taking	O	['N']	[15]
16	MMF	B-Drug	['Causes']	[8]
17	to	O	['N']	[17]
18	treat	O	['N']	[18]
19	pemphigus	O	['N']	[19]
20	.	O	['N']	[20]
#1687
0	Severe	B	['N']	[0]
1	diffuse	I	['N']	[1]
2	interstitial	I	['N']	[2]
3	pneumonitis	I-Adverse_Effect	['N']	[3]
4	induced	O	['N']	[4]
5	by	O	['N']	[5]
6	carmustine	B-Drug	['Causes']	[3]
7	(	O	['N']	[7]
8	BCNU	O	['N']	[8]
9	)	O	['N']	[9]
10	.	O	['N']	[10]
#1688
0	Recurrent	O	['N']	[0]
1	hypotension	O	['N']	[1]
2	immediately	O	['N']	[2]
3	after	O	['N']	[3]
4	seizures	B-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	nortriptyline	B-Drug	['Causes']	[4]
7	overdose	O	['N']	[7]
8	.	O	['N']	[8]
#1689
0	The	O	['N']	[0]
1	clinical	O	['N']	[1]
2	course	O	['N']	[2]
3	suggested	O	['N']	[3]
4	that	O	['N']	[4]
5	recombinant	B	['N']	[5]
6	alpha-2b	I	['N']	[6]
7	peginterferon	I-Drug	['Causes']	[14]
8	plus	O	['N']	[8]
9	ribavirin	O	['N']	[9]
10	provoked	O	['N']	[10]
11	type	B	['N']	[11]
12	1	I	['N']	[12]
13	diabetes	I	['N']	[13]
14	mellitus	I-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	therefore	O	['N']	[16]
17	,	O	['N']	[17]
18	in	O	['N']	[18]
19	patients	O	['N']	[19]
20	who	O	['N']	[20]
21	are	O	['N']	[21]
22	candidates	O	['N']	[22]
23	for	O	['N']	[23]
24	interferon	O	['N']	[24]
25	therapy	O	['N']	[25]
26	the	O	['N']	[26]
27	presence	O	['N']	[27]
28	of	O	['N']	[28]
29	pancreatic	O	['N']	[29]
30	autoantibodies	O	['N']	[30]
31	and	O	['N']	[31]
32	the	O	['N']	[32]
33	fasting	O	['N']	[33]
34	plasma	O	['N']	[34]
35	glucose	O	['N']	[35]
36	level	O	['N']	[36]
37	should	O	['N']	[37]
38	be	O	['N']	[38]
39	investigated	O	['N']	[39]
40	before	O	['N']	[40]
41	and	O	['N']	[41]
42	during	O	['N']	[42]
43	treatment	O	['N']	[43]
44	.	O	['N']	[44]
#1690
0	Severe	B	['N']	[0]
1	akathisia	I-Adverse_Effect	['N']	[1]
2	during	O	['N']	[2]
3	olanzapine	B-Drug	['Causes']	[1]
4	treatment	O	['N']	[4]
5	of	O	['N']	[5]
6	acute	O	['N']	[6]
7	schizophrenia	O	['N']	[7]
8	.	O	['N']	[8]
#1691
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	baclofen	B-Drug	['Causes']	[7]
6	withdrawal	B	['N']	[6]
7	syndrome	I-Adverse_Effect	['N']	[7]
8	resulting	O	['N']	[8]
9	from	O	['N']	[9]
10	oral	O	['N']	[10]
11	baclofen	O	['N']	[11]
12	underdosing	O	['N']	[12]
13	.	O	['N']	[13]
#1692
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	piloerection	B-Adverse_Effect	['N']	[3]
4	observed	O	['N']	[4]
5	after	O	['N']	[5]
6	the	O	['N']	[6]
7	replacement	O	['N']	[7]
8	of	O	['N']	[8]
9	fluvoxamine	B-Drug	['Causes']	[3]
10	with	O	['N']	[10]
11	milnacipran	O	['N']	[11]
12	in	O	['N']	[12]
13	this	O	['N']	[13]
14	patient	O	['N']	[14]
15	appears	O	['N']	[15]
16	to	O	['N']	[16]
17	have	O	['N']	[17]
18	been	O	['N']	[18]
19	due	O	['N']	[19]
20	to	O	['N']	[20]
21	an	O	['N']	[21]
22	increase	O	['N']	[22]
23	in	O	['N']	[23]
24	the	O	['N']	[24]
25	alpha(1)-adrenoceptor	O	['N']	[25]
26	occupancy	O	['N']	[26]
27	by	O	['N']	[27]
28	endogenous	O	['N']	[28]
29	norepinephrine	O	['N']	[29]
30	induced	O	['N']	[30]
31	by	O	['N']	[31]
32	milnacipran	O	['N']	[32]
33	.	O	['N']	[33]
#1693
0	This	O	['N']	[0]
1	profile	O	['N']	[1]
2	should	O	['N']	[2]
3	trigger	O	['N']	[3]
4	a	O	['N']	[4]
5	"	O	['N']	[5]
6	red	O	['N']	[6]
7	flag	O	['N']	[7]
8	"	O	['N']	[8]
9	as	O	['N']	[9]
10	to	O	['N']	[10]
11	the	O	['N']	[11]
12	possibility	O	['N']	[12]
13	of	O	['N']	[13]
14	phenobarbital	B-Drug	['Causes']	[17]
15	behavioral	B	['N']	[15]
16	side	I	['N']	[16]
17	effects	I-Adverse_Effect	['N']	[17]
18	or	O	['N']	[18]
19	exacerbation	O	['N']	[19]
20	of	O	['N']	[20]
21	preexisting	O	['N']	[21]
22	maladaptive	O	['N']	[22]
23	behaviors	O	['N']	[23]
24	.	O	['N']	[24]
#1694
0	Aseptic	B	['N']	[0]
1	meningitis	I-Adverse_Effect	['N']	[1]
2	,	O	['N']	[2]
3	hemolytic	O	['N']	[3]
4	anemia	O	['N']	[4]
5	,	O	['N']	[5]
6	hepatitis	O	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	orthostatic	O	['N']	[9]
10	hypotension	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	trimethoprim	B-Drug	['Causes']	[1]
17	-	O	['N']	[17]
18	sulfamethoxazole	O	['N']	[18]
19	.	O	['N']	[19]
#1695
0	Uveitis	B-Adverse_Effect	['N']	[0]
1	during	O	['N']	[1]
2	treatment	O	['N']	[2]
3	of	O	['N']	[3]
4	disseminated	O	['N']	[4]
5	Mycobacterium	O	['N']	[5]
6	avium	O	['N']	[6]
7	-	O	['N']	[7]
8	intracellulare	O	['N']	[8]
9	complex	O	['N']	[9]
10	infection	O	['N']	[10]
11	with	O	['N']	[11]
12	the	O	['N']	[12]
13	combination	O	['N']	[13]
14	of	O	['N']	[14]
15	rifabutin	B-Drug	['Causes']	[0]
16	,	O	['N']	[16]
17	clarithromycin	O	['N']	[17]
18	and	O	['N']	[18]
19	ethambutol	O	['N']	[19]
20	.	O	['N']	[20]
#1696
0	A	O	['N']	[0]
1	10-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	asthmatic	O	['N']	[4]
5	boy	O	['N']	[5]
6	began	O	['N']	[6]
7	to	O	['N']	[7]
8	suffer	O	['N']	[8]
9	from	O	['N']	[9]
10	urticarial	B	['N']	[10]
11	rash	I-Adverse_Effect	['N']	[11]
12	and	O	['N']	[12]
13	moderately	O	['N']	[13]
14	severe	O	['N']	[14]
15	bronchospasm	O	['N']	[15]
16	after	O	['N']	[16]
17	8	O	['N']	[17]
18	weeks	O	['N']	[18]
19	'	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	disodium	B	['N']	[22]
23	cromoglycate	I-Drug	['Causes']	[11]
24	.	O	['N']	[24]
#1697
0	Both	O	['N']	[0]
1	the	O	['N']	[1]
2	longitudinal	B	['N']	[2]
3	melanonychia	I-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	the	O	['N']	[5]
6	multiple	O	['N']	[6]
7	skin	O	['N']	[7]
8	cancers	O	['N']	[8]
9	first	O	['N']	[9]
10	appeared	O	['N']	[10]
11	after	O	['N']	[11]
12	approximately	O	['N']	[12]
13	6	O	['N']	[13]
14	months	O	['N']	[14]
15	of	O	['N']	[15]
16	hydroxyurea	B-Drug	['Causes']	[3]
17	treatment	O	['N']	[17]
18	.	O	['N']	[18]
#1698
0	Rapamycin	B-Drug	['Causes']	[31]
1	/	O	['N']	[1]
2	sirolimus	O	['N']	[2]
3	(	O	['N']	[3]
4	SR	O	['N']	[4]
5	)	O	['N']	[5]
6	,	O	['N']	[6]
7	trade	O	['N']	[7]
8	named	O	['N']	[8]
9	Rapammune	O	['N']	[9]
10	(	O	['N']	[10]
11	Wyeth	O	['N']	[11]
12	-	O	['N']	[12]
13	Ayerst	O	['N']	[13]
14	,	O	['N']	[14]
15	Sydney	O	['N']	[15]
16	,	O	['N']	[16]
17	Australia	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	is	O	['N']	[20]
21	a	O	['N']	[21]
22	potent	O	['N']	[22]
23	immunosuppressive	O	['N']	[23]
24	drug	O	['N']	[24]
25	associated	O	['N']	[25]
26	with	O	['N']	[26]
27	myelosuppression	O	['N']	[27]
28	,	O	['N']	[28]
29	hypertension	O	['N']	[29]
30	,	O	['N']	[30]
31	hyperlipidemia	B-Adverse_Effect	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	infection	O	['N']	[34]
35	.	O	['N']	[35]
#1699
0	Interferon	B	['N']	[0]
1	-	I	['N']	[1]
2	alpha	I-Drug	['Causes']	[15]
3	(	O	['N']	[3]
4	IFN	O	['N']	[4]
5	-	O	['N']	[5]
6	alpha	O	['N']	[6]
7	)	O	['N']	[7]
8	may	O	['N']	[8]
9	precipitate	O	['N']	[9]
10	or	O	['N']	[10]
11	exacerbate	O	['N']	[11]
12	the	O	['N']	[12]
13	occurrence	O	['N']	[13]
14	of	O	['N']	[14]
15	MPGN	B-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#1700
0	Twenty	O	['N']	[0]
1	-	O	['N']	[1]
2	four	O	['N']	[2]
3	hours	O	['N']	[3]
4	after	O	['N']	[4]
5	the	O	['N']	[5]
6	administration	O	['N']	[6]
7	of	O	['N']	[7]
8	gemcitabine	B-Drug	['Causes']	[16]
9	,	O	['N']	[9]
10	a	O	['N']	[10]
11	symmetric	B	['N']	[11]
12	,	I	['N']	[12]
13	bullous	I	['N']	[13]
14	,	I	['N']	[14]
15	herpetiform	I	['N']	[15]
16	eruption	I-Adverse_Effect	['N']	[16]
17	appeared	O	['N']	[17]
18	on	O	['N']	[18]
19	his	O	['N']	[19]
20	trunk	O	['N']	[20]
21	and	O	['N']	[21]
22	upper	O	['N']	[22]
23	limbs	O	['N']	[23]
24	.	O	['N']	[24]
#1701
0	Potential	O	['N']	[0]
1	causes	O	['N']	[1]
2	of	O	['N']	[2]
3	methamphetamine	O	['N']	[3]
4	-	O	['N']	[4]
5	related	O	['N']	[5]
6	keratitis	B-Adverse_Effect	['N']	[6]
7	can	O	['N']	[7]
8	be	O	['N']	[8]
9	divided	O	['N']	[9]
10	into	O	['N']	[10]
11	four	O	['N']	[11]
12	categories	O	['N']	[12]
13	resulting	O	['N']	[13]
14	from	O	['N']	[14]
15	(	O	['N']	[15]
16	a	O	['N']	[16]
17	)	O	['N']	[17]
18	direct	O	['N']	[18]
19	pharmacologic	O	['N']	[19]
20	and	O	['N']	[20]
21	physical	O	['N']	[21]
22	effects	O	['N']	[22]
23	of	O	['N']	[23]
24	methamphetamine	O	['N']	[24]
25	;	O	['N']	[25]
26	(	O	['N']	[26]
27	b	O	['N']	[27]
28	)	O	['N']	[28]
29	the	O	['N']	[29]
30	toxic	O	['N']	[30]
31	effects	O	['N']	[31]
32	of	O	['N']	[32]
33	diluting	O	['N']	[33]
34	or	O	['N']	[34]
35	"	O	['N']	[35]
36	cutting	O	['N']	[36]
37	"	O	['N']	[37]
38	agents	O	['N']	[38]
39	such	O	['N']	[39]
40	as	O	['N']	[40]
41	lidocaine	O	['N']	[41]
42	and	O	['N']	[42]
43	quinine	B-Drug	['Causes']	[6]
44	;	O	['N']	[44]
45	(	O	['N']	[45]
46	c	O	['N']	[46]
47	)	O	['N']	[47]
48	effects	O	['N']	[48]
49	related	O	['N']	[49]
50	to	O	['N']	[50]
51	the	O	['N']	[51]
52	route	O	['N']	[52]
53	of	O	['N']	[53]
54	drug	O	['N']	[54]
55	administration	O	['N']	[55]
56	(	O	['N']	[56]
57	intravenous	O	['N']	[57]
58	,	O	['N']	[58]
59	inhalation	O	['N']	[59]
60	,	O	['N']	[60]
61	smoking	O	['N']	[61]
62	)	O	['N']	[62]
63	;	O	['N']	[63]
64	and	O	['N']	[64]
65	(	O	['N']	[65]
66	d	O	['N']	[66]
67	)	O	['N']	[67]
68	manufacture	O	['N']	[68]
69	-	O	['N']	[69]
70	related	O	['N']	[70]
71	effects	O	['N']	[71]
72	of	O	['N']	[72]
73	exposure	O	['N']	[73]
74	to	O	['N']	[74]
75	unintentional	O	['N']	[75]
76	caustic	O	['N']	[76]
77	contaminants	O	['N']	[77]
78	in	O	['N']	[78]
79	the	O	['N']	[79]
80	final	O	['N']	[80]
81	product	O	['N']	[81]
82	.	O	['N']	[82]
#1702
0	A	O	['N']	[0]
1	57-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	developed	O	['N']	[5]
6	morphea	B-Adverse_Effect	['N']	[6]
7	while	O	['N']	[7]
8	taking	O	['N']	[8]
9	bromocriptine	B-Drug	['Causes']	[6]
10	.	O	['N']	[10]
#1703
0	During	O	['N']	[0]
1	clarithromycin	O	['N']	[1]
2	coadministration	O	['N']	[2]
3	,	O	['N']	[3]
4	four	O	['N']	[4]
5	out	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	seven	O	['N']	[8]
9	patients	O	['N']	[9]
10	developed	O	['N']	[10]
11	moderate	O	['N']	[11]
12	-	O	['N']	[12]
13	to	O	['N']	[13]
14	-	O	['N']	[14]
15	severe	O	['N']	[15]
16	toxic	O	['N']	[16]
17	symptoms	O	['N']	[17]
18	of	O	['N']	[18]
19	carbamazepine	B-Drug	['Causes']	[25]
20	,	O	['N']	[20]
21	such	O	['N']	[21]
22	as	O	['N']	[22]
23	drowsiness	O	['N']	[23]
24	,	O	['N']	[24]
25	dizziness	B-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	ataxia	O	['N']	[28]
29	,	O	['N']	[29]
30	which	O	['N']	[30]
31	resolved	O	['N']	[31]
32	within	O	['N']	[32]
33	5	O	['N']	[33]
34	days	O	['N']	[34]
35	after	O	['N']	[35]
36	clarithromycin	O	['N']	[36]
37	discontinuation	O	['N']	[37]
38	.	O	['N']	[38]
#1704
0	Oculomotor	B	['N']	[0]
1	disturbances	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	5-fluorouracil	B-Drug	['Causes']	[1]
5	chemotherapy	O	['N']	[5]
6	.	O	['N']	[6]
#1705
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	57-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	with	O	['N']	[7]
8	acral	O	['N']	[8]
9	erythrocyanosis	O	['N']	[9]
10	progressing	O	['N']	[10]
11	to	O	['N']	[11]
12	acute	B	['N']	[12]
13	digital	I	['N']	[13]
14	ischemia	I-Adverse_Effect	['N']	[14]
15	and	O	['N']	[15]
16	gangrene	O	['N']	[16]
17	that	O	['N']	[17]
18	developed	O	['N']	[18]
19	after	O	['N']	[19]
20	combined	O	['N']	[20]
21	chemotherapy	O	['N']	[21]
22	(	O	['N']	[22]
23	bleomycin	B-Drug	['Causes']	[14]
24	and	O	['N']	[24]
25	methotrexate	O	['N']	[25]
26	)	O	['N']	[26]
27	used	O	['N']	[27]
28	to	O	['N']	[28]
29	treat	O	['N']	[29]
30	a	O	['N']	[30]
31	metastatic	O	['N']	[31]
32	squamous	O	['N']	[32]
33	cell	O	['N']	[33]
34	carcinoma	O	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	hypopharynx	O	['N']	[37]
38	.	O	['N']	[38]
#1706
0	Intrahepatic	B	['N']	[0]
1	cholestasis	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	cutaneous	O	['N']	[3]
4	bullae	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	glibenclamide	B-Drug	['Causes']	[1]
8	therapy	O	['N']	[8]
9	.	O	['N']	[9]
#1707
0	Serotonin	B	['N']	[0]
1	syndrome	I-Adverse_Effect	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	transitioning	O	['N']	[4]
5	from	O	['N']	[5]
6	phenelzine	B-Drug	['Causes']	[1]
7	to	O	['N']	[7]
8	venlafaxine	O	['N']	[8]
9	:	O	['N']	[9]
10	four	O	['N']	[10]
11	patient	O	['N']	[11]
12	reports	O	['N']	[12]
13	.	O	['N']	[13]
#1708
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	herpes	B	['N']	[6]
7	esophagitis	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	renal	O	['N']	[10]
11	transplant	O	['N']	[11]
12	patient	O	['N']	[12]
13	treated	O	['N']	[13]
14	with	O	['N']	[14]
15	Cyclosporine	B	['N']	[15]
16	A	I-Drug	['Causes']	[7]
17	while	O	['N']	[17]
18	on	O	['N']	[18]
19	chronic	O	['N']	[19]
20	steroid	O	['N']	[20]
21	therapy	O	['N']	[21]
22	.	O	['N']	[22]
#1709
0	Naproxen	B-Drug	['Causes']	[6]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	sudden	B	['N']	[3]
4	sensorineural	I	['N']	[4]
5	hearing	I	['N']	[5]
6	loss	I-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#1710
0	Reversible	O	['N']	[0]
1	leukopenia	O	['N']	[1]
2	was	O	['N']	[2]
3	documented	O	['N']	[3]
4	in	O	['N']	[4]
5	an	O	['N']	[5]
6	81-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	adjunctive	O	['N']	[12]
13	ibopamine	B-Drug	['Dosage']	[15]
14	100	B	['N']	[14]
15	mg	I-Dose	['N']	[15]
16	t.i.d	O	['N']	[16]
17	.	O	['N']	[17]
18	for	O	['N']	[18]
19	chronic	O	['N']	[19]
20	congestive	O	['N']	[20]
21	heart	O	['N']	[21]
22	failure	O	['N']	[22]
23	.	O	['N']	[23]
#1711
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Colchicine	B-Drug	['Causes']	[5]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	myopathy	B-Adverse_Effect	['N']	[5]
6	should	O	['N']	[6]
7	be	O	['N']	[7]
8	excluded	O	['N']	[8]
9	in	O	['N']	[9]
10	patients	O	['N']	[10]
11	with	O	['N']	[11]
12	FMF	O	['N']	[12]
13	who	O	['N']	[13]
14	present	O	['N']	[14]
15	with	O	['N']	[15]
16	generalized	O	['N']	[16]
17	muscle	O	['N']	[17]
18	weakness	O	['N']	[18]
19	.	O	['N']	[19]
#1712
0	Though	O	['N']	[0]
1	proteinuria	B-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	nephrotic	O	['N']	[3]
4	syndrome	O	['N']	[4]
5	is	O	['N']	[5]
6	a	O	['N']	[6]
7	rare	O	['N']	[7]
8	adverse	O	['N']	[8]
9	effect	O	['N']	[9]
10	of	O	['N']	[10]
11	IFN	B	['N']	[11]
12	-	I	['N']	[12]
13	beta-1b	I-Drug	['Causes']	[1]
14	therapy	O	['N']	[14]
15	,	O	['N']	[15]
16	physicians	O	['N']	[16]
17	treating	O	['N']	[17]
18	MS	O	['N']	[18]
19	patients	O	['N']	[19]
20	with	O	['N']	[20]
21	this	O	['N']	[21]
22	agent	O	['N']	[22]
23	should	O	['N']	[23]
24	pay	O	['N']	[24]
25	careful	O	['N']	[25]
26	attention	O	['N']	[26]
27	to	O	['N']	[27]
28	new	O	['N']	[28]
29	clinical	O	['N']	[29]
30	symptoms	O	['N']	[30]
31	and	O	['N']	[31]
32	laboratory	O	['N']	[32]
33	findings	O	['N']	[33]
34	.	O	['N']	[34]
#1713
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Topical	O	['N']	[2]
3	brimonidine	B-Drug	['Causes']	[11]
4	may	O	['N']	[4]
5	be	O	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	central	B	['N']	[8]
9	nervous	I	['N']	[9]
10	system	I	['N']	[10]
11	depression	I-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	infants	O	['N']	[13]
14	.	O	['N']	[14]
#1714
0	Sulfasalazine	B-Drug	['Causes']	[17]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	lung	O	['N']	[3]
4	disorder	O	['N']	[4]
5	is	O	['N']	[5]
6	an	O	['N']	[6]
7	extremely	O	['N']	[7]
8	rare	O	['N']	[8]
9	entity	O	['N']	[9]
10	which	O	['N']	[10]
11	must	O	['N']	[11]
12	be	O	['N']	[12]
13	considered	O	['N']	[13]
14	in	O	['N']	[14]
15	all	O	['N']	[15]
16	ulcerative	B	['N']	[16]
17	colitis	I-Adverse_Effect	['N']	[17]
18	patients	O	['N']	[18]
19	while	O	['N']	[19]
20	on	O	['N']	[20]
21	sulfasalazine	O	['N']	[21]
22	therapy	O	['N']	[22]
23	,	O	['N']	[23]
24	despite	O	['N']	[24]
25	the	O	['N']	[25]
26	absence	O	['N']	[26]
27	of	O	['N']	[27]
28	pulmonary	O	['N']	[28]
29	symptomatology	O	['N']	[29]
30	.	O	['N']	[30]
#1715
0	Leukopenia	B-Adverse_Effect	['N']	[0]
1	due	O	['N']	[1]
2	to	O	['N']	[2]
3	parvovirus	O	['N']	[3]
4	B19	O	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	Crohn	O	['N']	[7]
8	's	O	['N']	[8]
9	disease	O	['N']	[9]
10	patient	O	['N']	[10]
11	using	O	['N']	[11]
12	azathioprine	B-Drug	['Causes']	[0]
13	.	O	['N']	[13]
#1716
0	A	O	['N']	[0]
1	57-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	right	O	['N']	[6]
7	bundle	O	['N']	[7]
8	branch	O	['N']	[8]
9	block	O	['N']	[9]
10	+	O	['N']	[10]
11	LPH	O	['N']	[11]
12	and	O	['N']	[12]
13	ventricular	O	['N']	[13]
14	premature	O	['N']	[14]
15	contractions	O	['N']	[15]
16	developed	O	['N']	[16]
17	complete	B	['N']	[17]
18	heart	I	['N']	[18]
19	block	I-Adverse_Effect	['N']	[19]
20	(	O	['N']	[20]
21	CHB	O	['N']	[21]
22	)	O	['N']	[22]
23	following	O	['N']	[23]
24	administration	O	['N']	[24]
25	of	O	['N']	[25]
26	disopyramide	O	['N']	[26]
27	phosphate	O	['N']	[27]
28	(	O	['N']	[28]
29	Norpace	B-Drug	['Causes']	[19]
30	)	O	['N']	[30]
31	.	O	['N']	[31]
#1717
0	Bortezomib	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	paralytic	B	['N']	[3]
4	ileus	I-Adverse_Effect	['N']	[4]
5	is	O	['N']	[5]
6	a	O	['N']	[6]
7	potential	O	['N']	[7]
8	gastrointestinal	O	['N']	[8]
9	side	O	['N']	[9]
10	effect	O	['N']	[10]
11	of	O	['N']	[11]
12	this	O	['N']	[12]
13	first	O	['N']	[13]
14	-	O	['N']	[14]
15	in	O	['N']	[15]
16	-	O	['N']	[16]
17	class	O	['N']	[17]
18	anticancer	O	['N']	[18]
19	proteasome	O	['N']	[19]
20	inhibitor	O	['N']	[20]
21	.	O	['N']	[21]
#1718
0	While	O	['N']	[0]
1	undergoing	O	['N']	[1]
2	treatment	O	['N']	[2]
3	with	O	['N']	[3]
4	albendazole	B-Drug	['Causes']	[12]
5	,	O	['N']	[5]
6	he	O	['N']	[6]
7	developed	O	['N']	[7]
8	worsening	O	['N']	[8]
9	diarrhea	O	['N']	[9]
10	with	O	['N']	[10]
11	abdominal	B	['N']	[11]
12	pain	I-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	fever	O	['N']	[14]
15	.	O	['N']	[15]
#1719
0	Physicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	risk	O	['N']	[6]
7	of	O	['N']	[7]
8	severe	O	['N']	[8]
9	AIHA	B-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	CLL	O	['N']	[11]
12	patients	O	['N']	[12]
13	with	O	['N']	[13]
14	a	O	['N']	[14]
15	history	O	['N']	[15]
16	of	O	['N']	[16]
17	AIHA	O	['N']	[17]
18	or	O	['N']	[18]
19	positivation	O	['N']	[19]
20	of	O	['N']	[20]
21	the	O	['N']	[21]
22	DAT	O	['N']	[22]
23	during	O	['N']	[23]
24	previous	O	['N']	[24]
25	fludarabine	B-Drug	['Causes']	[9]
26	administration	O	['N']	[26]
27	,	O	['N']	[27]
28	or	O	['N']	[28]
29	in	O	['N']	[29]
30	case	O	['N']	[30]
31	of	O	['N']	[31]
32	secondary	O	['N']	[32]
33	fixation	O	['N']	[33]
34	of	O	['N']	[34]
35	complement	O	['N']	[35]
36	to	O	['N']	[36]
37	the	O	['N']	[37]
38	red	O	['N']	[38]
39	cell	O	['N']	[39]
40	membrane	O	['N']	[40]
41	occurring	O	['N']	[41]
42	during	O	['N']	[42]
43	fludarabine	O	['N']	[43]
44	treatment	O	['N']	[44]
45	.	O	['N']	[45]
#1720
0	Anaphylaxis	B-Adverse_Effect	['N']	[0]
1	to	O	['N']	[1]
2	intravenous	O	['N']	[2]
3	cyclosporine	B-Drug	['Causes']	[0]
4	and	O	['N']	[4]
5	tolerance	O	['N']	[5]
6	to	O	['N']	[6]
7	oral	O	['N']	[7]
8	cyclosporine	O	['N']	[8]
9	:	O	['N']	[9]
10	case	O	['N']	[10]
11	report	O	['N']	[11]
12	and	O	['N']	[12]
13	review	O	['N']	[13]
14	.	O	['N']	[14]
#1721
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	a	O	['N']	[4]
5	probable	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	transient	B	['N']	[8]
9	global	I	['N']	[9]
10	amnesia	I-Adverse_Effect	['N']	[10]
11	caused	O	['N']	[11]
12	by	O	['N']	[12]
13	propafenone	B-Drug	['Causes']	[10]
14	.	O	['N']	[14]
#1722
0	Although	O	['N']	[0]
1	fluoxetine	B-Drug	['Causes']	[4]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	headache	B-Adverse_Effect	['N']	[4]
5	occurred	O	['N']	[5]
6	in	O	['N']	[6]
7	one	O	['N']	[7]
8	patient	O	['N']	[8]
9	,	O	['N']	[9]
10	the	O	['N']	[10]
11	other	O	['N']	[11]
12	five	O	['N']	[12]
13	reported	O	['N']	[13]
14	no	O	['N']	[14]
15	side	O	['N']	[15]
16	effects	O	['N']	[16]
17	at	O	['N']	[17]
18	the	O	['N']	[18]
19	doses	O	['N']	[19]
20	used	O	['N']	[20]
21	.	O	['N']	[21]
#1723
0	Acute	O	['N']	[0]
1	interstitial	B	['N']	[1]
2	pneumonia	I-Adverse_Effect	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	ONO-1078	O	['N']	[5]
6	(	O	['N']	[6]
7	pranlukast	B-Drug	['Causes']	[2]
8	)	O	['N']	[8]
9	,	O	['N']	[9]
10	a	O	['N']	[10]
11	leukotriene	O	['N']	[11]
12	receptor	O	['N']	[12]
13	antagonist	O	['N']	[13]
14	.	O	['N']	[14]
#1724
0	Amphotericin	B	['N']	[0]
1	B	I-Drug	['Causes']	[2]
2	nephrotoxicity	B-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	humans	O	['N']	[4]
5	decreased	O	['N']	[5]
6	by	O	['N']	[6]
7	salt	O	['N']	[7]
8	repletion	O	['N']	[8]
9	.	O	['N']	[9]
#1725
0	CASE	O	['N']	[0]
1	REPORT	O	['N']	[1]
2	:	O	['N']	[2]
3	Soon	O	['N']	[3]
4	after	O	['N']	[4]
5	initiation	O	['N']	[5]
6	of	O	['N']	[6]
7	amiodarone	B	['N']	[7]
8	HCl	I-Drug	['Causes']	[36]
9	(	O	['N']	[9]
10	200	O	['N']	[10]
11	mg	O	['N']	[11]
12	/	O	['N']	[12]
13	day	O	['N']	[13]
14	)	O	['N']	[14]
15	,	O	['N']	[15]
16	a	O	['N']	[16]
17	76-year	O	['N']	[17]
18	-	O	['N']	[18]
19	old	O	['N']	[19]
20	man	O	['N']	[20]
21	came	O	['N']	[21]
22	to	O	['N']	[22]
23	us	O	['N']	[23]
24	with	O	['N']	[24]
25	symptoms	O	['N']	[25]
26	of	O	['N']	[26]
27	visual	O	['N']	[27]
28	"	O	['N']	[28]
29	shining	O	['N']	[29]
30	,	O	['N']	[30]
31	"	O	['N']	[31]
32	glare	O	['N']	[32]
33	,	O	['N']	[33]
34	color	B	['N']	[34]
35	vision	I	['N']	[35]
36	anomalies	I-Adverse_Effect	['N']	[36]
37	,	O	['N']	[37]
38	and	O	['N']	[38]
39	gradually	O	['N']	[39]
40	decreased	O	['N']	[40]
41	vision	O	['N']	[41]
42	.	O	['N']	[42]
#1726
0	Tuberculous	B	['N']	[0]
1	uveitis	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	treatment	O	['N']	[3]
4	with	O	['N']	[4]
5	etanercept	B-Drug	['Causes']	[1]
6	.	O	['N']	[6]
#1727
0	A	O	['N']	[0]
1	toxic	O	['N']	[1]
2	encephalopathy	O	['N']	[2]
3	characterized	O	['N']	[3]
4	by	O	['N']	[4]
5	depressed	O	['N']	[5]
6	level	O	['N']	[6]
7	of	O	['N']	[7]
8	consciousness	O	['N']	[8]
9	,	O	['N']	[9]
10	marked	O	['N']	[10]
11	irritability	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	ataxia	B-Adverse_Effect	['N']	[14]
15	developed	O	['N']	[15]
16	in	O	['N']	[16]
17	seven	O	['N']	[17]
18	children	O	['N']	[18]
19	,	O	['N']	[19]
20	5	O	['N']	[20]
21	years	O	['N']	[21]
22	of	O	['N']	[22]
23	age	O	['N']	[23]
24	and	O	['N']	[24]
25	younger	O	['N']	[25]
26	,	O	['N']	[26]
27	following	O	['N']	[27]
28	administration	O	['N']	[28]
29	of	O	['N']	[29]
30	an	O	['N']	[30]
31	antiemetic	O	['N']	[31]
32	combination	O	['N']	[32]
33	of	O	['N']	[33]
34	pentobarbital	O	['N']	[34]
35	and	O	['N']	[35]
36	pyrilamine	B	['N']	[36]
37	maleate	I-Drug	['Causes']	[14]
38	.	O	['N']	[38]
#1728
0	Subcutaneous	O	['N']	[0]
1	IL-2	B-Drug	['Causes']	[13]
2	is	O	['N']	[2]
3	safe	O	['N']	[3]
4	and	O	['N']	[4]
5	well	O	['N']	[5]
6	tolerated	O	['N']	[6]
7	,	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	mortality	B	['N']	[10]
11	rate	I	['N']	[11]
12	<	I	['N']	[12]
13	3	I-Adverse_Effect	['N']	[13]
14	%	O	['N']	[14]
15	.	O	['N']	[15]
#1729
0	These	O	['N']	[0]
1	are	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	reported	O	['N']	[4]
5	patients	O	['N']	[5]
6	to	O	['N']	[6]
7	show	O	['N']	[7]
8	mfERG	O	['N']	[8]
9	abnormalities	O	['N']	[9]
10	that	O	['N']	[10]
11	correspond	O	['N']	[11]
12	to	O	['N']	[12]
13	bitemporal	B	['N']	[13]
14	visual	I	['N']	[14]
15	field	I	['N']	[15]
16	defects	I-Adverse_Effect	['N']	[16]
17	and	O	['N']	[17]
18	add	O	['N']	[18]
19	to	O	['N']	[19]
20	the	O	['N']	[20]
21	growing	O	['N']	[21]
22	evidence	O	['N']	[22]
23	that	O	['N']	[23]
24	ethambutol	B-Drug	['Causes']	[16]
25	damages	O	['N']	[25]
26	the	O	['N']	[26]
27	retina	O	['N']	[27]
28	.	O	['N']	[28]
#1730
0	The	O	['N']	[0]
1	clinical	O	['N']	[1]
2	symptoms	O	['N']	[2]
3	of	O	['N']	[3]
4	gastric	B	['N']	[4]
5	mucosa	I	['N']	[5]
6	foveolar	I	['N']	[6]
7	hyperplasia	I-Adverse_Effect	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	long	O	['N']	[10]
11	-	O	['N']	[11]
12	term	O	['N']	[12]
13	PGE1	B-Drug	['Causes']	[7]
14	therapy	O	['N']	[14]
15	simulate	O	['N']	[15]
16	hypertrophic	O	['N']	[16]
17	pyloric	O	['N']	[17]
18	stenosis	O	['N']	[18]
19	.	O	['N']	[19]
#1731
0	Sulfasalazine	O	['N']	[0]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	lung	O	['N']	[3]
4	disorder	O	['N']	[4]
5	is	O	['N']	[5]
6	an	O	['N']	[6]
7	extremely	O	['N']	[7]
8	rare	O	['N']	[8]
9	entity	O	['N']	[9]
10	which	O	['N']	[10]
11	must	O	['N']	[11]
12	be	O	['N']	[12]
13	considered	O	['N']	[13]
14	in	O	['N']	[14]
15	all	O	['N']	[15]
16	ulcerative	B	['N']	[16]
17	colitis	I-Adverse_Effect	['N']	[17]
18	patients	O	['N']	[18]
19	while	O	['N']	[19]
20	on	O	['N']	[20]
21	sulfasalazine	B-Drug	['Causes']	[17]
22	therapy	O	['N']	[22]
23	,	O	['N']	[23]
24	despite	O	['N']	[24]
25	the	O	['N']	[25]
26	absence	O	['N']	[26]
27	of	O	['N']	[27]
28	pulmonary	O	['N']	[28]
29	symptomatology	O	['N']	[29]
30	.	O	['N']	[30]
#1732
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	presented	O	['N']	[5]
6	with	O	['N']	[6]
7	bloody	O	['N']	[7]
8	diarrhoea	O	['N']	[8]
9	after	O	['N']	[9]
10	15	B	['N']	[10]
11	mg	I-Dose	['N']	[11]
12	meloxicam	B-Drug	['Dosage']	[11]
13	daily	O	['N']	[13]
14	for	O	['N']	[14]
15	10	O	['N']	[15]
16	days	O	['N']	[16]
17	for	O	['N']	[17]
18	osteoarthritis	O	['N']	[18]
19	.	O	['N']	[19]
#1733
0	Acute	B	['N']	[0]
1	neutrophilic	I	['N']	[1]
2	dermatosis	I-Adverse_Effect	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	all	B	['N']	[5]
6	-	I	['N']	[6]
7	trans	I	['N']	[7]
8	-	I	['N']	[8]
9	retinoic	I	['N']	[9]
10	acid	I-Drug	['Causes']	[2]
11	treatment	O	['N']	[11]
12	for	O	['N']	[12]
13	acute	O	['N']	[13]
14	promyelocytic	O	['N']	[14]
15	leukemia	O	['N']	[15]
16	.	O	['N']	[16]
#1734
0	The	O	['N']	[0]
1	currently	O	['N']	[1]
2	available	O	['N']	[2]
3	clinical	O	['N']	[3]
4	and	O	['N']	[4]
5	neuropharmacologic	O	['N']	[5]
6	data	O	['N']	[6]
7	suggest	O	['N']	[7]
8	that	O	['N']	[8]
9	carbamazepine	B-Drug	['Causes']	[26]
10	may	O	['N']	[10]
11	be	O	['N']	[11]
12	an	O	['N']	[12]
13	antagonist	O	['N']	[13]
14	of	O	['N']	[14]
15	dopamine	O	['N']	[15]
16	and	O	['N']	[16]
17	that	O	['N']	[17]
18	this	O	['N']	[18]
19	property	O	['N']	[19]
20	is	O	['N']	[20]
21	responsible	O	['N']	[21]
22	for	O	['N']	[22]
23	the	O	['N']	[23]
24	production	O	['N']	[24]
25	of	O	['N']	[25]
26	dystonia	B-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#1735
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	new	O	['N']	[3]
4	quinolone	O	['N']	[4]
5	derivatives	O	['N']	[5]
6	(	O	['N']	[6]
7	levofloxacin	O	['N']	[7]
8	,	O	['N']	[8]
9	sparfloxacin	O	['N']	[9]
10	,	O	['N']	[10]
11	grepafloxacin	O	['N']	[11]
12	,	O	['N']	[12]
13	trovafloxacin	O	['N']	[13]
14	,	O	['N']	[14]
15	gatifloxacin	B-Drug	['Causes']	[43]
16	and	O	['N']	[16]
17	moxifloxacin	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	also	O	['N']	[20]
21	called	O	['N']	[21]
22	gyrase	O	['N']	[22]
23	inhibitors	O	['N']	[23]
24	,	O	['N']	[24]
25	are	O	['N']	[25]
26	known	O	['N']	[26]
27	for	O	['N']	[27]
28	their	O	['N']	[28]
29	potential	O	['N']	[29]
30	to	O	['N']	[30]
31	cause	O	['N']	[31]
32	central	O	['N']	[32]
33	nervous	O	['N']	[33]
34	system	O	['N']	[34]
35	-	O	['N']	[35]
36	related	O	['N']	[36]
37	adverse	O	['N']	[37]
38	effects	O	['N']	[38]
39	,	O	['N']	[39]
40	including	O	['N']	[40]
41	headache	O	['N']	[41]
42	,	O	['N']	[42]
43	dizziness	B-Adverse_Effect	['N']	[43]
44	and	O	['N']	[44]
45	insomnia	O	['N']	[45]
46	.	O	['N']	[46]
#1736
0	Multiple	O	['N']	[0]
1	mechanisms	O	['N']	[1]
2	for	O	['N']	[2]
3	ciprofloxacin	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	nephrotoxicity	B-Adverse_Effect	['N']	[6]
7	have	O	['N']	[7]
8	been	O	['N']	[8]
9	proposed	O	['N']	[9]
10	.	O	['N']	[10]
#1737
0	Widespread	O	['N']	[0]
1	cutaneous	B	['N']	[1]
2	vasculitis	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	diltiazem	B-Drug	['Causes']	[2]
6	.	O	['N']	[6]
#1738
0	We	O	['N']	[0]
1	thus	O	['N']	[1]
2	concluded	O	['N']	[2]
3	that	O	['N']	[3]
4	an	O	['N']	[4]
5	excessive	O	['N']	[5]
6	dose	O	['N']	[6]
7	of	O	['N']	[7]
8	AZ	B-Drug	['Causes']	[32]
9	had	O	['N']	[9]
10	probably	O	['N']	[10]
11	destroyed	O	['N']	[11]
12	the	O	['N']	[12]
13	gastric	O	['N']	[13]
14	mucosal	O	['N']	[14]
15	barrier	O	['N']	[15]
16	or	O	['N']	[16]
17	thrombocytopenia	O	['N']	[17]
18	due	O	['N']	[18]
19	to	O	['N']	[19]
20	bone	O	['N']	[20]
21	marrow	O	['N']	[21]
22	disorder	O	['N']	[22]
23	and	O	['N']	[23]
24	thus	O	['N']	[24]
25	eventually	O	['N']	[25]
26	led	O	['N']	[26]
27	to	O	['N']	[27]
28	the	O	['N']	[28]
29	development	O	['N']	[29]
30	of	O	['N']	[30]
31	hemorrhagic	B	['N']	[31]
32	gastritis	I-Adverse_Effect	['N']	[32]
33	.	O	['N']	[33]
#1739
0	Intra	B	['N']	[0]
1	-	I	['N']	[1]
2	neural	I	['N']	[2]
3	ceroid	I	['N']	[3]
4	-	I	['N']	[4]
5	like	I	['N']	[5]
6	pigment	I-Adverse_Effect	['N']	[6]
7	following	O	['N']	[7]
8	the	O	['N']	[8]
9	treatment	O	['N']	[9]
10	of	O	['N']	[10]
11	lepromatous	O	['N']	[11]
12	leprosy	O	['N']	[12]
13	with	O	['N']	[13]
14	clofazimine	B-Drug	['Causes']	[6]
15	(	O	['N']	[15]
16	B663	O	['N']	[16]
17	;	O	['N']	[17]
18	Lamprene	O	['N']	[18]
19	)	O	['N']	[19]
20	.	O	['N']	[20]
#1740
0	We	O	['N']	[0]
1	suggest	O	['N']	[1]
2	that	O	['N']	[2]
3	meloxicam	B-Drug	['Causes']	[8]
4	might	O	['N']	[4]
5	have	O	['N']	[5]
6	intestinal	B	['N']	[6]
7	toxic	I	['N']	[7]
8	effects	I-Adverse_Effect	['N']	[8]
9	when	O	['N']	[9]
10	taken	O	['N']	[10]
11	in	O	['N']	[11]
12	high	O	['N']	[12]
13	doses	O	['N']	[13]
14	,	O	['N']	[14]
15	because	O	['N']	[15]
16	of	O	['N']	[16]
17	reduced	O	['N']	[17]
18	COX-2	O	['N']	[18]
19	selectivity	O	['N']	[19]
20	.	O	['N']	[20]
#1741
0	Localized	B	['N']	[0]
1	panniculitis	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	subsequent	O	['N']	[3]
4	lipoatrophy	O	['N']	[4]
5	with	O	['N']	[5]
6	subcutaneous	O	['N']	[6]
7	glatiramer	O	['N']	[7]
8	acetate	O	['N']	[8]
9	(	O	['N']	[9]
10	Copaxone	B-Drug	['Causes']	[1]
11	)	O	['N']	[11]
12	injection	O	['N']	[12]
13	for	O	['N']	[13]
14	the	O	['N']	[14]
15	treatment	O	['N']	[15]
16	of	O	['N']	[16]
17	multiple	O	['N']	[17]
18	sclerosis	O	['N']	[18]
19	.	O	['N']	[19]
#1742
0	Our	O	['N']	[0]
1	report	O	['N']	[1]
2	suggested	O	['N']	[2]
3	that	O	['N']	[3]
4	CBDCA	B-Drug	['Causes']	[5]
5	hypersensitivity	B-Adverse_Effect	['N']	[5]
6	was	O	['N']	[6]
7	correlated	O	['N']	[7]
8	with	O	['N']	[8]
9	the	O	['N']	[9]
10	total	O	['N']	[10]
11	dose	O	['N']	[11]
12	of	O	['N']	[12]
13	previously	O	['N']	[13]
14	administered	O	['N']	[14]
15	platinum	O	['N']	[15]
16	agents	O	['N']	[16]
17	and	O	['N']	[17]
18	that	O	['N']	[18]
19	CBDCA	O	['N']	[19]
20	should	O	['N']	[20]
21	be	O	['N']	[21]
22	excluded	O	['N']	[22]
23	in	O	['N']	[23]
24	patients	O	['N']	[24]
25	who	O	['N']	[25]
26	have	O	['N']	[26]
27	received	O	['N']	[27]
28	multiple	O	['N']	[28]
29	platinum	O	['N']	[29]
30	-	O	['N']	[30]
31	based	O	['N']	[31]
32	chemotherapy	O	['N']	[32]
33	,	O	['N']	[33]
34	even	O	['N']	[34]
35	in	O	['N']	[35]
36	platinum	O	['N']	[36]
37	-	O	['N']	[37]
38	sensitive	O	['N']	[38]
39	cases	O	['N']	[39]
40	,	O	['N']	[40]
41	because	O	['N']	[41]
42	CBDCA	O	['N']	[42]
43	hypersensitivity	O	['N']	[43]
44	can	O	['N']	[44]
45	occur	O	['N']	[45]
46	even	O	['N']	[46]
47	with	O	['N']	[47]
48	low	O	['N']	[48]
49	-	O	['N']	[49]
50	dose	O	['N']	[50]
51	CBDCA	O	['N']	[51]
52	administration	O	['N']	[52]
53	.	O	['N']	[53]
#1743
0	Syringotropic	B	['N']	[0]
1	hypersensitivity	I	['N']	[1]
2	reaction	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	infliximab	O	['N']	[5]
6	and	O	['N']	[6]
7	leflunomide	B-Drug	['Causes']	[2]
8	combination	O	['N']	[8]
9	therapy	O	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	child	O	['N']	[12]
13	with	O	['N']	[13]
14	psoriatic	O	['N']	[14]
15	arthritis	O	['N']	[15]
16	.	O	['N']	[16]
#1744
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	infant	O	['N']	[6]
7	with	O	['N']	[7]
8	complex	O	['N']	[8]
9	congenital	O	['N']	[9]
10	heart	O	['N']	[10]
11	disease	O	['N']	[11]
12	who	O	['N']	[12]
13	was	O	['N']	[13]
14	placed	O	['N']	[14]
15	on	O	['N']	[15]
16	captopril	B-Drug	['Causes']	[29]
17	for	O	['N']	[17]
18	afterload	O	['N']	[18]
19	reduction	O	['N']	[19]
20	following	O	['N']	[20]
21	cardiac	O	['N']	[21]
22	surgery	O	['N']	[22]
23	and	O	['N']	[23]
24	subsequently	O	['N']	[24]
25	developed	O	['N']	[25]
26	pulmonary	B	['N']	[26]
27	infiltrates	I	['N']	[27]
28	with	I	['N']	[28]
29	eosinophilia	I-Adverse_Effect	['N']	[29]
30	.	O	['N']	[30]
#1745
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	is	O	['N']	[2]
3	described	O	['N']	[3]
4	with	O	['N']	[4]
5	the	O	['N']	[5]
6	characteristic	O	['N']	[6]
7	features	O	['N']	[7]
8	of	O	['N']	[8]
9	phenytoin	B-Drug	['Causes']	[11]
10	hypersensitivity	I	['N']	[10]
11	syndrome	I-Adverse_Effect	['N']	[11]
12	(	O	['N']	[12]
13	PHS	O	['N']	[13]
14	)	O	['N']	[14]
15	including	O	['N']	[15]
16	fever	O	['N']	[16]
17	,	O	['N']	[17]
18	erythroderma	O	['N']	[18]
19	,	O	['N']	[19]
20	tibial	O	['N']	[20]
21	and	O	['N']	[21]
22	facial	O	['N']	[22]
23	oedema	O	['N']	[23]
24	,	O	['N']	[24]
25	pinhead	O	['N']	[25]
26	-	O	['N']	[26]
27	sized	O	['N']	[27]
28	facial	O	['N']	[28]
29	pustules	O	['N']	[29]
30	and	O	['N']	[30]
31	abnormal	O	['N']	[31]
32	liver	O	['N']	[32]
33	function	O	['N']	[33]
34	tests	O	['N']	[34]
35	.	O	['N']	[35]
#1746
0	Aminophylline	B	['N']	[0]
1	hypersensitivity	I-Adverse_Effect	['N']	[1]
2	apparently	O	['N']	[2]
3	due	O	['N']	[3]
4	to	O	['N']	[4]
5	ethylenediamine	B-Drug	['Causes']	[1]
6	.	O	['N']	[6]
#1747
0	Neurologic	O	['N']	[0]
1	symptoms	O	['N']	[1]
2	resolved	O	['N']	[2]
3	after	O	['N']	[3]
4	stopping	O	['N']	[4]
5	CAP	B-Drug	['Dosage']	[24]
6	for	O	['N']	[6]
7	4	O	['N']	[7]
8	weeks	O	['N']	[8]
9	in	O	['N']	[9]
10	Patient	O	['N']	[10]
11	A	O	['N']	[11]
12	,	O	['N']	[12]
13	with	O	['N']	[13]
14	no	O	['N']	[14]
15	recurrence	O	['N']	[15]
16	after	O	['N']	[16]
17	reinitiating	O	['N']	[17]
18	CAP	O	['N']	[18]
19	alone	O	['N']	[19]
20	at	O	['N']	[20]
21	2000	B	['N']	[21]
22	mg	I	['N']	[22]
23	/	I	['N']	[23]
24	m2	I-Dose	['N']	[24]
25	.	O	['N']	[25]
#1748
0	A	O	['N']	[0]
1	10-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	asthmatic	O	['N']	[4]
5	boy	O	['N']	[5]
6	began	O	['N']	[6]
7	to	O	['N']	[7]
8	suffer	O	['N']	[8]
9	from	O	['N']	[9]
10	urticarial	O	['N']	[10]
11	rash	O	['N']	[11]
12	and	O	['N']	[12]
13	moderately	B	['N']	[13]
14	severe	I	['N']	[14]
15	bronchospasm	I-Adverse_Effect	['N']	[15]
16	after	O	['N']	[16]
17	8	O	['N']	[17]
18	weeks	O	['N']	[18]
19	'	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	disodium	B	['N']	[22]
23	cromoglycate	I-Drug	['Causes']	[15]
24	.	O	['N']	[24]
#1749
0	Hepatolithiasis	B-Adverse_Effect	['N']	[0]
1	(	O	['N']	[1]
2	intrahepatic	O	['N']	[2]
3	stone	O	['N']	[3]
4	)	O	['N']	[4]
5	during	O	['N']	[5]
6	octreotide	B-Drug	['Causes']	[0]
7	therapy	O	['N']	[7]
8	for	O	['N']	[8]
9	acromegaly	O	['N']	[9]
10	:	O	['N']	[10]
11	a	O	['N']	[11]
12	case	O	['N']	[12]
13	report	O	['N']	[13]
14	.	O	['N']	[14]
#1750
0	We	O	['N']	[0]
1	reviewed	O	['N']	[1]
2	the	O	['N']	[2]
3	records	O	['N']	[3]
4	of	O	['N']	[4]
5	3	O	['N']	[5]
6	patients	O	['N']	[6]
7	with	O	['N']	[7]
8	lymphoproliferative	O	['N']	[8]
9	disorders	O	['N']	[9]
10	who	O	['N']	[10]
11	experienced	O	['N']	[11]
12	acute	B	['N']	[12]
13	coronary	I	['N']	[13]
14	syndromes	I-Adverse_Effect	['N']	[14]
15	associated	O	['N']	[15]
16	with	O	['N']	[16]
17	their	O	['N']	[17]
18	initial	O	['N']	[18]
19	infusion	O	['N']	[19]
20	of	O	['N']	[20]
21	rituximab	B-Drug	['Causes']	[14]
22	.	O	['N']	[22]
#1751
0	Methyldopa	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	liver	B	['N']	[3]
4	injury	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#1752
0	Anticonvulsant	B	['N']	[0]
1	hypersensitivity	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	Bellamine	B	['N']	[5]
6	S	I-Drug	['Causes']	[2]
7	,	O	['N']	[7]
8	a	O	['N']	[8]
9	therapy	O	['N']	[9]
10	for	O	['N']	[10]
11	menopausal	O	['N']	[11]
12	symptoms	O	['N']	[12]
13	.	O	['N']	[13]
#1753
0	The	O	['N']	[0]
1	changes	O	['N']	[1]
2	were	O	['N']	[2]
3	progressive	O	['N']	[3]
4	regardless	O	['N']	[4]
5	of	O	['N']	[5]
6	discontinuation	O	['N']	[6]
7	of	O	['N']	[7]
8	cyclophosphamide	B-Drug	['Causes']	[15]
9	and	O	['N']	[9]
10	led	O	['N']	[10]
11	to	O	['N']	[11]
12	severe	B	['N']	[12]
13	restrictive	I	['N']	[13]
14	ventilatory	I	['N']	[14]
15	defect	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#1754
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	thought	O	['N']	[2]
3	that	O	['N']	[3]
4	the	O	['N']	[4]
5	clinico	O	['N']	[5]
6	-	O	['N']	[6]
7	pathological	O	['N']	[7]
8	features	O	['N']	[8]
9	and	O	['N']	[9]
10	chronology	O	['N']	[10]
11	of	O	['N']	[11]
12	this	O	['N']	[12]
13	case	O	['N']	[13]
14	bore	O	['N']	[14]
15	the	O	['N']	[15]
16	hallmarks	O	['N']	[16]
17	of	O	['N']	[17]
18	the	O	['N']	[18]
19	so	O	['N']	[19]
20	-	O	['N']	[20]
21	called	O	['N']	[21]
22	"	O	['N']	[22]
23	3-week	O	['N']	[23]
24	sulphasalazine	B-Drug	['Causes']	[25]
25	syndrome	I-Adverse_Effect	['N']	[25]
26	"	O	['N']	[26]
27	,	O	['N']	[27]
28	a	O	['N']	[28]
29	rare	O	['N']	[29]
30	,	O	['N']	[30]
31	but	O	['N']	[31]
32	often	O	['N']	[32]
33	fatal	O	['N']	[33]
34	,	O	['N']	[34]
35	immunoallergic	O	['N']	[35]
36	reaction	O	['N']	[36]
37	to	O	['N']	[37]
38	sulphasalazine	O	['N']	[38]
39	.	O	['N']	[39]
#1755
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	renal	O	['N']	[6]
7	artery	O	['N']	[7]
8	stenosis	O	['N']	[8]
9	who	O	['N']	[9]
10	had	O	['N']	[10]
11	only	O	['N']	[11]
12	1	O	['N']	[12]
13	kidney	O	['N']	[13]
14	and	O	['N']	[14]
15	in	O	['N']	[15]
16	whom	O	['N']	[16]
17	acute	B	['N']	[17]
18	renal	I	['N']	[18]
19	impairment	I-Adverse_Effect	['N']	[19]
20	developed	O	['N']	[20]
21	with	O	['N']	[21]
22	transient	O	['N']	[22]
23	anuria	O	['N']	[23]
24	after	O	['N']	[24]
25	the	O	['N']	[25]
26	administration	O	['N']	[26]
27	of	O	['N']	[27]
28	captopril	B-Drug	['Causes']	[19]
29	.	O	['N']	[29]
#1756
0	A	O	['N']	[0]
1	45-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	steroid	O	['N']	[6]
7	-	O	['N']	[7]
8	dependent	O	['N']	[8]
9	Crohn	O	['N']	[9]
10	's	O	['N']	[10]
11	colitis	O	['N']	[11]
12	,	O	['N']	[12]
13	successfully	O	['N']	[13]
14	managed	O	['N']	[14]
15	with	O	['N']	[15]
16	maintenance	O	['N']	[16]
17	infliximab	O	['N']	[17]
18	infusions	O	['N']	[18]
19	and	O	['N']	[19]
20	methotrexate	B-Drug	['Causes']	[27]
21	,	O	['N']	[21]
22	developed	O	['N']	[22]
23	a	O	['N']	[23]
24	lupus	B	['N']	[24]
25	-	I	['N']	[25]
26	like	I	['N']	[26]
27	syndrome	I-Adverse_Effect	['N']	[27]
28	eight	O	['N']	[28]
29	months	O	['N']	[29]
30	after	O	['N']	[30]
31	her	O	['N']	[31]
32	initial	O	['N']	[32]
33	infusion	O	['N']	[33]
34	.	O	['N']	[34]
#1757
0	The	O	['N']	[0]
1	site	O	['N']	[1]
2	of	O	['N']	[2]
3	thrombosis	O	['N']	[3]
4	and	O	['N']	[4]
5	the	O	['N']	[5]
6	chronological	O	['N']	[6]
7	relationship	O	['N']	[7]
8	with	O	['N']	[8]
9	the	O	['N']	[9]
10	IIR	O	['N']	[10]
11	implicates	O	['N']	[11]
12	a	O	['N']	[12]
13	hypersensitivity	O	['N']	[13]
14	to	O	['N']	[14]
15	infliximab	B-Drug	['Causes']	[22]
16	in	O	['N']	[16]
17	the	O	['N']	[17]
18	causation	O	['N']	[18]
19	of	O	['N']	[19]
20	the	O	['N']	[20]
21	venous	B	['N']	[21]
22	thrombosis	I-Adverse_Effect	['N']	[22]
23	in	O	['N']	[23]
24	this	O	['N']	[24]
25	case	O	['N']	[25]
26	.	O	['N']	[26]
#1758
0	Gold	O	['N']	[0]
1	nephropathy	O	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	auranofin	O	['N']	[4]
5	obscured	O	['N']	[5]
6	by	O	['N']	[6]
7	tolmetin	B-Drug	['Causes']	[8]
8	pseudoproteinuria	B-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#1759
0	Acute	O	['N']	[0]
1	myocardial	O	['N']	[1]
2	infarction	O	['N']	[2]
3	during	O	['N']	[3]
4	high	B	['N']	[4]
5	-	I	['N']	[5]
6	dose	I-Dose	['N']	[6]
7	methylprednisolone	B-Drug	['Dosage']	[6]
8	therapy	O	['N']	[8]
9	for	O	['N']	[9]
10	Graves	O	['N']	[10]
11	'	O	['N']	[11]
12	ophthalmopathy	O	['N']	[12]
13	.	O	['N']	[13]
#1760
0	MI	B-Adverse_Effect	['N']	[0]
1	related	O	['N']	[1]
2	to	O	['N']	[2]
3	the	O	['N']	[3]
4	use	O	['N']	[4]
5	of	O	['N']	[5]
6	activated	O	['N']	[6]
7	and	O	['N']	[7]
8	non	O	['N']	[8]
9	-	O	['N']	[9]
10	activated	O	['N']	[10]
11	PCCs	B-Drug	['Causes']	[0]
12	predominantly	O	['N']	[12]
13	affects	O	['N']	[13]
14	young	O	['N']	[14]
15	patients	O	['N']	[15]
16	who	O	['N']	[16]
17	often	O	['N']	[17]
18	have	O	['N']	[18]
19	no	O	['N']	[19]
20	preceding	O	['N']	[20]
21	history	O	['N']	[21]
22	of	O	['N']	[22]
23	,	O	['N']	[23]
24	or	O	['N']	[24]
25	risk	O	['N']	[25]
26	factors	O	['N']	[26]
27	for	O	['N']	[27]
28	,	O	['N']	[28]
29	MI	O	['N']	[29]
30	and	O	['N']	[30]
31	tends	O	['N']	[31]
32	to	O	['N']	[32]
33	be	O	['N']	[33]
34	associated	O	['N']	[34]
35	with	O	['N']	[35]
36	large	O	['N']	[36]
37	cumulative	O	['N']	[37]
38	doses	O	['N']	[38]
39	of	O	['N']	[39]
40	concentrate	O	['N']	[40]
41	.	O	['N']	[41]
#1761
0	A	O	['N']	[0]
1	9-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	developed	O	['N']	[5]
6	acute	B	['N']	[6]
7	renal	I	['N']	[7]
8	failure	I-Adverse_Effect	['N']	[8]
9	following	O	['N']	[9]
10	intravenous	O	['N']	[10]
11	acyclovir	B-Drug	['Causes']	[8]
12	(	O	['N']	[12]
13	30	O	['N']	[13]
14	mg	O	['N']	[14]
15	/	O	['N']	[15]
16	kg	O	['N']	[16]
17	per	O	['N']	[17]
18	day	O	['N']	[18]
19	)	O	['N']	[19]
20	administered	O	['N']	[20]
21	for	O	['N']	[21]
22	6	O	['N']	[22]
23	days	O	['N']	[23]
24	to	O	['N']	[24]
25	treat	O	['N']	[25]
26	herpetic	O	['N']	[26]
27	encephalitis	O	['N']	[27]
28	.	O	['N']	[28]
#1762
0	The	O	['N']	[0]
1	association	O	['N']	[1]
2	of	O	['N']	[2]
3	central	O	['N']	[3]
4	diabetes	O	['N']	[4]
5	insipidus	O	['N']	[5]
6	(	O	['N']	[6]
7	CDI	B-Adverse_Effect	['N']	[7]
8	)	O	['N']	[8]
9	with	O	['N']	[9]
10	lithium	B-Drug	['Causes']	[7]
11	use	O	['N']	[11]
12	is	O	['N']	[12]
13	rare	O	['N']	[13]
14	.	O	['N']	[14]
#1763
0	There	O	['N']	[0]
1	have	O	['N']	[1]
2	been	O	['N']	[2]
3	only	O	['N']	[3]
4	two	O	['N']	[4]
5	reports	O	['N']	[5]
6	of	O	['N']	[6]
7	cimetidine	B-Drug	['Causes']	[10]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	hepatitis	B-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#1764
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	There	O	['N']	[2]
3	may	O	['N']	[3]
4	be	O	['N']	[4]
5	an	O	['N']	[5]
6	association	O	['N']	[6]
7	between	O	['N']	[7]
8	raloxifene	B-Drug	['Causes']	[16]
9	and	O	['N']	[9]
10	the	O	['N']	[10]
11	development	O	['N']	[11]
12	of	O	['N']	[12]
13	malignant	B	['N']	[13]
14	mixed	I	['N']	[14]
15	mesodermal	I	['N']	[15]
16	tumor	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#1765
0	Based	O	['N']	[0]
1	on	O	['N']	[1]
2	our	O	['N']	[2]
3	experience	O	['N']	[3]
4	and	O	['N']	[4]
5	on	O	['N']	[5]
6	previously	O	['N']	[6]
7	published	O	['N']	[7]
8	data	O	['N']	[8]
9	,	O	['N']	[9]
10	serum	O	['N']	[10]
11	ammonia	O	['N']	[11]
12	levels	O	['N']	[12]
13	appear	O	['N']	[13]
14	to	O	['N']	[14]
15	be	O	['N']	[15]
16	indicated	O	['N']	[16]
17	in	O	['N']	[17]
18	all	O	['N']	[18]
19	ED	O	['N']	[19]
20	patients	O	['N']	[20]
21	on	O	['N']	[21]
22	valproic	B	['N']	[22]
23	acid	I-Drug	['Causes']	[30]
24	therapy	O	['N']	[24]
25	who	O	['N']	[25]
26	present	O	['N']	[26]
27	with	O	['N']	[27]
28	altered	B	['N']	[28]
29	mental	I	['N']	[29]
30	status	I-Adverse_Effect	['N']	[30]
31	.	O	['N']	[31]
#1766
0	Development	O	['N']	[0]
1	of	O	['N']	[1]
2	nephrotic	B	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	acute	O	['N']	[8]
9	myeloblastic	O	['N']	[9]
10	leukemia	O	['N']	[10]
11	after	O	['N']	[11]
12	treatment	O	['N']	[12]
13	with	O	['N']	[13]
14	macrophage	B	['N']	[14]
15	-	I	['N']	[15]
16	colony	I	['N']	[16]
17	-	I	['N']	[17]
18	stimulating	I	['N']	[18]
19	factor	I-Drug	['Causes']	[3]
20	.	O	['N']	[20]
#1767
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	premenopausal	O	['N']	[3]
4	woman	O	['N']	[4]
5	who	O	['N']	[5]
6	,	O	['N']	[6]
7	while	O	['N']	[7]
8	having	O	['N']	[8]
9	tamoxifen	B-Drug	['Causes']	[21]
10	due	O	['N']	[10]
11	to	O	['N']	[11]
12	a	O	['N']	[12]
13	diagnosis	O	['N']	[13]
14	of	O	['N']	[14]
15	in	O	['N']	[15]
16	situ	O	['N']	[16]
17	ductal	O	['N']	[17]
18	carcinoma	O	['N']	[18]
19	,	O	['N']	[19]
20	developed	O	['N']	[20]
21	endometriosis	B-Adverse_Effect	['N']	[21]
22	requiring	O	['N']	[22]
23	surgery	O	['N']	[23]
24	.	O	['N']	[24]
#1768
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	combined	O	['N']	[6]
7	lithium	O	['N']	[7]
8	and	O	['N']	[8]
9	haloperidol	B-Drug	['Causes']	[13]
10	toxicity	O	['N']	[10]
11	characterized	O	['N']	[11]
12	by	O	['N']	[12]
13	hyperpyrexia	B-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	severe	O	['N']	[15]
16	rigidity	O	['N']	[16]
17	,	O	['N']	[17]
18	mutism	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	development	O	['N']	[21]
22	of	O	['N']	[22]
23	irreversible	O	['N']	[23]
24	tardive	O	['N']	[24]
25	dyskinesia	O	['N']	[25]
26	.	O	['N']	[26]
#1769
0	Acute	B	['N']	[0]
1	pancreatitis	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	long	O	['N']	[3]
4	-	O	['N']	[4]
5	term	O	['N']	[5]
6	5-aminosalicylic	B	['N']	[6]
7	acid	I-Drug	['Causes']	[1]
8	therapy	O	['N']	[8]
9	.	O	['N']	[9]
#1770
0	Managing	O	['N']	[0]
1	cardiovascular	B	['N']	[1]
2	collapse	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	severe	O	['N']	[4]
5	flecainide	B-Drug	['Causes']	[2]
6	overdose	O	['N']	[6]
7	without	O	['N']	[7]
8	recourse	O	['N']	[8]
9	to	O	['N']	[9]
10	extracorporeal	O	['N']	[10]
11	therapy	O	['N']	[11]
12	.	O	['N']	[12]
#1771
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	development	O	['N']	[3]
4	of	O	['N']	[4]
5	ischemic	O	['N']	[5]
6	colitis	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	woman	O	['N']	[9]
10	who	O	['N']	[10]
11	was	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	tegaserod	B-Drug	['Causes']	[29]
15	and	O	['N']	[15]
16	review	O	['N']	[16]
17	the	O	['N']	[17]
18	relationship	O	['N']	[18]
19	among	O	['N']	[19]
20	ischemic	O	['N']	[20]
21	colitis	O	['N']	[21]
22	,	O	['N']	[22]
23	tegaserod	O	['N']	[23]
24	use	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	irritable	B	['N']	[27]
28	bowel	I	['N']	[28]
29	syndrome	I-Adverse_Effect	['N']	[29]
30	.	O	['N']	[30]
#1772
0	The	O	['N']	[0]
1	oligohidrosis	B-Adverse_Effect	['N']	[1]
2	caused	O	['N']	[2]
3	by	O	['N']	[3]
4	zonisamide	B-Drug	['Causes']	[1]
5	was	O	['N']	[5]
6	reversible	O	['N']	[6]
7	in	O	['N']	[7]
8	that	O	['N']	[8]
9	the	O	['N']	[9]
10	patient	O	['N']	[10]
11	regained	O	['N']	[11]
12	the	O	['N']	[12]
13	ability	O	['N']	[13]
14	to	O	['N']	[14]
15	sweat	O	['N']	[15]
16	within	O	['N']	[16]
17	2	O	['N']	[17]
18	weeks	O	['N']	[18]
19	of	O	['N']	[19]
20	the	O	['N']	[20]
21	cessation	O	['N']	[21]
22	of	O	['N']	[22]
23	drug	O	['N']	[23]
24	administration	O	['N']	[24]
25	.	O	['N']	[25]
#1773
0	Risperidone	B-Drug	['Causes']	[5]
1	withdrawal	O	['N']	[1]
2	-	O	['N']	[2]
3	related	O	['N']	[3]
4	respiratory	B	['N']	[4]
5	dyskinesia	I-Adverse_Effect	['N']	[5]
6	:	O	['N']	[6]
7	a	O	['N']	[7]
8	case	O	['N']	[8]
9	diagnosed	O	['N']	[9]
10	by	O	['N']	[10]
11	spirography	O	['N']	[11]
12	and	O	['N']	[12]
13	fibroscopy	O	['N']	[13]
14	.	O	['N']	[14]
#1774
0	Clozapine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	tardive	B	['N']	[3]
4	dyskinesia	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	schizophrenic	O	['N']	[6]
7	patients	O	['N']	[7]
8	taking	O	['N']	[8]
9	clozapine	O	['N']	[9]
10	as	O	['N']	[10]
11	a	O	['N']	[11]
12	first	O	['N']	[12]
13	-	O	['N']	[13]
14	line	O	['N']	[14]
15	antipsychotic	O	['N']	[15]
16	drug	O	['N']	[16]
17	.	O	['N']	[17]
#1775
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	's	O	['N']	[2]
3	previous	O	['N']	[3]
4	rash	B-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	the	O	['N']	[6]
7	temporal	O	['N']	[7]
8	relation	O	['N']	[8]
9	of	O	['N']	[9]
10	this	O	['N']	[10]
11	event	O	['N']	[11]
12	and	O	['N']	[12]
13	the	O	['N']	[13]
14	ingestion	O	['N']	[14]
15	of	O	['N']	[15]
16	phenolphthalein	B-Drug	['Causes']	[4]
17	,	O	['N']	[17]
18	as	O	['N']	[18]
19	well	O	['N']	[19]
20	as	O	['N']	[20]
21	the	O	['N']	[21]
22	similarity	O	['N']	[22]
23	of	O	['N']	[23]
24	this	O	['N']	[24]
25	case	O	['N']	[25]
26	to	O	['N']	[26]
27	other	O	['N']	[27]
28	reports	O	['N']	[28]
29	,	O	['N']	[29]
30	point	O	['N']	[30]
31	to	O	['N']	[31]
32	phenolphthalein	O	['N']	[32]
33	as	O	['N']	[33]
34	the	O	['N']	[34]
35	cause	O	['N']	[35]
36	of	O	['N']	[36]
37	TEN	O	['N']	[37]
38	in	O	['N']	[38]
39	this	O	['N']	[39]
40	patient	O	['N']	[40]
41	.	O	['N']	[41]
#1776
0	Ciprofloxacin	B-Drug	['Causes']	[11]
1	is	O	['N']	[1]
2	one	O	['N']	[2]
3	drug	O	['N']	[3]
4	that	O	['N']	[4]
5	has	O	['N']	[5]
6	been	O	['N']	[6]
7	reported	O	['N']	[7]
8	to	O	['N']	[8]
9	cause	O	['N']	[9]
10	interstitial	B	['N']	[10]
11	nephritis	I-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#1777
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	present	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	CML	O	['N']	[10]
11	who	O	['N']	[11]
12	developed	O	['N']	[12]
13	KS	O	['N']	[13]
14	12	O	['N']	[14]
15	months	O	['N']	[15]
16	after	O	['N']	[16]
17	starting	O	['N']	[17]
18	treatment	O	['N']	[18]
19	with	O	['N']	[19]
20	imatinib	B-Drug	['Dosage']	[24]
21	400	B	['N']	[21]
22	mg	I	['N']	[22]
23	/	I	['N']	[23]
24	d	I-Dose	['N']	[24]
25	.	O	['N']	[25]
#1778
0	Massive	B	['N']	[0]
1	pulmonary	I	['N']	[1]
2	embolism	I-Adverse_Effect	['N']	[2]
3	complicating	O	['N']	[3]
4	streptokinase	B-Drug	['Causes']	[2]
5	treatment	O	['N']	[5]
6	for	O	['N']	[6]
7	deep	O	['N']	[7]
8	vein	O	['N']	[8]
9	thrombosis	O	['N']	[9]
10	.	O	['N']	[10]
#1779
0	Eleven	O	['N']	[0]
1	patients	O	['N']	[1]
2	developed	O	['N']	[2]
3	infection	O	['N']	[3]
4	requiring	O	['N']	[4]
5	hospitalization	O	['N']	[5]
6	while	O	['N']	[6]
7	taking	O	['N']	[7]
8	leflunomide	B-Drug	['Causes']	[45]
9	including	O	['N']	[9]
10	:	O	['N']	[10]
11	lower	O	['N']	[11]
12	respiratory	O	['N']	[12]
13	tract	O	['N']	[13]
14	infections	O	['N']	[14]
15	(	O	['N']	[15]
16	3	O	['N']	[16]
17	)	O	['N']	[17]
18	,	O	['N']	[18]
19	cellulitis	O	['N']	[19]
20	(	O	['N']	[20]
21	2	O	['N']	[21]
22	)	O	['N']	[22]
23	,	O	['N']	[23]
24	disseminated	O	['N']	[24]
25	herpes	O	['N']	[25]
26	zoster	O	['N']	[26]
27	(	O	['N']	[27]
28	2	O	['N']	[28]
29	)	O	['N']	[29]
30	,	O	['N']	[30]
31	probable	O	['N']	[31]
32	TB	O	['N']	[32]
33	liver	O	['N']	[33]
34	(	O	['N']	[34]
35	1	O	['N']	[35]
36	)	O	['N']	[36]
37	,	O	['N']	[37]
38	abdominal	O	['N']	[38]
39	sepsis	O	['N']	[39]
40	(	O	['N']	[40]
41	1	O	['N']	[41]
42	)	O	['N']	[42]
43	,	O	['N']	[43]
44	mycotic	B	['N']	[44]
45	aneurysm	I-Adverse_Effect	['N']	[45]
46	(	O	['N']	[46]
47	1	O	['N']	[47]
48	)	O	['N']	[48]
49	and	O	['N']	[49]
50	gastroenteritis	O	['N']	[50]
51	(	O	['N']	[51]
52	1	O	['N']	[52]
53	)	O	['N']	[53]
54	.	O	['N']	[54]
#1780
0	The	O	['N']	[0]
1	administration	O	['N']	[1]
2	of	O	['N']	[2]
3	"	O	['N']	[3]
4	sweet	B	['N']	[4]
5	spirits	I	['N']	[5]
6	of	I	['N']	[6]
7	nitre	I-Drug	['Causes']	[51]
8	"	O	['N']	[8]
9	(	O	['N']	[9]
10	4	O	['N']	[10]
11	%	O	['N']	[11]
12	ethyl	O	['N']	[12]
13	nitrite	O	['N']	[13]
14	CH3CH2ONO	O	['N']	[14]
15	in	O	['N']	[15]
16	70	O	['N']	[16]
17	%	O	['N']	[17]
18	ethyl	O	['N']	[18]
19	alcohol	O	['N']	[19]
20	)	O	['N']	[20]
21	was	O	['N']	[21]
22	followed	O	['N']	[22]
23	by	O	['N']	[23]
24	acute	O	['N']	[24]
25	methemoglobinemia	O	['N']	[25]
26	and	O	['N']	[26]
27	severe	O	['N']	[27]
28	anoxic	O	['N']	[28]
29	metabolic	O	['N']	[29]
30	acidosis	O	['N']	[30]
31	in	O	['N']	[31]
32	infant	O	['N']	[32]
33	twins	O	['N']	[33]
34	,	O	['N']	[34]
35	Methylene	O	['N']	[35]
36	blue	O	['N']	[36]
37	administration	O	['N']	[37]
38	reversed	O	['N']	[38]
39	methemoglobinemia	O	['N']	[39]
40	in	O	['N']	[40]
41	both	O	['N']	[41]
42	,	O	['N']	[42]
43	but	O	['N']	[43]
44	one	O	['N']	[44]
45	twin	O	['N']	[45]
46	died	O	['N']	[46]
47	from	O	['N']	[47]
48	the	O	['N']	[48]
49	consequences	O	['N']	[49]
50	of	O	['N']	[50]
51	hypoxemia	B-Adverse_Effect	['N']	[51]
52	.	O	['N']	[52]
#1781
0	a	O	['N']	[0]
1	67-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	bipolar	O	['N']	[6]
7	disorder	O	['N']	[7]
8	developed	O	['N']	[8]
9	a	O	['N']	[9]
10	Creutzfeldt	B	['N']	[10]
11	-	I	['N']	[11]
12	Jakob	I	['N']	[12]
13	like	I	['N']	[13]
14	syndrome	I-Adverse_Effect	['N']	[14]
15	during	O	['N']	[15]
16	lithium	B	['N']	[16]
17	carbonate	I-Drug	['Causes']	[14]
18	treatment	O	['N']	[18]
19	.	O	['N']	[19]
#1782
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	In	O	['N']	[2]
3	a	O	['N']	[3]
4	22-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	Thai	O	['N']	[7]
8	woman	O	['N']	[8]
9	with	O	['N']	[9]
10	Graves	O	['N']	[10]
11	'	O	['N']	[11]
12	disease	O	['N']	[12]
13	,	O	['N']	[13]
14	tinnitus	O	['N']	[14]
15	,	O	['N']	[15]
16	hearing	B	['N']	[16]
17	impairment	I	['N']	[17]
18	in	I	['N']	[18]
19	the	I	['N']	[19]
20	left	I	['N']	[20]
21	ear	I	['N']	[21]
22	(	I	['N']	[22]
23	with	I	['N']	[23]
24	progression	I	['N']	[24]
25	to	I	['N']	[25]
26	the	I	['N']	[26]
27	right	I	['N']	[27]
28	ear	I	['N']	[28]
29	)	I-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	vertigo	O	['N']	[32]
33	developed	O	['N']	[33]
34	after	O	['N']	[34]
35	3	O	['N']	[35]
36	years	O	['N']	[36]
37	of	O	['N']	[37]
38	therapy	O	['N']	[38]
39	with	O	['N']	[39]
40	PTU	B-Drug	['Causes']	[29]
41	.	O	['N']	[41]
#1783
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Itraconazole	B-Drug	['Causes']	[6]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	liver	B	['N']	[5]
6	injury	I-Adverse_Effect	['N']	[6]
7	presents	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	cholestatic	O	['N']	[10]
11	pattern	O	['N']	[11]
12	of	O	['N']	[12]
13	injury	O	['N']	[13]
14	with	O	['N']	[14]
15	damage	O	['N']	[15]
16	to	O	['N']	[16]
17	the	O	['N']	[17]
18	interlobular	O	['N']	[18]
19	bile	O	['N']	[19]
20	ducts	O	['N']	[20]
21	,	O	['N']	[21]
22	possibly	O	['N']	[22]
23	leading	O	['N']	[23]
24	to	O	['N']	[24]
25	ductopenia	O	['N']	[25]
26	.	O	['N']	[26]
#1784
0	Hypersensitivity	B	['N']	[0]
1	reactions	I-Adverse_Effect	['N']	[1]
2	to	O	['N']	[2]
3	cisplatin	B-Drug	['Causes']	[1]
4	following	O	['N']	[4]
5	multiple	O	['N']	[5]
6	uncomplicated	O	['N']	[6]
7	courses	O	['N']	[7]
8	:	O	['N']	[8]
9	a	O	['N']	[9]
10	report	O	['N']	[10]
11	on	O	['N']	[11]
12	two	O	['N']	[12]
13	cases	O	['N']	[13]
14	.	O	['N']	[14]
#1785
0	Heparin	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hyperkalemia	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#1786
0	L	B	['N']	[0]
1	-	I	['N']	[1]
2	asparaginase	I-Drug	['Causes']	[5]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	pancreatitis	B-Adverse_Effect	['N']	[5]
6	has	O	['N']	[6]
7	been	O	['N']	[7]
8	reported	O	['N']	[8]
9	during	O	['N']	[9]
10	or	O	['N']	[10]
11	closely	O	['N']	[11]
12	following	O	['N']	[12]
13	administration	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	drug	O	['N']	[16]
17	.	O	['N']	[17]
#1787
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	infectious	O	['N']	[3]
4	toxicities	O	['N']	[4]
5	experienced	O	['N']	[5]
6	by	O	['N']	[6]
7	the	O	['N']	[7]
8	first	O	['N']	[8]
9	two	O	['N']	[9]
10	patients	O	['N']	[10]
11	in	O	['N']	[11]
12	our	O	['N']	[12]
13	institution	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	dexamethasone	B-Drug	['Dosage']	[21]
17	(	O	['N']	[17]
18	10	B	['N']	[18]
19	mg	I	['N']	[19]
20	/	I	['N']	[20]
21	m(2)/day	I-Dose	['N']	[21]
22	for	O	['N']	[22]
23	4	O	['N']	[23]
24	weeks	O	['N']	[24]
25	with	O	['N']	[25]
26	gradual	O	['N']	[26]
27	tapering	O	['N']	[27]
28	)	O	['N']	[28]
29	during	O	['N']	[29]
30	induction	O	['N']	[30]
31	according	O	['N']	[31]
32	to	O	['N']	[32]
33	the	O	['N']	[33]
34	dexamethasone	O	['N']	[34]
35	arm	O	['N']	[35]
36	of	O	['N']	[36]
37	BFM	O	['N']	[37]
38	2000	O	['N']	[38]
39	and	O	['N']	[39]
40	review	O	['N']	[40]
41	the	O	['N']	[41]
42	relevant	O	['N']	[42]
43	literature	O	['N']	[43]
44	that	O	['N']	[44]
45	suggests	O	['N']	[45]
46	an	O	['N']	[46]
47	increased	O	['N']	[47]
48	risk	O	['N']	[48]
49	of	O	['N']	[49]
50	infectious	O	['N']	[50]
51	complications	O	['N']	[51]
52	with	O	['N']	[52]
53	dexamethasone	O	['N']	[53]
54	.	O	['N']	[54]
#1788
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	SD	O	['N']	[2]
3	-	O	['N']	[3]
4	OCT	O	['N']	[4]
5	and	O	['N']	[5]
6	AO	O	['N']	[6]
7	detected	O	['N']	[7]
8	abnormalities	O	['N']	[8]
9	that	O	['N']	[9]
10	correlate	O	['N']	[10]
11	topographically	O	['N']	[11]
12	with	O	['N']	[12]
13	visual	O	['N']	[13]
14	field	O	['N']	[14]
15	loss	O	['N']	[15]
16	from	O	['N']	[16]
17	hydroxychloroquine	B-Drug	['Causes']	[43]
18	toxicity	O	['N']	[18]
19	as	O	['N']	[19]
20	demonstrated	O	['N']	[20]
21	by	O	['N']	[21]
22	HVF	O	['N']	[22]
23	10	O	['N']	[23]
24	-	O	['N']	[24]
25	2	O	['N']	[25]
26	and	O	['N']	[26]
27	may	O	['N']	[27]
28	be	O	['N']	[28]
29	useful	O	['N']	[29]
30	in	O	['N']	[30]
31	the	O	['N']	[31]
32	detection	O	['N']	[32]
33	of	O	['N']	[33]
34	subclinical	O	['N']	[34]
35	abnormalities	O	['N']	[35]
36	that	O	['N']	[36]
37	precede	O	['N']	[37]
38	symptoms	O	['N']	[38]
39	or	O	['N']	[39]
40	objective	B	['N']	[40]
41	visual	I	['N']	[41]
42	field	I	['N']	[42]
43	loss	I-Adverse_Effect	['N']	[43]
44	.	O	['N']	[44]
#1789
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	acne	O	['N']	[5]
6	vulgaris	O	['N']	[6]
7	with	O	['N']	[7]
8	a	O	['N']	[8]
9	fourth	O	['N']	[9]
10	type	O	['N']	[10]
11	of	O	['N']	[11]
12	minocycline	B-Drug	['Causes']	[16]
13	-	O	['N']	[13]
14	induced	O	['N']	[14]
15	cutaneous	B	['N']	[15]
16	pigmentation	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#1790
0	Because	O	['N']	[0]
1	sumatriptan	B-Drug	['Causes']	[6]
2	can	O	['N']	[2]
3	cause	O	['N']	[3]
4	coronary	B	['N']	[4]
5	artery	I	['N']	[5]
6	vasospasm	I-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	patients	O	['N']	[8]
9	with	O	['N']	[9]
10	significant	O	['N']	[10]
11	risk	O	['N']	[11]
12	factors	O	['N']	[12]
13	for	O	['N']	[13]
14	coronary	O	['N']	[14]
15	artery	O	['N']	[15]
16	disease	O	['N']	[16]
17	should	O	['N']	[17]
18	be	O	['N']	[18]
19	carefully	O	['N']	[19]
20	evaluated	O	['N']	[20]
21	for	O	['N']	[21]
22	cardiovascular	O	['N']	[22]
23	disease	O	['N']	[23]
24	prior	O	['N']	[24]
25	to	O	['N']	[25]
26	the	O	['N']	[26]
27	use	O	['N']	[27]
28	of	O	['N']	[28]
29	sumatriptan	O	['N']	[29]
30	.	O	['N']	[30]
#1791
0	INTERPRETATION	O	['N']	[0]
1	:	O	['N']	[1]
2	When	O	['N']	[2]
3	high	O	['N']	[3]
4	doses	O	['N']	[4]
5	of	O	['N']	[5]
6	fluticasone	B	['N']	[6]
7	propionate	I-Drug	['Causes']	[14]
8	are	O	['N']	[8]
9	used	O	['N']	[9]
10	,	O	['N']	[10]
11	growth	B	['N']	[11]
12	may	I	['N']	[12]
13	be	I	['N']	[13]
14	retarded	I-Adverse_Effect	['N']	[14]
15	and	O	['N']	[15]
16	adrenal	O	['N']	[16]
17	suppression	O	['N']	[17]
18	may	O	['N']	[18]
19	occur	O	['N']	[19]
20	.	O	['N']	[20]
#1792
0	Methylphenidate	B-Drug	['Causes']	[6]
1	and	O	['N']	[1]
2	dextroamphetamine	O	['N']	[2]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	peripheral	B	['N']	[5]
6	vasculopathy	I-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#1793
0	The	O	['N']	[0]
1	development	O	['N']	[1]
2	of	O	['N']	[2]
3	an	O	['N']	[3]
4	IgG	O	['N']	[4]
5	lambda	O	['N']	[5]
6	-	O	['N']	[6]
7	type	O	['N']	[7]
8	monoclonal	O	['N']	[8]
9	gammopathy	O	['N']	[9]
10	and	O	['N']	[10]
11	subsequent	O	['N']	[11]
12	multiple	B	['N']	[12]
13	myeloma	I-Adverse_Effect	['N']	[13]
14	in	O	['N']	[14]
15	an	O	['N']	[15]
16	epilepsy	O	['N']	[16]
17	patient	O	['N']	[17]
18	on	O	['N']	[18]
19	diphenylhydantoin	B-Drug	['Causes']	[13]
20	(	O	['N']	[20]
21	DILANTIN	O	['N']	[21]
22	)	O	['N']	[22]
23	therapy	O	['N']	[23]
24	for	O	['N']	[24]
25	20	O	['N']	[25]
26	years	O	['N']	[26]
27	is	O	['N']	[27]
28	reported	O	['N']	[28]
29	.	O	['N']	[29]
#1794
0	Case	O	['N']	[0]
1	2	O	['N']	[1]
2	,	O	['N']	[2]
3	a	O	['N']	[3]
4	29-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	woman	O	['N']	[7]
8	,	O	['N']	[8]
9	developed	O	['N']	[9]
10	bilateral	O	['N']	[10]
11	optic	O	['N']	[11]
12	neuritis	O	['N']	[12]
13	combined	O	['N']	[13]
14	with	O	['N']	[14]
15	numbness	O	['N']	[15]
16	of	O	['N']	[16]
17	the	O	['N']	[17]
18	lower	O	['N']	[18]
19	extremities	O	['N']	[19]
20	as	O	['N']	[20]
21	well	O	['N']	[21]
22	as	O	['N']	[22]
23	bowel	B	['N']	[23]
24	and	I	['N']	[24]
25	bladder	I	['N']	[25]
26	dysfunction	I-Adverse_Effect	['N']	[26]
27	after	O	['N']	[27]
28	a	O	['N']	[28]
29	22-month	O	['N']	[29]
30	use	O	['N']	[30]
31	of	O	['N']	[31]
32	recombinant	B	['N']	[32]
33	interferon	I	['N']	[33]
34	alpha-2b	I-Drug	['Causes']	[26]
35	for	O	['N']	[35]
36	chronic	O	['N']	[36]
37	myelogenous	O	['N']	[37]
38	leukemia	O	['N']	[38]
39	.	O	['N']	[39]
#1795
0	Severe	O	['N']	[0]
1	rhabdomyolysis	B-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	massive	O	['N']	[3]
4	ingestion	O	['N']	[4]
5	of	O	['N']	[5]
6	oolong	O	['N']	[6]
7	tea	O	['N']	[7]
8	:	O	['N']	[8]
9	caffeine	B-Drug	['Causes']	[1]
10	intoxication	O	['N']	[10]
11	with	O	['N']	[11]
12	coexisting	O	['N']	[12]
13	hyponatremia	O	['N']	[13]
14	.	O	['N']	[14]
#1796
0	Trimethoprim	B	['N']	[0]
1	-	I	['N']	[1]
2	sulfamethoxazole	I-Drug	['Causes']	[6]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	aseptic	B	['N']	[5]
6	meningitis	I-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#1797
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	an	O	['N']	[2]
3	AIDS	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	severe	O	['N']	[6]
7	and	O	['N']	[7]
8	prolonged	O	['N']	[8]
9	lactic	B	['N']	[9]
10	acidosis	I-Adverse_Effect	['N']	[10]
11	on	O	['N']	[11]
12	stavudine	O	['N']	[12]
13	and	O	['N']	[13]
14	lamivudine	B-Drug	['Causes']	[10]
15	.	O	['N']	[15]
#1798
0	It	O	['N']	[0]
1	was	O	['N']	[1]
2	hypothesized	O	['N']	[2]
3	that	O	['N']	[3]
4	valproic	B	['N']	[4]
5	acid	I-Drug	['Causes']	[18]
6	may	O	['N']	[6]
7	interfere	O	['N']	[7]
8	with	O	['N']	[8]
9	glucuronidation	O	['N']	[9]
10	of	O	['N']	[10]
11	lamotrigine	O	['N']	[11]
12	,	O	['N']	[12]
13	leading	O	['N']	[13]
14	to	O	['N']	[14]
15	increased	B	['N']	[15]
16	serum	I	['N']	[16]
17	lamotrigine	I	['N']	[17]
18	levels	I-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	or	O	['N']	[20]
21	perhaps	O	['N']	[21]
22	alter	O	['N']	[22]
23	the	O	['N']	[23]
24	drug	O	['N']	[24]
25	's	O	['N']	[25]
26	metabolism	O	['N']	[26]
27	,	O	['N']	[27]
28	resulting	O	['N']	[28]
29	in	O	['N']	[29]
30	accumulation	O	['N']	[30]
31	of	O	['N']	[31]
32	a	O	['N']	[32]
33	toxic	O	['N']	[33]
34	intermediate	O	['N']	[34]
35	metabolite	O	['N']	[35]
36	.	O	['N']	[36]
#1799
0	Establishment	O	['N']	[0]
1	of	O	['N']	[1]
2	diuresis	O	['N']	[2]
3	with	O	['N']	[3]
4	fluids	O	['N']	[4]
5	and	O	['N']	[5]
6	IV	O	['N']	[6]
7	administration	O	['N']	[7]
8	of	O	['N']	[8]
9	calcium	O	['N']	[9]
10	may	O	['N']	[10]
11	provide	O	['N']	[11]
12	successful	O	['N']	[12]
13	treatment	O	['N']	[13]
14	of	O	['N']	[14]
15	magnesium	B-Drug	['Causes']	[16]
16	toxicosis	I-Adverse_Effect	['N']	[16]
17	in	O	['N']	[17]
18	horses	O	['N']	[18]
19	.	O	['N']	[19]
#1800
0	The	O	['N']	[0]
1	fourth	O	['N']	[1]
2	patient	O	['N']	[2]
3	showed	O	['N']	[3]
4	RLS	B	['N']	[4]
5	symptoms	I-Adverse_Effect	['N']	[5]
6	that	O	['N']	[6]
7	were	O	['N']	[7]
8	initially	O	['N']	[8]
9	caused	O	['N']	[9]
10	by	O	['N']	[10]
11	a	O	['N']	[11]
12	20-mg	O	['N']	[12]
13	daily	O	['N']	[13]
14	olanzapine	B-Drug	['Causes']	[5]
15	dosage	O	['N']	[15]
16	and	O	['N']	[16]
17	were	O	['N']	[17]
18	later	O	['N']	[18]
19	mitigated	O	['N']	[19]
20	when	O	['N']	[20]
21	olanzapine	O	['N']	[21]
22	was	O	['N']	[22]
23	reduced	O	['N']	[23]
24	and	O	['N']	[24]
25	ropinirole	O	['N']	[25]
26	was	O	['N']	[26]
27	administered	O	['N']	[27]
28	.	O	['N']	[28]
#1801
0	Abnormalities	O	['N']	[0]
1	of	O	['N']	[1]
2	the	O	['N']	[2]
3	pupil	O	['N']	[3]
4	and	O	['N']	[4]
5	visual	O	['N']	[5]
6	-	O	['N']	[6]
7	evoked	O	['N']	[7]
8	potential	O	['N']	[8]
9	in	O	['N']	[9]
10	quinine	B-Drug	['Causes']	[11]
11	amblyopia	B-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#1802
0	We	O	['N']	[0]
1	have	O	['N']	[1]
2	cared	O	['N']	[2]
3	for	O	['N']	[3]
4	three	O	['N']	[4]
5	children	O	['N']	[5]
6	in	O	['N']	[6]
7	whom	O	['N']	[7]
8	four	O	['N']	[8]
9	episodes	O	['N']	[9]
10	of	O	['N']	[10]
11	dystonia	B-Adverse_Effect	['N']	[11]
12	proceeding	O	['N']	[12]
13	to	O	['N']	[13]
14	opisthotonus	O	['N']	[14]
15	occurred	O	['N']	[15]
16	in	O	['N']	[16]
17	association	O	['N']	[17]
18	with	O	['N']	[18]
19	carbamazepine	B-Drug	['Causes']	[11]
20	use	O	['N']	[20]
21	.	O	['N']	[21]
#1803
0	During	O	['N']	[0]
1	the	O	['N']	[1]
2	first	O	['N']	[2]
3	treatment	O	['N']	[3]
4	,	O	['N']	[4]
5	dysarthria	B-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	ataxia	O	['N']	[7]
8	were	O	['N']	[8]
9	seen	O	['N']	[9]
10	after	O	['N']	[10]
11	completion	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	patient	O	['N']	[14]
15	's	O	['N']	[15]
16	eighth	O	['N']	[16]
17	and	O	['N']	[17]
18	final	O	['N']	[18]
19	dose	O	['N']	[19]
20	of	O	['N']	[20]
21	HDARAC	B-Drug	['Causes']	[5]
22	.	O	['N']	[22]
#1804
0	The	O	['N']	[0]
1	day	O	['N']	[1]
2	after	O	['N']	[2]
3	methotrexate	B-Drug	['Causes']	[15]
4	administration	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	patient	O	['N']	[7]
8	complained	O	['N']	[8]
9	of	O	['N']	[9]
10	severe	O	['N']	[10]
11	back	O	['N']	[11]
12	pain	O	['N']	[12]
13	and	O	['N']	[13]
14	urinary	B	['N']	[14]
15	retention	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#1805
0	Albendazole	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	pseudomembranous	B	['N']	[3]
4	colitis	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#1806
0	Although	O	['N']	[0]
1	the	O	['N']	[1]
2	movement	B	['N']	[2]
3	disorder	I-Adverse_Effect	['N']	[3]
4	could	O	['N']	[4]
5	not	O	['N']	[5]
6	with	O	['N']	[6]
7	certainty	O	['N']	[7]
8	be	O	['N']	[8]
9	attributed	O	['N']	[9]
10	to	O	['N']	[10]
11	trazodone	B-Drug	['Causes']	[3]
12	alone	O	['N']	[12]
13	,	O	['N']	[13]
14	the	O	['N']	[14]
15	drug	O	['N']	[15]
16	at	O	['N']	[16]
17	least	O	['N']	[17]
18	acted	O	['N']	[18]
19	as	O	['N']	[19]
20	an	O	['N']	[20]
21	eliciting	O	['N']	[21]
22	agent	O	['N']	[22]
23	.	O	['N']	[23]
#1807
0	Transient	B	['N']	[0]
1	acute	I	['N']	[1]
2	myopia	I-Adverse_Effect	['N']	[2]
3	resulting	O	['N']	[3]
4	from	O	['N']	[4]
5	isotretinoin	B-Drug	['Causes']	[2]
6	(	O	['N']	[6]
7	accutane	O	['N']	[7]
8	)	O	['N']	[8]
9	therapy	O	['N']	[9]
10	.	O	['N']	[10]
#1808
0	Troglitazone	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	fulminant	B	['N']	[3]
4	hepatic	I	['N']	[4]
5	failure	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#1809
0	Drug	O	['N']	[0]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	mammary	B	['N']	[3]
4	hyperplasias	I-Adverse_Effect	['N']	[4]
5	have	O	['N']	[5]
6	been	O	['N']	[6]
7	reported	O	['N']	[7]
8	as	O	['N']	[8]
9	rare	O	['N']	[9]
10	complications	O	['N']	[10]
11	of	O	['N']	[11]
12	D	B	['N']	[12]
13	-	I	['N']	[13]
14	penicillamine	I-Drug	['Causes']	[4]
15	and	O	['N']	[15]
16	Neothetazone	O	['N']	[16]
17	.	O	['N']	[17]
#1810
0	The	O	['N']	[0]
1	epivodes	O	['N']	[1]
2	of	O	['N']	[2]
3	NMS	B-Adverse_Effect	['N']	[3]
4	occured	O	['N']	[4]
5	under	O	['N']	[5]
6	treatment	O	['N']	[6]
7	with	O	['N']	[7]
8	clozapine	B-Drug	['Causes']	[3]
9	,	O	['N']	[9]
10	risperidone	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	amisulpride	O	['N']	[13]
14	.	O	['N']	[14]
#1811
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	seropositive	O	['N']	[3]
4	rheumatoid	O	['N']	[4]
5	arthritis	O	['N']	[5]
6	developed	O	['N']	[6]
7	ascites	B-Adverse_Effect	['N']	[7]
8	while	O	['N']	[8]
9	taking	O	['N']	[9]
10	weekly	O	['N']	[10]
11	doses	O	['N']	[11]
12	of	O	['N']	[12]
13	methotrexate	O	['N']	[13]
14	(	O	['N']	[14]
15	MTX	B-Drug	['Causes']	[7]
16	)	O	['N']	[16]
17	.	O	['N']	[17]
#1812
0	Photo	B	['N']	[0]
1	-	I	['N']	[1]
2	onycholysis	I-Adverse_Effect	['N']	[2]
3	caused	O	['N']	[3]
4	by	O	['N']	[4]
5	olanzapine	O	['N']	[5]
6	and	O	['N']	[6]
7	aripiprazole	B-Drug	['Causes']	[2]
8	.	O	['N']	[8]
#1813
0	These	O	['N']	[0]
1	cases	O	['N']	[1]
2	highlight	O	['N']	[2]
3	the	O	['N']	[3]
4	occurrence	O	['N']	[4]
5	of	O	['N']	[5]
6	livedo	B	['N']	[6]
7	reticularis	I-Adverse_Effect	['N']	[7]
8	as	O	['N']	[8]
9	an	O	['N']	[9]
10	uncommon	O	['N']	[10]
11	side	O	['N']	[11]
12	-	O	['N']	[12]
13	effect	O	['N']	[13]
14	of	O	['N']	[14]
15	interferon	B	['N']	[15]
16	alpha	I-Drug	['Causes']	[7]
17	treatment	O	['N']	[17]
18	.	O	['N']	[18]
#1814
0	These	O	['N']	[0]
1	in	O	['N']	[1]
2	vitro	O	['N']	[2]
3	findings	O	['N']	[3]
4	and	O	['N']	[4]
5	clinical	O	['N']	[5]
6	course	O	['N']	[6]
7	suggest	O	['N']	[7]
8	that	O	['N']	[8]
9	TRAb	B	['N']	[9]
10	/	I	['N']	[10]
11	TBII	I	['N']	[11]
12	without	I	['N']	[12]
13	thyroid	I	['N']	[13]
14	-	I	['N']	[14]
15	stimulating	I	['N']	[15]
16	activity	I-Adverse_Effect	['N']	[16]
17	may	O	['N']	[17]
18	develop	O	['N']	[18]
19	in	O	['N']	[19]
20	patients	O	['N']	[20]
21	with	O	['N']	[21]
22	amiodarone	B-Drug	['Causes']	[16]
23	-	O	['N']	[23]
24	induced	O	['N']	[24]
25	destructive	O	['N']	[25]
26	thyroiditis	O	['N']	[26]
27	,	O	['N']	[27]
28	as	O	['N']	[28]
29	reported	O	['N']	[29]
30	in	O	['N']	[30]
31	patients	O	['N']	[31]
32	with	O	['N']	[32]
33	destructive	O	['N']	[33]
34	thyroiditis	O	['N']	[34]
35	,	O	['N']	[35]
36	such	O	['N']	[36]
37	as	O	['N']	[37]
38	subacute	O	['N']	[38]
39	and	O	['N']	[39]
40	silent	O	['N']	[40]
41	thyroiditis	O	['N']	[41]
42	.	O	['N']	[42]
#1815
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	as	O	['N']	[2]
3	the	O	['N']	[3]
4	use	O	['N']	[4]
5	of	O	['N']	[5]
6	hepatitis	B	['N']	[6]
7	B	I	['N']	[7]
8	vaccination	I-Drug	['Causes']	[19]
9	is	O	['N']	[9]
10	growing	O	['N']	[10]
11	,	O	['N']	[11]
12	adverse	O	['N']	[12]
13	side	O	['N']	[13]
14	effects	O	['N']	[14]
15	,	O	['N']	[15]
16	including	O	['N']	[16]
17	mental	B	['N']	[17]
18	nerve	I	['N']	[18]
19	neuropathy	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	should	O	['N']	[21]
22	be	O	['N']	[22]
23	observed	O	['N']	[23]
24	with	O	['N']	[24]
25	an	O	['N']	[25]
26	increased	O	['N']	[26]
27	frequency	O	['N']	[27]
28	.	O	['N']	[28]
#1816
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Patients	O	['N']	[2]
3	with	O	['N']	[3]
4	5-FU	B-Drug	['Causes']	[14]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	ectropion	O	['N']	[7]
8	experience	O	['N']	[8]
9	tender	B	['N']	[9]
10	,	I	['N']	[10]
11	red	I	['N']	[11]
12	,	I	['N']	[12]
13	scaled	I	['N']	[13]
14	lids	I-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	making	O	['N']	[16]
17	contact	O	['N']	[17]
18	lens	O	['N']	[18]
19	wear	O	['N']	[19]
20	difficult	O	['N']	[20]
21	.	O	['N']	[21]
#1817
0	A	O	['N']	[0]
1	syndrome	B	['N']	[1]
2	of	I	['N']	[2]
3	increased	I	['N']	[3]
4	affect	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	response	O	['N']	[6]
7	to	O	['N']	[7]
8	risperidone	B-Drug	['Causes']	[4]
9	among	O	['N']	[9]
10	patients	O	['N']	[10]
11	with	O	['N']	[11]
12	schizophrenia	O	['N']	[12]
13	.	O	['N']	[13]
#1818
0	Visual	O	['N']	[0]
1	loss	O	['N']	[1]
2	after	O	['N']	[2]
3	a	O	['N']	[3]
4	single	B	['N']	[4]
5	small	I	['N']	[5]
6	dose	I-Dose	['N']	[6]
7	of	O	['N']	[7]
8	vincristine	B-Drug	['Dosage']	[6]
9	has	O	['N']	[9]
10	never	O	['N']	[10]
11	been	O	['N']	[11]
12	reported	O	['N']	[12]
13	.	O	['N']	[13]
#1819
0	Oxcarbazepine	B-Drug	['Causes']	[11]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	Drug	O	['N']	[3]
4	Reaction	O	['N']	[4]
5	with	O	['N']	[5]
6	Eosinophilia	O	['N']	[6]
7	and	O	['N']	[7]
8	Systemic	O	['N']	[8]
9	Symptoms	O	['N']	[9]
10	(	O	['N']	[10]
11	DRESS	B-Adverse_Effect	['N']	[11]
12	)	O	['N']	[12]
13	.	O	['N']	[13]
#1820
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	life	O	['N']	[5]
6	-	O	['N']	[6]
7	threatening	O	['N']	[7]
8	hyponatremia	B-Adverse_Effect	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	sibutramine	B-Drug	['Causes']	[8]
12	use	O	['N']	[12]
13	in	O	['N']	[13]
14	an	O	['N']	[14]
15	obese	O	['N']	[15]
16	woman	O	['N']	[16]
17	.	O	['N']	[17]
#1821
0	Musculoskeletal	B	['N']	[0]
1	complaints	I-Adverse_Effect	['N']	[1]
2	were	O	['N']	[2]
3	the	O	['N']	[3]
4	presenting	O	['N']	[4]
5	symptoms	O	['N']	[5]
6	in	O	['N']	[6]
7	four	O	['N']	[7]
8	of	O	['N']	[8]
9	44	O	['N']	[9]
10	children	O	['N']	[10]
11	(	O	['N']	[11]
12	9	O	['N']	[12]
13	%	O	['N']	[13]
14	)	O	['N']	[14]
15	treated	O	['N']	[15]
16	for	O	['N']	[16]
17	relapsed	O	['N']	[17]
18	Wilms	O	['N']	[18]
19	'	O	['N']	[19]
20	tumors	O	['N']	[20]
21	with	O	['N']	[21]
22	ifosfamide	B-Drug	['Causes']	[1]
23	,	O	['N']	[23]
24	a	O	['N']	[24]
25	derivative	O	['N']	[25]
26	of	O	['N']	[26]
27	cyclophosphamide	O	['N']	[27]
28	.	O	['N']	[28]
#1822
0	Therefore	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	diagnosed	O	['N']	[3]
4	her	O	['N']	[4]
5	eruption	B-Adverse_Effect	['N']	[5]
6	as	O	['N']	[6]
7	contact	O	['N']	[7]
8	dermatitis	O	['N']	[8]
9	due	O	['N']	[9]
10	to	O	['N']	[10]
11	sodium	B	['N']	[11]
12	bisulfite	I-Drug	['Causes']	[5]
13	.	O	['N']	[13]
#1823
0	Enoxaparin	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	generalized	B	['N']	[3]
4	exanthem	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#1824
0	Eosinophilia	B-Adverse_Effect	['N']	[0]
1	has	O	['N']	[1]
2	been	O	['N']	[2]
3	encountered	O	['N']	[3]
4	from	O	['N']	[4]
5	0.2	O	['N']	[5]
6	to	O	['N']	[6]
7	61.7	O	['N']	[7]
8	%	O	['N']	[8]
9	in	O	['N']	[9]
10	clozapine	B-Drug	['Causes']	[0]
11	-	O	['N']	[11]
12	treated	O	['N']	[12]
13	patients	O	['N']	[13]
14	,	O	['N']	[14]
15	mostly	O	['N']	[15]
16	with	O	['N']	[16]
17	a	O	['N']	[17]
18	transient	O	['N']	[18]
19	course	O	['N']	[19]
20	and	O	['N']	[20]
21	spontaneous	O	['N']	[21]
22	remission	O	['N']	[22]
23	.	O	['N']	[23]
#1825
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	skeletal	B	['N']	[3]
4	fluorosis	I-Adverse_Effect	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	prolonged	O	['N']	[7]
8	treatment	O	['N']	[8]
9	with	O	['N']	[9]
10	niflumic	B	['N']	[10]
11	acid	I-Drug	['Causes']	[4]
12	,	O	['N']	[12]
13	a	O	['N']	[13]
14	fast	O	['N']	[14]
15	-	O	['N']	[15]
16	acting	O	['N']	[16]
17	non	O	['N']	[17]
18	-	O	['N']	[18]
19	steroid	O	['N']	[19]
20	antiinflammatory	O	['N']	[20]
21	agent	O	['N']	[21]
22	,	O	['N']	[22]
23	is	O	['N']	[23]
24	reported	O	['N']	[24]
25	in	O	['N']	[25]
26	a	O	['N']	[26]
27	35-year	O	['N']	[27]
28	-	O	['N']	[28]
29	old	O	['N']	[29]
30	woman	O	['N']	[30]
31	suffering	O	['N']	[31]
32	from	O	['N']	[32]
33	rheumatoid	O	['N']	[33]
34	arthritis	O	['N']	[34]
35	and	O	['N']	[35]
36	treated	O	['N']	[36]
37	,	O	['N']	[37]
38	in	O	['N']	[38]
39	addition	O	['N']	[39]
40	,	O	['N']	[40]
41	with	O	['N']	[41]
42	corticosteroids	O	['N']	[42]
43	.	O	['N']	[43]
#1826
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	received	O	['N']	[2]
3	respectively	O	['N']	[3]
4	190	O	['N']	[4]
5	mg	O	['N']	[5]
6	,	O	['N']	[6]
7	175	O	['N']	[7]
8	mg	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	196	B	['N']	[11]
12	mg	I-Dose	['N']	[12]
13	of	O	['N']	[13]
14	methotrexate	B-Drug	['Dosage']	[12]
15	and	O	['N']	[15]
16	developed	O	['N']	[16]
17	bilateral	O	['N']	[17]
18	pulmonary	O	['N']	[18]
19	infiltrates	O	['N']	[19]
20	without	O	['N']	[20]
21	evidence	O	['N']	[21]
22	of	O	['N']	[22]
23	peripheral	O	['N']	[23]
24	blood	O	['N']	[24]
25	eosinophilia	O	['N']	[25]
26	.	O	['N']	[26]
#1827
0	Acute	B	['N']	[0]
1	myocardial	I	['N']	[1]
2	infarction	I-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	high	O	['N']	[4]
5	-	O	['N']	[5]
6	dose	O	['N']	[6]
7	methylprednisolone	B-Drug	['Causes']	[2]
8	therapy	O	['N']	[8]
9	for	O	['N']	[9]
10	Graves	O	['N']	[10]
11	'	O	['N']	[11]
12	ophthalmopathy	O	['N']	[12]
13	.	O	['N']	[13]
#1828
0	Severe	O	['N']	[0]
1	rhabdomyolysis	B-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	massive	O	['N']	[3]
4	ingestion	O	['N']	[4]
5	of	O	['N']	[5]
6	oolong	B	['N']	[6]
7	tea	I-Drug	['Causes']	[1]
8	:	O	['N']	[8]
9	caffeine	O	['N']	[9]
10	intoxication	O	['N']	[10]
11	with	O	['N']	[11]
12	coexisting	O	['N']	[12]
13	hyponatremia	O	['N']	[13]
14	.	O	['N']	[14]
#1829
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	CREST	O	['N']	[5]
6	syndrome	O	['N']	[6]
7	(	O	['N']	[7]
8	calcinosis	O	['N']	[8]
9	,	O	['N']	[9]
10	Raynaud	O	['N']	[10]
11	's	O	['N']	[11]
12	phenomenon	O	['N']	[12]
13	,	O	['N']	[13]
14	esophageal	O	['N']	[14]
15	dysfunction	O	['N']	[15]
16	,	O	['N']	[16]
17	sclerodactyly	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	telangiectasia	O	['N']	[20]
21	)	O	['N']	[21]
22	who	O	['N']	[22]
23	paradoxically	O	['N']	[23]
24	experienced	O	['N']	[24]
25	worsening	B	['N']	[25]
26	of	I	['N']	[26]
27	Raynaud	I	['N']	[27]
28	's	I	['N']	[28]
29	phenomenon	I-Adverse_Effect	['N']	[29]
30	when	O	['N']	[30]
31	using	O	['N']	[31]
32	yohimbine	B-Drug	['Causes']	[29]
33	for	O	['N']	[33]
34	ED	O	['N']	[34]
35	.	O	['N']	[35]
#1830
0	Seven	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	hematologic	O	['N']	[3]
4	malignancies	O	['N']	[4]
5	who	O	['N']	[5]
6	were	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	miconazole	B-Drug	['Causes']	[26]
10	for	O	['N']	[10]
11	either	O	['N']	[11]
12	suspected	O	['N']	[12]
13	or	O	['N']	[13]
14	proven	O	['N']	[14]
15	fungal	O	['N']	[15]
16	infections	O	['N']	[16]
17	developed	O	['N']	[17]
18	eight	O	['N']	[18]
19	episodes	O	['N']	[19]
20	of	O	['N']	[20]
21	major	O	['N']	[21]
22	adverse	O	['N']	[22]
23	cardiorespiratory	B	['N']	[23]
24	and	I	['N']	[24]
25	anaphylactic	I	['N']	[25]
26	reactions	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#1831
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	treated	O	['N']	[2]
3	for	O	['N']	[3]
4	chronic	O	['N']	[4]
5	myeloid	O	['N']	[5]
6	leukemia	O	['N']	[6]
7	with	O	['N']	[7]
8	high	O	['N']	[8]
9	doses	O	['N']	[9]
10	of	O	['N']	[10]
11	CCNU	B-Drug	['Dosage']	[16]
12	(	O	['N']	[12]
13	1100	B	['N']	[13]
14	mg	I	['N']	[14]
15	/	I	['N']	[15]
16	m2	I-Dose	['N']	[16]
17	and	O	['N']	[17]
18	1240	O	['N']	[18]
19	mg	O	['N']	[19]
20	/	O	['N']	[20]
21	m2	O	['N']	[21]
22	,	O	['N']	[22]
23	respectively	O	['N']	[23]
24	)	O	['N']	[24]
25	developed	O	['N']	[25]
26	a	O	['N']	[26]
27	fatal	O	['N']	[27]
28	pulmonary	O	['N']	[28]
29	fibrosis	O	['N']	[29]
30	.	O	['N']	[30]
#1832
0	Thrombocytosis	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	enoxaparin	B-Drug	['Causes']	[0]
4	:	O	['N']	[4]
5	A	O	['N']	[5]
6	very	O	['N']	[6]
7	rare	O	['N']	[7]
8	cause	O	['N']	[8]
9	in	O	['N']	[9]
10	newborns	O	['N']	[10]
11	.	O	['N']	[11]
#1833
0	Acute	B	['N']	[0]
1	pancreatitis	I-Adverse_Effect	['N']	[1]
2	is	O	['N']	[2]
3	a	O	['N']	[3]
4	known	O	['N']	[4]
5	,	O	['N']	[5]
6	although	O	['N']	[6]
7	rare	O	['N']	[7]
8	,	O	['N']	[8]
9	complication	O	['N']	[9]
10	of	O	['N']	[10]
11	mesalamine	B-Drug	['Causes']	[1]
12	treatment	O	['N']	[12]
13	.	O	['N']	[13]
#1834
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	two	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	delayed	O	['N']	[6]
7	elimination	O	['N']	[7]
8	of	O	['N']	[8]
9	methotrexate	O	['N']	[9]
10	in	O	['N']	[10]
11	patients	O	['N']	[11]
12	receiving	O	['N']	[12]
13	ciprofloxacin	B-Drug	['Causes']	[17]
14	,	O	['N']	[14]
15	with	O	['N']	[15]
16	severe	O	['N']	[16]
17	toxicity	B-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#1835
0	A	O	['N']	[0]
1	66-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	Japanese	O	['N']	[4]
5	woman	O	['N']	[5]
6	with	O	['N']	[6]
7	severe	O	['N']	[7]
8	scleroderma	O	['N']	[8]
9	developed	O	['N']	[9]
10	anemia	B-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	thrombocytopenia	O	['N']	[12]
13	due	O	['N']	[13]
14	to	O	['N']	[14]
15	D	O	['N']	[15]
16	-	O	['N']	[16]
17	penicillamine	O	['N']	[17]
18	(	O	['N']	[18]
19	D	B	['N']	[19]
20	-	I	['N']	[20]
21	Pen	I-Drug	['Causes']	[10]
22	)	O	['N']	[22]
23	treatment	O	['N']	[23]
24	,	O	['N']	[24]
25	although	O	['N']	[25]
26	the	O	['N']	[26]
27	leukopenia	O	['N']	[27]
28	was	O	['N']	[28]
29	not	O	['N']	[29]
30	markedly	O	['N']	[30]
31	severe	O	['N']	[31]
32	.	O	['N']	[32]
#1836
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	main	O	['N']	[3]
4	adverse	O	['N']	[4]
5	effects	O	['N']	[5]
6	of	O	['N']	[6]
7	leflunomide	B-Drug	['Causes']	[16]
8	consist	O	['N']	[8]
9	of	O	['N']	[9]
10	diarrhea	O	['N']	[10]
11	,	O	['N']	[11]
12	nausea	O	['N']	[12]
13	,	O	['N']	[13]
14	liver	B	['N']	[14]
15	enzyme	I	['N']	[15]
16	elevation	I-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	hypertension	O	['N']	[18]
19	,	O	['N']	[19]
20	alopecia	O	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	allergic	O	['N']	[23]
24	skin	O	['N']	[24]
25	reactions	O	['N']	[25]
26	.	O	['N']	[26]
#1837
0	Two	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	lepromatous	O	['N']	[3]
4	leprosy	O	['N']	[4]
5	with	O	['N']	[5]
6	erythema	O	['N']	[6]
7	nodosum	O	['N']	[7]
8	leprosum	O	['N']	[8]
9	who	O	['N']	[9]
10	were	O	['N']	[10]
11	on	O	['N']	[11]
12	high	O	['N']	[12]
13	doses	O	['N']	[13]
14	of	O	['N']	[14]
15	clofazimine	B-Drug	['Causes']	[26]
16	,	O	['N']	[16]
17	showed	O	['N']	[17]
18	discoloration	O	['N']	[18]
19	of	O	['N']	[19]
20	nail	O	['N']	[20]
21	plate	O	['N']	[21]
22	,	O	['N']	[22]
23	subungual	O	['N']	[23]
24	hyperkeratosis	O	['N']	[24]
25	and	O	['N']	[25]
26	onycholysis	B-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#1838
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	Stevens	O	['N']	[5]
6	-	O	['N']	[6]
7	Johnson	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	/	O	['N']	[9]
10	toxic	O	['N']	[10]
11	epidermal	O	['N']	[11]
12	necrolysis	O	['N']	[12]
13	(	O	['N']	[13]
14	SJS	B-Adverse_Effect	['N']	[14]
15	/	O	['N']	[15]
16	TEN	O	['N']	[16]
17	)	O	['N']	[17]
18	secondary	O	['N']	[18]
19	to	O	['N']	[19]
20	trimethoprim	B	['N']	[20]
21	-	I	['N']	[21]
22	sulfamethoxazole	I-Drug	['Causes']	[14]
23	(	O	['N']	[23]
24	TMP	O	['N']	[24]
25	-	O	['N']	[25]
26	Sx	O	['N']	[26]
27	)	O	['N']	[27]
28	therapy	O	['N']	[28]
29	for	O	['N']	[29]
30	presumed	O	['N']	[30]
31	community	O	['N']	[31]
32	-	O	['N']	[32]
33	associated	O	['N']	[33]
34	methicillin	O	['N']	[34]
35	-	O	['N']	[35]
36	resistant	O	['N']	[36]
37	Staphylococcus	O	['N']	[37]
38	aureus	O	['N']	[38]
39	(	O	['N']	[39]
40	CA	O	['N']	[40]
41	-	O	['N']	[41]
42	MRSA	O	['N']	[42]
43	)	O	['N']	[43]
44	infection	O	['N']	[44]
45	.	O	['N']	[45]
#1839
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	allogeneic	O	['N']	[3]
4	bone	O	['N']	[4]
5	marrow	O	['N']	[5]
6	transplant	O	['N']	[6]
7	recipient	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	CMV	B	['N']	[10]
11	infection	I-Adverse_Effect	['N']	[11]
12	refractory	O	['N']	[12]
13	to	O	['N']	[13]
14	sequential	O	['N']	[14]
15	therapy	O	['N']	[15]
16	with	O	['N']	[16]
17	ganciclovir	O	['N']	[17]
18	,	O	['N']	[18]
19	foscarnet	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	cidofovir	B-Drug	['Causes']	[11]
23	.	O	['N']	[23]
#1840
0	It	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	recognized	O	['N']	[3]
4	that	O	['N']	[4]
5	ibuprofen	B-Drug	['Causes']	[13]
6	may	O	['N']	[6]
7	be	O	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	salt	B	['N']	[10]
11	and	I	['N']	[11]
12	water	I	['N']	[12]
13	retention	I-Adverse_Effect	['N']	[13]
14	in	O	['N']	[14]
15	the	O	['N']	[15]
16	same	O	['N']	[16]
17	fashion	O	['N']	[17]
18	as	O	['N']	[18]
19	previously	O	['N']	[19]
20	described	O	['N']	[20]
21	with	O	['N']	[21]
22	phenylbutazone	O	['N']	[22]
23	and	O	['N']	[23]
24	indomethacin	O	['N']	[24]
25	.	O	['N']	[25]
#1841
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	normotensive	B	['N']	[3]
4	scleroderma	I	['N']	[4]
5	renal	I	['N']	[5]
6	crisis	I-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	high	O	['N']	[8]
9	-	O	['N']	[9]
10	dose	O	['N']	[10]
11	methylprednisolone	B-Drug	['Causes']	[6]
12	treatment	O	['N']	[12]
13	.	O	['N']	[13]
#1842
0	Papilledema	B-Adverse_Effect	['N']	[0]
1	without	O	['N']	[1]
2	peripheral	O	['N']	[2]
3	neuropathy	O	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	taking	O	['N']	[7]
8	perhexiline	B	['N']	[8]
9	maleate	I-Drug	['Causes']	[0]
10	.	O	['N']	[10]
#1843
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	new	O	['N']	[3]
4	quinolone	O	['N']	[4]
5	derivatives	O	['N']	[5]
6	(	O	['N']	[6]
7	levofloxacin	O	['N']	[7]
8	,	O	['N']	[8]
9	sparfloxacin	O	['N']	[9]
10	,	O	['N']	[10]
11	grepafloxacin	O	['N']	[11]
12	,	O	['N']	[12]
13	trovafloxacin	B-Drug	['Causes']	[45]
14	,	O	['N']	[14]
15	gatifloxacin	O	['N']	[15]
16	and	O	['N']	[16]
17	moxifloxacin	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	also	O	['N']	[20]
21	called	O	['N']	[21]
22	gyrase	O	['N']	[22]
23	inhibitors	O	['N']	[23]
24	,	O	['N']	[24]
25	are	O	['N']	[25]
26	known	O	['N']	[26]
27	for	O	['N']	[27]
28	their	O	['N']	[28]
29	potential	O	['N']	[29]
30	to	O	['N']	[30]
31	cause	O	['N']	[31]
32	central	O	['N']	[32]
33	nervous	O	['N']	[33]
34	system	O	['N']	[34]
35	-	O	['N']	[35]
36	related	O	['N']	[36]
37	adverse	O	['N']	[37]
38	effects	O	['N']	[38]
39	,	O	['N']	[39]
40	including	O	['N']	[40]
41	headache	O	['N']	[41]
42	,	O	['N']	[42]
43	dizziness	O	['N']	[43]
44	and	O	['N']	[44]
45	insomnia	B-Adverse_Effect	['N']	[45]
46	.	O	['N']	[46]
#1844
0	Dyspnea	B-Adverse_Effect	['N']	[0]
1	possibly	O	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	controlled	O	['N']	[4]
5	-	O	['N']	[5]
6	release	O	['N']	[6]
7	morphine	B	['N']	[7]
8	sulfate	I-Drug	['Causes']	[0]
9	tablets	O	['N']	[9]
10	.	O	['N']	[10]
#1845
0	Acute	B	['N']	[0]
1	dystonia	I-Adverse_Effect	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	lamivudine	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#1846
0	Priapism	B-Adverse_Effect	['N']	[0]
1	as	O	['N']	[1]
2	a	O	['N']	[2]
3	complication	O	['N']	[3]
4	of	O	['N']	[4]
5	heparin	B-Drug	['Causes']	[0]
6	therapy	O	['N']	[6]
7	.	O	['N']	[7]
#1847
0	Erythromycin	O	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	macrolide	O	['N']	[3]
4	antibiotic	O	['N']	[4]
5	that	O	['N']	[5]
6	may	O	['N']	[6]
7	increase	O	['N']	[7]
8	the	O	['N']	[8]
9	risk	O	['N']	[9]
10	of	O	['N']	[10]
11	lovastatin	B-Drug	['Causes']	[14]
12	-	O	['N']	[12]
13	induced	O	['N']	[13]
14	rhabdomyolysis	B-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#1848
0	Diarrhoea	O	['N']	[0]
1	,	O	['N']	[1]
2	T	B	['N']	[2]
3	-	I	['N']	[3]
4	CD4	I	['N']	[4]
5	+	I	['N']	[5]
6	lymphopenia	I-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	bilateral	O	['N']	[8]
9	patchy	O	['N']	[9]
10	pulmonary	O	['N']	[10]
11	infiltrates	O	['N']	[11]
12	developed	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	male	O	['N']	[15]
16	60	O	['N']	[16]
17	yrs	O	['N']	[17]
18	of	O	['N']	[18]
19	age	O	['N']	[19]
20	,	O	['N']	[20]
21	who	O	['N']	[21]
22	was	O	['N']	[22]
23	treated	O	['N']	[23]
24	with	O	['N']	[24]
25	oxaliplatinum	O	['N']	[25]
26	and	O	['N']	[26]
27	5-fluorouracil	B-Drug	['Causes']	[6]
28	for	O	['N']	[28]
29	unresectable	O	['N']	[29]
30	rectum	O	['N']	[30]
31	carcinoma	O	['N']	[31]
32	.	O	['N']	[32]
#1849
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	treated	O	['N']	[2]
3	with	O	['N']	[3]
4	acyclovir	B-Drug	['Causes']	[12]
5	and	O	['N']	[5]
6	subsequently	O	['N']	[6]
7	developed	O	['N']	[7]
8	VZV	B	['N']	[8]
9	antigen	I	['N']	[9]
10	-	I	['N']	[10]
11	positive	I	['N']	[11]
12	zoster	I-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#1850
0	Quinine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hearing	B	['N']	[3]
4	loss	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#1851
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	Double	O	['N']	[2]
3	-	O	['N']	[3]
4	blind	O	['N']	[4]
5	,	O	['N']	[5]
6	placebo	O	['N']	[6]
7	-	O	['N']	[7]
8	controlled	O	['N']	[8]
9	titrated	O	['N']	[9]
10	oral	O	['N']	[10]
11	challenges	O	['N']	[11]
12	with	O	['N']	[12]
13	pancreatic	O	['N']	[13]
14	enzymes	O	['N']	[14]
15	resulted	O	['N']	[15]
16	in	O	['N']	[16]
17	definite	O	['N']	[17]
18	vomiting	B-Adverse_Effect	['N']	[18]
19	within	O	['N']	[19]
20	1	O	['N']	[20]
21	to	O	['N']	[21]
22	1.5	O	['N']	[22]
23	hours	O	['N']	[23]
24	after	O	['N']	[24]
25	challenges	O	['N']	[25]
26	with	O	['N']	[26]
27	Viokase	B-Drug	['Causes']	[18]
28	and	O	['N']	[28]
29	Pancrease	O	['N']	[29]
30	MT	O	['N']	[30]
31	16	O	['N']	[31]
32	,	O	['N']	[32]
33	but	O	['N']	[33]
34	not	O	['N']	[34]
35	with	O	['N']	[35]
36	placebo	O	['N']	[36]
37	.	O	['N']	[37]
#1852
0	We	O	['N']	[0]
1	concluded	O	['N']	[1]
2	that	O	['N']	[2]
3	the	O	['N']	[3]
4	colonic	B	['N']	[4]
5	ulcer	I-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	the	O	['N']	[7]
8	sigmoidovesical	O	['N']	[8]
9	fistula	O	['N']	[9]
10	had	O	['N']	[10]
11	been	O	['N']	[11]
12	caused	O	['N']	[12]
13	by	O	['N']	[13]
14	the	O	['N']	[14]
15	administration	O	['N']	[15]
16	of	O	['N']	[16]
17	calcium	O	['N']	[17]
18	polystyrene	O	['N']	[18]
19	sulfonate	O	['N']	[19]
20	and	O	['N']	[20]
21	sorbitol	B-Drug	['Causes']	[5]
22	.	O	['N']	[22]
#1853
0	These	O	['N']	[0]
1	in	O	['N']	[1]
2	vitro	O	['N']	[2]
3	findings	O	['N']	[3]
4	and	O	['N']	[4]
5	clinical	O	['N']	[5]
6	course	O	['N']	[6]
7	suggest	O	['N']	[7]
8	that	O	['N']	[8]
9	TRAb	O	['N']	[9]
10	/	O	['N']	[10]
11	TBII	O	['N']	[11]
12	without	O	['N']	[12]
13	thyroid	O	['N']	[13]
14	-	O	['N']	[14]
15	stimulating	O	['N']	[15]
16	activity	O	['N']	[16]
17	may	O	['N']	[17]
18	develop	O	['N']	[18]
19	in	O	['N']	[19]
20	patients	O	['N']	[20]
21	with	O	['N']	[21]
22	amiodarone	B-Drug	['Causes']	[26]
23	-	O	['N']	[23]
24	induced	O	['N']	[24]
25	destructive	B	['N']	[25]
26	thyroiditis	I-Adverse_Effect	['N']	[26]
27	,	O	['N']	[27]
28	as	O	['N']	[28]
29	reported	O	['N']	[29]
30	in	O	['N']	[30]
31	patients	O	['N']	[31]
32	with	O	['N']	[32]
33	destructive	O	['N']	[33]
34	thyroiditis	O	['N']	[34]
35	,	O	['N']	[35]
36	such	O	['N']	[36]
37	as	O	['N']	[37]
38	subacute	O	['N']	[38]
39	and	O	['N']	[39]
40	silent	O	['N']	[40]
41	thyroiditis	O	['N']	[41]
42	.	O	['N']	[42]
#1854
0	The	O	['N']	[0]
1	reversal	O	['N']	[1]
2	of	O	['N']	[2]
3	heparin	O	['N']	[3]
4	by	O	['N']	[4]
5	protamine	B-Drug	['Causes']	[21]
6	may	O	['N']	[6]
7	cause	O	['N']	[7]
8	severe	O	['N']	[8]
9	hemodynamic	O	['N']	[9]
10	deterioration	O	['N']	[10]
11	,	O	['N']	[11]
12	characterized	O	['N']	[12]
13	by	O	['N']	[13]
14	systemic	O	['N']	[14]
15	hypotension	O	['N']	[15]
16	,	O	['N']	[16]
17	pulmonary	O	['N']	[17]
18	hypertension	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	bronchoconstriction	B-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#1855
0	Phantom	O	['N']	[0]
1	limb	O	['N']	[1]
2	pain	O	['N']	[2]
3	as	O	['N']	[3]
4	a	O	['N']	[4]
5	manifestation	O	['N']	[5]
6	of	O	['N']	[6]
7	paclitaxel	B-Drug	['Causes']	[8]
8	neurotoxicity	B-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#1856
0	Premature	B	['N']	[0]
1	closure	I	['N']	[1]
2	of	I	['N']	[2]
3	the	I	['N']	[3]
4	ductus	I	['N']	[4]
5	arteriosus	I-Adverse_Effect	['N']	[5]
6	:	O	['N']	[6]
7	variable	O	['N']	[7]
8	response	O	['N']	[8]
9	among	O	['N']	[9]
10	monozygotic	O	['N']	[10]
11	twins	O	['N']	[11]
12	after	O	['N']	[12]
13	in	O	['N']	[13]
14	utero	O	['N']	[14]
15	exposure	O	['N']	[15]
16	to	O	['N']	[16]
17	indomethacin	B-Drug	['Causes']	[5]
18	.	O	['N']	[18]
#1857
0	After	O	['N']	[0]
1	several	O	['N']	[1]
2	unrevealing	O	['N']	[2]
3	medical	O	['N']	[3]
4	work	O	['N']	[4]
5	-	O	['N']	[5]
6	ups	O	['N']	[6]
7	,	O	['N']	[7]
8	he	O	['N']	[8]
9	was	O	['N']	[9]
10	found	O	['N']	[10]
11	to	O	['N']	[11]
12	have	O	['N']	[12]
13	a	O	['N']	[13]
14	high	B	['N']	[14]
15	blood	I	['N']	[15]
16	lead	B-Drug	['Causes']	[17]
17	level	I-Adverse_Effect	['N']	[17]
18	(	O	['N']	[18]
19	122	O	['N']	[19]
20	microg	O	['N']	[20]
21	/	O	['N']	[21]
22	dL	O	['N']	[22]
23	)	O	['N']	[23]
24	;	O	['N']	[24]
25	he	O	['N']	[25]
26	has	O	['N']	[26]
27	a	O	['N']	[27]
28	history	O	['N']	[28]
29	of	O	['N']	[29]
30	scraping	O	['N']	[30]
31	and	O	['N']	[31]
32	sanding	O	['N']	[32]
33	lead	O	['N']	[33]
34	paint	O	['N']	[34]
35	without	O	['N']	[35]
36	adequate	O	['N']	[36]
37	protective	O	['N']	[37]
38	measures	O	['N']	[38]
39	.	O	['N']	[39]
#1858
0	Possible	O	['N']	[0]
1	heart	B	['N']	[1]
2	failure	I	['N']	[2]
3	exacerbation	I-Adverse_Effect	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	rosiglitazone	B-Drug	['Causes']	[3]
7	:	O	['N']	[7]
8	case	O	['N']	[8]
9	report	O	['N']	[9]
10	and	O	['N']	[10]
11	literature	O	['N']	[11]
12	review	O	['N']	[12]
13	.	O	['N']	[13]
#1859
0	Knowledge	O	['N']	[0]
1	regarding	O	['N']	[1]
2	potential	O	['N']	[2]
3	adverse	O	['N']	[3]
4	effects	O	['N']	[4]
5	of	O	['N']	[5]
6	CAP	B-Drug	['Causes']	[17]
7	is	O	['N']	[7]
8	paramount	O	['N']	[8]
9	and	O	['N']	[9]
10	dose	O	['N']	[10]
11	modification	O	['N']	[11]
12	is	O	['N']	[12]
13	indicated	O	['N']	[13]
14	with	O	['N']	[14]
15	development	O	['N']	[15]
16	of	O	['N']	[16]
17	neurotoxicity	B-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#1860
0	Fatal	B	['N']	[0]
1	ventricular	I	['N']	[1]
2	fibrillation	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	treatment	O	['N']	[4]
5	with	O	['N']	[5]
6	digoxin	B-Drug	['Causes']	[2]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	27-year	O	['N']	[9]
10	-	O	['N']	[10]
11	old	O	['N']	[11]
12	man	O	['N']	[12]
13	with	O	['N']	[13]
14	mitral	O	['N']	[14]
15	leaflet	O	['N']	[15]
16	prolapse	O	['N']	[16]
17	syndrome	O	['N']	[17]
18	.	O	['N']	[18]
#1861
0	Fatal	B	['N']	[0]
1	pulmonary	I	['N']	[1]
2	fibrosis	I-Adverse_Effect	['N']	[2]
3	following	O	['N']	[3]
4	1,3-bis(2-chloroethyl)-1-nitrosourea	B-Drug	['Causes']	[2]
5	(	O	['N']	[5]
6	BCNU	O	['N']	[6]
7	)	O	['N']	[7]
8	therapy	O	['N']	[8]
9	.	O	['N']	[9]
#1862
0	The	O	['N']	[0]
1	latter	O	['N']	[1]
2	form	O	['N']	[2]
3	(	O	['N']	[3]
4	Macrodantin	B-Drug	['Causes']	[36]
5	)	O	['N']	[5]
6	is	O	['N']	[6]
7	reported	O	['N']	[7]
8	to	O	['N']	[8]
9	engender	O	['N']	[9]
10	less	O	['N']	[10]
11	gastrointestinal	O	['N']	[11]
12	intolerance	O	['N']	[12]
13	but	O	['N']	[13]
14	it	O	['N']	[14]
15	can	O	['N']	[15]
16	produce	O	['N']	[16]
17	the	O	['N']	[17]
18	same	O	['N']	[18]
19	adverse	O	['N']	[19]
20	effects	O	['N']	[20]
21	as	O	['N']	[21]
22	the	O	['N']	[22]
23	conventional	O	['N']	[23]
24	form	O	['N']	[24]
25	--	O	['N']	[25]
26	liver	O	['N']	[26]
27	damage	O	['N']	[27]
28	,	O	['N']	[28]
29	acute	O	['N']	[29]
30	and	O	['N']	[30]
31	chronic	O	['N']	[31]
32	pulmonary	O	['N']	[32]
33	reactions	O	['N']	[33]
34	,	O	['N']	[34]
35	peripheral	B	['N']	[35]
36	neuropathy	I-Adverse_Effect	['N']	[36]
37	,	O	['N']	[37]
38	blood	O	['N']	[38]
39	dyscrasias	O	['N']	[39]
40	and	O	['N']	[40]
41	allergic	O	['N']	[41]
42	reactions	O	['N']	[42]
43	--	O	['N']	[43]
44	and	O	['N']	[44]
45	does	O	['N']	[45]
46	so	O	['N']	[46]
47	just	O	['N']	[47]
48	as	O	['N']	[48]
49	rapidly	O	['N']	[49]
50	and	O	['N']	[50]
51	floridly	O	['N']	[51]
52	;	O	['N']	[52]
53	one	O	['N']	[53]
54	such	O	['N']	[54]
55	case	O	['N']	[55]
56	is	O	['N']	[56]
57	reported	O	['N']	[57]
58	here	O	['N']	[58]
59	.	O	['N']	[59]
#1863
0	Amphotericin	O	['N']	[0]
1	B	O	['N']	[1]
2	(	O	['N']	[2]
3	AmB	B-Drug	['Causes']	[19]
4	)	O	['N']	[4]
5	is	O	['N']	[5]
6	effective	O	['N']	[6]
7	,	O	['N']	[7]
8	but	O	['N']	[8]
9	its	O	['N']	[9]
10	use	O	['N']	[10]
11	is	O	['N']	[11]
12	limited	O	['N']	[12]
13	by	O	['N']	[13]
14	toxicity	O	['N']	[14]
15	:	O	['N']	[15]
16	renal	O	['N']	[16]
17	impairment	O	['N']	[17]
18	,	O	['N']	[18]
19	anaemia	B-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	malaise	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	hypokalaemia	O	['N']	[26]
27	are	O	['N']	[27]
28	common	O	['N']	[28]
29	.	O	['N']	[29]
#1864
0	A	O	['N']	[0]
1	53-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	developed	O	['N']	[5]
6	lower	O	['N']	[6]
7	leg	O	['N']	[7]
8	edema	O	['N']	[8]
9	4	O	['N']	[9]
10	weeks	O	['N']	[10]
11	after	O	['N']	[11]
12	rosiglitazone	B-Drug	['Dosage']	[26]
13	was	O	['N']	[13]
14	increased	O	['N']	[14]
15	from	O	['N']	[15]
16	4	O	['N']	[16]
17	mg	O	['N']	[17]
18	once	O	['N']	[18]
19	/	O	['N']	[19]
20	day	O	['N']	[20]
21	to	O	['N']	[21]
22	4	B	['N']	[22]
23	mg	I	['N']	[23]
24	twice	I	['N']	[24]
25	/	I	['N']	[25]
26	day	I-Dose	['N']	[26]
27	.	O	['N']	[27]
#1865
0	A	O	['N']	[0]
1	59-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	myasthenia	O	['N']	[6]
7	gravis	O	['N']	[7]
8	who	O	['N']	[8]
9	received	O	['N']	[9]
10	a	O	['N']	[10]
11	large	O	['N']	[11]
12	dose	O	['N']	[12]
13	of	O	['N']	[13]
14	pyridostigmine	B	['N']	[14]
15	bromide	I-Drug	['Causes']	[25]
16	developed	O	['N']	[16]
17	postoperative	O	['N']	[17]
18	psychosis	O	['N']	[18]
19	and	O	['N']	[19]
20	was	O	['N']	[20]
21	diagnosed	O	['N']	[21]
22	as	O	['N']	[22]
23	having	O	['N']	[23]
24	bromide	B	['N']	[24]
25	intoxication	I-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#1866
0	A	O	['N']	[0]
1	14-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	developed	O	['N']	[5]
6	systemic	O	['N']	[6]
7	lupus	O	['N']	[7]
8	erythematosus	O	['N']	[8]
9	(	O	['N']	[9]
10	SLE)-like	O	['N']	[10]
11	symptoms	O	['N']	[11]
12	,	O	['N']	[12]
13	rash	O	['N']	[13]
14	,	O	['N']	[14]
15	fever	O	['N']	[15]
16	,	O	['N']	[16]
17	leukopenia	B-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	positive	O	['N']	[19]
20	anti	O	['N']	[20]
21	-	O	['N']	[21]
22	nuclear	O	['N']	[22]
23	antibody	O	['N']	[23]
24	(	O	['N']	[24]
25	ANA	O	['N']	[25]
26	)	O	['N']	[26]
27	two	O	['N']	[27]
28	weeks	O	['N']	[28]
29	after	O	['N']	[29]
30	administration	O	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	O	['N']	[32]
33	(	O	['N']	[33]
34	CBZ	O	['N']	[34]
35	;	O	['N']	[35]
36	Tegretol	B-Drug	['Causes']	[17]
37	)	O	['N']	[37]
38	used	O	['N']	[38]
39	against	O	['N']	[39]
40	benign	O	['N']	[40]
41	Rolandic	O	['N']	[41]
42	epilepsy	O	['N']	[42]
43	.	O	['N']	[43]
#1867
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	An	O	['N']	[3]
4	80-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	white	O	['N']	[7]
8	female	O	['N']	[8]
9	,	O	['N']	[9]
10	followed	O	['N']	[10]
11	up	O	['N']	[11]
12	at	O	['N']	[12]
13	the	O	['N']	[13]
14	Memory	O	['N']	[14]
15	Clinic	O	['N']	[15]
16	for	O	['N']	[16]
17	mild	O	['N']	[17]
18	cognitive	O	['N']	[18]
19	impairment	O	['N']	[19]
20	,	O	['N']	[20]
21	had	O	['N']	[21]
22	been	O	['N']	[22]
23	taking	O	['N']	[23]
24	propafenone	B-Drug	['Dosage']	[28]
25	900	B	['N']	[25]
26	mg	I	['N']	[26]
27	/	I	['N']	[27]
28	d	I-Dose	['N']	[28]
29	for	O	['N']	[29]
30	>	O	['N']	[30]
31	10	O	['N']	[31]
32	years	O	['N']	[32]
33	for	O	['N']	[33]
34	paroxysmal	O	['N']	[34]
35	atrial	O	['N']	[35]
36	fibrillation	O	['N']	[36]
37	without	O	['N']	[37]
38	adverse	O	['N']	[38]
39	effects	O	['N']	[39]
40	.	O	['N']	[40]
#1868
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	severe	B	['N']	[3]
4	visual	I	['N']	[4]
5	loss	I-Adverse_Effect	['N']	[5]
6	following	O	['N']	[6]
7	a	O	['N']	[7]
8	single	O	['N']	[8]
9	dose	O	['N']	[9]
10	of	O	['N']	[10]
11	vincristine	B-Drug	['Causes']	[5]
12	is	O	['N']	[12]
13	described	O	['N']	[13]
14	.	O	['N']	[14]
#1869
0	According	O	['N']	[0]
1	to	O	['N']	[1]
2	the	O	['N']	[2]
3	Naranjo	O	['N']	[3]
4	adverse	O	['N']	[4]
5	drug	O	['N']	[5]
6	reaction	O	['N']	[6]
7	probability	O	['N']	[7]
8	scale	O	['N']	[8]
9	,	O	['N']	[9]
10	the	O	['N']	[10]
11	likelihood	O	['N']	[11]
12	that	O	['N']	[12]
13	temozolomide	B-Drug	['Causes']	[22]
14	was	O	['N']	[14]
15	responsible	O	['N']	[15]
16	for	O	['N']	[16]
17	the	O	['N']	[17]
18	adverse	O	['N']	[18]
19	drug	O	['N']	[19]
20	reaction	O	['N']	[20]
21	of	O	['N']	[21]
22	fever	B-Adverse_Effect	['N']	[22]
23	was	O	['N']	[23]
24	probable	O	['N']	[24]
25	(	O	['N']	[25]
26	score	O	['N']	[26]
27	of	O	['N']	[27]
28	6	O	['N']	[28]
29	)	O	['N']	[29]
30	.	O	['N']	[30]
#1870
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Patients	O	['N']	[2]
3	receiving	O	['N']	[3]
4	intravitreal	O	['N']	[4]
5	injections	O	['N']	[5]
6	of	O	['N']	[6]
7	bevacizumab	B-Drug	['Causes']	[26]
8	should	O	['N']	[8]
9	be	O	['N']	[9]
10	evaluated	O	['N']	[10]
11	for	O	['N']	[11]
12	potential	O	['N']	[12]
13	systemic	O	['N']	[13]
14	risk	O	['N']	[14]
15	factors	O	['N']	[15]
16	such	O	['N']	[16]
17	as	O	['N']	[17]
18	carotid	O	['N']	[18]
19	insufficiency	O	['N']	[19]
20	,	O	['N']	[20]
21	coagulopathy	O	['N']	[21]
22	and	O	['N']	[22]
23	poorly	B	['N']	[23]
24	controlled	I	['N']	[24]
25	diabetes	I	['N']	[25]
26	mellitus	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#1871
0	A	O	['N']	[0]
1	7-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	with	O	['N']	[4]
5	congenital	O	['N']	[5]
6	toxoplasmosis	O	['N']	[6]
7	who	O	['N']	[7]
8	took	O	['N']	[8]
9	pyrimethamine	O	['N']	[9]
10	and	O	['N']	[10]
11	sulfadiazine	B-Drug	['Causes']	[25]
12	for	O	['N']	[12]
13	reactivated	O	['N']	[13]
14	chorioretinitis	O	['N']	[14]
15	developed	O	['N']	[15]
16	fever	O	['N']	[16]
17	,	O	['N']	[17]
18	severe	O	['N']	[18]
19	cutaneous	O	['N']	[19]
20	involvement	O	['N']	[20]
21	,	O	['N']	[21]
22	swelling	O	['N']	[22]
23	,	O	['N']	[23]
24	abdominal	B	['N']	[24]
25	pain	I-Adverse_Effect	['N']	[25]
26	and	O	['N']	[26]
27	transaminitis	O	['N']	[27]
28	,	O	['N']	[28]
29	persisting	O	['N']	[29]
30	weeks	O	['N']	[30]
31	after	O	['N']	[31]
32	withholding	O	['N']	[32]
33	medicines	O	['N']	[33]
34	.	O	['N']	[34]
#1872
0	Foscarnet	B-Drug	['Causes']	[8]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	severe	O	['N']	[3]
4	hypomagnesemia	O	['N']	[4]
5	and	O	['N']	[5]
6	other	O	['N']	[6]
7	electrolyte	B	['N']	[7]
8	disorders	I-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#1873
0	Syncope	B-Adverse_Effect	['N']	[0]
1	in	O	['N']	[1]
2	a	O	['N']	[2]
3	65-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	after	O	['N']	[7]
8	nitrate	B-Drug	['Causes']	[0]
9	ingestion	O	['N']	[9]
10	.	O	['N']	[10]
#1874
0	Possible	O	['N']	[0]
1	interaction	O	['N']	[1]
2	between	O	['N']	[2]
3	lopinavir	O	['N']	[3]
4	/	O	['N']	[4]
5	ritonavir	B-Drug	['Causes']	[11]
6	and	O	['N']	[6]
7	valproic	O	['N']	[7]
8	Acid	O	['N']	[8]
9	exacerbates	O	['N']	[9]
10	bipolar	B	['N']	[10]
11	disorder	I-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#1875
0	Methylphenidate	O	['N']	[0]
1	(	O	['N']	[1]
2	Ritalin)-associated	-	['N']	[2]
3	cataract	O	['N']	[3]
4	and	O	['N']	[4]
5	glaucoma	B-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#1876
0	Elderly	O	['N']	[0]
1	patients	O	['N']	[1]
2	for	O	['N']	[2]
3	whom	O	['N']	[3]
4	nitrate	B-Drug	['Causes']	[15]
5	has	O	['N']	[5]
6	been	O	['N']	[6]
7	prescribed	O	['N']	[7]
8	should	O	['N']	[8]
9	be	O	['N']	[9]
10	warned	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	occurrence	O	['N']	[13]
14	of	O	['N']	[14]
15	hypotension	B-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	leading	O	['N']	[17]
18	to	O	['N']	[18]
19	unconsciousness	O	['N']	[19]
20	.	O	['N']	[20]
#1877
0	A	O	['N']	[0]
1	clinically	O	['N']	[1]
2	atypical	O	['N']	[2]
3	,	O	['N']	[3]
4	neuropathologically	O	['N']	[4]
5	verified	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	Creutzfeldt	B	['N']	[8]
9	-	I	['N']	[9]
10	Jakob	I	['N']	[10]
11	disease	I-Adverse_Effect	['N']	[11]
12	is	O	['N']	[12]
13	described	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	32-year	O	['N']	[16]
17	-	O	['N']	[17]
18	old	O	['N']	[18]
19	New	O	['N']	[19]
20	Zealand	O	['N']	[20]
21	woman	O	['N']	[21]
22	with	O	['N']	[22]
23	idiopathic	O	['N']	[23]
24	hypopituitarism	O	['N']	[24]
25	who	O	['N']	[25]
26	had	O	['N']	[26]
27	been	O	['N']	[27]
28	treated	O	['N']	[28]
29	in	O	['N']	[29]
30	late	O	['N']	[30]
31	adolescence	O	['N']	[31]
32	(	O	['N']	[32]
33	1970	O	['N']	[33]
34	to	O	['N']	[34]
35	1973	O	['N']	[35]
36	)	O	['N']	[36]
37	with	O	['N']	[37]
38	human	B	['N']	[38]
39	growth	I	['N']	[39]
40	hormone	I-Drug	['Causes']	[11]
41	processed	O	['N']	[41]
42	from	O	['N']	[42]
43	pooled	O	['N']	[43]
44	cadaveric	O	['N']	[44]
45	pituitary	O	['N']	[45]
46	glands	O	['N']	[46]
47	.	O	['N']	[47]
#1878
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	history	O	['N']	[2]
3	and	O	['N']	[3]
4	toxicological	O	['N']	[4]
5	findings	O	['N']	[5]
6	of	O	['N']	[6]
7	an	O	['N']	[7]
8	infant	O	['N']	[8]
9	fatality	B-Adverse_Effect	['N']	[9]
10	involving	O	['N']	[10]
11	pseudoephedrine	O	['N']	[11]
12	,	O	['N']	[12]
13	brompheniramine	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	dextromethorphan	B-Drug	['Causes']	[9]
17	are	O	['N']	[17]
18	presented	O	['N']	[18]
19	.	O	['N']	[19]
#1879
0	A	O	['N']	[0]
1	59-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	myasthenia	O	['N']	[6]
7	gravis	O	['N']	[7]
8	who	O	['N']	[8]
9	received	O	['N']	[9]
10	a	O	['N']	[10]
11	large	O	['N']	[11]
12	dose	O	['N']	[12]
13	of	O	['N']	[13]
14	pyridostigmine	B	['N']	[14]
15	bromide	I-Drug	['Causes']	[18]
16	developed	O	['N']	[16]
17	postoperative	B	['N']	[17]
18	psychosis	I-Adverse_Effect	['N']	[18]
19	and	O	['N']	[19]
20	was	O	['N']	[20]
21	diagnosed	O	['N']	[21]
22	as	O	['N']	[22]
23	having	O	['N']	[23]
24	bromide	O	['N']	[24]
25	intoxication	O	['N']	[25]
26	.	O	['N']	[26]
#1880
0	Choanal	B	['N']	[0]
1	atresia	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	athelia	O	['N']	[3]
4	:	O	['N']	[4]
5	methimazole	B-Drug	['Causes']	[1]
6	teratogenicity	O	['N']	[6]
7	or	O	['N']	[7]
8	a	O	['N']	[8]
9	new	O	['N']	[9]
10	syndrome	O	['N']	[10]
11	?	O	['N']	[11]
#1881
0	Only	O	['N']	[0]
1	two	O	['N']	[1]
2	case	O	['N']	[2]
3	reports	O	['N']	[3]
4	of	O	['N']	[4]
5	adults	O	['N']	[5]
6	with	O	['N']	[6]
7	allergic	B	['N']	[7]
8	contact	I	['N']	[8]
9	dermatitis	I-Adverse_Effect	['N']	[9]
10	to	O	['N']	[10]
11	this	O	['N']	[11]
12	chemical	O	['N']	[12]
13	exist	O	['N']	[13]
14	in	O	['N']	[14]
15	the	O	['N']	[15]
16	literature	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	we	O	['N']	[19]
20	describe	O	['N']	[20]
21	three	O	['N']	[21]
22	more	O	['N']	[22]
23	cases	O	['N']	[23]
24	of	O	['N']	[24]
25	children	O	['N']	[25]
26	with	O	['N']	[26]
27	recalcitrant	O	['N']	[27]
28	atopic	O	['N']	[28]
29	dermatitis	O	['N']	[29]
30	found	O	['N']	[30]
31	to	O	['N']	[31]
32	have	O	['N']	[32]
33	potential	O	['N']	[33]
34	allergic	O	['N']	[34]
35	contact	O	['N']	[35]
36	dermatitis	O	['N']	[36]
37	to	O	['N']	[37]
38	bisabolol-	-	['N']	[38]
39	a	O	['N']	[39]
40	component	O	['N']	[40]
41	of	O	['N']	[41]
42	the	O	['N']	[42]
43	Aquaphor	O	['N']	[43]
44	emollient	O	['N']	[44]
45	they	O	['N']	[45]
46	were	O	['N']	[46]
47	using	O	['N']	[47]
48	to	O	['N']	[48]
49	treat	O	['N']	[49]
50	their	O	['N']	[50]
51	atopic	O	['N']	[51]
52	dermatitis	O	['N']	[52]
53	.	O	['N']	[53]
#1882
0	Thrombotic	B	['N']	[0]
1	stroke	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	the	O	['N']	[4]
5	use	O	['N']	[5]
6	of	O	['N']	[6]
7	porcine	B	['N']	[7]
8	factor	I	['N']	[8]
9	VIII	I-Drug	['Causes']	[1]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	patient	O	['N']	[12]
13	with	O	['N']	[13]
14	acquired	O	['N']	[14]
15	haemophilia	O	['N']	[15]
16	.	O	['N']	[16]
#1883
0	Lovastatin	O	['N']	[0]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	rhabdomyolysis	B-Adverse_Effect	['N']	[3]
4	possibly	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	clarithromycin	O	['N']	[7]
8	and	O	['N']	[8]
9	azithromycin	B-Drug	['Causes']	[3]
10	.	O	['N']	[10]
#1884
0	Valproate	B-Drug	['Causes']	[10]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hyperammonemia	O	['N']	[3]
4	as	O	['N']	[4]
5	a	O	['N']	[5]
6	cause	O	['N']	[6]
7	of	O	['N']	[7]
8	altered	B	['N']	[8]
9	mental	I	['N']	[9]
10	status	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#1885
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	3	O	['N']	[3]
4	cases	O	['N']	[4]
5	presented	O	['N']	[5]
6	here	O	['N']	[6]
7	illustrate	O	['N']	[7]
8	the	O	['N']	[8]
9	development	O	['N']	[9]
10	of	O	['N']	[10]
11	reproductive	B	['N']	[11]
12	endocrine	I	['N']	[12]
13	disorders	I-Adverse_Effect	['N']	[13]
14	after	O	['N']	[14]
15	the	O	['N']	[15]
16	initiation	O	['N']	[16]
17	of	O	['N']	[17]
18	valproate	B-Drug	['Causes']	[13]
19	therapy	O	['N']	[19]
20	in	O	['N']	[20]
21	women	O	['N']	[21]
22	with	O	['N']	[22]
23	epilepsy	O	['N']	[23]
24	.	O	['N']	[24]
#1886
0	Drug	O	['N']	[0]
1	induced	O	['N']	[1]
2	polymyositis	B-Adverse_Effect	['N']	[2]
3	secondary	O	['N']	[3]
4	to	O	['N']	[4]
5	leuprolide	B	['N']	[5]
6	acetate	I-Drug	['Causes']	[2]
7	(	O	['N']	[7]
8	Lupron	O	['N']	[8]
9	)	O	['N']	[9]
10	therapy	O	['N']	[10]
11	for	O	['N']	[11]
12	prostate	O	['N']	[12]
13	carcinoma	O	['N']	[13]
14	.	O	['N']	[14]
#1887
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	O	['N']	[19]
20	developed	O	['N']	[20]
21	confusion	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	agitation	O	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	O	['N']	[25]
26	,	O	['N']	[26]
27	tremors	O	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	O	['N']	[29]
30	jerks	O	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	O	['N']	[32]
33	gait	O	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	B-Drug	['Causes']	[21]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#1888
0	The	O	['N']	[0]
1	toxic	O	['N']	[1]
2	effects	O	['N']	[2]
3	of	O	['N']	[3]
4	methotrexate	B-Drug	['Causes']	[25]
5	included	O	['N']	[5]
6	elevated	O	['N']	[6]
7	liver	O	['N']	[7]
8	transaminases	O	['N']	[8]
9	(	O	['N']	[9]
10	3/4	O	['N']	[10]
11	)	O	['N']	[11]
12	,	O	['N']	[12]
13	nausea	O	['N']	[13]
14	(	O	['N']	[14]
15	2/4	O	['N']	[15]
16	)	O	['N']	[16]
17	,	O	['N']	[17]
18	abdominal	O	['N']	[18]
19	pain	O	['N']	[19]
20	(	O	['N']	[20]
21	2/4	O	['N']	[21]
22	)	O	['N']	[22]
23	,	O	['N']	[23]
24	bone	B	['N']	[24]
25	pain	I-Adverse_Effect	['N']	[25]
26	(	O	['N']	[26]
27	2/4	O	['N']	[27]
28	)	O	['N']	[28]
29	,	O	['N']	[29]
30	mild	O	['N']	[30]
31	neutropenia	O	['N']	[31]
32	(	O	['N']	[32]
33	1/4	O	['N']	[33]
34	)	O	['N']	[34]
35	,	O	['N']	[35]
36	and	O	['N']	[36]
37	mild	O	['N']	[37]
38	pruritus	O	['N']	[38]
39	(	O	['N']	[39]
40	1/4	O	['N']	[40]
41	)	O	['N']	[41]
42	.	O	['N']	[42]
#1889
0	In	O	['N']	[0]
1	a	O	['N']	[1]
2	series	O	['N']	[2]
3	of	O	['N']	[3]
4	104	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	intentional	O	['N']	[7]
8	or	O	['N']	[8]
9	inadvertent	O	['N']	[9]
10	use	O	['N']	[10]
11	of	O	['N']	[11]
12	zidovudine	B-Drug	['Causes']	[25]
13	at	O	['N']	[13]
14	differing	O	['N']	[14]
15	gestations	O	['N']	[15]
16	in	O	['N']	[16]
17	pregnancy	O	['N']	[17]
18	,	O	['N']	[18]
19	there	O	['N']	[19]
20	were	O	['N']	[20]
21	eight	O	['N']	[21]
22	spontaneous	O	['N']	[22]
23	first	B	['N']	[23]
24	trimester	I	['N']	[24]
25	abortions	I-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	eight	O	['N']	[27]
28	therapeutic	O	['N']	[28]
29	terminations	O	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	eight	O	['N']	[32]
33	cases	O	['N']	[33]
34	of	O	['N']	[34]
35	fetal	O	['N']	[35]
36	abnormality	O	['N']	[36]
37	occurring	O	['N']	[37]
38	among	O	['N']	[38]
39	a	O	['N']	[39]
40	total	O	['N']	[40]
41	of	O	['N']	[41]
42	88	O	['N']	[42]
43	cases	O	['N']	[43]
44	where	O	['N']	[44]
45	the	O	['N']	[45]
46	pregnancy	O	['N']	[46]
47	progressed	O	['N']	[47]
48	.	O	['N']	[48]
#1890
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	increasingly	O	['N']	[2]
3	recognized	O	['N']	[3]
4	that	O	['N']	[4]
5	dose	O	['N']	[5]
6	adjustment	O	['N']	[6]
7	of	O	['N']	[7]
8	oral	O	['N']	[8]
9	valacyclovir	B-Drug	['Causes']	[17]
10	in	O	['N']	[10]
11	renal	O	['N']	[11]
12	failure	O	['N']	[12]
13	is	O	['N']	[13]
14	necessary	O	['N']	[14]
15	to	O	['N']	[15]
16	avoid	O	['N']	[16]
17	neurotoxicity	B-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#1891
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	marked	O	['N']	[2]
3	QT	O	['N']	[3]
4	prolongation	O	['N']	[4]
5	and	O	['N']	[5]
6	torsades	O	['N']	[6]
7	de	O	['N']	[7]
8	pointes	O	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	setting	O	['N']	[11]
12	of	O	['N']	[12]
13	flash	B	['N']	[13]
14	pulmonary	I	['N']	[14]
15	edema	I-Adverse_Effect	['N']	[15]
16	resulting	O	['N']	[16]
17	from	O	['N']	[17]
18	acute	O	['N']	[18]
19	myocardial	O	['N']	[19]
20	ischemia	O	['N']	[20]
21	in	O	['N']	[21]
22	a	O	['N']	[22]
23	patient	O	['N']	[23]
24	who	O	['N']	[24]
25	was	O	['N']	[25]
26	being	O	['N']	[26]
27	treated	O	['N']	[27]
28	with	O	['N']	[28]
29	dofetilide	B-Drug	['Causes']	[15]
30	for	O	['N']	[30]
31	atrial	O	['N']	[31]
32	fibrillation	O	['N']	[32]
33	.	O	['N']	[33]
#1892
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	aseptic	B	['N']	[9]
10	meningitis	I-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	hemolytic	O	['N']	[12]
13	anemia	O	['N']	[13]
14	,	O	['N']	[14]
15	hepatitis	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	orthostatic	O	['N']	[18]
19	hypotension	O	['N']	[19]
20	simultaneously	O	['N']	[20]
21	during	O	['N']	[21]
22	treatment	O	['N']	[22]
23	with	O	['N']	[23]
24	trimethoprim	O	['N']	[24]
25	-	O	['N']	[25]
26	sulfamethoxazole	B-Drug	['Causes']	[10]
27	is	O	['N']	[27]
28	described	O	['N']	[28]
29	.	O	['N']	[29]
#1893
0	Flecainide	B-Drug	['Dosage']	[1]
1	overdose	B-Dose	['N']	[1]
2	can	O	['N']	[2]
3	rapidly	O	['N']	[3]
4	result	O	['N']	[4]
5	in	O	['N']	[5]
6	profound	O	['N']	[6]
7	cardiovascular	O	['N']	[7]
8	collapse	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	is	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	a	O	['N']	[14]
15	relatively	O	['N']	[15]
16	high	O	['N']	[16]
17	mortality	O	['N']	[17]
18	.	O	['N']	[18]
#1894
0	We	O	['N']	[0]
1	introduce	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	sixty	O	['N']	[6]
7	years	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	with	O	['N']	[10]
11	several	O	['N']	[11]
12	previous	O	['N']	[12]
13	episodes	O	['N']	[13]
14	of	O	['N']	[14]
15	rhinitis	O	['N']	[15]
16	,	O	['N']	[16]
17	conjunctivitis	O	['N']	[17]
18	and	O	['N']	[18]
19	perspiration	B-Adverse_Effect	['N']	[19]
20	immediately	O	['N']	[20]
21	after	O	['N']	[21]
22	the	O	['N']	[22]
23	administration	O	['N']	[23]
24	of	O	['N']	[24]
25	salmon	O	['N']	[25]
26	calcitonin	O	['N']	[26]
27	with	O	['N']	[27]
28	nasal	O	['N']	[28]
29	spray	O	['N']	[29]
30	or	O	['N']	[30]
31	intramuscular	O	['N']	[31]
32	administration	O	['N']	[32]
33	(	O	['N']	[33]
34	Calsynar	B-Drug	['Causes']	[19]
35	)	O	['N']	[35]
36	.	O	['N']	[36]
#1895
0	Recently	O	['N']	[0]
1	,	O	['N']	[1]
2	her	O	['N']	[2]
3	serum	O	['N']	[3]
4	theophylline	B	['N']	[4]
5	levels	I	['N']	[5]
6	had	I	['N']	[6]
7	increased	I	['N']	[7]
8	to	I	['N']	[8]
9	the	I	['N']	[9]
10	toxic	I	['N']	[10]
11	range	I-Adverse_Effect	['N']	[11]
12	(	O	['N']	[12]
13	133.2	O	['N']	[13]
14	micromol	O	['N']	[14]
15	/	O	['N']	[15]
16	L	O	['N']	[16]
17	[	O	['N']	[17]
18	24	O	['N']	[18]
19	microg	O	['N']	[19]
20	/	O	['N']	[20]
21	mL	O	['N']	[21]
22	]	O	['N']	[22]
23	)	O	['N']	[23]
24	shortly	O	['N']	[24]
25	after	O	['N']	[25]
26	the	O	['N']	[26]
27	addition	O	['N']	[27]
28	of	O	['N']	[28]
29	zafirlukast	B-Drug	['Causes']	[11]
30	(	O	['N']	[30]
31	Accolate	O	['N']	[31]
32	,	O	['N']	[32]
33	Zeneca	O	['N']	[33]
34	Pharmaceuticals	O	['N']	[34]
35	,	O	['N']	[35]
36	Wilmington	O	['N']	[36]
37	,	O	['N']	[37]
38	Del	O	['N']	[38]
39	)	O	['N']	[39]
40	to	O	['N']	[40]
41	her	O	['N']	[41]
42	regimen	O	['N']	[42]
43	.	O	['N']	[43]
#1896
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	clinical	O	['N']	[3]
4	response	O	['N']	[4]
5	,	O	['N']	[5]
6	as	O	['N']	[6]
7	determined	O	['N']	[7]
8	by	O	['N']	[8]
9	increases	B	['N']	[9]
10	in	I	['N']	[10]
11	total	I	['N']	[11]
12	Hb	I-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	decreased	O	['N']	[14]
15	transfusion	O	['N']	[15]
16	needs	O	['N']	[16]
17	,	O	['N']	[17]
18	in	O	['N']	[18]
19	five	O	['N']	[19]
20	patients	O	['N']	[20]
21	with	O	['N']	[21]
22	thalassemia	O	['N']	[22]
23	intermedia	O	['N']	[23]
24	treated	O	['N']	[24]
25	with	O	['N']	[25]
26	HU	O	['N']	[26]
27	alone	O	['N']	[27]
28	or	O	['N']	[28]
29	in	O	['N']	[29]
30	combination	O	['N']	[30]
31	with	O	['N']	[31]
32	SPB	B-Drug	['Causes']	[12]
33	.	O	['N']	[33]
#1897
0	A	O	['N']	[0]
1	49-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	Crohn	O	['N']	[6]
7	's	O	['N']	[7]
8	disease	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	prednisone	O	['N']	[11]
12	and	O	['N']	[12]
13	mesalamine	O	['N']	[13]
14	(	O	['N']	[14]
15	5-ASA	B-Drug	['Causes']	[20]
16	)	O	['N']	[16]
17	developed	O	['N']	[17]
18	worsening	B	['N']	[18]
19	respiratory	I	['N']	[19]
20	distress	I-Adverse_Effect	['N']	[20]
21	and	O	['N']	[21]
22	fever	O	['N']	[22]
23	.	O	['N']	[23]
#1898
0	Tacrolimus	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	HUS	B-Adverse_Effect	['N']	[3]
4	:	O	['N']	[4]
5	an	O	['N']	[5]
6	unusual	O	['N']	[6]
7	cause	O	['N']	[7]
8	of	O	['N']	[8]
9	acute	O	['N']	[9]
10	renal	O	['N']	[10]
11	failure	O	['N']	[11]
12	in	O	['N']	[12]
13	nephrotic	O	['N']	[13]
14	syndrome	O	['N']	[14]
15	.	O	['N']	[15]
#1899
0	Severe	O	['N']	[0]
1	vancomycin	B-Drug	['Causes']	[5]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	anaphylactic	B	['N']	[4]
5	reaction	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#1900
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	five	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	tremor	B-Adverse_Effect	['N']	[6]
7	related	O	['N']	[7]
8	to	O	['N']	[8]
9	itraconazole	B-Drug	['Causes']	[6]
10	therapy	O	['N']	[10]
11	,	O	['N']	[11]
12	which	O	['N']	[12]
13	occurred	O	['N']	[13]
14	within	O	['N']	[14]
15	1	O	['N']	[15]
16	-	O	['N']	[16]
17	12	O	['N']	[17]
18	months	O	['N']	[18]
19	of	O	['N']	[19]
20	initiating	O	['N']	[20]
21	treatment	O	['N']	[21]
22	and	O	['N']	[22]
23	resolved	O	['N']	[23]
24	gradually	O	['N']	[24]
25	following	O	['N']	[25]
26	itraconazole	O	['N']	[26]
27	withdrawal	O	['N']	[27]
28	.	O	['N']	[28]
#1901
0	A	O	['N']	[0]
1	58-year	O	['N']	[1]
2	old	O	['N']	[2]
3	patient	O	['N']	[3]
4	is	O	['N']	[4]
5	reported	O	['N']	[5]
6	who	O	['N']	[6]
7	developed	O	['N']	[7]
8	an	O	['N']	[8]
9	ischaemic	B	['N']	[9]
10	cerebrovascular	I	['N']	[10]
11	accident	I-Adverse_Effect	['N']	[11]
12	22	O	['N']	[12]
13	hours	O	['N']	[13]
14	after	O	['N']	[14]
15	successful	O	['N']	[15]
16	thrombolysis	O	['N']	[16]
17	with	O	['N']	[17]
18	streptokinase	B-Drug	['Causes']	[11]
19	for	O	['N']	[19]
20	life	O	['N']	[20]
21	-	O	['N']	[21]
22	threatening	O	['N']	[22]
23	pulmonary	O	['N']	[23]
24	emboli	O	['N']	[24]
25	.	O	['N']	[25]
#1902
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	1	O	['N']	[2]
3	)	O	['N']	[3]
4	To	O	['N']	[4]
5	describe	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	rheumatoid	O	['N']	[9]
10	arthritis	O	['N']	[10]
11	receiving	O	['N']	[11]
12	adalimumab	B-Drug	['Causes']	[23]
13	who	O	['N']	[13]
14	developed	O	['N']	[14]
15	fever	O	['N']	[15]
16	,	O	['N']	[16]
17	pancytopenia	O	['N']	[17]
18	,	O	['N']	[18]
19	splenomegaly	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	extreme	B	['N']	[22]
23	hyperferritinemia	I-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#1903
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	pancytopenia	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	23-year	O	['N']	[8]
9	-	O	['N']	[9]
10	old	O	['N']	[10]
11	man	O	['N']	[11]
12	with	O	['N']	[12]
13	Crohn	O	['N']	[13]
14	's	O	['N']	[14]
15	disease	O	['N']	[15]
16	who	O	['N']	[16]
17	was	O	['N']	[17]
18	treated	O	['N']	[18]
19	with	O	['N']	[19]
20	5-aminosalicylic	B	['N']	[20]
21	acid	I-Drug	['Dosage']	[34]
22	(	O	['N']	[22]
23	Pentasa	O	['N']	[23]
24	;	O	['N']	[24]
25	Nisshin	O	['N']	[25]
26	,	O	['N']	[26]
27	Tokyo	O	['N']	[27]
28	,	O	['N']	[28]
29	Japan	O	['N']	[29]
30	)	O	['N']	[30]
31	3.0	B	['N']	[31]
32	g	I	['N']	[32]
33	/	I	['N']	[33]
34	day	I-Dose	['N']	[34]
35	.	O	['N']	[35]
#1904
0	Potential	O	['N']	[0]
1	mechanisms	O	['N']	[1]
2	regarding	O	['N']	[2]
3	the	O	['N']	[3]
4	pathophysiology	O	['N']	[4]
5	of	O	['N']	[5]
6	lithium	B-Drug	['Causes']	[9]
7	-	O	['N']	[7]
8	associated	O	['N']	[8]
9	CDI	B-Adverse_Effect	['N']	[9]
10	are	O	['N']	[10]
11	discussed	O	['N']	[11]
12	.	O	['N']	[12]
#1905
0	A	O	['N']	[0]
1	drug	B	['N']	[1]
2	interaction	I-Adverse_Effect	['N']	[2]
3	between	O	['N']	[3]
4	zafirlukast	O	['N']	[4]
5	and	O	['N']	[5]
6	theophylline	B-Drug	['Causes']	[2]
7	.	O	['N']	[7]
#1906
0	Methotrexate	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	papular	B	['N']	[3]
4	eruption	I-Adverse_Effect	['N']	[4]
5	following	O	['N']	[5]
6	treatment	O	['N']	[6]
7	of	O	['N']	[7]
8	psoriasis	O	['N']	[8]
9	has	O	['N']	[9]
10	not	O	['N']	[10]
11	been	O	['N']	[11]
12	previously	O	['N']	[12]
13	reported	O	['N']	[13]
14	.	O	['N']	[14]
#1907
0	Bisphosphonate	B-Drug	['Causes']	[6]
1	-	O	['N']	[1]
2	related	O	['N']	[2]
3	osteonecrosis	B	['N']	[3]
4	of	I	['N']	[4]
5	the	I	['N']	[5]
6	jaw	I-Adverse_Effect	['N']	[6]
7	(	O	['N']	[7]
8	BRONJ	O	['N']	[8]
9	)	O	['N']	[9]
10	is	O	['N']	[10]
11	reported	O	['N']	[11]
12	in	O	['N']	[12]
13	up	O	['N']	[13]
14	to	O	['N']	[14]
15	18.6	O	['N']	[15]
16	%	O	['N']	[16]
17	of	O	['N']	[17]
18	patients	O	['N']	[18]
19	treated	O	['N']	[19]
20	with	O	['N']	[20]
21	intravenous	O	['N']	[21]
22	bisphosphonates	O	['N']	[22]
23	and	O	['N']	[23]
24	can	O	['N']	[24]
25	result	O	['N']	[25]
26	in	O	['N']	[26]
27	significant	O	['N']	[27]
28	morbidity	O	['N']	[28]
29	.	O	['N']	[29]
#1908
0	Anaphylaxis	B-Adverse_Effect	['N']	[0]
1	to	O	['N']	[1]
2	intrathecal	O	['N']	[2]
3	diamorphine	B-Drug	['Causes']	[0]
4	.	O	['N']	[4]
#1909
0	Successful	O	['N']	[0]
1	challenge	O	['N']	[1]
2	with	O	['N']	[2]
3	clozapine	B-Drug	['Causes']	[8]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	history	O	['N']	[6]
7	of	O	['N']	[7]
8	eosinophilia	B-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#1910
0	We	O	['N']	[0]
1	consider	O	['N']	[1]
2	asterixis	O	['N']	[2]
3	to	O	['N']	[3]
4	be	O	['N']	[4]
5	an	O	['N']	[5]
6	easily	O	['N']	[6]
7	overlooked	O	['N']	[7]
8	sign	O	['N']	[8]
9	of	O	['N']	[9]
10	neurotoxicity	O	['N']	[10]
11	,	O	['N']	[11]
12	which	O	['N']	[12]
13	may	O	['N']	[13]
14	occur	O	['N']	[14]
15	even	O	['N']	[15]
16	at	O	['N']	[16]
17	low	B	['N']	[17]
18	or	I	['N']	[18]
19	moderate	I	['N']	[19]
20	dosage	I-Dose	['N']	[20]
21	levels	O	['N']	[21]
22	,	O	['N']	[22]
23	if	O	['N']	[23]
24	certain	O	['N']	[24]
25	drugs	O	['N']	[25]
26	as	O	['N']	[26]
27	lithium	O	['N']	[27]
28	or	O	['N']	[28]
29	clozapine	O	['N']	[29]
30	are	O	['N']	[30]
31	used	O	['N']	[31]
32	in	O	['N']	[32]
33	combination	O	['N']	[33]
34	with	O	['N']	[34]
35	CBZ	B-Drug	['Dosage']	[20]
36	.	O	['N']	[36]
#1911
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	case	O	['N']	[2]
3	,	O	['N']	[3]
4	unlike	O	['N']	[4]
5	those	O	['N']	[5]
6	previously	O	['N']	[6]
7	reported	O	['N']	[7]
8	,	O	['N']	[8]
9	hyponatremia	B-Adverse_Effect	['N']	[9]
10	recurred	O	['N']	[10]
11	5	O	['N']	[11]
12	months	O	['N']	[12]
13	after	O	['N']	[13]
14	switching	O	['N']	[14]
15	from	O	['N']	[15]
16	citalopram	B-Drug	['Causes']	[9]
17	to	O	['N']	[17]
18	mirtazapine	O	['N']	[18]
19	,	O	['N']	[19]
20	which	O	['N']	[20]
21	is	O	['N']	[21]
22	believed	O	['N']	[22]
23	to	O	['N']	[23]
24	be	O	['N']	[24]
25	a	O	['N']	[25]
26	safe	O	['N']	[26]
27	antidepressant	O	['N']	[27]
28	.	O	['N']	[28]
#1912
0	Retinal	B	['N']	[0]
1	abnormalities	I-Adverse_Effect	['N']	[1]
2	,	O	['N']	[2]
3	including	O	['N']	[3]
4	retinal	O	['N']	[4]
5	hemorrhage	O	['N']	[5]
6	and	O	['N']	[6]
7	"	O	['N']	[7]
8	cotton	O	['N']	[8]
9	-	O	['N']	[9]
10	wool	O	['N']	[10]
11	"	O	['N']	[11]
12	spots	O	['N']	[12]
13	,	O	['N']	[13]
14	often	O	['N']	[14]
15	occur	O	['N']	[15]
16	within	O	['N']	[16]
17	the	O	['N']	[17]
18	first	O	['N']	[18]
19	8	O	['N']	[19]
20	weeks	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	course	O	['N']	[23]
24	of	O	['N']	[24]
25	interferon	B-Drug	['Causes']	[1]
26	therapy	O	['N']	[26]
27	in	O	['N']	[27]
28	patients	O	['N']	[28]
29	with	O	['N']	[29]
30	chronic	O	['N']	[30]
31	hepatitis	O	['N']	[31]
32	C.	O	['N']	[32]
#1913
0	Two	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	widespread	O	['N']	[3]
4	cutaneous	B	['N']	[4]
5	vasculitis	I-Adverse_Effect	['N']	[5]
6	are	O	['N']	[6]
7	described	O	['N']	[7]
8	in	O	['N']	[8]
9	association	O	['N']	[9]
10	with	O	['N']	[10]
11	diltiazem	B-Drug	['Causes']	[5]
12	,	O	['N']	[12]
13	a	O	['N']	[13]
14	recently	O	['N']	[14]
15	introduced	O	['N']	[15]
16	calcium	O	['N']	[16]
17	antagonist	O	['N']	[17]
18	.	O	['N']	[18]
#1914
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Topiramate	B-Drug	['Causes']	[17]
3	may	O	['N']	[3]
4	be	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	ciliochoroidal	O	['N']	[7]
8	effusion	O	['N']	[8]
9	with	O	['N']	[9]
10	forward	O	['N']	[10]
11	displacement	B	['N']	[11]
12	of	I	['N']	[12]
13	the	I	['N']	[13]
14	lens	I	['N']	[14]
15	-	I	['N']	[15]
16	iris	I	['N']	[16]
17	diaphragm	I-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	anterior	O	['N']	[19]
20	chamber	O	['N']	[20]
21	shallowing	O	['N']	[21]
22	,	O	['N']	[22]
23	resulting	O	['N']	[23]
24	in	O	['N']	[24]
25	acute	O	['N']	[25]
26	myopia	O	['N']	[26]
27	and	O	['N']	[27]
28	angle	O	['N']	[28]
29	-	O	['N']	[29]
30	closure	O	['N']	[30]
31	glaucoma	O	['N']	[31]
32	.	O	['N']	[32]
#1915
0	The	O	['N']	[0]
1	reversal	O	['N']	[1]
2	of	O	['N']	[2]
3	heparin	O	['N']	[3]
4	by	O	['N']	[4]
5	protamine	B-Drug	['Causes']	[15]
6	may	O	['N']	[6]
7	cause	O	['N']	[7]
8	severe	O	['N']	[8]
9	hemodynamic	O	['N']	[9]
10	deterioration	O	['N']	[10]
11	,	O	['N']	[11]
12	characterized	O	['N']	[12]
13	by	O	['N']	[13]
14	systemic	B	['N']	[14]
15	hypotension	I-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	pulmonary	O	['N']	[17]
18	hypertension	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	bronchoconstriction	O	['N']	[21]
22	.	O	['N']	[22]
#1916
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	53-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	-	O	['N']	[6]
7	man	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	rippling	B	['N']	[10]
11	muscle	I	['N']	[11]
12	disease	I-Adverse_Effect	['N']	[12]
13	(	O	['N']	[13]
14	RMD	O	['N']	[14]
15	)	O	['N']	[15]
16	2	O	['N']	[16]
17	months	O	['N']	[17]
18	after	O	['N']	[18]
19	starting	O	['N']	[19]
20	simvastatin	B-Drug	['Causes']	[12]
21	therapy	O	['N']	[21]
22	for	O	['N']	[22]
23	hypercholesterolemia	O	['N']	[23]
24	.	O	['N']	[24]
#1917
0	Halothane	B-Drug	['Causes']	[1]
1	hepatitis	B-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	prompt	O	['N']	[3]
4	resolution	O	['N']	[4]
5	with	O	['N']	[5]
6	methionine	O	['N']	[6]
7	therapy	O	['N']	[7]
8	:	O	['N']	[8]
9	case	O	['N']	[9]
10	report	O	['N']	[10]
11	.	O	['N']	[11]
#1918
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	prolongation	O	['N']	[2]
3	of	O	['N']	[3]
4	5-FU	O	['N']	[4]
5	half	O	['N']	[5]
6	-	O	['N']	[6]
7	life	O	['N']	[7]
8	and	O	['N']	[8]
9	an	O	['N']	[9]
10	increase	B	['N']	[10]
11	in	I	['N']	[11]
12	INR	I-Adverse_Effect	['N']	[12]
13	have	O	['N']	[13]
14	been	O	['N']	[14]
15	reported	O	['N']	[15]
16	with	O	['N']	[16]
17	the	O	['N']	[17]
18	concurrent	O	['N']	[18]
19	use	O	['N']	[19]
20	of	O	['N']	[20]
21	5-FU	O	['N']	[21]
22	and	O	['N']	[22]
23	warfarin	B-Drug	['Causes']	[12]
24	.	O	['N']	[24]
#1919
0	Onset	O	['N']	[0]
1	of	O	['N']	[1]
2	male	O	['N']	[2]
3	gynaecomastia	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	sunitinib	B-Drug	['Causes']	[3]
10	for	O	['N']	[10]
11	metastatic	O	['N']	[11]
12	renal	O	['N']	[12]
13	cell	O	['N']	[13]
14	carcinoma	O	['N']	[14]
15	.	O	['N']	[15]
#1920
0	We	O	['N']	[0]
1	have	O	['N']	[1]
2	reported	O	['N']	[2]
3	six	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	metoclopramide	B-Drug	['Causes']	[9]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	parkinsonism	B-Adverse_Effect	['N']	[9]
10	seen	O	['N']	[10]
11	in	O	['N']	[11]
12	consultation	O	['N']	[12]
13	over	O	['N']	[13]
14	a	O	['N']	[14]
15	two	O	['N']	[15]
16	-	O	['N']	[16]
17	year	O	['N']	[17]
18	period	O	['N']	[18]
19	.	O	['N']	[19]
#1921
0	Since	O	['N']	[0]
1	ethambutol	B-Drug	['Causes']	[32]
2	is	O	['N']	[2]
3	actively	O	['N']	[3]
4	excreted	O	['N']	[4]
5	via	O	['N']	[5]
6	the	O	['N']	[6]
7	renal	O	['N']	[7]
8	system	O	['N']	[8]
9	,	O	['N']	[9]
10	compromise	O	['N']	[10]
11	of	O	['N']	[11]
12	renal	O	['N']	[12]
13	function	O	['N']	[13]
14	such	O	['N']	[14]
15	as	O	['N']	[15]
16	due	O	['N']	[16]
17	to	O	['N']	[17]
18	renal	O	['N']	[18]
19	tuberculosis	O	['N']	[19]
20	may	O	['N']	[20]
21	lead	O	['N']	[21]
22	to	O	['N']	[22]
23	serum	O	['N']	[23]
24	concentration	O	['N']	[24]
25	elevations	O	['N']	[25]
26	of	O	['N']	[26]
27	ethambutol	O	['N']	[27]
28	sufficient	O	['N']	[28]
29	to	O	['N']	[29]
30	produce	O	['N']	[30]
31	optic	B	['N']	[31]
32	neuropathy	I-Adverse_Effect	['N']	[32]
33	.	O	['N']	[33]
#1922
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	Two	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	exudative	O	['N']	[5]
6	age	O	['N']	[6]
7	-	O	['N']	[7]
8	related	O	['N']	[8]
9	macular	O	['N']	[9]
10	degeneration	O	['N']	[10]
11	were	O	['N']	[11]
12	treated	O	['N']	[12]
13	sequentially	O	['N']	[13]
14	with	O	['N']	[14]
15	an	O	['N']	[15]
16	intravitreal	O	['N']	[16]
17	injection	O	['N']	[17]
18	of	O	['N']	[18]
19	bevacizumab	B-Drug	['Causes']	[28]
20	and	O	['N']	[20]
21	developed	O	['N']	[21]
22	signs	O	['N']	[22]
23	of	O	['N']	[23]
24	severe	O	['N']	[24]
25	but	O	['N']	[25]
26	painless	B	['N']	[26]
27	infectious	I	['N']	[27]
28	endophthalmitis	I-Adverse_Effect	['N']	[28]
29	2	O	['N']	[29]
30	days	O	['N']	[30]
31	later	O	['N']	[31]
32	.	O	['N']	[32]
#1923
0	Intrahepatic	B	['N']	[0]
1	cholestasis	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	sicca	O	['N']	[3]
4	complex	O	['N']	[4]
5	after	O	['N']	[5]
6	thiabendazole	B-Drug	['Causes']	[1]
7	.	O	['N']	[7]
#1924
0	The	O	['N']	[0]
1	clinical	O	['N']	[1]
2	aspect	O	['N']	[2]
3	closely	O	['N']	[3]
4	resembled	O	['N']	[4]
5	classical	O	['N']	[5]
6	transient	O	['N']	[6]
7	global	O	['N']	[7]
8	amnesia	O	['N']	[8]
9	but	O	['N']	[9]
10	the	O	['N']	[10]
11	episode	O	['N']	[11]
12	after	O	['N']	[12]
13	clioquinol	B-Drug	['Causes']	[30]
14	lasted	O	['N']	[14]
15	longer	O	['N']	[15]
16	(	O	['N']	[16]
17	24	O	['N']	[17]
18	hours	O	['N']	[18]
19	to	O	['N']	[19]
20	three	O	['N']	[20]
21	days	O	['N']	[21]
22	)	O	['N']	[22]
23	and	O	['N']	[23]
24	a	O	['N']	[24]
25	more	O	['N']	[25]
26	or	O	['N']	[26]
27	less	O	['N']	[27]
28	extensive	O	['N']	[28]
29	retrograde	B	['N']	[29]
30	amnesia	I-Adverse_Effect	['N']	[30]
31	persisted	O	['N']	[31]
32	permanently	O	['N']	[32]
33	.	O	['N']	[33]
#1925
0	The	O	['N']	[0]
1	aim	O	['N']	[1]
2	of	O	['N']	[2]
3	our	O	['N']	[3]
4	paper	O	['N']	[4]
5	was	O	['N']	[5]
6	to	O	['N']	[6]
7	describe	O	['N']	[7]
8	hepatotoxicity	B-Adverse_Effect	['N']	[8]
9	of	O	['N']	[9]
10	sirolimus	B-Drug	['Causes']	[8]
11	(	O	['N']	[11]
12	SRL	O	['N']	[12]
13	)	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	kidney	O	['N']	[16]
17	graft	O	['N']	[17]
18	recipient	O	['N']	[18]
19	.	O	['N']	[19]
#1926
0	Toxic	B	['N']	[0]
1	optic	I	['N']	[1]
2	neuropathy	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	ethambutol	B-Drug	['Causes']	[2]
6	:	O	['N']	[6]
7	implications	O	['N']	[7]
8	for	O	['N']	[8]
9	current	O	['N']	[9]
10	therapy	O	['N']	[10]
11	.	O	['N']	[11]
#1927
0	Liver	B	['N']	[0]
1	disease	I-Adverse_Effect	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	perhexiline	B	['N']	[4]
5	maleate	I-Drug	['Causes']	[1]
6	.	O	['N']	[6]
#1928
0	Fatal	B	['N']	[0]
1	toxic	I	['N']	[1]
2	epidermal	I	['N']	[2]
3	necrolysis	I-Adverse_Effect	['N']	[3]
4	related	O	['N']	[4]
5	to	O	['N']	[5]
6	lamotrigine	B-Drug	['Causes']	[3]
7	administration	O	['N']	[7]
8	.	O	['N']	[8]
#1929
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	pulmonary	O	['N']	[5]
6	adenocarcinoma	O	['N']	[6]
7	complicated	O	['N']	[7]
8	by	O	['N']	[8]
9	the	O	['N']	[9]
10	syndrome	B	['N']	[10]
11	of	I	['N']	[11]
12	inappropriate	I	['N']	[12]
13	secretion	I	['N']	[13]
14	of	I	['N']	[14]
15	antidiuretic	I	['N']	[15]
16	hormone	I-Adverse_Effect	['N']	[16]
17	(	O	['N']	[17]
18	SIADH	O	['N']	[18]
19	)	O	['N']	[19]
20	following	O	['N']	[20]
21	systemic	O	['N']	[21]
22	chemotherapy	O	['N']	[22]
23	with	O	['N']	[23]
24	cisplatin	O	['N']	[24]
25	(	O	['N']	[25]
26	CDDP	O	['N']	[26]
27	)	O	['N']	[27]
28	and	O	['N']	[28]
29	vindesine	O	['N']	[29]
30	(	O	['N']	[30]
31	VDS	B-Drug	['Causes']	[16]
32	)	O	['N']	[32]
33	.	O	['N']	[33]
#1930
0	While	O	['N']	[0]
1	undergoing	O	['N']	[1]
2	treatment	O	['N']	[2]
3	with	O	['N']	[3]
4	albendazole	B-Drug	['Causes']	[14]
5	,	O	['N']	[5]
6	he	O	['N']	[6]
7	developed	O	['N']	[7]
8	worsening	O	['N']	[8]
9	diarrhea	O	['N']	[9]
10	with	O	['N']	[10]
11	abdominal	O	['N']	[11]
12	pain	O	['N']	[12]
13	and	O	['N']	[13]
14	fever	B-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#1931
0	1	O	['N']	[0]
1	.	O	['N']	[1]
2	Changes	O	['N']	[2]
3	in	O	['N']	[3]
4	the	O	['N']	[4]
5	plasma	O	['N']	[5]
6	cortisol	O	['N']	[6]
7	level	O	['N']	[7]
8	were	O	['N']	[8]
9	reported	O	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	male	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	panic	O	['N']	[15]
16	disorder	O	['N']	[16]
17	during	O	['N']	[17]
18	the	O	['N']	[18]
19	period	O	['N']	[19]
20	of	O	['N']	[20]
21	low	B-Dose	['N']	[21]
22	-	O	['N']	[22]
23	dose	O	['N']	[23]
24	alprazolam	B-Drug	['Dosage']	[21]
25	treatment	O	['N']	[25]
26	(	O	['N']	[26]
27	mean	O	['N']	[27]
28	0.62	O	['N']	[28]
29	+	O	['N']	[29]
30	/-	O	['N']	[30]
31	0.15	O	['N']	[31]
32	mg	O	['N']	[32]
33	/	O	['N']	[33]
34	day	O	['N']	[34]
35	)	O	['N']	[35]
36	compared	O	['N']	[36]
37	with	O	['N']	[37]
38	during	O	['N']	[38]
39	the	O	['N']	[39]
40	period	O	['N']	[40]
41	of	O	['N']	[41]
42	high	O	['N']	[42]
43	-	O	['N']	[43]
44	dose	O	['N']	[44]
45	period	O	['N']	[45]
46	(	O	['N']	[46]
47	mean	O	['N']	[47]
48	1.08	O	['N']	[48]
49	+	O	['N']	[49]
50	/-	O	['N']	[50]
51	0.28	O	['N']	[51]
52	mg	O	['N']	[52]
53	/	O	['N']	[53]
54	day	O	['N']	[54]
55	)	O	['N']	[55]
56	.	O	['N']	[56]
#1932
0	Rifampin	B-Drug	['Causes']	[17]
1	can	O	['N']	[1]
2	be	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	severe	O	['N']	[5]
6	adverse	O	['N']	[6]
7	effects	O	['N']	[7]
8	such	O	['N']	[8]
9	as	O	['N']	[9]
10	hepatitis	O	['N']	[10]
11	,	O	['N']	[11]
12	acute	O	['N']	[12]
13	renal	O	['N']	[13]
14	failure	O	['N']	[14]
15	,	O	['N']	[15]
16	hemolytic	B	['N']	[16]
17	anemia	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	thrombocytopenia	O	['N']	[20]
21	.	O	['N']	[21]
#1933
0	Localized	O	['N']	[0]
1	panniculitis	O	['N']	[1]
2	and	O	['N']	[2]
3	subsequent	O	['N']	[3]
4	lipoatrophy	B-Adverse_Effect	['N']	[4]
5	with	O	['N']	[5]
6	subcutaneous	O	['N']	[6]
7	glatiramer	B	['N']	[7]
8	acetate	I-Drug	['Causes']	[4]
9	(	O	['N']	[9]
10	Copaxone	O	['N']	[10]
11	)	O	['N']	[11]
12	injection	O	['N']	[12]
13	for	O	['N']	[13]
14	the	O	['N']	[14]
15	treatment	O	['N']	[15]
16	of	O	['N']	[16]
17	multiple	O	['N']	[17]
18	sclerosis	O	['N']	[18]
19	.	O	['N']	[19]
#1934
0	Carbamazepine	B	['N']	[0]
1	toxicity	I-Adverse_Effect	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	clarithromycin	B-Drug	['Causes']	[1]
5	coadministration	O	['N']	[5]
6	in	O	['N']	[6]
7	psychiatric	O	['N']	[7]
8	patients	O	['N']	[8]
9	.	O	['N']	[9]
#1935
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	a	O	['N']	[3]
4	bipolar	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	developed	O	['N']	[7]
8	thyrotoxicosis	O	['N']	[8]
9	with	O	['N']	[9]
10	severe	B	['N']	[10]
11	exophthalmos	I-Adverse_Effect	['N']	[11]
12	while	O	['N']	[12]
13	on	O	['N']	[13]
14	lithium	B-Drug	['Causes']	[11]
15	therapy	O	['N']	[15]
16	is	O	['N']	[16]
17	described	O	['N']	[17]
18	.	O	['N']	[18]
#1936
0	Pheripheral	O	['N']	[0]
1	edema	O	['N']	[1]
2	was	O	['N']	[2]
3	observed	O	['N']	[3]
4	in	O	['N']	[4]
5	five	O	['N']	[5]
6	female	O	['N']	[6]
7	patients	O	['N']	[7]
8	after	O	['N']	[8]
9	taking	O	['N']	[9]
10	proton	O	['N']	[10]
11	pump	O	['N']	[11]
12	inhibitors	O	['N']	[12]
13	omeprazole	O	['N']	[13]
14	,	O	['N']	[14]
15	lansoprazole	O	['N']	[15]
16	,	O	['N']	[16]
17	or	O	['N']	[17]
18	pantoprazole	B-Drug	['Dosage']	[30]
19	for	O	['N']	[19]
20	7	O	['N']	[20]
21	-	O	['N']	[21]
22	15	O	['N']	[22]
23	days	O	['N']	[23]
24	for	O	['N']	[24]
25	peptic	O	['N']	[25]
26	acid	O	['N']	[26]
27	diseases	O	['N']	[27]
28	in	O	['N']	[28]
29	recommended	O	['N']	[29]
30	standard	B-Dose	['N']	[30]
31	doses	O	['N']	[31]
32	.	O	['N']	[32]
#1937
0	According	O	['N']	[0]
1	to	O	['N']	[1]
2	the	O	['N']	[2]
3	Naranjo	O	['N']	[3]
4	probability	O	['N']	[4]
5	scale	O	['N']	[5]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	relationship	O	['N']	[8]
9	of	O	['N']	[9]
10	gemcitabine	B-Drug	['Causes']	[14]
11	treatment	O	['N']	[11]
12	with	O	['N']	[12]
13	cutaneous	B	['N']	[13]
14	eruption	I-Adverse_Effect	['N']	[14]
15	in	O	['N']	[15]
16	our	O	['N']	[16]
17	patient	O	['N']	[17]
18	is	O	['N']	[18]
19	possible	O	['N']	[19]
20	.	O	['N']	[20]
#1938
0	An	O	['N']	[0]
1	83-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	receiving	O	['N']	[5]
6	glipizide	O	['N']	[6]
7	10	B	['N']	[7]
8	mg	I-Dose	['N']	[8]
9	bid	O	['N']	[9]
10	developed	O	['N']	[10]
11	symptomatic	O	['N']	[11]
12	hypoglycemia	O	['N']	[12]
13	within	O	['N']	[13]
14	three	O	['N']	[14]
15	days	O	['N']	[15]
16	of	O	['N']	[16]
17	adding	O	['N']	[17]
18	trimethoprim	O	['N']	[18]
19	/	O	['N']	[19]
20	sulfamethoxazole	O	['N']	[20]
21	(	O	['N']	[21]
22	TMP	O	['N']	[22]
23	/	O	['N']	[23]
24	SMX	B-Drug	['Dosage']	[8]
25	)	O	['N']	[25]
26	to	O	['N']	[26]
27	his	O	['N']	[27]
28	regimen	O	['N']	[28]
29	.	O	['N']	[29]
#1939
0	A	O	['N']	[0]
1	16-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	white	O	['N']	[4]
5	male	O	['N']	[5]
6	with	O	['N']	[6]
7	acute	O	['N']	[7]
8	biphenotypic	O	['N']	[8]
9	leukemia	O	['N']	[9]
10	developed	O	['N']	[10]
11	evidence	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	eosinophilia	B	['N']	[14]
15	myalgia	I	['N']	[15]
16	syndrome	I-Adverse_Effect	['N']	[16]
17	associated	O	['N']	[17]
18	with	O	['N']	[18]
19	total	O	['N']	[19]
20	parenteral	O	['N']	[20]
21	nutritional	O	['N']	[21]
22	support	O	['N']	[22]
23	with	O	['N']	[23]
24	solutions	O	['N']	[24]
25	containing	O	['N']	[25]
26	tryptophan	B-Drug	['Causes']	[16]
27	,	O	['N']	[27]
28	which	O	['N']	[28]
29	were	O	['N']	[29]
30	given	O	['N']	[30]
31	during	O	['N']	[31]
32	his	O	['N']	[32]
33	initial	O	['N']	[33]
34	induction	O	['N']	[34]
35	chemotherapy	O	['N']	[35]
36	and	O	['N']	[36]
37	also	O	['N']	[37]
38	after	O	['N']	[38]
39	autologous	O	['N']	[39]
40	marrow	O	['N']	[40]
41	transplantation	O	['N']	[41]
42	.	O	['N']	[42]
#1940
0	A	O	['N']	[0]
1	child	O	['N']	[1]
2	in	O	['N']	[2]
3	whom	O	['N']	[3]
4	a	O	['N']	[4]
5	phenobarbital	B-Drug	['Causes']	[13]
6	hypersensitivity	O	['N']	[6]
7	drug	O	['N']	[7]
8	reaction	O	['N']	[8]
9	developed	O	['N']	[9]
10	which	O	['N']	[10]
11	consisted	O	['N']	[11]
12	of	O	['N']	[12]
13	fever	B-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	a	O	['N']	[15]
16	pruritic	O	['N']	[16]
17	desquamating	O	['N']	[17]
18	erythrodermic	O	['N']	[18]
19	rash	O	['N']	[19]
20	,	O	['N']	[20]
21	alopecia	O	['N']	[21]
22	,	O	['N']	[22]
23	icterus	O	['N']	[23]
24	,	O	['N']	[24]
25	protein	O	['N']	[25]
26	-	O	['N']	[26]
27	losing	O	['N']	[27]
28	enteropathy	O	['N']	[28]
29	,	O	['N']	[29]
30	myositis	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	nephritis	O	['N']	[33]
34	,	O	['N']	[34]
35	is	O	['N']	[35]
36	described	O	['N']	[36]
37	.	O	['N']	[37]
#1941
0	Secondary	B	['N']	[0]
1	hyperparathyroidism	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	certain	O	['N']	[3]
4	patients	O	['N']	[4]
5	with	O	['N']	[5]
6	lithium	B-Drug	['Causes']	[1]
7	nephrotoxicity	O	['N']	[7]
8	is	O	['N']	[8]
9	also	O	['N']	[9]
10	possible	O	['N']	[10]
11	.	O	['N']	[11]
#1942
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	new	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	sarcoidosis	B-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	two	O	['N']	[8]
9	patients	O	['N']	[9]
10	with	O	['N']	[10]
11	hepatitis	O	['N']	[11]
12	C	O	['N']	[12]
13	virus	O	['N']	[13]
14	infection	O	['N']	[14]
15	treated	O	['N']	[15]
16	with	O	['N']	[16]
17	interferon	B	['N']	[17]
18	alfa	I-Drug	['Causes']	[6]
19	and	O	['N']	[19]
20	ribavirin	O	['N']	[20]
21	.	O	['N']	[21]
#1943
0	Interstitial	B	['N']	[0]
1	pneumonia	I-Adverse_Effect	['N']	[1]
2	probably	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	sorafenib	B-Drug	['Causes']	[1]
6	treatment	O	['N']	[6]
7	:	O	['N']	[7]
8	An	O	['N']	[8]
9	alert	O	['N']	[9]
10	of	O	['N']	[10]
11	an	O	['N']	[11]
12	adverse	O	['N']	[12]
13	event	O	['N']	[13]
14	.	O	['N']	[14]
#1944
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	severe	B	['N']	[3]
4	aplastic	I	['N']	[4]
5	anemia	I-Adverse_Effect	['N']	[5]
6	secondary	O	['N']	[6]
7	to	O	['N']	[7]
8	treatment	O	['N']	[8]
9	with	O	['N']	[9]
10	lenalidomide	B-Drug	['Causes']	[5]
11	for	O	['N']	[11]
12	multiple	O	['N']	[12]
13	myeloma	O	['N']	[13]
14	.	O	['N']	[14]
#1945
0	CASE	O	['N']	[0]
1	REPORT	O	['N']	[1]
2	:	O	['N']	[2]
3	Soon	O	['N']	[3]
4	after	O	['N']	[4]
5	initiation	O	['N']	[5]
6	of	O	['N']	[6]
7	amiodarone	B	['N']	[7]
8	HCl	I-Drug	['Dosage']	[13]
9	(	O	['N']	[9]
10	200	B	['N']	[10]
11	mg	I	['N']	[11]
12	/	I	['N']	[12]
13	day	I-Dose	['N']	[13]
14	)	O	['N']	[14]
15	,	O	['N']	[15]
16	a	O	['N']	[16]
17	76-year	O	['N']	[17]
18	-	O	['N']	[18]
19	old	O	['N']	[19]
20	man	O	['N']	[20]
21	came	O	['N']	[21]
22	to	O	['N']	[22]
23	us	O	['N']	[23]
24	with	O	['N']	[24]
25	symptoms	O	['N']	[25]
26	of	O	['N']	[26]
27	visual	O	['N']	[27]
28	"	O	['N']	[28]
29	shining	O	['N']	[29]
30	,	O	['N']	[30]
31	"	O	['N']	[31]
32	glare	O	['N']	[32]
33	,	O	['N']	[33]
34	color	O	['N']	[34]
35	vision	O	['N']	[35]
36	anomalies	O	['N']	[36]
37	,	O	['N']	[37]
38	and	O	['N']	[38]
39	gradually	O	['N']	[39]
40	decreased	O	['N']	[40]
41	vision	O	['N']	[41]
42	.	O	['N']	[42]
#1946
0	High	B	['N']	[0]
1	-	I	['N']	[1]
2	dose	I-Dose	['N']	[2]
3	intravenous	O	['N']	[3]
4	mannitol	B-Drug	['Dosage']	[2]
5	infusion	O	['N']	[5]
6	in	O	['N']	[6]
7	various	O	['N']	[7]
8	clinical	O	['N']	[8]
9	settings	O	['N']	[9]
10	may	O	['N']	[10]
11	result	O	['N']	[11]
12	in	O	['N']	[12]
13	acute	O	['N']	[13]
14	renal	O	['N']	[14]
15	failure	O	['N']	[15]
16	(	O	['N']	[16]
17	ARF	O	['N']	[17]
18	)	O	['N']	[18]
19	.	O	['N']	[19]
#1947
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	57-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	with	O	['N']	[7]
8	acral	O	['N']	[8]
9	erythrocyanosis	O	['N']	[9]
10	progressing	O	['N']	[10]
11	to	O	['N']	[11]
12	acute	O	['N']	[12]
13	digital	O	['N']	[13]
14	ischemia	O	['N']	[14]
15	and	O	['N']	[15]
16	gangrene	B-Adverse_Effect	['N']	[16]
17	that	O	['N']	[17]
18	developed	O	['N']	[18]
19	after	O	['N']	[19]
20	combined	O	['N']	[20]
21	chemotherapy	O	['N']	[21]
22	(	O	['N']	[22]
23	bleomycin	B-Drug	['Causes']	[16]
24	and	O	['N']	[24]
25	methotrexate	O	['N']	[25]
26	)	O	['N']	[26]
27	used	O	['N']	[27]
28	to	O	['N']	[28]
29	treat	O	['N']	[29]
30	a	O	['N']	[30]
31	metastatic	O	['N']	[31]
32	squamous	O	['N']	[32]
33	cell	O	['N']	[33]
34	carcinoma	O	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	hypopharynx	O	['N']	[37]
38	.	O	['N']	[38]
#1948
0	In	O	['N']	[0]
1	all	O	['N']	[1]
2	the	O	['N']	[2]
3	patients	O	['N']	[3]
4	,	O	['N']	[4]
5	pellagra	B-Adverse_Effect	['N']	[5]
6	symptoms	O	['N']	[6]
7	appeared	O	['N']	[7]
8	during	O	['N']	[8]
9	isoniazid	B-Drug	['Causes']	[5]
10	therapy	O	['N']	[10]
11	.	O	['N']	[11]
#1949
0	Dural	B	['N']	[0]
1	sinus	I	['N']	[1]
2	thrombosis	I-Adverse_Effect	['N']	[2]
3	developed	O	['N']	[3]
4	in	O	['N']	[4]
5	two	O	['N']	[5]
6	children	O	['N']	[6]
7	with	O	['N']	[7]
8	acute	O	['N']	[8]
9	lymphoblastic	O	['N']	[9]
10	leukemia	O	['N']	[10]
11	during	O	['N']	[11]
12	induction	O	['N']	[12]
13	treatment	O	['N']	[13]
14	with	O	['N']	[14]
15	vincristine	B	['N']	[15]
16	sulfate	I-Drug	['Causes']	[2]
17	,	O	['N']	[17]
18	prednisone	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	asparaginase	O	['N']	[21]
22	.	O	['N']	[22]
#1950
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	five	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	carboplatin	B-Drug	['Causes']	[9]
6	(	O	['N']	[6]
7	CBDCA	O	['N']	[7]
8	)	O	['N']	[8]
9	hypersensitivity	B-Adverse_Effect	['N']	[9]
10	after	O	['N']	[10]
11	weekly	O	['N']	[11]
12	low	O	['N']	[12]
13	-	O	['N']	[13]
14	dose	O	['N']	[14]
15	paclitaxel	O	['N']	[15]
16	(	O	['N']	[16]
17	60	O	['N']	[17]
18	mg	O	['N']	[18]
19	/	O	['N']	[19]
20	m2)/CBDCA	O	['N']	[20]
21	(	O	['N']	[21]
22	area	O	['N']	[22]
23	under	O	['N']	[23]
24	the	O	['N']	[24]
25	concentration	O	['N']	[25]
26	curve	O	['N']	[26]
27	=	O	['N']	[27]
28	2	O	['N']	[28]
29	)	O	['N']	[29]
30	therapy	O	['N']	[30]
31	in	O	['N']	[31]
32	patients	O	['N']	[32]
33	with	O	['N']	[33]
34	recurrent	O	['N']	[34]
35	ovarian	O	['N']	[35]
36	cancer	O	['N']	[36]
37	receiving	O	['N']	[37]
38	multiple	O	['N']	[38]
39	platinum	O	['N']	[39]
40	-	O	['N']	[40]
41	based	O	['N']	[41]
42	chemotherapy	O	['N']	[42]
43	.	O	['N']	[43]
#1951
0	First	O	['N']	[0]
1	,	O	['N']	[1]
2	a	O	['N']	[2]
3	review	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	literature	O	['N']	[6]
7	produced	O	['N']	[7]
8	41	O	['N']	[8]
9	anecdotic	O	['N']	[9]
10	cases	O	['N']	[10]
11	of	O	['N']	[11]
12	neutropenia	B-Adverse_Effect	['N']	[12]
13	or	O	['N']	[13]
14	agranulocytosis	O	['N']	[14]
15	during	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	olanzapine	O	['N']	[18]
19	(	O	['N']	[19]
20	Zyprexa	B-Drug	['Causes']	[12]
21	)	O	['N']	[21]
22	reported	O	['N']	[22]
23	in	O	['N']	[23]
24	a	O	['N']	[24]
25	total	O	['N']	[25]
26	of	O	['N']	[26]
27	24	O	['N']	[27]
28	publications	O	['N']	[28]
29	.	O	['N']	[29]
#1952
0	Anaphylaxis	B-Adverse_Effect	['N']	[0]
1	after	O	['N']	[1]
2	the	O	['N']	[2]
3	injection	O	['N']	[3]
4	of	O	['N']	[4]
5	chymopapain	B-Drug	['Causes']	[0]
6	occurs	O	['N']	[6]
7	in	O	['N']	[7]
8	about	O	['N']	[8]
9	1	O	['N']	[9]
10	%	O	['N']	[10]
11	of	O	['N']	[11]
12	such	O	['N']	[12]
13	cases	O	['N']	[13]
14	.	O	['N']	[14]
#1953
0	Fatal	O	['N']	[0]
1	radiation	O	['N']	[1]
2	myelopathy	O	['N']	[2]
3	after	O	['N']	[3]
4	high	B	['N']	[4]
5	-	I	['N']	[5]
6	dose	I-Dose	['N']	[6]
7	busulfan	B-Drug	['Dosage']	[6]
8	and	O	['N']	[8]
9	melphalan	O	['N']	[9]
10	chemotherapy	O	['N']	[10]
11	and	O	['N']	[11]
12	radiotherapy	O	['N']	[12]
13	for	O	['N']	[13]
14	Ewing	O	['N']	[14]
15	's	O	['N']	[15]
16	sarcoma	O	['N']	[16]
17	:	O	['N']	[17]
18	a	O	['N']	[18]
19	review	O	['N']	[19]
20	of	O	['N']	[20]
21	the	O	['N']	[21]
22	literature	O	['N']	[22]
23	and	O	['N']	[23]
24	implications	O	['N']	[24]
25	for	O	['N']	[25]
26	practice	O	['N']	[26]
27	.	O	['N']	[27]
#1954
0	Physicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	cognizant	O	['N']	[3]
4	of	O	['N']	[4]
5	this	O	['N']	[5]
6	potential	O	['N']	[6]
7	complication	O	['N']	[7]
8	in	O	['N']	[8]
9	patients	O	['N']	[9]
10	receiving	O	['N']	[10]
11	thalidomide	B-Drug	['Causes']	[23]
12	or	O	['N']	[12]
13	thalidomide	O	['N']	[13]
14	-	O	['N']	[14]
15	like	O	['N']	[15]
16	drugs	O	['N']	[16]
17	who	O	['N']	[17]
18	present	O	['N']	[18]
19	with	O	['N']	[19]
20	fever	O	['N']	[20]
21	and	O	['N']	[21]
22	pulmonary	B	['N']	[22]
23	infiltrates	I-Adverse_Effect	['N']	[23]
24	and	O	['N']	[24]
25	fail	O	['N']	[25]
26	to	O	['N']	[26]
27	improve	O	['N']	[27]
28	despite	O	['N']	[28]
29	treatment	O	['N']	[29]
30	with	O	['N']	[30]
31	broad	O	['N']	[31]
32	-	O	['N']	[32]
33	spectrum	O	['N']	[33]
34	antibiotics	O	['N']	[34]
35	.	O	['N']	[35]
#1955
0	This	O	['N']	[0]
1	entity	O	['N']	[1]
2	is	O	['N']	[2]
3	probably	O	['N']	[3]
4	related	O	['N']	[4]
5	to	O	['N']	[5]
6	a	O	['N']	[6]
7	combination	O	['N']	[7]
8	of	O	['N']	[8]
9	high	B	['N']	[9]
10	doses	I-Dose	['N']	[10]
11	of	O	['N']	[11]
12	corticosteroids	O	['N']	[12]
13	,	O	['N']	[13]
14	vecuronium	B-Drug	['Dosage']	[10]
15	administration	O	['N']	[15]
16	and	O	['N']	[16]
17	metabolic	O	['N']	[17]
18	abnormalities	O	['N']	[18]
19	associated	O	['N']	[19]
20	with	O	['N']	[20]
21	respiratory	O	['N']	[21]
22	failure	O	['N']	[22]
23	.	O	['N']	[23]
#1956
0	We	O	['N']	[0]
1	conclude	O	['N']	[1]
2	that	O	['N']	[2]
3	MB	O	['N']	[3]
4	is	O	['N']	[4]
5	an	O	['N']	[5]
6	effective	O	['N']	[6]
7	treatment	O	['N']	[7]
8	for	O	['N']	[8]
9	ifosfamide	B-Drug	['Causes']	[12]
10	-	I	['N']	[10]
11	induced	I	['N']	[11]
12	encephalopathy	I-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#1957
0	While	O	['N']	[0]
1	both	O	['N']	[1]
2	amiodarone	O	['N']	[2]
3	and	O	['N']	[3]
4	digoxin	B-Drug	['Causes']	[13]
5	can	O	['N']	[5]
6	cause	O	['N']	[6]
7	permanent	O	['N']	[7]
8	visual	O	['N']	[8]
9	changes	O	['N']	[9]
10	,	O	['N']	[10]
11	the	O	['N']	[11]
12	ocular	B	['N']	[12]
13	effects	I-Adverse_Effect	['N']	[13]
14	are	O	['N']	[14]
15	often	O	['N']	[15]
16	reversible	O	['N']	[16]
17	.	O	['N']	[17]
#1958
0	Although	O	['N']	[0]
1	gabapentin	B-Drug	['Causes']	[16]
2	withdrawal	O	['N']	[2]
3	has	O	['N']	[3]
4	been	O	['N']	[4]
5	previously	O	['N']	[5]
6	reported	O	['N']	[6]
7	and	O	['N']	[7]
8	usually	O	['N']	[8]
9	consists	O	['N']	[9]
10	of	O	['N']	[10]
11	anxiety	O	['N']	[11]
12	,	O	['N']	[12]
13	diaphoresis	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	palpitations	B-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	this	O	['N']	[18]
19	is	O	['N']	[19]
20	the	O	['N']	[20]
21	first	O	['N']	[21]
22	reported	O	['N']	[22]
23	patient	O	['N']	[23]
24	with	O	['N']	[24]
25	generalized	O	['N']	[25]
26	seizures	O	['N']	[26]
27	and	O	['N']	[27]
28	status	O	['N']	[28]
29	epilepticus	O	['N']	[29]
30	secondary	O	['N']	[30]
31	to	O	['N']	[31]
32	gabapentin	O	['N']	[32]
33	withdrawal	O	['N']	[33]
34	.	O	['N']	[34]
#1959
0	In	O	['N']	[0]
1	addition	O	['N']	[1]
2	to	O	['N']	[2]
3	the	O	['N']	[3]
4	recognized	O	['N']	[4]
5	arrhythmic	O	['N']	[5]
6	complications	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	authors	O	['N']	[9]
10	emphasize	O	['N']	[10]
11	myocardial	B	['N']	[11]
12	necrosis	I-Adverse_Effect	['N']	[12]
13	as	O	['N']	[13]
14	a	O	['N']	[14]
15	possible	O	['N']	[15]
16	further	O	['N']	[16]
17	manifestation	O	['N']	[17]
18	of	O	['N']	[18]
19	amsacrine	B-Drug	['Causes']	[12]
20	-	O	['N']	[20]
21	related	O	['N']	[21]
22	cardiotoxicity	O	['N']	[22]
23	.	O	['N']	[23]
#1960
0	Usefulness	O	['N']	[0]
1	of	O	['N']	[1]
2	antiplatelet	O	['N']	[2]
3	drugs	O	['N']	[3]
4	in	O	['N']	[4]
5	the	O	['N']	[5]
6	management	O	['N']	[6]
7	of	O	['N']	[7]
8	heparin	B-Drug	['Causes']	[13]
9	-	O	['N']	[9]
10	associated	O	['N']	[10]
11	thrombocytopenia	O	['N']	[11]
12	and	O	['N']	[12]
13	thrombosis	B-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#1961
0	Naproxen	B-Drug	['Causes']	[25]
1	,	O	['N']	[1]
2	the	O	['N']	[2]
3	most	O	['N']	[3]
4	common	O	['N']	[4]
5	offender	O	['N']	[5]
6	,	O	['N']	[6]
7	has	O	['N']	[7]
8	been	O	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	a	O	['N']	[11]
12	dimorphic	O	['N']	[12]
13	clinical	O	['N']	[13]
14	pattern	O	['N']	[14]
15	:	O	['N']	[15]
16	a	O	['N']	[16]
17	PCT	O	['N']	[17]
18	-	O	['N']	[18]
19	like	O	['N']	[19]
20	presentation	O	['N']	[20]
21	and	O	['N']	[21]
22	one	O	['N']	[22]
23	simulating	O	['N']	[23]
24	erythropoietic	B	['N']	[24]
25	protoporphyria	I-Adverse_Effect	['N']	[25]
26	in	O	['N']	[26]
27	the	O	['N']	[27]
28	pediatric	O	['N']	[28]
29	population	O	['N']	[29]
30	.	O	['N']	[30]
#1962
0	Two	O	['N']	[0]
1	heroin	B-Drug	['Dosage']	[16]
2	addicts	O	['N']	[2]
3	,	O	['N']	[3]
4	aged	O	['N']	[4]
5	34	O	['N']	[5]
6	and	O	['N']	[6]
7	19	O	['N']	[7]
8	years	O	['N']	[8]
9	,	O	['N']	[9]
10	developed	O	['N']	[10]
11	ballistic	O	['N']	[11]
12	movements	O	['N']	[12]
13	after	O	['N']	[13]
14	intravenous	O	['N']	[14]
15	heroin	O	['N']	[15]
16	overdose	B-Dose	['N']	[16]
17	.	O	['N']	[17]
#1963
0	Four	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	the	O	['N']	[3]
4	initial	O	['N']	[4]
5	injection	O	['N']	[5]
6	of	O	['N']	[6]
7	3.6	O	['N']	[7]
8	mg	O	['N']	[8]
9	of	O	['N']	[9]
10	goserelin	B	['N']	[10]
11	acetate	I-Drug	['Causes']	[20]
12	,	O	['N']	[12]
13	severe	O	['N']	[13]
14	dyspnea	O	['N']	[14]
15	developed	O	['N']	[15]
16	due	O	['N']	[16]
17	to	O	['N']	[17]
18	worsening	B	['N']	[18]
19	pleuritis	I	['N']	[19]
20	carcinomatosa	I-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	which	O	['N']	[22]
23	was	O	['N']	[23]
24	considered	O	['N']	[24]
25	as	O	['N']	[25]
26	a	O	['N']	[26]
27	flare	O	['N']	[27]
28	-	O	['N']	[28]
29	up	O	['N']	[29]
30	.	O	['N']	[30]
#1964
0	Prolonged	O	['N']	[0]
1	used	O	['N']	[1]
2	of	O	['N']	[2]
3	hydroxyurea	B-Drug	['Causes']	[15]
4	in	O	['N']	[4]
5	patients	O	['N']	[5]
6	with	O	['N']	[6]
7	ET	O	['N']	[7]
8	may	O	['N']	[8]
9	lead	O	['N']	[9]
10	to	O	['N']	[10]
11	therapy	O	['N']	[11]
12	-	O	['N']	[12]
13	associated	O	['N']	[13]
14	acute	B	['N']	[14]
15	leukemia	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#1965
0	Methadone	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	myoclonus	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	advanced	O	['N']	[5]
6	cancer	O	['N']	[6]
7	.	O	['N']	[7]
#1966
0	Systemic	B	['N']	[0]
1	allergic	I	['N']	[1]
2	contact	I	['N']	[2]
3	dermatitis	I-Adverse_Effect	['N']	[3]
4	to	O	['N']	[4]
5	8-methoxypsoralen	B-Drug	['Causes']	[3]
6	(	O	['N']	[6]
7	8-MOP	O	['N']	[7]
8	)	O	['N']	[8]
9	.	O	['N']	[9]
#1967
0	Acute	B	['N']	[0]
1	ocular	I	['N']	[1]
2	ischemic	I	['N']	[2]
3	change	I-Adverse_Effect	['N']	[3]
4	may	O	['N']	[4]
5	be	O	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	intravitreal	O	['N']	[8]
9	injection	O	['N']	[9]
10	of	O	['N']	[10]
11	bevacizumab	B-Drug	['Causes']	[3]
12	in	O	['N']	[12]
13	patients	O	['N']	[13]
14	with	O	['N']	[14]
15	vascular	O	['N']	[15]
16	compromised	O	['N']	[16]
17	diabetic	O	['N']	[17]
18	retinopathy	O	['N']	[18]
19	and/or	O	['N']	[19]
20	underlying	O	['N']	[20]
21	stenosis	O	['N']	[21]
22	of	O	['N']	[22]
23	the	O	['N']	[23]
24	carotid	O	['N']	[24]
25	artery	O	['N']	[25]
26	.	O	['N']	[26]
#1968
0	Reye	B	['N']	[0]
1	-	I	['N']	[1]
2	like	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	following	O	['N']	[4]
5	treatment	O	['N']	[5]
6	with	O	['N']	[6]
7	the	O	['N']	[7]
8	pantothenic	O	['N']	[8]
9	acid	O	['N']	[9]
10	antagonist	O	['N']	[10]
11	,	O	['N']	[11]
12	calcium	B	['N']	[12]
13	hopantenate	I-Drug	['Causes']	[3]
14	.	O	['N']	[14]
#1969
0	Cessation	O	['N']	[0]
1	of	O	['N']	[1]
2	D	B	['N']	[2]
3	-	I	['N']	[3]
4	Pen	I-Drug	['Causes']	[16]
5	and	O	['N']	[5]
6	the	O	['N']	[6]
7	start	O	['N']	[7]
8	of	O	['N']	[8]
9	corticosteroid	O	['N']	[9]
10	therapy	O	['N']	[10]
11	were	O	['N']	[11]
12	followed	O	['N']	[12]
13	by	O	['N']	[13]
14	recovery	O	['N']	[14]
15	from	O	['N']	[15]
16	bicytopenia	B-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#1970
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Methotrexate	B-Drug	['Causes']	[20]
3	(	O	['N']	[3]
4	MTX	O	['N']	[4]
5	)	O	['N']	[5]
6	may	O	['N']	[6]
7	induce	O	['N']	[7]
8	liver	O	['N']	[8]
9	damage	O	['N']	[9]
10	,	O	['N']	[10]
11	which	O	['N']	[11]
12	in	O	['N']	[12]
13	some	O	['N']	[13]
14	psoriatics	O	['N']	[14]
15	will	O	['N']	[15]
16	lead	O	['N']	[16]
17	to	O	['N']	[17]
18	fibrosis	O	['N']	[18]
19	or	O	['N']	[19]
20	cirrhosis	B-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#1971
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	contact	B	['N']	[5]
6	dermatitis	I-Adverse_Effect	['N']	[6]
7	due	O	['N']	[7]
8	to	O	['N']	[8]
9	sodium	B	['N']	[9]
10	bisulfite	I-Drug	['Causes']	[6]
11	in	O	['N']	[11]
12	Tathion	O	['N']	[12]
13	eye	O	['N']	[13]
14	drops	O	['N']	[14]
15	.	O	['N']	[15]
#1972
0	Delayed	B	['N']	[0]
1	pseudocyst	I	['N']	[1]
2	of	I	['N']	[2]
3	the	I	['N']	[3]
4	pancreas	I-Adverse_Effect	['N']	[4]
5	can	O	['N']	[5]
6	be	O	['N']	[6]
7	a	O	['N']	[7]
8	complication	O	['N']	[8]
9	of	O	['N']	[9]
10	intramuscular	O	['N']	[10]
11	L	B	['N']	[11]
12	-	I	['N']	[12]
13	asparaginase	I-Drug	['Causes']	[4]
14	.	O	['N']	[14]
#1973
0	Rosaceiform	B	['N']	[0]
1	eruption	I-Adverse_Effect	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	erlotinib	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#1974
0	Hepatotoxicity	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	choline	B	['N']	[3]
4	magnesium	I	['N']	[4]
5	trisalicylate	I-Drug	['Causes']	[0]
6	:	O	['N']	[6]
7	case	O	['N']	[7]
8	report	O	['N']	[8]
9	and	O	['N']	[9]
10	review	O	['N']	[10]
11	of	O	['N']	[11]
12	salicylate	O	['N']	[12]
13	-	O	['N']	[13]
14	induced	O	['N']	[14]
15	hepatotoxicity	O	['N']	[15]
16	.	O	['N']	[16]
#1975
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	development	O	['N']	[3]
4	of	O	['N']	[4]
5	ischemic	B	['N']	[5]
6	colitis	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	woman	O	['N']	[9]
10	who	O	['N']	[10]
11	was	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	tegaserod	B-Drug	['Causes']	[6]
15	and	O	['N']	[15]
16	review	O	['N']	[16]
17	the	O	['N']	[17]
18	relationship	O	['N']	[18]
19	among	O	['N']	[19]
20	ischemic	O	['N']	[20]
21	colitis	O	['N']	[21]
22	,	O	['N']	[22]
23	tegaserod	O	['N']	[23]
24	use	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	irritable	O	['N']	[27]
28	bowel	O	['N']	[28]
29	syndrome	O	['N']	[29]
30	.	O	['N']	[30]
#1976
0	An	O	['N']	[0]
1	intertrigo	B	['N']	[1]
2	-	I	['N']	[2]
3	like	I	['N']	[3]
4	eruption	I-Adverse_Effect	['N']	[4]
5	from	O	['N']	[5]
6	pegylated	O	['N']	[6]
7	liposomal	O	['N']	[7]
8	doxorubicin	B-Drug	['Causes']	[4]
9	.	O	['N']	[9]
#1977
0	Acute	O	['N']	[0]
1	myopathy	O	['N']	[1]
2	with	O	['N']	[2]
3	selective	O	['N']	[3]
4	degeneration	B	['N']	[4]
5	of	I	['N']	[5]
6	myosin	I	['N']	[6]
7	filaments	I-Adverse_Effect	['N']	[7]
8	following	O	['N']	[8]
9	status	O	['N']	[9]
10	asthmaticus	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	methylprednisolone	O	['N']	[13]
14	and	O	['N']	[14]
15	vecuronium	B-Drug	['Causes']	[7]
16	.	O	['N']	[16]
#1978
0	Our	O	['N']	[0]
1	cases	O	['N']	[1]
2	constitute	O	['N']	[2]
3	the	O	['N']	[3]
4	most	O	['N']	[4]
5	severe	O	['N']	[5]
6	cases	O	['N']	[6]
7	of	O	['N']	[7]
8	benzarone	B-Drug	['Causes']	[22]
9	hepatotoxicity	O	['N']	[9]
10	reported	O	['N']	[10]
11	so	O	['N']	[11]
12	far	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	comprise	O	['N']	[15]
16	the	O	['N']	[16]
17	first	O	['N']	[17]
18	cases	O	['N']	[18]
19	of	O	['N']	[19]
20	(	B	['N']	[20]
21	sub)fulminant	I	['N']	[21]
22	hepatitis	I-Adverse_Effect	['N']	[22]
23	and	O	['N']	[23]
24	cirrhosis	O	['N']	[24]
25	related	O	['N']	[25]
26	to	O	['N']	[26]
27	benzarone	O	['N']	[27]
28	.	O	['N']	[28]
#1979
0	Successful	O	['N']	[0]
1	treatment	O	['N']	[1]
2	of	O	['N']	[2]
3	hyperthyroidism	O	['N']	[3]
4	with	O	['N']	[4]
5	amiodarone	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	propylthiouracil	B-Drug	['Causes']	[15]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	acute	B	['N']	[13]
14	hepatic	I	['N']	[14]
15	failure	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#1980
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	androgen	O	['N']	[5]
6	-	O	['N']	[6]
7	independent	O	['N']	[7]
8	prostate	O	['N']	[8]
9	cancer	O	['N']	[9]
10	in	O	['N']	[10]
11	whom	O	['N']	[11]
12	PSA	B	['N']	[12]
13	continued	I	['N']	[13]
14	to	I	['N']	[14]
15	decrease	I-Adverse_Effect	['N']	[15]
16	for	O	['N']	[16]
17	a	O	['N']	[17]
18	period	O	['N']	[18]
19	of	O	['N']	[19]
20	15	O	['N']	[20]
21	months	O	['N']	[21]
22	after	O	['N']	[22]
23	flutamide	B-Drug	['Causes']	[15]
24	withdrawal	O	['N']	[24]
25	.	O	['N']	[25]
#1981
0	Paradoxical	B	['N']	[0]
1	precipitation	I	['N']	[1]
2	of	I	['N']	[2]
3	tonic	I	['N']	[3]
4	seizures	I-Adverse_Effect	['N']	[4]
5	by	O	['N']	[5]
6	lorazepam	B-Drug	['Causes']	[4]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	child	O	['N']	[9]
10	with	O	['N']	[10]
11	atypical	O	['N']	[11]
12	absence	O	['N']	[12]
13	seizures	O	['N']	[13]
14	.	O	['N']	[14]
#1982
0	Symptomatic	B	['N']	[0]
1	hypoglycemia	I-Adverse_Effect	['N']	[1]
2	secondary	O	['N']	[2]
3	to	O	['N']	[3]
4	a	O	['N']	[4]
5	glipizide	B-Drug	['Causes']	[1]
6	-	O	['N']	[6]
7	trimethoprim	O	['N']	[7]
8	/	O	['N']	[8]
9	sulfamethoxazole	O	['N']	[9]
10	drug	O	['N']	[10]
11	interaction	O	['N']	[11]
12	.	O	['N']	[12]
#1983
0	A	O	['N']	[0]
1	study	O	['N']	[1]
2	following	O	['N']	[2]
3	large	O	['N']	[3]
4	patient	O	['N']	[4]
5	groups	O	['N']	[5]
6	on	O	['N']	[6]
7	theophylline	B-Drug	['Causes']	[20]
8	and	O	['N']	[8]
9	a	O	['N']	[9]
10	combination	O	['N']	[10]
11	of	O	['N']	[11]
12	theophylline	O	['N']	[12]
13	and	O	['N']	[13]
14	steroids	O	['N']	[14]
15	might	O	['N']	[15]
16	clarify	O	['N']	[16]
17	the	O	['N']	[17]
18	risk	O	['N']	[18]
19	of	O	['N']	[19]
20	ulcer	B-Adverse_Effect	['N']	[20]
21	formation	O	['N']	[21]
22	in	O	['N']	[22]
23	patients	O	['N']	[23]
24	being	O	['N']	[24]
25	treated	O	['N']	[25]
26	with	O	['N']	[26]
27	these	O	['N']	[27]
28	medications	O	['N']	[28]
29	for	O	['N']	[29]
30	asthma	O	['N']	[30]
31	.	O	['N']	[31]
#1984
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	the	O	['N']	[2]
3	management	O	['N']	[3]
4	of	O	['N']	[4]
5	agranulocytosis	B-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	neutropenic	O	['N']	[7]
8	sepsis	O	['N']	[8]
9	secondary	O	['N']	[9]
10	to	O	['N']	[10]
11	carbimazole	B-Drug	['Causes']	[5]
12	with	O	['N']	[12]
13	recombinant	O	['N']	[13]
14	human	O	['N']	[14]
15	granulocyte	O	['N']	[15]
16	colony	O	['N']	[16]
17	stimulating	O	['N']	[17]
18	factor	O	['N']	[18]
19	(	O	['N']	[19]
20	G	O	['N']	[20]
21	-	O	['N']	[21]
22	CSF	O	['N']	[22]
23	)	O	['N']	[23]
24	.	O	['N']	[24]
#1985
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Peripheral	O	['N']	[2]
3	administration	O	['N']	[3]
4	of	O	['N']	[4]
5	low	O	['N']	[5]
6	-	O	['N']	[6]
7	dose	O	['N']	[7]
8	vasopressin	B-Drug	['Causes']	[22]
9	for	O	['N']	[9]
10	septic	O	['N']	[10]
11	shock	O	['N']	[11]
12	should	O	['N']	[12]
13	be	O	['N']	[13]
14	discouraged	O	['N']	[14]
15	because	O	['N']	[15]
16	of	O	['N']	[16]
17	the	O	['N']	[17]
18	risk	O	['N']	[18]
19	of	O	['N']	[19]
20	ischemic	B	['N']	[20]
21	skin	I	['N']	[21]
22	complications	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#1986
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	document	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	serotonin	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	(	O	['N']	[9]
10	SS	B-Adverse_Effect	['N']	[10]
11	)	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	mirtazapine	B-Drug	['Causes']	[10]
15	monotherapy	O	['N']	[15]
16	,	O	['N']	[16]
17	review	O	['N']	[17]
18	the	O	['N']	[18]
19	previously	O	['N']	[19]
20	reported	O	['N']	[20]
21	cases	O	['N']	[21]
22	of	O	['N']	[22]
23	SS	O	['N']	[23]
24	associated	O	['N']	[24]
25	with	O	['N']	[25]
26	this	O	['N']	[26]
27	tetracyclic	O	['N']	[27]
28	antidepressant	O	['N']	[28]
29	,	O	['N']	[29]
30	and	O	['N']	[30]
31	discuss	O	['N']	[31]
32	the	O	['N']	[32]
33	possible	O	['N']	[33]
34	pathogenic	O	['N']	[34]
35	mechanisms	O	['N']	[35]
36	leading	O	['N']	[36]
37	to	O	['N']	[37]
38	this	O	['N']	[38]
39	serious	O	['N']	[39]
40	adverse	O	['N']	[40]
41	drug	O	['N']	[41]
42	reaction	O	['N']	[42]
43	.	O	['N']	[43]
#1987
0	Marked	B	['N']	[0]
1	QT	I	['N']	[1]
2	prolongation	I-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	torsades	O	['N']	[4]
5	de	O	['N']	[5]
6	pointes	O	['N']	[6]
7	secondary	O	['N']	[7]
8	to	O	['N']	[8]
9	acute	O	['N']	[9]
10	ischemia	O	['N']	[10]
11	in	O	['N']	[11]
12	an	O	['N']	[12]
13	elderly	O	['N']	[13]
14	man	O	['N']	[14]
15	taking	O	['N']	[15]
16	dofetilide	B-Drug	['Causes']	[2]
17	for	O	['N']	[17]
18	atrial	O	['N']	[18]
19	fibrillation	O	['N']	[19]
20	:	O	['N']	[20]
21	a	O	['N']	[21]
22	cautionary	O	['N']	[22]
23	tale	O	['N']	[23]
24	.	O	['N']	[24]
#1988
0	Although	O	['N']	[0]
1	major	O	['N']	[1]
2	hazards	O	['N']	[2]
3	of	O	['N']	[3]
4	treatment	O	['N']	[4]
5	of	O	['N']	[5]
6	hypophosphatemic	O	['N']	[6]
7	osteomalacia	O	['N']	[7]
8	with	O	['N']	[8]
9	phosphate	O	['N']	[9]
10	and	O	['N']	[10]
11	calcitriol	B-Drug	['Causes']	[14]
12	are	O	['N']	[12]
13	secondary	B	['N']	[13]
14	hyperparathyroidism	I-Adverse_Effect	['N']	[14]
15	and	O	['N']	[15]
16	vitamin	O	['N']	[16]
17	D	O	['N']	[17]
18	intoxication	O	['N']	[18]
19	,	O	['N']	[19]
20	potassium	O	['N']	[20]
21	loss	O	['N']	[21]
22	also	O	['N']	[22]
23	should	O	['N']	[23]
24	be	O	['N']	[24]
25	kept	O	['N']	[25]
26	in	O	['N']	[26]
27	mind	O	['N']	[27]
28	.	O	['N']	[28]
#1989
0	Two	O	['N']	[0]
1	case	O	['N']	[1]
2	reports	O	['N']	[2]
3	of	O	['N']	[3]
4	bilateral	B	['N']	[4]
5	granulomatous	I	['N']	[5]
6	anterior	I	['N']	[6]
7	uveitis	I-Adverse_Effect	['N']	[7]
8	are	O	['N']	[8]
9	described	O	['N']	[9]
10	in	O	['N']	[10]
11	patients	O	['N']	[11]
12	with	O	['N']	[12]
13	open	O	['N']	[13]
14	angle	O	['N']	[14]
15	glaucoma	O	['N']	[15]
16	treated	O	['N']	[16]
17	with	O	['N']	[17]
18	metripranolol	B-Drug	['Causes']	[7]
19	0.6	O	['N']	[19]
20	%	O	['N']	[20]
21	eye	O	['N']	[21]
22	drops	O	['N']	[22]
23	.	O	['N']	[23]
#1990
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	dermatologists	O	['N']	[2]
3	should	O	['N']	[3]
4	be	O	['N']	[4]
5	cautious	O	['N']	[5]
6	about	O	['N']	[6]
7	a	O	['N']	[7]
8	photosensitivity	B-Adverse_Effect	['N']	[8]
9	reaction	O	['N']	[9]
10	induced	O	['N']	[10]
11	by	O	['N']	[11]
12	mequitazine	B-Drug	['Causes']	[8]
13	or	O	['N']	[13]
14	other	O	['N']	[14]
15	phenothiazine	O	['N']	[15]
16	-	O	['N']	[16]
17	derivative	O	['N']	[17]
18	drugs	O	['N']	[18]
19	.	O	['N']	[19]
#1991
0	After	O	['N']	[0]
1	reviewing	O	['N']	[1]
2	the	O	['N']	[2]
3	literature	O	['N']	[3]
4	we	O	['N']	[4]
5	suggest	O	['N']	[5]
6	the	O	['N']	[6]
7	CPM	B-Adverse_Effect	['N']	[7]
8	was	O	['N']	[8]
9	a	O	['N']	[9]
10	complication	O	['N']	[10]
11	of	O	['N']	[11]
12	lithium	B-Drug	['Causes']	[7]
13	toxicity	O	['N']	[13]
14	which	O	['N']	[14]
15	affected	O	['N']	[15]
16	the	O	['N']	[16]
17	lateral	O	['N']	[17]
18	geniculate	O	['N']	[18]
19	nucleus	O	['N']	[19]
20	which	O	['N']	[20]
21	produced	O	['N']	[21]
22	blindness	O	['N']	[22]
23	.	O	['N']	[23]
#1992
0	Tacrolimus	B-Drug	['Causes']	[11]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	HUS	O	['N']	[3]
4	:	O	['N']	[4]
5	an	O	['N']	[5]
6	unusual	O	['N']	[6]
7	cause	O	['N']	[7]
8	of	O	['N']	[8]
9	acute	B	['N']	[9]
10	renal	I	['N']	[10]
11	failure	I-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	nephrotic	O	['N']	[13]
14	syndrome	O	['N']	[14]
15	.	O	['N']	[15]
#1993
0	Camptocormia	B-Adverse_Effect	['N']	[0]
1	,	O	['N']	[1]
2	a	O	['N']	[2]
3	new	O	['N']	[3]
4	side	O	['N']	[4]
5	effect	O	['N']	[5]
6	of	O	['N']	[6]
7	sodium	B	['N']	[7]
8	valproate	I-Drug	['Causes']	[0]
9	.	O	['N']	[9]
#1994
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	two	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	acute	O	['N']	[6]
7	dystonic	O	['N']	[7]
8	reactions	O	['N']	[8]
9	(	O	['N']	[9]
10	ADRs	B-Adverse_Effect	['N']	[10]
11	)	O	['N']	[11]
12	as	O	['N']	[12]
13	a	O	['N']	[13]
14	side	O	['N']	[14]
15	effect	O	['N']	[15]
16	of	O	['N']	[16]
17	lamivudine	B-Drug	['Causes']	[10]
18	.	O	['N']	[18]
#1995
0	A	O	['N']	[0]
1	depressed	O	['N']	[1]
2	woman	O	['N']	[2]
3	with	O	['N']	[3]
4	no	O	['N']	[4]
5	history	O	['N']	[5]
6	of	O	['N']	[6]
7	bipolar	O	['N']	[7]
8	illness	O	['N']	[8]
9	developed	O	['N']	[9]
10	a	O	['N']	[10]
11	manic	B	['N']	[11]
12	episode	I-Adverse_Effect	['N']	[12]
13	during	O	['N']	[13]
14	treatment	O	['N']	[14]
15	with	O	['N']	[15]
16	fluoxetine	B-Drug	['Causes']	[12]
17	.	O	['N']	[17]
#1996
0	A	O	['N']	[0]
1	55-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	presented	O	['N']	[5]
6	an	O	['N']	[6]
7	episode	O	['N']	[7]
8	of	O	['N']	[8]
9	acute	B	['N']	[9]
10	urticaria	I-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	labial	O	['N']	[12]
13	angioedema	O	['N']	[13]
14	60	O	['N']	[14]
15	minutes	O	['N']	[15]
16	after	O	['N']	[16]
17	ingesting	O	['N']	[17]
18	500	O	['N']	[18]
19	mg	O	['N']	[19]
20	of	O	['N']	[20]
21	cloxacillin	B-Drug	['Causes']	[10]
22	for	O	['N']	[22]
23	a	O	['N']	[23]
24	skin	O	['N']	[24]
25	abscess	O	['N']	[25]
26	.	O	['N']	[26]
#1997
0	Although	O	['N']	[0]
1	there	O	['N']	[1]
2	is	O	['N']	[2]
3	one	O	['N']	[3]
4	case	O	['N']	[4]
5	report	O	['N']	[5]
6	of	O	['N']	[6]
7	cholesterol	B	['N']	[7]
8	crystal	I	['N']	[8]
9	embolization	I-Adverse_Effect	['N']	[9]
10	following	O	['N']	[10]
11	t	B	['N']	[11]
12	-	I	['N']	[12]
13	PA	I-Drug	['Causes']	[9]
14	therapy	O	['N']	[14]
15	with	O	['N']	[15]
16	only	O	['N']	[16]
17	extrarenal	O	['N']	[17]
18	manifestations	O	['N']	[18]
19	(	O	['N']	[19]
20	N	O	['N']	[20]
21	Engl	O	['N']	[21]
22	J	O	['N']	[22]
23	Med	O	['N']	[23]
24	321:1270	O	['N']	[24]
25	,	O	['N']	[25]
26	1989	O	['N']	[26]
27	)	O	['N']	[27]
28	,	O	['N']	[28]
29	this	O	['N']	[29]
30	is	O	['N']	[30]
31	the	O	['N']	[31]
32	first	O	['N']	[32]
33	reported	O	['N']	[33]
34	case	O	['N']	[34]
35	of	O	['N']	[35]
36	atheroembolic	O	['N']	[36]
37	acute	O	['N']	[37]
38	renal	O	['N']	[38]
39	failure	O	['N']	[39]
40	following	O	['N']	[40]
41	t	O	['N']	[41]
42	-	O	['N']	[42]
43	PA	O	['N']	[43]
44	therapy	O	['N']	[44]
45	.	O	['N']	[45]
#1998
0	Clozapine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	eosinophilia	B-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	switch	O	['N']	[5]
6	to	O	['N']	[6]
7	quetiapine	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	with	O	['N']	[11]
12	chronic	O	['N']	[12]
13	schizophrenia	O	['N']	[13]
14	with	O	['N']	[14]
15	suicidal	O	['N']	[15]
16	tendencies	O	['N']	[16]
17	.	O	['N']	[17]
#1999
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	and	O	['N']	[2]
3	a	O	['N']	[3]
4	review	O	['N']	[4]
5	of	O	['N']	[5]
6	the	O	['N']	[6]
7	literature	O	['N']	[7]
8	show	O	['N']	[8]
9	the	O	['N']	[9]
10	severe	O	['N']	[10]
11	and	O	['N']	[11]
12	unpredictable	O	['N']	[12]
13	nature	O	['N']	[13]
14	of	O	['N']	[14]
15	ethambutol	B-Drug	['Causes']	[23]
16	toxicity	O	['N']	[16]
17	and	O	['N']	[17]
18	its	O	['N']	[18]
19	potential	O	['N']	[19]
20	for	O	['N']	[20]
21	irreversible	O	['N']	[21]
22	vision	B	['N']	[22]
23	loss	I-Adverse_Effect	['N']	[23]
24	despite	O	['N']	[24]
25	careful	O	['N']	[25]
26	ophthalmologic	O	['N']	[26]
27	monitoring	O	['N']	[27]
28	.	O	['N']	[28]
#2000
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	focal	B	['N']	[6]
7	myocardial	I	['N']	[7]
8	necrosis	I-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	presenting	O	['N']	[10]
11	clinically	O	['N']	[11]
12	as	O	['N']	[12]
13	an	O	['N']	[13]
14	acute	O	['N']	[14]
15	myocardial	O	['N']	[15]
16	infarction	O	['N']	[16]
17	during	O	['N']	[17]
18	the	O	['N']	[18]
19	administration	O	['N']	[19]
20	of	O	['N']	[20]
21	the	O	['N']	[21]
22	antineoplastic	O	['N']	[22]
23	drug	O	['N']	[23]
24	,	O	['N']	[24]
25	amsacrine	B-Drug	['Causes']	[8]
26	,	O	['N']	[26]
27	in	O	['N']	[27]
28	a	O	['N']	[28]
29	patient	O	['N']	[29]
30	without	O	['N']	[30]
31	coronary	O	['N']	[31]
32	artery	O	['N']	[32]
33	disease	O	['N']	[33]
34	.	O	['N']	[34]
#2001
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	,	O	['N']	[3]
4	we	O	['N']	[4]
5	present	O	['N']	[5]
6	a	O	['N']	[6]
7	case	O	['N']	[7]
8	of	O	['N']	[8]
9	hypoglycaemic	B	['N']	[9]
10	coma	I-Adverse_Effect	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	SP	B-Drug	['Causes']	[10]
14	,	O	['N']	[14]
15	an	O	['N']	[15]
16	adverse	O	['N']	[16]
17	reaction	O	['N']	[17]
18	that	O	['N']	[18]
19	is	O	['N']	[19]
20	likely	O	['N']	[20]
21	to	O	['N']	[21]
22	be	O	['N']	[22]
23	underreported	O	['N']	[23]
24	and	O	['N']	[24]
25	expected	O	['N']	[25]
26	to	O	['N']	[26]
27	occur	O	['N']	[27]
28	with	O	['N']	[28]
29	greater	O	['N']	[29]
30	frequency	O	['N']	[30]
31	as	O	['N']	[31]
32	the	O	['N']	[32]
33	use	O	['N']	[33]
34	of	O	['N']	[34]
35	SP	O	['N']	[35]
36	increases	O	['N']	[36]
37	.	O	['N']	[37]
#2002
0	A	O	['N']	[0]
1	31-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	developed	O	['N']	[5]
6	multiple	O	['N']	[6]
7	episodes	O	['N']	[7]
8	of	O	['N']	[8]
9	grand	B	['N']	[9]
10	mal	I	['N']	[10]
11	seizures	I-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	combination	O	['N']	[13]
14	chemotherapy	O	['N']	[14]
15	with	O	['N']	[15]
16	cisplatin	O	['N']	[16]
17	,	O	['N']	[17]
18	vinblastine	O	['N']	[18]
19	and	O	['N']	[19]
20	bleomycin	B-Drug	['Causes']	[11]
21	for	O	['N']	[21]
22	germ	O	['N']	[22]
23	cell	O	['N']	[23]
24	ovarian	O	['N']	[24]
25	cancer	O	['N']	[25]
26	stage	O	['N']	[26]
27	Ic	O	['N']	[27]
28	.	O	['N']	[28]
#2003
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	fatal	B	['N']	[7]
8	hyperkalemia	I-Adverse_Effect	['N']	[8]
9	owing	O	['N']	[9]
10	to	O	['N']	[10]
11	succinylcholine	B-Drug	['Causes']	[8]
12	administration	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	patient	O	['N']	[15]
16	with	O	['N']	[16]
17	mucositis	O	['N']	[17]
18	secondary	O	['N']	[18]
19	to	O	['N']	[19]
20	chemotherapy	O	['N']	[20]
21	.	O	['N']	[21]
#2004
0	Cerebral	B	['N']	[0]
1	edema	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	Gliadel	B-Drug	['Causes']	[1]
5	wafers	O	['N']	[5]
6	:	O	['N']	[6]
7	two	O	['N']	[7]
8	case	O	['N']	[8]
9	studies	O	['N']	[9]
10	.	O	['N']	[10]
#2005
0	After	O	['N']	[0]
1	a	O	['N']	[1]
2	six	O	['N']	[2]
3	-	O	['N']	[3]
4	week	O	['N']	[4]
5	course	O	['N']	[5]
6	of	O	['N']	[6]
7	low	O	['N']	[7]
8	-	O	['N']	[8]
9	dose	O	['N']	[9]
10	cyclosporine	B	['N']	[10]
11	A	I-Drug	['Causes']	[23]
12	,	O	['N']	[12]
13	she	O	['N']	[13]
14	developed	O	['N']	[14]
15	a	O	['N']	[15]
16	severe	O	['N']	[16]
17	but	O	['N']	[17]
18	reversible	O	['N']	[18]
19	loss	B	['N']	[19]
20	of	I	['N']	[20]
21	glomerular	I	['N']	[21]
22	filtration	I	['N']	[22]
23	rate	I-Adverse_Effect	['N']	[23]
24	and	O	['N']	[24]
25	effective	O	['N']	[25]
26	renal	O	['N']	[26]
27	plasma	O	['N']	[27]
28	flow	O	['N']	[28]
29	despite	O	['N']	[29]
30	of	O	['N']	[30]
31	low	O	['N']	[31]
32	cyclosporine	O	['N']	[32]
33	A	O	['N']	[33]
34	plasma	O	['N']	[34]
35	levels	O	['N']	[35]
36	.	O	['N']	[36]
#2006
0	Beginning	O	['N']	[0]
1	ductopenia	O	['N']	[1]
2	was	O	['N']	[2]
3	present	O	['N']	[3]
4	in	O	['N']	[4]
5	two	O	['N']	[5]
6	,	O	['N']	[6]
7	suggesting	O	['N']	[7]
8	that	O	['N']	[8]
9	itraconazole	B-Drug	['Causes']	[21]
10	might	O	['N']	[10]
11	be	O	['N']	[11]
12	responsible	O	['N']	[12]
13	for	O	['N']	[13]
14	the	O	['N']	[14]
15	occurrence	O	['N']	[15]
16	of	O	['N']	[16]
17	prolonged	O	['N']	[17]
18	drug	O	['N']	[18]
19	-	O	['N']	[19]
20	induced	O	['N']	[20]
21	cholangiopathy	B-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#2007
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	generalized	B	['N']	[5]
6	cutaneous	I	['N']	[6]
7	sclerosis	I-Adverse_Effect	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	muscle	O	['N']	[10]
11	and	O	['N']	[11]
12	oesophageal	O	['N']	[12]
13	involvement	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	patient	O	['N']	[16]
17	exposed	O	['N']	[17]
18	to	O	['N']	[18]
19	herbicides	O	['N']	[19]
20	containing	O	['N']	[20]
21	bromocil	O	['N']	[21]
22	,	O	['N']	[22]
23	diuron	B-Drug	['Causes']	[7]
24	and	O	['N']	[24]
25	aminotriazole	O	['N']	[25]
26	.	O	['N']	[26]
#2008
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	case	O	['N']	[2]
3	,	O	['N']	[3]
4	it	O	['N']	[4]
5	was	O	['N']	[5]
6	suspected	O	['N']	[6]
7	that	O	['N']	[7]
8	a	O	['N']	[8]
9	combination	O	['N']	[9]
10	of	O	['N']	[10]
11	cigarette	O	['N']	[11]
12	smoking	O	['N']	[12]
13	,	O	['N']	[13]
14	pulmonary	O	['N']	[14]
15	fibrosis	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	low	O	['N']	[18]
19	-	O	['N']	[19]
20	dose	O	['N']	[20]
21	methotrexate	B-Drug	['Causes']	[30]
22	therapy	O	['N']	[22]
23	might	O	['N']	[23]
24	have	O	['N']	[24]
25	promoted	O	['N']	[25]
26	the	O	['N']	[26]
27	development	O	['N']	[27]
28	of	O	['N']	[28]
29	lung	B	['N']	[29]
30	cancer	I-Adverse_Effect	['N']	[30]
31	.	O	['N']	[31]
#2009
0	Central	O	['N']	[0]
1	pontine	O	['N']	[1]
2	myelinolysis	O	['N']	[2]
3	manifested	O	['N']	[3]
4	by	O	['N']	[4]
5	temporary	B	['N']	[5]
6	blindness	I-Adverse_Effect	['N']	[6]
7	:	O	['N']	[7]
8	a	O	['N']	[8]
9	possible	O	['N']	[9]
10	complication	O	['N']	[10]
11	of	O	['N']	[11]
12	lithium	B-Drug	['Causes']	[6]
13	toxicity	O	['N']	[13]
14	.	O	['N']	[14]
#2010
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	each	O	['N']	[2]
3	infant	O	['N']	[3]
4	demonstrated	O	['N']	[4]
5	hemodynamic	B	['N']	[5]
6	decompensation	I-Adverse_Effect	['N']	[6]
7	shortly	O	['N']	[7]
8	after	O	['N']	[8]
9	verapamil	B-Drug	['Causes']	[6]
10	administration	O	['N']	[10]
11	and	O	['N']	[11]
12	required	O	['N']	[12]
13	cardiopulmonary	O	['N']	[13]
14	resuscitation	O	['N']	[14]
15	.	O	['N']	[15]
#2011
0	We	O	['N']	[0]
1	discuss	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	severe	O	['N']	[6]
7	renal	O	['N']	[7]
8	tubular	O	['N']	[8]
9	dysfunction	O	['N']	[9]
10	secondary	O	['N']	[10]
11	to	O	['N']	[11]
12	short	O	['N']	[12]
13	-	O	['N']	[13]
14	term	O	['N']	[14]
15	therapy	O	['N']	[15]
16	with	O	['N']	[16]
17	Amikacin	B-Drug	['Causes']	[29]
18	,	O	['N']	[18]
19	resulting	O	['N']	[19]
20	in	O	['N']	[20]
21	refractory	O	['N']	[21]
22	hypokalemia	O	['N']	[22]
23	,	O	['N']	[23]
24	hypocalcemia	O	['N']	[24]
25	,	O	['N']	[25]
26	hypomagnesemia	O	['N']	[26]
27	,	O	['N']	[27]
28	metabolic	B	['N']	[28]
29	alkalosis	I-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	polyuria	O	['N']	[32]
33	.	O	['N']	[33]
#2012
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	received	O	['N']	[2]
3	only	O	['N']	[3]
4	the	O	['N']	[4]
5	ophthalmic	O	['N']	[5]
6	sulfonamide	B-Drug	['Causes']	[22]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	it	O	['N']	[9]
10	was	O	['N']	[10]
11	used	O	['N']	[11]
12	for	O	['N']	[12]
13	one	O	['N']	[13]
14	day	O	['N']	[14]
15	,	O	['N']	[15]
16	but	O	['N']	[16]
17	he	O	['N']	[17]
18	developed	O	['N']	[18]
19	Stevens	B	['N']	[19]
20	-	I	['N']	[20]
21	Johnson	I	['N']	[21]
22	syndrome	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#2013
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	,	O	['N']	[3]
4	one	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	developed	O	['N']	[7]
8	gangrene	O	['N']	[8]
9	after	O	['N']	[9]
10	bleomycin	O	['N']	[10]
11	and	O	['N']	[11]
12	vincristine	B-Drug	['Causes']	[36]
13	/	O	['N']	[13]
14	vinblastine	O	['N']	[14]
15	chemotherapy	O	['N']	[15]
16	for	O	['N']	[16]
17	AIDS	O	['N']	[17]
18	-	O	['N']	[18]
19	related	O	['N']	[19]
20	Kaposi	O	['N']	[20]
21	's	O	['N']	[21]
22	sarcoma	O	['N']	[22]
23	and	O	['N']	[23]
24	another	O	['N']	[24]
25	HIV	O	['N']	[25]
26	-	O	['N']	[26]
27	infected	O	['N']	[27]
28	patient	O	['N']	[28]
29	who	O	['N']	[29]
30	exhibited	O	['N']	[30]
31	symptoms	O	['N']	[31]
32	of	O	['N']	[32]
33	severe	B	['N']	[33]
34	Raynaud	I	['N']	[34]
35	's	I	['N']	[35]
36	phenomenon	I-Adverse_Effect	['N']	[36]
37	related	O	['N']	[37]
38	to	O	['N']	[38]
39	the	O	['N']	[39]
40	same	O	['N']	[40]
41	regimen	O	['N']	[41]
42	are	O	['N']	[42]
43	presented	O	['N']	[43]
44	.	O	['N']	[44]
#2014
0	Bleomycin	B-Drug	['Causes']	[6]
1	and	O	['N']	[1]
2	cyclophosphamide	O	['N']	[2]
3	toxicity	O	['N']	[3]
4	simulating	O	['N']	[4]
5	metastatic	B	['N']	[5]
6	nodules	I-Adverse_Effect	['N']	[6]
7	to	O	['N']	[7]
8	the	O	['N']	[8]
9	lungs	O	['N']	[9]
10	in	O	['N']	[10]
11	childhood	O	['N']	[11]
12	cancer	O	['N']	[12]
13	.	O	['N']	[13]
#2015
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	five	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	tremor	B-Adverse_Effect	['N']	[6]
7	related	O	['N']	[7]
8	to	O	['N']	[8]
9	itraconazole	B-Drug	['Causes']	[6]
10	therapy	O	['N']	[10]
11	,	O	['N']	[11]
12	which	O	['N']	[12]
13	occurred	O	['N']	[13]
14	within	O	['N']	[14]
15	1	O	['N']	[15]
16	-	O	['N']	[16]
17	12	O	['N']	[17]
18	months	O	['N']	[18]
19	of	O	['N']	[19]
20	initiating	O	['N']	[20]
21	treatment	O	['N']	[21]
22	and	O	['N']	[22]
23	resolved	O	['N']	[23]
24	gradually	O	['N']	[24]
25	following	O	['N']	[25]
26	itraconazole	O	['N']	[26]
27	withdrawal	O	['N']	[27]
28	.	O	['N']	[28]
#2016
0	The	O	['N']	[0]
1	nodules	B-Adverse_Effect	['N']	[1]
2	regressed	O	['N']	[2]
3	after	O	['N']	[3]
4	withdrawal	O	['N']	[4]
5	of	O	['N']	[5]
6	methotrexate	B-Drug	['Causes']	[1]
7	therapy	O	['N']	[7]
8	in	O	['N']	[8]
9	one	O	['N']	[9]
10	patient	O	['N']	[10]
11	and	O	['N']	[11]
12	were	O	['N']	[12]
13	arrested	O	['N']	[13]
14	with	O	['N']	[14]
15	the	O	['N']	[15]
16	addition	O	['N']	[16]
17	of	O	['N']	[17]
18	hydroxychloroquine	O	['N']	[18]
19	in	O	['N']	[19]
20	the	O	['N']	[20]
21	other	O	['N']	[21]
22	.	O	['N']	[22]
#2017
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	new	O	['N']	[3]
4	quinolone	O	['N']	[4]
5	derivatives	O	['N']	[5]
6	(	O	['N']	[6]
7	levofloxacin	O	['N']	[7]
8	,	O	['N']	[8]
9	sparfloxacin	B-Drug	['Causes']	[41]
10	,	O	['N']	[10]
11	grepafloxacin	O	['N']	[11]
12	,	O	['N']	[12]
13	trovafloxacin	O	['N']	[13]
14	,	O	['N']	[14]
15	gatifloxacin	O	['N']	[15]
16	and	O	['N']	[16]
17	moxifloxacin	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	also	O	['N']	[20]
21	called	O	['N']	[21]
22	gyrase	O	['N']	[22]
23	inhibitors	O	['N']	[23]
24	,	O	['N']	[24]
25	are	O	['N']	[25]
26	known	O	['N']	[26]
27	for	O	['N']	[27]
28	their	O	['N']	[28]
29	potential	O	['N']	[29]
30	to	O	['N']	[30]
31	cause	O	['N']	[31]
32	central	O	['N']	[32]
33	nervous	O	['N']	[33]
34	system	O	['N']	[34]
35	-	O	['N']	[35]
36	related	O	['N']	[36]
37	adverse	O	['N']	[37]
38	effects	O	['N']	[38]
39	,	O	['N']	[39]
40	including	O	['N']	[40]
41	headache	B-Adverse_Effect	['N']	[41]
42	,	O	['N']	[42]
43	dizziness	O	['N']	[43]
44	and	O	['N']	[44]
45	insomnia	O	['N']	[45]
46	.	O	['N']	[46]
#2018
0	Severe	O	['N']	[0]
1	sulfadiazine	B-Drug	['Causes']	[2]
2	hypersensitivity	B-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	child	O	['N']	[5]
6	with	O	['N']	[6]
7	reactivated	O	['N']	[7]
8	congenital	O	['N']	[8]
9	toxoplasmic	O	['N']	[9]
10	chorioretinitis	O	['N']	[10]
11	.	O	['N']	[11]
#2019
0	Response	O	['N']	[0]
1	of	O	['N']	[1]
2	a	O	['N']	[2]
3	promethazine	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	coma	B-Adverse_Effect	['N']	[6]
7	to	O	['N']	[7]
8	flumazenil	O	['N']	[8]
9	.	O	['N']	[9]
#2020
0	The	O	['N']	[0]
1	clinical	O	['N']	[1]
2	findings	O	['N']	[2]
3	and	O	['N']	[3]
4	laboratory	O	['N']	[4]
5	studies	O	['N']	[5]
6	suggested	O	['N']	[6]
7	an	O	['N']	[7]
8	autoimmune	B	['N']	[8]
9	cell	I	['N']	[9]
10	-	I	['N']	[10]
11	mediated	I	['N']	[11]
12	hypersensitivity	I-Adverse_Effect	['N']	[12]
13	reaction	O	['N']	[13]
14	triggered	O	['N']	[14]
15	by	O	['N']	[15]
16	phenobarbital	B-Drug	['Causes']	[12]
17	.	O	['N']	[17]
#2021
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	was	O	['N']	[2]
3	diagnosed	O	['N']	[3]
4	with	O	['N']	[4]
5	carbamazepine	B-Drug	['Causes']	[6]
6	toxicity	I-Adverse_Effect	['N']	[6]
7	related	O	['N']	[7]
8	to	O	['N']	[8]
9	the	O	['N']	[9]
10	introduction	O	['N']	[10]
11	of	O	['N']	[11]
12	ritonavir	O	['N']	[12]
13	.	O	['N']	[13]
#2022
0	The	O	['N']	[0]
1	male	O	['N']	[1]
2	patient	O	['N']	[2]
3	was	O	['N']	[3]
4	treated	O	['N']	[4]
5	with	O	['N']	[5]
6	225-mg	O	['N']	[6]
7	/	O	['N']	[7]
8	day	O	['N']	[8]
9	clozapine	B-Drug	['Causes']	[17]
10	and	O	['N']	[10]
11	the	O	['N']	[11]
12	time	O	['N']	[12]
13	to	O	['N']	[13]
14	the	O	['N']	[14]
15	diagnosis	O	['N']	[15]
16	of	O	['N']	[16]
17	agranulocytosis	B-Adverse_Effect	['N']	[17]
18	was	O	['N']	[18]
19	6	O	['N']	[19]
20	weeks	O	['N']	[20]
21	.	O	['N']	[21]
#2023
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Spontaneous	B	['N']	[2]
3	hemothorax	I-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	a	O	['N']	[5]
6	rare	O	['N']	[6]
7	phenomenon	O	['N']	[7]
8	in	O	['N']	[8]
9	conjunction	O	['N']	[9]
10	with	O	['N']	[10]
11	LMWH	B-Drug	['Causes']	[3]
12	but	O	['N']	[12]
13	should	O	['N']	[13]
14	be	O	['N']	[14]
15	considered	O	['N']	[15]
16	in	O	['N']	[16]
17	cases	O	['N']	[17]
18	of	O	['N']	[18]
19	acute	O	['N']	[19]
20	respiratory	O	['N']	[20]
21	distress	O	['N']	[21]
22	following	O	['N']	[22]
23	commencement	O	['N']	[23]
24	of	O	['N']	[24]
25	LMWH	O	['N']	[25]
26	.	O	['N']	[26]
#2024
0	Although	O	['N']	[0]
1	myelosuppression	O	['N']	[1]
2	is	O	['N']	[2]
3	mild	O	['N']	[3]
4	,	O	['N']	[4]
5	immunosuppression	O	['N']	[5]
6	and	O	['N']	[6]
7	superinfection	B-Adverse_Effect	['N']	[7]
8	are	O	['N']	[8]
9	potential	O	['N']	[9]
10	hazards	O	['N']	[10]
11	of	O	['N']	[11]
12	treatment	O	['N']	[12]
13	with	O	['N']	[13]
14	DCF	B-Drug	['Causes']	[7]
15	.	O	['N']	[15]
#2025
0	Does	O	['N']	[0]
1	the	O	['N']	[1]
2	use	O	['N']	[2]
3	of	O	['N']	[3]
4	insulin	B-Drug	['Causes']	[21]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	liver	O	['N']	[9]
10	dysfunction	O	['N']	[10]
11	increase	O	['N']	[11]
12	water	O	['N']	[12]
13	retention	O	['N']	[13]
14	in	O	['N']	[14]
15	the	O	['N']	[15]
16	body	O	['N']	[16]
17	,	O	['N']	[17]
18	i.e.	O	['N']	[18]
19	cause	O	['N']	[19]
20	insulin	O	['N']	[20]
21	oedema	B-Adverse_Effect	['N']	[21]
22	?	O	['N']	[22]
#2026
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	skin	O	['N']	[23]
24	eruptions	O	['N']	[24]
25	,	O	['N']	[25]
26	cervical	O	['N']	[26]
27	lymphadenopathy	O	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	O	['N']	[31]
32	lymphocytosis	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	O	['N']	[40]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	-	['N']	[42]
43	(	O	['N']	[43]
44	SMX	O	['N']	[44]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#2027
0	Fenclofenac	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	selective	O	['N']	[3]
4	IgA	B	['N']	[4]
5	deficiency	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	rheumatoid	O	['N']	[7]
8	arthritis	O	['N']	[8]
9	.	O	['N']	[9]
#2028
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	three	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	severe	B	['N']	[5]
6	hypocalcaemia	I-Adverse_Effect	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	i.v	O	['N']	[9]
10	.	O	['N']	[10]
11	bisphosphonate	B-Drug	['Causes']	[6]
12	treatment	O	['N']	[12]
13	in	O	['N']	[13]
14	patients	O	['N']	[14]
15	with	O	['N']	[15]
16	multiple	O	['N']	[16]
17	myeloma	O	['N']	[17]
18	.	O	['N']	[18]
#2029
0	A	O	['N']	[0]
1	23-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	systemic	O	['N']	[6]
7	lupus	O	['N']	[7]
8	erythematosus	O	['N']	[8]
9	had	O	['N']	[9]
10	a	O	['N']	[10]
11	severe	B	['N']	[11]
12	hypersensitivity	I	['N']	[12]
13	reaction	I-Adverse_Effect	['N']	[13]
14	to	O	['N']	[14]
15	the	O	['N']	[15]
16	drug	O	['N']	[16]
17	ibuprofen	B-Drug	['Causes']	[13]
18	.	O	['N']	[18]
#2030
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	,	O	['N']	[3]
4	one	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	developed	O	['N']	[7]
8	gangrene	B-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	bleomycin	B-Drug	['Causes']	[8]
11	and	O	['N']	[11]
12	vincristine	O	['N']	[12]
13	/	O	['N']	[13]
14	vinblastine	O	['N']	[14]
15	chemotherapy	O	['N']	[15]
16	for	O	['N']	[16]
17	AIDS	O	['N']	[17]
18	-	O	['N']	[18]
19	related	O	['N']	[19]
20	Kaposi	O	['N']	[20]
21	's	O	['N']	[21]
22	sarcoma	O	['N']	[22]
23	and	O	['N']	[23]
24	another	O	['N']	[24]
25	HIV	O	['N']	[25]
26	-	O	['N']	[26]
27	infected	O	['N']	[27]
28	patient	O	['N']	[28]
29	who	O	['N']	[29]
30	exhibited	O	['N']	[30]
31	symptoms	O	['N']	[31]
32	of	O	['N']	[32]
33	severe	O	['N']	[33]
34	Raynaud	O	['N']	[34]
35	's	O	['N']	[35]
36	phenomenon	O	['N']	[36]
37	related	O	['N']	[37]
38	to	O	['N']	[38]
39	the	O	['N']	[39]
40	same	O	['N']	[40]
41	regimen	O	['N']	[41]
42	are	O	['N']	[42]
43	presented	O	['N']	[43]
44	.	O	['N']	[44]
#2031
0	Rupture	B	['N']	[0]
1	of	I	['N']	[1]
2	a	I	['N']	[2]
3	cerebral	I	['N']	[3]
4	aneurysm	I-Adverse_Effect	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	nifedipine	B-Drug	['Causes']	[4]
8	treatment	O	['N']	[8]
9	.	O	['N']	[9]
#2032
0	Granulocytopenia	O	['N']	[0]
1	and	O	['N']	[1]
2	agranulocytosis	B-Adverse_Effect	['N']	[2]
3	are	O	['N']	[3]
4	considered	O	['N']	[4]
5	among	O	['N']	[5]
6	the	O	['N']	[6]
7	most	O	['N']	[7]
8	dangerous	O	['N']	[8]
9	adverse	O	['N']	[9]
10	effects	O	['N']	[10]
11	of	O	['N']	[11]
12	clozapine	B-Drug	['Causes']	[2]
13	.	O	['N']	[13]
#2033
0	Antibiotic	O	['N']	[0]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	colitis	B-Adverse_Effect	['N']	[3]
4	(	O	['N']	[4]
5	pseudomembranous	O	['N']	[5]
6	colitis	O	['N']	[6]
7	)	O	['N']	[7]
8	developed	O	['N']	[8]
9	in	O	['N']	[9]
10	four	O	['N']	[10]
11	patients	O	['N']	[11]
12	with	O	['N']	[12]
13	spinal	O	['N']	[13]
14	cord	O	['N']	[14]
15	injury	O	['N']	[15]
16	and	O	['N']	[16]
17	taking	O	['N']	[17]
18	oral	O	['N']	[18]
19	trimethoprim	O	['N']	[19]
20	-	O	['N']	[20]
21	sulfamethoxazole	B-Drug	['Causes']	[3]
22	.	O	['N']	[22]
#2034
0	De	B	['N']	[0]
1	novo	I	['N']	[1]
2	absence	I	['N']	[2]
3	status	I-Adverse_Effect	['N']	[3]
4	of	O	['N']	[4]
5	late	O	['N']	[5]
6	onset	O	['N']	[6]
7	following	O	['N']	[7]
8	withdrawal	O	['N']	[8]
9	of	O	['N']	[9]
10	lorazepam	B-Drug	['Causes']	[3]
11	:	O	['N']	[11]
12	a	O	['N']	[12]
13	case	O	['N']	[13]
14	report	O	['N']	[14]
15	.	O	['N']	[15]
#2035
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	patients	O	['N']	[4]
5	who	O	['N']	[5]
6	presented	O	['N']	[6]
7	to	O	['N']	[7]
8	the	O	['N']	[8]
9	oculoplastics	O	['N']	[9]
10	department	O	['N']	[10]
11	for	O	['N']	[11]
12	repair	O	['N']	[12]
13	of	O	['N']	[13]
14	cicatrical	B	['N']	[14]
15	entropion	I-Adverse_Effect	['N']	[15]
16	after	O	['N']	[16]
17	topical	O	['N']	[17]
18	use	O	['N']	[18]
19	of	O	['N']	[19]
20	dipivefrin	B-Drug	['Causes']	[15]
21	.	O	['N']	[21]
#2036
0	We	O	['N']	[0]
1	recommended	O	['N']	[1]
2	periodic	O	['N']	[2]
3	examination	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	serum	O	['N']	[6]
7	proteins	O	['N']	[7]
8	in	O	['N']	[8]
9	patients	O	['N']	[9]
10	receiving	O	['N']	[10]
11	diphenylhydantoin	B-Drug	['Causes']	[19]
12	in	O	['N']	[12]
13	order	O	['N']	[13]
14	to	O	['N']	[14]
15	detect	O	['N']	[15]
16	development	O	['N']	[16]
17	of	O	['N']	[17]
18	monoclonal	B	['N']	[18]
19	gammopathy	I-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#2037
0	She	O	['N']	[0]
1	developed	O	['N']	[1]
2	a	O	['N']	[2]
3	severe	B	['N']	[3]
4	urticarial	I	['N']	[4]
5	rash	I-Adverse_Effect	['N']	[5]
6	3	O	['N']	[6]
7	weeks	O	['N']	[7]
8	following	O	['N']	[8]
9	initiation	O	['N']	[9]
10	of	O	['N']	[10]
11	therapy	O	['N']	[11]
12	with	O	['N']	[12]
13	Enoxaparin	B-Drug	['Causes']	[5]
14	.	O	['N']	[14]
#2038
0	Co	B	['N']	[0]
1	-	I	['N']	[1]
2	trimoxazole	I-Drug	['Causes']	[5]
3	red	B	['N']	[3]
4	cell	I	['N']	[4]
5	aplasia	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	leukaemia	O	['N']	[7]
8	.	O	['N']	[8]
#2039
0	Retrospectively	O	['N']	[0]
1	,	O	['N']	[1]
2	bucillamine	B-Drug	['Causes']	[12]
3	was	O	['N']	[3]
4	believed	O	['N']	[4]
5	to	O	['N']	[5]
6	be	O	['N']	[6]
7	the	O	['N']	[7]
8	cause	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	giant	B	['N']	[11]
12	hypertrophy	I-Adverse_Effect	['N']	[12]
13	because	O	['N']	[13]
14	of	O	['N']	[14]
15	its	O	['N']	[15]
16	structural	O	['N']	[16]
17	similarity	O	['N']	[17]
18	to	O	['N']	[18]
19	D	O	['N']	[19]
20	-	O	['N']	[20]
21	penicillamine	O	['N']	[21]
22	,	O	['N']	[22]
23	which	O	['N']	[23]
24	was	O	['N']	[24]
25	the	O	['N']	[25]
26	subject	O	['N']	[26]
27	of	O	['N']	[27]
28	an	O	['N']	[28]
29	abundance	O	['N']	[29]
30	of	O	['N']	[30]
31	reports	O	['N']	[31]
32	of	O	['N']	[32]
33	mammary	O	['N']	[33]
34	hyperplasia	O	['N']	[34]
35	.	O	['N']	[35]
#2040
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	suggests	O	['N']	[2]
3	that	O	['N']	[3]
4	acyclovir	B-Drug	['Causes']	[20]
5	when	O	['N']	[5]
6	given	O	['N']	[6]
7	intravenously	O	['N']	[7]
8	in	O	['N']	[8]
9	doses	O	['N']	[9]
10	of	O	['N']	[10]
11	10	O	['N']	[11]
12	mg	O	['N']	[12]
13	/	O	['N']	[13]
14	kg	O	['N']	[14]
15	may	O	['N']	[15]
16	result	O	['N']	[16]
17	in	O	['N']	[17]
18	increased	B	['N']	[18]
19	serum	I	['N']	[19]
20	lithium	I-Adverse_Effect	['N']	[20]
21	concentrations	O	['N']	[21]
22	.	O	['N']	[22]
#2041
0	Exacerbation	O	['N']	[0]
1	of	O	['N']	[1]
2	anthracycline	B-Drug	['Causes']	[7]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	early	B	['N']	[5]
6	chronic	I	['N']	[6]
7	cardiomyopathy	I-Adverse_Effect	['N']	[7]
8	with	O	['N']	[8]
9	ATRA	O	['N']	[9]
10	:	O	['N']	[10]
11	role	O	['N']	[11]
12	of	O	['N']	[12]
13	B	O	['N']	[13]
14	-	O	['N']	[14]
15	type	O	['N']	[15]
16	natriuretic	O	['N']	[16]
17	peptide	O	['N']	[17]
18	as	O	['N']	[18]
19	an	O	['N']	[19]
20	indicator	O	['N']	[20]
21	of	O	['N']	[21]
22	cardiac	O	['N']	[22]
23	dysfunction	O	['N']	[23]
24	.	O	['N']	[24]
#2042
0	Neutropenia	O	['N']	[0]
1	and	O	['N']	[1]
2	agranulocytosis	B-Adverse_Effect	['N']	[2]
3	are	O	['N']	[3]
4	risks	O	['N']	[4]
5	known	O	['N']	[5]
6	to	O	['N']	[6]
7	occur	O	['N']	[7]
8	with	O	['N']	[8]
9	phenothiazines	O	['N']	[9]
10	and	O	['N']	[10]
11	clozapine	B-Drug	['Causes']	[2]
12	.	O	['N']	[12]
#2043
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	rare	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	colonic	B	['N']	[6]
7	mucosal	I	['N']	[7]
8	necrosis	I-Adverse_Effect	['N']	[8]
9	following	O	['N']	[9]
10	Kalimate	O	['N']	[10]
11	(	O	['N']	[11]
12	calcium	B	['N']	[12]
13	polystryrene	I	['N']	[13]
14	sulfonate	I-Drug	['Causes']	[8]
15	)	O	['N']	[15]
16	,	O	['N']	[16]
17	an	O	['N']	[17]
18	analogue	O	['N']	[18]
19	of	O	['N']	[19]
20	Kayexalate	O	['N']	[20]
21	without	O	['N']	[21]
22	sorbitol	O	['N']	[22]
23	in	O	['N']	[23]
24	a	O	['N']	[24]
25	34-yr	O	['N']	[25]
26	-	O	['N']	[26]
27	old	O	['N']	[27]
28	man	O	['N']	[28]
29	.	O	['N']	[29]
#2044
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Colchicine	B-Drug	['Causes']	[24]
3	has	O	['N']	[3]
4	a	O	['N']	[4]
5	known	O	['N']	[5]
6	adverse	O	['N']	[6]
7	effect	O	['N']	[7]
8	on	O	['N']	[8]
9	wound	O	['N']	[9]
10	healing	O	['N']	[10]
11	through	O	['N']	[11]
12	its	O	['N']	[12]
13	inhibitory	O	['N']	[13]
14	effect	O	['N']	[14]
15	on	O	['N']	[15]
16	tubulin	O	['N']	[16]
17	-	O	['N']	[17]
18	dependent	O	['N']	[18]
19	cell	O	['N']	[19]
20	functions	O	['N']	[20]
21	and	O	['N']	[21]
22	through	O	['N']	[22]
23	collagenase	B	['N']	[23]
24	activation	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#2045
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Our	O	['N']	[2]
3	patient	O	['N']	[3]
4	developed	O	['N']	[4]
5	Crohn	O	['N']	[5]
6	's	O	['N']	[6]
7	disease	O	['N']	[7]
8	while	O	['N']	[8]
9	on	O	['N']	[9]
10	Copaxone	B-Drug	['Causes']	[19]
11	treatment	O	['N']	[11]
12	as	O	['N']	[12]
13	a	O	['N']	[13]
14	consequence	O	['N']	[14]
15	of	O	['N']	[15]
16	long	B	['N']	[16]
17	-	I	['N']	[17]
18	term	I	['N']	[18]
19	immunosuppression	I-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#2046
0	The	O	['N']	[0]
1	possibility	O	['N']	[1]
2	of	O	['N']	[2]
3	phenytoin	B-Drug	['Causes']	[23]
4	hypersensitivity	O	['N']	[4]
5	reactions	O	['N']	[5]
6	should	O	['N']	[6]
7	be	O	['N']	[7]
8	considered	O	['N']	[8]
9	when	O	['N']	[9]
10	patients	O	['N']	[10]
11	receiving	O	['N']	[11]
12	phenytoin	O	['N']	[12]
13	have	O	['N']	[13]
14	unusual	O	['N']	[14]
15	symptoms	O	['N']	[15]
16	,	O	['N']	[16]
17	particularly	O	['N']	[17]
18	fever	O	['N']	[18]
19	,	O	['N']	[19]
20	rash	O	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	lymphadenopathy	B-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#2047
0	A	O	['N']	[0]
1	52-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	,	O	['N']	[4]
5	white	O	['N']	[5]
6	female	O	['N']	[6]
7	developed	O	['N']	[7]
8	low	B	['N']	[8]
9	-	I	['N']	[9]
10	grade	I	['N']	[10]
11	fever	I-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	cough	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	dyspnea	O	['N']	[16]
17	after	O	['N']	[17]
18	8	O	['N']	[18]
19	weeks	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	sodium	B	['N']	[22]
23	aurothiomalate	I-Drug	['Causes']	[11]
24	for	O	['N']	[24]
25	rheumatoid	O	['N']	[25]
26	arthritis	O	['N']	[26]
27	.	O	['N']	[27]
#2048
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	O	['N']	[19]
20	developed	O	['N']	[20]
21	confusion	O	['N']	[21]
22	,	O	['N']	[22]
23	agitation	O	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	O	['N']	[25]
26	,	O	['N']	[26]
27	tremors	B-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	O	['N']	[29]
30	jerks	O	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	O	['N']	[32]
33	gait	O	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	B-Drug	['Causes']	[27]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#2049
0	Studies	O	['N']	[0]
1	performed	O	['N']	[1]
2	10	O	['N']	[2]
3	years	O	['N']	[3]
4	ago	O	['N']	[4]
5	on	O	['N']	[5]
6	25	O	['N']	[6]
7	patients	O	['N']	[7]
8	with	O	['N']	[8]
9	MTX	B-Drug	['Causes']	[13]
10	-	O	['N']	[10]
11	induced	O	['N']	[11]
12	liver	B	['N']	[12]
13	cirrhosis	I-Adverse_Effect	['N']	[13]
14	indicated	O	['N']	[14]
15	that	O	['N']	[15]
16	this	O	['N']	[16]
17	type	O	['N']	[17]
18	of	O	['N']	[18]
19	cirrhosis	O	['N']	[19]
20	was	O	['N']	[20]
21	not	O	['N']	[21]
22	of	O	['N']	[22]
23	an	O	['N']	[23]
24	aggressive	O	['N']	[24]
25	nature	O	['N']	[25]
26	.	O	['N']	[26]
#2050
0	Hyperkalaemia	O	['N']	[0]
1	with	O	['N']	[1]
2	renal	B	['N']	[2]
3	tubular	I	['N']	[3]
4	dysfunction	I-Adverse_Effect	['N']	[4]
5	by	O	['N']	[5]
6	sulfamethoxazole	B	['N']	[6]
7	-	I	['N']	[7]
8	trimethoprim	I-Drug	['Causes']	[4]
9	for	O	['N']	[9]
10	Pneumocystis	O	['N']	[10]
11	carinii	O	['N']	[11]
12	pneumonia	O	['N']	[12]
13	in	O	['N']	[13]
14	patients	O	['N']	[14]
15	with	O	['N']	[15]
16	lymphoid	O	['N']	[16]
17	malignancy	O	['N']	[17]
18	.	O	['N']	[18]
#2051
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	2	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	nonconvulsive	O	['N']	[7]
8	status	O	['N']	[8]
9	epilepticus	O	['N']	[9]
10	(	O	['N']	[10]
11	NCSE	B-Adverse_Effect	['N']	[11]
12	)	O	['N']	[12]
13	following	O	['N']	[13]
14	infusion	O	['N']	[14]
15	of	O	['N']	[15]
16	ifosfamide	B-Drug	['Causes']	[11]
17	.	O	['N']	[17]
#2052
0	Pentazocine	B-Drug	['Causes']	[7]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	fibrous	O	['N']	[3]
4	myopathy	O	['N']	[4]
5	and	O	['N']	[5]
6	localized	O	['N']	[6]
7	neuropathy	B-Adverse_Effect	['N']	[7]
8	.	O	['N']	[8]
#2053
0	The	O	['N']	[0]
1	toxic	O	['N']	[1]
2	effects	O	['N']	[2]
3	of	O	['N']	[3]
4	methotrexate	B-Drug	['Causes']	[31]
5	included	O	['N']	[5]
6	elevated	O	['N']	[6]
7	liver	O	['N']	[7]
8	transaminases	O	['N']	[8]
9	(	O	['N']	[9]
10	3/4	O	['N']	[10]
11	)	O	['N']	[11]
12	,	O	['N']	[12]
13	nausea	O	['N']	[13]
14	(	O	['N']	[14]
15	2/4	O	['N']	[15]
16	)	O	['N']	[16]
17	,	O	['N']	[17]
18	abdominal	O	['N']	[18]
19	pain	O	['N']	[19]
20	(	O	['N']	[20]
21	2/4	O	['N']	[21]
22	)	O	['N']	[22]
23	,	O	['N']	[23]
24	bone	O	['N']	[24]
25	pain	O	['N']	[25]
26	(	O	['N']	[26]
27	2/4	O	['N']	[27]
28	)	O	['N']	[28]
29	,	O	['N']	[29]
30	mild	B	['N']	[30]
31	neutropenia	I-Adverse_Effect	['N']	[31]
32	(	O	['N']	[32]
33	1/4	O	['N']	[33]
34	)	O	['N']	[34]
35	,	O	['N']	[35]
36	and	O	['N']	[36]
37	mild	O	['N']	[37]
38	pruritus	O	['N']	[38]
39	(	O	['N']	[39]
40	1/4	O	['N']	[40]
41	)	O	['N']	[41]
42	.	O	['N']	[42]
#2054
0	Actinomycin	B	['N']	[0]
1	D	I-Drug	['Causes']	[7]
2	associated	O	['N']	[2]
3	hepatic	B	['N']	[3]
4	veno	I	['N']	[4]
5	-	I	['N']	[5]
6	occlusive	I	['N']	[6]
7	disease	I-Adverse_Effect	['N']	[7]
8	--	O	['N']	[8]
9	a	O	['N']	[9]
10	report	O	['N']	[10]
11	of	O	['N']	[11]
12	2	O	['N']	[12]
13	cases	O	['N']	[13]
14	.	O	['N']	[14]
#2055
0	Methotrexate	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hepatic	B	['N']	[3]
4	necrosis	I-Adverse_Effect	['N']	[4]
5	requiring	O	['N']	[5]
6	liver	O	['N']	[6]
7	transplantation	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	with	O	['N']	[11]
12	rheumatoid	O	['N']	[12]
13	arthritis	O	['N']	[13]
14	.	O	['N']	[14]
#2056
0	Cyclosporine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	pain	B	['N']	[3]
4	syndrome	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	child	O	['N']	[7]
8	undergoing	O	['N']	[8]
9	hematopoietic	O	['N']	[9]
10	stem	O	['N']	[10]
11	cell	O	['N']	[11]
12	transplant	O	['N']	[12]
13	.	O	['N']	[13]
#2057
0	We	O	['N']	[0]
1	hypothesize	O	['N']	[1]
2	that	O	['N']	[2]
3	decreased	O	['N']	[3]
4	renal	O	['N']	[4]
5	elimination	O	['N']	[5]
6	of	O	['N']	[6]
7	MTX	B-Drug	['Causes']	[17]
8	induced	O	['N']	[8]
9	by	O	['N']	[9]
10	the	O	['N']	[10]
11	COX-2	O	['N']	[11]
12	inhibitor	O	['N']	[12]
13	resulted	O	['N']	[13]
14	in	O	['N']	[14]
15	enhanced	O	['N']	[15]
16	hematopoietic	B	['N']	[16]
17	toxicity	I-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	immunosuppression	O	['N']	[19]
20	causing	O	['N']	[20]
21	the	O	['N']	[21]
22	EBV	O	['N']	[22]
23	-	O	['N']	[23]
24	associated	O	['N']	[24]
25	lymphoproliferative	O	['N']	[25]
26	disease	O	['N']	[26]
27	.	O	['N']	[27]
#2058
0	Pulmonary	B	['N']	[0]
1	oedema	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	hexoprenaline	B-Drug	['Causes']	[1]
4	administration	O	['N']	[4]
5	in	O	['N']	[5]
6	preterm	O	['N']	[6]
7	labour	O	['N']	[7]
8	.	O	['N']	[8]
#2059
0	Thrombolytic	O	['N']	[0]
1	therapy	O	['N']	[1]
2	with	O	['N']	[2]
3	tissue	O	['N']	[3]
4	plasminogen	O	['N']	[4]
5	activator	O	['N']	[5]
6	(	O	['N']	[6]
7	tPA	B-Drug	['Causes']	[24]
8	)	O	['N']	[8]
9	for	O	['N']	[9]
10	acute	O	['N']	[10]
11	myocardial	O	['N']	[11]
12	infarction	O	['N']	[12]
13	may	O	['N']	[13]
14	result	O	['N']	[14]
15	in	O	['N']	[15]
16	major	O	['N']	[16]
17	bleeding	O	['N']	[17]
18	complications	O	['N']	[18]
19	such	O	['N']	[19]
20	as	O	['N']	[20]
21	gastrointestinal	B	['N']	[21]
22	or	I	['N']	[22]
23	intracranial	I	['N']	[23]
24	bleeding	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#2060
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	82-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	ventricular	O	['N']	[9]
10	tachycardia	O	['N']	[10]
11	and	O	['N']	[11]
12	Torsades	O	['N']	[12]
13	de	O	['N']	[13]
14	Pointes	O	['N']	[14]
15	(	O	['N']	[15]
16	TdP	B-Adverse_Effect	['N']	[16]
17	)	O	['N']	[17]
18	after	O	['N']	[18]
19	oral	O	['N']	[19]
20	administration	O	['N']	[20]
21	of	O	['N']	[21]
22	garenoxacin	B-Drug	['Causes']	[16]
23	,	O	['N']	[23]
24	a	O	['N']	[24]
25	novel	O	['N']	[25]
26	quinolone	O	['N']	[26]
27	antibiotic	O	['N']	[27]
28	agent	O	['N']	[28]
29	that	O	['N']	[29]
30	differs	O	['N']	[30]
31	from	O	['N']	[31]
32	the	O	['N']	[32]
33	third	O	['N']	[33]
34	-	O	['N']	[34]
35	generation	O	['N']	[35]
36	quinolones	O	['N']	[36]
37	,	O	['N']	[37]
38	for	O	['N']	[38]
39	pneumonia	O	['N']	[39]
40	.	O	['N']	[40]
#2061
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	an	O	['N']	[6]
7	adverse	B	['N']	[7]
8	effect	I	['N']	[8]
9	of	I	['N']	[9]
10	fetal	I	['N']	[10]
11	renal	I	['N']	[11]
12	circulation	I-Adverse_Effect	['N']	[12]
13	by	O	['N']	[13]
14	maternal	O	['N']	[14]
15	ingestion	O	['N']	[15]
16	of	O	['N']	[16]
17	nimesulide	B-Drug	['Causes']	[12]
18	.	O	['N']	[18]
#2062
0	Pulmonary	B	['N']	[0]
1	eosinophilia	I-Adverse_Effect	['N']	[1]
2	or	O	['N']	[2]
3	granulomas	O	['N']	[3]
4	,	O	['N']	[4]
5	classically	O	['N']	[5]
6	seen	O	['N']	[6]
7	in	O	['N']	[7]
8	previously	O	['N']	[8]
9	reported	O	['N']	[9]
10	cases	O	['N']	[10]
11	of	O	['N']	[11]
12	methotrexate	B-Drug	['Causes']	[1]
13	pneumonitis	O	['N']	[13]
14	,	O	['N']	[14]
15	were	O	['N']	[15]
16	not	O	['N']	[16]
17	observed	O	['N']	[17]
18	.	O	['N']	[18]
#2063
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	who	O	['N']	[5]
6	developed	O	['N']	[6]
7	acute	B	['N']	[7]
8	rhabdomyolysis	I-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	taking	O	['N']	[10]
11	cerivastatin	B-Drug	['Causes']	[8]
12	.	O	['N']	[12]
#2064
0	A	O	['N']	[0]
1	10-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	with	O	['N']	[5]
6	osteosarcoma	O	['N']	[6]
7	and	O	['N']	[7]
8	normal	O	['N']	[8]
9	renal	O	['N']	[9]
10	function	O	['N']	[10]
11	manifested	O	['N']	[11]
12	laboratory	O	['N']	[12]
13	evidence	O	['N']	[13]
14	of	O	['N']	[14]
15	impending	O	['N']	[15]
16	renal	O	['N']	[16]
17	toxicity	O	['N']	[17]
18	and	O	['N']	[18]
19	extreme	O	['N']	[19]
20	elevation	B	['N']	[20]
21	of	I	['N']	[21]
22	aspartate	I	['N']	[22]
23	aminotrasferase	I-Adverse_Effect	['N']	[23]
24	and	O	['N']	[24]
25	alanine	O	['N']	[25]
26	aminotransferase	O	['N']	[26]
27	within	O	['N']	[27]
28	2	O	['N']	[28]
29	hours	O	['N']	[29]
30	after	O	['N']	[30]
31	the	O	['N']	[31]
32	completion	O	['N']	[32]
33	of	O	['N']	[33]
34	a	O	['N']	[34]
35	4-hour	O	['N']	[35]
36	infusion	O	['N']	[36]
37	of	O	['N']	[37]
38	high	O	['N']	[38]
39	-	O	['N']	[39]
40	dose	O	['N']	[40]
41	methotrexate	O	['N']	[41]
42	(	O	['N']	[42]
43	MTX	B-Drug	['Causes']	[23]
44	)	O	['N']	[44]
45	(	O	['N']	[45]
46	12	O	['N']	[46]
47	g	O	['N']	[47]
48	/	O	['N']	[48]
49	m2	O	['N']	[49]
50	)	O	['N']	[50]
51	,	O	['N']	[51]
52	and	O	['N']	[52]
53	went	O	['N']	[53]
54	on	O	['N']	[54]
55	to	O	['N']	[55]
56	develop	O	['N']	[56]
57	acute	O	['N']	[57]
58	renal	O	['N']	[58]
59	failure	O	['N']	[59]
60	with	O	['N']	[60]
61	life	O	['N']	[61]
62	-	O	['N']	[62]
63	threatening	O	['N']	[63]
64	hyperkalemia	O	['N']	[64]
65	29	O	['N']	[65]
66	hours	O	['N']	[66]
67	later	O	['N']	[67]
68	.	O	['N']	[68]
#2065
0	We	O	['N']	[0]
1	introduce	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	sixty	O	['N']	[6]
7	years	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	with	O	['N']	[10]
11	several	O	['N']	[11]
12	previous	O	['N']	[12]
13	episodes	O	['N']	[13]
14	of	O	['N']	[14]
15	rhinitis	B-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	conjunctivitis	O	['N']	[17]
18	and	O	['N']	[18]
19	perspiration	O	['N']	[19]
20	immediately	O	['N']	[20]
21	after	O	['N']	[21]
22	the	O	['N']	[22]
23	administration	O	['N']	[23]
24	of	O	['N']	[24]
25	salmon	O	['N']	[25]
26	calcitonin	B-Drug	['Causes']	[15]
27	with	O	['N']	[27]
28	nasal	O	['N']	[28]
29	spray	O	['N']	[29]
30	or	O	['N']	[30]
31	intramuscular	O	['N']	[31]
32	administration	O	['N']	[32]
33	(	O	['N']	[33]
34	Calsynar	O	['N']	[34]
35	)	O	['N']	[35]
36	.	O	['N']	[36]
#2066
0	Akathisia	B-Adverse_Effect	['N']	[0]
1	appeared	O	['N']	[1]
2	to	O	['N']	[2]
3	be	O	['N']	[3]
4	a	O	['N']	[4]
5	common	O	['N']	[5]
6	side	O	['N']	[6]
7	effect	O	['N']	[7]
8	of	O	['N']	[8]
9	fluoxetine	B-Drug	['Causes']	[0]
10	and	O	['N']	[10]
11	generally	O	['N']	[11]
12	responded	O	['N']	[12]
13	well	O	['N']	[13]
14	to	O	['N']	[14]
15	treatment	O	['N']	[15]
16	with	O	['N']	[16]
17	the	O	['N']	[17]
18	beta	O	['N']	[18]
19	-	O	['N']	[19]
20	adrenergic	O	['N']	[20]
21	antagonist	O	['N']	[21]
22	propranolol	O	['N']	[22]
23	,	O	['N']	[23]
24	dose	O	['N']	[24]
25	reduction	O	['N']	[25]
26	,	O	['N']	[26]
27	or	O	['N']	[27]
28	both	O	['N']	[28]
29	.	O	['N']	[29]
#2067
0	These	O	['N']	[0]
1	skin	B	['N']	[1]
2	lesions	I-Adverse_Effect	['N']	[2]
3	may	O	['N']	[3]
4	be	O	['N']	[4]
5	induced	O	['N']	[5]
6	or	O	['N']	[6]
7	worsened	O	['N']	[7]
8	during	O	['N']	[8]
9	antiviral	O	['N']	[9]
10	therapy	O	['N']	[10]
11	with	O	['N']	[11]
12	interferon	O	['N']	[12]
13	-	O	['N']	[13]
14	alpha	O	['N']	[14]
15	(	O	['N']	[15]
16	IFN	B-Drug	['Causes']	[2]
17	)	O	['N']	[17]
18	.	O	['N']	[18]
#2068
0	Tacrolimus	O	['N']	[0]
1	(	O	['N']	[1]
2	FK506	B-Drug	['Causes']	[12]
3	)	O	['N']	[3]
4	,	O	['N']	[4]
5	an	O	['N']	[5]
6	immunosuppressant	O	['N']	[6]
7	,	O	['N']	[7]
8	has	O	['N']	[8]
9	been	O	['N']	[9]
10	associated	O	['N']	[10]
11	with	O	['N']	[11]
12	mutism	B-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	adults	O	['N']	[14]
15	after	O	['N']	[15]
16	liver	O	['N']	[16]
17	transplant	O	['N']	[17]
18	.	O	['N']	[18]
#2069
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	study	O	['N']	[3]
4	therapy	O	['N']	[4]
5	with	O	['N']	[5]
6	indapamide	B-Drug	['Causes']	[23]
7	impairing	O	['N']	[7]
8	carbohydrate	O	['N']	[8]
9	metabolism	O	['N']	[9]
10	in	O	['N']	[10]
11	essential	O	['N']	[11]
12	hypertension	O	['N']	[12]
13	patients	O	['N']	[13]
14	and	O	['N']	[14]
15	achieve	O	['N']	[15]
16	earlier	O	['N']	[16]
17	prevention	O	['N']	[17]
18	,	O	['N']	[18]
19	diagnoses	O	['N']	[19]
20	and	O	['N']	[20]
21	treatment	O	['N']	[21]
22	of	O	['N']	[22]
23	diabetes	B-Adverse_Effect	['N']	[23]
24	induced	O	['N']	[24]
25	by	O	['N']	[25]
26	indapamide	O	['N']	[26]
27	.	O	['N']	[27]
#2070
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	is	O	['N']	[2]
3	presented	O	['N']	[3]
4	in	O	['N']	[4]
5	which	O	['N']	[5]
6	a	O	['N']	[6]
7	68-year	O	['N']	[7]
8	-	O	['N']	[8]
9	old	O	['N']	[9]
10	man	O	['N']	[10]
11	became	O	['N']	[11]
12	delirious	B-Adverse_Effect	['N']	[12]
13	after	O	['N']	[13]
14	being	O	['N']	[14]
15	withdrawn	O	['N']	[15]
16	from	O	['N']	[16]
17	a	O	['N']	[17]
18	low	O	['N']	[18]
19	dosage	O	['N']	[19]
20	of	O	['N']	[20]
21	alprazolam	B-Drug	['Causes']	[12]
22	.	O	['N']	[22]
#2071
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	HIV	O	['N']	[3]
4	-	O	['N']	[4]
5	infected	O	['N']	[5]
6	woman	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	mild	O	['N']	[9]
10	leukopenia	B-Adverse_Effect	['N']	[10]
11	as	O	['N']	[11]
12	the	O	['N']	[12]
13	first	O	['N']	[13]
14	sign	O	['N']	[14]
15	of	O	['N']	[15]
16	a	O	['N']	[16]
17	nevirapine	B-Drug	['Causes']	[10]
18	-	O	['N']	[18]
19	related	O	['N']	[19]
20	adverse	O	['N']	[20]
21	event	O	['N']	[21]
22	,	O	['N']	[22]
23	which	O	['N']	[23]
24	was	O	['N']	[24]
25	followed	O	['N']	[25]
26	by	O	['N']	[26]
27	skin	O	['N']	[27]
28	and	O	['N']	[28]
29	hepatic	O	['N']	[29]
30	toxicity	O	['N']	[30]
31	associated	O	['N']	[31]
32	with	O	['N']	[32]
33	a	O	['N']	[33]
34	more	O	['N']	[34]
35	severe	O	['N']	[35]
36	leukopenia	O	['N']	[36]
37	.	O	['N']	[37]
#2072
0	The	O	['N']	[0]
1	results	O	['N']	[1]
2	of	O	['N']	[2]
3	the	O	['N']	[3]
4	ultrasound	O	['N']	[4]
5	examination	O	['N']	[5]
6	combined	O	['N']	[6]
7	with	O	['N']	[7]
8	clinical	O	['N']	[8]
9	anamnesis	O	['N']	[9]
10	allowed	O	['N']	[10]
11	diagnosis	O	['N']	[11]
12	of	O	['N']	[12]
13	gastric	B	['N']	[13]
14	mucosa	I	['N']	[14]
15	foveolar	I	['N']	[15]
16	hyperplasia	I-Adverse_Effect	['N']	[16]
17	due	O	['N']	[17]
18	to	O	['N']	[18]
19	prolonged	O	['N']	[19]
20	PGE1	B-Drug	['Causes']	[16]
21	therapy	O	['N']	[21]
22	.	O	['N']	[22]
#2073
0	The	O	['N']	[0]
1	occurrence	O	['N']	[1]
2	of	O	['N']	[2]
3	neuromuscular	O	['N']	[3]
4	blockade	O	['N']	[4]
5	and	O	['N']	[5]
6	the	O	['N']	[6]
7	resulting	O	['N']	[7]
8	potentiation	B	['N']	[8]
9	of	I	['N']	[9]
10	muscle	I	['N']	[10]
11	relaxants	I-Adverse_Effect	['N']	[11]
12	during	O	['N']	[12]
13	magnesium	O	['N']	[13]
14	sulfate	O	['N']	[14]
15	(	O	['N']	[15]
16	MgSO4	B-Drug	['Causes']	[11]
17	)	O	['N']	[17]
18	administration	O	['N']	[18]
19	is	O	['N']	[19]
20	well	O	['N']	[20]
21	known	O	['N']	[21]
22	.	O	['N']	[22]
#2074
0	After	O	['N']	[0]
1	stopping	O	['N']	[1]
2	indapamide	B-Drug	['Causes']	[6]
3	,	O	['N']	[3]
4	glucose	B	['N']	[4]
5	tolerance	I	['N']	[5]
6	impairing	I-Adverse_Effect	['N']	[6]
7	may	O	['N']	[7]
8	be	O	['N']	[8]
9	reversed	O	['N']	[9]
10	.	O	['N']	[10]
#2075
0	He	O	['N']	[0]
1	was	O	['N']	[1]
2	started	O	['N']	[2]
3	on	O	['N']	[3]
4	oral	O	['N']	[4]
5	lansoprazole	B-Drug	['Causes']	[20]
6	60	O	['N']	[6]
7	mg	O	['N']	[7]
8	twice	O	['N']	[8]
9	daily	O	['N']	[9]
10	and	O	['N']	[10]
11	,	O	['N']	[11]
12	on	O	['N']	[12]
13	hospital	O	['N']	[13]
14	day	O	['N']	[14]
15	2	O	['N']	[15]
16	,	O	['N']	[16]
17	his	O	['N']	[17]
18	platelet	B	['N']	[18]
19	count	I	['N']	[19]
20	decreased	I-Adverse_Effect	['N']	[20]
21	to	O	['N']	[21]
22	102	O	['N']	[22]
23	x	O	['N']	[23]
24	10(3)/mm(3	O	['N']	[24]
25	)	O	['N']	[25]
26	;	O	['N']	[26]
27	on	O	['N']	[27]
28	hospital	O	['N']	[28]
29	day	O	['N']	[29]
30	3	O	['N']	[30]
31	,	O	['N']	[31]
32	the	O	['N']	[32]
33	platelet	O	['N']	[33]
34	count	O	['N']	[34]
35	was	O	['N']	[35]
36	36	O	['N']	[36]
37	x	O	['N']	[37]
38	10(3)/mm(3	O	['N']	[38]
39	)	O	['N']	[39]
40	.	O	['N']	[40]
#2076
0	Gold	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	aplastic	B	['N']	[3]
4	anemia	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#2077
0	Despite	O	['N']	[0]
1	these	O	['N']	[1]
2	antithrombotic	O	['N']	[2]
3	effects	O	['N']	[3]
4	,	O	['N']	[4]
5	the	O	['N']	[5]
6	patient	O	['N']	[6]
7	developed	O	['N']	[7]
8	repeated	O	['N']	[8]
9	venous	B	['N']	[9]
10	thromboembolism	I-Adverse_Effect	['N']	[10]
11	during	O	['N']	[11]
12	treatment	O	['N']	[12]
13	with	O	['N']	[13]
14	low	O	['N']	[14]
15	-	O	['N']	[15]
16	molecular	O	['N']	[16]
17	-	O	['N']	[17]
18	weight	O	['N']	[18]
19	heparin	B-Drug	['Causes']	[10]
20	.	O	['N']	[20]
#2078
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	new	O	['N']	[3]
4	quinolone	O	['N']	[4]
5	derivatives	O	['N']	[5]
6	(	O	['N']	[6]
7	levofloxacin	O	['N']	[7]
8	,	O	['N']	[8]
9	sparfloxacin	O	['N']	[9]
10	,	O	['N']	[10]
11	grepafloxacin	O	['N']	[11]
12	,	O	['N']	[12]
13	trovafloxacin	B-Drug	['Causes']	[43]
14	,	O	['N']	[14]
15	gatifloxacin	O	['N']	[15]
16	and	O	['N']	[16]
17	moxifloxacin	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	also	O	['N']	[20]
21	called	O	['N']	[21]
22	gyrase	O	['N']	[22]
23	inhibitors	O	['N']	[23]
24	,	O	['N']	[24]
25	are	O	['N']	[25]
26	known	O	['N']	[26]
27	for	O	['N']	[27]
28	their	O	['N']	[28]
29	potential	O	['N']	[29]
30	to	O	['N']	[30]
31	cause	O	['N']	[31]
32	central	O	['N']	[32]
33	nervous	O	['N']	[33]
34	system	O	['N']	[34]
35	-	O	['N']	[35]
36	related	O	['N']	[36]
37	adverse	O	['N']	[37]
38	effects	O	['N']	[38]
39	,	O	['N']	[39]
40	including	O	['N']	[40]
41	headache	O	['N']	[41]
42	,	O	['N']	[42]
43	dizziness	B-Adverse_Effect	['N']	[43]
44	and	O	['N']	[44]
45	insomnia	O	['N']	[45]
46	.	O	['N']	[46]
#2079
0	Therapy	O	['N']	[0]
1	with	O	['N']	[1]
2	IFN	B	['N']	[2]
3	-	I	['N']	[3]
4	beta	I-Drug	['Causes']	[14]
5	has	O	['N']	[5]
6	rarely	O	['N']	[6]
7	been	O	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	the	O	['N']	[10]
11	development	O	['N']	[11]
12	of	O	['N']	[12]
13	autoimmune	B	['N']	[13]
14	disorders	I-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#2080
0	Aseptic	B	['N']	[0]
1	meningitis	I-Adverse_Effect	['N']	[1]
2	,	O	['N']	[2]
3	hemolytic	O	['N']	[3]
4	anemia	O	['N']	[4]
5	,	O	['N']	[5]
6	hepatitis	O	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	orthostatic	O	['N']	[9]
10	hypotension	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	trimethoprim	O	['N']	[16]
17	-	O	['N']	[17]
18	sulfamethoxazole	B-Drug	['Causes']	[1]
19	.	O	['N']	[19]
#2081
0	Intracranial	B	['N']	[0]
1	hemorrhage	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	focal	O	['N']	[3]
4	seizures	O	['N']	[4]
5	secondary	O	['N']	[5]
6	to	O	['N']	[6]
7	use	O	['N']	[7]
8	of	O	['N']	[8]
9	L	B	['N']	[9]
10	-	I	['N']	[10]
11	asparaginase	I-Drug	['Causes']	[1]
12	during	O	['N']	[12]
13	induction	O	['N']	[13]
14	therapy	O	['N']	[14]
15	of	O	['N']	[15]
16	acute	O	['N']	[16]
17	lymphocytic	O	['N']	[17]
18	leukemia	O	['N']	[18]
19	.	O	['N']	[19]
#2082
0	Gemcitabine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	pericardial	B	['N']	[3]
4	effusion	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	tamponade	O	['N']	[6]
7	after	O	['N']	[7]
8	unblocked	O	['N']	[8]
9	cardiac	O	['N']	[9]
10	irradiation	O	['N']	[10]
11	.	O	['N']	[11]
#2083
0	Despite	O	['N']	[0]
1	a	O	['N']	[1]
2	response	O	['N']	[2]
3	of	O	['N']	[3]
4	the	O	['N']	[4]
5	meningeal	O	['N']	[5]
6	tumor	O	['N']	[6]
7	the	O	['N']	[7]
8	patient	O	['N']	[8]
9	developed	O	['N']	[9]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	third	O	['N']	[12]
13	week	O	['N']	[13]
14	of	O	['N']	[14]
15	MTX	B-Drug	['Causes']	[24]
16	treatment	O	['N']	[16]
17	a	O	['N']	[17]
18	progressive	O	['N']	[18]
19	visual	O	['N']	[19]
20	loss	O	['N']	[20]
21	and	O	['N']	[21]
22	loss	B	['N']	[22]
23	of	I	['N']	[23]
24	consciousness	I-Adverse_Effect	['N']	[24]
25	which	O	['N']	[25]
26	worsened	O	['N']	[26]
27	during	O	['N']	[27]
28	subsequent	O	['N']	[28]
29	Ara	O	['N']	[29]
30	-	O	['N']	[30]
31	C	O	['N']	[31]
32	treatment	O	['N']	[32]
33	and	O	['N']	[33]
34	led	O	['N']	[34]
35	to	O	['N']	[35]
36	death	O	['N']	[36]
37	within	O	['N']	[37]
38	3	O	['N']	[38]
39	weeks	O	['N']	[39]
40	.	O	['N']	[40]
#2084
0	Ballistic	O	['N']	[0]
1	movements	O	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	ischemic	O	['N']	[4]
5	infarcts	O	['N']	[5]
6	after	O	['N']	[6]
7	intravenous	O	['N']	[7]
8	heroin	B-Drug	['Dosage']	[9]
9	overdose	B-Dose	['N']	[9]
10	:	O	['N']	[10]
11	report	O	['N']	[11]
12	of	O	['N']	[12]
13	two	O	['N']	[13]
14	cases	O	['N']	[14]
15	.	O	['N']	[15]
#2085
0	Laryngeal	B	['N']	[0]
1	dyspnea	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	relation	O	['N']	[3]
4	to	O	['N']	[4]
5	an	O	['N']	[5]
6	interaction	O	['N']	[6]
7	between	O	['N']	[7]
8	acenocoumarol	B-Drug	['Causes']	[1]
9	and	O	['N']	[9]
10	topical	O	['N']	[10]
11	econazole	O	['N']	[11]
12	lotion	O	['N']	[12]
13	.	O	['N']	[13]
#2086
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	No	O	['N']	[2]
3	published	O	['N']	[3]
4	clinical	O	['N']	[4]
5	studies	O	['N']	[5]
6	in	O	['N']	[6]
7	patients	O	['N']	[7]
8	receiving	O	['N']	[8]
9	clindamycin	B-Drug	['Causes']	[26]
10	vaginal	O	['N']	[10]
11	cream	O	['N']	[11]
12	for	O	['N']	[12]
13	bacterial	O	['N']	[13]
14	vaginosis	O	['N']	[14]
15	have	O	['N']	[15]
16	documented	O	['N']	[16]
17	C.	O	['N']	[17]
18	difficile	O	['N']	[18]
19	toxin	O	['N']	[19]
20	in	O	['N']	[20]
21	stool	O	['N']	[21]
22	samples	O	['N']	[22]
23	of	O	['N']	[23]
24	patients	O	['N']	[24]
25	with	O	['N']	[25]
26	diarrhea	B-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#2087
0	Administration	O	['N']	[0]
1	of	O	['N']	[1]
2	pyridoxine	B-Drug	['Causes']	[16]
3	to	O	['N']	[3]
4	an	O	['N']	[4]
5	infant	O	['N']	[5]
6	after	O	['N']	[6]
7	a	O	['N']	[7]
8	long	O	['N']	[8]
9	period	O	['N']	[9]
10	of	O	['N']	[10]
11	convulsions	O	['N']	[11]
12	was	O	['N']	[12]
13	followed	O	['N']	[13]
14	by	O	['N']	[14]
15	acute	B	['N']	[15]
16	hypotonia	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#2088
0	In	O	['N']	[0]
1	conclusion	O	['N']	[1]
2	,	O	['N']	[2]
3	this	O	['N']	[3]
4	case	O	['N']	[4]
5	strongly	O	['N']	[5]
6	suggests	O	['N']	[6]
7	that	O	['N']	[7]
8	gliclazide	B-Drug	['Causes']	[16]
9	can	O	['N']	[9]
10	induce	O	['N']	[10]
11	acute	B	['N']	[11]
12	icteric	I	['N']	[12]
13	liver	I	['N']	[13]
14	necro	I	['N']	[14]
15	-	I	['N']	[15]
16	inflammation	I-Adverse_Effect	['N']	[16]
17	which	O	['N']	[17]
18	may	O	['N']	[18]
19	be	O	['N']	[19]
20	misdiagnosed	O	['N']	[20]
21	clinically	O	['N']	[21]
22	as	O	['N']	[22]
23	acute	O	['N']	[23]
24	viral	O	['N']	[24]
25	hepatitis	O	['N']	[25]
26	.	O	['N']	[26]
#2089
0	A	O	['N']	[0]
1	5-month	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	infant	O	['N']	[4]
5	became	O	['N']	[5]
6	lethargic	B-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	poorly	O	['N']	[8]
9	responsive	O	['N']	[9]
10	after	O	['N']	[10]
11	receiving	O	['N']	[11]
12	1	O	['N']	[12]
13	drop	O	['N']	[13]
14	of	O	['N']	[14]
15	brimonidine	B-Drug	['Causes']	[6]
16	in	O	['N']	[16]
17	each	O	['N']	[17]
18	eye	O	['N']	[18]
19	.	O	['N']	[19]
#2090
0	A	O	['N']	[0]
1	79-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	ischemic	O	['N']	[6]
7	heart	O	['N']	[7]
8	disease	O	['N']	[8]
9	,	O	['N']	[9]
10	chronic	O	['N']	[10]
11	atrial	O	['N']	[11]
12	fibrillation	O	['N']	[12]
13	,	O	['N']	[13]
14	chronic	O	['N']	[14]
15	renal	O	['N']	[15]
16	failure	O	['N']	[16]
17	,	O	['N']	[17]
18	hypothyroidism	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	gout	O	['N']	[21]
22	arthritis	O	['N']	[22]
23	was	O	['N']	[23]
24	hospitalized	O	['N']	[24]
25	because	O	['N']	[25]
26	of	O	['N']	[26]
27	fatigue	B-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	myalgia	O	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	leg	O	['N']	[32]
33	weakness	O	['N']	[33]
34	,	O	['N']	[34]
35	shortly	O	['N']	[35]
36	after	O	['N']	[36]
37	starting	O	['N']	[37]
38	treatment	O	['N']	[38]
39	with	O	['N']	[39]
40	colchicine	B-Drug	['Causes']	[27]
41	.	O	['N']	[41]
#2091
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	aseptic	O	['N']	[9]
10	meningitis	O	['N']	[10]
11	,	O	['N']	[11]
12	hemolytic	O	['N']	[12]
13	anemia	O	['N']	[13]
14	,	O	['N']	[14]
15	hepatitis	B-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	orthostatic	O	['N']	[18]
19	hypotension	O	['N']	[19]
20	simultaneously	O	['N']	[20]
21	during	O	['N']	[21]
22	treatment	O	['N']	[22]
23	with	O	['N']	[23]
24	trimethoprim	B-Drug	['Causes']	[15]
25	-	O	['N']	[25]
26	sulfamethoxazole	O	['N']	[26]
27	is	O	['N']	[27]
28	described	O	['N']	[28]
29	.	O	['N']	[29]
#2092
0	Treatment	O	['N']	[0]
1	-	O	['N']	[1]
2	related	O	['N']	[2]
3	myelodysplastic	B	['N']	[3]
4	syndrome	I-Adverse_Effect	['N']	[4]
5	after	O	['N']	[5]
6	temozolomide	B-Drug	['Causes']	[4]
7	for	O	['N']	[7]
8	recurrent	O	['N']	[8]
9	high	O	['N']	[9]
10	-	O	['N']	[10]
11	grade	O	['N']	[11]
12	glioma	O	['N']	[12]
13	.	O	['N']	[13]
#2093
0	A	O	['N']	[0]
1	74-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	hypercholestrerolaemic	O	['N']	[4]
5	woman	O	['N']	[5]
6	taking	O	['N']	[6]
7	cerivastatin	B-Drug	['Causes']	[24]
8	(	O	['N']	[8]
9	0.15	O	['N']	[9]
10	mg	O	['N']	[10]
11	/	O	['N']	[11]
12	day	O	['N']	[12]
13	)	O	['N']	[13]
14	for	O	['N']	[14]
15	22	O	['N']	[15]
16	days	O	['N']	[16]
17	complained	O	['N']	[17]
18	of	O	['N']	[18]
19	general	O	['N']	[19]
20	muscle	O	['N']	[20]
21	weakness	O	['N']	[21]
22	and	O	['N']	[22]
23	muscle	B	['N']	[23]
24	pain	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#2094
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	,	O	['N']	[3]
4	we	O	['N']	[4]
5	describe	O	['N']	[5]
6	a	O	['N']	[6]
7	fatal	O	['N']	[7]
8	gemcitabine	B-Drug	['Causes']	[12]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	pulmonary	B	['N']	[11]
12	toxicity	I-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	patient	O	['N']	[15]
16	with	O	['N']	[16]
17	gallbladder	O	['N']	[17]
18	metastatic	O	['N']	[18]
19	adenocarcinoma	O	['N']	[19]
20	.	O	['N']	[20]
#2095
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	cutaneous	B	['N']	[7]
8	and	I	['N']	[8]
9	hematologic	I	['N']	[9]
10	toxicity	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	IL-2	B-Drug	['Causes']	[10]
17	.	O	['N']	[17]
#2096
0	Pellagra	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	suspected	O	['N']	[3]
4	whenever	O	['N']	[4]
5	tuberculous	O	['N']	[5]
6	patients	O	['N']	[6]
7	under	O	['N']	[7]
8	treatment	O	['N']	[8]
9	with	O	['N']	[9]
10	isoniazid	B-Drug	['Causes']	[17]
11	develop	O	['N']	[11]
12	mental	B	['N']	[12]
13	,	I	['N']	[13]
14	neurological	I	['N']	[14]
15	or	I	['N']	[15]
16	gastrointestinal	I	['N']	[16]
17	symptoms	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	even	O	['N']	[19]
20	in	O	['N']	[20]
21	the	O	['N']	[21]
22	absence	O	['N']	[22]
23	of	O	['N']	[23]
24	typical	O	['N']	[24]
25	pellagra	O	['N']	[25]
26	dermatitis	O	['N']	[26]
27	.	O	['N']	[27]
#2097
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	recall	B	['N']	[3]
4	pneumonitis	I-Adverse_Effect	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	gemcitabine	B-Drug	['Causes']	[4]
8	is	O	['N']	[8]
9	reported	O	['N']	[9]
10	.	O	['N']	[10]
#2098
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	58-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	who	O	['N']	[10]
11	ingested	O	['N']	[11]
12	more	O	['N']	[12]
13	than	O	['N']	[13]
14	35	B	['N']	[14]
15	g	I-Dose	['N']	[15]
16	of	O	['N']	[16]
17	caffeine	B-Drug	['Dosage']	[15]
18	in	O	['N']	[18]
19	a	O	['N']	[19]
20	suicide	O	['N']	[20]
21	attempt	O	['N']	[21]
22	.	O	['N']	[22]
#2099
0	Despite	O	['N']	[0]
1	a	O	['N']	[1]
2	hematologic	O	['N']	[2]
3	response	O	['N']	[3]
4	in	O	['N']	[4]
5	all	O	['N']	[5]
6	3	O	['N']	[6]
7	patients	O	['N']	[7]
8	,	O	['N']	[8]
9	none	O	['N']	[9]
10	of	O	['N']	[10]
11	them	O	['N']	[11]
12	achieved	O	['N']	[12]
13	cytogenetic	O	['N']	[13]
14	remission	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	all	O	['N']	[17]
18	progressed	O	['N']	[18]
19	to	O	['N']	[19]
20	blast	B	['N']	[20]
21	crisis	I-Adverse_Effect	['N']	[21]
22	at	O	['N']	[22]
23	7	O	['N']	[23]
24	to	O	['N']	[24]
25	10	O	['N']	[25]
26	months	O	['N']	[26]
27	of	O	['N']	[27]
28	imatinib	B-Drug	['Causes']	[21]
29	therapy	O	['N']	[29]
30	.	O	['N']	[30]
#2100
0	Severe	O	['N']	[0]
1	rash	O	['N']	[1]
2	,	O	['N']	[2]
3	including	O	['N']	[3]
4	the	O	['N']	[4]
5	Stevens	O	['N']	[5]
6	-	O	['N']	[6]
7	Johnson	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	(	O	['N']	[9]
10	SJS	B-Adverse_Effect	['N']	[10]
11	)	O	['N']	[11]
12	,	O	['N']	[12]
13	is	O	['N']	[13]
14	the	O	['N']	[14]
15	major	O	['N']	[15]
16	toxicity	O	['N']	[16]
17	of	O	['N']	[17]
18	nevirapine	B-Drug	['Causes']	[10]
19	and	O	['N']	[19]
20	is	O	['N']	[20]
21	described	O	['N']	[21]
22	in	O	['N']	[22]
23	the	O	['N']	[23]
24	package	O	['N']	[24]
25	labeling	O	['N']	[25]
26	with	O	['N']	[26]
27	a	O	['N']	[27]
28	prominent	O	['N']	[28]
29	,	O	['N']	[29]
30	boxed	O	['N']	[30]
31	warning	O	['N']	[31]
32	.	O	['N']	[32]
#2101
0	The	O	['N']	[0]
1	biochemistry	O	['N']	[1]
2	of	O	['N']	[2]
3	paracetamol	B-Drug	['Causes']	[17]
4	hepatotoxicity	O	['N']	[4]
5	is	O	['N']	[5]
6	outlined	O	['N']	[6]
7	and	O	['N']	[7]
8	the	O	['N']	[8]
9	increased	O	['N']	[9]
10	susceptibility	O	['N']	[10]
11	of	O	['N']	[11]
12	alcoholic	O	['N']	[12]
13	patients	O	['N']	[13]
14	to	O	['N']	[14]
15	the	O	['N']	[15]
16	hepatotoxic	B	['N']	[16]
17	effects	I-Adverse_Effect	['N']	[17]
18	of	O	['N']	[18]
19	paracetamol	O	['N']	[19]
20	is	O	['N']	[20]
21	remarked	O	['N']	[21]
22	upon	O	['N']	[22]
23	.	O	['N']	[23]
#2102
0	Herein	O	['N']	[0]
1	we	O	['N']	[1]
2	report	O	['N']	[2]
3	four	O	['N']	[3]
4	patients	O	['N']	[4]
5	who	O	['N']	[5]
6	underwent	O	['N']	[6]
7	liver	O	['N']	[7]
8	transplantation	O	['N']	[8]
9	and	O	['N']	[9]
10	developed	O	['N']	[10]
11	neutropenia	B-Adverse_Effect	['N']	[11]
12	while	O	['N']	[12]
13	receiving	O	['N']	[13]
14	MMF	B-Drug	['Causes']	[11]
15	.	O	['N']	[15]
#2103
0	Retinal	B	['N']	[0]
1	dysfunction	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	anterior	O	['N']	[3]
4	segment	O	['N']	[4]
5	deposits	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	rifabutin	B-Drug	['Causes']	[1]
12	.	O	['N']	[12]
#2104
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	multiple	O	['N']	[8]
9	myeloma	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	acute	O	['N']	[12]
13	life	B	['N']	[13]
14	-	I	['N']	[14]
15	threatening	I	['N']	[15]
16	water	I	['N']	[16]
17	intoxication	I-Adverse_Effect	['N']	[17]
18	following	O	['N']	[18]
19	treatment	O	['N']	[19]
20	with	O	['N']	[20]
21	oral	O	['N']	[21]
22	indomethacin	B-Drug	['Causes']	[17]
23	and	O	['N']	[23]
24	low	O	['N']	[24]
25	dose	O	['N']	[25]
26	intravenous	O	['N']	[26]
27	cyclophosphamide	O	['N']	[27]
28	.	O	['N']	[28]
#2105
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Ethambutol	O	['N']	[2]
3	,	O	['N']	[3]
4	and	O	['N']	[4]
5	to	O	['N']	[5]
6	a	O	['N']	[6]
7	lesser	O	['N']	[7]
8	extent	O	['N']	[8]
9	isoniazid	B-Drug	['Causes']	[21]
10	,	O	['N']	[10]
11	are	O	['N']	[11]
12	both	O	['N']	[12]
13	implicated	O	['N']	[13]
14	in	O	['N']	[14]
15	the	O	['N']	[15]
16	development	B	['N']	[16]
17	of	I	['N']	[17]
18	visually	I	['N']	[18]
19	related	I	['N']	[19]
20	side	I	['N']	[20]
21	effects	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#2106
0	Priapism	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	trazodone	B-Drug	['Causes']	[0]
4	therapy	O	['N']	[4]
5	:	O	['N']	[5]
6	case	O	['N']	[6]
7	report	O	['N']	[7]
8	.	O	['N']	[8]
#2107
0	From	O	['N']	[0]
1	1996	O	['N']	[1]
2	to	O	['N']	[2]
3	2002	O	['N']	[3]
4	several	O	['N']	[4]
5	medications	O	['N']	[5]
6	were	O	['N']	[6]
7	changed	O	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	their	O	['N']	[10]
11	adverse	O	['N']	[11]
12	effects	O	['N']	[12]
13	:	O	['N']	[13]
14	indinavir	O	['N']	[14]
15	(	O	['N']	[15]
16	renal	O	['N']	[16]
17	colic	O	['N']	[17]
18	and	O	['N']	[18]
19	fever	O	['N']	[19]
20	)	O	['N']	[20]
21	,	O	['N']	[21]
22	nelfinavir	B-Drug	['Causes']	[25]
23	(	O	['N']	[23]
24	cutaneous	B	['N']	[24]
25	rash	I-Adverse_Effect	['N']	[25]
26	)	O	['N']	[26]
27	,	O	['N']	[27]
28	and	O	['N']	[28]
29	efavirenz	O	['N']	[29]
30	(	O	['N']	[30]
31	nausea	O	['N']	[31]
32	and	O	['N']	[32]
33	temporary	O	['N']	[33]
34	memory	O	['N']	[34]
35	loss	O	['N']	[35]
36	)	O	['N']	[36]
37	.	O	['N']	[37]
#2108
0	After	O	['N']	[0]
1	a	O	['N']	[1]
2	six	O	['N']	[2]
3	-	O	['N']	[3]
4	week	O	['N']	[4]
5	course	O	['N']	[5]
6	of	O	['N']	[6]
7	low	O	['N']	[7]
8	-	O	['N']	[8]
9	dose	O	['N']	[9]
10	cyclosporine	B	['N']	[10]
11	A	I-Drug	['Causes']	[28]
12	,	O	['N']	[12]
13	she	O	['N']	[13]
14	developed	O	['N']	[14]
15	a	O	['N']	[15]
16	severe	O	['N']	[16]
17	but	O	['N']	[17]
18	reversible	O	['N']	[18]
19	loss	O	['N']	[19]
20	of	O	['N']	[20]
21	glomerular	O	['N']	[21]
22	filtration	O	['N']	[22]
23	rate	O	['N']	[23]
24	and	O	['N']	[24]
25	effective	B	['N']	[25]
26	renal	I	['N']	[26]
27	plasma	I	['N']	[27]
28	flow	I-Adverse_Effect	['N']	[28]
29	despite	O	['N']	[29]
30	of	O	['N']	[30]
31	low	O	['N']	[31]
32	cyclosporine	O	['N']	[32]
33	A	O	['N']	[33]
34	plasma	O	['N']	[34]
35	levels	O	['N']	[35]
36	.	O	['N']	[36]
#2109
0	The	O	['N']	[0]
1	association	O	['N']	[1]
2	of	O	['N']	[2]
3	phenothiazine	B-Drug	['Dosage']	[4]
4	overdose	B-Dose	['N']	[4]
5	and	O	['N']	[5]
6	respiratory	O	['N']	[6]
7	distress	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	merits	O	['N']	[9]
10	consideration	O	['N']	[10]
11	.	O	['N']	[11]
#2110
0	A	O	['N']	[0]
1	66-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	Japanese	O	['N']	[4]
5	woman	O	['N']	[5]
6	with	O	['N']	[6]
7	severe	O	['N']	[7]
8	scleroderma	O	['N']	[8]
9	developed	O	['N']	[9]
10	anemia	O	['N']	[10]
11	and	O	['N']	[11]
12	thrombocytopenia	B-Adverse_Effect	['N']	[12]
13	due	O	['N']	[13]
14	to	O	['N']	[14]
15	D	O	['N']	[15]
16	-	O	['N']	[16]
17	penicillamine	O	['N']	[17]
18	(	O	['N']	[18]
19	D	B	['N']	[19]
20	-	I	['N']	[20]
21	Pen	I-Drug	['Causes']	[12]
22	)	O	['N']	[22]
23	treatment	O	['N']	[23]
24	,	O	['N']	[24]
25	although	O	['N']	[25]
26	the	O	['N']	[26]
27	leukopenia	O	['N']	[27]
28	was	O	['N']	[28]
29	not	O	['N']	[29]
30	markedly	O	['N']	[30]
31	severe	O	['N']	[31]
32	.	O	['N']	[32]
#2111
0	Marked	O	['N']	[0]
1	QT	O	['N']	[1]
2	prolongation	O	['N']	[2]
3	and	O	['N']	[3]
4	torsades	O	['N']	[4]
5	de	O	['N']	[5]
6	pointes	O	['N']	[6]
7	secondary	O	['N']	[7]
8	to	O	['N']	[8]
9	acute	B	['N']	[9]
10	ischemia	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	an	O	['N']	[12]
13	elderly	O	['N']	[13]
14	man	O	['N']	[14]
15	taking	O	['N']	[15]
16	dofetilide	B-Drug	['Causes']	[10]
17	for	O	['N']	[17]
18	atrial	O	['N']	[18]
19	fibrillation	O	['N']	[19]
20	:	O	['N']	[20]
21	a	O	['N']	[21]
22	cautionary	O	['N']	[22]
23	tale	O	['N']	[23]
24	.	O	['N']	[24]
#2112
0	The	O	['N']	[0]
1	successful	O	['N']	[1]
2	development	O	['N']	[2]
3	and	O	['N']	[3]
4	implementation	O	['N']	[4]
5	of	O	['N']	[5]
6	this	O	['N']	[6]
7	protocol	O	['N']	[7]
8	will	O	['N']	[8]
9	have	O	['N']	[9]
10	impact	O	['N']	[10]
11	on	O	['N']	[11]
12	patients	O	['N']	[12]
13	who	O	['N']	[13]
14	have	O	['N']	[14]
15	anaphylactic	B	['N']	[15]
16	reactions	I-Adverse_Effect	['N']	[16]
17	to	O	['N']	[17]
18	MTX	B-Drug	['Causes']	[16]
19	but	O	['N']	[19]
20	require	O	['N']	[20]
21	this	O	['N']	[21]
22	medication	O	['N']	[22]
23	for	O	['N']	[23]
24	specific	O	['N']	[24]
25	diseases	O	['N']	[25]
26	.	O	['N']	[26]
#2113
0	Verapamil	B-Drug	['Causes']	[6]
1	in	O	['N']	[1]
2	effort	O	['N']	[2]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	angina	B	['N']	[5]
6	pectoris	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	patients	O	['N']	[8]
9	with	O	['N']	[9]
10	normal	O	['N']	[10]
11	coronary	O	['N']	[11]
12	arteries	O	['N']	[12]
13	.	O	['N']	[13]
#2114
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	,	O	['N']	[2]
3	in	O	['N']	[3]
4	whom	O	['N']	[4]
5	tumour	O	['N']	[5]
6	overkill	O	['N']	[6]
7	by	O	['N']	[7]
8	cytotoxic	O	['N']	[8]
9	treatment	O	['N']	[9]
10	,	O	['N']	[10]
11	including	O	['N']	[11]
12	high	O	['N']	[12]
13	dose	O	['N']	[13]
14	methotrexate	B-Drug	['Causes']	[39]
15	with	O	['N']	[15]
16	folinic	O	['N']	[16]
17	acid	O	['N']	[17]
18	rescue	O	['N']	[18]
19	,	O	['N']	[19]
20	resulted	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	'	O	['N']	[23]
24	phosphate	O	['N']	[24]
25	shower	O	['N']	[25]
26	syndrome	O	['N']	[26]
27	'	O	['N']	[27]
28	(	O	['N']	[28]
29	hyper	O	['N']	[29]
30	-	O	['N']	[30]
31	uricaemia	O	['N']	[31]
32	,	O	['N']	[32]
33	hyperkalaemia	O	['N']	[33]
34	and	O	['N']	[34]
35	hyperphosphataemia	O	['N']	[35]
36	with	O	['N']	[36]
37	hypocalcaemia	O	['N']	[37]
38	and	O	['N']	[38]
39	tetany	B-Adverse_Effect	['N']	[39]
40	,	O	['N']	[40]
41	with	O	['N']	[41]
42	metabolic	O	['N']	[42]
43	acidosis	O	['N']	[43]
44	and	O	['N']	[44]
45	acute	O	['N']	[45]
46	renal	O	['N']	[46]
47	impairment	O	['N']	[47]
48	)	O	['N']	[48]
49	are	O	['N']	[49]
50	described	O	['N']	[50]
51	.	O	['N']	[51]
#2115
0	Sensory	B	['N']	[0]
1	neuropathy	I-Adverse_Effect	['N']	[1]
2	revealing	O	['N']	[2]
3	necrotizing	O	['N']	[3]
4	vasculitis	O	['N']	[4]
5	during	O	['N']	[5]
6	infliximab	B-Drug	['Causes']	[1]
7	therapy	O	['N']	[7]
8	for	O	['N']	[8]
9	rheumatoid	O	['N']	[9]
10	arthritis	O	['N']	[10]
11	.	O	['N']	[11]
#2116
0	Propylthiouracil	B-Drug	['Causes']	[10]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	sensorineural	O	['N']	[3]
4	hearing	O	['N']	[4]
5	loss	O	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	antineutrophil	B	['N']	[8]
9	cytoplasmic	I	['N']	[9]
10	antibodies	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#2117
0	Dental	B	['N']	[0]
1	and	I	['N']	[1]
2	gingival	I	['N']	[2]
3	pain	I-Adverse_Effect	['N']	[3]
4	as	O	['N']	[4]
5	side	O	['N']	[5]
6	effects	O	['N']	[6]
7	of	O	['N']	[7]
8	niacin	B-Drug	['Causes']	[3]
9	therapy	O	['N']	[9]
10	.	O	['N']	[10]
#2118
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	myeloma	O	['N']	[3]
4	patient	O	['N']	[4]
5	who	O	['N']	[5]
6	developed	O	['N']	[6]
7	severe	B	['N']	[7]
8	paralytic	I	['N']	[8]
9	ileus	I-Adverse_Effect	['N']	[9]
10	during	O	['N']	[10]
11	bortezomib	B-Drug	['Causes']	[9]
12	therapy	O	['N']	[12]
13	,	O	['N']	[13]
14	which	O	['N']	[14]
15	presented	O	['N']	[15]
16	in	O	['N']	[16]
17	the	O	['N']	[17]
18	context	O	['N']	[18]
19	of	O	['N']	[19]
20	progressive	O	['N']	[20]
21	constipation	O	['N']	[21]
22	without	O	['N']	[22]
23	other	O	['N']	[23]
24	known	O	['N']	[24]
25	causes	O	['N']	[25]
26	and	O	['N']	[26]
27	which	O	['N']	[27]
28	regressed	O	['N']	[28]
29	promptly	O	['N']	[29]
30	with	O	['N']	[30]
31	medical	O	['N']	[31]
32	management	O	['N']	[32]
33	after	O	['N']	[33]
34	drug	O	['N']	[34]
35	cessation	O	['N']	[35]
36	,	O	['N']	[36]
37	suggesting	O	['N']	[37]
38	a	O	['N']	[38]
39	direct	O	['N']	[39]
40	causal	O	['N']	[40]
41	relationship	O	['N']	[41]
42	.	O	['N']	[42]
#2119
0	Heparin	O	['N']	[0]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	thrombocytopenia	O	['N']	[3]
4	and	O	['N']	[4]
5	thrombosis	B-Adverse_Effect	['N']	[5]
6	is	O	['N']	[6]
7	a	O	['N']	[7]
8	severe	O	['N']	[8]
9	complication	O	['N']	[9]
10	of	O	['N']	[10]
11	systemic	O	['N']	[11]
12	heparin	B-Drug	['Causes']	[5]
13	therapy	O	['N']	[13]
14	.	O	['N']	[14]
#2120
0	A	O	['N']	[0]
1	72-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	a	O	['N']	[6]
7	history	O	['N']	[7]
8	of	O	['N']	[8]
9	thyrotoxicosis	O	['N']	[9]
10	presented	O	['N']	[10]
11	with	O	['N']	[11]
12	sore	B	['N']	[12]
13	throat	I-Adverse_Effect	['N']	[13]
14	and	O	['N']	[14]
15	fever	O	['N']	[15]
16	two	O	['N']	[16]
17	weeks	O	['N']	[17]
18	after	O	['N']	[18]
19	starting	O	['N']	[19]
20	carbimazole	B-Drug	['Causes']	[13]
21	.	O	['N']	[21]
#2121
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	this	O	['N']	[4]
5	is	O	['N']	[5]
6	the	O	['N']	[6]
7	first	O	['N']	[7]
8	report	O	['N']	[8]
9	of	O	['N']	[9]
10	insulin	B-Drug	['Causes']	[13]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	lipohypertrophy	B-Adverse_Effect	['N']	[13]
14	with	O	['N']	[14]
15	detailed	O	['N']	[15]
16	histological	O	['N']	[16]
17	examinations	O	['N']	[17]
18	.	O	['N']	[18]
#2122
0	Tamoxifen	B-Drug	['Causes']	[1]
1	retinopathy	B-Adverse_Effect	['N']	[1]
2	.	O	['N']	[2]
#2123
0	This	O	['N']	[0]
1	patient	O	['N']	[1]
2	,	O	['N']	[2]
3	who	O	['N']	[3]
4	had	O	['N']	[4]
5	a	O	['N']	[5]
6	history	O	['N']	[6]
7	of	O	['N']	[7]
8	osteoarthritis	O	['N']	[8]
9	,	O	['N']	[9]
10	had	O	['N']	[10]
11	severe	O	['N']	[11]
12	hepatitis	B-Adverse_Effect	['N']	[12]
13	5	O	['N']	[13]
14	weeks	O	['N']	[14]
15	after	O	['N']	[15]
16	being	O	['N']	[16]
17	started	O	['N']	[17]
18	on	O	['N']	[18]
19	diclofenac	B-Drug	['Causes']	[12]
20	for	O	['N']	[20]
21	increasing	O	['N']	[21]
22	pain	O	['N']	[22]
23	in	O	['N']	[23]
24	the	O	['N']	[24]
25	joints	O	['N']	[25]
26	.	O	['N']	[26]
#2124
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	given	O	['N']	[2]
3	the	O	['N']	[3]
4	clinically	O	['N']	[4]
5	significant	O	['N']	[5]
6	result	O	['N']	[6]
7	to	O	['N']	[7]
8	the	O	['N']	[8]
9	interaction	O	['N']	[9]
10	between	O	['N']	[10]
11	tolazoline	O	['N']	[11]
12	and	O	['N']	[12]
13	cimetidine	B-Drug	['Causes']	[26]
14	we	O	['N']	[14]
15	report	O	['N']	[15]
16	,	O	['N']	[16]
17	the	O	['N']	[17]
18	use	O	['N']	[18]
19	of	O	['N']	[19]
20	cimetidine	O	['N']	[20]
21	in	O	['N']	[21]
22	tolazoline	O	['N']	[22]
23	induced	O	['N']	[23]
24	upper	B	['N']	[24]
25	gastrointestinal	I	['N']	[25]
26	hemorrhage	I-Adverse_Effect	['N']	[26]
27	should	O	['N']	[27]
28	deserve	O	['N']	[28]
29	more	O	['N']	[29]
30	attention	O	['N']	[30]
31	.	O	['N']	[31]
#2125
0	Comparable	O	['N']	[0]
1	adverse	O	['N']	[1]
2	effects	O	['N']	[2]
3	,	O	['N']	[3]
4	such	O	['N']	[4]
5	as	O	['N']	[5]
6	disorientation	B-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	temporary	O	['N']	[8]
9	amnesia	O	['N']	[9]
10	,	O	['N']	[10]
11	have	O	['N']	[11]
12	been	O	['N']	[12]
13	reported	O	['N']	[13]
14	in	O	['N']	[14]
15	patients	O	['N']	[15]
16	in	O	['N']	[16]
17	the	O	['N']	[17]
18	analogous	O	['N']	[18]
19	agent	O	['N']	[19]
20	,	O	['N']	[20]
21	propranolol	B-Drug	['Causes']	[6]
22	.	O	['N']	[22]
#2126
0	Postoperatively	O	['N']	[0]
1	,	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	two	O	['N']	[4]
5	patients	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	1	O	['N']	[8]
9	to	O	['N']	[9]
10	2	O	['N']	[10]
11	cc	O	['N']	[11]
12	of	O	['N']	[12]
13	thrombin	B-Drug	['Causes']	[23]
14	were	O	['N']	[14]
15	slow	O	['N']	[15]
16	to	O	['N']	[16]
17	awaken	O	['N']	[17]
18	;	O	['N']	[18]
19	one	O	['N']	[19]
20	had	O	['N']	[20]
21	evidence	O	['N']	[21]
22	of	O	['N']	[22]
23	vasospasm	B-Adverse_Effect	['N']	[23]
24	by	O	['N']	[24]
25	transcranial	O	['N']	[25]
26	Doppler	O	['N']	[26]
27	ultrasound	O	['N']	[27]
28	studies	O	['N']	[28]
29	and	O	['N']	[29]
30	multiple	O	['N']	[30]
31	infarcts	O	['N']	[31]
32	on	O	['N']	[32]
33	cranial	O	['N']	[33]
34	computerized	O	['N']	[34]
35	tomography	O	['N']	[35]
36	,	O	['N']	[36]
37	while	O	['N']	[37]
38	the	O	['N']	[38]
39	other	O	['N']	[39]
40	had	O	['N']	[40]
41	a	O	['N']	[41]
42	moderate	O	['N']	[42]
43	-	O	['N']	[43]
44	sized	O	['N']	[44]
45	frontal	O	['N']	[45]
46	hematoma	O	['N']	[46]
47	with	O	['N']	[47]
48	intracranial	O	['N']	[48]
49	hypertension	O	['N']	[49]
50	.	O	['N']	[50]
#2127
0	Beneficial	O	['N']	[0]
1	effect	O	['N']	[1]
2	of	O	['N']	[2]
3	low	O	['N']	[3]
4	-	O	['N']	[4]
5	dose	O	['N']	[5]
6	mianserin	O	['N']	[6]
7	on	O	['N']	[7]
8	fluvoxamine	B-Drug	['Causes']	[11]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	akathisia	B-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	an	O	['N']	[13]
14	obsessive	O	['N']	[14]
15	-	O	['N']	[15]
16	compulsive	O	['N']	[16]
17	patient	O	['N']	[17]
18	.	O	['N']	[18]
#2128
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	44-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	taking	O	['N']	[7]
8	naproxen	B-Drug	['Causes']	[31]
9	for	O	['N']	[9]
10	chronic	O	['N']	[10]
11	low	O	['N']	[11]
12	back	O	['N']	[12]
13	pain	O	['N']	[13]
14	and	O	['N']	[14]
15	a	O	['N']	[15]
16	20-year	O	['N']	[16]
17	-	O	['N']	[17]
18	old	O	['N']	[18]
19	woman	O	['N']	[19]
20	on	O	['N']	[20]
21	oxaprozin	O	['N']	[21]
22	for	O	['N']	[22]
23	rheumatoid	O	['N']	[23]
24	arthritis	O	['N']	[24]
25	presented	O	['N']	[25]
26	with	O	['N']	[26]
27	tense	O	['N']	[27]
28	bullae	O	['N']	[28]
29	and	O	['N']	[29]
30	cutaneous	B	['N']	[30]
31	fragility	I-Adverse_Effect	['N']	[31]
32	on	O	['N']	[32]
33	the	O	['N']	[33]
34	face	O	['N']	[34]
35	and	O	['N']	[35]
36	the	O	['N']	[36]
37	back	O	['N']	[37]
38	of	O	['N']	[38]
39	the	O	['N']	[39]
40	hands	O	['N']	[40]
41	.	O	['N']	[41]
#2129
0	INTERVENTIONS	O	['N']	[0]
1	AND	O	['N']	[1]
2	RESULTS	O	['N']	[2]
3	:	O	['N']	[3]
4	Cardiac	O	['N']	[4]
5	complications	O	['N']	[5]
6	were	O	['N']	[6]
7	observed	O	['N']	[7]
8	in	O	['N']	[8]
9	five	O	['N']	[9]
10	pediatric	O	['N']	[10]
11	patients	O	['N']	[11]
12	who	O	['N']	[12]
13	received	O	['N']	[13]
14	between	B	['N']	[14]
15	4.6	I	['N']	[15]
16	and	I	['N']	[16]
17	40.8	I	['N']	[17]
18	mg	I	['N']	[18]
19	/	I	['N']	[19]
20	kg	I	['N']	[20]
21	/	I	['N']	[21]
22	d	I-Dose	['N']	[22]
23	of	O	['N']	[23]
24	amphotericin	-	['N']	[24]
25	B.	-	['N']	[25]
#2130
0	Tubulointerstitial	B	['N']	[0]
1	nephritis	I-Adverse_Effect	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	the	O	['N']	[4]
5	leukotriene	O	['N']	[5]
6	receptor	O	['N']	[6]
7	antagonist	O	['N']	[7]
8	pranlukast	B-Drug	['Causes']	[1]
9	.	O	['N']	[9]
#2131
0	Severe	B	['N']	[0]
1	diffuse	I	['N']	[1]
2	interstitial	I	['N']	[2]
3	pneumonitis	I-Adverse_Effect	['N']	[3]
4	induced	O	['N']	[4]
5	by	O	['N']	[5]
6	carmustine	O	['N']	[6]
7	(	O	['N']	[7]
8	BCNU	B-Drug	['Causes']	[3]
9	)	O	['N']	[9]
10	.	O	['N']	[10]
#2132
0	A	O	['N']	[0]
1	14-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	developed	O	['N']	[5]
6	systemic	O	['N']	[6]
7	lupus	O	['N']	[7]
8	erythematosus	O	['N']	[8]
9	(	O	['N']	[9]
10	SLE)-like	O	['N']	[10]
11	symptoms	O	['N']	[11]
12	,	O	['N']	[12]
13	rash	O	['N']	[13]
14	,	O	['N']	[14]
15	fever	O	['N']	[15]
16	,	O	['N']	[16]
17	leukopenia	O	['N']	[17]
18	and	O	['N']	[18]
19	positive	B	['N']	[19]
20	anti	I	['N']	[20]
21	-	I	['N']	[21]
22	nuclear	I	['N']	[22]
23	antibody	I-Adverse_Effect	['N']	[23]
24	(	O	['N']	[24]
25	ANA	O	['N']	[25]
26	)	O	['N']	[26]
27	two	O	['N']	[27]
28	weeks	O	['N']	[28]
29	after	O	['N']	[29]
30	administration	O	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	B-Drug	['Causes']	[23]
33	(	O	['N']	[33]
34	CBZ	O	['N']	[34]
35	;	O	['N']	[35]
36	Tegretol	O	['N']	[36]
37	)	O	['N']	[37]
38	used	O	['N']	[38]
39	against	O	['N']	[39]
40	benign	O	['N']	[40]
41	Rolandic	O	['N']	[41]
42	epilepsy	O	['N']	[42]
43	.	O	['N']	[43]
#2133
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	At	O	['N']	[2]
3	our	O	['N']	[3]
4	institution	O	['N']	[4]
5	,	O	['N']	[5]
6	no	O	['N']	[6]
7	children	O	['N']	[7]
8	appeared	O	['N']	[8]
9	with	O	['N']	[9]
10	acute	O	['N']	[10]
11	INH	B-Drug	['Causes']	[12]
12	neurotoxicity	B-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	the	O	['N']	[14]
15	period	O	['N']	[15]
16	1985	O	['N']	[16]
17	through	O	['N']	[17]
18	1990	O	['N']	[18]
19	,	O	['N']	[19]
20	whereas	O	['N']	[20]
21	seven	O	['N']	[21]
22	patients	O	['N']	[22]
23	were	O	['N']	[23]
24	treated	O	['N']	[24]
25	from	O	['N']	[25]
26	1991	O	['N']	[26]
27	through	O	['N']	[27]
28	1993	O	['N']	[28]
29	.	O	['N']	[29]
#2134
0	High	B	['N']	[0]
1	-	I	['N']	[1]
2	grade	I	['N']	[2]
3	atrioventricular	I	['N']	[3]
4	block	I-Adverse_Effect	['N']	[4]
5	during	O	['N']	[5]
6	dipyridamole	B-Drug	['Causes']	[4]
7	stress	O	['N']	[7]
8	testing	O	['N']	[8]
9	.	O	['N']	[9]
#2135
0	DATA	O	['N']	[0]
1	SYNTHESIS	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	49-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	man	O	['N']	[7]
8	developed	O	['N']	[8]
9	symptoms	O	['N']	[9]
10	of	O	['N']	[10]
11	severe	O	['N']	[11]
12	psychosis	O	['N']	[12]
13	concomitant	O	['N']	[13]
14	with	O	['N']	[14]
15	ciprofloxacin	B-Drug	['Dosage']	[19]
16	(	O	['N']	[16]
17	250	B	['N']	[17]
18	mg	I	['N']	[18]
19	bid	I-Dose	['N']	[19]
20	)	O	['N']	[20]
21	treatment	O	['N']	[21]
22	.	O	['N']	[22]
#2136
0	Sulfasalazine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	lupus	B	['N']	[3]
4	erythematosus	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#2137
0	Tremor	B-Adverse_Effect	['N']	[0]
1	:	O	['N']	[1]
2	a	O	['N']	[2]
3	newly	O	['N']	[3]
4	described	O	['N']	[4]
5	adverse	O	['N']	[5]
6	event	O	['N']	[6]
7	with	O	['N']	[7]
8	long	O	['N']	[8]
9	-	O	['N']	[9]
10	term	O	['N']	[10]
11	itraconazole	B-Drug	['Causes']	[0]
12	therapy	O	['N']	[12]
13	.	O	['N']	[13]
#2138
0	Marked	O	['N']	[0]
1	QT	O	['N']	[1]
2	prolongation	O	['N']	[2]
3	and	O	['N']	[3]
4	torsades	B	['N']	[4]
5	de	I	['N']	[5]
6	pointes	I-Adverse_Effect	['N']	[6]
7	secondary	O	['N']	[7]
8	to	O	['N']	[8]
9	acute	O	['N']	[9]
10	ischemia	O	['N']	[10]
11	in	O	['N']	[11]
12	an	O	['N']	[12]
13	elderly	O	['N']	[13]
14	man	O	['N']	[14]
15	taking	O	['N']	[15]
16	dofetilide	B-Drug	['Causes']	[6]
17	for	O	['N']	[17]
18	atrial	O	['N']	[18]
19	fibrillation	O	['N']	[19]
20	:	O	['N']	[20]
21	a	O	['N']	[21]
22	cautionary	O	['N']	[22]
23	tale	O	['N']	[23]
24	.	O	['N']	[24]
#2139
0	A	O	['N']	[0]
1	16-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	developed	O	['N']	[5]
6	fever	O	['N']	[6]
7	,	O	['N']	[7]
8	generalized	O	['N']	[8]
9	rigidity	O	['N']	[9]
10	,	O	['N']	[10]
11	leukocytosis	B-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	increased	O	['N']	[14]
15	serum	O	['N']	[15]
16	transaminase	O	['N']	[16]
17	and	O	['N']	[17]
18	creatine	O	['N']	[18]
19	kinase	O	['N']	[19]
20	levels	O	['N']	[20]
21	while	O	['N']	[21]
22	receiving	O	['N']	[22]
23	treatment	O	['N']	[23]
24	with	O	['N']	[24]
25	olanzapine	O	['N']	[25]
26	and	O	['N']	[26]
27	lithium	B-Drug	['Causes']	[11]
28	.	O	['N']	[28]
#2140
0	The	O	['N']	[0]
1	first	O	['N']	[1]
2	patient	O	['N']	[2]
3	developed	O	['N']	[3]
4	mild	O	['N']	[4]
5	nitritoid	O	['N']	[5]
6	symptoms	O	['N']	[6]
7	and	O	['N']	[7]
8	pain	O	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	band	O	['N']	[11]
12	-	O	['N']	[12]
13	like	O	['N']	[13]
14	distribution	O	['N']	[14]
15	,	O	['N']	[15]
16	corresponding	O	['N']	[16]
17	to	O	['N']	[17]
18	T10-T12	B	['N']	[18]
19	dermatomes	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	shortly	O	['N']	[21]
22	after	O	['N']	[22]
23	gold	O	['N']	[23]
24	sodium	O	['N']	[24]
25	thiomalate	O	['N']	[25]
26	(	O	['N']	[26]
27	GSTM	B-Drug	['Causes']	[19]
28	)	O	['N']	[28]
29	injection	O	['N']	[29]
30	.	O	['N']	[30]
#2141
0	The	O	['N']	[0]
1	ocular	O	['N']	[1]
2	toxicity	O	['N']	[2]
3	of	O	['N']	[3]
4	DCF	B-Drug	['Causes']	[9]
5	,	O	['N']	[5]
6	previously	O	['N']	[6]
7	described	O	['N']	[7]
8	as	O	['N']	[8]
9	conjunctivitis	B-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	appears	O	['N']	[11]
12	to	O	['N']	[12]
13	be	O	['N']	[13]
14	a	O	['N']	[14]
15	keratitis	O	['N']	[15]
16	of	O	['N']	[16]
17	moderate	O	['N']	[17]
18	severity	O	['N']	[18]
19	which	O	['N']	[19]
20	requires	O	['N']	[20]
21	further	O	['N']	[21]
22	study	O	['N']	[22]
23	.	O	['N']	[23]
#2142
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	severe	O	['N']	[7]
8	skin	B	['N']	[8]
9	necrosis	I-Adverse_Effect	['N']	[9]
10	resulting	O	['N']	[10]
11	from	O	['N']	[11]
12	peripheral	O	['N']	[12]
13	intravenous	O	['N']	[13]
14	administration	O	['N']	[14]
15	of	O	['N']	[15]
16	low	O	['N']	[16]
17	-	O	['N']	[17]
18	dose	O	['N']	[18]
19	vasopressin	B-Drug	['Causes']	[9]
20	in	O	['N']	[20]
21	a	O	['N']	[21]
22	patient	O	['N']	[22]
23	with	O	['N']	[23]
24	catecholamine	O	['N']	[24]
25	-	O	['N']	[25]
26	resistant	O	['N']	[26]
27	septic	O	['N']	[27]
28	shock	O	['N']	[28]
29	.	O	['N']	[29]
#2143
0	A	O	['N']	[0]
1	noninvasive	O	['N']	[1]
2	method	O	['N']	[2]
3	in	O	['N']	[3]
4	the	O	['N']	[4]
5	differential	O	['N']	[5]
6	diagnosis	O	['N']	[6]
7	of	O	['N']	[7]
8	vecuronium	O	['N']	[8]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	and	O	['N']	[11]
12	magnesium	B-Drug	['Causes']	[17]
13	-	O	['N']	[13]
14	induced	O	['N']	[14]
15	protracted	B	['N']	[15]
16	neuromuscular	I	['N']	[16]
17	block	I-Adverse_Effect	['N']	[17]
18	in	O	['N']	[18]
19	a	O	['N']	[19]
20	severely	O	['N']	[20]
21	preeclamptic	O	['N']	[21]
22	patient	O	['N']	[22]
23	.	O	['N']	[23]
#2144
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	use	O	['N']	[3]
4	of	O	['N']	[4]
5	pamidronate	O	['N']	[5]
6	for	O	['N']	[6]
7	acute	O	['N']	[7]
8	,	O	['N']	[8]
9	severe	O	['N']	[9]
10	hypercalcemia	O	['N']	[10]
11	secondary	O	['N']	[11]
12	to	O	['N']	[12]
13	iatrogenic	O	['N']	[13]
14	vitamin	B	['N']	[14]
15	D	I-Drug	['Causes']	[16]
16	poisoning	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#2145
0	A	O	['N']	[0]
1	34-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	lady	O	['N']	[4]
5	developed	O	['N']	[5]
6	a	O	['N']	[6]
7	constellation	O	['N']	[7]
8	of	O	['N']	[8]
9	dermatitis	O	['N']	[9]
10	,	O	['N']	[10]
11	fever	O	['N']	[11]
12	,	O	['N']	[12]
13	lymphadenopathy	B-Adverse_Effect	['N']	[13]
14	and	O	['N']	[14]
15	hepatitis	O	['N']	[15]
16	,	O	['N']	[16]
17	beginning	O	['N']	[17]
18	on	O	['N']	[18]
19	the	O	['N']	[19]
20	17th	O	['N']	[20]
21	day	O	['N']	[21]
22	of	O	['N']	[22]
23	a	O	['N']	[23]
24	course	O	['N']	[24]
25	of	O	['N']	[25]
26	oral	O	['N']	[26]
27	sulphasalazine	B-Drug	['Causes']	[13]
28	for	O	['N']	[28]
29	sero	O	['N']	[29]
30	-	O	['N']	[30]
31	negative	O	['N']	[31]
32	rheumatoid	O	['N']	[32]
33	arthritis	O	['N']	[33]
34	.	O	['N']	[34]
#2146
0	According	O	['N']	[0]
1	to	O	['N']	[1]
2	the	O	['N']	[2]
3	literature	O	['N']	[3]
4	,	O	['N']	[4]
5	chlorambucil	B-Drug	['Causes']	[8]
6	central	B	['N']	[6]
7	nervous	I	['N']	[7]
8	toxicity	I-Adverse_Effect	['N']	[8]
9	is	O	['N']	[9]
10	found	O	['N']	[10]
11	almost	O	['N']	[11]
12	exclusively	O	['N']	[12]
13	in	O	['N']	[13]
14	childhood	O	['N']	[14]
15	nephrotic	O	['N']	[15]
16	syndrome	O	['N']	[16]
17	.	O	['N']	[17]
#2147
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	2	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	nonconvulsive	B	['N']	[7]
8	status	I	['N']	[8]
9	epilepticus	I-Adverse_Effect	['N']	[9]
10	(	O	['N']	[10]
11	NCSE	O	['N']	[11]
12	)	O	['N']	[12]
13	following	O	['N']	[13]
14	infusion	O	['N']	[14]
15	of	O	['N']	[15]
16	ifosfamide	B-Drug	['Causes']	[9]
17	.	O	['N']	[17]
#2148
0	Dural	B	['N']	[0]
1	sinus	I	['N']	[1]
2	thrombosis	I-Adverse_Effect	['N']	[2]
3	developed	O	['N']	[3]
4	in	O	['N']	[4]
5	two	O	['N']	[5]
6	children	O	['N']	[6]
7	with	O	['N']	[7]
8	acute	O	['N']	[8]
9	lymphoblastic	O	['N']	[9]
10	leukemia	O	['N']	[10]
11	during	O	['N']	[11]
12	induction	O	['N']	[12]
13	treatment	O	['N']	[13]
14	with	O	['N']	[14]
15	vincristine	O	['N']	[15]
16	sulfate	O	['N']	[16]
17	,	O	['N']	[17]
18	prednisone	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	asparaginase	B-Drug	['Causes']	[2]
22	.	O	['N']	[22]
#2149
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	presented	O	['N']	[2]
3	with	O	['N']	[3]
4	a	O	['N']	[4]
5	painful	B	['N']	[5]
6	,	I	['N']	[6]
7	oedematous	I	['N']	[7]
8	,	I	['N']	[8]
9	cyanosed	I	['N']	[9]
10	hand	I-Adverse_Effect	['N']	[10]
11	having	O	['N']	[11]
12	injected	O	['N']	[12]
13	a	O	['N']	[13]
14	solution	O	['N']	[14]
15	of	O	['N']	[15]
16	diamorphine	O	['N']	[16]
17	and	O	['N']	[17]
18	methylphenidate	B-Drug	['Causes']	[10]
19	into	O	['N']	[19]
20	his	O	['N']	[20]
21	radial	O	['N']	[21]
22	artery	O	['N']	[22]
23	.	O	['N']	[23]
#2150
0	In	O	['N']	[0]
1	one	O	['N']	[1]
2	case	O	['N']	[2]
3	,	O	['N']	[3]
4	disulfiram	B-Drug	['Causes']	[9]
5	was	O	['N']	[5]
6	the	O	['N']	[6]
7	only	O	['N']	[7]
8	potential	O	['N']	[8]
9	teratogen	B-Adverse_Effect	['N']	[9]
10	exposed	O	['N']	[10]
11	to	O	['N']	[11]
12	the	O	['N']	[12]
13	fetus	O	['N']	[13]
14	.	O	['N']	[14]
#2151
0	Inappropriate	O	['N']	[0]
1	antidiuretic	O	['N']	[1]
2	hormone	O	['N']	[2]
3	secretion	O	['N']	[3]
4	after	O	['N']	[4]
5	high	B	['N']	[5]
6	dose	I-Dose	['N']	[6]
7	vinblastine	B-Drug	['Dosage']	[6]
8	.	O	['N']	[8]
#2152
0	The	O	['N']	[0]
1	increased	B	['N']	[1]
2	libido	I-Adverse_Effect	['N']	[2]
3	disappeared	O	['N']	[3]
4	after	O	['N']	[4]
5	fluvoxamine	B-Drug	['Causes']	[2]
6	was	O	['N']	[6]
7	discontinued	O	['N']	[7]
8	.	O	['N']	[8]
#2153
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	an	O	['N']	[3]
4	unexpected	O	['N']	[4]
5	drug	O	['N']	[5]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	hepatitis	B-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	previously	O	['N']	[11]
12	healthy	O	['N']	[12]
13	young	O	['N']	[13]
14	woman	O	['N']	[14]
15	exposed	O	['N']	[15]
16	to	O	['N']	[16]
17	2	O	['N']	[17]
18	doses	O	['N']	[18]
19	of	O	['N']	[19]
20	amodiaquine	O	['N']	[20]
21	and	O	['N']	[21]
22	artesunate	B-Drug	['Causes']	[8]
23	.	O	['N']	[23]
#2154
0	Linear	B	['N']	[0]
1	immunoglobulin	I	['N']	[1]
2	A	I	['N']	[2]
3	bullous	I	['N']	[3]
4	dermatosis	I-Adverse_Effect	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	gemcitabine	B-Drug	['Causes']	[4]
8	.	O	['N']	[8]
#2155
0	Acute	B	['N']	[0]
1	hemorrhagic	I	['N']	[1]
2	gastritis	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	acetazolamide	B-Drug	['Causes']	[2]
6	intoxication	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	chronic	O	['N']	[11]
12	renal	O	['N']	[12]
13	failure	O	['N']	[13]
14	.	O	['N']	[14]
#2156
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	developed	O	['N']	[7]
8	neutropenia	O	['N']	[8]
9	on	O	['N']	[9]
10	clozapine	B-Drug	['Causes']	[28]
11	,	O	['N']	[11]
12	but	O	['N']	[12]
13	behind	O	['N']	[13]
14	the	O	['N']	[14]
15	cell	O	['N']	[15]
16	count	O	['N']	[16]
17	decrease	O	['N']	[17]
18	showed	O	['N']	[18]
19	to	O	['N']	[19]
20	be	O	['N']	[20]
21	a	O	['N']	[21]
22	diurnal	B	['N']	[22]
23	variation	I	['N']	[23]
24	of	I	['N']	[24]
25	the	I	['N']	[25]
26	white	I	['N']	[26]
27	blood	I	['N']	[27]
28	cells	I-Adverse_Effect	['N']	[28]
29	(	O	['N']	[29]
30	WBC	O	['N']	[30]
31	)	O	['N']	[31]
32	.	O	['N']	[32]
#2157
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	case	O	['N']	[2]
3	,	O	['N']	[3]
4	discontinuing	O	['N']	[4]
5	piroxicam	B-Drug	['Causes']	[25]
6	,	O	['N']	[6]
7	a	O	['N']	[7]
8	nonsteroidal	O	['N']	[8]
9	anti	O	['N']	[9]
10	-	O	['N']	[10]
11	inflammatory	O	['N']	[11]
12	drug	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	starting	O	['N']	[15]
16	a	O	['N']	[16]
17	palliative	O	['N']	[17]
18	treatment	O	['N']	[18]
19	plan	O	['N']	[19]
20	helped	O	['N']	[20]
21	resolve	O	['N']	[21]
22	a	O	['N']	[22]
23	patient	O	['N']	[23]
24	's	O	['N']	[24]
25	ulcers	B-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#2158
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	Stevens	O	['N']	[5]
6	-	O	['N']	[6]
7	Johnson	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	/	O	['N']	[9]
10	toxic	O	['N']	[10]
11	epidermal	O	['N']	[11]
12	necrolysis	O	['N']	[12]
13	(	O	['N']	[13]
14	SJS	B-Adverse_Effect	['N']	[14]
15	/	O	['N']	[15]
16	TEN	O	['N']	[16]
17	)	O	['N']	[17]
18	secondary	O	['N']	[18]
19	to	O	['N']	[19]
20	trimethoprim	O	['N']	[20]
21	-	O	['N']	[21]
22	sulfamethoxazole	O	['N']	[22]
23	(	O	['N']	[23]
24	TMP	B	['N']	[24]
25	-	I	['N']	[25]
26	Sx	I-Drug	['Causes']	[14]
27	)	O	['N']	[27]
28	therapy	O	['N']	[28]
29	for	O	['N']	[29]
30	presumed	O	['N']	[30]
31	community	O	['N']	[31]
32	-	O	['N']	[32]
33	associated	O	['N']	[33]
34	methicillin	O	['N']	[34]
35	-	O	['N']	[35]
36	resistant	O	['N']	[36]
37	Staphylococcus	O	['N']	[37]
38	aureus	O	['N']	[38]
39	(	O	['N']	[39]
40	CA	O	['N']	[40]
41	-	O	['N']	[41]
42	MRSA	O	['N']	[42]
43	)	O	['N']	[43]
44	infection	O	['N']	[44]
45	.	O	['N']	[45]
#2159
0	A	O	['N']	[0]
1	transient	O	['N']	[1]
2	tonic	O	['N']	[2]
3	pupillary	O	['N']	[3]
4	response	O	['N']	[4]
5	,	O	['N']	[5]
6	denervation	O	['N']	[6]
7	supersensitivity	O	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	abnormal	B	['N']	[10]
11	visual	I	['N']	[11]
12	-	I	['N']	[12]
13	evoked	I	['N']	[13]
14	potentials	I-Adverse_Effect	['N']	[14]
15	in	O	['N']	[15]
16	quinine	B-Drug	['Causes']	[14]
17	toxicity	O	['N']	[17]
18	,	O	['N']	[18]
19	to	O	['N']	[19]
20	our	O	['N']	[20]
21	knowledge	O	['N']	[21]
22	,	O	['N']	[22]
23	have	O	['N']	[23]
24	not	O	['N']	[24]
25	been	O	['N']	[25]
26	previously	O	['N']	[26]
27	reported	O	['N']	[27]
28	.	O	['N']	[28]
#2160
0	On	O	['N']	[0]
1	the	O	['N']	[1]
2	fifth	O	['N']	[2]
3	day	O	['N']	[3]
4	after	O	['N']	[4]
5	administration	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	high	O	['N']	[8]
9	dose	O	['N']	[9]
10	of	O	['N']	[10]
11	ARA	B	['N']	[11]
12	-	I	['N']	[12]
13	C	I-Drug	['Causes']	[39]
14	(	O	['N']	[14]
15	2	O	['N']	[15]
16	g	O	['N']	[16]
17	/	O	['N']	[17]
18	m2	O	['N']	[18]
19	intravenously	O	['N']	[19]
20	every	O	['N']	[20]
21	12	O	['N']	[21]
22	hours	O	['N']	[22]
23	)	O	['N']	[23]
24	,	O	['N']	[24]
25	she	O	['N']	[25]
26	developed	O	['N']	[26]
27	bullous	B	['N']	[27]
28	lesions	I	['N']	[28]
29	on	I	['N']	[29]
30	the	I	['N']	[30]
31	hands	I	['N']	[31]
32	and	I	['N']	[32]
33	soles	I	['N']	[33]
34	that	I	['N']	[34]
35	disseminated	I	['N']	[35]
36	,	I	['N']	[36]
37	evolving	I	['N']	[37]
38	to	I	['N']	[38]
39	necrosis	I-Adverse_Effect	['N']	[39]
40	,	O	['N']	[40]
41	sepsis	O	['N']	[41]
42	,	O	['N']	[42]
43	and	O	['N']	[43]
44	death	O	['N']	[44]
45	on	O	['N']	[45]
46	the	O	['N']	[46]
47	22nd	O	['N']	[47]
48	day	O	['N']	[48]
49	.	O	['N']	[49]
#2161
0	A	O	['N']	[0]
1	woman	O	['N']	[1]
2	38-year	O	['N']	[2]
3	-	O	['N']	[3]
4	old	O	['N']	[4]
5	,	O	['N']	[5]
6	suffering	O	['N']	[6]
7	for	O	['N']	[7]
8	about	O	['N']	[8]
9	ten	O	['N']	[9]
10	years	O	['N']	[10]
11	from	O	['N']	[11]
12	multiple	O	['N']	[12]
13	sclerosis	O	['N']	[13]
14	and	O	['N']	[14]
15	treated	O	['N']	[15]
16	with	O	['N']	[16]
17	repeated	O	['N']	[17]
18	therapy	O	['N']	[18]
19	cycles	O	['N']	[19]
20	of	O	['N']	[20]
21	intrathecal	O	['N']	[21]
22	Depo	B	['N']	[22]
23	-	I	['N']	[23]
24	Medrol	I-Drug	['Causes']	[33]
25	,	O	['N']	[25]
26	developed	O	['N']	[26]
27	a	O	['N']	[27]
28	spastic	B	['N']	[28]
29	paraparesis	I	['N']	[29]
30	at	I	['N']	[30]
31	the	I	['N']	[31]
32	lower	I	['N']	[32]
33	limbs	I-Adverse_Effect	['N']	[33]
34	.	O	['N']	[34]
#2162
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	significant	O	['N']	[5]
6	elevation	B	['N']	[6]
7	of	I	['N']	[7]
8	serum	I	['N']	[8]
9	transaminases	I-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	patient	O	['N']	[12]
13	treated	O	['N']	[13]
14	with	O	['N']	[14]
15	6-TG	B-Drug	['Causes']	[9]
16	for	O	['N']	[16]
17	a	O	['N']	[17]
18	flare	O	['N']	[18]
19	of	O	['N']	[19]
20	Crohn	O	['N']	[20]
21	's	O	['N']	[21]
22	disease	O	['N']	[22]
23	.	O	['N']	[23]
#2163
0	We	O	['N']	[0]
1	believe	O	['N']	[1]
2	the	O	['N']	[2]
3	temporal	O	['N']	[3]
4	association	O	['N']	[4]
5	of	O	['N']	[5]
6	the	O	['N']	[6]
7	abnormal	O	['N']	[7]
8	liver	O	['N']	[8]
9	enzymes	O	['N']	[9]
10	in	O	['N']	[10]
11	this	O	['N']	[11]
12	patient	O	['N']	[12]
13	,	O	['N']	[13]
14	in	O	['N']	[14]
15	the	O	['N']	[15]
16	absence	O	['N']	[16]
17	of	O	['N']	[17]
18	other	O	['N']	[18]
19	offending	O	['N']	[19]
20	agents	O	['N']	[20]
21	,	O	['N']	[21]
22	argues	O	['N']	[22]
23	strongly	O	['N']	[23]
24	in	O	['N']	[24]
25	favor	O	['N']	[25]
26	of	O	['N']	[26]
27	6-TG	B-Drug	['Causes']	[34]
28	as	O	['N']	[28]
29	a	O	['N']	[29]
30	cause	O	['N']	[30]
31	of	O	['N']	[31]
32	liver	B	['N']	[32]
33	enzyme	I	['N']	[33]
34	abnormalities	I-Adverse_Effect	['N']	[34]
35	.	O	['N']	[35]
#2164
0	An	O	['N']	[0]
1	infant	O	['N']	[1]
2	girl	O	['N']	[2]
3	with	O	['N']	[3]
4	choanal	O	['N']	[4]
5	atresia	O	['N']	[5]
6	,	O	['N']	[6]
7	athelia	O	['N']	[7]
8	,	O	['N']	[8]
9	minor	O	['N']	[9]
10	anomalies	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	mild	O	['N']	[13]
14	to	O	['N']	[14]
15	moderate	O	['N']	[15]
16	mental	B	['N']	[16]
17	retardation	I-Adverse_Effect	['N']	[17]
18	was	O	['N']	[18]
19	born	O	['N']	[19]
20	to	O	['N']	[20]
21	a	O	['N']	[21]
22	woman	O	['N']	[22]
23	treated	O	['N']	[23]
24	for	O	['N']	[24]
25	hyperthyroidism	O	['N']	[25]
26	throughout	O	['N']	[26]
27	pregnancy	O	['N']	[27]
28	with	O	['N']	[28]
29	methimazole	O	['N']	[29]
30	and	O	['N']	[30]
31	propranolol	B-Drug	['Causes']	[17]
32	.	O	['N']	[32]
#2165
0	Intravenous	O	['N']	[0]
1	valproate	B-Drug	['Causes']	[5]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	significant	O	['N']	[4]
5	hypotension	B-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	the	O	['N']	[7]
8	treatment	O	['N']	[8]
9	of	O	['N']	[9]
10	status	O	['N']	[10]
11	epilepticus	O	['N']	[11]
12	.	O	['N']	[12]
#2166
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	sustained	B	['N']	[5]
6	hypotension	I-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	administration	O	['N']	[8]
9	of	O	['N']	[9]
10	parenteral	O	['N']	[10]
11	verapamil	B-Drug	['Causes']	[6]
12	.	O	['N']	[12]
#2167
0	How	O	['N']	[0]
1	low	O	['N']	[1]
2	can	O	['N']	[2]
3	you	O	['N']	[3]
4	go	O	['N']	[4]
5	?	O	['N']	[5]
6	Use	O	['N']	[6]
7	of	O	['N']	[7]
8	very	O	['N']	[8]
9	low	O	['N']	[9]
10	dosage	O	['N']	[10]
11	of	O	['N']	[11]
12	gold	B-Drug	['Causes']	[17]
13	in	O	['N']	[13]
14	patients	O	['N']	[14]
15	with	O	['N']	[15]
16	mucocutaneous	B	['N']	[16]
17	reactions	I-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#2168
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	case	O	['N']	[3]
4	report	O	['N']	[4]
5	outlines	O	['N']	[5]
6	a	O	['N']	[6]
7	significant	O	['N']	[7]
8	type	O	['N']	[8]
9	of	O	['N']	[9]
10	morbidity	O	['N']	[10]
11	due	O	['N']	[11]
12	to	O	['N']	[12]
13	continued	O	['N']	[13]
14	use	O	['N']	[14]
15	of	O	['N']	[15]
16	gabapentin	B-Drug	['Causes']	[23]
17	during	O	['N']	[17]
18	an	O	['N']	[18]
19	episode	O	['N']	[19]
20	of	O	['N']	[20]
21	acute	B	['N']	[21]
22	renal	I	['N']	[22]
23	failure	I-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#2169
0	Our	O	['N']	[0]
1	case	O	['N']	[1]
2	is	O	['N']	[2]
3	the	O	['N']	[3]
4	second	O	['N']	[4]
5	one	O	['N']	[5]
6	in	O	['N']	[6]
7	which	O	['N']	[7]
8	hemorrhage	B-Adverse_Effect	['N']	[8]
9	from	O	['N']	[9]
10	a	O	['N']	[10]
11	meningioma	O	['N']	[11]
12	may	O	['N']	[12]
13	have	O	['N']	[13]
14	been	O	['N']	[14]
15	induced	O	['N']	[15]
16	by	O	['N']	[16]
17	aspirin	B-Drug	['Causes']	[8]
18	prophylaxis	O	['N']	[18]
19	.	O	['N']	[19]
#2170
0	Acute	O	['N']	[0]
1	onset	O	['N']	[1]
2	of	O	['N']	[2]
3	nephrotic	B	['N']	[3]
4	syndrome	I-Adverse_Effect	['N']	[4]
5	during	O	['N']	[5]
6	interferon	B	['N']	[6]
7	-	I	['N']	[7]
8	alpha	I-Drug	['Causes']	[4]
9	retreatment	O	['N']	[9]
10	for	O	['N']	[10]
11	chronic	O	['N']	[11]
12	active	O	['N']	[12]
13	hepatitis	O	['N']	[13]
14	C.	O	['N']	[14]
#2171
0	Presentation	O	['N']	[0]
1	of	O	['N']	[1]
2	three	O	['N']	[2]
3	palliative	O	['N']	[3]
4	care	O	['N']	[4]
5	patients	O	['N']	[5]
6	who	O	['N']	[6]
7	were	O	['N']	[7]
8	given	O	['N']	[8]
9	ketamine	B-Drug	['Causes']	[20]
10	as	O	['N']	[10]
11	an	O	['N']	[11]
12	analgesic	O	['N']	[12]
13	and	O	['N']	[13]
14	subsequently	O	['N']	[14]
15	developed	O	['N']	[15]
16	significant	O	['N']	[16]
17	and	O	['N']	[17]
18	debilitating	O	['N']	[18]
19	urological	B	['N']	[19]
20	symptoms	I-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#2172
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	exacerbated	O	['N']	[7]
8	mania	B-Adverse_Effect	['N']	[8]
9	potentially	O	['N']	[9]
10	related	O	['N']	[10]
11	to	O	['N']	[11]
12	an	O	['N']	[12]
13	interaction	O	['N']	[13]
14	between	O	['N']	[14]
15	lopinavir	O	['N']	[15]
16	/	O	['N']	[16]
17	ritonavir	O	['N']	[17]
18	and	O	['N']	[18]
19	valproic	O	['N']	[19]
20	acid	O	['N']	[20]
21	(	O	['N']	[21]
22	VPA	B-Drug	['Causes']	[8]
23	)	O	['N']	[23]
24	and	O	['N']	[24]
25	propose	O	['N']	[25]
26	a	O	['N']	[26]
27	mechanism	O	['N']	[27]
28	of	O	['N']	[28]
29	action	O	['N']	[29]
30	for	O	['N']	[30]
31	this	O	['N']	[31]
32	interaction	O	['N']	[32]
33	.	O	['N']	[33]
#2173
0	Of	O	['N']	[0]
1	particular	O	['N']	[1]
2	interest	O	['N']	[2]
3	in	O	['N']	[3]
4	this	O	['N']	[4]
5	patient	O	['N']	[5]
6	is	O	['N']	[6]
7	the	O	['N']	[7]
8	fluctuation	B	['N']	[8]
9	of	I	['N']	[9]
10	the	I	['N']	[10]
11	QT	I	['N']	[11]
12	interval	I-Adverse_Effect	['N']	[12]
13	at	O	['N']	[13]
14	a	O	['N']	[14]
15	stable	O	['N']	[15]
16	dose	O	['N']	[16]
17	of	O	['N']	[17]
18	methadone	B-Drug	['Causes']	[12]
19	,	O	['N']	[19]
20	suggesting	O	['N']	[20]
21	that	O	['N']	[21]
22	a	O	['N']	[22]
23	single	O	['N']	[23]
24	normal	O	['N']	[24]
25	electrocardiogram	O	['N']	[25]
26	(	O	['N']	[26]
27	ECG	O	['N']	[27]
28	)	O	['N']	[28]
29	does	O	['N']	[29]
30	not	O	['N']	[30]
31	guarantee	O	['N']	[31]
32	that	O	['N']	[32]
33	the	O	['N']	[33]
34	patient	O	['N']	[34]
35	is	O	['N']	[35]
36	not	O	['N']	[36]
37	at	O	['N']	[37]
38	risk	O	['N']	[38]
39	of	O	['N']	[39]
40	ventricular	O	['N']	[40]
41	arrhythmias	O	['N']	[41]
42	.	O	['N']	[42]
#2174
0	A	O	['N']	[0]
1	fatal	B	['N']	[1]
2	massive	I	['N']	[2]
3	pulmonary	I	['N']	[3]
4	embolus	I-Adverse_Effect	['N']	[4]
5	developed	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	streptokinase	B-Drug	['Causes']	[4]
12	for	O	['N']	[12]
13	acute	O	['N']	[13]
14	deep	O	['N']	[14]
15	vein	O	['N']	[15]
16	thrombosis	O	['N']	[16]
17	.	O	['N']	[17]
#2175
0	Ulcerating	B	['N']	[0]
1	enteritis	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	flucytosine	B-Drug	['Causes']	[1]
5	therapy	O	['N']	[5]
6	.	O	['N']	[6]
#2176
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	NEH	B-Adverse_Effect	['N']	[6]
7	on	O	['N']	[7]
8	three	O	['N']	[8]
9	separate	O	['N']	[9]
10	occasions	O	['N']	[10]
11	provoked	O	['N']	[11]
12	by	O	['N']	[12]
13	two	O	['N']	[13]
14	different	O	['N']	[14]
15	chemotherapeutic	O	['N']	[15]
16	agents	O	['N']	[16]
17	--	O	['N']	[17]
18	cytarabine	B-Drug	['Causes']	[6]
19	and	O	['N']	[19]
20	mitoxantrone	O	['N']	[20]
21	.	O	['N']	[21]
#2177
0	A	O	['N']	[0]
1	retrospective	O	['N']	[1]
2	epidemiological	O	['N']	[2]
3	study	O	['N']	[3]
4	of	O	['N']	[4]
5	deaths	O	['N']	[5]
6	from	O	['N']	[6]
7	hepatic	B	['N']	[7]
8	angiosarcoma	I-Adverse_Effect	['N']	[8]
9	(	O	['N']	[9]
10	HAS	O	['N']	[10]
11	)	O	['N']	[11]
12	in	O	['N']	[12]
13	the	O	['N']	[13]
14	U.S.	O	['N']	[14]
15	showed	O	['N']	[15]
16	that	O	['N']	[16]
17	during	O	['N']	[17]
18	1964	O	['N']	[18]
19	-	O	['N']	[19]
20	-74	O	['N']	[20]
21	there	O	['N']	[21]
22	were	O	['N']	[22]
23	168	O	['N']	[23]
24	such	O	['N']	[24]
25	cases	O	['N']	[25]
26	,	O	['N']	[26]
27	of	O	['N']	[27]
28	which	O	['N']	[28]
29	37	O	['N']	[29]
30	(	O	['N']	[30]
31	22	O	['N']	[31]
32	%	O	['N']	[32]
33	)	O	['N']	[33]
34	were	O	['N']	[34]
35	associated	O	['N']	[35]
36	with	O	['N']	[36]
37	previously	O	['N']	[37]
38	known	O	['N']	[38]
39	causes	O	['N']	[39]
40	(	O	['N']	[40]
41	vinyl	O	['N']	[41]
42	chloride	O	['N']	[42]
43	,	O	['N']	[43]
44	'	O	['N']	[44]
45	Thorotrast	O	['N']	[45]
46	'	O	['N']	[46]
47	,	O	['N']	[47]
48	and	O	['N']	[48]
49	inorganic	B	['N']	[49]
50	arsenic	I-Drug	['Causes']	[8]
51	)	O	['N']	[51]
52	and	O	['N']	[52]
53	4	O	['N']	[53]
54	(	O	['N']	[54]
55	3.1	O	['N']	[55]
56	%	O	['N']	[56]
57	)	O	['N']	[57]
58	of	O	['N']	[58]
59	the	O	['N']	[59]
60	remaining	O	['N']	[60]
61	131	O	['N']	[61]
62	cases	O	['N']	[62]
63	with	O	['N']	[63]
64	the	O	['N']	[64]
65	use	O	['N']	[65]
66	of	O	['N']	[66]
67	androgenic	O	['N']	[67]
68	-	O	['N']	[68]
69	anabolic	O	['N']	[69]
70	steroids	O	['N']	[70]
71	.	O	['N']	[71]
#2178
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Therapy	O	['N']	[2]
3	with	O	['N']	[3]
4	indapamide	B-Drug	['Causes']	[7]
5	may	O	['N']	[5]
6	induce	O	['N']	[6]
7	diabetes	B-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	essential	O	['N']	[9]
10	hypertension	O	['N']	[10]
11	patients	O	['N']	[11]
12	.	O	['N']	[12]
#2179
0	Physicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	risk	O	['N']	[6]
7	of	O	['N']	[7]
8	severe	O	['N']	[8]
9	AIHA	O	['N']	[9]
10	in	O	['N']	[10]
11	CLL	O	['N']	[11]
12	patients	O	['N']	[12]
13	with	O	['N']	[13]
14	a	O	['N']	[14]
15	history	O	['N']	[15]
16	of	O	['N']	[16]
17	AIHA	O	['N']	[17]
18	or	O	['N']	[18]
19	positivation	B	['N']	[19]
20	of	I	['N']	[20]
21	the	I	['N']	[21]
22	DAT	I-Adverse_Effect	['N']	[22]
23	during	O	['N']	[23]
24	previous	O	['N']	[24]
25	fludarabine	B-Drug	['Causes']	[22]
26	administration	O	['N']	[26]
27	,	O	['N']	[27]
28	or	O	['N']	[28]
29	in	O	['N']	[29]
30	case	O	['N']	[30]
31	of	O	['N']	[31]
32	secondary	O	['N']	[32]
33	fixation	O	['N']	[33]
34	of	O	['N']	[34]
35	complement	O	['N']	[35]
36	to	O	['N']	[36]
37	the	O	['N']	[37]
38	red	O	['N']	[38]
39	cell	O	['N']	[39]
40	membrane	O	['N']	[40]
41	occurring	O	['N']	[41]
42	during	O	['N']	[42]
43	fludarabine	O	['N']	[43]
44	treatment	O	['N']	[44]
45	.	O	['N']	[45]
#2180
0	The	O	['N']	[0]
1	disease	O	['N']	[1]
2	predisposes	O	['N']	[2]
3	to	O	['N']	[3]
4	severe	O	['N']	[4]
5	vincristine	B-Drug	['Causes']	[6]
6	neurotoxicity	I-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#2181
0	1	O	['N']	[0]
1	.	O	['N']	[1]
2	Changes	B	['N']	[2]
3	in	I	['N']	[3]
4	the	I	['N']	[4]
5	plasma	I	['N']	[5]
6	cortisol	I	['N']	[6]
7	level	I-Adverse_Effect	['N']	[7]
8	were	O	['N']	[8]
9	reported	O	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	male	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	panic	O	['N']	[15]
16	disorder	O	['N']	[16]
17	during	O	['N']	[17]
18	the	O	['N']	[18]
19	period	O	['N']	[19]
20	of	O	['N']	[20]
21	low	O	['N']	[21]
22	-	O	['N']	[22]
23	dose	O	['N']	[23]
24	alprazolam	B-Drug	['Causes']	[7]
25	treatment	O	['N']	[25]
26	(	O	['N']	[26]
27	mean	O	['N']	[27]
28	0.62	O	['N']	[28]
29	+	O	['N']	[29]
30	/-	O	['N']	[30]
31	0.15	O	['N']	[31]
32	mg	O	['N']	[32]
33	/	O	['N']	[33]
34	day	O	['N']	[34]
35	)	O	['N']	[35]
36	compared	O	['N']	[36]
37	with	O	['N']	[37]
38	during	O	['N']	[38]
39	the	O	['N']	[39]
40	period	O	['N']	[40]
41	of	O	['N']	[41]
42	high	O	['N']	[42]
43	-	O	['N']	[43]
44	dose	O	['N']	[44]
45	period	O	['N']	[45]
46	(	O	['N']	[46]
47	mean	O	['N']	[47]
48	1.08	O	['N']	[48]
49	+	O	['N']	[49]
50	/-	O	['N']	[50]
51	0.28	O	['N']	[51]
52	mg	O	['N']	[52]
53	/	O	['N']	[53]
54	day	O	['N']	[54]
55	)	O	['N']	[55]
56	.	O	['N']	[56]
#2182
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	for	O	['N']	[2]
3	the	O	['N']	[3]
4	first	O	['N']	[4]
5	time	O	['N']	[5]
6	the	O	['N']	[6]
7	development	O	['N']	[7]
8	of	O	['N']	[8]
9	symptomatic	B	['N']	[9]
10	methemoglobinemia	I-Adverse_Effect	['N']	[10]
11	after	O	['N']	[11]
12	an	O	['N']	[12]
13	acute	O	['N']	[13]
14	ingestion	O	['N']	[14]
15	of	O	['N']	[15]
16	divalproex	B	['N']	[16]
17	sodium	I-Drug	['Causes']	[10]
18	(	O	['N']	[18]
19	Depakote	O	['N']	[19]
20	)	O	['N']	[20]
21	,	O	['N']	[21]
22	resulting	O	['N']	[22]
23	in	O	['N']	[23]
24	serum	O	['N']	[24]
25	concentrations	O	['N']	[25]
26	10	O	['N']	[26]
27	times	O	['N']	[27]
28	greater	O	['N']	[28]
29	than	O	['N']	[29]
30	the	O	['N']	[30]
31	therapeutic	O	['N']	[31]
32	range	O	['N']	[32]
33	.	O	['N']	[33]
#2183
0	Slow	O	['N']	[0]
1	acetylator	O	['N']	[1]
2	genotypes	O	['N']	[2]
3	as	O	['N']	[3]
4	a	O	['N']	[4]
5	possible	O	['N']	[5]
6	risk	O	['N']	[6]
7	factor	O	['N']	[7]
8	for	O	['N']	[8]
9	infectious	B	['N']	[9]
10	mononucleosis	I	['N']	[10]
11	-	I	['N']	[11]
12	like	I	['N']	[12]
13	syndrome	I-Adverse_Effect	['N']	[13]
14	induced	O	['N']	[14]
15	by	O	['N']	[15]
16	salazosulfapyridine	B-Drug	['Causes']	[13]
17	.	O	['N']	[17]
#2184
0	Sensorineural	B	['N']	[0]
1	hearing	I	['N']	[1]
2	loss	I-Adverse_Effect	['N']	[2]
3	due	O	['N']	[3]
4	to	O	['N']	[4]
5	quinine	B-Drug	['Causes']	[2]
6	therapy	O	['N']	[6]
7	for	O	['N']	[7]
8	malaria	O	['N']	[8]
9	has	O	['N']	[9]
10	frequently	O	['N']	[10]
11	been	O	['N']	[11]
12	mentioned	O	['N']	[12]
13	in	O	['N']	[13]
14	the	O	['N']	[14]
15	literature	O	['N']	[15]
16	but	O	['N']	[16]
17	has	O	['N']	[17]
18	not	O	['N']	[18]
19	been	O	['N']	[19]
20	a	O	['N']	[20]
21	subject	O	['N']	[21]
22	of	O	['N']	[22]
23	research	O	['N']	[23]
24	during	O	['N']	[24]
25	the	O	['N']	[25]
26	last	O	['N']	[26]
27	decades	O	['N']	[27]
28	.	O	['N']	[28]
#2185
0	Minimal	B	['N']	[0]
1	change	I	['N']	[1]
2	disease	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	receiving	O	['N']	[6]
7	IFN	B	['N']	[7]
8	-	I	['N']	[8]
9	alpha	I-Drug	['Causes']	[2]
10	therapy	O	['N']	[10]
11	for	O	['N']	[11]
12	chronic	O	['N']	[12]
13	hepatitis	O	['N']	[13]
14	C	O	['N']	[14]
15	virus	O	['N']	[15]
16	infection	O	['N']	[16]
17	.	O	['N']	[17]
#2186
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	infection	O	['N']	[5]
6	with	O	['N']	[6]
7	Mycobacterium	B	['N']	[7]
8	abscessus	I-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	67-year	O	['N']	[11]
12	-	O	['N']	[12]
13	old	O	['N']	[13]
14	woman	O	['N']	[14]
15	receiving	O	['N']	[15]
16	infliximab	B-Drug	['Causes']	[8]
17	as	O	['N']	[17]
18	a	O	['N']	[18]
19	component	O	['N']	[19]
20	of	O	['N']	[20]
21	her	O	['N']	[21]
22	therapy	O	['N']	[22]
23	for	O	['N']	[23]
24	RA	O	['N']	[24]
25	.	O	['N']	[25]
#2187
0	Mitomycin	B	['N']	[0]
1	C	I-Drug	['Causes']	[21]
2	(	O	['N']	[2]
3	MMC	O	['N']	[3]
4	)	O	['N']	[4]
5	is	O	['N']	[5]
6	an	O	['N']	[6]
7	alkylating	O	['N']	[7]
8	agent	O	['N']	[8]
9	that	O	['N']	[9]
10	has	O	['N']	[10]
11	been	O	['N']	[11]
12	recently	O	['N']	[12]
13	associated	O	['N']	[13]
14	with	O	['N']	[14]
15	the	O	['N']	[15]
16	hemolytic	O	['N']	[16]
17	-	O	['N']	[17]
18	uremic	O	['N']	[18]
19	syndrome	O	['N']	[19]
20	(	O	['N']	[20]
21	HUS	B-Adverse_Effect	['N']	[21]
22	)	O	['N']	[22]
23	.	O	['N']	[23]
#2188
0	Marked	O	['N']	[0]
1	sinus	B	['N']	[1]
2	tachycardia	I-Adverse_Effect	['N']	[2]
3	resulting	O	['N']	[3]
4	from	O	['N']	[4]
5	the	O	['N']	[5]
6	synergistic	O	['N']	[6]
7	effects	O	['N']	[7]
8	of	O	['N']	[8]
9	marijuana	O	['N']	[9]
10	and	O	['N']	[10]
11	nortriptyline	B-Drug	['Causes']	[2]
12	.	O	['N']	[12]
#2189
0	Patients	O	['N']	[0]
1	receiving	O	['N']	[1]
2	amifostine	B-Drug	['Causes']	[24]
3	who	O	['N']	[3]
4	develop	O	['N']	[4]
5	only	O	['N']	[5]
6	fever	O	['N']	[6]
7	should	O	['N']	[7]
8	be	O	['N']	[8]
9	evaluated	O	['N']	[9]
10	for	O	['N']	[10]
11	an	O	['N']	[11]
12	adverse	O	['N']	[12]
13	drug	O	['N']	[13]
14	reaction	O	['N']	[14]
15	,	O	['N']	[15]
16	as	O	['N']	[16]
17	well	O	['N']	[17]
18	as	O	['N']	[18]
19	for	O	['N']	[19]
20	sepsis	O	['N']	[20]
21	and	O	['N']	[21]
22	fevers	B	['N']	[22]
23	of	I	['N']	[23]
24	neutropenia	I-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	it	O	['N']	[27]
28	may	O	['N']	[28]
29	be	O	['N']	[29]
30	necessary	O	['N']	[30]
31	to	O	['N']	[31]
32	discontinue	O	['N']	[32]
33	the	O	['N']	[33]
34	drug	O	['N']	[34]
35	.	O	['N']	[35]
#2190
0	During	O	['N']	[0]
1	the	O	['N']	[1]
2	first	O	['N']	[2]
3	days	O	['N']	[3]
4	of	O	['N']	[4]
5	arsenic	B	['N']	[5]
6	trioxide	I-Drug	['Causes']	[35]
7	treatment	O	['N']	[7]
8	a	O	['N']	[8]
9	rapid	O	['N']	[9]
10	decrease	O	['N']	[10]
11	in	O	['N']	[11]
12	the	O	['N']	[12]
13	D	O	['N']	[13]
14	-	O	['N']	[14]
15	dimers	O	['N']	[15]
16	was	O	['N']	[16]
17	seen	O	['N']	[17]
18	(	O	['N']	[18]
19	normal	O	['N']	[19]
20	values	O	['N']	[20]
21	reached	O	['N']	[21]
22	until	O	['N']	[22]
23	day	O	['N']	[23]
24	7	O	['N']	[24]
25	)	O	['N']	[25]
26	,	O	['N']	[26]
27	together	O	['N']	[27]
28	with	O	['N']	[28]
29	a	O	['N']	[29]
30	slight	B	['N']	[30]
31	decrease	I	['N']	[31]
32	in	I	['N']	[32]
33	peripheral	I	['N']	[33]
34	blood	I	['N']	[34]
35	leukocytes	I-Adverse_Effect	['N']	[35]
36	.	O	['N']	[36]
#2191
0	Five	O	['N']	[0]
1	patients	O	['N']	[1]
2	are	O	['N']	[2]
3	described	O	['N']	[3]
4	in	O	['N']	[4]
5	whom	O	['N']	[5]
6	only	O	['N']	[6]
7	gentamicin	B	['N']	[7]
8	sulfate	I-Drug	['Causes']	[14]
9	appeared	O	['N']	[9]
10	responsible	O	['N']	[10]
11	for	O	['N']	[11]
12	acute	B	['N']	[12]
13	renal	I	['N']	[13]
14	failure	I-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#2192
0	A	O	['N']	[0]
1	49-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	Crohn	O	['N']	[6]
7	's	O	['N']	[7]
8	disease	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	prednisone	B-Drug	['Causes']	[20]
12	and	O	['N']	[12]
13	mesalamine	O	['N']	[13]
14	(	O	['N']	[14]
15	5-ASA	O	['N']	[15]
16	)	O	['N']	[16]
17	developed	O	['N']	[17]
18	worsening	B	['N']	[18]
19	respiratory	I	['N']	[19]
20	distress	I-Adverse_Effect	['N']	[20]
21	and	O	['N']	[21]
22	fever	O	['N']	[22]
23	.	O	['N']	[23]
#2193
0	Clinicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	fasting	B	['N']	[5]
6	hypoglycemia	I-Adverse_Effect	['N']	[6]
7	as	O	['N']	[7]
8	an	O	['N']	[8]
9	unusual	O	['N']	[9]
10	but	O	['N']	[10]
11	potentially	O	['N']	[11]
12	serious	O	['N']	[12]
13	complication	O	['N']	[13]
14	of	O	['N']	[14]
15	disopyramide	B-Drug	['Causes']	[6]
16	therapy	O	['N']	[16]
17	.	O	['N']	[17]
#2194
0	Painful	O	['N']	[0]
1	neutrophilic	B	['N']	[1]
2	skin	I	['N']	[2]
3	lesions	I-Adverse_Effect	['N']	[3]
4	were	O	['N']	[4]
5	observed	O	['N']	[5]
6	in	O	['N']	[6]
7	two	O	['N']	[7]
8	children	O	['N']	[8]
9	receiving	O	['N']	[9]
10	granulocyte	O	['N']	[10]
11	colony	O	['N']	[11]
12	-	O	['N']	[12]
13	stimulating	O	['N']	[13]
14	factor	O	['N']	[14]
15	(	O	['N']	[15]
16	G	B	['N']	[16]
17	-	I	['N']	[17]
18	CSF	I-Drug	['Causes']	[3]
19	)	O	['N']	[19]
20	for	O	['N']	[20]
21	treatment	O	['N']	[21]
22	of	O	['N']	[22]
23	idiopathic	O	['N']	[23]
24	neutropenia	O	['N']	[24]
25	.	O	['N']	[25]
#2195
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	Repeated	O	['N']	[2]
3	blood	O	['N']	[3]
4	samples	O	['N']	[4]
5	were	O	['N']	[5]
6	drawn	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	severe	O	['N']	[11]
12	acyclovir	B-Drug	['Causes']	[16]
13	overdose	O	['N']	[13]
14	who	O	['N']	[14]
15	developed	O	['N']	[15]
16	coma	B-Adverse_Effect	['N']	[16]
17	and	O	['N']	[17]
18	nonoliguric	O	['N']	[18]
19	renal	O	['N']	[19]
20	failure	O	['N']	[20]
21	.	O	['N']	[21]
#2196
0	Listeria	O	['N']	[0]
1	brain	O	['N']	[1]
2	abscess	O	['N']	[2]
3	,	O	['N']	[3]
4	Pneumocystis	O	['N']	[4]
5	pneumonia	O	['N']	[5]
6	and	O	['N']	[6]
7	Kaposi	B	['N']	[7]
8	's	I	['N']	[8]
9	sarcoma	I-Adverse_Effect	['N']	[9]
10	after	O	['N']	[10]
11	temozolomide	B-Drug	['Causes']	[9]
12	.	O	['N']	[12]
#2197
0	Restless	B	['N']	[0]
1	legs	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	periodic	O	['N']	[4]
5	limb	O	['N']	[5]
6	movements	O	['N']	[6]
7	during	O	['N']	[7]
8	sleep	O	['N']	[8]
9	probably	O	['N']	[9]
10	associated	O	['N']	[10]
11	with	O	['N']	[11]
12	olanzapine	B-Drug	['Causes']	[2]
13	.	O	['N']	[13]
#2198
0	Amiodarone	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	dysthyroidism	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#2199
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	two	O	['N']	[2]
3	children	O	['N']	[3]
4	with	O	['N']	[4]
5	acute	O	['N']	[5]
6	lymphocytic	O	['N']	[6]
7	leukemia	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	leukoencephalopathy	B-Adverse_Effect	['N']	[10]
11	following	O	['N']	[11]
12	administration	O	['N']	[12]
13	of	O	['N']	[13]
14	a	O	['N']	[14]
15	combination	O	['N']	[15]
16	of	O	['N']	[16]
17	intravenous	O	['N']	[17]
18	ara	O	['N']	[18]
19	=	O	['N']	[19]
20	C	O	['N']	[20]
21	and	O	['N']	[21]
22	methotrexate	B-Drug	['Causes']	[10]
23	during	O	['N']	[23]
24	the	O	['N']	[24]
25	consolidation	O	['N']	[25]
26	phase	O	['N']	[26]
27	of	O	['N']	[27]
28	chemotherapy	O	['N']	[28]
29	.	O	['N']	[29]
#2200
0	Prolonged	O	['N']	[0]
1	responses	O	['N']	[1]
2	were	O	['N']	[2]
3	achieved	O	['N']	[3]
4	with	O	['N']	[4]
5	low	O	['N']	[5]
6	doses	O	['N']	[6]
7	of	O	['N']	[7]
8	HU	B-Drug	['Causes']	[30]
9	(	O	['N']	[9]
10	3	O	['N']	[10]
11	-	O	['N']	[11]
12	10	O	['N']	[12]
13	mg	O	['N']	[13]
14	/	O	['N']	[14]
15	kg	O	['N']	[15]
16	/	O	['N']	[16]
17	day	O	['N']	[17]
18	)	O	['N']	[18]
19	and	O	['N']	[19]
20	higher	O	['N']	[20]
21	doses	O	['N']	[21]
22	were	O	['N']	[22]
23	associated	O	['N']	[23]
24	with	O	['N']	[24]
25	mild	O	['N']	[25]
26	reversible	O	['N']	[26]
27	hematologic	O	['N']	[27]
28	or	O	['N']	[28]
29	hepatic	B	['N']	[29]
30	toxicity	I-Adverse_Effect	['N']	[30]
31	and	O	['N']	[31]
32	no	O	['N']	[32]
33	further	O	['N']	[33]
34	increases	O	['N']	[34]
35	in	O	['N']	[35]
36	Hb	O	['N']	[36]
37	.	O	['N']	[37]
#2201
0	A	O	['N']	[0]
1	25-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	a	O	['N']	[6]
7	history	O	['N']	[7]
8	of	O	['N']	[8]
9	mid	O	['N']	[9]
10	-	O	['N']	[10]
11	borderline	O	['N']	[11]
12	(	O	['N']	[12]
13	BB	O	['N']	[13]
14	)	O	['N']	[14]
15	Hansen	O	['N']	[15]
16	's	O	['N']	[16]
17	disease	O	['N']	[17]
18	developing	O	['N']	[18]
19	a	O	['N']	[19]
20	reversal	B	['N']	[20]
21	reaction	I-Adverse_Effect	['N']	[21]
22	after	O	['N']	[22]
23	starting	O	['N']	[23]
24	dapsone	O	['N']	[24]
25	and	O	['N']	[25]
26	rifampin	B-Drug	['Causes']	[21]
27	therapy	O	['N']	[27]
28	is	O	['N']	[28]
29	presented	O	['N']	[29]
30	.	O	['N']	[30]
#2202
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	pulmonary	O	['N']	[5]
6	adenocarcinoma	O	['N']	[6]
7	complicated	O	['N']	[7]
8	by	O	['N']	[8]
9	the	O	['N']	[9]
10	syndrome	O	['N']	[10]
11	of	O	['N']	[11]
12	inappropriate	O	['N']	[12]
13	secretion	O	['N']	[13]
14	of	O	['N']	[14]
15	antidiuretic	O	['N']	[15]
16	hormone	O	['N']	[16]
17	(	O	['N']	[17]
18	SIADH	B-Adverse_Effect	['N']	[18]
19	)	O	['N']	[19]
20	following	O	['N']	[20]
21	systemic	O	['N']	[21]
22	chemotherapy	O	['N']	[22]
23	with	O	['N']	[23]
24	cisplatin	B-Drug	['Causes']	[18]
25	(	O	['N']	[25]
26	CDDP	O	['N']	[26]
27	)	O	['N']	[27]
28	and	O	['N']	[28]
29	vindesine	O	['N']	[29]
30	(	O	['N']	[30]
31	VDS	O	['N']	[31]
32	)	O	['N']	[32]
33	.	O	['N']	[33]
#2203
0	This	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	sequential	O	['N']	[3]
4	symptoms	O	['N']	[4]
5	including	O	['N']	[5]
6	alternative	O	['N']	[6]
7	hemiparesis	O	['N']	[7]
8	,	O	['N']	[8]
9	dysarthria	B-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	altered	O	['N']	[11]
12	consciousness	O	['N']	[12]
13	5	O	['N']	[13]
14	days	O	['N']	[14]
15	after	O	['N']	[15]
16	the	O	['N']	[16]
17	second	O	['N']	[17]
18	course	O	['N']	[18]
19	of	O	['N']	[19]
20	HD	B	['N']	[20]
21	-	I	['N']	[21]
22	MTX	I-Drug	['Causes']	[9]
23	(	O	['N']	[23]
24	8	O	['N']	[24]
25	gm	O	['N']	[25]
26	/	O	['N']	[26]
27	m2	O	['N']	[27]
28	by	O	['N']	[28]
29	6	O	['N']	[29]
30	h	O	['N']	[30]
31	continuous	O	['N']	[31]
32	infusion	O	['N']	[32]
33	)	O	['N']	[33]
34	with	O	['N']	[34]
35	leucovorin	O	['N']	[35]
36	rescue	O	['N']	[36]
37	.	O	['N']	[37]
#2204
0	Intravenous	O	['N']	[0]
1	sodium	O	['N']	[1]
2	bicarbonate	O	['N']	[2]
3	appears	O	['N']	[3]
4	to	O	['N']	[4]
5	be	O	['N']	[5]
6	indicated	O	['N']	[6]
7	prophylactically	O	['N']	[7]
8	in	O	['N']	[8]
9	combating	O	['N']	[9]
10	the	O	['N']	[10]
11	associated	O	['N']	[11]
12	metabolic	B	['N']	[12]
13	acidosis	I-Adverse_Effect	['N']	[13]
14	due	O	['N']	[14]
15	to	O	['N']	[15]
16	absorbed	O	['N']	[16]
17	formic	B	['N']	[17]
18	acid	I-Drug	['Causes']	[13]
19	.	O	['N']	[19]
#2205
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	There	O	['N']	[2]
3	was	O	['N']	[3]
4	a	O	['N']	[4]
5	temporal	O	['N']	[5]
6	relationship	O	['N']	[6]
7	between	O	['N']	[7]
8	the	O	['N']	[8]
9	onset	O	['N']	[9]
10	of	O	['N']	[10]
11	nonconvulsive	B	['N']	[11]
12	status	I	['N']	[12]
13	epilepticus	I-Adverse_Effect	['N']	[13]
14	and	O	['N']	[14]
15	initiation	O	['N']	[15]
16	of	O	['N']	[16]
17	ifosfamide	B-Drug	['Causes']	[13]
18	infusion	O	['N']	[18]
19	.	O	['N']	[19]
#2206
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Although	O	['N']	[2]
3	a	O	['N']	[3]
4	definite	O	['N']	[4]
5	association	O	['N']	[5]
6	has	O	['N']	[6]
7	not	O	['N']	[7]
8	been	O	['N']	[8]
9	proven	O	['N']	[9]
10	,	O	['N']	[10]
11	clinicians	O	['N']	[11]
12	should	O	['N']	[12]
13	be	O	['N']	[13]
14	aware	O	['N']	[14]
15	of	O	['N']	[15]
16	the	O	['N']	[16]
17	possibility	O	['N']	[17]
18	of	O	['N']	[18]
19	agranulocytosis	B-Adverse_Effect	['N']	[19]
20	while	O	['N']	[20]
21	using	O	['N']	[21]
22	quetiapine	B-Drug	['Causes']	[19]
23	.	O	['N']	[23]
#2207
0	Pamidronate	O	['N']	[0]
1	therapy	O	['N']	[1]
2	should	O	['N']	[2]
3	be	O	['N']	[3]
4	considered	O	['N']	[4]
5	in	O	['N']	[5]
6	patients	O	['N']	[6]
7	with	O	['N']	[7]
8	hypercalcemia	B-Adverse_Effect	['N']	[8]
9	secondary	O	['N']	[9]
10	to	O	['N']	[10]
11	acute	O	['N']	[11]
12	vitamin	B	['N']	[12]
13	D	I-Drug	['Causes']	[8]
14	poisoning	O	['N']	[14]
15	.	O	['N']	[15]
#2208
0	FSGS	B-Adverse_Effect	['N']	[0]
1	induced	O	['N']	[1]
2	by	O	['N']	[2]
3	Adriamycin	B-Drug	['Causes']	[0]
4	(	O	['N']	[4]
5	Pharmacia	O	['N']	[5]
6	&	O	['N']	[6]
7	Upjohn	O	['N']	[7]
8	,	O	['N']	[8]
9	Columbus	O	['N']	[9]
10	,	O	['N']	[10]
11	OH	O	['N']	[11]
12	)	O	['N']	[12]
13	has	O	['N']	[13]
14	been	O	['N']	[14]
15	observed	O	['N']	[15]
16	experimentally	O	['N']	[16]
17	in	O	['N']	[17]
18	rats	O	['N']	[18]
19	.	O	['N']	[19]
#2209
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	report	O	['N']	[2]
3	describes	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	was	O	['N']	[7]
8	previously	O	['N']	[8]
9	prescribed	O	['N']	[9]
10	alendronate	B-Drug	['Causes']	[21]
11	(	O	['N']	[11]
12	Fosamax	O	['N']	[12]
13	)	O	['N']	[13]
14	and	O	['N']	[14]
15	presented	O	['N']	[15]
16	with	O	['N']	[16]
17	postoperative	O	['N']	[17]
18	hypophosphatemia	O	['N']	[18]
19	and	O	['N']	[19]
20	hypocalcemic	B	['N']	[20]
21	tetany	I-Adverse_Effect	['N']	[21]
22	after	O	['N']	[22]
23	bowel	O	['N']	[23]
24	preparation	O	['N']	[24]
25	with	O	['N']	[25]
26	Fleet	O	['N']	[26]
27	Phospho	O	['N']	[27]
28	-	O	['N']	[28]
29	Soda	O	['N']	[29]
30	.	O	['N']	[30]
#2210
0	Despite	O	['N']	[0]
1	the	O	['N']	[1]
2	known	O	['N']	[2]
3	pulmonary	B	['N']	[3]
4	side	I	['N']	[4]
5	effects	I-Adverse_Effect	['N']	[5]
6	of	O	['N']	[6]
7	nitrofurantoin	B-Drug	['Causes']	[5]
8	,	O	['N']	[8]
9	there	O	['N']	[9]
10	is	O	['N']	[10]
11	no	O	['N']	[11]
12	report	O	['N']	[12]
13	of	O	['N']	[13]
14	this	O	['N']	[14]
15	toxicity	O	['N']	[15]
16	occurring	O	['N']	[16]
17	in	O	['N']	[17]
18	pregnant	O	['N']	[18]
19	patients	O	['N']	[19]
20	.	O	['N']	[20]
#2211
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	conclude	O	['N']	[3]
4	that	O	['N']	[4]
5	a	O	['N']	[5]
6	high	O	['N']	[6]
7	dose	O	['N']	[7]
8	combined	O	['N']	[8]
9	with	O	['N']	[9]
10	a	O	['N']	[10]
11	short	O	['N']	[11]
12	infusion	O	['N']	[12]
13	time	O	['N']	[13]
14	increases	O	['N']	[14]
15	the	O	['N']	[15]
16	risk	O	['N']	[16]
17	of	O	['N']	[17]
18	anaphylactoid	B	['N']	[18]
19	reactions	I-Adverse_Effect	['N']	[19]
20	with	O	['N']	[20]
21	the	O	['N']	[21]
22	administration	O	['N']	[22]
23	of	O	['N']	[23]
24	intraperitoneal	O	['N']	[24]
25	cisplatin	B-Drug	['Causes']	[19]
26	.	O	['N']	[26]
#2212
0	Myocardial	B	['N']	[0]
1	ischemia	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	high	O	['N']	[4]
5	-	O	['N']	[5]
6	dose	O	['N']	[6]
7	carmustine	B-Drug	['Causes']	[1]
8	infusion	O	['N']	[8]
9	.	O	['N']	[9]
#2213
0	Life	O	['N']	[0]
1	-	O	['N']	[1]
2	threatening	O	['N']	[2]
3	hyponatremia	B-Adverse_Effect	['N']	[3]
4	caused	O	['N']	[4]
5	by	O	['N']	[5]
6	vinblastine	B-Drug	['Causes']	[3]
7	.	O	['N']	[7]
#2214
0	Mechanism	O	['N']	[0]
1	of	O	['N']	[1]
2	topiramate	B-Drug	['Causes']	[8]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	acute	B	['N']	[5]
6	-	I	['N']	[6]
7	onset	I	['N']	[7]
8	myopia	I-Adverse_Effect	['N']	[8]
9	and	O	['N']	[9]
10	angle	O	['N']	[10]
11	closure	O	['N']	[11]
12	glaucoma	O	['N']	[12]
13	.	O	['N']	[13]
#2215
0	INTERVENTIONS	O	['N']	[0]
1	AND	O	['N']	[1]
2	RESULTS	O	['N']	[2]
3	:	O	['N']	[3]
4	Cardiac	B	['N']	[4]
5	complications	I-Adverse_Effect	['N']	[5]
6	were	O	['N']	[6]
7	observed	O	['N']	[7]
8	in	O	['N']	[8]
9	five	O	['N']	[9]
10	pediatric	O	['N']	[10]
11	patients	O	['N']	[11]
12	who	O	['N']	[12]
13	received	O	['N']	[13]
14	between	O	['N']	[14]
15	4.6	O	['N']	[15]
16	and	O	['N']	[16]
17	40.8	O	['N']	[17]
18	mg	O	['N']	[18]
19	/	O	['N']	[19]
20	kg	O	['N']	[20]
21	/	O	['N']	[21]
22	d	O	['N']	[22]
23	of	O	['N']	[23]
24	amphotericin	-	['N']	[24]
25	B.	-	['N']	[25]
#2216
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	woman	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	photo	B	['N']	[9]
10	-	I	['N']	[10]
11	onycholysis	I-Adverse_Effect	['N']	[11]
12	on	O	['N']	[12]
13	multiple	O	['N']	[13]
14	nails	O	['N']	[14]
15	after	O	['N']	[15]
16	uptake	O	['N']	[16]
17	of	O	['N']	[17]
18	olanzapine	B-Drug	['Causes']	[11]
19	.	O	['N']	[19]
#2217
0	Conventional	O	['N']	[0]
1	and	O	['N']	[1]
2	diffusion	O	['N']	[2]
3	-	O	['N']	[3]
4	weighted	O	['N']	[4]
5	MRI	O	['N']	[5]
6	findings	O	['N']	[6]
7	of	O	['N']	[7]
8	methotrexate	B-Drug	['Causes']	[13]
9	related	O	['N']	[9]
10	sub	B	['N']	[10]
11	-	I	['N']	[11]
12	acute	I	['N']	[12]
13	neurotoxicity	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#2218
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	acute	O	['N']	[5]
6	myeloblastic	O	['N']	[6]
7	leukemia	O	['N']	[7]
8	(	O	['N']	[8]
9	AML	O	['N']	[9]
10	)	O	['N']	[10]
11	who	O	['N']	[11]
12	developed	O	['N']	[12]
13	nephrotic	B	['N']	[13]
14	syndrome	I-Adverse_Effect	['N']	[14]
15	after	O	['N']	[15]
16	receiving	O	['N']	[16]
17	several	O	['N']	[17]
18	courses	O	['N']	[18]
19	of	O	['N']	[19]
20	chemotherapy	O	['N']	[20]
21	,	O	['N']	[21]
22	including	O	['N']	[22]
23	macrophage	O	['N']	[23]
24	-	O	['N']	[24]
25	colony	O	['N']	[25]
26	-	O	['N']	[26]
27	stimulating	O	['N']	[27]
28	factor	O	['N']	[28]
29	(	O	['N']	[29]
30	M	B	['N']	[30]
31	-	I	['N']	[31]
32	CSF	I-Drug	['Causes']	[14]
33	)	O	['N']	[33]
34	.	O	['N']	[34]
#2219
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	skin	O	['N']	[23]
24	eruptions	O	['N']	[24]
25	,	O	['N']	[25]
26	cervical	O	['N']	[26]
27	lymphadenopathy	O	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	O	['N']	[31]
32	lymphocytosis	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	B-Adverse_Effect	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	O	['N']	[40]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	-	['N']	[42]
43	(	O	['N']	[43]
44	SMX	O	['N']	[44]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#2220
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Gemcitabine	B-Drug	['Causes']	[19]
3	has	O	['N']	[3]
4	mild	O	['N']	[4]
5	renal	O	['N']	[5]
6	toxicity	O	['N']	[6]
7	,	O	['N']	[7]
8	but	O	['N']	[8]
9	cases	O	['N']	[9]
10	of	O	['N']	[10]
11	gemcitabine	O	['N']	[11]
12	-	O	['N']	[12]
13	associated	O	['N']	[13]
14	hemolytic	O	['N']	[14]
15	-	O	['N']	[15]
16	uremic	O	['N']	[16]
17	syndrome	O	['N']	[17]
18	(	O	['N']	[18]
19	HUS	B-Adverse_Effect	['N']	[19]
20	)	O	['N']	[20]
21	have	O	['N']	[21]
22	been	O	['N']	[22]
23	reported	O	['N']	[23]
24	.	O	['N']	[24]
#2221
0	Prolonged	O	['N']	[0]
1	responses	O	['N']	[1]
2	were	O	['N']	[2]
3	achieved	O	['N']	[3]
4	with	O	['N']	[4]
5	low	O	['N']	[5]
6	doses	O	['N']	[6]
7	of	O	['N']	[7]
8	HU	B-Drug	['Causes']	[27]
9	(	O	['N']	[9]
10	3	O	['N']	[10]
11	-	O	['N']	[11]
12	10	O	['N']	[12]
13	mg	O	['N']	[13]
14	/	O	['N']	[14]
15	kg	O	['N']	[15]
16	/	O	['N']	[16]
17	day	O	['N']	[17]
18	)	O	['N']	[18]
19	and	O	['N']	[19]
20	higher	O	['N']	[20]
21	doses	O	['N']	[21]
22	were	O	['N']	[22]
23	associated	O	['N']	[23]
24	with	O	['N']	[24]
25	mild	B	['N']	[25]
26	reversible	I	['N']	[26]
27	hematologic	I-Adverse_Effect	['N']	[27]
28	or	O	['N']	[28]
29	hepatic	O	['N']	[29]
30	toxicity	O	['N']	[30]
31	and	O	['N']	[31]
32	no	O	['N']	[32]
33	further	O	['N']	[33]
34	increases	O	['N']	[34]
35	in	O	['N']	[35]
36	Hb	O	['N']	[36]
37	.	O	['N']	[37]
#2222
0	Can	O	['N']	[0]
1	magnesium	B	['N']	[1]
2	sulfate	I-Drug	['Causes']	[5]
3	therapy	O	['N']	[3]
4	impact	O	['N']	[4]
5	lactogenesis	B-Adverse_Effect	['N']	[5]
6	?	O	['N']	[6]
#2223
0	In	O	['N']	[0]
1	rare	O	['N']	[1]
2	cases	O	['N']	[2]
3	mitomycin	B	['N']	[3]
4	C	I-Drug	['Causes']	[22]
5	(	O	['N']	[5]
6	MMC	O	['N']	[6]
7	)	O	['N']	[7]
8	may	O	['N']	[8]
9	induce	O	['N']	[9]
10	cancer	O	['N']	[10]
11	-	O	['N']	[11]
12	associated	O	['N']	[12]
13	hemolytic	O	['N']	[13]
14	uremic	O	['N']	[14]
15	syndrome	O	['N']	[15]
16	,	O	['N']	[16]
17	which	O	['N']	[17]
18	is	O	['N']	[18]
19	characterized	O	['N']	[19]
20	by	O	['N']	[20]
21	hemolytic	B	['N']	[21]
22	anemia	I-Adverse_Effect	['N']	[22]
23	,	O	['N']	[23]
24	thrombocytopenia	O	['N']	[24]
25	and	O	['N']	[25]
26	progressive	O	['N']	[26]
27	renal	O	['N']	[27]
28	failure	O	['N']	[28]
29	.	O	['N']	[29]
#2224
0	The	O	['N']	[0]
1	development	O	['N']	[1]
2	of	O	['N']	[2]
3	an	O	['N']	[3]
4	IgG	B	['N']	[4]
5	lambda	I	['N']	[5]
6	-	I	['N']	[6]
7	type	I	['N']	[7]
8	monoclonal	I	['N']	[8]
9	gammopathy	I-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	subsequent	O	['N']	[11]
12	multiple	O	['N']	[12]
13	myeloma	O	['N']	[13]
14	in	O	['N']	[14]
15	an	O	['N']	[15]
16	epilepsy	O	['N']	[16]
17	patient	O	['N']	[17]
18	on	O	['N']	[18]
19	diphenylhydantoin	B-Drug	['Causes']	[9]
20	(	O	['N']	[20]
21	DILANTIN	O	['N']	[21]
22	)	O	['N']	[22]
23	therapy	O	['N']	[23]
24	for	O	['N']	[24]
25	20	O	['N']	[25]
26	years	O	['N']	[26]
27	is	O	['N']	[27]
28	reported	O	['N']	[28]
29	.	O	['N']	[29]
#2225
0	Acute	B	['N']	[0]
1	myocardial	I	['N']	[1]
2	ischemia	I-Adverse_Effect	['N']	[2]
3	following	O	['N']	[3]
4	accidental	O	['N']	[4]
5	intravenous	O	['N']	[5]
6	administration	O	['N']	[6]
7	of	O	['N']	[7]
8	epinephrine	B-Drug	['Causes']	[2]
9	in	O	['N']	[9]
10	high	O	['N']	[10]
11	concentration	O	['N']	[11]
12	.	O	['N']	[12]
#2226
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	acute	O	['N']	[6]
7	kidney	O	['N']	[7]
8	injury	O	['N']	[8]
9	due	O	['N']	[9]
10	to	O	['N']	[10]
11	zonisamide	B-Drug	['Causes']	[16]
12	-	O	['N']	[12]
13	induced	O	['N']	[13]
14	DRESS	O	['N']	[14]
15	/	O	['N']	[15]
16	DIHS	B-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#2227
0	A	O	['N']	[0]
1	second	O	['N']	[1]
2	possibility	O	['N']	[2]
3	is	O	['N']	[3]
4	an	O	['N']	[4]
5	interaction	O	['N']	[5]
6	between	O	['N']	[6]
7	clarithromycin	O	['N']	[7]
8	and	O	['N']	[8]
9	isradipine	B-Drug	['Causes']	[15]
10	,	O	['N']	[10]
11	potentially	O	['N']	[11]
12	increasing	B	['N']	[12]
13	the	I	['N']	[13]
14	hepatic	I	['N']	[14]
15	toxicity	I-Adverse_Effect	['N']	[15]
16	of	O	['N']	[16]
17	isradipine	O	['N']	[17]
18	.	O	['N']	[18]
#2228
0	The	O	['N']	[0]
1	reported	O	['N']	[1]
2	cases	O	['N']	[2]
3	of	O	['N']	[3]
4	in	O	['N']	[4]
5	utero	O	['N']	[5]
6	exposure	O	['N']	[6]
7	to	O	['N']	[7]
8	cyclosposphamide	B-Drug	['Causes']	[29]
9	shared	O	['N']	[9]
10	the	O	['N']	[10]
11	following	O	['N']	[11]
12	manifestations	O	['N']	[12]
13	with	O	['N']	[13]
14	our	O	['N']	[14]
15	patient	O	['N']	[15]
16	:	O	['N']	[16]
17	growth	O	['N']	[17]
18	deficiency	O	['N']	[18]
19	,	O	['N']	[19]
20	developmental	O	['N']	[20]
21	delay	O	['N']	[21]
22	,	O	['N']	[22]
23	craniosynostosis	O	['N']	[23]
24	,	O	['N']	[24]
25	blepharophimosis	O	['N']	[25]
26	,	O	['N']	[26]
27	flat	B	['N']	[27]
28	nasal	I	['N']	[28]
29	bridge	I-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	abnormal	O	['N']	[31]
32	ears	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	distal	O	['N']	[35]
36	limb	O	['N']	[36]
37	defects	O	['N']	[37]
38	including	O	['N']	[38]
39	hypoplastic	O	['N']	[39]
40	thumbs	O	['N']	[40]
41	and	O	['N']	[41]
42	oligodactyly	O	['N']	[42]
43	.	O	['N']	[43]
#2229
0	Systemic	B	['N']	[0]
1	capillary	I	['N']	[1]
2	leak	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	granulocyte	B	['N']	[5]
6	colony	I	['N']	[6]
7	-	I	['N']	[7]
8	stimulating	I	['N']	[8]
9	factor	I-Drug	['Causes']	[3]
10	(	O	['N']	[10]
11	G	O	['N']	[11]
12	-	O	['N']	[12]
13	CSF	O	['N']	[13]
14	)	O	['N']	[14]
15	.	O	['N']	[15]
#2230
0	Overdose	O	['N']	[0]
1	of	O	['N']	[1]
2	magnesium	B	['N']	[2]
3	sulfate	I-Drug	['Causes']	[22]
4	in	O	['N']	[4]
5	combination	O	['N']	[5]
6	with	O	['N']	[6]
7	renal	O	['N']	[7]
8	insufficiency	O	['N']	[8]
9	,	O	['N']	[9]
10	hypocalcemia	O	['N']	[10]
11	,	O	['N']	[11]
12	or	O	['N']	[12]
13	compromise	O	['N']	[13]
14	of	O	['N']	[14]
15	intestinal	O	['N']	[15]
16	integrity	O	['N']	[16]
17	may	O	['N']	[17]
18	predispose	O	['N']	[18]
19	horses	O	['N']	[19]
20	to	O	['N']	[20]
21	magnesium	B	['N']	[21]
22	toxicosis	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#2231
0	Polyarthritis	B-Adverse_Effect	['N']	[0]
1	,	O	['N']	[1]
2	hepatitis	O	['N']	[2]
3	and	O	['N']	[3]
4	anti	O	['N']	[4]
5	-	O	['N']	[5]
6	native	O	['N']	[6]
7	DNA	O	['N']	[7]
8	antibodies	O	['N']	[8]
9	after	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	ethambutol	B-Drug	['Causes']	[0]
13	and	O	['N']	[13]
14	rifampicin	O	['N']	[14]
15	.	O	['N']	[15]
#2232
0	Chlorambucil	B-Drug	['Causes']	[3]
1	central	B	['N']	[1]
2	nervous	I	['N']	[2]
3	toxicity	I-Adverse_Effect	['N']	[3]
4	:	O	['N']	[4]
5	a	O	['N']	[5]
6	significant	O	['N']	[6]
7	side	O	['N']	[7]
8	effect	O	['N']	[8]
9	of	O	['N']	[9]
10	chlorambucil	O	['N']	[10]
11	therapy	O	['N']	[11]
12	in	O	['N']	[12]
13	childhood	O	['N']	[13]
14	nephrotic	O	['N']	[14]
15	syndrome	O	['N']	[15]
16	.	O	['N']	[16]
#2233
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	pulmonary	O	['N']	[8]
9	hypertension	O	['N']	[9]
10	and	O	['N']	[10]
11	undifferentiated	O	['N']	[11]
12	connective	O	['N']	[12]
13	tissue	O	['N']	[13]
14	disease	O	['N']	[14]
15	who	O	['N']	[15]
16	,	O	['N']	[16]
17	after	O	['N']	[17]
18	2	O	['N']	[18]
19	months	O	['N']	[19]
20	of	O	['N']	[20]
21	treatment	O	['N']	[21]
22	with	O	['N']	[22]
23	epoprostenol	B-Drug	['Causes']	[31]
24	,	O	['N']	[24]
25	presented	O	['N']	[25]
26	with	O	['N']	[26]
27	rapidly	O	['N']	[27]
28	progressive	O	['N']	[28]
29	erythema	O	['N']	[29]
30	,	O	['N']	[30]
31	scaling	B-Adverse_Effect	['N']	[31]
32	,	O	['N']	[32]
33	nausea	O	['N']	[33]
34	and	O	['N']	[34]
35	vomiting	O	['N']	[35]
36	,	O	['N']	[36]
37	and	O	['N']	[37]
38	fever	O	['N']	[38]
39	.	O	['N']	[39]
#2234
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	48-year	O	['N']	[5]
6	-	O	['N']	[6]
7	old	O	['N']	[7]
8	woman	O	['N']	[8]
9	with	O	['N']	[9]
10	seizure	O	['N']	[10]
11	disorder	O	['N']	[11]
12	on	O	['N']	[12]
13	divalproex	O	['N']	[13]
14	sodium	O	['N']	[14]
15	(	O	['N']	[15]
16	Depakote	B-Drug	['Causes']	[21]
17	)	O	['N']	[17]
18	who	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	dyspnea	B-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#2235
0	Hemodialysis	O	['N']	[0]
1	was	O	['N']	[1]
2	also	O	['N']	[2]
3	shown	O	['N']	[3]
4	to	O	['N']	[4]
5	reverse	O	['N']	[5]
6	ifosfamide	B-Drug	['Causes']	[9]
7	-	O	['N']	[7]
8	related	O	['N']	[8]
9	neurotoxicity	B-Adverse_Effect	['N']	[9]
10	.	O	['N']	[10]
#2236
0	A	O	['N']	[0]
1	61-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	early	O	['N']	[6]
7	diffuse	O	['N']	[7]
8	cutaneous	O	['N']	[8]
9	scleroderma	O	['N']	[9]
10	with	O	['N']	[10]
11	myositis	O	['N']	[11]
12	and	O	['N']	[12]
13	progressive	O	['N']	[13]
14	interstitial	O	['N']	[14]
15	pneumonia	O	['N']	[15]
16	developed	O	['N']	[16]
17	generalized	B	['N']	[17]
18	erythema	I-Adverse_Effect	['N']	[18]
19	with	O	['N']	[19]
20	high	O	['N']	[20]
21	fever	O	['N']	[21]
22	3	O	['N']	[22]
23	weeks	O	['N']	[23]
24	after	O	['N']	[24]
25	taking	O	['N']	[25]
26	sulfamethoxazole	B-Drug	['Causes']	[18]
27	/	O	['N']	[27]
28	trimethoprim	O	['N']	[28]
29	.	O	['N']	[29]
#2237
0	This	O	['N']	[0]
1	paper	O	['N']	[1]
2	reports	O	['N']	[2]
3	an	O	['N']	[3]
4	autopsy	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	78-year	O	['N']	[8]
9	-	O	['N']	[9]
10	old	O	['N']	[10]
11	male	O	['N']	[11]
12	with	O	['N']	[12]
13	multiple	B	['N']	[13]
14	nodules	I	['N']	[14]
15	in	I	['N']	[15]
16	the	I	['N']	[16]
17	liver	I-Adverse_Effect	['N']	[17]
18	developed	O	['N']	[18]
19	after	O	['N']	[19]
20	long	O	['N']	[20]
21	-	O	['N']	[21]
22	termed	O	['N']	[22]
23	administration	O	['N']	[23]
24	of	O	['N']	[24]
25	phosphate	B	['N']	[25]
26	diethylstilbestrol	I-Drug	['Causes']	[17]
27	(	O	['N']	[27]
28	PDES	O	['N']	[28]
29	)	O	['N']	[29]
30	for	O	['N']	[30]
31	prostatic	O	['N']	[31]
32	cancer	O	['N']	[32]
33	.	O	['N']	[33]
#2238
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	presents	O	['N']	[2]
3	a	O	['N']	[3]
4	potential	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	risperidone	B-Drug	['Causes']	[11]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	tardive	B	['N']	[10]
11	dyskinesia	I-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#2239
0	Two	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	lepromatous	O	['N']	[3]
4	leprosy	O	['N']	[4]
5	with	O	['N']	[5]
6	erythema	O	['N']	[6]
7	nodosum	O	['N']	[7]
8	leprosum	O	['N']	[8]
9	who	O	['N']	[9]
10	were	O	['N']	[10]
11	on	O	['N']	[11]
12	high	O	['N']	[12]
13	doses	O	['N']	[13]
14	of	O	['N']	[14]
15	clofazimine	B-Drug	['Causes']	[21]
16	,	O	['N']	[16]
17	showed	O	['N']	[17]
18	discoloration	B	['N']	[18]
19	of	I	['N']	[19]
20	nail	I	['N']	[20]
21	plate	I-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	subungual	O	['N']	[23]
24	hyperkeratosis	O	['N']	[24]
25	and	O	['N']	[25]
26	onycholysis	O	['N']	[26]
27	.	O	['N']	[27]
#2240
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	hepatolithiasis	B-Adverse_Effect	['N']	[5]
6	(	O	['N']	[6]
7	intrahepatic	O	['N']	[7]
8	stone	O	['N']	[8]
9	)	O	['N']	[9]
10	complicated	O	['N']	[10]
11	by	O	['N']	[11]
12	gram	O	['N']	[12]
13	-	O	['N']	[13]
14	negative	O	['N']	[14]
15	sepsis	O	['N']	[15]
16	in	O	['N']	[16]
17	a	O	['N']	[17]
18	37	O	['N']	[18]
19	year	O	['N']	[19]
20	old	O	['N']	[20]
21	male	O	['N']	[21]
22	with	O	['N']	[22]
23	acromegaly	O	['N']	[23]
24	being	O	['N']	[24]
25	treated	O	['N']	[25]
26	with	O	['N']	[26]
27	octreotide	B-Drug	['Causes']	[5]
28	.	O	['N']	[28]
#2241
0	Thrombocytopenia	O	['N']	[0]
1	with	O	['N']	[1]
2	or	O	['N']	[2]
3	without	O	['N']	[3]
4	microangiopathy	O	['N']	[4]
5	following	O	['N']	[5]
6	quinine	B-Drug	['Causes']	[31]
7	is	O	['N']	[7]
8	often	O	['N']	[8]
9	referred	O	['N']	[9]
10	to	O	['N']	[10]
11	as	O	['N']	[11]
12	quinine	O	['N']	[12]
13	"	O	['N']	[13]
14	hypersensitivity	O	['N']	[14]
15	.	O	['N']	[15]
16	"	O	['N']	[16]
17	When	O	['N']	[17]
18	schistocytes	O	['N']	[18]
19	are	O	['N']	[19]
20	present	O	['N']	[20]
21	it	O	['N']	[21]
22	is	O	['N']	[22]
23	frequently	O	['N']	[23]
24	termed	O	['N']	[24]
25	"	O	['N']	[25]
26	quinine	O	['N']	[26]
27	-	O	['N']	[27]
28	associated	O	['N']	[28]
29	TTP	B	['N']	[29]
30	/	I	['N']	[30]
31	HUS	I-Adverse_Effect	['N']	[31]
32	.	O	['N']	[32]
33	"	O	['N']	[33]
34	A	O	['N']	[34]
35	severe	O	['N']	[35]
36	deficiency	O	['N']	[36]
37	of	O	['N']	[37]
38	the	O	['N']	[38]
39	vWF	O	['N']	[39]
40	-	O	['N']	[40]
41	cleaving	O	['N']	[41]
42	protease	O	['N']	[42]
43	,	O	['N']	[43]
44	ADAMTS13	O	['N']	[44]
45	,	O	['N']	[45]
46	is	O	['N']	[46]
47	associated	O	['N']	[47]
48	with	O	['N']	[48]
49	idiopathic	O	['N']	[49]
50	TTP	O	['N']	[50]
51	.	O	['N']	[51]
#2242
0	The	O	['N']	[0]
1	toxicity	B-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	plasma	O	['N']	[3]
4	concentrations	O	['N']	[4]
5	of	O	['N']	[5]
6	ifosfamide	B-Drug	['Causes']	[1]
7	,	O	['N']	[7]
8	chloroacetaldehyde	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	4-hydroxyifosfamide	O	['N']	[11]
12	were	O	['N']	[12]
13	then	O	['N']	[13]
14	determined	O	['N']	[14]
15	over	O	['N']	[15]
16	24	O	['N']	[16]
17	h	O	['N']	[17]
18	after	O	['N']	[18]
19	a	O	['N']	[19]
20	single	O	['N']	[20]
21	1.6	O	['N']	[21]
22	g	O	['N']	[22]
23	/	O	['N']	[23]
24	m2	O	['N']	[24]
25	dose	O	['N']	[25]
26	of	O	['N']	[26]
27	ifosfamide	O	['N']	[27]
28	.	O	['N']	[28]
#2243
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Priapism	B-Adverse_Effect	['N']	[2]
3	is	O	['N']	[3]
4	an	O	['N']	[4]
5	uncommon	O	['N']	[5]
6	but	O	['N']	[6]
7	potentially	O	['N']	[7]
8	serious	O	['N']	[8]
9	adverse	O	['N']	[9]
10	effect	O	['N']	[10]
11	of	O	['N']	[11]
12	zuclopenthixol	B-Drug	['Causes']	[2]
13	that	O	['N']	[13]
14	practitioners	O	['N']	[14]
15	,	O	['N']	[15]
16	as	O	['N']	[16]
17	with	O	['N']	[17]
18	many	O	['N']	[18]
19	other	O	['N']	[19]
20	antipsychotics	O	['N']	[20]
21	,	O	['N']	[21]
22	should	O	['N']	[22]
23	be	O	['N']	[23]
24	aware	O	['N']	[24]
25	of	O	['N']	[25]
26	.	O	['N']	[26]
#2244
0	Administration	O	['N']	[0]
1	of	O	['N']	[1]
2	sumatriptan	B-Drug	['Causes']	[20]
3	in	O	['N']	[3]
4	subarachnoid	O	['N']	[4]
5	haemorrhage	O	['N']	[5]
6	(	O	['N']	[6]
7	SAH	O	['N']	[7]
8	)	O	['N']	[8]
9	patients	O	['N']	[9]
10	,	O	['N']	[10]
11	misdiagnosed	O	['N']	[11]
12	as	O	['N']	[12]
13	migraine	O	['N']	[13]
14	patients	O	['N']	[14]
15	,	O	['N']	[15]
16	may	O	['N']	[16]
17	induce	O	['N']	[17]
18	symptomatic	B	['N']	[18]
19	cerebral	I	['N']	[19]
20	vasospasm	I-Adverse_Effect	['N']	[20]
21	with	O	['N']	[21]
22	potentially	O	['N']	[22]
23	dangerous	O	['N']	[23]
24	consequences	O	['N']	[24]
25	.	O	['N']	[25]
#2245
0	Rapamycin	O	['N']	[0]
1	/	O	['N']	[1]
2	sirolimus	B-Drug	['Causes']	[34]
3	(	O	['N']	[3]
4	SR	O	['N']	[4]
5	)	O	['N']	[5]
6	,	O	['N']	[6]
7	trade	O	['N']	[7]
8	named	O	['N']	[8]
9	Rapammune	O	['N']	[9]
10	(	O	['N']	[10]
11	Wyeth	O	['N']	[11]
12	-	O	['N']	[12]
13	Ayerst	O	['N']	[13]
14	,	O	['N']	[14]
15	Sydney	O	['N']	[15]
16	,	O	['N']	[16]
17	Australia	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	is	O	['N']	[20]
21	a	O	['N']	[21]
22	potent	O	['N']	[22]
23	immunosuppressive	O	['N']	[23]
24	drug	O	['N']	[24]
25	associated	O	['N']	[25]
26	with	O	['N']	[26]
27	myelosuppression	O	['N']	[27]
28	,	O	['N']	[28]
29	hypertension	O	['N']	[29]
30	,	O	['N']	[30]
31	hyperlipidemia	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	infection	B-Adverse_Effect	['N']	[34]
35	.	O	['N']	[35]
#2246
0	Eighty	O	['N']	[0]
1	-	O	['N']	[1]
2	two	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	various	O	['N']	[5]
6	malignancies	O	['N']	[6]
7	who	O	['N']	[7]
8	received	O	['N']	[8]
9	imipenem	B-Drug	['Causes']	[16]
10	/	O	['N']	[10]
11	cilastatin	O	['N']	[11]
12	143	O	['N']	[12]
13	times	O	['N']	[13]
14	for	O	['N']	[14]
15	neutropenic	B	['N']	[15]
16	fever	I-Adverse_Effect	['N']	[16]
17	between	O	['N']	[17]
18	March	O	['N']	[18]
19	1994	O	['N']	[19]
20	and	O	['N']	[20]
21	October	O	['N']	[21]
22	1999	O	['N']	[22]
23	in	O	['N']	[23]
24	Department	O	['N']	[24]
25	of	O	['N']	[25]
26	Pediatric	O	['N']	[26]
27	Oncology	O	['N']	[27]
28	,	O	['N']	[28]
29	Gazi	O	['N']	[29]
30	University	O	['N']	[30]
31	,	O	['N']	[31]
32	were	O	['N']	[32]
33	identified	O	['N']	[33]
34	.	O	['N']	[34]
#2247
0	Infectious	B	['N']	[0]
1	toxicity	I-Adverse_Effect	['N']	[1]
2	of	O	['N']	[2]
3	dexamethasone	B-Drug	['Causes']	[1]
4	during	O	['N']	[4]
5	all	O	['N']	[5]
6	remission	O	['N']	[6]
7	-	O	['N']	[7]
8	induction	O	['N']	[8]
9	chemotherapy	O	['N']	[9]
10	:	O	['N']	[10]
11	report	O	['N']	[11]
12	of	O	['N']	[12]
13	two	O	['N']	[13]
14	cases	O	['N']	[14]
15	and	O	['N']	[15]
16	literature	O	['N']	[16]
17	review	O	['N']	[17]
18	.	O	['N']	[18]
#2248
0	Nicotinic	B	['N']	[0]
1	acid	I-Drug	['Causes']	[6]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	fulminant	B	['N']	[4]
5	hepatic	I	['N']	[5]
6	failure	I-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#2249
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	in	O	['N']	[4]
5	which	O	['N']	[5]
6	hemorrhage	O	['N']	[6]
7	occurred	O	['N']	[7]
8	in	O	['N']	[8]
9	an	O	['N']	[9]
10	asymptomatic	O	['N']	[10]
11	falx	O	['N']	[11]
12	meningioma	O	['N']	[12]
13	known	O	['N']	[13]
14	beforehand	O	['N']	[14]
15	,	O	['N']	[15]
16	after	O	['N']	[16]
17	the	O	['N']	[17]
18	internal	O	['N']	[18]
19	use	O	['N']	[19]
20	of	O	['N']	[20]
21	low	B	['N']	[21]
22	-	I	['N']	[22]
23	dose	I-Dose	['N']	[23]
24	aspirin	B-Drug	['Dosage']	[23]
25	for	O	['N']	[25]
26	16	O	['N']	[26]
27	months	O	['N']	[27]
28	.	O	['N']	[28]
#2250
0	A	O	['N']	[0]
1	17-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	with	O	['N']	[5]
6	acute	O	['N']	[6]
7	lymphoblastic	O	['N']	[7]
8	leukemia	O	['N']	[8]
9	developed	O	['N']	[9]
10	acute	O	['N']	[10]
11	renal	O	['N']	[11]
12	failure	O	['N']	[12]
13	within	O	['N']	[13]
14	48	O	['N']	[14]
15	h	O	['N']	[15]
16	of	O	['N']	[16]
17	an	O	['N']	[17]
18	intravenous	O	['N']	[18]
19	high	O	['N']	[19]
20	-	O	['N']	[20]
21	dose	O	['N']	[21]
22	methotrexate	B-Drug	['Dosage']	[27]
23	(	O	['N']	[23]
24	5	B	['N']	[24]
25	g	I	['N']	[25]
26	/	I	['N']	[26]
27	m2	I-Dose	['N']	[27]
28	)	O	['N']	[28]
29	infusion	O	['N']	[29]
30	.	O	['N']	[30]
#2251
0	SUBSEQUENT	O	['N']	[0]
1	COURSE	O	['N']	[1]
2	:	O	['N']	[2]
3	The	O	['N']	[3]
4	nephrosis	B-Adverse_Effect	['N']	[4]
5	resolved	O	['N']	[5]
6	almost	O	['N']	[6]
7	completely	O	['N']	[7]
8	once	O	['N']	[8]
9	the	O	['N']	[9]
10	interferon	B-Drug	['Causes']	[4]
11	was	O	['N']	[11]
12	stopped	O	['N']	[12]
13	and	O	['N']	[13]
14	after	O	['N']	[14]
15	immunosuppressive	O	['N']	[15]
16	treatment	O	['N']	[16]
17	.	O	['N']	[17]
#2252
0	A	O	['N']	[0]
1	cause	O	['N']	[1]
2	-	O	['N']	[2]
3	effect	O	['N']	[3]
4	relationship	O	['N']	[4]
5	to	O	['N']	[5]
6	capecitabine	B-Drug	['Causes']	[13]
7	was	O	['N']	[7]
8	suggested	O	['N']	[8]
9	due	O	['N']	[9]
10	to	O	['N']	[10]
11	resolution	O	['N']	[11]
12	of	O	['N']	[12]
13	headache	B-Adverse_Effect	['N']	[13]
14	with	O	['N']	[14]
15	capecitabine	O	['N']	[15]
16	withdrawal	O	['N']	[16]
17	and	O	['N']	[17]
18	reappearance	O	['N']	[18]
19	with	O	['N']	[19]
20	capecitabine	O	['N']	[20]
21	rechallenge	O	['N']	[21]
22	.	O	['N']	[22]
#2253
0	Abrupt	O	['N']	[0]
1	,	O	['N']	[1]
2	accidental	O	['N']	[2]
3	withdrawal	O	['N']	[3]
4	of	O	['N']	[4]
5	trihexyphenidyl	B-Drug	['Causes']	[12]
6	triggered	O	['N']	[6]
7	severe	O	['N']	[7]
8	exacerbation	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	cranial	B	['N']	[11]
12	dystonia	I-Adverse_Effect	['N']	[12]
13	associated	O	['N']	[13]
14	with	O	['N']	[14]
15	inspiratory	O	['N']	[15]
16	stridor	O	['N']	[16]
17	and	O	['N']	[17]
18	acute	O	['N']	[18]
19	respiratory	O	['N']	[19]
20	difficulties	O	['N']	[20]
21	,	O	['N']	[21]
22	prompting	O	['N']	[22]
23	emergency	O	['N']	[23]
24	admission	O	['N']	[24]
25	.	O	['N']	[25]
#2254
0	CASE	O	['N']	[0]
1	REPORT	O	['N']	[1]
2	:	O	['N']	[2]
3	We	O	['N']	[3]
4	describe	O	['N']	[4]
5	here	O	['N']	[5]
6	a	O	['N']	[6]
7	case	O	['N']	[7]
8	of	O	['N']	[8]
9	a	O	['N']	[9]
10	60	O	['N']	[10]
11	year	O	['N']	[11]
12	old	O	['N']	[12]
13	female	O	['N']	[13]
14	that	O	['N']	[14]
15	experienced	O	['N']	[15]
16	a	O	['N']	[16]
17	relapse	O	['N']	[17]
18	of	O	['N']	[18]
19	symptomatic	B	['N']	[19]
20	hyperlactatemia	I-Adverse_Effect	['N']	[20]
21	after	O	['N']	[21]
22	being	O	['N']	[22]
23	switched	O	['N']	[23]
24	from	O	['N']	[24]
25	stavudine	B-Drug	['Causes']	[20]
26	to	O	['N']	[26]
27	zidovudine	O	['N']	[27]
28	and	O	['N']	[28]
29	how	O	['N']	[29]
30	the	O	['N']	[30]
31	case	O	['N']	[31]
32	was	O	['N']	[32]
33	managed	O	['N']	[33]
34	at	O	['N']	[34]
35	the	O	['N']	[35]
36	Infectious	O	['N']	[36]
37	Diseases	O	['N']	[37]
38	Institute	O	['N']	[38]
39	,	O	['N']	[39]
40	Kampala	O	['N']	[40]
41	,	O	['N']	[41]
42	Uganda	O	['N']	[42]
43	.	O	['N']	[43]
#2255
0	Thrombolytic	O	['N']	[0]
1	therapy	O	['N']	[1]
2	with	O	['N']	[2]
3	tissue	B	['N']	[3]
4	plasminogen	I	['N']	[4]
5	activator	I-Drug	['Causes']	[24]
6	(	O	['N']	[6]
7	tPA	O	['N']	[7]
8	)	O	['N']	[8]
9	for	O	['N']	[9]
10	acute	O	['N']	[10]
11	myocardial	O	['N']	[11]
12	infarction	O	['N']	[12]
13	may	O	['N']	[13]
14	result	O	['N']	[14]
15	in	O	['N']	[15]
16	major	O	['N']	[16]
17	bleeding	O	['N']	[17]
18	complications	O	['N']	[18]
19	such	O	['N']	[19]
20	as	O	['N']	[20]
21	gastrointestinal	B	['N']	[21]
22	or	I	['N']	[22]
23	intracranial	I	['N']	[23]
24	bleeding	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#2256
0	Three	O	['N']	[0]
1	of	O	['N']	[1]
2	50	O	['N']	[2]
3	patients	O	['N']	[3]
4	treated	O	['N']	[4]
5	with	O	['N']	[5]
6	isotretinoin	B-Drug	['Causes']	[26]
7	(	O	['N']	[7]
8	1	O	['N']	[8]
9	mg	O	['N']	[9]
10	/	O	['N']	[10]
11	kg	O	['N']	[11]
12	/	O	['N']	[12]
13	day	O	['N']	[13]
14	)	O	['N']	[14]
15	for	O	['N']	[15]
16	cystic	O	['N']	[16]
17	acne	O	['N']	[17]
18	complained	O	['N']	[18]
19	of	O	['N']	[19]
20	poor	O	['N']	[20]
21	night	O	['N']	[21]
22	vision	O	['N']	[22]
23	and/or	O	['N']	[23]
24	excessive	B	['N']	[24]
25	glare	I	['N']	[25]
26	sensitivity	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#2257
0	Clozapine	B-Drug	['Causes']	[5]
1	is	O	['N']	[1]
2	speculated	O	['N']	[2]
3	to	O	['N']	[3]
4	cause	O	['N']	[4]
5	rhabdomyolysis	B-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	patients	O	['N']	[7]
8	with	O	['N']	[8]
9	defective	O	['N']	[9]
10	calcium	O	['N']	[10]
11	-	O	['N']	[11]
12	activated	O	['N']	[12]
13	K+	O	['N']	[13]
14	channels	O	['N']	[14]
15	.	O	['N']	[15]
#2258
0	These	O	['N']	[0]
1	cases	O	['N']	[1]
2	and	O	['N']	[2]
3	a	O	['N']	[3]
4	review	O	['N']	[4]
5	of	O	['N']	[5]
6	the	O	['N']	[6]
7	literature	O	['N']	[7]
8	suggested	O	['N']	[8]
9	that	O	['N']	[9]
10	hepatotoxicity	B-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	though	O	['N']	[12]
13	rare	O	['N']	[13]
14	,	O	['N']	[14]
15	should	O	['N']	[15]
16	be	O	['N']	[16]
17	added	O	['N']	[17]
18	to	O	['N']	[18]
19	the	O	['N']	[19]
20	list	O	['N']	[20]
21	of	O	['N']	[21]
22	adverse	O	['N']	[22]
23	reactions	O	['N']	[23]
24	to	O	['N']	[24]
25	D	B	['N']	[25]
26	-	I	['N']	[26]
27	penicillamine	I-Drug	['Causes']	[10]
28	.	O	['N']	[28]
#2259
0	Methotrexate	B-Drug	['Causes']	[6]
1	is	O	['N']	[1]
2	an	O	['N']	[2]
3	effective	O	['N']	[3]
4	but	O	['N']	[4]
5	potentially	B	['N']	[5]
6	toxic	I-Adverse_Effect	['N']	[6]
7	treatment	O	['N']	[7]
8	for	O	['N']	[8]
9	psoriasis	O	['N']	[9]
10	.	O	['N']	[10]
#2260
0	We	O	['N']	[0]
1	postulate	O	['N']	[1]
2	that	O	['N']	[2]
3	the	O	['N']	[3]
4	bolus	O	['N']	[4]
5	of	O	['N']	[5]
6	sulprostone	B-Drug	['Causes']	[11]
7	resulted	O	['N']	[7]
8	in	O	['N']	[8]
9	possible	O	['N']	[9]
10	coronary	B	['N']	[10]
11	spasm	I-Adverse_Effect	['N']	[11]
12	that	O	['N']	[12]
13	resulted	O	['N']	[13]
14	in	O	['N']	[14]
15	cardiac	O	['N']	[15]
16	arrest	O	['N']	[16]
17	.	O	['N']	[17]
#2261
0	A	O	['N']	[0]
1	well	O	['N']	[1]
2	-	O	['N']	[2]
3	recognized	O	['N']	[3]
4	complication	O	['N']	[4]
5	of	O	['N']	[5]
6	ethambutol	B-Drug	['Causes']	[10]
7	use	O	['N']	[7]
8	is	O	['N']	[8]
9	optic	B	['N']	[9]
10	neuropathy	I-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	but	O	['N']	[12]
13	the	O	['N']	[13]
14	potential	O	['N']	[14]
15	ocular	O	['N']	[15]
16	toxicity	O	['N']	[16]
17	of	O	['N']	[17]
18	isoniazid	O	['N']	[18]
19	is	O	['N']	[19]
20	often	O	['N']	[20]
21	overlooked	O	['N']	[21]
22	.	O	['N']	[22]
#2262
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	polymyositis	O	['N']	[3]
4	with	O	['N']	[4]
5	dilated	B	['N']	[5]
6	cardiomyopathy	I-Adverse_Effect	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	interferon	B	['N']	[9]
10	alpha	I-Drug	['Causes']	[6]
11	treatment	O	['N']	[11]
12	for	O	['N']	[12]
13	hepatitis	O	['N']	[13]
14	B.	O	['N']	[14]
#2263
0	Monoclonal	B	['N']	[0]
1	gammopathy	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	subsequent	O	['N']	[3]
4	multiple	O	['N']	[4]
5	myeloma	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	on	O	['N']	[9]
10	chronic	O	['N']	[10]
11	diphenylhydantoin	B-Drug	['Causes']	[1]
12	therapy	O	['N']	[12]
13	.	O	['N']	[13]
#2264
0	Antibiotic	O	['N']	[0]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	colitis	O	['N']	[3]
4	(	O	['N']	[4]
5	pseudomembranous	B	['N']	[5]
6	colitis	I-Adverse_Effect	['N']	[6]
7	)	O	['N']	[7]
8	developed	O	['N']	[8]
9	in	O	['N']	[9]
10	four	O	['N']	[10]
11	patients	O	['N']	[11]
12	with	O	['N']	[12]
13	spinal	O	['N']	[13]
14	cord	O	['N']	[14]
15	injury	O	['N']	[15]
16	and	O	['N']	[16]
17	taking	O	['N']	[17]
18	oral	O	['N']	[18]
19	trimethoprim	B-Drug	['Causes']	[6]
20	-	O	['N']	[20]
21	sulfamethoxazole	O	['N']	[21]
22	.	O	['N']	[22]
#2265
0	The	O	['N']	[0]
1	sulfonamides	B-Drug	['Causes']	[11]
2	are	O	['N']	[2]
3	the	O	['N']	[3]
4	best	O	['N']	[4]
5	verified	O	['N']	[5]
6	drug	O	['N']	[6]
7	-	O	['N']	[7]
8	trigger	O	['N']	[8]
9	for	O	['N']	[9]
10	erythema	B	['N']	[10]
11	multiforme	I-Adverse_Effect	['N']	[11]
12	and	O	['N']	[12]
13	Stevens	O	['N']	[13]
14	-	O	['N']	[14]
15	Johnson	O	['N']	[15]
16	syndrome	O	['N']	[16]
17	.	O	['N']	[17]
#2266
0	The	O	['N']	[0]
1	medical	O	['N']	[1]
2	examiner	O	['N']	[2]
3	's	O	['N']	[3]
4	report	O	['N']	[4]
5	indicated	O	['N']	[5]
6	death	O	['N']	[6]
7	caused	O	['N']	[7]
8	by	O	['N']	[8]
9	fluoxetine	B-Drug	['Causes']	[10]
10	toxicity	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#2267
0	Perinatal	O	['N']	[0]
1	vasoconstrictive	O	['N']	[1]
2	renal	B	['N']	[2]
3	insufficiency	I-Adverse_Effect	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	maternal	O	['N']	[6]
7	nimesulide	B-Drug	['Causes']	[3]
8	use	O	['N']	[8]
9	.	O	['N']	[9]
#2268
0	Thirty	O	['N']	[0]
1	-	O	['N']	[1]
2	six	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	AL	O	['N']	[5]
6	received	O	['N']	[6]
7	,	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	three	O	['N']	[10]
11	-	O	['N']	[11]
12	month	O	['N']	[12]
13	period	O	['N']	[13]
14	,	O	['N']	[14]
15	51	O	['N']	[15]
16	cycles	O	['N']	[16]
17	of	O	['N']	[17]
18	combined	O	['N']	[18]
19	chemotherapy	O	['N']	[19]
20	which	O	['N']	[20]
21	included	O	['N']	[21]
22	,	O	['N']	[22]
23	in	O	['N']	[23]
24	all	O	['N']	[24]
25	of	O	['N']	[25]
26	them	O	['N']	[26]
27	,	O	['N']	[27]
28	cytosine	O	['N']	[28]
29	arabinoside	O	['N']	[29]
30	(	O	['N']	[30]
31	ARA	B	['N']	[31]
32	-	I	['N']	[32]
33	C	I-Drug	['Causes']	[48]
34	)	O	['N']	[34]
35	;	O	['N']	[35]
36	among	O	['N']	[36]
37	them	O	['N']	[37]
38	,	O	['N']	[38]
39	along	O	['N']	[39]
40	with	O	['N']	[40]
41	myelosuppression	O	['N']	[41]
42	,	O	['N']	[42]
43	five	O	['N']	[43]
44	experienced	O	['N']	[44]
45	fever	O	['N']	[45]
46	,	O	['N']	[46]
47	infectious	B	['N']	[47]
48	complications	I-Adverse_Effect	['N']	[48]
49	,	O	['N']	[49]
50	gastrointestinal	O	['N']	[50]
51	tract	O	['N']	[51]
52	symptoms	O	['N']	[52]
53	and	O	['N']	[53]
54	severe	O	['N']	[54]
55	myalgias	O	['N']	[55]
56	.	O	['N']	[56]
#2269
0	The	O	['N']	[0]
1	incidence	O	['N']	[1]
2	of	O	['N']	[2]
3	5-fluorouracil	O	['N']	[3]
4	(	O	['N']	[4]
5	5-FU)-related	-	['N']	[5]
6	cardiotoxicity	B-Adverse_Effect	['N']	[6]
7	seems	O	['N']	[7]
8	to	O	['N']	[8]
9	be	O	['N']	[9]
10	dosage	O	['N']	[10]
11	and	O	['N']	[11]
12	schedule	O	['N']	[12]
13	dependent	O	['N']	[13]
14	.	O	['N']	[14]
#2270
0	Late	O	['N']	[0]
1	development	O	['N']	[1]
2	of	O	['N']	[2]
3	diabetes	B	['N']	[3]
4	mellitus	I-Adverse_Effect	['N']	[4]
5	after	O	['N']	[5]
6	interferon	B	['N']	[6]
7	-	I	['N']	[7]
8	alfa	I-Drug	['Causes']	[4]
9	and	O	['N']	[9]
10	ribavirin	O	['N']	[10]
11	therapy	O	['N']	[11]
12	for	O	['N']	[12]
13	chronic	O	['N']	[13]
14	hepatitis	O	['N']	[14]
15	C	O	['N']	[15]
16	:	O	['N']	[16]
17	a	O	['N']	[17]
18	case	O	['N']	[18]
19	report	O	['N']	[19]
20	.	O	['N']	[20]
#2271
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Interferon	B-Drug	['Causes']	[15]
3	(	O	['N']	[3]
4	IFN)-associated	O	['N']	[4]
5	retinopathy	O	['N']	[5]
6	is	O	['N']	[6]
7	typically	O	['N']	[7]
8	characterized	O	['N']	[8]
9	by	O	['N']	[9]
10	retinal	O	['N']	[10]
11	hemorrhages	O	['N']	[11]
12	and	O	['N']	[12]
13	cotton	B	['N']	[13]
14	wool	I	['N']	[14]
15	spots	I-Adverse_Effect	['N']	[15]
16	at	O	['N']	[16]
17	the	O	['N']	[17]
18	posterior	O	['N']	[18]
19	fundus	O	['N']	[19]
20	,	O	['N']	[20]
21	but	O	['N']	[21]
22	visual	O	['N']	[22]
23	function	O	['N']	[23]
24	is	O	['N']	[24]
25	usually	O	['N']	[25]
26	maintained	O	['N']	[26]
27	.	O	['N']	[27]
#2272
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	who	O	['N']	[2]
3	received	O	['N']	[3]
4	clindamycin	B-Drug	['Causes']	[11]
5	had	O	['N']	[5]
6	liver	O	['N']	[6]
7	biopsy	O	['N']	[7]
8	findings	O	['N']	[8]
9	of	O	['N']	[9]
10	marked	B	['N']	[10]
11	cholestasis	I-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	portal	O	['N']	[13]
14	inflammation	O	['N']	[14]
15	,	O	['N']	[15]
16	bile	O	['N']	[16]
17	duct	O	['N']	[17]
18	injury	O	['N']	[18]
19	and	O	['N']	[19]
20	bile	O	['N']	[20]
21	duct	O	['N']	[21]
22	paucity	O	['N']	[22]
23	(	O	['N']	[23]
24	ductopenia	O	['N']	[24]
25	)	O	['N']	[25]
26	.	O	['N']	[26]
#2273
0	Caution	O	['N']	[0]
1	is	O	['N']	[1]
2	,	O	['N']	[2]
3	therefore	O	['N']	[3]
4	,	O	['N']	[4]
5	needed	O	['N']	[5]
6	to	O	['N']	[6]
7	prevent	O	['N']	[7]
8	undesired	O	['N']	[8]
9	accumulation	O	['N']	[9]
10	of	O	['N']	[10]
11	TCA	B-Drug	['Causes']	[19]
12	that	O	['N']	[12]
13	may	O	['N']	[13]
14	lead	O	['N']	[14]
15	to	O	['N']	[15]
16	protracted	O	['N']	[16]
17	Cushing	B	['N']	[17]
18	's	I	['N']	[18]
19	syndrome	I-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#2274
0	Recently	O	['N']	[0]
1	,	O	['N']	[1]
2	CD20-negative	B	['N']	[2]
3	tumors	I-Adverse_Effect	['N']	[3]
4	have	O	['N']	[4]
5	been	O	['N']	[5]
6	described	O	['N']	[6]
7	after	O	['N']	[7]
8	Rituximab	B-Drug	['Causes']	[3]
9	therapy	O	['N']	[9]
10	.	O	['N']	[10]
#2275
0	CASE	O	['N']	[0]
1	REPORT	O	['N']	[1]
2	:	O	['N']	[2]
3	Soon	O	['N']	[3]
4	after	O	['N']	[4]
5	initiation	O	['N']	[5]
6	of	O	['N']	[6]
7	amiodarone	B	['N']	[7]
8	HCl	I-Drug	['Causes']	[29]
9	(	O	['N']	[9]
10	200	O	['N']	[10]
11	mg	O	['N']	[11]
12	/	O	['N']	[12]
13	day	O	['N']	[13]
14	)	O	['N']	[14]
15	,	O	['N']	[15]
16	a	O	['N']	[16]
17	76-year	O	['N']	[17]
18	-	O	['N']	[18]
19	old	O	['N']	[19]
20	man	O	['N']	[20]
21	came	O	['N']	[21]
22	to	O	['N']	[22]
23	us	O	['N']	[23]
24	with	O	['N']	[24]
25	symptoms	O	['N']	[25]
26	of	O	['N']	[26]
27	visual	B	['N']	[27]
28	"	I	['N']	[28]
29	shining	I-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	"	O	['N']	[31]
32	glare	O	['N']	[32]
33	,	O	['N']	[33]
34	color	O	['N']	[34]
35	vision	O	['N']	[35]
36	anomalies	O	['N']	[36]
37	,	O	['N']	[37]
38	and	O	['N']	[38]
39	gradually	O	['N']	[39]
40	decreased	O	['N']	[40]
41	vision	O	['N']	[41]
42	.	O	['N']	[42]
#2276
0	Baclofen	B-Drug	['Causes']	[2]
1	withdrawal	B	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	resulting	O	['N']	[3]
4	from	O	['N']	[4]
5	underdosing	O	['N']	[5]
6	of	O	['N']	[6]
7	oral	O	['N']	[7]
8	baclofen	O	['N']	[8]
9	should	O	['N']	[9]
10	be	O	['N']	[10]
11	considered	O	['N']	[11]
12	as	O	['N']	[12]
13	a	O	['N']	[13]
14	potential	O	['N']	[14]
15	source	O	['N']	[15]
16	of	O	['N']	[16]
17	prolonged	O	['N']	[17]
18	fever	O	['N']	[18]
19	in	O	['N']	[19]
20	the	O	['N']	[20]
21	intensive	O	['N']	[21]
22	care	O	['N']	[22]
23	unit	O	['N']	[23]
24	.	O	['N']	[24]
#2277
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	54-year	O	['N']	[7]
8	-	O	['N']	[8]
9	old	O	['N']	[9]
10	Turkish	O	['N']	[10]
11	woman	O	['N']	[11]
12	who	O	['N']	[12]
13	presented	O	['N']	[13]
14	with	O	['N']	[14]
15	ceftriaxone	B-Drug	['Causes']	[18]
16	-	O	['N']	[16]
17	induced	O	['N']	[17]
18	FDE	B-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#2278
0	An	O	['N']	[0]
1	acute	B	['N']	[1]
2	ischaemic	I	['N']	[2]
3	event	I-Adverse_Effect	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	the	O	['N']	[6]
7	use	O	['N']	[7]
8	of	O	['N']	[8]
9	venlafaxine	B-Drug	['Causes']	[3]
10	:	O	['N']	[10]
11	a	O	['N']	[11]
12	case	O	['N']	[12]
13	report	O	['N']	[13]
14	and	O	['N']	[14]
15	proposed	O	['N']	[15]
16	pathophysiological	O	['N']	[16]
17	mechanisms	O	['N']	[17]
18	.	O	['N']	[18]
#2279
0	In	O	['N']	[0]
1	eight	O	['N']	[1]
2	patients	O	['N']	[2]
3	,	O	['N']	[3]
4	a	O	['N']	[4]
5	mean	O	['N']	[5]
6	decrease	B	['N']	[6]
7	in	I	['N']	[7]
8	serum	I	['N']	[8]
9	Na+	I-Adverse_Effect	['N']	[9]
10	of	O	['N']	[10]
11	8.25	O	['N']	[11]
12	+	O	['N']	[12]
13	/-	O	['N']	[13]
14	3.2	O	['N']	[14]
15	mEq	O	['N']	[15]
16	/	O	['N']	[16]
17	L	O	['N']	[17]
18	was	O	['N']	[18]
19	observed	O	['N']	[19]
20	after	O	['N']	[20]
21	a	O	['N']	[21]
22	single	O	['N']	[22]
23	200	O	['N']	[23]
24	mg	O	['N']	[24]
25	intravenous	O	['N']	[25]
26	dose	O	['N']	[26]
27	of	O	['N']	[27]
28	lorcainide	B-Drug	['Causes']	[9]
29	.	O	['N']	[29]
#2280
0	Here	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	describe	O	['N']	[3]
4	levofloxacin	B-Drug	['Causes']	[10]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	delirium	B	['N']	[7]
8	with	I	['N']	[8]
9	psychotic	I	['N']	[9]
10	features	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	relatively	O	['N']	[13]
14	young	O	['N']	[14]
15	,	O	['N']	[15]
16	otherwise	O	['N']	[16]
17	healthy	O	['N']	[17]
18	female	O	['N']	[18]
19	.	O	['N']	[19]
#2281
0	Prior	O	['N']	[0]
1	neurologic	O	['N']	[1]
2	illness	O	['N']	[2]
3	or	O	['N']	[3]
4	CNS	O	['N']	[4]
5	insult	O	['N']	[5]
6	of	O	['N']	[6]
7	any	O	['N']	[7]
8	kind	O	['N']	[8]
9	is	O	['N']	[9]
10	known	O	['N']	[10]
11	to	O	['N']	[11]
12	increase	O	['N']	[12]
13	the	O	['N']	[13]
14	vulnerability	O	['N']	[14]
15	to	O	['N']	[15]
16	neurotoxicity	B-Adverse_Effect	['N']	[16]
17	of	O	['N']	[17]
18	lithium	B-Drug	['Causes']	[16]
19	.	O	['N']	[19]
#2282
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	intracranial	O	['N']	[3]
4	osteosarcoma	O	['N']	[4]
5	that	O	['N']	[5]
6	arose	O	['N']	[6]
7	16	O	['N']	[7]
8	years	O	['N']	[8]
9	after	O	['N']	[9]
10	radiation	O	['N']	[10]
11	therapy	O	['N']	[11]
12	for	O	['N']	[12]
13	hereditary	O	['N']	[13]
14	retinoblastoma	O	['N']	[14]
15	developed	O	['N']	[15]
16	fatal	O	['N']	[16]
17	cerebral	O	['N']	[17]
18	edema	O	['N']	[18]
19	and	O	['N']	[19]
20	brainstem	B	['N']	[20]
21	herniation	I-Adverse_Effect	['N']	[21]
22	after	O	['N']	[22]
23	she	O	['N']	[23]
24	received	O	['N']	[24]
25	a	O	['N']	[25]
26	single	O	['N']	[26]
27	dose	O	['N']	[27]
28	of	O	['N']	[28]
29	intravenous	O	['N']	[29]
30	methotrexate	B-Drug	['Causes']	[21]
31	.	O	['N']	[31]
#2283
0	Reactivation	B	['N']	[0]
1	of	I	['N']	[1]
2	cytomegalovirus	I-Adverse_Effect	['N']	[2]
3	probably	O	['N']	[3]
4	followed	O	['N']	[4]
5	the	O	['N']	[5]
6	treatment	O	['N']	[6]
7	of	O	['N']	[7]
8	Wegener	O	['N']	[8]
9	's	O	['N']	[9]
10	granulomatosis	O	['N']	[10]
11	with	O	['N']	[11]
12	corticosteroids	O	['N']	[12]
13	and	O	['N']	[13]
14	azathioprine	B-Drug	['Causes']	[2]
15	.	O	['N']	[15]
#2284
0	Loperamide	B-Drug	['Causes']	[1]
1	poisoning	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	the	O	['N']	[3]
4	dog	O	['N']	[4]
5	.	O	['N']	[5]
#2285
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	oculogyric	B	['N']	[3]
4	crisis	I-Adverse_Effect	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	metoclopramide	B-Drug	['Causes']	[4]
8	is	O	['N']	[8]
9	described	O	['N']	[9]
10	in	O	['N']	[10]
11	this	O	['N']	[11]
12	paper	O	['N']	[12]
13	.	O	['N']	[13]
#2286
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	our	O	['N']	[3]
4	knowledge	O	['N']	[4]
5	,	O	['N']	[5]
6	this	O	['N']	[6]
7	is	O	['N']	[7]
8	the	O	['N']	[8]
9	first	O	['N']	[9]
10	case	O	['N']	[10]
11	report	O	['N']	[11]
12	illustrating	O	['N']	[12]
13	neuralgic	B	['N']	[13]
14	amyotrophy	I-Adverse_Effect	['N']	[14]
15	triggered	O	['N']	[15]
16	by	O	['N']	[16]
17	exposure	O	['N']	[17]
18	to	O	['N']	[18]
19	the	O	['N']	[19]
20	antibiotics	O	['N']	[20]
21	vancomycin	B-Drug	['Causes']	[14]
22	,	O	['N']	[22]
23	tobramycin	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	piperacillin	O	['N']	[26]
27	/	O	['N']	[27]
28	tazobactam	O	['N']	[28]
29	.	O	['N']	[29]
#2287
0	Four	O	['N']	[0]
1	weeks	O	['N']	[1]
2	earlier	O	['N']	[2]
3	she	O	['N']	[3]
4	had	O	['N']	[4]
5	developed	O	['N']	[5]
6	hepatopathy	B-Adverse_Effect	['N']	[6]
7	during	O	['N']	[7]
8	a	O	['N']	[8]
9	regimen	O	['N']	[9]
10	of	O	['N']	[10]
11	carbamazepine	O	['N']	[11]
12	,	O	['N']	[12]
13	lynestrenol	B-Drug	['Causes']	[6]
14	and	O	['N']	[14]
15	sodium	O	['N']	[15]
16	valproate	O	['N']	[16]
17	.	O	['N']	[17]
#2288
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	children	O	['N']	[2]
3	and	O	['N']	[3]
4	adolescents	O	['N']	[4]
5	with	O	['N']	[5]
6	chronic	O	['N']	[6]
7	hematologic	O	['N']	[7]
8	and	O	['N']	[8]
9	oncologic	O	['N']	[9]
10	diseases	O	['N']	[10]
11	who	O	['N']	[11]
12	exhibited	O	['N']	[12]
13	drug	B	['N']	[13]
14	-	I	['N']	[14]
15	seeking	I	['N']	[15]
16	behavior	I-Adverse_Effect	['N']	[16]
17	or	O	['N']	[17]
18	anticholinergic	O	['N']	[18]
19	symptoms	O	['N']	[19]
20	with	O	['N']	[20]
21	the	O	['N']	[21]
22	use	O	['N']	[22]
23	of	O	['N']	[23]
24	diphenhydramine	B-Drug	['Causes']	[16]
25	.	O	['N']	[25]
#2289
0	Pulmonary	B	['N']	[0]
1	edema	I-Adverse_Effect	['N']	[1]
2	occurred	O	['N']	[2]
3	24	O	['N']	[3]
4	hours	O	['N']	[4]
5	after	O	['N']	[5]
6	intravenous	O	['N']	[6]
7	ritodrine	B-Drug	['Causes']	[1]
8	therapy	O	['N']	[8]
9	and	O	['N']	[9]
10	10	O	['N']	[10]
11	hours	O	['N']	[11]
12	after	O	['N']	[12]
13	subcutaneous	O	['N']	[13]
14	terbutaline	O	['N']	[14]
15	therapy	O	['N']	[15]
16	.	O	['N']	[16]
#2290
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	O	['N']	[19]
20	developed	O	['N']	[20]
21	confusion	O	['N']	[21]
22	,	O	['N']	[22]
23	agitation	B-Adverse_Effect	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	O	['N']	[25]
26	,	O	['N']	[26]
27	tremors	O	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	O	['N']	[29]
30	jerks	O	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	O	['N']	[32]
33	gait	O	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	B-Drug	['Causes']	[23]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#2291
0	Proliferation	B	['N']	[0]
1	of	I	['N']	[1]
2	abnormal	I	['N']	[2]
3	bone	I	['N']	[3]
4	marrow	I	['N']	[4]
5	histiocytes	I-Adverse_Effect	['N']	[5]
6	,	O	['N']	[6]
7	an	O	['N']	[7]
8	undesired	O	['N']	[8]
9	effect	O	['N']	[9]
10	of	O	['N']	[10]
11	granulocyte	B	['N']	[11]
12	macrophage	I	['N']	[12]
13	-	I	['N']	[13]
14	colony	I	['N']	[14]
15	-	I	['N']	[15]
16	stimulating	I	['N']	[16]
17	factor	I-Drug	['Causes']	[5]
18	therapy	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	patient	O	['N']	[21]
22	with	O	['N']	[22]
23	Hurler	O	['N']	[23]
24	's	O	['N']	[24]
25	syndrome	O	['N']	[25]
26	undergoing	O	['N']	[26]
27	bone	O	['N']	[27]
28	marrow	O	['N']	[28]
29	transplantation	O	['N']	[29]
30	.	O	['N']	[30]
#2292
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	study	O	['N']	[2]
3	,	O	['N']	[3]
4	we	O	['N']	[4]
5	report	O	['N']	[5]
6	on	O	['N']	[6]
7	three	O	['N']	[7]
8	individual	O	['N']	[8]
9	patients	O	['N']	[9]
10	who	O	['N']	[10]
11	received	O	['N']	[11]
12	BTX	B	['N']	[12]
13	-	I	['N']	[13]
14	B	I-Drug	['Causes']	[24]
15	and	O	['N']	[15]
16	who	O	['N']	[16]
17	subsequently	O	['N']	[17]
18	developed	O	['N']	[18]
19	parasympathetic	B	['N']	[19]
20	dysfunction	I	['N']	[20]
21	of	I	['N']	[21]
22	the	I	['N']	[22]
23	visual	I	['N']	[23]
24	system	I-Adverse_Effect	['N']	[24]
25	after	O	['N']	[25]
26	injections	O	['N']	[26]
27	of	O	['N']	[27]
28	BTX	O	['N']	[28]
29	-	O	['N']	[29]
30	B	O	['N']	[30]
31	at	O	['N']	[31]
32	remote	O	['N']	[32]
33	sites	O	['N']	[33]
34	.	O	['N']	[34]
#2293
0	The	O	['N']	[0]
1	purpose	O	['N']	[1]
2	of	O	['N']	[2]
3	this	O	['N']	[3]
4	article	O	['N']	[4]
5	is	O	['N']	[5]
6	to	O	['N']	[6]
7	present	O	['N']	[7]
8	the	O	['N']	[8]
9	first	O	['N']	[9]
10	case	O	['N']	[10]
11	-	O	['N']	[11]
12	series	O	['N']	[12]
13	of	O	['N']	[13]
14	posterior	B	['N']	[14]
15	reversible	I	['N']	[15]
16	encephalopathy	I	['N']	[16]
17	syndrome	I-Adverse_Effect	['N']	[17]
18	(	O	['N']	[18]
19	PRES	O	['N']	[19]
20	)	O	['N']	[20]
21	associated	O	['N']	[21]
22	with	O	['N']	[22]
23	L	B	['N']	[23]
24	-	I	['N']	[24]
25	asparaginase	I-Drug	['Causes']	[17]
26	treatment	O	['N']	[26]
27	.	O	['N']	[27]
#2294
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	is	O	['N']	[2]
3	presented	O	['N']	[3]
4	with	O	['N']	[4]
5	typical	O	['N']	[5]
6	hyperthyroidism	O	['N']	[6]
7	,	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	a	O	['N']	[10]
11	severe	O	['N']	[11]
12	proximal	O	['N']	[12]
13	muscle	O	['N']	[13]
14	weakness	O	['N']	[14]
15	and	O	['N']	[15]
16	a	O	['N']	[16]
17	raised	B	['N']	[17]
18	creatine	I	['N']	[18]
19	phosphokinase	I-Adverse_Effect	['N']	[19]
20	after	O	['N']	[20]
21	treatment	O	['N']	[21]
22	for	O	['N']	[22]
23	hyperthyroidism	O	['N']	[23]
24	with	O	['N']	[24]
25	propylthiouracil	B-Drug	['Causes']	[19]
26	(	O	['N']	[26]
27	100	O	['N']	[27]
28	mg	O	['N']	[28]
29	orally	O	['N']	[29]
30	,	O	['N']	[30]
31	three	O	['N']	[31]
32	times	O	['N']	[32]
33	a	O	['N']	[33]
34	day	O	['N']	[34]
35	)	O	['N']	[35]
36	.	O	['N']	[36]
#2295
0	Presented	O	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	story	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	woman	O	['N']	[7]
8	with	O	['N']	[8]
9	classical	O	['N']	[9]
10	rheumatoid	O	['N']	[10]
11	arthritis	O	['N']	[11]
12	,	O	['N']	[12]
13	who	O	['N']	[13]
14	during	O	['N']	[14]
15	introduction	O	['N']	[15]
16	of	O	['N']	[16]
17	sulphasalazine	B-Drug	['Causes']	[31]
18	(	O	['N']	[18]
19	SASP	O	['N']	[19]
20	)	O	['N']	[20]
21	therapy	O	['N']	[21]
22	developed	O	['N']	[22]
23	a	O	['N']	[23]
24	severe	O	['N']	[24]
25	and	O	['N']	[25]
26	lasting	O	['N']	[26]
27	psoriasis	B	['N']	[27]
28	-	I	['N']	[28]
29	like	I	['N']	[29]
30	skin	I	['N']	[30]
31	reaction	I-Adverse_Effect	['N']	[31]
32	.	O	['N']	[32]
#2296
0	INTRODUCTION	O	['N']	[0]
1	:	O	['N']	[1]
2	Although	O	['N']	[2]
3	gefitinib	B-Drug	['Causes']	[25]
4	used	O	['N']	[4]
5	for	O	['N']	[5]
6	the	O	['N']	[6]
7	treatment	O	['N']	[7]
8	of	O	['N']	[8]
9	non	O	['N']	[9]
10	-	O	['N']	[10]
11	small	O	['N']	[11]
12	-	O	['N']	[12]
13	cell	O	['N']	[13]
14	lung	O	['N']	[14]
15	cancer	O	['N']	[15]
16	is	O	['N']	[16]
17	a	O	['N']	[17]
18	well	O	['N']	[18]
19	-	O	['N']	[19]
20	known	O	['N']	[20]
21	cause	O	['N']	[21]
22	of	O	['N']	[22]
23	interstitial	B	['N']	[23]
24	lung	I	['N']	[24]
25	disease	I-Adverse_Effect	['N']	[25]
26	(	O	['N']	[26]
27	ILD	O	['N']	[27]
28	)	O	['N']	[28]
29	,	O	['N']	[29]
30	few	O	['N']	[30]
31	case	O	['N']	[31]
32	reports	O	['N']	[32]
33	on	O	['N']	[33]
34	erlotinib	O	['N']	[34]
35	-	O	['N']	[35]
36	induced	O	['N']	[36]
37	ILD	O	['N']	[37]
38	have	O	['N']	[38]
39	been	O	['N']	[39]
40	issued	O	['N']	[40]
41	.	O	['N']	[41]
#2297
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	7	O	['N']	[3]
4	patients	O	['N']	[4]
5	(	O	['N']	[5]
6	2	O	['N']	[6]
7	women	O	['N']	[7]
8	,	O	['N']	[8]
9	5	O	['N']	[9]
10	men	O	['N']	[10]
11	)	O	['N']	[11]
12	with	O	['N']	[12]
13	chronic	O	['N']	[13]
14	renal	O	['N']	[14]
15	failure	O	['N']	[15]
16	,	O	['N']	[16]
17	who	O	['N']	[17]
18	developed	O	['N']	[18]
19	under	O	['N']	[19]
20	a	O	['N']	[20]
21	high	O	['N']	[21]
22	dosage	O	['N']	[22]
23	of	O	['N']	[23]
24	the	O	['N']	[24]
25	new	O	['N']	[25]
26	diuretic	O	['N']	[26]
27	muzolimine	B-Drug	['Causes']	[38]
28	(	O	['N']	[28]
29	range	O	['N']	[29]
30	240	O	['N']	[30]
31	to	O	['N']	[31]
32	1440	O	['N']	[32]
33	mg	O	['N']	[33]
34	per	O	['N']	[34]
35	day	O	['N']	[35]
36	)	O	['N']	[36]
37	fatal	B	['N']	[37]
38	neuromyeloencephalopathy	I-Adverse_Effect	['N']	[38]
39	.	O	['N']	[39]
#2298
0	We	O	['N']	[0]
1	suggest	O	['N']	[1]
2	discontinuing	O	['N']	[2]
3	gemcitabine	B-Drug	['Causes']	[6]
4	if	O	['N']	[4]
5	radiation	B	['N']	[5]
6	recall	I-Adverse_Effect	['N']	[6]
7	is	O	['N']	[7]
8	observed	O	['N']	[8]
9	.	O	['N']	[9]
#2299
0	The	O	['N']	[0]
1	observations	O	['N']	[1]
2	suggest	O	['N']	[2]
3	that	O	['N']	[3]
4	testicular	B	['N']	[4]
5	swelling	I-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	pain	O	['N']	[7]
8	are	O	['N']	[8]
9	side	O	['N']	[9]
10	effects	O	['N']	[10]
11	of	O	['N']	[11]
12	desipramine	B-Drug	['Causes']	[5]
13	.	O	['N']	[13]
#2300
0	After	O	['N']	[0]
1	receiving	O	['N']	[1]
2	3	O	['N']	[2]
3	doses	O	['N']	[3]
4	of	O	['N']	[4]
5	ifosfamide	B-Drug	['Causes']	[14]
6	/	O	['N']	[6]
7	mesna	O	['N']	[7]
8	,	O	['N']	[8]
9	she	O	['N']	[9]
10	was	O	['N']	[10]
11	found	O	['N']	[11]
12	to	O	['N']	[12]
13	be	O	['N']	[13]
14	unresponsive	B-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#2301
0	Severe	O	['N']	[0]
1	steroid	O	['N']	[1]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	glaucoma	B-Adverse_Effect	['N']	[4]
5	following	O	['N']	[5]
6	intravitreal	O	['N']	[6]
7	injection	O	['N']	[7]
8	of	O	['N']	[8]
9	triamcinolone	B	['N']	[9]
10	acetonide	I-Drug	['Causes']	[4]
11	.	O	['N']	[11]
#2302
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	advanced	O	['N']	[5]
6	ovarian	O	['N']	[6]
7	carcinoma	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	difficulty	O	['N']	[10]
11	walking	O	['N']	[11]
12	because	O	['N']	[12]
13	of	O	['N']	[13]
14	marked	B	['N']	[14]
15	pain	I-Adverse_Effect	['N']	[15]
16	in	O	['N']	[16]
17	the	O	['N']	[17]
18	lower	O	['N']	[18]
19	extremities	O	['N']	[19]
20	and	O	['N']	[20]
21	loss	O	['N']	[21]
22	of	O	['N']	[22]
23	proprioception	O	['N']	[23]
24	25	O	['N']	[24]
25	days	O	['N']	[25]
26	after	O	['N']	[26]
27	treatment	O	['N']	[27]
28	with	O	['N']	[28]
29	weekly	O	['N']	[29]
30	taxol	B-Drug	['Causes']	[15]
31	(	O	['N']	[31]
32	80	O	['N']	[32]
33	mg	O	['N']	[33]
34	/	O	['N']	[34]
35	m(2)x3	O	['N']	[35]
36	)	O	['N']	[36]
37	.	O	['N']	[37]
#2303
0	On	O	['N']	[0]
1	the	O	['N']	[1]
2	next	O	['N']	[2]
3	day	O	['N']	[3]
4	,	O	['N']	[4]
5	after	O	['N']	[5]
6	a	O	['N']	[6]
7	total	O	['N']	[7]
8	dose	O	['N']	[8]
9	of	O	['N']	[9]
10	only	O	['N']	[10]
11	600	B	['N']	[11]
12	mg	I-Dose	['N']	[12]
13	of	O	['N']	[13]
14	danazol	B-Drug	['Dosage']	[12]
15	,	O	['N']	[15]
16	gingival	O	['N']	[16]
17	bleeding	O	['N']	[17]
18	and	O	['N']	[18]
19	purpura	O	['N']	[19]
20	occurred	O	['N']	[20]
21	.	O	['N']	[21]
#2304
0	Treatment	O	['N']	[0]
1	of	O	['N']	[1]
2	carbimazole	B-Drug	['Causes']	[7]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	agranulocytosis	O	['N']	[5]
6	and	O	['N']	[6]
7	sepsis	B-Adverse_Effect	['N']	[7]
8	with	O	['N']	[8]
9	granulocyte	O	['N']	[9]
10	colony	O	['N']	[10]
11	stimulating	O	['N']	[11]
12	factor	O	['N']	[12]
13	.	O	['N']	[13]
#2305
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	87-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	white	O	['N']	[9]
10	woman	O	['N']	[10]
11	with	O	['N']	[11]
12	myasthenia	O	['N']	[12]
13	gravis	O	['N']	[13]
14	who	O	['N']	[14]
15	presented	O	['N']	[15]
16	with	O	['N']	[16]
17	nausea	O	['N']	[17]
18	,	O	['N']	[18]
19	shortness	O	['N']	[19]
20	of	O	['N']	[20]
21	breath	O	['N']	[21]
22	,	O	['N']	[22]
23	azotemia	B-Adverse_Effect	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	hyperkalemia	O	['N']	[26]
27	shortly	O	['N']	[27]
28	after	O	['N']	[28]
29	completing	O	['N']	[29]
30	a	O	['N']	[30]
31	course	O	['N']	[31]
32	of	O	['N']	[32]
33	intravenous	O	['N']	[33]
34	immunoglobulin	B-Drug	['Causes']	[23]
35	(	O	['N']	[35]
36	IVIG	O	['N']	[36]
37	)	O	['N']	[37]
38	.	O	['N']	[38]
#2306
0	Arthritis	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	bursitis	O	['N']	[2]
3	in	O	['N']	[3]
4	multiple	O	['N']	[4]
5	sclerosis	O	['N']	[5]
6	patients	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	interferon	B	['N']	[9]
10	-	I	['N']	[10]
11	beta	I-Drug	['Causes']	[0]
12	.	O	['N']	[12]
#2307
0	Proton	O	['N']	[0]
1	MRS	O	['N']	[1]
2	examination	O	['N']	[2]
3	demonstrated	O	['N']	[3]
4	a	O	['N']	[4]
5	persistent	O	['N']	[5]
6	lactate	B	['N']	[6]
7	elevation	I-Adverse_Effect	['N']	[7]
8	during	O	['N']	[8]
9	metronidazole	B-Drug	['Causes']	[7]
10	treatment	O	['N']	[10]
11	.	O	['N']	[11]
#2308
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	significant	O	['N']	[5]
6	over	O	['N']	[6]
7	-	O	['N']	[7]
8	anticoagulation	O	['N']	[8]
9	temporally	O	['N']	[9]
10	associated	O	['N']	[10]
11	with	O	['N']	[11]
12	a	O	['N']	[12]
13	bout	O	['N']	[13]
14	of	O	['N']	[14]
15	protracted	O	['N']	[15]
16	diarrhea	B-Adverse_Effect	['N']	[16]
17	in	O	['N']	[17]
18	a	O	['N']	[18]
19	patient	O	['N']	[19]
20	on	O	['N']	[20]
21	warfarin	B-Drug	['Causes']	[16]
22	therapy	O	['N']	[22]
23	.	O	['N']	[23]
#2309
0	Vancomycin	B-Drug	['Causes']	[16]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	most	O	['N']	[3]
4	frequently	O	['N']	[4]
5	implicated	O	['N']	[5]
6	drug	O	['N']	[6]
7	,	O	['N']	[7]
8	but	O	['N']	[8]
9	other	O	['N']	[9]
10	agents	O	['N']	[10]
11	have	O	['N']	[11]
12	been	O	['N']	[12]
13	reported	O	['N']	[13]
14	to	O	['N']	[14]
15	cause	O	['N']	[15]
16	LABD	B-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#2310
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	metastatic	O	['N']	[5]
6	prostate	O	['N']	[6]
7	cancer	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	nonoliguric	B	['N']	[10]
11	renal	I	['N']	[11]
12	failure	I-Adverse_Effect	['N']	[12]
13	during	O	['N']	[13]
14	treatment	O	['N']	[14]
15	with	O	['N']	[15]
16	suramin	B-Drug	['Causes']	[12]
17	.	O	['N']	[17]
#2311
0	These	O	['N']	[0]
1	cases	O	['N']	[1]
2	indicate	O	['N']	[2]
3	that	O	['N']	[3]
4	sulpiride	B-Drug	['Causes']	[8]
5	can	O	['N']	[5]
6	cause	O	['N']	[6]
7	tardive	B	['N']	[7]
8	dyskinesia	I-Adverse_Effect	['N']	[8]
9	and	O	['N']	[9]
10	that	O	['N']	[10]
11	this	O	['N']	[11]
12	drug	O	['N']	[12]
13	should	O	['N']	[13]
14	be	O	['N']	[14]
15	administered	O	['N']	[15]
16	with	O	['N']	[16]
17	caution	O	['N']	[17]
18	.	O	['N']	[18]
#2312
0	Carbamazepine	B-Drug	['Causes']	[8]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	systemic	B	['N']	[3]
4	lupus	I	['N']	[4]
5	erythematosus	I	['N']	[5]
6	-	I	['N']	[6]
7	like	I	['N']	[7]
8	disease	I-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#2313
0	Neurologic	B	['N']	[0]
1	toxicity	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	hepatic	O	['N']	[4]
5	artery	O	['N']	[5]
6	infusion	O	['N']	[6]
7	HAI	O	['N']	[7]
8	of	O	['N']	[8]
9	FUdR.	-	['N']	[9]
#2314
0	A	O	['N']	[0]
1	71-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	paroxysmal	O	['N']	[6]
7	atrial	O	['N']	[7]
8	fibrillation	O	['N']	[8]
9	who	O	['N']	[9]
10	had	O	['N']	[10]
11	a	O	['N']	[11]
12	previous	O	['N']	[12]
13	anterior	O	['N']	[13]
14	myocardial	O	['N']	[14]
15	infarction	O	['N']	[15]
16	exhibited	O	['N']	[16]
17	granulocytopenia	O	['N']	[17]
18	8	O	['N']	[18]
19	days	O	['N']	[19]
20	following	O	['N']	[20]
21	the	O	['N']	[21]
22	administration	O	['N']	[22]
23	of	O	['N']	[23]
24	oral	O	['N']	[24]
25	sustained	O	['N']	[25]
26	-	O	['N']	[26]
27	release	O	['N']	[27]
28	procainamide	B-Drug	['Dosage']	[33]
29	(	O	['N']	[29]
30	750	B	['N']	[30]
31	mg	I	['N']	[31]
32	/	I	['N']	[32]
33	day	I-Dose	['N']	[33]
34	)	O	['N']	[34]
35	.	O	['N']	[35]
#2315
0	Six	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	starting	O	['N']	[3]
4	acyclovir	O	['N']	[4]
5	she	O	['N']	[5]
6	exhibited	O	['N']	[6]
7	signs	O	['N']	[7]
8	of	O	['N']	[8]
9	lithium	B-Drug	['Causes']	[10]
10	toxicity	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#2316
0	The	O	['N']	[0]
1	findings	O	['N']	[1]
2	were	O	['N']	[2]
3	judged	O	['N']	[3]
4	to	O	['N']	[4]
5	be	O	['N']	[5]
6	consistent	O	['N']	[6]
7	with	O	['N']	[7]
8	soft	B	['N']	[8]
9	-	I	['N']	[9]
10	tissue	I	['N']	[10]
11	injury	I-Adverse_Effect	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	intravenous	O	['N']	[14]
15	administration	O	['N']	[15]
16	of	O	['N']	[16]
17	phenytoin	B-Drug	['Causes']	[11]
18	,	O	['N']	[18]
19	also	O	['N']	[19]
20	termed	O	['N']	[20]
21	purple	O	['N']	[21]
22	glove	O	['N']	[22]
23	syndrome	O	['N']	[23]
24	.	O	['N']	[24]
#2317
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	suggests	O	['N']	[2]
3	that	O	['N']	[3]
4	bleomycin	B-Drug	['Causes']	[6]
5	lung	B	['N']	[5]
6	toxicity	I-Adverse_Effect	['N']	[6]
7	may	O	['N']	[7]
8	be	O	['N']	[8]
9	reversible	O	['N']	[9]
10	if	O	['N']	[10]
11	treated	O	['N']	[11]
12	aggressively	O	['N']	[12]
13	.	O	['N']	[13]
#2318
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	also	O	['N']	[2]
3	determined	O	['N']	[3]
4	that	O	['N']	[4]
5	their	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	myositis	B-Adverse_Effect	['N']	[8]
9	developing	O	['N']	[9]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	rectus	O	['N']	[12]
13	abdominus	O	['N']	[13]
14	muscle	O	['N']	[14]
15	of	O	['N']	[15]
16	a	O	['N']	[16]
17	patient	O	['N']	[17]
18	with	O	['N']	[18]
19	pancreatic	O	['N']	[19]
20	adenocarcinoma	O	['N']	[20]
21	was	O	['N']	[21]
22	the	O	['N']	[22]
23	manifestation	O	['N']	[23]
24	of	O	['N']	[24]
25	radiation	O	['N']	[25]
26	recall	O	['N']	[26]
27	,	O	['N']	[27]
28	thereby	O	['N']	[28]
29	bringing	O	['N']	[29]
30	the	O	['N']	[30]
31	number	O	['N']	[31]
32	of	O	['N']	[32]
33	patients	O	['N']	[33]
34	who	O	['N']	[34]
35	developed	O	['N']	[35]
36	radiation	O	['N']	[36]
37	recall	O	['N']	[37]
38	to	O	['N']	[38]
39	gemcitabine	B-Drug	['Causes']	[8]
40	and	O	['N']	[40]
41	were	O	['N']	[41]
42	discussed	O	['N']	[42]
43	in	O	['N']	[43]
44	the	O	['N']	[44]
45	current	O	['N']	[45]
46	study	O	['N']	[46]
47	to	O	['N']	[47]
48	13	O	['N']	[48]
49	.	O	['N']	[49]
#2319
0	Sweet	B	['N']	[0]
1	's	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	sargramostim	B-Drug	['Causes']	[2]
6	(	O	['N']	[6]
7	granulocyte	O	['N']	[7]
8	-	O	['N']	[8]
9	macrophage	O	['N']	[9]
10	colony	O	['N']	[10]
11	stimulating	O	['N']	[11]
12	factor	O	['N']	[12]
13	)	O	['N']	[13]
14	treatment	O	['N']	[14]
15	.	O	['N']	[15]
#2320
0	Acute	B	['N']	[0]
1	renal	I	['N']	[1]
2	insufficiency	I-Adverse_Effect	['N']	[2]
3	is	O	['N']	[3]
4	known	O	['N']	[4]
5	to	O	['N']	[5]
6	occur	O	['N']	[6]
7	in	O	['N']	[7]
8	patients	O	['N']	[8]
9	who	O	['N']	[9]
10	are	O	['N']	[10]
11	taking	O	['N']	[11]
12	ciprofloxacin	B-Drug	['Causes']	[2]
13	,	O	['N']	[13]
14	particularly	O	['N']	[14]
15	the	O	['N']	[15]
16	elderly	O	['N']	[16]
17	.	O	['N']	[17]
#2321
0	Intraventricular	O	['N']	[0]
1	vancomycin	B-Drug	['Causes']	[6]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	cerebrospinal	B	['N']	[4]
5	fluid	I	['N']	[5]
6	eosinophilia	I-Adverse_Effect	['N']	[6]
7	:	O	['N']	[7]
8	report	O	['N']	[8]
9	of	O	['N']	[9]
10	two	O	['N']	[10]
11	patients	O	['N']	[11]
12	.	O	['N']	[12]
#2322
0	So	O	['N']	[0]
1	far	O	['N']	[1]
2	,	O	['N']	[2]
3	few	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	pulmonary	B	['N']	[6]
7	side	I	['N']	[7]
8	effects	I-Adverse_Effect	['N']	[8]
9	caused	O	['N']	[9]
10	by	O	['N']	[10]
11	ticlopidine	B-Drug	['Causes']	[8]
12	have	O	['N']	[12]
13	been	O	['N']	[13]
14	reported	O	['N']	[14]
15	.	O	['N']	[15]
#2323
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	placed	O	['N']	[2]
3	on	O	['N']	[3]
4	adjuvant	O	['N']	[4]
5	Adriamycin	B-Drug	['Causes']	[18]
6	(	O	['N']	[6]
7	doxorubicin	O	['N']	[7]
8	)	O	['N']	[8]
9	chemotherapy	O	['N']	[9]
10	,	O	['N']	[10]
11	but	O	['N']	[11]
12	6	O	['N']	[12]
13	months	O	['N']	[13]
14	later	O	['N']	[14]
15	died	O	['N']	[15]
16	of	O	['N']	[16]
17	Adriamycin	B	['N']	[17]
18	toxicity	I-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#2324
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	renal	O	['N']	[3]
4	transplant	O	['N']	[4]
5	recipient	O	['N']	[5]
6	maintained	O	['N']	[6]
7	on	O	['N']	[7]
8	cyclosporine	O	['N']	[8]
9	and	O	['N']	[9]
10	prednisone	B-Drug	['Causes']	[15]
11	developing	O	['N']	[11]
12	Nocardia	B	['N']	[12]
13	Asteroides	I	['N']	[13]
14	brain	I	['N']	[14]
15	abscess	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#2325
0	Pemphigus	B	['N']	[0]
1	foliaceus	I-Adverse_Effect	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	rifampicin	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#2326
0	Severe	B	['N']	[0]
1	systemic	I	['N']	[1]
2	hypersensitivity	I	['N']	[2]
3	reaction	I-Adverse_Effect	['N']	[3]
4	to	O	['N']	[4]
5	ibuprofen	B-Drug	['Causes']	[3]
6	occurring	O	['N']	[6]
7	after	O	['N']	[7]
8	prolonged	O	['N']	[8]
9	therapy	O	['N']	[9]
10	.	O	['N']	[10]
#2327
0	Severe	O	['N']	[0]
1	autoimmune	B	['N']	[1]
2	hemolytic	I	['N']	[2]
3	anemia	I-Adverse_Effect	['N']	[3]
4	following	O	['N']	[4]
5	rituximab	B-Drug	['Causes']	[3]
6	therapy	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	a	O	['N']	[11]
12	lymphoproliferative	O	['N']	[12]
13	disorder	O	['N']	[13]
14	.	O	['N']	[14]
#2328
0	Extensive	B	['N']	[0]
1	forearm	I	['N']	[1]
2	deep	I	['N']	[2]
3	venous	I	['N']	[3]
4	thrombosis	I-Adverse_Effect	['N']	[4]
5	following	O	['N']	[5]
6	a	O	['N']	[6]
7	severe	O	['N']	[7]
8	infliximab	B-Drug	['Causes']	[4]
9	infusion	O	['N']	[9]
10	reaction	O	['N']	[10]
11	.	O	['N']	[11]
#2329
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	multiple	O	['N']	[7]
8	episodes	O	['N']	[8]
9	of	O	['N']	[9]
10	seizure	B-Adverse_Effect	['N']	[10]
11	activity	O	['N']	[11]
12	in	O	['N']	[12]
13	an	O	['N']	[13]
14	AIDS	O	['N']	[14]
15	patent	O	['N']	[15]
16	following	O	['N']	[16]
17	amphotericin	B	['N']	[17]
18	B	I-Drug	['Causes']	[10]
19	infusion	O	['N']	[19]
20	.	O	['N']	[20]
#2330
0	Possible	O	['N']	[0]
1	interaction	O	['N']	[1]
2	between	O	['N']	[2]
3	lopinavir	O	['N']	[3]
4	/	O	['N']	[4]
5	ritonavir	O	['N']	[5]
6	and	O	['N']	[6]
7	valproic	B	['N']	[7]
8	Acid	I-Drug	['Causes']	[11]
9	exacerbates	O	['N']	[9]
10	bipolar	B	['N']	[10]
11	disorder	I-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#2331
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	acute	B	['N']	[3]
4	subdural	I	['N']	[4]
5	haematoma	I-Adverse_Effect	['N']	[5]
6	originating	O	['N']	[6]
7	spontaneously	O	['N']	[7]
8	from	O	['N']	[8]
9	an	O	['N']	[9]
10	angiomatous	O	['N']	[10]
11	meningioma	O	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	patient	O	['N']	[14]
15	receiving	O	['N']	[15]
16	prophylactic	O	['N']	[16]
17	aspirin	B-Drug	['Causes']	[5]
18	therapy	O	['N']	[18]
19	is	O	['N']	[19]
20	presented	O	['N']	[20]
21	.	O	['N']	[21]
#2332
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	papillary	B	['N']	[5]
6	necrosis	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	indinavir	B-Drug	['Causes']	[6]
13	.	O	['N']	[13]
#2333
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Acetic	B	['N']	[2]
3	acid	I-Drug	['Causes']	[10]
4	is	O	['N']	[4]
5	corrosive	O	['N']	[5]
6	and	O	['N']	[6]
7	may	O	['N']	[7]
8	cause	O	['N']	[8]
9	vagina	B	['N']	[9]
10	bleeding	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#2334
0	Although	O	['N']	[0]
1	gabapentin	B-Drug	['Causes']	[26]
2	withdrawal	O	['N']	[2]
3	has	O	['N']	[3]
4	been	O	['N']	[4]
5	previously	O	['N']	[5]
6	reported	O	['N']	[6]
7	and	O	['N']	[7]
8	usually	O	['N']	[8]
9	consists	O	['N']	[9]
10	of	O	['N']	[10]
11	anxiety	O	['N']	[11]
12	,	O	['N']	[12]
13	diaphoresis	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	palpitations	O	['N']	[16]
17	,	O	['N']	[17]
18	this	O	['N']	[18]
19	is	O	['N']	[19]
20	the	O	['N']	[20]
21	first	O	['N']	[21]
22	reported	O	['N']	[22]
23	patient	O	['N']	[23]
24	with	O	['N']	[24]
25	generalized	B	['N']	[25]
26	seizures	I-Adverse_Effect	['N']	[26]
27	and	O	['N']	[27]
28	status	O	['N']	[28]
29	epilepticus	O	['N']	[29]
30	secondary	O	['N']	[30]
31	to	O	['N']	[31]
32	gabapentin	O	['N']	[32]
33	withdrawal	O	['N']	[33]
34	.	O	['N']	[34]
#2335
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	calcineurin	B-Drug	['Causes']	[11]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	pain	B	['N']	[10]
11	syndrome	I-Adverse_Effect	['N']	[11]
12	(	O	['N']	[12]
13	CIPS	O	['N']	[13]
14	)	O	['N']	[14]
15	in	O	['N']	[15]
16	a	O	['N']	[16]
17	child	O	['N']	[17]
18	undergoing	O	['N']	[18]
19	his	O	['N']	[19]
20	second	O	['N']	[20]
21	hematopoietic	O	['N']	[21]
22	stem	O	['N']	[22]
23	cell	O	['N']	[23]
24	transplant	O	['N']	[24]
25	(	O	['N']	[25]
26	HSCT	O	['N']	[26]
27	)	O	['N']	[27]
28	.	O	['N']	[28]
#2336
0	An	O	['N']	[0]
1	infant	O	['N']	[1]
2	who	O	['N']	[2]
3	developed	O	['N']	[3]
4	pancreatitis	B-Adverse_Effect	['N']	[4]
5	during	O	['N']	[5]
6	meglumine	B	['N']	[6]
7	antimoniate	I-Drug	['Causes']	[4]
8	treatment	O	['N']	[8]
9	for	O	['N']	[9]
10	visceral	O	['N']	[10]
11	leishmaniasis	O	['N']	[11]
12	and	O	['N']	[12]
13	who	O	['N']	[13]
14	was	O	['N']	[14]
15	successfully	O	['N']	[15]
16	treated	O	['N']	[16]
17	with	O	['N']	[17]
18	a	O	['N']	[18]
19	combination	O	['N']	[19]
20	of	O	['N']	[20]
21	allopurinol	O	['N']	[21]
22	and	O	['N']	[22]
23	ketoconazole	O	['N']	[23]
24	is	O	['N']	[24]
25	reported	O	['N']	[25]
26	.	O	['N']	[26]
#2337
0	In	O	['N']	[0]
1	a	O	['N']	[1]
2	61-year	O	['N']	[2]
3	-	O	['N']	[3]
4	old	O	['N']	[4]
5	man	O	['N']	[5]
6	receiving	O	['N']	[6]
7	chronic	O	['N']	[7]
8	low	O	['N']	[8]
9	-	O	['N']	[9]
10	dosage	O	['N']	[10]
11	amiodarone	B-Drug	['Causes']	[14]
12	an	O	['N']	[12]
13	interstitial	B	['N']	[13]
14	pneumopathy	I-Adverse_Effect	['N']	[14]
15	was	O	['N']	[15]
16	observed	O	['N']	[16]
17	.	O	['N']	[17]
#2338
0	These	O	['N']	[0]
1	findings	O	['N']	[1]
2	mean	O	['N']	[2]
3	that	O	['N']	[3]
4	the	O	['N']	[4]
5	effect	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	MP	B-Drug	['Causes']	[95]
9	pulse	O	['N']	[9]
10	therapy	O	['N']	[10]
11	on	O	['N']	[11]
12	renal	O	['N']	[12]
13	function	O	['N']	[13]
14	depends	O	['N']	[14]
15	on	O	['N']	[15]
16	the	O	['N']	[16]
17	clinical	O	['N']	[17]
18	state	O	['N']	[18]
19	of	O	['N']	[19]
20	the	O	['N']	[20]
21	patient	O	['N']	[21]
22	and	O	['N']	[22]
23	that	O	['N']	[23]
24	renal	O	['N']	[24]
25	deterioration	O	['N']	[25]
26	after	O	['N']	[26]
27	the	O	['N']	[27]
28	pulse	O	['N']	[28]
29	therapy	O	['N']	[29]
30	may	O	['N']	[30]
31	be	O	['N']	[31]
32	more	O	['N']	[32]
33	marked	O	['N']	[33]
34	in	O	['N']	[34]
35	patients	O	['N']	[35]
36	who	O	['N']	[36]
37	are	O	['N']	[37]
38	more	O	['N']	[38]
39	nephrotic	O	['N']	[39]
40	and	O	['N']	[40]
41	more	O	['N']	[41]
42	impaired	O	['N']	[42]
43	in	O	['N']	[43]
44	renal	O	['N']	[44]
45	function	O	['N']	[45]
46	and	O	['N']	[46]
47	suggest	O	['N']	[47]
48	that	O	['N']	[48]
49	increasing	O	['N']	[49]
50	sodium	O	['N']	[50]
51	and	O	['N']	[51]
52	water	O	['N']	[52]
53	retention	O	['N']	[53]
54	during	O	['N']	[54]
55	an	O	['N']	[55]
56	MP	O	['N']	[56]
57	therapy	O	['N']	[57]
58	and	O	['N']	[58]
59	the	O	['N']	[59]
60	associated	O	['N']	[60]
61	renal	O	['N']	[61]
62	interstitial	O	['N']	[62]
63	edema	O	['N']	[63]
64	,	O	['N']	[64]
65	proposed	O	['N']	[65]
66	as	O	['N']	[66]
67	one	O	['N']	[67]
68	of	O	['N']	[68]
69	the	O	['N']	[69]
70	mechanisms	O	['N']	[70]
71	of	O	['N']	[71]
72	acute	O	['N']	[72]
73	renal	O	['N']	[73]
74	failure	O	['N']	[74]
75	occurring	O	['N']	[75]
76	in	O	['N']	[76]
77	patients	O	['N']	[77]
78	with	O	['N']	[78]
79	minimal	O	['N']	[79]
80	-	O	['N']	[80]
81	change	O	['N']	[81]
82	nephrotic	O	['N']	[82]
83	syndrome	O	['N']	[83]
84	,	O	['N']	[84]
85	may	O	['N']	[85]
86	be	O	['N']	[86]
87	responsible	O	['N']	[87]
88	for	O	['N']	[88]
89	the	O	['N']	[89]
90	MP	O	['N']	[90]
91	-	O	['N']	[91]
92	induced	O	['N']	[92]
93	transient	B	['N']	[93]
94	renal	I	['N']	[94]
95	failure	I-Adverse_Effect	['N']	[95]
96	.	O	['N']	[96]
#2339
0	Rapamycin	B-Drug	['Causes']	[34]
1	/	O	['N']	[1]
2	sirolimus	O	['N']	[2]
3	(	O	['N']	[3]
4	SR	O	['N']	[4]
5	)	O	['N']	[5]
6	,	O	['N']	[6]
7	trade	O	['N']	[7]
8	named	O	['N']	[8]
9	Rapammune	O	['N']	[9]
10	(	O	['N']	[10]
11	Wyeth	O	['N']	[11]
12	-	O	['N']	[12]
13	Ayerst	O	['N']	[13]
14	,	O	['N']	[14]
15	Sydney	O	['N']	[15]
16	,	O	['N']	[16]
17	Australia	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	is	O	['N']	[20]
21	a	O	['N']	[21]
22	potent	O	['N']	[22]
23	immunosuppressive	O	['N']	[23]
24	drug	O	['N']	[24]
25	associated	O	['N']	[25]
26	with	O	['N']	[26]
27	myelosuppression	O	['N']	[27]
28	,	O	['N']	[28]
29	hypertension	O	['N']	[29]
30	,	O	['N']	[30]
31	hyperlipidemia	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	infection	B-Adverse_Effect	['N']	[34]
35	.	O	['N']	[35]
#2340
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	surprising	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	woman	O	['N']	[7]
8	schizophrenic	O	['N']	[8]
9	patient	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	clozapine	B-Drug	['Causes']	[15]
13	suffering	O	['N']	[13]
14	from	O	['N']	[14]
15	EPS	B-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#2341
0	FINDINGS	O	['N']	[0]
1	:	O	['N']	[1]
2	Six	O	['N']	[2]
3	children	O	['N']	[3]
4	with	O	['N']	[4]
5	growth	O	['N']	[5]
6	retardation	O	['N']	[6]
7	noted	O	['N']	[7]
8	after	O	['N']	[8]
9	treatment	O	['N']	[9]
10	with	O	['N']	[10]
11	high	O	['N']	[11]
12	-	O	['N']	[12]
13	dose	O	['N']	[13]
14	fluticasone	B	['N']	[14]
15	propionate	I-Drug	['Causes']	[21]
16	were	O	['N']	[16]
17	found	O	['N']	[17]
18	to	O	['N']	[18]
19	have	O	['N']	[19]
20	adrenal	B	['N']	[20]
21	suppression	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#2342
0	Although	O	['N']	[0]
1	an	O	['N']	[1]
2	association	O	['N']	[2]
3	between	O	['N']	[3]
4	exposure	O	['N']	[4]
5	to	O	['N']	[5]
6	bleomycin	B-Drug	['Causes']	[11]
7	and	O	['N']	[7]
8	the	O	['N']	[8]
9	development	O	['N']	[9]
10	of	O	['N']	[10]
11	scleroderma	B-Adverse_Effect	['N']	[11]
12	has	O	['N']	[12]
13	been	O	['N']	[13]
14	suspected	O	['N']	[14]
15	,	O	['N']	[15]
16	few	O	['N']	[16]
17	cases	O	['N']	[17]
18	are	O	['N']	[18]
19	reported	O	['N']	[19]
20	.	O	['N']	[20]
#2343
0	Abnormal	B	['N']	[0]
1	retinal	I	['N']	[1]
2	function	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	isotretinoin	B-Drug	['Causes']	[2]
6	therapy	O	['N']	[6]
7	for	O	['N']	[7]
8	acne	O	['N']	[8]
9	.	O	['N']	[9]
#2344
0	Hydroxyurea	B-Drug	['Causes']	[13]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	concomitant	O	['N']	[3]
4	occurrence	O	['N']	[4]
5	of	O	['N']	[5]
6	diffuse	O	['N']	[6]
7	longitudinal	O	['N']	[7]
8	melanonychia	O	['N']	[8]
9	and	O	['N']	[9]
10	multiple	B	['N']	[10]
11	squamous	I	['N']	[11]
12	cell	I	['N']	[12]
13	carcinomas	I-Adverse_Effect	['N']	[13]
14	in	O	['N']	[14]
15	an	O	['N']	[15]
16	elderly	O	['N']	[16]
17	subject	O	['N']	[17]
18	.	O	['N']	[18]
#2345
0	We	O	['N']	[0]
1	introduce	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	sixty	O	['N']	[6]
7	years	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	with	O	['N']	[10]
11	several	O	['N']	[11]
12	previous	O	['N']	[12]
13	episodes	O	['N']	[13]
14	of	O	['N']	[14]
15	rhinitis	O	['N']	[15]
16	,	O	['N']	[16]
17	conjunctivitis	B-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	perspiration	O	['N']	[19]
20	immediately	O	['N']	[20]
21	after	O	['N']	[21]
22	the	O	['N']	[22]
23	administration	O	['N']	[23]
24	of	O	['N']	[24]
25	salmon	O	['N']	[25]
26	calcitonin	B-Drug	['Causes']	[17]
27	with	O	['N']	[27]
28	nasal	O	['N']	[28]
29	spray	O	['N']	[29]
30	or	O	['N']	[30]
31	intramuscular	O	['N']	[31]
32	administration	O	['N']	[32]
33	(	O	['N']	[33]
34	Calsynar	O	['N']	[34]
35	)	O	['N']	[35]
36	.	O	['N']	[36]
#2346
0	A	O	['N']	[0]
1	young	O	['N']	[1]
2	diamond	O	['N']	[2]
3	dealer	O	['N']	[3]
4	developed	O	['N']	[4]
5	visual	O	['N']	[5]
6	impairment	O	['N']	[6]
7	attributed	O	['N']	[7]
8	to	O	['N']	[8]
9	bilateral	O	['N']	[9]
10	posterior	O	['N']	[10]
11	subcapsular	O	['N']	[11]
12	cataracts	O	['N']	[12]
13	following	O	['N']	[13]
14	only	O	['N']	[14]
15	four	O	['N']	[15]
16	courses	O	['N']	[16]
17	of	O	['N']	[17]
18	intermittent	O	['N']	[18]
19	Decadron	O	['N']	[19]
20	used	O	['N']	[20]
21	as	O	['N']	[21]
22	part	O	['N']	[22]
23	of	O	['N']	[23]
24	a	O	['N']	[24]
25	five	O	['N']	[25]
26	-	O	['N']	[26]
27	drug	O	['N']	[27]
28	antiemetic	O	['N']	[28]
29	regimen	O	['N']	[29]
30	for	O	['N']	[30]
31	cisplatin	B-Drug	['Causes']	[34]
32	-	O	['N']	[32]
33	associated	O	['N']	[33]
34	nausea	B-Adverse_Effect	['N']	[34]
35	.	O	['N']	[35]
#2347
0	Gemcitabine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	pulmonary	B	['N']	[3]
4	toxicity	I-Adverse_Effect	['N']	[4]
5	is	O	['N']	[5]
6	usually	O	['N']	[6]
7	a	O	['N']	[7]
8	dramatic	O	['N']	[8]
9	condition	O	['N']	[9]
10	.	O	['N']	[10]
#2348
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	admitted	O	['N']	[4]
5	with	O	['N']	[5]
6	a	O	['N']	[6]
7	first	O	['N']	[7]
8	-	O	['N']	[8]
9	detected	O	['N']	[9]
10	,	O	['N']	[10]
11	symptomatic	B	['N']	[11]
12	paroxysmal	I	['N']	[12]
13	atrial	I	['N']	[13]
14	fibrillation	I-Adverse_Effect	['N']	[14]
15	in	O	['N']	[15]
16	a	O	['N']	[16]
17	healthy	O	['N']	[17]
18	patient	O	['N']	[18]
19	after	O	['N']	[19]
20	self	O	['N']	[20]
21	-	O	['N']	[21]
22	medication	O	['N']	[22]
23	with	O	['N']	[23]
24	vardenafil	B-Drug	['Causes']	[14]
25	.	O	['N']	[25]
#2349
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	an	O	['N']	[2]
3	image	O	['N']	[3]
4	and	O	['N']	[4]
5	brief	O	['N']	[5]
6	case	O	['N']	[6]
7	report	O	['N']	[7]
8	of	O	['N']	[8]
9	a	O	['N']	[9]
10	13-year	O	['N']	[10]
11	-	O	['N']	[11]
12	old	O	['N']	[12]
13	boy	O	['N']	[13]
14	who	O	['N']	[14]
15	presented	O	['N']	[15]
16	with	O	['N']	[16]
17	severe	B	['N']	[17]
18	rash	I-Adverse_Effect	['N']	[18]
19	and	O	['N']	[19]
20	systemic	O	['N']	[20]
21	symptoms	O	['N']	[21]
22	after	O	['N']	[22]
23	starting	O	['N']	[23]
24	oxcarbazepine	B-Drug	['Causes']	[18]
25	.	O	['N']	[25]
#2350
0	Glomerulonephritis	O	['N']	[0]
1	in	O	['N']	[1]
2	procainamide	B-Drug	['Causes']	[5]
3	induced	O	['N']	[3]
4	lupus	B	['N']	[4]
5	erythematosus	I-Adverse_Effect	['N']	[5]
6	:	O	['N']	[6]
7	report	O	['N']	[7]
8	of	O	['N']	[8]
9	a	O	['N']	[9]
10	case	O	['N']	[10]
11	and	O	['N']	[11]
12	review	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	literature	O	['N']	[15]
16	.	O	['N']	[16]
#2351
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	high	O	['N']	[3]
4	-	O	['N']	[4]
5	grade	O	['N']	[5]
6	endometrial	O	['N']	[6]
7	stromal	O	['N']	[7]
8	sarcoma	O	['N']	[8]
9	,	O	['N']	[9]
10	confined	O	['N']	[10]
11	into	O	['N']	[11]
12	an	O	['N']	[12]
13	intrauterine	B	['N']	[13]
14	polypoid	I	['N']	[14]
15	growth	I-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	in	O	['N']	[17]
18	a	O	['N']	[18]
19	woman	O	['N']	[19]
20	with	O	['N']	[20]
21	a	O	['N']	[21]
22	history	O	['N']	[22]
23	of	O	['N']	[23]
24	breast	O	['N']	[24]
25	cancer	O	['N']	[25]
26	who	O	['N']	[26]
27	was	O	['N']	[27]
28	treated	O	['N']	[28]
29	with	O	['N']	[29]
30	adjuvant	O	['N']	[30]
31	tamoxifen	B-Drug	['Causes']	[15]
32	.	O	['N']	[32]
#2352
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	this	O	['N']	[4]
5	is	O	['N']	[5]
6	the	O	['N']	[6]
7	first	O	['N']	[7]
8	granulomatous	B	['N']	[8]
9	reaction	I-Adverse_Effect	['N']	[9]
10	described	O	['N']	[10]
11	after	O	['N']	[11]
12	calcium	B	['N']	[12]
13	hydroxylapatite	I-Drug	['Causes']	[9]
14	injection	O	['N']	[14]
15	.	O	['N']	[15]
#2353
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	subarachnoid	O	['N']	[6]
7	haemorrhage	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	an	O	['N']	[10]
11	acute	O	['N']	[11]
12	life	O	['N']	[12]
13	-	O	['N']	[13]
14	threatening	O	['N']	[14]
15	pseudo	O	['N']	[15]
16	-	O	['N']	[16]
17	obstruction	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	colon	O	['N']	[20]
21	,	O	['N']	[21]
22	a	O	['N']	[22]
23	variant	O	['N']	[23]
24	of	O	['N']	[24]
25	adynamic	B	['N']	[25]
26	ileus	I-Adverse_Effect	['N']	[26]
27	,	O	['N']	[27]
28	while	O	['N']	[28]
29	being	O	['N']	[29]
30	treated	O	['N']	[30]
31	with	O	['N']	[31]
32	intravenous	O	['N']	[32]
33	nimodipine	B-Drug	['Causes']	[26]
34	.	O	['N']	[34]
#2354
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	focal	O	['N']	[6]
7	myocardial	O	['N']	[7]
8	necrosis	O	['N']	[8]
9	,	O	['N']	[9]
10	presenting	O	['N']	[10]
11	clinically	O	['N']	[11]
12	as	O	['N']	[12]
13	an	O	['N']	[13]
14	acute	B	['N']	[14]
15	myocardial	I	['N']	[15]
16	infarction	I-Adverse_Effect	['N']	[16]
17	during	O	['N']	[17]
18	the	O	['N']	[18]
19	administration	O	['N']	[19]
20	of	O	['N']	[20]
21	the	O	['N']	[21]
22	antineoplastic	O	['N']	[22]
23	drug	O	['N']	[23]
24	,	O	['N']	[24]
25	amsacrine	B-Drug	['Causes']	[16]
26	,	O	['N']	[26]
27	in	O	['N']	[27]
28	a	O	['N']	[28]
29	patient	O	['N']	[29]
30	without	O	['N']	[30]
31	coronary	O	['N']	[31]
32	artery	O	['N']	[32]
33	disease	O	['N']	[33]
34	.	O	['N']	[34]
#2355
0	Pneumonitis	O	['N']	[0]
1	,	O	['N']	[1]
2	bilateral	O	['N']	[2]
3	pleural	O	['N']	[3]
4	effusions	O	['N']	[4]
5	,	O	['N']	[5]
6	echocardiographic	O	['N']	[6]
7	evidence	O	['N']	[7]
8	of	O	['N']	[8]
9	cardiac	O	['N']	[9]
10	tamponade	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	positive	B	['N']	[13]
14	autoantibodies	I-Adverse_Effect	['N']	[14]
15	developed	O	['N']	[15]
16	in	O	['N']	[16]
17	a	O	['N']	[17]
18	43-year	O	['N']	[18]
19	-	O	['N']	[19]
20	old	O	['N']	[20]
21	man	O	['N']	[21]
22	,	O	['N']	[22]
23	who	O	['N']	[23]
24	was	O	['N']	[24]
25	receiving	O	['N']	[25]
26	long	O	['N']	[26]
27	-	O	['N']	[27]
28	term	O	['N']	[28]
29	sulfasalazine	B-Drug	['Causes']	[14]
30	therapy	O	['N']	[30]
31	for	O	['N']	[31]
32	chronic	O	['N']	[32]
33	ulcerative	O	['N']	[33]
34	colitis	O	['N']	[34]
35	.	O	['N']	[35]
#2356
0	CASE	O	['N']	[0]
1	SUMMARIES	O	['N']	[1]
2	:	O	['N']	[2]
3	In	O	['N']	[3]
4	each	O	['N']	[4]
5	case	O	['N']	[5]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	patients	O	['N']	[8]
9	were	O	['N']	[9]
10	treated	O	['N']	[10]
11	over	O	['N']	[11]
12	5	O	['N']	[12]
13	years	O	['N']	[13]
14	with	O	['N']	[14]
15	lovastatin	B-Drug	['Causes']	[18]
16	and	O	['N']	[16]
17	developed	O	['N']	[17]
18	rhabdomyolysis	B-Adverse_Effect	['N']	[18]
19	that	O	['N']	[19]
20	coincided	O	['N']	[20]
21	with	O	['N']	[21]
22	the	O	['N']	[22]
23	completion	O	['N']	[23]
24	of	O	['N']	[24]
25	a	O	['N']	[25]
26	prescribed	O	['N']	[26]
27	regimen	O	['N']	[27]
28	of	O	['N']	[28]
29	a	O	['N']	[29]
30	newer	O	['N']	[30]
31	macrolide	O	['N']	[31]
32	antibiotic	O	['N']	[32]
33	.	O	['N']	[33]
#2357
0	Managing	O	['N']	[0]
1	cardiovascular	O	['N']	[1]
2	collapse	O	['N']	[2]
3	in	O	['N']	[3]
4	severe	O	['N']	[4]
5	flecainide	B-Drug	['Dosage']	[6]
6	overdose	B-Dose	['N']	[6]
7	without	O	['N']	[7]
8	recourse	O	['N']	[8]
9	to	O	['N']	[9]
10	extracorporeal	O	['N']	[10]
11	therapy	O	['N']	[11]
12	.	O	['N']	[12]
#2358
0	After	O	['N']	[0]
1	discontinuing	O	['N']	[1]
2	captopril	B-Drug	['Causes']	[15]
3	and	O	['N']	[3]
4	starting	O	['N']	[4]
5	systemic	O	['N']	[5]
6	steroids	O	['N']	[6]
7	,	O	['N']	[7]
8	her	O	['N']	[8]
9	symptomatology	O	['N']	[9]
10	rapidly	O	['N']	[10]
11	improved	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	her	O	['N']	[14]
15	eosinophilia	B-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	radiographic	O	['N']	[17]
18	abnormalities	O	['N']	[18]
19	both	O	['N']	[19]
20	resolved	O	['N']	[20]
21	.	O	['N']	[21]
#2359
0	Cutaneous	B	['N']	[0]
1	eruptions	I-Adverse_Effect	['N']	[1]
2	occur	O	['N']	[2]
3	in	O	['N']	[3]
4	3	O	['N']	[4]
5	%	O	['N']	[5]
6	of	O	['N']	[6]
7	individuals	O	['N']	[7]
8	administered	O	['N']	[8]
9	carbamazepine	B-Drug	['Causes']	[1]
10	.	O	['N']	[10]
#2360
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	mild	B	['N']	[8]
9	chronic	I	['N']	[9]
10	renal	I	['N']	[10]
11	insufficiency	I-Adverse_Effect	['N']	[11]
12	who	O	['N']	[12]
13	had	O	['N']	[13]
14	been	O	['N']	[14]
15	taking	O	['N']	[15]
16	simvastatin	B-Drug	['Causes']	[11]
17	for	O	['N']	[17]
18	over	O	['N']	[18]
19	a	O	['N']	[19]
20	year	O	['N']	[20]
21	and	O	['N']	[21]
22	developed	O	['N']	[22]
23	acute	O	['N']	[23]
24	weakness	O	['N']	[24]
25	within	O	['N']	[25]
26	3	O	['N']	[26]
27	weeks	O	['N']	[27]
28	after	O	['N']	[28]
29	the	O	['N']	[29]
30	start	O	['N']	[30]
31	of	O	['N']	[31]
32	treatment	O	['N']	[32]
33	with	O	['N']	[33]
34	colchicine	O	['N']	[34]
35	for	O	['N']	[35]
36	acute	O	['N']	[36]
37	gouty	O	['N']	[37]
38	bursitis	O	['N']	[38]
39	.	O	['N']	[39]
#2361
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	colchicine	B-Drug	['Causes']	[10]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	myopathy	B-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	teenager	O	['N']	[13]
14	with	O	['N']	[14]
15	familial	O	['N']	[15]
16	Mediterranean	O	['N']	[16]
17	fever	O	['N']	[17]
18	(	O	['N']	[18]
19	FMF	O	['N']	[19]
20	)	O	['N']	[20]
21	.	O	['N']	[21]
#2362
0	Hyperammonemia	O	['N']	[0]
1	secondary	O	['N']	[1]
2	to	O	['N']	[2]
3	valproic	B	['N']	[3]
4	acid	I-Drug	['Causes']	[9]
5	as	O	['N']	[5]
6	a	O	['N']	[6]
7	cause	O	['N']	[7]
8	of	O	['N']	[8]
9	lethargy	B-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	postictal	O	['N']	[12]
13	patient	O	['N']	[13]
14	.	O	['N']	[14]
#2363
0	Although	O	['N']	[0]
1	gabapentin	B-Drug	['Causes']	[11]
2	withdrawal	O	['N']	[2]
3	has	O	['N']	[3]
4	been	O	['N']	[4]
5	previously	O	['N']	[5]
6	reported	O	['N']	[6]
7	and	O	['N']	[7]
8	usually	O	['N']	[8]
9	consists	O	['N']	[9]
10	of	O	['N']	[10]
11	anxiety	B-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	diaphoresis	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	palpitations	O	['N']	[16]
17	,	O	['N']	[17]
18	this	O	['N']	[18]
19	is	O	['N']	[19]
20	the	O	['N']	[20]
21	first	O	['N']	[21]
22	reported	O	['N']	[22]
23	patient	O	['N']	[23]
24	with	O	['N']	[24]
25	generalized	O	['N']	[25]
26	seizures	O	['N']	[26]
27	and	O	['N']	[27]
28	status	O	['N']	[28]
29	epilepticus	O	['N']	[29]
30	secondary	O	['N']	[30]
31	to	O	['N']	[31]
32	gabapentin	O	['N']	[32]
33	withdrawal	O	['N']	[33]
34	.	O	['N']	[34]
#2364
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	exceptional	O	['N']	[3]
4	development	O	['N']	[4]
5	of	O	['N']	[5]
6	AML	O	['N']	[6]
7	and	O	['N']	[7]
8	lung	B	['N']	[8]
9	cancer	I-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	patient	O	['N']	[12]
13	with	O	['N']	[13]
14	previously	O	['N']	[14]
15	diagnosed	O	['N']	[15]
16	CLL	O	['N']	[16]
17	in	O	['N']	[17]
18	minimal	O	['N']	[18]
19	residual	O	['N']	[19]
20	disease	O	['N']	[20]
21	status	O	['N']	[21]
22	after	O	['N']	[22]
23	fludarabine	B-Drug	['Causes']	[9]
24	treatment	O	['N']	[24]
25	followed	O	['N']	[25]
26	by	O	['N']	[26]
27	autologous	O	['N']	[27]
28	peripheral	O	['N']	[28]
29	blood	O	['N']	[29]
30	stem	O	['N']	[30]
31	-	O	['N']	[31]
32	cell	O	['N']	[32]
33	transplantation	O	['N']	[33]
34	.	O	['N']	[34]
#2365
0	Extra	O	['N']	[0]
1	caution	O	['N']	[1]
2	should	O	['N']	[2]
3	be	O	['N']	[3]
4	taken	O	['N']	[4]
5	in	O	['N']	[5]
6	using	O	['N']	[6]
7	octreotide	B-Drug	['Causes']	[21]
8	or	O	['N']	[8]
9	its	O	['N']	[9]
10	long	O	['N']	[10]
11	-	O	['N']	[11]
12	acting	O	['N']	[12]
13	analog	O	['N']	[13]
14	in	O	['N']	[14]
15	patients	O	['N']	[15]
16	otherwise	O	['N']	[16]
17	predisposed	O	['N']	[17]
18	to	O	['N']	[18]
19	intrahepatic	B	['N']	[19]
20	bile	I	['N']	[20]
21	stasis	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#2366
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	pancytopenia	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	23-year	O	['N']	[8]
9	-	O	['N']	[9]
10	old	O	['N']	[10]
11	man	O	['N']	[11]
12	with	O	['N']	[12]
13	Crohn	O	['N']	[13]
14	's	O	['N']	[14]
15	disease	O	['N']	[15]
16	who	O	['N']	[16]
17	was	O	['N']	[17]
18	treated	O	['N']	[18]
19	with	O	['N']	[19]
20	5-aminosalicylic	O	['N']	[20]
21	acid	O	['N']	[21]
22	(	O	['N']	[22]
23	Pentasa	B-Drug	['Dosage']	[34]
24	;	O	['N']	[24]
25	Nisshin	O	['N']	[25]
26	,	O	['N']	[26]
27	Tokyo	O	['N']	[27]
28	,	O	['N']	[28]
29	Japan	O	['N']	[29]
30	)	O	['N']	[30]
31	3.0	B	['N']	[31]
32	g	I	['N']	[32]
33	/	I	['N']	[33]
34	day	I-Dose	['N']	[34]
35	.	O	['N']	[35]
#2367
0	Multiple	O	['N']	[0]
1	complications	O	['N']	[1]
2	of	O	['N']	[2]
3	propylthiouracil	B-Drug	['Causes']	[13]
4	treatment	O	['N']	[4]
5	:	O	['N']	[5]
6	granulocytopenia	O	['N']	[6]
7	,	O	['N']	[7]
8	eosinophilia	O	['N']	[8]
9	,	O	['N']	[9]
10	skin	O	['N']	[10]
11	reaction	O	['N']	[11]
12	and	O	['N']	[12]
13	hepatitis	B-Adverse_Effect	['N']	[13]
14	with	O	['N']	[14]
15	lymphocyte	O	['N']	[15]
16	sensitization	O	['N']	[16]
17	.	O	['N']	[17]
#2368
0	Psychotic	B	['N']	[0]
1	disorder	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	isoniazid	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#2369
0	Although	O	['N']	[0]
1	interferon	O	['N']	[1]
2	gamma	O	['N']	[2]
3	has	O	['N']	[3]
4	been	O	['N']	[4]
5	implicated	O	['N']	[5]
6	in	O	['N']	[6]
7	the	O	['N']	[7]
8	pathogenesis	O	['N']	[8]
9	of	O	['N']	[9]
10	sarcoidosis	B-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	only	O	['N']	[12]
13	a	O	['N']	[13]
14	few	O	['N']	[14]
15	cases	O	['N']	[15]
16	of	O	['N']	[16]
17	sarcoidosis	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	interferon	B	['N']	[20]
21	alpha	I-Drug	['Causes']	[10]
22	therapy	O	['N']	[22]
23	have	O	['N']	[23]
24	been	O	['N']	[24]
25	reported	O	['N']	[25]
26	.	O	['N']	[26]
#2370
0	Both	O	['N']	[0]
1	6-MP	B-Drug	['Causes']	[12]
2	and	O	['N']	[2]
3	AZA	O	['N']	[3]
4	are	O	['N']	[4]
5	widely	O	['N']	[5]
6	used	O	['N']	[6]
7	and	O	['N']	[7]
8	are	O	['N']	[8]
9	known	O	['N']	[9]
10	to	O	['N']	[10]
11	cause	O	['N']	[11]
12	hepatotoxicity	B-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	proportion	O	['N']	[15]
16	of	O	['N']	[16]
17	patients	O	['N']	[17]
18	.	O	['N']	[18]
#2371
0	The	O	['N']	[0]
1	evidence	O	['N']	[1]
2	of	O	['N']	[2]
3	high	O	['N']	[3]
4	plasmatic	O	['N']	[4]
5	levels	O	['N']	[5]
6	of	O	['N']	[6]
7	CBZ	B-Drug	['Dosage']	[22]
8	and	O	['N']	[8]
9	the	O	['N']	[9]
10	absence	O	['N']	[10]
11	of	O	['N']	[11]
12	other	O	['N']	[12]
13	aetiologic	O	['N']	[13]
14	factors	O	['N']	[14]
15	lead	O	['N']	[15]
16	the	O	['N']	[16]
17	authors	O	['N']	[17]
18	to	O	['N']	[18]
19	conclude	O	['N']	[19]
20	that	O	['N']	[20]
21	the	O	['N']	[21]
22	overdose	B-Dose	['N']	[22]
23	of	O	['N']	[23]
24	CBZ	O	['N']	[24]
25	could	O	['N']	[25]
26	have	O	['N']	[26]
27	represented	O	['N']	[27]
28	the	O	['N']	[28]
29	precipitating	O	['N']	[29]
30	of	O	['N']	[30]
31	the	O	['N']	[31]
32	episode	O	['N']	[32]
33	of	O	['N']	[33]
34	acute	O	['N']	[34]
35	pancreatitis	O	['N']	[35]
36	.	O	['N']	[36]
#2372
0	A	O	['N']	[0]
1	57-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	right	O	['N']	[6]
7	bundle	O	['N']	[7]
8	branch	O	['N']	[8]
9	block	O	['N']	[9]
10	+	O	['N']	[10]
11	LPH	O	['N']	[11]
12	and	O	['N']	[12]
13	ventricular	O	['N']	[13]
14	premature	O	['N']	[14]
15	contractions	O	['N']	[15]
16	developed	O	['N']	[16]
17	complete	O	['N']	[17]
18	heart	O	['N']	[18]
19	block	O	['N']	[19]
20	(	O	['N']	[20]
21	CHB	B-Adverse_Effect	['N']	[21]
22	)	O	['N']	[22]
23	following	O	['N']	[23]
24	administration	O	['N']	[24]
25	of	O	['N']	[25]
26	disopyramide	O	['N']	[26]
27	phosphate	O	['N']	[27]
28	(	O	['N']	[28]
29	Norpace	B-Drug	['Causes']	[21]
30	)	O	['N']	[30]
31	.	O	['N']	[31]
#2373
0	A	O	['N']	[0]
1	drug	B	['N']	[1]
2	interaction	I-Adverse_Effect	['N']	[2]
3	between	O	['N']	[3]
4	zafirlukast	B-Drug	['Causes']	[2]
5	and	O	['N']	[5]
6	theophylline	O	['N']	[6]
7	.	O	['N']	[7]
#2374
0	A	O	['N']	[0]
1	60-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	white	O	['N']	[4]
5	man	O	['N']	[5]
6	with	O	['N']	[6]
7	chronic	O	['N']	[7]
8	bronchitis	O	['N']	[8]
9	was	O	['N']	[9]
10	noted	O	['N']	[10]
11	to	O	['N']	[11]
12	develop	O	['N']	[12]
13	acute	B	['N']	[13]
14	respiratory	I	['N']	[14]
15	failure	I-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	metabolic	O	['N']	[17]
18	acidosis	O	['N']	[18]
19	four	O	['N']	[19]
20	days	O	['N']	[20]
21	after	O	['N']	[21]
22	being	O	['N']	[22]
23	started	O	['N']	[23]
24	on	O	['N']	[24]
25	methazolamide	O	['N']	[25]
26	(	O	['N']	[26]
27	Neptazane	B-Drug	['Causes']	[15]
28	)	O	['N']	[28]
29	for	O	['N']	[29]
30	an	O	['N']	[30]
31	ophthalmologic	O	['N']	[31]
32	problem	O	['N']	[32]
33	.	O	['N']	[33]
#2375
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	a	O	['N']	[5]
6	liver	O	['N']	[6]
7	abscess	O	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	Entamoeba	O	['N']	[10]
11	histolytica	O	['N']	[11]
12	,	O	['N']	[12]
13	in	O	['N']	[13]
14	whom	O	['N']	[14]
15	metronidazole	B-Drug	['Causes']	[31]
16	therapy	O	['N']	[16]
17	(	O	['N']	[17]
18	total	O	['N']	[18]
19	dose	O	['N']	[19]
20	,	O	['N']	[20]
21	21	O	['N']	[21]
22	g	O	['N']	[22]
23	over	O	['N']	[23]
24	14	O	['N']	[24]
25	days	O	['N']	[25]
26	)	O	['N']	[26]
27	was	O	['N']	[27]
28	complicated	O	['N']	[28]
29	by	O	['N']	[29]
30	reversible	B	['N']	[30]
31	deafness	I-Adverse_Effect	['N']	[31]
32	,	O	['N']	[32]
33	tinnitus	O	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	ataxia	O	['N']	[36]
37	and	O	['N']	[37]
38	who	O	['N']	[38]
39	relapsed	O	['N']	[39]
40	5	O	['N']	[40]
41	months	O	['N']	[41]
42	later	O	['N']	[42]
43	with	O	['N']	[43]
44	a	O	['N']	[44]
45	splenic	O	['N']	[45]
46	abscess	O	['N']	[46]
47	.	O	['N']	[47]
#2376
0	Dystonia	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	carbamazepine	B-Drug	['Causes']	[0]
4	administration	O	['N']	[4]
5	:	O	['N']	[5]
6	experience	O	['N']	[6]
7	in	O	['N']	[7]
8	brain	O	['N']	[8]
9	-	O	['N']	[9]
10	damaged	O	['N']	[10]
11	children	O	['N']	[11]
12	.	O	['N']	[12]
#2377
0	CASE	O	['N']	[0]
1	SUMMARIES	O	['N']	[1]
2	:	O	['N']	[2]
3	Two	O	['N']	[3]
4	patients	O	['N']	[4]
5	with	O	['N']	[5]
6	stable	O	['N']	[6]
7	hypothyroidism	O	['N']	[7]
8	experienced	O	['N']	[8]
9	symptoms	O	['N']	[9]
10	of	O	['N']	[10]
11	hypothyroidism	O	['N']	[11]
12	with	O	['N']	[12]
13	increased	B	['N']	[13]
14	serum	I	['N']	[14]
15	thyroid	I	['N']	[15]
16	-	I	['N']	[16]
17	stimulating	I	['N']	[17]
18	hormone	I-Adverse_Effect	['N']	[18]
19	(	O	['N']	[19]
20	TSH	O	['N']	[20]
21	)	O	['N']	[21]
22	concentrations	O	['N']	[22]
23	after	O	['N']	[23]
24	switching	O	['N']	[24]
25	from	O	['N']	[25]
26	1	O	['N']	[26]
27	levothyroxine	B-Drug	['Causes']	[18]
28	product	O	['N']	[28]
29	to	O	['N']	[29]
30	another	O	['N']	[30]
31	.	O	['N']	[31]
#2378
0	Hepatoxicity	B-Adverse_Effect	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	rare	O	['N']	[3]
4	complication	O	['N']	[4]
5	of	O	['N']	[5]
6	SRL	B-Drug	['Causes']	[0]
7	therapy	O	['N']	[7]
8	and	O	['N']	[8]
9	may	O	['N']	[9]
10	be	O	['N']	[10]
11	connected	O	['N']	[11]
12	with	O	['N']	[12]
13	some	O	['N']	[13]
14	diagnostic	O	['N']	[14]
15	and/or	O	['N']	[15]
16	therapeutic	O	['N']	[16]
17	problems	O	['N']	[17]
18	.	O	['N']	[18]
#2379
0	By	O	['N']	[0]
1	means	O	['N']	[1]
2	of	O	['N']	[2]
3	the	O	['N']	[3]
4	in	O	['N']	[4]
5	vitro	O	['N']	[5]
6	heparin	O	['N']	[6]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	platelet	B	['N']	[9]
10	activation	I-Adverse_Effect	['N']	[10]
11	(	O	['N']	[11]
12	HIPA	O	['N']	[12]
13	)	O	['N']	[13]
14	assay	O	['N']	[14]
15	it	O	['N']	[15]
16	was	O	['N']	[16]
17	shown	O	['N']	[17]
18	that	O	['N']	[18]
19	standard	O	['N']	[19]
20	heparin	O	['N']	[20]
21	and	O	['N']	[21]
22	the	O	['N']	[22]
23	LMW	O	['N']	[23]
24	heparins	O	['N']	[24]
25	Fragmin	O	['N']	[25]
26	and	O	['N']	[26]
27	Fraxiparin	B-Drug	['Causes']	[10]
28	(	O	['N']	[28]
29	Sanofi	O	['N']	[29]
30	Labaz	O	['N']	[30]
31	,	O	['N']	[31]
32	Munich	O	['N']	[32]
33	,	O	['N']	[33]
34	FRG	O	['N']	[34]
35	)	O	['N']	[35]
36	,	O	['N']	[36]
37	as	O	['N']	[37]
38	well	O	['N']	[38]
39	as	O	['N']	[39]
40	the	O	['N']	[40]
41	enoxaparine	O	['N']	[41]
42	Clexane	O	['N']	[42]
43	(	O	['N']	[43]
44	Nattermann	O	['N']	[44]
45	,	O	['N']	[45]
46	Cologne	O	['N']	[46]
47	,	O	['N']	[47]
48	FRG	O	['N']	[48]
49	)	O	['N']	[49]
50	,	O	['N']	[50]
51	all	O	['N']	[51]
52	induced	O	['N']	[52]
53	platelet	O	['N']	[53]
54	activation	O	['N']	[54]
55	with	O	['N']	[55]
56	the	O	['N']	[56]
57	patient	O	['N']	[57]
58	's	O	['N']	[58]
59	serum	O	['N']	[59]
60	.	O	['N']	[60]
#2380
0	Continuous	O	['N']	[0]
1	EEG	O	['N']	[1]
2	monitoring	O	['N']	[2]
3	is	O	['N']	[3]
4	helpful	O	['N']	[4]
5	in	O	['N']	[5]
6	managing	O	['N']	[6]
7	seizures	B-Adverse_Effect	['N']	[7]
8	that	O	['N']	[8]
9	occur	O	['N']	[9]
10	as	O	['N']	[10]
11	a	O	['N']	[11]
12	complication	O	['N']	[12]
13	of	O	['N']	[13]
14	CBZ	B-Drug	['Causes']	[7]
15	OD	O	['N']	[15]
16	,	O	['N']	[16]
17	after	O	['N']	[17]
18	the	O	['N']	[18]
19	course	O	['N']	[19]
20	of	O	['N']	[20]
21	recovery	O	['N']	[21]
22	or	O	['N']	[22]
23	worsening	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	in	O	['N']	[26]
27	providing	O	['N']	[27]
28	assistance	O	['N']	[28]
29	with	O	['N']	[29]
30	prognosis	O	['N']	[30]
31	.	O	['N']	[31]
#2381
0	Although	O	['N']	[0]
1	both	O	['N']	[1]
2	the	O	['N']	[2]
3	spontaneous	O	['N']	[3]
4	occurrence	O	['N']	[4]
5	of	O	['N']	[5]
6	SLE	B-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	the	O	['N']	[8]
9	psychosis	O	['N']	[9]
10	as	O	['N']	[10]
11	a	O	['N']	[11]
12	sign	O	['N']	[12]
13	of	O	['N']	[13]
14	CNS	O	['N']	[14]
15	involvement	O	['N']	[15]
16	of	O	['N']	[16]
17	SLE	O	['N']	[17]
18	can	O	['N']	[18]
19	not	O	['N']	[19]
20	be	O	['N']	[20]
21	excluded	O	['N']	[21]
22	,	O	['N']	[22]
23	SLE	O	['N']	[23]
24	could	O	['N']	[24]
25	be	O	['N']	[25]
26	considered	O	['N']	[26]
27	as	O	['N']	[27]
28	an	O	['N']	[28]
29	adverse	O	['N']	[29]
30	effect	O	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	B-Drug	['Causes']	[6]
33	.	O	['N']	[33]
#2382
0	METHOD	O	['N']	[0]
1	:	O	['N']	[1]
2	Case	O	['N']	[2]
3	analysis	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	poly	O	['N']	[6]
7	-	O	['N']	[7]
8	drug	O	['N']	[8]
9	overdose	O	['N']	[9]
10	(	O	['N']	[10]
11	venlafaxine	B-Drug	['Causes']	[28]
12	,	O	['N']	[12]
13	topiramate	O	['N']	[13]
14	,	O	['N']	[14]
15	divalproex	O	['N']	[15]
16	sodium	O	['N']	[16]
17	,	O	['N']	[17]
18	risperidone	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	carbamazepine	O	['N']	[21]
22	)	O	['N']	[22]
23	presenting	O	['N']	[23]
24	with	O	['N']	[24]
25	mixed	O	['N']	[25]
26	SS	O	['N']	[26]
27	/	O	['N']	[27]
28	NMS	B-Adverse_Effect	['N']	[28]
29	features	O	['N']	[29]
30	and	O	['N']	[30]
31	whose	O	['N']	[31]
32	clinical	O	['N']	[32]
33	management	O	['N']	[33]
34	suggests	O	['N']	[34]
35	a	O	['N']	[35]
36	practical	O	['N']	[36]
37	algorithm	O	['N']	[37]
38	for	O	['N']	[38]
39	treatment	O	['N']	[39]
40	of	O	['N']	[40]
41	undifferentiated	O	['N']	[41]
42	SS	O	['N']	[42]
43	/	O	['N']	[43]
44	NMS	O	['N']	[44]
45	in	O	['N']	[45]
46	critical	O	['N']	[46]
47	care	O	['N']	[47]
48	settings	O	['N']	[48]
49	.	O	['N']	[49]
#2383
0	Mechanisms	O	['N']	[0]
1	and	O	['N']	[1]
2	triggering	O	['N']	[2]
3	factors	O	['N']	[3]
4	of	O	['N']	[4]
5	hypoglycaemia	B-Adverse_Effect	['N']	[5]
6	induced	O	['N']	[6]
7	by	O	['N']	[7]
8	mefloquine	B-Drug	['Causes']	[5]
9	and	O	['N']	[9]
10	some	O	['N']	[10]
11	other	O	['N']	[11]
12	anti	O	['N']	[12]
13	-	O	['N']	[13]
14	malarial	O	['N']	[14]
15	quinine	O	['N']	[15]
16	analogues	O	['N']	[16]
17	are	O	['N']	[17]
18	discussed	O	['N']	[18]
19	.	O	['N']	[19]
#2384
0	Refractory	B	['N']	[0]
1	hypoglycemia	I-Adverse_Effect	['N']	[1]
2	from	O	['N']	[2]
3	ciprofloxacin	B-Drug	['Causes']	[1]
4	and	O	['N']	[4]
5	glyburide	O	['N']	[5]
6	interaction	O	['N']	[6]
7	.	O	['N']	[7]
#2385
0	The	O	['N']	[0]
1	hospital	O	['N']	[1]
2	course	O	['N']	[2]
3	of	O	['N']	[3]
4	the	O	['N']	[4]
5	acute	B	['N']	[5]
6	renal	I	['N']	[6]
7	failure	I-Adverse_Effect	['N']	[7]
8	is	O	['N']	[8]
9	presented	O	['N']	[9]
10	with	O	['N']	[10]
11	a	O	['N']	[11]
12	review	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	literature	O	['N']	[15]
16	on	O	['N']	[16]
17	cases	O	['N']	[17]
18	of	O	['N']	[18]
19	acute	O	['N']	[19]
20	renal	O	['N']	[20]
21	failure	O	['N']	[21]
22	after	O	['N']	[22]
23	IVIG	B-Drug	['Causes']	[7]
24	.	O	['N']	[24]
#2386
0	The	O	['N']	[0]
1	intramuscular	O	['N']	[1]
2	challenge	O	['N']	[2]
3	test	O	['N']	[3]
4	with	O	['N']	[4]
5	25	O	['N']	[5]
6	UI	O	['N']	[6]
7	of	O	['N']	[7]
8	Miacalcic	B-Drug	['Causes']	[15]
9	was	O	['N']	[9]
10	positive	O	['N']	[10]
11	with	O	['N']	[11]
12	an	O	['N']	[12]
13	immediate	O	['N']	[13]
14	anaphylactic	B	['N']	[14]
15	reaction	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#2387
0	Serotonin	B	['N']	[0]
1	syndrome	I-Adverse_Effect	['N']	[1]
2	caused	O	['N']	[2]
3	by	O	['N']	[3]
4	selective	O	['N']	[4]
5	serotonin	O	['N']	[5]
6	reuptake	O	['N']	[6]
7	-	O	['N']	[7]
8	inhibitors	O	['N']	[8]
9	-	O	['N']	[9]
10	metoclopramide	B-Drug	['Causes']	[1]
11	interaction	O	['N']	[11]
12	.	O	['N']	[12]
#2388
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	55-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	became	O	['N']	[7]
8	stuporous	O	['N']	[8]
9	after	O	['N']	[9]
10	overdose	B-Dose	['N']	[10]
11	with	O	['N']	[11]
12	lamotrigine	B-Drug	['Dosage']	[10]
13	(	O	['N']	[13]
14	LTG	O	['N']	[14]
15	)	O	['N']	[15]
16	and	O	['N']	[16]
17	valproic	O	['N']	[17]
18	acid	O	['N']	[18]
19	(	O	['N']	[19]
20	VPA	O	['N']	[20]
21	)	O	['N']	[21]
22	tablets	O	['N']	[22]
23	.	O	['N']	[23]
#2389
0	Interstitial	O	['N']	[0]
1	lung	O	['N']	[1]
2	disease	O	['N']	[2]
3	(	O	['N']	[3]
4	ILD	B-Adverse_Effect	['N']	[4]
5	)	O	['N']	[5]
6	related	O	['N']	[6]
7	to	O	['N']	[7]
8	therapy	O	['N']	[8]
9	with	O	['N']	[9]
10	the	O	['N']	[10]
11	drug	O	['N']	[11]
12	gefitinib	B-Drug	['Causes']	[4]
13	has	O	['N']	[13]
14	been	O	['N']	[14]
15	well	O	['N']	[15]
16	reported	O	['N']	[16]
17	.	O	['N']	[17]
#2390
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	17-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	male	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	chest	B	['N']	[12]
13	pain	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	elevated	O	['N']	[15]
16	cardiac	O	['N']	[16]
17	biomarkers	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	acute	O	['N']	[20]
21	left	O	['N']	[21]
22	ventricular	O	['N']	[22]
23	dysfunction	O	['N']	[23]
24	following	O	['N']	[24]
25	a	O	['N']	[25]
26	single	O	['N']	[26]
27	dose	O	['N']	[27]
28	of	O	['N']	[28]
29	methylphenidate	B-Drug	['Causes']	[13]
30	.	O	['N']	[30]
#2391
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	acute	B	['N']	[6]
7	renal	I	['N']	[7]
8	failure	I-Adverse_Effect	['N']	[8]
9	with	O	['N']	[9]
10	hyperkalemia	O	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	the	O	['N']	[13]
14	recently	O	['N']	[14]
15	marketed	O	['N']	[15]
16	direct	O	['N']	[16]
17	renin	O	['N']	[17]
18	inhibitor	O	['N']	[18]
19	aliskiren	B-Drug	['Causes']	[8]
20	.	O	['N']	[20]
#2392
0	Acute	O	['N']	[0]
1	dystonic	O	['N']	[1]
2	reaction	O	['N']	[2]
3	with	O	['N']	[3]
4	low	B-Dose	['N']	[4]
5	-	O	['N']	[5]
6	dose	O	['N']	[6]
7	pimozide	B-Drug	['Dosage']	[4]
8	.	O	['N']	[8]
#2393
0	Herein	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	describe	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	AIDS	O	['N']	[7]
8	who	O	['N']	[8]
9	presented	O	['N']	[9]
10	to	O	['N']	[10]
11	medical	O	['N']	[11]
12	attention	O	['N']	[12]
13	with	O	['N']	[13]
14	pancytopenia	B-Adverse_Effect	['N']	[14]
15	48	O	['N']	[15]
16	months	O	['N']	[16]
17	postchemotherapy	O	['N']	[17]
18	with	O	['N']	[18]
19	etoposide	O	['N']	[19]
20	,	O	['N']	[20]
21	prednisone	O	['N']	[21]
22	,	O	['N']	[22]
23	vincristine	B-Drug	['Causes']	[14]
24	,	O	['N']	[24]
25	cyclophosphamide	O	['N']	[25]
26	,	O	['N']	[26]
27	doxorubicin	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	rituximab	O	['N']	[30]
31	(	O	['N']	[31]
32	R	O	['N']	[32]
33	-	O	['N']	[33]
34	EPOCH	O	['N']	[34]
35	)	O	['N']	[35]
36	for	O	['N']	[36]
37	diffuse	O	['N']	[37]
38	large	O	['N']	[38]
39	B	O	['N']	[39]
40	-	O	['N']	[40]
41	cell	O	['N']	[41]
42	lymphoma	O	['N']	[42]
43	.	O	['N']	[43]
#2394
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Interferon	O	['N']	[2]
3	(	O	['N']	[3]
4	IFN)-associated	-	['N']	[4]
5	retinopathy	B-Adverse_Effect	['N']	[5]
6	is	O	['N']	[6]
7	typically	O	['N']	[7]
8	characterized	O	['N']	[8]
9	by	O	['N']	[9]
10	retinal	O	['N']	[10]
11	hemorrhages	O	['N']	[11]
12	and	O	['N']	[12]
13	cotton	O	['N']	[13]
14	wool	O	['N']	[14]
15	spots	O	['N']	[15]
16	at	O	['N']	[16]
17	the	O	['N']	[17]
18	posterior	O	['N']	[18]
19	fundus	O	['N']	[19]
20	,	O	['N']	[20]
21	but	O	['N']	[21]
22	visual	O	['N']	[22]
23	function	O	['N']	[23]
24	is	O	['N']	[24]
25	usually	O	['N']	[25]
26	maintained	O	['N']	[26]
27	.	O	['N']	[27]
#2395
0	This	O	['N']	[0]
1	confirmed	O	['N']	[1]
2	the	O	['N']	[2]
3	history	O	['N']	[3]
4	of	O	['N']	[4]
5	captopril	B-Drug	['Causes']	[8]
6	-	O	['N']	[6]
7	related	O	['N']	[7]
8	asthma	B-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#2396
0	Torsades	B	['N']	[0]
1	de	I	['N']	[1]
2	Pointes	I-Adverse_Effect	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	a	O	['N']	[5]
6	combination	O	['N']	[6]
7	of	O	['N']	[7]
8	garenoxacin	O	['N']	[8]
9	and	O	['N']	[9]
10	disopyramide	B-Drug	['Causes']	[2]
11	and	O	['N']	[11]
12	other	O	['N']	[12]
13	cytochrome	O	['N']	[13]
14	P450	O	['N']	[14]
15	,	O	['N']	[15]
16	family	O	['N']	[16]
17	3	O	['N']	[17]
18	,	O	['N']	[18]
19	subfamily	O	['N']	[19]
20	A	O	['N']	[20]
21	polypeptide-4-influencing	O	['N']	[21]
22	drugs	O	['N']	[22]
23	during	O	['N']	[23]
24	hypokalemia	O	['N']	[24]
25	due	O	['N']	[25]
26	to	O	['N']	[26]
27	licorice	O	['N']	[27]
28	.	O	['N']	[28]
#2397
0	Sexual	B	['N']	[0]
1	dysfunction	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	intrathecal	O	['N']	[4]
5	baclofen	B-Drug	['Causes']	[1]
6	use	O	['N']	[6]
7	:	O	['N']	[7]
8	a	O	['N']	[8]
9	report	O	['N']	[9]
10	of	O	['N']	[10]
11	two	O	['N']	[11]
12	cases	O	['N']	[12]
13	.	O	['N']	[13]
#2398
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	report	O	['N']	[3]
4	two	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	pseudoporphyria	B-Adverse_Effect	['N']	[7]
8	caused	O	['N']	[8]
9	by	O	['N']	[9]
10	naproxen	O	['N']	[10]
11	and	O	['N']	[11]
12	oxaprozin	B-Drug	['Causes']	[7]
13	.	O	['N']	[13]
#2399
0	The	O	['N']	[0]
1	clinical	O	['N']	[1]
2	aspect	O	['N']	[2]
3	closely	O	['N']	[3]
4	resembled	O	['N']	[4]
5	classical	O	['N']	[5]
6	transient	B	['N']	[6]
7	global	I	['N']	[7]
8	amnesia	I-Adverse_Effect	['N']	[8]
9	but	O	['N']	[9]
10	the	O	['N']	[10]
11	episode	O	['N']	[11]
12	after	O	['N']	[12]
13	clioquinol	B-Drug	['Causes']	[8]
14	lasted	O	['N']	[14]
15	longer	O	['N']	[15]
16	(	O	['N']	[16]
17	24	O	['N']	[17]
18	hours	O	['N']	[18]
19	to	O	['N']	[19]
20	three	O	['N']	[20]
21	days	O	['N']	[21]
22	)	O	['N']	[22]
23	and	O	['N']	[23]
24	a	O	['N']	[24]
25	more	O	['N']	[25]
26	or	O	['N']	[26]
27	less	O	['N']	[27]
28	extensive	O	['N']	[28]
29	retrograde	O	['N']	[29]
30	amnesia	O	['N']	[30]
31	persisted	O	['N']	[31]
32	permanently	O	['N']	[32]
33	.	O	['N']	[33]
#2400
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	present	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	CML	O	['N']	[10]
11	who	O	['N']	[11]
12	developed	O	['N']	[12]
13	KS	B-Adverse_Effect	['N']	[13]
14	12	O	['N']	[14]
15	months	O	['N']	[15]
16	after	O	['N']	[16]
17	starting	O	['N']	[17]
18	treatment	O	['N']	[18]
19	with	O	['N']	[19]
20	imatinib	B-Drug	['Causes']	[13]
21	400	O	['N']	[21]
22	mg	O	['N']	[22]
23	/	O	['N']	[23]
24	d	O	['N']	[24]
25	.	O	['N']	[25]
#2401
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	rare	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	colonic	B	['N']	[6]
7	mucosal	I	['N']	[7]
8	necrosis	I-Adverse_Effect	['N']	[8]
9	following	O	['N']	[9]
10	Kalimate	O	['N']	[10]
11	(	O	['N']	[11]
12	calcium	O	['N']	[12]
13	polystryrene	O	['N']	[13]
14	sulfonate	O	['N']	[14]
15	)	O	['N']	[15]
16	,	O	['N']	[16]
17	an	O	['N']	[17]
18	analogue	O	['N']	[18]
19	of	O	['N']	[19]
20	Kayexalate	B-Drug	['Causes']	[8]
21	without	O	['N']	[21]
22	sorbitol	O	['N']	[22]
23	in	O	['N']	[23]
24	a	O	['N']	[24]
25	34-yr	O	['N']	[25]
26	-	O	['N']	[26]
27	old	O	['N']	[27]
28	man	O	['N']	[28]
29	.	O	['N']	[29]
#2402
0	Findings	O	['N']	[0]
1	on	O	['N']	[1]
2	discontinuation	O	['N']	[2]
3	and	O	['N']	[3]
4	rechallenge	O	['N']	[4]
5	supported	O	['N']	[5]
6	the	O	['N']	[6]
7	assumption	O	['N']	[7]
8	that	O	['N']	[8]
9	the	O	['N']	[9]
10	hair	B	['N']	[10]
11	loss	I-Adverse_Effect	['N']	[11]
12	was	O	['N']	[12]
13	a	O	['N']	[13]
14	side	O	['N']	[14]
15	effect	O	['N']	[15]
16	of	O	['N']	[16]
17	the	O	['N']	[17]
18	paroxetine	B-Drug	['Causes']	[11]
19	.	O	['N']	[19]
#2403
0	Atypical	O	['N']	[0]
1	ventricular	O	['N']	[1]
2	tachycardia	O	['N']	[2]
3	(	O	['N']	[3]
4	torsade	O	['N']	[4]
5	de	O	['N']	[5]
6	pointes	O	['N']	[6]
7	)	O	['N']	[7]
8	induced	O	['N']	[8]
9	by	O	['N']	[9]
10	amiodarone	O	['N']	[10]
11	:	O	['N']	[11]
12	arrhythmia	B-Adverse_Effect	['N']	[12]
13	previously	O	['N']	[13]
14	induced	O	['N']	[14]
15	by	O	['N']	[15]
16	quinidine	B-Drug	['Causes']	[12]
17	and	O	['N']	[17]
18	disopyramide	O	['N']	[18]
19	.	O	['N']	[19]
#2404
0	A	O	['N']	[0]
1	31-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	developed	O	['N']	[5]
6	multiple	O	['N']	[6]
7	episodes	O	['N']	[7]
8	of	O	['N']	[8]
9	grand	B	['N']	[9]
10	mal	I	['N']	[10]
11	seizures	I-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	combination	O	['N']	[13]
14	chemotherapy	O	['N']	[14]
15	with	O	['N']	[15]
16	cisplatin	B-Drug	['Causes']	[11]
17	,	O	['N']	[17]
18	vinblastine	O	['N']	[18]
19	and	O	['N']	[19]
20	bleomycin	O	['N']	[20]
21	for	O	['N']	[21]
22	germ	O	['N']	[22]
23	cell	O	['N']	[23]
24	ovarian	O	['N']	[24]
25	cancer	O	['N']	[25]
26	stage	O	['N']	[26]
27	Ic	O	['N']	[27]
28	.	O	['N']	[28]
#2405
0	We	O	['N']	[0]
1	hypothesize	O	['N']	[1]
2	that	O	['N']	[2]
3	decreased	O	['N']	[3]
4	renal	O	['N']	[4]
5	elimination	O	['N']	[5]
6	of	O	['N']	[6]
7	MTX	B-Drug	['Causes']	[19]
8	induced	O	['N']	[8]
9	by	O	['N']	[9]
10	the	O	['N']	[10]
11	COX-2	O	['N']	[11]
12	inhibitor	O	['N']	[12]
13	resulted	O	['N']	[13]
14	in	O	['N']	[14]
15	enhanced	O	['N']	[15]
16	hematopoietic	O	['N']	[16]
17	toxicity	O	['N']	[17]
18	and	O	['N']	[18]
19	immunosuppression	B-Adverse_Effect	['N']	[19]
20	causing	O	['N']	[20]
21	the	O	['N']	[21]
22	EBV	O	['N']	[22]
23	-	O	['N']	[23]
24	associated	O	['N']	[24]
25	lymphoproliferative	O	['N']	[25]
26	disease	O	['N']	[26]
27	.	O	['N']	[27]
#2406
0	Rapid	O	['N']	[0]
1	onset	O	['N']	[1]
2	of	O	['N']	[2]
3	muscle	B	['N']	[3]
4	weakness	I-Adverse_Effect	['N']	[4]
5	(	O	['N']	[5]
6	rhabdomyolysis	O	['N']	[6]
7	)	O	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	the	O	['N']	[10]
11	combined	O	['N']	[11]
12	use	O	['N']	[12]
13	of	O	['N']	[13]
14	simvastatin	B-Drug	['Causes']	[4]
15	and	O	['N']	[15]
16	colchicine	O	['N']	[16]
17	.	O	['N']	[17]
#2407
0	Six	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	no	O	['N']	[3]
4	previous	O	['N']	[4]
5	signs	O	['N']	[5]
6	or	O	['N']	[6]
7	symptoms	O	['N']	[7]
8	suggestive	O	['N']	[8]
9	of	O	['N']	[9]
10	coronary	O	['N']	[10]
11	artery	O	['N']	[11]
12	disease	O	['N']	[12]
13	developed	O	['N']	[13]
14	acute	B	['N']	[14]
15	coronary	I	['N']	[15]
16	ischemia	I-Adverse_Effect	['N']	[16]
17	/	O	['N']	[17]
18	infarction	O	['N']	[18]
19	shortly	O	['N']	[19]
20	after	O	['N']	[20]
21	cis	O	['N']	[21]
22	-	O	['N']	[22]
23	diamine	O	['N']	[23]
24	-	O	['N']	[24]
25	dichloroplatinum	O	['N']	[25]
26	II	O	['N']	[26]
27	(	O	['N']	[27]
28	cisplatin	B-Drug	['Causes']	[16]
29	)	O	['N']	[29]
30	-based	O	['N']	[30]
31	chemotherapy	O	['N']	[31]
32	.	O	['N']	[32]
#2408
0	Succinylcholine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hyperkalemia	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	mucositis	O	['N']	[8]
9	secondary	O	['N']	[9]
10	to	O	['N']	[10]
11	chemotherapy	O	['N']	[11]
12	.	O	['N']	[12]
#2409
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	acromegaly	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	severe	O	['N']	[9]
10	drug	O	['N']	[10]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	hepatitis	B-Adverse_Effect	['N']	[13]
14	during	O	['N']	[14]
15	combined	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	the	O	['N']	[18]
19	long	O	['N']	[19]
20	-	O	['N']	[20]
21	acting	O	['N']	[21]
22	somatostatin	O	['N']	[22]
23	-	O	['N']	[23]
24	analog	O	['N']	[24]
25	octreotide	B-Drug	['Causes']	[13]
26	and	O	['N']	[26]
27	the	O	['N']	[27]
28	GH	O	['N']	[28]
29	receptor	O	['N']	[29]
30	antagonist	O	['N']	[30]
31	pegvisomant	O	['N']	[31]
32	.	O	['N']	[32]
#2410
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	anhedonic	O	['N']	[5]
6	ejaculation	O	['N']	[6]
7	(	O	['N']	[7]
8	ejaculation	B	['N']	[8]
9	without	I	['N']	[9]
10	orgasm	I-Adverse_Effect	['N']	[10]
11	)	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	initiation	O	['N']	[14]
15	of	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	desipramine	B-Drug	['Causes']	[10]
19	.	O	['N']	[19]
#2411
0	Secondary	O	['N']	[0]
1	hyperparathyroidism	O	['N']	[1]
2	in	O	['N']	[2]
3	certain	O	['N']	[3]
4	patients	O	['N']	[4]
5	with	O	['N']	[5]
6	lithium	B-Drug	['Causes']	[7]
7	nephrotoxicity	B-Adverse_Effect	['N']	[7]
8	is	O	['N']	[8]
9	also	O	['N']	[9]
10	possible	O	['N']	[10]
11	.	O	['N']	[11]
#2412
0	Since	O	['N']	[0]
1	tamoxifen	B-Drug	['Causes']	[6]
2	therapy	O	['N']	[2]
3	can	O	['N']	[3]
4	induce	O	['N']	[4]
5	endometrial	B	['N']	[5]
6	disorders	I-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	surveillance	O	['N']	[8]
9	schemes	O	['N']	[9]
10	of	O	['N']	[10]
11	women	O	['N']	[11]
12	taking	O	['N']	[12]
13	tamoxifen	O	['N']	[13]
14	have	O	['N']	[14]
15	been	O	['N']	[15]
16	recommended	O	['N']	[16]
17	.	O	['N']	[17]
#2413
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Clinicians	O	['N']	[2]
3	should	O	['N']	[3]
4	be	O	['N']	[4]
5	aware	O	['N']	[5]
6	that	O	['N']	[6]
7	Crohn	B	['N']	[7]
8	's	I	['N']	[8]
9	disease	I-Adverse_Effect	['N']	[9]
10	is	O	['N']	[10]
11	a	O	['N']	[11]
12	potential	O	['N']	[12]
13	novel	O	['N']	[13]
14	adverse	O	['N']	[14]
15	drug	O	['N']	[15]
16	effect	O	['N']	[16]
17	of	O	['N']	[17]
18	Copaxone	B-Drug	['Causes']	[9]
19	.	O	['N']	[19]
#2414
0	Less	O	['N']	[0]
1	common	O	['N']	[1]
2	adverse	O	['N']	[2]
3	events	O	['N']	[3]
4	to	O	['N']	[4]
5	dapsone	B-Drug	['Causes']	[21]
6	include	O	['N']	[6]
7	the	O	['N']	[7]
8	idiosyncratic	O	['N']	[8]
9	reactions	O	['N']	[9]
10	of	O	['N']	[10]
11	leukopenia	O	['N']	[11]
12	and	O	['N']	[12]
13	agranulocytosis	O	['N']	[13]
14	,	O	['N']	[14]
15	cutaneous	O	['N']	[15]
16	eruptions	O	['N']	[16]
17	,	O	['N']	[17]
18	peripheral	O	['N']	[18]
19	neuropathy	O	['N']	[19]
20	,	O	['N']	[20]
21	psychosis	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	toxic	O	['N']	[23]
24	hepatitis	O	['N']	[24]
25	,	O	['N']	[25]
26	cholestatic	O	['N']	[26]
27	jaundice	O	['N']	[27]
28	,	O	['N']	[28]
29	nephrotic	O	['N']	[29]
30	syndrome	O	['N']	[30]
31	,	O	['N']	[31]
32	renal	O	['N']	[32]
33	papillary	O	['N']	[33]
34	necrosis	O	['N']	[34]
35	,	O	['N']	[35]
36	severe	O	['N']	[36]
37	hypoalbuminemia	O	['N']	[37]
38	without	O	['N']	[38]
39	proteinuria	O	['N']	[39]
40	,	O	['N']	[40]
41	an	O	['N']	[41]
42	infectious	O	['N']	[42]
43	mononucleosis	O	['N']	[43]
44	-	O	['N']	[44]
45	like	O	['N']	[45]
46	syndrome	O	['N']	[46]
47	,	O	['N']	[47]
48	and	O	['N']	[48]
49	minor	O	['N']	[49]
50	neurological	O	['N']	[50]
51	and	O	['N']	[51]
52	gastrointestinal	O	['N']	[52]
53	complaints	O	['N']	[53]
54	.	O	['N']	[54]
#2415
0	Two	O	['N']	[0]
1	fatal	B-Adverse_Effect	['N']	[1]
2	cases	O	['N']	[2]
3	of	O	['N']	[3]
4	poisoning	O	['N']	[4]
5	by	O	['N']	[5]
6	paracetamol	B-Drug	['Causes']	[1]
7	are	O	['N']	[7]
8	described	O	['N']	[8]
9	.	O	['N']	[9]
#2416
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	osteomyelitis	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	reversible	B	['N']	[6]
7	cholestatic	I	['N']	[7]
8	jaundice	I-Adverse_Effect	['N']	[8]
9	during	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	oxacillin	B-Drug	['Causes']	[8]
13	derivatives	O	['N']	[13]
14	are	O	['N']	[14]
15	described	O	['N']	[15]
16	.	O	['N']	[16]
#2417
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	severe	B	['N']	[7]
8	chloroquine	B-Drug	['Causes']	[9]
9	toxicity	I-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	presence	O	['N']	[12]
13	of	O	['N']	[13]
14	high	O	['N']	[14]
15	-	O	['N']	[15]
16	grade	O	['N']	[16]
17	chloroquine	O	['N']	[17]
18	-	O	['N']	[18]
19	resistant	O	['N']	[19]
20	Plasmodium	O	['N']	[20]
21	vivax	O	['N']	[21]
22	.	O	['N']	[22]
#2418
0	Captopril	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	lichen	B	['N']	[3]
4	planus	I	['N']	[4]
5	pemphigoides	I-Adverse_Effect	['N']	[5]
6	with	O	['N']	[6]
7	pemphigus	O	['N']	[7]
8	-	O	['N']	[8]
9	like	O	['N']	[9]
10	features	O	['N']	[10]
11	.	O	['N']	[11]
#2419
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	senna	B-Drug	['Causes']	[9]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	cholestatic	B	['N']	[8]
9	hepatitis	I-Adverse_Effect	['N']	[9]
10	which	O	['N']	[10]
11	was	O	['N']	[11]
12	not	O	['N']	[12]
13	diagnosed	O	['N']	[13]
14	at	O	['N']	[14]
15	presentation	O	['N']	[15]
16	.	O	['N']	[16]
#2420
0	Skin	B	['N']	[0]
1	necrosis	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	extravasation	O	['N']	[3]
4	of	O	['N']	[4]
5	low	O	['N']	[5]
6	-	O	['N']	[6]
7	dose	O	['N']	[7]
8	vasopressin	B-Drug	['Causes']	[1]
9	administered	O	['N']	[9]
10	for	O	['N']	[10]
11	septic	O	['N']	[11]
12	shock	O	['N']	[12]
13	.	O	['N']	[13]
#2421
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	76-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	with	O	['N']	[7]
8	primary	O	['N']	[8]
9	open	O	['N']	[9]
10	-	O	['N']	[10]
11	angle	O	['N']	[11]
12	glaucoma	O	['N']	[12]
13	and	O	['N']	[13]
14	no	O	['N']	[14]
15	history	O	['N']	[15]
16	of	O	['N']	[16]
17	ocular	O	['N']	[17]
18	surgery	O	['N']	[18]
19	developed	O	['N']	[19]
20	a	O	['N']	[20]
21	choroidal	B	['N']	[21]
22	detachment	I-Adverse_Effect	['N']	[22]
23	12	O	['N']	[23]
24	hours	O	['N']	[24]
25	after	O	['N']	[25]
26	initiation	O	['N']	[26]
27	of	O	['N']	[27]
28	therapy	O	['N']	[28]
29	with	O	['N']	[29]
30	dorzolamide	B-Drug	['Causes']	[22]
31	eye	O	['N']	[31]
32	drops	O	['N']	[32]
33	.	O	['N']	[33]
#2422
0	Clinical	O	['N']	[0]
1	course	O	['N']	[1]
2	of	O	['N']	[2]
3	macular	O	['N']	[3]
4	edema	O	['N']	[4]
5	in	O	['N']	[5]
6	two	O	['N']	[6]
7	cases	O	['N']	[7]
8	of	O	['N']	[8]
9	interferon	B-Drug	['Causes']	[12]
10	-	O	['N']	[10]
11	associated	O	['N']	[11]
12	retinopathy	B-Adverse_Effect	['N']	[12]
13	observed	O	['N']	[13]
14	by	O	['N']	[14]
15	optical	O	['N']	[15]
16	coherence	O	['N']	[16]
17	tomography	O	['N']	[17]
18	.	O	['N']	[18]
#2423
0	We	O	['N']	[0]
1	strongly	O	['N']	[1]
2	suspect	O	['N']	[2]
3	that	O	['N']	[3]
4	this	O	['N']	[4]
5	lethal	B	['N']	[5]
6	anuria	I-Adverse_Effect	['N']	[6]
7	was	O	['N']	[7]
8	mainly	O	['N']	[8]
9	due	O	['N']	[9]
10	to	O	['N']	[10]
11	ifosfamide	B-Drug	['Causes']	[6]
12	,	O	['N']	[12]
13	occurring	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	patient	O	['N']	[16]
17	having	O	['N']	[17]
18	received	O	['N']	[18]
19	previous	O	['N']	[19]
20	cisplatin	O	['N']	[20]
21	chemotherapy	O	['N']	[21]
22	and	O	['N']	[22]
23	with	O	['N']	[23]
24	poor	O	['N']	[24]
25	kidney	O	['N']	[25]
26	perfusion	O	['N']	[26]
27	due	O	['N']	[27]
28	to	O	['N']	[28]
29	transient	O	['N']	[29]
30	hypotension	O	['N']	[30]
31	.	O	['N']	[31]
#2424
0	A	O	['N']	[0]
1	25-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	a	O	['N']	[6]
7	history	O	['N']	[7]
8	of	O	['N']	[8]
9	mid	O	['N']	[9]
10	-	O	['N']	[10]
11	borderline	O	['N']	[11]
12	(	O	['N']	[12]
13	BB	O	['N']	[13]
14	)	O	['N']	[14]
15	Hansen	O	['N']	[15]
16	's	O	['N']	[16]
17	disease	O	['N']	[17]
18	developing	O	['N']	[18]
19	a	O	['N']	[19]
20	reversal	B	['N']	[20]
21	reaction	I-Adverse_Effect	['N']	[21]
22	after	O	['N']	[22]
23	starting	O	['N']	[23]
24	dapsone	B-Drug	['Causes']	[21]
25	and	O	['N']	[25]
26	rifampin	O	['N']	[26]
27	therapy	O	['N']	[27]
28	is	O	['N']	[28]
29	presented	O	['N']	[29]
30	.	O	['N']	[30]
#2425
0	The	O	['N']	[0]
1	most	O	['N']	[1]
2	common	O	['N']	[2]
3	side	O	['N']	[3]
4	effects	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	amifostine	B-Drug	['Causes']	[13]
8	are	O	['N']	[8]
9	nausea	O	['N']	[9]
10	,	O	['N']	[10]
11	vomiting	O	['N']	[11]
12	,	O	['N']	[12]
13	hypotension	B-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	hypocalcemia	O	['N']	[15]
16	and	O	['N']	[16]
17	allergic	O	['N']	[17]
18	reactions	O	['N']	[18]
19	.	O	['N']	[19]
#2426
0	Incidence	O	['N']	[0]
1	of	O	['N']	[1]
2	seizures	B-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	pediatric	O	['N']	[4]
5	cancer	O	['N']	[5]
6	patients	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	imipenem	O	['N']	[9]
10	/	O	['N']	[10]
11	cilastatin	B-Drug	['Causes']	[2]
12	.	O	['N']	[12]
#2427
0	A	O	['N']	[0]
1	57-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	right	O	['N']	[6]
7	bundle	O	['N']	[7]
8	branch	O	['N']	[8]
9	block	O	['N']	[9]
10	+	O	['N']	[10]
11	LPH	O	['N']	[11]
12	and	O	['N']	[12]
13	ventricular	O	['N']	[13]
14	premature	O	['N']	[14]
15	contractions	O	['N']	[15]
16	developed	O	['N']	[16]
17	complete	O	['N']	[17]
18	heart	O	['N']	[18]
19	block	O	['N']	[19]
20	(	O	['N']	[20]
21	CHB	B-Adverse_Effect	['N']	[21]
22	)	O	['N']	[22]
23	following	O	['N']	[23]
24	administration	O	['N']	[24]
25	of	O	['N']	[25]
26	disopyramide	B	['N']	[26]
27	phosphate	I-Drug	['Causes']	[21]
28	(	O	['N']	[28]
29	Norpace	O	['N']	[29]
30	)	O	['N']	[30]
31	.	O	['N']	[31]
#2428
0	Patient	O	['N']	[0]
1	A	O	['N']	[1]
2	reported	O	['N']	[2]
3	right	O	['N']	[3]
4	leg	O	['N']	[4]
5	weakness	O	['N']	[5]
6	(	O	['N']	[6]
7	foot	O	['N']	[7]
8	drop	O	['N']	[8]
9	)	O	['N']	[9]
10	during	O	['N']	[10]
11	week	O	['N']	[11]
12	4	O	['N']	[12]
13	of	O	['N']	[13]
14	CAP	B	['N']	[14]
15	-	I	['N']	[15]
16	XRT	I-Drug	['Dosage']	[21]
17	(	O	['N']	[17]
18	1600	B	['N']	[18]
19	mg	I	['N']	[19]
20	/	I	['N']	[20]
21	m2	I-Dose	['N']	[21]
22	)	O	['N']	[22]
23	.	O	['N']	[23]
#2429
0	Development	O	['N']	[0]
1	of	O	['N']	[1]
2	an	O	['N']	[2]
3	extensive	B	['N']	[3]
4	skin	I	['N']	[4]
5	rash	I-Adverse_Effect	['N']	[5]
6	following	O	['N']	[6]
7	a	O	['N']	[7]
8	single	O	['N']	[8]
9	dose	O	['N']	[9]
10	of	O	['N']	[10]
11	MTX	B-Drug	['Causes']	[5]
12	may	O	['N']	[12]
13	be	O	['N']	[13]
14	an	O	['N']	[14]
15	early	O	['N']	[15]
16	warning	O	['N']	[16]
17	sign	O	['N']	[17]
18	for	O	['N']	[18]
19	life	O	['N']	[19]
20	-	O	['N']	[20]
21	threatening	O	['N']	[21]
22	bone	O	['N']	[22]
23	marrow	O	['N']	[23]
24	aplasia	O	['N']	[24]
25	.	O	['N']	[25]
#2430
0	These	O	['N']	[0]
1	skin	B	['N']	[1]
2	lesions	I-Adverse_Effect	['N']	[2]
3	may	O	['N']	[3]
4	be	O	['N']	[4]
5	induced	O	['N']	[5]
6	or	O	['N']	[6]
7	worsened	O	['N']	[7]
8	during	O	['N']	[8]
9	antiviral	O	['N']	[9]
10	therapy	O	['N']	[10]
11	with	O	['N']	[11]
12	interferon	B	['N']	[12]
13	-	I	['N']	[13]
14	alpha	I-Drug	['Causes']	[2]
15	(	O	['N']	[15]
16	IFN	O	['N']	[16]
17	)	O	['N']	[17]
18	.	O	['N']	[18]
#2431
0	We	O	['N']	[0]
1	consider	O	['N']	[1]
2	asterixis	B-Adverse_Effect	['N']	[2]
3	to	O	['N']	[3]
4	be	O	['N']	[4]
5	an	O	['N']	[5]
6	easily	O	['N']	[6]
7	overlooked	O	['N']	[7]
8	sign	O	['N']	[8]
9	of	O	['N']	[9]
10	neurotoxicity	O	['N']	[10]
11	,	O	['N']	[11]
12	which	O	['N']	[12]
13	may	O	['N']	[13]
14	occur	O	['N']	[14]
15	even	O	['N']	[15]
16	at	O	['N']	[16]
17	low	O	['N']	[17]
18	or	O	['N']	[18]
19	moderate	O	['N']	[19]
20	dosage	O	['N']	[20]
21	levels	O	['N']	[21]
22	,	O	['N']	[22]
23	if	O	['N']	[23]
24	certain	O	['N']	[24]
25	drugs	O	['N']	[25]
26	as	O	['N']	[26]
27	lithium	O	['N']	[27]
28	or	O	['N']	[28]
29	clozapine	O	['N']	[29]
30	are	O	['N']	[30]
31	used	O	['N']	[31]
32	in	O	['N']	[32]
33	combination	O	['N']	[33]
34	with	O	['N']	[34]
35	CBZ	B-Drug	['Causes']	[2]
36	.	O	['N']	[36]
#2432
0	Angio	B	['N']	[0]
1	-	I	['N']	[1]
2	oedema	I-Adverse_Effect	['N']	[2]
3	as	O	['N']	[3]
4	an	O	['N']	[4]
5	unusual	O	['N']	[5]
6	tolerable	O	['N']	[6]
7	side	O	['N']	[7]
8	effect	O	['N']	[8]
9	of	O	['N']	[9]
10	voriconazole	B-Drug	['Causes']	[2]
11	therapy	O	['N']	[11]
12	.	O	['N']	[12]
#2433
0	Hypotension	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	sinus	O	['N']	[2]
3	arrest	O	['N']	[3]
4	with	O	['N']	[4]
5	nifedipine	B-Drug	['Causes']	[0]
6	in	O	['N']	[6]
7	pulmonary	O	['N']	[7]
8	hypertension	O	['N']	[8]
9	.	O	['N']	[9]
#2434
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	chlorambucil	B-Drug	['Causes']	[10]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	DRESS	B	['N']	[9]
10	syndrome	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	70-year	O	['N']	[13]
14	-	O	['N']	[14]
15	old	O	['N']	[15]
16	man	O	['N']	[16]
17	recently	O	['N']	[17]
18	diagnosed	O	['N']	[18]
19	with	O	['N']	[19]
20	chronic	O	['N']	[20]
21	lymphocytic	O	['N']	[21]
22	leukaemia	O	['N']	[22]
23	.	O	['N']	[23]
#2435
0	Ptosis	B-Adverse_Effect	['N']	[0]
1	occurring	O	['N']	[1]
2	24	O	['N']	[2]
3	h	O	['N']	[3]
4	after	O	['N']	[4]
5	chloroquine	B-Drug	['Causes']	[0]
6	therapy	O	['N']	[6]
7	,	O	['N']	[7]
8	with	O	['N']	[8]
9	full	O	['N']	[9]
10	recovery	O	['N']	[10]
11	48	O	['N']	[11]
12	h	O	['N']	[12]
13	after	O	['N']	[13]
14	cessation	O	['N']	[14]
15	of	O	['N']	[15]
16	chloroquine	O	['N']	[16]
17	,	O	['N']	[17]
18	has	O	['N']	[18]
19	not	O	['N']	[19]
20	been	O	['N']	[20]
21	described	O	['N']	[21]
22	previously	O	['N']	[22]
23	.	O	['N']	[23]
#2436
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	acute	O	['N']	[6]
7	pancreatitis	B-Adverse_Effect	['N']	[7]
8	(	O	['N']	[8]
9	AP	O	['N']	[9]
10	)	O	['N']	[10]
11	occurring	O	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	patient	O	['N']	[14]
15	under	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	carbamazepine	O	['N']	[18]
19	(	O	['N']	[19]
20	CBZ	B-Drug	['Causes']	[7]
21	)	O	['N']	[21]
22	for	O	['N']	[22]
23	post	O	['N']	[23]
24	-	O	['N']	[24]
25	traumatic	O	['N']	[25]
26	petit	O	['N']	[26]
27	mal	O	['N']	[27]
28	epilepsy	O	['N']	[28]
29	,	O	['N']	[29]
30	and	O	['N']	[30]
31	review	O	['N']	[31]
32	the	O	['N']	[32]
33	current	O	['N']	[33]
34	literature	O	['N']	[34]
35	of	O	['N']	[35]
36	drug	O	['N']	[36]
37	-	O	['N']	[37]
38	induced	O	['N']	[38]
39	AP	O	['N']	[39]
40	.	O	['N']	[40]
#2437
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	50-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	with	O	['N']	[10]
11	advanced	O	['N']	[11]
12	non	O	['N']	[12]
13	-	O	['N']	[13]
14	small	O	['N']	[14]
15	cell	O	['N']	[15]
16	lung	O	['N']	[16]
17	cancer	O	['N']	[17]
18	who	O	['N']	[18]
19	developed	O	['N']	[19]
20	status	B	['N']	[20]
21	epilepticus	I-Adverse_Effect	['N']	[21]
22	shortly	O	['N']	[22]
23	after	O	['N']	[23]
24	receiving	O	['N']	[24]
25	cisplatin	B-Drug	['Causes']	[21]
26	and	O	['N']	[26]
27	gemcitabine	O	['N']	[27]
28	chemotherapy	O	['N']	[28]
29	.	O	['N']	[29]
#2438
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	histopathologically	O	['N']	[4]
5	documented	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	oral	B	['N']	[8]
9	mucosa	I	['N']	[9]
10	pigmentation	I-Adverse_Effect	['N']	[10]
11	after	O	['N']	[11]
12	OLP	O	['N']	[12]
13	treatment	O	['N']	[13]
14	with	O	['N']	[14]
15	topical	O	['N']	[15]
16	tacrolimus	B-Drug	['Causes']	[10]
17	.	O	['N']	[17]
#2439
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	rheumatoid	O	['N']	[3]
4	arthritis	O	['N']	[4]
5	developed	O	['N']	[5]
6	an	O	['N']	[6]
7	acute	O	['N']	[7]
8	intrahepatic	O	['N']	[8]
9	cholestasis	O	['N']	[9]
10	after	O	['N']	[10]
11	100	B	['N']	[11]
12	mg	I-Dose	['N']	[12]
13	of	O	['N']	[13]
14	sodium	B	['N']	[14]
15	aurothiomalate	I-Drug	['Dosage']	[12]
16	.	O	['N']	[16]
#2440
0	Observations	O	['N']	[0]
1	in	O	['N']	[1]
2	our	O	['N']	[2]
3	patient	O	['N']	[3]
4	suggest	O	['N']	[4]
5	that	O	['N']	[5]
6	the	O	['N']	[6]
7	leukoencephalopathy	B-Adverse_Effect	['N']	[7]
8	that	O	['N']	[8]
9	developed	O	['N']	[9]
10	in	O	['N']	[10]
11	previously	O	['N']	[11]
12	reported	O	['N']	[12]
13	patients	O	['N']	[13]
14	who	O	['N']	[14]
15	received	O	['N']	[15]
16	5-fluorouracil	B-Drug	['Causes']	[7]
17	and	O	['N']	[17]
18	levamisole	O	['N']	[18]
19	may	O	['N']	[19]
20	have	O	['N']	[20]
21	been	O	['N']	[21]
22	caused	O	['N']	[22]
23	at	O	['N']	[23]
24	least	O	['N']	[24]
25	partly	O	['N']	[25]
26	by	O	['N']	[26]
27	levamisole	O	['N']	[27]
28	.	O	['N']	[28]
#2441
0	The	O	['N']	[0]
1	day	O	['N']	[1]
2	after	O	['N']	[2]
3	clozapine	B-Drug	['Causes']	[27]
4	was	O	['N']	[4]
5	stopped	O	['N']	[5]
6	,	O	['N']	[6]
7	while	O	['N']	[7]
8	he	O	['N']	[8]
9	was	O	['N']	[9]
10	still	O	['N']	[10]
11	receiving	O	['N']	[11]
12	clomipramine	O	['N']	[12]
13	150	O	['N']	[13]
14	mg	O	['N']	[14]
15	/	O	['N']	[15]
16	d	O	['N']	[16]
17	,	O	['N']	[17]
18	he	O	['N']	[18]
19	began	O	['N']	[19]
20	behaving	O	['N']	[20]
21	oddly	O	['N']	[21]
22	,	O	['N']	[22]
23	started	O	['N']	[23]
24	sweating	O	['N']	[24]
25	profusely	O	['N']	[25]
26	,	O	['N']	[26]
27	shivering	B-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	became	O	['N']	[30]
31	tremulous	O	['N']	[31]
32	,	O	['N']	[32]
33	agitated	O	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	confused	O	['N']	[36]
37	.	O	['N']	[37]
#2442
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	experienced	O	['N']	[2]
3	muscle	O	['N']	[3]
4	twitches	O	['N']	[4]
5	,	O	['N']	[5]
6	tremulousness	B-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	anxiety	O	['N']	[9]
10	on	O	['N']	[10]
11	day	O	['N']	[11]
12	17	O	['N']	[12]
13	of	O	['N']	[13]
14	foscarnet	B-Drug	['Causes']	[6]
15	therapy	O	['N']	[15]
16	.	O	['N']	[16]
#2443
0	A	O	['N']	[0]
1	52-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	developed	O	['N']	[5]
6	symmetric	O	['N']	[6]
7	sensorimotor	O	['N']	[7]
8	polyneuropathy	O	['N']	[8]
9	and	O	['N']	[9]
10	cerebellar	B	['N']	[10]
11	syndrome	I-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	24	O	['N']	[13]
14	months	O	['N']	[14]
15	of	O	['N']	[15]
16	amiodarone	B-Drug	['Causes']	[11]
17	treatment	O	['N']	[17]
18	.	O	['N']	[18]
#2444
0	A	O	['N']	[0]
1	child	O	['N']	[1]
2	in	O	['N']	[2]
3	whom	O	['N']	[3]
4	a	O	['N']	[4]
5	phenobarbital	B-Drug	['Causes']	[6]
6	hypersensitivity	B-Adverse_Effect	['N']	[6]
7	drug	O	['N']	[7]
8	reaction	O	['N']	[8]
9	developed	O	['N']	[9]
10	which	O	['N']	[10]
11	consisted	O	['N']	[11]
12	of	O	['N']	[12]
13	fever	O	['N']	[13]
14	,	O	['N']	[14]
15	a	O	['N']	[15]
16	pruritic	O	['N']	[16]
17	desquamating	O	['N']	[17]
18	erythrodermic	O	['N']	[18]
19	rash	O	['N']	[19]
20	,	O	['N']	[20]
21	alopecia	O	['N']	[21]
22	,	O	['N']	[22]
23	icterus	O	['N']	[23]
24	,	O	['N']	[24]
25	protein	O	['N']	[25]
26	-	O	['N']	[26]
27	losing	O	['N']	[27]
28	enteropathy	O	['N']	[28]
29	,	O	['N']	[29]
30	myositis	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	nephritis	O	['N']	[33]
34	,	O	['N']	[34]
35	is	O	['N']	[35]
36	described	O	['N']	[36]
37	.	O	['N']	[37]
#2445
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Electrolyte	B	['N']	[2]
3	disorders	I-Adverse_Effect	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	foscarnet	B-Drug	['Causes']	[3]
7	are	O	['N']	[7]
8	reviewed	O	['N']	[8]
9	.	O	['N']	[9]
#2446
0	We	O	['N']	[0]
1	have	O	['N']	[1]
2	seen	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	terminal	O	['N']	[6]
7	malignant	O	['N']	[7]
8	melanoma	O	['N']	[8]
9	in	O	['N']	[9]
10	which	O	['N']	[10]
11	clinical	O	['N']	[11]
12	manifestations	O	['N']	[12]
13	,	O	['N']	[13]
14	indicative	O	['N']	[14]
15	of	O	['N']	[15]
16	anterior	B	['N']	[16]
17	spinal	I	['N']	[17]
18	artery	I	['N']	[18]
19	syndrome	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	developed	O	['N']	[21]
22	following	O	['N']	[22]
23	the	O	['N']	[23]
24	injection	O	['N']	[24]
25	of	O	['N']	[25]
26	0.3	O	['N']	[26]
27	ml	O	['N']	[27]
28	of	O	['N']	[28]
29	10	O	['N']	[29]
30	%	O	['N']	[30]
31	phenol	B	['N']	[31]
32	-	I	['N']	[32]
33	glycerine	I-Drug	['Causes']	[19]
34	into	O	['N']	[34]
35	the	O	['N']	[35]
36	cervical	O	['N']	[36]
37	subarachnoid	O	['N']	[37]
38	space	O	['N']	[38]
39	at	O	['N']	[39]
40	the	O	['N']	[40]
41	C4	O	['N']	[41]
42	-	O	['N']	[42]
43	-C5	O	['N']	[43]
44	level	O	['N']	[44]
45	for	O	['N']	[45]
46	the	O	['N']	[46]
47	control	O	['N']	[47]
48	of	O	['N']	[48]
49	severe	O	['N']	[49]
50	right	O	['N']	[50]
51	arm	O	['N']	[51]
52	pain	O	['N']	[52]
53	.	O	['N']	[53]
#2447
0	After	O	['N']	[0]
1	a	O	['N']	[1]
2	second	O	['N']	[2]
3	dose	O	['N']	[3]
4	of	O	['N']	[4]
5	metoclopramide	B-Drug	['Causes']	[22]
6	,	O	['N']	[6]
7	these	O	['N']	[7]
8	symptoms	O	['N']	[8]
9	recurred	O	['N']	[9]
10	and	O	['N']	[10]
11	were	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	confusion	O	['N']	[14]
15	,	O	['N']	[15]
16	agitation	O	['N']	[16]
17	,	O	['N']	[17]
18	fever	O	['N']	[18]
19	,	O	['N']	[19]
20	diaphoresis	O	['N']	[20]
21	,	O	['N']	[21]
22	tachypnea	B-Adverse_Effect	['N']	[22]
23	,	O	['N']	[23]
24	tachycardia	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	hypertension	O	['N']	[27]
28	.	O	['N']	[28]
#2448
0	The	O	['N']	[0]
1	day	O	['N']	[1]
2	after	O	['N']	[2]
3	clozapine	B-Drug	['Causes']	[31]
4	was	O	['N']	[4]
5	stopped	O	['N']	[5]
6	,	O	['N']	[6]
7	while	O	['N']	[7]
8	he	O	['N']	[8]
9	was	O	['N']	[9]
10	still	O	['N']	[10]
11	receiving	O	['N']	[11]
12	clomipramine	O	['N']	[12]
13	150	O	['N']	[13]
14	mg	O	['N']	[14]
15	/	O	['N']	[15]
16	d	O	['N']	[16]
17	,	O	['N']	[17]
18	he	O	['N']	[18]
19	began	O	['N']	[19]
20	behaving	O	['N']	[20]
21	oddly	O	['N']	[21]
22	,	O	['N']	[22]
23	started	O	['N']	[23]
24	sweating	O	['N']	[24]
25	profusely	O	['N']	[25]
26	,	O	['N']	[26]
27	shivering	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	became	O	['N']	[30]
31	tremulous	B-Adverse_Effect	['N']	[31]
32	,	O	['N']	[32]
33	agitated	O	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	confused	O	['N']	[36]
37	.	O	['N']	[37]
#2449
0	Intracranial	B	['N']	[0]
1	haemorrhage	I-Adverse_Effect	['N']	[1]
2	from	O	['N']	[2]
3	a	O	['N']	[3]
4	meningioma	O	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	receiving	O	['N']	[8]
9	aspirin	B-Drug	['Causes']	[1]
10	prophylaxis	O	['N']	[10]
11	:	O	['N']	[11]
12	a	O	['N']	[12]
13	case	O	['N']	[13]
14	report	O	['N']	[14]
15	.	O	['N']	[15]
#2450
0	A	O	['N']	[0]
1	77-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	developed	O	['N']	[5]
6	ankle	B	['N']	[6]
7	,	I	['N']	[7]
8	hand	I	['N']	[8]
9	,	I	['N']	[9]
10	and	I	['N']	[10]
11	facial	I	['N']	[11]
12	swelling	I-Adverse_Effect	['N']	[12]
13	2	O	['N']	[13]
14	weeks	O	['N']	[14]
15	after	O	['N']	[15]
16	starting	O	['N']	[16]
17	rosiglitazone	B-Drug	['Causes']	[12]
18	.	O	['N']	[18]
#2451
0	The	O	['N']	[0]
1	first	O	['N']	[1]
2	reported	O	['N']	[2]
3	case	O	['N']	[3]
4	,	O	['N']	[4]
5	in	O	['N']	[5]
6	an	O	['N']	[6]
7	adult	O	['N']	[7]
8	,	O	['N']	[8]
9	of	O	['N']	[9]
10	cholestyramine	B-Drug	['Causes']	[14]
11	induced	O	['N']	[11]
12	hyperchloremic	B	['N']	[12]
13	metabolic	I	['N']	[13]
14	acidosis	I-Adverse_Effect	['N']	[14]
15	is	O	['N']	[15]
16	a	O	['N']	[16]
17	70	O	['N']	[17]
18	year	O	['N']	[18]
19	old	O	['N']	[19]
20	female	O	['N']	[20]
21	with	O	['N']	[21]
22	a	O	['N']	[22]
23	two	O	['N']	[23]
24	year	O	['N']	[24]
25	history	O	['N']	[25]
26	of	O	['N']	[26]
27	primary	O	['N']	[27]
28	biliary	O	['N']	[28]
29	cirrhosis	O	['N']	[29]
30	confirmed	O	['N']	[30]
31	by	O	['N']	[31]
32	histologic	O	['N']	[32]
33	and	O	['N']	[33]
34	immunologic	O	['N']	[34]
35	criteria	O	['N']	[35]
36	.	O	['N']	[36]
#2452
0	In	O	['N']	[0]
1	two	O	['N']	[1]
2	patients	O	['N']	[2]
3	clozapine	B-Drug	['Causes']	[14]
4	was	O	['N']	[4]
5	reinstated	O	['N']	[5]
6	after	O	['N']	[6]
7	risperidone	O	['N']	[7]
8	was	O	['N']	[8]
9	discontinued	O	['N']	[9]
10	;	O	['N']	[10]
11	serum	B	['N']	[11]
12	triglyceride	I	['N']	[12]
13	levels	I	['N']	[13]
14	increased	I-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#2453
0	A	O	['N']	[0]
1	toxic	O	['N']	[1]
2	encephalopathy	O	['N']	[2]
3	characterized	O	['N']	[3]
4	by	O	['N']	[4]
5	depressed	B	['N']	[5]
6	level	I	['N']	[6]
7	of	I	['N']	[7]
8	consciousness	I-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	marked	O	['N']	[10]
11	irritability	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	ataxia	O	['N']	[14]
15	developed	O	['N']	[15]
16	in	O	['N']	[16]
17	seven	O	['N']	[17]
18	children	O	['N']	[18]
19	,	O	['N']	[19]
20	5	O	['N']	[20]
21	years	O	['N']	[21]
22	of	O	['N']	[22]
23	age	O	['N']	[23]
24	and	O	['N']	[24]
25	younger	O	['N']	[25]
26	,	O	['N']	[26]
27	following	O	['N']	[27]
28	administration	O	['N']	[28]
29	of	O	['N']	[29]
30	an	O	['N']	[30]
31	antiemetic	O	['N']	[31]
32	combination	O	['N']	[32]
33	of	O	['N']	[33]
34	pentobarbital	O	['N']	[34]
35	and	O	['N']	[35]
36	pyrilamine	B	['N']	[36]
37	maleate	I-Drug	['Causes']	[8]
38	.	O	['N']	[38]
#2454
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	ulcerative	O	['N']	[3]
4	colitis	O	['N']	[4]
5	developed	O	['N']	[5]
6	skin	O	['N']	[6]
7	pigmentation	O	['N']	[7]
8	and	O	['N']	[8]
9	diffuse	B	['N']	[9]
10	pulmonary	I	['N']	[10]
11	shadowing	I-Adverse_Effect	['N']	[11]
12	without	O	['N']	[12]
13	respiratory	O	['N']	[13]
14	symptomatology	O	['N']	[14]
15	,	O	['N']	[15]
16	while	O	['N']	[16]
17	taking	O	['N']	[17]
18	sulfasalazine	B-Drug	['Causes']	[11]
19	.	O	['N']	[19]
#2455
0	The	O	['N']	[0]
1	pharmaceutical	O	['N']	[1]
2	company	O	['N']	[2]
3	producing	O	['N']	[3]
4	Halfan	B-Drug	['Causes']	[9]
5	has	O	['N']	[5]
6	reported	O	['N']	[6]
7	8	O	['N']	[7]
8	cardiac	B	['N']	[8]
9	arrests	I-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	leading	O	['N']	[11]
12	to	O	['N']	[12]
13	6	O	['N']	[13]
14	deaths	O	['N']	[14]
15	,	O	['N']	[15]
16	when	O	['N']	[16]
17	a	O	['N']	[17]
18	higher	O	['N']	[18]
19	dose	O	['N']	[19]
20	than	O	['N']	[20]
21	recommended	O	['N']	[21]
22	was	O	['N']	[22]
23	used	O	['N']	[23]
24	,	O	['N']	[24]
25	there	O	['N']	[25]
26	was	O	['N']	[26]
27	recent	O	['N']	[27]
28	or	O	['N']	[28]
29	concomitant	O	['N']	[29]
30	treatment	O	['N']	[30]
31	with	O	['N']	[31]
32	mefloquine	O	['N']	[32]
33	,	O	['N']	[33]
34	there	O	['N']	[34]
35	was	O	['N']	[35]
36	pre	O	['N']	[36]
37	-	O	['N']	[37]
38	existing	O	['N']	[38]
39	prolongation	O	['N']	[39]
40	of	O	['N']	[40]
41	the	O	['N']	[41]
42	QT	O	['N']	[42]
43	interval	O	['N']	[43]
44	or	O	['N']	[44]
45	the	O	['N']	[45]
46	patient	O	['N']	[46]
47	had	O	['N']	[47]
48	a	O	['N']	[48]
49	thiamine	O	['N']	[49]
50	deficiency	O	['N']	[50]
51	.	O	['N']	[51]
#2456
0	Cardiac	B	['N']	[0]
1	arrest	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	sulprostone	B-Drug	['Causes']	[1]
5	use	O	['N']	[5]
6	during	O	['N']	[6]
7	caesarean	O	['N']	[7]
8	section	O	['N']	[8]
9	.	O	['N']	[9]
#2457
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	resembles	O	['N']	[2]
3	two	O	['N']	[3]
4	previously	O	['N']	[4]
5	reported	O	['N']	[5]
6	cases	O	['N']	[6]
7	of	O	['N']	[7]
8	optic	B	['N']	[8]
9	neuropathy	I-Adverse_Effect	['N']	[9]
10	which	O	['N']	[10]
11	occurred	O	['N']	[11]
12	in	O	['N']	[12]
13	patients	O	['N']	[13]
14	with	O	['N']	[14]
15	Wilson	O	['N']	[15]
16	's	O	['N']	[16]
17	disease	O	['N']	[17]
18	who	O	['N']	[18]
19	were	O	['N']	[19]
20	receiving	O	['N']	[20]
21	penicillamine	B-Drug	['Causes']	[9]
22	.	O	['N']	[22]
#2458
0	Nabumetone	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	interstitial	B	['N']	[3]
4	nephritis	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#2459
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	Symptomatic	O	['N']	[2]
3	visual	B	['N']	[3]
4	field	I	['N']	[4]
5	constriction	I-Adverse_Effect	['N']	[5]
6	thought	O	['N']	[6]
7	to	O	['N']	[7]
8	be	O	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	vigabatrin	B-Drug	['Causes']	[5]
12	has	O	['N']	[12]
13	been	O	['N']	[13]
14	reported	O	['N']	[14]
15	.	O	['N']	[15]
#2460
0	CASE	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	malignant	B	['N']	[3]
4	mixed	I	['N']	[4]
5	mesodermal	I	['N']	[5]
6	tumor	I-Adverse_Effect	['N']	[6]
7	was	O	['N']	[7]
8	diagnosed	O	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	64-year	O	['N']	[11]
12	-	O	['N']	[12]
13	old	O	['N']	[13]
14	woman	O	['N']	[14]
15	with	O	['N']	[15]
16	a	O	['N']	[16]
17	bicornuate	O	['N']	[17]
18	uterus	O	['N']	[18]
19	while	O	['N']	[19]
20	she	O	['N']	[20]
21	was	O	['N']	[21]
22	taking	O	['N']	[22]
23	raloxifene	B-Drug	['Causes']	[6]
24	for	O	['N']	[24]
25	osteoporosis	O	['N']	[25]
26	prevention	O	['N']	[26]
27	.	O	['N']	[27]
#2461
0	Horner	O	['N']	[0]
1	's	O	['N']	[1]
2	syndrome	O	['N']	[2]
3	and	O	['N']	[3]
4	demyelinating	O	['N']	[4]
5	peripheral	O	['N']	[5]
6	neuropathy	O	['N']	[6]
7	caused	O	['N']	[7]
8	by	O	['N']	[8]
9	high	B	['N']	[9]
10	-	I	['N']	[10]
11	dose	I-Dose	['N']	[11]
12	cytosine	B	['N']	[12]
13	arabinoside	I-Drug	['Dosage']	[11]
14	.	O	['N']	[14]
#2462
0	Amiodarone	B	['N']	[0]
1	hydrochloride	I-Drug	['Causes']	[22]
2	,	O	['N']	[2]
3	a	O	['N']	[3]
4	new	O	['N']	[4]
5	antiarrhythmic	O	['N']	[5]
6	agent	O	['N']	[6]
7	,	O	['N']	[7]
8	has	O	['N']	[8]
9	been	O	['N']	[9]
10	associated	O	['N']	[10]
11	with	O	['N']	[11]
12	pulmonary	O	['N']	[12]
13	toxicity	O	['N']	[13]
14	characterized	O	['N']	[14]
15	by	O	['N']	[15]
16	cough	O	['N']	[16]
17	,	O	['N']	[17]
18	dyspnea	O	['N']	[18]
19	and	O	['N']	[19]
20	diffuse	B	['N']	[20]
21	pulmonary	I	['N']	[21]
22	infiltrates	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#2463
0	On	O	['N']	[0]
1	the	O	['N']	[1]
2	fifth	O	['N']	[2]
3	day	O	['N']	[3]
4	of	O	['N']	[4]
5	tocolysis	O	['N']	[5]
6	with	O	['N']	[6]
7	magnesium	B	['N']	[7]
8	sulfate	I-Drug	['Causes']	[16]
9	,	O	['N']	[9]
10	nifedipine	O	['N']	[10]
11	,	O	['N']	[11]
12	terbutaline	O	['N']	[12]
13	and	O	['N']	[13]
14	betamethasone	O	['N']	[14]
15	,	O	['N']	[15]
16	edema	B-Adverse_Effect	['N']	[16]
17	developed	O	['N']	[17]
18	in	O	['N']	[18]
19	both	O	['N']	[19]
20	labia	O	['N']	[20]
21	.	O	['N']	[21]
#2464
0	Aminophylline	B-Drug	['Causes']	[1]
1	hypersensitivity	I-Adverse_Effect	['N']	[1]
2	apparently	O	['N']	[2]
3	due	O	['N']	[3]
4	to	O	['N']	[4]
5	ethylenediamine	O	['N']	[5]
6	.	O	['N']	[6]
#2465
0	Tumor	B	['N']	[0]
1	lysis	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	transcatheter	O	['N']	[4]
5	arterial	O	['N']	[5]
6	infusion	O	['N']	[6]
7	of	O	['N']	[7]
8	cisplatin	B-Drug	['Causes']	[2]
9	and	O	['N']	[9]
10	embolization	O	['N']	[10]
11	therapy	O	['N']	[11]
12	for	O	['N']	[12]
13	liver	O	['N']	[13]
14	metastases	O	['N']	[14]
15	of	O	['N']	[15]
16	melanoma	O	['N']	[16]
17	.	O	['N']	[17]
#2466
0	We	O	['N']	[0]
1	hypothesize	O	['N']	[1]
2	that	O	['N']	[2]
3	caffeine	B-Drug	['Causes']	[4]
4	toxicity	I-Adverse_Effect	['N']	[4]
5	injured	O	['N']	[5]
6	the	O	['N']	[6]
7	muscle	O	['N']	[7]
8	cells	O	['N']	[8]
9	,	O	['N']	[9]
10	which	O	['N']	[10]
11	were	O	['N']	[11]
12	fragile	O	['N']	[12]
13	due	O	['N']	[13]
14	to	O	['N']	[14]
15	the	O	['N']	[15]
16	potassium	O	['N']	[16]
17	depletion	O	['N']	[17]
18	induced	O	['N']	[18]
19	by	O	['N']	[19]
20	the	O	['N']	[20]
21	coexisting	O	['N']	[21]
22	hyponatremia	O	['N']	[22]
23	,	O	['N']	[23]
24	to	O	['N']	[24]
25	result	O	['N']	[25]
26	in	O	['N']	[26]
27	unusually	O	['N']	[27]
28	severe	O	['N']	[28]
29	rhabdomyolysis	O	['N']	[29]
30	.	O	['N']	[30]
#2467
0	We	O	['N']	[0]
1	also	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	new	O	['N']	[4]
5	,	O	['N']	[5]
6	noninvasive	O	['N']	[6]
7	method	O	['N']	[7]
8	to	O	['N']	[8]
9	assess	O	['N']	[9]
10	magnesium	B-Drug	['Causes']	[14]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	neuromuscular	B	['N']	[13]
14	block	I-Adverse_Effect	['N']	[14]
15	when	O	['N']	[15]
16	curariform	O	['N']	[16]
17	muscle	O	['N']	[17]
18	relaxant	O	['N']	[18]
19	was	O	['N']	[19]
20	given	O	['N']	[20]
21	simultaneously	O	['N']	[21]
22	.	O	['N']	[22]
#2468
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	3	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	children	O	['N']	[5]
6	with	O	['N']	[6]
7	acute	O	['N']	[7]
8	lymphoblastic	O	['N']	[8]
9	leukemia	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	seizures	O	['N']	[12]
13	and	O	['N']	[13]
14	altered	B	['N']	[14]
15	sensorium	I-Adverse_Effect	['N']	[15]
16	after	O	['N']	[16]
17	L	B	['N']	[17]
18	-	I	['N']	[18]
19	asparaginase	I-Drug	['Causes']	[15]
20	therapy	O	['N']	[20]
21	.	O	['N']	[21]
#2469
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	a	O	['N']	[3]
4	29-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	man	O	['N']	[7]
8	suffering	O	['N']	[8]
9	from	O	['N']	[9]
10	falciparum	O	['N']	[10]
11	malaria	O	['N']	[11]
12	disease	O	['N']	[12]
13	who	O	['N']	[13]
14	got	O	['N']	[14]
15	a	O	['N']	[15]
16	reversible	B	['N']	[16]
17	hearing	I	['N']	[17]
18	loss	I-Adverse_Effect	['N']	[18]
19	from	O	['N']	[19]
20	quinine	B-Drug	['Causes']	[18]
21	therapy	O	['N']	[21]
22	is	O	['N']	[22]
23	presented	O	['N']	[23]
24	.	O	['N']	[24]
#2470
0	Rituximab	O	['N']	[0]
1	-	O	['N']	[1]
2	based	O	['N']	[2]
3	therapy	O	['N']	[3]
4	for	O	['N']	[4]
5	gemcitabine	B-Drug	['Causes']	[10]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	hemolytic	B	['N']	[8]
9	uremic	I	['N']	[9]
10	syndrome	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	metastatic	O	['N']	[15]
16	pancreatic	O	['N']	[16]
17	adenocarcinoma	O	['N']	[17]
18	:	O	['N']	[18]
19	a	O	['N']	[19]
20	case	O	['N']	[20]
21	report	O	['N']	[21]
22	.	O	['N']	[22]
#2471
0	Reversible	O	['N']	[0]
1	valproic	B	['N']	[1]
2	acid	I-Drug	['Causes']	[5]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	dementia	B-Adverse_Effect	['N']	[5]
6	was	O	['N']	[6]
7	documented	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	21-year	O	['N']	[10]
11	-	O	['N']	[11]
12	old	O	['N']	[12]
13	man	O	['N']	[13]
14	with	O	['N']	[14]
15	epilepsy	O	['N']	[15]
16	who	O	['N']	[16]
17	had	O	['N']	[17]
18	a	O	['N']	[18]
19	3-year	O	['N']	[19]
20	history	O	['N']	[20]
21	of	O	['N']	[21]
22	insidious	O	['N']	[22]
23	progressive	O	['N']	[23]
24	decline	O	['N']	[24]
25	in	O	['N']	[25]
26	global	O	['N']	[26]
27	cognitive	O	['N']	[27]
28	abilities	O	['N']	[28]
29	documented	O	['N']	[29]
30	by	O	['N']	[30]
31	serial	O	['N']	[31]
32	neuropsychological	O	['N']	[32]
33	studies	O	['N']	[33]
34	.	O	['N']	[34]
#2472
0	Retinal	O	['N']	[0]
1	dysfunction	O	['N']	[1]
2	and	O	['N']	[2]
3	anterior	B	['N']	[3]
4	segment	I	['N']	[4]
5	deposits	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	rifabutin	B-Drug	['Causes']	[5]
12	.	O	['N']	[12]
#2473
0	Phenolphthalein	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	toxic	B	['N']	[3]
4	epidermal	I	['N']	[4]
5	necrolysis	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#2474
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	histologically	O	['N']	[4]
5	confirmed	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	NASH	B-Adverse_Effect	['N']	[8]
9	that	O	['N']	[9]
10	was	O	['N']	[10]
11	aggravated	O	['N']	[11]
12	by	O	['N']	[12]
13	raloxifene	B-Drug	['Causes']	[8]
14	.	O	['N']	[14]
#2475
0	Insulin	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	cardiac	B	['N']	[3]
4	failure	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#2476
0	Anaphylaxis	B-Adverse_Effect	['N']	[0]
1	to	O	['N']	[1]
2	calcitonin	B-Drug	['Causes']	[0]
3	.	O	['N']	[3]
#2477
0	MR	O	['N']	[0]
1	findings	O	['N']	[1]
2	in	O	['N']	[2]
3	methotrexate	B-Drug	['Causes']	[7]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	CNS	B	['N']	[6]
7	abnormalities	I-Adverse_Effect	['N']	[7]
8	.	O	['N']	[8]
#2478
0	The	O	['N']	[0]
1	current	O	['N']	[1]
2	report	O	['N']	[2]
3	describes	O	['N']	[3]
4	a	O	['N']	[4]
5	man	O	['N']	[5]
6	who	O	['N']	[6]
7	was	O	['N']	[7]
8	prescribed	O	['N']	[8]
9	zonisamide	B-Drug	['Causes']	[17]
10	for	O	['N']	[10]
11	epilepsy	O	['N']	[11]
12	and	O	['N']	[12]
13	subsequently	O	['N']	[13]
14	developed	O	['N']	[14]
15	widespread	O	['N']	[15]
16	skin	B	['N']	[16]
17	rash	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	acute	O	['N']	[19]
20	kidney	O	['N']	[20]
21	injury	O	['N']	[21]
22	,	O	['N']	[22]
23	high	O	['N']	[23]
24	-	O	['N']	[24]
25	grade	O	['N']	[25]
26	fever	O	['N']	[26]
27	,	O	['N']	[27]
28	eosinophilia	O	['N']	[28]
29	,	O	['N']	[29]
30	liver	O	['N']	[30]
31	dysfunction	O	['N']	[31]
32	,	O	['N']	[32]
33	lymphadenopathy	O	['N']	[33]
34	and	O	['N']	[34]
35	an	O	['N']	[35]
36	increase	O	['N']	[36]
37	in	O	['N']	[37]
38	antihuman	O	['N']	[38]
39	herpesvirus-6	O	['N']	[39]
40	immunoglobulin	O	['N']	[40]
41	G	O	['N']	[41]
42	titer	O	['N']	[42]
43	.	O	['N']	[43]
#2479
0	Seizures	O	['N']	[0]
1	and	O	['N']	[1]
2	extrapyramidal	B	['N']	[2]
3	symptoms	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	Tourette	O	['N']	[8]
9	's	O	['N']	[9]
10	syndrome	O	['N']	[10]
11	,	O	['N']	[11]
12	Asperger	O	['N']	[12]
13	's	O	['N']	[13]
14	syndrome	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	multiple	O	['N']	[17]
18	sclerosis	O	['N']	[18]
19	treated	O	['N']	[19]
20	with	O	['N']	[20]
21	interferon	B	['N']	[21]
22	beta-1a	I-Drug	['Causes']	[3]
23	and	O	['N']	[23]
24	clomipramine	O	['N']	[24]
25	.	O	['N']	[25]
#2480
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	no	O	['N']	[2]
3	.	O	['N']	[3]
4	2	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	pathogenic	O	['N']	[7]
8	mechanism	O	['N']	[8]
9	seemed	O	['N']	[9]
10	to	O	['N']	[10]
11	be	O	['N']	[11]
12	persistent	O	['N']	[12]
13	light	O	['N']	[13]
14	reaction	O	['N']	[14]
15	preceded	O	['N']	[15]
16	by	O	['N']	[16]
17	systemic	O	['N']	[17]
18	photoallergy	O	['N']	[18]
19	,	O	['N']	[19]
20	as	O	['N']	[20]
21	he	O	['N']	[21]
22	had	O	['N']	[22]
23	taken	O	['N']	[23]
24	mequitazine	B-Drug	['Causes']	[60]
25	for	O	['N']	[25]
26	6	O	['N']	[26]
27	months	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	there	O	['N']	[30]
31	were	O	['N']	[31]
32	strong	O	['N']	[32]
33	positive	O	['N']	[33]
34	photopatch	O	['N']	[34]
35	test	O	['N']	[35]
36	results	O	['N']	[36]
37	with	O	['N']	[37]
38	immediate	O	['N']	[38]
39	erythema	O	['N']	[39]
40	reaction	O	['N']	[40]
41	,	O	['N']	[41]
42	cross	O	['N']	[42]
43	-	O	['N']	[43]
44	reaction	O	['N']	[44]
45	to	O	['N']	[45]
46	promethazine	O	['N']	[46]
47	,	O	['N']	[47]
48	decreased	O	['N']	[48]
49	MED	O	['N']	[49]
50	to	O	['N']	[50]
51	both	O	['N']	[51]
52	UVA	O	['N']	[52]
53	and	O	['N']	[53]
54	UVB	O	['N']	[54]
55	,	O	['N']	[55]
56	and	O	['N']	[56]
57	persistence	B	['N']	[57]
58	of	I	['N']	[58]
59	the	I	['N']	[59]
60	photosensitivity	I-Adverse_Effect	['N']	[60]
61	over	O	['N']	[61]
62	a	O	['N']	[62]
63	3-year	O	['N']	[63]
64	follow	O	['N']	[64]
65	-	O	['N']	[65]
66	up	O	['N']	[66]
67	period	O	['N']	[67]
68	after	O	['N']	[68]
69	discontinuation	O	['N']	[69]
70	of	O	['N']	[70]
71	the	O	['N']	[71]
72	mequitazine	O	['N']	[72]
73	.	O	['N']	[73]
#2481
0	After	O	['N']	[0]
1	other	O	['N']	[1]
2	potential	O	['N']	[2]
3	causes	O	['N']	[3]
4	of	O	['N']	[4]
5	liver	O	['N']	[5]
6	toxicity	O	['N']	[6]
7	were	O	['N']	[7]
8	excluded	O	['N']	[8]
9	,	O	['N']	[9]
10	TMP	B	['N']	[10]
11	-	I	['N']	[11]
12	SMX	I-Drug	['Causes']	[23]
13	was	O	['N']	[13]
14	determined	O	['N']	[14]
15	to	O	['N']	[15]
16	be	O	['N']	[16]
17	the	O	['N']	[17]
18	cause	O	['N']	[18]
19	of	O	['N']	[19]
20	his	O	['N']	[20]
21	acute	B	['N']	[21]
22	liver	I	['N']	[22]
23	toxicity	I-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#2482
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	reported	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	BOOP	B-Adverse_Effect	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	single	O	['N']	[10]
11	-	O	['N']	[11]
12	agent	O	['N']	[12]
13	rituximab	B-Drug	['Causes']	[7]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	along	O	['N']	[16]
17	with	O	['N']	[17]
18	two	O	['N']	[18]
19	other	O	['N']	[19]
20	patients	O	['N']	[20]
21	we	O	['N']	[21]
22	describe	O	['N']	[22]
23	,	O	['N']	[23]
24	as	O	['N']	[24]
25	well	O	['N']	[25]
26	as	O	['N']	[26]
27	two	O	['N']	[27]
28	prior	O	['N']	[28]
29	reports	O	['N']	[29]
30	of	O	['N']	[30]
31	BOOP	O	['N']	[31]
32	in	O	['N']	[32]
33	NHL	O	['N']	[33]
34	patients	O	['N']	[34]
35	receiving	O	['N']	[35]
36	rituximab	O	['N']	[36]
37	-	O	['N']	[37]
38	based	O	['N']	[38]
39	combinations	O	['N']	[39]
40	,	O	['N']	[40]
41	strengthens	O	['N']	[41]
42	the	O	['N']	[42]
43	possibility	O	['N']	[43]
44	of	O	['N']	[44]
45	a	O	['N']	[45]
46	causal	O	['N']	[46]
47	relationship	O	['N']	[47]
48	.	O	['N']	[48]
#2483
0	Symptomatic	B	['N']	[0]
1	hypoglycemia	I-Adverse_Effect	['N']	[1]
2	secondary	O	['N']	[2]
3	to	O	['N']	[3]
4	a	O	['N']	[4]
5	glipizide	O	['N']	[5]
6	-	O	['N']	[6]
7	trimethoprim	B-Drug	['Causes']	[1]
8	/	O	['N']	[8]
9	sulfamethoxazole	O	['N']	[9]
10	drug	O	['N']	[10]
11	interaction	O	['N']	[11]
12	.	O	['N']	[12]
#2484
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	article	O	['N']	[2]
3	lithium	B-Drug	['Causes']	[19]
4	is	O	['N']	[4]
5	not	O	['N']	[5]
6	discussed	O	['N']	[6]
7	,	O	['N']	[7]
8	although	O	['N']	[8]
9	there	O	['N']	[9]
10	are	O	['N']	[10]
11	a	O	['N']	[11]
12	number	O	['N']	[12]
13	of	O	['N']	[13]
14	concerns	O	['N']	[14]
15	about	O	['N']	[15]
16	lithium	O	['N']	[16]
17	's	O	['N']	[17]
18	potential	O	['N']	[18]
19	teratogenicity	B-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	it	O	['N']	[22]
23	has	O	['N']	[23]
24	been	O	['N']	[24]
25	implicated	O	['N']	[25]
26	in	O	['N']	[26]
27	Epstein	O	['N']	[27]
28	's	O	['N']	[28]
29	anomaly	O	['N']	[29]
30	,	O	['N']	[30]
31	a	O	['N']	[31]
32	congenital	O	['N']	[32]
33	heart	O	['N']	[33]
34	defect	O	['N']	[34]
35	among	O	['N']	[35]
36	infants	O	['N']	[36]
37	born	O	['N']	[37]
38	to	O	['N']	[38]
39	women	O	['N']	[39]
40	taking	O	['N']	[40]
41	lithium	O	['N']	[41]
42	;	O	['N']	[42]
43	as	O	['N']	[43]
44	with	O	['N']	[44]
45	other	O	['N']	[45]
46	medications	O	['N']	[46]
47	,	O	['N']	[47]
48	however	O	['N']	[48]
49	,	O	['N']	[49]
50	the	O	['N']	[50]
51	data	O	['N']	[51]
52	have	O	['N']	[52]
53	specific	O	['N']	[53]
54	limitations	O	['N']	[54]
55	.	O	['N']	[55]
#2485
0	The	O	['N']	[0]
1	principle	O	['N']	[1]
2	treatment	O	['N']	[2]
3	for	O	['N']	[3]
4	DPD	O	['N']	[4]
5	-	O	['N']	[5]
6	deficient	O	['N']	[6]
7	patients	O	['N']	[7]
8	with	O	['N']	[8]
9	severe	O	['N']	[9]
10	acute	O	['N']	[10]
11	5-FU	B-Drug	['Causes']	[36]
12	reactions	O	['N']	[12]
13	is	O	['N']	[13]
14	supportive	O	['N']	[14]
15	care	O	['N']	[15]
16	;	O	['N']	[16]
17	however	O	['N']	[17]
18	,	O	['N']	[18]
19	the	O	['N']	[19]
20	administration	O	['N']	[20]
21	of	O	['N']	[21]
22	thymidine	O	['N']	[22]
23	potentially	O	['N']	[23]
24	may	O	['N']	[24]
25	reverse	O	['N']	[25]
26	severe	O	['N']	[26]
27	5-FU	O	['N']	[27]
28	-	O	['N']	[28]
29	induced	O	['N']	[29]
30	neurologic	O	['N']	[30]
31	symptoms	O	['N']	[31]
32	such	O	['N']	[32]
33	as	O	['N']	[33]
34	encephalopathy	O	['N']	[34]
35	and	O	['N']	[35]
36	coma	B-Adverse_Effect	['N']	[36]
37	.	O	['N']	[37]
#2486
0	Cicatricial	B	['N']	[0]
1	entropion	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	chronic	O	['N']	[4]
5	dipivefrin	B-Drug	['Causes']	[1]
6	application	O	['N']	[6]
7	.	O	['N']	[7]
#2487
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	report	O	['N']	[3]
4	indicates	O	['N']	[4]
5	clindamycin	B	['N']	[5]
6	phosphate	I-Drug	['Causes']	[40]
7	vaginal	O	['N']	[7]
8	cream	O	['N']	[8]
9	as	O	['N']	[9]
10	the	O	['N']	[10]
11	most	O	['N']	[11]
12	probable	O	['N']	[12]
13	cause	O	['N']	[13]
14	of	O	['N']	[14]
15	CDIC	O	['N']	[15]
16	due	O	['N']	[16]
17	to	O	['N']	[17]
18	the	O	['N']	[18]
19	temporal	O	['N']	[19]
20	relationship	O	['N']	[20]
21	between	O	['N']	[21]
22	the	O	['N']	[22]
23	occurrence	O	['N']	[23]
24	of	O	['N']	[24]
25	diarrhea	O	['N']	[25]
26	and	O	['N']	[26]
27	clindamycin	O	['N']	[27]
28	administration	O	['N']	[28]
29	,	O	['N']	[29]
30	lack	O	['N']	[30]
31	of	O	['N']	[31]
32	concomitant	O	['N']	[32]
33	medications	O	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	documentation	O	['N']	[36]
37	of	O	['N']	[37]
38	C.	B	['N']	[38]
39	difficile	I	['N']	[39]
40	toxin	I-Adverse_Effect	['N']	[40]
41	.	O	['N']	[41]
#2488
0	Pulmonary	O	['N']	[0]
1	hemorrhage	O	['N']	[1]
2	is	O	['N']	[2]
3	an	O	['N']	[3]
4	uncommon	O	['N']	[4]
5	feature	O	['N']	[5]
6	in	O	['N']	[6]
7	the	O	['N']	[7]
8	HUS	B-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	seems	O	['N']	[11]
12	to	O	['N']	[12]
13	appear	O	['N']	[13]
14	especially	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	HUS	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	MMC	B-Drug	['Causes']	[8]
21	therapy	O	['N']	[21]
22	.	O	['N']	[22]
#2489
0	Amiodarone	B-Drug	['Causes']	[8]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	thyrotoxicosis	O	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	thyrotropin	B	['N']	[6]
7	receptor	I	['N']	[7]
8	antibody	I-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#2490
0	Bromocriptine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	schizophrenia	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#2491
0	Rapamycin	O	['N']	[0]
1	/	O	['N']	[1]
2	sirolimus	O	['N']	[2]
3	(	O	['N']	[3]
4	SR	O	['N']	[4]
5	)	O	['N']	[5]
6	,	O	['N']	[6]
7	trade	O	['N']	[7]
8	named	O	['N']	[8]
9	Rapammune	B-Drug	['Causes']	[34]
10	(	O	['N']	[10]
11	Wyeth	O	['N']	[11]
12	-	O	['N']	[12]
13	Ayerst	O	['N']	[13]
14	,	O	['N']	[14]
15	Sydney	O	['N']	[15]
16	,	O	['N']	[16]
17	Australia	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	is	O	['N']	[20]
21	a	O	['N']	[21]
22	potent	O	['N']	[22]
23	immunosuppressive	O	['N']	[23]
24	drug	O	['N']	[24]
25	associated	O	['N']	[25]
26	with	O	['N']	[26]
27	myelosuppression	O	['N']	[27]
28	,	O	['N']	[28]
29	hypertension	O	['N']	[29]
30	,	O	['N']	[30]
31	hyperlipidemia	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	infection	B-Adverse_Effect	['N']	[34]
35	.	O	['N']	[35]
#2492
0	Previous	O	['N']	[0]
1	studies	O	['N']	[1]
2	have	O	['N']	[2]
3	demonstrated	O	['N']	[3]
4	the	O	['N']	[4]
5	interaction	O	['N']	[5]
6	of	O	['N']	[6]
7	MTX	B-Drug	['Causes']	[42]
8	and	O	['N']	[8]
9	a	O	['N']	[9]
10	variety	O	['N']	[10]
11	of	O	['N']	[11]
12	non	O	['N']	[12]
13	-	O	['N']	[13]
14	steroidal	O	['N']	[14]
15	,	O	['N']	[15]
16	anti	O	['N']	[16]
17	-	O	['N']	[17]
18	inflammatory	O	['N']	[18]
19	drugs	O	['N']	[19]
20	(	O	['N']	[20]
21	NSAIDs	O	['N']	[21]
22	)	O	['N']	[22]
23	with	O	['N']	[23]
24	various	O	['N']	[24]
25	clinical	O	['N']	[25]
26	manifestations	O	['N']	[26]
27	including	O	['N']	[27]
28	acute	O	['N']	[28]
29	renal	O	['N']	[29]
30	failure	O	['N']	[30]
31	,	O	['N']	[31]
32	pancytopenia	O	['N']	[32]
33	,	O	['N']	[33]
34	vomiting	O	['N']	[34]
35	,	O	['N']	[35]
36	diarrhea	O	['N']	[36]
37	,	O	['N']	[37]
38	elevated	O	['N']	[38]
39	liver	O	['N']	[39]
40	transaminases	O	['N']	[40]
41	,	O	['N']	[41]
42	jaundice	B-Adverse_Effect	['N']	[42]
43	,	O	['N']	[43]
44	mucosal	O	['N']	[44]
45	ulcerations	O	['N']	[45]
46	,	O	['N']	[46]
47	and	O	['N']	[47]
48	pyrexia	O	['N']	[48]
49	.	O	['N']	[49]
#2493
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	admitted	O	['N']	[2]
3	following	O	['N']	[3]
4	a	O	['N']	[4]
5	fall	O	['N']	[5]
6	and	O	['N']	[6]
7	,	O	['N']	[7]
8	after	O	['N']	[8]
9	being	O	['N']	[9]
10	given	O	['N']	[10]
11	metoclopramide	B-Drug	['Causes']	[20]
12	,	O	['N']	[12]
13	developed	O	['N']	[13]
14	movement	O	['N']	[14]
15	disorder	O	['N']	[15]
16	and	O	['N']	[16]
17	a	O	['N']	[17]
18	period	O	['N']	[18]
19	of	O	['N']	[19]
20	unresponsiveness	B-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#2494
0	A	O	['N']	[0]
1	62-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	who	O	['N']	[5]
6	was	O	['N']	[6]
7	being	O	['N']	[7]
8	treated	O	['N']	[8]
9	for	O	['N']	[9]
10	squamous	O	['N']	[10]
11	cell	O	['N']	[11]
12	carcinoma	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	head	O	['N']	[15]
16	and	O	['N']	[16]
17	neck	O	['N']	[17]
18	developed	O	['N']	[18]
19	a	O	['N']	[19]
20	chemotherapy	O	['N']	[20]
21	-	O	['N']	[21]
22	related	O	['N']	[22]
23	hemolytic	B	['N']	[23]
24	-	I	['N']	[24]
25	uremic	I	['N']	[25]
26	syndrome	I-Adverse_Effect	['N']	[26]
27	during	O	['N']	[27]
28	the	O	['N']	[28]
29	second	O	['N']	[29]
30	cycle	O	['N']	[30]
31	of	O	['N']	[31]
32	neoadjuvant	O	['N']	[32]
33	chemotherapy	O	['N']	[33]
34	consisting	O	['N']	[34]
35	of	O	['N']	[35]
36	cisplatin	O	['N']	[36]
37	,	O	['N']	[37]
38	bleomycin	O	['N']	[38]
39	,	O	['N']	[39]
40	and	O	['N']	[40]
41	methotrexate	B-Drug	['Causes']	[26]
42	.	O	['N']	[42]
#2495
0	Anaphylactoid	B	['N']	[0]
1	reaction	I-Adverse_Effect	['N']	[1]
2	to	O	['N']	[2]
3	methylprednisolone	B-Drug	['Causes']	[1]
4	pulsed	O	['N']	[4]
5	therapy	O	['N']	[5]
6	for	O	['N']	[6]
7	multiple	O	['N']	[7]
8	sclerosis	O	['N']	[8]
9	.	O	['N']	[9]
#2496
0	Cephalosporin	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	leukopenia	B-Adverse_Effect	['N']	[3]
4	following	O	['N']	[4]
5	rechallenge	O	['N']	[5]
6	with	O	['N']	[6]
7	cefoxitin	O	['N']	[7]
8	.	O	['N']	[8]
#2497
0	Celiac	B	['N']	[0]
1	disease	I-Adverse_Effect	['N']	[1]
2	onset	O	['N']	[2]
3	after	O	['N']	[3]
4	pegylated	B	['N']	[4]
5	interferon	I-Drug	['Causes']	[1]
6	and	O	['N']	[6]
7	ribavirin	O	['N']	[7]
8	treatment	O	['N']	[8]
9	of	O	['N']	[9]
10	chronic	O	['N']	[10]
11	hepatitis	O	['N']	[11]
12	C.	O	['N']	[12]
#2498
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	suffering	O	['N']	[2]
3	from	O	['N']	[3]
4	heparin	B-Drug	['Causes']	[9]
5	-	O	['N']	[5]
6	associated	O	['N']	[6]
7	thrombocytopenia	O	['N']	[7]
8	(	O	['N']	[8]
9	HAT	B-Adverse_Effect	['N']	[9]
10	)	O	['N']	[10]
11	,	O	['N']	[11]
12	recurrent	O	['N']	[12]
13	arteriothromboses	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	acute	O	['N']	[16]
17	renal	O	['N']	[17]
18	failure	O	['N']	[18]
19	after	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	standard	O	['N']	[22]
23	heparin	O	['N']	[23]
24	is	O	['N']	[24]
25	described	O	['N']	[25]
26	.	O	['N']	[26]
#2499
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	pulmonary	O	['N']	[5]
6	adenocarcinoma	O	['N']	[6]
7	complicated	O	['N']	[7]
8	by	O	['N']	[8]
9	the	O	['N']	[9]
10	syndrome	B	['N']	[10]
11	of	I	['N']	[11]
12	inappropriate	I	['N']	[12]
13	secretion	I	['N']	[13]
14	of	I	['N']	[14]
15	antidiuretic	I	['N']	[15]
16	hormone	I-Adverse_Effect	['N']	[16]
17	(	O	['N']	[17]
18	SIADH	O	['N']	[18]
19	)	O	['N']	[19]
20	following	O	['N']	[20]
21	systemic	O	['N']	[21]
22	chemotherapy	O	['N']	[22]
23	with	O	['N']	[23]
24	cisplatin	O	['N']	[24]
25	(	O	['N']	[25]
26	CDDP	O	['N']	[26]
27	)	O	['N']	[27]
28	and	O	['N']	[28]
29	vindesine	B-Drug	['Causes']	[16]
30	(	O	['N']	[30]
31	VDS	O	['N']	[31]
32	)	O	['N']	[32]
33	.	O	['N']	[33]
#2500
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	no	O	['N']	[2]
3	.	O	['N']	[3]
4	2	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	pathogenic	O	['N']	[7]
8	mechanism	O	['N']	[8]
9	seemed	O	['N']	[9]
10	to	O	['N']	[10]
11	be	O	['N']	[11]
12	persistent	O	['N']	[12]
13	light	O	['N']	[13]
14	reaction	O	['N']	[14]
15	preceded	O	['N']	[15]
16	by	O	['N']	[16]
17	systemic	O	['N']	[17]
18	photoallergy	O	['N']	[18]
19	,	O	['N']	[19]
20	as	O	['N']	[20]
21	he	O	['N']	[21]
22	had	O	['N']	[22]
23	taken	O	['N']	[23]
24	mequitazine	B-Drug	['Causes']	[54]
25	for	O	['N']	[25]
26	6	O	['N']	[26]
27	months	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	there	O	['N']	[30]
31	were	O	['N']	[31]
32	strong	O	['N']	[32]
33	positive	O	['N']	[33]
34	photopatch	O	['N']	[34]
35	test	O	['N']	[35]
36	results	O	['N']	[36]
37	with	O	['N']	[37]
38	immediate	O	['N']	[38]
39	erythema	O	['N']	[39]
40	reaction	O	['N']	[40]
41	,	O	['N']	[41]
42	cross	O	['N']	[42]
43	-	O	['N']	[43]
44	reaction	O	['N']	[44]
45	to	O	['N']	[45]
46	promethazine	O	['N']	[46]
47	,	O	['N']	[47]
48	decreased	B	['N']	[48]
49	MED	I	['N']	[49]
50	to	I	['N']	[50]
51	both	I	['N']	[51]
52	UVA	I	['N']	[52]
53	and	I	['N']	[53]
54	UVB	I-Adverse_Effect	['N']	[54]
55	,	O	['N']	[55]
56	and	O	['N']	[56]
57	persistence	O	['N']	[57]
58	of	O	['N']	[58]
59	the	O	['N']	[59]
60	photosensitivity	O	['N']	[60]
61	over	O	['N']	[61]
62	a	O	['N']	[62]
63	3-year	O	['N']	[63]
64	follow	O	['N']	[64]
65	-	O	['N']	[65]
66	up	O	['N']	[66]
67	period	O	['N']	[67]
68	after	O	['N']	[68]
69	discontinuation	O	['N']	[69]
70	of	O	['N']	[70]
71	the	O	['N']	[71]
72	mequitazine	O	['N']	[72]
73	.	O	['N']	[73]
#2501
0	Docetaxel	B-Drug	['Causes']	[10]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	Meibomian	O	['N']	[3]
4	duct	O	['N']	[4]
5	inflammation	O	['N']	[5]
6	and	O	['N']	[6]
7	blockage	O	['N']	[7]
8	leading	O	['N']	[8]
9	to	O	['N']	[9]
10	chalazion	B-Adverse_Effect	['N']	[10]
11	formation	O	['N']	[11]
12	.	O	['N']	[12]
#2502
0	DIAGNOSIS	O	['N']	[0]
1	:	O	['N']	[1]
2	Sustained	B	['N']	[2]
3	ventricular	I	['N']	[3]
4	tachycardia	I-Adverse_Effect	['N']	[4]
5	possibly	O	['N']	[5]
6	owing	O	['N']	[6]
7	to	O	['N']	[7]
8	thalidomide	B-Drug	['Causes']	[4]
9	treatment	O	['N']	[9]
10	.	O	['N']	[10]
#2503
0	The	O	['N']	[0]
1	present	O	['N']	[1]
2	case	O	['N']	[2]
3	is	O	['N']	[3]
4	the	O	['N']	[4]
5	first	O	['N']	[5]
6	report	O	['N']	[6]
7	of	O	['N']	[7]
8	hypercalcemia	B-Adverse_Effect	['N']	[8]
9	induced	O	['N']	[9]
10	by	O	['N']	[10]
11	vitamin	O	['N']	[11]
12	D3	O	['N']	[12]
13	ointment	O	['N']	[13]
14	and	O	['N']	[14]
15	thiazide	B-Drug	['Causes']	[8]
16	simultaneously	O	['N']	[16]
17	.	O	['N']	[17]
#2504
0	Although	O	['N']	[0]
1	this	O	['N']	[1]
2	combination	O	['N']	[2]
3	agent	O	['N']	[3]
4	has	O	['N']	[4]
5	been	O	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	a	O	['N']	[8]
9	hypersensitivity	B	['N']	[9]
10	syndrome	I-Adverse_Effect	['N']	[10]
11	involving	O	['N']	[11]
12	cutaneous	O	['N']	[12]
13	skin	O	['N']	[13]
14	eruptions	O	['N']	[14]
15	,	O	['N']	[15]
16	pediatric	O	['N']	[16]
17	cases	O	['N']	[17]
18	of	O	['N']	[18]
19	TMP	B	['N']	[19]
20	-	I	['N']	[20]
21	SMX	I-Drug	['Causes']	[10]
22	-	O	['N']	[22]
23	induced	O	['N']	[23]
24	hepatotoxicity	O	['N']	[24]
25	are	O	['N']	[25]
26	rare	O	['N']	[26]
27	.	O	['N']	[27]
#2505
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	on	O	['N']	[4]
5	the	O	['N']	[5]
6	possible	O	['N']	[6]
7	development	O	['N']	[7]
8	of	O	['N']	[8]
9	serotonin	B	['N']	[9]
10	syndrome	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	receiving	O	['N']	[14]
15	clomipramine	O	['N']	[15]
16	after	O	['N']	[16]
17	clozapine	B-Drug	['Causes']	[10]
18	was	O	['N']	[18]
19	withdrawn	O	['N']	[19]
20	from	O	['N']	[20]
21	the	O	['N']	[21]
22	treatment	O	['N']	[22]
23	regimen	O	['N']	[23]
24	.	O	['N']	[24]
#2506
0	We	O	['N']	[0]
1	discuss	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	severe	O	['N']	[6]
7	renal	O	['N']	[7]
8	tubular	O	['N']	[8]
9	dysfunction	O	['N']	[9]
10	secondary	O	['N']	[10]
11	to	O	['N']	[11]
12	short	O	['N']	[12]
13	-	O	['N']	[13]
14	term	O	['N']	[14]
15	therapy	O	['N']	[15]
16	with	O	['N']	[16]
17	Amikacin	B-Drug	['Causes']	[32]
18	,	O	['N']	[18]
19	resulting	O	['N']	[19]
20	in	O	['N']	[20]
21	refractory	O	['N']	[21]
22	hypokalemia	O	['N']	[22]
23	,	O	['N']	[23]
24	hypocalcemia	O	['N']	[24]
25	,	O	['N']	[25]
26	hypomagnesemia	O	['N']	[26]
27	,	O	['N']	[27]
28	metabolic	O	['N']	[28]
29	alkalosis	O	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	polyuria	B-Adverse_Effect	['N']	[32]
33	.	O	['N']	[33]
#2507
0	Although	O	['N']	[0]
1	transient	O	['N']	[1]
2	increases	O	['N']	[2]
3	in	O	['N']	[3]
4	ectopy	O	['N']	[4]
5	after	O	['N']	[5]
6	bretylium	B-Drug	['Causes']	[25]
7	therapy	O	['N']	[7]
8	have	O	['N']	[8]
9	been	O	['N']	[9]
10	described	O	['N']	[10]
11	,	O	['N']	[11]
12	presumably	O	['N']	[12]
13	due	O	['N']	[13]
14	to	O	['N']	[14]
15	catecholamine	O	['N']	[15]
16	release	O	['N']	[16]
17	,	O	['N']	[17]
18	the	O	['N']	[18]
19	occurrence	O	['N']	[19]
20	of	O	['N']	[20]
21	life	O	['N']	[21]
22	-	O	['N']	[22]
23	threatening	O	['N']	[23]
24	ventricular	B	['N']	[24]
25	arrhythmia	I-Adverse_Effect	['N']	[25]
26	leading	O	['N']	[26]
27	to	O	['N']	[27]
28	cardiac	O	['N']	[28]
29	arrest	O	['N']	[29]
30	has	O	['N']	[30]
31	not	O	['N']	[31]
32	previously	O	['N']	[32]
33	been	O	['N']	[33]
34	emphasized	O	['N']	[34]
35	.	O	['N']	[35]
#2508
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	hypereosinophilia	B-Adverse_Effect	['N']	[5]
6	related	O	['N']	[6]
7	to	O	['N']	[7]
8	zafirlukast	B-Drug	['Causes']	[5]
9	therapy	O	['N']	[9]
10	.	O	['N']	[10]
#2509
0	Children	O	['N']	[0]
1	with	O	['N']	[1]
2	acute	O	['N']	[2]
3	lymphoblastic	O	['N']	[3]
4	leukemia	O	['N']	[4]
5	(	O	['N']	[5]
6	ALL	O	['N']	[6]
7	)	O	['N']	[7]
8	,	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	L	B	['N']	[11]
12	-	I	['N']	[12]
13	asparaginase	I-Drug	['Causes']	[21]
14	are	O	['N']	[14]
15	at	O	['N']	[15]
16	risk	O	['N']	[16]
17	for	O	['N']	[17]
18	cerebral	O	['N']	[18]
19	thrombosis	O	['N']	[19]
20	or	O	['N']	[20]
21	hemorrhage	B-Adverse_Effect	['N']	[21]
22	because	O	['N']	[22]
23	of	O	['N']	[23]
24	coagulation	O	['N']	[24]
25	protein	O	['N']	[25]
26	deficiencies	O	['N']	[26]
27	.	O	['N']	[27]
#2510
0	Pneumonitis	O	['N']	[0]
1	,	O	['N']	[1]
2	bilateral	O	['N']	[2]
3	pleural	O	['N']	[3]
4	effusions	O	['N']	[4]
5	,	O	['N']	[5]
6	echocardiographic	O	['N']	[6]
7	evidence	O	['N']	[7]
8	of	O	['N']	[8]
9	cardiac	B	['N']	[9]
10	tamponade	I-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	positive	O	['N']	[13]
14	autoantibodies	O	['N']	[14]
15	developed	O	['N']	[15]
16	in	O	['N']	[16]
17	a	O	['N']	[17]
18	43-year	O	['N']	[18]
19	-	O	['N']	[19]
20	old	O	['N']	[20]
21	man	O	['N']	[21]
22	,	O	['N']	[22]
23	who	O	['N']	[23]
24	was	O	['N']	[24]
25	receiving	O	['N']	[25]
26	long	O	['N']	[26]
27	-	O	['N']	[27]
28	term	O	['N']	[28]
29	sulfasalazine	B-Drug	['Causes']	[10]
30	therapy	O	['N']	[30]
31	for	O	['N']	[31]
32	chronic	O	['N']	[32]
33	ulcerative	O	['N']	[33]
34	colitis	O	['N']	[34]
35	.	O	['N']	[35]
#2511
0	Adriamycin	O	['N']	[0]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	cardiomyopathy	O	['N']	[3]
4	aggravated	O	['N']	[4]
5	by	O	['N']	[5]
6	cis	B	['N']	[6]
7	-	I	['N']	[7]
8	platinum	I-Drug	['Causes']	[9]
9	nephrotoxicity	B-Adverse_Effect	['N']	[9]
10	requiring	O	['N']	[10]
11	dialysis	O	['N']	[11]
12	.	O	['N']	[12]
#2512
0	Five	O	['N']	[0]
1	and	O	['N']	[1]
2	one	O	['N']	[2]
3	-	O	['N']	[3]
4	half	O	['N']	[4]
5	years	O	['N']	[5]
6	after	O	['N']	[6]
7	the	O	['N']	[7]
8	diagnosis	O	['N']	[8]
9	of	O	['N']	[9]
10	myeloma	O	['N']	[10]
11	,	O	['N']	[11]
12	while	O	['N']	[12]
13	in	O	['N']	[13]
14	remission	O	['N']	[14]
15	on	O	['N']	[15]
16	cyclophosphamide	B-Drug	['Causes']	[27]
17	therapy	O	['N']	[17]
18	,	O	['N']	[18]
19	the	O	['N']	[19]
20	patient	O	['N']	[20]
21	experienced	O	['N']	[21]
22	severe	O	['N']	[22]
23	abdominal	B	['N']	[23]
24	right	I	['N']	[24]
25	lower	I	['N']	[25]
26	quadrant	I	['N']	[26]
27	pain	I-Adverse_Effect	['N']	[27]
28	due	O	['N']	[28]
29	to	O	['N']	[29]
30	a	O	['N']	[30]
31	large	O	['N']	[31]
32	cecal	O	['N']	[32]
33	lymphoma	O	['N']	[33]
34	.	O	['N']	[34]
#2513
0	Bone	B	['N']	[0]
1	formation	I-Adverse_Effect	['N']	[1]
2	induced	O	['N']	[2]
3	in	O	['N']	[3]
4	an	O	['N']	[4]
5	infant	O	['N']	[5]
6	by	O	['N']	[6]
7	systemic	O	['N']	[7]
8	prostaglandin	B	['N']	[8]
9	-	I	['N']	[9]
10	E2	I-Drug	['Causes']	[1]
11	administration	O	['N']	[11]
12	.	O	['N']	[12]
#2514
0	Spindle	B	['N']	[0]
1	coma	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	benzodiazepine	B-Drug	['Causes']	[1]
4	toxicity	O	['N']	[4]
5	:	O	['N']	[5]
6	case	O	['N']	[6]
7	report	O	['N']	[7]
8	.	O	['N']	[8]
#2515
0	Peripheral	O	['N']	[0]
1	neuropathy	O	['N']	[1]
2	and	O	['N']	[2]
3	cerebellar	B	['N']	[3]
4	syndrome	I-Adverse_Effect	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	amiodarone	B-Drug	['Causes']	[4]
8	therapy	O	['N']	[8]
9	.	O	['N']	[9]
#2516
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	postictal	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	lethargy	O	['N']	[9]
10	,	O	['N']	[10]
11	hyperammonemia	B-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	otherwise	O	['N']	[13]
14	normal	O	['N']	[14]
15	liver	O	['N']	[15]
16	function	O	['N']	[16]
17	tests	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	a	O	['N']	[20]
21	therapeutic	O	['N']	[21]
22	valproic	B	['N']	[22]
23	acid	I-Drug	['Causes']	[11]
24	level	O	['N']	[24]
25	.	O	['N']	[25]
#2517
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	the	O	['N']	[6]
7	catatonia	B	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	disulfiram	B-Drug	['Causes']	[8]
12	therapy	O	['N']	[12]
13	.	O	['N']	[13]
#2518
0	Three	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	pseudocyst	B	['N']	[3]
4	of	I	['N']	[4]
5	the	I	['N']	[5]
6	pancreas	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	two	O	['N']	[8]
9	women	O	['N']	[9]
10	and	O	['N']	[10]
11	one	O	['N']	[11]
12	man	O	['N']	[12]
13	have	O	['N']	[13]
14	previously	O	['N']	[14]
15	been	O	['N']	[15]
16	reported	O	['N']	[16]
17	with	O	['N']	[17]
18	the	O	['N']	[18]
19	use	O	['N']	[19]
20	of	O	['N']	[20]
21	intravenous	O	['N']	[21]
22	L	B	['N']	[22]
23	-	I	['N']	[23]
24	asparaginase	I-Drug	['Causes']	[6]
25	.	O	['N']	[25]
#2519
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	presented	O	['N']	[2]
3	with	O	['N']	[3]
4	fulminant	O	['N']	[4]
5	microangiopathic	O	['N']	[5]
6	hemolytic	O	['N']	[6]
7	anemia	O	['N']	[7]
8	and	O	['N']	[8]
9	thrombocytopenia	B-Adverse_Effect	['N']	[9]
10	within	O	['N']	[10]
11	48	O	['N']	[11]
12	hr	O	['N']	[12]
13	of	O	['N']	[13]
14	initiating	O	['N']	[14]
15	therapy	O	['N']	[15]
16	with	O	['N']	[16]
17	trimethoprim	B-Drug	['Causes']	[9]
18	-	O	['N']	[18]
19	sulfamethoxazole	O	['N']	[19]
20	.	O	['N']	[20]
#2520
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	NEH	B-Adverse_Effect	['N']	[5]
6	masquerading	O	['N']	[6]
7	as	O	['N']	[7]
8	cutaneous	O	['N']	[8]
9	vasculitis	O	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	woman	O	['N']	[12]
13	receiving	O	['N']	[13]
14	cyclophosphamide	B-Drug	['Causes']	[5]
15	for	O	['N']	[15]
16	lupus	O	['N']	[16]
17	nephritis	O	['N']	[17]
18	.	O	['N']	[18]
#2521
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	risk	O	['N']	[3]
4	of	O	['N']	[4]
5	drug	O	['N']	[5]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	rhabdomyolysis	B-Adverse_Effect	['N']	[8]
9	due	O	['N']	[9]
10	to	O	['N']	[10]
11	the	O	['N']	[11]
12	potential	O	['N']	[12]
13	interaction	O	['N']	[13]
14	between	O	['N']	[14]
15	lovastatin	O	['N']	[15]
16	and	O	['N']	[16]
17	azithromycin	O	['N']	[17]
18	or	O	['N']	[18]
19	clarithromycin	B-Drug	['Causes']	[8]
20	should	O	['N']	[20]
21	be	O	['N']	[21]
22	considered	O	['N']	[22]
23	before	O	['N']	[23]
24	the	O	['N']	[24]
25	concomitant	O	['N']	[25]
26	use	O	['N']	[26]
27	of	O	['N']	[27]
28	these	O	['N']	[28]
29	agents	O	['N']	[29]
30	.	O	['N']	[30]
#2522
0	Long	O	['N']	[0]
1	-	O	['N']	[1]
2	term	O	['N']	[2]
3	follow	O	['N']	[3]
4	-	O	['N']	[4]
5	up	O	['N']	[5]
6	after	O	['N']	[6]
7	neoplastic	B	['N']	[7]
8	seeding	I-Adverse_Effect	['N']	[8]
9	complicating	O	['N']	[9]
10	percutaneous	O	['N']	[10]
11	ethanol	B-Drug	['Causes']	[8]
12	injection	O	['N']	[12]
13	for	O	['N']	[13]
14	treatment	O	['N']	[14]
15	of	O	['N']	[15]
16	hepatocellular	O	['N']	[16]
17	carcinoma	O	['N']	[17]
18	.	O	['N']	[18]
#2523
0	2-CdA	B-Drug	['Causes']	[29]
1	typically	O	['N']	[1]
2	causes	O	['N']	[2]
3	a	O	['N']	[3]
4	long	O	['N']	[4]
5	-	O	['N']	[5]
6	lasting	O	['N']	[6]
7	state	O	['N']	[7]
8	of	O	['N']	[8]
9	immunodeficiency	O	['N']	[9]
10	and	O	['N']	[10]
11	the	O	['N']	[11]
12	profound	O	['N']	[12]
13	influence	O	['N']	[13]
14	of	O	['N']	[14]
15	this	O	['N']	[15]
16	drug	O	['N']	[16]
17	on	O	['N']	[17]
18	the	O	['N']	[18]
19	immune	O	['N']	[19]
20	system	O	['N']	[20]
21	has	O	['N']	[21]
22	raised	O	['N']	[22]
23	questions	O	['N']	[23]
24	concerning	O	['N']	[24]
25	the	O	['N']	[25]
26	emergence	O	['N']	[26]
27	of	O	['N']	[27]
28	secondary	B	['N']	[28]
29	neoplasms	I-Adverse_Effect	['N']	[29]
30	after	O	['N']	[30]
31	its	O	['N']	[31]
32	use	O	['N']	[32]
33	.	O	['N']	[33]
#2524
0	Life	O	['N']	[0]
1	-	O	['N']	[1]
2	threatening	O	['N']	[2]
3	alterations	B	['N']	[3]
4	in	I	['N']	[4]
5	heart	I	['N']	[5]
6	rate	I-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	the	O	['N']	[8]
9	use	O	['N']	[9]
10	of	O	['N']	[10]
11	adenosine	B-Drug	['Causes']	[6]
12	in	O	['N']	[12]
13	atrial	O	['N']	[13]
14	flutter	O	['N']	[14]
15	.	O	['N']	[15]
#2525
0	Two	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	administration	O	['N']	[3]
4	of	O	['N']	[4]
5	Kalimate	B-Drug	['Causes']	[23]
6	enema	O	['N']	[6]
7	,	O	['N']	[7]
8	he	O	['N']	[8]
9	had	O	['N']	[9]
10	profuse	O	['N']	[10]
11	hematochezia	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	a	O	['N']	[14]
15	sigmoidoscopy	O	['N']	[15]
16	showed	O	['N']	[16]
17	diffuse	O	['N']	[17]
18	colonic	B	['N']	[18]
19	mucosal	I	['N']	[19]
20	necrosis	I	['N']	[20]
21	in	I	['N']	[21]
22	the	I	['N']	[22]
23	rectum	I-Adverse_Effect	['N']	[23]
24	and	O	['N']	[24]
25	sigmoid	O	['N']	[25]
26	colon	O	['N']	[26]
27	.	O	['N']	[27]
#2526
0	A	O	['N']	[0]
1	teenage	O	['N']	[1]
2	girl	O	['N']	[2]
3	with	O	['N']	[3]
4	crescentic	O	['N']	[4]
5	glomerulonephritis	O	['N']	[5]
6	had	O	['N']	[6]
7	antineutrophil	B	['N']	[7]
8	cytoplasmic	I	['N']	[8]
9	antibody	I-Adverse_Effect	['N']	[9]
10	(	O	['N']	[10]
11	ANCA	O	['N']	[11]
12	)	O	['N']	[12]
13	detected	O	['N']	[13]
14	after	O	['N']	[14]
15	she	O	['N']	[15]
16	had	O	['N']	[16]
17	received	O	['N']	[17]
18	propylthiouracil	O	['N']	[18]
19	(	O	['N']	[19]
20	PTU	B-Drug	['Causes']	[9]
21	)	O	['N']	[21]
22	for	O	['N']	[22]
23	hyperthyroidism	O	['N']	[23]
24	without	O	['N']	[24]
25	cutaneous	O	['N']	[25]
26	vasculitis	O	['N']	[26]
27	.	O	['N']	[27]
#2527
0	Our	O	['N']	[0]
1	findings	O	['N']	[1]
2	suggest	O	['N']	[2]
3	that	O	['N']	[3]
4	hyperkalemia	O	['N']	[4]
5	can	O	['N']	[5]
6	develop	O	['N']	[6]
7	with	O	['N']	[7]
8	the	O	['N']	[8]
9	use	O	['N']	[9]
10	of	O	['N']	[10]
11	low	B	['N']	[11]
12	-	I	['N']	[12]
13	dose	I-Dose	['N']	[13]
14	heparin	B-Drug	['Dosage']	[13]
15	,	O	['N']	[15]
16	within	O	['N']	[16]
17	seven	O	['N']	[17]
18	days	O	['N']	[18]
19	of	O	['N']	[19]
20	initiating	O	['N']	[20]
21	heparin	O	['N']	[21]
22	therapy	O	['N']	[22]
23	,	O	['N']	[23]
24	and	O	['N']	[24]
25	that	O	['N']	[25]
26	patients	O	['N']	[26]
27	with	O	['N']	[27]
28	diabetes	O	['N']	[28]
29	mellitus	O	['N']	[29]
30	or	O	['N']	[30]
31	chronic	O	['N']	[31]
32	renal	O	['N']	[32]
33	insufficiency	O	['N']	[33]
34	are	O	['N']	[34]
35	especially	O	['N']	[35]
36	predisposed	O	['N']	[36]
37	to	O	['N']	[37]
38	this	O	['N']	[38]
39	complication	O	['N']	[39]
40	.	O	['N']	[40]
#2528
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	2	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	serotonin	B	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	with	O	['N']	[9]
10	serious	O	['N']	[10]
11	extrapyramidal	O	['N']	[11]
12	movement	O	['N']	[12]
13	disorders	O	['N']	[13]
14	occurring	O	['N']	[14]
15	when	O	['N']	[15]
16	metoclopramide	O	['N']	[16]
17	was	O	['N']	[17]
18	coadministered	O	['N']	[18]
19	with	O	['N']	[19]
20	sertraline	B-Drug	['Causes']	[8]
21	or	O	['N']	[21]
22	venlafaxine	O	['N']	[22]
23	.	O	['N']	[23]
#2529
0	Radiation	B	['N']	[0]
1	recall	I-Adverse_Effect	['N']	[1]
2	related	O	['N']	[2]
3	to	O	['N']	[3]
4	gemcitabine	B-Drug	['Causes']	[1]
5	has	O	['N']	[5]
6	been	O	['N']	[6]
7	reported	O	['N']	[7]
8	in	O	['N']	[8]
9	lung	O	['N']	[9]
10	and	O	['N']	[10]
11	breast	O	['N']	[11]
12	cancer	O	['N']	[12]
13	.	O	['N']	[13]
#2530
0	Beginning	O	['N']	[0]
1	ductopenia	B-Adverse_Effect	['N']	[1]
2	was	O	['N']	[2]
3	present	O	['N']	[3]
4	in	O	['N']	[4]
5	two	O	['N']	[5]
6	,	O	['N']	[6]
7	suggesting	O	['N']	[7]
8	that	O	['N']	[8]
9	itraconazole	B-Drug	['Causes']	[1]
10	might	O	['N']	[10]
11	be	O	['N']	[11]
12	responsible	O	['N']	[12]
13	for	O	['N']	[13]
14	the	O	['N']	[14]
15	occurrence	O	['N']	[15]
16	of	O	['N']	[16]
17	prolonged	O	['N']	[17]
18	drug	O	['N']	[18]
19	-	O	['N']	[19]
20	induced	O	['N']	[20]
21	cholangiopathy	O	['N']	[21]
22	.	O	['N']	[22]
#2531
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	the	O	['N']	[4]
5	first	O	['N']	[5]
6	five	O	['N']	[6]
7	cases	O	['N']	[7]
8	of	O	['N']	[8]
9	amphotericin	B	['N']	[9]
10	B	I-Drug	['Causes']	[15]
11	overdose	O	['N']	[11]
12	with	O	['N']	[12]
13	secondary	O	['N']	[13]
14	cardiac	B	['N']	[14]
15	complications	I-Adverse_Effect	['N']	[15]
16	in	O	['N']	[16]
17	a	O	['N']	[17]
18	pediatric	O	['N']	[18]
19	population	O	['N']	[19]
20	.	O	['N']	[20]
#2532
0	Increased	O	['N']	[0]
1	lash	O	['N']	[1]
2	length	O	['N']	[2]
3	,	O	['N']	[3]
4	thickness	O	['N']	[4]
5	,	O	['N']	[5]
6	and	O	['N']	[6]
7	pigmentation	B-Adverse_Effect	['N']	[7]
8	are	O	['N']	[8]
9	well	O	['N']	[9]
10	-	O	['N']	[10]
11	documented	O	['N']	[11]
12	side	O	['N']	[12]
13	effects	O	['N']	[13]
14	of	O	['N']	[14]
15	prostaglandin	B-Drug	['Causes']	[7]
16	analog	O	['N']	[16]
17	glaucoma	O	['N']	[17]
18	drops	O	['N']	[18]
19	.	O	['N']	[19]
#2533
0	Five	O	['N']	[0]
1	patients	O	['N']	[1]
2	receiving	O	['N']	[2]
3	fluoxetine	B-Drug	['Causes']	[15]
4	for	O	['N']	[4]
5	the	O	['N']	[5]
6	treatment	O	['N']	[6]
7	of	O	['N']	[7]
8	obsessive	O	['N']	[8]
9	compulsive	O	['N']	[9]
10	disorder	O	['N']	[10]
11	or	O	['N']	[11]
12	major	O	['N']	[12]
13	depression	O	['N']	[13]
14	developed	O	['N']	[14]
15	akathisia	B-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#2534
0	Post	O	['N']	[0]
1	marketing	O	['N']	[1]
2	studies	O	['N']	[2]
3	of	O	['N']	[3]
4	Interferon	B	['N']	[4]
5	-	I	['N']	[5]
6	beta	I-Drug	['Causes']	[24]
7	(	O	['N']	[7]
8	IFN	O	['N']	[8]
9	beta	O	['N']	[9]
10	)	O	['N']	[10]
11	therapy	O	['N']	[11]
12	in	O	['N']	[12]
13	multiple	O	['N']	[13]
14	sclerosis	O	['N']	[14]
15	(	O	['N']	[15]
16	MS	O	['N']	[16]
17	)	O	['N']	[17]
18	have	O	['N']	[18]
19	demonstrated	O	['N']	[19]
20	surprisingly	O	['N']	[20]
21	high	O	['N']	[21]
22	rates	O	['N']	[22]
23	of	O	['N']	[23]
24	hepatotoxicity	B-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#2535
0	Among	O	['N']	[0]
1	12	O	['N']	[1]
2	thyrotoxic	O	['N']	[2]
3	patients	O	['N']	[3]
4	,	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	arrhythmogenic	O	['N']	[8]
9	right	O	['N']	[9]
10	ventricular	O	['N']	[10]
11	dysplasia	O	['N']	[11]
12	,	O	['N']	[12]
13	who	O	['N']	[13]
14	had	O	['N']	[14]
15	been	O	['N']	[15]
16	taking	O	['N']	[16]
17	amiodarone	B-Drug	['Causes']	[37]
18	for	O	['N']	[18]
19	4	O	['N']	[19]
20	years	O	['N']	[20]
21	,	O	['N']	[21]
22	developed	O	['N']	[22]
23	thyrotoxicosis	O	['N']	[23]
24	with	O	['N']	[24]
25	subacute	O	['N']	[25]
26	onset	O	['N']	[26]
27	,	O	['N']	[27]
28	accompanied	O	['N']	[28]
29	by	O	['N']	[29]
30	transiently	B	['N']	[30]
31	positive	I	['N']	[31]
32	thyrotropin	I	['N']	[32]
33	(	I	['N']	[33]
34	TSH	I	['N']	[34]
35	)	I	['N']	[35]
36	receptor	I	['N']	[36]
37	antibody	I-Adverse_Effect	['N']	[37]
38	(	O	['N']	[38]
39	TRAb	O	['N']	[39]
40	)	O	['N']	[40]
41	,	O	['N']	[41]
42	or	O	['N']	[42]
43	thyrotropin	O	['N']	[43]
44	-	O	['N']	[44]
45	binding	O	['N']	[45]
46	inhibiting	O	['N']	[46]
47	immunoglobulin	O	['N']	[47]
48	(	O	['N']	[48]
49	TBII	O	['N']	[49]
50	)	O	['N']	[50]
51	.	O	['N']	[51]
#2536
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	type	O	['N']	[5]
6	2	O	['N']	[6]
7	diabetes	O	['N']	[7]
8	mellitus	O	['N']	[8]
9	who	O	['N']	[9]
10	,	O	['N']	[10]
11	while	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	the	O	['N']	[14]
15	antitumor	O	['N']	[15]
16	necrosis	O	['N']	[16]
17	factor	O	['N']	[17]
18	-	O	['N']	[18]
19	alpha	O	['N']	[19]
20	blocking	O	['N']	[20]
21	agent	O	['N']	[21]
22	etanercept	B-Drug	['Causes']	[30]
23	for	O	['N']	[23]
24	severe	O	['N']	[24]
25	plaque	O	['N']	[25]
26	psoriasis	O	['N']	[26]
27	,	O	['N']	[27]
28	experienced	O	['N']	[28]
29	persistent	B	['N']	[29]
30	hypoglycemia	I-Adverse_Effect	['N']	[30]
31	requiring	O	['N']	[31]
32	the	O	['N']	[32]
33	lowering	O	['N']	[33]
34	and	O	['N']	[34]
35	eventual	O	['N']	[35]
36	elimination	O	['N']	[36]
37	of	O	['N']	[37]
38	his	O	['N']	[38]
39	previous	O	['N']	[39]
40	insulin	O	['N']	[40]
41	regimen	O	['N']	[41]
42	.	O	['N']	[42]
#2537
0	Case	O	['N']	[0]
1	1	O	['N']	[1]
2	,	O	['N']	[2]
3	a	O	['N']	[3]
4	62-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	woman	O	['N']	[7]
8	,	O	['N']	[8]
9	developed	O	['N']	[9]
10	bilateral	O	['N']	[10]
11	optic	O	['N']	[11]
12	neuritis	O	['N']	[12]
13	with	O	['N']	[13]
14	decreased	O	['N']	[14]
15	sensation	O	['N']	[15]
16	of	O	['N']	[16]
17	vibration	O	['N']	[17]
18	and	O	['N']	[18]
19	increased	B	['N']	[19]
20	deep	I	['N']	[20]
21	tendon	I	['N']	[21]
22	reflex	I-Adverse_Effect	['N']	[22]
23	in	O	['N']	[23]
24	the	O	['N']	[24]
25	lower	O	['N']	[25]
26	extremities	O	['N']	[26]
27	after	O	['N']	[27]
28	a	O	['N']	[28]
29	seven	O	['N']	[29]
30	-	O	['N']	[30]
31	month	O	['N']	[31]
32	use	O	['N']	[32]
33	of	O	['N']	[33]
34	recombinant	B	['N']	[34]
35	interferon	I	['N']	[35]
36	alpha-2a	I-Drug	['Causes']	[22]
37	for	O	['N']	[37]
38	chronic	O	['N']	[38]
39	active	O	['N']	[39]
40	hepatitis	O	['N']	[40]
41	C.	O	['N']	[41]
#2538
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	one	O	['N']	[2]
3	patient	O	['N']	[3]
4	exhibited	O	['N']	[4]
5	severe	O	['N']	[5]
6	hypersensitivity	O	['N']	[6]
7	reactions	O	['N']	[7]
8	including	O	['N']	[8]
9	cardiac	O	['N']	[9]
10	arrest	O	['N']	[10]
11	and	O	['N']	[11]
12	apnea	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	another	O	['N']	[15]
16	four	O	['N']	[16]
17	patients	O	['N']	[17]
18	developed	O	['N']	[18]
19	eruptions	B-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	hypotension	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	tachycardia	O	['N']	[24]
25	soon	O	['N']	[25]
26	after	O	['N']	[26]
27	administration	O	['N']	[27]
28	of	O	['N']	[28]
29	CBDCA	B-Drug	['Causes']	[19]
30	.	O	['N']	[30]
#2539
0	Life	O	['N']	[0]
1	-	O	['N']	[1]
2	threatening	O	['N']	[2]
3	acute	B	['N']	[3]
4	hyponatraemia	I-Adverse_Effect	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	low	O	['N']	[7]
8	dose	O	['N']	[8]
9	cyclophosphamide	B-Drug	['Causes']	[4]
10	and	O	['N']	[10]
11	indomethacin	O	['N']	[11]
12	.	O	['N']	[12]
#2540
0	A	O	['N']	[0]
1	second	O	['N']	[1]
2	patient	O	['N']	[2]
3	with	O	['N']	[3]
4	a	O	['N']	[4]
5	similar	O	['N']	[5]
6	glucose	O	['N']	[6]
7	tolerance	O	['N']	[7]
8	test	O	['N']	[8]
9	result	O	['N']	[9]
10	showed	O	['N']	[10]
11	postprandial	B	['N']	[11]
12	hyperglycemia	I-Adverse_Effect	['N']	[12]
13	when	O	['N']	[13]
14	treated	O	['N']	[14]
15	similarly	O	['N']	[15]
16	with	O	['N']	[16]
17	betamethasone	B	['N']	[17]
18	valerate	I-Drug	['Causes']	[12]
19	cream	O	['N']	[19]
20	0.1	O	['N']	[20]
21	%	O	['N']	[21]
22	.	O	['N']	[22]
#2541
0	Two	O	['N']	[0]
1	of	O	['N']	[1]
2	our	O	['N']	[2]
3	patients	O	['N']	[3]
4	developed	O	['N']	[4]
5	TD	B-Adverse_Effect	['N']	[5]
6	after	O	['N']	[6]
7	23	O	['N']	[7]
8	months	O	['N']	[8]
9	and	O	['N']	[9]
10	34	O	['N']	[10]
11	months	O	['N']	[11]
12	of	O	['N']	[12]
13	ziprasidone	B-Drug	['Causes']	[5]
14	monotherapy	O	['N']	[14]
15	,	O	['N']	[15]
16	respectively	O	['N']	[16]
17	.	O	['N']	[17]
#2542
0	Sorafenib	B-Drug	['Causes']	[4]
1	induced	O	['N']	[1]
2	tumor	B	['N']	[2]
3	lysis	I	['N']	[3]
4	syndrome	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	an	O	['N']	[6]
7	advanced	O	['N']	[7]
8	hepatocellular	O	['N']	[8]
9	carcinoma	O	['N']	[9]
10	patient	O	['N']	[10]
11	.	O	['N']	[11]
#2543
0	No	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	renal	O	['N']	[3]
4	acidosis	O	['N']	[4]
5	,	O	['N']	[5]
6	and	O	['N']	[6]
7	only	O	['N']	[7]
8	one	O	['N']	[8]
9	case	O	['N']	[9]
10	of	O	['N']	[10]
11	nephrogenic	B	['N']	[11]
12	diabetes	I	['N']	[12]
13	insipidus	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	has	O	['N']	[15]
16	been	O	['N']	[16]
17	previously	O	['N']	[17]
18	reported	O	['N']	[18]
19	as	O	['N']	[19]
20	a	O	['N']	[20]
21	complication	O	['N']	[21]
22	of	O	['N']	[22]
23	foscarnet	B-Drug	['Causes']	[13]
24	treatment	O	['N']	[24]
25	.	O	['N']	[25]
#2544
0	Although	O	['N']	[0]
1	risk	O	['N']	[1]
2	factors	O	['N']	[2]
3	for	O	['N']	[3]
4	MTX	B-Drug	['Causes']	[68]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	pulmonary	O	['N']	[7]
8	toxicity	O	['N']	[8]
9	are	O	['N']	[9]
10	poorly	O	['N']	[10]
11	understood	O	['N']	[11]
12	,	O	['N']	[12]
13	the	O	['N']	[13]
14	presence	O	['N']	[14]
15	in	O	['N']	[15]
16	3	O	['N']	[16]
17	out	O	['N']	[17]
18	of	O	['N']	[18]
19	5	O	['N']	[19]
20	of	O	['N']	[20]
21	our	O	['N']	[21]
22	patients	O	['N']	[22]
23	of	O	['N']	[23]
24	pre	O	['N']	[24]
25	-	O	['N']	[25]
26	existing	O	['N']	[26]
27	lung	O	['N']	[27]
28	disease	O	['N']	[28]
29	,	O	['N']	[29]
30	represented	O	['N']	[30]
31	by	O	['N']	[31]
32	diffuse	O	['N']	[32]
33	interstitial	O	['N']	[33]
34	changes	O	['N']	[34]
35	on	O	['N']	[35]
36	chest	O	['N']	[36]
37	X	O	['N']	[37]
38	-	O	['N']	[38]
39	ray	O	['N']	[39]
40	,	O	['N']	[40]
41	and	O	['N']	[41]
42	mild	O	['N']	[42]
43	bronchial	O	['N']	[43]
44	asthma	O	['N']	[44]
45	in	O	['N']	[45]
46	two	O	['N']	[46]
47	RA	O	['N']	[47]
48	patients	O	['N']	[48]
49	and	O	['N']	[49]
50	by	O	['N']	[50]
51	pulmonary	O	['N']	[51]
52	silicosis	O	['N']	[52]
53	in	O	['N']	[53]
54	the	O	['N']	[54]
55	patient	O	['N']	[55]
56	with	O	['N']	[56]
57	PsA	O	['N']	[57]
58	may	O	['N']	[58]
59	account	O	['N']	[59]
60	for	O	['N']	[60]
61	a	O	['N']	[61]
62	predisposition	O	['N']	[62]
63	to	O	['N']	[63]
64	the	O	['N']	[64]
65	development	O	['N']	[65]
66	of	O	['N']	[66]
67	MTX	O	['N']	[67]
68	pneumonitis	B-Adverse_Effect	['N']	[68]
69	.	O	['N']	[69]
#2545
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	suggests	O	['N']	[2]
3	that	O	['N']	[3]
4	anemia	B-Adverse_Effect	['N']	[4]
5	can	O	['N']	[5]
6	occur	O	['N']	[6]
7	due	O	['N']	[7]
8	to	O	['N']	[8]
9	MMF	O	['N']	[9]
10	,	O	['N']	[10]
11	in	O	['N']	[11]
12	particular	O	['N']	[12]
13	when	O	['N']	[13]
14	it	O	['N']	[14]
15	is	O	['N']	[15]
16	given	O	['N']	[16]
17	with	O	['N']	[17]
18	prednisone	B-Drug	['Causes']	[4]
19	,	O	['N']	[19]
20	a	O	['N']	[20]
21	side	O	['N']	[21]
22	effect	O	['N']	[22]
23	well	O	['N']	[23]
24	documented	O	['N']	[24]
25	in	O	['N']	[25]
26	the	O	['N']	[26]
27	transplantation	O	['N']	[27]
28	literature	O	['N']	[28]
29	when	O	['N']	[29]
30	the	O	['N']	[30]
31	triple	O	['N']	[31]
32	combination	O	['N']	[32]
33	of	O	['N']	[33]
34	MMF	O	['N']	[34]
35	,	O	['N']	[35]
36	cyclosporine	O	['N']	[36]
37	and	O	['N']	[37]
38	prednisone	O	['N']	[38]
39	is	O	['N']	[39]
40	used	O	['N']	[40]
41	.	O	['N']	[41]
#2546
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	rupture	B	['N']	[2]
3	of	I	['N']	[3]
4	a	I	['N']	[4]
5	cerebral	I	['N']	[5]
6	arterial	I	['N']	[6]
7	aneurysm	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	32	O	['N']	[10]
11	year	O	['N']	[11]
12	old	O	['N']	[12]
13	hypertensive	O	['N']	[13]
14	woman	O	['N']	[14]
15	following	O	['N']	[15]
16	the	O	['N']	[16]
17	introduction	O	['N']	[17]
18	of	O	['N']	[18]
19	nifedipine	B-Drug	['Causes']	[7]
20	treatment	O	['N']	[20]
21	.	O	['N']	[21]
#2547
0	There	O	['N']	[0]
1	are	O	['N']	[1]
2	major	O	['N']	[2]
3	side	O	['N']	[3]
4	effects	O	['N']	[4]
5	of	O	['N']	[5]
6	anastrozole	B-Drug	['Causes']	[12]
7	including	O	['N']	[7]
8	decrease	B	['N']	[8]
9	in	I	['N']	[9]
10	both	I	['N']	[10]
11	lumbar	I	['N']	[11]
12	spine	I-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	total	O	['N']	[14]
15	hip	O	['N']	[15]
16	bone	O	['N']	[16]
17	mineral	O	['N']	[17]
18	density	O	['N']	[18]
19	,	O	['N']	[19]
20	increase	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	incidence	O	['N']	[23]
24	of	O	['N']	[24]
25	all	O	['N']	[25]
26	bone	O	['N']	[26]
27	fractures	O	['N']	[27]
28	(	O	['N']	[28]
29	especially	O	['N']	[29]
30	fractures	O	['N']	[30]
31	of	O	['N']	[31]
32	spine	O	['N']	[32]
33	,	O	['N']	[33]
34	hip	O	['N']	[34]
35	and	O	['N']	[35]
36	wrist	O	['N']	[36]
37	)	O	['N']	[37]
38	,	O	['N']	[38]
39	joint	O	['N']	[39]
40	disorders	O	['N']	[40]
41	and	O	['N']	[41]
42	increase	O	['N']	[42]
43	in	O	['N']	[43]
44	the	O	['N']	[44]
45	cholesterol	O	['N']	[45]
46	level	O	['N']	[46]
47	.	O	['N']	[47]
#2548
0	Management	O	['N']	[0]
1	of	O	['N']	[1]
2	hypophosphatemia	O	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	high	O	['N']	[5]
6	-	O	['N']	[6]
7	flux	O	['N']	[7]
8	hemodiafiltration	O	['N']	[8]
9	for	O	['N']	[9]
10	the	O	['N']	[10]
11	treatment	O	['N']	[11]
12	of	O	['N']	[12]
13	vancomycin	B-Drug	['Causes']	[14]
14	toxicity	I-Adverse_Effect	['N']	[14]
15	:	O	['N']	[15]
16	intravenous	O	['N']	[16]
17	phosphorus	O	['N']	[17]
18	therapy	O	['N']	[18]
19	versus	O	['N']	[19]
20	use	O	['N']	[20]
21	of	O	['N']	[21]
22	a	O	['N']	[22]
23	phosphorus	O	['N']	[23]
24	-	O	['N']	[24]
25	enriched	O	['N']	[25]
26	dialysate	O	['N']	[26]
27	.	O	['N']	[27]
#2549
0	Itch	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	skin	O	['N']	[2]
3	rash	O	['N']	[3]
4	from	O	['N']	[4]
5	chocolate	O	['N']	[5]
6	during	O	['N']	[6]
7	fluoxetine	O	['N']	[7]
8	and	O	['N']	[8]
9	sertraline	B-Drug	['Causes']	[0]
10	treatment	O	['N']	[10]
11	:	O	['N']	[11]
12	case	O	['N']	[12]
13	report	O	['N']	[13]
14	.	O	['N']	[14]
#2550
0	A	O	['N']	[0]
1	44-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	is	O	['N']	[5]
6	described	O	['N']	[6]
7	in	O	['N']	[7]
8	whom	O	['N']	[8]
9	amiodarone	B-Drug	['Causes']	[29]
10	,	O	['N']	[10]
11	disopyramide	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	quinidine	O	['N']	[14]
15	,	O	['N']	[15]
16	administered	O	['N']	[16]
17	alone	O	['N']	[17]
18	separately	O	['N']	[18]
19	,	O	['N']	[19]
20	induced	O	['N']	[20]
21	atypical	O	['N']	[21]
22	ventricular	O	['N']	[22]
23	tachycardia	O	['N']	[23]
24	(	O	['N']	[24]
25	AVT	O	['N']	[25]
26	,	O	['N']	[26]
27	torsade	B	['N']	[27]
28	de	I	['N']	[28]
29	pointes	I-Adverse_Effect	['N']	[29]
30	)	O	['N']	[30]
31	.	O	['N']	[31]
#2551
0	However	O	['N']	[0]
1	here	O	['N']	[1]
2	we	O	['N']	[2]
3	reported	O	['N']	[3]
4	two	O	['N']	[4]
5	patients	O	['N']	[5]
6	,	O	['N']	[6]
7	presenting	O	['N']	[7]
8	with	O	['N']	[8]
9	PD	B-Adverse_Effect	['N']	[9]
10	during	O	['N']	[10]
11	high	O	['N']	[11]
12	dose	O	['N']	[12]
13	colchicine	B-Drug	['Causes']	[9]
14	treatment	O	['N']	[14]
15	for	O	['N']	[15]
16	familiar	O	['N']	[16]
17	mediterranean	O	['N']	[17]
18	fever	O	['N']	[18]
19	(	O	['N']	[19]
20	FMF	O	['N']	[20]
21	)	O	['N']	[21]
22	.	O	['N']	[22]
#2552
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	is	O	['N']	[2]
3	described	O	['N']	[3]
4	with	O	['N']	[4]
5	the	O	['N']	[5]
6	characteristic	O	['N']	[6]
7	features	O	['N']	[7]
8	of	O	['N']	[8]
9	phenytoin	B-Drug	['Causes']	[23]
10	hypersensitivity	O	['N']	[10]
11	syndrome	O	['N']	[11]
12	(	O	['N']	[12]
13	PHS	O	['N']	[13]
14	)	O	['N']	[14]
15	including	O	['N']	[15]
16	fever	O	['N']	[16]
17	,	O	['N']	[17]
18	erythroderma	O	['N']	[18]
19	,	O	['N']	[19]
20	tibial	B	['N']	[20]
21	and	I	['N']	[21]
22	facial	I	['N']	[22]
23	oedema	I-Adverse_Effect	['N']	[23]
24	,	O	['N']	[24]
25	pinhead	O	['N']	[25]
26	-	O	['N']	[26]
27	sized	O	['N']	[27]
28	facial	O	['N']	[28]
29	pustules	O	['N']	[29]
30	and	O	['N']	[30]
31	abnormal	O	['N']	[31]
32	liver	O	['N']	[32]
33	function	O	['N']	[33]
34	tests	O	['N']	[34]
35	.	O	['N']	[35]
#2553
0	An	O	['N']	[0]
1	episode	O	['N']	[1]
2	of	O	['N']	[2]
3	leukoencephalopathy	O	['N']	[3]
4	is	O	['N']	[4]
5	reported	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	13-year	O	['N']	[8]
9	-	O	['N']	[9]
10	old	O	['N']	[10]
11	girl	O	['N']	[11]
12	who	O	['N']	[12]
13	,	O	['N']	[13]
14	after	O	['N']	[14]
15	standard	O	['N']	[15]
16	radiotherapy	O	['N']	[16]
17	for	O	['N']	[17]
18	a	O	['N']	[18]
19	posterior	O	['N']	[19]
20	fossa	O	['N']	[20]
21	medulloblastoma	O	['N']	[21]
22	,	O	['N']	[22]
23	received	O	['N']	[23]
24	8	O	['N']	[24]
25	treatments	O	['N']	[25]
26	with	O	['N']	[26]
27	a	O	['N']	[27]
28	protocol	O	['N']	[28]
29	containing	O	['N']	[29]
30	a	O	['N']	[30]
31	4-hour	O	['N']	[31]
32	infusion	O	['N']	[32]
33	of	O	['N']	[33]
34	500	B	['N']	[34]
35	mg	I	['N']	[35]
36	/	I	['N']	[36]
37	m2	I-Dose	['N']	[37]
38	methotrexate	B-Drug	['Dosage']	[37]
39	and	O	['N']	[39]
40	12	O	['N']	[40]
41	mg	O	['N']	[41]
42	intrathecal	O	['N']	[42]
43	methotrexate	O	['N']	[43]
44	.	O	['N']	[44]
#2554
0	A	O	['N']	[0]
1	64	O	['N']	[1]
2	year	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	previous	O	['N']	[6]
7	history	O	['N']	[7]
8	of	O	['N']	[8]
9	coronary	O	['N']	[9]
10	stenting	O	['N']	[10]
11	five	O	['N']	[11]
12	days	O	['N']	[12]
13	before	O	['N']	[13]
14	was	O	['N']	[14]
15	admitted	O	['N']	[15]
16	in	O	['N']	[16]
17	our	O	['N']	[17]
18	institution	O	['N']	[18]
19	for	O	['N']	[19]
20	intracranial	B	['N']	[20]
21	bleeding	I-Adverse_Effect	['N']	[21]
22	while	O	['N']	[22]
23	receiving	O	['N']	[23]
24	aspirin	B-Drug	['Causes']	[21]
25	and	O	['N']	[25]
26	clopidogrel	O	['N']	[26]
27	.	O	['N']	[27]
#2555
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	a	O	['N']	[3]
4	37-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	female	O	['N']	[7]
8	who	O	['N']	[8]
9	complained	O	['N']	[9]
10	of	O	['N']	[10]
11	moderate	O	['N']	[11]
12	hair	B	['N']	[12]
13	loss	I-Adverse_Effect	['N']	[13]
14	during	O	['N']	[14]
15	paroxetine	B-Drug	['Causes']	[13]
16	treatment	O	['N']	[16]
17	.	O	['N']	[17]
#2556
0	A	O	['N']	[0]
1	65-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	on	O	['N']	[5]
6	warfarin	B-Drug	['Causes']	[17]
7	therapy	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	sudden	O	['N']	[10]
11	spontaneous	O	['N']	[11]
12	onset	O	['N']	[12]
13	of	O	['N']	[13]
14	sub	B	['N']	[14]
15	-	I	['N']	[15]
16	conjunctival	I	['N']	[16]
17	haematoma	I-Adverse_Effect	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	bloody	O	['N']	[20]
21	tears	O	['N']	[21]
22	was	O	['N']	[22]
23	assessed	O	['N']	[23]
24	in	O	['N']	[24]
25	the	O	['N']	[25]
26	clinic	O	['N']	[26]
27	following	O	['N']	[27]
28	a	O	['N']	[28]
29	referral	O	['N']	[29]
30	from	O	['N']	[30]
31	an	O	['N']	[31]
32	optometrist	O	['N']	[32]
33	.	O	['N']	[33]
#2557
0	Zidovudine	B-Drug	['Causes']	[5]
1	induced	O	['N']	[1]
2	pure	B	['N']	[2]
3	red	I	['N']	[3]
4	cell	I	['N']	[4]
5	aplasia	I-Adverse_Effect	['N']	[5]
6	:	O	['N']	[6]
7	a	O	['N']	[7]
8	case	O	['N']	[8]
9	report	O	['N']	[9]
10	.	O	['N']	[10]
#2558
0	The	O	['N']	[0]
1	intramuscular	O	['N']	[1]
2	challenge	O	['N']	[2]
3	test	O	['N']	[3]
4	with	O	['N']	[4]
5	25	B	['N']	[5]
6	UI	I-Dose	['N']	[6]
7	of	O	['N']	[7]
8	Miacalcic	B-Drug	['Dosage']	[6]
9	was	O	['N']	[9]
10	positive	O	['N']	[10]
11	with	O	['N']	[11]
12	an	O	['N']	[12]
13	immediate	O	['N']	[13]
14	anaphylactic	O	['N']	[14]
15	reaction	O	['N']	[15]
16	.	O	['N']	[16]
#2559
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	20-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	female	O	['N']	[9]
10	with	O	['N']	[10]
11	polyarteritis	O	['N']	[11]
12	nodosa	O	['N']	[12]
13	(	O	['N']	[13]
14	PAN	O	['N']	[14]
15	)	O	['N']	[15]
16	who	O	['N']	[16]
17	developed	O	['N']	[17]
18	bilateral	O	['N']	[18]
19	sensorineural	O	['N']	[19]
20	hearing	O	['N']	[20]
21	loss	O	['N']	[21]
22	25	O	['N']	[22]
23	minutes	O	['N']	[23]
24	after	O	['N']	[24]
25	receiving	O	['N']	[25]
26	30	B	['N']	[26]
27	mg	I-Dose	['N']	[27]
28	of	O	['N']	[28]
29	intravenous	O	['N']	[29]
30	ketoralac	B-Drug	['Dosage']	[27]
31	.	O	['N']	[31]
#2560
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	promethazine	B-Drug	['Causes']	[13]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	coma	B-Adverse_Effect	['N']	[13]
14	responding	O	['N']	[14]
15	to	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	flumazenil	O	['N']	[18]
19	.	O	['N']	[19]
#2561
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	significant	O	['N']	[7]
8	hepatic	O	['N']	[8]
9	and	O	['N']	[9]
10	renal	O	['N']	[10]
11	failure	O	['N']	[11]
12	with	O	['N']	[12]
13	the	O	['N']	[13]
14	use	O	['N']	[14]
15	of	O	['N']	[15]
16	argatroban	O	['N']	[16]
17	in	O	['N']	[17]
18	a	O	['N']	[18]
19	patient	O	['N']	[19]
20	with	O	['N']	[20]
21	heparin	B-Drug	['Causes']	[24]
22	-	O	['N']	[22]
23	induced	O	['N']	[23]
24	thrombocytopenia	B-Adverse_Effect	['N']	[24]
25	(	O	['N']	[25]
26	HIT	O	['N']	[26]
27	)	O	['N']	[27]
28	requiring	O	['N']	[28]
29	continuous	O	['N']	[29]
30	veno	O	['N']	[30]
31	-	O	['N']	[31]
32	veno	O	['N']	[32]
33	hemodialysis	O	['N']	[33]
34	(	O	['N']	[34]
35	CVVHD	O	['N']	[35]
36	)	O	['N']	[36]
37	.	O	['N']	[37]
#2562
0	Corneal	B	['N']	[0]
1	endothelial	I	['N']	[1]
2	deposits	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	rifabutin	B-Drug	['Causes']	[2]
6	use	O	['N']	[6]
7	.	O	['N']	[7]
#2563
0	The	O	['N']	[0]
1	literature	O	['N']	[1]
2	search	O	['N']	[2]
3	found	O	['N']	[3]
4	12	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	radiation	B	['N']	[7]
8	recall	I-Adverse_Effect	['N']	[8]
9	caused	O	['N']	[9]
10	by	O	['N']	[10]
11	gemcitabine	B-Drug	['Causes']	[8]
12	.	O	['N']	[12]
#2564
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Methotrexate	O	['N']	[2]
3	(	O	['N']	[3]
4	MTX	B-Drug	['Causes']	[9]
5	)	O	['N']	[5]
6	may	O	['N']	[6]
7	induce	O	['N']	[7]
8	liver	B	['N']	[8]
9	damage	I-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	which	O	['N']	[11]
12	in	O	['N']	[12]
13	some	O	['N']	[13]
14	psoriatics	O	['N']	[14]
15	will	O	['N']	[15]
16	lead	O	['N']	[16]
17	to	O	['N']	[17]
18	fibrosis	O	['N']	[18]
19	or	O	['N']	[19]
20	cirrhosis	O	['N']	[20]
21	.	O	['N']	[21]
#2565
0	In	O	['N']	[0]
1	addition	O	['N']	[1]
2	,	O	['N']	[2]
3	the	O	['N']	[3]
4	tachycardia	B-Adverse_Effect	['N']	[4]
5	persisted	O	['N']	[5]
6	and	O	['N']	[6]
7	was	O	['N']	[7]
8	repeatedly	O	['N']	[8]
9	spontaneously	O	['N']	[9]
10	reinitiated	O	['N']	[10]
11	for	O	['N']	[11]
12	prolonged	O	['N']	[12]
13	periods	O	['N']	[13]
14	after	O	['N']	[14]
15	procainamide	B-Drug	['Causes']	[4]
16	.	O	['N']	[16]
#2566
0	He	O	['N']	[0]
1	was	O	['N']	[1]
2	started	O	['N']	[2]
3	on	O	['N']	[3]
4	digoxin	B-Drug	['Causes']	[16]
5	,	O	['N']	[5]
6	0.25	O	['N']	[6]
7	mg	O	['N']	[7]
8	daily	O	['N']	[8]
9	,	O	['N']	[9]
10	because	O	['N']	[10]
11	of	O	['N']	[11]
12	echocardiographically	O	['N']	[12]
13	demonstrated	O	['N']	[13]
14	left	B	['N']	[14]
15	ventricular	I	['N']	[15]
16	dilatation	I-Adverse_Effect	['N']	[16]
17	and	O	['N']	[17]
18	functional	O	['N']	[18]
19	impairment	O	['N']	[19]
20	;	O	['N']	[20]
21	he	O	['N']	[21]
22	died	O	['N']	[22]
23	of	O	['N']	[23]
24	ventricular	O	['N']	[24]
25	fibrillation	O	['N']	[25]
26	15	O	['N']	[26]
27	days	O	['N']	[27]
28	later	O	['N']	[28]
29	.	O	['N']	[29]
#2567
0	Lamotrigine	B-Drug	['Causes']	[1]
1	toxicity	I-Adverse_Effect	['N']	[1]
2	secondary	O	['N']	[2]
3	to	O	['N']	[3]
4	sertraline	O	['N']	[4]
5	.	O	['N']	[5]
#2568
0	Ritonavir	B-Drug	['Causes']	[19]
1	acted	O	['N']	[1]
2	as	O	['N']	[2]
3	a	O	['N']	[3]
4	CYP3A4	O	['N']	[4]
5	inhibitor	O	['N']	[5]
6	,	O	['N']	[6]
7	diminishing	O	['N']	[7]
8	carbamazepine	O	['N']	[8]
9	metabolism	O	['N']	[9]
10	and	O	['N']	[10]
11	provoking	O	['N']	[11]
12	an	O	['N']	[12]
13	increase	O	['N']	[13]
14	in	O	['N']	[14]
15	serum	O	['N']	[15]
16	levels	O	['N']	[16]
17	and	O	['N']	[17]
18	clinical	B	['N']	[18]
19	toxicity	I-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#2569
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	two	O	['N']	[4]
5	cases	O	['N']	[5]
6	in	O	['N']	[6]
7	which	O	['N']	[7]
8	topical	O	['N']	[8]
9	brimonidine	B-Drug	['Causes']	[16]
10	resulted	O	['N']	[10]
11	in	O	['N']	[11]
12	apparent	O	['N']	[12]
13	central	B	['N']	[13]
14	nervous	I	['N']	[14]
15	system	I	['N']	[15]
16	depression	I-Adverse_Effect	['N']	[16]
17	and	O	['N']	[17]
18	unresponsiveness	O	['N']	[18]
19	in	O	['N']	[19]
20	an	O	['N']	[20]
21	infant	O	['N']	[21]
22	.	O	['N']	[22]
#2570
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	healthy	O	['N']	[2]
3	population	O	['N']	[3]
4	,	O	['N']	[4]
5	the	O	['N']	[5]
6	relative	O	['N']	[6]
7	risk	O	['N']	[7]
8	of	O	['N']	[8]
9	developing	O	['N']	[9]
10	endometrial	B	['N']	[10]
11	carcinoma	I-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	the	O	['N']	[13]
14	tamoxifen	B-Drug	['Causes']	[11]
15	arm	O	['N']	[15]
16	was	O	['N']	[16]
17	2.54	O	['N']	[17]
18	,	O	['N']	[18]
19	although	O	['N']	[19]
20	when	O	['N']	[20]
21	stratified	O	['N']	[21]
22	by	O	['N']	[22]
23	age	O	['N']	[23]
24	,	O	['N']	[24]
25	in	O	['N']	[25]
26	women	O	['N']	[26]
27	over	O	['N']	[27]
28	50	O	['N']	[28]
29	,	O	['N']	[29]
30	the	O	['N']	[30]
31	risk	O	['N']	[31]
32	grew	O	['N']	[32]
33	to	O	['N']	[33]
34	4.01	O	['N']	[34]
35	.	O	['N']	[35]
#2571
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	in	O	['N']	[2]
3	1993	O	['N']	[3]
4	,	O	['N']	[4]
5	a	O	['N']	[5]
6	clinical	O	['N']	[6]
7	study	O	['N']	[7]
8	involving	O	['N']	[8]
9	400	O	['N']	[9]
10	patients	O	['N']	[10]
11	on	O	['N']	[11]
12	the	O	['N']	[12]
13	Thai	O	['N']	[13]
14	-	O	['N']	[14]
15	Burmese	O	['N']	[15]
16	border	O	['N']	[16]
17	revealed	O	['N']	[17]
18	cardiac	B	['N']	[18]
19	effects	I-Adverse_Effect	['N']	[19]
20	of	O	['N']	[20]
21	antimalarial	O	['N']	[21]
22	treatment	O	['N']	[22]
23	with	O	['N']	[23]
24	halofantrine	B-Drug	['Causes']	[19]
25	,	O	['N']	[25]
26	including	O	['N']	[26]
27	one	O	['N']	[27]
28	sudden	O	['N']	[28]
29	death	O	['N']	[29]
30	after	O	['N']	[30]
31	the	O	['N']	[31]
32	treatment	O	['N']	[32]
33	.	O	['N']	[33]
#2572
0	A	O	['N']	[0]
1	60-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	white	O	['N']	[4]
5	man	O	['N']	[5]
6	with	O	['N']	[6]
7	chronic	O	['N']	[7]
8	bronchitis	O	['N']	[8]
9	was	O	['N']	[9]
10	noted	O	['N']	[10]
11	to	O	['N']	[11]
12	develop	O	['N']	[12]
13	acute	O	['N']	[13]
14	respiratory	O	['N']	[14]
15	failure	O	['N']	[15]
16	and	O	['N']	[16]
17	metabolic	B	['N']	[17]
18	acidosis	I-Adverse_Effect	['N']	[18]
19	four	O	['N']	[19]
20	days	O	['N']	[20]
21	after	O	['N']	[21]
22	being	O	['N']	[22]
23	started	O	['N']	[23]
24	on	O	['N']	[24]
25	methazolamide	B-Drug	['Causes']	[18]
26	(	O	['N']	[26]
27	Neptazane	O	['N']	[27]
28	)	O	['N']	[28]
29	for	O	['N']	[29]
30	an	O	['N']	[30]
31	ophthalmologic	O	['N']	[31]
32	problem	O	['N']	[32]
33	.	O	['N']	[33]
#2573
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	46-yr	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	with	O	['N']	[7]
8	ovarian	O	['N']	[8]
9	carcinoma	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	porphyria	B	['N']	[12]
13	cutanea	I	['N']	[13]
14	tarda	I-Adverse_Effect	['N']	[14]
15	while	O	['N']	[15]
16	undergoing	O	['N']	[16]
17	treatment	O	['N']	[17]
18	with	O	['N']	[18]
19	cisplatin	B-Drug	['Causes']	[14]
20	and	O	['N']	[20]
21	cyclophosphamide	O	['N']	[21]
22	.	O	['N']	[22]
#2574
0	Hepatotoxicity	B-Adverse_Effect	['N']	[0]
1	related	O	['N']	[1]
2	to	O	['N']	[2]
3	itraconazole	B-Drug	['Causes']	[0]
4	:	O	['N']	[4]
5	report	O	['N']	[5]
6	of	O	['N']	[6]
7	three	O	['N']	[7]
8	cases	O	['N']	[8]
9	.	O	['N']	[9]
#2575
0	We	O	['N']	[0]
1	believe	O	['N']	[1]
2	that	O	['N']	[2]
3	this	O	['N']	[3]
4	is	O	['N']	[4]
5	the	O	['N']	[5]
6	first	O	['N']	[6]
7	description	O	['N']	[7]
8	of	O	['N']	[8]
9	acute	B	['N']	[9]
10	hepatitis	I-Adverse_Effect	['N']	[10]
11	caused	O	['N']	[11]
12	by	O	['N']	[12]
13	an	O	['N']	[13]
14	idiosyncratic	O	['N']	[14]
15	adverse	O	['N']	[15]
16	reaction	O	['N']	[16]
17	to	O	['N']	[17]
18	gliclazide	B-Drug	['Causes']	[10]
19	or	O	['N']	[19]
20	to	O	['N']	[20]
21	one	O	['N']	[21]
22	of	O	['N']	[22]
23	its	O	['N']	[23]
24	metabolites	O	['N']	[24]
25	.	O	['N']	[25]
#2576
0	In	O	['N']	[0]
1	the	O	['N']	[1]
2	present	O	['N']	[2]
3	paper	O	['N']	[3]
4	,	O	['N']	[4]
5	we	O	['N']	[5]
6	describe	O	['N']	[6]
7	two	O	['N']	[7]
8	patients	O	['N']	[8]
9	with	O	['N']	[9]
10	active	O	['N']	[10]
11	UC	O	['N']	[11]
12	who	O	['N']	[12]
13	developed	O	['N']	[13]
14	a	O	['N']	[14]
15	severe	B	['N']	[15]
16	systemic	I	['N']	[16]
17	CMV	I	['N']	[17]
18	infection	I-Adverse_Effect	['N']	[18]
19	during	O	['N']	[19]
20	a	O	['N']	[20]
21	treatment	O	['N']	[21]
22	with	O	['N']	[22]
23	an	O	['N']	[23]
24	oral	O	['N']	[24]
25	microemulsion	O	['N']	[25]
26	form	O	['N']	[26]
27	of	O	['N']	[27]
28	cyclosporine	B-Drug	['Causes']	[18]
29	.	O	['N']	[29]
#2577
0	Sarcoma	B-Adverse_Effect	['N']	[0]
1	complicating	O	['N']	[1]
2	therapy	O	['N']	[2]
3	with	O	['N']	[3]
4	cyclophosphamide	B-Drug	['Causes']	[0]
5	.	O	['N']	[5]
#2578
0	A	O	['N']	[0]
1	75-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	developed	O	['N']	[5]
6	bilateral	B	['N']	[6]
7	lower	I	['N']	[7]
8	leg	I	['N']	[8]
9	edema	I-Adverse_Effect	['N']	[9]
10	6	O	['N']	[10]
11	months	O	['N']	[11]
12	after	O	['N']	[12]
13	switching	O	['N']	[13]
14	from	O	['N']	[14]
15	troglitazone	O	['N']	[15]
16	to	O	['N']	[16]
17	pioglitazone	B-Drug	['Causes']	[9]
18	.	O	['N']	[18]
#2579
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	two	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	rheumatoid	O	['N']	[5]
6	factor	O	['N']	[6]
7	-	O	['N']	[7]
8	positive	O	['N']	[8]
9	,	O	['N']	[9]
10	polyarticular	O	['N']	[10]
11	-	O	['N']	[11]
12	onset	O	['N']	[12]
13	juvenile	O	['N']	[13]
14	rheumatoid	O	['N']	[14]
15	arthritis	O	['N']	[15]
16	in	O	['N']	[16]
17	whom	O	['N']	[17]
18	accelerated	B	['N']	[18]
19	nodulosis	I-Adverse_Effect	['N']	[19]
20	developed	O	['N']	[20]
21	during	O	['N']	[21]
22	methotrexate	B-Drug	['Causes']	[19]
23	therapy	O	['N']	[23]
24	.	O	['N']	[24]
#2580
0	The	O	['N']	[0]
1	female	O	['N']	[1]
2	patient	O	['N']	[2]
3	received	O	['N']	[3]
4	clozapine	B-Drug	['Causes']	[15]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	daily	O	['N']	[7]
8	dose	O	['N']	[8]
9	of	O	['N']	[9]
10	400	O	['N']	[10]
11	mg	O	['N']	[11]
12	,	O	['N']	[12]
13	which	O	['N']	[13]
14	induced	O	['N']	[14]
15	agranulocytosis	B-Adverse_Effect	['N']	[15]
16	after	O	['N']	[16]
17	2	O	['N']	[17]
18	months	O	['N']	[18]
19	.	O	['N']	[19]
#2581
0	Osteonecrosis	B-Adverse_Effect	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	serious	O	['N']	[3]
4	side	O	['N']	[4]
5	effect	O	['N']	[5]
6	of	O	['N']	[6]
7	antiemetic	O	['N']	[7]
8	treatment	O	['N']	[8]
9	with	O	['N']	[9]
10	dexamethasone	B-Drug	['Causes']	[0]
11	and	O	['N']	[11]
12	this	O	['N']	[12]
13	serious	O	['N']	[13]
14	complication	O	['N']	[14]
15	should	O	['N']	[15]
16	be	O	['N']	[16]
17	incorporated	O	['N']	[17]
18	in	O	['N']	[18]
19	the	O	['N']	[19]
20	current	O	['N']	[20]
21	guidelines	O	['N']	[21]
22	.	O	['N']	[22]
#2582
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	45-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	HIV	O	['N']	[7]
8	-	O	['N']	[8]
9	positive	O	['N']	[9]
10	man	O	['N']	[10]
11	(	O	['N']	[11]
12	CD4	O	['N']	[12]
13	+	O	['N']	[13]
14	count	O	['N']	[14]
15	450	O	['N']	[15]
16	cells	O	['N']	[16]
17	/	O	['N']	[17]
18	mm(3	O	['N']	[18]
19	)	O	['N']	[19]
20	and	O	['N']	[20]
21	history	O	['N']	[21]
22	of	O	['N']	[22]
23	AIDS	O	['N']	[23]
24	-	O	['N']	[24]
25	defining	O	['N']	[25]
26	illness	O	['N']	[26]
27	)	O	['N']	[27]
28	presented	O	['N']	[28]
29	with	O	['N']	[29]
30	JHR	B-Adverse_Effect	['N']	[30]
31	after	O	['N']	[31]
32	an	O	['N']	[32]
33	initial	O	['N']	[33]
34	intravenous	O	['N']	[34]
35	dose	O	['N']	[35]
36	of	O	['N']	[36]
37	penicillin	B	['N']	[37]
38	G	I-Drug	['Causes']	[30]
39	for	O	['N']	[39]
40	presumed	O	['N']	[40]
41	neurosyphilis	O	['N']	[41]
42	.	O	['N']	[42]
#2583
0	Several	O	['N']	[0]
1	such	O	['N']	[1]
2	HBV	B	['N']	[2]
3	reactivations	I-Adverse_Effect	['N']	[3]
4	were	O	['N']	[4]
5	reported	O	['N']	[5]
6	after	O	['N']	[6]
7	combined	O	['N']	[7]
8	rituximab	B-Drug	['Causes']	[3]
9	and	O	['N']	[9]
10	multiagent	O	['N']	[10]
11	chemotherapy	O	['N']	[11]
12	for	O	['N']	[12]
13	B	O	['N']	[13]
14	-	O	['N']	[14]
15	cell	O	['N']	[15]
16	lymphomas	O	['N']	[16]
17	.	O	['N']	[17]
#2584
0	Review	O	['N']	[0]
1	of	O	['N']	[1]
2	the	O	['N']	[2]
3	literature	O	['N']	[3]
4	relating	O	['N']	[4]
5	to	O	['N']	[5]
6	methicillin	B-Drug	['Causes']	[9]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	nephropathy	B-Adverse_Effect	['N']	[9]
10	suggests	O	['N']	[10]
11	a	O	['N']	[11]
12	hypersensitivity	O	['N']	[12]
13	origin	O	['N']	[13]
14	for	O	['N']	[14]
15	this	O	['N']	[15]
16	disorder	O	['N']	[16]
17	,	O	['N']	[17]
18	but	O	['N']	[18]
19	immunologic	O	['N']	[19]
20	and	O	['N']	[20]
21	ultrastructural	O	['N']	[21]
22	investigation	O	['N']	[22]
23	to	O	['N']	[23]
24	date	O	['N']	[24]
25	has	O	['N']	[25]
26	failed	O	['N']	[26]
27	to	O	['N']	[27]
28	elucidate	O	['N']	[28]
29	pathogenesis	O	['N']	[29]
30	.	O	['N']	[30]
#2585
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	rules	O	['N']	[2]
3	out	O	['N']	[3]
4	other	O	['N']	[4]
5	causes	O	['N']	[5]
6	of	O	['N']	[6]
7	toxic	B	['N']	[7]
8	epidermal	I	['N']	[8]
9	necrolysis	I-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	implicates	O	['N']	[11]
12	ofloxacin	B-Drug	['Causes']	[9]
13	in	O	['N']	[13]
14	what	O	['N']	[14]
15	appears	O	['N']	[15]
16	to	O	['N']	[16]
17	be	O	['N']	[17]
18	an	O	['N']	[18]
19	atypical	O	['N']	[19]
20	presentation	O	['N']	[20]
21	of	O	['N']	[21]
22	drug	O	['N']	[22]
23	-	O	['N']	[23]
24	induced	O	['N']	[24]
25	toxic	O	['N']	[25]
26	epidermal	O	['N']	[26]
27	necrolysis	O	['N']	[27]
28	.	O	['N']	[28]
#2586
0	Within	O	['N']	[0]
1	6	O	['N']	[1]
2	months	O	['N']	[2]
3	of	O	['N']	[3]
4	pranlukast	B-Drug	['Causes']	[7]
5	withdrawal	O	['N']	[5]
6	,	O	['N']	[6]
7	anemia	B-Adverse_Effect	['N']	[7]
8	resolved	O	['N']	[8]
9	and	O	['N']	[9]
10	urinary	O	['N']	[10]
11	sediment	O	['N']	[11]
12	and	O	['N']	[12]
13	renal	O	['N']	[13]
14	function	O	['N']	[14]
15	normalized	O	['N']	[15]
16	.	O	['N']	[16]
#2587
0	Development	O	['N']	[0]
1	of	O	['N']	[1]
2	essential	O	['N']	[2]
3	thrombocythemia	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	interferon	O	['N']	[9]
10	alfa	O	['N']	[10]
11	and	O	['N']	[11]
12	pentostatin	B-Drug	['Causes']	[3]
13	for	O	['N']	[13]
14	hairy	O	['N']	[14]
15	cell	O	['N']	[15]
16	leukemia	O	['N']	[16]
17	.	O	['N']	[17]
#2588
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	2	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	cutaneous	O	['N']	[5]
6	lupus	O	['N']	[6]
7	erythematosus	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	severe	O	['N']	[10]
11	dapsone	B-Drug	['Causes']	[20]
12	reaction	O	['N']	[12]
13	after	O	['N']	[13]
14	low	O	['N']	[14]
15	dose	O	['N']	[15]
16	therapy	O	['N']	[16]
17	,	O	['N']	[17]
18	with	O	['N']	[18]
19	a	O	['N']	[19]
20	fatal	B-Adverse_Effect	['N']	[20]
21	outcome	O	['N']	[21]
22	in	O	['N']	[22]
23	one	O	['N']	[23]
24	.	O	['N']	[24]
#2589
0	OBSERVATIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	48-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	presented	O	['N']	[7]
8	with	O	['N']	[8]
9	disfiguring	B	['N']	[9]
10	facial	I	['N']	[10]
11	edema	I-Adverse_Effect	['N']	[11]
12	10	O	['N']	[12]
13	weeks	O	['N']	[13]
14	after	O	['N']	[14]
15	she	O	['N']	[15]
16	began	O	['N']	[16]
17	antiviral	O	['N']	[17]
18	therapy	O	['N']	[18]
19	with	O	['N']	[19]
20	peginterferon	B	['N']	[20]
21	alfa-2a	I-Drug	['Causes']	[11]
22	and	O	['N']	[22]
23	ribavirin	O	['N']	[23]
24	for	O	['N']	[24]
25	chronic	O	['N']	[25]
26	hepatitis	O	['N']	[26]
27	C	O	['N']	[27]
28	infection	O	['N']	[28]
29	.	O	['N']	[29]
#2590
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	ovarian	O	['N']	[3]
4	cancer	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	received	O	['N']	[7]
8	multiple	O	['N']	[8]
9	courses	O	['N']	[9]
10	of	O	['N']	[10]
11	cisplatin	B-Drug	['Causes']	[51]
12	without	O	['N']	[12]
13	complications	O	['N']	[13]
14	experienced	O	['N']	[14]
15	hypersensitivity	O	['N']	[15]
16	reactions	O	['N']	[16]
17	to	O	['N']	[17]
18	cisplatin	O	['N']	[18]
19	:	O	['N']	[19]
20	one	O	['N']	[20]
21	,	O	['N']	[21]
22	involving	O	['N']	[22]
23	intrahepatic	O	['N']	[23]
24	artery	O	['N']	[24]
25	infusion	O	['N']	[25]
26	,	O	['N']	[26]
27	manifested	O	['N']	[27]
28	general	O	['N']	[28]
29	erythema	O	['N']	[29]
30	,	O	['N']	[30]
31	dyspnea	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	hypotension	O	['N']	[34]
35	;	O	['N']	[35]
36	the	O	['N']	[36]
37	other	O	['N']	[37]
38	,	O	['N']	[38]
39	involving	O	['N']	[39]
40	intravenous	O	['N']	[40]
41	infusion	O	['N']	[41]
42	,	O	['N']	[42]
43	manifested	O	['N']	[43]
44	abdominal	O	['N']	[44]
45	pain	O	['N']	[45]
46	,	O	['N']	[46]
47	general	O	['N']	[47]
48	erythema	O	['N']	[48]
49	,	O	['N']	[49]
50	and	O	['N']	[50]
51	fever	B-Adverse_Effect	['N']	[51]
52	.	O	['N']	[52]
#2591
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	second	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	acute	O	['N']	[6]
7	lung	O	['N']	[7]
8	injury	O	['N']	[8]
9	and	O	['N']	[9]
10	diffuse	B	['N']	[10]
11	alveolar	I	['N']	[11]
12	damage	I-Adverse_Effect	['N']	[12]
13	caused	O	['N']	[13]
14	by	O	['N']	[14]
15	mefloquine	B-Drug	['Causes']	[12]
16	.	O	['N']	[16]
#2592
0	Thalidomide	B-Drug	['Causes']	[1]
1	neuropathy	B-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	childhood	O	['N']	[3]
4	.	O	['N']	[4]
#2593
0	Sagittal	O	['N']	[0]
1	sinus	O	['N']	[1]
2	thrombosis	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	transient	B	['N']	[5]
6	free	I	['N']	[6]
7	protein	I	['N']	[7]
8	S	I	['N']	[8]
9	deficiency	I-Adverse_Effect	['N']	[9]
10	after	O	['N']	[10]
11	L	B	['N']	[11]
12	-	I	['N']	[12]
13	asparaginase	I-Drug	['Causes']	[9]
14	treatment	O	['N']	[14]
15	:	O	['N']	[15]
16	case	O	['N']	[16]
17	report	O	['N']	[17]
18	and	O	['N']	[18]
19	review	O	['N']	[19]
20	of	O	['N']	[20]
21	the	O	['N']	[21]
22	literature	O	['N']	[22]
23	.	O	['N']	[23]
#2594
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	because	O	['N']	[2]
3	diphenhydramine	B-Drug	['Causes']	[13]
4	also	O	['N']	[4]
5	exhibits	O	['N']	[5]
6	type	O	['N']	[6]
7	IA	O	['N']	[7]
8	sodium	O	['N']	[8]
9	channel	O	['N']	[9]
10	blockade	O	['N']	[10]
11	,	O	['N']	[11]
12	cardiac	B	['N']	[12]
13	toxicity	I-Adverse_Effect	['N']	[13]
14	is	O	['N']	[14]
15	also	O	['N']	[15]
16	possible	O	['N']	[16]
17	.	O	['N']	[17]
#2595
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	our	O	['N']	[3]
4	knowledge	O	['N']	[4]
5	,	O	['N']	[5]
6	this	O	['N']	[6]
7	is	O	['N']	[7]
8	the	O	['N']	[8]
9	first	O	['N']	[9]
10	case	O	['N']	[10]
11	report	O	['N']	[11]
12	illustrating	O	['N']	[12]
13	neuralgic	B	['N']	[13]
14	amyotrophy	I-Adverse_Effect	['N']	[14]
15	triggered	O	['N']	[15]
16	by	O	['N']	[16]
17	exposure	O	['N']	[17]
18	to	O	['N']	[18]
19	the	O	['N']	[19]
20	antibiotics	O	['N']	[20]
21	vancomycin	O	['N']	[21]
22	,	O	['N']	[22]
23	tobramycin	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	piperacillin	B-Drug	['Causes']	[14]
27	/	O	['N']	[27]
28	tazobactam	O	['N']	[28]
29	.	O	['N']	[29]
#2596
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	3	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	children	O	['N']	[5]
6	with	O	['N']	[6]
7	acute	O	['N']	[7]
8	lymphoblastic	O	['N']	[8]
9	leukemia	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	seizures	B-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	altered	O	['N']	[14]
15	sensorium	O	['N']	[15]
16	after	O	['N']	[16]
17	L	B	['N']	[17]
18	-	I	['N']	[18]
19	asparaginase	I-Drug	['Causes']	[12]
20	therapy	O	['N']	[20]
21	.	O	['N']	[21]
#2597
0	Administration	O	['N']	[0]
1	of	O	['N']	[1]
2	intrathecal	O	['N']	[2]
3	Ara	B	['N']	[3]
4	-	I	['N']	[4]
5	C	I-Drug	['Causes']	[29]
6	in	O	['N']	[6]
7	the	O	['N']	[7]
8	same	O	['N']	[8]
9	dose	O	['N']	[9]
10	over	O	['N']	[10]
11	longer	O	['N']	[11]
12	intervals	O	['N']	[12]
13	within	O	['N']	[13]
14	3	O	['N']	[14]
15	-	O	['N']	[15]
16	5	O	['N']	[16]
17	days	O	['N']	[17]
18	between	O	['N']	[18]
19	consecutive	O	['N']	[19]
20	doses	O	['N']	[20]
21	resulted	O	['N']	[21]
22	in	O	['N']	[22]
23	mild	O	['N']	[23]
24	,	O	['N']	[24]
25	transient	O	['N']	[25]
26	neurological	O	['N']	[26]
27	symptoms	O	['N']	[27]
28	(	O	['N']	[28]
29	paresthesias	B-Adverse_Effect	['N']	[29]
30	)	O	['N']	[30]
31	in	O	['N']	[31]
32	only	O	['N']	[32]
33	one	O	['N']	[33]
34	of	O	['N']	[34]
35	30	O	['N']	[35]
36	patients	O	['N']	[36]
37	so	O	['N']	[37]
38	treated	O	['N']	[38]
39	.	O	['N']	[39]
#2598
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	a	O	['N']	[3]
4	probable	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	infliximab	B-Drug	['Causes']	[11]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	membranous	B	['N']	[10]
11	nephropathy	I-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#2599
0	Development	O	['N']	[0]
1	of	O	['N']	[1]
2	essential	O	['N']	[2]
3	thrombocythemia	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	interferon	B	['N']	[9]
10	alfa	I-Drug	['Causes']	[3]
11	and	O	['N']	[11]
12	pentostatin	O	['N']	[12]
13	for	O	['N']	[13]
14	hairy	O	['N']	[14]
15	cell	O	['N']	[15]
16	leukemia	O	['N']	[16]
17	.	O	['N']	[17]
#2600
0	Extrapyramidal	B	['N']	[0]
1	symptoms	I-Adverse_Effect	['N']	[1]
2	are	O	['N']	[2]
3	well	O	['N']	[3]
4	-	O	['N']	[4]
5	documented	O	['N']	[5]
6	complications	O	['N']	[6]
7	of	O	['N']	[7]
8	therapy	O	['N']	[8]
9	with	O	['N']	[9]
10	haloperidol	B-Drug	['Causes']	[1]
11	,	O	['N']	[11]
12	even	O	['N']	[12]
13	when	O	['N']	[13]
14	small	O	['N']	[14]
15	doses	O	['N']	[15]
16	are	O	['N']	[16]
17	used	O	['N']	[17]
18	.	O	['N']	[18]
#2601
0	A	O	['N']	[0]
1	60-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	white	O	['N']	[4]
5	man	O	['N']	[5]
6	with	O	['N']	[6]
7	chronic	O	['N']	[7]
8	bronchitis	O	['N']	[8]
9	was	O	['N']	[9]
10	noted	O	['N']	[10]
11	to	O	['N']	[11]
12	develop	O	['N']	[12]
13	acute	B	['N']	[13]
14	respiratory	I	['N']	[14]
15	failure	I-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	metabolic	O	['N']	[17]
18	acidosis	O	['N']	[18]
19	four	O	['N']	[19]
20	days	O	['N']	[20]
21	after	O	['N']	[21]
22	being	O	['N']	[22]
23	started	O	['N']	[23]
24	on	O	['N']	[24]
25	methazolamide	B-Drug	['Causes']	[15]
26	(	O	['N']	[26]
27	Neptazane	O	['N']	[27]
28	)	O	['N']	[28]
29	for	O	['N']	[29]
30	an	O	['N']	[30]
31	ophthalmologic	O	['N']	[31]
32	problem	O	['N']	[32]
33	.	O	['N']	[33]
#2602
0	Drug	O	['N']	[0]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hepatitis	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	an	O	['N']	[5]
6	acromegalic	O	['N']	[6]
7	patient	O	['N']	[7]
8	during	O	['N']	[8]
9	combined	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	pegvisomant	B-Drug	['Causes']	[3]
13	and	O	['N']	[13]
14	octreotide	O	['N']	[14]
15	long	O	['N']	[15]
16	-	O	['N']	[16]
17	acting	O	['N']	[17]
18	repeatable	O	['N']	[18]
19	attributed	O	['N']	[19]
20	to	O	['N']	[20]
21	the	O	['N']	[21]
22	use	O	['N']	[22]
23	of	O	['N']	[23]
24	pegvisomant	O	['N']	[24]
25	.	O	['N']	[25]
#2603
0	Quinapril	B-Drug	['Causes']	[27]
1	is	O	['N']	[1]
2	an	O	['N']	[2]
3	angiotensin	O	['N']	[3]
4	-	O	['N']	[4]
5	converting	O	['N']	[5]
6	enzyme	O	['N']	[6]
7	inhibitor	O	['N']	[7]
8	(	O	['N']	[8]
9	ACE	O	['N']	[9]
10	-	O	['N']	[10]
11	inhibitor	O	['N']	[11]
12	)	O	['N']	[12]
13	and	O	['N']	[13]
14	overdose	O	['N']	[14]
15	can	O	['N']	[15]
16	lead	O	['N']	[16]
17	to	O	['N']	[17]
18	prolonged	O	['N']	[18]
19	hypotension	O	['N']	[19]
20	and	O	['N']	[20]
21	,	O	['N']	[21]
22	less	O	['N']	[22]
23	frequently	O	['N']	[23]
24	,	O	['N']	[24]
25	transient	B	['N']	[25]
26	renal	I	['N']	[26]
27	impairment	I-Adverse_Effect	['N']	[27]
28	.	O	['N']	[28]
#2604
0	Cutaneous	B	['N']	[0]
1	reactions	I-Adverse_Effect	['N']	[1]
2	to	O	['N']	[2]
3	propylthiouracil	O	['N']	[3]
4	and	O	['N']	[4]
5	methimazole	B-Drug	['Causes']	[1]
6	occur	O	['N']	[6]
7	in	O	['N']	[7]
8	3%-5	O	['N']	[8]
9	%	O	['N']	[9]
10	of	O	['N']	[10]
11	adults	O	['N']	[11]
12	.	O	['N']	[12]
#2605
0	Rofecoxib	B-Drug	['Causes']	[11]
1	,	O	['N']	[1]
2	used	O	['N']	[2]
3	for	O	['N']	[3]
4	dysmenorrhea	O	['N']	[4]
5	,	O	['N']	[5]
6	caused	O	['N']	[6]
7	a	O	['N']	[7]
8	herpetiform	B	['N']	[8]
9	fixed	I	['N']	[9]
10	drug	I	['N']	[10]
11	eruption	I-Adverse_Effect	['N']	[11]
12	predominantly	O	['N']	[12]
13	involving	O	['N']	[13]
14	the	O	['N']	[14]
15	lips	O	['N']	[15]
16	with	O	['N']	[16]
17	classic	O	['N']	[17]
18	clinical	O	['N']	[18]
19	and	O	['N']	[19]
20	histological	O	['N']	[20]
21	findings	O	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	red	O	['N']	[24]
25	-	O	['N']	[25]
26	brown	O	['N']	[26]
27	lesion	O	['N']	[27]
28	on	O	['N']	[28]
29	the	O	['N']	[29]
30	dorsal	O	['N']	[30]
31	hand	O	['N']	[31]
32	.	O	['N']	[32]
#2606
0	Verapamil	B-Drug	['Causes']	[17]
1	is	O	['N']	[1]
2	widely	O	['N']	[2]
3	used	O	['N']	[3]
4	for	O	['N']	[4]
5	the	O	['N']	[5]
6	termination	O	['N']	[6]
7	of	O	['N']	[7]
8	paroxysmal	O	['N']	[8]
9	supraventricular	O	['N']	[9]
10	tachycardia	O	['N']	[10]
11	(	O	['N']	[11]
12	PSVT	O	['N']	[12]
13	)	O	['N']	[13]
14	with	O	['N']	[14]
15	little	O	['N']	[15]
16	proarrhythmic	B	['N']	[16]
17	effect	I-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#2607
0	Lichen	O	['N']	[0]
1	planus	O	['N']	[1]
2	and	O	['N']	[2]
3	acne	B-Adverse_Effect	['N']	[3]
4	provoked	O	['N']	[4]
5	by	O	['N']	[5]
6	gold	B-Drug	['Causes']	[3]
7	.	O	['N']	[7]
#2608
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	administration	O	['N']	[3]
4	of	O	['N']	[4]
5	prostaglandin	B	['N']	[5]
6	E1	I-Drug	['Causes']	[14]
7	to	O	['N']	[7]
8	neonates	O	['N']	[8]
9	can	O	['N']	[9]
10	cause	O	['N']	[10]
11	gastric	B	['N']	[11]
12	-	I	['N']	[12]
13	outlet	I	['N']	[13]
14	obstruction	I-Adverse_Effect	['N']	[14]
15	due	O	['N']	[15]
16	to	O	['N']	[16]
17	antral	O	['N']	[17]
18	hyperplasia	O	['N']	[18]
19	.	O	['N']	[19]
#2609
0	The	O	['N']	[0]
1	dose	O	['N']	[1]
2	-	O	['N']	[2]
3	limiting	O	['N']	[3]
4	toxicity	O	['N']	[4]
5	of	O	['N']	[5]
6	KW-2149	B-Drug	['Causes']	[9]
7	is	O	['N']	[7]
8	pulmonary	B	['N']	[8]
9	toxicity	I-Adverse_Effect	['N']	[9]
10	.	O	['N']	[10]
#2610
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	case	O	['N']	[2]
3	,	O	['N']	[3]
4	it	O	['N']	[4]
5	was	O	['N']	[5]
6	suspected	O	['N']	[6]
7	that	O	['N']	[7]
8	a	O	['N']	[8]
9	combination	O	['N']	[9]
10	of	O	['N']	[10]
11	cigarette	O	['N']	[11]
12	smoking	O	['N']	[12]
13	,	O	['N']	[13]
14	pulmonary	O	['N']	[14]
15	fibrosis	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	low	B-Dose	['N']	[18]
19	-	O	['N']	[19]
20	dose	O	['N']	[20]
21	methotrexate	B-Drug	['Dosage']	[18]
22	therapy	O	['N']	[22]
23	might	O	['N']	[23]
24	have	O	['N']	[24]
25	promoted	O	['N']	[25]
26	the	O	['N']	[26]
27	development	O	['N']	[27]
28	of	O	['N']	[28]
29	lung	O	['N']	[29]
30	cancer	O	['N']	[30]
31	.	O	['N']	[31]
#2611
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Five	O	['N']	[2]
3	of	O	['N']	[3]
4	70	O	['N']	[4]
5	patients	O	['N']	[5]
6	who	O	['N']	[6]
7	had	O	['N']	[7]
8	begun	O	['N']	[8]
9	leflunomide	B-Drug	['Causes']	[14]
10	therapy	O	['N']	[10]
11	had	O	['N']	[11]
12	significant	O	['N']	[12]
13	weight	B	['N']	[13]
14	loss	I-Adverse_Effect	['N']	[14]
15	that	O	['N']	[15]
16	could	O	['N']	[16]
17	not	O	['N']	[17]
18	be	O	['N']	[18]
19	linked	O	['N']	[19]
20	to	O	['N']	[20]
21	other	O	['N']	[21]
22	identifiable	O	['N']	[22]
23	etiologies	O	['N']	[23]
24	.	O	['N']	[24]
#2612
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	1	O	['N']	[2]
3	,	O	['N']	[3]
4	a	O	['N']	[4]
5	total	O	['N']	[5]
6	daily	O	['N']	[6]
7	dose	O	['N']	[7]
8	of	O	['N']	[8]
9	25	O	['N']	[9]
10	mg	O	['N']	[10]
11	sertraline	B-Drug	['Causes']	[33]
12	,	O	['N']	[12]
13	with	O	['N']	[13]
14	nondetectable	O	['N']	[14]
15	sertraline	O	['N']	[15]
16	and	O	['N']	[16]
17	desmethylsertraline	O	['N']	[17]
18	blood	O	['N']	[18]
19	levels	O	['N']	[19]
20	,	O	['N']	[20]
21	resulted	O	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	doubling	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	lamotrigine	O	['N']	[27]
28	blood	O	['N']	[28]
29	level	O	['N']	[29]
30	with	O	['N']	[30]
31	symptoms	B	['N']	[31]
32	of	I	['N']	[32]
33	toxicity	I-Adverse_Effect	['N']	[33]
34	.	O	['N']	[34]
#2613
0	Thus	O	['N']	[0]
1	,	O	['N']	[1]
2	clinical	O	['N']	[2]
3	recognition	O	['N']	[3]
4	of	O	['N']	[4]
5	sleep	B	['N']	[5]
6	disordered	I	['N']	[6]
7	breathing	I-Adverse_Effect	['N']	[7]
8	should	O	['N']	[8]
9	be	O	['N']	[9]
10	taken	O	['N']	[10]
11	into	O	['N']	[11]
12	account	O	['N']	[12]
13	when	O	['N']	[13]
14	rheumatoid	O	['N']	[14]
15	arthritis	O	['N']	[15]
16	patients	O	['N']	[16]
17	are	O	['N']	[17]
18	to	O	['N']	[18]
19	be	O	['N']	[19]
20	treated	O	['N']	[20]
21	with	O	['N']	[21]
22	infliximab	B-Drug	['Causes']	[7]
23	.	O	['N']	[23]
#2614
0	Nonsustained	B	['N']	[0]
1	polymorphous	I	['N']	[1]
2	ventricular	I	['N']	[2]
3	tachycardia	I-Adverse_Effect	['N']	[3]
4	during	O	['N']	[4]
5	amiodarone	B-Drug	['Causes']	[3]
6	therapy	O	['N']	[6]
7	for	O	['N']	[7]
8	atrial	O	['N']	[8]
9	fibrillation	O	['N']	[9]
10	complicating	O	['N']	[10]
11	cardiomyopathy	O	['N']	[11]
12	.	O	['N']	[12]
#2615
0	Acute	O	['N']	[0]
1	kidney	O	['N']	[1]
2	injury	O	['N']	[2]
3	caused	O	['N']	[3]
4	by	O	['N']	[4]
5	zonisamide	B-Drug	['Causes']	[9]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	hypersensitivity	B	['N']	[8]
9	syndrome	I-Adverse_Effect	['N']	[9]
10	.	O	['N']	[10]
#2616
0	Propecia	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	bilateral	B	['N']	[3]
4	cataract	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#2617
0	Combining	O	['N']	[0]
1	methylephedrine	B-Drug	['Causes']	[11]
2	and	O	['N']	[2]
3	Chinese	O	['N']	[3]
4	herbal	O	['N']	[4]
5	drugs	O	['N']	[5]
6	might	O	['N']	[6]
7	carry	O	['N']	[7]
8	a	O	['N']	[8]
9	risk	O	['N']	[9]
10	of	O	['N']	[10]
11	stroke	B-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#2618
0	Although	O	['N']	[0]
1	both	O	['N']	[1]
2	the	O	['N']	[2]
3	spontaneous	O	['N']	[3]
4	occurrence	O	['N']	[4]
5	of	O	['N']	[5]
6	SLE	B-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	the	O	['N']	[8]
9	psychosis	O	['N']	[9]
10	as	O	['N']	[10]
11	a	O	['N']	[11]
12	sign	O	['N']	[12]
13	of	O	['N']	[13]
14	CNS	O	['N']	[14]
15	involvement	O	['N']	[15]
16	of	O	['N']	[16]
17	SLE	O	['N']	[17]
18	can	O	['N']	[18]
19	not	O	['N']	[19]
20	be	O	['N']	[20]
21	excluded	O	['N']	[21]
22	,	O	['N']	[22]
23	SLE	O	['N']	[23]
24	could	O	['N']	[24]
25	be	O	['N']	[25]
26	considered	O	['N']	[26]
27	as	O	['N']	[27]
28	an	O	['N']	[28]
29	adverse	O	['N']	[29]
30	effect	O	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	B-Drug	['Causes']	[6]
33	.	O	['N']	[33]
#2619
0	Used	O	['N']	[0]
1	injudiciously	O	['N']	[1]
2	,	O	['N']	[2]
3	naloxone	B-Drug	['Causes']	[8]
4	can	O	['N']	[4]
5	lead	O	['N']	[5]
6	to	O	['N']	[6]
7	withdrawal	B	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	return	O	['N']	[10]
11	of	O	['N']	[11]
12	severe	O	['N']	[12]
13	pain	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	other	O	['N']	[16]
17	adverse	O	['N']	[17]
18	effects	O	['N']	[18]
19	.	O	['N']	[19]
#2620
0	Ciprofloxacin	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	renal	B	['N']	[3]
4	insufficiency	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	cystic	O	['N']	[6]
7	fibrosis	O	['N']	[7]
8	.	O	['N']	[8]
#2621
0	Inadvertent	O	['N']	[0]
1	and	O	['N']	[1]
2	accidental	O	['N']	[2]
3	epinephrine	B-Drug	['Dosage']	[4]
4	overdose	B-Dose	['N']	[4]
5	might	O	['N']	[5]
6	result	O	['N']	[6]
7	in	O	['N']	[7]
8	potentially	O	['N']	[8]
9	lethal	O	['N']	[9]
10	complications	O	['N']	[10]
11	.	O	['N']	[11]
#2622
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	one	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	non	B	['N']	[5]
6	-	I	['N']	[6]
7	Hodgkin	I	['N']	[7]
8	lymphoma	I-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	patient	O	['N']	[11]
12	,	O	['N']	[12]
13	with	O	['N']	[13]
14	a	O	['N']	[14]
15	30-year	O	['N']	[15]
16	history	O	['N']	[16]
17	of	O	['N']	[17]
18	rheumatoid	O	['N']	[18]
19	arthritis	O	['N']	[19]
20	,	O	['N']	[20]
21	taking	O	['N']	[21]
22	low	O	['N']	[22]
23	dose	O	['N']	[23]
24	methotrexate	B-Drug	['Causes']	[8]
25	weekly	O	['N']	[25]
26	over	O	['N']	[26]
27	a	O	['N']	[27]
28	10-month	O	['N']	[28]
29	period	O	['N']	[29]
30	.	O	['N']	[30]
#2623
0	Clinical	O	['N']	[0]
1	signs	O	['N']	[1]
2	of	O	['N']	[2]
3	hypermagnesemia	B-Adverse_Effect	['N']	[3]
4	are	O	['N']	[4]
5	an	O	['N']	[5]
6	uncommon	O	['N']	[6]
7	complication	O	['N']	[7]
8	following	O	['N']	[8]
9	oral	O	['N']	[9]
10	administration	O	['N']	[10]
11	of	O	['N']	[11]
12	magnesium	B	['N']	[12]
13	sulfate	I-Drug	['Causes']	[3]
14	.	O	['N']	[14]
#2624
0	The	O	['N']	[0]
1	day	O	['N']	[1]
2	after	O	['N']	[2]
3	clozapine	B-Drug	['Causes']	[25]
4	was	O	['N']	[4]
5	stopped	O	['N']	[5]
6	,	O	['N']	[6]
7	while	O	['N']	[7]
8	he	O	['N']	[8]
9	was	O	['N']	[9]
10	still	O	['N']	[10]
11	receiving	O	['N']	[11]
12	clomipramine	O	['N']	[12]
13	150	O	['N']	[13]
14	mg	O	['N']	[14]
15	/	O	['N']	[15]
16	d	O	['N']	[16]
17	,	O	['N']	[17]
18	he	O	['N']	[18]
19	began	O	['N']	[19]
20	behaving	O	['N']	[20]
21	oddly	O	['N']	[21]
22	,	O	['N']	[22]
23	started	O	['N']	[23]
24	sweating	B	['N']	[24]
25	profusely	I-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	shivering	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	became	O	['N']	[30]
31	tremulous	O	['N']	[31]
32	,	O	['N']	[32]
33	agitated	O	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	confused	O	['N']	[36]
37	.	O	['N']	[37]
#2625
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	acute	O	['N']	[5]
6	leukemia	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	Horner	O	['N']	[9]
10	's	O	['N']	[10]
11	syndrome	O	['N']	[11]
12	and	O	['N']	[12]
13	a	O	['N']	[13]
14	severe	O	['N']	[14]
15	demyelinating	O	['N']	[15]
16	peripheral	O	['N']	[16]
17	neuropathy	O	['N']	[17]
18	leading	O	['N']	[18]
19	to	O	['N']	[19]
20	death	B-Adverse_Effect	['N']	[20]
21	after	O	['N']	[21]
22	receiving	O	['N']	[22]
23	high	O	['N']	[23]
24	-	O	['N']	[24]
25	dose	O	['N']	[25]
26	cytosine	B	['N']	[26]
27	arabinoside	I-Drug	['Causes']	[20]
28	.	O	['N']	[28]
#2626
0	In	O	['N']	[0]
1	rare	O	['N']	[1]
2	cases	O	['N']	[2]
3	mitomycin	O	['N']	[3]
4	C	O	['N']	[4]
5	(	O	['N']	[5]
6	MMC	B-Drug	['Causes']	[15]
7	)	O	['N']	[7]
8	may	O	['N']	[8]
9	induce	O	['N']	[9]
10	cancer	O	['N']	[10]
11	-	O	['N']	[11]
12	associated	O	['N']	[12]
13	hemolytic	B	['N']	[13]
14	uremic	I	['N']	[14]
15	syndrome	I-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	which	O	['N']	[17]
18	is	O	['N']	[18]
19	characterized	O	['N']	[19]
20	by	O	['N']	[20]
21	hemolytic	O	['N']	[21]
22	anemia	O	['N']	[22]
23	,	O	['N']	[23]
24	thrombocytopenia	O	['N']	[24]
25	and	O	['N']	[25]
26	progressive	O	['N']	[26]
27	renal	O	['N']	[27]
28	failure	O	['N']	[28]
29	.	O	['N']	[29]
#2627
0	Histopathology	O	['N']	[0]
1	of	O	['N']	[1]
2	the	O	['N']	[2]
3	thyroid	O	['N']	[3]
4	in	O	['N']	[4]
5	amiodarone	B-Drug	['Causes']	[8]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	hypothyroidism	B-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#2628
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	acute	B	['N']	[5]
6	generalized	I	['N']	[6]
7	exanthematous	I	['N']	[7]
8	pustulosis	I-Adverse_Effect	['N']	[8]
9	(	O	['N']	[9]
10	AGEP	O	['N']	[10]
11	)	O	['N']	[11]
12	induced	O	['N']	[12]
13	by	O	['N']	[13]
14	salazosulfapyridine	B-Drug	['Causes']	[8]
15	in	O	['N']	[15]
16	a	O	['N']	[16]
17	patient	O	['N']	[17]
18	with	O	['N']	[18]
19	ulcerative	O	['N']	[19]
20	colitis	O	['N']	[20]
21	.	O	['N']	[21]
#2629
0	Although	O	['N']	[0]
1	this	O	['N']	[1]
2	G	B	['N']	[2]
3	-	I	['N']	[3]
4	CSF	I-Drug	['Causes']	[7]
5	-	O	['N']	[5]
6	driven	O	['N']	[6]
7	leucocytosis	B-Adverse_Effect	['N']	[7]
8	was	O	['N']	[8]
9	alarming	O	['N']	[9]
10	it	O	['N']	[10]
11	did	O	['N']	[11]
12	not	O	['N']	[12]
13	appear	O	['N']	[13]
14	to	O	['N']	[14]
15	have	O	['N']	[15]
16	adversely	O	['N']	[16]
17	affected	O	['N']	[17]
18	the	O	['N']	[18]
19	patient	O	['N']	[19]
20	's	O	['N']	[20]
21	prognosis	O	['N']	[21]
22	.	O	['N']	[22]
#2630
0	Hypersensitivity	O	['N']	[0]
1	to	O	['N']	[1]
2	aspirin	B-Drug	['Causes']	[10]
3	can	O	['N']	[3]
4	be	O	['N']	[4]
5	manifested	O	['N']	[5]
6	as	O	['N']	[6]
7	acute	O	['N']	[7]
8	asthma	O	['N']	[8]
9	,	O	['N']	[9]
10	urticaria	B-Adverse_Effect	['N']	[10]
11	and/or	O	['N']	[11]
12	angioedema	O	['N']	[12]
13	,	O	['N']	[13]
14	or	O	['N']	[14]
15	a	O	['N']	[15]
16	systemic	O	['N']	[16]
17	anaphylactoid	O	['N']	[17]
18	reaction	O	['N']	[18]
19	.	O	['N']	[19]
#2631
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	15-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	female	O	['N']	[6]
7	patient	O	['N']	[7]
8	diagnosed	O	['N']	[8]
9	with	O	['N']	[9]
10	acute	B	['N']	[10]
11	lymphoblastic	I	['N']	[11]
12	leukemia	I-Adverse_Effect	['N']	[12]
13	presenting	O	['N']	[13]
14	with	O	['N']	[14]
15	status	O	['N']	[15]
16	epilepticus	O	['N']	[16]
17	after	O	['N']	[17]
18	receiving	O	['N']	[18]
19	intrathecal	O	['N']	[19]
20	methotrexate	B-Drug	['Causes']	[12]
21	.	O	['N']	[21]
#2632
0	Potential	O	['N']	[0]
1	mechanisms	O	['N']	[1]
2	involved	O	['N']	[2]
3	in	O	['N']	[3]
4	the	O	['N']	[4]
5	occurrence	O	['N']	[5]
6	of	O	['N']	[6]
7	ischemic	B	['N']	[7]
8	colitis	I-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	patients	O	['N']	[10]
11	receiving	O	['N']	[11]
12	tegaserod	B-Drug	['Causes']	[8]
13	are	O	['N']	[13]
14	also	O	['N']	[14]
15	discussed	O	['N']	[15]
16	.	O	['N']	[16]
#2633
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	SIADH	B-Adverse_Effect	['N']	[3]
4	induced	O	['N']	[4]
5	by	O	['N']	[5]
6	mizoribin	B-Drug	['Causes']	[3]
7	administration	O	['N']	[7]
8	.	O	['N']	[8]
#2634
0	To	O	['N']	[0]
1	date	O	['N']	[1]
2	,	O	['N']	[2]
3	this	O	['N']	[3]
4	is	O	['N']	[4]
5	the	O	['N']	[5]
6	first	O	['N']	[6]
7	reported	O	['N']	[7]
8	case	O	['N']	[8]
9	of	O	['N']	[9]
10	what	O	['N']	[10]
11	appears	O	['N']	[11]
12	to	O	['N']	[12]
13	be	O	['N']	[13]
14	isolated	O	['N']	[14]
15	thrombocytopenia	B-Adverse_Effect	['N']	[15]
16	associated	O	['N']	[16]
17	with	O	['N']	[17]
18	lansoprazole	B-Drug	['Causes']	[15]
19	.	O	['N']	[19]
#2635
0	We	O	['N']	[0]
1	hypothesize	O	['N']	[1]
2	that	O	['N']	[2]
3	decreased	O	['N']	[3]
4	renal	O	['N']	[4]
5	elimination	O	['N']	[5]
6	of	O	['N']	[6]
7	MTX	B-Drug	['Causes']	[26]
8	induced	O	['N']	[8]
9	by	O	['N']	[9]
10	the	O	['N']	[10]
11	COX-2	O	['N']	[11]
12	inhibitor	O	['N']	[12]
13	resulted	O	['N']	[13]
14	in	O	['N']	[14]
15	enhanced	O	['N']	[15]
16	hematopoietic	O	['N']	[16]
17	toxicity	O	['N']	[17]
18	and	O	['N']	[18]
19	immunosuppression	O	['N']	[19]
20	causing	O	['N']	[20]
21	the	O	['N']	[21]
22	EBV	B	['N']	[22]
23	-	I	['N']	[23]
24	associated	I	['N']	[24]
25	lymphoproliferative	I	['N']	[25]
26	disease	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#2636
0	A	O	['N']	[0]
1	36-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	being	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	cisplatinum	O	['N']	[8]
9	,	O	['N']	[9]
10	vinblastine	B-Drug	['Causes']	[22]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	bleomycin	O	['N']	[13]
14	for	O	['N']	[14]
15	testicular	O	['N']	[15]
16	carcinoma	O	['N']	[16]
17	developed	O	['N']	[17]
18	a	O	['N']	[18]
19	dense	O	['N']	[19]
20	left	B	['N']	[20]
21	homonymous	I	['N']	[21]
22	hemianopsia	I-Adverse_Effect	['N']	[22]
23	,	O	['N']	[23]
24	encephalopathy	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	a	O	['N']	[27]
28	partial	O	['N']	[28]
29	nondominant	O	['N']	[29]
30	parietal	O	['N']	[30]
31	lobe	O	['N']	[31]
32	syndrome	O	['N']	[32]
33	.	O	['N']	[33]
#2637
0	Glaucoma	B-Adverse_Effect	['N']	[0]
1	secondary	O	['N']	[1]
2	to	O	['N']	[2]
3	epithelial	O	['N']	[3]
4	downgrowth	O	['N']	[4]
5	and	O	['N']	[5]
6	5-fluorouracil	B-Drug	['Causes']	[0]
7	.	O	['N']	[7]
#2638
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	acute	O	['N']	[6]
7	compromise	O	['N']	[7]
8	of	O	['N']	[8]
9	renal	O	['N']	[9]
10	function	O	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	hypotension	B-Adverse_Effect	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	7-year	O	['N']	[16]
17	-	O	['N']	[17]
18	old	O	['N']	[18]
19	boy	O	['N']	[19]
20	treated	O	['N']	[20]
21	with	O	['N']	[21]
22	the	O	['N']	[22]
23	ACE	O	['N']	[23]
24	inhibitor	O	['N']	[24]
25	lisinopril	O	['N']	[25]
26	and	O	['N']	[26]
27	the	O	['N']	[27]
28	ARB	O	['N']	[28]
29	losartan	B-Drug	['Causes']	[13]
30	.	O	['N']	[30]
#2639
0	Fulminant	B	['N']	[0]
1	hepatic	I	['N']	[1]
2	failure	I-Adverse_Effect	['N']	[2]
3	developed	O	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	24-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	black	O	['N']	[9]
10	woman	O	['N']	[10]
11	who	O	['N']	[11]
12	had	O	['N']	[12]
13	been	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	propylthiouracil	B-Drug	['Causes']	[2]
17	and	O	['N']	[17]
18	propranolol	O	['N']	[18]
19	for	O	['N']	[19]
20	hyperthyroidism	O	['N']	[20]
21	.	O	['N']	[21]
#2640
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	imminent	O	['N']	[3]
4	gangrene	O	['N']	[4]
5	of	O	['N']	[5]
6	the	O	['N']	[6]
7	extremities	O	['N']	[7]
8	caused	O	['N']	[8]
9	by	O	['N']	[9]
10	ergot	B-Drug	['Causes']	[13]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	arteriospasm	B-Adverse_Effect	['N']	[13]
14	underwent	O	['N']	[14]
15	mechanical	O	['N']	[15]
16	dilatation	O	['N']	[16]
17	of	O	['N']	[17]
18	the	O	['N']	[18]
19	arteries	O	['N']	[19]
20	when	O	['N']	[20]
21	conventional	O	['N']	[21]
22	measures	O	['N']	[22]
23	such	O	['N']	[23]
24	as	O	['N']	[24]
25	anticoagulation	O	['N']	[25]
26	,	O	['N']	[26]
27	vasodilation	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	sympathetic	O	['N']	[30]
31	blockade	O	['N']	[31]
32	produced	O	['N']	[32]
33	no	O	['N']	[33]
34	improvement	O	['N']	[34]
35	.	O	['N']	[35]
#2641
0	The	O	['N']	[0]
1	two	O	['N']	[1]
2	middle	O	['N']	[2]
3	aged	O	['N']	[3]
4	women	O	['N']	[4]
5	presented	O	['N']	[5]
6	with	O	['N']	[6]
7	respiratory	B	['N']	[7]
8	symptoms	I-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	prolonged	O	['N']	[10]
11	treatment	O	['N']	[11]
12	with	O	['N']	[12]
13	nitrofurantoin	B-Drug	['Causes']	[8]
14	.	O	['N']	[14]
#2642
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	angioedema	B-Adverse_Effect	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	losartan	B-Drug	['Causes']	[7]
11	administration	O	['N']	[11]
12	.	O	['N']	[12]
#2643
0	Nonspecific	O	['N']	[0]
1	but	O	['N']	[1]
2	significant	B	['N']	[2]
3	abnormalities	I-Adverse_Effect	['N']	[3]
4	have	O	['N']	[4]
5	been	O	['N']	[5]
6	described	O	['N']	[6]
7	in	O	['N']	[7]
8	the	O	['N']	[8]
9	infants	O	['N']	[9]
10	of	O	['N']	[10]
11	women	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	disulfiram	B-Drug	['Causes']	[3]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	first	O	['N']	[17]
18	trimester	O	['N']	[18]
19	of	O	['N']	[19]
20	their	O	['N']	[20]
21	pregnancies	O	['N']	[21]
22	.	O	['N']	[22]
#2644
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	receiving	O	['N']	[2]
3	vancomycin	B-Drug	['Causes']	[19]
4	for	O	['N']	[4]
5	a	O	['N']	[5]
6	serious	O	['N']	[6]
7	staphylococcal	O	['N']	[7]
8	infection	O	['N']	[8]
9	had	O	['N']	[9]
10	a	O	['N']	[10]
11	lupus	O	['N']	[11]
12	-	O	['N']	[12]
13	like	O	['N']	[13]
14	syndrome	O	['N']	[14]
15	characterized	O	['N']	[15]
16	by	O	['N']	[16]
17	a	O	['N']	[17]
18	malar	B	['N']	[18]
19	rash	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	pain	O	['N']	[21]
22	and	O	['N']	[22]
23	erythema	O	['N']	[23]
24	of	O	['N']	[24]
25	the	O	['N']	[25]
26	cartilage	O	['N']	[26]
27	of	O	['N']	[27]
28	both	O	['N']	[28]
29	ears	O	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	tender	O	['N']	[32]
33	erythematous	O	['N']	[33]
34	and	O	['N']	[34]
35	hemorrhagic	O	['N']	[35]
36	lesions	O	['N']	[36]
37	of	O	['N']	[37]
38	the	O	['N']	[38]
39	finger	O	['N']	[39]
40	tips	O	['N']	[40]
41	.	O	['N']	[41]
#2645
0	Acute	B	['N']	[0]
1	renal	I	['N']	[1]
2	failure	I-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	lisinopril	O	['N']	[4]
5	and	O	['N']	[5]
6	losartan	B-Drug	['Causes']	[2]
7	therapy	O	['N']	[7]
8	for	O	['N']	[8]
9	proteinuria	O	['N']	[9]
10	.	O	['N']	[10]
#2646
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	postulate	O	['N']	[2]
3	that	O	['N']	[3]
4	two	O	['N']	[4]
5	types	O	['N']	[5]
6	of	O	['N']	[6]
7	combined	O	['N']	[7]
8	lithium	B-Drug	['Causes']	[18]
9	-	O	['N']	[9]
10	neuroleptic	O	['N']	[10]
11	toxicity	O	['N']	[11]
12	occur	O	['N']	[12]
13	:	O	['N']	[13]
14	a	O	['N']	[14]
15	neuroleptic	B	['N']	[15]
16	malignant	I	['N']	[16]
17	extrapyramidal	I	['N']	[17]
18	syndrome	I-Adverse_Effect	['N']	[18]
19	and	O	['N']	[19]
20	a	O	['N']	[20]
21	lithium	O	['N']	[21]
22	toxicity	O	['N']	[22]
23	that	O	['N']	[23]
24	occurs	O	['N']	[24]
25	in	O	['N']	[25]
26	combination	O	['N']	[26]
27	with	O	['N']	[27]
28	phenothiazines	O	['N']	[28]
29	,	O	['N']	[29]
30	primarily	O	['N']	[30]
31	thioridazine	O	['N']	[31]
32	.	O	['N']	[32]
#2647
0	The	O	['N']	[0]
1	day	O	['N']	[1]
2	after	O	['N']	[2]
3	clozapine	O	['N']	[3]
4	was	O	['N']	[4]
5	stopped	O	['N']	[5]
6	,	O	['N']	[6]
7	while	O	['N']	[7]
8	he	O	['N']	[8]
9	was	O	['N']	[9]
10	still	O	['N']	[10]
11	receiving	O	['N']	[11]
12	clomipramine	B-Drug	['Causes']	[21]
13	150	O	['N']	[13]
14	mg	O	['N']	[14]
15	/	O	['N']	[15]
16	d	O	['N']	[16]
17	,	O	['N']	[17]
18	he	O	['N']	[18]
19	began	O	['N']	[19]
20	behaving	B	['N']	[20]
21	oddly	I-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	started	O	['N']	[23]
24	sweating	O	['N']	[24]
25	profusely	O	['N']	[25]
26	,	O	['N']	[26]
27	shivering	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	became	O	['N']	[30]
31	tremulous	O	['N']	[31]
32	,	O	['N']	[32]
33	agitated	O	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	confused	O	['N']	[36]
37	.	O	['N']	[37]
#2648
0	Brugada	B	['N']	[0]
1	type	I	['N']	[1]
2	electrocardiographic	I	['N']	[2]
3	changes	I-Adverse_Effect	['N']	[3]
4	induced	O	['N']	[4]
5	by	O	['N']	[5]
6	concomitant	O	['N']	[6]
7	use	O	['N']	[7]
8	of	O	['N']	[8]
9	lithium	B-Drug	['Causes']	[3]
10	and	O	['N']	[10]
11	propafenone	O	['N']	[11]
12	in	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	Wolff	O	['N']	[15]
16	-	O	['N']	[16]
17	Parkinson	O	['N']	[17]
18	-	O	['N']	[18]
19	White	O	['N']	[19]
20	syndrome	O	['N']	[20]
21	.	O	['N']	[21]
#2649
0	The	O	['N']	[0]
1	first	O	['N']	[1]
2	patient	O	['N']	[2]
3	developed	O	['N']	[3]
4	mild	B	['N']	[4]
5	nitritoid	I	['N']	[5]
6	symptoms	I-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	pain	O	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	band	O	['N']	[11]
12	-	O	['N']	[12]
13	like	O	['N']	[13]
14	distribution	O	['N']	[14]
15	,	O	['N']	[15]
16	corresponding	O	['N']	[16]
17	to	O	['N']	[17]
18	T10-T12	O	['N']	[18]
19	dermatomes	O	['N']	[19]
20	,	O	['N']	[20]
21	shortly	O	['N']	[21]
22	after	O	['N']	[22]
23	gold	O	['N']	[23]
24	sodium	O	['N']	[24]
25	thiomalate	O	['N']	[25]
26	(	O	['N']	[26]
27	GSTM	B-Drug	['Causes']	[6]
28	)	O	['N']	[28]
29	injection	O	['N']	[29]
30	.	O	['N']	[30]
#2650
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	disseminated	B	['N']	[6]
7	salmonellosis	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	temozolomide	B-Drug	['Causes']	[7]
14	.	O	['N']	[14]
#2651
0	Goiter	O	['N']	[0]
1	and	O	['N']	[1]
2	hypothyroidism	O	['N']	[2]
3	during	O	['N']	[3]
4	re	O	['N']	[4]
5	-	O	['N']	[5]
6	treatment	O	['N']	[6]
7	with	O	['N']	[7]
8	amiodarone	B-Drug	['Causes']	[18]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	patient	O	['N']	[11]
12	who	O	['N']	[12]
13	previously	O	['N']	[13]
14	experienced	O	['N']	[14]
15	amiodarone	O	['N']	[15]
16	-	O	['N']	[16]
17	induced	O	['N']	[17]
18	thyrotoxicosis	B-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#2652
0	Ethambutol	B-Drug	['Causes']	[14]
1	is	O	['N']	[1]
2	frequently	O	['N']	[2]
3	used	O	['N']	[3]
4	in	O	['N']	[4]
5	the	O	['N']	[5]
6	treatment	O	['N']	[6]
7	of	O	['N']	[7]
8	tuberculosis	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	,	O	['N']	[11]
12	although	O	['N']	[12]
13	optic	B	['N']	[13]
14	neuropathies	I-Adverse_Effect	['N']	[14]
15	have	O	['N']	[15]
16	been	O	['N']	[16]
17	reported	O	['N']	[17]
18	with	O	['N']	[18]
19	the	O	['N']	[19]
20	use	O	['N']	[20]
21	of	O	['N']	[21]
22	ethambutol	O	['N']	[22]
23	,	O	['N']	[23]
24	this	O	['N']	[24]
25	adverse	O	['N']	[25]
26	side	O	['N']	[26]
27	effect	O	['N']	[27]
28	has	O	['N']	[28]
29	been	O	['N']	[29]
30	considered	O	['N']	[30]
31	to	O	['N']	[31]
32	be	O	['N']	[32]
33	rare	O	['N']	[33]
34	and	O	['N']	[34]
35	generally	O	['N']	[35]
36	reversible	O	['N']	[36]
37	with	O	['N']	[37]
38	discontinuation	O	['N']	[38]
39	of	O	['N']	[39]
40	the	O	['N']	[40]
41	medication	O	['N']	[41]
42	.	O	['N']	[42]
#2653
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	demonstrates	O	['N']	[2]
3	the	O	['N']	[3]
4	value	O	['N']	[4]
5	of	O	['N']	[5]
6	DWI	O	['N']	[6]
7	in	O	['N']	[7]
8	evaluation	O	['N']	[8]
9	and	O	['N']	[9]
10	diagnosis	O	['N']	[10]
11	of	O	['N']	[11]
12	sub	B	['N']	[12]
13	-	I	['N']	[13]
14	acute	I	['N']	[14]
15	toxic	I	['N']	[15]
16	leukoencephalopathy	I-Adverse_Effect	['N']	[16]
17	in	O	['N']	[17]
18	patients	O	['N']	[18]
19	being	O	['N']	[19]
20	treated	O	['N']	[20]
21	with	O	['N']	[21]
22	methotrexate	B-Drug	['Causes']	[16]
23	.	O	['N']	[23]
#2654
0	Corneal	B	['N']	[0]
1	edema	I-Adverse_Effect	['N']	[1]
2	recurred	O	['N']	[2]
3	when	O	['N']	[3]
4	the	O	['N']	[4]
5	administration	O	['N']	[5]
6	of	O	['N']	[6]
7	amantadine	B-Drug	['Causes']	[1]
8	was	O	['N']	[8]
9	resumed	O	['N']	[9]
10	.	O	['N']	[10]
#2655
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	suffering	O	['N']	[2]
3	from	O	['N']	[3]
4	heparin	B-Drug	['Causes']	[18]
5	-	O	['N']	[5]
6	associated	O	['N']	[6]
7	thrombocytopenia	O	['N']	[7]
8	(	O	['N']	[8]
9	HAT	O	['N']	[9]
10	)	O	['N']	[10]
11	,	O	['N']	[11]
12	recurrent	O	['N']	[12]
13	arteriothromboses	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	acute	B	['N']	[16]
17	renal	I	['N']	[17]
18	failure	I-Adverse_Effect	['N']	[18]
19	after	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	standard	O	['N']	[22]
23	heparin	O	['N']	[23]
24	is	O	['N']	[24]
25	described	O	['N']	[25]
26	.	O	['N']	[26]
#2656
0	Lithium	B-Drug	['Causes']	[20]
1	is	O	['N']	[1]
2	known	O	['N']	[2]
3	to	O	['N']	[3]
4	cause	O	['N']	[4]
5	acute	O	['N']	[5]
6	renal	O	['N']	[6]
7	failure	O	['N']	[7]
8	and	O	['N']	[8]
9	tubulo	O	['N']	[9]
10	-	O	['N']	[10]
11	interstitial	O	['N']	[11]
12	disease	O	['N']	[12]
13	,	O	['N']	[13]
14	but	O	['N']	[14]
15	the	O	['N']	[15]
16	recently	O	['N']	[16]
17	described	O	['N']	[17]
18	association	O	['N']	[18]
19	with	O	['N']	[19]
20	proteinuria	B-Adverse_Effect	['N']	[20]
21	or	O	['N']	[21]
22	nephrotic	O	['N']	[22]
23	syndrome	O	['N']	[23]
24	is	O	['N']	[24]
25	little	O	['N']	[25]
26	recognized	O	['N']	[26]
27	.	O	['N']	[27]
#2657
0	CASE	O	['N']	[0]
1	REPORT	O	['N']	[1]
2	:	O	['N']	[2]
3	We	O	['N']	[3]
4	report	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	a	O	['N']	[9]
10	DAT	B	['N']	[10]
11	-	I	['N']	[11]
12	positive	I	['N']	[12]
13	hemolytic	I	['N']	[13]
14	episode	I-Adverse_Effect	['N']	[14]
15	after	O	['N']	[15]
16	a	O	['N']	[16]
17	red	O	['N']	[17]
18	cell	O	['N']	[18]
19	(	O	['N']	[19]
20	RBC	O	['N']	[20]
21	)	O	['N']	[21]
22	transfusion	O	['N']	[22]
23	was	O	['N']	[23]
24	delivered	O	['N']	[24]
25	during	O	['N']	[25]
26	the	O	['N']	[26]
27	infusion	O	['N']	[27]
28	of	O	['N']	[28]
29	her	O	['N']	[29]
30	17th	O	['N']	[30]
31	cycle	O	['N']	[31]
32	of	O	['N']	[32]
33	oxaliplatin	B-Drug	['Causes']	[14]
34	.	O	['N']	[34]
#2658
0	Hepatic	B	['N']	[0]
1	angiosarcoma	I-Adverse_Effect	['N']	[1]
2	occurring	O	['N']	[2]
3	after	O	['N']	[3]
4	cyclophosphamide	B-Drug	['Causes']	[1]
5	therapy	O	['N']	[5]
6	:	O	['N']	[6]
7	case	O	['N']	[7]
8	report	O	['N']	[8]
9	and	O	['N']	[9]
10	review	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	literature	O	['N']	[13]
14	.	O	['N']	[14]
#2659
0	Mycophenolate	B	['N']	[0]
1	mofetil	I-Drug	['Causes']	[4]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	neutropenia	B-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	liver	O	['N']	[6]
7	transplantation	O	['N']	[7]
8	.	O	['N']	[8]
#2660
0	The	O	['N']	[0]
1	first	O	['N']	[1]
2	case	O	['N']	[2]
3	concerns	O	['N']	[3]
4	a	O	['N']	[4]
5	70-year	O	['N']	[5]
6	-	O	['N']	[6]
7	old	O	['N']	[7]
8	man	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	severe	O	['N']	[11]
12	aplastic	B	['N']	[12]
13	anemia	I-Adverse_Effect	['N']	[13]
14	7	O	['N']	[14]
15	weeks	O	['N']	[15]
16	after	O	['N']	[16]
17	treatment	O	['N']	[17]
18	with	O	['N']	[18]
19	500	O	['N']	[19]
20	mg	O	['N']	[20]
21	of	O	['N']	[21]
22	ticlopidine	B-Drug	['Causes']	[13]
23	daily	O	['N']	[23]
24	.	O	['N']	[24]
#2661
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	ovarian	O	['N']	[3]
4	cancer	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	received	O	['N']	[7]
8	multiple	O	['N']	[8]
9	courses	O	['N']	[9]
10	of	O	['N']	[10]
11	cisplatin	B-Drug	['Causes']	[51]
12	without	O	['N']	[12]
13	complications	O	['N']	[13]
14	experienced	O	['N']	[14]
15	hypersensitivity	O	['N']	[15]
16	reactions	O	['N']	[16]
17	to	O	['N']	[17]
18	cisplatin	O	['N']	[18]
19	:	O	['N']	[19]
20	one	O	['N']	[20]
21	,	O	['N']	[21]
22	involving	O	['N']	[22]
23	intrahepatic	O	['N']	[23]
24	artery	O	['N']	[24]
25	infusion	O	['N']	[25]
26	,	O	['N']	[26]
27	manifested	O	['N']	[27]
28	general	O	['N']	[28]
29	erythema	O	['N']	[29]
30	,	O	['N']	[30]
31	dyspnea	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	hypotension	O	['N']	[34]
35	;	O	['N']	[35]
36	the	O	['N']	[36]
37	other	O	['N']	[37]
38	,	O	['N']	[38]
39	involving	O	['N']	[39]
40	intravenous	O	['N']	[40]
41	infusion	O	['N']	[41]
42	,	O	['N']	[42]
43	manifested	O	['N']	[43]
44	abdominal	O	['N']	[44]
45	pain	O	['N']	[45]
46	,	O	['N']	[46]
47	general	O	['N']	[47]
48	erythema	O	['N']	[48]
49	,	O	['N']	[49]
50	and	O	['N']	[50]
51	fever	B-Adverse_Effect	['N']	[51]
52	.	O	['N']	[52]
#2662
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	Stevens	O	['N']	[5]
6	-	O	['N']	[6]
7	Johnson	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	/	O	['N']	[9]
10	toxic	B	['N']	[10]
11	epidermal	I	['N']	[11]
12	necrolysis	I-Adverse_Effect	['N']	[12]
13	(	O	['N']	[13]
14	SJS	O	['N']	[14]
15	/	O	['N']	[15]
16	TEN	O	['N']	[16]
17	)	O	['N']	[17]
18	secondary	O	['N']	[18]
19	to	O	['N']	[19]
20	trimethoprim	O	['N']	[20]
21	-	O	['N']	[21]
22	sulfamethoxazole	O	['N']	[22]
23	(	O	['N']	[23]
24	TMP	B	['N']	[24]
25	-	I	['N']	[25]
26	Sx	I-Drug	['Causes']	[12]
27	)	O	['N']	[27]
28	therapy	O	['N']	[28]
29	for	O	['N']	[29]
30	presumed	O	['N']	[30]
31	community	O	['N']	[31]
32	-	O	['N']	[32]
33	associated	O	['N']	[33]
34	methicillin	O	['N']	[34]
35	-	O	['N']	[35]
36	resistant	O	['N']	[36]
37	Staphylococcus	O	['N']	[37]
38	aureus	O	['N']	[38]
39	(	O	['N']	[39]
40	CA	O	['N']	[40]
41	-	O	['N']	[41]
42	MRSA	O	['N']	[42]
43	)	O	['N']	[43]
44	infection	O	['N']	[44]
45	.	O	['N']	[45]
#2663
0	There	O	['N']	[0]
1	have	O	['N']	[1]
2	been	O	['N']	[2]
3	many	O	['N']	[3]
4	reports	O	['N']	[4]
5	of	O	['N']	[5]
6	probable	O	['N']	[6]
7	lithium	B-Drug	['Causes']	[12]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	organic	B	['N']	[10]
11	brain	I	['N']	[11]
12	syndromes	I-Adverse_Effect	['N']	[12]
13	occurring	O	['N']	[13]
14	when	O	['N']	[14]
15	serum	O	['N']	[15]
16	lithium	O	['N']	[16]
17	levels	O	['N']	[17]
18	are	O	['N']	[18]
19	within	O	['N']	[19]
20	or	O	['N']	[20]
21	close	O	['N']	[21]
22	to	O	['N']	[22]
23	the	O	['N']	[23]
24	therapeutic	O	['N']	[24]
25	range	O	['N']	[25]
26	.	O	['N']	[26]
#2664
0	Nephrogenic	B	['N']	[0]
1	diabetes	I	['N']	[1]
2	insipidus	I-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	renal	O	['N']	[4]
5	tubular	O	['N']	[5]
6	acidosis	O	['N']	[6]
7	secondary	O	['N']	[7]
8	to	O	['N']	[8]
9	foscarnet	B-Drug	['Causes']	[2]
10	therapy	O	['N']	[10]
11	.	O	['N']	[11]
#2665
0	The	O	['N']	[0]
1	polycystic	B	['N']	[1]
2	changes	I-Adverse_Effect	['N']	[2]
3	disappeared	O	['N']	[3]
4	from	O	['N']	[4]
5	the	O	['N']	[5]
6	ovaries	O	['N']	[6]
7	in	O	['N']	[7]
8	2	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	women	O	['N']	[11]
12	after	O	['N']	[12]
13	valproate	B-Drug	['Causes']	[2]
14	therapy	O	['N']	[14]
15	was	O	['N']	[15]
16	discontinued	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	the	O	['N']	[19]
20	2	O	['N']	[20]
21	women	O	['N']	[21]
22	who	O	['N']	[22]
23	had	O	['N']	[23]
24	gained	O	['N']	[24]
25	weight	O	['N']	[25]
26	and	O	['N']	[26]
27	developed	O	['N']	[27]
28	amenorrhea	O	['N']	[28]
29	while	O	['N']	[29]
30	being	O	['N']	[30]
31	treated	O	['N']	[31]
32	with	O	['N']	[32]
33	valproate	O	['N']	[33]
34	lost	O	['N']	[34]
35	weight	O	['N']	[35]
36	and	O	['N']	[36]
37	resumed	O	['N']	[37]
38	menstruating	O	['N']	[38]
39	after	O	['N']	[39]
40	the	O	['N']	[40]
41	change	O	['N']	[41]
42	in	O	['N']	[42]
43	medication	O	['N']	[43]
44	.	O	['N']	[44]
#2666
0	Prominent	B	['N']	[0]
1	eye	I	['N']	[1]
2	movements	I	['N']	[2]
3	during	I	['N']	[3]
4	NREM	I	['N']	[4]
5	sleep	I-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	REM	O	['N']	[7]
8	sleep	O	['N']	[8]
9	behavior	O	['N']	[9]
10	disorder	O	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	fluoxetine	B-Drug	['Causes']	[5]
14	treatment	O	['N']	[14]
15	of	O	['N']	[15]
16	depression	O	['N']	[16]
17	and	O	['N']	[17]
18	obsessive	O	['N']	[18]
19	-	O	['N']	[19]
20	compulsive	O	['N']	[20]
21	disorder	O	['N']	[21]
22	.	O	['N']	[22]
#2667
0	Pemphigus	B	['N']	[0]
1	vulgaris	I-Adverse_Effect	['N']	[1]
2	precipitated	O	['N']	[2]
3	by	O	['N']	[3]
4	glibenclamide	B-Drug	['Causes']	[1]
5	therapy	O	['N']	[5]
6	.	O	['N']	[6]
#2668
0	Pulmonary	B	['N']	[0]
1	toxicity	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	erlotinib	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#2669
0	Pericardial	B	['N']	[0]
1	hemorrhage	I-Adverse_Effect	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	acetylsalicylic	B	['N']	[4]
5	acid	I-Drug	['Causes']	[1]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	essential	O	['N']	[10]
11	thrombocythemia	O	['N']	[11]
12	.	O	['N']	[12]
#2670
0	Disulfiram	B	['N']	[0]
1	-	I	['N']	[1]
2	like	I	['N']	[2]
3	reactions	I-Adverse_Effect	['N']	[3]
4	with	O	['N']	[4]
5	newer	O	['N']	[5]
6	cephalosporins	O	['N']	[6]
7	:	O	['N']	[7]
8	cefmenoxime	B-Drug	['Causes']	[3]
9	.	O	['N']	[9]
#2671
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	skin	O	['N']	[23]
24	eruptions	O	['N']	[24]
25	,	O	['N']	[25]
26	cervical	O	['N']	[26]
27	lymphadenopathy	O	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	B-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	atypical	O	['N']	[31]
32	lymphocytosis	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	O	['N']	[40]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	-	['N']	[42]
43	(	O	['N']	[43]
44	SMX	O	['N']	[44]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#2672
0	Similar	O	['N']	[0]
1	to	O	['N']	[1]
2	reports	O	['N']	[2]
3	in	O	['N']	[3]
4	patients	O	['N']	[4]
5	receiving	O	['N']	[5]
6	gefitinib	O	['N']	[6]
7	,	O	['N']	[7]
8	those	O	['N']	[8]
9	with	O	['N']	[9]
10	pathologic	O	['N']	[10]
11	findings	O	['N']	[11]
12	of	O	['N']	[12]
13	UIP	O	['N']	[13]
14	on	O	['N']	[14]
15	resected	O	['N']	[15]
16	lung	O	['N']	[16]
17	specimens	O	['N']	[17]
18	or	O	['N']	[18]
19	known	O	['N']	[19]
20	pulmonary	O	['N']	[20]
21	fibrosis	O	['N']	[21]
22	may	O	['N']	[22]
23	be	O	['N']	[23]
24	at	O	['N']	[24]
25	particular	O	['N']	[25]
26	risk	O	['N']	[26]
27	for	O	['N']	[27]
28	erlotinib	B-Drug	['Causes']	[30]
29	pulmonary	B	['N']	[29]
30	toxicity	I-Adverse_Effect	['N']	[30]
31	.	O	['N']	[31]
#2673
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	O	['N']	[19]
20	developed	O	['N']	[20]
21	confusion	O	['N']	[21]
22	,	O	['N']	[22]
23	agitation	B-Adverse_Effect	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	O	['N']	[25]
26	,	O	['N']	[26]
27	tremors	O	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	O	['N']	[29]
30	jerks	O	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	O	['N']	[32]
33	gait	O	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	B-Drug	['Causes']	[23]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#2674
0	Although	O	['N']	[0]
1	taxol	B-Drug	['Causes']	[12]
2	has	O	['N']	[2]
3	shown	O	['N']	[3]
4	significant	O	['N']	[4]
5	activity	O	['N']	[5]
6	in	O	['N']	[6]
7	advanced	O	['N']	[7]
8	ovarian	O	['N']	[8]
9	cancer	O	['N']	[9]
10	,	O	['N']	[10]
11	peripheral	B	['N']	[11]
12	neuropathy	I-Adverse_Effect	['N']	[12]
13	is	O	['N']	[13]
14	likely	O	['N']	[14]
15	to	O	['N']	[15]
16	become	O	['N']	[16]
17	the	O	['N']	[17]
18	major	O	['N']	[18]
19	dose	O	['N']	[19]
20	-	O	['N']	[20]
21	limiting	O	['N']	[21]
22	toxicity	O	['N']	[22]
23	.	O	['N']	[23]
#2675
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	clinical	O	['N']	[3]
4	diagnosis	O	['N']	[4]
5	of	O	['N']	[5]
6	fixed	B	['N']	[6]
7	drug	I	['N']	[7]
8	eruption	I-Adverse_Effect	['N']	[8]
9	owing	O	['N']	[9]
10	to	O	['N']	[10]
11	use	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	PDE5	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	tadalafil	B-Drug	['Causes']	[8]
17	(	O	['N']	[17]
18	Cialis	O	['N']	[18]
19	)	O	['N']	[19]
20	was	O	['N']	[20]
21	made	O	['N']	[21]
22	.	O	['N']	[22]
#2676
0	Muzolimine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	severe	B	['N']	[3]
4	neuromyeloencephalopathy	I-Adverse_Effect	['N']	[4]
5	:	O	['N']	[5]
6	report	O	['N']	[6]
7	of	O	['N']	[7]
8	seven	O	['N']	[8]
9	cases	O	['N']	[9]
10	.	O	['N']	[10]
#2677
0	Polyarthritis	O	['N']	[0]
1	,	O	['N']	[1]
2	hepatitis	O	['N']	[2]
3	and	O	['N']	[3]
4	anti	B	['N']	[4]
5	-	I	['N']	[5]
6	native	I	['N']	[6]
7	DNA	I	['N']	[7]
8	antibodies	I-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	ethambutol	O	['N']	[12]
13	and	O	['N']	[13]
14	rifampicin	B-Drug	['Causes']	[8]
15	.	O	['N']	[15]
#2678
0	Capecitabine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	headache	B-Adverse_Effect	['N']	[3]
4	responding	O	['N']	[4]
5	to	O	['N']	[5]
6	diltiazem	O	['N']	[6]
7	.	O	['N']	[7]
#2679
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	experienced	O	['N']	[5]
6	a	O	['N']	[6]
7	lichenoid	B	['N']	[7]
8	eruption	I-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	the	O	['N']	[10]
11	initiation	O	['N']	[11]
12	of	O	['N']	[12]
13	salsalate	B-Drug	['Causes']	[8]
14	for	O	['N']	[14]
15	relief	O	['N']	[15]
16	of	O	['N']	[16]
17	arthritic	O	['N']	[17]
18	pain	O	['N']	[18]
19	.	O	['N']	[19]
#2680
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	fatal	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	subacute	O	['N']	[6]
7	methanol	B-Drug	['Causes']	[13]
8	toxicity	O	['N']	[8]
9	with	O	['N']	[9]
10	associated	O	['N']	[10]
11	diffuse	B	['N']	[11]
12	brain	I	['N']	[12]
13	involvement	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	including	O	['N']	[15]
16	bilateral	O	['N']	[16]
17	putaminal	O	['N']	[17]
18	necrosis	O	['N']	[18]
19	and	O	['N']	[19]
20	cerebral	O	['N']	[20]
21	edema	O	['N']	[21]
22	with	O	['N']	[22]
23	ventricular	O	['N']	[23]
24	compression	O	['N']	[24]
25	.	O	['N']	[25]
#2681
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	2	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	severe	O	['N']	[5]
6	erosive	O	['N']	[6]
7	rheumatoid	O	['N']	[7]
8	arthritis	O	['N']	[8]
9	and	O	['N']	[9]
10	rheumatoid	O	['N']	[10]
11	vasculitis	O	['N']	[11]
12	,	O	['N']	[12]
13	respectively	O	['N']	[13]
14	,	O	['N']	[14]
15	in	O	['N']	[15]
16	whom	O	['N']	[16]
17	infliximab	B-Drug	['Causes']	[27]
18	therapy	O	['N']	[18]
19	was	O	['N']	[19]
20	associated	O	['N']	[20]
21	with	O	['N']	[21]
22	peripheral	O	['N']	[22]
23	neuropathy	O	['N']	[23]
24	due	O	['N']	[24]
25	to	O	['N']	[25]
26	necrotizing	B	['N']	[26]
27	vasculitis	I-Adverse_Effect	['N']	[27]
28	in	O	['N']	[28]
29	one	O	['N']	[29]
30	patient	O	['N']	[30]
31	and	O	['N']	[31]
32	to	O	['N']	[32]
33	progression	O	['N']	[33]
34	of	O	['N']	[34]
35	preexisting	O	['N']	[35]
36	mononeuritis	O	['N']	[36]
37	multiplex	O	['N']	[37]
38	in	O	['N']	[38]
39	the	O	['N']	[39]
40	other	O	['N']	[40]
41	.	O	['N']	[41]
#2682
0	Sulfasalazine	B-Drug	['Causes']	[10]
1	has	O	['N']	[1]
2	been	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	bronchopulmonary	B	['N']	[5]
6	complications	I	['N']	[6]
7	of	I	['N']	[7]
8	inflammatory	I	['N']	[8]
9	bowel	I	['N']	[9]
10	disease	I-Adverse_Effect	['N']	[10]
11	(	O	['N']	[11]
12	IBD	O	['N']	[12]
13	)	O	['N']	[13]
14	in	O	['N']	[14]
15	adults	O	['N']	[15]
16	.	O	['N']	[16]
#2683
0	The	O	['N']	[0]
1	occurrence	O	['N']	[1]
2	of	O	['N']	[2]
3	BMTN	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	two	O	['N']	[5]
6	children	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	RA	B-Drug	['Causes']	[3]
10	in	O	['N']	[10]
11	our	O	['N']	[11]
12	unit	O	['N']	[12]
13	is	O	['N']	[13]
14	unlikely	O	['N']	[14]
15	to	O	['N']	[15]
16	be	O	['N']	[16]
17	coincidental	O	['N']	[17]
18	.	O	['N']	[18]
#2684
0	Treatment	O	['N']	[0]
1	of	O	['N']	[1]
2	carbimazole	B-Drug	['Causes']	[5]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	agranulocytosis	B-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	sepsis	O	['N']	[7]
8	with	O	['N']	[8]
9	granulocyte	O	['N']	[9]
10	colony	O	['N']	[10]
11	stimulating	O	['N']	[11]
12	factor	O	['N']	[12]
13	.	O	['N']	[13]
#2685
0	Cardiac	B	['N']	[0]
1	decompensation	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	verapamil	B-Drug	['Causes']	[1]
4	therapy	O	['N']	[4]
5	in	O	['N']	[5]
6	infants	O	['N']	[6]
7	with	O	['N']	[7]
8	supraventricular	O	['N']	[8]
9	tachycardia	O	['N']	[9]
10	.	O	['N']	[10]
#2686
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	present	O	['N']	[2]
3	an	O	['N']	[3]
4	elderly	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	mixed	O	['N']	[7]
8	dementia	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	TD	B-Adverse_Effect	['N']	[11]
12	at	O	['N']	[12]
13	multiple	O	['N']	[13]
14	sites	O	['N']	[14]
15	,	O	['N']	[15]
16	(	O	['N']	[16]
17	including	O	['N']	[17]
18	respiratory	O	['N']	[18]
19	dyskinesia	O	['N']	[19]
20	[	O	['N']	[20]
21	RD	O	['N']	[21]
22	]	O	['N']	[22]
23	,	O	['N']	[23]
24	limb	O	['N']	[24]
25	dyskinesia	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	orofacial	O	['N']	[28]
29	dyskinesia	O	['N']	[29]
30	)	O	['N']	[30]
31	following	O	['N']	[31]
32	abrupt	O	['N']	[32]
33	withdrawal	O	['N']	[33]
34	of	O	['N']	[34]
35	risperidone	B-Drug	['Causes']	[11]
36	therapy	O	['N']	[36]
37	.	O	['N']	[37]
#2687
0	Methylphenidate	B-Drug	['Causes']	[5]
1	(	O	['N']	[1]
2	Ritalin)-associated	O	['N']	[2]
3	cataract	O	['N']	[3]
4	and	O	['N']	[4]
5	glaucoma	B-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#2688
0	Conversely	O	['N']	[0]
1	,	O	['N']	[1]
2	diffuse	O	['N']	[2]
3	interstitial	O	['N']	[3]
4	pulmonary	O	['N']	[4]
5	fibrosis	O	['N']	[5]
6	should	O	['N']	[6]
7	be	O	['N']	[7]
8	considered	O	['N']	[8]
9	in	O	['N']	[9]
10	the	O	['N']	[10]
11	differential	O	['N']	[11]
12	diagnosis	O	['N']	[12]
13	of	O	['N']	[13]
14	patients	O	['N']	[14]
15	receiving	O	['N']	[15]
16	methotrexate	B-Drug	['Causes']	[21]
17	who	O	['N']	[17]
18	develop	O	['N']	[18]
19	bilateral	B	['N']	[19]
20	pulmonary	I	['N']	[20]
21	infiltrates	I-Adverse_Effect	['N']	[21]
22	seen	O	['N']	[22]
23	on	O	['N']	[23]
24	chest	O	['N']	[24]
25	roentgenograms	O	['N']	[25]
26	.	O	['N']	[26]
#2689
0	Cardiac	B	['N']	[0]
1	arrest	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	use	O	['N']	[3]
4	of	O	['N']	[4]
5	sumatriptan	B-Drug	['Causes']	[1]
6	.	O	['N']	[6]
#2690
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	unintentional	O	['N']	[5]
6	overdose	O	['N']	[6]
7	of	O	['N']	[7]
8	oral	O	['N']	[8]
9	pilocarpine	B-Drug	['Causes']	[21]
10	tablets	O	['N']	[10]
11	that	O	['N']	[11]
12	resulted	O	['N']	[12]
13	in	O	['N']	[13]
14	bradycardia	O	['N']	[14]
15	,	O	['N']	[15]
16	mild	O	['N']	[16]
17	hypotension	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	muscarinic	B	['N']	[20]
21	symptoms	I-Adverse_Effect	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	patient	O	['N']	[24]
25	with	O	['N']	[25]
26	Sjogren	O	['N']	[26]
27	's	O	['N']	[27]
28	syndrome	O	['N']	[28]
29	.	O	['N']	[29]
#2691
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	demonstrates	O	['N']	[2]
3	that	O	['N']	[3]
4	hypersensitivity	B	['N']	[4]
5	reaction	I-Adverse_Effect	['N']	[5]
6	to	O	['N']	[6]
7	pranlukast	B-Drug	['Causes']	[5]
8	and	O	['N']	[8]
9	resultant	O	['N']	[9]
10	ATIN	O	['N']	[10]
11	is	O	['N']	[11]
12	possible	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	that	O	['N']	[15]
16	periodic	O	['N']	[16]
17	urine	O	['N']	[17]
18	testing	O	['N']	[18]
19	in	O	['N']	[19]
20	patients	O	['N']	[20]
21	receiving	O	['N']	[21]
22	pranlukast	O	['N']	[22]
23	should	O	['N']	[23]
24	be	O	['N']	[24]
25	considered	O	['N']	[25]
26	.	O	['N']	[26]
#2692
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	acute	O	['N']	[6]
7	kidney	O	['N']	[7]
8	injury	O	['N']	[8]
9	due	O	['N']	[9]
10	to	O	['N']	[10]
11	zonisamide	B-Drug	['Causes']	[14]
12	-	O	['N']	[12]
13	induced	O	['N']	[13]
14	DRESS	B-Adverse_Effect	['N']	[14]
15	/	O	['N']	[15]
16	DIHS	O	['N']	[16]
17	.	O	['N']	[17]
#2693
0	We	O	['N']	[0]
1	consider	O	['N']	[1]
2	asterixis	O	['N']	[2]
3	to	O	['N']	[3]
4	be	O	['N']	[4]
5	an	O	['N']	[5]
6	easily	O	['N']	[6]
7	overlooked	O	['N']	[7]
8	sign	O	['N']	[8]
9	of	O	['N']	[9]
10	neurotoxicity	B-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	which	O	['N']	[12]
13	may	O	['N']	[13]
14	occur	O	['N']	[14]
15	even	O	['N']	[15]
16	at	O	['N']	[16]
17	low	O	['N']	[17]
18	or	O	['N']	[18]
19	moderate	O	['N']	[19]
20	dosage	O	['N']	[20]
21	levels	O	['N']	[21]
22	,	O	['N']	[22]
23	if	O	['N']	[23]
24	certain	O	['N']	[24]
25	drugs	O	['N']	[25]
26	as	O	['N']	[26]
27	lithium	O	['N']	[27]
28	or	O	['N']	[28]
29	clozapine	B-Drug	['Causes']	[10]
30	are	O	['N']	[30]
31	used	O	['N']	[31]
32	in	O	['N']	[32]
33	combination	O	['N']	[33]
34	with	O	['N']	[34]
35	CBZ	O	['N']	[35]
36	.	O	['N']	[36]
#2694
0	Easily	O	['N']	[0]
1	reversible	O	['N']	[1]
2	hypoxemia	B-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	hypotension	O	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	nimodipine	B-Drug	['Causes']	[2]
8	.	O	['N']	[8]
#2695
0	Most	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	pancreatitis	B-Adverse_Effect	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	L	B	['N']	[6]
7	-	I	['N']	[7]
8	asparaginase	I-Drug	['Causes']	[3]
9	toxicity	O	['N']	[9]
10	are	O	['N']	[10]
11	self	O	['N']	[11]
12	-	O	['N']	[12]
13	limiting	O	['N']	[13]
14	and	O	['N']	[14]
15	respond	O	['N']	[15]
16	favorably	O	['N']	[16]
17	to	O	['N']	[17]
18	nasogastric	O	['N']	[18]
19	decompression	O	['N']	[19]
20	and	O	['N']	[20]
21	intravenous	O	['N']	[21]
22	hyperalimentation	O	['N']	[22]
23	.	O	['N']	[23]
#2696
0	Suspected	O	['N']	[0]
1	ciprofloxacin	B-Drug	['Causes']	[5]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	interstitial	B	['N']	[4]
5	nephritis	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#2697
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	experienced	O	['N']	[5]
6	LABD	B-Adverse_Effect	['N']	[6]
7	shortly	O	['N']	[7]
8	after	O	['N']	[8]
9	starting	O	['N']	[9]
10	carbamazepine	B-Drug	['Causes']	[6]
11	therapy	O	['N']	[11]
12	.	O	['N']	[12]
#2698
0	A	O	['N']	[0]
1	review	O	['N']	[1]
2	of	O	['N']	[2]
3	the	O	['N']	[3]
4	literature	O	['N']	[4]
5	revealed	O	['N']	[5]
6	two	O	['N']	[6]
7	other	O	['N']	[7]
8	cases	O	['N']	[8]
9	of	O	['N']	[9]
10	hepatic	B	['N']	[10]
11	angiosarcoma	I-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	patients	O	['N']	[13]
14	after	O	['N']	[14]
15	long	O	['N']	[15]
16	-	O	['N']	[16]
17	term	O	['N']	[17]
18	cyclophosphamide	B-Drug	['Causes']	[11]
19	treatment	O	['N']	[19]
20	.	O	['N']	[20]
#2699
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	whose	O	['N']	[2]
3	case	O	['N']	[3]
4	is	O	['N']	[4]
5	reviewed	O	['N']	[5]
6	had	O	['N']	[6]
7	migraine	B	['N']	[7]
8	headaches	I-Adverse_Effect	['N']	[8]
9	and	O	['N']	[9]
10	received	O	['N']	[10]
11	methysergide	B-Drug	['Causes']	[8]
12	maleate	O	['N']	[12]
13	for	O	['N']	[13]
14	13	O	['N']	[14]
15	years	O	['N']	[15]
16	.	O	['N']	[16]
#2700
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	In	O	['N']	[2]
3	some	O	['N']	[3]
4	abstainers	O	['N']	[4]
5	who	O	['N']	[5]
6	take	O	['N']	[6]
7	cyanamide	B-Drug	['Causes']	[27]
8	for	O	['N']	[8]
9	several	O	['N']	[9]
10	years	O	['N']	[10]
11	,	O	['N']	[11]
12	thin	O	['N']	[12]
13	septum	O	['N']	[13]
14	-	O	['N']	[14]
15	like	O	['N']	[15]
16	liver	O	['N']	[16]
17	fibrosis	O	['N']	[17]
18	progresses	O	['N']	[18]
19	along	O	['N']	[19]
20	with	O	['N']	[20]
21	the	O	['N']	[21]
22	emergence	O	['N']	[22]
23	of	O	['N']	[23]
24	ground	B	['N']	[24]
25	-	I	['N']	[25]
26	glass	I	['N']	[26]
27	hepatocytes	I-Adverse_Effect	['N']	[27]
28	.	O	['N']	[28]
#2701
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Patients	O	['N']	[2]
3	receiving	O	['N']	[3]
4	intravitreal	O	['N']	[4]
5	injections	O	['N']	[5]
6	of	O	['N']	[6]
7	bevacizumab	B-Drug	['Causes']	[21]
8	should	O	['N']	[8]
9	be	O	['N']	[9]
10	evaluated	O	['N']	[10]
11	for	O	['N']	[11]
12	potential	O	['N']	[12]
13	systemic	O	['N']	[13]
14	risk	O	['N']	[14]
15	factors	O	['N']	[15]
16	such	O	['N']	[16]
17	as	O	['N']	[17]
18	carotid	O	['N']	[18]
19	insufficiency	O	['N']	[19]
20	,	O	['N']	[20]
21	coagulopathy	B-Adverse_Effect	['N']	[21]
22	and	O	['N']	[22]
23	poorly	O	['N']	[23]
24	controlled	O	['N']	[24]
25	diabetes	O	['N']	[25]
26	mellitus	O	['N']	[26]
27	.	O	['N']	[27]
#2702
0	As	O	['N']	[0]
1	linezolid	B-Drug	['Causes']	[9]
2	has	O	['N']	[2]
3	been	O	['N']	[3]
4	shown	O	['N']	[4]
5	to	O	['N']	[5]
6	have	O	['N']	[6]
7	hematologic	B	['N']	[7]
8	side	I	['N']	[8]
9	effects	I-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	blood	O	['N']	[11]
12	count	O	['N']	[12]
13	monitoring	O	['N']	[13]
14	is	O	['N']	[14]
15	recommended	O	['N']	[15]
16	in	O	['N']	[16]
17	patients	O	['N']	[17]
18	receiving	O	['N']	[18]
19	this	O	['N']	[19]
20	drug	O	['N']	[20]
21	for	O	['N']	[21]
22	long	O	['N']	[22]
23	-	O	['N']	[23]
24	term	O	['N']	[24]
25	therapy	O	['N']	[25]
26	.	O	['N']	[26]
#2703
0	It	O	['N']	[0]
1	may	O	['N']	[1]
2	cause	O	['N']	[2]
3	a	O	['N']	[3]
4	severe	O	['N']	[4]
5	adverse	O	['N']	[5]
6	drug	O	['N']	[6]
7	reaction	O	['N']	[7]
8	with	O	['N']	[8]
9	multiorgan	O	['N']	[9]
10	involvement	O	['N']	[10]
11	known	O	['N']	[11]
12	as	O	['N']	[12]
13	dapsone	B-Drug	['Causes']	[15]
14	hypersensitivity	B	['N']	[14]
15	syndrome	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#2704
0	D	B	['N']	[0]
1	-	I	['N']	[1]
2	penicillamine	I-Drug	['Causes']	[5]
3	induced	O	['N']	[3]
4	crescentic	B	['N']	[4]
5	glomerulonephritis	I-Adverse_Effect	['N']	[5]
6	:	O	['N']	[6]
7	report	O	['N']	[7]
8	and	O	['N']	[8]
9	review	O	['N']	[9]
10	of	O	['N']	[10]
11	the	O	['N']	[11]
12	literature	O	['N']	[12]
13	.	O	['N']	[13]
#2705
0	Naproxen	B-Drug	['Causes']	[17]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	commonly	O	['N']	[3]
4	used	O	['N']	[4]
5	nonsteroidal	O	['N']	[5]
6	anti	O	['N']	[6]
7	-	O	['N']	[7]
8	inflammatory	O	['N']	[8]
9	drug	O	['N']	[9]
10	(	O	['N']	[10]
11	NSAID	O	['N']	[11]
12	)	O	['N']	[12]
13	whose	O	['N']	[13]
14	side	O	['N']	[14]
15	effects	O	['N']	[15]
16	include	O	['N']	[16]
17	tinnitus	B-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	transient	O	['N']	[19]
20	hearing	O	['N']	[20]
21	loss	O	['N']	[21]
22	.	O	['N']	[22]
#2706
0	Quetiapine	B-Drug	['Causes']	[7]
1	and	O	['N']	[1]
2	obsessive	O	['N']	[2]
3	-	O	['N']	[3]
4	compulsive	O	['N']	[4]
5	symptoms	O	['N']	[5]
6	(	O	['N']	[6]
7	OCS	B-Adverse_Effect	['N']	[7]
8	)	O	['N']	[8]
9	:	O	['N']	[9]
10	case	O	['N']	[10]
11	report	O	['N']	[11]
12	and	O	['N']	[12]
13	review	O	['N']	[13]
14	of	O	['N']	[14]
15	atypical	O	['N']	[15]
16	antipsychotic	O	['N']	[16]
17	-	O	['N']	[17]
18	induced	O	['N']	[18]
19	OCS	O	['N']	[19]
20	.	O	['N']	[20]
#2707
0	A	O	['N']	[0]
1	52-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	,	O	['N']	[4]
5	white	O	['N']	[5]
6	female	O	['N']	[6]
7	developed	O	['N']	[7]
8	low	O	['N']	[8]
9	-	O	['N']	[9]
10	grade	O	['N']	[10]
11	fever	O	['N']	[11]
12	,	O	['N']	[12]
13	cough	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	dyspnea	B-Adverse_Effect	['N']	[16]
17	after	O	['N']	[17]
18	8	O	['N']	[18]
19	weeks	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	sodium	B	['N']	[22]
23	aurothiomalate	I-Drug	['Causes']	[16]
24	for	O	['N']	[24]
25	rheumatoid	O	['N']	[25]
26	arthritis	O	['N']	[26]
27	.	O	['N']	[27]
#2708
0	Progression	O	['N']	[0]
1	of	O	['N']	[1]
2	chronic	O	['N']	[2]
3	myeloid	O	['N']	[3]
4	leukemia	O	['N']	[4]
5	to	O	['N']	[5]
6	blast	B	['N']	[6]
7	crisis	I-Adverse_Effect	['N']	[7]
8	during	O	['N']	[8]
9	treatment	O	['N']	[9]
10	with	O	['N']	[10]
11	imatinib	B	['N']	[11]
12	mesylate	I-Drug	['Causes']	[7]
13	.	O	['N']	[13]
#2709
0	Edema	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	ibuprofen	B-Drug	['Causes']	[0]
4	therapy	O	['N']	[4]
5	.	O	['N']	[5]
#2710
0	A	O	['N']	[0]
1	retrospective	O	['N']	[1]
2	study	O	['N']	[2]
3	was	O	['N']	[3]
4	conducted	O	['N']	[4]
5	of	O	['N']	[5]
6	40	O	['N']	[6]
7	loperamide	B-Drug	['Causes']	[8]
8	poisoning	I-Adverse_Effect	['N']	[8]
9	cases	O	['N']	[9]
10	recorded	O	['N']	[10]
11	at	O	['N']	[11]
12	the	O	['N']	[12]
13	Centre	O	['N']	[13]
14	National	O	['N']	[14]
15	d'Informations	O	['N']	[15]
16	Toxicologiques	O	['N']	[16]
17	Veterinaires	O	['N']	[17]
18	.	O	['N']	[18]
#2711
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Life	O	['N']	[2]
3	-	O	['N']	[3]
4	threatening	O	['N']	[4]
5	adrenal	B	['N']	[5]
6	suppression	I-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	requiring	O	['N']	[8]
9	hydrocortisone	O	['N']	[9]
10	supplementation	O	['N']	[10]
11	and	O	['N']	[11]
12	intensive	O	['N']	[12]
13	therapy	O	['N']	[13]
14	,	O	['N']	[14]
15	was	O	['N']	[15]
16	observed	O	['N']	[16]
17	and	O	['N']	[17]
18	successfully	O	['N']	[18]
19	treated	O	['N']	[19]
20	in	O	['N']	[20]
21	a	O	['N']	[21]
22	newborn	O	['N']	[22]
23	,	O	['N']	[23]
24	whose	O	['N']	[24]
25	mother	O	['N']	[25]
26	had	O	['N']	[26]
27	received	O	['N']	[27]
28	high	O	['N']	[28]
29	-	O	['N']	[29]
30	dose	O	['N']	[30]
31	methylprednisolone	B-Drug	['Causes']	[6]
32	in	O	['N']	[32]
33	late	O	['N']	[33]
34	pregnancy	O	['N']	[34]
35	.	O	['N']	[35]
#2712
0	Drug	O	['N']	[0]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	mammary	B	['N']	[3]
4	hyperplasias	I-Adverse_Effect	['N']	[4]
5	have	O	['N']	[5]
6	been	O	['N']	[6]
7	reported	O	['N']	[7]
8	as	O	['N']	[8]
9	rare	O	['N']	[9]
10	complications	O	['N']	[10]
11	of	O	['N']	[11]
12	D	O	['N']	[12]
13	-	O	['N']	[13]
14	penicillamine	O	['N']	[14]
15	and	O	['N']	[15]
16	Neothetazone	B-Drug	['Causes']	[4]
17	.	O	['N']	[17]
#2713
0	Visual	B	['N']	[0]
1	hallucinations	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	intravitreal	O	['N']	[3]
4	injection	O	['N']	[4]
5	of	O	['N']	[5]
6	bevacizumab	B-Drug	['Causes']	[1]
7	in	O	['N']	[7]
8	vascular	O	['N']	[8]
9	age	O	['N']	[9]
10	-	O	['N']	[10]
11	related	O	['N']	[11]
12	macular	O	['N']	[12]
13	degeneration	O	['N']	[13]
14	.	O	['N']	[14]
#2714
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	skin	O	['N']	[23]
24	eruptions	O	['N']	[24]
25	,	O	['N']	[25]
26	cervical	B	['N']	[26]
27	lymphadenopathy	I-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	O	['N']	[31]
32	lymphocytosis	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	O	['N']	[40]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	O	['N']	[42]
43	(	O	['N']	[43]
44	SMX	B-Drug	['Causes']	[27]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#2715
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	treated	O	['N']	[2]
3	with	O	['N']	[3]
4	alprazolam	B-Drug	['Causes']	[18]
5	had	O	['N']	[5]
6	histories	O	['N']	[6]
7	suggestive	O	['N']	[7]
8	of	O	['N']	[8]
9	a	O	['N']	[9]
10	bipolar	O	['N']	[10]
11	disorder	O	['N']	[11]
12	and	O	['N']	[12]
13	developed	O	['N']	[13]
14	lithium	O	['N']	[14]
15	-	O	['N']	[15]
16	responsive	O	['N']	[16]
17	manic	B	['N']	[17]
18	episodes	I-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#2716
0	The	O	['N']	[0]
1	possible	O	['N']	[1]
2	effects	O	['N']	[2]
3	of	O	['N']	[3]
4	tamoxifen	B-Drug	['Causes']	[23]
5	upon	O	['N']	[5]
6	the	O	['N']	[6]
7	uterus	O	['N']	[7]
8	are	O	['N']	[8]
9	discussed	O	['N']	[9]
10	in	O	['N']	[10]
11	this	O	['N']	[11]
12	article	O	['N']	[12]
13	,	O	['N']	[13]
14	in	O	['N']	[14]
15	view	O	['N']	[15]
16	of	O	['N']	[16]
17	reports	O	['N']	[17]
18	of	O	['N']	[18]
19	tamoxifen	O	['N']	[19]
20	associated	O	['N']	[20]
21	with	O	['N']	[21]
22	endometrial	B	['N']	[22]
23	carcinoma	I-Adverse_Effect	['N']	[23]
24	and	O	['N']	[24]
25	endometriosis	O	['N']	[25]
26	.	O	['N']	[26]
#2717
0	Acyclovir	B-Drug	['Causes']	[1]
1	neurotoxicity	B-Adverse_Effect	['N']	[1]
2	:	O	['N']	[2]
3	clinical	O	['N']	[3]
4	experience	O	['N']	[4]
5	and	O	['N']	[5]
6	review	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	literature	O	['N']	[9]
10	.	O	['N']	[10]
#2718
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	reversible	O	['N']	[5]
6	encephalopathy	B	['N']	[6]
7	syndrome	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	16-year	O	['N']	[10]
11	-	O	['N']	[11]
12	old	O	['N']	[12]
13	girl	O	['N']	[13]
14	with	O	['N']	[14]
15	acute	O	['N']	[15]
16	myelogenous	O	['N']	[16]
17	leukemia	O	['N']	[17]
18	(	O	['N']	[18]
19	AML	O	['N']	[19]
20	)	O	['N']	[20]
21	,	O	['N']	[21]
22	who	O	['N']	[22]
23	is	O	['N']	[23]
24	undergoing	O	['N']	[24]
25	during	O	['N']	[25]
26	consolidation	O	['N']	[26]
27	chemotherapy	O	['N']	[27]
28	composed	O	['N']	[28]
29	of	O	['N']	[29]
30	BH	B	['N']	[30]
31	-	I	['N']	[31]
32	AC	I-Drug	['Causes']	[7]
33	(	O	['N']	[33]
34	N4-behenoyl-1-beta	O	['N']	[34]
35	-	O	['N']	[35]
36	D	O	['N']	[36]
37	-	O	['N']	[37]
38	arabinofuranosyl	O	['N']	[38]
39	cytosine	O	['N']	[39]
40	)	O	['N']	[40]
41	and	O	['N']	[41]
42	idarubicin	O	['N']	[42]
43	.	O	['N']	[43]
#2719
0	Indinavir	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	nephrolithiasis	B-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	chronic	O	['N']	[5]
6	interstitial	O	['N']	[6]
7	nephritis	O	['N']	[7]
8	were	O	['N']	[8]
9	the	O	['N']	[9]
10	only	O	['N']	[10]
11	possible	O	['N']	[11]
12	causes	O	['N']	[12]
13	identified	O	['N']	[13]
14	in	O	['N']	[14]
15	this	O	['N']	[15]
16	patient	O	['N']	[16]
17	.	O	['N']	[17]
#2720
0	Phantom	B	['N']	[0]
1	limb	I	['N']	[1]
2	pain	I-Adverse_Effect	['N']	[2]
3	as	O	['N']	[3]
4	a	O	['N']	[4]
5	manifestation	O	['N']	[5]
6	of	O	['N']	[6]
7	paclitaxel	B-Drug	['Causes']	[2]
8	neurotoxicity	O	['N']	[8]
9	.	O	['N']	[9]
#2721
0	It	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	recognized	O	['N']	[3]
4	that	O	['N']	[4]
5	ibuprofen	O	['N']	[5]
6	may	O	['N']	[6]
7	be	O	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	salt	B	['N']	[10]
11	and	I	['N']	[11]
12	water	I	['N']	[12]
13	retention	I-Adverse_Effect	['N']	[13]
14	in	O	['N']	[14]
15	the	O	['N']	[15]
16	same	O	['N']	[16]
17	fashion	O	['N']	[17]
18	as	O	['N']	[18]
19	previously	O	['N']	[19]
20	described	O	['N']	[20]
21	with	O	['N']	[21]
22	phenylbutazone	B-Drug	['Causes']	[13]
23	and	O	['N']	[23]
24	indomethacin	O	['N']	[24]
25	.	O	['N']	[25]
#2722
0	The	O	['N']	[0]
1	more	O	['N']	[1]
2	common	O	['N']	[2]
3	grade	O	['N']	[3]
4	3	O	['N']	[4]
5	or	O	['N']	[5]
6	4	O	['N']	[6]
7	adverse	O	['N']	[7]
8	effects	O	['N']	[8]
9	of	O	['N']	[9]
10	sunitinib	B-Drug	['Causes']	[14]
11	include	O	['N']	[11]
12	hypertension	O	['N']	[12]
13	,	O	['N']	[13]
14	fatigue	B-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	hand	O	['N']	[16]
17	-	O	['N']	[17]
18	foot	O	['N']	[18]
19	syndrome	O	['N']	[19]
20	,	O	['N']	[20]
21	elevated	O	['N']	[21]
22	lipase	O	['N']	[22]
23	and	O	['N']	[23]
24	lymphopenia	O	['N']	[24]
25	.	O	['N']	[25]
#2723
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	heparin	B-Drug	['Causes']	[8]
7	associated	O	['N']	[7]
8	thrombocytopenia	B-Adverse_Effect	['N']	[8]
9	during	O	['N']	[9]
10	continuous	O	['N']	[10]
11	arteriovenous	O	['N']	[11]
12	haemofiltration	O	['N']	[12]
13	and	O	['N']	[13]
14	discuss	O	['N']	[14]
15	its	O	['N']	[15]
16	implications	O	['N']	[16]
17	and	O	['N']	[17]
18	alternative	O	['N']	[18]
19	anticoagulant	O	['N']	[19]
20	treatment	O	['N']	[20]
21	.	O	['N']	[21]
#2724
0	After	O	['N']	[0]
1	5	O	['N']	[1]
2	days	O	['N']	[2]
3	of	O	['N']	[3]
4	treatment	O	['N']	[4]
5	with	O	['N']	[5]
6	IL-2	B-Drug	['Causes']	[26]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	patient	O	['N']	[9]
10	developed	O	['N']	[10]
11	a	O	['N']	[11]
12	hemorrhagic	O	['N']	[12]
13	lesion	O	['N']	[13]
14	that	O	['N']	[14]
15	progressed	O	['N']	[15]
16	to	O	['N']	[16]
17	toxic	O	['N']	[17]
18	epidermal	O	['N']	[18]
19	necrolysis	O	['N']	[19]
20	,	O	['N']	[20]
21	as	O	['N']	[21]
22	well	O	['N']	[22]
23	as	O	['N']	[23]
24	grade	O	['N']	[24]
25	4	O	['N']	[25]
26	pancytopenia	B-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#2725
0	Thrombotic	B	['N']	[0]
1	thrombocytopenic	I	['N']	[1]
2	purpura	I-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	penicillamine	B-Drug	['Causes']	[2]
5	therapy	O	['N']	[5]
6	in	O	['N']	[6]
7	rheumatoid	O	['N']	[7]
8	arthritis	O	['N']	[8]
9	.	O	['N']	[9]
#2726
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	main	O	['N']	[3]
4	adverse	O	['N']	[4]
5	effects	O	['N']	[5]
6	of	O	['N']	[6]
7	leflunomide	B-Drug	['Causes']	[10]
8	consist	O	['N']	[8]
9	of	O	['N']	[9]
10	diarrhea	B-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	nausea	O	['N']	[12]
13	,	O	['N']	[13]
14	liver	O	['N']	[14]
15	enzyme	O	['N']	[15]
16	elevation	O	['N']	[16]
17	,	O	['N']	[17]
18	hypertension	O	['N']	[18]
19	,	O	['N']	[19]
20	alopecia	O	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	allergic	O	['N']	[23]
24	skin	O	['N']	[24]
25	reactions	O	['N']	[25]
26	.	O	['N']	[26]
#2727
0	Here	O	['N']	[0]
1	we	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	Crohn	O	['N']	[6]
7	's	O	['N']	[7]
8	disease	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	a	O	['N']	[11]
12	severe	O	['N']	[12]
13	infliximab	B-Drug	['Causes']	[17]
14	infusion	O	['N']	[14]
15	reaction	O	['N']	[15]
16	(	O	['N']	[16]
17	IIR	B-Adverse_Effect	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	complicated	O	['N']	[20]
21	1	O	['N']	[21]
22	day	O	['N']	[22]
23	later	O	['N']	[23]
24	by	O	['N']	[24]
25	severe	O	['N']	[25]
26	swelling	O	['N']	[26]
27	of	O	['N']	[27]
28	the	O	['N']	[28]
29	forearm	O	['N']	[29]
30	and	O	['N']	[30]
31	hand	O	['N']	[31]
32	ipsilateral	O	['N']	[32]
33	to	O	['N']	[33]
34	the	O	['N']	[34]
35	site	O	['N']	[35]
36	of	O	['N']	[36]
37	infliximab	O	['N']	[37]
38	infusion	O	['N']	[38]
39	.	O	['N']	[39]
#2728
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	acute	B	['N']	[6]
7	cerebellar	I	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	prophylactic	O	['N']	[10]
11	intrathecal	O	['N']	[11]
12	methotrexate	B-Drug	['Causes']	[8]
13	administration	O	['N']	[13]
14	and	O	['N']	[14]
15	recovered	O	['N']	[15]
16	spontaneously	O	['N']	[16]
17	.	O	['N']	[17]
#2729
0	The	O	['N']	[0]
1	polycystic	O	['N']	[1]
2	changes	O	['N']	[2]
3	disappeared	O	['N']	[3]
4	from	O	['N']	[4]
5	the	O	['N']	[5]
6	ovaries	O	['N']	[6]
7	in	O	['N']	[7]
8	2	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	women	O	['N']	[11]
12	after	O	['N']	[12]
13	valproate	B-Drug	['Causes']	[28]
14	therapy	O	['N']	[14]
15	was	O	['N']	[15]
16	discontinued	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	the	O	['N']	[19]
20	2	O	['N']	[20]
21	women	O	['N']	[21]
22	who	O	['N']	[22]
23	had	O	['N']	[23]
24	gained	O	['N']	[24]
25	weight	O	['N']	[25]
26	and	O	['N']	[26]
27	developed	O	['N']	[27]
28	amenorrhea	B-Adverse_Effect	['N']	[28]
29	while	O	['N']	[29]
30	being	O	['N']	[30]
31	treated	O	['N']	[31]
32	with	O	['N']	[32]
33	valproate	O	['N']	[33]
34	lost	O	['N']	[34]
35	weight	O	['N']	[35]
36	and	O	['N']	[36]
37	resumed	O	['N']	[37]
38	menstruating	O	['N']	[38]
39	after	O	['N']	[39]
40	the	O	['N']	[40]
41	change	O	['N']	[41]
42	in	O	['N']	[42]
43	medication	O	['N']	[43]
44	.	O	['N']	[44]
#2730
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	multiple	O	['N']	[8]
9	myeloma	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	acute	O	['N']	[12]
13	life	O	['N']	[13]
14	-	O	['N']	[14]
15	threatening	O	['N']	[15]
16	water	O	['N']	[16]
17	intoxication	O	['N']	[17]
18	following	O	['N']	[18]
19	treatment	O	['N']	[19]
20	with	O	['N']	[20]
21	oral	O	['N']	[21]
22	indomethacin	O	['N']	[22]
23	and	O	['N']	[23]
24	low	B	['N']	[24]
25	dose	I-Dose	['N']	[25]
26	intravenous	O	['N']	[26]
27	cyclophosphamide	B-Drug	['Dosage']	[25]
28	.	O	['N']	[28]
#2731
0	Recent	O	['N']	[0]
1	reports	O	['N']	[1]
2	have	O	['N']	[2]
3	shown	O	['N']	[3]
4	that	O	['N']	[4]
5	Decadron	O	['N']	[5]
6	(	O	['N']	[6]
7	dexamethasone	O	['N']	[7]
8	;	O	['N']	[8]
9	Merck	O	['N']	[9]
10	Sharp	O	['N']	[10]
11	&	O	['N']	[11]
12	Dohme	O	['N']	[12]
13	,	O	['N']	[13]
14	West	O	['N']	[14]
15	Point	O	['N']	[15]
16	,	O	['N']	[16]
17	Pa	O	['N']	[17]
18	)	O	['N']	[18]
19	has	O	['N']	[19]
20	a	O	['N']	[20]
21	significant	O	['N']	[21]
22	antiemetic	O	['N']	[22]
23	effect	O	['N']	[23]
24	on	O	['N']	[24]
25	cisplatin	B-Drug	['Causes']	[28]
26	-	O	['N']	[26]
27	induced	O	['N']	[27]
28	vomiting	B-Adverse_Effect	['N']	[28]
29	.	O	['N']	[29]
#2732
0	Theophylline	B-Drug	['Causes']	[1]
1	intoxication	I-Adverse_Effect	['N']	[1]
2	mimicking	O	['N']	[2]
3	diabetic	O	['N']	[3]
4	ketoacidosis	O	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	child	O	['N']	[7]
8	.	O	['N']	[8]
#2733
0	Occasionally	O	['N']	[0]
1	,	O	['N']	[1]
2	despite	O	['N']	[2]
3	good	O	['N']	[3]
4	therapeutic	O	['N']	[4]
5	response	O	['N']	[5]
6	,	O	['N']	[6]
7	clozapine	B-Drug	['Causes']	[18]
8	must	O	['N']	[8]
9	be	O	['N']	[9]
10	stopped	O	['N']	[10]
11	due	O	['N']	[11]
12	to	O	['N']	[12]
13	dangerous	O	['N']	[13]
14	side	O	['N']	[14]
15	effects	O	['N']	[15]
16	such	O	['N']	[16]
17	as	O	['N']	[17]
18	agranulocytosis	B-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#2734
0	Recurrent	O	['N']	[0]
1	septicemia	O	['N']	[1]
2	with	O	['N']	[2]
3	lethal	B-Adverse_Effect	['N']	[3]
4	outcome	O	['N']	[4]
5	during	O	['N']	[5]
6	and	O	['N']	[6]
7	after	O	['N']	[7]
8	cyclosporine	B-Drug	['Causes']	[3]
9	therapy	O	['N']	[9]
10	in	O	['N']	[10]
11	severe	O	['N']	[11]
12	ulcerative	O	['N']	[12]
13	colitis	O	['N']	[13]
14	.	O	['N']	[14]
#2735
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	who	O	['N']	[2]
3	developed	O	['N']	[3]
4	decreased	O	['N']	[4]
5	visual	O	['N']	[5]
6	acuity	O	['N']	[6]
7	after	O	['N']	[7]
8	several	O	['N']	[8]
9	months	O	['N']	[9]
10	of	O	['N']	[10]
11	ethambutol	B-Drug	['Causes']	[23]
12	treatment	O	['N']	[12]
13	for	O	['N']	[13]
14	Mycobacterium	O	['N']	[14]
15	avium	O	['N']	[15]
16	-	O	['N']	[16]
17	intracellulare	O	['N']	[17]
18	infection	O	['N']	[18]
19	had	O	['N']	[19]
20	bitemporal	B	['N']	[20]
21	visual	I	['N']	[21]
22	field	I	['N']	[22]
23	defects	I-Adverse_Effect	['N']	[23]
24	that	O	['N']	[24]
25	suggested	O	['N']	[25]
26	optic	O	['N']	[26]
27	chiasm	O	['N']	[27]
28	damage	O	['N']	[28]
29	.	O	['N']	[29]
#2736
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	a	O	['N']	[3]
4	14-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	boy	O	['N']	[7]
8	with	O	['N']	[8]
9	severe	O	['N']	[9]
10	haemophilia	O	['N']	[10]
11	A	O	['N']	[11]
12	who	O	['N']	[12]
13	developed	O	['N']	[13]
14	a	O	['N']	[14]
15	portal	B	['N']	[15]
16	vein	I	['N']	[16]
17	thrombosis	I-Adverse_Effect	['N']	[17]
18	during	O	['N']	[18]
19	continuous	O	['N']	[19]
20	infusion	O	['N']	[20]
21	of	O	['N']	[21]
22	F	B	['N']	[22]
23	VIII	I-Drug	['Causes']	[17]
24	.	O	['N']	[24]
#2737
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	,	O	['N']	[2]
3	to	O	['N']	[3]
4	the	O	['N']	[4]
5	best	O	['N']	[5]
6	of	O	['N']	[6]
7	our	O	['N']	[7]
8	knowledge	O	['N']	[8]
9	,	O	['N']	[9]
10	the	O	['N']	[10]
11	first	O	['N']	[11]
12	report	O	['N']	[12]
13	of	O	['N']	[13]
14	a	O	['N']	[14]
15	case	O	['N']	[15]
16	in	O	['N']	[16]
17	which	O	['N']	[17]
18	agranulocytosis	B-Adverse_Effect	['N']	[18]
19	followed	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	both	O	['N']	[22]
23	propylthiouracil	B-Drug	['Causes']	[18]
24	and	O	['N']	[24]
25	methimazole	O	['N']	[25]
26	in	O	['N']	[26]
27	the	O	['N']	[27]
28	same	O	['N']	[28]
29	patient	O	['N']	[29]
30	.	O	['N']	[30]
#2738
0	Ramipril	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	cutaneous	B	['N']	[3]
4	vasculitis	I-Adverse_Effect	['N']	[4]
5	is	O	['N']	[5]
6	particularly	O	['N']	[6]
7	rare	O	['N']	[7]
8	and	O	['N']	[8]
9	our	O	['N']	[9]
10	case	O	['N']	[10]
11	was	O	['N']	[11]
12	atypical	O	['N']	[12]
13	because	O	['N']	[13]
14	the	O	['N']	[14]
15	patient	O	['N']	[15]
16	had	O	['N']	[16]
17	tolerated	O	['N']	[17]
18	lisinopril	O	['N']	[18]
19	before	O	['N']	[19]
20	.	O	['N']	[20]
#2739
0	The	O	['N']	[0]
1	exacerbation	B	['N']	[1]
2	of	I	['N']	[2]
3	psoriasis	I-Adverse_Effect	['N']	[3]
4	was	O	['N']	[4]
5	accompanied	O	['N']	[5]
6	by	O	['N']	[6]
7	a	O	['N']	[7]
8	massive	O	['N']	[8]
9	induction	O	['N']	[9]
10	of	O	['N']	[10]
11	lesional	O	['N']	[11]
12	type	O	['N']	[12]
13	I	O	['N']	[13]
14	interferon	O	['N']	[14]
15	activity	O	['N']	[15]
16	,	O	['N']	[16]
17	detected	O	['N']	[17]
18	by	O	['N']	[18]
19	MxA	O	['N']	[19]
20	expression	O	['N']	[20]
21	after	O	['N']	[21]
22	imiquimod	B-Drug	['Causes']	[3]
23	therapy	O	['N']	[23]
24	.	O	['N']	[24]
#2740
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	clinical	O	['N']	[3]
4	response	O	['N']	[4]
5	,	O	['N']	[5]
6	as	O	['N']	[6]
7	determined	O	['N']	[7]
8	by	O	['N']	[8]
9	increases	B	['N']	[9]
10	in	I	['N']	[10]
11	total	I	['N']	[11]
12	Hb	I-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	decreased	O	['N']	[14]
15	transfusion	O	['N']	[15]
16	needs	O	['N']	[16]
17	,	O	['N']	[17]
18	in	O	['N']	[18]
19	five	O	['N']	[19]
20	patients	O	['N']	[20]
21	with	O	['N']	[21]
22	thalassemia	O	['N']	[22]
23	intermedia	O	['N']	[23]
24	treated	O	['N']	[24]
25	with	O	['N']	[25]
26	HU	B-Drug	['Causes']	[12]
27	alone	O	['N']	[27]
28	or	O	['N']	[28]
29	in	O	['N']	[29]
30	combination	O	['N']	[30]
31	with	O	['N']	[31]
32	SPB	O	['N']	[32]
33	.	O	['N']	[33]
#2741
0	Thirty	O	['N']	[0]
1	-	O	['N']	[1]
2	six	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	AL	O	['N']	[5]
6	received	O	['N']	[6]
7	,	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	three	O	['N']	[10]
11	-	O	['N']	[11]
12	month	O	['N']	[12]
13	period	O	['N']	[13]
14	,	O	['N']	[14]
15	51	O	['N']	[15]
16	cycles	O	['N']	[16]
17	of	O	['N']	[17]
18	combined	O	['N']	[18]
19	chemotherapy	O	['N']	[19]
20	which	O	['N']	[20]
21	included	O	['N']	[21]
22	,	O	['N']	[22]
23	in	O	['N']	[23]
24	all	O	['N']	[24]
25	of	O	['N']	[25]
26	them	O	['N']	[26]
27	,	O	['N']	[27]
28	cytosine	O	['N']	[28]
29	arabinoside	O	['N']	[29]
30	(	O	['N']	[30]
31	ARA	B	['N']	[31]
32	-	I	['N']	[32]
33	C	I-Drug	['Causes']	[45]
34	)	O	['N']	[34]
35	;	O	['N']	[35]
36	among	O	['N']	[36]
37	them	O	['N']	[37]
38	,	O	['N']	[38]
39	along	O	['N']	[39]
40	with	O	['N']	[40]
41	myelosuppression	O	['N']	[41]
42	,	O	['N']	[42]
43	five	O	['N']	[43]
44	experienced	O	['N']	[44]
45	fever	B-Adverse_Effect	['N']	[45]
46	,	O	['N']	[46]
47	infectious	O	['N']	[47]
48	complications	O	['N']	[48]
49	,	O	['N']	[49]
50	gastrointestinal	O	['N']	[50]
51	tract	O	['N']	[51]
52	symptoms	O	['N']	[52]
53	and	O	['N']	[53]
54	severe	O	['N']	[54]
55	myalgias	O	['N']	[55]
56	.	O	['N']	[56]
#2742
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	a	O	['N']	[3]
4	4-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	girl	O	['N']	[7]
8	with	O	['N']	[8]
9	valproate	B-Drug	['Causes']	[12]
10	-	O	['N']	[10]
11	induced	O	['N']	[11]
12	stupor	B-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	electroencephalographic	O	['N']	[14]
15	pattern	O	['N']	[15]
16	of	O	['N']	[16]
17	increased	O	['N']	[17]
18	fast	O	['N']	[18]
19	activity	O	['N']	[19]
20	is	O	['N']	[20]
21	reported	O	['N']	[21]
22	.	O	['N']	[22]
#2743
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	clinical	O	['N']	[3]
4	and	O	['N']	[4]
5	liver	O	['N']	[5]
6	biopsy	O	['N']	[6]
7	morphologic	O	['N']	[7]
8	features	O	['N']	[8]
9	for	O	['N']	[9]
10	4	O	['N']	[10]
11	patients	O	['N']	[11]
12	with	O	['N']	[12]
13	minocycline	B-Drug	['Causes']	[17]
14	-	O	['N']	[14]
15	induced	O	['N']	[15]
16	autoimmune	B	['N']	[16]
17	hepatitis	I-Adverse_Effect	['N']	[17]
18	(	O	['N']	[18]
19	group	O	['N']	[19]
20	1	O	['N']	[20]
21	)	O	['N']	[21]
22	.	O	['N']	[22]
#2744
0	A	O	['N']	[0]
1	generalized	B	['N']	[1]
2	tonic	I	['N']	[2]
3	-	I	['N']	[3]
4	clonic	I	['N']	[4]
5	seizure	I-Adverse_Effect	['N']	[5]
6	occurred	O	['N']	[6]
7	a	O	['N']	[7]
8	few	O	['N']	[8]
9	minutes	O	['N']	[9]
10	after	O	['N']	[10]
11	injection	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	morphine	O	['N']	[14]
15	antagonist	O	['N']	[15]
16	naloxone	B-Drug	['Causes']	[5]
17	.	O	['N']	[17]
#2745
0	He	O	['N']	[0]
1	had	O	['N']	[1]
2	been	O	['N']	[2]
3	taking	O	['N']	[3]
4	trimethoprim	B-Drug	['Causes']	[26]
5	-	O	['N']	[5]
6	sulfamethoxazole	O	['N']	[6]
7	for	O	['N']	[7]
8	approximately	O	['N']	[8]
9	eight	O	['N']	[9]
10	days	O	['N']	[10]
11	when	O	['N']	[11]
12	he	O	['N']	[12]
13	revisited	O	['N']	[13]
14	his	O	['N']	[14]
15	family	O	['N']	[15]
16	physician	O	['N']	[16]
17	,	O	['N']	[17]
18	complaining	O	['N']	[18]
19	of	O	['N']	[19]
20	headaches	O	['N']	[20]
21	,	O	['N']	[21]
22	dizziness	O	['N']	[22]
23	,	O	['N']	[23]
24	difficulty	B	['N']	[24]
25	with	I	['N']	[25]
26	speech	I-Adverse_Effect	['N']	[26]
27	,	O	['N']	[27]
28	weakness	O	['N']	[28]
29	,	O	['N']	[29]
30	and	O	['N']	[30]
31	itching	O	['N']	[31]
32	on	O	['N']	[32]
33	the	O	['N']	[33]
34	trunk	O	['N']	[34]
35	of	O	['N']	[35]
36	his	O	['N']	[36]
37	body	O	['N']	[37]
38	and	O	['N']	[38]
39	legs	O	['N']	[39]
40	,	O	['N']	[40]
41	where	O	['N']	[41]
42	a	O	['N']	[42]
43	maculopapular	O	['N']	[43]
44	rash	O	['N']	[44]
45	was	O	['N']	[45]
46	noted	O	['N']	[46]
47	.	O	['N']	[47]
#2746
0	Ischaemic	B	['N']	[0]
1	colitis	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	taking	O	['N']	[5]
6	meloxicam	B-Drug	['Causes']	[1]
7	.	O	['N']	[7]
#2747
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	supports	O	['N']	[2]
3	the	O	['N']	[3]
4	view	O	['N']	[4]
5	that	O	['N']	[5]
6	in	O	['N']	[6]
7	gold	B-Drug	['Causes']	[10]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	pneumonitis	B-Adverse_Effect	['N']	[10]
11	a	O	['N']	[11]
12	prolonged	O	['N']	[12]
13	treatment	O	['N']	[13]
14	with	O	['N']	[14]
15	corticosteroids	O	['N']	[15]
16	may	O	['N']	[16]
17	be	O	['N']	[17]
18	necessary	O	['N']	[18]
19	,	O	['N']	[19]
20	as	O	['N']	[20]
21	lung	O	['N']	[21]
22	function	O	['N']	[22]
23	continued	O	['N']	[23]
24	to	O	['N']	[24]
25	improve	O	['N']	[25]
26	.	O	['N']	[26]
#2748
0	Cerebral	B	['N']	[0]
1	and	I	['N']	[1]
2	ocular	I	['N']	[2]
3	toxicity	I-Adverse_Effect	['N']	[3]
4	induced	O	['N']	[4]
5	by	O	['N']	[5]
6	desferrioxamine	B-Drug	['Causes']	[3]
7	.	O	['N']	[7]
#2749
0	The	O	['N']	[0]
1	pharmaceutical	O	['N']	[1]
2	company	O	['N']	[2]
3	producing	O	['N']	[3]
4	Halfan	B-Drug	['Dosage']	[18]
5	has	O	['N']	[5]
6	reported	O	['N']	[6]
7	8	O	['N']	[7]
8	cardiac	O	['N']	[8]
9	arrests	O	['N']	[9]
10	,	O	['N']	[10]
11	leading	O	['N']	[11]
12	to	O	['N']	[12]
13	6	O	['N']	[13]
14	deaths	O	['N']	[14]
15	,	O	['N']	[15]
16	when	O	['N']	[16]
17	a	O	['N']	[17]
18	higher	B-Dose	['N']	[18]
19	dose	O	['N']	[19]
20	than	O	['N']	[20]
21	recommended	O	['N']	[21]
22	was	O	['N']	[22]
23	used	O	['N']	[23]
24	,	O	['N']	[24]
25	there	O	['N']	[25]
26	was	O	['N']	[26]
27	recent	O	['N']	[27]
28	or	O	['N']	[28]
29	concomitant	O	['N']	[29]
30	treatment	O	['N']	[30]
31	with	O	['N']	[31]
32	mefloquine	O	['N']	[32]
33	,	O	['N']	[33]
34	there	O	['N']	[34]
35	was	O	['N']	[35]
36	pre	O	['N']	[36]
37	-	O	['N']	[37]
38	existing	O	['N']	[38]
39	prolongation	O	['N']	[39]
40	of	O	['N']	[40]
41	the	O	['N']	[41]
42	QT	O	['N']	[42]
43	interval	O	['N']	[43]
44	or	O	['N']	[44]
45	the	O	['N']	[45]
46	patient	O	['N']	[46]
47	had	O	['N']	[47]
48	a	O	['N']	[48]
49	thiamine	O	['N']	[49]
50	deficiency	O	['N']	[50]
51	.	O	['N']	[51]
#2750
0	Controversy	O	['N']	[0]
1	concerning	O	['N']	[1]
2	the	O	['N']	[2]
3	nephrotoxicity	O	['N']	[3]
4	of	O	['N']	[4]
5	lithium	B-Drug	['Causes']	[16]
6	is	O	['N']	[6]
7	discussed	O	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	recommendations	O	['N']	[10]
11	for	O	['N']	[11]
12	the	O	['N']	[12]
13	evaluation	O	['N']	[13]
14	of	O	['N']	[14]
15	renal	B	['N']	[15]
16	failure	I-Adverse_Effect	['N']	[16]
17	during	O	['N']	[17]
18	lithium	O	['N']	[18]
19	therapy	O	['N']	[19]
20	are	O	['N']	[20]
21	provided	O	['N']	[21]
22	.	O	['N']	[22]
#2751
0	A	O	['N']	[0]
1	female	O	['N']	[1]
2	patient	O	['N']	[2]
3	with	O	['N']	[3]
4	HER2	O	['N']	[4]
5	positive	O	['N']	[5]
6	,	O	['N']	[6]
7	metastatic	O	['N']	[7]
8	breast	O	['N']	[8]
9	cancer	O	['N']	[9]
10	presented	O	['N']	[10]
11	with	O	['N']	[11]
12	pulmonary	B	['N']	[12]
13	infiltrates	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	a	O	['N']	[16]
17	plural	O	['N']	[17]
18	effusion	O	['N']	[18]
19	dyspnoea	O	['N']	[19]
20	after	O	['N']	[20]
21	several	O	['N']	[21]
22	months	O	['N']	[22]
23	of	O	['N']	[23]
24	trastuzumab	B-Drug	['Causes']	[13]
25	treatment	O	['N']	[25]
26	.	O	['N']	[26]
#2752
0	Severe	B	['N']	[0]
1	Raynaud	I	['N']	[1]
2	's	I	['N']	[2]
3	phenomenon	I-Adverse_Effect	['N']	[3]
4	with	O	['N']	[4]
5	yohimbine	B-Drug	['Causes']	[3]
6	therapy	O	['N']	[6]
7	for	O	['N']	[7]
8	erectile	O	['N']	[8]
9	dysfunction	O	['N']	[9]
10	.	O	['N']	[10]
#2753
0	A	O	['N']	[0]
1	65-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	bipolar	O	['N']	[6]
7	disorder	O	['N']	[7]
8	and	O	['N']	[8]
9	complicated	O	['N']	[9]
10	cardiovascular	O	['N']	[10]
11	disease	O	['N']	[11]
12	who	O	['N']	[12]
13	was	O	['N']	[13]
14	on	O	['N']	[14]
15	maintenance	O	['N']	[15]
16	lithium	B-Drug	['Causes']	[21]
17	therapy	O	['N']	[17]
18	developed	O	['N']	[18]
19	a	O	['N']	[19]
20	movement	B	['N']	[20]
21	disorder	I-Adverse_Effect	['N']	[21]
22	following	O	['N']	[22]
23	high	O	['N']	[23]
24	doses	O	['N']	[24]
25	of	O	['N']	[25]
26	trazodone	O	['N']	[26]
27	for	O	['N']	[27]
28	treatment	O	['N']	[28]
29	of	O	['N']	[29]
30	an	O	['N']	[30]
31	acute	O	['N']	[31]
32	depression	O	['N']	[32]
33	.	O	['N']	[33]
#2754
0	Reflex	B	['N']	[0]
1	sympathetic	I	['N']	[1]
2	dystrophy	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	renal	O	['N']	[5]
6	transplanted	O	['N']	[6]
7	patients	O	['N']	[7]
8	under	O	['N']	[8]
9	immunosuppression	O	['N']	[9]
10	with	O	['N']	[10]
11	tacrolimus	B-Drug	['Causes']	[3]
12	.	O	['N']	[12]
#2755
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	interstitial	B	['N']	[6]
7	granulomatous	I	['N']	[7]
8	dermatitis	I-Adverse_Effect	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	darifenacin	B-Drug	['Causes']	[8]
12	.	O	['N']	[12]
#2756
0	The	O	['N']	[0]
1	sub	B	['N']	[1]
2	-	I	['N']	[2]
3	conjunctival	I	['N']	[3]
4	haematoma	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	receiving	O	['N']	[8]
9	warfarin	B-Drug	['Causes']	[4]
10	can	O	['N']	[10]
11	pose	O	['N']	[11]
12	a	O	['N']	[12]
13	significant	O	['N']	[13]
14	management	O	['N']	[14]
15	challenge	O	['N']	[15]
16	.	O	['N']	[16]
#2757
0	Celiprolol	B-Drug	['Causes']	[1]
1	pneumonitis	B-Adverse_Effect	['N']	[1]
2	.	O	['N']	[2]
#2758
0	Carbamazepine	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	systemic	B	['N']	[3]
4	lupus	I	['N']	[4]
5	erythematosus	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#2759
0	Early	O	['N']	[0]
1	overanticoagulation	B-Adverse_Effect	['N']	[1]
2	with	O	['N']	[2]
3	acenocoumarol	B-Drug	['Causes']	[1]
4	due	O	['N']	[4]
5	to	O	['N']	[5]
6	a	O	['N']	[6]
7	genetic	O	['N']	[7]
8	polymorphism	O	['N']	[8]
9	of	O	['N']	[9]
10	cytochrome	O	['N']	[10]
11	P450	O	['N']	[11]
12	CYP2C9	O	['N']	[12]
13	.	O	['N']	[13]
#2760
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	is	O	['N']	[3]
4	the	O	['N']	[4]
5	first	O	['N']	[5]
6	report	O	['N']	[6]
7	of	O	['N']	[7]
8	a	O	['N']	[8]
9	possible	O	['N']	[9]
10	interaction	O	['N']	[10]
11	between	O	['N']	[11]
12	propafenone	B-Drug	['Causes']	[26]
13	and	O	['N']	[13]
14	citalopram	O	['N']	[14]
15	,	O	['N']	[15]
16	which	O	['N']	[16]
17	caused	O	['N']	[17]
18	propafenone	O	['N']	[18]
19	adverse	O	['N']	[19]
20	effects	O	['N']	[20]
21	(	O	['N']	[21]
22	eg	O	['N']	[22]
23	,	O	['N']	[23]
24	dizziness	O	['N']	[24]
25	,	O	['N']	[25]
26	falls	B-Adverse_Effect	['N']	[26]
27	)	O	['N']	[27]
28	and	O	['N']	[28]
29	mimicked	O	['N']	[29]
30	coronary	O	['N']	[30]
31	artery	O	['N']	[31]
32	disease	O	['N']	[32]
33	.	O	['N']	[33]
#2761
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	paper	O	['N']	[2]
3	we	O	['N']	[3]
4	report	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	nimodipine	B-Drug	['Causes']	[13]
9	overdosage	O	['N']	[9]
10	resulting	O	['N']	[10]
11	in	O	['N']	[11]
12	prolonged	B	['N']	[12]
13	hypotension	I-Adverse_Effect	['N']	[13]
14	and	O	['N']	[14]
15	hypoxemia	O	['N']	[15]
16	,	O	['N']	[16]
17	which	O	['N']	[17]
18	was	O	['N']	[18]
19	successfully	O	['N']	[19]
20	treated	O	['N']	[20]
21	with	O	['N']	[21]
22	calcium	O	['N']	[22]
23	gluconate	O	['N']	[23]
24	.	O	['N']	[24]
#2762
0	Hemorrhagic	B	['N']	[0]
1	cystitis	I-Adverse_Effect	['N']	[1]
2	is	O	['N']	[2]
3	a	O	['N']	[3]
4	significant	O	['N']	[4]
5	toxic	O	['N']	[5]
6	effect	O	['N']	[6]
7	of	O	['N']	[7]
8	cyclophosphamide	B-Drug	['Causes']	[1]
9	therapy	O	['N']	[9]
10	.	O	['N']	[10]
#2763
0	A	O	['N']	[0]
1	diagnosis	O	['N']	[1]
2	of	O	['N']	[2]
3	masked	O	['N']	[3]
4	theophylline	B-Drug	['Causes']	[5]
5	poisoning	I-Adverse_Effect	['N']	[5]
6	should	O	['N']	[6]
7	be	O	['N']	[7]
8	considered	O	['N']	[8]
9	in	O	['N']	[9]
10	similar	O	['N']	[10]
11	situations	O	['N']	[11]
12	involving	O	['N']	[12]
13	a	O	['N']	[13]
14	rapid	O	['N']	[14]
15	decrease	O	['N']	[15]
16	of	O	['N']	[16]
17	insulin	O	['N']	[17]
18	requirements	O	['N']	[18]
19	.	O	['N']	[19]
#2764
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	the	O	['N']	[8]
9	acquired	O	['N']	[9]
10	immunodeficiency	O	['N']	[10]
11	syndrome	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	rifampicin	B-Drug	['Causes']	[33]
15	who	O	['N']	[15]
16	had	O	['N']	[16]
17	a	O	['N']	[17]
18	'	O	['N']	[18]
19	normal	O	['N']	[19]
20	'	O	['N']	[20]
21	screening	O	['N']	[21]
22	test	O	['N']	[22]
23	for	O	['N']	[23]
24	adrenal	O	['N']	[24]
25	insufficiency	O	['N']	[25]
26	,	O	['N']	[26]
27	yet	O	['N']	[27]
28	had	O	['N']	[28]
29	clinical	O	['N']	[29]
30	evidence	O	['N']	[30]
31	of	O	['N']	[31]
32	adrenal	B	['N']	[32]
33	failure	I-Adverse_Effect	['N']	[33]
34	.	O	['N']	[34]
#2765
0	Cataracts	B-Adverse_Effect	['N']	[0]
1	induced	O	['N']	[1]
2	by	O	['N']	[2]
3	intermittent	O	['N']	[3]
4	Decadron	B-Drug	['Causes']	[0]
5	used	O	['N']	[5]
6	as	O	['N']	[6]
7	an	O	['N']	[7]
8	antiemetic	O	['N']	[8]
9	.	O	['N']	[9]
#2766
0	Syringotropic	B	['N']	[0]
1	hypersensitivity	I	['N']	[1]
2	reaction	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	infliximab	B-Drug	['Causes']	[2]
6	and	O	['N']	[6]
7	leflunomide	O	['N']	[7]
8	combination	O	['N']	[8]
9	therapy	O	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	child	O	['N']	[12]
13	with	O	['N']	[13]
14	psoriatic	O	['N']	[14]
15	arthritis	O	['N']	[15]
16	.	O	['N']	[16]
#2767
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	There	O	['N']	[2]
3	is	O	['N']	[3]
4	very	O	['N']	[4]
5	little	O	['N']	[5]
6	published	O	['N']	[6]
7	information	O	['N']	[7]
8	regarding	O	['N']	[8]
9	ofloxacin	B-Drug	['Causes']	[14]
10	-	O	['N']	[10]
11	induced	O	['N']	[11]
12	toxic	B	['N']	[12]
13	epidermal	I	['N']	[13]
14	necrolysis	I-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#2768
0	Catatonia	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	disulfiram	B-Drug	['Causes']	[0]
4	therapy	O	['N']	[4]
5	.	O	['N']	[5]
#2769
0	Progressive	B	['N']	[0]
1	interstitial	I	['N']	[1]
2	lung	I	['N']	[2]
3	disease	I-Adverse_Effect	['N']	[3]
4	from	O	['N']	[4]
5	prolonged	O	['N']	[5]
6	methotrexate	B-Drug	['Causes']	[3]
7	therapy	O	['N']	[7]
8	.	O	['N']	[8]
#2770
0	Graft	B	['N']	[0]
1	versus	I	['N']	[1]
2	host	I	['N']	[2]
3	-	I	['N']	[3]
4	like	I	['N']	[4]
5	illness	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	child	O	['N']	[8]
9	with	O	['N']	[9]
10	phenobarbital	B-Drug	['Causes']	[5]
11	hypersensitivity	O	['N']	[11]
12	.	O	['N']	[12]
#2771
0	Although	O	['N']	[0]
1	the	O	['N']	[1]
2	essential	O	['N']	[2]
3	cause	O	['N']	[3]
4	of	O	['N']	[4]
5	PV	B-Adverse_Effect	['N']	[5]
6	is	O	['N']	[6]
7	unclear	O	['N']	[7]
8	,	O	['N']	[8]
9	its	O	['N']	[9]
10	onset	O	['N']	[10]
11	has	O	['N']	[11]
12	occasionally	O	['N']	[12]
13	been	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	drug	O	['N']	[16]
17	therapy	O	['N']	[17]
18	,	O	['N']	[18]
19	in	O	['N']	[19]
20	particular	O	['N']	[20]
21	penicillamine	B-Drug	['Causes']	[5]
22	.	O	['N']	[22]
#2772
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	who	O	['N']	[2]
3	had	O	['N']	[3]
4	experienced	O	['N']	[4]
5	neuroleptic	O	['N']	[5]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	akathisia	B-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	the	O	['N']	[10]
11	past	O	['N']	[11]
12	reported	O	['N']	[12]
13	that	O	['N']	[13]
14	the	O	['N']	[14]
15	symptoms	O	['N']	[15]
16	of	O	['N']	[16]
17	fluoxetine	B-Drug	['Causes']	[8]
18	-	O	['N']	[18]
19	induced	O	['N']	[19]
20	akathisia	O	['N']	[20]
21	were	O	['N']	[21]
22	identical	O	['N']	[22]
23	,	O	['N']	[23]
24	although	O	['N']	[24]
25	somewhat	O	['N']	[25]
26	milder	O	['N']	[26]
27	.	O	['N']	[27]
#2773
0	Ten	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	itraconazole	B-Drug	['Causes']	[31]
4	was	O	['N']	[4]
5	started	O	['N']	[5]
6	,	O	['N']	[6]
7	he	O	['N']	[7]
8	developed	O	['N']	[8]
9	paralytic	O	['N']	[9]
10	ileus	O	['N']	[10]
11	,	O	['N']	[11]
12	neurogenic	O	['N']	[12]
13	bladder	O	['N']	[13]
14	,	O	['N']	[14]
15	mild	O	['N']	[15]
16	left	O	['N']	[16]
17	ptosis	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	absence	O	['N']	[20]
21	of	O	['N']	[21]
22	deep	O	['N']	[22]
23	reflexes	O	['N']	[23]
24	,	O	['N']	[24]
25	with	O	['N']	[25]
26	severe	B	['N']	[26]
27	paralysis	I	['N']	[27]
28	of	I	['N']	[28]
29	the	I	['N']	[29]
30	lower	I	['N']	[30]
31	extremities	I-Adverse_Effect	['N']	[31]
32	and	O	['N']	[32]
33	mild	O	['N']	[33]
34	weakness	O	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	upper	O	['N']	[37]
38	extremities	O	['N']	[38]
39	.	O	['N']	[39]
#2774
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	study	O	['N']	[3]
4	confirmed	O	['N']	[4]
5	that	O	['N']	[5]
6	in	O	['N']	[6]
7	most	O	['N']	[7]
8	patients	O	['N']	[8]
9	MTX	B-Drug	['Causes']	[13]
10	-	O	['N']	[10]
11	induced	O	['N']	[11]
12	liver	B	['N']	[12]
13	cirrhosis	I-Adverse_Effect	['N']	[13]
14	is	O	['N']	[14]
15	not	O	['N']	[15]
16	aggressive	O	['N']	[16]
17	.	O	['N']	[17]
#2775
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	a	O	['N']	[3]
4	large	O	['N']	[4]
5	hydatid	O	['N']	[5]
6	cyst	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	left	O	['N']	[9]
10	lobe	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	liver	O	['N']	[13]
14	developed	O	['N']	[14]
15	metabolic	B	['N']	[15]
16	acidosis	I-Adverse_Effect	['N']	[16]
17	following	O	['N']	[17]
18	rather	O	['N']	[18]
19	liberal	O	['N']	[19]
20	use	O	['N']	[20]
21	of	O	['N']	[21]
22	cetrimide	O	['N']	[22]
23	-	O	['N']	[23]
24	chlorhexidine	B-Drug	['Causes']	[16]
25	solution	O	['N']	[25]
26	as	O	['N']	[26]
27	a	O	['N']	[27]
28	scolicidal	O	['N']	[28]
29	agent	O	['N']	[29]
30	.	O	['N']	[30]
#2776
0	Serious	O	['N']	[0]
1	phenytoin	B-Drug	['Causes']	[3]
2	hypersensitivity	B	['N']	[2]
3	reactions	I-Adverse_Effect	['N']	[3]
4	may	O	['N']	[4]
5	appear	O	['N']	[5]
6	as	O	['N']	[6]
7	dermatologic	O	['N']	[7]
8	,	O	['N']	[8]
9	lymphoid	O	['N']	[9]
10	,	O	['N']	[10]
11	or	O	['N']	[11]
12	hepatic	O	['N']	[12]
13	syndromes	O	['N']	[13]
14	.	O	['N']	[14]
#2777
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	present	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	report	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	granulomatous	O	['N']	[8]
9	reaction	O	['N']	[9]
10	leading	O	['N']	[10]
11	to	O	['N']	[11]
12	urethral	B	['N']	[12]
13	prolapse	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	3	O	['N']	[15]
16	months	O	['N']	[16]
17	after	O	['N']	[17]
18	the	O	['N']	[18]
19	transurethral	O	['N']	[19]
20	injection	O	['N']	[20]
21	of	O	['N']	[21]
22	calcium	B	['N']	[22]
23	hydroxylapatite	I-Drug	['Causes']	[13]
24	.	O	['N']	[24]
#2778
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	chronic	O	['N']	[3]
4	myelomonocytic	O	['N']	[4]
5	leukemia	O	['N']	[5]
6	developed	O	['N']	[6]
7	drug	O	['N']	[7]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	pulmonary	B	['N']	[10]
11	toxicity	I-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	using	O	['N']	[13]
14	low	O	['N']	[14]
15	dose	O	['N']	[15]
16	oral	O	['N']	[16]
17	etoposide	B-Drug	['Causes']	[11]
18	.	O	['N']	[18]
#2779
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Three	O	['N']	[2]
3	patients	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	symptoms	O	['N']	[6]
7	of	O	['N']	[7]
8	inflammatory	B	['N']	[8]
9	bowel	I	['N']	[9]
10	disease	I-Adverse_Effect	['N']	[10]
11	(	O	['N']	[11]
12	IBD	O	['N']	[12]
13	)	O	['N']	[13]
14	during	O	['N']	[14]
15	rofecoxib	B-Drug	['Causes']	[10]
16	exposure	O	['N']	[16]
17	are	O	['N']	[17]
18	described	O	['N']	[18]
19	along	O	['N']	[19]
20	with	O	['N']	[20]
21	pathology	O	['N']	[21]
22	findings	O	['N']	[22]
23	.	O	['N']	[23]
#2780
0	MTX	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hepatic	B	['N']	[3]
4	injury	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	liver	O	['N']	[6]
7	enzyme	O	['N']	[7]
8	elevations	O	['N']	[8]
9	have	O	['N']	[9]
10	been	O	['N']	[10]
11	demonstrated	O	['N']	[11]
12	after	O	['N']	[12]
13	treatment	O	['N']	[13]
14	of	O	['N']	[14]
15	leukemia	O	['N']	[15]
16	,	O	['N']	[16]
17	gestational	O	['N']	[17]
18	disease	O	['N']	[18]
19	and	O	['N']	[19]
20	during	O	['N']	[20]
21	treatment	O	['N']	[21]
22	of	O	['N']	[22]
23	psoriasis	O	['N']	[23]
24	and	O	['N']	[24]
25	rheumatoid	O	['N']	[25]
26	arthritis	O	['N']	[26]
27	.	O	['N']	[27]
#2781
0	In	O	['N']	[0]
1	both	O	['N']	[1]
2	cases	O	['N']	[2]
3	,	O	['N']	[3]
4	high	O	['N']	[4]
5	fever	O	['N']	[5]
6	,	O	['N']	[6]
7	skin	O	['N']	[7]
8	rash	O	['N']	[8]
9	,	O	['N']	[9]
10	liver	O	['N']	[10]
11	dysfunction	O	['N']	[11]
12	and	O	['N']	[12]
13	atypical	B	['N']	[13]
14	lymphocytosis	I-Adverse_Effect	['N']	[14]
15	developed	O	['N']	[15]
16	3	O	['N']	[16]
17	weeks	O	['N']	[17]
18	after	O	['N']	[18]
19	initiating	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	SASP	B-Drug	['Causes']	[14]
23	.	O	['N']	[23]
#2782
0	With	O	['N']	[0]
1	the	O	['N']	[1]
2	negative	O	['N']	[2]
3	viral	O	['N']	[3]
4	serologies	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	clinical	O	['N']	[7]
8	picture	O	['N']	[8]
9	was	O	['N']	[9]
10	most	O	['N']	[10]
11	consistent	O	['N']	[11]
12	with	O	['N']	[12]
13	an	O	['N']	[13]
14	infectious	O	['N']	[14]
15	mononucleosis	B	['N']	[15]
16	-	I	['N']	[16]
17	like	I	['N']	[17]
18	syndrome	I-Adverse_Effect	['N']	[18]
19	produced	O	['N']	[19]
20	by	O	['N']	[20]
21	the	O	['N']	[21]
22	minocycline	-	['N']	[22]
23	ingestion	O	['N']	[23]
24	.	O	['N']	[24]
#2783
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	required	O	['N']	[2]
3	nursing	O	['N']	[3]
4	home	O	['N']	[4]
5	placement	O	['N']	[5]
6	and	O	['N']	[6]
7	a	O	['N']	[7]
8	feeding	B	['N']	[8]
9	gastrostomy	I-Adverse_Effect	['N']	[9]
10	as	O	['N']	[10]
11	a	O	['N']	[11]
12	result	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	worsening	O	['N']	[15]
16	parkinsonism	O	['N']	[16]
17	during	O	['N']	[17]
18	risperidone	B-Drug	['Causes']	[9]
19	treatment	O	['N']	[19]
20	,	O	['N']	[20]
21	but	O	['N']	[21]
22	was	O	['N']	[22]
23	able	O	['N']	[23]
24	to	O	['N']	[24]
25	return	O	['N']	[25]
26	home	O	['N']	[26]
27	and	O	['N']	[27]
28	have	O	['N']	[28]
29	the	O	['N']	[29]
30	gastrostomy	O	['N']	[30]
31	removed	O	['N']	[31]
32	after	O	['N']	[32]
33	switching	O	['N']	[33]
34	from	O	['N']	[34]
35	risperidone	O	['N']	[35]
36	to	O	['N']	[36]
37	clozapine	O	['N']	[37]
38	.	O	['N']	[38]
#2784
0	The	O	['N']	[0]
1	hearing	O	['N']	[1]
2	impairment	O	['N']	[2]
3	and	O	['N']	[3]
4	tinnitus	B-Adverse_Effect	['N']	[4]
5	were	O	['N']	[5]
6	gradually	O	['N']	[6]
7	reduced	O	['N']	[7]
8	after	O	['N']	[8]
9	PTU	B-Drug	['Causes']	[4]
10	withdrawal	O	['N']	[10]
11	and	O	['N']	[11]
12	corticosteroid	O	['N']	[12]
13	and	O	['N']	[13]
14	azathioprine	O	['N']	[14]
15	treatment	O	['N']	[15]
16	.	O	['N']	[16]
#2785
0	Adult	B	['N']	[0]
1	respiratory	I	['N']	[1]
2	distress	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	treatment	O	['N']	[5]
6	with	O	['N']	[6]
7	pegylated	O	['N']	[7]
8	interferon	O	['N']	[8]
9	alpha-2a	O	['N']	[9]
10	and	O	['N']	[10]
11	ribavirin	B-Drug	['Causes']	[3]
12	.	O	['N']	[12]
#2786
0	Despite	O	['N']	[0]
1	a	O	['N']	[1]
2	response	O	['N']	[2]
3	of	O	['N']	[3]
4	the	O	['N']	[4]
5	meningeal	O	['N']	[5]
6	tumor	O	['N']	[6]
7	the	O	['N']	[7]
8	patient	O	['N']	[8]
9	developed	O	['N']	[9]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	third	O	['N']	[12]
13	week	O	['N']	[13]
14	of	O	['N']	[14]
15	MTX	O	['N']	[15]
16	treatment	O	['N']	[16]
17	a	O	['N']	[17]
18	progressive	B	['N']	[18]
19	visual	I	['N']	[19]
20	loss	I-Adverse_Effect	['N']	[20]
21	and	O	['N']	[21]
22	loss	O	['N']	[22]
23	of	O	['N']	[23]
24	consciousness	O	['N']	[24]
25	which	O	['N']	[25]
26	worsened	O	['N']	[26]
27	during	O	['N']	[27]
28	subsequent	O	['N']	[28]
29	Ara	B	['N']	[29]
30	-	I	['N']	[30]
31	C	I-Drug	['Causes']	[20]
32	treatment	O	['N']	[32]
33	and	O	['N']	[33]
34	led	O	['N']	[34]
35	to	O	['N']	[35]
36	death	O	['N']	[36]
37	within	O	['N']	[37]
38	3	O	['N']	[38]
39	weeks	O	['N']	[39]
40	.	O	['N']	[40]
#2787
0	Relapse	B	['N']	[0]
1	in	I	['N']	[1]
2	the	I	['N']	[2]
3	external	I	['N']	[3]
4	auditory	I	['N']	[4]
5	canal	I	['N']	[5]
6	of	I	['N']	[6]
7	acute	I	['N']	[7]
8	promyelocytic	I	['N']	[8]
9	leukemia	I-Adverse_Effect	['N']	[9]
10	after	O	['N']	[10]
11	treatment	O	['N']	[11]
12	with	O	['N']	[12]
13	all	B	['N']	[13]
14	-	I	['N']	[14]
15	trans	I	['N']	[15]
16	retinoic	I	['N']	[16]
17	acid	I-Drug	['Causes']	[9]
18	.	O	['N']	[18]
#2788
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	main	O	['N']	[3]
4	adverse	O	['N']	[4]
5	effects	O	['N']	[5]
6	of	O	['N']	[6]
7	leflunomide	B-Drug	['Causes']	[18]
8	consist	O	['N']	[8]
9	of	O	['N']	[9]
10	diarrhea	O	['N']	[10]
11	,	O	['N']	[11]
12	nausea	O	['N']	[12]
13	,	O	['N']	[13]
14	liver	O	['N']	[14]
15	enzyme	O	['N']	[15]
16	elevation	O	['N']	[16]
17	,	O	['N']	[17]
18	hypertension	B-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	alopecia	O	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	allergic	O	['N']	[23]
24	skin	O	['N']	[24]
25	reactions	O	['N']	[25]
26	.	O	['N']	[26]
#2789
0	The	O	['N']	[0]
1	other	O	['N']	[1]
2	patient	O	['N']	[2]
3	developed	O	['N']	[3]
4	transient	B	['N']	[4]
5	intraoperative	I	['N']	[5]
6	hypertension	I-Adverse_Effect	['N']	[6]
7	immediately	O	['N']	[7]
8	after	O	['N']	[8]
9	inadvertent	O	['N']	[9]
10	submucosal	O	['N']	[10]
11	injection	O	['N']	[11]
12	of	O	['N']	[12]
13	concentrated	O	['N']	[13]
14	epinephrine	B-Drug	['Causes']	[6]
15	.	O	['N']	[15]
#2790
0	Temsirolimus	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	glomerulopathy	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#2791
0	Here	O	['N']	[0]
1	we	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	Crohn	O	['N']	[6]
7	's	O	['N']	[7]
8	disease	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	a	O	['N']	[11]
12	severe	B	['N']	[12]
13	infliximab	B-Drug	['Causes']	[15]
14	infusion	I	['N']	[14]
15	reaction	I-Adverse_Effect	['N']	[15]
16	(	O	['N']	[16]
17	IIR	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	complicated	O	['N']	[20]
21	1	O	['N']	[21]
22	day	O	['N']	[22]
23	later	O	['N']	[23]
24	by	O	['N']	[24]
25	severe	O	['N']	[25]
26	swelling	O	['N']	[26]
27	of	O	['N']	[27]
28	the	O	['N']	[28]
29	forearm	O	['N']	[29]
30	and	O	['N']	[30]
31	hand	O	['N']	[31]
32	ipsilateral	O	['N']	[32]
33	to	O	['N']	[33]
34	the	O	['N']	[34]
35	site	O	['N']	[35]
36	of	O	['N']	[36]
37	infliximab	O	['N']	[37]
38	infusion	O	['N']	[38]
39	.	O	['N']	[39]
#2792
0	Both	O	['N']	[0]
1	patients	O	['N']	[1]
2	were	O	['N']	[2]
3	then	O	['N']	[3]
4	treated	O	['N']	[4]
5	with	O	['N']	[5]
6	a	O	['N']	[6]
7	carboplatin	O	['N']	[7]
8	alternative	O	['N']	[8]
9	to	O	['N']	[9]
10	cisplatin	B-Drug	['Causes']	[24]
11	in	O	['N']	[11]
12	the	O	['N']	[12]
13	following	O	['N']	[13]
14	courses	O	['N']	[14]
15	,	O	['N']	[15]
16	which	O	['N']	[16]
17	resulted	O	['N']	[17]
18	in	O	['N']	[18]
19	neither	O	['N']	[19]
20	a	O	['N']	[20]
21	relapse	O	['N']	[21]
22	of	O	['N']	[22]
23	the	O	['N']	[23]
24	colitis	B-Adverse_Effect	['N']	[24]
25	nor	O	['N']	[25]
26	a	O	['N']	[26]
27	recurrence	O	['N']	[27]
28	of	O	['N']	[28]
29	the	O	['N']	[29]
30	malignancies	O	['N']	[30]
31	up	O	['N']	[31]
32	to	O	['N']	[32]
33	this	O	['N']	[33]
34	time	O	['N']	[34]
35	.	O	['N']	[35]
#2793
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Cicatrization	O	['N']	[2]
3	in	O	['N']	[3]
4	the	O	['N']	[4]
5	substantia	O	['N']	[5]
6	propria	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	conjunctiva	O	['N']	[9]
10	by	O	['N']	[10]
11	excessive	O	['N']	[11]
12	lymphocytic	O	['N']	[12]
13	infiltration	O	['N']	[13]
14	after	O	['N']	[14]
15	topically	O	['N']	[15]
16	administered	O	['N']	[16]
17	antiglaucoma	O	['N']	[17]
18	drugs	O	['N']	[18]
19	including	O	['N']	[19]
20	dipivefrin	B-Drug	['Causes']	[28]
21	is	O	['N']	[21]
22	a	O	['N']	[22]
23	possible	O	['N']	[23]
24	mechanism	O	['N']	[24]
25	of	O	['N']	[25]
26	action	O	['N']	[26]
27	for	O	['N']	[27]
28	entropion	B-Adverse_Effect	['N']	[28]
29	.	O	['N']	[29]
#2794
0	Renal	B	['N']	[0]
1	failure	I-Adverse_Effect	['N']	[1]
2	appeared	O	['N']	[2]
3	8	O	['N']	[3]
4	to	O	['N']	[4]
5	17	O	['N']	[5]
6	days	O	['N']	[6]
7	after	O	['N']	[7]
8	beginning	O	['N']	[8]
9	gentamicin	B-Drug	['Causes']	[1]
10	therapy	O	['N']	[10]
11	and	O	['N']	[11]
12	was	O	['N']	[12]
13	characterized	O	['N']	[13]
14	by	O	['N']	[14]
15	creatinine	O	['N']	[15]
16	clearances	O	['N']	[16]
17	4	O	['N']	[17]
18	to	O	['N']	[18]
19	10	O	['N']	[19]
20	ml	O	['N']	[20]
21	/	O	['N']	[21]
22	min	O	['N']	[22]
23	,	O	['N']	[23]
24	urine	O	['N']	[24]
25	to	O	['N']	[25]
26	plasma	O	['N']	[26]
27	creatinine	O	['N']	[27]
28	ratios	O	['N']	[28]
29	less	O	['N']	[29]
30	than	O	['N']	[30]
31	20	O	['N']	[31]
32	,	O	['N']	[32]
33	urinary	O	['N']	[33]
34	sodium	O	['N']	[34]
35	concentrations	O	['N']	[35]
36	16	O	['N']	[36]
37	to	O	['N']	[37]
38	60	O	['N']	[38]
39	mEq	O	['N']	[39]
40	/	O	['N']	[40]
41	liter	O	['N']	[41]
42	,	O	['N']	[42]
43	proteinuria	O	['N']	[43]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	cylindruria	O	['N']	[46]
47	.	O	['N']	[47]
#2795
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	two	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	fixed	B	['N']	[7]
8	drug	I	['N']	[8]
9	eruption	I-Adverse_Effect	['N']	[9]
10	induced	O	['N']	[10]
11	by	O	['N']	[11]
12	methylphenidate	B-Drug	['Causes']	[9]
13	.	O	['N']	[13]
#2796
0	AIM	O	['N']	[0]
1	:	O	['N']	[1]
2	Report	O	['N']	[2]
3	of	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	woman	O	['N']	[8]
9	patient	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	celiac	B	['N']	[12]
13	disease	I-Adverse_Effect	['N']	[13]
14	after	O	['N']	[14]
15	pegylated	O	['N']	[15]
16	interferon	O	['N']	[16]
17	alpha-2a	O	['N']	[17]
18	and	O	['N']	[18]
19	ribavirin	B-Drug	['Causes']	[13]
20	use	O	['N']	[20]
21	for	O	['N']	[21]
22	chronic	O	['N']	[22]
23	hepatitis	O	['N']	[23]
24	C.	O	['N']	[24]
#2797
0	This	O	['N']	[0]
1	panic	B	['N']	[1]
2	anxiety	I-Adverse_Effect	['N']	[2]
3	was	O	['N']	[3]
4	not	O	['N']	[4]
5	relieved	O	['N']	[5]
6	by	O	['N']	[6]
7	taking	O	['N']	[7]
8	etizolam	O	['N']	[8]
9	and	O	['N']	[9]
10	flunitrazepam	O	['N']	[10]
11	again	O	['N']	[11]
12	,	O	['N']	[12]
13	but	O	['N']	[13]
14	subsided	O	['N']	[14]
15	rapidly	O	['N']	[15]
16	by	O	['N']	[16]
17	the	O	['N']	[17]
18	re	O	['N']	[18]
19	-	O	['N']	[19]
20	administration	O	['N']	[20]
21	of	O	['N']	[21]
22	mianserin	B-Drug	['Causes']	[2]
23	30	O	['N']	[23]
24	mg	O	['N']	[24]
25	/	O	['N']	[25]
26	day	O	['N']	[26]
27	,	O	['N']	[27]
28	and	O	['N']	[28]
29	because	O	['N']	[29]
30	of	O	['N']	[30]
31	that	O	['N']	[31]
32	the	O	['N']	[32]
33	depressive	O	['N']	[33]
34	symptom	O	['N']	[34]
35	also	O	['N']	[35]
36	disappeared	O	['N']	[36]
37	.	O	['N']	[37]
#2798
0	The	O	['N']	[0]
1	mechanism	O	['N']	[1]
2	of	O	['N']	[2]
3	RTA	B-Adverse_Effect	['N']	[3]
4	induced	O	['N']	[4]
5	by	O	['N']	[5]
6	FK506	B-Drug	['Causes']	[3]
7	has	O	['N']	[7]
8	not	O	['N']	[8]
9	yet	O	['N']	[9]
10	been	O	['N']	[10]
11	clearly	O	['N']	[11]
12	elucidated	O	['N']	[12]
13	.	O	['N']	[13]
#2799
0	A	O	['N']	[0]
1	44-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	is	O	['N']	[5]
6	described	O	['N']	[6]
7	in	O	['N']	[7]
8	whom	O	['N']	[8]
9	amiodarone	B-Drug	['Causes']	[23]
10	,	O	['N']	[10]
11	disopyramide	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	quinidine	O	['N']	[14]
15	,	O	['N']	[15]
16	administered	O	['N']	[16]
17	alone	O	['N']	[17]
18	separately	O	['N']	[18]
19	,	O	['N']	[19]
20	induced	O	['N']	[20]
21	atypical	B	['N']	[21]
22	ventricular	I	['N']	[22]
23	tachycardia	I-Adverse_Effect	['N']	[23]
24	(	O	['N']	[24]
25	AVT	O	['N']	[25]
26	,	O	['N']	[26]
27	torsade	O	['N']	[27]
28	de	O	['N']	[28]
29	pointes	O	['N']	[29]
30	)	O	['N']	[30]
31	.	O	['N']	[31]
#2800
0	One	O	['N']	[0]
1	week	O	['N']	[1]
2	after	O	['N']	[2]
3	the	O	['N']	[3]
4	initial	O	['N']	[4]
5	-	O	['N']	[5]
6	dose	O	['N']	[6]
7	of	O	['N']	[7]
8	adalimumab	B-Drug	['Causes']	[32]
9	(	O	['N']	[9]
10	160	O	['N']	[10]
11	mg	O	['N']	[11]
12	)	O	['N']	[12]
13	,	O	['N']	[13]
14	which	O	['N']	[14]
15	was	O	['N']	[15]
16	initiated	O	['N']	[16]
17	due	O	['N']	[17]
18	to	O	['N']	[18]
19	an	O	['N']	[19]
20	acute	O	['N']	[20]
21	exacerbation	O	['N']	[21]
22	of	O	['N']	[22]
23	Crohn	O	['N']	[23]
24	's	O	['N']	[24]
25	disease	O	['N']	[25]
26	,	O	['N']	[26]
27	the	O	['N']	[27]
28	patient	O	['N']	[28]
29	developed	O	['N']	[29]
30	a	O	['N']	[30]
31	fulminant	B	['N']	[31]
32	cardiomyopathy	I-Adverse_Effect	['N']	[32]
33	.	O	['N']	[33]
#2801
0	Bleomycin	O	['N']	[0]
1	and	O	['N']	[1]
2	cyclophosphamide	B-Drug	['Causes']	[6]
3	toxicity	O	['N']	[3]
4	simulating	O	['N']	[4]
5	metastatic	B	['N']	[5]
6	nodules	I-Adverse_Effect	['N']	[6]
7	to	O	['N']	[7]
8	the	O	['N']	[8]
9	lungs	O	['N']	[9]
10	in	O	['N']	[10]
11	childhood	O	['N']	[11]
12	cancer	O	['N']	[12]
13	.	O	['N']	[13]
#2802
0	Early	O	['N']	[0]
1	-	O	['N']	[1]
2	onset	O	['N']	[2]
3	pentamidine	B-Drug	['Causes']	[13]
4	-	O	['N']	[4]
5	associated	O	['N']	[5]
6	second	O	['N']	[6]
7	-	O	['N']	[7]
8	degree	O	['N']	[8]
9	heart	O	['N']	[9]
10	block	O	['N']	[10]
11	and	O	['N']	[11]
12	sinus	B	['N']	[12]
13	bradycardia	I-Adverse_Effect	['N']	[13]
14	:	O	['N']	[14]
15	case	O	['N']	[15]
16	report	O	['N']	[16]
17	and	O	['N']	[17]
18	review	O	['N']	[18]
19	of	O	['N']	[19]
20	the	O	['N']	[20]
21	literature	O	['N']	[21]
22	.	O	['N']	[22]
#2803
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	three	O	['N']	[3]
4	cases	O	['N']	[4]
5	wherein	O	['N']	[5]
6	treatment	O	['N']	[6]
7	of	O	['N']	[7]
8	dexmedetomidine	O	['N']	[8]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	bradycardia	O	['N']	[11]
12	with	O	['N']	[12]
13	i.v	O	['N']	[13]
14	.	O	['N']	[14]
15	glycopyrrolate	B-Drug	['Causes']	[39]
16	(	O	['N']	[16]
17	5.0	O	['N']	[17]
18	microg	O	['N']	[18]
19	/	O	['N']	[19]
20	kg	O	['N']	[20]
21	)	O	['N']	[21]
22	not	O	['N']	[22]
23	only	O	['N']	[23]
24	resulting	O	['N']	[24]
25	in	O	['N']	[25]
26	resolution	O	['N']	[26]
27	of	O	['N']	[27]
28	bradycardia	O	['N']	[28]
29	but	O	['N']	[29]
30	also	O	['N']	[30]
31	resulting	O	['N']	[31]
32	in	O	['N']	[32]
33	an	O	['N']	[33]
34	exaggerated	B	['N']	[34]
35	increase	I	['N']	[35]
36	of	I	['N']	[36]
37	arterial	I	['N']	[37]
38	blood	I	['N']	[38]
39	pressure	I-Adverse_Effect	['N']	[39]
40	.	O	['N']	[40]
#2804
0	The	O	['N']	[0]
1	concomitant	O	['N']	[1]
2	use	O	['N']	[2]
3	,	O	['N']	[3]
4	however	O	['N']	[4]
5	,	O	['N']	[5]
6	of	O	['N']	[6]
7	colchicine	B-Drug	['Causes']	[19]
8	and	O	['N']	[8]
9	statin	O	['N']	[9]
10	has	O	['N']	[10]
11	been	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	the	O	['N']	[14]
15	rapid	O	['N']	[15]
16	onset	O	['N']	[16]
17	of	O	['N']	[17]
18	muscle	B	['N']	[18]
19	weakness	I-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#2805
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	two	O	['N']	[2]
3	women	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	HUS	B-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	MMC	B-Drug	['Causes']	[6]
9	therapy	O	['N']	[9]
10	and	O	['N']	[10]
11	presented	O	['N']	[11]
12	massive	O	['N']	[12]
13	pulmonary	O	['N']	[13]
14	bleeding	O	['N']	[14]
15	.	O	['N']	[15]
#2806
0	A	O	['N']	[0]
1	35-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	seropositive	O	['N']	[6]
7	rheumatoid	O	['N']	[7]
8	arthritis	O	['N']	[8]
9	developed	O	['N']	[9]
10	selective	O	['N']	[10]
11	IgA	B	['N']	[11]
12	deficiency	I-Adverse_Effect	['N']	[12]
13	during	O	['N']	[13]
14	treatment	O	['N']	[14]
15	with	O	['N']	[15]
16	fenclofenac	B-Drug	['Causes']	[12]
17	.	O	['N']	[17]
#2807
0	Nephrotic	B	['N']	[0]
1	syndrome	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	a	O	['N']	[3]
4	multiple	O	['N']	[4]
5	sclerosis	O	['N']	[5]
6	patient	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	interferon	B	['N']	[9]
10	beta	I	['N']	[10]
11	1a	I-Drug	['Causes']	[1]
12	.	O	['N']	[12]
#2808
0	An	O	['N']	[0]
1	83-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	receiving	O	['N']	[5]
6	glipizide	B-Drug	['Dosage']	[8]
7	10	B	['N']	[7]
8	mg	I-Dose	['N']	[8]
9	bid	O	['N']	[9]
10	developed	O	['N']	[10]
11	symptomatic	O	['N']	[11]
12	hypoglycemia	O	['N']	[12]
13	within	O	['N']	[13]
14	three	O	['N']	[14]
15	days	O	['N']	[15]
16	of	O	['N']	[16]
17	adding	O	['N']	[17]
18	trimethoprim	O	['N']	[18]
19	/	O	['N']	[19]
20	sulfamethoxazole	O	['N']	[20]
21	(	O	['N']	[21]
22	TMP	O	['N']	[22]
23	/	O	['N']	[23]
24	SMX	O	['N']	[24]
25	)	O	['N']	[25]
26	to	O	['N']	[26]
27	his	O	['N']	[27]
28	regimen	O	['N']	[28]
29	.	O	['N']	[29]
#2809
0	She	O	['N']	[0]
1	continued	O	['N']	[1]
2	to	O	['N']	[2]
3	receive	O	['N']	[3]
4	regular	O	['N']	[4]
5	insulin	B-Drug	['Causes']	[18]
6	4	O	['N']	[6]
7	times	O	['N']	[7]
8	per	O	['N']	[8]
9	day	O	['N']	[9]
10	over	O	['N']	[10]
11	the	O	['N']	[11]
12	following	O	['N']	[12]
13	3	O	['N']	[13]
14	years	O	['N']	[14]
15	with	O	['N']	[15]
16	only	O	['N']	[16]
17	occasional	O	['N']	[17]
18	hives	B-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#2810
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	continued	O	['N']	[2]
3	to	O	['N']	[3]
4	have	O	['N']	[4]
5	fever	O	['N']	[5]
6	and	O	['N']	[6]
7	autonomic	B	['N']	[7]
8	instability	I-Adverse_Effect	['N']	[8]
9	without	O	['N']	[9]
10	evidence	O	['N']	[10]
11	of	O	['N']	[11]
12	infection	O	['N']	[12]
13	which	O	['N']	[13]
14	entirely	O	['N']	[14]
15	resolved	O	['N']	[15]
16	within	O	['N']	[16]
17	24	O	['N']	[17]
18	hours	O	['N']	[18]
19	of	O	['N']	[19]
20	reinstitution	O	['N']	[20]
21	of	O	['N']	[21]
22	full	O	['N']	[22]
23	preadmission	O	['N']	[23]
24	dosing	O	['N']	[24]
25	of	O	['N']	[25]
26	oral	O	['N']	[26]
27	baclofen	B-Drug	['Causes']	[8]
28	.	O	['N']	[28]
#2811
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	Ritalin	B-Drug	['Causes']	[8]
6	-	O	['N']	[6]
7	associated	O	['N']	[7]
8	cataract	B-Adverse_Effect	['N']	[8]
9	and	O	['N']	[9]
10	glaucoma	O	['N']	[10]
11	.	O	['N']	[11]
#2812
0	We	O	['N']	[0]
1	speculate	O	['N']	[1]
2	that	O	['N']	[2]
3	platelet	O	['N']	[3]
4	activation	O	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	pFVIII	B-Drug	['Causes']	[12]
8	may	O	['N']	[8]
9	have	O	['N']	[9]
10	contributed	O	['N']	[10]
11	to	O	['N']	[11]
12	thrombosis	B-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	suggest	O	['N']	[14]
15	that	O	['N']	[15]
16	pFVIII	O	['N']	[16]
17	be	O	['N']	[17]
18	used	O	['N']	[18]
19	with	O	['N']	[19]
20	caution	O	['N']	[20]
21	in	O	['N']	[21]
22	elderly	O	['N']	[22]
23	patients	O	['N']	[23]
24	with	O	['N']	[24]
25	pre	O	['N']	[25]
26	-	O	['N']	[26]
27	existing	O	['N']	[27]
28	cardiovascular	O	['N']	[28]
29	risk	O	['N']	[29]
30	factors	O	['N']	[30]
31	.	O	['N']	[31]
#2813
0	Pulmonary	O	['N']	[0]
1	eosinophilia	O	['N']	[1]
2	or	O	['N']	[2]
3	granulomas	O	['N']	[3]
4	,	O	['N']	[4]
5	classically	O	['N']	[5]
6	seen	O	['N']	[6]
7	in	O	['N']	[7]
8	previously	O	['N']	[8]
9	reported	O	['N']	[9]
10	cases	O	['N']	[10]
11	of	O	['N']	[11]
12	methotrexate	B-Drug	['Causes']	[13]
13	pneumonitis	B-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	were	O	['N']	[15]
16	not	O	['N']	[16]
17	observed	O	['N']	[17]
18	.	O	['N']	[18]
#2814
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	a	O	['N']	[2]
3	large	O	['N']	[3]
4	case	O	['N']	[4]
5	-	O	['N']	[5]
6	control	O	['N']	[6]
7	study	O	['N']	[7]
8	included	O	['N']	[8]
9	three	O	['N']	[9]
10	cases	O	['N']	[10]
11	of	O	['N']	[11]
12	either	O	['N']	[12]
13	Stevens	B	['N']	[13]
14	-	I	['N']	[14]
15	Johnson	I	['N']	[15]
16	syndrome	I-Adverse_Effect	['N']	[16]
17	or	O	['N']	[17]
18	toxic	O	['N']	[18]
19	epidermal	O	['N']	[19]
20	necrolysis	O	['N']	[20]
21	associated	O	['N']	[21]
22	with	O	['N']	[22]
23	ofloxacin	B-Drug	['Causes']	[16]
24	use	O	['N']	[24]
25	,	O	['N']	[25]
26	but	O	['N']	[26]
27	no	O	['N']	[27]
28	details	O	['N']	[28]
29	of	O	['N']	[29]
30	the	O	['N']	[30]
31	cases	O	['N']	[31]
32	were	O	['N']	[32]
33	given	O	['N']	[33]
34	.	O	['N']	[34]
#2815
0	Restless	O	['N']	[0]
1	legs	O	['N']	[1]
2	syndrome	O	['N']	[2]
3	and	O	['N']	[3]
4	periodic	B	['N']	[4]
5	limb	I	['N']	[5]
6	movements	I	['N']	[6]
7	during	I	['N']	[7]
8	sleep	I-Adverse_Effect	['N']	[8]
9	probably	O	['N']	[9]
10	associated	O	['N']	[10]
11	with	O	['N']	[11]
12	olanzapine	B-Drug	['Causes']	[8]
13	.	O	['N']	[13]
#2816
0	Acute	B	['N']	[0]
1	syphilitic	I	['N']	[1]
2	posterior	I	['N']	[2]
3	placoid	I	['N']	[3]
4	chorioretinitis	I-Adverse_Effect	['N']	[4]
5	following	O	['N']	[5]
6	intravitreal	O	['N']	[6]
7	triamcinolone	B	['N']	[7]
8	acetonide	I-Drug	['Causes']	[4]
9	injection	O	['N']	[9]
10	.	O	['N']	[10]
#2817
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	Carbamazepine	B	['N']	[7]
8	toxicity	I-Adverse_Effect	['N']	[8]
9	following	O	['N']	[9]
10	the	O	['N']	[10]
11	administration	O	['N']	[11]
12	of	O	['N']	[12]
13	Oxybutynin	O	['N']	[13]
14	and	O	['N']	[14]
15	Dantrolene	B-Drug	['Causes']	[8]
16	.	O	['N']	[16]
#2818
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	fatal	B-Adverse_Effect	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	subacute	O	['N']	[6]
7	methanol	B-Drug	['Causes']	[3]
8	toxicity	O	['N']	[8]
9	with	O	['N']	[9]
10	associated	O	['N']	[10]
11	diffuse	O	['N']	[11]
12	brain	O	['N']	[12]
13	involvement	O	['N']	[13]
14	,	O	['N']	[14]
15	including	O	['N']	[15]
16	bilateral	O	['N']	[16]
17	putaminal	O	['N']	[17]
18	necrosis	O	['N']	[18]
19	and	O	['N']	[19]
20	cerebral	O	['N']	[20]
21	edema	O	['N']	[21]
22	with	O	['N']	[22]
23	ventricular	O	['N']	[23]
24	compression	O	['N']	[24]
25	.	O	['N']	[25]
#2819
0	Since	O	['N']	[0]
1	recent	O	['N']	[1]
2	studies	O	['N']	[2]
3	have	O	['N']	[3]
4	reported	O	['N']	[4]
5	no	O	['N']	[5]
6	negative	O	['N']	[6]
7	interactions	O	['N']	[7]
8	with	O	['N']	[8]
9	concurrent	O	['N']	[9]
10	use	O	['N']	[10]
11	,	O	['N']	[11]
12	we	O	['N']	[12]
13	here	O	['N']	[13]
14	report	O	['N']	[14]
15	three	O	['N']	[15]
16	cases	O	['N']	[16]
17	(	O	['N']	[17]
18	one	O	['N']	[18]
19	case	O	['N']	[19]
20	of	O	['N']	[20]
21	a	O	['N']	[21]
22	prolonged	O	['N']	[22]
23	seizure	O	['N']	[23]
24	,	O	['N']	[24]
25	a	O	['N']	[25]
26	serotonin	O	['N']	[26]
27	syndrome	O	['N']	[27]
28	and	O	['N']	[28]
29	a	O	['N']	[29]
30	focal	B	['N']	[30]
31	seizure	I-Adverse_Effect	['N']	[31]
32	)	O	['N']	[32]
33	of	O	['N']	[33]
34	severe	O	['N']	[34]
35	lithium	B-Drug	['Causes']	[31]
36	-	O	['N']	[36]
37	induced	O	['N']	[37]
38	side	O	['N']	[38]
39	effects	O	['N']	[39]
40	while	O	['N']	[40]
41	patients	O	['N']	[41]
42	underwent	O	['N']	[42]
43	ECT	O	['N']	[43]
44	without	O	['N']	[44]
45	complications	O	['N']	[45]
46	and	O	['N']	[46]
47	lithium	O	['N']	[47]
48	serum	O	['N']	[48]
49	levels	O	['N']	[49]
50	were	O	['N']	[50]
51	still	O	['N']	[51]
52	subtherapeutic	O	['N']	[52]
53	.	O	['N']	[53]
#2820
0	Eighty	O	['N']	[0]
1	-	O	['N']	[1]
2	two	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	various	O	['N']	[5]
6	malignancies	O	['N']	[6]
7	who	O	['N']	[7]
8	received	O	['N']	[8]
9	imipenem	O	['N']	[9]
10	/	O	['N']	[10]
11	cilastatin	B-Drug	['Causes']	[16]
12	143	O	['N']	[12]
13	times	O	['N']	[13]
14	for	O	['N']	[14]
15	neutropenic	B	['N']	[15]
16	fever	I-Adverse_Effect	['N']	[16]
17	between	O	['N']	[17]
18	March	O	['N']	[18]
19	1994	O	['N']	[19]
20	and	O	['N']	[20]
21	October	O	['N']	[21]
22	1999	O	['N']	[22]
23	in	O	['N']	[23]
24	Department	O	['N']	[24]
25	of	O	['N']	[25]
26	Pediatric	O	['N']	[26]
27	Oncology	O	['N']	[27]
28	,	O	['N']	[28]
29	Gazi	O	['N']	[29]
30	University	O	['N']	[30]
31	,	O	['N']	[31]
32	were	O	['N']	[32]
33	identified	O	['N']	[33]
34	.	O	['N']	[34]
#2821
0	Hypersensitivity	B	['N']	[0]
1	reaction	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	chloramphenicol	B-Drug	['Causes']	[1]
4	administration	O	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	typhoid	O	['N']	[9]
10	fever	O	['N']	[10]
11	.	O	['N']	[11]
#2822
0	We	O	['N']	[0]
1	have	O	['N']	[1]
2	successfully	O	['N']	[2]
3	overcome	O	['N']	[3]
4	severe	B	['N']	[4]
5	neutropenia	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	an	O	['N']	[7]
8	RA	O	['N']	[8]
9	patient	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	gold	B-Drug	['Causes']	[5]
13	salts	O	['N']	[13]
14	,	O	['N']	[14]
15	using	O	['N']	[15]
16	granulocyte	O	['N']	[16]
17	colony	O	['N']	[17]
18	-	O	['N']	[18]
19	stimulating	O	['N']	[19]
20	factor	O	['N']	[20]
21	(	O	['N']	[21]
22	G	O	['N']	[22]
23	-	O	['N']	[23]
24	CSF	O	['N']	[24]
25	)	O	['N']	[25]
26	,	O	['N']	[26]
27	reducing	O	['N']	[27]
28	the	O	['N']	[28]
29	duration	O	['N']	[29]
30	of	O	['N']	[30]
31	neutropenia	O	['N']	[31]
32	and	O	['N']	[32]
33	risk	O	['N']	[33]
34	of	O	['N']	[34]
35	infection	O	['N']	[35]
36	.	O	['N']	[36]
#2823
0	Behavioral	O	['N']	[0]
1	side	O	['N']	[1]
2	effects	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	clonazepam	B-Drug	['Causes']	[10]
6	may	O	['N']	[6]
7	include	O	['N']	[7]
8	agitation	O	['N']	[8]
9	,	O	['N']	[9]
10	aggression	B-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	hyperactivity	O	['N']	[12]
13	,	O	['N']	[13]
14	irritability	O	['N']	[14]
15	,	O	['N']	[15]
16	property	O	['N']	[16]
17	destruction	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	temper	O	['N']	[20]
21	tantrums	O	['N']	[21]
22	.	O	['N']	[22]
#2824
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Although	O	['N']	[2]
3	budesonide	B-Drug	['Causes']	[25]
4	may	O	['N']	[4]
5	be	O	['N']	[5]
6	beneficial	O	['N']	[6]
7	because	O	['N']	[7]
8	of	O	['N']	[8]
9	its	O	['N']	[9]
10	anti	O	['N']	[10]
11	-	O	['N']	[11]
12	inflammatory	O	['N']	[12]
13	effects	O	['N']	[13]
14	,	O	['N']	[14]
15	clinicians	O	['N']	[15]
16	should	O	['N']	[16]
17	be	O	['N']	[17]
18	alert	O	['N']	[18]
19	to	O	['N']	[19]
20	its	O	['N']	[20]
21	potential	O	['N']	[21]
22	for	O	['N']	[22]
23	causing	O	['N']	[23]
24	contact	B	['N']	[24]
25	dermatitis	I-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#2825
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	barbiturate	B-Drug	['Causes']	[8]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	submassive	B	['N']	[6]
7	hepatic	I	['N']	[7]
8	necrosis	I-Adverse_Effect	['N']	[8]
9	is	O	['N']	[9]
10	presented	O	['N']	[10]
11	and	O	['N']	[11]
12	the	O	['N']	[12]
13	literature	O	['N']	[13]
14	is	O	['N']	[14]
15	reviewed	O	['N']	[15]
16	.	O	['N']	[16]
#2826
0	The	O	['N']	[0]
1	possibility	O	['N']	[1]
2	of	O	['N']	[2]
3	phenytoin	B-Drug	['Causes']	[5]
4	hypersensitivity	B	['N']	[4]
5	reactions	I-Adverse_Effect	['N']	[5]
6	should	O	['N']	[6]
7	be	O	['N']	[7]
8	considered	O	['N']	[8]
9	when	O	['N']	[9]
10	patients	O	['N']	[10]
11	receiving	O	['N']	[11]
12	phenytoin	O	['N']	[12]
13	have	O	['N']	[13]
14	unusual	O	['N']	[14]
15	symptoms	O	['N']	[15]
16	,	O	['N']	[16]
17	particularly	O	['N']	[17]
18	fever	O	['N']	[18]
19	,	O	['N']	[19]
20	rash	O	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	lymphadenopathy	O	['N']	[23]
24	.	O	['N']	[24]
#2827
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	this	O	['N']	[4]
5	is	O	['N']	[5]
6	the	O	['N']	[6]
7	first	O	['N']	[7]
8	case	O	['N']	[8]
9	of	O	['N']	[9]
10	ivermectin	B-Drug	['Causes']	[15]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	severe	B	['N']	[13]
14	liver	I	['N']	[14]
15	disease	I-Adverse_Effect	['N']	[15]
16	published	O	['N']	[16]
17	in	O	['N']	[17]
18	the	O	['N']	[18]
19	literature	O	['N']	[19]
20	.	O	['N']	[20]
#2828
0	Diarrhoea	O	['N']	[0]
1	,	O	['N']	[1]
2	T	O	['N']	[2]
3	-	O	['N']	[3]
4	CD4	O	['N']	[4]
5	+	O	['N']	[5]
6	lymphopenia	O	['N']	[6]
7	and	O	['N']	[7]
8	bilateral	B	['N']	[8]
9	patchy	I	['N']	[9]
10	pulmonary	I	['N']	[10]
11	infiltrates	I-Adverse_Effect	['N']	[11]
12	developed	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	male	O	['N']	[15]
16	60	O	['N']	[16]
17	yrs	O	['N']	[17]
18	of	O	['N']	[18]
19	age	O	['N']	[19]
20	,	O	['N']	[20]
21	who	O	['N']	[21]
22	was	O	['N']	[22]
23	treated	O	['N']	[23]
24	with	O	['N']	[24]
25	oxaliplatinum	O	['N']	[25]
26	and	O	['N']	[26]
27	5-fluorouracil	B-Drug	['Causes']	[11]
28	for	O	['N']	[28]
29	unresectable	O	['N']	[29]
30	rectum	O	['N']	[30]
31	carcinoma	O	['N']	[31]
32	.	O	['N']	[32]
#2829
0	Seizures	O	['N']	[0]
1	and	O	['N']	[1]
2	transient	B	['N']	[2]
3	blindness	I-Adverse_Effect	['N']	[3]
4	following	O	['N']	[4]
5	intravenous	O	['N']	[5]
6	pulse	O	['N']	[6]
7	methylprednisolone	B-Drug	['Causes']	[3]
8	in	O	['N']	[8]
9	children	O	['N']	[9]
10	with	O	['N']	[10]
11	primary	O	['N']	[11]
12	glomerulonephritis	O	['N']	[12]
13	.	O	['N']	[13]
#2830
0	Previous	O	['N']	[0]
1	studies	O	['N']	[1]
2	have	O	['N']	[2]
3	demonstrated	O	['N']	[3]
4	the	O	['N']	[4]
5	interaction	O	['N']	[5]
6	of	O	['N']	[6]
7	MTX	B-Drug	['Causes']	[32]
8	and	O	['N']	[8]
9	a	O	['N']	[9]
10	variety	O	['N']	[10]
11	of	O	['N']	[11]
12	non	O	['N']	[12]
13	-	O	['N']	[13]
14	steroidal	O	['N']	[14]
15	,	O	['N']	[15]
16	anti	O	['N']	[16]
17	-	O	['N']	[17]
18	inflammatory	O	['N']	[18]
19	drugs	O	['N']	[19]
20	(	O	['N']	[20]
21	NSAIDs	O	['N']	[21]
22	)	O	['N']	[22]
23	with	O	['N']	[23]
24	various	O	['N']	[24]
25	clinical	O	['N']	[25]
26	manifestations	O	['N']	[26]
27	including	O	['N']	[27]
28	acute	O	['N']	[28]
29	renal	O	['N']	[29]
30	failure	O	['N']	[30]
31	,	O	['N']	[31]
32	pancytopenia	B-Adverse_Effect	['N']	[32]
33	,	O	['N']	[33]
34	vomiting	O	['N']	[34]
35	,	O	['N']	[35]
36	diarrhea	O	['N']	[36]
37	,	O	['N']	[37]
38	elevated	O	['N']	[38]
39	liver	O	['N']	[39]
40	transaminases	O	['N']	[40]
41	,	O	['N']	[41]
42	jaundice	O	['N']	[42]
43	,	O	['N']	[43]
44	mucosal	O	['N']	[44]
45	ulcerations	O	['N']	[45]
46	,	O	['N']	[46]
47	and	O	['N']	[47]
48	pyrexia	O	['N']	[48]
49	.	O	['N']	[49]
#2831
0	After	O	['N']	[0]
1	the	O	['N']	[1]
2	first	O	['N']	[2]
3	oral	O	['N']	[3]
4	dose	O	['N']	[4]
5	of	O	['N']	[5]
6	propranolol	B-Drug	['Causes']	[13]
7	,	O	['N']	[7]
8	syncope	O	['N']	[8]
9	developed	O	['N']	[9]
10	together	O	['N']	[10]
11	with	O	['N']	[11]
12	atrioventricular	B	['N']	[12]
13	block	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#2832
0	Phenylpropanolamine	O	['N']	[0]
1	(	O	['N']	[1]
2	PPA	B-Drug	['Causes']	[13]
3	)	O	['N']	[3]
4	recently	O	['N']	[4]
5	has	O	['N']	[5]
6	been	O	['N']	[6]
7	publicly	O	['N']	[7]
8	implicated	O	['N']	[8]
9	as	O	['N']	[9]
10	a	O	['N']	[10]
11	cause	O	['N']	[11]
12	of	O	['N']	[12]
13	stroke	B-Adverse_Effect	['N']	[13]
14	and	O	['N']	[14]
15	other	O	['N']	[15]
16	neurologic	O	['N']	[16]
17	events	O	['N']	[17]
18	.	O	['N']	[18]
#2833
0	Cystoid	B	['N']	[0]
1	macular	I	['N']	[1]
2	edema	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	low	O	['N']	[5]
6	-	O	['N']	[6]
7	risk	O	['N']	[7]
8	patient	O	['N']	[8]
9	after	O	['N']	[9]
10	switching	O	['N']	[10]
11	from	O	['N']	[11]
12	latanoprost	O	['N']	[12]
13	to	O	['N']	[13]
14	bimatoprost	B-Drug	['Causes']	[2]
15	.	O	['N']	[15]
#2834
0	CASE	O	['N']	[0]
1	PRESENTATION	O	['N']	[1]
2	:	O	['N']	[2]
3	We	O	['N']	[3]
4	report	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	CF	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	recurrent	O	['N']	[11]
12	eosinophilia	O	['N']	[12]
13	and	O	['N']	[13]
14	severe	B	['N']	[14]
15	persistent	I	['N']	[15]
16	bronchospasm	I-Adverse_Effect	['N']	[16]
17	following	O	['N']	[17]
18	repeated	O	['N']	[18]
19	administration	O	['N']	[19]
20	of	O	['N']	[20]
21	preservative	O	['N']	[21]
22	-	O	['N']	[22]
23	free	O	['N']	[23]
24	tobramycin	B-Drug	['Causes']	[16]
25	by	O	['N']	[25]
26	inhalation	O	['N']	[26]
27	,	O	['N']	[27]
28	beginning	O	['N']	[28]
29	at	O	['N']	[29]
30	16	O	['N']	[30]
31	months	O	['N']	[31]
32	of	O	['N']	[32]
33	age	O	['N']	[33]
34	.	O	['N']	[34]
#2835
0	We	O	['N']	[0]
1	suggest	O	['N']	[1]
2	that	O	['N']	[2]
3	sarcoidosis	B-Adverse_Effect	['N']	[3]
4	may	O	['N']	[4]
5	develop	O	['N']	[5]
6	in	O	['N']	[6]
7	chronic	O	['N']	[7]
8	hepatitis	O	['N']	[8]
9	C	O	['N']	[9]
10	patients	O	['N']	[10]
11	during	O	['N']	[11]
12	interferon	B	['N']	[12]
13	alpha	I-Drug	['Causes']	[3]
14	and/or	O	['N']	[14]
15	ribavirin	O	['N']	[15]
16	treatment	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	diagnostic	O	['N']	[19]
20	tests	O	['N']	[20]
21	for	O	['N']	[21]
22	this	O	['N']	[22]
23	adverse	O	['N']	[23]
24	effect	O	['N']	[24]
25	should	O	['N']	[25]
26	be	O	['N']	[26]
27	performed	O	['N']	[27]
28	during	O	['N']	[28]
29	the	O	['N']	[29]
30	follow	O	['N']	[30]
31	-	O	['N']	[31]
32	ups	O	['N']	[32]
33	.	O	['N']	[33]
#2836
0	Overdose	O	['N']	[0]
1	of	O	['N']	[1]
2	magnesium	B-Drug	['Causes']	[22]
3	sulfate	O	['N']	[3]
4	in	O	['N']	[4]
5	combination	O	['N']	[5]
6	with	O	['N']	[6]
7	renal	O	['N']	[7]
8	insufficiency	O	['N']	[8]
9	,	O	['N']	[9]
10	hypocalcemia	O	['N']	[10]
11	,	O	['N']	[11]
12	or	O	['N']	[12]
13	compromise	O	['N']	[13]
14	of	O	['N']	[14]
15	intestinal	O	['N']	[15]
16	integrity	O	['N']	[16]
17	may	O	['N']	[17]
18	predispose	O	['N']	[18]
19	horses	O	['N']	[19]
20	to	O	['N']	[20]
21	magnesium	B	['N']	[21]
22	toxicosis	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#2837
0	Methylphenidate	B-Drug	['Causes']	[3]
1	(	O	['N']	[1]
2	Ritalin)-associated	O	['N']	[2]
3	cataract	B-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	glaucoma	O	['N']	[5]
6	.	O	['N']	[6]
#2838
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	reported	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	hepatolithiasis	B-Adverse_Effect	['N']	[7]
8	during	O	['N']	[8]
9	octreotide	B-Drug	['Causes']	[7]
10	therapy	O	['N']	[10]
11	.	O	['N']	[11]
#2839
0	Papilloedema	O	['N']	[0]
1	and	O	['N']	[1]
2	hepatic	B	['N']	[2]
3	dysfunction	I-Adverse_Effect	['N']	[3]
4	apparently	O	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	perhexiline	O	['N']	[7]
8	maleate	O	['N']	[8]
9	(	O	['N']	[9]
10	Pexid	B-Drug	['Causes']	[3]
11	)	O	['N']	[11]
12	.	O	['N']	[12]
#2840
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	with	O	['N']	[4]
5	chronic	O	['N']	[5]
6	hepatitis	O	['N']	[6]
7	C	O	['N']	[7]
8	(	O	['N']	[8]
9	CHC	O	['N']	[9]
10	)	O	['N']	[10]
11	who	O	['N']	[11]
12	developed	O	['N']	[12]
13	sarcoidosis	B-Adverse_Effect	['N']	[13]
14	after	O	['N']	[14]
15	the	O	['N']	[15]
16	treatment	O	['N']	[16]
17	by	O	['N']	[17]
18	interferon	B	['N']	[18]
19	alpha	I-Drug	['Causes']	[13]
20	and	O	['N']	[20]
21	ribavirin	O	['N']	[21]
22	.	O	['N']	[22]
#2841
0	A	O	['N']	[0]
1	64	O	['N']	[1]
2	year	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	recurrent	O	['N']	[6]
7	metastatic	O	['N']	[7]
8	squamous	O	['N']	[8]
9	cell	O	['N']	[9]
10	carcinoma	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	head	O	['N']	[13]
14	and	O	['N']	[14]
15	neck	O	['N']	[15]
16	developed	O	['N']	[16]
17	severe	O	['N']	[17]
18	skin	O	['N']	[18]
19	rash	O	['N']	[19]
20	and	O	['N']	[20]
21	bone	O	['N']	[21]
22	marrow	O	['N']	[22]
23	aplasia	O	['N']	[23]
24	4	O	['N']	[24]
25	and	O	['N']	[25]
26	7	O	['N']	[26]
27	days	O	['N']	[27]
28	,	O	['N']	[28]
29	respectively	O	['N']	[29]
30	,	O	['N']	[30]
31	following	O	['N']	[31]
32	a	O	['N']	[32]
33	single	O	['N']	[33]
34	dose	O	['N']	[34]
35	of	O	['N']	[35]
36	40	B	['N']	[36]
37	mg	I	['N']	[37]
38	/	I	['N']	[38]
39	m2	I-Dose	['N']	[39]
40	methotrexate	B-Drug	['Dosage']	[39]
41	(	O	['N']	[41]
42	MTX	O	['N']	[42]
43	)	O	['N']	[43]
44	.	O	['N']	[44]
#2842
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	fulminant	O	['N']	[5]
6	neuroleptic	B	['N']	[6]
7	malignant	I	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	man	O	['N']	[11]
12	aged	O	['N']	[12]
13	70	O	['N']	[13]
14	developing	O	['N']	[14]
15	within	O	['N']	[15]
16	12	O	['N']	[16]
17	hours	O	['N']	[17]
18	of	O	['N']	[18]
19	starting	O	['N']	[19]
20	six	O	['N']	[20]
21	-	O	['N']	[21]
22	hourly	O	['N']	[22]
23	intravenous	O	['N']	[23]
24	metoclopramide	B-Drug	['Causes']	[8]
25	.	O	['N']	[25]
#2843
0	The	O	['N']	[0]
1	main	O	['N']	[1]
2	side	O	['N']	[2]
3	-	O	['N']	[3]
4	effects	O	['N']	[4]
5	of	O	['N']	[5]
6	Lp	B	['N']	[6]
7	-	I	['N']	[7]
8	TAE	I-Drug	['Causes']	[23]
9	combined	O	['N']	[9]
10	with	O	['N']	[10]
11	HT	O	['N']	[11]
12	were	O	['N']	[12]
13	low	O	['N']	[13]
14	-	O	['N']	[14]
15	grade	O	['N']	[15]
16	fever	O	['N']	[16]
17	,	O	['N']	[17]
18	localized	O	['N']	[18]
19	pain	O	['N']	[19]
20	,	O	['N']	[20]
21	myelo	B	['N']	[21]
22	-	I	['N']	[22]
23	suppression	I-Adverse_Effect	['N']	[23]
24	and	O	['N']	[24]
25	liver	O	['N']	[25]
26	dysfunction	O	['N']	[26]
27	,	O	['N']	[27]
28	but	O	['N']	[28]
29	these	O	['N']	[29]
30	were	O	['N']	[30]
31	transient	O	['N']	[31]
32	and	O	['N']	[32]
33	eventually	O	['N']	[33]
34	disappeared	O	['N']	[34]
35	.	O	['N']	[35]
#2844
0	Reported	O	['N']	[0]
1	are	O	['N']	[1]
2	three	O	['N']	[2]
3	children	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	progressive	B	['N']	[6]
7	paraparesis	I-Adverse_Effect	['N']	[7]
8	after	O	['N']	[8]
9	intrathecal	O	['N']	[9]
10	methotrexate	B-Drug	['Causes']	[7]
11	administration	O	['N']	[11]
12	followed	O	['N']	[12]
13	by	O	['N']	[13]
14	complete	O	['N']	[14]
15	or	O	['N']	[15]
16	partial	O	['N']	[16]
17	recovery	O	['N']	[17]
18	.	O	['N']	[18]
#2845
0	Desipramine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	SIADH	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	an	O	['N']	[5]
6	elderly	O	['N']	[6]
7	woman	O	['N']	[7]
8	:	O	['N']	[8]
9	case	O	['N']	[9]
10	report	O	['N']	[10]
11	.	O	['N']	[11]
#2846
0	CD4	O	['N']	[0]
1	T	O	['N']	[1]
2	-	O	['N']	[2]
3	lymphocyte	O	['N']	[3]
4	depletion	O	['N']	[4]
5	,	O	['N']	[5]
6	myelosuppression	B-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	subsequent	O	['N']	[9]
10	severe	O	['N']	[10]
11	infections	O	['N']	[11]
12	are	O	['N']	[12]
13	the	O	['N']	[13]
14	major	O	['N']	[14]
15	side	O	['N']	[15]
16	effects	O	['N']	[16]
17	of	O	['N']	[17]
18	fludarabine	B	['N']	[18]
19	phosphate	I-Drug	['Causes']	[6]
20	therapy	O	['N']	[20]
21	.	O	['N']	[21]
#2847
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	administered	O	['N']	[2]
3	metoclopramide	B-Drug	['Causes']	[18]
4	because	O	['N']	[4]
5	of	O	['N']	[5]
6	nausea	O	['N']	[6]
7	and	O	['N']	[7]
8	,	O	['N']	[8]
9	within	O	['N']	[9]
10	2	O	['N']	[10]
11	hours	O	['N']	[11]
12	,	O	['N']	[12]
13	developed	O	['N']	[13]
14	agitation	O	['N']	[14]
15	,	O	['N']	[15]
16	dysarthria	O	['N']	[16]
17	,	O	['N']	[17]
18	diaphoresis	B-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	a	O	['N']	[21]
22	movement	O	['N']	[22]
23	disorder	O	['N']	[23]
24	.	O	['N']	[24]
#2848
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	,	O	['N']	[3]
4	we	O	['N']	[4]
5	describe	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	receiving	O	['N']	[8]
9	lenalidomide	B-Drug	['Causes']	[16]
10	in	O	['N']	[10]
11	whom	O	['N']	[11]
12	dyspnea	O	['N']	[12]
13	,	O	['N']	[13]
14	fever	O	['N']	[14]
15	,	O	['N']	[15]
16	hypoxia	B-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	diffuse	O	['N']	[19]
20	pulmonary	O	['N']	[20]
21	infiltrates	O	['N']	[21]
22	developed	O	['N']	[22]
23	.	O	['N']	[23]
#2849
0	Evidence	O	['N']	[0]
1	obtained	O	['N']	[1]
2	indicated	O	['N']	[2]
3	that	O	['N']	[3]
4	the	O	['N']	[4]
5	Reye	O	['N']	[5]
6	-	O	['N']	[6]
7	like	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	might	O	['N']	[9]
10	be	O	['N']	[10]
11	caused	O	['N']	[11]
12	by	O	['N']	[12]
13	calcium	B	['N']	[13]
14	hopantenate	I-Drug	['Causes']	[23]
15	possibly	O	['N']	[15]
16	due	O	['N']	[16]
17	to	O	['N']	[17]
18	the	O	['N']	[18]
19	induction	O	['N']	[19]
20	of	O	['N']	[20]
21	pantothenic	B	['N']	[21]
22	acid	I	['N']	[22]
23	deficiency	I-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#2850
0	Methanol	B-Drug	['Causes']	[8]
1	toxicity	O	['N']	[1]
2	can	O	['N']	[2]
3	cause	O	['N']	[3]
4	severe	B	['N']	[4]
5	central	I	['N']	[5]
6	nervous	I	['N']	[6]
7	system	I	['N']	[7]
8	insult	I-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	which	O	['N']	[10]
11	a	O	['N']	[11]
12	characteristic	O	['N']	[12]
13	pattern	O	['N']	[13]
14	of	O	['N']	[14]
15	bilateral	O	['N']	[15]
16	putaminal	O	['N']	[16]
17	injury	O	['N']	[17]
18	is	O	['N']	[18]
19	noted	O	['N']	[19]
20	on	O	['N']	[20]
21	brain	O	['N']	[21]
22	imaging	O	['N']	[22]
23	studies	O	['N']	[23]
24	.	O	['N']	[24]
#2851
0	Patients	O	['N']	[0]
1	with	O	['N']	[1]
2	lymphoblastic	O	['N']	[2]
3	lymphoma	O	['N']	[3]
4	who	O	['N']	[4]
5	had	O	['N']	[5]
6	treatment	O	['N']	[6]
7	with	O	['N']	[7]
8	L	B	['N']	[8]
9	-	I	['N']	[9]
10	asparaginase	I-Drug	['Causes']	[21]
11	and	O	['N']	[11]
12	steroid	O	['N']	[12]
13	are	O	['N']	[13]
14	predisposed	O	['N']	[14]
15	to	O	['N']	[15]
16	the	O	['N']	[16]
17	development	O	['N']	[17]
18	of	O	['N']	[18]
19	cortical	B	['N']	[19]
20	venous	I	['N']	[20]
21	thrombosis	I-Adverse_Effect	['N']	[21]
22	and	O	['N']	[22]
23	may	O	['N']	[23]
24	have	O	['N']	[24]
25	this	O	['N']	[25]
26	syndrome	O	['N']	[26]
27	in	O	['N']	[27]
28	addition	O	['N']	[28]
29	to	O	['N']	[29]
30	a	O	['N']	[30]
31	dural	O	['N']	[31]
32	puncture	O	['N']	[32]
33	headache	O	['N']	[33]
34	.	O	['N']	[34]
#2852
0	The	O	['N']	[0]
1	main	O	['N']	[1]
2	clinical	O	['N']	[2]
3	features	O	['N']	[3]
4	of	O	['N']	[4]
5	this	O	['N']	[5]
6	58-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	female	O	['N']	[9]
10	patient	O	['N']	[10]
11	were	O	['N']	[11]
12	laboratory	O	['N']	[12]
13	evidence	O	['N']	[13]
14	of	O	['N']	[14]
15	leucopenia	O	['N']	[15]
16	and	O	['N']	[16]
17	cholestasis	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	biopsy	O	['N']	[20]
21	features	O	['N']	[21]
22	of	O	['N']	[22]
23	fatty	B	['N']	[23]
24	liver	I	['N']	[24]
25	parenchyma	I	['N']	[25]
26	degeneration	I-Adverse_Effect	['N']	[26]
27	with	O	['N']	[27]
28	granulocytic	O	['N']	[28]
29	portal	O	['N']	[29]
30	infiltration	O	['N']	[30]
31	and	O	['N']	[31]
32	bile	O	['N']	[32]
33	stasis	O	['N']	[33]
34	,	O	['N']	[34]
35	demonstrated	O	['N']	[35]
36	20	O	['N']	[36]
37	days	O	['N']	[37]
38	after	O	['N']	[38]
39	the	O	['N']	[39]
40	initiation	O	['N']	[40]
41	of	O	['N']	[41]
42	antithyroid	O	['N']	[42]
43	therapy	O	['N']	[43]
44	with	O	['N']	[44]
45	20	O	['N']	[45]
46	mg	O	['N']	[46]
47	methimazole	B-Drug	['Causes']	[26]
48	daily	O	['N']	[48]
49	.	O	['N']	[49]
#2853
0	An	O	['N']	[0]
1	infant	O	['N']	[1]
2	girl	O	['N']	[2]
3	with	O	['N']	[3]
4	choanal	B	['N']	[4]
5	atresia	I-Adverse_Effect	['N']	[5]
6	,	O	['N']	[6]
7	athelia	O	['N']	[7]
8	,	O	['N']	[8]
9	minor	O	['N']	[9]
10	anomalies	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	mild	O	['N']	[13]
14	to	O	['N']	[14]
15	moderate	O	['N']	[15]
16	mental	O	['N']	[16]
17	retardation	O	['N']	[17]
18	was	O	['N']	[18]
19	born	O	['N']	[19]
20	to	O	['N']	[20]
21	a	O	['N']	[21]
22	woman	O	['N']	[22]
23	treated	O	['N']	[23]
24	for	O	['N']	[24]
25	hyperthyroidism	O	['N']	[25]
26	throughout	O	['N']	[26]
27	pregnancy	O	['N']	[27]
28	with	O	['N']	[28]
29	methimazole	B-Drug	['Causes']	[5]
30	and	O	['N']	[30]
31	propranolol	O	['N']	[31]
32	.	O	['N']	[32]
#2854
0	Choroidal	B	['N']	[0]
1	hemorrhage	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	systemic	O	['N']	[4]
5	tissue	B	['N']	[5]
6	plasminogen	I	['N']	[6]
7	activator	I-Drug	['Causes']	[1]
8	.	O	['N']	[8]
#2855
0	In	O	['N']	[0]
1	the	O	['N']	[1]
2	other	O	['N']	[2]
3	patient	O	['N']	[3]
4	,	O	['N']	[4]
5	a	O	['N']	[5]
6	78-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	,	O	['N']	[10]
11	Neisseria	B	['N']	[11]
12	mucosa	I	['N']	[12]
13	knee	I	['N']	[13]
14	arthritis	I-Adverse_Effect	['N']	[14]
15	occurred	O	['N']	[15]
16	after	O	['N']	[16]
17	a	O	['N']	[17]
18	single	O	['N']	[18]
19	sodium	B	['N']	[19]
20	hyaluronate	I-Drug	['Causes']	[14]
21	injection	O	['N']	[21]
22	.	O	['N']	[22]
#2856
0	Until	O	['N']	[0]
1	additional	O	['N']	[1]
2	data	O	['N']	[2]
3	are	O	['N']	[3]
4	available	O	['N']	[4]
5	,	O	['N']	[5]
6	if	O	['N']	[6]
7	intravenous	O	['N']	[7]
8	acyclovir	B-Drug	['Causes']	[24]
9	is	O	['N']	[9]
10	administered	O	['N']	[10]
11	concurrently	O	['N']	[11]
12	with	O	['N']	[12]
13	lithium	O	['N']	[13]
14	,	O	['N']	[14]
15	we	O	['N']	[15]
16	recommend	O	['N']	[16]
17	closely	O	['N']	[17]
18	monitoring	O	['N']	[18]
19	patients	O	['N']	[19]
20	for	O	['N']	[20]
21	signs	O	['N']	[21]
22	of	O	['N']	[22]
23	lithium	B	['N']	[23]
24	toxicity	I-Adverse_Effect	['N']	[24]
25	and	O	['N']	[25]
26	measuring	O	['N']	[26]
27	serum	O	['N']	[27]
28	lithium	O	['N']	[28]
29	levels	O	['N']	[29]
30	every	O	['N']	[30]
31	second	O	['N']	[31]
32	or	O	['N']	[32]
33	third	O	['N']	[33]
34	day	O	['N']	[34]
35	.	O	['N']	[35]
#2857
0	The	O	['N']	[0]
1	allopurinol	B-Drug	['Causes']	[3]
2	hypersensitivity	B	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	a	O	['N']	[5]
6	rare	O	['N']	[6]
7	adverse	O	['N']	[7]
8	drug	O	['N']	[8]
9	reaction	O	['N']	[9]
10	.	O	['N']	[10]
#2858
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	contact	B	['N']	[3]
4	dermatitis	I-Adverse_Effect	['N']	[4]
5	due	O	['N']	[5]
6	to	O	['N']	[6]
7	sodium	B	['N']	[7]
8	bisulfite	I-Drug	['Causes']	[4]
9	in	O	['N']	[9]
10	an	O	['N']	[10]
11	ophthalmic	O	['N']	[11]
12	solution	O	['N']	[12]
13	.	O	['N']	[13]
#2859
0	Six	O	['N']	[0]
1	of	O	['N']	[1]
2	13	O	['N']	[2]
3	outpatients	O	['N']	[3]
4	with	O	['N']	[4]
5	schizophrenia	O	['N']	[5]
6	who	O	['N']	[6]
7	participated	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	ten	O	['N']	[10]
11	-	O	['N']	[11]
12	week	O	['N']	[12]
13	open	O	['N']	[13]
14	trial	O	['N']	[14]
15	of	O	['N']	[15]
16	risperidone	B-Drug	['Causes']	[35]
17	had	O	['N']	[17]
18	an	O	['N']	[18]
19	initial	O	['N']	[19]
20	good	O	['N']	[20]
21	response	O	['N']	[21]
22	to	O	['N']	[22]
23	the	O	['N']	[23]
24	medication	O	['N']	[24]
25	followed	O	['N']	[25]
26	by	O	['N']	[26]
27	development	O	['N']	[27]
28	of	O	['N']	[28]
29	intolerable	O	['N']	[29]
30	affect	O	['N']	[30]
31	,	O	['N']	[31]
32	including	O	['N']	[32]
33	feelings	B	['N']	[33]
34	of	I	['N']	[34]
35	agitation	I-Adverse_Effect	['N']	[35]
36	and	O	['N']	[36]
37	depression	O	['N']	[37]
38	and	O	['N']	[38]
39	periods	O	['N']	[39]
40	of	O	['N']	[40]
41	crying	O	['N']	[41]
42	and	O	['N']	[42]
43	insomnia	O	['N']	[43]
44	.	O	['N']	[44]
#2860
0	Trimethoprim	B	['N']	[0]
1	-	I	['N']	[1]
2	sulfamethoxazole	I-Drug	['Causes']	[5]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	hepatotoxicity	B-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	pediatric	O	['N']	[8]
9	patient	O	['N']	[9]
10	.	O	['N']	[10]
#2861
0	A	O	['N']	[0]
1	58-yr	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	male	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	essential	O	['N']	[7]
8	thrombocythaemia	O	['N']	[8]
9	(	O	['N']	[9]
10	ET	O	['N']	[10]
11	)	O	['N']	[11]
12	developed	O	['N']	[12]
13	chronic	O	['N']	[13]
14	myeloid	O	['N']	[14]
15	leukaemia	O	['N']	[15]
16	(	O	['N']	[16]
17	CML	B-Adverse_Effect	['N']	[17]
18	)	O	['N']	[18]
19	after	O	['N']	[19]
20	continuous	O	['N']	[20]
21	uneventful	O	['N']	[21]
22	treatment	O	['N']	[22]
23	with	O	['N']	[23]
24	hydroxyurea	B-Drug	['Causes']	[17]
25	for	O	['N']	[25]
26	18	O	['N']	[26]
27	yr	O	['N']	[27]
28	.	O	['N']	[28]
#2862
0	After	O	['N']	[0]
1	a	O	['N']	[1]
2	second	O	['N']	[2]
3	dose	O	['N']	[3]
4	of	O	['N']	[4]
5	metoclopramide	B-Drug	['Causes']	[18]
6	,	O	['N']	[6]
7	these	O	['N']	[7]
8	symptoms	O	['N']	[8]
9	recurred	O	['N']	[9]
10	and	O	['N']	[10]
11	were	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	confusion	O	['N']	[14]
15	,	O	['N']	[15]
16	agitation	O	['N']	[16]
17	,	O	['N']	[17]
18	fever	B-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	diaphoresis	O	['N']	[20]
21	,	O	['N']	[21]
22	tachypnea	O	['N']	[22]
23	,	O	['N']	[23]
24	tachycardia	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	hypertension	O	['N']	[27]
28	.	O	['N']	[28]
#2863
0	Heparin	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	thrombocytopenia	B-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	a	O	['N']	[5]
6	rare	O	['N']	[6]
7	and	O	['N']	[7]
8	serious	O	['N']	[8]
9	complication	O	['N']	[9]
10	of	O	['N']	[10]
11	anticoagulation	O	['N']	[11]
12	therapy	O	['N']	[12]
13	.	O	['N']	[13]
#2864
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	this	O	['N']	[4]
5	is	O	['N']	[5]
6	the	O	['N']	[6]
7	first	O	['N']	[7]
8	case	O	['N']	[8]
9	of	O	['N']	[9]
10	griseofulvin	B-Drug	['Causes']	[17]
11	-	O	['N']	[11]
12	exacerbated	O	['N']	[12]
13	lupus	O	['N']	[13]
14	in	O	['N']	[14]
15	which	O	['N']	[15]
16	nephrotic	B	['N']	[16]
17	syndrome	I-Adverse_Effect	['N']	[17]
18	has	O	['N']	[18]
19	been	O	['N']	[19]
20	observed	O	['N']	[20]
21	.	O	['N']	[21]
#2865
0	An	O	['N']	[0]
1	episode	O	['N']	[1]
2	of	O	['N']	[2]
3	subacute	O	['N']	[3]
4	encephalopathy	O	['N']	[4]
5	after	O	['N']	[5]
6	the	O	['N']	[6]
7	infusion	O	['N']	[7]
8	of	O	['N']	[8]
9	a	O	['N']	[9]
10	moderate	O	['N']	[10]
11	dose	O	['N']	[11]
12	of	O	['N']	[12]
13	methotrexate	B-Drug	['Dosage']	[18]
14	(	O	['N']	[14]
15	1500	B	['N']	[15]
16	mg	I	['N']	[16]
17	/	I	['N']	[17]
18	m2	I-Dose	['N']	[18]
19	)	O	['N']	[19]
20	(	O	['N']	[20]
21	MTX	O	['N']	[21]
22	)	O	['N']	[22]
23	is	O	['N']	[23]
24	reported	O	['N']	[24]
25	in	O	['N']	[25]
26	a	O	['N']	[26]
27	young	O	['N']	[27]
28	adult	O	['N']	[28]
29	with	O	['N']	[29]
30	metastastic	O	['N']	[30]
31	gastric	O	['N']	[31]
32	cancer	O	['N']	[32]
33	.	O	['N']	[33]
#2866
0	DATA	O	['N']	[0]
1	SYNTHESIS	O	['N']	[1]
2	:	O	['N']	[2]
3	Genetic	O	['N']	[3]
4	deficiencies	O	['N']	[4]
5	in	O	['N']	[5]
6	DPD	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	rate	O	['N']	[9]
10	-	O	['N']	[10]
11	limiting	O	['N']	[11]
12	enzyme	O	['N']	[12]
13	responsible	O	['N']	[13]
14	for	O	['N']	[14]
15	5-FU	B-Drug	['Causes']	[42]
16	catabolism	O	['N']	[16]
17	,	O	['N']	[17]
18	may	O	['N']	[18]
19	occur	O	['N']	[19]
20	in	O	['N']	[20]
21	3	O	['N']	[21]
22	%	O	['N']	[22]
23	or	O	['N']	[23]
24	more	O	['N']	[24]
25	of	O	['N']	[25]
26	patients	O	['N']	[26]
27	with	O	['N']	[27]
28	cancer	O	['N']	[28]
29	putting	O	['N']	[29]
30	them	O	['N']	[30]
31	at	O	['N']	[31]
32	increased	O	['N']	[32]
33	risk	O	['N']	[33]
34	for	O	['N']	[34]
35	unusually	O	['N']	[35]
36	severe	O	['N']	[36]
37	adverse	O	['N']	[37]
38	reactions	O	['N']	[38]
39	(	O	['N']	[39]
40	e.g.	O	['N']	[40]
41	,	O	['N']	[41]
42	diarrhea	B-Adverse_Effect	['N']	[42]
43	,	O	['N']	[43]
44	stomatitis	O	['N']	[44]
45	,	O	['N']	[45]
46	mucositis	O	['N']	[46]
47	,	O	['N']	[47]
48	myelosuppression	O	['N']	[48]
49	,	O	['N']	[49]
50	neurotoxicity	O	['N']	[50]
51	)	O	['N']	[51]
52	to	O	['N']	[52]
53	standard	O	['N']	[53]
54	doses	O	['N']	[54]
55	of	O	['N']	[55]
56	5-FU	O	['N']	[56]
57	.	O	['N']	[57]
#2867
0	Five	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	clindamycin	B-Drug	['Causes']	[7]
4	-	O	['N']	[4]
5	associated	O	['N']	[5]
6	pseudomembranous	B	['N']	[6]
7	colitis	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	leukaemic	O	['N']	[9]
10	patients	O	['N']	[10]
11	are	O	['N']	[11]
12	reported	O	['N']	[12]
13	.	O	['N']	[13]
#2868
0	During	O	['N']	[0]
1	intravenous	O	['N']	[1]
2	treatment	O	['N']	[2]
3	with	O	['N']	[3]
4	terlipressin	B-Drug	['Causes']	[29]
5	for	O	['N']	[5]
6	recurrent	O	['N']	[6]
7	gastrointestinal	O	['N']	[7]
8	(	O	['N']	[8]
9	GI	O	['N']	[9]
10	)	O	['N']	[10]
11	bleeding	O	['N']	[11]
12	,	O	['N']	[12]
13	a	O	['N']	[13]
14	50-year	O	['N']	[14]
15	-	O	['N']	[15]
16	old	O	['N']	[16]
17	male	O	['N']	[17]
18	with	O	['N']	[18]
19	no	O	['N']	[19]
20	history	O	['N']	[20]
21	of	O	['N']	[21]
22	heart	O	['N']	[22]
23	disease	O	['N']	[23]
24	developed	O	['N']	[24]
25	a	O	['N']	[25]
26	newly	O	['N']	[26]
27	prolonged	B	['N']	[27]
28	QT	I	['N']	[28]
29	interval	I-Adverse_Effect	['N']	[29]
30	and	O	['N']	[30]
31	torsade	O	['N']	[31]
32	de	O	['N']	[32]
33	pointes	O	['N']	[33]
34	.	O	['N']	[34]
#2869
0	Dose	O	['N']	[0]
1	-	O	['N']	[1]
2	dependent	O	['N']	[2]
3	olanzapine	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	associated	O	['N']	[5]
6	leukopenia	B-Adverse_Effect	['N']	[6]
7	:	O	['N']	[7]
8	three	O	['N']	[8]
9	case	O	['N']	[9]
10	reports	O	['N']	[10]
11	.	O	['N']	[11]
#2870
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	a	O	['N']	[3]
4	child	O	['N']	[4]
5	with	O	['N']	[5]
6	fatal	O	['N']	[6]
7	valproate	B-Drug	['Causes']	[11]
8	-	O	['N']	[8]
9	related	O	['N']	[9]
10	hepatotoxic	B	['N']	[10]
11	effects	I-Adverse_Effect	['N']	[11]
12	despite	O	['N']	[12]
13	this	O	['N']	[13]
14	supplementation	O	['N']	[14]
15	.	O	['N']	[15]
#2871
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	five	O	['N']	[3]
4	additional	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	capecitabine	B-Drug	['Causes']	[11]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	multifocal	B	['N']	[10]
11	leukoencephalopathy	I-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#2872
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	systemic	O	['N']	[3]
4	lupus	O	['N']	[4]
5	erythematosus	O	['N']	[5]
6	developed	O	['N']	[6]
7	erythema	B	['N']	[7]
8	multiforme	I-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	taking	O	['N']	[10]
11	griseofulvin	B-Drug	['Causes']	[8]
12	.	O	['N']	[12]
#2873
0	When	O	['N']	[0]
1	co	B	['N']	[1]
2	-	I	['N']	[2]
3	trimoxazole	I-Drug	['Causes']	[9]
4	was	O	['N']	[4]
5	stopped	O	['N']	[5]
6	the	O	['N']	[6]
7	red	B	['N']	[7]
8	cell	I	['N']	[8]
9	aplasia	I-Adverse_Effect	['N']	[9]
10	resolved	O	['N']	[10]
11	.	O	['N']	[11]
#2874
0	Severe	B	['N']	[0]
1	adenovirus	I	['N']	[1]
2	pneumonia	I-Adverse_Effect	['N']	[2]
3	(	O	['N']	[3]
4	AVP	O	['N']	[4]
5	)	O	['N']	[5]
6	following	O	['N']	[6]
7	infliximab	B-Drug	['Causes']	[2]
8	infusion	O	['N']	[8]
9	for	O	['N']	[9]
10	the	O	['N']	[10]
11	treatment	O	['N']	[11]
12	of	O	['N']	[12]
13	Crohn	O	['N']	[13]
14	's	O	['N']	[14]
15	disease	O	['N']	[15]
16	.	O	['N']	[16]
#2875
0	Flare	O	['N']	[0]
1	of	O	['N']	[1]
2	Kaposi	B	['N']	[2]
3	's	I	['N']	[3]
4	sarcoma	I-Adverse_Effect	['N']	[4]
5	(	O	['N']	[5]
6	KS	O	['N']	[6]
7	)	O	['N']	[7]
8	is	O	['N']	[8]
9	well	O	['N']	[9]
10	described	O	['N']	[10]
11	in	O	['N']	[11]
12	immunosuppressed	O	['N']	[12]
13	patients	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	corticosteroids	O	['N']	[16]
17	and	O	['N']	[17]
18	rituximab	B-Drug	['Causes']	[4]
19	,	O	['N']	[19]
20	but	O	['N']	[20]
21	has	O	['N']	[21]
22	not	O	['N']	[22]
23	yet	O	['N']	[23]
24	been	O	['N']	[24]
25	reported	O	['N']	[25]
26	during	O	['N']	[26]
27	treatment	O	['N']	[27]
28	with	O	['N']	[28]
29	imatinib	O	['N']	[29]
30	.	O	['N']	[30]
#2876
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	disseminated	O	['N']	[5]
6	muscular	O	['N']	[6]
7	cysticercosis	O	['N']	[7]
8	followed	O	['N']	[8]
9	by	O	['N']	[9]
10	myositis	O	['N']	[10]
11	(	O	['N']	[11]
12	fever	O	['N']	[12]
13	,	O	['N']	[13]
14	diffuse	O	['N']	[14]
15	myalgia	O	['N']	[15]
16	,	O	['N']	[16]
17	weakness	B	['N']	[17]
18	of	I	['N']	[18]
19	the	I	['N']	[19]
20	lower	I	['N']	[20]
21	limbs	I-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	inflammatory	O	['N']	[24]
25	reaction	O	['N']	[25]
26	around	O	['N']	[26]
27	dying	O	['N']	[27]
28	cysticerci	O	['N']	[28]
29	)	O	['N']	[29]
30	induced	O	['N']	[30]
31	by	O	['N']	[31]
32	praziquantel	B-Drug	['Causes']	[21]
33	therapy	O	['N']	[33]
34	,	O	['N']	[34]
35	an	O	['N']	[35]
36	event	O	['N']	[36]
37	not	O	['N']	[37]
38	described	O	['N']	[38]
39	previously	O	['N']	[39]
40	.	O	['N']	[40]
#2877
0	These	O	['N']	[0]
1	findings	O	['N']	[1]
2	support	O	['N']	[2]
3	previous	O	['N']	[3]
4	studies	O	['N']	[4]
5	that	O	['N']	[5]
6	showed	O	['N']	[6]
7	that	O	['N']	[7]
8	the	O	['N']	[8]
9	use	O	['N']	[9]
10	of	O	['N']	[10]
11	aspirin	B-Drug	['Causes']	[25]
12	during	O	['N']	[12]
13	the	O	['N']	[13]
14	antecedent	O	['N']	[14]
15	illness	O	['N']	[15]
16	may	O	['N']	[16]
17	be	O	['N']	[17]
18	a	O	['N']	[18]
19	risk	O	['N']	[19]
20	factor	O	['N']	[20]
21	for	O	['N']	[21]
22	the	O	['N']	[22]
23	development	O	['N']	[23]
24	of	O	['N']	[24]
25	RS	B-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#2878
0	We	O	['N']	[0]
1	suggest	O	['N']	[1]
2	that	O	['N']	[2]
3	the	O	['N']	[3]
4	previous	O	['N']	[4]
5	classification	O	['N']	[5]
6	of	O	['N']	[6]
7	nitrofurantoin	B-Drug	['Causes']	[10]
8	induced	I	['N']	[8]
9	lung	I	['N']	[9]
10	injury	I-Adverse_Effect	['N']	[10]
11	into	O	['N']	[11]
12	"	O	['N']	[12]
13	acute	O	['N']	[13]
14	"	O	['N']	[14]
15	and	O	['N']	[15]
16	"	O	['N']	[16]
17	chronic	O	['N']	[17]
18	"	O	['N']	[18]
19	injury	O	['N']	[19]
20	is	O	['N']	[20]
21	an	O	['N']	[21]
22	oversimplification	O	['N']	[22]
23	in	O	['N']	[23]
24	view	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	wide	O	['N']	[27]
28	variety	O	['N']	[28]
29	of	O	['N']	[29]
30	pathological	O	['N']	[30]
31	entities	O	['N']	[31]
32	that	O	['N']	[32]
33	have	O	['N']	[33]
34	subsequently	O	['N']	[34]
35	emerged	O	['N']	[35]
36	.	O	['N']	[36]
#2879
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Sustained	O	['N']	[2]
3	-	O	['N']	[3]
4	release	O	['N']	[4]
5	verapamil	B-Drug	['Causes']	[15]
6	is	O	['N']	[6]
7	thought	O	['N']	[7]
8	to	O	['N']	[8]
9	be	O	['N']	[9]
10	the	O	['N']	[10]
11	cause	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	asthma	B	['N']	[14]
15	attack	I-Adverse_Effect	['N']	[15]
16	in	O	['N']	[16]
17	this	O	['N']	[17]
18	patient	O	['N']	[18]
19	because	O	['N']	[19]
20	she	O	['N']	[20]
21	was	O	['N']	[21]
22	not	O	['N']	[22]
23	taking	O	['N']	[23]
24	any	O	['N']	[24]
25	other	O	['N']	[25]
26	preparations	O	['N']	[26]
27	;	O	['N']	[27]
28	the	O	['N']	[28]
29	symptoms	O	['N']	[29]
30	started	O	['N']	[30]
31	with	O	['N']	[31]
32	the	O	['N']	[32]
33	administration	O	['N']	[33]
34	of	O	['N']	[34]
35	sustained	O	['N']	[35]
36	-	O	['N']	[36]
37	release	O	['N']	[37]
38	verapamil	O	['N']	[38]
39	and	O	['N']	[39]
40	were	O	['N']	[40]
41	relieved	O	['N']	[41]
42	after	O	['N']	[42]
43	its	O	['N']	[43]
44	discontinuation	O	['N']	[44]
45	.	O	['N']	[45]
#2880
0	This	O	['N']	[0]
1	article	O	['N']	[1]
2	describes	O	['N']	[2]
3	two	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	aplastic	B	['N']	[6]
7	anemia	I-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	at	O	['N']	[9]
10	least	O	['N']	[10]
11	one	O	['N']	[11]
12	of	O	['N']	[12]
13	which	O	['N']	[13]
14	was	O	['N']	[14]
15	almost	O	['N']	[15]
16	certainly	O	['N']	[16]
17	induced	O	['N']	[17]
18	by	O	['N']	[18]
19	the	O	['N']	[19]
20	use	O	['N']	[20]
21	of	O	['N']	[21]
22	methazolamide	B-Drug	['Causes']	[7]
23	,	O	['N']	[23]
24	and	O	['N']	[24]
25	one	O	['N']	[25]
26	case	O	['N']	[26]
27	of	O	['N']	[27]
28	agranulocytosis	O	['N']	[28]
29	related	O	['N']	[29]
30	to	O	['N']	[30]
31	the	O	['N']	[31]
32	use	O	['N']	[32]
33	of	O	['N']	[33]
34	methazolamide	O	['N']	[34]
35	.	O	['N']	[35]
#2881
0	Although	O	['N']	[0]
1	the	O	['N']	[1]
2	two	O	['N']	[2]
3	local	O	['N']	[3]
4	anesthetics	O	['N']	[4]
5	usually	O	['N']	[5]
6	do	O	['N']	[6]
7	not	O	['N']	[7]
8	cause	O	['N']	[8]
9	methemoglobinemia	B-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	we	O	['N']	[11]
12	suspect	O	['N']	[12]
13	that	O	['N']	[13]
14	the	O	['N']	[14]
15	displacement	O	['N']	[15]
16	of	O	['N']	[16]
17	lidocaine	B-Drug	['Causes']	[9]
18	from	O	['N']	[18]
19	protein	O	['N']	[19]
20	binding	O	['N']	[20]
21	by	O	['N']	[21]
22	bupivacaine	O	['N']	[22]
23	,	O	['N']	[23]
24	in	O	['N']	[24]
25	combination	O	['N']	[25]
26	with	O	['N']	[26]
27	metabolic	O	['N']	[27]
28	acidosis	O	['N']	[28]
29	and	O	['N']	[29]
30	treatment	O	['N']	[30]
31	with	O	['N']	[31]
32	other	O	['N']	[32]
33	oxidants	O	['N']	[33]
34	,	O	['N']	[34]
35	was	O	['N']	[35]
36	the	O	['N']	[36]
37	reason	O	['N']	[37]
38	for	O	['N']	[38]
39	the	O	['N']	[39]
40	development	O	['N']	[40]
41	of	O	['N']	[41]
42	methemoglobinemia	O	['N']	[42]
43	.	O	['N']	[43]
#2882
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	report	O	['N']	[2]
3	illustrates	O	['N']	[3]
4	the	O	['N']	[4]
5	neurotoxicity	B-Adverse_Effect	['N']	[5]
6	unique	O	['N']	[6]
7	to	O	['N']	[7]
8	HDARAC	B-Drug	['Causes']	[5]
9	.	O	['N']	[9]
#2883
0	The	O	['N']	[0]
1	concomitant	O	['N']	[1]
2	use	O	['N']	[2]
3	,	O	['N']	[3]
4	however	O	['N']	[4]
5	,	O	['N']	[5]
6	of	O	['N']	[6]
7	colchicine	O	['N']	[7]
8	and	O	['N']	[8]
9	statin	B-Drug	['Causes']	[19]
10	has	O	['N']	[10]
11	been	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	the	O	['N']	[14]
15	rapid	O	['N']	[15]
16	onset	O	['N']	[16]
17	of	O	['N']	[17]
18	muscle	B	['N']	[18]
19	weakness	I-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#2884
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	oral	B	['N']	[6]
7	-	I	['N']	[7]
8	facial	I	['N']	[8]
9	dyskinesia	I-Adverse_Effect	['N']	[9]
10	that	O	['N']	[10]
11	occurred	O	['N']	[11]
12	after	O	['N']	[12]
13	discontinuation	O	['N']	[13]
14	of	O	['N']	[14]
15	amoxapine	B-Drug	['Causes']	[9]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	antidepressant	O	['N']	[18]
19	which	O	['N']	[19]
20	may	O	['N']	[20]
21	also	O	['N']	[21]
22	have	O	['N']	[22]
23	neuroleptic	O	['N']	[23]
24	effects	O	['N']	[24]
25	.	O	['N']	[25]
#2885
0	A	O	['N']	[0]
1	60-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	diabetes	O	['N']	[6]
7	mellitus	O	['N']	[7]
8	(	O	['N']	[8]
9	type	O	['N']	[9]
10	2	O	['N']	[10]
11	)	O	['N']	[11]
12	developed	O	['N']	[12]
13	an	O	['N']	[13]
14	acute	B	['N']	[14]
15	icteric	I	['N']	[15]
16	hepatitis	I	['N']	[16]
17	-	I	['N']	[17]
18	like	I	['N']	[18]
19	illness	I-Adverse_Effect	['N']	[19]
20	6	O	['N']	[20]
21	weeks	O	['N']	[21]
22	after	O	['N']	[22]
23	the	O	['N']	[23]
24	initiation	O	['N']	[24]
25	of	O	['N']	[25]
26	gliclazide	B-Drug	['Causes']	[19]
27	therapy	O	['N']	[27]
28	.	O	['N']	[28]
#2886
0	Ziprasidone	B-Drug	['Causes']	[17]
1	is	O	['N']	[1]
2	an	O	['N']	[2]
3	atypical	O	['N']	[3]
4	antipsychotic	O	['N']	[4]
5	drug	O	['N']	[5]
6	that	O	['N']	[6]
7	is	O	['N']	[7]
8	believed	O	['N']	[8]
9	to	O	['N']	[9]
10	have	O	['N']	[10]
11	a	O	['N']	[11]
12	low	O	['N']	[12]
13	propensity	O	['N']	[13]
14	for	O	['N']	[14]
15	inducing	O	['N']	[15]
16	extrapyramidal	B	['N']	[16]
17	symptoms	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	including	O	['N']	[19]
20	tardive	O	['N']	[20]
21	dyskinesia	O	['N']	[21]
22	(	O	['N']	[22]
23	TD	O	['N']	[23]
24	)	O	['N']	[24]
25	.	O	['N']	[25]
#2887
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	that	O	['N']	[4]
5	illustrate	O	['N']	[5]
6	the	O	['N']	[6]
7	use	O	['N']	[7]
8	of	O	['N']	[8]
9	lithium	B-Drug	['Causes']	[26]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	treatment	O	['N']	[12]
13	of	O	['N']	[13]
14	veterans	O	['N']	[14]
15	with	O	['N']	[15]
16	PTSD	O	['N']	[16]
17	who	O	['N']	[17]
18	complained	O	['N']	[18]
19	of	O	['N']	[19]
20	serious	O	['N']	[20]
21	problems	O	['N']	[21]
22	with	O	['N']	[22]
23	irritability	O	['N']	[23]
24	or	O	['N']	[24]
25	angry	B	['N']	[25]
26	outbursts	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#2888
0	Here	O	['N']	[0]
1	we	O	['N']	[1]
2	present	O	['N']	[2]
3	the	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	generalized	B	['N']	[7]
8	lichen	I	['N']	[8]
9	nitidus	I-Adverse_Effect	['N']	[9]
10	with	O	['N']	[10]
11	involvement	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	palms	O	['N']	[14]
15	in	O	['N']	[15]
16	a	O	['N']	[16]
17	patient	O	['N']	[17]
18	with	O	['N']	[18]
19	hepatitis	O	['N']	[19]
20	C	O	['N']	[20]
21	after	O	['N']	[21]
22	systemic	O	['N']	[22]
23	treatment	O	['N']	[23]
24	with	O	['N']	[24]
25	interferon	B	['N']	[25]
26	alpha	I-Drug	['Causes']	[9]
27	and	O	['N']	[27]
28	ribavirin	O	['N']	[28]
29	.	O	['N']	[29]
#2889
0	The	O	['N']	[0]
1	goal	O	['N']	[1]
2	of	O	['N']	[2]
3	this	O	['N']	[3]
4	study	O	['N']	[4]
5	is	O	['N']	[5]
6	to	O	['N']	[6]
7	describe	O	['N']	[7]
8	three	O	['N']	[8]
9	patients	O	['N']	[9]
10	diagnosed	O	['N']	[10]
11	with	O	['N']	[11]
12	migraine	O	['N']	[12]
13	and	O	['N']	[13]
14	epilepsy	O	['N']	[14]
15	(	O	['N']	[15]
16	both	O	['N']	[16]
17	under	O	['N']	[17]
18	control	O	['N']	[18]
19	)	O	['N']	[19]
20	who	O	['N']	[20]
21	evolved	O	['N']	[21]
22	into	O	['N']	[22]
23	status	B	['N']	[23]
24	migrainosus	I-Adverse_Effect	['N']	[24]
25	after	O	['N']	[25]
26	the	O	['N']	[26]
27	introduction	O	['N']	[27]
28	of	O	['N']	[28]
29	oxcarbazepine	O	['N']	[29]
30	(	O	['N']	[30]
31	OXC	B-Drug	['Causes']	[24]
32	)	O	['N']	[32]
33	,	O	['N']	[33]
34	as	O	['N']	[34]
35	part	O	['N']	[35]
36	of	O	['N']	[36]
37	a	O	['N']	[37]
38	switch	O	['N']	[38]
39	off	O	['N']	[39]
40	from	O	['N']	[40]
41	carbamazepine	O	['N']	[41]
42	(	O	['N']	[42]
43	CBZ	O	['N']	[43]
44	)	O	['N']	[44]
45	.	O	['N']	[45]
#2890
0	Haemolytic	B	['N']	[0]
1	-	I	['N']	[1]
2	uraemic	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	complicating	O	['N']	[4]
5	long	O	['N']	[5]
6	-	O	['N']	[6]
7	term	O	['N']	[7]
8	mitomycin	B	['N']	[8]
9	C	I-Drug	['Causes']	[3]
10	and	O	['N']	[10]
11	5-fluorouracil	O	['N']	[11]
12	therapy	O	['N']	[12]
13	for	O	['N']	[13]
14	gastric	O	['N']	[14]
15	carcinoma	O	['N']	[15]
16	.	O	['N']	[16]
#2891
0	Hemolytic	B	['N']	[0]
1	uremic	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	on	O	['N']	[6]
7	cis	O	['N']	[7]
8	-	O	['N']	[8]
9	platinum	O	['N']	[9]
10	,	O	['N']	[10]
11	vinblastine	B-Drug	['Causes']	[2]
12	and	O	['N']	[12]
13	bleomycin	O	['N']	[13]
14	.	O	['N']	[14]
#2892
0	Isoniazid	B-Drug	['Causes']	[2]
1	induced	O	['N']	[1]
2	gynaecomastia	B-Adverse_Effect	['N']	[2]
3	:	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	report	O	['N']	[6]
7	.	O	['N']	[7]
#2893
0	The	O	['N']	[0]
1	nephrotic	B	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	developed	O	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	receiving	O	['N']	[7]
8	therapy	O	['N']	[8]
9	with	O	['N']	[9]
10	gold	B-Drug	['Causes']	[2]
11	for	O	['N']	[11]
12	rheumatoid	O	['N']	[12]
13	arthritis	O	['N']	[13]
14	.	O	['N']	[14]
#2894
0	We	O	['N']	[0]
1	postulate	O	['N']	[1]
2	that	O	['N']	[2]
3	gastritis	O	['N']	[3]
4	caused	O	['N']	[4]
5	by	O	['N']	[5]
6	dexamethasone	O	['N']	[6]
7	,	O	['N']	[7]
8	mucositis	B-Adverse_Effect	['N']	[8]
9	caused	O	['N']	[9]
10	by	O	['N']	[10]
11	doxorubicin	B-Drug	['Causes']	[8]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	the	O	['N']	[14]
15	unique	O	['N']	[15]
16	anatomic	O	['N']	[16]
17	nature	O	['N']	[17]
18	of	O	['N']	[18]
19	a	O	['N']	[19]
20	Meckel	O	['N']	[20]
21	diverticulum	O	['N']	[21]
22	may	O	['N']	[22]
23	have	O	['N']	[23]
24	contributed	O	['N']	[24]
25	to	O	['N']	[25]
26	this	O	['N']	[26]
27	extremely	O	['N']	[27]
28	unlikely	O	['N']	[28]
29	and	O	['N']	[29]
30	previously	O	['N']	[30]
31	unreported	O	['N']	[31]
32	event	O	['N']	[32]
33	.	O	['N']	[33]
#2895
0	Intra	B	['N']	[0]
1	-	I	['N']	[1]
2	neural	I	['N']	[2]
3	ceroid	I	['N']	[3]
4	-	I	['N']	[4]
5	like	I	['N']	[5]
6	pigment	I-Adverse_Effect	['N']	[6]
7	following	O	['N']	[7]
8	the	O	['N']	[8]
9	treatment	O	['N']	[9]
10	of	O	['N']	[10]
11	lepromatous	O	['N']	[11]
12	leprosy	O	['N']	[12]
13	with	O	['N']	[13]
14	clofazimine	O	['N']	[14]
15	(	O	['N']	[15]
16	B663	B-Drug	['Causes']	[6]
17	;	O	['N']	[17]
18	Lamprene	O	['N']	[18]
19	)	O	['N']	[19]
20	.	O	['N']	[20]
#2896
0	METHOD	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	authors	O	['N']	[3]
4	followed	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	chronic	O	['N']	[8]
9	HCV	O	['N']	[9]
10	who	O	['N']	[10]
11	received	O	['N']	[11]
12	interferon	O	['N']	[12]
13	and	O	['N']	[13]
14	ribavirin	B-Drug	['Causes']	[18]
15	and	O	['N']	[15]
16	who	O	['N']	[16]
17	developed	O	['N']	[17]
18	hallucinations	B-Adverse_Effect	['N']	[18]
19	ultimately	O	['N']	[19]
20	requiring	O	['N']	[20]
21	psychiatric	O	['N']	[21]
22	hospitalization	O	['N']	[22]
23	.	O	['N']	[23]
#2897
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	sulfadiazine	B-Drug	['Causes']	[11]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	crystalluria	O	['N']	[8]
9	and	O	['N']	[9]
10	renal	B	['N']	[10]
11	failure	I-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	patients	O	['N']	[13]
14	with	O	['N']	[14]
15	acquired	O	['N']	[15]
16	immunodeficiency	O	['N']	[16]
17	syndrome	O	['N']	[17]
18	,	O	['N']	[18]
19	review	O	['N']	[19]
20	the	O	['N']	[20]
21	pertinent	O	['N']	[21]
22	literature	O	['N']	[22]
23	,	O	['N']	[23]
24	and	O	['N']	[24]
25	discuss	O	['N']	[25]
26	the	O	['N']	[26]
27	pathogenesis	O	['N']	[27]
28	.	O	['N']	[28]
#2898
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	on	O	['N']	[3]
4	two	O	['N']	[4]
5	patients	O	['N']	[5]
6	with	O	['N']	[6]
7	corneal	B	['N']	[7]
8	ulcers	I	['N']	[8]
9	refractory	I	['N']	[9]
10	to	I	['N']	[10]
11	conventional	I	['N']	[11]
12	treatment	I-Adverse_Effect	['N']	[12]
13	while	O	['N']	[13]
14	the	O	['N']	[14]
15	patients	O	['N']	[15]
16	were	O	['N']	[16]
17	undergoing	O	['N']	[17]
18	oral	O	['N']	[18]
19	colchicine	B-Drug	['Causes']	[12]
20	therapy	O	['N']	[20]
21	.	O	['N']	[21]
#2899
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	pulmonary	B	['N']	[6]
7	hypertension	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	an	O	['N']	[9]
10	adult	O	['N']	[10]
11	patient	O	['N']	[11]
12	during	O	['N']	[12]
13	lithium	B-Drug	['Causes']	[7]
14	therapy	O	['N']	[14]
15	.	O	['N']	[15]
#2900
0	Although	O	['N']	[0]
1	gabapentin	B-Drug	['Causes']	[29]
2	withdrawal	O	['N']	[2]
3	has	O	['N']	[3]
4	been	O	['N']	[4]
5	previously	O	['N']	[5]
6	reported	O	['N']	[6]
7	and	O	['N']	[7]
8	usually	O	['N']	[8]
9	consists	O	['N']	[9]
10	of	O	['N']	[10]
11	anxiety	O	['N']	[11]
12	,	O	['N']	[12]
13	diaphoresis	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	palpitations	O	['N']	[16]
17	,	O	['N']	[17]
18	this	O	['N']	[18]
19	is	O	['N']	[19]
20	the	O	['N']	[20]
21	first	O	['N']	[21]
22	reported	O	['N']	[22]
23	patient	O	['N']	[23]
24	with	O	['N']	[24]
25	generalized	O	['N']	[25]
26	seizures	O	['N']	[26]
27	and	O	['N']	[27]
28	status	B	['N']	[28]
29	epilepticus	I-Adverse_Effect	['N']	[29]
30	secondary	O	['N']	[30]
31	to	O	['N']	[31]
32	gabapentin	O	['N']	[32]
33	withdrawal	O	['N']	[33]
34	.	O	['N']	[34]
#2901
0	A	O	['N']	[0]
1	high	O	['N']	[1]
2	dose	O	['N']	[2]
3	of	O	['N']	[3]
4	cotrimoxazole	B-Drug	['Causes']	[15]
5	induced	O	['N']	[5]
6	hyperkalaemia	O	['N']	[6]
7	with	O	['N']	[7]
8	the	O	['N']	[8]
9	elevation	B	['N']	[9]
10	of	I	['N']	[10]
11	serum	I	['N']	[11]
12	creatinine	I	['N']	[12]
13	and	I	['N']	[13]
14	blood	I	['N']	[14]
15	urea	I-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	increased	O	['N']	[18]
19	urinary	O	['N']	[19]
20	N	O	['N']	[20]
21	-	O	['N']	[21]
22	acetyl	O	['N']	[22]
23	glucosaminase	O	['N']	[23]
24	after	O	['N']	[24]
25	several	O	['N']	[25]
26	days	O	['N']	[26]
27	of	O	['N']	[27]
28	the	O	['N']	[28]
29	drug	O	['N']	[29]
30	administration	O	['N']	[30]
31	in	O	['N']	[31]
32	these	O	['N']	[32]
33	patients	O	['N']	[33]
34	;	O	['N']	[34]
35	one	O	['N']	[35]
36	patient	O	['N']	[36]
37	became	O	['N']	[37]
38	unconscious	O	['N']	[38]
39	.	O	['N']	[39]
#2902
0	Atrioventricular	O	['N']	[0]
1	block	O	['N']	[1]
2	complicating	O	['N']	[2]
3	amiodarone	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	hypothyroidism	B-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	pre	O	['N']	[11]
12	-	O	['N']	[12]
13	excitation	O	['N']	[13]
14	and	O	['N']	[14]
15	rate	O	['N']	[15]
16	-	O	['N']	[16]
17	dependent	O	['N']	[17]
18	bilateral	O	['N']	[18]
19	bundle	O	['N']	[19]
20	branch	O	['N']	[20]
21	block	O	['N']	[21]
22	.	O	['N']	[22]
#2903
0	Transient	B	['N']	[0]
1	neurological	I	['N']	[1]
2	disturbances	I-Adverse_Effect	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	the	O	['N']	[5]
6	chemotherapy	O	['N']	[6]
7	of	O	['N']	[7]
8	high	O	['N']	[8]
9	-	O	['N']	[9]
10	dose	O	['N']	[10]
11	methotrexate	B-Drug	['Causes']	[2]
12	for	O	['N']	[12]
13	osteogenic	O	['N']	[13]
14	sarcoma	O	['N']	[14]
15	.	O	['N']	[15]
#2904
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	teicoplanin	B-Drug	['Causes']	[7]
5	-	O	['N']	[5]
6	related	O	['N']	[6]
7	neutropenia	B-Adverse_Effect	['N']	[7]
8	that	O	['N']	[8]
9	developed	O	['N']	[9]
10	after	O	['N']	[10]
11	an	O	['N']	[11]
12	episode	O	['N']	[12]
13	of	O	['N']	[13]
14	neutropenia	O	['N']	[14]
15	induced	O	['N']	[15]
16	by	O	['N']	[16]
17	vancomycin	O	['N']	[17]
18	therapy	O	['N']	[18]
19	.	O	['N']	[19]
#2905
0	Patient	O	['N']	[0]
1	A	O	['N']	[1]
2	reported	O	['N']	[2]
3	right	O	['N']	[3]
4	leg	O	['N']	[4]
5	weakness	O	['N']	[5]
6	(	O	['N']	[6]
7	foot	B	['N']	[7]
8	drop	I-Adverse_Effect	['N']	[8]
9	)	O	['N']	[9]
10	during	O	['N']	[10]
11	week	O	['N']	[11]
12	4	O	['N']	[12]
13	of	O	['N']	[13]
14	CAP	B	['N']	[14]
15	-	I	['N']	[15]
16	XRT	I-Drug	['Causes']	[8]
17	(	O	['N']	[17]
18	1600	O	['N']	[18]
19	mg	O	['N']	[19]
20	/	O	['N']	[20]
21	m2	O	['N']	[21]
22	)	O	['N']	[22]
23	.	O	['N']	[23]
#2906
0	Vancomycin	B-Drug	['Causes']	[37]
1	is	O	['N']	[1]
2	widely	O	['N']	[2]
3	used	O	['N']	[3]
4	against	O	['N']	[4]
5	methicillin	O	['N']	[5]
6	-	O	['N']	[6]
7	resistant	O	['N']	[7]
8	Staphylococcus	O	['N']	[8]
9	aureus	O	['N']	[9]
10	infections	O	['N']	[10]
11	,	O	['N']	[11]
12	but	O	['N']	[12]
13	it	O	['N']	[13]
14	is	O	['N']	[14]
15	associated	O	['N']	[15]
16	with	O	['N']	[16]
17	many	O	['N']	[17]
18	adverse	O	['N']	[18]
19	effects	O	['N']	[19]
20	such	O	['N']	[20]
21	as	O	['N']	[21]
22	nephrotoxicity	O	['N']	[22]
23	,	O	['N']	[23]
24	ototoxicity	O	['N']	[24]
25	,	O	['N']	[25]
26	gastrointestinal	O	['N']	[26]
27	disturbances	O	['N']	[27]
28	,	O	['N']	[28]
29	blood	O	['N']	[29]
30	disorders	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	two	O	['N']	[33]
34	types	O	['N']	[34]
35	of	O	['N']	[35]
36	hypersensitivity	B	['N']	[36]
37	reactions	I-Adverse_Effect	['N']	[37]
38	-	O	['N']	[38]
39	an	O	['N']	[39]
40	anaphylactoid	O	['N']	[40]
41	reaction	O	['N']	[41]
42	known	O	['N']	[42]
43	as	O	['N']	[43]
44	"	O	['N']	[44]
45	red	O	['N']	[45]
46	man	O	['N']	[46]
47	syndrome	O	['N']	[47]
48	"	O	['N']	[48]
49	and	O	['N']	[49]
50	anaphylaxis	O	['N']	[50]
51	.	O	['N']	[51]
#2907
0	A	O	['N']	[0]
1	14-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	developed	O	['N']	[5]
6	systemic	O	['N']	[6]
7	lupus	O	['N']	[7]
8	erythematosus	O	['N']	[8]
9	(	O	['N']	[9]
10	SLE)-like	O	['N']	[10]
11	symptoms	O	['N']	[11]
12	,	O	['N']	[12]
13	rash	O	['N']	[13]
14	,	O	['N']	[14]
15	fever	O	['N']	[15]
16	,	O	['N']	[16]
17	leukopenia	B-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	positive	O	['N']	[19]
20	anti	O	['N']	[20]
21	-	O	['N']	[21]
22	nuclear	O	['N']	[22]
23	antibody	O	['N']	[23]
24	(	O	['N']	[24]
25	ANA	O	['N']	[25]
26	)	O	['N']	[26]
27	two	O	['N']	[27]
28	weeks	O	['N']	[28]
29	after	O	['N']	[29]
30	administration	O	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	O	['N']	[32]
33	(	O	['N']	[33]
34	CBZ	B-Drug	['Causes']	[17]
35	;	O	['N']	[35]
36	Tegretol	O	['N']	[36]
37	)	O	['N']	[37]
38	used	O	['N']	[38]
39	against	O	['N']	[39]
40	benign	O	['N']	[40]
41	Rolandic	O	['N']	[41]
42	epilepsy	O	['N']	[42]
43	.	O	['N']	[43]
#2908
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	follow	O	['N']	[2]
3	-	O	['N']	[3]
4	up	O	['N']	[4]
5	revealed	O	['N']	[5]
6	that	O	['N']	[6]
7	gestational	O	['N']	[7]
8	diabetes	O	['N']	[8]
9	when	O	['N']	[9]
10	associated	O	['N']	[10]
11	with	O	['N']	[11]
12	norethisterone	B-Drug	['Causes']	[20]
13	had	O	['N']	[13]
14	a	O	['N']	[14]
15	lesser	O	['N']	[15]
16	risk	O	['N']	[16]
17	of	O	['N']	[17]
18	emerging	O	['N']	[18]
19	diabetes	B	['N']	[19]
20	mellitus	I-Adverse_Effect	['N']	[20]
21	and	O	['N']	[21]
22	impaired	O	['N']	[22]
23	glucose	O	['N']	[23]
24	tolerance	O	['N']	[24]
25	.	O	['N']	[25]
#2909
0	Theoretical	O	['N']	[0]
1	basal	O	['N']	[1]
2	ganglia	O	['N']	[2]
3	toxicologic	O	['N']	[3]
4	mechanisms	O	['N']	[4]
5	of	O	['N']	[5]
6	methanol	B-Drug	['Causes']	[7]
7	poisoning	I-Adverse_Effect	['N']	[7]
8	are	O	['N']	[8]
9	reviewed	O	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	the	O	['N']	[12]
13	role	O	['N']	[13]
14	of	O	['N']	[14]
15	brain	O	['N']	[15]
16	imaging	O	['N']	[16]
17	studies	O	['N']	[17]
18	will	O	['N']	[18]
19	regard	O	['N']	[19]
20	to	O	['N']	[20]
21	diagnosis	O	['N']	[21]
22	,	O	['N']	[22]
23	prognosis	O	['N']	[23]
24	and	O	['N']	[24]
25	impact	O	['N']	[25]
26	on	O	['N']	[26]
27	management	O	['N']	[27]
28	is	O	['N']	[28]
29	discussed	O	['N']	[29]
30	.	O	['N']	[30]
#2910
0	Morphine	B-Drug	['Causes']	[15]
1	,	O	['N']	[1]
2	an	O	['N']	[2]
3	opium	O	['N']	[3]
4	alkaloid	O	['N']	[4]
5	,	O	['N']	[5]
6	frequently	O	['N']	[6]
7	causes	O	['N']	[7]
8	side	O	['N']	[8]
9	effects	O	['N']	[9]
10	such	O	['N']	[10]
11	as	O	['N']	[11]
12	hyperhidrosis	O	['N']	[12]
13	and	O	['N']	[13]
14	facial	B	['N']	[14]
15	flushing	I-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	but	O	['N']	[17]
18	serious	O	['N']	[18]
19	cutaneous	O	['N']	[19]
20	adverse	O	['N']	[20]
21	drug	O	['N']	[21]
22	reactions	O	['N']	[22]
23	are	O	['N']	[23]
24	seldom	O	['N']	[24]
25	observed	O	['N']	[25]
26	.	O	['N']	[26]
#2911
0	A	O	['N']	[0]
1	few	O	['N']	[1]
2	recent	O	['N']	[2]
3	individual	O	['N']	[3]
4	case	O	['N']	[4]
5	reports	O	['N']	[5]
6	have	O	['N']	[6]
7	suggested	O	['N']	[7]
8	that	O	['N']	[8]
9	a	O	['N']	[9]
10	myasthenic	B	['N']	[10]
11	syndrome	I-Adverse_Effect	['N']	[11]
12	may	O	['N']	[12]
13	be	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	statin	B-Drug	['Causes']	[11]
17	treatment	O	['N']	[17]
18	,	O	['N']	[18]
19	but	O	['N']	[19]
20	this	O	['N']	[20]
21	association	O	['N']	[21]
22	is	O	['N']	[22]
23	not	O	['N']	[23]
24	well	O	['N']	[24]
25	described	O	['N']	[25]
26	.	O	['N']	[26]
#2912
0	Many	O	['N']	[0]
1	clinicians	O	['N']	[1]
2	appear	O	['N']	[2]
3	to	O	['N']	[3]
4	be	O	['N']	[4]
5	concerned	O	['N']	[5]
6	about	O	['N']	[6]
7	the	O	['N']	[7]
8	potential	O	['N']	[8]
9	hepatotoxicity	B-Adverse_Effect	['N']	[9]
10	of	O	['N']	[10]
11	the	O	['N']	[11]
12	opiate	O	['N']	[12]
13	antagonist	O	['N']	[13]
14	naltrexone	B-Drug	['Causes']	[9]
15	(	O	['N']	[15]
16	NTX	O	['N']	[16]
17	)	O	['N']	[17]
18	and	O	['N']	[18]
19	this	O	['N']	[19]
20	may	O	['N']	[20]
21	be	O	['N']	[21]
22	one	O	['N']	[22]
23	reason	O	['N']	[23]
24	why	O	['N']	[24]
25	it	O	['N']	[25]
26	is	O	['N']	[26]
27	not	O	['N']	[27]
28	used	O	['N']	[28]
29	more	O	['N']	[29]
30	widely	O	['N']	[30]
31	in	O	['N']	[31]
32	treating	O	['N']	[32]
33	both	O	['N']	[33]
34	heroin	O	['N']	[34]
35	and	O	['N']	[35]
36	alcohol	O	['N']	[36]
37	abusers	O	['N']	[37]
38	.	O	['N']	[38]
#2913
0	Less	O	['N']	[0]
1	common	O	['N']	[1]
2	adverse	O	['N']	[2]
3	events	O	['N']	[3]
4	to	O	['N']	[4]
5	dapsone	B-Drug	['Causes']	[30]
6	include	O	['N']	[6]
7	the	O	['N']	[7]
8	idiosyncratic	O	['N']	[8]
9	reactions	O	['N']	[9]
10	of	O	['N']	[10]
11	leukopenia	O	['N']	[11]
12	and	O	['N']	[12]
13	agranulocytosis	O	['N']	[13]
14	,	O	['N']	[14]
15	cutaneous	O	['N']	[15]
16	eruptions	O	['N']	[16]
17	,	O	['N']	[17]
18	peripheral	O	['N']	[18]
19	neuropathy	O	['N']	[19]
20	,	O	['N']	[20]
21	psychosis	O	['N']	[21]
22	,	O	['N']	[22]
23	toxic	O	['N']	[23]
24	hepatitis	O	['N']	[24]
25	,	O	['N']	[25]
26	cholestatic	O	['N']	[26]
27	jaundice	O	['N']	[27]
28	,	O	['N']	[28]
29	nephrotic	B	['N']	[29]
30	syndrome	I-Adverse_Effect	['N']	[30]
31	,	O	['N']	[31]
32	renal	O	['N']	[32]
33	papillary	O	['N']	[33]
34	necrosis	O	['N']	[34]
35	,	O	['N']	[35]
36	severe	O	['N']	[36]
37	hypoalbuminemia	O	['N']	[37]
38	without	O	['N']	[38]
39	proteinuria	O	['N']	[39]
40	,	O	['N']	[40]
41	an	O	['N']	[41]
42	infectious	O	['N']	[42]
43	mononucleosis	O	['N']	[43]
44	-	O	['N']	[44]
45	like	O	['N']	[45]
46	syndrome	O	['N']	[46]
47	,	O	['N']	[47]
48	and	O	['N']	[48]
49	minor	O	['N']	[49]
50	neurological	O	['N']	[50]
51	and	O	['N']	[51]
52	gastrointestinal	O	['N']	[52]
53	complaints	O	['N']	[53]
54	.	O	['N']	[54]
#2914
0	Gabapentin	B-Drug	['Causes']	[6]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	mood	O	['N']	[3]
4	changes	O	['N']	[4]
5	with	O	['N']	[5]
6	hypomanic	B-Adverse_Effect	['N']	[6]
7	features	O	['N']	[7]
8	in	O	['N']	[8]
9	adults	O	['N']	[9]
10	.	O	['N']	[10]
#2915
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	a	O	['N']	[3]
4	further	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	methimazole	B-Drug	['Causes']	[11]
8	-	O	['N']	[8]
9	associated	O	['N']	[9]
10	liver	B	['N']	[10]
11	damage	I-Adverse_Effect	['N']	[11]
12	and	O	['N']	[12]
13	present	O	['N']	[13]
14	a	O	['N']	[14]
15	brief	O	['N']	[15]
16	review	O	['N']	[16]
17	of	O	['N']	[17]
18	eleven	O	['N']	[18]
19	previous	O	['N']	[19]
20	cases	O	['N']	[20]
21	found	O	['N']	[21]
22	in	O	['N']	[22]
23	the	O	['N']	[23]
24	literature	O	['N']	[24]
25	.	O	['N']	[25]
#2916
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	suggests	O	['N']	[2]
3	that	O	['N']	[3]
4	sarcoidosis	O	['N']	[4]
5	and	O	['N']	[5]
6	pravastatin	B-Drug	['Causes']	[14]
7	,	O	['N']	[7]
8	two	O	['N']	[8]
9	entities	O	['N']	[9]
10	not	O	['N']	[10]
11	frequently	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	myotonia	B-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	may	O	['N']	[16]
17	interact	O	['N']	[17]
18	in	O	['N']	[18]
19	a	O	['N']	[19]
20	synergistic	O	['N']	[20]
21	manner	O	['N']	[21]
22	to	O	['N']	[22]
23	produce	O	['N']	[23]
24	severe	O	['N']	[24]
25	clinical	O	['N']	[25]
26	myotonia	O	['N']	[26]
27	in	O	['N']	[27]
28	humans	O	['N']	[28]
29	.	O	['N']	[29]
#2917
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	55-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	became	O	['N']	[7]
8	stuporous	B-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	overdose	O	['N']	[10]
11	with	O	['N']	[11]
12	lamotrigine	B-Drug	['Causes']	[8]
13	(	O	['N']	[13]
14	LTG	O	['N']	[14]
15	)	O	['N']	[15]
16	and	O	['N']	[16]
17	valproic	O	['N']	[17]
18	acid	O	['N']	[18]
19	(	O	['N']	[19]
20	VPA	O	['N']	[20]
21	)	O	['N']	[21]
22	tablets	O	['N']	[22]
23	.	O	['N']	[23]
#2918
0	Chronic	O	['N']	[0]
1	hydroxychloroquine	B-Drug	['Causes']	[6]
2	use	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	QT	B	['N']	[5]
6	prolongation	I-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	refractory	O	['N']	[8]
9	ventricular	O	['N']	[9]
10	arrhythmia	O	['N']	[10]
11	.	O	['N']	[11]
#2919
0	Lower	O	['N']	[0]
1	extremity	O	['N']	[1]
2	arterial	B	['N']	[2]
3	insufficiency	I-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	long	O	['N']	[5]
6	-	O	['N']	[6]
7	term	O	['N']	[7]
8	methysergide	B	['N']	[8]
9	maleate	I-Drug	['Causes']	[3]
10	therapy	O	['N']	[10]
11	.	O	['N']	[11]
#2920
0	Celiac	B	['N']	[0]
1	disease	I-Adverse_Effect	['N']	[1]
2	onset	O	['N']	[2]
3	after	O	['N']	[3]
4	pegylated	O	['N']	[4]
5	interferon	O	['N']	[5]
6	and	O	['N']	[6]
7	ribavirin	B-Drug	['Causes']	[1]
8	treatment	O	['N']	[8]
9	of	O	['N']	[9]
10	chronic	O	['N']	[10]
11	hepatitis	O	['N']	[11]
12	C.	O	['N']	[12]
#2921
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	An	O	['N']	[3]
4	80-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	white	O	['N']	[7]
8	female	O	['N']	[8]
9	,	O	['N']	[9]
10	followed	O	['N']	[10]
11	up	O	['N']	[11]
12	at	O	['N']	[12]
13	the	O	['N']	[13]
14	Memory	O	['N']	[14]
15	Clinic	O	['N']	[15]
16	for	O	['N']	[16]
17	mild	B	['N']	[17]
18	cognitive	I	['N']	[18]
19	impairment	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	had	O	['N']	[21]
22	been	O	['N']	[22]
23	taking	O	['N']	[23]
24	propafenone	B-Drug	['Causes']	[19]
25	900	O	['N']	[25]
26	mg	O	['N']	[26]
27	/	O	['N']	[27]
28	d	O	['N']	[28]
29	for	O	['N']	[29]
30	>	O	['N']	[30]
31	10	O	['N']	[31]
32	years	O	['N']	[32]
33	for	O	['N']	[33]
34	paroxysmal	O	['N']	[34]
35	atrial	O	['N']	[35]
36	fibrillation	O	['N']	[36]
37	without	O	['N']	[37]
38	adverse	O	['N']	[38]
39	effects	O	['N']	[39]
40	.	O	['N']	[40]
#2922
0	Retinopathy	B-Adverse_Effect	['N']	[0]
1	in	O	['N']	[1]
2	hepatitis	O	['N']	[2]
3	C	O	['N']	[3]
4	patients	O	['N']	[4]
5	due	O	['N']	[5]
6	to	O	['N']	[6]
7	combination	O	['N']	[7]
8	therapy	O	['N']	[8]
9	with	O	['N']	[9]
10	pegylated	B	['N']	[10]
11	interferon	I-Drug	['Causes']	[0]
12	and	O	['N']	[12]
13	ribavirin	O	['N']	[13]
14	.	O	['N']	[14]
#2923
0	Polyarthritis	O	['N']	[0]
1	,	O	['N']	[1]
2	hepatitis	O	['N']	[2]
3	and	O	['N']	[3]
4	anti	B	['N']	[4]
5	-	I	['N']	[5]
6	native	I	['N']	[6]
7	DNA	I	['N']	[7]
8	antibodies	I-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	ethambutol	B-Drug	['Causes']	[8]
13	and	O	['N']	[13]
14	rifampicin	O	['N']	[14]
15	.	O	['N']	[15]
#2924
0	Massive	O	['N']	[0]
1	plasmocytosis	O	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	methimazole	B-Drug	['Causes']	[9]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	bone	B	['N']	[7]
8	marrow	I	['N']	[8]
9	toxicity	I-Adverse_Effect	['N']	[9]
10	.	O	['N']	[10]
#2925
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	authors	O	['N']	[3]
4	described	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	interferon	B-Drug	['Causes']	[11]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	psychosis	B-Adverse_Effect	['N']	[11]
12	as	O	['N']	[12]
13	a	O	['N']	[13]
14	framework	O	['N']	[14]
15	to	O	['N']	[15]
16	review	O	['N']	[16]
17	the	O	['N']	[17]
18	literature	O	['N']	[18]
19	and	O	['N']	[19]
20	discuss	O	['N']	[20]
21	the	O	['N']	[21]
22	decision	O	['N']	[22]
23	to	O	['N']	[23]
24	pursue	O	['N']	[24]
25	antiviral	O	['N']	[25]
26	treatment	O	['N']	[26]
27	in	O	['N']	[27]
28	psychiatrically	O	['N']	[28]
29	ill	O	['N']	[29]
30	patients	O	['N']	[30]
31	with	O	['N']	[31]
32	hepatitis	O	['N']	[32]
33	C.	O	['N']	[33]
#2926
0	It	O	['N']	[0]
1	remains	O	['N']	[1]
2	to	O	['N']	[2]
3	be	O	['N']	[3]
4	seen	O	['N']	[4]
5	whether	O	['N']	[5]
6	the	O	['N']	[6]
7	hepatotoxicity	B-Adverse_Effect	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	troglitazone	B-Drug	['Causes']	[7]
11	is	O	['N']	[11]
12	a	O	['N']	[12]
13	drug	O	['N']	[13]
14	-	O	['N']	[14]
15	class	O	['N']	[15]
16	effect	O	['N']	[16]
17	or	O	['N']	[17]
18	specific	O	['N']	[18]
19	to	O	['N']	[19]
20	troglitazone	O	['N']	[20]
21	.	O	['N']	[21]
#2927
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	specifics	O	['N']	[3]
4	of	O	['N']	[4]
5	12	O	['N']	[5]
6	cases	O	['N']	[6]
7	of	O	['N']	[7]
8	severe	B	['N']	[8]
9	hypertension	I-Adverse_Effect	['N']	[9]
10	after	O	['N']	[10]
11	the	O	['N']	[11]
12	intraoperative	O	['N']	[12]
13	use	O	['N']	[13]
14	of	O	['N']	[14]
15	topical	O	['N']	[15]
16	phenylephrine	B-Drug	['Causes']	[9]
17	,	O	['N']	[17]
18	submucosal	O	['N']	[18]
19	epinephrine	O	['N']	[19]
20	,	O	['N']	[20]
21	or	O	['N']	[21]
22	both	O	['N']	[22]
23	.	O	['N']	[23]
#2928
0	Early	O	['N']	[0]
1	-	O	['N']	[1]
2	onset	O	['N']	[2]
3	pentamidine	B-Drug	['Causes']	[10]
4	-	O	['N']	[4]
5	associated	O	['N']	[5]
6	second	B	['N']	[6]
7	-	I	['N']	[7]
8	degree	I	['N']	[8]
9	heart	I	['N']	[9]
10	block	I-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	sinus	O	['N']	[12]
13	bradycardia	O	['N']	[13]
14	:	O	['N']	[14]
15	case	O	['N']	[15]
16	report	O	['N']	[16]
17	and	O	['N']	[17]
18	review	O	['N']	[18]
19	of	O	['N']	[19]
20	the	O	['N']	[20]
21	literature	O	['N']	[21]
22	.	O	['N']	[22]
#2929
0	Amphotericin	O	['N']	[0]
1	B	O	['N']	[1]
2	(	O	['N']	[2]
3	AmB	B-Drug	['Causes']	[23]
4	)	O	['N']	[4]
5	is	O	['N']	[5]
6	effective	O	['N']	[6]
7	,	O	['N']	[7]
8	but	O	['N']	[8]
9	its	O	['N']	[9]
10	use	O	['N']	[10]
11	is	O	['N']	[11]
12	limited	O	['N']	[12]
13	by	O	['N']	[13]
14	toxicity	O	['N']	[14]
15	:	O	['N']	[15]
16	renal	O	['N']	[16]
17	impairment	O	['N']	[17]
18	,	O	['N']	[18]
19	anaemia	O	['N']	[19]
20	,	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	malaise	B-Adverse_Effect	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	hypokalaemia	O	['N']	[26]
27	are	O	['N']	[27]
28	common	O	['N']	[28]
29	.	O	['N']	[29]
#2930
0	Replicate	O	['N']	[0]
1	brain	O	['N']	[1]
2	magnetic	O	['N']	[2]
3	resonance	O	['N']	[3]
4	imaging	O	['N']	[4]
5	examinations	O	['N']	[5]
6	after	O	['N']	[6]
7	six	O	['N']	[7]
8	weeks	O	['N']	[8]
9	and	O	['N']	[9]
10	11	O	['N']	[10]
11	months	O	['N']	[11]
12	of	O	['N']	[12]
13	penicillamine	B-Drug	['Causes']	[21]
14	therapy	O	['N']	[14]
15	documented	O	['N']	[15]
16	the	O	['N']	[16]
17	development	O	['N']	[17]
18	of	O	['N']	[18]
19	new	O	['N']	[19]
20	brain	B	['N']	[20]
21	lesions	I-Adverse_Effect	['N']	[21]
22	during	O	['N']	[22]
23	this	O	['N']	[23]
24	period	O	['N']	[24]
25	,	O	['N']	[25]
26	while	O	['N']	[26]
27	liver	O	['N']	[27]
28	biopsy	O	['N']	[28]
29	specimen	O	['N']	[29]
30	data	O	['N']	[30]
31	disclosed	O	['N']	[31]
32	that	O	['N']	[32]
33	excellent	O	['N']	[33]
34	hepatic	O	['N']	[34]
35	decoppering	O	['N']	[35]
36	had	O	['N']	[36]
37	occurred	O	['N']	[37]
38	.	O	['N']	[38]
#2931
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	significant	O	['N']	[5]
6	over	B	['N']	[6]
7	-	I	['N']	[7]
8	anticoagulation	I-Adverse_Effect	['N']	[8]
9	temporally	O	['N']	[9]
10	associated	O	['N']	[10]
11	with	O	['N']	[11]
12	a	O	['N']	[12]
13	bout	O	['N']	[13]
14	of	O	['N']	[14]
15	protracted	O	['N']	[15]
16	diarrhea	O	['N']	[16]
17	in	O	['N']	[17]
18	a	O	['N']	[18]
19	patient	O	['N']	[19]
20	on	O	['N']	[20]
21	warfarin	B-Drug	['Causes']	[8]
22	therapy	O	['N']	[22]
23	.	O	['N']	[23]
#2932
0	Both	O	['N']	[0]
1	colchicine	B-Drug	['Causes']	[9]
2	and	O	['N']	[2]
3	statin	O	['N']	[3]
4	therapy	O	['N']	[4]
5	may	O	['N']	[5]
6	be	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	myopathy	B-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	which	O	['N']	[11]
12	usually	O	['N']	[12]
13	occurs	O	['N']	[13]
14	after	O	['N']	[14]
15	several	O	['N']	[15]
16	months	O	['N']	[16]
17	of	O	['N']	[17]
18	therapy	O	['N']	[18]
19	.	O	['N']	[19]
#2933
0	STUDY	O	['N']	[0]
1	DESIGN	O	['N']	[1]
2	:	O	['N']	[2]
3	Case	O	['N']	[3]
4	reports	O	['N']	[4]
5	are	O	['N']	[5]
6	presented	O	['N']	[6]
7	of	O	['N']	[7]
8	three	O	['N']	[8]
9	premature	O	['N']	[9]
10	infants	O	['N']	[10]
11	(	O	['N']	[11]
12	mean	O	['N']	[12]
13	gestational	O	['N']	[13]
14	age	O	['N']	[14]
15	27	O	['N']	[15]
16	weeks	O	['N']	[16]
17	)	O	['N']	[17]
18	cared	O	['N']	[18]
19	for	O	['N']	[19]
20	in	O	['N']	[20]
21	the	O	['N']	[21]
22	intensive	O	['N']	[22]
23	care	O	['N']	[23]
24	nursery	O	['N']	[24]
25	in	O	['N']	[25]
26	whom	O	['N']	[26]
27	clinically	O	['N']	[27]
28	significant	O	['N']	[28]
29	septal	B	['N']	[29]
30	hypertrophy	I-Adverse_Effect	['N']	[30]
31	and	O	['N']	[31]
32	left	O	['N']	[32]
33	ventricular	O	['N']	[33]
34	outflow	O	['N']	[34]
35	tract	O	['N']	[35]
36	obstruction	O	['N']	[36]
37	developed	O	['N']	[37]
38	during	O	['N']	[38]
39	dexamethasone	B-Drug	['Causes']	[30]
40	treatment	O	['N']	[40]
41	for	O	['N']	[41]
42	bronchopulmonary	O	['N']	[42]
43	dysplasia	O	['N']	[43]
44	.	O	['N']	[44]
#2934
0	The	O	['N']	[0]
1	administration	O	['N']	[1]
2	of	O	['N']	[2]
3	"	O	['N']	[3]
4	sweet	B	['N']	[4]
5	spirits	I	['N']	[5]
6	of	I	['N']	[6]
7	nitre	I-Drug	['Causes']	[25]
8	"	O	['N']	[8]
9	(	O	['N']	[9]
10	4	O	['N']	[10]
11	%	O	['N']	[11]
12	ethyl	O	['N']	[12]
13	nitrite	O	['N']	[13]
14	CH3CH2ONO	O	['N']	[14]
15	in	O	['N']	[15]
16	70	O	['N']	[16]
17	%	O	['N']	[17]
18	ethyl	O	['N']	[18]
19	alcohol	O	['N']	[19]
20	)	O	['N']	[20]
21	was	O	['N']	[21]
22	followed	O	['N']	[22]
23	by	O	['N']	[23]
24	acute	B	['N']	[24]
25	methemoglobinemia	I-Adverse_Effect	['N']	[25]
26	and	O	['N']	[26]
27	severe	O	['N']	[27]
28	anoxic	O	['N']	[28]
29	metabolic	O	['N']	[29]
30	acidosis	O	['N']	[30]
31	in	O	['N']	[31]
32	infant	O	['N']	[32]
33	twins	O	['N']	[33]
34	,	O	['N']	[34]
35	Methylene	O	['N']	[35]
36	blue	O	['N']	[36]
37	administration	O	['N']	[37]
38	reversed	O	['N']	[38]
39	methemoglobinemia	O	['N']	[39]
40	in	O	['N']	[40]
41	both	O	['N']	[41]
42	,	O	['N']	[42]
43	but	O	['N']	[43]
44	one	O	['N']	[44]
45	twin	O	['N']	[45]
46	died	O	['N']	[46]
47	from	O	['N']	[47]
48	the	O	['N']	[48]
49	consequences	O	['N']	[49]
50	of	O	['N']	[50]
51	hypoxemia	O	['N']	[51]
52	.	O	['N']	[52]
#2935
0	Terlipressin	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	ventricular	B	['N']	[3]
4	arrhythmia	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#2936
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	extends	O	['N']	[2]
3	the	O	['N']	[3]
4	spectrum	O	['N']	[4]
5	of	O	['N']	[5]
6	fludarabine	B-Drug	['Causes']	[12]
7	pulmonary	O	['N']	[7]
8	toxicity	O	['N']	[8]
9	to	O	['N']	[9]
10	include	O	['N']	[10]
11	pulmonary	B	['N']	[11]
12	nodules	I-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#2937
0	FDE	B-Adverse_Effect	['N']	[0]
1	from	O	['N']	[1]
2	cephalosporins	B-Drug	['Causes']	[0]
3	has	O	['N']	[3]
4	been	O	['N']	[4]
5	rarely	O	['N']	[5]
6	reported	O	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	to	O	['N']	[9]
10	the	O	['N']	[10]
11	best	O	['N']	[11]
12	of	O	['N']	[12]
13	our	O	['N']	[13]
14	knowledge	O	['N']	[14]
15	there	O	['N']	[15]
16	is	O	['N']	[16]
17	no	O	['N']	[17]
18	published	O	['N']	[18]
19	report	O	['N']	[19]
20	of	O	['N']	[20]
21	ceftriaxone	O	['N']	[21]
22	-	O	['N']	[22]
23	induced	O	['N']	[23]
24	FDE	O	['N']	[24]
25	in	O	['N']	[25]
26	the	O	['N']	[26]
27	literature	O	['N']	[27]
28	.	O	['N']	[28]
#2938
0	In	O	['N']	[0]
1	three	O	['N']	[1]
2	of	O	['N']	[2]
3	these	O	['N']	[3]
4	patients	O	['N']	[4]
5	the	O	['N']	[5]
6	infection	O	['N']	[6]
7	was	O	['N']	[7]
8	clinically	O	['N']	[8]
9	unsuspected	O	['N']	[9]
10	;	O	['N']	[10]
11	in	O	['N']	[11]
12	the	O	['N']	[12]
13	fourth	O	['N']	[13]
14	,	O	['N']	[14]
15	cutaneous	O	['N']	[15]
16	herpes	O	['N']	[16]
17	zoster	O	['N']	[17]
18	developed	O	['N']	[18]
19	after	O	['N']	[19]
20	administration	O	['N']	[20]
21	of	O	['N']	[21]
22	300	B	['N']	[22]
23	mg	I-Dose	['N']	[23]
24	of	O	['N']	[24]
25	cytarabine	B-Drug	['Dosage']	[23]
26	daily	O	['N']	[26]
27	for	O	['N']	[27]
28	the	O	['N']	[28]
29	preceding	O	['N']	[29]
30	five	O	['N']	[30]
31	days	O	['N']	[31]
32	.	O	['N']	[32]
#2939
0	A	O	['N']	[0]
1	36-y	O	['N']	[1]
2	-	O	['N']	[2]
3	o	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	schizophrenia	O	['N']	[6]
7	,	O	['N']	[7]
8	who	O	['N']	[8]
9	had	O	['N']	[9]
10	consumed	O	['N']	[10]
11	gradually	O	['N']	[11]
12	increasing	O	['N']	[12]
13	quantities	O	['N']	[13]
14	of	O	['N']	[14]
15	oolong	B	['N']	[15]
16	tea	I-Drug	['Causes']	[26]
17	that	O	['N']	[17]
18	eventually	O	['N']	[18]
19	reached	O	['N']	[19]
20	15	O	['N']	[20]
21	L	O	['N']	[21]
22	each	O	['N']	[22]
23	day	O	['N']	[23]
24	,	O	['N']	[24]
25	became	O	['N']	[25]
26	delirious	B-Adverse_Effect	['N']	[26]
27	and	O	['N']	[27]
28	was	O	['N']	[28]
29	admitted	O	['N']	[29]
30	to	O	['N']	[30]
31	a	O	['N']	[31]
32	psychiatric	O	['N']	[32]
33	hospital	O	['N']	[33]
34	.	O	['N']	[34]
#2940
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	linezolid	B-Drug	['Causes']	[8]
4	-	O	['N']	[4]
5	associated	O	['N']	[5]
6	acute	B	['N']	[6]
7	interstitial	I	['N']	[7]
8	nephritis	I-Adverse_Effect	['N']	[8]
9	within	O	['N']	[9]
10	the	O	['N']	[10]
11	context	O	['N']	[11]
12	of	O	['N']	[12]
13	a	O	['N']	[13]
14	drug	O	['N']	[14]
15	rash	O	['N']	[15]
16	with	O	['N']	[16]
17	eosinophilia	O	['N']	[17]
18	and	O	['N']	[18]
19	systemic	O	['N']	[19]
20	symptoms	O	['N']	[20]
21	(	O	['N']	[21]
22	DRESS	O	['N']	[22]
23	)	O	['N']	[23]
24	syndrome	O	['N']	[24]
25	in	O	['N']	[25]
26	a	O	['N']	[26]
27	patient	O	['N']	[27]
28	treated	O	['N']	[28]
29	with	O	['N']	[29]
30	linezolid	O	['N']	[30]
31	raises	O	['N']	[31]
32	concerns	O	['N']	[32]
33	about	O	['N']	[33]
34	the	O	['N']	[34]
35	presumed	O	['N']	[35]
36	renal	O	['N']	[36]
37	safety	O	['N']	[37]
38	of	O	['N']	[38]
39	this	O	['N']	[39]
40	drug	O	['N']	[40]
41	.	O	['N']	[41]
#2941
0	The	O	['N']	[0]
1	mechanism	O	['N']	[1]
2	of	O	['N']	[2]
3	the	O	['N']	[3]
4	decrease	B	['N']	[4]
5	in	I	['N']	[5]
6	plasma	I	['N']	[6]
7	potassium	I-Adverse_Effect	['N']	[7]
8	induced	O	['N']	[8]
9	by	O	['N']	[9]
10	phosphate	B-Drug	['Causes']	[7]
11	treatment	O	['N']	[11]
12	was	O	['N']	[12]
13	investigated	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	24-year	O	['N']	[16]
17	-	O	['N']	[17]
18	old	O	['N']	[18]
19	hypertensive	O	['N']	[19]
20	patient	O	['N']	[20]
21	with	O	['N']	[21]
22	hypophosphatemic	O	['N']	[22]
23	osteomalacia	O	['N']	[23]
24	,	O	['N']	[24]
25	who	O	['N']	[25]
26	was	O	['N']	[26]
27	the	O	['N']	[27]
28	youngest	O	['N']	[28]
29	of	O	['N']	[29]
30	four	O	['N']	[30]
31	patients	O	['N']	[31]
32	,	O	['N']	[32]
33	belonging	O	['N']	[33]
34	to	O	['N']	[34]
35	a	O	['N']	[35]
36	23	O	['N']	[36]
37	number	O	['N']	[37]
38	kindred	O	['N']	[38]
39	of	O	['N']	[39]
40	five	O	['N']	[40]
41	generations	O	['N']	[41]
42	.	O	['N']	[42]
#2942
0	Based	O	['N']	[0]
1	on	O	['N']	[1]
2	our	O	['N']	[2]
3	findings	O	['N']	[3]
4	,	O	['N']	[4]
5	it	O	['N']	[5]
6	is	O	['N']	[6]
7	thus	O	['N']	[7]
8	concluded	O	['N']	[8]
9	that	O	['N']	[9]
10	cisplatin	B-Drug	['Causes']	[15]
11	may	O	['N']	[11]
12	cause	O	['N']	[12]
13	C.	B	['N']	[13]
14	difficile	I	['N']	[14]
15	colitis	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#2943
0	Risperidone	B-Drug	['Causes']	[46]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	frequently	O	['N']	[3]
4	used	O	['N']	[4]
5	member	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	new	O	['N']	[8]
9	class	O	['N']	[9]
10	of	O	['N']	[10]
11	atypical	O	['N']	[11]
12	antipsychotics	O	['N']	[12]
13	-	O	['N']	[13]
14	the	O	['N']	[14]
15	serotonin	O	['N']	[15]
16	-	O	['N']	[16]
17	dopamine	O	['N']	[17]
18	antagonists	O	['N']	[18]
19	(	O	['N']	[19]
20	SDAs)-due	O	['N']	[20]
21	to	O	['N']	[21]
22	its	O	['N']	[22]
23	comparatively	O	['N']	[23]
24	high	O	['N']	[24]
25	efficacy	O	['N']	[25]
26	and	O	['N']	[26]
27	low	O	['N']	[27]
28	D2/5HT2	O	['N']	[28]
29	binding	O	['N']	[29]
30	ratio	O	['N']	[30]
31	,	O	['N']	[31]
32	which	O	['N']	[32]
33	results	O	['N']	[33]
34	in	O	['N']	[34]
35	a	O	['N']	[35]
36	low	O	['N']	[36]
37	incidence	O	['N']	[37]
38	of	O	['N']	[38]
39	extrapyramidal	O	['N']	[39]
40	side	O	['N']	[40]
41	effects	O	['N']	[41]
42	including	O	['N']	[42]
43	tardive	O	['N']	[43]
44	dyskinesia	O	['N']	[44]
45	(	O	['N']	[45]
46	TD	B-Adverse_Effect	['N']	[46]
47	)	O	['N']	[47]
48	.	O	['N']	[48]
#2944
0	After	O	['N']	[0]
1	5	O	['N']	[1]
2	days	O	['N']	[2]
3	of	O	['N']	[3]
4	treatment	O	['N']	[4]
5	with	O	['N']	[5]
6	IL-2	B-Drug	['Causes']	[13]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	patient	O	['N']	[9]
10	developed	O	['N']	[10]
11	a	O	['N']	[11]
12	hemorrhagic	B	['N']	[12]
13	lesion	I-Adverse_Effect	['N']	[13]
14	that	O	['N']	[14]
15	progressed	O	['N']	[15]
16	to	O	['N']	[16]
17	toxic	O	['N']	[17]
18	epidermal	O	['N']	[18]
19	necrolysis	O	['N']	[19]
20	,	O	['N']	[20]
21	as	O	['N']	[21]
22	well	O	['N']	[22]
23	as	O	['N']	[23]
24	grade	O	['N']	[24]
25	4	O	['N']	[25]
26	pancytopenia	O	['N']	[26]
27	.	O	['N']	[27]
#2945
0	Carbamazepine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	tics	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#2946
0	Bradycardia	O	['N']	[0]
1	and	O	['N']	[1]
2	congestive	B	['N']	[2]
3	heart	I	['N']	[3]
4	failure	I-Adverse_Effect	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	ocular	O	['N']	[7]
8	timolol	B	['N']	[8]
9	maleate	I-Drug	['Causes']	[4]
10	.	O	['N']	[10]
#2947
0	Rapamycin	B-Drug	['Causes']	[30]
1	/	O	['N']	[1]
2	sirolimus	O	['N']	[2]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	pneumonitis	O	['N']	[5]
6	has	O	['N']	[6]
7	been	O	['N']	[7]
8	described	O	['N']	[8]
9	previously	O	['N']	[9]
10	in	O	['N']	[10]
11	renal	O	['N']	[11]
12	transplant	O	['N']	[12]
13	recipients	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	this	O	['N']	[16]
17	report	O	['N']	[17]
18	describes	O	['N']	[18]
19	a	O	['N']	[19]
20	stable	O	['N']	[20]
21	heart	O	['N']	[21]
22	-	O	['N']	[22]
23	lung	O	['N']	[23]
24	transplant	O	['N']	[24]
25	recipient	O	['N']	[25]
26	who	O	['N']	[26]
27	developed	O	['N']	[27]
28	a	O	['N']	[28]
29	pulmonary	B	['N']	[29]
30	infiltrate	I-Adverse_Effect	['N']	[30]
31	that	O	['N']	[31]
32	reversed	O	['N']	[32]
33	after	O	['N']	[33]
34	ceasing	O	['N']	[34]
35	SR	O	['N']	[35]
36	therapy	O	['N']	[36]
37	.	O	['N']	[37]
#2948
0	The	O	['N']	[0]
1	bleeding	B-Adverse_Effect	['N']	[1]
2	resolved	O	['N']	[2]
3	on	O	['N']	[3]
4	discontinuation	O	['N']	[4]
5	of	O	['N']	[5]
6	APV	B-Drug	['Causes']	[1]
7	.	O	['N']	[7]
#2949
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	After	O	['N']	[2]
3	4-	O	['N']	[3]
4	to	O	['N']	[4]
5	14-month	O	['N']	[5]
6	period	O	['N']	[6]
7	of	O	['N']	[7]
8	therapy	O	['N']	[8]
9	with	O	['N']	[9]
10	the	O	['N']	[10]
11	combination	O	['N']	[11]
12	of	O	['N']	[12]
13	indapamide	B-Drug	['Causes']	[58]
14	(	O	['N']	[14]
15	2.5	O	['N']	[15]
16	mg	O	['N']	[16]
17	/	O	['N']	[17]
18	day	O	['N']	[18]
19	)	O	['N']	[19]
20	and	O	['N']	[20]
21	fosinopril	O	['N']	[21]
22	(	O	['N']	[22]
23	10	O	['N']	[23]
24	mg	O	['N']	[24]
25	/	O	['N']	[25]
26	day	O	['N']	[26]
27	)	O	['N']	[27]
28	in	O	['N']	[28]
29	three	O	['N']	[29]
30	patients	O	['N']	[30]
31	and	O	['N']	[31]
32	6-month	O	['N']	[32]
33	period	O	['N']	[33]
34	of	O	['N']	[34]
35	monotherapy	O	['N']	[35]
36	with	O	['N']	[36]
37	indapamide	O	['N']	[37]
38	(	O	['N']	[38]
39	2.5	O	['N']	[39]
40	mg	O	['N']	[40]
41	/	O	['N']	[41]
42	day	O	['N']	[42]
43	)	O	['N']	[43]
44	in	O	['N']	[44]
45	one	O	['N']	[45]
46	patient	O	['N']	[46]
47	,	O	['N']	[47]
48	glucose	O	['N']	[48]
49	levels	O	['N']	[49]
50	of	O	['N']	[50]
51	all	O	['N']	[51]
52	patients	O	['N']	[52]
53	increased	O	['N']	[53]
54	and	O	['N']	[54]
55	achieve	O	['N']	[55]
56	criteria	O	['N']	[56]
57	of	O	['N']	[57]
58	diabetes	B-Adverse_Effect	['N']	[58]
59	diagnoses	O	['N']	[59]
60	.	O	['N']	[60]
#2950
0	Diagnosis	O	['N']	[0]
1	of	O	['N']	[1]
2	hypothyroidism	B-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	treatment	O	['N']	[4]
5	can	O	['N']	[5]
6	be	O	['N']	[6]
7	difficult	O	['N']	[7]
8	because	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	common	O	['N']	[11]
12	side	O	['N']	[12]
13	effects	O	['N']	[13]
14	of	O	['N']	[14]
15	alpha	B	['N']	[15]
16	interferon	I-Drug	['Causes']	[2]
17	.	O	['N']	[17]
#2951
0	Fatal	O	['N']	[0]
1	gemcitabine	B-Drug	['Causes']	[5]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	pulmonary	B	['N']	[4]
5	toxicity	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	metastatic	O	['N']	[7]
8	gallbladder	O	['N']	[8]
9	adenocarcinoma	O	['N']	[9]
10	.	O	['N']	[10]
#2952
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	two	O	['N']	[3]
4	patients	O	['N']	[4]
5	who	O	['N']	[5]
6	developed	O	['N']	[6]
7	acute	B	['N']	[7]
8	myelocytic	I	['N']	[8]
9	leukemia	I-Adverse_Effect	['N']	[9]
10	only	O	['N']	[10]
11	after	O	['N']	[11]
12	exposure	O	['N']	[12]
13	to	O	['N']	[13]
14	cyclophosphamide	B-Drug	['Causes']	[9]
15	,	O	['N']	[15]
16	methotrexate	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	5-fluorouracil	O	['N']	[19]
20	adjuvant	O	['N']	[20]
21	therapy	O	['N']	[21]
22	.	O	['N']	[22]
#2953
0	These	O	['N']	[0]
1	multiple	O	['N']	[1]
2	overlapping	O	['N']	[2]
3	factors	O	['N']	[3]
4	probably	O	['N']	[4]
5	lead	O	['N']	[5]
6	to	O	['N']	[6]
7	rhabdomyolysis	B-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	minority	O	['N']	[10]
11	of	O	['N']	[11]
12	patients	O	['N']	[12]
13	receiving	O	['N']	[13]
14	vasopressin	B-Drug	['Causes']	[7]
15	infusion	O	['N']	[15]
16	.	O	['N']	[16]
#2954
0	A	O	['N']	[0]
1	second	O	['N']	[1]
2	possibility	O	['N']	[2]
3	is	O	['N']	[3]
4	an	O	['N']	[4]
5	interaction	O	['N']	[5]
6	between	O	['N']	[6]
7	clarithromycin	O	['N']	[7]
8	and	O	['N']	[8]
9	isradipine	B-Drug	['Causes']	[15]
10	,	O	['N']	[10]
11	potentially	O	['N']	[11]
12	increasing	B	['N']	[12]
13	the	I	['N']	[13]
14	hepatic	I	['N']	[14]
15	toxicity	I-Adverse_Effect	['N']	[15]
16	of	O	['N']	[16]
17	isradipine	O	['N']	[17]
18	.	O	['N']	[18]
#2955
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	report	O	['N']	[3]
4	indicates	O	['N']	[4]
5	clindamycin	B	['N']	[5]
6	phosphate	I-Drug	['Causes']	[15]
7	vaginal	O	['N']	[7]
8	cream	O	['N']	[8]
9	as	O	['N']	[9]
10	the	O	['N']	[10]
11	most	O	['N']	[11]
12	probable	O	['N']	[12]
13	cause	O	['N']	[13]
14	of	O	['N']	[14]
15	CDIC	B-Adverse_Effect	['N']	[15]
16	due	O	['N']	[16]
17	to	O	['N']	[17]
18	the	O	['N']	[18]
19	temporal	O	['N']	[19]
20	relationship	O	['N']	[20]
21	between	O	['N']	[21]
22	the	O	['N']	[22]
23	occurrence	O	['N']	[23]
24	of	O	['N']	[24]
25	diarrhea	O	['N']	[25]
26	and	O	['N']	[26]
27	clindamycin	O	['N']	[27]
28	administration	O	['N']	[28]
29	,	O	['N']	[29]
30	lack	O	['N']	[30]
31	of	O	['N']	[31]
32	concomitant	O	['N']	[32]
33	medications	O	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	documentation	O	['N']	[36]
37	of	O	['N']	[37]
38	C.	O	['N']	[38]
39	difficile	O	['N']	[39]
40	toxin	O	['N']	[40]
41	.	O	['N']	[41]
#2956
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	administration	O	['N']	[3]
4	of	O	['N']	[4]
5	prostaglandin	B	['N']	[5]
6	E1	I-Drug	['Causes']	[18]
7	to	O	['N']	[7]
8	neonates	O	['N']	[8]
9	can	O	['N']	[9]
10	cause	O	['N']	[10]
11	gastric	O	['N']	[11]
12	-	O	['N']	[12]
13	outlet	O	['N']	[13]
14	obstruction	O	['N']	[14]
15	due	O	['N']	[15]
16	to	O	['N']	[16]
17	antral	B	['N']	[17]
18	hyperplasia	I-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#2957
0	Severe	O	['N']	[0]
1	histological	O	['N']	[1]
2	osteomalacia	B-Adverse_Effect	['N']	[2]
3	developed	O	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	woman	O	['N']	[6]
7	with	O	['N']	[7]
8	Crohn	O	['N']	[8]
9	's	O	['N']	[9]
10	disease	O	['N']	[10]
11	2	O	['N']	[11]
12	years	O	['N']	[12]
13	after	O	['N']	[13]
14	ileal	O	['N']	[14]
15	resection	O	['N']	[15]
16	and	O	['N']	[16]
17	the	O	['N']	[17]
18	start	O	['N']	[18]
19	of	O	['N']	[19]
20	cholestyramine	B-Drug	['Causes']	[2]
21	therapy	O	['N']	[21]
22	.	O	['N']	[22]
#2958
0	Hydrocortisone	O	['N']	[0]
1	may	O	['N']	[1]
2	decrease	O	['N']	[2]
3	the	O	['N']	[3]
4	incidence	O	['N']	[4]
5	of	O	['N']	[5]
6	mortality	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	cardiac	O	['N']	[9]
10	arrhythmias	O	['N']	[10]
11	in	O	['N']	[11]
12	children	O	['N']	[12]
13	receiving	O	['N']	[13]
14	amphotericin	B	['N']	[14]
15	B	I-Drug	['Dosage']	[16]
16	overdoses	B-Dose	['N']	[16]
17	.	O	['N']	[17]
#2959
0	In	O	['N']	[0]
1	a	O	['N']	[1]
2	patient	O	['N']	[2]
3	suffering	O	['N']	[3]
4	from	O	['N']	[4]
5	rheumatoid	O	['N']	[5]
6	arthritis	O	['N']	[6]
7	,	O	['N']	[7]
8	we	O	['N']	[8]
9	report	O	['N']	[9]
10	the	O	['N']	[10]
11	first	O	['N']	[11]
12	simultaneous	O	['N']	[12]
13	occurrence	O	['N']	[13]
14	of	O	['N']	[14]
15	two	O	['N']	[15]
16	side	O	['N']	[16]
17	effects	O	['N']	[17]
18	of	O	['N']	[18]
19	low	B	['N']	[19]
20	-	I	['N']	[20]
21	dose	I-Dose	['N']	[21]
22	methotrexate	B-Drug	['Dosage']	[21]
23	:	O	['N']	[23]
24	an	O	['N']	[24]
25	acute	O	['N']	[25]
26	megaloblastic	O	['N']	[26]
27	anaemia	O	['N']	[27]
28	and	O	['N']	[28]
29	a	O	['N']	[29]
30	pneumonitis	O	['N']	[30]
31	.	O	['N']	[31]
#2960
0	Benzocaine	B-Drug	['Causes']	[14]
1	,	O	['N']	[1]
2	an	O	['N']	[2]
3	ester	O	['N']	[3]
4	-	O	['N']	[4]
5	type	O	['N']	[5]
6	local	O	['N']	[6]
7	anesthetic	O	['N']	[7]
8	,	O	['N']	[8]
9	was	O	['N']	[9]
10	believed	O	['N']	[10]
11	responsible	O	['N']	[11]
12	for	O	['N']	[12]
13	apparent	O	['N']	[13]
14	methemoglobinemia	B-Adverse_Effect	['N']	[14]
15	in	O	['N']	[15]
16	a	O	['N']	[16]
17	cat	O	['N']	[17]
18	.	O	['N']	[18]
#2961
0	Amiodarone	B	['N']	[0]
1	hydrochloride	I-Drug	['Causes']	[16]
2	,	O	['N']	[2]
3	a	O	['N']	[3]
4	new	O	['N']	[4]
5	antiarrhythmic	O	['N']	[5]
6	agent	O	['N']	[6]
7	,	O	['N']	[7]
8	has	O	['N']	[8]
9	been	O	['N']	[9]
10	associated	O	['N']	[10]
11	with	O	['N']	[11]
12	pulmonary	O	['N']	[12]
13	toxicity	O	['N']	[13]
14	characterized	O	['N']	[14]
15	by	O	['N']	[15]
16	cough	B-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	dyspnea	O	['N']	[18]
19	and	O	['N']	[19]
20	diffuse	O	['N']	[20]
21	pulmonary	O	['N']	[21]
22	infiltrates	O	['N']	[22]
23	.	O	['N']	[23]
#2962
0	Paraplegia	O	['N']	[0]
1	following	O	['N']	[1]
2	prophylactic	O	['N']	[2]
3	intrathecal	O	['N']	[3]
4	cytosine	O	['N']	[4]
5	arabinoside	O	['N']	[5]
6	(	O	['N']	[6]
7	Ara	B	['N']	[7]
8	-	I	['N']	[8]
9	C	I-Drug	['Dosage']	[29]
10	)	O	['N']	[10]
11	is	O	['N']	[11]
12	described	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	patient	O	['N']	[15]
16	with	O	['N']	[16]
17	acute	O	['N']	[17]
18	myelogenous	O	['N']	[18]
19	leukemia	O	['N']	[19]
20	in	O	['N']	[20]
21	remission	O	['N']	[21]
22	who	O	['N']	[22]
23	received	O	['N']	[23]
24	doses	O	['N']	[24]
25	of	O	['N']	[25]
26	100	B	['N']	[26]
27	mg	I	['N']	[27]
28	/	I	['N']	[28]
29	m2/d	I-Dose	['N']	[29]
30	for	O	['N']	[30]
31	5	O	['N']	[31]
32	consecutive	O	['N']	[32]
33	days	O	['N']	[33]
34	.	O	['N']	[34]
#2963
0	INTRODUCTION	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	describe	O	['N']	[3]
4	the	O	['N']	[4]
5	neurointensive	O	['N']	[5]
6	care	O	['N']	[6]
7	(	O	['N']	[7]
8	NIC	O	['N']	[8]
9	)	O	['N']	[9]
10	management	O	['N']	[10]
11	of	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	severe	B	['N']	[15]
16	cerebral	I	['N']	[16]
17	swelling	I-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	raised	O	['N']	[19]
20	intracranial	O	['N']	[20]
21	pressure	O	['N']	[21]
22	(	O	['N']	[22]
23	ICP	O	['N']	[23]
24	)	O	['N']	[24]
25	after	O	['N']	[25]
26	severe	O	['N']	[26]
27	sodium	O	['N']	[27]
28	valproic	O	['N']	[28]
29	acid	O	['N']	[29]
30	(	O	['N']	[30]
31	VPA	B-Drug	['Causes']	[17]
32	)	O	['N']	[32]
33	intoxication	O	['N']	[33]
34	.	O	['N']	[34]
#2964
0	Polysomnographic	O	['N']	[0]
1	and	O	['N']	[1]
2	pharmacokinetic	O	['N']	[2]
3	findings	O	['N']	[3]
4	in	O	['N']	[4]
5	levodopa	B-Drug	['Causes']	[12]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	augmentation	O	['N']	[8]
9	of	O	['N']	[9]
10	restless	B	['N']	[10]
11	legs	I	['N']	[11]
12	syndrome	I-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#2965
0	k	O	['N']	[0]
1	bipolar	O	['N']	[1]
2	manic	O	['N']	[2]
3	-	O	['N']	[3]
4	depressive	O	['N']	[4]
5	patient	O	['N']	[5]
6	,	O	['N']	[6]
7	developed	O	['N']	[7]
8	while	O	['N']	[8]
9	on	O	['N']	[9]
10	lithium	B-Drug	['Causes']	[26]
11	prophylaxis	O	['N']	[11]
12	,	O	['N']	[12]
13	akathisia	O	['N']	[13]
14	at	O	['N']	[14]
15	therapeutic	O	['N']	[15]
16	serum	O	['N']	[16]
17	lithium	O	['N']	[17]
18	levels	O	['N']	[18]
19	and	O	['N']	[19]
20	subsequently	O	['N']	[20]
21	bucco	B	['N']	[21]
22	-	I	['N']	[22]
23	linguo	I	['N']	[23]
24	-	I	['N']	[24]
25	masticatory	I	['N']	[25]
26	dyskinesia	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#2966
0	Here	O	['N']	[0]
1	we	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	Crohn	O	['N']	[6]
7	's	O	['N']	[7]
8	disease	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	a	O	['N']	[11]
12	severe	O	['N']	[12]
13	infliximab	B-Drug	['Causes']	[32]
14	infusion	O	['N']	[14]
15	reaction	O	['N']	[15]
16	(	O	['N']	[16]
17	IIR	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	complicated	O	['N']	[20]
21	1	O	['N']	[21]
22	day	O	['N']	[22]
23	later	O	['N']	[23]
24	by	O	['N']	[24]
25	severe	B	['N']	[25]
26	swelling	I	['N']	[26]
27	of	I	['N']	[27]
28	the	I	['N']	[28]
29	forearm	I	['N']	[29]
30	and	I	['N']	[30]
31	hand	I	['N']	[31]
32	ipsilateral	I-Adverse_Effect	['N']	[32]
33	to	O	['N']	[33]
34	the	O	['N']	[34]
35	site	O	['N']	[35]
36	of	O	['N']	[36]
37	infliximab	O	['N']	[37]
38	infusion	O	['N']	[38]
39	.	O	['N']	[39]
#2967
0	Inappropriate	B	['N']	[0]
1	antidiuretic	I	['N']	[1]
2	hormone	I	['N']	[2]
3	secretion	I-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	high	O	['N']	[5]
6	dose	O	['N']	[6]
7	vinblastine	B-Drug	['Causes']	[3]
8	.	O	['N']	[8]
#2968
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	,	O	['N']	[2]
3	in	O	['N']	[3]
4	whom	O	['N']	[4]
5	tumour	O	['N']	[5]
6	overkill	O	['N']	[6]
7	by	O	['N']	[7]
8	cytotoxic	O	['N']	[8]
9	treatment	O	['N']	[9]
10	,	O	['N']	[10]
11	including	O	['N']	[11]
12	high	O	['N']	[12]
13	dose	O	['N']	[13]
14	methotrexate	O	['N']	[14]
15	with	O	['N']	[15]
16	folinic	B	['N']	[16]
17	acid	I-Drug	['Causes']	[35]
18	rescue	O	['N']	[18]
19	,	O	['N']	[19]
20	resulted	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	'	O	['N']	[23]
24	phosphate	O	['N']	[24]
25	shower	O	['N']	[25]
26	syndrome	O	['N']	[26]
27	'	O	['N']	[27]
28	(	O	['N']	[28]
29	hyper	O	['N']	[29]
30	-	O	['N']	[30]
31	uricaemia	O	['N']	[31]
32	,	O	['N']	[32]
33	hyperkalaemia	O	['N']	[33]
34	and	O	['N']	[34]
35	hyperphosphataemia	B-Adverse_Effect	['N']	[35]
36	with	O	['N']	[36]
37	hypocalcaemia	O	['N']	[37]
38	and	O	['N']	[38]
39	tetany	O	['N']	[39]
40	,	O	['N']	[40]
41	with	O	['N']	[41]
42	metabolic	O	['N']	[42]
43	acidosis	O	['N']	[43]
44	and	O	['N']	[44]
45	acute	O	['N']	[45]
46	renal	O	['N']	[46]
47	impairment	O	['N']	[47]
48	)	O	['N']	[48]
49	are	O	['N']	[49]
50	described	O	['N']	[50]
51	.	O	['N']	[51]
#2969
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	in	O	['N']	[2]
3	detail	O	['N']	[3]
4	an	O	['N']	[4]
5	unusual	O	['N']	[5]
6	adverse	O	['N']	[6]
7	reaction	O	['N']	[7]
8	to	O	['N']	[8]
9	infliximab	B-Drug	['Causes']	[20]
10	therapy	O	['N']	[10]
11	,	O	['N']	[11]
12	a	O	['N']	[12]
13	drug	O	['N']	[13]
14	-	O	['N']	[14]
15	induced	O	['N']	[15]
16	lupus	B	['N']	[16]
17	-	I	['N']	[17]
18	like	I	['N']	[18]
19	clinical	I	['N']	[19]
20	syndrome	I-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#2970
0	After	O	['N']	[0]
1	other	O	['N']	[1]
2	potential	O	['N']	[2]
3	causes	O	['N']	[3]
4	of	O	['N']	[4]
5	liver	B	['N']	[5]
6	toxicity	I-Adverse_Effect	['N']	[6]
7	were	O	['N']	[7]
8	excluded	O	['N']	[8]
9	,	O	['N']	[9]
10	TMP	B	['N']	[10]
11	-	I	['N']	[11]
12	SMX	I-Drug	['Causes']	[6]
13	was	O	['N']	[13]
14	determined	O	['N']	[14]
15	to	O	['N']	[15]
16	be	O	['N']	[16]
17	the	O	['N']	[17]
18	cause	O	['N']	[18]
19	of	O	['N']	[19]
20	his	O	['N']	[20]
21	acute	O	['N']	[21]
22	liver	O	['N']	[22]
23	toxicity	O	['N']	[23]
24	.	O	['N']	[24]
#2971
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	pulmonary	O	['N']	[5]
6	adenocarcinoma	O	['N']	[6]
7	complicated	O	['N']	[7]
8	by	O	['N']	[8]
9	the	O	['N']	[9]
10	syndrome	B	['N']	[10]
11	of	I	['N']	[11]
12	inappropriate	I	['N']	[12]
13	secretion	I	['N']	[13]
14	of	I	['N']	[14]
15	antidiuretic	I	['N']	[15]
16	hormone	I-Adverse_Effect	['N']	[16]
17	(	O	['N']	[17]
18	SIADH	O	['N']	[18]
19	)	O	['N']	[19]
20	following	O	['N']	[20]
21	systemic	O	['N']	[21]
22	chemotherapy	O	['N']	[22]
23	with	O	['N']	[23]
24	cisplatin	B-Drug	['Causes']	[16]
25	(	O	['N']	[25]
26	CDDP	O	['N']	[26]
27	)	O	['N']	[27]
28	and	O	['N']	[28]
29	vindesine	O	['N']	[29]
30	(	O	['N']	[30]
31	VDS	O	['N']	[31]
32	)	O	['N']	[32]
33	.	O	['N']	[33]
#2972
0	This	O	['N']	[0]
1	concerns	O	['N']	[1]
2	2	O	['N']	[2]
3	male	O	['N']	[3]
4	patients	O	['N']	[4]
5	who	O	['N']	[5]
6	experienced	O	['N']	[6]
7	incontinence	B-Adverse_Effect	['N']	[7]
8	while	O	['N']	[8]
9	taking	O	['N']	[9]
10	venlafaxine	B-Drug	['Causes']	[7]
11	.	O	['N']	[11]
#2973
0	Stupor	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	fast	O	['N']	[2]
3	activity	O	['N']	[3]
4	on	O	['N']	[4]
5	electroencephalography	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	child	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	valproate	B-Drug	['Causes']	[0]
12	.	O	['N']	[12]
#2974
0	They	O	['N']	[0]
1	continued	O	['N']	[1]
2	to	O	['N']	[2]
3	rise	O	['N']	[3]
4	for	O	['N']	[4]
5	five	O	['N']	[5]
6	more	O	['N']	[6]
7	days	O	['N']	[7]
8	before	O	['N']	[8]
9	salicylate	B-Drug	['Causes']	[10]
10	hepatotoxicity	B-Adverse_Effect	['N']	[10]
11	was	O	['N']	[11]
12	suspected	O	['N']	[12]
13	.	O	['N']	[13]
#2975
0	From	O	['N']	[0]
1	these	O	['N']	[1]
2	data	O	['N']	[2]
3	,	O	['N']	[3]
4	acute	O	['N']	[4]
5	generalized	O	['N']	[5]
6	dystonia	O	['N']	[6]
7	with	O	['N']	[7]
8	brainstem	B	['N']	[8]
9	and	I	['N']	[9]
10	thalamic	I	['N']	[10]
11	lesions	I-Adverse_Effect	['N']	[11]
12	may	O	['N']	[12]
13	occur	O	['N']	[13]
14	in	O	['N']	[14]
15	WD	O	['N']	[15]
16	patients	O	['N']	[16]
17	after	O	['N']	[17]
18	an	O	['N']	[18]
19	initial	O	['N']	[19]
20	d	B	['N']	[20]
21	-	I	['N']	[21]
22	penicillamine	I-Drug	['Causes']	[11]
23	therapy	O	['N']	[23]
24	.	O	['N']	[24]
#2976
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Gemcitabine	B-Drug	['Causes']	[6]
3	has	O	['N']	[3]
4	mild	O	['N']	[4]
5	renal	B	['N']	[5]
6	toxicity	I-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	but	O	['N']	[8]
9	cases	O	['N']	[9]
10	of	O	['N']	[10]
11	gemcitabine	O	['N']	[11]
12	-	O	['N']	[12]
13	associated	O	['N']	[13]
14	hemolytic	O	['N']	[14]
15	-	O	['N']	[15]
16	uremic	O	['N']	[16]
17	syndrome	O	['N']	[17]
18	(	O	['N']	[18]
19	HUS	O	['N']	[19]
20	)	O	['N']	[20]
21	have	O	['N']	[21]
22	been	O	['N']	[22]
23	reported	O	['N']	[23]
24	.	O	['N']	[24]
#2977
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	restless	B	['N']	[3]
4	legs	I	['N']	[4]
5	symptoms	I-Adverse_Effect	['N']	[5]
6	paralleling	O	['N']	[6]
7	the	O	['N']	[7]
8	course	O	['N']	[8]
9	of	O	['N']	[9]
10	interferon	O	['N']	[10]
11	-	O	['N']	[11]
12	alpha	O	['N']	[12]
13	(	O	['N']	[13]
14	IFN	B	['N']	[14]
15	alpha	I-Drug	['Causes']	[5]
16	)	O	['N']	[16]
17	therapy	O	['N']	[17]
18	for	O	['N']	[18]
19	chronic	O	['N']	[19]
20	hepatitis	O	['N']	[20]
21	C.	O	['N']	[21]
#2978
0	Six	O	['N']	[0]
1	patients	O	['N']	[1]
2	developed	O	['N']	[2]
3	peripheral	B	['N']	[3]
4	neuropathy	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	five	O	['N']	[6]
7	patients	O	['N']	[7]
8	bone	O	['N']	[8]
9	marrow	O	['N']	[9]
10	depression	O	['N']	[10]
11	,	O	['N']	[11]
12	blood	O	['N']	[12]
13	transfusions	O	['N']	[13]
14	were	O	['N']	[14]
15	given	O	['N']	[15]
16	to	O	['N']	[16]
17	three	O	['N']	[17]
18	patients	O	['N']	[18]
19	and	O	['N']	[19]
20	in	O	['N']	[20]
21	all	O	['N']	[21]
22	five	O	['N']	[22]
23	patients	O	['N']	[23]
24	bone	O	['N']	[24]
25	marrow	O	['N']	[25]
26	function	O	['N']	[26]
27	normalized	O	['N']	[27]
28	after	O	['N']	[28]
29	cessation	O	['N']	[29]
30	of	O	['N']	[30]
31	linezolid	B-Drug	['Causes']	[4]
32	.	O	['N']	[32]
#2979
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	treated	O	['N']	[2]
3	for	O	['N']	[3]
4	chronic	O	['N']	[4]
5	myeloid	O	['N']	[5]
6	leukemia	O	['N']	[6]
7	with	O	['N']	[7]
8	high	O	['N']	[8]
9	doses	O	['N']	[9]
10	of	O	['N']	[10]
11	CCNU	B-Drug	['Causes']	[29]
12	(	O	['N']	[12]
13	1100	O	['N']	[13]
14	mg	O	['N']	[14]
15	/	O	['N']	[15]
16	m2	O	['N']	[16]
17	and	O	['N']	[17]
18	1240	O	['N']	[18]
19	mg	O	['N']	[19]
20	/	O	['N']	[20]
21	m2	O	['N']	[21]
22	,	O	['N']	[22]
23	respectively	O	['N']	[23]
24	)	O	['N']	[24]
25	developed	O	['N']	[25]
26	a	O	['N']	[26]
27	fatal	B	['N']	[27]
28	pulmonary	I	['N']	[28]
29	fibrosis	I-Adverse_Effect	['N']	[29]
30	.	O	['N']	[30]
#2980
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Headaches	B-Adverse_Effect	['N']	[2]
3	have	O	['N']	[3]
4	been	O	['N']	[4]
5	reported	O	['N']	[5]
6	as	O	['N']	[6]
7	a	O	['N']	[7]
8	potential	O	['N']	[8]
9	side	O	['N']	[9]
10	effect	O	['N']	[10]
11	of	O	['N']	[11]
12	capecitabine	B-Drug	['Causes']	[2]
13	therapy	O	['N']	[13]
14	.	O	['N']	[14]
#2981
0	Massive	O	['N']	[0]
1	pulmonary	O	['N']	[1]
2	embolism	O	['N']	[2]
3	due	O	['N']	[3]
4	to	O	['N']	[4]
5	late	O	['N']	[5]
6	-	O	['N']	[6]
7	onset	O	['N']	[7]
8	heparin	B-Drug	['Causes']	[11]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	thrombocytopenia	B-Adverse_Effect	['N']	[11]
12	following	O	['N']	[12]
13	coronary	O	['N']	[13]
14	artery	O	['N']	[14]
15	bypass	O	['N']	[15]
16	graft	O	['N']	[16]
17	surgery	O	['N']	[17]
18	:	O	['N']	[18]
19	successful	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	lepirudin	O	['N']	[22]
23	.	O	['N']	[23]
#2982
0	Type	B	['N']	[0]
1	1	I	['N']	[1]
2	diabetes	I	['N']	[2]
3	mellitus	I-Adverse_Effect	['N']	[3]
4	provoked	O	['N']	[4]
5	by	O	['N']	[5]
6	peginterferon	O	['N']	[6]
7	alpha-2b	O	['N']	[7]
8	plus	O	['N']	[8]
9	ribavirin	B-Drug	['Causes']	[3]
10	treatment	O	['N']	[10]
11	for	O	['N']	[11]
12	chronic	O	['N']	[12]
13	hepatitis	O	['N']	[13]
14	C.	O	['N']	[14]
#2983
0	Aggressive	O	['N']	[0]
1	management	O	['N']	[1]
2	of	O	['N']	[2]
3	doxorubicin	B-Drug	['Dosage']	[12]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	cardiomyopathy	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	'	B	['N']	[9]
10	low	I	['N']	[10]
11	'	I	['N']	[11]
12	doses	I-Dose	['N']	[12]
13	of	O	['N']	[13]
14	doxorubicin	O	['N']	[14]
15	.	O	['N']	[15]
#2984
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	presented	O	['N']	[2]
3	with	O	['N']	[3]
4	fulminant	O	['N']	[4]
5	microangiopathic	O	['N']	[5]
6	hemolytic	O	['N']	[6]
7	anemia	O	['N']	[7]
8	and	O	['N']	[8]
9	thrombocytopenia	B-Adverse_Effect	['N']	[9]
10	within	O	['N']	[10]
11	48	O	['N']	[11]
12	hr	O	['N']	[12]
13	of	O	['N']	[13]
14	initiating	O	['N']	[14]
15	therapy	O	['N']	[15]
16	with	O	['N']	[16]
17	trimethoprim	O	['N']	[17]
18	-	O	['N']	[18]
19	sulfamethoxazole	B-Drug	['Causes']	[9]
20	.	O	['N']	[20]
#2985
0	Albuterol	B-Drug	['Causes']	[8]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hypokalemia	O	['N']	[3]
4	and	O	['N']	[4]
5	its	O	['N']	[5]
6	potential	O	['N']	[6]
7	cardiac	B	['N']	[7]
8	toxicity	I-Adverse_Effect	['N']	[8]
9	are	O	['N']	[9]
10	discussed	O	['N']	[10]
11	briefly	O	['N']	[11]
12	.	O	['N']	[12]
#2986
0	As	O	['N']	[0]
1	this	O	['N']	[1]
2	relapse	O	['N']	[2]
3	coincided	O	['N']	[3]
4	with	O	['N']	[4]
5	development	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	strong	O	['N']	[8]
9	delayed	O	['N']	[9]
10	-	O	['N']	[10]
11	type	O	['N']	[11]
12	hypersensitivity	B	['N']	[12]
13	response	I-Adverse_Effect	['N']	[13]
14	to	O	['N']	[14]
15	tuberculin	B-Drug	['Causes']	[13]
16	and	O	['N']	[16]
17	improved	O	['N']	[17]
18	after	O	['N']	[18]
19	treatment	O	['N']	[19]
20	with	O	['N']	[20]
21	the	O	['N']	[21]
22	anti	O	['N']	[22]
23	-	O	['N']	[23]
24	inflammatory	O	['N']	[24]
25	agent	O	['N']	[25]
26	oxpentifylline	O	['N']	[26]
27	,	O	['N']	[27]
28	it	O	['N']	[28]
29	was	O	['N']	[29]
30	probably	O	['N']	[30]
31	caused	O	['N']	[31]
32	by	O	['N']	[32]
33	restoration	O	['N']	[33]
34	of	O	['N']	[34]
35	pathogen	O	['N']	[35]
36	-	O	['N']	[36]
37	specific	O	['N']	[37]
38	cellular	O	['N']	[38]
39	immunity	O	['N']	[39]
40	.	O	['N']	[40]
#2987
0	Intravitreal	O	['N']	[0]
1	triamcinolone	B-Drug	['Causes']	[11]
2	may	O	['N']	[2]
3	have	O	['N']	[3]
4	had	O	['N']	[4]
5	an	O	['N']	[5]
6	influence	O	['N']	[6]
7	on	O	['N']	[7]
8	the	O	['N']	[8]
9	exacerbation	B	['N']	[9]
10	of	I	['N']	[10]
11	retinochoroiditis	I-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	the	O	['N']	[13]
14	posterior	O	['N']	[14]
15	pole	O	['N']	[15]
16	of	O	['N']	[16]
17	the	O	['N']	[17]
18	patient	O	['N']	[18]
19	.	O	['N']	[19]
#2988
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	skin	O	['N']	[23]
24	eruptions	O	['N']	[24]
25	,	O	['N']	[25]
26	cervical	O	['N']	[26]
27	lymphadenopathy	O	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	O	['N']	[31]
32	lymphocytosis	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	O	['N']	[40]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	-	['N']	[42]
43	(	O	['N']	[43]
44	SMX	O	['N']	[44]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#2989
0	Complete	O	['N']	[0]
1	remission	O	['N']	[1]
2	of	O	['N']	[2]
3	the	O	['N']	[3]
4	nephrosis	B-Adverse_Effect	['N']	[4]
5	occurred	O	['N']	[5]
6	after	O	['N']	[6]
7	discontinuation	O	['N']	[7]
8	of	O	['N']	[8]
9	hydroxychloroquine	B-Drug	['Causes']	[4]
10	therapy	O	['N']	[10]
11	.	O	['N']	[11]
#2990
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	a	O	['N']	[3]
4	bipolar	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	developed	O	['N']	[7]
8	thyrotoxicosis	B-Adverse_Effect	['N']	[8]
9	with	O	['N']	[9]
10	severe	O	['N']	[10]
11	exophthalmos	O	['N']	[11]
12	while	O	['N']	[12]
13	on	O	['N']	[13]
14	lithium	B-Drug	['Causes']	[8]
15	therapy	O	['N']	[15]
16	is	O	['N']	[16]
17	described	O	['N']	[17]
18	.	O	['N']	[18]
#2991
0	A	O	['N']	[0]
1	14-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	developed	O	['N']	[5]
6	systemic	O	['N']	[6]
7	lupus	O	['N']	[7]
8	erythematosus	O	['N']	[8]
9	(	O	['N']	[9]
10	SLE)-like	O	['N']	[10]
11	symptoms	O	['N']	[11]
12	,	O	['N']	[12]
13	rash	O	['N']	[13]
14	,	O	['N']	[14]
15	fever	B-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	leukopenia	O	['N']	[17]
18	and	O	['N']	[18]
19	positive	O	['N']	[19]
20	anti	O	['N']	[20]
21	-	O	['N']	[21]
22	nuclear	O	['N']	[22]
23	antibody	O	['N']	[23]
24	(	O	['N']	[24]
25	ANA	O	['N']	[25]
26	)	O	['N']	[26]
27	two	O	['N']	[27]
28	weeks	O	['N']	[28]
29	after	O	['N']	[29]
30	administration	O	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	B-Drug	['Causes']	[15]
33	(	O	['N']	[33]
34	CBZ	O	['N']	[34]
35	;	O	['N']	[35]
36	Tegretol	O	['N']	[36]
37	)	O	['N']	[37]
38	used	O	['N']	[38]
39	against	O	['N']	[39]
40	benign	O	['N']	[40]
41	Rolandic	O	['N']	[41]
42	epilepsy	O	['N']	[42]
43	.	O	['N']	[43]
#2992
0	The	O	['N']	[0]
1	ampicillin	B-Drug	['Causes']	[2]
2	rash	I-Adverse_Effect	['N']	[2]
3	occurring	O	['N']	[3]
4	in	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	infectious	O	['N']	[7]
8	mononucleosis	O	['N']	[8]
9	is	O	['N']	[9]
10	well	O	['N']	[10]
11	documented	O	['N']	[11]
12	.	O	['N']	[12]
#2993
0	It	O	['N']	[0]
1	was	O	['N']	[1]
2	hypothesized	O	['N']	[2]
3	that	O	['N']	[3]
4	valproic	B	['N']	[4]
5	acid	I-Drug	['Causes']	[35]
6	may	O	['N']	[6]
7	interfere	O	['N']	[7]
8	with	O	['N']	[8]
9	glucuronidation	O	['N']	[9]
10	of	O	['N']	[10]
11	lamotrigine	O	['N']	[11]
12	,	O	['N']	[12]
13	leading	O	['N']	[13]
14	to	O	['N']	[14]
15	increased	O	['N']	[15]
16	serum	O	['N']	[16]
17	lamotrigine	O	['N']	[17]
18	levels	O	['N']	[18]
19	,	O	['N']	[19]
20	or	O	['N']	[20]
21	perhaps	O	['N']	[21]
22	alter	O	['N']	[22]
23	the	O	['N']	[23]
24	drug	O	['N']	[24]
25	's	O	['N']	[25]
26	metabolism	O	['N']	[26]
27	,	O	['N']	[27]
28	resulting	O	['N']	[28]
29	in	O	['N']	[29]
30	accumulation	B	['N']	[30]
31	of	I	['N']	[31]
32	a	I	['N']	[32]
33	toxic	I	['N']	[33]
34	intermediate	I	['N']	[34]
35	metabolite	I-Adverse_Effect	['N']	[35]
36	.	O	['N']	[36]
#2994
0	The	O	['N']	[0]
1	incidence	O	['N']	[1]
2	of	O	['N']	[2]
3	5-fluorouracil	B-Drug	['Causes']	[6]
4	(	O	['N']	[4]
5	5-FU)-related	O	['N']	[5]
6	cardiotoxicity	B-Adverse_Effect	['N']	[6]
7	seems	O	['N']	[7]
8	to	O	['N']	[8]
9	be	O	['N']	[9]
10	dosage	O	['N']	[10]
11	and	O	['N']	[11]
12	schedule	O	['N']	[12]
13	dependent	O	['N']	[13]
14	.	O	['N']	[14]
#2995
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	Stevens	B	['N']	[5]
6	-	I	['N']	[6]
7	Johnson	I	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	/	O	['N']	[9]
10	toxic	O	['N']	[10]
11	epidermal	O	['N']	[11]
12	necrolysis	O	['N']	[12]
13	(	O	['N']	[13]
14	SJS	O	['N']	[14]
15	/	O	['N']	[15]
16	TEN	O	['N']	[16]
17	)	O	['N']	[17]
18	secondary	O	['N']	[18]
19	to	O	['N']	[19]
20	trimethoprim	B	['N']	[20]
21	-	I	['N']	[21]
22	sulfamethoxazole	I-Drug	['Causes']	[8]
23	(	O	['N']	[23]
24	TMP	O	['N']	[24]
25	-	O	['N']	[25]
26	Sx	O	['N']	[26]
27	)	O	['N']	[27]
28	therapy	O	['N']	[28]
29	for	O	['N']	[29]
30	presumed	O	['N']	[30]
31	community	O	['N']	[31]
32	-	O	['N']	[32]
33	associated	O	['N']	[33]
34	methicillin	O	['N']	[34]
35	-	O	['N']	[35]
36	resistant	O	['N']	[36]
37	Staphylococcus	O	['N']	[37]
38	aureus	O	['N']	[38]
39	(	O	['N']	[39]
40	CA	O	['N']	[40]
41	-	O	['N']	[41]
42	MRSA	O	['N']	[42]
43	)	O	['N']	[43]
44	infection	O	['N']	[44]
45	.	O	['N']	[45]
#2996
0	In	O	['N']	[0]
1	one	O	['N']	[1]
2	child	O	['N']	[2]
3	,	O	['N']	[3]
4	a	O	['N']	[4]
5	second	O	['N']	[5]
6	course	O	['N']	[6]
7	of	O	['N']	[7]
8	carbamazepine	B-Drug	['Causes']	[15]
9	resulted	O	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	return	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	dystonia	B-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#2997
0	Heparin	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	thrombocytopenia	B-Adverse_Effect	['N']	[3]
4	:	O	['N']	[4]
5	successful	O	['N']	[5]
6	therapy	O	['N']	[6]
7	with	O	['N']	[7]
8	the	O	['N']	[8]
9	heparinoid	O	['N']	[9]
10	Org	O	['N']	[10]
11	10172	O	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	patient	O	['N']	[14]
15	showing	O	['N']	[15]
16	cross	O	['N']	[16]
17	-	O	['N']	[17]
18	reaction	O	['N']	[18]
19	to	O	['N']	[19]
20	LMW	O	['N']	[20]
21	heparins	O	['N']	[21]
22	.	O	['N']	[22]
#2998
0	Evidence	O	['N']	[0]
1	is	O	['N']	[1]
2	shown	O	['N']	[2]
3	in	O	['N']	[3]
4	this	O	['N']	[4]
5	report	O	['N']	[5]
6	that	O	['N']	[6]
7	adenosine	B-Drug	['Causes']	[14]
8	was	O	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	dangerous	O	['N']	[11]
12	worsening	O	['N']	[12]
13	of	O	['N']	[13]
14	arrhythmia	B-Adverse_Effect	['N']	[14]
15	in	O	['N']	[15]
16	patients	O	['N']	[16]
17	with	O	['N']	[17]
18	atrial	O	['N']	[18]
19	flutter	O	['N']	[19]
20	.	O	['N']	[20]
#2999
0	Stuttering	B	['N']	[0]
1	priapism	I-Adverse_Effect	['N']	[1]
2	complicating	O	['N']	[2]
3	warfarin	B-Drug	['Causes']	[1]
4	therapy	O	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	protein	O	['N']	[9]
10	C	O	['N']	[10]
11	deficiency	O	['N']	[11]
12	.	O	['N']	[12]
#3000
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	intraoperative	O	['N']	[5]
6	gelatine	B-Drug	['Causes']	[9]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	anaphylaxis	B-Adverse_Effect	['N']	[9]
10	whose	O	['N']	[10]
11	diagnosis	O	['N']	[11]
12	was	O	['N']	[12]
13	delayed	O	['N']	[13]
14	as	O	['N']	[14]
15	the	O	['N']	[15]
16	use	O	['N']	[16]
17	of	O	['N']	[17]
18	gelatine	O	['N']	[18]
19	during	O	['N']	[19]
20	surgical	O	['N']	[20]
21	procedures	O	['N']	[21]
22	was	O	['N']	[22]
23	omitted	O	['N']	[23]
24	for	O	['N']	[24]
25	two	O	['N']	[25]
26	times	O	['N']	[26]
27	in	O	['N']	[27]
28	patient	O	['N']	[28]
29	's	O	['N']	[29]
30	medical	O	['N']	[30]
31	records	O	['N']	[31]
32	.	O	['N']	[32]
#3001
0	A	O	['N']	[0]
1	young	O	['N']	[1]
2	diamond	O	['N']	[2]
3	dealer	O	['N']	[3]
4	developed	O	['N']	[4]
5	visual	B	['N']	[5]
6	impairment	I-Adverse_Effect	['N']	[6]
7	attributed	O	['N']	[7]
8	to	O	['N']	[8]
9	bilateral	O	['N']	[9]
10	posterior	O	['N']	[10]
11	subcapsular	O	['N']	[11]
12	cataracts	O	['N']	[12]
13	following	O	['N']	[13]
14	only	O	['N']	[14]
15	four	O	['N']	[15]
16	courses	O	['N']	[16]
17	of	O	['N']	[17]
18	intermittent	O	['N']	[18]
19	Decadron	B-Drug	['Causes']	[6]
20	used	O	['N']	[20]
21	as	O	['N']	[21]
22	part	O	['N']	[22]
23	of	O	['N']	[23]
24	a	O	['N']	[24]
25	five	O	['N']	[25]
26	-	O	['N']	[26]
27	drug	O	['N']	[27]
28	antiemetic	O	['N']	[28]
29	regimen	O	['N']	[29]
30	for	O	['N']	[30]
31	cisplatin	O	['N']	[31]
32	-	O	['N']	[32]
33	associated	O	['N']	[33]
34	nausea	O	['N']	[34]
35	.	O	['N']	[35]
#3002
0	Adverse	O	['N']	[0]
1	effects	O	['N']	[1]
2	of	O	['N']	[2]
3	amiodarone	B-Drug	['Causes']	[8]
4	including	O	['N']	[4]
5	pulmonary	O	['N']	[5]
6	toxicity	O	['N']	[6]
7	,	O	['N']	[7]
8	hepatotoxicity	B-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	aggravation	O	['N']	[10]
11	of	O	['N']	[11]
12	arrhythmia	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	thyroid	O	['N']	[15]
16	diseases	O	['N']	[16]
17	are	O	['N']	[17]
18	well	O	['N']	[18]
19	understood	O	['N']	[19]
20	.	O	['N']	[20]
#3003
0	The	O	['N']	[0]
1	second	O	['N']	[1]
2	is	O	['N']	[2]
3	a	O	['N']	[3]
4	29-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	man	O	['N']	[7]
8	with	O	['N']	[8]
9	CD	O	['N']	[9]
10	in	O	['N']	[10]
11	whom	O	['N']	[11]
12	nodular	B	['N']	[12]
13	sclerosing	I	['N']	[13]
14	Hodgkin	I	['N']	[14]
15	's	I	['N']	[15]
16	lymphoma	I-Adverse_Effect	['N']	[16]
17	was	O	['N']	[17]
18	diagnosed	O	['N']	[18]
19	3	O	['N']	[19]
20	weeks	O	['N']	[20]
21	after	O	['N']	[21]
22	infusion	O	['N']	[22]
23	with	O	['N']	[23]
24	infliximab	B-Drug	['Causes']	[16]
25	.	O	['N']	[25]
#3004
0	We	O	['N']	[0]
1	conjectured	O	['N']	[1]
2	that	O	['N']	[2]
3	the	O	['N']	[3]
4	side	O	['N']	[4]
5	effects	O	['N']	[5]
6	of	O	['N']	[6]
7	insulin	B-Drug	['Causes']	[36]
8	,	O	['N']	[8]
9	such	O	['N']	[9]
10	as	O	['N']	[10]
11	anti	O	['N']	[11]
12	-	O	['N']	[12]
13	natriuresis	O	['N']	[13]
14	and	O	['N']	[14]
15	increased	O	['N']	[15]
16	vascular	O	['N']	[16]
17	permeability	O	['N']	[17]
18	,	O	['N']	[18]
19	might	O	['N']	[19]
20	be	O	['N']	[20]
21	pronounced	O	['N']	[21]
22	in	O	['N']	[22]
23	the	O	['N']	[23]
24	presence	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	hepatic	O	['N']	[27]
28	dysfunction	O	['N']	[28]
29	that	O	['N']	[29]
30	accompanies	O	['N']	[30]
31	insulin	O	['N']	[31]
32	insensitivity	O	['N']	[32]
33	,	O	['N']	[33]
34	hyperinsulinaemia	O	['N']	[34]
35	and	O	['N']	[35]
36	hypoalbuminaemia	B-Adverse_Effect	['N']	[36]
37	.	O	['N']	[37]
#3005
0	Upon	O	['N']	[0]
1	discontinuation	O	['N']	[1]
2	of	O	['N']	[2]
3	MTX	B-Drug	['Causes']	[6]
4	,	O	['N']	[4]
5	her	O	['N']	[5]
6	ascites	B-Adverse_Effect	['N']	[6]
7	resolved	O	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	her	O	['N']	[10]
11	arthritis	O	['N']	[11]
12	became	O	['N']	[12]
13	more	O	['N']	[13]
14	active	O	['N']	[14]
15	.	O	['N']	[15]
#3006
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	46-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	African	O	['N']	[6]
7	-	O	['N']	[7]
8	American	O	['N']	[8]
9	man	O	['N']	[9]
10	with	O	['N']	[10]
11	AIDS	O	['N']	[11]
12	who	O	['N']	[12]
13	was	O	['N']	[13]
14	admitted	O	['N']	[14]
15	on	O	['N']	[15]
16	two	O	['N']	[16]
17	different	O	['N']	[17]
18	occasions	O	['N']	[18]
19	within	O	['N']	[19]
20	three	O	['N']	[20]
21	weeks	O	['N']	[21]
22	for	O	['N']	[22]
23	signs	O	['N']	[23]
24	and	O	['N']	[24]
25	symptoms	O	['N']	[25]
26	of	O	['N']	[26]
27	meningitis	B-Adverse_Effect	['N']	[27]
28	after	O	['N']	[28]
29	using	O	['N']	[29]
30	trimethoprim	B-Drug	['Causes']	[27]
31	/	O	['N']	[31]
32	sulfamethoxazole	O	['N']	[32]
33	(	O	['N']	[33]
34	TMP	O	['N']	[34]
35	/	O	['N']	[35]
36	SMX	O	['N']	[36]
37	)	O	['N']	[37]
38	.	O	['N']	[38]
#3007
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	suggested	O	['N']	[2]
3	therefore	O	['N']	[3]
4	that	O	['N']	[4]
5	methotrexate	B-Drug	['Causes']	[19]
6	be	O	['N']	[6]
7	added	O	['N']	[7]
8	to	O	['N']	[8]
9	the	O	['N']	[9]
10	list	O	['N']	[10]
11	of	O	['N']	[11]
12	agents	O	['N']	[12]
13	capable	O	['N']	[13]
14	of	O	['N']	[14]
15	inducing	O	['N']	[15]
16	diffuse	B	['N']	[16]
17	interstitial	I	['N']	[17]
18	pulmonary	I	['N']	[18]
19	fibrosis	I-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#3008
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	10-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	white	O	['N']	[7]
8	girl	O	['N']	[8]
9	with	O	['N']	[9]
10	bilateral	O	['N']	[10]
11	optic	O	['N']	[11]
12	glioma	O	['N']	[12]
13	developed	O	['N']	[13]
14	a	O	['N']	[14]
15	hypersensitivity	B-Adverse_Effect	['N']	[15]
16	reaction	O	['N']	[16]
17	to	O	['N']	[17]
18	carboplatin	B-Drug	['Causes']	[15]
19	after	O	['N']	[19]
20	nine	O	['N']	[20]
21	courses	O	['N']	[21]
22	.	O	['N']	[22]
#3009
0	He	O	['N']	[0]
1	was	O	['N']	[1]
2	started	O	['N']	[2]
3	on	O	['N']	[3]
4	digoxin	B-Drug	['Dosage']	[7]
5	,	O	['N']	[5]
6	0.25	B	['N']	[6]
7	mg	I-Dose	['N']	[7]
8	daily	O	['N']	[8]
9	,	O	['N']	[9]
10	because	O	['N']	[10]
11	of	O	['N']	[11]
12	echocardiographically	O	['N']	[12]
13	demonstrated	O	['N']	[13]
14	left	O	['N']	[14]
15	ventricular	O	['N']	[15]
16	dilatation	O	['N']	[16]
17	and	O	['N']	[17]
18	functional	O	['N']	[18]
19	impairment	O	['N']	[19]
20	;	O	['N']	[20]
21	he	O	['N']	[21]
22	died	O	['N']	[22]
23	of	O	['N']	[23]
24	ventricular	O	['N']	[24]
25	fibrillation	O	['N']	[25]
26	15	O	['N']	[26]
27	days	O	['N']	[27]
28	later	O	['N']	[28]
29	.	O	['N']	[29]
#3010
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	,	O	['N']	[3]
4	one	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	developed	O	['N']	[7]
8	gangrene	O	['N']	[8]
9	after	O	['N']	[9]
10	bleomycin	B-Drug	['Causes']	[36]
11	and	O	['N']	[11]
12	vincristine	O	['N']	[12]
13	/	O	['N']	[13]
14	vinblastine	O	['N']	[14]
15	chemotherapy	O	['N']	[15]
16	for	O	['N']	[16]
17	AIDS	O	['N']	[17]
18	-	O	['N']	[18]
19	related	O	['N']	[19]
20	Kaposi	O	['N']	[20]
21	's	O	['N']	[21]
22	sarcoma	O	['N']	[22]
23	and	O	['N']	[23]
24	another	O	['N']	[24]
25	HIV	O	['N']	[25]
26	-	O	['N']	[26]
27	infected	O	['N']	[27]
28	patient	O	['N']	[28]
29	who	O	['N']	[29]
30	exhibited	O	['N']	[30]
31	symptoms	O	['N']	[31]
32	of	O	['N']	[32]
33	severe	B	['N']	[33]
34	Raynaud	I	['N']	[34]
35	's	I	['N']	[35]
36	phenomenon	I-Adverse_Effect	['N']	[36]
37	related	O	['N']	[37]
38	to	O	['N']	[38]
39	the	O	['N']	[39]
40	same	O	['N']	[40]
41	regimen	O	['N']	[41]
42	are	O	['N']	[42]
43	presented	O	['N']	[43]
44	.	O	['N']	[44]
#3011
0	No	O	['N']	[0]
1	explanation	O	['N']	[1]
2	for	O	['N']	[2]
3	this	O	['N']	[3]
4	delay	O	['N']	[4]
5	was	O	['N']	[5]
6	found	O	['N']	[6]
7	,	O	['N']	[7]
8	other	O	['N']	[8]
9	than	O	['N']	[9]
10	the	O	['N']	[10]
11	possibility	O	['N']	[11]
12	that	O	['N']	[12]
13	magnesium	B	['N']	[13]
14	sulfate	I-Drug	['Causes']	[17]
15	treatment	O	['N']	[15]
16	impeded	B	['N']	[16]
17	lactogenesis	I-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#3012
0	The	O	['N']	[0]
1	ocular	B	['N']	[1]
2	motor	I	['N']	[2]
3	disturbances	I-Adverse_Effect	['N']	[3]
4	are	O	['N']	[4]
5	probably	O	['N']	[5]
6	an	O	['N']	[6]
7	expression	O	['N']	[7]
8	of	O	['N']	[8]
9	regional	O	['N']	[9]
10	5-FU	B-Drug	['Causes']	[3]
11	neurotoxicity	O	['N']	[11]
12	primarily	O	['N']	[12]
13	affecting	O	['N']	[13]
14	the	O	['N']	[14]
15	brain	O	['N']	[15]
16	stem	O	['N']	[16]
17	.	O	['N']	[17]
#3013
0	Neurotoxicity	B-Adverse_Effect	['N']	[0]
1	of	O	['N']	[1]
2	intrathecal	O	['N']	[2]
3	administration	O	['N']	[3]
4	of	O	['N']	[4]
5	amphotericin	-	['N']	[5]
6	B.	-	['N']	[6]
#3014
0	Drug	O	['N']	[0]
1	induced	O	['N']	[1]
2	liver	B	['N']	[2]
3	injury	I-Adverse_Effect	['N']	[3]
4	secondary	O	['N']	[4]
5	to	O	['N']	[5]
6	interferon	B	['N']	[6]
7	-	I	['N']	[7]
8	beta	I-Drug	['Causes']	[3]
9	(	O	['N']	[9]
10	IFN	O	['N']	[10]
11	-	O	['N']	[11]
12	beta	O	['N']	[12]
13	)	O	['N']	[13]
14	in	O	['N']	[14]
15	multiple	O	['N']	[15]
16	sclerosis	O	['N']	[16]
17	.	O	['N']	[17]
#3015
0	Hemolytic	B	['N']	[0]
1	uremic	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	following	O	['N']	[3]
4	the	O	['N']	[4]
5	infusion	O	['N']	[5]
6	of	O	['N']	[6]
7	oxaliplatin	B-Drug	['Causes']	[2]
8	:	O	['N']	[8]
9	case	O	['N']	[9]
10	report	O	['N']	[10]
11	.	O	['N']	[11]
#3016
0	There	O	['N']	[0]
1	are	O	['N']	[1]
2	major	O	['N']	[2]
3	side	O	['N']	[3]
4	effects	O	['N']	[4]
5	of	O	['N']	[5]
6	anastrozole	B-Drug	['Causes']	[40]
7	including	O	['N']	[7]
8	decrease	O	['N']	[8]
9	in	O	['N']	[9]
10	both	O	['N']	[10]
11	lumbar	O	['N']	[11]
12	spine	O	['N']	[12]
13	and	O	['N']	[13]
14	total	O	['N']	[14]
15	hip	O	['N']	[15]
16	bone	O	['N']	[16]
17	mineral	O	['N']	[17]
18	density	O	['N']	[18]
19	,	O	['N']	[19]
20	increase	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	incidence	O	['N']	[23]
24	of	O	['N']	[24]
25	all	O	['N']	[25]
26	bone	O	['N']	[26]
27	fractures	O	['N']	[27]
28	(	O	['N']	[28]
29	especially	O	['N']	[29]
30	fractures	O	['N']	[30]
31	of	O	['N']	[31]
32	spine	O	['N']	[32]
33	,	O	['N']	[33]
34	hip	O	['N']	[34]
35	and	O	['N']	[35]
36	wrist	O	['N']	[36]
37	)	O	['N']	[37]
38	,	O	['N']	[38]
39	joint	B	['N']	[39]
40	disorders	I-Adverse_Effect	['N']	[40]
41	and	O	['N']	[41]
42	increase	O	['N']	[42]
43	in	O	['N']	[43]
44	the	O	['N']	[44]
45	cholesterol	O	['N']	[45]
46	level	O	['N']	[46]
47	.	O	['N']	[47]
#3017
0	A	O	['N']	[0]
1	dapsone	B-Drug	['Causes']	[19]
2	hypersensitivity	O	['N']	[2]
3	syndrome	O	['N']	[3]
4	,	O	['N']	[4]
5	consisting	O	['N']	[5]
6	of	O	['N']	[6]
7	fever	O	['N']	[7]
8	,	O	['N']	[8]
9	headache	O	['N']	[9]
10	,	O	['N']	[10]
11	nausea	O	['N']	[11]
12	,	O	['N']	[12]
13	vomiting	O	['N']	[13]
14	,	O	['N']	[14]
15	lymphadenopathy	O	['N']	[15]
16	,	O	['N']	[16]
17	hepatitis	O	['N']	[17]
18	,	O	['N']	[18]
19	hemolysis	B-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	leukopenia	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	mononucleosis	O	['N']	[24]
25	,	O	['N']	[25]
26	has	O	['N']	[26]
27	been	O	['N']	[27]
28	described	O	['N']	[28]
29	in	O	['N']	[29]
30	patients	O	['N']	[30]
31	treated	O	['N']	[31]
32	with	O	['N']	[32]
33	the	O	['N']	[33]
34	drug	O	['N']	[34]
35	for	O	['N']	[35]
36	leprosy	O	['N']	[36]
37	.	O	['N']	[37]
#3018
0	Five	O	['N']	[0]
1	personal	O	['N']	[1]
2	observations	O	['N']	[2]
3	of	O	['N']	[3]
4	an	O	['N']	[4]
5	acute	B	['N']	[5]
6	amnestic	I	['N']	[6]
7	episode	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	younger	O	['N']	[9]
10	individuals	O	['N']	[10]
11	after	O	['N']	[11]
12	intake	O	['N']	[12]
13	of	O	['N']	[13]
14	clioquinol	B-Drug	['Causes']	[7]
15	are	O	['N']	[15]
16	described	O	['N']	[16]
17	together	O	['N']	[17]
18	with	O	['N']	[18]
19	three	O	['N']	[19]
20	observations	O	['N']	[20]
21	from	O	['N']	[21]
22	the	O	['N']	[22]
23	medical	O	['N']	[23]
24	literature	O	['N']	[24]
25	.	O	['N']	[25]
#3019
0	Our	O	['N']	[0]
1	cases	O	['N']	[1]
2	constitute	O	['N']	[2]
3	the	O	['N']	[3]
4	most	O	['N']	[4]
5	severe	O	['N']	[5]
6	cases	O	['N']	[6]
7	of	O	['N']	[7]
8	benzarone	B-Drug	['Causes']	[24]
9	hepatotoxicity	O	['N']	[9]
10	reported	O	['N']	[10]
11	so	O	['N']	[11]
12	far	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	comprise	O	['N']	[15]
16	the	O	['N']	[16]
17	first	O	['N']	[17]
18	cases	O	['N']	[18]
19	of	O	['N']	[19]
20	(	O	['N']	[20]
21	sub)fulminant	O	['N']	[21]
22	hepatitis	O	['N']	[22]
23	and	O	['N']	[23]
24	cirrhosis	B-Adverse_Effect	['N']	[24]
25	related	O	['N']	[25]
26	to	O	['N']	[26]
27	benzarone	O	['N']	[27]
28	.	O	['N']	[28]
#3020
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Budesonide	B-Drug	['Causes']	[7]
3	use	O	['N']	[3]
4	can	O	['N']	[4]
5	cause	O	['N']	[5]
6	contact	B	['N']	[6]
7	dermatitis	I-Adverse_Effect	['N']	[7]
8	.	O	['N']	[8]
#3021
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	fatal	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	toxic	O	['N']	[6]
7	epidermal	O	['N']	[7]
8	necrolysis	O	['N']	[8]
9	(	O	['N']	[9]
10	TEN	O	['N']	[10]
11	)	O	['N']	[11]
12	resulting	O	['N']	[12]
13	from	O	['N']	[13]
14	a	O	['N']	[14]
15	high	B-Dose	['N']	[15]
16	dose	O	['N']	[16]
17	of	O	['N']	[17]
18	cytosine	O	['N']	[18]
19	arabinoside	O	['N']	[19]
20	(	O	['N']	[20]
21	ARA	B	['N']	[21]
22	-	I	['N']	[22]
23	C	I-Drug	['Dosage']	[15]
24	)	O	['N']	[24]
25	.	O	['N']	[25]
#3022
0	In	O	['N']	[0]
1	vitro	O	['N']	[1]
2	inhibition	B	['N']	[2]
3	of	I	['N']	[3]
4	hematopoiesis	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	systemic	O	['N']	[9]
10	sclerosis	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	D	B	['N']	[13]
14	-	I	['N']	[14]
15	penicillamine	I-Drug	['Causes']	[4]
16	.	O	['N']	[16]
#3023
0	Neutropenic	B	['N']	[0]
1	colitis	I-Adverse_Effect	['N']	[1]
2	during	O	['N']	[2]
3	standard	O	['N']	[3]
4	dose	O	['N']	[4]
5	combination	O	['N']	[5]
6	chemotherapy	O	['N']	[6]
7	with	O	['N']	[7]
8	nedaplatin	O	['N']	[8]
9	and	O	['N']	[9]
10	irinotecan	B-Drug	['Causes']	[1]
11	for	O	['N']	[11]
12	testicular	O	['N']	[12]
13	cancer	O	['N']	[13]
14	.	O	['N']	[14]
#3024
0	Our	O	['N']	[0]
1	findings	O	['N']	[1]
2	suggest	O	['N']	[2]
3	that	O	['N']	[3]
4	hyperkalemia	B-Adverse_Effect	['N']	[4]
5	can	O	['N']	[5]
6	develop	O	['N']	[6]
7	with	O	['N']	[7]
8	the	O	['N']	[8]
9	use	O	['N']	[9]
10	of	O	['N']	[10]
11	low	O	['N']	[11]
12	-	O	['N']	[12]
13	dose	O	['N']	[13]
14	heparin	B-Drug	['Causes']	[4]
15	,	O	['N']	[15]
16	within	O	['N']	[16]
17	seven	O	['N']	[17]
18	days	O	['N']	[18]
19	of	O	['N']	[19]
20	initiating	O	['N']	[20]
21	heparin	O	['N']	[21]
22	therapy	O	['N']	[22]
23	,	O	['N']	[23]
24	and	O	['N']	[24]
25	that	O	['N']	[25]
26	patients	O	['N']	[26]
27	with	O	['N']	[27]
28	diabetes	O	['N']	[28]
29	mellitus	O	['N']	[29]
30	or	O	['N']	[30]
31	chronic	O	['N']	[31]
32	renal	O	['N']	[32]
33	insufficiency	O	['N']	[33]
34	are	O	['N']	[34]
35	especially	O	['N']	[35]
36	predisposed	O	['N']	[36]
37	to	O	['N']	[37]
38	this	O	['N']	[38]
39	complication	O	['N']	[39]
40	.	O	['N']	[40]
#3025
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	1	O	['N']	[2]
3	)	O	['N']	[3]
4	To	O	['N']	[4]
5	describe	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	rheumatoid	O	['N']	[9]
10	arthritis	O	['N']	[10]
11	receiving	O	['N']	[11]
12	adalimumab	B-Drug	['Causes']	[17]
13	who	O	['N']	[13]
14	developed	O	['N']	[14]
15	fever	O	['N']	[15]
16	,	O	['N']	[16]
17	pancytopenia	B-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	splenomegaly	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	extreme	O	['N']	[22]
23	hyperferritinemia	O	['N']	[23]
24	.	O	['N']	[24]
#3026
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	report	O	['N']	[2]
3	describes	O	['N']	[3]
4	the	O	['N']	[4]
5	development	O	['N']	[5]
6	of	O	['N']	[6]
7	asymptomatic	O	['N']	[7]
8	visual	B	['N']	[8]
9	field	I	['N']	[9]
10	defects	I-Adverse_Effect	['N']	[10]
11	(	O	['N']	[11]
12	VFDs	O	['N']	[12]
13	)	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	psychiatric	O	['N']	[16]
17	patient	O	['N']	[17]
18	with	O	['N']	[18]
19	bipolar	O	['N']	[19]
20	disorder	O	['N']	[20]
21	receiving	O	['N']	[21]
22	adjunctive	O	['N']	[22]
23	tiagabine	B-Drug	['Causes']	[10]
24	treatment	O	['N']	[24]
25	.	O	['N']	[25]
#3027
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	63	O	['N']	[3]
4	year	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	with	O	['N']	[7]
8	a	O	['N']	[8]
9	suppurative	O	['N']	[9]
10	mediastinitis	O	['N']	[10]
11	,	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	continuous	O	['N']	[14]
15	PI	B-Drug	['Causes']	[23]
16	irrigation	O	['N']	[16]
17	who	O	['N']	[17]
18	developed	O	['N']	[18]
19	an	O	['N']	[19]
20	acute	B	['N']	[20]
21	oliguric	I	['N']	[21]
22	renal	I	['N']	[22]
23	failure	I-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#3028
0	Clinicians	O	['N']	[0]
1	have	O	['N']	[1]
2	been	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	lithium	B-Drug	['Causes']	[24]
6	toxicity	O	['N']	[6]
7	for	O	['N']	[7]
8	many	O	['N']	[8]
9	years	O	['N']	[9]
10	and	O	['N']	[10]
11	traditionally	O	['N']	[11]
12	have	O	['N']	[12]
13	administered	O	['N']	[13]
14	thiazide	O	['N']	[14]
15	diuretics	O	['N']	[15]
16	for	O	['N']	[16]
17	lithium	O	['N']	[17]
18	-	O	['N']	[18]
19	induced	O	['N']	[19]
20	polyuria	O	['N']	[20]
21	and	O	['N']	[21]
22	nephrogenic	B	['N']	[22]
23	diabetes	I	['N']	[23]
24	insipidus	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#3029
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	new	O	['N']	[3]
4	quinolone	O	['N']	[4]
5	derivatives	O	['N']	[5]
6	(	O	['N']	[6]
7	levofloxacin	B-Drug	['Causes']	[45]
8	,	O	['N']	[8]
9	sparfloxacin	O	['N']	[9]
10	,	O	['N']	[10]
11	grepafloxacin	O	['N']	[11]
12	,	O	['N']	[12]
13	trovafloxacin	O	['N']	[13]
14	,	O	['N']	[14]
15	gatifloxacin	O	['N']	[15]
16	and	O	['N']	[16]
17	moxifloxacin	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	also	O	['N']	[20]
21	called	O	['N']	[21]
22	gyrase	O	['N']	[22]
23	inhibitors	O	['N']	[23]
24	,	O	['N']	[24]
25	are	O	['N']	[25]
26	known	O	['N']	[26]
27	for	O	['N']	[27]
28	their	O	['N']	[28]
29	potential	O	['N']	[29]
30	to	O	['N']	[30]
31	cause	O	['N']	[31]
32	central	O	['N']	[32]
33	nervous	O	['N']	[33]
34	system	O	['N']	[34]
35	-	O	['N']	[35]
36	related	O	['N']	[36]
37	adverse	O	['N']	[37]
38	effects	O	['N']	[38]
39	,	O	['N']	[39]
40	including	O	['N']	[40]
41	headache	O	['N']	[41]
42	,	O	['N']	[42]
43	dizziness	O	['N']	[43]
44	and	O	['N']	[44]
45	insomnia	B-Adverse_Effect	['N']	[45]
46	.	O	['N']	[46]
#3030
0	DIAGNOSIS	O	['N']	[0]
1	:	O	['N']	[1]
2	Severe	O	['N']	[2]
3	temozolomide	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	immunosuppression	B-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	exacerbated	O	['N']	[8]
9	by	O	['N']	[9]
10	corticosteroids	O	['N']	[10]
11	,	O	['N']	[11]
12	with	O	['N']	[12]
13	profound	O	['N']	[13]
14	T	O	['N']	[14]
15	-	O	['N']	[15]
16	cell	O	['N']	[16]
17	lymphocytopenia	O	['N']	[17]
18	and	O	['N']	[18]
19	simultaneous	O	['N']	[19]
20	opportunistic	O	['N']	[20]
21	infections	O	['N']	[21]
22	with	O	['N']	[22]
23	Pneumocystis	O	['N']	[23]
24	jiroveci	O	['N']	[24]
25	pneumonia	O	['N']	[25]
26	,	O	['N']	[26]
27	brain	O	['N']	[27]
28	abscess	O	['N']	[28]
29	with	O	['N']	[29]
30	Listeria	O	['N']	[30]
31	monocytogenes	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	cutaneous	O	['N']	[34]
35	Kaposi	O	['N']	[35]
36	's	O	['N']	[36]
37	sarcoma	O	['N']	[37]
38	.	O	['N']	[38]
#3031
0	Retinal	O	['N']	[0]
1	abnormalities	O	['N']	[1]
2	,	O	['N']	[2]
3	including	O	['N']	[3]
4	retinal	B	['N']	[4]
5	hemorrhage	I-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	"	O	['N']	[7]
8	cotton	O	['N']	[8]
9	-	O	['N']	[9]
10	wool	O	['N']	[10]
11	"	O	['N']	[11]
12	spots	O	['N']	[12]
13	,	O	['N']	[13]
14	often	O	['N']	[14]
15	occur	O	['N']	[15]
16	within	O	['N']	[16]
17	the	O	['N']	[17]
18	first	O	['N']	[18]
19	8	O	['N']	[19]
20	weeks	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	course	O	['N']	[23]
24	of	O	['N']	[24]
25	interferon	B-Drug	['Causes']	[5]
26	therapy	O	['N']	[26]
27	in	O	['N']	[27]
28	patients	O	['N']	[28]
29	with	O	['N']	[29]
30	chronic	O	['N']	[30]
31	hepatitis	O	['N']	[31]
32	C.	O	['N']	[32]
#3032
0	Cerebral	B	['N']	[0]
1	infarcts	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	a	O	['N']	[3]
4	pediatric	O	['N']	[4]
5	patient	O	['N']	[5]
6	secondary	O	['N']	[6]
7	to	O	['N']	[7]
8	phenylpropanolamine	B-Drug	['Causes']	[1]
9	,	O	['N']	[9]
10	a	O	['N']	[10]
11	recalled	O	['N']	[11]
12	medication	O	['N']	[12]
13	.	O	['N']	[13]
#3033
0	The	O	['N']	[0]
1	literature	O	['N']	[1]
2	on	O	['N']	[2]
3	thiabendazole	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	cholestasis	B-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	its	O	['N']	[8]
9	association	O	['N']	[9]
10	with	O	['N']	[10]
11	sicca	O	['N']	[11]
12	complex	O	['N']	[12]
13	is	O	['N']	[13]
14	reviewed	O	['N']	[14]
15	.	O	['N']	[15]
#3034
0	Its	O	['N']	[0]
1	overall	O	['N']	[1]
2	toxicity	O	['N']	[2]
3	is	O	['N']	[3]
4	considerably	O	['N']	[4]
5	less	O	['N']	[5]
6	compared	O	['N']	[6]
7	to	O	['N']	[7]
8	standard	O	['N']	[8]
9	induction	O	['N']	[9]
10	chemotherapy	O	['N']	[10]
11	;	O	['N']	[11]
12	however	O	['N']	[12]
13	,	O	['N']	[13]
14	it	O	['N']	[14]
15	is	O	['N']	[15]
16	associated	O	['N']	[16]
17	with	O	['N']	[17]
18	a	O	['N']	[18]
19	high	O	['N']	[19]
20	incidence	O	['N']	[20]
21	of	O	['N']	[21]
22	a	O	['N']	[22]
23	potentially	B	['N']	[23]
24	fatal	I	['N']	[24]
25	symptom	I-Adverse_Effect	['N']	[25]
26	complex	O	['N']	[26]
27	referred	O	['N']	[27]
28	to	O	['N']	[28]
29	as	O	['N']	[29]
30	"	O	['N']	[30]
31	retinoic	B	['N']	[31]
32	acid	I-Drug	['Causes']	[25]
33	syndrome	O	['N']	[33]
34	.	O	['N']	[34]
35	"	O	['N']	[35]
36	This	O	['N']	[36]
37	report	O	['N']	[37]
38	describes	O	['N']	[38]
39	a	O	['N']	[39]
40	patient	O	['N']	[40]
41	with	O	['N']	[41]
42	APL	O	['N']	[42]
43	who	O	['N']	[43]
44	developed	O	['N']	[44]
45	the	O	['N']	[45]
46	syndrome	O	['N']	[46]
47	a	O	['N']	[47]
48	few	O	['N']	[48]
49	weeks	O	['N']	[49]
50	after	O	['N']	[50]
51	initiating	O	['N']	[51]
52	induction	O	['N']	[52]
53	therapy	O	['N']	[53]
54	with	O	['N']	[54]
55	ATRA	O	['N']	[55]
56	despite	O	['N']	[56]
57	being	O	['N']	[57]
58	treated	O	['N']	[58]
59	for	O	['N']	[59]
60	hyperleukocytosis	O	['N']	[60]
61	.	O	['N']	[61]
#3035
0	Based	O	['N']	[0]
1	on	O	['N']	[1]
2	the	O	['N']	[2]
3	Naranjo	O	['N']	[3]
4	probability	O	['N']	[4]
5	scale	O	['N']	[5]
6	,	O	['N']	[6]
7	serotonin	B	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	was	O	['N']	[9]
10	a	O	['N']	[10]
11	probable	O	['N']	[11]
12	adverse	O	['N']	[12]
13	reaction	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	co	O	['N']	[16]
17	-	O	['N']	[17]
18	administration	O	['N']	[18]
19	of	O	['N']	[19]
20	citalopram	B-Drug	['Causes']	[8]
21	and	O	['N']	[21]
22	fentanyl	O	['N']	[22]
23	.	O	['N']	[23]
#3036
0	Among	O	['N']	[0]
1	12	O	['N']	[1]
2	thyrotoxic	O	['N']	[2]
3	patients	O	['N']	[3]
4	,	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	arrhythmogenic	O	['N']	[8]
9	right	O	['N']	[9]
10	ventricular	O	['N']	[10]
11	dysplasia	O	['N']	[11]
12	,	O	['N']	[12]
13	who	O	['N']	[13]
14	had	O	['N']	[14]
15	been	O	['N']	[15]
16	taking	O	['N']	[16]
17	amiodarone	B-Drug	['Causes']	[47]
18	for	O	['N']	[18]
19	4	O	['N']	[19]
20	years	O	['N']	[20]
21	,	O	['N']	[21]
22	developed	O	['N']	[22]
23	thyrotoxicosis	O	['N']	[23]
24	with	O	['N']	[24]
25	subacute	O	['N']	[25]
26	onset	O	['N']	[26]
27	,	O	['N']	[27]
28	accompanied	O	['N']	[28]
29	by	O	['N']	[29]
30	transiently	O	['N']	[30]
31	positive	O	['N']	[31]
32	thyrotropin	O	['N']	[32]
33	(	O	['N']	[33]
34	TSH	O	['N']	[34]
35	)	O	['N']	[35]
36	receptor	O	['N']	[36]
37	antibody	O	['N']	[37]
38	(	O	['N']	[38]
39	TRAb	O	['N']	[39]
40	)	O	['N']	[40]
41	,	O	['N']	[41]
42	or	O	['N']	[42]
43	thyrotropin	B	['N']	[43]
44	-	I	['N']	[44]
45	binding	I	['N']	[45]
46	inhibiting	I	['N']	[46]
47	immunoglobulin	I-Adverse_Effect	['N']	[47]
48	(	O	['N']	[48]
49	TBII	O	['N']	[49]
50	)	O	['N']	[50]
51	.	O	['N']	[51]
#3037
0	Myoglobinuria	O	['N']	[0]
1	and	O	['N']	[1]
2	acute	B	['N']	[2]
3	renal	I	['N']	[3]
4	failure	I-Adverse_Effect	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	intravenous	O	['N']	[7]
8	vasopressin	B-Drug	['Causes']	[4]
9	infusion	O	['N']	[9]
10	.	O	['N']	[10]
#3038
0	Grade	B	['N']	[0]
1	3	I	['N']	[1]
2	hepatotoxicity	I-Adverse_Effect	['N']	[2]
3	(	O	['N']	[3]
4	AST	O	['N']	[4]
5	and	O	['N']	[5]
6	ALT	O	['N']	[6]
7	>	O	['N']	[7]
8	5	O	['N']	[8]
9	to	O	['N']	[9]
10	20	O	['N']	[10]
11	upper	O	['N']	[11]
12	limit	O	['N']	[12]
13	normal	O	['N']	[13]
14	)	O	['N']	[14]
15	or	O	['N']	[15]
16	higher	O	['N']	[16]
17	has	O	['N']	[17]
18	been	O	['N']	[18]
19	observed	O	['N']	[19]
20	in	O	['N']	[20]
21	as	O	['N']	[21]
22	many	O	['N']	[22]
23	as	O	['N']	[23]
24	1.4	O	['N']	[24]
25	%	O	['N']	[25]
26	of	O	['N']	[26]
27	MS	O	['N']	[27]
28	patients	O	['N']	[28]
29	on	O	['N']	[29]
30	IFN	B	['N']	[30]
31	beta	I-Drug	['Causes']	[2]
32	.	O	['N']	[32]
#3039
0	Clonidine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	bradycardia	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	patients	O	['N']	[5]
6	with	O	['N']	[6]
7	spinal	O	['N']	[7]
8	cord	O	['N']	[8]
9	injury	O	['N']	[9]
10	.	O	['N']	[10]
#3040
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	Growth	O	['N']	[2]
3	retardation	O	['N']	[3]
4	was	O	['N']	[4]
5	observed	O	['N']	[5]
6	in	O	['N']	[6]
7	six	O	['N']	[7]
8	severely	O	['N']	[8]
9	asthmatic	O	['N']	[9]
10	children	O	['N']	[10]
11	after	O	['N']	[11]
12	introduction	O	['N']	[12]
13	of	O	['N']	[13]
14	high	B-Dose	['N']	[14]
15	-	O	['N']	[15]
16	dose	O	['N']	[16]
17	fluticasone	B	['N']	[17]
18	propionate	I-Drug	['Dosage']	[14]
19	treatment	O	['N']	[19]
20	(	O	['N']	[20]
21	dry	O	['N']	[21]
22	powder	O	['N']	[22]
23	)	O	['N']	[23]
24	.	O	['N']	[24]
#3041
0	Vancomycin	B-Drug	['Causes']	[27]
1	is	O	['N']	[1]
2	widely	O	['N']	[2]
3	used	O	['N']	[3]
4	against	O	['N']	[4]
5	methicillin	O	['N']	[5]
6	-	O	['N']	[6]
7	resistant	O	['N']	[7]
8	Staphylococcus	O	['N']	[8]
9	aureus	O	['N']	[9]
10	infections	O	['N']	[10]
11	,	O	['N']	[11]
12	but	O	['N']	[12]
13	it	O	['N']	[13]
14	is	O	['N']	[14]
15	associated	O	['N']	[15]
16	with	O	['N']	[16]
17	many	O	['N']	[17]
18	adverse	O	['N']	[18]
19	effects	O	['N']	[19]
20	such	O	['N']	[20]
21	as	O	['N']	[21]
22	nephrotoxicity	O	['N']	[22]
23	,	O	['N']	[23]
24	ototoxicity	O	['N']	[24]
25	,	O	['N']	[25]
26	gastrointestinal	B	['N']	[26]
27	disturbances	I-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	blood	O	['N']	[29]
30	disorders	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	two	O	['N']	[33]
34	types	O	['N']	[34]
35	of	O	['N']	[35]
36	hypersensitivity	O	['N']	[36]
37	reactions	O	['N']	[37]
38	-	O	['N']	[38]
39	an	O	['N']	[39]
40	anaphylactoid	O	['N']	[40]
41	reaction	O	['N']	[41]
42	known	O	['N']	[42]
43	as	O	['N']	[43]
44	"	O	['N']	[44]
45	red	O	['N']	[45]
46	man	O	['N']	[46]
47	syndrome	O	['N']	[47]
48	"	O	['N']	[48]
49	and	O	['N']	[49]
50	anaphylaxis	O	['N']	[50]
51	.	O	['N']	[51]
#3042
0	The	O	['N']	[0]
1	hyperpigmentation	O	['N']	[1]
2	was	O	['N']	[2]
3	diffuse	O	['N']	[3]
4	scattered	O	['N']	[4]
5	,	O	['N']	[5]
6	flagellate	O	['N']	[6]
7	like	O	['N']	[7]
8	and	O	['N']	[8]
9	linear	O	['N']	[9]
10	streaking	O	['N']	[10]
11	which	O	['N']	[11]
12	was	O	['N']	[12]
13	thought	O	['N']	[13]
14	to	O	['N']	[14]
15	be	O	['N']	[15]
16	mainly	O	['N']	[16]
17	related	O	['N']	[17]
18	to	O	['N']	[18]
19	the	O	['N']	[19]
20	skin	B	['N']	[20]
21	toxicity	I-Adverse_Effect	['N']	[21]
22	of	O	['N']	[22]
23	bleomycin	B-Drug	['Causes']	[21]
24	.	O	['N']	[24]
#3043
0	Severe	B	['N']	[0]
1	symptomatic	I	['N']	[1]
2	hyponatremia	I-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	sibutramine	B-Drug	['Causes']	[2]
5	therapy	O	['N']	[5]
6	:	O	['N']	[6]
7	a	O	['N']	[7]
8	case	O	['N']	[8]
9	report	O	['N']	[9]
10	.	O	['N']	[10]
#3044
0	The	O	['N']	[0]
1	responsibility	O	['N']	[1]
2	of	O	['N']	[2]
3	CCNU	B-Drug	['Causes']	[9]
4	in	O	['N']	[4]
5	the	O	['N']	[5]
6	pathogenesis	O	['N']	[6]
7	of	O	['N']	[7]
8	pulmonary	B	['N']	[8]
9	fibrosis	I-Adverse_Effect	['N']	[9]
10	seems	O	['N']	[10]
11	very	O	['N']	[11]
12	likely	O	['N']	[12]
13	.	O	['N']	[13]
#3045
0	Severe	B	['N']	[0]
1	leukopenia	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	mild	O	['N']	[4]
5	hepatotoxicity	O	['N']	[5]
6	in	O	['N']	[6]
7	an	O	['N']	[7]
8	HIV	O	['N']	[8]
9	carrier	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	nevirapine	B-Drug	['Causes']	[1]
13	.	O	['N']	[13]
#3046
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	hyponatremia	B-Adverse_Effect	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	a	O	['N']	[8]
9	grand	O	['N']	[9]
10	mal	O	['N']	[10]
11	seizure	O	['N']	[11]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	28	O	['N']	[14]
15	month	O	['N']	[15]
16	-	O	['N']	[16]
17	old	O	['N']	[17]
18	child	O	['N']	[18]
19	after	O	['N']	[19]
20	intra	O	['N']	[20]
21	-	O	['N']	[21]
22	nasal	O	['N']	[22]
23	desmopressin	B-Drug	['Causes']	[5]
24	administration	O	['N']	[24]
25	for	O	['N']	[25]
26	high	O	['N']	[26]
27	fluid	O	['N']	[27]
28	intake	O	['N']	[28]
29	with	O	['N']	[29]
30	nocturnal	O	['N']	[30]
31	enuresis	O	['N']	[31]
32	.	O	['N']	[32]
#3047
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Low	O	['N']	[2]
3	dosages	O	['N']	[3]
4	of	O	['N']	[4]
5	quinacrine	B-Drug	['Causes']	[18]
6	used	O	['N']	[6]
7	for	O	['N']	[7]
8	malaria	O	['N']	[8]
9	prophylaxis	O	['N']	[9]
10	can	O	['N']	[10]
11	be	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	a	O	['N']	[14]
15	delayed	O	['N']	[15]
16	,	O	['N']	[16]
17	severe	B	['N']	[17]
18	maculopathy	I-Adverse_Effect	['N']	[18]
19	indistinguishable	O	['N']	[19]
20	from	O	['N']	[20]
21	chloroquine	O	['N']	[21]
22	maculopathy	O	['N']	[22]
23	in	O	['N']	[23]
24	certain	O	['N']	[24]
25	patients	O	['N']	[25]
26	.	O	['N']	[26]
#3048
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	Thrombotic	B	['N']	[5]
6	Thrombocytopenic	I	['N']	[6]
7	Purpura	I-Adverse_Effect	['N']	[7]
8	occurring	O	['N']	[8]
9	as	O	['N']	[9]
10	an	O	['N']	[10]
11	allergic	O	['N']	[11]
12	response	O	['N']	[12]
13	to	O	['N']	[13]
14	trimethoprim	B-Drug	['Causes']	[7]
15	-	O	['N']	[15]
16	sulfamethoxazole	O	['N']	[16]
17	therapy	O	['N']	[17]
18	(	O	['N']	[18]
19	Bactrim	O	['N']	[19]
20	,	O	['N']	[20]
21	Septra	O	['N']	[21]
22	)	O	['N']	[22]
23	in	O	['N']	[23]
24	a	O	['N']	[24]
25	Jehovah	O	['N']	[25]
26	's	O	['N']	[26]
27	Witness	O	['N']	[27]
28	patient	O	['N']	[28]
29	.	O	['N']	[29]
#3049
0	I	O	['N']	[0]
1	saw	O	['N']	[1]
2	two	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	kala	O	['N']	[5]
6	-	O	['N']	[6]
7	azar	O	['N']	[7]
8	resistant	O	['N']	[8]
9	to	O	['N']	[9]
10	sodium	O	['N']	[10]
11	stibogluconate	O	['N']	[11]
12	who	O	['N']	[12]
13	developed	O	['N']	[13]
14	cardiac	B	['N']	[14]
15	arrest	I-Adverse_Effect	['N']	[15]
16	after	O	['N']	[16]
17	amphotericin	B-Drug	['Causes']	[15]
18	infusion	O	['N']	[18]
19	(	O	['N']	[19]
20	in	O	['N']	[20]
21	spite	O	['N']	[21]
22	of	O	['N']	[22]
23	tolerating	O	['N']	[23]
24	a	O	['N']	[24]
25	test	O	['N']	[25]
26	dose	O	['N']	[26]
27	)	O	['N']	[27]
28	.	O	['N']	[28]
#3050
0	DATA	O	['N']	[0]
1	SYNTHESIS	O	['N']	[1]
2	:	O	['N']	[2]
3	Genetic	O	['N']	[3]
4	deficiencies	O	['N']	[4]
5	in	O	['N']	[5]
6	DPD	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	rate	O	['N']	[9]
10	-	O	['N']	[10]
11	limiting	O	['N']	[11]
12	enzyme	O	['N']	[12]
13	responsible	O	['N']	[13]
14	for	O	['N']	[14]
15	5-FU	B-Drug	['Causes']	[46]
16	catabolism	O	['N']	[16]
17	,	O	['N']	[17]
18	may	O	['N']	[18]
19	occur	O	['N']	[19]
20	in	O	['N']	[20]
21	3	O	['N']	[21]
22	%	O	['N']	[22]
23	or	O	['N']	[23]
24	more	O	['N']	[24]
25	of	O	['N']	[25]
26	patients	O	['N']	[26]
27	with	O	['N']	[27]
28	cancer	O	['N']	[28]
29	putting	O	['N']	[29]
30	them	O	['N']	[30]
31	at	O	['N']	[31]
32	increased	O	['N']	[32]
33	risk	O	['N']	[33]
34	for	O	['N']	[34]
35	unusually	O	['N']	[35]
36	severe	O	['N']	[36]
37	adverse	O	['N']	[37]
38	reactions	O	['N']	[38]
39	(	O	['N']	[39]
40	e.g.	O	['N']	[40]
41	,	O	['N']	[41]
42	diarrhea	O	['N']	[42]
43	,	O	['N']	[43]
44	stomatitis	O	['N']	[44]
45	,	O	['N']	[45]
46	mucositis	B-Adverse_Effect	['N']	[46]
47	,	O	['N']	[47]
48	myelosuppression	O	['N']	[48]
49	,	O	['N']	[49]
50	neurotoxicity	O	['N']	[50]
51	)	O	['N']	[51]
52	to	O	['N']	[52]
53	standard	O	['N']	[53]
54	doses	O	['N']	[54]
55	of	O	['N']	[55]
56	5-FU	O	['N']	[56]
57	.	O	['N']	[57]
#3051
0	There	O	['N']	[0]
1	are	O	['N']	[1]
2	major	O	['N']	[2]
3	side	O	['N']	[3]
4	effects	O	['N']	[4]
5	of	O	['N']	[5]
6	anastrozole	B-Drug	['Causes']	[27]
7	including	O	['N']	[7]
8	decrease	O	['N']	[8]
9	in	O	['N']	[9]
10	both	O	['N']	[10]
11	lumbar	O	['N']	[11]
12	spine	O	['N']	[12]
13	and	O	['N']	[13]
14	total	O	['N']	[14]
15	hip	O	['N']	[15]
16	bone	O	['N']	[16]
17	mineral	O	['N']	[17]
18	density	O	['N']	[18]
19	,	O	['N']	[19]
20	increase	B	['N']	[20]
21	in	I	['N']	[21]
22	the	I	['N']	[22]
23	incidence	I	['N']	[23]
24	of	I	['N']	[24]
25	all	I	['N']	[25]
26	bone	I	['N']	[26]
27	fractures	I-Adverse_Effect	['N']	[27]
28	(	O	['N']	[28]
29	especially	O	['N']	[29]
30	fractures	O	['N']	[30]
31	of	O	['N']	[31]
32	spine	O	['N']	[32]
33	,	O	['N']	[33]
34	hip	O	['N']	[34]
35	and	O	['N']	[35]
36	wrist	O	['N']	[36]
37	)	O	['N']	[37]
38	,	O	['N']	[38]
39	joint	O	['N']	[39]
40	disorders	O	['N']	[40]
41	and	O	['N']	[41]
42	increase	O	['N']	[42]
43	in	O	['N']	[43]
44	the	O	['N']	[44]
45	cholesterol	O	['N']	[45]
46	level	O	['N']	[46]
47	.	O	['N']	[47]
#3052
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	adult	O	['N']	[6]
7	Crohn	O	['N']	[7]
8	's	O	['N']	[8]
9	disease	O	['N']	[9]
10	patient	O	['N']	[10]
11	with	O	['N']	[11]
12	a	O	['N']	[12]
13	parvovirus	O	['N']	[13]
14	B19	O	['N']	[14]
15	infection	O	['N']	[15]
16	and	O	['N']	[16]
17	leukopenia	B-Adverse_Effect	['N']	[17]
18	during	O	['N']	[18]
19	long	O	['N']	[19]
20	-	O	['N']	[20]
21	term	O	['N']	[21]
22	AZA	B-Drug	['Causes']	[17]
23	therapy	O	['N']	[23]
24	.	O	['N']	[24]
#3053
0	Methysergide	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	retroperitoneal	B	['N']	[3]
4	fibrosis	I-Adverse_Effect	['N']	[4]
5	:	O	['N']	[5]
6	successful	O	['N']	[6]
7	outcome	O	['N']	[7]
8	and	O	['N']	[8]
9	two	O	['N']	[9]
10	new	O	['N']	[10]
11	laboratory	O	['N']	[11]
12	features	O	['N']	[12]
13	.	O	['N']	[13]
#3054
0	Transtubular	B	['N']	[0]
1	potassium	I	['N']	[1]
2	gradient	I	['N']	[2]
3	(	I	['N']	[3]
4	TTKG	I	['N']	[4]
5	)	I	['N']	[5]
6	also	I	['N']	[6]
7	decreased	I-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	an	O	['N']	[9]
10	inverse	O	['N']	[10]
11	correlation	O	['N']	[11]
12	was	O	['N']	[12]
13	found	O	['N']	[13]
14	between	O	['N']	[14]
15	TTKG	O	['N']	[15]
16	and	O	['N']	[16]
17	doses	O	['N']	[17]
18	of	O	['N']	[18]
19	phosphate	B-Drug	['Causes']	[7]
20	(	O	['N']	[20]
21	r	O	['N']	[21]
22	=	O	['N']	[22]
23	-0.37	O	['N']	[23]
24	;	O	['N']	[24]
25	p	O	['N']	[25]
26	<	O	['N']	[26]
27	0.02	O	['N']	[27]
28	;	O	['N']	[28]
29	N	O	['N']	[29]
30	=	O	['N']	[30]
31	38	O	['N']	[31]
32	)	O	['N']	[32]
33	.	O	['N']	[33]
#3055
0	Amoxapine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	cognitive	B	['N']	[3]
4	impairment	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	two	O	['N']	[6]
7	patients	O	['N']	[7]
8	.	O	['N']	[8]
#3056
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	RTA	B-Adverse_Effect	['N']	[5]
6	secondary	O	['N']	[6]
7	to	O	['N']	[7]
8	FK506	B-Drug	['Causes']	[5]
9	administration	O	['N']	[9]
10	in	O	['N']	[10]
11	liver	O	['N']	[11]
12	transplantation	O	['N']	[12]
13	.	O	['N']	[13]
#3057
0	We	O	['N']	[0]
1	have	O	['N']	[1]
2	described	O	['N']	[2]
3	three	O	['N']	[3]
4	patients	O	['N']	[4]
5	with	O	['N']	[5]
6	hepatitis	O	['N']	[6]
7	C	O	['N']	[7]
8	for	O	['N']	[8]
9	whom	O	['N']	[9]
10	IFN	B	['N']	[10]
11	-	I	['N']	[11]
12	alpha	I-Drug	['Causes']	[25]
13	and	O	['N']	[13]
14	ribavirin	O	['N']	[14]
15	were	O	['N']	[15]
16	prescribed	O	['N']	[16]
17	and	O	['N']	[17]
18	who	O	['N']	[18]
19	developed	O	['N']	[19]
20	two	O	['N']	[20]
21	successive	O	['N']	[21]
22	phases	O	['N']	[22]
23	of	O	['N']	[23]
24	silent	O	['N']	[24]
25	thyroiditis	B-Adverse_Effect	['N']	[25]
26	followed	O	['N']	[26]
27	by	O	['N']	[27]
28	hyperthryroidism	O	['N']	[28]
29	relapse	O	['N']	[29]
30	due	O	['N']	[30]
31	to	O	['N']	[31]
32	Graves	O	['N']	[32]
33	'	O	['N']	[33]
34	disease	O	['N']	[34]
35	.	O	['N']	[35]
#3058
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	risk	O	['N']	[3]
4	/	O	['N']	[4]
5	benefit	O	['N']	[5]
6	ratio	O	['N']	[6]
7	of	O	['N']	[7]
8	warfarin	B-Drug	['Causes']	[20]
9	therapy	O	['N']	[9]
10	changes	O	['N']	[10]
11	in	O	['N']	[11]
12	the	O	['N']	[12]
13	over	O	['N']	[13]
14	75s	O	['N']	[14]
15	,	O	['N']	[15]
16	when	O	['N']	[16]
17	haemorrhagic	B	['N']	[17]
18	side	I	['N']	[18]
19	-	I	['N']	[19]
20	effects	I-Adverse_Effect	['N']	[20]
21	become	O	['N']	[21]
22	more	O	['N']	[22]
23	common	O	['N']	[23]
24	.	O	['N']	[24]
#3059
0	In	O	['N']	[0]
1	the	O	['N']	[1]
2	present	O	['N']	[2]
3	paper	O	['N']	[3]
4	the	O	['N']	[4]
5	authors	O	['N']	[5]
6	describe	O	['N']	[6]
7	2	O	['N']	[7]
8	female	O	['N']	[8]
9	patients	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	incontinence	B-Adverse_Effect	['N']	[12]
13	secondary	O	['N']	[13]
14	to	O	['N']	[14]
15	the	O	['N']	[15]
16	selective	O	['N']	[16]
17	serotonin	O	['N']	[17]
18	reuptake	O	['N']	[18]
19	inhibitors	O	['N']	[19]
20	paroxetine	O	['N']	[20]
21	and	O	['N']	[21]
22	sertraline	B-Drug	['Causes']	[12]
23	,	O	['N']	[23]
24	as	O	['N']	[24]
25	well	O	['N']	[25]
26	as	O	['N']	[26]
27	a	O	['N']	[27]
28	third	O	['N']	[28]
29	who	O	['N']	[29]
30	developed	O	['N']	[30]
31	this	O	['N']	[31]
32	side	O	['N']	[32]
33	effect	O	['N']	[33]
34	on	O	['N']	[34]
35	venlafaxine	O	['N']	[35]
36	.	O	['N']	[36]
#3060
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	,	O	['N']	[2]
3	in	O	['N']	[3]
4	whom	O	['N']	[4]
5	tumour	O	['N']	[5]
6	overkill	O	['N']	[6]
7	by	O	['N']	[7]
8	cytotoxic	O	['N']	[8]
9	treatment	O	['N']	[9]
10	,	O	['N']	[10]
11	including	O	['N']	[11]
12	high	O	['N']	[12]
13	dose	O	['N']	[13]
14	methotrexate	O	['N']	[14]
15	with	O	['N']	[15]
16	folinic	B	['N']	[16]
17	acid	I-Drug	['Causes']	[26]
18	rescue	O	['N']	[18]
19	,	O	['N']	[19]
20	resulted	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	'	O	['N']	[23]
24	phosphate	B	['N']	[24]
25	shower	I	['N']	[25]
26	syndrome	I-Adverse_Effect	['N']	[26]
27	'	O	['N']	[27]
28	(	O	['N']	[28]
29	hyper	O	['N']	[29]
30	-	O	['N']	[30]
31	uricaemia	O	['N']	[31]
32	,	O	['N']	[32]
33	hyperkalaemia	O	['N']	[33]
34	and	O	['N']	[34]
35	hyperphosphataemia	O	['N']	[35]
36	with	O	['N']	[36]
37	hypocalcaemia	O	['N']	[37]
38	and	O	['N']	[38]
39	tetany	O	['N']	[39]
40	,	O	['N']	[40]
41	with	O	['N']	[41]
42	metabolic	O	['N']	[42]
43	acidosis	O	['N']	[43]
44	and	O	['N']	[44]
45	acute	O	['N']	[45]
46	renal	O	['N']	[46]
47	impairment	O	['N']	[47]
48	)	O	['N']	[48]
49	are	O	['N']	[49]
50	described	O	['N']	[50]
51	.	O	['N']	[51]
#3061
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	use	O	['N']	[3]
4	of	O	['N']	[4]
5	pamidronate	O	['N']	[5]
6	for	O	['N']	[6]
7	acute	O	['N']	[7]
8	,	O	['N']	[8]
9	severe	B	['N']	[9]
10	hypercalcemia	I-Adverse_Effect	['N']	[10]
11	secondary	O	['N']	[11]
12	to	O	['N']	[12]
13	iatrogenic	O	['N']	[13]
14	vitamin	B	['N']	[14]
15	D	I-Drug	['Causes']	[10]
16	poisoning	O	['N']	[16]
17	.	O	['N']	[17]
#3062
0	Meperidine	B-Drug	['Causes']	[10]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	central	B	['N']	[3]
4	nervous	I	['N']	[4]
5	system	I	['N']	[5]
6	(	I	['N']	[6]
7	CNS	I	['N']	[7]
8	)	I	['N']	[8]
9	excitatory	I	['N']	[9]
10	toxicities	I-Adverse_Effect	['N']	[10]
11	are	O	['N']	[11]
12	believed	O	['N']	[12]
13	to	O	['N']	[13]
14	be	O	['N']	[14]
15	caused	O	['N']	[15]
16	by	O	['N']	[16]
17	accumulation	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	active	O	['N']	[20]
21	metabolite	O	['N']	[21]
22	normeperidine	O	['N']	[22]
23	.	O	['N']	[23]
#3063
0	Case	O	['N']	[0]
1	report	O	['N']	[1]
2	:	O	['N']	[2]
3	life	B	['N']	[3]
4	-	I	['N']	[4]
5	threatening	I	['N']	[5]
6	hypoglycaemia	I-Adverse_Effect	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	sulfadoxine	B	['N']	[9]
10	-	I	['N']	[10]
11	pyrimethamine	I-Drug	['Causes']	[6]
12	,	O	['N']	[12]
13	a	O	['N']	[13]
14	commonly	O	['N']	[14]
15	used	O	['N']	[15]
16	antimalarial	O	['N']	[16]
17	drug	O	['N']	[17]
18	.	O	['N']	[18]
#3064
0	Flutamide	B	['N']	[0]
1	withdrawal	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	is	O	['N']	[3]
4	characterized	O	['N']	[4]
5	by	O	['N']	[5]
6	a	O	['N']	[6]
7	decrease	O	['N']	[7]
8	in	O	['N']	[8]
9	prostate	O	['N']	[9]
10	-	O	['N']	[10]
11	specific	O	['N']	[11]
12	antigen	O	['N']	[12]
13	(	O	['N']	[13]
14	PSA	O	['N']	[14]
15	)	O	['N']	[15]
16	after	O	['N']	[16]
17	flutamide	B-Drug	['Causes']	[2]
18	withdrawal	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	subset	O	['N']	[21]
22	of	O	['N']	[22]
23	patients	O	['N']	[23]
24	with	O	['N']	[24]
25	progressing	O	['N']	[25]
26	metastatic	O	['N']	[26]
27	carcinoma	O	['N']	[27]
28	of	O	['N']	[28]
29	the	O	['N']	[29]
30	prostate	O	['N']	[30]
31	.	O	['N']	[31]
#3065
0	These	O	['N']	[0]
1	features	O	['N']	[1]
2	have	O	['N']	[2]
3	not	O	['N']	[3]
4	previously	O	['N']	[4]
5	been	O	['N']	[5]
6	reported	O	['N']	[6]
7	as	O	['N']	[7]
8	side	O	['N']	[8]
9	effects	O	['N']	[9]
10	of	O	['N']	[10]
11	glibenclamide	O	['N']	[11]
12	therapy	O	['N']	[12]
13	,	O	['N']	[13]
14	but	O	['N']	[14]
15	intrahepatic	B	['N']	[15]
16	cholestasis	I-Adverse_Effect	['N']	[16]
17	may	O	['N']	[17]
18	occur	O	['N']	[18]
19	with	O	['N']	[19]
20	chlorpropamide	B-Drug	['Causes']	[16]
21	,	O	['N']	[21]
22	a	O	['N']	[22]
23	similar	O	['N']	[23]
24	sulphonylurea	O	['N']	[24]
25	agent	O	['N']	[25]
26	.	O	['N']	[26]
#3066
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	new	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	sarcoidosis	B-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	two	O	['N']	[8]
9	patients	O	['N']	[9]
10	with	O	['N']	[10]
11	hepatitis	O	['N']	[11]
12	C	O	['N']	[12]
13	virus	O	['N']	[13]
14	infection	O	['N']	[14]
15	treated	O	['N']	[15]
16	with	O	['N']	[16]
17	interferon	O	['N']	[17]
18	alfa	O	['N']	[18]
19	and	O	['N']	[19]
20	ribavirin	B-Drug	['Causes']	[6]
21	.	O	['N']	[21]
#3067
0	Severe	O	['N']	[0]
1	visual	O	['N']	[1]
2	loss	O	['N']	[2]
3	after	O	['N']	[3]
4	a	O	['N']	[4]
5	single	B	['N']	[5]
6	dose	I-Dose	['N']	[6]
7	of	O	['N']	[7]
8	vincristine	B-Drug	['Dosage']	[6]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	patient	O	['N']	[11]
12	with	O	['N']	[12]
13	spinal	O	['N']	[13]
14	cord	O	['N']	[14]
15	astrocytoma	O	['N']	[15]
16	.	O	['N']	[16]
#3068
0	The	O	['N']	[0]
1	fetal	O	['N']	[1]
2	valproate	B-Drug	['Causes']	[5]
3	syndrome	O	['N']	[3]
4	(	O	['N']	[4]
5	FVS	B-Adverse_Effect	['N']	[5]
6	)	O	['N']	[6]
7	is	O	['N']	[7]
8	characterized	O	['N']	[8]
9	by	O	['N']	[9]
10	distinctive	O	['N']	[10]
11	facial	O	['N']	[11]
12	appearance	O	['N']	[12]
13	,	O	['N']	[13]
14	major	O	['N']	[14]
15	and	O	['N']	[15]
16	minor	O	['N']	[16]
17	malformations	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	developmental	O	['N']	[20]
21	delay	O	['N']	[21]
22	.	O	['N']	[22]
#3069
0	A	O	['N']	[0]
1	73-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	non	O	['N']	[6]
7	-	O	['N']	[7]
8	Hodgkin	O	['N']	[8]
9	's	O	['N']	[9]
10	lymphoma	O	['N']	[10]
11	had	O	['N']	[11]
12	two	O	['N']	[12]
13	episodes	O	['N']	[13]
14	of	O	['N']	[14]
15	severe	O	['N']	[15]
16	,	O	['N']	[16]
17	bilateral	O	['N']	[17]
18	,	O	['N']	[18]
19	sensori	B	['N']	[19]
20	-	I	['N']	[20]
21	neural	I	['N']	[21]
22	hearing	I	['N']	[22]
23	loss	I-Adverse_Effect	['N']	[23]
24	after	O	['N']	[24]
25	vincristine	B-Drug	['Causes']	[23]
26	therapy	O	['N']	[26]
27	.	O	['N']	[27]
#3070
0	Four	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	fat	B	['N']	[3]
4	embolism	I-Adverse_Effect	['N']	[4]
5	are	O	['N']	[5]
6	described	O	['N']	[6]
7	in	O	['N']	[7]
8	infants	O	['N']	[8]
9	receiving	O	['N']	[9]
10	prolonged	O	['N']	[10]
11	intravenous	O	['N']	[11]
12	infusion	O	['N']	[12]
13	of	O	['N']	[13]
14	fat	O	['N']	[14]
15	(	O	['N']	[15]
16	Intralipid	B-Drug	['Causes']	[4]
17	20	O	['N']	[17]
18	%	O	['N']	[18]
19	)	O	['N']	[19]
20	.	O	['N']	[20]
#3071
0	Prolonged	O	['N']	[0]
1	prostate	O	['N']	[1]
2	-	O	['N']	[2]
3	specific	O	['N']	[3]
4	antigen	O	['N']	[4]
5	response	O	['N']	[5]
6	in	O	['N']	[6]
7	flutamide	B-Drug	['Causes']	[9]
8	withdrawal	I	['N']	[8]
9	syndrome	I-Adverse_Effect	['N']	[9]
10	despite	O	['N']	[10]
11	disease	O	['N']	[11]
12	progression	O	['N']	[12]
13	.	O	['N']	[13]
#3072
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	a	O	['N']	[5]
6	liver	O	['N']	[6]
7	abscess	O	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	Entamoeba	O	['N']	[10]
11	histolytica	O	['N']	[11]
12	,	O	['N']	[12]
13	in	O	['N']	[13]
14	whom	O	['N']	[14]
15	metronidazole	B-Drug	['Causes']	[33]
16	therapy	O	['N']	[16]
17	(	O	['N']	[17]
18	total	O	['N']	[18]
19	dose	O	['N']	[19]
20	,	O	['N']	[20]
21	21	O	['N']	[21]
22	g	O	['N']	[22]
23	over	O	['N']	[23]
24	14	O	['N']	[24]
25	days	O	['N']	[25]
26	)	O	['N']	[26]
27	was	O	['N']	[27]
28	complicated	O	['N']	[28]
29	by	O	['N']	[29]
30	reversible	O	['N']	[30]
31	deafness	O	['N']	[31]
32	,	O	['N']	[32]
33	tinnitus	B-Adverse_Effect	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	ataxia	O	['N']	[36]
37	and	O	['N']	[37]
38	who	O	['N']	[38]
39	relapsed	O	['N']	[39]
40	5	O	['N']	[40]
41	months	O	['N']	[41]
42	later	O	['N']	[42]
43	with	O	['N']	[43]
44	a	O	['N']	[44]
45	splenic	O	['N']	[45]
46	abscess	O	['N']	[46]
47	.	O	['N']	[47]
#3073
0	Losartan	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	angioedema	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#3074
0	CASE	O	['N']	[0]
1	REPORT	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	six	O	['N']	[4]
5	-	O	['N']	[5]
6	year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	boy	O	['N']	[9]
10	with	O	['N']	[10]
11	transfusion	O	['N']	[11]
12	-	O	['N']	[12]
13	dependent	O	['N']	[13]
14	beta	O	['N']	[14]
15	-	O	['N']	[15]
16	thalassaemia	O	['N']	[16]
17	developed	O	['N']	[17]
18	a	O	['N']	[18]
19	unilateral	B	['N']	[19]
20	hearing	I	['N']	[20]
21	loss	I-Adverse_Effect	['N']	[21]
22	shortly	O	['N']	[22]
23	after	O	['N']	[23]
24	commencing	O	['N']	[24]
25	desferrioxamine	B-Drug	['Causes']	[21]
26	therapy	O	['N']	[26]
27	.	O	['N']	[27]
#3075
0	Drug	O	['N']	[0]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hepatitis	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	an	O	['N']	[5]
6	acromegalic	O	['N']	[6]
7	patient	O	['N']	[7]
8	during	O	['N']	[8]
9	combined	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	pegvisomant	B-Drug	['Causes']	[3]
13	and	O	['N']	[13]
14	octreotide	O	['N']	[14]
15	long	O	['N']	[15]
16	-	O	['N']	[16]
17	acting	O	['N']	[17]
18	repeatable	O	['N']	[18]
19	attributed	O	['N']	[19]
20	to	O	['N']	[20]
21	the	O	['N']	[21]
22	use	O	['N']	[22]
23	of	O	['N']	[23]
24	pegvisomant	O	['N']	[24]
25	.	O	['N']	[25]
#3076
0	Procainamide	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	incessant	B	['N']	[3]
4	supraventricular	I	['N']	[4]
5	tachycardia	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	the	O	['N']	[7]
8	Wolff	O	['N']	[8]
9	-	O	['N']	[9]
10	Parkinson	O	['N']	[10]
11	-	O	['N']	[11]
12	White	O	['N']	[12]
13	syndrome	O	['N']	[13]
14	.	O	['N']	[14]
#3077
0	Toxic	B	['N']	[0]
1	epidermal	I	['N']	[1]
2	necrolysis	I-Adverse_Effect	['N']	[2]
3	resulted	O	['N']	[3]
4	after	O	['N']	[4]
5	19	O	['N']	[5]
6	days	O	['N']	[6]
7	of	O	['N']	[7]
8	treatment	O	['N']	[8]
9	with	O	['N']	[9]
10	5-fluorocytosine	O	['N']	[10]
11	and	O	['N']	[11]
12	amphotericin	-	['N']	[12]
13	B.	-	['N']	[13]
#3078
0	This	O	['N']	[0]
1	clinical	O	['N']	[1]
2	course	O	['N']	[2]
3	suggests	O	['N']	[3]
4	that	O	['N']	[4]
5	the	O	['N']	[5]
6	sensorimotor	B	['N']	[6]
7	polyneuropathy	I-Adverse_Effect	['N']	[7]
8	may	O	['N']	[8]
9	have	O	['N']	[9]
10	been	O	['N']	[10]
11	caused	O	['N']	[11]
12	by	O	['N']	[12]
13	5-ASA	B-Drug	['Causes']	[7]
14	.	O	['N']	[14]
#3079
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	no	O	['N']	[2]
3	.	O	['N']	[3]
4	2	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	pathogenic	O	['N']	[7]
8	mechanism	O	['N']	[8]
9	seemed	O	['N']	[9]
10	to	O	['N']	[10]
11	be	O	['N']	[11]
12	persistent	O	['N']	[12]
13	light	O	['N']	[13]
14	reaction	O	['N']	[14]
15	preceded	O	['N']	[15]
16	by	O	['N']	[16]
17	systemic	O	['N']	[17]
18	photoallergy	O	['N']	[18]
19	,	O	['N']	[19]
20	as	O	['N']	[20]
21	he	O	['N']	[21]
22	had	O	['N']	[22]
23	taken	O	['N']	[23]
24	mequitazine	B-Drug	['Causes']	[60]
25	for	O	['N']	[25]
26	6	O	['N']	[26]
27	months	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	there	O	['N']	[30]
31	were	O	['N']	[31]
32	strong	O	['N']	[32]
33	positive	O	['N']	[33]
34	photopatch	O	['N']	[34]
35	test	O	['N']	[35]
36	results	O	['N']	[36]
37	with	O	['N']	[37]
38	immediate	O	['N']	[38]
39	erythema	O	['N']	[39]
40	reaction	O	['N']	[40]
41	,	O	['N']	[41]
42	cross	O	['N']	[42]
43	-	O	['N']	[43]
44	reaction	O	['N']	[44]
45	to	O	['N']	[45]
46	promethazine	O	['N']	[46]
47	,	O	['N']	[47]
48	decreased	O	['N']	[48]
49	MED	O	['N']	[49]
50	to	O	['N']	[50]
51	both	O	['N']	[51]
52	UVA	O	['N']	[52]
53	and	O	['N']	[53]
54	UVB	O	['N']	[54]
55	,	O	['N']	[55]
56	and	O	['N']	[56]
57	persistence	B	['N']	[57]
58	of	I	['N']	[58]
59	the	I	['N']	[59]
60	photosensitivity	I-Adverse_Effect	['N']	[60]
61	over	O	['N']	[61]
62	a	O	['N']	[62]
63	3-year	O	['N']	[63]
64	follow	O	['N']	[64]
65	-	O	['N']	[65]
66	up	O	['N']	[66]
67	period	O	['N']	[67]
68	after	O	['N']	[68]
69	discontinuation	O	['N']	[69]
70	of	O	['N']	[70]
71	the	O	['N']	[71]
72	mequitazine	O	['N']	[72]
73	.	O	['N']	[73]
#3080
0	Cyclosporin	B-Drug	['Causes']	[14]
1	side	O	['N']	[1]
2	effects	O	['N']	[2]
3	included	O	['N']	[3]
4	hirsutism	O	['N']	[4]
5	,	O	['N']	[5]
6	hypertension	O	['N']	[6]
7	,	O	['N']	[7]
8	increased	B	['N']	[8]
9	blood	I	['N']	[9]
10	levels	I	['N']	[10]
11	of	I	['N']	[11]
12	urea	I	['N']	[12]
13	and	I	['N']	[13]
14	creatinine	I-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	abnormalities	O	['N']	[17]
18	in	O	['N']	[18]
19	liver	O	['N']	[19]
20	function	O	['N']	[20]
21	tests	O	['N']	[21]
22	.	O	['N']	[22]
#3081
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	1	O	['N']	[2]
3	,	O	['N']	[3]
4	a	O	['N']	[4]
5	total	O	['N']	[5]
6	daily	O	['N']	[6]
7	dose	O	['N']	[7]
8	of	O	['N']	[8]
9	25	B	['N']	[9]
10	mg	I-Dose	['N']	[10]
11	sertraline	O	['N']	[11]
12	,	O	['N']	[12]
13	with	O	['N']	[13]
14	nondetectable	O	['N']	[14]
15	sertraline	O	['N']	[15]
16	and	O	['N']	[16]
17	desmethylsertraline	B-Drug	['Dosage']	[10]
18	blood	O	['N']	[18]
19	levels	O	['N']	[19]
20	,	O	['N']	[20]
21	resulted	O	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	doubling	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	lamotrigine	O	['N']	[27]
28	blood	O	['N']	[28]
29	level	O	['N']	[29]
30	with	O	['N']	[30]
31	symptoms	O	['N']	[31]
32	of	O	['N']	[32]
33	toxicity	O	['N']	[33]
34	.	O	['N']	[34]
#3082
0	The	O	['N']	[0]
1	occurrence	O	['N']	[1]
2	of	O	['N']	[2]
3	neuromuscular	B	['N']	[3]
4	blockade	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	the	O	['N']	[6]
7	resulting	O	['N']	[7]
8	potentiation	O	['N']	[8]
9	of	O	['N']	[9]
10	muscle	O	['N']	[10]
11	relaxants	O	['N']	[11]
12	during	O	['N']	[12]
13	magnesium	B	['N']	[13]
14	sulfate	I-Drug	['Causes']	[4]
15	(	O	['N']	[15]
16	MgSO4	O	['N']	[16]
17	)	O	['N']	[17]
18	administration	O	['N']	[18]
19	is	O	['N']	[19]
20	well	O	['N']	[20]
21	known	O	['N']	[21]
22	.	O	['N']	[22]
#3083
0	Three	O	['N']	[0]
1	senile	O	['N']	[1]
2	patients	O	['N']	[2]
3	developed	O	['N']	[3]
4	fatal	B	['N']	[4]
5	acute	I	['N']	[5]
6	encephalopathy	I-Adverse_Effect	['N']	[6]
7	while	O	['N']	[7]
8	receiving	O	['N']	[8]
9	calcium	B	['N']	[9]
10	hopantenate	I-Drug	['Causes']	[6]
11	.	O	['N']	[11]
#3084
0	The	O	['N']	[0]
1	association	O	['N']	[1]
2	of	O	['N']	[2]
3	venlafaxine	B-Drug	['Causes']	[7]
4	treatment	O	['N']	[4]
5	with	O	['N']	[5]
6	ischaemic	B	['N']	[6]
7	events	I-Adverse_Effect	['N']	[7]
8	could	O	['N']	[8]
9	be	O	['N']	[9]
10	explained	O	['N']	[10]
11	by	O	['N']	[11]
12	its	O	['N']	[12]
13	unique	O	['N']	[13]
14	pharmacological	O	['N']	[14]
15	and	O	['N']	[15]
16	haemodynamic	O	['N']	[16]
17	properties	O	['N']	[17]
18	.	O	['N']	[18]
#3085
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	20-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	who	O	['N']	[10]
11	ingested	O	['N']	[11]
12	900	O	['N']	[12]
13	mg	O	['N']	[13]
14	of	O	['N']	[14]
15	glyburide	B-Drug	['Causes']	[18]
16	causing	O	['N']	[16]
17	refractory	O	['N']	[17]
18	hypoglycemia	B-Adverse_Effect	['N']	[18]
19	resistant	O	['N']	[19]
20	to	O	['N']	[20]
21	treatment	O	['N']	[21]
22	with	O	['N']	[22]
23	intravenous	O	['N']	[23]
24	dextrose	O	['N']	[24]
25	,	O	['N']	[25]
26	glucagon	O	['N']	[26]
27	,	O	['N']	[27]
28	and	O	['N']	[28]
29	diazoxide	O	['N']	[29]
30	.	O	['N']	[30]
#3086
0	Rapamycin	B-Drug	['Causes']	[27]
1	/	O	['N']	[1]
2	sirolimus	O	['N']	[2]
3	(	O	['N']	[3]
4	SR	O	['N']	[4]
5	)	O	['N']	[5]
6	,	O	['N']	[6]
7	trade	O	['N']	[7]
8	named	O	['N']	[8]
9	Rapammune	O	['N']	[9]
10	(	O	['N']	[10]
11	Wyeth	O	['N']	[11]
12	-	O	['N']	[12]
13	Ayerst	O	['N']	[13]
14	,	O	['N']	[14]
15	Sydney	O	['N']	[15]
16	,	O	['N']	[16]
17	Australia	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	is	O	['N']	[20]
21	a	O	['N']	[21]
22	potent	O	['N']	[22]
23	immunosuppressive	O	['N']	[23]
24	drug	O	['N']	[24]
25	associated	O	['N']	[25]
26	with	O	['N']	[26]
27	myelosuppression	B-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	hypertension	O	['N']	[29]
30	,	O	['N']	[30]
31	hyperlipidemia	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	infection	O	['N']	[34]
35	.	O	['N']	[35]
#3087
0	Rofecoxib	B-Drug	['Causes']	[27]
1	,	O	['N']	[1]
2	used	O	['N']	[2]
3	for	O	['N']	[3]
4	dysmenorrhea	O	['N']	[4]
5	,	O	['N']	[5]
6	caused	O	['N']	[6]
7	a	O	['N']	[7]
8	herpetiform	O	['N']	[8]
9	fixed	O	['N']	[9]
10	drug	O	['N']	[10]
11	eruption	O	['N']	[11]
12	predominantly	O	['N']	[12]
13	involving	O	['N']	[13]
14	the	O	['N']	[14]
15	lips	O	['N']	[15]
16	with	O	['N']	[16]
17	classic	O	['N']	[17]
18	clinical	O	['N']	[18]
19	and	O	['N']	[19]
20	histological	O	['N']	[20]
21	findings	O	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	red	B	['N']	[24]
25	-	I	['N']	[25]
26	brown	I	['N']	[26]
27	lesion	I-Adverse_Effect	['N']	[27]
28	on	O	['N']	[28]
29	the	O	['N']	[29]
30	dorsal	O	['N']	[30]
31	hand	O	['N']	[31]
32	.	O	['N']	[32]
#3088
0	Atrial	B	['N']	[0]
1	fibrillation	I-Adverse_Effect	['N']	[1]
2	occurring	O	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	taking	O	['N']	[6]
7	etanercept	O	['N']	[7]
8	plus	O	['N']	[8]
9	methotrexate	B-Drug	['Causes']	[1]
10	for	O	['N']	[10]
11	rheumatoid	O	['N']	[11]
12	arthritis	O	['N']	[12]
13	.	O	['N']	[13]
#3089
0	Gemcitabine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	related	O	['N']	[2]
3	radiation	B	['N']	[3]
4	recall	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	pancreatic	O	['N']	[9]
10	cancer	O	['N']	[10]
11	.	O	['N']	[11]
#3090
0	This	O	['N']	[0]
1	article	O	['N']	[1]
2	reports	O	['N']	[2]
3	the	O	['N']	[3]
4	occurrence	O	['N']	[4]
5	of	O	['N']	[5]
6	rifampin	B-Drug	['Causes']	[9]
7	-	O	['N']	[7]
8	associated	O	['N']	[8]
9	thrombocytopenia	B-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	an	O	['N']	[11]
12	indigent	O	['N']	[12]
13	patient	O	['N']	[13]
14	after	O	['N']	[14]
15	a	O	['N']	[15]
16	four	O	['N']	[16]
17	-	O	['N']	[17]
18	month	O	['N']	[18]
19	lapse	O	['N']	[19]
20	in	O	['N']	[20]
21	therapy	O	['N']	[21]
22	for	O	['N']	[22]
23	pulmonary	O	['N']	[23]
24	tuberculosis	O	['N']	[24]
25	.	O	['N']	[25]
#3091
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	ulcerative	B	['N']	[5]
6	proctitis	I-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	ibuprofen	B-Drug	['Causes']	[6]
9	treatment	O	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	girl	O	['N']	[12]
13	with	O	['N']	[13]
14	juvenile	O	['N']	[14]
15	systemic	O	['N']	[15]
16	lupus	O	['N']	[16]
17	erythematosus	O	['N']	[17]
18	.	O	['N']	[18]
#3092
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	chronic	O	['N']	[5]
6	renal	O	['N']	[6]
7	failure	O	['N']	[7]
8	and	O	['N']	[8]
9	ischemic	O	['N']	[9]
10	heart	O	['N']	[10]
11	disease	O	['N']	[11]
12	who	O	['N']	[12]
13	developed	O	['N']	[13]
14	clinically	O	['N']	[14]
15	significant	O	['N']	[15]
16	methemoglobinemia	B-Adverse_Effect	['N']	[16]
17	after	O	['N']	[17]
18	an	O	['N']	[18]
19	axillary	O	['N']	[19]
20	block	O	['N']	[20]
21	with	O	['N']	[21]
22	bupivacaine	B-Drug	['Causes']	[16]
23	and	O	['N']	[23]
24	additional	O	['N']	[24]
25	injection	O	['N']	[25]
26	of	O	['N']	[26]
27	lidocaine	O	['N']	[27]
28	in	O	['N']	[28]
29	the	O	['N']	[29]
30	operative	O	['N']	[30]
31	field	O	['N']	[31]
32	.	O	['N']	[32]
#3093
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	here	O	['N']	[2]
3	a	O	['N']	[3]
4	female	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	developed	O	['N']	[7]
8	acute	B	['N']	[8]
9	bilateral	I	['N']	[9]
10	parotitis	I-Adverse_Effect	['N']	[10]
11	within	O	['N']	[11]
12	minutes	O	['N']	[12]
13	of	O	['N']	[13]
14	i.v	O	['N']	[14]
15	.	O	['N']	[15]
16	enalaprilat	B-Drug	['Causes']	[10]
17	injection	O	['N']	[17]
18	and	O	['N']	[18]
19	recovered	O	['N']	[19]
20	within	O	['N']	[20]
21	24	O	['N']	[21]
22	hours	O	['N']	[22]
23	of	O	['N']	[23]
24	stopping	O	['N']	[24]
25	the	O	['N']	[25]
26	drug	O	['N']	[26]
27	and	O	['N']	[27]
28	with	O	['N']	[28]
29	symptomatic	O	['N']	[29]
30	treatment	O	['N']	[30]
31	.	O	['N']	[31]
#3094
0	Isoniazid	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	anaphylaxis	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#3095
0	A	O	['N']	[0]
1	17-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	with	O	['N']	[5]
6	acute	O	['N']	[6]
7	lymphoblastic	O	['N']	[7]
8	leukemia	O	['N']	[8]
9	developed	O	['N']	[9]
10	acute	B	['N']	[10]
11	renal	I	['N']	[11]
12	failure	I-Adverse_Effect	['N']	[12]
13	within	O	['N']	[13]
14	48	O	['N']	[14]
15	h	O	['N']	[15]
16	of	O	['N']	[16]
17	an	O	['N']	[17]
18	intravenous	O	['N']	[18]
19	high	O	['N']	[19]
20	-	O	['N']	[20]
21	dose	O	['N']	[21]
22	methotrexate	B-Drug	['Causes']	[12]
23	(	O	['N']	[23]
24	5	O	['N']	[24]
25	g	O	['N']	[25]
26	/	O	['N']	[26]
27	m2	O	['N']	[27]
28	)	O	['N']	[28]
29	infusion	O	['N']	[29]
30	.	O	['N']	[30]
#3096
0	A	O	['N']	[0]
1	14-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	developed	O	['N']	[5]
6	systemic	O	['N']	[6]
7	lupus	O	['N']	[7]
8	erythematosus	O	['N']	[8]
9	(	O	['N']	[9]
10	SLE)-like	O	['N']	[10]
11	symptoms	O	['N']	[11]
12	,	O	['N']	[12]
13	rash	O	['N']	[13]
14	,	O	['N']	[14]
15	fever	O	['N']	[15]
16	,	O	['N']	[16]
17	leukopenia	O	['N']	[17]
18	and	O	['N']	[18]
19	positive	B	['N']	[19]
20	anti	I	['N']	[20]
21	-	I	['N']	[21]
22	nuclear	I	['N']	[22]
23	antibody	I-Adverse_Effect	['N']	[23]
24	(	O	['N']	[24]
25	ANA	O	['N']	[25]
26	)	O	['N']	[26]
27	two	O	['N']	[27]
28	weeks	O	['N']	[28]
29	after	O	['N']	[29]
30	administration	O	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	O	['N']	[32]
33	(	O	['N']	[33]
34	CBZ	O	['N']	[34]
35	;	O	['N']	[35]
36	Tegretol	B-Drug	['Causes']	[23]
37	)	O	['N']	[37]
38	used	O	['N']	[38]
39	against	O	['N']	[39]
40	benign	O	['N']	[40]
41	Rolandic	O	['N']	[41]
42	epilepsy	O	['N']	[42]
43	.	O	['N']	[43]
#3097
0	Regardless	O	['N']	[0]
1	of	O	['N']	[1]
2	a	O	['N']	[2]
3	negative	O	['N']	[3]
4	history	O	['N']	[4]
5	of	O	['N']	[5]
6	asthma	O	['N']	[6]
7	,	O	['N']	[7]
8	therefore	O	['N']	[8]
9	,	O	['N']	[9]
10	life	O	['N']	[10]
11	-	O	['N']	[11]
12	threatening	O	['N']	[12]
13	bronchospasm	B-Adverse_Effect	['N']	[13]
14	must	O	['N']	[14]
15	be	O	['N']	[15]
16	considered	O	['N']	[16]
17	a	O	['N']	[17]
18	possible	O	['N']	[18]
19	complication	O	['N']	[19]
20	of	O	['N']	[20]
21	propranolol	B-Drug	['Causes']	[13]
22	therapy	O	['N']	[22]
23	.	O	['N']	[23]
#3098
0	METHOD	O	['N']	[0]
1	:	O	['N']	[1]
2	Case	O	['N']	[2]
3	analysis	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	poly	O	['N']	[6]
7	-	O	['N']	[7]
8	drug	O	['N']	[8]
9	overdose	O	['N']	[9]
10	(	O	['N']	[10]
11	venlafaxine	O	['N']	[11]
12	,	O	['N']	[12]
13	topiramate	O	['N']	[13]
14	,	O	['N']	[14]
15	divalproex	B	['N']	[15]
16	sodium	I-Drug	['Causes']	[28]
17	,	O	['N']	[17]
18	risperidone	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	carbamazepine	O	['N']	[21]
22	)	O	['N']	[22]
23	presenting	O	['N']	[23]
24	with	O	['N']	[24]
25	mixed	O	['N']	[25]
26	SS	O	['N']	[26]
27	/	O	['N']	[27]
28	NMS	B-Adverse_Effect	['N']	[28]
29	features	O	['N']	[29]
30	and	O	['N']	[30]
31	whose	O	['N']	[31]
32	clinical	O	['N']	[32]
33	management	O	['N']	[33]
34	suggests	O	['N']	[34]
35	a	O	['N']	[35]
36	practical	O	['N']	[36]
37	algorithm	O	['N']	[37]
38	for	O	['N']	[38]
39	treatment	O	['N']	[39]
40	of	O	['N']	[40]
41	undifferentiated	O	['N']	[41]
42	SS	O	['N']	[42]
43	/	O	['N']	[43]
44	NMS	O	['N']	[44]
45	in	O	['N']	[45]
46	critical	O	['N']	[46]
47	care	O	['N']	[47]
48	settings	O	['N']	[48]
49	.	O	['N']	[49]
#3099
0	The	O	['N']	[0]
1	elicitation	O	['N']	[1]
2	of	O	['N']	[2]
3	a	O	['N']	[3]
4	movement	B	['N']	[4]
5	disorder	I-Adverse_Effect	['N']	[5]
6	by	O	['N']	[6]
7	trazodone	B-Drug	['Causes']	[5]
8	:	O	['N']	[8]
9	case	O	['N']	[9]
10	report	O	['N']	[10]
11	.	O	['N']	[11]
#3100
0	Ibuprofen	B-Drug	['Causes']	[13]
1	overdose	O	['N']	[1]
2	is	O	['N']	[2]
3	usually	O	['N']	[3]
4	characterized	O	['N']	[4]
5	by	O	['N']	[5]
6	GI	O	['N']	[6]
7	upset	O	['N']	[7]
8	,	O	['N']	[8]
9	dizziness	O	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	mild	B	['N']	[12]
13	sedation	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#3101
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	lung	O	['N']	[6]
7	cancer	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	bronquiloalveolar	O	['N']	[10]
11	carcinoma	O	['N']	[11]
12	(	O	['N']	[12]
13	BAC	O	['N']	[13]
14	)	O	['N']	[14]
15	presenting	O	['N']	[15]
16	with	O	['N']	[16]
17	BOOP	O	['N']	[17]
18	after	O	['N']	[18]
19	chemotherapy	O	['N']	[19]
20	with	O	['N']	[20]
21	docetaxel	B-Drug	['Causes']	[35]
22	and	O	['N']	[22]
23	gemcitabine	O	['N']	[23]
24	producing	O	['N']	[24]
25	severe	O	['N']	[25]
26	respiratory	O	['N']	[26]
27	insufficiency	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	simulating	O	['N']	[30]
31	a	O	['N']	[31]
32	progression	B	['N']	[32]
33	of	I	['N']	[33]
34	the	I	['N']	[34]
35	tumor	I-Adverse_Effect	['N']	[35]
36	.	O	['N']	[36]
#3102
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	39-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	white	O	['N']	[7]
8	Jewish	O	['N']	[8]
9	schizophrenic	O	['N']	[9]
10	man	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	olanzapine	B-Drug	['Causes']	[19]
14	developed	O	['N']	[14]
15	an	O	['N']	[15]
16	elevated	B	['N']	[16]
17	serum	I	['N']	[17]
18	CK	I	['N']	[18]
19	concentration	I-Adverse_Effect	['N']	[19]
20	with	O	['N']	[20]
21	a	O	['N']	[21]
22	peak	O	['N']	[22]
23	concentration	O	['N']	[23]
24	of	O	['N']	[24]
25	4000	O	['N']	[25]
26	IU	O	['N']	[26]
27	/	O	['N']	[27]
28	L	O	['N']	[28]
29	(	O	['N']	[29]
30	normal	O	['N']	[30]
31	<	O	['N']	[31]
32	230	O	['N']	[32]
33	)	O	['N']	[33]
34	.	O	['N']	[34]
#3103
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	These	O	['N']	[2]
3	cases	O	['N']	[3]
4	suggest	O	['N']	[4]
5	that	O	['N']	[5]
6	moxifloxacin	B-Drug	['Causes']	[14]
7	may	O	['N']	[7]
8	interfere	O	['N']	[8]
9	with	O	['N']	[9]
10	the	O	['N']	[10]
11	healing	O	['N']	[11]
12	of	O	['N']	[12]
13	corneal	B	['N']	[13]
14	ulcers	I-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#3104
0	A	O	['N']	[0]
1	lupus	B	['N']	[1]
2	-	I	['N']	[2]
3	like	I	['N']	[3]
4	syndrome	I-Adverse_Effect	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	infliximab	B-Drug	['Causes']	[4]
8	therapy	O	['N']	[8]
9	.	O	['N']	[9]
#3105
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Life	O	['N']	[2]
3	-	O	['N']	[3]
4	threatening	O	['N']	[4]
5	adrenal	O	['N']	[5]
6	suppression	O	['N']	[6]
7	,	O	['N']	[7]
8	requiring	O	['N']	[8]
9	hydrocortisone	O	['N']	[9]
10	supplementation	O	['N']	[10]
11	and	O	['N']	[11]
12	intensive	O	['N']	[12]
13	therapy	O	['N']	[13]
14	,	O	['N']	[14]
15	was	O	['N']	[15]
16	observed	O	['N']	[16]
17	and	O	['N']	[17]
18	successfully	O	['N']	[18]
19	treated	O	['N']	[19]
20	in	O	['N']	[20]
21	a	O	['N']	[21]
22	newborn	O	['N']	[22]
23	,	O	['N']	[23]
24	whose	O	['N']	[24]
25	mother	O	['N']	[25]
26	had	O	['N']	[26]
27	received	O	['N']	[27]
28	high	B	['N']	[28]
29	-	I	['N']	[29]
30	dose	I-Dose	['N']	[30]
31	methylprednisolone	B-Drug	['Dosage']	[30]
32	in	O	['N']	[32]
33	late	O	['N']	[33]
34	pregnancy	O	['N']	[34]
35	.	O	['N']	[35]
#3106
0	After	O	['N']	[0]
1	initiation	O	['N']	[1]
2	of	O	['N']	[2]
3	topical	O	['N']	[3]
4	vitamin	B	['N']	[4]
5	D3	I-Drug	['Causes']	[36]
6	ointment	O	['N']	[6]
7	(	O	['N']	[7]
8	20	O	['N']	[8]
9	micro	O	['N']	[9]
10	g	O	['N']	[10]
11	/	O	['N']	[11]
12	g	O	['N']	[12]
13	of	O	['N']	[13]
14	tacalcitol	O	['N']	[14]
15	)	O	['N']	[15]
16	10	O	['N']	[16]
17	g	O	['N']	[17]
18	/	O	['N']	[18]
19	day	O	['N']	[19]
20	for	O	['N']	[20]
21	the	O	['N']	[21]
22	skin	O	['N']	[22]
23	lesions	O	['N']	[23]
24	,	O	['N']	[24]
25	both	O	['N']	[25]
26	the	O	['N']	[26]
27	serum	B	['N']	[27]
28	level	I	['N']	[28]
29	of	I	['N']	[29]
30	calcium	I	['N']	[30]
31	and	I	['N']	[31]
32	urinary	I	['N']	[32]
33	excretion	I	['N']	[33]
34	of	I	['N']	[34]
35	calcium	I	['N']	[35]
36	increased	I-Adverse_Effect	['N']	[36]
37	gradually	O	['N']	[37]
38	.	O	['N']	[38]
#3107
0	Hepatotoxicity	B-Adverse_Effect	['N']	[0]
1	after	O	['N']	[1]
2	high	O	['N']	[2]
3	-	O	['N']	[3]
4	dose	O	['N']	[4]
5	methylprednisolone	B-Drug	['Causes']	[0]
6	for	O	['N']	[6]
7	demyelinating	O	['N']	[7]
8	disease	O	['N']	[8]
9	.	O	['N']	[9]
#3108
0	Fracture	B	['N']	[0]
1	of	I	['N']	[1]
2	the	I	['N']	[2]
3	femoral	I	['N']	[3]
4	neck	I-Adverse_Effect	['N']	[4]
5	occurred	O	['N']	[5]
6	in	O	['N']	[6]
7	one	O	['N']	[7]
8	patient	O	['N']	[8]
9	during	O	['N']	[9]
10	PSL	B-Drug	['Causes']	[4]
11	therapy	O	['N']	[11]
12	,	O	['N']	[12]
13	although	O	['N']	[13]
14	the	O	['N']	[14]
15	relationship	O	['N']	[15]
16	between	O	['N']	[16]
17	the	O	['N']	[17]
18	fracture	O	['N']	[18]
19	and	O	['N']	[19]
20	PSL	O	['N']	[20]
21	therapy	O	['N']	[21]
22	was	O	['N']	[22]
23	uncertain	O	['N']	[23]
24	.	O	['N']	[24]
#3109
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	reported	O	['N']	[2]
3	here	O	['N']	[3]
4	is	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	child	O	['N']	[7]
8	given	O	['N']	[8]
9	a	O	['N']	[9]
10	large	O	['N']	[10]
11	dose	O	['N']	[11]
12	of	O	['N']	[12]
13	intravenous	O	['N']	[13]
14	iron	B	['N']	[14]
15	sucrose	I-Drug	['Causes']	[33]
16	(	O	['N']	[16]
17	16	O	['N']	[17]
18	mg	O	['N']	[18]
19	/	O	['N']	[19]
20	kg	O	['N']	[20]
21	)	O	['N']	[21]
22	over	O	['N']	[22]
23	3	O	['N']	[23]
24	hours	O	['N']	[24]
25	,	O	['N']	[25]
26	who	O	['N']	[26]
27	subsequently	O	['N']	[27]
28	developed	O	['N']	[28]
29	features	O	['N']	[29]
30	of	O	['N']	[30]
31	systemic	B	['N']	[31]
32	iron	I	['N']	[32]
33	toxicity	I-Adverse_Effect	['N']	[33]
34	.	O	['N']	[34]
#3110
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	postulate	O	['N']	[2]
3	that	O	['N']	[3]
4	two	O	['N']	[4]
5	types	O	['N']	[5]
6	of	O	['N']	[6]
7	combined	O	['N']	[7]
8	lithium	B-Drug	['Causes']	[22]
9	-	O	['N']	[9]
10	neuroleptic	O	['N']	[10]
11	toxicity	O	['N']	[11]
12	occur	O	['N']	[12]
13	:	O	['N']	[13]
14	a	O	['N']	[14]
15	neuroleptic	O	['N']	[15]
16	malignant	O	['N']	[16]
17	extrapyramidal	O	['N']	[17]
18	syndrome	O	['N']	[18]
19	and	O	['N']	[19]
20	a	O	['N']	[20]
21	lithium	B	['N']	[21]
22	toxicity	I-Adverse_Effect	['N']	[22]
23	that	O	['N']	[23]
24	occurs	O	['N']	[24]
25	in	O	['N']	[25]
26	combination	O	['N']	[26]
27	with	O	['N']	[27]
28	phenothiazines	O	['N']	[28]
29	,	O	['N']	[29]
30	primarily	O	['N']	[30]
31	thioridazine	O	['N']	[31]
32	.	O	['N']	[32]
#3111
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	skin	O	['N']	[23]
24	eruptions	O	['N']	[24]
25	,	O	['N']	[25]
26	cervical	O	['N']	[26]
27	lymphadenopathy	O	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	O	['N']	[31]
32	lymphocytosis	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	B-Adverse_Effect	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	B-Drug	['Causes']	[35]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	O	['N']	[42]
43	(	O	['N']	[43]
44	SMX	O	['N']	[44]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#3112
0	ARDS	B-Adverse_Effect	['N']	[0]
1	is	O	['N']	[1]
2	rarely	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	rituximab	B-Drug	['Causes']	[0]
6	infusion	O	['N']	[6]
7	for	O	['N']	[7]
8	lympho	O	['N']	[8]
9	-	O	['N']	[9]
10	proliferative	O	['N']	[10]
11	disorders	O	['N']	[11]
12	,	O	['N']	[12]
13	but	O	['N']	[13]
14	it	O	['N']	[14]
15	should	O	['N']	[15]
16	be	O	['N']	[16]
17	considered	O	['N']	[17]
18	by	O	['N']	[18]
19	those	O	['N']	[19]
20	administering	O	['N']	[20]
21	rituximab	O	['N']	[21]
22	,	O	['N']	[22]
23	especially	O	['N']	[23]
24	when	O	['N']	[24]
25	a	O	['N']	[25]
26	patient	O	['N']	[26]
27	develops	O	['N']	[27]
28	severe	O	['N']	[28]
29	pulmonary	O	['N']	[29]
30	symptoms	O	['N']	[30]
31	soon	O	['N']	[31]
32	after	O	['N']	[32]
33	infusion	O	['N']	[33]
34	.	O	['N']	[34]
#3113
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Alendronate	B-Drug	['Causes']	[6]
3	led	O	['N']	[3]
4	to	O	['N']	[4]
5	nodular	B	['N']	[5]
6	scleritis	I-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	rechallenge	O	['N']	[8]
9	caused	O	['N']	[9]
10	recurrence	O	['N']	[10]
11	of	O	['N']	[11]
12	scleritis	O	['N']	[12]
13	.	O	['N']	[13]
#3114
0	Although	O	['N']	[0]
1	neurotoxicity	B-Adverse_Effect	['N']	[1]
2	is	O	['N']	[2]
3	a	O	['N']	[3]
4	frequent	O	['N']	[4]
5	complication	O	['N']	[5]
6	of	O	['N']	[6]
7	methotrexate	B-Drug	['Causes']	[1]
8	therapy	O	['N']	[8]
9	,	O	['N']	[9]
10	fatal	O	['N']	[10]
11	acute	O	['N']	[11]
12	neurotoxicity	O	['N']	[12]
13	is	O	['N']	[13]
14	extremely	O	['N']	[14]
15	uncommon	O	['N']	[15]
16	,	O	['N']	[16]
17	especially	O	['N']	[17]
18	in	O	['N']	[18]
19	adults	O	['N']	[19]
20	.	O	['N']	[20]
#3115
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	HIV	O	['N']	[3]
4	-	O	['N']	[4]
5	infected	O	['N']	[5]
6	woman	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	mild	O	['N']	[9]
10	leukopenia	B-Adverse_Effect	['N']	[10]
11	as	O	['N']	[11]
12	the	O	['N']	[12]
13	first	O	['N']	[13]
14	sign	O	['N']	[14]
15	of	O	['N']	[15]
16	a	O	['N']	[16]
17	nevirapine	B-Drug	['Causes']	[10]
18	-	O	['N']	[18]
19	related	O	['N']	[19]
20	adverse	O	['N']	[20]
21	event	O	['N']	[21]
22	,	O	['N']	[22]
23	which	O	['N']	[23]
24	was	O	['N']	[24]
25	followed	O	['N']	[25]
26	by	O	['N']	[26]
27	skin	O	['N']	[27]
28	and	O	['N']	[28]
29	hepatic	O	['N']	[29]
30	toxicity	O	['N']	[30]
31	associated	O	['N']	[31]
32	with	O	['N']	[32]
33	a	O	['N']	[33]
34	more	O	['N']	[34]
35	severe	O	['N']	[35]
36	leukopenia	O	['N']	[36]
37	.	O	['N']	[37]
#3116
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	phenolphthalein	B-Drug	['Causes']	[14]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	toxic	O	['N']	[10]
11	epidermal	O	['N']	[11]
12	necrolysis	O	['N']	[12]
13	(	O	['N']	[13]
14	TEN	B-Adverse_Effect	['N']	[14]
15	)	O	['N']	[15]
16	in	O	['N']	[16]
17	a	O	['N']	[17]
18	patient	O	['N']	[18]
19	maintained	O	['N']	[19]
20	on	O	['N']	[20]
21	several	O	['N']	[21]
22	other	O	['N']	[22]
23	medications	O	['N']	[23]
24	more	O	['N']	[24]
25	commonly	O	['N']	[25]
26	known	O	['N']	[26]
27	to	O	['N']	[27]
28	be	O	['N']	[28]
29	associated	O	['N']	[29]
30	with	O	['N']	[30]
31	TEN	O	['N']	[31]
32	.	O	['N']	[32]
#3117
0	She	O	['N']	[0]
1	had	O	['N']	[1]
2	just	O	['N']	[2]
3	finished	O	['N']	[3]
4	a	O	['N']	[4]
5	3-week	O	['N']	[5]
6	course	O	['N']	[6]
7	of	O	['N']	[7]
8	intravenous	O	['N']	[8]
9	tobramycin	B-Drug	['Causes']	[26]
10	for	O	['N']	[10]
11	bronchiectasis	O	['N']	[11]
12	and	O	['N']	[12]
13	had	O	['N']	[13]
14	an	O	['N']	[14]
15	elevated	O	['N']	[15]
16	serum	O	['N']	[16]
17	tobramycin	O	['N']	[17]
18	trough	O	['N']	[18]
19	level	O	['N']	[19]
20	1	O	['N']	[20]
21	week	O	['N']	[21]
22	before	O	['N']	[22]
23	the	O	['N']	[23]
24	onset	O	['N']	[24]
25	of	O	['N']	[25]
26	tetany	B-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#3118
0	Large	O	['N']	[0]
1	dose	O	['N']	[1]
2	of	O	['N']	[2]
3	methylphenidate	B-Drug	['Causes']	[6]
4	may	O	['N']	[4]
5	cause	O	['N']	[5]
6	cataract	B-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	glaucoma	O	['N']	[8]
9	.	O	['N']	[9]
#3119
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	lung	O	['N']	[6]
7	cancer	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	bronquiloalveolar	O	['N']	[10]
11	carcinoma	O	['N']	[11]
12	(	O	['N']	[12]
13	BAC	O	['N']	[13]
14	)	O	['N']	[14]
15	presenting	O	['N']	[15]
16	with	O	['N']	[16]
17	BOOP	B-Adverse_Effect	['N']	[17]
18	after	O	['N']	[18]
19	chemotherapy	O	['N']	[19]
20	with	O	['N']	[20]
21	docetaxel	O	['N']	[21]
22	and	O	['N']	[22]
23	gemcitabine	B-Drug	['Causes']	[17]
24	producing	O	['N']	[24]
25	severe	O	['N']	[25]
26	respiratory	O	['N']	[26]
27	insufficiency	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	simulating	O	['N']	[30]
31	a	O	['N']	[31]
32	progression	O	['N']	[32]
33	of	O	['N']	[33]
34	the	O	['N']	[34]
35	tumor	O	['N']	[35]
36	.	O	['N']	[36]
#3120
0	The	O	['N']	[0]
1	development	O	['N']	[1]
2	of	O	['N']	[2]
3	cutaneous	B	['N']	[3]
4	ecchymosis	I-Adverse_Effect	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	a	O	['N']	[7]
8	sudden	O	['N']	[8]
9	fall	O	['N']	[9]
10	in	O	['N']	[10]
11	hemoglobin	O	['N']	[11]
12	after	O	['N']	[12]
13	the	O	['N']	[13]
14	administration	O	['N']	[14]
15	of	O	['N']	[15]
16	alteplase	B-Drug	['Causes']	[4]
17	should	O	['N']	[17]
18	strongly	O	['N']	[18]
19	suggest	O	['N']	[19]
20	the	O	['N']	[20]
21	possibility	O	['N']	[21]
22	of	O	['N']	[22]
23	diffuse	O	['N']	[23]
24	subfascial	O	['N']	[24]
25	hematoma	O	['N']	[25]
26	.	O	['N']	[26]
#3121
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	an	O	['N']	[3]
4	adult	O	['N']	[4]
5	who	O	['N']	[5]
6	developed	O	['N']	[6]
7	both	O	['N']	[7]
8	hepatic	O	['N']	[8]
9	dysfunction	O	['N']	[9]
10	and	O	['N']	[10]
11	an	O	['N']	[11]
12	impaired	B	['N']	[12]
13	macrophage	I	['N']	[13]
14	migration	I-Adverse_Effect	['N']	[14]
15	after	O	['N']	[15]
16	exposure	O	['N']	[16]
17	to	O	['N']	[17]
18	cimetidine	B-Drug	['Causes']	[14]
19	is	O	['N']	[19]
20	discussed	O	['N']	[20]
21	.	O	['N']	[21]
#3122
0	We	O	['N']	[0]
1	conclude	O	['N']	[1]
2	that	O	['N']	[2]
3	while	O	['N']	[3]
4	thrombocytopenia	B-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	schistocytosis	O	['N']	[6]
7	can	O	['N']	[7]
8	be	O	['N']	[8]
9	seen	O	['N']	[9]
10	in	O	['N']	[10]
11	quinine	B-Drug	['Causes']	[4]
12	-	O	['N']	[12]
13	associated	O	['N']	[13]
14	TTP	O	['N']	[14]
15	/	O	['N']	[15]
16	HUS	O	['N']	[16]
17	,	O	['N']	[17]
18	the	O	['N']	[18]
19	pathophysiology	O	['N']	[19]
20	seems	O	['N']	[20]
21	to	O	['N']	[21]
22	be	O	['N']	[22]
23	distinct	O	['N']	[23]
24	from	O	['N']	[24]
25	that	O	['N']	[25]
26	seen	O	['N']	[26]
27	in	O	['N']	[27]
28	most	O	['N']	[28]
29	cases	O	['N']	[29]
30	of	O	['N']	[30]
31	idiopathic	O	['N']	[31]
32	TTP	O	['N']	[32]
33	(	O	['N']	[33]
34	i.e.	O	['N']	[34]
35	,	O	['N']	[35]
36	severely	O	['N']	[36]
37	decreased	O	['N']	[37]
38	ADAMTS13	O	['N']	[38]
39	with	O	['N']	[39]
40	an	O	['N']	[40]
41	inhibitor	O	['N']	[41]
42	)	O	['N']	[42]
43	.	O	['N']	[43]
#3123
0	A	O	['N']	[0]
1	reversible	B	['N']	[1]
2	toxic	I	['N']	[2]
3	liver	I	['N']	[3]
4	damage	I-Adverse_Effect	['N']	[4]
5	was	O	['N']	[5]
6	observed	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	non	O	['N']	[9]
10	-	O	['N']	[10]
11	alcoholic	O	['N']	[11]
12	woman	O	['N']	[12]
13	treated	O	['N']	[13]
14	with	O	['N']	[14]
15	disulfiram	B-Drug	['Causes']	[4]
16	.	O	['N']	[16]
#3124
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	present	O	['N']	[2]
3	an	O	['N']	[3]
4	elderly	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	mixed	O	['N']	[7]
8	dementia	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	TD	O	['N']	[11]
12	at	O	['N']	[12]
13	multiple	O	['N']	[13]
14	sites	O	['N']	[14]
15	,	O	['N']	[15]
16	(	O	['N']	[16]
17	including	O	['N']	[17]
18	respiratory	B	['N']	[18]
19	dyskinesia	I-Adverse_Effect	['N']	[19]
20	[	O	['N']	[20]
21	RD	O	['N']	[21]
22	]	O	['N']	[22]
23	,	O	['N']	[23]
24	limb	O	['N']	[24]
25	dyskinesia	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	orofacial	O	['N']	[28]
29	dyskinesia	O	['N']	[29]
30	)	O	['N']	[30]
31	following	O	['N']	[31]
32	abrupt	O	['N']	[32]
33	withdrawal	O	['N']	[33]
34	of	O	['N']	[34]
35	risperidone	B-Drug	['Causes']	[19]
36	therapy	O	['N']	[36]
37	.	O	['N']	[37]
#3125
0	Epoprostenol	B-Drug	['Causes']	[7]
1	may	O	['N']	[1]
2	be	O	['N']	[2]
3	associated	O	['N']	[3]
4	rarely	O	['N']	[4]
5	with	O	['N']	[5]
6	severe	O	['N']	[6]
7	erythroderma	B-Adverse_Effect	['N']	[7]
8	.	O	['N']	[8]
#3126
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	1	O	['N']	[2]
3	eye	O	['N']	[3]
4	had	O	['N']	[4]
5	vitreous	B	['N']	[5]
6	hemorrhage	I-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	repeated	O	['N']	[8]
9	injections	O	['N']	[9]
10	of	O	['N']	[10]
11	tPA	B-Drug	['Causes']	[6]
12	.	O	['N']	[12]
#3127
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	presented	O	['N']	[2]
3	with	O	['N']	[3]
4	fulminant	B	['N']	[4]
5	microangiopathic	I	['N']	[5]
6	hemolytic	I	['N']	[6]
7	anemia	I-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	thrombocytopenia	O	['N']	[9]
10	within	O	['N']	[10]
11	48	O	['N']	[11]
12	hr	O	['N']	[12]
13	of	O	['N']	[13]
14	initiating	O	['N']	[14]
15	therapy	O	['N']	[15]
16	with	O	['N']	[16]
17	trimethoprim	O	['N']	[17]
18	-	O	['N']	[18]
19	sulfamethoxazole	B-Drug	['Causes']	[7]
20	.	O	['N']	[20]
#3128
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	an	O	['N']	[6]
7	embryonal	O	['N']	[7]
8	teratocarcinoma	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	testicle	O	['N']	[11]
12	who	O	['N']	[12]
13	had	O	['N']	[13]
14	the	O	['N']	[14]
15	syndrome	O	['N']	[15]
16	of	O	['N']	[16]
17	inappropriate	B	['N']	[17]
18	secretion	I	['N']	[18]
19	of	I	['N']	[19]
20	antidiuretic	I	['N']	[20]
21	hormone	I-Adverse_Effect	['N']	[21]
22	after	O	['N']	[22]
23	receiving	O	['N']	[23]
24	a	O	['N']	[24]
25	high	O	['N']	[25]
26	dose	O	['N']	[26]
27	of	O	['N']	[27]
28	vinblastine	B-Drug	['Causes']	[21]
29	.	O	['N']	[29]
#3129
0	Uveitis	B-Adverse_Effect	['N']	[0]
1	during	O	['N']	[1]
2	treatment	O	['N']	[2]
3	of	O	['N']	[3]
4	disseminated	O	['N']	[4]
5	Mycobacterium	O	['N']	[5]
6	avium	O	['N']	[6]
7	-	O	['N']	[7]
8	intracellulare	O	['N']	[8]
9	complex	O	['N']	[9]
10	infection	O	['N']	[10]
11	with	O	['N']	[11]
12	the	O	['N']	[12]
13	combination	O	['N']	[13]
14	of	O	['N']	[14]
15	rifabutin	O	['N']	[15]
16	,	O	['N']	[16]
17	clarithromycin	B-Drug	['Causes']	[0]
18	and	O	['N']	[18]
19	ethambutol	O	['N']	[19]
20	.	O	['N']	[20]
#3130
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	suggested	O	['N']	[2]
3	that	O	['N']	[3]
4	the	O	['N']	[4]
5	patient	O	['N']	[5]
6	had	O	['N']	[6]
7	sulfasalazine	B-Drug	['Causes']	[10]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	lupus	B-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	which	O	['N']	[12]
13	manifested	O	['N']	[13]
14	with	O	['N']	[14]
15	serositis	O	['N']	[15]
16	and	O	['N']	[16]
17	pulmonary	O	['N']	[17]
18	parenchymal	O	['N']	[18]
19	involvement	O	['N']	[19]
20	in	O	['N']	[20]
21	the	O	['N']	[21]
22	absence	O	['N']	[22]
23	of	O	['N']	[23]
24	joint	O	['N']	[24]
25	symptoms	O	['N']	[25]
26	.	O	['N']	[26]
#3131
0	This	O	['N']	[0]
1	article	O	['N']	[1]
2	presents	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	hypoparathyroidism	O	['N']	[6]
7	who	O	['N']	[7]
8	was	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	calcium	O	['N']	[11]
12	carbonate	O	['N']	[12]
13	and	O	['N']	[13]
14	calcitriol	B-Drug	['Causes']	[26]
15	resulting	O	['N']	[15]
16	in	O	['N']	[16]
17	two	O	['N']	[17]
18	admissions	O	['N']	[18]
19	to	O	['N']	[19]
20	the	O	['N']	[20]
21	hospital	O	['N']	[21]
22	for	O	['N']	[22]
23	milk	B	['N']	[23]
24	-	I	['N']	[24]
25	alkali	I	['N']	[25]
26	syndrome	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#3132
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	suggested	O	['N']	[2]
3	that	O	['N']	[3]
4	the	O	['N']	[4]
5	patient	O	['N']	[5]
6	had	O	['N']	[6]
7	sulfasalazine	B-Drug	['Causes']	[15]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	lupus	O	['N']	[10]
11	,	O	['N']	[11]
12	which	O	['N']	[12]
13	manifested	O	['N']	[13]
14	with	O	['N']	[14]
15	serositis	B-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	pulmonary	O	['N']	[17]
18	parenchymal	O	['N']	[18]
19	involvement	O	['N']	[19]
20	in	O	['N']	[20]
21	the	O	['N']	[21]
22	absence	O	['N']	[22]
23	of	O	['N']	[23]
24	joint	O	['N']	[24]
25	symptoms	O	['N']	[25]
26	.	O	['N']	[26]
#3133
0	Several	O	['N']	[0]
1	hypersensitivity	O	['N']	[1]
2	reactions	O	['N']	[2]
3	to	O	['N']	[3]
4	cloxacillin	B-Drug	['Causes']	[14]
5	have	O	['N']	[5]
6	been	O	['N']	[6]
7	reported	O	['N']	[7]
8	,	O	['N']	[8]
9	although	O	['N']	[9]
10	IgE	B	['N']	[10]
11	-	I	['N']	[11]
12	mediated	I	['N']	[12]
13	allergic	I	['N']	[13]
14	reactions	I-Adverse_Effect	['N']	[14]
15	to	O	['N']	[15]
16	the	O	['N']	[16]
17	drug	O	['N']	[17]
18	are	O	['N']	[18]
19	rare	O	['N']	[19]
20	and	O	['N']	[20]
21	there	O	['N']	[21]
22	is	O	['N']	[22]
23	little	O	['N']	[23]
24	information	O	['N']	[24]
25	about	O	['N']	[25]
26	possible	O	['N']	[26]
27	tolerance	O	['N']	[27]
28	to	O	['N']	[28]
29	other	O	['N']	[29]
30	semisynthetic	O	['N']	[30]
31	penicillins	O	['N']	[31]
32	or	O	['N']	[32]
33	cephalosporins	O	['N']	[33]
34	in	O	['N']	[34]
35	patients	O	['N']	[35]
36	with	O	['N']	[36]
37	cloxacillin	O	['N']	[37]
38	allergy	O	['N']	[38]
39	.	O	['N']	[39]
#3134
0	Amiodarone	B-Drug	['Causes']	[5]
1	was	O	['N']	[1]
2	discontinued	O	['N']	[2]
3	,	O	['N']	[3]
4	and	O	['N']	[4]
5	thyrotoxicosis	B-Adverse_Effect	['N']	[5]
6	gradually	O	['N']	[6]
7	abated	O	['N']	[7]
8	.	O	['N']	[8]
#3135
0	Amphotericin	B	['N']	[0]
1	B	I-Drug	['Causes']	[9]
2	overdose	O	['N']	[2]
3	in	O	['N']	[3]
4	pediatric	O	['N']	[4]
5	patients	O	['N']	[5]
6	with	O	['N']	[6]
7	associated	O	['N']	[7]
8	cardiac	B	['N']	[8]
9	arrest	I-Adverse_Effect	['N']	[9]
10	.	O	['N']	[10]
#3136
0	Severe	B	['N']	[0]
1	aphthous	I	['N']	[1]
2	stomatitis	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	oral	O	['N']	[5]
6	calcineurin	B-Drug	['Causes']	[2]
7	and	O	['N']	[7]
8	mTOR	O	['N']	[8]
9	inhibitors	O	['N']	[9]
10	.	O	['N']	[10]
#3137
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	histories	O	['N']	[2]
3	are	O	['N']	[3]
4	presented	O	['N']	[4]
5	of	O	['N']	[5]
6	two	O	['N']	[6]
7	patients	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	lung	B	['N']	[10]
11	disease	I-Adverse_Effect	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	the	O	['N']	[14]
15	use	O	['N']	[15]
16	of	O	['N']	[16]
17	nitrofurantoin	B-Drug	['Causes']	[11]
18	with	O	['N']	[18]
19	histological	O	['N']	[19]
20	features	O	['N']	[20]
21	of	O	['N']	[21]
22	bronchiolitis	O	['N']	[22]
23	obliterans	O	['N']	[23]
24	organising	O	['N']	[24]
25	pneumonia	O	['N']	[25]
26	(	O	['N']	[26]
27	BOOP	O	['N']	[27]
28	)	O	['N']	[28]
29	,	O	['N']	[29]
30	a	O	['N']	[30]
31	rare	O	['N']	[31]
32	but	O	['N']	[32]
33	recognised	O	['N']	[33]
34	form	O	['N']	[34]
35	of	O	['N']	[35]
36	drug	O	['N']	[36]
37	induced	O	['N']	[37]
38	injury	O	['N']	[38]
39	.	O	['N']	[39]
#3138
0	Emergence	O	['N']	[0]
1	of	O	['N']	[1]
2	Philadelphia	B	['N']	[2]
3	positive	I	['N']	[3]
4	chronic	I	['N']	[4]
5	myeloid	I	['N']	[5]
6	leukaemia	I-Adverse_Effect	['N']	[6]
7	during	O	['N']	[7]
8	treatment	O	['N']	[8]
9	with	O	['N']	[9]
10	hydroxyurea	B-Drug	['Causes']	[6]
11	for	O	['N']	[11]
12	Philadelphia	O	['N']	[12]
13	negative	O	['N']	[13]
14	essential	O	['N']	[14]
15	thrombocythaemia	O	['N']	[15]
16	.	O	['N']	[16]
#3139
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	histories	O	['N']	[4]
5	of	O	['N']	[5]
6	identical	O	['N']	[6]
7	twin	O	['N']	[7]
8	brothers	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	concordant	O	['N']	[11]
12	acute	O	['N']	[12]
13	lymphoblastic	O	['N']	[13]
14	leukemia	O	['N']	[14]
15	at	O	['N']	[15]
16	the	O	['N']	[16]
17	age	O	['N']	[17]
18	of	O	['N']	[18]
19	4	O	['N']	[19]
20	years	O	['N']	[20]
21	and	O	['N']	[21]
22	who	O	['N']	[22]
23	later	O	['N']	[23]
24	developed	O	['N']	[24]
25	leukoencephalopathy	O	['N']	[25]
26	and	O	['N']	[26]
27	hydrocephalus	B-Adverse_Effect	['N']	[27]
28	related	O	['N']	[28]
29	to	O	['N']	[29]
30	central	O	['N']	[30]
31	nervous	O	['N']	[31]
32	system	O	['N']	[32]
33	prophylaxis	O	['N']	[33]
34	by	O	['N']	[34]
35	,	O	['N']	[35]
36	in	O	['N']	[36]
37	the	O	['N']	[37]
38	first	O	['N']	[38]
39	case	O	['N']	[39]
40	intrathecally	O	['N']	[40]
41	administered	O	['N']	[41]
42	methotrexate	B-Drug	['Causes']	[27]
43	and	O	['N']	[43]
44	,	O	['N']	[44]
45	in	O	['N']	[45]
46	the	O	['N']	[46]
47	second	O	['N']	[47]
48	by	O	['N']	[48]
49	intrathecally	O	['N']	[49]
50	administered	O	['N']	[50]
51	methotrexate	O	['N']	[51]
52	and	O	['N']	[52]
53	cranial	O	['N']	[53]
54	irradiation	O	['N']	[54]
55	.	O	['N']	[55]
#3140
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	paradoxical	O	['N']	[6]
7	,	O	['N']	[7]
8	intravenous	O	['N']	[8]
9	valproic	B	['N']	[9]
10	acid	I-Drug	['Causes']	[14]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	seizure	B	['N']	[13]
14	exacerbation	I-Adverse_Effect	['N']	[14]
15	in	O	['N']	[15]
16	a	O	['N']	[16]
17	child	O	['N']	[17]
18	with	O	['N']	[18]
19	juvenile	O	['N']	[19]
20	absence	O	['N']	[20]
21	epilepsy	O	['N']	[21]
22	,	O	['N']	[22]
23	documented	O	['N']	[23]
24	by	O	['N']	[24]
25	video	O	['N']	[25]
26	-	O	['N']	[26]
27	electroencephalography	O	['N']	[27]
28	.	O	['N']	[28]
#3141
0	After	O	['N']	[0]
1	a	O	['N']	[1]
2	six	O	['N']	[2]
3	-	O	['N']	[3]
4	week	O	['N']	[4]
5	course	O	['N']	[5]
6	of	O	['N']	[6]
7	low	B	['N']	[7]
8	-	I	['N']	[8]
9	dose	I-Dose	['N']	[9]
10	cyclosporine	B	['N']	[10]
11	A	I-Drug	['Dosage']	[9]
12	,	O	['N']	[12]
13	she	O	['N']	[13]
14	developed	O	['N']	[14]
15	a	O	['N']	[15]
16	severe	O	['N']	[16]
17	but	O	['N']	[17]
18	reversible	O	['N']	[18]
19	loss	O	['N']	[19]
20	of	O	['N']	[20]
21	glomerular	O	['N']	[21]
22	filtration	O	['N']	[22]
23	rate	O	['N']	[23]
24	and	O	['N']	[24]
25	effective	O	['N']	[25]
26	renal	O	['N']	[26]
27	plasma	O	['N']	[27]
28	flow	O	['N']	[28]
29	despite	O	['N']	[29]
30	of	O	['N']	[30]
31	low	O	['N']	[31]
32	cyclosporine	O	['N']	[32]
33	A	O	['N']	[33]
34	plasma	O	['N']	[34]
35	levels	O	['N']	[35]
36	.	O	['N']	[36]
#3142
0	Six	O	['N']	[0]
1	patients	O	['N']	[1]
2	developed	O	['N']	[2]
3	peripheral	O	['N']	[3]
4	neuropathy	O	['N']	[4]
5	and	O	['N']	[5]
6	five	O	['N']	[6]
7	patients	O	['N']	[7]
8	bone	B	['N']	[8]
9	marrow	I	['N']	[9]
10	depression	I-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	blood	O	['N']	[12]
13	transfusions	O	['N']	[13]
14	were	O	['N']	[14]
15	given	O	['N']	[15]
16	to	O	['N']	[16]
17	three	O	['N']	[17]
18	patients	O	['N']	[18]
19	and	O	['N']	[19]
20	in	O	['N']	[20]
21	all	O	['N']	[21]
22	five	O	['N']	[22]
23	patients	O	['N']	[23]
24	bone	O	['N']	[24]
25	marrow	O	['N']	[25]
26	function	O	['N']	[26]
27	normalized	O	['N']	[27]
28	after	O	['N']	[28]
29	cessation	O	['N']	[29]
30	of	O	['N']	[30]
31	linezolid	B-Drug	['Causes']	[10]
32	.	O	['N']	[32]
#3143
0	Delayed	B	['N']	[0]
1	hypersensitivity	I-Adverse_Effect	['N']	[1]
2	to	O	['N']	[2]
3	flurbiprofen	B-Drug	['Causes']	[1]
4	.	O	['N']	[4]
#3144
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Hypersensitivity	B	['N']	[2]
3	reactions	I-Adverse_Effect	['N']	[3]
4	to	O	['N']	[4]
5	cyclosporine	B-Drug	['Causes']	[3]
6	are	O	['N']	[6]
7	due	O	['N']	[7]
8	to	O	['N']	[8]
9	Cremophor	O	['N']	[9]
10	EL	O	['N']	[10]
11	.	O	['N']	[11]
#3145
0	Three	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	acute	B	['N']	[3]
4	renal	I	['N']	[4]
5	toxicity	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	patients	O	['N']	[7]
8	receiving	O	['N']	[8]
9	long	O	['N']	[9]
10	-	O	['N']	[10]
11	term	O	['N']	[11]
12	therapy	O	['N']	[12]
13	with	O	['N']	[13]
14	mitomycin	B	['N']	[14]
15	C	I-Drug	['Causes']	[5]
16	and	O	['N']	[16]
17	5-fluorouracil	O	['N']	[17]
18	are	O	['N']	[18]
19	reported	O	['N']	[19]
20	.	O	['N']	[20]
#3146
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	hyperpigmentation	B-Adverse_Effect	['N']	[5]
6	due	O	['N']	[6]
7	to	O	['N']	[7]
8	bleomycin	B-Drug	['Causes']	[5]
9	treatment	O	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	patient	O	['N']	[12]
13	with	O	['N']	[13]
14	acquired	O	['N']	[14]
15	immune	O	['N']	[15]
16	deficiency	O	['N']	[16]
17	syndrome	O	['N']	[17]
18	(	O	['N']	[18]
19	AIDS	O	['N']	[19]
20	)	O	['N']	[20]
21	.	O	['N']	[21]
#3147
0	Pure	B	['N']	[0]
1	red	I	['N']	[1]
2	cell	I	['N']	[2]
3	aplasia	I-Adverse_Effect	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	fenoprofen	B-Drug	['Causes']	[3]
7	.	O	['N']	[7]
#3148
0	We	O	['N']	[0]
1	conclude	O	['N']	[1]
2	that	O	['N']	[2]
3	myocardial	O	['N']	[3]
4	infarction	O	['N']	[4]
5	may	O	['N']	[5]
6	develop	O	['N']	[6]
7	in	O	['N']	[7]
8	patients	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	high	B	['N']	[11]
12	-	I	['N']	[12]
13	dose	I-Dose	['N']	[13]
14	glucocorticoids	B-Drug	['Dosage']	[13]
15	for	O	['N']	[15]
16	Graves	O	['N']	[16]
17	'	O	['N']	[17]
18	ophthalmopathy	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	increased	O	['N']	[21]
22	blood	O	['N']	[22]
23	pressure	O	['N']	[23]
24	may	O	['N']	[24]
25	herald	O	['N']	[25]
26	this	O	['N']	[26]
27	complication	O	['N']	[27]
28	.	O	['N']	[28]
#3149
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	ethylenediamine	O	['N']	[5]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	delayed	B	['N']	[8]
9	hypersensitivity	I	['N']	[9]
10	reaction	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	46-year	O	['N']	[13]
14	-	O	['N']	[14]
15	old	O	['N']	[15]
16	woman	O	['N']	[16]
17	who	O	['N']	[17]
18	received	O	['N']	[18]
19	parenteral	O	['N']	[19]
20	aminophylline	B-Drug	['Causes']	[10]
21	for	O	['N']	[21]
22	an	O	['N']	[22]
23	acute	O	['N']	[23]
24	asthma	O	['N']	[24]
25	exacerbation	O	['N']	[25]
26	.	O	['N']	[26]
#3150
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	treated	O	['N']	[2]
3	with	O	['N']	[3]
4	5-fluorouracil	O	['N']	[4]
5	(	O	['N']	[5]
6	5-FU	B-Drug	['Causes']	[16]
7	)	O	['N']	[7]
8	for	O	['N']	[8]
9	disseminated	O	['N']	[9]
10	adenocarcinoma	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	colon	O	['N']	[13]
14	developed	O	['N']	[14]
15	cerebellar	B	['N']	[15]
16	dysfunction	I-Adverse_Effect	['N']	[16]
17	typical	O	['N']	[17]
18	of	O	['N']	[18]
19	5-FU	O	['N']	[19]
20	neurotoxicity	O	['N']	[20]
21	.	O	['N']	[21]
#3151
0	We	O	['N']	[0]
1	discuss	O	['N']	[1]
2	the	O	['N']	[2]
3	association	O	['N']	[3]
4	between	O	['N']	[4]
5	carbamazepine	B-Drug	['Causes']	[7]
6	and	O	['N']	[6]
7	hyponatremia	B-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	the	O	['N']	[9]
10	causes	O	['N']	[10]
11	of	O	['N']	[11]
12	hyponatremia	O	['N']	[12]
13	after	O	['N']	[13]
14	cardiopulmonary	O	['N']	[14]
15	bypass	O	['N']	[15]
16	.	O	['N']	[16]
#3152
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Gemcitabine	O	['N']	[2]
3	has	O	['N']	[3]
4	mild	O	['N']	[4]
5	renal	O	['N']	[5]
6	toxicity	O	['N']	[6]
7	,	O	['N']	[7]
8	but	O	['N']	[8]
9	cases	O	['N']	[9]
10	of	O	['N']	[10]
11	gemcitabine	B-Drug	['Causes']	[17]
12	-	O	['N']	[12]
13	associated	O	['N']	[13]
14	hemolytic	B	['N']	[14]
15	-	I	['N']	[15]
16	uremic	I	['N']	[16]
17	syndrome	I-Adverse_Effect	['N']	[17]
18	(	O	['N']	[18]
19	HUS	O	['N']	[19]
20	)	O	['N']	[20]
21	have	O	['N']	[21]
22	been	O	['N']	[22]
23	reported	O	['N']	[23]
24	.	O	['N']	[24]
#3153
0	It	O	['N']	[0]
1	has	O	['N']	[1]
2	been	O	['N']	[2]
3	reported	O	['N']	[3]
4	that	O	['N']	[4]
5	fluoroquinolone	B-Drug	['Causes']	[17]
6	antimicrobials	O	['N']	[6]
7	prolong	O	['N']	[7]
8	the	O	['N']	[8]
9	corrected	O	['N']	[9]
10	QT	O	['N']	[10]
11	interval	O	['N']	[11]
12	but	O	['N']	[12]
13	rarely	O	['N']	[13]
14	cause	O	['N']	[14]
15	torsade	B	['N']	[15]
16	de	I	['N']	[16]
17	pointes	I-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#3154
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	in	O	['N']	[4]
5	whom	O	['N']	[5]
6	the	O	['N']	[6]
7	anti	O	['N']	[7]
8	-	O	['N']	[8]
9	depressant	O	['N']	[9]
10	trazodone	B	['N']	[10]
11	hydrochloride	I-Drug	['Causes']	[25]
12	(	O	['N']	[12]
13	Molipaxin	O	['N']	[13]
14	,	O	['N']	[14]
15	Roussel	O	['N']	[15]
16	)	O	['N']	[16]
17	,	O	['N']	[17]
18	a	O	['N']	[18]
19	serotonin	O	['N']	[19]
20	antagonist	O	['N']	[20]
21	,	O	['N']	[21]
22	provoked	O	['N']	[22]
23	generalized	B	['N']	[23]
24	pustular	I	['N']	[24]
25	psoriasis	I-Adverse_Effect	['N']	[25]
26	(	O	['N']	[26]
27	GPP	O	['N']	[27]
28	)	O	['N']	[28]
29	.	O	['N']	[29]
#3155
0	Probable	O	['N']	[0]
1	early	O	['N']	[1]
2	acute	B	['N']	[2]
3	hepatitis	I-Adverse_Effect	['N']	[3]
4	with	O	['N']	[4]
5	parenteral	O	['N']	[5]
6	amiodarone	B-Drug	['Causes']	[3]
7	.	O	['N']	[7]
#3156
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	serotonin	B	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	interaction	O	['N']	[11]
12	between	O	['N']	[12]
13	fentanyl	B-Drug	['Causes']	[8]
14	and	O	['N']	[14]
15	citalopram	O	['N']	[15]
16	,	O	['N']	[16]
17	as	O	['N']	[17]
18	evidenced	O	['N']	[18]
19	by	O	['N']	[19]
20	medication	O	['N']	[20]
21	history	O	['N']	[21]
22	,	O	['N']	[22]
23	clinical	O	['N']	[23]
24	features	O	['N']	[24]
25	and	O	['N']	[25]
26	reversal	O	['N']	[26]
27	following	O	['N']	[27]
28	discontinuation	O	['N']	[28]
29	of	O	['N']	[29]
30	fentanyl	O	['N']	[30]
31	.	O	['N']	[31]
#3157
0	Anti	O	['N']	[0]
1	-	O	['N']	[1]
2	tuberculous	O	['N']	[2]
3	drugs	O	['N']	[3]
4	had	O	['N']	[4]
5	been	O	['N']	[5]
6	stopped	O	['N']	[6]
7	on	O	['N']	[7]
8	the	O	['N']	[8]
9	2nd	O	['N']	[9]
10	day	O	['N']	[10]
11	of	O	['N']	[11]
12	therapy	O	['N']	[12]
13	due	O	['N']	[13]
14	to	O	['N']	[14]
15	development	O	['N']	[15]
16	of	O	['N']	[16]
17	optic	B	['N']	[17]
18	neuritis	I-Adverse_Effect	['N']	[18]
19	secondary	O	['N']	[19]
20	to	O	['N']	[20]
21	ethambutol	B-Drug	['Causes']	[18]
22	administration	O	['N']	[22]
23	at	O	['N']	[23]
24	another	O	['N']	[24]
25	hospital	O	['N']	[25]
26	.	O	['N']	[26]
#3158
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	Naranjo	O	['N']	[3]
4	probability	O	['N']	[4]
5	scale	O	['N']	[5]
6	indicated	O	['N']	[6]
7	a	O	['N']	[7]
8	probable	O	['N']	[8]
9	relationship	O	['N']	[9]
10	between	O	['N']	[10]
11	sertraline	B-Drug	['Causes']	[17]
12	treatment	O	['N']	[12]
13	and	O	['N']	[13]
14	the	O	['N']	[14]
15	onset	O	['N']	[15]
16	of	O	['N']	[16]
17	rhabdomyolysis	B-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#3159
0	We	O	['N']	[0]
1	also	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	timolol	B-Drug	['Causes']	[10]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	ocular	B	['N']	[9]
10	pemphigoid	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#3160
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	this	O	['N']	[4]
5	is	O	['N']	[5]
6	the	O	['N']	[6]
7	first	O	['N']	[7]
8	reported	O	['N']	[8]
9	case	O	['N']	[9]
10	of	O	['N']	[10]
11	bromide	B	['N']	[11]
12	intoxication	I-Adverse_Effect	['N']	[12]
13	due	O	['N']	[13]
14	to	O	['N']	[14]
15	pyridostigmine	B	['N']	[15]
16	bromide	I-Drug	['Causes']	[12]
17	administration	O	['N']	[17]
18	.	O	['N']	[18]
#3161
0	Thus	O	['N']	[0]
1	,	O	['N']	[1]
2	the	O	['N']	[2]
3	possible	O	['N']	[3]
4	in	O	['N']	[4]
5	vivo	O	['N']	[5]
6	effects	O	['N']	[6]
7	of	O	['N']	[7]
8	insulin	B-Drug	['Causes']	[21]
9	on	O	['N']	[9]
10	adipocytes	O	['N']	[10]
11	were	O	['N']	[11]
12	clearly	O	['N']	[12]
13	observed	O	['N']	[13]
14	in	O	['N']	[14]
15	this	O	['N']	[15]
16	case	O	['N']	[16]
17	of	O	['N']	[17]
18	insulin	O	['N']	[18]
19	-	O	['N']	[19]
20	induced	O	['N']	[20]
21	lipohypertrophy	B-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#3162
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	report	O	['N']	[2]
3	describes	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	was	O	['N']	[7]
8	previously	O	['N']	[8]
9	prescribed	O	['N']	[9]
10	alendronate	O	['N']	[10]
11	(	O	['N']	[11]
12	Fosamax	O	['N']	[12]
13	)	O	['N']	[13]
14	and	O	['N']	[14]
15	presented	O	['N']	[15]
16	with	O	['N']	[16]
17	postoperative	O	['N']	[17]
18	hypophosphatemia	B-Adverse_Effect	['N']	[18]
19	and	O	['N']	[19]
20	hypocalcemic	O	['N']	[20]
21	tetany	O	['N']	[21]
22	after	O	['N']	[22]
23	bowel	O	['N']	[23]
24	preparation	O	['N']	[24]
25	with	O	['N']	[25]
26	Fleet	B	['N']	[26]
27	Phospho	I	['N']	[27]
28	-	I	['N']	[28]
29	Soda	I-Drug	['Causes']	[18]
30	.	O	['N']	[30]
#3163
0	We	O	['N']	[0]
1	hypothesize	O	['N']	[1]
2	that	O	['N']	[2]
3	caffeine	B-Drug	['Causes']	[29]
4	toxicity	O	['N']	[4]
5	injured	O	['N']	[5]
6	the	O	['N']	[6]
7	muscle	O	['N']	[7]
8	cells	O	['N']	[8]
9	,	O	['N']	[9]
10	which	O	['N']	[10]
11	were	O	['N']	[11]
12	fragile	O	['N']	[12]
13	due	O	['N']	[13]
14	to	O	['N']	[14]
15	the	O	['N']	[15]
16	potassium	O	['N']	[16]
17	depletion	O	['N']	[17]
18	induced	O	['N']	[18]
19	by	O	['N']	[19]
20	the	O	['N']	[20]
21	coexisting	O	['N']	[21]
22	hyponatremia	O	['N']	[22]
23	,	O	['N']	[23]
24	to	O	['N']	[24]
25	result	O	['N']	[25]
26	in	O	['N']	[26]
27	unusually	O	['N']	[27]
28	severe	O	['N']	[28]
29	rhabdomyolysis	B-Adverse_Effect	['N']	[29]
30	.	O	['N']	[30]
#3164
0	Focal	B	['N']	[0]
1	renal	I	['N']	[1]
2	cortical	I	['N']	[2]
3	necrosis	I-Adverse_Effect	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	zomepirac	B-Drug	['Causes']	[3]
7	.	O	['N']	[7]
#3165
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	allopurinol	B-Drug	['Causes']	[4]
4	hypersensitivity	B-Adverse_Effect	['N']	[4]
5	,	O	['N']	[5]
6	possibly	O	['N']	[6]
7	the	O	['N']	[7]
8	first	O	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	black	O	['N']	[11]
12	African	O	['N']	[12]
13	,	O	['N']	[13]
14	is	O	['N']	[14]
15	reported	O	['N']	[15]
16	.	O	['N']	[16]
#3166
0	A	O	['N']	[0]
1	fatal	B	['N']	[1]
2	pancytopenia	I-Adverse_Effect	['N']	[2]
3	occurred	O	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	an	O	['N']	[8]
9	history	O	['N']	[9]
10	of	O	['N']	[10]
11	depression	O	['N']	[11]
12	with	O	['N']	[12]
13	hypomanic	O	['N']	[13]
14	rebounds	O	['N']	[14]
15	,	O	['N']	[15]
16	admitted	O	['N']	[16]
17	for	O	['N']	[17]
18	a	O	['N']	[18]
19	manic	O	['N']	[19]
20	episode	O	['N']	[20]
21	and	O	['N']	[21]
22	treated	O	['N']	[22]
23	with	O	['N']	[23]
24	levomepromazine	B-Drug	['Causes']	[2]
25	,	O	['N']	[25]
26	diazepam	O	['N']	[26]
27	and	O	['N']	[27]
28	lithium	O	['N']	[28]
29	carbonate	O	['N']	[29]
30	.	O	['N']	[30]
#3167
0	Here	O	['N']	[0]
1	we	O	['N']	[1]
2	report	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	newly	O	['N']	[6]
7	diagnosed	O	['N']	[7]
8	acute	O	['N']	[8]
9	promyelocytic	O	['N']	[9]
10	leukemia	O	['N']	[10]
11	who	O	['N']	[11]
12	developed	O	['N']	[12]
13	acute	O	['N']	[13]
14	focal	O	['N']	[14]
15	myositis	O	['N']	[15]
16	,	O	['N']	[16]
17	synovitis	B-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	possible	O	['N']	[20]
21	vasculitis	O	['N']	[21]
22	,	O	['N']	[22]
23	after	O	['N']	[23]
24	receiving	O	['N']	[24]
25	all	B	['N']	[25]
26	-	I	['N']	[26]
27	trans	I	['N']	[27]
28	retinoic	I	['N']	[28]
29	acid	I-Drug	['Causes']	[17]
30	therapy	O	['N']	[30]
31	.	O	['N']	[31]
#3168
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	a	O	['N']	[10]
11	prolonged	B	['N']	[11]
12	QT	I-Adverse_Effect	['N']	[12]
13	while	O	['N']	[13]
14	being	O	['N']	[14]
15	treated	O	['N']	[15]
16	with	O	['N']	[16]
17	oral	O	['N']	[17]
18	methadone	B-Drug	['Causes']	[12]
19	for	O	['N']	[19]
20	a	O	['N']	[20]
21	chronic	O	['N']	[21]
22	pain	O	['N']	[22]
23	syndrome	O	['N']	[23]
24	.	O	['N']	[24]
#3169
0	We	O	['N']	[0]
1	experienced	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	chronic	O	['N']	[5]
6	renal	O	['N']	[6]
7	failure	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	suffering	O	['N']	[11]
12	from	O	['N']	[12]
13	acute	B	['N']	[13]
14	hemorrhagic	I	['N']	[14]
15	gastritis	I-Adverse_Effect	['N']	[15]
16	associated	O	['N']	[16]
17	with	O	['N']	[17]
18	AZ	B-Drug	['Causes']	[15]
19	intoxication	O	['N']	[19]
20	.	O	['N']	[20]
#3170
0	Our	O	['N']	[0]
1	cases	O	['N']	[1]
2	constitute	O	['N']	[2]
3	the	O	['N']	[3]
4	most	O	['N']	[4]
5	severe	O	['N']	[5]
6	cases	O	['N']	[6]
7	of	O	['N']	[7]
8	benzarone	B-Drug	['Causes']	[24]
9	hepatotoxicity	O	['N']	[9]
10	reported	O	['N']	[10]
11	so	O	['N']	[11]
12	far	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	comprise	O	['N']	[15]
16	the	O	['N']	[16]
17	first	O	['N']	[17]
18	cases	O	['N']	[18]
19	of	O	['N']	[19]
20	(	O	['N']	[20]
21	sub)fulminant	O	['N']	[21]
22	hepatitis	O	['N']	[22]
23	and	O	['N']	[23]
24	cirrhosis	B-Adverse_Effect	['N']	[24]
25	related	O	['N']	[25]
26	to	O	['N']	[26]
27	benzarone	O	['N']	[27]
28	.	O	['N']	[28]
#3171
0	A	O	['N']	[0]
1	study	O	['N']	[1]
2	of	O	['N']	[2]
3	in	O	['N']	[3]
4	vitro	O	['N']	[4]
5	reactivity	O	['N']	[5]
6	to	O	['N']	[6]
7	L	B	['N']	[7]
8	-	I	['N']	[8]
9	T4	I-Drug	['Causes']	[31]
10	,	O	['N']	[10]
11	as	O	['N']	[11]
12	assessed	O	['N']	[12]
13	by	O	['N']	[13]
14	peripheral	O	['N']	[14]
15	blood	O	['N']	[15]
16	lymphocyte	O	['N']	[16]
17	transformation	O	['N']	[17]
18	,	O	['N']	[18]
19	was	O	['N']	[19]
20	carried	O	['N']	[20]
21	out	O	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	patient	O	['N']	[24]
25	with	O	['N']	[25]
26	Hashimoto	O	['N']	[26]
27	's	O	['N']	[27]
28	disease	O	['N']	[28]
29	who	O	['N']	[29]
30	developed	O	['N']	[30]
31	leukopenia	B-Adverse_Effect	['N']	[31]
32	during	O	['N']	[32]
33	treatment	O	['N']	[33]
34	with	O	['N']	[34]
35	L	O	['N']	[35]
36	-	O	['N']	[36]
37	T4	O	['N']	[37]
38	.	O	['N']	[38]
#3172
0	Three	O	['N']	[0]
1	months	O	['N']	[1]
2	after	O	['N']	[2]
3	starting	O	['N']	[3]
4	citalopram	B-Drug	['Causes']	[11]
5	,	O	['N']	[5]
6	she	O	['N']	[6]
7	experienced	O	['N']	[7]
8	episodes	O	['N']	[8]
9	of	O	['N']	[9]
10	chest	B	['N']	[10]
11	tightness	I-Adverse_Effect	['N']	[11]
12	and	O	['N']	[12]
13	dizziness	O	['N']	[13]
14	.	O	['N']	[14]
#3173
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Anterior	B	['N']	[2]
3	ischemic	I	['N']	[3]
4	optic	I	['N']	[4]
5	neuropathy	I-Adverse_Effect	['N']	[5]
6	may	O	['N']	[6]
7	complicate	O	['N']	[7]
8	treatment	O	['N']	[8]
9	with	O	['N']	[9]
10	interferon	B	['N']	[10]
11	alfa	I-Drug	['Causes']	[5]
12	.	O	['N']	[12]
#3174
0	Pulmonary	B	['N']	[0]
1	toxicity	I-Adverse_Effect	['N']	[1]
2	secondary	O	['N']	[2]
3	to	O	['N']	[3]
4	procarbazine	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#3175
0	Possible	O	['N']	[0]
1	mechanisms	O	['N']	[1]
2	for	O	['N']	[2]
3	damage	B	['N']	[3]
4	to	I	['N']	[4]
5	the	I	['N']	[5]
6	urothelium	I-Adverse_Effect	['N']	[6]
7	by	O	['N']	[7]
8	ketamine	B-Drug	['Causes']	[6]
9	are	O	['N']	[9]
10	suggested	O	['N']	[10]
11	.	O	['N']	[11]
#3176
0	L	B	['N']	[0]
1	-	I	['N']	[1]
2	Thyroxine	I-Drug	['Causes']	[5]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	leukopenia	B-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	Hashimoto	O	['N']	[10]
11	's	O	['N']	[11]
12	disease	O	['N']	[12]
13	:	O	['N']	[13]
14	involvement	O	['N']	[14]
15	of	O	['N']	[15]
16	suppressor	O	['N']	[16]
17	-	O	['N']	[17]
18	cytotoxic	O	['N']	[18]
19	T	O	['N']	[19]
20	cells	O	['N']	[20]
21	.	O	['N']	[21]
#3177
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	suggested	O	['N']	[2]
3	that	O	['N']	[3]
4	the	O	['N']	[4]
5	fatal	O	['N']	[5]
6	stroke	O	['N']	[6]
7	may	O	['N']	[7]
8	have	O	['N']	[8]
9	resulted	O	['N']	[9]
10	from	O	['N']	[10]
11	arterial	B	['N']	[11]
12	spasm	I-Adverse_Effect	['N']	[12]
13	caused	O	['N']	[13]
14	by	O	['N']	[14]
15	ergotamine	B-Drug	['Causes']	[12]
16	overdosage	O	['N']	[16]
17	and	O	['N']	[17]
18	possibly	O	['N']	[18]
19	complicated	O	['N']	[19]
20	by	O	['N']	[20]
21	thrombosis	O	['N']	[21]
22	.	O	['N']	[22]
#3178
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	supports	O	['N']	[2]
3	the	O	['N']	[3]
4	assessment	O	['N']	[4]
5	that	O	['N']	[5]
6	MH	B-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	diabetes	O	['N']	[8]
9	are	O	['N']	[9]
10	associated	O	['N']	[10]
11	diseases	O	['N']	[11]
12	and	O	['N']	[12]
13	that	O	['N']	[13]
14	cresol	B-Drug	['Causes']	[6]
15	could	O	['N']	[15]
16	possibly	O	['N']	[16]
17	trigger	O	['N']	[17]
18	MH	O	['N']	[18]
19	.	O	['N']	[19]
#3179
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	In	O	['N']	[2]
3	our	O	['N']	[3]
4	reported	O	['N']	[4]
5	case	O	['N']	[5]
6	,	O	['N']	[6]
7	a	O	['N']	[7]
8	local	O	['N']	[8]
9	hyperproduction	B	['N']	[9]
10	of	I	['N']	[10]
11	TNF	I	['N']	[11]
12	-	I	['N']	[12]
13	alpha	I-Adverse_Effect	['N']	[13]
14	from	O	['N']	[14]
15	macrophages	O	['N']	[15]
16	that	O	['N']	[16]
17	was	O	['N']	[17]
18	induced	O	['N']	[18]
19	by	O	['N']	[19]
20	the	O	['N']	[20]
21	injected	O	['N']	[21]
22	insulin	B-Drug	['Causes']	[13]
23	could	O	['N']	[23]
24	explain	O	['N']	[24]
25	the	O	['N']	[25]
26	dedifferentiation	O	['N']	[26]
27	of	O	['N']	[27]
28	the	O	['N']	[28]
29	adipocytes	O	['N']	[29]
30	of	O	['N']	[30]
31	the	O	['N']	[31]
32	subcutaneous	O	['N']	[32]
33	tissue	O	['N']	[33]
34	and	O	['N']	[34]
35	the	O	['N']	[35]
36	reversion	O	['N']	[36]
37	that	O	['N']	[37]
38	was	O	['N']	[38]
39	induced	O	['N']	[39]
40	by	O	['N']	[40]
41	the	O	['N']	[41]
42	local	O	['N']	[42]
43	injection	O	['N']	[43]
44	of	O	['N']	[44]
45	dexamethasone	O	['N']	[45]
46	.	O	['N']	[46]
#3180
0	METHOD	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	authors	O	['N']	[3]
4	followed	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	chronic	O	['N']	[8]
9	HCV	O	['N']	[9]
10	who	O	['N']	[10]
11	received	O	['N']	[11]
12	interferon	B-Drug	['Causes']	[18]
13	and	O	['N']	[13]
14	ribavirin	O	['N']	[14]
15	and	O	['N']	[15]
16	who	O	['N']	[16]
17	developed	O	['N']	[17]
18	hallucinations	B-Adverse_Effect	['N']	[18]
19	ultimately	O	['N']	[19]
20	requiring	O	['N']	[20]
21	psychiatric	O	['N']	[21]
22	hospitalization	O	['N']	[22]
23	.	O	['N']	[23]
#3181
0	Significant	O	['N']	[0]
1	clinical	O	['N']	[1]
2	improvement	O	['N']	[2]
3	of	O	['N']	[3]
4	the	O	['N']	[4]
5	porphyria	B-Adverse_Effect	['N']	[5]
6	followed	O	['N']	[6]
7	withdrawal	O	['N']	[7]
8	of	O	['N']	[8]
9	the	O	['N']	[9]
10	diphenylhydantoin	B-Drug	['Causes']	[5]
11	.	O	['N']	[11]
#3182
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	ulcerative	O	['N']	[3]
4	colitis	O	['N']	[4]
5	developed	O	['N']	[5]
6	skin	B	['N']	[6]
7	pigmentation	I-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	diffuse	O	['N']	[9]
10	pulmonary	O	['N']	[10]
11	shadowing	O	['N']	[11]
12	without	O	['N']	[12]
13	respiratory	O	['N']	[13]
14	symptomatology	O	['N']	[14]
15	,	O	['N']	[15]
16	while	O	['N']	[16]
17	taking	O	['N']	[17]
18	sulfasalazine	B-Drug	['Causes']	[7]
19	.	O	['N']	[19]
#3183
0	Several	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	lithium	B-Drug	['Causes']	[9]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	Creutzfeldt	B	['N']	[6]
7	-	I	['N']	[7]
8	Jakob	I	['N']	[8]
9	syndrome	I-Adverse_Effect	['N']	[9]
10	have	O	['N']	[10]
11	been	O	['N']	[11]
12	reported	O	['N']	[12]
13	to	O	['N']	[13]
14	date	O	['N']	[14]
15	;	O	['N']	[15]
16	all	O	['N']	[16]
17	of	O	['N']	[17]
18	them	O	['N']	[18]
19	were	O	['N']	[19]
20	elderly	O	['N']	[20]
21	patients	O	['N']	[21]
22	and	O	['N']	[22]
23	a	O	['N']	[23]
24	half	O	['N']	[24]
25	had	O	['N']	[25]
26	"	O	['N']	[26]
27	therapeutic	O	['N']	[27]
28	"	O	['N']	[28]
29	lithium	O	['N']	[29]
30	serum	O	['N']	[30]
31	levels	O	['N']	[31]
32	.	O	['N']	[32]
#3184
0	Lithium	B-Drug	['Causes']	[1]
1	neurotoxicity	I-Adverse_Effect	['N']	[1]
2	should	O	['N']	[2]
3	be	O	['N']	[3]
4	considered	O	['N']	[4]
5	in	O	['N']	[5]
6	Creutzfeldt	O	['N']	[6]
7	-	O	['N']	[7]
8	Jakob	O	['N']	[8]
9	disease	O	['N']	[9]
10	differential	O	['N']	[10]
11	diagnosis	O	['N']	[11]
12	,	O	['N']	[12]
13	serial	O	['N']	[13]
14	electroencephalograms	O	['N']	[14]
15	being	O	['N']	[15]
16	the	O	['N']	[16]
17	most	O	['N']	[17]
18	valuable	O	['N']	[18]
19	.	O	['N']	[19]
#3185
0	Dapsone	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	erythroderma	B-Adverse_Effect	['N']	[3]
4	with	O	['N']	[4]
5	Beau	O	['N']	[5]
6	's	O	['N']	[6]
7	lines	O	['N']	[7]
8	.	O	['N']	[8]
#3186
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	report	O	['N']	[3]
4	this	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	concomitant	O	['N']	[8]
9	appearance	O	['N']	[9]
10	of	O	['N']	[10]
11	multiple	B	['N']	[11]
12	skin	I	['N']	[12]
13	cancers	I-Adverse_Effect	['N']	[13]
14	and	O	['N']	[14]
15	nail	O	['N']	[15]
16	changes	O	['N']	[16]
17	associated	O	['N']	[17]
18	with	O	['N']	[18]
19	hydroxyurea	B-Drug	['Causes']	[13]
20	use	O	['N']	[20]
21	.	O	['N']	[21]
#3187
0	Severe	B	['N']	[0]
1	respiratory	I	['N']	[1]
2	syncytial	I	['N']	[2]
3	virus	I	['N']	[3]
4	pulmonary	I	['N']	[4]
5	infection	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	fludarabine	B-Drug	['Causes']	[5]
12	for	O	['N']	[12]
13	chronic	O	['N']	[13]
14	lymphocytic	O	['N']	[14]
15	leukemia	O	['N']	[15]
16	.	O	['N']	[16]
#3188
0	Intravenous	O	['N']	[0]
1	verapamil	O	['N']	[1]
2	therapy	O	['N']	[2]
3	in	O	['N']	[3]
4	babies	O	['N']	[4]
5	may	O	['N']	[5]
6	cause	O	['N']	[6]
7	apnea	O	['N']	[7]
8	,	O	['N']	[8]
9	hypotension	O	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	bradycardia	O	['N']	[12]
13	;	O	['N']	[13]
14	continued	O	['N']	[14]
15	episodes	O	['N']	[15]
16	of	O	['N']	[16]
17	atrial	O	['N']	[17]
18	flutter	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	child	O	['N']	[21]
22	may	O	['N']	[22]
23	cause	O	['N']	[23]
24	sudden	O	['N']	[24]
25	death	O	['N']	[25]
26	;	O	['N']	[26]
27	quinidine	B-Drug	['Causes']	[50]
28	may	O	['N']	[28]
29	be	O	['N']	[29]
30	related	O	['N']	[30]
31	to	O	['N']	[31]
32	the	O	['N']	[32]
33	death	O	['N']	[33]
34	;	O	['N']	[34]
35	children	O	['N']	[35]
36	with	O	['N']	[36]
37	"	O	['N']	[37]
38	familial	O	['N']	[38]
39	seizure	O	['N']	[39]
40	disorders	O	['N']	[40]
41	"	O	['N']	[41]
42	may	O	['N']	[42]
43	in	O	['N']	[43]
44	fact	O	['N']	[44]
45	have	O	['N']	[45]
46	the	O	['N']	[46]
47	long	B	['N']	[47]
48	QT	I	['N']	[48]
49	interval	I	['N']	[49]
50	syndrome	I-Adverse_Effect	['N']	[50]
51	.	O	['N']	[51]
#3189
0	Colchicine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	rhabdomyolysis	B-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	a	O	['N']	[5]
6	rare	O	['N']	[6]
7	complication	O	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	the	O	['N']	[10]
11	postulated	O	['N']	[11]
12	mechanisms	O	['N']	[12]
13	and	O	['N']	[13]
14	risk	O	['N']	[14]
15	factors	O	['N']	[15]
16	for	O	['N']	[16]
17	this	O	['N']	[17]
18	severe	O	['N']	[18]
19	complication	O	['N']	[19]
20	are	O	['N']	[20]
21	discussed	O	['N']	[21]
22	.	O	['N']	[22]
#3190
0	Encephalopathy	O	['N']	[0]
1	and	O	['N']	[1]
2	seizures	B-Adverse_Effect	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	intravesical	O	['N']	[5]
6	alum	B-Drug	['Causes']	[2]
7	irrigations	O	['N']	[7]
8	.	O	['N']	[8]
#3191
0	Three	O	['N']	[0]
1	nephrotic	O	['N']	[1]
2	patients	O	['N']	[2]
3	who	O	['N']	[3]
4	had	O	['N']	[4]
5	reduced	O	['N']	[5]
6	renal	O	['N']	[6]
7	function	O	['N']	[7]
8	and	O	['N']	[8]
9	active	O	['N']	[9]
10	renal	O	['N']	[10]
11	disease	O	['N']	[11]
12	with	O	['N']	[12]
13	progressive	O	['N']	[13]
14	deterioration	O	['N']	[14]
15	of	O	['N']	[15]
16	renal	O	['N']	[16]
17	function	O	['N']	[17]
18	prior	O	['N']	[18]
19	to	O	['N']	[19]
20	the	O	['N']	[20]
21	use	O	['N']	[21]
22	of	O	['N']	[22]
23	MP	B-Drug	['Causes']	[27]
24	developed	O	['N']	[24]
25	transient	B	['N']	[25]
26	renal	I	['N']	[26]
27	failure	I-Adverse_Effect	['N']	[27]
28	following	O	['N']	[28]
29	an	O	['N']	[29]
30	MP	O	['N']	[30]
31	pulse	O	['N']	[31]
32	therapy	O	['N']	[32]
33	.	O	['N']	[33]
#3192
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	occurrence	O	['N']	[3]
4	of	O	['N']	[4]
5	priapism	B-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	our	O	['N']	[7]
8	patient	O	['N']	[8]
9	was	O	['N']	[9]
10	related	O	['N']	[10]
11	to	O	['N']	[11]
12	zuclopenthixol	B-Drug	['Causes']	[5]
13	.	O	['N']	[13]
#3193
0	In	O	['N']	[0]
1	two	O	['N']	[1]
2	of	O	['N']	[2]
3	these	O	['N']	[3]
4	cases	O	['N']	[4]
5	akathisia	B-Adverse_Effect	['N']	[5]
6	resolved	O	['N']	[6]
7	after	O	['N']	[7]
8	withdrawal	O	['N']	[8]
9	of	O	['N']	[9]
10	olanzapine	B-Drug	['Causes']	[5]
11	and	O	['N']	[11]
12	substitution	O	['N']	[12]
13	by	O	['N']	[13]
14	a	O	['N']	[14]
15	classical	O	['N']	[15]
16	or	O	['N']	[16]
17	an	O	['N']	[17]
18	atypical	O	['N']	[18]
19	neuroleptic	O	['N']	[19]
20	agent	O	['N']	[20]
21	,	O	['N']	[21]
22	respectively	O	['N']	[22]
23	.	O	['N']	[23]
#3194
0	A	O	['N']	[0]
1	56-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	white	O	['N']	[4]
5	woman	O	['N']	[5]
6	with	O	['N']	[6]
7	a	O	['N']	[7]
8	diagnosis	O	['N']	[8]
9	of	O	['N']	[9]
10	reactive	O	['N']	[10]
11	depression	O	['N']	[11]
12	developed	O	['N']	[12]
13	severe	O	['N']	[13]
14	UI	B-Adverse_Effect	['N']	[14]
15	after	O	['N']	[15]
16	a	O	['N']	[16]
17	30	O	['N']	[17]
18	days	O	['N']	[18]
19	'	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	venlafaxine	B-Drug	['Causes']	[14]
23	75	O	['N']	[23]
24	mg	O	['N']	[24]
25	/	O	['N']	[25]
26	day	O	['N']	[26]
27	.	O	['N']	[27]
#3195
0	A	O	['N']	[0]
1	64	O	['N']	[1]
2	year	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	recurrent	O	['N']	[6]
7	metastatic	O	['N']	[7]
8	squamous	O	['N']	[8]
9	cell	O	['N']	[9]
10	carcinoma	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	head	O	['N']	[13]
14	and	O	['N']	[14]
15	neck	O	['N']	[15]
16	developed	O	['N']	[16]
17	severe	B	['N']	[17]
18	skin	I	['N']	[18]
19	rash	I-Adverse_Effect	['N']	[19]
20	and	O	['N']	[20]
21	bone	O	['N']	[21]
22	marrow	O	['N']	[22]
23	aplasia	O	['N']	[23]
24	4	O	['N']	[24]
25	and	O	['N']	[25]
26	7	O	['N']	[26]
27	days	O	['N']	[27]
28	,	O	['N']	[28]
29	respectively	O	['N']	[29]
30	,	O	['N']	[30]
31	following	O	['N']	[31]
32	a	O	['N']	[32]
33	single	O	['N']	[33]
34	dose	O	['N']	[34]
35	of	O	['N']	[35]
36	40	O	['N']	[36]
37	mg	O	['N']	[37]
38	/	O	['N']	[38]
39	m2	O	['N']	[39]
40	methotrexate	B-Drug	['Causes']	[19]
41	(	O	['N']	[41]
42	MTX	O	['N']	[42]
43	)	O	['N']	[43]
44	.	O	['N']	[44]
#3196
0	Acute	B	['N']	[0]
1	acoustic	I	['N']	[1]
2	nerve	I	['N']	[2]
3	palsy	I-Adverse_Effect	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	vincristine	B-Drug	['Causes']	[3]
7	therapy	O	['N']	[7]
8	.	O	['N']	[8]
#3197
0	Severe	B	['N']	[0]
1	hypo	I	['N']	[1]
2	-	I	['N']	[2]
3	alpha	I	['N']	[3]
4	-	I	['N']	[4]
5	lipoproteinemia	I-Adverse_Effect	['N']	[5]
6	during	O	['N']	[6]
7	treatment	O	['N']	[7]
8	with	O	['N']	[8]
9	rosiglitazone	B-Drug	['Causes']	[5]
10	.	O	['N']	[10]
#3198
0	Case	O	['N']	[0]
1	2	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	43-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	male	O	['N']	[7]
8	alcoholic	O	['N']	[8]
9	remained	O	['N']	[9]
10	completely	O	['N']	[10]
11	abstinent	O	['N']	[11]
12	with	O	['N']	[12]
13	cyanamide	B-Drug	['Causes']	[22]
14	treatment	O	['N']	[14]
15	for	O	['N']	[15]
16	5	O	['N']	[16]
17	years	O	['N']	[17]
18	and	O	['N']	[18]
19	complained	O	['N']	[19]
20	of	O	['N']	[20]
21	general	B	['N']	[21]
22	fatigue	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#3199
0	Zolpidem	B-Drug	['Causes']	[17]
1	(	O	['N']	[1]
2	Ambien	O	['N']	[2]
3	)	O	['N']	[3]
4	,	O	['N']	[4]
5	a	O	['N']	[5]
6	relatively	O	['N']	[6]
7	new	O	['N']	[7]
8	nonbenzodiazepine	O	['N']	[8]
9	sedative	O	['N']	[9]
10	-	O	['N']	[10]
11	hypnotic	O	['N']	[11]
12	,	O	['N']	[12]
13	was	O	['N']	[13]
14	involved	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	death	B-Adverse_Effect	['N']	[17]
18	of	O	['N']	[18]
19	a	O	['N']	[19]
20	39-year	O	['N']	[20]
21	-	O	['N']	[21]
22	old	O	['N']	[22]
23	obese	O	['N']	[23]
24	male	O	['N']	[24]
25	who	O	['N']	[25]
26	was	O	['N']	[26]
27	being	O	['N']	[27]
28	treated	O	['N']	[28]
29	for	O	['N']	[29]
30	depression	O	['N']	[30]
31	and	O	['N']	[31]
32	insomnia	O	['N']	[32]
33	.	O	['N']	[33]
#3200
0	Calcipotriol	B-Drug	['Causes']	[17]
1	(	O	['N']	[1]
2	Daivonex	O	['N']	[2]
3	R	O	['N']	[3]
4	;	O	['N']	[4]
5	Leo	O	['N']	[5]
6	Pharmaceuticals	O	['N']	[6]
7	,	O	['N']	[7]
8	Zurich	O	['N']	[8]
9	,	O	['N']	[9]
10	Switzerland	O	['N']	[10]
11	)	O	['N']	[11]
12	may	O	['N']	[12]
13	cause	O	['N']	[13]
14	irritation	B	['N']	[14]
15	of	I	['N']	[15]
16	the	I	['N']	[16]
17	skin	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	whereas	O	['N']	[19]
20	allergic	O	['N']	[20]
21	reactions	O	['N']	[21]
22	are	O	['N']	[22]
23	less	O	['N']	[23]
24	common	O	['N']	[24]
25	.	O	['N']	[25]
#3201
0	Patients	O	['N']	[0]
1	treated	O	['N']	[1]
2	with	O	['N']	[2]
3	L	B	['N']	[3]
4	-	I	['N']	[4]
5	asparaginase	I-Drug	['Causes']	[9]
6	may	O	['N']	[6]
7	present	O	['N']	[7]
8	with	O	['N']	[8]
9	hemorrhagic	B-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	thrombotic	O	['N']	[11]
12	cerebrovascular	O	['N']	[12]
13	events	O	['N']	[13]
14	.	O	['N']	[14]
#3202
0	Diffusion	O	['N']	[0]
1	-	O	['N']	[1]
2	weighted	O	['N']	[2]
3	MRI	O	['N']	[3]
4	correlates	O	['N']	[4]
5	of	O	['N']	[5]
6	subacute	O	['N']	[6]
7	methotrexate	B-Drug	['Causes']	[10]
8	-	O	['N']	[8]
9	related	O	['N']	[9]
10	neurotoxicity	B-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#3203
0	Drug	O	['N']	[0]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	eosinophilia	B-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	a	O	['N']	[5]
6	non	O	['N']	[6]
7	-	O	['N']	[7]
8	dose	O	['N']	[8]
9	-	O	['N']	[9]
10	dependent	O	['N']	[10]
11	side	O	['N']	[11]
12	effect	O	['N']	[12]
13	of	O	['N']	[13]
14	clozapine	B-Drug	['Causes']	[3]
15	.	O	['N']	[15]
#3204
0	We	O	['N']	[0]
1	have	O	['N']	[1]
2	described	O	['N']	[2]
3	three	O	['N']	[3]
4	patients	O	['N']	[4]
5	with	O	['N']	[5]
6	hepatitis	O	['N']	[6]
7	C	O	['N']	[7]
8	for	O	['N']	[8]
9	whom	O	['N']	[9]
10	IFN	O	['N']	[10]
11	-	O	['N']	[11]
12	alpha	O	['N']	[12]
13	and	O	['N']	[13]
14	ribavirin	B-Drug	['Causes']	[28]
15	were	O	['N']	[15]
16	prescribed	O	['N']	[16]
17	and	O	['N']	[17]
18	who	O	['N']	[18]
19	developed	O	['N']	[19]
20	two	O	['N']	[20]
21	successive	O	['N']	[21]
22	phases	O	['N']	[22]
23	of	O	['N']	[23]
24	silent	O	['N']	[24]
25	thyroiditis	O	['N']	[25]
26	followed	O	['N']	[26]
27	by	O	['N']	[27]
28	hyperthryroidism	B-Adverse_Effect	['N']	[28]
29	relapse	O	['N']	[29]
30	due	O	['N']	[30]
31	to	O	['N']	[31]
32	Graves	O	['N']	[32]
33	'	O	['N']	[33]
34	disease	O	['N']	[34]
35	.	O	['N']	[35]
#3205
0	Progressive	B	['N']	[0]
1	anemia	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	combination	O	['N']	[3]
4	therapy	O	['N']	[4]
5	with	O	['N']	[5]
6	interferon	O	['N']	[6]
7	-	O	['N']	[7]
8	alpha	O	['N']	[8]
9	and	O	['N']	[9]
10	interleukin-2	B-Drug	['Causes']	[1]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	metastatic	O	['N']	[15]
16	renal	O	['N']	[16]
17	cell	O	['N']	[17]
18	carcinoma	O	['N']	[18]
19	.	O	['N']	[19]
#3206
0	In	O	['N']	[0]
1	rare	O	['N']	[1]
2	cases	O	['N']	[2]
3	mitomycin	B	['N']	[3]
4	C	I-Drug	['Causes']	[28]
5	(	O	['N']	[5]
6	MMC	O	['N']	[6]
7	)	O	['N']	[7]
8	may	O	['N']	[8]
9	induce	O	['N']	[9]
10	cancer	O	['N']	[10]
11	-	O	['N']	[11]
12	associated	O	['N']	[12]
13	hemolytic	O	['N']	[13]
14	uremic	O	['N']	[14]
15	syndrome	O	['N']	[15]
16	,	O	['N']	[16]
17	which	O	['N']	[17]
18	is	O	['N']	[18]
19	characterized	O	['N']	[19]
20	by	O	['N']	[20]
21	hemolytic	O	['N']	[21]
22	anemia	O	['N']	[22]
23	,	O	['N']	[23]
24	thrombocytopenia	O	['N']	[24]
25	and	O	['N']	[25]
26	progressive	B	['N']	[26]
27	renal	I	['N']	[27]
28	failure	I-Adverse_Effect	['N']	[28]
29	.	O	['N']	[29]
#3207
0	One	O	['N']	[0]
1	of	O	['N']	[1]
2	the	O	['N']	[2]
3	subjects	O	['N']	[3]
4	who	O	['N']	[4]
5	was	O	['N']	[5]
6	using	O	['N']	[6]
7	extemporaneous	O	['N']	[7]
8	topical	O	['N']	[8]
9	minoxidil	B-Drug	['Causes']	[14]
10	had	O	['N']	[10]
11	hypertension	O	['N']	[11]
12	and	O	['N']	[12]
13	arteriosclerotic	B	['N']	[13]
14	disease	I-Adverse_Effect	['N']	[14]
15	and	O	['N']	[15]
16	the	O	['N']	[16]
17	other	O	['N']	[17]
18	died	O	['N']	[18]
19	of	O	['N']	[19]
20	a	O	['N']	[20]
21	myocardial	O	['N']	[21]
22	infarction	O	['N']	[22]
23	.	O	['N']	[23]
#3208
0	Papillary	B	['N']	[0]
1	necrosis	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	the	O	['N']	[4]
5	HIV	O	['N']	[5]
6	protease	O	['N']	[6]
7	inhibitor	O	['N']	[7]
8	indinavir	B-Drug	['Causes']	[1]
9	.	O	['N']	[9]
#3209
0	Well	O	['N']	[0]
1	-	O	['N']	[1]
2	differentiated	O	['N']	[2]
3	endometrial	B	['N']	[3]
4	adenocarcinoma	I	['N']	[4]
5	of	I	['N']	[5]
6	the	I	['N']	[6]
7	secretory	I	['N']	[7]
8	type	I-Adverse_Effect	['N']	[8]
9	(	O	['N']	[9]
10	FIGO	O	['N']	[10]
11	Grade	O	['N']	[11]
12	1	O	['N']	[12]
13	)	O	['N']	[13]
14	with	O	['N']	[14]
15	minimal	O	['N']	[15]
16	myometrial	O	['N']	[16]
17	invasion	O	['N']	[17]
18	occurred	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	postmenopausal	O	['N']	[21]
22	patient	O	['N']	[22]
23	on	O	['N']	[23]
24	tamoxifen	B-Drug	['Causes']	[8]
25	therapy	O	['N']	[25]
26	5	O	['N']	[26]
27	years	O	['N']	[27]
28	after	O	['N']	[28]
29	mastectomy	O	['N']	[29]
30	for	O	['N']	[30]
31	breast	O	['N']	[31]
32	carcinoma	O	['N']	[32]
33	.	O	['N']	[33]
#3210
0	An	O	['N']	[0]
1	11-day	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	infant	O	['N']	[4]
5	became	O	['N']	[5]
6	lethargic	O	['N']	[6]
7	and	O	['N']	[7]
8	apneic	B-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	a	O	['N']	[10]
11	single	O	['N']	[11]
12	drop	O	['N']	[12]
13	of	O	['N']	[13]
14	brimonidine	B-Drug	['Causes']	[8]
15	.	O	['N']	[15]
#3211
0	A	O	['N']	[0]
1	64	O	['N']	[1]
2	year	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	recurrent	O	['N']	[6]
7	metastatic	O	['N']	[7]
8	squamous	O	['N']	[8]
9	cell	O	['N']	[9]
10	carcinoma	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	head	O	['N']	[13]
14	and	O	['N']	[14]
15	neck	O	['N']	[15]
16	developed	O	['N']	[16]
17	severe	O	['N']	[17]
18	skin	O	['N']	[18]
19	rash	O	['N']	[19]
20	and	O	['N']	[20]
21	bone	B	['N']	[21]
22	marrow	I	['N']	[22]
23	aplasia	I-Adverse_Effect	['N']	[23]
24	4	O	['N']	[24]
25	and	O	['N']	[25]
26	7	O	['N']	[26]
27	days	O	['N']	[27]
28	,	O	['N']	[28]
29	respectively	O	['N']	[29]
30	,	O	['N']	[30]
31	following	O	['N']	[31]
32	a	O	['N']	[32]
33	single	O	['N']	[33]
34	dose	O	['N']	[34]
35	of	O	['N']	[35]
36	40	O	['N']	[36]
37	mg	O	['N']	[37]
38	/	O	['N']	[38]
39	m2	O	['N']	[39]
40	methotrexate	B-Drug	['Causes']	[23]
41	(	O	['N']	[41]
42	MTX	O	['N']	[42]
43	)	O	['N']	[43]
44	.	O	['N']	[44]
#3212
0	Neurologic	B	['N']	[0]
1	degeneration	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	nitrous	B	['N']	[4]
5	oxide	I-Drug	['Causes']	[1]
6	anesthesia	O	['N']	[6]
7	in	O	['N']	[7]
8	patients	O	['N']	[8]
9	with	O	['N']	[9]
10	vitamin	O	['N']	[10]
11	B12	O	['N']	[11]
12	deficiency	O	['N']	[12]
13	.	O	['N']	[13]
#3213
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	the	O	['N']	[4]
5	finding	O	['N']	[5]
6	of	O	['N']	[6]
7	squamous	B	['N']	[7]
8	metaplasia	I	['N']	[8]
9	within	I	['N']	[9]
10	endometrial	I	['N']	[10]
11	glands	I-Adverse_Effect	['N']	[11]
12	occurring	O	['N']	[12]
13	as	O	['N']	[13]
14	a	O	['N']	[14]
15	result	O	['N']	[15]
16	of	O	['N']	[16]
17	progestin	B-Drug	['Causes']	[11]
18	therapy	O	['N']	[18]
19	of	O	['N']	[19]
20	hyperplasia	O	['N']	[20]
21	.	O	['N']	[21]
#3214
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	disseminated	O	['N']	[5]
6	muscular	O	['N']	[6]
7	cysticercosis	O	['N']	[7]
8	followed	O	['N']	[8]
9	by	O	['N']	[9]
10	myositis	O	['N']	[10]
11	(	O	['N']	[11]
12	fever	B-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	diffuse	O	['N']	[14]
15	myalgia	O	['N']	[15]
16	,	O	['N']	[16]
17	weakness	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	lower	O	['N']	[20]
21	limbs	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	inflammatory	O	['N']	[24]
25	reaction	O	['N']	[25]
26	around	O	['N']	[26]
27	dying	O	['N']	[27]
28	cysticerci	O	['N']	[28]
29	)	O	['N']	[29]
30	induced	O	['N']	[30]
31	by	O	['N']	[31]
32	praziquantel	B-Drug	['Causes']	[12]
33	therapy	O	['N']	[33]
34	,	O	['N']	[34]
35	an	O	['N']	[35]
36	event	O	['N']	[36]
37	not	O	['N']	[37]
38	described	O	['N']	[38]
39	previously	O	['N']	[39]
40	.	O	['N']	[40]
#3215
0	There	O	['N']	[0]
1	is	O	['N']	[1]
2	no	O	['N']	[2]
3	consensus	O	['N']	[3]
4	on	O	['N']	[4]
5	the	O	['N']	[5]
6	treatment	O	['N']	[6]
7	of	O	['N']	[7]
8	ticlopidine	B-Drug	['Causes']	[12]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	marrow	B	['N']	[11]
12	aplasia	I-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#3216
0	Serotonin	B	['N']	[0]
1	syndrome	I-Adverse_Effect	['N']	[1]
2	caused	O	['N']	[2]
3	by	O	['N']	[3]
4	interaction	O	['N']	[4]
5	between	O	['N']	[5]
6	citalopram	B-Drug	['Causes']	[1]
7	and	O	['N']	[7]
8	fentanyl	O	['N']	[8]
9	.	O	['N']	[9]
#3217
0	Described	O	['N']	[0]
1	here	O	['N']	[1]
2	are	O	['N']	[2]
3	2	O	['N']	[3]
4	patients	O	['N']	[4]
5	who	O	['N']	[5]
6	developed	O	['N']	[6]
7	thrombotic	B	['N']	[7]
8	microangiopathy	I-Adverse_Effect	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	kidneys	O	['N']	[11]
12	after	O	['N']	[12]
13	receiving	O	['N']	[13]
14	high	O	['N']	[14]
15	cumulative	O	['N']	[15]
16	doses	O	['N']	[16]
17	of	O	['N']	[17]
18	the	O	['N']	[18]
19	new	O	['N']	[19]
20	anticancer	O	['N']	[20]
21	drug	O	['N']	[21]
22	gemcitabine	B-Drug	['Causes']	[8]
23	.	O	['N']	[23]
#3218
0	After	O	['N']	[0]
1	taking	O	['N']	[1]
2	cholestyramine	B	['N']	[2]
3	II	I-Drug	['Causes']	[17]
4	sachets	O	['N']	[4]
5	twice	O	['N']	[5]
6	daily	O	['N']	[6]
7	for	O	['N']	[7]
8	two	O	['N']	[8]
9	months	O	['N']	[9]
10	she	O	['N']	[10]
11	presented	O	['N']	[11]
12	with	O	['N']	[12]
13	lethargy	O	['N']	[13]
14	,	O	['N']	[14]
15	confusion	O	['N']	[15]
16	and	O	['N']	[16]
17	drowsiness	B-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#3219
0	Propylthiouracil	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	sensorineural	B	['N']	[3]
4	hearing	I	['N']	[4]
5	loss	I-Adverse_Effect	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	antineutrophil	O	['N']	[8]
9	cytoplasmic	O	['N']	[9]
10	antibodies	O	['N']	[10]
11	.	O	['N']	[11]
#3220
0	This	O	['N']	[0]
1	regimen	O	['N']	[1]
2	could	O	['N']	[2]
3	prove	O	['N']	[3]
4	useful	O	['N']	[4]
5	for	O	['N']	[5]
6	other	O	['N']	[6]
7	patients	O	['N']	[7]
8	who	O	['N']	[8]
9	develop	O	['N']	[9]
10	hypersensitivity	B-Adverse_Effect	['N']	[10]
11	reactions	O	['N']	[11]
12	to	O	['N']	[12]
13	carboplatin	B-Drug	['Causes']	[10]
14	and	O	['N']	[14]
15	allow	O	['N']	[15]
16	therapy	O	['N']	[16]
17	to	O	['N']	[17]
18	continue	O	['N']	[18]
19	.	O	['N']	[19]
#3221
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Hypersensitivity	B	['N']	[2]
3	reactions	I-Adverse_Effect	['N']	[3]
4	to	O	['N']	[4]
5	cyclosporine	O	['N']	[5]
6	are	O	['N']	[6]
7	due	O	['N']	[7]
8	to	O	['N']	[8]
9	Cremophor	B	['N']	[9]
10	EL	I-Drug	['Causes']	[3]
11	.	O	['N']	[11]
#3222
0	A	O	['N']	[0]
1	female	O	['N']	[1]
2	patient	O	['N']	[2]
3	with	O	['N']	[3]
4	HER2	O	['N']	[4]
5	positive	O	['N']	[5]
6	,	O	['N']	[6]
7	metastatic	O	['N']	[7]
8	breast	O	['N']	[8]
9	cancer	O	['N']	[9]
10	presented	O	['N']	[10]
11	with	O	['N']	[11]
12	pulmonary	O	['N']	[12]
13	infiltrates	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	a	O	['N']	[16]
17	plural	B	['N']	[17]
18	effusion	I	['N']	[18]
19	dyspnoea	I-Adverse_Effect	['N']	[19]
20	after	O	['N']	[20]
21	several	O	['N']	[21]
22	months	O	['N']	[22]
23	of	O	['N']	[23]
24	trastuzumab	B-Drug	['Causes']	[19]
25	treatment	O	['N']	[25]
26	.	O	['N']	[26]
#3223
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Clinicians	O	['N']	[2]
3	should	O	['N']	[3]
4	be	O	['N']	[4]
5	aware	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	risk	O	['N']	[8]
9	of	O	['N']	[9]
10	serotonin	O	['N']	[10]
11	syndrome	O	['N']	[11]
12	with	O	['N']	[12]
13	serious	O	['N']	[13]
14	extrapyramidal	B	['N']	[14]
15	reactions	I-Adverse_Effect	['N']	[15]
16	in	O	['N']	[16]
17	patients	O	['N']	[17]
18	receiving	O	['N']	[18]
19	sertraline	O	['N']	[19]
20	or	O	['N']	[20]
21	venlafaxine	O	['N']	[21]
22	when	O	['N']	[22]
23	metoclopramide	B-Drug	['Causes']	[15]
24	is	O	['N']	[24]
25	coadministered	O	['N']	[25]
26	even	O	['N']	[26]
27	in	O	['N']	[27]
28	a	O	['N']	[28]
29	single	O	['N']	[29]
30	,	O	['N']	[30]
31	conventional	O	['N']	[31]
32	dose	O	['N']	[32]
33	.	O	['N']	[33]
#3224
0	A	O	['N']	[0]
1	53-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	male	O	['N']	[4]
5	,	O	['N']	[5]
6	without	O	['N']	[6]
7	any	O	['N']	[7]
8	prior	O	['N']	[8]
9	history	O	['N']	[9]
10	of	O	['N']	[10]
11	psychosis	O	['N']	[11]
12	,	O	['N']	[12]
13	developed	O	['N']	[13]
14	schizophrenia	B-Adverse_Effect	['N']	[14]
15	4	O	['N']	[15]
16	days	O	['N']	[16]
17	after	O	['N']	[17]
18	starting	O	['N']	[18]
19	low	O	['N']	[19]
20	-	O	['N']	[20]
21	dose	O	['N']	[21]
22	bromocriptine	B-Drug	['Causes']	[14]
23	therapy	O	['N']	[23]
24	for	O	['N']	[24]
25	a	O	['N']	[25]
26	macroprolactinoma	O	['N']	[26]
27	.	O	['N']	[27]
#3225
0	Common	O	['N']	[0]
1	adverse	O	['N']	[1]
2	events	O	['N']	[2]
3	(	O	['N']	[3]
4	frequency	O	['N']	[4]
5	10	O	['N']	[5]
6	%	O	['N']	[6]
7	)	O	['N']	[7]
8	of	O	['N']	[8]
9	lacosamide	B-Drug	['Dosage']	[16]
10	doses	O	['N']	[10]
11	up	O	['N']	[11]
12	to	O	['N']	[12]
13	600	B	['N']	[13]
14	mg	I	['N']	[14]
15	/	I	['N']	[15]
16	day	I-Dose	['N']	[16]
17	include	O	['N']	[17]
18	nonspecific	O	['N']	[18]
19	central	O	['N']	[19]
20	nervous	O	['N']	[20]
21	system	O	['N']	[21]
22	effects	O	['N']	[22]
23	(	O	['N']	[23]
24	e.g.	O	['N']	[24]
25	,	O	['N']	[25]
26	dizziness	O	['N']	[26]
27	,	O	['N']	[27]
28	ataxia	O	['N']	[28]
29	,	O	['N']	[29]
30	diplopia	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	somnolence	O	['N']	[33]
34	)	O	['N']	[34]
35	.	O	['N']	[35]
#3226
0	The	O	['N']	[0]
1	present	O	['N']	[1]
2	report	O	['N']	[2]
3	suggests	O	['N']	[3]
4	that	O	['N']	[4]
5	clarithromycin	O	['N']	[5]
6	coadministration	O	['N']	[6]
7	induces	O	['N']	[7]
8	increased	O	['N']	[8]
9	plasma	O	['N']	[9]
10	carbamazepine	B-Drug	['Causes']	[18]
11	concentrations	O	['N']	[11]
12	,	O	['N']	[12]
13	which	O	['N']	[13]
14	may	O	['N']	[14]
15	result	O	['N']	[15]
16	in	O	['N']	[16]
17	carbamazepine	B	['N']	[17]
18	toxicity	I-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#3227
0	Fixed	B	['N']	[0]
1	drug	I	['N']	[1]
2	eruption	I	['N']	[2]
3	of	I	['N']	[3]
4	the	I	['N']	[4]
5	scrotum	I-Adverse_Effect	['N']	[5]
6	due	O	['N']	[6]
7	to	O	['N']	[7]
8	methylphenidate	B-Drug	['Causes']	[5]
9	.	O	['N']	[9]
#3228
0	Possible	O	['N']	[0]
1	serotonin	B	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	clomipramine	B-Drug	['Causes']	[2]
6	after	O	['N']	[6]
7	withdrawal	O	['N']	[7]
8	of	O	['N']	[8]
9	clozapine	O	['N']	[9]
10	.	O	['N']	[10]
#3229
0	Severe	B	['N']	[0]
1	hemolytic	I	['N']	[1]
2	uremic	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	an	O	['N']	[5]
6	advanced	O	['N']	[6]
7	ovarian	O	['N']	[7]
8	cancer	O	['N']	[8]
9	patient	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	carboplatin	B-Drug	['Causes']	[3]
13	and	O	['N']	[13]
14	gemcitabine	O	['N']	[14]
15	.	O	['N']	[15]
#3230
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	report	O	['N']	[2]
3	describes	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	was	O	['N']	[7]
8	previously	O	['N']	[8]
9	prescribed	O	['N']	[9]
10	alendronate	O	['N']	[10]
11	(	O	['N']	[11]
12	Fosamax	B-Drug	['Causes']	[18]
13	)	O	['N']	[13]
14	and	O	['N']	[14]
15	presented	O	['N']	[15]
16	with	O	['N']	[16]
17	postoperative	O	['N']	[17]
18	hypophosphatemia	B-Adverse_Effect	['N']	[18]
19	and	O	['N']	[19]
20	hypocalcemic	O	['N']	[20]
21	tetany	O	['N']	[21]
22	after	O	['N']	[22]
23	bowel	O	['N']	[23]
24	preparation	O	['N']	[24]
25	with	O	['N']	[25]
26	Fleet	O	['N']	[26]
27	Phospho	O	['N']	[27]
28	-	O	['N']	[28]
29	Soda	O	['N']	[29]
30	.	O	['N']	[30]
#3231
0	Life	O	['N']	[0]
1	-	O	['N']	[1]
2	threatening	O	['N']	[2]
3	interstitial	B	['N']	[3]
4	lung	I	['N']	[4]
5	disease	I-Adverse_Effect	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	trastuzumab	B-Drug	['Causes']	[5]
9	:	O	['N']	[9]
10	case	O	['N']	[10]
11	report	O	['N']	[11]
12	.	O	['N']	[12]
#3232
0	An	O	['N']	[0]
1	asymptomatic	O	['N']	[1]
2	HIV	O	['N']	[2]
3	-	O	['N']	[3]
4	infected	O	['N']	[4]
5	woman	O	['N']	[5]
6	experienced	O	['N']	[6]
7	right	O	['N']	[7]
8	-	O	['N']	[8]
9	sided	O	['N']	[9]
10	renal	B	['N']	[10]
11	colicky	I	['N']	[11]
12	pain	I-Adverse_Effect	['N']	[12]
13	during	O	['N']	[13]
14	treatment	O	['N']	[14]
15	with	O	['N']	[15]
16	indinavir	B-Drug	['Causes']	[12]
17	.	O	['N']	[17]
#3233
0	Less	O	['N']	[0]
1	common	O	['N']	[1]
2	adverse	O	['N']	[2]
3	events	O	['N']	[3]
4	to	O	['N']	[4]
5	dapsone	B-Drug	['Causes']	[53]
6	include	O	['N']	[6]
7	the	O	['N']	[7]
8	idiosyncratic	O	['N']	[8]
9	reactions	O	['N']	[9]
10	of	O	['N']	[10]
11	leukopenia	O	['N']	[11]
12	and	O	['N']	[12]
13	agranulocytosis	O	['N']	[13]
14	,	O	['N']	[14]
15	cutaneous	O	['N']	[15]
16	eruptions	O	['N']	[16]
17	,	O	['N']	[17]
18	peripheral	O	['N']	[18]
19	neuropathy	O	['N']	[19]
20	,	O	['N']	[20]
21	psychosis	O	['N']	[21]
22	,	O	['N']	[22]
23	toxic	O	['N']	[23]
24	hepatitis	O	['N']	[24]
25	,	O	['N']	[25]
26	cholestatic	O	['N']	[26]
27	jaundice	O	['N']	[27]
28	,	O	['N']	[28]
29	nephrotic	O	['N']	[29]
30	syndrome	O	['N']	[30]
31	,	O	['N']	[31]
32	renal	O	['N']	[32]
33	papillary	O	['N']	[33]
34	necrosis	O	['N']	[34]
35	,	O	['N']	[35]
36	severe	O	['N']	[36]
37	hypoalbuminemia	O	['N']	[37]
38	without	O	['N']	[38]
39	proteinuria	O	['N']	[39]
40	,	O	['N']	[40]
41	an	O	['N']	[41]
42	infectious	O	['N']	[42]
43	mononucleosis	O	['N']	[43]
44	-	O	['N']	[44]
45	like	O	['N']	[45]
46	syndrome	O	['N']	[46]
47	,	O	['N']	[47]
48	and	O	['N']	[48]
49	minor	B	['N']	[49]
50	neurological	I	['N']	[50]
51	and	I	['N']	[51]
52	gastrointestinal	I	['N']	[52]
53	complaints	I-Adverse_Effect	['N']	[53]
54	.	O	['N']	[54]
#3234
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	three	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	amiodarone	B-Drug	['Causes']	[10]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	torsades	B	['N']	[8]
9	de	I	['N']	[9]
10	pointe	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#3235
0	Recognition	O	['N']	[0]
1	of	O	['N']	[1]
2	a	O	['N']	[2]
3	potential	O	['N']	[3]
4	drug	O	['N']	[4]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	Fanconi	B	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	is	O	['N']	[9]
10	important	O	['N']	[10]
11	when	O	['N']	[11]
12	managing	O	['N']	[12]
13	pediatric	O	['N']	[13]
14	oncology	O	['N']	[14]
15	patients	O	['N']	[15]
16	previously	O	['N']	[16]
17	treated	O	['N']	[17]
18	with	O	['N']	[18]
19	ifosfamide	B-Drug	['Causes']	[8]
20	.	O	['N']	[20]
#3236
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	the	O	['N']	[4]
5	syndrome	O	['N']	[5]
6	of	O	['N']	[6]
7	fever	B-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	pulmonary	O	['N']	[9]
10	infiltrates	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	pleural	O	['N']	[13]
14	effusion	O	['N']	[14]
15	following	O	['N']	[15]
16	use	O	['N']	[16]
17	of	O	['N']	[17]
18	acyclovir	B-Drug	['Causes']	[7]
19	has	O	['N']	[19]
20	not	O	['N']	[20]
21	been	O	['N']	[21]
22	previously	O	['N']	[22]
23	reported	O	['N']	[23]
24	.	O	['N']	[24]
#3237
0	An	O	['N']	[0]
1	episode	O	['N']	[1]
2	of	O	['N']	[2]
3	leukoencephalopathy	B-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	reported	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	13-year	O	['N']	[8]
9	-	O	['N']	[9]
10	old	O	['N']	[10]
11	girl	O	['N']	[11]
12	who	O	['N']	[12]
13	,	O	['N']	[13]
14	after	O	['N']	[14]
15	standard	O	['N']	[15]
16	radiotherapy	O	['N']	[16]
17	for	O	['N']	[17]
18	a	O	['N']	[18]
19	posterior	O	['N']	[19]
20	fossa	O	['N']	[20]
21	medulloblastoma	O	['N']	[21]
22	,	O	['N']	[22]
23	received	O	['N']	[23]
24	8	O	['N']	[24]
25	treatments	O	['N']	[25]
26	with	O	['N']	[26]
27	a	O	['N']	[27]
28	protocol	O	['N']	[28]
29	containing	O	['N']	[29]
30	a	O	['N']	[30]
31	4-hour	O	['N']	[31]
32	infusion	O	['N']	[32]
33	of	O	['N']	[33]
34	500	O	['N']	[34]
35	mg	O	['N']	[35]
36	/	O	['N']	[36]
37	m2	O	['N']	[37]
38	methotrexate	B-Drug	['Causes']	[3]
39	and	O	['N']	[39]
40	12	O	['N']	[40]
41	mg	O	['N']	[41]
42	intrathecal	O	['N']	[42]
43	methotrexate	O	['N']	[43]
44	.	O	['N']	[44]
#3238
0	Gastro	B	['N']	[0]
1	-	I	['N']	[1]
2	oesophageal	I	['N']	[2]
3	reflux	I-Adverse_Effect	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	nifedipine	B-Drug	['Causes']	[3]
7	.	O	['N']	[7]
#3239
0	Acute	O	['N']	[0]
1	myopathy	O	['N']	[1]
2	with	O	['N']	[2]
3	selective	O	['N']	[3]
4	degeneration	B	['N']	[4]
5	of	I	['N']	[5]
6	myosin	I	['N']	[6]
7	filaments	I-Adverse_Effect	['N']	[7]
8	following	O	['N']	[8]
9	status	O	['N']	[9]
10	asthmaticus	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	methylprednisolone	B-Drug	['Causes']	[7]
14	and	O	['N']	[14]
15	vecuronium	O	['N']	[15]
16	.	O	['N']	[16]
#3240
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	For	O	['N']	[2]
3	all	O	['N']	[3]
4	patients	O	['N']	[4]
5	with	O	['N']	[5]
6	vancomycin	B-Drug	['Causes']	[9]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	neutropenia	B-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	possible	O	['N']	[11]
12	cross	O	['N']	[12]
13	-	O	['N']	[13]
14	reactivity	O	['N']	[14]
15	of	O	['N']	[15]
16	teicoplanin	O	['N']	[16]
17	should	O	['N']	[17]
18	be	O	['N']	[18]
19	monitored	O	['N']	[19]
20	.	O	['N']	[20]
#3241
0	Three	O	['N']	[0]
1	of	O	['N']	[1]
2	these	O	['N']	[2]
3	patients	O	['N']	[3]
4	had	O	['N']	[4]
5	convulsions	O	['N']	[5]
6	attributed	O	['N']	[6]
7	to	O	['N']	[7]
8	imipenem	O	['N']	[8]
9	/	O	['N']	[9]
10	cilastatin	B-Drug	['Causes']	[18]
11	;	O	['N']	[11]
12	3.6	O	['N']	[12]
13	%	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	patients	O	['N']	[16]
17	had	O	['N']	[17]
18	seizure	B-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	or	O	['N']	[20]
21	2	O	['N']	[21]
22	%	O	['N']	[22]
23	of	O	['N']	[23]
24	imipenem	O	['N']	[24]
25	/	O	['N']	[25]
26	cilastatin	O	['N']	[26]
27	administrations	O	['N']	[27]
28	was	O	['N']	[28]
29	followed	O	['N']	[29]
30	by	O	['N']	[30]
31	a	O	['N']	[31]
32	seizure	O	['N']	[32]
33	attack	O	['N']	[33]
34	.	O	['N']	[34]
#3242
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	chronic	O	['N']	[8]
9	lymphocytic	O	['N']	[9]
10	leukemia	O	['N']	[10]
11	(	O	['N']	[11]
12	CLL	O	['N']	[12]
13	)	O	['N']	[13]
14	who	O	['N']	[14]
15	developed	O	['N']	[15]
16	fatal	B	['N']	[16]
17	intravascular	I	['N']	[17]
18	autoimmune	I	['N']	[18]
19	hemolytic	I	['N']	[19]
20	anemia	I-Adverse_Effect	['N']	[20]
21	(	O	['N']	[21]
22	AIHA	O	['N']	[22]
23	)	O	['N']	[23]
24	after	O	['N']	[24]
25	fludarabine	B-Drug	['Causes']	[20]
26	treatment	O	['N']	[26]
27	.	O	['N']	[27]
#3243
0	CASE	O	['N']	[0]
1	PRESENTATION	O	['N']	[1]
2	:	O	['N']	[2]
3	We	O	['N']	[3]
4	report	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	CF	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	recurrent	B	['N']	[11]
12	eosinophilia	I-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	severe	O	['N']	[14]
15	persistent	O	['N']	[15]
16	bronchospasm	O	['N']	[16]
17	following	O	['N']	[17]
18	repeated	O	['N']	[18]
19	administration	O	['N']	[19]
20	of	O	['N']	[20]
21	preservative	O	['N']	[21]
22	-	O	['N']	[22]
23	free	O	['N']	[23]
24	tobramycin	B-Drug	['Causes']	[12]
25	by	O	['N']	[25]
26	inhalation	O	['N']	[26]
27	,	O	['N']	[27]
28	beginning	O	['N']	[28]
29	at	O	['N']	[29]
30	16	O	['N']	[30]
31	months	O	['N']	[31]
32	of	O	['N']	[32]
33	age	O	['N']	[33]
34	.	O	['N']	[34]
#3244
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	study	O	['N']	[2]
3	describes	O	['N']	[3]
4	an	O	['N']	[4]
5	atypical	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	refractory	O	['N']	[8]
9	,	O	['N']	[9]
10	sodium	B	['N']	[10]
11	warfarin	I-Drug	['Causes']	[15]
12	-	O	['N']	[12]
13	induced	O	['N']	[13]
14	necrotizing	B	['N']	[14]
15	fasciitis	I-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	myonecrosis	O	['N']	[17]
18	.	O	['N']	[18]
#3245
0	Acute	B	['N']	[0]
1	non	I	['N']	[1]
2	-	I	['N']	[2]
3	lymphocytic	I	['N']	[3]
4	leukemia	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	patients	O	['N']	[6]
7	with	O	['N']	[7]
8	ovarian	O	['N']	[8]
9	carcinoma	O	['N']	[9]
10	following	O	['N']	[10]
11	long	O	['N']	[11]
12	-	O	['N']	[12]
13	term	O	['N']	[13]
14	treatment	O	['N']	[14]
15	with	O	['N']	[15]
16	Treosulfan	B-Drug	['Causes']	[4]
17	(=	O	['N']	[17]
18	dihydroxybusulfan	O	['N']	[18]
19	)	O	['N']	[19]
20	.	O	['N']	[20]
#3246
0	A	O	['N']	[0]
1	40-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	relapsing	O	['N']	[6]
7	-	O	['N']	[7]
8	remitting	O	['N']	[8]
9	multiple	O	['N']	[9]
10	sclerosis	O	['N']	[10]
11	(	O	['N']	[11]
12	MS	O	['N']	[12]
13	)	O	['N']	[13]
14	developed	O	['N']	[14]
15	primary	O	['N']	[15]
16	central	O	['N']	[16]
17	nervous	O	['N']	[17]
18	system	O	['N']	[18]
19	lymphoma	O	['N']	[19]
20	(	O	['N']	[20]
21	PCNSL	B-Adverse_Effect	['N']	[21]
22	)	O	['N']	[22]
23	after	O	['N']	[23]
24	having	O	['N']	[24]
25	received	O	['N']	[25]
26	21	O	['N']	[26]
27	doses	O	['N']	[27]
28	of	O	['N']	[28]
29	natalizumab	B-Drug	['Causes']	[21]
30	monotherapy	O	['N']	[30]
31	.	O	['N']	[31]
#3247
0	We	O	['N']	[0]
1	postulate	O	['N']	[1]
2	that	O	['N']	[2]
3	gastritis	B-Adverse_Effect	['N']	[3]
4	caused	O	['N']	[4]
5	by	O	['N']	[5]
6	dexamethasone	B-Drug	['Causes']	[3]
7	,	O	['N']	[7]
8	mucositis	O	['N']	[8]
9	caused	O	['N']	[9]
10	by	O	['N']	[10]
11	doxorubicin	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	the	O	['N']	[14]
15	unique	O	['N']	[15]
16	anatomic	O	['N']	[16]
17	nature	O	['N']	[17]
18	of	O	['N']	[18]
19	a	O	['N']	[19]
20	Meckel	O	['N']	[20]
21	diverticulum	O	['N']	[21]
22	may	O	['N']	[22]
23	have	O	['N']	[23]
24	contributed	O	['N']	[24]
25	to	O	['N']	[25]
26	this	O	['N']	[26]
27	extremely	O	['N']	[27]
28	unlikely	O	['N']	[28]
29	and	O	['N']	[29]
30	previously	O	['N']	[30]
31	unreported	O	['N']	[31]
32	event	O	['N']	[32]
33	.	O	['N']	[33]
#3248
0	Gold	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	pneumonitis	B-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	a	O	['N']	[5]
6	rare	O	['N']	[6]
7	complication	O	['N']	[7]
8	of	O	['N']	[8]
9	gold	O	['N']	[9]
10	salt	O	['N']	[10]
11	therapy	O	['N']	[11]
12	.	O	['N']	[12]
#3249
0	Intracranial	O	['N']	[0]
1	hemorrhage	O	['N']	[1]
2	and	O	['N']	[2]
3	focal	B	['N']	[3]
4	seizures	I-Adverse_Effect	['N']	[4]
5	secondary	O	['N']	[5]
6	to	O	['N']	[6]
7	use	O	['N']	[7]
8	of	O	['N']	[8]
9	L	B	['N']	[9]
10	-	I	['N']	[10]
11	asparaginase	I-Drug	['Causes']	[4]
12	during	O	['N']	[12]
13	induction	O	['N']	[13]
14	therapy	O	['N']	[14]
15	of	O	['N']	[15]
16	acute	O	['N']	[16]
17	lymphocytic	O	['N']	[17]
18	leukemia	O	['N']	[18]
19	.	O	['N']	[19]
#3250
0	The	O	['N']	[0]
1	cause	O	['N']	[1]
2	of	O	['N']	[2]
3	these	O	['N']	[3]
4	previously	O	['N']	[4]
5	unreported	O	['N']	[5]
6	side	O	['N']	[6]
7	effects	O	['N']	[7]
8	of	O	['N']	[8]
9	niacin	B-Drug	['Causes']	[42]
10	therapy	O	['N']	[10]
11	is	O	['N']	[11]
12	uncertain	O	['N']	[12]
13	but	O	['N']	[13]
14	may	O	['N']	[14]
15	be	O	['N']	[15]
16	related	O	['N']	[16]
17	to	O	['N']	[17]
18	prostaglandin	O	['N']	[18]
19	-	O	['N']	[19]
20	mediated	O	['N']	[20]
21	vasodilatation	O	['N']	[21]
22	,	O	['N']	[22]
23	hyperalgesia	O	['N']	[23]
24	of	O	['N']	[24]
25	sensory	O	['N']	[25]
26	nerve	O	['N']	[26]
27	receptors	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	potentiation	O	['N']	[30]
31	of	O	['N']	[31]
32	inflammation	O	['N']	[32]
33	in	O	['N']	[33]
34	the	O	['N']	[34]
35	gingiva	O	['N']	[35]
36	with	O	['N']	[36]
37	referral	O	['N']	[37]
38	of	O	['N']	[38]
39	pain	B	['N']	[39]
40	to	I	['N']	[40]
41	the	I	['N']	[41]
42	teeth	I-Adverse_Effect	['N']	[42]
43	.	O	['N']	[43]
#3251
0	Cimetidine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	fever	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#3252
0	The	O	['N']	[0]
1	principle	O	['N']	[1]
2	treatment	O	['N']	[2]
3	for	O	['N']	[3]
4	DPD	O	['N']	[4]
5	-	O	['N']	[5]
6	deficient	O	['N']	[6]
7	patients	O	['N']	[7]
8	with	O	['N']	[8]
9	severe	O	['N']	[9]
10	acute	O	['N']	[10]
11	5-FU	B-Drug	['Causes']	[36]
12	reactions	O	['N']	[12]
13	is	O	['N']	[13]
14	supportive	O	['N']	[14]
15	care	O	['N']	[15]
16	;	O	['N']	[16]
17	however	O	['N']	[17]
18	,	O	['N']	[18]
19	the	O	['N']	[19]
20	administration	O	['N']	[20]
21	of	O	['N']	[21]
22	thymidine	O	['N']	[22]
23	potentially	O	['N']	[23]
24	may	O	['N']	[24]
25	reverse	O	['N']	[25]
26	severe	O	['N']	[26]
27	5-FU	O	['N']	[27]
28	-	O	['N']	[28]
29	induced	O	['N']	[29]
30	neurologic	O	['N']	[30]
31	symptoms	O	['N']	[31]
32	such	O	['N']	[32]
33	as	O	['N']	[33]
34	encephalopathy	O	['N']	[34]
35	and	O	['N']	[35]
36	coma	B-Adverse_Effect	['N']	[36]
37	.	O	['N']	[37]
#3253
0	Hepatitis	B-Adverse_Effect	['N']	[0]
1	with	O	['N']	[1]
2	bridging	O	['N']	[2]
3	fibrosis	O	['N']	[3]
4	and	O	['N']	[4]
5	reversible	O	['N']	[5]
6	hepatic	O	['N']	[6]
7	insufficiency	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	woman	O	['N']	[10]
11	with	O	['N']	[11]
12	rheumatoid	O	['N']	[12]
13	arthritis	O	['N']	[13]
14	taking	O	['N']	[14]
15	methotrexate	B-Drug	['Causes']	[0]
16	.	O	['N']	[16]
#3254
0	A	O	['N']	[0]
1	51-year	O	['N']	[1]
2	old	O	['N']	[2]
3	physically	O	['N']	[3]
4	fit	O	['N']	[4]
5	woman	O	['N']	[5]
6	experienced	O	['N']	[6]
7	angio	O	['N']	[7]
8	-	O	['N']	[8]
9	oedema	O	['N']	[9]
10	and	O	['N']	[10]
11	hypotensive	B	['N']	[11]
12	shock	I-Adverse_Effect	['N']	[12]
13	after	O	['N']	[13]
14	irbesartan	B-Drug	['Causes']	[12]
15	ingestion	O	['N']	[15]
16	requiring	O	['N']	[16]
17	noradrenaline	O	['N']	[17]
18	infusion	O	['N']	[18]
19	.	O	['N']	[19]
#3255
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	three	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	paradoxical	O	['N']	[5]
6	seizures	B-Adverse_Effect	['N']	[6]
7	;	O	['N']	[7]
8	their	O	['N']	[8]
9	serum	O	['N']	[9]
10	phenytoin	B-Drug	['Causes']	[6]
11	levels	O	['N']	[11]
12	were	O	['N']	[12]
13	43.5	O	['N']	[13]
14	mcg	O	['N']	[14]
15	/	O	['N']	[15]
16	mL	O	['N']	[16]
17	,	O	['N']	[17]
18	46.5	O	['N']	[18]
19	mcg	O	['N']	[19]
20	/	O	['N']	[20]
21	mL	O	['N']	[21]
22	and	O	['N']	[22]
23	38.3	O	['N']	[23]
24	mcg	O	['N']	[24]
25	/	O	['N']	[25]
26	mL.	O	['N']	[26]
#3256
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	receiving	O	['N']	[2]
3	vancomycin	B-Drug	['Causes']	[21]
4	for	O	['N']	[4]
5	a	O	['N']	[5]
6	serious	O	['N']	[6]
7	staphylococcal	O	['N']	[7]
8	infection	O	['N']	[8]
9	had	O	['N']	[9]
10	a	O	['N']	[10]
11	lupus	O	['N']	[11]
12	-	O	['N']	[12]
13	like	O	['N']	[13]
14	syndrome	O	['N']	[14]
15	characterized	O	['N']	[15]
16	by	O	['N']	[16]
17	a	O	['N']	[17]
18	malar	O	['N']	[18]
19	rash	O	['N']	[19]
20	,	O	['N']	[20]
21	pain	B-Adverse_Effect	['N']	[21]
22	and	O	['N']	[22]
23	erythema	O	['N']	[23]
24	of	O	['N']	[24]
25	the	O	['N']	[25]
26	cartilage	O	['N']	[26]
27	of	O	['N']	[27]
28	both	O	['N']	[28]
29	ears	O	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	tender	O	['N']	[32]
33	erythematous	O	['N']	[33]
34	and	O	['N']	[34]
35	hemorrhagic	O	['N']	[35]
36	lesions	O	['N']	[36]
37	of	O	['N']	[37]
38	the	O	['N']	[38]
39	finger	O	['N']	[39]
40	tips	O	['N']	[40]
41	.	O	['N']	[41]
#3257
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	male	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	advanced	O	['N']	[6]
7	AIDS	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	hypercalcemia	B-Adverse_Effect	['N']	[10]
11	2	O	['N']	[11]
12	weeks	O	['N']	[12]
13	after	O	['N']	[13]
14	institution	O	['N']	[14]
15	of	O	['N']	[15]
16	rhGH	B-Drug	['Causes']	[10]
17	therapy	O	['N']	[17]
18	.	O	['N']	[18]
#3258
0	Cardiomyopathy	B-Adverse_Effect	['N']	[0]
1	after	O	['N']	[1]
2	widely	O	['N']	[2]
3	separated	O	['N']	[3]
4	courses	O	['N']	[4]
5	of	O	['N']	[5]
6	adriamycin	O	['N']	[6]
7	exacerbated	O	['N']	[7]
8	by	O	['N']	[8]
9	actinomycin	O	['N']	[9]
10	-	O	['N']	[10]
11	D	O	['N']	[11]
12	and	O	['N']	[12]
13	mithramycin	B-Drug	['Causes']	[0]
14	.	O	['N']	[14]
#3259
0	Protease	O	['N']	[0]
1	inhibitors	O	['N']	[1]
2	(	O	['N']	[2]
3	ritonavir	O	['N']	[3]
4	and	O	['N']	[4]
5	saquinavir	B-Drug	['Causes']	[17]
6	)	O	['N']	[6]
7	were	O	['N']	[7]
8	added	O	['N']	[8]
9	to	O	['N']	[9]
10	the	O	['N']	[10]
11	treatment	O	['N']	[11]
12	and	O	['N']	[12]
13	the	O	['N']	[13]
14	patient	O	['N']	[14]
15	developed	O	['N']	[15]
16	progressive	B	['N']	[16]
17	ataxia	I-Adverse_Effect	['N']	[17]
18	related	O	['N']	[18]
19	to	O	['N']	[19]
20	carbamazepine	O	['N']	[20]
21	toxicity	O	['N']	[21]
22	.	O	['N']	[22]
#3260
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	an	O	['N']	[3]
4	adult	O	['N']	[4]
5	who	O	['N']	[5]
6	developed	O	['N']	[6]
7	both	O	['N']	[7]
8	hepatic	B	['N']	[8]
9	dysfunction	I-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	an	O	['N']	[11]
12	impaired	O	['N']	[12]
13	macrophage	O	['N']	[13]
14	migration	O	['N']	[14]
15	after	O	['N']	[15]
16	exposure	O	['N']	[16]
17	to	O	['N']	[17]
18	cimetidine	B-Drug	['Causes']	[9]
19	is	O	['N']	[19]
20	discussed	O	['N']	[20]
21	.	O	['N']	[21]
#3261
0	Physicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	that	O	['N']	[4]
5	indinavir	B-Drug	['Causes']	[6]
6	nephrolithiasis	B-Adverse_Effect	['N']	[6]
7	may	O	['N']	[7]
8	cause	O	['N']	[8]
9	papillary	O	['N']	[9]
10	necrosis	O	['N']	[10]
11	.	O	['N']	[11]
#3262
0	After	O	['N']	[0]
1	therapy	O	['N']	[1]
2	with	O	['N']	[2]
3	parenteral	O	['N']	[3]
4	amiodarone	B-Drug	['Causes']	[27]
5	(	O	['N']	[5]
6	2300	O	['N']	[6]
7	mg	O	['N']	[7]
8	in	O	['N']	[8]
9	3	O	['N']	[9]
10	days	O	['N']	[10]
11	)	O	['N']	[11]
12	and	O	['N']	[12]
13	other	O	['N']	[13]
14	measures	O	['N']	[14]
15	,	O	['N']	[15]
16	signs	O	['N']	[16]
17	of	O	['N']	[17]
18	congestive	O	['N']	[18]
19	heart	O	['N']	[19]
20	failure	O	['N']	[20]
21	disappeared	O	['N']	[21]
22	;	O	['N']	[22]
23	subsequently	O	['N']	[23]
24	the	O	['N']	[24]
25	patient	O	['N']	[25]
26	developed	O	['N']	[26]
27	jaundice	B-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	marked	O	['N']	[29]
30	increase	O	['N']	[30]
31	in	O	['N']	[31]
32	serum	O	['N']	[32]
33	transaminase	O	['N']	[33]
34	levels	O	['N']	[34]
35	and	O	['N']	[35]
36	fall	O	['N']	[36]
37	in	O	['N']	[37]
38	prothrombin	O	['N']	[38]
39	time	O	['N']	[39]
40	,	O	['N']	[40]
41	and	O	['N']	[41]
42	histologic	O	['N']	[42]
43	changes	O	['N']	[43]
44	of	O	['N']	[44]
45	severe	O	['N']	[45]
46	centrilobular	O	['N']	[46]
47	necrosis	O	['N']	[47]
48	were	O	['N']	[48]
49	observed	O	['N']	[49]
50	in	O	['N']	[50]
51	hepatic	O	['N']	[51]
52	biopsy	O	['N']	[52]
53	.	O	['N']	[53]
#3263
0	Nineteen	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	unusual	O	['N']	[3]
4	enhanced	O	['N']	[4]
5	vincristine	B-Drug	['Causes']	[6]
6	neurotoxicity	B-Adverse_Effect	['N']	[6]
7	related	O	['N']	[7]
8	to	O	['N']	[8]
9	itraconazole	O	['N']	[9]
10	have	O	['N']	[10]
11	been	O	['N']	[11]
12	reported	O	['N']	[12]
13	in	O	['N']	[13]
14	children	O	['N']	[14]
15	.	O	['N']	[15]
#3264
0	Clofazimine	B-Drug	['Causes']	[10]
1	enteropathy	O	['N']	[1]
2	caused	O	['N']	[2]
3	by	O	['N']	[3]
4	crystal	O	['N']	[4]
5	deposition	O	['N']	[5]
6	can	O	['N']	[6]
7	be	O	['N']	[7]
8	life	B	['N']	[8]
9	-	I	['N']	[9]
10	threatening	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#3265
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	tuberculosis	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	on	O	['N']	[7]
8	Efalizumab	B-Drug	['Causes']	[3]
9	and	O	['N']	[9]
10	Etanercept	O	['N']	[10]
11	for	O	['N']	[11]
12	treatment	O	['N']	[12]
13	of	O	['N']	[13]
14	refractory	O	['N']	[14]
15	palmopustular	O	['N']	[15]
16	psoriasis	O	['N']	[16]
17	and	O	['N']	[17]
18	psoriatic	O	['N']	[18]
19	arthritis	O	['N']	[19]
20	.	O	['N']	[20]
#3266
0	It	O	['N']	[0]
1	carries	O	['N']	[1]
2	a	O	['N']	[2]
3	well	O	['N']	[3]
4	-	O	['N']	[4]
5	known	O	['N']	[5]
6	risk	O	['N']	[6]
7	of	O	['N']	[7]
8	neutropenia	B-Adverse_Effect	['N']	[8]
9	and	O	['N']	[9]
10	agranulocytosis	O	['N']	[10]
11	,	O	['N']	[11]
12	which	O	['N']	[12]
13	necessitates	O	['N']	[13]
14	the	O	['N']	[14]
15	immediate	O	['N']	[15]
16	discontinuation	O	['N']	[16]
17	of	O	['N']	[17]
18	clozapine	B-Drug	['Causes']	[8]
19	.	O	['N']	[19]
#3267
0	Purple	O	['N']	[0]
1	glove	O	['N']	[1]
2	syndrome	O	['N']	[2]
3	,	O	['N']	[3]
4	named	O	['N']	[4]
5	for	O	['N']	[5]
6	its	O	['N']	[6]
7	distinctive	O	['N']	[7]
8	purple	O	['N']	[8]
9	discoloration	O	['N']	[9]
10	and	O	['N']	[10]
11	swelling	B	['N']	[11]
12	of	I	['N']	[12]
13	the	I	['N']	[13]
14	hands	I-Adverse_Effect	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	distribution	O	['N']	[17]
18	of	O	['N']	[18]
19	a	O	['N']	[19]
20	glove	O	['N']	[20]
21	,	O	['N']	[21]
22	is	O	['N']	[22]
23	an	O	['N']	[23]
24	uncommon	O	['N']	[24]
25	complication	O	['N']	[25]
26	of	O	['N']	[26]
27	intravenous	O	['N']	[27]
28	phenytoin	B-Drug	['Causes']	[14]
29	administration	O	['N']	[29]
30	through	O	['N']	[30]
31	small	O	['N']	[31]
32	dorsal	O	['N']	[32]
33	veins	O	['N']	[33]
34	of	O	['N']	[34]
35	the	O	['N']	[35]
36	hands	O	['N']	[36]
37	.	O	['N']	[37]
#3268
0	Aluminum	B-Drug	['Causes']	[1]
1	intoxication	I-Adverse_Effect	['N']	[1]
2	,	O	['N']	[2]
3	along	O	['N']	[3]
4	with	O	['N']	[4]
5	other	O	['N']	[5]
6	factors	O	['N']	[6]
7	,	O	['N']	[7]
8	was	O	['N']	[8]
9	considered	O	['N']	[9]
10	to	O	['N']	[10]
11	be	O	['N']	[11]
12	the	O	['N']	[12]
13	cause	O	['N']	[13]
14	of	O	['N']	[14]
15	TC	O	['N']	[15]
16	development	O	['N']	[16]
17	.	O	['N']	[17]
#3269
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	describe	O	['N']	[3]
4	the	O	['N']	[4]
5	ophthalmic	O	['N']	[5]
6	features	O	['N']	[6]
7	and	O	['N']	[7]
8	clinical	O	['N']	[8]
9	course	O	['N']	[9]
10	of	O	['N']	[10]
11	two	O	['N']	[11]
12	cases	O	['N']	[12]
13	of	O	['N']	[13]
14	acute	B	['N']	[14]
15	syphilitic	I	['N']	[15]
16	posterior	I	['N']	[16]
17	placoid	I	['N']	[17]
18	chorioretinitis	I-Adverse_Effect	['N']	[18]
19	(	O	['N']	[19]
20	ASPPC	O	['N']	[20]
21	)	O	['N']	[21]
22	that	O	['N']	[22]
23	developed	O	['N']	[23]
24	after	O	['N']	[24]
25	intravitreal	O	['N']	[25]
26	triamcinolone	O	['N']	[26]
27	acetonide	O	['N']	[27]
28	(	O	['N']	[28]
29	IVTA	B-Drug	['Causes']	[18]
30	)	O	['N']	[30]
31	injection	O	['N']	[31]
32	.	O	['N']	[32]
#3270
0	Acute	B	['N']	[0]
1	myeloid	I	['N']	[1]
2	leukemia	I-Adverse_Effect	['N']	[2]
3	evolving	O	['N']	[3]
4	from	O	['N']	[4]
5	essential	O	['N']	[5]
6	thrombocythemia	O	['N']	[6]
7	in	O	['N']	[7]
8	two	O	['N']	[8]
9	patients	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	hydroxyurea	B-Drug	['Causes']	[2]
13	.	O	['N']	[13]
#3271
0	The	O	['N']	[0]
1	fourth	O	['N']	[1]
2	patient	O	['N']	[2]
3	showed	O	['N']	[3]
4	RLS	O	['N']	[4]
5	symptoms	O	['N']	[5]
6	that	O	['N']	[6]
7	were	O	['N']	[7]
8	initially	O	['N']	[8]
9	caused	O	['N']	[9]
10	by	O	['N']	[10]
11	a	O	['N']	[11]
12	20-mg	B	['N']	[12]
13	daily	I-Dose	['N']	[13]
14	olanzapine	B-Drug	['Dosage']	[13]
15	dosage	O	['N']	[15]
16	and	O	['N']	[16]
17	were	O	['N']	[17]
18	later	O	['N']	[18]
19	mitigated	O	['N']	[19]
20	when	O	['N']	[20]
21	olanzapine	O	['N']	[21]
22	was	O	['N']	[22]
23	reduced	O	['N']	[23]
24	and	O	['N']	[24]
25	ropinirole	O	['N']	[25]
26	was	O	['N']	[26]
27	administered	O	['N']	[27]
28	.	O	['N']	[28]
#3272
0	Several	O	['N']	[0]
1	hypersensitivity	B-Adverse_Effect	['N']	[1]
2	reactions	O	['N']	[2]
3	to	O	['N']	[3]
4	cloxacillin	B-Drug	['Causes']	[1]
5	have	O	['N']	[5]
6	been	O	['N']	[6]
7	reported	O	['N']	[7]
8	,	O	['N']	[8]
9	although	O	['N']	[9]
10	IgE	O	['N']	[10]
11	-	O	['N']	[11]
12	mediated	O	['N']	[12]
13	allergic	O	['N']	[13]
14	reactions	O	['N']	[14]
15	to	O	['N']	[15]
16	the	O	['N']	[16]
17	drug	O	['N']	[17]
18	are	O	['N']	[18]
19	rare	O	['N']	[19]
20	and	O	['N']	[20]
21	there	O	['N']	[21]
22	is	O	['N']	[22]
23	little	O	['N']	[23]
24	information	O	['N']	[24]
25	about	O	['N']	[25]
26	possible	O	['N']	[26]
27	tolerance	O	['N']	[27]
28	to	O	['N']	[28]
29	other	O	['N']	[29]
30	semisynthetic	O	['N']	[30]
31	penicillins	O	['N']	[31]
32	or	O	['N']	[32]
33	cephalosporins	O	['N']	[33]
34	in	O	['N']	[34]
35	patients	O	['N']	[35]
36	with	O	['N']	[36]
37	cloxacillin	O	['N']	[37]
38	allergy	O	['N']	[38]
39	.	O	['N']	[39]
#3273
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	fatal	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	toxic	O	['N']	[6]
7	epidermal	O	['N']	[7]
8	necrolysis	O	['N']	[8]
9	(	O	['N']	[9]
10	TEN	O	['N']	[10]
11	)	O	['N']	[11]
12	resulting	O	['N']	[12]
13	from	O	['N']	[13]
14	a	O	['N']	[14]
15	high	B-Dose	['N']	[15]
16	dose	O	['N']	[16]
17	of	O	['N']	[17]
18	cytosine	B	['N']	[18]
19	arabinoside	I-Drug	['Dosage']	[15]
20	(	O	['N']	[20]
21	ARA	O	['N']	[21]
22	-	O	['N']	[22]
23	C	O	['N']	[23]
24	)	O	['N']	[24]
25	.	O	['N']	[25]
#3274
0	The	O	['N']	[0]
1	pharmaceutical	O	['N']	[1]
2	company	O	['N']	[2]
3	producing	O	['N']	[3]
4	Halfan	O	['N']	[4]
5	has	O	['N']	[5]
6	reported	O	['N']	[6]
7	8	O	['N']	[7]
8	cardiac	B	['N']	[8]
9	arrests	I-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	leading	O	['N']	[11]
12	to	O	['N']	[12]
13	6	O	['N']	[13]
14	deaths	O	['N']	[14]
15	,	O	['N']	[15]
16	when	O	['N']	[16]
17	a	O	['N']	[17]
18	higher	O	['N']	[18]
19	dose	O	['N']	[19]
20	than	O	['N']	[20]
21	recommended	O	['N']	[21]
22	was	O	['N']	[22]
23	used	O	['N']	[23]
24	,	O	['N']	[24]
25	there	O	['N']	[25]
26	was	O	['N']	[26]
27	recent	O	['N']	[27]
28	or	O	['N']	[28]
29	concomitant	O	['N']	[29]
30	treatment	O	['N']	[30]
31	with	O	['N']	[31]
32	mefloquine	B-Drug	['Causes']	[9]
33	,	O	['N']	[33]
34	there	O	['N']	[34]
35	was	O	['N']	[35]
36	pre	O	['N']	[36]
37	-	O	['N']	[37]
38	existing	O	['N']	[38]
39	prolongation	O	['N']	[39]
40	of	O	['N']	[40]
41	the	O	['N']	[41]
42	QT	O	['N']	[42]
43	interval	O	['N']	[43]
44	or	O	['N']	[44]
45	the	O	['N']	[45]
46	patient	O	['N']	[46]
47	had	O	['N']	[47]
48	a	O	['N']	[48]
49	thiamine	O	['N']	[49]
50	deficiency	O	['N']	[50]
51	.	O	['N']	[51]
#3275
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	findings	O	['N']	[3]
4	in	O	['N']	[4]
5	these	O	['N']	[5]
6	two	O	['N']	[6]
7	patients	O	['N']	[7]
8	suggest	O	['N']	[8]
9	that	O	['N']	[9]
10	colchicine	B-Drug	['Causes']	[15]
11	may	O	['N']	[11]
12	delay	B	['N']	[12]
13	corneal	I	['N']	[13]
14	wound	I	['N']	[14]
15	healing	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#3276
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	purpose	O	['N']	[3]
4	of	O	['N']	[4]
5	this	O	['N']	[5]
6	study	O	['N']	[6]
7	was	O	['N']	[7]
8	to	O	['N']	[8]
9	determine	O	['N']	[9]
10	whether	O	['N']	[10]
11	desensitization	O	['N']	[11]
12	to	O	['N']	[12]
13	NPH	O	['N']	[13]
14	insulin	B-Drug	['Causes']	[26]
15	,	O	['N']	[15]
16	as	O	['N']	[16]
17	well	O	['N']	[17]
18	as	O	['N']	[18]
19	standard	O	['N']	[19]
20	insulin	O	['N']	[20]
21	desensitization	O	['N']	[21]
22	,	O	['N']	[22]
23	could	O	['N']	[23]
24	control	O	['N']	[24]
25	allergic	B	['N']	[25]
26	symptoms	I-Adverse_Effect	['N']	[26]
27	in	O	['N']	[27]
28	a	O	['N']	[28]
29	patient	O	['N']	[29]
30	allergic	O	['N']	[30]
31	to	O	['N']	[31]
32	both	O	['N']	[32]
33	NPH	O	['N']	[33]
34	and	O	['N']	[34]
35	regular	O	['N']	[35]
36	insulin	O	['N']	[36]
37	.	O	['N']	[37]
#3277
0	Although	O	['N']	[0]
1	useful	O	['N']	[1]
2	in	O	['N']	[2]
3	the	O	['N']	[3]
4	management	O	['N']	[4]
5	of	O	['N']	[5]
6	chronic	O	['N']	[6]
7	alcoholism	O	['N']	[7]
8	,	O	['N']	[8]
9	disulfiram	B-Drug	['Causes']	[29]
10	is	O	['N']	[10]
11	being	O	['N']	[11]
12	increasingly	O	['N']	[12]
13	associated	O	['N']	[13]
14	with	O	['N']	[14]
15	a	O	['N']	[15]
16	wide	O	['N']	[16]
17	spectrum	O	['N']	[17]
18	of	O	['N']	[18]
19	side	O	['N']	[19]
20	effects	O	['N']	[20]
21	and	O	['N']	[21]
22	untoward	O	['N']	[22]
23	medical	O	['N']	[23]
24	sequelae	O	['N']	[24]
25	,	O	['N']	[25]
26	which	O	['N']	[26]
27	now	O	['N']	[27]
28	include	O	['N']	[28]
29	catatonia	B-Adverse_Effect	['N']	[29]
30	.	O	['N']	[30]
#3278
0	Idiosyncratic	O	['N']	[0]
1	pulmonary	O	['N']	[1]
2	reactions	O	['N']	[2]
3	to	O	['N']	[3]
4	nitrofurantoin	B-Drug	['Causes']	[13]
5	are	O	['N']	[5]
6	not	O	['N']	[6]
7	unusual	O	['N']	[7]
8	,	O	['N']	[8]
9	often	O	['N']	[9]
10	presenting	O	['N']	[10]
11	as	O	['N']	[11]
12	eosinophilic	B	['N']	[12]
13	pneumonia	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#3279
0	Propoxyphene	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	wide	B	['N']	[3]
4	complex	I	['N']	[4]
5	dysrhythmia	I-Adverse_Effect	['N']	[5]
6	responsive	O	['N']	[6]
7	to	O	['N']	[7]
8	sodium	O	['N']	[8]
9	bicarbonate	O	['N']	[9]
10	therapy	O	['N']	[10]
11	has	O	['N']	[11]
12	not	O	['N']	[12]
13	been	O	['N']	[13]
14	previously	O	['N']	[14]
15	reported	O	['N']	[15]
16	in	O	['N']	[16]
17	the	O	['N']	[17]
18	literature	O	['N']	[18]
19	.	O	['N']	[19]
#3280
0	3	O	['N']	[0]
1	.	O	['N']	[1]
2	Thus	O	['N']	[2]
3	,	O	['N']	[3]
4	the	O	['N']	[4]
5	decreased	B	['N']	[5]
6	plasma	I	['N']	[6]
7	cortisol	I	['N']	[7]
8	level	I-Adverse_Effect	['N']	[8]
9	during	O	['N']	[9]
10	alprazolam	B-Drug	['Causes']	[8]
11	treatment	O	['N']	[11]
12	of	O	['N']	[12]
13	panic	O	['N']	[13]
14	disorder	O	['N']	[14]
15	was	O	['N']	[15]
16	suggested	O	['N']	[16]
17	to	O	['N']	[17]
18	be	O	['N']	[18]
19	caused	O	['N']	[19]
20	not	O	['N']	[20]
21	by	O	['N']	[21]
22	symptom	O	['N']	[22]
23	alleviation	O	['N']	[23]
24	due	O	['N']	[24]
25	to	O	['N']	[25]
26	alprazolam	O	['N']	[26]
27	but	O	['N']	[27]
28	by	O	['N']	[28]
29	alprazolam	O	['N']	[29]
30	administration	O	['N']	[30]
31	itself	O	['N']	[31]
32	.	O	['N']	[32]
#3281
0	Multicentric	B	['N']	[0]
1	hepatocellular	I	['N']	[1]
2	carcinoma	I-Adverse_Effect	['N']	[2]
3	following	O	['N']	[3]
4	phosphate	B	['N']	[4]
5	diethylstilbestrol	I-Drug	['Causes']	[2]
6	therapy	O	['N']	[6]
7	for	O	['N']	[7]
8	prostatic	O	['N']	[8]
9	cancer	O	['N']	[9]
10	.	O	['N']	[10]
#3282
0	Potential	O	['N']	[0]
1	causes	O	['N']	[1]
2	of	O	['N']	[2]
3	methamphetamine	O	['N']	[3]
4	-	O	['N']	[4]
5	related	O	['N']	[5]
6	keratitis	O	['N']	[6]
7	can	O	['N']	[7]
8	be	O	['N']	[8]
9	divided	O	['N']	[9]
10	into	O	['N']	[10]
11	four	O	['N']	[11]
12	categories	O	['N']	[12]
13	resulting	O	['N']	[13]
14	from	O	['N']	[14]
15	(	O	['N']	[15]
16	a	O	['N']	[16]
17	)	O	['N']	[17]
18	direct	O	['N']	[18]
19	pharmacologic	O	['N']	[19]
20	and	O	['N']	[20]
21	physical	O	['N']	[21]
22	effects	O	['N']	[22]
23	of	O	['N']	[23]
24	methamphetamine	O	['N']	[24]
25	;	O	['N']	[25]
26	(	O	['N']	[26]
27	b	O	['N']	[27]
28	)	O	['N']	[28]
29	the	O	['N']	[29]
30	toxic	B	['N']	[30]
31	effects	I-Adverse_Effect	['N']	[31]
32	of	O	['N']	[32]
33	diluting	O	['N']	[33]
34	or	O	['N']	[34]
35	"	O	['N']	[35]
36	cutting	O	['N']	[36]
37	"	O	['N']	[37]
38	agents	O	['N']	[38]
39	such	O	['N']	[39]
40	as	O	['N']	[40]
41	lidocaine	B-Drug	['Causes']	[31]
42	and	O	['N']	[42]
43	quinine	O	['N']	[43]
44	;	O	['N']	[44]
45	(	O	['N']	[45]
46	c	O	['N']	[46]
47	)	O	['N']	[47]
48	effects	O	['N']	[48]
49	related	O	['N']	[49]
50	to	O	['N']	[50]
51	the	O	['N']	[51]
52	route	O	['N']	[52]
53	of	O	['N']	[53]
54	drug	O	['N']	[54]
55	administration	O	['N']	[55]
56	(	O	['N']	[56]
57	intravenous	O	['N']	[57]
58	,	O	['N']	[58]
59	inhalation	O	['N']	[59]
60	,	O	['N']	[60]
61	smoking	O	['N']	[61]
62	)	O	['N']	[62]
63	;	O	['N']	[63]
64	and	O	['N']	[64]
65	(	O	['N']	[65]
66	d	O	['N']	[66]
67	)	O	['N']	[67]
68	manufacture	O	['N']	[68]
69	-	O	['N']	[69]
70	related	O	['N']	[70]
71	effects	O	['N']	[71]
72	of	O	['N']	[72]
73	exposure	O	['N']	[73]
74	to	O	['N']	[74]
75	unintentional	O	['N']	[75]
76	caustic	O	['N']	[76]
77	contaminants	O	['N']	[77]
78	in	O	['N']	[78]
79	the	O	['N']	[79]
80	final	O	['N']	[80]
81	product	O	['N']	[81]
82	.	O	['N']	[82]
#3283
0	We	O	['N']	[0]
1	postulate	O	['N']	[1]
2	that	O	['N']	[2]
3	cyclosporin	O	['N']	[3]
4	,	O	['N']	[4]
5	possibly	O	['N']	[5]
6	together	O	['N']	[6]
7	with	O	['N']	[7]
8	ganciclovir	B-Drug	['Causes']	[17]
9	,	O	['N']	[9]
10	can	O	['N']	[10]
11	produce	O	['N']	[11]
12	transient	B	['N']	[12]
13	brain	I	['N']	[13]
14	stem	I	['N']	[14]
15	or	I	['N']	[15]
16	neuromuscular	I	['N']	[16]
17	dysfunction	I-Adverse_Effect	['N']	[17]
18	with	O	['N']	[18]
19	eye	O	['N']	[19]
20	movement	O	['N']	[20]
21	abnormality	O	['N']	[21]
22	in	O	['N']	[22]
23	occasional	O	['N']	[23]
24	patients	O	['N']	[24]
25	.	O	['N']	[25]
#3284
0	Thus	O	['N']	[0]
1	,	O	['N']	[1]
2	an	O	['N']	[2]
3	immunological	O	['N']	[3]
4	mechanism	O	['N']	[4]
5	might	O	['N']	[5]
6	be	O	['N']	[6]
7	involved	O	['N']	[7]
8	in	O	['N']	[8]
9	the	O	['N']	[9]
10	mechanism	O	['N']	[10]
11	of	O	['N']	[11]
12	pirmenol	B-Drug	['Causes']	[20]
13	-	O	['N']	[13]
14	induced	O	['N']	[14]
15	QT	O	['N']	[15]
16	prolongation	O	['N']	[16]
17	and	O	['N']	[17]
18	T	B	['N']	[18]
19	wave	I	['N']	[19]
20	inversion	I-Adverse_Effect	['N']	[20]
21	on	O	['N']	[21]
22	the	O	['N']	[22]
23	electrocardiogram	O	['N']	[23]
24	.	O	['N']	[24]
#3285
0	Aluminum	B-Drug	['Causes']	[15]
1	intoxication	O	['N']	[1]
2	,	O	['N']	[2]
3	along	O	['N']	[3]
4	with	O	['N']	[4]
5	other	O	['N']	[5]
6	factors	O	['N']	[6]
7	,	O	['N']	[7]
8	was	O	['N']	[8]
9	considered	O	['N']	[9]
10	to	O	['N']	[10]
11	be	O	['N']	[11]
12	the	O	['N']	[12]
13	cause	O	['N']	[13]
14	of	O	['N']	[14]
15	TC	B-Adverse_Effect	['N']	[15]
16	development	O	['N']	[16]
17	.	O	['N']	[17]
#3286
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	also	O	['N']	[2]
3	determined	O	['N']	[3]
4	that	O	['N']	[4]
5	their	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	myositis	O	['N']	[8]
9	developing	O	['N']	[9]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	rectus	O	['N']	[12]
13	abdominus	O	['N']	[13]
14	muscle	O	['N']	[14]
15	of	O	['N']	[15]
16	a	O	['N']	[16]
17	patient	O	['N']	[17]
18	with	O	['N']	[18]
19	pancreatic	O	['N']	[19]
20	adenocarcinoma	O	['N']	[20]
21	was	O	['N']	[21]
22	the	O	['N']	[22]
23	manifestation	O	['N']	[23]
24	of	O	['N']	[24]
25	radiation	B	['N']	[25]
26	recall	I-Adverse_Effect	['N']	[26]
27	,	O	['N']	[27]
28	thereby	O	['N']	[28]
29	bringing	O	['N']	[29]
30	the	O	['N']	[30]
31	number	O	['N']	[31]
32	of	O	['N']	[32]
33	patients	O	['N']	[33]
34	who	O	['N']	[34]
35	developed	O	['N']	[35]
36	radiation	O	['N']	[36]
37	recall	O	['N']	[37]
38	to	O	['N']	[38]
39	gemcitabine	B-Drug	['Causes']	[26]
40	and	O	['N']	[40]
41	were	O	['N']	[41]
42	discussed	O	['N']	[42]
43	in	O	['N']	[43]
44	the	O	['N']	[44]
45	current	O	['N']	[45]
46	study	O	['N']	[46]
47	to	O	['N']	[47]
48	13	O	['N']	[48]
49	.	O	['N']	[49]
#3287
0	Due	O	['N']	[0]
1	to	O	['N']	[1]
2	the	O	['N']	[2]
3	severity	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	rash	B-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	temozolomide	B-Drug	['Causes']	[6]
9	was	O	['N']	[9]
10	permanently	O	['N']	[10]
11	discontinued	O	['N']	[11]
12	.	O	['N']	[12]
#3288
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	two	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	aspergillus	B	['N']	[5]
6	arthritis	I	['N']	[6]
7	of	I	['N']	[7]
8	the	I	['N']	[8]
9	knee	I	['N']	[9]
10	joint	I-Adverse_Effect	['N']	[10]
11	following	O	['N']	[11]
12	fludarabine	B-Drug	['Causes']	[10]
13	-	O	['N']	[13]
14	based	O	['N']	[14]
15	non	O	['N']	[15]
16	-	O	['N']	[16]
17	myeloablative	O	['N']	[17]
18	stem	O	['N']	[18]
19	cell	O	['N']	[19]
20	transplantation	O	['N']	[20]
21	.	O	['N']	[21]
#3289
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	acute	O	['N']	[5]
6	leukemia	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	Horner	O	['N']	[9]
10	's	O	['N']	[10]
11	syndrome	O	['N']	[11]
12	and	O	['N']	[12]
13	a	O	['N']	[13]
14	severe	B	['N']	[14]
15	demyelinating	I	['N']	[15]
16	peripheral	I	['N']	[16]
17	neuropathy	I-Adverse_Effect	['N']	[17]
18	leading	O	['N']	[18]
19	to	O	['N']	[19]
20	death	O	['N']	[20]
21	after	O	['N']	[21]
22	receiving	O	['N']	[22]
23	high	O	['N']	[23]
24	-	O	['N']	[24]
25	dose	O	['N']	[25]
26	cytosine	B	['N']	[26]
27	arabinoside	I-Drug	['Causes']	[17]
28	.	O	['N']	[28]
#3290
0	METHOD	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	describe	O	['N']	[3]
4	three	O	['N']	[4]
5	case	O	['N']	[5]
6	-	O	['N']	[6]
7	reports	O	['N']	[7]
8	concerning	O	['N']	[8]
9	haematological	B	['N']	[9]
10	adverse	I	['N']	[10]
11	effects	I-Adverse_Effect	['N']	[11]
12	of	O	['N']	[12]
13	quetiapine	B-Drug	['Causes']	[11]
14	.	O	['N']	[14]
#3291
0	Bone	O	['N']	[0]
1	marrow	O	['N']	[1]
2	aplasia	O	['N']	[2]
3	and	O	['N']	[3]
4	severe	B	['N']	[4]
5	skin	I	['N']	[5]
6	rash	I-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	a	O	['N']	[8]
9	single	O	['N']	[9]
10	low	O	['N']	[10]
11	dose	O	['N']	[11]
12	of	O	['N']	[12]
13	methotrexate	B-Drug	['Causes']	[6]
14	.	O	['N']	[14]
#3292
0	Drug	O	['N']	[0]
1	induced	O	['N']	[1]
2	polymyositis	B-Adverse_Effect	['N']	[2]
3	secondary	O	['N']	[3]
4	to	O	['N']	[4]
5	leuprolide	O	['N']	[5]
6	acetate	O	['N']	[6]
7	(	O	['N']	[7]
8	Lupron	B-Drug	['Causes']	[2]
9	)	O	['N']	[9]
10	therapy	O	['N']	[10]
11	for	O	['N']	[11]
12	prostate	O	['N']	[12]
13	carcinoma	O	['N']	[13]
14	.	O	['N']	[14]
#3293
0	Acute	B	['N']	[0]
1	dystonic	I	['N']	[1]
2	reaction	I-Adverse_Effect	['N']	[2]
3	with	O	['N']	[3]
4	low	O	['N']	[4]
5	-	O	['N']	[5]
6	dose	O	['N']	[6]
7	pimozide	B-Drug	['Causes']	[2]
8	.	O	['N']	[8]
#3294
0	Although	O	['N']	[0]
1	this	O	['N']	[1]
2	type	O	['N']	[2]
3	of	O	['N']	[3]
4	hyperpigmentation	B-Adverse_Effect	['N']	[4]
5	has	O	['N']	[5]
6	been	O	['N']	[6]
7	previously	O	['N']	[7]
8	seen	O	['N']	[8]
9	in	O	['N']	[9]
10	patients	O	['N']	[10]
11	with	O	['N']	[11]
12	cancer	O	['N']	[12]
13	who	O	['N']	[13]
14	are	O	['N']	[14]
15	receiving	O	['N']	[15]
16	bleomycin	B-Drug	['Causes']	[4]
17	,	O	['N']	[17]
18	this	O	['N']	[18]
19	is	O	['N']	[19]
20	,	O	['N']	[20]
21	to	O	['N']	[21]
22	our	O	['N']	[22]
23	knowledge	O	['N']	[23]
24	,	O	['N']	[24]
25	the	O	['N']	[25]
26	first	O	['N']	[26]
27	reported	O	['N']	[27]
28	case	O	['N']	[28]
29	of	O	['N']	[29]
30	bleomycin	O	['N']	[30]
31	-	O	['N']	[31]
32	induced	O	['N']	[32]
33	hyperpigmentation	O	['N']	[33]
34	in	O	['N']	[34]
35	an	O	['N']	[35]
36	AIDS	O	['N']	[36]
37	patient	O	['N']	[37]
38	and	O	['N']	[38]
39	should	O	['N']	[39]
40	be	O	['N']	[40]
41	added	O	['N']	[41]
42	to	O	['N']	[42]
43	the	O	['N']	[43]
44	growing	O	['N']	[44]
45	list	O	['N']	[45]
46	of	O	['N']	[46]
47	cutaneous	O	['N']	[47]
48	eruptions	O	['N']	[48]
49	seen	O	['N']	[49]
50	in	O	['N']	[50]
51	these	O	['N']	[51]
52	patients	O	['N']	[52]
53	.	O	['N']	[53]
#3295
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	All	O	['N']	[2]
3	cases	O	['N']	[3]
4	developed	O	['N']	[4]
5	corneal	B	['N']	[5]
6	endothelial	I	['N']	[6]
7	deposits	I-Adverse_Effect	['N']	[7]
8	after	O	['N']	[8]
9	previous	O	['N']	[9]
10	use	O	['N']	[10]
11	of	O	['N']	[11]
12	rifabutin	B-Drug	['Causes']	[7]
13	.	O	['N']	[13]
#3296
0	There	O	['N']	[0]
1	have	O	['N']	[1]
2	been	O	['N']	[2]
3	numerous	O	['N']	[3]
4	case	O	['N']	[4]
5	reports	O	['N']	[5]
6	of	O	['N']	[6]
7	hyperglycemia	B-Adverse_Effect	['N']	[7]
8	with	O	['N']	[8]
9	olanzapine	B-Drug	['Causes']	[7]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	literature	O	['N']	[12]
13	,	O	['N']	[13]
14	but	O	['N']	[14]
15	none	O	['N']	[15]
16	reported	O	['N']	[16]
17	hyperglycemia	O	['N']	[17]
18	within	O	['N']	[18]
19	days	O	['N']	[19]
20	of	O	['N']	[20]
21	initiation	O	['N']	[21]
22	of	O	['N']	[22]
23	the	O	['N']	[23]
24	medication	O	['N']	[24]
25	.	O	['N']	[25]
#3297
0	A	O	['N']	[0]
1	36-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	being	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	cisplatinum	O	['N']	[8]
9	,	O	['N']	[9]
10	vinblastine	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	bleomycin	B-Drug	['Causes']	[32]
14	for	O	['N']	[14]
15	testicular	O	['N']	[15]
16	carcinoma	O	['N']	[16]
17	developed	O	['N']	[17]
18	a	O	['N']	[18]
19	dense	O	['N']	[19]
20	left	O	['N']	[20]
21	homonymous	O	['N']	[21]
22	hemianopsia	O	['N']	[22]
23	,	O	['N']	[23]
24	encephalopathy	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	a	O	['N']	[27]
28	partial	B	['N']	[28]
29	nondominant	I	['N']	[29]
30	parietal	I	['N']	[30]
31	lobe	I	['N']	[31]
32	syndrome	I-Adverse_Effect	['N']	[32]
33	.	O	['N']	[33]
#3298
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Aphthous	B	['N']	[2]
3	stomatitis	I-Adverse_Effect	['N']	[3]
4	,	O	['N']	[4]
5	a	O	['N']	[5]
6	common	O	['N']	[6]
7	mucocutaneous	O	['N']	[7]
8	disorder	O	['N']	[8]
9	,	O	['N']	[9]
10	is	O	['N']	[10]
11	a	O	['N']	[11]
12	well	O	['N']	[12]
13	accepted	O	['N']	[13]
14	complication	O	['N']	[14]
15	of	O	['N']	[15]
16	sirolimus	B-Drug	['Causes']	[3]
17	therapy	O	['N']	[17]
18	.	O	['N']	[18]
#3299
0	Development	O	['N']	[0]
1	of	O	['N']	[1]
2	Peyronie	B	['N']	[2]
3	's	I	['N']	[3]
4	disease	I-Adverse_Effect	['N']	[4]
5	during	O	['N']	[5]
6	long	O	['N']	[6]
7	-	O	['N']	[7]
8	term	O	['N']	[8]
9	colchicine	B-Drug	['Causes']	[4]
10	treatment	O	['N']	[10]
11	.	O	['N']	[11]
#3300
0	OBJECTIVES	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	delayed	O	['N']	[3]
4	stroke	B	['N']	[4]
5	-	I	['N']	[5]
6	like	I	['N']	[6]
7	leukoencephalopathy	I-Adverse_Effect	['N']	[7]
8	has	O	['N']	[8]
9	been	O	['N']	[9]
10	observed	O	['N']	[10]
11	in	O	['N']	[11]
12	patients	O	['N']	[12]
13	receiving	O	['N']	[13]
14	methotrexate	B-Drug	['Causes']	[7]
15	(	O	['N']	[15]
16	MTX	O	['N']	[16]
17	)	O	['N']	[17]
18	for	O	['N']	[18]
19	childhood	O	['N']	[19]
20	leukemia	O	['N']	[20]
21	.	O	['N']	[21]
#3301
0	The	O	['N']	[0]
1	possible	O	['N']	[1]
2	role	O	['N']	[2]
3	of	O	['N']	[3]
4	interferon	B	['N']	[4]
5	beta	I-Drug	['Causes']	[10]
6	in	O	['N']	[6]
7	the	O	['N']	[7]
8	pathogenesis	O	['N']	[8]
9	of	O	['N']	[9]
10	sarcoidosis	B-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	this	O	['N']	[12]
13	patient	O	['N']	[13]
14	is	O	['N']	[14]
15	discussed	O	['N']	[15]
16	.	O	['N']	[16]
#3302
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	B-Drug	['Causes']	[33]
20	developed	O	['N']	[20]
21	confusion	O	['N']	[21]
22	,	O	['N']	[22]
23	agitation	O	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	O	['N']	[25]
26	,	O	['N']	[26]
27	tremors	O	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	O	['N']	[29]
30	jerks	O	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	B	['N']	[32]
33	gait	I-Adverse_Effect	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	O	['N']	[43]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#3303
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	are	O	['N']	[2]
3	described	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	testicular	B	['N']	[6]
7	swelling	I-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	pain	O	['N']	[9]
10	during	O	['N']	[10]
11	treatment	O	['N']	[11]
12	with	O	['N']	[12]
13	desipramine	B-Drug	['Causes']	[7]
14	.	O	['N']	[14]
#3304
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	reported	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	suspected	O	['N']	[7]
8	DIAN	B-Adverse_Effect	['N']	[8]
9	due	O	['N']	[9]
10	to	O	['N']	[10]
11	cefuroxime	B-Drug	['Causes']	[8]
12	.	O	['N']	[12]
#3305
0	CD4	O	['N']	[0]
1	T	O	['N']	[1]
2	-	O	['N']	[2]
3	lymphocyte	O	['N']	[3]
4	depletion	O	['N']	[4]
5	,	O	['N']	[5]
6	myelosuppression	O	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	subsequent	O	['N']	[9]
10	severe	B	['N']	[10]
11	infections	I-Adverse_Effect	['N']	[11]
12	are	O	['N']	[12]
13	the	O	['N']	[13]
14	major	O	['N']	[14]
15	side	O	['N']	[15]
16	effects	O	['N']	[16]
17	of	O	['N']	[17]
18	fludarabine	B	['N']	[18]
19	phosphate	I-Drug	['Causes']	[11]
20	therapy	O	['N']	[20]
21	.	O	['N']	[21]
#3306
0	A	O	['N']	[0]
1	37-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	relapsing	O	['N']	[6]
7	invasive	O	['N']	[7]
8	vertebral	O	['N']	[8]
9	aspergillosis	O	['N']	[9]
10	received	O	['N']	[10]
11	intravenous	O	['N']	[11]
12	VRC	B-Drug	['Causes']	[17]
13	and	O	['N']	[13]
14	developed	O	['N']	[14]
15	angio	B	['N']	[15]
16	-	I	['N']	[16]
17	oedema	I-Adverse_Effect	['N']	[17]
18	10	O	['N']	[18]
19	days	O	['N']	[19]
20	after	O	['N']	[20]
21	starting	O	['N']	[21]
22	therapy	O	['N']	[22]
23	.	O	['N']	[23]
#3307
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Methotrexate	B-Drug	['Causes']	[6]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	papular	B	['N']	[5]
6	eruption	I-Adverse_Effect	['N']	[6]
7	is	O	['N']	[7]
8	rarely	O	['N']	[8]
9	reported	O	['N']	[9]
10	shortly	O	['N']	[10]
11	after	O	['N']	[11]
12	beginning	O	['N']	[12]
13	methotrexate	O	['N']	[13]
14	therapy	O	['N']	[14]
15	in	O	['N']	[15]
16	patients	O	['N']	[16]
17	with	O	['N']	[17]
18	acute	O	['N']	[18]
19	exacerbation	O	['N']	[19]
20	of	O	['N']	[20]
21	collagen	O	['N']	[21]
22	vascular	O	['N']	[22]
23	diseases	O	['N']	[23]
24	.	O	['N']	[24]
#3308
0	Cough	B-Adverse_Effect	['N']	[0]
1	induced	O	['N']	[1]
2	by	O	['N']	[2]
3	quinapril	B-Drug	['Causes']	[0]
4	with	O	['N']	[4]
5	resolution	O	['N']	[5]
6	after	O	['N']	[6]
7	changing	O	['N']	[7]
8	to	O	['N']	[8]
9	fosinopril	O	['N']	[9]
10	.	O	['N']	[10]
#3309
0	Autopsy	O	['N']	[0]
1	findings	O	['N']	[1]
2	were	O	['N']	[2]
3	consistent	O	['N']	[3]
4	with	O	['N']	[4]
5	bleomycin	B-Drug	['Causes']	[11]
6	and	O	['N']	[6]
7	oxygen	O	['N']	[7]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	pulmonary	B	['N']	[10]
11	damage	I-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#3310
0	Mucosal	B	['N']	[0]
1	pigmentation	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	oral	O	['N']	[3]
4	lichen	O	['N']	[4]
5	planus	O	['N']	[5]
6	treatment	O	['N']	[6]
7	with	O	['N']	[7]
8	topical	O	['N']	[8]
9	tacrolimus	B-Drug	['Causes']	[1]
10	.	O	['N']	[10]
#3311
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	as	O	['N']	[2]
3	illustrated	O	['N']	[3]
4	by	O	['N']	[4]
5	these	O	['N']	[5]
6	and	O	['N']	[6]
7	other	O	['N']	[7]
8	cases	O	['N']	[8]
9	reported	O	['N']	[9]
10	to	O	['N']	[10]
11	date	O	['N']	[11]
12	,	O	['N']	[12]
13	the	O	['N']	[13]
14	onset	O	['N']	[14]
15	of	O	['N']	[15]
16	troglitazone	B-Drug	['Causes']	[20]
17	-	O	['N']	[17]
18	induced	O	['N']	[18]
19	liver	B	['N']	[19]
20	injury	I-Adverse_Effect	['N']	[20]
21	is	O	['N']	[21]
22	insidious	O	['N']	[22]
23	and	O	['N']	[23]
24	temporally	O	['N']	[24]
25	variable	O	['N']	[25]
26	.	O	['N']	[26]
#3312
0	Ifosfamide	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	neurotoxicity	B-Adverse_Effect	['N']	[3]
4	was	O	['N']	[4]
5	noted	O	['N']	[5]
6	within	O	['N']	[6]
7	hours	O	['N']	[7]
8	of	O	['N']	[8]
9	drug	O	['N']	[9]
10	administration	O	['N']	[10]
11	and	O	['N']	[11]
12	improved	O	['N']	[12]
13	rapidly	O	['N']	[13]
14	following	O	['N']	[14]
15	hemodialysis	O	['N']	[15]
16	.	O	['N']	[16]
#3313
0	We	O	['N']	[0]
1	diagnosed	O	['N']	[1]
2	this	O	['N']	[2]
3	case	O	['N']	[3]
4	as	O	['N']	[4]
5	danazol	B-Drug	['Causes']	[7]
6	induced	O	['N']	[6]
7	thrombocytopenia	B-Adverse_Effect	['N']	[7]
8	.	O	['N']	[8]
#3314
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Gemcitabine	O	['N']	[2]
3	has	O	['N']	[3]
4	mild	O	['N']	[4]
5	renal	O	['N']	[5]
6	toxicity	O	['N']	[6]
7	,	O	['N']	[7]
8	but	O	['N']	[8]
9	cases	O	['N']	[9]
10	of	O	['N']	[10]
11	gemcitabine	B-Drug	['Causes']	[19]
12	-	O	['N']	[12]
13	associated	O	['N']	[13]
14	hemolytic	O	['N']	[14]
15	-	O	['N']	[15]
16	uremic	O	['N']	[16]
17	syndrome	O	['N']	[17]
18	(	O	['N']	[18]
19	HUS	B-Adverse_Effect	['N']	[19]
20	)	O	['N']	[20]
21	have	O	['N']	[21]
22	been	O	['N']	[22]
23	reported	O	['N']	[23]
24	.	O	['N']	[24]
#3315
0	Sirolimus	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	hepatotoxicity	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	the	O	['N']	[5]
6	kidney	O	['N']	[6]
7	graft	O	['N']	[7]
8	recipient	O	['N']	[8]
9	.	O	['N']	[9]
#3316
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	here	O	['N']	[2]
3	a	O	['N']	[3]
4	rare	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	pleuropericarditis	B-Adverse_Effect	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	methotrexate	B-Drug	['Causes']	[7]
11	.	O	['N']	[11]
#3317
0	Mycobacterium	B	['N']	[0]
1	marinum	I	['N']	[1]
2	infection	I-Adverse_Effect	['N']	[2]
3	complicating	O	['N']	[3]
4	Crohn	O	['N']	[4]
5	's	O	['N']	[5]
6	disease	O	['N']	[6]
7	,	O	['N']	[7]
8	treated	O	['N']	[8]
9	with	O	['N']	[9]
10	infliximab	B-Drug	['Causes']	[2]
11	.	O	['N']	[11]
#3318
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	five	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	restless	B	['N']	[5]
6	legs	I	['N']	[6]
7	syndrome	I-Adverse_Effect	['N']	[7]
8	(	O	['N']	[8]
9	RLS	O	['N']	[9]
10	)	O	['N']	[10]
11	and	O	['N']	[11]
12	periodic	O	['N']	[12]
13	limb	O	['N']	[13]
14	movements	O	['N']	[14]
15	during	O	['N']	[15]
16	sleep	O	['N']	[16]
17	(	O	['N']	[17]
18	PLMS	O	['N']	[18]
19	)	O	['N']	[19]
20	that	O	['N']	[20]
21	were	O	['N']	[21]
22	probably	O	['N']	[22]
23	associated	O	['N']	[23]
24	with	O	['N']	[24]
25	olanzapine	B-Drug	['Causes']	[7]
26	.	O	['N']	[26]
#3319
0	Herein	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	describe	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	AIDS	O	['N']	[7]
8	who	O	['N']	[8]
9	presented	O	['N']	[9]
10	to	O	['N']	[10]
11	medical	O	['N']	[11]
12	attention	O	['N']	[12]
13	with	O	['N']	[13]
14	pancytopenia	B-Adverse_Effect	['N']	[14]
15	48	O	['N']	[15]
16	months	O	['N']	[16]
17	postchemotherapy	O	['N']	[17]
18	with	O	['N']	[18]
19	etoposide	O	['N']	[19]
20	,	O	['N']	[20]
21	prednisone	O	['N']	[21]
22	,	O	['N']	[22]
23	vincristine	O	['N']	[23]
24	,	O	['N']	[24]
25	cyclophosphamide	O	['N']	[25]
26	,	O	['N']	[26]
27	doxorubicin	B-Drug	['Causes']	[14]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	rituximab	O	['N']	[30]
31	(	O	['N']	[31]
32	R	O	['N']	[32]
33	-	O	['N']	[33]
34	EPOCH	O	['N']	[34]
35	)	O	['N']	[35]
36	for	O	['N']	[36]
37	diffuse	O	['N']	[37]
38	large	O	['N']	[38]
39	B	O	['N']	[39]
40	-	O	['N']	[40]
41	cell	O	['N']	[41]
42	lymphoma	O	['N']	[42]
43	.	O	['N']	[43]
#3320
0	These	O	['N']	[0]
1	findings	O	['N']	[1]
2	suggest	O	['N']	[2]
3	that	O	['N']	[3]
4	the	O	['N']	[4]
5	corneal	B	['N']	[5]
6	and	I	['N']	[6]
7	retinal	I	['N']	[7]
8	changes	I-Adverse_Effect	['N']	[8]
9	are	O	['N']	[9]
10	the	O	['N']	[10]
11	result	O	['N']	[11]
12	of	O	['N']	[12]
13	a	O	['N']	[13]
14	toxic	O	['N']	[14]
15	effect	O	['N']	[15]
16	of	O	['N']	[16]
17	tamoxifen	B-Drug	['Causes']	[8]
18	when	O	['N']	[18]
19	used	O	['N']	[19]
20	in	O	['N']	[20]
21	the	O	['N']	[21]
22	doses	O	['N']	[22]
23	and	O	['N']	[23]
24	duration	O	['N']	[24]
25	described	O	['N']	[25]
26	.	O	['N']	[26]
#3321
0	That	O	['N']	[0]
1	review	O	['N']	[1]
2	suggested	O	['N']	[2]
3	that	O	['N']	[3]
4	patients	O	['N']	[4]
5	receiving	O	['N']	[5]
6	anti	B	['N']	[6]
7	-	I	['N']	[7]
8	D	I	['N']	[8]
9	IGIV	I-Drug	['Causes']	[24]
10	be	O	['N']	[10]
11	monitored	O	['N']	[11]
12	for	O	['N']	[12]
13	those	O	['N']	[13]
14	and	O	['N']	[14]
15	other	O	['N']	[15]
16	potential	O	['N']	[16]
17	complications	O	['N']	[17]
18	of	O	['N']	[18]
19	hemoglobinemia	O	['N']	[19]
20	,	O	['N']	[20]
21	particularly	O	['N']	[21]
22	disseminated	B	['N']	[22]
23	intravascular	I	['N']	[23]
24	coagulation	I-Adverse_Effect	['N']	[24]
25	(	O	['N']	[25]
26	DIC	O	['N']	[26]
27	)	O	['N']	[27]
28	.	O	['N']	[28]
#3322
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	Clozapine	B-Drug	['Causes']	[6]
3	causes	O	['N']	[3]
4	few	O	['N']	[4]
5	extrapyramidal	B	['N']	[5]
6	symptoms	I-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	is	O	['N']	[8]
9	recommended	O	['N']	[9]
10	as	O	['N']	[10]
11	a	O	['N']	[11]
12	treatment	O	['N']	[12]
13	drug	O	['N']	[13]
14	for	O	['N']	[14]
15	severe	O	['N']	[15]
16	tardive	O	['N']	[16]
17	dyskinesia	O	['N']	[17]
18	(	O	['N']	[18]
19	TD	O	['N']	[19]
20	)	O	['N']	[20]
21	.	O	['N']	[21]
#3323
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	lung	O	['N']	[6]
7	cancer	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	bronquiloalveolar	O	['N']	[10]
11	carcinoma	O	['N']	[11]
12	(	O	['N']	[12]
13	BAC	O	['N']	[13]
14	)	O	['N']	[14]
15	presenting	O	['N']	[15]
16	with	O	['N']	[16]
17	BOOP	O	['N']	[17]
18	after	O	['N']	[18]
19	chemotherapy	O	['N']	[19]
20	with	O	['N']	[20]
21	docetaxel	O	['N']	[21]
22	and	O	['N']	[22]
23	gemcitabine	B-Drug	['Causes']	[27]
24	producing	O	['N']	[24]
25	severe	B	['N']	[25]
26	respiratory	I	['N']	[26]
27	insufficiency	I-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	simulating	O	['N']	[30]
31	a	O	['N']	[31]
32	progression	O	['N']	[32]
33	of	O	['N']	[33]
34	the	O	['N']	[34]
35	tumor	O	['N']	[35]
36	.	O	['N']	[36]
#3324
0	The	O	['N']	[0]
1	presented	O	['N']	[1]
2	patient	O	['N']	[2]
3	was	O	['N']	[3]
4	treated	O	['N']	[4]
5	with	O	['N']	[5]
6	200	O	['N']	[6]
7	mg	O	['N']	[7]
8	TCA	B-Drug	['Causes']	[13]
9	and	O	['N']	[9]
10	developed	O	['N']	[10]
11	Cushing	B	['N']	[11]
12	's	I	['N']	[12]
13	syndrome	I-Adverse_Effect	['N']	[13]
14	6	O	['N']	[14]
15	weeks	O	['N']	[15]
16	later	O	['N']	[16]
17	(	O	['N']	[17]
18	cortisol	O	['N']	[18]
19	and	O	['N']	[19]
20	ACTH	O	['N']	[20]
21	concentrations	O	['N']	[21]
22	were	O	['N']	[22]
23	below	O	['N']	[23]
24	limits	O	['N']	[24]
25	of	O	['N']	[25]
26	detection	O	['N']	[26]
27	,	O	['N']	[27]
28	TCA	O	['N']	[28]
29	concentrations	O	['N']	[29]
30	were	O	['N']	[30]
31	>	O	['N']	[31]
32	3	O	['N']	[32]
33	micrograms	O	['N']	[33]
34	/	O	['N']	[34]
35	l	O	['N']	[35]
36	)	O	['N']	[36]
37	.	O	['N']	[37]
#3325
0	Hepatotoxic	B	['N']	[0]
1	effects	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	a	O	['N']	[3]
4	child	O	['N']	[4]
5	receiving	O	['N']	[5]
6	valproate	B-Drug	['Causes']	[1]
7	and	O	['N']	[7]
8	carnitine	O	['N']	[8]
9	.	O	['N']	[9]
#3326
0	Sunburn	B-Adverse_Effect	['N']	[0]
1	may	O	['N']	[1]
2	sometimes	O	['N']	[2]
3	be	O	['N']	[3]
4	a	O	['N']	[4]
5	major	O	['N']	[5]
6	injury	O	['N']	[6]
7	in	O	['N']	[7]
8	psoralen	B-Drug	['Causes']	[0]
9	users	O	['N']	[9]
10	because	O	['N']	[10]
11	high	O	['N']	[11]
12	doses	O	['N']	[12]
13	or	O	['N']	[13]
14	inappropriate	O	['N']	[14]
15	use	O	['N']	[15]
16	of	O	['N']	[16]
17	the	O	['N']	[17]
18	drug	O	['N']	[18]
19	may	O	['N']	[19]
20	render	O	['N']	[20]
21	the	O	['N']	[21]
22	skin	O	['N']	[22]
23	extremely	O	['N']	[23]
24	sensitive	O	['N']	[24]
25	.	O	['N']	[25]
#3327
0	Recurrent	O	['N']	[0]
1	palmar	B	['N']	[1]
2	-	I	['N']	[2]
3	plantar	I	['N']	[3]
4	erythrodysaesthesia	I-Adverse_Effect	['N']	[4]
5	following	O	['N']	[5]
6	high	O	['N']	[6]
7	-	O	['N']	[7]
8	dose	O	['N']	[8]
9	cytarabine	B-Drug	['Causes']	[4]
10	treatment	O	['N']	[10]
11	for	O	['N']	[11]
12	acute	O	['N']	[12]
13	lymphoblastic	O	['N']	[13]
14	leukemia	O	['N']	[14]
15	.	O	['N']	[15]
#3328
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	one	O	['N']	[2]
3	patient	O	['N']	[3]
4	exhibited	O	['N']	[4]
5	severe	O	['N']	[5]
6	hypersensitivity	O	['N']	[6]
7	reactions	O	['N']	[7]
8	including	O	['N']	[8]
9	cardiac	B	['N']	[9]
10	arrest	I-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	apnea	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	another	O	['N']	[15]
16	four	O	['N']	[16]
17	patients	O	['N']	[17]
18	developed	O	['N']	[18]
19	eruptions	O	['N']	[19]
20	,	O	['N']	[20]
21	hypotension	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	tachycardia	O	['N']	[24]
25	soon	O	['N']	[25]
26	after	O	['N']	[26]
27	administration	O	['N']	[27]
28	of	O	['N']	[28]
29	CBDCA	B-Drug	['Causes']	[10]
30	.	O	['N']	[30]
#3329
0	Tardive	B	['N']	[0]
1	dyskinesia	I-Adverse_Effect	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	sulpiride	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#3330
0	A	O	['N']	[0]
1	51-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	developed	O	['N']	[5]
6	type	B	['N']	[6]
7	1	I	['N']	[7]
8	diabetes	I	['N']	[8]
9	mellitus	I-Adverse_Effect	['N']	[9]
10	following	O	['N']	[10]
11	24	O	['N']	[11]
12	weeks	O	['N']	[12]
13	of	O	['N']	[13]
14	treatment	O	['N']	[14]
15	with	O	['N']	[15]
16	recombinant	O	['N']	[16]
17	alpha-2b	B	['N']	[17]
18	peginterferon	I-Drug	['Causes']	[9]
19	plus	O	['N']	[19]
20	ribavirin	O	['N']	[20]
21	for	O	['N']	[21]
22	chronic	O	['N']	[22]
23	hepatitis	O	['N']	[23]
24	C.	O	['N']	[24]
#3331
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	hypoglycaemia	B-Adverse_Effect	['N']	[5]
6	after	O	['N']	[6]
7	mefloquine	B-Drug	['Causes']	[5]
8	therapy	O	['N']	[8]
9	(	O	['N']	[9]
10	1,500	O	['N']	[10]
11	mg	O	['N']	[11]
12	over	O	['N']	[12]
13	two	O	['N']	[13]
14	days	O	['N']	[14]
15	)	O	['N']	[15]
16	for	O	['N']	[16]
17	severe	O	['N']	[17]
18	gastrointestinal	O	['N']	[18]
19	cryptosporidiasis	O	['N']	[19]
20	in	O	['N']	[20]
21	a	O	['N']	[21]
22	cachectic	O	['N']	[22]
23	AIDS	O	['N']	[23]
24	patient	O	['N']	[24]
25	with	O	['N']	[25]
26	protracted	O	['N']	[26]
27	diarrhoea	O	['N']	[27]
28	.	O	['N']	[28]
#3332
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	he	O	['N']	[2]
3	developed	O	['N']	[3]
4	acute	B	['N']	[4]
5	renal	I	['N']	[5]
6	failure	I-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	hyperkalemia	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	hyperuricemia	O	['N']	[11]
12	30	O	['N']	[12]
13	d	O	['N']	[13]
14	after	O	['N']	[14]
15	receiving	O	['N']	[15]
16	the	O	['N']	[16]
17	sorafenib	B-Drug	['Causes']	[6]
18	treatment	O	['N']	[18]
19	.	O	['N']	[19]
#3333
0	After	O	['N']	[0]
1	infliximab	B-Drug	['Causes']	[18]
2	treatment	O	['N']	[2]
3	,	O	['N']	[3]
4	additional	O	['N']	[4]
5	sleep	O	['N']	[5]
6	studies	O	['N']	[6]
7	revealed	O	['N']	[7]
8	an	O	['N']	[8]
9	increase	O	['N']	[9]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	number	O	['N']	[12]
13	of	O	['N']	[13]
14	apneic	O	['N']	[14]
15	events	O	['N']	[15]
16	and	O	['N']	[16]
17	SaO2	B	['N']	[17]
18	dips	I-Adverse_Effect	['N']	[18]
19	suggesting	O	['N']	[19]
20	that	O	['N']	[20]
21	TNFalpha	O	['N']	[21]
22	plays	O	['N']	[22]
23	an	O	['N']	[23]
24	important	O	['N']	[24]
25	role	O	['N']	[25]
26	in	O	['N']	[26]
27	the	O	['N']	[27]
28	pathophysiology	O	['N']	[28]
29	of	O	['N']	[29]
30	sleep	O	['N']	[30]
31	apnea	O	['N']	[31]
32	.	O	['N']	[32]
#3334
0	The	O	['N']	[0]
1	fetal	O	['N']	[1]
2	valproate	B-Drug	['Causes']	[17]
3	syndrome	O	['N']	[3]
4	(	O	['N']	[4]
5	FVS	O	['N']	[5]
6	)	O	['N']	[6]
7	is	O	['N']	[7]
8	characterized	O	['N']	[8]
9	by	O	['N']	[9]
10	distinctive	O	['N']	[10]
11	facial	O	['N']	[11]
12	appearance	O	['N']	[12]
13	,	O	['N']	[13]
14	major	B	['N']	[14]
15	and	I	['N']	[15]
16	minor	I	['N']	[16]
17	malformations	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	developmental	O	['N']	[20]
21	delay	O	['N']	[21]
22	.	O	['N']	[22]
#3335
0	Treatment	O	['N']	[0]
1	of	O	['N']	[1]
2	lithium	B-Drug	['Causes']	[3]
3	tremor	B-Adverse_Effect	['N']	[3]
4	with	O	['N']	[4]
5	metoprolol	O	['N']	[5]
6	.	O	['N']	[6]
#3336
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	suggest	O	['N']	[2]
3	that	O	['N']	[3]
4	fluoxetine	B-Drug	['Causes']	[7]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	akathisia	B-Adverse_Effect	['N']	[7]
8	may	O	['N']	[8]
9	be	O	['N']	[9]
10	caused	O	['N']	[10]
11	by	O	['N']	[11]
12	serotonergically	O	['N']	[12]
13	mediated	O	['N']	[13]
14	inhibition	O	['N']	[14]
15	of	O	['N']	[15]
16	dopaminergic	O	['N']	[16]
17	neurotransmission	O	['N']	[17]
18	and	O	['N']	[18]
19	that	O	['N']	[19]
20	the	O	['N']	[20]
21	pathophysiology	O	['N']	[21]
22	of	O	['N']	[22]
23	fluoxetine	O	['N']	[23]
24	-	O	['N']	[24]
25	induced	O	['N']	[25]
26	akathisia	O	['N']	[26]
27	and	O	['N']	[27]
28	tricyclic	O	['N']	[28]
29	antidepressant	O	['N']	[29]
30	-	O	['N']	[30]
31	induced	O	['N']	[31]
32	"	O	['N']	[32]
33	jitteriness	O	['N']	[33]
34	"	O	['N']	[34]
35	may	O	['N']	[35]
36	be	O	['N']	[36]
37	identical	O	['N']	[37]
38	.	O	['N']	[38]
#3337
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	55-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	became	O	['N']	[7]
8	stuporous	O	['N']	[8]
9	after	O	['N']	[9]
10	overdose	B-Dose	['N']	[10]
11	with	O	['N']	[11]
12	lamotrigine	O	['N']	[12]
13	(	O	['N']	[13]
14	LTG	O	['N']	[14]
15	)	O	['N']	[15]
16	and	O	['N']	[16]
17	valproic	O	['N']	[17]
18	acid	O	['N']	[18]
19	(	O	['N']	[19]
20	VPA	B-Drug	['Dosage']	[10]
21	)	O	['N']	[21]
22	tablets	O	['N']	[22]
23	.	O	['N']	[23]
#3338
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	report	O	['N']	[2]
3	describes	O	['N']	[3]
4	a	O	['N']	[4]
5	38-year	O	['N']	[5]
6	-	O	['N']	[6]
7	old	O	['N']	[7]
8	male	O	['N']	[8]
9	in	O	['N']	[9]
10	whom	O	['N']	[10]
11	SIADH	B-Adverse_Effect	['N']	[11]
12	was	O	['N']	[12]
13	strongly	O	['N']	[13]
14	suspected	O	['N']	[14]
15	secondary	O	['N']	[15]
16	to	O	['N']	[16]
17	Tegretol	B-Drug	['Causes']	[11]
18	therapy	O	['N']	[18]
19	to	O	['N']	[19]
20	control	O	['N']	[20]
21	a	O	['N']	[21]
22	seizure	O	['N']	[22]
23	disorder	O	['N']	[23]
24	.	O	['N']	[24]
#3339
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	is	O	['N']	[3]
4	the	O	['N']	[4]
5	first	O	['N']	[5]
6	report	O	['N']	[6]
7	of	O	['N']	[7]
8	a	O	['N']	[8]
9	possible	O	['N']	[9]
10	interaction	O	['N']	[10]
11	between	O	['N']	[11]
12	propafenone	O	['N']	[12]
13	and	O	['N']	[13]
14	citalopram	B-Drug	['Causes']	[26]
15	,	O	['N']	[15]
16	which	O	['N']	[16]
17	caused	O	['N']	[17]
18	propafenone	O	['N']	[18]
19	adverse	O	['N']	[19]
20	effects	O	['N']	[20]
21	(	O	['N']	[21]
22	eg	O	['N']	[22]
23	,	O	['N']	[23]
24	dizziness	O	['N']	[24]
25	,	O	['N']	[25]
26	falls	B-Adverse_Effect	['N']	[26]
27	)	O	['N']	[27]
28	and	O	['N']	[28]
29	mimicked	O	['N']	[29]
30	coronary	O	['N']	[30]
31	artery	O	['N']	[31]
32	disease	O	['N']	[32]
33	.	O	['N']	[33]
#3340
0	PVT	O	['N']	[0]
1	during	O	['N']	[1]
2	chemotherapy	O	['N']	[2]
3	in	O	['N']	[3]
4	children	O	['N']	[4]
5	is	O	['N']	[5]
6	a	O	['N']	[6]
7	rare	O	['N']	[7]
8	event	O	['N']	[8]
9	and	O	['N']	[9]
10	appears	O	['N']	[10]
11	to	O	['N']	[11]
12	be	O	['N']	[12]
13	closely	O	['N']	[13]
14	related	O	['N']	[14]
15	to	O	['N']	[15]
16	intensive	O	['N']	[16]
17	chemotherapy	O	['N']	[17]
18	containing	O	['N']	[18]
19	busulfan	B-Drug	['Causes']	[25]
20	and	O	['N']	[20]
21	to	O	['N']	[21]
22	be	O	['N']	[22]
23	associated	O	['N']	[23]
24	with	O	['N']	[24]
25	HVOD	B-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#3341
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	concluded	O	['N']	[2]
3	that	O	['N']	[3]
4	the	O	['N']	[4]
5	aforementioned	O	['N']	[5]
6	pathological	O	['N']	[6]
7	manifestations	O	['N']	[7]
8	were	O	['N']	[8]
9	due	O	['N']	[9]
10	to	O	['N']	[10]
11	chemotherapy	O	['N']	[11]
12	and	O	['N']	[12]
13	included	O	['N']	[13]
14	a	O	['N']	[14]
15	pulmonary	B	['N']	[15]
16	adverse	I	['N']	[16]
17	reaction	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	a	O	['N']	[19]
20	feature	O	['N']	[20]
21	never	O	['N']	[21]
22	previously	O	['N']	[22]
23	associated	O	['N']	[23]
24	with	O	['N']	[24]
25	oxaliplatinum	O	['N']	[25]
26	and	O	['N']	[26]
27	5-fluorouracil	B-Drug	['Causes']	[17]
28	regimens	O	['N']	[28]
29	.	O	['N']	[29]
#3342
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	's	O	['N']	[2]
3	arthritis	B-Adverse_Effect	['N']	[3]
4	flared	O	['N']	[4]
5	after	O	['N']	[5]
6	the	O	['N']	[6]
7	second	O	['N']	[7]
8	infusion	O	['N']	[8]
9	of	O	['N']	[9]
10	infliximab	B-Drug	['Causes']	[3]
11	,	O	['N']	[11]
12	which	O	['N']	[12]
13	was	O	['N']	[13]
14	discontinued	O	['N']	[14]
15	.	O	['N']	[15]
#3343
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	present	O	['N']	[3]
4	findings	O	['N']	[4]
5	suggest	O	['N']	[5]
6	that	O	['N']	[6]
7	:	O	['N']	[7]
8	(	O	['N']	[8]
9	i	O	['N']	[9]
10	)	O	['N']	[10]
11	amantadine	O	['N']	[11]
12	probably	O	['N']	[12]
13	exerts	O	['N']	[13]
14	its	O	['N']	[14]
15	anti	O	['N']	[15]
16	-	O	['N']	[16]
17	dyskinetic	O	['N']	[17]
18	effect	O	['N']	[18]
19	by	O	['N']	[19]
20	acting	O	['N']	[20]
21	on	O	['N']	[21]
22	the	O	['N']	[22]
23	"	O	['N']	[23]
24	indirect	O	['N']	[24]
25	"	O	['N']	[25]
26	pathway	O	['N']	[26]
27	;	O	['N']	[27]
28	(	O	['N']	[28]
29	ii	O	['N']	[29]
30	)	O	['N']	[30]
31	the	O	['N']	[31]
32	pathophysiological	O	['N']	[32]
33	mechanisms	O	['N']	[33]
34	of	O	['N']	[34]
35	subthalamotomy	O	['N']	[35]
36	induced	O	['N']	[36]
37	dyskinesias	B-Adverse_Effect	['N']	[37]
38	may	O	['N']	[38]
39	differ	O	['N']	[39]
40	from	O	['N']	[40]
41	those	O	['N']	[41]
42	involved	O	['N']	[42]
43	in	O	['N']	[43]
44	L	B	['N']	[44]
45	-	I	['N']	[45]
46	dopa	I-Drug	['Causes']	[37]
47	induced	O	['N']	[47]
48	dyskinesias	O	['N']	[48]
49	;	O	['N']	[49]
50	(	O	['N']	[50]
51	iii	O	['N']	[51]
52	)	O	['N']	[52]
53	dyskinesias	O	['N']	[53]
54	induced	O	['N']	[54]
55	by	O	['N']	[55]
56	STN	O	['N']	[56]
57	surgery	O	['N']	[57]
58	resolve	O	['N']	[58]
59	spontaneously	O	['N']	[59]
60	as	O	['N']	[60]
61	compensatory	O	['N']	[61]
62	mechanisms	O	['N']	[62]
63	develop	O	['N']	[63]
64	.	O	['N']	[64]
#3344
0	When	O	['N']	[0]
1	the	O	['N']	[1]
2	data	O	['N']	[2]
3	of	O	['N']	[3]
4	the	O	['N']	[4]
5	57	O	['N']	[5]
6	patients	O	['N']	[6]
7	are	O	['N']	[7]
8	evaluated	O	['N']	[8]
9	,	O	['N']	[9]
10	a	O	['N']	[10]
11	reversible	O	['N']	[11]
12	direct	O	['N']	[12]
13	cytotoxic	B	['N']	[13]
14	effect	I-Adverse_Effect	['N']	[14]
15	of	O	['N']	[15]
16	ticlopidine	B-Drug	['Causes']	[14]
17	on	O	['N']	[17]
18	the	O	['N']	[18]
19	pluripotent	O	['N']	[19]
20	/	O	['N']	[20]
21	bipotent	O	['N']	[21]
22	hematopoietic	O	['N']	[22]
23	progenitor	O	['N']	[23]
24	stem	O	['N']	[24]
25	cell	O	['N']	[25]
26	is	O	['N']	[26]
27	proposed	O	['N']	[27]
28	.	O	['N']	[28]
#3345
0	Hepatotoxicity	B-Adverse_Effect	['N']	[0]
1	induced	O	['N']	[1]
2	by	O	['N']	[2]
3	cyproterone	B	['N']	[3]
4	acetate	I-Drug	['Causes']	[0]
5	:	O	['N']	[5]
6	a	O	['N']	[6]
7	report	O	['N']	[7]
8	of	O	['N']	[8]
9	three	O	['N']	[9]
10	cases	O	['N']	[10]
11	.	O	['N']	[11]
#3346
0	During	O	['N']	[0]
1	clarithromycin	B-Drug	['Causes']	[23]
2	coadministration	O	['N']	[2]
3	,	O	['N']	[3]
4	four	O	['N']	[4]
5	out	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	seven	O	['N']	[8]
9	patients	O	['N']	[9]
10	developed	O	['N']	[10]
11	moderate	O	['N']	[11]
12	-	O	['N']	[12]
13	to	O	['N']	[13]
14	-	O	['N']	[14]
15	severe	O	['N']	[15]
16	toxic	O	['N']	[16]
17	symptoms	O	['N']	[17]
18	of	O	['N']	[18]
19	carbamazepine	O	['N']	[19]
20	,	O	['N']	[20]
21	such	O	['N']	[21]
22	as	O	['N']	[22]
23	drowsiness	B-Adverse_Effect	['N']	[23]
24	,	O	['N']	[24]
25	dizziness	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	ataxia	O	['N']	[28]
29	,	O	['N']	[29]
30	which	O	['N']	[30]
31	resolved	O	['N']	[31]
32	within	O	['N']	[32]
33	5	O	['N']	[33]
34	days	O	['N']	[34]
35	after	O	['N']	[35]
36	clarithromycin	O	['N']	[36]
37	discontinuation	O	['N']	[37]
38	.	O	['N']	[38]
#3347
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	postulate	O	['N']	[2]
3	that	O	['N']	[3]
4	two	O	['N']	[4]
5	types	O	['N']	[5]
6	of	O	['N']	[6]
7	combined	O	['N']	[7]
8	lithium	O	['N']	[8]
9	-	O	['N']	[9]
10	neuroleptic	O	['N']	[10]
11	toxicity	O	['N']	[11]
12	occur	O	['N']	[12]
13	:	O	['N']	[13]
14	a	O	['N']	[14]
15	neuroleptic	B	['N']	[15]
16	malignant	I	['N']	[16]
17	extrapyramidal	I	['N']	[17]
18	syndrome	I-Adverse_Effect	['N']	[18]
19	and	O	['N']	[19]
20	a	O	['N']	[20]
21	lithium	O	['N']	[21]
22	toxicity	O	['N']	[22]
23	that	O	['N']	[23]
24	occurs	O	['N']	[24]
25	in	O	['N']	[25]
26	combination	O	['N']	[26]
27	with	O	['N']	[27]
28	phenothiazines	O	['N']	[28]
29	,	O	['N']	[29]
30	primarily	O	['N']	[30]
31	thioridazine	B-Drug	['Causes']	[18]
32	.	O	['N']	[32]
#3348
0	Cutaneous	B	['N']	[0]
1	necrosis	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	injection	O	['N']	[3]
4	of	O	['N']	[4]
5	polyethylene	O	['N']	[5]
6	glycol	O	['N']	[6]
7	-	O	['N']	[7]
8	modified	O	['N']	[8]
9	interferon	B	['N']	[9]
10	alfa	I-Drug	['Causes']	[1]
11	.	O	['N']	[11]
#3349
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	these	O	['N']	[4]
5	cases	O	['N']	[5]
6	represent	O	['N']	[6]
7	the	O	['N']	[7]
8	first	O	['N']	[8]
9	reports	O	['N']	[9]
10	of	O	['N']	[10]
11	TDF	B-Drug	['Causes']	[16]
12	-	O	['N']	[12]
13	associated	O	['N']	[13]
14	irreversible	B	['N']	[14]
15	renal	I	['N']	[15]
16	failure	I-Adverse_Effect	['N']	[16]
17	and	O	['N']	[17]
18	rickets	O	['N']	[18]
19	in	O	['N']	[19]
20	pediatric	O	['N']	[20]
21	patients	O	['N']	[21]
22	.	O	['N']	[22]
#3350
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	two	O	['N']	[2]
3	dark	O	['N']	[3]
4	-	O	['N']	[4]
5	skinned	O	['N']	[5]
6	patients	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	hyperpigmented	O	['N']	[9]
10	skin	O	['N']	[10]
11	and	O	['N']	[11]
12	tongue	B	['N']	[12]
13	lesions	I-Adverse_Effect	['N']	[13]
14	during	O	['N']	[14]
15	combination	O	['N']	[15]
16	therapy	O	['N']	[16]
17	with	O	['N']	[17]
18	IFN	O	['N']	[18]
19	and	O	['N']	[19]
20	ribavirin	B-Drug	['Causes']	[13]
21	.	O	['N']	[21]
#3351
0	Cutaneous	B	['N']	[0]
1	seeding	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	ultrasound	O	['N']	[3]
4	-	O	['N']	[4]
5	guided	O	['N']	[5]
6	percutaneous	O	['N']	[6]
7	ethanol	B	['N']	[7]
8	injection	I-Drug	['Causes']	[1]
9	for	O	['N']	[9]
10	treatment	O	['N']	[10]
11	of	O	['N']	[11]
12	hepatocellular	O	['N']	[12]
13	carcinoma	O	['N']	[13]
14	.	O	['N']	[14]
#3352
0	A	O	['N']	[0]
1	43-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	multiple	O	['N']	[6]
7	sclerosis	O	['N']	[7]
8	(	O	['N']	[8]
9	MS	O	['N']	[9]
10	)	O	['N']	[10]
11	had	O	['N']	[11]
12	nephrotic	B	['N']	[12]
13	syndrome	I-Adverse_Effect	['N']	[13]
14	21	O	['N']	[14]
15	months	O	['N']	[15]
16	after	O	['N']	[16]
17	starting	O	['N']	[17]
18	treatment	O	['N']	[18]
19	with	O	['N']	[19]
20	interferon	B	['N']	[20]
21	(	I	['N']	[21]
22	IFN)-beta-1b	I-Drug	['Causes']	[13]
23	(	O	['N']	[23]
24	subcutaneous	O	['N']	[24]
25	administration	O	['N']	[25]
26	)	O	['N']	[26]
27	.	O	['N']	[27]
#3353
0	Nonconvulsive	B	['N']	[0]
1	status	I	['N']	[1]
2	epilepticus	I-Adverse_Effect	['N']	[2]
3	:	O	['N']	[3]
4	the	O	['N']	[4]
5	role	O	['N']	[5]
6	of	O	['N']	[6]
7	morphine	B-Drug	['Causes']	[2]
8	and	O	['N']	[8]
9	its	O	['N']	[9]
10	antagonist	O	['N']	[10]
11	.	O	['N']	[11]
#3354
0	Ibuprofen	B-Drug	['Dosage']	[1]
1	overdose	B-Dose	['N']	[1]
2	is	O	['N']	[2]
3	usually	O	['N']	[3]
4	characterized	O	['N']	[4]
5	by	O	['N']	[5]
6	GI	O	['N']	[6]
7	upset	O	['N']	[7]
8	,	O	['N']	[8]
9	dizziness	O	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	mild	O	['N']	[12]
13	sedation	O	['N']	[13]
14	.	O	['N']	[14]
#3355
0	The	O	['N']	[0]
1	use	O	['N']	[1]
2	of	O	['N']	[2]
3	cyclosporin	B-Drug	['Causes']	[11]
4	has	O	['N']	[4]
5	been	O	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	the	O	['N']	[8]
9	development	O	['N']	[9]
10	of	O	['N']	[10]
11	cholelithiasis	B-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	transplant	O	['N']	[13]
14	recipients	O	['N']	[14]
15	.	O	['N']	[15]
#3356
0	Less	O	['N']	[0]
1	common	O	['N']	[1]
2	adverse	O	['N']	[2]
3	events	O	['N']	[3]
4	to	O	['N']	[4]
5	dapsone	B-Drug	['Causes']	[16]
6	include	O	['N']	[6]
7	the	O	['N']	[7]
8	idiosyncratic	O	['N']	[8]
9	reactions	O	['N']	[9]
10	of	O	['N']	[10]
11	leukopenia	O	['N']	[11]
12	and	O	['N']	[12]
13	agranulocytosis	O	['N']	[13]
14	,	O	['N']	[14]
15	cutaneous	B	['N']	[15]
16	eruptions	I-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	peripheral	O	['N']	[18]
19	neuropathy	O	['N']	[19]
20	,	O	['N']	[20]
21	psychosis	O	['N']	[21]
22	,	O	['N']	[22]
23	toxic	O	['N']	[23]
24	hepatitis	O	['N']	[24]
25	,	O	['N']	[25]
26	cholestatic	O	['N']	[26]
27	jaundice	O	['N']	[27]
28	,	O	['N']	[28]
29	nephrotic	O	['N']	[29]
30	syndrome	O	['N']	[30]
31	,	O	['N']	[31]
32	renal	O	['N']	[32]
33	papillary	O	['N']	[33]
34	necrosis	O	['N']	[34]
35	,	O	['N']	[35]
36	severe	O	['N']	[36]
37	hypoalbuminemia	O	['N']	[37]
38	without	O	['N']	[38]
39	proteinuria	O	['N']	[39]
40	,	O	['N']	[40]
41	an	O	['N']	[41]
42	infectious	O	['N']	[42]
43	mononucleosis	O	['N']	[43]
44	-	O	['N']	[44]
45	like	O	['N']	[45]
46	syndrome	O	['N']	[46]
47	,	O	['N']	[47]
48	and	O	['N']	[48]
49	minor	O	['N']	[49]
50	neurological	O	['N']	[50]
51	and	O	['N']	[51]
52	gastrointestinal	O	['N']	[52]
53	complaints	O	['N']	[53]
54	.	O	['N']	[54]
#3357
0	After	O	['N']	[0]
1	therapy	O	['N']	[1]
2	for	O	['N']	[2]
3	diabetic	O	['N']	[3]
4	coma	O	['N']	[4]
5	with	O	['N']	[5]
6	insulin	O	['N']	[6]
7	(	O	['N']	[7]
8	containing	O	['N']	[8]
9	the	O	['N']	[9]
10	preservative	O	['N']	[10]
11	cresol	B-Drug	['Causes']	[37]
12	)	O	['N']	[12]
13	and	O	['N']	[13]
14	electrolyte	O	['N']	[14]
15	solutions	O	['N']	[15]
16	was	O	['N']	[16]
17	started	O	['N']	[17]
18	,	O	['N']	[18]
19	the	O	['N']	[19]
20	patient	O	['N']	[20]
21	complained	O	['N']	[21]
22	of	O	['N']	[22]
23	increasing	O	['N']	[23]
24	myalgia	O	['N']	[24]
25	,	O	['N']	[25]
26	developed	O	['N']	[26]
27	a	O	['N']	[27]
28	high	O	['N']	[28]
29	fever	O	['N']	[29]
30	and	O	['N']	[30]
31	respiratory	O	['N']	[31]
32	and	O	['N']	[32]
33	metabolic	O	['N']	[33]
34	acidosis	O	['N']	[34]
35	and	O	['N']	[35]
36	lost	B	['N']	[36]
37	consciousness	I-Adverse_Effect	['N']	[37]
38	.	O	['N']	[38]
#3358
0	Niacin	B-Drug	['Causes']	[6]
1	causes	O	['N']	[1]
2	a	O	['N']	[2]
3	reversible	B	['N']	[3]
4	toxic	I	['N']	[4]
5	cystoid	I	['N']	[5]
6	maculopathy	I-Adverse_Effect	['N']	[6]
7	that	O	['N']	[7]
8	occurs	O	['N']	[8]
9	in	O	['N']	[9]
10	approximately	O	['N']	[10]
11	0.67	O	['N']	[11]
12	%	O	['N']	[12]
13	of	O	['N']	[13]
14	patients	O	['N']	[14]
15	taking	O	['N']	[15]
16	high	O	['N']	[16]
17	doses	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	drug	O	['N']	[20]
21	.	O	['N']	[21]
#3359
0	Bortezomib	B-Drug	['Causes']	[10]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	paralytic	O	['N']	[3]
4	ileus	O	['N']	[4]
5	is	O	['N']	[5]
6	a	O	['N']	[6]
7	potential	O	['N']	[7]
8	gastrointestinal	B	['N']	[8]
9	side	I	['N']	[9]
10	effect	I-Adverse_Effect	['N']	[10]
11	of	O	['N']	[11]
12	this	O	['N']	[12]
13	first	O	['N']	[13]
14	-	O	['N']	[14]
15	in	O	['N']	[15]
16	-	O	['N']	[16]
17	class	O	['N']	[17]
18	anticancer	O	['N']	[18]
19	proteasome	O	['N']	[19]
20	inhibitor	O	['N']	[20]
21	.	O	['N']	[21]
#3360
0	Methemoglobinemia	B-Adverse_Effect	['N']	[0]
1	after	O	['N']	[1]
2	axillary	O	['N']	[2]
3	block	O	['N']	[3]
4	with	O	['N']	[4]
5	bupivacaine	O	['N']	[5]
6	and	O	['N']	[6]
7	additional	O	['N']	[7]
8	injection	O	['N']	[8]
9	of	O	['N']	[9]
10	lidocaine	B-Drug	['Causes']	[0]
11	in	O	['N']	[11]
12	the	O	['N']	[12]
13	operative	O	['N']	[13]
14	field	O	['N']	[14]
15	.	O	['N']	[15]
#3361
0	We	O	['N']	[0]
1	cared	O	['N']	[1]
2	for	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	progressive	O	['N']	[6]
7	renal	O	['N']	[7]
8	impairment	O	['N']	[8]
9	who	O	['N']	[9]
10	presented	O	['N']	[10]
11	with	O	['N']	[11]
12	blurred	O	['N']	[12]
13	vision	O	['N']	[13]
14	,	O	['N']	[14]
15	QRS	B	['N']	[15]
16	broadening	I-Adverse_Effect	['N']	[16]
17	and	O	['N']	[17]
18	cardiac	O	['N']	[18]
19	failure	O	['N']	[19]
20	due	O	['N']	[20]
21	to	O	['N']	[21]
22	chronic	O	['N']	[22]
23	cibenzoline	B-Drug	['Causes']	[16]
24	intoxication	O	['N']	[24]
25	.	O	['N']	[25]
#3362
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	37-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	African-	O	['N']	[6]
7	American	O	['N']	[7]
8	man	O	['N']	[8]
9	with	O	['N']	[9]
10	G6PD	O	['N']	[10]
11	deficiency	O	['N']	[11]
12	developed	O	['N']	[12]
13	hemolytic	O	['N']	[13]
14	anemia	O	['N']	[14]
15	,	O	['N']	[15]
16	hepatitis	B-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	orthostatic	O	['N']	[18]
19	hypotension	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	aseptic	O	['N']	[22]
23	meningitis	O	['N']	[23]
24	simultaneously	O	['N']	[24]
25	after	O	['N']	[25]
26	using	O	['N']	[26]
27	trimethoprim	O	['N']	[27]
28	-	O	['N']	[28]
29	sulfamethoxazole	B-Drug	['Causes']	[16]
30	.	O	['N']	[30]
#3363
0	Gemcitabine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	related	O	['N']	[2]
3	radiation	B	['N']	[3]
4	recall	I-Adverse_Effect	['N']	[4]
5	preferentially	O	['N']	[5]
6	involves	O	['N']	[6]
7	internal	O	['N']	[7]
8	tissue	O	['N']	[8]
9	and	O	['N']	[9]
10	organs	O	['N']	[10]
11	.	O	['N']	[11]
#3364
0	Zoledronic	B	['N']	[0]
1	acid	I-Drug	['Causes']	[5]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	severe	B	['N']	[4]
5	hypocalcaemia	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	prostate	O	['N']	[8]
9	cancer	O	['N']	[9]
10	patient	O	['N']	[10]
11	with	O	['N']	[11]
12	extensive	O	['N']	[12]
13	osteoblastic	O	['N']	[13]
14	bone	O	['N']	[14]
15	metastases	O	['N']	[15]
16	.	O	['N']	[16]
#3365
0	Gallstones	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	bile	O	['N']	[2]
3	sludge	O	['N']	[3]
4	are	O	['N']	[4]
5	common	O	['N']	[5]
6	side	O	['N']	[6]
7	effects	O	['N']	[7]
8	of	O	['N']	[8]
9	octreotide	B-Drug	['Causes']	[0]
10	therapy	O	['N']	[10]
11	but	O	['N']	[11]
12	rarely	O	['N']	[12]
13	become	O	['N']	[13]
14	symptomatic	O	['N']	[14]
15	or	O	['N']	[15]
16	require	O	['N']	[16]
17	treatment	O	['N']	[17]
18	.	O	['N']	[18]
#3366
0	Oral	O	['N']	[0]
1	25-hydroxyvitain	B	['N']	[1]
2	D3	I-Drug	['Causes']	[10]
3	in	O	['N']	[3]
4	treatment	O	['N']	[4]
5	of	O	['N']	[5]
6	osteomalacia	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	ileal	B	['N']	[9]
10	resection	I-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	cholestyramine	O	['N']	[12]
13	therapy	O	['N']	[13]
14	.	O	['N']	[14]
#3367
0	Abrupt	O	['N']	[0]
1	,	O	['N']	[1]
2	accidental	O	['N']	[2]
3	withdrawal	O	['N']	[3]
4	of	O	['N']	[4]
5	trihexyphenidyl	B-Drug	['Causes']	[20]
6	triggered	O	['N']	[6]
7	severe	O	['N']	[7]
8	exacerbation	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	cranial	O	['N']	[11]
12	dystonia	O	['N']	[12]
13	associated	O	['N']	[13]
14	with	O	['N']	[14]
15	inspiratory	O	['N']	[15]
16	stridor	O	['N']	[16]
17	and	O	['N']	[17]
18	acute	B	['N']	[18]
19	respiratory	I	['N']	[19]
20	difficulties	I-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	prompting	O	['N']	[22]
23	emergency	O	['N']	[23]
24	admission	O	['N']	[24]
25	.	O	['N']	[25]
#3368
0	To	O	['N']	[0]
1	develop	O	['N']	[1]
2	information	O	['N']	[2]
3	on	O	['N']	[3]
4	the	O	['N']	[4]
5	relative	O	['N']	[5]
6	rarity	O	['N']	[6]
7	or	O	['N']	[7]
8	frequency	O	['N']	[8]
9	of	O	['N']	[9]
10	neurologic	O	['N']	[10]
11	worsening	O	['N']	[11]
12	with	O	['N']	[12]
13	the	O	['N']	[13]
14	initiation	O	['N']	[14]
15	of	O	['N']	[15]
16	penicillamine	B-Drug	['Causes']	[40]
17	therapy	O	['N']	[17]
18	,	O	['N']	[18]
19	we	O	['N']	[19]
20	conducted	O	['N']	[20]
21	a	O	['N']	[21]
22	retrospective	O	['N']	[22]
23	survey	O	['N']	[23]
24	of	O	['N']	[24]
25	25	O	['N']	[25]
26	additional	O	['N']	[26]
27	patients	O	['N']	[27]
28	with	O	['N']	[28]
29	Wilson	O	['N']	[29]
30	's	O	['N']	[30]
31	disease	O	['N']	[31]
32	who	O	['N']	[32]
33	met	O	['N']	[33]
34	the	O	['N']	[34]
35	criteria	O	['N']	[35]
36	of	O	['N']	[36]
37	presenting	O	['N']	[37]
38	with	O	['N']	[38]
39	neurologic	B	['N']	[39]
40	disease	I-Adverse_Effect	['N']	[40]
41	and	O	['N']	[41]
42	having	O	['N']	[42]
43	been	O	['N']	[43]
44	treated	O	['N']	[44]
45	with	O	['N']	[45]
46	penicillamine	O	['N']	[46]
47	.	O	['N']	[47]
#3369
0	Fatal	B	['N']	[0]
1	pulmonary	I	['N']	[1]
2	fibrosis	I-Adverse_Effect	['N']	[2]
3	following	O	['N']	[3]
4	1,3-bis(2-chloroethyl)-1-nitrosourea	O	['N']	[4]
5	(	O	['N']	[5]
6	BCNU	B-Drug	['Causes']	[2]
7	)	O	['N']	[7]
8	therapy	O	['N']	[8]
9	.	O	['N']	[9]
#3370
0	Methylphenidate	O	['N']	[0]
1	(	O	['N']	[1]
2	Ritalin)-associated	-	['N']	[2]
3	cataract	B-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	glaucoma	O	['N']	[5]
6	.	O	['N']	[6]
#3371
0	Lethargy	O	['N']	[0]
1	in	O	['N']	[1]
2	a	O	['N']	[2]
3	newborn	O	['N']	[3]
4	:	O	['N']	[4]
5	lithium	B-Drug	['Causes']	[6]
6	toxicity	I-Adverse_Effect	['N']	[6]
7	or	O	['N']	[7]
8	lab	O	['N']	[8]
9	error	O	['N']	[9]
10	?	O	['N']	[10]
#3372
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	syndrome	O	['N']	[6]
7	of	O	['N']	[7]
8	inappropriate	O	['N']	[8]
9	antidiuretic	O	['N']	[9]
10	hormone	O	['N']	[10]
11	(	O	['N']	[11]
12	SIADH	B-Adverse_Effect	['N']	[12]
13	)	O	['N']	[13]
14	secondary	O	['N']	[14]
15	to	O	['N']	[15]
16	cisplatin	B-Drug	['Causes']	[12]
17	therapy	O	['N']	[17]
18	in	O	['N']	[18]
19	a	O	['N']	[19]
20	patient	O	['N']	[20]
21	with	O	['N']	[21]
22	advanced	O	['N']	[22]
23	-	O	['N']	[23]
24	stage	O	['N']	[24]
25	large	O	['N']	[25]
26	cell	O	['N']	[26]
27	neuroendocrine	O	['N']	[27]
28	carcinoma	O	['N']	[28]
29	of	O	['N']	[29]
30	the	O	['N']	[30]
31	cervix	O	['N']	[31]
32	.	O	['N']	[32]
#3373
0	The	O	['N']	[0]
1	3-week	O	['N']	[1]
2	sulphasalazine	B-Drug	['Causes']	[3]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	strikes	O	['N']	[4]
5	again	O	['N']	[5]
6	.	O	['N']	[6]
#3374
0	Four	O	['N']	[0]
1	patients	O	['N']	[1]
2	receiving	O	['N']	[2]
3	high	B	['N']	[3]
4	-	I	['N']	[4]
5	dose	I-Dose	['N']	[5]
6	tamoxifen	B-Drug	['Dosage']	[5]
7	for	O	['N']	[7]
8	greater	O	['N']	[8]
9	than	O	['N']	[9]
10	1	O	['N']	[10]
11	year	O	['N']	[11]
12	have	O	['N']	[12]
13	demonstrated	O	['N']	[13]
14	similar	O	['N']	[14]
15	retinal	O	['N']	[15]
16	changes	O	['N']	[16]
17	.	O	['N']	[17]
#3375
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	2	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	serotonin	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	with	O	['N']	[9]
10	serious	O	['N']	[10]
11	extrapyramidal	B	['N']	[11]
12	movement	I	['N']	[12]
13	disorders	I-Adverse_Effect	['N']	[13]
14	occurring	O	['N']	[14]
15	when	O	['N']	[15]
16	metoclopramide	B-Drug	['Causes']	[13]
17	was	O	['N']	[17]
18	coadministered	O	['N']	[18]
19	with	O	['N']	[19]
20	sertraline	O	['N']	[20]
21	or	O	['N']	[21]
22	venlafaxine	O	['N']	[22]
23	.	O	['N']	[23]
#3376
0	After	O	['N']	[0]
1	having	O	['N']	[1]
2	received	O	['N']	[2]
3	gemcitabine	B-Drug	['Causes']	[16]
4	on	O	['N']	[4]
5	day	O	['N']	[5]
6	1	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	second	O	['N']	[9]
10	course	O	['N']	[10]
11	,	O	['N']	[11]
12	the	O	['N']	[12]
13	patient	O	['N']	[13]
14	developed	O	['N']	[14]
15	dry	B	['N']	[15]
16	cough	I-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	subfebrile	O	['N']	[18]
19	temperatures	O	['N']	[19]
20	and	O	['N']	[20]
21	dyspnea	O	['N']	[21]
22	within	O	['N']	[22]
23	48	O	['N']	[23]
24	h.	O	['N']	[24]
#3377
0	After	O	['N']	[0]
1	a	O	['N']	[1]
2	second	O	['N']	[2]
3	dose	O	['N']	[3]
4	of	O	['N']	[4]
5	metoclopramide	B-Drug	['Causes']	[27]
6	,	O	['N']	[6]
7	these	O	['N']	[7]
8	symptoms	O	['N']	[8]
9	recurred	O	['N']	[9]
10	and	O	['N']	[10]
11	were	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	confusion	O	['N']	[14]
15	,	O	['N']	[15]
16	agitation	O	['N']	[16]
17	,	O	['N']	[17]
18	fever	O	['N']	[18]
19	,	O	['N']	[19]
20	diaphoresis	O	['N']	[20]
21	,	O	['N']	[21]
22	tachypnea	O	['N']	[22]
23	,	O	['N']	[23]
24	tachycardia	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	hypertension	B-Adverse_Effect	['N']	[27]
28	.	O	['N']	[28]
#3378
0	Alopecia	B-Adverse_Effect	['N']	[0]
1	,	O	['N']	[1]
2	nausea	O	['N']	[2]
3	,	O	['N']	[3]
4	and	O	['N']	[4]
5	vomiting	O	['N']	[5]
6	were	O	['N']	[6]
7	attributed	O	['N']	[7]
8	to	O	['N']	[8]
9	the	O	['N']	[9]
10	cyclophosphamide	B-Drug	['Causes']	[0]
11	component	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	therapy	O	['N']	[14]
15	.	O	['N']	[15]
#3379
0	Psychosis	B-Adverse_Effect	['N']	[0]
1	in	O	['N']	[1]
2	a	O	['N']	[2]
3	12-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	HIV	O	['N']	[6]
7	-	O	['N']	[7]
8	positive	O	['N']	[8]
9	girl	O	['N']	[9]
10	with	O	['N']	[10]
11	an	O	['N']	[11]
12	increased	O	['N']	[12]
13	serum	O	['N']	[13]
14	concentration	O	['N']	[14]
15	of	O	['N']	[15]
16	efavirenz	B-Drug	['Causes']	[0]
17	.	O	['N']	[17]
#3380
0	Disopyramide	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	heart	B	['N']	[3]
4	block	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#3381
0	Hepatic	B	['N']	[0]
1	damage	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	danazol	B-Drug	['Causes']	[1]
4	treatment	O	['N']	[4]
5	.	O	['N']	[5]
#3382
0	A	O	['N']	[0]
1	variety	O	['N']	[1]
2	of	O	['N']	[2]
3	movement	B	['N']	[3]
4	disorders	I-Adverse_Effect	['N']	[4]
5	are	O	['N']	[5]
6	known	O	['N']	[6]
7	to	O	['N']	[7]
8	occur	O	['N']	[8]
9	in	O	['N']	[9]
10	association	O	['N']	[10]
11	with	O	['N']	[11]
12	carbamazepine	B-Drug	['Causes']	[4]
13	(	O	['N']	[13]
14	CBZ	O	['N']	[14]
15	)	O	['N']	[15]
16	therapy	O	['N']	[16]
17	in	O	['N']	[17]
18	adults	O	['N']	[18]
19	and	O	['N']	[19]
20	children	O	['N']	[20]
21	,	O	['N']	[21]
22	but	O	['N']	[22]
23	development	O	['N']	[23]
24	of	O	['N']	[24]
25	tics	O	['N']	[25]
26	has	O	['N']	[26]
27	been	O	['N']	[27]
28	described	O	['N']	[28]
29	infrequently	O	['N']	[29]
30	and	O	['N']	[30]
31	only	O	['N']	[31]
32	in	O	['N']	[32]
33	patients	O	['N']	[33]
34	with	O	['N']	[34]
35	underlying	O	['N']	[35]
36	Tourette	O	['N']	[36]
37	's	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	or	O	['N']	[39]
40	other	O	['N']	[40]
41	movement	O	['N']	[41]
42	disorders	O	['N']	[42]
43	.	O	['N']	[43]
#3383
0	An	O	['N']	[0]
1	apparent	O	['N']	[1]
2	link	O	['N']	[2]
3	is	O	['N']	[3]
4	described	O	['N']	[4]
5	between	O	['N']	[5]
6	the	O	['N']	[6]
7	use	O	['N']	[7]
8	of	O	['N']	[8]
9	MMF	O	['N']	[9]
10	with	O	['N']	[10]
11	prednisone	B-Drug	['Causes']	[23]
12	to	O	['N']	[12]
13	treat	O	['N']	[13]
14	pemphigus	O	['N']	[14]
15	vulgaris	O	['N']	[15]
16	and	O	['N']	[16]
17	the	O	['N']	[17]
18	development	O	['N']	[18]
19	of	O	['N']	[19]
20	red	B	['N']	[20]
21	blood	I	['N']	[21]
22	cell	I	['N']	[22]
23	anemia	I-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#3384
0	Favorable	O	['N']	[0]
1	outcome	O	['N']	[1]
2	of	O	['N']	[2]
3	de	O	['N']	[3]
4	novo	O	['N']	[4]
5	hepatitis	B	['N']	[5]
6	B	I	['N']	[6]
7	infection	I-Adverse_Effect	['N']	[7]
8	after	O	['N']	[8]
9	liver	O	['N']	[9]
10	transplantation	O	['N']	[10]
11	with	O	['N']	[11]
12	lamivudine	B-Drug	['Causes']	[7]
13	and	O	['N']	[13]
14	adefovir	O	['N']	[14]
15	therapy	O	['N']	[15]
16	.	O	['N']	[16]
#3385
0	To	O	['N']	[0]
1	date	O	['N']	[1]
2	,	O	['N']	[2]
3	there	O	['N']	[3]
4	have	O	['N']	[4]
5	been	O	['N']	[5]
6	few	O	['N']	[6]
7	reports	O	['N']	[7]
8	of	O	['N']	[8]
9	visual	B	['N']	[9]
10	disturbances	I-Adverse_Effect	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	BTX	B	['N']	[13]
14	-	I	['N']	[14]
15	B	I-Drug	['Causes']	[10]
16	use	O	['N']	[16]
17	.	O	['N']	[17]
#3386
0	With	O	['N']	[0]
1	the	O	['N']	[1]
2	use	O	['N']	[2]
3	of	O	['N']	[3]
4	optical	O	['N']	[4]
5	coherence	O	['N']	[5]
6	tomography	O	['N']	[6]
7	(	O	['N']	[7]
8	OCT	O	['N']	[8]
9	)	O	['N']	[9]
10	,	O	['N']	[10]
11	two	O	['N']	[11]
12	patients	O	['N']	[12]
13	with	O	['N']	[13]
14	IFN	B-Drug	['Causes']	[22]
15	-	O	['N']	[15]
16	associated	O	['N']	[16]
17	retinopathy	O	['N']	[17]
18	who	O	['N']	[18]
19	had	O	['N']	[19]
20	developed	O	['N']	[20]
21	macular	B	['N']	[21]
22	edema	I-Adverse_Effect	['N']	[22]
23	and	O	['N']	[23]
24	reduced	O	['N']	[24]
25	visual	O	['N']	[25]
26	acuity	O	['N']	[26]
27	during	O	['N']	[27]
28	the	O	['N']	[28]
29	clinical	O	['N']	[29]
30	course	O	['N']	[30]
31	of	O	['N']	[31]
32	IFN	O	['N']	[32]
33	therapy	O	['N']	[33]
34	were	O	['N']	[34]
35	observed	O	['N']	[35]
36	.	O	['N']	[36]
#3387
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	basilar	B	['N']	[3]
4	invagination	I-Adverse_Effect	['N']	[4]
5	which	O	['N']	[5]
6	is	O	['N']	[6]
7	thought	O	['N']	[7]
8	to	O	['N']	[8]
9	have	O	['N']	[9]
10	arisen	O	['N']	[10]
11	from	O	['N']	[11]
12	the	O	['N']	[12]
13	patient	O	['N']	[13]
14	's	O	['N']	[14]
15	intrauterine	O	['N']	[15]
16	exposure	O	['N']	[16]
17	to	O	['N']	[17]
18	phenytoin	B-Drug	['Causes']	[4]
19	is	O	['N']	[19]
20	presented	O	['N']	[20]
21	.	O	['N']	[21]
#3388
0	Interaction	B-Adverse_Effect	['N']	[0]
1	between	O	['N']	[1]
2	tacrolimus	O	['N']	[2]
3	and	O	['N']	[3]
4	nefazodone	B-Drug	['Causes']	[0]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	stable	O	['N']	[7]
8	renal	O	['N']	[8]
9	transplant	O	['N']	[9]
10	recipient	O	['N']	[10]
11	.	O	['N']	[11]
#3389
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	transitional	O	['N']	[5]
6	cell	O	['N']	[6]
7	carcinoma	O	['N']	[7]
8	of	O	['N']	[8]
9	the	O	['N']	[9]
10	renal	O	['N']	[10]
11	pelvis	O	['N']	[11]
12	who	O	['N']	[12]
13	developed	O	['N']	[13]
14	respiratory	O	['N']	[14]
15	dysfunction	O	['N']	[15]
16	and	O	['N']	[16]
17	an	O	['N']	[17]
18	abnormal	B	['N']	[18]
19	chest	I	['N']	[19]
20	x	I	['N']	[20]
21	-	I	['N']	[21]
22	ray	I	['N']	[22]
23	with	I	['N']	[23]
24	diffuse	I	['N']	[24]
25	interstitial	I	['N']	[25]
26	opacities	I-Adverse_Effect	['N']	[26]
27	while	O	['N']	[27]
28	on	O	['N']	[28]
29	chemotherapy	O	['N']	[29]
30	with	O	['N']	[30]
31	piritrexim	B-Drug	['Causes']	[26]
32	,	O	['N']	[32]
33	a	O	['N']	[33]
34	methotrexate	O	['N']	[34]
35	analog	O	['N']	[35]
36	.	O	['N']	[36]
#3390
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	advanced	O	['N']	[5]
6	ovarian	O	['N']	[6]
7	carcinoma	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	difficulty	B	['N']	[10]
11	walking	I-Adverse_Effect	['N']	[11]
12	because	O	['N']	[12]
13	of	O	['N']	[13]
14	marked	O	['N']	[14]
15	pain	O	['N']	[15]
16	in	O	['N']	[16]
17	the	O	['N']	[17]
18	lower	O	['N']	[18]
19	extremities	O	['N']	[19]
20	and	O	['N']	[20]
21	loss	O	['N']	[21]
22	of	O	['N']	[22]
23	proprioception	O	['N']	[23]
24	25	O	['N']	[24]
25	days	O	['N']	[25]
26	after	O	['N']	[26]
27	treatment	O	['N']	[27]
28	with	O	['N']	[28]
29	weekly	O	['N']	[29]
30	taxol	B-Drug	['Causes']	[11]
31	(	O	['N']	[31]
32	80	O	['N']	[32]
33	mg	O	['N']	[33]
34	/	O	['N']	[34]
35	m(2)x3	O	['N']	[35]
36	)	O	['N']	[36]
37	.	O	['N']	[37]
#3391
0	AIM	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	three	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	extensive	O	['N']	[7]
8	skin	B	['N']	[8]
9	necrosis	I-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	cirrhotic	O	['N']	[11]
12	patients	O	['N']	[12]
13	treated	O	['N']	[13]
14	with	O	['N']	[14]
15	the	O	['N']	[15]
16	vasoconstrictor	O	['N']	[16]
17	agent	O	['N']	[17]
18	terlipressin	B-Drug	['Causes']	[9]
19	(	O	['N']	[19]
20	Glypressin	O	['N']	[20]
21	)	O	['N']	[21]
22	.	O	['N']	[22]
#3392
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	1	O	['N']	[2]
3	,	O	['N']	[3]
4	a	O	['N']	[4]
5	total	O	['N']	[5]
6	daily	O	['N']	[6]
7	dose	O	['N']	[7]
8	of	O	['N']	[8]
9	25	O	['N']	[9]
10	mg	O	['N']	[10]
11	sertraline	O	['N']	[11]
12	,	O	['N']	[12]
13	with	O	['N']	[13]
14	nondetectable	O	['N']	[14]
15	sertraline	O	['N']	[15]
16	and	O	['N']	[16]
17	desmethylsertraline	B-Drug	['Causes']	[29]
18	blood	O	['N']	[18]
19	levels	O	['N']	[19]
20	,	O	['N']	[20]
21	resulted	O	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	doubling	B	['N']	[24]
25	of	I	['N']	[25]
26	the	I	['N']	[26]
27	lamotrigine	I	['N']	[27]
28	blood	I	['N']	[28]
29	level	I-Adverse_Effect	['N']	[29]
30	with	O	['N']	[30]
31	symptoms	O	['N']	[31]
32	of	O	['N']	[32]
33	toxicity	O	['N']	[33]
34	.	O	['N']	[34]
#3393
0	She	O	['N']	[0]
1	developed	O	['N']	[1]
2	a	O	['N']	[2]
3	generalized	O	['N']	[3]
4	rash	O	['N']	[4]
5	and	O	['N']	[5]
6	itching	O	['N']	[6]
7	,	O	['N']	[7]
8	sore	B	['N']	[8]
9	throat	I-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	dizziness	O	['N']	[12]
13	approximately	O	['N']	[13]
14	4	O	['N']	[14]
15	hours	O	['N']	[15]
16	after	O	['N']	[16]
17	the	O	['N']	[17]
18	first	O	['N']	[18]
19	dose	O	['N']	[19]
20	of	O	['N']	[20]
21	capecitabine	B-Drug	['Causes']	[9]
22	.	O	['N']	[22]
#3394
0	On	O	['N']	[0]
1	the	O	['N']	[1]
2	fifth	O	['N']	[2]
3	day	O	['N']	[3]
4	of	O	['N']	[4]
5	tocolysis	O	['N']	[5]
6	with	O	['N']	[6]
7	magnesium	O	['N']	[7]
8	sulfate	O	['N']	[8]
9	,	O	['N']	[9]
10	nifedipine	O	['N']	[10]
11	,	O	['N']	[11]
12	terbutaline	O	['N']	[12]
13	and	O	['N']	[13]
14	betamethasone	B-Drug	['Causes']	[16]
15	,	O	['N']	[15]
16	edema	B-Adverse_Effect	['N']	[16]
17	developed	O	['N']	[17]
18	in	O	['N']	[18]
19	both	O	['N']	[19]
20	labia	O	['N']	[20]
21	.	O	['N']	[21]
#3395
0	Prolongation	B	['N']	[0]
1	of	I	['N']	[1]
2	the	I	['N']	[2]
3	QT	I	['N']	[3]
4	interval	I-Adverse_Effect	['N']	[4]
5	observed	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	Japanese	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	vivax	O	['N']	[11]
12	malaria	O	['N']	[12]
13	following	O	['N']	[13]
14	treatment	O	['N']	[14]
15	with	O	['N']	[15]
16	halofantrine	B-Drug	['Causes']	[4]
17	.	O	['N']	[17]
#3396
0	In	O	['N']	[0]
1	contrast	O	['N']	[1]
2	to	O	['N']	[2]
3	chronic	O	['N']	[3]
4	or	O	['N']	[4]
5	subacute	B	['N']	[5]
6	thyroiditis	I-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	Graves	O	['N']	[8]
9	'	O	['N']	[9]
10	disease	O	['N']	[10]
11	rarely	O	['N']	[11]
12	complicates	O	['N']	[12]
13	IFN	B	['N']	[13]
14	-	I	['N']	[14]
15	alpha	I-Drug	['Causes']	[6]
16	therapy	O	['N']	[16]
17	for	O	['N']	[17]
18	chronic	O	['N']	[18]
19	viral	O	['N']	[19]
20	C	O	['N']	[20]
21	hepatitis	O	['N']	[21]
22	.	O	['N']	[22]
#3397
0	During	O	['N']	[0]
1	clarithromycin	B-Drug	['Causes']	[25]
2	coadministration	O	['N']	[2]
3	,	O	['N']	[3]
4	four	O	['N']	[4]
5	out	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	seven	O	['N']	[8]
9	patients	O	['N']	[9]
10	developed	O	['N']	[10]
11	moderate	O	['N']	[11]
12	-	O	['N']	[12]
13	to	O	['N']	[13]
14	-	O	['N']	[14]
15	severe	O	['N']	[15]
16	toxic	O	['N']	[16]
17	symptoms	O	['N']	[17]
18	of	O	['N']	[18]
19	carbamazepine	O	['N']	[19]
20	,	O	['N']	[20]
21	such	O	['N']	[21]
22	as	O	['N']	[22]
23	drowsiness	O	['N']	[23]
24	,	O	['N']	[24]
25	dizziness	B-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	ataxia	O	['N']	[28]
29	,	O	['N']	[29]
30	which	O	['N']	[30]
31	resolved	O	['N']	[31]
32	within	O	['N']	[32]
33	5	O	['N']	[33]
34	days	O	['N']	[34]
35	after	O	['N']	[35]
36	clarithromycin	O	['N']	[36]
37	discontinuation	O	['N']	[37]
38	.	O	['N']	[38]
#3398
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	82-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	ventricular	O	['N']	[9]
10	tachycardia	O	['N']	[10]
11	and	O	['N']	[11]
12	Torsades	B	['N']	[12]
13	de	I	['N']	[13]
14	Pointes	I-Adverse_Effect	['N']	[14]
15	(	O	['N']	[15]
16	TdP	O	['N']	[16]
17	)	O	['N']	[17]
18	after	O	['N']	[18]
19	oral	O	['N']	[19]
20	administration	O	['N']	[20]
21	of	O	['N']	[21]
22	garenoxacin	B-Drug	['Causes']	[14]
23	,	O	['N']	[23]
24	a	O	['N']	[24]
25	novel	O	['N']	[25]
26	quinolone	O	['N']	[26]
27	antibiotic	O	['N']	[27]
28	agent	O	['N']	[28]
29	that	O	['N']	[29]
30	differs	O	['N']	[30]
31	from	O	['N']	[31]
32	the	O	['N']	[32]
33	third	O	['N']	[33]
34	-	O	['N']	[34]
35	generation	O	['N']	[35]
36	quinolones	O	['N']	[36]
37	,	O	['N']	[37]
38	for	O	['N']	[38]
39	pneumonia	O	['N']	[39]
40	.	O	['N']	[40]
#3399
0	The	O	['N']	[0]
1	association	O	['N']	[1]
2	of	O	['N']	[2]
3	phenothiazine	B-Drug	['Causes']	[8]
4	overdose	O	['N']	[4]
5	and	O	['N']	[5]
6	respiratory	B	['N']	[6]
7	distress	I	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	merits	O	['N']	[9]
10	consideration	O	['N']	[10]
11	.	O	['N']	[11]
#3400
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	infectious	O	['N']	[6]
7	mononucleosis	O	['N']	[7]
8	treated	O	['N']	[8]
9	with	O	['N']	[9]
10	cephalexin	B-Drug	['Causes']	[15]
11	who	O	['N']	[11]
12	later	O	['N']	[12]
13	showed	O	['N']	[13]
14	a	O	['N']	[14]
15	rash	B-Adverse_Effect	['N']	[15]
16	is	O	['N']	[16]
17	presented	O	['N']	[17]
18	and	O	['N']	[18]
19	the	O	['N']	[19]
20	previous	O	['N']	[20]
21	literature	O	['N']	[21]
22	is	O	['N']	[22]
23	reviewed	O	['N']	[23]
24	.	O	['N']	[24]
#3401
0	Skin	B	['N']	[0]
1	rash	I-Adverse_Effect	['N']	[1]
2	began	O	['N']	[2]
3	after	O	['N']	[3]
4	2	O	['N']	[4]
5	weeks	O	['N']	[5]
6	of	O	['N']	[6]
7	treatment	O	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	signs	O	['N']	[10]
11	of	O	['N']	[11]
12	hepatocellular	O	['N']	[12]
13	failure	O	['N']	[13]
14	developed	O	['N']	[14]
15	3	O	['N']	[15]
16	weeks	O	['N']	[16]
17	after	O	['N']	[17]
18	phenobarbital	B-Drug	['Causes']	[1]
19	had	O	['N']	[19]
20	been	O	['N']	[20]
21	started	O	['N']	[21]
22	.	O	['N']	[22]
#3402
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	a	O	['N']	[3]
4	53-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	man	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	acute	B	['N']	[10]
11	pneumonitis	I-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	bleomycin	B-Drug	['Causes']	[11]
14	and	O	['N']	[14]
15	moderate	O	['N']	[15]
16	oxygen	O	['N']	[16]
17	administration	O	['N']	[17]
18	is	O	['N']	[18]
19	presented	O	['N']	[19]
20	.	O	['N']	[20]
#3403
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	suffering	O	['N']	[2]
3	from	O	['N']	[3]
4	heparin	B-Drug	['Causes']	[9]
5	-	O	['N']	[5]
6	associated	O	['N']	[6]
7	thrombocytopenia	O	['N']	[7]
8	(	O	['N']	[8]
9	HAT	B-Adverse_Effect	['N']	[9]
10	)	O	['N']	[10]
11	,	O	['N']	[11]
12	recurrent	O	['N']	[12]
13	arteriothromboses	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	acute	O	['N']	[16]
17	renal	O	['N']	[17]
18	failure	O	['N']	[18]
19	after	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	standard	O	['N']	[22]
23	heparin	O	['N']	[23]
24	is	O	['N']	[24]
25	described	O	['N']	[25]
26	.	O	['N']	[26]
#3404
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	de	O	['N']	[6]
7	novo	O	['N']	[7]
8	asthma	B-Adverse_Effect	['N']	[8]
9	following	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	the	O	['N']	[12]
13	angiotensin	O	['N']	[13]
14	converting	O	['N']	[14]
15	enzyme	O	['N']	[15]
16	(	O	['N']	[16]
17	ACE	O	['N']	[17]
18	)	O	['N']	[18]
19	inhibitor	O	['N']	[19]
20	captopril	B-Drug	['Causes']	[8]
21	.	O	['N']	[21]
#3405
0	A	O	['N']	[0]
1	literature	O	['N']	[1]
2	review	O	['N']	[2]
3	revealed	O	['N']	[3]
4	83	O	['N']	[4]
5	other	O	['N']	[5]
6	reported	O	['N']	[6]
7	cases	O	['N']	[7]
8	of	O	['N']	[8]
9	rifampicin	B-Drug	['Causes']	[13]
10	-	O	['N']	[10]
11	induced	O	['N']	[11]
12	renal	B	['N']	[12]
13	insufficiency	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#3406
0	Chronic	B	['N']	[0]
1	photosensitivity	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	hydrochlorothiazide	B-Drug	['Causes']	[1]
5	ingestion	O	['N']	[5]
6	occurred	O	['N']	[6]
7	in	O	['N']	[7]
8	four	O	['N']	[8]
9	patients	O	['N']	[9]
10	.	O	['N']	[10]
#3407
0	5-Fluorouracil	B-Drug	['Causes']	[1]
1	cardiotoxicity	B-Adverse_Effect	['N']	[1]
2	complicating	O	['N']	[2]
3	treatment	O	['N']	[3]
4	of	O	['N']	[4]
5	stage	O	['N']	[5]
6	IIB	O	['N']	[6]
7	cervical	O	['N']	[7]
8	cancer	O	['N']	[8]
9	--	O	['N']	[9]
10	case	O	['N']	[10]
11	report	O	['N']	[11]
12	.	O	['N']	[12]
#3408
0	Flecainide	B-Drug	['Causes']	[7]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	rare	O	['N']	[3]
4	cause	O	['N']	[4]
5	of	O	['N']	[5]
6	hypersensitivity	B	['N']	[6]
7	pneumonitis	I-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	few	O	['N']	[10]
11	cases	O	['N']	[11]
12	have	O	['N']	[12]
13	been	O	['N']	[13]
14	reported	O	['N']	[14]
15	.	O	['N']	[15]
#3409
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	serotonin	B	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	interaction	O	['N']	[11]
12	between	O	['N']	[12]
13	fentanyl	B-Drug	['Causes']	[8]
14	and	O	['N']	[14]
15	citalopram	O	['N']	[15]
16	,	O	['N']	[16]
17	as	O	['N']	[17]
18	evidenced	O	['N']	[18]
19	by	O	['N']	[19]
20	medication	O	['N']	[20]
21	history	O	['N']	[21]
22	,	O	['N']	[22]
23	clinical	O	['N']	[23]
24	features	O	['N']	[24]
25	and	O	['N']	[25]
26	reversal	O	['N']	[26]
27	following	O	['N']	[27]
28	discontinuation	O	['N']	[28]
29	of	O	['N']	[29]
30	fentanyl	O	['N']	[30]
31	.	O	['N']	[31]
#3410
0	Our	O	['N']	[0]
1	report	O	['N']	[1]
2	suggested	O	['N']	[2]
3	that	O	['N']	[3]
4	CBDCA	B-Drug	['Causes']	[5]
5	hypersensitivity	B-Adverse_Effect	['N']	[5]
6	was	O	['N']	[6]
7	correlated	O	['N']	[7]
8	with	O	['N']	[8]
9	the	O	['N']	[9]
10	total	O	['N']	[10]
11	dose	O	['N']	[11]
12	of	O	['N']	[12]
13	previously	O	['N']	[13]
14	administered	O	['N']	[14]
15	platinum	O	['N']	[15]
16	agents	O	['N']	[16]
17	and	O	['N']	[17]
18	that	O	['N']	[18]
19	CBDCA	O	['N']	[19]
20	should	O	['N']	[20]
21	be	O	['N']	[21]
22	excluded	O	['N']	[22]
23	in	O	['N']	[23]
24	patients	O	['N']	[24]
25	who	O	['N']	[25]
26	have	O	['N']	[26]
27	received	O	['N']	[27]
28	multiple	O	['N']	[28]
29	platinum	O	['N']	[29]
30	-	O	['N']	[30]
31	based	O	['N']	[31]
32	chemotherapy	O	['N']	[32]
33	,	O	['N']	[33]
34	even	O	['N']	[34]
35	in	O	['N']	[35]
36	platinum	O	['N']	[36]
37	-	O	['N']	[37]
38	sensitive	O	['N']	[38]
39	cases	O	['N']	[39]
40	,	O	['N']	[40]
41	because	O	['N']	[41]
42	CBDCA	O	['N']	[42]
43	hypersensitivity	O	['N']	[43]
44	can	O	['N']	[44]
45	occur	O	['N']	[45]
46	even	O	['N']	[46]
47	with	O	['N']	[47]
48	low	O	['N']	[48]
49	-	O	['N']	[49]
50	dose	O	['N']	[50]
51	CBDCA	O	['N']	[51]
52	administration	O	['N']	[52]
53	.	O	['N']	[53]
#3411
0	Antithyroid	O	['N']	[0]
1	treatment	O	['N']	[1]
2	with	O	['N']	[2]
3	propylthiouracil	O	['N']	[3]
4	(	O	['N']	[4]
5	PTU	B-Drug	['Causes']	[11]
6	)	O	['N']	[6]
7	resulted	O	['N']	[7]
8	in	O	['N']	[8]
9	elevated	B	['N']	[9]
10	hepatic	I	['N']	[10]
11	enzymes	I-Adverse_Effect	['N']	[11]
12	and	O	['N']	[12]
13	after	O	['N']	[13]
14	the	O	['N']	[14]
15	12th	O	['N']	[15]
16	week	O	['N']	[16]
17	of	O	['N']	[17]
18	pregnancy	O	['N']	[18]
19	treatment	O	['N']	[19]
20	was	O	['N']	[20]
21	changed	O	['N']	[21]
22	to	O	['N']	[22]
23	carbimazole	O	['N']	[23]
24	(	O	['N']	[24]
25	CBZ	O	['N']	[25]
26	)	O	['N']	[26]
27	.	O	['N']	[27]
#3412
0	It	O	['N']	[0]
1	remains	O	['N']	[1]
2	to	O	['N']	[2]
3	be	O	['N']	[3]
4	seen	O	['N']	[4]
5	whether	O	['N']	[5]
6	the	O	['N']	[6]
7	hepatotoxicity	B-Adverse_Effect	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	troglitazone	B-Drug	['Causes']	[7]
11	is	O	['N']	[11]
12	a	O	['N']	[12]
13	drug	O	['N']	[13]
14	-	O	['N']	[14]
15	class	O	['N']	[15]
16	effect	O	['N']	[16]
17	or	O	['N']	[17]
18	specific	O	['N']	[18]
19	to	O	['N']	[19]
20	troglitazone	O	['N']	[20]
21	.	O	['N']	[21]
#3413
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	non	B	['N']	[6]
7	-	I	['N']	[7]
8	convulsive	I	['N']	[8]
9	status	I	['N']	[9]
10	epilepticus	I-Adverse_Effect	['N']	[10]
11	provoked	O	['N']	[11]
12	by	O	['N']	[12]
13	tiagabine	B-Drug	['Causes']	[10]
14	in	O	['N']	[14]
15	adolescent	O	['N']	[15]
16	patients	O	['N']	[16]
17	.	O	['N']	[17]
#3414
0	Rapid	O	['N']	[0]
1	onset	O	['N']	[1]
2	of	O	['N']	[2]
3	muscle	O	['N']	[3]
4	weakness	O	['N']	[4]
5	(	O	['N']	[5]
6	rhabdomyolysis	B-Adverse_Effect	['N']	[6]
7	)	O	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	the	O	['N']	[10]
11	combined	O	['N']	[11]
12	use	O	['N']	[12]
13	of	O	['N']	[13]
14	simvastatin	O	['N']	[14]
15	and	O	['N']	[15]
16	colchicine	B-Drug	['Causes']	[6]
17	.	O	['N']	[17]
#3415
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	paper	O	['N']	[2]
3	,	O	['N']	[3]
4	we	O	['N']	[4]
5	report	O	['N']	[5]
6	a	O	['N']	[6]
7	case	O	['N']	[7]
8	of	O	['N']	[8]
9	3	O	['N']	[9]
10	years	O	['N']	[10]
11	-	O	['N']	[11]
12	old	O	['N']	[12]
13	boy	O	['N']	[13]
14	who	O	['N']	[14]
15	developed	O	['N']	[15]
16	acute	B	['N']	[16]
17	onset	I	['N']	[17]
18	tetraparesia	I-Adverse_Effect	['N']	[18]
19	following	O	['N']	[19]
20	a	O	['N']	[20]
21	viral	O	['N']	[21]
22	respiratory	O	['N']	[22]
23	infecction	O	['N']	[23]
24	and	O	['N']	[24]
25	hepatitis	B	['N']	[25]
26	B	I	['N']	[26]
27	vaccination	I-Drug	['Causes']	[18]
28	.	O	['N']	[28]
#3416
0	Our	O	['N']	[0]
1	literature	O	['N']	[1]
2	review	O	['N']	[2]
3	revealed	O	['N']	[3]
4	an	O	['N']	[4]
5	additional	O	['N']	[5]
6	six	O	['N']	[6]
7	cases	O	['N']	[7]
8	of	O	['N']	[8]
9	onset	O	['N']	[9]
10	of	O	['N']	[10]
11	inflammatory	B	['N']	[11]
12	arthritis	I-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	MS	O	['N']	[14]
15	patients	O	['N']	[15]
16	receiving	O	['N']	[16]
17	IFN	B	['N']	[17]
18	-	I	['N']	[18]
19	beta	I-Drug	['Causes']	[12]
20	.	O	['N']	[20]
#3417
0	In	O	['N']	[0]
1	a	O	['N']	[1]
2	postural	O	['N']	[2]
3	challenge	O	['N']	[3]
4	test	O	['N']	[4]
5	after	O	['N']	[5]
6	administration	O	['N']	[6]
7	of	O	['N']	[7]
8	isosorbide	B	['N']	[8]
9	dinitrate	I-Drug	['Causes']	[26]
10	(	O	['N']	[10]
11	5	O	['N']	[11]
12	mg	O	['N']	[12]
13	)	O	['N']	[13]
14	,	O	['N']	[14]
15	blood	O	['N']	[15]
16	pressure	O	['N']	[16]
17	decreased	O	['N']	[17]
18	from	O	['N']	[18]
19	120/67	O	['N']	[19]
20	to	O	['N']	[20]
21	65/35	O	['N']	[21]
22	mmHg	O	['N']	[22]
23	,	O	['N']	[23]
24	followed	O	['N']	[24]
25	by	O	['N']	[25]
26	syncope	B-Adverse_Effect	['N']	[26]
27	with	O	['N']	[27]
28	a	O	['N']	[28]
29	sudden	O	['N']	[29]
30	decrease	O	['N']	[30]
31	in	O	['N']	[31]
32	pulse	O	['N']	[32]
33	rate	O	['N']	[33]
34	from	O	['N']	[34]
35	85	O	['N']	[35]
36	to	O	['N']	[36]
37	60	O	['N']	[37]
38	beats	O	['N']	[38]
39	/	O	['N']	[39]
40	min	O	['N']	[40]
41	.	O	['N']	[41]
#3418
0	The	O	['N']	[0]
1	second	O	['N']	[1]
2	had	O	['N']	[2]
3	acute	O	['N']	[3]
4	cystitis	O	['N']	[4]
5	and	O	['N']	[5]
6	was	O	['N']	[6]
7	treated	O	['N']	[7]
8	by	O	['N']	[8]
9	sulphonamide	O	['N']	[9]
10	and	O	['N']	[10]
11	the	O	['N']	[11]
12	third	O	['N']	[12]
13	developed	O	['N']	[13]
14	myopia	B-Adverse_Effect	['N']	[14]
15	coincident	O	['N']	[15]
16	with	O	['N']	[16]
17	metronidazole	B-Drug	['Causes']	[14]
18	treatment	O	['N']	[18]
19	for	O	['N']	[19]
20	trichomonas	O	['N']	[20]
21	vaginalis	O	['N']	[21]
22	.	O	['N']	[22]
#3419
0	Extrapyramidal	B	['N']	[0]
1	side	I	['N']	[1]
2	effects	I-Adverse_Effect	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	some	O	['N']	[5]
6	selective	O	['N']	[6]
7	serotonin	O	['N']	[7]
8	reuptake	O	['N']	[8]
9	inhibitors	O	['N']	[9]
10	(	O	['N']	[10]
11	SSRIs	O	['N']	[11]
12	)	O	['N']	[12]
13	,	O	['N']	[13]
14	i.e.	O	['N']	[14]
15	fluoxetine	O	['N']	[15]
16	and	O	['N']	[16]
17	sertraline	B-Drug	['Causes']	[2]
18	,	O	['N']	[18]
19	have	O	['N']	[19]
20	been	O	['N']	[20]
21	previously	O	['N']	[21]
22	reported	O	['N']	[22]
23	in	O	['N']	[23]
24	patients	O	['N']	[24]
25	with	O	['N']	[25]
26	depression	O	['N']	[26]
27	and	O	['N']	[27]
28	obsessive	O	['N']	[28]
29	-	O	['N']	[29]
30	compulsive	O	['N']	[30]
31	disorder	O	['N']	[31]
32	(	O	['N']	[32]
33	OCD	O	['N']	[33]
34	)	O	['N']	[34]
35	.	O	['N']	[35]
#3420
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	report	O	['N']	[2]
3	describes	O	['N']	[3]
4	an	O	['N']	[4]
5	adolescent	O	['N']	[5]
6	with	O	['N']	[6]
7	severe	B	['N']	[7]
8	lupus	I	['N']	[8]
9	erythematosus	I-Adverse_Effect	['N']	[9]
10	who	O	['N']	[10]
11	received	O	['N']	[11]
12	cyclophosphamide	B-Drug	['Causes']	[9]
13	(	O	['N']	[13]
14	CY	O	['N']	[14]
15	)	O	['N']	[15]
16	paired	O	['N']	[16]
17	with	O	['N']	[17]
18	taste	O	['N']	[18]
19	(	O	['N']	[19]
20	cod	O	['N']	[20]
21	liver	O	['N']	[21]
22	oil	O	['N']	[22]
23	)	O	['N']	[23]
24	and	O	['N']	[24]
25	smell	O	['N']	[25]
26	(	O	['N']	[26]
27	rose	O	['N']	[27]
28	perfume	O	['N']	[28]
29	)	O	['N']	[29]
30	as	O	['N']	[30]
31	conditioned	O	['N']	[31]
32	stimuli	O	['N']	[32]
33	.	O	['N']	[33]
#3421
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	HUS	B-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	an	O	['N']	[7]
8	advanced	O	['N']	[8]
9	ovarian	O	['N']	[9]
10	cancer	O	['N']	[10]
11	patient	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	carboplatin	B-Drug	['Causes']	[5]
15	and	O	['N']	[15]
16	gemcitabine	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	described	O	['N']	[19]
20	its	O	['N']	[20]
21	favorable	O	['N']	[21]
22	outcome	O	['N']	[22]
23	after	O	['N']	[23]
24	chemotherapy	O	['N']	[24]
25	interruption	O	['N']	[25]
26	and	O	['N']	[26]
27	supportive	O	['N']	[27]
28	care	O	['N']	[28]
29	with	O	['N']	[29]
30	a	O	['N']	[30]
31	1	O	['N']	[31]
32	year	O	['N']	[32]
33	follow	O	['N']	[33]
34	-	O	['N']	[34]
35	up	O	['N']	[35]
36	.	O	['N']	[36]
#3422
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	68-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	developed	O	['N']	[7]
8	intense	O	['N']	[8]
9	conjunctival	O	['N']	[9]
10	hyperemia	O	['N']	[10]
11	and	O	['N']	[11]
12	cystoid	B	['N']	[12]
13	macula	I	['N']	[13]
14	edema	I-Adverse_Effect	['N']	[14]
15	after	O	['N']	[15]
16	switching	O	['N']	[16]
17	from	O	['N']	[17]
18	latanoprost	B-Drug	['Causes']	[14]
19	to	O	['N']	[19]
20	bimatoprost	O	['N']	[20]
21	9	O	['N']	[21]
22	months	O	['N']	[22]
23	after	O	['N']	[23]
24	cataract	O	['N']	[24]
25	surgery	O	['N']	[25]
26	in	O	['N']	[26]
27	an	O	['N']	[27]
28	eye	O	['N']	[28]
29	at	O	['N']	[29]
30	low	O	['N']	[30]
31	-	O	['N']	[31]
32	risk	O	['N']	[32]
33	for	O	['N']	[33]
34	this	O	['N']	[34]
35	cystoid	O	['N']	[35]
36	macular	O	['N']	[36]
37	edema	O	['N']	[37]
38	.	O	['N']	[38]
#3423
0	The	O	['N']	[0]
1	possibility	O	['N']	[1]
2	of	O	['N']	[2]
3	severe	O	['N']	[3]
4	rhabdomyolysis	O	['N']	[4]
5	should	O	['N']	[5]
6	be	O	['N']	[6]
7	considered	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	with	O	['N']	[11]
12	water	B	['N']	[12]
13	intoxication	I-Adverse_Effect	['N']	[13]
14	due	O	['N']	[14]
15	to	O	['N']	[15]
16	massive	O	['N']	[16]
17	ingestion	O	['N']	[17]
18	of	O	['N']	[18]
19	caffeine	B-Drug	['Causes']	[13]
20	-	O	['N']	[20]
21	containing	O	['N']	[21]
22	beverages	O	['N']	[22]
23	.	O	['N']	[23]
#3424
0	Rifampin	O	['N']	[0]
1	(	O	['N']	[1]
2	RFP	B-Drug	['Causes']	[19]
3	)	O	['N']	[3]
4	increases	O	['N']	[4]
5	hepatic	O	['N']	[5]
6	microsomal	O	['N']	[6]
7	enzyme	O	['N']	[7]
8	activity	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	there	O	['N']	[11]
12	are	O	['N']	[12]
13	case	O	['N']	[13]
14	reports	O	['N']	[14]
15	of	O	['N']	[15]
16	RFP	O	['N']	[16]
17	-	O	['N']	[17]
18	induced	O	['N']	[18]
19	hypothyroidism	B-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	all	O	['N']	[21]
22	associated	O	['N']	[22]
23	with	O	['N']	[23]
24	Hashimoto	O	['N']	[24]
25	's	O	['N']	[25]
26	thyroiditis	O	['N']	[26]
27	.	O	['N']	[27]
#3425
0	Factors	O	['N']	[0]
1	that	O	['N']	[1]
2	suggested	O	['N']	[2]
3	an	O	['N']	[3]
4	association	O	['N']	[4]
5	between	O	['N']	[5]
6	the	O	['N']	[6]
7	severe	B	['N']	[7]
8	angioedematous	I	['N']	[8]
9	reaction	I-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	BP	B-Drug	['Causes']	[9]
12	topical	O	['N']	[12]
13	application	O	['N']	[13]
14	include	O	['N']	[14]
15	the	O	['N']	[15]
16	strong	O	['N']	[16]
17	reaction	O	['N']	[17]
18	to	O	['N']	[18]
19	BP	O	['N']	[19]
20	in	O	['N']	[20]
21	the	O	['N']	[21]
22	patch	O	['N']	[22]
23	-	O	['N']	[23]
24	test	O	['N']	[24]
25	,	O	['N']	[25]
26	the	O	['N']	[26]
27	temporal	O	['N']	[27]
28	relationship	O	['N']	[28]
29	,	O	['N']	[29]
30	the	O	['N']	[30]
31	complete	O	['N']	[31]
32	resolution	O	['N']	[32]
33	of	O	['N']	[33]
34	symptoms	O	['N']	[34]
35	after	O	['N']	[35]
36	the	O	['N']	[36]
37	drug	O	['N']	[37]
38	was	O	['N']	[38]
39	withdrawn	O	['N']	[39]
40	and	O	['N']	[40]
41	the	O	['N']	[41]
42	absence	O	['N']	[42]
43	of	O	['N']	[43]
44	other	O	['N']	[44]
45	identified	O	['N']	[45]
46	explanations	O	['N']	[46]
47	.	O	['N']	[47]
#3426
0	A	O	['N']	[0]
1	16-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	developed	O	['N']	[5]
6	fever	O	['N']	[6]
7	,	O	['N']	[7]
8	generalized	B	['N']	[8]
9	rigidity	I-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	leukocytosis	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	increased	O	['N']	[14]
15	serum	O	['N']	[15]
16	transaminase	O	['N']	[16]
17	and	O	['N']	[17]
18	creatine	O	['N']	[18]
19	kinase	O	['N']	[19]
20	levels	O	['N']	[20]
21	while	O	['N']	[21]
22	receiving	O	['N']	[22]
23	treatment	O	['N']	[23]
24	with	O	['N']	[24]
25	olanzapine	B-Drug	['Causes']	[9]
26	and	O	['N']	[26]
27	lithium	O	['N']	[27]
28	.	O	['N']	[28]
#3427
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	68-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	developed	O	['N']	[7]
8	intense	O	['N']	[8]
9	conjunctival	O	['N']	[9]
10	hyperemia	O	['N']	[10]
11	and	O	['N']	[11]
12	cystoid	O	['N']	[12]
13	macula	O	['N']	[13]
14	edema	O	['N']	[14]
15	after	O	['N']	[15]
16	switching	O	['N']	[16]
17	from	O	['N']	[17]
18	latanoprost	O	['N']	[18]
19	to	O	['N']	[19]
20	bimatoprost	B-Drug	['Causes']	[37]
21	9	O	['N']	[21]
22	months	O	['N']	[22]
23	after	O	['N']	[23]
24	cataract	O	['N']	[24]
25	surgery	O	['N']	[25]
26	in	O	['N']	[26]
27	an	O	['N']	[27]
28	eye	O	['N']	[28]
29	at	O	['N']	[29]
30	low	O	['N']	[30]
31	-	O	['N']	[31]
32	risk	O	['N']	[32]
33	for	O	['N']	[33]
34	this	O	['N']	[34]
35	cystoid	B	['N']	[35]
36	macular	I	['N']	[36]
37	edema	I-Adverse_Effect	['N']	[37]
38	.	O	['N']	[38]
#3428
0	A	O	['N']	[0]
1	55-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	presented	O	['N']	[5]
6	an	O	['N']	[6]
7	episode	O	['N']	[7]
8	of	O	['N']	[8]
9	acute	O	['N']	[9]
10	urticaria	O	['N']	[10]
11	and	O	['N']	[11]
12	labial	B	['N']	[12]
13	angioedema	I-Adverse_Effect	['N']	[13]
14	60	O	['N']	[14]
15	minutes	O	['N']	[15]
16	after	O	['N']	[16]
17	ingesting	O	['N']	[17]
18	500	O	['N']	[18]
19	mg	O	['N']	[19]
20	of	O	['N']	[20]
21	cloxacillin	B-Drug	['Causes']	[13]
22	for	O	['N']	[22]
23	a	O	['N']	[23]
24	skin	O	['N']	[24]
25	abscess	O	['N']	[25]
26	.	O	['N']	[26]
#3429
0	Videopolysomnographic	O	['N']	[0]
1	and	O	['N']	[1]
2	pharmacokinetic	O	['N']	[2]
3	studies	O	['N']	[3]
4	with	O	['N']	[4]
5	monitoring	O	['N']	[5]
6	of	O	['N']	[6]
7	plasma	O	['N']	[7]
8	levodopa	B-Drug	['Causes']	[35]
9	levels	O	['N']	[9]
10	demonstrated	O	['N']	[10]
11	marked	O	['N']	[11]
12	motor	O	['N']	[12]
13	hyperactivity	O	['N']	[13]
14	during	O	['N']	[14]
15	augmentation	O	['N']	[15]
16	,	O	['N']	[16]
17	with	O	['N']	[17]
18	anarchic	O	['N']	[18]
19	discharges	O	['N']	[19]
20	of	O	['N']	[20]
21	motor	O	['N']	[21]
22	unit	O	['N']	[22]
23	potentials	O	['N']	[23]
24	,	O	['N']	[24]
25	tonic	O	['N']	[25]
26	grouped	O	['N']	[26]
27	discharges	O	['N']	[27]
28	and	O	['N']	[28]
29	flexor	O	['N']	[29]
30	spasms	O	['N']	[30]
31	,	O	['N']	[31]
32	associated	O	['N']	[32]
33	with	O	['N']	[33]
34	painful	B	['N']	[34]
35	dysesthesia	I-Adverse_Effect	['N']	[35]
36	.	O	['N']	[36]
#3430
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	4	O	['N']	[2]
3	patients	O	['N']	[3]
4	,	O	['N']	[4]
5	2	O	['N']	[5]
6	on	O	['N']	[6]
7	methylphenidate	B-Drug	['Causes']	[23]
8	and	O	['N']	[8]
9	2	O	['N']	[9]
10	on	O	['N']	[10]
11	dextroamphetamine	O	['N']	[11]
12	who	O	['N']	[12]
13	presented	O	['N']	[13]
14	with	O	['N']	[14]
15	acral	O	['N']	[15]
16	cyanosis	O	['N']	[16]
17	,	O	['N']	[17]
18	livedo	O	['N']	[18]
19	reticularis	O	['N']	[19]
20	,	O	['N']	[20]
21	or	O	['N']	[21]
22	Raynaud	B	['N']	[22]
23	phenomenon	I-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#3431
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	46-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	African	O	['N']	[6]
7	-	O	['N']	[7]
8	American	O	['N']	[8]
9	man	O	['N']	[9]
10	with	O	['N']	[10]
11	AIDS	O	['N']	[11]
12	who	O	['N']	[12]
13	was	O	['N']	[13]
14	admitted	O	['N']	[14]
15	on	O	['N']	[15]
16	two	O	['N']	[16]
17	different	O	['N']	[17]
18	occasions	O	['N']	[18]
19	within	O	['N']	[19]
20	three	O	['N']	[20]
21	weeks	O	['N']	[21]
22	for	O	['N']	[22]
23	signs	O	['N']	[23]
24	and	O	['N']	[24]
25	symptoms	O	['N']	[25]
26	of	O	['N']	[26]
27	meningitis	B-Adverse_Effect	['N']	[27]
28	after	O	['N']	[28]
29	using	O	['N']	[29]
30	trimethoprim	O	['N']	[30]
31	/	O	['N']	[31]
32	sulfamethoxazole	O	['N']	[32]
33	(	O	['N']	[33]
34	TMP	B-Drug	['Causes']	[27]
35	/	O	['N']	[35]
36	SMX	O	['N']	[36]
37	)	O	['N']	[37]
38	.	O	['N']	[38]
#3432
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	in	O	['N']	[4]
5	whom	O	['N']	[5]
6	the	O	['N']	[6]
7	anti	O	['N']	[7]
8	-	O	['N']	[8]
9	depressant	O	['N']	[9]
10	trazodone	O	['N']	[10]
11	hydrochloride	O	['N']	[11]
12	(	O	['N']	[12]
13	Molipaxin	B-Drug	['Causes']	[25]
14	,	O	['N']	[14]
15	Roussel	O	['N']	[15]
16	)	O	['N']	[16]
17	,	O	['N']	[17]
18	a	O	['N']	[18]
19	serotonin	O	['N']	[19]
20	antagonist	O	['N']	[20]
21	,	O	['N']	[21]
22	provoked	O	['N']	[22]
23	generalized	B	['N']	[23]
24	pustular	I	['N']	[24]
25	psoriasis	I-Adverse_Effect	['N']	[25]
26	(	O	['N']	[26]
27	GPP	O	['N']	[27]
28	)	O	['N']	[28]
29	.	O	['N']	[29]
#3433
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	advanced	O	['N']	[5]
6	ovarian	O	['N']	[6]
7	carcinoma	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	difficulty	O	['N']	[10]
11	walking	O	['N']	[11]
12	because	O	['N']	[12]
13	of	O	['N']	[13]
14	marked	O	['N']	[14]
15	pain	O	['N']	[15]
16	in	O	['N']	[16]
17	the	O	['N']	[17]
18	lower	O	['N']	[18]
19	extremities	O	['N']	[19]
20	and	O	['N']	[20]
21	loss	O	['N']	[21]
22	of	O	['N']	[22]
23	proprioception	O	['N']	[23]
24	25	O	['N']	[24]
25	days	O	['N']	[25]
26	after	O	['N']	[26]
27	treatment	O	['N']	[27]
28	with	O	['N']	[28]
29	weekly	O	['N']	[29]
30	taxol	B-Drug	['Dosage']	[35]
31	(	O	['N']	[31]
32	80	B	['N']	[32]
33	mg	I	['N']	[33]
34	/	I	['N']	[34]
35	m(2)x3	I-Dose	['N']	[35]
36	)	O	['N']	[36]
37	.	O	['N']	[37]
#3434
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	subarachnoid	O	['N']	[6]
7	haemorrhage	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	an	O	['N']	[10]
11	acute	O	['N']	[11]
12	life	O	['N']	[12]
13	-	O	['N']	[13]
14	threatening	O	['N']	[14]
15	pseudo	B	['N']	[15]
16	-	I	['N']	[16]
17	obstruction	I	['N']	[17]
18	of	I	['N']	[18]
19	the	I	['N']	[19]
20	colon	I-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	a	O	['N']	[22]
23	variant	O	['N']	[23]
24	of	O	['N']	[24]
25	adynamic	O	['N']	[25]
26	ileus	O	['N']	[26]
27	,	O	['N']	[27]
28	while	O	['N']	[28]
29	being	O	['N']	[29]
30	treated	O	['N']	[30]
31	with	O	['N']	[31]
32	intravenous	O	['N']	[32]
33	nimodipine	B-Drug	['Causes']	[20]
34	.	O	['N']	[34]
#3435
0	After	O	['N']	[0]
1	only	O	['N']	[1]
2	the	O	['N']	[2]
3	third	O	['N']	[3]
4	dose	O	['N']	[4]
5	of	O	['N']	[5]
6	pentamidine	B-Drug	['Causes']	[18]
7	,	O	['N']	[7]
8	it	O	['N']	[8]
9	was	O	['N']	[9]
10	noted	O	['N']	[10]
11	that	O	['N']	[11]
12	the	O	['N']	[12]
13	patient	O	['N']	[13]
14	's	O	['N']	[14]
15	heart	B	['N']	[15]
16	rate	I	['N']	[16]
17	had	I	['N']	[17]
18	decreased	I-Adverse_Effect	['N']	[18]
19	to	O	['N']	[19]
20	48	O	['N']	[20]
21	beats	O	['N']	[21]
22	/	O	['N']	[22]
23	minute	O	['N']	[23]
24	.	O	['N']	[24]
#3436
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	73-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	serious	O	['N']	[9]
10	systemic	B	['N']	[10]
11	vasculitis	I-Adverse_Effect	['N']	[11]
12	with	O	['N']	[12]
13	associated	O	['N']	[13]
14	thrombocytopenia	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	course	O	['N']	[17]
18	of	O	['N']	[18]
19	treatment	O	['N']	[19]
20	with	O	['N']	[20]
21	cladribine	B-Drug	['Causes']	[11]
22	.	O	['N']	[22]
#3437
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	,	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	had	O	['N']	[7]
8	undergone	O	['N']	[8]
9	a	O	['N']	[9]
10	renal	O	['N']	[10]
11	transplantation	O	['N']	[11]
12	as	O	['N']	[12]
13	a	O	['N']	[13]
14	result	O	['N']	[14]
15	of	O	['N']	[15]
16	malignant	O	['N']	[16]
17	hypertension	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	who	O	['N']	[20]
21	was	O	['N']	[21]
22	on	O	['N']	[22]
23	immunosuppressive	O	['N']	[23]
24	therapy	O	['N']	[24]
25	consisting	O	['N']	[25]
26	of	O	['N']	[26]
27	cyclosporin	O	['N']	[27]
28	,	O	['N']	[28]
29	prednisone	O	['N']	[29]
30	and	O	['N']	[30]
31	azathioprine	B-Drug	['Causes']	[34]
32	,	O	['N']	[32]
33	developed	O	['N']	[33]
34	thrombosis	B-Adverse_Effect	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	central	O	['N']	[37]
38	retinal	O	['N']	[38]
39	vein	O	['N']	[39]
40	5	O	['N']	[40]
41	years	O	['N']	[41]
42	following	O	['N']	[42]
43	the	O	['N']	[43]
44	transplantation	O	['N']	[44]
45	.	O	['N']	[45]
#3438
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	Balint	B	['N']	[6]
7	syndrome	I-Adverse_Effect	['N']	[7]
8	with	O	['N']	[8]
9	irreversible	O	['N']	[9]
10	posterior	O	['N']	[10]
11	leukoencephalopathy	O	['N']	[11]
12	on	O	['N']	[12]
13	MRI	O	['N']	[13]
14	following	O	['N']	[14]
15	intrathecal	O	['N']	[15]
16	methotrexate	O	['N']	[16]
17	and	O	['N']	[17]
18	cytarabine	B-Drug	['Causes']	[7]
19	.	O	['N']	[19]
#3439
0	An	O	['N']	[0]
1	adolescent	O	['N']	[1]
2	male	O	['N']	[2]
3	developed	O	['N']	[3]
4	acute	B	['N']	[4]
5	pancreatitis	I-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	pseudocyst	O	['N']	[7]
8	of	O	['N']	[8]
9	the	O	['N']	[9]
10	pancreas	O	['N']	[10]
11	16	O	['N']	[11]
12	weeks	O	['N']	[12]
13	after	O	['N']	[13]
14	cessation	O	['N']	[14]
15	of	O	['N']	[15]
16	intramuscular	O	['N']	[16]
17	L	B	['N']	[17]
18	-	I	['N']	[18]
19	asparaginase	I-Drug	['Causes']	[5]
20	.	O	['N']	[20]
#3440
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	peripheral	O	['N']	[2]
3	neuropathy	O	['N']	[3]
4	and	O	['N']	[4]
5	bone	B	['N']	[5]
6	marrow	I	['N']	[6]
7	depression	I-Adverse_Effect	['N']	[7]
8	led	O	['N']	[8]
9	to	O	['N']	[9]
10	linezolid	B-Drug	['Causes']	[7]
11	withdrawal	O	['N']	[11]
12	in	O	['N']	[12]
13	seven	O	['N']	[13]
14	patients	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	neuropathy	O	['N']	[17]
18	may	O	['N']	[18]
19	not	O	['N']	[19]
20	be	O	['N']	[20]
21	fully	O	['N']	[21]
22	reversible	O	['N']	[22]
23	in	O	['N']	[23]
24	all	O	['N']	[24]
25	patients	O	['N']	[25]
26	.	O	['N']	[26]
#3441
0	Simvastatin	O	['N']	[0]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	rhabdomyolysis	B-Adverse_Effect	['N']	[3]
4	following	O	['N']	[4]
5	cyclosporine	B-Drug	['Causes']	[3]
6	treatment	O	['N']	[6]
7	for	O	['N']	[7]
8	uveitis	O	['N']	[8]
9	.	O	['N']	[9]
#3442
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	MMC	B-Drug	['Causes']	[10]
6	-	O	['N']	[6]
7	related	O	['N']	[7]
8	hemolytic	B	['N']	[8]
9	uremic	I	['N']	[9]
10	syndrome	I-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	discuss	O	['N']	[13]
14	the	O	['N']	[14]
15	etiologic	O	['N']	[15]
16	parameters	O	['N']	[16]
17	,	O	['N']	[17]
18	clinical	O	['N']	[18]
19	aspects	O	['N']	[19]
20	,	O	['N']	[20]
21	prognosis	O	['N']	[21]
22	and	O	['N']	[22]
23	treatment	O	['N']	[23]
24	modalities	O	['N']	[24]
25	of	O	['N']	[25]
26	this	O	['N']	[26]
27	severe	O	['N']	[27]
28	syndrome	O	['N']	[28]
29	.	O	['N']	[29]
#3443
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	rheumatoid	O	['N']	[3]
4	arthritis	O	['N']	[4]
5	developed	O	['N']	[5]
6	evidence	O	['N']	[6]
7	of	O	['N']	[7]
8	hepatotoxicity	B-Adverse_Effect	['N']	[8]
9	while	O	['N']	[9]
10	receiving	O	['N']	[10]
11	D	B	['N']	[11]
12	-	I	['N']	[12]
13	penicillamine	I-Drug	['Causes']	[8]
14	.	O	['N']	[14]
#3444
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	paper	O	['N']	[2]
3	we	O	['N']	[3]
4	report	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	nimodipine	B-Drug	['Causes']	[15]
9	overdosage	O	['N']	[9]
10	resulting	O	['N']	[10]
11	in	O	['N']	[11]
12	prolonged	O	['N']	[12]
13	hypotension	O	['N']	[13]
14	and	O	['N']	[14]
15	hypoxemia	B-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	which	O	['N']	[17]
18	was	O	['N']	[18]
19	successfully	O	['N']	[19]
20	treated	O	['N']	[20]
21	with	O	['N']	[21]
22	calcium	O	['N']	[22]
23	gluconate	O	['N']	[23]
24	.	O	['N']	[24]
#3445
0	Many	O	['N']	[0]
1	clinicians	O	['N']	[1]
2	appear	O	['N']	[2]
3	to	O	['N']	[3]
4	be	O	['N']	[4]
5	concerned	O	['N']	[5]
6	about	O	['N']	[6]
7	the	O	['N']	[7]
8	potential	O	['N']	[8]
9	hepatotoxicity	B-Adverse_Effect	['N']	[9]
10	of	O	['N']	[10]
11	the	O	['N']	[11]
12	opiate	O	['N']	[12]
13	antagonist	O	['N']	[13]
14	naltrexone	O	['N']	[14]
15	(	O	['N']	[15]
16	NTX	B-Drug	['Causes']	[9]
17	)	O	['N']	[17]
18	and	O	['N']	[18]
19	this	O	['N']	[19]
20	may	O	['N']	[20]
21	be	O	['N']	[21]
22	one	O	['N']	[22]
23	reason	O	['N']	[23]
24	why	O	['N']	[24]
25	it	O	['N']	[25]
26	is	O	['N']	[26]
27	not	O	['N']	[27]
28	used	O	['N']	[28]
29	more	O	['N']	[29]
30	widely	O	['N']	[30]
31	in	O	['N']	[31]
32	treating	O	['N']	[32]
33	both	O	['N']	[33]
34	heroin	O	['N']	[34]
35	and	O	['N']	[35]
36	alcohol	O	['N']	[36]
37	abusers	O	['N']	[37]
38	.	O	['N']	[38]
#3446
0	Delayed	O	['N']	[0]
1	neurotoxicity	B-Adverse_Effect	['N']	[1]
2	of	O	['N']	[2]
3	intraventricular	O	['N']	[3]
4	interleukin-2	B-Drug	['Causes']	[1]
5	:	O	['N']	[5]
6	a	O	['N']	[6]
7	case	O	['N']	[7]
8	report	O	['N']	[8]
9	.	O	['N']	[9]
#3447
0	Ampicillin	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	seizures	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#3448
0	Multiple	O	['N']	[0]
1	seizures	O	['N']	[1]
2	after	O	['N']	[2]
3	bupropion	B-Drug	['Dosage']	[4]
4	overdose	B-Dose	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	small	O	['N']	[7]
8	child	O	['N']	[8]
9	.	O	['N']	[9]
#3449
0	The	O	['N']	[0]
1	more	O	['N']	[1]
2	common	O	['N']	[2]
3	grade	O	['N']	[3]
4	3	O	['N']	[4]
5	or	O	['N']	[5]
6	4	O	['N']	[6]
7	adverse	O	['N']	[7]
8	effects	O	['N']	[8]
9	of	O	['N']	[9]
10	sunitinib	B-Drug	['Causes']	[24]
11	include	O	['N']	[11]
12	hypertension	O	['N']	[12]
13	,	O	['N']	[13]
14	fatigue	O	['N']	[14]
15	,	O	['N']	[15]
16	hand	O	['N']	[16]
17	-	O	['N']	[17]
18	foot	O	['N']	[18]
19	syndrome	O	['N']	[19]
20	,	O	['N']	[20]
21	elevated	O	['N']	[21]
22	lipase	O	['N']	[22]
23	and	O	['N']	[23]
24	lymphopenia	B-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#3450
0	A	O	['N']	[0]
1	69-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	developed	O	['N']	[5]
6	pure	B	['N']	[6]
7	red	I	['N']	[7]
8	cell	I	['N']	[8]
9	aplasia	I-Adverse_Effect	['N']	[9]
10	after	O	['N']	[10]
11	taking	O	['N']	[11]
12	fenoprofen	B-Drug	['Causes']	[9]
13	for	O	['N']	[13]
14	ten	O	['N']	[14]
15	months	O	['N']	[15]
16	.	O	['N']	[16]
#3451
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	continued	O	['N']	[2]
3	low	O	['N']	[3]
4	-	O	['N']	[4]
5	dose	O	['N']	[5]
6	MTX	B-Drug	['Causes']	[24]
7	led	O	['N']	[7]
8	,	O	['N']	[8]
9	in	O	['N']	[9]
10	spite	O	['N']	[10]
11	of	O	['N']	[11]
12	normal	O	['N']	[12]
13	liver	O	['N']	[13]
14	tests	O	['N']	[14]
15	,	O	['N']	[15]
16	8	O	['N']	[16]
17	years	O	['N']	[17]
18	after	O	['N']	[18]
19	the	O	['N']	[19]
20	last	O	['N']	[20]
21	biopsy	O	['N']	[21]
22	to	O	['N']	[22]
23	liver	B	['N']	[23]
24	failure	I-Adverse_Effect	['N']	[24]
25	and	O	['N']	[25]
26	death	O	['N']	[26]
27	in	O	['N']	[27]
28	1	O	['N']	[28]
29	of	O	['N']	[29]
30	our	O	['N']	[30]
31	patients	O	['N']	[31]
32	.	O	['N']	[32]
#3452
0	Videopolysomnographic	O	['N']	[0]
1	and	O	['N']	[1]
2	pharmacokinetic	O	['N']	[2]
3	studies	O	['N']	[3]
4	with	O	['N']	[4]
5	monitoring	O	['N']	[5]
6	of	O	['N']	[6]
7	plasma	O	['N']	[7]
8	levodopa	B-Drug	['Causes']	[27]
9	levels	O	['N']	[9]
10	demonstrated	O	['N']	[10]
11	marked	O	['N']	[11]
12	motor	O	['N']	[12]
13	hyperactivity	O	['N']	[13]
14	during	O	['N']	[14]
15	augmentation	O	['N']	[15]
16	,	O	['N']	[16]
17	with	O	['N']	[17]
18	anarchic	O	['N']	[18]
19	discharges	O	['N']	[19]
20	of	O	['N']	[20]
21	motor	O	['N']	[21]
22	unit	O	['N']	[22]
23	potentials	O	['N']	[23]
24	,	O	['N']	[24]
25	tonic	B	['N']	[25]
26	grouped	I	['N']	[26]
27	discharges	I-Adverse_Effect	['N']	[27]
28	and	O	['N']	[28]
29	flexor	O	['N']	[29]
30	spasms	O	['N']	[30]
31	,	O	['N']	[31]
32	associated	O	['N']	[32]
33	with	O	['N']	[33]
34	painful	O	['N']	[34]
35	dysesthesia	O	['N']	[35]
36	.	O	['N']	[36]
#3453
0	In	O	['N']	[0]
1	addition	O	['N']	[1]
2	,	O	['N']	[2]
3	a	O	['N']	[3]
4	31-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	man	O	['N']	[7]
8	with	O	['N']	[8]
9	obsessive	O	['N']	[9]
10	-	O	['N']	[10]
11	compulsive	O	['N']	[11]
12	disorder	O	['N']	[12]
13	developed	O	['N']	[13]
14	RBD	B-Adverse_Effect	['N']	[14]
15	soon	O	['N']	[15]
16	after	O	['N']	[16]
17	starting	O	['N']	[17]
18	fluoxetine	B-Drug	['Causes']	[14]
19	therapy	O	['N']	[19]
20	,	O	['N']	[20]
21	which	O	['N']	[21]
22	persisted	O	['N']	[22]
23	at	O	['N']	[23]
24	PSG	O	['N']	[24]
25	study	O	['N']	[25]
26	19	O	['N']	[26]
27	months	O	['N']	[27]
28	after	O	['N']	[28]
29	fluoxetine	O	['N']	[29]
30	discontinuation	O	['N']	[30]
31	.	O	['N']	[31]
#3454
0	The	O	['N']	[0]
1	psychotic	B	['N']	[1]
2	behavior	I-Adverse_Effect	['N']	[2]
3	resolved	O	['N']	[3]
4	completely	O	['N']	[4]
5	soon	O	['N']	[5]
6	after	O	['N']	[6]
7	the	O	['N']	[7]
8	discontinuation	O	['N']	[8]
9	of	O	['N']	[9]
10	levetiracetam	B-Drug	['Causes']	[2]
11	.	O	['N']	[11]
#3455
0	Because	O	['N']	[0]
1	etoposide	B-Drug	['Causes']	[5]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	pulmonary	B	['N']	[4]
5	toxicity	I-Adverse_Effect	['N']	[5]
6	is	O	['N']	[6]
7	an	O	['N']	[7]
8	uncommon	O	['N']	[8]
9	but	O	['N']	[9]
10	serious	O	['N']	[10]
11	adverse	O	['N']	[11]
12	event	O	['N']	[12]
13	,	O	['N']	[13]
14	clinicians	O	['N']	[14]
15	must	O	['N']	[15]
16	be	O	['N']	[16]
17	vigilant	O	['N']	[17]
18	about	O	['N']	[18]
19	the	O	['N']	[19]
20	possibility	O	['N']	[20]
21	of	O	['N']	[21]
22	it	O	['N']	[22]
23	,	O	['N']	[23]
24	so	O	['N']	[24]
25	that	O	['N']	[25]
26	the	O	['N']	[26]
27	optimal	O	['N']	[27]
28	treatment	O	['N']	[28]
29	can	O	['N']	[29]
30	start	O	['N']	[30]
31	as	O	['N']	[31]
32	soon	O	['N']	[32]
33	as	O	['N']	[33]
34	possible	O	['N']	[34]
35	.	O	['N']	[35]
#3456
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	55-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	became	O	['N']	[7]
8	stuporous	O	['N']	[8]
9	after	O	['N']	[9]
10	overdose	B-Dose	['N']	[10]
11	with	O	['N']	[11]
12	lamotrigine	O	['N']	[12]
13	(	O	['N']	[13]
14	LTG	B-Drug	['Dosage']	[10]
15	)	O	['N']	[15]
16	and	O	['N']	[16]
17	valproic	O	['N']	[17]
18	acid	O	['N']	[18]
19	(	O	['N']	[19]
20	VPA	O	['N']	[20]
21	)	O	['N']	[21]
22	tablets	O	['N']	[22]
23	.	O	['N']	[23]
#3457
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Olanzapine	B-Drug	['Causes']	[19]
3	,	O	['N']	[3]
4	like	O	['N']	[4]
5	other	O	['N']	[5]
6	atypical	O	['N']	[6]
7	antipsychotic	O	['N']	[7]
8	drugs	O	['N']	[8]
9	,	O	['N']	[9]
10	may	O	['N']	[10]
11	cause	O	['N']	[11]
12	muscle	B	['N']	[12]
13	injury	I	['N']	[13]
14	with	I	['N']	[14]
15	concomitant	I	['N']	[15]
16	elevations	I	['N']	[16]
17	of	I	['N']	[17]
18	serum	I	['N']	[18]
19	CK	I-Adverse_Effect	['N']	[19]
20	of	O	['N']	[20]
21	muscle	O	['N']	[21]
22	origin	O	['N']	[22]
23	.	O	['N']	[23]
#3458
0	We	O	['N']	[0]
1	suggest	O	['N']	[1]
2	that	O	['N']	[2]
3	sarcoidosis	B-Adverse_Effect	['N']	[3]
4	may	O	['N']	[4]
5	develop	O	['N']	[5]
6	in	O	['N']	[6]
7	chronic	O	['N']	[7]
8	hepatitis	O	['N']	[8]
9	C	O	['N']	[9]
10	patients	O	['N']	[10]
11	during	O	['N']	[11]
12	interferon	O	['N']	[12]
13	alpha	O	['N']	[13]
14	and/or	O	['N']	[14]
15	ribavirin	B-Drug	['Causes']	[3]
16	treatment	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	diagnostic	O	['N']	[19]
20	tests	O	['N']	[20]
21	for	O	['N']	[21]
22	this	O	['N']	[22]
23	adverse	O	['N']	[23]
24	effect	O	['N']	[24]
25	should	O	['N']	[25]
26	be	O	['N']	[26]
27	performed	O	['N']	[27]
28	during	O	['N']	[28]
29	the	O	['N']	[29]
30	follow	O	['N']	[30]
31	-	O	['N']	[31]
32	ups	O	['N']	[32]
33	.	O	['N']	[33]
#3459
0	Attenuation	O	['N']	[0]
1	of	O	['N']	[1]
2	asparaginase	B-Drug	['Causes']	[5]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	hyperglycemia	B-Adverse_Effect	['N']	[5]
6	after	O	['N']	[6]
7	substitution	O	['N']	[7]
8	of	O	['N']	[8]
9	the	O	['N']	[9]
10	Erwinia	O	['N']	[10]
11	carotovora	O	['N']	[11]
12	for	O	['N']	[12]
13	the	O	['N']	[13]
14	Escherichia	O	['N']	[14]
15	coli	O	['N']	[15]
16	enzyme	O	['N']	[16]
17	preparation	O	['N']	[17]
18	.	O	['N']	[18]
#3460
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	young	O	['N']	[6]
7	man	O	['N']	[7]
8	,	O	['N']	[8]
9	affected	O	['N']	[9]
10	by	O	['N']	[10]
11	rheumatoid	O	['N']	[11]
12	arthritis	O	['N']	[12]
13	who	O	['N']	[13]
14	developed	O	['N']	[14]
15	a	O	['N']	[15]
16	rapid	O	['N']	[16]
17	-	O	['N']	[17]
18	onset	O	['N']	[18]
19	short	B	['N']	[19]
20	-	I	['N']	[20]
21	of	I	['N']	[21]
22	-	I	['N']	[22]
23	breath	I-Adverse_Effect	['N']	[23]
24	,	O	['N']	[24]
25	hemoptysis	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	severe	O	['N']	[28]
29	weakness	O	['N']	[29]
30	,	O	['N']	[30]
31	about	O	['N']	[31]
32	2	O	['N']	[32]
33	weeks	O	['N']	[33]
34	after	O	['N']	[34]
35	the	O	['N']	[35]
36	administration	O	['N']	[36]
37	of	O	['N']	[37]
38	leflunomide	B-Drug	['Causes']	[23]
39	.	O	['N']	[39]
#3461
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	disseminated	O	['N']	[5]
6	muscular	O	['N']	[6]
7	cysticercosis	O	['N']	[7]
8	followed	O	['N']	[8]
9	by	O	['N']	[9]
10	myositis	O	['N']	[10]
11	(	O	['N']	[11]
12	fever	O	['N']	[12]
13	,	O	['N']	[13]
14	diffuse	B	['N']	[14]
15	myalgia	I-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	weakness	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	lower	O	['N']	[20]
21	limbs	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	inflammatory	O	['N']	[24]
25	reaction	O	['N']	[25]
26	around	O	['N']	[26]
27	dying	O	['N']	[27]
28	cysticerci	O	['N']	[28]
29	)	O	['N']	[29]
30	induced	O	['N']	[30]
31	by	O	['N']	[31]
32	praziquantel	B-Drug	['Causes']	[15]
33	therapy	O	['N']	[33]
34	,	O	['N']	[34]
35	an	O	['N']	[35]
36	event	O	['N']	[36]
37	not	O	['N']	[37]
38	described	O	['N']	[38]
39	previously	O	['N']	[39]
40	.	O	['N']	[40]
#3462
0	Mefloquine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	hypoglycaemia	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	cachectic	O	['N']	[6]
7	AIDS	O	['N']	[7]
8	patient	O	['N']	[8]
9	.	O	['N']	[9]
#3463
0	When	O	['N']	[0]
1	tuberculosis	O	['N']	[1]
2	patients	O	['N']	[2]
3	on	O	['N']	[3]
4	isoniazid	B-Drug	['Causes']	[15]
5	eat	O	['N']	[5]
6	certain	O	['N']	[6]
7	varieties	O	['N']	[7]
8	of	O	['N']	[8]
9	fish	O	['N']	[9]
10	they	O	['N']	[10]
11	may	O	['N']	[11]
12	develop	O	['N']	[12]
13	a	O	['N']	[13]
14	histamine	B	['N']	[14]
15	reaction	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#3464
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	investigate	O	['N']	[3]
4	the	O	['N']	[4]
5	concentration	O	['N']	[5]
6	-	O	['N']	[6]
7	side	O	['N']	[7]
8	effect	O	['N']	[8]
9	relationship	O	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	patient	O	['N']	[12]
13	with	O	['N']	[13]
14	severe	O	['N']	[14]
15	acyclovir	B-Drug	['Causes']	[18]
16	-	O	['N']	[16]
17	induced	O	['N']	[17]
18	neurotoxicity	B-Adverse_Effect	['N']	[18]
19	and	O	['N']	[19]
20	to	O	['N']	[20]
21	summarize	O	['N']	[21]
22	the	O	['N']	[22]
23	information	O	['N']	[23]
24	available	O	['N']	[24]
25	in	O	['N']	[25]
26	the	O	['N']	[26]
27	literature	O	['N']	[27]
28	about	O	['N']	[28]
29	central	O	['N']	[29]
30	nervous	O	['N']	[30]
31	system	O	['N']	[31]
32	side	O	['N']	[32]
33	effects	O	['N']	[33]
34	due	O	['N']	[34]
35	to	O	['N']	[35]
36	acyclovir	O	['N']	[36]
37	.	O	['N']	[37]
#3465
0	A	O	['N']	[0]
1	53-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	male	O	['N']	[4]
5	,	O	['N']	[5]
6	without	O	['N']	[6]
7	any	O	['N']	[7]
8	prior	O	['N']	[8]
9	history	O	['N']	[9]
10	of	O	['N']	[10]
11	psychosis	O	['N']	[11]
12	,	O	['N']	[12]
13	developed	O	['N']	[13]
14	schizophrenia	O	['N']	[14]
15	4	O	['N']	[15]
16	days	O	['N']	[16]
17	after	O	['N']	[17]
18	starting	O	['N']	[18]
19	low	B	['N']	[19]
20	-	I	['N']	[20]
21	dose	I-Dose	['N']	[21]
22	bromocriptine	B-Drug	['Dosage']	[21]
23	therapy	O	['N']	[23]
24	for	O	['N']	[24]
25	a	O	['N']	[25]
26	macroprolactinoma	O	['N']	[26]
27	.	O	['N']	[27]
#3466
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	young	O	['N']	[6]
7	man	O	['N']	[7]
8	,	O	['N']	[8]
9	affected	O	['N']	[9]
10	by	O	['N']	[10]
11	rheumatoid	O	['N']	[11]
12	arthritis	O	['N']	[12]
13	who	O	['N']	[13]
14	developed	O	['N']	[14]
15	a	O	['N']	[15]
16	rapid	O	['N']	[16]
17	-	O	['N']	[17]
18	onset	O	['N']	[18]
19	short	O	['N']	[19]
20	-	O	['N']	[20]
21	of	O	['N']	[21]
22	-	O	['N']	[22]
23	breath	O	['N']	[23]
24	,	O	['N']	[24]
25	hemoptysis	B-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	severe	O	['N']	[28]
29	weakness	O	['N']	[29]
30	,	O	['N']	[30]
31	about	O	['N']	[31]
32	2	O	['N']	[32]
33	weeks	O	['N']	[33]
34	after	O	['N']	[34]
35	the	O	['N']	[35]
36	administration	O	['N']	[36]
37	of	O	['N']	[37]
38	leflunomide	B-Drug	['Causes']	[25]
39	.	O	['N']	[39]
#3467
0	The	O	['N']	[0]
1	most	O	['N']	[1]
2	common	O	['N']	[2]
3	complication	O	['N']	[3]
4	of	O	['N']	[4]
5	warfarin	B-Drug	['Causes']	[9]
6	use	O	['N']	[6]
7	is	O	['N']	[7]
8	adverse	O	['N']	[8]
9	bleeding	B-Adverse_Effect	['N']	[9]
10	.	O	['N']	[10]
#3468
0	A	O	['N']	[0]
1	previous	O	['N']	[1]
2	review	O	['N']	[2]
3	described	O	['N']	[3]
4	data	O	['N']	[4]
5	on	O	['N']	[5]
6	15	O	['N']	[6]
7	patients	O	['N']	[7]
8	who	O	['N']	[8]
9	experienced	O	['N']	[9]
10	acute	B	['N']	[10]
11	hemoglobinemia	I-Adverse_Effect	['N']	[11]
12	or	O	['N']	[12]
13	hemoglobinuria	O	['N']	[13]
14	following	O	['N']	[14]
15	anti	B	['N']	[15]
16	-	I	['N']	[16]
17	D	I	['N']	[17]
18	IGIV	I-Drug	['Causes']	[11]
19	administration	O	['N']	[19]
20	for	O	['N']	[20]
21	ITP	O	['N']	[21]
22	or	O	['N']	[22]
23	secondary	O	['N']	[23]
24	thrombocytopenia	O	['N']	[24]
25	.	O	['N']	[25]
#3469
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	HUS	B-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	an	O	['N']	[7]
8	advanced	O	['N']	[8]
9	ovarian	O	['N']	[9]
10	cancer	O	['N']	[10]
11	patient	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	carboplatin	O	['N']	[14]
15	and	O	['N']	[15]
16	gemcitabine	B-Drug	['Causes']	[5]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	described	O	['N']	[19]
20	its	O	['N']	[20]
21	favorable	O	['N']	[21]
22	outcome	O	['N']	[22]
23	after	O	['N']	[23]
24	chemotherapy	O	['N']	[24]
25	interruption	O	['N']	[25]
26	and	O	['N']	[26]
27	supportive	O	['N']	[27]
28	care	O	['N']	[28]
29	with	O	['N']	[29]
30	a	O	['N']	[30]
31	1	O	['N']	[31]
32	year	O	['N']	[32]
33	follow	O	['N']	[33]
34	-	O	['N']	[34]
35	up	O	['N']	[35]
36	.	O	['N']	[36]
#3470
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	describe	O	['N']	[3]
4	the	O	['N']	[4]
5	ophthalmic	O	['N']	[5]
6	features	O	['N']	[6]
7	and	O	['N']	[7]
8	clinical	O	['N']	[8]
9	course	O	['N']	[9]
10	of	O	['N']	[10]
11	two	O	['N']	[11]
12	cases	O	['N']	[12]
13	of	O	['N']	[13]
14	acute	B	['N']	[14]
15	syphilitic	I	['N']	[15]
16	posterior	I	['N']	[16]
17	placoid	I	['N']	[17]
18	chorioretinitis	I-Adverse_Effect	['N']	[18]
19	(	O	['N']	[19]
20	ASPPC	O	['N']	[20]
21	)	O	['N']	[21]
22	that	O	['N']	[22]
23	developed	O	['N']	[23]
24	after	O	['N']	[24]
25	intravitreal	O	['N']	[25]
26	triamcinolone	B	['N']	[26]
27	acetonide	I-Drug	['Causes']	[18]
28	(	O	['N']	[28]
29	IVTA	O	['N']	[29]
30	)	O	['N']	[30]
31	injection	O	['N']	[31]
32	.	O	['N']	[32]
#3471
0	Localized	B	['N']	[0]
1	purpura	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	lamotrigine	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#3472
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Clarithromycin	B-Drug	['Causes']	[10]
3	may	O	['N']	[3]
4	be	O	['N']	[4]
5	a	O	['N']	[5]
6	cause	O	['N']	[6]
7	of	O	['N']	[7]
8	fulminant	B	['N']	[8]
9	liver	I	['N']	[9]
10	failure	I-Adverse_Effect	['N']	[10]
11	either	O	['N']	[11]
12	alone	O	['N']	[12]
13	or	O	['N']	[13]
14	by	O	['N']	[14]
15	inhibiting	O	['N']	[15]
16	the	O	['N']	[16]
17	metabolism	O	['N']	[17]
18	of	O	['N']	[18]
19	other	O	['N']	[19]
20	drugs	O	['N']	[20]
21	.	O	['N']	[21]
#3473
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Healthcare	O	['N']	[2]
3	professionals	O	['N']	[3]
4	should	O	['N']	[4]
5	be	O	['N']	[5]
6	aware	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	possible	O	['N']	[9]
10	development	O	['N']	[10]
11	of	O	['N']	[11]
12	serotonin	B	['N']	[12]
13	syndrome	I-Adverse_Effect	['N']	[13]
14	as	O	['N']	[14]
15	a	O	['N']	[15]
16	complication	O	['N']	[16]
17	of	O	['N']	[17]
18	initiation	O	['N']	[18]
19	of	O	['N']	[19]
20	fentanyl	B-Drug	['Causes']	[13]
21	and	O	['N']	[21]
22	other	O	['N']	[22]
23	phenylpiperidine	O	['N']	[23]
24	opioids	O	['N']	[24]
25	in	O	['N']	[25]
26	patients	O	['N']	[26]
27	treated	O	['N']	[27]
28	with	O	['N']	[28]
29	SSRIs	O	['N']	[29]
30	.	O	['N']	[30]
#3474
0	The	O	['N']	[0]
1	multiple	O	['N']	[1]
2	comedones	O	['N']	[2]
3	and	O	['N']	[3]
4	ruptured	B	['N']	[4]
5	epidermoid	I	['N']	[5]
6	cysts	I-Adverse_Effect	['N']	[6]
7	are	O	['N']	[7]
8	newly	O	['N']	[8]
9	reported	O	['N']	[9]
10	adverse	O	['N']	[10]
11	effects	O	['N']	[11]
12	of	O	['N']	[12]
13	imiquimod	B-Drug	['Causes']	[6]
14	therapy	O	['N']	[14]
15	.	O	['N']	[15]
#3475
0	Valvular	B	['N']	[0]
1	heart	I	['N']	[1]
2	disease	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	taking	O	['N']	[6]
7	benfluorex	B-Drug	['Causes']	[2]
8	.	O	['N']	[8]
#3476
0	Pancreatitis	O	['N']	[0]
1	has	O	['N']	[1]
2	been	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	the	O	['N']	[5]
6	tetracycline	O	['N']	[6]
7	class	O	['N']	[7]
8	of	O	['N']	[8]
9	antibiotics	O	['N']	[9]
10	and	O	['N']	[10]
11	concerns	O	['N']	[11]
12	about	O	['N']	[12]
13	tigecycline	B-Drug	['Causes']	[17]
14	-	O	['N']	[14]
15	induced	O	['N']	[15]
16	acute	B	['N']	[16]
17	pancreatitis	I-Adverse_Effect	['N']	[17]
18	have	O	['N']	[18]
19	recently	O	['N']	[19]
20	been	O	['N']	[20]
21	raised	O	['N']	[21]
22	.	O	['N']	[22]
#3477
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	anaphylactoid	B	['N']	[3]
4	reaction	I-Adverse_Effect	['N']	[4]
5	due	O	['N']	[5]
6	solely	O	['N']	[6]
7	to	O	['N']	[7]
8	the	O	['N']	[8]
9	use	O	['N']	[9]
10	of	O	['N']	[10]
11	Gelofusine	B-Drug	['Causes']	[4]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	patient	O	['N']	[14]
15	with	O	['N']	[15]
16	non	O	['N']	[16]
17	-	O	['N']	[17]
18	haemorrhagic	O	['N']	[18]
19	hypovolaemia	O	['N']	[19]
20	is	O	['N']	[20]
21	presented	O	['N']	[21]
22	,	O	['N']	[22]
23	with	O	['N']	[23]
24	a	O	['N']	[24]
25	discussion	O	['N']	[25]
26	on	O	['N']	[26]
27	the	O	['N']	[27]
28	management	O	['N']	[28]
29	and	O	['N']	[29]
30	the	O	['N']	[30]
31	use	O	['N']	[31]
32	of	O	['N']	[32]
33	allergy	O	['N']	[33]
34	identification	O	['N']	[34]
35	jewellery	O	['N']	[35]
36	.	O	['N']	[36]
#3478
0	The	O	['N']	[0]
1	possibility	O	['N']	[1]
2	can	O	['N']	[2]
3	be	O	['N']	[3]
4	raised	O	['N']	[4]
5	that	O	['N']	[5]
6	M	B	['N']	[6]
7	-	I	['N']	[7]
8	CSF	I-Drug	['Causes']	[31]
9	accelerated	O	['N']	[9]
10	the	O	['N']	[10]
11	underlying	O	['N']	[11]
12	renal	O	['N']	[12]
13	disease	O	['N']	[13]
14	in	O	['N']	[14]
15	this	O	['N']	[15]
16	case	O	['N']	[16]
17	through	O	['N']	[17]
18	enhancing	O	['N']	[18]
19	macrophage	O	['N']	[19]
20	accumulation	O	['N']	[20]
21	into	O	['N']	[21]
22	the	O	['N']	[22]
23	glomerulus	O	['N']	[23]
24	,	O	['N']	[24]
25	leading	O	['N']	[25]
26	to	O	['N']	[26]
27	the	O	['N']	[27]
28	development	O	['N']	[28]
29	of	O	['N']	[29]
30	nephrotic	B	['N']	[30]
31	syndrome	I-Adverse_Effect	['N']	[31]
32	.	O	['N']	[32]
#3479
0	A	O	['N']	[0]
1	22-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	black	O	['N']	[4]
5	man	O	['N']	[5]
6	developed	O	['N']	[6]
7	fever	O	['N']	[7]
8	,	O	['N']	[8]
9	chills	B-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	fatigue	O	['N']	[11]
12	,	O	['N']	[12]
13	night	O	['N']	[13]
14	sweats	O	['N']	[14]
15	,	O	['N']	[15]
16	tender	O	['N']	[16]
17	lymphadenopathy	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	a	O	['N']	[20]
21	generalized	O	['N']	[21]
22	,	O	['N']	[22]
23	pruritic	O	['N']	[23]
24	,	O	['N']	[24]
25	macular	O	['N']	[25]
26	eruption	O	['N']	[26]
27	3	O	['N']	[27]
28	weeks	O	['N']	[28]
29	after	O	['N']	[29]
30	starting	O	['N']	[30]
31	minocycline	B-Drug	['Causes']	[9]
32	therapy	O	['N']	[32]
33	for	O	['N']	[33]
34	acne	O	['N']	[34]
35	.	O	['N']	[35]
#3480
0	The	O	['N']	[0]
1	most	O	['N']	[1]
2	serious	O	['N']	[2]
3	dental	O	['N']	[3]
4	side	O	['N']	[4]
5	effect	O	['N']	[5]
6	of	O	['N']	[6]
7	bisphosphonate	B-Drug	['Causes']	[24]
8	treatment	O	['N']	[8]
9	(	O	['N']	[9]
10	particularly	O	['N']	[10]
11	when	O	['N']	[11]
12	it	O	['N']	[12]
13	is	O	['N']	[13]
14	administered	O	['N']	[14]
15	intravenously	O	['N']	[15]
16	)	O	['N']	[16]
17	is	O	['N']	[17]
18	,	O	['N']	[18]
19	paradoxically	O	['N']	[19]
20	,	O	['N']	[20]
21	osteonecrosis	B	['N']	[21]
22	of	I	['N']	[22]
23	the	I	['N']	[23]
24	mandible	I-Adverse_Effect	['N']	[24]
25	or	O	['N']	[25]
26	the	O	['N']	[26]
27	maxilla	O	['N']	[27]
28	represented	O	['N']	[28]
29	by	O	['N']	[29]
30	exposed	O	['N']	[30]
31	nonhealing	O	['N']	[31]
32	bone	O	['N']	[32]
33	.	O	['N']	[33]
#3481
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	unique	O	['N']	[3]
4	autopsy	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	hepatocellular	B	['N']	[7]
8	carcinoma	I-Adverse_Effect	['N']	[8]
9	closely	O	['N']	[9]
10	related	O	['N']	[10]
11	to	O	['N']	[11]
12	diethylstilbestrol	O	['N']	[12]
13	(	O	['N']	[13]
14	DES	B-Drug	['Causes']	[8]
15	)	O	['N']	[15]
16	therapy	O	['N']	[16]
17	for	O	['N']	[17]
18	prostatic	O	['N']	[18]
19	cancer	O	['N']	[19]
20	.	O	['N']	[20]
#3482
0	Amphotericin	B	['N']	[0]
1	B	I-Drug	['Causes']	[17]
2	(	O	['N']	[2]
3	AmB	O	['N']	[3]
4	)	O	['N']	[4]
5	is	O	['N']	[5]
6	effective	O	['N']	[6]
7	,	O	['N']	[7]
8	but	O	['N']	[8]
9	its	O	['N']	[9]
10	use	O	['N']	[10]
11	is	O	['N']	[11]
12	limited	O	['N']	[12]
13	by	O	['N']	[13]
14	toxicity	O	['N']	[14]
15	:	O	['N']	[15]
16	renal	B	['N']	[16]
17	impairment	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	anaemia	O	['N']	[19]
20	,	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	malaise	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	hypokalaemia	O	['N']	[26]
27	are	O	['N']	[27]
28	common	O	['N']	[28]
29	.	O	['N']	[29]
#3483
0	Potential	O	['N']	[0]
1	causes	O	['N']	[1]
2	of	O	['N']	[2]
3	methamphetamine	B-Drug	['Causes']	[31]
4	-	O	['N']	[4]
5	related	O	['N']	[5]
6	keratitis	O	['N']	[6]
7	can	O	['N']	[7]
8	be	O	['N']	[8]
9	divided	O	['N']	[9]
10	into	O	['N']	[10]
11	four	O	['N']	[11]
12	categories	O	['N']	[12]
13	resulting	O	['N']	[13]
14	from	O	['N']	[14]
15	(	O	['N']	[15]
16	a	O	['N']	[16]
17	)	O	['N']	[17]
18	direct	O	['N']	[18]
19	pharmacologic	O	['N']	[19]
20	and	O	['N']	[20]
21	physical	O	['N']	[21]
22	effects	O	['N']	[22]
23	of	O	['N']	[23]
24	methamphetamine	O	['N']	[24]
25	;	O	['N']	[25]
26	(	O	['N']	[26]
27	b	O	['N']	[27]
28	)	O	['N']	[28]
29	the	O	['N']	[29]
30	toxic	B	['N']	[30]
31	effects	I-Adverse_Effect	['N']	[31]
32	of	O	['N']	[32]
33	diluting	O	['N']	[33]
34	or	O	['N']	[34]
35	"	O	['N']	[35]
36	cutting	O	['N']	[36]
37	"	O	['N']	[37]
38	agents	O	['N']	[38]
39	such	O	['N']	[39]
40	as	O	['N']	[40]
41	lidocaine	O	['N']	[41]
42	and	O	['N']	[42]
43	quinine	O	['N']	[43]
44	;	O	['N']	[44]
45	(	O	['N']	[45]
46	c	O	['N']	[46]
47	)	O	['N']	[47]
48	effects	O	['N']	[48]
49	related	O	['N']	[49]
50	to	O	['N']	[50]
51	the	O	['N']	[51]
52	route	O	['N']	[52]
53	of	O	['N']	[53]
54	drug	O	['N']	[54]
55	administration	O	['N']	[55]
56	(	O	['N']	[56]
57	intravenous	O	['N']	[57]
58	,	O	['N']	[58]
59	inhalation	O	['N']	[59]
60	,	O	['N']	[60]
61	smoking	O	['N']	[61]
62	)	O	['N']	[62]
63	;	O	['N']	[63]
64	and	O	['N']	[64]
65	(	O	['N']	[65]
66	d	O	['N']	[66]
67	)	O	['N']	[67]
68	manufacture	O	['N']	[68]
69	-	O	['N']	[69]
70	related	O	['N']	[70]
71	effects	O	['N']	[71]
72	of	O	['N']	[72]
73	exposure	O	['N']	[73]
74	to	O	['N']	[74]
75	unintentional	O	['N']	[75]
76	caustic	O	['N']	[76]
77	contaminants	O	['N']	[77]
78	in	O	['N']	[78]
79	the	O	['N']	[79]
80	final	O	['N']	[80]
81	product	O	['N']	[81]
82	.	O	['N']	[82]
#3484
0	The	O	['N']	[0]
1	current	O	['N']	[1]
2	report	O	['N']	[2]
3	describes	O	['N']	[3]
4	a	O	['N']	[4]
5	man	O	['N']	[5]
6	who	O	['N']	[6]
7	was	O	['N']	[7]
8	prescribed	O	['N']	[8]
9	zonisamide	B-Drug	['Causes']	[42]
10	for	O	['N']	[10]
11	epilepsy	O	['N']	[11]
12	and	O	['N']	[12]
13	subsequently	O	['N']	[13]
14	developed	O	['N']	[14]
15	widespread	O	['N']	[15]
16	skin	O	['N']	[16]
17	rash	O	['N']	[17]
18	,	O	['N']	[18]
19	acute	O	['N']	[19]
20	kidney	O	['N']	[20]
21	injury	O	['N']	[21]
22	,	O	['N']	[22]
23	high	O	['N']	[23]
24	-	O	['N']	[24]
25	grade	O	['N']	[25]
26	fever	O	['N']	[26]
27	,	O	['N']	[27]
28	eosinophilia	O	['N']	[28]
29	,	O	['N']	[29]
30	liver	O	['N']	[30]
31	dysfunction	O	['N']	[31]
32	,	O	['N']	[32]
33	lymphadenopathy	O	['N']	[33]
34	and	O	['N']	[34]
35	an	B	['N']	[35]
36	increase	I	['N']	[36]
37	in	I	['N']	[37]
38	antihuman	I	['N']	[38]
39	herpesvirus-6	I	['N']	[39]
40	immunoglobulin	I	['N']	[40]
41	G	I	['N']	[41]
42	titer	I-Adverse_Effect	['N']	[42]
43	.	O	['N']	[43]
#3485
0	Prolonged	O	['N']	[0]
1	severe	B	['N']	[1]
2	cholestasis	I-Adverse_Effect	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	oxacillin	B-Drug	['Causes']	[2]
6	derivatives	O	['N']	[6]
7	.	O	['N']	[7]
#3486
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	case	O	['N']	[2]
3	,	O	['N']	[3]
4	CIPS	B-Adverse_Effect	['N']	[4]
5	was	O	['N']	[5]
6	considered	O	['N']	[6]
7	to	O	['N']	[7]
8	be	O	['N']	[8]
9	probably	O	['N']	[9]
10	associated	O	['N']	[10]
11	with	O	['N']	[11]
12	cyclosporine	B-Drug	['Causes']	[4]
13	according	O	['N']	[13]
14	to	O	['N']	[14]
15	the	O	['N']	[15]
16	Naranjo	O	['N']	[16]
17	probability	O	['N']	[17]
18	scale	O	['N']	[18]
19	.	O	['N']	[19]
#3487
0	There	O	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	dose	O	['N']	[3]
4	-	O	['N']	[4]
5	effect	O	['N']	[5]
6	relationship	O	['N']	[6]
7	between	O	['N']	[7]
8	doxorubicin	B-Drug	['Causes']	[15]
9	and	O	['N']	[9]
10	the	O	['N']	[10]
11	incidence	O	['N']	[11]
12	of	O	['N']	[12]
13	symptomatic	B	['N']	[13]
14	cardiac	I	['N']	[14]
15	failure	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#3488
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	second	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	acute	B	['N']	[6]
7	lung	I	['N']	[7]
8	injury	I-Adverse_Effect	['N']	[8]
9	and	O	['N']	[9]
10	diffuse	O	['N']	[10]
11	alveolar	O	['N']	[11]
12	damage	O	['N']	[12]
13	caused	O	['N']	[13]
14	by	O	['N']	[14]
15	mefloquine	B-Drug	['Causes']	[8]
16	.	O	['N']	[16]
#3489
0	Transient	B	['N']	[0]
1	asymptomatic	I	['N']	[1]
2	bradycardia	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	patients	O	['N']	[4]
5	on	O	['N']	[5]
6	infusional	O	['N']	[6]
7	5-fluorouracil	B-Drug	['Causes']	[2]
8	.	O	['N']	[8]
#3490
0	Skin	O	['N']	[0]
1	rash	O	['N']	[1]
2	and	O	['N']	[2]
3	splinter	B	['N']	[3]
4	hemorrhages	I-Adverse_Effect	['N']	[4]
5	from	O	['N']	[5]
6	ganciclovir	B-Drug	['Causes']	[4]
7	.	O	['N']	[7]
#3491
0	A	O	['N']	[0]
1	33-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	male	O	['N']	[4]
5	presented	O	['N']	[5]
6	with	O	['N']	[6]
7	brown	B	['N']	[7]
8	discolouration	I	['N']	[8]
9	of	I	['N']	[9]
10	the	I	['N']	[10]
11	fingernails	I-Adverse_Effect	['N']	[11]
12	following	O	['N']	[12]
13	the	O	['N']	[13]
14	application	O	['N']	[14]
15	of	O	['N']	[15]
16	4	O	['N']	[16]
17	%	O	['N']	[17]
18	hydroquinone	O	['N']	[18]
19	in	O	['N']	[19]
20	sorbolene	O	['N']	[20]
21	cream	O	['N']	[21]
22	and	O	['N']	[22]
23	0.1	B	['N']	[23]
24	%	I	['N']	[24]
25	tretinoin	I	['N']	[25]
26	cream	I-Drug	['Causes']	[11]
27	to	O	['N']	[27]
28	the	O	['N']	[28]
29	face	O	['N']	[29]
30	intermittently	O	['N']	[30]
31	for	O	['N']	[31]
32	9	O	['N']	[32]
33	months	O	['N']	[33]
34	.	O	['N']	[34]
#3492
0	The	O	['N']	[0]
1	pulmonary	B	['N']	[1]
2	toxicity	I-Adverse_Effect	['N']	[2]
3	of	O	['N']	[3]
4	gold	B-Drug	['Causes']	[2]
5	salts	O	['N']	[5]
6	is	O	['N']	[6]
7	an	O	['N']	[7]
8	uncommon	O	['N']	[8]
9	cause	O	['N']	[9]
10	of	O	['N']	[10]
11	life	O	['N']	[11]
12	-	O	['N']	[12]
13	threatening	O	['N']	[13]
14	respiratory	O	['N']	[14]
15	failure	O	['N']	[15]
16	.	O	['N']	[16]
#3493
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Patients	O	['N']	[2]
3	with	O	['N']	[3]
4	5-FU	B-Drug	['Causes']	[7]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	ectropion	B-Adverse_Effect	['N']	[7]
8	experience	O	['N']	[8]
9	tender	O	['N']	[9]
10	,	O	['N']	[10]
11	red	O	['N']	[11]
12	,	O	['N']	[12]
13	scaled	O	['N']	[13]
14	lids	O	['N']	[14]
15	,	O	['N']	[15]
16	making	O	['N']	[16]
17	contact	O	['N']	[17]
18	lens	O	['N']	[18]
19	wear	O	['N']	[19]
20	difficult	O	['N']	[20]
21	.	O	['N']	[21]
#3494
0	Moreover	O	['N']	[0]
1	,	O	['N']	[1]
2	treatment	O	['N']	[2]
3	with	O	['N']	[3]
4	immunosuppressive	O	['N']	[4]
5	drugs	O	['N']	[5]
6	such	O	['N']	[6]
7	as	O	['N']	[7]
8	cyclosporine	O	['N']	[8]
9	,	O	['N']	[9]
10	cisplatin	O	['N']	[10]
11	,	O	['N']	[11]
12	tacrolimus	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	interferon	B	['N']	[15]
16	-	I	['N']	[16]
17	alpha	I-Drug	['Causes']	[23]
18	can	O	['N']	[18]
19	induce	O	['N']	[19]
20	a	O	['N']	[20]
21	condition	O	['N']	[21]
22	resembling	O	['N']	[22]
23	RPLS	B-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#3495
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	There	O	['N']	[2]
3	are	O	['N']	[3]
4	only	O	['N']	[4]
5	a	O	['N']	[5]
6	few	O	['N']	[6]
7	confirmed	O	['N']	[7]
8	cases	O	['N']	[8]
9	of	O	['N']	[9]
10	gemcitabine	B-Drug	['Causes']	[13]
11	-	O	['N']	[11]
12	associated	O	['N']	[12]
13	HUS	B-Adverse_Effect	['N']	[13]
14	despite	O	['N']	[14]
15	the	O	['N']	[15]
16	widespread	O	['N']	[16]
17	use	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	drug	O	['N']	[20]
21	.	O	['N']	[21]
#3496
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	recently	O	['N']	[3]
4	saw	O	['N']	[4]
5	two	O	['N']	[5]
6	patients	O	['N']	[6]
7	with	O	['N']	[7]
8	renal	O	['N']	[8]
9	tuberculosis	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	ethambutol	B-Drug	['Causes']	[16]
13	in	O	['N']	[13]
14	whom	O	['N']	[14]
15	visual	B	['N']	[15]
16	loss	I-Adverse_Effect	['N']	[16]
17	from	O	['N']	[17]
18	toxic	O	['N']	[18]
19	optic	O	['N']	[19]
20	neuropathies	O	['N']	[20]
21	was	O	['N']	[21]
22	severe	O	['N']	[22]
23	and	O	['N']	[23]
24	irreversible	O	['N']	[24]
25	despite	O	['N']	[25]
26	careful	O	['N']	[26]
27	ophthalmological	O	['N']	[27]
28	monitoring	O	['N']	[28]
29	and	O	['N']	[29]
30	prompt	O	['N']	[30]
31	discontinuation	O	['N']	[31]
32	of	O	['N']	[32]
33	the	O	['N']	[33]
34	agent	O	['N']	[34]
35	at	O	['N']	[35]
36	the	O	['N']	[36]
37	first	O	['N']	[37]
38	sign	O	['N']	[38]
39	of	O	['N']	[39]
40	impaired	O	['N']	[40]
41	visual	O	['N']	[41]
42	function	O	['N']	[42]
43	.	O	['N']	[43]
#3497
0	Benzocaine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	methemoglobinemia	B-Adverse_Effect	['N']	[3]
4	has	O	['N']	[4]
5	been	O	['N']	[5]
6	reported	O	['N']	[6]
7	in	O	['N']	[7]
8	man	O	['N']	[8]
9	,	O	['N']	[9]
10	dogs	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	cats	O	['N']	[13]
14	.	O	['N']	[14]
#3498
0	Pulmonary	B	['N']	[0]
1	fibrosis	I-Adverse_Effect	['N']	[1]
2	is	O	['N']	[2]
3	a	O	['N']	[3]
4	severe	O	['N']	[4]
5	complication	O	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	bis	B	['N']	[8]
9	-	I	['N']	[9]
10	chloronitrosourea	I-Drug	['Causes']	[1]
11	(	O	['N']	[11]
12	BCNU	O	['N']	[12]
13	)	O	['N']	[13]
14	therapy	O	['N']	[14]
15	.	O	['N']	[15]
#3499
0	The	O	['N']	[0]
1	purpose	O	['N']	[1]
2	of	O	['N']	[2]
3	this	O	['N']	[3]
4	report	O	['N']	[4]
5	is	O	['N']	[5]
6	to	O	['N']	[6]
7	document	O	['N']	[7]
8	a	O	['N']	[8]
9	new	O	['N']	[9]
10	case	O	['N']	[10]
11	of	O	['N']	[11]
12	in	O	['N']	[12]
13	utero	O	['N']	[13]
14	CP	B-Drug	['Causes']	[19]
15	exposure	O	['N']	[15]
16	with	O	['N']	[16]
17	multiple	B	['N']	[17]
18	congenital	I	['N']	[18]
19	anomalies	I-Adverse_Effect	['N']	[19]
20	and	O	['N']	[20]
21	to	O	['N']	[21]
22	establish	O	['N']	[22]
23	an	O	['N']	[23]
24	apparent	O	['N']	[24]
25	CP	O	['N']	[25]
26	embryopathy	O	['N']	[26]
27	phenotype	O	['N']	[27]
28	.	O	['N']	[28]
#3500
0	The	O	['N']	[0]
1	development	O	['N']	[1]
2	of	O	['N']	[2]
3	erythroid	O	['N']	[3]
4	leukemia	O	['N']	[4]
5	plus	O	['N']	[5]
6	carcinoma	B-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	these	O	['N']	[8]
9	two	O	['N']	[9]
10	men	O	['N']	[10]
11	suggests	O	['N']	[11]
12	mutagenic	O	['N']	[12]
13	change	O	['N']	[13]
14	secondary	O	['N']	[14]
15	to	O	['N']	[15]
16	cyclophosphamide	B-Drug	['Causes']	[6]
17	therapy	O	['N']	[17]
18	.	O	['N']	[18]
#3501
0	A	O	['N']	[0]
1	small	O	['N']	[1]
2	initial	O	['N']	[2]
3	dose	O	['N']	[3]
4	of	O	['N']	[4]
5	prazosin	B-Drug	['Causes']	[31]
6	ranging	O	['N']	[6]
7	from	O	['N']	[7]
8	0.5	O	['N']	[8]
9	to	O	['N']	[9]
10	1	O	['N']	[10]
11	mg	O	['N']	[11]
12	has	O	['N']	[12]
13	been	O	['N']	[13]
14	recommended	O	['N']	[14]
15	to	O	['N']	[15]
16	avoid	O	['N']	[16]
17	the	O	['N']	[17]
18	first	O	['N']	[18]
19	-	O	['N']	[19]
20	dose	O	['N']	[20]
21	phenomenon	O	['N']	[21]
22	characterized	O	['N']	[22]
23	by	O	['N']	[23]
24	a	O	['N']	[24]
25	sudden	O	['N']	[25]
26	and	O	['N']	[26]
27	severe	B	['N']	[27]
28	drop	I	['N']	[28]
29	in	I	['N']	[29]
30	blood	I	['N']	[30]
31	pressure	I-Adverse_Effect	['N']	[31]
32	after	O	['N']	[32]
33	the	O	['N']	[33]
34	administration	O	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	first	O	['N']	[37]
38	dose	O	['N']	[38]
39	of	O	['N']	[39]
40	prazosin	O	['N']	[40]
41	.	O	['N']	[41]
#3502
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	noncardiogenic	B	['N']	[3]
4	pulmonary	I	['N']	[4]
5	edema	I-Adverse_Effect	['N']	[5]
6	by	O	['N']	[6]
7	ethanolamine	B	['N']	[7]
8	oleate	I-Drug	['Causes']	[5]
9	.	O	['N']	[9]
#3503
0	Hypersensitivity	B-Adverse_Effect	['N']	[0]
1	to	O	['N']	[1]
2	zonisamide	B-Drug	['Causes']	[0]
3	was	O	['N']	[3]
4	confirmed	O	['N']	[4]
5	by	O	['N']	[5]
6	the	O	['N']	[6]
7	skin	O	['N']	[7]
8	patch	O	['N']	[8]
9	test	O	['N']	[9]
10	.	O	['N']	[10]
#3504
0	Methamphetamine	B-Drug	['Causes']	[22]
1	's	O	['N']	[1]
2	extensive	O	['N']	[2]
3	physiologic	O	['N']	[3]
4	effects	O	['N']	[4]
5	,	O	['N']	[5]
6	inconsistent	O	['N']	[6]
7	street	O	['N']	[7]
8	purity	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	multiple	O	['N']	[11]
12	routes	O	['N']	[12]
13	of	O	['N']	[13]
14	administration	O	['N']	[14]
15	offer	O	['N']	[15]
16	many	O	['N']	[16]
17	possibilities	O	['N']	[17]
18	for	O	['N']	[18]
19	injury	B	['N']	[19]
20	to	I	['N']	[20]
21	the	I	['N']	[21]
22	cornea	I-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#3505
0	A	O	['N']	[0]
1	71-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	,	O	['N']	[5]
6	who	O	['N']	[6]
7	had	O	['N']	[7]
8	a	O	['N']	[8]
9	history	O	['N']	[9]
10	of	O	['N']	[10]
11	a	O	['N']	[11]
12	previous	O	['N']	[12]
13	bullous	B	['N']	[13]
14	drug	I	['N']	[14]
15	reaction	I-Adverse_Effect	['N']	[15]
16	to	O	['N']	[16]
17	a	O	['N']	[17]
18	sulfonamide	B-Drug	['Causes']	[15]
19	,	O	['N']	[19]
20	began	O	['N']	[20]
21	receiving	O	['N']	[21]
22	an	O	['N']	[22]
23	ophthalmic	O	['N']	[23]
24	preparation	O	['N']	[24]
25	that	O	['N']	[25]
26	contained	O	['N']	[26]
27	sulfacetamide	O	['N']	[27]
28	sodium	O	['N']	[28]
29	.	O	['N']	[29]
#3506
0	By	O	['N']	[0]
1	means	O	['N']	[1]
2	of	O	['N']	[2]
3	the	O	['N']	[3]
4	in	O	['N']	[4]
5	vitro	O	['N']	[5]
6	heparin	B-Drug	['Causes']	[10]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	platelet	B	['N']	[9]
10	activation	I-Adverse_Effect	['N']	[10]
11	(	O	['N']	[11]
12	HIPA	O	['N']	[12]
13	)	O	['N']	[13]
14	assay	O	['N']	[14]
15	it	O	['N']	[15]
16	was	O	['N']	[16]
17	shown	O	['N']	[17]
18	that	O	['N']	[18]
19	standard	O	['N']	[19]
20	heparin	O	['N']	[20]
21	and	O	['N']	[21]
22	the	O	['N']	[22]
23	LMW	O	['N']	[23]
24	heparins	O	['N']	[24]
25	Fragmin	O	['N']	[25]
26	and	O	['N']	[26]
27	Fraxiparin	O	['N']	[27]
28	(	O	['N']	[28]
29	Sanofi	O	['N']	[29]
30	Labaz	O	['N']	[30]
31	,	O	['N']	[31]
32	Munich	O	['N']	[32]
33	,	O	['N']	[33]
34	FRG	O	['N']	[34]
35	)	O	['N']	[35]
36	,	O	['N']	[36]
37	as	O	['N']	[37]
38	well	O	['N']	[38]
39	as	O	['N']	[39]
40	the	O	['N']	[40]
41	enoxaparine	O	['N']	[41]
42	Clexane	O	['N']	[42]
43	(	O	['N']	[43]
44	Nattermann	O	['N']	[44]
45	,	O	['N']	[45]
46	Cologne	O	['N']	[46]
47	,	O	['N']	[47]
48	FRG	O	['N']	[48]
49	)	O	['N']	[49]
50	,	O	['N']	[50]
51	all	O	['N']	[51]
52	induced	O	['N']	[52]
53	platelet	O	['N']	[53]
54	activation	O	['N']	[54]
55	with	O	['N']	[55]
56	the	O	['N']	[56]
57	patient	O	['N']	[57]
58	's	O	['N']	[58]
59	serum	O	['N']	[59]
60	.	O	['N']	[60]
#3507
0	This	O	['N']	[0]
1	patient	O	['N']	[1]
2	rapidly	O	['N']	[2]
3	progressed	O	['N']	[3]
4	from	O	['N']	[4]
5	mild	B	['N']	[5]
6	neurotoxicity	I-Adverse_Effect	['N']	[6]
7	to	O	['N']	[7]
8	fatal	O	['N']	[8]
9	encephalopathy	O	['N']	[9]
10	after	O	['N']	[10]
11	one	O	['N']	[11]
12	dose	O	['N']	[12]
13	of	O	['N']	[13]
14	intrathecal	O	['N']	[14]
15	methotrexate	B-Drug	['Causes']	[6]
16	during	O	['N']	[16]
17	his	O	['N']	[17]
18	third	O	['N']	[18]
19	cycle	O	['N']	[19]
20	of	O	['N']	[20]
21	chemotherapy	O	['N']	[21]
22	.	O	['N']	[22]
#3508
0	Case	O	['N']	[0]
1	report	O	['N']	[1]
2	:	O	['N']	[2]
3	mannitol	B-Drug	['Causes']	[5]
4	nephrotoxicity	B	['N']	[4]
5	syndrome	I-Adverse_Effect	['N']	[5]
6	:	O	['N']	[6]
7	role	O	['N']	[7]
8	of	O	['N']	[8]
9	hemodialysis	O	['N']	[9]
10	and	O	['N']	[10]
11	postulate	O	['N']	[11]
12	of	O	['N']	[12]
13	mechanisms	O	['N']	[13]
14	.	O	['N']	[14]
#3509
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	skin	O	['N']	[23]
24	eruptions	O	['N']	[24]
25	,	O	['N']	[25]
26	cervical	B	['N']	[26]
27	lymphadenopathy	I-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	O	['N']	[31]
32	lymphocytosis	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	O	['N']	[40]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	-	['N']	[42]
43	(	O	['N']	[43]
44	SMX	O	['N']	[44]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#3510
0	Ritonavir	B-Drug	['Causes']	[16]
1	acted	O	['N']	[1]
2	as	O	['N']	[2]
3	a	O	['N']	[3]
4	CYP3A4	O	['N']	[4]
5	inhibitor	O	['N']	[5]
6	,	O	['N']	[6]
7	diminishing	O	['N']	[7]
8	carbamazepine	O	['N']	[8]
9	metabolism	O	['N']	[9]
10	and	O	['N']	[10]
11	provoking	O	['N']	[11]
12	an	O	['N']	[12]
13	increase	B	['N']	[13]
14	in	I	['N']	[14]
15	serum	I	['N']	[15]
16	levels	I-Adverse_Effect	['N']	[16]
17	and	O	['N']	[17]
18	clinical	O	['N']	[18]
19	toxicity	O	['N']	[19]
20	.	O	['N']	[20]
#3511
0	Laryngeal	B	['N']	[0]
1	dyspnea	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	relation	O	['N']	[3]
4	to	O	['N']	[4]
5	an	O	['N']	[5]
6	interaction	O	['N']	[6]
7	between	O	['N']	[7]
8	acenocoumarol	O	['N']	[8]
9	and	O	['N']	[9]
10	topical	O	['N']	[10]
11	econazole	B-Drug	['Causes']	[1]
12	lotion	O	['N']	[12]
13	.	O	['N']	[13]
#3512
0	Encephalopathy	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	seizures	O	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	intravesical	O	['N']	[5]
6	alum	B-Drug	['Causes']	[0]
7	irrigations	O	['N']	[7]
8	.	O	['N']	[8]
#3513
0	Discontinuation	O	['N']	[0]
1	of	O	['N']	[1]
2	simvastatin	O	['N']	[2]
3	and	O	['N']	[3]
4	cyclosporine	B-Drug	['Causes']	[9]
5	resulted	O	['N']	[5]
6	in	O	['N']	[6]
7	resolution	O	['N']	[7]
8	of	O	['N']	[8]
9	rhabdomyolysis	B-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	normalization	O	['N']	[11]
12	of	O	['N']	[12]
13	renal	O	['N']	[13]
14	function	O	['N']	[14]
15	.	O	['N']	[15]
#3514
0	From	O	['N']	[0]
1	1996	O	['N']	[1]
2	to	O	['N']	[2]
3	2002	O	['N']	[3]
4	several	O	['N']	[4]
5	medications	O	['N']	[5]
6	were	O	['N']	[6]
7	changed	O	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	their	O	['N']	[10]
11	adverse	O	['N']	[11]
12	effects	O	['N']	[12]
13	:	O	['N']	[13]
14	indinavir	O	['N']	[14]
15	(	O	['N']	[15]
16	renal	O	['N']	[16]
17	colic	O	['N']	[17]
18	and	O	['N']	[18]
19	fever	O	['N']	[19]
20	)	O	['N']	[20]
21	,	O	['N']	[21]
22	nelfinavir	O	['N']	[22]
23	(	O	['N']	[23]
24	cutaneous	O	['N']	[24]
25	rash	O	['N']	[25]
26	)	O	['N']	[26]
27	,	O	['N']	[27]
28	and	O	['N']	[28]
29	efavirenz	B-Drug	['Causes']	[31]
30	(	O	['N']	[30]
31	nausea	B-Adverse_Effect	['N']	[31]
32	and	O	['N']	[32]
33	temporary	O	['N']	[33]
34	memory	O	['N']	[34]
35	loss	O	['N']	[35]
36	)	O	['N']	[36]
37	.	O	['N']	[37]
#3515
0	We	O	['N']	[0]
1	observed	O	['N']	[1]
2	ventricular	B	['N']	[2]
3	fibrillation	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	2	O	['N']	[5]
6	patients	O	['N']	[6]
7	who	O	['N']	[7]
8	presented	O	['N']	[8]
9	to	O	['N']	[9]
10	the	O	['N']	[10]
11	emergency	O	['N']	[11]
12	department	O	['N']	[12]
13	with	O	['N']	[13]
14	pre	O	['N']	[14]
15	-	O	['N']	[15]
16	excited	O	['N']	[16]
17	atrial	O	['N']	[17]
18	fibrillation	O	['N']	[18]
19	and	O	['N']	[19]
20	were	O	['N']	[20]
21	given	O	['N']	[21]
22	12	O	['N']	[22]
23	mg	O	['N']	[23]
24	of	O	['N']	[24]
25	adenosine	B-Drug	['Causes']	[3]
26	.	O	['N']	[26]
#3516
0	Gynecomastia	O	['N']	[0]
1	developed	O	['N']	[1]
2	in	O	['N']	[2]
3	two	O	['N']	[3]
4	epileptic	O	['N']	[4]
5	patients	O	['N']	[5]
6	some	O	['N']	[6]
7	months	O	['N']	[7]
8	after	O	['N']	[8]
9	the	O	['N']	[9]
10	addition	O	['N']	[10]
11	of	O	['N']	[11]
12	oral	O	['N']	[12]
13	fluoresone	O	['N']	[13]
14	750	B	['N']	[14]
15	mg	I-Dose	['N']	[15]
16	daily	O	['N']	[16]
17	to	O	['N']	[17]
18	the	O	['N']	[18]
19	phenobarbital	B-Drug	['Dosage']	[15]
20	and	O	['N']	[20]
21	phenytoin	O	['N']	[21]
22	already	O	['N']	[22]
23	being	O	['N']	[23]
24	administered	O	['N']	[24]
25	.	O	['N']	[25]
#3517
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	no	O	['N']	[2]
3	.	O	['N']	[3]
4	2	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	pathogenic	O	['N']	[7]
8	mechanism	O	['N']	[8]
9	seemed	O	['N']	[9]
10	to	O	['N']	[10]
11	be	O	['N']	[11]
12	persistent	O	['N']	[12]
13	light	O	['N']	[13]
14	reaction	O	['N']	[14]
15	preceded	O	['N']	[15]
16	by	O	['N']	[16]
17	systemic	O	['N']	[17]
18	photoallergy	O	['N']	[18]
19	,	O	['N']	[19]
20	as	O	['N']	[20]
21	he	O	['N']	[21]
22	had	O	['N']	[22]
23	taken	O	['N']	[23]
24	mequitazine	B-Drug	['Causes']	[39]
25	for	O	['N']	[25]
26	6	O	['N']	[26]
27	months	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	there	O	['N']	[30]
31	were	O	['N']	[31]
32	strong	O	['N']	[32]
33	positive	O	['N']	[33]
34	photopatch	O	['N']	[34]
35	test	O	['N']	[35]
36	results	O	['N']	[36]
37	with	O	['N']	[37]
38	immediate	O	['N']	[38]
39	erythema	B-Adverse_Effect	['N']	[39]
40	reaction	O	['N']	[40]
41	,	O	['N']	[41]
42	cross	O	['N']	[42]
43	-	O	['N']	[43]
44	reaction	O	['N']	[44]
45	to	O	['N']	[45]
46	promethazine	O	['N']	[46]
47	,	O	['N']	[47]
48	decreased	O	['N']	[48]
49	MED	O	['N']	[49]
50	to	O	['N']	[50]
51	both	O	['N']	[51]
52	UVA	O	['N']	[52]
53	and	O	['N']	[53]
54	UVB	O	['N']	[54]
55	,	O	['N']	[55]
56	and	O	['N']	[56]
57	persistence	O	['N']	[57]
58	of	O	['N']	[58]
59	the	O	['N']	[59]
60	photosensitivity	O	['N']	[60]
61	over	O	['N']	[61]
62	a	O	['N']	[62]
63	3-year	O	['N']	[63]
64	follow	O	['N']	[64]
65	-	O	['N']	[65]
66	up	O	['N']	[66]
67	period	O	['N']	[67]
68	after	O	['N']	[68]
69	discontinuation	O	['N']	[69]
70	of	O	['N']	[70]
71	the	O	['N']	[71]
72	mequitazine	O	['N']	[72]
73	.	O	['N']	[73]
#3518
0	Soon	O	['N']	[0]
1	after	O	['N']	[1]
2	introduction	O	['N']	[2]
3	of	O	['N']	[3]
4	insulin	B-Drug	['Causes']	[10]
5	therapy	O	['N']	[5]
6	,	O	['N']	[6]
7	she	O	['N']	[7]
8	developed	O	['N']	[8]
9	severe	B	['N']	[9]
10	anasarca	I-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	including	O	['N']	[12]
13	marked	O	['N']	[13]
14	peripheral	O	['N']	[14]
15	oedema	O	['N']	[15]
16	,	O	['N']	[16]
17	ascites	O	['N']	[17]
18	and	O	['N']	[18]
19	pleural	O	['N']	[19]
20	effusion	O	['N']	[20]
21	.	O	['N']	[21]
#3519
0	Less	O	['N']	[0]
1	common	O	['N']	[1]
2	adverse	O	['N']	[2]
3	events	O	['N']	[3]
4	to	O	['N']	[4]
5	dapsone	B-Drug	['Causes']	[46]
6	include	O	['N']	[6]
7	the	O	['N']	[7]
8	idiosyncratic	O	['N']	[8]
9	reactions	O	['N']	[9]
10	of	O	['N']	[10]
11	leukopenia	O	['N']	[11]
12	and	O	['N']	[12]
13	agranulocytosis	O	['N']	[13]
14	,	O	['N']	[14]
15	cutaneous	O	['N']	[15]
16	eruptions	O	['N']	[16]
17	,	O	['N']	[17]
18	peripheral	O	['N']	[18]
19	neuropathy	O	['N']	[19]
20	,	O	['N']	[20]
21	psychosis	O	['N']	[21]
22	,	O	['N']	[22]
23	toxic	O	['N']	[23]
24	hepatitis	O	['N']	[24]
25	,	O	['N']	[25]
26	cholestatic	O	['N']	[26]
27	jaundice	O	['N']	[27]
28	,	O	['N']	[28]
29	nephrotic	O	['N']	[29]
30	syndrome	O	['N']	[30]
31	,	O	['N']	[31]
32	renal	O	['N']	[32]
33	papillary	O	['N']	[33]
34	necrosis	O	['N']	[34]
35	,	O	['N']	[35]
36	severe	O	['N']	[36]
37	hypoalbuminemia	O	['N']	[37]
38	without	O	['N']	[38]
39	proteinuria	O	['N']	[39]
40	,	O	['N']	[40]
41	an	B	['N']	[41]
42	infectious	I	['N']	[42]
43	mononucleosis	I	['N']	[43]
44	-	I	['N']	[44]
45	like	I	['N']	[45]
46	syndrome	I-Adverse_Effect	['N']	[46]
47	,	O	['N']	[47]
48	and	O	['N']	[48]
49	minor	O	['N']	[49]
50	neurological	O	['N']	[50]
51	and	O	['N']	[51]
52	gastrointestinal	O	['N']	[52]
53	complaints	O	['N']	[53]
54	.	O	['N']	[54]
#3520
0	Cerebral	B	['N']	[0]
1	demyelinating	I	['N']	[1]
2	disease	I-Adverse_Effect	['N']	[2]
3	developed	O	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	during	O	['N']	[7]
8	adjuvant	O	['N']	[8]
9	therapy	O	['N']	[9]
10	with	O	['N']	[10]
11	levamisole	B-Drug	['Causes']	[2]
12	for	O	['N']	[12]
13	malignant	O	['N']	[13]
14	melanoma	O	['N']	[14]
15	.	O	['N']	[15]
#3521
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	details	O	['N']	[2]
3	the	O	['N']	[3]
4	pulmonary	O	['N']	[4]
5	pathologic	O	['N']	[5]
6	findings	O	['N']	[6]
7	in	O	['N']	[7]
8	four	O	['N']	[8]
9	patients	O	['N']	[9]
10	with	O	['N']	[10]
11	rheumatoid	O	['N']	[11]
12	arthritis	O	['N']	[12]
13	,	O	['N']	[13]
14	who	O	['N']	[14]
15	developed	O	['N']	[15]
16	new	O	['N']	[16]
17	onset	O	['N']	[17]
18	of	O	['N']	[18]
19	pulmonary	B	['N']	[19]
20	signs	I	['N']	[20]
21	and	I	['N']	[21]
22	symptoms	I	['N']	[22]
23	with	I	['N']	[23]
24	alveolar	I	['N']	[24]
25	infiltrates	I-Adverse_Effect	['N']	[25]
26	temporally	O	['N']	[26]
27	related	O	['N']	[27]
28	to	O	['N']	[28]
29	the	O	['N']	[29]
30	institution	O	['N']	[30]
31	of	O	['N']	[31]
32	etanercept	B-Drug	['Causes']	[25]
33	therapy	O	['N']	[33]
34	.	O	['N']	[34]
#3522
0	In	O	['N']	[0]
1	view	O	['N']	[1]
2	of	O	['N']	[2]
3	our	O	['N']	[3]
4	experience	O	['N']	[4]
5	in	O	['N']	[5]
6	the	O	['N']	[6]
7	present	O	['N']	[7]
8	case	O	['N']	[8]
9	,	O	['N']	[9]
10	it	O	['N']	[10]
11	should	O	['N']	[11]
12	be	O	['N']	[12]
13	stressed	O	['N']	[13]
14	that	O	['N']	[14]
15	close	O	['N']	[15]
16	monitoring	O	['N']	[16]
17	of	O	['N']	[17]
18	coagulation	O	['N']	[18]
19	capacity	O	['N']	[19]
20	is	O	['N']	[20]
21	necessary	O	['N']	[21]
22	in	O	['N']	[22]
23	critically	O	['N']	[23]
24	ill	O	['N']	[24]
25	patients	O	['N']	[25]
26	in	O	['N']	[26]
27	order	O	['N']	[27]
28	to	O	['N']	[28]
29	avoid	O	['N']	[29]
30	fatal	B	['N']	[30]
31	haemorrhage	I-Adverse_Effect	['N']	[31]
32	after	O	['N']	[32]
33	initiating	O	['N']	[33]
34	warfarin	B-Drug	['Causes']	[31]
35	therapy	O	['N']	[35]
36	regardless	O	['N']	[36]
37	of	O	['N']	[37]
38	the	O	['N']	[38]
39	dosage	O	['N']	[39]
40	.	O	['N']	[40]
#3523
0	Toxic	O	['N']	[0]
1	epidermal	O	['N']	[1]
2	necrolysis	O	['N']	[2]
3	after	O	['N']	[3]
4	the	O	['N']	[4]
5	use	O	['N']	[5]
6	of	O	['N']	[6]
7	high	B-Dose	['N']	[7]
8	-	O	['N']	[8]
9	dose	O	['N']	[9]
10	cytosine	B	['N']	[10]
11	arabinoside	I-Drug	['Dosage']	[7]
12	.	O	['N']	[12]
#3524
0	Amphotericin	B	['N']	[0]
1	B	I-Drug	['Causes']	[19]
2	(	O	['N']	[2]
3	AmB	O	['N']	[3]
4	)	O	['N']	[4]
5	is	O	['N']	[5]
6	effective	O	['N']	[6]
7	,	O	['N']	[7]
8	but	O	['N']	[8]
9	its	O	['N']	[9]
10	use	O	['N']	[10]
11	is	O	['N']	[11]
12	limited	O	['N']	[12]
13	by	O	['N']	[13]
14	toxicity	O	['N']	[14]
15	:	O	['N']	[15]
16	renal	O	['N']	[16]
17	impairment	O	['N']	[17]
18	,	O	['N']	[18]
19	anaemia	B-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	malaise	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	hypokalaemia	O	['N']	[26]
27	are	O	['N']	[27]
28	common	O	['N']	[28]
29	.	O	['N']	[29]
#3525
0	Exacerbations	B	['N']	[0]
1	of	I	['N']	[1]
2	the	I	['N']	[2]
3	heart	I	['N']	[3]
4	failure	I-Adverse_Effect	['N']	[4]
5	were	O	['N']	[5]
6	temporally	O	['N']	[6]
7	related	O	['N']	[7]
8	to	O	['N']	[8]
9	the	O	['N']	[9]
10	administration	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	antitumor	O	['N']	[13]
14	antibiotics	O	['N']	[14]
15	actinomycin	O	['N']	[15]
16	-	O	['N']	[16]
17	D	O	['N']	[17]
18	(	O	['N']	[18]
19	NSC-3053	B-Drug	['Causes']	[4]
20	)	O	['N']	[20]
21	and	O	['N']	[21]
22	mithramycin	O	['N']	[22]
23	(	O	['N']	[23]
24	NSC-24559	O	['N']	[24]
25	)	O	['N']	[25]
26	.	O	['N']	[26]
#3526
0	This	O	['N']	[0]
1	sulfonamide	O	['N']	[1]
2	like	O	['N']	[2]
3	nephropathy	O	['N']	[3]
4	should	O	['N']	[4]
5	be	O	['N']	[5]
6	differentiated	O	['N']	[6]
7	from	O	['N']	[7]
8	acetazolamide	B-Drug	['Causes']	[13]
9	-	O	['N']	[9]
10	related	O	['N']	[10]
11	calcium	B	['N']	[11]
12	phosphate	I	['N']	[12]
13	nephrolithiasis	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#3527
0	A	O	['N']	[0]
1	64	O	['N']	[1]
2	year	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	previous	O	['N']	[6]
7	history	O	['N']	[7]
8	of	O	['N']	[8]
9	coronary	O	['N']	[9]
10	stenting	O	['N']	[10]
11	five	O	['N']	[11]
12	days	O	['N']	[12]
13	before	O	['N']	[13]
14	was	O	['N']	[14]
15	admitted	O	['N']	[15]
16	in	O	['N']	[16]
17	our	O	['N']	[17]
18	institution	O	['N']	[18]
19	for	O	['N']	[19]
20	intracranial	B	['N']	[20]
21	bleeding	I-Adverse_Effect	['N']	[21]
22	while	O	['N']	[22]
23	receiving	O	['N']	[23]
24	aspirin	O	['N']	[24]
25	and	O	['N']	[25]
26	clopidogrel	B-Drug	['Causes']	[21]
27	.	O	['N']	[27]
#3528
0	PATIENT	O	['N']	[0]
1	AND	O	['N']	[1]
2	METHOD	O	['N']	[2]
3	:	O	['N']	[3]
4	A	O	['N']	[4]
5	34-year	O	['N']	[5]
6	-	O	['N']	[6]
7	old	O	['N']	[7]
8	woman	O	['N']	[8]
9	with	O	['N']	[9]
10	chronic	O	['N']	[10]
11	hepatitis	O	['N']	[11]
12	C	O	['N']	[12]
13	,	O	['N']	[13]
14	genotype	O	['N']	[14]
15	3	O	['N']	[15]
16	,	O	['N']	[16]
17	receiving	O	['N']	[17]
18	pegylated	B	['N']	[18]
19	interferon	I	['N']	[19]
20	alpha-2a	I-Drug	['Causes']	[31]
21	and	O	['N']	[21]
22	ribavirin	O	['N']	[22]
23	for	O	['N']	[23]
24	6	O	['N']	[24]
25	months	O	['N']	[25]
26	,	O	['N']	[26]
27	developed	O	['N']	[27]
28	progressive	O	['N']	[28]
29	malaise	O	['N']	[29]
30	and	O	['N']	[30]
31	anemia	B-Adverse_Effect	['N']	[31]
32	6	O	['N']	[32]
33	months	O	['N']	[33]
34	after	O	['N']	[34]
35	the	O	['N']	[35]
36	end	O	['N']	[36]
37	of	O	['N']	[37]
38	treatment	O	['N']	[38]
39	.	O	['N']	[39]
#3529
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	57-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	with	O	['N']	[7]
8	acral	O	['N']	[8]
9	erythrocyanosis	O	['N']	[9]
10	progressing	O	['N']	[10]
11	to	O	['N']	[11]
12	acute	O	['N']	[12]
13	digital	O	['N']	[13]
14	ischemia	O	['N']	[14]
15	and	O	['N']	[15]
16	gangrene	B-Adverse_Effect	['N']	[16]
17	that	O	['N']	[17]
18	developed	O	['N']	[18]
19	after	O	['N']	[19]
20	combined	O	['N']	[20]
21	chemotherapy	O	['N']	[21]
22	(	O	['N']	[22]
23	bleomycin	O	['N']	[23]
24	and	O	['N']	[24]
25	methotrexate	B-Drug	['Causes']	[16]
26	)	O	['N']	[26]
27	used	O	['N']	[27]
28	to	O	['N']	[28]
29	treat	O	['N']	[29]
30	a	O	['N']	[30]
31	metastatic	O	['N']	[31]
32	squamous	O	['N']	[32]
33	cell	O	['N']	[33]
34	carcinoma	O	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	hypopharynx	O	['N']	[37]
38	.	O	['N']	[38]
#3530
0	Macular	B	['N']	[0]
1	infarction	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	endophthalmitis	O	['N']	[3]
4	treated	O	['N']	[4]
5	with	O	['N']	[5]
6	vitrectomy	O	['N']	[6]
7	and	O	['N']	[7]
8	intravitreal	O	['N']	[8]
9	gentamicin	B-Drug	['Causes']	[1]
10	.	O	['N']	[10]
#3531
0	Thrombotic	O	['N']	[0]
1	thrombocytopenic	O	['N']	[1]
2	purpura	O	['N']	[2]
3	(	O	['N']	[3]
4	TTP	B-Adverse_Effect	['N']	[4]
5	)	O	['N']	[5]
6	developed	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	seropositive	O	['N']	[11]
12	rheumatoid	O	['N']	[12]
13	arthritis	O	['N']	[13]
14	(	O	['N']	[14]
15	RA	O	['N']	[15]
16	)	O	['N']	[16]
17	after	O	['N']	[17]
18	2	O	['N']	[18]
19	1/2	O	['N']	[19]
20	months	O	['N']	[20]
21	of	O	['N']	[21]
22	treatment	O	['N']	[22]
23	with	O	['N']	[23]
24	penicillamine	B-Drug	['Causes']	[4]
25	.	O	['N']	[25]
#3532
0	A	O	['N']	[0]
1	previous	O	['N']	[1]
2	study	O	['N']	[2]
3	of	O	['N']	[3]
4	patients	O	['N']	[4]
5	with	O	['N']	[5]
6	"	O	['N']	[6]
7	quinine	B-Drug	['Causes']	[12]
8	-	O	['N']	[8]
9	associated	O	['N']	[9]
10	TTP	B	['N']	[10]
11	/	I	['N']	[11]
12	HUS	I-Adverse_Effect	['N']	[12]
13	"	O	['N']	[13]
14	found	O	['N']	[14]
15	that	O	['N']	[15]
16	ADAMTS13	O	['N']	[16]
17	activities	O	['N']	[17]
18	were	O	['N']	[18]
19	not	O	['N']	[19]
20	abnormal	O	['N']	[20]
21	in	O	['N']	[21]
22	12/12	O	['N']	[22]
23	patients	O	['N']	[23]
24	.	O	['N']	[24]
#3533
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	unintentional	O	['N']	[5]
6	overdose	O	['N']	[6]
7	of	O	['N']	[7]
8	oral	O	['N']	[8]
9	pilocarpine	B-Drug	['Causes']	[17]
10	tablets	O	['N']	[10]
11	that	O	['N']	[11]
12	resulted	O	['N']	[12]
13	in	O	['N']	[13]
14	bradycardia	O	['N']	[14]
15	,	O	['N']	[15]
16	mild	B	['N']	[16]
17	hypotension	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	muscarinic	O	['N']	[20]
21	symptoms	O	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	patient	O	['N']	[24]
25	with	O	['N']	[25]
26	Sjogren	O	['N']	[26]
27	's	O	['N']	[27]
28	syndrome	O	['N']	[28]
29	.	O	['N']	[29]
#3534
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Two	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	ocular	O	['N']	[5]
6	inflammation	O	['N']	[6]
7	of	O	['N']	[7]
8	unknown	O	['N']	[8]
9	origin	O	['N']	[9]
10	developed	O	['N']	[10]
11	severe	B	['N']	[11]
12	chorioretinitis	I-Adverse_Effect	['N']	[12]
13	after	O	['N']	[13]
14	IVTA	B-Drug	['Causes']	[12]
15	injection	O	['N']	[15]
16	.	O	['N']	[16]
#3535
0	Posthypoglycemic	O	['N']	[0]
1	hyperglycemia	O	['N']	[1]
2	(	O	['N']	[2]
3	rebound	B	['N']	[3]
4	hyperglycemia	I-Adverse_Effect	['N']	[4]
5	)	O	['N']	[5]
6	after	O	['N']	[6]
7	overdosing	O	['N']	[7]
8	of	O	['N']	[8]
9	insulin	B-Drug	['Causes']	[4]
10	was	O	['N']	[10]
11	diagnosed	O	['N']	[11]
12	in	O	['N']	[12]
13	6	O	['N']	[13]
14	cats	O	['N']	[14]
15	with	O	['N']	[15]
16	diabetes	O	['N']	[16]
17	mellitus	O	['N']	[17]
18	.	O	['N']	[18]
#3536
0	Several	O	['N']	[0]
1	case	O	['N']	[1]
2	reports	O	['N']	[2]
3	of	O	['N']	[3]
4	aplastic	B	['N']	[4]
5	anemia	I-Adverse_Effect	['N']	[5]
6	with	O	['N']	[6]
7	use	O	['N']	[7]
8	of	O	['N']	[8]
9	acetazolamide	B-Drug	['Causes']	[5]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	two	O	['N']	[12]
13	cases	O	['N']	[13]
14	with	O	['N']	[14]
15	use	O	['N']	[15]
16	of	O	['N']	[16]
17	methazolamide	O	['N']	[17]
18	,	O	['N']	[18]
19	have	O	['N']	[19]
20	appeared	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	literature	O	['N']	[23]
24	.	O	['N']	[24]
#3537
0	Alopecia	O	['N']	[0]
1	,	O	['N']	[1]
2	nausea	O	['N']	[2]
3	,	O	['N']	[3]
4	and	O	['N']	[4]
5	vomiting	B-Adverse_Effect	['N']	[5]
6	were	O	['N']	[6]
7	attributed	O	['N']	[7]
8	to	O	['N']	[8]
9	the	O	['N']	[9]
10	cyclophosphamide	B-Drug	['Causes']	[5]
11	component	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	therapy	O	['N']	[14]
15	.	O	['N']	[15]
#3538
0	Pulmonary	B	['N']	[0]
1	fibrosis	I-Adverse_Effect	['N']	[1]
2	is	O	['N']	[2]
3	a	O	['N']	[3]
4	complication	O	['N']	[4]
5	of	O	['N']	[5]
6	paclitaxel	B-Drug	['Causes']	[1]
7	therapy	O	['N']	[7]
8	that	O	['N']	[8]
9	may	O	['N']	[9]
10	occur	O	['N']	[10]
11	despite	O	['N']	[11]
12	treatments	O	['N']	[12]
13	with	O	['N']	[13]
14	corticosteroids	O	['N']	[14]
15	.	O	['N']	[15]
#3539
0	Physicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	possible	O	['N']	[6]
7	association	O	['N']	[7]
8	between	O	['N']	[8]
9	the	O	['N']	[9]
10	use	O	['N']	[10]
11	of	O	['N']	[11]
12	alteplase	B-Drug	['Causes']	[18]
13	and	O	['N']	[13]
14	the	O	['N']	[14]
15	development	O	['N']	[15]
16	of	O	['N']	[16]
17	subfascial	B	['N']	[17]
18	hemorrhage	I-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#3540
0	A	O	['N']	[0]
1	17-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	with	O	['N']	[5]
6	refractory	O	['N']	[6]
7	psoriatic	O	['N']	[7]
8	arthritis	O	['N']	[8]
9	and	O	['N']	[9]
10	alpha-1	O	['N']	[10]
11	antitrypsin	O	['N']	[11]
12	deficiency	O	['N']	[12]
13	who	O	['N']	[13]
14	developed	O	['N']	[14]
15	a	O	['N']	[15]
16	syringotropic	B	['N']	[16]
17	hypersensitivity	I	['N']	[17]
18	reaction	I-Adverse_Effect	['N']	[18]
19	after	O	['N']	[19]
20	9	O	['N']	[20]
21	months	O	['N']	[21]
22	of	O	['N']	[22]
23	therapy	O	['N']	[23]
24	with	O	['N']	[24]
25	infliximab	O	['N']	[25]
26	and	O	['N']	[26]
27	leflunomide	B-Drug	['Causes']	[18]
28	is	O	['N']	[28]
29	described	O	['N']	[29]
30	.	O	['N']	[30]
#3541
0	The	O	['N']	[0]
1	second	O	['N']	[1]
2	patient	O	['N']	[2]
3	exhibited	O	['N']	[3]
4	sudden	O	['N']	[4]
5	PLMS	B-Adverse_Effect	['N']	[5]
6	following	O	['N']	[6]
7	olanzapine	B-Drug	['Causes']	[5]
8	injection	O	['N']	[8]
9	.	O	['N']	[9]
#3542
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	development	O	['N']	[3]
4	of	O	['N']	[4]
5	cutaneous	O	['N']	[5]
6	scleroderma	O	['N']	[6]
7	in	O	['N']	[7]
8	3	O	['N']	[8]
9	patients	O	['N']	[9]
10	coincident	O	['N']	[10]
11	with	O	['N']	[11]
12	the	O	['N']	[12]
13	use	O	['N']	[13]
14	of	O	['N']	[14]
15	bleomycin	B-Drug	['N']	[15]
16	in	O	['N']	[16]
17	low	O	['N']	[17]
18	cumulative	O	['N']	[18]
19	doses	O	['N']	[19]
20	of	O	['N']	[20]
21	less	O	['N']	[21]
22	than	O	['N']	[22]
23	100	-	['N']	[23]
24	U.	-	['N']	[24]
#3543
0	Hyponatraemia	B-Adverse_Effect	['N']	[0]
1	developed	O	['N']	[1]
2	after	O	['N']	[2]
3	rechallenge	O	['N']	[3]
4	with	O	['N']	[4]
5	controlled	O	['N']	[5]
6	release	O	['N']	[6]
7	carbamazepine	B-Drug	['Causes']	[0]
8	.	O	['N']	[8]
#3544
0	We	O	['N']	[0]
1	cared	O	['N']	[1]
2	for	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	progressive	O	['N']	[6]
7	renal	O	['N']	[7]
8	impairment	O	['N']	[8]
9	who	O	['N']	[9]
10	presented	O	['N']	[10]
11	with	O	['N']	[11]
12	blurred	O	['N']	[12]
13	vision	O	['N']	[13]
14	,	O	['N']	[14]
15	QRS	O	['N']	[15]
16	broadening	O	['N']	[16]
17	and	O	['N']	[17]
18	cardiac	B	['N']	[18]
19	failure	I-Adverse_Effect	['N']	[19]
20	due	O	['N']	[20]
21	to	O	['N']	[21]
22	chronic	O	['N']	[22]
23	cibenzoline	B-Drug	['Causes']	[19]
24	intoxication	O	['N']	[24]
25	.	O	['N']	[25]
#3545
0	Videopolysomnographic	O	['N']	[0]
1	and	O	['N']	[1]
2	pharmacokinetic	O	['N']	[2]
3	studies	O	['N']	[3]
4	with	O	['N']	[4]
5	monitoring	O	['N']	[5]
6	of	O	['N']	[6]
7	plasma	O	['N']	[7]
8	levodopa	B-Drug	['Causes']	[23]
9	levels	O	['N']	[9]
10	demonstrated	O	['N']	[10]
11	marked	O	['N']	[11]
12	motor	O	['N']	[12]
13	hyperactivity	O	['N']	[13]
14	during	O	['N']	[14]
15	augmentation	O	['N']	[15]
16	,	O	['N']	[16]
17	with	O	['N']	[17]
18	anarchic	B	['N']	[18]
19	discharges	I	['N']	[19]
20	of	I	['N']	[20]
21	motor	I	['N']	[21]
22	unit	I	['N']	[22]
23	potentials	I-Adverse_Effect	['N']	[23]
24	,	O	['N']	[24]
25	tonic	O	['N']	[25]
26	grouped	O	['N']	[26]
27	discharges	O	['N']	[27]
28	and	O	['N']	[28]
29	flexor	O	['N']	[29]
30	spasms	O	['N']	[30]
31	,	O	['N']	[31]
32	associated	O	['N']	[32]
33	with	O	['N']	[33]
34	painful	O	['N']	[34]
35	dysesthesia	O	['N']	[35]
36	.	O	['N']	[36]
#3546
0	Pneumocystis	B	['N']	[0]
1	pneumonia	I-Adverse_Effect	['N']	[1]
2	should	O	['N']	[2]
3	be	O	['N']	[3]
4	considered	O	['N']	[4]
5	in	O	['N']	[5]
6	asthmatic	O	['N']	[6]
7	patients	O	['N']	[7]
8	taking	O	['N']	[8]
9	methotrexate	B-Drug	['Causes']	[1]
10	who	O	['N']	[10]
11	present	O	['N']	[11]
12	with	O	['N']	[12]
13	fever	O	['N']	[13]
14	,	O	['N']	[14]
15	pulmonary	O	['N']	[15]
16	infiltrates	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	hypoxia	O	['N']	[19]
20	.	O	['N']	[20]
#3547
0	He	O	['N']	[0]
1	developed	O	['N']	[1]
2	recurrent	O	['N']	[2]
3	skin	B	['N']	[3]
4	rash	I-Adverse_Effect	['N']	[4]
5	,	O	['N']	[5]
6	fever	O	['N']	[6]
7	,	O	['N']	[7]
8	hypereosinophilia	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	acute	O	['N']	[11]
12	renal	O	['N']	[12]
13	failure	O	['N']	[13]
14	after	O	['N']	[14]
15	rechallenge	O	['N']	[15]
16	with	O	['N']	[16]
17	chlorambucil	B-Drug	['Causes']	[4]
18	.	O	['N']	[18]
#3548
0	The	O	['N']	[0]
1	cause	O	['N']	[1]
2	of	O	['N']	[2]
3	these	O	['N']	[3]
4	previously	O	['N']	[4]
5	unreported	O	['N']	[5]
6	side	O	['N']	[6]
7	effects	O	['N']	[7]
8	of	O	['N']	[8]
9	niacin	B-Drug	['Causes']	[35]
10	therapy	O	['N']	[10]
11	is	O	['N']	[11]
12	uncertain	O	['N']	[12]
13	but	O	['N']	[13]
14	may	O	['N']	[14]
15	be	O	['N']	[15]
16	related	O	['N']	[16]
17	to	O	['N']	[17]
18	prostaglandin	O	['N']	[18]
19	-	O	['N']	[19]
20	mediated	O	['N']	[20]
21	vasodilatation	O	['N']	[21]
22	,	O	['N']	[22]
23	hyperalgesia	O	['N']	[23]
24	of	O	['N']	[24]
25	sensory	O	['N']	[25]
26	nerve	O	['N']	[26]
27	receptors	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	potentiation	B	['N']	[30]
31	of	I	['N']	[31]
32	inflammation	I	['N']	[32]
33	in	I	['N']	[33]
34	the	I	['N']	[34]
35	gingiva	I-Adverse_Effect	['N']	[35]
36	with	O	['N']	[36]
37	referral	O	['N']	[37]
38	of	O	['N']	[38]
39	pain	O	['N']	[39]
40	to	O	['N']	[40]
41	the	O	['N']	[41]
42	teeth	O	['N']	[42]
43	.	O	['N']	[43]
#3549
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	reversible	O	['N']	[7]
8	nonthrombocytopenic	B	['N']	[8]
9	palpable	I	['N']	[9]
10	purpura	I-Adverse_Effect	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	metoclopramide	B-Drug	['Causes']	[10]
14	.	O	['N']	[14]
#3550
0	Case	O	['N']	[0]
1	study	O	['N']	[1]
2	:	O	['N']	[2]
3	a	O	['N']	[3]
4	modified	O	['N']	[4]
5	topical	O	['N']	[5]
6	treatment	O	['N']	[6]
7	regimen	O	['N']	[7]
8	for	O	['N']	[8]
9	sodium	O	['N']	[9]
10	warfarin	B-Drug	['Causes']	[14]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	necrotizing	B	['N']	[13]
14	fasciitis	I-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#3551
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	is	O	['N']	[2]
3	described	O	['N']	[3]
4	with	O	['N']	[4]
5	the	O	['N']	[5]
6	characteristic	O	['N']	[6]
7	features	O	['N']	[7]
8	of	O	['N']	[8]
9	phenytoin	B-Drug	['Causes']	[34]
10	hypersensitivity	O	['N']	[10]
11	syndrome	O	['N']	[11]
12	(	O	['N']	[12]
13	PHS	O	['N']	[13]
14	)	O	['N']	[14]
15	including	O	['N']	[15]
16	fever	O	['N']	[16]
17	,	O	['N']	[17]
18	erythroderma	O	['N']	[18]
19	,	O	['N']	[19]
20	tibial	O	['N']	[20]
21	and	O	['N']	[21]
22	facial	O	['N']	[22]
23	oedema	O	['N']	[23]
24	,	O	['N']	[24]
25	pinhead	O	['N']	[25]
26	-	O	['N']	[26]
27	sized	O	['N']	[27]
28	facial	O	['N']	[28]
29	pustules	O	['N']	[29]
30	and	O	['N']	[30]
31	abnormal	B	['N']	[31]
32	liver	I	['N']	[32]
33	function	I	['N']	[33]
34	tests	I-Adverse_Effect	['N']	[34]
35	.	O	['N']	[35]
#3552
0	A	O	['N']	[0]
1	26-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	Japanese	O	['N']	[4]
5	man	O	['N']	[5]
6	,	O	['N']	[6]
7	who	O	['N']	[7]
8	had	O	['N']	[8]
9	been	O	['N']	[9]
10	receiving	O	['N']	[10]
11	medical	O	['N']	[11]
12	attention	O	['N']	[12]
13	for	O	['N']	[13]
14	ulcerative	O	['N']	[14]
15	colitis	O	['N']	[15]
16	for	O	['N']	[16]
17	one	O	['N']	[17]
18	year	O	['N']	[18]
19	,	O	['N']	[19]
20	presented	O	['N']	[20]
21	with	O	['N']	[21]
22	diffuse	O	['N']	[22]
23	erythema	O	['N']	[23]
24	and	O	['N']	[24]
25	pustules	B-Adverse_Effect	['N']	[25]
26	on	O	['N']	[26]
27	his	O	['N']	[27]
28	face	O	['N']	[28]
29	and	O	['N']	[29]
30	trunk	O	['N']	[30]
31	,	O	['N']	[31]
32	malaise	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	fever	O	['N']	[35]
36	up	O	['N']	[36]
37	to	O	['N']	[37]
38	39	O	['N']	[38]
39	degrees	O	['N']	[39]
40	C	O	['N']	[40]
41	one	O	['N']	[41]
42	day	O	['N']	[42]
43	after	O	['N']	[43]
44	the	O	['N']	[44]
45	administration	O	['N']	[45]
46	of	O	['N']	[46]
47	salazosulfapyridine	B-Drug	['Causes']	[25]
48	.	O	['N']	[48]
#3553
0	Observations	O	['N']	[0]
1	in	O	['N']	[1]
2	our	O	['N']	[2]
3	patient	O	['N']	[3]
4	suggest	O	['N']	[4]
5	that	O	['N']	[5]
6	the	O	['N']	[6]
7	leukoencephalopathy	B-Adverse_Effect	['N']	[7]
8	that	O	['N']	[8]
9	developed	O	['N']	[9]
10	in	O	['N']	[10]
11	previously	O	['N']	[11]
12	reported	O	['N']	[12]
13	patients	O	['N']	[13]
14	who	O	['N']	[14]
15	received	O	['N']	[15]
16	5-fluorouracil	O	['N']	[16]
17	and	O	['N']	[17]
18	levamisole	B-Drug	['Causes']	[7]
19	may	O	['N']	[19]
20	have	O	['N']	[20]
21	been	O	['N']	[21]
22	caused	O	['N']	[22]
23	at	O	['N']	[23]
24	least	O	['N']	[24]
25	partly	O	['N']	[25]
26	by	O	['N']	[26]
27	levamisole	O	['N']	[27]
28	.	O	['N']	[28]
#3554
0	Bull's	B	['N']	[0]
1	-	I	['N']	[1]
2	eye	I	['N']	[2]
3	maculopathy	I-Adverse_Effect	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	quinacrine	B-Drug	['Causes']	[3]
7	therapy	O	['N']	[7]
8	for	O	['N']	[8]
9	malaria	O	['N']	[9]
10	.	O	['N']	[10]
#3555
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	CHF	O	['N']	[5]
6	and	O	['N']	[6]
7	ESRD	O	['N']	[7]
8	developed	O	['N']	[8]
9	myoclonic	B	['N']	[9]
10	muscle	I	['N']	[10]
11	spasms	I-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	receiving	O	['N']	[13]
14	dobutamine	B-Drug	['Causes']	[11]
15	by	O	['N']	[15]
16	continuous	O	['N']	[16]
17	i.v	O	['N']	[17]
18	.	O	['N']	[18]
19	infusion	O	['N']	[19]
20	.	O	['N']	[20]
#3556
0	The	O	['N']	[0]
1	frequency	O	['N']	[1]
2	and	O	['N']	[2]
3	relationship	O	['N']	[3]
4	of	O	['N']	[4]
5	granulocytopenia	B-Adverse_Effect	['N']	[5]
6	caused	O	['N']	[6]
7	by	O	['N']	[7]
8	sustained	O	['N']	[8]
9	-	O	['N']	[9]
10	release	O	['N']	[10]
11	procainamide	B-Drug	['Causes']	[5]
12	in	O	['N']	[12]
13	patients	O	['N']	[13]
14	with	O	['N']	[14]
15	tachyarrhythmias	O	['N']	[15]
16	are	O	['N']	[16]
17	briefly	O	['N']	[17]
18	discussed	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	prior	O	['N']	[21]
22	reported	O	['N']	[22]
23	cases	O	['N']	[23]
24	are	O	['N']	[24]
25	reviewed	O	['N']	[25]
26	.	O	['N']	[26]
#3557
0	Methylphenidate	O	['N']	[0]
1	and	O	['N']	[1]
2	dextroamphetamine	B-Drug	['Causes']	[6]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	peripheral	B	['N']	[5]
6	vasculopathy	I-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#3558
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	histories	O	['N']	[2]
3	are	O	['N']	[3]
4	presented	O	['N']	[4]
5	of	O	['N']	[5]
6	two	O	['N']	[6]
7	patients	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	lung	O	['N']	[10]
11	disease	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	the	O	['N']	[14]
15	use	O	['N']	[15]
16	of	O	['N']	[16]
17	nitrofurantoin	B-Drug	['Causes']	[25]
18	with	O	['N']	[18]
19	histological	O	['N']	[19]
20	features	O	['N']	[20]
21	of	O	['N']	[21]
22	bronchiolitis	B	['N']	[22]
23	obliterans	I	['N']	[23]
24	organising	I	['N']	[24]
25	pneumonia	I-Adverse_Effect	['N']	[25]
26	(	O	['N']	[26]
27	BOOP	O	['N']	[27]
28	)	O	['N']	[28]
29	,	O	['N']	[29]
30	a	O	['N']	[30]
31	rare	O	['N']	[31]
32	but	O	['N']	[32]
33	recognised	O	['N']	[33]
34	form	O	['N']	[34]
35	of	O	['N']	[35]
36	drug	O	['N']	[36]
37	induced	O	['N']	[37]
38	injury	O	['N']	[38]
39	.	O	['N']	[39]
#3559
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	diabetic	O	['N']	[6]
7	patient	O	['N']	[7]
8	taking	O	['N']	[8]
9	glyburide	O	['N']	[9]
10	who	O	['N']	[10]
11	was	O	['N']	[11]
12	prescribed	O	['N']	[12]
13	ciprofloxacin	B-Drug	['Causes']	[17]
14	and	O	['N']	[14]
15	developed	O	['N']	[15]
16	prolonged	B	['N']	[16]
17	hypoglycemia	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	which	O	['N']	[19]
20	persisted	O	['N']	[20]
21	for	O	['N']	[21]
22	over	O	['N']	[22]
23	24	O	['N']	[23]
24	hours	O	['N']	[24]
25	.	O	['N']	[25]
#3560
0	When	O	['N']	[0]
1	SASP	O	['N']	[1]
2	was	O	['N']	[2]
3	changed	O	['N']	[3]
4	to	O	['N']	[4]
5	5-aminosalicylic	B	['N']	[5]
6	acid	I-Drug	['Causes']	[21]
7	(	O	['N']	[7]
8	5-ASA	O	['N']	[8]
9	)	O	['N']	[9]
10	,	O	['N']	[10]
11	his	O	['N']	[11]
12	skin	O	['N']	[12]
13	eruptions	O	['N']	[13]
14	were	O	['N']	[14]
15	resolved	O	['N']	[15]
16	,	O	['N']	[16]
17	however	O	['N']	[17]
18	,	O	['N']	[18]
19	he	O	['N']	[19]
20	developed	O	['N']	[20]
21	weakness	B-Adverse_Effect	['N']	[21]
22	and	O	['N']	[22]
23	atrophy	O	['N']	[23]
24	in	O	['N']	[24]
25	his	O	['N']	[25]
26	right	O	['N']	[26]
27	arm	O	['N']	[27]
28	as	O	['N']	[28]
29	well	O	['N']	[29]
30	as	O	['N']	[30]
31	progressive	O	['N']	[31]
32	worsening	O	['N']	[32]
33	of	O	['N']	[33]
34	the	O	['N']	[34]
35	dysesthesia	O	['N']	[35]
36	in	O	['N']	[36]
37	his	O	['N']	[37]
38	legs	O	['N']	[38]
39	and	O	['N']	[39]
40	gait	O	['N']	[40]
41	disturbance	O	['N']	[41]
42	.	O	['N']	[42]
#3561
0	Gelofusine	B-Drug	['Causes']	[1]
1	allergy	I-Adverse_Effect	['N']	[1]
2	--	O	['N']	[2]
3	the	O	['N']	[3]
4	need	O	['N']	[4]
5	for	O	['N']	[5]
6	identification	O	['N']	[6]
7	jewellery	O	['N']	[7]
8	.	O	['N']	[8]
#3562
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	acute	O	['N']	[6]
7	renal	O	['N']	[7]
8	failure	O	['N']	[8]
9	with	O	['N']	[9]
10	hyperkalemia	B-Adverse_Effect	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	the	O	['N']	[13]
14	recently	O	['N']	[14]
15	marketed	O	['N']	[15]
16	direct	O	['N']	[16]
17	renin	O	['N']	[17]
18	inhibitor	O	['N']	[18]
19	aliskiren	B-Drug	['Causes']	[10]
20	.	O	['N']	[20]
#3563
0	DATA	O	['N']	[0]
1	SYNTHESIS	O	['N']	[1]
2	:	O	['N']	[2]
3	Genetic	O	['N']	[3]
4	deficiencies	O	['N']	[4]
5	in	O	['N']	[5]
6	DPD	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	rate	O	['N']	[9]
10	-	O	['N']	[10]
11	limiting	O	['N']	[11]
12	enzyme	O	['N']	[12]
13	responsible	O	['N']	[13]
14	for	O	['N']	[14]
15	5-FU	B-Drug	['Causes']	[48]
16	catabolism	O	['N']	[16]
17	,	O	['N']	[17]
18	may	O	['N']	[18]
19	occur	O	['N']	[19]
20	in	O	['N']	[20]
21	3	O	['N']	[21]
22	%	O	['N']	[22]
23	or	O	['N']	[23]
24	more	O	['N']	[24]
25	of	O	['N']	[25]
26	patients	O	['N']	[26]
27	with	O	['N']	[27]
28	cancer	O	['N']	[28]
29	putting	O	['N']	[29]
30	them	O	['N']	[30]
31	at	O	['N']	[31]
32	increased	O	['N']	[32]
33	risk	O	['N']	[33]
34	for	O	['N']	[34]
35	unusually	O	['N']	[35]
36	severe	O	['N']	[36]
37	adverse	O	['N']	[37]
38	reactions	O	['N']	[38]
39	(	O	['N']	[39]
40	e.g.	O	['N']	[40]
41	,	O	['N']	[41]
42	diarrhea	O	['N']	[42]
43	,	O	['N']	[43]
44	stomatitis	O	['N']	[44]
45	,	O	['N']	[45]
46	mucositis	O	['N']	[46]
47	,	O	['N']	[47]
48	myelosuppression	B-Adverse_Effect	['N']	[48]
49	,	O	['N']	[49]
50	neurotoxicity	O	['N']	[50]
51	)	O	['N']	[51]
52	to	O	['N']	[52]
53	standard	O	['N']	[53]
54	doses	O	['N']	[54]
55	of	O	['N']	[55]
56	5-FU	O	['N']	[56]
57	.	O	['N']	[57]
#3564
0	Massive	B	['N']	[0]
1	subfascial	I	['N']	[1]
2	hematoma	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	alteplase	B-Drug	['Causes']	[2]
5	therapy	O	['N']	[5]
6	for	O	['N']	[6]
7	acute	O	['N']	[7]
8	myocardial	O	['N']	[8]
9	infarction	O	['N']	[9]
10	.	O	['N']	[10]
#3565
0	A	O	['N']	[0]
1	7-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	with	O	['N']	[4]
5	congenital	O	['N']	[5]
6	toxoplasmosis	O	['N']	[6]
7	who	O	['N']	[7]
8	took	O	['N']	[8]
9	pyrimethamine	B-Drug	['Causes']	[20]
10	and	O	['N']	[10]
11	sulfadiazine	O	['N']	[11]
12	for	O	['N']	[12]
13	reactivated	O	['N']	[13]
14	chorioretinitis	O	['N']	[14]
15	developed	O	['N']	[15]
16	fever	O	['N']	[16]
17	,	O	['N']	[17]
18	severe	B	['N']	[18]
19	cutaneous	I	['N']	[19]
20	involvement	I-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	swelling	O	['N']	[22]
23	,	O	['N']	[23]
24	abdominal	O	['N']	[24]
25	pain	O	['N']	[25]
26	and	O	['N']	[26]
27	transaminitis	O	['N']	[27]
28	,	O	['N']	[28]
29	persisting	O	['N']	[29]
30	weeks	O	['N']	[30]
31	after	O	['N']	[31]
32	withholding	O	['N']	[32]
33	medicines	O	['N']	[33]
34	.	O	['N']	[34]
#3566
0	New	O	['N']	[0]
1	onset	O	['N']	[1]
2	of	O	['N']	[2]
3	CD	O	['N']	[3]
4	may	O	['N']	[4]
5	be	O	['N']	[5]
6	considered	O	['N']	[6]
7	as	O	['N']	[7]
8	an	O	['N']	[8]
9	immune	B	['N']	[9]
10	-	I	['N']	[10]
11	mediated	I	['N']	[11]
12	injury	I-Adverse_Effect	['N']	[12]
13	induced	O	['N']	[13]
14	by	O	['N']	[14]
15	etanercept	B-Drug	['Causes']	[12]
16	.	O	['N']	[16]
#3567
0	L	B	['N']	[0]
1	-	I	['N']	[1]
2	asparaginase	I-Drug	['Causes']	[7]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	severe	B	['N']	[5]
6	necrotizing	I	['N']	[6]
7	pancreatitis	I-Adverse_Effect	['N']	[7]
8	successfully	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	percutaneous	O	['N']	[11]
12	drainage	O	['N']	[12]
13	.	O	['N']	[13]
#3568
0	A	O	['N']	[0]
1	54-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	developed	O	['N']	[5]
6	TEN	B-Adverse_Effect	['N']	[6]
7	4	O	['N']	[7]
8	weeks	O	['N']	[8]
9	after	O	['N']	[9]
10	beginning	O	['N']	[10]
11	lamotrigine	B-Drug	['Causes']	[6]
12	for	O	['N']	[12]
13	complex	O	['N']	[13]
14	partial	O	['N']	[14]
15	seizures	O	['N']	[15]
16	related	O	['N']	[16]
17	to	O	['N']	[17]
18	a	O	['N']	[18]
19	glioblastoma	O	['N']	[19]
20	multiforme	O	['N']	[20]
21	brain	O	['N']	[21]
22	tumor	O	['N']	[22]
23	.	O	['N']	[23]
#3569
0	In	O	['N']	[0]
1	eight	O	['N']	[1]
2	patients	O	['N']	[2]
3	,	O	['N']	[3]
4	a	O	['N']	[4]
5	mean	O	['N']	[5]
6	decrease	O	['N']	[6]
7	in	O	['N']	[7]
8	serum	O	['N']	[8]
9	Na+	O	['N']	[9]
10	of	O	['N']	[10]
11	8.25	O	['N']	[11]
12	+	O	['N']	[12]
13	/-	O	['N']	[13]
14	3.2	O	['N']	[14]
15	mEq	O	['N']	[15]
16	/	O	['N']	[16]
17	L	O	['N']	[17]
18	was	O	['N']	[18]
19	observed	O	['N']	[19]
20	after	O	['N']	[20]
21	a	O	['N']	[21]
22	single	O	['N']	[22]
23	200	B	['N']	[23]
24	mg	I-Dose	['N']	[24]
25	intravenous	O	['N']	[25]
26	dose	O	['N']	[26]
27	of	O	['N']	[27]
28	lorcainide	B-Drug	['Dosage']	[24]
29	.	O	['N']	[29]
#3570
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	aseptic	B	['N']	[9]
10	meningitis	I-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	hemolytic	O	['N']	[12]
13	anemia	O	['N']	[13]
14	,	O	['N']	[14]
15	hepatitis	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	orthostatic	O	['N']	[18]
19	hypotension	O	['N']	[19]
20	simultaneously	O	['N']	[20]
21	during	O	['N']	[21]
22	treatment	O	['N']	[22]
23	with	O	['N']	[23]
24	trimethoprim	B-Drug	['Causes']	[10]
25	-	O	['N']	[25]
26	sulfamethoxazole	O	['N']	[26]
27	is	O	['N']	[27]
28	described	O	['N']	[28]
29	.	O	['N']	[29]
#3571
0	This	O	['N']	[0]
1	pattern	O	['N']	[1]
2	is	O	['N']	[2]
3	suggestive	O	['N']	[3]
4	of	O	['N']	[4]
5	renal	B	['N']	[5]
6	toxicity	I-Adverse_Effect	['N']	[6]
7	due	O	['N']	[7]
8	to	O	['N']	[8]
9	tobramycin	B-Drug	['Causes']	[6]
10	.	O	['N']	[10]
#3572
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	HBV	B	['N']	[6]
7	reactivation	I-Adverse_Effect	['N']	[7]
8	occurring	O	['N']	[8]
9	during	O	['N']	[9]
10	the	O	['N']	[10]
11	year	O	['N']	[11]
12	following	O	['N']	[12]
13	rituximab	B-Drug	['Causes']	[7]
14	monotherapy	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	absence	O	['N']	[17]
18	of	O	['N']	[18]
19	any	O	['N']	[19]
20	other	O	['N']	[20]
21	immunosuppressive	O	['N']	[21]
22	factor	O	['N']	[22]
23	.	O	['N']	[23]
#3573
0	Behavioral	O	['N']	[0]
1	side	O	['N']	[1]
2	effects	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	clonazepam	B-Drug	['Causes']	[21]
6	may	O	['N']	[6]
7	include	O	['N']	[7]
8	agitation	O	['N']	[8]
9	,	O	['N']	[9]
10	aggression	O	['N']	[10]
11	,	O	['N']	[11]
12	hyperactivity	O	['N']	[12]
13	,	O	['N']	[13]
14	irritability	O	['N']	[14]
15	,	O	['N']	[15]
16	property	O	['N']	[16]
17	destruction	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	temper	B	['N']	[20]
21	tantrums	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#3574
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	an	O	['N']	[3]
4	individual	O	['N']	[4]
5	with	O	['N']	[5]
6	mental	O	['N']	[6]
7	retardation	O	['N']	[7]
8	who	O	['N']	[8]
9	experienced	O	['N']	[9]
10	behavioral	B	['N']	[10]
11	exacerbation	I-Adverse_Effect	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	clonazepam	B-Drug	['Causes']	[11]
15	prescribed	O	['N']	[15]
16	at	O	['N']	[16]
17	2	O	['N']	[17]
18	mg	O	['N']	[18]
19	/	O	['N']	[19]
20	day	O	['N']	[20]
21	(	O	['N']	[21]
22	0.02	O	['N']	[22]
23	mg	O	['N']	[23]
24	/	O	['N']	[24]
25	kg	O	['N']	[25]
26	/	O	['N']	[26]
27	day	O	['N']	[27]
28	)	O	['N']	[28]
29	to	O	['N']	[29]
30	treat	O	['N']	[30]
31	aggression	O	['N']	[31]
32	,	O	['N']	[32]
33	self	O	['N']	[33]
34	-	O	['N']	[34]
35	injurious	O	['N']	[35]
36	behavior	O	['N']	[36]
37	,	O	['N']	[37]
38	property	O	['N']	[38]
39	destruction	O	['N']	[39]
40	,	O	['N']	[40]
41	and	O	['N']	[41]
42	screaming	O	['N']	[42]
43	,	O	['N']	[43]
44	which	O	['N']	[44]
45	was	O	['N']	[45]
46	measured	O	['N']	[46]
47	with	O	['N']	[47]
48	a	O	['N']	[48]
49	15-minute	O	['N']	[49]
50	partial	O	['N']	[50]
51	interval	O	['N']	[51]
52	recording	O	['N']	[52]
53	measurement	O	['N']	[53]
54	method	O	['N']	[54]
55	.	O	['N']	[55]
#3575
0	Total	B	['N']	[0]
1	blindness	I	['N']	[1]
2	with	I	['N']	[2]
3	a	I	['N']	[3]
4	transient	I	['N']	[4]
5	tonic	I	['N']	[5]
6	pupillary	I	['N']	[6]
7	response	I-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	denervation	O	['N']	[9]
10	supersensitivity	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	abnormal	O	['N']	[13]
14	visual	O	['N']	[14]
15	-	O	['N']	[15]
16	evoked	O	['N']	[16]
17	potentials	O	['N']	[17]
18	developed	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	54-year	O	['N']	[21]
22	-	O	['N']	[22]
23	old	O	['N']	[23]
24	man	O	['N']	[24]
25	after	O	['N']	[25]
26	the	O	['N']	[26]
27	use	O	['N']	[27]
28	of	O	['N']	[28]
29	quinine	B	['N']	[29]
30	sulfate	I-Drug	['Causes']	[7]
31	for	O	['N']	[31]
32	leg	O	['N']	[32]
33	cramps	O	['N']	[33]
34	.	O	['N']	[34]
#3576
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	PRES	B-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	collapsing	O	['N']	[10]
11	focal	O	['N']	[11]
12	glomeruloesclerosis	O	['N']	[12]
13	(	O	['N']	[13]
14	collapsing	O	['N']	[14]
15	FGS	O	['N']	[15]
16	)	O	['N']	[16]
17	with	O	['N']	[17]
18	complete	O	['N']	[18]
19	recovery	O	['N']	[19]
20	after	O	['N']	[20]
21	withdrawal	O	['N']	[21]
22	of	O	['N']	[22]
23	cyclosporine	O	['N']	[23]
24	(	O	['N']	[24]
25	CSA	B-Drug	['Causes']	[5]
26	)	O	['N']	[26]
27	.	O	['N']	[27]
#3577
0	Although	O	['N']	[0]
1	major	O	['N']	[1]
2	hazards	O	['N']	[2]
3	of	O	['N']	[3]
4	treatment	O	['N']	[4]
5	of	O	['N']	[5]
6	hypophosphatemic	O	['N']	[6]
7	osteomalacia	O	['N']	[7]
8	with	O	['N']	[8]
9	phosphate	O	['N']	[9]
10	and	O	['N']	[10]
11	calcitriol	B-Drug	['Causes']	[18]
12	are	O	['N']	[12]
13	secondary	O	['N']	[13]
14	hyperparathyroidism	O	['N']	[14]
15	and	O	['N']	[15]
16	vitamin	B	['N']	[16]
17	D	I	['N']	[17]
18	intoxication	I-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	potassium	O	['N']	[20]
21	loss	O	['N']	[21]
22	also	O	['N']	[22]
23	should	O	['N']	[23]
24	be	O	['N']	[24]
25	kept	O	['N']	[25]
26	in	O	['N']	[26]
27	mind	O	['N']	[27]
28	.	O	['N']	[28]
#3578
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	article	O	['N']	[2]
3	lithium	B-Drug	['Causes']	[19]
4	is	O	['N']	[4]
5	not	O	['N']	[5]
6	discussed	O	['N']	[6]
7	,	O	['N']	[7]
8	although	O	['N']	[8]
9	there	O	['N']	[9]
10	are	O	['N']	[10]
11	a	O	['N']	[11]
12	number	O	['N']	[12]
13	of	O	['N']	[13]
14	concerns	O	['N']	[14]
15	about	O	['N']	[15]
16	lithium	O	['N']	[16]
17	's	O	['N']	[17]
18	potential	O	['N']	[18]
19	teratogenicity	B-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	it	O	['N']	[22]
23	has	O	['N']	[23]
24	been	O	['N']	[24]
25	implicated	O	['N']	[25]
26	in	O	['N']	[26]
27	Epstein	O	['N']	[27]
28	's	O	['N']	[28]
29	anomaly	O	['N']	[29]
30	,	O	['N']	[30]
31	a	O	['N']	[31]
32	congenital	O	['N']	[32]
33	heart	O	['N']	[33]
34	defect	O	['N']	[34]
35	among	O	['N']	[35]
36	infants	O	['N']	[36]
37	born	O	['N']	[37]
38	to	O	['N']	[38]
39	women	O	['N']	[39]
40	taking	O	['N']	[40]
41	lithium	O	['N']	[41]
42	;	O	['N']	[42]
43	as	O	['N']	[43]
44	with	O	['N']	[44]
45	other	O	['N']	[45]
46	medications	O	['N']	[46]
47	,	O	['N']	[47]
48	however	O	['N']	[48]
49	,	O	['N']	[49]
50	the	O	['N']	[50]
51	data	O	['N']	[51]
52	have	O	['N']	[52]
53	specific	O	['N']	[53]
54	limitations	O	['N']	[54]
55	.	O	['N']	[55]
#3579
0	Spontaneous	B	['N']	[0]
1	splenic	I	['N']	[1]
2	infarction	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	sumatriptan	B-Drug	['Causes']	[2]
6	use	O	['N']	[6]
7	.	O	['N']	[7]
#3580
0	The	O	['N']	[0]
1	events	O	['N']	[1]
2	of	O	['N']	[2]
3	non	B	['N']	[3]
4	-	I	['N']	[4]
5	convulsive	I	['N']	[5]
6	status	I	['N']	[6]
7	epilepticus	I-Adverse_Effect	['N']	[7]
8	subsided	O	['N']	[8]
9	following	O	['N']	[9]
10	reduction	O	['N']	[10]
11	in	O	['N']	[11]
12	tiagabine	B-Drug	['Causes']	[7]
13	dosages	O	['N']	[13]
14	.	O	['N']	[14]
#3581
0	Eye	B	['N']	[0]
1	movement	I	['N']	[1]
2	disorders	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	bone	O	['N']	[4]
5	marrow	O	['N']	[5]
6	transplant	O	['N']	[6]
7	patients	O	['N']	[7]
8	on	O	['N']	[8]
9	cyclosporin	O	['N']	[9]
10	and	O	['N']	[10]
11	ganciclovir	B-Drug	['Causes']	[2]
12	.	O	['N']	[12]
#3582
0	This	O	['N']	[0]
1	experience	O	['N']	[1]
2	supports	O	['N']	[2]
3	the	O	['N']	[3]
4	hypothesis	O	['N']	[4]
5	that	O	['N']	[5]
6	heparin	B-Drug	['Causes']	[19]
7	can	O	['N']	[7]
8	be	O	['N']	[8]
9	readministered	O	['N']	[9]
10	early	O	['N']	[10]
11	to	O	['N']	[11]
12	patients	O	['N']	[12]
13	with	O	['N']	[13]
14	heparin	O	['N']	[14]
15	-	O	['N']	[15]
16	associated	O	['N']	[16]
17	thrombocytopenia	O	['N']	[17]
18	and	O	['N']	[18]
19	thrombosis	B-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	provided	O	['N']	[21]
22	antiplatelet	O	['N']	[22]
23	therapy	O	['N']	[23]
24	is	O	['N']	[24]
25	given	O	['N']	[25]
26	.	O	['N']	[26]
#3583
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	,	O	['N']	[2]
3	in	O	['N']	[3]
4	whom	O	['N']	[4]
5	tumour	O	['N']	[5]
6	overkill	O	['N']	[6]
7	by	O	['N']	[7]
8	cytotoxic	O	['N']	[8]
9	treatment	O	['N']	[9]
10	,	O	['N']	[10]
11	including	O	['N']	[11]
12	high	O	['N']	[12]
13	dose	O	['N']	[13]
14	methotrexate	B-Drug	['Causes']	[33]
15	with	O	['N']	[15]
16	folinic	O	['N']	[16]
17	acid	O	['N']	[17]
18	rescue	O	['N']	[18]
19	,	O	['N']	[19]
20	resulted	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	'	O	['N']	[23]
24	phosphate	O	['N']	[24]
25	shower	O	['N']	[25]
26	syndrome	O	['N']	[26]
27	'	O	['N']	[27]
28	(	O	['N']	[28]
29	hyper	O	['N']	[29]
30	-	O	['N']	[30]
31	uricaemia	O	['N']	[31]
32	,	O	['N']	[32]
33	hyperkalaemia	B-Adverse_Effect	['N']	[33]
34	and	O	['N']	[34]
35	hyperphosphataemia	O	['N']	[35]
36	with	O	['N']	[36]
37	hypocalcaemia	O	['N']	[37]
38	and	O	['N']	[38]
39	tetany	O	['N']	[39]
40	,	O	['N']	[40]
41	with	O	['N']	[41]
42	metabolic	O	['N']	[42]
43	acidosis	O	['N']	[43]
44	and	O	['N']	[44]
45	acute	O	['N']	[45]
46	renal	O	['N']	[46]
47	impairment	O	['N']	[47]
48	)	O	['N']	[48]
49	are	O	['N']	[49]
50	described	O	['N']	[50]
51	.	O	['N']	[51]
#3584
0	Painful	O	['N']	[0]
1	erosion	O	['N']	[1]
2	of	O	['N']	[2]
3	psoriatic	O	['N']	[3]
4	plaques	O	['N']	[4]
5	is	O	['N']	[5]
6	a	O	['N']	[6]
7	less	O	['N']	[7]
8	common	O	['N']	[8]
9	sign	O	['N']	[9]
10	of	O	['N']	[10]
11	methotrexate	B-Drug	['Causes']	[20]
12	toxicity	O	['N']	[12]
13	that	O	['N']	[13]
14	may	O	['N']	[14]
15	precede	O	['N']	[15]
16	evidence	O	['N']	[16]
17	of	O	['N']	[17]
18	bone	B	['N']	[18]
19	marrow	I	['N']	[19]
20	suppression	I-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#3585
0	A	O	['N']	[0]
1	7-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	with	O	['N']	[4]
5	congenital	O	['N']	[5]
6	toxoplasmosis	O	['N']	[6]
7	who	O	['N']	[7]
8	took	O	['N']	[8]
9	pyrimethamine	B-Drug	['Causes']	[16]
10	and	O	['N']	[10]
11	sulfadiazine	O	['N']	[11]
12	for	O	['N']	[12]
13	reactivated	O	['N']	[13]
14	chorioretinitis	O	['N']	[14]
15	developed	O	['N']	[15]
16	fever	B-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	severe	O	['N']	[18]
19	cutaneous	O	['N']	[19]
20	involvement	O	['N']	[20]
21	,	O	['N']	[21]
22	swelling	O	['N']	[22]
23	,	O	['N']	[23]
24	abdominal	O	['N']	[24]
25	pain	O	['N']	[25]
26	and	O	['N']	[26]
27	transaminitis	O	['N']	[27]
28	,	O	['N']	[28]
29	persisting	O	['N']	[29]
30	weeks	O	['N']	[30]
31	after	O	['N']	[31]
32	withholding	O	['N']	[32]
33	medicines	O	['N']	[33]
34	.	O	['N']	[34]
#3586
0	Therefore	O	['N']	[0]
1	,	O	['N']	[1]
2	clinicians	O	['N']	[2]
3	should	O	['N']	[3]
4	pay	O	['N']	[4]
5	close	O	['N']	[5]
6	attention	O	['N']	[6]
7	to	O	['N']	[7]
8	possible	O	['N']	[8]
9	onset	O	['N']	[9]
10	of	O	['N']	[10]
11	RD	B-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	patients	O	['N']	[13]
14	with	O	['N']	[14]
15	multiple	O	['N']	[15]
16	risk	O	['N']	[16]
17	factors	O	['N']	[17]
18	for	O	['N']	[18]
19	TD	O	['N']	[19]
20	,	O	['N']	[20]
21	even	O	['N']	[21]
22	when	O	['N']	[22]
23	SDA	B-Drug	['Causes']	[11]
24	therapy	O	['N']	[24]
25	is	O	['N']	[25]
26	used	O	['N']	[26]
27	.	O	['N']	[27]
#3587
0	Intrahepatic	B	['N']	[0]
1	cholestasis	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	cutaneous	O	['N']	[3]
4	bullae	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	glibenclamide	B-Drug	['Causes']	[1]
8	therapy	O	['N']	[8]
9	are	O	['N']	[9]
10	described	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	61-year	O	['N']	[13]
14	-	O	['N']	[14]
15	old	O	['N']	[15]
16	diabetic	O	['N']	[16]
17	patient	O	['N']	[17]
18	who	O	['N']	[18]
19	presented	O	['N']	[19]
20	wit	O	['N']	[20]
21	hypoglycaemic	O	['N']	[21]
22	coma	O	['N']	[22]
23	.	O	['N']	[23]
#3588
0	Treatment	O	['N']	[0]
1	of	O	['N']	[1]
2	amiodarone	B-Drug	['Causes']	[5]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	thyrotoxicosis	B-Adverse_Effect	['N']	[5]
6	(	O	['N']	[6]
7	AIT	O	['N']	[7]
8	)	O	['N']	[8]
9	with	O	['N']	[9]
10	thionamide	O	['N']	[10]
11	,	O	['N']	[11]
12	lithium	O	['N']	[12]
13	or	O	['N']	[13]
14	radioactive	O	['N']	[14]
15	iodine	O	['N']	[15]
16	is	O	['N']	[16]
17	ineffective	O	['N']	[17]
18	.	O	['N']	[18]
#3589
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	five	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	carboplatin	B-Drug	['Dosage']	[14]
6	(	O	['N']	[6]
7	CBDCA	O	['N']	[7]
8	)	O	['N']	[8]
9	hypersensitivity	O	['N']	[9]
10	after	O	['N']	[10]
11	weekly	O	['N']	[11]
12	low	B	['N']	[12]
13	-	I	['N']	[13]
14	dose	I-Dose	['N']	[14]
15	paclitaxel	O	['N']	[15]
16	(	O	['N']	[16]
17	60	O	['N']	[17]
18	mg	O	['N']	[18]
19	/	O	['N']	[19]
20	m2)/CBDCA	O	['N']	[20]
21	(	O	['N']	[21]
22	area	O	['N']	[22]
23	under	O	['N']	[23]
24	the	O	['N']	[24]
25	concentration	O	['N']	[25]
26	curve	O	['N']	[26]
27	=	O	['N']	[27]
28	2	O	['N']	[28]
29	)	O	['N']	[29]
30	therapy	O	['N']	[30]
31	in	O	['N']	[31]
32	patients	O	['N']	[32]
33	with	O	['N']	[33]
34	recurrent	O	['N']	[34]
35	ovarian	O	['N']	[35]
36	cancer	O	['N']	[36]
37	receiving	O	['N']	[37]
38	multiple	O	['N']	[38]
39	platinum	O	['N']	[39]
40	-	O	['N']	[40]
41	based	O	['N']	[41]
42	chemotherapy	O	['N']	[42]
43	.	O	['N']	[43]
#3590
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	present	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	respiratory	B	['N']	[7]
8	depression	I-Adverse_Effect	['N']	[8]
9	following	O	['N']	[9]
10	the	O	['N']	[10]
11	administration	O	['N']	[11]
12	of	O	['N']	[12]
13	nebulised	O	['N']	[13]
14	morphine	B-Drug	['Causes']	[8]
15	.	O	['N']	[15]
#3591
0	Esophageal	B	['N']	[0]
1	candidiasis	I-Adverse_Effect	['N']	[1]
2	was	O	['N']	[2]
3	diagnosed	O	['N']	[3]
4	at	O	['N']	[4]
5	endoscopy	O	['N']	[5]
6	in	O	['N']	[6]
7	two	O	['N']	[7]
8	patients	O	['N']	[8]
9	receiving	O	['N']	[9]
10	omeprazole	B-Drug	['Causes']	[1]
11	therapy	O	['N']	[11]
12	.	O	['N']	[12]
#3592
0	Vancomycin	B-Drug	['Causes']	[40]
1	is	O	['N']	[1]
2	widely	O	['N']	[2]
3	used	O	['N']	[3]
4	against	O	['N']	[4]
5	methicillin	O	['N']	[5]
6	-	O	['N']	[6]
7	resistant	O	['N']	[7]
8	Staphylococcus	O	['N']	[8]
9	aureus	O	['N']	[9]
10	infections	O	['N']	[10]
11	,	O	['N']	[11]
12	but	O	['N']	[12]
13	it	O	['N']	[13]
14	is	O	['N']	[14]
15	associated	O	['N']	[15]
16	with	O	['N']	[16]
17	many	O	['N']	[17]
18	adverse	O	['N']	[18]
19	effects	O	['N']	[19]
20	such	O	['N']	[20]
21	as	O	['N']	[21]
22	nephrotoxicity	O	['N']	[22]
23	,	O	['N']	[23]
24	ototoxicity	O	['N']	[24]
25	,	O	['N']	[25]
26	gastrointestinal	O	['N']	[26]
27	disturbances	O	['N']	[27]
28	,	O	['N']	[28]
29	blood	O	['N']	[29]
30	disorders	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	two	O	['N']	[33]
34	types	O	['N']	[34]
35	of	O	['N']	[35]
36	hypersensitivity	O	['N']	[36]
37	reactions	O	['N']	[37]
38	-	O	['N']	[38]
39	an	O	['N']	[39]
40	anaphylactoid	B-Adverse_Effect	['N']	[40]
41	reaction	O	['N']	[41]
42	known	O	['N']	[42]
43	as	O	['N']	[43]
44	"	O	['N']	[44]
45	red	O	['N']	[45]
46	man	O	['N']	[46]
47	syndrome	O	['N']	[47]
48	"	O	['N']	[48]
49	and	O	['N']	[49]
50	anaphylaxis	O	['N']	[50]
51	.	O	['N']	[51]
#3593
0	Paradoxical	B	['N']	[0]
1	cerebral	I	['N']	[1]
2	cortical	I	['N']	[2]
3	hyperexcitability	I-Adverse_Effect	['N']	[3]
4	following	O	['N']	[4]
5	flupirtine	B-Drug	['Causes']	[3]
6	overdose	O	['N']	[6]
7	.	O	['N']	[7]
#3594
0	Calcification	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	ossification	O	['N']	[2]
3	of	O	['N']	[3]
4	the	O	['N']	[4]
5	spinal	O	['N']	[5]
6	arachnoid	O	['N']	[6]
7	after	O	['N']	[7]
8	intrathecal	O	['N']	[8]
9	administration	O	['N']	[9]
10	of	O	['N']	[10]
11	Depo	B	['N']	[11]
12	-	I	['N']	[12]
13	Medrol	I-Drug	['Causes']	[0]
14	.	O	['N']	[14]
#3595
0	Several	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	lithium	B-Drug	['Causes']	[9]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	Creutzfeldt	B	['N']	[6]
7	-	I	['N']	[7]
8	Jakob	I	['N']	[8]
9	syndrome	I-Adverse_Effect	['N']	[9]
10	have	O	['N']	[10]
11	been	O	['N']	[11]
12	reported	O	['N']	[12]
13	to	O	['N']	[13]
14	date	O	['N']	[14]
15	;	O	['N']	[15]
16	all	O	['N']	[16]
17	of	O	['N']	[17]
18	them	O	['N']	[18]
19	were	O	['N']	[19]
20	elderly	O	['N']	[20]
21	patients	O	['N']	[21]
22	and	O	['N']	[22]
23	a	O	['N']	[23]
24	half	O	['N']	[24]
25	had	O	['N']	[25]
26	"	O	['N']	[26]
27	therapeutic	O	['N']	[27]
28	"	O	['N']	[28]
29	lithium	O	['N']	[29]
30	serum	O	['N']	[30]
31	levels	O	['N']	[31]
32	.	O	['N']	[32]
#3596
0	Although	O	['N']	[0]
1	adverse	O	['N']	[1]
2	effects	O	['N']	[2]
3	are	O	['N']	[3]
4	usually	O	['N']	[4]
5	mild	O	['N']	[5]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	author	O	['N']	[8]
9	reports	O	['N']	[9]
10	here	O	['N']	[10]
11	a	O	['N']	[11]
12	case	O	['N']	[12]
13	of	O	['N']	[13]
14	leucocytopenia	O	['N']	[14]
15	and	O	['N']	[15]
16	thrombocytopenia	B-Adverse_Effect	['N']	[16]
17	with	O	['N']	[17]
18	quetiapine	B-Drug	['Causes']	[16]
19	treatment	O	['N']	[19]
20	that	O	['N']	[20]
21	required	O	['N']	[21]
22	its	O	['N']	[22]
23	discontinuation	O	['N']	[23]
24	.	O	['N']	[24]
#3597
0	Here	O	['N']	[0]
1	we	O	['N']	[1]
2	report	O	['N']	[2]
3	ramipril	B-Drug	['Causes']	[7]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	cutaneous	B	['N']	[6]
7	vasculitis	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	who	O	['N']	[11]
12	required	O	['N']	[12]
13	steroid	O	['N']	[13]
14	therapy	O	['N']	[14]
15	to	O	['N']	[15]
16	control	O	['N']	[16]
17	it	O	['N']	[17]
18	.	O	['N']	[18]
#3598
0	We	O	['N']	[0]
1	described	O	['N']	[1]
2	the	O	['N']	[2]
3	occurrence	O	['N']	[3]
4	of	O	['N']	[4]
5	L	B	['N']	[5]
6	-	I	['N']	[6]
7	dopa	I-Drug	['Causes']	[12]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	myoclonus	O	['N']	[10]
11	and	O	['N']	[11]
12	seizures	B-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	case	O	['N']	[15]
16	of	O	['N']	[16]
17	parkinsonism	O	['N']	[17]
18	with	O	['N']	[18]
19	its	O	['N']	[19]
20	SEPs	O	['N']	[20]
21	findings	O	['N']	[21]
22	.	O	['N']	[22]
#3599
0	A	O	['N']	[0]
1	7-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	with	O	['N']	[4]
5	congenital	O	['N']	[5]
6	toxoplasmosis	O	['N']	[6]
7	who	O	['N']	[7]
8	took	O	['N']	[8]
9	pyrimethamine	B-Drug	['Causes']	[25]
10	and	O	['N']	[10]
11	sulfadiazine	O	['N']	[11]
12	for	O	['N']	[12]
13	reactivated	O	['N']	[13]
14	chorioretinitis	O	['N']	[14]
15	developed	O	['N']	[15]
16	fever	O	['N']	[16]
17	,	O	['N']	[17]
18	severe	O	['N']	[18]
19	cutaneous	O	['N']	[19]
20	involvement	O	['N']	[20]
21	,	O	['N']	[21]
22	swelling	O	['N']	[22]
23	,	O	['N']	[23]
24	abdominal	B	['N']	[24]
25	pain	I-Adverse_Effect	['N']	[25]
26	and	O	['N']	[26]
27	transaminitis	O	['N']	[27]
28	,	O	['N']	[28]
29	persisting	O	['N']	[29]
30	weeks	O	['N']	[30]
31	after	O	['N']	[31]
32	withholding	O	['N']	[32]
33	medicines	O	['N']	[33]
34	.	O	['N']	[34]
#3600
0	Disopyramide	O	['N']	[0]
1	(	O	['N']	[1]
2	Norpace)-induced	-	['N']	[2]
3	hypoglycemia	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#3601
0	Clinicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	possibility	O	['N']	[6]
7	that	O	['N']	[7]
8	vinorelbine	B-Drug	['Causes']	[14]
9	may	O	['N']	[9]
10	cause	O	['N']	[10]
11	SIADH	O	['N']	[11]
12	and	O	['N']	[12]
13	possibly	O	['N']	[13]
14	hypokalemia	B-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#3602
0	Only	O	['N']	[0]
1	3	O	['N']	[1]
2	cases	O	['N']	[2]
3	of	O	['N']	[3]
4	imatinib	B-Drug	['Causes']	[9]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	tumor	B	['N']	[7]
8	lysis	I	['N']	[8]
9	syndrome	I-Adverse_Effect	['N']	[9]
10	have	O	['N']	[10]
11	been	O	['N']	[11]
12	reported	O	['N']	[12]
13	.	O	['N']	[13]
#3603
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	fibrosing	B	['N']	[5]
6	alveolitis	I-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	diagnosed	O	['N']	[8]
9	by	O	['N']	[9]
10	lung	O	['N']	[10]
11	biopsy	O	['N']	[11]
12	,	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	patient	O	['N']	[15]
16	receiving	O	['N']	[16]
17	amiodarone	B-Drug	['Causes']	[6]
18	which	O	['N']	[18]
19	responded	O	['N']	[19]
20	to	O	['N']	[20]
21	corticosteroid	O	['N']	[21]
22	therapy	O	['N']	[22]
23	.	O	['N']	[23]
#3604
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	likely	O	['N']	[2]
3	that	O	['N']	[3]
4	RA	B-Drug	['Causes']	[11]
5	contributed	O	['N']	[5]
6	to	O	['N']	[6]
7	the	O	['N']	[7]
8	deterioration	B	['N']	[8]
9	in	I	['N']	[9]
10	renal	I	['N']	[10]
11	function	I-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	these	O	['N']	[13]
14	patients	O	['N']	[14]
15	.	O	['N']	[15]
#3605
0	Autopsy	O	['N']	[0]
1	findings	O	['N']	[1]
2	were	O	['N']	[2]
3	consistent	O	['N']	[3]
4	with	O	['N']	[4]
5	bleomycin	O	['N']	[5]
6	and	O	['N']	[6]
7	oxygen	B-Drug	['Causes']	[11]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	pulmonary	B	['N']	[10]
11	damage	I-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#3606
0	ARDS	B-Adverse_Effect	['N']	[0]
1	has	O	['N']	[1]
2	been	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	the	O	['N']	[5]
6	administration	O	['N']	[6]
7	of	O	['N']	[7]
8	other	O	['N']	[8]
9	monoclonal	O	['N']	[9]
10	antibodies	O	['N']	[10]
11	,	O	['N']	[11]
12	such	O	['N']	[12]
13	as	O	['N']	[13]
14	infliximab	O	['N']	[14]
15	,	O	['N']	[15]
16	gemtuzumab	B	['N']	[16]
17	ozogamicin	I-Drug	['Causes']	[0]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	OKT3	O	['N']	[20]
21	and	O	['N']	[21]
22	is	O	['N']	[22]
23	believed	O	['N']	[23]
24	to	O	['N']	[24]
25	be	O	['N']	[25]
26	directly	O	['N']	[26]
27	mediated	O	['N']	[27]
28	by	O	['N']	[28]
29	release	O	['N']	[29]
30	of	O	['N']	[30]
31	proinflammatory	O	['N']	[31]
32	cytokines	O	['N']	[32]
33	.	O	['N']	[33]
#3607
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	a	O	['N']	[3]
4	large	O	['N']	[4]
5	hydatid	O	['N']	[5]
6	cyst	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	left	O	['N']	[9]
10	lobe	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	liver	O	['N']	[13]
14	developed	O	['N']	[14]
15	metabolic	B	['N']	[15]
16	acidosis	I-Adverse_Effect	['N']	[16]
17	following	O	['N']	[17]
18	rather	O	['N']	[18]
19	liberal	O	['N']	[19]
20	use	O	['N']	[20]
21	of	O	['N']	[21]
22	cetrimide	B-Drug	['Causes']	[16]
23	-	O	['N']	[23]
24	chlorhexidine	O	['N']	[24]
25	solution	O	['N']	[25]
26	as	O	['N']	[26]
27	a	O	['N']	[27]
28	scolicidal	O	['N']	[28]
29	agent	O	['N']	[29]
30	.	O	['N']	[30]
#3608
0	A	O	['N']	[0]
1	child	O	['N']	[1]
2	in	O	['N']	[2]
3	whom	O	['N']	[3]
4	a	O	['N']	[4]
5	phenobarbital	B-Drug	['Causes']	[30]
6	hypersensitivity	O	['N']	[6]
7	drug	O	['N']	[7]
8	reaction	O	['N']	[8]
9	developed	O	['N']	[9]
10	which	O	['N']	[10]
11	consisted	O	['N']	[11]
12	of	O	['N']	[12]
13	fever	O	['N']	[13]
14	,	O	['N']	[14]
15	a	O	['N']	[15]
16	pruritic	O	['N']	[16]
17	desquamating	O	['N']	[17]
18	erythrodermic	O	['N']	[18]
19	rash	O	['N']	[19]
20	,	O	['N']	[20]
21	alopecia	O	['N']	[21]
22	,	O	['N']	[22]
23	icterus	O	['N']	[23]
24	,	O	['N']	[24]
25	protein	O	['N']	[25]
26	-	O	['N']	[26]
27	losing	O	['N']	[27]
28	enteropathy	O	['N']	[28]
29	,	O	['N']	[29]
30	myositis	B-Adverse_Effect	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	nephritis	O	['N']	[33]
34	,	O	['N']	[34]
35	is	O	['N']	[35]
36	described	O	['N']	[36]
37	.	O	['N']	[37]
#3609
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	O	['N']	[19]
20	developed	O	['N']	[20]
21	confusion	O	['N']	[21]
22	,	O	['N']	[22]
23	agitation	O	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	O	['N']	[25]
26	,	O	['N']	[26]
27	tremors	O	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	B	['N']	[29]
30	jerks	I-Adverse_Effect	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	O	['N']	[32]
33	gait	O	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	B-Drug	['Causes']	[30]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#3610
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	acromegaly	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	severe	O	['N']	[9]
10	drug	O	['N']	[10]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	hepatitis	B-Adverse_Effect	['N']	[13]
14	during	O	['N']	[14]
15	combined	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	the	O	['N']	[18]
19	long	O	['N']	[19]
20	-	O	['N']	[20]
21	acting	O	['N']	[21]
22	somatostatin	O	['N']	[22]
23	-	O	['N']	[23]
24	analog	O	['N']	[24]
25	octreotide	O	['N']	[25]
26	and	O	['N']	[26]
27	the	O	['N']	[27]
28	GH	O	['N']	[28]
29	receptor	O	['N']	[29]
30	antagonist	O	['N']	[30]
31	pegvisomant	B-Drug	['Causes']	[13]
32	.	O	['N']	[32]
#3611
0	Agranulocytosis	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	ticlopidine	B-Drug	['Causes']	[0]
4	:	O	['N']	[4]
5	a	O	['N']	[5]
6	possible	O	['N']	[6]
7	benefit	O	['N']	[7]
8	with	O	['N']	[8]
9	filgastim	O	['N']	[9]
10	.	O	['N']	[10]
#3612
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	is	O	['N']	[2]
3	presented	O	['N']	[3]
4	with	O	['N']	[4]
5	typical	O	['N']	[5]
6	hyperthyroidism	B-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	a	O	['N']	[10]
11	severe	O	['N']	[11]
12	proximal	O	['N']	[12]
13	muscle	O	['N']	[13]
14	weakness	O	['N']	[14]
15	and	O	['N']	[15]
16	a	O	['N']	[16]
17	raised	O	['N']	[17]
18	creatine	O	['N']	[18]
19	phosphokinase	O	['N']	[19]
20	after	O	['N']	[20]
21	treatment	O	['N']	[21]
22	for	O	['N']	[22]
23	hyperthyroidism	O	['N']	[23]
24	with	O	['N']	[24]
25	propylthiouracil	B-Drug	['Causes']	[6]
26	(	O	['N']	[26]
27	100	O	['N']	[27]
28	mg	O	['N']	[28]
29	orally	O	['N']	[29]
30	,	O	['N']	[30]
31	three	O	['N']	[31]
32	times	O	['N']	[32]
33	a	O	['N']	[33]
34	day	O	['N']	[34]
35	)	O	['N']	[35]
36	.	O	['N']	[36]
#3613
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Clinicians	O	['N']	[2]
3	should	O	['N']	[3]
4	be	O	['N']	[4]
5	aware	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	risk	O	['N']	[8]
9	of	O	['N']	[9]
10	serotonin	B	['N']	[10]
11	syndrome	I-Adverse_Effect	['N']	[11]
12	with	O	['N']	[12]
13	serious	O	['N']	[13]
14	extrapyramidal	O	['N']	[14]
15	reactions	O	['N']	[15]
16	in	O	['N']	[16]
17	patients	O	['N']	[17]
18	receiving	O	['N']	[18]
19	sertraline	B-Drug	['Causes']	[11]
20	or	O	['N']	[20]
21	venlafaxine	O	['N']	[21]
22	when	O	['N']	[22]
23	metoclopramide	O	['N']	[23]
24	is	O	['N']	[24]
25	coadministered	O	['N']	[25]
26	even	O	['N']	[26]
27	in	O	['N']	[27]
28	a	O	['N']	[28]
29	single	O	['N']	[29]
30	,	O	['N']	[30]
31	conventional	O	['N']	[31]
32	dose	O	['N']	[32]
33	.	O	['N']	[33]
#3614
0	Administration	O	['N']	[0]
1	of	O	['N']	[1]
2	lamotrigine	B-Drug	['Causes']	[17]
3	,	O	['N']	[3]
4	especially	O	['N']	[4]
5	in	O	['N']	[5]
6	combination	O	['N']	[6]
7	with	O	['N']	[7]
8	valproic	O	['N']	[8]
9	acid	O	['N']	[9]
10	,	O	['N']	[10]
11	may	O	['N']	[11]
12	lead	O	['N']	[12]
13	to	O	['N']	[13]
14	the	O	['N']	[14]
15	development	O	['N']	[15]
16	of	O	['N']	[16]
17	TEN	B-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#3615
0	Torsemide	B-Drug	['Causes']	[16]
1	appears	O	['N']	[1]
2	to	O	['N']	[2]
3	also	O	['N']	[3]
4	be	O	['N']	[4]
5	a	O	['N']	[5]
6	part	O	['N']	[6]
7	of	O	['N']	[7]
8	a	O	['N']	[8]
9	long	O	['N']	[9]
10	list	O	['N']	[10]
11	of	O	['N']	[11]
12	agents	O	['N']	[12]
13	that	O	['N']	[13]
14	can	O	['N']	[14]
15	cause	O	['N']	[15]
16	pancreatitis	B-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#3616
0	Furosemide	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	fever	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#3617
0	We	O	['N']	[0]
1	recommend	O	['N']	[1]
2	the	O	['N']	[2]
3	cautious	O	['N']	[3]
4	use	O	['N']	[4]
5	of	O	['N']	[5]
6	ketorolac	B-Drug	['Causes']	[16]
7	in	O	['N']	[7]
8	patients	O	['N']	[8]
9	with	O	['N']	[9]
10	underlying	O	['N']	[10]
11	illnesses	O	['N']	[11]
12	where	O	['N']	[12]
13	NSAID	O	['N']	[13]
14	-	O	['N']	[14]
15	induced	O	['N']	[15]
16	ototoxicity	B-Adverse_Effect	['N']	[16]
17	could	O	['N']	[17]
18	result	O	['N']	[18]
19	in	O	['N']	[19]
20	adverse	O	['N']	[20]
21	otologic	O	['N']	[21]
22	consequences	O	['N']	[22]
23	.	O	['N']	[23]
#3618
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	coccidioidal	O	['N']	[3]
4	meningitis	O	['N']	[4]
5	was	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	intrathecally	O	['N']	[8]
9	administered	O	['N']	[9]
10	amphotericin	B	['N']	[10]
11	B	I-Drug	['Causes']	[17]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	an	O	['N']	[14]
15	acute	B	['N']	[15]
16	toxic	I	['N']	[16]
17	delirium	I-Adverse_Effect	['N']	[17]
18	with	O	['N']	[18]
19	EEG	O	['N']	[19]
20	abnormalities	O	['N']	[20]
21	developed	O	['N']	[21]
22	.	O	['N']	[22]
#3619
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	a	O	['N']	[5]
6	liver	O	['N']	[6]
7	abscess	O	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	Entamoeba	O	['N']	[10]
11	histolytica	O	['N']	[11]
12	,	O	['N']	[12]
13	in	O	['N']	[13]
14	whom	O	['N']	[14]
15	metronidazole	B-Drug	['Causes']	[46]
16	therapy	O	['N']	[16]
17	(	O	['N']	[17]
18	total	O	['N']	[18]
19	dose	O	['N']	[19]
20	,	O	['N']	[20]
21	21	O	['N']	[21]
22	g	O	['N']	[22]
23	over	O	['N']	[23]
24	14	O	['N']	[24]
25	days	O	['N']	[25]
26	)	O	['N']	[26]
27	was	O	['N']	[27]
28	complicated	O	['N']	[28]
29	by	O	['N']	[29]
30	reversible	O	['N']	[30]
31	deafness	O	['N']	[31]
32	,	O	['N']	[32]
33	tinnitus	O	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	ataxia	O	['N']	[36]
37	and	O	['N']	[37]
38	who	O	['N']	[38]
39	relapsed	O	['N']	[39]
40	5	O	['N']	[40]
41	months	O	['N']	[41]
42	later	O	['N']	[42]
43	with	O	['N']	[43]
44	a	O	['N']	[44]
45	splenic	B	['N']	[45]
46	abscess	I-Adverse_Effect	['N']	[46]
47	.	O	['N']	[47]
#3620
0	In	O	['N']	[0]
1	all	O	['N']	[1]
2	three	O	['N']	[2]
3	cases	O	['N']	[3]
4	,	O	['N']	[4]
5	autopsy	O	['N']	[5]
6	revealed	O	['N']	[6]
7	gross	O	['N']	[7]
8	and	O	['N']	[8]
9	microscopic	O	['N']	[9]
10	features	O	['N']	[10]
11	indistinguishable	O	['N']	[11]
12	from	O	['N']	[12]
13	those	O	['N']	[13]
14	seen	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	Hamman	O	['N']	[17]
18	-	O	['N']	[18]
19	Rich	O	['N']	[19]
20	syndrome	O	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	methotrexate	B-Drug	['Causes']	[24]
24	hepatotoxicity	B-Adverse_Effect	['N']	[24]
25	was	O	['N']	[25]
26	present	O	['N']	[26]
27	in	O	['N']	[27]
28	one	O	['N']	[28]
29	.	O	['N']	[29]
#3621
0	It	O	['N']	[0]
1	was	O	['N']	[1]
2	concluded	O	['N']	[2]
3	that	O	['N']	[3]
4	ANCA	B-Adverse_Effect	['N']	[4]
5	is	O	['N']	[5]
6	closely	O	['N']	[6]
7	related	O	['N']	[7]
8	to	O	['N']	[8]
9	the	O	['N']	[9]
10	pathogenesis	O	['N']	[10]
11	of	O	['N']	[11]
12	crescentic	O	['N']	[12]
13	glomerulonephritis	O	['N']	[13]
14	and	O	['N']	[14]
15	that	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	PTU	B-Drug	['Causes']	[4]
19	appeared	O	['N']	[19]
20	to	O	['N']	[20]
21	induce	O	['N']	[21]
22	ANCA	O	['N']	[22]
23	.	O	['N']	[23]
#3622
0	The	O	['N']	[0]
1	induced	O	['N']	[1]
2	hyperglycaemia	O	['N']	[2]
3	could	O	['N']	[3]
4	not	O	['N']	[4]
5	be	O	['N']	[5]
6	controlled	O	['N']	[6]
7	sufficiently	O	['N']	[7]
8	,	O	['N']	[8]
9	despite	O	['N']	[9]
10	a	O	['N']	[10]
11	high	O	['N']	[11]
12	dose	O	['N']	[12]
13	of	O	['N']	[13]
14	insulin	B-Drug	['Causes']	[28]
15	(	O	['N']	[15]
16	>	O	['N']	[16]
17	110	O	['N']	[17]
18	units	O	['N']	[18]
19	/	O	['N']	[19]
20	day	O	['N']	[20]
21	)	O	['N']	[21]
22	,	O	['N']	[22]
23	suggesting	O	['N']	[23]
24	the	O	['N']	[24]
25	existence	O	['N']	[25]
26	of	O	['N']	[26]
27	insulin	B	['N']	[27]
28	insensitivity	I-Adverse_Effect	['N']	[28]
29	and	O	['N']	[29]
30	hyperinsulinaemia	O	['N']	[30]
31	.	O	['N']	[31]
#3623
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	phenytoin	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	hepatitis	B-Adverse_Effect	['N']	[6]
7	with	O	['N']	[7]
8	mononucleosis	O	['N']	[8]
9	is	O	['N']	[9]
10	reported	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	syndromes	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	phenytoin	O	['N']	[16]
17	hypersensitivity	O	['N']	[17]
18	reactions	O	['N']	[18]
19	are	O	['N']	[19]
20	discussed	O	['N']	[20]
21	.	O	['N']	[21]
#3624
0	Recognizing	O	['N']	[0]
1	early	O	['N']	[1]
2	signs	O	['N']	[2]
3	of	O	['N']	[3]
4	HMSN	O	['N']	[4]
5	,	O	['N']	[5]
6	such	O	['N']	[6]
7	as	O	['N']	[7]
8	areflexia	O	['N']	[8]
9	and	O	['N']	[9]
10	pes	O	['N']	[10]
11	cavus	O	['N']	[11]
12	deformity	O	['N']	[12]
13	,	O	['N']	[13]
14	can	O	['N']	[14]
15	prevent	O	['N']	[15]
16	severe	B	['N']	[16]
17	neurotoxicity	I-Adverse_Effect	['N']	[17]
18	of	O	['N']	[18]
19	polychemotherapy	O	['N']	[19]
20	by	O	['N']	[20]
21	avoiding	O	['N']	[21]
22	vincristine	B-Drug	['Causes']	[17]
23	.	O	['N']	[23]
#3625
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	suffering	O	['N']	[2]
3	from	O	['N']	[3]
4	heparin	B-Drug	['Causes']	[18]
5	-	O	['N']	[5]
6	associated	O	['N']	[6]
7	thrombocytopenia	O	['N']	[7]
8	(	O	['N']	[8]
9	HAT	O	['N']	[9]
10	)	O	['N']	[10]
11	,	O	['N']	[11]
12	recurrent	O	['N']	[12]
13	arteriothromboses	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	acute	B	['N']	[16]
17	renal	I	['N']	[17]
18	failure	I-Adverse_Effect	['N']	[18]
19	after	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	standard	O	['N']	[22]
23	heparin	O	['N']	[23]
24	is	O	['N']	[24]
25	described	O	['N']	[25]
26	.	O	['N']	[26]
#3626
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	HUS	O	['N']	[6]
7	after	O	['N']	[7]
8	treatment	O	['N']	[8]
9	with	O	['N']	[9]
10	mitomycin	B	['N']	[10]
11	C	I-Drug	['Dosage']	[18]
12	(	O	['N']	[12]
13	total	O	['N']	[13]
14	dose	O	['N']	[14]
15	144	B	['N']	[15]
16	mg	I	['N']	[16]
17	/	I	['N']	[17]
18	m2	I-Dose	['N']	[18]
19	)	O	['N']	[19]
20	due	O	['N']	[20]
21	to	O	['N']	[21]
22	a	O	['N']	[22]
23	carcinoma	O	['N']	[23]
24	of	O	['N']	[24]
25	the	O	['N']	[25]
26	ascending	O	['N']	[26]
27	colon	O	['N']	[27]
28	.	O	['N']	[28]
#3627
0	Soon	O	['N']	[0]
1	after	O	['N']	[1]
2	introduction	O	['N']	[2]
3	of	O	['N']	[3]
4	insulin	B-Drug	['Causes']	[15]
5	therapy	O	['N']	[5]
6	,	O	['N']	[6]
7	she	O	['N']	[7]
8	developed	O	['N']	[8]
9	severe	O	['N']	[9]
10	anasarca	O	['N']	[10]
11	,	O	['N']	[11]
12	including	O	['N']	[12]
13	marked	O	['N']	[13]
14	peripheral	B	['N']	[14]
15	oedema	I-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	ascites	O	['N']	[17]
18	and	O	['N']	[18]
19	pleural	O	['N']	[19]
20	effusion	O	['N']	[20]
21	.	O	['N']	[21]
#3628
0	We	O	['N']	[0]
1	thus	O	['N']	[1]
2	concluded	O	['N']	[2]
3	that	O	['N']	[3]
4	an	O	['N']	[4]
5	excessive	O	['N']	[5]
6	dose	O	['N']	[6]
7	of	O	['N']	[7]
8	AZ	B-Drug	['Causes']	[15]
9	had	O	['N']	[9]
10	probably	O	['N']	[10]
11	destroyed	B	['N']	[11]
12	the	I	['N']	[12]
13	gastric	I	['N']	[13]
14	mucosal	I	['N']	[14]
15	barrier	I-Adverse_Effect	['N']	[15]
16	or	O	['N']	[16]
17	thrombocytopenia	O	['N']	[17]
18	due	O	['N']	[18]
19	to	O	['N']	[19]
20	bone	O	['N']	[20]
21	marrow	O	['N']	[21]
22	disorder	O	['N']	[22]
23	and	O	['N']	[23]
24	thus	O	['N']	[24]
25	eventually	O	['N']	[25]
26	led	O	['N']	[26]
27	to	O	['N']	[27]
28	the	O	['N']	[28]
29	development	O	['N']	[29]
30	of	O	['N']	[30]
31	hemorrhagic	O	['N']	[31]
32	gastritis	O	['N']	[32]
33	.	O	['N']	[33]
#3629
0	Neuropathy	B-Adverse_Effect	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	significant	O	['N']	[3]
4	side	O	['N']	[4]
5	effect	O	['N']	[5]
6	of	O	['N']	[6]
7	thalidomide	B-Drug	['Causes']	[0]
8	therapy	O	['N']	[8]
9	,	O	['N']	[9]
10	which	O	['N']	[10]
11	may	O	['N']	[11]
12	limit	O	['N']	[12]
13	its	O	['N']	[13]
14	clinical	O	['N']	[14]
15	use	O	['N']	[15]
16	.	O	['N']	[16]
#3630
0	The	O	['N']	[0]
1	day	O	['N']	[1]
2	after	O	['N']	[2]
3	methotrexate	B-Drug	['Causes']	[12]
4	administration	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	patient	O	['N']	[7]
8	complained	O	['N']	[8]
9	of	O	['N']	[9]
10	severe	B	['N']	[10]
11	back	I	['N']	[11]
12	pain	I-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	urinary	O	['N']	[14]
15	retention	O	['N']	[15]
16	.	O	['N']	[16]
#3631
0	Regression	O	['N']	[0]
1	of	O	['N']	[1]
2	thyrotoxic	B	['N']	[2]
3	ophthalmopathy	I-Adverse_Effect	['N']	[3]
4	following	O	['N']	[4]
5	lithium	B-Drug	['Causes']	[3]
6	withdrawal	O	['N']	[6]
7	.	O	['N']	[7]
#3632
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	occurrence	O	['N']	[3]
4	of	O	['N']	[4]
5	renal	B	['N']	[5]
6	failure	I-Adverse_Effect	['N']	[6]
7	due	O	['N']	[7]
8	to	O	['N']	[8]
9	cholesterol	O	['N']	[9]
10	crystal	O	['N']	[10]
11	embolization	O	['N']	[11]
12	following	O	['N']	[12]
13	thrombolytic	O	['N']	[13]
14	therapy	O	['N']	[14]
15	with	O	['N']	[15]
16	intravenous	O	['N']	[16]
17	recombinant	B	['N']	[17]
18	tissue	I	['N']	[18]
19	-	I	['N']	[19]
20	type	I	['N']	[20]
21	plasminogen	I	['N']	[21]
22	activator	I-Drug	['Causes']	[6]
23	(	O	['N']	[23]
24	t	O	['N']	[24]
25	-	O	['N']	[25]
26	PA	O	['N']	[26]
27	)	O	['N']	[27]
28	.	O	['N']	[28]
#3633
0	Concomitant	O	['N']	[0]
1	irradiation	O	['N']	[1]
2	apparently	O	['N']	[2]
3	enhanced	O	['N']	[3]
4	the	O	['N']	[4]
5	skin	B	['N']	[5]
6	toxicity	I-Adverse_Effect	['N']	[6]
7	of	O	['N']	[7]
8	aminoglutethimide	B-Drug	['Causes']	[6]
9	or	O	['N']	[9]
10	possibly	O	['N']	[10]
11	aminoglutethimide	O	['N']	[11]
12	had	O	['N']	[12]
13	a	O	['N']	[13]
14	radiosensitizing	O	['N']	[14]
15	role	O	['N']	[15]
16	in	O	['N']	[16]
17	this	O	['N']	[17]
18	patient	O	['N']	[18]
19	.	O	['N']	[19]
#3634
0	Severe	B	['N']	[0]
1	corneal	I	['N']	[1]
2	toxicity	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	topical	O	['N']	[4]
5	fluoroquinolone	B-Drug	['Causes']	[2]
6	therapy	O	['N']	[6]
7	:	O	['N']	[7]
8	report	O	['N']	[8]
9	of	O	['N']	[9]
10	two	O	['N']	[10]
11	cases	O	['N']	[11]
12	.	O	['N']	[12]
#3635
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	here	O	['N']	[2]
3	a	O	['N']	[3]
4	rare	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	ritodrine	B	['N']	[7]
8	-	I	['N']	[8]
9	hydrochloride	I-Drug	['Causes']	[12]
10	-	O	['N']	[10]
11	induced	O	['N']	[11]
12	rhabdomyolysis	B-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	pregnant	O	['N']	[15]
16	patient	O	['N']	[16]
17	with	O	['N']	[17]
18	myotonic	O	['N']	[18]
19	dystrophy	O	['N']	[19]
20	.	O	['N']	[20]
#3636
0	Although	O	['N']	[0]
1	gabapentin	B-Drug	['Causes']	[26]
2	withdrawal	O	['N']	[2]
3	has	O	['N']	[3]
4	been	O	['N']	[4]
5	previously	O	['N']	[5]
6	reported	O	['N']	[6]
7	and	O	['N']	[7]
8	usually	O	['N']	[8]
9	consists	O	['N']	[9]
10	of	O	['N']	[10]
11	anxiety	O	['N']	[11]
12	,	O	['N']	[12]
13	diaphoresis	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	palpitations	O	['N']	[16]
17	,	O	['N']	[17]
18	this	O	['N']	[18]
19	is	O	['N']	[19]
20	the	O	['N']	[20]
21	first	O	['N']	[21]
22	reported	O	['N']	[22]
23	patient	O	['N']	[23]
24	with	O	['N']	[24]
25	generalized	B	['N']	[25]
26	seizures	I-Adverse_Effect	['N']	[26]
27	and	O	['N']	[27]
28	status	O	['N']	[28]
29	epilepticus	O	['N']	[29]
30	secondary	O	['N']	[30]
31	to	O	['N']	[31]
32	gabapentin	O	['N']	[32]
33	withdrawal	O	['N']	[33]
34	.	O	['N']	[34]
#3637
0	This	O	['N']	[0]
1	article	O	['N']	[1]
2	presents	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	hypoparathyroidism	O	['N']	[6]
7	who	O	['N']	[7]
8	was	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	calcium	B	['N']	[11]
12	carbonate	I-Drug	['Causes']	[26]
13	and	O	['N']	[13]
14	calcitriol	O	['N']	[14]
15	resulting	O	['N']	[15]
16	in	O	['N']	[16]
17	two	O	['N']	[17]
18	admissions	O	['N']	[18]
19	to	O	['N']	[19]
20	the	O	['N']	[20]
21	hospital	O	['N']	[21]
22	for	O	['N']	[22]
23	milk	B	['N']	[23]
24	-	I	['N']	[24]
25	alkali	I	['N']	[25]
26	syndrome	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#3638
0	The	O	['N']	[0]
1	reported	O	['N']	[1]
2	cases	O	['N']	[2]
3	of	O	['N']	[3]
4	in	O	['N']	[4]
5	utero	O	['N']	[5]
6	exposure	O	['N']	[6]
7	to	O	['N']	[7]
8	cyclosposphamide	B-Drug	['Causes']	[23]
9	shared	O	['N']	[9]
10	the	O	['N']	[10]
11	following	O	['N']	[11]
12	manifestations	O	['N']	[12]
13	with	O	['N']	[13]
14	our	O	['N']	[14]
15	patient	O	['N']	[15]
16	:	O	['N']	[16]
17	growth	O	['N']	[17]
18	deficiency	O	['N']	[18]
19	,	O	['N']	[19]
20	developmental	O	['N']	[20]
21	delay	O	['N']	[21]
22	,	O	['N']	[22]
23	craniosynostosis	B-Adverse_Effect	['N']	[23]
24	,	O	['N']	[24]
25	blepharophimosis	O	['N']	[25]
26	,	O	['N']	[26]
27	flat	O	['N']	[27]
28	nasal	O	['N']	[28]
29	bridge	O	['N']	[29]
30	,	O	['N']	[30]
31	abnormal	O	['N']	[31]
32	ears	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	distal	O	['N']	[35]
36	limb	O	['N']	[36]
37	defects	O	['N']	[37]
38	including	O	['N']	[38]
39	hypoplastic	O	['N']	[39]
40	thumbs	O	['N']	[40]
41	and	O	['N']	[41]
42	oligodactyly	O	['N']	[42]
43	.	O	['N']	[43]
#3639
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	emphasizes	O	['N']	[2]
3	the	O	['N']	[3]
4	importance	O	['N']	[4]
5	of	O	['N']	[5]
6	the	O	['N']	[6]
7	evaluation	O	['N']	[7]
8	of	O	['N']	[8]
9	lithium	B-Drug	['Causes']	[12]
10	-	O	['N']	[10]
11	associated	O	['N']	[11]
12	polyuria	B-Adverse_Effect	['N']	[12]
13	with	O	['N']	[13]
14	a	O	['N']	[14]
15	direct	O	['N']	[15]
16	measurement	O	['N']	[16]
17	of	O	['N']	[17]
18	plasma	O	['N']	[18]
19	vasopressin	O	['N']	[19]
20	,	O	['N']	[20]
21	interpreted	O	['N']	[21]
22	with	O	['N']	[22]
23	simultaneous	O	['N']	[23]
24	plasma	O	['N']	[24]
25	and	O	['N']	[25]
26	urine	O	['N']	[26]
27	osmolality	O	['N']	[27]
28	to	O	['N']	[28]
29	secure	O	['N']	[29]
30	the	O	['N']	[30]
31	correct	O	['N']	[31]
32	diagnosis	O	['N']	[32]
33	and	O	['N']	[33]
34	ensure	O	['N']	[34]
35	appropriate	O	['N']	[35]
36	therapeutic	O	['N']	[36]
37	management	O	['N']	[37]
38	.	O	['N']	[38]
#3640
0	A	O	['N']	[0]
1	35-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	with	O	['N']	[5]
6	borderline	O	['N']	[6]
7	lepromatous	O	['N']	[7]
8	(	O	['N']	[8]
9	BL	O	['N']	[9]
10	)	O	['N']	[10]
11	leprosy	O	['N']	[11]
12	who	O	['N']	[12]
13	suffered	O	['N']	[13]
14	from	O	['N']	[14]
15	dapsone	B-Drug	['Causes']	[18]
16	-	O	['N']	[16]
17	induced	O	['N']	[17]
18	erythroderma	B-Adverse_Effect	['N']	[18]
19	is	O	['N']	[19]
20	reported	O	['N']	[20]
21	.	O	['N']	[21]
#3641
0	This	O	['N']	[0]
1	selective	O	['N']	[1]
2	closure	O	['N']	[2]
3	of	O	['N']	[3]
4	the	O	['N']	[4]
5	ductus	O	['N']	[5]
6	arteriosus	O	['N']	[6]
7	suggests	O	['N']	[7]
8	that	O	['N']	[8]
9	the	O	['N']	[9]
10	affected	O	['N']	[10]
11	twin	O	['N']	[11]
12	was	O	['N']	[12]
13	predisposed	O	['N']	[13]
14	to	O	['N']	[14]
15	hypoxia	B-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	thus	O	['N']	[17]
18	was	O	['N']	[18]
19	more	O	['N']	[19]
20	susceptible	O	['N']	[20]
21	to	O	['N']	[21]
22	ductal	O	['N']	[22]
23	closure	O	['N']	[23]
24	in	O	['N']	[24]
25	response	O	['N']	[25]
26	to	O	['N']	[26]
27	indomethacin	B-Drug	['Causes']	[15]
28	exposure	O	['N']	[28]
29	.	O	['N']	[29]
#3642
0	Although	O	['N']	[0]
1	they	O	['N']	[1]
2	had	O	['N']	[2]
3	only	O	['N']	[3]
4	a	O	['N']	[4]
5	few	O	['N']	[5]
6	nodules	B-Adverse_Effect	['N']	[6]
7	at	O	['N']	[7]
8	diagnosis	O	['N']	[8]
9	,	O	['N']	[9]
10	the	O	['N']	[10]
11	nodules	O	['N']	[11]
12	increased	O	['N']	[12]
13	in	O	['N']	[13]
14	number	O	['N']	[14]
15	and	O	['N']	[15]
16	size	O	['N']	[16]
17	3	O	['N']	[17]
18	to	O	['N']	[18]
19	4	O	['N']	[19]
20	months	O	['N']	[20]
21	after	O	['N']	[21]
22	the	O	['N']	[22]
23	start	O	['N']	[23]
24	of	O	['N']	[24]
25	methotrexate	B-Drug	['Causes']	[6]
26	therapy	O	['N']	[26]
27	in	O	['N']	[27]
28	both	O	['N']	[28]
29	patients	O	['N']	[29]
30	.	O	['N']	[30]
#3643
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	documented	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	azathioprine	B-Drug	['Causes']	[11]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	severe	O	['N']	[10]
11	myelosuppression	B-Adverse_Effect	['N']	[11]
12	due	O	['N']	[12]
13	to	O	['N']	[13]
14	thiopurine	O	['N']	[14]
15	methyltransferase	O	['N']	[15]
16	deficiency	O	['N']	[16]
17	in	O	['N']	[17]
18	autoimmune	O	['N']	[18]
19	liver	O	['N']	[19]
20	disease	O	['N']	[20]
21	.	O	['N']	[21]
#3644
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	aseptic	O	['N']	[9]
10	meningitis	O	['N']	[10]
11	,	O	['N']	[11]
12	hemolytic	B	['N']	[12]
13	anemia	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	hepatitis	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	orthostatic	O	['N']	[18]
19	hypotension	O	['N']	[19]
20	simultaneously	O	['N']	[20]
21	during	O	['N']	[21]
22	treatment	O	['N']	[22]
23	with	O	['N']	[23]
24	trimethoprim	B-Drug	['Causes']	[13]
25	-	O	['N']	[25]
26	sulfamethoxazole	O	['N']	[26]
27	is	O	['N']	[27]
28	described	O	['N']	[28]
29	.	O	['N']	[29]
#3645
0	Induction	O	['N']	[0]
1	of	O	['N']	[1]
2	systemic	B	['N']	[2]
3	lupus	I	['N']	[3]
4	erythematosus	I-Adverse_Effect	['N']	[4]
5	by	O	['N']	[5]
6	interferon	B	['N']	[6]
7	-	I	['N']	[7]
8	gamma	I-Drug	['Causes']	[4]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	patient	O	['N']	[11]
12	with	O	['N']	[12]
13	rheumatoid	O	['N']	[13]
14	arthritis	O	['N']	[14]
15	.	O	['N']	[15]
#3646
0	When	O	['N']	[0]
1	cyanamide	B-Drug	['Causes']	[11]
2	-	O	['N']	[2]
3	treated	O	['N']	[3]
4	alcoholics	O	['N']	[4]
5	relapse	O	['N']	[5]
6	into	O	['N']	[6]
7	drinking	O	['N']	[7]
8	,	O	['N']	[8]
9	more	O	['N']	[9]
10	severe	O	['N']	[10]
11	inflammation	B-Adverse_Effect	['N']	[11]
12	develops	O	['N']	[12]
13	in	O	['N']	[13]
14	the	O	['N']	[14]
15	liver	O	['N']	[15]
16	.	O	['N']	[16]
#3647
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	recurrent	O	['N']	[5]
6	,	O	['N']	[6]
7	increasingly	O	['N']	[7]
8	severe	O	['N']	[8]
9	episodes	O	['N']	[9]
10	of	O	['N']	[10]
11	PPE	O	['N']	[11]
12	,	O	['N']	[12]
13	ultimately	O	['N']	[13]
14	complicated	O	['N']	[14]
15	by	O	['N']	[15]
16	a	O	['N']	[16]
17	severe	O	['N']	[17]
18	bullous	B	['N']	[18]
19	eruption	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	following	O	['N']	[21]
22	successive	O	['N']	[22]
23	cycles	O	['N']	[23]
24	of	O	['N']	[24]
25	high	O	['N']	[25]
26	-	O	['N']	[26]
27	dose	O	['N']	[27]
28	cytarabine	B-Drug	['Causes']	[19]
29	for	O	['N']	[29]
30	the	O	['N']	[30]
31	treatment	O	['N']	[31]
32	of	O	['N']	[32]
33	acute	O	['N']	[33]
34	lymphoblastic	O	['N']	[34]
35	leukaemia	O	['N']	[35]
36	.	O	['N']	[36]
#3648
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	serotonin	B	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	interaction	O	['N']	[11]
12	between	O	['N']	[12]
13	fentanyl	O	['N']	[13]
14	and	O	['N']	[14]
15	citalopram	B-Drug	['Causes']	[8]
16	,	O	['N']	[16]
17	as	O	['N']	[17]
18	evidenced	O	['N']	[18]
19	by	O	['N']	[19]
20	medication	O	['N']	[20]
21	history	O	['N']	[21]
22	,	O	['N']	[22]
23	clinical	O	['N']	[23]
24	features	O	['N']	[24]
25	and	O	['N']	[25]
26	reversal	O	['N']	[26]
27	following	O	['N']	[27]
28	discontinuation	O	['N']	[28]
29	of	O	['N']	[29]
30	fentanyl	O	['N']	[30]
31	.	O	['N']	[31]
#3649
0	Peripheral	O	['N']	[0]
1	nerve	O	['N']	[1]
2	dysfunction	O	['N']	[2]
3	is	O	['N']	[3]
4	a	O	['N']	[4]
5	potentially	O	['N']	[5]
6	serious	O	['N']	[6]
7	complication	O	['N']	[7]
8	of	O	['N']	[8]
9	high	B	['N']	[9]
10	-	I	['N']	[10]
11	dose	I-Dose	['N']	[11]
12	cytosine	B	['N']	[12]
13	arabinoside	I-Drug	['Dosage']	[11]
14	.	O	['N']	[14]
#3650
0	The	O	['N']	[0]
1	purpose	O	['N']	[1]
2	of	O	['N']	[2]
3	this	O	['N']	[3]
4	report	O	['N']	[4]
5	is	O	['N']	[5]
6	to	O	['N']	[6]
7	document	O	['N']	[7]
8	a	O	['N']	[8]
9	new	O	['N']	[9]
10	case	O	['N']	[10]
11	of	O	['N']	[11]
12	in	O	['N']	[12]
13	utero	O	['N']	[13]
14	CP	B-Drug	['Causes']	[26]
15	exposure	O	['N']	[15]
16	with	O	['N']	[16]
17	multiple	O	['N']	[17]
18	congenital	O	['N']	[18]
19	anomalies	O	['N']	[19]
20	and	O	['N']	[20]
21	to	O	['N']	[21]
22	establish	O	['N']	[22]
23	an	O	['N']	[23]
24	apparent	O	['N']	[24]
25	CP	O	['N']	[25]
26	embryopathy	B-Adverse_Effect	['N']	[26]
27	phenotype	O	['N']	[27]
28	.	O	['N']	[28]
#3651
0	The	O	['N']	[0]
1	mean	O	['N']	[1]
2	time	O	['N']	[2]
3	from	O	['N']	[3]
4	starting	O	['N']	[4]
5	MMF	B-Drug	['Causes']	[10]
6	to	O	['N']	[6]
7	the	O	['N']	[7]
8	development	O	['N']	[8]
9	of	O	['N']	[9]
10	neutropenia	B-Adverse_Effect	['N']	[10]
11	was	O	['N']	[11]
12	4	O	['N']	[12]
13	months	O	['N']	[13]
14	.	O	['N']	[14]
#3652
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	present	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	report	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	granulomatous	B	['N']	[8]
9	reaction	I-Adverse_Effect	['N']	[9]
10	leading	O	['N']	[10]
11	to	O	['N']	[11]
12	urethral	O	['N']	[12]
13	prolapse	O	['N']	[13]
14	,	O	['N']	[14]
15	3	O	['N']	[15]
16	months	O	['N']	[16]
17	after	O	['N']	[17]
18	the	O	['N']	[18]
19	transurethral	O	['N']	[19]
20	injection	O	['N']	[20]
21	of	O	['N']	[21]
22	calcium	B	['N']	[22]
23	hydroxylapatite	I-Drug	['Causes']	[9]
24	.	O	['N']	[24]
#3653
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Hypersensitivity	B	['N']	[2]
3	reactions	I-Adverse_Effect	['N']	[3]
4	to	O	['N']	[4]
5	cyclosporine	B-Drug	['Causes']	[3]
6	are	O	['N']	[6]
7	rare	O	['N']	[7]
8	.	O	['N']	[8]
#3654
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	sotalol	B-Drug	['Causes']	[8]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	bradycardia	B-Adverse_Effect	['N']	[8]
9	reversed	O	['N']	[9]
10	by	O	['N']	[10]
11	glucagon	O	['N']	[11]
12	.	O	['N']	[12]
#3655
0	The	O	['N']	[0]
1	goal	O	['N']	[1]
2	of	O	['N']	[2]
3	this	O	['N']	[3]
4	study	O	['N']	[4]
5	is	O	['N']	[5]
6	to	O	['N']	[6]
7	describe	O	['N']	[7]
8	three	O	['N']	[8]
9	patients	O	['N']	[9]
10	diagnosed	O	['N']	[10]
11	with	O	['N']	[11]
12	migraine	O	['N']	[12]
13	and	O	['N']	[13]
14	epilepsy	O	['N']	[14]
15	(	O	['N']	[15]
16	both	O	['N']	[16]
17	under	O	['N']	[17]
18	control	O	['N']	[18]
19	)	O	['N']	[19]
20	who	O	['N']	[20]
21	evolved	O	['N']	[21]
22	into	O	['N']	[22]
23	status	B	['N']	[23]
24	migrainosus	I-Adverse_Effect	['N']	[24]
25	after	O	['N']	[25]
26	the	O	['N']	[26]
27	introduction	O	['N']	[27]
28	of	O	['N']	[28]
29	oxcarbazepine	O	['N']	[29]
30	(	O	['N']	[30]
31	OXC	O	['N']	[31]
32	)	O	['N']	[32]
33	,	O	['N']	[33]
34	as	O	['N']	[34]
35	part	O	['N']	[35]
36	of	O	['N']	[36]
37	a	O	['N']	[37]
38	switch	O	['N']	[38]
39	off	O	['N']	[39]
40	from	O	['N']	[40]
41	carbamazepine	O	['N']	[41]
42	(	O	['N']	[42]
43	CBZ	B-Drug	['Causes']	[24]
44	)	O	['N']	[44]
45	.	O	['N']	[45]
#3656
0	In	O	['N']	[0]
1	a	O	['N']	[1]
2	postoperative	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	pre	O	['N']	[5]
6	-	O	['N']	[6]
7	existent	O	['N']	[7]
8	myasthenia	O	['N']	[8]
9	gravis	O	['N']	[9]
10	,	O	['N']	[10]
11	oral	O	['N']	[11]
12	verapamil	B-Drug	['Causes']	[19]
13	caused	O	['N']	[13]
14	a	O	['N']	[14]
15	marked	O	['N']	[15]
16	exacerbation	B	['N']	[16]
17	in	I	['N']	[17]
18	myasthenic	I	['N']	[18]
19	weakness	I-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#3657
0	Muscle	O	['N']	[0]
1	biopsy	O	['N']	[1]
2	revealed	O	['N']	[2]
3	variation	O	['N']	[3]
4	in	O	['N']	[4]
5	muscle	O	['N']	[5]
6	fiber	O	['N']	[6]
7	size	O	['N']	[7]
8	and	O	['N']	[8]
9	few	O	['N']	[9]
10	vacuolated	B	['N']	[10]
11	fibers	I-Adverse_Effect	['N']	[11]
12	which	O	['N']	[12]
13	were	O	['N']	[13]
14	features	O	['N']	[14]
15	of	O	['N']	[15]
16	colchicine	B-Drug	['Causes']	[11]
17	-	O	['N']	[17]
18	induced	O	['N']	[18]
19	myopathy	O	['N']	[19]
20	.	O	['N']	[20]
#3658
0	Chromosome	B	['N']	[0]
1	abnormalities	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	chlorambucil	B-Drug	['Causes']	[1]
4	therapy	O	['N']	[4]
5	of	O	['N']	[5]
6	polycythaemia	O	['N']	[6]
7	vera	O	['N']	[7]
8	.	O	['N']	[8]
#3659
0	Ritonavir	B-Drug	['Causes']	[9]
1	acted	O	['N']	[1]
2	as	O	['N']	[2]
3	a	O	['N']	[3]
4	CYP3A4	O	['N']	[4]
5	inhibitor	O	['N']	[5]
6	,	O	['N']	[6]
7	diminishing	B	['N']	[7]
8	carbamazepine	I	['N']	[8]
9	metabolism	I-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	provoking	O	['N']	[11]
12	an	O	['N']	[12]
13	increase	O	['N']	[13]
14	in	O	['N']	[14]
15	serum	O	['N']	[15]
16	levels	O	['N']	[16]
17	and	O	['N']	[17]
18	clinical	O	['N']	[18]
19	toxicity	O	['N']	[19]
20	.	O	['N']	[20]
#3660
0	Reversible	O	['N']	[0]
1	methotrexate	B-Drug	['Causes']	[5]
2	-	O	['N']	[2]
3	associated	O	['N']	[3]
4	lymphoproliferative	B	['N']	[4]
5	disorder	I-Adverse_Effect	['N']	[5]
6	resembling	O	['N']	[6]
7	advanced	O	['N']	[7]
8	gastric	O	['N']	[8]
9	cancer	O	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	patient	O	['N']	[12]
13	with	O	['N']	[13]
14	rheumatoid	O	['N']	[14]
15	arthritis	O	['N']	[15]
16	.	O	['N']	[16]
#3661
0	IV	O	['N']	[0]
1	propranolol	B-Drug	['Causes']	[19]
2	was	O	['N']	[2]
3	used	O	['N']	[3]
4	as	O	['N']	[4]
5	the	O	['N']	[5]
6	initial	O	['N']	[6]
7	treatment	O	['N']	[7]
8	for	O	['N']	[8]
9	his	O	['N']	[9]
10	hyperadrenergic	O	['N']	[10]
11	state	O	['N']	[11]
12	,	O	['N']	[12]
13	resulting	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	decrease	B	['N']	[16]
17	in	I	['N']	[17]
18	heart	I	['N']	[18]
19	rate	I-Adverse_Effect	['N']	[19]
20	but	O	['N']	[20]
21	a	O	['N']	[21]
22	paroxsymal	O	['N']	[22]
23	increase	O	['N']	[23]
24	in	O	['N']	[24]
25	blood	O	['N']	[25]
26	pressure	O	['N']	[26]
27	.	O	['N']	[27]
#3662
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	acute	B	['N']	[6]
7	pancreatitis	I-Adverse_Effect	['N']	[7]
8	during	O	['N']	[8]
9	amiodarone	B-Drug	['Causes']	[7]
10	therapy	O	['N']	[10]
11	.	O	['N']	[11]
#3663
0	Awareness	O	['N']	[0]
1	of	O	['N']	[1]
2	this	O	['N']	[2]
3	route	O	['N']	[3]
4	of	O	['N']	[4]
5	intoxication	O	['N']	[5]
6	might	O	['N']	[6]
7	be	O	['N']	[7]
8	important	O	['N']	[8]
9	in	O	['N']	[9]
10	patients	O	['N']	[10]
11	in	O	['N']	[11]
12	whom	O	['N']	[12]
13	neurologic	O	['N']	[13]
14	or	O	['N']	[14]
15	psychiatric	B	['N']	[15]
16	symptoms	I-Adverse_Effect	['N']	[16]
17	develop	O	['N']	[17]
18	while	O	['N']	[18]
19	large	O	['N']	[19]
20	amounts	O	['N']	[20]
21	of	O	['N']	[21]
22	lidocaine	B-Drug	['Causes']	[16]
23	cream	O	['N']	[23]
24	are	O	['N']	[24]
25	being	O	['N']	[25]
26	used	O	['N']	[26]
27	.	O	['N']	[27]
#3664
0	Withdrawal	O	['N']	[0]
1	of	O	['N']	[1]
2	Depakote	B-Drug	['Causes']	[8]
3	resulted	O	['N']	[3]
4	in	O	['N']	[4]
5	resolution	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	effusion	B-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#3665
0	Bronchiolitis	B	['N']	[0]
1	obliterans	I	['N']	[1]
2	organising	I	['N']	[2]
3	pneumonia	I-Adverse_Effect	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	the	O	['N']	[6]
7	use	O	['N']	[7]
8	of	O	['N']	[8]
9	nitrofurantoin	B-Drug	['Causes']	[3]
10	.	O	['N']	[10]
#3666
0	The	O	['N']	[0]
1	fifth	O	['N']	[1]
2	patient	O	['N']	[2]
3	exhibited	O	['N']	[3]
4	paraesthesia	O	['N']	[4]
5	and	O	['N']	[5]
6	agitation	B-Adverse_Effect	['N']	[6]
7	caused	O	['N']	[7]
8	by	O	['N']	[8]
9	olanzapine	B-Drug	['Causes']	[6]
10	that	O	['N']	[10]
11	was	O	['N']	[11]
12	misdiagnosed	O	['N']	[12]
13	as	O	['N']	[13]
14	psychotic	O	['N']	[14]
15	agitation	O	['N']	[15]
16	.	O	['N']	[16]
#3667
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	87-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	white	O	['N']	[9]
10	woman	O	['N']	[10]
11	with	O	['N']	[11]
12	myasthenia	O	['N']	[12]
13	gravis	O	['N']	[13]
14	who	O	['N']	[14]
15	presented	O	['N']	[15]
16	with	O	['N']	[16]
17	nausea	O	['N']	[17]
18	,	O	['N']	[18]
19	shortness	O	['N']	[19]
20	of	O	['N']	[20]
21	breath	O	['N']	[21]
22	,	O	['N']	[22]
23	azotemia	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	hyperkalemia	B-Adverse_Effect	['N']	[26]
27	shortly	O	['N']	[27]
28	after	O	['N']	[28]
29	completing	O	['N']	[29]
30	a	O	['N']	[30]
31	course	O	['N']	[31]
32	of	O	['N']	[32]
33	intravenous	O	['N']	[33]
34	immunoglobulin	B-Drug	['Causes']	[26]
35	(	O	['N']	[35]
36	IVIG	O	['N']	[36]
37	)	O	['N']	[37]
38	.	O	['N']	[38]
#3668
0	In	O	['N']	[0]
1	the	O	['N']	[1]
2	absence	O	['N']	[2]
3	of	O	['N']	[3]
4	mucositis	O	['N']	[4]
5	or	O	['N']	[5]
6	diarrhea	O	['N']	[6]
7	,	O	['N']	[7]
8	severe	B	['N']	[8]
9	dermatologic	I	['N']	[9]
10	toxicity	I-Adverse_Effect	['N']	[10]
11	following	O	['N']	[11]
12	a	O	['N']	[12]
13	single	O	['N']	[13]
14	low	O	['N']	[14]
15	dose	O	['N']	[15]
16	of	O	['N']	[16]
17	the	O	['N']	[17]
18	drug	O	['N']	[18]
19	suggests	O	['N']	[19]
20	an	O	['N']	[20]
21	'	O	['N']	[21]
22	allergic	O	['N']	[22]
23	'	O	['N']	[23]
24	or	O	['N']	[24]
25	acute	O	['N']	[25]
26	hypersensitivity	O	['N']	[26]
27	reaction	O	['N']	[27]
28	to	O	['N']	[28]
29	MTX	B-Drug	['Causes']	[10]
30	in	O	['N']	[30]
31	this	O	['N']	[31]
32	patient	O	['N']	[32]
33	.	O	['N']	[33]
#3669
0	Though	O	['N']	[0]
1	they	O	['N']	[1]
2	are	O	['N']	[2]
3	generally	O	['N']	[3]
4	considered	O	['N']	[4]
5	safe	O	['N']	[5]
6	,	O	['N']	[6]
7	there	O	['N']	[7]
8	have	O	['N']	[8]
9	been	O	['N']	[9]
10	a	O	['N']	[10]
11	few	O	['N']	[11]
12	reports	O	['N']	[12]
13	of	O	['N']	[13]
14	myocardial	O	['N']	[14]
15	infarction	O	['N']	[15]
16	and	O	['N']	[16]
17	stroke	B-Adverse_Effect	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	triptan	B-Drug	['Causes']	[17]
21	use	O	['N']	[21]
22	.	O	['N']	[22]
#3670
0	The	O	['N']	[0]
1	principle	O	['N']	[1]
2	treatment	O	['N']	[2]
3	for	O	['N']	[3]
4	DPD	O	['N']	[4]
5	-	O	['N']	[5]
6	deficient	O	['N']	[6]
7	patients	O	['N']	[7]
8	with	O	['N']	[8]
9	severe	B	['N']	[9]
10	acute	I	['N']	[10]
11	5-FU	B-Drug	['Causes']	[12]
12	reactions	I-Adverse_Effect	['N']	[12]
13	is	O	['N']	[13]
14	supportive	O	['N']	[14]
15	care	O	['N']	[15]
16	;	O	['N']	[16]
17	however	O	['N']	[17]
18	,	O	['N']	[18]
19	the	O	['N']	[19]
20	administration	O	['N']	[20]
21	of	O	['N']	[21]
22	thymidine	O	['N']	[22]
23	potentially	O	['N']	[23]
24	may	O	['N']	[24]
25	reverse	O	['N']	[25]
26	severe	O	['N']	[26]
27	5-FU	O	['N']	[27]
28	-	O	['N']	[28]
29	induced	O	['N']	[29]
30	neurologic	O	['N']	[30]
31	symptoms	O	['N']	[31]
32	such	O	['N']	[32]
33	as	O	['N']	[33]
34	encephalopathy	O	['N']	[34]
35	and	O	['N']	[35]
36	coma	O	['N']	[36]
37	.	O	['N']	[37]
#3671
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	exceptional	O	['N']	[3]
4	development	O	['N']	[4]
5	of	O	['N']	[5]
6	AML	B-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	lung	O	['N']	[8]
9	cancer	O	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	patient	O	['N']	[12]
13	with	O	['N']	[13]
14	previously	O	['N']	[14]
15	diagnosed	O	['N']	[15]
16	CLL	O	['N']	[16]
17	in	O	['N']	[17]
18	minimal	O	['N']	[18]
19	residual	O	['N']	[19]
20	disease	O	['N']	[20]
21	status	O	['N']	[21]
22	after	O	['N']	[22]
23	fludarabine	B-Drug	['Causes']	[6]
24	treatment	O	['N']	[24]
25	followed	O	['N']	[25]
26	by	O	['N']	[26]
27	autologous	O	['N']	[27]
28	peripheral	O	['N']	[28]
29	blood	O	['N']	[29]
30	stem	O	['N']	[30]
31	-	O	['N']	[31]
32	cell	O	['N']	[32]
33	transplantation	O	['N']	[33]
34	.	O	['N']	[34]
#3672
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	rheumatoid	O	['N']	[5]
6	arthritis	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	gold	B-Drug	['Causes']	[17]
10	salts	O	['N']	[10]
11	,	O	['N']	[11]
12	who	O	['N']	[12]
13	developed	O	['N']	[13]
14	bilateral	B	['N']	[14]
15	interstitial	I	['N']	[15]
16	pulmonary	I	['N']	[16]
17	abnormalities	I-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	showed	O	['N']	[19]
20	a	O	['N']	[20]
21	dramatic	O	['N']	[21]
22	response	O	['N']	[22]
23	on	O	['N']	[23]
24	corticosteroid	O	['N']	[24]
25	therapy	O	['N']	[25]
26	.	O	['N']	[26]
#3673
0	Methylene	O	['N']	[0]
1	blue	O	['N']	[1]
2	in	O	['N']	[2]
3	the	O	['N']	[3]
4	treatment	O	['N']	[4]
5	and	O	['N']	[5]
6	prevention	O	['N']	[6]
7	of	O	['N']	[7]
8	ifosfamide	B-Drug	['Causes']	[11]
9	-	I	['N']	[9]
10	induced	I	['N']	[10]
11	encephalopathy	I-Adverse_Effect	['N']	[11]
12	:	O	['N']	[12]
13	report	O	['N']	[13]
14	of	O	['N']	[14]
15	12	O	['N']	[15]
16	cases	O	['N']	[16]
17	and	O	['N']	[17]
18	a	O	['N']	[18]
19	review	O	['N']	[19]
20	of	O	['N']	[20]
21	the	O	['N']	[21]
22	literature	O	['N']	[22]
23	.	O	['N']	[23]
#3674
0	Proconvulsive	B-Adverse_Effect	['N']	[0]
1	tendency	O	['N']	[1]
2	of	O	['N']	[2]
3	imipenem	O	['N']	[3]
4	/	O	['N']	[4]
5	cilastatin	B-Drug	['Causes']	[0]
6	is	O	['N']	[6]
7	one	O	['N']	[7]
8	of	O	['N']	[8]
9	its	O	['N']	[9]
10	well	O	['N']	[10]
11	-	O	['N']	[11]
12	known	O	['N']	[12]
13	side	O	['N']	[13]
14	effects	O	['N']	[14]
15	.	O	['N']	[15]
#3675
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	given	O	['N']	[2]
3	the	O	['N']	[3]
4	clinically	O	['N']	[4]
5	significant	O	['N']	[5]
6	result	O	['N']	[6]
7	to	O	['N']	[7]
8	the	O	['N']	[8]
9	interaction	O	['N']	[9]
10	between	O	['N']	[10]
11	tolazoline	O	['N']	[11]
12	and	O	['N']	[12]
13	cimetidine	B-Drug	['Causes']	[26]
14	we	O	['N']	[14]
15	report	O	['N']	[15]
16	,	O	['N']	[16]
17	the	O	['N']	[17]
18	use	O	['N']	[18]
19	of	O	['N']	[19]
20	cimetidine	O	['N']	[20]
21	in	O	['N']	[21]
22	tolazoline	O	['N']	[22]
23	induced	O	['N']	[23]
24	upper	B	['N']	[24]
25	gastrointestinal	I	['N']	[25]
26	hemorrhage	I-Adverse_Effect	['N']	[26]
27	should	O	['N']	[27]
28	deserve	O	['N']	[28]
29	more	O	['N']	[29]
30	attention	O	['N']	[30]
31	.	O	['N']	[31]
#3676
0	Gynecomastia	B-Adverse_Effect	['N']	[0]
1	in	O	['N']	[1]
2	epileptics	O	['N']	[2]
3	treated	O	['N']	[3]
4	with	O	['N']	[4]
5	phenobarbital	O	['N']	[5]
6	,	O	['N']	[6]
7	phenytoin	O	['N']	[7]
8	and	O	['N']	[8]
9	fluoresone	B-Drug	['Causes']	[0]
10	:	O	['N']	[10]
11	two	O	['N']	[11]
12	case	O	['N']	[12]
13	reports	O	['N']	[13]
14	.	O	['N']	[14]
#3677
0	Fever	B-Adverse_Effect	['N']	[0]
1	,	O	['N']	[1]
2	lymphadenopathy	O	['N']	[2]
3	,	O	['N']	[3]
4	eosinophilia	O	['N']	[4]
5	,	O	['N']	[5]
6	lymphocytosis	O	['N']	[6]
7	,	O	['N']	[7]
8	hepatitis	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	dermatitis	O	['N']	[11]
12	:	O	['N']	[12]
13	a	O	['N']	[13]
14	severe	O	['N']	[14]
15	adverse	O	['N']	[15]
16	reaction	O	['N']	[16]
17	to	O	['N']	[17]
18	minocycline	B-Drug	['Causes']	[0]
19	.	O	['N']	[19]
#3678
0	Risperidone	B-Drug	['Causes']	[6]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	obsessive	B	['N']	[3]
4	-	I	['N']	[4]
5	compulsive	I	['N']	[5]
6	symptoms	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	two	O	['N']	[8]
9	children	O	['N']	[9]
10	.	O	['N']	[10]
#3679
0	An	O	['N']	[0]
1	11-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	who	O	['N']	[5]
6	was	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	relatively	O	['N']	[10]
11	high	B	['N']	[11]
12	dose	I-Dose	['N']	[12]
13	of	O	['N']	[13]
14	methotrimeprazine	O	['N']	[14]
15	meleate	O	['N']	[15]
16	(	O	['N']	[16]
17	Levemepromazine	B-Drug	['Dosage']	[12]
18	)	O	['N']	[18]
19	a	O	['N']	[19]
20	phenothiazine	O	['N']	[20]
21	antipsychotic	O	['N']	[21]
22	drug	O	['N']	[22]
23	,	O	['N']	[23]
24	was	O	['N']	[24]
25	admitted	O	['N']	[25]
26	to	O	['N']	[26]
27	the	O	['N']	[27]
28	pediatric	O	['N']	[28]
29	intensive	O	['N']	[29]
30	care	O	['N']	[30]
31	unit	O	['N']	[31]
32	suffering	O	['N']	[32]
33	from	O	['N']	[33]
34	respiratory	O	['N']	[34]
35	distress	O	['N']	[35]
36	syndrome	O	['N']	[36]
37	.	O	['N']	[37]
#3680
0	Caution	O	['N']	[0]
1	in	O	['N']	[1]
2	longterm	O	['N']	[2]
3	usage	O	['N']	[3]
4	and	O	['N']	[4]
5	early	O	['N']	[5]
6	recognition	O	['N']	[6]
7	of	O	['N']	[7]
8	pentazocine	B-Drug	['Causes']	[9]
9	toxicity	I-Adverse_Effect	['N']	[9]
10	as	O	['N']	[10]
11	a	O	['N']	[11]
12	neuromuscular	O	['N']	[12]
13	complication	O	['N']	[13]
14	are	O	['N']	[14]
15	important	O	['N']	[15]
16	in	O	['N']	[16]
17	order	O	['N']	[17]
18	to	O	['N']	[18]
19	prevent	O	['N']	[19]
20	irreversible	O	['N']	[20]
21	drug	O	['N']	[21]
22	-	O	['N']	[22]
23	induced	O	['N']	[23]
24	fibrous	O	['N']	[24]
25	myopathy	O	['N']	[25]
26	and	O	['N']	[26]
27	localized	O	['N']	[27]
28	neuropathy	O	['N']	[28]
29	.	O	['N']	[29]
#3681
0	The	O	['N']	[0]
1	typical	O	['N']	[1]
2	fluoxetine	B-Drug	['Causes']	[10]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	symptoms	O	['N']	[5]
6	of	O	['N']	[6]
7	restlessness	O	['N']	[7]
8	,	O	['N']	[8]
9	constant	B	['N']	[9]
10	pacing	I-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	purposeless	O	['N']	[12]
13	movements	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	feet	O	['N']	[16]
17	and	O	['N']	[17]
18	legs	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	marked	O	['N']	[21]
22	anxiety	O	['N']	[22]
23	were	O	['N']	[23]
24	indistinguishable	O	['N']	[24]
25	from	O	['N']	[25]
26	those	O	['N']	[26]
27	of	O	['N']	[27]
28	neuroleptic	O	['N']	[28]
29	-	O	['N']	[29]
30	induced	O	['N']	[30]
31	akathisia	O	['N']	[31]
32	.	O	['N']	[32]
#3682
0	Sotalol	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	bradycardia	B-Adverse_Effect	['N']	[3]
4	reversed	O	['N']	[4]
5	by	O	['N']	[5]
6	glucagon	O	['N']	[6]
7	.	O	['N']	[7]
#3683
0	Psoriasis	B-Adverse_Effect	['N']	[0]
1	induced	O	['N']	[1]
2	by	O	['N']	[2]
3	interferon	B	['N']	[3]
4	-	I	['N']	[4]
5	alpha	I-Drug	['Causes']	[0]
6	.	O	['N']	[6]
#3684
0	In	O	['N']	[0]
1	the	O	['N']	[1]
2	present	O	['N']	[2]
3	paper	O	['N']	[3]
4	the	O	['N']	[4]
5	authors	O	['N']	[5]
6	describe	O	['N']	[6]
7	2	O	['N']	[7]
8	female	O	['N']	[8]
9	patients	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	incontinence	B-Adverse_Effect	['N']	[12]
13	secondary	O	['N']	[13]
14	to	O	['N']	[14]
15	the	O	['N']	[15]
16	selective	O	['N']	[16]
17	serotonin	O	['N']	[17]
18	reuptake	O	['N']	[18]
19	inhibitors	O	['N']	[19]
20	paroxetine	O	['N']	[20]
21	and	O	['N']	[21]
22	sertraline	O	['N']	[22]
23	,	O	['N']	[23]
24	as	O	['N']	[24]
25	well	O	['N']	[25]
26	as	O	['N']	[26]
27	a	O	['N']	[27]
28	third	O	['N']	[28]
29	who	O	['N']	[29]
30	developed	O	['N']	[30]
31	this	O	['N']	[31]
32	side	O	['N']	[32]
33	effect	O	['N']	[33]
34	on	O	['N']	[34]
35	venlafaxine	B-Drug	['Causes']	[12]
36	.	O	['N']	[36]
#3685
0	OBJECTIVES	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	delayed	O	['N']	[3]
4	stroke	B	['N']	[4]
5	-	I	['N']	[5]
6	like	I	['N']	[6]
7	leukoencephalopathy	I-Adverse_Effect	['N']	[7]
8	has	O	['N']	[8]
9	been	O	['N']	[9]
10	observed	O	['N']	[10]
11	in	O	['N']	[11]
12	patients	O	['N']	[12]
13	receiving	O	['N']	[13]
14	methotrexate	O	['N']	[14]
15	(	O	['N']	[15]
16	MTX	B-Drug	['Causes']	[7]
17	)	O	['N']	[17]
18	for	O	['N']	[18]
19	childhood	O	['N']	[19]
20	leukemia	O	['N']	[20]
21	.	O	['N']	[21]
#3686
0	Priapism	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	zuclopenthixol	B-Drug	['Causes']	[0]
4	.	O	['N']	[4]
#3687
0	Acute	B	['N']	[0]
1	leukopenia	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	silver	B	['N']	[4]
5	sulfadiazine	I-Drug	['Causes']	[1]
6	therapy	O	['N']	[6]
7	.	O	['N']	[7]
#3688
0	Insulin	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	lipohypertrophy	B-Adverse_Effect	['N']	[3]
4	:	O	['N']	[4]
5	report	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	case	O	['N']	[8]
9	with	O	['N']	[9]
10	histopathology	O	['N']	[10]
11	.	O	['N']	[11]
#3689
0	Panic	B	['N']	[0]
1	anxiety	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	abrupt	O	['N']	[3]
4	discontinuation	O	['N']	[4]
5	of	O	['N']	[5]
6	mianserin	B-Drug	['Causes']	[1]
7	.	O	['N']	[7]
#3690
0	The	O	['N']	[0]
1	day	O	['N']	[1]
2	after	O	['N']	[2]
3	clozapine	B-Drug	['Causes']	[36]
4	was	O	['N']	[4]
5	stopped	O	['N']	[5]
6	,	O	['N']	[6]
7	while	O	['N']	[7]
8	he	O	['N']	[8]
9	was	O	['N']	[9]
10	still	O	['N']	[10]
11	receiving	O	['N']	[11]
12	clomipramine	O	['N']	[12]
13	150	O	['N']	[13]
14	mg	O	['N']	[14]
15	/	O	['N']	[15]
16	d	O	['N']	[16]
17	,	O	['N']	[17]
18	he	O	['N']	[18]
19	began	O	['N']	[19]
20	behaving	O	['N']	[20]
21	oddly	O	['N']	[21]
22	,	O	['N']	[22]
23	started	O	['N']	[23]
24	sweating	O	['N']	[24]
25	profusely	O	['N']	[25]
26	,	O	['N']	[26]
27	shivering	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	became	O	['N']	[30]
31	tremulous	O	['N']	[31]
32	,	O	['N']	[32]
33	agitated	O	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	confused	B-Adverse_Effect	['N']	[36]
37	.	O	['N']	[37]
#3691
0	Thalidomide	B-Drug	['Causes']	[7]
1	neuropathy	O	['N']	[1]
2	is	O	['N']	[2]
3	often	O	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	proximal	B	['N']	[6]
7	weakness	I-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	may	O	['N']	[9]
10	progress	O	['N']	[10]
11	even	O	['N']	[11]
12	after	O	['N']	[12]
13	discontinuation	O	['N']	[13]
14	of	O	['N']	[14]
15	treatment	O	['N']	[15]
16	,	O	['N']	[16]
17	in	O	['N']	[17]
18	the	O	['N']	[18]
19	phenomenon	O	['N']	[19]
20	of	O	['N']	[20]
21	'	O	['N']	[21]
22	coasting	O	['N']	[22]
23	'	O	['N']	[23]
24	.	O	['N']	[24]
#3692
0	Seizure	B-Adverse_Effect	['N']	[0]
1	with	O	['N']	[1]
2	hyponatremia	O	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	child	O	['N']	[5]
6	prescribed	O	['N']	[6]
7	desmopressin	B-Drug	['Causes']	[0]
8	for	O	['N']	[8]
9	nocturnal	O	['N']	[9]
10	enuresis	O	['N']	[10]
11	.	O	['N']	[11]
#3693
0	We	O	['N']	[0]
1	postulate	O	['N']	[1]
2	that	O	['N']	[2]
3	cyclosporin	B-Drug	['Causes']	[17]
4	,	O	['N']	[4]
5	possibly	O	['N']	[5]
6	together	O	['N']	[6]
7	with	O	['N']	[7]
8	ganciclovir	O	['N']	[8]
9	,	O	['N']	[9]
10	can	O	['N']	[10]
11	produce	O	['N']	[11]
12	transient	B	['N']	[12]
13	brain	I	['N']	[13]
14	stem	I	['N']	[14]
15	or	I	['N']	[15]
16	neuromuscular	I	['N']	[16]
17	dysfunction	I-Adverse_Effect	['N']	[17]
18	with	O	['N']	[18]
19	eye	O	['N']	[19]
20	movement	O	['N']	[20]
21	abnormality	O	['N']	[21]
22	in	O	['N']	[22]
23	occasional	O	['N']	[23]
24	patients	O	['N']	[24]
25	.	O	['N']	[25]
#3694
0	She	O	['N']	[0]
1	received	O	['N']	[1]
2	an	O	['N']	[2]
3	accidental	O	['N']	[3]
4	450-mg	O	['N']	[4]
5	bolus	O	['N']	[5]
6	injection	O	['N']	[6]
7	of	O	['N']	[7]
8	morphine	B-Drug	['Causes']	[18]
9	intrathecally	O	['N']	[9]
10	and	O	['N']	[10]
11	developed	O	['N']	[11]
12	hypertension	O	['N']	[12]
13	,	O	['N']	[13]
14	status	O	['N']	[14]
15	epilepticus	O	['N']	[15]
16	,	O	['N']	[16]
17	intracerebral	B	['N']	[17]
18	hemorrhage	I-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	respiratory	O	['N']	[21]
22	failure	O	['N']	[22]
23	.	O	['N']	[23]
#3695
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	valproate	B-Drug	['Causes']	[10]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	hyperammonemia	O	['N']	[6]
7	and	O	['N']	[7]
8	mental	B	['N']	[8]
9	status	I	['N']	[9]
10	changes	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	an	O	['N']	[12]
13	88-year	O	['N']	[13]
14	-	O	['N']	[14]
15	old	O	['N']	[15]
16	man	O	['N']	[16]
17	,	O	['N']	[17]
18	the	O	['N']	[18]
19	first	O	['N']	[19]
20	known	O	['N']	[20]
21	reported	O	['N']	[21]
22	case	O	['N']	[22]
23	in	O	['N']	[23]
24	an	O	['N']	[24]
25	elderly	O	['N']	[25]
26	patient	O	['N']	[26]
27	.	O	['N']	[27]
#3696
0	A	O	['N']	[0]
1	16-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	developed	O	['N']	[5]
6	fever	O	['N']	[6]
7	,	O	['N']	[7]
8	generalized	O	['N']	[8]
9	rigidity	O	['N']	[9]
10	,	O	['N']	[10]
11	leukocytosis	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	increased	B	['N']	[14]
15	serum	I	['N']	[15]
16	transaminase	I	['N']	[16]
17	and	I	['N']	[17]
18	creatine	I	['N']	[18]
19	kinase	I-Adverse_Effect	['N']	[19]
20	levels	O	['N']	[20]
21	while	O	['N']	[21]
22	receiving	O	['N']	[22]
23	treatment	O	['N']	[23]
24	with	O	['N']	[24]
25	olanzapine	B-Drug	['Causes']	[19]
26	and	O	['N']	[26]
27	lithium	O	['N']	[27]
28	.	O	['N']	[28]
#3697
0	Insulin	B	['N']	[0]
1	-	I	['N']	[1]
2	dependent	I	['N']	[2]
3	diabetes	I	['N']	[3]
4	mellitus	I-Adverse_Effect	['N']	[4]
5	developed	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	young	O	['N']	[8]
9	woman	O	['N']	[9]
10	8	O	['N']	[10]
11	weeks	O	['N']	[11]
12	after	O	['N']	[12]
13	the	O	['N']	[13]
14	initiation	O	['N']	[14]
15	of	O	['N']	[15]
16	danazol	B-Drug	['Causes']	[4]
17	for	O	['N']	[17]
18	treatment	O	['N']	[18]
19	of	O	['N']	[19]
20	pelvic	O	['N']	[20]
21	endometriosis	O	['N']	[21]
22	.	O	['N']	[22]
#3698
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	presents	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	acute	B	['N']	[6]
7	lung	I	['N']	[7]
8	injury	I-Adverse_Effect	['N']	[8]
9	developing	O	['N']	[9]
10	within	O	['N']	[10]
11	hours	O	['N']	[11]
12	after	O	['N']	[12]
13	administration	O	['N']	[13]
14	of	O	['N']	[14]
15	mefloquine	B-Drug	['Causes']	[8]
16	for	O	['N']	[16]
17	a	O	['N']	[17]
18	low	O	['N']	[18]
19	-	O	['N']	[19]
20	level	O	['N']	[20]
21	Plasmodium	O	['N']	[21]
22	falciparum	O	['N']	[22]
23	malaria	O	['N']	[23]
24	,	O	['N']	[24]
25	which	O	['N']	[25]
26	was	O	['N']	[26]
27	persistent	O	['N']	[27]
28	despite	O	['N']	[28]
29	halofantrine	O	['N']	[29]
30	therapy	O	['N']	[30]
31	.	O	['N']	[31]
#3699
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	infectious	O	['N']	[3]
4	toxicities	O	['N']	[4]
5	experienced	O	['N']	[5]
6	by	O	['N']	[6]
7	the	O	['N']	[7]
8	first	O	['N']	[8]
9	two	O	['N']	[9]
10	patients	O	['N']	[10]
11	in	O	['N']	[11]
12	our	O	['N']	[12]
13	institution	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	dexamethasone	B-Drug	['Causes']	[51]
17	(	O	['N']	[17]
18	10	O	['N']	[18]
19	mg	O	['N']	[19]
20	/	O	['N']	[20]
21	m(2)/day	O	['N']	[21]
22	for	O	['N']	[22]
23	4	O	['N']	[23]
24	weeks	O	['N']	[24]
25	with	O	['N']	[25]
26	gradual	O	['N']	[26]
27	tapering	O	['N']	[27]
28	)	O	['N']	[28]
29	during	O	['N']	[29]
30	induction	O	['N']	[30]
31	according	O	['N']	[31]
32	to	O	['N']	[32]
33	the	O	['N']	[33]
34	dexamethasone	O	['N']	[34]
35	arm	O	['N']	[35]
36	of	O	['N']	[36]
37	BFM	O	['N']	[37]
38	2000	O	['N']	[38]
39	and	O	['N']	[39]
40	review	O	['N']	[40]
41	the	O	['N']	[41]
42	relevant	O	['N']	[42]
43	literature	O	['N']	[43]
44	that	O	['N']	[44]
45	suggests	O	['N']	[45]
46	an	O	['N']	[46]
47	increased	O	['N']	[47]
48	risk	O	['N']	[48]
49	of	O	['N']	[49]
50	infectious	B	['N']	[50]
51	complications	I-Adverse_Effect	['N']	[51]
52	with	O	['N']	[52]
53	dexamethasone	O	['N']	[53]
54	.	O	['N']	[54]
#3700
0	A	O	['N']	[0]
1	14-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	developed	O	['N']	[5]
6	systemic	O	['N']	[6]
7	lupus	O	['N']	[7]
8	erythematosus	O	['N']	[8]
9	(	O	['N']	[9]
10	SLE)-like	O	['N']	[10]
11	symptoms	O	['N']	[11]
12	,	O	['N']	[12]
13	rash	B-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	fever	O	['N']	[15]
16	,	O	['N']	[16]
17	leukopenia	O	['N']	[17]
18	and	O	['N']	[18]
19	positive	O	['N']	[19]
20	anti	O	['N']	[20]
21	-	O	['N']	[21]
22	nuclear	O	['N']	[22]
23	antibody	O	['N']	[23]
24	(	O	['N']	[24]
25	ANA	O	['N']	[25]
26	)	O	['N']	[26]
27	two	O	['N']	[27]
28	weeks	O	['N']	[28]
29	after	O	['N']	[29]
30	administration	O	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	B-Drug	['Causes']	[13]
33	(	O	['N']	[33]
34	CBZ	O	['N']	[34]
35	;	O	['N']	[35]
36	Tegretol	O	['N']	[36]
37	)	O	['N']	[37]
38	used	O	['N']	[38]
39	against	O	['N']	[39]
40	benign	O	['N']	[40]
41	Rolandic	O	['N']	[41]
42	epilepsy	O	['N']	[42]
43	.	O	['N']	[43]
#3701
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	here	O	['N']	[2]
3	a	O	['N']	[3]
4	26-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	female	O	['N']	[7]
8	with	O	['N']	[8]
9	diffuse	O	['N']	[9]
10	large	O	['N']	[10]
11	B	O	['N']	[11]
12	-	O	['N']	[12]
13	cell	O	['N']	[13]
14	lymphoma	O	['N']	[14]
15	who	O	['N']	[15]
16	died	O	['N']	[16]
17	of	O	['N']	[17]
18	severe	B	['N']	[18]
19	pulmonary	I	['N']	[19]
20	fibrosis	I-Adverse_Effect	['N']	[20]
21	81	O	['N']	[21]
22	days	O	['N']	[22]
23	after	O	['N']	[23]
24	the	O	['N']	[24]
25	administration	O	['N']	[25]
26	of	O	['N']	[26]
27	high	O	['N']	[27]
28	-	O	['N']	[28]
29	dose	O	['N']	[29]
30	BCNU	B-Drug	['Causes']	[20]
31	(	O	['N']	[31]
32	600	O	['N']	[32]
33	mg	O	['N']	[33]
34	/	O	['N']	[34]
35	m2	O	['N']	[35]
36	)	O	['N']	[36]
37	.	O	['N']	[37]
#3702
0	Amebic	O	['N']	[0]
1	abscess	O	['N']	[1]
2	of	O	['N']	[2]
3	the	O	['N']	[3]
4	spleen	O	['N']	[4]
5	complicated	O	['N']	[5]
6	by	O	['N']	[6]
7	metronidazole	B-Drug	['Causes']	[10]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	neurotoxicity	B-Adverse_Effect	['N']	[10]
11	:	O	['N']	[11]
12	case	O	['N']	[12]
13	report	O	['N']	[13]
14	.	O	['N']	[14]
#3703
0	Pancreatitis	B-Adverse_Effect	['N']	[0]
1	has	O	['N']	[1]
2	been	O	['N']	[2]
3	noted	O	['N']	[3]
4	to	O	['N']	[4]
5	be	O	['N']	[5]
6	a	O	['N']	[6]
7	complication	O	['N']	[7]
8	in	O	['N']	[8]
9	2	O	['N']	[9]
10	-	O	['N']	[10]
11	16	O	['N']	[11]
12	%	O	['N']	[12]
13	of	O	['N']	[13]
14	patients	O	['N']	[14]
15	undergoing	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	L	B	['N']	[18]
19	-	I	['N']	[19]
20	asparaginase	I-Drug	['Causes']	[0]
21	for	O	['N']	[21]
22	a	O	['N']	[22]
23	variety	O	['N']	[23]
24	of	O	['N']	[24]
25	pediatric	O	['N']	[25]
26	neoplasms	O	['N']	[26]
27	.	O	['N']	[27]
#3704
0	Typically	O	['N']	[0]
1	,	O	['N']	[1]
2	drug	O	['N']	[2]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	neutropenia	B-Adverse_Effect	['N']	[5]
6	occurs	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	receiving	O	['N']	[10]
11	a	O	['N']	[11]
12	semisynthetic	O	['N']	[12]
13	penicillin	B-Drug	['Causes']	[5]
14	for	O	['N']	[14]
15	two	O	['N']	[15]
16	weeks	O	['N']	[16]
17	or	O	['N']	[17]
18	more	O	['N']	[18]
19	.	O	['N']	[19]
#3705
0	Metformin	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	lactic	B	['N']	[3]
4	acidosis	I-Adverse_Effect	['N']	[4]
5	precipitated	O	['N']	[5]
6	by	O	['N']	[6]
7	diarrhea	O	['N']	[7]
8	.	O	['N']	[8]
#3706
0	Recently	O	['N']	[0]
1	,	O	['N']	[1]
2	her	O	['N']	[2]
3	serum	O	['N']	[3]
4	theophylline	B-Drug	['Causes']	[11]
5	levels	I	['N']	[5]
6	had	I	['N']	[6]
7	increased	I	['N']	[7]
8	to	I	['N']	[8]
9	the	I	['N']	[9]
10	toxic	I	['N']	[10]
11	range	I-Adverse_Effect	['N']	[11]
12	(	O	['N']	[12]
13	133.2	O	['N']	[13]
14	micromol	O	['N']	[14]
15	/	O	['N']	[15]
16	L	O	['N']	[16]
17	[	O	['N']	[17]
18	24	O	['N']	[18]
19	microg	O	['N']	[19]
20	/	O	['N']	[20]
21	mL	O	['N']	[21]
22	]	O	['N']	[22]
23	)	O	['N']	[23]
24	shortly	O	['N']	[24]
25	after	O	['N']	[25]
26	the	O	['N']	[26]
27	addition	O	['N']	[27]
28	of	O	['N']	[28]
29	zafirlukast	O	['N']	[29]
30	(	O	['N']	[30]
31	Accolate	O	['N']	[31]
32	,	O	['N']	[32]
33	Zeneca	O	['N']	[33]
34	Pharmaceuticals	O	['N']	[34]
35	,	O	['N']	[35]
36	Wilmington	O	['N']	[36]
37	,	O	['N']	[37]
38	Del	O	['N']	[38]
39	)	O	['N']	[39]
40	to	O	['N']	[40]
41	her	O	['N']	[41]
42	regimen	O	['N']	[42]
43	.	O	['N']	[43]
#3707
0	Increasing	O	['N']	[0]
1	the	O	['N']	[1]
2	olanzapine	B-Drug	['Causes']	[9]
3	dosage	O	['N']	[3]
4	severely	O	['N']	[4]
5	aggravated	O	['N']	[5]
6	the	O	['N']	[6]
7	symptoms	O	['N']	[7]
8	of	O	['N']	[8]
9	RLS	B-Adverse_Effect	['N']	[9]
10	.	O	['N']	[10]
#3708
0	Since	O	['N']	[0]
1	recent	O	['N']	[1]
2	studies	O	['N']	[2]
3	have	O	['N']	[3]
4	reported	O	['N']	[4]
5	no	O	['N']	[5]
6	negative	O	['N']	[6]
7	interactions	O	['N']	[7]
8	with	O	['N']	[8]
9	concurrent	O	['N']	[9]
10	use	O	['N']	[10]
11	,	O	['N']	[11]
12	we	O	['N']	[12]
13	here	O	['N']	[13]
14	report	O	['N']	[14]
15	three	O	['N']	[15]
16	cases	O	['N']	[16]
17	(	O	['N']	[17]
18	one	O	['N']	[18]
19	case	O	['N']	[19]
20	of	O	['N']	[20]
21	a	O	['N']	[21]
22	prolonged	O	['N']	[22]
23	seizure	O	['N']	[23]
24	,	O	['N']	[24]
25	a	O	['N']	[25]
26	serotonin	B	['N']	[26]
27	syndrome	I-Adverse_Effect	['N']	[27]
28	and	O	['N']	[28]
29	a	O	['N']	[29]
30	focal	O	['N']	[30]
31	seizure	O	['N']	[31]
32	)	O	['N']	[32]
33	of	O	['N']	[33]
34	severe	O	['N']	[34]
35	lithium	B-Drug	['Causes']	[27]
36	-	O	['N']	[36]
37	induced	O	['N']	[37]
38	side	O	['N']	[38]
39	effects	O	['N']	[39]
40	while	O	['N']	[40]
41	patients	O	['N']	[41]
42	underwent	O	['N']	[42]
43	ECT	O	['N']	[43]
44	without	O	['N']	[44]
45	complications	O	['N']	[45]
46	and	O	['N']	[46]
47	lithium	O	['N']	[47]
48	serum	O	['N']	[48]
49	levels	O	['N']	[49]
50	were	O	['N']	[50]
51	still	O	['N']	[51]
52	subtherapeutic	O	['N']	[52]
53	.	O	['N']	[53]
#3709
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	are	O	['N']	[2]
3	reported	O	['N']	[3]
4	without	O	['N']	[4]
5	a	O	['N']	[5]
6	history	O	['N']	[6]
7	of	O	['N']	[7]
8	angina	O	['N']	[8]
9	pectoris	O	['N']	[9]
10	who	O	['N']	[10]
11	had	O	['N']	[11]
12	clinical	O	['N']	[12]
13	and	O	['N']	[13]
14	electrocardiographic	O	['N']	[14]
15	evidence	O	['N']	[15]
16	of	O	['N']	[16]
17	myocardial	B	['N']	[17]
18	ischemia	I-Adverse_Effect	['N']	[18]
19	during	O	['N']	[19]
20	and	O	['N']	[20]
21	immediately	O	['N']	[21]
22	after	O	['N']	[22]
23	BCNU	B-Drug	['Causes']	[18]
24	infusion	O	['N']	[24]
25	.	O	['N']	[25]
#3710
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	papilloedema	O	['N']	[3]
4	and	O	['N']	[4]
5	hepatic	B	['N']	[5]
6	dysfunction	I-Adverse_Effect	['N']	[6]
7	while	O	['N']	[7]
8	being	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	perhexiline	B	['N']	[11]
12	maleate	I-Drug	['Causes']	[6]
13	.	O	['N']	[13]
#3711
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	alveolar	O	['N']	[9]
10	hydatid	O	['N']	[10]
11	disease	O	['N']	[11]
12	,	O	['N']	[12]
13	whose	O	['N']	[13]
14	treatment	O	['N']	[14]
15	with	O	['N']	[15]
16	mebendazole	B-Drug	['Causes']	[24]
17	was	O	['N']	[17]
18	brief	O	['N']	[18]
19	due	O	['N']	[19]
20	to	O	['N']	[20]
21	side	O	['N']	[21]
22	effects	O	['N']	[22]
23	of	O	['N']	[23]
24	alopecia	B-Adverse_Effect	['N']	[24]
25	and	O	['N']	[25]
26	granulocytopenia	O	['N']	[26]
27	;	O	['N']	[27]
28	and	O	['N']	[28]
29	review	O	['N']	[29]
30	the	O	['N']	[30]
31	features	O	['N']	[31]
32	of	O	['N']	[32]
33	this	O	['N']	[33]
34	disease	O	['N']	[34]
35	which	O	['N']	[35]
36	,	O	['N']	[36]
37	with	O	['N']	[37]
38	increasing	O	['N']	[38]
39	international	O	['N']	[39]
40	migration	O	['N']	[40]
41	,	O	['N']	[41]
42	may	O	['N']	[42]
43	be	O	['N']	[43]
44	encountered	O	['N']	[44]
45	more	O	['N']	[45]
46	frequently	O	['N']	[46]
47	in	O	['N']	[47]
48	Australia	O	['N']	[48]
49	.	O	['N']	[49]
#3712
0	The	O	['N']	[0]
1	noted	O	['N']	[1]
2	increase	B	['N']	[2]
3	in	I	['N']	[3]
4	the	I	['N']	[4]
5	theophylline	B-Drug	['Causes']	[6]
6	level	I-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	zafirlukast	O	['N']	[8]
9	administration	O	['N']	[9]
10	is	O	['N']	[10]
11	in	O	['N']	[11]
12	contrast	O	['N']	[12]
13	to	O	['N']	[13]
14	the	O	['N']	[14]
15	original	O	['N']	[15]
16	reports	O	['N']	[16]
17	by	O	['N']	[17]
18	the	O	['N']	[18]
19	manufacturer	O	['N']	[19]
20	.	O	['N']	[20]
#3713
0	Potential	O	['N']	[0]
1	causes	O	['N']	[1]
2	of	O	['N']	[2]
3	methamphetamine	O	['N']	[3]
4	-	O	['N']	[4]
5	related	O	['N']	[5]
6	keratitis	O	['N']	[6]
7	can	O	['N']	[7]
8	be	O	['N']	[8]
9	divided	O	['N']	[9]
10	into	O	['N']	[10]
11	four	O	['N']	[11]
12	categories	O	['N']	[12]
13	resulting	O	['N']	[13]
14	from	O	['N']	[14]
15	(	O	['N']	[15]
16	a	O	['N']	[16]
17	)	O	['N']	[17]
18	direct	O	['N']	[18]
19	pharmacologic	O	['N']	[19]
20	and	O	['N']	[20]
21	physical	O	['N']	[21]
22	effects	O	['N']	[22]
23	of	O	['N']	[23]
24	methamphetamine	O	['N']	[24]
25	;	O	['N']	[25]
26	(	O	['N']	[26]
27	b	O	['N']	[27]
28	)	O	['N']	[28]
29	the	O	['N']	[29]
30	toxic	B	['N']	[30]
31	effects	I-Adverse_Effect	['N']	[31]
32	of	O	['N']	[32]
33	diluting	O	['N']	[33]
34	or	O	['N']	[34]
35	"	O	['N']	[35]
36	cutting	O	['N']	[36]
37	"	O	['N']	[37]
38	agents	O	['N']	[38]
39	such	O	['N']	[39]
40	as	O	['N']	[40]
41	lidocaine	O	['N']	[41]
42	and	O	['N']	[42]
43	quinine	B-Drug	['Causes']	[31]
44	;	O	['N']	[44]
45	(	O	['N']	[45]
46	c	O	['N']	[46]
47	)	O	['N']	[47]
48	effects	O	['N']	[48]
49	related	O	['N']	[49]
50	to	O	['N']	[50]
51	the	O	['N']	[51]
52	route	O	['N']	[52]
53	of	O	['N']	[53]
54	drug	O	['N']	[54]
55	administration	O	['N']	[55]
56	(	O	['N']	[56]
57	intravenous	O	['N']	[57]
58	,	O	['N']	[58]
59	inhalation	O	['N']	[59]
60	,	O	['N']	[60]
61	smoking	O	['N']	[61]
62	)	O	['N']	[62]
63	;	O	['N']	[63]
64	and	O	['N']	[64]
65	(	O	['N']	[65]
66	d	O	['N']	[66]
67	)	O	['N']	[67]
68	manufacture	O	['N']	[68]
69	-	O	['N']	[69]
70	related	O	['N']	[70]
71	effects	O	['N']	[71]
72	of	O	['N']	[72]
73	exposure	O	['N']	[73]
74	to	O	['N']	[74]
75	unintentional	O	['N']	[75]
76	caustic	O	['N']	[76]
77	contaminants	O	['N']	[77]
78	in	O	['N']	[78]
79	the	O	['N']	[79]
80	final	O	['N']	[80]
81	product	O	['N']	[81]
82	.	O	['N']	[82]
#3714
0	Neutrophilic	B	['N']	[0]
1	eccrine	I	['N']	[1]
2	hidradenitis	I-Adverse_Effect	['N']	[2]
3	mimicking	O	['N']	[3]
4	cutaneous	O	['N']	[4]
5	vasculitis	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	lupus	O	['N']	[8]
9	patient	O	['N']	[9]
10	:	O	['N']	[10]
11	a	O	['N']	[11]
12	complication	O	['N']	[12]
13	of	O	['N']	[13]
14	cyclophosphamide	B-Drug	['Causes']	[2]
15	.	O	['N']	[15]
#3715
0	Protamine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	fatal	B	['N']	[3]
4	anaphylaxis	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#3716
0	Drug	O	['N']	[0]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	psychosis	O	['N']	[3]
4	resulted	O	['N']	[4]
5	from	O	['N']	[5]
6	the	O	['N']	[6]
7	administration	O	['N']	[7]
8	of	O	['N']	[8]
9	quinacrine	B	['N']	[9]
10	hydrochloride	I-Drug	['Dosage']	[16]
11	at	O	['N']	[11]
12	a	O	['N']	[12]
13	dosage	O	['N']	[13]
14	of	O	['N']	[14]
15	100	B	['N']	[15]
16	mg	I-Dose	['N']	[16]
17	twice	O	['N']	[17]
18	daily	O	['N']	[18]
19	for	O	['N']	[19]
20	the	O	['N']	[20]
21	treatment	O	['N']	[21]
22	of	O	['N']	[22]
23	discoid	O	['N']	[23]
24	lupus	O	['N']	[24]
25	.	O	['N']	[25]
#3717
0	Exacerbations	B	['N']	[0]
1	of	I	['N']	[1]
2	the	I	['N']	[2]
3	heart	I	['N']	[3]
4	failure	I-Adverse_Effect	['N']	[4]
5	were	O	['N']	[5]
6	temporally	O	['N']	[6]
7	related	O	['N']	[7]
8	to	O	['N']	[8]
9	the	O	['N']	[9]
10	administration	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	antitumor	O	['N']	[13]
14	antibiotics	O	['N']	[14]
15	actinomycin	O	['N']	[15]
16	-	O	['N']	[16]
17	D	O	['N']	[17]
18	(	O	['N']	[18]
19	NSC-3053	O	['N']	[19]
20	)	O	['N']	[20]
21	and	O	['N']	[21]
22	mithramycin	B-Drug	['Causes']	[4]
23	(	O	['N']	[23]
24	NSC-24559	O	['N']	[24]
25	)	O	['N']	[25]
26	.	O	['N']	[26]
#3718
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	purpose	O	['N']	[3]
4	of	O	['N']	[4]
5	this	O	['N']	[5]
6	study	O	['N']	[6]
7	was	O	['N']	[7]
8	to	O	['N']	[8]
9	determine	O	['N']	[9]
10	whether	O	['N']	[10]
11	desensitization	O	['N']	[11]
12	to	O	['N']	[12]
13	NPH	B	['N']	[13]
14	insulin	I-Drug	['Causes']	[26]
15	,	O	['N']	[15]
16	as	O	['N']	[16]
17	well	O	['N']	[17]
18	as	O	['N']	[18]
19	standard	O	['N']	[19]
20	insulin	O	['N']	[20]
21	desensitization	O	['N']	[21]
22	,	O	['N']	[22]
23	could	O	['N']	[23]
24	control	O	['N']	[24]
25	allergic	B	['N']	[25]
26	symptoms	I-Adverse_Effect	['N']	[26]
27	in	O	['N']	[27]
28	a	O	['N']	[28]
29	patient	O	['N']	[29]
30	allergic	O	['N']	[30]
31	to	O	['N']	[31]
32	both	O	['N']	[32]
33	NPH	O	['N']	[33]
34	and	O	['N']	[34]
35	regular	O	['N']	[35]
36	insulin	O	['N']	[36]
37	.	O	['N']	[37]
#3719
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	we	O	['N']	[3]
4	present	O	['N']	[4]
5	four	O	['N']	[5]
6	patients	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	combination	O	['N']	[10]
11	of	O	['N']	[11]
12	different	O	['N']	[12]
13	psychotropic	O	['N']	[13]
14	drugs	O	['N']	[14]
15	,	O	['N']	[15]
16	in	O	['N']	[16]
17	whom	O	['N']	[17]
18	asterixis	B-Adverse_Effect	['N']	[18]
19	was	O	['N']	[19]
20	triggered	O	['N']	[20]
21	either	O	['N']	[21]
22	by	O	['N']	[22]
23	adding	O	['N']	[23]
24	carbamazepine	B-Drug	['Causes']	[18]
25	(	O	['N']	[25]
26	CBZ	O	['N']	[26]
27	)	O	['N']	[27]
28	to	O	['N']	[28]
29	a	O	['N']	[29]
30	treatment	O	['N']	[30]
31	regimen	O	['N']	[31]
32	,	O	['N']	[32]
33	or	O	['N']	[33]
34	by	O	['N']	[34]
35	increasing	O	['N']	[35]
36	its	O	['N']	[36]
37	dosage	O	['N']	[37]
38	.	O	['N']	[38]
#3720
0	Posterior	B	['N']	[0]
1	leukoencephalopathy	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	cisplatin	B-Drug	['Causes']	[1]
4	,	O	['N']	[4]
5	bleomycin	O	['N']	[5]
6	and	O	['N']	[6]
7	vinblastine	O	['N']	[7]
8	therapy	O	['N']	[8]
9	for	O	['N']	[9]
10	germ	O	['N']	[10]
11	cell	O	['N']	[11]
12	tumor	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	ovary	O	['N']	[15]
16	.	O	['N']	[16]
#3721
0	CASE	O	['N']	[0]
1	SUMMARIES	O	['N']	[1]
2	:	O	['N']	[2]
3	Two	O	['N']	[3]
4	patients	O	['N']	[4]
5	who	O	['N']	[5]
6	received	O	['N']	[6]
7	ifosfamide	B-Drug	['Causes']	[12]
8	-	O	['N']	[8]
9	containing	O	['N']	[9]
10	chemotherapy	O	['N']	[10]
11	developed	O	['N']	[11]
12	NCSE	B-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#3722
0	Flumazenil	O	['N']	[0]
1	reversal	O	['N']	[1]
2	of	O	['N']	[2]
3	benzodiazepine	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	sedation	B-Adverse_Effect	['N']	[6]
7	for	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	severe	O	['N']	[11]
12	pre	O	['N']	[12]
13	-	O	['N']	[13]
14	ECT	O	['N']	[14]
15	anxiety	O	['N']	[15]
16	.	O	['N']	[16]
#3723
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	report	O	['N']	[3]
4	describes	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	a	O	['N']	[8]
9	probable	O	['N']	[9]
10	interaction	O	['N']	[10]
11	between	O	['N']	[11]
12	topical	O	['N']	[12]
13	econazole	O	['N']	[13]
14	lotion	O	['N']	[14]
15	1	O	['N']	[15]
16	%	O	['N']	[16]
17	and	O	['N']	[17]
18	acenocoumarol	B-Drug	['Causes']	[29]
19	that	O	['N']	[19]
20	resulted	O	['N']	[20]
21	in	O	['N']	[21]
22	overanticoagulation	O	['N']	[22]
23	and	O	['N']	[23]
24	a	O	['N']	[24]
25	life	O	['N']	[25]
26	-	O	['N']	[26]
27	threatening	O	['N']	[27]
28	laryngeal	B	['N']	[28]
29	hematoma	I-Adverse_Effect	['N']	[29]
30	in	O	['N']	[30]
31	this	O	['N']	[31]
32	elderly	O	['N']	[32]
33	patient	O	['N']	[33]
34	.	O	['N']	[34]
#3724
0	After	O	['N']	[0]
1	approximately	O	['N']	[1]
2	two	O	['N']	[2]
3	weeks	O	['N']	[3]
4	of	O	['N']	[4]
5	sertraline	B-Drug	['Causes']	[12]
6	treatment	O	['N']	[6]
7	he	O	['N']	[7]
8	noted	O	['N']	[8]
9	an	O	['N']	[9]
10	intense	B	['N']	[10]
11	itching	I	['N']	[11]
12	sensation	I-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	his	O	['N']	[14]
15	scalp	O	['N']	[15]
16	after	O	['N']	[16]
17	eating	O	['N']	[17]
18	a	O	['N']	[18]
19	piece	O	['N']	[19]
20	of	O	['N']	[20]
21	chocolate	O	['N']	[21]
22	cake	O	['N']	[22]
23	.	O	['N']	[23]
#3725
0	Prolongation	B	['N']	[0]
1	of	I	['N']	[1]
2	the	I	['N']	[2]
3	QT	I	['N']	[3]
4	interval	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	ventricular	O	['N']	[6]
7	tachyarrhymias	O	['N']	[7]
8	have	O	['N']	[8]
9	been	O	['N']	[9]
10	described	O	['N']	[10]
11	in	O	['N']	[11]
12	patients	O	['N']	[12]
13	on	O	['N']	[13]
14	amiodarone	B-Drug	['Causes']	[4]
15	therapy	O	['N']	[15]
16	.	O	['N']	[16]
#3726
0	Although	O	['N']	[0]
1	neurotoxicity	O	['N']	[1]
2	is	O	['N']	[2]
3	a	O	['N']	[3]
4	frequent	O	['N']	[4]
5	complication	O	['N']	[5]
6	of	O	['N']	[6]
7	methotrexate	B-Drug	['Causes']	[12]
8	therapy	O	['N']	[8]
9	,	O	['N']	[9]
10	fatal	B	['N']	[10]
11	acute	I	['N']	[11]
12	neurotoxicity	I-Adverse_Effect	['N']	[12]
13	is	O	['N']	[13]
14	extremely	O	['N']	[14]
15	uncommon	O	['N']	[15]
16	,	O	['N']	[16]
17	especially	O	['N']	[17]
18	in	O	['N']	[18]
19	adults	O	['N']	[19]
20	.	O	['N']	[20]
#3727
0	Currently	O	['N']	[0]
1	the	O	['N']	[1]
2	use	O	['N']	[2]
3	of	O	['N']	[3]
4	zidovudine	B-Drug	['Causes']	[20]
5	is	O	['N']	[5]
6	one	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	few	O	['N']	[9]
10	specific	O	['N']	[10]
11	measures	O	['N']	[11]
12	available	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	as	O	['N']	[15]
16	a	O	['N']	[16]
17	potentially	O	['N']	[17]
18	teratogenic	O	['N']	[18]
19	and	O	['N']	[19]
20	fetotoxic	B-Adverse_Effect	['N']	[20]
21	agent	O	['N']	[21]
22	,	O	['N']	[22]
23	any	O	['N']	[23]
24	decision	O	['N']	[24]
25	for	O	['N']	[25]
26	its	O	['N']	[26]
27	use	O	['N']	[27]
28	requires	O	['N']	[28]
29	evaluation	O	['N']	[29]
30	of	O	['N']	[30]
31	the	O	['N']	[31]
32	potential	O	['N']	[32]
33	for	O	['N']	[33]
34	fetal	O	['N']	[34]
35	damage	O	['N']	[35]
36	.	O	['N']	[36]
#3728
0	Clinicians	O	['N']	[0]
1	have	O	['N']	[1]
2	been	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	lithium	B-Drug	['Causes']	[24]
6	toxicity	O	['N']	[6]
7	for	O	['N']	[7]
8	many	O	['N']	[8]
9	years	O	['N']	[9]
10	and	O	['N']	[10]
11	traditionally	O	['N']	[11]
12	have	O	['N']	[12]
13	administered	O	['N']	[13]
14	thiazide	O	['N']	[14]
15	diuretics	O	['N']	[15]
16	for	O	['N']	[16]
17	lithium	O	['N']	[17]
18	-	O	['N']	[18]
19	induced	O	['N']	[19]
20	polyuria	O	['N']	[20]
21	and	O	['N']	[21]
22	nephrogenic	B	['N']	[22]
23	diabetes	I	['N']	[23]
24	insipidus	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#3729
0	Diarrhoea	B-Adverse_Effect	['N']	[0]
1	,	O	['N']	[1]
2	T	O	['N']	[2]
3	-	O	['N']	[3]
4	CD4	O	['N']	[4]
5	+	O	['N']	[5]
6	lymphopenia	O	['N']	[6]
7	and	O	['N']	[7]
8	bilateral	O	['N']	[8]
9	patchy	O	['N']	[9]
10	pulmonary	O	['N']	[10]
11	infiltrates	O	['N']	[11]
12	developed	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	male	O	['N']	[15]
16	60	O	['N']	[16]
17	yrs	O	['N']	[17]
18	of	O	['N']	[18]
19	age	O	['N']	[19]
20	,	O	['N']	[20]
21	who	O	['N']	[21]
22	was	O	['N']	[22]
23	treated	O	['N']	[23]
24	with	O	['N']	[24]
25	oxaliplatinum	B-Drug	['Causes']	[0]
26	and	O	['N']	[26]
27	5-fluorouracil	O	['N']	[27]
28	for	O	['N']	[28]
29	unresectable	O	['N']	[29]
30	rectum	O	['N']	[30]
31	carcinoma	O	['N']	[31]
32	.	O	['N']	[32]
#3730
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	young	O	['N']	[6]
7	woman	O	['N']	[7]
8	with	O	['N']	[8]
9	SLE	O	['N']	[9]
10	and	O	['N']	[10]
11	thrombocytopenia	O	['N']	[11]
12	,	O	['N']	[12]
13	who	O	['N']	[13]
14	developed	O	['N']	[14]
15	severe	B	['N']	[15]
16	perspiration	I-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	headache	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	seizure	O	['N']	[21]
22	after	O	['N']	[22]
23	receiving	O	['N']	[23]
24	cyclosporine	B-Drug	['Causes']	[16]
25	.	O	['N']	[25]
#3731
0	In	O	['N']	[0]
1	the	O	['N']	[1]
2	present	O	['N']	[2]
3	paper	O	['N']	[3]
4	the	O	['N']	[4]
5	authors	O	['N']	[5]
6	describe	O	['N']	[6]
7	2	O	['N']	[7]
8	female	O	['N']	[8]
9	patients	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	incontinence	B-Adverse_Effect	['N']	[12]
13	secondary	O	['N']	[13]
14	to	O	['N']	[14]
15	the	O	['N']	[15]
16	selective	O	['N']	[16]
17	serotonin	O	['N']	[17]
18	reuptake	O	['N']	[18]
19	inhibitors	O	['N']	[19]
20	paroxetine	B-Drug	['Causes']	[12]
21	and	O	['N']	[21]
22	sertraline	O	['N']	[22]
23	,	O	['N']	[23]
24	as	O	['N']	[24]
25	well	O	['N']	[25]
26	as	O	['N']	[26]
27	a	O	['N']	[27]
28	third	O	['N']	[28]
29	who	O	['N']	[29]
30	developed	O	['N']	[30]
31	this	O	['N']	[31]
32	side	O	['N']	[32]
33	effect	O	['N']	[33]
34	on	O	['N']	[34]
35	venlafaxine	O	['N']	[35]
36	.	O	['N']	[36]
#3732
0	An	O	['N']	[0]
1	83-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	receiving	O	['N']	[5]
6	glipizide	O	['N']	[6]
7	10	O	['N']	[7]
8	mg	O	['N']	[8]
9	bid	O	['N']	[9]
10	developed	O	['N']	[10]
11	symptomatic	B	['N']	[11]
12	hypoglycemia	I-Adverse_Effect	['N']	[12]
13	within	O	['N']	[13]
14	three	O	['N']	[14]
15	days	O	['N']	[15]
16	of	O	['N']	[16]
17	adding	O	['N']	[17]
18	trimethoprim	B-Drug	['Causes']	[12]
19	/	O	['N']	[19]
20	sulfamethoxazole	O	['N']	[20]
21	(	O	['N']	[21]
22	TMP	O	['N']	[22]
23	/	O	['N']	[23]
24	SMX	O	['N']	[24]
25	)	O	['N']	[25]
26	to	O	['N']	[26]
27	his	O	['N']	[27]
28	regimen	O	['N']	[28]
29	.	O	['N']	[29]
#3733
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	suggests	O	['N']	[2]
3	that	O	['N']	[3]
4	acyclovir	O	['N']	[4]
5	when	O	['N']	[5]
6	given	O	['N']	[6]
7	intravenously	O	['N']	[7]
8	in	O	['N']	[8]
9	doses	O	['N']	[9]
10	of	O	['N']	[10]
11	10	B	['N']	[11]
12	mg	I	['N']	[12]
13	/	I	['N']	[13]
14	kg	I-Dose	['N']	[14]
15	may	O	['N']	[15]
16	result	O	['N']	[16]
17	in	O	['N']	[17]
18	increased	O	['N']	[18]
19	serum	O	['N']	[19]
20	lithium	B-Drug	['Dosage']	[14]
21	concentrations	O	['N']	[21]
22	.	O	['N']	[22]
#3734
0	The	O	['N']	[0]
1	presented	O	['N']	[1]
2	patient	O	['N']	[2]
3	was	O	['N']	[3]
4	treated	O	['N']	[4]
5	with	O	['N']	[5]
6	200	B	['N']	[6]
7	mg	I-Dose	['N']	[7]
8	TCA	B-Drug	['Dosage']	[7]
9	and	O	['N']	[9]
10	developed	O	['N']	[10]
11	Cushing	O	['N']	[11]
12	's	O	['N']	[12]
13	syndrome	O	['N']	[13]
14	6	O	['N']	[14]
15	weeks	O	['N']	[15]
16	later	O	['N']	[16]
17	(	O	['N']	[17]
18	cortisol	O	['N']	[18]
19	and	O	['N']	[19]
20	ACTH	O	['N']	[20]
21	concentrations	O	['N']	[21]
22	were	O	['N']	[22]
23	below	O	['N']	[23]
24	limits	O	['N']	[24]
25	of	O	['N']	[25]
26	detection	O	['N']	[26]
27	,	O	['N']	[27]
28	TCA	O	['N']	[28]
29	concentrations	O	['N']	[29]
30	were	O	['N']	[30]
31	>	O	['N']	[31]
32	3	O	['N']	[32]
33	micrograms	O	['N']	[33]
34	/	O	['N']	[34]
35	l	O	['N']	[35]
36	)	O	['N']	[36]
37	.	O	['N']	[37]
#3735
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	history	O	['N']	[2]
3	and	O	['N']	[3]
4	toxicological	O	['N']	[4]
5	findings	O	['N']	[5]
6	of	O	['N']	[6]
7	an	O	['N']	[7]
8	infant	O	['N']	[8]
9	fatality	B-Adverse_Effect	['N']	[9]
10	involving	O	['N']	[10]
11	pseudoephedrine	B-Drug	['Causes']	[9]
12	,	O	['N']	[12]
13	brompheniramine	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	dextromethorphan	O	['N']	[16]
17	are	O	['N']	[17]
18	presented	O	['N']	[18]
19	.	O	['N']	[19]
#3736
0	Hypoglycemia	B-Adverse_Effect	['N']	[0]
1	induced	O	['N']	[1]
2	by	O	['N']	[2]
3	long	O	['N']	[3]
4	-	O	['N']	[4]
5	acting	O	['N']	[5]
6	somatostatin	B-Drug	['Causes']	[0]
7	analogues	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	with	O	['N']	[11]
12	nonfunctional	O	['N']	[12]
13	neuroendocrine	O	['N']	[13]
14	tumor	O	['N']	[14]
15	.	O	['N']	[15]
#3737
0	Massive	O	['N']	[0]
1	CBZ	B-Drug	['Dosage']	[2]
2	OD	B-Dose	['N']	[2]
3	may	O	['N']	[3]
4	produce	O	['N']	[4]
5	a	O	['N']	[5]
6	reversible	O	['N']	[6]
7	encephalopathy	O	['N']	[7]
8	that	O	['N']	[8]
9	includes	O	['N']	[9]
10	cortical	O	['N']	[10]
11	hyperexcitability	O	['N']	[11]
12	,	O	['N']	[12]
13	a	O	['N']	[13]
14	profound	O	['N']	[14]
15	burst	O	['N']	[15]
16	-	O	['N']	[16]
17	suppression	O	['N']	[17]
18	EEG	O	['N']	[18]
19	pattern	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	cranial	O	['N']	[22]
23	nerve	O	['N']	[23]
24	areflexia	O	['N']	[24]
25	.	O	['N']	[25]
#3738
0	Increased	B	['N']	[0]
1	ocular	I	['N']	[1]
2	pressure	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	two	O	['N']	[4]
5	patients	O	['N']	[5]
6	with	O	['N']	[6]
7	narrow	O	['N']	[7]
8	angle	O	['N']	[8]
9	glaucoma	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	venlafaxine	B-Drug	['Causes']	[2]
13	.	O	['N']	[13]
#3739
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	2	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	maculopapular	B	['N']	[5]
6	eruption	I-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	fever	O	['N']	[8]
9	in	O	['N']	[9]
10	patients	O	['N']	[10]
11	infected	O	['N']	[11]
12	with	O	['N']	[12]
13	human	O	['N']	[13]
14	immunodeficiency	O	['N']	[14]
15	virus	O	['N']	[15]
16	(	O	['N']	[16]
17	HIV	O	['N']	[17]
18	)	O	['N']	[18]
19	on	O	['N']	[19]
20	the	O	['N']	[20]
21	2nd	O	['N']	[21]
22	day	O	['N']	[22]
23	of	O	['N']	[23]
24	first	O	['N']	[24]
25	administration	O	['N']	[25]
26	of	O	['N']	[26]
27	ritonavir	B-Drug	['Causes']	[6]
28	,	O	['N']	[28]
29	a	O	['N']	[29]
30	protease	O	['N']	[30]
31	inhibitor	O	['N']	[31]
32	.	O	['N']	[32]
#3740
0	This	O	['N']	[0]
1	article	O	['N']	[1]
2	reports	O	['N']	[2]
3	the	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	an	O	['N']	[6]
7	otherwise	O	['N']	[7]
8	healthy	O	['N']	[8]
9	patient	O	['N']	[9]
10	who	O	['N']	[10]
11	experienced	O	['N']	[11]
12	permanent	O	['N']	[12]
13	sensorineural	B	['N']	[13]
14	hearing	I	['N']	[14]
15	loss	I-Adverse_Effect	['N']	[15]
16	after	O	['N']	[16]
17	a	O	['N']	[17]
18	brief	O	['N']	[18]
19	course	O	['N']	[19]
20	of	O	['N']	[20]
21	naproxen	B-Drug	['Causes']	[15]
22	and	O	['N']	[22]
23	reviews	O	['N']	[23]
24	the	O	['N']	[24]
25	literature	O	['N']	[25]
26	on	O	['N']	[26]
27	NSAID	O	['N']	[27]
28	-	O	['N']	[28]
29	related	O	['N']	[29]
30	permanent	O	['N']	[30]
31	sensorineural	O	['N']	[31]
32	hearing	O	['N']	[32]
33	loss	O	['N']	[33]
34	.	O	['N']	[34]
#3741
0	Warfarin	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	skin	B	['N']	[3]
4	necrosis	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	heparin	O	['N']	[6]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	thrombocytopenia	O	['N']	[9]
10	following	O	['N']	[10]
11	mitral	O	['N']	[11]
12	valve	O	['N']	[12]
13	replacement	O	['N']	[13]
14	for	O	['N']	[14]
15	marantic	O	['N']	[15]
16	endocarditis	O	['N']	[16]
17	.	O	['N']	[17]
#3742
0	Massive	B	['N']	[0]
1	pulmonary	I	['N']	[1]
2	embolism	I-Adverse_Effect	['N']	[2]
3	due	O	['N']	[3]
4	to	O	['N']	[4]
5	late	O	['N']	[5]
6	-	O	['N']	[6]
7	onset	O	['N']	[7]
8	heparin	B-Drug	['Causes']	[2]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	thrombocytopenia	O	['N']	[11]
12	following	O	['N']	[12]
13	coronary	O	['N']	[13]
14	artery	O	['N']	[14]
15	bypass	O	['N']	[15]
16	graft	O	['N']	[16]
17	surgery	O	['N']	[17]
18	:	O	['N']	[18]
19	successful	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	lepirudin	O	['N']	[22]
23	.	O	['N']	[23]
#3743
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	87-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	white	O	['N']	[9]
10	woman	O	['N']	[10]
11	with	O	['N']	[11]
12	myasthenia	O	['N']	[12]
13	gravis	O	['N']	[13]
14	who	O	['N']	[14]
15	presented	O	['N']	[15]
16	with	O	['N']	[16]
17	nausea	O	['N']	[17]
18	,	O	['N']	[18]
19	shortness	B	['N']	[19]
20	of	I	['N']	[20]
21	breath	I-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	azotemia	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	hyperkalemia	O	['N']	[26]
27	shortly	O	['N']	[27]
28	after	O	['N']	[28]
29	completing	O	['N']	[29]
30	a	O	['N']	[30]
31	course	O	['N']	[31]
32	of	O	['N']	[32]
33	intravenous	O	['N']	[33]
34	immunoglobulin	B-Drug	['Causes']	[21]
35	(	O	['N']	[35]
36	IVIG	O	['N']	[36]
37	)	O	['N']	[37]
38	.	O	['N']	[38]
#3744
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	acute	O	['N']	[3]
4	cardiomyopathy	O	['N']	[4]
5	and	O	['N']	[5]
6	pericarditis	B-Adverse_Effect	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	methylphenidate	B-Drug	['Causes']	[6]
10	.	O	['N']	[10]
#3745
0	Less	O	['N']	[0]
1	common	O	['N']	[1]
2	adverse	O	['N']	[2]
3	events	O	['N']	[3]
4	to	O	['N']	[4]
5	dapsone	B-Drug	['Causes']	[34]
6	include	O	['N']	[6]
7	the	O	['N']	[7]
8	idiosyncratic	O	['N']	[8]
9	reactions	O	['N']	[9]
10	of	O	['N']	[10]
11	leukopenia	O	['N']	[11]
12	and	O	['N']	[12]
13	agranulocytosis	O	['N']	[13]
14	,	O	['N']	[14]
15	cutaneous	O	['N']	[15]
16	eruptions	O	['N']	[16]
17	,	O	['N']	[17]
18	peripheral	O	['N']	[18]
19	neuropathy	O	['N']	[19]
20	,	O	['N']	[20]
21	psychosis	O	['N']	[21]
22	,	O	['N']	[22]
23	toxic	O	['N']	[23]
24	hepatitis	O	['N']	[24]
25	,	O	['N']	[25]
26	cholestatic	O	['N']	[26]
27	jaundice	O	['N']	[27]
28	,	O	['N']	[28]
29	nephrotic	O	['N']	[29]
30	syndrome	O	['N']	[30]
31	,	O	['N']	[31]
32	renal	B	['N']	[32]
33	papillary	I	['N']	[33]
34	necrosis	I-Adverse_Effect	['N']	[34]
35	,	O	['N']	[35]
36	severe	O	['N']	[36]
37	hypoalbuminemia	O	['N']	[37]
38	without	O	['N']	[38]
39	proteinuria	O	['N']	[39]
40	,	O	['N']	[40]
41	an	O	['N']	[41]
42	infectious	O	['N']	[42]
43	mononucleosis	O	['N']	[43]
44	-	O	['N']	[44]
45	like	O	['N']	[45]
46	syndrome	O	['N']	[46]
47	,	O	['N']	[47]
48	and	O	['N']	[48]
49	minor	O	['N']	[49]
50	neurological	O	['N']	[50]
51	and	O	['N']	[51]
52	gastrointestinal	O	['N']	[52]
53	complaints	O	['N']	[53]
54	.	O	['N']	[54]
#3746
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	rheumatoid	O	['N']	[8]
9	arthritis	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	low	O	['N']	[12]
13	-	O	['N']	[13]
14	dose	O	['N']	[14]
15	methotrexate	B-Drug	['Dosage']	[20]
16	(	O	['N']	[16]
17	15	B	['N']	[17]
18	mg	I	['N']	[18]
19	/	I	['N']	[19]
20	week	I-Dose	['N']	[20]
21	)	O	['N']	[21]
22	who	O	['N']	[22]
23	developed	O	['N']	[23]
24	infection	O	['N']	[24]
25	with	O	['N']	[25]
26	both	O	['N']	[26]
27	M.	O	['N']	[27]
28	tuberculosis	O	['N']	[28]
29	and	O	['N']	[29]
30	M.	O	['N']	[30]
31	chelonae	O	['N']	[31]
32	after	O	['N']	[32]
33	the	O	['N']	[33]
34	revision	O	['N']	[34]
35	of	O	['N']	[35]
36	a	O	['N']	[36]
37	prosthetic	O	['N']	[37]
38	hip	O	['N']	[38]
39	.	O	['N']	[39]
#3747
0	Acute	O	['N']	[0]
1	valproate	B-Drug	['Causes']	[5]
2	ingestion	O	['N']	[2]
3	induces	O	['N']	[3]
4	symptomatic	B	['N']	[4]
5	methemoglobinemia	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#3748
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	present	O	['N']	[2]
3	an	O	['N']	[3]
4	elderly	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	mixed	O	['N']	[7]
8	dementia	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	TD	O	['N']	[11]
12	at	O	['N']	[12]
13	multiple	O	['N']	[13]
14	sites	O	['N']	[14]
15	,	O	['N']	[15]
16	(	O	['N']	[16]
17	including	O	['N']	[17]
18	respiratory	O	['N']	[18]
19	dyskinesia	O	['N']	[19]
20	[	O	['N']	[20]
21	RD	B-Adverse_Effect	['N']	[21]
22	]	O	['N']	[22]
23	,	O	['N']	[23]
24	limb	O	['N']	[24]
25	dyskinesia	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	orofacial	O	['N']	[28]
29	dyskinesia	O	['N']	[29]
30	)	O	['N']	[30]
31	following	O	['N']	[31]
32	abrupt	O	['N']	[32]
33	withdrawal	O	['N']	[33]
34	of	O	['N']	[34]
35	risperidone	B-Drug	['Causes']	[21]
36	therapy	O	['N']	[36]
37	.	O	['N']	[37]
#3749
0	The	O	['N']	[0]
1	reversal	O	['N']	[1]
2	of	O	['N']	[2]
3	heparin	O	['N']	[3]
4	by	O	['N']	[4]
5	protamine	B-Drug	['Causes']	[10]
6	may	O	['N']	[6]
7	cause	O	['N']	[7]
8	severe	B	['N']	[8]
9	hemodynamic	I	['N']	[9]
10	deterioration	I-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	characterized	O	['N']	[12]
13	by	O	['N']	[13]
14	systemic	O	['N']	[14]
15	hypotension	O	['N']	[15]
16	,	O	['N']	[16]
17	pulmonary	O	['N']	[17]
18	hypertension	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	bronchoconstriction	O	['N']	[21]
22	.	O	['N']	[22]
#3750
0	Bone	O	['N']	[0]
1	marrow	O	['N']	[1]
2	aplasia	O	['N']	[2]
3	and	O	['N']	[3]
4	severe	O	['N']	[4]
5	skin	O	['N']	[5]
6	rash	O	['N']	[6]
7	after	O	['N']	[7]
8	a	O	['N']	[8]
9	single	O	['N']	[9]
10	low	B	['N']	[10]
11	dose	I-Dose	['N']	[11]
12	of	O	['N']	[12]
13	methotrexate	B-Drug	['Dosage']	[11]
14	.	O	['N']	[14]
#3751
0	L	B	['N']	[0]
1	-	I	['N']	[1]
2	asparaginase	I-Drug	['Causes']	[7]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	posterior	B	['N']	[5]
6	reversible	I	['N']	[6]
7	encephalopathy	I-Adverse_Effect	['N']	[7]
8	syndrome	O	['N']	[8]
9	during	O	['N']	[9]
10	acute	O	['N']	[10]
11	lymphoblastic	O	['N']	[11]
12	leukemia	O	['N']	[12]
13	treatment	O	['N']	[13]
14	in	O	['N']	[14]
15	children	O	['N']	[15]
16	.	O	['N']	[16]
#3752
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	skin	O	['N']	[23]
24	eruptions	O	['N']	[24]
25	,	O	['N']	[25]
26	cervical	O	['N']	[26]
27	lymphadenopathy	O	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	O	['N']	[31]
32	lymphocytosis	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	B-Adverse_Effect	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	O	['N']	[40]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	O	['N']	[42]
43	(	O	['N']	[43]
44	SMX	B-Drug	['Causes']	[35]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#3753
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Although	O	['N']	[2]
3	mirtazapine	B-Drug	['Causes']	[18]
4	offers	O	['N']	[4]
5	clinicians	O	['N']	[5]
6	a	O	['N']	[6]
7	combination	O	['N']	[7]
8	of	O	['N']	[8]
9	strong	O	['N']	[9]
10	efficacy	O	['N']	[10]
11	and	O	['N']	[11]
12	good	O	['N']	[12]
13	safety	O	['N']	[13]
14	,	O	['N']	[14]
15	we	O	['N']	[15]
16	suggest	O	['N']	[16]
17	bearing	O	['N']	[17]
18	SS	B-Adverse_Effect	['N']	[18]
19	in	O	['N']	[19]
20	mind	O	['N']	[20]
21	when	O	['N']	[21]
22	prescribing	O	['N']	[22]
23	this	O	['N']	[23]
24	drug	O	['N']	[24]
25	,	O	['N']	[25]
26	especially	O	['N']	[26]
27	in	O	['N']	[27]
28	frail	O	['N']	[28]
29	,	O	['N']	[29]
30	elderly	O	['N']	[30]
31	patients	O	['N']	[31]
32	with	O	['N']	[32]
33	underlying	O	['N']	[33]
34	chronic	O	['N']	[34]
35	conditions	O	['N']	[35]
36	.	O	['N']	[36]
#3754
0	Six	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	no	O	['N']	[3]
4	previous	O	['N']	[4]
5	signs	O	['N']	[5]
6	or	O	['N']	[6]
7	symptoms	O	['N']	[7]
8	suggestive	O	['N']	[8]
9	of	O	['N']	[9]
10	coronary	O	['N']	[10]
11	artery	O	['N']	[11]
12	disease	O	['N']	[12]
13	developed	O	['N']	[13]
14	acute	O	['N']	[14]
15	coronary	O	['N']	[15]
16	ischemia	O	['N']	[16]
17	/	O	['N']	[17]
18	infarction	B-Adverse_Effect	['N']	[18]
19	shortly	O	['N']	[19]
20	after	O	['N']	[20]
21	cis	O	['N']	[21]
22	-	O	['N']	[22]
23	diamine	O	['N']	[23]
24	-	O	['N']	[24]
25	dichloroplatinum	O	['N']	[25]
26	II	O	['N']	[26]
27	(	O	['N']	[27]
28	cisplatin	B-Drug	['Causes']	[18]
29	)	O	['N']	[29]
30	-based	O	['N']	[30]
31	chemotherapy	O	['N']	[31]
32	.	O	['N']	[32]
#3755
0	The	O	['N']	[0]
1	possibility	O	['N']	[1]
2	of	O	['N']	[2]
3	deep	B	['N']	[3]
4	vein	I	['N']	[4]
5	thrombosis	I-Adverse_Effect	['N']	[5]
6	caused	O	['N']	[6]
7	by	O	['N']	[7]
8	the	O	['N']	[8]
9	compression	O	['N']	[9]
10	of	O	['N']	[10]
11	the	O	['N']	[11]
12	veins	O	['N']	[12]
13	by	O	['N']	[13]
14	necrotic	O	['N']	[14]
15	tumor	O	['N']	[15]
16	should	O	['N']	[16]
17	be	O	['N']	[17]
18	considered	O	['N']	[18]
19	in	O	['N']	[19]
20	patients	O	['N']	[20]
21	with	O	['N']	[21]
22	abdominal	O	['N']	[22]
23	or	O	['N']	[23]
24	pelvic	O	['N']	[24]
25	metastases	O	['N']	[25]
26	of	O	['N']	[26]
27	GIST	O	['N']	[27]
28	,	O	['N']	[28]
29	including	O	['N']	[29]
30	patients	O	['N']	[30]
31	treated	O	['N']	[31]
32	with	O	['N']	[32]
33	imatinib	B-Drug	['Causes']	[5]
34	.	O	['N']	[34]
#3756
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	reversible	O	['N']	[5]
6	DKA	B-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	new	O	['N']	[8]
9	-	O	['N']	[9]
10	onset	O	['N']	[10]
11	DM	O	['N']	[11]
12	that	O	['N']	[12]
13	developed	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	demented	O	['N']	[16]
17	patient	O	['N']	[17]
18	who	O	['N']	[18]
19	was	O	['N']	[19]
20	treated	O	['N']	[20]
21	with	O	['N']	[21]
22	quetiapine	B-Drug	['Causes']	[6]
23	for	O	['N']	[23]
24	14	O	['N']	[24]
25	days	O	['N']	[25]
26	.	O	['N']	[26]
#3757
0	She	O	['N']	[0]
1	received	O	['N']	[1]
2	an	O	['N']	[2]
3	accidental	O	['N']	[3]
4	450-mg	B-Dose	['N']	[4]
5	bolus	O	['N']	[5]
6	injection	O	['N']	[6]
7	of	O	['N']	[7]
8	morphine	B-Drug	['Dosage']	[4]
9	intrathecally	O	['N']	[9]
10	and	O	['N']	[10]
11	developed	O	['N']	[11]
12	hypertension	O	['N']	[12]
13	,	O	['N']	[13]
14	status	O	['N']	[14]
15	epilepticus	O	['N']	[15]
16	,	O	['N']	[16]
17	intracerebral	O	['N']	[17]
18	hemorrhage	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	respiratory	O	['N']	[21]
22	failure	O	['N']	[22]
23	.	O	['N']	[23]
#3758
0	A	O	['N']	[0]
1	52-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	developed	O	['N']	[5]
6	symmetric	B	['N']	[6]
7	sensorimotor	I	['N']	[7]
8	polyneuropathy	I-Adverse_Effect	['N']	[8]
9	and	O	['N']	[9]
10	cerebellar	O	['N']	[10]
11	syndrome	O	['N']	[11]
12	after	O	['N']	[12]
13	24	O	['N']	[13]
14	months	O	['N']	[14]
15	of	O	['N']	[15]
16	amiodarone	B-Drug	['Causes']	[8]
17	treatment	O	['N']	[17]
18	.	O	['N']	[18]
#3759
0	Thrombotic	B	['N']	[0]
1	thrombocytopenic	I	['N']	[1]
2	purpura	I-Adverse_Effect	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	trimethoprim	O	['N']	[5]
6	-	O	['N']	[6]
7	sulfamethoxazole	B-Drug	['Causes']	[2]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	Jehovah	O	['N']	[10]
11	's	O	['N']	[11]
12	Witness	O	['N']	[12]
13	.	O	['N']	[13]
#3760
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	timolol	B-Drug	['Causes']	[7]
4	-	O	['N']	[4]
5	associated	O	['N']	[5]
6	heart	B	['N']	[6]
7	failure	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	73-year	O	['N']	[10]
11	old	O	['N']	[11]
12	white	O	['N']	[12]
13	man	O	['N']	[13]
14	is	O	['N']	[14]
15	reported	O	['N']	[15]
16	.	O	['N']	[16]
#3761
0	Restless	B	['N']	[0]
1	legs	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	due	O	['N']	[3]
4	to	O	['N']	[4]
5	interferon	B	['N']	[5]
6	-	I	['N']	[6]
7	alpha	I-Drug	['Causes']	[2]
8	.	O	['N']	[8]
#3762
0	L	B	['N']	[0]
1	-	I	['N']	[1]
2	asparaginase	I-Drug	['Causes']	[5]
3	-	O	['N']	[3]
4	provoked	O	['N']	[4]
5	seizures	B-Adverse_Effect	['N']	[5]
6	as	O	['N']	[6]
7	singular	O	['N']	[7]
8	expression	O	['N']	[8]
9	of	O	['N']	[9]
10	central	O	['N']	[10]
11	nervous	O	['N']	[11]
12	toxicity	O	['N']	[12]
13	.	O	['N']	[13]
#3763
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	are	O	['N']	[2]
3	described	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	testicular	O	['N']	[6]
7	swelling	O	['N']	[7]
8	and	O	['N']	[8]
9	pain	B-Adverse_Effect	['N']	[9]
10	during	O	['N']	[10]
11	treatment	O	['N']	[11]
12	with	O	['N']	[12]
13	desipramine	B-Drug	['Causes']	[9]
14	.	O	['N']	[14]
#3764
0	Intravenous	O	['N']	[0]
1	cytarabine	O	['N']	[1]
2	and	O	['N']	[2]
3	methotrexate	B-Drug	['Causes']	[16]
4	appear	O	['N']	[4]
5	to	O	['N']	[5]
6	act	O	['N']	[6]
7	synergistically	O	['N']	[7]
8	to	O	['N']	[8]
9	enhance	O	['N']	[9]
10	the	O	['N']	[10]
11	potential	O	['N']	[11]
12	for	O	['N']	[12]
13	central	B	['N']	[13]
14	nervous	I	['N']	[14]
15	system	I	['N']	[15]
16	toxicity	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#3765
0	During	O	['N']	[0]
1	clarithromycin	B-Drug	['Causes']	[23]
2	coadministration	O	['N']	[2]
3	,	O	['N']	[3]
4	four	O	['N']	[4]
5	out	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	seven	O	['N']	[8]
9	patients	O	['N']	[9]
10	developed	O	['N']	[10]
11	moderate	O	['N']	[11]
12	-	O	['N']	[12]
13	to	O	['N']	[13]
14	-	O	['N']	[14]
15	severe	O	['N']	[15]
16	toxic	O	['N']	[16]
17	symptoms	O	['N']	[17]
18	of	O	['N']	[18]
19	carbamazepine	O	['N']	[19]
20	,	O	['N']	[20]
21	such	O	['N']	[21]
22	as	O	['N']	[22]
23	drowsiness	B-Adverse_Effect	['N']	[23]
24	,	O	['N']	[24]
25	dizziness	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	ataxia	O	['N']	[28]
29	,	O	['N']	[29]
30	which	O	['N']	[30]
31	resolved	O	['N']	[31]
32	within	O	['N']	[32]
33	5	O	['N']	[33]
34	days	O	['N']	[34]
35	after	O	['N']	[35]
36	clarithromycin	O	['N']	[36]
37	discontinuation	O	['N']	[37]
38	.	O	['N']	[38]
#3766
0	Bradycardia	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	congestive	O	['N']	[2]
3	heart	O	['N']	[3]
4	failure	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	ocular	O	['N']	[7]
8	timolol	B	['N']	[8]
9	maleate	I-Drug	['Causes']	[0]
10	.	O	['N']	[10]
#3767
0	A	O	['N']	[0]
1	boy	O	['N']	[1]
2	with	O	['N']	[2]
3	chronic	O	['N']	[3]
4	neutropenia	O	['N']	[4]
5	and	O	['N']	[5]
6	recurrent	O	['N']	[6]
7	inflammatory	O	['N']	[7]
8	skin	O	['N']	[8]
9	lesions	O	['N']	[9]
10	developed	O	['N']	[10]
11	multiple	B	['N']	[11]
12	erythematous	I	['N']	[12]
13	nodules	I-Adverse_Effect	['N']	[13]
14	following	O	['N']	[14]
15	administration	O	['N']	[15]
16	of	O	['N']	[16]
17	G	B	['N']	[17]
18	-	I	['N']	[18]
19	CSF	I-Drug	['Causes']	[13]
20	.	O	['N']	[20]
#3768
0	Exacerbations	B	['N']	[0]
1	of	I	['N']	[1]
2	the	I	['N']	[2]
3	heart	I	['N']	[3]
4	failure	I-Adverse_Effect	['N']	[4]
5	were	O	['N']	[5]
6	temporally	O	['N']	[6]
7	related	O	['N']	[7]
8	to	O	['N']	[8]
9	the	O	['N']	[9]
10	administration	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	antitumor	O	['N']	[13]
14	antibiotics	O	['N']	[14]
15	actinomycin	B	['N']	[15]
16	-	I	['N']	[16]
17	D	I-Drug	['Causes']	[4]
18	(	O	['N']	[18]
19	NSC-3053	O	['N']	[19]
20	)	O	['N']	[20]
21	and	O	['N']	[21]
22	mithramycin	O	['N']	[22]
23	(	O	['N']	[23]
24	NSC-24559	O	['N']	[24]
25	)	O	['N']	[25]
26	.	O	['N']	[26]
#3769
0	A	O	['N']	[0]
1	56-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	scleroderma	O	['N']	[6]
7	developed	O	['N']	[7]
8	rapidly	B	['N']	[8]
9	progressive	I	['N']	[9]
10	glomerulonephritis	I-Adverse_Effect	['N']	[10]
11	with	O	['N']	[11]
12	epithelial	O	['N']	[12]
13	crescents	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	hemoptysis	O	['N']	[16]
17	after	O	['N']	[17]
18	27	O	['N']	[18]
19	months	O	['N']	[19]
20	of	O	['N']	[20]
21	D	B	['N']	[21]
22	-	I	['N']	[22]
23	penicillamine	I-Drug	['Causes']	[10]
24	therapy	O	['N']	[24]
25	and	O	['N']	[25]
26	a	O	['N']	[26]
27	cumulative	O	['N']	[27]
28	dose	O	['N']	[28]
29	of	O	['N']	[29]
30	1,200	O	['N']	[30]
31	g.	O	['N']	[31]
#3770
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	is	O	['N']	[2]
3	described	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	a	O	['N']	[6]
7	rapid	O	['N']	[7]
8	onset	O	['N']	[8]
9	of	O	['N']	[9]
10	pulmonary	B	['N']	[10]
11	fibrosis	I-Adverse_Effect	['N']	[11]
12	following	O	['N']	[12]
13	treatment	O	['N']	[13]
14	with	O	['N']	[14]
15	a	O	['N']	[15]
16	new	O	['N']	[16]
17	non	O	['N']	[17]
18	-	O	['N']	[18]
19	steroidal	O	['N']	[19]
20	anti	O	['N']	[20]
21	-	O	['N']	[21]
22	inflammatory	O	['N']	[22]
23	drug	O	['N']	[23]
24	,	O	['N']	[24]
25	nabumetone	B-Drug	['Causes']	[11]
26	.	O	['N']	[26]
#3771
0	We	O	['N']	[0]
1	suggest	O	['N']	[1]
2	that	O	['N']	[2]
3	objective	O	['N']	[3]
4	evaluation	O	['N']	[4]
5	of	O	['N']	[5]
6	retinal	O	['N']	[6]
7	function	O	['N']	[7]
8	with	O	['N']	[8]
9	electrophysiological	O	['N']	[9]
10	methods	O	['N']	[10]
11	should	O	['N']	[11]
12	be	O	['N']	[12]
13	performed	O	['N']	[13]
14	in	O	['N']	[14]
15	patients	O	['N']	[15]
16	with	O	['N']	[16]
17	visual	B	['N']	[17]
18	disturbance	I-Adverse_Effect	['N']	[18]
19	during	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	rifabutin	B-Drug	['Causes']	[18]
23	.	O	['N']	[23]
#3772
0	DATA	O	['N']	[0]
1	SYNTHESIS	O	['N']	[1]
2	:	O	['N']	[2]
3	Genetic	O	['N']	[3]
4	deficiencies	O	['N']	[4]
5	in	O	['N']	[5]
6	DPD	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	rate	O	['N']	[9]
10	-	O	['N']	[10]
11	limiting	O	['N']	[11]
12	enzyme	O	['N']	[12]
13	responsible	O	['N']	[13]
14	for	O	['N']	[14]
15	5-FU	B-Drug	['Causes']	[44]
16	catabolism	O	['N']	[16]
17	,	O	['N']	[17]
18	may	O	['N']	[18]
19	occur	O	['N']	[19]
20	in	O	['N']	[20]
21	3	O	['N']	[21]
22	%	O	['N']	[22]
23	or	O	['N']	[23]
24	more	O	['N']	[24]
25	of	O	['N']	[25]
26	patients	O	['N']	[26]
27	with	O	['N']	[27]
28	cancer	O	['N']	[28]
29	putting	O	['N']	[29]
30	them	O	['N']	[30]
31	at	O	['N']	[31]
32	increased	O	['N']	[32]
33	risk	O	['N']	[33]
34	for	O	['N']	[34]
35	unusually	O	['N']	[35]
36	severe	O	['N']	[36]
37	adverse	O	['N']	[37]
38	reactions	O	['N']	[38]
39	(	O	['N']	[39]
40	e.g.	O	['N']	[40]
41	,	O	['N']	[41]
42	diarrhea	O	['N']	[42]
43	,	O	['N']	[43]
44	stomatitis	B-Adverse_Effect	['N']	[44]
45	,	O	['N']	[45]
46	mucositis	O	['N']	[46]
47	,	O	['N']	[47]
48	myelosuppression	O	['N']	[48]
49	,	O	['N']	[49]
50	neurotoxicity	O	['N']	[50]
51	)	O	['N']	[51]
52	to	O	['N']	[52]
53	standard	O	['N']	[53]
54	doses	O	['N']	[54]
55	of	O	['N']	[55]
56	5-FU	O	['N']	[56]
57	.	O	['N']	[57]
#3773
0	Interstitial	B	['N']	[0]
1	pneumonitis	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	sirolimus	B-Drug	['Causes']	[1]
5	:	O	['N']	[5]
6	a	O	['N']	[6]
7	dilemma	O	['N']	[7]
8	for	O	['N']	[8]
9	lung	O	['N']	[9]
10	transplantation	O	['N']	[10]
11	.	O	['N']	[11]
#3774
0	In	O	['N']	[0]
1	a	O	['N']	[1]
2	single	O	['N']	[2]
3	practice	O	['N']	[3]
4	during	O	['N']	[4]
5	the	O	['N']	[5]
6	21	O	['N']	[6]
7	years	O	['N']	[7]
8	1971	O	['N']	[8]
9	-	O	['N']	[9]
10	1991	O	['N']	[10]
11	,	O	['N']	[11]
12	the	O	['N']	[12]
13	incidence	O	['N']	[13]
14	of	O	['N']	[14]
15	gestational	B	['N']	[15]
16	diabetes	I-Adverse_Effect	['N']	[16]
17	in	O	['N']	[17]
18	pregnancies	O	['N']	[18]
19	in	O	['N']	[19]
20	which	O	['N']	[20]
21	norethisterone	B-Drug	['Causes']	[16]
22	was	O	['N']	[22]
23	prescribed	O	['N']	[23]
24	was	O	['N']	[24]
25	32.4	O	['N']	[25]
26	%	O	['N']	[26]
27	(	O	['N']	[27]
28	22	O	['N']	[28]
29	of	O	['N']	[29]
30	69	O	['N']	[30]
31	)	O	['N']	[31]
32	in	O	['N']	[32]
33	comparison	O	['N']	[33]
34	with	O	['N']	[34]
35	7.1	O	['N']	[35]
36	%	O	['N']	[36]
37	in	O	['N']	[37]
38	pregnancies	O	['N']	[38]
39	in	O	['N']	[39]
40	which	O	['N']	[40]
41	the	O	['N']	[41]
42	women	O	['N']	[42]
43	did	O	['N']	[43]
44	not	O	['N']	[44]
45	take	O	['N']	[45]
46	norethisterone	O	['N']	[46]
47	(	O	['N']	[47]
48	137	O	['N']	[48]
49	of	O	['N']	[49]
50	1,684	O	['N']	[50]
51	)	O	['N']	[51]
52	(	O	['N']	[52]
53	p	O	['N']	[53]
54	<	O	['N']	[54]
55	0.001	O	['N']	[55]
56	)	O	['N']	[56]
57	.	O	['N']	[57]
#3775
0	An	O	['N']	[0]
1	adolescent	O	['N']	[1]
2	male	O	['N']	[2]
3	developed	O	['N']	[3]
4	acute	O	['N']	[4]
5	pancreatitis	O	['N']	[5]
6	and	O	['N']	[6]
7	pseudocyst	B	['N']	[7]
8	of	I	['N']	[8]
9	the	I	['N']	[9]
10	pancreas	I-Adverse_Effect	['N']	[10]
11	16	O	['N']	[11]
12	weeks	O	['N']	[12]
13	after	O	['N']	[13]
14	cessation	O	['N']	[14]
15	of	O	['N']	[15]
16	intramuscular	O	['N']	[16]
17	L	B	['N']	[17]
18	-	I	['N']	[18]
19	asparaginase	I-Drug	['Causes']	[10]
20	.	O	['N']	[20]
#3776
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	study	O	['N']	[3]
4	therapy	O	['N']	[4]
5	with	O	['N']	[5]
6	indapamide	B-Drug	['Causes']	[23]
7	impairing	O	['N']	[7]
8	carbohydrate	O	['N']	[8]
9	metabolism	O	['N']	[9]
10	in	O	['N']	[10]
11	essential	O	['N']	[11]
12	hypertension	O	['N']	[12]
13	patients	O	['N']	[13]
14	and	O	['N']	[14]
15	achieve	O	['N']	[15]
16	earlier	O	['N']	[16]
17	prevention	O	['N']	[17]
18	,	O	['N']	[18]
19	diagnoses	O	['N']	[19]
20	and	O	['N']	[20]
21	treatment	O	['N']	[21]
22	of	O	['N']	[22]
23	diabetes	B-Adverse_Effect	['N']	[23]
24	induced	O	['N']	[24]
25	by	O	['N']	[25]
26	indapamide	O	['N']	[26]
27	.	O	['N']	[27]
#3777
0	Neutropenia	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	agranulocytosis	O	['N']	[2]
3	are	O	['N']	[3]
4	risks	O	['N']	[4]
5	known	O	['N']	[5]
6	to	O	['N']	[6]
7	occur	O	['N']	[7]
8	with	O	['N']	[8]
9	phenothiazines	O	['N']	[9]
10	and	O	['N']	[10]
11	clozapine	B-Drug	['Causes']	[0]
12	.	O	['N']	[12]
#3778
0	A	O	['N']	[0]
1	67-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	patient	O	['N']	[4]
5	,	O	['N']	[5]
6	with	O	['N']	[6]
7	primary	O	['N']	[7]
8	polymyositis	O	['N']	[8]
9	and	O	['N']	[9]
10	without	O	['N']	[10]
11	previous	O	['N']	[11]
12	evidence	O	['N']	[12]
13	of	O	['N']	[13]
14	liver	O	['N']	[14]
15	disease	O	['N']	[15]
16	,	O	['N']	[16]
17	developed	O	['N']	[17]
18	clinical	O	['N']	[18]
19	and	O	['N']	[19]
20	biochemical	O	['N']	[20]
21	features	O	['N']	[21]
22	of	O	['N']	[22]
23	severe	B	['N']	[23]
24	cholestasis	I-Adverse_Effect	['N']	[24]
25	3	O	['N']	[25]
26	months	O	['N']	[26]
27	after	O	['N']	[27]
28	initiation	O	['N']	[28]
29	of	O	['N']	[29]
30	azathioprine	B-Drug	['Causes']	[24]
31	therapy	O	['N']	[31]
32	.	O	['N']	[32]
#3779
0	Paraplegia	B-Adverse_Effect	['N']	[0]
1	following	O	['N']	[1]
2	intrathecal	O	['N']	[2]
3	cytosine	B	['N']	[3]
4	arabinoside	I-Drug	['Causes']	[0]
5	.	O	['N']	[5]
#3780
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	generalized	B	['N']	[5]
6	cutaneous	I	['N']	[6]
7	sclerosis	I-Adverse_Effect	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	muscle	O	['N']	[10]
11	and	O	['N']	[11]
12	oesophageal	O	['N']	[12]
13	involvement	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	patient	O	['N']	[16]
17	exposed	O	['N']	[17]
18	to	O	['N']	[18]
19	herbicides	O	['N']	[19]
20	containing	O	['N']	[20]
21	bromocil	O	['N']	[21]
22	,	O	['N']	[22]
23	diuron	O	['N']	[23]
24	and	O	['N']	[24]
25	aminotriazole	B-Drug	['Causes']	[7]
26	.	O	['N']	[26]
#3781
0	Six	O	['N']	[0]
1	of	O	['N']	[1]
2	13	O	['N']	[2]
3	outpatients	O	['N']	[3]
4	with	O	['N']	[4]
5	schizophrenia	O	['N']	[5]
6	who	O	['N']	[6]
7	participated	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	ten	O	['N']	[10]
11	-	O	['N']	[11]
12	week	O	['N']	[12]
13	open	O	['N']	[13]
14	trial	O	['N']	[14]
15	of	O	['N']	[15]
16	risperidone	B-Drug	['Causes']	[41]
17	had	O	['N']	[17]
18	an	O	['N']	[18]
19	initial	O	['N']	[19]
20	good	O	['N']	[20]
21	response	O	['N']	[21]
22	to	O	['N']	[22]
23	the	O	['N']	[23]
24	medication	O	['N']	[24]
25	followed	O	['N']	[25]
26	by	O	['N']	[26]
27	development	O	['N']	[27]
28	of	O	['N']	[28]
29	intolerable	O	['N']	[29]
30	affect	O	['N']	[30]
31	,	O	['N']	[31]
32	including	O	['N']	[32]
33	feelings	O	['N']	[33]
34	of	O	['N']	[34]
35	agitation	O	['N']	[35]
36	and	O	['N']	[36]
37	depression	O	['N']	[37]
38	and	O	['N']	[38]
39	periods	B	['N']	[39]
40	of	I	['N']	[40]
41	crying	I-Adverse_Effect	['N']	[41]
42	and	O	['N']	[42]
43	insomnia	O	['N']	[43]
44	.	O	['N']	[44]
#3782
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	a	O	['N']	[5]
6	liver	O	['N']	[6]
7	abscess	O	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	Entamoeba	O	['N']	[10]
11	histolytica	O	['N']	[11]
12	,	O	['N']	[12]
13	in	O	['N']	[13]
14	whom	O	['N']	[14]
15	metronidazole	B-Drug	['Causes']	[36]
16	therapy	O	['N']	[16]
17	(	O	['N']	[17]
18	total	O	['N']	[18]
19	dose	O	['N']	[19]
20	,	O	['N']	[20]
21	21	O	['N']	[21]
22	g	O	['N']	[22]
23	over	O	['N']	[23]
24	14	O	['N']	[24]
25	days	O	['N']	[25]
26	)	O	['N']	[26]
27	was	O	['N']	[27]
28	complicated	O	['N']	[28]
29	by	O	['N']	[29]
30	reversible	O	['N']	[30]
31	deafness	O	['N']	[31]
32	,	O	['N']	[32]
33	tinnitus	O	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	ataxia	B-Adverse_Effect	['N']	[36]
37	and	O	['N']	[37]
38	who	O	['N']	[38]
39	relapsed	O	['N']	[39]
40	5	O	['N']	[40]
41	months	O	['N']	[41]
42	later	O	['N']	[42]
43	with	O	['N']	[43]
44	a	O	['N']	[44]
45	splenic	O	['N']	[45]
46	abscess	O	['N']	[46]
47	.	O	['N']	[47]
#3783
0	We	O	['N']	[0]
1	propose	O	['N']	[1]
2	that	O	['N']	[2]
3	cyclophosphamide	B-Drug	['Causes']	[15]
4	be	O	['N']	[4]
5	added	O	['N']	[5]
6	to	O	['N']	[6]
7	the	O	['N']	[7]
8	list	O	['N']	[8]
9	of	O	['N']	[9]
10	exposures	O	['N']	[10]
11	potentially	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	hepatic	B	['N']	[14]
15	angiosarcoma	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#3784
0	Methotrexate	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	nephropathy	B-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	a	O	['N']	[5]
6	rare	O	['N']	[6]
7	complication	O	['N']	[7]
8	in	O	['N']	[8]
9	pediatric	O	['N']	[9]
10	oncology	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	a	O	['N']	[13]
14	review	O	['N']	[14]
15	of	O	['N']	[15]
16	the	O	['N']	[16]
17	literature	O	['N']	[17]
18	suggests	O	['N']	[18]
19	that	O	['N']	[19]
20	exposure	O	['N']	[20]
21	to	O	['N']	[21]
22	nephrotoxic	O	['N']	[22]
23	agents	O	['N']	[23]
24	may	O	['N']	[24]
25	be	O	['N']	[25]
26	a	O	['N']	[26]
27	significant	O	['N']	[27]
28	but	O	['N']	[28]
29	perhaps	O	['N']	[29]
30	underrecognized	O	['N']	[30]
31	risk	O	['N']	[31]
32	factor	O	['N']	[32]
33	for	O	['N']	[33]
34	its	O	['N']	[34]
35	development	O	['N']	[35]
36	.	O	['N']	[36]
#3785
0	Systemic	O	['N']	[0]
1	disease	O	['N']	[1]
2	,	O	['N']	[2]
3	most	O	['N']	[3]
4	commonly	O	['N']	[4]
5	renal	O	['N']	[5]
6	dysfunction	O	['N']	[6]
7	,	O	['N']	[7]
8	preceded	O	['N']	[8]
9	all	O	['N']	[9]
10	30	O	['N']	[10]
11	reported	O	['N']	[11]
12	cases	O	['N']	[12]
13	of	O	['N']	[13]
14	acyclovir	B-Drug	['Causes']	[15]
15	neurotoxicity	B-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#3786
0	The	O	['N']	[0]
1	administration	O	['N']	[1]
2	of	O	['N']	[2]
3	"	O	['N']	[3]
4	sweet	B	['N']	[4]
5	spirits	I	['N']	[5]
6	of	I	['N']	[6]
7	nitre	I-Drug	['Causes']	[46]
8	"	O	['N']	[8]
9	(	O	['N']	[9]
10	4	O	['N']	[10]
11	%	O	['N']	[11]
12	ethyl	O	['N']	[12]
13	nitrite	O	['N']	[13]
14	CH3CH2ONO	O	['N']	[14]
15	in	O	['N']	[15]
16	70	O	['N']	[16]
17	%	O	['N']	[17]
18	ethyl	O	['N']	[18]
19	alcohol	O	['N']	[19]
20	)	O	['N']	[20]
21	was	O	['N']	[21]
22	followed	O	['N']	[22]
23	by	O	['N']	[23]
24	acute	O	['N']	[24]
25	methemoglobinemia	O	['N']	[25]
26	and	O	['N']	[26]
27	severe	O	['N']	[27]
28	anoxic	O	['N']	[28]
29	metabolic	O	['N']	[29]
30	acidosis	O	['N']	[30]
31	in	O	['N']	[31]
32	infant	O	['N']	[32]
33	twins	O	['N']	[33]
34	,	O	['N']	[34]
35	Methylene	O	['N']	[35]
36	blue	O	['N']	[36]
37	administration	O	['N']	[37]
38	reversed	O	['N']	[38]
39	methemoglobinemia	O	['N']	[39]
40	in	O	['N']	[40]
41	both	O	['N']	[41]
42	,	O	['N']	[42]
43	but	O	['N']	[43]
44	one	O	['N']	[44]
45	twin	O	['N']	[45]
46	died	B-Adverse_Effect	['N']	[46]
47	from	O	['N']	[47]
48	the	O	['N']	[48]
49	consequences	O	['N']	[49]
50	of	O	['N']	[50]
51	hypoxemia	O	['N']	[51]
52	.	O	['N']	[52]
#3787
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	68-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	developed	O	['N']	[7]
8	intense	O	['N']	[8]
9	conjunctival	O	['N']	[9]
10	hyperemia	O	['N']	[10]
11	and	O	['N']	[11]
12	cystoid	O	['N']	[12]
13	macula	O	['N']	[13]
14	edema	O	['N']	[14]
15	after	O	['N']	[15]
16	switching	O	['N']	[16]
17	from	O	['N']	[17]
18	latanoprost	B-Drug	['Causes']	[37]
19	to	O	['N']	[19]
20	bimatoprost	O	['N']	[20]
21	9	O	['N']	[21]
22	months	O	['N']	[22]
23	after	O	['N']	[23]
24	cataract	O	['N']	[24]
25	surgery	O	['N']	[25]
26	in	O	['N']	[26]
27	an	O	['N']	[27]
28	eye	O	['N']	[28]
29	at	O	['N']	[29]
30	low	O	['N']	[30]
31	-	O	['N']	[31]
32	risk	O	['N']	[32]
33	for	O	['N']	[33]
34	this	O	['N']	[34]
35	cystoid	B	['N']	[35]
36	macular	I	['N']	[36]
37	edema	I-Adverse_Effect	['N']	[37]
38	.	O	['N']	[38]
#3788
0	He	O	['N']	[0]
1	had	O	['N']	[1]
2	an	O	['N']	[2]
3	immediate	O	['N']	[3]
4	hypersensitivity	O	['N']	[4]
5	reaction	O	['N']	[5]
6	during	O	['N']	[6]
7	the	O	['N']	[7]
8	initiation	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	MTX	B-Drug	['Causes']	[18]
12	infusion	O	['N']	[12]
13	with	O	['N']	[13]
14	diffuse	O	['N']	[14]
15	urticaria	O	['N']	[15]
16	,	O	['N']	[16]
17	facial	B	['N']	[17]
18	swelling	I-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	cough	O	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	chest	O	['N']	[23]
24	tightness	O	['N']	[24]
25	.	O	['N']	[25]
#3789
0	The	O	['N']	[0]
1	possibility	O	['N']	[1]
2	of	O	['N']	[2]
3	phenytoin	B-Drug	['Causes']	[18]
4	hypersensitivity	O	['N']	[4]
5	reactions	O	['N']	[5]
6	should	O	['N']	[6]
7	be	O	['N']	[7]
8	considered	O	['N']	[8]
9	when	O	['N']	[9]
10	patients	O	['N']	[10]
11	receiving	O	['N']	[11]
12	phenytoin	O	['N']	[12]
13	have	O	['N']	[13]
14	unusual	O	['N']	[14]
15	symptoms	O	['N']	[15]
16	,	O	['N']	[16]
17	particularly	O	['N']	[17]
18	fever	B-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	rash	O	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	lymphadenopathy	O	['N']	[23]
24	.	O	['N']	[24]
#3790
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Severe	O	['N']	[2]
3	and	O	['N']	[3]
4	sustained	B	['N']	[4]
5	ocular	I	['N']	[5]
6	hypertension	I-Adverse_Effect	['N']	[6]
7	may	O	['N']	[7]
8	occur	O	['N']	[8]
9	after	O	['N']	[9]
10	intravitreal	O	['N']	[10]
11	ranibizumab	B-Drug	['Causes']	[6]
12	.	O	['N']	[12]
#3791
0	In	O	['N']	[0]
1	both	O	['N']	[1]
2	patients	O	['N']	[2]
3	the	O	['N']	[3]
4	rippling	B	['N']	[4]
5	phenomena	I	['N']	[5]
6	worsened	I-Adverse_Effect	['N']	[6]
7	with	O	['N']	[7]
8	pyridostigmine	B-Drug	['Causes']	[6]
9	treatment	O	['N']	[9]
10	but	O	['N']	[10]
11	markedly	O	['N']	[11]
12	improved	O	['N']	[12]
13	after	O	['N']	[13]
14	immunosuppression	O	['N']	[14]
15	with	O	['N']	[15]
16	azathioprine	O	['N']	[16]
17	.	O	['N']	[17]
#3792
0	METHOD	O	['N']	[0]
1	:	O	['N']	[1]
2	Case	O	['N']	[2]
3	analysis	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	poly	O	['N']	[6]
7	-	O	['N']	[7]
8	drug	O	['N']	[8]
9	overdose	O	['N']	[9]
10	(	O	['N']	[10]
11	venlafaxine	O	['N']	[11]
12	,	O	['N']	[12]
13	topiramate	B-Drug	['Causes']	[26]
14	,	O	['N']	[14]
15	divalproex	O	['N']	[15]
16	sodium	O	['N']	[16]
17	,	O	['N']	[17]
18	risperidone	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	carbamazepine	O	['N']	[21]
22	)	O	['N']	[22]
23	presenting	O	['N']	[23]
24	with	O	['N']	[24]
25	mixed	O	['N']	[25]
26	SS	B-Adverse_Effect	['N']	[26]
27	/	O	['N']	[27]
28	NMS	O	['N']	[28]
29	features	O	['N']	[29]
30	and	O	['N']	[30]
31	whose	O	['N']	[31]
32	clinical	O	['N']	[32]
33	management	O	['N']	[33]
34	suggests	O	['N']	[34]
35	a	O	['N']	[35]
36	practical	O	['N']	[36]
37	algorithm	O	['N']	[37]
38	for	O	['N']	[38]
39	treatment	O	['N']	[39]
40	of	O	['N']	[40]
41	undifferentiated	O	['N']	[41]
42	SS	O	['N']	[42]
43	/	O	['N']	[43]
44	NMS	O	['N']	[44]
45	in	O	['N']	[45]
46	critical	O	['N']	[46]
47	care	O	['N']	[47]
48	settings	O	['N']	[48]
49	.	O	['N']	[49]
#3793
0	In	O	['N']	[0]
1	two	O	['N']	[1]
2	patients	O	['N']	[2]
3	with	O	['N']	[3]
4	mycosis	O	['N']	[4]
5	fungoides	O	['N']	[5]
6	,	O	['N']	[6]
7	a	O	['N']	[7]
8	squamous	B	['N']	[8]
9	cell	I	['N']	[9]
10	carcinoma	I-Adverse_Effect	['N']	[10]
11	developed	O	['N']	[11]
12	during	O	['N']	[12]
13	therapy	O	['N']	[13]
14	with	O	['N']	[14]
15	psoralens	B-Drug	['Causes']	[10]
16	plus	O	['N']	[16]
17	long	O	['N']	[17]
18	-	O	['N']	[18]
19	wave	O	['N']	[19]
20	ultraviolet	O	['N']	[20]
21	radiation	O	['N']	[21]
22	(	O	['N']	[22]
23	PUVA	O	['N']	[23]
24	)	O	['N']	[24]
25	.	O	['N']	[25]
#3794
0	A	O	['N']	[0]
1	7-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	developed	O	['N']	[5]
6	a	O	['N']	[6]
7	severe	B	['N']	[7]
8	unilateral	I	['N']	[8]
9	grand	I	['N']	[9]
10	mal	I	['N']	[10]
11	seizure	I-Adverse_Effect	['N']	[11]
12	at	O	['N']	[12]
13	the	O	['N']	[13]
14	age	O	['N']	[14]
15	of	O	['N']	[15]
16	5	O	['N']	[16]
17	years	O	['N']	[17]
18	(	O	['N']	[18]
19	phenobarbitone	O	['N']	[19]
20	therapy	O	['N']	[20]
21	)	O	['N']	[21]
22	;	O	['N']	[22]
23	1.5	O	['N']	[23]
24	years	O	['N']	[24]
25	later	O	['N']	[25]
26	valproate	O	['N']	[26]
27	(	O	['N']	[27]
28	2-propylpentanoic	O	['N']	[28]
29	acid	O	['N']	[29]
30	,	O	['N']	[30]
31	VPA	B-Drug	['Causes']	[11]
32	)	O	['N']	[32]
33	was	O	['N']	[33]
34	added	O	['N']	[34]
35	to	O	['N']	[35]
36	the	O	['N']	[36]
37	therapy	O	['N']	[37]
38	.	O	['N']	[38]
#3795
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Long	O	['N']	[2]
3	-	O	['N']	[3]
4	term	O	['N']	[4]
5	treatment	O	['N']	[5]
6	with	O	['N']	[6]
7	rifabutin	B-Drug	['Causes']	[20]
8	may	O	['N']	[8]
9	have	O	['N']	[9]
10	a	O	['N']	[10]
11	reversible	O	['N']	[11]
12	and	O	['N']	[12]
13	previously	O	['N']	[13]
14	undescribed	O	['N']	[14]
15	side	B	['N']	[15]
16	-	I	['N']	[16]
17	effect	I	['N']	[17]
18	on	I	['N']	[18]
19	retinal	I	['N']	[19]
20	function	I-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#3796
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	2	O	['N']	[2]
3	patients	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	polyarteritis	B	['N']	[6]
7	nodosa	I-Adverse_Effect	['N']	[7]
8	following	O	['N']	[8]
9	vaccination	-	['N']	[9]
10	against	-	['N']	[10]
11	hepatitis	-	['N']	[11]
12	B.	-	['N']	[12]
#3797
0	A	O	['N']	[0]
1	26-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	Japanese	O	['N']	[4]
5	man	O	['N']	[5]
6	,	O	['N']	[6]
7	who	O	['N']	[7]
8	had	O	['N']	[8]
9	been	O	['N']	[9]
10	receiving	O	['N']	[10]
11	medical	O	['N']	[11]
12	attention	O	['N']	[12]
13	for	O	['N']	[13]
14	ulcerative	O	['N']	[14]
15	colitis	O	['N']	[15]
16	for	O	['N']	[16]
17	one	O	['N']	[17]
18	year	O	['N']	[18]
19	,	O	['N']	[19]
20	presented	O	['N']	[20]
21	with	O	['N']	[21]
22	diffuse	O	['N']	[22]
23	erythema	O	['N']	[23]
24	and	O	['N']	[24]
25	pustules	O	['N']	[25]
26	on	O	['N']	[26]
27	his	O	['N']	[27]
28	face	O	['N']	[28]
29	and	O	['N']	[29]
30	trunk	O	['N']	[30]
31	,	O	['N']	[31]
32	malaise	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	fever	B	['N']	[35]
36	up	I	['N']	[36]
37	to	I	['N']	[37]
38	39	I	['N']	[38]
39	degrees	I	['N']	[39]
40	C	I-Adverse_Effect	['N']	[40]
41	one	O	['N']	[41]
42	day	O	['N']	[42]
43	after	O	['N']	[43]
44	the	O	['N']	[44]
45	administration	O	['N']	[45]
46	of	O	['N']	[46]
47	salazosulfapyridine	B-Drug	['Causes']	[40]
48	.	O	['N']	[48]
#3798
0	Antineutrophil	B	['N']	[0]
1	cytoplasmic	I	['N']	[1]
2	antibody	I	['N']	[2]
3	-	I	['N']	[3]
4	positive	I	['N']	[4]
5	crescentic	I	['N']	[5]
6	glomerulonephritis	I-Adverse_Effect	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	propylthiouracil	B-Drug	['Causes']	[6]
10	therapy	O	['N']	[10]
11	.	O	['N']	[11]
#3799
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	experienced	O	['N']	[5]
6	chronic	B	['N']	[6]
7	nausea	I-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	an	O	['N']	[9]
10	episode	O	['N']	[10]
11	of	O	['N']	[11]
12	confusion	O	['N']	[12]
13	while	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	a	O	['N']	[16]
17	small	O	['N']	[17]
18	,	O	['N']	[18]
19	stable	O	['N']	[19]
20	dose	O	['N']	[20]
21	of	O	['N']	[21]
22	oral	O	['N']	[22]
23	morphine	B-Drug	['Causes']	[7]
24	in	O	['N']	[24]
25	the	O	['N']	[25]
26	setting	O	['N']	[26]
27	of	O	['N']	[27]
28	mild	O	['N']	[28]
29	renal	O	['N']	[29]
30	insufficiency	O	['N']	[30]
31	.	O	['N']	[31]
#3800
0	Multiple	O	['N']	[0]
1	complications	O	['N']	[1]
2	of	O	['N']	[2]
3	propylthiouracil	B-Drug	['Causes']	[11]
4	treatment	O	['N']	[4]
5	:	O	['N']	[5]
6	granulocytopenia	O	['N']	[6]
7	,	O	['N']	[7]
8	eosinophilia	O	['N']	[8]
9	,	O	['N']	[9]
10	skin	B	['N']	[10]
11	reaction	I-Adverse_Effect	['N']	[11]
12	and	O	['N']	[12]
13	hepatitis	O	['N']	[13]
14	with	O	['N']	[14]
15	lymphocyte	O	['N']	[15]
16	sensitization	O	['N']	[16]
17	.	O	['N']	[17]
#3801
0	Vigabatrin	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	visual	B	['N']	[3]
4	field	I	['N']	[4]
5	defects	I-Adverse_Effect	['N']	[5]
6	are	O	['N']	[6]
7	at	O	['N']	[7]
8	present	O	['N']	[8]
9	the	O	['N']	[9]
10	most	O	['N']	[10]
11	important	O	['N']	[11]
12	safety	O	['N']	[12]
13	issue	O	['N']	[13]
14	in	O	['N']	[14]
15	the	O	['N']	[15]
16	use	O	['N']	[16]
17	of	O	['N']	[17]
18	the	O	['N']	[18]
19	drug	O	['N']	[19]
20	.	O	['N']	[20]
#3802
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	histories	O	['N']	[4]
5	of	O	['N']	[5]
6	two	O	['N']	[6]
7	patients	O	['N']	[7]
8	with	O	['N']	[8]
9	histologically	O	['N']	[9]
10	confirmed	O	['N']	[10]
11	adenocarcinoma	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	prostate	O	['N']	[14]
15	,	O	['N']	[15]
16	both	O	['N']	[16]
17	of	O	['N']	[17]
18	whom	O	['N']	[18]
19	had	O	['N']	[19]
20	been	O	['N']	[20]
21	treated	O	['N']	[21]
22	with	O	['N']	[22]
23	steroidal	O	['N']	[23]
24	anti	O	['N']	[24]
25	-	O	['N']	[25]
26	androgen	O	['N']	[26]
27	therapy	O	['N']	[27]
28	in	O	['N']	[28]
29	the	O	['N']	[29]
30	form	O	['N']	[30]
31	of	O	['N']	[31]
32	cyproterone	B	['N']	[32]
33	acetate	I-Drug	['Causes']	[49]
34	prior	O	['N']	[34]
35	to	O	['N']	[35]
36	radical	O	['N']	[36]
37	or	O	['N']	[37]
38	palliative	O	['N']	[38]
39	pelvic	O	['N']	[39]
40	irradiation	O	['N']	[40]
41	,	O	['N']	[41]
42	and	O	['N']	[42]
43	who	O	['N']	[43]
44	subsequently	O	['N']	[44]
45	developed	O	['N']	[45]
46	femoral	B	['N']	[46]
47	head	I	['N']	[47]
48	avascular	I	['N']	[48]
49	necrosis	I-Adverse_Effect	['N']	[49]
50	.	O	['N']	[50]
#3803
0	Cholestatic	O	['N']	[0]
1	liver	O	['N']	[1]
2	disease	O	['N']	[2]
3	with	O	['N']	[3]
4	ductopenia	B-Adverse_Effect	['N']	[4]
5	(	O	['N']	[5]
6	vanishing	O	['N']	[6]
7	bile	O	['N']	[7]
8	duct	O	['N']	[8]
9	syndrome	O	['N']	[9]
10	)	O	['N']	[10]
11	after	O	['N']	[11]
12	administration	O	['N']	[12]
13	of	O	['N']	[13]
14	clindamycin	B-Drug	['Causes']	[4]
15	and	O	['N']	[15]
16	trimethoprim	O	['N']	[16]
17	-	O	['N']	[17]
18	sulfamethoxazole	O	['N']	[18]
19	.	O	['N']	[19]
#3804
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	B-Drug	['Causes']	[21]
20	developed	O	['N']	[20]
21	confusion	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	agitation	O	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	O	['N']	[25]
26	,	O	['N']	[26]
27	tremors	O	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	O	['N']	[29]
30	jerks	O	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	O	['N']	[32]
33	gait	O	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	O	['N']	[43]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#3805
0	Hypoglycemia	B-Adverse_Effect	['N']	[0]
1	can	O	['N']	[1]
2	be	O	['N']	[2]
3	a	O	['N']	[3]
4	serious	O	['N']	[4]
5	side	O	['N']	[5]
6	effect	O	['N']	[6]
7	of	O	['N']	[7]
8	etanercept	B-Drug	['Causes']	[0]
9	in	O	['N']	[9]
10	patients	O	['N']	[10]
11	already	O	['N']	[11]
12	on	O	['N']	[12]
13	antidiabetic	O	['N']	[13]
14	medications	O	['N']	[14]
15	known	O	['N']	[15]
16	to	O	['N']	[16]
17	cause	O	['N']	[17]
18	hypoglycemia	O	['N']	[18]
19	,	O	['N']	[19]
20	such	O	['N']	[20]
21	as	O	['N']	[21]
22	sulfonylureas	O	['N']	[22]
23	,	O	['N']	[23]
24	meglitinides	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	insulin	O	['N']	[27]
28	.	O	['N']	[28]
#3806
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	experienced	O	['N']	[2]
3	hallucinations	O	['N']	[3]
4	,	O	['N']	[4]
5	agitation	B-Adverse_Effect	['N']	[5]
6	,	O	['N']	[6]
7	vomiting	O	['N']	[7]
8	,	O	['N']	[8]
9	tachycardia	O	['N']	[9]
10	and	O	['N']	[10]
11	seizures	O	['N']	[11]
12	after	O	['N']	[12]
13	ingestion	O	['N']	[13]
14	of	O	['N']	[14]
15	1050	O	['N']	[15]
16	(	O	['N']	[16]
17	48	O	['N']	[17]
18	mg	O	['N']	[18]
19	/	O	['N']	[19]
20	kg	O	['N']	[20]
21	)	O	['N']	[21]
22	of	O	['N']	[22]
23	extended	O	['N']	[23]
24	-	O	['N']	[24]
25	release	O	['N']	[25]
26	bupropion	B-Drug	['Causes']	[5]
27	.	O	['N']	[27]
#3807
0	An	O	['N']	[0]
1	83-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	receiving	O	['N']	[5]
6	glipizide	O	['N']	[6]
7	10	O	['N']	[7]
8	mg	O	['N']	[8]
9	bid	O	['N']	[9]
10	developed	O	['N']	[10]
11	symptomatic	B	['N']	[11]
12	hypoglycemia	I-Adverse_Effect	['N']	[12]
13	within	O	['N']	[13]
14	three	O	['N']	[14]
15	days	O	['N']	[15]
16	of	O	['N']	[16]
17	adding	O	['N']	[17]
18	trimethoprim	O	['N']	[18]
19	/	O	['N']	[19]
20	sulfamethoxazole	O	['N']	[20]
21	(	O	['N']	[21]
22	TMP	B-Drug	['Causes']	[12]
23	/	O	['N']	[23]
24	SMX	O	['N']	[24]
25	)	O	['N']	[25]
26	to	O	['N']	[26]
27	his	O	['N']	[27]
28	regimen	O	['N']	[28]
29	.	O	['N']	[29]
#3808
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	suffering	O	['N']	[2]
3	from	O	['N']	[3]
4	a	O	['N']	[4]
5	rare	O	['N']	[5]
6	enzyme	O	['N']	[6]
7	deficiency	O	['N']	[7]
8	developed	O	['N']	[8]
9	a	O	['N']	[9]
10	malignant	B	['N']	[10]
11	neuroleptic	I	['N']	[11]
12	syndrome	I-Adverse_Effect	['N']	[12]
13	after	O	['N']	[13]
14	having	O	['N']	[14]
15	been	O	['N']	[15]
16	treated	O	['N']	[16]
17	with	O	['N']	[17]
18	one	O	['N']	[18]
19	single	O	['N']	[19]
20	dose	O	['N']	[20]
21	of	O	['N']	[21]
22	haloperidol	B-Drug	['Causes']	[12]
23	.	O	['N']	[23]
#3809
0	One	O	['N']	[0]
1	explanation	O	['N']	[1]
2	for	O	['N']	[2]
3	the	O	['N']	[3]
4	noted	O	['N']	[4]
5	increase	B	['N']	[5]
6	in	I	['N']	[6]
7	the	I	['N']	[7]
8	theophylline	B-Drug	['Causes']	[9]
9	level	I-Adverse_Effect	['N']	[9]
10	is	O	['N']	[10]
11	that	O	['N']	[11]
12	metabolism	O	['N']	[12]
13	occurs	O	['N']	[13]
14	mainly	O	['N']	[14]
15	by	O	['N']	[15]
16	cytochrome	O	['N']	[16]
17	P450	O	['N']	[17]
18	(	O	['N']	[18]
19	CYP	O	['N']	[19]
20	1A2	O	['N']	[20]
21	)	O	['N']	[21]
22	,	O	['N']	[22]
23	an	O	['N']	[23]
24	enzyme	O	['N']	[24]
25	that	O	['N']	[25]
26	is	O	['N']	[26]
27	known	O	['N']	[27]
28	to	O	['N']	[28]
29	be	O	['N']	[29]
30	inhibited	O	['N']	[30]
31	with	O	['N']	[31]
32	high	O	['N']	[32]
33	concentrations	O	['N']	[33]
34	of	O	['N']	[34]
35	zafirlukast	O	['N']	[35]
36	.	O	['N']	[36]
#3810
0	Pilocarpine	B-Drug	['Causes']	[1]
1	toxicity	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	the	O	['N']	[3]
4	treatment	O	['N']	[4]
5	of	O	['N']	[5]
6	xerostomia	O	['N']	[6]
7	.	O	['N']	[7]
#3811
0	A	O	['N']	[0]
1	severe	O	['N']	[1]
2	form	O	['N']	[2]
3	of	O	['N']	[3]
4	exophthalmos	B-Adverse_Effect	['N']	[4]
5	resulting	O	['N']	[5]
6	from	O	['N']	[6]
7	lithium	B-Drug	['Causes']	[4]
8	therapy	O	['N']	[8]
9	has	O	['N']	[9]
10	not	O	['N']	[10]
11	been	O	['N']	[11]
12	described	O	['N']	[12]
13	in	O	['N']	[13]
14	the	O	['N']	[14]
15	literature	O	['N']	[15]
16	.	O	['N']	[16]
#3812
0	Because	O	['N']	[0]
1	the	O	['N']	[1]
2	combination	O	['N']	[2]
3	of	O	['N']	[3]
4	bleomycin	B-Drug	['Causes']	[39]
5	and	O	['N']	[5]
6	vinca	O	['N']	[6]
7	alkaloids	O	['N']	[7]
8	is	O	['N']	[8]
9	commonly	O	['N']	[9]
10	used	O	['N']	[10]
11	for	O	['N']	[11]
12	the	O	['N']	[12]
13	treatment	O	['N']	[13]
14	of	O	['N']	[14]
15	AIDS	O	['N']	[15]
16	-	O	['N']	[16]
17	related	O	['N']	[17]
18	Kaposi	O	['N']	[18]
19	's	O	['N']	[19]
20	sarcoma	O	['N']	[20]
21	,	O	['N']	[21]
22	clinicians	O	['N']	[22]
23	should	O	['N']	[23]
24	be	O	['N']	[24]
25	aware	O	['N']	[25]
26	of	O	['N']	[26]
27	the	O	['N']	[27]
28	risk	O	['N']	[28]
29	of	O	['N']	[29]
30	provoking	O	['N']	[30]
31	acral	O	['N']	[31]
32	necrosis	O	['N']	[32]
33	in	O	['N']	[33]
34	patients	O	['N']	[34]
35	who	O	['N']	[35]
36	develop	O	['N']	[36]
37	Raynaud	B	['N']	[37]
38	's	I	['N']	[38]
39	phenomenon	I-Adverse_Effect	['N']	[39]
40	under	O	['N']	[40]
41	chemotherapy	O	['N']	[41]
42	.	O	['N']	[42]
#3813
0	Hyperglycemia	O	['N']	[0]
1	and	O	['N']	[1]
2	diabetic	B	['N']	[2]
3	coma	I-Adverse_Effect	['N']	[3]
4	:	O	['N']	[4]
5	possible	O	['N']	[5]
6	relationship	O	['N']	[6]
7	to	O	['N']	[7]
8	diuretic	O	['N']	[8]
9	-	O	['N']	[9]
10	propranolol	B-Drug	['Causes']	[3]
11	therapy	O	['N']	[11]
12	.	O	['N']	[12]
#3814
0	Triiodothyronine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	thyrotoxicosis	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	ophthalmic	O	['N']	[5]
6	Graves	O	['N']	[6]
7	disease	O	['N']	[7]
8	.	O	['N']	[8]
#3815
0	In	O	['N']	[0]
1	a	O	['N']	[1]
2	postural	O	['N']	[2]
3	challenge	O	['N']	[3]
4	test	O	['N']	[4]
5	after	O	['N']	[5]
6	administration	O	['N']	[6]
7	of	O	['N']	[7]
8	isosorbide	B	['N']	[8]
9	dinitrate	I-Drug	['Causes']	[33]
10	(	O	['N']	[10]
11	5	O	['N']	[11]
12	mg	O	['N']	[12]
13	)	O	['N']	[13]
14	,	O	['N']	[14]
15	blood	O	['N']	[15]
16	pressure	O	['N']	[16]
17	decreased	O	['N']	[17]
18	from	O	['N']	[18]
19	120/67	O	['N']	[19]
20	to	O	['N']	[20]
21	65/35	O	['N']	[21]
22	mmHg	O	['N']	[22]
23	,	O	['N']	[23]
24	followed	O	['N']	[24]
25	by	O	['N']	[25]
26	syncope	O	['N']	[26]
27	with	O	['N']	[27]
28	a	O	['N']	[28]
29	sudden	B	['N']	[29]
30	decrease	I	['N']	[30]
31	in	I	['N']	[31]
32	pulse	I	['N']	[32]
33	rate	I-Adverse_Effect	['N']	[33]
34	from	O	['N']	[34]
35	85	O	['N']	[35]
36	to	O	['N']	[36]
37	60	O	['N']	[37]
38	beats	O	['N']	[38]
39	/	O	['N']	[39]
40	min	O	['N']	[40]
41	.	O	['N']	[41]
#3816
0	Supravenous	B	['N']	[0]
1	hyperpigmentation	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	association	O	['N']	[3]
4	with	O	['N']	[4]
5	CHOP	B-Drug	['Causes']	[1]
6	chemotherapy	O	['N']	[6]
7	of	O	['N']	[7]
8	a	O	['N']	[8]
9	CD30	O	['N']	[9]
10	(	O	['N']	[10]
11	Ki-1)-positive	O	['N']	[11]
12	anaplastic	O	['N']	[12]
13	large	O	['N']	[13]
14	-	O	['N']	[14]
15	cell	O	['N']	[15]
16	lymphoma	O	['N']	[16]
17	.	O	['N']	[17]
#3817
0	k	O	['N']	[0]
1	bipolar	O	['N']	[1]
2	manic	O	['N']	[2]
3	-	O	['N']	[3]
4	depressive	O	['N']	[4]
5	patient	O	['N']	[5]
6	,	O	['N']	[6]
7	developed	O	['N']	[7]
8	while	O	['N']	[8]
9	on	O	['N']	[9]
10	lithium	B-Drug	['Causes']	[13]
11	prophylaxis	O	['N']	[11]
12	,	O	['N']	[12]
13	akathisia	B-Adverse_Effect	['N']	[13]
14	at	O	['N']	[14]
15	therapeutic	O	['N']	[15]
16	serum	O	['N']	[16]
17	lithium	O	['N']	[17]
18	levels	O	['N']	[18]
19	and	O	['N']	[19]
20	subsequently	O	['N']	[20]
21	bucco	O	['N']	[21]
22	-	O	['N']	[22]
23	linguo	O	['N']	[23]
24	-	O	['N']	[24]
25	masticatory	O	['N']	[25]
26	dyskinesia	O	['N']	[26]
27	.	O	['N']	[27]
#3818
0	During	O	['N']	[0]
1	clarithromycin	B-Drug	['Causes']	[28]
2	coadministration	O	['N']	[2]
3	,	O	['N']	[3]
4	four	O	['N']	[4]
5	out	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	seven	O	['N']	[8]
9	patients	O	['N']	[9]
10	developed	O	['N']	[10]
11	moderate	O	['N']	[11]
12	-	O	['N']	[12]
13	to	O	['N']	[13]
14	-	O	['N']	[14]
15	severe	O	['N']	[15]
16	toxic	O	['N']	[16]
17	symptoms	O	['N']	[17]
18	of	O	['N']	[18]
19	carbamazepine	O	['N']	[19]
20	,	O	['N']	[20]
21	such	O	['N']	[21]
22	as	O	['N']	[22]
23	drowsiness	O	['N']	[23]
24	,	O	['N']	[24]
25	dizziness	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	ataxia	B-Adverse_Effect	['N']	[28]
29	,	O	['N']	[29]
30	which	O	['N']	[30]
31	resolved	O	['N']	[31]
32	within	O	['N']	[32]
33	5	O	['N']	[33]
34	days	O	['N']	[34]
35	after	O	['N']	[35]
36	clarithromycin	O	['N']	[36]
37	discontinuation	O	['N']	[37]
38	.	O	['N']	[38]
#3819
0	After	O	['N']	[0]
1	the	O	['N']	[1]
2	dose	O	['N']	[2]
3	of	O	['N']	[3]
4	methylprednisolone	B-Drug	['Dosage']	[9]
5	was	O	['N']	[5]
6	reduced	O	['N']	[6]
7	from	O	['N']	[7]
8	40	B	['N']	[8]
9	mg	I-Dose	['N']	[9]
10	to	O	['N']	[10]
11	20	O	['N']	[11]
12	mg	O	['N']	[12]
13	i.v	O	['N']	[13]
14	.	O	['N']	[14]
15	q6h	O	['N']	[15]
16	and	O	['N']	[16]
17	shifted	O	['N']	[17]
18	to	O	['N']	[18]
19	other	O	['N']	[19]
20	anti	O	['N']	[20]
21	-	O	['N']	[21]
22	asthma	O	['N']	[22]
23	treatment	O	['N']	[23]
24	by	O	['N']	[24]
25	procaterol	O	['N']	[25]
26	metered	O	['N']	[26]
27	dose	O	['N']	[27]
28	inhaler	O	['N']	[28]
29	via	O	['N']	[29]
30	spacer	O	['N']	[30]
31	,	O	['N']	[31]
32	the	O	['N']	[32]
33	psychotic	O	['N']	[33]
34	reaction	O	['N']	[34]
35	disappeared	O	['N']	[35]
36	a	O	['N']	[36]
37	few	O	['N']	[37]
38	hours	O	['N']	[38]
39	later	O	['N']	[39]
40	.	O	['N']	[40]
#3820
0	Interstitial	B	['N']	[0]
1	lung	I	['N']	[1]
2	disease	I-Adverse_Effect	['N']	[2]
3	(	O	['N']	[3]
4	ILD	O	['N']	[4]
5	)	O	['N']	[5]
6	related	O	['N']	[6]
7	to	O	['N']	[7]
8	therapy	O	['N']	[8]
9	with	O	['N']	[9]
10	the	O	['N']	[10]
11	drug	O	['N']	[11]
12	gefitinib	B-Drug	['Causes']	[2]
13	has	O	['N']	[13]
14	been	O	['N']	[14]
15	well	O	['N']	[15]
16	reported	O	['N']	[16]
17	.	O	['N']	[17]
#3821
0	Hemorrhage	O	['N']	[0]
1	from	O	['N']	[1]
2	a	O	['N']	[2]
3	falx	O	['N']	[3]
4	meningioma	O	['N']	[4]
5	after	O	['N']	[5]
6	internal	O	['N']	[6]
7	use	O	['N']	[7]
8	of	O	['N']	[8]
9	low	B	['N']	[9]
10	-	I	['N']	[10]
11	dose	I-Dose	['N']	[11]
12	aspirin	B-Drug	['Dosage']	[11]
13	.	O	['N']	[13]
#3822
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	two	O	['N']	[2]
3	patients	O	['N']	[3]
4	in	O	['N']	[4]
5	whom	O	['N']	[5]
6	painful	O	['N']	[6]
7	erosions	O	['N']	[7]
8	of	O	['N']	[8]
9	their	O	['N']	[9]
10	psoriasis	O	['N']	[10]
11	developed	O	['N']	[11]
12	as	O	['N']	[12]
13	the	O	['N']	[13]
14	presenting	O	['N']	[14]
15	sign	O	['N']	[15]
16	of	O	['N']	[16]
17	methotrexate	B-Drug	['Causes']	[18]
18	toxicity	I-Adverse_Effect	['N']	[18]
19	and	O	['N']	[19]
20	review	O	['N']	[20]
21	the	O	['N']	[21]
22	literature	O	['N']	[22]
23	,	O	['N']	[23]
24	emphasizing	O	['N']	[24]
25	the	O	['N']	[25]
26	risk	O	['N']	[26]
27	factors	O	['N']	[27]
28	associated	O	['N']	[28]
29	with	O	['N']	[29]
30	this	O	['N']	[30]
31	manifestation	O	['N']	[31]
32	.	O	['N']	[32]
#3823
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	radiotherapy	O	['N']	[5]
6	-	O	['N']	[6]
7	enhanced	O	['N']	[7]
8	aminoglutethimide	B-Drug	['Causes']	[10]
9	skin	B	['N']	[9]
10	toxicity	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	metastatic	O	['N']	[15]
16	breast	O	['N']	[16]
17	cancer	O	['N']	[17]
18	.	O	['N']	[18]
#3824
0	AIMS	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	present	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	piloerection	B-Adverse_Effect	['N']	[7]
8	after	O	['N']	[8]
9	replacing	O	['N']	[9]
10	fluvoxamine	O	['N']	[10]
11	maleate	O	['N']	[11]
12	with	O	['N']	[12]
13	milnacipran	B	['N']	[13]
14	hydrochloride	I-Drug	['Causes']	[7]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	to	O	['N']	[17]
18	analyse	O	['N']	[18]
19	this	O	['N']	[19]
20	effect	O	['N']	[20]
21	based	O	['N']	[21]
22	on	O	['N']	[22]
23	receptor	O	['N']	[23]
24	occupancy	O	['N']	[24]
25	theory	O	['N']	[25]
26	.	O	['N']	[26]
#3825
0	Pulmonary	B	['N']	[0]
1	hemorrhage	I-Adverse_Effect	['N']	[1]
2	as	O	['N']	[2]
3	a	O	['N']	[3]
4	clinical	O	['N']	[4]
5	manifestation	O	['N']	[5]
6	of	O	['N']	[6]
7	hemolytic	O	['N']	[7]
8	-	O	['N']	[8]
9	uremic	O	['N']	[9]
10	syndrome	O	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	mitomycin	B	['N']	[13]
14	C	I-Drug	['Causes']	[1]
15	therapy	O	['N']	[15]
16	.	O	['N']	[16]
#3826
0	Adenosine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	ventricular	B	['N']	[3]
4	fibrillation	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#3827
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	fulminant	O	['N']	[6]
7	adult	O	['N']	[7]
8	respiratory	O	['N']	[8]
9	distress	O	['N']	[9]
10	syndrome	O	['N']	[10]
11	(	O	['N']	[11]
12	ARDS	B-Adverse_Effect	['N']	[12]
13	)	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	pegylated	B	['N']	[16]
17	interferon	I	['N']	[17]
18	alpha-2a	I-Drug	['Causes']	[12]
19	(	O	['N']	[19]
20	pegIFNalpha-2a	O	['N']	[20]
21	)	O	['N']	[21]
22	and	O	['N']	[22]
23	ribavirin	O	['N']	[23]
24	use	O	['N']	[24]
25	for	O	['N']	[25]
26	hepatitis	O	['N']	[26]
27	C	O	['N']	[27]
28	,	O	['N']	[28]
29	complicated	O	['N']	[29]
30	by	O	['N']	[30]
31	subsequent	O	['N']	[31]
32	and	O	['N']	[32]
33	ultimately	O	['N']	[33]
34	fatal	O	['N']	[34]
35	sepsis	O	['N']	[35]
36	and	O	['N']	[36]
37	multiorgan	O	['N']	[37]
38	failure	O	['N']	[38]
39	.	O	['N']	[39]
#3828
0	Amphotericin	B	['N']	[0]
1	B	I-Drug	['Causes']	[6]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	cutaneous	B	['N']	[4]
5	leucocytoclastic	I	['N']	[5]
6	vasculitis	I-Adverse_Effect	['N']	[6]
7	:	O	['N']	[7]
8	case	O	['N']	[8]
9	report	O	['N']	[9]
10	.	O	['N']	[10]
#3829
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	results	O	['N']	[3]
4	suggest	O	['N']	[4]
5	that	O	['N']	[5]
6	olanzapine	O	['N']	[6]
7	may	O	['N']	[7]
8	be	O	['N']	[8]
9	useful	O	['N']	[9]
10	in	O	['N']	[10]
11	treating	O	['N']	[11]
12	patients	O	['N']	[12]
13	with	O	['N']	[13]
14	clozapine	B-Drug	['Causes']	[17]
15	-	O	['N']	[15]
16	induced	O	['N']	[16]
17	granulocytopenia	B-Adverse_Effect	['N']	[17]
18	without	O	['N']	[18]
19	the	O	['N']	[19]
20	risk	O	['N']	[20]
21	of	O	['N']	[21]
22	recurrence	O	['N']	[22]
23	of	O	['N']	[23]
24	hematologic	O	['N']	[24]
25	side	O	['N']	[25]
26	effects	O	['N']	[26]
27	.	O	['N']	[27]
#3830
0	Moreover	O	['N']	[0]
1	,	O	['N']	[1]
2	treatment	O	['N']	[2]
3	with	O	['N']	[3]
4	immunosuppressive	O	['N']	[4]
5	drugs	O	['N']	[5]
6	such	O	['N']	[6]
7	as	O	['N']	[7]
8	cyclosporine	B-Drug	['Causes']	[23]
9	,	O	['N']	[9]
10	cisplatin	O	['N']	[10]
11	,	O	['N']	[11]
12	tacrolimus	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	interferon	O	['N']	[15]
16	-	O	['N']	[16]
17	alpha	O	['N']	[17]
18	can	O	['N']	[18]
19	induce	O	['N']	[19]
20	a	O	['N']	[20]
21	condition	O	['N']	[21]
22	resembling	O	['N']	[22]
23	RPLS	B-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#3831
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	extends	O	['N']	[2]
3	the	O	['N']	[3]
4	spectrum	O	['N']	[4]
5	of	O	['N']	[5]
6	fludarabine	B-Drug	['Causes']	[8]
7	pulmonary	B	['N']	[7]
8	toxicity	I-Adverse_Effect	['N']	[8]
9	to	O	['N']	[9]
10	include	O	['N']	[10]
11	pulmonary	O	['N']	[11]
12	nodules	O	['N']	[12]
13	.	O	['N']	[13]
#3832
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	bilateral	B	['N']	[6]
7	ptosis	I-Adverse_Effect	['N']	[7]
8	induced	O	['N']	[8]
9	by	O	['N']	[9]
10	chloroquine	B-Drug	['Causes']	[7]
11	.	O	['N']	[11]
#3833
0	Prolonged	B	['N']	[0]
1	prostate	I	['N']	[1]
2	-	I	['N']	[2]
3	specific	I	['N']	[3]
4	antigen	I	['N']	[4]
5	response	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	flutamide	B-Drug	['Causes']	[5]
8	withdrawal	O	['N']	[8]
9	syndrome	O	['N']	[9]
10	despite	O	['N']	[10]
11	disease	O	['N']	[11]
12	progression	O	['N']	[12]
13	.	O	['N']	[13]
#3834
0	The	O	['N']	[0]
1	main	O	['N']	[1]
2	clinical	O	['N']	[2]
3	features	O	['N']	[3]
4	of	O	['N']	[4]
5	this	O	['N']	[5]
6	58-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	female	O	['N']	[9]
10	patient	O	['N']	[10]
11	were	O	['N']	[11]
12	laboratory	O	['N']	[12]
13	evidence	O	['N']	[13]
14	of	O	['N']	[14]
15	leucopenia	O	['N']	[15]
16	and	O	['N']	[16]
17	cholestasis	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	biopsy	O	['N']	[20]
21	features	O	['N']	[21]
22	of	O	['N']	[22]
23	fatty	O	['N']	[23]
24	liver	O	['N']	[24]
25	parenchyma	O	['N']	[25]
26	degeneration	O	['N']	[26]
27	with	O	['N']	[27]
28	granulocytic	B	['N']	[28]
29	portal	I	['N']	[29]
30	infiltration	I-Adverse_Effect	['N']	[30]
31	and	O	['N']	[31]
32	bile	O	['N']	[32]
33	stasis	O	['N']	[33]
34	,	O	['N']	[34]
35	demonstrated	O	['N']	[35]
36	20	O	['N']	[36]
37	days	O	['N']	[37]
38	after	O	['N']	[38]
39	the	O	['N']	[39]
40	initiation	O	['N']	[40]
41	of	O	['N']	[41]
42	antithyroid	O	['N']	[42]
43	therapy	O	['N']	[43]
44	with	O	['N']	[44]
45	20	O	['N']	[45]
46	mg	O	['N']	[46]
47	methimazole	B-Drug	['Causes']	[30]
48	daily	O	['N']	[48]
49	.	O	['N']	[49]
#3835
0	OBJECTIVES	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	authors	O	['N']	[3]
4	described	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	Hashimoto	B	['N']	[8]
9	's	I	['N']	[9]
10	disease	I-Adverse_Effect	['N']	[10]
11	during	O	['N']	[11]
12	interferon	O	['N']	[12]
13	-	O	['N']	[13]
14	alpha	O	['N']	[14]
15	(	O	['N']	[15]
16	IFN	B	['N']	[16]
17	-	I	['N']	[17]
18	alpha	I-Drug	['Causes']	[10]
19	)	O	['N']	[19]
20	treatment	O	['N']	[20]
21	for	O	['N']	[21]
22	chronic	O	['N']	[22]
23	viral	O	['N']	[23]
24	C	O	['N']	[24]
25	hepatitis	O	['N']	[25]
26	in	O	['N']	[26]
27	a	O	['N']	[27]
28	patient	O	['N']	[28]
29	with	O	['N']	[29]
30	the	O	['N']	[30]
31	specific	O	['N']	[31]
32	genetic	O	['N']	[32]
33	susceptibility	O	['N']	[33]
34	associated	O	['N']	[34]
35	with	O	['N']	[35]
36	the	O	['N']	[36]
37	thyroid	O	['N']	[37]
38	disease	O	['N']	[38]
39	.	O	['N']	[39]
#3836
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	article	O	['N']	[2]
3	lithium	B-Drug	['Causes']	[29]
4	is	O	['N']	[4]
5	not	O	['N']	[5]
6	discussed	O	['N']	[6]
7	,	O	['N']	[7]
8	although	O	['N']	[8]
9	there	O	['N']	[9]
10	are	O	['N']	[10]
11	a	O	['N']	[11]
12	number	O	['N']	[12]
13	of	O	['N']	[13]
14	concerns	O	['N']	[14]
15	about	O	['N']	[15]
16	lithium	O	['N']	[16]
17	's	O	['N']	[17]
18	potential	O	['N']	[18]
19	teratogenicity	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	it	O	['N']	[22]
23	has	O	['N']	[23]
24	been	O	['N']	[24]
25	implicated	O	['N']	[25]
26	in	O	['N']	[26]
27	Epstein	B	['N']	[27]
28	's	I	['N']	[28]
29	anomaly	I-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	a	O	['N']	[31]
32	congenital	O	['N']	[32]
33	heart	O	['N']	[33]
34	defect	O	['N']	[34]
35	among	O	['N']	[35]
36	infants	O	['N']	[36]
37	born	O	['N']	[37]
38	to	O	['N']	[38]
39	women	O	['N']	[39]
40	taking	O	['N']	[40]
41	lithium	O	['N']	[41]
42	;	O	['N']	[42]
43	as	O	['N']	[43]
44	with	O	['N']	[44]
45	other	O	['N']	[45]
46	medications	O	['N']	[46]
47	,	O	['N']	[47]
48	however	O	['N']	[48]
49	,	O	['N']	[49]
50	the	O	['N']	[50]
51	data	O	['N']	[51]
52	have	O	['N']	[52]
53	specific	O	['N']	[53]
54	limitations	O	['N']	[54]
55	.	O	['N']	[55]
#3837
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	renal	O	['N']	[6]
7	artery	O	['N']	[7]
8	stenosis	O	['N']	[8]
9	who	O	['N']	[9]
10	had	O	['N']	[10]
11	only	O	['N']	[11]
12	1	O	['N']	[12]
13	kidney	O	['N']	[13]
14	and	O	['N']	[14]
15	in	O	['N']	[15]
16	whom	O	['N']	[16]
17	acute	O	['N']	[17]
18	renal	O	['N']	[18]
19	impairment	O	['N']	[19]
20	developed	O	['N']	[20]
21	with	O	['N']	[21]
22	transient	B	['N']	[22]
23	anuria	I-Adverse_Effect	['N']	[23]
24	after	O	['N']	[24]
25	the	O	['N']	[25]
26	administration	O	['N']	[26]
27	of	O	['N']	[27]
28	captopril	B-Drug	['Causes']	[23]
29	.	O	['N']	[29]
#3838
0	The	O	['N']	[0]
1	chemotherapeutics	O	['N']	[1]
2	,	O	['N']	[2]
3	including	O	['N']	[3]
4	vincristine	O	['N']	[4]
5	,	O	['N']	[5]
6	actinomycin	O	['N']	[6]
7	D	O	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	epirubicin	B-Drug	['Causes']	[27]
11	in	O	['N']	[11]
12	case	O	['N']	[12]
13	1	O	['N']	[13]
14	and	O	['N']	[14]
15	vincristine	O	['N']	[15]
16	and	O	['N']	[16]
17	actinomycin	O	['N']	[17]
18	D	O	['N']	[18]
19	in	O	['N']	[19]
20	case	O	['N']	[20]
21	2	O	['N']	[21]
22	,	O	['N']	[22]
23	were	O	['N']	[23]
24	given	O	['N']	[24]
25	before	O	['N']	[25]
26	the	O	['N']	[26]
27	hepatotoxicity	B-Adverse_Effect	['N']	[27]
28	developed	O	['N']	[28]
29	.	O	['N']	[29]
#3839
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	six	O	['N']	[2]
3	patients	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	tardive	B	['N']	[6]
7	dyskinesia	I-Adverse_Effect	['N']	[7]
8	after	O	['N']	[8]
9	treatment	O	['N']	[9]
10	with	O	['N']	[10]
11	sulpiride	B-Drug	['Causes']	[7]
12	for	O	['N']	[12]
13	depression	O	['N']	[13]
14	or	O	['N']	[14]
15	gastrointestinal	O	['N']	[15]
16	symptoms	O	['N']	[16]
17	.	O	['N']	[17]
#3840
0	Acute	B	['N']	[0]
1	ischaemia	I	['N']	[1]
2	of	I	['N']	[2]
3	the	I	['N']	[3]
4	leg	I-Adverse_Effect	['N']	[4]
5	following	O	['N']	[5]
6	accidental	O	['N']	[6]
7	intra	O	['N']	[7]
8	-	O	['N']	[8]
9	arterial	O	['N']	[9]
10	injection	O	['N']	[10]
11	of	O	['N']	[11]
12	dissolved	O	['N']	[12]
13	flunitrazepam	B-Drug	['Causes']	[4]
14	tablets	O	['N']	[14]
15	.	O	['N']	[15]
#3841
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Topiramate	B-Drug	['Causes']	[26]
3	may	O	['N']	[3]
4	be	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	ciliochoroidal	O	['N']	[7]
8	effusion	O	['N']	[8]
9	with	O	['N']	[9]
10	forward	O	['N']	[10]
11	displacement	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	lens	O	['N']	[14]
15	-	O	['N']	[15]
16	iris	O	['N']	[16]
17	diaphragm	O	['N']	[17]
18	and	O	['N']	[18]
19	anterior	O	['N']	[19]
20	chamber	O	['N']	[20]
21	shallowing	O	['N']	[21]
22	,	O	['N']	[22]
23	resulting	O	['N']	[23]
24	in	O	['N']	[24]
25	acute	B	['N']	[25]
26	myopia	I-Adverse_Effect	['N']	[26]
27	and	O	['N']	[27]
28	angle	O	['N']	[28]
29	-	O	['N']	[29]
30	closure	O	['N']	[30]
31	glaucoma	O	['N']	[31]
32	.	O	['N']	[32]
#3842
0	Fatal	B	['N']	[0]
1	digoxin	B-Drug	['Causes']	[2]
2	poisoning	I-Adverse_Effect	['N']	[2]
3	:	O	['N']	[3]
4	an	O	['N']	[4]
5	unsuccessful	O	['N']	[5]
6	resuscitation	O	['N']	[6]
7	with	O	['N']	[7]
8	use	O	['N']	[8]
9	of	O	['N']	[9]
10	digoxin	O	['N']	[10]
11	-	O	['N']	[11]
12	immune	O	['N']	[12]
13	Fab	O	['N']	[13]
14	.	O	['N']	[14]
#3843
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	these	O	['N']	[4]
5	cases	O	['N']	[5]
6	are	O	['N']	[6]
7	the	O	['N']	[7]
8	first	O	['N']	[8]
9	published	O	['N']	[9]
10	reports	O	['N']	[10]
11	of	O	['N']	[11]
12	lovastatin	B-Drug	['Causes']	[15]
13	-	O	['N']	[13]
14	induced	O	['N']	[14]
15	rhabdomyolysis	B-Adverse_Effect	['N']	[15]
16	associated	O	['N']	[16]
17	with	O	['N']	[17]
18	azithromycin	O	['N']	[18]
19	and	O	['N']	[19]
20	clarithromycin	O	['N']	[20]
21	.	O	['N']	[21]
#3844
0	Albeit	O	['N']	[0]
1	rare	O	['N']	[1]
2	among	O	['N']	[2]
3	Western	O	['N']	[3]
4	patients	O	['N']	[4]
5	,	O	['N']	[5]
6	such	O	['N']	[6]
7	lithium	B-Drug	['Causes']	[11]
8	-	O	['N']	[8]
9	associated	O	['N']	[9]
10	thyroid	B	['N']	[10]
11	dysfunctions	I-Adverse_Effect	['N']	[11]
12	appeared	O	['N']	[12]
13	to	O	['N']	[13]
14	be	O	['N']	[14]
15	more	O	['N']	[15]
16	likely	O	['N']	[16]
17	to	O	['N']	[17]
18	occur	O	['N']	[18]
19	in	O	['N']	[19]
20	Hong	O	['N']	[20]
21	Kong	O	['N']	[21]
22	Chinese	O	['N']	[22]
23	.	O	['N']	[23]
#3845
0	Dasatinib	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	pleural	B	['N']	[3]
4	effusions	I-Adverse_Effect	['N']	[4]
5	:	O	['N']	[5]
6	a	O	['N']	[6]
7	lymphatic	O	['N']	[7]
8	network	O	['N']	[8]
9	disorder	O	['N']	[9]
10	?	O	['N']	[10]
#3846
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	there	O	['N']	[2]
3	remain	O	['N']	[3]
4	questions	O	['N']	[4]
5	concerning	O	['N']	[5]
6	whether	O	['N']	[6]
7	these	O	['N']	[7]
8	drugs	O	['N']	[8]
9	,	O	['N']	[9]
10	especially	O	['N']	[10]
11	methimazole	B-Drug	['Causes']	[22]
12	(	O	['N']	[12]
13	MMI	O	['N']	[13]
14	)	O	['N']	[14]
15	,	O	['N']	[15]
16	may	O	['N']	[16]
17	be	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	aplasia	B	['N']	[20]
21	cutis	I	['N']	[21]
22	congenita	I-Adverse_Effect	['N']	[22]
23	(	O	['N']	[23]
24	ACC	O	['N']	[24]
25	)	O	['N']	[25]
26	and	O	['N']	[26]
27	how	O	['N']	[27]
28	best	O	['N']	[28]
29	to	O	['N']	[29]
30	avoid	O	['N']	[30]
31	impairment	O	['N']	[31]
32	of	O	['N']	[32]
33	fetal	O	['N']	[33]
34	thyroid	O	['N']	[34]
35	function	O	['N']	[35]
36	during	O	['N']	[36]
37	their	O	['N']	[37]
38	use	O	['N']	[38]
39	.	O	['N']	[39]
#3847
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	thought	O	['N']	[2]
3	that	O	['N']	[3]
4	the	O	['N']	[4]
5	clinico	O	['N']	[5]
6	-	O	['N']	[6]
7	pathological	O	['N']	[7]
8	features	O	['N']	[8]
9	and	O	['N']	[9]
10	chronology	O	['N']	[10]
11	of	O	['N']	[11]
12	this	O	['N']	[12]
13	case	O	['N']	[13]
14	bore	O	['N']	[14]
15	the	O	['N']	[15]
16	hallmarks	O	['N']	[16]
17	of	O	['N']	[17]
18	the	O	['N']	[18]
19	so	O	['N']	[19]
20	-	O	['N']	[20]
21	called	O	['N']	[21]
22	"	O	['N']	[22]
23	3-week	O	['N']	[23]
24	sulphasalazine	B-Drug	['Causes']	[36]
25	syndrome	O	['N']	[25]
26	"	O	['N']	[26]
27	,	O	['N']	[27]
28	a	O	['N']	[28]
29	rare	O	['N']	[29]
30	,	O	['N']	[30]
31	but	O	['N']	[31]
32	often	O	['N']	[32]
33	fatal	O	['N']	[33]
34	,	O	['N']	[34]
35	immunoallergic	B	['N']	[35]
36	reaction	I-Adverse_Effect	['N']	[36]
37	to	O	['N']	[37]
38	sulphasalazine	O	['N']	[38]
39	.	O	['N']	[39]
#3848
0	Based	O	['N']	[0]
1	on	O	['N']	[1]
2	the	O	['N']	[2]
3	Naranjo	O	['N']	[3]
4	algorithm	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	adverse	O	['N']	[7]
8	reaction	O	['N']	[8]
9	observed	O	['N']	[9]
10	was	O	['N']	[10]
11	probably	O	['N']	[11]
12	related	O	['N']	[12]
13	to	O	['N']	[13]
14	the	O	['N']	[14]
15	hydroxyurea	B-Drug	['Causes']	[36]
16	treatment	O	['N']	[16]
17	(	O	['N']	[17]
18	score	O	['N']	[18]
19	=	O	['N']	[19]
20	6	O	['N']	[20]
21	)	O	['N']	[21]
22	;	O	['N']	[22]
23	however	O	['N']	[23]
24	,	O	['N']	[24]
25	the	O	['N']	[25]
26	hydroxyurea	O	['N']	[26]
27	chemotherapy	O	['N']	[27]
28	could	O	['N']	[28]
29	not	O	['N']	[29]
30	be	O	['N']	[30]
31	discontinued	O	['N']	[31]
32	because	O	['N']	[32]
33	of	O	['N']	[33]
34	the	O	['N']	[34]
35	myeloproliferative	B	['N']	[35]
36	disorder	I-Adverse_Effect	['N']	[36]
37	.	O	['N']	[37]
#3849
0	Hypersensitivity	B	['N']	[0]
1	pneumonitis	I	['N']	[1]
2	-	I	['N']	[2]
3	like	I	['N']	[3]
4	syndrome	I-Adverse_Effect	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	the	O	['N']	[7]
8	use	O	['N']	[8]
9	of	O	['N']	[9]
10	lenalidomide	B-Drug	['Causes']	[4]
11	.	O	['N']	[11]
#3850
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	completed	O	['N']	[2]
3	a	O	['N']	[3]
4	10-month	O	['N']	[4]
5	follow	O	['N']	[5]
6	-	O	['N']	[6]
7	up	O	['N']	[7]
8	,	O	['N']	[8]
9	maintaining	O	['N']	[9]
10	a	O	['N']	[10]
11	complete	O	['N']	[11]
12	resolution	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	treated	O	['N']	[15]
16	skin	O	['N']	[16]
17	lesions	O	['N']	[17]
18	;	O	['N']	[18]
19	however	O	['N']	[19]
20	,	O	['N']	[20]
21	the	O	['N']	[21]
22	development	O	['N']	[22]
23	of	O	['N']	[23]
24	a	O	['N']	[24]
25	painful	B	['N']	[25]
26	hand	I	['N']	[26]
27	ulcer	I-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	possibly	O	['N']	[29]
30	associated	O	['N']	[30]
31	with	O	['N']	[31]
32	the	O	['N']	[32]
33	hydroxyurea	B-Drug	['Causes']	[27]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	new	O	['N']	[36]
37	skin	O	['N']	[37]
38	cancers	O	['N']	[38]
39	were	O	['N']	[39]
40	observed	O	['N']	[40]
41	at	O	['N']	[41]
42	the	O	['N']	[42]
43	last	O	['N']	[43]
44	follow	O	['N']	[44]
45	-	O	['N']	[45]
46	up	O	['N']	[46]
47	visit	O	['N']	[47]
48	.	O	['N']	[48]
#3851
0	Two	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	hypothyroidism	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	patients	O	['N']	[5]
6	with	O	['N']	[6]
7	chronic	O	['N']	[7]
8	hepatitis	O	['N']	[8]
9	C	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	recombinant	B	['N']	[12]
13	alpha	I	['N']	[13]
14	interferon	I-Drug	['Causes']	[3]
15	are	O	['N']	[15]
16	reported	O	['N']	[16]
17	.	O	['N']	[17]
#3852
0	Prick	O	['N']	[0]
1	tests	O	['N']	[1]
2	and	O	['N']	[2]
3	intradermal	O	['N']	[3]
4	tests	O	['N']	[4]
5	with	O	['N']	[5]
6	a	O	['N']	[6]
7	series	O	['N']	[7]
8	of	O	['N']	[8]
9	dilutions	O	['N']	[9]
10	of	O	['N']	[10]
11	carboplatin	B-Drug	['Causes']	[25]
12	and	O	['N']	[12]
13	cisplatin	O	['N']	[13]
14	were	O	['N']	[14]
15	performed	O	['N']	[15]
16	on	O	['N']	[16]
17	three	O	['N']	[17]
18	patients	O	['N']	[18]
19	who	O	['N']	[19]
20	had	O	['N']	[20]
21	exhibited	O	['N']	[21]
22	medium	O	['N']	[22]
23	and	O	['N']	[23]
24	severe	B	['N']	[24]
25	hypersensitivity	I-Adverse_Effect	['N']	[25]
26	reactions	O	['N']	[26]
27	to	O	['N']	[27]
28	carboplatin	O	['N']	[28]
29	.	O	['N']	[29]
#3853
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	,	O	['N']	[3]
4	two	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	ET	O	['N']	[7]
8	which	O	['N']	[8]
9	evolved	O	['N']	[9]
10	into	O	['N']	[10]
11	AL	B-Adverse_Effect	['N']	[11]
12	without	O	['N']	[12]
13	prior	O	['N']	[13]
14	exposure	O	['N']	[14]
15	to	O	['N']	[15]
16	radiation	O	['N']	[16]
17	or	O	['N']	[17]
18	alkylating	O	['N']	[18]
19	agents	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	which	O	['N']	[22]
23	were	O	['N']	[23]
24	treated	O	['N']	[24]
25	with	O	['N']	[25]
26	long	O	['N']	[26]
27	-	O	['N']	[27]
28	term	O	['N']	[28]
29	hydroxyurea	B-Drug	['Causes']	[11]
30	therapy	O	['N']	[30]
31	,	O	['N']	[31]
32	are	O	['N']	[32]
33	described	O	['N']	[33]
34	.	O	['N']	[34]
#3854
0	While	O	['N']	[0]
1	the	O	['N']	[1]
2	introduction	O	['N']	[2]
3	of	O	['N']	[3]
4	carmustine	O	['N']	[4]
5	wafers	O	['N']	[5]
6	(	O	['N']	[6]
7	Gliadel	B-Drug	['Causes']	[34]
8	wafers	O	['N']	[8]
9	)	O	['N']	[9]
10	into	O	['N']	[10]
11	the	O	['N']	[11]
12	tumor	O	['N']	[12]
13	resection	O	['N']	[13]
14	cavity	O	['N']	[14]
15	has	O	['N']	[15]
16	been	O	['N']	[16]
17	shown	O	['N']	[17]
18	to	O	['N']	[18]
19	be	O	['N']	[19]
20	a	O	['N']	[20]
21	beneficial	O	['N']	[21]
22	therapy	O	['N']	[22]
23	for	O	['N']	[23]
24	malignant	O	['N']	[24]
25	glioma	O	['N']	[25]
26	,	O	['N']	[26]
27	it	O	['N']	[27]
28	is	O	['N']	[28]
29	recognized	O	['N']	[29]
30	that	O	['N']	[30]
31	clinically	O	['N']	[31]
32	significant	O	['N']	[32]
33	cerebral	B	['N']	[33]
34	edema	I-Adverse_Effect	['N']	[34]
35	is	O	['N']	[35]
36	a	O	['N']	[36]
37	potential	O	['N']	[37]
38	adverse	O	['N']	[38]
39	effect	O	['N']	[39]
40	.	O	['N']	[40]
#3855
0	Review	O	['N']	[0]
1	of	O	['N']	[1]
2	this	O	['N']	[2]
3	and	O	['N']	[3]
4	previously	O	['N']	[4]
5	reported	O	['N']	[5]
6	cases	O	['N']	[6]
7	indicates	O	['N']	[7]
8	the	O	['N']	[8]
9	need	O	['N']	[9]
10	for	O	['N']	[10]
11	early	O	['N']	[11]
12	diagnosis	O	['N']	[12]
13	of	O	['N']	[13]
14	amiodarone	B-Drug	['Causes']	[15]
15	pneumonitis	B-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	immediate	O	['N']	[17]
18	withdrawal	O	['N']	[18]
19	of	O	['N']	[19]
20	amiodarone	O	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	prompt	O	['N']	[23]
24	but	O	['N']	[24]
25	continued	O	['N']	[25]
26	steroid	O	['N']	[26]
27	therapy	O	['N']	[27]
28	to	O	['N']	[28]
29	ensure	O	['N']	[29]
30	full	O	['N']	[30]
31	recovery	O	['N']	[31]
32	.	O	['N']	[32]
#3856
0	Less	O	['N']	[0]
1	common	O	['N']	[1]
2	adverse	O	['N']	[2]
3	events	O	['N']	[3]
4	to	O	['N']	[4]
5	dapsone	B-Drug	['Causes']	[24]
6	include	O	['N']	[6]
7	the	O	['N']	[7]
8	idiosyncratic	O	['N']	[8]
9	reactions	O	['N']	[9]
10	of	O	['N']	[10]
11	leukopenia	O	['N']	[11]
12	and	O	['N']	[12]
13	agranulocytosis	O	['N']	[13]
14	,	O	['N']	[14]
15	cutaneous	O	['N']	[15]
16	eruptions	O	['N']	[16]
17	,	O	['N']	[17]
18	peripheral	O	['N']	[18]
19	neuropathy	O	['N']	[19]
20	,	O	['N']	[20]
21	psychosis	O	['N']	[21]
22	,	O	['N']	[22]
23	toxic	B	['N']	[23]
24	hepatitis	I-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	cholestatic	O	['N']	[26]
27	jaundice	O	['N']	[27]
28	,	O	['N']	[28]
29	nephrotic	O	['N']	[29]
30	syndrome	O	['N']	[30]
31	,	O	['N']	[31]
32	renal	O	['N']	[32]
33	papillary	O	['N']	[33]
34	necrosis	O	['N']	[34]
35	,	O	['N']	[35]
36	severe	O	['N']	[36]
37	hypoalbuminemia	O	['N']	[37]
38	without	O	['N']	[38]
39	proteinuria	O	['N']	[39]
40	,	O	['N']	[40]
41	an	O	['N']	[41]
42	infectious	O	['N']	[42]
43	mononucleosis	O	['N']	[43]
44	-	O	['N']	[44]
45	like	O	['N']	[45]
46	syndrome	O	['N']	[46]
47	,	O	['N']	[47]
48	and	O	['N']	[48]
49	minor	O	['N']	[49]
50	neurological	O	['N']	[50]
51	and	O	['N']	[51]
52	gastrointestinal	O	['N']	[52]
53	complaints	O	['N']	[53]
54	.	O	['N']	[54]
#3857
0	Fever	B-Adverse_Effect	['N']	[0]
1	,	O	['N']	[1]
2	pulmonary	O	['N']	[2]
3	infiltrates	O	['N']	[3]
4	,	O	['N']	[4]
5	and	O	['N']	[5]
6	pleural	O	['N']	[6]
7	effusion	O	['N']	[7]
8	following	O	['N']	[8]
9	acyclovir	B-Drug	['Causes']	[0]
10	therapy	O	['N']	[10]
11	for	O	['N']	[11]
12	herpes	O	['N']	[12]
13	zoster	O	['N']	[13]
14	ophthalmicus	O	['N']	[14]
15	.	O	['N']	[15]
#3858
0	Agranulocytosis	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	granulocytopenia	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	quetiapine	B-Drug	['Causes']	[0]
6	.	O	['N']	[6]
#3859
0	Cyclosporine	O	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	potent	O	['N']	[3]
4	inhibitor	O	['N']	[4]
5	of	O	['N']	[5]
6	simvastatin	B-Drug	['Causes']	[16]
7	metabolism	O	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	may	O	['N']	[10]
11	therefore	O	['N']	[11]
12	facilitate	O	['N']	[12]
13	simvastatin	O	['N']	[13]
14	-	O	['N']	[14]
15	induced	O	['N']	[15]
16	rhabdomyolysis	B-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#3860
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	required	O	['N']	[2]
3	nursing	O	['N']	[3]
4	home	O	['N']	[4]
5	placement	O	['N']	[5]
6	and	O	['N']	[6]
7	a	O	['N']	[7]
8	feeding	O	['N']	[8]
9	gastrostomy	O	['N']	[9]
10	as	O	['N']	[10]
11	a	O	['N']	[11]
12	result	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	worsening	B	['N']	[15]
16	parkinsonism	I-Adverse_Effect	['N']	[16]
17	during	O	['N']	[17]
18	risperidone	B-Drug	['Causes']	[16]
19	treatment	O	['N']	[19]
20	,	O	['N']	[20]
21	but	O	['N']	[21]
22	was	O	['N']	[22]
23	able	O	['N']	[23]
24	to	O	['N']	[24]
25	return	O	['N']	[25]
26	home	O	['N']	[26]
27	and	O	['N']	[27]
28	have	O	['N']	[28]
29	the	O	['N']	[29]
30	gastrostomy	O	['N']	[30]
31	removed	O	['N']	[31]
32	after	O	['N']	[32]
33	switching	O	['N']	[33]
34	from	O	['N']	[34]
35	risperidone	O	['N']	[35]
36	to	O	['N']	[36]
37	clozapine	O	['N']	[37]
38	.	O	['N']	[38]
#3861
0	Renal	B	['N']	[0]
1	toxicities	I-Adverse_Effect	['N']	[1]
2	have	O	['N']	[2]
3	been	O	['N']	[3]
4	reported	O	['N']	[4]
5	in	O	['N']	[5]
6	less	O	['N']	[6]
7	than	O	['N']	[7]
8	one	O	['N']	[8]
9	percent	O	['N']	[9]
10	of	O	['N']	[10]
11	the	O	['N']	[11]
12	patients	O	['N']	[12]
13	receiving	O	['N']	[13]
14	ciprofloxacin	B-Drug	['Causes']	[1]
15	therapy	O	['N']	[15]
16	.	O	['N']	[16]
#3862
0	The	O	['N']	[0]
1	reported	O	['N']	[1]
2	cases	O	['N']	[2]
3	of	O	['N']	[3]
4	in	O	['N']	[4]
5	utero	O	['N']	[5]
6	exposure	O	['N']	[6]
7	to	O	['N']	[7]
8	cyclosposphamide	B-Drug	['Causes']	[40]
9	shared	O	['N']	[9]
10	the	O	['N']	[10]
11	following	O	['N']	[11]
12	manifestations	O	['N']	[12]
13	with	O	['N']	[13]
14	our	O	['N']	[14]
15	patient	O	['N']	[15]
16	:	O	['N']	[16]
17	growth	O	['N']	[17]
18	deficiency	O	['N']	[18]
19	,	O	['N']	[19]
20	developmental	O	['N']	[20]
21	delay	O	['N']	[21]
22	,	O	['N']	[22]
23	craniosynostosis	O	['N']	[23]
24	,	O	['N']	[24]
25	blepharophimosis	O	['N']	[25]
26	,	O	['N']	[26]
27	flat	O	['N']	[27]
28	nasal	O	['N']	[28]
29	bridge	O	['N']	[29]
30	,	O	['N']	[30]
31	abnormal	O	['N']	[31]
32	ears	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	distal	O	['N']	[35]
36	limb	O	['N']	[36]
37	defects	O	['N']	[37]
38	including	O	['N']	[38]
39	hypoplastic	B	['N']	[39]
40	thumbs	I-Adverse_Effect	['N']	[40]
41	and	O	['N']	[41]
42	oligodactyly	O	['N']	[42]
43	.	O	['N']	[43]
#3863
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	we	O	['N']	[3]
4	described	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	juvenile	O	['N']	[8]
9	idiopathic	O	['N']	[9]
10	arthritis	O	['N']	[10]
11	patient	O	['N']	[11]
12	who	O	['N']	[12]
13	developed	O	['N']	[13]
14	thymic	O	['N']	[14]
15	enlargement	O	['N']	[15]
16	(	O	['N']	[16]
17	true	O	['N']	[17]
18	thymic	O	['N']	[18]
19	hyperplasia	O	['N']	[19]
20	)	O	['N']	[20]
21	,	O	['N']	[21]
22	mediastinal	O	['N']	[22]
23	lymphadenopathy	O	['N']	[23]
24	and	O	['N']	[24]
25	pleurisy	B-Adverse_Effect	['N']	[25]
26	associated	O	['N']	[26]
27	with	O	['N']	[27]
28	systemic	O	['N']	[28]
29	symptoms	O	['N']	[29]
30	under	O	['N']	[30]
31	Etanercept	B-Drug	['Causes']	[25]
32	treatment	O	['N']	[32]
33	.	O	['N']	[33]
#3864
0	Provocation	O	['N']	[0]
1	of	O	['N']	[1]
2	non	B	['N']	[2]
3	-	I	['N']	[3]
4	convulsive	I	['N']	[4]
5	status	I	['N']	[5]
6	epilepticus	I-Adverse_Effect	['N']	[6]
7	by	O	['N']	[7]
8	tiagabine	B-Drug	['Causes']	[6]
9	in	O	['N']	[9]
10	three	O	['N']	[10]
11	adolescent	O	['N']	[11]
12	patients	O	['N']	[12]
13	.	O	['N']	[13]
#3865
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	skin	O	['N']	[23]
24	eruptions	O	['N']	[24]
25	,	O	['N']	[25]
26	cervical	O	['N']	[26]
27	lymphadenopathy	O	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	B-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	atypical	O	['N']	[31]
32	lymphocytosis	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	B-Drug	['Causes']	[29]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	O	['N']	[42]
43	(	O	['N']	[43]
44	SMX	O	['N']	[44]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#3866
0	Fatal	B	['N']	[0]
1	agranulocytosis	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	an	O	['N']	[3]
4	Indian	O	['N']	[4]
5	male	O	['N']	[5]
6	receiving	O	['N']	[6]
7	100	O	['N']	[7]
8	mg	O	['N']	[8]
9	of	O	['N']	[9]
10	dapsone	B-Drug	['Causes']	[1]
11	daily	O	['N']	[11]
12	,	O	['N']	[12]
13	hospitalized	O	['N']	[13]
14	for	O	['N']	[14]
15	mid	O	['N']	[15]
16	-	O	['N']	[16]
17	borderline	O	['N']	[17]
18	leprosy	O	['N']	[18]
19	in	O	['N']	[19]
20	type	O	['N']	[20]
21	I	O	['N']	[21]
22	reaction	O	['N']	[22]
23	with	O	['N']	[23]
24	triple	O	['N']	[24]
25	nerve	O	['N']	[25]
26	paralysis	O	['N']	[26]
27	is	O	['N']	[27]
28	reported	O	['N']	[28]
29	.	O	['N']	[29]
#3867
0	Fatal	B	['N']	[0]
1	interstitial	I	['N']	[1]
2	lung	I	['N']	[2]
3	disease	I-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	erlotinib	B-Drug	['Causes']	[3]
6	administration	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	radiation	O	['N']	[11]
12	fibrosis	O	['N']	[12]
13	.	O	['N']	[13]
#3868
0	Renal	B	['N']	[0]
1	tubular	I	['N']	[1]
2	acidosis	I-Adverse_Effect	['N']	[2]
3	secondary	O	['N']	[3]
4	to	O	['N']	[4]
5	FK506	B-Drug	['Causes']	[2]
6	in	O	['N']	[6]
7	living	O	['N']	[7]
8	donor	O	['N']	[8]
9	liver	O	['N']	[9]
10	transplantation	O	['N']	[10]
11	:	O	['N']	[11]
12	a	O	['N']	[12]
13	case	O	['N']	[13]
14	report	O	['N']	[14]
15	.	O	['N']	[15]
#3869
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	patients	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	intense	O	['N']	[6]
7	livedo	B	['N']	[7]
8	reticularis	I-Adverse_Effect	['N']	[8]
9	clearly	O	['N']	[9]
10	related	O	['N']	[10]
11	to	O	['N']	[11]
12	the	O	['N']	[12]
13	administration	O	['N']	[13]
14	of	O	['N']	[14]
15	interferon	B	['N']	[15]
16	alpha	I	['N']	[16]
17	2b	I-Drug	['Causes']	[8]
18	as	O	['N']	[18]
19	an	O	['N']	[19]
20	adjuvant	O	['N']	[20]
21	therapy	O	['N']	[21]
22	for	O	['N']	[22]
23	melanoma	O	['N']	[23]
24	.	O	['N']	[24]
#3870
0	Quetiapine	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	leucopenia	O	['N']	[3]
4	and	O	['N']	[4]
5	thrombocytopenia	B-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#3871
0	Clozapine	B-Drug	['Causes']	[2]
1	induced	O	['N']	[1]
2	polyserositis	B-Adverse_Effect	['N']	[2]
3	.	O	['N']	[3]
#3872
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	the	O	['N']	[2]
3	amount	O	['N']	[3]
4	of	O	['N']	[4]
5	prednisone	B-Drug	['Causes']	[13]
6	required	O	['N']	[6]
7	to	O	['N']	[7]
8	maintain	O	['N']	[8]
9	normotension	O	['N']	[9]
10	resulted	O	['N']	[10]
11	in	O	['N']	[11]
12	Cushingoid	B	['N']	[12]
13	features	I-Adverse_Effect	['N']	[13]
14	and	O	['N']	[14]
15	has	O	['N']	[15]
16	been	O	['N']	[16]
17	discontinued	O	['N']	[17]
18	.	O	['N']	[18]
#3873
0	A	O	['N']	[0]
1	child	O	['N']	[1]
2	in	O	['N']	[2]
3	whom	O	['N']	[3]
4	a	O	['N']	[4]
5	phenobarbital	B-Drug	['Causes']	[21]
6	hypersensitivity	O	['N']	[6]
7	drug	O	['N']	[7]
8	reaction	O	['N']	[8]
9	developed	O	['N']	[9]
10	which	O	['N']	[10]
11	consisted	O	['N']	[11]
12	of	O	['N']	[12]
13	fever	O	['N']	[13]
14	,	O	['N']	[14]
15	a	O	['N']	[15]
16	pruritic	O	['N']	[16]
17	desquamating	O	['N']	[17]
18	erythrodermic	O	['N']	[18]
19	rash	O	['N']	[19]
20	,	O	['N']	[20]
21	alopecia	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	icterus	O	['N']	[23]
24	,	O	['N']	[24]
25	protein	O	['N']	[25]
26	-	O	['N']	[26]
27	losing	O	['N']	[27]
28	enteropathy	O	['N']	[28]
29	,	O	['N']	[29]
30	myositis	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	nephritis	O	['N']	[33]
34	,	O	['N']	[34]
35	is	O	['N']	[35]
36	described	O	['N']	[36]
37	.	O	['N']	[37]
#3874
0	Papilloedema	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	hepatic	O	['N']	[2]
3	dysfunction	O	['N']	[3]
4	apparently	O	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	perhexiline	O	['N']	[7]
8	maleate	O	['N']	[8]
9	(	O	['N']	[9]
10	Pexid	B-Drug	['Causes']	[0]
11	)	O	['N']	[11]
12	.	O	['N']	[12]
#3875
0	These	O	['N']	[0]
1	cases	O	['N']	[1]
2	were	O	['N']	[2]
3	considered	O	['N']	[3]
4	unusual	O	['N']	[4]
5	in	O	['N']	[5]
6	light	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	short	O	['N']	[9]
10	delay	O	['N']	[10]
11	of	O	['N']	[11]
12	their	O	['N']	[12]
13	onset	O	['N']	[13]
14	after	O	['N']	[14]
15	initiation	O	['N']	[15]
16	of	O	['N']	[16]
17	immunosuppressive	O	['N']	[17]
18	therapy	O	['N']	[18]
19	and	O	['N']	[19]
20	their	O	['N']	[20]
21	fulminant	O	['N']	[21]
22	course	O	['N']	[22]
23	:	O	['N']	[23]
24	3	O	['N']	[24]
25	of	O	['N']	[25]
26	these	O	['N']	[26]
27	patients	O	['N']	[27]
28	died	B-Adverse_Effect	['N']	[28]
29	of	O	['N']	[29]
30	PCP	O	['N']	[30]
31	occurring	O	['N']	[31]
32	during	O	['N']	[32]
33	the	O	['N']	[33]
34	first	O	['N']	[34]
35	month	O	['N']	[35]
36	of	O	['N']	[36]
37	treatment	O	['N']	[37]
38	with	O	['N']	[38]
39	prednisone	B-Drug	['Causes']	[28]
40	.	O	['N']	[40]
#3876
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	he	O	['N']	[2]
3	developed	O	['N']	[3]
4	acute	O	['N']	[4]
5	renal	O	['N']	[5]
6	failure	O	['N']	[6]
7	,	O	['N']	[7]
8	hyperkalemia	B-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	hyperuricemia	O	['N']	[11]
12	30	O	['N']	[12]
13	d	O	['N']	[13]
14	after	O	['N']	[14]
15	receiving	O	['N']	[15]
16	the	O	['N']	[16]
17	sorafenib	B-Drug	['Causes']	[8]
18	treatment	O	['N']	[18]
19	.	O	['N']	[19]
#3877
0	Without	O	['N']	[0]
1	other	O	['N']	[1]
2	causes	O	['N']	[2]
3	for	O	['N']	[3]
4	the	O	['N']	[4]
5	hyponatremia	B-Adverse_Effect	['N']	[5]
6	,	O	['N']	[6]
7	she	O	['N']	[7]
8	was	O	['N']	[8]
9	diagnosed	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	syndrome	O	['N']	[12]
13	of	O	['N']	[13]
14	inappropriate	O	['N']	[14]
15	antidiuretic	O	['N']	[15]
16	hormone	O	['N']	[16]
17	,	O	['N']	[17]
18	presumably	O	['N']	[18]
19	caused	O	['N']	[19]
20	by	O	['N']	[20]
21	desmopressin	B-Drug	['Causes']	[5]
22	.	O	['N']	[22]
#3878
0	We	O	['N']	[0]
1	have	O	['N']	[1]
2	described	O	['N']	[2]
3	three	O	['N']	[3]
4	patients	O	['N']	[4]
5	with	O	['N']	[5]
6	hepatitis	O	['N']	[6]
7	C	O	['N']	[7]
8	for	O	['N']	[8]
9	whom	O	['N']	[9]
10	IFN	B	['N']	[10]
11	-	I	['N']	[11]
12	alpha	I-Drug	['Causes']	[28]
13	and	O	['N']	[13]
14	ribavirin	O	['N']	[14]
15	were	O	['N']	[15]
16	prescribed	O	['N']	[16]
17	and	O	['N']	[17]
18	who	O	['N']	[18]
19	developed	O	['N']	[19]
20	two	O	['N']	[20]
21	successive	O	['N']	[21]
22	phases	O	['N']	[22]
23	of	O	['N']	[23]
24	silent	O	['N']	[24]
25	thyroiditis	O	['N']	[25]
26	followed	O	['N']	[26]
27	by	O	['N']	[27]
28	hyperthryroidism	B-Adverse_Effect	['N']	[28]
29	relapse	O	['N']	[29]
30	due	O	['N']	[30]
31	to	O	['N']	[31]
32	Graves	O	['N']	[32]
33	'	O	['N']	[33]
34	disease	O	['N']	[34]
35	.	O	['N']	[35]
#3879
0	Intrahepatic	O	['N']	[0]
1	cholestasis	O	['N']	[1]
2	and	O	['N']	[2]
3	sicca	B	['N']	[3]
4	complex	I-Adverse_Effect	['N']	[4]
5	after	O	['N']	[5]
6	thiabendazole	B-Drug	['Causes']	[4]
7	.	O	['N']	[7]
#3880
0	Captopril	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	bone	B	['N']	[3]
4	marrow	I	['N']	[4]
5	suppression	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	two	O	['N']	[7]
8	cardiac	O	['N']	[8]
9	patients	O	['N']	[9]
10	with	O	['N']	[10]
11	trisomy	O	['N']	[11]
12	21	O	['N']	[12]
13	.	O	['N']	[13]
#3881
0	Zolpidem	B-Drug	['Causes']	[8]
1	tissue	O	['N']	[1]
2	concentrations	O	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	multiple	O	['N']	[5]
6	drug	O	['N']	[6]
7	related	O	['N']	[7]
8	death	B-Adverse_Effect	['N']	[8]
9	involving	O	['N']	[9]
10	Ambien	O	['N']	[10]
11	.	O	['N']	[11]
#3882
0	In	O	['N']	[0]
1	the	O	['N']	[1]
2	second	O	['N']	[2]
3	case	O	['N']	[3]
4	,	O	['N']	[4]
5	five	O	['N']	[5]
6	cardiac	O	['N']	[6]
7	arrests	O	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	ventricular	B	['N']	[10]
11	tachycardia	I-Adverse_Effect	['N']	[11]
12	and	O	['N']	[12]
13	fibrillation	O	['N']	[13]
14	occurred	O	['N']	[14]
15	during	O	['N']	[15]
16	several	O	['N']	[16]
17	hours	O	['N']	[17]
18	after	O	['N']	[18]
19	beginning	O	['N']	[19]
20	a	O	['N']	[20]
21	trial	O	['N']	[21]
22	of	O	['N']	[22]
23	bretylium	B-Drug	['Causes']	[11]
24	maintenance	O	['N']	[24]
25	therapy	O	['N']	[25]
26	for	O	['N']	[26]
27	complex	O	['N']	[27]
28	ventricular	O	['N']	[28]
29	ectopy	O	['N']	[29]
30	.	O	['N']	[30]
#3883
0	Because	O	['N']	[0]
1	there	O	['N']	[1]
2	were	O	['N']	[2]
3	no	O	['N']	[3]
4	other	O	['N']	[4]
5	obvious	O	['N']	[5]
6	causes	O	['N']	[6]
7	of	O	['N']	[7]
8	renal	O	['N']	[8]
9	failure	O	['N']	[9]
10	in	O	['N']	[10]
11	either	O	['N']	[11]
12	patient	O	['N']	[12]
13	,	O	['N']	[13]
14	we	O	['N']	[14]
15	propose	O	['N']	[15]
16	that	O	['N']	[16]
17	skeletal	O	['N']	[17]
18	muscle	O	['N']	[18]
19	ischemia	O	['N']	[19]
20	developed	O	['N']	[20]
21	during	O	['N']	[21]
22	vasopressin	B-Drug	['Causes']	[32]
23	infusion	O	['N']	[23]
24	,	O	['N']	[24]
25	followed	O	['N']	[25]
26	by	O	['N']	[26]
27	release	O	['N']	[27]
28	of	O	['N']	[28]
29	myoglobin	O	['N']	[29]
30	and	O	['N']	[30]
31	renal	B	['N']	[31]
32	damage	I-Adverse_Effect	['N']	[32]
33	.	O	['N']	[33]
#3884
0	Herein	O	['N']	[0]
1	is	O	['N']	[1]
2	reported	O	['N']	[2]
3	an	O	['N']	[3]
4	unusual	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	coexistent	O	['N']	[7]
8	warfarin	B-Drug	['Causes']	[12]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	skin	B	['N']	[11]
12	necrosis	I-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	heparin	O	['N']	[14]
15	-	O	['N']	[15]
16	induced	O	['N']	[16]
17	thrombocytopenia	O	['N']	[17]
18	following	O	['N']	[18]
19	mitral	O	['N']	[19]
20	valve	O	['N']	[20]
21	replacement	O	['N']	[21]
22	for	O	['N']	[22]
23	thromboembolic	O	['N']	[23]
24	phenomena	O	['N']	[24]
25	associated	O	['N']	[25]
26	with	O	['N']	[26]
27	marantic	O	['N']	[27]
28	endocarditis	O	['N']	[28]
29	and	O	['N']	[29]
30	bronchial	O	['N']	[30]
31	adenocarcinoma	O	['N']	[31]
32	.	O	['N']	[32]
#3885
0	He	O	['N']	[0]
1	was	O	['N']	[1]
2	started	O	['N']	[2]
3	on	O	['N']	[3]
4	digoxin	B-Drug	['Causes']	[19]
5	,	O	['N']	[5]
6	0.25	O	['N']	[6]
7	mg	O	['N']	[7]
8	daily	O	['N']	[8]
9	,	O	['N']	[9]
10	because	O	['N']	[10]
11	of	O	['N']	[11]
12	echocardiographically	O	['N']	[12]
13	demonstrated	O	['N']	[13]
14	left	O	['N']	[14]
15	ventricular	O	['N']	[15]
16	dilatation	O	['N']	[16]
17	and	O	['N']	[17]
18	functional	B	['N']	[18]
19	impairment	I-Adverse_Effect	['N']	[19]
20	;	O	['N']	[20]
21	he	O	['N']	[21]
22	died	O	['N']	[22]
23	of	O	['N']	[23]
24	ventricular	O	['N']	[24]
25	fibrillation	O	['N']	[25]
26	15	O	['N']	[26]
27	days	O	['N']	[27]
28	later	O	['N']	[28]
29	.	O	['N']	[29]
#3886
0	Both	O	['N']	[0]
1	had	O	['N']	[1]
2	impaired	B	['N']	[2]
3	lung	I	['N']	[3]
4	function	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	abnormal	O	['N']	[6]
7	computed	O	['N']	[7]
8	tomographic	O	['N']	[8]
9	scans	O	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	their	O	['N']	[12]
13	condition	O	['N']	[13]
14	improved	O	['N']	[14]
15	when	O	['N']	[15]
16	nitrofurantoin	B-Drug	['Causes']	[4]
17	was	O	['N']	[17]
18	withdrawn	O	['N']	[18]
19	and	O	['N']	[19]
20	corticosteroid	O	['N']	[20]
21	treatment	O	['N']	[21]
22	commenced	O	['N']	[22]
23	.	O	['N']	[23]
#3887
0	Despite	O	['N']	[0]
1	administration	O	['N']	[1]
2	of	O	['N']	[2]
3	phenytoin	O	['N']	[3]
4	and	O	['N']	[4]
5	lorazepam	O	['N']	[5]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	seizures	B-Adverse_Effect	['N']	[8]
9	persisted	O	['N']	[9]
10	and	O	['N']	[10]
11	occurred	O	['N']	[11]
12	only	O	['N']	[12]
13	during	O	['N']	[13]
14	amphotercin	B	['N']	[14]
15	B	I-Drug	['Causes']	[8]
16	administration	O	['N']	[16]
17	.	O	['N']	[17]
#3888
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	three	O	['N']	[3]
4	families	O	['N']	[4]
5	in	O	['N']	[5]
6	whom	O	['N']	[6]
7	the	O	['N']	[7]
8	occurrence	O	['N']	[8]
9	of	O	['N']	[9]
10	FVS	B-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	all	O	['N']	[12]
13	the	O	['N']	[13]
14	siblings	O	['N']	[14]
15	strongly	O	['N']	[15]
16	suggests	O	['N']	[16]
17	hereditary	O	['N']	[17]
18	susceptibility	O	['N']	[18]
19	to	O	['N']	[19]
20	valproic	B	['N']	[20]
21	acid	I-Drug	['Causes']	[10]
22	-	O	['N']	[22]
23	induced	O	['N']	[23]
24	adverse	O	['N']	[24]
25	outcome	O	['N']	[25]
26	.	O	['N']	[26]
#3889
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	,	O	['N']	[2]
3	in	O	['N']	[3]
4	whom	O	['N']	[4]
5	tumour	O	['N']	[5]
6	overkill	O	['N']	[6]
7	by	O	['N']	[7]
8	cytotoxic	O	['N']	[8]
9	treatment	O	['N']	[9]
10	,	O	['N']	[10]
11	including	O	['N']	[11]
12	high	O	['N']	[12]
13	dose	O	['N']	[13]
14	methotrexate	B-Drug	['Causes']	[31]
15	with	O	['N']	[15]
16	folinic	O	['N']	[16]
17	acid	O	['N']	[17]
18	rescue	O	['N']	[18]
19	,	O	['N']	[19]
20	resulted	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	'	O	['N']	[23]
24	phosphate	O	['N']	[24]
25	shower	O	['N']	[25]
26	syndrome	O	['N']	[26]
27	'	O	['N']	[27]
28	(	O	['N']	[28]
29	hyper	B	['N']	[29]
30	-	I	['N']	[30]
31	uricaemia	I-Adverse_Effect	['N']	[31]
32	,	O	['N']	[32]
33	hyperkalaemia	O	['N']	[33]
34	and	O	['N']	[34]
35	hyperphosphataemia	O	['N']	[35]
36	with	O	['N']	[36]
37	hypocalcaemia	O	['N']	[37]
38	and	O	['N']	[38]
39	tetany	O	['N']	[39]
40	,	O	['N']	[40]
41	with	O	['N']	[41]
42	metabolic	O	['N']	[42]
43	acidosis	O	['N']	[43]
44	and	O	['N']	[44]
45	acute	O	['N']	[45]
46	renal	O	['N']	[46]
47	impairment	O	['N']	[47]
48	)	O	['N']	[48]
49	are	O	['N']	[49]
50	described	O	['N']	[50]
51	.	O	['N']	[51]
#3890
0	The	O	['N']	[0]
1	former	O	['N']	[1]
2	patient	O	['N']	[2]
3	had	O	['N']	[3]
4	complained	O	['N']	[4]
5	once	O	['N']	[5]
6	that	O	['N']	[6]
7	his	O	['N']	[7]
8	visual	B	['N']	[8]
9	acuity	I	['N']	[9]
10	had	I	['N']	[10]
11	decreased	I-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	the	O	['N']	[13]
14	termination	O	['N']	[14]
15	of	O	['N']	[15]
16	IFN	B-Drug	['Causes']	[11]
17	therapy	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	the	O	['N']	[20]
21	latter	O	['N']	[21]
22	patient	O	['N']	[22]
23	complained	O	['N']	[23]
24	twice	O	['N']	[24]
25	during	O	['N']	[25]
26	IFN	O	['N']	[26]
27	therapy	O	['N']	[27]
28	that	O	['N']	[28]
29	his	O	['N']	[29]
30	visual	O	['N']	[30]
31	acuity	O	['N']	[31]
32	had	O	['N']	[32]
33	decreased	O	['N']	[33]
34	.	O	['N']	[34]
#3891
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	aim	O	['N']	[3]
4	of	O	['N']	[4]
5	this	O	['N']	[5]
6	paper	O	['N']	[6]
7	is	O	['N']	[7]
8	to	O	['N']	[8]
9	describe	O	['N']	[9]
10	a	O	['N']	[10]
11	case	O	['N']	[11]
12	of	O	['N']	[12]
13	increased	B	['N']	[13]
14	libido	I-Adverse_Effect	['N']	[14]
15	during	O	['N']	[15]
16	fluvoxamine	B-Drug	['Causes']	[14]
17	therapy	O	['N']	[17]
18	.	O	['N']	[18]
#3892
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	paper	O	['N']	[2]
3	,	O	['N']	[3]
4	we	O	['N']	[4]
5	report	O	['N']	[5]
6	a	O	['N']	[6]
7	case	O	['N']	[7]
8	of	O	['N']	[8]
9	severe	B	['N']	[9]
10	hypercalcemia	I-Adverse_Effect	['N']	[10]
11	of	O	['N']	[11]
12	immobilization	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	40-year	O	['N']	[15]
16	-	O	['N']	[16]
17	old	O	['N']	[17]
18	hemodialyzed	O	['N']	[18]
19	woman	O	['N']	[19]
20	treated	O	['N']	[20]
21	by	O	['N']	[21]
22	cinacalcet	B	['N']	[22]
23	HCl	I-Drug	['Causes']	[10]
24	for	O	['N']	[24]
25	a	O	['N']	[25]
26	severe	O	['N']	[26]
27	HPTH	O	['N']	[27]
28	-	O	['N']	[28]
29	II	O	['N']	[29]
30	(	O	['N']	[30]
31	PTH>1,000	O	['N']	[31]
32	pg	O	['N']	[32]
33	/	O	['N']	[33]
34	mL	O	['N']	[34]
35	)	O	['N']	[35]
36	.	O	['N']	[36]
#3893
0	Myoclonus	O	['N']	[0]
1	was	O	['N']	[1]
2	induced	O	['N']	[2]
3	and	O	['N']	[3]
4	enhanced	O	['N']	[4]
5	by	O	['N']	[5]
6	L	B	['N']	[6]
7	-	I	['N']	[7]
8	dopa	I-Drug	['Causes']	[13]
9	,	O	['N']	[9]
10	developing	O	['N']	[10]
11	into	O	['N']	[11]
12	generalized	B	['N']	[12]
13	seizures	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#3894
0	The	O	['N']	[0]
1	present	O	['N']	[1]
2	report	O	['N']	[2]
3	suggests	O	['N']	[3]
4	that	O	['N']	[4]
5	clarithromycin	O	['N']	[5]
6	coadministration	O	['N']	[6]
7	induces	O	['N']	[7]
8	increased	O	['N']	[8]
9	plasma	O	['N']	[9]
10	carbamazepine	B-Drug	['Causes']	[18]
11	concentrations	O	['N']	[11]
12	,	O	['N']	[12]
13	which	O	['N']	[13]
14	may	O	['N']	[14]
15	result	O	['N']	[15]
16	in	O	['N']	[16]
17	carbamazepine	B	['N']	[17]
18	toxicity	I-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#3895
0	The	O	['N']	[0]
1	cause	O	['N']	[1]
2	of	O	['N']	[2]
3	these	O	['N']	[3]
4	previously	O	['N']	[4]
5	unreported	O	['N']	[5]
6	side	O	['N']	[6]
7	effects	O	['N']	[7]
8	of	O	['N']	[8]
9	niacin	B-Drug	['Causes']	[21]
10	therapy	O	['N']	[10]
11	is	O	['N']	[11]
12	uncertain	O	['N']	[12]
13	but	O	['N']	[13]
14	may	O	['N']	[14]
15	be	O	['N']	[15]
16	related	O	['N']	[16]
17	to	O	['N']	[17]
18	prostaglandin	B	['N']	[18]
19	-	I	['N']	[19]
20	mediated	I	['N']	[20]
21	vasodilatation	I-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	hyperalgesia	O	['N']	[23]
24	of	O	['N']	[24]
25	sensory	O	['N']	[25]
26	nerve	O	['N']	[26]
27	receptors	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	potentiation	O	['N']	[30]
31	of	O	['N']	[31]
32	inflammation	O	['N']	[32]
33	in	O	['N']	[33]
34	the	O	['N']	[34]
35	gingiva	O	['N']	[35]
36	with	O	['N']	[36]
37	referral	O	['N']	[37]
38	of	O	['N']	[38]
39	pain	O	['N']	[39]
40	to	O	['N']	[40]
41	the	O	['N']	[41]
42	teeth	O	['N']	[42]
43	.	O	['N']	[43]
#3896
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	renal	O	['N']	[3]
4	transplant	O	['N']	[4]
5	recipient	O	['N']	[5]
6	maintained	O	['N']	[6]
7	on	O	['N']	[7]
8	cyclosporine	B-Drug	['Causes']	[15]
9	and	O	['N']	[9]
10	prednisone	O	['N']	[10]
11	developing	O	['N']	[11]
12	Nocardia	B	['N']	[12]
13	Asteroides	I	['N']	[13]
14	brain	I	['N']	[14]
15	abscess	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#3897
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	in	O	['N']	[2]
3	the	O	['N']	[3]
4	mid	O	['N']	[4]
5	-	O	['N']	[5]
6	to	O	['N']	[6]
7	-	O	['N']	[7]
8	late	O	['N']	[8]
9	1980s	O	['N']	[9]
10	,	O	['N']	[10]
11	a	O	['N']	[11]
12	series	O	['N']	[12]
13	of	O	['N']	[13]
14	letters	O	['N']	[14]
15	to	O	['N']	[15]
16	the	O	['N']	[16]
17	editor	O	['N']	[17]
18	and	O	['N']	[18]
19	case	O	['N']	[19]
20	reports	O	['N']	[20]
21	announced	O	['N']	[21]
22	an	O	['N']	[22]
23	association	O	['N']	[23]
24	between	O	['N']	[24]
25	tamoxifen	B-Drug	['Causes']	[37]
26	therapy	O	['N']	[26]
27	in	O	['N']	[27]
28	women	O	['N']	[28]
29	with	O	['N']	[29]
30	breast	O	['N']	[30]
31	cancer	O	['N']	[31]
32	and	O	['N']	[32]
33	the	O	['N']	[33]
34	development	O	['N']	[34]
35	of	O	['N']	[35]
36	endometrial	B	['N']	[36]
37	carcinoma	I-Adverse_Effect	['N']	[37]
38	.	O	['N']	[38]
#3898
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	is	O	['N']	[2]
3	reported	O	['N']	[3]
4	of	O	['N']	[4]
5	theophylline	B	['N']	[5]
6	intoxication	I-Adverse_Effect	['N']	[6]
7	due	O	['N']	[7]
8	to	O	['N']	[8]
9	a	O	['N']	[9]
10	dramatic	O	['N']	[10]
11	decrease	O	['N']	[11]
12	in	O	['N']	[12]
13	theophylline	O	['N']	[13]
14	clearance	O	['N']	[14]
15	following	O	['N']	[15]
16	concomitant	O	['N']	[16]
17	administration	O	['N']	[17]
18	of	O	['N']	[18]
19	viloxazine	B-Drug	['Causes']	[6]
20	.	O	['N']	[20]
#3899
0	Gabapentin	B-Drug	['Causes']	[4]
1	toxicity	O	['N']	[1]
2	in	O	['N']	[2]
3	renal	B	['N']	[3]
4	failure	I-Adverse_Effect	['N']	[4]
5	:	O	['N']	[5]
6	the	O	['N']	[6]
7	importance	O	['N']	[7]
8	of	O	['N']	[8]
9	dose	O	['N']	[9]
10	adjustment	O	['N']	[10]
11	.	O	['N']	[11]
#3900
0	Since	O	['N']	[0]
1	amiodarone	B-Drug	['Causes']	[16]
2	was	O	['N']	[2]
3	first	O	['N']	[3]
4	marketed	O	['N']	[4]
5	in	O	['N']	[5]
6	1992	O	['N']	[6]
7	in	O	['N']	[7]
8	Japan	O	['N']	[8]
9	,	O	['N']	[9]
10	the	O	['N']	[10]
11	incidence	O	['N']	[11]
12	of	O	['N']	[12]
13	amiodarone	O	['N']	[13]
14	-	O	['N']	[14]
15	induced	O	['N']	[15]
16	thyrotoxicosis	B-Adverse_Effect	['N']	[16]
17	(	O	['N']	[17]
18	AIT	O	['N']	[18]
19	)	O	['N']	[19]
20	has	O	['N']	[20]
21	been	O	['N']	[21]
22	increasing	O	['N']	[22]
23	.	O	['N']	[23]
#3901
0	Seventy	O	['N']	[0]
1	-	O	['N']	[1]
2	four	O	['N']	[2]
3	per	O	['N']	[3]
4	cent	O	['N']	[4]
5	of	O	['N']	[5]
6	patients	O	['N']	[6]
7	with	O	['N']	[7]
8	epileptogenic	O	['N']	[8]
9	disorders	O	['N']	[9]
10	seen	O	['N']	[10]
11	at	O	['N']	[11]
12	the	O	['N']	[12]
13	Emergency	O	['N']	[13]
14	Unit	O	['N']	[14]
15	at	O	['N']	[15]
16	Groote	O	['N']	[16]
17	Schuur	O	['N']	[17]
18	Hospital	O	['N']	[18]
19	were	O	['N']	[19]
20	on	O	['N']	[20]
21	phenytoin	B-Drug	['Causes']	[33]
22	and	O	['N']	[22]
23	11.6	O	['N']	[23]
24	%	O	['N']	[24]
25	of	O	['N']	[25]
26	these	O	['N']	[26]
27	had	O	['N']	[27]
28	blood	B	['N']	[28]
29	levels	I	['N']	[29]
30	in	I	['N']	[30]
31	the	I	['N']	[31]
32	toxic	I	['N']	[32]
33	range	I-Adverse_Effect	['N']	[33]
34	.	O	['N']	[34]
#3902
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	87-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	white	O	['N']	[9]
10	woman	O	['N']	[10]
11	with	O	['N']	[11]
12	myasthenia	O	['N']	[12]
13	gravis	O	['N']	[13]
14	who	O	['N']	[14]
15	presented	O	['N']	[15]
16	with	O	['N']	[16]
17	nausea	B-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	shortness	O	['N']	[19]
20	of	O	['N']	[20]
21	breath	O	['N']	[21]
22	,	O	['N']	[22]
23	azotemia	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	hyperkalemia	O	['N']	[26]
27	shortly	O	['N']	[27]
28	after	O	['N']	[28]
29	completing	O	['N']	[29]
30	a	O	['N']	[30]
31	course	O	['N']	[31]
32	of	O	['N']	[32]
33	intravenous	O	['N']	[33]
34	immunoglobulin	O	['N']	[34]
35	(	O	['N']	[35]
36	IVIG	B-Drug	['Causes']	[17]
37	)	O	['N']	[37]
38	.	O	['N']	[38]
#3903
0	We	O	['N']	[0]
1	conclude	O	['N']	[1]
2	that	O	['N']	[2]
3	while	O	['N']	[3]
4	thrombocytopenia	O	['N']	[4]
5	and	O	['N']	[5]
6	schistocytosis	B-Adverse_Effect	['N']	[6]
7	can	O	['N']	[7]
8	be	O	['N']	[8]
9	seen	O	['N']	[9]
10	in	O	['N']	[10]
11	quinine	B-Drug	['Causes']	[6]
12	-	O	['N']	[12]
13	associated	O	['N']	[13]
14	TTP	O	['N']	[14]
15	/	O	['N']	[15]
16	HUS	O	['N']	[16]
17	,	O	['N']	[17]
18	the	O	['N']	[18]
19	pathophysiology	O	['N']	[19]
20	seems	O	['N']	[20]
21	to	O	['N']	[21]
22	be	O	['N']	[22]
23	distinct	O	['N']	[23]
24	from	O	['N']	[24]
25	that	O	['N']	[25]
26	seen	O	['N']	[26]
27	in	O	['N']	[27]
28	most	O	['N']	[28]
29	cases	O	['N']	[29]
30	of	O	['N']	[30]
31	idiopathic	O	['N']	[31]
32	TTP	O	['N']	[32]
33	(	O	['N']	[33]
34	i.e.	O	['N']	[34]
35	,	O	['N']	[35]
36	severely	O	['N']	[36]
37	decreased	O	['N']	[37]
38	ADAMTS13	O	['N']	[38]
39	with	O	['N']	[39]
40	an	O	['N']	[40]
41	inhibitor	O	['N']	[41]
42	)	O	['N']	[42]
43	.	O	['N']	[43]
#3904
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	Erythema	B	['N']	[3]
4	Multiforme	I	['N']	[4]
5	Bullosum	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	patient	O	['N']	[7]
8	of	O	['N']	[8]
9	lepromatous	O	['N']	[9]
10	leprosy	O	['N']	[10]
11	with	O	['N']	[11]
12	pulmonary	O	['N']	[12]
13	tuberculosis	O	['N']	[13]
14	due	O	['N']	[14]
15	to	O	['N']	[15]
16	Rifampicin	B-Drug	['Causes']	[5]
17	is	O	['N']	[17]
18	described	O	['N']	[18]
19	.	O	['N']	[19]
#3905
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	administered	O	['N']	[2]
3	metoclopramide	B-Drug	['Causes']	[16]
4	because	O	['N']	[4]
5	of	O	['N']	[5]
6	nausea	O	['N']	[6]
7	and	O	['N']	[7]
8	,	O	['N']	[8]
9	within	O	['N']	[9]
10	2	O	['N']	[10]
11	hours	O	['N']	[11]
12	,	O	['N']	[12]
13	developed	O	['N']	[13]
14	agitation	O	['N']	[14]
15	,	O	['N']	[15]
16	dysarthria	B-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	diaphoresis	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	a	O	['N']	[21]
22	movement	O	['N']	[22]
23	disorder	O	['N']	[23]
24	.	O	['N']	[24]
#3906
0	Destructive	O	['N']	[0]
1	thyrotoxicosis	B-Adverse_Effect	['N']	[1]
2	appeared	O	['N']	[2]
3	4	O	['N']	[3]
4	-	O	['N']	[4]
5	6	O	['N']	[5]
6	months	O	['N']	[6]
7	after	O	['N']	[7]
8	starting	O	['N']	[8]
9	IFN	B	['N']	[9]
10	-	I	['N']	[10]
11	alpha	I-Drug	['Causes']	[1]
12	,	O	['N']	[12]
13	followed	O	['N']	[13]
14	by	O	['N']	[14]
15	Graves	O	['N']	[15]
16	'	O	['N']	[16]
17	hyperthyroidism	O	['N']	[17]
18	within	O	['N']	[18]
19	8	O	['N']	[19]
20	to	O	['N']	[20]
21	11	O	['N']	[21]
22	months	O	['N']	[22]
23	.	O	['N']	[23]
#3907
0	The	O	['N']	[0]
1	first	O	['N']	[1]
2	patient	O	['N']	[2]
3	developed	O	['N']	[3]
4	a	O	['N']	[4]
5	monoarthritis	B-Adverse_Effect	['N']	[5]
6	2	O	['N']	[6]
7	weeks	O	['N']	[7]
8	after	O	['N']	[8]
9	initiation	O	['N']	[9]
10	of	O	['N']	[10]
11	IFN	B	['N']	[11]
12	-	I	['N']	[12]
13	beta	I-Drug	['Causes']	[5]
14	,	O	['N']	[14]
15	which	O	['N']	[15]
16	persisted	O	['N']	[16]
17	during	O	['N']	[17]
18	the	O	['N']	[18]
19	14	O	['N']	[19]
20	months	O	['N']	[20]
21	of	O	['N']	[21]
22	therapy	O	['N']	[22]
23	and	O	['N']	[23]
24	resolved	O	['N']	[24]
25	with	O	['N']	[25]
26	discontinuation	O	['N']	[26]
27	of	O	['N']	[27]
28	the	O	['N']	[28]
29	medication	O	['N']	[29]
30	.	O	['N']	[30]
#3908
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	the	O	['N']	[4]
5	clinical	O	['N']	[5]
6	and	O	['N']	[6]
7	electrophysiological	O	['N']	[7]
8	findings	O	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	young	O	['N']	[11]
12	boy	O	['N']	[12]
13	with	O	['N']	[13]
14	decreased	B	['N']	[14]
15	vision	I-Adverse_Effect	['N']	[15]
16	possibly	O	['N']	[16]
17	due	O	['N']	[17]
18	to	O	['N']	[18]
19	retinal	O	['N']	[19]
20	damage	O	['N']	[20]
21	by	O	['N']	[21]
22	rifabutin	B-Drug	['Causes']	[15]
23	.	O	['N']	[23]
#3909
0	Although	O	['N']	[0]
1	the	O	['N']	[1]
2	data	O	['N']	[2]
3	indicate	O	['N']	[3]
4	an	O	['N']	[4]
5	immune	O	['N']	[5]
6	-	O	['N']	[6]
7	complex	O	['N']	[7]
8	cause	O	['N']	[8]
9	for	O	['N']	[9]
10	gold	B	['N']	[10]
11	-	I	['N']	[11]
12	salt	I-Drug	['Causes']	[13]
13	nephropathy	B-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	the	O	['N']	[15]
16	incident	O	['N']	[16]
17	antigen	O	['N']	[17]
18	(	O	['N']	[18]
19	or	O	['N']	[19]
20	antigens	O	['N']	[20]
21	)	O	['N']	[21]
22	and	O	['N']	[22]
23	mechanism	O	['N']	[23]
24	of	O	['N']	[24]
25	action	O	['N']	[25]
26	remain	O	['N']	[26]
27	unidentified	O	['N']	[27]
28	.	O	['N']	[28]
#3910
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	piloerection	B-Adverse_Effect	['N']	[3]
4	observed	O	['N']	[4]
5	after	O	['N']	[5]
6	the	O	['N']	[6]
7	replacement	O	['N']	[7]
8	of	O	['N']	[8]
9	fluvoxamine	O	['N']	[9]
10	with	O	['N']	[10]
11	milnacipran	B-Drug	['Causes']	[3]
12	in	O	['N']	[12]
13	this	O	['N']	[13]
14	patient	O	['N']	[14]
15	appears	O	['N']	[15]
16	to	O	['N']	[16]
17	have	O	['N']	[17]
18	been	O	['N']	[18]
19	due	O	['N']	[19]
20	to	O	['N']	[20]
21	an	O	['N']	[21]
22	increase	O	['N']	[22]
23	in	O	['N']	[23]
24	the	O	['N']	[24]
25	alpha(1)-adrenoceptor	O	['N']	[25]
26	occupancy	O	['N']	[26]
27	by	O	['N']	[27]
28	endogenous	O	['N']	[28]
29	norepinephrine	O	['N']	[29]
30	induced	O	['N']	[30]
31	by	O	['N']	[31]
32	milnacipran	O	['N']	[32]
33	.	O	['N']	[33]
#3911
0	Divalproex	B	['N']	[0]
1	sodium	I-Drug	['Causes']	[6]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	eosinophilic	B	['N']	[4]
5	pleural	I	['N']	[5]
6	effusion	I-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#3912
0	Basilar	O	['N']	[0]
1	invagination	O	['N']	[1]
2	and	O	['N']	[2]
3	mid	B	['N']	[3]
4	-	I	['N']	[4]
5	line	I	['N']	[5]
6	skeletal	I	['N']	[6]
7	abnormalities	I-Adverse_Effect	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	in	O	['N']	[10]
11	utero	O	['N']	[11]
12	exposure	O	['N']	[12]
13	to	O	['N']	[13]
14	phenytoin	B-Drug	['Causes']	[7]
15	.	O	['N']	[15]
#3913
0	DATA	O	['N']	[0]
1	SYNTHESIS	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	49-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	man	O	['N']	[7]
8	developed	O	['N']	[8]
9	symptoms	O	['N']	[9]
10	of	O	['N']	[10]
11	severe	B	['N']	[11]
12	psychosis	I-Adverse_Effect	['N']	[12]
13	concomitant	O	['N']	[13]
14	with	O	['N']	[14]
15	ciprofloxacin	B-Drug	['Causes']	[12]
16	(	O	['N']	[16]
17	250	O	['N']	[17]
18	mg	O	['N']	[18]
19	bid	O	['N']	[19]
20	)	O	['N']	[20]
21	treatment	O	['N']	[21]
22	.	O	['N']	[22]
#3914
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	advanced	O	['N']	[5]
6	colonic	O	['N']	[6]
7	carcinoma	O	['N']	[7]
8	who	O	['N']	[8]
9	was	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	concomitant	O	['N']	[12]
13	chemoirradiation	O	['N']	[13]
14	with	O	['N']	[14]
15	oxaliplatin	B-Drug	['Causes']	[20]
16	and	O	['N']	[16]
17	developed	O	['N']	[17]
18	a	O	['N']	[18]
19	peculiar	O	['N']	[19]
20	dermnatitis	B-Adverse_Effect	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	irradiated	O	['N']	[23]
24	field	O	['N']	[24]
25	after	O	['N']	[25]
26	being	O	['N']	[26]
27	exposed	O	['N']	[27]
28	to	O	['N']	[28]
29	subsequent	O	['N']	[29]
30	chemotherapy	O	['N']	[30]
31	with	O	['N']	[31]
32	oxaliplatin	O	['N']	[32]
33	.	O	['N']	[33]
#3915
0	In	O	['N']	[0]
1	association	O	['N']	[1]
2	with	O	['N']	[2]
3	this	O	['N']	[3]
4	tocolysis	O	['N']	[4]
5	,	O	['N']	[5]
6	urinary	B	['N']	[6]
7	calculus	I-Adverse_Effect	['N']	[7]
8	of	O	['N']	[8]
9	magnesium	B	['N']	[9]
10	ammonium	I	['N']	[10]
11	phosphate	I-Drug	['Causes']	[7]
12	occurred	O	['N']	[12]
13	at	O	['N']	[13]
14	34	O	['N']	[14]
15	weeks	O	['N']	[15]
16	gestation	O	['N']	[16]
17	.	O	['N']	[17]
#3916
0	Because	O	['N']	[0]
1	of	O	['N']	[1]
2	serious	O	['N']	[2]
3	side	O	['N']	[3]
4	effects	O	['N']	[4]
5	of	O	['N']	[5]
6	an	O	['N']	[6]
7	increase	B	['N']	[7]
8	in	I	['N']	[8]
9	the	I	['N']	[9]
10	QT	I	['N']	[10]
11	interval	I-Adverse_Effect	['N']	[11]
12	causing	O	['N']	[12]
13	torsades	O	['N']	[13]
14	de	O	['N']	[14]
15	pointes	O	['N']	[15]
16	,	O	['N']	[16]
17	dofetilide	B-Drug	['Causes']	[11]
18	must	O	['N']	[18]
19	be	O	['N']	[19]
20	initiated	O	['N']	[20]
21	with	O	['N']	[21]
22	close	O	['N']	[22]
23	monitoring	O	['N']	[23]
24	of	O	['N']	[24]
25	the	O	['N']	[25]
26	QT	O	['N']	[26]
27	interval	O	['N']	[27]
28	in	O	['N']	[28]
29	an	O	['N']	[29]
30	inpatient	O	['N']	[30]
31	setting	O	['N']	[31]
32	.	O	['N']	[32]
#3917
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	seizure	B-Adverse_Effect	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	L	B	['N']	[8]
9	-	I	['N']	[9]
10	asparaginase	I-Drug	['Causes']	[5]
11	therapy	O	['N']	[11]
12	but	O	['N']	[12]
13	no	O	['N']	[13]
14	evidence	O	['N']	[14]
15	of	O	['N']	[15]
16	hemorrhagic	O	['N']	[16]
17	or	O	['N']	[17]
18	thrombotic	O	['N']	[18]
19	cerebrovascular	O	['N']	[19]
20	events	O	['N']	[20]
21	.	O	['N']	[21]
#3918
0	CASE	O	['N']	[0]
1	SUMMARIES	O	['N']	[1]
2	:	O	['N']	[2]
3	While	O	['N']	[3]
4	conducting	O	['N']	[4]
5	a	O	['N']	[5]
6	protocol	O	['N']	[6]
7	evaluating	O	['N']	[7]
8	the	O	['N']	[8]
9	efficacy	O	['N']	[9]
10	of	O	['N']	[10]
11	intraperitoneal	O	['N']	[11]
12	cisplatin	B-Drug	['Causes']	[30]
13	and	O	['N']	[13]
14	hyperthermia	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	treatment	O	['N']	[17]
18	of	O	['N']	[18]
19	recurrent	O	['N']	[19]
20	ovarian	O	['N']	[20]
21	cancer	O	['N']	[21]
22	,	O	['N']	[22]
23	3	O	['N']	[23]
24	patients	O	['N']	[24]
25	were	O	['N']	[25]
26	noted	O	['N']	[26]
27	to	O	['N']	[27]
28	exhibit	O	['N']	[28]
29	anaphylactoid	B	['N']	[29]
30	reactions	I-Adverse_Effect	['N']	[30]
31	.	O	['N']	[31]
#3919
0	Patients	O	['N']	[0]
1	treated	O	['N']	[1]
2	with	O	['N']	[2]
3	captopril	B-Drug	['Causes']	[19]
4	who	O	['N']	[4]
5	develop	O	['N']	[5]
6	"	O	['N']	[6]
7	atypical	O	['N']	[7]
8	cholangitis	O	['N']	[8]
9	"	O	['N']	[9]
10	should	O	['N']	[10]
11	be	O	['N']	[11]
12	suspected	O	['N']	[12]
13	of	O	['N']	[13]
14	having	O	['N']	[14]
15	captopril	O	['N']	[15]
16	-	O	['N']	[16]
17	associated	O	['N']	[17]
18	liver	B	['N']	[18]
19	damage	I-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#3920
0	A	O	['N']	[0]
1	54-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	,	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	amiodarone	B-Drug	['Causes']	[11]
9	,	O	['N']	[9]
10	developed	O	['N']	[10]
11	thyrotoxicosis	B-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#3921
0	Nine	O	['N']	[0]
1	azotemic	O	['N']	[1]
2	patients	O	['N']	[2]
3	who	O	['N']	[3]
4	developed	O	['N']	[4]
5	a	O	['N']	[5]
6	coagulopathy	B-Adverse_Effect	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	the	O	['N']	[9]
10	use	O	['N']	[10]
11	of	O	['N']	[11]
12	either	O	['N']	[12]
13	cephalosporin	O	['N']	[13]
14	or	O	['N']	[14]
15	moxalactam	B-Drug	['Causes']	[6]
16	antibiotics	O	['N']	[16]
17	are	O	['N']	[17]
18	reported	O	['N']	[18]
19	.	O	['N']	[19]
#3922
0	Eleven	O	['N']	[0]
1	patients	O	['N']	[1]
2	developed	O	['N']	[2]
3	infection	O	['N']	[3]
4	requiring	O	['N']	[4]
5	hospitalization	O	['N']	[5]
6	while	O	['N']	[6]
7	taking	O	['N']	[7]
8	leflunomide	B-Drug	['Causes']	[26]
9	including	O	['N']	[9]
10	:	O	['N']	[10]
11	lower	O	['N']	[11]
12	respiratory	O	['N']	[12]
13	tract	O	['N']	[13]
14	infections	O	['N']	[14]
15	(	O	['N']	[15]
16	3	O	['N']	[16]
17	)	O	['N']	[17]
18	,	O	['N']	[18]
19	cellulitis	O	['N']	[19]
20	(	O	['N']	[20]
21	2	O	['N']	[21]
22	)	O	['N']	[22]
23	,	O	['N']	[23]
24	disseminated	B	['N']	[24]
25	herpes	I	['N']	[25]
26	zoster	I-Adverse_Effect	['N']	[26]
27	(	O	['N']	[27]
28	2	O	['N']	[28]
29	)	O	['N']	[29]
30	,	O	['N']	[30]
31	probable	O	['N']	[31]
32	TB	O	['N']	[32]
33	liver	O	['N']	[33]
34	(	O	['N']	[34]
35	1	O	['N']	[35]
36	)	O	['N']	[36]
37	,	O	['N']	[37]
38	abdominal	O	['N']	[38]
39	sepsis	O	['N']	[39]
40	(	O	['N']	[40]
41	1	O	['N']	[41]
42	)	O	['N']	[42]
43	,	O	['N']	[43]
44	mycotic	O	['N']	[44]
45	aneurysm	O	['N']	[45]
46	(	O	['N']	[46]
47	1	O	['N']	[47]
48	)	O	['N']	[48]
49	and	O	['N']	[49]
50	gastroenteritis	O	['N']	[50]
51	(	O	['N']	[51]
52	1	O	['N']	[52]
53	)	O	['N']	[53]
54	.	O	['N']	[54]
#3923
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	polyserositis	O	['N']	[9]
10	(	O	['N']	[10]
11	pericardial	O	['N']	[11]
12	effusion	O	['N']	[12]
13	,	O	['N']	[13]
14	pleural	O	['N']	[14]
15	effusion	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	pericarditis	B-Adverse_Effect	['N']	[18]
19	)	O	['N']	[19]
20	after	O	['N']	[20]
21	being	O	['N']	[21]
22	started	O	['N']	[22]
23	on	O	['N']	[23]
24	clozapine	B-Drug	['Causes']	[18]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	whose	O	['N']	[27]
28	symptoms	O	['N']	[28]
29	remitted	O	['N']	[29]
30	upon	O	['N']	[30]
31	discontinuation	O	['N']	[31]
32	of	O	['N']	[32]
33	clozapine	O	['N']	[33]
34	.	O	['N']	[34]
#3924
0	While	O	['N']	[0]
1	both	O	['N']	[1]
2	amiodarone	O	['N']	[2]
3	and	O	['N']	[3]
4	digoxin	B-Drug	['Causes']	[9]
5	can	O	['N']	[5]
6	cause	O	['N']	[6]
7	permanent	O	['N']	[7]
8	visual	B	['N']	[8]
9	changes	I-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	the	O	['N']	[11]
12	ocular	O	['N']	[12]
13	effects	O	['N']	[13]
14	are	O	['N']	[14]
15	often	O	['N']	[15]
16	reversible	O	['N']	[16]
17	.	O	['N']	[17]
#3925
0	One	O	['N']	[0]
1	other	O	['N']	[1]
2	patient	O	['N']	[2]
3	on	O	['N']	[3]
4	digoxin	B-Drug	['Causes']	[10]
5	stopped	O	['N']	[5]
6	taking	O	['N']	[6]
7	it	O	['N']	[7]
8	and	O	['N']	[8]
9	developed	O	['N']	[9]
10	cardiomyopathy	B-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#3926
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Interferon	O	['N']	[2]
3	(	O	['N']	[3]
4	IFN)-associated	-	['N']	[4]
5	retinopathy	O	['N']	[5]
6	is	O	['N']	[6]
7	typically	O	['N']	[7]
8	characterized	O	['N']	[8]
9	by	O	['N']	[9]
10	retinal	O	['N']	[10]
11	hemorrhages	O	['N']	[11]
12	and	O	['N']	[12]
13	cotton	B	['N']	[13]
14	wool	I	['N']	[14]
15	spots	I-Adverse_Effect	['N']	[15]
16	at	O	['N']	[16]
17	the	O	['N']	[17]
18	posterior	O	['N']	[18]
19	fundus	O	['N']	[19]
20	,	O	['N']	[20]
21	but	O	['N']	[21]
22	visual	O	['N']	[22]
23	function	O	['N']	[23]
24	is	O	['N']	[24]
25	usually	O	['N']	[25]
26	maintained	O	['N']	[26]
27	.	O	['N']	[27]
#3927
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	on	O	['N']	[2]
3	long	O	['N']	[3]
4	-	O	['N']	[4]
5	term	O	['N']	[5]
6	lithium	B-Drug	['Causes']	[11]
7	therapy	O	['N']	[7]
8	developed	O	['N']	[8]
9	the	O	['N']	[9]
10	nephrotic	B	['N']	[10]
11	syndrome	I-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#3928
0	In	O	['N']	[0]
1	a	O	['N']	[1]
2	61-year	O	['N']	[2]
3	-	O	['N']	[3]
4	old	O	['N']	[4]
5	man	O	['N']	[5]
6	receiving	O	['N']	[6]
7	chronic	O	['N']	[7]
8	low	B	['N']	[8]
9	-	I	['N']	[9]
10	dosage	I-Dose	['N']	[10]
11	amiodarone	B-Drug	['Dosage']	[10]
12	an	O	['N']	[12]
13	interstitial	O	['N']	[13]
14	pneumopathy	O	['N']	[14]
15	was	O	['N']	[15]
16	observed	O	['N']	[16]
17	.	O	['N']	[17]
#3929
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	59-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	chronic	O	['N']	[8]
9	myeloid	O	['N']	[9]
10	leukemia	O	['N']	[10]
11	,	O	['N']	[11]
12	who	O	['N']	[12]
13	developed	O	['N']	[13]
14	severe	B	['N']	[14]
15	interstitial	I	['N']	[15]
16	lung	I	['N']	[16]
17	fibrosis	I-Adverse_Effect	['N']	[17]
18	after	O	['N']	[18]
19	short	O	['N']	[19]
20	term	O	['N']	[20]
21	and	O	['N']	[21]
22	sequential	O	['N']	[22]
23	treatment	O	['N']	[23]
24	with	O	['N']	[24]
25	melphalan	B-Drug	['Causes']	[17]
26	and	O	['N']	[26]
27	busulfan	O	['N']	[27]
28	.	O	['N']	[28]
#3930
0	Fatal	B	['N']	[0]
1	intravascular	I	['N']	[1]
2	autoimmune	I	['N']	[2]
3	hemolytic	I	['N']	[3]
4	anemia	I-Adverse_Effect	['N']	[4]
5	after	O	['N']	[5]
6	fludarabine	B-Drug	['Causes']	[4]
7	treatment	O	['N']	[7]
8	for	O	['N']	[8]
9	chronic	O	['N']	[9]
10	lymphocytic	O	['N']	[10]
11	leukemia	O	['N']	[11]
12	.	O	['N']	[12]
#3931
0	Anaphylactoid	B	['N']	[0]
1	reactions	I-Adverse_Effect	['N']	[1]
2	with	O	['N']	[2]
3	intraperitoneal	O	['N']	[3]
4	cisplatin	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#3932
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	this	O	['N']	[4]
5	is	O	['N']	[5]
6	the	O	['N']	[6]
7	first	O	['N']	[7]
8	case	O	['N']	[8]
9	of	O	['N']	[9]
10	spontaneous	O	['N']	[10]
11	remission	O	['N']	[11]
12	of	O	['N']	[12]
13	MTX	B-Drug	['Causes']	[17]
14	-	O	['N']	[14]
15	associated	O	['N']	[15]
16	gastric	B	['N']	[16]
17	LPD	I-Adverse_Effect	['N']	[17]
18	after	O	['N']	[18]
19	discontinuation	O	['N']	[19]
20	of	O	['N']	[20]
21	MTX	O	['N']	[21]
22	therapy	O	['N']	[22]
23	.	O	['N']	[23]
#3933
0	Behavioral	O	['N']	[0]
1	side	O	['N']	[1]
2	effects	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	clonazepam	B-Drug	['Causes']	[14]
6	may	O	['N']	[6]
7	include	O	['N']	[7]
8	agitation	O	['N']	[8]
9	,	O	['N']	[9]
10	aggression	O	['N']	[10]
11	,	O	['N']	[11]
12	hyperactivity	O	['N']	[12]
13	,	O	['N']	[13]
14	irritability	B-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	property	O	['N']	[16]
17	destruction	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	temper	O	['N']	[20]
21	tantrums	O	['N']	[21]
22	.	O	['N']	[22]
#3934
0	Intrathecal	O	['N']	[0]
1	methotrexate	B-Drug	['Causes']	[6]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	acute	B	['N']	[4]
5	cerebellar	I	['N']	[5]
6	syndrome	I-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#3935
0	Carboplatin	O	['N']	[0]
1	hypersensitivity	O	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	low	B	['N']	[4]
5	-	I	['N']	[5]
6	dose	I-Dose	['N']	[6]
7	paclitaxel	O	['N']	[7]
8	/	O	['N']	[8]
9	carboplatin	B-Drug	['Dosage']	[6]
10	in	O	['N']	[10]
11	multiple	O	['N']	[11]
12	platinum	O	['N']	[12]
13	-	O	['N']	[13]
14	treated	O	['N']	[14]
15	patients	O	['N']	[15]
16	with	O	['N']	[16]
17	recurrent	O	['N']	[17]
18	ovarian	O	['N']	[18]
19	cancer	O	['N']	[19]
20	.	O	['N']	[20]
#3936
0	Here	O	['N']	[0]
1	we	O	['N']	[1]
2	report	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	newly	O	['N']	[6]
7	diagnosed	O	['N']	[7]
8	acute	O	['N']	[8]
9	promyelocytic	O	['N']	[9]
10	leukemia	O	['N']	[10]
11	who	O	['N']	[11]
12	developed	O	['N']	[12]
13	acute	B	['N']	[13]
14	focal	I	['N']	[14]
15	myositis	I-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	synovitis	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	possible	O	['N']	[20]
21	vasculitis	O	['N']	[21]
22	,	O	['N']	[22]
23	after	O	['N']	[23]
24	receiving	O	['N']	[24]
25	all	B	['N']	[25]
26	-	I	['N']	[26]
27	trans	I	['N']	[27]
28	retinoic	I	['N']	[28]
29	acid	I-Drug	['Causes']	[15]
30	therapy	O	['N']	[30]
31	.	O	['N']	[31]
#3937
0	Hepatotoxicity	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	6-thioguanine	B-Drug	['Causes']	[0]
4	therapy	O	['N']	[4]
5	for	O	['N']	[5]
6	Crohn	O	['N']	[6]
7	's	O	['N']	[7]
8	disease	O	['N']	[8]
9	.	O	['N']	[9]
#3938
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	three	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	patients	O	['N']	[5]
6	who	O	['N']	[6]
7	developed	O	['N']	[7]
8	leukopenia	B-Adverse_Effect	['N']	[8]
9	during	O	['N']	[9]
10	olanzapine	B-Drug	['Causes']	[8]
11	treatment	O	['N']	[11]
12	.	O	['N']	[12]
#3939
0	Charcoal	O	['N']	[0]
1	haemoperfusion	O	['N']	[1]
2	and	O	['N']	[2]
3	cysteamine	O	['N']	[3]
4	therapy	O	['N']	[4]
5	led	O	['N']	[5]
6	to	O	['N']	[6]
7	the	O	['N']	[7]
8	rapid	O	['N']	[8]
9	removal	O	['N']	[9]
10	of	O	['N']	[10]
11	the	O	['N']	[11]
12	paracetamol	B-Drug	['Causes']	[24]
13	from	O	['N']	[13]
14	the	O	['N']	[14]
15	body	O	['N']	[15]
16	and	O	['N']	[16]
17	consequently	O	['N']	[17]
18	prevented	O	['N']	[18]
19	the	O	['N']	[19]
20	development	O	['N']	[20]
21	of	O	['N']	[21]
22	severe	B	['N']	[22]
23	hepatic	I	['N']	[23]
24	necrosis	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#3940
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	describe	O	['N']	[3]
4	the	O	['N']	[4]
5	ophthalmic	O	['N']	[5]
6	features	O	['N']	[6]
7	and	O	['N']	[7]
8	clinical	O	['N']	[8]
9	course	O	['N']	[9]
10	of	O	['N']	[10]
11	two	O	['N']	[11]
12	cases	O	['N']	[12]
13	of	O	['N']	[13]
14	acute	O	['N']	[14]
15	syphilitic	O	['N']	[15]
16	posterior	O	['N']	[16]
17	placoid	O	['N']	[17]
18	chorioretinitis	O	['N']	[18]
19	(	O	['N']	[19]
20	ASPPC	B-Adverse_Effect	['N']	[20]
21	)	O	['N']	[21]
22	that	O	['N']	[22]
23	developed	O	['N']	[23]
24	after	O	['N']	[24]
25	intravitreal	O	['N']	[25]
26	triamcinolone	O	['N']	[26]
27	acetonide	O	['N']	[27]
28	(	O	['N']	[28]
29	IVTA	B-Drug	['Causes']	[20]
30	)	O	['N']	[30]
31	injection	O	['N']	[31]
32	.	O	['N']	[32]
#3941
0	We	O	['N']	[0]
1	review	O	['N']	[1]
2	the	O	['N']	[2]
3	literature	O	['N']	[3]
4	on	O	['N']	[4]
5	previously	O	['N']	[5]
6	reported	O	['N']	[6]
7	cases	O	['N']	[7]
8	of	O	['N']	[8]
9	cutaneous	B	['N']	[9]
10	necrosis	I-Adverse_Effect	['N']	[10]
11	after	O	['N']	[11]
12	injection	O	['N']	[12]
13	of	O	['N']	[13]
14	standard	O	['N']	[14]
15	interferon	B	['N']	[15]
16	alfa	I-Drug	['Causes']	[10]
17	or	O	['N']	[17]
18	pegylated	O	['N']	[18]
19	interferon	O	['N']	[19]
20	alfa-2b	O	['N']	[20]
21	and	O	['N']	[21]
22	discuss	O	['N']	[22]
23	the	O	['N']	[23]
24	different	O	['N']	[24]
25	pathophysiologic	O	['N']	[25]
26	mechanisms	O	['N']	[26]
27	that	O	['N']	[27]
28	might	O	['N']	[28]
29	be	O	['N']	[29]
30	involved	O	['N']	[30]
31	.	O	['N']	[31]
#3942
0	Two	O	['N']	[0]
1	65-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	white	O	['N']	[4]
5	men	O	['N']	[5]
6	with	O	['N']	[6]
7	coronary	O	['N']	[7]
8	heart	O	['N']	[8]
9	disease	O	['N']	[9]
10	,	O	['N']	[10]
11	given	O	['N']	[11]
12	niacin	B-Drug	['Causes']	[25]
13	therapy	O	['N']	[13]
14	for	O	['N']	[14]
15	dyslipidemia	O	['N']	[15]
16	for	O	['N']	[16]
17	5	O	['N']	[17]
18	months	O	['N']	[18]
19	,	O	['N']	[19]
20	developed	O	['N']	[20]
21	intense	B	['N']	[21]
22	dental	I	['N']	[22]
23	and	I	['N']	[23]
24	gingival	I	['N']	[24]
25	pain	I-Adverse_Effect	['N']	[25]
26	that	O	['N']	[26]
27	was	O	['N']	[27]
28	associated	O	['N']	[28]
29	with	O	['N']	[29]
30	increases	O	['N']	[30]
31	in	O	['N']	[31]
32	dose	O	['N']	[32]
33	and	O	['N']	[33]
34	that	O	['N']	[34]
35	was	O	['N']	[35]
36	relieved	O	['N']	[36]
37	with	O	['N']	[37]
38	discontinuance	O	['N']	[38]
39	of	O	['N']	[39]
40	niacin	O	['N']	[40]
41	treatment	O	['N']	[41]
42	.	O	['N']	[42]
#3943
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	O	['N']	[19]
20	developed	O	['N']	[20]
21	confusion	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	agitation	O	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	O	['N']	[25]
26	,	O	['N']	[26]
27	tremors	O	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	O	['N']	[29]
30	jerks	O	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	O	['N']	[32]
33	gait	O	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	B-Drug	['Causes']	[21]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#3944
0	An	O	['N']	[0]
1	83-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	receiving	O	['N']	[5]
6	glipizide	O	['N']	[6]
7	10	B	['N']	[7]
8	mg	I-Dose	['N']	[8]
9	bid	O	['N']	[9]
10	developed	O	['N']	[10]
11	symptomatic	O	['N']	[11]
12	hypoglycemia	O	['N']	[12]
13	within	O	['N']	[13]
14	three	O	['N']	[14]
15	days	O	['N']	[15]
16	of	O	['N']	[16]
17	adding	O	['N']	[17]
18	trimethoprim	O	['N']	[18]
19	/	O	['N']	[19]
20	sulfamethoxazole	B-Drug	['Dosage']	[8]
21	(	O	['N']	[21]
22	TMP	O	['N']	[22]
23	/	O	['N']	[23]
24	SMX	O	['N']	[24]
25	)	O	['N']	[25]
26	to	O	['N']	[26]
27	his	O	['N']	[27]
28	regimen	O	['N']	[28]
29	.	O	['N']	[29]
#3945
0	Amiodarone	B	['N']	[0]
1	hydrochloride	I-Drug	['Causes']	[18]
2	,	O	['N']	[2]
3	a	O	['N']	[3]
4	new	O	['N']	[4]
5	antiarrhythmic	O	['N']	[5]
6	agent	O	['N']	[6]
7	,	O	['N']	[7]
8	has	O	['N']	[8]
9	been	O	['N']	[9]
10	associated	O	['N']	[10]
11	with	O	['N']	[11]
12	pulmonary	O	['N']	[12]
13	toxicity	O	['N']	[13]
14	characterized	O	['N']	[14]
15	by	O	['N']	[15]
16	cough	O	['N']	[16]
17	,	O	['N']	[17]
18	dyspnea	B-Adverse_Effect	['N']	[18]
19	and	O	['N']	[19]
20	diffuse	O	['N']	[20]
21	pulmonary	O	['N']	[21]
22	infiltrates	O	['N']	[22]
23	.	O	['N']	[23]
#3946
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	IDDM	B-Adverse_Effect	['N']	[5]
6	which	O	['N']	[6]
7	occurred	O	['N']	[7]
8	during	O	['N']	[8]
9	interferon	B-Drug	['Causes']	[5]
10	therapy	O	['N']	[10]
11	for	O	['N']	[11]
12	chronic	O	['N']	[12]
13	hepatitis	O	['N']	[13]
14	.	O	['N']	[14]
#3947
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	demonstrates	O	['N']	[2]
3	that	O	['N']	[3]
4	hypersensitivity	O	['N']	[4]
5	reaction	O	['N']	[5]
6	to	O	['N']	[6]
7	pranlukast	B-Drug	['Causes']	[10]
8	and	O	['N']	[8]
9	resultant	O	['N']	[9]
10	ATIN	B-Adverse_Effect	['N']	[10]
11	is	O	['N']	[11]
12	possible	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	that	O	['N']	[15]
16	periodic	O	['N']	[16]
17	urine	O	['N']	[17]
18	testing	O	['N']	[18]
19	in	O	['N']	[19]
20	patients	O	['N']	[20]
21	receiving	O	['N']	[21]
22	pranlukast	O	['N']	[22]
23	should	O	['N']	[23]
24	be	O	['N']	[24]
25	considered	O	['N']	[25]
26	.	O	['N']	[26]
#3948
0	A	O	['N']	[0]
1	dapsone	B-Drug	['Causes']	[21]
2	hypersensitivity	O	['N']	[2]
3	syndrome	O	['N']	[3]
4	,	O	['N']	[4]
5	consisting	O	['N']	[5]
6	of	O	['N']	[6]
7	fever	O	['N']	[7]
8	,	O	['N']	[8]
9	headache	O	['N']	[9]
10	,	O	['N']	[10]
11	nausea	O	['N']	[11]
12	,	O	['N']	[12]
13	vomiting	O	['N']	[13]
14	,	O	['N']	[14]
15	lymphadenopathy	O	['N']	[15]
16	,	O	['N']	[16]
17	hepatitis	O	['N']	[17]
18	,	O	['N']	[18]
19	hemolysis	O	['N']	[19]
20	,	O	['N']	[20]
21	leukopenia	B-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	mononucleosis	O	['N']	[24]
25	,	O	['N']	[25]
26	has	O	['N']	[26]
27	been	O	['N']	[27]
28	described	O	['N']	[28]
29	in	O	['N']	[29]
30	patients	O	['N']	[30]
31	treated	O	['N']	[31]
32	with	O	['N']	[32]
33	the	O	['N']	[33]
34	drug	O	['N']	[34]
35	for	O	['N']	[35]
36	leprosy	O	['N']	[36]
37	.	O	['N']	[37]
#3949
0	Possible	O	['N']	[0]
1	serotonin	B	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	clomipramine	O	['N']	[5]
6	after	O	['N']	[6]
7	withdrawal	O	['N']	[7]
8	of	O	['N']	[8]
9	clozapine	B-Drug	['Causes']	[2]
10	.	O	['N']	[10]
#3950
0	A	O	['N']	[0]
1	major	O	['N']	[1]
2	limitation	O	['N']	[2]
3	in	O	['N']	[3]
4	the	O	['N']	[4]
5	use	O	['N']	[5]
6	of	O	['N']	[6]
7	amphotericin	B	['N']	[7]
8	B	I-Drug	['Causes']	[14]
9	is	O	['N']	[9]
10	its	O	['N']	[10]
11	potential	O	['N']	[11]
12	to	O	['N']	[12]
13	cause	O	['N']	[13]
14	nephrotoxicity	B-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#3951
0	A	O	['N']	[0]
1	child	O	['N']	[1]
2	in	O	['N']	[2]
3	whom	O	['N']	[3]
4	a	O	['N']	[4]
5	phenobarbital	B-Drug	['Causes']	[19]
6	hypersensitivity	O	['N']	[6]
7	drug	O	['N']	[7]
8	reaction	O	['N']	[8]
9	developed	O	['N']	[9]
10	which	O	['N']	[10]
11	consisted	O	['N']	[11]
12	of	O	['N']	[12]
13	fever	O	['N']	[13]
14	,	O	['N']	[14]
15	a	B	['N']	[15]
16	pruritic	I	['N']	[16]
17	desquamating	I	['N']	[17]
18	erythrodermic	I	['N']	[18]
19	rash	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	alopecia	O	['N']	[21]
22	,	O	['N']	[22]
23	icterus	O	['N']	[23]
24	,	O	['N']	[24]
25	protein	O	['N']	[25]
26	-	O	['N']	[26]
27	losing	O	['N']	[27]
28	enteropathy	O	['N']	[28]
29	,	O	['N']	[29]
30	myositis	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	nephritis	O	['N']	[33]
34	,	O	['N']	[34]
35	is	O	['N']	[35]
36	described	O	['N']	[36]
37	.	O	['N']	[37]
#3952
0	Upper	B	['N']	[0]
1	gastrointestinal	I	['N']	[1]
2	haemorrhage	I-Adverse_Effect	['N']	[2]
3	is	O	['N']	[3]
4	a	O	['N']	[4]
5	serious	O	['N']	[5]
6	complication	O	['N']	[6]
7	of	O	['N']	[7]
8	aspirin	B-Drug	['Causes']	[2]
9	and	O	['N']	[9]
10	clopidogrel	O	['N']	[10]
11	(	O	['N']	[11]
12	dual	O	['N']	[12]
13	)	O	['N']	[13]
14	anti	O	['N']	[14]
15	-	O	['N']	[15]
16	platelet	O	['N']	[16]
17	therapy	O	['N']	[17]
18	with	O	['N']	[18]
19	a	O	['N']	[19]
20	high	O	['N']	[20]
21	morbidity	O	['N']	[21]
22	and	O	['N']	[22]
23	mortality	O	['N']	[23]
24	.	O	['N']	[24]
#3953
0	Its	O	['N']	[0]
1	overall	O	['N']	[1]
2	toxicity	O	['N']	[2]
3	is	O	['N']	[3]
4	considerably	O	['N']	[4]
5	less	O	['N']	[5]
6	compared	O	['N']	[6]
7	to	O	['N']	[7]
8	standard	O	['N']	[8]
9	induction	O	['N']	[9]
10	chemotherapy	O	['N']	[10]
11	;	O	['N']	[11]
12	however	O	['N']	[12]
13	,	O	['N']	[13]
14	it	O	['N']	[14]
15	is	O	['N']	[15]
16	associated	O	['N']	[16]
17	with	O	['N']	[17]
18	a	O	['N']	[18]
19	high	O	['N']	[19]
20	incidence	O	['N']	[20]
21	of	O	['N']	[21]
22	a	O	['N']	[22]
23	potentially	O	['N']	[23]
24	fatal	O	['N']	[24]
25	symptom	O	['N']	[25]
26	complex	O	['N']	[26]
27	referred	O	['N']	[27]
28	to	O	['N']	[28]
29	as	O	['N']	[29]
30	"	O	['N']	[30]
31	retinoic	B	['N']	[31]
32	acid	I-Drug	['Causes']	[33]
33	syndrome	I-Adverse_Effect	['N']	[33]
34	.	O	['N']	[34]
35	"	O	['N']	[35]
36	This	O	['N']	[36]
37	report	O	['N']	[37]
38	describes	O	['N']	[38]
39	a	O	['N']	[39]
40	patient	O	['N']	[40]
41	with	O	['N']	[41]
42	APL	O	['N']	[42]
43	who	O	['N']	[43]
44	developed	O	['N']	[44]
45	the	O	['N']	[45]
46	syndrome	O	['N']	[46]
47	a	O	['N']	[47]
48	few	O	['N']	[48]
49	weeks	O	['N']	[49]
50	after	O	['N']	[50]
51	initiating	O	['N']	[51]
52	induction	O	['N']	[52]
53	therapy	O	['N']	[53]
54	with	O	['N']	[54]
55	ATRA	O	['N']	[55]
56	despite	O	['N']	[56]
57	being	O	['N']	[57]
58	treated	O	['N']	[58]
59	for	O	['N']	[59]
60	hyperleukocytosis	O	['N']	[60]
61	.	O	['N']	[61]
#3954
0	The	O	['N']	[0]
1	renal	B	['N']	[1]
2	insufficiency	I-Adverse_Effect	['N']	[2]
3	of	O	['N']	[3]
4	three	O	['N']	[4]
5	patients	O	['N']	[5]
6	and	O	['N']	[6]
7	the	O	['N']	[7]
8	timing	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	seizures	O	['N']	[11]
12	implicate	O	['N']	[12]
13	accumulation	O	['N']	[13]
14	of	O	['N']	[14]
15	ofloxacin	B-Drug	['Causes']	[2]
16	as	O	['N']	[16]
17	a	O	['N']	[17]
18	contributing	O	['N']	[18]
19	factor	O	['N']	[19]
20	.	O	['N']	[20]
#3955
0	Painful	O	['N']	[0]
1	neutrophilic	B	['N']	[1]
2	skin	I	['N']	[2]
3	lesions	I-Adverse_Effect	['N']	[3]
4	were	O	['N']	[4]
5	observed	O	['N']	[5]
6	in	O	['N']	[6]
7	two	O	['N']	[7]
8	children	O	['N']	[8]
9	receiving	O	['N']	[9]
10	granulocyte	B	['N']	[10]
11	colony	I	['N']	[11]
12	-	I	['N']	[12]
13	stimulating	I	['N']	[13]
14	factor	I-Drug	['Causes']	[3]
15	(	O	['N']	[15]
16	G	O	['N']	[16]
17	-	O	['N']	[17]
18	CSF	O	['N']	[18]
19	)	O	['N']	[19]
20	for	O	['N']	[20]
21	treatment	O	['N']	[21]
22	of	O	['N']	[22]
23	idiopathic	O	['N']	[23]
24	neutropenia	O	['N']	[24]
25	.	O	['N']	[25]
#3956
0	Carboplatin	B-Drug	['Causes']	[1]
1	hypersensitivity	B-Adverse_Effect	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	low	O	['N']	[4]
5	-	O	['N']	[5]
6	dose	O	['N']	[6]
7	paclitaxel	O	['N']	[7]
8	/	O	['N']	[8]
9	carboplatin	O	['N']	[9]
10	in	O	['N']	[10]
11	multiple	O	['N']	[11]
12	platinum	O	['N']	[12]
13	-	O	['N']	[13]
14	treated	O	['N']	[14]
15	patients	O	['N']	[15]
16	with	O	['N']	[16]
17	recurrent	O	['N']	[17]
18	ovarian	O	['N']	[18]
19	cancer	O	['N']	[19]
20	.	O	['N']	[20]
#3957
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Clinicians	O	['N']	[2]
3	should	O	['N']	[3]
4	be	O	['N']	[4]
5	aware	O	['N']	[5]
6	of	O	['N']	[6]
7	this	O	['N']	[7]
8	adverse	O	['N']	[8]
9	reaction	O	['N']	[9]
10	when	O	['N']	[10]
11	facing	O	['N']	[11]
12	similar	O	['N']	[12]
13	complex	O	['N']	[13]
14	neurologic	B	['N']	[14]
15	symptoms	I-Adverse_Effect	['N']	[15]
16	in	O	['N']	[16]
17	patients	O	['N']	[17]
18	who	O	['N']	[18]
19	are	O	['N']	[19]
20	receiving	O	['N']	[20]
21	the	O	['N']	[21]
22	antibiotic	O	['N']	[22]
23	treatment	O	['N']	[23]
24	described	O	['N']	[24]
25	here	O	['N']	[25]
26	,	O	['N']	[26]
27	especially	O	['N']	[27]
28	vancomycin	B-Drug	['Causes']	[15]
29	.	O	['N']	[29]
#3958
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	there	O	['N']	[2]
3	remain	O	['N']	[3]
4	questions	O	['N']	[4]
5	concerning	O	['N']	[5]
6	whether	O	['N']	[6]
7	these	O	['N']	[7]
8	drugs	O	['N']	[8]
9	,	O	['N']	[9]
10	especially	O	['N']	[10]
11	methimazole	O	['N']	[11]
12	(	O	['N']	[12]
13	MMI	B-Drug	['Causes']	[22]
14	)	O	['N']	[14]
15	,	O	['N']	[15]
16	may	O	['N']	[16]
17	be	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	aplasia	B	['N']	[20]
21	cutis	I	['N']	[21]
22	congenita	I-Adverse_Effect	['N']	[22]
23	(	O	['N']	[23]
24	ACC	O	['N']	[24]
25	)	O	['N']	[25]
26	and	O	['N']	[26]
27	how	O	['N']	[27]
28	best	O	['N']	[28]
29	to	O	['N']	[29]
30	avoid	O	['N']	[30]
31	impairment	O	['N']	[31]
32	of	O	['N']	[32]
33	fetal	O	['N']	[33]
34	thyroid	O	['N']	[34]
35	function	O	['N']	[35]
36	during	O	['N']	[36]
37	their	O	['N']	[37]
38	use	O	['N']	[38]
39	.	O	['N']	[39]
#3959
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	skin	B	['N']	[23]
24	eruptions	I-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	cervical	O	['N']	[26]
27	lymphadenopathy	O	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	O	['N']	[31]
32	lymphocytosis	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	B-Drug	['Causes']	[24]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	O	['N']	[42]
43	(	O	['N']	[43]
44	SMX	O	['N']	[44]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#3960
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	rare	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	PTU	B-Drug	['Causes']	[15]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	ANCA	O	['N']	[9]
10	-	O	['N']	[10]
11	associated	O	['N']	[11]
12	vasculitis	O	['N']	[12]
13	manifested	O	['N']	[13]
14	with	O	['N']	[14]
15	ototoxicity	B-Adverse_Effect	['N']	[15]
16	in	O	['N']	[16]
17	combination	O	['N']	[17]
18	with	O	['N']	[18]
19	systemic	O	['N']	[19]
20	involvement	O	['N']	[20]
21	.	O	['N']	[21]
#3961
0	Ciprofloxacin	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hemorrhagic	B	['N']	[3]
4	vasculitis	I-Adverse_Effect	['N']	[4]
5	is	O	['N']	[5]
6	a	O	['N']	[6]
7	rare	O	['N']	[7]
8	side	O	['N']	[8]
9	effect	O	['N']	[9]
10	.	O	['N']	[10]
#3962
0	Drug	B	['N']	[0]
1	eruption	I-Adverse_Effect	['N']	[1]
2	caused	O	['N']	[2]
3	by	O	['N']	[3]
4	azathioprine	B-Drug	['Causes']	[1]
5	:	O	['N']	[5]
6	value	O	['N']	[6]
7	of	O	['N']	[7]
8	using	O	['N']	[8]
9	the	O	['N']	[9]
10	drug	O	['N']	[10]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	lymphocytes	O	['N']	[13]
14	stimulation	O	['N']	[14]
15	test	O	['N']	[15]
16	for	O	['N']	[16]
17	diagnosis	O	['N']	[17]
18	.	O	['N']	[18]
#3963
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	Wegener	O	['N']	[3]
4	's	O	['N']	[4]
5	granulomatosis	O	['N']	[5]
6	rapidly	O	['N']	[6]
7	developed	O	['N']	[7]
8	a	O	['N']	[8]
9	circumferential	B	['N']	[9]
10	subglottic	I	['N']	[10]
11	stenosis	I-Adverse_Effect	['N']	[11]
12	while	O	['N']	[12]
13	on	O	['N']	[13]
14	a	O	['N']	[14]
15	cyclophosphamide	B-Drug	['Causes']	[11]
16	regimen	O	['N']	[16]
17	that	O	['N']	[17]
18	had	O	['N']	[18]
19	caused	O	['N']	[19]
20	resolution	O	['N']	[20]
21	of	O	['N']	[21]
22	systemic	O	['N']	[22]
23	symptoms	O	['N']	[23]
24	and	O	['N']	[24]
25	pulmonary	O	['N']	[25]
26	infiltrates	O	['N']	[26]
27	.	O	['N']	[27]
#3964
0	In	O	['N']	[0]
1	a	O	['N']	[1]
2	postural	O	['N']	[2]
3	challenge	O	['N']	[3]
4	test	O	['N']	[4]
5	after	O	['N']	[5]
6	administration	O	['N']	[6]
7	of	O	['N']	[7]
8	isosorbide	B	['N']	[8]
9	dinitrate	I-Drug	['Causes']	[17]
10	(	O	['N']	[10]
11	5	O	['N']	[11]
12	mg	O	['N']	[12]
13	)	O	['N']	[13]
14	,	O	['N']	[14]
15	blood	B	['N']	[15]
16	pressure	I	['N']	[16]
17	decreased	I-Adverse_Effect	['N']	[17]
18	from	O	['N']	[18]
19	120/67	O	['N']	[19]
20	to	O	['N']	[20]
21	65/35	O	['N']	[21]
22	mmHg	O	['N']	[22]
23	,	O	['N']	[23]
24	followed	O	['N']	[24]
25	by	O	['N']	[25]
26	syncope	O	['N']	[26]
27	with	O	['N']	[27]
28	a	O	['N']	[28]
29	sudden	O	['N']	[29]
30	decrease	O	['N']	[30]
31	in	O	['N']	[31]
32	pulse	O	['N']	[32]
33	rate	O	['N']	[33]
34	from	O	['N']	[34]
35	85	O	['N']	[35]
36	to	O	['N']	[36]
37	60	O	['N']	[37]
38	beats	O	['N']	[38]
39	/	O	['N']	[39]
40	min	O	['N']	[40]
41	.	O	['N']	[41]
#3965
0	Angioedema	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	maculopapular	O	['N']	[2]
3	eruptions	O	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	carbamazepine	B-Drug	['Causes']	[0]
7	administration	O	['N']	[7]
8	.	O	['N']	[8]
#3966
0	Contact	B	['N']	[0]
1	dermatitis	I-Adverse_Effect	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	budesonide	B-Drug	['Causes']	[1]
5	:	O	['N']	[5]
6	report	O	['N']	[6]
7	of	O	['N']	[7]
8	five	O	['N']	[8]
9	cases	O	['N']	[9]
10	and	O	['N']	[10]
11	review	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	Japanese	O	['N']	[14]
15	literature	O	['N']	[15]
16	.	O	['N']	[16]
#3967
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	treated	O	['N']	[2]
3	with	O	['N']	[3]
4	5-fluorouracil	O	['N']	[4]
5	(	O	['N']	[5]
6	5-FU	B-Drug	['Causes']	[20]
7	)	O	['N']	[7]
8	for	O	['N']	[8]
9	disseminated	O	['N']	[9]
10	adenocarcinoma	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	colon	O	['N']	[13]
14	developed	O	['N']	[14]
15	cerebellar	O	['N']	[15]
16	dysfunction	O	['N']	[16]
17	typical	O	['N']	[17]
18	of	O	['N']	[18]
19	5-FU	O	['N']	[19]
20	neurotoxicity	B-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#3968
0	Carbamazepine	B	['N']	[0]
1	toxicity	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	Oxybutynin	O	['N']	[3]
4	and	O	['N']	[4]
5	Dantrolene	B-Drug	['Causes']	[1]
6	administration	O	['N']	[6]
7	:	O	['N']	[7]
8	a	O	['N']	[8]
9	case	O	['N']	[9]
10	report	O	['N']	[10]
11	.	O	['N']	[11]
#3969
0	Capecitabine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	multifocal	B	['N']	[3]
4	leukoencephalopathy	I-Adverse_Effect	['N']	[4]
5	:	O	['N']	[5]
6	a	O	['N']	[6]
7	report	O	['N']	[7]
8	of	O	['N']	[8]
9	five	O	['N']	[9]
10	cases	O	['N']	[10]
11	.	O	['N']	[11]
#3970
0	An	O	['N']	[0]
1	encephalopathy	O	['N']	[1]
2	and	O	['N']	[2]
3	cardiomyopathy	B-Adverse_Effect	['N']	[3]
4	developed	O	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	seventeen	O	['N']	[7]
8	-	O	['N']	[8]
9	year	O	['N']	[9]
10	-	O	['N']	[10]
11	old	O	['N']	[11]
12	girl	O	['N']	[12]
13	with	O	['N']	[13]
14	chemotherapy	O	['N']	[14]
15	-	O	['N']	[15]
16	induced	O	['N']	[16]
17	renal	O	['N']	[17]
18	failure	O	['N']	[18]
19	while	O	['N']	[19]
20	receiving	O	['N']	[20]
21	an	O	['N']	[21]
22	intravesical	O	['N']	[22]
23	aluminum	B-Drug	['Causes']	[3]
24	infusion	O	['N']	[24]
25	for	O	['N']	[25]
26	hemorrhagic	O	['N']	[26]
27	cystitis	O	['N']	[27]
28	.	O	['N']	[28]
#3971
0	Four	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	intravenous	O	['N']	[3]
4	Zoledronic	B	['N']	[4]
5	acid	I-Drug	['Causes']	[19]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	patient	O	['N']	[8]
9	presented	O	['N']	[9]
10	to	O	['N']	[10]
11	emergency	O	['N']	[11]
12	room	O	['N']	[12]
13	with	O	['N']	[13]
14	complaints	O	['N']	[14]
15	of	O	['N']	[15]
16	carpopedal	O	['N']	[16]
17	spasm	O	['N']	[17]
18	and	O	['N']	[18]
19	bronchospasm	B-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#3972
0	On	O	['N']	[0]
1	the	O	['N']	[1]
2	fifth	O	['N']	[2]
3	day	O	['N']	[3]
4	after	O	['N']	[4]
5	administration	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	high	O	['N']	[8]
9	dose	O	['N']	[9]
10	of	O	['N']	[10]
11	ARA	B	['N']	[11]
12	-	I	['N']	[12]
13	C	I-Drug	['Causes']	[41]
14	(	O	['N']	[14]
15	2	O	['N']	[15]
16	g	O	['N']	[16]
17	/	O	['N']	[17]
18	m2	O	['N']	[18]
19	intravenously	O	['N']	[19]
20	every	O	['N']	[20]
21	12	O	['N']	[21]
22	hours	O	['N']	[22]
23	)	O	['N']	[23]
24	,	O	['N']	[24]
25	she	O	['N']	[25]
26	developed	O	['N']	[26]
27	bullous	O	['N']	[27]
28	lesions	O	['N']	[28]
29	on	O	['N']	[29]
30	the	O	['N']	[30]
31	hands	O	['N']	[31]
32	and	O	['N']	[32]
33	soles	O	['N']	[33]
34	that	O	['N']	[34]
35	disseminated	O	['N']	[35]
36	,	O	['N']	[36]
37	evolving	O	['N']	[37]
38	to	O	['N']	[38]
39	necrosis	O	['N']	[39]
40	,	O	['N']	[40]
41	sepsis	B-Adverse_Effect	['N']	[41]
42	,	O	['N']	[42]
43	and	O	['N']	[43]
44	death	O	['N']	[44]
45	on	O	['N']	[45]
46	the	O	['N']	[46]
47	22nd	O	['N']	[47]
48	day	O	['N']	[48]
49	.	O	['N']	[49]
#3973
0	Allergic	O	['N']	[0]
1	side	O	['N']	[1]
2	effects	O	['N']	[2]
3	of	O	['N']	[3]
4	AZA	B-Drug	['Causes']	[12]
5	are	O	['N']	[5]
6	rare	O	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	reported	O	['N']	[9]
10	allergic	B	['N']	[10]
11	skin	I	['N']	[11]
12	eruptions	I-Adverse_Effect	['N']	[12]
13	from	O	['N']	[13]
14	AZA	O	['N']	[14]
15	are	O	['N']	[15]
16	very	O	['N']	[16]
17	limited	O	['N']	[17]
18	in	O	['N']	[18]
19	Japan	O	['N']	[19]
20	.	O	['N']	[20]
#3974
0	Use	O	['N']	[0]
1	of	O	['N']	[1]
2	the	O	['N']	[2]
3	Naranjo	O	['N']	[3]
4	probability	O	['N']	[4]
5	scale	O	['N']	[5]
6	indicated	O	['N']	[6]
7	a	O	['N']	[7]
8	highly	O	['N']	[8]
9	probable	O	['N']	[9]
10	relationship	O	['N']	[10]
11	between	O	['N']	[11]
12	the	O	['N']	[12]
13	observed	O	['N']	[13]
14	cardiac	B	['N']	[14]
15	toxicity	I-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	amphotericin	B	['N']	[17]
18	B	I	['N']	[18]
19	deoxycholate	I-Drug	['Causes']	[15]
20	therapy	O	['N']	[20]
21	in	O	['N']	[21]
22	this	O	['N']	[22]
23	patient	O	['N']	[23]
24	.	O	['N']	[24]
#3975
0	Fever	O	['N']	[0]
1	,	O	['N']	[1]
2	lymphadenopathy	O	['N']	[2]
3	,	O	['N']	[3]
4	eosinophilia	O	['N']	[4]
5	,	O	['N']	[5]
6	lymphocytosis	B-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	hepatitis	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	dermatitis	O	['N']	[11]
12	:	O	['N']	[12]
13	a	O	['N']	[13]
14	severe	O	['N']	[14]
15	adverse	O	['N']	[15]
16	reaction	O	['N']	[16]
17	to	O	['N']	[17]
18	minocycline	B-Drug	['Causes']	[6]
19	.	O	['N']	[19]
#3976
0	After	O	['N']	[0]
1	1	O	['N']	[1]
2	week	O	['N']	[2]
3	of	O	['N']	[3]
4	nefazodone	B-Drug	['Causes']	[9]
5	therapy	O	['N']	[5]
6	the	O	['N']	[6]
7	patient	O	['N']	[7]
8	experienced	O	['N']	[8]
9	headache	B-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	confusion	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	"	O	['N']	[14]
15	gray	O	['N']	[15]
16	areas	O	['N']	[16]
17	"	O	['N']	[17]
18	in	O	['N']	[18]
19	her	O	['N']	[19]
20	vision	O	['N']	[20]
21	,	O	['N']	[21]
22	without	O	['N']	[22]
23	abnormal	O	['N']	[23]
24	ophthalmologic	O	['N']	[24]
25	findings	O	['N']	[25]
26	.	O	['N']	[26]
#3977
0	Bowel	B	['N']	[0]
1	perforation	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	intraperitoneal	O	['N']	[4]
5	chromic	B	['N']	[5]
6	phosphate	I-Drug	['Causes']	[1]
7	instillation	O	['N']	[7]
8	.	O	['N']	[8]
#3978
0	It	O	['N']	[0]
1	was	O	['N']	[1]
2	concluded	O	['N']	[2]
3	that	O	['N']	[3]
4	potassium	B	['N']	[4]
5	loss	I-Adverse_Effect	['N']	[5]
6	occurred	O	['N']	[6]
7	by	O	['N']	[7]
8	a	O	['N']	[8]
9	non	O	['N']	[9]
10	-	O	['N']	[10]
11	renal	O	['N']	[11]
12	(	O	['N']	[12]
13	intestinal	O	['N']	[13]
14	)	O	['N']	[14]
15	route	O	['N']	[15]
16	in	O	['N']	[16]
17	phosphate	B-Drug	['Causes']	[5]
18	-	O	['N']	[18]
19	induced	O	['N']	[19]
20	hypokalemia	O	['N']	[20]
21	.	O	['N']	[21]
#3979
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Three	O	['N']	[2]
3	patients	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	symptoms	O	['N']	[6]
7	of	O	['N']	[7]
8	inflammatory	O	['N']	[8]
9	bowel	O	['N']	[9]
10	disease	O	['N']	[10]
11	(	O	['N']	[11]
12	IBD	B-Adverse_Effect	['N']	[12]
13	)	O	['N']	[13]
14	during	O	['N']	[14]
15	rofecoxib	B-Drug	['Causes']	[12]
16	exposure	O	['N']	[16]
17	are	O	['N']	[17]
18	described	O	['N']	[18]
19	along	O	['N']	[19]
20	with	O	['N']	[20]
21	pathology	O	['N']	[21]
22	findings	O	['N']	[22]
23	.	O	['N']	[23]
#3980
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	women	O	['N']	[6]
7	in	O	['N']	[7]
8	whom	O	['N']	[8]
9	a	O	['N']	[9]
10	malignant	B	['N']	[10]
11	mixed	I	['N']	[11]
12	mesodermal	I	['N']	[12]
13	tumor	I-Adverse_Effect	['N']	[13]
14	was	O	['N']	[14]
15	diagnosed	O	['N']	[15]
16	while	O	['N']	[16]
17	she	O	['N']	[17]
18	was	O	['N']	[18]
19	taking	O	['N']	[19]
20	raloxifene	B-Drug	['Causes']	[13]
21	,	O	['N']	[21]
22	which	O	['N']	[22]
23	is	O	['N']	[23]
24	also	O	['N']	[24]
25	a	O	['N']	[25]
26	selective	O	['N']	[26]
27	estrogen	O	['N']	[27]
28	receptor	O	['N']	[28]
29	modulator	O	['N']	[29]
30	.	O	['N']	[30]
#3981
0	Colchicine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	myopathy	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	renal	O	['N']	[5]
6	failure	O	['N']	[6]
7	.	O	['N']	[7]
#3982
0	Spontaneous	B	['N']	[0]
1	nasal	I	['N']	[1]
2	septal	I	['N']	[2]
3	perforation	I-Adverse_Effect	['N']	[3]
4	with	O	['N']	[4]
5	antiangiogenic	O	['N']	[5]
6	bevacizumab	B-Drug	['Causes']	[3]
7	therapy	O	['N']	[7]
8	.	O	['N']	[8]
#3983
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	here	O	['N']	[2]
3	two	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	dyserythropoietic	O	['N']	[6]
7	anaemia	O	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	long	O	['N']	[10]
11	-	O	['N']	[11]
12	term	O	['N']	[12]
13	linezolid	O	['N']	[13]
14	use	O	['N']	[14]
15	that	O	['N']	[15]
16	share	O	['N']	[16]
17	striking	O	['N']	[17]
18	similarities	O	['N']	[18]
19	to	O	['N']	[19]
20	chloramphenicol	B-Drug	['Causes']	[23]
21	-	O	['N']	[21]
22	associated	O	['N']	[22]
23	myelotoxicity	B-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#3984
0	Generalized	B	['N']	[0]
1	argyria	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	habitual	O	['N']	[3]
4	use	O	['N']	[4]
5	of	O	['N']	[5]
6	AgNO3	B-Drug	['Causes']	[1]
7	.	O	['N']	[7]
#3985
0	Observations	O	['N']	[0]
1	in	O	['N']	[1]
2	our	O	['N']	[2]
3	patient	O	['N']	[3]
4	suggest	O	['N']	[4]
5	that	O	['N']	[5]
6	the	O	['N']	[6]
7	leukoencephalopathy	B-Adverse_Effect	['N']	[7]
8	that	O	['N']	[8]
9	developed	O	['N']	[9]
10	in	O	['N']	[10]
11	previously	O	['N']	[11]
12	reported	O	['N']	[12]
13	patients	O	['N']	[13]
14	who	O	['N']	[14]
15	received	O	['N']	[15]
16	5-fluorouracil	O	['N']	[16]
17	and	O	['N']	[17]
18	levamisole	B-Drug	['Causes']	[7]
19	may	O	['N']	[19]
20	have	O	['N']	[20]
21	been	O	['N']	[21]
22	caused	O	['N']	[22]
23	at	O	['N']	[23]
24	least	O	['N']	[24]
25	partly	O	['N']	[25]
26	by	O	['N']	[26]
27	levamisole	O	['N']	[27]
28	.	O	['N']	[28]
#3986
0	Acute	O	['N']	[0]
1	hemorrhagic	O	['N']	[1]
2	gastritis	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	acetazolamide	B-Drug	['Causes']	[6]
6	intoxication	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	chronic	O	['N']	[11]
12	renal	O	['N']	[12]
13	failure	O	['N']	[13]
14	.	O	['N']	[14]
#3987
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	chronic	O	['N']	[5]
6	use	O	['N']	[6]
7	of	O	['N']	[7]
8	HCQ	B-Drug	['Causes']	[13]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	torsade	B	['N']	[11]
12	de	I	['N']	[12]
13	pointes	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#3988
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Clinicians	O	['N']	[2]
3	should	O	['N']	[3]
4	be	O	['N']	[4]
5	aware	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	risk	O	['N']	[8]
9	of	O	['N']	[9]
10	serotonin	O	['N']	[10]
11	syndrome	O	['N']	[11]
12	with	O	['N']	[12]
13	serious	O	['N']	[13]
14	extrapyramidal	O	['N']	[14]
15	reactions	O	['N']	[15]
16	in	O	['N']	[16]
17	patients	O	['N']	[17]
18	receiving	O	['N']	[18]
19	sertraline	B-Drug	['Dosage']	[31]
20	or	O	['N']	[20]
21	venlafaxine	O	['N']	[21]
22	when	O	['N']	[22]
23	metoclopramide	O	['N']	[23]
24	is	O	['N']	[24]
25	coadministered	O	['N']	[25]
26	even	O	['N']	[26]
27	in	O	['N']	[27]
28	a	O	['N']	[28]
29	single	O	['N']	[29]
30	,	O	['N']	[30]
31	conventional	B-Dose	['N']	[31]
32	dose	O	['N']	[32]
33	.	O	['N']	[33]
#3989
0	Itch	O	['N']	[0]
1	and	O	['N']	[1]
2	skin	B	['N']	[2]
3	rash	I-Adverse_Effect	['N']	[3]
4	from	O	['N']	[4]
5	chocolate	O	['N']	[5]
6	during	O	['N']	[6]
7	fluoxetine	O	['N']	[7]
8	and	O	['N']	[8]
9	sertraline	B-Drug	['Causes']	[3]
10	treatment	O	['N']	[10]
11	:	O	['N']	[11]
12	case	O	['N']	[12]
13	report	O	['N']	[13]
14	.	O	['N']	[14]
#3990
0	Temporary	O	['N']	[0]
1	neurologic	O	['N']	[1]
2	abnormalities	O	['N']	[2]
3	were	O	['N']	[3]
4	observed	O	['N']	[4]
5	in	O	['N']	[5]
6	one	O	['N']	[6]
7	out	O	['N']	[7]
8	of	O	['N']	[8]
9	23	O	['N']	[9]
10	patients	O	['N']	[10]
11	undergoing	O	['N']	[11]
12	chemotherapy	O	['N']	[12]
13	with	O	['N']	[13]
14	high	B	['N']	[14]
15	-	I	['N']	[15]
16	dose	I-Dose	['N']	[16]
17	methotrexate	B-Drug	['Dosage']	[16]
18	(	O	['N']	[18]
19	HD	O	['N']	[19]
20	-	O	['N']	[20]
21	MTX	O	['N']	[21]
22	)	O	['N']	[22]
23	for	O	['N']	[23]
24	osteogenic	O	['N']	[24]
25	sarcoma	O	['N']	[25]
26	.	O	['N']	[26]
#3991
0	Trichiasis	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	prostaglandin	B-Drug	['Causes']	[0]
4	analog	O	['N']	[4]
5	use	O	['N']	[5]
6	.	O	['N']	[6]
#3992
0	Patients	O	['N']	[0]
1	treated	O	['N']	[1]
2	with	O	['N']	[2]
3	L	B	['N']	[3]
4	-	I	['N']	[4]
5	asparaginase	I-Drug	['Causes']	[13]
6	may	O	['N']	[6]
7	present	O	['N']	[7]
8	with	O	['N']	[8]
9	hemorrhagic	O	['N']	[9]
10	and	O	['N']	[10]
11	thrombotic	B	['N']	[11]
12	cerebrovascular	I	['N']	[12]
13	events	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#3993
0	Methotrexate	B-Drug	['Causes']	[4]
1	may	O	['N']	[1]
2	rarely	O	['N']	[2]
3	provoke	O	['N']	[3]
4	serositis	B-Adverse_Effect	['N']	[4]
5	,	O	['N']	[5]
6	even	O	['N']	[6]
7	with	O	['N']	[7]
8	low	O	['N']	[8]
9	doses	O	['N']	[9]
10	and	O	['N']	[10]
11	after	O	['N']	[11]
12	just	O	['N']	[12]
13	a	O	['N']	[13]
14	few	O	['N']	[14]
15	weeks	O	['N']	[15]
16	of	O	['N']	[16]
17	therapy	O	['N']	[17]
18	.	O	['N']	[18]
#3994
0	One	O	['N']	[0]
1	type	O	['N']	[1]
2	of	O	['N']	[2]
3	SMON	O	['N']	[3]
4	is	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	acrodermatitis	B	['N']	[7]
8	enteropathica	I-Adverse_Effect	['N']	[8]
9	which	O	['N']	[9]
10	has	O	['N']	[10]
11	a	O	['N']	[11]
12	very	O	['N']	[12]
13	high	O	['N']	[13]
14	frequency	O	['N']	[14]
15	of	O	['N']	[15]
16	occurrence	O	['N']	[16]
17	in	O	['N']	[17]
18	association	O	['N']	[18]
19	with	O	['N']	[19]
20	administration	O	['N']	[20]
21	of	O	['N']	[21]
22	clioquinol	B-Drug	['Causes']	[8]
23	.	O	['N']	[23]
#3995
0	The	O	['N']	[0]
1	main	O	['N']	[1]
2	clinical	O	['N']	[2]
3	features	O	['N']	[3]
4	of	O	['N']	[4]
5	this	O	['N']	[5]
6	58-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	female	O	['N']	[9]
10	patient	O	['N']	[10]
11	were	O	['N']	[11]
12	laboratory	O	['N']	[12]
13	evidence	O	['N']	[13]
14	of	O	['N']	[14]
15	leucopenia	O	['N']	[15]
16	and	O	['N']	[16]
17	cholestasis	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	biopsy	O	['N']	[20]
21	features	O	['N']	[21]
22	of	O	['N']	[22]
23	fatty	O	['N']	[23]
24	liver	O	['N']	[24]
25	parenchyma	O	['N']	[25]
26	degeneration	O	['N']	[26]
27	with	O	['N']	[27]
28	granulocytic	O	['N']	[28]
29	portal	O	['N']	[29]
30	infiltration	O	['N']	[30]
31	and	O	['N']	[31]
32	bile	B	['N']	[32]
33	stasis	I-Adverse_Effect	['N']	[33]
34	,	O	['N']	[34]
35	demonstrated	O	['N']	[35]
36	20	O	['N']	[36]
37	days	O	['N']	[37]
38	after	O	['N']	[38]
39	the	O	['N']	[39]
40	initiation	O	['N']	[40]
41	of	O	['N']	[41]
42	antithyroid	O	['N']	[42]
43	therapy	O	['N']	[43]
44	with	O	['N']	[44]
45	20	O	['N']	[45]
46	mg	O	['N']	[46]
47	methimazole	B-Drug	['Causes']	[33]
48	daily	O	['N']	[48]
49	.	O	['N']	[49]
#3996
0	On	O	['N']	[0]
1	the	O	['N']	[1]
2	next	O	['N']	[2]
3	day	O	['N']	[3]
4	,	O	['N']	[4]
5	after	O	['N']	[5]
6	a	O	['N']	[6]
7	total	O	['N']	[7]
8	dose	O	['N']	[8]
9	of	O	['N']	[9]
10	only	O	['N']	[10]
11	600	O	['N']	[11]
12	mg	O	['N']	[12]
13	of	O	['N']	[13]
14	danazol	B-Drug	['Causes']	[19]
15	,	O	['N']	[15]
16	gingival	O	['N']	[16]
17	bleeding	O	['N']	[17]
18	and	O	['N']	[18]
19	purpura	B-Adverse_Effect	['N']	[19]
20	occurred	O	['N']	[20]
21	.	O	['N']	[21]
#3997
0	In	O	['N']	[0]
1	rare	O	['N']	[1]
2	cases	O	['N']	[2]
3	mitomycin	O	['N']	[3]
4	C	O	['N']	[4]
5	(	O	['N']	[5]
6	MMC	B-Drug	['Causes']	[28]
7	)	O	['N']	[7]
8	may	O	['N']	[8]
9	induce	O	['N']	[9]
10	cancer	O	['N']	[10]
11	-	O	['N']	[11]
12	associated	O	['N']	[12]
13	hemolytic	O	['N']	[13]
14	uremic	O	['N']	[14]
15	syndrome	O	['N']	[15]
16	,	O	['N']	[16]
17	which	O	['N']	[17]
18	is	O	['N']	[18]
19	characterized	O	['N']	[19]
20	by	O	['N']	[20]
21	hemolytic	O	['N']	[21]
22	anemia	O	['N']	[22]
23	,	O	['N']	[23]
24	thrombocytopenia	O	['N']	[24]
25	and	O	['N']	[25]
26	progressive	B	['N']	[26]
27	renal	I	['N']	[27]
28	failure	I-Adverse_Effect	['N']	[28]
29	.	O	['N']	[29]
#3998
0	Diarrhoea	O	['N']	[0]
1	,	O	['N']	[1]
2	T	B	['N']	[2]
3	-	I	['N']	[3]
4	CD4	I	['N']	[4]
5	+	I	['N']	[5]
6	lymphopenia	I-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	bilateral	O	['N']	[8]
9	patchy	O	['N']	[9]
10	pulmonary	O	['N']	[10]
11	infiltrates	O	['N']	[11]
12	developed	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	male	O	['N']	[15]
16	60	O	['N']	[16]
17	yrs	O	['N']	[17]
18	of	O	['N']	[18]
19	age	O	['N']	[19]
20	,	O	['N']	[20]
21	who	O	['N']	[21]
22	was	O	['N']	[22]
23	treated	O	['N']	[23]
24	with	O	['N']	[24]
25	oxaliplatinum	B-Drug	['Causes']	[6]
26	and	O	['N']	[26]
27	5-fluorouracil	O	['N']	[27]
28	for	O	['N']	[28]
29	unresectable	O	['N']	[29]
30	rectum	O	['N']	[30]
31	carcinoma	O	['N']	[31]
32	.	O	['N']	[32]
#3999
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	suggest	O	['N']	[2]
3	that	O	['N']	[3]
4	in	O	['N']	[4]
5	patients	O	['N']	[5]
6	with	O	['N']	[6]
7	corneal	B	['N']	[7]
8	ulcers	I	['N']	[8]
9	refractory	I	['N']	[9]
10	to	I	['N']	[10]
11	conventional	I	['N']	[11]
12	treatment	I-Adverse_Effect	['N']	[12]
13	who	O	['N']	[13]
14	are	O	['N']	[14]
15	receiving	O	['N']	[15]
16	colchicine	B-Drug	['Causes']	[12]
17	,	O	['N']	[17]
18	cessation	O	['N']	[18]
19	of	O	['N']	[19]
20	colchicine	O	['N']	[20]
21	therapy	O	['N']	[21]
22	should	O	['N']	[22]
23	be	O	['N']	[23]
24	considered	O	['N']	[24]
25	.	O	['N']	[25]
#4000
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	the	O	['N']	[3]
4	best	O	['N']	[4]
5	of	O	['N']	[5]
6	our	O	['N']	[6]
7	knowledge	O	['N']	[7]
8	,	O	['N']	[8]
9	this	O	['N']	[9]
10	is	O	['N']	[10]
11	the	O	['N']	[11]
12	first	O	['N']	[12]
13	time	O	['N']	[13]
14	colchicine	B-Drug	['Causes']	[15]
15	intoxication	I-Adverse_Effect	['N']	[15]
16	in	O	['N']	[16]
17	this	O	['N']	[17]
18	age	O	['N']	[18]
19	group	O	['N']	[19]
20	has	O	['N']	[20]
21	been	O	['N']	[21]
22	described	O	['N']	[22]
23	in	O	['N']	[23]
24	the	O	['N']	[24]
25	English	O	['N']	[25]
26	literature	O	['N']	[26]
27	.	O	['N']	[27]
#4001
0	We	O	['N']	[0]
1	conjectured	O	['N']	[1]
2	that	O	['N']	[2]
3	the	O	['N']	[3]
4	side	O	['N']	[4]
5	effects	O	['N']	[5]
6	of	O	['N']	[6]
7	insulin	B-Drug	['Causes']	[34]
8	,	O	['N']	[8]
9	such	O	['N']	[9]
10	as	O	['N']	[10]
11	anti	O	['N']	[11]
12	-	O	['N']	[12]
13	natriuresis	O	['N']	[13]
14	and	O	['N']	[14]
15	increased	O	['N']	[15]
16	vascular	O	['N']	[16]
17	permeability	O	['N']	[17]
18	,	O	['N']	[18]
19	might	O	['N']	[19]
20	be	O	['N']	[20]
21	pronounced	O	['N']	[21]
22	in	O	['N']	[22]
23	the	O	['N']	[23]
24	presence	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	hepatic	O	['N']	[27]
28	dysfunction	O	['N']	[28]
29	that	O	['N']	[29]
30	accompanies	O	['N']	[30]
31	insulin	O	['N']	[31]
32	insensitivity	O	['N']	[32]
33	,	O	['N']	[33]
34	hyperinsulinaemia	B-Adverse_Effect	['N']	[34]
35	and	O	['N']	[35]
36	hypoalbuminaemia	O	['N']	[36]
37	.	O	['N']	[37]
#4002
0	Preliminary	O	['N']	[0]
1	results	O	['N']	[1]
2	suggest	O	['N']	[2]
3	that	O	['N']	[3]
4	the	O	['N']	[4]
5	higher	O	['N']	[5]
6	concentrations	O	['N']	[6]
7	of	O	['N']	[7]
8	dextrose	B-Drug	['Causes']	[12]
9	induce	O	['N']	[9]
10	increased	B	['N']	[10]
11	histamine	I	['N']	[11]
12	release	I-Adverse_Effect	['N']	[12]
13	from	O	['N']	[13]
14	blood	O	['N']	[14]
15	cells	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	that	O	['N']	[18]
19	this	O	['N']	[19]
20	phenomenon	O	['N']	[20]
21	is	O	['N']	[21]
22	more	O	['N']	[22]
23	marked	O	['N']	[23]
24	in	O	['N']	[24]
25	diabetic	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	particularly	O	['N']	[28]
29	diabetic	O	['N']	[29]
30	-	O	['N']	[30]
31	allergic	O	['N']	[31]
32	,	O	['N']	[32]
33	individuals	O	['N']	[33]
34	.	O	['N']	[34]
#4003
0	The	O	['N']	[0]
1	potential	O	['N']	[1]
2	role	O	['N']	[2]
3	of	O	['N']	[3]
4	propranolol	B-Drug	['Causes']	[10]
5	in	O	['N']	[5]
6	inducing	O	['N']	[6]
7	central	B	['N']	[7]
8	nervous	I	['N']	[8]
9	system	I	['N']	[9]
10	disturbances	I-Adverse_Effect	['N']	[10]
11	is	O	['N']	[11]
12	emphasized	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	the	O	['N']	[15]
16	literature	O	['N']	[16]
17	on	O	['N']	[17]
18	the	O	['N']	[18]
19	subject	O	['N']	[19]
20	is	O	['N']	[20]
21	reviewed	O	['N']	[21]
22	.	O	['N']	[22]
#4004
0	Clinical	B	['N']	[0]
1	,	I	['N']	[1]
2	spectroscopic	I	['N']	[2]
3	,	I	['N']	[3]
4	and	I	['N']	[4]
5	imaging	I	['N']	[5]
6	abnormalities	I-Adverse_Effect	['N']	[6]
7	resolved	O	['N']	[7]
8	with	O	['N']	[8]
9	discontinuation	O	['N']	[9]
10	of	O	['N']	[10]
11	metronidazole	B-Drug	['Causes']	[6]
12	.	O	['N']	[12]
#4005
0	Acute	B	['N']	[0]
1	renal	I	['N']	[1]
2	failure	I-Adverse_Effect	['N']	[2]
3	with	O	['N']	[3]
4	severe	O	['N']	[4]
5	tubulointerstitial	O	['N']	[5]
6	changes	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	minimal	O	['N']	[11]
12	change	O	['N']	[12]
13	nephrotic	O	['N']	[13]
14	syndrome	O	['N']	[14]
15	treated	O	['N']	[15]
16	with	O	['N']	[16]
17	enalapril	B-Drug	['Causes']	[2]
18	.	O	['N']	[18]
#4006
0	Hemolytic	B	['N']	[0]
1	uremic	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	on	O	['N']	[6]
7	cis	B	['N']	[7]
8	-	I	['N']	[8]
9	platinum	I-Drug	['Causes']	[2]
10	,	O	['N']	[10]
11	vinblastine	O	['N']	[11]
12	and	O	['N']	[12]
13	bleomycin	O	['N']	[13]
14	.	O	['N']	[14]
#4007
0	Doxycycline	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	photo	B	['N']	[3]
4	-	I	['N']	[4]
5	onycholysis	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#4008
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	report	O	['N']	[3]
4	indicates	O	['N']	[4]
5	clindamycin	B-Drug	['Causes']	[25]
6	phosphate	O	['N']	[6]
7	vaginal	O	['N']	[7]
8	cream	O	['N']	[8]
9	as	O	['N']	[9]
10	the	O	['N']	[10]
11	most	O	['N']	[11]
12	probable	O	['N']	[12]
13	cause	O	['N']	[13]
14	of	O	['N']	[14]
15	CDIC	O	['N']	[15]
16	due	O	['N']	[16]
17	to	O	['N']	[17]
18	the	O	['N']	[18]
19	temporal	O	['N']	[19]
20	relationship	O	['N']	[20]
21	between	O	['N']	[21]
22	the	O	['N']	[22]
23	occurrence	O	['N']	[23]
24	of	O	['N']	[24]
25	diarrhea	B-Adverse_Effect	['N']	[25]
26	and	O	['N']	[26]
27	clindamycin	O	['N']	[27]
28	administration	O	['N']	[28]
29	,	O	['N']	[29]
30	lack	O	['N']	[30]
31	of	O	['N']	[31]
32	concomitant	O	['N']	[32]
33	medications	O	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	documentation	O	['N']	[36]
37	of	O	['N']	[37]
38	C.	O	['N']	[38]
39	difficile	O	['N']	[39]
40	toxin	O	['N']	[40]
41	.	O	['N']	[41]
#4009
0	We	O	['N']	[0]
1	conclude	O	['N']	[1]
2	that	O	['N']	[2]
3	neurosurgeons	O	['N']	[3]
4	and	O	['N']	[4]
5	neurologists	O	['N']	[5]
6	should	O	['N']	[6]
7	be	O	['N']	[7]
8	aware	O	['N']	[8]
9	of	O	['N']	[9]
10	calcium	O	['N']	[10]
11	antagonist	O	['N']	[11]
12	--	O	['N']	[12]
13	related	O	['N']	[13]
14	ileus	B-Adverse_Effect	['N']	[14]
15	in	O	['N']	[15]
16	patients	O	['N']	[16]
17	treated	O	['N']	[17]
18	with	O	['N']	[18]
19	nimodipine	B-Drug	['Causes']	[14]
20	.	O	['N']	[20]
#4010
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	pyridoxine	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	dependent	O	['N']	[5]
6	seizures	B-Adverse_Effect	['N']	[6]
7	is	O	['N']	[7]
8	reported	O	['N']	[8]
9	.	O	['N']	[9]
#4011
0	A	O	['N']	[0]
1	65-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	on	O	['N']	[5]
6	warfarin	B-Drug	['Causes']	[21]
7	therapy	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	sudden	O	['N']	[10]
11	spontaneous	O	['N']	[11]
12	onset	O	['N']	[12]
13	of	O	['N']	[13]
14	sub	O	['N']	[14]
15	-	O	['N']	[15]
16	conjunctival	O	['N']	[16]
17	haematoma	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	bloody	B	['N']	[20]
21	tears	I-Adverse_Effect	['N']	[21]
22	was	O	['N']	[22]
23	assessed	O	['N']	[23]
24	in	O	['N']	[24]
25	the	O	['N']	[25]
26	clinic	O	['N']	[26]
27	following	O	['N']	[27]
28	a	O	['N']	[28]
29	referral	O	['N']	[29]
30	from	O	['N']	[30]
31	an	O	['N']	[31]
32	optometrist	O	['N']	[32]
33	.	O	['N']	[33]
#4012
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	suffered	O	['N']	[2]
3	a	O	['N']	[3]
4	life	B	['N']	[4]
5	-	I	['N']	[5]
6	threatening	I	['N']	[6]
7	anaphylactoid	I	['N']	[7]
8	reaction	I-Adverse_Effect	['N']	[8]
9	to	O	['N']	[9]
10	amifostine	B-Drug	['Causes']	[8]
11	.	O	['N']	[11]
#4013
0	In	O	['N']	[0]
1	the	O	['N']	[1]
2	first	O	['N']	[2]
3	patient	O	['N']	[3]
4	,	O	['N']	[4]
5	two	O	['N']	[5]
6	episodes	O	['N']	[6]
7	of	O	['N']	[7]
8	ventricular	B	['N']	[8]
9	tachycardia	I-Adverse_Effect	['N']	[9]
10	requiring	O	['N']	[10]
11	cardioversion	O	['N']	[11]
12	occurred	O	['N']	[12]
13	in	O	['N']	[13]
14	close	O	['N']	[14]
15	temporal	O	['N']	[15]
16	sequence	O	['N']	[16]
17	with	O	['N']	[17]
18	administering	O	['N']	[18]
19	bretylium	B-Drug	['Causes']	[9]
20	.	O	['N']	[20]
#4014
0	DATA	O	['N']	[0]
1	SYNTHESIS	O	['N']	[1]
2	:	O	['N']	[2]
3	Genetic	O	['N']	[3]
4	deficiencies	O	['N']	[4]
5	in	O	['N']	[5]
6	DPD	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	rate	O	['N']	[9]
10	-	O	['N']	[10]
11	limiting	O	['N']	[11]
12	enzyme	O	['N']	[12]
13	responsible	O	['N']	[13]
14	for	O	['N']	[14]
15	5-FU	B-Drug	['Causes']	[50]
16	catabolism	O	['N']	[16]
17	,	O	['N']	[17]
18	may	O	['N']	[18]
19	occur	O	['N']	[19]
20	in	O	['N']	[20]
21	3	O	['N']	[21]
22	%	O	['N']	[22]
23	or	O	['N']	[23]
24	more	O	['N']	[24]
25	of	O	['N']	[25]
26	patients	O	['N']	[26]
27	with	O	['N']	[27]
28	cancer	O	['N']	[28]
29	putting	O	['N']	[29]
30	them	O	['N']	[30]
31	at	O	['N']	[31]
32	increased	O	['N']	[32]
33	risk	O	['N']	[33]
34	for	O	['N']	[34]
35	unusually	O	['N']	[35]
36	severe	O	['N']	[36]
37	adverse	O	['N']	[37]
38	reactions	O	['N']	[38]
39	(	O	['N']	[39]
40	e.g.	O	['N']	[40]
41	,	O	['N']	[41]
42	diarrhea	O	['N']	[42]
43	,	O	['N']	[43]
44	stomatitis	O	['N']	[44]
45	,	O	['N']	[45]
46	mucositis	O	['N']	[46]
47	,	O	['N']	[47]
48	myelosuppression	O	['N']	[48]
49	,	O	['N']	[49]
50	neurotoxicity	B-Adverse_Effect	['N']	[50]
51	)	O	['N']	[51]
52	to	O	['N']	[52]
53	standard	O	['N']	[53]
54	doses	O	['N']	[54]
55	of	O	['N']	[55]
56	5-FU	O	['N']	[56]
57	.	O	['N']	[57]
#4015
0	In	O	['N']	[0]
1	one	O	['N']	[1]
2	patient	O	['N']	[2]
3	the	O	['N']	[3]
4	vasculitis	O	['N']	[4]
5	resolved	O	['N']	[5]
6	after	O	['N']	[6]
7	termination	O	['N']	[7]
8	of	O	['N']	[8]
9	the	O	['N']	[9]
10	ciprofloxacin	B-Drug	['Causes']	[40]
11	therapy	O	['N']	[11]
12	;	O	['N']	[12]
13	in	O	['N']	[13]
14	the	O	['N']	[14]
15	other	O	['N']	[15]
16	patient	O	['N']	[16]
17	the	O	['N']	[17]
18	ciprofloxacin	O	['N']	[18]
19	-	O	['N']	[19]
20	induced	O	['N']	[20]
21	hemorrhagic	O	['N']	[21]
22	vasculitis	O	['N']	[22]
23	was	O	['N']	[23]
24	superimposed	O	['N']	[24]
25	on	O	['N']	[25]
26	a	O	['N']	[26]
27	severe	O	['N']	[27]
28	forefoot	O	['N']	[28]
29	infection	O	['N']	[29]
30	,	O	['N']	[30]
31	leading	O	['N']	[31]
32	to	O	['N']	[32]
33	progressive	O	['N']	[33]
34	gangrene	O	['N']	[34]
35	and	O	['N']	[35]
36	a	O	['N']	[36]
37	below	B	['N']	[37]
38	-	I	['N']	[38]
39	knee	I	['N']	[39]
40	amputation	I-Adverse_Effect	['N']	[40]
41	.	O	['N']	[41]
#4016
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	toxic	B	['N']	[3]
4	hepatitis	I-Adverse_Effect	['N']	[4]
5	caused	O	['N']	[5]
6	by	O	['N']	[6]
7	combination	O	['N']	[7]
8	therapy	O	['N']	[8]
9	with	O	['N']	[9]
10	methotrexate	O	['N']	[10]
11	and	O	['N']	[11]
12	etretinate	B-Drug	['Causes']	[4]
13	in	O	['N']	[13]
14	the	O	['N']	[14]
15	treatment	O	['N']	[15]
16	of	O	['N']	[16]
17	severe	O	['N']	[17]
18	psoriasis	O	['N']	[18]
19	is	O	['N']	[19]
20	presented	O	['N']	[20]
21	in	O	['N']	[21]
22	a	O	['N']	[22]
23	47-year	O	['N']	[23]
24	-	O	['N']	[24]
25	old	O	['N']	[25]
26	woman	O	['N']	[26]
27	.	O	['N']	[27]
#4017
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	43-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	sore	O	['N']	[9]
10	throat	O	['N']	[10]
11	,	O	['N']	[11]
12	swelling	B	['N']	[12]
13	of	I	['N']	[13]
14	the	I	['N']	[14]
15	lips	I	['N']	[15]
16	and	I	['N']	[16]
17	oral	I	['N']	[17]
18	cavity	I-Adverse_Effect	['N']	[18]
19	and	O	['N']	[19]
20	dysphagia	O	['N']	[20]
21	,	O	['N']	[21]
22	2	O	['N']	[22]
23	weeks	O	['N']	[23]
24	after	O	['N']	[24]
25	the	O	['N']	[25]
26	use	O	['N']	[26]
27	of	O	['N']	[27]
28	budesonide	B-Drug	['Causes']	[18]
29	spray	O	['N']	[29]
30	(	O	['N']	[30]
31	Budefat	O	['N']	[31]
32	)	O	['N']	[32]
33	for	O	['N']	[33]
34	treatment	O	['N']	[34]
35	of	O	['N']	[35]
36	bronchial	O	['N']	[36]
37	asthma	O	['N']	[37]
38	.	O	['N']	[38]
#4018
0	In	O	['N']	[0]
1	addition	O	['N']	[1]
2	,	O	['N']	[2]
3	there	O	['N']	[3]
4	is	O	['N']	[4]
5	a	O	['N']	[5]
6	report	O	['N']	[6]
7	on	O	['N']	[7]
8	prolonged	B	['N']	[8]
9	ECT	I	['N']	[9]
10	seizure	I-Adverse_Effect	['N']	[10]
11	related	O	['N']	[11]
12	to	O	['N']	[12]
13	ciprofloxacin	B-Drug	['Causes']	[10]
14	,	O	['N']	[14]
15	which	O	['N']	[15]
16	has	O	['N']	[16]
17	an	O	['N']	[17]
18	epileptogenic	O	['N']	[18]
19	property	O	['N']	[19]
20	with	O	['N']	[20]
21	a	O	['N']	[21]
22	similar	O	['N']	[22]
23	action	O	['N']	[23]
24	to	O	['N']	[24]
25	beta	O	['N']	[25]
26	-	O	['N']	[26]
27	lactam	O	['N']	[27]
28	antibiotics	O	['N']	[28]
29	.	O	['N']	[29]
#4019
0	Cyclophosphamide	B-Drug	['Causes']	[5]
1	can	O	['N']	[1]
2	rarely	O	['N']	[2]
3	cause	O	['N']	[3]
4	interstitial	B	['N']	[4]
5	pneumonitis	I-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	fibrosis	O	['N']	[7]
8	.	O	['N']	[8]
#4020
0	Patients	O	['N']	[0]
1	receiving	O	['N']	[1]
2	neutral	B	['N']	[2]
3	protamine	I	['N']	[3]
4	Hagedorn	I	['N']	[4]
5	(	I	['N']	[5]
6	NPH	I	['N']	[6]
7	)	I	['N']	[7]
8	insulin	I-Drug	['Causes']	[18]
9	are	O	['N']	[9]
10	at	O	['N']	[10]
11	increased	O	['N']	[11]
12	risk	O	['N']	[12]
13	for	O	['N']	[13]
14	the	O	['N']	[14]
15	development	O	['N']	[15]
16	of	O	['N']	[16]
17	protamine	B	['N']	[17]
18	hypersensitivity	I-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#4021
0	A	O	['N']	[0]
1	61-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	developed	O	['N']	[5]
6	clinical	O	['N']	[6]
7	lupus	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	with	O	['N']	[9]
10	positive	O	['N']	[10]
11	antinuclear	O	['N']	[11]
12	antibody	O	['N']	[12]
13	,	O	['N']	[13]
14	positive	O	['N']	[14]
15	lupus	B	['N']	[15]
16	erythematosus	I-Adverse_Effect	['N']	[16]
17	(	O	['N']	[17]
18	LE	O	['N']	[18]
19	)	O	['N']	[19]
20	cell	O	['N']	[20]
21	preparation	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	diffuse	O	['N']	[24]
25	proliferative	O	['N']	[25]
26	glomerulonephritis	O	['N']	[26]
27	following	O	['N']	[27]
28	26	O	['N']	[28]
29	months	O	['N']	[29]
30	of	O	['N']	[30]
31	procainamide	B-Drug	['Causes']	[16]
32	therapy	O	['N']	[32]
33	.	O	['N']	[33]
#4022
0	In	O	['N']	[0]
1	one	O	['N']	[1]
2	patient	O	['N']	[2]
3	,	O	['N']	[3]
4	treatment	O	['N']	[4]
5	with	O	['N']	[5]
6	DCA	B-Drug	['Causes']	[15]
7	was	O	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	a	O	['N']	[10]
11	decrease	B	['N']	[11]
12	in	I	['N']	[12]
13	blood	I	['N']	[13]
14	lactate	I	['N']	[14]
15	levels	I-Adverse_Effect	['N']	[15]
16	from	O	['N']	[16]
17	11.2	O	['N']	[17]
18	mM	O	['N']	[18]
19	before	O	['N']	[19]
20	treatment	O	['N']	[20]
21	to	O	['N']	[21]
22	0.8	O	['N']	[22]
23	mM	O	['N']	[23]
24	16	O	['N']	[24]
25	h	O	['N']	[25]
26	later	O	['N']	[26]
27	.	O	['N']	[27]
#4023
0	The	O	['N']	[0]
1	induced	O	['N']	[1]
2	hyperglycaemia	O	['N']	[2]
3	could	O	['N']	[3]
4	not	O	['N']	[4]
5	be	O	['N']	[5]
6	controlled	O	['N']	[6]
7	sufficiently	O	['N']	[7]
8	,	O	['N']	[8]
9	despite	O	['N']	[9]
10	a	O	['N']	[10]
11	high	O	['N']	[11]
12	dose	O	['N']	[12]
13	of	O	['N']	[13]
14	insulin	B-Drug	['Causes']	[30]
15	(	O	['N']	[15]
16	>	O	['N']	[16]
17	110	O	['N']	[17]
18	units	O	['N']	[18]
19	/	O	['N']	[19]
20	day	O	['N']	[20]
21	)	O	['N']	[21]
22	,	O	['N']	[22]
23	suggesting	O	['N']	[23]
24	the	O	['N']	[24]
25	existence	O	['N']	[25]
26	of	O	['N']	[26]
27	insulin	O	['N']	[27]
28	insensitivity	O	['N']	[28]
29	and	O	['N']	[29]
30	hyperinsulinaemia	B-Adverse_Effect	['N']	[30]
31	.	O	['N']	[31]
#4024
0	A	O	['N']	[0]
1	61	O	['N']	[1]
2	year	O	['N']	[2]
3	-	O	['N']	[3]
4	old	O	['N']	[4]
5	male	O	['N']	[5]
6	patient	O	['N']	[6]
7	developed	O	['N']	[7]
8	gynecomastia	B-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	starting	O	['N']	[10]
11	theophylline	B-Drug	['Causes']	[8]
12	.	O	['N']	[12]
#4025
0	Neutropenic	B	['N']	[0]
1	colitis	I-Adverse_Effect	['N']	[1]
2	during	O	['N']	[2]
3	standard	O	['N']	[3]
4	dose	O	['N']	[4]
5	combination	O	['N']	[5]
6	chemotherapy	O	['N']	[6]
7	with	O	['N']	[7]
8	nedaplatin	B-Drug	['Causes']	[1]
9	and	O	['N']	[9]
10	irinotecan	O	['N']	[10]
11	for	O	['N']	[11]
12	testicular	O	['N']	[12]
13	cancer	O	['N']	[13]
14	.	O	['N']	[14]
#4026
0	Radiation	B	['N']	[0]
1	recall	I	['N']	[1]
2	pneumonitis	I-Adverse_Effect	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	gemcitabine	B-Drug	['Causes']	[2]
6	.	O	['N']	[6]
#4027
0	Transient	B	['N']	[0]
1	cardiac	I	['N']	[1]
2	arrhythmias	I-Adverse_Effect	['N']	[2]
3	related	O	['N']	[3]
4	to	O	['N']	[4]
5	lopinavir	B-Drug	['Causes']	[2]
6	/	O	['N']	[6]
7	ritonavir	O	['N']	[7]
8	in	O	['N']	[8]
9	two	O	['N']	[9]
10	patients	O	['N']	[10]
11	with	O	['N']	[11]
12	HIV	O	['N']	[12]
13	infection	O	['N']	[13]
14	.	O	['N']	[14]
#4028
0	Amifostine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	fever	B-Adverse_Effect	['N']	[3]
4	:	O	['N']	[4]
5	case	O	['N']	[5]
6	report	O	['N']	[6]
7	and	O	['N']	[7]
8	review	O	['N']	[8]
9	of	O	['N']	[9]
10	the	O	['N']	[10]
11	literature	O	['N']	[11]
12	.	O	['N']	[12]
#4029
0	After	O	['N']	[0]
1	ruling	O	['N']	[1]
2	out	O	['N']	[2]
3	a	O	['N']	[3]
4	hydrotelluric	O	['N']	[4]
5	source	O	['N']	[5]
6	of	O	['N']	[6]
7	fluorine	O	['N']	[7]
8	,	O	['N']	[8]
9	the	O	['N']	[9]
10	patient	O	['N']	[10]
11	's	O	['N']	[11]
12	fluorosis	B-Adverse_Effect	['N']	[12]
13	was	O	['N']	[13]
14	linked	O	['N']	[14]
15	to	O	['N']	[15]
16	chronic	O	['N']	[16]
17	use	O	['N']	[17]
18	of	O	['N']	[18]
19	niflumic	B	['N']	[19]
20	acid	I-Drug	['Causes']	[12]
21	,	O	['N']	[21]
22	following	O	['N']	[22]
23	the	O	['N']	[23]
24	publication	O	['N']	[24]
25	in	O	['N']	[25]
26	1978	O	['N']	[26]
27	of	O	['N']	[27]
28	the	O	['N']	[28]
29	2	O	['N']	[29]
30	previously	O	['N']	[30]
31	reported	O	['N']	[31]
32	cases	O	['N']	[32]
33	affected	O	['N']	[33]
34	by	O	['N']	[34]
35	this	O	['N']	[35]
36	drug	O	['N']	[36]
37	.	O	['N']	[37]
#4030
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	IHA	B-Adverse_Effect	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	cefuroxime	B-Drug	['Causes']	[6]
10	administration	O	['N']	[10]
11	.	O	['N']	[11]
#4031
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Fixed	B	['N']	[2]
3	drug	I	['N']	[3]
4	rash	I-Adverse_Effect	['N']	[4]
5	induced	O	['N']	[5]
6	by	O	['N']	[6]
7	methylphenidate	B-Drug	['Causes']	[4]
8	is	O	['N']	[8]
9	a	O	['N']	[9]
10	possible	O	['N']	[10]
11	but	O	['N']	[11]
12	rare	O	['N']	[12]
13	phenomenon	O	['N']	[13]
14	.	O	['N']	[14]
#4032
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	acute	O	['N']	[5]
6	hyperphosphatemia	B-Adverse_Effect	['N']	[6]
7	secondary	O	['N']	[7]
8	to	O	['N']	[8]
9	rectal	O	['N']	[9]
10	administration	O	['N']	[10]
11	of	O	['N']	[11]
12	sodium	B	['N']	[12]
13	phosphate	I-Drug	['Causes']	[6]
14	and	O	['N']	[14]
15	sodium	O	['N']	[15]
16	biphosphate	O	['N']	[16]
17	(	O	['N']	[17]
18	Fleet	O	['N']	[18]
19	enema	O	['N']	[19]
20	)	O	['N']	[20]
21	.	O	['N']	[21]
#4033
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	treated	O	['N']	[2]
3	with	O	['N']	[3]
4	5-fluorouracil	O	['N']	[4]
5	(	O	['N']	[5]
6	5-FU	B-Drug	['Causes']	[16]
7	)	O	['N']	[7]
8	for	O	['N']	[8]
9	disseminated	O	['N']	[9]
10	adenocarcinoma	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	colon	O	['N']	[13]
14	developed	O	['N']	[14]
15	cerebellar	B	['N']	[15]
16	dysfunction	I-Adverse_Effect	['N']	[16]
17	typical	O	['N']	[17]
18	of	O	['N']	[18]
19	5-FU	O	['N']	[19]
20	neurotoxicity	O	['N']	[20]
21	.	O	['N']	[21]
#4034
0	Previous	O	['N']	[0]
1	studies	O	['N']	[1]
2	have	O	['N']	[2]
3	demonstrated	O	['N']	[3]
4	the	O	['N']	[4]
5	interaction	O	['N']	[5]
6	of	O	['N']	[6]
7	MTX	B-Drug	['Causes']	[34]
8	and	O	['N']	[8]
9	a	O	['N']	[9]
10	variety	O	['N']	[10]
11	of	O	['N']	[11]
12	non	O	['N']	[12]
13	-	O	['N']	[13]
14	steroidal	O	['N']	[14]
15	,	O	['N']	[15]
16	anti	O	['N']	[16]
17	-	O	['N']	[17]
18	inflammatory	O	['N']	[18]
19	drugs	O	['N']	[19]
20	(	O	['N']	[20]
21	NSAIDs	O	['N']	[21]
22	)	O	['N']	[22]
23	with	O	['N']	[23]
24	various	O	['N']	[24]
25	clinical	O	['N']	[25]
26	manifestations	O	['N']	[26]
27	including	O	['N']	[27]
28	acute	O	['N']	[28]
29	renal	O	['N']	[29]
30	failure	O	['N']	[30]
31	,	O	['N']	[31]
32	pancytopenia	O	['N']	[32]
33	,	O	['N']	[33]
34	vomiting	B-Adverse_Effect	['N']	[34]
35	,	O	['N']	[35]
36	diarrhea	O	['N']	[36]
37	,	O	['N']	[37]
38	elevated	O	['N']	[38]
39	liver	O	['N']	[39]
40	transaminases	O	['N']	[40]
41	,	O	['N']	[41]
42	jaundice	O	['N']	[42]
43	,	O	['N']	[43]
44	mucosal	O	['N']	[44]
45	ulcerations	O	['N']	[45]
46	,	O	['N']	[46]
47	and	O	['N']	[47]
48	pyrexia	O	['N']	[48]
49	.	O	['N']	[49]
#4035
0	Adverse	O	['N']	[0]
1	effects	O	['N']	[1]
2	of	O	['N']	[2]
3	amiodarone	B-Drug	['Causes']	[6]
4	including	O	['N']	[4]
5	pulmonary	B	['N']	[5]
6	toxicity	I-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	hepatotoxicity	O	['N']	[8]
9	,	O	['N']	[9]
10	aggravation	O	['N']	[10]
11	of	O	['N']	[11]
12	arrhythmia	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	thyroid	O	['N']	[15]
16	diseases	O	['N']	[16]
17	are	O	['N']	[17]
18	well	O	['N']	[18]
19	understood	O	['N']	[19]
20	.	O	['N']	[20]
#4036
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	report	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	anuric	O	['N']	[8]
9	ARF	O	['N']	[9]
10	after	O	['N']	[10]
11	high	B	['N']	[11]
12	-	I	['N']	[12]
13	dose	I-Dose	['N']	[13]
14	mannitol	B-Drug	['Dosage']	[13]
15	infusion	O	['N']	[15]
16	for	O	['N']	[16]
17	treatment	O	['N']	[17]
18	of	O	['N']	[18]
19	narrow	O	['N']	[19]
20	-	O	['N']	[20]
21	angle	O	['N']	[21]
22	glaucoma	O	['N']	[22]
23	that	O	['N']	[23]
24	readily	O	['N']	[24]
25	responded	O	['N']	[25]
26	to	O	['N']	[26]
27	acute	O	['N']	[27]
28	hemodialysis	O	['N']	[28]
29	.	O	['N']	[29]
#4037
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	five	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	restless	O	['N']	[5]
6	legs	O	['N']	[6]
7	syndrome	O	['N']	[7]
8	(	O	['N']	[8]
9	RLS	B-Adverse_Effect	['N']	[9]
10	)	O	['N']	[10]
11	and	O	['N']	[11]
12	periodic	O	['N']	[12]
13	limb	O	['N']	[13]
14	movements	O	['N']	[14]
15	during	O	['N']	[15]
16	sleep	O	['N']	[16]
17	(	O	['N']	[17]
18	PLMS	O	['N']	[18]
19	)	O	['N']	[19]
20	that	O	['N']	[20]
21	were	O	['N']	[21]
22	probably	O	['N']	[22]
23	associated	O	['N']	[23]
24	with	O	['N']	[24]
25	olanzapine	B-Drug	['Causes']	[9]
26	.	O	['N']	[26]
#4038
0	Fulminant	B	['N']	[0]
1	hepatitis	I-Adverse_Effect	['N']	[1]
2	with	O	['N']	[2]
3	severe	O	['N']	[3]
4	lactate	O	['N']	[4]
5	acidosis	O	['N']	[5]
6	in	O	['N']	[6]
7	HIV	O	['N']	[7]
8	-	O	['N']	[8]
9	infected	O	['N']	[9]
10	patients	O	['N']	[10]
11	on	O	['N']	[11]
12	didanosine	B-Drug	['Causes']	[1]
13	therapy	O	['N']	[13]
14	.	O	['N']	[14]
#4039
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	One	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	recurrent	O	['N']	[5]
6	primary	O	['N']	[6]
7	peritoneal	O	['N']	[7]
8	carcinoma	O	['N']	[8]
9	previously	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	a	O	['N']	[12]
13	carboplatin	B-Drug	['Causes']	[21]
14	-	O	['N']	[14]
15	based	O	['N']	[15]
16	regimen	O	['N']	[16]
17	,	O	['N']	[17]
18	developed	O	['N']	[18]
19	a	O	['N']	[19]
20	platinum	B	['N']	[20]
21	hypersensitivity	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#4040
0	CASE	O	['N']	[0]
1	REPORT	O	['N']	[1]
2	:	O	['N']	[2]
3	Soon	O	['N']	[3]
4	after	O	['N']	[4]
5	initiation	O	['N']	[5]
6	of	O	['N']	[6]
7	amiodarone	B	['N']	[7]
8	HCl	I-Drug	['Causes']	[32]
9	(	O	['N']	[9]
10	200	O	['N']	[10]
11	mg	O	['N']	[11]
12	/	O	['N']	[12]
13	day	O	['N']	[13]
14	)	O	['N']	[14]
15	,	O	['N']	[15]
16	a	O	['N']	[16]
17	76-year	O	['N']	[17]
18	-	O	['N']	[18]
19	old	O	['N']	[19]
20	man	O	['N']	[20]
21	came	O	['N']	[21]
22	to	O	['N']	[22]
23	us	O	['N']	[23]
24	with	O	['N']	[24]
25	symptoms	O	['N']	[25]
26	of	O	['N']	[26]
27	visual	O	['N']	[27]
28	"	O	['N']	[28]
29	shining	O	['N']	[29]
30	,	O	['N']	[30]
31	"	O	['N']	[31]
32	glare	B-Adverse_Effect	['N']	[32]
33	,	O	['N']	[33]
34	color	O	['N']	[34]
35	vision	O	['N']	[35]
36	anomalies	O	['N']	[36]
37	,	O	['N']	[37]
38	and	O	['N']	[38]
39	gradually	O	['N']	[39]
40	decreased	O	['N']	[40]
41	vision	O	['N']	[41]
42	.	O	['N']	[42]
#4041
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	purpose	O	['N']	[3]
4	of	O	['N']	[4]
5	this	O	['N']	[5]
6	study	O	['N']	[6]
7	was	O	['N']	[7]
8	to	O	['N']	[8]
9	report	O	['N']	[9]
10	the	O	['N']	[10]
11	concomitant	O	['N']	[11]
12	occurrence	O	['N']	[12]
13	of	O	['N']	[13]
14	multiple	O	['N']	[14]
15	squamous	O	['N']	[15]
16	cell	O	['N']	[16]
17	carcinomas	O	['N']	[17]
18	and	O	['N']	[18]
19	diffuse	B	['N']	[19]
20	nail	I	['N']	[20]
21	hyperpigmentation	I-Adverse_Effect	['N']	[21]
22	associated	O	['N']	[22]
23	with	O	['N']	[23]
24	hydroxyurea	B-Drug	['Causes']	[21]
25	treatment	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	to	O	['N']	[28]
29	describe	O	['N']	[29]
30	a	O	['N']	[30]
31	successful	O	['N']	[31]
32	therapeutic	O	['N']	[32]
33	approach	O	['N']	[33]
34	using	O	['N']	[34]
35	imiquimod	O	['N']	[35]
36	5	O	['N']	[36]
37	%	O	['N']	[37]
38	.	O	['N']	[38]
#4042
0	A	O	['N']	[0]
1	complex	O	['N']	[1]
2	pattern	O	['N']	[2]
3	of	O	['N']	[3]
4	melanonychia	B-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	onycholysis	O	['N']	[6]
7	after	O	['N']	[7]
8	treatment	O	['N']	[8]
9	with	O	['N']	[9]
10	pemetrexed	B-Drug	['Causes']	[4]
11	for	O	['N']	[11]
12	lung	O	['N']	[12]
13	cancer	O	['N']	[13]
14	.	O	['N']	[14]
#4043
0	Hepatopathy	B-Adverse_Effect	['N']	[0]
1	subsided	O	['N']	[1]
2	after	O	['N']	[2]
3	the	O	['N']	[3]
4	cessation	O	['N']	[4]
5	of	O	['N']	[5]
6	carbamazepine	O	['N']	[6]
7	and	O	['N']	[7]
8	lynestrenol	B-Drug	['Causes']	[0]
9	.	O	['N']	[9]
#4044
0	This	O	['N']	[0]
1	supports	O	['N']	[1]
2	the	O	['N']	[2]
3	well	O	['N']	[3]
4	-	O	['N']	[4]
5	reported	O	['N']	[5]
6	potential	O	['N']	[6]
7	of	O	['N']	[7]
8	bleomycin	B-Drug	['Causes']	[13]
9	to	O	['N']	[9]
10	trigger	O	['N']	[10]
11	acral	B	['N']	[11]
12	vascular	I	['N']	[12]
13	toxicity	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#4045
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	two	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	rhabdomyolysis	B-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	patients	O	['N']	[9]
10	taking	O	['N']	[10]
11	lovastatin	B-Drug	['Causes']	[7]
12	that	O	['N']	[12]
13	were	O	['N']	[13]
14	precipitated	O	['N']	[14]
15	by	O	['N']	[15]
16	the	O	['N']	[16]
17	use	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	newer	O	['N']	[20]
21	macrolide	O	['N']	[21]
22	antibiotics	O	['N']	[22]
23	clarithromycin	O	['N']	[23]
24	and	O	['N']	[24]
25	azithromycin	O	['N']	[25]
26	.	O	['N']	[26]
#4046
0	DISCUSSION	-	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	review	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	cases	O	['N']	[6]
7	of	O	['N']	[7]
8	SS	O	['N']	[8]
9	with	O	['N']	[9]
10	implication	O	['N']	[10]
11	of	O	['N']	[11]
12	mirtazapine	B-Drug	['N']	[12]
13	as	O	['N']	[13]
14	the	O	['N']	[14]
15	cause	O	['N']	[15]
16	was	O	['N']	[16]
17	performed	O	['N']	[17]
18	.	O	['N']	[18]
#4047
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	was	O	['N']	[2]
3	enrolled	O	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	weight	O	['N']	[6]
7	-	O	['N']	[7]
8	loss	O	['N']	[8]
9	clinic	O	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	his	O	['N']	[12]
13	diabetes	O	['N']	[13]
14	medications	O	['N']	[14]
15	were	O	['N']	[15]
16	adjusted	O	['N']	[16]
17	.	O	['N']	[17]
18	Subsequently	O	['N']	[18]
19	,	O	['N']	[19]
20	olanzapine	B-Drug	['Causes']	[29]
21	was	O	['N']	[21]
22	discontinued	O	['N']	[22]
23	because	O	['N']	[23]
24	of	O	['N']	[24]
25	weight	O	['N']	[25]
26	gain	O	['N']	[26]
27	and	O	['N']	[27]
28	uncontrolled	B	['N']	[28]
29	diabetes	I-Adverse_Effect	['N']	[29]
30	.	O	['N']	[30]
#4048
0	Uveitis	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	rifabutin	B-Drug	['Causes']	[0]
4	therapy	O	['N']	[4]
5	:	O	['N']	[5]
6	a	O	['N']	[6]
7	clinical	O	['N']	[7]
8	alert	O	['N']	[8]
9	.	O	['N']	[9]
#4049
0	Acute	B	['N']	[0]
1	lung	I	['N']	[1]
2	injury	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	5-fluorouracil	O	['N']	[5]
6	and	O	['N']	[6]
7	oxaliplatinum	B-Drug	['Causes']	[2]
8	combined	O	['N']	[8]
9	chemotherapy	O	['N']	[9]
10	.	O	['N']	[10]
#4050
0	Diazepam	B-Drug	['Causes']	[14]
1	use	O	['N']	[1]
2	by	O	['N']	[2]
3	pregnant	O	['N']	[3]
4	women	O	['N']	[4]
5	can	O	['N']	[5]
6	be	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	later	O	['N']	[10]
11	presentation	O	['N']	[11]
12	of	O	['N']	[12]
13	withdrawal	B	['N']	[13]
14	symptoms	I-Adverse_Effect	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	neonate	O	['N']	[17]
18	than	O	['N']	[18]
19	that	O	['N']	[19]
20	induced	O	['N']	[20]
21	by	O	['N']	[21]
22	the	O	['N']	[22]
23	use	O	['N']	[23]
24	of	O	['N']	[24]
25	other	O	['N']	[25]
26	drugs	O	['N']	[26]
27	.	O	['N']	[27]
#4051
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	such	O	['N']	[2]
3	a	O	['N']	[3]
4	series	O	['N']	[4]
5	of	O	['N']	[5]
6	patients	O	['N']	[6]
7	who	O	['N']	[7]
8	had	O	['N']	[8]
9	transient	B	['N']	[9]
10	asymptomatic	I	['N']	[10]
11	bradycardia	I-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	being	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	continuous	O	['N']	[16]
17	infusion	O	['N']	[17]
18	5-FU	B-Drug	['Causes']	[11]
19	.	O	['N']	[19]
#4052
0	Our	O	['N']	[0]
1	experience	O	['N']	[1]
2	supports	O	['N']	[2]
3	hemodialysis	O	['N']	[3]
4	for	O	['N']	[4]
5	ESRF	O	['N']	[5]
6	patients	O	['N']	[6]
7	with	O	['N']	[7]
8	atenolol	B-Drug	['Causes']	[9]
9	toxicity	I-Adverse_Effect	['N']	[9]
10	.	O	['N']	[10]
#4053
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	patient	O	['N']	[3]
4	required	O	['N']	[4]
5	insulin	B-Drug	['Causes']	[15]
6	desensitization	O	['N']	[6]
7	for	O	['N']	[7]
8	severe	O	['N']	[8]
9	urticaria	O	['N']	[9]
10	,	O	['N']	[10]
11	angioedema	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	occasional	O	['N']	[14]
15	wheezing	B-Adverse_Effect	['N']	[15]
16	resulting	O	['N']	[16]
17	from	O	['N']	[17]
18	her	O	['N']	[18]
19	insulin	O	['N']	[19]
20	dose	O	['N']	[20]
21	.	O	['N']	[21]
#4054
0	Pulmonary	B	['N']	[0]
1	lymphohistiocytic	I	['N']	[1]
2	reactions	I-Adverse_Effect	['N']	[2]
3	temporally	O	['N']	[3]
4	related	O	['N']	[4]
5	to	O	['N']	[5]
6	etanercept	B-Drug	['Causes']	[2]
7	therapy	O	['N']	[7]
8	.	O	['N']	[8]
#4055
0	Hepatitis	O	['N']	[0]
1	with	O	['N']	[1]
2	bridging	B	['N']	[2]
3	fibrosis	I-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	reversible	O	['N']	[5]
6	hepatic	O	['N']	[6]
7	insufficiency	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	woman	O	['N']	[10]
11	with	O	['N']	[11]
12	rheumatoid	O	['N']	[12]
13	arthritis	O	['N']	[13]
14	taking	O	['N']	[14]
15	methotrexate	B-Drug	['Causes']	[3]
16	.	O	['N']	[16]
#4056
0	During	O	['N']	[0]
1	clarithromycin	B-Drug	['Causes']	[17]
2	coadministration	O	['N']	[2]
3	,	O	['N']	[3]
4	four	O	['N']	[4]
5	out	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	seven	O	['N']	[8]
9	patients	O	['N']	[9]
10	developed	O	['N']	[10]
11	moderate	O	['N']	[11]
12	-	O	['N']	[12]
13	to	O	['N']	[13]
14	-	O	['N']	[14]
15	severe	O	['N']	[15]
16	toxic	B	['N']	[16]
17	symptoms	I-Adverse_Effect	['N']	[17]
18	of	O	['N']	[18]
19	carbamazepine	O	['N']	[19]
20	,	O	['N']	[20]
21	such	O	['N']	[21]
22	as	O	['N']	[22]
23	drowsiness	O	['N']	[23]
24	,	O	['N']	[24]
25	dizziness	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	ataxia	O	['N']	[28]
29	,	O	['N']	[29]
30	which	O	['N']	[30]
31	resolved	O	['N']	[31]
32	within	O	['N']	[32]
33	5	O	['N']	[33]
34	days	O	['N']	[34]
35	after	O	['N']	[35]
36	clarithromycin	O	['N']	[36]
37	discontinuation	O	['N']	[37]
38	.	O	['N']	[38]
#4057
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	there	O	['N']	[2]
3	remain	O	['N']	[3]
4	questions	O	['N']	[4]
5	concerning	O	['N']	[5]
6	whether	O	['N']	[6]
7	these	O	['N']	[7]
8	drugs	O	['N']	[8]
9	,	O	['N']	[9]
10	especially	O	['N']	[10]
11	methimazole	B-Drug	['Causes']	[24]
12	(	O	['N']	[12]
13	MMI	O	['N']	[13]
14	)	O	['N']	[14]
15	,	O	['N']	[15]
16	may	O	['N']	[16]
17	be	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	aplasia	O	['N']	[20]
21	cutis	O	['N']	[21]
22	congenita	O	['N']	[22]
23	(	O	['N']	[23]
24	ACC	B-Adverse_Effect	['N']	[24]
25	)	O	['N']	[25]
26	and	O	['N']	[26]
27	how	O	['N']	[27]
28	best	O	['N']	[28]
29	to	O	['N']	[29]
30	avoid	O	['N']	[30]
31	impairment	O	['N']	[31]
32	of	O	['N']	[32]
33	fetal	O	['N']	[33]
34	thyroid	O	['N']	[34]
35	function	O	['N']	[35]
36	during	O	['N']	[36]
37	their	O	['N']	[37]
38	use	O	['N']	[38]
39	.	O	['N']	[39]
#4058
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	patient	O	['N']	[3]
4	,	O	['N']	[4]
5	a	O	['N']	[5]
6	27-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	married	O	['N']	[9]
10	Japanese	O	['N']	[10]
11	woman	O	['N']	[11]
12	with	O	['N']	[12]
13	borderline	O	['N']	[13]
14	personality	O	['N']	[14]
15	disorder	O	['N']	[15]
16	,	O	['N']	[16]
17	developed	O	['N']	[17]
18	an	O	['N']	[18]
19	increased	B	['N']	[19]
20	libido	I-Adverse_Effect	['N']	[20]
21	with	O	['N']	[21]
22	the	O	['N']	[22]
23	administration	O	['N']	[23]
24	of	O	['N']	[24]
25	fluvoxamine	B-Drug	['Causes']	[20]
26	.	O	['N']	[26]
#4059
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	reversible	O	['N']	[5]
6	encephalopathy	B	['N']	[6]
7	syndrome	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	16-year	O	['N']	[10]
11	-	O	['N']	[11]
12	old	O	['N']	[12]
13	girl	O	['N']	[13]
14	with	O	['N']	[14]
15	acute	O	['N']	[15]
16	myelogenous	O	['N']	[16]
17	leukemia	O	['N']	[17]
18	(	O	['N']	[18]
19	AML	O	['N']	[19]
20	)	O	['N']	[20]
21	,	O	['N']	[21]
22	who	O	['N']	[22]
23	is	O	['N']	[23]
24	undergoing	O	['N']	[24]
25	during	O	['N']	[25]
26	consolidation	O	['N']	[26]
27	chemotherapy	O	['N']	[27]
28	composed	O	['N']	[28]
29	of	O	['N']	[29]
30	BH	O	['N']	[30]
31	-	O	['N']	[31]
32	AC	O	['N']	[32]
33	(	O	['N']	[33]
34	N4-behenoyl-1-beta	O	['N']	[34]
35	-	O	['N']	[35]
36	D	O	['N']	[36]
37	-	O	['N']	[37]
38	arabinofuranosyl	O	['N']	[38]
39	cytosine	O	['N']	[39]
40	)	O	['N']	[40]
41	and	O	['N']	[41]
42	idarubicin	B-Drug	['Causes']	[7]
43	.	O	['N']	[43]
#4060
0	Clinicians	O	['N']	[0]
1	should	O	['N']	[1]
2	include	O	['N']	[2]
3	phenolphthalein	B-Drug	['Causes']	[14]
4	in	O	['N']	[4]
5	their	O	['N']	[5]
6	list	O	['N']	[6]
7	of	O	['N']	[7]
8	possible	O	['N']	[8]
9	causes	O	['N']	[9]
10	of	O	['N']	[10]
11	drug	O	['N']	[11]
12	-	O	['N']	[12]
13	induced	O	['N']	[13]
14	TEN	B-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#4061
0	Amikacin	B-Drug	['Causes']	[8]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	type	B	['N']	[3]
4	5	I	['N']	[4]
5	Bartter	I	['N']	[5]
6	-	I	['N']	[6]
7	like	I	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	with	O	['N']	[9]
10	severe	O	['N']	[10]
11	hypocalcemia	O	['N']	[11]
12	.	O	['N']	[12]
#4062
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	our	O	['N']	[3]
4	knowledge	O	['N']	[4]
5	,	O	['N']	[5]
6	this	O	['N']	[6]
7	is	O	['N']	[7]
8	the	O	['N']	[8]
9	first	O	['N']	[9]
10	case	O	['N']	[10]
11	report	O	['N']	[11]
12	illustrating	O	['N']	[12]
13	neuralgic	B	['N']	[13]
14	amyotrophy	I-Adverse_Effect	['N']	[14]
15	triggered	O	['N']	[15]
16	by	O	['N']	[16]
17	exposure	O	['N']	[17]
18	to	O	['N']	[18]
19	the	O	['N']	[19]
20	antibiotics	O	['N']	[20]
21	vancomycin	O	['N']	[21]
22	,	O	['N']	[22]
23	tobramycin	B-Drug	['Causes']	[14]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	piperacillin	O	['N']	[26]
27	/	O	['N']	[27]
28	tazobactam	O	['N']	[28]
29	.	O	['N']	[29]
#4063
0	Psoriasis	B	['N']	[0]
1	-	I	['N']	[1]
2	like	I	['N']	[2]
3	skin	I	['N']	[3]
4	reaction	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	rheumatoid	O	['N']	[9]
10	arthritis	O	['N']	[10]
11	after	O	['N']	[11]
12	sulphasalazine	B-Drug	['Causes']	[4]
13	therapy	O	['N']	[13]
14	.	O	['N']	[14]
#4064
0	Pigmentary	B	['N']	[0]
1	disorders	I-Adverse_Effect	['N']	[1]
2	are	O	['N']	[2]
3	recognized	O	['N']	[3]
4	adverse	O	['N']	[4]
5	effects	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	semi	O	['N']	[8]
9	-	O	['N']	[9]
10	synthetic	O	['N']	[10]
11	tetracycline	O	['N']	[11]
12	derivative	O	['N']	[12]
13	antibiotic	O	['N']	[13]
14	,	O	['N']	[14]
15	minocycline	B-Drug	['Causes']	[1]
16	.	O	['N']	[16]
#4065
0	A	O	['N']	[0]
1	small	O	['N']	[1]
2	number	O	['N']	[2]
3	of	O	['N']	[3]
4	oxaliplatin	B-Drug	['Causes']	[10]
5	-	O	['N']	[5]
6	related	O	['N']	[6]
7	hemolytic	B	['N']	[7]
8	and/or	I	['N']	[8]
9	thrombocytopenic	I	['N']	[9]
10	reactions	I-Adverse_Effect	['N']	[10]
11	have	O	['N']	[11]
12	been	O	['N']	[12]
13	reported	O	['N']	[13]
14	.	O	['N']	[14]
#4066
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	are	O	['N']	[2]
3	described	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	sensory	B	['N']	[6]
7	neuropathy	I-Adverse_Effect	['N']	[7]
8	after	O	['N']	[8]
9	the	O	['N']	[9]
10	ingestion	O	['N']	[10]
11	of	O	['N']	[11]
12	30.6	O	['N']	[12]
13	and	O	['N']	[13]
14	114	O	['N']	[14]
15	g	O	['N']	[15]
16	metronidazole	B-Drug	['Causes']	[7]
17	respectively	O	['N']	[17]
18	.	O	['N']	[18]
#4067
0	Hypoglycemia	O	['N']	[0]
1	can	O	['N']	[1]
2	be	O	['N']	[2]
3	a	O	['N']	[3]
4	serious	O	['N']	[4]
5	side	O	['N']	[5]
6	effect	O	['N']	[6]
7	of	O	['N']	[7]
8	etanercept	B-Drug	['Causes']	[18]
9	in	O	['N']	[9]
10	patients	O	['N']	[10]
11	already	O	['N']	[11]
12	on	O	['N']	[12]
13	antidiabetic	O	['N']	[13]
14	medications	O	['N']	[14]
15	known	O	['N']	[15]
16	to	O	['N']	[16]
17	cause	O	['N']	[17]
18	hypoglycemia	B-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	such	O	['N']	[20]
21	as	O	['N']	[21]
22	sulfonylureas	O	['N']	[22]
23	,	O	['N']	[23]
24	meglitinides	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	insulin	O	['N']	[27]
28	.	O	['N']	[28]
#4068
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	mania	B-Adverse_Effect	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	fluoxetine	B-Drug	['Causes']	[3]
7	.	O	['N']	[7]
#4069
0	DATA	O	['N']	[0]
1	SYNTHESIS	O	['N']	[1]
2	:	O	['N']	[2]
3	Genetic	O	['N']	[3]
4	deficiencies	O	['N']	[4]
5	in	O	['N']	[5]
6	DPD	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	rate	O	['N']	[9]
10	-	O	['N']	[10]
11	limiting	O	['N']	[11]
12	enzyme	O	['N']	[12]
13	responsible	O	['N']	[13]
14	for	O	['N']	[14]
15	5-FU	B-Drug	['Causes']	[50]
16	catabolism	O	['N']	[16]
17	,	O	['N']	[17]
18	may	O	['N']	[18]
19	occur	O	['N']	[19]
20	in	O	['N']	[20]
21	3	O	['N']	[21]
22	%	O	['N']	[22]
23	or	O	['N']	[23]
24	more	O	['N']	[24]
25	of	O	['N']	[25]
26	patients	O	['N']	[26]
27	with	O	['N']	[27]
28	cancer	O	['N']	[28]
29	putting	O	['N']	[29]
30	them	O	['N']	[30]
31	at	O	['N']	[31]
32	increased	O	['N']	[32]
33	risk	O	['N']	[33]
34	for	O	['N']	[34]
35	unusually	O	['N']	[35]
36	severe	O	['N']	[36]
37	adverse	O	['N']	[37]
38	reactions	O	['N']	[38]
39	(	O	['N']	[39]
40	e.g.	O	['N']	[40]
41	,	O	['N']	[41]
42	diarrhea	O	['N']	[42]
43	,	O	['N']	[43]
44	stomatitis	O	['N']	[44]
45	,	O	['N']	[45]
46	mucositis	O	['N']	[46]
47	,	O	['N']	[47]
48	myelosuppression	O	['N']	[48]
49	,	O	['N']	[49]
50	neurotoxicity	B-Adverse_Effect	['N']	[50]
51	)	O	['N']	[51]
52	to	O	['N']	[52]
53	standard	O	['N']	[53]
54	doses	O	['N']	[54]
55	of	O	['N']	[55]
56	5-FU	O	['N']	[56]
57	.	O	['N']	[57]
#4070
0	Fever	O	['N']	[0]
1	,	O	['N']	[1]
2	lymphadenopathy	O	['N']	[2]
3	,	O	['N']	[3]
4	eosinophilia	B-Adverse_Effect	['N']	[4]
5	,	O	['N']	[5]
6	lymphocytosis	O	['N']	[6]
7	,	O	['N']	[7]
8	hepatitis	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	dermatitis	O	['N']	[11]
12	:	O	['N']	[12]
13	a	O	['N']	[13]
14	severe	O	['N']	[14]
15	adverse	O	['N']	[15]
16	reaction	O	['N']	[16]
17	to	O	['N']	[17]
18	minocycline	B-Drug	['Causes']	[4]
19	.	O	['N']	[19]
#4071
0	Successful	O	['N']	[0]
1	recovery	O	['N']	[1]
2	from	O	['N']	[2]
3	interstitial	B	['N']	[3]
4	pneumonitis	I-Adverse_Effect	['N']	[4]
5	,	O	['N']	[5]
6	induced	O	['N']	[6]
7	by	O	['N']	[7]
8	bicalutamide	B-Drug	['Causes']	[4]
9	and	O	['N']	[9]
10	leuprorelin	O	['N']	[10]
11	acetate	O	['N']	[11]
12	given	O	['N']	[12]
13	as	O	['N']	[13]
14	treatment	O	['N']	[14]
15	for	O	['N']	[15]
16	prostate	O	['N']	[16]
17	cancer	O	['N']	[17]
18	.	O	['N']	[18]
#4072
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	ovarian	O	['N']	[3]
4	cancer	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	received	O	['N']	[7]
8	multiple	O	['N']	[8]
9	courses	O	['N']	[9]
10	of	O	['N']	[10]
11	cisplatin	B-Drug	['Causes']	[45]
12	without	O	['N']	[12]
13	complications	O	['N']	[13]
14	experienced	O	['N']	[14]
15	hypersensitivity	O	['N']	[15]
16	reactions	O	['N']	[16]
17	to	O	['N']	[17]
18	cisplatin	O	['N']	[18]
19	:	O	['N']	[19]
20	one	O	['N']	[20]
21	,	O	['N']	[21]
22	involving	O	['N']	[22]
23	intrahepatic	O	['N']	[23]
24	artery	O	['N']	[24]
25	infusion	O	['N']	[25]
26	,	O	['N']	[26]
27	manifested	O	['N']	[27]
28	general	O	['N']	[28]
29	erythema	O	['N']	[29]
30	,	O	['N']	[30]
31	dyspnea	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	hypotension	O	['N']	[34]
35	;	O	['N']	[35]
36	the	O	['N']	[36]
37	other	O	['N']	[37]
38	,	O	['N']	[38]
39	involving	O	['N']	[39]
40	intravenous	O	['N']	[40]
41	infusion	O	['N']	[41]
42	,	O	['N']	[42]
43	manifested	O	['N']	[43]
44	abdominal	B	['N']	[44]
45	pain	I-Adverse_Effect	['N']	[45]
46	,	O	['N']	[46]
47	general	O	['N']	[47]
48	erythema	O	['N']	[48]
49	,	O	['N']	[49]
50	and	O	['N']	[50]
51	fever	O	['N']	[51]
52	.	O	['N']	[52]
#4073
0	From	O	['N']	[0]
1	1996	O	['N']	[1]
2	to	O	['N']	[2]
3	2002	O	['N']	[3]
4	several	O	['N']	[4]
5	medications	O	['N']	[5]
6	were	O	['N']	[6]
7	changed	O	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	their	O	['N']	[10]
11	adverse	O	['N']	[11]
12	effects	O	['N']	[12]
13	:	O	['N']	[13]
14	indinavir	B-Drug	['Causes']	[19]
15	(	O	['N']	[15]
16	renal	O	['N']	[16]
17	colic	O	['N']	[17]
18	and	O	['N']	[18]
19	fever	B-Adverse_Effect	['N']	[19]
20	)	O	['N']	[20]
21	,	O	['N']	[21]
22	nelfinavir	O	['N']	[22]
23	(	O	['N']	[23]
24	cutaneous	O	['N']	[24]
25	rash	O	['N']	[25]
26	)	O	['N']	[26]
27	,	O	['N']	[27]
28	and	O	['N']	[28]
29	efavirenz	O	['N']	[29]
30	(	O	['N']	[30]
31	nausea	O	['N']	[31]
32	and	O	['N']	[32]
33	temporary	O	['N']	[33]
34	memory	O	['N']	[34]
35	loss	O	['N']	[35]
36	)	O	['N']	[36]
37	.	O	['N']	[37]
#4074
0	Upper	B	['N']	[0]
1	gastrointestinal	I	['N']	[1]
2	haemorrhage	I-Adverse_Effect	['N']	[2]
3	is	O	['N']	[3]
4	a	O	['N']	[4]
5	serious	O	['N']	[5]
6	complication	O	['N']	[6]
7	of	O	['N']	[7]
8	aspirin	O	['N']	[8]
9	and	O	['N']	[9]
10	clopidogrel	B-Drug	['Causes']	[2]
11	(	O	['N']	[11]
12	dual	O	['N']	[12]
13	)	O	['N']	[13]
14	anti	O	['N']	[14]
15	-	O	['N']	[15]
16	platelet	O	['N']	[16]
17	therapy	O	['N']	[17]
18	with	O	['N']	[18]
19	a	O	['N']	[19]
20	high	O	['N']	[20]
21	morbidity	O	['N']	[21]
22	and	O	['N']	[22]
23	mortality	O	['N']	[23]
24	.	O	['N']	[24]
#4075
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	linezolid	B-Drug	['Causes']	[8]
4	-	O	['N']	[4]
5	associated	O	['N']	[5]
6	acute	B	['N']	[6]
7	interstitial	I	['N']	[7]
8	nephritis	I-Adverse_Effect	['N']	[8]
9	within	O	['N']	[9]
10	the	O	['N']	[10]
11	context	O	['N']	[11]
12	of	O	['N']	[12]
13	a	O	['N']	[13]
14	drug	O	['N']	[14]
15	rash	O	['N']	[15]
16	with	O	['N']	[16]
17	eosinophilia	O	['N']	[17]
18	and	O	['N']	[18]
19	systemic	O	['N']	[19]
20	symptoms	O	['N']	[20]
21	(	O	['N']	[21]
22	DRESS	O	['N']	[22]
23	)	O	['N']	[23]
24	syndrome	O	['N']	[24]
25	in	O	['N']	[25]
26	a	O	['N']	[26]
27	patient	O	['N']	[27]
28	treated	O	['N']	[28]
29	with	O	['N']	[29]
30	linezolid	O	['N']	[30]
31	raises	O	['N']	[31]
32	concerns	O	['N']	[32]
33	about	O	['N']	[33]
34	the	O	['N']	[34]
35	presumed	O	['N']	[35]
36	renal	O	['N']	[36]
37	safety	O	['N']	[37]
38	of	O	['N']	[38]
39	this	O	['N']	[39]
40	drug	O	['N']	[40]
41	.	O	['N']	[41]
#4076
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	prolonged	O	['N']	[3]
4	suxamethonium	B-Drug	['Causes']	[5]
5	apnoea	B-Adverse_Effect	['N']	[5]
6	successfully	O	['N']	[6]
7	terminated	O	['N']	[7]
8	by	O	['N']	[8]
9	the	O	['N']	[9]
10	infusion	O	['N']	[10]
11	of	O	['N']	[11]
12	a	O	['N']	[12]
13	commercial	O	['N']	[13]
14	preparation	O	['N']	[14]
15	of	O	['N']	[15]
16	serumcholinesterase	O	['N']	[16]
17	is	O	['N']	[17]
18	reported	O	['N']	[18]
19	.	O	['N']	[19]
#4077
0	Cephalosporins	B-Drug	['Causes']	[8]
1	are	O	['N']	[1]
2	most	O	['N']	[2]
3	likely	O	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	Vitamin	B	['N']	[6]
7	K	I	['N']	[7]
8	deficiency	I-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#4078
0	Lichen	B	['N']	[0]
1	planus	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	acne	O	['N']	[3]
4	provoked	O	['N']	[4]
5	by	O	['N']	[5]
6	gold	B-Drug	['Causes']	[1]
7	.	O	['N']	[7]
#4079
0	Bulbar	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	pseudobulbar	O	['N']	[2]
3	palsy	O	['N']	[3]
4	complicating	O	['N']	[4]
5	therapy	O	['N']	[5]
6	with	O	['N']	[6]
7	high	O	['N']	[7]
8	-	O	['N']	[8]
9	dose	O	['N']	[9]
10	cytosine	B	['N']	[10]
11	arabinoside	I-Drug	['Causes']	[0]
12	in	O	['N']	[12]
13	children	O	['N']	[13]
14	with	O	['N']	[14]
15	leukemia	O	['N']	[15]
16	.	O	['N']	[16]
#4080
0	Disseminated	B	['N']	[0]
1	cellulitic	I	['N']	[1]
2	cryptococcosis	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	the	O	['N']	[4]
5	setting	O	['N']	[5]
6	of	O	['N']	[6]
7	prednisone	B-Drug	['Causes']	[2]
8	monotherapy	O	['N']	[8]
9	for	O	['N']	[9]
10	pemphigus	O	['N']	[10]
11	vulgaris	O	['N']	[11]
12	.	O	['N']	[12]
#4081
0	Six	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	starting	O	['N']	[3]
4	acyclovir	B-Drug	['Causes']	[10]
5	she	O	['N']	[5]
6	exhibited	O	['N']	[6]
7	signs	O	['N']	[7]
8	of	O	['N']	[8]
9	lithium	B	['N']	[9]
10	toxicity	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#4082
0	Because	O	['N']	[0]
1	the	O	['N']	[1]
2	cerebellar	B	['N']	[2]
3	toxicity	I-Adverse_Effect	['N']	[3]
4	may	O	['N']	[4]
5	be	O	['N']	[5]
6	worsened	O	['N']	[6]
7	by	O	['N']	[7]
8	continuation	O	['N']	[8]
9	of	O	['N']	[9]
10	therapy	O	['N']	[10]
11	after	O	['N']	[11]
12	initial	O	['N']	[12]
13	onset	O	['N']	[13]
14	of	O	['N']	[14]
15	symptoms	O	['N']	[15]
16	,	O	['N']	[16]
17	prompt	O	['N']	[17]
18	termination	O	['N']	[18]
19	of	O	['N']	[19]
20	HDARAC	B-Drug	['Causes']	[3]
21	is	O	['N']	[21]
22	recommended	O	['N']	[22]
23	.	O	['N']	[23]
#4083
0	CASE	O	['N']	[0]
1	REPORT	O	['N']	[1]
2	:	O	['N']	[2]
3	We	O	['N']	[3]
4	describe	O	['N']	[4]
5	here	O	['N']	[5]
6	a	O	['N']	[6]
7	case	O	['N']	[7]
8	of	O	['N']	[8]
9	a	O	['N']	[9]
10	60	O	['N']	[10]
11	year	O	['N']	[11]
12	old	O	['N']	[12]
13	female	O	['N']	[13]
14	that	O	['N']	[14]
15	experienced	O	['N']	[15]
16	a	O	['N']	[16]
17	relapse	O	['N']	[17]
18	of	O	['N']	[18]
19	symptomatic	B	['N']	[19]
20	hyperlactatemia	I-Adverse_Effect	['N']	[20]
21	after	O	['N']	[21]
22	being	O	['N']	[22]
23	switched	O	['N']	[23]
24	from	O	['N']	[24]
25	stavudine	O	['N']	[25]
26	to	O	['N']	[26]
27	zidovudine	B-Drug	['Causes']	[20]
28	and	O	['N']	[28]
29	how	O	['N']	[29]
30	the	O	['N']	[30]
31	case	O	['N']	[31]
32	was	O	['N']	[32]
33	managed	O	['N']	[33]
34	at	O	['N']	[34]
35	the	O	['N']	[35]
36	Infectious	O	['N']	[36]
37	Diseases	O	['N']	[37]
38	Institute	O	['N']	[38]
39	,	O	['N']	[39]
40	Kampala	O	['N']	[40]
41	,	O	['N']	[41]
42	Uganda	O	['N']	[42]
43	.	O	['N']	[43]
#4084
0	An	O	['N']	[0]
1	infant	O	['N']	[1]
2	girl	O	['N']	[2]
3	with	O	['N']	[3]
4	choanal	O	['N']	[4]
5	atresia	O	['N']	[5]
6	,	O	['N']	[6]
7	athelia	O	['N']	[7]
8	,	O	['N']	[8]
9	minor	O	['N']	[9]
10	anomalies	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	mild	O	['N']	[13]
14	to	O	['N']	[14]
15	moderate	O	['N']	[15]
16	mental	B	['N']	[16]
17	retardation	I-Adverse_Effect	['N']	[17]
18	was	O	['N']	[18]
19	born	O	['N']	[19]
20	to	O	['N']	[20]
21	a	O	['N']	[21]
22	woman	O	['N']	[22]
23	treated	O	['N']	[23]
24	for	O	['N']	[24]
25	hyperthyroidism	O	['N']	[25]
26	throughout	O	['N']	[26]
27	pregnancy	O	['N']	[27]
28	with	O	['N']	[28]
29	methimazole	B-Drug	['Causes']	[17]
30	and	O	['N']	[30]
31	propranolol	O	['N']	[31]
32	.	O	['N']	[32]
#4085
0	Amiodarone	B	['N']	[0]
1	hydrochloride	I-Drug	['Causes']	[13]
2	,	O	['N']	[2]
3	a	O	['N']	[3]
4	new	O	['N']	[4]
5	antiarrhythmic	O	['N']	[5]
6	agent	O	['N']	[6]
7	,	O	['N']	[7]
8	has	O	['N']	[8]
9	been	O	['N']	[9]
10	associated	O	['N']	[10]
11	with	O	['N']	[11]
12	pulmonary	B	['N']	[12]
13	toxicity	I-Adverse_Effect	['N']	[13]
14	characterized	O	['N']	[14]
15	by	O	['N']	[15]
16	cough	O	['N']	[16]
17	,	O	['N']	[17]
18	dyspnea	O	['N']	[18]
19	and	O	['N']	[19]
20	diffuse	O	['N']	[20]
21	pulmonary	O	['N']	[21]
22	infiltrates	O	['N']	[22]
23	.	O	['N']	[23]
#4086
0	The	O	['N']	[0]
1	development	O	['N']	[1]
2	of	O	['N']	[2]
3	systemic	O	['N']	[3]
4	lupus	O	['N']	[4]
5	erythematosus	O	['N']	[5]
6	(	O	['N']	[6]
7	SLE	B-Adverse_Effect	['N']	[7]
8	)	O	['N']	[8]
9	after	O	['N']	[9]
10	38	O	['N']	[10]
11	months	O	['N']	[11]
12	of	O	['N']	[12]
13	therapy	O	['N']	[13]
14	with	O	['N']	[14]
15	recombinant	B	['N']	[15]
16	human	I	['N']	[16]
17	interferon	I	['N']	[17]
18	gamma	I-Drug	['Causes']	[7]
19	(	O	['N']	[19]
20	rIFN	O	['N']	[20]
21	-	O	['N']	[21]
22	gamma	O	['N']	[22]
23	)	O	['N']	[23]
24	was	O	['N']	[24]
25	observed	O	['N']	[25]
26	in	O	['N']	[26]
27	a	O	['N']	[27]
28	patient	O	['N']	[28]
29	with	O	['N']	[29]
30	rheumatoid	O	['N']	[30]
31	arthritis	O	['N']	[31]
32	.	O	['N']	[32]
#4087
0	Although	O	['N']	[0]
1	lung	O	['N']	[1]
2	specimens	O	['N']	[2]
3	were	O	['N']	[3]
4	lacking	O	['N']	[4]
5	from	O	['N']	[5]
6	these	O	['N']	[6]
7	three	O	['N']	[7]
8	patients	O	['N']	[8]
9	,	O	['N']	[9]
10	it	O	['N']	[10]
11	is	O	['N']	[11]
12	suggested	O	['N']	[12]
13	that	O	['N']	[13]
14	the	O	['N']	[14]
15	pulmonary	B	['N']	[15]
16	toxicity	I-Adverse_Effect	['N']	[16]
17	of	O	['N']	[17]
18	CCNU	B-Drug	['Causes']	[16]
19	may	O	['N']	[19]
20	be	O	['N']	[20]
21	dose	O	['N']	[21]
22	-	O	['N']	[22]
23	related	O	['N']	[23]
24	.	O	['N']	[24]
#4088
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Central	B	['N']	[2]
3	nervous	I	['N']	[3]
4	system	I	['N']	[4]
5	(	I	['N']	[5]
6	CNS	I	['N']	[6]
7	)	I	['N']	[7]
8	toxicity	I-Adverse_Effect	['N']	[8]
9	has	O	['N']	[9]
10	been	O	['N']	[10]
11	described	O	['N']	[11]
12	with	O	['N']	[12]
13	ifosfamide	B-Drug	['Causes']	[8]
14	,	O	['N']	[14]
15	with	O	['N']	[15]
16	most	O	['N']	[16]
17	cases	O	['N']	[17]
18	reported	O	['N']	[18]
19	in	O	['N']	[19]
20	the	O	['N']	[20]
21	pediatric	O	['N']	[21]
22	population	O	['N']	[22]
23	.	O	['N']	[23]
#4089
0	When	O	['N']	[0]
1	vague	B	['N']	[1]
2	symptoms	I-Adverse_Effect	['N']	[2]
3	develop	O	['N']	[3]
4	during	O	['N']	[4]
5	desmopressin	B-Drug	['Causes']	[2]
6	therapy	O	['N']	[6]
7	,	O	['N']	[7]
8	hyponatremia	O	['N']	[8]
9	must	O	['N']	[9]
10	be	O	['N']	[10]
11	considered	O	['N']	[11]
12	as	O	['N']	[12]
13	part	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	differential	O	['N']	[16]
17	diagnosis	O	['N']	[17]
18	.	O	['N']	[18]
#4090
0	The	O	['N']	[0]
1	current	O	['N']	[1]
2	report	O	['N']	[2]
3	describes	O	['N']	[3]
4	a	O	['N']	[4]
5	man	O	['N']	[5]
6	who	O	['N']	[6]
7	was	O	['N']	[7]
8	prescribed	O	['N']	[8]
9	zonisamide	B-Drug	['Causes']	[21]
10	for	O	['N']	[10]
11	epilepsy	O	['N']	[11]
12	and	O	['N']	[12]
13	subsequently	O	['N']	[13]
14	developed	O	['N']	[14]
15	widespread	O	['N']	[15]
16	skin	O	['N']	[16]
17	rash	O	['N']	[17]
18	,	O	['N']	[18]
19	acute	B	['N']	[19]
20	kidney	I	['N']	[20]
21	injury	I-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	high	O	['N']	[23]
24	-	O	['N']	[24]
25	grade	O	['N']	[25]
26	fever	O	['N']	[26]
27	,	O	['N']	[27]
28	eosinophilia	O	['N']	[28]
29	,	O	['N']	[29]
30	liver	O	['N']	[30]
31	dysfunction	O	['N']	[31]
32	,	O	['N']	[32]
33	lymphadenopathy	O	['N']	[33]
34	and	O	['N']	[34]
35	an	O	['N']	[35]
36	increase	O	['N']	[36]
37	in	O	['N']	[37]
38	antihuman	O	['N']	[38]
39	herpesvirus-6	O	['N']	[39]
40	immunoglobulin	O	['N']	[40]
41	G	O	['N']	[41]
42	titer	O	['N']	[42]
43	.	O	['N']	[43]
#4091
0	Acetazolamide	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	accelerated	O	['N']	[2]
3	anticonvulsant	O	['N']	[3]
4	osteomalacia	B-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#4092
0	Two	O	['N']	[0]
1	infants	O	['N']	[1]
2	developed	O	['N']	[2]
3	hyperkalemia	B-Adverse_Effect	['N']	[3]
4	shortly	O	['N']	[4]
5	after	O	['N']	[5]
6	cessation	O	['N']	[6]
7	of	O	['N']	[7]
8	prolonged	O	['N']	[8]
9	ACTH	B-Drug	['Causes']	[3]
10	therapy	O	['N']	[10]
11	for	O	['N']	[11]
12	infantile	O	['N']	[12]
13	spasms	O	['N']	[13]
14	.	O	['N']	[14]
#4093
0	These	O	['N']	[0]
1	in	O	['N']	[1]
2	vitro	O	['N']	[2]
3	findings	O	['N']	[3]
4	and	O	['N']	[4]
5	clinical	O	['N']	[5]
6	course	O	['N']	[6]
7	suggest	O	['N']	[7]
8	that	O	['N']	[8]
9	TRAb	O	['N']	[9]
10	/	O	['N']	[10]
11	TBII	O	['N']	[11]
12	without	O	['N']	[12]
13	thyroid	O	['N']	[13]
14	-	O	['N']	[14]
15	stimulating	O	['N']	[15]
16	activity	O	['N']	[16]
17	may	O	['N']	[17]
18	develop	O	['N']	[18]
19	in	O	['N']	[19]
20	patients	O	['N']	[20]
21	with	O	['N']	[21]
22	amiodarone	B-Drug	['Causes']	[26]
23	-	O	['N']	[23]
24	induced	O	['N']	[24]
25	destructive	B	['N']	[25]
26	thyroiditis	I-Adverse_Effect	['N']	[26]
27	,	O	['N']	[27]
28	as	O	['N']	[28]
29	reported	O	['N']	[29]
30	in	O	['N']	[30]
31	patients	O	['N']	[31]
32	with	O	['N']	[32]
33	destructive	O	['N']	[33]
34	thyroiditis	O	['N']	[34]
35	,	O	['N']	[35]
36	such	O	['N']	[36]
37	as	O	['N']	[37]
38	subacute	O	['N']	[38]
39	and	O	['N']	[39]
40	silent	O	['N']	[40]
41	thyroiditis	O	['N']	[41]
42	.	O	['N']	[42]
#4094
0	Gynaecomastia	B-Adverse_Effect	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	rarely	O	['N']	[3]
4	reported	O	['N']	[4]
5	adverse	O	['N']	[5]
6	drug	O	['N']	[6]
7	reaction	O	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	isoniazid	B-Drug	['Causes']	[0]
11	therapy	O	['N']	[11]
12	.	O	['N']	[12]
#4095
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	's	O	['N']	[2]
3	previous	O	['N']	[3]
4	rash	O	['N']	[4]
5	and	O	['N']	[5]
6	the	O	['N']	[6]
7	temporal	O	['N']	[7]
8	relation	O	['N']	[8]
9	of	O	['N']	[9]
10	this	O	['N']	[10]
11	event	O	['N']	[11]
12	and	O	['N']	[12]
13	the	O	['N']	[13]
14	ingestion	O	['N']	[14]
15	of	O	['N']	[15]
16	phenolphthalein	B-Drug	['Causes']	[37]
17	,	O	['N']	[17]
18	as	O	['N']	[18]
19	well	O	['N']	[19]
20	as	O	['N']	[20]
21	the	O	['N']	[21]
22	similarity	O	['N']	[22]
23	of	O	['N']	[23]
24	this	O	['N']	[24]
25	case	O	['N']	[25]
26	to	O	['N']	[26]
27	other	O	['N']	[27]
28	reports	O	['N']	[28]
29	,	O	['N']	[29]
30	point	O	['N']	[30]
31	to	O	['N']	[31]
32	phenolphthalein	O	['N']	[32]
33	as	O	['N']	[33]
34	the	O	['N']	[34]
35	cause	O	['N']	[35]
36	of	O	['N']	[36]
37	TEN	B-Adverse_Effect	['N']	[37]
38	in	O	['N']	[38]
39	this	O	['N']	[39]
40	patient	O	['N']	[40]
41	.	O	['N']	[41]
#4096
0	The	O	['N']	[0]
1	development	O	['N']	[1]
2	of	O	['N']	[2]
3	cutaneous	O	['N']	[3]
4	ecchymosis	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	a	O	['N']	[7]
8	sudden	B	['N']	[8]
9	fall	I	['N']	[9]
10	in	I	['N']	[10]
11	hemoglobin	I-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	the	O	['N']	[13]
14	administration	O	['N']	[14]
15	of	O	['N']	[15]
16	alteplase	B-Drug	['Causes']	[11]
17	should	O	['N']	[17]
18	strongly	O	['N']	[18]
19	suggest	O	['N']	[19]
20	the	O	['N']	[20]
21	possibility	O	['N']	[21]
22	of	O	['N']	[22]
23	diffuse	O	['N']	[23]
24	subfascial	O	['N']	[24]
25	hematoma	O	['N']	[25]
26	.	O	['N']	[26]
#4097
0	Acute	B	['N']	[0]
1	generalized	I	['N']	[1]
2	exanthematous	I	['N']	[2]
3	pustulosis	I-Adverse_Effect	['N']	[3]
4	caused	O	['N']	[4]
5	by	O	['N']	[5]
6	morphine	B-Drug	['Causes']	[3]
7	,	O	['N']	[7]
8	confirmed	O	['N']	[8]
9	by	O	['N']	[9]
10	positive	O	['N']	[10]
11	patch	O	['N']	[11]
12	test	O	['N']	[12]
13	and	O	['N']	[13]
14	lymphocyte	O	['N']	[14]
15	transformation	O	['N']	[15]
16	test	O	['N']	[16]
17	.	O	['N']	[17]
#4098
0	Growth	B	['N']	[0]
1	and	I	['N']	[1]
2	adrenal	I	['N']	[2]
3	suppression	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	asthmatic	O	['N']	[5]
6	children	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	high	O	['N']	[9]
10	-	O	['N']	[10]
11	dose	O	['N']	[11]
12	fluticasone	B	['N']	[12]
13	propionate	I-Drug	['Causes']	[3]
14	.	O	['N']	[14]
#4099
0	Prominent	O	['N']	[0]
1	eye	O	['N']	[1]
2	movements	O	['N']	[2]
3	during	O	['N']	[3]
4	NREM	O	['N']	[4]
5	sleep	O	['N']	[5]
6	and	O	['N']	[6]
7	REM	B	['N']	[7]
8	sleep	I	['N']	[8]
9	behavior	I	['N']	[9]
10	disorder	I-Adverse_Effect	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	fluoxetine	B-Drug	['Causes']	[10]
14	treatment	O	['N']	[14]
15	of	O	['N']	[15]
16	depression	O	['N']	[16]
17	and	O	['N']	[17]
18	obsessive	O	['N']	[18]
19	-	O	['N']	[19]
20	compulsive	O	['N']	[20]
21	disorder	O	['N']	[21]
22	.	O	['N']	[22]
#4100
0	Although	O	['N']	[0]
1	they	O	['N']	[1]
2	had	O	['N']	[2]
3	complex	O	['N']	[3]
4	medical	O	['N']	[4]
5	problems	O	['N']	[5]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	high	O	['N']	[8]
9	serum	O	['N']	[9]
10	concentrations	O	['N']	[10]
11	of	O	['N']	[11]
12	ampicillin	B-Drug	['Causes']	[17]
13	at	O	['N']	[13]
14	the	O	['N']	[14]
15	time	O	['N']	[15]
16	of	O	['N']	[16]
17	seizures	B-Adverse_Effect	['N']	[17]
18	without	O	['N']	[18]
19	their	O	['N']	[19]
20	recurrence	O	['N']	[20]
21	after	O	['N']	[21]
22	discontinuing	O	['N']	[22]
23	the	O	['N']	[23]
24	antibiotic	O	['N']	[24]
25	suggest	O	['N']	[25]
26	that	O	['N']	[26]
27	the	O	['N']	[27]
28	seizures	O	['N']	[28]
29	were	O	['N']	[29]
30	related	O	['N']	[30]
31	to	O	['N']	[31]
32	the	O	['N']	[32]
33	ampicillin	O	['N']	[33]
34	therapy	O	['N']	[34]
35	.	O	['N']	[35]
#4101
0	A	O	['N']	[0]
1	30-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	pharmacist	O	['N']	[4]
5	suffered	O	['N']	[5]
6	from	O	['N']	[6]
7	acute	B	['N']	[7]
8	allergic	I	['N']	[8]
9	contact	I	['N']	[9]
10	dermatitis	I-Adverse_Effect	['N']	[10]
11	due	O	['N']	[11]
12	to	O	['N']	[12]
13	4-chloro-7-nitrobenzofurazan	B-Drug	['Causes']	[10]
14	(	O	['N']	[14]
15	NBD	O	['N']	[15]
16	-	O	['N']	[16]
17	Cl	O	['N']	[17]
18	)	O	['N']	[18]
19	.	O	['N']	[19]
#4102
0	Central	O	['N']	[0]
1	nervous	O	['N']	[1]
2	system	O	['N']	[2]
3	effects	O	['N']	[3]
4	secondary	O	['N']	[4]
5	to	O	['N']	[5]
6	ciprofloxacin	B-Drug	['Causes']	[19]
7	treatment	O	['N']	[7]
8	are	O	['N']	[8]
9	uncommon	O	['N']	[9]
10	and	O	['N']	[10]
11	usually	O	['N']	[11]
12	consist	O	['N']	[12]
13	only	O	['N']	[13]
14	of	O	['N']	[14]
15	minor	O	['N']	[15]
16	dizziness	O	['N']	[16]
17	or	O	['N']	[17]
18	mild	B	['N']	[18]
19	headache	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	although	O	['N']	[21]
22	rare	O	['N']	[22]
23	occurrences	O	['N']	[23]
24	of	O	['N']	[24]
25	seizures	O	['N']	[25]
26	and	O	['N']	[26]
27	hallucinations	O	['N']	[27]
28	have	O	['N']	[28]
29	been	O	['N']	[29]
30	reported	O	['N']	[30]
31	.	O	['N']	[31]
#4103
0	The	O	['N']	[0]
1	main	O	['N']	[1]
2	clinical	O	['N']	[2]
3	features	O	['N']	[3]
4	of	O	['N']	[4]
5	this	O	['N']	[5]
6	58-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	female	O	['N']	[9]
10	patient	O	['N']	[10]
11	were	O	['N']	[11]
12	laboratory	O	['N']	[12]
13	evidence	O	['N']	[13]
14	of	O	['N']	[14]
15	leucopenia	O	['N']	[15]
16	and	O	['N']	[16]
17	cholestasis	B-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	biopsy	O	['N']	[20]
21	features	O	['N']	[21]
22	of	O	['N']	[22]
23	fatty	O	['N']	[23]
24	liver	O	['N']	[24]
25	parenchyma	O	['N']	[25]
26	degeneration	O	['N']	[26]
27	with	O	['N']	[27]
28	granulocytic	O	['N']	[28]
29	portal	O	['N']	[29]
30	infiltration	O	['N']	[30]
31	and	O	['N']	[31]
32	bile	O	['N']	[32]
33	stasis	O	['N']	[33]
34	,	O	['N']	[34]
35	demonstrated	O	['N']	[35]
36	20	O	['N']	[36]
37	days	O	['N']	[37]
38	after	O	['N']	[38]
39	the	O	['N']	[39]
40	initiation	O	['N']	[40]
41	of	O	['N']	[41]
42	antithyroid	O	['N']	[42]
43	therapy	O	['N']	[43]
44	with	O	['N']	[44]
45	20	O	['N']	[45]
46	mg	O	['N']	[46]
47	methimazole	B-Drug	['Causes']	[17]
48	daily	O	['N']	[48]
49	.	O	['N']	[49]
#4104
0	Ezetimibe	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	acute	B	['N']	[3]
4	pancreatitis	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#4105
0	Fatal	B	['N']	[0]
1	radiation	I	['N']	[1]
2	myelopathy	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	high	O	['N']	[4]
5	-	O	['N']	[5]
6	dose	O	['N']	[6]
7	busulfan	B-Drug	['Causes']	[2]
8	and	O	['N']	[8]
9	melphalan	O	['N']	[9]
10	chemotherapy	O	['N']	[10]
11	and	O	['N']	[11]
12	radiotherapy	O	['N']	[12]
13	for	O	['N']	[13]
14	Ewing	O	['N']	[14]
15	's	O	['N']	[15]
16	sarcoma	O	['N']	[16]
17	:	O	['N']	[17]
18	a	O	['N']	[18]
19	review	O	['N']	[19]
20	of	O	['N']	[20]
21	the	O	['N']	[21]
22	literature	O	['N']	[22]
23	and	O	['N']	[23]
24	implications	O	['N']	[24]
25	for	O	['N']	[25]
26	practice	O	['N']	[26]
27	.	O	['N']	[27]
#4106
0	Seizures	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	extrapyramidal	O	['N']	[2]
3	symptoms	O	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	Tourette	O	['N']	[8]
9	's	O	['N']	[9]
10	syndrome	O	['N']	[10]
11	,	O	['N']	[11]
12	Asperger	O	['N']	[12]
13	's	O	['N']	[13]
14	syndrome	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	multiple	O	['N']	[17]
18	sclerosis	O	['N']	[18]
19	treated	O	['N']	[19]
20	with	O	['N']	[20]
21	interferon	O	['N']	[21]
22	beta-1a	O	['N']	[22]
23	and	O	['N']	[23]
24	clomipramine	B-Drug	['Causes']	[0]
25	.	O	['N']	[25]
#4107
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	receiving	O	['N']	[2]
3	phenytoin	B	['N']	[3]
4	sodium	I-Drug	['Dosage']	[8]
5	300	B	['N']	[5]
6	mg	I	['N']	[6]
7	/	I	['N']	[7]
8	day	I-Dose	['N']	[8]
9	;	O	['N']	[9]
10	carbamazepine	O	['N']	[10]
11	200	O	['N']	[11]
12	mg	O	['N']	[12]
13	four	O	['N']	[13]
14	times	O	['N']	[14]
15	daily	O	['N']	[15]
16	had	O	['N']	[16]
17	been	O	['N']	[17]
18	discontinued	O	['N']	[18]
19	four	O	['N']	[19]
20	days	O	['N']	[20]
21	before	O	['N']	[21]
22	admission	O	['N']	[22]
23	because	O	['N']	[23]
24	of	O	['N']	[24]
25	leukopenia	O	['N']	[25]
26	.	O	['N']	[26]
#4108
0	Sustained	O	['N']	[0]
1	-	O	['N']	[1]
2	release	O	['N']	[2]
3	procainamide	B-Drug	['Causes']	[7]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	reversible	B	['N']	[6]
7	granulocytopenia	I-Adverse_Effect	['N']	[7]
8	after	O	['N']	[8]
9	myocardial	O	['N']	[9]
10	infarction	O	['N']	[10]
11	.	O	['N']	[11]
#4109
0	Due	O	['N']	[0]
1	to	O	['N']	[1]
2	discomfort	B-Adverse_Effect	['N']	[2]
3	,	O	['N']	[3]
4	diplopia	O	['N']	[4]
5	and	O	['N']	[5]
6	lagophthalmos	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	haematoma	O	['N']	[9]
10	necessitated	O	['N']	[10]
11	suspension	O	['N']	[11]
12	of	O	['N']	[12]
13	warfarin	B-Drug	['Causes']	[2]
14	therapy	O	['N']	[14]
15	and	O	['N']	[15]
16	a	O	['N']	[16]
17	surgical	O	['N']	[17]
18	evacuation	O	['N']	[18]
19	.	O	['N']	[19]
#4110
0	Herein	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	describe	O	['N']	[3]
4	2	O	['N']	[4]
5	patients	O	['N']	[5]
6	who	O	['N']	[6]
7	developed	O	['N']	[7]
8	unusual	O	['N']	[8]
9	CD8	B	['N']	[9]
10	+	I	['N']	[10]
11	cutaneous	I	['N']	[11]
12	lymphoproliferative	I	['N']	[12]
13	disorders	I-Adverse_Effect	['N']	[13]
14	after	O	['N']	[14]
15	treatment	O	['N']	[15]
16	with	O	['N']	[16]
17	efalizumab	B-Drug	['Causes']	[13]
18	and	O	['N']	[18]
19	infliximab	O	['N']	[19]
20	.	O	['N']	[20]
#4111
0	Three	O	['N']	[0]
1	of	O	['N']	[1]
2	these	O	['N']	[2]
3	patients	O	['N']	[3]
4	had	O	['N']	[4]
5	convulsions	O	['N']	[5]
6	attributed	O	['N']	[6]
7	to	O	['N']	[7]
8	imipenem	B-Drug	['Causes']	[18]
9	/	O	['N']	[9]
10	cilastatin	O	['N']	[10]
11	;	O	['N']	[11]
12	3.6	O	['N']	[12]
13	%	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	patients	O	['N']	[16]
17	had	O	['N']	[17]
18	seizure	B-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	or	O	['N']	[20]
21	2	O	['N']	[21]
22	%	O	['N']	[22]
23	of	O	['N']	[23]
24	imipenem	O	['N']	[24]
25	/	O	['N']	[25]
26	cilastatin	O	['N']	[26]
27	administrations	O	['N']	[27]
28	was	O	['N']	[28]
29	followed	O	['N']	[29]
30	by	O	['N']	[30]
31	a	O	['N']	[31]
32	seizure	O	['N']	[32]
33	attack	O	['N']	[33]
34	.	O	['N']	[34]
#4112
0	The	O	['N']	[0]
1	diagnosis	O	['N']	[1]
2	was	O	['N']	[2]
3	based	O	['N']	[3]
4	on	O	['N']	[4]
5	the	O	['N']	[5]
6	rapid	O	['N']	[6]
7	onset	O	['N']	[7]
8	of	O	['N']	[8]
9	renal	O	['N']	[9]
10	failure	O	['N']	[10]
11	,	O	['N']	[11]
12	presence	O	['N']	[12]
13	of	O	['N']	[13]
14	eosinophilia	B-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	skin	O	['N']	[16]
17	rash	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	characteristic	O	['N']	[20]
21	renal	O	['N']	[21]
22	biopsy	O	['N']	[22]
23	finding	O	['N']	[23]
24	,	O	['N']	[24]
25	following	O	['N']	[25]
26	the	O	['N']	[26]
27	administration	O	['N']	[27]
28	of	O	['N']	[28]
29	ampicillin	B-Drug	['Causes']	[14]
30	.	O	['N']	[30]
#4113
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	Repeated	O	['N']	[2]
3	blood	O	['N']	[3]
4	samples	O	['N']	[4]
5	were	O	['N']	[5]
6	drawn	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	severe	O	['N']	[11]
12	acyclovir	B-Drug	['Causes']	[20]
13	overdose	O	['N']	[13]
14	who	O	['N']	[14]
15	developed	O	['N']	[15]
16	coma	O	['N']	[16]
17	and	O	['N']	[17]
18	nonoliguric	B	['N']	[18]
19	renal	I	['N']	[19]
20	failure	I-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#4114
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	previously	O	['N']	[6]
7	healthy	O	['N']	[7]
8	,	O	['N']	[8]
9	postmenopausal	O	['N']	[9]
10	woman	O	['N']	[10]
11	who	O	['N']	[11]
12	developed	O	['N']	[12]
13	anticonvulsant	B	['N']	[13]
14	hypersensitivity	I	['N']	[14]
15	syndrome	I-Adverse_Effect	['N']	[15]
16	while	O	['N']	[16]
17	taking	O	['N']	[17]
18	Bellamine	O	['N']	[18]
19	S	O	['N']	[19]
20	(	O	['N']	[20]
21	belladonna	B	['N']	[21]
22	alkaloids	I-Drug	['Causes']	[15]
23	;	O	['N']	[23]
24	ergotamine	O	['N']	[24]
25	;	O	['N']	[25]
26	phenobarbital	O	['N']	[26]
27	)	O	['N']	[27]
28	for	O	['N']	[28]
29	hot	O	['N']	[29]
30	flashes	O	['N']	[30]
31	.	O	['N']	[31]
#4115
0	An	O	['N']	[0]
1	unusual	O	['N']	[1]
2	case	O	['N']	[2]
3	of	O	['N']	[3]
4	Ecstasy	B-Drug	['Causes']	[5]
5	poisoning	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#4116
0	Acyclovir	B-Drug	['Causes']	[3]
1	produces	O	['N']	[1]
2	neurologic	B	['N']	[2]
3	symptoms	I-Adverse_Effect	['N']	[3]
4	that	O	['N']	[4]
5	resemble	O	['N']	[5]
6	extension	O	['N']	[6]
7	of	O	['N']	[7]
8	viral	O	['N']	[8]
9	infection	O	['N']	[9]
10	into	O	['N']	[10]
11	the	O	['N']	[11]
12	central	O	['N']	[12]
13	nervous	O	['N']	[13]
14	system	O	['N']	[14]
15	.	O	['N']	[15]
#4117
0	Argatroban	B-Drug	['Causes']	[27]
1	is	O	['N']	[1]
2	hepatically	O	['N']	[2]
3	cleared	O	['N']	[3]
4	and	O	['N']	[4]
5	may	O	['N']	[5]
6	be	O	['N']	[6]
7	the	O	['N']	[7]
8	preferred	O	['N']	[8]
9	direct	O	['N']	[9]
10	thrombin	O	['N']	[10]
11	inhibitor	O	['N']	[11]
12	in	O	['N']	[12]
13	the	O	['N']	[13]
14	presence	O	['N']	[14]
15	of	O	['N']	[15]
16	significant	O	['N']	[16]
17	renal	O	['N']	[17]
18	impairment	O	['N']	[18]
19	,	O	['N']	[19]
20	but	O	['N']	[20]
21	conversely	O	['N']	[21]
22	has	O	['N']	[22]
23	prolonged	O	['N']	[23]
24	effects	O	['N']	[24]
25	in	O	['N']	[25]
26	hepatic	B	['N']	[26]
27	failure	I-Adverse_Effect	['N']	[27]
28	.	O	['N']	[28]
#4118
0	Systemic	B	['N']	[0]
1	vasculitis	I-Adverse_Effect	['N']	[1]
2	complicating	O	['N']	[2]
3	hairy	O	['N']	[3]
4	cell	O	['N']	[4]
5	leukaemia	O	['N']	[5]
6	treatment	O	['N']	[6]
7	with	O	['N']	[7]
8	cladribine	B-Drug	['Causes']	[1]
9	.	O	['N']	[9]
#4119
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	report	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	anuric	B	['N']	[8]
9	ARF	I-Adverse_Effect	['N']	[9]
10	after	O	['N']	[10]
11	high	O	['N']	[11]
12	-	O	['N']	[12]
13	dose	O	['N']	[13]
14	mannitol	B-Drug	['Causes']	[9]
15	infusion	O	['N']	[15]
16	for	O	['N']	[16]
17	treatment	O	['N']	[17]
18	of	O	['N']	[18]
19	narrow	O	['N']	[19]
20	-	O	['N']	[20]
21	angle	O	['N']	[21]
22	glaucoma	O	['N']	[22]
23	that	O	['N']	[23]
24	readily	O	['N']	[24]
25	responded	O	['N']	[25]
26	to	O	['N']	[26]
27	acute	O	['N']	[27]
28	hemodialysis	O	['N']	[28]
29	.	O	['N']	[29]
#4120
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	No	O	['N']	[2]
3	published	O	['N']	[3]
4	clinical	O	['N']	[4]
5	studies	O	['N']	[5]
6	in	O	['N']	[6]
7	patients	O	['N']	[7]
8	receiving	O	['N']	[8]
9	clindamycin	B-Drug	['Causes']	[21]
10	vaginal	O	['N']	[10]
11	cream	O	['N']	[11]
12	for	O	['N']	[12]
13	bacterial	O	['N']	[13]
14	vaginosis	O	['N']	[14]
15	have	O	['N']	[15]
16	documented	O	['N']	[16]
17	C.	B	['N']	[17]
18	difficile	I	['N']	[18]
19	toxin	I	['N']	[19]
20	in	I	['N']	[20]
21	stool	I-Adverse_Effect	['N']	[21]
22	samples	O	['N']	[22]
23	of	O	['N']	[23]
24	patients	O	['N']	[24]
25	with	O	['N']	[25]
26	diarrhea	O	['N']	[26]
27	.	O	['N']	[27]
#4121
0	He	O	['N']	[0]
1	was	O	['N']	[1]
2	started	O	['N']	[2]
3	on	O	['N']	[3]
4	digoxin	B-Drug	['Causes']	[25]
5	,	O	['N']	[5]
6	0.25	O	['N']	[6]
7	mg	O	['N']	[7]
8	daily	O	['N']	[8]
9	,	O	['N']	[9]
10	because	O	['N']	[10]
11	of	O	['N']	[11]
12	echocardiographically	O	['N']	[12]
13	demonstrated	O	['N']	[13]
14	left	O	['N']	[14]
15	ventricular	O	['N']	[15]
16	dilatation	O	['N']	[16]
17	and	O	['N']	[17]
18	functional	O	['N']	[18]
19	impairment	O	['N']	[19]
20	;	O	['N']	[20]
21	he	O	['N']	[21]
22	died	O	['N']	[22]
23	of	O	['N']	[23]
24	ventricular	B	['N']	[24]
25	fibrillation	I-Adverse_Effect	['N']	[25]
26	15	O	['N']	[26]
27	days	O	['N']	[27]
28	later	O	['N']	[28]
29	.	O	['N']	[29]
#4122
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	23-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	man	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	a	O	['N']	[12]
13	vancomycin	B-Drug	['Causes']	[17]
14	-	O	['N']	[14]
15	induced	O	['N']	[15]
16	anaphylactic	B	['N']	[16]
17	reaction	I-Adverse_Effect	['N']	[17]
18	in	O	['N']	[18]
19	the	O	['N']	[19]
20	treatment	O	['N']	[20]
21	of	O	['N']	[21]
22	methicillin	O	['N']	[22]
23	-	O	['N']	[23]
24	resistant	O	['N']	[24]
25	Staphylococcus	O	['N']	[25]
26	aureus	O	['N']	[26]
27	infection	O	['N']	[27]
28	.	O	['N']	[28]
#4123
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	report	O	['N']	[4]
5	on	O	['N']	[5]
6	the	O	['N']	[6]
7	histopathological	O	['N']	[7]
8	findings	O	['N']	[8]
9	of	O	['N']	[9]
10	thyroid	O	['N']	[10]
11	tissue	O	['N']	[11]
12	from	O	['N']	[12]
13	a	O	['N']	[13]
14	patient	O	['N']	[14]
15	with	O	['N']	[15]
16	amiodarone	B-Drug	['Causes']	[19]
17	-	O	['N']	[17]
18	induced	O	['N']	[18]
19	hypothyroidism	B-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#4124
0	Possible	O	['N']	[0]
1	mechanisms	O	['N']	[1]
2	by	O	['N']	[2]
3	which	O	['N']	[3]
4	clonidine	B-Drug	['Causes']	[14]
5	decreases	O	['N']	[5]
6	spasticity	O	['N']	[6]
7	are	O	['N']	[7]
8	described	O	['N']	[8]
9	,	O	['N']	[9]
10	probable	O	['N']	[10]
11	mechanisms	O	['N']	[11]
12	of	O	['N']	[12]
13	induced	O	['N']	[13]
14	bradycardia	B-Adverse_Effect	['N']	[14]
15	are	O	['N']	[15]
16	reviewed	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	specific	O	['N']	[19]
20	treatment	O	['N']	[20]
21	recommendations	O	['N']	[21]
22	for	O	['N']	[22]
23	the	O	['N']	[23]
24	use	O	['N']	[24]
25	of	O	['N']	[25]
26	clonidine	O	['N']	[26]
27	in	O	['N']	[27]
28	spinal	O	['N']	[28]
29	cord	O	['N']	[29]
30	injured	O	['N']	[30]
31	patients	O	['N']	[31]
32	are	O	['N']	[32]
33	presented	O	['N']	[33]
34	.	O	['N']	[34]
#4125
0	The	O	['N']	[0]
1	reversal	O	['N']	[1]
2	of	O	['N']	[2]
3	heparin	O	['N']	[3]
4	by	O	['N']	[4]
5	protamine	B-Drug	['Causes']	[18]
6	may	O	['N']	[6]
7	cause	O	['N']	[7]
8	severe	O	['N']	[8]
9	hemodynamic	O	['N']	[9]
10	deterioration	O	['N']	[10]
11	,	O	['N']	[11]
12	characterized	O	['N']	[12]
13	by	O	['N']	[13]
14	systemic	O	['N']	[14]
15	hypotension	O	['N']	[15]
16	,	O	['N']	[16]
17	pulmonary	B	['N']	[17]
18	hypertension	I-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	bronchoconstriction	O	['N']	[21]
22	.	O	['N']	[22]
#4126
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	severe	B	['N']	[3]
4	hyponatremia	I-Adverse_Effect	['N']	[4]
5	with	O	['N']	[5]
6	serum	O	['N']	[6]
7	Na+	O	['N']	[7]
8	of	O	['N']	[8]
9	108	O	['N']	[9]
10	mEq	O	['N']	[10]
11	/	O	['N']	[11]
12	L	O	['N']	[12]
13	when	O	['N']	[13]
14	hydrochlorothiazide	B-Drug	['Causes']	[4]
15	was	O	['N']	[15]
16	given	O	['N']	[16]
17	to	O	['N']	[17]
18	control	O	['N']	[18]
19	hypertension	O	['N']	[19]
20	.	O	['N']	[20]
#4127
0	The	O	['N']	[0]
1	delayed	O	['N']	[1]
2	encephalopathy	B-Adverse_Effect	['N']	[2]
3	developed	O	['N']	[3]
4	9	O	['N']	[4]
5	and	O	['N']	[5]
6	22	O	['N']	[6]
7	months	O	['N']	[7]
8	respectively	O	['N']	[8]
9	after	O	['N']	[9]
10	the	O	['N']	[10]
11	first	O	['N']	[11]
12	dose	O	['N']	[12]
13	of	O	['N']	[13]
14	intrathecal	O	['N']	[14]
15	methotrexate	B-Drug	['Causes']	[2]
16	.	O	['N']	[16]
#4128
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	87-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	white	O	['N']	[9]
10	woman	O	['N']	[10]
11	with	O	['N']	[11]
12	myasthenia	O	['N']	[12]
13	gravis	O	['N']	[13]
14	who	O	['N']	[14]
15	presented	O	['N']	[15]
16	with	O	['N']	[16]
17	nausea	O	['N']	[17]
18	,	O	['N']	[18]
19	shortness	B	['N']	[19]
20	of	I	['N']	[20]
21	breath	I-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	azotemia	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	hyperkalemia	O	['N']	[26]
27	shortly	O	['N']	[27]
28	after	O	['N']	[28]
29	completing	O	['N']	[29]
30	a	O	['N']	[30]
31	course	O	['N']	[31]
32	of	O	['N']	[32]
33	intravenous	O	['N']	[33]
34	immunoglobulin	O	['N']	[34]
35	(	O	['N']	[35]
36	IVIG	B-Drug	['Causes']	[21]
37	)	O	['N']	[37]
38	.	O	['N']	[38]
#4129
0	Angioedema	O	['N']	[0]
1	and	O	['N']	[1]
2	dysphagia	B-Adverse_Effect	['N']	[2]
3	caused	O	['N']	[3]
4	by	O	['N']	[4]
5	contact	O	['N']	[5]
6	allergy	O	['N']	[6]
7	to	O	['N']	[7]
8	inhaled	O	['N']	[8]
9	budesonide	B-Drug	['Causes']	[2]
10	.	O	['N']	[10]
#4130
0	Eleven	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	initiation	O	['N']	[3]
4	of	O	['N']	[4]
5	therapy	O	['N']	[5]
6	with	O	['N']	[6]
7	amiodarone	B-Drug	['Causes']	[23]
8	,	O	['N']	[8]
9	the	O	['N']	[9]
10	patient	O	['N']	[10]
11	experienced	O	['N']	[11]
12	syncope	O	['N']	[12]
13	and	O	['N']	[13]
14	was	O	['N']	[14]
15	noted	O	['N']	[15]
16	to	O	['N']	[16]
17	have	O	['N']	[17]
18	recurrent	O	['N']	[18]
19	episodes	O	['N']	[19]
20	of	O	['N']	[20]
21	polymorphous	B	['N']	[21]
22	ventricular	I	['N']	[22]
23	tachycardia	I-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#4131
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	metoclopramide	B-Drug	['Causes']	[7]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	oculogyric	B	['N']	[6]
7	crisis	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	16-year	O	['N']	[10]
11	-	O	['N']	[11]
12	old	O	['N']	[12]
13	girl	O	['N']	[13]
14	with	O	['N']	[14]
15	cystic	O	['N']	[15]
16	fibrosis	O	['N']	[16]
17	.	O	['N']	[17]
#4132
0	Metabolic	B	['N']	[0]
1	acidosis	I-Adverse_Effect	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	acetazolamide	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#4133
0	Although	O	['N']	[0]
1	the	O	['N']	[1]
2	literature	O	['N']	[2]
3	on	O	['N']	[3]
4	the	O	['N']	[4]
5	use	O	['N']	[5]
6	of	O	['N']	[6]
7	risperidone	B-Drug	['Causes']	[50]
8	in	O	['N']	[8]
9	elderly	O	['N']	[9]
10	patients	O	['N']	[10]
11	with	O	['N']	[11]
12	dementia	O	['N']	[12]
13	consists	O	['N']	[13]
14	largely	O	['N']	[14]
15	of	O	['N']	[15]
16	uncontrolled	O	['N']	[16]
17	trials	O	['N']	[17]
18	,	O	['N']	[18]
19	case	O	['N']	[19]
20	reports	O	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	chart	O	['N']	[23]
24	reviews	O	['N']	[24]
25	,	O	['N']	[25]
26	it	O	['N']	[26]
27	appears	O	['N']	[27]
28	that	O	['N']	[28]
29	this	O	['N']	[29]
30	agent	O	['N']	[30]
31	is	O	['N']	[31]
32	effective	O	['N']	[32]
33	for	O	['N']	[33]
34	managing	O	['N']	[34]
35	agitation	O	['N']	[35]
36	in	O	['N']	[36]
37	this	O	['N']	[37]
38	population	O	['N']	[38]
39	and	O	['N']	[39]
40	does	O	['N']	[40]
41	so	O	['N']	[41]
42	with	O	['N']	[42]
43	a	O	['N']	[43]
44	low	O	['N']	[44]
45	frequency	O	['N']	[45]
46	of	O	['N']	[46]
47	extrapyramidal	O	['N']	[47]
48	symptoms	O	['N']	[48]
49	(	O	['N']	[49]
50	EPS	B-Adverse_Effect	['N']	[50]
51	)	O	['N']	[51]
52	.	O	['N']	[52]
#4134
0	A	O	['N']	[0]
1	58-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	advanced	O	['N']	[6]
7	renal	O	['N']	[7]
8	cell	O	['N']	[8]
9	carcinoma	O	['N']	[9]
10	developed	O	['N']	[10]
11	grade	O	['N']	[11]
12	3	O	['N']	[12]
13	proteinuria	B-Adverse_Effect	['N']	[13]
14	(	O	['N']	[14]
15	8.5	O	['N']	[15]
16	g/24	O	['N']	[16]
17	h	O	['N']	[17]
18	)	O	['N']	[18]
19	without	O	['N']	[19]
20	microscopic	O	['N']	[20]
21	hematuria	O	['N']	[21]
22	or	O	['N']	[22]
23	renal	O	['N']	[23]
24	insufficiency	O	['N']	[24]
25	five	O	['N']	[25]
26	days	O	['N']	[26]
27	after	O	['N']	[27]
28	temsirolimus	B-Drug	['Causes']	[13]
29	infusion	O	['N']	[29]
30	.	O	['N']	[30]
#4135
0	Favorable	O	['N']	[0]
1	outcome	O	['N']	[1]
2	of	O	['N']	[2]
3	de	O	['N']	[3]
4	novo	O	['N']	[4]
5	hepatitis	B	['N']	[5]
6	B	I	['N']	[6]
7	infection	I-Adverse_Effect	['N']	[7]
8	after	O	['N']	[8]
9	liver	O	['N']	[9]
10	transplantation	O	['N']	[10]
11	with	O	['N']	[11]
12	lamivudine	O	['N']	[12]
13	and	O	['N']	[13]
14	adefovir	B-Drug	['Causes']	[7]
15	therapy	O	['N']	[15]
16	.	O	['N']	[16]
#4136
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	child	O	['N']	[3]
4	with	O	['N']	[4]
5	yolk	O	['N']	[5]
6	sac	O	['N']	[6]
7	tumor	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	localized	B	['N']	[10]
11	pigmentation	I-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	the	O	['N']	[13]
14	first	O	['N']	[14]
15	course	O	['N']	[15]
16	of	O	['N']	[16]
17	chemotherapy	O	['N']	[17]
18	regimen	O	['N']	[18]
19	that	O	['N']	[19]
20	included	O	['N']	[20]
21	cisplatin	O	['N']	[21]
22	,	O	['N']	[22]
23	etoposide	B-Drug	['Causes']	[11]
24	and	O	['N']	[24]
25	bleomycin	O	['N']	[25]
26	.	O	['N']	[26]
#4137
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	aseptic	O	['N']	[9]
10	meningitis	O	['N']	[10]
11	,	O	['N']	[11]
12	hemolytic	O	['N']	[12]
13	anemia	O	['N']	[13]
14	,	O	['N']	[14]
15	hepatitis	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	orthostatic	B	['N']	[18]
19	hypotension	I-Adverse_Effect	['N']	[19]
20	simultaneously	O	['N']	[20]
21	during	O	['N']	[21]
22	treatment	O	['N']	[22]
23	with	O	['N']	[23]
24	trimethoprim	B-Drug	['Causes']	[19]
25	-	O	['N']	[25]
26	sulfamethoxazole	O	['N']	[26]
27	is	O	['N']	[27]
28	described	O	['N']	[28]
29	.	O	['N']	[29]
#4138
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	fulminant	O	['N']	[6]
7	adult	B	['N']	[7]
8	respiratory	I	['N']	[8]
9	distress	I	['N']	[9]
10	syndrome	I-Adverse_Effect	['N']	[10]
11	(	O	['N']	[11]
12	ARDS	O	['N']	[12]
13	)	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	pegylated	O	['N']	[16]
17	interferon	O	['N']	[17]
18	alpha-2a	O	['N']	[18]
19	(	O	['N']	[19]
20	pegIFNalpha-2a	O	['N']	[20]
21	)	O	['N']	[21]
22	and	O	['N']	[22]
23	ribavirin	B-Drug	['Causes']	[10]
24	use	O	['N']	[24]
25	for	O	['N']	[25]
26	hepatitis	O	['N']	[26]
27	C	O	['N']	[27]
28	,	O	['N']	[28]
29	complicated	O	['N']	[29]
30	by	O	['N']	[30]
31	subsequent	O	['N']	[31]
32	and	O	['N']	[32]
33	ultimately	O	['N']	[33]
34	fatal	O	['N']	[34]
35	sepsis	O	['N']	[35]
36	and	O	['N']	[36]
37	multiorgan	O	['N']	[37]
38	failure	O	['N']	[38]
39	.	O	['N']	[39]
#4139
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	three	O	['N']	[2]
3	patients	O	['N']	[3]
4	,	O	['N']	[4]
5	all	O	['N']	[5]
6	of	O	['N']	[6]
7	whom	O	['N']	[7]
8	had	O	['N']	[8]
9	preexisting	O	['N']	[9]
10	diabetic	O	['N']	[10]
11	dyslipidemia	O	['N']	[11]
12	,	O	['N']	[12]
13	who	O	['N']	[13]
14	showed	O	['N']	[14]
15	a	O	['N']	[15]
16	profound	O	['N']	[16]
17	reduction	B	['N']	[17]
18	in	I	['N']	[18]
19	plasma	I	['N']	[19]
20	HDL	I	['N']	[20]
21	cholesterol	I	['N']	[21]
22	and	I	['N']	[22]
23	apolipoprotein	I	['N']	[23]
24	AI	I	['N']	[24]
25	levels	I-Adverse_Effect	['N']	[25]
26	soon	O	['N']	[26]
27	after	O	['N']	[27]
28	the	O	['N']	[28]
29	initiation	O	['N']	[29]
30	of	O	['N']	[30]
31	rosiglitazone	B-Drug	['Causes']	[25]
32	therapy	O	['N']	[32]
33	.	O	['N']	[33]
#4140
0	Recently	O	['N']	[0]
1	,	O	['N']	[1]
2	her	O	['N']	[2]
3	serum	O	['N']	[3]
4	theophylline	B	['N']	[4]
5	levels	I	['N']	[5]
6	had	I	['N']	[6]
7	increased	I	['N']	[7]
8	to	I	['N']	[8]
9	the	I	['N']	[9]
10	toxic	I	['N']	[10]
11	range	I-Adverse_Effect	['N']	[11]
12	(	O	['N']	[12]
13	133.2	O	['N']	[13]
14	micromol	O	['N']	[14]
15	/	O	['N']	[15]
16	L	O	['N']	[16]
17	[	O	['N']	[17]
18	24	O	['N']	[18]
19	microg	O	['N']	[19]
20	/	O	['N']	[20]
21	mL	O	['N']	[21]
22	]	O	['N']	[22]
23	)	O	['N']	[23]
24	shortly	O	['N']	[24]
25	after	O	['N']	[25]
26	the	O	['N']	[26]
27	addition	O	['N']	[27]
28	of	O	['N']	[28]
29	zafirlukast	O	['N']	[29]
30	(	O	['N']	[30]
31	Accolate	B-Drug	['Causes']	[11]
32	,	O	['N']	[32]
33	Zeneca	O	['N']	[33]
34	Pharmaceuticals	O	['N']	[34]
35	,	O	['N']	[35]
36	Wilmington	O	['N']	[36]
37	,	O	['N']	[37]
38	Del	O	['N']	[38]
39	)	O	['N']	[39]
40	to	O	['N']	[40]
41	her	O	['N']	[41]
42	regimen	O	['N']	[42]
43	.	O	['N']	[43]
#4141
0	Rapamycin	O	['N']	[0]
1	/	O	['N']	[1]
2	sirolimus	O	['N']	[2]
3	(	O	['N']	[3]
4	SR	B-Drug	['Causes']	[34]
5	)	O	['N']	[5]
6	,	O	['N']	[6]
7	trade	O	['N']	[7]
8	named	O	['N']	[8]
9	Rapammune	O	['N']	[9]
10	(	O	['N']	[10]
11	Wyeth	O	['N']	[11]
12	-	O	['N']	[12]
13	Ayerst	O	['N']	[13]
14	,	O	['N']	[14]
15	Sydney	O	['N']	[15]
16	,	O	['N']	[16]
17	Australia	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	is	O	['N']	[20]
21	a	O	['N']	[21]
22	potent	O	['N']	[22]
23	immunosuppressive	O	['N']	[23]
24	drug	O	['N']	[24]
25	associated	O	['N']	[25]
26	with	O	['N']	[26]
27	myelosuppression	O	['N']	[27]
28	,	O	['N']	[28]
29	hypertension	O	['N']	[29]
30	,	O	['N']	[30]
31	hyperlipidemia	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	infection	B-Adverse_Effect	['N']	[34]
35	.	O	['N']	[35]
#4142
0	Fibrosis	B	['N']	[0]
1	of	I	['N']	[1]
2	corpus	I	['N']	[2]
3	cavernosum	I-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	intracavernous	O	['N']	[5]
6	injection	O	['N']	[6]
7	of	O	['N']	[7]
8	phentolamine	B-Drug	['Causes']	[3]
9	/	O	['N']	[9]
10	papaverine	O	['N']	[10]
11	.	O	['N']	[11]
#4143
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	poisoning	B-Adverse_Effect	['N']	[5]
6	with	O	['N']	[6]
7	3,4-methylenedioxymet	B	['N']	[7]
8	-	I	['N']	[8]
9	amphetamine	I	['N']	[9]
10	Ecstasy	I-Drug	['Causes']	[5]
11	that	O	['N']	[11]
12	presented	O	['N']	[12]
13	with	O	['N']	[13]
14	all	O	['N']	[14]
15	the	O	['N']	[15]
16	features	O	['N']	[16]
17	suggestive	O	['N']	[17]
18	of	O	['N']	[18]
19	a	O	['N']	[19]
20	fatal	O	['N']	[20]
21	outcome	O	['N']	[21]
22	,	O	['N']	[22]
23	including	O	['N']	[23]
24	a	O	['N']	[24]
25	creatinine	O	['N']	[25]
26	phosphokinase	O	['N']	[26]
27	level	O	['N']	[27]
28	markedly	O	['N']	[28]
29	higher	O	['N']	[29]
30	than	O	['N']	[30]
31	any	O	['N']	[31]
32	previously	O	['N']	[32]
33	reported	O	['N']	[33]
34	.	O	['N']	[34]
#4144
0	Foscarnet	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	severe	B	['N']	[3]
4	hypomagnesemia	I-Adverse_Effect	['N']	[4]
5	and	O	['N']	[5]
6	other	O	['N']	[6]
7	electrolyte	O	['N']	[7]
8	disorders	O	['N']	[8]
9	.	O	['N']	[9]
#4145
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	that	O	['N']	[2]
3	received	O	['N']	[3]
4	methadone	B-Drug	['Causes']	[11]
5	for	O	['N']	[5]
6	cancer	O	['N']	[6]
7	-	O	['N']	[7]
8	associated	O	['N']	[8]
9	pain	O	['N']	[9]
10	developed	O	['N']	[10]
11	myoclonus	B-Adverse_Effect	['N']	[11]
12	as	O	['N']	[12]
13	a	O	['N']	[13]
14	side	O	['N']	[14]
15	effect	O	['N']	[15]
16	.	O	['N']	[16]
#4146
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	is	O	['N']	[2]
3	reported	O	['N']	[3]
4	of	O	['N']	[4]
5	theophylline	B-Drug	['Causes']	[6]
6	intoxication	I-Adverse_Effect	['N']	[6]
7	due	O	['N']	[7]
8	to	O	['N']	[8]
9	a	O	['N']	[9]
10	dramatic	O	['N']	[10]
11	decrease	O	['N']	[11]
12	in	O	['N']	[12]
13	theophylline	O	['N']	[13]
14	clearance	O	['N']	[14]
15	following	O	['N']	[15]
16	concomitant	O	['N']	[16]
17	administration	O	['N']	[17]
18	of	O	['N']	[18]
19	viloxazine	O	['N']	[19]
20	.	O	['N']	[20]
#4147
0	Acute	O	['N']	[0]
1	hyperphosphatemia	B-Adverse_Effect	['N']	[1]
2	caused	O	['N']	[2]
3	by	O	['N']	[3]
4	sodium	B	['N']	[4]
5	phosphate	I-Drug	['Causes']	[1]
6	enema	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	with	O	['N']	[10]
11	liver	O	['N']	[11]
12	dysfunction	O	['N']	[12]
13	and	O	['N']	[13]
14	chronic	O	['N']	[14]
15	renal	O	['N']	[15]
16	failure	O	['N']	[16]
17	.	O	['N']	[17]
#4148
0	Fever	O	['N']	[0]
1	,	O	['N']	[1]
2	lymphadenopathy	O	['N']	[2]
3	,	O	['N']	[3]
4	eosinophilia	O	['N']	[4]
5	,	O	['N']	[5]
6	lymphocytosis	O	['N']	[6]
7	,	O	['N']	[7]
8	hepatitis	B-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	dermatitis	O	['N']	[11]
12	:	O	['N']	[12]
13	a	O	['N']	[13]
14	severe	O	['N']	[14]
15	adverse	O	['N']	[15]
16	reaction	O	['N']	[16]
17	to	O	['N']	[17]
18	minocycline	B-Drug	['Causes']	[8]
19	.	O	['N']	[19]
#4149
0	After	O	['N']	[0]
1	the	O	['N']	[1]
2	second	O	['N']	[2]
3	infliximab	B-Drug	['Causes']	[14]
4	infusion	O	['N']	[4]
5	,	O	['N']	[5]
6	he	O	['N']	[6]
7	was	O	['N']	[7]
8	found	O	['N']	[8]
9	to	O	['N']	[9]
10	have	O	['N']	[10]
11	a	O	['N']	[11]
12	severe	B	['N']	[12]
13	transient	I	['N']	[13]
14	neutropenia	I-Adverse_Effect	['N']	[14]
15	(	O	['N']	[15]
16	0.5	O	['N']	[16]
17	x	O	['N']	[17]
18	10(9)/L	O	['N']	[18]
19	)	O	['N']	[19]
20	.	O	['N']	[20]
#4150
0	Erythema	B	['N']	[0]
1	multiforme	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	phenytoin	B-Drug	['Causes']	[1]
5	and	O	['N']	[5]
6	cranial	O	['N']	[6]
7	radiation	O	['N']	[7]
8	therapy	O	['N']	[8]
9	:	O	['N']	[9]
10	a	O	['N']	[10]
11	report	O	['N']	[11]
12	of	O	['N']	[12]
13	three	O	['N']	[13]
14	patients	O	['N']	[14]
15	and	O	['N']	[15]
16	review	O	['N']	[16]
17	of	O	['N']	[17]
18	the	O	['N']	[18]
19	literature	O	['N']	[19]
20	.	O	['N']	[20]
#4151
0	This	O	['N']	[0]
1	treatment	O	['N']	[1]
2	has	O	['N']	[2]
3	the	O	['N']	[3]
4	potential	O	['N']	[4]
5	to	O	['N']	[5]
6	cause	O	['N']	[6]
7	severe	O	['N']	[7]
8	vision	O	['N']	[8]
9	loss	O	['N']	[9]
10	as	O	['N']	[10]
11	a	O	['N']	[11]
12	result	O	['N']	[12]
13	of	O	['N']	[13]
14	intractable	O	['N']	[14]
15	corticosteroid	B-Drug	['Causes']	[18]
16	-	O	['N']	[16]
17	induced	O	['N']	[17]
18	glaucoma	B-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#4152
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	successful	O	['N']	[3]
4	treatment	O	['N']	[4]
5	of	O	['N']	[5]
6	heparin	B-Drug	['Causes']	[13]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	thrombocytopenia	O	['N']	[9]
10	and	O	['N']	[10]
11	subsequent	O	['N']	[11]
12	hemorrhagic	B	['N']	[12]
13	complications	I-Adverse_Effect	['N']	[13]
14	postoperatively	O	['N']	[14]
15	in	O	['N']	[15]
16	a	O	['N']	[16]
17	2-year	O	['N']	[17]
18	-	O	['N']	[18]
19	old	O	['N']	[19]
20	child	O	['N']	[20]
21	with	O	['N']	[21]
22	Danaparoid	O	['N']	[22]
23	(	O	['N']	[23]
24	orgaran	O	['N']	[24]
25	)	O	['N']	[25]
26	.	O	['N']	[26]
#4153
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	children	O	['N']	[2]
3	and	O	['N']	[3]
4	adolescents	O	['N']	[4]
5	with	O	['N']	[5]
6	chronic	O	['N']	[6]
7	hematologic	O	['N']	[7]
8	and	O	['N']	[8]
9	oncologic	O	['N']	[9]
10	diseases	O	['N']	[10]
11	who	O	['N']	[11]
12	exhibited	O	['N']	[12]
13	drug	O	['N']	[13]
14	-	O	['N']	[14]
15	seeking	O	['N']	[15]
16	behavior	O	['N']	[16]
17	or	O	['N']	[17]
18	anticholinergic	B	['N']	[18]
19	symptoms	I-Adverse_Effect	['N']	[19]
20	with	O	['N']	[20]
21	the	O	['N']	[21]
22	use	O	['N']	[22]
23	of	O	['N']	[23]
24	diphenhydramine	B-Drug	['Causes']	[19]
25	.	O	['N']	[25]
#4154
0	These	O	['N']	[0]
1	two	O	['N']	[1]
2	cases	O	['N']	[2]
3	highlight	O	['N']	[3]
4	the	O	['N']	[4]
5	importance	O	['N']	[5]
6	of	O	['N']	[6]
7	considering	O	['N']	[7]
8	lopinavir	O	['N']	[8]
9	/	O	['N']	[9]
10	ritonavir	B-Drug	['Causes']	[12]
11	induced	O	['N']	[11]
12	arrhythmias	B-Adverse_Effect	['N']	[12]
13	when	O	['N']	[13]
14	dealing	O	['N']	[14]
15	with	O	['N']	[15]
16	HIV	O	['N']	[16]
17	-	O	['N']	[17]
18	positive	O	['N']	[18]
19	individuals	O	['N']	[19]
20	.	O	['N']	[20]
#4155
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Lipoid	B	['N']	[2]
3	pneumonia	I-Adverse_Effect	['N']	[3]
4	as	O	['N']	[4]
5	a	O	['N']	[5]
6	result	O	['N']	[6]
7	of	O	['N']	[7]
8	mineral	B	['N']	[8]
9	oil	I-Drug	['Causes']	[3]
10	aspiration	O	['N']	[10]
11	still	O	['N']	[11]
12	occurs	O	['N']	[12]
13	in	O	['N']	[13]
14	the	O	['N']	[14]
15	pediatric	O	['N']	[15]
16	population	O	['N']	[16]
17	.	O	['N']	[17]
#4156
0	Rapid	O	['N']	[0]
1	resolution	O	['N']	[1]
2	of	O	['N']	[2]
3	topiramate	B-Drug	['Causes']	[9]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	angle	B	['N']	[6]
7	-	I	['N']	[7]
8	closure	I	['N']	[8]
9	glaucoma	I-Adverse_Effect	['N']	[9]
10	with	O	['N']	[10]
11	methylprednisolone	O	['N']	[11]
12	and	O	['N']	[12]
13	mannitol	O	['N']	[13]
14	.	O	['N']	[14]
#4157
0	Acute	B	['N']	[0]
1	renal	I	['N']	[1]
2	failure	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	treated	O	['N']	[6]
7	by	O	['N']	[7]
8	continuous	O	['N']	[8]
9	povidone	B-Drug	['Causes']	[2]
10	-	O	['N']	[10]
11	iodine	O	['N']	[11]
12	mediastinal	O	['N']	[12]
13	irrigation	O	['N']	[13]
14	.	O	['N']	[14]
#4158
0	AIMS	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	present	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	piloerection	B-Adverse_Effect	['N']	[7]
8	after	O	['N']	[8]
9	replacing	O	['N']	[9]
10	fluvoxamine	B	['N']	[10]
11	maleate	I-Drug	['Causes']	[7]
12	with	O	['N']	[12]
13	milnacipran	O	['N']	[13]
14	hydrochloride	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	to	O	['N']	[17]
18	analyse	O	['N']	[18]
19	this	O	['N']	[19]
20	effect	O	['N']	[20]
21	based	O	['N']	[21]
22	on	O	['N']	[22]
23	receptor	O	['N']	[23]
24	occupancy	O	['N']	[24]
25	theory	O	['N']	[25]
26	.	O	['N']	[26]
#4159
0	Insulin	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	lipoatrophy	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	type	O	['N']	[5]
6	I	O	['N']	[6]
7	diabetes	O	['N']	[7]
8	.	O	['N']	[8]
#4160
0	Two	O	['N']	[0]
1	cases	O	['N']	[1]
2	are	O	['N']	[2]
3	reported	O	['N']	[3]
4	of	O	['N']	[4]
5	patients	O	['N']	[5]
6	who	O	['N']	[6]
7	developed	O	['N']	[7]
8	a	O	['N']	[8]
9	hematologic	B	['N']	[9]
10	malignancy	I-Adverse_Effect	['N']	[10]
11	several	O	['N']	[11]
12	years	O	['N']	[12]
13	after	O	['N']	[13]
14	intravesical	O	['N']	[14]
15	chemotherapy	O	['N']	[15]
16	of	O	['N']	[16]
17	superficial	O	['N']	[17]
18	bladder	O	['N']	[18]
19	cancer	O	['N']	[19]
20	with	O	['N']	[20]
21	etoglucid	O	['N']	[21]
22	,	O	['N']	[22]
23	doxorubicin	B-Drug	['Causes']	[10]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	mitomycin	O	['N']	[26]
27	C.	O	['N']	[27]
#4161
0	Finally	O	['N']	[0]
1	,	O	['N']	[1]
2	reserpine	B-Drug	['Causes']	[3]
3	toxicity	I-Adverse_Effect	['N']	[3]
4	,	O	['N']	[4]
5	in	O	['N']	[5]
6	particular	O	['N']	[6]
7	central	O	['N']	[7]
8	nervous	O	['N']	[8]
9	system	O	['N']	[9]
10	(	O	['N']	[10]
11	CNS	O	['N']	[11]
12	)	O	['N']	[12]
13	disturbances	O	['N']	[13]
14	,	O	['N']	[14]
15	was	O	['N']	[15]
16	reported	O	['N']	[16]
17	more	O	['N']	[17]
18	frequently	O	['N']	[18]
19	in	O	['N']	[19]
20	patients	O	['N']	[20]
21	also	O	['N']	[21]
22	receiving	O	['N']	[22]
23	barbiturates	O	['N']	[23]
24	,	O	['N']	[24]
25	suggesting	O	['N']	[25]
26	additive	O	['N']	[26]
27	CNS	O	['N']	[27]
28	effects	O	['N']	[28]
29	.	O	['N']	[29]
#4162
0	Traumatic	B	['N']	[0]
1	late	I	['N']	[1]
2	flap	I	['N']	[2]
3	dehiscence	I-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	Enterobacter	O	['N']	[5]
6	keratitis	O	['N']	[6]
7	following	O	['N']	[7]
8	LASIK	B-Drug	['Causes']	[3]
9	.	O	['N']	[9]
#4163
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	elderly	O	['N']	[6]
7	woman	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	pre	O	['N']	[10]
11	-	O	['N']	[11]
12	existing	O	['N']	[12]
13	history	O	['N']	[13]
14	of	O	['N']	[14]
15	ischaemic	O	['N']	[15]
16	heart	O	['N']	[16]
17	disease	O	['N']	[17]
18	,	O	['N']	[18]
19	who	O	['N']	[19]
20	was	O	['N']	[20]
21	treated	O	['N']	[21]
22	with	O	['N']	[22]
23	venlafaxine	B-Drug	['Causes']	[29]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	developed	O	['N']	[26]
27	acute	B	['N']	[27]
28	myocardial	I	['N']	[28]
29	ischaemia	I-Adverse_Effect	['N']	[29]
30	within	O	['N']	[30]
31	the	O	['N']	[31]
32	first	O	['N']	[32]
33	week	O	['N']	[33]
34	of	O	['N']	[34]
35	treatment	O	['N']	[35]
36	.	O	['N']	[36]
#4164
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	78-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	who	O	['N']	[7]
8	had	O	['N']	[8]
9	acute	B	['N']	[9]
10	unilateral	I	['N']	[10]
11	total	I	['N']	[11]
12	visual	I	['N']	[12]
13	loss	I-Adverse_Effect	['N']	[13]
14	after	O	['N']	[14]
15	retrogasserian	O	['N']	[15]
16	phenol	B-Drug	['Causes']	[13]
17	injection	O	['N']	[17]
18	for	O	['N']	[18]
19	the	O	['N']	[19]
20	treatment	O	['N']	[20]
21	of	O	['N']	[21]
22	trigeminal	O	['N']	[22]
23	neuralgia	O	['N']	[23]
24	.	O	['N']	[24]
#4165
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	ifosfamide	B-Drug	['Causes']	[12]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	nonconvulsive	B	['N']	[10]
11	status	I	['N']	[11]
12	epilepticus	I-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#4166
0	Although	O	['N']	[0]
1	there	O	['N']	[1]
2	is	O	['N']	[2]
3	one	O	['N']	[3]
4	case	O	['N']	[4]
5	report	O	['N']	[5]
6	of	O	['N']	[6]
7	cholesterol	O	['N']	[7]
8	crystal	O	['N']	[8]
9	embolization	O	['N']	[9]
10	following	O	['N']	[10]
11	t	B	['N']	[11]
12	-	I	['N']	[12]
13	PA	I-Drug	['Causes']	[18]
14	therapy	O	['N']	[14]
15	with	O	['N']	[15]
16	only	O	['N']	[16]
17	extrarenal	B	['N']	[17]
18	manifestations	I-Adverse_Effect	['N']	[18]
19	(	O	['N']	[19]
20	N	O	['N']	[20]
21	Engl	O	['N']	[21]
22	J	O	['N']	[22]
23	Med	O	['N']	[23]
24	321:1270	O	['N']	[24]
25	,	O	['N']	[25]
26	1989	O	['N']	[26]
27	)	O	['N']	[27]
28	,	O	['N']	[28]
29	this	O	['N']	[29]
30	is	O	['N']	[30]
31	the	O	['N']	[31]
32	first	O	['N']	[32]
33	reported	O	['N']	[33]
34	case	O	['N']	[34]
35	of	O	['N']	[35]
36	atheroembolic	O	['N']	[36]
37	acute	O	['N']	[37]
38	renal	O	['N']	[38]
39	failure	O	['N']	[39]
40	following	O	['N']	[40]
41	t	O	['N']	[41]
42	-	O	['N']	[42]
43	PA	O	['N']	[43]
44	therapy	O	['N']	[44]
45	.	O	['N']	[45]
#4167
0	Ritonavir	B-Drug	['Causes']	[14]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	added	O	['N']	[3]
4	to	O	['N']	[4]
5	the	O	['N']	[5]
6	list	O	['N']	[6]
7	of	O	['N']	[7]
8	drugs	O	['N']	[8]
9	that	O	['N']	[9]
10	can	O	['N']	[10]
11	induce	O	['N']	[11]
12	adverse	B	['N']	[12]
13	cutaneous	I	['N']	[13]
14	reactions	I-Adverse_Effect	['N']	[14]
15	in	O	['N']	[15]
16	HIV	O	['N']	[16]
17	patients	O	['N']	[17]
18	.	O	['N']	[18]
#4168
0	Herein	O	['N']	[0]
1	is	O	['N']	[1]
2	reported	O	['N']	[2]
3	an	O	['N']	[3]
4	unusual	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	coexistent	O	['N']	[7]
8	warfarin	O	['N']	[8]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	skin	O	['N']	[11]
12	necrosis	O	['N']	[12]
13	and	O	['N']	[13]
14	heparin	B-Drug	['Causes']	[17]
15	-	O	['N']	[15]
16	induced	O	['N']	[16]
17	thrombocytopenia	B-Adverse_Effect	['N']	[17]
18	following	O	['N']	[18]
19	mitral	O	['N']	[19]
20	valve	O	['N']	[20]
21	replacement	O	['N']	[21]
22	for	O	['N']	[22]
23	thromboembolic	O	['N']	[23]
24	phenomena	O	['N']	[24]
25	associated	O	['N']	[25]
26	with	O	['N']	[26]
27	marantic	O	['N']	[27]
28	endocarditis	O	['N']	[28]
29	and	O	['N']	[29]
30	bronchial	O	['N']	[30]
31	adenocarcinoma	O	['N']	[31]
32	.	O	['N']	[32]
#4169
0	Teicoplanin	O	['N']	[0]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	agranulocytosis	B-Adverse_Effect	['N']	[3]
4	that	O	['N']	[4]
5	followed	O	['N']	[5]
6	vancomycin	B-Drug	['Causes']	[3]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	agranulocytosis	O	['N']	[9]
10	suggests	O	['N']	[10]
11	a	O	['N']	[11]
12	possible	O	['N']	[12]
13	cross	O	['N']	[13]
14	-	O	['N']	[14]
15	reactivity	O	['N']	[15]
16	between	O	['N']	[16]
17	the	O	['N']	[17]
18	2	O	['N']	[18]
19	drugs	O	['N']	[19]
20	.	O	['N']	[20]
#4170
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	is	O	['N']	[2]
3	reported	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	child	O	['N']	[6]
7	with	O	['N']	[7]
8	fatal	B	['N']	[8]
9	pulmonary	I	['N']	[9]
10	fibrosis	I-Adverse_Effect	['N']	[10]
11	following	O	['N']	[11]
12	BCNU	B-Drug	['Causes']	[10]
13	therapy	O	['N']	[13]
14	.	O	['N']	[14]
#4171
0	Caution	O	['N']	[0]
1	in	O	['N']	[1]
2	longterm	O	['N']	[2]
3	usage	O	['N']	[3]
4	and	O	['N']	[4]
5	early	O	['N']	[5]
6	recognition	O	['N']	[6]
7	of	O	['N']	[7]
8	pentazocine	B-Drug	['Causes']	[13]
9	toxicity	O	['N']	[9]
10	as	O	['N']	[10]
11	a	O	['N']	[11]
12	neuromuscular	B	['N']	[12]
13	complication	I-Adverse_Effect	['N']	[13]
14	are	O	['N']	[14]
15	important	O	['N']	[15]
16	in	O	['N']	[16]
17	order	O	['N']	[17]
18	to	O	['N']	[18]
19	prevent	O	['N']	[19]
20	irreversible	O	['N']	[20]
21	drug	O	['N']	[21]
22	-	O	['N']	[22]
23	induced	O	['N']	[23]
24	fibrous	O	['N']	[24]
25	myopathy	O	['N']	[25]
26	and	O	['N']	[26]
27	localized	O	['N']	[27]
28	neuropathy	O	['N']	[28]
29	.	O	['N']	[29]
#4172
0	Fatal	B	['N']	[0]
1	lung	I	['N']	[1]
2	fibrosis	I-Adverse_Effect	['N']	[2]
3	caused	O	['N']	[3]
4	by	O	['N']	[4]
5	paclitaxel	B-Drug	['Causes']	[2]
6	toxicity	O	['N']	[6]
7	has	O	['N']	[7]
8	not	O	['N']	[8]
9	been	O	['N']	[9]
10	reported	O	['N']	[10]
11	In	O	['N']	[11]
12	this	O	['N']	[12]
13	report	O	['N']	[13]
14	,	O	['N']	[14]
15	we	O	['N']	[15]
16	describe	O	['N']	[16]
17	the	O	['N']	[17]
18	case	O	['N']	[18]
19	of	O	['N']	[19]
20	a	O	['N']	[20]
21	62-year	O	['N']	[21]
22	-	O	['N']	[22]
23	old	O	['N']	[23]
24	woman	O	['N']	[24]
25	who	O	['N']	[25]
26	received	O	['N']	[26]
27	six	O	['N']	[27]
28	cycles	O	['N']	[28]
29	of	O	['N']	[29]
30	paclitaxel	O	['N']	[30]
31	and	O	['N']	[31]
32	carboplatin	O	['N']	[32]
33	as	O	['N']	[33]
34	combination	O	['N']	[34]
35	chemotherapy	O	['N']	[35]
36	for	O	['N']	[36]
37	advanced	O	['N']	[37]
38	ovarian	O	['N']	[38]
39	cancer	O	['N']	[39]
40	.	O	['N']	[40]
#4173
0	Cutaneous	B	['N']	[0]
1	mycobacterial	I	['N']	[1]
2	infection	I-Adverse_Effect	['N']	[2]
3	post	O	['N']	[3]
4	intravesical	O	['N']	[4]
5	BCG	B-Drug	['Causes']	[2]
6	installation	O	['N']	[6]
7	.	O	['N']	[7]
#4174
0	Eosinophilic	B	['N']	[0]
1	cystitis	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	bladder	O	['N']	[3]
4	instillation	O	['N']	[4]
5	with	O	['N']	[5]
6	dimethyl	B	['N']	[6]
7	sulfoxide	I-Drug	['Causes']	[1]
8	.	O	['N']	[8]
#4175
0	Because	O	['N']	[0]
1	of	O	['N']	[1]
2	serious	O	['N']	[2]
3	side	O	['N']	[3]
4	effects	O	['N']	[4]
5	of	O	['N']	[5]
6	an	O	['N']	[6]
7	increase	O	['N']	[7]
8	in	O	['N']	[8]
9	the	O	['N']	[9]
10	QT	O	['N']	[10]
11	interval	O	['N']	[11]
12	causing	O	['N']	[12]
13	torsades	B	['N']	[13]
14	de	I	['N']	[14]
15	pointes	I-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	dofetilide	B-Drug	['Causes']	[15]
18	must	O	['N']	[18]
19	be	O	['N']	[19]
20	initiated	O	['N']	[20]
21	with	O	['N']	[21]
22	close	O	['N']	[22]
23	monitoring	O	['N']	[23]
24	of	O	['N']	[24]
25	the	O	['N']	[25]
26	QT	O	['N']	[26]
27	interval	O	['N']	[27]
28	in	O	['N']	[28]
29	an	O	['N']	[29]
30	inpatient	O	['N']	[30]
31	setting	O	['N']	[31]
32	.	O	['N']	[32]
#4176
0	Although	O	['N']	[0]
1	gabapentin	B-Drug	['Causes']	[29]
2	withdrawal	O	['N']	[2]
3	has	O	['N']	[3]
4	been	O	['N']	[4]
5	previously	O	['N']	[5]
6	reported	O	['N']	[6]
7	and	O	['N']	[7]
8	usually	O	['N']	[8]
9	consists	O	['N']	[9]
10	of	O	['N']	[10]
11	anxiety	O	['N']	[11]
12	,	O	['N']	[12]
13	diaphoresis	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	palpitations	O	['N']	[16]
17	,	O	['N']	[17]
18	this	O	['N']	[18]
19	is	O	['N']	[19]
20	the	O	['N']	[20]
21	first	O	['N']	[21]
22	reported	O	['N']	[22]
23	patient	O	['N']	[23]
24	with	O	['N']	[24]
25	generalized	O	['N']	[25]
26	seizures	O	['N']	[26]
27	and	O	['N']	[27]
28	status	B	['N']	[28]
29	epilepticus	I-Adverse_Effect	['N']	[29]
30	secondary	O	['N']	[30]
31	to	O	['N']	[31]
32	gabapentin	O	['N']	[32]
33	withdrawal	O	['N']	[33]
34	.	O	['N']	[34]
#4177
0	Sweet	O	['N']	[0]
1	's	O	['N']	[1]
2	syndrome	O	['N']	[2]
3	is	O	['N']	[3]
4	an	O	['N']	[4]
5	acute	B	['N']	[5]
6	febrile	I	['N']	[6]
7	neutrophilic	I	['N']	[7]
8	dermatosis	I-Adverse_Effect	['N']	[8]
9	that	O	['N']	[9]
10	is	O	['N']	[10]
11	a	O	['N']	[11]
12	known	O	['N']	[12]
13	complication	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	administration	O	['N']	[16]
17	of	O	['N']	[17]
18	filgrastim	B-Drug	['Causes']	[8]
19	,	O	['N']	[19]
20	a	O	['N']	[20]
21	drug	O	['N']	[21]
22	that	O	['N']	[22]
23	causes	O	['N']	[23]
24	increased	O	['N']	[24]
25	neutrophil	O	['N']	[25]
26	proliferation	O	['N']	[26]
27	and	O	['N']	[27]
28	differentiation	O	['N']	[28]
29	.	O	['N']	[29]
#4178
0	The	O	['N']	[0]
1	incidence	O	['N']	[1]
2	of	O	['N']	[2]
3	angioedema	B-Adverse_Effect	['N']	[3]
4	secondary	O	['N']	[4]
5	to	O	['N']	[5]
6	losartan	B-Drug	['Causes']	[3]
7	,	O	['N']	[7]
8	an	O	['N']	[8]
9	angiotensin	O	['N']	[9]
10	II	O	['N']	[10]
11	receptor	O	['N']	[11]
12	antagonist	O	['N']	[12]
13	,	O	['N']	[13]
14	is	O	['N']	[14]
15	unknown	O	['N']	[15]
16	.	O	['N']	[16]
#4179
0	L	B	['N']	[0]
1	-	I	['N']	[1]
2	asparaginase	I-Drug	['Causes']	[12]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	pancreatitis	O	['N']	[5]
6	is	O	['N']	[6]
7	an	O	['N']	[7]
8	uncommon	O	['N']	[8]
9	but	O	['N']	[9]
10	potential	O	['N']	[10]
11	lethal	B	['N']	[11]
12	complication	I-Adverse_Effect	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	treatment	O	['N']	[15]
16	of	O	['N']	[16]
17	leukemia	O	['N']	[17]
18	.	O	['N']	[18]
#4180
0	Persistent	B	['N']	[0]
1	hypoglycemia	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	diabetes	O	['N']	[6]
7	taking	O	['N']	[7]
8	etanercept	B-Drug	['Causes']	[1]
9	for	O	['N']	[9]
10	the	O	['N']	[10]
11	treatment	O	['N']	[11]
12	of	O	['N']	[12]
13	psoriasis	O	['N']	[13]
14	.	O	['N']	[14]
#4181
0	Acute	B	['N']	[0]
1	renal	I	['N']	[1]
2	failure	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	child	O	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	acyclovir	B-Drug	['Causes']	[2]
9	.	O	['N']	[9]
#4182
0	Idiosyncratic	O	['N']	[0]
1	factors	O	['N']	[1]
2	involving	O	['N']	[2]
3	vasopressin	B-Drug	['Causes']	[35]
4	receptor	O	['N']	[4]
5	affinity	O	['N']	[5]
6	and	O	['N']	[6]
7	distribution	O	['N']	[7]
8	,	O	['N']	[8]
9	vasopressin	O	['N']	[9]
10	-	O	['N']	[10]
11	associated	O	['N']	[11]
12	vasodilation	O	['N']	[12]
13	in	O	['N']	[13]
14	some	O	['N']	[14]
15	vascular	O	['N']	[15]
16	beds	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	the	O	['N']	[19]
20	effect	O	['N']	[20]
21	of	O	['N']	[21]
22	vasopressin	O	['N']	[22]
23	on	O	['N']	[23]
24	the	O	['N']	[24]
25	renin	O	['N']	[25]
26	-	O	['N']	[26]
27	angiotensin	O	['N']	[27]
28	system	O	['N']	[28]
29	may	O	['N']	[29]
30	further	O	['N']	[30]
31	contribute	O	['N']	[31]
32	to	O	['N']	[32]
33	impaired	B	['N']	[33]
34	tissue	I	['N']	[34]
35	perfusion	I-Adverse_Effect	['N']	[35]
36	.	O	['N']	[36]
#4183
0	Shortly	O	['N']	[0]
1	after	O	['N']	[1]
2	chemotherapy	O	['N']	[2]
3	and	O	['N']	[3]
4	an	O	['N']	[4]
5	injection	O	['N']	[5]
6	of	O	['N']	[6]
7	pegfilgrastim	B-Drug	['Causes']	[26]
8	,	O	['N']	[8]
9	the	O	['N']	[9]
10	patient	O	['N']	[10]
11	developed	O	['N']	[11]
12	poorly	O	['N']	[12]
13	defined	O	['N']	[13]
14	,	O	['N']	[14]
15	rapidly	O	['N']	[15]
16	progressive	O	['N']	[16]
17	erythema	O	['N']	[17]
18	,	O	['N']	[18]
19	edema	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	pain	B	['N']	[22]
23	in	I	['N']	[23]
24	his	I	['N']	[24]
25	right	I	['N']	[25]
26	forearm	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#4184
0	A	O	['N']	[0]
1	30-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	pharmacist	O	['N']	[4]
5	suffered	O	['N']	[5]
6	from	O	['N']	[6]
7	acute	B	['N']	[7]
8	allergic	I	['N']	[8]
9	contact	I	['N']	[9]
10	dermatitis	I-Adverse_Effect	['N']	[10]
11	due	O	['N']	[11]
12	to	O	['N']	[12]
13	4-chloro-7-nitrobenzofurazan	O	['N']	[13]
14	(	O	['N']	[14]
15	NBD	B	['N']	[15]
16	-	I	['N']	[16]
17	Cl	I-Drug	['Causes']	[10]
18	)	O	['N']	[18]
19	.	O	['N']	[19]
#4185
0	Subsequently	O	['N']	[0]
1	,	O	['N']	[1]
2	he	O	['N']	[2]
3	developed	O	['N']	[3]
4	hyperglycemia	B-Adverse_Effect	['N']	[4]
5	(	O	['N']	[5]
6	fasting	O	['N']	[6]
7	blood	O	['N']	[7]
8	glucose	O	['N']	[8]
9	138	O	['N']	[9]
10	mg	O	['N']	[10]
11	/	O	['N']	[11]
12	dL	O	['N']	[12]
13	)	O	['N']	[13]
14	that	O	['N']	[14]
15	resolved	O	['N']	[15]
16	when	O	['N']	[16]
17	olanzapine	B-Drug	['Causes']	[4]
18	was	O	['N']	[18]
19	stopped	O	['N']	[19]
20	and	O	['N']	[20]
21	recurred	O	['N']	[21]
22	(	O	['N']	[22]
23	fasting	O	['N']	[23]
24	blood	O	['N']	[24]
25	glucose	O	['N']	[25]
26	150	O	['N']	[26]
27	mg	O	['N']	[27]
28	/	O	['N']	[28]
29	dL	O	['N']	[29]
30	)	O	['N']	[30]
31	after	O	['N']	[31]
32	2	O	['N']	[32]
33	days	O	['N']	[33]
34	of	O	['N']	[34]
35	rechallenge	O	['N']	[35]
36	with	O	['N']	[36]
37	olanzapine	O	['N']	[37]
38	2.5	O	['N']	[38]
39	mg	O	['N']	[39]
40	twice	O	['N']	[40]
41	daily	O	['N']	[41]
42	.	O	['N']	[42]
#4186
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	the	O	['N']	[4]
5	occurrence	O	['N']	[5]
6	of	O	['N']	[6]
7	acute	O	['N']	[7]
8	cytolytic	O	['N']	[8]
9	hepatitis	B-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	patient	O	['N']	[12]
13	exposed	O	['N']	[13]
14	to	O	['N']	[14]
15	pulse	O	['N']	[15]
16	itraconazole	B-Drug	['Causes']	[9]
17	therapy	O	['N']	[17]
18	for	O	['N']	[18]
19	24	O	['N']	[19]
20	weeks	O	['N']	[20]
21	and	O	['N']	[21]
22	provide	O	['N']	[22]
23	a	O	['N']	[23]
24	concise	O	['N']	[24]
25	review	O	['N']	[25]
26	of	O	['N']	[26]
27	the	O	['N']	[27]
28	literature	O	['N']	[28]
29	on	O	['N']	[29]
30	cases	O	['N']	[30]
31	of	O	['N']	[31]
32	itraconazole	O	['N']	[32]
33	-	O	['N']	[33]
34	induced	O	['N']	[34]
35	hepatitis	O	['N']	[35]
36	.	O	['N']	[36]
#4187
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	2	O	['N']	[2]
3	patients	O	['N']	[3]
4	with	O	['N']	[4]
5	prior	O	['N']	[5]
6	amputation	O	['N']	[6]
7	who	O	['N']	[7]
8	experienced	O	['N']	[8]
9	phantom	B	['N']	[9]
10	limb	I	['N']	[10]
11	pain	I-Adverse_Effect	['N']	[11]
12	(	O	['N']	[12]
13	PLP	O	['N']	[13]
14	)	O	['N']	[14]
15	after	O	['N']	[15]
16	receiving	O	['N']	[16]
17	paclitaxel	B-Drug	['Causes']	[11]
18	therapy	O	['N']	[18]
19	.	O	['N']	[19]
#4188
0	The	O	['N']	[0]
1	chemotherapeutics	O	['N']	[1]
2	,	O	['N']	[2]
3	including	O	['N']	[3]
4	vincristine	O	['N']	[4]
5	,	O	['N']	[5]
6	actinomycin	B	['N']	[6]
7	D	I-Drug	['Causes']	[27]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	epirubicin	O	['N']	[10]
11	in	O	['N']	[11]
12	case	O	['N']	[12]
13	1	O	['N']	[13]
14	and	O	['N']	[14]
15	vincristine	O	['N']	[15]
16	and	O	['N']	[16]
17	actinomycin	O	['N']	[17]
18	D	O	['N']	[18]
19	in	O	['N']	[19]
20	case	O	['N']	[20]
21	2	O	['N']	[21]
22	,	O	['N']	[22]
23	were	O	['N']	[23]
24	given	O	['N']	[24]
25	before	O	['N']	[25]
26	the	O	['N']	[26]
27	hepatotoxicity	B-Adverse_Effect	['N']	[27]
28	developed	O	['N']	[28]
29	.	O	['N']	[29]
#4189
0	Posterior	B	['N']	[0]
1	reversible	I	['N']	[1]
2	encephalopathy	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	methotrexate	B-Drug	['Causes']	[3]
7	neurotoxicity	O	['N']	[7]
8	:	O	['N']	[8]
9	conventional	O	['N']	[9]
10	magnetic	O	['N']	[10]
11	resonance	O	['N']	[11]
12	and	O	['N']	[12]
13	diffusion	O	['N']	[13]
14	-	O	['N']	[14]
15	weighted	O	['N']	[15]
16	imaging	O	['N']	[16]
17	findings	O	['N']	[17]
18	.	O	['N']	[18]
#4190
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	50-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	male	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	15-year	O	['N']	[10]
11	history	O	['N']	[11]
12	of	O	['N']	[12]
13	psoriasis	O	['N']	[13]
14	including	O	['N']	[14]
15	mutilating	O	['N']	[15]
16	psoriatic	O	['N']	[16]
17	arthritis	O	['N']	[17]
18	,	O	['N']	[18]
19	in	O	['N']	[19]
20	whom	O	['N']	[20]
21	the	O	['N']	[21]
22	withdrawal	O	['N']	[22]
23	of	O	['N']	[23]
24	cyclosporin	B	['N']	[24]
25	A	I-Drug	['Causes']	[37]
26	induced	O	['N']	[26]
27	a	O	['N']	[27]
28	generalised	O	['N']	[28]
29	pustular	O	['N']	[29]
30	exacerbation	O	['N']	[30]
31	and	O	['N']	[31]
32	a	O	['N']	[32]
33	aggravation	B	['N']	[33]
34	of	I	['N']	[34]
35	the	I	['N']	[35]
36	joint	I	['N']	[36]
37	condition	I-Adverse_Effect	['N']	[37]
38	.	O	['N']	[38]
#4191
0	Herein	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	describe	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	AIDS	O	['N']	[7]
8	who	O	['N']	[8]
9	presented	O	['N']	[9]
10	to	O	['N']	[10]
11	medical	O	['N']	[11]
12	attention	O	['N']	[12]
13	with	O	['N']	[13]
14	pancytopenia	B-Adverse_Effect	['N']	[14]
15	48	O	['N']	[15]
16	months	O	['N']	[16]
17	postchemotherapy	O	['N']	[17]
18	with	O	['N']	[18]
19	etoposide	B-Drug	['Causes']	[14]
20	,	O	['N']	[20]
21	prednisone	O	['N']	[21]
22	,	O	['N']	[22]
23	vincristine	O	['N']	[23]
24	,	O	['N']	[24]
25	cyclophosphamide	O	['N']	[25]
26	,	O	['N']	[26]
27	doxorubicin	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	rituximab	O	['N']	[30]
31	(	O	['N']	[31]
32	R	O	['N']	[32]
33	-	O	['N']	[33]
34	EPOCH	O	['N']	[34]
35	)	O	['N']	[35]
36	for	O	['N']	[36]
37	diffuse	O	['N']	[37]
38	large	O	['N']	[38]
39	B	O	['N']	[39]
40	-	O	['N']	[40]
41	cell	O	['N']	[41]
42	lymphoma	O	['N']	[42]
43	.	O	['N']	[43]
#4192
0	Since	O	['N']	[0]
1	tamoxifen	B-Drug	['Causes']	[6]
2	therapy	O	['N']	[2]
3	can	O	['N']	[3]
4	induce	O	['N']	[4]
5	endometrial	B	['N']	[5]
6	disorders	I-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	surveillance	O	['N']	[8]
9	schemes	O	['N']	[9]
10	of	O	['N']	[10]
11	women	O	['N']	[11]
12	taking	O	['N']	[12]
13	tamoxifen	O	['N']	[13]
14	have	O	['N']	[14]
15	been	O	['N']	[15]
16	recommended	O	['N']	[16]
17	.	O	['N']	[17]
#4193
0	Skin	B	['N']	[0]
1	necrosis	I-Adverse_Effect	['N']	[1]
2	secondary	O	['N']	[2]
3	to	O	['N']	[3]
4	low	B	['N']	[4]
5	-	I	['N']	[5]
6	molecular	I	['N']	[6]
7	weight	I	['N']	[7]
8	heparin	I-Drug	['Causes']	[1]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	patient	O	['N']	[11]
12	with	O	['N']	[12]
13	antiphospholipid	O	['N']	[13]
14	antibody	O	['N']	[14]
15	syndrome	O	['N']	[15]
16	.	O	['N']	[16]
#4194
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	1	O	['N']	[2]
3	,	O	['N']	[3]
4	a	O	['N']	[4]
5	total	O	['N']	[5]
6	daily	O	['N']	[6]
7	dose	O	['N']	[7]
8	of	O	['N']	[8]
9	25	O	['N']	[9]
10	mg	O	['N']	[10]
11	sertraline	B-Drug	['Causes']	[33]
12	,	O	['N']	[12]
13	with	O	['N']	[13]
14	nondetectable	O	['N']	[14]
15	sertraline	O	['N']	[15]
16	and	O	['N']	[16]
17	desmethylsertraline	O	['N']	[17]
18	blood	O	['N']	[18]
19	levels	O	['N']	[19]
20	,	O	['N']	[20]
21	resulted	O	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	doubling	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	lamotrigine	O	['N']	[27]
28	blood	O	['N']	[28]
29	level	O	['N']	[29]
30	with	O	['N']	[30]
31	symptoms	B	['N']	[31]
32	of	I	['N']	[32]
33	toxicity	I-Adverse_Effect	['N']	[33]
34	.	O	['N']	[34]
#4195
0	Subsequent	O	['N']	[0]
1	in	O	['N']	[1]
2	vivo	O	['N']	[2]
3	/	O	['N']	[3]
4	vitro	O	['N']	[4]
5	studies	O	['N']	[5]
6	clearly	O	['N']	[6]
7	demonstrated	O	['N']	[7]
8	that	O	['N']	[8]
9	the	O	['N']	[9]
10	neurological	B	['N']	[10]
11	effects	I-Adverse_Effect	['N']	[11]
12	were	O	['N']	[12]
13	due	O	['N']	[13]
14	to	O	['N']	[14]
15	a	O	['N']	[15]
16	synergistic	O	['N']	[16]
17	action	O	['N']	[17]
18	of	O	['N']	[18]
19	desferrioxamine	B-Drug	['Causes']	[11]
20	and	O	['N']	[20]
21	prochlorperazine	O	['N']	[21]
22	,	O	['N']	[22]
23	probably	O	['N']	[23]
24	resulting	O	['N']	[24]
25	in	O	['N']	[25]
26	exceptional	O	['N']	[26]
27	fluxes	O	['N']	[27]
28	of	O	['N']	[28]
29	intra	O	['N']	[29]
30	/	O	['N']	[30]
31	extra	O	['N']	[31]
32	cellular	O	['N']	[32]
33	iron	O	['N']	[33]
34	/	O	['N']	[34]
35	copper	O	['N']	[35]
36	disturbing	O	['N']	[36]
37	noradrenergic	O	['N']	[37]
38	and	O	['N']	[38]
39	serotonergic	O	['N']	[39]
40	systems	O	['N']	[40]
41	.	O	['N']	[41]
#4196
0	A	O	['N']	[0]
1	40-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	a	O	['N']	[6]
7	long	O	['N']	[7]
8	standing	O	['N']	[8]
9	history	O	['N']	[9]
10	of	O	['N']	[10]
11	rheumatoid	O	['N']	[11]
12	arthritis	O	['N']	[12]
13	was	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	MTX	B-Drug	['Causes']	[27]
17	over	O	['N']	[17]
18	a	O	['N']	[18]
19	6	O	['N']	[19]
20	month	O	['N']	[20]
21	period	O	['N']	[21]
22	and	O	['N']	[22]
23	developed	O	['N']	[23]
24	an	O	['N']	[24]
25	overwhelming	B	['N']	[25]
26	hepatic	I	['N']	[26]
27	necrosis	I-Adverse_Effect	['N']	[27]
28	.	O	['N']	[28]
#4197
0	A	O	['N']	[0]
1	7-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	with	O	['N']	[4]
5	congenital	O	['N']	[5]
6	toxoplasmosis	O	['N']	[6]
7	who	O	['N']	[7]
8	took	O	['N']	[8]
9	pyrimethamine	O	['N']	[9]
10	and	O	['N']	[10]
11	sulfadiazine	B-Drug	['Causes']	[22]
12	for	O	['N']	[12]
13	reactivated	O	['N']	[13]
14	chorioretinitis	O	['N']	[14]
15	developed	O	['N']	[15]
16	fever	O	['N']	[16]
17	,	O	['N']	[17]
18	severe	O	['N']	[18]
19	cutaneous	O	['N']	[19]
20	involvement	O	['N']	[20]
21	,	O	['N']	[21]
22	swelling	B-Adverse_Effect	['N']	[22]
23	,	O	['N']	[23]
24	abdominal	O	['N']	[24]
25	pain	O	['N']	[25]
26	and	O	['N']	[26]
27	transaminitis	O	['N']	[27]
28	,	O	['N']	[28]
29	persisting	O	['N']	[29]
30	weeks	O	['N']	[30]
31	after	O	['N']	[31]
32	withholding	O	['N']	[32]
33	medicines	O	['N']	[33]
34	.	O	['N']	[34]
#4198
0	The	O	['N']	[0]
1	clinical	O	['N']	[1]
2	course	O	['N']	[2]
3	suggests	O	['N']	[3]
4	that	O	['N']	[4]
5	caffeine	B-Drug	['Causes']	[24]
6	,	O	['N']	[6]
7	which	O	['N']	[7]
8	is	O	['N']	[8]
9	present	O	['N']	[9]
10	in	O	['N']	[10]
11	oolong	O	['N']	[11]
12	tea	O	['N']	[12]
13	,	O	['N']	[13]
14	was	O	['N']	[14]
15	mainly	O	['N']	[15]
16	responsible	O	['N']	[16]
17	for	O	['N']	[17]
18	the	O	['N']	[18]
19	rhabdomyolysis	O	['N']	[19]
20	as	O	['N']	[20]
21	well	O	['N']	[21]
22	as	O	['N']	[22]
23	the	O	['N']	[23]
24	delirium	B-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	although	O	['N']	[26]
27	severe	O	['N']	[27]
28	hyponatremia	O	['N']	[28]
29	has	O	['N']	[29]
30	been	O	['N']	[30]
31	reported	O	['N']	[31]
32	to	O	['N']	[32]
33	cause	O	['N']	[33]
34	rhabdomyolysis	O	['N']	[34]
35	on	O	['N']	[35]
36	rare	O	['N']	[36]
37	occasions	O	['N']	[37]
38	.	O	['N']	[38]
#4199
0	OBJECTIVES	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	the	O	['N']	[4]
5	presentation	O	['N']	[5]
6	and	O	['N']	[6]
7	treatment	O	['N']	[7]
8	of	O	['N']	[8]
9	acute	O	['N']	[9]
10	isoniazid	O	['N']	[10]
11	(	O	['N']	[11]
12	INH	B-Drug	['Causes']	[14]
13	)	O	['N']	[13]
14	neurotoxicity	B-Adverse_Effect	['N']	[14]
15	appearing	O	['N']	[15]
16	at	O	['N']	[16]
17	an	O	['N']	[17]
18	inner	O	['N']	[18]
19	-	O	['N']	[19]
20	city	O	['N']	[20]
21	municipal	O	['N']	[21]
22	hospital	O	['N']	[22]
23	.	O	['N']	[23]
#4200
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	no	O	['N']	[2]
3	.	O	['N']	[3]
4	2	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	pathogenic	O	['N']	[7]
8	mechanism	O	['N']	[8]
9	seemed	O	['N']	[9]
10	to	O	['N']	[10]
11	be	O	['N']	[11]
12	persistent	O	['N']	[12]
13	light	O	['N']	[13]
14	reaction	O	['N']	[14]
15	preceded	O	['N']	[15]
16	by	O	['N']	[16]
17	systemic	O	['N']	[17]
18	photoallergy	O	['N']	[18]
19	,	O	['N']	[19]
20	as	O	['N']	[20]
21	he	O	['N']	[21]
22	had	O	['N']	[22]
23	taken	O	['N']	[23]
24	mequitazine	B-Drug	['Causes']	[54]
25	for	O	['N']	[25]
26	6	O	['N']	[26]
27	months	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	there	O	['N']	[30]
31	were	O	['N']	[31]
32	strong	O	['N']	[32]
33	positive	O	['N']	[33]
34	photopatch	O	['N']	[34]
35	test	O	['N']	[35]
36	results	O	['N']	[36]
37	with	O	['N']	[37]
38	immediate	O	['N']	[38]
39	erythema	O	['N']	[39]
40	reaction	O	['N']	[40]
41	,	O	['N']	[41]
42	cross	O	['N']	[42]
43	-	O	['N']	[43]
44	reaction	O	['N']	[44]
45	to	O	['N']	[45]
46	promethazine	O	['N']	[46]
47	,	O	['N']	[47]
48	decreased	B	['N']	[48]
49	MED	I	['N']	[49]
50	to	I	['N']	[50]
51	both	I	['N']	[51]
52	UVA	I	['N']	[52]
53	and	I	['N']	[53]
54	UVB	I-Adverse_Effect	['N']	[54]
55	,	O	['N']	[55]
56	and	O	['N']	[56]
57	persistence	O	['N']	[57]
58	of	O	['N']	[58]
59	the	O	['N']	[59]
60	photosensitivity	O	['N']	[60]
61	over	O	['N']	[61]
62	a	O	['N']	[62]
63	3-year	O	['N']	[63]
64	follow	O	['N']	[64]
65	-	O	['N']	[65]
66	up	O	['N']	[66]
67	period	O	['N']	[67]
68	after	O	['N']	[68]
69	discontinuation	O	['N']	[69]
70	of	O	['N']	[70]
71	the	O	['N']	[71]
72	mequitazine	O	['N']	[72]
73	.	O	['N']	[73]
#4201
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	who	O	['N']	[2]
3	received	O	['N']	[3]
4	clindamycin	B-Drug	['Causes']	[22]
5	had	O	['N']	[5]
6	liver	O	['N']	[6]
7	biopsy	O	['N']	[7]
8	findings	O	['N']	[8]
9	of	O	['N']	[9]
10	marked	O	['N']	[10]
11	cholestasis	O	['N']	[11]
12	,	O	['N']	[12]
13	portal	O	['N']	[13]
14	inflammation	O	['N']	[14]
15	,	O	['N']	[15]
16	bile	O	['N']	[16]
17	duct	O	['N']	[17]
18	injury	O	['N']	[18]
19	and	O	['N']	[19]
20	bile	B	['N']	[20]
21	duct	I	['N']	[21]
22	paucity	I-Adverse_Effect	['N']	[22]
23	(	O	['N']	[23]
24	ductopenia	O	['N']	[24]
25	)	O	['N']	[25]
26	.	O	['N']	[26]
#4202
0	A	O	['N']	[0]
1	57-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	developed	O	['N']	[5]
6	chronic	B	['N']	[6]
7	,	I	['N']	[7]
8	watery	I	['N']	[8]
9	diarrhea	I-Adverse_Effect	['N']	[9]
10	four	O	['N']	[10]
11	weeks	O	['N']	[11]
12	after	O	['N']	[12]
13	Helicobacter	O	['N']	[13]
14	pylori	O	['N']	[14]
15	eradication	O	['N']	[15]
16	therapy	O	['N']	[16]
17	including	O	['N']	[17]
18	lansoprazole	B-Drug	['Causes']	[9]
19	followed	O	['N']	[19]
20	by	O	['N']	[20]
21	lansoprazole	O	['N']	[21]
22	monotherapy	O	['N']	[22]
23	for	O	['N']	[23]
24	gastroesophageal	O	['N']	[24]
25	reflux	O	['N']	[25]
26	disease	O	['N']	[26]
27	.	O	['N']	[27]
#4203
0	Infants	O	['N']	[0]
1	are	O	['N']	[1]
2	particularly	O	['N']	[2]
3	susceptible	O	['N']	[3]
4	to	O	['N']	[4]
5	chronic	O	['N']	[5]
6	nitrate	B-Drug	['Causes']	[9]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	methemoglobinemia	B-Adverse_Effect	['N']	[9]
10	because	O	['N']	[10]
11	of	O	['N']	[11]
12	their	O	['N']	[12]
13	low	O	['N']	[13]
14	stomach	O	['N']	[14]
15	acid	O	['N']	[15]
16	production	O	['N']	[16]
17	,	O	['N']	[17]
18	large	O	['N']	[18]
19	numbers	O	['N']	[19]
20	of	O	['N']	[20]
21	nitrite	O	['N']	[21]
22	-	O	['N']	[22]
23	reducing	O	['N']	[23]
24	bacteria	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	the	O	['N']	[27]
28	relatively	O	['N']	[28]
29	easy	O	['N']	[29]
30	oxidation	O	['N']	[30]
31	of	O	['N']	[31]
32	fetal	O	['N']	[32]
33	hemoglobin	O	['N']	[33]
34	.	O	['N']	[34]
#4204
0	DIAGNOSIS	O	['N']	[0]
1	:	O	['N']	[1]
2	Severe	O	['N']	[2]
3	temozolomide	B-Drug	['Causes']	[17]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	immunosuppression	O	['N']	[6]
7	,	O	['N']	[7]
8	exacerbated	O	['N']	[8]
9	by	O	['N']	[9]
10	corticosteroids	O	['N']	[10]
11	,	O	['N']	[11]
12	with	O	['N']	[12]
13	profound	O	['N']	[13]
14	T	B	['N']	[14]
15	-	I	['N']	[15]
16	cell	I	['N']	[16]
17	lymphocytopenia	I-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	simultaneous	O	['N']	[19]
20	opportunistic	O	['N']	[20]
21	infections	O	['N']	[21]
22	with	O	['N']	[22]
23	Pneumocystis	O	['N']	[23]
24	jiroveci	O	['N']	[24]
25	pneumonia	O	['N']	[25]
26	,	O	['N']	[26]
27	brain	O	['N']	[27]
28	abscess	O	['N']	[28]
29	with	O	['N']	[29]
30	Listeria	O	['N']	[30]
31	monocytogenes	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	cutaneous	O	['N']	[34]
35	Kaposi	O	['N']	[35]
36	's	O	['N']	[36]
37	sarcoma	O	['N']	[37]
38	.	O	['N']	[38]
#4205
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	5	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	acute	B	['N']	[5]
6	reversible	I	['N']	[6]
7	renal	I	['N']	[7]
8	failure	I-Adverse_Effect	['N']	[8]
9	coinciding	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	onset	O	['N']	[12]
13	of	O	['N']	[13]
14	treatment	O	['N']	[14]
15	with	O	['N']	[15]
16	captopril	B-Drug	['Causes']	[8]
17	in	O	['N']	[17]
18	patients	O	['N']	[18]
19	with	O	['N']	[19]
20	severe	O	['N']	[20]
21	drug	O	['N']	[21]
22	-	O	['N']	[22]
23	resistant	O	['N']	[23]
24	hypertension	O	['N']	[24]
25	.	O	['N']	[25]
#4206
0	Data	O	['N']	[0]
1	have	O	['N']	[1]
2	been	O	['N']	[2]
3	published	O	['N']	[3]
4	regarding	O	['N']	[4]
5	the	O	['N']	[5]
6	possibility	O	['N']	[6]
7	that	O	['N']	[7]
8	tamoxifen	B-Drug	['Causes']	[21]
9	may	O	['N']	[9]
10	be	O	['N']	[10]
11	responsible	O	['N']	[11]
12	for	O	['N']	[12]
13	the	O	['N']	[13]
14	subsequent	O	['N']	[14]
15	development	O	['N']	[15]
16	of	O	['N']	[16]
17	carcinoma	B	['N']	[17]
18	of	I	['N']	[18]
19	the	I	['N']	[19]
20	corpus	I	['N']	[20]
21	uteri	I-Adverse_Effect	['N']	[21]
22	in	O	['N']	[22]
23	these	O	['N']	[23]
24	patients	O	['N']	[24]
25	.	O	['N']	[25]
#4207
0	Kaposi	B	['N']	[0]
1	's	I	['N']	[1]
2	sarcoma	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	imatinib	B	['N']	[8]
9	mesylate	I-Drug	['Causes']	[2]
10	for	O	['N']	[10]
11	chronic	O	['N']	[11]
12	myeloid	O	['N']	[12]
13	leukemia	O	['N']	[13]
14	.	O	['N']	[14]
#4208
0	The	O	['N']	[0]
1	most	O	['N']	[1]
2	common	O	['N']	[2]
3	side	O	['N']	[3]
4	effects	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	amifostine	B-Drug	['Causes']	[11]
8	are	O	['N']	[8]
9	nausea	O	['N']	[9]
10	,	O	['N']	[10]
11	vomiting	B-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	hypotension	O	['N']	[13]
14	,	O	['N']	[14]
15	hypocalcemia	O	['N']	[15]
16	and	O	['N']	[16]
17	allergic	O	['N']	[17]
18	reactions	O	['N']	[18]
19	.	O	['N']	[19]
#4209
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	an	O	['N']	[2]
3	AIDS	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	severe	O	['N']	[6]
7	and	O	['N']	[7]
8	prolonged	O	['N']	[8]
9	lactic	B	['N']	[9]
10	acidosis	I-Adverse_Effect	['N']	[10]
11	on	O	['N']	[11]
12	stavudine	B-Drug	['Causes']	[10]
13	and	O	['N']	[13]
14	lamivudine	O	['N']	[14]
15	.	O	['N']	[15]
#4210
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	patient	O	['N']	[3]
4	required	O	['N']	[4]
5	insulin	B-Drug	['Causes']	[11]
6	desensitization	O	['N']	[6]
7	for	O	['N']	[7]
8	severe	O	['N']	[8]
9	urticaria	O	['N']	[9]
10	,	O	['N']	[10]
11	angioedema	B-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	occasional	O	['N']	[14]
15	wheezing	O	['N']	[15]
16	resulting	O	['N']	[16]
17	from	O	['N']	[17]
18	her	O	['N']	[18]
19	insulin	O	['N']	[19]
20	dose	O	['N']	[20]
21	.	O	['N']	[21]
#4211
0	Postoperative	O	['N']	[0]
1	hypocalcemic	B	['N']	[1]
2	tetany	I-Adverse_Effect	['N']	[2]
3	caused	O	['N']	[3]
4	by	O	['N']	[4]
5	fleet	B	['N']	[5]
6	phospho	I	['N']	[6]
7	-	I	['N']	[7]
8	soda	I-Drug	['Causes']	[2]
9	preparation	O	['N']	[9]
10	in	O	['N']	[10]
11	a	O	['N']	[11]
12	patient	O	['N']	[12]
13	taking	O	['N']	[13]
14	alendronate	O	['N']	[14]
15	sodium	O	['N']	[15]
16	:	O	['N']	[16]
17	report	O	['N']	[17]
18	of	O	['N']	[18]
19	a	O	['N']	[19]
20	case	O	['N']	[20]
21	.	O	['N']	[21]
#4212
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	was	O	['N']	[2]
3	an	O	['N']	[3]
4	80-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	woman	O	['N']	[7]
8	who	O	['N']	[8]
9	was	O	['N']	[9]
10	admitted	O	['N']	[10]
11	for	O	['N']	[11]
12	Staphylococcus	B	['N']	[12]
13	aureus	I	['N']	[13]
14	knee	I	['N']	[14]
15	arthritis	I-Adverse_Effect	['N']	[15]
16	after	O	['N']	[16]
17	several	O	['N']	[17]
18	intraarticular	O	['N']	[18]
19	injections	O	['N']	[19]
20	of	O	['N']	[20]
21	sodium	O	['N']	[21]
22	hyaluronate	O	['N']	[22]
23	and	O	['N']	[23]
24	corticosteroids	B-Drug	['Causes']	[15]
25	.	O	['N']	[25]
#4213
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	the	O	['N']	[2]
3	side	O	['N']	[3]
4	effects	O	['N']	[4]
5	of	O	['N']	[5]
6	5-FU	B-Drug	['Causes']	[21]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	colon	O	['N']	[9]
10	cancer	O	['N']	[10]
11	patient	O	['N']	[11]
12	who	O	['N']	[12]
13	suffered	O	['N']	[13]
14	severe	O	['N']	[14]
15	mucositis	O	['N']	[15]
16	,	O	['N']	[16]
17	desquamating	O	['N']	[17]
18	dermatitis	O	['N']	[18]
19	,	O	['N']	[19]
20	prolonged	B	['N']	[20]
21	myelosuppression	I-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	neurologic	O	['N']	[24]
25	toxicity	O	['N']	[25]
26	that	O	['N']	[26]
27	required	O	['N']	[27]
28	admission	O	['N']	[28]
29	to	O	['N']	[29]
30	the	O	['N']	[30]
31	intensive	O	['N']	[31]
32	care	O	['N']	[32]
33	unit	O	['N']	[33]
34	.	O	['N']	[34]
#4214
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	codeine	B-Drug	['Causes']	[6]
6	intoxication	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	the	O	['N']	[8]
9	neonate	O	['N']	[9]
10	,	O	['N']	[10]
11	in	O	['N']	[11]
12	which	O	['N']	[12]
13	the	O	['N']	[13]
14	drug	O	['N']	[14]
15	was	O	['N']	[15]
16	prescribed	O	['N']	[16]
17	for	O	['N']	[17]
18	cough	O	['N']	[18]
19	control	O	['N']	[19]
20	during	O	['N']	[20]
21	an	O	['N']	[21]
22	emergency	O	['N']	[22]
23	department	O	['N']	[23]
24	visit	O	['N']	[24]
25	.	O	['N']	[25]
#4215
0	This	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	sequential	O	['N']	[3]
4	symptoms	O	['N']	[4]
5	including	O	['N']	[5]
6	alternative	O	['N']	[6]
7	hemiparesis	O	['N']	[7]
8	,	O	['N']	[8]
9	dysarthria	O	['N']	[9]
10	and	O	['N']	[10]
11	altered	O	['N']	[11]
12	consciousness	O	['N']	[12]
13	5	O	['N']	[13]
14	days	O	['N']	[14]
15	after	O	['N']	[15]
16	the	O	['N']	[16]
17	second	O	['N']	[17]
18	course	O	['N']	[18]
19	of	O	['N']	[19]
20	HD	B	['N']	[20]
21	-	I	['N']	[21]
22	MTX	I-Drug	['Dosage']	[32]
23	(	O	['N']	[23]
24	8	B	['N']	[24]
25	gm	I	['N']	[25]
26	/	I	['N']	[26]
27	m2	I	['N']	[27]
28	by	I	['N']	[28]
29	6	I	['N']	[29]
30	h	I	['N']	[30]
31	continuous	I	['N']	[31]
32	infusion	I-Dose	['N']	[32]
33	)	O	['N']	[33]
34	with	O	['N']	[34]
35	leucovorin	O	['N']	[35]
36	rescue	O	['N']	[36]
37	.	O	['N']	[37]
#4216
0	Myelodysplasia	O	['N']	[0]
1	terminating	O	['N']	[1]
2	in	O	['N']	[2]
3	acute	B	['N']	[3]
4	myeloid	I	['N']	[4]
5	leukemia	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	hairy	O	['N']	[8]
9	cell	O	['N']	[9]
10	leukemia	O	['N']	[10]
11	patient	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	2-deoxycoformycin	B-Drug	['Causes']	[5]
15	.	O	['N']	[15]
#4217
0	Severe	B	['N']	[0]
1	hyperkalemia	I-Adverse_Effect	['N']	[1]
2	as	O	['N']	[2]
3	a	O	['N']	[3]
4	complication	O	['N']	[4]
5	of	O	['N']	[5]
6	timolol	B-Drug	['Causes']	[1]
7	,	O	['N']	[7]
8	a	O	['N']	[8]
9	topically	O	['N']	[9]
10	applied	O	['N']	[10]
11	beta	O	['N']	[11]
12	-	O	['N']	[12]
13	adrenergic	O	['N']	[13]
14	antagonist	O	['N']	[14]
15	.	O	['N']	[15]
#4218
0	A	O	['N']	[0]
1	50-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	a	O	['N']	[6]
7	history	O	['N']	[7]
8	of	O	['N']	[8]
9	migraine	O	['N']	[9]
10	without	O	['N']	[10]
11	aura	O	['N']	[11]
12	,	O	['N']	[12]
13	predominantly	O	['N']	[13]
14	occurring	O	['N']	[14]
15	around	O	['N']	[15]
16	her	O	['N']	[16]
17	menstrual	O	['N']	[17]
18	periods	O	['N']	[18]
19	,	O	['N']	[19]
20	developed	O	['N']	[20]
21	a	O	['N']	[21]
22	spinal	B	['N']	[22]
23	cord	I	['N']	[23]
24	lesion	I-Adverse_Effect	['N']	[24]
25	following	O	['N']	[25]
26	the	O	['N']	[26]
27	use	O	['N']	[27]
28	of	O	['N']	[28]
29	zolmitriptan	B-Drug	['Causes']	[24]
30	.	O	['N']	[30]
#4219
0	Secondary	O	['N']	[0]
1	acute	B	['N']	[1]
2	myeloid	I	['N']	[2]
3	leukemia	I-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	etoposide	B-Drug	['Causes']	[3]
6	therapy	O	['N']	[6]
7	for	O	['N']	[7]
8	haemophagocytic	O	['N']	[8]
9	lymphohistiocytosis	O	['N']	[9]
10	.	O	['N']	[10]
#4220
0	Hepatopathy	B-Adverse_Effect	['N']	[0]
1	subsided	O	['N']	[1]
2	after	O	['N']	[2]
3	the	O	['N']	[3]
4	cessation	O	['N']	[4]
5	of	O	['N']	[5]
6	carbamazepine	B-Drug	['Causes']	[0]
7	and	O	['N']	[7]
8	lynestrenol	O	['N']	[8]
9	.	O	['N']	[9]
#4221
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	chronic	O	['N']	[3]
4	myeloid	O	['N']	[4]
5	leukaemia	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	busulphan	B-Drug	['Causes']	[24]
9	for	O	['N']	[9]
10	4	O	['N']	[10]
11	-	O	['N']	[11]
12	5	O	['N']	[12]
13	years	O	['N']	[13]
14	,	O	['N']	[14]
15	developed	O	['N']	[15]
16	signs	O	['N']	[16]
17	of	O	['N']	[17]
18	busulphan	O	['N']	[18]
19	toxicity	O	['N']	[19]
20	and	O	['N']	[20]
21	portal	O	['N']	[21]
22	hypertension	O	['N']	[22]
23	with	O	['N']	[23]
24	ascites	B-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	oesophageal	O	['N']	[26]
27	varices	O	['N']	[27]
28	and	O	['N']	[28]
29	jaundice	O	['N']	[29]
30	.	O	['N']	[30]
#4222
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	with	O	['N']	[4]
5	chronic	O	['N']	[5]
6	hepatitis	O	['N']	[6]
7	C	O	['N']	[7]
8	(	O	['N']	[8]
9	CHC	O	['N']	[9]
10	)	O	['N']	[10]
11	who	O	['N']	[11]
12	developed	O	['N']	[12]
13	sarcoidosis	B-Adverse_Effect	['N']	[13]
14	after	O	['N']	[14]
15	the	O	['N']	[15]
16	treatment	O	['N']	[16]
17	by	O	['N']	[17]
18	interferon	O	['N']	[18]
19	alpha	O	['N']	[19]
20	and	O	['N']	[20]
21	ribavirin	B-Drug	['Causes']	[13]
22	.	O	['N']	[22]
#4223
0	Hyponatremia	B-Adverse_Effect	['N']	[0]
1	in	O	['N']	[1]
2	patients	O	['N']	[2]
3	treated	O	['N']	[3]
4	with	O	['N']	[4]
5	lorcainide	B-Drug	['Causes']	[0]
6	,	O	['N']	[6]
7	a	O	['N']	[7]
8	new	O	['N']	[8]
9	antiarrhythmic	O	['N']	[9]
10	drug	O	['N']	[10]
11	.	O	['N']	[11]
#4224
0	Primary	B	['N']	[0]
1	cutaneous	I	['N']	[1]
2	coccidioidomycosis	I-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	subsequent	O	['N']	[4]
5	drug	O	['N']	[5]
6	eruption	O	['N']	[6]
7	to	O	['N']	[7]
8	itraconazole	B-Drug	['Causes']	[2]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	dog	O	['N']	[11]
12	.	O	['N']	[12]
#4225
0	A	O	['N']	[0]
1	14-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	developed	O	['N']	[5]
6	systemic	O	['N']	[6]
7	lupus	O	['N']	[7]
8	erythematosus	O	['N']	[8]
9	(	O	['N']	[9]
10	SLE)-like	O	['N']	[10]
11	symptoms	O	['N']	[11]
12	,	O	['N']	[12]
13	rash	B-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	fever	O	['N']	[15]
16	,	O	['N']	[16]
17	leukopenia	O	['N']	[17]
18	and	O	['N']	[18]
19	positive	O	['N']	[19]
20	anti	O	['N']	[20]
21	-	O	['N']	[21]
22	nuclear	O	['N']	[22]
23	antibody	O	['N']	[23]
24	(	O	['N']	[24]
25	ANA	O	['N']	[25]
26	)	O	['N']	[26]
27	two	O	['N']	[27]
28	weeks	O	['N']	[28]
29	after	O	['N']	[29]
30	administration	O	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	O	['N']	[32]
33	(	O	['N']	[33]
34	CBZ	O	['N']	[34]
35	;	O	['N']	[35]
36	Tegretol	B-Drug	['Causes']	[13]
37	)	O	['N']	[37]
38	used	O	['N']	[38]
39	against	O	['N']	[39]
40	benign	O	['N']	[40]
41	Rolandic	O	['N']	[41]
42	epilepsy	O	['N']	[42]
43	.	O	['N']	[43]
#4226
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	severe	B	['N']	[5]
6	aplastic	I	['N']	[6]
7	anemia	I-Adverse_Effect	['N']	[7]
8	(	O	['N']	[8]
9	AA	O	['N']	[9]
10	)	O	['N']	[10]
11	that	O	['N']	[11]
12	was	O	['N']	[12]
13	probably	O	['N']	[13]
14	induced	O	['N']	[14]
15	by	O	['N']	[15]
16	lenalidomide	B-Drug	['Causes']	[7]
17	.	O	['N']	[17]
#4227
0	A	O	['N']	[0]
1	rechallenge	O	['N']	[1]
2	,	O	['N']	[2]
3	performed	O	['N']	[3]
4	in	O	['N']	[4]
5	both	O	['N']	[5]
6	patients	O	['N']	[6]
7	,	O	['N']	[7]
8	confirmed	O	['N']	[8]
9	the	O	['N']	[9]
10	diagnosis	O	['N']	[10]
11	of	O	['N']	[11]
12	mesalamine	B-Drug	['Causes']	[15]
13	-	O	['N']	[13]
14	induced	O	['N']	[14]
15	pancreatitis	B-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#4228
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	68-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	developed	O	['N']	[7]
8	intense	O	['N']	[8]
9	conjunctival	O	['N']	[9]
10	hyperemia	O	['N']	[10]
11	and	O	['N']	[11]
12	cystoid	B	['N']	[12]
13	macula	I	['N']	[13]
14	edema	I-Adverse_Effect	['N']	[14]
15	after	O	['N']	[15]
16	switching	O	['N']	[16]
17	from	O	['N']	[17]
18	latanoprost	O	['N']	[18]
19	to	O	['N']	[19]
20	bimatoprost	B-Drug	['Causes']	[14]
21	9	O	['N']	[21]
22	months	O	['N']	[22]
23	after	O	['N']	[23]
24	cataract	O	['N']	[24]
25	surgery	O	['N']	[25]
26	in	O	['N']	[26]
27	an	O	['N']	[27]
28	eye	O	['N']	[28]
29	at	O	['N']	[29]
30	low	O	['N']	[30]
31	-	O	['N']	[31]
32	risk	O	['N']	[32]
33	for	O	['N']	[33]
34	this	O	['N']	[34]
35	cystoid	O	['N']	[35]
36	macular	O	['N']	[36]
37	edema	O	['N']	[37]
38	.	O	['N']	[38]
#4229
0	Acute	B	['N']	[0]
1	coronary	I	['N']	[1]
2	events	I-Adverse_Effect	['N']	[2]
3	following	O	['N']	[3]
4	cisplatin	B-Drug	['Causes']	[2]
5	-	O	['N']	[5]
6	based	O	['N']	[6]
7	chemotherapy	O	['N']	[7]
8	.	O	['N']	[8]
#4230
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	patient	O	['N']	[3]
4	required	O	['N']	[4]
5	insulin	B-Drug	['Causes']	[15]
6	desensitization	O	['N']	[6]
7	for	O	['N']	[7]
8	severe	O	['N']	[8]
9	urticaria	O	['N']	[9]
10	,	O	['N']	[10]
11	angioedema	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	occasional	O	['N']	[14]
15	wheezing	B-Adverse_Effect	['N']	[15]
16	resulting	O	['N']	[16]
17	from	O	['N']	[17]
18	her	O	['N']	[18]
19	insulin	O	['N']	[19]
20	dose	O	['N']	[20]
21	.	O	['N']	[21]
#4231
0	Gold	B-Drug	['Causes']	[1]
1	nephropathy	B-Adverse_Effect	['N']	[1]
2	.	O	['N']	[2]
#4232
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	37-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	African-	O	['N']	[6]
7	American	O	['N']	[7]
8	man	O	['N']	[8]
9	with	O	['N']	[9]
10	G6PD	O	['N']	[10]
11	deficiency	O	['N']	[11]
12	developed	O	['N']	[12]
13	hemolytic	O	['N']	[13]
14	anemia	O	['N']	[14]
15	,	O	['N']	[15]
16	hepatitis	O	['N']	[16]
17	,	O	['N']	[17]
18	orthostatic	B	['N']	[18]
19	hypotension	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	aseptic	O	['N']	[22]
23	meningitis	O	['N']	[23]
24	simultaneously	O	['N']	[24]
25	after	O	['N']	[25]
26	using	O	['N']	[26]
27	trimethoprim	O	['N']	[27]
28	-	O	['N']	[28]
29	sulfamethoxazole	B-Drug	['Causes']	[19]
30	.	O	['N']	[30]
#4233
0	A	O	['N']	[0]
1	74-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	received	O	['N']	[5]
6	oral	O	['N']	[6]
7	administration	O	['N']	[7]
8	of	O	['N']	[8]
9	pilsicainide	B-Drug	['Causes']	[33]
10	,	O	['N']	[10]
11	a	O	['N']	[11]
12	pure	O	['N']	[12]
13	sodium	O	['N']	[13]
14	channel	O	['N']	[14]
15	blocker	O	['N']	[15]
16	with	O	['N']	[16]
17	slow	O	['N']	[17]
18	recovery	O	['N']	[18]
19	kinetics	O	['N']	[19]
20	,	O	['N']	[20]
21	to	O	['N']	[21]
22	convert	O	['N']	[22]
23	paroxysmal	O	['N']	[23]
24	atrial	O	['N']	[24]
25	fibrillation	O	['N']	[25]
26	to	O	['N']	[26]
27	sinus	O	['N']	[27]
28	rhythm	O	['N']	[28]
29	and	O	['N']	[29]
30	developed	O	['N']	[30]
31	loss	B	['N']	[31]
32	of	I	['N']	[32]
33	consciousness	I-Adverse_Effect	['N']	[33]
34	two	O	['N']	[34]
35	days	O	['N']	[35]
36	later	O	['N']	[36]
37	.	O	['N']	[37]
#4234
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	receiving	O	['N']	[2]
3	vancomycin	B-Drug	['Causes']	[14]
4	for	O	['N']	[4]
5	a	O	['N']	[5]
6	serious	O	['N']	[6]
7	staphylococcal	O	['N']	[7]
8	infection	O	['N']	[8]
9	had	O	['N']	[9]
10	a	O	['N']	[10]
11	lupus	B	['N']	[11]
12	-	I	['N']	[12]
13	like	I	['N']	[13]
14	syndrome	I-Adverse_Effect	['N']	[14]
15	characterized	O	['N']	[15]
16	by	O	['N']	[16]
17	a	O	['N']	[17]
18	malar	O	['N']	[18]
19	rash	O	['N']	[19]
20	,	O	['N']	[20]
21	pain	O	['N']	[21]
22	and	O	['N']	[22]
23	erythema	O	['N']	[23]
24	of	O	['N']	[24]
25	the	O	['N']	[25]
26	cartilage	O	['N']	[26]
27	of	O	['N']	[27]
28	both	O	['N']	[28]
29	ears	O	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	tender	O	['N']	[32]
33	erythematous	O	['N']	[33]
34	and	O	['N']	[34]
35	hemorrhagic	O	['N']	[35]
36	lesions	O	['N']	[36]
37	of	O	['N']	[37]
38	the	O	['N']	[38]
39	finger	O	['N']	[39]
40	tips	O	['N']	[40]
41	.	O	['N']	[41]
#4235
0	Lethal	B	['N']	[0]
1	anuria	I-Adverse_Effect	['N']	[1]
2	complicating	O	['N']	[2]
3	high	O	['N']	[3]
4	dose	O	['N']	[4]
5	ifosfamide	B-Drug	['Causes']	[1]
6	chemotherapy	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	breast	O	['N']	[9]
10	cancer	O	['N']	[10]
11	patient	O	['N']	[11]
12	with	O	['N']	[12]
13	an	O	['N']	[13]
14	impaired	O	['N']	[14]
15	renal	O	['N']	[15]
16	function	O	['N']	[16]
17	.	O	['N']	[17]
#4236
0	In	O	['N']	[0]
1	addition	O	['N']	[1]
2	to	O	['N']	[2]
3	its	O	['N']	[3]
4	known	O	['N']	[4]
5	effect	O	['N']	[5]
6	on	O	['N']	[6]
7	gallbladder	B	['N']	[7]
8	stasis	I-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	octreotide	B-Drug	['Causes']	[8]
11	alters	O	['N']	[11]
12	bile	O	['N']	[12]
13	acid	O	['N']	[13]
14	composition	O	['N']	[14]
15	and	O	['N']	[15]
16	may	O	['N']	[16]
17	thus	O	['N']	[17]
18	hasten	O	['N']	[18]
19	intrahepatic	O	['N']	[19]
20	sludge	O	['N']	[20]
21	and	O	['N']	[21]
22	stone	O	['N']	[22]
23	formation	O	['N']	[23]
24	.	O	['N']	[24]
#4237
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	mild	O	['N']	[8]
9	chronic	O	['N']	[9]
10	renal	O	['N']	[10]
11	insufficiency	O	['N']	[11]
12	who	O	['N']	[12]
13	had	O	['N']	[13]
14	been	O	['N']	[14]
15	taking	O	['N']	[15]
16	simvastatin	O	['N']	[16]
17	for	O	['N']	[17]
18	over	O	['N']	[18]
19	a	O	['N']	[19]
20	year	O	['N']	[20]
21	and	O	['N']	[21]
22	developed	O	['N']	[22]
23	acute	B	['N']	[23]
24	weakness	I-Adverse_Effect	['N']	[24]
25	within	O	['N']	[25]
26	3	O	['N']	[26]
27	weeks	O	['N']	[27]
28	after	O	['N']	[28]
29	the	O	['N']	[29]
30	start	O	['N']	[30]
31	of	O	['N']	[31]
32	treatment	O	['N']	[32]
33	with	O	['N']	[33]
34	colchicine	B-Drug	['Causes']	[24]
35	for	O	['N']	[35]
36	acute	O	['N']	[36]
37	gouty	O	['N']	[37]
38	bursitis	O	['N']	[38]
39	.	O	['N']	[39]
#4238
0	Lithium	B-Drug	['Causes']	[9]
1	neurotoxicity	O	['N']	[1]
2	should	O	['N']	[2]
3	be	O	['N']	[3]
4	considered	O	['N']	[4]
5	in	O	['N']	[5]
6	Creutzfeldt	B	['N']	[6]
7	-	I	['N']	[7]
8	Jakob	I	['N']	[8]
9	disease	I-Adverse_Effect	['N']	[9]
10	differential	O	['N']	[10]
11	diagnosis	O	['N']	[11]
12	,	O	['N']	[12]
13	serial	O	['N']	[13]
14	electroencephalograms	O	['N']	[14]
15	being	O	['N']	[15]
16	the	O	['N']	[16]
17	most	O	['N']	[17]
18	valuable	O	['N']	[18]
19	.	O	['N']	[19]
#4239
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	highlights	O	['N']	[2]
3	the	O	['N']	[3]
4	possible	O	['N']	[4]
5	development	O	['N']	[5]
6	of	O	['N']	[6]
7	acute	B	['N']	[7]
8	coronary	I	['N']	[8]
9	syndrome	I-Adverse_Effect	['N']	[9]
10	as	O	['N']	[10]
11	a	O	['N']	[11]
12	side	O	['N']	[12]
13	effect	O	['N']	[13]
14	of	O	['N']	[14]
15	Capecitabine	B-Drug	['Causes']	[9]
16	therapy	O	['N']	[16]
17	.	O	['N']	[17]
#4240
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	evaluated	O	['N']	[3]
4	the	O	['N']	[4]
5	in	O	['N']	[5]
6	vitro	O	['N']	[6]
7	hemodialysis	O	['N']	[7]
8	ratio	O	['N']	[8]
9	and	O	['N']	[9]
10	subsequent	O	['N']	[10]
11	toxicity	B-Drug	['Causes']	[15]
12	and	O	['N']	[12]
13	pharmacokinetics	O	['N']	[13]
14	of	O	['N']	[14]
15	ifosfamide	B-Adverse_Effect	['N']	[15]
16	in	O	['N']	[16]
17	an	O	['N']	[17]
18	anephric	O	['N']	[18]
19	patient	O	['N']	[19]
20	with	O	['N']	[20]
21	Wilms	O	['N']	[21]
22	'	O	['N']	[22]
23	tumor	O	['N']	[23]
24	.	O	['N']	[24]
#4241
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	secondary	O	['N']	[5]
6	glaucoma	B-Adverse_Effect	['N']	[6]
7	caused	O	['N']	[7]
8	by	O	['N']	[8]
9	epithelial	O	['N']	[9]
10	downgrowth	O	['N']	[10]
11	in	O	['N']	[11]
12	which	O	['N']	[12]
13	filtration	O	['N']	[13]
14	surgery	O	['N']	[14]
15	was	O	['N']	[15]
16	performed	O	['N']	[16]
17	with	O	['N']	[17]
18	adjunctive	O	['N']	[18]
19	use	O	['N']	[19]
20	of	O	['N']	[20]
21	subconjunctival	O	['N']	[21]
22	5-fluorouracil	B-Drug	['Causes']	[6]
23	.	O	['N']	[23]
#4242
0	Generalised	B	['N']	[0]
1	pustular	I	['N']	[1]
2	psoriasis	I-Adverse_Effect	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	cyclosporin	B	['N']	[5]
6	a	I-Drug	['Causes']	[2]
7	withdrawal	O	['N']	[7]
8	responding	O	['N']	[8]
9	to	O	['N']	[9]
10	the	O	['N']	[10]
11	tumour	O	['N']	[11]
12	necrosis	O	['N']	[12]
13	factor	O	['N']	[13]
14	alpha	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	etanercept	O	['N']	[16]
17	.	O	['N']	[17]
#4243
0	Within	O	['N']	[0]
1	3	O	['N']	[1]
2	weeks	O	['N']	[2]
3	of	O	['N']	[3]
4	beginning	O	['N']	[4]
5	continuous	O	['N']	[5]
6	daily	O	['N']	[6]
7	isoniazid	O	['N']	[7]
8	and	O	['N']	[8]
9	rifampin	B-Drug	['Causes']	[20]
10	therapy	O	['N']	[10]
11	for	O	['N']	[11]
12	pulmonary	O	['N']	[12]
13	tuberculosis	O	['N']	[13]
14	,	O	['N']	[14]
15	a	O	['N']	[15]
16	patient	O	['N']	[16]
17	developed	O	['N']	[17]
18	acute	B	['N']	[18]
19	renal	I	['N']	[19]
20	failure	I-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#4244
0	Six	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	no	O	['N']	[3]
4	previous	O	['N']	[4]
5	signs	O	['N']	[5]
6	or	O	['N']	[6]
7	symptoms	O	['N']	[7]
8	suggestive	O	['N']	[8]
9	of	O	['N']	[9]
10	coronary	O	['N']	[10]
11	artery	O	['N']	[11]
12	disease	O	['N']	[12]
13	developed	O	['N']	[13]
14	acute	B	['N']	[14]
15	coronary	I	['N']	[15]
16	ischemia	I-Adverse_Effect	['N']	[16]
17	/	O	['N']	[17]
18	infarction	O	['N']	[18]
19	shortly	O	['N']	[19]
20	after	O	['N']	[20]
21	cis	B	['N']	[21]
22	-	I	['N']	[22]
23	diamine	I	['N']	[23]
24	-	I	['N']	[24]
25	dichloroplatinum	I	['N']	[25]
26	II	I-Drug	['Causes']	[16]
27	(	O	['N']	[27]
28	cisplatin	O	['N']	[28]
29	)	O	['N']	[29]
30	-based	O	['N']	[30]
31	chemotherapy	O	['N']	[31]
32	.	O	['N']	[32]
#4245
0	Case	O	['N']	[0]
1	3	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	29-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	female	O	['N']	[7]
8	alcoholic	O	['N']	[8]
9	complained	O	['N']	[9]
10	of	O	['N']	[10]
11	general	O	['N']	[11]
12	fatigue	O	['N']	[12]
13	and	O	['N']	[13]
14	a	O	['N']	[14]
15	slight	O	['N']	[15]
16	fever	B-Adverse_Effect	['N']	[16]
17	after	O	['N']	[17]
18	1.5	O	['N']	[18]
19	years	O	['N']	[19]
20	of	O	['N']	[20]
21	abstinence	O	['N']	[21]
22	with	O	['N']	[22]
23	cyanamide	B-Drug	['Causes']	[16]
24	treatment	O	['N']	[24]
25	.	O	['N']	[25]
#4246
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	acute	O	['N']	[5]
6	hyperphosphatemia	B-Adverse_Effect	['N']	[6]
7	secondary	O	['N']	[7]
8	to	O	['N']	[8]
9	rectal	O	['N']	[9]
10	administration	O	['N']	[10]
11	of	O	['N']	[11]
12	sodium	O	['N']	[12]
13	phosphate	O	['N']	[13]
14	and	O	['N']	[14]
15	sodium	B	['N']	[15]
16	biphosphate	I-Drug	['Causes']	[6]
17	(	O	['N']	[17]
18	Fleet	O	['N']	[18]
19	enema	O	['N']	[19]
20	)	O	['N']	[20]
21	.	O	['N']	[21]
#4247
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	reversible	O	['N']	[5]
6	DKA	O	['N']	[6]
7	and	O	['N']	[7]
8	new	O	['N']	[8]
9	-	O	['N']	[9]
10	onset	O	['N']	[10]
11	DM	B-Adverse_Effect	['N']	[11]
12	that	O	['N']	[12]
13	developed	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	demented	O	['N']	[16]
17	patient	O	['N']	[17]
18	who	O	['N']	[18]
19	was	O	['N']	[19]
20	treated	O	['N']	[20]
21	with	O	['N']	[21]
22	quetiapine	B-Drug	['Causes']	[11]
23	for	O	['N']	[23]
24	14	O	['N']	[24]
25	days	O	['N']	[25]
26	.	O	['N']	[26]
#4248
0	The	O	['N']	[0]
1	capacity	O	['N']	[1]
2	of	O	['N']	[2]
3	zuclopenthixol	B-Drug	['Causes']	[6]
4	to	O	['N']	[4]
5	induce	O	['N']	[5]
6	priapism	B-Adverse_Effect	['N']	[6]
7	is	O	['N']	[7]
8	thought	O	['N']	[8]
9	to	O	['N']	[9]
10	be	O	['N']	[10]
11	due	O	['N']	[11]
12	to	O	['N']	[12]
13	its	O	['N']	[13]
14	antagonist	O	['N']	[14]
15	activity	O	['N']	[15]
16	on	O	['N']	[16]
17	alpha	O	['N']	[17]
18	-	O	['N']	[18]
19	adrenergic	O	['N']	[19]
20	receptors	O	['N']	[20]
21	.	O	['N']	[21]
#4249
0	In	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	swallowing	O	['N']	[3]
4	dysfunction	O	['N']	[4]
5	and	O	['N']	[5]
6	pneumonia	O	['N']	[6]
7	,	O	['N']	[7]
8	a	O	['N']	[8]
9	history	O	['N']	[9]
10	of	O	['N']	[10]
11	mineral	B	['N']	[11]
12	oil	I-Drug	['Causes']	[21]
13	use	O	['N']	[13]
14	should	O	['N']	[14]
15	be	O	['N']	[15]
16	obtained	O	['N']	[16]
17	and	O	['N']	[17]
18	a	O	['N']	[18]
19	diagnosis	O	['N']	[19]
20	of	O	['N']	[20]
21	ELP	B-Adverse_Effect	['N']	[21]
22	should	O	['N']	[22]
23	be	O	['N']	[23]
24	considered	O	['N']	[24]
25	in	O	['N']	[25]
26	the	O	['N']	[26]
27	differential	O	['N']	[27]
28	diagnoses	O	['N']	[28]
29	if	O	['N']	[29]
30	mineral	O	['N']	[30]
31	oil	O	['N']	[31]
32	use	O	['N']	[32]
33	has	O	['N']	[33]
34	occurred	O	['N']	[34]
35	.	O	['N']	[35]
#4250
0	A	O	['N']	[0]
1	44-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	is	O	['N']	[5]
6	described	O	['N']	[6]
7	in	O	['N']	[7]
8	whom	O	['N']	[8]
9	amiodarone	O	['N']	[9]
10	,	O	['N']	[10]
11	disopyramide	B-Drug	['Causes']	[25]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	quinidine	O	['N']	[14]
15	,	O	['N']	[15]
16	administered	O	['N']	[16]
17	alone	O	['N']	[17]
18	separately	O	['N']	[18]
19	,	O	['N']	[19]
20	induced	O	['N']	[20]
21	atypical	O	['N']	[21]
22	ventricular	O	['N']	[22]
23	tachycardia	O	['N']	[23]
24	(	O	['N']	[24]
25	AVT	B-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	torsade	O	['N']	[27]
28	de	O	['N']	[28]
29	pointes	O	['N']	[29]
30	)	O	['N']	[30]
31	.	O	['N']	[31]
#4251
0	An	O	['N']	[0]
1	episode	O	['N']	[1]
2	of	O	['N']	[2]
3	leukoencephalopathy	O	['N']	[3]
4	is	O	['N']	[4]
5	reported	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	13-year	O	['N']	[8]
9	-	O	['N']	[9]
10	old	O	['N']	[10]
11	girl	O	['N']	[11]
12	who	O	['N']	[12]
13	,	O	['N']	[13]
14	after	O	['N']	[14]
15	standard	O	['N']	[15]
16	radiotherapy	O	['N']	[16]
17	for	O	['N']	[17]
18	a	O	['N']	[18]
19	posterior	O	['N']	[19]
20	fossa	O	['N']	[20]
21	medulloblastoma	O	['N']	[21]
22	,	O	['N']	[22]
23	received	O	['N']	[23]
24	8	O	['N']	[24]
25	treatments	O	['N']	[25]
26	with	O	['N']	[26]
27	a	O	['N']	[27]
28	protocol	O	['N']	[28]
29	containing	O	['N']	[29]
30	a	O	['N']	[30]
31	4-hour	O	['N']	[31]
32	infusion	O	['N']	[32]
33	of	O	['N']	[33]
34	500	O	['N']	[34]
35	mg	O	['N']	[35]
36	/	O	['N']	[36]
37	m2	O	['N']	[37]
38	methotrexate	B-Drug	['Dosage']	[41]
39	and	O	['N']	[39]
40	12	B	['N']	[40]
41	mg	I-Dose	['N']	[41]
42	intrathecal	O	['N']	[42]
43	methotrexate	O	['N']	[43]
44	.	O	['N']	[44]
#4252
0	Parenteral	O	['N']	[0]
1	-	O	['N']	[1]
2	verapamil	B-Drug	['Causes']	[6]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	sustained	B	['N']	[5]
6	hypotension	I-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#4253
0	The	O	['N']	[0]
1	clinical	O	['N']	[1]
2	course	O	['N']	[2]
3	suggested	O	['N']	[3]
4	that	O	['N']	[4]
5	recombinant	O	['N']	[5]
6	alpha-2b	O	['N']	[6]
7	peginterferon	O	['N']	[7]
8	plus	O	['N']	[8]
9	ribavirin	B-Drug	['Causes']	[14]
10	provoked	O	['N']	[10]
11	type	B	['N']	[11]
12	1	I	['N']	[12]
13	diabetes	I	['N']	[13]
14	mellitus	I-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	therefore	O	['N']	[16]
17	,	O	['N']	[17]
18	in	O	['N']	[18]
19	patients	O	['N']	[19]
20	who	O	['N']	[20]
21	are	O	['N']	[21]
22	candidates	O	['N']	[22]
23	for	O	['N']	[23]
24	interferon	O	['N']	[24]
25	therapy	O	['N']	[25]
26	the	O	['N']	[26]
27	presence	O	['N']	[27]
28	of	O	['N']	[28]
29	pancreatic	O	['N']	[29]
30	autoantibodies	O	['N']	[30]
31	and	O	['N']	[31]
32	the	O	['N']	[32]
33	fasting	O	['N']	[33]
34	plasma	O	['N']	[34]
35	glucose	O	['N']	[35]
36	level	O	['N']	[36]
37	should	O	['N']	[37]
38	be	O	['N']	[38]
39	investigated	O	['N']	[39]
40	before	O	['N']	[40]
41	and	O	['N']	[41]
42	during	O	['N']	[42]
43	treatment	O	['N']	[43]
44	.	O	['N']	[44]
#4254
0	Seven	O	['N']	[0]
1	of	O	['N']	[1]
2	the	O	['N']	[2]
3	eight	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	acute	B	['N']	[6]
7	leukemia	I-Adverse_Effect	['N']	[7]
8	occurred	O	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	series	O	['N']	[11]
12	of	O	['N']	[12]
13	553	O	['N']	[13]
14	patients	O	['N']	[14]
15	treated	O	['N']	[15]
16	with	O	['N']	[16]
17	Treosulfan	B-Drug	['Causes']	[7]
18	for	O	['N']	[18]
19	ovarian	O	['N']	[19]
20	cancer	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	period	O	['N']	[23]
24	from	O	['N']	[24]
25	1970	O	['N']	[25]
26	to	O	['N']	[26]
27	1977	O	['N']	[27]
28	and	O	['N']	[28]
29	followed	O	['N']	[29]
30	closely	O	['N']	[30]
31	for	O	['N']	[31]
32	a	O	['N']	[32]
33	total	O	['N']	[33]
34	of	O	['N']	[34]
35	1159	O	['N']	[35]
36	patient	O	['N']	[36]
37	-	O	['N']	[37]
38	years	O	['N']	[38]
39	up	O	['N']	[39]
40	to	O	['N']	[40]
41	February	O	['N']	[41]
42	1978	O	['N']	[42]
43	.	O	['N']	[43]
#4255
0	Voriconazole	B-Drug	['Causes']	[13]
1	(	O	['N']	[1]
2	VRC	O	['N']	[2]
3	)	O	['N']	[3]
4	has	O	['N']	[4]
5	not	O	['N']	[5]
6	previously	O	['N']	[6]
7	been	O	['N']	[7]
8	reported	O	['N']	[8]
9	to	O	['N']	[9]
10	cause	O	['N']	[10]
11	angio	B	['N']	[11]
12	-	I	['N']	[12]
13	oedema	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#4256
0	We	O	['N']	[0]
1	believe	O	['N']	[1]
2	that	O	['N']	[2]
3	this	O	['N']	[3]
4	is	O	['N']	[4]
5	the	O	['N']	[5]
6	first	O	['N']	[6]
7	report	O	['N']	[7]
8	of	O	['N']	[8]
9	secretory	B	['N']	[9]
10	carcinoma	I	['N']	[10]
11	of	I	['N']	[11]
12	the	I	['N']	[12]
13	endometrium	I-Adverse_Effect	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	tamoxifen	B-Drug	['Causes']	[13]
17	use	O	['N']	[17]
18	.	O	['N']	[18]
#4257
0	Mineral	B	['N']	[0]
1	oil	I-Drug	['Causes']	[18]
2	,	O	['N']	[2]
3	a	O	['N']	[3]
4	hydrocarbon	O	['N']	[4]
5	,	O	['N']	[5]
6	may	O	['N']	[6]
7	not	O	['N']	[7]
8	elicit	O	['N']	[8]
9	a	O	['N']	[9]
10	normal	O	['N']	[10]
11	protective	O	['N']	[11]
12	cough	O	['N']	[12]
13	reflex	O	['N']	[13]
14	and	O	['N']	[14]
15	may	O	['N']	[15]
16	impair	B	['N']	[16]
17	mucociliary	I	['N']	[17]
18	transport	I-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#4258
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	our	O	['N']	[3]
4	knowledge	O	['N']	[4]
5	,	O	['N']	[5]
6	this	O	['N']	[6]
7	is	O	['N']	[7]
8	the	O	['N']	[8]
9	first	O	['N']	[9]
10	case	O	['N']	[10]
11	report	O	['N']	[11]
12	illustrating	O	['N']	[12]
13	neuralgic	B	['N']	[13]
14	amyotrophy	I-Adverse_Effect	['N']	[14]
15	triggered	O	['N']	[15]
16	by	O	['N']	[16]
17	exposure	O	['N']	[17]
18	to	O	['N']	[18]
19	the	O	['N']	[19]
20	antibiotics	O	['N']	[20]
21	vancomycin	O	['N']	[21]
22	,	O	['N']	[22]
23	tobramycin	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	piperacillin	O	['N']	[26]
27	/	O	['N']	[27]
28	tazobactam	B-Drug	['Causes']	[14]
29	.	O	['N']	[29]
#4259
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	46-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	African	O	['N']	[7]
8	-	O	['N']	[8]
9	American	O	['N']	[9]
10	man	O	['N']	[10]
11	experienced	O	['N']	[11]
12	recurrent	O	['N']	[12]
13	grand	B	['N']	[13]
14	mal	I	['N']	[14]
15	seizures	I-Adverse_Effect	['N']	[15]
16	during	O	['N']	[16]
17	intravenous	O	['N']	[17]
18	infusion	O	['N']	[18]
19	of	O	['N']	[19]
20	amphotericin	B	['N']	[20]
21	B	I-Drug	['Causes']	[15]
22	,	O	['N']	[22]
23	then	O	['N']	[23]
24	petit	O	['N']	[24]
25	mal	O	['N']	[25]
26	seizures	O	['N']	[26]
27	as	O	['N']	[27]
28	the	O	['N']	[28]
29	infusion	O	['N']	[29]
30	was	O	['N']	[30]
31	stopped	O	['N']	[31]
32	and	O	['N']	[32]
33	the	O	['N']	[33]
34	drug	O	['N']	[34]
35	concentrations	O	['N']	[35]
36	decreased	O	['N']	[36]
37	with	O	['N']	[37]
38	time	O	['N']	[38]
39	.	O	['N']	[39]
#4260
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	an	O	['N']	[2]
3	association	O	['N']	[3]
4	of	O	['N']	[4]
5	Ritalin	B-Drug	['Causes']	[7]
6	with	O	['N']	[6]
7	glaucoma	B-Adverse_Effect	['N']	[7]
8	has	O	['N']	[8]
9	been	O	['N']	[9]
10	reported	O	['N']	[10]
11	.	O	['N']	[11]
#4261
0	Cutaneous	B	['N']	[0]
1	necrosis	I-Adverse_Effect	['N']	[1]
2	as	O	['N']	[2]
3	a	O	['N']	[3]
4	result	O	['N']	[4]
5	of	O	['N']	[5]
6	interferon	B	['N']	[6]
7	alfa	I-Drug	['Causes']	[1]
8	is	O	['N']	[8]
9	an	O	['N']	[9]
10	infrequent	O	['N']	[10]
11	complication	O	['N']	[11]
12	with	O	['N']	[12]
13	unknown	O	['N']	[13]
14	pathogenesis	O	['N']	[14]
15	,	O	['N']	[15]
16	in	O	['N']	[16]
17	which	O	['N']	[17]
18	a	O	['N']	[18]
19	cutaneous	O	['N']	[19]
20	local	O	['N']	[20]
21	immune	O	['N']	[21]
22	-	O	['N']	[22]
23	mediated	O	['N']	[23]
24	inflammatory	O	['N']	[24]
25	process	O	['N']	[25]
26	might	O	['N']	[26]
27	be	O	['N']	[27]
28	involved	O	['N']	[28]
29	.	O	['N']	[29]
#4262
0	CASE	O	['N']	[0]
1	SUMMARY	O	['N']	[1]
2	:	O	['N']	[2]
3	A	O	['N']	[3]
4	65-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	patient	O	['N']	[7]
8	chronically	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	selective	O	['N']	[12]
13	serotonin	O	['N']	[13]
14	reuptake	O	['N']	[14]
15	inhibitor	O	['N']	[15]
16	(	O	['N']	[16]
17	SSRI	O	['N']	[17]
18	)	O	['N']	[18]
19	citalopram	O	['N']	[19]
20	developed	O	['N']	[20]
21	confusion	O	['N']	[21]
22	,	O	['N']	[22]
23	agitation	O	['N']	[23]
24	,	O	['N']	[24]
25	tachycardia	B-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	tremors	O	['N']	[27]
28	,	O	['N']	[28]
29	myoclonic	O	['N']	[29]
30	jerks	O	['N']	[30]
31	and	O	['N']	[31]
32	unsteady	O	['N']	[32]
33	gait	O	['N']	[33]
34	,	O	['N']	[34]
35	consistent	O	['N']	[35]
36	with	O	['N']	[36]
37	serotonin	O	['N']	[37]
38	syndrome	O	['N']	[38]
39	,	O	['N']	[39]
40	following	O	['N']	[40]
41	initiation	O	['N']	[41]
42	of	O	['N']	[42]
43	fentanyl	B-Drug	['Causes']	[25]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	all	O	['N']	[46]
47	symptoms	O	['N']	[47]
48	and	O	['N']	[48]
49	signs	O	['N']	[49]
50	resolved	O	['N']	[50]
51	following	O	['N']	[51]
52	discontinuation	O	['N']	[52]
53	of	O	['N']	[53]
54	fentanyl	O	['N']	[54]
55	.	O	['N']	[55]
#4263
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	increasing	O	['N']	[3]
4	prevalence	O	['N']	[4]
5	of	O	['N']	[5]
6	Type	O	['N']	[6]
7	2	O	['N']	[7]
8	diabetes	O	['N']	[8]
9	and	O	['N']	[9]
10	its	O	['N']	[10]
11	treatment	O	['N']	[11]
12	with	O	['N']	[12]
13	metformin	B-Drug	['Causes']	[21]
14	might	O	['N']	[14]
15	result	O	['N']	[15]
16	in	O	['N']	[16]
17	more	O	['N']	[17]
18	cases	O	['N']	[18]
19	of	O	['N']	[19]
20	lactic	B	['N']	[20]
21	acidosis	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#4264
0	The	O	['N']	[0]
1	side	O	['N']	[1]
2	effects	O	['N']	[2]
3	of	O	['N']	[3]
4	MMF	B-Drug	['Causes']	[10]
5	,	O	['N']	[5]
6	such	O	['N']	[6]
7	as	O	['N']	[7]
8	bone	B	['N']	[8]
9	marrow	I	['N']	[9]
10	toxicity	I-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	have	O	['N']	[12]
13	been	O	['N']	[13]
14	reported	O	['N']	[14]
15	.	O	['N']	[15]
#4265
0	Temozolomide	B-Drug	['Causes']	[5]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	desquamative	B	['N']	[3]
4	skin	I	['N']	[4]
5	rash	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	metastatic	O	['N']	[10]
11	melanoma	O	['N']	[11]
12	.	O	['N']	[12]
#4266
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	nitrofurantoin	B-Drug	['Causes']	[9]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	pulmonary	B	['N']	[8]
9	toxicity	I-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	which	O	['N']	[11]
12	the	O	['N']	[12]
13	initial	O	['N']	[13]
14	HRCT	O	['N']	[14]
15	showed	O	['N']	[15]
16	a	O	['N']	[16]
17	widespread	O	['N']	[17]
18	reticular	O	['N']	[18]
19	pattern	O	['N']	[19]
20	and	O	['N']	[20]
21	associated	O	['N']	[21]
22	distortion	O	['N']	[22]
23	of	O	['N']	[23]
24	the	O	['N']	[24]
25	lung	O	['N']	[25]
26	parenchyma	O	['N']	[26]
27	,	O	['N']	[27]
28	thought	O	['N']	[28]
29	to	O	['N']	[29]
30	represent	O	['N']	[30]
31	established	O	['N']	[31]
32	fibrosis	O	['N']	[32]
33	.	O	['N']	[33]
#4267
0	During	O	['N']	[0]
1	the	O	['N']	[1]
2	first	O	['N']	[2]
3	treatment	O	['N']	[3]
4	,	O	['N']	[4]
5	dysarthria	O	['N']	[5]
6	and	O	['N']	[6]
7	ataxia	B-Adverse_Effect	['N']	[7]
8	were	O	['N']	[8]
9	seen	O	['N']	[9]
10	after	O	['N']	[10]
11	completion	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	patient	O	['N']	[14]
15	's	O	['N']	[15]
16	eighth	O	['N']	[16]
17	and	O	['N']	[17]
18	final	O	['N']	[18]
19	dose	O	['N']	[19]
20	of	O	['N']	[20]
21	HDARAC	B-Drug	['Causes']	[7]
22	.	O	['N']	[22]
#4268
0	Hydrocortisone	O	['N']	[0]
1	may	O	['N']	[1]
2	decrease	O	['N']	[2]
3	the	O	['N']	[3]
4	incidence	O	['N']	[4]
5	of	O	['N']	[5]
6	mortality	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	cardiac	B	['N']	[9]
10	arrhythmias	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	children	O	['N']	[12]
13	receiving	O	['N']	[13]
14	amphotericin	B	['N']	[14]
15	B	I-Drug	['Causes']	[10]
16	overdoses	O	['N']	[16]
17	.	O	['N']	[17]
#4269
0	CD20-negative	B	['N']	[0]
1	T	I	['N']	[1]
2	-	I	['N']	[2]
3	cell	I	['N']	[3]
4	-	I	['N']	[4]
5	rich	I	['N']	[5]
6	B	I	['N']	[6]
7	-	I	['N']	[7]
8	cell	I	['N']	[8]
9	lymphoma	I-Adverse_Effect	['N']	[9]
10	as	O	['N']	[10]
11	a	O	['N']	[11]
12	progression	O	['N']	[12]
13	of	O	['N']	[13]
14	a	O	['N']	[14]
15	nodular	O	['N']	[15]
16	lymphocyte	O	['N']	[16]
17	-	O	['N']	[17]
18	predominant	O	['N']	[18]
19	Hodgkin	O	['N']	[19]
20	's	O	['N']	[20]
21	lymphoma	O	['N']	[21]
22	treated	O	['N']	[22]
23	with	O	['N']	[23]
24	rituximab	B-Drug	['Causes']	[9]
25	:	O	['N']	[25]
26	a	O	['N']	[26]
27	molecular	O	['N']	[27]
28	analysis	O	['N']	[28]
29	using	O	['N']	[29]
30	laser	O	['N']	[30]
31	capture	O	['N']	[31]
32	microdissection	O	['N']	[32]
33	.	O	['N']	[33]
#4270
0	The	O	['N']	[0]
1	possibility	O	['N']	[1]
2	of	O	['N']	[2]
3	phenytoin	B-Drug	['Causes']	[5]
4	hypersensitivity	B	['N']	[4]
5	reactions	I-Adverse_Effect	['N']	[5]
6	should	O	['N']	[6]
7	be	O	['N']	[7]
8	considered	O	['N']	[8]
9	when	O	['N']	[9]
10	patients	O	['N']	[10]
11	receiving	O	['N']	[11]
12	phenytoin	O	['N']	[12]
13	have	O	['N']	[13]
14	unusual	O	['N']	[14]
15	symptoms	O	['N']	[15]
16	,	O	['N']	[16]
17	particularly	O	['N']	[17]
18	fever	O	['N']	[18]
19	,	O	['N']	[19]
20	rash	O	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	lymphadenopathy	O	['N']	[23]
24	.	O	['N']	[24]
#4271
0	Reversal	O	['N']	[0]
1	of	O	['N']	[1]
2	gold	B-Drug	['Causes']	[5]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	neutropenia	B-Adverse_Effect	['N']	[5]
6	with	O	['N']	[6]
7	granulocyte	O	['N']	[7]
8	colony	O	['N']	[8]
9	-	O	['N']	[9]
10	stimulating	O	['N']	[10]
11	factor	O	['N']	[11]
12	(	O	['N']	[12]
13	G	O	['N']	[13]
14	-	O	['N']	[14]
15	CSF	O	['N']	[15]
16	)	O	['N']	[16]
17	.	O	['N']	[17]
#4272
0	Three	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	receiving	O	['N']	[3]
4	intravitreal	O	['N']	[4]
5	injection	O	['N']	[5]
6	of	O	['N']	[6]
7	bevacizumab	B-Drug	['Dosage']	[13]
8	(	O	['N']	[8]
9	1.25	B	['N']	[9]
10	mg	I	['N']	[10]
11	in	I	['N']	[11]
12	0.1	I	['N']	[12]
13	ml	I-Dose	['N']	[13]
14	)	O	['N']	[14]
15	,	O	['N']	[15]
16	he	O	['N']	[16]
17	developed	O	['N']	[17]
18	acute	O	['N']	[18]
19	vision	O	['N']	[19]
20	loss	O	['N']	[20]
21	and	O	['N']	[21]
22	change	O	['N']	[22]
23	of	O	['N']	[23]
24	consciousness	O	['N']	[24]
25	.	O	['N']	[25]
#4273
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	nitrofurantoin	B-Drug	['Causes']	[19]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	pulmonary	O	['N']	[8]
9	toxicity	O	['N']	[9]
10	in	O	['N']	[10]
11	which	O	['N']	[11]
12	the	O	['N']	[12]
13	initial	O	['N']	[13]
14	HRCT	O	['N']	[14]
15	showed	O	['N']	[15]
16	a	O	['N']	[16]
17	widespread	B	['N']	[17]
18	reticular	I	['N']	[18]
19	pattern	I-Adverse_Effect	['N']	[19]
20	and	O	['N']	[20]
21	associated	O	['N']	[21]
22	distortion	O	['N']	[22]
23	of	O	['N']	[23]
24	the	O	['N']	[24]
25	lung	O	['N']	[25]
26	parenchyma	O	['N']	[26]
27	,	O	['N']	[27]
28	thought	O	['N']	[28]
29	to	O	['N']	[29]
30	represent	O	['N']	[30]
31	established	O	['N']	[31]
32	fibrosis	O	['N']	[32]
33	.	O	['N']	[33]
#4274
0	Posterior	B	['N']	[0]
1	reversible	I	['N']	[1]
2	encephalopathy	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	(	O	['N']	[4]
5	PRES	B-Drug	['Causes']	[3]
6	)	O	['N']	[6]
7	induced	O	['N']	[7]
8	by	O	['N']	[8]
9	cyclosporine	O	['N']	[9]
10	use	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	collapsing	O	['N']	[15]
16	focal	O	['N']	[16]
17	glomeruloesclerosis	O	['N']	[17]
18	.	O	['N']	[18]
#4275
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	2	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	renal	B	['N']	[6]
7	damage	I-Adverse_Effect	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	lithium	B	['N']	[10]
11	carbonate	I-Drug	['Causes']	[7]
12	treatment	O	['N']	[12]
13	.	O	['N']	[13]
#4276
0	Bronchiolitis	B	['N']	[0]
1	obliterans	I	['N']	[1]
2	with	I	['N']	[2]
3	organizing	I	['N']	[3]
4	pneumonia	I-Adverse_Effect	['N']	[4]
5	after	O	['N']	[5]
6	rituximab	B-Drug	['Causes']	[4]
7	therapy	O	['N']	[7]
8	for	O	['N']	[8]
9	non	O	['N']	[9]
10	-	O	['N']	[10]
11	Hodgkin	O	['N']	[11]
12	's	O	['N']	[12]
13	lymphoma	O	['N']	[13]
14	.	O	['N']	[14]
#4277
0	We	O	['N']	[0]
1	concluded	O	['N']	[1]
2	that	O	['N']	[2]
3	the	O	['N']	[3]
4	colonic	B	['N']	[4]
5	ulcer	I-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	the	O	['N']	[7]
8	sigmoidovesical	O	['N']	[8]
9	fistula	O	['N']	[9]
10	had	O	['N']	[10]
11	been	O	['N']	[11]
12	caused	O	['N']	[12]
13	by	O	['N']	[13]
14	the	O	['N']	[14]
15	administration	O	['N']	[15]
16	of	O	['N']	[16]
17	calcium	B	['N']	[17]
18	polystyrene	I	['N']	[18]
19	sulfonate	I-Drug	['Causes']	[5]
20	and	O	['N']	[20]
21	sorbitol	O	['N']	[21]
22	.	O	['N']	[22]
#4278
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	biopsy	O	['N']	[5]
6	-	O	['N']	[6]
7	proven	O	['N']	[7]
8	acute	B	['N']	[8]
9	tubulointerstitial	I	['N']	[9]
10	nephritis	I-Adverse_Effect	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	a	O	['N']	[13]
14	second	O	['N']	[14]
15	course	O	['N']	[15]
16	of	O	['N']	[16]
17	flurbiprofen	B-Drug	['Causes']	[10]
18	,	O	['N']	[18]
19	a	O	['N']	[19]
20	nonsteroidal	O	['N']	[20]
21	anti	O	['N']	[21]
22	-	O	['N']	[22]
23	inflammatory	O	['N']	[23]
24	drug	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	propionic	O	['N']	[27]
28	acid	O	['N']	[28]
29	class	O	['N']	[29]
30	.	O	['N']	[30]
#4279
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Accutane	B-Drug	['Causes']	[4]
3	a	O	['N']	[3]
4	teratogenic	B-Adverse_Effect	['N']	[4]
5	prescription	O	['N']	[5]
6	drug	O	['N']	[6]
7	licensed	O	['N']	[7]
8	to	O	['N']	[8]
9	treat	O	['N']	[9]
10	severe	O	['N']	[10]
11	,	O	['N']	[11]
12	recalcitrant	O	['N']	[12]
13	nodular	O	['N']	[13]
14	acne	O	['N']	[14]
15	.	O	['N']	[15]
#4280
0	In	O	['N']	[0]
1	four	O	['N']	[1]
2	patients	O	['N']	[2]
3	,	O	['N']	[3]
4	thrombosis	O	['N']	[4]
5	occurred	O	['N']	[5]
6	2	O	['N']	[6]
7	-	O	['N']	[7]
8	45	O	['N']	[8]
9	days	O	['N']	[9]
10	after	O	['N']	[10]
11	severe	O	['N']	[11]
12	hepatic	O	['N']	[12]
13	veno	O	['N']	[13]
14	-	O	['N']	[14]
15	occlusive	O	['N']	[15]
16	disease	O	['N']	[16]
17	(	O	['N']	[17]
18	HVOD	B-Adverse_Effect	['N']	[18]
19	)	O	['N']	[19]
20	secondary	O	['N']	[20]
21	to	O	['N']	[21]
22	intensive	O	['N']	[22]
23	chemotherapy	O	['N']	[23]
24	containing	O	['N']	[24]
25	busulfan	B-Drug	['Causes']	[18]
26	.	O	['N']	[26]
#4281
0	A	O	['N']	[0]
1	7-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	with	O	['N']	[4]
5	congenital	O	['N']	[5]
6	toxoplasmosis	O	['N']	[6]
7	who	O	['N']	[7]
8	took	O	['N']	[8]
9	pyrimethamine	B-Drug	['Causes']	[27]
10	and	O	['N']	[10]
11	sulfadiazine	O	['N']	[11]
12	for	O	['N']	[12]
13	reactivated	O	['N']	[13]
14	chorioretinitis	O	['N']	[14]
15	developed	O	['N']	[15]
16	fever	O	['N']	[16]
17	,	O	['N']	[17]
18	severe	O	['N']	[18]
19	cutaneous	O	['N']	[19]
20	involvement	O	['N']	[20]
21	,	O	['N']	[21]
22	swelling	O	['N']	[22]
23	,	O	['N']	[23]
24	abdominal	O	['N']	[24]
25	pain	O	['N']	[25]
26	and	O	['N']	[26]
27	transaminitis	B-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	persisting	O	['N']	[29]
30	weeks	O	['N']	[30]
31	after	O	['N']	[31]
32	withholding	O	['N']	[32]
33	medicines	O	['N']	[33]
34	.	O	['N']	[34]
#4282
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	suggest	O	['N']	[2]
3	that	O	['N']	[3]
4	fluoxetine	B-Drug	['Causes']	[7]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	akathisia	B-Adverse_Effect	['N']	[7]
8	may	O	['N']	[8]
9	be	O	['N']	[9]
10	caused	O	['N']	[10]
11	by	O	['N']	[11]
12	serotonergically	O	['N']	[12]
13	mediated	O	['N']	[13]
14	inhibition	O	['N']	[14]
15	of	O	['N']	[15]
16	dopaminergic	O	['N']	[16]
17	neurotransmission	O	['N']	[17]
18	and	O	['N']	[18]
19	that	O	['N']	[19]
20	the	O	['N']	[20]
21	pathophysiology	O	['N']	[21]
22	of	O	['N']	[22]
23	fluoxetine	O	['N']	[23]
24	-	O	['N']	[24]
25	induced	O	['N']	[25]
26	akathisia	O	['N']	[26]
27	and	O	['N']	[27]
28	tricyclic	O	['N']	[28]
29	antidepressant	O	['N']	[29]
30	-	O	['N']	[30]
31	induced	O	['N']	[31]
32	"	O	['N']	[32]
33	jitteriness	O	['N']	[33]
34	"	O	['N']	[34]
35	may	O	['N']	[35]
36	be	O	['N']	[36]
37	identical	O	['N']	[37]
38	.	O	['N']	[38]
#4283
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	five	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	carboplatin	O	['N']	[5]
6	(	O	['N']	[6]
7	CBDCA	B-Drug	['Causes']	[9]
8	)	O	['N']	[8]
9	hypersensitivity	B-Adverse_Effect	['N']	[9]
10	after	O	['N']	[10]
11	weekly	O	['N']	[11]
12	low	O	['N']	[12]
13	-	O	['N']	[13]
14	dose	O	['N']	[14]
15	paclitaxel	O	['N']	[15]
16	(	O	['N']	[16]
17	60	O	['N']	[17]
18	mg	O	['N']	[18]
19	/	O	['N']	[19]
20	m2)/CBDCA	O	['N']	[20]
21	(	O	['N']	[21]
22	area	O	['N']	[22]
23	under	O	['N']	[23]
24	the	O	['N']	[24]
25	concentration	O	['N']	[25]
26	curve	O	['N']	[26]
27	=	O	['N']	[27]
28	2	O	['N']	[28]
29	)	O	['N']	[29]
30	therapy	O	['N']	[30]
31	in	O	['N']	[31]
32	patients	O	['N']	[32]
33	with	O	['N']	[33]
34	recurrent	O	['N']	[34]
35	ovarian	O	['N']	[35]
36	cancer	O	['N']	[36]
37	receiving	O	['N']	[37]
38	multiple	O	['N']	[38]
39	platinum	O	['N']	[39]
40	-	O	['N']	[40]
41	based	O	['N']	[41]
42	chemotherapy	O	['N']	[42]
43	.	O	['N']	[43]
#4284
0	Two	O	['N']	[0]
1	cases	O	['N']	[1]
2	are	O	['N']	[2]
3	reported	O	['N']	[3]
4	of	O	['N']	[4]
5	patients	O	['N']	[5]
6	who	O	['N']	[6]
7	developed	O	['N']	[7]
8	a	O	['N']	[8]
9	hematologic	B	['N']	[9]
10	malignancy	I-Adverse_Effect	['N']	[10]
11	several	O	['N']	[11]
12	years	O	['N']	[12]
13	after	O	['N']	[13]
14	intravesical	O	['N']	[14]
15	chemotherapy	O	['N']	[15]
16	of	O	['N']	[16]
17	superficial	O	['N']	[17]
18	bladder	O	['N']	[18]
19	cancer	O	['N']	[19]
20	with	O	['N']	[20]
21	etoglucid	B-Drug	['Causes']	[10]
22	,	O	['N']	[22]
23	doxorubicin	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	mitomycin	O	['N']	[26]
27	C.	O	['N']	[27]
#4285
0	Gold	B	['N']	[0]
1	-	I	['N']	[1]
2	salt	I-Drug	['Causes']	[10]
3	therapy	O	['N']	[3]
4	may	O	['N']	[4]
5	result	O	['N']	[5]
6	in	O	['N']	[6]
7	damage	B	['N']	[7]
8	to	I	['N']	[8]
9	proximal	I	['N']	[9]
10	tubules	I-Adverse_Effect	['N']	[10]
11	that	O	['N']	[11]
12	leak	O	['N']	[12]
13	renal	O	['N']	[13]
14	tubular	O	['N']	[14]
15	antigens	O	['N']	[15]
16	,	O	['N']	[16]
17	which	O	['N']	[17]
18	in	O	['N']	[18]
19	turn	O	['N']	[19]
20	complex	O	['N']	[20]
21	with	O	['N']	[21]
22	autoantibody	O	['N']	[22]
23	and	O	['N']	[23]
24	produce	O	['N']	[24]
25	an	O	['N']	[25]
26	autoimmune	O	['N']	[26]
27	membranous	O	['N']	[27]
28	nephropathy	O	['N']	[28]
29	.	O	['N']	[29]
#4286
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	three	O	['N']	[3]
4	patients	O	['N']	[4]
5	with	O	['N']	[5]
6	acute	O	['N']	[6]
7	schizophrenia	O	['N']	[7]
8	,	O	['N']	[8]
9	who	O	['N']	[9]
10	developed	O	['N']	[10]
11	severe	B	['N']	[11]
12	akathisia	I-Adverse_Effect	['N']	[12]
13	during	O	['N']	[13]
14	treatment	O	['N']	[14]
15	with	O	['N']	[15]
16	olanzapine	B-Drug	['Causes']	[12]
17	(	O	['N']	[17]
18	20	O	['N']	[18]
19	-	O	['N']	[19]
20	25	O	['N']	[20]
21	mg	O	['N']	[21]
22	/	O	['N']	[22]
23	d	O	['N']	[23]
24	)	O	['N']	[24]
25	.	O	['N']	[25]
#4287
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	who	O	['N']	[8]
9	received	O	['N']	[9]
10	alteplase	B-Drug	['Causes']	[19]
11	for	O	['N']	[11]
12	acute	O	['N']	[12]
13	myocardial	O	['N']	[13]
14	infarction	O	['N']	[14]
15	and	O	['N']	[15]
16	developed	O	['N']	[16]
17	spontaneous	O	['N']	[17]
18	subfascial	B	['N']	[18]
19	hematoma	I-Adverse_Effect	['N']	[19]
20	without	O	['N']	[20]
21	any	O	['N']	[21]
22	evidence	O	['N']	[22]
23	of	O	['N']	[23]
24	direct	O	['N']	[24]
25	trauma	O	['N']	[25]
26	.	O	['N']	[26]
#4288
0	Toxic	B	['N']	[0]
1	hepatitis	I-Adverse_Effect	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	combination	O	['N']	[4]
5	therapy	O	['N']	[5]
6	with	O	['N']	[6]
7	methotrexate	B-Drug	['Causes']	[1]
8	and	O	['N']	[8]
9	etretinate	O	['N']	[9]
10	in	O	['N']	[10]
11	psoriasis	O	['N']	[11]
12	.	O	['N']	[12]
#4289
0	Up	O	['N']	[0]
1	to	O	['N']	[1]
2	four	O	['N']	[2]
3	percent	O	['N']	[3]
4	of	O	['N']	[4]
5	patients	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	imatinib	B-Drug	['Causes']	[11]
9	may	O	['N']	[9]
10	develop	O	['N']	[10]
11	hepatotoxicity	B-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	which	O	['N']	[13]
14	usually	O	['N']	[14]
15	resolves	O	['N']	[15]
16	with	O	['N']	[16]
17	discontinuation	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	drug	O	['N']	[20]
21	.	O	['N']	[21]
#4290
0	Despite	O	['N']	[0]
1	a	O	['N']	[1]
2	response	O	['N']	[2]
3	of	O	['N']	[3]
4	the	O	['N']	[4]
5	meningeal	O	['N']	[5]
6	tumor	O	['N']	[6]
7	the	O	['N']	[7]
8	patient	O	['N']	[8]
9	developed	O	['N']	[9]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	third	O	['N']	[12]
13	week	O	['N']	[13]
14	of	O	['N']	[14]
15	MTX	O	['N']	[15]
16	treatment	O	['N']	[16]
17	a	O	['N']	[17]
18	progressive	O	['N']	[18]
19	visual	O	['N']	[19]
20	loss	O	['N']	[20]
21	and	O	['N']	[21]
22	loss	O	['N']	[22]
23	of	O	['N']	[23]
24	consciousness	O	['N']	[24]
25	which	O	['N']	[25]
26	worsened	O	['N']	[26]
27	during	O	['N']	[27]
28	subsequent	O	['N']	[28]
29	Ara	B	['N']	[29]
30	-	I	['N']	[30]
31	C	I-Drug	['Causes']	[36]
32	treatment	O	['N']	[32]
33	and	O	['N']	[33]
34	led	O	['N']	[34]
35	to	O	['N']	[35]
36	death	B-Adverse_Effect	['N']	[36]
37	within	O	['N']	[37]
38	3	O	['N']	[38]
39	weeks	O	['N']	[39]
40	.	O	['N']	[40]
#4291
0	At	O	['N']	[0]
1	the	O	['N']	[1]
2	end	O	['N']	[2]
3	of	O	['N']	[3]
4	his	O	['N']	[4]
5	fifth	O	['N']	[5]
6	cycle	O	['N']	[6]
7	of	O	['N']	[7]
8	sunitinib	B-Drug	['Causes']	[29]
9	therapy	O	['N']	[9]
10	,	O	['N']	[10]
11	the	O	['N']	[11]
12	patient	O	['N']	[12]
13	complained	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	development	O	['N']	[16]
17	of	O	['N']	[17]
18	abnormally	O	['N']	[18]
19	large	O	['N']	[19]
20	mammary	O	['N']	[20]
21	glands	O	['N']	[21]
22	associated	O	['N']	[22]
23	with	O	['N']	[23]
24	pain	O	['N']	[24]
25	and	O	['N']	[25]
26	peri	B	['N']	[26]
27	-	I	['N']	[27]
28	areolar	I	['N']	[28]
29	erythema	I-Adverse_Effect	['N']	[29]
30	.	O	['N']	[30]
#4292
0	When	O	['N']	[0]
1	the	O	['N']	[1]
2	disease	O	['N']	[2]
3	recurred	O	['N']	[3]
4	conventional	O	['N']	[4]
5	amphotericin	B	['N']	[5]
6	B	I-Drug	['Causes']	[20]
7	was	O	['N']	[7]
8	used	O	['N']	[8]
9	again	O	['N']	[9]
10	,	O	['N']	[10]
11	but	O	['N']	[11]
12	had	O	['N']	[12]
13	to	O	['N']	[13]
14	be	O	['N']	[14]
15	stopped	O	['N']	[15]
16	because	O	['N']	[16]
17	of	O	['N']	[17]
18	severe	B	['N']	[18]
19	side	I	['N']	[19]
20	effects	I-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#4293
0	A	O	['N']	[0]
1	49-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	Crohn	O	['N']	[6]
7	's	O	['N']	[7]
8	disease	O	['N']	[8]
9	treated	O	['N']	[9]
10	with	O	['N']	[10]
11	prednisone	B-Drug	['Causes']	[22]
12	and	O	['N']	[12]
13	mesalamine	O	['N']	[13]
14	(	O	['N']	[14]
15	5-ASA	O	['N']	[15]
16	)	O	['N']	[16]
17	developed	O	['N']	[17]
18	worsening	O	['N']	[18]
19	respiratory	O	['N']	[19]
20	distress	O	['N']	[20]
21	and	O	['N']	[21]
22	fever	B-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#4294
0	Hyperkalaemia	O	['N']	[0]
1	with	O	['N']	[1]
2	renal	B	['N']	[2]
3	tubular	I	['N']	[3]
4	dysfunction	I-Adverse_Effect	['N']	[4]
5	by	O	['N']	[5]
6	oral	O	['N']	[6]
7	therapy	O	['N']	[7]
8	of	O	['N']	[8]
9	sulfamethoxazole	B	['N']	[9]
10	-	I	['N']	[10]
11	trimethoprim	I-Drug	['Causes']	[4]
12	(	O	['N']	[12]
13	co	O	['N']	[13]
14	-	O	['N']	[14]
15	trimoxazole	O	['N']	[15]
16	)	O	['N']	[16]
17	is	O	['N']	[17]
18	described	O	['N']	[18]
19	in	O	['N']	[19]
20	2	O	['N']	[20]
21	elderly	O	['N']	[21]
22	Japanese	O	['N']	[22]
23	patients	O	['N']	[23]
24	with	O	['N']	[24]
25	lymphoid	O	['N']	[25]
26	malignancy	O	['N']	[26]
27	,	O	['N']	[27]
28	who	O	['N']	[28]
29	developed	O	['N']	[29]
30	Pneumocystis	O	['N']	[30]
31	carinii	O	['N']	[31]
32	pneumonia	O	['N']	[32]
33	and	O	['N']	[33]
34	improved	O	['N']	[34]
35	.	O	['N']	[35]
#4295
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	in	O	['N']	[4]
5	which	O	['N']	[5]
6	dipyridamole	B-Drug	['Causes']	[15]
7	induced	O	['N']	[7]
8	high	B	['N']	[8]
9	-	I	['N']	[9]
10	grade	I	['N']	[10]
11	atrioventricular	I	['N']	[11]
12	(	I	['N']	[12]
13	AV	I	['N']	[13]
14	)	I	['N']	[14]
15	block	I-Adverse_Effect	['N']	[15]
16	that	O	['N']	[16]
17	responded	O	['N']	[17]
18	promptly	O	['N']	[18]
19	to	O	['N']	[19]
20	intravenous	O	['N']	[20]
21	aminophylline	O	['N']	[21]
22	but	O	['N']	[22]
23	not	O	['N']	[23]
24	to	O	['N']	[24]
25	atropine	O	['N']	[25]
26	.	O	['N']	[26]
#4296
0	We	O	['N']	[0]
1	suggest	O	['N']	[1]
2	that	O	['N']	[2]
3	itraconazole	B-Drug	['Causes']	[24]
4	should	O	['N']	[4]
5	be	O	['N']	[5]
6	added	O	['N']	[6]
7	to	O	['N']	[7]
8	the	O	['N']	[8]
9	list	O	['N']	[9]
10	of	O	['N']	[10]
11	drugs	O	['N']	[11]
12	that	O	['N']	[12]
13	may	O	['N']	[13]
14	be	O	['N']	[14]
15	responsible	O	['N']	[15]
16	for	O	['N']	[16]
17	a	O	['N']	[17]
18	drug	O	['N']	[18]
19	-	O	['N']	[19]
20	induced	O	['N']	[20]
21	vanishing	B	['N']	[21]
22	bile	I	['N']	[22]
23	duct	I	['N']	[23]
24	syndrome	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#4297
0	A	O	['N']	[0]
1	55-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	presented	O	['N']	[5]
6	an	O	['N']	[6]
7	episode	O	['N']	[7]
8	of	O	['N']	[8]
9	acute	O	['N']	[9]
10	urticaria	O	['N']	[10]
11	and	O	['N']	[11]
12	labial	O	['N']	[12]
13	angioedema	O	['N']	[13]
14	60	O	['N']	[14]
15	minutes	O	['N']	[15]
16	after	O	['N']	[16]
17	ingesting	O	['N']	[17]
18	500	B	['N']	[18]
19	mg	I-Dose	['N']	[19]
20	of	O	['N']	[20]
21	cloxacillin	B-Drug	['Dosage']	[19]
22	for	O	['N']	[22]
23	a	O	['N']	[23]
24	skin	O	['N']	[24]
25	abscess	O	['N']	[25]
26	.	O	['N']	[26]
#4298
0	The	O	['N']	[0]
1	present	O	['N']	[1]
2	case	O	['N']	[2]
3	is	O	['N']	[3]
4	the	O	['N']	[4]
5	first	O	['N']	[5]
6	report	O	['N']	[6]
7	of	O	['N']	[7]
8	hypercalcemia	B-Adverse_Effect	['N']	[8]
9	induced	O	['N']	[9]
10	by	O	['N']	[10]
11	vitamin	B	['N']	[11]
12	D3	I-Drug	['Causes']	[8]
13	ointment	O	['N']	[13]
14	and	O	['N']	[14]
15	thiazide	O	['N']	[15]
16	simultaneously	O	['N']	[16]
17	.	O	['N']	[17]
#4299
0	Two	O	['N']	[0]
1	of	O	['N']	[1]
2	the	O	['N']	[2]
3	five	O	['N']	[3]
4	patients	O	['N']	[4]
5	who	O	['N']	[5]
6	worsened	O	['N']	[6]
7	motorically	O	['N']	[7]
8	also	O	['N']	[8]
9	developed	O	['N']	[9]
10	encephalopathy	B-Adverse_Effect	['N']	[10]
11	during	O	['N']	[11]
12	risperidone	B-Drug	['Causes']	[10]
13	treatment	O	['N']	[13]
14	;	O	['N']	[14]
15	the	O	['N']	[15]
16	encephalopathy	O	['N']	[16]
17	resolved	O	['N']	[17]
18	when	O	['N']	[18]
19	the	O	['N']	[19]
20	patients	O	['N']	[20]
21	were	O	['N']	[21]
22	switched	O	['N']	[22]
23	to	O	['N']	[23]
24	clozapine	O	['N']	[24]
25	treatment	O	['N']	[25]
26	.	O	['N']	[26]
#4300
0	Propoxyphene	B-Drug	['Causes']	[6]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	wide	B	['N']	[3]
4	QRS	I	['N']	[4]
5	complex	I	['N']	[5]
6	dysrhythmia	I-Adverse_Effect	['N']	[6]
7	responsive	O	['N']	[7]
8	to	O	['N']	[8]
9	sodium	O	['N']	[9]
10	bicarbonate	O	['N']	[10]
11	--	O	['N']	[11]
12	a	O	['N']	[12]
13	case	O	['N']	[13]
14	report	O	['N']	[14]
15	.	O	['N']	[15]
#4301
0	Following	O	['N']	[0]
1	the	O	['N']	[1]
2	institution	O	['N']	[2]
3	of	O	['N']	[3]
4	intravenous	O	['N']	[4]
5	therapy	O	['N']	[5]
6	with	O	['N']	[6]
7	acyclovir	B-Drug	['Causes']	[14]
8	,	O	['N']	[8]
9	the	O	['N']	[9]
10	patient	O	['N']	[10]
11	developed	O	['N']	[11]
12	fever	O	['N']	[12]
13	,	O	['N']	[13]
14	hemoptysis	B-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	a	O	['N']	[17]
18	pleural	O	['N']	[18]
19	friction	O	['N']	[19]
20	rub	O	['N']	[20]
21	.	O	['N']	[21]
#4302
0	A	O	['N']	[0]
1	60	O	['N']	[1]
2	year	O	['N']	[2]
3	-	O	['N']	[3]
4	old	O	['N']	[4]
5	woman	O	['N']	[5]
6	with	O	['N']	[6]
7	chronic	O	['N']	[7]
8	renal	O	['N']	[8]
9	failure	O	['N']	[9]
10	developed	O	['N']	[10]
11	acute	O	['N']	[11]
12	proximal	B	['N']	[12]
13	muscle	I	['N']	[13]
14	weakness	I-Adverse_Effect	['N']	[14]
15	after	O	['N']	[15]
16	receiving	O	['N']	[16]
17	a	O	['N']	[17]
18	regular	O	['N']	[18]
19	dosage	O	['N']	[19]
20	of	O	['N']	[20]
21	colchicine	B-Drug	['Causes']	[14]
22	.	O	['N']	[22]
#4303
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	neuroleptic	B	['N']	[6]
7	malignant	I	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	due	O	['N']	[9]
10	to	O	['N']	[10]
11	risperidone	B-Drug	['Causes']	[8]
12	in	O	['N']	[12]
13	a	O	['N']	[13]
14	child	O	['N']	[14]
15	with	O	['N']	[15]
16	Joubert	O	['N']	[16]
17	syndrome	O	['N']	[17]
18	.	O	['N']	[18]
#4304
0	Propylthiouracil	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	cutaneous	B	['N']	[3]
4	vasculitis	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#4305
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	no	O	['N']	[4]
5	prior	O	['N']	[5]
6	cases	O	['N']	[6]
7	of	O	['N']	[7]
8	penicillamine	B-Drug	['Causes']	[11]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	TTP	B-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	RA	O	['N']	[13]
14	have	O	['N']	[14]
15	been	O	['N']	[15]
16	reported	O	['N']	[16]
17	.	O	['N']	[17]
#4306
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	additional	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	isotretinoin	B-Drug	['Causes']	[7]
7	teratogenicity	B-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	which	O	['N']	[9]
10	the	O	['N']	[10]
11	patient	O	['N']	[11]
12	had	O	['N']	[12]
13	agenesis	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	cerebellar	O	['N']	[16]
17	vermis	O	['N']	[17]
18	,	O	['N']	[18]
19	multiple	O	['N']	[19]
20	leptomeningeal	O	['N']	[20]
21	neuroglial	O	['N']	[21]
22	heterotopias	O	['N']	[22]
23	,	O	['N']	[23]
24	hydrocephalus	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	abnormalities	O	['N']	[27]
28	of	O	['N']	[28]
29	the	O	['N']	[29]
30	corticospinal	O	['N']	[30]
31	tracts	O	['N']	[31]
32	.	O	['N']	[32]
#4307
0	Stroke	B	['N']	[0]
1	-	I	['N']	[1]
2	like	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	gold	B	['N']	[5]
6	sodium	I	['N']	[6]
7	thiomalate	I-Drug	['Causes']	[3]
8	induced	O	['N']	[8]
9	vasomotor	O	['N']	[9]
10	reaction	O	['N']	[10]
11	.	O	['N']	[11]
#4308
0	We	O	['N']	[0]
1	experienced	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	chronic	O	['N']	[5]
6	renal	O	['N']	[6]
7	failure	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	suffering	O	['N']	[11]
12	from	O	['N']	[12]
13	acute	O	['N']	[13]
14	hemorrhagic	O	['N']	[14]
15	gastritis	O	['N']	[15]
16	associated	O	['N']	[16]
17	with	O	['N']	[17]
18	AZ	B-Drug	['Causes']	[19]
19	intoxication	I-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#4309
0	Vancomycin	B-Drug	['Causes']	[30]
1	is	O	['N']	[1]
2	widely	O	['N']	[2]
3	used	O	['N']	[3]
4	against	O	['N']	[4]
5	methicillin	O	['N']	[5]
6	-	O	['N']	[6]
7	resistant	O	['N']	[7]
8	Staphylococcus	O	['N']	[8]
9	aureus	O	['N']	[9]
10	infections	O	['N']	[10]
11	,	O	['N']	[11]
12	but	O	['N']	[12]
13	it	O	['N']	[13]
14	is	O	['N']	[14]
15	associated	O	['N']	[15]
16	with	O	['N']	[16]
17	many	O	['N']	[17]
18	adverse	O	['N']	[18]
19	effects	O	['N']	[19]
20	such	O	['N']	[20]
21	as	O	['N']	[21]
22	nephrotoxicity	O	['N']	[22]
23	,	O	['N']	[23]
24	ototoxicity	O	['N']	[24]
25	,	O	['N']	[25]
26	gastrointestinal	O	['N']	[26]
27	disturbances	O	['N']	[27]
28	,	O	['N']	[28]
29	blood	B	['N']	[29]
30	disorders	I-Adverse_Effect	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	two	O	['N']	[33]
34	types	O	['N']	[34]
35	of	O	['N']	[35]
36	hypersensitivity	O	['N']	[36]
37	reactions	O	['N']	[37]
38	-	O	['N']	[38]
39	an	O	['N']	[39]
40	anaphylactoid	O	['N']	[40]
41	reaction	O	['N']	[41]
42	known	O	['N']	[42]
43	as	O	['N']	[43]
44	"	O	['N']	[44]
45	red	O	['N']	[45]
46	man	O	['N']	[46]
47	syndrome	O	['N']	[47]
48	"	O	['N']	[48]
49	and	O	['N']	[49]
50	anaphylaxis	O	['N']	[50]
51	.	O	['N']	[51]
#4310
0	He	O	['N']	[0]
1	had	O	['N']	[1]
2	been	O	['N']	[2]
3	taking	O	['N']	[3]
4	trimethoprim	O	['N']	[4]
5	-	O	['N']	[5]
6	sulfamethoxazole	B-Drug	['Causes']	[26]
7	for	O	['N']	[7]
8	approximately	O	['N']	[8]
9	eight	O	['N']	[9]
10	days	O	['N']	[10]
11	when	O	['N']	[11]
12	he	O	['N']	[12]
13	revisited	O	['N']	[13]
14	his	O	['N']	[14]
15	family	O	['N']	[15]
16	physician	O	['N']	[16]
17	,	O	['N']	[17]
18	complaining	O	['N']	[18]
19	of	O	['N']	[19]
20	headaches	O	['N']	[20]
21	,	O	['N']	[21]
22	dizziness	O	['N']	[22]
23	,	O	['N']	[23]
24	difficulty	B	['N']	[24]
25	with	I	['N']	[25]
26	speech	I-Adverse_Effect	['N']	[26]
27	,	O	['N']	[27]
28	weakness	O	['N']	[28]
29	,	O	['N']	[29]
30	and	O	['N']	[30]
31	itching	O	['N']	[31]
32	on	O	['N']	[32]
33	the	O	['N']	[33]
34	trunk	O	['N']	[34]
35	of	O	['N']	[35]
36	his	O	['N']	[36]
37	body	O	['N']	[37]
38	and	O	['N']	[38]
39	legs	O	['N']	[39]
40	,	O	['N']	[40]
41	where	O	['N']	[41]
42	a	O	['N']	[42]
43	maculopapular	O	['N']	[43]
44	rash	O	['N']	[44]
45	was	O	['N']	[45]
46	noted	O	['N']	[46]
47	.	O	['N']	[47]
#4311
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	neutropenia	B-Adverse_Effect	['N']	[5]
6	following	O	['N']	[6]
7	captopril	B-Drug	['Causes']	[5]
8	use	O	['N']	[8]
9	in	O	['N']	[9]
10	cardiac	O	['N']	[10]
11	patients	O	['N']	[11]
12	with	O	['N']	[12]
13	trisomy	O	['N']	[13]
14	21	O	['N']	[14]
15	.	O	['N']	[15]
#4312
0	Methotrexate	B-Drug	['Causes']	[5]
1	induced	O	['N']	[1]
2	sprue	B	['N']	[2]
3	-	I	['N']	[3]
4	like	I	['N']	[4]
5	syndrome	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#4313
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	ovarian	B	['N']	[6]
7	endometrioid	I	['N']	[7]
8	carcinoma	I-Adverse_Effect	['N']	[8]
9	and	O	['N']	[9]
10	endometriosis	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	postmenopausal	O	['N']	[13]
14	patient	O	['N']	[14]
15	who	O	['N']	[15]
16	was	O	['N']	[16]
17	treated	O	['N']	[17]
18	with	O	['N']	[18]
19	tamoxifen	B-Drug	['Causes']	[8]
20	for	O	['N']	[20]
21	breast	O	['N']	[21]
22	cancer	O	['N']	[22]
23	.	O	['N']	[23]
#4314
0	CASE	O	['N']	[0]
1	REPORT	O	['N']	[1]
2	:	O	['N']	[2]
3	Soon	O	['N']	[3]
4	after	O	['N']	[4]
5	initiation	O	['N']	[5]
6	of	O	['N']	[6]
7	amiodarone	B	['N']	[7]
8	HCl	I-Drug	['Causes']	[41]
9	(	O	['N']	[9]
10	200	O	['N']	[10]
11	mg	O	['N']	[11]
12	/	O	['N']	[12]
13	day	O	['N']	[13]
14	)	O	['N']	[14]
15	,	O	['N']	[15]
16	a	O	['N']	[16]
17	76-year	O	['N']	[17]
18	-	O	['N']	[18]
19	old	O	['N']	[19]
20	man	O	['N']	[20]
21	came	O	['N']	[21]
22	to	O	['N']	[22]
23	us	O	['N']	[23]
24	with	O	['N']	[24]
25	symptoms	O	['N']	[25]
26	of	O	['N']	[26]
27	visual	O	['N']	[27]
28	"	O	['N']	[28]
29	shining	O	['N']	[29]
30	,	O	['N']	[30]
31	"	O	['N']	[31]
32	glare	O	['N']	[32]
33	,	O	['N']	[33]
34	color	O	['N']	[34]
35	vision	O	['N']	[35]
36	anomalies	O	['N']	[36]
37	,	O	['N']	[37]
38	and	O	['N']	[38]
39	gradually	O	['N']	[39]
40	decreased	B	['N']	[40]
41	vision	I-Adverse_Effect	['N']	[41]
42	.	O	['N']	[42]
#4315
0	The	O	['N']	[0]
1	aim	O	['N']	[1]
2	of	O	['N']	[2]
3	this	O	['N']	[3]
4	paper	O	['N']	[4]
5	is	O	['N']	[5]
6	to	O	['N']	[6]
7	report	O	['N']	[7]
8	the	O	['N']	[8]
9	case	O	['N']	[9]
10	of	O	['N']	[10]
11	rosaceiform	B	['N']	[11]
12	eruption	I-Adverse_Effect	['N']	[12]
13	induced	O	['N']	[13]
14	by	O	['N']	[14]
15	erlotinib	B-Drug	['Causes']	[12]
16	in	O	['N']	[16]
17	an	O	['N']	[17]
18	81-year	O	['N']	[18]
19	-	O	['N']	[19]
20	old	O	['N']	[20]
21	-	O	['N']	[21]
22	man	O	['N']	[22]
23	and	O	['N']	[23]
24	to	O	['N']	[24]
25	discuss	O	['N']	[25]
26	the	O	['N']	[26]
27	pathogenetic	O	['N']	[27]
28	role	O	['N']	[28]
29	of	O	['N']	[29]
30	Demodex	O	['N']	[30]
31	folliculorum	O	['N']	[31]
32	mites	O	['N']	[32]
33	,	O	['N']	[33]
34	found	O	['N']	[34]
35	in	O	['N']	[35]
36	the	O	['N']	[36]
37	present	O	['N']	[37]
38	patient	O	['N']	[38]
39	,	O	['N']	[39]
40	using	O	['N']	[40]
41	skin	O	['N']	[41]
42	scraping	O	['N']	[42]
43	.	O	['N']	[43]
#4316
0	Our	O	['N']	[0]
1	findings	O	['N']	[1]
2	suggest	O	['N']	[2]
3	that	O	['N']	[3]
4	significant	O	['N']	[4]
5	progression	B	['N']	[5]
6	of	I	['N']	[6]
7	marrow	I	['N']	[7]
8	reticulin	I	['N']	[8]
9	fibrosis	I-Adverse_Effect	['N']	[9]
10	during	O	['N']	[10]
11	imatinib	B-Drug	['Causes']	[9]
12	therapy	O	['N']	[12]
13	can	O	['N']	[13]
14	be	O	['N']	[14]
15	an	O	['N']	[15]
16	indicator	O	['N']	[16]
17	for	O	['N']	[17]
18	a	O	['N']	[18]
19	return	O	['N']	[19]
20	or	O	['N']	[20]
21	progression	O	['N']	[21]
22	of	O	['N']	[22]
23	CML	O	['N']	[23]
24	and	O	['N']	[24]
25	,	O	['N']	[25]
26	in	O	['N']	[26]
27	some	O	['N']	[27]
28	patients	O	['N']	[28]
29	with	O	['N']	[29]
30	CML	O	['N']	[30]
31	,	O	['N']	[31]
32	imatinib	O	['N']	[32]
33	may	O	['N']	[33]
34	promote	O	['N']	[34]
35	cytogenetic	O	['N']	[35]
36	clonal	O	['N']	[36]
37	evolution	O	['N']	[37]
38	,	O	['N']	[38]
39	resulting	O	['N']	[39]
40	in	O	['N']	[40]
41	a	O	['N']	[41]
42	poor	O	['N']	[42]
43	response	O	['N']	[43]
44	to	O	['N']	[44]
45	treatment	O	['N']	[45]
46	.	O	['N']	[46]
#4317
0	In	O	['N']	[0]
1	conclusion	O	['N']	[1]
2	,	O	['N']	[2]
3	RSDS	B-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	a	O	['N']	[5]
6	relevant	O	['N']	[6]
7	osteoarticular	O	['N']	[7]
8	complication	O	['N']	[8]
9	in	O	['N']	[9]
10	patients	O	['N']	[10]
11	receiving	O	['N']	[11]
12	either	O	['N']	[12]
13	anticalcineurinic	O	['N']	[13]
14	drug	O	['N']	[14]
15	(	O	['N']	[15]
16	CyA	B-Drug	['Causes']	[3]
17	or	O	['N']	[17]
18	tacrolimus	O	['N']	[18]
19	)	O	['N']	[19]
20	,	O	['N']	[20]
21	even	O	['N']	[21]
22	under	O	['N']	[22]
23	monotherapy	O	['N']	[23]
24	or	O	['N']	[24]
25	with	O	['N']	[25]
26	a	O	['N']	[26]
27	low	O	['N']	[27]
28	steroid	O	['N']	[28]
29	dose	O	['N']	[29]
30	.	O	['N']	[30]
#4318
0	Sodium	O	['N']	[0]
1	valproate	O	['N']	[1]
2	and	O	['N']	[2]
3	carbamazepine	B-Drug	['Causes']	[32]
4	,	O	['N']	[4]
5	antiepileptic	O	['N']	[5]
6	drugs	O	['N']	[6]
7	that	O	['N']	[7]
8	are	O	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	a	O	['N']	[11]
12	relatively	O	['N']	[12]
13	low	O	['N']	[13]
14	rate	O	['N']	[14]
15	of	O	['N']	[15]
16	adverse	O	['N']	[16]
17	cutaneous	O	['N']	[17]
18	reactions	O	['N']	[18]
19	,	O	['N']	[19]
20	should	O	['N']	[20]
21	be	O	['N']	[21]
22	added	O	['N']	[22]
23	to	O	['N']	[23]
24	the	O	['N']	[24]
25	growing	O	['N']	[25]
26	list	O	['N']	[26]
27	of	O	['N']	[27]
28	drugs	O	['N']	[28]
29	that	O	['N']	[29]
30	produce	O	['N']	[30]
31	psoriasiform	B	['N']	[31]
32	eruptions	I-Adverse_Effect	['N']	[32]
33	.	O	['N']	[33]
#4319
0	Minocycline	B-Drug	['Causes']	[9]
1	as	O	['N']	[1]
2	a	O	['N']	[2]
3	cause	O	['N']	[3]
4	of	O	['N']	[4]
5	drug	O	['N']	[5]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	autoimmune	B	['N']	[8]
9	hepatitis	I-Adverse_Effect	['N']	[9]
10	.	O	['N']	[10]
#4320
0	Eleven	O	['N']	[0]
1	patients	O	['N']	[1]
2	developed	O	['N']	[2]
3	infection	B-Adverse_Effect	['N']	[3]
4	requiring	O	['N']	[4]
5	hospitalization	O	['N']	[5]
6	while	O	['N']	[6]
7	taking	O	['N']	[7]
8	leflunomide	B-Drug	['Causes']	[3]
9	including	O	['N']	[9]
10	:	O	['N']	[10]
11	lower	O	['N']	[11]
12	respiratory	O	['N']	[12]
13	tract	O	['N']	[13]
14	infections	O	['N']	[14]
15	(	O	['N']	[15]
16	3	O	['N']	[16]
17	)	O	['N']	[17]
18	,	O	['N']	[18]
19	cellulitis	O	['N']	[19]
20	(	O	['N']	[20]
21	2	O	['N']	[21]
22	)	O	['N']	[22]
23	,	O	['N']	[23]
24	disseminated	O	['N']	[24]
25	herpes	O	['N']	[25]
26	zoster	O	['N']	[26]
27	(	O	['N']	[27]
28	2	O	['N']	[28]
29	)	O	['N']	[29]
30	,	O	['N']	[30]
31	probable	O	['N']	[31]
32	TB	O	['N']	[32]
33	liver	O	['N']	[33]
34	(	O	['N']	[34]
35	1	O	['N']	[35]
36	)	O	['N']	[36]
37	,	O	['N']	[37]
38	abdominal	O	['N']	[38]
39	sepsis	O	['N']	[39]
40	(	O	['N']	[40]
41	1	O	['N']	[41]
42	)	O	['N']	[42]
43	,	O	['N']	[43]
44	mycotic	O	['N']	[44]
45	aneurysm	O	['N']	[45]
46	(	O	['N']	[46]
47	1	O	['N']	[47]
48	)	O	['N']	[48]
49	and	O	['N']	[49]
50	gastroenteritis	O	['N']	[50]
51	(	O	['N']	[51]
52	1	O	['N']	[52]
53	)	O	['N']	[53]
54	.	O	['N']	[54]
#4321
0	Drug	O	['N']	[0]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	fever	B-Adverse_Effect	['N']	[3]
4	due	O	['N']	[4]
5	to	O	['N']	[5]
6	diltiazem	B-Drug	['Causes']	[3]
7	.	O	['N']	[7]
#4322
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	7	O	['N']	[3]
4	patients	O	['N']	[4]
5	(	O	['N']	[5]
6	2	O	['N']	[6]
7	women	O	['N']	[7]
8	,	O	['N']	[8]
9	5	O	['N']	[9]
10	men	O	['N']	[10]
11	)	O	['N']	[11]
12	with	O	['N']	[12]
13	chronic	O	['N']	[13]
14	renal	O	['N']	[14]
15	failure	O	['N']	[15]
16	,	O	['N']	[16]
17	who	O	['N']	[17]
18	developed	O	['N']	[18]
19	under	O	['N']	[19]
20	a	O	['N']	[20]
21	high	O	['N']	[21]
22	dosage	O	['N']	[22]
23	of	O	['N']	[23]
24	the	O	['N']	[24]
25	new	O	['N']	[25]
26	diuretic	O	['N']	[26]
27	muzolimine	B-Drug	['Dosage']	[35]
28	(	O	['N']	[28]
29	range	O	['N']	[29]
30	240	B	['N']	[30]
31	to	I	['N']	[31]
32	1440	I	['N']	[32]
33	mg	I	['N']	[33]
34	per	I	['N']	[34]
35	day	I-Dose	['N']	[35]
36	)	O	['N']	[36]
37	fatal	O	['N']	[37]
38	neuromyeloencephalopathy	O	['N']	[38]
39	.	O	['N']	[39]
#4323
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	to	O	['N']	[2]
3	our	O	['N']	[3]
4	knowledge	O	['N']	[4]
5	,	O	['N']	[5]
6	in	O	['N']	[6]
7	newborns	O	['N']	[7]
8	there	O	['N']	[8]
9	have	O	['N']	[9]
10	been	O	['N']	[10]
11	no	O	['N']	[11]
12	reported	O	['N']	[12]
13	cases	O	['N']	[13]
14	to	O	['N']	[14]
15	date	O	['N']	[15]
16	of	O	['N']	[16]
17	thrombocytosis	B-Adverse_Effect	['N']	[17]
18	induced	O	['N']	[18]
19	by	O	['N']	[19]
20	enoxaparin	B-Drug	['Causes']	[17]
21	.	O	['N']	[21]
#4324
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	2	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	SJS	B-Adverse_Effect	['N']	[5]
6	related	O	['N']	[6]
7	to	O	['N']	[7]
8	nevirapine	B-Drug	['Causes']	[5]
9	use	O	['N']	[9]
10	and	O	['N']	[10]
11	review	O	['N']	[11]
12	the	O	['N']	[12]
13	literature	O	['N']	[13]
14	on	O	['N']	[14]
15	this	O	['N']	[15]
16	newly	O	['N']	[16]
17	recognized	O	['N']	[17]
18	association	O	['N']	[18]
19	.	O	['N']	[19]
#4325
0	Myoclonus	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	seizures	O	['N']	[2]
3	disappeared	O	['N']	[3]
4	after	O	['N']	[4]
5	discontinuation	O	['N']	[5]
6	of	O	['N']	[6]
7	L	B	['N']	[7]
8	-	I	['N']	[8]
9	dopa	I-Drug	['Causes']	[0]
10	and	O	['N']	[10]
11	the	O	['N']	[11]
12	introduction	O	['N']	[12]
13	of	O	['N']	[13]
14	valproate	O	['N']	[14]
15	sodium	O	['N']	[15]
16	(	O	['N']	[16]
17	VPA	O	['N']	[17]
18	)	O	['N']	[18]
19	.	O	['N']	[19]
#4326
0	We	O	['N']	[0]
1	hypothesize	O	['N']	[1]
2	that	O	['N']	[2]
3	caffeine	B-Drug	['Causes']	[8]
4	toxicity	O	['N']	[4]
5	injured	B	['N']	[5]
6	the	I	['N']	[6]
7	muscle	I	['N']	[7]
8	cells	I-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	which	O	['N']	[10]
11	were	O	['N']	[11]
12	fragile	O	['N']	[12]
13	due	O	['N']	[13]
14	to	O	['N']	[14]
15	the	O	['N']	[15]
16	potassium	O	['N']	[16]
17	depletion	O	['N']	[17]
18	induced	O	['N']	[18]
19	by	O	['N']	[19]
20	the	O	['N']	[20]
21	coexisting	O	['N']	[21]
22	hyponatremia	O	['N']	[22]
23	,	O	['N']	[23]
24	to	O	['N']	[24]
25	result	O	['N']	[25]
26	in	O	['N']	[26]
27	unusually	O	['N']	[27]
28	severe	O	['N']	[28]
29	rhabdomyolysis	O	['N']	[29]
30	.	O	['N']	[30]
#4327
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	two	O	['N']	[2]
3	dark	O	['N']	[3]
4	-	O	['N']	[4]
5	skinned	O	['N']	[5]
6	patients	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	hyperpigmented	B	['N']	[9]
10	skin	I-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	tongue	O	['N']	[12]
13	lesions	O	['N']	[13]
14	during	O	['N']	[14]
15	combination	O	['N']	[15]
16	therapy	O	['N']	[16]
17	with	O	['N']	[17]
18	IFN	O	['N']	[18]
19	and	O	['N']	[19]
20	ribavirin	B-Drug	['Causes']	[10]
21	.	O	['N']	[21]
#4328
0	Gastric	O	['N']	[0]
1	tumor	O	['N']	[1]
2	,	O	['N']	[2]
3	endometrial	O	['N']	[3]
4	carcinoma	O	['N']	[4]
5	and	O	['N']	[5]
6	cervical	B	['N']	[6]
7	adenocarcinoma	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	situ	O	['N']	[9]
10	were	O	['N']	[10]
11	detected	O	['N']	[11]
12	after	O	['N']	[12]
13	treatment	O	['N']	[13]
14	with	O	['N']	[14]
15	tamoxifen	B-Drug	['Causes']	[7]
16	for	O	['N']	[16]
17	breast	O	['N']	[17]
18	cancer	O	['N']	[18]
19	.	O	['N']	[19]
#4329
0	Markedly	O	['N']	[0]
1	increased	B	['N']	[1]
2	pigmementation	I	['N']	[2]
3	of	I	['N']	[3]
4	skin	I-Adverse_Effect	['N']	[4]
5	immediately	O	['N']	[5]
6	overlying	O	['N']	[6]
7	veins	O	['N']	[7]
8	used	O	['N']	[8]
9	for	O	['N']	[9]
10	multiple	O	['N']	[10]
11	5-fluorouracil	B-Drug	['Causes']	[4]
12	infusions	O	['N']	[12]
13	was	O	['N']	[13]
14	noted	O	['N']	[14]
15	.	O	['N']	[15]
#4330
0	Multifocal	B	['N']	[0]
1	inflammatory	I	['N']	[1]
2	leukoencephalopathy	I-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	levamisole	B-Drug	['Causes']	[2]
6	therapy	O	['N']	[6]
7	.	O	['N']	[7]
#4331
0	Rebound	O	['N']	[0]
1	hyperglycemia	B-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	overdosing	O	['N']	[3]
4	of	O	['N']	[4]
5	insulin	B-Drug	['Causes']	[1]
6	in	O	['N']	[6]
7	cats	O	['N']	[7]
8	with	O	['N']	[8]
9	diabetes	O	['N']	[9]
10	mellitus	O	['N']	[10]
11	.	O	['N']	[11]
#4332
0	Prior	O	['N']	[0]
1	to	O	['N']	[1]
2	surgery	O	['N']	[2]
3	,	O	['N']	[3]
4	levodopa	B-Drug	['Causes']	[6]
5	induced	O	['N']	[5]
6	dyskinesia	B-Adverse_Effect	['N']	[6]
7	had	O	['N']	[7]
8	improved	O	['N']	[8]
9	(	O	['N']	[9]
10	<	O	['N']	[10]
11	or	O	['N']	[11]
12	=	O	['N']	[12]
13	50	O	['N']	[13]
14	%	O	['N']	[14]
15	)	O	['N']	[15]
16	under	O	['N']	[16]
17	treatment	O	['N']	[17]
18	with	O	['N']	[18]
19	amantadine	O	['N']	[19]
20	(	O	['N']	[20]
21	400	O	['N']	[21]
22	mg	O	['N']	[22]
23	/	O	['N']	[23]
24	day	O	['N']	[24]
25	,	O	['N']	[25]
26	po	O	['N']	[26]
27	)	O	['N']	[27]
28	in	O	['N']	[28]
29	all	O	['N']	[29]
30	three	O	['N']	[30]
31	patients	O	['N']	[31]
32	.	O	['N']	[32]
#4333
0	46-year	O	['N']	[0]
1	-	O	['N']	[1]
2	old	O	['N']	[2]
3	woman	O	['N']	[3]
4	developed	O	['N']	[4]
5	painful	O	['N']	[5]
6	ulcers	O	['N']	[6]
7	over	O	['N']	[7]
8	her	O	['N']	[8]
9	lower	O	['N']	[9]
10	abdomen	O	['N']	[10]
11	in	O	['N']	[11]
12	the	O	['N']	[12]
13	form	O	['N']	[13]
14	of	O	['N']	[14]
15	reticulate	B	['N']	[15]
16	erythema	I-Adverse_Effect	['N']	[16]
17	after	O	['N']	[17]
18	injecting	O	['N']	[18]
19	interferon	B	['N']	[19]
20	beta-1b	I-Drug	['Causes']	[16]
21	subcutaneously	O	['N']	[21]
22	for	O	['N']	[22]
23	multiple	O	['N']	[23]
24	sclerosis	O	['N']	[24]
25	.	O	['N']	[25]
#4334
0	Four	O	['N']	[0]
1	years	O	['N']	[1]
2	after	O	['N']	[2]
3	the	O	['N']	[3]
4	beginning	O	['N']	[4]
5	of	O	['N']	[5]
6	IFN	B-Drug	['Causes']	[16]
7	therapy	O	['N']	[7]
8	,	O	['N']	[8]
9	he	O	['N']	[9]
10	acutely	O	['N']	[10]
11	developed	O	['N']	[11]
12	moderate	O	['N']	[12]
13	hyperglycemia	O	['N']	[13]
14	and	O	['N']	[14]
15	severe	B	['N']	[15]
16	ketonuria	I-Adverse_Effect	['N']	[16]
17	with	O	['N']	[17]
18	positive	O	['N']	[18]
19	islet	O	['N']	[19]
20	cell	O	['N']	[20]
21	antibody	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	then	O	['N']	[24]
25	28	O	['N']	[25]
26	units	O	['N']	[26]
27	/	O	['N']	[27]
28	day	O	['N']	[28]
29	of	O	['N']	[29]
30	insulin	O	['N']	[30]
31	injection	O	['N']	[31]
32	was	O	['N']	[32]
33	started	O	['N']	[33]
34	.	O	['N']	[34]
#4335
0	Four	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	fat	O	['N']	[3]
4	embolism	O	['N']	[4]
5	are	O	['N']	[5]
6	described	O	['N']	[6]
7	in	O	['N']	[7]
8	infants	O	['N']	[8]
9	receiving	O	['N']	[9]
10	prolonged	O	['N']	[10]
11	intravenous	O	['N']	[11]
12	infusion	O	['N']	[12]
13	of	O	['N']	[13]
14	fat	O	['N']	[14]
15	(	O	['N']	[15]
16	Intralipid	B-Drug	['Dosage']	[18]
17	20	B	['N']	[17]
18	%	I-Dose	['N']	[18]
19	)	O	['N']	[19]
20	.	O	['N']	[20]
#4336
0	Captopril	B-Drug	['Causes']	[6]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	acute	B	['N']	[3]
4	reversible	I	['N']	[4]
5	renal	I	['N']	[5]
6	failure	I-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#4337
0	By	O	['N']	[0]
1	means	O	['N']	[1]
2	of	O	['N']	[2]
3	the	O	['N']	[3]
4	in	O	['N']	[4]
5	vitro	O	['N']	[5]
6	heparin	O	['N']	[6]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	platelet	B	['N']	[9]
10	activation	I-Adverse_Effect	['N']	[10]
11	(	O	['N']	[11]
12	HIPA	O	['N']	[12]
13	)	O	['N']	[13]
14	assay	O	['N']	[14]
15	it	O	['N']	[15]
16	was	O	['N']	[16]
17	shown	O	['N']	[17]
18	that	O	['N']	[18]
19	standard	O	['N']	[19]
20	heparin	O	['N']	[20]
21	and	O	['N']	[21]
22	the	O	['N']	[22]
23	LMW	O	['N']	[23]
24	heparins	O	['N']	[24]
25	Fragmin	O	['N']	[25]
26	and	O	['N']	[26]
27	Fraxiparin	O	['N']	[27]
28	(	O	['N']	[28]
29	Sanofi	O	['N']	[29]
30	Labaz	O	['N']	[30]
31	,	O	['N']	[31]
32	Munich	O	['N']	[32]
33	,	O	['N']	[33]
34	FRG	O	['N']	[34]
35	)	O	['N']	[35]
36	,	O	['N']	[36]
37	as	O	['N']	[37]
38	well	O	['N']	[38]
39	as	O	['N']	[39]
40	the	O	['N']	[40]
41	enoxaparine	O	['N']	[41]
42	Clexane	B-Drug	['Causes']	[10]
43	(	O	['N']	[43]
44	Nattermann	O	['N']	[44]
45	,	O	['N']	[45]
46	Cologne	O	['N']	[46]
47	,	O	['N']	[47]
48	FRG	O	['N']	[48]
49	)	O	['N']	[49]
50	,	O	['N']	[50]
51	all	O	['N']	[51]
52	induced	O	['N']	[52]
53	platelet	O	['N']	[53]
54	activation	O	['N']	[54]
55	with	O	['N']	[55]
56	the	O	['N']	[56]
57	patient	O	['N']	[57]
58	's	O	['N']	[58]
59	serum	O	['N']	[59]
60	.	O	['N']	[60]
#4338
0	The	O	['N']	[0]
1	toxicity	B-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	plasma	O	['N']	[3]
4	concentrations	O	['N']	[4]
5	of	O	['N']	[5]
6	ifosfamide	O	['N']	[6]
7	,	O	['N']	[7]
8	chloroacetaldehyde	B-Drug	['Causes']	[1]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	4-hydroxyifosfamide	O	['N']	[11]
12	were	O	['N']	[12]
13	then	O	['N']	[13]
14	determined	O	['N']	[14]
15	over	O	['N']	[15]
16	24	O	['N']	[16]
17	h	O	['N']	[17]
18	after	O	['N']	[18]
19	a	O	['N']	[19]
20	single	O	['N']	[20]
21	1.6	O	['N']	[21]
22	g	O	['N']	[22]
23	/	O	['N']	[23]
24	m2	O	['N']	[24]
25	dose	O	['N']	[25]
26	of	O	['N']	[26]
27	ifosfamide	O	['N']	[27]
28	.	O	['N']	[28]
#4339
0	The	O	['N']	[0]
1	vomiting	B-Adverse_Effect	['N']	[1]
2	occurred	O	['N']	[2]
3	on	O	['N']	[3]
4	switching	O	['N']	[4]
5	to	O	['N']	[5]
6	different	O	['N']	[6]
7	pancreatic	O	['N']	[7]
8	enzymes	O	['N']	[8]
9	preparations	O	['N']	[9]
10	,	O	['N']	[10]
11	ie	O	['N']	[11]
12	,	O	['N']	[12]
13	Creon	O	['N']	[13]
14	10	O	['N']	[14]
15	,	O	['N']	[15]
16	Viokase	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	Pancrease	B	['N']	[19]
20	MT	I	['N']	[20]
21	16	I-Drug	['Causes']	[1]
22	.	O	['N']	[22]
#4340
0	Cardiopulmonary	B	['N']	[0]
1	arrest	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	intravenous	O	['N']	[3]
4	phenytoin	B-Drug	['Causes']	[1]
5	loading	O	['N']	[5]
6	.	O	['N']	[6]
#4341
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	,	O	['N']	[3]
4	we	O	['N']	[4]
5	describe	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	receiving	O	['N']	[8]
9	lenalidomide	B-Drug	['Causes']	[21]
10	in	O	['N']	[10]
11	whom	O	['N']	[11]
12	dyspnea	O	['N']	[12]
13	,	O	['N']	[13]
14	fever	O	['N']	[14]
15	,	O	['N']	[15]
16	hypoxia	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	diffuse	B	['N']	[19]
20	pulmonary	I	['N']	[20]
21	infiltrates	I-Adverse_Effect	['N']	[21]
22	developed	O	['N']	[22]
23	.	O	['N']	[23]
#4342
0	Excluding	O	['N']	[0]
1	other	O	['N']	[1]
2	causes	O	['N']	[2]
3	,	O	['N']	[3]
4	Pentasa	B-Drug	['Causes']	[7]
5	-	O	['N']	[5]
6	associated	O	['N']	[6]
7	pancytopenia	B-Adverse_Effect	['N']	[7]
8	was	O	['N']	[8]
9	considered	O	['N']	[9]
10	.	O	['N']	[10]
#4343
0	The	O	['N']	[0]
1	probability	O	['N']	[1]
2	of	O	['N']	[2]
3	developing	O	['N']	[3]
4	acute	B	['N']	[4]
5	leukemia	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	this	O	['N']	[7]
8	study	O	['N']	[8]
9	was	O	['N']	[9]
10	not	O	['N']	[10]
11	significantly	O	['N']	[11]
12	correlated	O	['N']	[12]
13	to	O	['N']	[13]
14	the	O	['N']	[14]
15	total	O	['N']	[15]
16	cumulative	O	['N']	[16]
17	dosage	O	['N']	[17]
18	of	O	['N']	[18]
19	Treosulfan	B-Drug	['Causes']	[5]
20	.	O	['N']	[20]
#4344
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	4	O	['N']	[2]
3	patients	O	['N']	[3]
4	,	O	['N']	[4]
5	2	O	['N']	[5]
6	on	O	['N']	[6]
7	methylphenidate	O	['N']	[7]
8	and	O	['N']	[8]
9	2	O	['N']	[9]
10	on	O	['N']	[10]
11	dextroamphetamine	B-Drug	['Causes']	[23]
12	who	O	['N']	[12]
13	presented	O	['N']	[13]
14	with	O	['N']	[14]
15	acral	O	['N']	[15]
16	cyanosis	O	['N']	[16]
17	,	O	['N']	[17]
18	livedo	O	['N']	[18]
19	reticularis	O	['N']	[19]
20	,	O	['N']	[20]
21	or	O	['N']	[21]
22	Raynaud	B	['N']	[22]
23	phenomenon	I-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#4345
0	This	O	['N']	[0]
1	severe	O	['N']	[1]
2	illness	O	['N']	[2]
3	was	O	['N']	[3]
4	likely	O	['N']	[4]
5	caused	O	['N']	[5]
6	by	O	['N']	[6]
7	minocycline	B-Drug	['Causes']	[29]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	we	O	['N']	[10]
11	speculate	O	['N']	[11]
12	that	O	['N']	[12]
13	minocycline	O	['N']	[13]
14	may	O	['N']	[14]
15	have	O	['N']	[15]
16	acted	O	['N']	[16]
17	as	O	['N']	[17]
18	a	O	['N']	[18]
19	superantigen	O	['N']	[19]
20	,	O	['N']	[20]
21	causing	O	['N']	[21]
22	lymphocyte	O	['N']	[22]
23	over	O	['N']	[23]
24	-	O	['N']	[24]
25	activation	O	['N']	[25]
26	and	O	['N']	[26]
27	massive	B	['N']	[27]
28	cytokine	I	['N']	[28]
29	release	I-Adverse_Effect	['N']	[29]
30	.	O	['N']	[30]
#4346
0	After	O	['N']	[0]
1	a	O	['N']	[1]
2	two	O	['N']	[2]
3	-	O	['N']	[3]
4	month	O	['N']	[4]
5	interruption	O	['N']	[5]
6	of	O	['N']	[6]
7	interferon	O	['N']	[7]
8	administration	O	['N']	[8]
9	,	O	['N']	[9]
10	natural	O	['N']	[10]
11	interferon	B	['N']	[11]
12	alpha	I-Drug	['Causes']	[24]
13	was	O	['N']	[13]
14	given	O	['N']	[14]
15	but	O	['N']	[15]
16	followed	O	['N']	[16]
17	by	O	['N']	[17]
18	another	O	['N']	[18]
19	episode	O	['N']	[19]
20	of	O	['N']	[20]
21	the	O	['N']	[21]
22	same	O	['N']	[22]
23	neurological	B	['N']	[23]
24	manifestations	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#4347
0	Nonconvulsive	B	['N']	[0]
1	status	I	['N']	[1]
2	epilepticus	I-Adverse_Effect	['N']	[2]
3	due	O	['N']	[3]
4	to	O	['N']	[4]
5	ifosfamide	B-Drug	['Causes']	[2]
6	.	O	['N']	[6]
#4348
0	A	O	['N']	[0]
1	10-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	girl	O	['N']	[4]
5	with	O	['N']	[5]
6	Lennox	O	['N']	[6]
7	-	O	['N']	[7]
8	Gastaut	O	['N']	[8]
9	syndrome	O	['N']	[9]
10	who	O	['N']	[10]
11	received	O	['N']	[11]
12	intravenous	O	['N']	[12]
13	lorazepam	B-Drug	['Causes']	[18]
14	for	O	['N']	[14]
15	atypical	O	['N']	[15]
16	absence	O	['N']	[16]
17	status	O	['N']	[17]
18	seizures	B-Adverse_Effect	['N']	[18]
19	is	O	['N']	[19]
20	reported	O	['N']	[20]
21	.	O	['N']	[21]
#4349
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Rhabdomyolysis	O	['N']	[2]
3	is	O	['N']	[3]
4	a	O	['N']	[4]
5	clinical	O	['N']	[5]
6	syndrome	O	['N']	[6]
7	resulting	O	['N']	[7]
8	from	O	['N']	[8]
9	the	O	['N']	[9]
10	destruction	O	['N']	[10]
11	of	O	['N']	[11]
12	skeletal	O	['N']	[12]
13	muscle	O	['N']	[13]
14	that	O	['N']	[14]
15	may	O	['N']	[15]
16	progress	O	['N']	[16]
17	to	O	['N']	[17]
18	renal	O	['N']	[18]
19	failure	O	['N']	[19]
20	Several	O	['N']	[20]
21	drugs	O	['N']	[21]
22	have	O	['N']	[22]
23	been	O	['N']	[23]
24	associated	O	['N']	[24]
25	with	O	['N']	[25]
26	rhabdomyolysis	B-Adverse_Effect	['N']	[26]
27	,	O	['N']	[27]
28	including	O	['N']	[28]
29	lovastatin	B-Drug	['Causes']	[26]
30	,	O	['N']	[30]
31	a	O	['N']	[31]
32	hydroxymethylglutaryl	O	['N']	[32]
33	-	O	['N']	[33]
34	coenzyme	O	['N']	[34]
35	A	O	['N']	[35]
36	reductase	O	['N']	[36]
37	inhibitor	O	['N']	[37]
38	.	O	['N']	[38]
#4350
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	linezolid	B-Drug	['Causes']	[22]
4	-	O	['N']	[4]
5	associated	O	['N']	[5]
6	acute	O	['N']	[6]
7	interstitial	O	['N']	[7]
8	nephritis	O	['N']	[8]
9	within	O	['N']	[9]
10	the	O	['N']	[10]
11	context	O	['N']	[11]
12	of	O	['N']	[12]
13	a	O	['N']	[13]
14	drug	O	['N']	[14]
15	rash	O	['N']	[15]
16	with	O	['N']	[16]
17	eosinophilia	O	['N']	[17]
18	and	O	['N']	[18]
19	systemic	O	['N']	[19]
20	symptoms	O	['N']	[20]
21	(	O	['N']	[21]
22	DRESS	B-Adverse_Effect	['N']	[22]
23	)	O	['N']	[23]
24	syndrome	O	['N']	[24]
25	in	O	['N']	[25]
26	a	O	['N']	[26]
27	patient	O	['N']	[27]
28	treated	O	['N']	[28]
29	with	O	['N']	[29]
30	linezolid	O	['N']	[30]
31	raises	O	['N']	[31]
32	concerns	O	['N']	[32]
33	about	O	['N']	[33]
34	the	O	['N']	[34]
35	presumed	O	['N']	[35]
36	renal	O	['N']	[36]
37	safety	O	['N']	[37]
38	of	O	['N']	[38]
39	this	O	['N']	[39]
40	drug	O	['N']	[40]
41	.	O	['N']	[41]
#4351
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	four	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	sensorimotor	B	['N']	[5]
6	axonal	I	['N']	[6]
7	neuropathy	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	children	O	['N']	[9]
10	aged	O	['N']	[10]
11	10	O	['N']	[11]
12	-	O	['N']	[12]
13	15	O	['N']	[13]
14	years	O	['N']	[14]
15	,	O	['N']	[15]
16	treated	O	['N']	[16]
17	with	O	['N']	[17]
18	thalidomide	B-Drug	['Causes']	[7]
19	for	O	['N']	[19]
20	myxopapillary	O	['N']	[20]
21	ependymoma	O	['N']	[21]
22	,	O	['N']	[22]
23	Crohn	O	['N']	[23]
24	's	O	['N']	[24]
25	disease	O	['N']	[25]
26	and	O	['N']	[26]
27	recurrent	O	['N']	[27]
28	giant	O	['N']	[28]
29	aphthous	O	['N']	[29]
30	ulceration	O	['N']	[30]
31	.	O	['N']	[31]
#4352
0	Hyperammonemia	B-Adverse_Effect	['N']	[0]
1	has	O	['N']	[1]
2	been	O	['N']	[2]
3	described	O	['N']	[3]
4	as	O	['N']	[4]
5	a	O	['N']	[5]
6	complication	O	['N']	[6]
7	of	O	['N']	[7]
8	valproic	B	['N']	[8]
9	acid	I-Drug	['Causes']	[0]
10	therapy	O	['N']	[10]
11	but	O	['N']	[11]
12	may	O	['N']	[12]
13	often	O	['N']	[13]
14	be	O	['N']	[14]
15	overlooked	O	['N']	[15]
16	as	O	['N']	[16]
17	a	O	['N']	[17]
18	cause	O	['N']	[18]
19	of	O	['N']	[19]
20	lethargy	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	postictal	O	['N']	[23]
24	patient	O	['N']	[24]
25	who	O	['N']	[25]
26	presents	O	['N']	[26]
27	to	O	['N']	[27]
28	the	O	['N']	[28]
29	emergency	O	['N']	[29]
30	department	O	['N']	[30]
31	.	O	['N']	[31]
#4353
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	that	O	['N']	[4]
5	acute	O	['N']	[5]
6	lamotrigine	B-Drug	['Causes']	[12]
7	poisoning	O	['N']	[7]
8	may	O	['N']	[8]
9	result	O	['N']	[9]
10	in	O	['N']	[10]
11	severe	O	['N']	[11]
12	encephalopathy	B-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#4354
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	flucytosine	B-Drug	['Causes']	[24]
7	-	O	['N']	[7]
8	associated	O	['N']	[8]
9	ulcerating	O	['N']	[9]
10	enteritis	O	['N']	[10]
11	in	O	['N']	[11]
12	which	O	['N']	[12]
13	the	O	['N']	[13]
14	small	O	['N']	[14]
15	bowel	O	['N']	[15]
16	x	O	['N']	[16]
17	-	O	['N']	[17]
18	ray	O	['N']	[18]
19	demonstrated	O	['N']	[19]
20	severe	O	['N']	[20]
21	luminal	O	['N']	[21]
22	narrowing	O	['N']	[22]
23	,	O	['N']	[23]
24	ulceration	B-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	marked	O	['N']	[27]
28	separation	O	['N']	[28]
29	of	O	['N']	[29]
30	loops	O	['N']	[30]
31	of	O	['N']	[31]
32	bowel	O	['N']	[32]
33	.	O	['N']	[33]
#4355
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	is	O	['N']	[2]
3	described	O	['N']	[3]
4	with	O	['N']	[4]
5	the	O	['N']	[5]
6	characteristic	O	['N']	[6]
7	features	O	['N']	[7]
8	of	O	['N']	[8]
9	phenytoin	B-Drug	['Causes']	[16]
10	hypersensitivity	O	['N']	[10]
11	syndrome	O	['N']	[11]
12	(	O	['N']	[12]
13	PHS	O	['N']	[13]
14	)	O	['N']	[14]
15	including	O	['N']	[15]
16	fever	B-Adverse_Effect	['N']	[16]
17	,	O	['N']	[17]
18	erythroderma	O	['N']	[18]
19	,	O	['N']	[19]
20	tibial	O	['N']	[20]
21	and	O	['N']	[21]
22	facial	O	['N']	[22]
23	oedema	O	['N']	[23]
24	,	O	['N']	[24]
25	pinhead	O	['N']	[25]
26	-	O	['N']	[26]
27	sized	O	['N']	[27]
28	facial	O	['N']	[28]
29	pustules	O	['N']	[29]
30	and	O	['N']	[30]
31	abnormal	O	['N']	[31]
32	liver	O	['N']	[32]
33	function	O	['N']	[33]
34	tests	O	['N']	[34]
35	.	O	['N']	[35]
#4356
0	Tacrolimus	B-Drug	['Causes']	[12]
1	(	O	['N']	[1]
2	FK506	O	['N']	[2]
3	)	O	['N']	[3]
4	,	O	['N']	[4]
5	an	O	['N']	[5]
6	immunosuppressant	O	['N']	[6]
7	,	O	['N']	[7]
8	has	O	['N']	[8]
9	been	O	['N']	[9]
10	associated	O	['N']	[10]
11	with	O	['N']	[11]
12	mutism	B-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	adults	O	['N']	[14]
15	after	O	['N']	[15]
16	liver	O	['N']	[16]
17	transplant	O	['N']	[17]
18	.	O	['N']	[18]
#4357
0	Interferon	B	['N']	[0]
1	-	I	['N']	[1]
2	alpha	I-Drug	['Causes']	[5]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	hyperthyroidism	B-Adverse_Effect	['N']	[5]
6	:	O	['N']	[6]
7	a	O	['N']	[7]
8	three	O	['N']	[8]
9	-	O	['N']	[9]
10	stage	O	['N']	[10]
11	evolution	O	['N']	[11]
12	from	O	['N']	[12]
13	silent	O	['N']	[13]
14	thyroiditis	O	['N']	[14]
15	towards	O	['N']	[15]
16	Graves	O	['N']	[16]
17	'	O	['N']	[17]
18	disease	O	['N']	[18]
19	.	O	['N']	[19]
#4358
0	Aplastic	B	['N']	[0]
1	anemia	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	agranulocytosis	O	['N']	[3]
4	in	O	['N']	[4]
5	patients	O	['N']	[5]
6	using	O	['N']	[6]
7	methazolamide	B-Drug	['Causes']	[1]
8	for	O	['N']	[8]
9	glaucoma	O	['N']	[9]
10	.	O	['N']	[10]
#4359
0	He	O	['N']	[0]
1	developed	O	['N']	[1]
2	fever	O	['N']	[2]
3	,	O	['N']	[3]
4	nausea	O	['N']	[4]
5	,	O	['N']	[5]
6	diarrhea	O	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	malaise	B-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	stopped	O	['N']	[11]
12	taking	O	['N']	[12]
13	on	O	['N']	[13]
14	the	O	['N']	[14]
15	third	O	['N']	[15]
16	day	O	['N']	[16]
17	after	O	['N']	[17]
18	commencing	O	['N']	[18]
19	Pentasa	B-Drug	['Causes']	[9]
20	.	O	['N']	[20]
#4360
0	The	O	['N']	[0]
1	relation	O	['N']	[1]
2	between	O	['N']	[2]
3	tacrolimus	B-Drug	['Causes']	[13]
4	treatment	O	['N']	[4]
5	and	O	['N']	[5]
6	staining	O	['N']	[6]
7	was	O	['N']	[7]
8	suggested	O	['N']	[8]
9	by	O	['N']	[9]
10	the	O	['N']	[10]
11	appearance	O	['N']	[11]
12	of	O	['N']	[12]
13	pigmentation	B-Adverse_Effect	['N']	[13]
14	during	O	['N']	[14]
15	topical	O	['N']	[15]
16	tacrolimus	O	['N']	[16]
17	treatment	O	['N']	[17]
18	and	O	['N']	[18]
19	its	O	['N']	[19]
20	clinical	O	['N']	[20]
21	disappearance	O	['N']	[21]
22	when	O	['N']	[22]
23	treatment	O	['N']	[23]
24	was	O	['N']	[24]
25	stopped	O	['N']	[25]
26	.	O	['N']	[26]
#4361
0	We	O	['N']	[0]
1	have	O	['N']	[1]
2	safely	O	['N']	[2]
3	used	O	['N']	[3]
4	recombinant	O	['N']	[4]
5	factor	O	['N']	[5]
6	VIIa	O	['N']	[6]
7	to	O	['N']	[7]
8	treat	O	['N']	[8]
9	bleeding	O	['N']	[9]
10	in	O	['N']	[10]
11	the	O	['N']	[11]
12	immediate	O	['N']	[12]
13	and	O	['N']	[13]
14	long	O	['N']	[14]
15	-	O	['N']	[15]
16	term	O	['N']	[16]
17	period	O	['N']	[17]
18	following	O	['N']	[18]
19	PCC	B-Drug	['Causes']	[22]
20	-	O	['N']	[20]
21	related	O	['N']	[21]
22	MI	B-Adverse_Effect	['N']	[22]
23	.	O	['N']	[23]
#4362
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	chronic	O	['N']	[3]
4	myeloid	O	['N']	[4]
5	leukaemia	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	busulphan	B-Drug	['Causes']	[27]
9	for	O	['N']	[9]
10	4	O	['N']	[10]
11	-	O	['N']	[11]
12	5	O	['N']	[12]
13	years	O	['N']	[13]
14	,	O	['N']	[14]
15	developed	O	['N']	[15]
16	signs	O	['N']	[16]
17	of	O	['N']	[17]
18	busulphan	O	['N']	[18]
19	toxicity	O	['N']	[19]
20	and	O	['N']	[20]
21	portal	O	['N']	[21]
22	hypertension	O	['N']	[22]
23	with	O	['N']	[23]
24	ascites	O	['N']	[24]
25	,	O	['N']	[25]
26	oesophageal	B	['N']	[26]
27	varices	I-Adverse_Effect	['N']	[27]
28	and	O	['N']	[28]
29	jaundice	O	['N']	[29]
30	.	O	['N']	[30]
#4363
0	CASE	O	['N']	[0]
1	PRESENTATION	O	['N']	[1]
2	:	O	['N']	[2]
3	Three	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	Leishmania	O	['N']	[6]
7	infantum	O	['N']	[7]
8	leishmaniasis	O	['N']	[8]
9	in	O	['N']	[9]
10	corticosteroid	O	['N']	[10]
11	(	O	['N']	[11]
12	CS)-treated	-	['N']	[12]
13	patients	O	['N']	[13]
14	are	O	['N']	[14]
15	reported	O	['N']	[15]
16	:	O	['N']	[16]
17	an	O	['N']	[17]
18	isolated	O	['N']	[18]
19	lingual	O	['N']	[19]
20	leishmaniasis	O	['N']	[20]
21	in	O	['N']	[21]
22	a	O	['N']	[22]
23	farmer	O	['N']	[23]
24	treated	O	['N']	[24]
25	with	O	['N']	[25]
26	CS	O	['N']	[26]
27	for	O	['N']	[27]
28	asthma	O	['N']	[28]
29	,	O	['N']	[29]
30	a	O	['N']	[30]
31	severe	O	['N']	[31]
32	visceral	O	['N']	[32]
33	leishmaniasis	O	['N']	[33]
34	associated	O	['N']	[34]
35	with	O	['N']	[35]
36	cutaneous	O	['N']	[36]
37	lesions	O	['N']	[37]
38	in	O	['N']	[38]
39	a	O	['N']	[39]
40	woman	O	['N']	[40]
41	with	O	['N']	[41]
42	myasthenia	O	['N']	[42]
43	gravis	O	['N']	[43]
44	,	O	['N']	[44]
45	and	O	['N']	[45]
46	a	O	['N']	[46]
47	visceral	O	['N']	[47]
48	involvement	O	['N']	[48]
49	after	O	['N']	[49]
50	cutaneous	B	['N']	[50]
51	leishmaniasis	I-Adverse_Effect	['N']	[51]
52	in	O	['N']	[52]
53	a	O	['N']	[53]
54	man	O	['N']	[54]
55	receiving	O	['N']	[55]
56	CS	O	['N']	[56]
57	.	O	['N']	[57]
#4364
0	A	O	['N']	[0]
1	36-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	being	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	cisplatinum	O	['N']	[8]
9	,	O	['N']	[9]
10	vinblastine	B-Drug	['Causes']	[32]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	bleomycin	O	['N']	[13]
14	for	O	['N']	[14]
15	testicular	O	['N']	[15]
16	carcinoma	O	['N']	[16]
17	developed	O	['N']	[17]
18	a	O	['N']	[18]
19	dense	O	['N']	[19]
20	left	O	['N']	[20]
21	homonymous	O	['N']	[21]
22	hemianopsia	O	['N']	[22]
23	,	O	['N']	[23]
24	encephalopathy	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	a	O	['N']	[27]
28	partial	B	['N']	[28]
29	nondominant	I	['N']	[29]
30	parietal	I	['N']	[30]
31	lobe	I	['N']	[31]
32	syndrome	I-Adverse_Effect	['N']	[32]
33	.	O	['N']	[33]
#4365
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	suggests	O	['N']	[2]
3	that	O	['N']	[3]
4	anemia	B-Adverse_Effect	['N']	[4]
5	can	O	['N']	[5]
6	occur	O	['N']	[6]
7	due	O	['N']	[7]
8	to	O	['N']	[8]
9	MMF	B-Drug	['Causes']	[4]
10	,	O	['N']	[10]
11	in	O	['N']	[11]
12	particular	O	['N']	[12]
13	when	O	['N']	[13]
14	it	O	['N']	[14]
15	is	O	['N']	[15]
16	given	O	['N']	[16]
17	with	O	['N']	[17]
18	prednisone	O	['N']	[18]
19	,	O	['N']	[19]
20	a	O	['N']	[20]
21	side	O	['N']	[21]
22	effect	O	['N']	[22]
23	well	O	['N']	[23]
24	documented	O	['N']	[24]
25	in	O	['N']	[25]
26	the	O	['N']	[26]
27	transplantation	O	['N']	[27]
28	literature	O	['N']	[28]
29	when	O	['N']	[29]
30	the	O	['N']	[30]
31	triple	O	['N']	[31]
32	combination	O	['N']	[32]
33	of	O	['N']	[33]
34	MMF	O	['N']	[34]
35	,	O	['N']	[35]
36	cyclosporine	O	['N']	[36]
37	and	O	['N']	[37]
38	prednisone	O	['N']	[38]
39	is	O	['N']	[39]
40	used	O	['N']	[40]
41	.	O	['N']	[41]
#4366
0	The	O	['N']	[0]
1	aim	O	['N']	[1]
2	of	O	['N']	[2]
3	this	O	['N']	[3]
4	report	O	['N']	[4]
5	is	O	['N']	[5]
6	to	O	['N']	[6]
7	describe	O	['N']	[7]
8	the	O	['N']	[8]
9	clinical	O	['N']	[9]
10	and	O	['N']	[10]
11	electroencephalographic	O	['N']	[11]
12	findings	O	['N']	[12]
13	seen	O	['N']	[13]
14	in	O	['N']	[14]
15	an	O	['N']	[15]
16	elderly	O	['N']	[16]
17	woman	O	['N']	[17]
18	without	O	['N']	[18]
19	previous	O	['N']	[19]
20	history	O	['N']	[20]
21	of	O	['N']	[21]
22	seizures	O	['N']	[22]
23	who	O	['N']	[23]
24	developed	O	['N']	[24]
25	a	O	['N']	[25]
26	nonconvulsive	B	['N']	[26]
27	generalized	I	['N']	[27]
28	status	I	['N']	[28]
29	epilepticus	I-Adverse_Effect	['N']	[29]
30	following	O	['N']	[30]
31	acute	O	['N']	[31]
32	withdrawal	O	['N']	[32]
33	of	O	['N']	[33]
34	lorazepam	B-Drug	['Causes']	[29]
35	.	O	['N']	[35]
#4367
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	phenytoin	B-Drug	['Causes']	[8]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	hepatitis	O	['N']	[6]
7	with	O	['N']	[7]
8	mononucleosis	B-Adverse_Effect	['N']	[8]
9	is	O	['N']	[9]
10	reported	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	syndromes	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	phenytoin	O	['N']	[16]
17	hypersensitivity	O	['N']	[17]
18	reactions	O	['N']	[18]
19	are	O	['N']	[19]
20	discussed	O	['N']	[20]
21	.	O	['N']	[21]
#4368
0	These	O	['N']	[0]
1	case	O	['N']	[1]
2	reports	O	['N']	[2]
3	provide	O	['N']	[3]
4	evidence	O	['N']	[4]
5	that	O	['N']	[5]
6	5-aminosalicylic	B	['N']	[6]
7	acid	I-Drug	['Causes']	[11]
8	may	O	['N']	[8]
9	induce	O	['N']	[9]
10	acute	B	['N']	[10]
11	pancreatitis	I-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	long	O	['N']	[13]
14	term	O	['N']	[14]
15	treatment	O	['N']	[15]
16	.	O	['N']	[16]
#4369
0	Anaphylaxis	B-Adverse_Effect	['N']	[0]
1	from	O	['N']	[1]
2	isoniazid	B-Drug	['Causes']	[0]
3	is	O	['N']	[3]
4	a	O	['N']	[4]
5	possible	O	['N']	[5]
6	side	O	['N']	[6]
7	effect	O	['N']	[7]
8	to	O	['N']	[8]
9	this	O	['N']	[9]
10	commonly	O	['N']	[10]
11	prescribed	O	['N']	[11]
12	antibiotic	O	['N']	[12]
13	.	O	['N']	[13]
#4370
0	Tacrolimus	O	['N']	[0]
1	(	O	['N']	[1]
2	FK506)-induced	-	['N']	[2]
3	mutism	B-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	liver	O	['N']	[5]
6	transplant	O	['N']	[6]
7	.	O	['N']	[7]
#4371
0	Rapamycin	O	['N']	[0]
1	/	O	['N']	[1]
2	sirolimus	O	['N']	[2]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	pneumonitis	O	['N']	[5]
6	has	O	['N']	[6]
7	been	O	['N']	[7]
8	described	O	['N']	[8]
9	previously	O	['N']	[9]
10	in	O	['N']	[10]
11	renal	O	['N']	[11]
12	transplant	O	['N']	[12]
13	recipients	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	this	O	['N']	[16]
17	report	O	['N']	[17]
18	describes	O	['N']	[18]
19	a	O	['N']	[19]
20	stable	O	['N']	[20]
21	heart	O	['N']	[21]
22	-	O	['N']	[22]
23	lung	O	['N']	[23]
24	transplant	O	['N']	[24]
25	recipient	O	['N']	[25]
26	who	O	['N']	[26]
27	developed	O	['N']	[27]
28	a	O	['N']	[28]
29	pulmonary	B	['N']	[29]
30	infiltrate	I-Adverse_Effect	['N']	[30]
31	that	O	['N']	[31]
32	reversed	O	['N']	[32]
33	after	O	['N']	[33]
34	ceasing	O	['N']	[34]
35	SR	B-Drug	['Causes']	[30]
36	therapy	O	['N']	[36]
37	.	O	['N']	[37]
#4372
0	The	O	['N']	[0]
1	day	O	['N']	[1]
2	after	O	['N']	[2]
3	clozapine	B-Drug	['Causes']	[21]
4	was	O	['N']	[4]
5	stopped	O	['N']	[5]
6	,	O	['N']	[6]
7	while	O	['N']	[7]
8	he	O	['N']	[8]
9	was	O	['N']	[9]
10	still	O	['N']	[10]
11	receiving	O	['N']	[11]
12	clomipramine	O	['N']	[12]
13	150	O	['N']	[13]
14	mg	O	['N']	[14]
15	/	O	['N']	[15]
16	d	O	['N']	[16]
17	,	O	['N']	[17]
18	he	O	['N']	[18]
19	began	O	['N']	[19]
20	behaving	B	['N']	[20]
21	oddly	I-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	started	O	['N']	[23]
24	sweating	O	['N']	[24]
25	profusely	O	['N']	[25]
26	,	O	['N']	[26]
27	shivering	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	became	O	['N']	[30]
31	tremulous	O	['N']	[31]
32	,	O	['N']	[32]
33	agitated	O	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	confused	O	['N']	[36]
37	.	O	['N']	[37]
#4373
0	Correction	O	['N']	[0]
1	of	O	['N']	[1]
2	serum	O	['N']	[2]
3	electrolyte	O	['N']	[3]
4	imbalance	O	['N']	[4]
5	prevents	O	['N']	[5]
6	cardiac	B	['N']	[6]
7	arrhythmia	I-Adverse_Effect	['N']	[7]
8	during	O	['N']	[8]
9	amphotericin	B	['N']	[9]
10	B	I-Drug	['Causes']	[7]
11	administration	O	['N']	[11]
12	.	O	['N']	[12]
#4374
0	The	O	['N']	[0]
1	use	O	['N']	[1]
2	of	O	['N']	[2]
3	methotrexate	B-Drug	['Causes']	[37]
4	(	O	['N']	[4]
5	MTX	O	['N']	[5]
6	)	O	['N']	[6]
7	has	O	['N']	[7]
8	been	O	['N']	[8]
9	contraindicated	O	['N']	[9]
10	for	O	['N']	[10]
11	treatment	O	['N']	[11]
12	of	O	['N']	[12]
13	severe	O	['N']	[13]
14	psoriasis	O	['N']	[14]
15	in	O	['N']	[15]
16	HIV	O	['N']	[16]
17	infection	O	['N']	[17]
18	on	O	['N']	[18]
19	the	O	['N']	[19]
20	basis	O	['N']	[20]
21	of	O	['N']	[21]
22	six	O	['N']	[22]
23	previously	O	['N']	[23]
24	reported	O	['N']	[24]
25	cases	O	['N']	[25]
26	in	O	['N']	[26]
27	which	O	['N']	[27]
28	MTX	O	['N']	[28]
29	appeared	O	['N']	[29]
30	to	O	['N']	[30]
31	potentiate	O	['N']	[31]
32	opportunistic	O	['N']	[32]
33	infections	O	['N']	[33]
34	and	O	['N']	[34]
35	accelerate	B	['N']	[35]
36	HIV	I	['N']	[36]
37	disease	I-Adverse_Effect	['N']	[37]
38	.	O	['N']	[38]
#4375
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	was	O	['N']	[2]
3	found	O	['N']	[3]
4	to	O	['N']	[4]
5	have	O	['N']	[5]
6	no	B	['N']	[6]
7	motile	I	['N']	[7]
8	sperm	I-Adverse_Effect	['N']	[8]
9	with	O	['N']	[9]
10	a	O	['N']	[10]
11	normal	O	['N']	[11]
12	sperm	O	['N']	[12]
13	count	O	['N']	[13]
14	,	O	['N']	[14]
15	while	O	['N']	[15]
16	taking	O	['N']	[16]
17	a	O	['N']	[17]
18	dose	O	['N']	[18]
19	of	O	['N']	[19]
20	400	O	['N']	[20]
21	mg	O	['N']	[21]
22	/	O	['N']	[22]
23	day	O	['N']	[23]
24	of	O	['N']	[24]
25	carbamazepine	B-Drug	['Causes']	[8]
26	.	O	['N']	[26]
#4376
0	Flecainide	B-Drug	['Causes']	[7]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	pneumonitis	O	['N']	[3]
4	with	O	['N']	[4]
5	acute	B	['N']	[5]
6	respiratory	I	['N']	[6]
7	failure	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	patient	O	['N']	[10]
11	with	O	['N']	[11]
12	the	O	['N']	[12]
13	LEOPARD	O	['N']	[13]
14	syndrome	O	['N']	[14]
15	.	O	['N']	[15]
#4377
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	ovarian	O	['N']	[3]
4	cancer	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	received	O	['N']	[7]
8	multiple	O	['N']	[8]
9	courses	O	['N']	[9]
10	of	O	['N']	[10]
11	cisplatin	B-Drug	['Causes']	[16]
12	without	O	['N']	[12]
13	complications	O	['N']	[13]
14	experienced	O	['N']	[14]
15	hypersensitivity	B	['N']	[15]
16	reactions	I-Adverse_Effect	['N']	[16]
17	to	O	['N']	[17]
18	cisplatin	O	['N']	[18]
19	:	O	['N']	[19]
20	one	O	['N']	[20]
21	,	O	['N']	[21]
22	involving	O	['N']	[22]
23	intrahepatic	O	['N']	[23]
24	artery	O	['N']	[24]
25	infusion	O	['N']	[25]
26	,	O	['N']	[26]
27	manifested	O	['N']	[27]
28	general	O	['N']	[28]
29	erythema	O	['N']	[29]
30	,	O	['N']	[30]
31	dyspnea	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	hypotension	O	['N']	[34]
35	;	O	['N']	[35]
36	the	O	['N']	[36]
37	other	O	['N']	[37]
38	,	O	['N']	[38]
39	involving	O	['N']	[39]
40	intravenous	O	['N']	[40]
41	infusion	O	['N']	[41]
42	,	O	['N']	[42]
43	manifested	O	['N']	[43]
44	abdominal	O	['N']	[44]
45	pain	O	['N']	[45]
46	,	O	['N']	[46]
47	general	O	['N']	[47]
48	erythema	O	['N']	[48]
49	,	O	['N']	[49]
50	and	O	['N']	[50]
51	fever	O	['N']	[51]
52	.	O	['N']	[52]
#4378
0	A	O	['N']	[0]
1	21-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	suffering	O	['N']	[5]
6	from	O	['N']	[6]
7	bipolar	O	['N']	[7]
8	affective	O	['N']	[8]
9	disorder	O	['N']	[9]
10	developed	O	['N']	[10]
11	systemic	B	['N']	[11]
12	lupus	I	['N']	[12]
13	erythematosus	I-Adverse_Effect	['N']	[13]
14	(	O	['N']	[14]
15	SLE	O	['N']	[15]
16	)	O	['N']	[16]
17	with	O	['N']	[17]
18	characteristic	O	['N']	[18]
19	laboratory	O	['N']	[19]
20	findings	O	['N']	[20]
21	,	O	['N']	[21]
22	18	O	['N']	[22]
23	months	O	['N']	[23]
24	after	O	['N']	[24]
25	starting	O	['N']	[25]
26	carbamazepine	B-Drug	['Causes']	[13]
27	maintenance	O	['N']	[27]
28	treatment	O	['N']	[28]
29	.	O	['N']	[29]
#4379
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	article	O	['N']	[2]
3	,	O	['N']	[3]
4	we	O	['N']	[4]
5	describe	O	['N']	[5]
6	another	O	['N']	[6]
7	case	O	['N']	[7]
8	of	O	['N']	[8]
9	subcutaneous	O	['N']	[9]
10	changes	O	['N']	[10]
11	following	O	['N']	[11]
12	repeated	O	['N']	[12]
13	glatiramer	B	['N']	[13]
14	acetate	I-Drug	['Causes']	[20]
15	injection	O	['N']	[15]
16	,	O	['N']	[16]
17	presented	O	['N']	[17]
18	as	O	['N']	[18]
19	localized	B	['N']	[19]
20	panniculitis	I-Adverse_Effect	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	area	O	['N']	[23]
24	around	O	['N']	[24]
25	the	O	['N']	[25]
26	injection	O	['N']	[26]
27	sites	O	['N']	[27]
28	,	O	['N']	[28]
29	in	O	['N']	[29]
30	a	O	['N']	[30]
31	46-year	O	['N']	[31]
32	-	O	['N']	[32]
33	old	O	['N']	[33]
34	female	O	['N']	[34]
35	patient	O	['N']	[35]
36	who	O	['N']	[36]
37	was	O	['N']	[37]
38	treated	O	['N']	[38]
39	with	O	['N']	[39]
40	glatiramer	O	['N']	[40]
41	acetate	O	['N']	[41]
42	for	O	['N']	[42]
43	18	O	['N']	[43]
44	months	O	['N']	[44]
45	.	O	['N']	[45]
#4380
0	Mechanism	O	['N']	[0]
1	of	O	['N']	[1]
2	topiramate	B-Drug	['Causes']	[12]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	acute	O	['N']	[5]
6	-	O	['N']	[6]
7	onset	O	['N']	[7]
8	myopia	O	['N']	[8]
9	and	O	['N']	[9]
10	angle	B	['N']	[10]
11	closure	I	['N']	[11]
12	glaucoma	I-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#4381
0	A	O	['N']	[0]
1	14-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	developed	O	['N']	[5]
6	systemic	B	['N']	[6]
7	lupus	I	['N']	[7]
8	erythematosus	I	['N']	[8]
9	(	I	['N']	[9]
10	SLE)-like	I	['N']	[10]
11	symptoms	I-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	rash	O	['N']	[13]
14	,	O	['N']	[14]
15	fever	O	['N']	[15]
16	,	O	['N']	[16]
17	leukopenia	O	['N']	[17]
18	and	O	['N']	[18]
19	positive	O	['N']	[19]
20	anti	O	['N']	[20]
21	-	O	['N']	[21]
22	nuclear	O	['N']	[22]
23	antibody	O	['N']	[23]
24	(	O	['N']	[24]
25	ANA	O	['N']	[25]
26	)	O	['N']	[26]
27	two	O	['N']	[27]
28	weeks	O	['N']	[28]
29	after	O	['N']	[29]
30	administration	O	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	B-Drug	['Causes']	[11]
33	(	O	['N']	[33]
34	CBZ	O	['N']	[34]
35	;	O	['N']	[35]
36	Tegretol	O	['N']	[36]
37	)	O	['N']	[37]
38	used	O	['N']	[38]
39	against	O	['N']	[39]
40	benign	O	['N']	[40]
41	Rolandic	O	['N']	[41]
42	epilepsy	O	['N']	[42]
43	.	O	['N']	[43]
#4382
0	The	O	['N']	[0]
1	present	O	['N']	[1]
2	report	O	['N']	[2]
3	suggests	O	['N']	[3]
4	that	O	['N']	[4]
5	clarithromycin	B-Drug	['Causes']	[10]
6	coadministration	O	['N']	[6]
7	induces	O	['N']	[7]
8	increased	B	['N']	[8]
9	plasma	I	['N']	[9]
10	carbamazepine	I-Adverse_Effect	['N']	[10]
11	concentrations	O	['N']	[11]
12	,	O	['N']	[12]
13	which	O	['N']	[13]
14	may	O	['N']	[14]
15	result	O	['N']	[15]
16	in	O	['N']	[16]
17	carbamazepine	O	['N']	[17]
18	toxicity	O	['N']	[18]
19	.	O	['N']	[19]
#4383
0	Tamoxifen	B-Drug	['Causes']	[5]
1	is	O	['N']	[1]
2	suggested	O	['N']	[2]
3	to	O	['N']	[3]
4	be	O	['N']	[4]
5	carcinogenic	B-Adverse_Effect	['N']	[5]
6	both	O	['N']	[6]
7	through	O	['N']	[7]
8	direct	O	['N']	[8]
9	genotoxic	O	['N']	[9]
10	and	O	['N']	[10]
11	epigenetic	O	['N']	[11]
12	mechanisms	O	['N']	[12]
13	.	O	['N']	[13]
#4384
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Sustained	O	['N']	[2]
3	-	O	['N']	[3]
4	release	O	['N']	[4]
5	verapamil	B-Drug	['Causes']	[15]
6	is	O	['N']	[6]
7	thought	O	['N']	[7]
8	to	O	['N']	[8]
9	be	O	['N']	[9]
10	the	O	['N']	[10]
11	cause	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	asthma	B	['N']	[14]
15	attack	I-Adverse_Effect	['N']	[15]
16	in	O	['N']	[16]
17	this	O	['N']	[17]
18	patient	O	['N']	[18]
19	because	O	['N']	[19]
20	she	O	['N']	[20]
21	was	O	['N']	[21]
22	not	O	['N']	[22]
23	taking	O	['N']	[23]
24	any	O	['N']	[24]
25	other	O	['N']	[25]
26	preparations	O	['N']	[26]
27	;	O	['N']	[27]
28	the	O	['N']	[28]
29	symptoms	O	['N']	[29]
30	started	O	['N']	[30]
31	with	O	['N']	[31]
32	the	O	['N']	[32]
33	administration	O	['N']	[33]
34	of	O	['N']	[34]
35	sustained	O	['N']	[35]
36	-	O	['N']	[36]
37	release	O	['N']	[37]
38	verapamil	O	['N']	[38]
39	and	O	['N']	[39]
40	were	O	['N']	[40]
41	relieved	O	['N']	[41]
42	after	O	['N']	[42]
43	its	O	['N']	[43]
44	discontinuation	O	['N']	[44]
45	.	O	['N']	[45]
#4385
0	Serious	B	['N']	[0]
1	adverse	I	['N']	[1]
2	events	I-Adverse_Effect	['N']	[2]
3	experienced	O	['N']	[3]
4	by	O	['N']	[4]
5	patients	O	['N']	[5]
6	with	O	['N']	[6]
7	chronic	O	['N']	[7]
8	heart	O	['N']	[8]
9	failure	O	['N']	[9]
10	taking	O	['N']	[10]
11	spironolactone	B-Drug	['Causes']	[2]
12	.	O	['N']	[12]
#4386
0	While	O	['N']	[0]
1	most	O	['N']	[1]
2	physicians	O	['N']	[2]
3	are	O	['N']	[3]
4	aware	O	['N']	[4]
5	of	O	['N']	[5]
6	heparin	B-Drug	['Causes']	[9]
7	-	O	['N']	[7]
8	induced	O	['N']	[8]
9	thrombocytopenia	B-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	skin	O	['N']	[11]
12	necrosis	O	['N']	[12]
13	,	O	['N']	[13]
14	the	O	['N']	[14]
15	association	O	['N']	[15]
16	of	O	['N']	[16]
17	heparin	O	['N']	[17]
18	and	O	['N']	[18]
19	hyperkalemia	O	['N']	[19]
20	is	O	['N']	[20]
21	less	O	['N']	[21]
22	well	O	['N']	[22]
23	recognized	O	['N']	[23]
24	.	O	['N']	[24]
#4387
0	Acute	B	['N']	[0]
1	unilateral	I	['N']	[1]
2	total	I	['N']	[2]
3	visual	I	['N']	[3]
4	loss	I-Adverse_Effect	['N']	[4]
5	after	O	['N']	[5]
6	retrogasserian	O	['N']	[6]
7	phenol	B-Drug	['Causes']	[4]
8	injection	O	['N']	[8]
9	for	O	['N']	[9]
10	the	O	['N']	[10]
11	treatment	O	['N']	[11]
12	of	O	['N']	[12]
13	trigeminal	O	['N']	[13]
14	neuralgia	O	['N']	[14]
15	:	O	['N']	[15]
16	a	O	['N']	[16]
17	case	O	['N']	[17]
18	report	O	['N']	[18]
19	.	O	['N']	[19]
#4388
0	Thrombo	B	['N']	[0]
1	-	I	['N']	[1]
2	embolic	I	['N']	[2]
3	complication	I-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	streptokinase	B-Drug	['Causes']	[3]
6	therapy	O	['N']	[6]
7	of	O	['N']	[7]
8	pulmonary	O	['N']	[8]
9	emboli	O	['N']	[9]
10	.	O	['N']	[10]
#4389
0	Near	B	['N']	[0]
1	fatal	I-Adverse_Effect	['N']	[1]
2	acute	O	['N']	[2]
3	colchicine	B-Drug	['Causes']	[1]
4	intoxication	O	['N']	[4]
5	in	O	['N']	[5]
6	a	O	['N']	[6]
7	child	O	['N']	[7]
8	.	O	['N']	[8]
#4390
0	We	O	['N']	[0]
1	discuss	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	severe	B	['N']	[6]
7	renal	I	['N']	[7]
8	tubular	I	['N']	[8]
9	dysfunction	I-Adverse_Effect	['N']	[9]
10	secondary	O	['N']	[10]
11	to	O	['N']	[11]
12	short	O	['N']	[12]
13	-	O	['N']	[13]
14	term	O	['N']	[14]
15	therapy	O	['N']	[15]
16	with	O	['N']	[16]
17	Amikacin	B-Drug	['Causes']	[9]
18	,	O	['N']	[18]
19	resulting	O	['N']	[19]
20	in	O	['N']	[20]
21	refractory	O	['N']	[21]
22	hypokalemia	O	['N']	[22]
23	,	O	['N']	[23]
24	hypocalcemia	O	['N']	[24]
25	,	O	['N']	[25]
26	hypomagnesemia	O	['N']	[26]
27	,	O	['N']	[27]
28	metabolic	O	['N']	[28]
29	alkalosis	O	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	polyuria	O	['N']	[32]
33	.	O	['N']	[33]
#4391
0	Severe	B	['N']	[0]
1	acidosis	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	patients	O	['N']	[3]
4	taking	O	['N']	[4]
5	metformin	B-Drug	['Causes']	[1]
6	--	O	['N']	[6]
7	rapid	O	['N']	[7]
8	reversal	O	['N']	[8]
9	and	O	['N']	[9]
10	survival	O	['N']	[10]
11	despite	O	['N']	[11]
12	high	O	['N']	[12]
13	APACHE	O	['N']	[13]
14	score	O	['N']	[14]
15	.	O	['N']	[15]
#4392
0	This	O	['N']	[0]
1	paper	O	['N']	[1]
2	reports	O	['N']	[2]
3	on	O	['N']	[3]
4	a	O	['N']	[4]
5	6.9-year	O	['N']	[5]
6	-	O	['N']	[6]
7	old	O	['N']	[7]
8	autistic	O	['N']	[8]
9	male	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	repeated	O	['N']	[12]
13	episodes	O	['N']	[13]
14	of	O	['N']	[14]
15	acute	O	['N']	[15]
16	dystonic	O	['N']	[16]
17	reactions	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	pimozide	B-Drug	['Dosage']	[38]
21	administration	O	['N']	[21]
22	at	O	['N']	[22]
23	the	O	['N']	[23]
24	doses	O	['N']	[24]
25	of	O	['N']	[25]
26	0.096	O	['N']	[26]
27	mg	O	['N']	[27]
28	/	O	['N']	[28]
29	kg	O	['N']	[29]
30	/	O	['N']	[30]
31	day	O	['N']	[31]
32	and	O	['N']	[32]
33	0.032	B	['N']	[33]
34	mg	I	['N']	[34]
35	/	I	['N']	[35]
36	kg	I	['N']	[36]
37	/	I	['N']	[37]
38	day	I-Dose	['N']	[38]
39	and	O	['N']	[39]
40	32	O	['N']	[40]
41	hours	O	['N']	[41]
42	following	O	['N']	[42]
43	pimozide	O	['N']	[43]
44	withdrawal	O	['N']	[44]
45	,	O	['N']	[45]
46	as	O	['N']	[46]
47	well	O	['N']	[47]
48	as	O	['N']	[48]
49	during	O	['N']	[49]
50	subsequent	O	['N']	[50]
51	thioridazine	O	['N']	[51]
52	administration	O	['N']	[52]
53	.	O	['N']	[53]
#4393
0	The	O	['N']	[0]
1	Naranjo	O	['N']	[1]
2	probability	O	['N']	[2]
3	scale	O	['N']	[3]
4	indicated	O	['N']	[4]
5	a	O	['N']	[5]
6	probable	O	['N']	[6]
7	relationship	O	['N']	[7]
8	between	O	['N']	[8]
9	apnea	B-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	exposure	O	['N']	[11]
12	to	O	['N']	[12]
13	lamotrigine	B-Drug	['Causes']	[9]
14	through	O	['N']	[14]
15	breast	O	['N']	[15]
16	-	O	['N']	[16]
17	feeding	O	['N']	[17]
18	in	O	['N']	[18]
19	this	O	['N']	[19]
20	infant	O	['N']	[20]
21	.	O	['N']	[21]
#4394
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	treated	O	['N']	[2]
3	with	O	['N']	[3]
4	5-fluorouracil	B-Drug	['Causes']	[20]
5	(	O	['N']	[5]
6	5-FU	O	['N']	[6]
7	)	O	['N']	[7]
8	for	O	['N']	[8]
9	disseminated	O	['N']	[9]
10	adenocarcinoma	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	colon	O	['N']	[13]
14	developed	O	['N']	[14]
15	cerebellar	O	['N']	[15]
16	dysfunction	O	['N']	[16]
17	typical	O	['N']	[17]
18	of	O	['N']	[18]
19	5-FU	O	['N']	[19]
20	neurotoxicity	B-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#4395
0	The	O	['N']	[0]
1	second	O	['N']	[1]
2	patient	O	['N']	[2]
3	developed	O	['N']	[3]
4	both	O	['N']	[4]
5	autoimmune	O	['N']	[5]
6	thyroid	O	['N']	[6]
7	disease	O	['N']	[7]
8	and	O	['N']	[8]
9	a	O	['N']	[9]
10	refractory	B	['N']	[10]
11	pre	I	['N']	[11]
12	-	I	['N']	[12]
13	patellar	I	['N']	[13]
14	bursitis	I-Adverse_Effect	['N']	[14]
15	after	O	['N']	[15]
16	50	O	['N']	[16]
17	months	O	['N']	[17]
18	of	O	['N']	[18]
19	IFN	B	['N']	[19]
20	-	I	['N']	[20]
21	beta	I-Drug	['Causes']	[14]
22	therapy	O	['N']	[22]
23	.	O	['N']	[23]
#4396
0	A	O	['N']	[0]
1	toxic	O	['N']	[1]
2	encephalopathy	O	['N']	[2]
3	characterized	O	['N']	[3]
4	by	O	['N']	[4]
5	depressed	O	['N']	[5]
6	level	O	['N']	[6]
7	of	O	['N']	[7]
8	consciousness	O	['N']	[8]
9	,	O	['N']	[9]
10	marked	O	['N']	[10]
11	irritability	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	ataxia	B-Adverse_Effect	['N']	[14]
15	developed	O	['N']	[15]
16	in	O	['N']	[16]
17	seven	O	['N']	[17]
18	children	O	['N']	[18]
19	,	O	['N']	[19]
20	5	O	['N']	[20]
21	years	O	['N']	[21]
22	of	O	['N']	[22]
23	age	O	['N']	[23]
24	and	O	['N']	[24]
25	younger	O	['N']	[25]
26	,	O	['N']	[26]
27	following	O	['N']	[27]
28	administration	O	['N']	[28]
29	of	O	['N']	[29]
30	an	O	['N']	[30]
31	antiemetic	O	['N']	[31]
32	combination	O	['N']	[32]
33	of	O	['N']	[33]
34	pentobarbital	B-Drug	['Causes']	[14]
35	and	O	['N']	[35]
36	pyrilamine	O	['N']	[36]
37	maleate	O	['N']	[37]
38	.	O	['N']	[38]
#4397
0	Lithium	B-Drug	['Causes']	[7]
1	is	O	['N']	[1]
2	known	O	['N']	[2]
3	to	O	['N']	[3]
4	cause	O	['N']	[4]
5	acute	B	['N']	[5]
6	renal	I	['N']	[6]
7	failure	I-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	tubulo	O	['N']	[9]
10	-	O	['N']	[10]
11	interstitial	O	['N']	[11]
12	disease	O	['N']	[12]
13	,	O	['N']	[13]
14	but	O	['N']	[14]
15	the	O	['N']	[15]
16	recently	O	['N']	[16]
17	described	O	['N']	[17]
18	association	O	['N']	[18]
19	with	O	['N']	[19]
20	proteinuria	O	['N']	[20]
21	or	O	['N']	[21]
22	nephrotic	O	['N']	[22]
23	syndrome	O	['N']	[23]
24	is	O	['N']	[24]
25	little	O	['N']	[25]
26	recognized	O	['N']	[26]
27	.	O	['N']	[27]
#4398
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	drug	O	['N']	[5]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	pemphigus	B-Adverse_Effect	['N']	[8]
9	caused	O	['N']	[9]
10	by	O	['N']	[10]
11	an	O	['N']	[11]
12	angiotensin	O	['N']	[12]
13	-	O	['N']	[13]
14	converting	O	['N']	[14]
15	enzyme	O	['N']	[15]
16	inhibitor	O	['N']	[16]
17	,	O	['N']	[17]
18	captopril	B-Drug	['Causes']	[8]
19	.	O	['N']	[19]
#4399
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	,	O	['N']	[2]
3	in	O	['N']	[3]
4	whom	O	['N']	[4]
5	tumour	O	['N']	[5]
6	overkill	O	['N']	[6]
7	by	O	['N']	[7]
8	cytotoxic	O	['N']	[8]
9	treatment	O	['N']	[9]
10	,	O	['N']	[10]
11	including	O	['N']	[11]
12	high	O	['N']	[12]
13	dose	O	['N']	[13]
14	methotrexate	B-Drug	['Causes']	[35]
15	with	O	['N']	[15]
16	folinic	O	['N']	[16]
17	acid	O	['N']	[17]
18	rescue	O	['N']	[18]
19	,	O	['N']	[19]
20	resulted	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	'	O	['N']	[23]
24	phosphate	O	['N']	[24]
25	shower	O	['N']	[25]
26	syndrome	O	['N']	[26]
27	'	O	['N']	[27]
28	(	O	['N']	[28]
29	hyper	O	['N']	[29]
30	-	O	['N']	[30]
31	uricaemia	O	['N']	[31]
32	,	O	['N']	[32]
33	hyperkalaemia	O	['N']	[33]
34	and	O	['N']	[34]
35	hyperphosphataemia	B-Adverse_Effect	['N']	[35]
36	with	O	['N']	[36]
37	hypocalcaemia	O	['N']	[37]
38	and	O	['N']	[38]
39	tetany	O	['N']	[39]
40	,	O	['N']	[40]
41	with	O	['N']	[41]
42	metabolic	O	['N']	[42]
43	acidosis	O	['N']	[43]
44	and	O	['N']	[44]
45	acute	O	['N']	[45]
46	renal	O	['N']	[46]
47	impairment	O	['N']	[47]
48	)	O	['N']	[48]
49	are	O	['N']	[49]
50	described	O	['N']	[50]
51	.	O	['N']	[51]
#4400
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	intend	O	['N']	[2]
3	to	O	['N']	[3]
4	carry	O	['N']	[4]
5	out	O	['N']	[5]
6	a	O	['N']	[6]
7	case	O	['N']	[7]
8	-	O	['N']	[8]
9	control	O	['N']	[9]
10	study	O	['N']	[10]
11	on	O	['N']	[11]
12	patients	O	['N']	[12]
13	treated	O	['N']	[13]
14	with	O	['N']	[14]
15	tamoxifen	B-Drug	['Causes']	[26]
16	for	O	['N']	[16]
17	breast	O	['N']	[17]
18	carcinoma	O	['N']	[18]
19	to	O	['N']	[19]
20	reveal	O	['N']	[20]
21	the	O	['N']	[21]
22	possible	O	['N']	[22]
23	presence	O	['N']	[23]
24	of	O	['N']	[24]
25	endometrial	B	['N']	[25]
26	carcinoma	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#4401
0	Seizures	O	['N']	[0]
1	and	O	['N']	[1]
2	extrapyramidal	B	['N']	[2]
3	symptoms	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	Tourette	O	['N']	[8]
9	's	O	['N']	[9]
10	syndrome	O	['N']	[10]
11	,	O	['N']	[11]
12	Asperger	O	['N']	[12]
13	's	O	['N']	[13]
14	syndrome	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	multiple	O	['N']	[17]
18	sclerosis	O	['N']	[18]
19	treated	O	['N']	[19]
20	with	O	['N']	[20]
21	interferon	O	['N']	[21]
22	beta-1a	O	['N']	[22]
23	and	O	['N']	[23]
24	clomipramine	B-Drug	['Causes']	[3]
25	.	O	['N']	[25]
#4402
0	Prominent	O	['N']	[0]
1	positive	O	['N']	[1]
2	U	O	['N']	[2]
3	waves	O	['N']	[3]
4	appearing	O	['N']	[4]
5	with	O	['N']	[5]
6	high	B	['N']	[6]
7	-	I	['N']	[7]
8	dose	I-Dose	['N']	[8]
9	intravenous	O	['N']	[9]
10	phenylephrine	B-Drug	['Dosage']	[8]
11	.	O	['N']	[11]
#4403
0	A	O	['N']	[0]
1	dapsone	B-Drug	['Causes']	[13]
2	hypersensitivity	O	['N']	[2]
3	syndrome	O	['N']	[3]
4	,	O	['N']	[4]
5	consisting	O	['N']	[5]
6	of	O	['N']	[6]
7	fever	O	['N']	[7]
8	,	O	['N']	[8]
9	headache	O	['N']	[9]
10	,	O	['N']	[10]
11	nausea	O	['N']	[11]
12	,	O	['N']	[12]
13	vomiting	B-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	lymphadenopathy	O	['N']	[15]
16	,	O	['N']	[16]
17	hepatitis	O	['N']	[17]
18	,	O	['N']	[18]
19	hemolysis	O	['N']	[19]
20	,	O	['N']	[20]
21	leukopenia	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	mononucleosis	O	['N']	[24]
25	,	O	['N']	[25]
26	has	O	['N']	[26]
27	been	O	['N']	[27]
28	described	O	['N']	[28]
29	in	O	['N']	[29]
30	patients	O	['N']	[30]
31	treated	O	['N']	[31]
32	with	O	['N']	[32]
33	the	O	['N']	[33]
34	drug	O	['N']	[34]
35	for	O	['N']	[35]
36	leprosy	O	['N']	[36]
37	.	O	['N']	[37]
#4404
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	two	O	['N']	[2]
3	dark	O	['N']	[3]
4	-	O	['N']	[4]
5	skinned	O	['N']	[5]
6	patients	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	hyperpigmented	O	['N']	[9]
10	skin	O	['N']	[10]
11	and	O	['N']	[11]
12	tongue	B	['N']	[12]
13	lesions	I-Adverse_Effect	['N']	[13]
14	during	O	['N']	[14]
15	combination	O	['N']	[15]
16	therapy	O	['N']	[16]
17	with	O	['N']	[17]
18	IFN	B-Drug	['Causes']	[13]
19	and	O	['N']	[19]
20	ribavirin	O	['N']	[20]
21	.	O	['N']	[21]
#4405
0	There	O	['N']	[0]
1	have	O	['N']	[1]
2	been	O	['N']	[2]
3	more	O	['N']	[3]
4	than	O	['N']	[4]
5	20	O	['N']	[5]
6	observations	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	appearance	O	['N']	[9]
10	or	O	['N']	[10]
11	aggravation	O	['N']	[11]
12	of	O	['N']	[12]
13	this	O	['N']	[13]
14	granulomatosis	B-Adverse_Effect	['N']	[14]
15	with	O	['N']	[15]
16	interferon	B	['N']	[16]
17	alfa	I-Drug	['Causes']	[14]
18	and	O	['N']	[18]
19	more	O	['N']	[19]
20	recently	O	['N']	[20]
21	with	O	['N']	[21]
22	the	O	['N']	[22]
23	combination	O	['N']	[23]
24	of	O	['N']	[24]
25	interferon	O	['N']	[25]
26	alfa	O	['N']	[26]
27	plus	O	['N']	[27]
28	ribavirin	O	['N']	[28]
29	.	O	['N']	[29]
#4406
0	The	O	['N']	[0]
1	reported	O	['N']	[1]
2	case	O	['N']	[2]
3	represents	O	['N']	[3]
4	an	O	['N']	[4]
5	unusual	O	['N']	[5]
6	association	O	['N']	[6]
7	between	O	['N']	[7]
8	medication	O	['N']	[8]
9	with	O	['N']	[9]
10	the	O	['N']	[10]
11	proton	O	['N']	[11]
12	pump	O	['N']	[12]
13	inhibitor	O	['N']	[13]
14	lansoprazole	B-Drug	['Causes']	[20]
15	and	O	['N']	[15]
16	the	O	['N']	[16]
17	development	O	['N']	[17]
18	of	O	['N']	[18]
19	collagenous	B	['N']	[19]
20	colitis	I-Adverse_Effect	['N']	[20]
21	suggesting	O	['N']	[21]
22	the	O	['N']	[22]
23	importance	O	['N']	[23]
24	of	O	['N']	[24]
25	evaluation	O	['N']	[25]
26	of	O	['N']	[26]
27	drug	O	['N']	[27]
28	use	O	['N']	[28]
29	in	O	['N']	[29]
30	patients	O	['N']	[30]
31	with	O	['N']	[31]
32	microscopic	O	['N']	[32]
33	colitis	O	['N']	[33]
34	.	O	['N']	[34]
#4407
0	The	O	['N']	[0]
1	vomiting	B-Adverse_Effect	['N']	[1]
2	occurred	O	['N']	[2]
3	on	O	['N']	[3]
4	switching	O	['N']	[4]
5	to	O	['N']	[5]
6	different	O	['N']	[6]
7	pancreatic	O	['N']	[7]
8	enzymes	O	['N']	[8]
9	preparations	O	['N']	[9]
10	,	O	['N']	[10]
11	ie	O	['N']	[11]
12	,	O	['N']	[12]
13	Creon	B	['N']	[13]
14	10	I-Drug	['Causes']	[1]
15	,	O	['N']	[15]
16	Viokase	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	Pancrease	O	['N']	[19]
20	MT	O	['N']	[20]
21	16	O	['N']	[21]
22	.	O	['N']	[22]
#4408
0	While	O	['N']	[0]
1	doxorubicin	B-Drug	['Causes']	[9]
2	was	O	['N']	[2]
3	administered	O	['N']	[3]
4	,	O	['N']	[4]
5	the	O	['N']	[5]
6	patient	O	['N']	[6]
7	presented	O	['N']	[7]
8	thoracic	B	['N']	[8]
9	pain	I-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	breathing	O	['N']	[11]
12	distress	O	['N']	[12]
13	due	O	['N']	[13]
14	to	O	['N']	[14]
15	superior	O	['N']	[15]
16	vena	O	['N']	[16]
17	cava	O	['N']	[17]
18	perforation	O	['N']	[18]
19	by	O	['N']	[19]
20	the	O	['N']	[20]
21	central	O	['N']	[21]
22	catheter	O	['N']	[22]
23	and	O	['N']	[23]
24	subsequent	O	['N']	[24]
25	extravasation	O	['N']	[25]
26	of	O	['N']	[26]
27	the	O	['N']	[27]
28	drug	O	['N']	[28]
29	into	O	['N']	[29]
30	the	O	['N']	[30]
31	mediastinum	O	['N']	[31]
32	.	O	['N']	[32]
#4409
0	The	O	['N']	[0]
1	present	O	['N']	[1]
2	report	O	['N']	[2]
3	illustrates	O	['N']	[3]
4	a	O	['N']	[4]
5	rare	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	refractory	O	['N']	[8]
9	akathisia	O	['N']	[9]
10	after	O	['N']	[10]
11	interferon	B	['N']	[11]
12	-	I	['N']	[12]
13	alpha	I-Drug	['Causes']	[29]
14	treatment	O	['N']	[14]
15	and	O	['N']	[15]
16	also	O	['N']	[16]
17	that	O	['N']	[17]
18	levodopa	O	['N']	[18]
19	treatment	O	['N']	[19]
20	would	O	['N']	[20]
21	be	O	['N']	[21]
22	theoretically	O	['N']	[22]
23	and	O	['N']	[23]
24	practically	O	['N']	[24]
25	useful	O	['N']	[25]
26	in	O	['N']	[26]
27	reducing	O	['N']	[27]
28	the	O	['N']	[28]
29	neurotoxicity	B-Adverse_Effect	['N']	[29]
30	associated	O	['N']	[30]
31	with	O	['N']	[31]
32	interferon	O	['N']	[32]
33	-	O	['N']	[33]
34	alpha	O	['N']	[34]
35	.	O	['N']	[35]
#4410
0	Decreased	B	['N']	[0]
1	plasma	I	['N']	[1]
2	cortisol	I	['N']	[2]
3	level	I-Adverse_Effect	['N']	[3]
4	during	O	['N']	[4]
5	alprazolam	B-Drug	['Causes']	[3]
6	treatment	O	['N']	[6]
7	of	O	['N']	[7]
8	panic	O	['N']	[8]
9	disorder	O	['N']	[9]
10	:	O	['N']	[10]
11	a	O	['N']	[11]
12	case	O	['N']	[12]
13	report	O	['N']	[13]
14	.	O	['N']	[14]
#4411
0	We	O	['N']	[0]
1	discuss	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	severe	O	['N']	[6]
7	renal	O	['N']	[7]
8	tubular	O	['N']	[8]
9	dysfunction	O	['N']	[9]
10	secondary	O	['N']	[10]
11	to	O	['N']	[11]
12	short	O	['N']	[12]
13	-	O	['N']	[13]
14	term	O	['N']	[14]
15	therapy	O	['N']	[15]
16	with	O	['N']	[16]
17	Amikacin	B-Drug	['Causes']	[24]
18	,	O	['N']	[18]
19	resulting	O	['N']	[19]
20	in	O	['N']	[20]
21	refractory	O	['N']	[21]
22	hypokalemia	O	['N']	[22]
23	,	O	['N']	[23]
24	hypocalcemia	B-Adverse_Effect	['N']	[24]
25	,	O	['N']	[25]
26	hypomagnesemia	O	['N']	[26]
27	,	O	['N']	[27]
28	metabolic	O	['N']	[28]
29	alkalosis	O	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	polyuria	O	['N']	[32]
33	.	O	['N']	[33]
#4412
0	Two	O	['N']	[0]
1	renal	O	['N']	[1]
2	transplant	O	['N']	[2]
3	patients	O	['N']	[3]
4	developed	O	['N']	[4]
5	anemia	B-Adverse_Effect	['N']	[5]
6	during	O	['N']	[6]
7	treatment	O	['N']	[7]
8	of	O	['N']	[8]
9	hypertension	O	['N']	[9]
10	with	O	['N']	[10]
11	enalapril	B-Drug	['Causes']	[5]
12	medication	O	['N']	[12]
13	.	O	['N']	[13]
#4413
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	human	O	['N']	[5]
6	immunodeficiency	O	['N']	[6]
7	virus	O	['N']	[7]
8	infection	O	['N']	[8]
9	under	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	foscarnet	B-Drug	['Causes']	[19]
13	for	O	['N']	[13]
14	CMV	O	['N']	[14]
15	retinitis	O	['N']	[15]
16	who	O	['N']	[16]
17	complained	O	['N']	[17]
18	of	O	['N']	[18]
19	thirst	B-Adverse_Effect	['N']	[19]
20	and	O	['N']	[20]
21	polyuria	O	['N']	[21]
22	.	O	['N']	[22]
#4414
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	LTG	B-Drug	['Dosage']	[3]
3	overdose	B-Dose	['N']	[3]
4	may	O	['N']	[4]
5	result	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	severe	O	['N']	[8]
9	but	O	['N']	[9]
10	reversible	O	['N']	[10]
11	encephalopathy	O	['N']	[11]
12	,	O	['N']	[12]
13	a	O	['N']	[13]
14	previously	O	['N']	[14]
15	undescribed	O	['N']	[15]
16	phenomenon	O	['N']	[16]
17	.	O	['N']	[17]
#4415
0	Severe	O	['N']	[0]
1	rash	O	['N']	[1]
2	,	O	['N']	[2]
3	including	O	['N']	[3]
4	the	O	['N']	[4]
5	Stevens	B	['N']	[5]
6	-	I	['N']	[6]
7	Johnson	I	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	(	O	['N']	[9]
10	SJS	O	['N']	[10]
11	)	O	['N']	[11]
12	,	O	['N']	[12]
13	is	O	['N']	[13]
14	the	O	['N']	[14]
15	major	O	['N']	[15]
16	toxicity	O	['N']	[16]
17	of	O	['N']	[17]
18	nevirapine	B-Drug	['Causes']	[8]
19	and	O	['N']	[19]
20	is	O	['N']	[20]
21	described	O	['N']	[21]
22	in	O	['N']	[22]
23	the	O	['N']	[23]
24	package	O	['N']	[24]
25	labeling	O	['N']	[25]
26	with	O	['N']	[26]
27	a	O	['N']	[27]
28	prominent	O	['N']	[28]
29	,	O	['N']	[29]
30	boxed	O	['N']	[30]
31	warning	O	['N']	[31]
32	.	O	['N']	[32]
#4416
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	suggest	O	['N']	[2]
3	that	O	['N']	[3]
4	in	O	['N']	[4]
5	the	O	['N']	[5]
6	absence	O	['N']	[6]
7	of	O	['N']	[7]
8	any	O	['N']	[8]
9	proven	O	['N']	[9]
10	benefit	O	['N']	[10]
11	of	O	['N']	[11]
12	itraconazole	B-Drug	['Causes']	[31]
13	prophylaxis	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	given	O	['N']	[16]
17	the	O	['N']	[17]
18	interaction	O	['N']	[18]
19	of	O	['N']	[19]
20	this	O	['N']	[20]
21	drug	O	['N']	[21]
22	with	O	['N']	[22]
23	vincristine	O	['N']	[23]
24	leading	O	['N']	[24]
25	to	O	['N']	[25]
26	severe	O	['N']	[26]
27	and	O	['N']	[27]
28	even	O	['N']	[28]
29	potentially	O	['N']	[29]
30	fatal	B	['N']	[30]
31	toxicities	I-Adverse_Effect	['N']	[31]
32	,	O	['N']	[32]
33	the	O	['N']	[33]
34	combination	O	['N']	[34]
35	use	O	['N']	[35]
36	of	O	['N']	[36]
37	these	O	['N']	[37]
38	drugs	O	['N']	[38]
39	should	O	['N']	[39]
40	be	O	['N']	[40]
41	avoided	O	['N']	[41]
42	.	O	['N']	[42]
#4417
0	Presented	O	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	acute	B	['N']	[5]
6	renal	I	['N']	[6]
7	failure	I-Adverse_Effect	['N']	[7]
8	induced	O	['N']	[8]
9	by	O	['N']	[9]
10	acetazolamide	B-Drug	['Causes']	[7]
11	therapy	O	['N']	[11]
12	for	O	['N']	[12]
13	glaucoma	O	['N']	[13]
14	.	O	['N']	[14]
#4418
0	A	O	['N']	[0]
1	12	O	['N']	[1]
2	year	O	['N']	[2]
3	old	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	atrial	O	['N']	[6]
7	flutter	O	['N']	[7]
8	is	O	['N']	[8]
9	presented	O	['N']	[9]
10	,	O	['N']	[10]
11	in	O	['N']	[11]
12	whom	O	['N']	[12]
13	intravenous	O	['N']	[13]
14	adenosine	B-Drug	['Causes']	[27]
15	was	O	['N']	[15]
16	followed	O	['N']	[16]
17	by	O	['N']	[17]
18	acceleration	O	['N']	[18]
19	of	O	['N']	[19]
20	the	O	['N']	[20]
21	heart	O	['N']	[21]
22	rate	O	['N']	[22]
23	to	O	['N']	[23]
24	a	O	['N']	[24]
25	potentially	O	['N']	[25]
26	dangerous	O	['N']	[26]
27	arrhythmia	B-Adverse_Effect	['N']	[27]
28	.	O	['N']	[28]
#4419
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	report	O	['N']	[2]
3	describes	O	['N']	[3]
4	the	O	['N']	[4]
5	development	O	['N']	[5]
6	of	O	['N']	[6]
7	asymptomatic	O	['N']	[7]
8	visual	O	['N']	[8]
9	field	O	['N']	[9]
10	defects	O	['N']	[10]
11	(	O	['N']	[11]
12	VFDs	B-Adverse_Effect	['N']	[12]
13	)	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	psychiatric	O	['N']	[16]
17	patient	O	['N']	[17]
18	with	O	['N']	[18]
19	bipolar	O	['N']	[19]
20	disorder	O	['N']	[20]
21	receiving	O	['N']	[21]
22	adjunctive	O	['N']	[22]
23	tiagabine	B-Drug	['Causes']	[12]
24	treatment	O	['N']	[24]
25	.	O	['N']	[25]
#4420
0	Although	O	['N']	[0]
1	it	O	['N']	[1]
2	is	O	['N']	[2]
3	difficult	O	['N']	[3]
4	to	O	['N']	[4]
5	be	O	['N']	[5]
6	certain	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	direct	O	['N']	[9]
10	link	O	['N']	[10]
11	of	O	['N']	[11]
12	amiodarone	B-Drug	['Causes']	[35]
13	on	O	['N']	[13]
14	the	O	['N']	[14]
15	basis	O	['N']	[15]
16	of	O	['N']	[16]
17	a	O	['N']	[17]
18	single	O	['N']	[18]
19	case	O	['N']	[19]
20	,	O	['N']	[20]
21	it	O	['N']	[21]
22	is	O	['N']	[22]
23	reasonable	O	['N']	[23]
24	to	O	['N']	[24]
25	presume	O	['N']	[25]
26	that	O	['N']	[26]
27	this	O	['N']	[27]
28	histopathology	O	['N']	[28]
29	is	O	['N']	[29]
30	associated	O	['N']	[30]
31	with	O	['N']	[31]
32	amiodarone	O	['N']	[32]
33	-	O	['N']	[33]
34	induced	O	['N']	[34]
35	hypothyroidism	B-Adverse_Effect	['N']	[35]
36	and	O	['N']	[36]
37	that	O	['N']	[37]
38	involution	O	['N']	[38]
39	changes	O	['N']	[39]
40	represent	O	['N']	[40]
41	the	O	['N']	[41]
42	hypofunctional	O	['N']	[42]
43	status	O	['N']	[43]
44	of	O	['N']	[44]
45	this	O	['N']	[45]
46	drug	O	['N']	[46]
47	-	O	['N']	[47]
48	induced	O	['N']	[48]
49	disorder	O	['N']	[49]
50	.	O	['N']	[50]
#4421
0	Zolpidem	O	['N']	[0]
1	tissue	O	['N']	[1]
2	concentrations	O	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	multiple	O	['N']	[5]
6	drug	O	['N']	[6]
7	related	O	['N']	[7]
8	death	B-Adverse_Effect	['N']	[8]
9	involving	O	['N']	[9]
10	Ambien	B-Drug	['Causes']	[8]
11	.	O	['N']	[11]
#4422
0	A	O	['N']	[0]
1	young	O	['N']	[1]
2	patient	O	['N']	[2]
3	experienced	O	['N']	[3]
4	marked	O	['N']	[4]
5	sinus	B	['N']	[5]
6	tachycardia	I-Adverse_Effect	['N']	[6]
7	while	O	['N']	[7]
8	smoking	O	['N']	[8]
9	marijuana	O	['N']	[9]
10	and	O	['N']	[10]
11	receiving	O	['N']	[11]
12	therapeutic	O	['N']	[12]
13	doses	O	['N']	[13]
14	of	O	['N']	[14]
15	nortriptyline	B-Drug	['Causes']	[6]
16	.	O	['N']	[16]
#4423
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	extranodal	O	['N']	[5]
6	non	O	['N']	[6]
7	-	O	['N']	[7]
8	Hodgkin	O	['N']	[8]
9	lymphoma	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	systemic	B	['N']	[12]
13	candidiasis	I-Adverse_Effect	['N']	[13]
14	after	O	['N']	[14]
15	treatment	O	['N']	[15]
16	with	O	['N']	[16]
17	a	O	['N']	[17]
18	cyclophosphamide	B-Drug	['Causes']	[13]
19	-	O	['N']	[19]
20	based	O	['N']	[20]
21	chemotherapy	O	['N']	[21]
22	regimen	O	['N']	[22]
23	.	O	['N']	[23]
#4424
0	A	O	['N']	[0]
1	review	O	['N']	[1]
2	of	O	['N']	[2]
3	the	O	['N']	[3]
4	literature	O	['N']	[4]
5	found	O	['N']	[5]
6	11	O	['N']	[6]
7	children	O	['N']	[7]
8	and	O	['N']	[8]
9	2	O	['N']	[9]
10	adults	O	['N']	[10]
11	in	O	['N']	[11]
12	whom	O	['N']	[12]
13	intranasal	O	['N']	[13]
14	desmopressin	B-Drug	['Causes']	[24]
15	was	O	['N']	[15]
16	associated	O	['N']	[16]
17	with	O	['N']	[17]
18	hyponatremia	O	['N']	[18]
19	,	O	['N']	[19]
20	all	O	['N']	[20]
21	of	O	['N']	[21]
22	whom	O	['N']	[22]
23	experienced	O	['N']	[23]
24	seizures	B-Adverse_Effect	['N']	[24]
25	or	O	['N']	[25]
26	altered	O	['N']	[26]
27	mental	O	['N']	[27]
28	status	O	['N']	[28]
29	.	O	['N']	[29]
#4425
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	rules	O	['N']	[2]
3	out	O	['N']	[3]
4	other	O	['N']	[4]
5	causes	O	['N']	[5]
6	of	O	['N']	[6]
7	toxic	B	['N']	[7]
8	epidermal	I	['N']	[8]
9	necrolysis	I-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	implicates	O	['N']	[11]
12	ofloxacin	B-Drug	['Causes']	[9]
13	in	O	['N']	[13]
14	what	O	['N']	[14]
15	appears	O	['N']	[15]
16	to	O	['N']	[16]
17	be	O	['N']	[17]
18	an	O	['N']	[18]
19	atypical	O	['N']	[19]
20	presentation	O	['N']	[20]
21	of	O	['N']	[21]
22	drug	O	['N']	[22]
23	-	O	['N']	[23]
24	induced	O	['N']	[24]
25	toxic	O	['N']	[25]
26	epidermal	O	['N']	[26]
27	necrolysis	O	['N']	[27]
28	.	O	['N']	[28]
#4426
0	When	O	['N']	[0]
1	SASP	O	['N']	[1]
2	was	O	['N']	[2]
3	changed	O	['N']	[3]
4	to	O	['N']	[4]
5	5-aminosalicylic	B	['N']	[5]
6	acid	I-Drug	['Causes']	[23]
7	(	O	['N']	[7]
8	5-ASA	O	['N']	[8]
9	)	O	['N']	[9]
10	,	O	['N']	[10]
11	his	O	['N']	[11]
12	skin	O	['N']	[12]
13	eruptions	O	['N']	[13]
14	were	O	['N']	[14]
15	resolved	O	['N']	[15]
16	,	O	['N']	[16]
17	however	O	['N']	[17]
18	,	O	['N']	[18]
19	he	O	['N']	[19]
20	developed	O	['N']	[20]
21	weakness	O	['N']	[21]
22	and	O	['N']	[22]
23	atrophy	B-Adverse_Effect	['N']	[23]
24	in	O	['N']	[24]
25	his	O	['N']	[25]
26	right	O	['N']	[26]
27	arm	O	['N']	[27]
28	as	O	['N']	[28]
29	well	O	['N']	[29]
30	as	O	['N']	[30]
31	progressive	O	['N']	[31]
32	worsening	O	['N']	[32]
33	of	O	['N']	[33]
34	the	O	['N']	[34]
35	dysesthesia	O	['N']	[35]
36	in	O	['N']	[36]
37	his	O	['N']	[37]
38	legs	O	['N']	[38]
39	and	O	['N']	[39]
40	gait	O	['N']	[40]
41	disturbance	O	['N']	[41]
42	.	O	['N']	[42]
#4427
0	Rapamycin	O	['N']	[0]
1	/	O	['N']	[1]
2	sirolimus	B-Drug	['Causes']	[31]
3	(	O	['N']	[3]
4	SR	O	['N']	[4]
5	)	O	['N']	[5]
6	,	O	['N']	[6]
7	trade	O	['N']	[7]
8	named	O	['N']	[8]
9	Rapammune	O	['N']	[9]
10	(	O	['N']	[10]
11	Wyeth	O	['N']	[11]
12	-	O	['N']	[12]
13	Ayerst	O	['N']	[13]
14	,	O	['N']	[14]
15	Sydney	O	['N']	[15]
16	,	O	['N']	[16]
17	Australia	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	is	O	['N']	[20]
21	a	O	['N']	[21]
22	potent	O	['N']	[22]
23	immunosuppressive	O	['N']	[23]
24	drug	O	['N']	[24]
25	associated	O	['N']	[25]
26	with	O	['N']	[26]
27	myelosuppression	O	['N']	[27]
28	,	O	['N']	[28]
29	hypertension	O	['N']	[29]
30	,	O	['N']	[30]
31	hyperlipidemia	B-Adverse_Effect	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	infection	O	['N']	[34]
35	.	O	['N']	[35]
#4428
0	The	O	['N']	[0]
1	principle	O	['N']	[1]
2	treatment	O	['N']	[2]
3	for	O	['N']	[3]
4	DPD	O	['N']	[4]
5	-	O	['N']	[5]
6	deficient	O	['N']	[6]
7	patients	O	['N']	[7]
8	with	O	['N']	[8]
9	severe	B	['N']	[9]
10	acute	I	['N']	[10]
11	5-FU	B-Drug	['Causes']	[12]
12	reactions	I-Adverse_Effect	['N']	[12]
13	is	O	['N']	[13]
14	supportive	O	['N']	[14]
15	care	O	['N']	[15]
16	;	O	['N']	[16]
17	however	O	['N']	[17]
18	,	O	['N']	[18]
19	the	O	['N']	[19]
20	administration	O	['N']	[20]
21	of	O	['N']	[21]
22	thymidine	O	['N']	[22]
23	potentially	O	['N']	[23]
24	may	O	['N']	[24]
25	reverse	O	['N']	[25]
26	severe	O	['N']	[26]
27	5-FU	O	['N']	[27]
28	-	O	['N']	[28]
29	induced	O	['N']	[29]
30	neurologic	O	['N']	[30]
31	symptoms	O	['N']	[31]
32	such	O	['N']	[32]
33	as	O	['N']	[33]
34	encephalopathy	O	['N']	[34]
35	and	O	['N']	[35]
36	coma	O	['N']	[36]
37	.	O	['N']	[37]
#4429
0	The	O	['N']	[0]
1	day	O	['N']	[1]
2	after	O	['N']	[2]
3	clozapine	O	['N']	[3]
4	was	O	['N']	[4]
5	stopped	O	['N']	[5]
6	,	O	['N']	[6]
7	while	O	['N']	[7]
8	he	O	['N']	[8]
9	was	O	['N']	[9]
10	still	O	['N']	[10]
11	receiving	O	['N']	[11]
12	clomipramine	B-Drug	['Causes']	[36]
13	150	O	['N']	[13]
14	mg	O	['N']	[14]
15	/	O	['N']	[15]
16	d	O	['N']	[16]
17	,	O	['N']	[17]
18	he	O	['N']	[18]
19	began	O	['N']	[19]
20	behaving	O	['N']	[20]
21	oddly	O	['N']	[21]
22	,	O	['N']	[22]
23	started	O	['N']	[23]
24	sweating	O	['N']	[24]
25	profusely	O	['N']	[25]
26	,	O	['N']	[26]
27	shivering	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	became	O	['N']	[30]
31	tremulous	O	['N']	[31]
32	,	O	['N']	[32]
33	agitated	O	['N']	[33]
34	,	O	['N']	[34]
35	and	O	['N']	[35]
36	confused	B-Adverse_Effect	['N']	[36]
37	.	O	['N']	[37]
#4430
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	young	O	['N']	[6]
7	woman	O	['N']	[7]
8	with	O	['N']	[8]
9	SLE	O	['N']	[9]
10	and	O	['N']	[10]
11	thrombocytopenia	O	['N']	[11]
12	,	O	['N']	[12]
13	who	O	['N']	[13]
14	developed	O	['N']	[14]
15	severe	O	['N']	[15]
16	perspiration	O	['N']	[16]
17	,	O	['N']	[17]
18	headache	B-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	seizure	O	['N']	[21]
22	after	O	['N']	[22]
23	receiving	O	['N']	[23]
24	cyclosporine	B-Drug	['Causes']	[18]
25	.	O	['N']	[25]
#4431
0	We	O	['N']	[0]
1	experienced	O	['N']	[1]
2	a	O	['N']	[2]
3	male	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	psoriasis	O	['N']	[6]
7	and	O	['N']	[7]
8	hypertension	O	['N']	[8]
9	whose	O	['N']	[9]
10	conditions	O	['N']	[10]
11	were	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	tacalcitol	O	['N']	[14]
15	ointment	O	['N']	[15]
16	and	O	['N']	[16]
17	thiazide	B-Drug	['Causes']	[23]
18	,	O	['N']	[18]
19	respectively	O	['N']	[19]
20	,	O	['N']	[20]
21	resulting	O	['N']	[21]
22	in	O	['N']	[22]
23	hypercalciuria	B-Adverse_Effect	['N']	[23]
24	and	O	['N']	[24]
25	hypercalcemia	O	['N']	[25]
26	.	O	['N']	[26]
#4432
0	Carbamazepine	B-Drug	['Causes']	[1]
1	toxicity	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	Oxybutynin	O	['N']	[3]
4	and	O	['N']	[4]
5	Dantrolene	O	['N']	[5]
6	administration	O	['N']	[6]
7	:	O	['N']	[7]
8	a	O	['N']	[8]
9	case	O	['N']	[9]
10	report	O	['N']	[10]
11	.	O	['N']	[11]
#4433
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	In	O	['N']	[2]
3	some	O	['N']	[3]
4	abstainers	O	['N']	[4]
5	who	O	['N']	[5]
6	take	O	['N']	[6]
7	cyanamide	B-Drug	['Causes']	[17]
8	for	O	['N']	[8]
9	several	O	['N']	[9]
10	years	O	['N']	[10]
11	,	O	['N']	[11]
12	thin	O	['N']	[12]
13	septum	B	['N']	[13]
14	-	I	['N']	[14]
15	like	I	['N']	[15]
16	liver	I	['N']	[16]
17	fibrosis	I-Adverse_Effect	['N']	[17]
18	progresses	O	['N']	[18]
19	along	O	['N']	[19]
20	with	O	['N']	[20]
21	the	O	['N']	[21]
22	emergence	O	['N']	[22]
23	of	O	['N']	[23]
24	ground	O	['N']	[24]
25	-	O	['N']	[25]
26	glass	O	['N']	[26]
27	hepatocytes	O	['N']	[27]
28	.	O	['N']	[28]
#4434
0	Moxalactam	B-Drug	['Causes']	[9]
1	is	O	['N']	[1]
2	more	O	['N']	[2]
3	likely	O	['N']	[3]
4	to	O	['N']	[4]
5	be	O	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	platelet	B	['N']	[8]
9	dysfunction	I-Adverse_Effect	['N']	[9]
10	.	O	['N']	[10]
#4435
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	that	O	['N']	[4]
5	developed	O	['N']	[5]
6	acute	B	['N']	[6]
7	myeloid	I	['N']	[7]
8	leukaemia	I-Adverse_Effect	['N']	[8]
9	(	O	['N']	[9]
10	AML	O	['N']	[10]
11	)	O	['N']	[11]
12	during	O	['N']	[12]
13	tamoxifen	B-Drug	['Causes']	[8]
14	therapy	O	['N']	[14]
15	for	O	['N']	[15]
16	breast	O	['N']	[16]
17	cancer	O	['N']	[17]
18	.	O	['N']	[18]
#4436
0	Therapy	O	['N']	[0]
1	with	O	['N']	[1]
2	IFN	B	['N']	[2]
3	-	I	['N']	[3]
4	alpha	I-Drug	['Causes']	[25]
5	may	O	['N']	[5]
6	be	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	number	O	['N']	[10]
11	of	O	['N']	[11]
12	neuropsychiatric	O	['N']	[12]
13	symptoms	O	['N']	[13]
14	,	O	['N']	[14]
15	such	O	['N']	[15]
16	as	O	['N']	[16]
17	Parkinsonism	O	['N']	[17]
18	,	O	['N']	[18]
19	akathisia	O	['N']	[19]
20	,	O	['N']	[20]
21	seizure	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	depressive	B	['N']	[24]
25	disorders	I-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#4437
0	Its	O	['N']	[0]
1	overall	O	['N']	[1]
2	toxicity	B-Adverse_Effect	['N']	[2]
3	is	O	['N']	[3]
4	considerably	O	['N']	[4]
5	less	O	['N']	[5]
6	compared	O	['N']	[6]
7	to	O	['N']	[7]
8	standard	O	['N']	[8]
9	induction	O	['N']	[9]
10	chemotherapy	O	['N']	[10]
11	;	O	['N']	[11]
12	however	O	['N']	[12]
13	,	O	['N']	[13]
14	it	O	['N']	[14]
15	is	O	['N']	[15]
16	associated	O	['N']	[16]
17	with	O	['N']	[17]
18	a	O	['N']	[18]
19	high	O	['N']	[19]
20	incidence	O	['N']	[20]
21	of	O	['N']	[21]
22	a	O	['N']	[22]
23	potentially	O	['N']	[23]
24	fatal	O	['N']	[24]
25	symptom	O	['N']	[25]
26	complex	O	['N']	[26]
27	referred	O	['N']	[27]
28	to	O	['N']	[28]
29	as	O	['N']	[29]
30	"	O	['N']	[30]
31	retinoic	B	['N']	[31]
32	acid	I-Drug	['Causes']	[2]
33	syndrome	O	['N']	[33]
34	.	O	['N']	[34]
35	"	O	['N']	[35]
36	This	O	['N']	[36]
37	report	O	['N']	[37]
38	describes	O	['N']	[38]
39	a	O	['N']	[39]
40	patient	O	['N']	[40]
41	with	O	['N']	[41]
42	APL	O	['N']	[42]
43	who	O	['N']	[43]
44	developed	O	['N']	[44]
45	the	O	['N']	[45]
46	syndrome	O	['N']	[46]
47	a	O	['N']	[47]
48	few	O	['N']	[48]
49	weeks	O	['N']	[49]
50	after	O	['N']	[50]
51	initiating	O	['N']	[51]
52	induction	O	['N']	[52]
53	therapy	O	['N']	[53]
54	with	O	['N']	[54]
55	ATRA	O	['N']	[55]
56	despite	O	['N']	[56]
57	being	O	['N']	[57]
58	treated	O	['N']	[58]
59	for	O	['N']	[59]
60	hyperleukocytosis	O	['N']	[60]
61	.	O	['N']	[61]
#4438
0	Use	O	['N']	[0]
1	of	O	['N']	[1]
2	the	O	['N']	[2]
3	Naranjo	O	['N']	[3]
4	adverse	O	['N']	[4]
5	drug	O	['N']	[5]
6	reaction	O	['N']	[6]
7	probability	O	['N']	[7]
8	scale	O	['N']	[8]
9	indicated	O	['N']	[9]
10	a	O	['N']	[10]
11	probable	O	['N']	[11]
12	relationship	O	['N']	[12]
13	(	O	['N']	[13]
14	score	O	['N']	[14]
15	of	O	['N']	[15]
16	5	O	['N']	[16]
17	)	O	['N']	[17]
18	between	O	['N']	[18]
19	the	O	['N']	[19]
20	patient	O	['N']	[20]
21	's	O	['N']	[21]
22	development	O	['N']	[22]
23	of	O	['N']	[23]
24	hepatotoxicity	B-Adverse_Effect	['N']	[24]
25	and	O	['N']	[25]
26	the	O	['N']	[26]
27	TMP	B	['N']	[27]
28	-	I	['N']	[28]
29	SMX	I-Drug	['Causes']	[24]
30	therapy	O	['N']	[30]
31	.	O	['N']	[31]
#4439
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	suggests	O	['N']	[2]
3	that	O	['N']	[3]
4	anemia	B-Adverse_Effect	['N']	[4]
5	can	O	['N']	[5]
6	occur	O	['N']	[6]
7	due	O	['N']	[7]
8	to	O	['N']	[8]
9	MMF	B-Drug	['Causes']	[4]
10	,	O	['N']	[10]
11	in	O	['N']	[11]
12	particular	O	['N']	[12]
13	when	O	['N']	[13]
14	it	O	['N']	[14]
15	is	O	['N']	[15]
16	given	O	['N']	[16]
17	with	O	['N']	[17]
18	prednisone	O	['N']	[18]
19	,	O	['N']	[19]
20	a	O	['N']	[20]
21	side	O	['N']	[21]
22	effect	O	['N']	[22]
23	well	O	['N']	[23]
24	documented	O	['N']	[24]
25	in	O	['N']	[25]
26	the	O	['N']	[26]
27	transplantation	O	['N']	[27]
28	literature	O	['N']	[28]
29	when	O	['N']	[29]
30	the	O	['N']	[30]
31	triple	O	['N']	[31]
32	combination	O	['N']	[32]
33	of	O	['N']	[33]
34	MMF	O	['N']	[34]
35	,	O	['N']	[35]
36	cyclosporine	O	['N']	[36]
37	and	O	['N']	[37]
38	prednisone	O	['N']	[38]
39	is	O	['N']	[39]
40	used	O	['N']	[40]
41	.	O	['N']	[41]
#4440
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	this	O	['N']	[3]
4	is	O	['N']	[4]
5	the	O	['N']	[5]
6	first	O	['N']	[6]
7	report	O	['N']	[7]
8	that	O	['N']	[8]
9	demonstrates	O	['N']	[9]
10	histological	B	['N']	[10]
11	abnormalities	I	['N']	[11]
12	of	I	['N']	[12]
13	the	I	['N']	[13]
14	glomerulus	I-Adverse_Effect	['N']	[14]
15	associated	O	['N']	[15]
16	with	O	['N']	[16]
17	postoperative	O	['N']	[17]
18	IFN	B	['N']	[18]
19	-	I	['N']	[19]
20	beta	I-Drug	['Causes']	[14]
21	therapy	O	['N']	[21]
22	for	O	['N']	[22]
23	the	O	['N']	[23]
24	malignant	O	['N']	[24]
25	melanoma	O	['N']	[25]
26	.	O	['N']	[26]
#4441
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	disseminated	O	['N']	[5]
6	muscular	O	['N']	[6]
7	cysticercosis	O	['N']	[7]
8	followed	O	['N']	[8]
9	by	O	['N']	[9]
10	myositis	B-Adverse_Effect	['N']	[10]
11	(	O	['N']	[11]
12	fever	O	['N']	[12]
13	,	O	['N']	[13]
14	diffuse	O	['N']	[14]
15	myalgia	O	['N']	[15]
16	,	O	['N']	[16]
17	weakness	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	lower	O	['N']	[20]
21	limbs	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	inflammatory	O	['N']	[24]
25	reaction	O	['N']	[25]
26	around	O	['N']	[26]
27	dying	O	['N']	[27]
28	cysticerci	O	['N']	[28]
29	)	O	['N']	[29]
30	induced	O	['N']	[30]
31	by	O	['N']	[31]
32	praziquantel	B-Drug	['Causes']	[10]
33	therapy	O	['N']	[33]
34	,	O	['N']	[34]
35	an	O	['N']	[35]
36	event	O	['N']	[36]
37	not	O	['N']	[37]
38	described	O	['N']	[38]
39	previously	O	['N']	[39]
40	.	O	['N']	[40]
#4442
0	Nodular	B	['N']	[0]
1	scleritis	I-Adverse_Effect	['N']	[1]
2	following	O	['N']	[2]
3	alendronate	B-Drug	['Causes']	[1]
4	therapy	O	['N']	[4]
5	.	O	['N']	[5]
#4443
0	Early	O	['N']	[0]
1	ritonavir	B-Drug	['Causes']	[5]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	maculopapular	B	['N']	[4]
5	eruption	I-Adverse_Effect	['N']	[5]
6	.	O	['N']	[6]
#4444
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	In	O	['N']	[2]
3	an	O	['N']	[3]
4	institutional	O	['N']	[4]
5	practice	O	['N']	[5]
6	setting	O	['N']	[6]
7	,	O	['N']	[7]
8	two	O	['N']	[8]
9	women	O	['N']	[9]
10	,	O	['N']	[10]
11	aged	O	['N']	[11]
12	25	O	['N']	[12]
13	and	O	['N']	[13]
14	45	O	['N']	[14]
15	,	O	['N']	[15]
16	developed	O	['N']	[16]
17	acute	B	['N']	[17]
18	myopia	I-Adverse_Effect	['N']	[18]
19	after	O	['N']	[19]
20	starting	O	['N']	[20]
21	topiramate	B-Drug	['Causes']	[18]
22	for	O	['N']	[22]
23	epilepsy	O	['N']	[23]
24	.	O	['N']	[24]
#4445
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	hemolytic	B	['N']	[5]
6	-	I	['N']	[6]
7	uremic	I	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	that	O	['N']	[9]
10	developed	O	['N']	[10]
11	during	O	['N']	[11]
12	the	O	['N']	[12]
13	4th	O	['N']	[13]
14	cycle	O	['N']	[14]
15	of	O	['N']	[15]
16	combination	O	['N']	[16]
17	chemotherapy	O	['N']	[17]
18	with	O	['N']	[18]
19	oxaliplatin	O	['N']	[19]
20	,	O	['N']	[20]
21	5-fluorouracil	O	['N']	[21]
22	and	O	['N']	[22]
23	leucovorin	B-Drug	['Causes']	[8]
24	.	O	['N']	[24]
#4446
0	With	O	['N']	[0]
1	the	O	['N']	[1]
2	first	O	['N']	[2]
3	cyclosporine	B-Drug	['Causes']	[11]
4	dose	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	patient	O	['N']	[7]
8	complained	O	['N']	[8]
9	of	O	['N']	[9]
10	leg	B	['N']	[10]
11	pain	I-Adverse_Effect	['N']	[11]
12	that	O	['N']	[12]
13	was	O	['N']	[13]
14	most	O	['N']	[14]
15	severe	O	['N']	[15]
16	during	O	['N']	[16]
17	the	O	['N']	[17]
18	cyclosporine	O	['N']	[18]
19	infusion	O	['N']	[19]
20	.	O	['N']	[20]
#4447
0	Occult	O	['N']	[0]
1	quinine	B-Drug	['Causes']	[4]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	thrombocytopenia	B-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#4448
0	With	O	['N']	[0]
1	the	O	['N']	[1]
2	increasing	O	['N']	[2]
3	use	O	['N']	[3]
4	of	O	['N']	[4]
5	Cyclosporine	B	['N']	[5]
6	A	I-Drug	['Causes']	[15]
7	in	O	['N']	[7]
8	transplant	O	['N']	[8]
9	patients	O	['N']	[9]
10	,	O	['N']	[10]
11	the	O	['N']	[11]
12	incidence	O	['N']	[12]
13	of	O	['N']	[13]
14	herpes	B	['N']	[14]
15	esophagitis	I-Adverse_Effect	['N']	[15]
16	may	O	['N']	[16]
17	increase	O	['N']	[17]
18	.	O	['N']	[18]
#4449
0	Since	O	['N']	[0]
1	the	O	['N']	[1]
2	thrombocyte	B	['N']	[2]
3	count	I	['N']	[3]
4	started	I	['N']	[4]
5	to	I	['N']	[5]
6	increase	I-Adverse_Effect	['N']	[6]
7	immediately	O	['N']	[7]
8	after	O	['N']	[8]
9	initiation	O	['N']	[9]
10	and	O	['N']	[10]
11	dropped	O	['N']	[11]
12	immediately	O	['N']	[12]
13	after	O	['N']	[13]
14	discontinuation	O	['N']	[14]
15	of	O	['N']	[15]
16	ciprofloxacin	O	['N']	[16]
17	and	O	['N']	[17]
18	tazobactam	B-Drug	['Causes']	[6]
19	/	O	['N']	[19]
20	piperacillin	O	['N']	[20]
21	and	O	['N']	[21]
22	all	O	['N']	[22]
23	other	O	['N']	[23]
24	drugs	O	['N']	[24]
25	were	O	['N']	[25]
26	discontinued	O	['N']	[26]
27	already	O	['N']	[27]
28	before	O	['N']	[28]
29	or	O	['N']	[29]
30	were	O	['N']	[30]
31	started	O	['N']	[31]
32	after	O	['N']	[32]
33	the	O	['N']	[33]
34	nadir	O	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	thrombocyte	O	['N']	[37]
38	count	O	['N']	[38]
39	,	O	['N']	[39]
40	these	O	['N']	[40]
41	two	O	['N']	[41]
42	antibiotics	O	['N']	[42]
43	were	O	['N']	[43]
44	regarded	O	['N']	[44]
45	causative	O	['N']	[45]
46	.	O	['N']	[46]
#4450
0	Captopril	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	"	O	['N']	[3]
4	pseudocholangitis	B-Adverse_Effect	['N']	[4]
5	'	O	['N']	[5]
6	.	O	['N']	[6]
#4451
0	Our	O	['N']	[0]
1	findings	O	['N']	[1]
2	reveal	O	['N']	[2]
3	that	O	['N']	[3]
4	even	O	['N']	[4]
5	in	O	['N']	[5]
6	patients	O	['N']	[6]
7	without	O	['N']	[7]
8	a	O	['N']	[8]
9	history	O	['N']	[9]
10	of	O	['N']	[10]
11	seizures	O	['N']	[11]
12	,	O	['N']	[12]
13	pregabalin	B-Drug	['Causes']	[19]
14	can	O	['N']	[14]
15	cause	O	['N']	[15]
16	a	O	['N']	[16]
17	cortical	B	['N']	[17]
18	negative	I	['N']	[18]
19	myoclonus	I-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#4452
0	Interstitial	B	['N']	[0]
1	fibrosis	I	['N']	[1]
2	of	I	['N']	[2]
3	the	I	['N']	[3]
4	lung	I-Adverse_Effect	['N']	[4]
5	is	O	['N']	[5]
6	a	O	['N']	[6]
7	potential	O	['N']	[7]
8	complication	O	['N']	[8]
9	of	O	['N']	[9]
10	methotrexate	B-Drug	['Causes']	[4]
11	therapy	O	['N']	[11]
12	for	O	['N']	[12]
13	psoriasis	O	['N']	[13]
14	.	O	['N']	[14]
#4453
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	Wilson	O	['N']	[5]
6	's	O	['N']	[6]
7	disease	O	['N']	[7]
8	who	O	['N']	[8]
9	presented	O	['N']	[9]
10	with	O	['N']	[10]
11	neurologic	O	['N']	[11]
12	disease	O	['N']	[12]
13	,	O	['N']	[13]
14	was	O	['N']	[14]
15	treated	O	['N']	[15]
16	with	O	['N']	[16]
17	D	B	['N']	[17]
18	-	I	['N']	[18]
19	penicillamine	I-Drug	['Causes']	[25]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	suffered	O	['N']	[22]
23	sudden	O	['N']	[23]
24	neurologic	B	['N']	[24]
25	deterioration	I-Adverse_Effect	['N']	[25]
26	coincident	O	['N']	[26]
27	with	O	['N']	[27]
28	therapy	O	['N']	[28]
29	.	O	['N']	[29]
#4454
0	Unusual	O	['N']	[0]
1	hypersensitivity	B-Adverse_Effect	['N']	[1]
2	to	O	['N']	[2]
3	warfarin	B-Drug	['Causes']	[1]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	critically	O	['N']	[6]
7	ill	O	['N']	[7]
8	patient	O	['N']	[8]
9	.	O	['N']	[9]
#4455
0	The	O	['N']	[0]
1	mild	O	['N']	[1]
2	immunosuppression	O	['N']	[2]
3	that	O	['N']	[3]
4	occurs	O	['N']	[4]
5	with	O	['N']	[5]
6	methotrexate	B-Drug	['Causes']	[20]
7	therapy	O	['N']	[7]
8	probably	O	['N']	[8]
9	places	O	['N']	[9]
10	patients	O	['N']	[10]
11	with	O	['N']	[11]
12	rheumatoid	O	['N']	[12]
13	arthritis	O	['N']	[13]
14	at	O	['N']	[14]
15	added	O	['N']	[15]
16	risk	O	['N']	[16]
17	of	O	['N']	[17]
18	developing	O	['N']	[18]
19	lymphoproliferative	B	['N']	[19]
20	diseases	I-Adverse_Effect	['N']	[20]
21	,	O	['N']	[21]
22	but	O	['N']	[22]
23	coincidence	O	['N']	[23]
24	can	O	['N']	[24]
25	not	O	['N']	[25]
26	be	O	['N']	[26]
27	excluded	O	['N']	[27]
28	.	O	['N']	[28]
#4456
0	We	O	['N']	[0]
1	conjectured	O	['N']	[1]
2	that	O	['N']	[2]
3	the	O	['N']	[3]
4	side	O	['N']	[4]
5	effects	O	['N']	[5]
6	of	O	['N']	[6]
7	insulin	B-Drug	['Causes']	[13]
8	,	O	['N']	[8]
9	such	O	['N']	[9]
10	as	O	['N']	[10]
11	anti	B	['N']	[11]
12	-	I	['N']	[12]
13	natriuresis	I-Adverse_Effect	['N']	[13]
14	and	O	['N']	[14]
15	increased	O	['N']	[15]
16	vascular	O	['N']	[16]
17	permeability	O	['N']	[17]
18	,	O	['N']	[18]
19	might	O	['N']	[19]
20	be	O	['N']	[20]
21	pronounced	O	['N']	[21]
22	in	O	['N']	[22]
23	the	O	['N']	[23]
24	presence	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	hepatic	O	['N']	[27]
28	dysfunction	O	['N']	[28]
29	that	O	['N']	[29]
30	accompanies	O	['N']	[30]
31	insulin	O	['N']	[31]
32	insensitivity	O	['N']	[32]
33	,	O	['N']	[33]
34	hyperinsulinaemia	O	['N']	[34]
35	and	O	['N']	[35]
36	hypoalbuminaemia	O	['N']	[36]
37	.	O	['N']	[37]
#4457
0	An	O	['N']	[0]
1	infant	O	['N']	[1]
2	girl	O	['N']	[2]
3	with	O	['N']	[3]
4	choanal	O	['N']	[4]
5	atresia	O	['N']	[5]
6	,	O	['N']	[6]
7	athelia	B-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	minor	O	['N']	[9]
10	anomalies	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	mild	O	['N']	[13]
14	to	O	['N']	[14]
15	moderate	O	['N']	[15]
16	mental	O	['N']	[16]
17	retardation	O	['N']	[17]
18	was	O	['N']	[18]
19	born	O	['N']	[19]
20	to	O	['N']	[20]
21	a	O	['N']	[21]
22	woman	O	['N']	[22]
23	treated	O	['N']	[23]
24	for	O	['N']	[24]
25	hyperthyroidism	O	['N']	[25]
26	throughout	O	['N']	[26]
27	pregnancy	O	['N']	[27]
28	with	O	['N']	[28]
29	methimazole	B-Drug	['Causes']	[7]
30	and	O	['N']	[30]
31	propranolol	O	['N']	[31]
32	.	O	['N']	[32]
#4458
0	Lithium	B-Drug	['Causes']	[16]
1	treatment	O	['N']	[1]
2	was	O	['N']	[2]
3	terminated	O	['N']	[3]
4	in	O	['N']	[4]
5	1975	O	['N']	[5]
6	because	O	['N']	[6]
7	of	O	['N']	[7]
8	lithium	O	['N']	[8]
9	intoxication	O	['N']	[9]
10	with	O	['N']	[10]
11	a	O	['N']	[11]
12	diabetes	B	['N']	[12]
13	insipidus	I	['N']	[13]
14	-	I	['N']	[14]
15	like	I	['N']	[15]
16	syndrome	I-Adverse_Effect	['N']	[16]
17	.	O	['N']	[17]
#4459
0	Severe	O	['N']	[0]
1	serotonin	B	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	mirtazapine	B-Drug	['Causes']	[2]
6	monotherapy	O	['N']	[6]
7	.	O	['N']	[7]
#4460
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	adults	O	['N']	[3]
4	who	O	['N']	[4]
5	received	O	['N']	[5]
6	gabapentin	B-Drug	['Causes']	[15]
7	(	O	['N']	[7]
8	GBP	O	['N']	[8]
9	)	O	['N']	[9]
10	and	O	['N']	[10]
11	subsequently	O	['N']	[11]
12	developed	O	['N']	[12]
13	behavioural	B	['N']	[13]
14	side	I	['N']	[14]
15	effects	I-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#4461
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	no	O	['N']	[2]
3	.	O	['N']	[3]
4	2	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	pathogenic	O	['N']	[7]
8	mechanism	O	['N']	[8]
9	seemed	O	['N']	[9]
10	to	O	['N']	[10]
11	be	O	['N']	[11]
12	persistent	O	['N']	[12]
13	light	O	['N']	[13]
14	reaction	O	['N']	[14]
15	preceded	O	['N']	[15]
16	by	O	['N']	[16]
17	systemic	O	['N']	[17]
18	photoallergy	O	['N']	[18]
19	,	O	['N']	[19]
20	as	O	['N']	[20]
21	he	O	['N']	[21]
22	had	O	['N']	[22]
23	taken	O	['N']	[23]
24	mequitazine	O	['N']	[24]
25	for	O	['N']	[25]
26	6	O	['N']	[26]
27	months	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	there	O	['N']	[30]
31	were	O	['N']	[31]
32	strong	O	['N']	[32]
33	positive	O	['N']	[33]
34	photopatch	O	['N']	[34]
35	test	O	['N']	[35]
36	results	O	['N']	[36]
37	with	O	['N']	[37]
38	immediate	O	['N']	[38]
39	erythema	O	['N']	[39]
40	reaction	O	['N']	[40]
41	,	O	['N']	[41]
42	cross	B	['N']	[42]
43	-	I	['N']	[43]
44	reaction	I	['N']	[44]
45	to	I	['N']	[45]
46	promethazine	B-Drug	['N']	[46]
47	,	O	['N']	[47]
48	decreased	O	['N']	[48]
49	MED	O	['N']	[49]
50	to	O	['N']	[50]
51	both	O	['N']	[51]
52	UVA	O	['N']	[52]
53	and	O	['N']	[53]
54	UVB	O	['N']	[54]
55	,	O	['N']	[55]
56	and	O	['N']	[56]
57	persistence	O	['N']	[57]
58	of	O	['N']	[58]
59	the	O	['N']	[59]
60	photosensitivity	O	['N']	[60]
61	over	O	['N']	[61]
62	a	O	['N']	[62]
63	3-year	O	['N']	[63]
64	follow	O	['N']	[64]
65	-	O	['N']	[65]
66	up	O	['N']	[66]
67	period	O	['N']	[67]
68	after	O	['N']	[68]
69	discontinuation	O	['N']	[69]
70	of	O	['N']	[70]
71	the	O	['N']	[71]
72	mequitazine	O	['N']	[72]
73	.	O	['N']	[73]
#4462
0	Effect	O	['N']	[0]
1	of	O	['N']	[1]
2	beta	O	['N']	[2]
3	-	O	['N']	[3]
4	blockade	O	['N']	[4]
5	on	O	['N']	[5]
6	symptomatic	O	['N']	[6]
7	dexamethasone	B-Drug	['Causes']	[12]
8	-	O	['N']	[8]
9	induced	O	['N']	[9]
10	hypertrophic	B	['N']	[10]
11	obstructive	I	['N']	[11]
12	cardiomyopathy	I-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	premature	O	['N']	[14]
15	infants	O	['N']	[15]
16	:	O	['N']	[16]
17	three	O	['N']	[17]
18	case	O	['N']	[18]
19	reports	O	['N']	[19]
20	and	O	['N']	[20]
21	literature	O	['N']	[21]
22	review	O	['N']	[22]
23	.	O	['N']	[23]
#4463
0	Reversible	B	['N']	[0]
1	cardiomyopathy	I-Adverse_Effect	['N']	[1]
2	caused	O	['N']	[2]
3	by	O	['N']	[3]
4	administration	O	['N']	[4]
5	of	O	['N']	[5]
6	interferon	B	['N']	[6]
7	alpha	I-Drug	['Causes']	[1]
8	.	O	['N']	[8]
#4464
0	Most	O	['N']	[0]
1	cardiac	O	['N']	[1]
2	surgical	O	['N']	[2]
3	patients	O	['N']	[3]
4	have	O	['N']	[4]
5	had	O	['N']	[5]
6	previous	O	['N']	[6]
7	exposure	O	['N']	[7]
8	to	O	['N']	[8]
9	heparin	B-Drug	['Causes']	[26]
10	for	O	['N']	[10]
11	diagnostic	O	['N']	[11]
12	or	O	['N']	[12]
13	therapeutic	O	['N']	[13]
14	interventions	O	['N']	[14]
15	and	O	['N']	[15]
16	hence	O	['N']	[16]
17	have	O	['N']	[17]
18	an	O	['N']	[18]
19	increased	O	['N']	[19]
20	susceptibility	O	['N']	[20]
21	to	O	['N']	[21]
22	developing	O	['N']	[22]
23	heparin	O	['N']	[23]
24	-	O	['N']	[24]
25	induced	O	['N']	[25]
26	thrombocytopenia	B-Adverse_Effect	['N']	[26]
27	(	O	['N']	[27]
28	HIT	O	['N']	[28]
29	)	O	['N']	[29]
30	postoperatively	O	['N']	[30]
31	.	O	['N']	[31]
#4465
0	Painful	B	['N']	[0]
1	erosion	I	['N']	[1]
2	of	I	['N']	[2]
3	psoriatic	I	['N']	[3]
4	plaques	I-Adverse_Effect	['N']	[4]
5	is	O	['N']	[5]
6	a	O	['N']	[6]
7	less	O	['N']	[7]
8	common	O	['N']	[8]
9	sign	O	['N']	[9]
10	of	O	['N']	[10]
11	methotrexate	B-Drug	['Causes']	[4]
12	toxicity	O	['N']	[12]
13	that	O	['N']	[13]
14	may	O	['N']	[14]
15	precede	O	['N']	[15]
16	evidence	O	['N']	[16]
17	of	O	['N']	[17]
18	bone	O	['N']	[18]
19	marrow	O	['N']	[19]
20	suppression	O	['N']	[20]
21	.	O	['N']	[21]
#4466
0	Development	O	['N']	[0]
1	of	O	['N']	[1]
2	tics	B-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	thirteen	O	['N']	[5]
6	-	O	['N']	[6]
7	year	O	['N']	[7]
8	-	O	['N']	[8]
9	old	O	['N']	[9]
10	male	O	['N']	[10]
11	following	O	['N']	[11]
12	atomoxetine	B-Drug	['Causes']	[2]
13	use	O	['N']	[13]
14	.	O	['N']	[14]
#4467
0	Transient	O	['N']	[0]
1	leucopenia	O	['N']	[1]
2	and	O	['N']	[2]
3	thrombocytopenia	B-Adverse_Effect	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	sodium	B	['N']	[6]
7	nitroprusside	I-Drug	['Causes']	[3]
8	infusion	O	['N']	[8]
9	.	O	['N']	[9]
#4468
0	Acute	O	['N']	[0]
1	severe	O	['N']	[1]
2	intoxication	O	['N']	[2]
3	with	O	['N']	[3]
4	carbamazepine	B-Drug	['Causes']	[10]
5	is	O	['N']	[5]
6	associated	O	['N']	[6]
7	with	O	['N']	[7]
8	seizures	O	['N']	[8]
9	,	O	['N']	[9]
10	coma	B-Adverse_Effect	['N']	[10]
11	and	O	['N']	[11]
12	respiratory	O	['N']	[12]
13	depression	O	['N']	[13]
14	.	O	['N']	[14]
#4469
0	The	O	['N']	[0]
1	neurotoxicity	B-Adverse_Effect	['N']	[1]
2	seen	O	['N']	[2]
3	with	O	['N']	[3]
4	HDARAC	B-Drug	['Causes']	[1]
5	is	O	['N']	[5]
6	dose	O	['N']	[6]
7	-	O	['N']	[7]
8	related	O	['N']	[8]
9	and	O	['N']	[9]
10	has	O	['N']	[10]
11	occurred	O	['N']	[11]
12	in	O	['N']	[12]
13	up	O	['N']	[13]
14	to	O	['N']	[14]
15	60	O	['N']	[15]
16	percent	O	['N']	[16]
17	of	O	['N']	[17]
18	treated	O	['N']	[18]
19	patients	O	['N']	[19]
20	.	O	['N']	[20]
#4470
0	Capecitabine	B-Drug	['Causes']	[6]
1	was	O	['N']	[1]
2	discontinued	O	['N']	[2]
3	and	O	['N']	[3]
4	the	O	['N']	[4]
5	allergic	B	['N']	[5]
6	reactions	I-Adverse_Effect	['N']	[6]
7	resolved	O	['N']	[7]
8	after	O	['N']	[8]
9	the	O	['N']	[9]
10	woman	O	['N']	[10]
11	took	O	['N']	[11]
12	diphenhydramine	O	['N']	[12]
13	for	O	['N']	[13]
14	1	O	['N']	[14]
15	week	O	['N']	[15]
16	.	O	['N']	[16]
#4471
0	Although	O	['N']	[0]
1	there	O	['N']	[1]
2	is	O	['N']	[2]
3	one	O	['N']	[3]
4	case	O	['N']	[4]
5	report	O	['N']	[5]
6	of	O	['N']	[6]
7	cholesterol	O	['N']	[7]
8	crystal	O	['N']	[8]
9	embolization	O	['N']	[9]
10	following	O	['N']	[10]
11	t	B	['N']	[11]
12	-	I	['N']	[12]
13	PA	I-Drug	['Causes']	[39]
14	therapy	O	['N']	[14]
15	with	O	['N']	[15]
16	only	O	['N']	[16]
17	extrarenal	O	['N']	[17]
18	manifestations	O	['N']	[18]
19	(	O	['N']	[19]
20	N	O	['N']	[20]
21	Engl	O	['N']	[21]
22	J	O	['N']	[22]
23	Med	O	['N']	[23]
24	321:1270	O	['N']	[24]
25	,	O	['N']	[25]
26	1989	O	['N']	[26]
27	)	O	['N']	[27]
28	,	O	['N']	[28]
29	this	O	['N']	[29]
30	is	O	['N']	[30]
31	the	O	['N']	[31]
32	first	O	['N']	[32]
33	reported	O	['N']	[33]
34	case	O	['N']	[34]
35	of	O	['N']	[35]
36	atheroembolic	B	['N']	[36]
37	acute	I	['N']	[37]
38	renal	I	['N']	[38]
39	failure	I-Adverse_Effect	['N']	[39]
40	following	O	['N']	[40]
41	t	O	['N']	[41]
42	-	O	['N']	[42]
43	PA	O	['N']	[43]
44	therapy	O	['N']	[44]
45	.	O	['N']	[45]
#4472
0	Pseudoephedrine	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hemorrhage	B-Adverse_Effect	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	a	O	['N']	[6]
7	cerebral	O	['N']	[7]
8	vascular	O	['N']	[8]
9	malformation	O	['N']	[9]
10	.	O	['N']	[10]
#4473
0	This	O	['N']	[0]
1	report	O	['N']	[1]
2	describes	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	flucytosine	B-Drug	['Causes']	[10]
7	-	O	['N']	[7]
8	associated	O	['N']	[8]
9	ulcerating	B	['N']	[9]
10	enteritis	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	which	O	['N']	[12]
13	the	O	['N']	[13]
14	small	O	['N']	[14]
15	bowel	O	['N']	[15]
16	x	O	['N']	[16]
17	-	O	['N']	[17]
18	ray	O	['N']	[18]
19	demonstrated	O	['N']	[19]
20	severe	O	['N']	[20]
21	luminal	O	['N']	[21]
22	narrowing	O	['N']	[22]
23	,	O	['N']	[23]
24	ulceration	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	marked	O	['N']	[27]
28	separation	O	['N']	[28]
29	of	O	['N']	[29]
30	loops	O	['N']	[30]
31	of	O	['N']	[31]
32	bowel	O	['N']	[32]
33	.	O	['N']	[33]
#4474
0	Thrombin	B-Drug	['Causes']	[29]
1	is	O	['N']	[1]
2	highly	O	['N']	[2]
3	effective	O	['N']	[3]
4	for	O	['N']	[4]
5	stopping	O	['N']	[5]
6	intractable	O	['N']	[6]
7	arterial	O	['N']	[7]
8	hemorrhage	O	['N']	[8]
9	during	O	['N']	[9]
10	stereotactic	O	['N']	[10]
11	brain	O	['N']	[11]
12	biopsy	O	['N']	[12]
13	;	O	['N']	[13]
14	however	O	['N']	[14]
15	,	O	['N']	[15]
16	it	O	['N']	[16]
17	is	O	['N']	[17]
18	a	O	['N']	[18]
19	vasospastic	O	['N']	[19]
20	agent	O	['N']	[20]
21	and	O	['N']	[21]
22	may	O	['N']	[22]
23	have	O	['N']	[23]
24	been	O	['N']	[24]
25	responsible	O	['N']	[25]
26	for	O	['N']	[26]
27	the	O	['N']	[27]
28	cerebral	B	['N']	[28]
29	infarctions	I-Adverse_Effect	['N']	[29]
30	in	O	['N']	[30]
31	one	O	['N']	[31]
32	patient	O	['N']	[32]
33	.	O	['N']	[33]
#4475
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	placed	O	['N']	[2]
3	on	O	['N']	[3]
4	adjuvant	O	['N']	[4]
5	Adriamycin	B-Drug	['Causes']	[15]
6	(	O	['N']	[6]
7	doxorubicin	O	['N']	[7]
8	)	O	['N']	[8]
9	chemotherapy	O	['N']	[9]
10	,	O	['N']	[10]
11	but	O	['N']	[11]
12	6	O	['N']	[12]
13	months	O	['N']	[13]
14	later	O	['N']	[14]
15	died	B-Adverse_Effect	['N']	[15]
16	of	O	['N']	[16]
17	Adriamycin	O	['N']	[17]
18	toxicity	O	['N']	[18]
19	.	O	['N']	[19]
#4476
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Acute	B	['N']	[2]
3	severe	I	['N']	[3]
4	hepatitis	I-Adverse_Effect	['N']	[4]
5	though	O	['N']	[5]
6	rare	O	['N']	[6]
7	is	O	['N']	[7]
8	occasionally	O	['N']	[8]
9	observed	O	['N']	[9]
10	with	O	['N']	[10]
11	EGFR	O	['N']	[11]
12	inhibitors	O	['N']	[12]
13	gefitinib	B-Drug	['Causes']	[4]
14	or	O	['N']	[14]
15	erlotinib	O	['N']	[15]
16	.	O	['N']	[16]
#4477
0	The	O	['N']	[0]
1	syndrome	O	['N']	[1]
2	of	O	['N']	[2]
3	irreversible	O	['N']	[3]
4	lithium	B-Drug	['Causes']	[7]
5	-	O	['N']	[5]
6	effectuated	O	['N']	[6]
7	neurotoxicity	B-Adverse_Effect	['N']	[7]
8	(	O	['N']	[8]
9	SILENT	O	['N']	[9]
10	)	O	['N']	[10]
11	.	O	['N']	[11]
#4478
0	Four	O	['N']	[0]
1	patients	O	['N']	[1]
2	who	O	['N']	[2]
3	manifested	O	['N']	[3]
4	symptoms	O	['N']	[4]
5	of	O	['N']	[5]
6	the	O	['N']	[6]
7	antiepileptic	O	['N']	[7]
8	drug	O	['N']	[8]
9	(	O	['N']	[9]
10	AED	O	['N']	[10]
11	)	O	['N']	[11]
12	hypersensitivity	B	['N']	[12]
13	syndrome	I-Adverse_Effect	['N']	[13]
14	during	O	['N']	[14]
15	therapy	O	['N']	[15]
16	with	O	['N']	[16]
17	carbamazepine	B-Drug	['Causes']	[13]
18	are	O	['N']	[18]
19	reported	O	['N']	[19]
20	.	O	['N']	[20]
#4479
0	Successful	O	['N']	[0]
1	desensitization	O	['N']	[1]
2	to	O	['N']	[2]
3	high	O	['N']	[3]
4	-	O	['N']	[4]
5	dose	O	['N']	[5]
6	methotrexate	B-Drug	['Causes']	[9]
7	after	O	['N']	[7]
8	systemic	B	['N']	[8]
9	anaphylaxis	I-Adverse_Effect	['N']	[9]
10	.	O	['N']	[10]
#4480
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	previously	O	['N']	[3]
4	healthy	O	['N']	[4]
5	42-year	O	['N']	[5]
6	-	O	['N']	[6]
7	old	O	['N']	[7]
8	woman	O	['N']	[8]
9	presented	O	['N']	[9]
10	with	O	['N']	[10]
11	acute	B	['N']	[11]
12	-	I	['N']	[12]
13	onset	I	['N']	[13]
14	delirium	I	['N']	[14]
15	with	I	['N']	[15]
16	psychotic	I	['N']	[16]
17	features	I-Adverse_Effect	['N']	[17]
18	as	O	['N']	[18]
19	a	O	['N']	[19]
20	consequence	O	['N']	[20]
21	of	O	['N']	[21]
22	levofloxacin	B-Drug	['Causes']	[17]
23	therapy	O	['N']	[23]
24	.	O	['N']	[24]
#4481
0	Although	O	['N']	[0]
1	adverse	O	['N']	[1]
2	effects	O	['N']	[2]
3	are	O	['N']	[3]
4	usually	O	['N']	[4]
5	mild	O	['N']	[5]
6	,	O	['N']	[6]
7	the	O	['N']	[7]
8	author	O	['N']	[8]
9	reports	O	['N']	[9]
10	here	O	['N']	[10]
11	a	O	['N']	[11]
12	case	O	['N']	[12]
13	of	O	['N']	[13]
14	leucocytopenia	B-Adverse_Effect	['N']	[14]
15	and	O	['N']	[15]
16	thrombocytopenia	O	['N']	[16]
17	with	O	['N']	[17]
18	quetiapine	B-Drug	['Causes']	[14]
19	treatment	O	['N']	[19]
20	that	O	['N']	[20]
21	required	O	['N']	[21]
22	its	O	['N']	[22]
23	discontinuation	O	['N']	[23]
24	.	O	['N']	[24]
#4482
0	The	O	['N']	[0]
1	site	O	['N']	[1]
2	of	O	['N']	[2]
3	thrombosis	O	['N']	[3]
4	and	O	['N']	[4]
5	the	O	['N']	[5]
6	chronological	O	['N']	[6]
7	relationship	O	['N']	[7]
8	with	O	['N']	[8]
9	the	O	['N']	[9]
10	IIR	B-Adverse_Effect	['N']	[10]
11	implicates	O	['N']	[11]
12	a	O	['N']	[12]
13	hypersensitivity	O	['N']	[13]
14	to	O	['N']	[14]
15	infliximab	B-Drug	['Causes']	[10]
16	in	O	['N']	[16]
17	the	O	['N']	[17]
18	causation	O	['N']	[18]
19	of	O	['N']	[19]
20	the	O	['N']	[20]
21	venous	O	['N']	[21]
22	thrombosis	O	['N']	[22]
23	in	O	['N']	[23]
24	this	O	['N']	[24]
25	case	O	['N']	[25]
26	.	O	['N']	[26]
#4483
0	These	O	['N']	[0]
1	cases	O	['N']	[1]
2	suggest	O	['N']	[2]
3	the	O	['N']	[3]
4	possibility	O	['N']	[4]
5	that	O	['N']	[5]
6	,	O	['N']	[6]
7	in	O	['N']	[7]
8	some	O	['N']	[8]
9	patients	O	['N']	[9]
10	,	O	['N']	[10]
11	leukopenia	B-Adverse_Effect	['N']	[11]
12	or	O	['N']	[12]
13	agranulocytosis	O	['N']	[13]
14	during	O	['N']	[14]
15	olanzapine	B-Drug	['Causes']	[11]
16	treatment	O	['N']	[16]
17	might	O	['N']	[17]
18	be	O	['N']	[18]
19	dose	O	['N']	[19]
20	-	O	['N']	[20]
21	related	O	['N']	[21]
22	.	O	['N']	[22]
#4484
0	A	O	['N']	[0]
1	review	O	['N']	[1]
2	of	O	['N']	[2]
3	the	O	['N']	[3]
4	literature	O	['N']	[4]
5	found	O	['N']	[5]
6	11	O	['N']	[6]
7	children	O	['N']	[7]
8	and	O	['N']	[8]
9	2	O	['N']	[9]
10	adults	O	['N']	[10]
11	in	O	['N']	[11]
12	whom	O	['N']	[12]
13	intranasal	O	['N']	[13]
14	desmopressin	B-Drug	['Causes']	[28]
15	was	O	['N']	[15]
16	associated	O	['N']	[16]
17	with	O	['N']	[17]
18	hyponatremia	O	['N']	[18]
19	,	O	['N']	[19]
20	all	O	['N']	[20]
21	of	O	['N']	[21]
22	whom	O	['N']	[22]
23	experienced	O	['N']	[23]
24	seizures	O	['N']	[24]
25	or	O	['N']	[25]
26	altered	B	['N']	[26]
27	mental	I	['N']	[27]
28	status	I-Adverse_Effect	['N']	[28]
29	.	O	['N']	[29]
#4485
0	Ibuprofen	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	meningitis	B-Adverse_Effect	['N']	[3]
4	:	O	['N']	[4]
5	detection	O	['N']	[5]
6	of	O	['N']	[6]
7	intrathecal	O	['N']	[7]
8	IgG	O	['N']	[8]
9	synthesis	O	['N']	[9]
10	and	O	['N']	[10]
11	immune	O	['N']	[11]
12	complexes	O	['N']	[12]
13	.	O	['N']	[13]
#4486
0	Based	O	['N']	[0]
1	on	O	['N']	[1]
2	these	O	['N']	[2]
3	findings	O	['N']	[3]
4	,	O	['N']	[4]
5	the	O	['N']	[5]
6	patient	O	['N']	[6]
7	was	O	['N']	[7]
8	diagnosed	O	['N']	[8]
9	with	O	['N']	[9]
10	diabetes	B	['N']	[10]
11	insipidus	I-Adverse_Effect	['N']	[11]
12	secondary	O	['N']	[12]
13	to	O	['N']	[13]
14	lithium	B-Drug	['Causes']	[11]
15	therapy	O	['N']	[15]
16	and	O	['N']	[16]
17	was	O	['N']	[17]
18	treated	O	['N']	[18]
19	successfully	O	['N']	[19]
20	with	O	['N']	[20]
21	amiloride	O	['N']	[21]
22	.	O	['N']	[22]
#4487
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	disulfiram	B	['N']	[7]
8	-	I	['N']	[8]
9	like	I	['N']	[9]
10	reaction	I-Adverse_Effect	['N']	[10]
11	with	O	['N']	[11]
12	cefmenoxime	B-Drug	['Causes']	[10]
13	.	O	['N']	[13]
#4488
0	The	O	['N']	[0]
1	favourable	O	['N']	[1]
2	outcome	O	['N']	[2]
3	in	O	['N']	[3]
4	these	O	['N']	[4]
5	two	O	['N']	[5]
6	patients	O	['N']	[6]
7	contrasts	O	['N']	[7]
8	with	O	['N']	[8]
9	the	O	['N']	[9]
10	fatal	O	['N']	[10]
11	outcome	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	two	O	['N']	[14]
15	other	O	['N']	[15]
16	reported	O	['N']	[16]
17	cases	O	['N']	[17]
18	of	O	['N']	[18]
19	nitrofurantoin	B-Drug	['Causes']	[21]
20	induced	I	['N']	[20]
21	BOOP	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#4489
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	Parkinson	O	['N']	[3]
4	's	O	['N']	[4]
5	disease	O	['N']	[5]
6	,	O	['N']	[6]
7	initially	O	['N']	[7]
8	treated	O	['N']	[8]
9	with	O	['N']	[9]
10	bromocriptine	B-Drug	['Causes']	[19]
11	and	O	['N']	[11]
12	subsequently	O	['N']	[12]
13	with	O	['N']	[13]
14	cabergoline	O	['N']	[14]
15	,	O	['N']	[15]
16	developed	O	['N']	[16]
17	progressive	O	['N']	[17]
18	pleuropulmonary	B	['N']	[18]
19	abnormalities	I-Adverse_Effect	['N']	[19]
20	during	O	['N']	[20]
21	the	O	['N']	[21]
22	latter	O	['N']	[22]
23	therapy	O	['N']	[23]
24	.	O	['N']	[24]
#4490
0	Coadministration	O	['N']	[0]
1	of	O	['N']	[1]
2	antidepressant	O	['N']	[2]
3	agents	O	['N']	[3]
4	such	O	['N']	[4]
5	as	O	['N']	[5]
6	nefazodone	B-Drug	['Causes']	[26]
7	,	O	['N']	[7]
8	or	O	['N']	[8]
9	any	O	['N']	[9]
10	other	O	['N']	[10]
11	drug	O	['N']	[11]
12	that	O	['N']	[12]
13	inhibits	O	['N']	[13]
14	the	O	['N']	[14]
15	CYP3A4	O	['N']	[15]
16	isoenzyme	O	['N']	[16]
17	subfamily	O	['N']	[17]
18	,	O	['N']	[18]
19	should	O	['N']	[19]
20	be	O	['N']	[20]
21	anticipated	O	['N']	[21]
22	to	O	['N']	[22]
23	interfere	B	['N']	[23]
24	with	I	['N']	[24]
25	tacrolimus	I	['N']	[25]
26	metabolism	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#4491
0	Intravenous	O	['N']	[0]
1	verapamil	O	['N']	[1]
2	therapy	O	['N']	[2]
3	in	O	['N']	[3]
4	babies	O	['N']	[4]
5	may	O	['N']	[5]
6	cause	O	['N']	[6]
7	apnea	O	['N']	[7]
8	,	O	['N']	[8]
9	hypotension	O	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	bradycardia	O	['N']	[12]
13	;	O	['N']	[13]
14	continued	O	['N']	[14]
15	episodes	O	['N']	[15]
16	of	O	['N']	[16]
17	atrial	O	['N']	[17]
18	flutter	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	child	O	['N']	[21]
22	may	O	['N']	[22]
23	cause	O	['N']	[23]
24	sudden	O	['N']	[24]
25	death	B-Adverse_Effect	['N']	[25]
26	;	O	['N']	[26]
27	quinidine	B-Drug	['Causes']	[25]
28	may	O	['N']	[28]
29	be	O	['N']	[29]
30	related	O	['N']	[30]
31	to	O	['N']	[31]
32	the	O	['N']	[32]
33	death	O	['N']	[33]
34	;	O	['N']	[34]
35	children	O	['N']	[35]
36	with	O	['N']	[36]
37	"	O	['N']	[37]
38	familial	O	['N']	[38]
39	seizure	O	['N']	[39]
40	disorders	O	['N']	[40]
41	"	O	['N']	[41]
42	may	O	['N']	[42]
43	in	O	['N']	[43]
44	fact	O	['N']	[44]
45	have	O	['N']	[45]
46	the	O	['N']	[46]
47	long	O	['N']	[47]
48	QT	O	['N']	[48]
49	interval	O	['N']	[49]
50	syndrome	O	['N']	[50]
51	.	O	['N']	[51]
#4492
0	CASE	O	['N']	[0]
1	REPORT	O	['N']	[1]
2	:	O	['N']	[2]
3	We	O	['N']	[3]
4	report	O	['N']	[4]
5	the	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	a	O	['N']	[8]
9	58	O	['N']	[9]
10	year	O	['N']	[10]
11	old	O	['N']	[11]
12	patient	O	['N']	[12]
13	who	O	['N']	[13]
14	,	O	['N']	[14]
15	after	O	['N']	[15]
16	2	O	['N']	[16]
17	days	O	['N']	[17]
18	of	O	['N']	[18]
19	treatment	O	['N']	[19]
20	with	O	['N']	[20]
21	roxithromycin	O	['N']	[21]
22	and	O	['N']	[22]
23	betamethasone	B-Drug	['Causes']	[27]
24	,	O	['N']	[24]
25	manifested	O	['N']	[25]
26	acute	B	['N']	[26]
27	pancreatitis	I-Adverse_Effect	['N']	[27]
28	.	O	['N']	[28]
#4493
0	A	O	['N']	[0]
1	44-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	is	O	['N']	[5]
6	described	O	['N']	[6]
7	in	O	['N']	[7]
8	whom	O	['N']	[8]
9	amiodarone	O	['N']	[9]
10	,	O	['N']	[10]
11	disopyramide	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	quinidine	B-Drug	['Causes']	[25]
15	,	O	['N']	[15]
16	administered	O	['N']	[16]
17	alone	O	['N']	[17]
18	separately	O	['N']	[18]
19	,	O	['N']	[19]
20	induced	O	['N']	[20]
21	atypical	O	['N']	[21]
22	ventricular	O	['N']	[22]
23	tachycardia	O	['N']	[23]
24	(	O	['N']	[24]
25	AVT	B-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	torsade	O	['N']	[27]
28	de	O	['N']	[28]
29	pointes	O	['N']	[29]
30	)	O	['N']	[30]
31	.	O	['N']	[31]
#4494
0	Intravenous	O	['N']	[0]
1	verapamil	B-Drug	['Causes']	[9]
2	therapy	O	['N']	[2]
3	in	O	['N']	[3]
4	babies	O	['N']	[4]
5	may	O	['N']	[5]
6	cause	O	['N']	[6]
7	apnea	O	['N']	[7]
8	,	O	['N']	[8]
9	hypotension	B-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	and	O	['N']	[11]
12	bradycardia	O	['N']	[12]
13	;	O	['N']	[13]
14	continued	O	['N']	[14]
15	episodes	O	['N']	[15]
16	of	O	['N']	[16]
17	atrial	O	['N']	[17]
18	flutter	O	['N']	[18]
19	in	O	['N']	[19]
20	a	O	['N']	[20]
21	child	O	['N']	[21]
22	may	O	['N']	[22]
23	cause	O	['N']	[23]
24	sudden	O	['N']	[24]
25	death	O	['N']	[25]
26	;	O	['N']	[26]
27	quinidine	O	['N']	[27]
28	may	O	['N']	[28]
29	be	O	['N']	[29]
30	related	O	['N']	[30]
31	to	O	['N']	[31]
32	the	O	['N']	[32]
33	death	O	['N']	[33]
34	;	O	['N']	[34]
35	children	O	['N']	[35]
36	with	O	['N']	[36]
37	"	O	['N']	[37]
38	familial	O	['N']	[38]
39	seizure	O	['N']	[39]
40	disorders	O	['N']	[40]
41	"	O	['N']	[41]
42	may	O	['N']	[42]
43	in	O	['N']	[43]
44	fact	O	['N']	[44]
45	have	O	['N']	[45]
46	the	O	['N']	[46]
47	long	O	['N']	[47]
48	QT	O	['N']	[48]
49	interval	O	['N']	[49]
50	syndrome	O	['N']	[50]
51	.	O	['N']	[51]
#4495
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	's	O	['N']	[2]
3	defects	O	['N']	[3]
4	may	O	['N']	[4]
5	be	O	['N']	[5]
6	due	O	['N']	[6]
7	to	O	['N']	[7]
8	methimazole	B-Drug	['Causes']	[9]
9	teratogenicity	B-Adverse_Effect	['N']	[9]
10	or	O	['N']	[10]
11	could	O	['N']	[11]
12	represent	O	['N']	[12]
13	a	O	['N']	[13]
14	previously	O	['N']	[14]
15	undescribed	O	['N']	[15]
16	syndrome	O	['N']	[16]
17	affecting	O	['N']	[17]
18	ectodermal	O	['N']	[18]
19	structures	O	['N']	[19]
20	.	O	['N']	[20]
#4496
0	In	O	['N']	[0]
1	one	O	['N']	[1]
2	patient	O	['N']	[2]
3	the	O	['N']	[3]
4	vasculitis	O	['N']	[4]
5	resolved	O	['N']	[5]
6	after	O	['N']	[6]
7	termination	O	['N']	[7]
8	of	O	['N']	[8]
9	the	O	['N']	[9]
10	ciprofloxacin	B-Drug	['Causes']	[29]
11	therapy	O	['N']	[11]
12	;	O	['N']	[12]
13	in	O	['N']	[13]
14	the	O	['N']	[14]
15	other	O	['N']	[15]
16	patient	O	['N']	[16]
17	the	O	['N']	[17]
18	ciprofloxacin	O	['N']	[18]
19	-	O	['N']	[19]
20	induced	O	['N']	[20]
21	hemorrhagic	O	['N']	[21]
22	vasculitis	O	['N']	[22]
23	was	O	['N']	[23]
24	superimposed	O	['N']	[24]
25	on	O	['N']	[25]
26	a	O	['N']	[26]
27	severe	B	['N']	[27]
28	forefoot	I	['N']	[28]
29	infection	I-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	leading	O	['N']	[31]
32	to	O	['N']	[32]
33	progressive	O	['N']	[33]
34	gangrene	O	['N']	[34]
35	and	O	['N']	[35]
36	a	O	['N']	[36]
37	below	O	['N']	[37]
38	-	O	['N']	[38]
39	knee	O	['N']	[39]
40	amputation	O	['N']	[40]
41	.	O	['N']	[41]
#4497
0	A	O	['N']	[0]
1	34-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	lady	O	['N']	[4]
5	developed	O	['N']	[5]
6	a	O	['N']	[6]
7	constellation	O	['N']	[7]
8	of	O	['N']	[8]
9	dermatitis	O	['N']	[9]
10	,	O	['N']	[10]
11	fever	O	['N']	[11]
12	,	O	['N']	[12]
13	lymphadenopathy	O	['N']	[13]
14	and	O	['N']	[14]
15	hepatitis	B-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	beginning	O	['N']	[17]
18	on	O	['N']	[18]
19	the	O	['N']	[19]
20	17th	O	['N']	[20]
21	day	O	['N']	[21]
22	of	O	['N']	[22]
23	a	O	['N']	[23]
24	course	O	['N']	[24]
25	of	O	['N']	[25]
26	oral	O	['N']	[26]
27	sulphasalazine	B-Drug	['Causes']	[15]
28	for	O	['N']	[28]
29	sero	O	['N']	[29]
30	-	O	['N']	[30]
31	negative	O	['N']	[31]
32	rheumatoid	O	['N']	[32]
33	arthritis	O	['N']	[33]
34	.	O	['N']	[34]
#4498
0	We	O	['N']	[0]
1	observed	O	['N']	[1]
2	transient	O	['N']	[2]
3	panhypogammaglobulinaemia	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	neuropsychiatric	O	['N']	[8]
9	SLE	O	['N']	[9]
10	after	O	['N']	[10]
11	treatment	O	['N']	[11]
12	with	O	['N']	[12]
13	prednisolone	O	['N']	[13]
14	and	O	['N']	[14]
15	cyclophosphamide	B-Drug	['Causes']	[3]
16	.	O	['N']	[16]
#4499
0	Acute	B	['N']	[0]
1	reversible	I	['N']	[1]
2	ataxo	I	['N']	[2]
3	-	I	['N']	[3]
4	myoclonic	I	['N']	[4]
5	encephalopathy	I-Adverse_Effect	['N']	[5]
6	with	O	['N']	[6]
7	flecainide	B-Drug	['Causes']	[5]
8	therapy	O	['N']	[8]
9	.	O	['N']	[9]
#4500
0	In	O	['N']	[0]
1	both	O	['N']	[1]
2	cases	O	['N']	[2]
3	,	O	['N']	[3]
4	high	O	['N']	[4]
5	fever	O	['N']	[5]
6	,	O	['N']	[6]
7	skin	B	['N']	[7]
8	rash	I-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	liver	O	['N']	[10]
11	dysfunction	O	['N']	[11]
12	and	O	['N']	[12]
13	atypical	O	['N']	[13]
14	lymphocytosis	O	['N']	[14]
15	developed	O	['N']	[15]
16	3	O	['N']	[16]
17	weeks	O	['N']	[17]
18	after	O	['N']	[18]
19	initiating	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	SASP	B-Drug	['Causes']	[8]
23	.	O	['N']	[23]
#4501
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	NHL	O	['N']	[6]
7	patient	O	['N']	[7]
8	who	O	['N']	[8]
9	received	O	['N']	[9]
10	rituximab	B-Drug	['Causes']	[23]
11	and	O	['N']	[11]
12	developed	O	['N']	[12]
13	symptomatic	O	['N']	[13]
14	,	O	['N']	[14]
15	biopsy	O	['N']	[15]
16	-	O	['N']	[16]
17	proven	O	['N']	[17]
18	multinodular	O	['N']	[18]
19	bronchiolitis	B	['N']	[19]
20	obliterans	I	['N']	[20]
21	with	I	['N']	[21]
22	organizing	I	['N']	[22]
23	pneumonia	I-Adverse_Effect	['N']	[23]
24	(	O	['N']	[24]
25	BOOP	O	['N']	[25]
26	)	O	['N']	[26]
27	.	O	['N']	[27]
#4502
0	The	O	['N']	[0]
1	literature	O	['N']	[1]
2	is	O	['N']	[2]
3	also	O	['N']	[3]
4	reviewed	O	['N']	[4]
5	for	O	['N']	[5]
6	ARF	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	mannitol	B-Drug	['Causes']	[31]
10	infusion	O	['N']	[10]
11	in	O	['N']	[11]
12	patients	O	['N']	[12]
13	who	O	['N']	[13]
14	received	O	['N']	[14]
15	dialysis	O	['N']	[15]
16	and	O	['N']	[16]
17	those	O	['N']	[17]
18	who	O	['N']	[18]
19	did	O	['N']	[19]
20	not	O	['N']	[20]
21	receive	O	['N']	[21]
22	dialysis	O	['N']	[22]
23	;	O	['N']	[23]
24	and	O	['N']	[24]
25	the	O	['N']	[25]
26	possible	O	['N']	[26]
27	mechanism(s	O	['N']	[27]
28	)	O	['N']	[28]
29	of	O	['N']	[29]
30	mannitol	O	['N']	[30]
31	nephrotoxicity	B-Adverse_Effect	['N']	[31]
32	are	O	['N']	[32]
33	discussed	O	['N']	[33]
34	.	O	['N']	[34]
#4503
0	Reports	O	['N']	[0]
1	of	O	['N']	[1]
2	colonic	B	['N']	[2]
3	perforation	I-Adverse_Effect	['N']	[3]
4	as	O	['N']	[4]
5	a	O	['N']	[5]
6	result	O	['N']	[6]
7	of	O	['N']	[7]
8	the	O	['N']	[8]
9	administration	O	['N']	[9]
10	of	O	['N']	[10]
11	calcium	B	['N']	[11]
12	polystyrene	I	['N']	[12]
13	sulfonate	I-Drug	['Causes']	[3]
14	and	O	['N']	[14]
15	sorbitol	O	['N']	[15]
16	are	O	['N']	[16]
17	rare	O	['N']	[17]
18	.	O	['N']	[18]
#4504
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	unusual	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	simultaneous	O	['N']	[6]
7	transitional	O	['N']	[7]
8	cell	O	['N']	[8]
9	carcinoma	O	['N']	[9]
10	of	O	['N']	[10]
11	the	O	['N']	[11]
12	renal	O	['N']	[12]
13	pelvis	O	['N']	[13]
14	and	O	['N']	[14]
15	distal	B	['N']	[15]
16	ureter	I	['N']	[16]
17	without	I	['N']	[17]
18	transitional	I	['N']	[18]
19	cell	I	['N']	[19]
20	carcinoma	I	['N']	[20]
21	of	I	['N']	[21]
22	the	I	['N']	[22]
23	bladder	I-Adverse_Effect	['N']	[23]
24	occurring	O	['N']	[24]
25	after	O	['N']	[25]
26	chronic	O	['N']	[26]
27	cyclophosphamide	B-Drug	['Causes']	[23]
28	therapy	O	['N']	[28]
29	for	O	['N']	[29]
30	nonHodgkin	O	['N']	[30]
31	's	O	['N']	[31]
32	lymphoma	O	['N']	[32]
33	.	O	['N']	[33]
#4505
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	depressive	O	['N']	[3]
4	patient	O	['N']	[4]
5	who	O	['N']	[5]
6	developed	O	['N']	[6]
7	mild	B	['N']	[7]
8	parkinsonian	I	['N']	[8]
9	signs	I-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	camptocormia	O	['N']	[11]
12	after	O	['N']	[12]
13	the	O	['N']	[13]
14	introduction	O	['N']	[14]
15	of	O	['N']	[15]
16	olanzapine	B-Drug	['Causes']	[9]
17	.	O	['N']	[17]
#4506
0	Can	O	['N']	[0]
1	ketamine	B-Drug	['Causes']	[10]
2	prescribed	O	['N']	[2]
3	for	O	['N']	[3]
4	pain	O	['N']	[4]
5	cause	O	['N']	[5]
6	damage	B	['N']	[6]
7	to	I	['N']	[7]
8	the	I	['N']	[8]
9	urinary	I	['N']	[9]
10	tract	I-Adverse_Effect	['N']	[10]
11	?	O	['N']	[11]
#4507
0	An	O	['N']	[0]
1	83-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	receiving	O	['N']	[5]
6	glipizide	O	['N']	[6]
7	10	O	['N']	[7]
8	mg	O	['N']	[8]
9	bid	O	['N']	[9]
10	developed	O	['N']	[10]
11	symptomatic	B	['N']	[11]
12	hypoglycemia	I-Adverse_Effect	['N']	[12]
13	within	O	['N']	[13]
14	three	O	['N']	[14]
15	days	O	['N']	[15]
16	of	O	['N']	[16]
17	adding	O	['N']	[17]
18	trimethoprim	O	['N']	[18]
19	/	O	['N']	[19]
20	sulfamethoxazole	B-Drug	['Causes']	[12]
21	(	O	['N']	[21]
22	TMP	O	['N']	[22]
23	/	O	['N']	[23]
24	SMX	O	['N']	[24]
25	)	O	['N']	[25]
26	to	O	['N']	[26]
27	his	O	['N']	[27]
28	regimen	O	['N']	[28]
29	.	O	['N']	[29]
#4508
0	A	O	['N']	[0]
1	16-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	developed	O	['N']	[5]
6	fever	B-Adverse_Effect	['N']	[6]
7	,	O	['N']	[7]
8	generalized	O	['N']	[8]
9	rigidity	O	['N']	[9]
10	,	O	['N']	[10]
11	leukocytosis	O	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	increased	O	['N']	[14]
15	serum	O	['N']	[15]
16	transaminase	O	['N']	[16]
17	and	O	['N']	[17]
18	creatine	O	['N']	[18]
19	kinase	O	['N']	[19]
20	levels	O	['N']	[20]
21	while	O	['N']	[21]
22	receiving	O	['N']	[22]
23	treatment	O	['N']	[23]
24	with	O	['N']	[24]
25	olanzapine	B-Drug	['Causes']	[6]
26	and	O	['N']	[26]
27	lithium	O	['N']	[27]
28	.	O	['N']	[28]
#4509
0	A	O	['N']	[0]
1	22-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	black	O	['N']	[4]
5	man	O	['N']	[5]
6	developed	O	['N']	[6]
7	fever	O	['N']	[7]
8	,	O	['N']	[8]
9	chills	O	['N']	[9]
10	,	O	['N']	[10]
11	fatigue	O	['N']	[11]
12	,	O	['N']	[12]
13	night	O	['N']	[13]
14	sweats	O	['N']	[14]
15	,	O	['N']	[15]
16	tender	O	['N']	[16]
17	lymphadenopathy	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	a	O	['N']	[20]
21	generalized	B	['N']	[21]
22	,	I	['N']	[22]
23	pruritic	I	['N']	[23]
24	,	I	['N']	[24]
25	macular	I	['N']	[25]
26	eruption	I-Adverse_Effect	['N']	[26]
27	3	O	['N']	[27]
28	weeks	O	['N']	[28]
29	after	O	['N']	[29]
30	starting	O	['N']	[30]
31	minocycline	B-Drug	['Causes']	[26]
32	therapy	O	['N']	[32]
33	for	O	['N']	[33]
34	acne	O	['N']	[34]
35	.	O	['N']	[35]
#4510
0	A	O	['N']	[0]
1	33-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	a	O	['N']	[6]
7	history	O	['N']	[7]
8	of	O	['N']	[8]
9	recreational	O	['N']	[9]
10	benztropine	B-Drug	['Causes']	[24]
11	abuse	O	['N']	[11]
12	presented	O	['N']	[12]
13	to	O	['N']	[13]
14	the	O	['N']	[14]
15	emergency	O	['N']	[15]
16	department	O	['N']	[16]
17	with	O	['N']	[17]
18	confusion	O	['N']	[18]
19	,	O	['N']	[19]
20	abdominal	O	['N']	[20]
21	pain	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	distention	B-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#4511
0	The	O	['N']	[0]
1	HIV	O	['N']	[1]
2	protease	O	['N']	[2]
3	inhibitor	O	['N']	[3]
4	indinavir	B-Drug	['Causes']	[7]
5	may	O	['N']	[5]
6	cause	O	['N']	[6]
7	nephrolithiasis	B-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	interstitial	O	['N']	[9]
10	nephritis	O	['N']	[10]
11	.	O	['N']	[11]
#4512
0	Therefore	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	diagnosed	O	['N']	[3]
4	her	O	['N']	[4]
5	eruption	O	['N']	[5]
6	as	O	['N']	[6]
7	contact	B	['N']	[7]
8	dermatitis	I-Adverse_Effect	['N']	[8]
9	due	O	['N']	[9]
10	to	O	['N']	[10]
11	sodium	B	['N']	[11]
12	bisulfite	I-Drug	['Causes']	[8]
13	.	O	['N']	[13]
#4513
0	Symptoms	O	['N']	[0]
1	and	O	['N']	[1]
2	endoscopic	B	['N']	[2]
3	lesions	I-Adverse_Effect	['N']	[3]
4	quickly	O	['N']	[4]
5	regressed	O	['N']	[5]
6	within	O	['N']	[6]
7	1	O	['N']	[7]
8	week	O	['N']	[8]
9	of	O	['N']	[9]
10	meloxicam	B-Drug	['Causes']	[3]
11	withdrawal	O	['N']	[11]
12	.	O	['N']	[12]
#4514
0	Bulbar	O	['N']	[0]
1	and	O	['N']	[1]
2	pseudobulbar	O	['N']	[2]
3	palsy	O	['N']	[3]
4	complicating	O	['N']	[4]
5	therapy	O	['N']	[5]
6	with	O	['N']	[6]
7	high	B	['N']	[7]
8	-	I	['N']	[8]
9	dose	I-Dose	['N']	[9]
10	cytosine	B	['N']	[10]
11	arabinoside	I-Drug	['Dosage']	[9]
12	in	O	['N']	[12]
13	children	O	['N']	[13]
14	with	O	['N']	[14]
15	leukemia	O	['N']	[15]
16	.	O	['N']	[16]
#4515
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	rare	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	colonic	B	['N']	[6]
7	mucosal	I	['N']	[7]
8	necrosis	I-Adverse_Effect	['N']	[8]
9	following	O	['N']	[9]
10	Kalimate	B-Drug	['Causes']	[8]
11	(	O	['N']	[11]
12	calcium	O	['N']	[12]
13	polystryrene	O	['N']	[13]
14	sulfonate	O	['N']	[14]
15	)	O	['N']	[15]
16	,	O	['N']	[16]
17	an	O	['N']	[17]
18	analogue	O	['N']	[18]
19	of	O	['N']	[19]
20	Kayexalate	O	['N']	[20]
21	without	O	['N']	[21]
22	sorbitol	O	['N']	[22]
23	in	O	['N']	[23]
24	a	O	['N']	[24]
25	34-yr	O	['N']	[25]
26	-	O	['N']	[26]
27	old	O	['N']	[27]
28	man	O	['N']	[28]
29	.	O	['N']	[29]
#4516
0	While	O	['N']	[0]
1	40	B	['N']	[1]
2	mg	I	['N']	[2]
3	/	I	['N']	[3]
4	day	I-Dose	['N']	[4]
5	of	O	['N']	[5]
6	prednisolone	B-Drug	['Dosage']	[4]
7	improved	O	['N']	[7]
8	hepatic	O	['N']	[8]
9	dysfunction	O	['N']	[9]
10	dramatically	O	['N']	[10]
11	,	O	['N']	[11]
12	her	O	['N']	[12]
13	diabetic	O	['N']	[13]
14	milieu	O	['N']	[14]
15	deteriorated	O	['N']	[15]
16	seriously	O	['N']	[16]
17	.	O	['N']	[17]
#4517
0	Infliximab	O	['N']	[0]
1	and	O	['N']	[1]
2	its	O	['N']	[2]
3	serious	O	['N']	[3]
4	adverse	O	['N']	[4]
5	effects	O	['N']	[5]
6	are	O	['N']	[6]
7	discussed	O	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	other	O	['N']	[10]
11	cases	O	['N']	[11]
12	of	O	['N']	[12]
13	osteomyelitis	B-Adverse_Effect	['N']	[13]
14	with	O	['N']	[14]
15	infliximab	B-Drug	['Causes']	[13]
16	use	O	['N']	[16]
17	are	O	['N']	[17]
18	also	O	['N']	[18]
19	reviewed	O	['N']	[19]
20	.	O	['N']	[20]
#4518
0	FDE	B-Adverse_Effect	['N']	[0]
1	from	O	['N']	[1]
2	cephalosporins	O	['N']	[2]
3	has	O	['N']	[3]
4	been	O	['N']	[4]
5	rarely	O	['N']	[5]
6	reported	O	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	to	O	['N']	[9]
10	the	O	['N']	[10]
11	best	O	['N']	[11]
12	of	O	['N']	[12]
13	our	O	['N']	[13]
14	knowledge	O	['N']	[14]
15	there	O	['N']	[15]
16	is	O	['N']	[16]
17	no	O	['N']	[17]
18	published	O	['N']	[18]
19	report	O	['N']	[19]
20	of	O	['N']	[20]
21	ceftriaxone	B-Drug	['Causes']	[0]
22	-	O	['N']	[22]
23	induced	O	['N']	[23]
24	FDE	O	['N']	[24]
25	in	O	['N']	[25]
26	the	O	['N']	[26]
27	literature	O	['N']	[27]
28	.	O	['N']	[28]
#4519
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	acute	B	['N']	[2]
3	cardiomyopathy	I-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	pericarditis	O	['N']	[5]
6	secondary	O	['N']	[6]
7	to	O	['N']	[7]
8	methylphenidate	B-Drug	['Causes']	[3]
9	use	O	['N']	[9]
10	has	O	['N']	[10]
11	been	O	['N']	[11]
12	rarely	O	['N']	[12]
13	reported	O	['N']	[13]
14	.	O	['N']	[14]
#4520
0	Carboplatin	O	['N']	[0]
1	hypersensitivity	O	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	low	B	['N']	[4]
5	-	I	['N']	[5]
6	dose	I-Dose	['N']	[6]
7	paclitaxel	B-Drug	['Dosage']	[6]
8	/	O	['N']	[8]
9	carboplatin	O	['N']	[9]
10	in	O	['N']	[10]
11	multiple	O	['N']	[11]
12	platinum	O	['N']	[12]
13	-	O	['N']	[13]
14	treated	O	['N']	[14]
15	patients	O	['N']	[15]
16	with	O	['N']	[16]
17	recurrent	O	['N']	[17]
18	ovarian	O	['N']	[18]
19	cancer	O	['N']	[19]
20	.	O	['N']	[20]
#4521
0	Methimazole	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	aplastic	B	['N']	[3]
4	anemia	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	third	O	['N']	[6]
7	exposure	O	['N']	[7]
8	:	O	['N']	[8]
9	successful	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	recombinant	O	['N']	[12]
13	human	O	['N']	[13]
14	granulocyte	O	['N']	[14]
15	colony	O	['N']	[15]
16	-	O	['N']	[16]
17	stimulating	O	['N']	[17]
18	factor	O	['N']	[18]
19	.	O	['N']	[19]
#4522
0	He	O	['N']	[0]
1	had	O	['N']	[1]
2	been	O	['N']	[2]
3	taking	O	['N']	[3]
4	trimethoprim	B-Drug	['Causes']	[34]
5	-	O	['N']	[5]
6	sulfamethoxazole	O	['N']	[6]
7	for	O	['N']	[7]
8	approximately	O	['N']	[8]
9	eight	O	['N']	[9]
10	days	O	['N']	[10]
11	when	O	['N']	[11]
12	he	O	['N']	[12]
13	revisited	O	['N']	[13]
14	his	O	['N']	[14]
15	family	O	['N']	[15]
16	physician	O	['N']	[16]
17	,	O	['N']	[17]
18	complaining	O	['N']	[18]
19	of	O	['N']	[19]
20	headaches	O	['N']	[20]
21	,	O	['N']	[21]
22	dizziness	O	['N']	[22]
23	,	O	['N']	[23]
24	difficulty	O	['N']	[24]
25	with	O	['N']	[25]
26	speech	O	['N']	[26]
27	,	O	['N']	[27]
28	weakness	O	['N']	[28]
29	,	O	['N']	[29]
30	and	O	['N']	[30]
31	itching	B	['N']	[31]
32	on	I	['N']	[32]
33	the	I	['N']	[33]
34	trunk	I-Adverse_Effect	['N']	[34]
35	of	O	['N']	[35]
36	his	O	['N']	[36]
37	body	O	['N']	[37]
38	and	O	['N']	[38]
39	legs	O	['N']	[39]
40	,	O	['N']	[40]
41	where	O	['N']	[41]
42	a	O	['N']	[42]
43	maculopapular	O	['N']	[43]
44	rash	O	['N']	[44]
45	was	O	['N']	[45]
46	noted	O	['N']	[46]
47	.	O	['N']	[47]
#4523
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Among	O	['N']	[2]
3	the	O	['N']	[3]
4	many	O	['N']	[4]
5	presentations	O	['N']	[5]
6	of	O	['N']	[6]
7	ifosfamide	B-Drug	['Causes']	[8]
8	neurotoxicity	B-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	clinicians	O	['N']	[10]
11	should	O	['N']	[11]
12	consider	O	['N']	[12]
13	NCSE	O	['N']	[13]
14	as	O	['N']	[14]
15	a	O	['N']	[15]
16	possible	O	['N']	[16]
17	explanation	O	['N']	[17]
18	for	O	['N']	[18]
19	changes	O	['N']	[19]
20	in	O	['N']	[20]
21	consciousness	O	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	patient	O	['N']	[24]
25	receiving	O	['N']	[25]
26	this	O	['N']	[26]
27	agent	O	['N']	[27]
28	.	O	['N']	[28]
#4524
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	received	O	['N']	[2]
3	respectively	O	['N']	[3]
4	190	O	['N']	[4]
5	mg	O	['N']	[5]
6	,	O	['N']	[6]
7	175	B	['N']	[7]
8	mg	I-Dose	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	196	O	['N']	[11]
12	mg	O	['N']	[12]
13	of	O	['N']	[13]
14	methotrexate	B-Drug	['Dosage']	[8]
15	and	O	['N']	[15]
16	developed	O	['N']	[16]
17	bilateral	O	['N']	[17]
18	pulmonary	O	['N']	[18]
19	infiltrates	O	['N']	[19]
20	without	O	['N']	[20]
21	evidence	O	['N']	[21]
22	of	O	['N']	[22]
23	peripheral	O	['N']	[23]
24	blood	O	['N']	[24]
25	eosinophilia	O	['N']	[25]
26	.	O	['N']	[26]
#4525
0	In	O	['N']	[0]
1	each	O	['N']	[1]
2	of	O	['N']	[2]
3	the	O	['N']	[3]
4	three	O	['N']	[4]
5	reported	O	['N']	[5]
6	patients	O	['N']	[6]
7	,	O	['N']	[7]
8	alteration	B	['N']	[8]
9	of	I	['N']	[9]
10	eyelid	I	['N']	[10]
11	appearance	I-Adverse_Effect	['N']	[11]
12	with	O	['N']	[12]
13	deepening	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	lid	O	['N']	[16]
17	sulcus	O	['N']	[17]
18	was	O	['N']	[18]
19	evident	O	['N']	[19]
20	as	O	['N']	[20]
21	the	O	['N']	[21]
22	result	O	['N']	[22]
23	of	O	['N']	[23]
24	topical	O	['N']	[24]
25	bimatoprost	B-Drug	['Causes']	[11]
26	therapy	O	['N']	[26]
27	.	O	['N']	[27]
#4526
0	To	O	['N']	[0]
1	our	O	['N']	[1]
2	knowledge	O	['N']	[2]
3	,	O	['N']	[3]
4	this	O	['N']	[4]
5	is	O	['N']	[5]
6	the	O	['N']	[6]
7	first	O	['N']	[7]
8	case	O	['N']	[8]
9	report	O	['N']	[9]
10	that	O	['N']	[10]
11	demonstrates	O	['N']	[11]
12	the	O	['N']	[12]
13	occurrence	O	['N']	[13]
14	of	O	['N']	[14]
15	fever	B-Adverse_Effect	['N']	[15]
16	with	O	['N']	[16]
17	low	O	['N']	[17]
18	-	O	['N']	[18]
19	dose	O	['N']	[19]
20	amifostine	B-Drug	['Causes']	[15]
21	therapy	O	['N']	[21]
22	without	O	['N']	[22]
23	the	O	['N']	[23]
24	manifestation	O	['N']	[24]
25	of	O	['N']	[25]
26	accompanying	O	['N']	[26]
27	rash	O	['N']	[27]
28	or	O	['N']	[28]
29	hypotension	O	['N']	[29]
30	.	O	['N']	[30]
#4527
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	2	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	serotonin	O	['N']	[7]
8	syndrome	O	['N']	[8]
9	with	O	['N']	[9]
10	serious	O	['N']	[10]
11	extrapyramidal	B	['N']	[11]
12	movement	I	['N']	[12]
13	disorders	I-Adverse_Effect	['N']	[13]
14	occurring	O	['N']	[14]
15	when	O	['N']	[15]
16	metoclopramide	O	['N']	[16]
17	was	O	['N']	[17]
18	coadministered	O	['N']	[18]
19	with	O	['N']	[19]
20	sertraline	B-Drug	['Causes']	[13]
21	or	O	['N']	[21]
22	venlafaxine	O	['N']	[22]
23	.	O	['N']	[23]
#4528
0	A	O	['N']	[0]
1	diagnosis	O	['N']	[1]
2	of	O	['N']	[2]
3	trastuzumab	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	pneumonitis	B-Adverse_Effect	['N']	[6]
7	was	O	['N']	[7]
8	made	O	['N']	[8]
9	.	O	['N']	[9]
#4529
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	intrathecal	O	['N']	[5]
6	methotrexate	B-Drug	['Causes']	[7]
7	neurotoxicity	B-Adverse_Effect	['N']	[7]
8	manifesting	O	['N']	[8]
9	as	O	['N']	[9]
10	left	O	['N']	[10]
11	arm	O	['N']	[11]
12	weakness	O	['N']	[12]
13	and	O	['N']	[13]
14	aphasia	O	['N']	[14]
15	.	O	['N']	[15]
#4530
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	2	O	['N']	[4]
5	cases	O	['N']	[5]
6	of	O	['N']	[6]
7	serotonin	B	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	with	O	['N']	[9]
10	serious	O	['N']	[10]
11	extrapyramidal	O	['N']	[11]
12	movement	O	['N']	[12]
13	disorders	O	['N']	[13]
14	occurring	O	['N']	[14]
15	when	O	['N']	[15]
16	metoclopramide	O	['N']	[16]
17	was	O	['N']	[17]
18	coadministered	O	['N']	[18]
19	with	O	['N']	[19]
20	sertraline	O	['N']	[20]
21	or	O	['N']	[21]
22	venlafaxine	B-Drug	['Causes']	[8]
23	.	O	['N']	[23]
#4531
0	The	O	['N']	[0]
1	favourable	O	['N']	[1]
2	outcome	O	['N']	[2]
3	in	O	['N']	[3]
4	these	O	['N']	[4]
5	two	O	['N']	[5]
6	patients	O	['N']	[6]
7	contrasts	O	['N']	[7]
8	with	O	['N']	[8]
9	the	O	['N']	[9]
10	fatal	B	['N']	[10]
11	outcome	I-Adverse_Effect	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	two	O	['N']	[14]
15	other	O	['N']	[15]
16	reported	O	['N']	[16]
17	cases	O	['N']	[17]
18	of	O	['N']	[18]
19	nitrofurantoin	B-Drug	['Causes']	[11]
20	induced	O	['N']	[20]
21	BOOP	O	['N']	[21]
22	.	O	['N']	[22]
#4532
0	PVT	B-Adverse_Effect	['N']	[0]
1	during	O	['N']	[1]
2	chemotherapy	O	['N']	[2]
3	in	O	['N']	[3]
4	children	O	['N']	[4]
5	is	O	['N']	[5]
6	a	O	['N']	[6]
7	rare	O	['N']	[7]
8	event	O	['N']	[8]
9	and	O	['N']	[9]
10	appears	O	['N']	[10]
11	to	O	['N']	[11]
12	be	O	['N']	[12]
13	closely	O	['N']	[13]
14	related	O	['N']	[14]
15	to	O	['N']	[15]
16	intensive	O	['N']	[16]
17	chemotherapy	O	['N']	[17]
18	containing	O	['N']	[18]
19	busulfan	B-Drug	['Causes']	[0]
20	and	O	['N']	[20]
21	to	O	['N']	[21]
22	be	O	['N']	[22]
23	associated	O	['N']	[23]
24	with	O	['N']	[24]
25	HVOD	O	['N']	[25]
26	.	O	['N']	[26]
#4533
0	Symptomatic	O	['N']	[0]
1	hypocalcaemia	O	['N']	[1]
2	and	O	['N']	[2]
3	renal	B	['N']	[3]
4	impairment	I-Adverse_Effect	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	bisphosphonate	B-Drug	['Causes']	[4]
8	treatment	O	['N']	[8]
9	in	O	['N']	[9]
10	patients	O	['N']	[10]
11	with	O	['N']	[11]
12	multiple	O	['N']	[12]
13	myeloma	O	['N']	[13]
14	.	O	['N']	[14]
#4534
0	Cholesterol	B	['N']	[0]
1	crystal	I	['N']	[1]
2	embolization	I-Adverse_Effect	['N']	[2]
3	-	O	['N']	[3]
4	associated	O	['N']	[4]
5	renal	O	['N']	[5]
6	failure	O	['N']	[6]
7	after	O	['N']	[7]
8	therapy	O	['N']	[8]
9	with	O	['N']	[9]
10	recombinant	O	['N']	[10]
11	tissue	B	['N']	[11]
12	-	I	['N']	[12]
13	type	I	['N']	[13]
14	plasminogen	I	['N']	[14]
15	activator	I-Drug	['Causes']	[2]
16	.	O	['N']	[16]
#4535
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	significant	O	['N']	[7]
8	hepatic	B	['N']	[8]
9	and	I	['N']	[9]
10	renal	I	['N']	[10]
11	failure	I-Adverse_Effect	['N']	[11]
12	with	O	['N']	[12]
13	the	O	['N']	[13]
14	use	O	['N']	[14]
15	of	O	['N']	[15]
16	argatroban	B-Drug	['Causes']	[11]
17	in	O	['N']	[17]
18	a	O	['N']	[18]
19	patient	O	['N']	[19]
20	with	O	['N']	[20]
21	heparin	O	['N']	[21]
22	-	O	['N']	[22]
23	induced	O	['N']	[23]
24	thrombocytopenia	O	['N']	[24]
25	(	O	['N']	[25]
26	HIT	O	['N']	[26]
27	)	O	['N']	[27]
28	requiring	O	['N']	[28]
29	continuous	O	['N']	[29]
30	veno	O	['N']	[30]
31	-	O	['N']	[31]
32	veno	O	['N']	[32]
33	hemodialysis	O	['N']	[33]
34	(	O	['N']	[34]
35	CVVHD	O	['N']	[35]
36	)	O	['N']	[36]
37	.	O	['N']	[37]
#4536
0	Renal	B	['N']	[0]
1	damage	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	long	O	['N']	[4]
5	term	O	['N']	[5]
6	use	O	['N']	[6]
7	of	O	['N']	[7]
8	lithium	B	['N']	[8]
9	carbonate	I-Drug	['Causes']	[1]
10	.	O	['N']	[10]
#4537
0	Ten	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	itraconazole	B-Drug	['Causes']	[38]
4	was	O	['N']	[4]
5	started	O	['N']	[5]
6	,	O	['N']	[6]
7	he	O	['N']	[7]
8	developed	O	['N']	[8]
9	paralytic	O	['N']	[9]
10	ileus	O	['N']	[10]
11	,	O	['N']	[11]
12	neurogenic	O	['N']	[12]
13	bladder	O	['N']	[13]
14	,	O	['N']	[14]
15	mild	O	['N']	[15]
16	left	O	['N']	[16]
17	ptosis	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	absence	O	['N']	[20]
21	of	O	['N']	[21]
22	deep	O	['N']	[22]
23	reflexes	O	['N']	[23]
24	,	O	['N']	[24]
25	with	O	['N']	[25]
26	severe	O	['N']	[26]
27	paralysis	O	['N']	[27]
28	of	O	['N']	[28]
29	the	O	['N']	[29]
30	lower	O	['N']	[30]
31	extremities	O	['N']	[31]
32	and	O	['N']	[32]
33	mild	B	['N']	[33]
34	weakness	I	['N']	[34]
35	of	I	['N']	[35]
36	the	I	['N']	[36]
37	upper	I	['N']	[37]
38	extremities	I-Adverse_Effect	['N']	[38]
39	.	O	['N']	[39]
#4538
0	Early	O	['N']	[0]
1	recognition	O	['N']	[1]
2	of	O	['N']	[2]
3	renal	O	['N']	[3]
4	toxicity	O	['N']	[4]
5	of	O	['N']	[5]
6	high	B	['N']	[6]
7	-	I	['N']	[7]
8	dose	I-Dose	['N']	[8]
9	methotrexate	B-Drug	['Dosage']	[8]
10	therapy	O	['N']	[10]
11	:	O	['N']	[11]
12	a	O	['N']	[12]
13	case	O	['N']	[13]
14	report	O	['N']	[14]
15	.	O	['N']	[15]
#4539
0	For	O	['N']	[0]
1	patients	O	['N']	[1]
2	who	O	['N']	[2]
3	suffer	O	['N']	[3]
4	from	O	['N']	[4]
5	osteogenic	O	['N']	[5]
6	sarcoma	O	['N']	[6]
7	and	O	['N']	[7]
8	have	O	['N']	[8]
9	anaphylactic	B	['N']	[9]
10	reactions	I-Adverse_Effect	['N']	[10]
11	to	O	['N']	[11]
12	MTX	B-Drug	['Causes']	[10]
13	,	O	['N']	[13]
14	this	O	['N']	[14]
15	desensitization	O	['N']	[15]
16	protocol	O	['N']	[16]
17	will	O	['N']	[17]
18	allow	O	['N']	[18]
19	these	O	['N']	[19]
20	patients	O	['N']	[20]
21	to	O	['N']	[21]
22	continue	O	['N']	[22]
23	with	O	['N']	[23]
24	needed	O	['N']	[24]
25	therapeutic	O	['N']	[25]
26	or	O	['N']	[26]
27	palliative	O	['N']	[27]
28	chemotherapy	O	['N']	[28]
29	.	O	['N']	[29]
#4540
0	Some	O	['N']	[0]
1	patients	O	['N']	[1]
2	develop	O	['N']	[2]
3	hypersensitivity	B	['N']	[3]
4	rash	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	response	O	['N']	[6]
7	to	O	['N']	[7]
8	HCQ	B-Drug	['Causes']	[4]
9	.	O	['N']	[9]
#4541
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	child	O	['N']	[6]
7	with	O	['N']	[7]
8	neurodevelopmental	O	['N']	[8]
9	delay	O	['N']	[9]
10	with	O	['N']	[10]
11	chronic	O	['N']	[11]
12	constipation	O	['N']	[12]
13	and	O	['N']	[13]
14	a	O	['N']	[14]
15	history	O	['N']	[15]
16	of	O	['N']	[16]
17	chronic	O	['N']	[17]
18	mineral	B	['N']	[18]
19	oil	I-Drug	['Causes']	[28]
20	ingestion	O	['N']	[20]
21	presenting	O	['N']	[21]
22	as	O	['N']	[22]
23	asymptomatic	O	['N']	[23]
24	exogenous	O	['N']	[24]
25	lipoid	O	['N']	[25]
26	pneumonia	O	['N']	[26]
27	(	O	['N']	[27]
28	ELP	B-Adverse_Effect	['N']	[28]
29	)	O	['N']	[29]
30	.	O	['N']	[30]
#4542
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	case	O	['N']	[2]
3	report	O	['N']	[3]
4	,	O	['N']	[4]
5	we	O	['N']	[5]
6	present	O	['N']	[6]
7	clinical	O	['N']	[7]
8	and	O	['N']	[8]
9	laboratory	O	['N']	[9]
10	findings	O	['N']	[10]
11	of	O	['N']	[11]
12	a	O	['N']	[12]
13	case	O	['N']	[13]
14	with	O	['N']	[14]
15	chronic	O	['N']	[15]
16	hepatitis	O	['N']	[16]
17	B	O	['N']	[17]
18	that	O	['N']	[18]
19	developed	O	['N']	[19]
20	acute	B	['N']	[20]
21	dystonia	I-Adverse_Effect	['N']	[21]
22	soon	O	['N']	[22]
23	after	O	['N']	[23]
24	the	O	['N']	[24]
25	first	O	['N']	[25]
26	dose	O	['N']	[26]
27	of	O	['N']	[27]
28	pegylated	B	['N']	[28]
29	interferon	I	['N']	[29]
30	alpha	I-Drug	['Causes']	[21]
31	.	O	['N']	[31]
#4543
0	Sustained	B	['N']	[0]
1	hypothyroidism	I-Adverse_Effect	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	recombinant	B	['N']	[4]
5	alpha	I	['N']	[5]
6	interferon	I-Drug	['Causes']	[1]
7	in	O	['N']	[7]
8	patients	O	['N']	[8]
9	with	O	['N']	[9]
10	chronic	O	['N']	[10]
11	hepatitis	O	['N']	[11]
12	C.	O	['N']	[12]
#4544
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	Double	O	['N']	[2]
3	-	O	['N']	[3]
4	blind	O	['N']	[4]
5	,	O	['N']	[5]
6	placebo	O	['N']	[6]
7	-	O	['N']	[7]
8	controlled	O	['N']	[8]
9	titrated	O	['N']	[9]
10	oral	O	['N']	[10]
11	challenges	O	['N']	[11]
12	with	O	['N']	[12]
13	pancreatic	O	['N']	[13]
14	enzymes	O	['N']	[14]
15	resulted	O	['N']	[15]
16	in	O	['N']	[16]
17	definite	O	['N']	[17]
18	vomiting	B-Adverse_Effect	['N']	[18]
19	within	O	['N']	[19]
20	1	O	['N']	[20]
21	to	O	['N']	[21]
22	1.5	O	['N']	[22]
23	hours	O	['N']	[23]
24	after	O	['N']	[24]
25	challenges	O	['N']	[25]
26	with	O	['N']	[26]
27	Viokase	O	['N']	[27]
28	and	O	['N']	[28]
29	Pancrease	B	['N']	[29]
30	MT	I	['N']	[30]
31	16	I-Drug	['Causes']	[18]
32	,	O	['N']	[32]
33	but	O	['N']	[33]
34	not	O	['N']	[34]
35	with	O	['N']	[35]
36	placebo	O	['N']	[36]
37	.	O	['N']	[37]
#4545
0	Therapy	O	['N']	[0]
1	with	O	['N']	[1]
2	IFN	B	['N']	[2]
3	-	I	['N']	[3]
4	alpha	I-Drug	['Causes']	[17]
5	may	O	['N']	[5]
6	be	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	number	O	['N']	[10]
11	of	O	['N']	[11]
12	neuropsychiatric	O	['N']	[12]
13	symptoms	O	['N']	[13]
14	,	O	['N']	[14]
15	such	O	['N']	[15]
16	as	O	['N']	[16]
17	Parkinsonism	B-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	akathisia	O	['N']	[19]
20	,	O	['N']	[20]
21	seizure	O	['N']	[21]
22	,	O	['N']	[22]
23	and	O	['N']	[23]
24	depressive	O	['N']	[24]
25	disorders	O	['N']	[25]
26	.	O	['N']	[26]
#4546
0	A	O	['N']	[0]
1	61-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	early	O	['N']	[6]
7	diffuse	O	['N']	[7]
8	cutaneous	O	['N']	[8]
9	scleroderma	O	['N']	[9]
10	with	O	['N']	[10]
11	myositis	O	['N']	[11]
12	and	O	['N']	[12]
13	progressive	O	['N']	[13]
14	interstitial	O	['N']	[14]
15	pneumonia	O	['N']	[15]
16	developed	O	['N']	[16]
17	generalized	B	['N']	[17]
18	erythema	I-Adverse_Effect	['N']	[18]
19	with	O	['N']	[19]
20	high	O	['N']	[20]
21	fever	O	['N']	[21]
22	3	O	['N']	[22]
23	weeks	O	['N']	[23]
24	after	O	['N']	[24]
25	taking	O	['N']	[25]
26	sulfamethoxazole	O	['N']	[26]
27	/	O	['N']	[27]
28	trimethoprim	B-Drug	['Causes']	[18]
29	.	O	['N']	[29]
#4547
0	During	O	['N']	[0]
1	clarithromycin	B-Drug	['Causes']	[28]
2	coadministration	O	['N']	[2]
3	,	O	['N']	[3]
4	four	O	['N']	[4]
5	out	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	seven	O	['N']	[8]
9	patients	O	['N']	[9]
10	developed	O	['N']	[10]
11	moderate	O	['N']	[11]
12	-	O	['N']	[12]
13	to	O	['N']	[13]
14	-	O	['N']	[14]
15	severe	O	['N']	[15]
16	toxic	O	['N']	[16]
17	symptoms	O	['N']	[17]
18	of	O	['N']	[18]
19	carbamazepine	O	['N']	[19]
20	,	O	['N']	[20]
21	such	O	['N']	[21]
22	as	O	['N']	[22]
23	drowsiness	O	['N']	[23]
24	,	O	['N']	[24]
25	dizziness	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	ataxia	B-Adverse_Effect	['N']	[28]
29	,	O	['N']	[29]
30	which	O	['N']	[30]
31	resolved	O	['N']	[31]
32	within	O	['N']	[32]
33	5	O	['N']	[33]
34	days	O	['N']	[34]
35	after	O	['N']	[35]
36	clarithromycin	O	['N']	[36]
37	discontinuation	O	['N']	[37]
38	.	O	['N']	[38]
#4548
0	A	O	['N']	[0]
1	transient	O	['N']	[1]
2	tonic	O	['N']	[2]
3	pupillary	O	['N']	[3]
4	response	O	['N']	[4]
5	,	O	['N']	[5]
6	denervation	B	['N']	[6]
7	supersensitivity	I-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	abnormal	O	['N']	[10]
11	visual	O	['N']	[11]
12	-	O	['N']	[12]
13	evoked	O	['N']	[13]
14	potentials	O	['N']	[14]
15	in	O	['N']	[15]
16	quinine	B-Drug	['Causes']	[7]
17	toxicity	O	['N']	[17]
18	,	O	['N']	[18]
19	to	O	['N']	[19]
20	our	O	['N']	[20]
21	knowledge	O	['N']	[21]
22	,	O	['N']	[22]
23	have	O	['N']	[23]
24	not	O	['N']	[24]
25	been	O	['N']	[25]
26	previously	O	['N']	[26]
27	reported	O	['N']	[27]
28	.	O	['N']	[28]
#4549
0	Elderly	O	['N']	[0]
1	patients	O	['N']	[1]
2	for	O	['N']	[2]
3	whom	O	['N']	[3]
4	nitrate	B-Drug	['Causes']	[19]
5	has	O	['N']	[5]
6	been	O	['N']	[6]
7	prescribed	O	['N']	[7]
8	should	O	['N']	[8]
9	be	O	['N']	[9]
10	warned	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	occurrence	O	['N']	[13]
14	of	O	['N']	[14]
15	hypotension	O	['N']	[15]
16	,	O	['N']	[16]
17	leading	O	['N']	[17]
18	to	O	['N']	[18]
19	unconsciousness	B-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#4550
0	Possible	O	['N']	[0]
1	induction	O	['N']	[1]
2	of	O	['N']	[2]
3	diabetes	B-Adverse_Effect	['N']	[3]
4	by	O	['N']	[4]
5	treatment	O	['N']	[5]
6	of	O	['N']	[6]
7	hypertension	O	['N']	[7]
8	with	O	['N']	[8]
9	indapamide	B-Drug	['Causes']	[3]
10	(	O	['N']	[10]
11	with	O	['N']	[11]
12	four	O	['N']	[12]
13	case	O	['N']	[13]
14	reports	O	['N']	[14]
15	)	O	['N']	[15]
16	.	O	['N']	[16]
#4551
0	Atrial	B	['N']	[0]
1	fibrillation	I-Adverse_Effect	['N']	[1]
2	was	O	['N']	[2]
3	induced	O	['N']	[3]
4	by	O	['N']	[4]
5	diltiazem	B-Drug	['Causes']	[1]
6	in	O	['N']	[6]
7	two	O	['N']	[7]
8	patients	O	['N']	[8]
9	and	O	['N']	[9]
10	verapamil	O	['N']	[10]
11	induced	O	['N']	[11]
12	syncope	O	['N']	[12]
13	in	O	['N']	[13]
14	one	O	['N']	[14]
15	patient	O	['N']	[15]
16	.	O	['N']	[16]
#4552
0	On	O	['N']	[0]
1	the	O	['N']	[1]
2	fifth	O	['N']	[2]
3	day	O	['N']	[3]
4	of	O	['N']	[4]
5	tocolysis	O	['N']	[5]
6	with	O	['N']	[6]
7	magnesium	O	['N']	[7]
8	sulfate	O	['N']	[8]
9	,	O	['N']	[9]
10	nifedipine	O	['N']	[10]
11	,	O	['N']	[11]
12	terbutaline	B-Drug	['Causes']	[16]
13	and	O	['N']	[13]
14	betamethasone	O	['N']	[14]
15	,	O	['N']	[15]
16	edema	B-Adverse_Effect	['N']	[16]
17	developed	O	['N']	[17]
18	in	O	['N']	[18]
19	both	O	['N']	[19]
20	labia	O	['N']	[20]
21	.	O	['N']	[21]
#4553
0	A	O	['N']	[0]
1	53	O	['N']	[1]
2	year	O	['N']	[2]
3	old	O	['N']	[3]
4	Greenlandic	O	['N']	[4]
5	male	O	['N']	[5]
6	was	O	['N']	[6]
7	admitted	O	['N']	[7]
8	twice	O	['N']	[8]
9	over	O	['N']	[9]
10	a	O	['N']	[10]
11	period	O	['N']	[11]
12	of	O	['N']	[12]
13	4	O	['N']	[13]
14	years	O	['N']	[14]
15	with	O	['N']	[15]
16	a	O	['N']	[16]
17	new	O	['N']	[17]
18	complete	O	['N']	[18]
19	right	O	['N']	[19]
20	bundle	O	['N']	[20]
21	branch	O	['N']	[21]
22	block	O	['N']	[22]
23	after	O	['N']	[23]
24	ingestion	O	['N']	[24]
25	of	O	['N']	[25]
26	10	B	['N']	[26]
27	g	I-Dose	['N']	[27]
28	and	O	['N']	[28]
29	4	O	['N']	[29]
30	g	O	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	B-Drug	['Dosage']	[27]
33	respectively	O	['N']	[33]
34	.	O	['N']	[34]
#4554
0	Late	O	['N']	[0]
1	development	O	['N']	[1]
2	of	O	['N']	[2]
3	diabetes	B	['N']	[3]
4	mellitus	I-Adverse_Effect	['N']	[4]
5	after	O	['N']	[5]
6	interferon	O	['N']	[6]
7	-	O	['N']	[7]
8	alfa	O	['N']	[8]
9	and	O	['N']	[9]
10	ribavirin	B-Drug	['Causes']	[4]
11	therapy	O	['N']	[11]
12	for	O	['N']	[12]
13	chronic	O	['N']	[13]
14	hepatitis	O	['N']	[14]
15	C	O	['N']	[15]
16	:	O	['N']	[16]
17	a	O	['N']	[17]
18	case	O	['N']	[18]
19	report	O	['N']	[19]
20	.	O	['N']	[20]
#4555
0	A	O	['N']	[0]
1	72-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	a	O	['N']	[6]
7	history	O	['N']	[7]
8	of	O	['N']	[8]
9	thyrotoxicosis	O	['N']	[9]
10	presented	O	['N']	[10]
11	with	O	['N']	[11]
12	sore	O	['N']	[12]
13	throat	O	['N']	[13]
14	and	O	['N']	[14]
15	fever	B-Adverse_Effect	['N']	[15]
16	two	O	['N']	[16]
17	weeks	O	['N']	[17]
18	after	O	['N']	[18]
19	starting	O	['N']	[19]
20	carbimazole	B-Drug	['Causes']	[15]
21	.	O	['N']	[21]
#4556
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	experienced	O	['N']	[5]
6	chronic	O	['N']	[6]
7	nausea	O	['N']	[7]
8	and	O	['N']	[8]
9	an	O	['N']	[9]
10	episode	O	['N']	[10]
11	of	O	['N']	[11]
12	confusion	B-Adverse_Effect	['N']	[12]
13	while	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	a	O	['N']	[16]
17	small	O	['N']	[17]
18	,	O	['N']	[18]
19	stable	O	['N']	[19]
20	dose	O	['N']	[20]
21	of	O	['N']	[21]
22	oral	O	['N']	[22]
23	morphine	B-Drug	['Causes']	[12]
24	in	O	['N']	[24]
25	the	O	['N']	[25]
26	setting	O	['N']	[26]
27	of	O	['N']	[27]
28	mild	O	['N']	[28]
29	renal	O	['N']	[29]
30	insufficiency	O	['N']	[30]
31	.	O	['N']	[31]
#4557
0	Lovastatin	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	rhabdomyolysis	B-Adverse_Effect	['N']	[3]
4	possibly	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	clarithromycin	O	['N']	[7]
8	and	O	['N']	[8]
9	azithromycin	O	['N']	[9]
10	.	O	['N']	[10]
#4558
0	Angioedema	O	['N']	[0]
1	and	O	['N']	[1]
2	maculopapular	B	['N']	[2]
3	eruptions	I-Adverse_Effect	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	carbamazepine	B-Drug	['Causes']	[3]
7	administration	O	['N']	[7]
8	.	O	['N']	[8]
#4559
0	Aseptic	O	['N']	[0]
1	meningitis	O	['N']	[1]
2	,	O	['N']	[2]
3	hemolytic	O	['N']	[3]
4	anemia	O	['N']	[4]
5	,	O	['N']	[5]
6	hepatitis	O	['N']	[6]
7	,	O	['N']	[7]
8	and	O	['N']	[8]
9	orthostatic	B	['N']	[9]
10	hypotension	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	treated	O	['N']	[14]
15	with	O	['N']	[15]
16	trimethoprim	B-Drug	['Causes']	[10]
17	-	O	['N']	[17]
18	sulfamethoxazole	O	['N']	[18]
19	.	O	['N']	[19]
#4560
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	admitted	O	['N']	[2]
3	following	O	['N']	[3]
4	a	O	['N']	[4]
5	fall	O	['N']	[5]
6	and	O	['N']	[6]
7	,	O	['N']	[7]
8	after	O	['N']	[8]
9	being	O	['N']	[9]
10	given	O	['N']	[10]
11	metoclopramide	B-Drug	['Causes']	[15]
12	,	O	['N']	[12]
13	developed	O	['N']	[13]
14	movement	B	['N']	[14]
15	disorder	I-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	a	O	['N']	[17]
18	period	O	['N']	[18]
19	of	O	['N']	[19]
20	unresponsiveness	O	['N']	[20]
21	.	O	['N']	[21]
#4561
0	He	O	['N']	[0]
1	developed	O	['N']	[1]
2	recurrent	O	['N']	[2]
3	skin	O	['N']	[3]
4	rash	O	['N']	[4]
5	,	O	['N']	[5]
6	fever	O	['N']	[6]
7	,	O	['N']	[7]
8	hypereosinophilia	B-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	acute	O	['N']	[11]
12	renal	O	['N']	[12]
13	failure	O	['N']	[13]
14	after	O	['N']	[14]
15	rechallenge	O	['N']	[15]
16	with	O	['N']	[16]
17	chlorambucil	B-Drug	['Causes']	[8]
18	.	O	['N']	[18]
#4562
0	Seizures	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	transient	O	['N']	[2]
3	blindness	O	['N']	[3]
4	following	O	['N']	[4]
5	intravenous	O	['N']	[5]
6	pulse	O	['N']	[6]
7	methylprednisolone	B-Drug	['Causes']	[0]
8	in	O	['N']	[8]
9	children	O	['N']	[9]
10	with	O	['N']	[10]
11	primary	O	['N']	[11]
12	glomerulonephritis	O	['N']	[12]
13	.	O	['N']	[13]
#4563
0	A	O	['N']	[0]
1	64	O	['N']	[1]
2	year	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	recurrent	O	['N']	[6]
7	metastatic	O	['N']	[7]
8	squamous	O	['N']	[8]
9	cell	O	['N']	[9]
10	carcinoma	O	['N']	[10]
11	of	O	['N']	[11]
12	the	O	['N']	[12]
13	head	O	['N']	[13]
14	and	O	['N']	[14]
15	neck	O	['N']	[15]
16	developed	O	['N']	[16]
17	severe	O	['N']	[17]
18	skin	O	['N']	[18]
19	rash	O	['N']	[19]
20	and	O	['N']	[20]
21	bone	B	['N']	[21]
22	marrow	I	['N']	[22]
23	aplasia	I-Adverse_Effect	['N']	[23]
24	4	O	['N']	[24]
25	and	O	['N']	[25]
26	7	O	['N']	[26]
27	days	O	['N']	[27]
28	,	O	['N']	[28]
29	respectively	O	['N']	[29]
30	,	O	['N']	[30]
31	following	O	['N']	[31]
32	a	O	['N']	[32]
33	single	O	['N']	[33]
34	dose	O	['N']	[34]
35	of	O	['N']	[35]
36	40	O	['N']	[36]
37	mg	O	['N']	[37]
38	/	O	['N']	[38]
39	m2	O	['N']	[39]
40	methotrexate	O	['N']	[40]
41	(	O	['N']	[41]
42	MTX	B-Drug	['Causes']	[23]
43	)	O	['N']	[43]
44	.	O	['N']	[44]
#4564
0	Differential	O	['N']	[0]
1	diagnoses	O	['N']	[1]
2	included	O	['N']	[2]
3	ocular	O	['N']	[3]
4	rosacea	O	['N']	[4]
5	with	O	['N']	[5]
6	cicatrizing	O	['N']	[6]
7	conjunctivitis	O	['N']	[7]
8	and	O	['N']	[8]
9	5-FU	B-Drug	['Causes']	[12]
10	-	O	['N']	[10]
11	induced	O	['N']	[11]
12	ectropion	B-Adverse_Effect	['N']	[12]
13	.	O	['N']	[13]
#4565
0	CCBs	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	considered	O	['N']	[3]
4	in	O	['N']	[4]
5	the	O	['N']	[5]
6	treatment	O	['N']	[6]
7	of	O	['N']	[7]
8	5-FU	B-Drug	['Causes']	[13]
9	or	O	['N']	[9]
10	capecitabine	O	['N']	[10]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	headaches	B-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#4566
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	four	O	['N']	[2]
3	patients	O	['N']	[3]
4	who	O	['N']	[4]
5	had	O	['N']	[5]
6	seizures	B-Adverse_Effect	['N']	[6]
7	while	O	['N']	[7]
8	receiving	O	['N']	[8]
9	ofloxacin	B-Drug	['Causes']	[6]
10	;	O	['N']	[10]
11	no	O	['N']	[11]
12	other	O	['N']	[12]
13	causes	O	['N']	[13]
14	were	O	['N']	[14]
15	evident	O	['N']	[15]
16	.	O	['N']	[16]
#4567
0	One	O	['N']	[0]
1	patient	O	['N']	[1]
2	on	O	['N']	[2]
3	ouabain	B-Drug	['Causes']	[6]
4	also	O	['N']	[4]
5	developed	O	['N']	[5]
6	cardiomyopathy	B-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#4568
0	Cytarabine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	cerebellar	B	['N']	[3]
4	syndrome	I-Adverse_Effect	['N']	[4]
5	:	O	['N']	[5]
6	case	O	['N']	[6]
7	report	O	['N']	[7]
8	and	O	['N']	[8]
9	literature	O	['N']	[9]
10	review	O	['N']	[10]
11	.	O	['N']	[11]
#4569
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	concluded	O	['N']	[2]
3	that	O	['N']	[3]
4	simultaneous	O	['N']	[4]
5	administration	O	['N']	[5]
6	of	O	['N']	[6]
7	ciprofloxacin	O	['N']	[7]
8	and	O	['N']	[8]
9	tazobactam	B-Drug	['Causes']	[15]
10	/	O	['N']	[10]
11	piperacillin	O	['N']	[11]
12	may	O	['N']	[12]
13	cause	O	['N']	[13]
14	marked	O	['N']	[14]
15	thrombocytosis	B-Adverse_Effect	['N']	[15]
16	.	O	['N']	[16]
#4570
0	During	O	['N']	[0]
1	clarithromycin	O	['N']	[1]
2	coadministration	O	['N']	[2]
3	,	O	['N']	[3]
4	four	O	['N']	[4]
5	out	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	seven	O	['N']	[8]
9	patients	O	['N']	[9]
10	developed	O	['N']	[10]
11	moderate	O	['N']	[11]
12	-	O	['N']	[12]
13	to	O	['N']	[13]
14	-	O	['N']	[14]
15	severe	O	['N']	[15]
16	toxic	O	['N']	[16]
17	symptoms	O	['N']	[17]
18	of	O	['N']	[18]
19	carbamazepine	B-Drug	['Causes']	[23]
20	,	O	['N']	[20]
21	such	O	['N']	[21]
22	as	O	['N']	[22]
23	drowsiness	B-Adverse_Effect	['N']	[23]
24	,	O	['N']	[24]
25	dizziness	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	ataxia	O	['N']	[28]
29	,	O	['N']	[29]
30	which	O	['N']	[30]
31	resolved	O	['N']	[31]
32	within	O	['N']	[32]
33	5	O	['N']	[33]
34	days	O	['N']	[34]
35	after	O	['N']	[35]
36	clarithromycin	O	['N']	[36]
37	discontinuation	O	['N']	[37]
38	.	O	['N']	[38]
#4571
0	Atypical	O	['N']	[0]
1	ventricular	O	['N']	[1]
2	tachycardia	O	['N']	[2]
3	(	O	['N']	[3]
4	torsade	B	['N']	[4]
5	de	I	['N']	[5]
6	pointes	I-Adverse_Effect	['N']	[6]
7	)	O	['N']	[7]
8	induced	O	['N']	[8]
9	by	O	['N']	[9]
10	amiodarone	B-Drug	['Causes']	[6]
11	:	O	['N']	[11]
12	arrhythmia	O	['N']	[12]
13	previously	O	['N']	[13]
14	induced	O	['N']	[14]
15	by	O	['N']	[15]
16	quinidine	O	['N']	[16]
17	and	O	['N']	[17]
18	disopyramide	O	['N']	[18]
19	.	O	['N']	[19]
#4572
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Low	O	['N']	[2]
3	dosages	O	['N']	[3]
4	of	O	['N']	[4]
5	quinacrine	O	['N']	[5]
6	used	O	['N']	[6]
7	for	O	['N']	[7]
8	malaria	O	['N']	[8]
9	prophylaxis	O	['N']	[9]
10	can	O	['N']	[10]
11	be	O	['N']	[11]
12	associated	O	['N']	[12]
13	with	O	['N']	[13]
14	a	O	['N']	[14]
15	delayed	O	['N']	[15]
16	,	O	['N']	[16]
17	severe	O	['N']	[17]
18	maculopathy	B-Adverse_Effect	['N']	[18]
19	indistinguishable	O	['N']	[19]
20	from	O	['N']	[20]
21	chloroquine	B-Drug	['Causes']	[18]
22	maculopathy	O	['N']	[22]
23	in	O	['N']	[23]
24	certain	O	['N']	[24]
25	patients	O	['N']	[25]
26	.	O	['N']	[26]
#4573
0	Our	O	['N']	[0]
1	report	O	['N']	[1]
2	suggested	O	['N']	[2]
3	that	O	['N']	[3]
4	CBDCA	B-Drug	['Causes']	[5]
5	hypersensitivity	B-Adverse_Effect	['N']	[5]
6	was	O	['N']	[6]
7	correlated	O	['N']	[7]
8	with	O	['N']	[8]
9	the	O	['N']	[9]
10	total	O	['N']	[10]
11	dose	O	['N']	[11]
12	of	O	['N']	[12]
13	previously	O	['N']	[13]
14	administered	O	['N']	[14]
15	platinum	O	['N']	[15]
16	agents	O	['N']	[16]
17	and	O	['N']	[17]
18	that	O	['N']	[18]
19	CBDCA	O	['N']	[19]
20	should	O	['N']	[20]
21	be	O	['N']	[21]
22	excluded	O	['N']	[22]
23	in	O	['N']	[23]
24	patients	O	['N']	[24]
25	who	O	['N']	[25]
26	have	O	['N']	[26]
27	received	O	['N']	[27]
28	multiple	O	['N']	[28]
29	platinum	O	['N']	[29]
30	-	O	['N']	[30]
31	based	O	['N']	[31]
32	chemotherapy	O	['N']	[32]
33	,	O	['N']	[33]
34	even	O	['N']	[34]
35	in	O	['N']	[35]
36	platinum	O	['N']	[36]
37	-	O	['N']	[37]
38	sensitive	O	['N']	[38]
39	cases	O	['N']	[39]
40	,	O	['N']	[40]
41	because	O	['N']	[41]
42	CBDCA	O	['N']	[42]
43	hypersensitivity	O	['N']	[43]
44	can	O	['N']	[44]
45	occur	O	['N']	[45]
46	even	O	['N']	[46]
47	with	O	['N']	[47]
48	low	O	['N']	[48]
49	-	O	['N']	[49]
50	dose	O	['N']	[50]
51	CBDCA	O	['N']	[51]
52	administration	O	['N']	[52]
53	.	O	['N']	[53]
#4574
0	Based	O	['N']	[0]
1	upon	O	['N']	[1]
2	the	O	['N']	[2]
3	observed	O	['N']	[3]
4	fall	B	['N']	[4]
5	of	I	['N']	[5]
6	the	I	['N']	[6]
7	filtration	I	['N']	[7]
8	fraction	I-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	the	O	['N']	[10]
11	rise	O	['N']	[11]
12	in	O	['N']	[12]
13	the	O	['N']	[13]
14	relative	O	['N']	[14]
15	clearance	O	['N']	[15]
16	of	O	['N']	[16]
17	99Tc	O	['N']	[17]
18	-	O	['N']	[18]
19	dimercaptosuccinic	O	['N']	[19]
20	acid	O	['N']	[20]
21	and	O	['N']	[21]
22	the	O	['N']	[22]
23	increase	O	['N']	[23]
24	in	O	['N']	[24]
25	proteinuria	O	['N']	[25]
26	,	O	['N']	[26]
27	we	O	['N']	[27]
28	suggest	O	['N']	[28]
29	that	O	['N']	[29]
30	in	O	['N']	[30]
31	this	O	['N']	[31]
32	case	O	['N']	[32]
33	the	O	['N']	[33]
34	tubules	O	['N']	[34]
35	and/or	O	['N']	[35]
36	interstitium	O	['N']	[36]
37	are	O	['N']	[37]
38	the	O	['N']	[38]
39	main	O	['N']	[39]
40	targets	O	['N']	[40]
41	for	O	['N']	[41]
42	cyclosporine	B	['N']	[42]
43	A	I-Drug	['Causes']	[8]
44	nephrotoxicity	O	['N']	[44]
45	.	O	['N']	[45]
#4575
0	With	O	['N']	[0]
1	the	O	['N']	[1]
2	first	O	['N']	[2]
3	cyclosporine	B-Drug	['Causes']	[11]
4	dose	O	['N']	[4]
5	,	O	['N']	[5]
6	the	O	['N']	[6]
7	patient	O	['N']	[7]
8	complained	O	['N']	[8]
9	of	O	['N']	[9]
10	leg	B	['N']	[10]
11	pain	I-Adverse_Effect	['N']	[11]
12	that	O	['N']	[12]
13	was	O	['N']	[13]
14	most	O	['N']	[14]
15	severe	O	['N']	[15]
16	during	O	['N']	[16]
17	the	O	['N']	[17]
18	cyclosporine	O	['N']	[18]
19	infusion	O	['N']	[19]
20	.	O	['N']	[20]
#4576
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	linezolid	B-Drug	['Causes']	[22]
4	-	O	['N']	[4]
5	associated	O	['N']	[5]
6	acute	O	['N']	[6]
7	interstitial	O	['N']	[7]
8	nephritis	O	['N']	[8]
9	within	O	['N']	[9]
10	the	O	['N']	[10]
11	context	O	['N']	[11]
12	of	O	['N']	[12]
13	a	O	['N']	[13]
14	drug	O	['N']	[14]
15	rash	O	['N']	[15]
16	with	O	['N']	[16]
17	eosinophilia	O	['N']	[17]
18	and	O	['N']	[18]
19	systemic	O	['N']	[19]
20	symptoms	O	['N']	[20]
21	(	O	['N']	[21]
22	DRESS	B-Adverse_Effect	['N']	[22]
23	)	O	['N']	[23]
24	syndrome	O	['N']	[24]
25	in	O	['N']	[25]
26	a	O	['N']	[26]
27	patient	O	['N']	[27]
28	treated	O	['N']	[28]
29	with	O	['N']	[29]
30	linezolid	O	['N']	[30]
31	raises	O	['N']	[31]
32	concerns	O	['N']	[32]
33	about	O	['N']	[33]
34	the	O	['N']	[34]
35	presumed	O	['N']	[35]
36	renal	O	['N']	[36]
37	safety	O	['N']	[37]
38	of	O	['N']	[38]
39	this	O	['N']	[39]
40	drug	O	['N']	[40]
41	.	O	['N']	[41]
#4577
0	A	O	['N']	[0]
1	57-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	right	O	['N']	[6]
7	bundle	O	['N']	[7]
8	branch	O	['N']	[8]
9	block	O	['N']	[9]
10	+	O	['N']	[10]
11	LPH	O	['N']	[11]
12	and	O	['N']	[12]
13	ventricular	O	['N']	[13]
14	premature	O	['N']	[14]
15	contractions	O	['N']	[15]
16	developed	O	['N']	[16]
17	complete	B	['N']	[17]
18	heart	I	['N']	[18]
19	block	I-Adverse_Effect	['N']	[19]
20	(	O	['N']	[20]
21	CHB	O	['N']	[21]
22	)	O	['N']	[22]
23	following	O	['N']	[23]
24	administration	O	['N']	[24]
25	of	O	['N']	[25]
26	disopyramide	B	['N']	[26]
27	phosphate	I-Drug	['Causes']	[19]
28	(	O	['N']	[28]
29	Norpace	O	['N']	[29]
30	)	O	['N']	[30]
31	.	O	['N']	[31]
#4578
0	Methylphenidate	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	enuresis	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	attention	O	['N']	[5]
6	deficit	O	['N']	[6]
7	hyperactivity	O	['N']	[7]
8	disorder	O	['N']	[8]
9	.	O	['N']	[9]
#4579
0	Based	O	['N']	[0]
1	upon	O	['N']	[1]
2	the	O	['N']	[2]
3	observed	O	['N']	[3]
4	fall	O	['N']	[4]
5	of	O	['N']	[5]
6	the	O	['N']	[6]
7	filtration	O	['N']	[7]
8	fraction	O	['N']	[8]
9	,	O	['N']	[9]
10	the	O	['N']	[10]
11	rise	B	['N']	[11]
12	in	I	['N']	[12]
13	the	I	['N']	[13]
14	relative	I	['N']	[14]
15	clearance	I	['N']	[15]
16	of	I	['N']	[16]
17	99Tc	I	['N']	[17]
18	-	I	['N']	[18]
19	dimercaptosuccinic	I	['N']	[19]
20	acid	I-Adverse_Effect	['N']	[20]
21	and	O	['N']	[21]
22	the	O	['N']	[22]
23	increase	O	['N']	[23]
24	in	O	['N']	[24]
25	proteinuria	O	['N']	[25]
26	,	O	['N']	[26]
27	we	O	['N']	[27]
28	suggest	O	['N']	[28]
29	that	O	['N']	[29]
30	in	O	['N']	[30]
31	this	O	['N']	[31]
32	case	O	['N']	[32]
33	the	O	['N']	[33]
34	tubules	O	['N']	[34]
35	and/or	O	['N']	[35]
36	interstitium	O	['N']	[36]
37	are	O	['N']	[37]
38	the	O	['N']	[38]
39	main	O	['N']	[39]
40	targets	O	['N']	[40]
41	for	O	['N']	[41]
42	cyclosporine	B	['N']	[42]
43	A	I-Drug	['Causes']	[20]
44	nephrotoxicity	O	['N']	[44]
45	.	O	['N']	[45]
#4580
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	use	O	['N']	[8]
9	of	O	['N']	[9]
10	pamidronate	O	['N']	[10]
11	for	O	['N']	[11]
12	significant	O	['N']	[12]
13	hypercalcemia	O	['N']	[13]
14	secondary	O	['N']	[14]
15	to	O	['N']	[15]
16	acute	B	['N']	[16]
17	vitamin	B	['N']	[17]
18	D	I-Drug	['Causes']	[19]
19	poisoning	I-Adverse_Effect	['N']	[19]
20	.	O	['N']	[20]
#4581
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	is	O	['N']	[2]
3	reported	O	['N']	[3]
4	in	O	['N']	[4]
5	which	O	['N']	[5]
6	severe	B	['N']	[6]
7	hypocalcemia	I-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	with	O	['N']	[9]
10	a	O	['N']	[10]
11	low	O	['N']	[11]
12	plasma	O	['N']	[12]
13	parathyroid	O	['N']	[13]
14	hormone	O	['N']	[14]
15	(	O	['N']	[15]
16	PTH	O	['N']	[16]
17	)	O	['N']	[17]
18	concentration	O	['N']	[18]
19	,	O	['N']	[19]
20	resulted	O	['N']	[20]
21	from	O	['N']	[21]
22	the	O	['N']	[22]
23	therapeutic	O	['N']	[23]
24	use	O	['N']	[24]
25	of	O	['N']	[25]
26	magnesium	B	['N']	[26]
27	sulfate	I-Drug	['Causes']	[7]
28	for	O	['N']	[28]
29	toxemia	O	['N']	[29]
30	of	O	['N']	[30]
31	pregnancy	O	['N']	[31]
32	.	O	['N']	[32]
#4582
0	These	O	['N']	[0]
1	findings	O	['N']	[1]
2	suggest	O	['N']	[2]
3	that	O	['N']	[3]
4	clozapine	B-Drug	['Causes']	[7]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	seizures	B-Adverse_Effect	['N']	[7]
8	can	O	['N']	[8]
9	be	O	['N']	[9]
10	successfully	O	['N']	[10]
11	treated	O	['N']	[11]
12	,	O	['N']	[12]
13	that	O	['N']	[13]
14	gradual	O	['N']	[14]
15	dose	O	['N']	[15]
16	titration	O	['N']	[16]
17	can	O	['N']	[17]
18	reduce	O	['N']	[18]
19	the	O	['N']	[19]
20	likelihood	O	['N']	[20]
21	of	O	['N']	[21]
22	further	O	['N']	[22]
23	episodes	O	['N']	[23]
24	of	O	['N']	[24]
25	seizures	O	['N']	[25]
26	and	O	['N']	[26]
27	that	O	['N']	[27]
28	concomitant	O	['N']	[28]
29	use	O	['N']	[29]
30	of	O	['N']	[30]
31	a	O	['N']	[31]
32	suitable	O	['N']	[32]
33	mood	O	['N']	[33]
34	stabilizer	O	['N']	[34]
35	/	O	['N']	[35]
36	anti	O	['N']	[36]
37	-	O	['N']	[37]
38	epileptic	O	['N']	[38]
39	medication	O	['N']	[39]
40	can	O	['N']	[40]
41	improve	O	['N']	[41]
42	the	O	['N']	[42]
43	outcome	O	['N']	[43]
44	of	O	['N']	[44]
45	treatment	O	['N']	[45]
46	-	O	['N']	[46]
47	resistant	O	['N']	[47]
48	schizophrenia	O	['N']	[48]
49	.	O	['N']	[49]
#4583
0	Colonic	B	['N']	[0]
1	necrosis	I-Adverse_Effect	['N']	[1]
2	is	O	['N']	[2]
3	known	O	['N']	[3]
4	as	O	['N']	[4]
5	a	O	['N']	[5]
6	rare	O	['N']	[6]
7	complication	O	['N']	[7]
8	following	O	['N']	[8]
9	the	O	['N']	[9]
10	administration	O	['N']	[10]
11	of	O	['N']	[11]
12	Kayexalate	O	['N']	[12]
13	(	O	['N']	[13]
14	sodium	B	['N']	[14]
15	polystryrene	I	['N']	[15]
16	sulfonate	I-Drug	['Causes']	[1]
17	)	O	['N']	[17]
18	in	O	['N']	[18]
19	sorbitol	O	['N']	[19]
20	.	O	['N']	[20]
#4584
0	Usefulness	O	['N']	[0]
1	of	O	['N']	[1]
2	antiplatelet	O	['N']	[2]
3	drugs	O	['N']	[3]
4	in	O	['N']	[4]
5	the	O	['N']	[5]
6	management	O	['N']	[6]
7	of	O	['N']	[7]
8	heparin	B-Drug	['Causes']	[11]
9	-	O	['N']	[9]
10	associated	O	['N']	[10]
11	thrombocytopenia	B-Adverse_Effect	['N']	[11]
12	and	O	['N']	[12]
13	thrombosis	O	['N']	[13]
14	.	O	['N']	[14]
#4585
0	Infant	O	['N']	[0]
1	twins	O	['N']	[1]
2	sustained	O	['N']	[2]
3	severe	O	['N']	[3]
4	circumoral	B	['N']	[4]
5	and	I	['N']	[5]
6	pharyngeal	I	['N']	[6]
7	burns	I-Adverse_Effect	['N']	[7]
8	from	O	['N']	[8]
9	a	O	['N']	[9]
10	concentrated	O	['N']	[10]
11	solution	O	['N']	[11]
12	of	O	['N']	[12]
13	benzalkonium	O	['N']	[13]
14	(	O	['N']	[14]
15	Zephiran	B-Drug	['Causes']	[7]
16	)	O	['N']	[16]
17	chloride	O	['N']	[17]
18	prescribed	O	['N']	[18]
19	for	O	['N']	[19]
20	treatment	O	['N']	[20]
21	of	O	['N']	[21]
22	candidiasis	O	['N']	[22]
23	.	O	['N']	[23]
#4586
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	developed	O	['N']	[2]
3	typical	O	['N']	[3]
4	ECM	B-Adverse_Effect	['N']	[4]
5	after	O	['N']	[5]
6	subcutaneous	O	['N']	[6]
7	selfinjection	O	['N']	[7]
8	of	O	['N']	[8]
9	glatiramer	B	['N']	[9]
10	acetate	I-Drug	['Causes']	[4]
11	for	O	['N']	[11]
12	multiple	O	['N']	[12]
13	sclerosis	O	['N']	[13]
14	.	O	['N']	[14]
#4587
0	A	O	['N']	[0]
1	9-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	developed	O	['N']	[5]
6	acute	O	['N']	[6]
7	renal	O	['N']	[7]
8	failure	O	['N']	[8]
9	following	O	['N']	[9]
10	intravenous	O	['N']	[10]
11	acyclovir	B-Drug	['Dosage']	[18]
12	(	O	['N']	[12]
13	30	B	['N']	[13]
14	mg	I	['N']	[14]
15	/	I	['N']	[15]
16	kg	I	['N']	[16]
17	per	I	['N']	[17]
18	day	I-Dose	['N']	[18]
19	)	O	['N']	[19]
20	administered	O	['N']	[20]
21	for	O	['N']	[21]
22	6	O	['N']	[22]
23	days	O	['N']	[23]
24	to	O	['N']	[24]
25	treat	O	['N']	[25]
26	herpetic	O	['N']	[26]
27	encephalitis	O	['N']	[27]
28	.	O	['N']	[28]
#4588
0	Nevertheless	O	['N']	[0]
1	,	O	['N']	[1]
2	the	O	['N']	[2]
3	coagulopathy	B-Adverse_Effect	['N']	[3]
4	seemed	O	['N']	[4]
5	to	O	['N']	[5]
6	be	O	['N']	[6]
7	most	O	['N']	[7]
8	closely	O	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	the	O	['N']	[11]
12	administration	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	cephalosporin	B-Drug	['Causes']	[3]
16	.	O	['N']	[16]
#4589
0	Severe	O	['N']	[0]
1	abdominal	B	['N']	[1]
2	pain	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	low	O	['N']	[4]
5	dosage	O	['N']	[5]
6	clofazimine	B-Drug	['Causes']	[2]
7	.	O	['N']	[7]
#4590
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Hypersensitivity	O	['N']	[2]
3	reaction	O	['N']	[3]
4	should	O	['N']	[4]
5	be	O	['N']	[5]
6	considered	O	['N']	[6]
7	in	O	['N']	[7]
8	patients	O	['N']	[8]
9	who	O	['N']	[9]
10	develop	O	['N']	[10]
11	recurrent	B	['N']	[11]
12	eosinophilia	I-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	deterioration	O	['N']	[14]
15	of	O	['N']	[15]
16	pulmonary	O	['N']	[16]
17	function	O	['N']	[17]
18	following	O	['N']	[18]
19	the	O	['N']	[19]
20	use	O	['N']	[20]
21	of	O	['N']	[21]
22	tobramycin	B-Drug	['Causes']	[12]
23	by	O	['N']	[23]
24	inhalation	O	['N']	[24]
25	or	O	['N']	[25]
26	by	O	['N']	[26]
27	intravenous	O	['N']	[27]
28	administration	O	['N']	[28]
29	.	O	['N']	[29]
#4591
0	We	O	['N']	[0]
1	recommend	O	['N']	[1]
2	that	O	['N']	[2]
3	a	O	['N']	[3]
4	TMA	O	['N']	[4]
5	in	O	['N']	[5]
6	association	O	['N']	[6]
7	with	O	['N']	[7]
8	quinine	B-Drug	['Causes']	[18]
9	be	O	['N']	[9]
10	consistently	O	['N']	[10]
11	referred	O	['N']	[11]
12	to	O	['N']	[12]
13	as	O	['N']	[13]
14	quinine	O	['N']	[14]
15	-	O	['N']	[15]
16	associated	O	['N']	[16]
17	thrombotic	B	['N']	[17]
18	microangiopathy	I-Adverse_Effect	['N']	[18]
19	(	O	['N']	[19]
20	quinine	O	['N']	[20]
21	-	O	['N']	[21]
22	TMA	O	['N']	[22]
23	)	O	['N']	[23]
24	to	O	['N']	[24]
25	better	O	['N']	[25]
26	distinguish	O	['N']	[26]
27	this	O	['N']	[27]
28	entity	O	['N']	[28]
29	from	O	['N']	[29]
30	idiopathic	O	['N']	[30]
31	TTP	O	['N']	[31]
32	.	O	['N']	[32]
#4592
0	It	O	['N']	[0]
1	occasionally	O	['N']	[1]
2	accompanies	O	['N']	[2]
3	the	O	['N']	[3]
4	heparin	B-Drug	['Causes']	[7]
5	-	O	['N']	[5]
6	associated	O	['N']	[6]
7	thrombocytopenia	B-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	thrombosis	O	['N']	[9]
10	syndrome	O	['N']	[10]
11	.	O	['N']	[11]
#4593
0	During	O	['N']	[0]
1	clarithromycin	B-Drug	['Causes']	[25]
2	coadministration	O	['N']	[2]
3	,	O	['N']	[3]
4	four	O	['N']	[4]
5	out	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	seven	O	['N']	[8]
9	patients	O	['N']	[9]
10	developed	O	['N']	[10]
11	moderate	O	['N']	[11]
12	-	O	['N']	[12]
13	to	O	['N']	[13]
14	-	O	['N']	[14]
15	severe	O	['N']	[15]
16	toxic	O	['N']	[16]
17	symptoms	O	['N']	[17]
18	of	O	['N']	[18]
19	carbamazepine	O	['N']	[19]
20	,	O	['N']	[20]
21	such	O	['N']	[21]
22	as	O	['N']	[22]
23	drowsiness	O	['N']	[23]
24	,	O	['N']	[24]
25	dizziness	B-Adverse_Effect	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	ataxia	O	['N']	[28]
29	,	O	['N']	[29]
30	which	O	['N']	[30]
31	resolved	O	['N']	[31]
32	within	O	['N']	[32]
33	5	O	['N']	[33]
34	days	O	['N']	[34]
35	after	O	['N']	[35]
36	clarithromycin	O	['N']	[36]
37	discontinuation	O	['N']	[37]
38	.	O	['N']	[38]
#4594
0	He	O	['N']	[0]
1	was	O	['N']	[1]
2	started	O	['N']	[2]
3	on	O	['N']	[3]
4	oral	O	['N']	[4]
5	lansoprazole	B-Drug	['Dosage']	[9]
6	60	B	['N']	[6]
7	mg	I	['N']	[7]
8	twice	I	['N']	[8]
9	daily	I-Dose	['N']	[9]
10	and	O	['N']	[10]
11	,	O	['N']	[11]
12	on	O	['N']	[12]
13	hospital	O	['N']	[13]
14	day	O	['N']	[14]
15	2	O	['N']	[15]
16	,	O	['N']	[16]
17	his	O	['N']	[17]
18	platelet	O	['N']	[18]
19	count	O	['N']	[19]
20	decreased	O	['N']	[20]
21	to	O	['N']	[21]
22	102	O	['N']	[22]
23	x	O	['N']	[23]
24	10(3)/mm(3	O	['N']	[24]
25	)	O	['N']	[25]
26	;	O	['N']	[26]
27	on	O	['N']	[27]
28	hospital	O	['N']	[28]
29	day	O	['N']	[29]
30	3	O	['N']	[30]
31	,	O	['N']	[31]
32	the	O	['N']	[32]
33	platelet	O	['N']	[33]
34	count	O	['N']	[34]
35	was	O	['N']	[35]
36	36	O	['N']	[36]
37	x	O	['N']	[37]
38	10(3)/mm(3	O	['N']	[38]
39	)	O	['N']	[39]
40	.	O	['N']	[40]
#4595
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	in	O	['N']	[2]
3	order	O	['N']	[3]
4	to	O	['N']	[4]
5	avoid	O	['N']	[5]
6	neuropathic	B	['N']	[6]
7	side	I	['N']	[7]
8	effects	I-Adverse_Effect	['N']	[8]
9	,	O	['N']	[9]
10	patients	O	['N']	[10]
11	under	O	['N']	[11]
12	thalidomide	B-Drug	['Causes']	[8]
13	therapy	O	['N']	[13]
14	should	O	['N']	[14]
15	be	O	['N']	[15]
16	monitored	O	['N']	[16]
17	every	O	['N']	[17]
18	6	O	['N']	[18]
19	months	O	['N']	[19]
20	with	O	['N']	[20]
21	nerve	O	['N']	[21]
22	conduction	O	['N']	[22]
23	studies	O	['N']	[23]
24	while	O	['N']	[24]
25	taking	O	['N']	[25]
26	the	O	['N']	[26]
27	drug	O	['N']	[27]
28	.	O	['N']	[28]
#4596
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	describe	O	['N']	[3]
4	onset	O	['N']	[4]
5	of	O	['N']	[5]
6	syndrome	B	['N']	[6]
7	of	I	['N']	[7]
8	inappropriate	I	['N']	[8]
9	antidiuretic	I	['N']	[9]
10	hormone	I-Adverse_Effect	['N']	[10]
11	(	O	['N']	[11]
12	SIADH	O	['N']	[12]
13	)	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	vinorelbine	B-Drug	['Causes']	[10]
17	therapy	O	['N']	[17]
18	for	O	['N']	[18]
19	advanced	O	['N']	[19]
20	breast	O	['N']	[20]
21	cancer	O	['N']	[21]
22	.	O	['N']	[22]
#4597
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	11-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	female	O	['N']	[9]
10	treated	O	['N']	[10]
11	for	O	['N']	[11]
12	mediastinal	O	['N']	[12]
13	T	O	['N']	[13]
14	-	O	['N']	[14]
15	cell	O	['N']	[15]
16	lymphoma	O	['N']	[16]
17	who	O	['N']	[17]
18	presented	O	['N']	[18]
19	renal	B	['N']	[19]
20	failure	I-Adverse_Effect	['N']	[20]
21	following	O	['N']	[21]
22	the	O	['N']	[22]
23	second	O	['N']	[23]
24	cycle	O	['N']	[24]
25	of	O	['N']	[25]
26	high	O	['N']	[26]
27	-	O	['N']	[27]
28	dose	O	['N']	[28]
29	methotrexate	O	['N']	[29]
30	(	O	['N']	[30]
31	HDMTX	B-Drug	['Causes']	[20]
32	)	O	['N']	[32]
33	.	O	['N']	[33]
#4598
0	Both	O	['N']	[0]
1	6-MP	O	['N']	[1]
2	and	O	['N']	[2]
3	AZA	B-Drug	['Causes']	[12]
4	are	O	['N']	[4]
5	widely	O	['N']	[5]
6	used	O	['N']	[6]
7	and	O	['N']	[7]
8	are	O	['N']	[8]
9	known	O	['N']	[9]
10	to	O	['N']	[10]
11	cause	O	['N']	[11]
12	hepatotoxicity	B-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	proportion	O	['N']	[15]
16	of	O	['N']	[16]
17	patients	O	['N']	[17]
18	.	O	['N']	[18]
#4599
0	It	O	['N']	[0]
1	was	O	['N']	[1]
2	postulated	O	['N']	[2]
3	that	O	['N']	[3]
4	the	O	['N']	[4]
5	allergic	B	['N']	[5]
6	reaction	I-Adverse_Effect	['N']	[6]
7	was	O	['N']	[7]
8	most	O	['N']	[8]
9	likely	O	['N']	[9]
10	caused	O	['N']	[10]
11	by	O	['N']	[11]
12	capecitabine	B-Drug	['Causes']	[6]
13	or	O	['N']	[13]
14	the	O	['N']	[14]
15	intermediate	O	['N']	[15]
16	metabolites	O	['N']	[16]
17	based	O	['N']	[17]
18	on	O	['N']	[18]
19	the	O	['N']	[19]
20	immediate	O	['N']	[20]
21	reappearance	O	['N']	[21]
22	of	O	['N']	[22]
23	symptoms	O	['N']	[23]
24	from	O	['N']	[24]
25	the	O	['N']	[25]
26	rechallenge	O	['N']	[26]
27	,	O	['N']	[27]
28	pharmacokinetic	O	['N']	[28]
29	data	O	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	well	O	['N']	[32]
33	-	O	['N']	[33]
34	tolerance	O	['N']	[34]
35	of	O	['N']	[35]
36	fluorouracil	O	['N']	[36]
37	.	O	['N']	[37]
#4600
0	Three	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	receiving	O	['N']	[3]
4	intravitreal	O	['N']	[4]
5	injection	O	['N']	[5]
6	of	O	['N']	[6]
7	bevacizumab	B-Drug	['Causes']	[20]
8	(	O	['N']	[8]
9	1.25	O	['N']	[9]
10	mg	O	['N']	[10]
11	in	O	['N']	[11]
12	0.1	O	['N']	[12]
13	ml	O	['N']	[13]
14	)	O	['N']	[14]
15	,	O	['N']	[15]
16	he	O	['N']	[16]
17	developed	O	['N']	[17]
18	acute	B	['N']	[18]
19	vision	I	['N']	[19]
20	loss	I-Adverse_Effect	['N']	[20]
21	and	O	['N']	[21]
22	change	O	['N']	[22]
23	of	O	['N']	[23]
24	consciousness	O	['N']	[24]
25	.	O	['N']	[25]
#4601
0	Physicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	that	O	['N']	[4]
5	indinavir	B-Drug	['Causes']	[10]
6	nephrolithiasis	O	['N']	[6]
7	may	O	['N']	[7]
8	cause	O	['N']	[8]
9	papillary	B	['N']	[9]
10	necrosis	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#4602
0	Disseminated	O	['N']	[0]
1	intravascular	O	['N']	[1]
2	coagulation	O	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	acute	O	['N']	[5]
6	hemoglobinemia	O	['N']	[6]
7	or	O	['N']	[7]
8	hemoglobinuria	B-Adverse_Effect	['N']	[8]
9	following	O	['N']	[9]
10	Rh(0)(D	B	['N']	[10]
11	)	I	['N']	[11]
12	immune	I	['N']	[12]
13	globulin	I-Drug	['Causes']	[8]
14	intravenous	O	['N']	[14]
15	administration	O	['N']	[15]
16	for	O	['N']	[16]
17	immune	O	['N']	[17]
18	thrombocytopenic	O	['N']	[18]
19	purpura	O	['N']	[19]
20	.	O	['N']	[20]
#4603
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	transitional	O	['N']	[5]
6	cell	O	['N']	[6]
7	carcinoma	O	['N']	[7]
8	of	O	['N']	[8]
9	the	O	['N']	[9]
10	renal	O	['N']	[10]
11	pelvis	O	['N']	[11]
12	who	O	['N']	[12]
13	developed	O	['N']	[13]
14	respiratory	B	['N']	[14]
15	dysfunction	I-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	an	O	['N']	[17]
18	abnormal	O	['N']	[18]
19	chest	O	['N']	[19]
20	x	O	['N']	[20]
21	-	O	['N']	[21]
22	ray	O	['N']	[22]
23	with	O	['N']	[23]
24	diffuse	O	['N']	[24]
25	interstitial	O	['N']	[25]
26	opacities	O	['N']	[26]
27	while	O	['N']	[27]
28	on	O	['N']	[28]
29	chemotherapy	O	['N']	[29]
30	with	O	['N']	[30]
31	piritrexim	B-Drug	['Causes']	[15]
32	,	O	['N']	[32]
33	a	O	['N']	[33]
34	methotrexate	O	['N']	[34]
35	analog	O	['N']	[35]
36	.	O	['N']	[36]
#4604
0	One	O	['N']	[0]
1	of	O	['N']	[1]
2	these	O	['N']	[2]
3	was	O	['N']	[3]
4	clofazimine	B-Drug	['Causes']	[17]
5	,	O	['N']	[5]
6	an	O	['N']	[6]
7	aniline	O	['N']	[7]
8	aposafranine	O	['N']	[8]
9	derivative	O	['N']	[9]
10	known	O	['N']	[10]
11	to	O	['N']	[11]
12	produce	O	['N']	[12]
13	a	O	['N']	[13]
14	ceroid	B	['N']	[14]
15	-	I	['N']	[15]
16	like	I	['N']	[16]
17	pigment	I-Adverse_Effect	['N']	[17]
18	in	O	['N']	[18]
19	the	O	['N']	[19]
20	tissues	O	['N']	[20]
21	of	O	['N']	[21]
22	patients	O	['N']	[22]
23	treated	O	['N']	[23]
24	with	O	['N']	[24]
25	this	O	['N']	[25]
26	drug	O	['N']	[26]
27	or	O	['N']	[27]
28	lepromatous	O	['N']	[28]
29	leprosy	O	['N']	[29]
30	.	O	['N']	[30]
#4605
0	Agranulocytosis	O	['N']	[0]
1	and	O	['N']	[1]
2	granulocytopenia	B-Adverse_Effect	['N']	[2]
3	associated	O	['N']	[3]
4	with	O	['N']	[4]
5	quetiapine	B-Drug	['Causes']	[2]
6	.	O	['N']	[6]
#4606
0	After	O	['N']	[0]
1	therapy	O	['N']	[1]
2	with	O	['N']	[2]
3	parenteral	O	['N']	[3]
4	amiodarone	B-Drug	['Causes']	[34]
5	(	O	['N']	[5]
6	2300	O	['N']	[6]
7	mg	O	['N']	[7]
8	in	O	['N']	[8]
9	3	O	['N']	[9]
10	days	O	['N']	[10]
11	)	O	['N']	[11]
12	and	O	['N']	[12]
13	other	O	['N']	[13]
14	measures	O	['N']	[14]
15	,	O	['N']	[15]
16	signs	O	['N']	[16]
17	of	O	['N']	[17]
18	congestive	O	['N']	[18]
19	heart	O	['N']	[19]
20	failure	O	['N']	[20]
21	disappeared	O	['N']	[21]
22	;	O	['N']	[22]
23	subsequently	O	['N']	[23]
24	the	O	['N']	[24]
25	patient	O	['N']	[25]
26	developed	O	['N']	[26]
27	jaundice	O	['N']	[27]
28	,	O	['N']	[28]
29	marked	B	['N']	[29]
30	increase	I	['N']	[30]
31	in	I	['N']	[31]
32	serum	I	['N']	[32]
33	transaminase	I	['N']	[33]
34	levels	I-Adverse_Effect	['N']	[34]
35	and	O	['N']	[35]
36	fall	O	['N']	[36]
37	in	O	['N']	[37]
38	prothrombin	O	['N']	[38]
39	time	O	['N']	[39]
40	,	O	['N']	[40]
41	and	O	['N']	[41]
42	histologic	O	['N']	[42]
43	changes	O	['N']	[43]
44	of	O	['N']	[44]
45	severe	O	['N']	[45]
46	centrilobular	O	['N']	[46]
47	necrosis	O	['N']	[47]
48	were	O	['N']	[48]
49	observed	O	['N']	[49]
50	in	O	['N']	[50]
51	hepatic	O	['N']	[51]
52	biopsy	O	['N']	[52]
53	.	O	['N']	[53]
#4607
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	skin	O	['N']	[23]
24	eruptions	O	['N']	[24]
25	,	O	['N']	[25]
26	cervical	B	['N']	[26]
27	lymphadenopathy	I-Adverse_Effect	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	O	['N']	[31]
32	lymphocytosis	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	B-Drug	['Causes']	[27]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	O	['N']	[42]
43	(	O	['N']	[43]
44	SMX	O	['N']	[44]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#4608
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	who	O	['N']	[5]
6	developed	O	['N']	[6]
7	hypersensitivity	B	['N']	[7]
8	pneumonitis	I-Adverse_Effect	['N']	[8]
9	during	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	the	O	['N']	[12]
13	beta	O	['N']	[13]
14	-	O	['N']	[14]
15	blocker	O	['N']	[15]
16	,	O	['N']	[16]
17	celiprolol	B-Drug	['Causes']	[8]
18	.	O	['N']	[18]
#4609
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	,	O	['N']	[2]
3	in	O	['N']	[3]
4	whom	O	['N']	[4]
5	tumour	O	['N']	[5]
6	overkill	O	['N']	[6]
7	by	O	['N']	[7]
8	cytotoxic	O	['N']	[8]
9	treatment	O	['N']	[9]
10	,	O	['N']	[10]
11	including	O	['N']	[11]
12	high	O	['N']	[12]
13	dose	O	['N']	[13]
14	methotrexate	O	['N']	[14]
15	with	O	['N']	[15]
16	folinic	B	['N']	[16]
17	acid	I-Drug	['Causes']	[31]
18	rescue	O	['N']	[18]
19	,	O	['N']	[19]
20	resulted	O	['N']	[20]
21	in	O	['N']	[21]
22	the	O	['N']	[22]
23	'	O	['N']	[23]
24	phosphate	O	['N']	[24]
25	shower	O	['N']	[25]
26	syndrome	O	['N']	[26]
27	'	O	['N']	[27]
28	(	O	['N']	[28]
29	hyper	B	['N']	[29]
30	-	I	['N']	[30]
31	uricaemia	I-Adverse_Effect	['N']	[31]
32	,	O	['N']	[32]
33	hyperkalaemia	O	['N']	[33]
34	and	O	['N']	[34]
35	hyperphosphataemia	O	['N']	[35]
36	with	O	['N']	[36]
37	hypocalcaemia	O	['N']	[37]
38	and	O	['N']	[38]
39	tetany	O	['N']	[39]
40	,	O	['N']	[40]
41	with	O	['N']	[41]
42	metabolic	O	['N']	[42]
43	acidosis	O	['N']	[43]
44	and	O	['N']	[44]
45	acute	O	['N']	[45]
46	renal	O	['N']	[46]
47	impairment	O	['N']	[47]
48	)	O	['N']	[48]
49	are	O	['N']	[49]
50	described	O	['N']	[50]
51	.	O	['N']	[51]
#4610
0	Previous	O	['N']	[0]
1	studies	O	['N']	[1]
2	have	O	['N']	[2]
3	demonstrated	O	['N']	[3]
4	the	O	['N']	[4]
5	interaction	O	['N']	[5]
6	of	O	['N']	[6]
7	MTX	B-Drug	['Causes']	[45]
8	and	O	['N']	[8]
9	a	O	['N']	[9]
10	variety	O	['N']	[10]
11	of	O	['N']	[11]
12	non	O	['N']	[12]
13	-	O	['N']	[13]
14	steroidal	O	['N']	[14]
15	,	O	['N']	[15]
16	anti	O	['N']	[16]
17	-	O	['N']	[17]
18	inflammatory	O	['N']	[18]
19	drugs	O	['N']	[19]
20	(	O	['N']	[20]
21	NSAIDs	O	['N']	[21]
22	)	O	['N']	[22]
23	with	O	['N']	[23]
24	various	O	['N']	[24]
25	clinical	O	['N']	[25]
26	manifestations	O	['N']	[26]
27	including	O	['N']	[27]
28	acute	O	['N']	[28]
29	renal	O	['N']	[29]
30	failure	O	['N']	[30]
31	,	O	['N']	[31]
32	pancytopenia	O	['N']	[32]
33	,	O	['N']	[33]
34	vomiting	O	['N']	[34]
35	,	O	['N']	[35]
36	diarrhea	O	['N']	[36]
37	,	O	['N']	[37]
38	elevated	O	['N']	[38]
39	liver	O	['N']	[39]
40	transaminases	O	['N']	[40]
41	,	O	['N']	[41]
42	jaundice	O	['N']	[42]
43	,	O	['N']	[43]
44	mucosal	B	['N']	[44]
45	ulcerations	I-Adverse_Effect	['N']	[45]
46	,	O	['N']	[46]
47	and	O	['N']	[47]
48	pyrexia	O	['N']	[48]
49	.	O	['N']	[49]
#4611
0	The	O	['N']	[0]
1	following	O	['N']	[1]
2	is	O	['N']	[2]
3	a	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	2	O	['N']	[6]
7	cases	O	['N']	[7]
8	of	O	['N']	[8]
9	rifampicin	B-Drug	['Causes']	[13]
10	-	O	['N']	[10]
11	induced	O	['N']	[11]
12	renal	B	['N']	[12]
13	insufficiency	I-Adverse_Effect	['N']	[13]
14	.	O	['N']	[14]
#4612
0	Vancomycin	B-Drug	['Causes']	[22]
1	is	O	['N']	[1]
2	widely	O	['N']	[2]
3	used	O	['N']	[3]
4	against	O	['N']	[4]
5	methicillin	O	['N']	[5]
6	-	O	['N']	[6]
7	resistant	O	['N']	[7]
8	Staphylococcus	O	['N']	[8]
9	aureus	O	['N']	[9]
10	infections	O	['N']	[10]
11	,	O	['N']	[11]
12	but	O	['N']	[12]
13	it	O	['N']	[13]
14	is	O	['N']	[14]
15	associated	O	['N']	[15]
16	with	O	['N']	[16]
17	many	O	['N']	[17]
18	adverse	O	['N']	[18]
19	effects	O	['N']	[19]
20	such	O	['N']	[20]
21	as	O	['N']	[21]
22	nephrotoxicity	B-Adverse_Effect	['N']	[22]
23	,	O	['N']	[23]
24	ototoxicity	O	['N']	[24]
25	,	O	['N']	[25]
26	gastrointestinal	O	['N']	[26]
27	disturbances	O	['N']	[27]
28	,	O	['N']	[28]
29	blood	O	['N']	[29]
30	disorders	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	two	O	['N']	[33]
34	types	O	['N']	[34]
35	of	O	['N']	[35]
36	hypersensitivity	O	['N']	[36]
37	reactions	O	['N']	[37]
38	-	O	['N']	[38]
39	an	O	['N']	[39]
40	anaphylactoid	O	['N']	[40]
41	reaction	O	['N']	[41]
42	known	O	['N']	[42]
43	as	O	['N']	[43]
44	"	O	['N']	[44]
45	red	O	['N']	[45]
46	man	O	['N']	[46]
47	syndrome	O	['N']	[47]
48	"	O	['N']	[48]
49	and	O	['N']	[49]
50	anaphylaxis	O	['N']	[50]
51	.	O	['N']	[51]
#4613
0	The	O	['N']	[0]
1	three	O	['N']	[1]
2	reported	O	['N']	[2]
3	cases	O	['N']	[3]
4	demonstrate	O	['N']	[4]
5	that	O	['N']	[5]
6	troglitazone	B-Drug	['Causes']	[17]
7	is	O	['N']	[7]
8	an	O	['N']	[8]
9	idiosyncratic	O	['N']	[9]
10	hepatotoxin	O	['N']	[10]
11	that	O	['N']	[11]
12	can	O	['N']	[12]
13	lead	O	['N']	[13]
14	to	O	['N']	[14]
15	irreversible	B	['N']	[15]
16	liver	I	['N']	[16]
17	injury	I-Adverse_Effect	['N']	[17]
18	.	O	['N']	[18]
#4614
0	The	O	['N']	[0]
1	third	O	['N']	[1]
2	patient	O	['N']	[2]
3	had	O	['N']	[3]
4	been	O	['N']	[4]
5	suffering	O	['N']	[5]
6	from	O	['N']	[6]
7	serious	O	['N']	[7]
8	akathisia	O	['N']	[8]
9	while	O	['N']	[9]
10	on	O	['N']	[10]
11	risperidone	B-Drug	['Causes']	[27]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	was	O	['N']	[14]
15	cured	O	['N']	[15]
16	after	O	['N']	[16]
17	switching	O	['N']	[17]
18	to	O	['N']	[18]
19	olanzapine	O	['N']	[19]
20	,	O	['N']	[20]
21	but	O	['N']	[21]
22	thereafter	O	['N']	[22]
23	the	O	['N']	[23]
24	patient	O	['N']	[24]
25	suffered	O	['N']	[25]
26	from	O	['N']	[26]
27	RLS	B-Adverse_Effect	['N']	[27]
28	at	O	['N']	[28]
29	nighttime	O	['N']	[29]
30	.	O	['N']	[30]
#4615
0	In	O	['N']	[0]
1	addition	O	['N']	[1]
2	to	O	['N']	[2]
3	disease	O	['N']	[3]
4	refractoriness	O	['N']	[4]
5	,	O	['N']	[5]
6	rare	O	['N']	[6]
7	instances	O	['N']	[7]
8	of	O	['N']	[8]
9	disease	O	['N']	[9]
10	progression	O	['N']	[10]
11	from	O	['N']	[11]
12	chronic	O	['N']	[12]
13	phase	O	['N']	[13]
14	to	O	['N']	[14]
15	blast	B	['N']	[15]
16	crisis	I-Adverse_Effect	['N']	[16]
17	during	O	['N']	[17]
18	imatinib	B-Drug	['Causes']	[16]
19	therapy	O	['N']	[19]
20	have	O	['N']	[20]
21	recently	O	['N']	[21]
22	been	O	['N']	[22]
23	anecdotally	O	['N']	[23]
24	reported	O	['N']	[24]
25	.	O	['N']	[25]
#4616
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	,	O	['N']	[3]
4	we	O	['N']	[4]
5	present	O	['N']	[5]
6	a	O	['N']	[6]
7	case	O	['N']	[7]
8	of	O	['N']	[8]
9	hypoglycaemic	B	['N']	[9]
10	coma	I-Adverse_Effect	['N']	[10]
11	associated	O	['N']	[11]
12	with	O	['N']	[12]
13	SP	B-Drug	['Causes']	[10]
14	,	O	['N']	[14]
15	an	O	['N']	[15]
16	adverse	O	['N']	[16]
17	reaction	O	['N']	[17]
18	that	O	['N']	[18]
19	is	O	['N']	[19]
20	likely	O	['N']	[20]
21	to	O	['N']	[21]
22	be	O	['N']	[22]
23	underreported	O	['N']	[23]
24	and	O	['N']	[24]
25	expected	O	['N']	[25]
26	to	O	['N']	[26]
27	occur	O	['N']	[27]
28	with	O	['N']	[28]
29	greater	O	['N']	[29]
30	frequency	O	['N']	[30]
31	as	O	['N']	[31]
32	the	O	['N']	[32]
33	use	O	['N']	[33]
34	of	O	['N']	[34]
35	SP	O	['N']	[35]
36	increases	O	['N']	[36]
37	.	O	['N']	[37]
#4617
0	We	O	['N']	[0]
1	document	O	['N']	[1]
2	the	O	['N']	[2]
3	abrupt	O	['N']	[3]
4	development	O	['N']	[4]
5	of	O	['N']	[5]
6	an	O	['N']	[6]
7	extensive	O	['N']	[7]
8	choroidal	B	['N']	[8]
9	detachment	I-Adverse_Effect	['N']	[9]
10	after	O	['N']	[10]
11	initiation	O	['N']	[11]
12	of	O	['N']	[12]
13	dorzolamide	B-Drug	['Causes']	[9]
14	therapy	O	['N']	[14]
15	in	O	['N']	[15]
16	a	O	['N']	[16]
17	surgically	O	['N']	[17]
18	untreated	O	['N']	[18]
19	eye	O	['N']	[19]
20	with	O	['N']	[20]
21	primary	O	['N']	[21]
22	open	O	['N']	[22]
23	-	O	['N']	[23]
24	angle	O	['N']	[24]
25	glaucoma	O	['N']	[25]
26	.	O	['N']	[26]
#4618
0	The	O	['N']	[0]
1	chemotherapeutics	O	['N']	[1]
2	,	O	['N']	[2]
3	including	O	['N']	[3]
4	vincristine	O	['N']	[4]
5	,	O	['N']	[5]
6	actinomycin	B	['N']	[6]
7	D	I-Drug	['Causes']	[27]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	epirubicin	O	['N']	[10]
11	in	O	['N']	[11]
12	case	O	['N']	[12]
13	1	O	['N']	[13]
14	and	O	['N']	[14]
15	vincristine	O	['N']	[15]
16	and	O	['N']	[16]
17	actinomycin	O	['N']	[17]
18	D	O	['N']	[18]
19	in	O	['N']	[19]
20	case	O	['N']	[20]
21	2	O	['N']	[21]
22	,	O	['N']	[22]
23	were	O	['N']	[23]
24	given	O	['N']	[24]
25	before	O	['N']	[25]
26	the	O	['N']	[26]
27	hepatotoxicity	B-Adverse_Effect	['N']	[27]
28	developed	O	['N']	[28]
29	.	O	['N']	[29]
#4619
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	receiving	O	['N']	[2]
3	phenytoin	B	['N']	[3]
4	sodium	I-Drug	['Causes']	[25]
5	300	O	['N']	[5]
6	mg	O	['N']	[6]
7	/	O	['N']	[7]
8	day	O	['N']	[8]
9	;	O	['N']	[9]
10	carbamazepine	O	['N']	[10]
11	200	O	['N']	[11]
12	mg	O	['N']	[12]
13	four	O	['N']	[13]
14	times	O	['N']	[14]
15	daily	O	['N']	[15]
16	had	O	['N']	[16]
17	been	O	['N']	[17]
18	discontinued	O	['N']	[18]
19	four	O	['N']	[19]
20	days	O	['N']	[20]
21	before	O	['N']	[21]
22	admission	O	['N']	[22]
23	because	O	['N']	[23]
24	of	O	['N']	[24]
25	leukopenia	B-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#4620
0	An	O	['N']	[0]
1	11-day	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	infant	O	['N']	[4]
5	became	O	['N']	[5]
6	lethargic	B-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	apneic	O	['N']	[8]
9	after	O	['N']	[9]
10	a	O	['N']	[10]
11	single	O	['N']	[11]
12	drop	O	['N']	[12]
13	of	O	['N']	[13]
14	brimonidine	B-Drug	['Causes']	[6]
15	.	O	['N']	[15]
#4621
0	A	O	['N']	[0]
1	7-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	girl	O	['N']	[4]
5	developed	O	['N']	[5]
6	diabetes	O	['N']	[6]
7	mellitus	O	['N']	[7]
8	and	O	['N']	[8]
9	exocrine	B	['N']	[9]
10	pancreatic	I	['N']	[10]
11	insufficiency	I-Adverse_Effect	['N']	[11]
12	after	O	['N']	[12]
13	3.5	O	['N']	[13]
14	years	O	['N']	[14]
15	of	O	['N']	[15]
16	almost	O	['N']	[16]
17	continuous	O	['N']	[17]
18	treatment	O	['N']	[18]
19	with	O	['N']	[19]
20	azathioprine	B-Drug	['Causes']	[11]
21	and/or	O	['N']	[21]
22	prednisone	O	['N']	[22]
23	for	O	['N']	[23]
24	idiopathic	O	['N']	[24]
25	auto	O	['N']	[25]
26	-	O	['N']	[26]
27	immune	O	['N']	[27]
28	haemolytic	O	['N']	[28]
29	anaemia	O	['N']	[29]
30	.	O	['N']	[30]
#4622
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	treated	O	['N']	[2]
3	for	O	['N']	[3]
4	chronic	O	['N']	[4]
5	myeloid	O	['N']	[5]
6	leukemia	O	['N']	[6]
7	with	O	['N']	[7]
8	high	O	['N']	[8]
9	doses	O	['N']	[9]
10	of	O	['N']	[10]
11	CCNU	B-Drug	['Dosage']	[21]
12	(	O	['N']	[12]
13	1100	O	['N']	[13]
14	mg	O	['N']	[14]
15	/	O	['N']	[15]
16	m2	O	['N']	[16]
17	and	O	['N']	[17]
18	1240	B	['N']	[18]
19	mg	I	['N']	[19]
20	/	I	['N']	[20]
21	m2	I-Dose	['N']	[21]
22	,	O	['N']	[22]
23	respectively	O	['N']	[23]
24	)	O	['N']	[24]
25	developed	O	['N']	[25]
26	a	O	['N']	[26]
27	fatal	O	['N']	[27]
28	pulmonary	O	['N']	[28]
29	fibrosis	O	['N']	[29]
30	.	O	['N']	[30]
#4623
0	These	O	['N']	[0]
1	cases	O	['N']	[1]
2	were	O	['N']	[2]
3	chosen	O	['N']	[3]
4	for	O	['N']	[4]
5	study	O	['N']	[5]
6	because	O	['N']	[6]
7	they	O	['N']	[7]
8	were	O	['N']	[8]
9	all	O	['N']	[9]
10	deaths	B-Adverse_Effect	['N']	[10]
11	as	O	['N']	[11]
12	a	O	['N']	[12]
13	result	O	['N']	[13]
14	of	O	['N']	[14]
15	suicidal	O	['N']	[15]
16	ingestion	O	['N']	[16]
17	of	O	['N']	[17]
18	drugs	O	['N']	[18]
19	in	O	['N']	[19]
20	which	O	['N']	[20]
21	quetiapine	B-Drug	['Causes']	[10]
22	was	O	['N']	[22]
23	considered	O	['N']	[23]
24	a	O	['N']	[24]
25	significant	O	['N']	[25]
26	factor	O	['N']	[26]
27	.	O	['N']	[27]
#4624
0	Proconvulsive	B-Adverse_Effect	['N']	[0]
1	tendency	O	['N']	[1]
2	of	O	['N']	[2]
3	imipenem	B-Drug	['Causes']	[0]
4	/	O	['N']	[4]
5	cilastatin	O	['N']	[5]
6	is	O	['N']	[6]
7	one	O	['N']	[7]
8	of	O	['N']	[8]
9	its	O	['N']	[9]
10	well	O	['N']	[10]
11	-	O	['N']	[11]
12	known	O	['N']	[12]
13	side	O	['N']	[13]
14	effects	O	['N']	[14]
15	.	O	['N']	[15]
#4625
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	given	O	['N']	[2]
3	the	O	['N']	[3]
4	clinically	O	['N']	[4]
5	significant	O	['N']	[5]
6	result	O	['N']	[6]
7	to	O	['N']	[7]
8	the	O	['N']	[8]
9	interaction	O	['N']	[9]
10	between	O	['N']	[10]
11	tolazoline	B-Drug	['Causes']	[26]
12	and	O	['N']	[12]
13	cimetidine	O	['N']	[13]
14	we	O	['N']	[14]
15	report	O	['N']	[15]
16	,	O	['N']	[16]
17	the	O	['N']	[17]
18	use	O	['N']	[18]
19	of	O	['N']	[19]
20	cimetidine	O	['N']	[20]
21	in	O	['N']	[21]
22	tolazoline	O	['N']	[22]
23	induced	O	['N']	[23]
24	upper	B	['N']	[24]
25	gastrointestinal	I	['N']	[25]
26	hemorrhage	I-Adverse_Effect	['N']	[26]
27	should	O	['N']	[27]
28	deserve	O	['N']	[28]
29	more	O	['N']	[29]
30	attention	O	['N']	[30]
31	.	O	['N']	[31]
#4626
0	The	O	['N']	[0]
1	fluorine	O	['N']	[1]
2	contained	O	['N']	[2]
3	in	O	['N']	[3]
4	niflumic	B	['N']	[4]
5	acid	I-Drug	['Causes']	[12]
6	induced	O	['N']	[6]
7	a	O	['N']	[7]
8	marked	O	['N']	[8]
9	densification	B	['N']	[9]
10	of	I	['N']	[10]
11	trabecular	I	['N']	[11]
12	bone	I-Adverse_Effect	['N']	[12]
13	in	O	['N']	[13]
14	all	O	['N']	[14]
15	3	O	['N']	[15]
16	cases	O	['N']	[16]
17	.	O	['N']	[17]
#4627
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	combined	O	['N']	[6]
7	lithium	O	['N']	[7]
8	and	O	['N']	[8]
9	haloperidol	B-Drug	['Causes']	[18]
10	toxicity	O	['N']	[10]
11	characterized	O	['N']	[11]
12	by	O	['N']	[12]
13	hyperpyrexia	O	['N']	[13]
14	,	O	['N']	[14]
15	severe	O	['N']	[15]
16	rigidity	O	['N']	[16]
17	,	O	['N']	[17]
18	mutism	B-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	development	O	['N']	[21]
22	of	O	['N']	[22]
23	irreversible	O	['N']	[23]
24	tardive	O	['N']	[24]
25	dyskinesia	O	['N']	[25]
26	.	O	['N']	[26]
#4628
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	Ritalin	B-Drug	['Causes']	[10]
6	-	O	['N']	[6]
7	associated	O	['N']	[7]
8	cataract	O	['N']	[8]
9	and	O	['N']	[9]
10	glaucoma	B-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#4629
0	Clinical	O	['N']	[0]
1	profile	O	['N']	[1]
2	of	O	['N']	[2]
3	oxcarbazepine	B-Drug	['Causes']	[7]
4	-	O	['N']	[4]
5	related	O	['N']	[5]
6	angioneurotic	B	['N']	[6]
7	edema	I-Adverse_Effect	['N']	[7]
8	:	O	['N']	[8]
9	case	O	['N']	[9]
10	report	O	['N']	[10]
11	and	O	['N']	[11]
12	review	O	['N']	[12]
13	.	O	['N']	[13]
#4630
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	the	O	['N']	[3]
4	Wolff	O	['N']	[4]
5	-	O	['N']	[5]
6	Parkinson	O	['N']	[6]
7	-	O	['N']	[7]
8	White	O	['N']	[8]
9	syndrome	O	['N']	[9]
10	presented	O	['N']	[10]
11	with	O	['N']	[11]
12	incessant	B	['N']	[12]
13	orthodromic	I	['N']	[13]
14	atrioventricular	I	['N']	[14]
15	tachycardia	I-Adverse_Effect	['N']	[15]
16	following	O	['N']	[16]
17	initiation	O	['N']	[17]
18	of	O	['N']	[18]
19	procainamide	B-Drug	['Causes']	[15]
20	therapy	O	['N']	[20]
21	.	O	['N']	[21]
#4631
0	Vision	B	['N']	[0]
1	declined	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	treatment	O	['N']	[3]
4	with	O	['N']	[4]
5	methylprednisolone	B-Drug	['Causes']	[1]
6	,	O	['N']	[6]
7	after	O	['N']	[7]
8	which	O	['N']	[8]
9	fundus	O	['N']	[9]
10	examination	O	['N']	[10]
11	became	O	['N']	[11]
12	consistent	O	['N']	[12]
13	with	O	['N']	[13]
14	progressive	O	['N']	[14]
15	outer	O	['N']	[15]
16	retinal	O	['N']	[16]
17	necrosis	O	['N']	[17]
18	.	O	['N']	[18]
#4632
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	present	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	t	B	['N']	[6]
7	-	I	['N']	[7]
8	AML	I-Adverse_Effect	['N']	[8]
9	that	O	['N']	[9]
10	developed	O	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	child	O	['N']	[13]
14	with	O	['N']	[14]
15	metastatic	O	['N']	[15]
16	neuroblastoma	O	['N']	[16]
17	18	O	['N']	[17]
18	months	O	['N']	[18]
19	after	O	['N']	[19]
20	he	O	['N']	[20]
21	received	O	['N']	[21]
22	oral	O	['N']	[22]
23	etoposide	B-Drug	['Causes']	[8]
24	,	O	['N']	[24]
25	given	O	['N']	[25]
26	for	O	['N']	[26]
27	palliation	O	['N']	[27]
28	purpose	O	['N']	[28]
29	.	O	['N']	[29]
#4633
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	on	O	['N']	[2]
3	three	O	['N']	[3]
4	cases	O	['N']	[4]
5	wherein	O	['N']	[5]
6	treatment	O	['N']	[6]
7	of	O	['N']	[7]
8	dexmedetomidine	B-Drug	['Dosage']	[20]
9	-	O	['N']	[9]
10	induced	O	['N']	[10]
11	bradycardia	O	['N']	[11]
12	with	O	['N']	[12]
13	i.v	O	['N']	[13]
14	.	O	['N']	[14]
15	glycopyrrolate	O	['N']	[15]
16	(	O	['N']	[16]
17	5.0	B	['N']	[17]
18	microg	I	['N']	[18]
19	/	I	['N']	[19]
20	kg	I-Dose	['N']	[20]
21	)	O	['N']	[21]
22	not	O	['N']	[22]
23	only	O	['N']	[23]
24	resulting	O	['N']	[24]
25	in	O	['N']	[25]
26	resolution	O	['N']	[26]
27	of	O	['N']	[27]
28	bradycardia	O	['N']	[28]
29	but	O	['N']	[29]
30	also	O	['N']	[30]
31	resulting	O	['N']	[31]
32	in	O	['N']	[32]
33	an	O	['N']	[33]
34	exaggerated	O	['N']	[34]
35	increase	O	['N']	[35]
36	of	O	['N']	[36]
37	arterial	O	['N']	[37]
38	blood	O	['N']	[38]
39	pressure	O	['N']	[39]
40	.	O	['N']	[40]
#4634
0	Autopsy	O	['N']	[0]
1	evidence	O	['N']	[1]
2	of	O	['N']	[2]
3	herpesvirus	B	['N']	[3]
4	infection	I-Adverse_Effect	['N']	[4]
5	was	O	['N']	[5]
6	found	O	['N']	[6]
7	in	O	['N']	[7]
8	visceral	O	['N']	[8]
9	organs	O	['N']	[9]
10	of	O	['N']	[10]
11	four	O	['N']	[11]
12	leukemic	O	['N']	[12]
13	patients	O	['N']	[13]
14	who	O	['N']	[14]
15	had	O	['N']	[15]
16	received	O	['N']	[16]
17	large	O	['N']	[17]
18	doses	O	['N']	[18]
19	of	O	['N']	[19]
20	cytarabine	O	['N']	[20]
21	(	O	['N']	[21]
22	cytosine	O	['N']	[22]
23	arabinoside	O	['N']	[23]
24	;	O	['N']	[24]
25	Ara	B	['N']	[25]
26	-	I	['N']	[26]
27	C	I-Drug	['Causes']	[4]
28	)	O	['N']	[28]
29	shortly	O	['N']	[29]
30	before	O	['N']	[30]
31	their	O	['N']	[31]
32	death	O	['N']	[32]
33	.	O	['N']	[33]
#4635
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Marked	O	['N']	[2]
3	visual	B	['N']	[3]
4	field	I	['N']	[4]
5	constriction	I-Adverse_Effect	['N']	[5]
6	appears	O	['N']	[6]
7	to	O	['N']	[7]
8	be	O	['N']	[8]
9	associated	O	['N']	[9]
10	with	O	['N']	[10]
11	vigabatrin	B-Drug	['Causes']	[5]
12	therapy	O	['N']	[12]
13	.	O	['N']	[13]
#4636
0	Treatment	O	['N']	[0]
1	of	O	['N']	[1]
2	ELP	O	['N']	[2]
3	in	O	['N']	[3]
4	children	O	['N']	[4]
5	is	O	['N']	[5]
6	generally	O	['N']	[6]
7	supportive	O	['N']	[7]
8	,	O	['N']	[8]
9	with	O	['N']	[9]
10	the	O	['N']	[10]
11	symptoms	O	['N']	[11]
12	and	O	['N']	[12]
13	roentgenographic	B	['N']	[13]
14	abnormalities	I-Adverse_Effect	['N']	[14]
15	resolving	O	['N']	[15]
16	within	O	['N']	[16]
17	months	O	['N']	[17]
18	after	O	['N']	[18]
19	stopping	O	['N']	[19]
20	the	O	['N']	[20]
21	use	O	['N']	[21]
22	of	O	['N']	[22]
23	mineral	B	['N']	[23]
24	oil	I-Drug	['Causes']	[14]
25	.	O	['N']	[25]
#4637
0	Postoperatively	O	['N']	[0]
1	,	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	two	O	['N']	[4]
5	patients	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	1	O	['N']	[8]
9	to	O	['N']	[9]
10	2	O	['N']	[10]
11	cc	O	['N']	[11]
12	of	O	['N']	[12]
13	thrombin	B-Drug	['Causes']	[31]
14	were	O	['N']	[14]
15	slow	O	['N']	[15]
16	to	O	['N']	[16]
17	awaken	O	['N']	[17]
18	;	O	['N']	[18]
19	one	O	['N']	[19]
20	had	O	['N']	[20]
21	evidence	O	['N']	[21]
22	of	O	['N']	[22]
23	vasospasm	O	['N']	[23]
24	by	O	['N']	[24]
25	transcranial	O	['N']	[25]
26	Doppler	O	['N']	[26]
27	ultrasound	O	['N']	[27]
28	studies	O	['N']	[28]
29	and	O	['N']	[29]
30	multiple	B	['N']	[30]
31	infarcts	I-Adverse_Effect	['N']	[31]
32	on	O	['N']	[32]
33	cranial	O	['N']	[33]
34	computerized	O	['N']	[34]
35	tomography	O	['N']	[35]
36	,	O	['N']	[36]
37	while	O	['N']	[37]
38	the	O	['N']	[38]
39	other	O	['N']	[39]
40	had	O	['N']	[40]
41	a	O	['N']	[41]
42	moderate	O	['N']	[42]
43	-	O	['N']	[43]
44	sized	O	['N']	[44]
45	frontal	O	['N']	[45]
46	hematoma	O	['N']	[46]
47	with	O	['N']	[47]
48	intracranial	O	['N']	[48]
49	hypertension	O	['N']	[49]
50	.	O	['N']	[50]
#4638
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Gemcitabine	B-Drug	['Causes']	[17]
3	has	O	['N']	[3]
4	mild	O	['N']	[4]
5	renal	O	['N']	[5]
6	toxicity	O	['N']	[6]
7	,	O	['N']	[7]
8	but	O	['N']	[8]
9	cases	O	['N']	[9]
10	of	O	['N']	[10]
11	gemcitabine	O	['N']	[11]
12	-	O	['N']	[12]
13	associated	O	['N']	[13]
14	hemolytic	B	['N']	[14]
15	-	I	['N']	[15]
16	uremic	I	['N']	[16]
17	syndrome	I-Adverse_Effect	['N']	[17]
18	(	O	['N']	[18]
19	HUS	O	['N']	[19]
20	)	O	['N']	[20]
21	have	O	['N']	[21]
22	been	O	['N']	[22]
23	reported	O	['N']	[23]
24	.	O	['N']	[24]
#4639
0	Pulmonary	B	['N']	[0]
1	hemorrhage	I-Adverse_Effect	['N']	[1]
2	is	O	['N']	[2]
3	an	O	['N']	[3]
4	uncommon	O	['N']	[4]
5	feature	O	['N']	[5]
6	in	O	['N']	[6]
7	the	O	['N']	[7]
8	HUS	O	['N']	[8]
9	,	O	['N']	[9]
10	and	O	['N']	[10]
11	seems	O	['N']	[11]
12	to	O	['N']	[12]
13	appear	O	['N']	[13]
14	especially	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	HUS	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	MMC	B-Drug	['Causes']	[1]
21	therapy	O	['N']	[21]
22	.	O	['N']	[22]
#4640
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	skin	O	['N']	[23]
24	eruptions	O	['N']	[24]
25	,	O	['N']	[25]
26	cervical	O	['N']	[26]
27	lymphadenopathy	O	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	B-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	atypical	O	['N']	[31]
32	lymphocytosis	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	O	['N']	[40]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	-	['N']	[42]
43	(	O	['N']	[43]
44	SMX	O	['N']	[44]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#4641
0	Three	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	acute	B	['N']	[3]
4	renal	I	['N']	[4]
5	toxicity	I-Adverse_Effect	['N']	[5]
6	in	O	['N']	[6]
7	patients	O	['N']	[7]
8	receiving	O	['N']	[8]
9	long	O	['N']	[9]
10	-	O	['N']	[10]
11	term	O	['N']	[11]
12	therapy	O	['N']	[12]
13	with	O	['N']	[13]
14	mitomycin	O	['N']	[14]
15	C	O	['N']	[15]
16	and	O	['N']	[16]
17	5-fluorouracil	B-Drug	['Causes']	[5]
18	are	O	['N']	[18]
19	reported	O	['N']	[19]
20	.	O	['N']	[20]
#4642
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	developed	O	['N']	[2]
3	diabetic	B	['N']	[3]
4	coma	I-Adverse_Effect	['N']	[4]
5	when	O	['N']	[5]
6	taking	O	['N']	[6]
7	a	O	['N']	[7]
8	combination	O	['N']	[8]
9	of	O	['N']	[9]
10	a	O	['N']	[10]
11	thiazide	O	['N']	[11]
12	diuretic	O	['N']	[12]
13	and	O	['N']	[13]
14	propranolol	B-Drug	['Causes']	[4]
15	.	O	['N']	[15]
#4643
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	main	O	['N']	[3]
4	adverse	O	['N']	[4]
5	effects	O	['N']	[5]
6	of	O	['N']	[6]
7	leflunomide	B-Drug	['Causes']	[25]
8	consist	O	['N']	[8]
9	of	O	['N']	[9]
10	diarrhea	O	['N']	[10]
11	,	O	['N']	[11]
12	nausea	O	['N']	[12]
13	,	O	['N']	[13]
14	liver	O	['N']	[14]
15	enzyme	O	['N']	[15]
16	elevation	O	['N']	[16]
17	,	O	['N']	[17]
18	hypertension	O	['N']	[18]
19	,	O	['N']	[19]
20	alopecia	O	['N']	[20]
21	,	O	['N']	[21]
22	and	O	['N']	[22]
23	allergic	B	['N']	[23]
24	skin	I	['N']	[24]
25	reactions	I-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#4644
0	5-fluorouracil	O	['N']	[0]
1	(	O	['N']	[1]
2	5-FU)-associated	-	['N']	[2]
3	peripheral	B	['N']	[3]
4	neuropathy	I-Adverse_Effect	['N']	[4]
5	is	O	['N']	[5]
6	an	O	['N']	[6]
7	uncommon	O	['N']	[7]
8	event	O	['N']	[8]
9	.	O	['N']	[9]
#4645
0	Naproxen	B-Drug	['Causes']	[21]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	commonly	O	['N']	[3]
4	used	O	['N']	[4]
5	nonsteroidal	O	['N']	[5]
6	anti	O	['N']	[6]
7	-	O	['N']	[7]
8	inflammatory	O	['N']	[8]
9	drug	O	['N']	[9]
10	(	O	['N']	[10]
11	NSAID	O	['N']	[11]
12	)	O	['N']	[12]
13	whose	O	['N']	[13]
14	side	O	['N']	[14]
15	effects	O	['N']	[15]
16	include	O	['N']	[16]
17	tinnitus	O	['N']	[17]
18	and	O	['N']	[18]
19	transient	B	['N']	[19]
20	hearing	I	['N']	[20]
21	loss	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#4646
0	The	O	['N']	[0]
1	5	O	['N']	[1]
2	patients	O	['N']	[2]
3	had	O	['N']	[3]
4	severe	O	['N']	[4]
5	renovascular	O	['N']	[5]
6	disease	O	['N']	[6]
7	which	O	['N']	[7]
8	might	O	['N']	[8]
9	thus	O	['N']	[9]
10	represent	O	['N']	[10]
11	a	O	['N']	[11]
12	significant	O	['N']	[12]
13	risk	O	['N']	[13]
14	factor	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	development	O	['N']	[17]
18	of	O	['N']	[18]
19	captopril	B-Drug	['Causes']	[24]
20	-	O	['N']	[20]
21	induced	O	['N']	[21]
22	acute	B	['N']	[22]
23	renal	I	['N']	[23]
24	failure	I-Adverse_Effect	['N']	[24]
25	.	O	['N']	[25]
#4647
0	Acute	B	['N']	[0]
1	myeloid	I	['N']	[1]
2	leukemia	I-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	lung	O	['N']	[4]
5	cancer	O	['N']	[5]
6	occurring	O	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	chronic	O	['N']	[9]
10	lymphocytic	O	['N']	[10]
11	leukemia	O	['N']	[11]
12	patient	O	['N']	[12]
13	treated	O	['N']	[13]
14	with	O	['N']	[14]
15	fludarabine	B-Drug	['Causes']	[2]
16	and	O	['N']	[16]
17	autologous	O	['N']	[17]
18	peripheral	O	['N']	[18]
19	blood	O	['N']	[19]
20	stem	O	['N']	[20]
21	-	O	['N']	[21]
22	cell	O	['N']	[22]
23	transplantation	O	['N']	[23]
24	.	O	['N']	[24]
#4648
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	linear	B	['N']	[7]
8	immunoglobulin	I	['N']	[8]
9	(	I	['N']	[9]
10	Ig	I	['N']	[10]
11	)	I	['N']	[11]
12	A	I	['N']	[12]
13	bullous	I	['N']	[13]
14	dermatosis	I-Adverse_Effect	['N']	[14]
15	(	O	['N']	[15]
16	LABD	O	['N']	[16]
17	)	O	['N']	[17]
18	induced	O	['N']	[18]
19	by	O	['N']	[19]
20	gemcitabine	B-Drug	['Causes']	[14]
21	.	O	['N']	[21]
#4649
0	Mean	O	['N']	[0]
1	time	O	['N']	[1]
2	between	O	['N']	[2]
3	initiation	O	['N']	[3]
4	of	O	['N']	[4]
5	gemcitabine	B-Drug	['Dosage']	[22]
6	therapy	O	['N']	[6]
7	and	O	['N']	[7]
8	onset	O	['N']	[8]
9	of	O	['N']	[9]
10	HUS	O	['N']	[10]
11	was	O	['N']	[11]
12	7.4	O	['N']	[12]
13	+	O	['N']	[13]
14	/-	O	['N']	[14]
15	3.5	O	['N']	[15]
16	months	O	['N']	[16]
17	,	O	['N']	[17]
18	or	O	['N']	[18]
19	21.9	B	['N']	[19]
20	+	I	['N']	[20]
21	/-	I	['N']	[21]
22	10.9	I-Dose	['N']	[22]
23	doses	O	['N']	[23]
24	of	O	['N']	[24]
25	gemcitabine	O	['N']	[25]
26	.	O	['N']	[26]
#4650
0	Optic	B	['N']	[0]
1	neuropathy	I-Adverse_Effect	['N']	[1]
2	developed	O	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	rheumatoid	O	['N']	[7]
8	arthritis	O	['N']	[8]
9	who	O	['N']	[9]
10	had	O	['N']	[10]
11	been	O	['N']	[11]
12	receiving	O	['N']	[12]
13	D	B	['N']	[13]
14	-	I	['N']	[14]
15	penicillamine	I-Drug	['Causes']	[1]
16	for	O	['N']	[16]
17	about	O	['N']	[17]
18	1	O	['N']	[18]
19	year	O	['N']	[19]
20	.	O	['N']	[20]
#4651
0	Brugada	B	['N']	[0]
1	type	I	['N']	[1]
2	electrocardiographic	I	['N']	[2]
3	changes	I-Adverse_Effect	['N']	[3]
4	induced	O	['N']	[4]
5	by	O	['N']	[5]
6	concomitant	O	['N']	[6]
7	use	O	['N']	[7]
8	of	O	['N']	[8]
9	lithium	O	['N']	[9]
10	and	O	['N']	[10]
11	propafenone	B-Drug	['Causes']	[3]
12	in	O	['N']	[12]
13	patient	O	['N']	[13]
14	with	O	['N']	[14]
15	Wolff	O	['N']	[15]
16	-	O	['N']	[16]
17	Parkinson	O	['N']	[17]
18	-	O	['N']	[18]
19	White	O	['N']	[19]
20	syndrome	O	['N']	[20]
21	.	O	['N']	[21]
#4652
0	Putaminal	B	['N']	[0]
1	infarct	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	methanol	B-Drug	['Causes']	[1]
4	intoxication	O	['N']	[4]
5	:	O	['N']	[5]
6	case	O	['N']	[6]
7	report	O	['N']	[7]
8	and	O	['N']	[8]
9	role	O	['N']	[9]
10	of	O	['N']	[10]
11	brain	O	['N']	[11]
12	imaging	O	['N']	[12]
13	studies	O	['N']	[13]
14	.	O	['N']	[14]
#4653
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	AILD	O	['N']	[5]
6	in	O	['N']	[6]
7	an	O	['N']	[7]
8	80-year	O	['N']	[8]
9	-	O	['N']	[9]
10	old	O	['N']	[10]
11	male	O	['N']	[11]
12	who	O	['N']	[12]
13	presented	O	['N']	[13]
14	with	O	['N']	[14]
15	a	O	['N']	[15]
16	generalized	B	['N']	[16]
17	pruritic	I	['N']	[17]
18	maculopapular	I	['N']	[18]
19	eruption	I-Adverse_Effect	['N']	[19]
20	and	O	['N']	[20]
21	fever	O	['N']	[21]
22	following	O	['N']	[22]
23	doxycycline	B-Drug	['Causes']	[19]
24	administration	O	['N']	[24]
25	.	O	['N']	[25]
#4654
0	Development	O	['N']	[0]
1	of	O	['N']	[1]
2	sarcoidosis	B-Adverse_Effect	['N']	[2]
3	during	O	['N']	[3]
4	interferon	B	['N']	[4]
5	alpha	I	['N']	[5]
6	2b	I-Drug	['Causes']	[2]
7	and	O	['N']	[7]
8	ribavirin	O	['N']	[8]
9	combination	O	['N']	[9]
10	therapy	O	['N']	[10]
11	for	O	['N']	[11]
12	chronic	O	['N']	[12]
13	hepatitis	O	['N']	[13]
14	C	O	['N']	[14]
15	--	O	['N']	[15]
16	a	O	['N']	[16]
17	case	O	['N']	[17]
18	report	O	['N']	[18]
19	and	O	['N']	[19]
20	review	O	['N']	[20]
21	of	O	['N']	[21]
22	the	O	['N']	[22]
23	literature	O	['N']	[23]
24	.	O	['N']	[24]
#4655
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	50-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	male	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	15-year	O	['N']	[10]
11	history	O	['N']	[11]
12	of	O	['N']	[12]
13	psoriasis	O	['N']	[13]
14	including	O	['N']	[14]
15	mutilating	O	['N']	[15]
16	psoriatic	O	['N']	[16]
17	arthritis	O	['N']	[17]
18	,	O	['N']	[18]
19	in	O	['N']	[19]
20	whom	O	['N']	[20]
21	the	O	['N']	[21]
22	withdrawal	O	['N']	[22]
23	of	O	['N']	[23]
24	cyclosporin	B	['N']	[24]
25	A	I-Drug	['Causes']	[30]
26	induced	O	['N']	[26]
27	a	O	['N']	[27]
28	generalised	B	['N']	[28]
29	pustular	I	['N']	[29]
30	exacerbation	I-Adverse_Effect	['N']	[30]
31	and	O	['N']	[31]
32	a	O	['N']	[32]
33	aggravation	O	['N']	[33]
34	of	O	['N']	[34]
35	the	O	['N']	[35]
36	joint	O	['N']	[36]
37	condition	O	['N']	[37]
38	.	O	['N']	[38]
#4656
0	Severe	O	['N']	[0]
1	loss	O	['N']	[1]
2	of	O	['N']	[2]
3	vision	O	['N']	[3]
4	after	O	['N']	[4]
5	removal	O	['N']	[5]
6	of	O	['N']	[6]
7	cataract	B-Adverse_Effect	['N']	[7]
8	caused	O	['N']	[8]
9	by	O	['N']	[9]
10	intravitreal	O	['N']	[10]
11	triamcinolone	B-Drug	['Causes']	[7]
12	in	O	['N']	[12]
13	combination	O	['N']	[13]
14	with	O	['N']	[14]
15	photodynamic	O	['N']	[15]
16	therapy	O	['N']	[16]
17	for	O	['N']	[17]
18	exudative	O	['N']	[18]
19	age	O	['N']	[19]
20	-	O	['N']	[20]
21	related	O	['N']	[21]
22	macular	O	['N']	[22]
23	degeneration	O	['N']	[23]
24	.	O	['N']	[24]
#4657
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	31-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	women	O	['N']	[6]
7	with	O	['N']	[7]
8	recurrent	O	['N']	[8]
9	Hodgkin	O	['N']	[9]
10	's	O	['N']	[10]
11	lymphoma	O	['N']	[11]
12	and	O	['N']	[12]
13	unrecognized	O	['N']	[13]
14	HMSN-1	O	['N']	[14]
15	who	O	['N']	[15]
16	developed	O	['N']	[16]
17	severe	B	['N']	[17]
18	motor	I	['N']	[18]
19	neuropathy	I-Adverse_Effect	['N']	[19]
20	3	O	['N']	[20]
21	weeks	O	['N']	[21]
22	after	O	['N']	[22]
23	the	O	['N']	[23]
24	first	O	['N']	[24]
25	cycle	O	['N']	[25]
26	of	O	['N']	[26]
27	treatment	O	['N']	[27]
28	including	O	['N']	[28]
29	2	O	['N']	[29]
30	mg	O	['N']	[30]
31	of	O	['N']	[31]
32	vincristine	B-Drug	['Causes']	[19]
33	.	O	['N']	[33]
#4658
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	is	O	['N']	[3]
4	,	O	['N']	[4]
5	to	O	['N']	[5]
6	our	O	['N']	[6]
7	knowledge	O	['N']	[7]
8	,	O	['N']	[8]
9	the	O	['N']	[9]
10	first	O	['N']	[10]
11	report	O	['N']	[11]
12	of	O	['N']	[12]
13	severe	B	['N']	[13]
14	myelopathy	I-Adverse_Effect	['N']	[14]
15	following	O	['N']	[15]
16	accidental	O	['N']	[16]
17	intrathecal	O	['N']	[17]
18	administration	O	['N']	[18]
19	of	O	['N']	[19]
20	doxorubicin	B-Drug	['Causes']	[14]
21	.	O	['N']	[21]
#4659
0	A	O	['N']	[0]
1	17-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	patient	O	['N']	[5]
6	who	O	['N']	[6]
7	had	O	['N']	[7]
8	been	O	['N']	[8]
9	taking	O	['N']	[9]
10	oral	O	['N']	[10]
11	minocycline	B-Drug	['Dosage']	[16]
12	(	O	['N']	[12]
13	50	B	['N']	[13]
14	mg	I	['N']	[14]
15	twice	I	['N']	[15]
16	daily	I-Dose	['N']	[16]
17	)	O	['N']	[17]
18	for	O	['N']	[18]
19	3	O	['N']	[19]
20	weeks	O	['N']	[20]
21	for	O	['N']	[21]
22	acne	O	['N']	[22]
23	developed	O	['N']	[23]
24	an	O	['N']	[24]
25	eruption	O	['N']	[25]
26	that	O	['N']	[26]
27	progressed	O	['N']	[27]
28	to	O	['N']	[28]
29	an	O	['N']	[29]
30	exfoliative	O	['N']	[30]
31	dermatitis	O	['N']	[31]
32	.	O	['N']	[32]
#4660
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	a	O	['N']	[3]
4	21-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	woman	O	['N']	[7]
8	who	O	['N']	[8]
9	had	O	['N']	[9]
10	developed	O	['N']	[10]
11	mild	O	['N']	[11]
12	hepatotoxicity	B-Adverse_Effect	['N']	[12]
13	while	O	['N']	[13]
14	receiving	O	['N']	[14]
15	choline	B	['N']	[15]
16	magnesium	I	['N']	[16]
17	trisalicylate	I-Drug	['Causes']	[12]
18	therapy	O	['N']	[18]
19	is	O	['N']	[19]
20	described	O	['N']	[20]
21	.	O	['N']	[21]
#4661
0	In	O	['N']	[0]
1	rare	O	['N']	[1]
2	cases	O	['N']	[2]
3	mitomycin	O	['N']	[3]
4	C	O	['N']	[4]
5	(	O	['N']	[5]
6	MMC	B-Drug	['Causes']	[24]
7	)	O	['N']	[7]
8	may	O	['N']	[8]
9	induce	O	['N']	[9]
10	cancer	O	['N']	[10]
11	-	O	['N']	[11]
12	associated	O	['N']	[12]
13	hemolytic	O	['N']	[13]
14	uremic	O	['N']	[14]
15	syndrome	O	['N']	[15]
16	,	O	['N']	[16]
17	which	O	['N']	[17]
18	is	O	['N']	[18]
19	characterized	O	['N']	[19]
20	by	O	['N']	[20]
21	hemolytic	O	['N']	[21]
22	anemia	O	['N']	[22]
23	,	O	['N']	[23]
24	thrombocytopenia	B-Adverse_Effect	['N']	[24]
25	and	O	['N']	[25]
26	progressive	O	['N']	[26]
27	renal	O	['N']	[27]
28	failure	O	['N']	[28]
29	.	O	['N']	[29]
#4662
0	Herpes	B	['N']	[0]
1	simplex	I	['N']	[1]
2	esophagitis	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	renal	O	['N']	[5]
6	transplant	O	['N']	[6]
7	patient	O	['N']	[7]
8	treated	O	['N']	[8]
9	with	O	['N']	[9]
10	cyclosporine	B	['N']	[10]
11	A	I-Drug	['Causes']	[2]
12	:	O	['N']	[12]
13	a	O	['N']	[13]
14	case	O	['N']	[14]
15	report	O	['N']	[15]
16	.	O	['N']	[16]
#4663
0	Fatal	B	['N']	[0]
1	radiation	I	['N']	[1]
2	myelopathy	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	high	O	['N']	[4]
5	-	O	['N']	[5]
6	dose	O	['N']	[6]
7	busulfan	O	['N']	[7]
8	and	O	['N']	[8]
9	melphalan	B-Drug	['Causes']	[2]
10	chemotherapy	O	['N']	[10]
11	and	O	['N']	[11]
12	radiotherapy	O	['N']	[12]
13	for	O	['N']	[13]
14	Ewing	O	['N']	[14]
15	's	O	['N']	[15]
16	sarcoma	O	['N']	[16]
17	:	O	['N']	[17]
18	a	O	['N']	[18]
19	review	O	['N']	[19]
20	of	O	['N']	[20]
21	the	O	['N']	[21]
22	literature	O	['N']	[22]
23	and	O	['N']	[23]
24	implications	O	['N']	[24]
25	for	O	['N']	[25]
26	practice	O	['N']	[26]
27	.	O	['N']	[27]
#4664
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	new	O	['N']	[3]
4	quinolone	O	['N']	[4]
5	derivatives	O	['N']	[5]
6	(	O	['N']	[6]
7	levofloxacin	O	['N']	[7]
8	,	O	['N']	[8]
9	sparfloxacin	B-Drug	['Causes']	[45]
10	,	O	['N']	[10]
11	grepafloxacin	O	['N']	[11]
12	,	O	['N']	[12]
13	trovafloxacin	O	['N']	[13]
14	,	O	['N']	[14]
15	gatifloxacin	O	['N']	[15]
16	and	O	['N']	[16]
17	moxifloxacin	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	also	O	['N']	[20]
21	called	O	['N']	[21]
22	gyrase	O	['N']	[22]
23	inhibitors	O	['N']	[23]
24	,	O	['N']	[24]
25	are	O	['N']	[25]
26	known	O	['N']	[26]
27	for	O	['N']	[27]
28	their	O	['N']	[28]
29	potential	O	['N']	[29]
30	to	O	['N']	[30]
31	cause	O	['N']	[31]
32	central	O	['N']	[32]
33	nervous	O	['N']	[33]
34	system	O	['N']	[34]
35	-	O	['N']	[35]
36	related	O	['N']	[36]
37	adverse	O	['N']	[37]
38	effects	O	['N']	[38]
39	,	O	['N']	[39]
40	including	O	['N']	[40]
41	headache	O	['N']	[41]
42	,	O	['N']	[42]
43	dizziness	O	['N']	[43]
44	and	O	['N']	[44]
45	insomnia	B-Adverse_Effect	['N']	[45]
46	.	O	['N']	[46]
#4665
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	is	O	['N']	[3]
4	the	O	['N']	[4]
5	second	O	['N']	[5]
6	case	O	['N']	[6]
7	report	O	['N']	[7]
8	that	O	['N']	[8]
9	describes	O	['N']	[9]
10	gemcitabine	B-Drug	['Causes']	[14]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	radiation	B	['N']	[13]
14	recall	I-Adverse_Effect	['N']	[14]
15	in	O	['N']	[15]
16	rectus	O	['N']	[16]
17	abdominus	O	['N']	[17]
18	muscles	O	['N']	[18]
19	after	O	['N']	[19]
20	gemcitabine	O	['N']	[20]
21	-	O	['N']	[21]
22	based	O	['N']	[22]
23	radiation	O	['N']	[23]
24	therapy	O	['N']	[24]
25	.	O	['N']	[25]
#4666
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	have	O	['N']	[3]
4	seen	O	['N']	[4]
5	an	O	['N']	[5]
6	increased	O	['N']	[6]
7	incidence	O	['N']	[7]
8	of	O	['N']	[8]
9	acute	O	['N']	[9]
10	INH	B-Drug	['Causes']	[11]
11	neurotoxicity	B-Adverse_Effect	['N']	[11]
12	because	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	resurgence	O	['N']	[15]
16	of	O	['N']	[16]
17	TB	O	['N']	[17]
18	in	O	['N']	[18]
19	New	O	['N']	[19]
20	York	O	['N']	[20]
21	City	O	['N']	[21]
22	.	O	['N']	[22]
#4667
0	Acute	B	['N']	[0]
1	bilateral	I	['N']	[1]
2	phrenic	I	['N']	[2]
3	neuropathy	I-Adverse_Effect	['N']	[3]
4	following	O	['N']	[4]
5	treatment	O	['N']	[5]
6	with	O	['N']	[6]
7	adalimumab	B-Drug	['Causes']	[3]
8	.	O	['N']	[8]
#4668
0	Reversible	O	['N']	[0]
1	nonthrombocytopenic	B	['N']	[1]
2	palpable	I	['N']	[2]
3	purpura	I-Adverse_Effect	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	metoclopramide	B-Drug	['Causes']	[3]
7	.	O	['N']	[7]
#4669
0	Administration	O	['N']	[0]
1	of	O	['N']	[1]
2	cisplatin	O	['N']	[2]
3	in	O	['N']	[3]
4	three	O	['N']	[4]
5	patients	O	['N']	[5]
6	with	O	['N']	[6]
7	carboplatin	B-Drug	['Causes']	[8]
8	hypersensitivity	B-Adverse_Effect	['N']	[8]
9	:	O	['N']	[9]
10	is	O	['N']	[10]
11	skin	O	['N']	[11]
12	testing	O	['N']	[12]
13	useful	O	['N']	[13]
14	?	O	['N']	[14]
#4670
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	new	O	['N']	[3]
4	quinolone	O	['N']	[4]
5	derivatives	O	['N']	[5]
6	(	O	['N']	[6]
7	levofloxacin	O	['N']	[7]
8	,	O	['N']	[8]
9	sparfloxacin	O	['N']	[9]
10	,	O	['N']	[10]
11	grepafloxacin	O	['N']	[11]
12	,	O	['N']	[12]
13	trovafloxacin	B-Drug	['Causes']	[41]
14	,	O	['N']	[14]
15	gatifloxacin	O	['N']	[15]
16	and	O	['N']	[16]
17	moxifloxacin	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	also	O	['N']	[20]
21	called	O	['N']	[21]
22	gyrase	O	['N']	[22]
23	inhibitors	O	['N']	[23]
24	,	O	['N']	[24]
25	are	O	['N']	[25]
26	known	O	['N']	[26]
27	for	O	['N']	[27]
28	their	O	['N']	[28]
29	potential	O	['N']	[29]
30	to	O	['N']	[30]
31	cause	O	['N']	[31]
32	central	O	['N']	[32]
33	nervous	O	['N']	[33]
34	system	O	['N']	[34]
35	-	O	['N']	[35]
36	related	O	['N']	[36]
37	adverse	O	['N']	[37]
38	effects	O	['N']	[38]
39	,	O	['N']	[39]
40	including	O	['N']	[40]
41	headache	B-Adverse_Effect	['N']	[41]
42	,	O	['N']	[42]
43	dizziness	O	['N']	[43]
44	and	O	['N']	[44]
45	insomnia	O	['N']	[45]
46	.	O	['N']	[46]
#4671
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	experienced	O	['N']	[2]
3	hallucinations	O	['N']	[3]
4	,	O	['N']	[4]
5	agitation	O	['N']	[5]
6	,	O	['N']	[6]
7	vomiting	O	['N']	[7]
8	,	O	['N']	[8]
9	tachycardia	B-Adverse_Effect	['N']	[9]
10	and	O	['N']	[10]
11	seizures	O	['N']	[11]
12	after	O	['N']	[12]
13	ingestion	O	['N']	[13]
14	of	O	['N']	[14]
15	1050	O	['N']	[15]
16	(	O	['N']	[16]
17	48	O	['N']	[17]
18	mg	O	['N']	[18]
19	/	O	['N']	[19]
20	kg	O	['N']	[20]
21	)	O	['N']	[21]
22	of	O	['N']	[22]
23	extended	O	['N']	[23]
24	-	O	['N']	[24]
25	release	O	['N']	[25]
26	bupropion	B-Drug	['Causes']	[9]
27	.	O	['N']	[27]
#4672
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	scleroderma	B	['N']	[6]
7	-	I	['N']	[7]
8	like	I	['N']	[8]
9	reaction	I-Adverse_Effect	['N']	[9]
10	induced	O	['N']	[10]
11	by	O	['N']	[11]
12	long	O	['N']	[12]
13	-	O	['N']	[13]
14	term	O	['N']	[14]
15	administration	O	['N']	[15]
16	of	O	['N']	[16]
17	UFT	B-Drug	['Causes']	[9]
18	.	O	['N']	[18]
#4673
0	The	O	['N']	[0]
1	occurrence	O	['N']	[1]
2	of	O	['N']	[2]
3	symptoms	O	['N']	[3]
4	that	O	['N']	[4]
5	could	O	['N']	[5]
6	be	O	['N']	[6]
7	ascribed	O	['N']	[7]
8	to	O	['N']	[8]
9	an	O	['N']	[9]
10	acute	B	['N']	[10]
11	coronary	I	['N']	[11]
12	syndrome	I-Adverse_Effect	['N']	[12]
13	should	O	['N']	[13]
14	always	O	['N']	[14]
15	be	O	['N']	[15]
16	taken	O	['N']	[16]
17	seriously	O	['N']	[17]
18	during	O	['N']	[18]
19	the	O	['N']	[19]
20	first	O	['N']	[20]
21	rituximab	B-Drug	['Causes']	[12]
22	infusion	O	['N']	[22]
23	and	O	['N']	[23]
24	investigated	O	['N']	[24]
25	aggressively	O	['N']	[25]
26	.	O	['N']	[26]
#4674
0	Both	O	['N']	[0]
1	patients	O	['N']	[1]
2	suddenly	O	['N']	[2]
3	became	O	['N']	[3]
4	hypotensive	B-Adverse_Effect	['N']	[4]
5	after	O	['N']	[5]
6	injection	O	['N']	[6]
7	of	O	['N']	[7]
8	chymopapain	B-Drug	['Causes']	[4]
9	into	O	['N']	[9]
10	a	O	['N']	[10]
11	disk	O	['N']	[11]
12	.	O	['N']	[12]
#4675
0	Two	O	['N']	[0]
1	elderly	O	['N']	[1]
2	women	O	['N']	[2]
3	suffered	O	['N']	[3]
4	an	O	['N']	[4]
5	acute	B	['N']	[5]
6	deterioration	I	['N']	[6]
7	of	I	['N']	[7]
8	renal	I	['N']	[8]
9	function	I-Adverse_Effect	['N']	[9]
10	after	O	['N']	[10]
11	treatment	O	['N']	[11]
12	with	O	['N']	[12]
13	cefoxitin	B	['N']	[13]
14	sodium	I-Drug	['Causes']	[9]
15	.	O	['N']	[15]
#4676
0	In	O	['N']	[0]
1	the	O	['N']	[1]
2	presented	O	['N']	[2]
3	case	O	['N']	[3]
4	fluvoxamine	B-Drug	['Causes']	[7]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	akathisia	B-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	an	O	['N']	[9]
10	OCD	O	['N']	[10]
11	patient	O	['N']	[11]
12	was	O	['N']	[12]
13	partially	O	['N']	[13]
14	resistant	O	['N']	[14]
15	to	O	['N']	[15]
16	the	O	['N']	[16]
17	anticholinergic	O	['N']	[17]
18	agent	O	['N']	[18]
19	biperiden	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	was	O	['N']	[22]
23	successfully	O	['N']	[23]
24	treated	O	['N']	[24]
25	with	O	['N']	[25]
26	the	O	['N']	[26]
27	5-HT2A/5-HT2C	O	['N']	[27]
28	antagonist	O	['N']	[28]
29	mianserin	O	['N']	[29]
30	.	O	['N']	[30]
#4677
0	They	O	['N']	[0]
1	seemed	O	['N']	[1]
2	to	O	['N']	[2]
3	involve	O	['N']	[3]
4	multiple	O	['N']	[4]
5	aetiological	O	['N']	[5]
6	factors	O	['N']	[6]
7	,	O	['N']	[7]
8	such	O	['N']	[8]
9	as	O	['N']	[9]
10	autoimmune	O	['N']	[10]
11	thyroid	O	['N']	[11]
12	disease	O	['N']	[12]
13	,	O	['N']	[13]
14	the	O	['N']	[14]
15	toxic	B	['N']	[15]
16	and	I	['N']	[16]
17	immunomodulatory	I	['N']	[17]
18	roles	I-Adverse_Effect	['N']	[18]
19	of	O	['N']	[19]
20	lithium	B-Drug	['Causes']	[18]
21	and	O	['N']	[21]
22	perhaps	O	['N']	[22]
23	genetic	O	['N']	[23]
24	and	O	['N']	[24]
25	dietary	O	['N']	[25]
26	factors	O	['N']	[26]
27	.	O	['N']	[27]
#4678
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	58-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	woman	O	['N']	[9]
10	who	O	['N']	[10]
11	ingested	O	['N']	[11]
12	more	O	['N']	[12]
13	than	O	['N']	[13]
14	35	O	['N']	[14]
15	g	O	['N']	[15]
16	of	O	['N']	[16]
17	caffeine	B-Drug	['Causes']	[21]
18	in	O	['N']	[18]
19	a	O	['N']	[19]
20	suicide	B	['N']	[20]
21	attempt	I-Adverse_Effect	['N']	[21]
22	.	O	['N']	[22]
#4679
0	Abdominal	O	['N']	[0]
1	wall	O	['N']	[1]
2	ulceration	O	['N']	[2]
3	and	O	['N']	[3]
4	mucinosis	B-Adverse_Effect	['N']	[4]
5	secondary	O	['N']	[5]
6	to	O	['N']	[6]
7	recombinant	B	['N']	[7]
8	human	I	['N']	[8]
9	interferon	I	['N']	[9]
10	-	I	['N']	[10]
11	beta-1b	I-Drug	['Causes']	[4]
12	.	O	['N']	[12]
#4680
0	Although	O	['N']	[0]
1	high	O	['N']	[1]
2	-	O	['N']	[2]
3	dose	O	['N']	[3]
4	methotrexate	B-Drug	['Causes']	[33]
5	has	O	['N']	[5]
6	been	O	['N']	[6]
7	shown	O	['N']	[7]
8	to	O	['N']	[8]
9	be	O	['N']	[9]
10	useful	O	['N']	[10]
11	in	O	['N']	[11]
12	the	O	['N']	[12]
13	treatment	O	['N']	[13]
14	of	O	['N']	[14]
15	primary	O	['N']	[15]
16	osteogenic	O	['N']	[16]
17	sarcoma	O	['N']	[17]
18	,	O	['N']	[18]
19	the	O	['N']	[19]
20	tumoricidal	O	['N']	[20]
21	effects	O	['N']	[21]
22	of	O	['N']	[22]
23	therapy	O	['N']	[23]
24	appear	O	['N']	[24]
25	to	O	['N']	[25]
26	have	O	['N']	[26]
27	caused	O	['N']	[27]
28	a	O	['N']	[28]
29	fatal	B	['N']	[29]
30	rise	I	['N']	[30]
31	in	I	['N']	[31]
32	intracranial	I	['N']	[32]
33	pressure	I-Adverse_Effect	['N']	[33]
34	.	O	['N']	[34]
#4681
0	Animals	O	['N']	[0]
1	treated	O	['N']	[1]
2	with	O	['N']	[2]
3	HAL	B-Drug	['Causes']	[18]
4	showed	O	['N']	[4]
5	a	O	['N']	[5]
6	highly	O	['N']	[6]
7	significant	B	['N']	[7]
8	32%-46	I	['N']	[8]
9	%	I	['N']	[9]
10	loss	I	['N']	[10]
11	of	I	['N']	[11]
12	tyrosine	I	['N']	[12]
13	hydroxylase	I	['N']	[13]
14	(	I	['N']	[14]
15	TH	I	['N']	[15]
16	)	I	['N']	[16]
17	immunoreactive	I	['N']	[17]
18	neurons	I-Adverse_Effect	['N']	[18]
19	in	O	['N']	[19]
20	the	O	['N']	[20]
21	substantia	O	['N']	[21]
22	nigra	O	['N']	[22]
23	,	O	['N']	[23]
24	and	O	['N']	[24]
25	20	O	['N']	[25]
26	%	O	['N']	[26]
27	contraction	O	['N']	[27]
28	of	O	['N']	[28]
29	the	O	['N']	[29]
30	TH	O	['N']	[30]
31	stained	O	['N']	[31]
32	dendritic	O	['N']	[32]
33	arbour	O	['N']	[33]
34	.	O	['N']	[34]
#4682
0	Our	O	['N']	[0]
1	patient	O	['N']	[1]
2	had	O	['N']	[2]
3	headache	O	['N']	[3]
4	,	O	['N']	[4]
5	mild	O	['N']	[5]
6	fever	O	['N']	[6]
7	,	O	['N']	[7]
8	nausea	O	['N']	[8]
9	,	O	['N']	[9]
10	vomiting	B-Adverse_Effect	['N']	[10]
11	,	O	['N']	[11]
12	rash	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	eosinophilia	O	['N']	[15]
16	after	O	['N']	[16]
17	3	O	['N']	[17]
18	weeks	O	['N']	[18]
19	of	O	['N']	[19]
20	disulfiram	B-Drug	['Causes']	[10]
21	therapy	O	['N']	[21]
22	.	O	['N']	[22]
#4683
0	A	O	['N']	[0]
1	sixty	O	['N']	[1]
2	-	O	['N']	[2]
3	year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	with	O	['N']	[7]
8	advanced	O	['N']	[8]
9	breast	O	['N']	[9]
10	cancer	O	['N']	[10]
11	,	O	['N']	[11]
12	previously	O	['N']	[12]
13	treated	O	['N']	[13]
14	with	O	['N']	[14]
15	cisplatin	O	['N']	[15]
16	,	O	['N']	[16]
17	developed	O	['N']	[17]
18	an	O	['N']	[18]
19	irreversible	B	['N']	[19]
20	lethal	I	['N']	[20]
21	renal	I	['N']	[21]
22	failure	I-Adverse_Effect	['N']	[22]
23	with	O	['N']	[23]
24	anuria	O	['N']	[24]
25	,	O	['N']	[25]
26	the	O	['N']	[26]
27	day	O	['N']	[27]
28	after	O	['N']	[28]
29	5	O	['N']	[29]
30	g	O	['N']	[30]
31	/	O	['N']	[31]
32	m2	O	['N']	[32]
33	bolus	O	['N']	[33]
34	ifosfamide	B-Drug	['Causes']	[22]
35	.	O	['N']	[35]
#4684
0	Second	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	neutropenia	B-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	which	O	['N']	[9]
10	proved	O	['N']	[10]
11	to	O	['N']	[11]
12	be	O	['N']	[12]
13	fatal	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	schizophrenia	O	['N']	[16]
17	patient	O	['N']	[17]
18	receiving	O	['N']	[18]
19	olanzapine	O	['N']	[19]
20	and	O	['N']	[20]
21	thiazide	B-Drug	['Causes']	[7]
22	.	O	['N']	[22]
#4685
0	In	O	['N']	[0]
1	case	O	['N']	[1]
2	1	O	['N']	[2]
3	,	O	['N']	[3]
4	a	O	['N']	[4]
5	total	O	['N']	[5]
6	daily	O	['N']	[6]
7	dose	O	['N']	[7]
8	of	O	['N']	[8]
9	25	O	['N']	[9]
10	mg	O	['N']	[10]
11	sertraline	O	['N']	[11]
12	,	O	['N']	[12]
13	with	O	['N']	[13]
14	nondetectable	O	['N']	[14]
15	sertraline	O	['N']	[15]
16	and	O	['N']	[16]
17	desmethylsertraline	B-Drug	['Causes']	[33]
18	blood	O	['N']	[18]
19	levels	O	['N']	[19]
20	,	O	['N']	[20]
21	resulted	O	['N']	[21]
22	in	O	['N']	[22]
23	a	O	['N']	[23]
24	doubling	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	lamotrigine	O	['N']	[27]
28	blood	O	['N']	[28]
29	level	O	['N']	[29]
30	with	O	['N']	[30]
31	symptoms	B	['N']	[31]
32	of	I	['N']	[32]
33	toxicity	I-Adverse_Effect	['N']	[33]
34	.	O	['N']	[34]
#4686
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	case	O	['N']	[2]
3	senna	B-Drug	['Causes']	[12]
4	was	O	['N']	[4]
5	likely	O	['N']	[5]
6	the	O	['N']	[6]
7	cause	O	['N']	[7]
8	of	O	['N']	[8]
9	a	O	['N']	[9]
10	subacute	B	['N']	[10]
11	cholestatic	I	['N']	[11]
12	hepatitis	I-Adverse_Effect	['N']	[12]
13	exemplifying	O	['N']	[13]
14	again	O	['N']	[14]
15	the	O	['N']	[15]
16	potential	O	['N']	[16]
17	role	O	['N']	[17]
18	of	O	['N']	[18]
19	herbal	O	['N']	[19]
20	related	O	['N']	[20]
21	liver	O	['N']	[21]
22	injury	O	['N']	[22]
23	.	O	['N']	[23]
#4687
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	intrathecal	O	['N']	[5]
6	methotrexate	B-Drug	['Causes']	[12]
7	neurotoxicity	O	['N']	[7]
8	manifesting	O	['N']	[8]
9	as	O	['N']	[9]
10	left	B	['N']	[10]
11	arm	I	['N']	[11]
12	weakness	I-Adverse_Effect	['N']	[12]
13	and	O	['N']	[13]
14	aphasia	O	['N']	[14]
15	.	O	['N']	[15]
#4688
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	2	O	['N']	[2]
3	children	O	['N']	[3]
4	with	O	['N']	[4]
5	cerebral	O	['N']	[5]
6	palsy	O	['N']	[6]
7	who	O	['N']	[7]
8	suffered	O	['N']	[8]
9	significant	O	['N']	[9]
10	morbidity	B-Adverse_Effect	['N']	[10]
11	immediately	O	['N']	[11]
12	after	O	['N']	[12]
13	treatment	O	['N']	[13]
14	with	O	['N']	[14]
15	hyperbaric	B	['N']	[15]
16	oxygen	I-Drug	['Causes']	[10]
17	.	O	['N']	[17]
#4689
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Cefazolin	B-Drug	['Causes']	[11]
3	was	O	['N']	[3]
4	a	O	['N']	[4]
5	probable	O	['N']	[5]
6	cause	O	['N']	[6]
7	of	O	['N']	[7]
8	this	O	['N']	[8]
9	patient	O	['N']	[9]
10	's	O	['N']	[10]
11	leukopenia	B-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#4690
0	Cis	B	['N']	[0]
1	-	I	['N']	[1]
2	retinoic	I	['N']	[2]
3	acid	I-Drug	['Causes']	[14]
4	(	O	['N']	[4]
5	RA	O	['N']	[5]
6	)	O	['N']	[6]
7	may	O	['N']	[7]
8	further	O	['N']	[8]
9	increase	O	['N']	[9]
10	the	O	['N']	[10]
11	risk	O	['N']	[11]
12	of	O	['N']	[12]
13	developing	O	['N']	[13]
14	BMTN	B-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#4691
0	The	O	['N']	[0]
1	more	O	['N']	[1]
2	common	O	['N']	[2]
3	grade	O	['N']	[3]
4	3	O	['N']	[4]
5	or	O	['N']	[5]
6	4	O	['N']	[6]
7	adverse	O	['N']	[7]
8	effects	O	['N']	[8]
9	of	O	['N']	[9]
10	sunitinib	B-Drug	['Causes']	[22]
11	include	O	['N']	[11]
12	hypertension	O	['N']	[12]
13	,	O	['N']	[13]
14	fatigue	O	['N']	[14]
15	,	O	['N']	[15]
16	hand	O	['N']	[16]
17	-	O	['N']	[17]
18	foot	O	['N']	[18]
19	syndrome	O	['N']	[19]
20	,	O	['N']	[20]
21	elevated	B	['N']	[21]
22	lipase	I-Adverse_Effect	['N']	[22]
23	and	O	['N']	[23]
24	lymphopenia	O	['N']	[24]
25	.	O	['N']	[25]
#4692
0	In	O	['N']	[0]
1	one	O	['N']	[1]
2	case	O	['N']	[2]
3	,	O	['N']	[3]
4	the	O	['N']	[4]
5	readministration	O	['N']	[5]
6	of	O	['N']	[6]
7	riluzole	B-Drug	['Causes']	[14]
8	was	O	['N']	[8]
9	followed	O	['N']	[9]
10	by	O	['N']	[10]
11	the	O	['N']	[11]
12	relapse	O	['N']	[12]
13	of	O	['N']	[13]
14	hepatitis	B-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#4693
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	We	O	['N']	[2]
3	have	O	['N']	[3]
4	introduced	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	anaphylaxis	-	['N']	[8]
9	by	O	['N']	[9]
10	calcitonin	B-Drug	['N']	[10]
11	that	O	['N']	[11]
12	suggest	O	['N']	[12]
13	an	O	['N']	[13]
14	IgE	O	['N']	[14]
15	mediated	O	['N']	[15]
16	hypersensitivity	O	['N']	[16]
17	reaction	O	['N']	[17]
18	.	O	['N']	[18]
#4694
0	Methotrexate	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	leukoencephalopathy	B-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	treatable	O	['N']	[5]
6	with	O	['N']	[6]
7	high	O	['N']	[7]
8	-	O	['N']	[8]
9	dose	O	['N']	[9]
10	folinic	O	['N']	[10]
11	acid	O	['N']	[11]
12	:	O	['N']	[12]
13	a	O	['N']	[13]
14	case	O	['N']	[14]
15	report	O	['N']	[15]
16	and	O	['N']	[16]
17	analysis	O	['N']	[17]
18	of	O	['N']	[18]
19	the	O	['N']	[19]
20	literature	O	['N']	[20]
21	.	O	['N']	[21]
#4695
0	A	O	['N']	[0]
1	10-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	with	O	['N']	[5]
6	osteosarcoma	O	['N']	[6]
7	and	O	['N']	[7]
8	normal	O	['N']	[8]
9	renal	O	['N']	[9]
10	function	O	['N']	[10]
11	manifested	O	['N']	[11]
12	laboratory	O	['N']	[12]
13	evidence	O	['N']	[13]
14	of	O	['N']	[14]
15	impending	O	['N']	[15]
16	renal	B	['N']	[16]
17	toxicity	I-Adverse_Effect	['N']	[17]
18	and	O	['N']	[18]
19	extreme	O	['N']	[19]
20	elevation	O	['N']	[20]
21	of	O	['N']	[21]
22	aspartate	O	['N']	[22]
23	aminotrasferase	O	['N']	[23]
24	and	O	['N']	[24]
25	alanine	O	['N']	[25]
26	aminotransferase	O	['N']	[26]
27	within	O	['N']	[27]
28	2	O	['N']	[28]
29	hours	O	['N']	[29]
30	after	O	['N']	[30]
31	the	O	['N']	[31]
32	completion	O	['N']	[32]
33	of	O	['N']	[33]
34	a	O	['N']	[34]
35	4-hour	O	['N']	[35]
36	infusion	O	['N']	[36]
37	of	O	['N']	[37]
38	high	O	['N']	[38]
39	-	O	['N']	[39]
40	dose	O	['N']	[40]
41	methotrexate	B-Drug	['Causes']	[17]
42	(	O	['N']	[42]
43	MTX	O	['N']	[43]
44	)	O	['N']	[44]
45	(	O	['N']	[45]
46	12	O	['N']	[46]
47	g	O	['N']	[47]
48	/	O	['N']	[48]
49	m2	O	['N']	[49]
50	)	O	['N']	[50]
51	,	O	['N']	[51]
52	and	O	['N']	[52]
53	went	O	['N']	[53]
54	on	O	['N']	[54]
55	to	O	['N']	[55]
56	develop	O	['N']	[56]
57	acute	O	['N']	[57]
58	renal	O	['N']	[58]
59	failure	O	['N']	[59]
60	with	O	['N']	[60]
61	life	O	['N']	[61]
62	-	O	['N']	[62]
63	threatening	O	['N']	[63]
64	hyperkalemia	O	['N']	[64]
65	29	O	['N']	[65]
66	hours	O	['N']	[66]
67	later	O	['N']	[67]
68	.	O	['N']	[68]
#4696
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	Quetiapine	B-Drug	['Causes']	[13]
3	was	O	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	leucopenia	O	['N']	[6]
7	in	O	['N']	[7]
8	two	O	['N']	[8]
9	patients	O	['N']	[9]
10	and	O	['N']	[10]
11	clinically	O	['N']	[11]
12	apparent	O	['N']	[12]
13	agranulocytosis	B-Adverse_Effect	['N']	[13]
14	in	O	['N']	[14]
15	one	O	['N']	[15]
16	patient	O	['N']	[16]
17	.	O	['N']	[17]
#4697
0	Malignant	B	['N']	[0]
1	mixed	I	['N']	[1]
2	mullerian	I	['N']	[2]
3	tumor	I	['N']	[3]
4	of	I	['N']	[4]
5	the	I	['N']	[5]
6	uterus	I-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	a	O	['N']	[8]
9	patient	O	['N']	[9]
10	taking	O	['N']	[10]
11	raloxifene	B-Drug	['Causes']	[6]
12	.	O	['N']	[12]
#4698
0	Neurointensive	O	['N']	[0]
1	care	O	['N']	[1]
2	management	O	['N']	[2]
3	of	O	['N']	[3]
4	raised	B	['N']	[4]
5	intracranial	I	['N']	[5]
6	pressure	I-Adverse_Effect	['N']	[6]
7	caused	O	['N']	[7]
8	by	O	['N']	[8]
9	severe	O	['N']	[9]
10	valproic	B	['N']	[10]
11	acid	I-Drug	['Causes']	[6]
12	intoxication	O	['N']	[12]
13	.	O	['N']	[13]
#4699
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	3	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	diphenhydramine	B-Drug	['Causes']	[9]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	cardiac	B	['N']	[8]
9	toxicity	I-Adverse_Effect	['N']	[9]
10	that	O	['N']	[10]
11	were	O	['N']	[11]
12	responsive	O	['N']	[12]
13	to	O	['N']	[13]
14	bicarbonate	O	['N']	[14]
15	.	O	['N']	[15]
#4700
0	Although	O	['N']	[0]
1	myelosuppression	O	['N']	[1]
2	is	O	['N']	[2]
3	mild	O	['N']	[3]
4	,	O	['N']	[4]
5	immunosuppression	B-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	superinfection	O	['N']	[7]
8	are	O	['N']	[8]
9	potential	O	['N']	[9]
10	hazards	O	['N']	[10]
11	of	O	['N']	[11]
12	treatment	O	['N']	[12]
13	with	O	['N']	[13]
14	DCF	B-Drug	['Causes']	[5]
15	.	O	['N']	[15]
#4701
0	A	O	['N']	[0]
1	26-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	Japanese	O	['N']	[4]
5	man	O	['N']	[5]
6	,	O	['N']	[6]
7	who	O	['N']	[7]
8	had	O	['N']	[8]
9	been	O	['N']	[9]
10	receiving	O	['N']	[10]
11	medical	O	['N']	[11]
12	attention	O	['N']	[12]
13	for	O	['N']	[13]
14	ulcerative	O	['N']	[14]
15	colitis	O	['N']	[15]
16	for	O	['N']	[16]
17	one	O	['N']	[17]
18	year	O	['N']	[18]
19	,	O	['N']	[19]
20	presented	O	['N']	[20]
21	with	O	['N']	[21]
22	diffuse	O	['N']	[22]
23	erythema	O	['N']	[23]
24	and	O	['N']	[24]
25	pustules	O	['N']	[25]
26	on	O	['N']	[26]
27	his	O	['N']	[27]
28	face	O	['N']	[28]
29	and	O	['N']	[29]
30	trunk	O	['N']	[30]
31	,	O	['N']	[31]
32	malaise	B-Adverse_Effect	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	fever	O	['N']	[35]
36	up	O	['N']	[36]
37	to	O	['N']	[37]
38	39	O	['N']	[38]
39	degrees	O	['N']	[39]
40	C	O	['N']	[40]
41	one	O	['N']	[41]
42	day	O	['N']	[42]
43	after	O	['N']	[43]
44	the	O	['N']	[44]
45	administration	O	['N']	[45]
46	of	O	['N']	[46]
47	salazosulfapyridine	B-Drug	['Causes']	[32]
48	.	O	['N']	[48]
#4702
0	Metabolic	B	['N']	[0]
1	acidosis	I-Adverse_Effect	['N']	[1]
2	induced	O	['N']	[2]
3	by	O	['N']	[3]
4	cetrimide	B-Drug	['Causes']	[1]
5	-	O	['N']	[5]
6	chlorhexidine	O	['N']	[6]
7	solution	O	['N']	[7]
8	in	O	['N']	[8]
9	hydatid	O	['N']	[9]
10	cyst	O	['N']	[10]
11	surgery	O	['N']	[11]
12	.	O	['N']	[12]
#4703
0	Isoniazid	O	['N']	[0]
1	and	O	['N']	[1]
2	ethambutol	B-Drug	['Causes']	[8]
3	as	O	['N']	[3]
4	a	O	['N']	[4]
5	cause	O	['N']	[5]
6	of	O	['N']	[6]
7	optic	B	['N']	[7]
8	neuropathy	I-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#4704
0	Pulmonary	B	['N']	[0]
1	infiltrates	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	skin	O	['N']	[3]
4	pigmentation	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	sulfasalazine	B-Drug	['Causes']	[1]
8	.	O	['N']	[8]
#4705
0	A	O	['N']	[0]
1	14-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	girl	O	['N']	[4]
5	with	O	['N']	[5]
6	newly	O	['N']	[6]
7	diagnosed	O	['N']	[7]
8	SLE	O	['N']	[8]
9	developed	O	['N']	[9]
10	a	O	['N']	[10]
11	pruritic	B	['N']	[11]
12	bullous	I	['N']	[12]
13	eruption	I-Adverse_Effect	['N']	[13]
14	while	O	['N']	[14]
15	on	O	['N']	[15]
16	prednisone	B-Drug	['Causes']	[13]
17	.	O	['N']	[17]
#4706
0	Purple	B	['N']	[0]
1	glove	I	['N']	[1]
2	syndrome	I-Adverse_Effect	['N']	[2]
3	,	O	['N']	[3]
4	named	O	['N']	[4]
5	for	O	['N']	[5]
6	its	O	['N']	[6]
7	distinctive	O	['N']	[7]
8	purple	O	['N']	[8]
9	discoloration	O	['N']	[9]
10	and	O	['N']	[10]
11	swelling	O	['N']	[11]
12	of	O	['N']	[12]
13	the	O	['N']	[13]
14	hands	O	['N']	[14]
15	in	O	['N']	[15]
16	the	O	['N']	[16]
17	distribution	O	['N']	[17]
18	of	O	['N']	[18]
19	a	O	['N']	[19]
20	glove	O	['N']	[20]
21	,	O	['N']	[21]
22	is	O	['N']	[22]
23	an	O	['N']	[23]
24	uncommon	O	['N']	[24]
25	complication	O	['N']	[25]
26	of	O	['N']	[26]
27	intravenous	O	['N']	[27]
28	phenytoin	B-Drug	['Causes']	[2]
29	administration	O	['N']	[29]
30	through	O	['N']	[30]
31	small	O	['N']	[31]
32	dorsal	O	['N']	[32]
33	veins	O	['N']	[33]
34	of	O	['N']	[34]
35	the	O	['N']	[35]
36	hands	O	['N']	[36]
37	.	O	['N']	[37]
#4707
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	ovarian	O	['N']	[3]
4	cancer	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	received	O	['N']	[7]
8	multiple	O	['N']	[8]
9	courses	O	['N']	[9]
10	of	O	['N']	[10]
11	cisplatin	B-Drug	['Causes']	[29]
12	without	O	['N']	[12]
13	complications	O	['N']	[13]
14	experienced	O	['N']	[14]
15	hypersensitivity	O	['N']	[15]
16	reactions	O	['N']	[16]
17	to	O	['N']	[17]
18	cisplatin	O	['N']	[18]
19	:	O	['N']	[19]
20	one	O	['N']	[20]
21	,	O	['N']	[21]
22	involving	O	['N']	[22]
23	intrahepatic	O	['N']	[23]
24	artery	O	['N']	[24]
25	infusion	O	['N']	[25]
26	,	O	['N']	[26]
27	manifested	O	['N']	[27]
28	general	B	['N']	[28]
29	erythema	I-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	dyspnea	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	hypotension	O	['N']	[34]
35	;	O	['N']	[35]
36	the	O	['N']	[36]
37	other	O	['N']	[37]
38	,	O	['N']	[38]
39	involving	O	['N']	[39]
40	intravenous	O	['N']	[40]
41	infusion	O	['N']	[41]
42	,	O	['N']	[42]
43	manifested	O	['N']	[43]
44	abdominal	O	['N']	[44]
45	pain	O	['N']	[45]
46	,	O	['N']	[46]
47	general	O	['N']	[47]
48	erythema	O	['N']	[48]
49	,	O	['N']	[49]
50	and	O	['N']	[50]
51	fever	O	['N']	[51]
52	.	O	['N']	[52]
#4708
0	A	O	['N']	[0]
1	74-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	idiopathic	O	['N']	[6]
7	Parkinson	O	['N']	[7]
8	's	O	['N']	[8]
9	disease	O	['N']	[9]
10	was	O	['N']	[10]
11	evaluated	O	['N']	[11]
12	for	O	['N']	[12]
13	unintended	B	['N']	[13]
14	sleep	I	['N']	[14]
15	episodes	I-Adverse_Effect	['N']	[15]
16	that	O	['N']	[16]
17	occurred	O	['N']	[17]
18	after	O	['N']	[18]
19	long	O	['N']	[19]
20	-	O	['N']	[20]
21	term	O	['N']	[21]
22	treatment	O	['N']	[22]
23	with	O	['N']	[23]
24	400	O	['N']	[24]
25	mg	O	['N']	[25]
26	/	O	['N']	[26]
27	day	O	['N']	[27]
28	of	O	['N']	[28]
29	L	B	['N']	[29]
30	-	I	['N']	[30]
31	dopa	I-Drug	['Causes']	[15]
32	.	O	['N']	[32]
#4709
0	Seizures	B-Adverse_Effect	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	fluoxetine	B-Drug	['Causes']	[0]
4	therapy	O	['N']	[4]
5	are	O	['N']	[5]
6	uncommon	O	['N']	[6]
7	.	O	['N']	[7]
#4710
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	polymyositis	B-Adverse_Effect	['N']	[3]
4	with	O	['N']	[4]
5	dilated	O	['N']	[5]
6	cardiomyopathy	O	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	interferon	B	['N']	[9]
10	alpha	I-Drug	['Causes']	[3]
11	treatment	O	['N']	[11]
12	for	O	['N']	[12]
13	hepatitis	O	['N']	[13]
14	B.	O	['N']	[14]
#4711
0	Mitomycin	B	['N']	[0]
1	C	I-Drug	['Causes']	[19]
2	(	O	['N']	[2]
3	MMC	O	['N']	[3]
4	)	O	['N']	[4]
5	is	O	['N']	[5]
6	an	O	['N']	[6]
7	alkylating	O	['N']	[7]
8	agent	O	['N']	[8]
9	that	O	['N']	[9]
10	has	O	['N']	[10]
11	been	O	['N']	[11]
12	recently	O	['N']	[12]
13	associated	O	['N']	[13]
14	with	O	['N']	[14]
15	the	O	['N']	[15]
16	hemolytic	B	['N']	[16]
17	-	I	['N']	[17]
18	uremic	I	['N']	[18]
19	syndrome	I-Adverse_Effect	['N']	[19]
20	(	O	['N']	[20]
21	HUS	O	['N']	[21]
22	)	O	['N']	[22]
23	.	O	['N']	[23]
#4712
0	A	O	['N']	[0]
1	65-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	bipolar	O	['N']	[6]
7	disorder	O	['N']	[7]
8	and	O	['N']	[8]
9	complicated	O	['N']	[9]
10	cardiovascular	O	['N']	[10]
11	disease	O	['N']	[11]
12	who	O	['N']	[12]
13	was	O	['N']	[13]
14	on	O	['N']	[14]
15	maintenance	O	['N']	[15]
16	lithium	B-Drug	['Dosage']	[24]
17	therapy	O	['N']	[17]
18	developed	O	['N']	[18]
19	a	O	['N']	[19]
20	movement	O	['N']	[20]
21	disorder	O	['N']	[21]
22	following	O	['N']	[22]
23	high	B	['N']	[23]
24	doses	I-Dose	['N']	[24]
25	of	O	['N']	[25]
26	trazodone	O	['N']	[26]
27	for	O	['N']	[27]
28	treatment	O	['N']	[28]
29	of	O	['N']	[29]
30	an	O	['N']	[30]
31	acute	O	['N']	[31]
32	depression	O	['N']	[32]
33	.	O	['N']	[33]
#4713
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	additional	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	isotretinoin	B-Drug	['Causes']	[17]
7	teratogenicity	O	['N']	[7]
8	in	O	['N']	[8]
9	which	O	['N']	[9]
10	the	O	['N']	[10]
11	patient	O	['N']	[11]
12	had	O	['N']	[12]
13	agenesis	B	['N']	[13]
14	of	I	['N']	[14]
15	the	I	['N']	[15]
16	cerebellar	I	['N']	[16]
17	vermis	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	multiple	O	['N']	[19]
20	leptomeningeal	O	['N']	[20]
21	neuroglial	O	['N']	[21]
22	heterotopias	O	['N']	[22]
23	,	O	['N']	[23]
24	hydrocephalus	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	abnormalities	O	['N']	[27]
28	of	O	['N']	[28]
29	the	O	['N']	[29]
30	corticospinal	O	['N']	[30]
31	tracts	O	['N']	[31]
32	.	O	['N']	[32]
#4714
0	This	O	['N']	[0]
1	finding	O	['N']	[1]
2	suggests	O	['N']	[2]
3	that	O	['N']	[3]
4	fluvoxamine	B-Drug	['Causes']	[11]
5	can	O	['N']	[5]
6	precipitate	O	['N']	[6]
7	Schneiderian	B	['N']	[7]
8	first	I	['N']	[8]
9	-	I	['N']	[9]
10	rank	I	['N']	[10]
11	symptoms	I-Adverse_Effect	['N']	[11]
12	in	O	['N']	[12]
13	some	O	['N']	[13]
14	susceptible	O	['N']	[14]
15	patients	O	['N']	[15]
16	.	O	['N']	[16]
#4715
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	polyserositis	O	['N']	[9]
10	(	O	['N']	[10]
11	pericardial	B	['N']	[11]
12	effusion	I-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	pleural	O	['N']	[14]
15	effusion	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	pericarditis	O	['N']	[18]
19	)	O	['N']	[19]
20	after	O	['N']	[20]
21	being	O	['N']	[21]
22	started	O	['N']	[22]
23	on	O	['N']	[23]
24	clozapine	B-Drug	['Causes']	[12]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	whose	O	['N']	[27]
28	symptoms	O	['N']	[28]
29	remitted	O	['N']	[29]
30	upon	O	['N']	[30]
31	discontinuation	O	['N']	[31]
32	of	O	['N']	[32]
33	clozapine	O	['N']	[33]
34	.	O	['N']	[34]
#4716
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	previously	O	['N']	[6]
7	healthy	O	['N']	[7]
8	,	O	['N']	[8]
9	postmenopausal	O	['N']	[9]
10	woman	O	['N']	[10]
11	who	O	['N']	[11]
12	developed	O	['N']	[12]
13	anticonvulsant	B	['N']	[13]
14	hypersensitivity	I	['N']	[14]
15	syndrome	I-Adverse_Effect	['N']	[15]
16	while	O	['N']	[16]
17	taking	O	['N']	[17]
18	Bellamine	O	['N']	[18]
19	S	O	['N']	[19]
20	(	O	['N']	[20]
21	belladonna	O	['N']	[21]
22	alkaloids	O	['N']	[22]
23	;	O	['N']	[23]
24	ergotamine	B-Drug	['Causes']	[15]
25	;	O	['N']	[25]
26	phenobarbital	O	['N']	[26]
27	)	O	['N']	[27]
28	for	O	['N']	[28]
29	hot	O	['N']	[29]
30	flashes	O	['N']	[30]
31	.	O	['N']	[31]
#4717
0	On	O	['N']	[0]
1	the	O	['N']	[1]
2	fifth	O	['N']	[2]
3	day	O	['N']	[3]
4	after	O	['N']	[4]
5	administration	O	['N']	[5]
6	of	O	['N']	[6]
7	a	O	['N']	[7]
8	high	O	['N']	[8]
9	dose	O	['N']	[9]
10	of	O	['N']	[10]
11	ARA	B	['N']	[11]
12	-	I	['N']	[12]
13	C	I-Drug	['Dosage']	[22]
14	(	O	['N']	[14]
15	2	B	['N']	[15]
16	g	I	['N']	[16]
17	/	I	['N']	[17]
18	m2	I	['N']	[18]
19	intravenously	I	['N']	[19]
20	every	I	['N']	[20]
21	12	I	['N']	[21]
22	hours	I-Dose	['N']	[22]
23	)	O	['N']	[23]
24	,	O	['N']	[24]
25	she	O	['N']	[25]
26	developed	O	['N']	[26]
27	bullous	O	['N']	[27]
28	lesions	O	['N']	[28]
29	on	O	['N']	[29]
30	the	O	['N']	[30]
31	hands	O	['N']	[31]
32	and	O	['N']	[32]
33	soles	O	['N']	[33]
34	that	O	['N']	[34]
35	disseminated	O	['N']	[35]
36	,	O	['N']	[36]
37	evolving	O	['N']	[37]
38	to	O	['N']	[38]
39	necrosis	O	['N']	[39]
40	,	O	['N']	[40]
41	sepsis	O	['N']	[41]
42	,	O	['N']	[42]
43	and	O	['N']	[43]
44	death	O	['N']	[44]
45	on	O	['N']	[45]
46	the	O	['N']	[46]
47	22nd	O	['N']	[47]
48	day	O	['N']	[48]
49	.	O	['N']	[49]
#4718
0	Digestive	B	['N']	[0]
1	hemorrhage	I-Adverse_Effect	['N']	[1]
2	caused	O	['N']	[2]
3	by	O	['N']	[3]
4	a	O	['N']	[4]
5	Meckel	O	['N']	[5]
6	's	O	['N']	[6]
7	diverticulum	O	['N']	[7]
8	in	O	['N']	[8]
9	a	O	['N']	[9]
10	metformin	B-Drug	['Causes']	[1]
11	-	O	['N']	[11]
12	treated	O	['N']	[12]
13	patient	O	['N']	[13]
14	:	O	['N']	[14]
15	is	O	['N']	[15]
16	there	O	['N']	[16]
17	any	O	['N']	[17]
18	connection	O	['N']	[18]
19	?	O	['N']	[19]
#4719
0	After	O	['N']	[0]
1	1	O	['N']	[1]
2	week	O	['N']	[2]
3	of	O	['N']	[3]
4	nefazodone	B-Drug	['Causes']	[11]
5	therapy	O	['N']	[5]
6	the	O	['N']	[6]
7	patient	O	['N']	[7]
8	experienced	O	['N']	[8]
9	headache	O	['N']	[9]
10	,	O	['N']	[10]
11	confusion	B-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	and	O	['N']	[13]
14	"	O	['N']	[14]
15	gray	O	['N']	[15]
16	areas	O	['N']	[16]
17	"	O	['N']	[17]
18	in	O	['N']	[18]
19	her	O	['N']	[19]
20	vision	O	['N']	[20]
21	,	O	['N']	[21]
22	without	O	['N']	[22]
23	abnormal	O	['N']	[23]
24	ophthalmologic	O	['N']	[24]
25	findings	O	['N']	[25]
26	.	O	['N']	[26]
#4720
0	It	O	['N']	[0]
1	is	O	['N']	[1]
2	very	O	['N']	[2]
3	likely	O	['N']	[3]
4	that	O	['N']	[4]
5	the	O	['N']	[5]
6	dexamethasone	B-Drug	['Causes']	[18]
7	used	O	['N']	[7]
8	in	O	['N']	[8]
9	the	O	['N']	[9]
10	antiemetic	O	['N']	[10]
11	drug	O	['N']	[11]
12	regimen	O	['N']	[12]
13	contributed	O	['N']	[13]
14	to	O	['N']	[14]
15	the	O	['N']	[15]
16	development	O	['N']	[16]
17	of	O	['N']	[17]
18	osteonecrosis	B-Adverse_Effect	['N']	[18]
19	in	O	['N']	[19]
20	these	O	['N']	[20]
21	patients	O	['N']	[21]
22	.	O	['N']	[22]
#4721
0	While	O	['N']	[0]
1	doxorubicin	B-Drug	['Causes']	[12]
2	was	O	['N']	[2]
3	administered	O	['N']	[3]
4	,	O	['N']	[4]
5	the	O	['N']	[5]
6	patient	O	['N']	[6]
7	presented	O	['N']	[7]
8	thoracic	O	['N']	[8]
9	pain	O	['N']	[9]
10	and	O	['N']	[10]
11	breathing	B	['N']	[11]
12	distress	I-Adverse_Effect	['N']	[12]
13	due	O	['N']	[13]
14	to	O	['N']	[14]
15	superior	O	['N']	[15]
16	vena	O	['N']	[16]
17	cava	O	['N']	[17]
18	perforation	O	['N']	[18]
19	by	O	['N']	[19]
20	the	O	['N']	[20]
21	central	O	['N']	[21]
22	catheter	O	['N']	[22]
23	and	O	['N']	[23]
24	subsequent	O	['N']	[24]
25	extravasation	O	['N']	[25]
26	of	O	['N']	[26]
27	the	O	['N']	[27]
28	drug	O	['N']	[28]
29	into	O	['N']	[29]
30	the	O	['N']	[30]
31	mediastinum	O	['N']	[31]
32	.	O	['N']	[32]
#4722
0	A	O	['N']	[0]
1	7-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	developed	O	['N']	[5]
6	a	O	['N']	[6]
7	severe	B	['N']	[7]
8	unilateral	I	['N']	[8]
9	grand	I	['N']	[9]
10	mal	I	['N']	[10]
11	seizure	I-Adverse_Effect	['N']	[11]
12	at	O	['N']	[12]
13	the	O	['N']	[13]
14	age	O	['N']	[14]
15	of	O	['N']	[15]
16	5	O	['N']	[16]
17	years	O	['N']	[17]
18	(	O	['N']	[18]
19	phenobarbitone	O	['N']	[19]
20	therapy	O	['N']	[20]
21	)	O	['N']	[21]
22	;	O	['N']	[22]
23	1.5	O	['N']	[23]
24	years	O	['N']	[24]
25	later	O	['N']	[25]
26	valproate	O	['N']	[26]
27	(	O	['N']	[27]
28	2-propylpentanoic	B	['N']	[28]
29	acid	I-Drug	['Causes']	[11]
30	,	O	['N']	[30]
31	VPA	O	['N']	[31]
32	)	O	['N']	[32]
33	was	O	['N']	[33]
34	added	O	['N']	[34]
35	to	O	['N']	[35]
36	the	O	['N']	[36]
37	therapy	O	['N']	[37]
38	.	O	['N']	[38]
#4723
0	This	O	['N']	[0]
1	paper	O	['N']	[1]
2	reports	O	['N']	[2]
3	on	O	['N']	[3]
4	a	O	['N']	[4]
5	6.9-year	O	['N']	[5]
6	-	O	['N']	[6]
7	old	O	['N']	[7]
8	autistic	O	['N']	[8]
9	male	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	repeated	O	['N']	[12]
13	episodes	O	['N']	[13]
14	of	O	['N']	[14]
15	acute	B	['N']	[15]
16	dystonic	I	['N']	[16]
17	reactions	I-Adverse_Effect	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	pimozide	B-Drug	['Causes']	[17]
21	administration	O	['N']	[21]
22	at	O	['N']	[22]
23	the	O	['N']	[23]
24	doses	O	['N']	[24]
25	of	O	['N']	[25]
26	0.096	O	['N']	[26]
27	mg	O	['N']	[27]
28	/	O	['N']	[28]
29	kg	O	['N']	[29]
30	/	O	['N']	[30]
31	day	O	['N']	[31]
32	and	O	['N']	[32]
33	0.032	O	['N']	[33]
34	mg	O	['N']	[34]
35	/	O	['N']	[35]
36	kg	O	['N']	[36]
37	/	O	['N']	[37]
38	day	O	['N']	[38]
39	and	O	['N']	[39]
40	32	O	['N']	[40]
41	hours	O	['N']	[41]
42	following	O	['N']	[42]
43	pimozide	O	['N']	[43]
44	withdrawal	O	['N']	[44]
45	,	O	['N']	[45]
46	as	O	['N']	[46]
47	well	O	['N']	[47]
48	as	O	['N']	[48]
49	during	O	['N']	[49]
50	subsequent	O	['N']	[50]
51	thioridazine	O	['N']	[51]
52	administration	O	['N']	[52]
53	.	O	['N']	[53]
#4724
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	developed	O	['N']	[5]
6	dramatic	O	['N']	[6]
7	,	O	['N']	[7]
8	permanent	O	['N']	[8]
9	vision	B	['N']	[9]
10	loss	I-Adverse_Effect	['N']	[10]
11	after	O	['N']	[11]
12	a	O	['N']	[12]
13	9-month	O	['N']	[13]
14	course	O	['N']	[14]
15	of	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	ethambutol	B-Drug	['Causes']	[10]
19	and	O	['N']	[19]
20	isoniazid	O	['N']	[20]
21	for	O	['N']	[21]
22	pulmonary	O	['N']	[22]
23	tuberculosis	O	['N']	[23]
24	is	O	['N']	[24]
25	presented	O	['N']	[25]
26	.	O	['N']	[26]
#4725
0	Videopolysomnographic	O	['N']	[0]
1	and	O	['N']	[1]
2	pharmacokinetic	O	['N']	[2]
3	studies	O	['N']	[3]
4	with	O	['N']	[4]
5	monitoring	O	['N']	[5]
6	of	O	['N']	[6]
7	plasma	O	['N']	[7]
8	levodopa	B-Drug	['Causes']	[30]
9	levels	O	['N']	[9]
10	demonstrated	O	['N']	[10]
11	marked	O	['N']	[11]
12	motor	O	['N']	[12]
13	hyperactivity	O	['N']	[13]
14	during	O	['N']	[14]
15	augmentation	O	['N']	[15]
16	,	O	['N']	[16]
17	with	O	['N']	[17]
18	anarchic	O	['N']	[18]
19	discharges	O	['N']	[19]
20	of	O	['N']	[20]
21	motor	O	['N']	[21]
22	unit	O	['N']	[22]
23	potentials	O	['N']	[23]
24	,	O	['N']	[24]
25	tonic	O	['N']	[25]
26	grouped	O	['N']	[26]
27	discharges	O	['N']	[27]
28	and	O	['N']	[28]
29	flexor	B	['N']	[29]
30	spasms	I-Adverse_Effect	['N']	[30]
31	,	O	['N']	[31]
32	associated	O	['N']	[32]
33	with	O	['N']	[33]
34	painful	O	['N']	[34]
35	dysesthesia	O	['N']	[35]
36	.	O	['N']	[36]
#4726
0	The	O	['N']	[0]
1	incidence	O	['N']	[1]
2	of	O	['N']	[2]
3	oral	O	['N']	[3]
4	-	O	['N']	[4]
5	verapamil	B-Drug	['Causes']	[8]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	hypotension	B-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	the	O	['N']	[10]
11	presence	O	['N']	[11]
12	of	O	['N']	[12]
13	concomitant	O	['N']	[13]
14	beta	O	['N']	[14]
15	-	O	['N']	[15]
16	adrenergic	O	['N']	[16]
17	blockade	O	['N']	[17]
18	by	O	['N']	[18]
19	the	O	['N']	[19]
20	oral	O	['N']	[20]
21	route	O	['N']	[21]
22	is	O	['N']	[22]
23	quite	O	['N']	[23]
24	rare	O	['N']	[24]
25	.	O	['N']	[25]
#4727
0	DIAGNOSIS	O	['N']	[0]
1	:	O	['N']	[1]
2	Severe	O	['N']	[2]
3	temozolomide	B-Drug	['Causes']	[31]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	immunosuppression	O	['N']	[6]
7	,	O	['N']	[7]
8	exacerbated	O	['N']	[8]
9	by	O	['N']	[9]
10	corticosteroids	O	['N']	[10]
11	,	O	['N']	[11]
12	with	O	['N']	[12]
13	profound	O	['N']	[13]
14	T	O	['N']	[14]
15	-	O	['N']	[15]
16	cell	O	['N']	[16]
17	lymphocytopenia	O	['N']	[17]
18	and	O	['N']	[18]
19	simultaneous	O	['N']	[19]
20	opportunistic	O	['N']	[20]
21	infections	O	['N']	[21]
22	with	O	['N']	[22]
23	Pneumocystis	O	['N']	[23]
24	jiroveci	O	['N']	[24]
25	pneumonia	O	['N']	[25]
26	,	O	['N']	[26]
27	brain	B	['N']	[27]
28	abscess	I	['N']	[28]
29	with	I	['N']	[29]
30	Listeria	I	['N']	[30]
31	monocytogenes	I-Adverse_Effect	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	cutaneous	O	['N']	[34]
35	Kaposi	O	['N']	[35]
36	's	O	['N']	[36]
37	sarcoma	O	['N']	[37]
38	.	O	['N']	[38]
#4728
0	A	O	['N']	[0]
1	wide	O	['N']	[1]
2	variety	O	['N']	[2]
3	of	O	['N']	[3]
4	adverse	O	['N']	[4]
5	central	O	['N']	[5]
6	nervous	O	['N']	[6]
7	system	O	['N']	[7]
8	effects	O	['N']	[8]
9	have	O	['N']	[9]
10	been	O	['N']	[10]
11	reported	O	['N']	[11]
12	in	O	['N']	[12]
13	association	O	['N']	[13]
14	with	O	['N']	[14]
15	propafenone	B-Drug	['Causes']	[17]
16	;	O	['N']	[16]
17	dizziness	B-Adverse_Effect	['N']	[17]
18	is	O	['N']	[18]
19	the	O	['N']	[19]
20	most	O	['N']	[20]
21	common	O	['N']	[21]
22	.	O	['N']	[22]
#4729
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	report	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	Balint	B	['N']	[6]
7	syndrome	I-Adverse_Effect	['N']	[7]
8	with	O	['N']	[8]
9	irreversible	O	['N']	[9]
10	posterior	O	['N']	[10]
11	leukoencephalopathy	O	['N']	[11]
12	on	O	['N']	[12]
13	MRI	O	['N']	[13]
14	following	O	['N']	[14]
15	intrathecal	O	['N']	[15]
16	methotrexate	B-Drug	['Causes']	[7]
17	and	O	['N']	[17]
18	cytarabine	O	['N']	[18]
19	.	O	['N']	[19]
#4730
0	METHODS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	55-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	woman	O	['N']	[6]
7	became	O	['N']	[7]
8	stuporous	B-Adverse_Effect	['N']	[8]
9	after	O	['N']	[9]
10	overdose	O	['N']	[10]
11	with	O	['N']	[11]
12	lamotrigine	O	['N']	[12]
13	(	O	['N']	[13]
14	LTG	B-Drug	['Causes']	[8]
15	)	O	['N']	[15]
16	and	O	['N']	[16]
17	valproic	O	['N']	[17]
18	acid	O	['N']	[18]
19	(	O	['N']	[19]
20	VPA	O	['N']	[20]
21	)	O	['N']	[21]
22	tablets	O	['N']	[22]
23	.	O	['N']	[23]
#4731
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	5-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	boy	O	['N']	[6]
7	with	O	['N']	[7]
8	CF	O	['N']	[8]
9	who	O	['N']	[9]
10	had	O	['N']	[10]
11	a	O	['N']	[11]
12	stricture	O	['N']	[12]
13	of	O	['N']	[13]
14	the	O	['N']	[14]
15	hepatic	O	['N']	[15]
16	flexure	O	['N']	[16]
17	region	O	['N']	[17]
18	with	O	['N']	[18]
19	associated	O	['N']	[19]
20	narrowing	O	['N']	[20]
21	due	O	['N']	[21]
22	to	O	['N']	[22]
23	submucosal	B	['N']	[23]
24	fibrosis	I	['N']	[24]
25	of	I	['N']	[25]
26	the	I	['N']	[26]
27	transverse	I	['N']	[27]
28	colon	I-Adverse_Effect	['N']	[28]
29	,	O	['N']	[29]
30	secondary	O	['N']	[30]
31	to	O	['N']	[31]
32	high	B	['N']	[32]
33	-	I	['N']	[33]
34	lipase	I	['N']	[34]
35	pancreatin	I-Drug	['Causes']	[28]
36	therapy	O	['N']	[36]
37	.	O	['N']	[37]
#4732
0	Administration	O	['N']	[0]
1	of	O	['N']	[1]
2	amantadine	B-Drug	['Causes']	[7]
3	was	O	['N']	[3]
4	associated	O	['N']	[4]
5	with	O	['N']	[5]
6	psychotic	B	['N']	[6]
7	decompensations	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	two	O	['N']	[9]
10	schizophrenic	O	['N']	[10]
11	patients	O	['N']	[11]
12	being	O	['N']	[12]
13	maintained	O	['N']	[13]
14	on	O	['N']	[14]
15	concomitant	O	['N']	[15]
16	neuroleptic	O	['N']	[16]
17	medication	O	['N']	[17]
18	.	O	['N']	[18]
#4733
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	37-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	African-	O	['N']	[6]
7	American	O	['N']	[7]
8	man	O	['N']	[8]
9	with	O	['N']	[9]
10	G6PD	O	['N']	[10]
11	deficiency	O	['N']	[11]
12	developed	O	['N']	[12]
13	hemolytic	B	['N']	[13]
14	anemia	I-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	hepatitis	O	['N']	[16]
17	,	O	['N']	[17]
18	orthostatic	O	['N']	[18]
19	hypotension	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	aseptic	O	['N']	[22]
23	meningitis	O	['N']	[23]
24	simultaneously	O	['N']	[24]
25	after	O	['N']	[25]
26	using	O	['N']	[26]
27	trimethoprim	O	['N']	[27]
28	-	O	['N']	[28]
29	sulfamethoxazole	B-Drug	['Causes']	[14]
30	.	O	['N']	[30]
#4734
0	Second	O	['N']	[0]
1	,	O	['N']	[1]
2	we	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	neutropenia	B-Adverse_Effect	['N']	[7]
8	,	O	['N']	[8]
9	which	O	['N']	[9]
10	proved	O	['N']	[10]
11	to	O	['N']	[11]
12	be	O	['N']	[12]
13	fatal	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	schizophrenia	O	['N']	[16]
17	patient	O	['N']	[17]
18	receiving	O	['N']	[18]
19	olanzapine	B-Drug	['Causes']	[7]
20	and	O	['N']	[20]
21	thiazide	O	['N']	[21]
22	.	O	['N']	[22]
#4735
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	an	O	['N']	[5]
6	87-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	white	O	['N']	[9]
10	woman	O	['N']	[10]
11	with	O	['N']	[11]
12	myasthenia	O	['N']	[12]
13	gravis	O	['N']	[13]
14	who	O	['N']	[14]
15	presented	O	['N']	[15]
16	with	O	['N']	[16]
17	nausea	O	['N']	[17]
18	,	O	['N']	[18]
19	shortness	O	['N']	[19]
20	of	O	['N']	[20]
21	breath	O	['N']	[21]
22	,	O	['N']	[22]
23	azotemia	B-Adverse_Effect	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	hyperkalemia	O	['N']	[26]
27	shortly	O	['N']	[27]
28	after	O	['N']	[28]
29	completing	O	['N']	[29]
30	a	O	['N']	[30]
31	course	O	['N']	[31]
32	of	O	['N']	[32]
33	intravenous	O	['N']	[33]
34	immunoglobulin	O	['N']	[34]
35	(	O	['N']	[35]
36	IVIG	B-Drug	['Causes']	[23]
37	)	O	['N']	[37]
38	.	O	['N']	[38]
#4736
0	Two	O	['N']	[0]
1	years	O	['N']	[1]
2	later	O	['N']	[2]
3	,	O	['N']	[3]
4	24	O	['N']	[4]
5	hours	O	['N']	[5]
6	following	O	['N']	[6]
7	an	O	['N']	[7]
8	increase	O	['N']	[8]
9	in	O	['N']	[9]
10	the	O	['N']	[10]
11	dose	O	['N']	[11]
12	of	O	['N']	[12]
13	disopyramide	B-Drug	['Causes']	[24]
14	from	O	['N']	[14]
15	300	O	['N']	[15]
16	to	O	['N']	[16]
17	600	O	['N']	[17]
18	mg	O	['N']	[18]
19	/	O	['N']	[19]
20	day	O	['N']	[20]
21	,	O	['N']	[21]
22	AVT	O	['N']	[22]
23	with	O	['N']	[23]
24	syncope	B-Adverse_Effect	['N']	[24]
25	occurred	O	['N']	[25]
26	;	O	['N']	[26]
27	isoproterenol	O	['N']	[27]
28	abolished	O	['N']	[28]
29	the	O	['N']	[29]
30	arrhythmia	O	['N']	[30]
31	instantly	O	['N']	[31]
32	.	O	['N']	[32]
#4737
0	Etoposide	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	related	O	['N']	[2]
3	myocardial	B	['N']	[3]
4	infarction	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#4738
0	A	O	['N']	[0]
1	51-yr	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	nonsmoking	O	['N']	[4]
5	male	O	['N']	[5]
6	patient	O	['N']	[6]
7	without	O	['N']	[7]
8	any	O	['N']	[8]
9	history	O	['N']	[9]
10	of	O	['N']	[10]
11	previous	O	['N']	[11]
12	allergies	O	['N']	[12]
13	,	O	['N']	[13]
14	asthma	O	['N']	[14]
15	,	O	['N']	[15]
16	hay	O	['N']	[16]
17	fever	O	['N']	[17]
18	,	O	['N']	[18]
19	or	O	['N']	[19]
20	urticaria	O	['N']	[20]
21	developed	O	['N']	[21]
22	attacks	B	['N']	[22]
23	of	I	['N']	[23]
24	asthma	I-Adverse_Effect	['N']	[24]
25	when	O	['N']	[25]
26	captopril	B-Drug	['Causes']	[24]
27	was	O	['N']	[27]
28	added	O	['N']	[28]
29	to	O	['N']	[29]
30	the	O	['N']	[30]
31	nadolol	O	['N']	[31]
32	and	O	['N']	[32]
33	dyazide	O	['N']	[33]
34	treatment	O	['N']	[34]
35	for	O	['N']	[35]
36	his	O	['N']	[36]
37	high	O	['N']	[37]
38	blood	O	['N']	[38]
39	pressure	O	['N']	[39]
40	.	O	['N']	[40]
#4739
0	Quinine	O	['N']	[0]
1	and	O	['N']	[1]
2	its	O	['N']	[2]
3	isomer	O	['N']	[3]
4	quinidine	B-Drug	['Causes']	[12]
5	are	O	['N']	[5]
6	well	O	['N']	[6]
7	-	O	['N']	[7]
8	known	O	['N']	[8]
9	causes	O	['N']	[9]
10	of	O	['N']	[10]
11	iatrogenic	B	['N']	[11]
12	hypoglycaemia	I-Adverse_Effect	['N']	[12]
13	,	O	['N']	[13]
14	due	O	['N']	[14]
15	to	O	['N']	[15]
16	excessive	O	['N']	[16]
17	insulin	O	['N']	[17]
18	secretion	O	['N']	[18]
19	.	O	['N']	[19]
#4740
0	Exposure	O	['N']	[0]
1	of	O	['N']	[1]
2	the	O	['N']	[2]
3	fetus	O	['N']	[3]
4	to	O	['N']	[4]
5	indomethacin	B-Drug	['Causes']	[26]
6	by	O	['N']	[6]
7	administration	O	['N']	[7]
8	of	O	['N']	[8]
9	the	O	['N']	[9]
10	drug	O	['N']	[10]
11	to	O	['N']	[11]
12	the	O	['N']	[12]
13	mother	O	['N']	[13]
14	may	O	['N']	[14]
15	cause	O	['N']	[15]
16	many	O	['N']	[16]
17	side	O	['N']	[17]
18	effects	O	['N']	[18]
19	,	O	['N']	[19]
20	including	O	['N']	[20]
21	premature	B	['N']	[21]
22	closure	I	['N']	[22]
23	of	I	['N']	[23]
24	the	I	['N']	[24]
25	ductus	I	['N']	[25]
26	arteriosus	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#4741
0	Cutaneous	B	['N']	[0]
1	ulceration	I-Adverse_Effect	['N']	[1]
2	:	O	['N']	[2]
3	an	O	['N']	[3]
4	unusual	O	['N']	[4]
5	complication	O	['N']	[5]
6	of	O	['N']	[6]
7	intravenous	O	['N']	[7]
8	pentamidine	B-Drug	['Causes']	[1]
9	therapy	O	['N']	[9]
10	.	O	['N']	[10]
#4742
0	Disseminated	B	['N']	[0]
1	eruptive	I	['N']	[1]
2	giant	I	['N']	[2]
3	mollusca	I	['N']	[3]
4	contagiosa	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	an	O	['N']	[6]
7	adult	O	['N']	[7]
8	psoriasis	O	['N']	[8]
9	patient	O	['N']	[9]
10	during	O	['N']	[10]
11	efalizumab	B-Drug	['Causes']	[4]
12	therapy	O	['N']	[12]
13	.	O	['N']	[13]
#4743
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	report	O	['N']	[2]
3	of	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	with	O	['N']	[6]
7	probable	O	['N']	[7]
8	cisplatin	O	['N']	[8]
9	and	O	['N']	[9]
10	bleomycin	B-Drug	['Causes']	[13]
11	-	O	['N']	[11]
12	induced	O	['N']	[12]
13	TMA	B-Adverse_Effect	['N']	[13]
14	is	O	['N']	[14]
15	presented	O	['N']	[15]
16	.	O	['N']	[16]
#4744
0	Patients	O	['N']	[0]
1	with	O	['N']	[1]
2	lymphoblastic	O	['N']	[2]
3	lymphoma	O	['N']	[3]
4	who	O	['N']	[4]
5	had	O	['N']	[5]
6	treatment	O	['N']	[6]
7	with	O	['N']	[7]
8	L	B	['N']	[8]
9	-	I	['N']	[9]
10	asparaginase	I-Drug	['Causes']	[33]
11	and	O	['N']	[11]
12	steroid	O	['N']	[12]
13	are	O	['N']	[13]
14	predisposed	O	['N']	[14]
15	to	O	['N']	[15]
16	the	O	['N']	[16]
17	development	O	['N']	[17]
18	of	O	['N']	[18]
19	cortical	O	['N']	[19]
20	venous	O	['N']	[20]
21	thrombosis	O	['N']	[21]
22	and	O	['N']	[22]
23	may	O	['N']	[23]
24	have	O	['N']	[24]
25	this	O	['N']	[25]
26	syndrome	O	['N']	[26]
27	in	O	['N']	[27]
28	addition	O	['N']	[28]
29	to	O	['N']	[29]
30	a	O	['N']	[30]
31	dural	B	['N']	[31]
32	puncture	I	['N']	[32]
33	headache	I-Adverse_Effect	['N']	[33]
34	.	O	['N']	[34]
#4745
0	Selective	O	['N']	[0]
1	estrogen	O	['N']	[1]
2	receptor	O	['N']	[2]
3	modulator	O	['N']	[3]
4	raloxifene	B-Drug	['Causes']	[10]
5	-	O	['N']	[5]
6	associated	O	['N']	[6]
7	aggravation	B	['N']	[7]
8	of	I	['N']	[8]
9	nonalcoholic	I	['N']	[9]
10	steatohepatitis	I-Adverse_Effect	['N']	[10]
11	.	O	['N']	[11]
#4746
0	When	O	['N']	[0]
1	SASP	O	['N']	[1]
2	was	O	['N']	[2]
3	changed	O	['N']	[3]
4	to	O	['N']	[4]
5	5-aminosalicylic	O	['N']	[5]
6	acid	O	['N']	[6]
7	(	O	['N']	[7]
8	5-ASA	B-Drug	['Causes']	[41]
9	)	O	['N']	[9]
10	,	O	['N']	[10]
11	his	O	['N']	[11]
12	skin	O	['N']	[12]
13	eruptions	O	['N']	[13]
14	were	O	['N']	[14]
15	resolved	O	['N']	[15]
16	,	O	['N']	[16]
17	however	O	['N']	[17]
18	,	O	['N']	[18]
19	he	O	['N']	[19]
20	developed	O	['N']	[20]
21	weakness	O	['N']	[21]
22	and	O	['N']	[22]
23	atrophy	O	['N']	[23]
24	in	O	['N']	[24]
25	his	O	['N']	[25]
26	right	O	['N']	[26]
27	arm	O	['N']	[27]
28	as	O	['N']	[28]
29	well	O	['N']	[29]
30	as	O	['N']	[30]
31	progressive	O	['N']	[31]
32	worsening	O	['N']	[32]
33	of	O	['N']	[33]
34	the	O	['N']	[34]
35	dysesthesia	O	['N']	[35]
36	in	O	['N']	[36]
37	his	O	['N']	[37]
38	legs	O	['N']	[38]
39	and	O	['N']	[39]
40	gait	B	['N']	[40]
41	disturbance	I-Adverse_Effect	['N']	[41]
42	.	O	['N']	[42]
#4747
0	This	O	['N']	[0]
1	case	O	['N']	[1]
2	presentation	O	['N']	[2]
3	is	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	had	O	['N']	[8]
9	the	O	['N']	[9]
10	clinical	O	['N']	[10]
11	appearance	O	['N']	[11]
12	of	O	['N']	[12]
13	epiglottitis	O	['N']	[13]
14	,	O	['N']	[14]
15	but	O	['N']	[15]
16	actually	O	['N']	[16]
17	had	O	['N']	[17]
18	an	O	['N']	[18]
19	oro	B	['N']	[19]
20	-	I	['N']	[20]
21	pharyngeal	I	['N']	[21]
22	dystonic	I	['N']	[22]
23	reaction	I-Adverse_Effect	['N']	[23]
24	to	O	['N']	[24]
25	prochlorperazine	B-Drug	['Causes']	[23]
26	.	O	['N']	[26]
#4748
0	CONCLUSION	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	administration	O	['N']	[3]
4	of	O	['N']	[4]
5	tissue	B	['N']	[5]
6	plasminogen	I	['N']	[6]
7	activator	I-Drug	['Causes']	[27]
8	was	O	['N']	[8]
9	responsible	O	['N']	[9]
10	for	O	['N']	[10]
11	the	O	['N']	[11]
12	large	O	['N']	[12]
13	extent	O	['N']	[13]
14	of	O	['N']	[14]
15	hemorrhage	O	['N']	[15]
16	and	O	['N']	[16]
17	should	O	['N']	[17]
18	be	O	['N']	[18]
19	considered	O	['N']	[19]
20	in	O	['N']	[20]
21	the	O	['N']	[21]
22	differential	O	['N']	[22]
23	diagnosis	O	['N']	[23]
24	of	O	['N']	[24]
25	hemorrhagic	B	['N']	[25]
26	choroidal	I	['N']	[26]
27	detachment	I-Adverse_Effect	['N']	[27]
28	.	O	['N']	[28]
#4749
0	Neutropenia	B-Adverse_Effect	['N']	[0]
1	and	O	['N']	[1]
2	agranulocytosis	O	['N']	[2]
3	are	O	['N']	[3]
4	risks	O	['N']	[4]
5	known	O	['N']	[5]
6	to	O	['N']	[6]
7	occur	O	['N']	[7]
8	with	O	['N']	[8]
9	phenothiazines	B-Drug	['Causes']	[0]
10	and	O	['N']	[10]
11	clozapine	O	['N']	[11]
12	.	O	['N']	[12]
#4750
0	He	O	['N']	[0]
1	had	O	['N']	[1]
2	been	O	['N']	[2]
3	taking	O	['N']	[3]
4	trimethoprim	B-Drug	['Causes']	[28]
5	-	O	['N']	[5]
6	sulfamethoxazole	O	['N']	[6]
7	for	O	['N']	[7]
8	approximately	O	['N']	[8]
9	eight	O	['N']	[9]
10	days	O	['N']	[10]
11	when	O	['N']	[11]
12	he	O	['N']	[12]
13	revisited	O	['N']	[13]
14	his	O	['N']	[14]
15	family	O	['N']	[15]
16	physician	O	['N']	[16]
17	,	O	['N']	[17]
18	complaining	O	['N']	[18]
19	of	O	['N']	[19]
20	headaches	O	['N']	[20]
21	,	O	['N']	[21]
22	dizziness	O	['N']	[22]
23	,	O	['N']	[23]
24	difficulty	O	['N']	[24]
25	with	O	['N']	[25]
26	speech	O	['N']	[26]
27	,	O	['N']	[27]
28	weakness	B-Adverse_Effect	['N']	[28]
29	,	O	['N']	[29]
30	and	O	['N']	[30]
31	itching	O	['N']	[31]
32	on	O	['N']	[32]
33	the	O	['N']	[33]
34	trunk	O	['N']	[34]
35	of	O	['N']	[35]
36	his	O	['N']	[36]
37	body	O	['N']	[37]
38	and	O	['N']	[38]
39	legs	O	['N']	[39]
40	,	O	['N']	[40]
41	where	O	['N']	[41]
42	a	O	['N']	[42]
43	maculopapular	O	['N']	[43]
44	rash	O	['N']	[44]
45	was	O	['N']	[45]
46	noted	O	['N']	[46]
47	.	O	['N']	[47]
#4751
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	an	O	['N']	[2]
3	unusual	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	massive	B-Dose	['N']	[6]
7	fluoxetine	B-Drug	['Dosage']	[6]
8	ingestion	O	['N']	[8]
9	resulting	O	['N']	[9]
10	in	O	['N']	[10]
11	neurological	O	['N']	[11]
12	and	O	['N']	[12]
13	cardiovascular	O	['N']	[13]
14	toxicity	O	['N']	[14]
15	resulting	O	['N']	[15]
16	in	O	['N']	[16]
17	death	O	['N']	[17]
18	.	O	['N']	[18]
#4752
0	Relief	O	['N']	[0]
1	by	O	['N']	[1]
2	naloxone	O	['N']	[2]
3	of	O	['N']	[3]
4	morphine	B-Drug	['Causes']	[7]
5	-	O	['N']	[5]
6	induced	O	['N']	[6]
7	spasm	B-Adverse_Effect	['N']	[7]
8	of	O	['N']	[8]
9	the	O	['N']	[9]
10	sphincter	O	['N']	[10]
11	of	O	['N']	[11]
12	Oddi	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	post	O	['N']	[15]
16	-	O	['N']	[16]
17	cholecystectomy	O	['N']	[17]
18	patient	O	['N']	[18]
19	.	O	['N']	[19]
#4753
0	We	O	['N']	[0]
1	believe	O	['N']	[1]
2	that	O	['N']	[2]
3	these	O	['N']	[3]
4	skin	O	['N']	[4]
5	eruptions	O	['N']	[5]
6	belong	O	['N']	[6]
7	to	O	['N']	[7]
8	a	O	['N']	[8]
9	spectrum	O	['N']	[9]
10	of	O	['N']	[10]
11	neutrophilic	B	['N']	[11]
12	dermatoses	I-Adverse_Effect	['N']	[12]
13	that	O	['N']	[13]
14	can	O	['N']	[14]
15	be	O	['N']	[15]
16	induced	O	['N']	[16]
17	or	O	['N']	[17]
18	aggravated	O	['N']	[18]
19	by	O	['N']	[19]
20	G	B	['N']	[20]
21	-	I	['N']	[21]
22	CSF	I-Drug	['Causes']	[12]
23	therapy	O	['N']	[23]
24	.	O	['N']	[24]
#4754
0	The	O	['N']	[0]
1	occurrence	O	['N']	[1]
2	of	O	['N']	[2]
3	acute	O	['N']	[3]
4	hepatitis	B-Adverse_Effect	['N']	[4]
5	is	O	['N']	[5]
6	best	O	['N']	[6]
7	known	O	['N']	[7]
8	for	O	['N']	[8]
9	ketoconazole	B-Drug	['Causes']	[4]
10	.	O	['N']	[10]
#4755
0	Patients	O	['N']	[0]
1	treated	O	['N']	[1]
2	with	O	['N']	[2]
3	captopril	B-Drug	['Causes']	[8]
4	who	O	['N']	[4]
5	develop	O	['N']	[5]
6	"	O	['N']	[6]
7	atypical	B	['N']	[7]
8	cholangitis	I-Adverse_Effect	['N']	[8]
9	"	O	['N']	[9]
10	should	O	['N']	[10]
11	be	O	['N']	[11]
12	suspected	O	['N']	[12]
13	of	O	['N']	[13]
14	having	O	['N']	[14]
15	captopril	O	['N']	[15]
16	-	O	['N']	[16]
17	associated	O	['N']	[17]
18	liver	O	['N']	[18]
19	damage	O	['N']	[19]
20	.	O	['N']	[20]
#4756
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	suffering	O	['N']	[2]
3	from	O	['N']	[3]
4	heparin	B-Drug	['Causes']	[7]
5	-	O	['N']	[5]
6	associated	O	['N']	[6]
7	thrombocytopenia	B-Adverse_Effect	['N']	[7]
8	(	O	['N']	[8]
9	HAT	O	['N']	[9]
10	)	O	['N']	[10]
11	,	O	['N']	[11]
12	recurrent	O	['N']	[12]
13	arteriothromboses	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	acute	O	['N']	[16]
17	renal	O	['N']	[17]
18	failure	O	['N']	[18]
19	after	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	standard	O	['N']	[22]
23	heparin	O	['N']	[23]
24	is	O	['N']	[24]
25	described	O	['N']	[25]
26	.	O	['N']	[26]
#4757
0	The	O	['N']	[0]
1	development	O	['N']	[1]
2	of	O	['N']	[2]
3	systemic	B	['N']	[3]
4	lupus	I	['N']	[4]
5	erythematosus	I-Adverse_Effect	['N']	[5]
6	(	O	['N']	[6]
7	SLE	O	['N']	[7]
8	)	O	['N']	[8]
9	after	O	['N']	[9]
10	38	O	['N']	[10]
11	months	O	['N']	[11]
12	of	O	['N']	[12]
13	therapy	O	['N']	[13]
14	with	O	['N']	[14]
15	recombinant	O	['N']	[15]
16	human	O	['N']	[16]
17	interferon	O	['N']	[17]
18	gamma	O	['N']	[18]
19	(	O	['N']	[19]
20	rIFN	B	['N']	[20]
21	-	I	['N']	[21]
22	gamma	I-Drug	['Causes']	[5]
23	)	O	['N']	[23]
24	was	O	['N']	[24]
25	observed	O	['N']	[25]
26	in	O	['N']	[26]
27	a	O	['N']	[27]
28	patient	O	['N']	[28]
29	with	O	['N']	[29]
30	rheumatoid	O	['N']	[30]
31	arthritis	O	['N']	[31]
32	.	O	['N']	[32]
#4758
0	A	O	['N']	[0]
1	65-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	patient	O	['N']	[5]
6	presented	O	['N']	[6]
7	with	O	['N']	[7]
8	jaundice	O	['N']	[8]
9	followed	O	['N']	[9]
10	2	O	['N']	[10]
11	days	O	['N']	[11]
12	later	O	['N']	[12]
13	by	O	['N']	[13]
14	severe	O	['N']	[14]
15	dyspnea	O	['N']	[15]
16	and	O	['N']	[16]
17	tachypnea	B-Adverse_Effect	['N']	[17]
18	which	O	['N']	[18]
19	worsened	O	['N']	[19]
20	when	O	['N']	[20]
21	patient	O	['N']	[21]
22	was	O	['N']	[22]
23	lying	O	['N']	[23]
24	flat	O	['N']	[24]
25	,	O	['N']	[25]
26	1	O	['N']	[26]
27	week	O	['N']	[27]
28	after	O	['N']	[28]
29	the	O	['N']	[29]
30	fourth	O	['N']	[30]
31	dose	O	['N']	[31]
32	of	O	['N']	[32]
33	adalimumab	B-Drug	['Causes']	[17]
34	.	O	['N']	[34]
#4759
0	Gastric	B	['N']	[0]
1	tumor	I-Adverse_Effect	['N']	[1]
2	,	O	['N']	[2]
3	endometrial	O	['N']	[3]
4	carcinoma	O	['N']	[4]
5	and	O	['N']	[5]
6	cervical	O	['N']	[6]
7	adenocarcinoma	O	['N']	[7]
8	in	O	['N']	[8]
9	situ	O	['N']	[9]
10	were	O	['N']	[10]
11	detected	O	['N']	[11]
12	after	O	['N']	[12]
13	treatment	O	['N']	[13]
14	with	O	['N']	[14]
15	tamoxifen	B-Drug	['Causes']	[1]
16	for	O	['N']	[16]
17	breast	O	['N']	[17]
18	cancer	O	['N']	[18]
19	.	O	['N']	[19]
#4760
0	Shortly	O	['N']	[0]
1	after	O	['N']	[1]
2	chemotherapy	O	['N']	[2]
3	and	O	['N']	[3]
4	an	O	['N']	[4]
5	injection	O	['N']	[5]
6	of	O	['N']	[6]
7	pegfilgrastim	B-Drug	['Causes']	[17]
8	,	O	['N']	[8]
9	the	O	['N']	[9]
10	patient	O	['N']	[10]
11	developed	O	['N']	[11]
12	poorly	O	['N']	[12]
13	defined	O	['N']	[13]
14	,	O	['N']	[14]
15	rapidly	B	['N']	[15]
16	progressive	I	['N']	[16]
17	erythema	I-Adverse_Effect	['N']	[17]
18	,	O	['N']	[18]
19	edema	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	pain	O	['N']	[22]
23	in	O	['N']	[23]
24	his	O	['N']	[24]
25	right	O	['N']	[25]
26	forearm	O	['N']	[26]
27	.	O	['N']	[27]
#4761
0	Gallstones	O	['N']	[0]
1	and	O	['N']	[1]
2	bile	B	['N']	[2]
3	sludge	I-Adverse_Effect	['N']	[3]
4	are	O	['N']	[4]
5	common	O	['N']	[5]
6	side	O	['N']	[6]
7	effects	O	['N']	[7]
8	of	O	['N']	[8]
9	octreotide	B-Drug	['Causes']	[3]
10	therapy	O	['N']	[10]
11	but	O	['N']	[11]
12	rarely	O	['N']	[12]
13	become	O	['N']	[13]
14	symptomatic	O	['N']	[14]
15	or	O	['N']	[15]
16	require	O	['N']	[16]
17	treatment	O	['N']	[17]
18	.	O	['N']	[18]
#4762
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	placed	O	['N']	[2]
3	on	O	['N']	[3]
4	adjuvant	O	['N']	[4]
5	Adriamycin	O	['N']	[5]
6	(	O	['N']	[6]
7	doxorubicin	B-Drug	['Causes']	[15]
8	)	O	['N']	[8]
9	chemotherapy	O	['N']	[9]
10	,	O	['N']	[10]
11	but	O	['N']	[11]
12	6	O	['N']	[12]
13	months	O	['N']	[13]
14	later	O	['N']	[14]
15	died	B-Adverse_Effect	['N']	[15]
16	of	O	['N']	[16]
17	Adriamycin	O	['N']	[17]
18	toxicity	O	['N']	[18]
19	.	O	['N']	[19]
#4763
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	M4	O	['N']	[5]
6	AML	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	standard	O	['N']	[9]
10	chemotherapy	O	['N']	[10]
11	followed	O	['N']	[11]
12	by	O	['N']	[12]
13	G	B	['N']	[13]
14	-	I	['N']	[14]
15	CSF	I-Drug	['Causes']	[19]
16	who	O	['N']	[16]
17	developed	O	['N']	[17]
18	marked	O	['N']	[18]
19	monocytosis	B-Adverse_Effect	['N']	[19]
20	on	O	['N']	[20]
21	day	O	['N']	[21]
22	8	O	['N']	[22]
23	of	O	['N']	[23]
24	G	O	['N']	[24]
25	-	O	['N']	[25]
26	CSF	O	['N']	[26]
27	therapy	O	['N']	[27]
28	.	O	['N']	[28]
#4764
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	,	O	['N']	[2]
3	to	O	['N']	[3]
4	the	O	['N']	[4]
5	best	O	['N']	[5]
6	of	O	['N']	[6]
7	our	O	['N']	[7]
8	knowledge	O	['N']	[8]
9	,	O	['N']	[9]
10	the	O	['N']	[10]
11	first	O	['N']	[11]
12	report	O	['N']	[12]
13	of	O	['N']	[13]
14	a	O	['N']	[14]
15	case	O	['N']	[15]
16	in	O	['N']	[16]
17	which	O	['N']	[17]
18	agranulocytosis	B-Adverse_Effect	['N']	[18]
19	followed	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	both	O	['N']	[22]
23	propylthiouracil	O	['N']	[23]
24	and	O	['N']	[24]
25	methimazole	B-Drug	['Causes']	[18]
26	in	O	['N']	[26]
27	the	O	['N']	[27]
28	same	O	['N']	[28]
29	patient	O	['N']	[29]
30	.	O	['N']	[30]
#4765
0	Cystoid	B	['N']	[0]
1	macular	I	['N']	[1]
2	edema	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	low	O	['N']	[5]
6	-	O	['N']	[6]
7	risk	O	['N']	[7]
8	patient	O	['N']	[8]
9	after	O	['N']	[9]
10	switching	O	['N']	[10]
11	from	O	['N']	[11]
12	latanoprost	B-Drug	['Causes']	[2]
13	to	O	['N']	[13]
14	bimatoprost	O	['N']	[14]
15	.	O	['N']	[15]
#4766
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	Colchicine	B-Drug	['Causes']	[15]
3	,	O	['N']	[3]
4	the	O	['N']	[4]
5	most	O	['N']	[5]
6	important	O	['N']	[6]
7	drug	O	['N']	[7]
8	in	O	['N']	[8]
9	treatment	O	['N']	[9]
10	of	O	['N']	[10]
11	FMF	O	['N']	[11]
12	,	O	['N']	[12]
13	can	O	['N']	[13]
14	cause	O	['N']	[14]
15	myopathy	B-Adverse_Effect	['N']	[15]
16	in	O	['N']	[16]
17	patients	O	['N']	[17]
18	with	O	['N']	[18]
19	impaired	O	['N']	[19]
20	renal	O	['N']	[20]
21	and	O	['N']	[21]
22	hepatic	O	['N']	[22]
23	function	O	['N']	[23]
24	.	O	['N']	[24]
#4767
0	Transient	O	['N']	[0]
1	phenytoin	B-Drug	['Causes']	[8]
2	induced	O	['N']	[2]
3	IgA	O	['N']	[3]
4	deficiency	O	['N']	[4]
5	and	O	['N']	[5]
6	permanent	O	['N']	[6]
7	IgE	B	['N']	[7]
8	increase	I-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#4768
0	The	O	['N']	[0]
1	cases	O	['N']	[1]
2	of	O	['N']	[2]
3	CBZ	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	SLE	B-Adverse_Effect	['N']	[6]
7	reported	O	['N']	[7]
8	in	O	['N']	[8]
9	the	O	['N']	[9]
10	literature	O	['N']	[10]
11	were	O	['N']	[11]
12	reviewed	O	['N']	[12]
13	.	O	['N']	[13]
#4769
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	is	O	['N']	[2]
3	presented	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	72-year	O	['N']	[6]
7	-	O	['N']	[7]
8	old	O	['N']	[8]
9	man	O	['N']	[9]
10	with	O	['N']	[10]
11	hormone	O	['N']	[11]
12	-	O	['N']	[12]
13	refractory	O	['N']	[13]
14	prostate	O	['N']	[14]
15	cancer	O	['N']	[15]
16	and	O	['N']	[16]
17	weekly	O	['N']	[17]
18	administration	O	['N']	[18]
19	of	O	['N']	[19]
20	30	O	['N']	[20]
21	mg	O	['N']	[21]
22	/	O	['N']	[22]
23	m2	O	['N']	[23]
24	docetaxel	B-Drug	['Causes']	[33]
25	who	O	['N']	[25]
26	developed	O	['N']	[26]
27	subacute	B	['N']	[27]
28	interstitial	I	['N']	[28]
29	pneumonitis	I	['N']	[29]
30	-	I	['N']	[30]
31	related	I	['N']	[31]
32	pulmonary	I	['N']	[32]
33	fibrosis	I-Adverse_Effect	['N']	[33]
34	after	O	['N']	[34]
35	seven	O	['N']	[35]
36	doses	O	['N']	[36]
37	and	O	['N']	[37]
38	died	O	['N']	[38]
39	despite	O	['N']	[39]
40	mechanical	O	['N']	[40]
41	ventilation	O	['N']	[41]
42	and	O	['N']	[42]
43	high	O	['N']	[43]
44	-	O	['N']	[44]
45	dose	O	['N']	[45]
46	corticosteroid	O	['N']	[46]
47	treatment	O	['N']	[47]
48	.	O	['N']	[48]
#4770
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	study	O	['N']	[3]
4	therapy	O	['N']	[4]
5	with	O	['N']	[5]
6	indapamide	B-Drug	['Causes']	[9]
7	impairing	B	['N']	[7]
8	carbohydrate	I	['N']	[8]
9	metabolism	I-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	essential	O	['N']	[11]
12	hypertension	O	['N']	[12]
13	patients	O	['N']	[13]
14	and	O	['N']	[14]
15	achieve	O	['N']	[15]
16	earlier	O	['N']	[16]
17	prevention	O	['N']	[17]
18	,	O	['N']	[18]
19	diagnoses	O	['N']	[19]
20	and	O	['N']	[20]
21	treatment	O	['N']	[21]
22	of	O	['N']	[22]
23	diabetes	O	['N']	[23]
24	induced	O	['N']	[24]
25	by	O	['N']	[25]
26	indapamide	O	['N']	[26]
27	.	O	['N']	[27]
#4771
0	Acute	B	['N']	[0]
1	renal	I	['N']	[1]
2	failure	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	patient	O	['N']	[5]
6	treated	O	['N']	[6]
7	by	O	['N']	[7]
8	continuous	O	['N']	[8]
9	povidone	O	['N']	[9]
10	-	O	['N']	[10]
11	iodine	B-Drug	['Causes']	[2]
12	mediastinal	O	['N']	[12]
13	irrigation	O	['N']	[13]
14	.	O	['N']	[14]
#4772
0	The	O	['N']	[0]
1	case	O	['N']	[1]
2	history	O	['N']	[2]
3	and	O	['N']	[3]
4	toxicological	O	['N']	[4]
5	findings	O	['N']	[5]
6	of	O	['N']	[6]
7	an	O	['N']	[7]
8	infant	O	['N']	[8]
9	fatality	B-Adverse_Effect	['N']	[9]
10	involving	O	['N']	[10]
11	pseudoephedrine	O	['N']	[11]
12	,	O	['N']	[12]
13	brompheniramine	B-Drug	['Causes']	[9]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	dextromethorphan	O	['N']	[16]
17	are	O	['N']	[17]
18	presented	O	['N']	[18]
19	.	O	['N']	[19]
#4773
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	inoperable	O	['N']	[5]
6	pancreatic	O	['N']	[6]
7	cancer	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	gastrointestinal	B	['N']	[10]
11	bleeding	I-Adverse_Effect	['N']	[11]
12	secondary	O	['N']	[12]
13	to	O	['N']	[13]
14	radiation	O	['N']	[14]
15	-	O	['N']	[15]
16	recall	O	['N']	[16]
17	related	O	['N']	[17]
18	to	O	['N']	[18]
19	gemcitabine	B-Drug	['Causes']	[11]
20	and	O	['N']	[20]
21	review	O	['N']	[21]
22	literature	O	['N']	[22]
23	.	O	['N']	[23]
#4774
0	He	O	['N']	[0]
1	became	O	['N']	[1]
2	hyperkalemic	B-Adverse_Effect	['N']	[2]
3	on	O	['N']	[3]
4	rechallenge	O	['N']	[4]
5	with	O	['N']	[5]
6	timolol	B-Drug	['Causes']	[2]
7	and	O	['N']	[7]
8	normokalemic	O	['N']	[8]
9	following	O	['N']	[9]
10	its	O	['N']	[10]
11	withdrawal	O	['N']	[11]
12	.	O	['N']	[12]
#4775
0	A	O	['N']	[0]
1	52-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	,	O	['N']	[4]
5	white	O	['N']	[5]
6	female	O	['N']	[6]
7	developed	O	['N']	[7]
8	low	O	['N']	[8]
9	-	O	['N']	[9]
10	grade	O	['N']	[10]
11	fever	O	['N']	[11]
12	,	O	['N']	[12]
13	cough	B-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	dyspnea	O	['N']	[16]
17	after	O	['N']	[17]
18	8	O	['N']	[18]
19	weeks	O	['N']	[19]
20	treatment	O	['N']	[20]
21	with	O	['N']	[21]
22	sodium	B	['N']	[22]
23	aurothiomalate	I-Drug	['Causes']	[13]
24	for	O	['N']	[24]
25	rheumatoid	O	['N']	[25]
26	arthritis	O	['N']	[26]
27	.	O	['N']	[27]
#4776
0	Cardiac	O	['N']	[0]
1	hypersensitivity	O	['N']	[1]
2	and	O	['N']	[2]
3	myopericarditis	B-Adverse_Effect	['N']	[3]
4	have	O	['N']	[4]
5	been	O	['N']	[5]
6	reported	O	['N']	[6]
7	during	O	['N']	[7]
8	long	O	['N']	[8]
9	-	O	['N']	[9]
10	term	O	['N']	[10]
11	treatment	O	['N']	[11]
12	with	O	['N']	[12]
13	mesalazine	B-Drug	['Causes']	[3]
14	.	O	['N']	[14]
#4777
0	We	O	['N']	[0]
1	experienced	O	['N']	[1]
2	2	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	mequitazine	B-Drug	['Causes']	[9]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	photosensitivity	B	['N']	[8]
9	reaction	I-Adverse_Effect	['N']	[9]
10	in	O	['N']	[10]
11	patients	O	['N']	[11]
12	who	O	['N']	[12]
13	took	O	['N']	[13]
14	mequitazine	O	['N']	[14]
15	for	O	['N']	[15]
16	their	O	['N']	[16]
17	dermatologic	O	['N']	[17]
18	problems	O	['N']	[18]
19	.	O	['N']	[19]
#4778
0	These	O	['N']	[0]
1	results	O	['N']	[1]
2	indicate	O	['N']	[2]
3	that	O	['N']	[3]
4	lithium	B-Drug	['Causes']	[8]
5	may	O	['N']	[5]
6	cause	O	['N']	[6]
7	biochemical	B	['N']	[7]
8	hyperparathyroidism	I-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#4779
0	This	O	['N']	[0]
1	represents	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	nonconvulsive	B	['N']	[6]
7	status	I	['N']	[7]
8	epilepticus	I-Adverse_Effect	['N']	[8]
9	induced	O	['N']	[9]
10	by	O	['N']	[10]
11	ifosfamide	B-Drug	['Causes']	[8]
12	.	O	['N']	[12]
#4780
0	CASES	O	['N']	[0]
1	:	O	['N']	[1]
2	"	O	['N']	[2]
3	A	O	['N']	[3]
4	"	O	['N']	[4]
5	was	O	['N']	[5]
6	an	O	['N']	[6]
7	8-year	O	['N']	[7]
8	-	O	['N']	[8]
9	old	O	['N']	[9]
10	boy	O	['N']	[10]
11	with	O	['N']	[11]
12	attention	O	['N']	[12]
13	deficit	O	['N']	[13]
14	and	O	['N']	[14]
15	chronic	O	['N']	[15]
16	tic	O	['N']	[16]
17	disorder	O	['N']	[17]
18	who	O	['N']	[18]
19	developed	O	['N']	[19]
20	obsessive	B	['N']	[20]
21	-	I	['N']	[21]
22	compulsive	I	['N']	[22]
23	symptoms	I-Adverse_Effect	['N']	[23]
24	within	O	['N']	[24]
25	2	O	['N']	[25]
26	weeks	O	['N']	[26]
27	of	O	['N']	[27]
28	starting	O	['N']	[28]
29	risperidone	B-Drug	['Causes']	[23]
30	.	O	['N']	[30]
#4781
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	valproate	B-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	hyperammonemia	B-Adverse_Effect	['N']	[6]
7	and	O	['N']	[7]
8	mental	O	['N']	[8]
9	status	O	['N']	[9]
10	changes	O	['N']	[10]
11	in	O	['N']	[11]
12	an	O	['N']	[12]
13	88-year	O	['N']	[13]
14	-	O	['N']	[14]
15	old	O	['N']	[15]
16	man	O	['N']	[16]
17	,	O	['N']	[17]
18	the	O	['N']	[18]
19	first	O	['N']	[19]
20	known	O	['N']	[20]
21	reported	O	['N']	[21]
22	case	O	['N']	[22]
23	in	O	['N']	[23]
24	an	O	['N']	[24]
25	elderly	O	['N']	[25]
26	patient	O	['N']	[26]
27	.	O	['N']	[27]
#4782
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	,	O	['N']	[3]
4	we	O	['N']	[4]
5	describe	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	receiving	O	['N']	[8]
9	lenalidomide	B-Drug	['Causes']	[14]
10	in	O	['N']	[10]
11	whom	O	['N']	[11]
12	dyspnea	O	['N']	[12]
13	,	O	['N']	[13]
14	fever	B-Adverse_Effect	['N']	[14]
15	,	O	['N']	[15]
16	hypoxia	O	['N']	[16]
17	,	O	['N']	[17]
18	and	O	['N']	[18]
19	diffuse	O	['N']	[19]
20	pulmonary	O	['N']	[20]
21	infiltrates	O	['N']	[21]
22	developed	O	['N']	[22]
23	.	O	['N']	[23]
#4783
0	Adrenal	B	['N']	[0]
1	suppression	I	['N']	[1]
2	in	I	['N']	[2]
3	a	I	['N']	[3]
4	fetus	I-Adverse_Effect	['N']	[4]
5	due	O	['N']	[5]
6	to	O	['N']	[6]
7	administration	O	['N']	[7]
8	of	O	['N']	[8]
9	methylprednisolone	B-Drug	['Causes']	[4]
10	has	O	['N']	[10]
11	hitherto	O	['N']	[11]
12	been	O	['N']	[12]
13	rarely	O	['N']	[13]
14	published	O	['N']	[14]
15	.	O	['N']	[15]
#4784
0	Although	O	['N']	[0]
1	major	O	['N']	[1]
2	hazards	O	['N']	[2]
3	of	O	['N']	[3]
4	treatment	O	['N']	[4]
5	of	O	['N']	[5]
6	hypophosphatemic	-	['N']	[6]
7	osteomalacia	O	['N']	[7]
8	with	O	['N']	[8]
9	phosphate	O	['N']	[9]
10	and	O	['N']	[10]
11	calcitriol	O	['N']	[11]
12	are	O	['N']	[12]
13	secondary	B	['N']	[13]
14	hyperparathyroidism	I-Adverse_Effect	['N']	[14]
15	and	O	['N']	[15]
16	vitamin	O	['N']	[16]
17	D	O	['N']	[17]
18	intoxication	O	['N']	[18]
19	,	O	['N']	[19]
20	potassium	O	['N']	[20]
21	loss	O	['N']	[21]
22	also	O	['N']	[22]
23	should	O	['N']	[23]
24	be	O	['N']	[24]
25	kept	O	['N']	[25]
26	in	O	['N']	[26]
27	mind	O	['N']	[27]
28	.	O	['N']	[28]
#4785
0	Methotrexate	B-Drug	['Causes']	[6]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	diffuse	B	['N']	[3]
4	interstitial	I	['N']	[4]
5	pulmonary	I	['N']	[5]
6	fibrosis	I-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#4786
0	Transient	B	['N']	[0]
1	central	I	['N']	[1]
2	diabetes	I	['N']	[2]
3	insipidus	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	the	O	['N']	[5]
6	setting	O	['N']	[6]
7	of	O	['N']	[7]
8	underlying	O	['N']	[8]
9	chronic	O	['N']	[9]
10	nephrogenic	O	['N']	[10]
11	diabetes	O	['N']	[11]
12	insipidus	O	['N']	[12]
13	associated	O	['N']	[13]
14	with	O	['N']	[14]
15	lithium	B-Drug	['Causes']	[3]
16	use	O	['N']	[16]
17	.	O	['N']	[17]
#4787
0	Less	O	['N']	[0]
1	common	O	['N']	[1]
2	adverse	O	['N']	[2]
3	events	O	['N']	[3]
4	to	O	['N']	[4]
5	dapsone	B-Drug	['Causes']	[39]
6	include	O	['N']	[6]
7	the	O	['N']	[7]
8	idiosyncratic	O	['N']	[8]
9	reactions	O	['N']	[9]
10	of	O	['N']	[10]
11	leukopenia	O	['N']	[11]
12	and	O	['N']	[12]
13	agranulocytosis	O	['N']	[13]
14	,	O	['N']	[14]
15	cutaneous	O	['N']	[15]
16	eruptions	O	['N']	[16]
17	,	O	['N']	[17]
18	peripheral	O	['N']	[18]
19	neuropathy	O	['N']	[19]
20	,	O	['N']	[20]
21	psychosis	O	['N']	[21]
22	,	O	['N']	[22]
23	toxic	O	['N']	[23]
24	hepatitis	O	['N']	[24]
25	,	O	['N']	[25]
26	cholestatic	O	['N']	[26]
27	jaundice	O	['N']	[27]
28	,	O	['N']	[28]
29	nephrotic	O	['N']	[29]
30	syndrome	O	['N']	[30]
31	,	O	['N']	[31]
32	renal	O	['N']	[32]
33	papillary	O	['N']	[33]
34	necrosis	O	['N']	[34]
35	,	O	['N']	[35]
36	severe	B	['N']	[36]
37	hypoalbuminemia	I	['N']	[37]
38	without	I	['N']	[38]
39	proteinuria	I-Adverse_Effect	['N']	[39]
40	,	O	['N']	[40]
41	an	O	['N']	[41]
42	infectious	O	['N']	[42]
43	mononucleosis	O	['N']	[43]
44	-	O	['N']	[44]
45	like	O	['N']	[45]
46	syndrome	O	['N']	[46]
47	,	O	['N']	[47]
48	and	O	['N']	[48]
49	minor	O	['N']	[49]
50	neurological	O	['N']	[50]
51	and	O	['N']	[51]
52	gastrointestinal	O	['N']	[52]
53	complaints	O	['N']	[53]
54	.	O	['N']	[54]
#4788
0	CASE	O	['N']	[0]
1	REPORT	O	['N']	[1]
2	:	O	['N']	[2]
3	We	O	['N']	[3]
4	hereby	O	['N']	[4]
5	report	O	['N']	[5]
6	a	O	['N']	[6]
7	case	O	['N']	[7]
8	of	O	['N']	[8]
9	radiation	B	['N']	[9]
10	recall	I	['N']	[10]
11	dermatitis	I-Adverse_Effect	['N']	[11]
12	and	O	['N']	[12]
13	myositis	O	['N']	[13]
14	occurring	O	['N']	[14]
15	on	O	['N']	[15]
16	gemcitabine	B-Drug	['Causes']	[11]
17	monotherapy	O	['N']	[17]
18	,	O	['N']	[18]
19	five	O	['N']	[19]
20	months	O	['N']	[20]
21	after	O	['N']	[21]
22	completing	O	['N']	[22]
23	chemoradiation	O	['N']	[23]
24	for	O	['N']	[24]
25	locally	O	['N']	[25]
26	advanced	O	['N']	[26]
27	pancreatic	O	['N']	[27]
28	cancer	O	['N']	[28]
29	.	O	['N']	[29]
#4789
0	Acute	B	['N']	[0]
1	generalized	I	['N']	[1]
2	exanthematous	I	['N']	[2]
3	pustulosis	I-Adverse_Effect	['N']	[3]
4	induced	O	['N']	[4]
5	by	O	['N']	[5]
6	nimesulide	B-Drug	['Causes']	[3]
7	.	O	['N']	[7]
#4790
0	Complications	O	['N']	[0]
1	associated	O	['N']	[1]
2	with	O	['N']	[2]
3	primary	B	['N']	[3]
4	and	I	['N']	[4]
5	secondary	I	['N']	[5]
6	perforation	I	['N']	[6]
7	of	I	['N']	[7]
8	the	I	['N']	[8]
9	bladder	I-Adverse_Effect	['N']	[9]
10	following	O	['N']	[10]
11	immediate	O	['N']	[11]
12	instillations	O	['N']	[12]
13	of	O	['N']	[13]
14	epirubicin	B-Drug	['Causes']	[9]
15	after	O	['N']	[15]
16	transurethral	O	['N']	[16]
17	resection	O	['N']	[17]
18	of	O	['N']	[18]
19	superficial	O	['N']	[19]
20	urothelial	O	['N']	[20]
21	tumours	O	['N']	[21]
22	.	O	['N']	[22]
#4791
0	Methotrexate	B-Drug	['Causes']	[32]
1	(	O	['N']	[1]
2	MTX	O	['N']	[2]
3	)	O	['N']	[3]
4	is	O	['N']	[4]
5	a	O	['N']	[5]
6	commonly	O	['N']	[6]
7	used	O	['N']	[7]
8	second	O	['N']	[8]
9	line	O	['N']	[9]
10	agent	O	['N']	[10]
11	for	O	['N']	[11]
12	RA	O	['N']	[12]
13	,	O	['N']	[13]
14	and	O	['N']	[14]
15	there	O	['N']	[15]
16	have	O	['N']	[16]
17	been	O	['N']	[17]
18	several	O	['N']	[18]
19	recent	O	['N']	[19]
20	reports	O	['N']	[20]
21	of	O	['N']	[21]
22	Epstein	B	['N']	[22]
23	-	I	['N']	[23]
24	Barr	I	['N']	[24]
25	virus	I	['N']	[25]
26	(	I	['N']	[26]
27	EBV)-associated	I	['N']	[27]
28	polyclonal	I	['N']	[28]
29	B	I	['N']	[29]
30	cell	I	['N']	[30]
31	lymphoproliferative	I	['N']	[31]
32	disorder	I-Adverse_Effect	['N']	[32]
33	in	O	['N']	[33]
34	MTX	O	['N']	[34]
35	-	O	['N']	[35]
36	treated	O	['N']	[36]
37	RA	O	['N']	[37]
38	patients	O	['N']	[38]
39	.	O	['N']	[39]
#4792
0	To	O	['N']	[0]
1	the	O	['N']	[1]
2	best	O	['N']	[2]
3	of	O	['N']	[3]
4	our	O	['N']	[4]
5	knowledge	O	['N']	[5]
6	,	O	['N']	[6]
7	this	O	['N']	[7]
8	is	O	['N']	[8]
9	the	O	['N']	[9]
10	first	O	['N']	[10]
11	case	O	['N']	[11]
12	of	O	['N']	[12]
13	lithium	B-Drug	['Causes']	[16]
14	-	O	['N']	[14]
15	associated	O	['N']	[15]
16	CDI	B-Adverse_Effect	['N']	[16]
17	and	O	['N']	[17]
18	NDI	O	['N']	[18]
19	presenting	O	['N']	[19]
20	concurrently	O	['N']	[20]
21	.	O	['N']	[21]
#4793
0	Despite	O	['N']	[0]
1	the	O	['N']	[1]
2	low	O	['N']	[2]
3	dosage	O	['N']	[3]
4	of	O	['N']	[4]
5	warfarin	B-Drug	['Causes']	[27]
6	,	O	['N']	[6]
7	international	O	['N']	[7]
8	normalized	O	['N']	[8]
9	ratio	O	['N']	[9]
10	(	O	['N']	[10]
11	INR	O	['N']	[11]
12	)	O	['N']	[12]
13	was	O	['N']	[13]
14	markedly	O	['N']	[14]
15	elevated	O	['N']	[15]
16	from	O	['N']	[16]
17	1.15	O	['N']	[17]
18	to	O	['N']	[18]
19	11.28	O	['N']	[19]
20	for	O	['N']	[20]
21	only	O	['N']	[21]
22	4	O	['N']	[22]
23	days	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	bleeding	B	['N']	[26]
27	symptoms	I-Adverse_Effect	['N']	[27]
28	concurrently	O	['N']	[28]
29	developed	O	['N']	[29]
30	.	O	['N']	[30]
#4794
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	multiple	O	['N']	[8]
9	myeloma	O	['N']	[9]
10	who	O	['N']	[10]
11	developed	O	['N']	[11]
12	acute	O	['N']	[12]
13	life	O	['N']	[13]
14	-	O	['N']	[14]
15	threatening	O	['N']	[15]
16	water	O	['N']	[16]
17	intoxication	O	['N']	[17]
18	following	O	['N']	[18]
19	treatment	O	['N']	[19]
20	with	O	['N']	[20]
21	oral	O	['N']	[21]
22	indomethacin	B-Drug	['Dosage']	[25]
23	and	O	['N']	[23]
24	low	B	['N']	[24]
25	dose	I-Dose	['N']	[25]
26	intravenous	O	['N']	[26]
27	cyclophosphamide	O	['N']	[27]
28	.	O	['N']	[28]
#4795
0	Two	O	['N']	[0]
1	patients	O	['N']	[1]
2	with	O	['N']	[2]
3	ovarian	O	['N']	[3]
4	cancer	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	received	O	['N']	[7]
8	multiple	O	['N']	[8]
9	courses	O	['N']	[9]
10	of	O	['N']	[10]
11	cisplatin	B-Drug	['Causes']	[34]
12	without	O	['N']	[12]
13	complications	O	['N']	[13]
14	experienced	O	['N']	[14]
15	hypersensitivity	O	['N']	[15]
16	reactions	O	['N']	[16]
17	to	O	['N']	[17]
18	cisplatin	O	['N']	[18]
19	:	O	['N']	[19]
20	one	O	['N']	[20]
21	,	O	['N']	[21]
22	involving	O	['N']	[22]
23	intrahepatic	O	['N']	[23]
24	artery	O	['N']	[24]
25	infusion	O	['N']	[25]
26	,	O	['N']	[26]
27	manifested	O	['N']	[27]
28	general	O	['N']	[28]
29	erythema	O	['N']	[29]
30	,	O	['N']	[30]
31	dyspnea	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	hypotension	B-Adverse_Effect	['N']	[34]
35	;	O	['N']	[35]
36	the	O	['N']	[36]
37	other	O	['N']	[37]
38	,	O	['N']	[38]
39	involving	O	['N']	[39]
40	intravenous	O	['N']	[40]
41	infusion	O	['N']	[41]
42	,	O	['N']	[42]
43	manifested	O	['N']	[43]
44	abdominal	O	['N']	[44]
45	pain	O	['N']	[45]
46	,	O	['N']	[46]
47	general	O	['N']	[47]
48	erythema	O	['N']	[48]
49	,	O	['N']	[49]
50	and	O	['N']	[50]
51	fever	O	['N']	[51]
52	.	O	['N']	[52]
#4796
0	Acute	B	['N']	[0]
1	coronary	I	['N']	[1]
2	syndromes	I-Adverse_Effect	['N']	[2]
3	complicating	O	['N']	[3]
4	the	O	['N']	[4]
5	first	O	['N']	[5]
6	infusion	O	['N']	[6]
7	of	O	['N']	[7]
8	rituximab	B-Drug	['Causes']	[2]
9	.	O	['N']	[9]
#4797
0	In	O	['N']	[0]
1	one	O	['N']	[1]
2	instance	O	['N']	[2]
3	a	O	['N']	[3]
4	systemic	B	['N']	[4]
5	hypoglycemic	I	['N']	[5]
6	reaction	I-Adverse_Effect	['N']	[6]
7	resulting	O	['N']	[7]
8	in	O	['N']	[8]
9	head	O	['N']	[9]
10	trauma	O	['N']	[10]
11	and	O	['N']	[11]
12	confusion	O	['N']	[12]
13	ended	O	['N']	[13]
14	in	O	['N']	[14]
15	an	O	['N']	[15]
16	emegency	O	['N']	[16]
17	hospital	O	['N']	[17]
18	admission	O	['N']	[18]
19	following	O	['N']	[19]
20	the	O	['N']	[20]
21	substitution	O	['N']	[21]
22	of	O	['N']	[22]
23	acetohexamide	B-Drug	['Causes']	[6]
24	for	O	['N']	[24]
25	acetazolamide	O	['N']	[25]
26	.	O	['N']	[26]
#4798
0	The	O	['N']	[0]
1	administration	O	['N']	[1]
2	of	O	['N']	[2]
3	"	O	['N']	[3]
4	sweet	O	['N']	[4]
5	spirits	O	['N']	[5]
6	of	O	['N']	[6]
7	nitre	O	['N']	[7]
8	"	O	['N']	[8]
9	(	O	['N']	[9]
10	4	B	['N']	[10]
11	%	I	['N']	[11]
12	ethyl	I	['N']	[12]
13	nitrite	I	['N']	[13]
14	CH3CH2ONO	I	['N']	[14]
15	in	I	['N']	[15]
16	70	I	['N']	[16]
17	%	I	['N']	[17]
18	ethyl	I	['N']	[18]
19	alcohol	I-Drug	['Causes']	[30]
20	)	O	['N']	[20]
21	was	O	['N']	[21]
22	followed	O	['N']	[22]
23	by	O	['N']	[23]
24	acute	O	['N']	[24]
25	methemoglobinemia	O	['N']	[25]
26	and	O	['N']	[26]
27	severe	B	['N']	[27]
28	anoxic	I	['N']	[28]
29	metabolic	I	['N']	[29]
30	acidosis	I-Adverse_Effect	['N']	[30]
31	in	O	['N']	[31]
32	infant	O	['N']	[32]
33	twins	O	['N']	[33]
34	,	O	['N']	[34]
35	Methylene	O	['N']	[35]
36	blue	O	['N']	[36]
37	administration	O	['N']	[37]
38	reversed	O	['N']	[38]
39	methemoglobinemia	O	['N']	[39]
40	in	O	['N']	[40]
41	both	O	['N']	[41]
42	,	O	['N']	[42]
43	but	O	['N']	[43]
44	one	O	['N']	[44]
45	twin	O	['N']	[45]
46	died	O	['N']	[46]
47	from	O	['N']	[47]
48	the	O	['N']	[48]
49	consequences	O	['N']	[49]
50	of	O	['N']	[50]
51	hypoxemia	O	['N']	[51]
52	.	O	['N']	[52]
#4799
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	on	O	['N']	[4]
5	the	O	['N']	[5]
6	possible	O	['N']	[6]
7	development	O	['N']	[7]
8	of	O	['N']	[8]
9	serotonin	B	['N']	[9]
10	syndrome	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	receiving	O	['N']	[14]
15	clomipramine	B-Drug	['Causes']	[10]
16	after	O	['N']	[16]
17	clozapine	O	['N']	[17]
18	was	O	['N']	[18]
19	withdrawn	O	['N']	[19]
20	from	O	['N']	[20]
21	the	O	['N']	[21]
22	treatment	O	['N']	[22]
23	regimen	O	['N']	[23]
24	.	O	['N']	[24]
#4800
0	Rifampicin	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	adrenal	B	['N']	[3]
4	insufficiency	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	the	O	['N']	[6]
7	acquired	O	['N']	[7]
8	immunodeficiency	O	['N']	[8]
9	syndrome	O	['N']	[9]
10	:	O	['N']	[10]
11	difficulties	O	['N']	[11]
12	in	O	['N']	[12]
13	diagnosis	O	['N']	[13]
14	and	O	['N']	[14]
15	treatment	O	['N']	[15]
16	.	O	['N']	[16]
#4801
0	Ethambutol	B-Drug	['Causes']	[6]
1	toxicity	O	['N']	[1]
2	manifesting	O	['N']	[2]
3	as	O	['N']	[3]
4	acute	B	['N']	[4]
5	onset	I	['N']	[5]
6	psychosis	I-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#4802
0	Rapamycin	B-Drug	['Causes']	[29]
1	/	O	['N']	[1]
2	sirolimus	O	['N']	[2]
3	(	O	['N']	[3]
4	SR	O	['N']	[4]
5	)	O	['N']	[5]
6	,	O	['N']	[6]
7	trade	O	['N']	[7]
8	named	O	['N']	[8]
9	Rapammune	O	['N']	[9]
10	(	O	['N']	[10]
11	Wyeth	O	['N']	[11]
12	-	O	['N']	[12]
13	Ayerst	O	['N']	[13]
14	,	O	['N']	[14]
15	Sydney	O	['N']	[15]
16	,	O	['N']	[16]
17	Australia	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	is	O	['N']	[20]
21	a	O	['N']	[21]
22	potent	O	['N']	[22]
23	immunosuppressive	O	['N']	[23]
24	drug	O	['N']	[24]
25	associated	O	['N']	[25]
26	with	O	['N']	[26]
27	myelosuppression	O	['N']	[27]
28	,	O	['N']	[28]
29	hypertension	B-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	hyperlipidemia	O	['N']	[31]
32	,	O	['N']	[32]
33	and	O	['N']	[33]
34	infection	O	['N']	[34]
35	.	O	['N']	[35]
#4803
0	Although	O	['N']	[0]
1	tardive	B	['N']	[1]
2	dyskinesia	I-Adverse_Effect	['N']	[2]
3	is	O	['N']	[3]
4	a	O	['N']	[4]
5	known	O	['N']	[5]
6	adverse	O	['N']	[6]
7	reaction	O	['N']	[7]
8	of	O	['N']	[8]
9	sustained	O	['N']	[9]
10	treatment	O	['N']	[10]
11	with	O	['N']	[11]
12	traditional	O	['N']	[12]
13	neuroleptic	O	['N']	[13]
14	agents	O	['N']	[14]
15	,	O	['N']	[15]
16	it	O	['N']	[16]
17	was	O	['N']	[17]
18	only	O	['N']	[18]
19	rarely	O	['N']	[19]
20	reported	O	['N']	[20]
21	in	O	['N']	[21]
22	association	O	['N']	[22]
23	with	O	['N']	[23]
24	sulpiride	B-Drug	['Causes']	[2]
25	,	O	['N']	[25]
26	a	O	['N']	[26]
27	selective	O	['N']	[27]
28	D2-receptor	O	['N']	[28]
29	antagonist	O	['N']	[29]
30	.	O	['N']	[30]
#4804
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	3	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	HIV-1	O	['N']	[5]
6	infected	O	['N']	[6]
7	patients	O	['N']	[7]
8	who	O	['N']	[8]
9	experienced	O	['N']	[9]
10	symptomatic	O	['N']	[10]
11	angiolipomas	B-Adverse_Effect	['N']	[11]
12	shortly	O	['N']	[12]
13	after	O	['N']	[13]
14	starting	O	['N']	[14]
15	antiretroviral	O	['N']	[15]
16	therapy	O	['N']	[16]
17	including	O	['N']	[17]
18	the	O	['N']	[18]
19	protease	O	['N']	[19]
20	inhibitor	O	['N']	[20]
21	indinavir	B-Drug	['Causes']	[11]
22	.	O	['N']	[22]
#4805
0	In	O	['N']	[0]
1	four	O	['N']	[1]
2	patients	O	['N']	[2]
3	,	O	['N']	[3]
4	thrombosis	O	['N']	[4]
5	occurred	O	['N']	[5]
6	2	O	['N']	[6]
7	-	O	['N']	[7]
8	45	O	['N']	[8]
9	days	O	['N']	[9]
10	after	O	['N']	[10]
11	severe	O	['N']	[11]
12	hepatic	B	['N']	[12]
13	veno	I	['N']	[13]
14	-	I	['N']	[14]
15	occlusive	I	['N']	[15]
16	disease	I-Adverse_Effect	['N']	[16]
17	(	O	['N']	[17]
18	HVOD	O	['N']	[18]
19	)	O	['N']	[19]
20	secondary	O	['N']	[20]
21	to	O	['N']	[21]
22	intensive	O	['N']	[22]
23	chemotherapy	O	['N']	[23]
24	containing	O	['N']	[24]
25	busulfan	B-Drug	['Causes']	[16]
26	.	O	['N']	[26]
#4806
0	Case	O	['N']	[0]
1	report	O	['N']	[1]
2	:	O	['N']	[2]
3	acute	B	['N']	[3]
4	renal	I	['N']	[4]
5	failure	I-Adverse_Effect	['N']	[5]
6	after	O	['N']	[6]
7	administering	O	['N']	[7]
8	intravenous	O	['N']	[8]
9	immunoglobulin	B-Drug	['Causes']	[5]
10	.	O	['N']	[10]
#4807
0	A	O	['N']	[0]
1	17-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	with	O	['N']	[5]
6	acute	O	['N']	[6]
7	lymphoblastic	O	['N']	[7]
8	leukemia	O	['N']	[8]
9	developed	O	['N']	[9]
10	acute	O	['N']	[10]
11	renal	O	['N']	[11]
12	failure	O	['N']	[12]
13	within	O	['N']	[13]
14	48	O	['N']	[14]
15	h	O	['N']	[15]
16	of	O	['N']	[16]
17	an	O	['N']	[17]
18	intravenous	O	['N']	[18]
19	high	B	['N']	[19]
20	-	I	['N']	[20]
21	dose	I-Dose	['N']	[21]
22	methotrexate	B-Drug	['Dosage']	[21]
23	(	O	['N']	[23]
24	5	O	['N']	[24]
25	g	O	['N']	[25]
26	/	O	['N']	[26]
27	m2	O	['N']	[27]
28	)	O	['N']	[28]
29	infusion	O	['N']	[29]
30	.	O	['N']	[30]
#4808
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	report	O	['N']	[4]
5	of	O	['N']	[5]
6	a	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	alveolar	O	['N']	[9]
10	hydatid	O	['N']	[10]
11	disease	O	['N']	[11]
12	,	O	['N']	[12]
13	whose	O	['N']	[13]
14	treatment	O	['N']	[14]
15	with	O	['N']	[15]
16	mebendazole	B-Drug	['Causes']	[26]
17	was	O	['N']	[17]
18	brief	O	['N']	[18]
19	due	O	['N']	[19]
20	to	O	['N']	[20]
21	side	O	['N']	[21]
22	effects	O	['N']	[22]
23	of	O	['N']	[23]
24	alopecia	O	['N']	[24]
25	and	O	['N']	[25]
26	granulocytopenia	B-Adverse_Effect	['N']	[26]
27	;	O	['N']	[27]
28	and	O	['N']	[28]
29	review	O	['N']	[29]
30	the	O	['N']	[30]
31	features	O	['N']	[31]
32	of	O	['N']	[32]
33	this	O	['N']	[33]
34	disease	O	['N']	[34]
35	which	O	['N']	[35]
36	,	O	['N']	[36]
37	with	O	['N']	[37]
38	increasing	O	['N']	[38]
39	international	O	['N']	[39]
40	migration	O	['N']	[40]
41	,	O	['N']	[41]
42	may	O	['N']	[42]
43	be	O	['N']	[43]
44	encountered	O	['N']	[44]
45	more	O	['N']	[45]
46	frequently	O	['N']	[46]
47	in	O	['N']	[47]
48	Australia	O	['N']	[48]
49	.	O	['N']	[49]
#4809
0	She	O	['N']	[0]
1	was	O	['N']	[1]
2	thus	O	['N']	[2]
3	diagnosed	O	['N']	[3]
4	as	O	['N']	[4]
5	having	O	['N']	[5]
6	AZ	B-Drug	['Causes']	[7]
7	intoxication	I-Adverse_Effect	['N']	[7]
8	.	O	['N']	[8]
#4810
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	heroin	O	['N']	[3]
4	abuser	O	['N']	[4]
5	in	O	['N']	[5]
6	whom	O	['N']	[6]
7	clinical	O	['N']	[7]
8	and	O	['N']	[8]
9	laboratory	O	['N']	[9]
10	manifestations	O	['N']	[10]
11	of	O	['N']	[11]
12	acute	B	['N']	[12]
13	hepatitis	I	['N']	[13]
14	B	I	['N']	[14]
15	and	I	['N']	[15]
16	C	I-Adverse_Effect	['N']	[16]
17	appeared	O	['N']	[17]
18	a	O	['N']	[18]
19	few	O	['N']	[19]
20	days	O	['N']	[20]
21	after	O	['N']	[21]
22	the	O	['N']	[22]
23	insertion	O	['N']	[23]
24	of	O	['N']	[24]
25	a	O	['N']	[25]
26	subcutaneous	O	['N']	[26]
27	naltrexone	B-Drug	['Causes']	[16]
28	implant	O	['N']	[28]
29	.	O	['N']	[29]
#4811
0	Symptoms	O	['N']	[0]
1	and	O	['N']	[1]
2	signs	O	['N']	[2]
3	of	O	['N']	[3]
4	augmentation	B-Adverse_Effect	['N']	[4]
5	were	O	['N']	[5]
6	related	O	['N']	[6]
7	to	O	['N']	[7]
8	low	O	['N']	[8]
9	plasma	O	['N']	[9]
10	levodopa	B-Drug	['Causes']	[4]
11	levels	O	['N']	[11]
12	,	O	['N']	[12]
13	abating	O	['N']	[13]
14	75	O	['N']	[14]
15	minutes	O	['N']	[15]
16	after	O	['N']	[16]
17	oral	O	['N']	[17]
18	levodopa	O	['N']	[18]
19	administration	O	['N']	[19]
20	and	O	['N']	[20]
21	reappearing	O	['N']	[21]
22	after	O	['N']	[22]
23	3	O	['N']	[23]
24	hours	O	['N']	[24]
25	,	O	['N']	[25]
26	closely	O	['N']	[26]
27	mirroring	O	['N']	[27]
28	the	O	['N']	[28]
29	rapid	O	['N']	[29]
30	rise	O	['N']	[30]
31	and	O	['N']	[31]
32	fall	O	['N']	[32]
33	of	O	['N']	[33]
34	plasma	O	['N']	[34]
35	levodopa	O	['N']	[35]
36	concentration	O	['N']	[36]
37	.	O	['N']	[37]
#4812
0	Physicians	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	that	O	['N']	[4]
5	PLP	B-Adverse_Effect	['N']	[5]
6	can	O	['N']	[6]
7	occur	O	['N']	[7]
8	after	O	['N']	[8]
9	initiation	O	['N']	[9]
10	of	O	['N']	[10]
11	paclitaxel	B-Drug	['Causes']	[5]
12	.	O	['N']	[12]
#4813
0	It	O	['N']	[0]
1	was	O	['N']	[1]
2	hypothesized	O	['N']	[2]
3	that	O	['N']	[3]
4	valproic	O	['N']	[4]
5	acid	O	['N']	[5]
6	may	O	['N']	[6]
7	interfere	O	['N']	[7]
8	with	O	['N']	[8]
9	glucuronidation	O	['N']	[9]
10	of	O	['N']	[10]
11	lamotrigine	B-Drug	['Causes']	[35]
12	,	O	['N']	[12]
13	leading	O	['N']	[13]
14	to	O	['N']	[14]
15	increased	O	['N']	[15]
16	serum	O	['N']	[16]
17	lamotrigine	O	['N']	[17]
18	levels	O	['N']	[18]
19	,	O	['N']	[19]
20	or	O	['N']	[20]
21	perhaps	O	['N']	[21]
22	alter	O	['N']	[22]
23	the	O	['N']	[23]
24	drug	O	['N']	[24]
25	's	O	['N']	[25]
26	metabolism	O	['N']	[26]
27	,	O	['N']	[27]
28	resulting	O	['N']	[28]
29	in	O	['N']	[29]
30	accumulation	B	['N']	[30]
31	of	I	['N']	[31]
32	a	I	['N']	[32]
33	toxic	I	['N']	[33]
34	intermediate	I	['N']	[34]
35	metabolite	I-Adverse_Effect	['N']	[35]
36	.	O	['N']	[36]
#4814
0	A	O	['N']	[0]
1	short	O	['N']	[1]
2	review	O	['N']	[2]
3	on	O	['N']	[3]
4	imatinib	B-Drug	['Causes']	[7]
5	-	O	['N']	[5]
6	related	O	['N']	[6]
7	hepatotoxicity	B-Adverse_Effect	['N']	[7]
8	is	O	['N']	[8]
9	also	O	['N']	[9]
10	presented	O	['N']	[10]
11	.	O	['N']	[11]
#4815
0	Continuous	O	['N']	[0]
1	EEG	O	['N']	[1]
2	monitoring	O	['N']	[2]
3	is	O	['N']	[3]
4	helpful	O	['N']	[4]
5	in	O	['N']	[5]
6	managing	O	['N']	[6]
7	seizures	O	['N']	[7]
8	that	O	['N']	[8]
9	occur	O	['N']	[9]
10	as	O	['N']	[10]
11	a	O	['N']	[11]
12	complication	O	['N']	[12]
13	of	O	['N']	[13]
14	CBZ	B-Drug	['Dosage']	[15]
15	OD	B-Dose	['N']	[15]
16	,	O	['N']	[16]
17	after	O	['N']	[17]
18	the	O	['N']	[18]
19	course	O	['N']	[19]
20	of	O	['N']	[20]
21	recovery	O	['N']	[21]
22	or	O	['N']	[22]
23	worsening	O	['N']	[23]
24	,	O	['N']	[24]
25	and	O	['N']	[25]
26	in	O	['N']	[26]
27	providing	O	['N']	[27]
28	assistance	O	['N']	[28]
29	with	O	['N']	[29]
30	prognosis	O	['N']	[30]
31	.	O	['N']	[31]
#4816
0	Anaphylactic	B	['N']	[0]
1	reaction	I-Adverse_Effect	['N']	[1]
2	to	O	['N']	[2]
3	recombinant	-	['N']	[3]
4	insulin	-	['N']	[4]
5	-	-	['N']	[5]
6	like	-	['N']	[6]
7	growth	-	['N']	[7]
8	factor	-	['N']	[8]
9	-	-	['N']	[9]
10	I.	-	['N']	[10]
#4817
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	phenobarbital	B-Drug	['Causes']	[9]
4	exacerbation	B	['N']	[4]
5	of	I	['N']	[5]
6	a	I	['N']	[6]
7	preexisting	I	['N']	[7]
8	maladaptive	I	['N']	[8]
9	behavior	I-Adverse_Effect	['N']	[9]
10	partially	O	['N']	[10]
11	suppressed	O	['N']	[11]
12	by	O	['N']	[12]
13	chlorpromazine	O	['N']	[13]
14	and	O	['N']	[14]
15	misinterpreted	O	['N']	[15]
16	as	O	['N']	[16]
17	chlorpromazine	O	['N']	[17]
18	efficacy	O	['N']	[18]
19	.	O	['N']	[19]
#4818
0	High	O	['N']	[0]
1	-	O	['N']	[1]
2	dose	O	['N']	[2]
3	intravenous	O	['N']	[3]
4	mannitol	B-Drug	['Causes']	[15]
5	infusion	O	['N']	[5]
6	in	O	['N']	[6]
7	various	O	['N']	[7]
8	clinical	O	['N']	[8]
9	settings	O	['N']	[9]
10	may	O	['N']	[10]
11	result	O	['N']	[11]
12	in	O	['N']	[12]
13	acute	B	['N']	[13]
14	renal	I	['N']	[14]
15	failure	I-Adverse_Effect	['N']	[15]
16	(	O	['N']	[16]
17	ARF	O	['N']	[17]
18	)	O	['N']	[18]
19	.	O	['N']	[19]
#4819
0	Ofloxacin	B-Drug	['Causes']	[8]
1	:	O	['N']	[1]
2	a	O	['N']	[2]
3	probable	O	['N']	[3]
4	cause	O	['N']	[4]
5	of	O	['N']	[5]
6	toxic	B	['N']	[6]
7	epidermal	I	['N']	[7]
8	necrolysis	I-Adverse_Effect	['N']	[8]
9	.	O	['N']	[9]
#4820
0	Vasomotor	B	['N']	[0]
1	reactions	I-Adverse_Effect	['N']	[1]
2	after	O	['N']	[2]
3	gold	B	['N']	[3]
4	sodium	I	['N']	[4]
5	thiomalate	I-Drug	['Causes']	[1]
6	are	O	['N']	[6]
7	well	O	['N']	[7]
8	recognized	O	['N']	[8]
9	.	O	['N']	[9]
#4821
0	Since	O	['N']	[0]
1	imiquimod	B-Drug	['Causes']	[9]
2	induces	O	['N']	[2]
3	large	B	['N']	[3]
4	amounts	I	['N']	[4]
5	of	I	['N']	[5]
6	type	I	['N']	[6]
7	I	I	['N']	[7]
8	interferon	I	['N']	[8]
9	production	I-Adverse_Effect	['N']	[9]
10	from	O	['N']	[10]
11	TLR7-expressing	O	['N']	[11]
12	plasmacytoid	O	['N']	[12]
13	dendritic	O	['N']	[13]
14	cell	O	['N']	[14]
15	precursors	O	['N']	[15]
16	(	O	['N']	[16]
17	PDCs	O	['N']	[17]
18	)	O	['N']	[18]
19	,	O	['N']	[19]
20	the	O	['N']	[20]
21	natural	O	['N']	[21]
22	interferon	O	['N']	[22]
23	-	O	['N']	[23]
24	producing	O	['N']	[24]
25	cells	O	['N']	[25]
26	of	O	['N']	[26]
27	the	O	['N']	[27]
28	peripheral	O	['N']	[28]
29	blood	O	['N']	[29]
30	,	O	['N']	[30]
31	we	O	['N']	[31]
32	asked	O	['N']	[32]
33	whether	O	['N']	[33]
34	PDCs	O	['N']	[34]
35	are	O	['N']	[35]
36	present	O	['N']	[36]
37	in	O	['N']	[37]
38	psoriatic	O	['N']	[38]
39	skin	O	['N']	[39]
40	.	O	['N']	[40]
#4822
0	Hydroxyurea	B-Drug	['Causes']	[16]
1	(	O	['N']	[1]
2	HU	O	['N']	[2]
3	)	O	['N']	[3]
4	and	O	['N']	[4]
5	sodium	O	['N']	[5]
6	phenylbutyrate	O	['N']	[6]
7	(	O	['N']	[7]
8	SPB	O	['N']	[8]
9	)	O	['N']	[9]
10	have	O	['N']	[10]
11	been	O	['N']	[11]
12	shown	O	['N']	[12]
13	to	O	['N']	[13]
14	increase	B	['N']	[14]
15	fetal	I	['N']	[15]
16	hemoglobin	I-Adverse_Effect	['N']	[16]
17	(	O	['N']	[17]
18	Hb	O	['N']	[18]
19	F	O	['N']	[19]
20	)	O	['N']	[20]
21	levels	O	['N']	[21]
22	in	O	['N']	[22]
23	patients	O	['N']	[23]
24	with	O	['N']	[24]
25	thalassemia	O	['N']	[25]
26	intermedia	O	['N']	[26]
27	.	O	['N']	[27]
#4823
0	When	O	['N']	[0]
1	the	O	['N']	[1]
2	patient	O	['N']	[2]
3	was	O	['N']	[3]
4	treated	O	['N']	[4]
5	again	O	['N']	[5]
6	with	O	['N']	[6]
7	fludarabine	B-Drug	['Causes']	[24]
8	nine	O	['N']	[8]
9	months	O	['N']	[9]
10	later	O	['N']	[10]
11	,	O	['N']	[11]
12	the	O	['N']	[12]
13	DAT	B	['N']	[13]
14	became	I	['N']	[14]
15	positive	I	['N']	[15]
16	with	I	['N']	[16]
17	anti	I	['N']	[17]
18	-	I	['N']	[18]
19	IgG	I	['N']	[19]
20	and	I	['N']	[20]
21	anti	I	['N']	[21]
22	-	I	['N']	[22]
23	C3d	I	['N']	[23]
24	antiglobulins	I-Adverse_Effect	['N']	[24]
25	after	O	['N']	[25]
26	the	O	['N']	[26]
27	second	O	['N']	[27]
28	course	O	['N']	[28]
29	of	O	['N']	[29]
30	treatment	O	['N']	[30]
31	.	O	['N']	[31]
#4824
0	Pamidronate	O	['N']	[0]
1	therapy	O	['N']	[1]
2	should	O	['N']	[2]
3	be	O	['N']	[3]
4	considered	O	['N']	[4]
5	in	O	['N']	[5]
6	patients	O	['N']	[6]
7	with	O	['N']	[7]
8	hypercalcemia	O	['N']	[8]
9	secondary	O	['N']	[9]
10	to	O	['N']	[10]
11	acute	B	['N']	[11]
12	vitamin	B	['N']	[12]
13	D	I-Drug	['Causes']	[14]
14	poisoning	I-Adverse_Effect	['N']	[14]
15	.	O	['N']	[15]
#4825
0	Vanishing	O	['N']	[0]
1	bile	O	['N']	[1]
2	duct	O	['N']	[2]
3	and	O	['N']	[3]
4	Stevens	B	['N']	[4]
5	-	I	['N']	[5]
6	Johnson	I	['N']	[6]
7	syndrome	I-Adverse_Effect	['N']	[7]
8	associated	O	['N']	[8]
9	with	O	['N']	[9]
10	ciprofloxacin	B-Drug	['Causes']	[7]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	tacrolimus	O	['N']	[13]
14	.	O	['N']	[14]
#4826
0	Although	O	['N']	[0]
1	visual	O	['N']	[1]
2	hallucinations	O	['N']	[2]
3	have	O	['N']	[3]
4	not	O	['N']	[4]
5	been	O	['N']	[5]
6	reported	O	['N']	[6]
7	as	O	['N']	[7]
8	an	O	['N']	[8]
9	adverse	O	['N']	[9]
10	effect	O	['N']	[10]
11	of	O	['N']	[11]
12	this	O	['N']	[12]
13	agent	O	['N']	[13]
14	,	O	['N']	[14]
15	we	O	['N']	[15]
16	describe	O	['N']	[16]
17	three	O	['N']	[17]
18	patients	O	['N']	[18]
19	who	O	['N']	[19]
20	experienced	O	['N']	[20]
21	complex	O	['N']	[21]
22	visual	O	['N']	[22]
23	hallucinations	O	['N']	[23]
24	and	O	['N']	[24]
25	altered	B	['N']	[25]
26	mental	I	['N']	[26]
27	status	I-Adverse_Effect	['N']	[27]
28	after	O	['N']	[28]
29	zonisamide	B-Drug	['Causes']	[27]
30	treatment	O	['N']	[30]
31	was	O	['N']	[31]
32	begun	O	['N']	[32]
33	or	O	['N']	[33]
34	its	O	['N']	[34]
35	dosage	O	['N']	[35]
36	increased	O	['N']	[36]
37	.	O	['N']	[37]
#4827
0	When	O	['N']	[0]
1	SASP	O	['N']	[1]
2	was	O	['N']	[2]
3	changed	O	['N']	[3]
4	to	O	['N']	[4]
5	5-aminosalicylic	B	['N']	[5]
6	acid	I-Drug	['Causes']	[35]
7	(	O	['N']	[7]
8	5-ASA	O	['N']	[8]
9	)	O	['N']	[9]
10	,	O	['N']	[10]
11	his	O	['N']	[11]
12	skin	O	['N']	[12]
13	eruptions	O	['N']	[13]
14	were	O	['N']	[14]
15	resolved	O	['N']	[15]
16	,	O	['N']	[16]
17	however	O	['N']	[17]
18	,	O	['N']	[18]
19	he	O	['N']	[19]
20	developed	O	['N']	[20]
21	weakness	O	['N']	[21]
22	and	O	['N']	[22]
23	atrophy	O	['N']	[23]
24	in	O	['N']	[24]
25	his	O	['N']	[25]
26	right	O	['N']	[26]
27	arm	O	['N']	[27]
28	as	O	['N']	[28]
29	well	O	['N']	[29]
30	as	O	['N']	[30]
31	progressive	O	['N']	[31]
32	worsening	B	['N']	[32]
33	of	I	['N']	[33]
34	the	I	['N']	[34]
35	dysesthesia	I-Adverse_Effect	['N']	[35]
36	in	O	['N']	[36]
37	his	O	['N']	[37]
38	legs	O	['N']	[38]
39	and	O	['N']	[39]
40	gait	O	['N']	[40]
41	disturbance	O	['N']	[41]
42	.	O	['N']	[42]
#4828
0	Acute	O	['N']	[0]
1	asymptomatic	B	['N']	[1]
2	hepatitis	I-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	a	O	['N']	[4]
5	healthy	O	['N']	[5]
6	normal	O	['N']	[6]
7	volunteer	O	['N']	[7]
8	exposed	O	['N']	[8]
9	to	O	['N']	[9]
10	2	O	['N']	[10]
11	oral	O	['N']	[11]
12	doses	O	['N']	[12]
13	of	O	['N']	[13]
14	amodiaquine	B-Drug	['Causes']	[2]
15	and	O	['N']	[15]
16	artesunate	O	['N']	[16]
17	.	O	['N']	[17]
#4829
0	Lansoprazole	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	thrombocytopenia	B-Adverse_Effect	['N']	[3]
4	.	O	['N']	[4]
#4830
0	Diarrhoea	O	['N']	[0]
1	,	O	['N']	[1]
2	T	O	['N']	[2]
3	-	O	['N']	[3]
4	CD4	O	['N']	[4]
5	+	O	['N']	[5]
6	lymphopenia	O	['N']	[6]
7	and	O	['N']	[7]
8	bilateral	B	['N']	[8]
9	patchy	I	['N']	[9]
10	pulmonary	I	['N']	[10]
11	infiltrates	I-Adverse_Effect	['N']	[11]
12	developed	O	['N']	[12]
13	in	O	['N']	[13]
14	a	O	['N']	[14]
15	male	O	['N']	[15]
16	60	O	['N']	[16]
17	yrs	O	['N']	[17]
18	of	O	['N']	[18]
19	age	O	['N']	[19]
20	,	O	['N']	[20]
21	who	O	['N']	[21]
22	was	O	['N']	[22]
23	treated	O	['N']	[23]
24	with	O	['N']	[24]
25	oxaliplatinum	B-Drug	['Causes']	[11]
26	and	O	['N']	[26]
27	5-fluorouracil	O	['N']	[27]
28	for	O	['N']	[28]
29	unresectable	O	['N']	[29]
30	rectum	O	['N']	[30]
31	carcinoma	O	['N']	[31]
32	.	O	['N']	[32]
#4831
0	A	O	['N']	[0]
1	36-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	being	O	['N']	[5]
6	treated	O	['N']	[6]
7	with	O	['N']	[7]
8	cisplatinum	B-Drug	['Causes']	[22]
9	,	O	['N']	[9]
10	vinblastine	O	['N']	[10]
11	,	O	['N']	[11]
12	and	O	['N']	[12]
13	bleomycin	O	['N']	[13]
14	for	O	['N']	[14]
15	testicular	O	['N']	[15]
16	carcinoma	O	['N']	[16]
17	developed	O	['N']	[17]
18	a	O	['N']	[18]
19	dense	O	['N']	[19]
20	left	B	['N']	[20]
21	homonymous	I	['N']	[21]
22	hemianopsia	I-Adverse_Effect	['N']	[22]
23	,	O	['N']	[23]
24	encephalopathy	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	a	O	['N']	[27]
28	partial	O	['N']	[28]
29	nondominant	O	['N']	[29]
30	parietal	O	['N']	[30]
31	lobe	O	['N']	[31]
32	syndrome	O	['N']	[32]
33	.	O	['N']	[33]
#4832
0	Musculoskeletal	B	['N']	[0]
1	complaints	I-Adverse_Effect	['N']	[1]
2	were	O	['N']	[2]
3	the	O	['N']	[3]
4	presenting	O	['N']	[4]
5	symptoms	O	['N']	[5]
6	in	O	['N']	[6]
7	four	O	['N']	[7]
8	of	O	['N']	[8]
9	44	O	['N']	[9]
10	children	O	['N']	[10]
11	(	O	['N']	[11]
12	9	O	['N']	[12]
13	%	O	['N']	[13]
14	)	O	['N']	[14]
15	treated	O	['N']	[15]
16	for	O	['N']	[16]
17	relapsed	O	['N']	[17]
18	Wilms	O	['N']	[18]
19	'	O	['N']	[19]
20	tumors	O	['N']	[20]
21	with	O	['N']	[21]
22	ifosfamide	O	['N']	[22]
23	,	O	['N']	[23]
24	a	O	['N']	[24]
25	derivative	O	['N']	[25]
26	of	O	['N']	[26]
27	cyclophosphamide	B-Drug	['Causes']	[1]
28	.	O	['N']	[28]
#4833
0	The	O	['N']	[0]
1	first	O	['N']	[1]
2	patient	O	['N']	[2]
3	was	O	['N']	[3]
4	a	O	['N']	[4]
5	61-year	O	['N']	[5]
6	-	O	['N']	[6]
7	old	O	['N']	[7]
8	man	O	['N']	[8]
9	with	O	['N']	[9]
10	a	O	['N']	[10]
11	30-year	O	['N']	[11]
12	history	O	['N']	[12]
13	of	O	['N']	[13]
14	fistulizing	O	['N']	[14]
15	CD	O	['N']	[15]
16	in	O	['N']	[16]
17	whom	O	['N']	[17]
18	B	B	['N']	[18]
19	-	I	['N']	[19]
20	cell	I	['N']	[20]
21	non	I	['N']	[21]
22	-	I	['N']	[22]
23	Hodgkin	I	['N']	[23]
24	's	I	['N']	[24]
25	lymphoma	I-Adverse_Effect	['N']	[25]
26	was	O	['N']	[26]
27	diagnosed	O	['N']	[27]
28	9	O	['N']	[28]
29	months	O	['N']	[29]
30	after	O	['N']	[30]
31	treatment	O	['N']	[31]
32	with	O	['N']	[32]
33	infliximab	B-Drug	['Causes']	[25]
34	.	O	['N']	[34]
#4834
0	A	O	['N']	[0]
1	34-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	lady	O	['N']	[4]
5	developed	O	['N']	[5]
6	a	O	['N']	[6]
7	constellation	B	['N']	[7]
8	of	I	['N']	[8]
9	dermatitis	I-Adverse_Effect	['N']	[9]
10	,	O	['N']	[10]
11	fever	O	['N']	[11]
12	,	O	['N']	[12]
13	lymphadenopathy	O	['N']	[13]
14	and	O	['N']	[14]
15	hepatitis	O	['N']	[15]
16	,	O	['N']	[16]
17	beginning	O	['N']	[17]
18	on	O	['N']	[18]
19	the	O	['N']	[19]
20	17th	O	['N']	[20]
21	day	O	['N']	[21]
22	of	O	['N']	[22]
23	a	O	['N']	[23]
24	course	O	['N']	[24]
25	of	O	['N']	[25]
26	oral	O	['N']	[26]
27	sulphasalazine	B-Drug	['Causes']	[9]
28	for	O	['N']	[28]
29	sero	O	['N']	[29]
30	-	O	['N']	[30]
31	negative	O	['N']	[31]
32	rheumatoid	O	['N']	[32]
33	arthritis	O	['N']	[33]
34	.	O	['N']	[34]
#4835
0	Tiagabine	B-Drug	['Dosage']	[1]
1	overdose	B-Dose	['N']	[1]
2	causes	O	['N']	[2]
3	an	O	['N']	[3]
4	unusual	O	['N']	[4]
5	array	O	['N']	[5]
6	of	O	['N']	[6]
7	neurological	O	['N']	[7]
8	symptoms	O	['N']	[8]
9	,	O	['N']	[9]
10	many	O	['N']	[10]
11	similar	O	['N']	[11]
12	to	O	['N']	[12]
13	reported	O	['N']	[13]
14	adverse	O	['N']	[14]
15	effects	O	['N']	[15]
16	during	O	['N']	[16]
17	therapeutic	O	['N']	[17]
18	use	O	['N']	[18]
19	.	O	['N']	[19]
#4836
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	here	O	['N']	[2]
3	a	O	['N']	[3]
4	26-year	O	['N']	[4]
5	-	O	['N']	[5]
6	old	O	['N']	[6]
7	female	O	['N']	[7]
8	with	O	['N']	[8]
9	diffuse	O	['N']	[9]
10	large	O	['N']	[10]
11	B	O	['N']	[11]
12	-	O	['N']	[12]
13	cell	O	['N']	[13]
14	lymphoma	O	['N']	[14]
15	who	O	['N']	[15]
16	died	O	['N']	[16]
17	of	O	['N']	[17]
18	severe	O	['N']	[18]
19	pulmonary	O	['N']	[19]
20	fibrosis	O	['N']	[20]
21	81	O	['N']	[21]
22	days	O	['N']	[22]
23	after	O	['N']	[23]
24	the	O	['N']	[24]
25	administration	O	['N']	[25]
26	of	O	['N']	[26]
27	high	O	['N']	[27]
28	-	O	['N']	[28]
29	dose	O	['N']	[29]
30	BCNU	B-Drug	['Dosage']	[35]
31	(	O	['N']	[31]
32	600	B	['N']	[32]
33	mg	I	['N']	[33]
34	/	I	['N']	[34]
35	m2	I-Dose	['N']	[35]
36	)	O	['N']	[36]
37	.	O	['N']	[37]
#4837
0	Ulcer	B	['N']	[0]
1	became	I	['N']	[1]
2	worse	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	tobramycin	O	['N']	[4]
5	and	O	['N']	[5]
6	gentamycin	B-Drug	['Causes']	[2]
7	treatment	O	['N']	[7]
8	for	O	['N']	[8]
9	2	O	['N']	[9]
10	days	O	['N']	[10]
11	.	O	['N']	[11]
#4838
0	Acute	B	['N']	[0]
1	myopathy	I-Adverse_Effect	['N']	[1]
2	with	O	['N']	[2]
3	selective	O	['N']	[3]
4	degeneration	O	['N']	[4]
5	of	O	['N']	[5]
6	myosin	O	['N']	[6]
7	filaments	O	['N']	[7]
8	following	O	['N']	[8]
9	status	O	['N']	[9]
10	asthmaticus	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	methylprednisolone	O	['N']	[13]
14	and	O	['N']	[14]
15	vecuronium	B-Drug	['Causes']	[1]
16	.	O	['N']	[16]
#4839
0	In	O	['N']	[0]
1	all	O	['N']	[1]
2	cases	O	['N']	[2]
3	,	O	['N']	[3]
4	drugs	O	['N']	[4]
5	in	O	['N']	[5]
6	addition	O	['N']	[6]
7	to	O	['N']	[7]
8	quetiapine	B-Drug	['Dosage']	[31]
9	were	O	['N']	[9]
10	detected	O	['N']	[10]
11	,	O	['N']	[11]
12	but	O	['N']	[12]
13	in	O	['N']	[13]
14	cases	O	['N']	[14]
15	#	O	['N']	[15]
16	1	O	['N']	[16]
17	and	O	['N']	[17]
18	#	O	['N']	[18]
19	2	O	['N']	[19]
20	,	O	['N']	[20]
21	the	O	['N']	[21]
22	cause	O	['N']	[22]
23	of	O	['N']	[23]
24	death	O	['N']	[24]
25	was	O	['N']	[25]
26	considered	O	['N']	[26]
27	to	O	['N']	[27]
28	be	O	['N']	[28]
29	a	O	['N']	[29]
30	quetiapine	O	['N']	[30]
31	overdose	B-Dose	['N']	[31]
32	and	O	['N']	[32]
33	the	O	['N']	[33]
34	other	O	['N']	[34]
35	drugs	O	['N']	[35]
36	were	O	['N']	[36]
37	not	O	['N']	[37]
38	considered	O	['N']	[38]
39	to	O	['N']	[39]
40	be	O	['N']	[40]
41	contributory	O	['N']	[41]
42	.	O	['N']	[42]
#4840
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	fatal	B	['N']	[3]
4	case	I	['N']	[4]
5	of	I	['N']	[5]
6	acute	I	['N']	[6]
7	interstitial	I	['N']	[7]
8	pneumonitis	I-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	a	O	['N']	[10]
11	patient	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	carmustine	B-Drug	['Causes']	[8]
15	(	O	['N']	[15]
16	BCNU	O	['N']	[16]
17	)	O	['N']	[17]
18	for	O	['N']	[18]
19	a	O	['N']	[19]
20	brain	O	['N']	[20]
21	tumor	O	['N']	[21]
22	.	O	['N']	[22]
#4841
0	We	O	['N']	[0]
1	suggest	O	['N']	[1]
2	that	O	['N']	[2]
3	nicotinic	B	['N']	[3]
4	acid	I-Drug	['Causes']	[11]
5	was	O	['N']	[5]
6	the	O	['N']	[6]
7	cause	O	['N']	[7]
8	of	O	['N']	[8]
9	his	O	['N']	[9]
10	liver	B	['N']	[10]
11	disease	I-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	that	O	['N']	[13]
14	this	O	['N']	[14]
15	case	O	['N']	[15]
16	is	O	['N']	[16]
17	of	O	['N']	[17]
18	particular	O	['N']	[18]
19	note	O	['N']	[19]
20	because	O	['N']	[20]
21	of	O	['N']	[21]
22	the	O	['N']	[22]
23	rather	O	['N']	[23]
24	short	O	['N']	[24]
25	period	O	['N']	[25]
26	of	O	['N']	[26]
27	therapy	O	['N']	[27]
28	before	O	['N']	[28]
29	the	O	['N']	[29]
30	onset	O	['N']	[30]
31	of	O	['N']	[31]
32	liver	O	['N']	[32]
33	injury	O	['N']	[33]
34	and	O	['N']	[34]
35	the	O	['N']	[35]
36	severity	O	['N']	[36]
37	of	O	['N']	[37]
38	the	O	['N']	[38]
39	hepatic	O	['N']	[39]
40	failure	O	['N']	[40]
41	,	O	['N']	[41]
42	and	O	['N']	[42]
43	that	O	['N']	[43]
44	the	O	['N']	[44]
45	probable	O	['N']	[45]
46	increased	O	['N']	[46]
47	use	O	['N']	[47]
48	of	O	['N']	[48]
49	nicotinic	O	['N']	[49]
50	acid	O	['N']	[50]
51	for	O	['N']	[51]
52	serum	O	['N']	[52]
53	cholesterol	O	['N']	[53]
54	control	O	['N']	[54]
55	makes	O	['N']	[55]
56	it	O	['N']	[56]
57	especially	O	['N']	[57]
58	important	O	['N']	[58]
59	for	O	['N']	[59]
60	physicians	O	['N']	[60]
61	and	O	['N']	[61]
62	their	O	['N']	[62]
63	patients	O	['N']	[63]
64	to	O	['N']	[64]
65	be	O	['N']	[65]
66	alert	O	['N']	[66]
67	to	O	['N']	[67]
68	the	O	['N']	[68]
69	signs	O	['N']	[69]
70	of	O	['N']	[70]
71	hepatotoxicity	O	['N']	[71]
72	.	O	['N']	[72]
#4842
0	Abdominal	B	['N']	[0]
1	wall	I	['N']	[1]
2	ulceration	I-Adverse_Effect	['N']	[2]
3	and	O	['N']	[3]
4	mucinosis	O	['N']	[4]
5	secondary	O	['N']	[5]
6	to	O	['N']	[6]
7	recombinant	B	['N']	[7]
8	human	I	['N']	[8]
9	interferon	I	['N']	[9]
10	-	I	['N']	[10]
11	beta-1b	I-Drug	['Causes']	[2]
12	.	O	['N']	[12]
#4843
0	Sixteen	O	['N']	[0]
1	hours	O	['N']	[1]
2	after	O	['N']	[2]
3	the	O	['N']	[3]
4	first	O	['N']	[4]
5	administration	O	['N']	[5]
6	of	O	['N']	[6]
7	IFN	B-Drug	['Causes']	[20]
8	,	O	['N']	[8]
9	IFN	O	['N']	[9]
10	was	O	['N']	[10]
11	suspended	O	['N']	[11]
12	by	O	['N']	[12]
13	the	O	['N']	[13]
14	symptoms	O	['N']	[14]
15	of	O	['N']	[15]
16	congestive	O	['N']	[16]
17	heart	O	['N']	[17]
18	failure	O	['N']	[18]
19	(	O	['N']	[19]
20	CHF	B-Adverse_Effect	['N']	[20]
21	)	O	['N']	[21]
22	.	O	['N']	[22]
#4844
0	One	O	['N']	[0]
1	case	O	['N']	[1]
2	of	O	['N']	[2]
3	priapism	B-Adverse_Effect	['N']	[3]
4	occurred	O	['N']	[4]
5	during	O	['N']	[5]
6	heparin	B-Drug	['Causes']	[3]
7	therapy	O	['N']	[7]
8	for	O	['N']	[8]
9	a	O	['N']	[9]
10	previous	O	['N']	[10]
11	surgical	O	['N']	[11]
12	operation	O	['N']	[12]
13	to	O	['N']	[13]
14	the	O	['N']	[14]
15	knee	O	['N']	[15]
16	is	O	['N']	[16]
17	reported	O	['N']	[17]
18	.	O	['N']	[18]
#4845
0	Fatal	O	['N']	[0]
1	interstitial	O	['N']	[1]
2	pneumonitis	O	['N']	[2]
3	following	O	['N']	[3]
4	high	B	['N']	[4]
5	-	I	['N']	[5]
6	dose	I-Dose	['N']	[6]
7	intermittent	O	['N']	[7]
8	chlorambucil	B-Drug	['Dosage']	[6]
9	therapy	O	['N']	[9]
10	for	O	['N']	[10]
11	chronic	O	['N']	[11]
12	lymphocyte	O	['N']	[12]
13	leukemia	O	['N']	[13]
14	.	O	['N']	[14]
#4846
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	describe	O	['N']	[2]
3	a	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	chronic	O	['N']	[6]
7	schizophrenia	O	['N']	[7]
8	who	O	['N']	[8]
9	experienced	O	['N']	[9]
10	delirium	O	['N']	[10]
11	,	O	['N']	[11]
12	grand	O	['N']	[12]
13	mal	O	['N']	[13]
14	seizure	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	photosensitivity	B-Adverse_Effect	['N']	[17]
18	after	O	['N']	[18]
19	the	O	['N']	[19]
20	addition	O	['N']	[20]
21	of	O	['N']	[21]
22	propranolol	B-Drug	['Causes']	[17]
23	to	O	['N']	[23]
24	her	O	['N']	[24]
25	neuroleptic	O	['N']	[25]
26	regimen	O	['N']	[26]
27	.	O	['N']	[27]
#4847
0	Torsade	B	['N']	[0]
1	de	I	['N']	[1]
2	pointes	I-Adverse_Effect	['N']	[2]
3	represents	O	['N']	[3]
4	a	O	['N']	[4]
5	potential	O	['N']	[5]
6	complication	O	['N']	[6]
7	of	O	['N']	[7]
8	chronic	O	['N']	[8]
9	amiodarone	B-Drug	['Causes']	[2]
10	therapy	O	['N']	[10]
11	.	O	['N']	[11]
#4848
0	A	O	['N']	[0]
1	7-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	developed	O	['N']	[5]
6	a	O	['N']	[6]
7	severe	B	['N']	[7]
8	unilateral	I	['N']	[8]
9	grand	I	['N']	[9]
10	mal	I	['N']	[10]
11	seizure	I-Adverse_Effect	['N']	[11]
12	at	O	['N']	[12]
13	the	O	['N']	[13]
14	age	O	['N']	[14]
15	of	O	['N']	[15]
16	5	O	['N']	[16]
17	years	O	['N']	[17]
18	(	O	['N']	[18]
19	phenobarbitone	O	['N']	[19]
20	therapy	O	['N']	[20]
21	)	O	['N']	[21]
22	;	O	['N']	[22]
23	1.5	O	['N']	[23]
24	years	O	['N']	[24]
25	later	O	['N']	[25]
26	valproate	B-Drug	['Causes']	[11]
27	(	O	['N']	[27]
28	2-propylpentanoic	O	['N']	[28]
29	acid	O	['N']	[29]
30	,	O	['N']	[30]
31	VPA	O	['N']	[31]
32	)	O	['N']	[32]
33	was	O	['N']	[33]
34	added	O	['N']	[34]
35	to	O	['N']	[35]
36	the	O	['N']	[36]
37	therapy	O	['N']	[37]
38	.	O	['N']	[38]
#4849
0	Acute	O	['N']	[0]
1	drug	O	['N']	[1]
2	induced	O	['N']	[2]
3	hepatitis	B-Adverse_Effect	['N']	[3]
4	due	O	['N']	[4]
5	to	O	['N']	[5]
6	erlotinib	B-Drug	['Causes']	[3]
7	.	O	['N']	[7]
#4850
0	Methemoglobinemia	B-Adverse_Effect	['N']	[0]
1	after	O	['N']	[1]
2	axillary	O	['N']	[2]
3	block	O	['N']	[3]
4	with	O	['N']	[4]
5	bupivacaine	B-Drug	['Causes']	[0]
6	and	O	['N']	[6]
7	additional	O	['N']	[7]
8	injection	O	['N']	[8]
9	of	O	['N']	[9]
10	lidocaine	O	['N']	[10]
11	in	O	['N']	[11]
12	the	O	['N']	[12]
13	operative	O	['N']	[13]
14	field	O	['N']	[14]
15	.	O	['N']	[15]
#4851
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	two	O	['N']	[2]
3	cases	O	['N']	[3]
4	of	O	['N']	[4]
5	fulminant	B	['N']	[5]
6	hepatic	I	['N']	[6]
7	failure	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	HIV-1-infected	O	['N']	[9]
10	patients	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	didanosine	O	['N']	[13]
14	(	O	['N']	[14]
15	ddI	B-Drug	['Causes']	[7]
16	)	O	['N']	[16]
17	.	O	['N']	[17]
#4852
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	,	O	['N']	[2]
3	while	O	['N']	[3]
4	on	O	['N']	[4]
5	intravenous	O	['N']	[5]
6	ritodrine	B-Drug	['Causes']	[18]
7	therapy	O	['N']	[7]
8	for	O	['N']	[8]
9	preterm	O	['N']	[9]
10	labor	O	['N']	[10]
11	,	O	['N']	[11]
12	experienced	O	['N']	[12]
13	an	O	['N']	[13]
14	episode	O	['N']	[14]
15	of	O	['N']	[15]
16	acute	B	['N']	[16]
17	chest	I	['N']	[17]
18	pain	I-Adverse_Effect	['N']	[18]
19	.	O	['N']	[19]
#4853
0	Acute	B	['N']	[0]
1	leukaemia	I-Adverse_Effect	['N']	[1]
2	during	O	['N']	[2]
3	tamoxifen	B-Drug	['Causes']	[1]
4	therapy	O	['N']	[4]
5	.	O	['N']	[5]
#4854
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	16-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	male	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	nephrotic	B	['N']	[9]
10	syndrome	I-Adverse_Effect	['N']	[10]
11	related	O	['N']	[11]
12	to	O	['N']	[12]
13	membranous	O	['N']	[13]
14	glomerulopathy	O	['N']	[14]
15	with	O	['N']	[15]
16	clinical	O	['N']	[16]
17	and	O	['N']	[17]
18	serological	O	['N']	[18]
19	evidence	O	['N']	[19]
20	of	O	['N']	[20]
21	systemic	O	['N']	[21]
22	lupus	O	['N']	[22]
23	erythematosus	O	['N']	[23]
24	after	O	['N']	[24]
25	treatment	O	['N']	[25]
26	with	O	['N']	[26]
27	griseofulvin	B-Drug	['Causes']	[10]
28	.	O	['N']	[28]
#4855
0	Chlorpropamide	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hemolytic	B	['N']	[3]
4	anemia	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#4856
0	Carbamazepine	B-Drug	['Causes']	[4]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	Diabetes	B	['N']	[3]
4	mellitus	I-Adverse_Effect	['N']	[4]
5	.	O	['N']	[5]
#4857
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	suggest	O	['N']	[2]
3	that	O	['N']	[3]
4	in	O	['N']	[4]
5	the	O	['N']	[5]
6	absence	O	['N']	[6]
7	of	O	['N']	[7]
8	any	O	['N']	[8]
9	proven	O	['N']	[9]
10	benefit	O	['N']	[10]
11	of	O	['N']	[11]
12	itraconazole	O	['N']	[12]
13	prophylaxis	O	['N']	[13]
14	,	O	['N']	[14]
15	and	O	['N']	[15]
16	given	O	['N']	[16]
17	the	O	['N']	[17]
18	interaction	O	['N']	[18]
19	of	O	['N']	[19]
20	this	O	['N']	[20]
21	drug	O	['N']	[21]
22	with	O	['N']	[22]
23	vincristine	B-Drug	['Causes']	[31]
24	leading	O	['N']	[24]
25	to	O	['N']	[25]
26	severe	O	['N']	[26]
27	and	O	['N']	[27]
28	even	O	['N']	[28]
29	potentially	O	['N']	[29]
30	fatal	B	['N']	[30]
31	toxicities	I-Adverse_Effect	['N']	[31]
32	,	O	['N']	[32]
33	the	O	['N']	[33]
34	combination	O	['N']	[34]
35	use	O	['N']	[35]
36	of	O	['N']	[36]
37	these	O	['N']	[37]
38	drugs	O	['N']	[38]
39	should	O	['N']	[39]
40	be	O	['N']	[40]
41	avoided	O	['N']	[41]
42	.	O	['N']	[42]
#4858
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	article	O	['N']	[2]
3	lithium	B-Drug	['Causes']	[29]
4	is	O	['N']	[4]
5	not	O	['N']	[5]
6	discussed	O	['N']	[6]
7	,	O	['N']	[7]
8	although	O	['N']	[8]
9	there	O	['N']	[9]
10	are	O	['N']	[10]
11	a	O	['N']	[11]
12	number	O	['N']	[12]
13	of	O	['N']	[13]
14	concerns	O	['N']	[14]
15	about	O	['N']	[15]
16	lithium	O	['N']	[16]
17	's	O	['N']	[17]
18	potential	O	['N']	[18]
19	teratogenicity	O	['N']	[19]
20	,	O	['N']	[20]
21	and	O	['N']	[21]
22	it	O	['N']	[22]
23	has	O	['N']	[23]
24	been	O	['N']	[24]
25	implicated	O	['N']	[25]
26	in	O	['N']	[26]
27	Epstein	B	['N']	[27]
28	's	I	['N']	[28]
29	anomaly	I-Adverse_Effect	['N']	[29]
30	,	O	['N']	[30]
31	a	O	['N']	[31]
32	congenital	O	['N']	[32]
33	heart	O	['N']	[33]
34	defect	O	['N']	[34]
35	among	O	['N']	[35]
36	infants	O	['N']	[36]
37	born	O	['N']	[37]
38	to	O	['N']	[38]
39	women	O	['N']	[39]
40	taking	O	['N']	[40]
41	lithium	O	['N']	[41]
42	;	O	['N']	[42]
43	as	O	['N']	[43]
44	with	O	['N']	[44]
45	other	O	['N']	[45]
46	medications	O	['N']	[46]
47	,	O	['N']	[47]
48	however	O	['N']	[48]
49	,	O	['N']	[49]
50	the	O	['N']	[50]
51	data	O	['N']	[51]
52	have	O	['N']	[52]
53	specific	O	['N']	[53]
54	limitations	O	['N']	[54]
55	.	O	['N']	[55]
#4859
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	Carbamazepine	B-Drug	['Causes']	[8]
8	toxicity	I-Adverse_Effect	['N']	[8]
9	following	O	['N']	[9]
10	the	O	['N']	[10]
11	administration	O	['N']	[11]
12	of	O	['N']	[12]
13	Oxybutynin	O	['N']	[13]
14	and	O	['N']	[14]
15	Dantrolene	O	['N']	[15]
16	.	O	['N']	[16]
#4860
0	We	O	['N']	[0]
1	experienced	O	['N']	[1]
2	a	O	['N']	[2]
3	male	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	psoriasis	O	['N']	[6]
7	and	O	['N']	[7]
8	hypertension	O	['N']	[8]
9	whose	O	['N']	[9]
10	conditions	O	['N']	[10]
11	were	O	['N']	[11]
12	treated	O	['N']	[12]
13	with	O	['N']	[13]
14	tacalcitol	B-Drug	['Causes']	[23]
15	ointment	O	['N']	[15]
16	and	O	['N']	[16]
17	thiazide	O	['N']	[17]
18	,	O	['N']	[18]
19	respectively	O	['N']	[19]
20	,	O	['N']	[20]
21	resulting	O	['N']	[21]
22	in	O	['N']	[22]
23	hypercalciuria	B-Adverse_Effect	['N']	[23]
24	and	O	['N']	[24]
25	hypercalcemia	O	['N']	[25]
26	.	O	['N']	[26]
#4861
0	We	O	['N']	[0]
1	now	O	['N']	[1]
2	present	O	['N']	[2]
3	four	O	['N']	[3]
4	cases	O	['N']	[4]
5	of	O	['N']	[5]
6	RSDS	B-Adverse_Effect	['N']	[6]
7	in	O	['N']	[7]
8	kidney	O	['N']	[8]
9	transplant	O	['N']	[9]
10	recipients	O	['N']	[10]
11	treated	O	['N']	[11]
12	with	O	['N']	[12]
13	tacrolimus	B-Drug	['Causes']	[6]
14	.	O	['N']	[14]
#4862
0	A	O	['N']	[0]
1	27-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	who	O	['N']	[5]
6	had	O	['N']	[6]
7	a	O	['N']	[7]
8	history	O	['N']	[8]
9	of	O	['N']	[9]
10	bronchial	O	['N']	[10]
11	asthma	O	['N']	[11]
12	,	O	['N']	[12]
13	eosinophilic	O	['N']	[13]
14	enteritis	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	eosinophilic	O	['N']	[17]
18	pneumonia	O	['N']	[18]
19	presented	O	['N']	[19]
20	with	O	['N']	[20]
21	fever	O	['N']	[21]
22	,	O	['N']	[22]
23	skin	O	['N']	[23]
24	eruptions	O	['N']	[24]
25	,	O	['N']	[25]
26	cervical	O	['N']	[26]
27	lymphadenopathy	O	['N']	[27]
28	,	O	['N']	[28]
29	hepatosplenomegaly	O	['N']	[29]
30	,	O	['N']	[30]
31	atypical	B	['N']	[31]
32	lymphocytosis	I-Adverse_Effect	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	eosinophilia	O	['N']	[35]
36	two	O	['N']	[36]
37	weeks	O	['N']	[37]
38	after	O	['N']	[38]
39	receiving	O	['N']	[39]
40	trimethoprim	O	['N']	[40]
41	(	O	['N']	[41]
42	TMP)-sulfamethoxazole	O	['N']	[42]
43	(	O	['N']	[43]
44	SMX	B-Drug	['Causes']	[32]
45	)	O	['N']	[45]
46	treatment	O	['N']	[46]
47	.	O	['N']	[47]
#4863
0	Thymic	B	['N']	[0]
1	enlargement	I-Adverse_Effect	['N']	[1]
2	in	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	juvenile	O	['N']	[6]
7	idiopathic	O	['N']	[7]
8	arthritis	O	['N']	[8]
9	during	O	['N']	[9]
10	etanercept	B-Drug	['Causes']	[1]
11	therapy	O	['N']	[11]
12	.	O	['N']	[12]
#4864
0	Scleroderma	B	['N']	[0]
1	-	I	['N']	[1]
2	like	I	['N']	[2]
3	reaction	I-Adverse_Effect	['N']	[3]
4	induced	O	['N']	[4]
5	by	O	['N']	[5]
6	uracil	B	['N']	[6]
7	-	I	['N']	[7]
8	tegafur	I-Drug	['Causes']	[3]
9	(	O	['N']	[9]
10	UFT	O	['N']	[10]
11	)	O	['N']	[11]
12	,	O	['N']	[12]
13	a	O	['N']	[13]
14	second	O	['N']	[14]
15	-	O	['N']	[15]
16	generation	O	['N']	[16]
17	anticancer	O	['N']	[17]
18	agent	O	['N']	[18]
19	.	O	['N']	[19]
#4865
0	Incidence	O	['N']	[0]
1	of	O	['N']	[1]
2	seizures	B-Adverse_Effect	['N']	[2]
3	in	O	['N']	[3]
4	pediatric	O	['N']	[4]
5	cancer	O	['N']	[5]
6	patients	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	imipenem	B-Drug	['Causes']	[2]
10	/	O	['N']	[10]
11	cilastatin	O	['N']	[11]
12	.	O	['N']	[12]
#4866
0	Propranolol	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	related	O	['N']	[2]
3	bronchospasm	B-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	patients	O	['N']	[5]
6	without	O	['N']	[6]
7	history	O	['N']	[7]
8	of	O	['N']	[8]
9	asthma	O	['N']	[9]
10	.	O	['N']	[10]
#4867
0	DIAGNOSIS	O	['N']	[0]
1	:	O	['N']	[1]
2	Interferon	B	['N']	[2]
3	alpha-2b	I-Drug	['Causes']	[6]
4	-	O	['N']	[4]
5	induced	O	['N']	[5]
6	cardiomyopathy	B-Adverse_Effect	['N']	[6]
7	.	O	['N']	[7]
#4868
0	Red	B	['N']	[0]
1	blood	I	['N']	[1]
2	cell	I	['N']	[2]
3	anemia	I-Adverse_Effect	['N']	[3]
4	in	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	pemphigus	O	['N']	[8]
9	vulgaris	O	['N']	[9]
10	induced	O	['N']	[10]
11	by	O	['N']	[11]
12	the	O	['N']	[12]
13	use	O	['N']	[13]
14	of	O	['N']	[14]
15	mycophenolate	O	['N']	[15]
16	mofetil	O	['N']	[16]
17	and	O	['N']	[17]
18	prednisone	B-Drug	['Causes']	[3]
19	.	O	['N']	[19]
#4869
0	OBJECTIVE	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	report	O	['N']	[3]
4	a	O	['N']	[4]
5	case	O	['N']	[5]
6	of	O	['N']	[6]
7	severe	B	['N']	[7]
8	apnea	I-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	an	O	['N']	[10]
11	infant	O	['N']	[11]
12	exposed	O	['N']	[12]
13	to	O	['N']	[13]
14	lamotrigine	B-Drug	['Causes']	[8]
15	through	O	['N']	[15]
16	breast	O	['N']	[16]
17	-	O	['N']	[17]
18	feeding	O	['N']	[18]
19	.	O	['N']	[19]
#4870
0	Anaphylactoid	B	['N']	[0]
1	shock	I-Adverse_Effect	['N']	[1]
2	,	O	['N']	[2]
3	disseminated	O	['N']	[3]
4	intravascular	O	['N']	[4]
5	coagulation	O	['N']	[5]
6	,	O	['N']	[6]
7	and	O	['N']	[7]
8	anuric	O	['N']	[8]
9	renal	O	['N']	[9]
10	failure	O	['N']	[10]
11	requiring	O	['N']	[11]
12	dialysis	O	['N']	[12]
13	occurred	O	['N']	[13]
14	in	O	['N']	[14]
15	a	O	['N']	[15]
16	patient	O	['N']	[16]
17	receiving	O	['N']	[17]
18	zomepirac	B-Drug	['Causes']	[1]
19	sodium	O	['N']	[19]
20	for	O	['N']	[20]
21	toothache	O	['N']	[21]
22	.	O	['N']	[22]
#4871
0	A	O	['N']	[0]
1	case	O	['N']	[1]
2	report	O	['N']	[2]
3	of	O	['N']	[3]
4	fatal	O	['N']	[4]
5	dapsone	B-Drug	['Causes']	[8]
6	-	O	['N']	[6]
7	induced	O	['N']	[7]
8	agranulocytosis	B-Adverse_Effect	['N']	[8]
9	in	O	['N']	[9]
10	an	O	['N']	[10]
11	Indian	O	['N']	[11]
12	mid	O	['N']	[12]
13	-	O	['N']	[13]
14	borderline	O	['N']	[14]
15	leprosy	O	['N']	[15]
16	patient	O	['N']	[16]
17	.	O	['N']	[17]
#4872
0	Possible	O	['N']	[0]
1	interaction	O	['N']	[1]
2	between	O	['N']	[2]
3	lopinavir	B-Drug	['Causes']	[11]
4	/	O	['N']	[4]
5	ritonavir	O	['N']	[5]
6	and	O	['N']	[6]
7	valproic	O	['N']	[7]
8	Acid	O	['N']	[8]
9	exacerbates	O	['N']	[9]
10	bipolar	B	['N']	[10]
11	disorder	I-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#4873
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	receiving	O	['N']	[2]
3	vancomycin	B-Drug	['Causes']	[33]
4	for	O	['N']	[4]
5	a	O	['N']	[5]
6	serious	O	['N']	[6]
7	staphylococcal	O	['N']	[7]
8	infection	O	['N']	[8]
9	had	O	['N']	[9]
10	a	O	['N']	[10]
11	lupus	O	['N']	[11]
12	-	O	['N']	[12]
13	like	O	['N']	[13]
14	syndrome	O	['N']	[14]
15	characterized	O	['N']	[15]
16	by	O	['N']	[16]
17	a	O	['N']	[17]
18	malar	O	['N']	[18]
19	rash	O	['N']	[19]
20	,	O	['N']	[20]
21	pain	O	['N']	[21]
22	and	O	['N']	[22]
23	erythema	O	['N']	[23]
24	of	O	['N']	[24]
25	the	O	['N']	[25]
26	cartilage	O	['N']	[26]
27	of	O	['N']	[27]
28	both	O	['N']	[28]
29	ears	O	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	tender	B	['N']	[32]
33	erythematous	I-Adverse_Effect	['N']	[33]
34	and	O	['N']	[34]
35	hemorrhagic	O	['N']	[35]
36	lesions	O	['N']	[36]
37	of	O	['N']	[37]
38	the	O	['N']	[38]
39	finger	O	['N']	[39]
40	tips	O	['N']	[40]
41	.	O	['N']	[41]
#4874
0	Ballistic	B	['N']	[0]
1	movements	I-Adverse_Effect	['N']	[1]
2	due	O	['N']	[2]
3	to	O	['N']	[3]
4	ischemic	O	['N']	[4]
5	infarcts	O	['N']	[5]
6	after	O	['N']	[6]
7	intravenous	O	['N']	[7]
8	heroin	B-Drug	['Causes']	[1]
9	overdose	O	['N']	[9]
10	:	O	['N']	[10]
11	report	O	['N']	[11]
12	of	O	['N']	[12]
13	two	O	['N']	[13]
14	cases	O	['N']	[14]
15	.	O	['N']	[15]
#4875
0	A	O	['N']	[0]
1	55-yr	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	developed	O	['N']	[5]
6	prolonged	B	['N']	[6]
7	jaundice	I-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	sicca	O	['N']	[9]
10	complex	O	['N']	[10]
11	after	O	['N']	[11]
12	a	O	['N']	[12]
13	course	O	['N']	[13]
14	of	O	['N']	[14]
15	thiabendazole	B-Drug	['Causes']	[7]
16	therapy	O	['N']	[16]
17	.	O	['N']	[17]
#4876
0	The	O	['N']	[0]
1	reported	O	['N']	[1]
2	cases	O	['N']	[2]
3	of	O	['N']	[3]
4	in	O	['N']	[4]
5	utero	O	['N']	[5]
6	exposure	O	['N']	[6]
7	to	O	['N']	[7]
8	cyclosposphamide	B-Drug	['Causes']	[42]
9	shared	O	['N']	[9]
10	the	O	['N']	[10]
11	following	O	['N']	[11]
12	manifestations	O	['N']	[12]
13	with	O	['N']	[13]
14	our	O	['N']	[14]
15	patient	O	['N']	[15]
16	:	O	['N']	[16]
17	growth	O	['N']	[17]
18	deficiency	O	['N']	[18]
19	,	O	['N']	[19]
20	developmental	O	['N']	[20]
21	delay	O	['N']	[21]
22	,	O	['N']	[22]
23	craniosynostosis	O	['N']	[23]
24	,	O	['N']	[24]
25	blepharophimosis	O	['N']	[25]
26	,	O	['N']	[26]
27	flat	O	['N']	[27]
28	nasal	O	['N']	[28]
29	bridge	O	['N']	[29]
30	,	O	['N']	[30]
31	abnormal	O	['N']	[31]
32	ears	O	['N']	[32]
33	,	O	['N']	[33]
34	and	O	['N']	[34]
35	distal	O	['N']	[35]
36	limb	O	['N']	[36]
37	defects	O	['N']	[37]
38	including	O	['N']	[38]
39	hypoplastic	O	['N']	[39]
40	thumbs	O	['N']	[40]
41	and	O	['N']	[41]
42	oligodactyly	B-Adverse_Effect	['N']	[42]
43	.	O	['N']	[43]
#4877
0	Infliximab	B-Drug	['Causes']	[8]
1	therapy	O	['N']	[1]
2	may	O	['N']	[2]
3	cause	O	['N']	[3]
4	a	O	['N']	[4]
5	lupus	B	['N']	[5]
6	-	I	['N']	[6]
7	like	I	['N']	[7]
8	syndrome	I-Adverse_Effect	['N']	[8]
9	that	O	['N']	[9]
10	is	O	['N']	[10]
11	reversible	O	['N']	[11]
12	upon	O	['N']	[12]
13	discontinuing	O	['N']	[13]
14	this	O	['N']	[14]
15	agent	O	['N']	[15]
16	.	O	['N']	[16]
#4878
0	Ovarian	O	['N']	[0]
1	endometrioid	O	['N']	[1]
2	carcinoma	O	['N']	[2]
3	and	O	['N']	[3]
4	endometriosis	B-Adverse_Effect	['N']	[4]
5	developing	O	['N']	[5]
6	in	O	['N']	[6]
7	a	O	['N']	[7]
8	postmenopausal	O	['N']	[8]
9	breast	O	['N']	[9]
10	cancer	O	['N']	[10]
11	patient	O	['N']	[11]
12	during	O	['N']	[12]
13	tamoxifen	B-Drug	['Causes']	[4]
14	therapy	O	['N']	[14]
15	:	O	['N']	[15]
16	a	O	['N']	[16]
17	case	O	['N']	[17]
18	report	O	['N']	[18]
19	and	O	['N']	[19]
20	review	O	['N']	[20]
21	of	O	['N']	[21]
22	the	O	['N']	[22]
23	literature	O	['N']	[23]
24	.	O	['N']	[24]
#4879
0	The	O	['N']	[0]
1	evidence	O	['N']	[1]
2	of	O	['N']	[2]
3	high	O	['N']	[3]
4	plasmatic	O	['N']	[4]
5	levels	O	['N']	[5]
6	of	O	['N']	[6]
7	CBZ	B-Drug	['Causes']	[35]
8	and	O	['N']	[8]
9	the	O	['N']	[9]
10	absence	O	['N']	[10]
11	of	O	['N']	[11]
12	other	O	['N']	[12]
13	aetiologic	O	['N']	[13]
14	factors	O	['N']	[14]
15	lead	O	['N']	[15]
16	the	O	['N']	[16]
17	authors	O	['N']	[17]
18	to	O	['N']	[18]
19	conclude	O	['N']	[19]
20	that	O	['N']	[20]
21	the	O	['N']	[21]
22	overdose	O	['N']	[22]
23	of	O	['N']	[23]
24	CBZ	O	['N']	[24]
25	could	O	['N']	[25]
26	have	O	['N']	[26]
27	represented	O	['N']	[27]
28	the	O	['N']	[28]
29	precipitating	O	['N']	[29]
30	of	O	['N']	[30]
31	the	O	['N']	[31]
32	episode	O	['N']	[32]
33	of	O	['N']	[33]
34	acute	B	['N']	[34]
35	pancreatitis	I-Adverse_Effect	['N']	[35]
36	.	O	['N']	[36]
#4880
0	We	O	['N']	[0]
1	present	O	['N']	[1]
2	the	O	['N']	[2]
3	management	O	['N']	[3]
4	of	O	['N']	[4]
5	agranulocytosis	O	['N']	[5]
6	and	O	['N']	[6]
7	neutropenic	B	['N']	[7]
8	sepsis	I-Adverse_Effect	['N']	[8]
9	secondary	O	['N']	[9]
10	to	O	['N']	[10]
11	carbimazole	B-Drug	['Causes']	[8]
12	with	O	['N']	[12]
13	recombinant	O	['N']	[13]
14	human	O	['N']	[14]
15	granulocyte	O	['N']	[15]
16	colony	O	['N']	[16]
17	stimulating	O	['N']	[17]
18	factor	O	['N']	[18]
19	(	O	['N']	[19]
20	G	O	['N']	[20]
21	-	O	['N']	[21]
22	CSF	O	['N']	[22]
23	)	O	['N']	[23]
24	.	O	['N']	[24]
#4881
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	inoperable	O	['N']	[5]
6	pancreatic	O	['N']	[6]
7	cancer	O	['N']	[7]
8	who	O	['N']	[8]
9	developed	O	['N']	[9]
10	gastrointestinal	O	['N']	[10]
11	bleeding	O	['N']	[11]
12	secondary	O	['N']	[12]
13	to	O	['N']	[13]
14	radiation	B	['N']	[14]
15	-	I	['N']	[15]
16	recall	I-Adverse_Effect	['N']	[16]
17	related	O	['N']	[17]
18	to	O	['N']	[18]
19	gemcitabine	B-Drug	['Causes']	[16]
20	and	O	['N']	[20]
21	review	O	['N']	[21]
22	literature	O	['N']	[22]
23	.	O	['N']	[23]
#4882
0	Pirmenol	B	['N']	[0]
1	hydrochloride	I-Drug	['Causes']	[5]
2	-	O	['N']	[2]
3	induced	O	['N']	[3]
4	QT	B	['N']	[4]
5	prolongation	I-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	T	O	['N']	[7]
8	wave	O	['N']	[8]
9	inversion	O	['N']	[9]
10	on	O	['N']	[10]
11	electrocardiogram	O	['N']	[11]
12	during	O	['N']	[12]
13	treatment	O	['N']	[13]
14	for	O	['N']	[14]
15	symptomatic	O	['N']	[15]
16	atrial	O	['N']	[16]
17	fibrillation	O	['N']	[17]
18	.	O	['N']	[18]
#4883
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	case	O	['N']	[2]
3	,	O	['N']	[3]
4	unlike	O	['N']	[4]
5	those	O	['N']	[5]
6	previously	O	['N']	[6]
7	reported	O	['N']	[7]
8	,	O	['N']	[8]
9	hyponatremia	B-Adverse_Effect	['N']	[9]
10	recurred	O	['N']	[10]
11	5	O	['N']	[11]
12	months	O	['N']	[12]
13	after	O	['N']	[13]
14	switching	O	['N']	[14]
15	from	O	['N']	[15]
16	citalopram	O	['N']	[16]
17	to	O	['N']	[17]
18	mirtazapine	B-Drug	['Causes']	[9]
19	,	O	['N']	[19]
20	which	O	['N']	[20]
21	is	O	['N']	[21]
22	believed	O	['N']	[22]
23	to	O	['N']	[23]
24	be	O	['N']	[24]
25	a	O	['N']	[25]
26	safe	O	['N']	[26]
27	antidepressant	O	['N']	[27]
28	.	O	['N']	[28]
#4884
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	acute	O	['N']	[3]
4	esophageal	O	['N']	[4]
5	variceal	O	['N']	[5]
6	bleeding	O	['N']	[6]
7	developed	O	['N']	[7]
8	fatal	B	['N']	[8]
9	rhabdomyolysis	I-Adverse_Effect	['N']	[9]
10	during	O	['N']	[10]
11	treatment	O	['N']	[11]
12	with	O	['N']	[12]
13	a	O	['N']	[13]
14	continuous	O	['N']	[14]
15	intravenous	O	['N']	[15]
16	infusion	O	['N']	[16]
17	of	O	['N']	[17]
18	vasopressin	B-Drug	['Causes']	[9]
19	.	O	['N']	[19]
#4885
0	Transient	B	['N']	[0]
1	global	I	['N']	[1]
2	amnesia	I-Adverse_Effect	['N']	[2]
3	after	O	['N']	[3]
4	clioquinol	B-Drug	['Causes']	[2]
5	:	O	['N']	[5]
6	five	O	['N']	[6]
7	personal	O	['N']	[7]
8	observations	O	['N']	[8]
9	from	O	['N']	[9]
10	outside	O	['N']	[10]
11	Japan	O	['N']	[11]
12	.	O	['N']	[12]
#4886
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	Hydroxyurea	B-Drug	['Causes']	[25]
3	is	O	['N']	[3]
4	a	O	['N']	[4]
5	cytostatic	O	['N']	[5]
6	agent	O	['N']	[6]
7	used	O	['N']	[7]
8	to	O	['N']	[8]
9	treat	O	['N']	[9]
10	myeloproliferative	O	['N']	[10]
11	disorders	O	['N']	[11]
12	and	O	['N']	[12]
13	long	O	['N']	[13]
14	-	O	['N']	[14]
15	term	O	['N']	[15]
16	treatment	O	['N']	[16]
17	is	O	['N']	[17]
18	associated	O	['N']	[18]
19	with	O	['N']	[19]
20	mucocutaneous	O	['N']	[20]
21	adverse	O	['N']	[21]
22	events	O	['N']	[22]
23	and	O	['N']	[23]
24	nail	B	['N']	[24]
25	hyperpigmentation	I-Adverse_Effect	['N']	[25]
26	.	O	['N']	[26]
#4887
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	with	O	['N']	[7]
8	pulmonary	O	['N']	[8]
9	hypertension	O	['N']	[9]
10	and	O	['N']	[10]
11	undifferentiated	O	['N']	[11]
12	connective	O	['N']	[12]
13	tissue	O	['N']	[13]
14	disease	O	['N']	[14]
15	who	O	['N']	[15]
16	,	O	['N']	[16]
17	after	O	['N']	[17]
18	2	O	['N']	[18]
19	months	O	['N']	[19]
20	of	O	['N']	[20]
21	treatment	O	['N']	[21]
22	with	O	['N']	[22]
23	epoprostenol	B-Drug	['Causes']	[35]
24	,	O	['N']	[24]
25	presented	O	['N']	[25]
26	with	O	['N']	[26]
27	rapidly	O	['N']	[27]
28	progressive	O	['N']	[28]
29	erythema	O	['N']	[29]
30	,	O	['N']	[30]
31	scaling	O	['N']	[31]
32	,	O	['N']	[32]
33	nausea	O	['N']	[33]
34	and	O	['N']	[34]
35	vomiting	B-Adverse_Effect	['N']	[35]
36	,	O	['N']	[36]
37	and	O	['N']	[37]
38	fever	O	['N']	[38]
39	.	O	['N']	[39]
#4888
0	Case	O	['N']	[0]
1	report	O	['N']	[1]
2	:	O	['N']	[2]
3	lack	O	['N']	[3]
4	of	O	['N']	[4]
5	control	O	['N']	[5]
6	of	O	['N']	[6]
7	diabetes	O	['N']	[7]
8	and	O	['N']	[8]
9	weight	B	['N']	[9]
10	gain	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	on	O	['N']	[14]
15	initiation	O	['N']	[15]
16	and	O	['N']	[16]
17	rechallenge	O	['N']	[17]
18	of	O	['N']	[18]
19	therapy	O	['N']	[19]
20	with	O	['N']	[20]
21	olanzapine	B-Drug	['Causes']	[10]
22	.	O	['N']	[22]
#4889
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	peripheral	B	['N']	[2]
3	neuropathy	I-Adverse_Effect	['N']	[3]
4	and	O	['N']	[4]
5	bone	O	['N']	[5]
6	marrow	O	['N']	[6]
7	depression	O	['N']	[7]
8	led	O	['N']	[8]
9	to	O	['N']	[9]
10	linezolid	B-Drug	['Causes']	[3]
11	withdrawal	O	['N']	[11]
12	in	O	['N']	[12]
13	seven	O	['N']	[13]
14	patients	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	neuropathy	O	['N']	[17]
18	may	O	['N']	[18]
19	not	O	['N']	[19]
20	be	O	['N']	[20]
21	fully	O	['N']	[21]
22	reversible	O	['N']	[22]
23	in	O	['N']	[23]
24	all	O	['N']	[24]
25	patients	O	['N']	[25]
26	.	O	['N']	[26]
#4890
0	Although	O	['N']	[0]
1	major	O	['N']	[1]
2	hazards	O	['N']	[2]
3	of	O	['N']	[3]
4	treatment	O	['N']	[4]
5	of	O	['N']	[5]
6	hypophosphatemic	-	['N']	[6]
7	osteomalacia	O	['N']	[7]
8	with	O	['N']	[8]
9	phosphate	O	['N']	[9]
10	and	O	['N']	[10]
11	calcitriol	O	['N']	[11]
12	are	O	['N']	[12]
13	secondary	O	['N']	[13]
14	hyperparathyroidism	O	['N']	[14]
15	and	O	['N']	[15]
16	vitamin	B	['N']	[16]
17	D	I	['N']	[17]
18	intoxication	I-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	potassium	O	['N']	[20]
21	loss	O	['N']	[21]
22	also	O	['N']	[22]
23	should	O	['N']	[23]
24	be	O	['N']	[24]
25	kept	O	['N']	[25]
26	in	O	['N']	[26]
27	mind	O	['N']	[27]
28	.	O	['N']	[28]
#4891
0	Hydrocortisone	O	['N']	[0]
1	may	O	['N']	[1]
2	decrease	O	['N']	[2]
3	the	O	['N']	[3]
4	incidence	O	['N']	[4]
5	of	O	['N']	[5]
6	mortality	B-Adverse_Effect	['N']	[6]
7	associated	O	['N']	[7]
8	with	O	['N']	[8]
9	cardiac	O	['N']	[9]
10	arrhythmias	O	['N']	[10]
11	in	O	['N']	[11]
12	children	O	['N']	[12]
13	receiving	O	['N']	[13]
14	amphotericin	B	['N']	[14]
15	B	I-Drug	['Causes']	[6]
16	overdoses	O	['N']	[16]
17	.	O	['N']	[17]
#4892
0	Improved	O	['N']	[0]
1	awareness	O	['N']	[1]
2	of	O	['N']	[2]
3	and	O	['N']	[3]
4	further	O	['N']	[4]
5	investigation	O	['N']	[5]
6	into	O	['N']	[6]
7	the	O	['N']	[7]
8	neurotoxic	B	['N']	[8]
9	effects	I-Adverse_Effect	['N']	[9]
10	of	O	['N']	[10]
11	ofloxacin	B-Drug	['Causes']	[9]
12	may	O	['N']	[12]
13	enhance	O	['N']	[13]
14	its	O	['N']	[14]
15	safe	O	['N']	[15]
16	use	O	['N']	[16]
17	.	O	['N']	[17]
#4893
0	Acute	B	['N']	[0]
1	intravascular	I	['N']	[1]
2	hemolysis	I-Adverse_Effect	['N']	[2]
3	developed	O	['N']	[3]
4	when	O	['N']	[4]
5	a	O	['N']	[5]
6	diabetic	O	['N']	[6]
7	patient	O	['N']	[7]
8	,	O	['N']	[8]
9	previously	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	glyburide	O	['N']	[12]
13	,	O	['N']	[13]
14	was	O	['N']	[14]
15	started	O	['N']	[15]
16	on	O	['N']	[16]
17	another	O	['N']	[17]
18	oral	O	['N']	[18]
19	sulfonylurea	O	['N']	[19]
20	drug	O	['N']	[20]
21	,	O	['N']	[21]
22	chlorpropamide	B-Drug	['Causes']	[2]
23	.	O	['N']	[23]
#4894
0	Symptomatic	B	['N']	[0]
1	hypocalcaemia	I-Adverse_Effect	['N']	[1]
2	and	O	['N']	[2]
3	renal	O	['N']	[3]
4	impairment	O	['N']	[4]
5	associated	O	['N']	[5]
6	with	O	['N']	[6]
7	bisphosphonate	B-Drug	['Causes']	[1]
8	treatment	O	['N']	[8]
9	in	O	['N']	[9]
10	patients	O	['N']	[10]
11	with	O	['N']	[11]
12	multiple	O	['N']	[12]
13	myeloma	O	['N']	[13]
14	.	O	['N']	[14]
#4895
0	After	O	['N']	[0]
1	therapy	O	['N']	[1]
2	for	O	['N']	[2]
3	diabetic	O	['N']	[3]
4	coma	O	['N']	[4]
5	with	O	['N']	[5]
6	insulin	O	['N']	[6]
7	(	O	['N']	[7]
8	containing	O	['N']	[8]
9	the	O	['N']	[9]
10	preservative	O	['N']	[10]
11	cresol	B-Drug	['Causes']	[34]
12	)	O	['N']	[12]
13	and	O	['N']	[13]
14	electrolyte	O	['N']	[14]
15	solutions	O	['N']	[15]
16	was	O	['N']	[16]
17	started	O	['N']	[17]
18	,	O	['N']	[18]
19	the	O	['N']	[19]
20	patient	O	['N']	[20]
21	complained	O	['N']	[21]
22	of	O	['N']	[22]
23	increasing	O	['N']	[23]
24	myalgia	O	['N']	[24]
25	,	O	['N']	[25]
26	developed	O	['N']	[26]
27	a	O	['N']	[27]
28	high	O	['N']	[28]
29	fever	O	['N']	[29]
30	and	O	['N']	[30]
31	respiratory	B	['N']	[31]
32	and	I	['N']	[32]
33	metabolic	I	['N']	[33]
34	acidosis	I-Adverse_Effect	['N']	[34]
35	and	O	['N']	[35]
36	lost	O	['N']	[36]
37	consciousness	O	['N']	[37]
38	.	O	['N']	[38]
#4896
0	Hypoglycemia	O	['N']	[0]
1	can	O	['N']	[1]
2	be	O	['N']	[2]
3	a	O	['N']	[3]
4	serious	O	['N']	[4]
5	side	O	['N']	[5]
6	effect	O	['N']	[6]
7	of	O	['N']	[7]
8	etanercept	O	['N']	[8]
9	in	O	['N']	[9]
10	patients	O	['N']	[10]
11	already	O	['N']	[11]
12	on	O	['N']	[12]
13	antidiabetic	O	['N']	[13]
14	medications	O	['N']	[14]
15	known	O	['N']	[15]
16	to	O	['N']	[16]
17	cause	O	['N']	[17]
18	hypoglycemia	B-Adverse_Effect	['N']	[18]
19	,	O	['N']	[19]
20	such	O	['N']	[20]
21	as	O	['N']	[21]
22	sulfonylureas	B-Drug	['Causes']	[18]
23	,	O	['N']	[23]
24	meglitinides	O	['N']	[24]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	insulin	O	['N']	[27]
28	.	O	['N']	[28]
#4897
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	first	O	['N']	[3]
4	biopsy	O	['N']	[4]
5	confirmed	O	['N']	[5]
6	occurrence	O	['N']	[6]
7	of	O	['N']	[7]
8	acute	B	['N']	[8]
9	interstitial	I	['N']	[9]
10	nephritis	I-Adverse_Effect	['N']	[10]
11	in	O	['N']	[11]
12	a	O	['N']	[12]
13	patient	O	['N']	[13]
14	receiving	O	['N']	[14]
15	treatment	O	['N']	[15]
16	with	O	['N']	[16]
17	Sunitinib	B-Drug	['Causes']	[10]
18	for	O	['N']	[18]
19	metastatic	O	['N']	[19]
20	renal	O	['N']	[20]
21	cell	O	['N']	[21]
22	cancer	O	['N']	[22]
23	.	O	['N']	[23]
#4898
0	However	O	['N']	[0]
1	,	O	['N']	[1]
2	recurrent	O	['N']	[2]
3	staphylococcus	B	['N']	[3]
4	aureus	I	['N']	[4]
5	sepsis	I-Adverse_Effect	['N']	[5]
6	developed	O	['N']	[6]
7	during	O	['N']	[7]
8	CyA	B-Drug	['Causes']	[5]
9	therapy	O	['N']	[9]
10	.	O	['N']	[10]
#4899
0	Serotonin	B	['N']	[0]
1	syndrome	I-Adverse_Effect	['N']	[1]
2	caused	O	['N']	[2]
3	by	O	['N']	[3]
4	interaction	O	['N']	[4]
5	between	O	['N']	[5]
6	citalopram	O	['N']	[6]
7	and	O	['N']	[7]
8	fentanyl	B-Drug	['Causes']	[1]
9	.	O	['N']	[9]
#4900
0	Four	O	['N']	[0]
1	days	O	['N']	[1]
2	after	O	['N']	[2]
3	the	O	['N']	[3]
4	initial	O	['N']	[4]
5	injection	O	['N']	[5]
6	of	O	['N']	[6]
7	3.6	O	['N']	[7]
8	mg	O	['N']	[8]
9	of	O	['N']	[9]
10	goserelin	B	['N']	[10]
11	acetate	I-Drug	['Causes']	[14]
12	,	O	['N']	[12]
13	severe	B	['N']	[13]
14	dyspnea	I-Adverse_Effect	['N']	[14]
15	developed	O	['N']	[15]
16	due	O	['N']	[16]
17	to	O	['N']	[17]
18	worsening	O	['N']	[18]
19	pleuritis	O	['N']	[19]
20	carcinomatosa	O	['N']	[20]
21	,	O	['N']	[21]
22	which	O	['N']	[22]
23	was	O	['N']	[23]
24	considered	O	['N']	[24]
25	as	O	['N']	[25]
26	a	O	['N']	[26]
27	flare	O	['N']	[27]
28	-	O	['N']	[28]
29	up	O	['N']	[29]
30	.	O	['N']	[30]
#4901
0	Coadministration	O	['N']	[0]
1	of	O	['N']	[1]
2	antidepressant	O	['N']	[2]
3	agents	O	['N']	[3]
4	such	O	['N']	[4]
5	as	O	['N']	[5]
6	nefazodone	O	['N']	[6]
7	,	O	['N']	[7]
8	or	O	['N']	[8]
9	any	O	['N']	[9]
10	other	O	['N']	[10]
11	drug	O	['N']	[11]
12	that	O	['N']	[12]
13	inhibits	O	['N']	[13]
14	the	O	['N']	[14]
15	CYP3A4	O	['N']	[15]
16	isoenzyme	O	['N']	[16]
17	subfamily	O	['N']	[17]
18	,	O	['N']	[18]
19	should	O	['N']	[19]
20	be	O	['N']	[20]
21	anticipated	O	['N']	[21]
22	to	O	['N']	[22]
23	interfere	B	['N']	[23]
24	with	I	['N']	[24]
25	tacrolimus	B-Drug	['Causes']	[26]
26	metabolism	I-Adverse_Effect	['N']	[26]
27	.	O	['N']	[27]
#4902
0	PURPOSE	O	['N']	[0]
1	:	O	['N']	[1]
2	The	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	aseptic	O	['N']	[9]
10	meningitis	O	['N']	[10]
11	,	O	['N']	[11]
12	hemolytic	O	['N']	[12]
13	anemia	O	['N']	[13]
14	,	O	['N']	[14]
15	hepatitis	O	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	orthostatic	B	['N']	[18]
19	hypotension	I-Adverse_Effect	['N']	[19]
20	simultaneously	O	['N']	[20]
21	during	O	['N']	[21]
22	treatment	O	['N']	[22]
23	with	O	['N']	[23]
24	trimethoprim	O	['N']	[24]
25	-	O	['N']	[25]
26	sulfamethoxazole	B-Drug	['Causes']	[19]
27	is	O	['N']	[27]
28	described	O	['N']	[28]
29	.	O	['N']	[29]
#4903
0	A	O	['N']	[0]
1	teenage	O	['N']	[1]
2	girl	O	['N']	[2]
3	with	O	['N']	[3]
4	crescentic	O	['N']	[4]
5	glomerulonephritis	O	['N']	[5]
6	had	O	['N']	[6]
7	antineutrophil	B	['N']	[7]
8	cytoplasmic	I	['N']	[8]
9	antibody	I-Adverse_Effect	['N']	[9]
10	(	O	['N']	[10]
11	ANCA	O	['N']	[11]
12	)	O	['N']	[12]
13	detected	O	['N']	[13]
14	after	O	['N']	[14]
15	she	O	['N']	[15]
16	had	O	['N']	[16]
17	received	O	['N']	[17]
18	propylthiouracil	B-Drug	['Causes']	[9]
19	(	O	['N']	[19]
20	PTU	O	['N']	[20]
21	)	O	['N']	[21]
22	for	O	['N']	[22]
23	hyperthyroidism	O	['N']	[23]
24	without	O	['N']	[24]
25	cutaneous	O	['N']	[25]
26	vasculitis	O	['N']	[26]
27	.	O	['N']	[27]
#4904
0	Nephrotic	B	['N']	[0]
1	syndrome	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	lithium	B-Drug	['Causes']	[1]
5	therapy	O	['N']	[5]
6	.	O	['N']	[6]
#4905
0	The	O	['N']	[0]
1	authors	O	['N']	[1]
2	conclude	O	['N']	[2]
3	that	O	['N']	[3]
4	among	O	['N']	[4]
5	patients	O	['N']	[5]
6	taking	O	['N']	[6]
7	high	O	['N']	[7]
8	doses	O	['N']	[8]
9	of	O	['N']	[9]
10	oral	O	['N']	[10]
11	niacin	B-Drug	['Causes']	[17]
12	only	O	['N']	[12]
13	those	O	['N']	[13]
14	who	O	['N']	[14]
15	experience	O	['N']	[15]
16	visual	B	['N']	[16]
17	symptoms	I-Adverse_Effect	['N']	[17]
18	need	O	['N']	[18]
19	to	O	['N']	[19]
20	be	O	['N']	[20]
21	ophthalmologically	O	['N']	[21]
22	evaluated	O	['N']	[22]
23	.	O	['N']	[23]
#4906
0	Children	O	['N']	[0]
1	receiving	O	['N']	[1]
2	zonisamide	B-Drug	['Causes']	[7]
3	should	O	['N']	[3]
4	be	O	['N']	[4]
5	monitored	O	['N']	[5]
6	for	O	['N']	[6]
7	oligohidrosis	B-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	the	O	['N']	[9]
10	development	O	['N']	[10]
11	of	O	['N']	[11]
12	neurological	O	['N']	[12]
13	symptoms	O	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	an	O	['N']	[16]
17	elevation	O	['N']	[17]
18	of	O	['N']	[18]
19	body	O	['N']	[19]
20	temperature	O	['N']	[20]
21	.	O	['N']	[21]
#4907
0	The	O	['N']	[0]
1	pharmacology	O	['N']	[1]
2	and	O	['N']	[2]
3	toxicology	O	['N']	[3]
4	of	O	['N']	[4]
5	chloral	B	['N']	[5]
6	hydrate	I-Drug	['Causes']	[15]
7	are	O	['N']	[7]
8	discussed	O	['N']	[8]
9	with	O	['N']	[9]
10	particular	O	['N']	[10]
11	reference	O	['N']	[11]
12	to	O	['N']	[12]
13	the	O	['N']	[13]
14	cardiac	B	['N']	[14]
15	arrhythmias	I-Adverse_Effect	['N']	[15]
16	that	O	['N']	[16]
17	are	O	['N']	[17]
18	seen	O	['N']	[18]
19	with	O	['N']	[19]
20	overdosage	O	['N']	[20]
21	.	O	['N']	[21]
#4908
0	Fulminant	B	['N']	[0]
1	hepatitis	I-Adverse_Effect	['N']	[1]
2	associated	O	['N']	[2]
3	with	O	['N']	[3]
4	disulfiram	B-Drug	['Causes']	[1]
5	.	O	['N']	[5]
#4909
0	A	O	['N']	[0]
1	selective	O	['N']	[1]
2	association	O	['N']	[2]
3	between	O	['N']	[3]
4	fluoxetine	B-Drug	['Causes']	[18]
5	and	O	['N']	[5]
6	extensive	O	['N']	[6]
7	,	O	['N']	[7]
8	prominent	O	['N']	[8]
9	eye	B	['N']	[9]
10	movements	I	['N']	[10]
11	in	I	['N']	[11]
12	nonrapid	I	['N']	[12]
13	eye	I	['N']	[13]
14	movement	I	['N']	[14]
15	(	I	['N']	[15]
16	NREM	I	['N']	[16]
17	)	I	['N']	[17]
18	sleep	I-Adverse_Effect	['N']	[18]
19	was	O	['N']	[19]
20	detected	O	['N']	[20]
21	,	O	['N']	[21]
22	utilizing	O	['N']	[22]
23	Fisher	O	['N']	[23]
24	's	O	['N']	[24]
25	exact	O	['N']	[25]
26	one	O	['N']	[26]
27	-	O	['N']	[27]
28	tailed	O	['N']	[28]
29	statistic	O	['N']	[29]
30	(	O	['N']	[30]
31	p	O	['N']	[31]
32	less	O	['N']	[32]
33	than	O	['N']	[33]
34	0.00001	O	['N']	[34]
35	for	O	['N']	[35]
36	each	O	['N']	[36]
37	comparison	O	['N']	[37]
38	)	O	['N']	[38]
39	.	O	['N']	[39]
#4910
0	Antibiotic	O	['N']	[0]
1	-	O	['N']	[1]
2	associated	O	['N']	[2]
3	colitis	O	['N']	[3]
4	(	O	['N']	[4]
5	pseudomembranous	B	['N']	[5]
6	colitis	I-Adverse_Effect	['N']	[6]
7	)	O	['N']	[7]
8	developed	O	['N']	[8]
9	in	O	['N']	[9]
10	four	O	['N']	[10]
11	patients	O	['N']	[11]
12	with	O	['N']	[12]
13	spinal	O	['N']	[13]
14	cord	O	['N']	[14]
15	injury	O	['N']	[15]
16	and	O	['N']	[16]
17	taking	O	['N']	[17]
18	oral	O	['N']	[18]
19	trimethoprim	O	['N']	[19]
20	-	O	['N']	[20]
21	sulfamethoxazole	B-Drug	['Causes']	[6]
22	.	O	['N']	[22]
#4911
0	L	B	['N']	[0]
1	-	I	['N']	[1]
2	DOPA	I-Drug	['Causes']	[7]
3	-	O	['N']	[3]
4	induced	O	['N']	[4]
5	excessive	O	['N']	[5]
6	daytime	B	['N']	[6]
7	sleepiness	I-Adverse_Effect	['N']	[7]
8	in	O	['N']	[8]
9	PD	O	['N']	[9]
10	:	O	['N']	[10]
11	a	O	['N']	[11]
12	placebo	O	['N']	[12]
13	-	O	['N']	[13]
14	controlled	O	['N']	[14]
15	case	O	['N']	[15]
16	with	O	['N']	[16]
17	MSLT	O	['N']	[17]
18	assessment	O	['N']	[18]
19	.	O	['N']	[19]
#4912
0	The	O	['N']	[0]
1	azathioprine	B-Drug	['Dosage']	[9]
2	dose	O	['N']	[2]
3	was	O	['N']	[3]
4	low	O	['N']	[4]
5	(	O	['N']	[5]
6	1	B	['N']	[6]
7	mg	I	['N']	[7]
8	/	I	['N']	[8]
9	kg	I-Dose	['N']	[9]
10	)	O	['N']	[10]
11	and	O	['N']	[11]
12	pancytopenia	O	['N']	[12]
13	occurred	O	['N']	[13]
14	after	O	['N']	[14]
15	56	O	['N']	[15]
16	days	O	['N']	[16]
17	therapy	O	['N']	[17]
18	.	O	['N']	[18]
#4913
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	here	O	['N']	[2]
3	a	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	TEN	B-Adverse_Effect	['N']	[6]
7	after	O	['N']	[7]
8	administration	O	['N']	[8]
9	of	O	['N']	[9]
10	ciprofloxacin	B-Drug	['Causes']	[6]
11	.	O	['N']	[11]
#4914
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	After	O	['N']	[2]
3	4-	O	['N']	[3]
4	to	O	['N']	[4]
5	14-month	O	['N']	[5]
6	period	O	['N']	[6]
7	of	O	['N']	[7]
8	therapy	O	['N']	[8]
9	with	O	['N']	[9]
10	the	O	['N']	[10]
11	combination	O	['N']	[11]
12	of	O	['N']	[12]
13	indapamide	O	['N']	[13]
14	(	O	['N']	[14]
15	2.5	O	['N']	[15]
16	mg	O	['N']	[16]
17	/	O	['N']	[17]
18	day	O	['N']	[18]
19	)	O	['N']	[19]
20	and	O	['N']	[20]
21	fosinopril	B-Drug	['Causes']	[58]
22	(	O	['N']	[22]
23	10	O	['N']	[23]
24	mg	O	['N']	[24]
25	/	O	['N']	[25]
26	day	O	['N']	[26]
27	)	O	['N']	[27]
28	in	O	['N']	[28]
29	three	O	['N']	[29]
30	patients	O	['N']	[30]
31	and	O	['N']	[31]
32	6-month	O	['N']	[32]
33	period	O	['N']	[33]
34	of	O	['N']	[34]
35	monotherapy	O	['N']	[35]
36	with	O	['N']	[36]
37	indapamide	O	['N']	[37]
38	(	O	['N']	[38]
39	2.5	O	['N']	[39]
40	mg	O	['N']	[40]
41	/	O	['N']	[41]
42	day	O	['N']	[42]
43	)	O	['N']	[43]
44	in	O	['N']	[44]
45	one	O	['N']	[45]
46	patient	O	['N']	[46]
47	,	O	['N']	[47]
48	glucose	O	['N']	[48]
49	levels	O	['N']	[49]
50	of	O	['N']	[50]
51	all	O	['N']	[51]
52	patients	O	['N']	[52]
53	increased	O	['N']	[53]
54	and	O	['N']	[54]
55	achieve	O	['N']	[55]
56	criteria	O	['N']	[56]
57	of	O	['N']	[57]
58	diabetes	B-Adverse_Effect	['N']	[58]
59	diagnoses	O	['N']	[59]
60	.	O	['N']	[60]
#4915
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	observation	O	['N']	[3]
4	of	O	['N']	[4]
5	"	O	['N']	[5]
6	on	O	['N']	[6]
7	-	O	['N']	[7]
8	off	O	['N']	[8]
9	"	O	['N']	[9]
10	risperidone	B-Drug	['Causes']	[22]
11	treatment	O	['N']	[11]
12	suggests	O	['N']	[12]
13	that	O	['N']	[13]
14	risperidone	O	['N']	[14]
15	may	O	['N']	[15]
16	have	O	['N']	[16]
17	worsened	O	['N']	[17]
18	both	O	['N']	[18]
19	psychiatric	B	['N']	[19]
20	and	I	['N']	[20]
21	physical	I	['N']	[21]
22	manifestations	I-Adverse_Effect	['N']	[22]
23	of	O	['N']	[23]
24	the	O	['N']	[24]
25	mitochondrial	O	['N']	[25]
26	disorder	O	['N']	[26]
27	in	O	['N']	[27]
28	this	O	['N']	[28]
29	adolescent	O	['N']	[29]
30	.	O	['N']	[30]
#4916
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	31-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	women	O	['N']	[6]
7	with	O	['N']	[7]
8	recurrent	O	['N']	[8]
9	Hodgkin	O	['N']	[9]
10	's	O	['N']	[10]
11	lymphoma	O	['N']	[11]
12	and	O	['N']	[12]
13	unrecognized	O	['N']	[13]
14	HMSN-1	O	['N']	[14]
15	who	O	['N']	[15]
16	developed	O	['N']	[16]
17	severe	O	['N']	[17]
18	motor	O	['N']	[18]
19	neuropathy	O	['N']	[19]
20	3	O	['N']	[20]
21	weeks	O	['N']	[21]
22	after	O	['N']	[22]
23	the	O	['N']	[23]
24	first	O	['N']	[24]
25	cycle	O	['N']	[25]
26	of	O	['N']	[26]
27	treatment	O	['N']	[27]
28	including	O	['N']	[28]
29	2	B	['N']	[29]
30	mg	I-Dose	['N']	[30]
31	of	O	['N']	[31]
32	vincristine	B-Drug	['Dosage']	[30]
33	.	O	['N']	[33]
#4917
0	Apparent	O	['N']	[0]
1	central	B	['N']	[1]
2	nervous	I	['N']	[2]
3	system	I	['N']	[3]
4	depression	I-Adverse_Effect	['N']	[4]
5	in	O	['N']	[5]
6	infants	O	['N']	[6]
7	after	O	['N']	[7]
8	the	O	['N']	[8]
9	use	O	['N']	[9]
10	of	O	['N']	[10]
11	topical	O	['N']	[11]
12	brimonidine	B-Drug	['Causes']	[4]
13	.	O	['N']	[13]
#4918
0	Fever	B-Adverse_Effect	['N']	[0]
1	caused	O	['N']	[1]
2	by	O	['N']	[2]
3	the	O	['N']	[3]
4	use	O	['N']	[4]
5	of	O	['N']	[5]
6	furosemide	B-Drug	['Causes']	[0]
7	was	O	['N']	[7]
8	proved	O	['N']	[8]
9	;	O	['N']	[9]
10	the	O	['N']	[10]
11	fever	O	['N']	[11]
12	resolved	O	['N']	[12]
13	after	O	['N']	[13]
14	discontinuation	O	['N']	[14]
15	of	O	['N']	[15]
16	this	O	['N']	[16]
17	medication	O	['N']	[17]
18	and	O	['N']	[18]
19	recurred	O	['N']	[19]
20	after	O	['N']	[20]
21	its	O	['N']	[21]
22	reintroduction	O	['N']	[22]
23	.	O	['N']	[23]
#4919
0	In	O	['N']	[0]
1	keeping	O	['N']	[1]
2	with	O	['N']	[2]
3	findings	O	['N']	[3]
4	in	O	['N']	[4]
5	the	O	['N']	[5]
6	literature	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	aortic	B	['N']	[9]
10	wall	I	['N']	[10]
11	in	I	['N']	[11]
12	this	I	['N']	[12]
13	case	I	['N']	[13]
14	was	I	['N']	[14]
15	damaged	I-Adverse_Effect	['N']	[15]
16	by	O	['N']	[16]
17	secondary	O	['N']	[17]
18	changes	O	['N']	[18]
19	following	O	['N']	[19]
20	irradiation	O	['N']	[20]
21	and	O	['N']	[21]
22	Bleomycin	B-Drug	['Causes']	[15]
23	treatment	O	['N']	[23]
24	.	O	['N']	[24]
#4920
0	Muscle	O	['N']	[0]
1	biopsy	O	['N']	[1]
2	revealed	O	['N']	[2]
3	variation	B	['N']	[3]
4	in	I	['N']	[4]
5	muscle	I	['N']	[5]
6	fiber	I	['N']	[6]
7	size	I-Adverse_Effect	['N']	[7]
8	and	O	['N']	[8]
9	few	O	['N']	[9]
10	vacuolated	O	['N']	[10]
11	fibers	O	['N']	[11]
12	which	O	['N']	[12]
13	were	O	['N']	[13]
14	features	O	['N']	[14]
15	of	O	['N']	[15]
16	colchicine	B-Drug	['Causes']	[7]
17	-	O	['N']	[17]
18	induced	O	['N']	[18]
19	myopathy	O	['N']	[19]
20	.	O	['N']	[20]
#4921
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	34-year	O	['N']	[3]
4	-	O	['N']	[4]
5	old	O	['N']	[5]
6	man	O	['N']	[6]
7	acquired	O	['N']	[7]
8	visual	O	['N']	[8]
9	field	O	['N']	[9]
10	defects	O	['N']	[10]
11	and	O	['N']	[11]
12	severe	B	['N']	[12]
13	vision	I	['N']	[13]
14	loss	I-Adverse_Effect	['N']	[14]
15	in	O	['N']	[15]
16	both	O	['N']	[16]
17	eyes	O	['N']	[17]
18	after	O	['N']	[18]
19	intravitreal	O	['N']	[19]
20	injection	O	['N']	[20]
21	of	O	['N']	[21]
22	triamcinolone	B-Drug	['Causes']	[14]
23	for	O	['N']	[23]
24	diabetic	O	['N']	[24]
25	macular	O	['N']	[25]
26	edema	O	['N']	[26]
27	.	O	['N']	[27]
#4922
0	During	O	['N']	[0]
1	clarithromycin	B-Drug	['Causes']	[17]
2	coadministration	O	['N']	[2]
3	,	O	['N']	[3]
4	four	O	['N']	[4]
5	out	O	['N']	[5]
6	of	O	['N']	[6]
7	the	O	['N']	[7]
8	seven	O	['N']	[8]
9	patients	O	['N']	[9]
10	developed	O	['N']	[10]
11	moderate	O	['N']	[11]
12	-	O	['N']	[12]
13	to	O	['N']	[13]
14	-	O	['N']	[14]
15	severe	O	['N']	[15]
16	toxic	B	['N']	[16]
17	symptoms	I-Adverse_Effect	['N']	[17]
18	of	O	['N']	[18]
19	carbamazepine	O	['N']	[19]
20	,	O	['N']	[20]
21	such	O	['N']	[21]
22	as	O	['N']	[22]
23	drowsiness	O	['N']	[23]
24	,	O	['N']	[24]
25	dizziness	O	['N']	[25]
26	,	O	['N']	[26]
27	and	O	['N']	[27]
28	ataxia	O	['N']	[28]
29	,	O	['N']	[29]
30	which	O	['N']	[30]
31	resolved	O	['N']	[31]
32	within	O	['N']	[32]
33	5	O	['N']	[33]
34	days	O	['N']	[34]
35	after	O	['N']	[35]
36	clarithromycin	O	['N']	[36]
37	discontinuation	O	['N']	[37]
38	.	O	['N']	[38]
#4923
0	Reversible	O	['N']	[0]
1	sclerotic	B	['N']	[1]
2	changes	I	['N']	[2]
3	of	I	['N']	[3]
4	lumbar	I	['N']	[4]
5	spine	I	['N']	[5]
6	and	I	['N']	[6]
7	femur	I-Adverse_Effect	['N']	[7]
8	due	O	['N']	[8]
9	to	O	['N']	[9]
10	long	O	['N']	[10]
11	-	O	['N']	[11]
12	term	O	['N']	[12]
13	oral	O	['N']	[13]
14	isotretinoin	B-Drug	['Causes']	[7]
15	therapy	O	['N']	[15]
16	.	O	['N']	[16]
#4924
0	A	O	['N']	[0]
1	74-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	hypercholestrerolaemic	O	['N']	[4]
5	woman	O	['N']	[5]
6	taking	O	['N']	[6]
7	cerivastatin	B-Drug	['Dosage']	[12]
8	(	O	['N']	[8]
9	0.15	B	['N']	[9]
10	mg	I	['N']	[10]
11	/	I	['N']	[11]
12	day	I-Dose	['N']	[12]
13	)	O	['N']	[13]
14	for	O	['N']	[14]
15	22	O	['N']	[15]
16	days	O	['N']	[16]
17	complained	O	['N']	[17]
18	of	O	['N']	[18]
19	general	O	['N']	[19]
20	muscle	O	['N']	[20]
21	weakness	O	['N']	[21]
22	and	O	['N']	[22]
23	muscle	O	['N']	[23]
24	pain	O	['N']	[24]
25	.	O	['N']	[25]
#4925
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	pediatric	O	['N']	[5]
6	bupropion	B-Drug	['Causes']	[11]
7	ingestion	O	['N']	[7]
8	resulting	O	['N']	[8]
9	in	O	['N']	[9]
10	multiple	B	['N']	[10]
11	seizures	I-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#4926
0	Systemic	B	['N']	[0]
1	capillary	I	['N']	[1]
2	leak	I	['N']	[2]
3	syndrome	I-Adverse_Effect	['N']	[3]
4	after	O	['N']	[4]
5	granulocyte	O	['N']	[5]
6	colony	O	['N']	[6]
7	-	O	['N']	[7]
8	stimulating	O	['N']	[8]
9	factor	O	['N']	[9]
10	(	O	['N']	[10]
11	G	B	['N']	[11]
12	-	I	['N']	[12]
13	CSF	I-Drug	['Causes']	[3]
14	)	O	['N']	[14]
15	.	O	['N']	[15]
#4927
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	This	O	['N']	[2]
3	is	O	['N']	[3]
4	the	O	['N']	[4]
5	first	O	['N']	[5]
6	report	O	['N']	[6]
7	of	O	['N']	[7]
8	a	O	['N']	[8]
9	possible	O	['N']	[9]
10	interaction	O	['N']	[10]
11	between	O	['N']	[11]
12	propafenone	B-Drug	['Causes']	[32]
13	and	O	['N']	[13]
14	citalopram	O	['N']	[14]
15	,	O	['N']	[15]
16	which	O	['N']	[16]
17	caused	O	['N']	[17]
18	propafenone	O	['N']	[18]
19	adverse	O	['N']	[19]
20	effects	O	['N']	[20]
21	(	O	['N']	[21]
22	eg	O	['N']	[22]
23	,	O	['N']	[23]
24	dizziness	O	['N']	[24]
25	,	O	['N']	[25]
26	falls	O	['N']	[26]
27	)	O	['N']	[27]
28	and	O	['N']	[28]
29	mimicked	O	['N']	[29]
30	coronary	B	['N']	[30]
31	artery	I	['N']	[31]
32	disease	I-Adverse_Effect	['N']	[32]
33	.	O	['N']	[33]
#4928
0	We	O	['N']	[0]
1	presented	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	with	O	['N']	[4]
5	status	O	['N']	[5]
6	asthmaticus	O	['N']	[6]
7	treated	O	['N']	[7]
8	with	O	['N']	[8]
9	a	O	['N']	[9]
10	combination	O	['N']	[10]
11	of	O	['N']	[11]
12	theophylline	O	['N']	[12]
13	and	O	['N']	[13]
14	prednisone	B-Drug	['Causes']	[20]
15	who	O	['N']	[15]
16	developed	O	['N']	[16]
17	a	O	['N']	[17]
18	perforated	B	['N']	[18]
19	gastric	I	['N']	[19]
20	ulcer	I-Adverse_Effect	['N']	[20]
21	.	O	['N']	[21]
#4929
0	DISCUSSION	O	['N']	[0]
1	:	O	['N']	[1]
2	After	O	['N']	[2]
3	exclusion	O	['N']	[3]
4	of	O	['N']	[4]
5	other	O	['N']	[5]
6	causes	O	['N']	[6]
7	,	O	['N']	[7]
8	the	O	['N']	[8]
9	onset	O	['N']	[9]
10	of	O	['N']	[10]
11	thrombocytopenia	O	['N']	[11]
12	after	O	['N']	[12]
13	administration	O	['N']	[13]
14	of	O	['N']	[14]
15	lansoprazole	B-Drug	['Causes']	[53]
16	,	O	['N']	[16]
17	the	O	['N']	[17]
18	resolution	O	['N']	[18]
19	of	O	['N']	[19]
20	the	O	['N']	[20]
21	adverse	O	['N']	[21]
22	reaction	O	['N']	[22]
23	after	O	['N']	[23]
24	discontinuation	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	drug	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	the	O	['N']	[30]
31	fact	O	['N']	[31]
32	that	O	['N']	[32]
33	no	O	['N']	[33]
34	other	O	['N']	[34]
35	medicines	O	['N']	[35]
36	were	O	['N']	[36]
37	introduced	O	['N']	[37]
38	during	O	['N']	[38]
39	this	O	['N']	[39]
40	time	O	['N']	[40]
41	frame	O	['N']	[41]
42	lead	O	['N']	[42]
43	us	O	['N']	[43]
44	to	O	['N']	[44]
45	believe	O	['N']	[45]
46	that	O	['N']	[46]
47	this	O	['N']	[47]
48	was	O	['N']	[48]
49	most	O	['N']	[49]
50	likely	O	['N']	[50]
51	an	O	['N']	[51]
52	idiosyncratic	O	['N']	[52]
53	thrombocytopenic	B-Adverse_Effect	['N']	[53]
54	response	O	['N']	[54]
55	to	O	['N']	[55]
56	lansoprazole	O	['N']	[56]
57	.	O	['N']	[57]
#4930
0	Acute	B	['N']	[0]
1	delirium	I-Adverse_Effect	['N']	[1]
2	resulting	O	['N']	[2]
3	from	O	['N']	[3]
4	levofloxacin	B-Drug	['Causes']	[1]
5	therapy	O	['N']	[5]
6	is	O	['N']	[6]
7	an	O	['N']	[7]
8	exceedingly	O	['N']	[8]
9	rare	O	['N']	[9]
10	complication	O	['N']	[10]
11	that	O	['N']	[11]
12	has	O	['N']	[12]
13	been	O	['N']	[13]
14	thought	O	['N']	[14]
15	to	O	['N']	[15]
16	occur	O	['N']	[16]
17	more	O	['N']	[17]
18	commonly	O	['N']	[18]
19	in	O	['N']	[19]
20	elderly	O	['N']	[20]
21	patients	O	['N']	[21]
22	.	O	['N']	[22]
#4931
0	A	O	['N']	[0]
1	79-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	man	O	['N']	[4]
5	with	O	['N']	[5]
6	ischemic	O	['N']	[6]
7	heart	O	['N']	[7]
8	disease	O	['N']	[8]
9	,	O	['N']	[9]
10	chronic	O	['N']	[10]
11	atrial	O	['N']	[11]
12	fibrillation	O	['N']	[12]
13	,	O	['N']	[13]
14	chronic	O	['N']	[14]
15	renal	O	['N']	[15]
16	failure	O	['N']	[16]
17	,	O	['N']	[17]
18	hypothyroidism	O	['N']	[18]
19	,	O	['N']	[19]
20	and	O	['N']	[20]
21	gout	O	['N']	[21]
22	arthritis	O	['N']	[22]
23	was	O	['N']	[23]
24	hospitalized	O	['N']	[24]
25	because	O	['N']	[25]
26	of	O	['N']	[26]
27	fatigue	O	['N']	[27]
28	,	O	['N']	[28]
29	myalgia	O	['N']	[29]
30	,	O	['N']	[30]
31	and	O	['N']	[31]
32	leg	B	['N']	[32]
33	weakness	I-Adverse_Effect	['N']	[33]
34	,	O	['N']	[34]
35	shortly	O	['N']	[35]
36	after	O	['N']	[36]
37	starting	O	['N']	[37]
38	treatment	O	['N']	[38]
39	with	O	['N']	[39]
40	colchicine	B-Drug	['Causes']	[33]
41	.	O	['N']	[41]
#4932
0	CONCLUSIONS	O	['N']	[0]
1	:	O	['N']	[1]
2	Peripheral	O	['N']	[2]
3	administration	O	['N']	[3]
4	of	O	['N']	[4]
5	low	B-Dose	['N']	[5]
6	-	O	['N']	[6]
7	dose	O	['N']	[7]
8	vasopressin	B-Drug	['Dosage']	[5]
9	for	O	['N']	[9]
10	septic	O	['N']	[10]
11	shock	O	['N']	[11]
12	should	O	['N']	[12]
13	be	O	['N']	[13]
14	discouraged	O	['N']	[14]
15	because	O	['N']	[15]
16	of	O	['N']	[16]
17	the	O	['N']	[17]
18	risk	O	['N']	[18]
19	of	O	['N']	[19]
20	ischemic	O	['N']	[20]
21	skin	O	['N']	[21]
22	complications	O	['N']	[22]
23	.	O	['N']	[23]
#4933
0	Case	O	['N']	[0]
1	2	O	['N']	[1]
2	demonstrated	O	['N']	[2]
3	after	O	['N']	[3]
4	40	O	['N']	[4]
5	months	O	['N']	[5]
6	on	O	['N']	[6]
7	chlorambucil	B-Drug	['Causes']	[13]
8	the	O	['N']	[8]
9	presence	O	['N']	[9]
10	of	O	['N']	[10]
11	a	O	['N']	[11]
12	balanced	B	['N']	[12]
13	translocation	I-Adverse_Effect	['N']	[13]
14	,	O	['N']	[14]
15	t	O	['N']	[15]
16	(	O	['N']	[16]
17	1;5	O	['N']	[17]
18	)	O	['N']	[18]
19	(	O	['N']	[19]
20	p36;q31	O	['N']	[20]
21	)	O	['N']	[21]
22	in	O	['N']	[22]
23	90	O	['N']	[23]
24	%	O	['N']	[24]
25	of	O	['N']	[25]
26	the	O	['N']	[26]
27	cells	O	['N']	[27]
28	.	O	['N']	[28]
#4934
0	Ophthalmologists	O	['N']	[0]
1	should	O	['N']	[1]
2	be	O	['N']	[2]
3	aware	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	ocular	O	['N']	[6]
7	side	O	['N']	[7]
8	effects	O	['N']	[8]
9	of	O	['N']	[9]
10	IFN	B-Drug	['Causes']	[23]
11	therapy	O	['N']	[11]
12	and	O	['N']	[12]
13	carefully	O	['N']	[13]
14	monitor	O	['N']	[14]
15	patients	O	['N']	[15]
16	for	O	['N']	[16]
17	the	O	['N']	[17]
18	possible	O	['N']	[18]
19	occurrence	O	['N']	[19]
20	of	O	['N']	[20]
21	hypoalbuminemia	O	['N']	[21]
22	and	O	['N']	[22]
23	thrombocytopenia	B-Adverse_Effect	['N']	[23]
24	.	O	['N']	[24]
#4935
0	This	O	['N']	[0]
1	is	O	['N']	[1]
2	a	O	['N']	[2]
3	report	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	renal	O	['N']	[6]
7	transplant	O	['N']	[7]
8	patient	O	['N']	[8]
9	with	O	['N']	[9]
10	Pneumocystis	O	['N']	[10]
11	pneumonia	O	['N']	[11]
12	who	O	['N']	[12]
13	developed	O	['N']	[13]
14	chemical	B	['N']	[14]
15	cellulitis	I-Adverse_Effect	['N']	[15]
16	and	O	['N']	[16]
17	ulceration	O	['N']	[17]
18	following	O	['N']	[18]
19	the	O	['N']	[19]
20	extravasation	O	['N']	[20]
21	of	O	['N']	[21]
22	intravenous	O	['N']	[22]
23	pentamidine	B-Drug	['Causes']	[15]
24	into	O	['N']	[24]
25	the	O	['N']	[25]
26	soft	O	['N']	[26]
27	tissues	O	['N']	[27]
28	of	O	['N']	[28]
29	the	O	['N']	[29]
30	left	O	['N']	[30]
31	hand	O	['N']	[31]
32	and	O	['N']	[32]
33	forearm	O	['N']	[33]
34	.	O	['N']	[34]
#4936
0	A	O	['N']	[0]
1	14-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	female	O	['N']	[4]
5	developed	O	['N']	[5]
6	systemic	B	['N']	[6]
7	lupus	I	['N']	[7]
8	erythematosus	I	['N']	[8]
9	(	I	['N']	[9]
10	SLE)-like	I	['N']	[10]
11	symptoms	I-Adverse_Effect	['N']	[11]
12	,	O	['N']	[12]
13	rash	O	['N']	[13]
14	,	O	['N']	[14]
15	fever	O	['N']	[15]
16	,	O	['N']	[16]
17	leukopenia	O	['N']	[17]
18	and	O	['N']	[18]
19	positive	O	['N']	[19]
20	anti	O	['N']	[20]
21	-	O	['N']	[21]
22	nuclear	O	['N']	[22]
23	antibody	O	['N']	[23]
24	(	O	['N']	[24]
25	ANA	O	['N']	[25]
26	)	O	['N']	[26]
27	two	O	['N']	[27]
28	weeks	O	['N']	[28]
29	after	O	['N']	[29]
30	administration	O	['N']	[30]
31	of	O	['N']	[31]
32	carbamazepine	O	['N']	[32]
33	(	O	['N']	[33]
34	CBZ	B-Drug	['Causes']	[11]
35	;	O	['N']	[35]
36	Tegretol	O	['N']	[36]
37	)	O	['N']	[37]
38	used	O	['N']	[38]
39	against	O	['N']	[39]
40	benign	O	['N']	[40]
41	Rolandic	O	['N']	[41]
42	epilepsy	O	['N']	[42]
43	.	O	['N']	[43]
#4937
0	A	O	['N']	[0]
1	wide	O	['N']	[1]
2	variety	O	['N']	[2]
3	of	O	['N']	[3]
4	adverse	B	['N']	[4]
5	central	I	['N']	[5]
6	nervous	I	['N']	[6]
7	system	I	['N']	[7]
8	effects	I-Adverse_Effect	['N']	[8]
9	have	O	['N']	[9]
10	been	O	['N']	[10]
11	reported	O	['N']	[11]
12	in	O	['N']	[12]
13	association	O	['N']	[13]
14	with	O	['N']	[14]
15	propafenone	B-Drug	['Causes']	[8]
16	;	O	['N']	[16]
17	dizziness	O	['N']	[17]
18	is	O	['N']	[18]
19	the	O	['N']	[19]
20	most	O	['N']	[20]
21	common	O	['N']	[21]
22	.	O	['N']	[22]
#4938
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	report	O	['N']	[2]
3	we	O	['N']	[3]
4	described	O	['N']	[4]
5	a	O	['N']	[5]
6	case	O	['N']	[6]
7	of	O	['N']	[7]
8	juvenile	O	['N']	[8]
9	idiopathic	O	['N']	[9]
10	arthritis	O	['N']	[10]
11	patient	O	['N']	[11]
12	who	O	['N']	[12]
13	developed	O	['N']	[13]
14	thymic	B	['N']	[14]
15	enlargement	I-Adverse_Effect	['N']	[15]
16	(	O	['N']	[16]
17	true	O	['N']	[17]
18	thymic	O	['N']	[18]
19	hyperplasia	O	['N']	[19]
20	)	O	['N']	[20]
21	,	O	['N']	[21]
22	mediastinal	O	['N']	[22]
23	lymphadenopathy	O	['N']	[23]
24	and	O	['N']	[24]
25	pleurisy	O	['N']	[25]
26	associated	O	['N']	[26]
27	with	O	['N']	[27]
28	systemic	O	['N']	[28]
29	symptoms	O	['N']	[29]
30	under	O	['N']	[30]
31	Etanercept	B-Drug	['Causes']	[15]
32	treatment	O	['N']	[32]
33	.	O	['N']	[33]
#4939
0	Indolent	O	['N']	[0]
1	aspergillus	B	['N']	[1]
2	arthritis	I-Adverse_Effect	['N']	[2]
3	complicating	O	['N']	[3]
4	fludarabine	B-Drug	['Causes']	[2]
5	-	O	['N']	[5]
6	based	O	['N']	[6]
7	non	O	['N']	[7]
8	-	O	['N']	[8]
9	myeloablative	O	['N']	[9]
10	stem	O	['N']	[10]
11	cell	O	['N']	[11]
12	transplantation	O	['N']	[12]
13	.	O	['N']	[13]
#4940
0	Eruptive	B	['N']	[0]
1	epidermoid	I	['N']	[1]
2	cysts	I-Adverse_Effect	['N']	[2]
3	resulting	O	['N']	[3]
4	from	O	['N']	[4]
5	treatment	O	['N']	[5]
6	with	O	['N']	[6]
7	imiquimod	B-Drug	['Causes']	[2]
8	.	O	['N']	[8]
#4941
0	Fludarabine	B-Drug	['Causes']	[3]
1	induced	O	['N']	[1]
2	lung	B	['N']	[2]
3	toxicity	I-Adverse_Effect	['N']	[3]
4	must	O	['N']	[4]
5	be	O	['N']	[5]
6	considered	O	['N']	[6]
7	in	O	['N']	[7]
8	all	O	['N']	[8]
9	patients	O	['N']	[9]
10	who	O	['N']	[10]
11	develop	O	['N']	[11]
12	unexplained	O	['N']	[12]
13	lung	O	['N']	[13]
14	disease	O	['N']	[14]
15	while	O	['N']	[15]
16	receiving	O	['N']	[16]
17	fludarabine	O	['N']	[17]
18	.	O	['N']	[18]
#4942
0	The	O	['N']	[0]
1	disease	O	['N']	[1]
2	-	O	['N']	[2]
3	modifying	O	['N']	[3]
4	drugs	O	['N']	[4]
5	he	O	['N']	[5]
6	was	O	['N']	[6]
7	taking	O	['N']	[7]
8	,	O	['N']	[8]
9	cyclosporin	O	['N']	[9]
10	and	O	['N']	[10]
11	methotrexate	B-Drug	['Causes']	[18]
12	,	O	['N']	[12]
13	were	O	['N']	[13]
14	stopped	O	['N']	[14]
15	,	O	['N']	[15]
16	and	O	['N']	[16]
17	the	O	['N']	[17]
18	lymphoma	B-Adverse_Effect	['N']	[18]
19	resolved	O	['N']	[19]
20	spontaneously	O	['N']	[20]
21	without	O	['N']	[21]
22	the	O	['N']	[22]
23	use	O	['N']	[23]
24	of	O	['N']	[24]
25	chemotherapy	O	['N']	[25]
26	.	O	['N']	[26]
#4943
0	RESULTS	O	['N']	[0]
1	:	O	['N']	[1]
2	A	O	['N']	[2]
3	male	O	['N']	[3]
4	and	O	['N']	[4]
5	a	O	['N']	[5]
6	female	O	['N']	[6]
7	patient	O	['N']	[7]
8	with	O	['N']	[8]
9	spasticity	O	['N']	[9]
10	treated	O	['N']	[10]
11	with	O	['N']	[11]
12	intrathecal	O	['N']	[12]
13	baclofen	B-Drug	['Causes']	[19]
14	were	O	['N']	[14]
15	recognized	O	['N']	[15]
16	to	O	['N']	[16]
17	have	O	['N']	[17]
18	sexual	B	['N']	[18]
19	dysfunction	I-Adverse_Effect	['N']	[19]
20	side	O	['N']	[20]
21	effects	O	['N']	[21]
22	from	O	['N']	[22]
23	treatment	O	['N']	[23]
24	.	O	['N']	[24]
#4944
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	the	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	a	O	['N']	[5]
6	patient	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	polyserositis	O	['N']	[9]
10	(	O	['N']	[10]
11	pericardial	O	['N']	[11]
12	effusion	O	['N']	[12]
13	,	O	['N']	[13]
14	pleural	B	['N']	[14]
15	effusion	I-Adverse_Effect	['N']	[15]
16	,	O	['N']	[16]
17	and	O	['N']	[17]
18	pericarditis	O	['N']	[18]
19	)	O	['N']	[19]
20	after	O	['N']	[20]
21	being	O	['N']	[21]
22	started	O	['N']	[22]
23	on	O	['N']	[23]
24	clozapine	B-Drug	['Causes']	[15]
25	,	O	['N']	[25]
26	and	O	['N']	[26]
27	whose	O	['N']	[27]
28	symptoms	O	['N']	[28]
29	remitted	O	['N']	[29]
30	upon	O	['N']	[30]
31	discontinuation	O	['N']	[31]
32	of	O	['N']	[32]
33	clozapine	O	['N']	[33]
34	.	O	['N']	[34]
#4945
0	The	O	['N']	[0]
1	patient	O	['N']	[1]
2	had	O	['N']	[2]
3	recurrence	O	['N']	[3]
4	of	O	['N']	[4]
5	urticaria	B-Adverse_Effect	['N']	[5]
6	and	O	['N']	[6]
7	angioedema	O	['N']	[7]
8	a	O	['N']	[8]
9	year	O	['N']	[9]
10	and	O	['N']	[10]
11	a	O	['N']	[11]
12	half	O	['N']	[12]
13	later	O	['N']	[13]
14	,	O	['N']	[14]
15	at	O	['N']	[15]
16	which	O	['N']	[16]
17	point	O	['N']	[17]
18	the	O	['N']	[18]
19	NPH	B-Drug	['Causes']	[5]
20	was	O	['N']	[20]
21	stopped	O	['N']	[21]
22	and	O	['N']	[22]
23	she	O	['N']	[23]
24	was	O	['N']	[24]
25	desensitized	O	['N']	[25]
26	to	O	['N']	[26]
27	regular	O	['N']	[27]
28	insulin	O	['N']	[28]
29	.	O	['N']	[29]
#4946
0	Tetany	B-Adverse_Effect	['N']	[0]
1	in	O	['N']	[1]
2	a	O	['N']	[2]
3	child	O	['N']	[3]
4	with	O	['N']	[4]
5	AIDS	O	['N']	[5]
6	receiving	O	['N']	[6]
7	intravenous	O	['N']	[7]
8	tobramycin	B-Drug	['Causes']	[0]
9	.	O	['N']	[9]
#4947
0	Salicylate	B-Drug	['Causes']	[3]
1	-	O	['N']	[1]
2	induced	O	['N']	[2]
3	hepatotoxicity	B-Adverse_Effect	['N']	[3]
4	is	O	['N']	[4]
5	reviewed	O	['N']	[5]
6	.	O	['N']	[6]
#4948
0	In	O	['N']	[0]
1	this	O	['N']	[1]
2	article	O	['N']	[2]
3	,	O	['N']	[3]
4	we	O	['N']	[4]
5	present	O	['N']	[5]
6	the	O	['N']	[6]
7	case	O	['N']	[7]
8	of	O	['N']	[8]
9	a	O	['N']	[9]
10	vitiligo	O	['N']	[10]
11	patient	O	['N']	[11]
12	who	O	['N']	[12]
13	was	O	['N']	[13]
14	admitted	O	['N']	[14]
15	to	O	['N']	[15]
16	our	O	['N']	[16]
17	facility	O	['N']	[17]
18	with	O	['N']	[18]
19	an	O	['N']	[19]
20	intense	B	['N']	[20]
21	burn	I-Adverse_Effect	['N']	[21]
22	after	O	['N']	[22]
23	the	O	['N']	[23]
24	topical	O	['N']	[24]
25	use	O	['N']	[25]
26	of	O	['N']	[26]
27	8-methoxypsoralen	B-Drug	['Causes']	[21]
28	solution	O	['N']	[28]
29	as	O	['N']	[29]
30	a	O	['N']	[30]
31	suntanning	O	['N']	[31]
32	agent	O	['N']	[32]
33	.	O	['N']	[33]
#4949
0	A	O	['N']	[0]
1	10-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	boy	O	['N']	[4]
5	with	O	['N']	[5]
6	osteosarcoma	O	['N']	[6]
7	and	O	['N']	[7]
8	normal	O	['N']	[8]
9	renal	O	['N']	[9]
10	function	O	['N']	[10]
11	manifested	O	['N']	[11]
12	laboratory	O	['N']	[12]
13	evidence	O	['N']	[13]
14	of	O	['N']	[14]
15	impending	O	['N']	[15]
16	renal	O	['N']	[16]
17	toxicity	O	['N']	[17]
18	and	O	['N']	[18]
19	extreme	O	['N']	[19]
20	elevation	B	['N']	[20]
21	of	I	['N']	[21]
22	aspartate	I	['N']	[22]
23	aminotrasferase	I-Adverse_Effect	['N']	[23]
24	and	O	['N']	[24]
25	alanine	O	['N']	[25]
26	aminotransferase	O	['N']	[26]
27	within	O	['N']	[27]
28	2	O	['N']	[28]
29	hours	O	['N']	[29]
30	after	O	['N']	[30]
31	the	O	['N']	[31]
32	completion	O	['N']	[32]
33	of	O	['N']	[33]
34	a	O	['N']	[34]
35	4-hour	O	['N']	[35]
36	infusion	O	['N']	[36]
37	of	O	['N']	[37]
38	high	O	['N']	[38]
39	-	O	['N']	[39]
40	dose	O	['N']	[40]
41	methotrexate	B-Drug	['Causes']	[23]
42	(	O	['N']	[42]
43	MTX	O	['N']	[43]
44	)	O	['N']	[44]
45	(	O	['N']	[45]
46	12	O	['N']	[46]
47	g	O	['N']	[47]
48	/	O	['N']	[48]
49	m2	O	['N']	[49]
50	)	O	['N']	[50]
51	,	O	['N']	[51]
52	and	O	['N']	[52]
53	went	O	['N']	[53]
54	on	O	['N']	[54]
55	to	O	['N']	[55]
56	develop	O	['N']	[56]
57	acute	O	['N']	[57]
58	renal	O	['N']	[58]
59	failure	O	['N']	[59]
60	with	O	['N']	[60]
61	life	O	['N']	[61]
62	-	O	['N']	[62]
63	threatening	O	['N']	[63]
64	hyperkalemia	O	['N']	[64]
65	29	O	['N']	[65]
66	hours	O	['N']	[66]
67	later	O	['N']	[67]
68	.	O	['N']	[68]
#4950
0	A	O	['N']	[0]
1	rare	O	['N']	[1]
2	case	O	['N']	[2]
3	of	O	['N']	[3]
4	advanced	O	['N']	[4]
5	ovarian	O	['N']	[5]
6	carcinoma	O	['N']	[6]
7	who	O	['N']	[7]
8	developed	O	['N']	[8]
9	difficulty	B	['N']	[9]
10	walking	I-Adverse_Effect	['N']	[10]
11	25	O	['N']	[11]
12	days	O	['N']	[12]
13	after	O	['N']	[13]
14	treatment	O	['N']	[14]
15	with	O	['N']	[15]
16	weekly	O	['N']	[16]
17	paclitaxel	B-Drug	['Causes']	[10]
18	.	O	['N']	[18]
#4951
0	A	O	['N']	[0]
1	45-year	O	['N']	[1]
2	-	O	['N']	[2]
3	old	O	['N']	[3]
4	woman	O	['N']	[4]
5	with	O	['N']	[5]
6	steroid	O	['N']	[6]
7	-	O	['N']	[7]
8	dependent	O	['N']	[8]
9	Crohn	O	['N']	[9]
10	's	O	['N']	[10]
11	colitis	O	['N']	[11]
12	,	O	['N']	[12]
13	successfully	O	['N']	[13]
14	managed	O	['N']	[14]
15	with	O	['N']	[15]
16	maintenance	O	['N']	[16]
17	infliximab	B-Drug	['Causes']	[27]
18	infusions	O	['N']	[18]
19	and	O	['N']	[19]
20	methotrexate	O	['N']	[20]
21	,	O	['N']	[21]
22	developed	O	['N']	[22]
23	a	O	['N']	[23]
24	lupus	B	['N']	[24]
25	-	I	['N']	[25]
26	like	I	['N']	[26]
27	syndrome	I-Adverse_Effect	['N']	[27]
28	eight	O	['N']	[28]
29	months	O	['N']	[29]
30	after	O	['N']	[30]
31	her	O	['N']	[31]
32	initial	O	['N']	[32]
33	infusion	O	['N']	[33]
34	.	O	['N']	[34]
#4952
0	Eleven	O	['N']	[0]
1	patients	O	['N']	[1]
2	developed	O	['N']	[2]
3	infection	O	['N']	[3]
4	requiring	O	['N']	[4]
5	hospitalization	O	['N']	[5]
6	while	O	['N']	[6]
7	taking	O	['N']	[7]
8	leflunomide	B-Drug	['Causes']	[33]
9	including	O	['N']	[9]
10	:	O	['N']	[10]
11	lower	O	['N']	[11]
12	respiratory	O	['N']	[12]
13	tract	O	['N']	[13]
14	infections	O	['N']	[14]
15	(	O	['N']	[15]
16	3	O	['N']	[16]
17	)	O	['N']	[17]
18	,	O	['N']	[18]
19	cellulitis	O	['N']	[19]
20	(	O	['N']	[20]
21	2	O	['N']	[21]
22	)	O	['N']	[22]
23	,	O	['N']	[23]
24	disseminated	O	['N']	[24]
25	herpes	O	['N']	[25]
26	zoster	O	['N']	[26]
27	(	O	['N']	[27]
28	2	O	['N']	[28]
29	)	O	['N']	[29]
30	,	O	['N']	[30]
31	probable	O	['N']	[31]
32	TB	B	['N']	[32]
33	liver	I-Adverse_Effect	['N']	[33]
34	(	O	['N']	[34]
35	1	O	['N']	[35]
36	)	O	['N']	[36]
37	,	O	['N']	[37]
38	abdominal	O	['N']	[38]
39	sepsis	O	['N']	[39]
40	(	O	['N']	[40]
41	1	O	['N']	[41]
42	)	O	['N']	[42]
43	,	O	['N']	[43]
44	mycotic	O	['N']	[44]
45	aneurysm	O	['N']	[45]
46	(	O	['N']	[46]
47	1	O	['N']	[47]
48	)	O	['N']	[48]
49	and	O	['N']	[49]
50	gastroenteritis	O	['N']	[50]
51	(	O	['N']	[51]
52	1	O	['N']	[52]
53	)	O	['N']	[53]
54	.	O	['N']	[54]
#4953
0	Duodenal	B	['N']	[0]
1	ulceration	I-Adverse_Effect	['N']	[1]
2	:	O	['N']	[2]
3	a	O	['N']	[3]
4	complication	O	['N']	[4]
5	of	O	['N']	[5]
6	tolazoline	B-Drug	['Causes']	[1]
7	therapy	O	['N']	[7]
8	.	O	['N']	[8]
#4954
0	Acute	O	['N']	[0]
1	nitrite	B-Drug	['Causes']	[2]
2	toxicity	I-Adverse_Effect	['N']	[2]
3	results	O	['N']	[3]
4	from	O	['N']	[4]
5	industrial	O	['N']	[5]
6	exposure	O	['N']	[6]
7	,	O	['N']	[7]
8	accidental	O	['N']	[8]
9	ingestion	O	['N']	[9]
10	(	O	['N']	[10]
11	e.g.	O	['N']	[11]
12	,	O	['N']	[12]
13	abuse	O	['N']	[13]
14	of	O	['N']	[14]
15	organic	O	['N']	[15]
16	nitrites	O	['N']	[16]
17	as	O	['N']	[17]
18	an	O	['N']	[18]
19	aphrodisiac	O	['N']	[19]
20	,	O	['N']	[20]
21	especially	O	['N']	[21]
22	in	O	['N']	[22]
23	the	O	['N']	[23]
24	male	O	['N']	[24]
25	homosexual	O	['N']	[25]
26	population	O	['N']	[26]
27	)	O	['N']	[27]
28	,	O	['N']	[28]
29	and	O	['N']	[29]
30	suicidal	O	['N']	[30]
31	ingestion	O	['N']	[31]
32	.	O	['N']	[32]
#4955
0	Caution	O	['N']	[0]
1	in	O	['N']	[1]
2	longterm	O	['N']	[2]
3	usage	O	['N']	[3]
4	and	O	['N']	[4]
5	early	O	['N']	[5]
6	recognition	O	['N']	[6]
7	of	O	['N']	[7]
8	pentazocine	B-Drug	['Causes']	[25]
9	toxicity	O	['N']	[9]
10	as	O	['N']	[10]
11	a	O	['N']	[11]
12	neuromuscular	O	['N']	[12]
13	complication	O	['N']	[13]
14	are	O	['N']	[14]
15	important	O	['N']	[15]
16	in	O	['N']	[16]
17	order	O	['N']	[17]
18	to	O	['N']	[18]
19	prevent	O	['N']	[19]
20	irreversible	O	['N']	[20]
21	drug	O	['N']	[21]
22	-	O	['N']	[22]
23	induced	O	['N']	[23]
24	fibrous	B	['N']	[24]
25	myopathy	I-Adverse_Effect	['N']	[25]
26	and	O	['N']	[26]
27	localized	O	['N']	[27]
28	neuropathy	O	['N']	[28]
29	.	O	['N']	[29]
#4956
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	4	O	['N']	[2]
3	patients	O	['N']	[3]
4	,	O	['N']	[4]
5	2	O	['N']	[5]
6	on	O	['N']	[6]
7	methylphenidate	B-Drug	['Causes']	[19]
8	and	O	['N']	[8]
9	2	O	['N']	[9]
10	on	O	['N']	[10]
11	dextroamphetamine	O	['N']	[11]
12	who	O	['N']	[12]
13	presented	O	['N']	[13]
14	with	O	['N']	[14]
15	acral	O	['N']	[15]
16	cyanosis	O	['N']	[16]
17	,	O	['N']	[17]
18	livedo	B	['N']	[18]
19	reticularis	I-Adverse_Effect	['N']	[19]
20	,	O	['N']	[20]
21	or	O	['N']	[21]
22	Raynaud	O	['N']	[22]
23	phenomenon	O	['N']	[23]
24	.	O	['N']	[24]
#4957
0	A	O	['N']	[0]
1	patient	O	['N']	[1]
2	with	O	['N']	[2]
3	psoriasis	O	['N']	[3]
4	is	O	['N']	[4]
5	described	O	['N']	[5]
6	who	O	['N']	[6]
7	had	O	['N']	[7]
8	an	O	['N']	[8]
9	abnormal	O	['N']	[9]
10	response	O	['N']	[10]
11	to	O	['N']	[11]
12	the	O	['N']	[12]
13	glucose	O	['N']	[13]
14	tolerance	O	['N']	[14]
15	test	O	['N']	[15]
16	without	O	['N']	[16]
17	other	O	['N']	[17]
18	evidence	O	['N']	[18]
19	of	O	['N']	[19]
20	diabetes	O	['N']	[20]
21	and	O	['N']	[21]
22	then	O	['N']	[22]
23	developed	O	['N']	[23]
24	postprandial	O	['N']	[24]
25	hyperglycemia	O	['N']	[25]
26	and	O	['N']	[26]
27	glycosuria	B-Adverse_Effect	['N']	[27]
28	during	O	['N']	[28]
29	a	O	['N']	[29]
30	period	O	['N']	[30]
31	of	O	['N']	[31]
32	topical	O	['N']	[32]
33	administration	O	['N']	[33]
34	of	O	['N']	[34]
35	a	O	['N']	[35]
36	corticosteroid	O	['N']	[36]
37	cream	O	['N']	[37]
38	,	O	['N']	[38]
39	halcinonide	B-Drug	['Causes']	[27]
40	cream	O	['N']	[40]
41	0.1	O	['N']	[41]
42	%	O	['N']	[42]
43	,	O	['N']	[43]
44	under	O	['N']	[44]
45	occlusion	O	['N']	[45]
46	.	O	['N']	[46]
#4958
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	patient	O	['N']	[3]
4	who	O	['N']	[4]
5	had	O	['N']	[5]
6	a	O	['N']	[6]
7	systemic	B	['N']	[7]
8	allergic	I	['N']	[8]
9	contact	I	['N']	[9]
10	dermatitis	I-Adverse_Effect	['N']	[10]
11	to	O	['N']	[11]
12	8-MOP	B-Drug	['Causes']	[10]
13	develop	O	['N']	[13]
14	during	O	['N']	[14]
15	her	O	['N']	[15]
16	second	O	['N']	[16]
17	course	O	['N']	[17]
18	of	O	['N']	[18]
19	PUVA	O	['N']	[19]
20	treatment	O	['N']	[20]
21	for	O	['N']	[21]
22	psoriasis	O	['N']	[22]
23	.	O	['N']	[23]
#4959
0	We	O	['N']	[0]
1	describe	O	['N']	[1]
2	a	O	['N']	[2]
3	detailed	O	['N']	[3]
4	case	O	['N']	[4]
5	of	O	['N']	[5]
6	fulminant	B	['N']	[6]
7	hepatitis	I-Adverse_Effect	['N']	[7]
8	induced	O	['N']	[8]
9	by	O	['N']	[9]
10	nevirapine	O	['N']	[10]
11	(	O	['N']	[11]
12	Viramune	B-Drug	['Causes']	[7]
13	)	O	['N']	[13]
14	and	O	['N']	[14]
15	treated	O	['N']	[15]
16	by	O	['N']	[16]
17	liver	O	['N']	[17]
18	transplantation	O	['N']	[18]
19	.	O	['N']	[19]
#4960
0	Here	O	['N']	[0]
1	we	O	['N']	[1]
2	report	O	['N']	[2]
3	a	O	['N']	[3]
4	patient	O	['N']	[4]
5	with	O	['N']	[5]
6	newly	O	['N']	[6]
7	diagnosed	O	['N']	[7]
8	acute	O	['N']	[8]
9	promyelocytic	O	['N']	[9]
10	leukemia	O	['N']	[10]
11	who	O	['N']	[11]
12	developed	O	['N']	[12]
13	acute	O	['N']	[13]
14	focal	O	['N']	[14]
15	myositis	O	['N']	[15]
16	,	O	['N']	[16]
17	synovitis	O	['N']	[17]
18	,	O	['N']	[18]
19	and	O	['N']	[19]
20	possible	B	['N']	[20]
21	vasculitis	I-Adverse_Effect	['N']	[21]
22	,	O	['N']	[22]
23	after	O	['N']	[23]
24	receiving	O	['N']	[24]
25	all	B	['N']	[25]
26	-	I	['N']	[26]
27	trans	I	['N']	[27]
28	retinoic	I	['N']	[28]
29	acid	I-Drug	['Causes']	[21]
30	therapy	O	['N']	[30]
31	.	O	['N']	[31]
#4961
0	First	O	['N']	[0]
1	,	O	['N']	[1]
2	a	O	['N']	[2]
3	review	O	['N']	[3]
4	of	O	['N']	[4]
5	the	O	['N']	[5]
6	literature	O	['N']	[6]
7	produced	O	['N']	[7]
8	41	O	['N']	[8]
9	anecdotic	O	['N']	[9]
10	cases	O	['N']	[10]
11	of	O	['N']	[11]
12	neutropenia	O	['N']	[12]
13	or	O	['N']	[13]
14	agranulocytosis	B-Adverse_Effect	['N']	[14]
15	during	O	['N']	[15]
16	treatment	O	['N']	[16]
17	with	O	['N']	[17]
18	olanzapine	O	['N']	[18]
19	(	O	['N']	[19]
20	Zyprexa	B-Drug	['Causes']	[14]
21	)	O	['N']	[21]
22	reported	O	['N']	[22]
23	in	O	['N']	[23]
24	a	O	['N']	[24]
25	total	O	['N']	[25]
26	of	O	['N']	[26]
27	24	O	['N']	[27]
28	publications	O	['N']	[28]
29	.	O	['N']	[29]
#4962
0	Three	O	['N']	[0]
1	patients	O	['N']	[1]
2	developed	O	['N']	[2]
3	proteinuria	B-Adverse_Effect	['N']	[3]
4	following	O	['N']	[4]
5	gold	B-Drug	['Causes']	[3]
6	therapy	O	['N']	[6]
7	for	O	['N']	[7]
8	rheumatoid	O	['N']	[8]
9	arthritis	O	['N']	[9]
10	.	O	['N']	[10]
#4963
0	In	O	['N']	[0]
1	deciding	O	['N']	[1]
2	if	O	['N']	[2]
3	tamoxifen	B-Drug	['Causes']	[27]
4	therapy	O	['N']	[4]
5	is	O	['N']	[5]
6	warranted	O	['N']	[6]
7	,	O	['N']	[7]
8	all	O	['N']	[8]
9	potentially	O	['N']	[9]
10	life	O	['N']	[10]
11	-	O	['N']	[11]
12	threatening	O	['N']	[12]
13	adverse	O	['N']	[13]
14	events	O	['N']	[14]
15	associated	O	['N']	[15]
16	with	O	['N']	[16]
17	tamoxifen	O	['N']	[17]
18	should	O	['N']	[18]
19	be	O	['N']	[19]
20	considered	O	['N']	[20]
21	,	O	['N']	[21]
22	including	O	['N']	[22]
23	endometrial	O	['N']	[23]
24	adenocarcinoma	O	['N']	[24]
25	or	O	['N']	[25]
26	uterine	B	['N']	[26]
27	sarcoma	I-Adverse_Effect	['N']	[27]
28	.	O	['N']	[28]
#4964
0	In	O	['N']	[0]
1	these	O	['N']	[1]
2	patients	O	['N']	[2]
3	,	O	['N']	[3]
4	long	O	['N']	[4]
5	-	O	['N']	[5]
6	acting	O	['N']	[6]
7	octreotide	B-Drug	['Causes']	[11]
8	may	O	['N']	[8]
9	trigger	O	['N']	[9]
10	serious	B	['N']	[10]
11	hypoglycemia	I-Adverse_Effect	['N']	[11]
12	.	O	['N']	[12]
#4965
0	Only	O	['N']	[0]
1	one	O	['N']	[1]
2	case	O	['N']	[2]
3	of	O	['N']	[3]
4	a	O	['N']	[4]
5	generalized	B	['N']	[5]
6	maculopapular	I	['N']	[6]
7	rash	I-Adverse_Effect	['N']	[7]
8	with	O	['N']	[8]
9	enoxaparin	B-Drug	['Causes']	[7]
10	has	O	['N']	[10]
11	been	O	['N']	[11]
12	reported	O	['N']	[12]
13	in	O	['N']	[13]
14	Europe	O	['N']	[14]
15	.	O	['N']	[15]
#4966
0	Alprazolam	B-Drug	['Causes']	[2]
1	withdrawal	O	['N']	[1]
2	delirium	B-Adverse_Effect	['N']	[2]
3	unresponsive	O	['N']	[3]
4	to	O	['N']	[4]
5	diazepam	O	['N']	[5]
6	:	O	['N']	[6]
7	case	O	['N']	[7]
8	report	O	['N']	[8]
9	.	O	['N']	[9]
#4967
0	BACKGROUND	O	['N']	[0]
1	:	O	['N']	[1]
2	To	O	['N']	[2]
3	assess	O	['N']	[3]
4	the	O	['N']	[4]
5	nature	O	['N']	[5]
6	,	O	['N']	[6]
7	incidence	O	['N']	[7]
8	,	O	['N']	[8]
9	and	O	['N']	[9]
10	risk	O	['N']	[10]
11	factors	O	['N']	[11]
12	of	O	['N']	[12]
13	retinopathy	B-Adverse_Effect	['N']	[13]
14	associated	O	['N']	[14]
15	with	O	['N']	[15]
16	pegylated	O	['N']	[16]
17	interferon	O	['N']	[17]
18	and	O	['N']	[18]
19	ribavirin	B-Drug	['Causes']	[13]
20	combination	O	['N']	[20]
21	therapy	O	['N']	[21]
22	in	O	['N']	[22]
23	chronic	O	['N']	[23]
24	hepatitis	O	['N']	[24]
25	C	O	['N']	[25]
26	patients	O	['N']	[26]
27	.	O	['N']	[27]
#4968
0	We	O	['N']	[0]
1	report	O	['N']	[1]
2	a	O	['N']	[2]
3	case	O	['N']	[3]
4	of	O	['N']	[4]
5	torsade	B	['N']	[5]
6	de	I	['N']	[6]
7	pointes	I-Adverse_Effect	['N']	[7]
8	following	O	['N']	[8]
9	a	O	['N']	[9]
10	single	O	['N']	[10]
11	oral	O	['N']	[11]
12	dose	O	['N']	[12]
13	of	O	['N']	[13]
14	amiodarone	B-Drug	['Causes']	[7]
15	(	O	['N']	[15]
16	1400	O	['N']	[16]
17	mg	O	['N']	[17]
18	or	O	['N']	[18]
19	30	O	['N']	[19]
20	mg	O	['N']	[20]
21	kg-1	O	['N']	[21]
22	)	O	['N']	[22]
23	administered	O	['N']	[23]
24	after	O	['N']	[24]
25	short	O	['N']	[25]
26	intravenous	O	['N']	[26]
27	loading	O	['N']	[27]
28	for	O	['N']	[28]
29	prevention	O	['N']	[29]
30	of	O	['N']	[30]
31	paroxysmal	O	['N']	[31]
32	atrial	O	['N']	[32]
33	flutter	O	['N']	[33]
34	.	O	['N']	[34]
#4969
0	Although	O	['N']	[0]
1	the	O	['N']	[1]
2	existence	O	['N']	[2]
3	of	O	['N']	[3]
4	an	O	['N']	[4]
5	acute	O	['N']	[5]
6	pericarditis	O	['N']	[6]
7	or	O	['N']	[7]
8	an	O	['N']	[8]
9	acute	O	['N']	[9]
10	myocarditis	O	['N']	[10]
11	as	O	['N']	[11]
12	possible	O	['N']	[12]
13	causes	O	['N']	[13]
14	of	O	['N']	[14]
15	the	O	['N']	[15]
16	ST	O	['N']	[16]
17	elevation	O	['N']	[17]
18	can	O	['N']	[18]
19	not	O	['N']	[19]
20	be	O	['N']	[20]
21	fully	O	['N']	[21]
22	ruled	O	['N']	[22]
23	out	O	['N']	[23]
24	,	O	['N']	[24]
25	the	O	['N']	[25]
26	sudden	O	['N']	[26]
27	onset	O	['N']	[27]
28	,	O	['N']	[28]
29	prominent	O	['N']	[29]
30	magnitude	O	['N']	[30]
31	,	O	['N']	[31]
32	and	O	['N']	[32]
33	brief	O	['N']	[33]
34	duration	O	['N']	[34]
35	of	O	['N']	[35]
36	the	O	['N']	[36]
37	ST	O	['N']	[37]
38	elevation	O	['N']	[38]
39	are	O	['N']	[39]
40	perhaps	O	['N']	[40]
41	more	O	['N']	[41]
42	indicative	O	['N']	[42]
43	of	O	['N']	[43]
44	an	O	['N']	[44]
45	acute	O	['N']	[45]
46	ischemic	O	['N']	[46]
47	event	O	['N']	[47]
48	,	O	['N']	[48]
49	possibly	O	['N']	[49]
50	related	O	['N']	[50]
51	to	O	['N']	[51]
52	a	O	['N']	[52]
53	transient	O	['N']	[53]
54	coronary	B	['N']	[54]
55	vasoconstriction	I-Adverse_Effect	['N']	[55]
56	induced	O	['N']	[56]
57	by	O	['N']	[57]
58	the	O	['N']	[58]
59	dopamine	B-Drug	['Causes']	[55]
60	infusion	O	['N']	[60]
61	.	O	['N']	[61]
